Systemic	O
toxicity	O
following	O
administration	O
of	O
sirolimus	B
(	O
formerly	O
rapamycin	B
)	O
for	O
psoriasis	O
:	O
association	O
of	O
capillary	O
leak	O
syndrome	O
with	O
apoptosis	O
of	O
lesional	O
lymphocytes	O
.	O

BACKGROUND	O
:	O
Sirolimus	B
(	O
formerly	O
rapamycin	B
)	O
is	O
an	O
immunosuppressive	O
agent	O
that	O
interferes	O
with	O
T	O
-	O
cell	O
activation	O
.	O

After	O
2	O
individuals	O
with	O
psoriasis	O
developed	O
a	O
capillary	O
leak	O
syndrome	O
following	O
treatment	O
with	O
oral	O
sirolimus	B
lesional	O
skin	O
cells	O
and	O
activated	O
peripheral	O
blood	O
cells	O
were	O
analyzed	O
for	O
induction	O
of	O
apoptosis	O
.	O

OBSERVATIONS	O
:	O
A	O
keratome	O
skin	O
specimen	O
from	O
1	O
patient	O
with	O
sirolimus	B
-	O
induced	O
capillary	O
leak	O
syndrome	O
had	O
a	O
2.3-fold	O
increase	O
in	O
percentage	O
of	O
apoptotic	O
cells	O
(	O
to	O
48	O
%	O
)	O
compared	O
with	O
an	O
unaffected	O
sirolimus	B
-	O
treated	O
patient	O
with	O
psoriasis	O
(	O
21	O
%	O
)	O
.	O

Activated	O
peripheral	O
blood	O
T	O
cells	O
from	O
patients	O
with	O
psoriasis	O
tended	O
to	O
exhibit	O
greater	O
spontaneous	O
or	O
dexamethasone	B
-	O
induced	O
apoptosis	O
than	O
did	O
normal	O
T	O
cells	O
,	O
particularly	O
in	O
the	O
presence	O
of	O
sirolimus	B
.	O

CONCLUSIONS	O
:	O
Severe	O
adverse	O
effects	O
of	O
sirolimus	B
include	O
fever	O
,	O
anemia	O
,	O
and	O
capillary	O
leak	O
syndrome	O
.	O

These	O
symptoms	O
may	O
be	O
the	O
result	O
of	O
drug	O
-	O
induced	O
apoptosis	O
of	O
lesional	O
leukocytes	O
,	O
especially	O
activated	O
T	O
lymphocytes	O
,	O
and	O
possibly	O
release	O
of	O
inflammatory	O
mediators	O
.	O

Because	O
patients	O
with	O
severe	O
psoriasis	O
may	O
develop	O
capillary	O
leak	O
from	O
various	O
systemic	O
therapies	O
,	O
clinical	O
monitoring	O
is	O
advisable	O
for	O
patients	O
with	O
inflammatory	O
diseases	O
who	O
are	O
treated	O
with	O
immune	O
modulators	O
.	O

Effect	O
of	O
lithium	B
maintenance	O
therapy	O
on	O
thyroid	O
and	O
parathyroid	O
function	O
.	O

OBJECTIVES	O
:	O
To	O
assess	O
changes	O
induced	O
by	O
lithium	B
maintenance	O
therapy	O
on	O
the	O
incidence	O
of	O
thyroid	O
,	O
parathyroid	O
and	O
ion	O
alterations	O
.	O

These	O
were	O
evaluated	O
with	O
respect	O
to	O
the	O
duration	O
of	O
lithium	B
therapy	O
,	O
age	O
,	O
sex	O
,	O
and	O
family	O
history	O
(	O
whether	O
or	O
not	O
the	O
patient	O
had	O
a	O
first	O
-	O
degree	O
relative	O
with	O
thyroid	O
disease	O
)	O
.	O

DESIGN	O
:	O
Prospective	O
study	O
.	O

SETTING	O
:	O
Affective	O
Disorders	O
Clinic	O
at	O
St.	O
Mary	O
's	O
Hospital	O
,	O
Montreal	O
.	O

PATIENTS	O
:	O
One	O
hundred	O
and	O
one	O
patients	O
(	O
28	O
men	O
and	O
73	O
women	O
)	O
with	O
bipolar	O
disorder	O
receiving	O
lithium	B
maintenance	O
therapy	O
ranging	O
from	O
1	O
year	O
's	O
to	O
32	O
years	O
'	O
duration	O
.	O

The	O
control	O
group	O
consisted	O
of	O
82	O
patients	O
with	O
no	O
psychiatric	O
or	O
endocrinological	O
diagnoses	O
from	O
the	O
hospital	O
's	O
out	O
-	O
patient	O
clinics	O
.	O

OUTCOME	O
MEASURES	O
:	O
Laboratory	O
analyses	O
of	O
calcium	B
,	O
magnesium	B
and	O
thyroid	O
-	O
stimulating	O
hormone	O
levels	O
performed	O
before	O
beginning	O
lithium	B
therapy	O
and	O
at	O
biannual	O
follow	O
-	O
up	O
.	O

RESULTS	O
:	O
Hypothyroidism	O
developed	O
in	O
40	O
patients	O
,	O
excluding	O
8	O
patients	O
who	O
were	O
hypothyroid	O
at	O
baseline	O
.	O

All	O
patients	O
having	O
first	O
-	O
degree	O
relatives	O
affected	O
by	O
thyroid	O
illness	O
had	O
accelerated	O
onset	O
of	O
hypothyroidism	O
(	O
3.7	O
years	O
after	O
onset	O
of	O
lithium	B
therapy	O
)	O
compared	O
with	O
patients	O
without	O
a	O
family	O
history	O
(	O
8.6	O
years	O
after	O
onset	O
of	O
lithium	B
therapy	O
)	O
.	O

Women	O
over	O
60	O
years	O
of	O
age	O
were	O
more	O
often	O
affected	O
by	O
hypothyroidism	O
than	O
women	O
under	O
60	O
years	O
of	O
age	O
(	O
34.6	O
%	O
versus	O
31.9	O
%	O
)	O
.	O

Magnesium	B
levels	O
in	O
patients	O
on	O
lithium	B
treatment	O
were	O
unchanged	O
from	O
baseline	O
levels	O
.	O

After	O
lithium	B
treatment	O
,	O
calcium	B
levels	O
were	O
higher	O
than	O
either	O
baseline	O
levels	O
or	O
control	O
levels	O
.	O

Thus	O
,	O
lithium	B
treatment	O
counteracted	O
the	O
decrease	O
in	O
plasma	O
calcium	B
levels	O
associated	O
with	O
aging	O
.	O

CONCLUSIONS	O
:	O
Familial	O
thyroid	O
illness	O
is	O
a	O
risk	O
factor	O
for	O
hypothyroidism	O
and	O
hypercalcemia	O
during	O
lithium	B
therapy	O
.	O

Hypomania	O
-	O
like	O
syndrome	O
induced	O
by	O
olanzapine	B
.	O

We	O
report	O
a	O
female	O
patient	O
with	O
a	O
diagnosis	O
of	O
a	O
not	O
otherwise	O
specified	O
psychotic	O
disorder	O
(	O
DSM	O
-	O
IV	O
)	O
who	O
developed	O
hypomania	O
shortly	O
after	O
the	O
introduction	O
of	O
olanzapine	B
treatment	O
.	O

Acetazolamide	B
-	O
induced	O
Gerstmann	O
syndrome	O
.	O

Acute	O
confusion	O
induced	O
by	O
acetazolamide	B
is	O
a	O
well	O
known	O
adverse	O
drug	O
reaction	O
in	O
patients	O
with	O
renal	O
impairment	O
.	O

We	O
report	O
a	O
case	O
of	O
acetazolamide	B
-	O
induced	O
Gerstmann	O
syndrome	O
in	O
a	O
patient	O
with	O
normal	O
renal	O
function	O
,	O
to	O
highlight	O
predisposing	O
factors	O
that	O
are	O
frequently	O
overlooked	O
.	O

Ocular	O
manifestations	O
of	O
juvenile	O
rheumatoid	O
arthritis	O
.	O

We	O
followed	O
210	O
cases	O
of	O
juvenile	O
rheumatoid	O
arthritis	O
closely	O
for	O
eleven	O
years	O
.	O

Thirty	O
-	O
six	O
of	O
the	O
210	O
patients	O
(	O
17.2	O
%	O
)	O
developed	O
iridocyclitis	O
.	O

Iridocyclitis	O
was	O
seen	O
most	O
frequently	O
in	O
young	O
female	O
patients	O
(	O
0	O
to	O
4	O
years	O
)	O
with	O
the	O
monoarticular	O
or	O
pauciatricular	O
form	O
of	O
the	O
arthritis	O
.	O

However	O
,	O
30	O
%	O
of	O
the	O
patients	O
developed	O
uveitis	O
after	O
16	O
years	O
of	O
age	O
.	O

Although	O
61	O
%	O
of	O
patients	O
had	O
a	O
noncontributory	O
ocular	O
history	O
on	O
entry	O
,	O
42	O
%	O
had	O
active	O
uveitis	O
on	O
entry	O
.	O

Our	O
approach	O
was	O
effective	O
in	O
detecting	O
uveitis	O
in	O
new	O
cases	O
and	O
exacerbations	O
of	O
uveitis	O
in	O
established	O
cases	O
.	O

Forty	O
-	O
four	O
percent	O
of	O
patients	O
with	O
uveitis	O
had	O
one	O
or	O
more	O
identifiable	O
signs	O
or	O
symptoms	O
,	O
such	O
as	O
red	O
eye	O
,	O
ocular	O
pain	O
,	O
decreased	O
visual	O
acuity	O
,	O
or	O
photophobia	O
,	O
in	O
order	O
of	O
decreasing	O
frequency	O
.	O

Even	O
after	O
early	O
detection	O
and	O
prompt	O
treatment	O
,	O
41	O
%	O
of	O
cases	O
of	O
uveitis	O
did	O
not	O
respond	O
to	O
more	O
than	O
six	O
months	O
of	O
intensive	O
topical	O
treatment	O
with	O
corticosteroids	B
and	O
mydriatics	O
.	O

Despite	O
this	O
,	O
there	O
was	O
a	O
dramatic	O
decrease	O
in	O
the	O
50	O
%	O
incidence	O
of	O
blinding	O
complications	O
of	O
uveitis	O
cited	O
in	O
earlier	O
studies	O
.	O

Cataract	O
and	O
band	O
keratopathy	O
occurred	O
in	O
only	O
22	O
and	O
13	O
%	O
of	O
our	O
group	O
,	O
respectively	O
.	O

We	O
used	O
chloroquine	B
or	O
hydroxychloroquine	B
in	O
173	O
of	O
210	O
cases	O
and	O
found	O
only	O
one	O
case	O
of	O
chorioretinopathy	O
attributable	O
to	O
these	O
drugs	O
.	O

Systemically	O
administered	O
corticosteroids	B
were	O
used	O
in	O
75	O
of	O
210	O
cases	O
;	O
a	O
significant	O
number	O
of	O
posterior	O
subcapsular	O
cataracts	O
was	O
found	O
.	O

Typical	O
keratoconjunctivitis	O
sicca	O
developed	O
in	O
three	O
of	O
the	O
uveitis	O
cases	O
.	O

This	O
association	O
with	O
uveitis	O
and	O
JRA	O
was	O
not	O
noted	O
previously	O
.	O

Surgical	O
treatment	O
of	O
cataracts	O
,	O
band	O
keratopathy	O
,	O
and	O
glaucoma	O
achieved	O
uniformly	O
discouraging	O
results	O
.	O

Cyclophosphamide	B
-	O
induced	O
cystitis	O
in	O
freely	O
-	O
moving	O
conscious	O
rats	O
:	O
behavioral	O
approach	O
to	O
a	O
new	O
model	O
of	O
visceral	O
pain	O
.	O

PURPOSE	O
:	O
To	O
develop	O
a	O
model	O
of	O
visceral	O
pain	O
in	O
rats	O
using	O
a	O
behavioral	O
approach	O
.	O

Cyclophosphamide	B
(	O
CP	B
)	O
,	O
an	O
antitumoral	O
agent	O
known	O
to	O
produce	O
toxic	O
effects	O
on	O
the	O
bladder	O
wall	O
through	O
its	O
main	O
toxic	O
metabolite	O
acrolein	B
,	O
was	O
used	O
to	O
induce	O
cystitis	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
CP	B
was	O
administered	O
at	O
doses	O
of	O
50	O
,	O
100	O
and	O
200	O
mg.	O
/	O
kg	O
.	O

i.p	O
.	O
to	O
male	O
rats	O
,	O
and	O
their	O
behavior	O
observed	O
and	O
scored	O
.	O

The	O
effects	O
of	O
morphine	B
(	O
0.5	O
to	O
4	O
mg.	O
/	O
kg	O
.	O

i.v	O
.	O
)	O
on	O
CP	B
-	O
induced	O
behavioral	O
modifications	O
were	O
tested	O
administered	O
alone	O
and	O
after	O
naloxone	B
(	O
1	O
mg.	O
/	O
kg	O
.	O

s.c	O
.	O
)	O
.	O

In	O
addition	O
,	O
90	O
minutes	O
after	O
CP	B
injection	O
,	O
that	O
is	O
,	O
at	O
the	O
time	O
of	O
administration	O
of	O
morphine	B
,	O
the	O
bladder	O
was	O
removed	O
in	O
some	O
rats	O
for	O
histological	O
examination	O
.	O

Finally	O
,	O
to	O
show	O
that	O
the	O
bladder	O
is	O
essential	O
for	O
the	O
CP	B
-	O
induced	O
behavioral	O
modifications	O
,	O
female	O
rats	O
also	O
received	O
CP	B
at	O
doses	O
of	O
200	O
mg.	O
/	O
kg	O
.	O

i.p	O
.	O
and	O
of	O
20	O
mg	O
.	O

by	O
the	O
intravesical	O
route	O
,	O
and	O
acrolein	B
at	O
doses	O
of	O
0.5	O
mg	O
.	O

by	O
the	O
intravesical	O
route	O
and	O
of	O
5	O
mg.	O
/	O
kg	O
.	O

i.v	O
.	O

RESULTS	O
:	O
CP	B
dose	O
-	O
relatedly	O
induced	O
marked	O
behavioral	O
modifications	O
in	O
male	O
rats	O
:	O
breathing	O
rate	O
decrease	O
,	O
closing	O
of	O
the	O
eyes	O
and	O
occurrence	O
of	O
specific	O
postures	O
.	O

Morphine	B
dose	O
-	O
dependently	O
reversed	O
these	O
behavioral	O
disorders	O
.	O

A	O
dose	O
of	O
0.5	O
mg.	O
/	O
kg	O
.	O
produced	O
a	O
reduction	O
of	O
almost	O
50	O
%	O
of	O
the	O
behavioral	O
score	O
induced	O
by	O
CP	B
200	O
mg.	O
/	O
kg	O
.	O

This	O
effect	O
was	O
completely	O
prevented	O
by	O
pretreatment	O
with	O
naloxone	B
.	O

At	O
the	O
time	O
of	O
administration	O
of	O
morphine	B
,	O
histological	O
modifications	O
of	O
the	O
bladder	O
wall	O
,	O
such	O
as	O
chorionic	O
and	O
muscle	O
layer	O
edema	O
,	O
were	O
observed	O
.	O

In	O
female	O
rats	O
,	O
CP	B
200	O
mg.	O
/	O
kg	O
.	O

i.p	O
.	O
produced	O
the	O
same	O
marked	O
behavioral	O
modifications	O
as	O
those	O
observed	O
in	O
male	O
rats	O
.	O

Administered	O
at	O
the	O
dose	O
of	O
20	O
mg	O
.	O

intravesically	O
,	O
CP	B
did	O
not	O
produce	O
any	O
behavioral	O
effects	O
,	O
whereas	O
acrolein	B
at	O
0.5	O
mg	O
.	O

intravesically	O
induced	O
behavioral	O
modifications	O
identical	O
to	O
those	O
under	O
CP	B
200	O
mg.	O
/	O
kg	O
.	O

i.p	O
.	O
,	O
with	O
the	O
same	O
maximal	O
levels	O
.	O

Conversely	O
,	O
acrolein	B
5	O
mg.	O
/	O
kg	O
.	O

i.v	O
.	O
did	O
not	O
produce	O
any	O
behavioral	O
effects	O
at	O
all	O
.	O

CONCLUSIONS	O
:	O
Overall	O
,	O
these	O
results	O
indicate	O
that	O
this	O
experimental	O
model	O
of	O
CP	B
-	O
induced	O
cystitis	O
may	O
be	O
an	O
interesting	O
new	O
behavioral	O
model	O
of	O
inflammatory	O
visceral	O
pain	O
,	O
allowing	O
a	O
better	O
understanding	O
of	O
these	O
painful	O
syndromes	O
and	O
thus	O
a	O
better	O
therapeutic	O
approach	O
to	O
them	O
.	O

Apomorphine	B
:	O
an	O
underutilized	O
therapy	O
for	O
Parkinson	O
's	O
disease	O
.	O

Apomorphine	B
was	O
the	O
first	O
dopaminergic	O
drug	O
ever	O
used	O
to	O
treat	O
symptoms	O
of	O
Parkinson	O
's	O
disease	O
.	O

While	O
powerful	O
antiparkinsonian	O
effects	O
had	O
been	O
observed	O
as	O
early	O
as	O
1951	O
,	O
the	O
potential	O
of	O
treating	O
fluctuating	O
Parkinson	O
's	O
disease	O
by	O
subcutaneous	O
administration	O
of	O
apomorphine	B
has	O
only	O
recently	O
become	O
the	O
subject	O
of	O
systematic	O
study	O
.	O

A	O
number	O
of	O
small	O
scale	O
clinical	O
trials	O
have	O
unequivocally	O
shown	O
that	O
intermittent	O
subcutaneous	O
apomorphine	B
injections	O
produce	O
antiparkinsonian	O
benefit	O
close	O
if	O
not	O
identical	O
to	O
that	O
seen	O
with	O
levodopa	B
and	O
that	O
apomorphine	B
rescue	O
injections	O
can	O
reliably	O
revert	O
off	O
-	O
periods	O
even	O
in	O
patients	O
with	O
complex	O
on	O
-	O
off	O
motor	O
swings	O
.	O

Continuous	O
subcutaneous	O
apomorphine	B
infusions	O
can	O
reduce	O
daily	O
off	O
-	O
time	O
by	O
more	O
than	O
50	O
%	O
in	O
this	O
group	O
of	O
patients	O
,	O
which	O
appears	O
to	O
be	O
a	O
stronger	O
effect	O
than	O
that	O
generally	O
seen	O
with	O
add	O
-	O
on	O
therapy	O
with	O
oral	O
dopamine	B
agonists	O
or	O
COMT	O
inhibitors	O
.	O

Extended	O
follow	O
-	O
up	O
studies	O
of	O
up	O
to	O
8	O
years	O
have	O
demonstrated	O
long	O
-	O
term	O
persistence	O
of	O
apomorphine	B
efficacy	O
.	O

In	O
addition	O
,	O
there	O
is	O
convincing	O
clinical	O
evidence	O
that	O
monotherapy	O
with	O
continuous	O
subcutaneous	O
apomorphine	B
infusions	O
is	O
associated	O
with	O
marked	O
reductions	O
of	O
preexisting	O
levodopa	B
-	O
induced	O
dyskinesias	O
.	O

The	O
main	O
side	O
effects	O
of	O
subcutaneous	O
apomorphine	B
treatment	O
are	O
related	O
to	O
cutaneous	O
tolerability	O
problems	O
,	O
whereas	O
sedation	O
and	O
psychiatric	O
complications	O
play	O
a	O
lesser	O
role	O
.	O

Given	O
the	O
marked	O
degree	O
of	O
efficacy	O
of	O
subcutaneous	O
apomorphine	B
treatment	O
in	O
fluctuating	O
Parkinson	O
's	O
disease	O
,	O
this	O
approach	O
seems	O
to	O
deserve	O
more	O
widespread	O
clinical	O
use	O
.	O

Probing	O
peripheral	O
and	O
central	O
cholinergic	O
system	O
responses	O
.	O

OBJECTIVE	O
:	O
The	O
pharmacological	O
response	O
to	O
drugs	O
that	O
act	O
on	O
the	O
cholinergic	O
system	O
of	O
the	O
iris	O
has	O
been	O
used	O
to	O
predict	O
deficits	O
in	O
central	O
cholinergic	O
functioning	O
due	O
to	O
diseases	O
such	O
as	O
Alzheimer	O
's	O
disease	O
,	O
yet	O
correlations	O
between	O
central	O
and	O
peripheral	O
responses	O
have	O
not	O
been	O
properly	O
studied	O
.	O

This	O
study	O
assessed	O
the	O
effect	O
of	O
normal	O
aging	O
on	O
(	O
1	O
)	O
the	O
tropicamide	B
-	O
induced	O
increase	O
in	O
pupil	O
diameter	O
,	O
and	O
(	O
2	O
)	O
the	O
reversal	O
of	O
this	O
effect	O
with	O
pilocarpine	B
.	O

Scopolamine	B
was	O
used	O
as	O
a	O
positive	O
control	O
to	O
detect	O
age	O
-	O
dependent	O
changes	O
in	O
central	O
cholinergic	O
functioning	O
in	O
the	O
elderly	O
.	O

DESIGN	O
:	O
Randomized	O
double	O
-	O
blind	O
controlled	O
trial	O
.	O

PARTICIPANTS	O
:	O
Ten	O
healthy	O
elderly	O
(	O
mean	O
age	O
70	O
)	O
and	O
9	O
young	O
(	O
mean	O
age	O
33	O
)	O
volunteers	O
.	O

INTERVENTIONS	O
:	O
Pupil	O
diameter	O
was	O
monitored	O
using	O
a	O
computerized	O
infrared	O
pupillometer	O
over	O
4	O
hours	O
.	O

The	O
study	O
involved	O
4	O
sessions	O
.	O

In	O
1	O
session	O
,	O
tropicamide	B
(	O
20	O
microL	O
,	O
0.01	O
%	O
)	O
was	O
administered	O
to	O
one	O
eye	O
and	O
placebo	O
to	O
the	O
other	O
.	O

In	O
another	O
session	O
,	O
tropicamide	B
(	O
20	O
microL	O
,	O
0.01	O
%	O
)	O
was	O
administered	O
to	O
both	O
eyes	O
,	O
followed	O
23	O
minutes	O
later	O
by	O
the	O
application	O
of	O
pilocarpine	B
(	O
20	O
microL	O
,	O
0.1	O
%	O
)	O
to	O
one	O
eye	O
and	O
placebo	O
to	O
the	O
other	O
.	O

All	O
eye	O
drops	O
were	O
given	O
in	O
a	O
randomized	O
order	O
.	O

In	O
2	O
separate	O
sessions	O
,	O
a	O
single	O
dose	O
of	O
scopolamine	B
(	O
0.5	O
mg	O
,	O
intravenously	O
)	O
or	O
placebo	O
was	O
administered	O
,	O
and	O
the	O
effects	O
on	O
word	O
recall	O
were	O
measured	O
using	O
the	O
Buschke	O
Selective	O
Reminding	O
Test	O
over	O
2	O
hours	O
.	O

OUTCOME	O
MEASURES	O
:	O
Pupil	O
size	O
at	O
time	O
points	O
after	O
administration	O
of	O
tropicamide	B
and	O
pilocarpine	B
;	O
scopolamine	B
-	O
induced	O
impairment	O
in	O
word	O
recall	O
.	O

RESULTS	O
:	O
There	O
was	O
no	O
significant	O
difference	O
between	O
elderly	O
and	O
young	O
volunteers	O
in	O
pupillary	O
response	O
to	O
tropicamide	B
at	O
any	O
time	O
point	O
(	O
p	O
>	O
0.05	O
)	O
.	O

The	O
elderly	O
group	O
had	O
a	O
significantly	O
greater	O
pilocarpine	B
-	O
induced	O
net	O
decrease	O
in	O
pupil	O
size	O
85	O
,	O
125	O
,	O
165	O
and	O
215	O
minutes	O
after	O
administration	O
,	O
compared	O
with	O
the	O
young	O
group	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Compared	O
with	O
the	O
young	O
group	O
,	O
the	O
elderly	O
group	O
had	O
greater	O
scopolamine	B
-	O
induced	O
impairment	O
in	O
word	O
recall	O
60	O
,	O
90	O
and	O
120	O
minutes	O
after	O
administration	O
(	O
p	O
<	O
0.05	O
)	O
.	O

CONCLUSION	O
:	O
There	O
is	O
an	O
age	O
-	O
related	O
pupillary	O
response	O
to	O
pilocarpine	B
that	O
is	O
not	O
found	O
with	O
tropicamide	B
.	O

Thus	O
,	O
pilocarpine	B
may	O
be	O
useful	O
to	O
assess	O
variations	O
in	O
central	O
cholinergic	O
function	O
in	O
elderly	O
patients	O
.	O

High	O
-	O
dose	O
methylprednisolone	B
may	O
do	O
more	O
harm	O
for	O
spinal	O
cord	O
injury	O
.	O

Because	O
of	O
the	O
National	O
Acute	O
Spinal	O
Cord	O
Injury	O
Studies	O
(	O
NASCIS	O
)	O
,	O
high	O
-	O
dose	O
methylprednisolone	B
became	O
the	O
standard	O
of	O
care	O
for	O
the	O
acute	O
spinal	O
cord	O
injury	O
.	O

In	O
the	O
NASCIS	O
,	O
there	O
was	O
no	O
mention	O
regarding	O
the	O
possibility	O
of	O
acute	O
corticosteroid	B
myopathy	O
that	O
high	O
-	O
dose	O
methylprednisolone	B
may	O
cause	O
.	O

The	O
dosage	O
of	O
methylprednisolone	B
recommended	O
by	O
the	O
NASCIS	O
3	O
is	O
the	O
highest	O
dose	O
of	O
steroids	B
ever	O
being	O
used	O
during	O
a	O
2-day	O
period	O
for	O
any	O
clinical	O
condition	O
.	O

We	O
hypothesize	O
that	O
it	O
may	O
cause	O
some	O
damage	O
to	O
the	O
muscle	O
of	O
spinal	O
cord	O
injury	O
patients	O
.	O

Further	O
,	O
steroid	B
myopathy	O
recovers	O
naturally	O
and	O
the	O
neurological	O
improvement	O
shown	O
in	O
the	O
NASCIS	O
may	O
be	O
just	O
a	O
recording	O
of	O
this	O
natural	O
motor	O
recovery	O
from	O
the	O
steroid	B
myopathy	O
,	O
instead	O
of	O
any	O
protection	O
that	O
methylprednisolone	B
offers	O
to	O
the	O
spinal	O
cord	O
injury	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
discussion	O
considering	O
the	O
possibility	O
that	O
the	O
methylprednisolone	B
recommended	O
by	O
NASCIS	O
may	O
cause	O
acute	O
corticosteroid	B
myopathy	O
.	O

Reduced	O
cardiotoxicity	O
and	O
preserved	O
antitumor	O
efficacy	O
of	O
liposome	O
-	O
encapsulated	O
doxorubicin	B
and	O
cyclophosphamide	B
compared	O
with	O
conventional	O
doxorubicin	B
and	O
cyclophosphamide	B
in	O
a	O
randomized	O
,	O
multicenter	O
trial	O
of	O
metastatic	O
breast	O
cancer	O
.	O

PURPOSE	O
:	O
To	O
determine	O
whether	O
Myocet	B
(	O
liposome	O
-	O
encapsulated	O
doxorubicin	B
;	O
The	O
Liposome	O
Company	O
,	O
Elan	O
Corporation	O
,	O
Princeton	O
,	O
NJ	O
)	O
in	O
combination	O
with	O
cyclophosphamide	B
significantly	O
reduces	O
doxorubicin	B
cardiotoxicity	O
while	O
providing	O
comparable	O
antitumor	O
efficacy	O
in	O
first	O
-	O
line	O
treatment	O
of	O
metastatic	O
breast	O
cancer	O
(	O
MBC	O
)	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Two	O
hundred	O
ninety	O
-	O
seven	O
patients	O
with	O
MBC	O
and	O
no	O
prior	O
chemotherapy	O
for	O
metastatic	O
disease	O
were	O
randomized	O
to	O
receive	O
either	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
of	O
Myocet	B
(	O
M	O
)	O
or	O
conventional	O
doxorubicin	B
(	O
A	O
)	O
,	O
in	O
combination	O
with	O
600	O
mg	O
/	O
m	O
(	O
2	O
)	O
of	O
cyclophosphamide	B
(	O
C	O
)	O
,	O
every	O
3	O
weeks	O
until	O
disease	O
progression	O
or	O
unacceptable	O
toxicity	O
.	O

Cardiotoxicity	O
was	O
defined	O
by	O
reductions	O
in	O
left	O
-	O
ventricular	O
ejection	O
fraction	O
,	O
assessed	O
by	O
serial	O
multigated	O
radionuclide	O
angiography	O
scans	O
,	O
or	O
congestive	O
heart	O
failure	O
(	O
CHF	O
)	O
.	O

Antitumor	O
efficacy	O
was	O
assessed	O
by	O
objective	O
tumor	O
response	O
rates	O
(	O
World	O
Health	O
Organization	O
criteria	O
)	O
,	O
time	O
to	O
progression	O
,	O
and	O
survival	O
.	O

RESULTS	O
:	O
Six	O
percent	O
of	O
MC	O
patients	O
versus	O
21	O
%	O
(	O
including	O
five	O
cases	O
of	O
CHF	O
)	O
of	O
AC	O
patients	O
developed	O
cardiotoxicity	O
(	O
P	O
=	O
.0002	O
)	O
.	O

Median	O
cumulative	O
doxorubicin	B
dose	O
at	O
onset	O
was	O
more	O
than	O
2,220	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
MC	O
versus	O
480	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
AC	O
(	O
P	O
=	O
.0001	O
,	O
hazard	O
ratio	O
,	O
5.04	O
)	O
.	O

MC	O
patients	O
also	O
experienced	O
less	O
grade	O
4	O
neutropenia	O
.	O

Antitumor	O
efficacy	O
of	O
MC	O
versus	O
AC	O
was	O
comparable	O
:	O
objective	O
response	O
rates	O
,	O
43	O
%	O
versus	O
43	O
%	O
;	O
median	O
time	O
to	O
progression	O
,	O
5.1	O
%	O
versus	O
5.5	O
months	O
;	O
median	O
time	O
to	O
treatment	O
failure	O
,	O
4.6	O
versus	O
4.4	O
months	O
;	O
and	O
median	O
survival	O
,	O
19	O
versus	O
16	O
months	O
.	O

CONCLUSION	O
:	O
Myocet	B
improves	O
the	O
therapeutic	O
index	O
of	O
doxorubicin	B
by	O
significantly	O
reducing	O
cardiotoxicity	O
and	O
grade	O
4	O
neutropenia	O
and	O
provides	O
comparable	O
antitumor	O
efficacy	O
,	O
when	O
used	O
in	O
combination	O
with	O
cyclophosphamide	B
as	O
first	O
-	O
line	O
therapy	O
for	O
MBC	O
.	O

Fluconazole	B
-	O
induced	O
torsade	O
de	O
pointes	O
.	O

OBJECTIVE	O
:	O
To	O
present	O
a	O
case	O
of	O
fluconazole	B
-	O
associated	O
torsade	O
de	O
pointes	O
(	O
TDP	O
)	O
and	O
discuss	O
fluconazole	B
's	O
role	O
in	O
causing	O
TDP	O
.	O

CASE	O
SUMMARY	O
:	O
A	O
68-year	O
-	O
old	O
white	O
woman	O
with	O
Candida	O
glabrata	O
isolated	O
from	O
a	O
presacral	O
abscess	O
developed	O
TDP	O
eight	O
days	O
after	O
commencing	O
oral	O
fluconazole	B
The	O
patient	O
had	O
no	O
other	O
risk	O
factors	O
for	O
TDP	O
,	O
including	O
coronary	O
artery	O
disease	O
,	O
cardiomyopathy	O
,	O
congestive	O
heart	O
failure	O
,	O
and	O
electrolyte	O
abnormalities	O
There	O
was	O
a	O
temporal	O
association	O
between	O
the	O
initiation	O
of	O
fluconazole	B
and	O
TDP	O
.	O

The	O
TDP	O
resolved	O
when	O
fluconazole	B
was	O
discontinued	O
;	O
however	O
,	O
the	O
patient	O
continued	O
to	O
have	O
premature	O
ventricular	O
contractions	O
and	O
nonsustained	O
ventricular	O
tachycardia	O
(	O
NSVT	O
)	O
until	O
six	O
days	O
after	O
drug	O
cessation	O
DISCUSSION	O
:	O
Use	O
of	O
the	O
Naranjo	O
probability	O
scale	O
indicates	O
a	O
probable	O
relationship	O
between	O
the	O
use	O
of	O
fluconazole	B
and	O
the	O
development	O
of	O
TDP	O
.	O

The	O
possible	O
mechanism	O
is	O
depression	O
of	O
rapidly	O
activating	O
delayed	O
rectifier	O
potassium	B
currents	O
.	O

In	O
our	O
patient	O
,	O
there	O
was	O
no	O
other	O
etiology	O
identified	O
that	O
could	O
explain	O
QT	O
prolongation	O
or	O
TDP	O
The	O
complete	O
disappearance	O
of	O
NSVT	O
and	O
premature	O
ventricular	O
contractions	O
followed	O
by	O
normalization	O
of	O
QT	O
interval	O
after	O
the	O
drug	O
was	O
stopped	O
strongly	O
suggests	O
fluconazole	B
as	O
the	O
etiology	O
.	O

CONCLUSIONS	O
:	O
Clinicians	O
should	O
be	O
aware	O
that	O
fluconazole	B
,	O
even	O
at	O
low	O
doses	O
,	O
may	O
cause	O
prolongation	O
of	O
the	O
QT	O
interval	O
,	O
leading	O
to	O
TDP	O
.	O

Serial	O
electrocardiographic	O
monitoring	O
may	O
be	O
considered	O
when	O
fluconazole	B
is	O
administered	O
in	O
patients	O
who	O
are	O
at	O
risk	O
for	O
ventricular	O
arrhythmias	O
.	O

Cutaneous	O
leucocytoclastic	O
vasculitis	O
associated	O
with	O
oxacillin	B
.	O

A	O
67-year	O
-	O
old	O
man	O
who	O
was	O
treated	O
with	O
oxacillin	B
for	O
one	O
week	O
because	O
of	O
Staphylococcus	O
aureus	O
bacteremia	O
,	O
developed	O
renal	O
failure	O
and	O
diffuse	O
,	O
symmetric	O
,	O
palpable	O
purpuric	O
lesions	O
on	O
his	O
feet	O
.	O

Necrotic	O
blisters	O
were	O
noted	O
on	O
his	O
fingers	O
.	O

Skin	O
biopsies	O
showed	O
findings	O
diagnostic	O
of	O
leucocytoclastic	O
vasculitis	O
.	O

Oxacillin	B
was	O
discontinued	O
and	O
patient	O
was	O
treated	O
with	O
corticosteroids	B
.	O

The	O
rash	O
disappeared	O
after	O
three	O
weeks	O
and	O
renal	O
function	O
returned	O
to	O
normal	O
.	O

Leucocytoclastic	O
vasculitis	O
presents	O
as	O
palpable	O
purpura	O
of	O
the	O
lower	O
extremities	O
often	O
accompanied	O
by	O
abdominal	O
pain	O
,	O
arthralgia	O
,	O
and	O
renal	O
involvement	O
.	O

Etiologic	O
factors	O
or	O
associated	O
disorders	O
include	O
infections	O
,	O
medications	O
,	O
collagen	O
vascular	O
disease	O
and	O
neoplasia	O
.	O

However	O
,	O
in	O
half	O
of	O
the	O
cases	O
no	O
etiologic	O
factor	O
is	O
identified	O
.	O

Usually	O
it	O
is	O
a	O
self	O
-	O
limited	O
disorder	O
,	O
but	O
corticosteroid	B
therapy	O
may	O
be	O
needed	O
in	O
life	O
-	O
threatening	O
cases	O
since	O
early	O
treatment	O
with	O
corticosteroids	B
in	O
severe	O
cases	O
can	O
prevent	O
complications	O
.	O

Oxacillin	B
should	O
be	O
included	O
among	O
the	O
drugs	O
that	O
can	O
cause	O
leucocytoclastic	O
vasculitis	O
.	O

Preliminary	O
efficacy	O
assessment	O
of	O
intrathecal	O
injection	O
of	O
an	O
American	O
formulation	O
of	O
adenosine	B
in	O
humans	O
.	O

BACKGROUND	O
:	O
Preclinical	O
studies	O
of	O
intrathecal	O
adenosine	B
suggest	O
it	O
may	O
be	O
effective	O
in	O
the	O
treatment	O
of	O
acute	O
and	O
chronic	O
pain	O
in	O
humans	O
,	O
and	O
preliminary	O
studies	O
in	O
volunteers	O
and	O
patients	O
with	O
a	O
Swedish	O
formulation	O
of	O
adenosine	B
suggests	O
it	O
may	O
be	O
effective	O
in	O
hypersensitivity	O
states	O
but	O
not	O
with	O
acute	O
noxious	O
stimulation	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
screen	O
for	O
efficacy	O
of	O
a	O
different	O
formulation	O
of	O
adenosine	B
marketed	O
in	O
the	O
US	O
,	O
using	O
both	O
acute	O
noxious	O
stimulation	O
and	O
capsaicin	B
-	O
evoked	O
mechanical	O
hypersensitivity	O
.	O

METHODS	O
:	O
Following	O
Food	O
and	O
Drug	O
Administration	O
and	O
institutional	O
review	O
board	O
approval	O
and	O
written	O
informed	O
consent	O
,	O
65	O
volunteers	O
were	O
studied	O
in	O
two	O
trials	O
:	O
an	O
open	O
-	O
label	O
,	O
dose	O
-	O
escalating	O
trial	O
with	O
intrathecal	O
adenosine	B
doses	O
of	O
0.25	O
-	O
2.0	O
mg	O
and	O
a	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
of	O
adenosine	B
,	O
2	O
mg	O
.	O

Cerebrospinal	O
fluid	O
was	O
obtained	O
for	O
pharmacokinetic	O
analysis	O
,	O
and	O
pain	O
ratings	O
in	O
response	O
to	O
acute	O
heat	O
stimuli	O
and	O
areas	O
of	O
mechanical	O
hyperalgesia	O
and	O
allodynia	O
after	O
intradermal	O
capsaicin	B
injection	O
were	O
determined	O
.	O

RESULTS	O
:	O
Adenosine	B
produced	O
no	O
effect	O
on	O
pain	O
report	O
to	O
acute	O
noxious	O
thermal	O
or	O
chemical	O
stimulation	O
but	O
reduced	O
mechanical	O
hyperalgesia	O
and	O
allodynia	O
from	O
intradermal	O
capsaicin	B
injection	O
for	O
at	O
least	O
24	O
h.	O
In	O
contrast	O
,	O
residence	O
time	O
of	O
adenosine	B
in	O
cerebrospinal	O
fluid	O
was	O
short	O
(	O
<	O
4	O
h	O
)	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
show	O
selective	O
inhibition	O
by	O
intrathecal	O
adenosine	B
of	O
hypersensitivity	O
,	O
presumed	O
to	O
reflect	O
central	O
sensitization	O
in	O
humans	O
after	O
peripheral	O
capsaicin	B
injection	O
.	O

The	O
long	O
-	O
lasting	O
effect	O
is	O
consistent	O
with	O
that	O
observed	O
in	O
preliminary	O
reports	O
of	O
patients	O
with	O
chronic	O
neuropathic	O
pain	O
and	O
is	O
not	O
due	O
to	O
prolonged	O
residence	O
of	O
adenosine	B
in	O
cerebrospinal	O
fluid	O
.	O

Delayed	O
-	O
onset	O
heparin	B
-	O
induced	O
thrombocytopenia	O
.	O

BACKGROUND	O
:	O
Heparin	B
-	O
induced	O
thrombocytopenia	O
presents	O
5	O
to	O
12	O
days	O
after	O
heparin	B
exposure	O
,	O
with	O
or	O
without	O
arterial	O
or	O
venous	O
thromboemboli	O
.	O

Delayed	O
recognition	O
and	O
treatment	O
of	O
heparin	B
-	O
induced	O
thrombocytopenia	O
contribute	O
to	O
poor	O
patient	O
outcomes	O
.	O

OBJECTIVE	O
:	O
To	O
describe	O
and	O
increase	O
awareness	O
of	O
a	O
clinical	O
scenario	O
in	O
which	O
the	O
onset	O
or	O
manifestations	O
of	O
heparin	B
-	O
induced	O
thrombocytopenia	O
are	O
delayed	O
.	O

DESIGN	O
:	O
Retrospective	O
case	O
series	O
.	O

SETTING	O
:	O
Three	O
large	O
urban	O
hospitals	O
(	O
with	O
active	O
cardiovascular	O
surgery	O
programs	O
)	O
.	O

PATIENTS	O
:	O
14	O
patients	O
seen	O
over	O
a	O
3-year	O
period	O
in	O
whom	O
heparin	B
-	O
induced	O
thrombocytopenia	O
became	O
apparent	O
on	O
delayed	O
presentation	O
with	O
thromboembolic	O
complications	O
.	O

MEASUREMENTS	O
:	O
Platelet	O
counts	O
,	O
onset	O
of	O
objectively	O
determined	O
thromboembolism	O
,	O
results	O
of	O
heparin	B
-	O
induced	O
platelet	O
factor	O
4	O
antibody	O
tests	O
,	O
and	O
outcomes	O
.	O

RESULTS	O
:	O
Patients	O
went	O
home	O
after	O
hospitalizations	O
that	O
had	O
included	O
heparin	B
exposure	O
--	O
in	O
most	O
cases	O
,	O
with	O
no	O
thrombocytopenia	O
recognized	O
--	O
only	O
to	O
return	O
to	O
the	O
hospital	O
(	O
median	O
,	O
day	O
14	O
)	O
with	O
thromboembolic	O
complications	O
.	O

Thromboemboli	O
were	O
venous	O
(	O
12	O
patients	O
,	O
7	O
with	O
pulmonary	O
emboli	O
)	O
or	O
arterial	O
(	O
4	O
patients	O
)	O
or	O
both	O
.	O

Platelet	O
counts	O
were	O
mildly	O
decreased	O
in	O
all	O
but	O
2	O
patients	O
on	O
second	O
presentation	O
.	O

On	O
readmission	O
,	O
11	O
patients	O
received	O
therapeutic	O
heparin	B
,	O
which	O
worsened	O
the	O
patients	O
'	O
clinical	O
condition	O
and	O
,	O
in	O
all	O
11	O
cases	O
,	O
decreased	O
the	O
platelet	O
count	O
(	O
mean	O
at	O
readmission	O
,	O
143	O
x	O
10	O
(	O
9	O
)	O
cells	O
/	O
L	O
;	O
mean	O
nadir	O
after	O
heparin	B
re	O
-	O
exposure	O
,	O
39	O
x	O
10	O
(	O
9	O
)	O
cells	O
/	O
L	O
)	O
.	O

Results	O
of	O
serologic	O
tests	O
for	O
heparin	B
-	O
induced	O
antibodies	O
were	O
positive	O
in	O
all	O
patients	O
.	O

Subsequent	O
treatments	O
included	O
alternative	O
anticoagulants	O
(	O
11	O
patients	O
)	O
,	O
thrombolytic	O
drugs	O
(	O
3	O
patients	O
)	O
,	O
inferior	O
vena	O
cava	O
filters	O
(	O
3	O
patients	O
)	O
and	O
,	O
eventually	O
,	O
warfarin	B
(	O
11	O
patients	O
)	O
.	O

Three	O
patients	O
died	O
.	O

CONCLUSIONS	O
:	O
Delayed	O
-	O
onset	O
heparin	B
-	O
induced	O
thrombocytopenia	O
is	O
increasingly	O
being	O
recognized	O
.	O

To	O
avoid	O
disastrous	O
outcomes	O
,	O
physicians	O
must	O
consider	O
heparin	B
-	O
induced	O
thrombocytopenia	O
whenever	O
a	O
recently	O
hospitalized	O
patient	O
returns	O
with	O
thromboembolism	O
;	O
therapy	O
with	O
alternative	O
anticoagulants	O
,	O
not	O
heparin	B
,	O
should	O
be	O
initiated	O
.	O

Torsade	O
de	O
pointes	O
induced	O
by	O
metoclopramide	B
in	O
an	O
elderly	O
woman	O
with	O
preexisting	O
complete	O
left	O
bundle	O
branch	O
block	O
.	O

There	O
is	O
a	O
growing	O
list	O
of	O
drugs	O
implicated	O
in	O
acquired	O
long	O
QT	O
syndrome	O
and	O
torsade	O
de	O
pointes	O
.	O

However	O
,	O
the	O
torsadogenic	O
potential	O
of	O
metoclopramide	B
,	O
a	O
commonly	O
used	O
antiemetic	O
and	O
prokinetic	O
drug	O
,	O
has	O
not	O
been	O
reported	O
in	O
the	O
literature	O
,	O
despite	O
its	O
chemical	O
similarity	O
to	O
procainamide	B
.	O

We	O
report	O
on	O
a	O
92-year	O
-	O
old	O
woman	O
with	O
preexisting	O
complete	O
left	O
bundle	O
branch	O
block	O
who	O
developed	O
torsade	O
de	O
pointes	O
after	O
intravenous	O
and	O
oral	O
administration	O
of	O
metoclopramide	B
.	O

This	O
patient	O
also	O
developed	O
torsade	O
de	O
pointes	O
when	O
cisapride	B
and	O
erythromycin	B
were	O
given	O
simultaneously	O
.	O

These	O
two	O
episodes	O
were	O
suppressed	O
successfully	O
after	O
discontinuing	O
the	O
offending	O
drugs	O
and	O
administering	O
class	O
IB	O
drugs	O
.	O

This	O
is	O
the	O
first	O
documentation	O
that	O
metoclopramide	B
provokes	O
torsade	O
de	O
pointes	O
clinically	O
.	O

Metoclopramide	B
should	O
be	O
used	O
cautiously	O
in	O
patients	O
with	O
a	O
risk	O
of	O
torsade	O
de	O
pointes	O
.	O

Steroid	B
structure	O
and	O
pharmacological	O
properties	O
determine	O
the	O
anti	O
-	O
amnesic	O
effects	O
of	O
pregnenolone	B
sulphate	I
in	O
the	O
passive	O
avoidance	O
task	O
in	O
rats	O
.	O

Pregnenolone	B
sulphate	I
(	O
PREGS	B
)	O
has	O
generated	O
interest	O
as	O
one	O
of	O
the	O
most	O
potent	O
memory	O
-	O
enhancing	O
neurosteroids	O
to	O
be	O
examined	O
in	O
rodent	O
learning	O
studies	O
,	O
with	O
particular	O
importance	O
in	O
the	O
ageing	O
process	O
.	O

The	O
mechanism	O
by	O
which	O
this	O
endogenous	O
steroid	B
enhances	O
memory	O
formation	O
is	O
hypothesized	O
to	O
involve	O
actions	O
on	O
glutamatergic	O
and	O
GABAergic	O
systems	O
.	O

This	O
hypothesis	O
stems	O
from	O
findings	O
that	O
PREGS	B
is	O
a	O
potent	O
positive	O
modulator	O
of	O
N	B
-	I
methyl	I
-	I
d	I
-	I
aspartate	I
receptors	O
(	O
NMDARs	O
)	O
and	O
a	O
negative	O
modulator	O
of	O
gamma	B
-	I
aminobutyric	I
acid	I
(	O
A	O
)	O
receptors	O
(	O
GABA	B
(	O
A	O
)	O
Rs	O
)	O
.	O

Moreover	O
,	O
PREGS	B
is	O
able	O
to	O
reverse	O
the	O
amnesic	O
-	O
like	O
effects	O
of	O
NMDAR	O
and	O
GABA	B
(	O
A	O
)	O
R	O
ligands	O
.	O

To	O
investigate	O
this	O
hypothesis	O
,	O
the	O
present	O
study	O
in	O
rats	O
examined	O
the	O
memory	O
-	O
altering	O
abilities	O
of	O
structural	O
analogs	O
of	O
PREGS	B
,	O
which	O
differ	O
in	O
their	O
modulation	O
of	O
NMDAR	O
and/or	O
GABA	B
(	O
A	O
)	O
R	O
function	O
.	O

The	O
analogs	O
tested	O
were	O
:	O
11-ketopregnenolone	B
sulphate	I
(	O
an	O
agent	O
that	O
is	O
inactive	O
at	O
GABA	B
(	O
A	O
)	O
Rs	O
and	O
NMDARs	O
)	O
,	O
epipregnanolone	B
(	I
[	I
3beta	I
-	I
hydroxy-5beta	I
-	I
pregnan-20-one	I
]	I
sulphate	I
,	O
an	O
inhibitor	O
of	O
both	O
GABA	B
(	O
A	O
)	O
Rs	O
and	O
NMDARs	O
)	O
,	O
and	O
a	O
newly	O
synthesized	O
(	O
-	O
)	O
PREGS	B
enantiomer	O
(	O
which	O
is	O
identical	O
to	O
PREGS	B
in	O
effects	O
on	O
GABA	B
(	O
A	O
)	O
Rs	O
and	O
NMDARs	O
)	O
.	O

The	O
memory	O
-	O
enhancing	O
effects	O
of	O
PREGS	B
and	O
its	O
analogs	O
were	O
tested	O
in	O
the	O
passive	O
avoidance	O
task	O
using	O
the	O
model	O
of	O
scopolamine	B
-	O
induced	O
amnesia	O
.	O

Both	O
PREGS	B
and	O
its	O
(	O
-	O
)	O
enantiomer	O
blocked	O
the	O
effects	O
of	O
scopolamine	B
.	O

The	O
results	O
show	O
that	O
,	O
unlike	O
PREGS	B
,	O
11-ketopregnenolone	B
sulphate	I
and	O
epipregnanolone	B
sulphate	I
failed	O
to	O
block	O
the	O
effect	O
of	O
scopolamine	B
,	O
suggesting	O
that	O
altering	O
the	O
modulation	O
of	O
NMDA	B
receptors	O
diminishes	O
the	O
memory	O
-	O
enhancing	O
effects	O
of	O
PREGS	B
.	O

Moreover	O
,	O
enantioselectivity	O
was	O
demonstrated	O
by	O
the	O
ability	O
of	O
natural	O
PREGS	B
to	O
be	O
an	O
order	O
of	O
magnitude	O
more	O
effective	O
than	O
its	O
synthetic	O
enantiomer	O
in	O
reversing	O
scopolamine	B
-	O
induced	O
amnesia	O
.	O

These	O
results	O
identify	O
a	O
novel	O
neuropharmacological	O
site	O
for	O
the	O
modulation	O
of	O
memory	O
processes	O
by	O
neuroactive	O
steroids	B
.	O

Activation	O
of	O
poly	B
(	I
ADP	I
-	I
ribose	I
)	I
polymerase	O
contributes	O
to	O
development	O
of	O
doxorubicin	B
-	O
induced	O
heart	O
failure	O
.	O

Activation	O
of	O
the	O
nuclear	O
enzyme	O
poly	B
(	I
ADP	I
-	I
ribose	I
)	I
polymerase	O
(	O
PARP	O
)	O
by	O
oxidant	O
-	O
mediated	O
DNA	O
damage	O
is	O
an	O
important	O
pathway	O
of	O
cell	O
dysfunction	O
and	O
tissue	O
injury	O
in	O
conditions	O
associated	O
with	O
oxidative	O
stress	O
.	O

Increased	O
oxidative	O
stress	O
is	O
a	O
major	O
factor	O
implicated	O
in	O
the	O
cardiotoxicity	O
of	O
doxorubicin	B
(	O
DOX	B
)	O
,	O
a	O
widely	O
used	O
antitumor	O
anthracycline	B
antibiotic	O
.	O

Thus	O
,	O
we	O
hypothesized	O
that	O
the	O
activation	O
of	O
PARP	O
may	O
contribute	O
to	O
the	O
DOX	B
-	O
induced	O
cardiotoxicity	O
.	O

Using	O
a	O
dual	O
approach	O
of	O
PARP-1	O
suppression	O
,	O
by	O
genetic	O
deletion	O
or	O
pharmacological	O
inhibition	O
with	O
the	O
phenanthridinone	O
PARP	O
inhibitor	O
PJ34	B
,	O
we	O
now	O
demonstrate	O
the	O
role	O
of	O
PARP	O
in	O
the	O
development	O
of	O
cardiac	O
dysfunction	O
induced	O
by	O
DOX	B
.	O

PARP-1+	O
/	O
+	O
and	O
PARP-1-	O
/	O
-	O
mice	O
received	O
a	O
single	O
injection	O
of	O
DOX	B
(	O
25	O
mg	O
/	O
kg	O
i.p	O
)	O
.	O

Five	O
days	O
after	O
DOX	B
administration	O
,	O
left	O
ventricular	O
performance	O
was	O
significantly	O
depressed	O
in	O
PARP-1+	O
/	O
+	O
mice	O
,	O
but	O
only	O
to	O
a	O
smaller	O
extent	O
in	O
PARP-1-	O
/	O
-	O
ones	O
.	O

Similar	O
experiments	O
were	O
conducted	O
in	O
BALB	O
/	O
c	O
mice	O
treated	O
with	O
PJ34	B
or	O
vehicle	O
.	O

Treatment	O
with	O
a	O
PJ34	B
significantly	O
improved	O
cardiac	O
dysfunction	O
and	O
increased	O
the	O
survival	O
of	O
the	O
animals	O
.	O

In	O
addition	O
PJ34	B
significantly	O
reduced	O
the	O
DOX	B
-	O
induced	O
increase	O
in	O
the	O
serum	O
lactate	B
dehydrogenase	O
and	O
creatine	B
kinase	O
activities	O
but	O
not	O
metalloproteinase	O
activation	O
in	O
the	O
heart	O
.	O

Thus	O
,	O
PARP	O
activation	O
contributes	O
to	O
the	O
cardiotoxicity	O
of	O
DOX	B
.	O

PARP	O
inhibitors	O
may	O
exert	O
protective	O
effects	O
against	O
the	O
development	O
of	O
severe	O
cardiac	O
complications	O
associated	O
with	O
the	O
DOX	B
treatment	O
.	O

Nicotine	B
potentiation	O
of	O
morphine	B
-	O
induced	O
catalepsy	O
in	O
mice	O
.	O

In	O
the	O
present	O
study	O
,	O
effects	O
of	O
nicotine	B
on	O
catalepsy	O
induced	O
by	O
morphine	B
in	O
mice	O
have	O
been	O
investigated	O
.	O

Morphine	B
but	O
not	O
nicotine	B
induced	O
a	O
dose	O
-	O
dependent	O
catalepsy	O
.	O

The	O
response	O
of	O
morphine	B
was	O
potentiated	O
by	O
nicotine	B
.	O

Intraperitoneal	O
administration	O
of	O
atropine	B
,	O
naloxone	B
,	O
mecamylamine	B
,	O
and	O
hexamethonium	B
to	O
mice	O
reduced	O
catalepsy	O
induced	O
by	O
a	O
combination	O
of	O
morphine	B
with	O
nicotine	B
.	O

Intracerebroventricular	O
injection	O
of	O
atropine	B
,	O
hexamethonium	B
,	O
and	O
naloxone	B
also	O
decreased	O
catalepsy	O
induced	O
by	O
morphine	B
plus	O
nicotine	B
.	O

Intraperitoneal	O
administration	O
of	O
atropine	B
,	O
but	O
not	O
intraperitoneal	O
or	O
intracerebroventricular	O
injection	O
of	O
hexamethonium	B
,	O
decreased	O
the	O
effect	O
of	O
a	O
single	O
dose	O
of	O
morphine	B
.	O

It	O
was	O
concluded	O
that	O
morphine	B
catalepsy	O
can	O
be	O
elicited	O
by	O
opioid	O
and	O
cholinergic	O
receptors	O
,	O
and	O
the	O
potentiation	O
of	O
morphine	B
induced	O
by	O
nicotine	B
may	O
also	O
be	O
mediated	O
through	O
cholinergic	O
receptor	O
mechanisms	O
.	O

Risperidone	B
-	O
associated	O
,	O
benign	O
transient	O
visual	O
disturbances	O
in	O
schizophrenic	O
patients	O
with	O
a	O
past	O
history	O
of	O
LSD	B
abuse	O
.	O

Two	O
schizophrenic	O
patients	O
,	O
who	O
had	O
a	O
prior	O
history	O
of	O
LSD	B
abuse	O
and	O
who	O
had	O
previously	O
developed	O
EPS	O
with	O
classic	O
antipsychotics	O
,	O
were	O
successfully	O
treated	O
with	O
risperidone	B
.	O

They	O
both	O
reported	O
short	O
episodes	O
of	O
transient	O
visual	O
disturbances	O
,	O
which	O
appeared	O
immediately	O
after	O
starting	O
treatment	O
with	O
risperidone	B
.	O

This	O
imagery	O
resembled	O
visual	O
disturbances	O
previously	O
experienced	O
as	O
"	O
flashbacks	O
"	O
related	O
to	O
prior	O
LSD	B
consumption	O
.	O

Risperidone	B
administration	O
was	O
continued	O
and	O
the	O
visual	O
disturbances	O
gradually	O
wore	O
off	O
.	O

During	O
a	O
six	O
-	O
month	O
follow	O
-	O
up	O
period	O
,	O
there	O
was	O
no	O
recurrence	O
of	O
visual	O
disturbances	O
.	O

This	O
phenomenon	O
may	O
be	O
interpreted	O
as	O
a	O
benign	O
,	O
short	O
-	O
term	O
and	O
self	O
-	O
limiting	O
side	O
effect	O
which	O
does	O
not	O
contraindicate	O
the	O
use	O
of	O
risperidone	B
or	O
interfere	O
with	O
treatment	O
.	O

Conclusions	O
based	O
on	O
two	O
case	O
reports	O
should	O
be	O
taken	O
with	O
appropriate	O
caution	O
.	O

Ketamine	B
in	O
war	O
/	O
tropical	O
surgery	O
(	O
a	O
final	O
tribute	O
to	O
the	O
racemic	O
mixture	O
)	O
.	O

A	O
technique	O
of	O
continuous	O
intravenous	O
anaesthesia	O
with	O
ketamine	B
was	O
used	O
successfully	O
during	O
the	O
Somalia	O
civil	O
war	O
in	O
1994	O
and	O
in	O
north	O
Uganda	O
in	O
1999	O
for	O
64	O
operations	O
in	O
62	O
patients	O
,	O
aged	O
from	O
6	O
weeks	O
to	O
70	O
years	O
,	O
undergoing	O
limb	O
and	O
abdominal	O
surgery	O
including	O
caesarian	O
sections	O
and	O
interventions	O
in	O
neonates	O
.	O

Operations	O
lasting	O
up	O
to	O
2h	O
could	O
be	O
performed	O
in	O
the	O
absence	O
of	O
sophisticated	O
equipment	O
such	O
as	O
pulse	O
oximeters	O
or	O
ventilators	O
in	O
patients	O
on	O
spontaneous	O
ventilation	O
breathing	O
air	O
/	O
oxygen	B
only	O
.	O

After	O
premedication	O
with	O
diazepam	B
,	O
glycopyrrolate	B
and	O
local	O
anaesthesia	O
,	O
and	O
induction	O
with	O
standard	O
doses	O
of	O
ketamine	B
,	O
a	O
maintenance	O
dose	O
of	O
10	O
-	O
20	O
microg	O
/	O
kg	O
/	O
min	O
of	O
ketamine	B
proved	O
safe	O
and	O
effective	O
.	O

Emphasis	O
was	O
placed	O
on	O
bedside	O
clinical	O
monitoring	O
,	O
relying	O
heavily	O
on	O
the	O
heart	O
rate	O
.	O

Diazepam	B
,	O
unless	O
contraindicated	O
or	O
risky	O
,	O
remains	O
the	O
only	O
necessary	O
complementary	O
drug	O
to	O
ketamine	B
as	O
it	O
buffers	O
its	O
cardiovascular	O
response	O
and	O
decreases	O
the	O
duration	O
and	O
intensity	O
of	O
operative	O
and	O
postoperative	O
hallucinations	O
.	O

Local	O
anaesthetic	O
blocks	O
were	O
useful	O
in	O
decreasing	O
the	O
requirement	O
for	O
postoperative	O
analgesia	O
.	O

An	O
antisialogue	O
was	O
usually	O
unnecessary	O
in	O
operations	O
lasting	O
up	O
to	O
2	O
h	O
,	O
glycopyrrolate	B
being	O
the	O
best	O
choice	O
for	O
its	O
lowest	O
psychotropic	O
and	O
chronotropic	O
effects	O
,	O
especially	O
in	O
a	O
hot	O
climate	O
.	O

Experience	O
in	O
war	O
/	O
tropical	O
settings	O
suggests	O
this	O
technique	O
could	O
be	O
useful	O
in	O
civilian	O
contexts	O
such	O
as	O
outdoor	O
life	O
-	O
saving	O
emergency	O
surgery	O
or	O
in	O
mass	O
casualties	O
where	O
,	O
e.g.	O
amputation	O
and	O
rapid	O
extrication	O
were	O
required	O
.	O

Pyeloureteral	O
filling	O
defects	O
associated	O
with	O
systemic	O
anticoagulation	O
:	O
a	O
case	O
report	O
.	O

The	O
etiology	O
of	O
pyeloureteritis	O
cystica	O
has	O
long	O
been	O
attributed	O
to	O
chronic	O
infection	O
and	O
inflammation	O
.	O

A	O
case	O
is	O
presented	O
that	O
is	O
unique	O
in	O
that	O
the	O
acute	O
onset	O
and	O
the	O
rapid	O
resolution	O
of	O
pyeloureteral	O
filling	O
defects	O
in	O
this	O
patient	O
were	O
documented	O
by	O
radiography	O
.	O

There	O
is	O
no	O
evidence	O
of	O
antecedent	O
or	O
concurrent	O
infection	O
in	O
this	O
patient	O
.	O

The	O
disease	O
occurred	O
subsequent	O
to	O
the	O
initiation	O
of	O
heparin	B
therapy	O
for	O
suspected	O
pelvic	O
thrombophlebitis	O
and	O
cleared	O
rapidly	O
subsequent	O
to	O
its	O
discontinuation	O
.	O

The	O
rate	O
of	O
resolution	O
of	O
the	O
radiographic	O
findings	O
may	O
be	O
helpful	O
in	O
distinguishing	O
between	O
true	O
pyeloureteritis	O
cystica	O
and	O
submucosal	O
hemorrhage	O
.	O

Protective	O
effect	O
of	O
edaravone	B
against	O
streptomycin	B
-	O
induced	O
vestibulotoxicity	O
in	O
the	O
guinea	O
pig	O
.	O

This	O
study	O
investigated	O
alleviation	O
of	O
streptomycin	B
-	O
induced	O
vestibulotoxicity	O
by	O
edaravone	B
in	O
guinea	O
pigs	O
.	O

Edaravone	B
,	O
a	O
free	O
radical	O
scavenger	O
,	O
has	O
potent	O
free	O
radical	O
quenching	O
action	O
and	O
is	O
used	O
in	O
clinical	O
practice	O
to	O
treat	O
cerebral	O
infarction	O
.	O

Streptomycin	B
was	O
administered	O
to	O
the	O
inner	O
ear	O
by	O
osmotic	O
pump	O
for	O
24	O
h	O
,	O
and	O
edaravone	B
(	O
n=8	O
)	O
or	O
saline	O
(	O
n=6	O
)	O
was	O
intraperitoneally	O
injected	O
once	O
a	O
day	O
for	O
7	O
days	O
.	O

We	O
observed	O
horizontal	O
vestibulo	O
-	O
ocular	O
reflex	O
as	O
a	O
marker	O
of	O
postoperative	O
vestibular	O
function	O
.	O

Animals	O
injected	O
with	O
saline	O
showed	O
statistically	O
smaller	O
gains	O
than	O
those	O
injected	O
with	O
edaravone	B
.	O

These	O
results	O
suggest	O
that	O
edaravone	B
suppresses	O
streptomycin	B
-	O
induced	O
vestibulotoxicity	O
.	O

Levodopa	B
-	O
induced	O
oromandibular	O
dystonia	O
in	O
progressive	O
supranuclear	O
palsy	O
.	O

Levodopa	B
-	O
induced	O
dyskinesias	O
have	O
been	O
reported	O
in	O
Parkinson	O
's	O
disease	O
and	O
multiple	O
system	O
atrophy	O
.	O

Cranial	O
dystonias	O
are	O
rare	O
in	O
patients	O
with	O
progressive	O
supranuclear	O
palsy	O
(	O
PSP	O
)	O
.	O

In	O
this	O
report	O
we	O
describe	O
an	O
unusual	O
case	O
of	O
reversible	O
levodopa	B
-	O
induced	O
Oromandibular	O
dystonia	O
(	O
OMD	O
)	O
in	O
a	O
PSP	O
patient	O
to	O
highlight	O
the	O
importance	O
of	O
recognizing	O
this	O
drug	O
related	O
complication	O
in	O
the	O
management	O
of	O
PSP	O
,	O
and	O
discuss	O
the	O
possible	O
underlying	O
pathophysiology	O
.	O

Case	O
report	O
:	O
Dexatrim	B
(	O
Phenylpropanolamine	B
)	O
as	O
a	O
cause	O
of	O
myocardial	O
infarction	O
.	O

Phenylpropanolamine	B
(	O
PPA	B
)	O
is	O
a	O
sympathetic	O
amine	B
used	O
in	O
over	O
-	O
the	O
-	O
counter	O
cold	O
remedies	O
and	O
weight	O
-	O
control	O
preparations	O
worldwide	O
.	O

Its	O
use	O
has	O
been	O
associated	O
with	O
hypertensive	O
episodes	O
and	O
hemorrhagic	O
strokes	O
in	O
younger	O
women	O
.	O

Several	O
reports	O
have	O
linked	O
the	O
abuse	O
of	O
PPA	B
with	O
myocardial	O
injury	O
,	O
especially	O
when	O
overdose	O
is	O
involved	O
.	O

We	O
report	O
here	O
the	O
first	O
case	O
of	O
Dexatrim	B
(	O
PPA	B
)	O
-induced	O
myocardial	O
injury	O
in	O
a	O
young	O
woman	O
who	O
was	O
using	O
it	O
at	O
recommended	O
doses	O
for	O
weight	O
control	O
.	O

In	O
addition	O
,	O
we	O
review	O
the	O
7	O
other	O
cases	O
of	O
PPA	B
related	O
myocardial	O
injury	O
that	O
have	O
been	O
reported	O
so	O
far	O
.	O

Physicians	O
and	O
patients	O
should	O
be	O
alert	O
to	O
the	O
potential	O
cardiac	O
risk	O
associated	O
with	O
the	O
use	O
of	O
PPA	B
,	O
even	O
at	O
doses	O
generally	O
considered	O
to	O
be	O
safe	O
.	O

Postoperative	O
myalgia	O
after	O
succinylcholine	B
:	O
no	O
evidence	O
for	O
an	O
inflammatory	O
origin	O
.	O

A	O
common	O
side	O
effect	O
associated	O
with	O
succinylcholine	B
is	O
postoperative	O
myalgia	O
.	O

The	O
pathogenesis	O
of	O
this	O
myalgia	O
is	O
still	O
unclear	O
;	O
inflammation	O
has	O
been	O
suggested	O
but	O
without	O
convincing	O
evidence	O
.	O

We	O
designed	O
the	O
present	O
study	O
to	O
investigate	O
whether	O
an	O
inflammatory	O
reaction	O
contributes	O
to	O
this	O
myalgia	O
.	O

The	O
incidence	O
and	O
severity	O
of	O
succinylcholine	B
-	O
associated	O
myalgia	O
was	O
determined	O
in	O
64	O
patients	O
pretreated	O
with	O
saline	O
or	O
dexamethasone	B
before	O
succinylcholine	B
(	O
n	O
=	O
32	O
for	O
each	O
)	O
.	O

Incidence	O
and	O
severity	O
of	O
myalgia	O
did	O
not	O
differ	O
significantly	O
between	O
the	O
two	O
groups	O
:	O
15	O
patients	O
in	O
the	O
dexamethasone	B
group	O
complained	O
of	O
myalgia	O
compared	O
with	O
18	O
patients	O
in	O
the	O
saline	O
group	O
,	O
and	O
severe	O
myalgia	O
was	O
reported	O
by	O
five	O
patients	O
and	O
three	O
patients	O
,	O
respectively	O
(	O
not	O
significant	O
)	O
.	O

At	O
48	O
h	O
after	O
surgery	O
,	O
12	O
patients	O
in	O
both	O
groups	O
still	O
suffered	O
from	O
myalgia	O
(	O
not	O
significant	O
)	O
.	O

In	O
addition	O
,	O
interleukin-6	O
(	O
IL-6	O
)	O
as	O
an	O
early	O
marker	O
of	O
inflammation	O
was	O
assessed	O
in	O
a	O
subgroup	O
of	O
10	O
patients	O
pretreated	O
with	O
saline	O
.	O

We	O
found	O
an	O
increase	O
of	O
IL-6	O
for	O
only	O
three	O
patients	O
,	O
but	O
only	O
one	O
patient	O
reported	O
myalgia	O
;	O
no	O
relationship	O
between	O
myalgia	O
and	O
the	O
increase	O
of	O
IL-6	O
was	O
found	O
.	O

In	O
conclusion	O
,	O
there	O
is	O
no	O
evidence	O
for	O
an	O
inflammatory	O
origin	O
of	O
succinylcholine	B
-	O
associated	O
myalgia	O
.	O

IMPLICATIONS	O
:	O
Administration	O
of	O
dexamethasone	B
before	O
succinylcholine	B
was	O
not	O
effective	O
in	O
decreasing	O
the	O
incidence	O
or	O
the	O
severity	O
of	O
succinylcholine	B
-	O
induced	O
postoperative	O
myalgia	O
.	O

Furthermore	O
,	O
there	O
was	O
no	O
significant	O
relationship	O
between	O
postoperative	O
myalgia	O
and	O
time	O
course	O
of	O
interleukin-6	O
concentrations	O
,	O
a	O
marker	O
of	O
inflammation	O
.	O

Pretreatment	O
with	O
dexamethasone	B
is	O
not	O
justified	O
to	O
prevent	O
postoperative	O
myalgia	O
after	O
succinylcholine	B
.	O

Comparison	O
of	O
developmental	O
toxicology	O
of	O
aspirin	B
(	O
acetylsalicylic	B
acid	I
)	O
in	O
rats	O
using	O
selected	O
dosing	O
paradigms	O
.	O

BACKGROUND	O
:	O
Analysis	O
of	O
the	O
literature	O
for	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
suggests	O
that	O
a	O
low	O
incidence	O
of	O
developmental	O
anomalies	O
occurs	O
in	O
rats	O
given	O
NSAIDs	O
on	O
specific	O
days	O
during	O
organogenesis	O
.	O

Aspirin	B
(	O
acetylsalicylic	B
acid	I
[	O
ASA	B
]	O
)	O
,	O
an	O
irreversible	O
cyclooxygenase	O
1	O
and	O
2	O
inhibitor	O
,	O
induces	O
developmental	O
anomalies	O
when	O
administered	O
to	O
Wistar	O
rats	O
on	O
gestational	O
day	O
(	O
GD	O
)	O
9	O
,	O
10	O
,	O
or	O
11	O
(	O
Kimmel	O
CA	O
,	O
Wilson	O
JG	O
,	O
Schumacher	O
HJ	O
.	O

Teratology	O
4:15	O
-	O
24	O
,	O
1971	O
)	O
.	O

There	O
are	O
no	O
published	O
ASA	B
studies	O
using	O
the	O
multiple	O
dosing	O
paradigm	O
of	O
GDs	O
6	O
to	O
17	O
.	O

Objectives	O
of	O
the	O
current	O
study	O
were	O
to	O
compare	O
results	O
between	O
Sprague	O
-	O
Dawley	O
(	O
SD	O
)	O
and	O
Wistar	O
strains	O
when	O
ASA	B
is	O
administered	O
on	O
GD	O
9	O
,	O
10	O
,	O
or	O
11	O
;	O
to	O
compare	O
the	O
malformation	O
patterns	O
following	O
single	O
and	O
multiple	O
dosings	O
during	O
organogenesis	O
in	O
SD	O
rats	O
;	O
and	O
to	O
test	O
the	O
hypothesis	O
that	O
maternal	O
gastrointestinal	O
toxicity	O
confounds	O
the	O
detection	O
of	O
low	O
incidence	O
malformations	O
with	O
ASA	B
when	O
a	O
multiple	O
dosing	O
paradigm	O
is	O
used	O
.	O

METHODS	O
:	O
ASA	B
was	O
administered	O
as	O
a	O
single	O
dose	O
on	O
GD	O
9	O
(	O
0	O
,	O
250	O
,	O
500	O
,	O
or	O
625	O
mg	O
/	O
kg	O
)	O
,	O
10	O
(	O
0	O
,	O
500	O
,	O
625	O
,	O
or	O
750	O
mg	O
/	O
kg	O
)	O
,	O
or	O
11	O
(	O
0	O
,	O
500	O
,	O
750	O
,	O
or	O
1000	O
mg	O
/	O
kg	O
)	O
and	O
from	O
GD	O
6	O
to	O
GD	O
17	O
(	O
0	O
,	O
50	O
,	O
125	O
,	O
or	O
250	O
mg	O
/	O
kg	O
a	O
day	O
)	O
in	O
the	O
multiple	O
dose	O
study	O
to	O
SD	O
rats	O
.	O

Animals	O
were	O
killed	O
on	O
GD	O
21	O
,	O
and	O
fetuses	O
were	O
examined	O
viscerally	O
.	O

RESULTS	O
:	O
The	O
literature	O
evaluation	O
suggested	O
that	O
NSAIDs	O
induce	O
ventricular	O
septal	O
defects	O
(	O
VSDs	O
)	O
and	O
midline	O
defects	O
(	O
MDs	O
)	O
in	O
rats	O
and	O
diaphragmatic	O
hernia	O
(	O
DH	O
)	O
,	O
MDs	O
,	O
and	O
VSDs	O
in	O
rabbits	O
(	O
Cook	O
JC	O
et	O
al.	O
,	O
2003	O
)	O
;	O
hence	O
,	O
the	O
present	O
study	O
focused	O
on	O
these	O
malformations	O
,	O
even	O
though	O
ASA	B
induces	O
several	O
other	O
low	O
-	O
incidence	O
malformations	O
.	O

In	O
single	O
dose	O
studies	O
,	O
DH	O
,	O
MD	O
,	O
and	O
VSD	O
were	O
induced	O
on	O
GDs	O
9	O
and	O
10	O
.	O

VSD	O
also	O
was	O
noted	O
following	O
treatment	O
on	O
GD	O
11	O
.	O

In	O
contrast	O
,	O
DH	O
and	O
MD	O
were	O
noted	O
in	O
the	O
multiple	O
dose	O
study	O
design	O
only	O
in	O
the	O
high	O
-	O
dose	O
group	O
,	O
and	O
VSD	O
was	O
noted	O
across	O
all	O
dose	O
groups	O
.	O

CONCLUSIONS	O
:	O
High	O
concordance	O
in	O
major	O
developmental	O
anomalies	O
between	O
Wistar	O
and	O
SD	O
rats	O
were	O
noted	O
with	O
the	O
exception	O
of	O
VSD	O
in	O
the	O
SD	O
rats	O
and	O
hydrocephalus	O
in	O
the	O
Wistar	O
rats	O
.	O

Variations	O
and	O
malformations	O
were	O
similar	O
when	O
ASA	B
was	O
administered	O
as	O
a	O
single	O
dose	O
or	O
during	O
the	O
period	O
of	O
organogenesis	O
(	O
GDs	O
6	O
to	O
17	O
)	O
.	O

It	O
was	O
also	O
evident	O
that	O
,	O
by	O
titrating	O
the	O
dose	O
to	O
achieve	O
a	O
maximum	O
tolerated	O
dose	O
,	O
malformations	O
that	O
normally	O
occur	O
at	O
low	O
incidence	O
,	O
as	O
reported	O
from	O
previous	O
single	O
dose	O
studies	O
,	O
could	O
also	O
be	O
induced	O
with	O
ASA	B
given	O
at	O
multiple	O
doses	O
.	O

Hemolytic	O
-	O
uremic	O
syndrome	O
associated	O
with	O
ingestion	O
of	O
quinine	B
.	O

Hemolytic	O
-	O
uremic	O
syndrome	O
following	O
quinine	B
ingestion	O
is	O
a	O
newly	O
described	O
phenomenon	O
,	O
with	O
just	O
two	O
previous	O
descriptions	O
of	O
4	O
cases	O
in	O
the	O
literature	O
.	O

We	O
describe	O
a	O
5th	O
case	O
.	O

The	O
reaction	O
may	O
be	O
mediated	O
by	O
the	O
presence	O
of	O
antibodies	O
reactive	O
against	O
platelets	O
in	O
the	O
presence	O
of	O
quinine	B
.	O

Treatment	O
has	O
included	O
use	O
of	O
plasma	O
exchange	O
,	O
prednisone	B
,	O
aspirin	B
,	O
and	O
dipyridamole	B
.	O

The	O
patients	O
have	O
all	O
regained	O
some	O
degree	O
of	O
renal	O
function	O
.	O

However	O
,	O
it	O
is	O
unclear	O
whether	O
pharmacological	O
treatment	O
or	O
spontaneous	O
resolution	O
is	O
responsible	O
for	O
the	O
improvement	O
.	O

Quinine	B
-	O
associated	O
hemolytic	O
-	O
uremic	O
syndrome	O
probably	O
occurs	O
more	O
often	O
than	O
is	O
recognized	O
.	O

It	O
is	O
important	O
to	O
recognize	O
this	O
reaction	O
when	O
it	O
occurs	O
and	O
to	O
avoid	O
further	O
quinine	B
exposure	O
,	O
since	O
the	O
reaction	O
seems	O
to	O
be	O
recurrent	O
.	O

All-	B
trans	I
-	I
retinoic	I
acid	I
-	O
induced	O
erythema	O
nodosum	O
in	O
patients	O
with	O
acute	O
promyelocytic	O
leukemia	O
.	O

Erythema	O
nodosum	O
associated	O
with	O
all-	B
trans	I
-	I
retinoic	I
acid	I
(	O
ATRA	B
)	O
for	O
acute	O
promyelocytic	O
leukemia	O
(	O
APL	O
)	O
is	O
very	O
rare	O
.	O

We	O
describe	O
four	O
patients	O
with	O
classic	O
APL	O
who	O
developed	O
erythema	O
nodosum	O
during	O
ATRA	B
therapy	O
.	O

Fever	O
and	O
subsequent	O
multiple	O
painful	O
erythematous	O
nodules	O
over	O
extremities	O
developed	O
on	O
D11	O
,	O
D16	O
,	O
D17	O
,	O
and	O
D19	O
,	O
respectively	O
,	O
after	O
ATRA	B
therapy	O
.	O

The	O
skin	O
biopsy	O
taken	O
from	O
each	O
patient	O
was	O
consistent	O
with	O
erythema	O
nodosum	O
.	O

All	O
patients	O
received	O
short	O
course	O
of	O
steroids	B
.	O

Fever	O
subsided	O
rapidly	O
and	O
the	O
skin	O
lesions	O
regressed	O
completely	O
.	O

All	O
patients	O
achieved	O
complete	O
remission	O
without	O
withdrawal	O
of	O
ATRA	B
.	O

ATRA	B
seemed	O
to	O
be	O
the	O
most	O
possible	O
etiology	O
of	O
erythema	O
nodosum	O
in	O
our	O
patients	O
.	O

Short	O
-	O
term	O
use	O
of	O
steroid	B
is	O
very	O
effective	O
in	O
ATRA	B
-	O
induced	O
erythema	O
nodosum	O
.	O

Pallidal	O
stimulation	O
:	O
an	O
alternative	O
to	O
pallidotomy	O
?	O

A	O
resurgence	O
of	O
interest	O
in	O
the	O
surgical	O
treatment	O
of	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
came	O
with	O
the	O
rediscovery	O
of	O
posteroventral	O
pallidotomy	O
by	O
Laitinen	O
in	O
1985	O
.	O

Laitinen	O
's	O
procedure	O
improved	O
most	O
symptoms	O
in	O
drug	O
-	O
resistant	O
PD	O
,	O
which	O
engendered	O
wide	O
interest	O
in	O
the	O
neurosurgical	O
community	O
.	O

Another	O
lesioning	O
procedure	O
,	O
ventrolateral	O
thalamotomy	O
,	O
has	O
become	O
a	O
powerful	O
alternative	O
to	O
stimulate	O
the	O
nucleus	O
ventralis	O
intermedius	O
,	O
producing	O
high	O
long	O
-	O
term	O
success	O
rates	O
and	O
low	O
morbidity	O
rates	O
.	O

Pallidal	O
stimulation	O
has	O
not	O
met	O
with	O
the	O
same	O
success	O
.	O

According	O
to	O
the	O
literature	O
pallidotomy	O
improves	O
the	O
"	O
on	O
"	O
symptoms	O
of	O
PD	O
,	O
such	O
as	O
dyskinesias	O
,	O
as	O
well	O
as	O
the	O
"	O
off	O
"	O
symptoms	O
,	O
such	O
as	O
rigidity	O
,	O
bradykinesia	O
,	O
and	O
on	O
-	O
off	O
fluctuations	O
.	O

Pallidal	O
stimulation	O
improves	O
bradykinesia	O
and	O
rigidity	O
to	O
a	O
minor	O
extent	O
;	O
however	O
,	O
its	O
strength	O
seems	O
to	O
be	O
in	O
improving	O
levodopa	B
-	O
induced	O
dyskinesias	O
.	O

Stimulation	O
often	O
produces	O
an	O
improvement	O
in	O
the	O
hyper-	O
or	O
dyskinetic	O
upper	O
limbs	O
,	O
but	O
increases	O
the	O
"	O
freezing	O
"	O
phenomenon	O
in	O
the	O
lower	O
limbs	O
at	O
the	O
same	O
time	O
.	O

Considering	O
the	O
small	O
increase	O
in	O
the	O
patient	O
's	O
independence	O
,	O
the	O
high	O
costs	O
of	O
bilateral	O
implants	O
,	O
and	O
the	O
difficulty	O
most	O
patients	O
experience	O
in	O
handling	O
the	O
devices	O
,	O
the	O
question	O
arises	O
as	O
to	O
whether	O
bilateral	O
pallidal	O
stimulation	O
is	O
a	O
real	O
alternative	O
to	O
pallidotomy	O
.	O

Hypersensitivity	O
myocarditis	O
complicating	O
hypertrophic	O
cardiomyopathy	O
heart	O
.	O

The	O
present	O
report	O
describes	O
a	O
case	O
of	O
eosinophilic	O
myocarditis	O
complicating	O
hypertrophic	O
cardiomyopathy	O
.	O

The	O
47-year	O
-	O
old	O
female	O
patient	O
,	O
known	O
to	O
have	O
hypertrophic	O
cardiomyopathy	O
,	O
was	O
admitted	O
with	O
biventricular	O
failure	O
and	O
managed	O
aggressively	O
with	O
dobutamine	B
infusion	O
and	O
other	O
drugs	O
while	O
being	O
assessed	O
for	O
heart	O
transplantation	O
.	O

On	O
transthoracic	O
echocardiogram	O
,	O
she	O
had	O
moderate	O
left	O
ventricular	O
dysfunction	O
with	O
regional	O
variability	O
and	O
moderate	O
mitral	O
regurgitation	O
.	O

The	O
recipient	O
's	O
heart	O
showed	O
the	O
features	O
of	O
apical	O
hypertrophic	O
cardiomyopathy	O
and	O
myocarditis	O
with	O
abundant	O
eosinophils	O
.	O

Myocarditis	O
is	O
rare	O
and	O
eosinophilic	O
myocarditis	O
is	O
rarer	O
.	O

It	O
is	O
likely	O
that	O
the	O
hypersensitivity	O
(	O
eosinophilic	O
)	O
myocarditis	O
was	O
related	O
to	O
dobutamine	B
infusion	O
therapy	O
.	O

Eosinophilic	O
myocarditis	O
has	O
been	O
reported	O
with	O
an	O
incidence	O
of	O
2.4	O
%	O
to	O
7.2	O
%	O
in	O
explanted	O
hearts	O
and	O
may	O
be	O
related	O
to	O
multidrug	O
therapy	O
.	O

Acute	O
low	O
back	O
pain	O
during	O
intravenous	O
administration	O
of	O
amiodarone	B
:	O
a	O
report	O
of	O
two	O
cases	O
.	O

Amiodarone	B
represents	O
an	O
effective	O
antiarrhythmic	O
drug	O
for	O
cardioversion	O
of	O
recent	O
-	O
onset	O
atrial	O
fibrillation	O
(	O
AF	O
)	O
and	O
maintenance	O
of	O
sinus	O
rhythm	O
.	O

We	O
briefly	O
describe	O
two	O
patients	O
suffering	O
from	O
recent	O
-	O
onset	O
atrial	O
fibrillation	O
,	O
who	O
experienced	O
an	O
acute	O
devastating	O
low	O
back	O
pain	O
a	O
few	O
minutes	O
after	O
initiation	O
of	O
intravenous	O
amiodarone	B
loading	O
.	O

Notably	O
,	O
this	O
side	O
effect	O
has	O
not	O
been	O
ever	O
reported	O
in	O
the	O
medical	O
literature	O
.	O

Clinicians	O
should	O
be	O
aware	O
of	O
this	O
reaction	O
since	O
prompt	O
termination	O
of	O
parenteral	O
administration	O
leads	O
to	O
complete	O
resolution	O
.	O

Dexrazoxane	B
protects	O
against	O
myelosuppression	O
from	O
the	O
DNA	O
cleavage	O
-	O
enhancing	O
drugs	O
etoposide	B
and	O
daunorubicin	B
but	O
not	O
doxorubicin	B
.	O

PURPOSE	O
:	O
The	O
anthracyclines	B
daunorubicin	B
and	O
doxorubicin	B
and	O
the	O
epipodophyllotoxin	B
etoposide	B
are	O
potent	O
DNA	O
cleavage	O
-	O
enhancing	O
drugs	O
that	O
are	O
widely	O
used	O
in	O
clinical	O
oncology	O
;	O
however	O
,	O
myelosuppression	O
and	O
cardiac	O
toxicity	O
limit	O
their	O
use	O
.	O

Dexrazoxane	B
(	O
ICRF-187	B
)	O
is	O
recommended	O
for	O
protection	O
against	O
anthracycline	B
-	O
induced	O
cardiotoxicity	O
.	O

EXPERIMENTAL	O
DESIGN	O
:	O
Because	O
of	O
their	O
widespread	O
use	O
,	O
the	O
hematologic	O
toxicity	O
following	O
coadministration	O
of	O
dexrazoxane	B
and	O
these	O
three	O
structurally	O
different	O
DNA	O
cleavage	O
enhancers	O
was	O
investigated	O
:	O
Sensitivity	O
of	O
human	O
and	O
murine	O
blood	O
progenitor	O
cells	O
to	O
etoposide	B
,	O
daunorubicin	B
,	O
and	O
doxorubicin	B
+	O
/-	O

dexrazoxane	B
was	O
determined	O
in	O
granulocyte	O
-	O
macrophage	O
colony	O
forming	O
assays	O
.	O

Likewise	O
,	O
in	O
vivo	O
,	O
B6D2F1	O
mice	O
were	O
treated	O
with	O
etoposide	B
,	O
daunorubicin	B
,	O
and	O
doxorubicin	B
,	O
with	O
or	O
without	O
dexrazoxane	B
over	O
a	O
wide	O
range	O
of	O
doses	O
:	O
posttreatment	O
,	O
a	O
full	O
hematologic	O
evaluation	O
was	O
done	O
.	O

RESULTS	O
:	O
Nontoxic	O
doses	O
of	O
dexrazoxane	B
reduced	O
myelosuppression	O
and	O
weight	O
loss	O
from	O
daunorubicin	B
and	O
etoposide	B
in	O
mice	O
and	O
antagonized	O
their	O
antiproliferative	O
effects	O
in	O
the	O
colony	O
assay	O
;	O
however	O
,	O
dexrazoxane	B
neither	O
reduced	O
myelosuppression	O
,	O
weight	O
loss	O
,	O
nor	O
the	O
in	O
vitro	O
cytotoxicity	O
from	O
doxorubicin	B
.	O

CONCLUSION	O
:	O
Although	O
our	O
findings	O
support	O
the	O
observation	O
that	O
dexrazoxane	B
reduces	O
neither	O
hematologic	O
activity	O
nor	O
antitumor	O
activity	O
from	O
doxorubicin	B
clinically	O
,	O
the	O
potent	O
antagonism	O
of	O
daunorubicin	B
activity	O
raises	O
concern	O
;	O
a	O
possible	O
interference	O
with	O
anticancer	O
efficacy	O
certainly	O
would	O
call	O
for	O
renewed	O
attention	O
.	O

Our	O
data	O
also	O
suggest	O
that	O
significant	O
etoposide	B
dose	O
escalation	O
is	O
perhaps	O
possible	O
by	O
the	O
use	O
of	O
dexrazoxane	B
.	O

Clinical	O
trials	O
in	O
patients	O
with	O
brain	O
metastases	O
combining	O
dexrazoxane	B
and	O
high	O
doses	O
of	O
etoposide	B
is	O
ongoing	O
with	O
the	O
aim	O
of	O
improving	O
efficacy	O
without	O
aggravating	O
hematologic	O
toxicity	O
.	O

If	O
successful	O
,	O
this	O
represents	O
an	O
exciting	O
mechanism	O
for	O
pharmacologic	O
regulation	O
of	O
side	O
effects	O
from	O
cytotoxic	O
chemotherapy	O
.	O

Amiodarone	B
pulmonary	O
toxicity	O
.	O

Amiodarone	B
is	O
an	O
effective	O
antiarrhythmic	O
agent	O
whose	O
utility	O
is	O
limited	O
by	O
many	O
side	O
-	O
effects	O
,	O
the	O
most	O
problematic	O
being	O
pneumonitis	O
.	O

The	O
pulmonary	O
toxicity	O
of	O
amiodarone	B
is	O
thought	O
to	O
result	O
from	O
direct	O
injury	O
related	O
to	O
the	O
intracellular	O
accumulation	O
of	O
phospholipid	O
and	O
T	O
cell	O
-	O
mediated	O
hypersensitivity	O
pneumonitis	O
.	O

The	O
clinical	O
and	O
radiographic	O
features	O
of	O
amiodarone	B
-	O
induced	O
pulmonary	O
toxicity	O
are	O
characteristic	O
but	O
nonspecific	O
.	O

The	O
diagnosis	O
depends	O
on	O
exclusion	O
of	O
other	O
entities	O
,	O
such	O
as	O
heart	O
failure	O
,	O
infection	O
,	O
and	O
malignancy	O
.	O

While	O
withdrawal	O
of	O
amiodarone	B
leads	O
to	O
clinical	O
improvement	O
in	O
majority	O
of	O
cases	O
,	O
this	O
is	O
not	O
always	O
possible	O
or	O
advisable	O
.	O

Dose	O
reduction	O
or	O
concomitant	O
steroid	B
therapy	O
may	O
have	O
a	O
role	O
in	O
selected	O
patients	O
.	O

Amisulpride	B
related	O
tic	O
-	O
like	O
symptoms	O
in	O
an	O
adolescent	O
schizophrenic	O
.	O

Tic	O
disorders	O
can	O
be	O
effectively	O
treated	O
by	O
atypical	O
antipsychotics	O
such	O
as	O
risperidone	B
,	O
olanzapine	B
and	O
ziprasidone	B
.	O

However	O
,	O
there	O
are	O
two	O
case	O
reports	O
that	O
show	O
tic	O
-	O
like	O
symptoms	O
,	O
including	O
motor	O
and	O
phonic	O
variants	O
,	O
occurring	O
during	O
treatment	O
with	O
quetiapine	B
or	O
clozapine	B
.	O

We	O
present	O
a	O
15-year	O
-	O
old	O
girl	O
schizophrenic	O
who	O
developed	O
frequent	O
involuntary	O
eye	O
-	O
blinking	O
movements	O
after	O
5	O
months	O
of	O
amisulpride	B
treatment	O
(	O
1000	O
mg	O
per	O
day	O
)	O
.	O

The	O
tic	O
-	O
like	O
symptoms	O
resolved	O
completely	O
after	O
we	O
reduced	O
the	O
dose	O
of	O
amisulpride	B
down	O
to	O
800	O
mg	O
per	O
day	O
.	O

However	O
,	O
her	O
psychosis	O
recurred	O
after	O
the	O
dose	O
reduction	O
.	O

We	O
then	O
placed	O
her	O
on	O
an	O
additional	O
100	O
mg	O
per	O
day	O
of	O
quetiapine	B
.	O

She	O
has	O
been	O
in	O
complete	O
remission	O
under	O
the	O
combined	O
medications	O
for	O
more	O
than	O
one	O
year	O
and	O
maintains	O
a	O
fair	O
role	O
function	O
.	O

No	O
more	O
tic	O
-	O
like	O
symptoms	O
or	O
other	O
side	O
effects	O
have	O
been	O
reported	O
.	O

Together	O
with	O
previously	O
reported	O
cases	O
,	O
our	O
patient	O
suggests	O
that	O
tic	O
-	O
like	O
symptoms	O
might	O
occur	O
in	O
certain	O
vulnerable	O
individuals	O
during	O
treatment	O
with	O
atypical	O
antipsychotics	O
such	O
as	O
quetiapine	B
,	O
clozapine	B
,	O
or	O
amisulpride	B
.	O

Nerve	O
growth	O
factor	O
and	O
prostaglandins	B
in	O
the	O
urine	O
of	O
female	O
patients	O
with	O
overactive	O
bladder	O
.	O

PURPOSE	O
:	O
NGF	O
and	O
PGs	B
in	O
the	O
bladder	O
can	O
be	O
affected	O
by	O
pathological	O
changes	O
in	O
the	O
bladder	O
and	O
these	O
changes	O
can	O
be	O
detected	O
in	O
urine	O
.	O

We	O
investigated	O
changes	O
in	O
urinary	O
NGF	O
and	O
PGs	B
in	O
women	O
with	O
OAB	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
The	O
study	O
groups	O
included	O
65	O
women	O
with	O
OAB	O
and	O
20	O
without	O
bladder	O
symptoms	O
who	O
served	O
as	O
controls	O
.	O

Evaluation	O
included	O
patient	O
history	O
,	O
urinalysis	O
,	O
a	O
voiding	O
diary	O
and	O
urodynamic	O
studies	O
.	O

Urine	O
samples	O
were	O
collected	O
.	O

NGF	O
,	O
PGE2	B
,	O
PGF2alpha	B
and	O
PGI2	B
were	O
measured	O
using	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
and	O
compared	O
between	O
the	O
groups	O
.	O

In	O
addition	O
,	O
correlations	O
between	O
urinary	O
NGF	O
and	O
PG	B
,	O
and	O
urodynamic	O
parameters	O
in	O
patients	O
with	O
OAB	O
were	O
examined	O
.	O

RESULTS	O
:	O
Urinary	O
NGF	O
,	O
PGE2	B
and	O
PGF2alpha	B
were	O
significantly	O
increased	O
in	O
patients	O
with	O
OAB	O
compared	O
with	O
controls	O
(	O
p	O
<	O
0.05	O
)	O
.	O

However	O
,	O
urinary	O
PGI2	B
was	O
not	O
different	O
between	O
controls	O
and	O
patients	O
with	O
OAB	O
.	O

In	O
patients	O
with	O
OAB	O
urinary	O
PGE2	B
positively	O
correlated	O
with	O
volume	O
at	O
first	O
desire	O
to	O
void	O
and	O
maximum	O
cystometric	O
capacity	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Urinary	O
NGF	O
,	O
PGF2alpha	B
and	O
PGI2	B
did	O
not	O
correlate	O
with	O
urodynamic	O
parameters	O
in	O
patients	O
with	O
OAB	O
.	O

CONCLUSIONS	O
:	O
NGF	O
and	O
PGs	B
have	O
important	O
roles	O
in	O
the	O
development	O
of	O
OAB	O
symptoms	O
in	O
female	O
patients	O
.	O

Urinary	O
levels	O
of	O
these	O
factors	O
may	O
be	O
used	O
as	O
markers	O
to	O
evaluate	O
OAB	O
symptoms	O
.	O

Blockade	O
of	O
both	O
D-1	O
and	O
D-2	O
dopamine	B
receptors	O
may	O
induce	O
catalepsy	O
in	O
mice	O
.	O

1	O
.	O

The	O
catalepsy	O
induced	O
by	O
dopamine	B
antagonists	O
has	O
been	O
tested	O
and	O
the	O
possible	O
dopamine	B
subtypes	O
involved	O
in	O
catalepsy	O
was	O
determined	O
.	O

2	O
.	O

Dopamine	B
antagonist	O
fluphenazine	B
,	O
D-1	O
antagonist	O
SCH	B
23390	I
or	O
D-2	O
antagonist	O
sulpiride	B
induced	O
catalepsy	O
.	O

The	O
effect	O
of	O
fluphenazine	B
and	O
sulpiride	B
was	O
dose	O
-	O
dependent	O
.	O

Combination	O
of	O
SCH	B
23390	I
with	O
sulpiride	B
did	O
not	O
induce	O
catalepsy	O
potentiation	O
.	O

3	O
.	O
D-1	O
agonist	O
SKF	B
38393	I
or	O
D-2	O
agonist	O
quinpirole	B
decreased	O
the	O
catalepsy	O
induced	O
by	O
fluphenazine	B
,	O
SCH	B
23390	I
or	O
sulpiride	B
.	O

4	O
.	O

Combination	O
of	O
SKF	B
38393	I
with	O
quinpirole	B
did	O
not	O
cause	O
potentiated	O
inhibitory	O
effect	O
on	O
catalepsy	O
induced	O
by	O
dopamine	B
antagonists	O
.	O

5	O
.	O

The	O
data	O
may	O
indicate	O
that	O
although	O
D-2	O
receptor	O
blockade	O
is	O
involved	O
in	O
catalepsy	O
,	O
the	O
D-1	O
receptor	O
may	O
plan	O
a	O
role	O
.	O

Is	O
phenytoin	B
administration	O
safe	O
in	O
a	O
hypothermic	O
child	O
?	O

A	O
male	O
neonate	O
with	O
a	O
Chiari	O
malformation	O
and	O
a	O
leaking	O
myelomeningocoele	O
underwent	O
ventriculoperitoneal	O
shunt	O
insertion	O
followed	O
by	O
repair	O
of	O
myelomeningocoele	O
.	O

During	O
anaesthesia	O
and	O
surgery	O
,	O
he	O
inadvertently	O
became	O
moderately	O
hypothermic	O
.	O

Intravenous	O
phenytoin	B
was	O
administered	O
during	O
the	O
later	O
part	O
of	O
the	O
surgery	O
for	O
seizure	O
prophylaxis	O
.	O

Following	O
phenytoin	B
administration	O
,	O
the	O
patient	O
developed	O
acute	O
severe	O
bradycardia	O
,	O
refractory	O
to	O
atropine	B
and	O
adrenaline	B
.	O

The	O
cardiac	O
depressant	O
actions	O
of	O
phenytoin	B
and	O
hypothermia	O
can	O
be	O
additive	O
.	O

Administration	O
of	O
phenytoin	B
in	O
the	O
presence	O
of	O
hypothermia	O
may	O
lead	O
to	O
an	O
adverse	O
cardiac	O
event	O
in	O
children	O
.	O

As	O
phenytoin	B
is	O
a	O
commonly	O
used	O
drug	O
,	O
clinicians	O
need	O
to	O
be	O
aware	O
of	O
this	O
interaction	O
.	O

Delayed	O
institution	O
of	O
hypertension	O
during	O
focal	O
cerebral	O
ischemia	O
:	O
effect	O
on	O
brain	O
edema	O
.	O

The	O
effect	O
of	O
induced	O
hypertension	O
instituted	O
after	O
a	O
2-h	O
delay	O
following	O
middle	O
cerebral	O
artery	O
occlusion	O
(	O
MCAO	O
)	O
on	O
brain	O
edema	O
formation	O
and	O
histochemical	O
injury	O
was	O
studied	O
.	O

Under	O
isoflurane	B
anesthesia	O
,	O
the	O
MCA	O
of	O
14	O
spontaneously	O
hypertensive	O
rats	O
was	O
occluded	O
.	O

In	O
the	O
control	O
group	O
(	O
n	O
=	O
7	O
)	O
,	O
the	O
mean	O
arterial	O
pressure	O
(	O
MAP	O
)	O
was	O
not	O
manipulated	O
.	O

In	O
the	O
hypertensive	O
group	O
(	O
n	O
=	O
7	O
)	O
,	O
the	O
MAP	O
was	O
elevated	O
by	O
25	O
-	O
30	O
mm	O
Hg	O
beginning	O
2	O
h	O
after	O
MCAO	O
.	O

Four	O
hours	O
after	O
MCAO	O
,	O
the	O
rats	O
were	O
killed	O
and	O
the	O
brains	O
harvested	O
.	O

The	O
brains	O
were	O
sectioned	O
along	O
coronal	O
planes	O
spanning	O
the	O
distribution	O
of	O
ischemia	O
produced	O
by	O
MCAO	O
.	O

Specific	O
gravity	O
(	O
SG	O
)	O
was	O
determined	O
in	O
the	O
subcortex	O
and	O
in	O
two	O
sites	O
in	O
the	O
cortex	O
(	O
core	O
and	O
periphery	O
of	O
the	O
ischemic	O
territory	O
)	O
.	O

The	O
extent	O
of	O
neuronal	O
injury	O
was	O
determined	O
by	O
2,3,5-triphenyltetrazolium	B
staining	O
.	O

In	O
the	O
ischemic	O
core	O
,	O
there	O
was	O
no	O
difference	O
in	O
SG	O
in	O
the	O
subcortex	O
and	O
cortex	O
in	O
the	O
two	O
groups	O
.	O

In	O
the	O
periphery	O
of	O
the	O
ischemic	O
territory	O
,	O
SG	O
in	O
the	O
cortex	O
was	O
greater	O
(	O
less	O
edema	O
accumulation	O
)	O
in	O
the	O
hypertensive	O
group	O
(	O
1.041	O
+	O
/-	O

0.001	O
vs	O
1.039	O
+	O
/-	O

0.001	O
,	O
P	O
less	O
than	O
0.05	O
)	O
.	O

The	O
area	O
of	O
histochemical	O
injury	O
(	O
as	O
a	O
percent	O
of	O
the	O
cross	O
-	O
sectional	O
area	O
of	O
the	O
hemisphere	O
)	O
was	O
less	O
in	O
the	O
hypertensive	O
group	O
(	O
33	O
+	O
/-	O

3	O
%	O
vs	O
21	O
+	O
/-	O

2	O
%	O
,	O
P	O
less	O
than	O
0.05	O
)	O
.	O

The	O
data	O
indicate	O
that	O
phenylephrine	B
-	O
induced	O
hypertension	O
instituted	O
2	O
h	O
after	O
MCAO	O
does	O
not	O
aggravate	O
edema	O
in	O
the	O
ischemic	O
core	O
,	O
that	O
it	O
improves	O
edema	O
in	O
the	O
periphery	O
of	O
the	O
ischemic	O
territory	O
,	O
and	O
that	O
it	O
reduces	O
the	O
area	O
of	O
histochemical	O
neuronal	O
dysfunction	O
.	O

Intraocular	O
pressure	O
in	O
patients	O
with	O
uveitis	O
treated	O
with	O
fluocinolone	B
acetonide	I
implants	O
.	O

OBJECTIVE	O
:	O
To	O
report	O
the	O
incidence	O
and	O
management	O
of	O
elevated	O
intraocular	O
pressure	O
(	O
IOP	O
)	O
in	O
patients	O
with	O
uveitis	O
treated	O
with	O
the	O
fluocinolone	B
acetonide	I
(	O
FA	B
)	O
intravitreal	O
implant	O
.	O

DESIGN	O
:	O
Pooled	O
data	O
from	O
3	O
multicenter	O
,	O
double	O
-	O
masked	O
,	O
randomized	O
,	O
controlled	O
,	O
phase	O
2b	O
/	O
3	O
clinical	O
trials	O
evaluating	O
the	O
safety	O
and	O
efficacy	O
of	O
the	O
0.59-mg	O
or	O
2.1-mg	O
FA	B
intravitreal	O
implant	O
or	O
standard	O
therapy	O
were	O
analyzed	O
.	O

RESULTS	O
:	O
During	O
the	O
3-year	O
follow	O
-	O
up	O
,	O
71.0	O
%	O
of	O
implanted	O
eyes	O
had	O
an	O
IOP	O
increase	O
of	O
10	O
mm	O
Hg	O
or	O
more	O
than	O
baseline	O
and	O
55.1	O
%	O
,	O
24.7	O
%	O
,	O
and	O
6.2	O
%	O
of	O
eyes	O
reached	O
an	O
IOP	O
of	O
30	O
mm	O
Hg	O
or	O
more	O
,	O
40	O
mm	O
Hg	O
or	O
more	O
,	O
and	O
50	O
mm	O
Hg	O
or	O
more	O
,	O
respectively	O
.	O

Topical	O
IOP	O
-	O
lowering	O
medication	O
was	O
administered	O
in	O
74.8	O
%	O
of	O
implanted	O
eyes	O
,	O
and	O
IOP	O
-	O
lowering	O
surgeries	O
,	O
most	O
of	O
which	O
were	O
trabeculectomies	O
(	O
76.2	O
%	O
)	O
,	O
were	O
performed	O
on	O
36.6	O
%	O
of	O
implanted	O
eyes	O
.	O

Intraocular	O
pressure	O
-	O
lowering	O
surgeries	O
were	O
considered	O
a	O
success	O
(	O
postoperative	O
IOP	O
of	O
6	O
-	O
21	O
mm	O
Hg	O
with	O
or	O
without	O
additional	O
IOP	O
-	O
lowering	O
medication	O
)	O
in	O
85.1	O
%	O
of	O
eyes	O
at	O
1	O
year	O
.	O

The	O
rate	O
of	O
hypotony	O
(	O
IOP	O
<	O
/=	O
5	O
mm	O
Hg	O
)	O
following	O
IOP	O
-	O
lowering	O
surgery	O
(	O
42.5	O
%	O
)	O
was	O
not	O
different	O
from	O
that	O
of	O
implanted	O
eyes	O
not	O
subjected	O
to	O
surgery	O
(	O
35.4	O
%	O
)	O
(	O
P	O
=	O
.09	O
)	O
.	O

CONCLUSION	O
:	O
Elevated	O
IOP	O
is	O
a	O
significant	O
complication	O
with	O
the	O
FA	O
intravitreal	O
implant	O
but	O
may	O
be	O
controlled	O
with	O
medication	O
and	O
surgery	O
.	O

Results	O
of	O
a	O
comparative	O
,	O
phase	O
III	O
,	O
12-week	O
,	O
multicenter	O
,	O
prospective	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
assessment	O
of	O
the	O
efficacy	O
and	O
tolerability	O
of	O
a	O
fixed	O
-	O
dose	O
combination	O
of	O
telmisartan	B
and	O
amlodipine	B
versus	O
amlodipine	B
monotherapy	O
in	O
Indian	O
adults	O
with	O
stage	O
II	O
hypertension	O
.	O

OBJECTIVE	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
efficacy	O
and	O
tolerability	O
of	O
a	O
new	O
fixed	O
-	O
dose	O
combination	O
(	O
FDC	O
)	O
of	O
telmisartan	B
40	O
mg	O
+	O
amlodipine	B
5	O
mg	O
(	O
T+A	O
)	O
compared	O
with	O
amlodipine	B
5-mg	O
monotherapy	O
(	O
A	O
)	O
in	O
adult	O
Indian	O
patients	O
with	O
stage	O
II	O
hypertension	O
.	O

METHODS	O
:	O
This	O
comparative	O
,	O
Phase	O
III	O
,	O
12-week	O
,	O
multicenter	O
,	O
prospective	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
study	O
was	O
conducted	O
in	O
Indian	O
patients	O
aged	O
18	O
to	O
65	O
years	O
with	O
established	O
stage	O
II	O
hypertension	O
.	O

Patients	O
were	O
treated	O
with	O
oral	O
FDC	O
of	O
T+A	O
or	O
A	O
QD	O
before	O
breakfast	O
for	O
12	O
weeks	O
;	O
blood	O
pressure	O
(	O
BP	O
)	O
and	O
heart	O
rate	O
were	O
measured	O
in	O
the	O
sitting	O
position	O
.	O

Primary	O
efficacy	O
end	O
points	O
were	O
reduction	O
in	O
clinical	O
systolic	O
BP	O
(	O
SBP	O
)	O
/	O
diastolic	O
BP	O
(	O
DBP	O
)	O
from	O
baseline	O
to	O
study	O
end	O
and	O
number	O
of	O
responders	O
(	O
ie	O
,	O
patients	O
who	O
achieved	O
target	O
SBP	O
/	O
DBP	O
<	O
130	O
/	O
<80	O
mm	O
Hg	O
)	O
at	O
end	O
of	O
study	O
.	O

Tolerability	O
was	O
assessed	O
by	O
treatment	O
-	O
emergent	O
adverse	O
events	O
,	O
identified	O
using	O
physical	O
examination	O
,	O
laboratory	O
analysis	O
,	O
and	O
electrocardiography	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
210	O
patients	O
were	O
enrolled	O
in	O
the	O
study	O
;	O
203	O
patients	O
(	O
143	O
men	O
,	O
60	O
women	O
)	O
completed	O
the	O
study	O
while	O
7	O
were	O
lost	O
to	O
follow	O
-	O
up	O
(	O
4	O
patients	O
in	O
the	O
T+A	O
group	O
and	O
3	O
in	O
the	O
A	O
group	O
)	O
and	O
considered	O
with	O
-	O
drawn	O
.	O

At	O
study	O
end	O
,	O
statistically	O
significant	O
percentage	O
reductions	O
from	O
baseline	O
within	O
groups	O
and	O
between	O
groups	O
were	O
observed	O
in	O
SBP	O
(	O
T+A	O
[	O
-27.4	O
%	O
]	O
;	O
A	O
[	O
-16.6	O
%	O
]	O
)	O
and	O
DBP	O
(	O
T+A	O
[	O
-20.1	O
%	O
]	O
;	O
A	O
[	O
-13.3	O
%	O
]	O
)	O
(	O
all	O
,	O
P	O
<	O
0.05	O
)	O
.	O

Response	O
rates	O
were	O
87.3	O
%	O
(	O
89	O
/	O
102	O
)	O
in	O
the	O
T+A	O
group	O
and	O
69.3	O
%	O
(	O
70	O
/	O
101	O
)	O
in	O
the	O
A	O
group	O
(	O
P	O
<	O
0.05	O
)	O
.	O

The	O
prevalences	O
of	O
adverse	O
events	O
were	O
not	O
significantly	O
different	O
between	O
the	O
2	O
treatment	O
groups	O
(	O
T+A	O
,	O
16.0	O
%	O
[	O
17	O
/	O
106	O
]	O
;	O
A	O
,	O
15.4	O
%	O
[	O
16	O
/	O
104	O
]	O
)	O
.	O

Peripheral	O
edema	O
was	O
reported	O
in	O
8.5	O
%	O
patients	O
(	O
9	O
/	O
106	O
)	O
in	O
the	O
T+A	O
group	O
compared	O
with	O
13.5	O
%	O
(	O
14	O
/	O
104	O
)	O
in	O
the	O
A	O
group	O
,	O
and	O
cough	O
was	O
reported	O
in	O
3.8	O
%	O
patients	O
(	O
4	O
/	O
106	O
)	O
in	O
the	O
T+A	O
group	O
and	O
1.0	O
%	O
(	O
1	O
/	O
104	O
)	O
patients	O
in	O
the	O
A	O
group	O
;	O
these	O
differences	O
did	O
not	O
reach	O
statistical	O
significance	O
.	O

The	O
incidences	O
of	O
headache	O
,	O
dizziness	O
,	O
and	O
diarrhea	O
were	O
similar	O
between	O
the	O
2	O
groups	O
.	O

CONCLUSIONS	O
:	O
Among	O
these	O
Indian	O
patients	O
with	O
stage	O
II	O
hypertension	O
,	O
the	O
FDC	O
of	O
T+A	O
was	O
found	O
to	O
be	O
significantly	O
more	O
effective	O
,	O
with	O
regard	O
to	O
BP	O
reductions	O
,	O
than	O
A	O
,	O
and	O
both	O
treatments	O
were	O
well	O
tolerated	O
.	O

Exaggerated	O
expression	O
of	O
inflammatory	O
mediators	O
in	O
vasoactive	O
intestinal	O
polypeptide	O
knockout	O
(	O
VIP-	O
/	O
-	O
)	O
mice	O
with	O
cyclophosphamide	B
(	O
CYP	B
)	O
-induced	O
cystitis	O
.	O

Vasoactive	O
intestinal	O
polypeptide	O
(	O
VIP	O
)	O
is	O
an	O
immunomodulatory	O
neuropeptide	O
distributed	O
in	O
micturition	O
pathways	O
.	O

VIP	O
(	O
-	O
/	O
-	O
)	O
mice	O
exhibit	O
altered	O
bladder	O
function	O
and	O
neurochemical	O
properties	O
in	O
micturition	O
pathways	O
after	O
cyclophosphamide	B
(	O
CYP	B
)	O
-induced	O
cystitis	O
.	O

Given	O
VIP	O
's	O
role	O
as	O
an	O
anti	O
-	O
inflammatory	O
mediator	O
,	O
we	O
hypothesized	O
that	O
VIP	O
(	O
-	O
/	O
-	O
)	O
mice	O
would	O
exhibit	O
enhanced	O
inflammatory	O
mediator	O
expression	O
after	O
cystitis	O
.	O

A	O
mouse	O
inflammatory	O
cytokine	O
and	O
receptor	O
RT2	O
profiler	O
array	O
was	O
used	O
to	O
determine	O
regulated	O
transcripts	O
in	O
the	O
urinary	O
bladder	O
of	O
wild	O
type	O
(	O
WT	O
)	O
and	O
VIP	O
(	O
-	O
/	O
-	O
)	O
mice	O
with	O
or	O
without	O
CYP	B
-	O
induced	O
cystitis	O
(	O
150	O
mg	O
/	O
kg	O
;	O
i.p	O
.	O
;	O
48	O
h	O
)	O
.	O

Four	O
binary	O
comparisons	O
were	O
made	O
:	O
WT	O
control	O
versus	O
CYP	B
treatment	O
(	O
48	O
h	O
)	O
,	O
VIP	O
(	O
-	O
/	O
-	O
)	O
control	O
versus	O
CYP	B
treatment	O
(	O
48	O
h	O
)	O
,	O
WT	O
control	O
versus	O
VIP	O
(	O
-	O
/	O
-	O
)	O
control	O
,	O
and	O
WT	O
with	O
CYP	B
treatment	O
(	O
48	O
h	O
)	O
versus	O
VIP	O
(	O
-	O
/	O
-	O
)	O
with	O
CYP	B
treatment	O
(	O
48	O
h	O
)	O
.	O

The	O
genes	O
presented	O
represent	O
(	O
1	O
)	O
greater	O
than	O
1.5-fold	O
change	O
in	O
either	O
direction	O
and	O
(	O
2	O
)	O
the	O
p	O
value	O
is	O
less	O
than	O
0.05	O
for	O
the	O
comparison	O
being	O
made	O
.	O

Several	O
regulated	O
genes	O
were	O
validated	O
using	O
enzyme	O
-	O
linked	O
immunoassays	O
including	O
IL-1beta	O
and	O
CXCL1	O
.	O

CYP	B
treatment	O
significantly	O
(	O
p	O
<	O
or	O
=	O
0.001	O
)	O
increased	O
expression	O
of	O
CXCL1	O
and	O
IL-1beta	O
in	O
the	O
urinary	O
bladder	O
of	O
WT	O
and	O
VIP	O
(	O
-	O
/	O
-	O
)	O
mice	O
,	O
but	O
expression	O
in	O
VIP	O
(	O
-	O
/	O
-	O
)	O
mice	O
with	O
CYP	B
treatment	O
was	O
significantly	O
(	O
p	O
<	O
or	O
=	O
0.001	O
)	O
greater	O
(	O
4.2-	O
to	O
13-fold	O
increase	O
)	O
than	O
that	O
observed	O
in	O
WT	O
urinary	O
bladder	O
(	O
3.6-	O
to	O
5-fold	O
increase	O
)	O
.	O

The	O
data	O
suggest	O
that	O
in	O
VIP	O
(	O
-	O
/	O
-	O
)	O
mice	O
with	O
bladder	O
inflammation	O
,	O
inflammatory	O
mediators	O
are	O
increased	O
above	O
that	O
observed	O
in	O
WT	O
with	O
CYP	B
.	O

This	O
shift	O
in	O
balance	O
may	O
contribute	O
to	O
increased	O
bladder	O
dysfunction	O
in	O
VIP	O
(	O
-	O
/	O
-	O
)	O
mice	O
with	O
bladder	O
inflammation	O
and	O
altered	O
neurochemical	O
expression	O
in	O
micturition	O
pathways	O
.	O

The	O
hemodynamics	O
of	O
oxytocin	B
and	O
other	O
vasoactive	O
agents	O
during	O
neuraxial	O
anesthesia	O
for	O
cesarean	O
delivery	O
:	O
findings	O
in	O
six	O
cases	O
.	O

Oxytocin	B
is	O
a	O
commonly	O
used	O
uterotonic	O
that	O
can	O
cause	O
significant	O
and	O
even	O
fatal	O
hypotension	O
,	O
particularly	O
when	O
given	O
as	O
a	O
bolus	O
.	O

The	O
resulting	O
hypotension	O
can	O
be	O
produced	O
by	O
a	O
decrease	O
in	O
systemic	O
vascular	O
resistance	O
or	O
cardiac	O
output	O
through	O
a	O
decrease	O
in	O
venous	O
return	O
.	O

Parturients	O
with	O
normal	O
volume	O
status	O
,	O
heart	O
valves	O
and	O
pulmonary	O
vasculature	O
most	O
often	O
respond	O
to	O
this	O
hypotension	O
with	O
a	O
compensatory	O
increase	O
in	O
heart	O
rate	O
and	O
stroke	O
volume	O
.	O

Oxytocin	B
-	O
induced	O
hypotension	O
at	O
cesarean	O
delivery	O
may	O
be	O
incorrectly	O
attributed	O
to	O
blood	O
loss	O
.	O

Pulse	O
power	O
analysis	O
(	O
also	O
called	O
"	O
pulse	O
contour	O
analysis	O
"	O
)	O
of	O
an	O
arterial	O
pressure	O
wave	O
form	O
allows	O
continuous	O
evaluation	O
of	O
systemic	O
vascular	O
resistance	O
and	O
cardiac	O
output	O
in	O
real	O
time	O
,	O
thereby	O
elucidating	O
the	O
causative	O
factors	O
behind	O
changes	O
in	O
blood	O
pressure	O
.	O

Pulse	O
power	O
analysis	O
was	O
conducted	O
in	O
six	O
cases	O
of	O
cesarean	O
delivery	O
performed	O
under	O
neuraxial	O
anesthesia	O
.	O

Hypotension	O
in	O
response	O
to	O
oxytocin	B
was	O
associated	O
with	O
a	O
decrease	O
in	O
systemic	O
vascular	O
resistance	O
and	O
a	O
compensatory	O
increase	O
in	O
stroke	O
volume	O
,	O
heart	O
rate	O
and	O
cardiac	O
output	O
.	O

Pulse	O
power	O
analysis	O
may	O
be	O
helpful	O
in	O
determining	O
the	O
etiology	O
of	O
and	O
treating	O
hypotension	O
during	O
cesarean	O
delivery	O
under	O
neuraxial	O
anesthesia	O
.	O

Proteinase	O
3-antineutrophil	O
cytoplasmic	O
antibody-	O
(	O
PR3-ANCA	O
)	O
positive	O
necrotizing	O
glomerulonephritis	O
after	O
restarting	O
sulphasalazine	B
treatment	O
.	O

A	O
59-year	O
-	O
old	O
woman	O
with	O
ulcerative	O
colitis	O
developed	O
red	O
eyes	O
,	O
pleural	O
effusion	O
,	O
eosinophilia	O
and	O
urinary	O
abnormalities	O
after	O
restarting	O
of	O
sulphasalazine	B
treatment	O
.	O

Light	O
microscopy	O
of	O
a	O
kidney	O
biopsy	O
revealed	O
segmental	O
necrotizing	O
glomerulonephritis	O
without	O
deposition	O
of	O
immunoglobulin	O
or	O
complement	O
.	O

Proteinase	O
3-antineutrophil	O
cytoplasmic	O
antibody	O
(	O
PR3-ANCA	O
)	O
titer	O
was	O
elevated	O
at	O
183	O
ELISA	O
units	O
(	O
EU	O
)	O
in	O
sera	O
(	O
normal	O
range	O
less	O
than	O
10	O
EU	O
)	O
,	O
myeloperoxidase	O
-	O
ANCA	O
was	O
negative	O
.	O

PR3-ANCA	O
titer	O
was	O
250	O
and	O
1,070	O
EU	O
in	O
pleural	O
effusions	O
on	O
right	O
and	O
left	O
side	O
,	O
respectively	O
.	O

Although	O
cessation	O
of	O
sulphasalazine	B
treatment	O
resulted	O
in	O
improvements	O
in	O
fever	O
,	O
red	O
eyes	O
,	O
chest	O
pain	O
,	O
titer	O
of	O
C	O
-	O
reactive	O
protein	O
and	O
volume	O
of	O
the	O
pleural	O
effusions	O
,	O
we	O
initiated	O
steroid	B
therapy	O
,	O
because	O
PR3-ANCA	O
titer	O
rose	O
to	O
320	O
EU	O
,	O
eosinophil	O
count	O
increased	O
to	O
1,100	O
cells	O
/	O
microl	O
,	O
and	O
the	O
pleural	O
effusion	O
remained	O
.	O

One	O
month	O
after	O
steroid	B
therapy	O
,	O
the	O
pleural	O
effusion	O
disappeared	O
,	O
and	O
PR3-ANCA	O
titer	O
normalized	O
3	O
months	O
later	O
.	O

This	O
case	O
suggests	O
that	O
sulphasalazine	B
can	O
induce	O
PR3-ANCA	O
-	O
positive	O
necrotizing	O
glomerulonephritis	O
.	O

DSMM	O
XI	O
study	O
:	O
dose	O
definition	O
for	O
intravenous	O
cyclophosphamide	B
in	O
combination	O
with	O
bortezomib	B
/	O
dexamethasone	B
for	O
remission	O
induction	O
in	O
patients	O
with	O
newly	O
diagnosed	O
myeloma	O
.	O

A	O
clinical	O
trial	O
was	O
initiated	O
to	O
evaluate	O
the	O
recommended	O
dose	O
of	O
cyclophosphamide	B
in	O
combination	O
with	O
bortezomib	B
and	O
dexamethasone	B
as	O
induction	O
treatment	O
before	O
stem	O
cell	O
transplantation	O
for	O
younger	O
patients	O
with	O
newly	O
diagnosed	O
multiple	O
myeloma	O
(	O
MM	O
)	O
.	O

Thirty	O
patients	O
were	O
treated	O
with	O
three	O
21-day	O
cycles	O
of	O
bortezomib	B
1.3	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1	O
,	O
4	O
,	O
8	O
,	O
and	O
11	O
plus	O
dexamethasone	B
40	O
mg	O
on	O
the	O
day	O
of	O
bortezomib	B
injection	O
and	O
the	O
day	O
after	O
plus	O
cyclophosphamide	B
at	O
900	O
,	O
1,200	O
,	O
or	O
1,500	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
day	O
1	O
.	O

The	O
maximum	O
tolerated	O
dose	O
of	O
cyclophosphamide	B
was	O
defined	O
as	O
900	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O

At	O
this	O
dose	O
level	O
,	O
92	O
%	O
of	O
patients	O
achieved	O
at	O
least	O
a	O
partial	O
response	O
.	O

The	O
overall	O
response	O
rate	O
[	O
complete	O
response	O
(	O
CR	O
)	O
plus	O
partial	O
response	O
(	O
PR	O
)	O
]	O
across	O
all	O
dose	O
levels	O
was	O
77	O
%	O
,	O
with	O
a	O
10	O
%	O
CR	O
rate	O
.	O

No	O
patient	O
experienced	O
progressive	O
disease	O
.	O

The	O
most	O
frequent	O
adverse	O
events	O
were	O
hematological	O
and	O
gastrointestinal	O
toxicities	O
as	O
well	O
as	O
neuropathy	O
.	O

The	O
results	O
suggest	O
that	O
bortezomib	B
in	O
combination	O
with	O
cyclophosphamide	B
at	O
900	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
dexamethasone	B
is	O
an	O
effective	O
induction	O
treatment	O
for	O
patients	O
with	O
newly	O
diagnosed	O
MM	O
that	O
warrants	O
further	O
investigation	O
.	O

Dextran	B
-	O
etodolac	B
conjugates	O
:	O
synthesis	O
,	O
in	O
vitro	O
and	O
in	O
vivo	O
evaluation	O
.	O

Etodolac	B
(	B
E	O
)	O
,	O
is	O
a	O
non	O
-	O
narcotic	O
analgesic	O
and	O
antiinflammatory	O
drug	O
.	O

A	O
biodegradable	O
polymer	O
dextran	B
has	O
been	O
utilized	O
as	O
a	O
carrier	O
for	O
synthesis	O
of	O
etodolac	B
-	O
dextran	B
conjugates	O
(	O
ED	O
)	O
to	O
improve	O
its	O
aqueous	O
solubility	O
and	O
reduce	O
gastrointestinal	O
side	O
effects	O
.	O

An	O
activated	O
moiety	O
,	O
i.e.	O
N	B
-	I
acylimidazole	I
derivative	O
of	O
etodolac	B
(	O
EAI	B
)	O
,	O
was	O
condensed	O
with	O
the	O
polysaccharide	O
polymer	O
dextran	B
of	O
different	O
molecular	O
weights	O
(	O
40000	O
,	O
60000	O
,	O
110000	O
and	O
200000	O
)	O
.	O

IR	O
spectral	O
data	O
confirmed	O
formation	O
of	O
ester	O
bonding	O
in	O
the	O
conjugates	O
.	O

Etodolac	B
contents	O
were	O
evaluated	O
by	O
UV	O
-	O
spectrophotometric	O
analysis	O
.	O

The	O
molecular	O
weights	O
were	O
determined	O
by	O
measuring	O
viscosity	O
using	O
the	O
Mark	O
-	O
Howink	O
-	O
Sakurada	O
equation	O
.	O

In	O
vitro	O
hydrolysis	O
of	O
ED	O
was	O
done	O
in	O
aqueous	O
buffers	O
(	O
pH	O
1.2	O
,	O
7.4	O
,	O
9	O
)	O
and	O
in	O
80	O
%	O
(	O
v	O
/	O
v	O
)	O
human	O
plasma	O
(	O
pH	O
7.4	O
)	O
.	O

At	O
pH	O
9	O
,	O
a	O
higher	O
rate	O
of	O
etodolac	B
release	O
from	O
ED	O
was	O
observed	O
as	O
compared	O
to	O
aqueous	O
buffer	O
of	O
pH	O
7.4	O
and	O
80	O
%	O
human	O
plasma	O
(	O
pH	O
7.4	O
)	O
,	O
following	O
first	O
-	O
order	O
kinetics	O
.	O

In	O
vivo	O
investigations	O
were	O
performed	O
in	O
animals	O
.	O

Acute	O
analgesic	O
and	O
antiinflammatory	O
activities	O
were	O
ascertained	O
using	O
acetic	B
acid	I
induced	O
writhing	O
model	O
(	O
mice	O
)	O
and	O
carrageenan	B
-	O
induced	O
rat	O
paw	O
edema	O
model	O
,	O
respectively	O
.	O

In	O
comparison	O
to	O
control	O
,	O
E	O
and	O
ED1-ED4	O
showed	O
highly	O
significant	O
analgesic	O
and	O
antiinflammatory	O
activities	O
(	O
p	O
<	O
0.001	O
)	O
.	O

Biological	O
evaluation	O
suggested	O
that	O
conjugates	O
(	O
ED1-ED4	O
)	O
retained	O
comparable	O
analgesic	O
and	O
antiinflammatory	O
activities	O
with	O
remarkably	O
reduced	O
ulcerogenicity	O
as	O
compared	O
to	O
their	O
parent	O
drug	O
--	O
etodolac	B
.	O

Dynamic	O
response	O
of	O
blood	O
vessel	O
in	O
acute	O
renal	O
failure	O
.	O

In	O
this	O
study	O
we	O
postulated	O
that	O
during	O
acute	O
renal	O
failure	O
induced	O
by	O
gentamicin	B
the	O
transient	O
or	O
dynamic	O
response	O
of	O
blood	O
vessels	O
could	O
be	O
affected	O
,	O
and	O
that	O
antioxidants	O
can	O
prevent	O
the	O
changes	O
in	O
dynamic	O
responses	O
of	O
blood	O
vessels	O
.	O

The	O
new	O
approach	O
to	O
ex	O
vivo	O
blood	O
vessel	O
experiments	O
in	O
which	O
not	O
only	O
the	O
end	O
points	O
of	O
vessels	O
response	O
within	O
the	O
time	O
interval	O
is	O
considered	O
,	O
but	O
also	O
dynamics	O
of	O
this	O
response	O
,	O
was	O
used	O
in	O
this	O
paper	O
.	O

Our	O
results	O
confirm	O
the	O
alteration	O
in	O
dynamic	O
response	O
of	O
blood	O
vessels	O
during	O
the	O
change	O
of	O
pressure	O
in	O
gentamicin	B
-	O
treated	O
animals	O
.	O

The	O
beneficial	O
effects	O
of	O
vitamin	B
C	I
administration	O
to	O
gentamicin	B
-	O
treated	O
animals	O
are	O
also	O
confirmed	O
through	O
:	O
lower	O
level	O
of	O
blood	O
urea	B
and	O
creatinine	B
and	O
higher	O
level	O
of	O
potassium	B
.	O

The	O
pressure	O
dynamic	O
responses	O
of	O
isolated	O
blood	O
vessels	O
show	O
a	O
faster	O
pressure	O
change	O
in	O
gentamicin	B
-	O
treated	O
animals	O
(	O
8.07	O
+	O
/-	O

1.7	O
s	O
vs.	O
5.64	O
+	O
/-	O

0.18	O
s	O
)	O
.	O

Vitamin	B
C	I
administration	O
induced	O
slowdown	O
of	O
pressure	O
change	O
back	O
to	O
the	O
control	O
values	O
.	O

The	O
pressure	O
dynamic	O
properties	O
,	O
quantitatively	O
defined	O
by	O
comparative	O
pressure	O
dynamic	O
and	O
total	O
pressure	O
dynamic	O
,	O
confirm	O
the	O
alteration	O
in	O
dynamic	O
response	O
of	O
blood	O
vessels	O
during	O
the	O
change	O
of	O
pressure	O
in	O
gentamicin	B
-	O
treated	O
animals	O
and	O
beneficial	O
effects	O
of	O
vitamin	B
C	I
administration	O
.	O

Fear	O
-	O
potentiated	O
startle	O
,	O
but	O
not	O
light	O
-	O
enhanced	O
startle	O
,	O
is	O
enhanced	O
by	O
anxiogenic	O
drugs	O
.	O

RATIONALE	O
AND	O
OBJECTIVES	O
:	O
The	O
light	O
-	O
enhanced	O
startle	O
paradigm	O
(	O
LES	O
)	O
is	O
suggested	O
to	O
model	O
anxiety	O
,	O
because	O
of	O
the	O
non	O
-	O
specific	O
cue	O
and	O
the	O
long	O
-	O
term	O
effect	O
.	O

In	O
contrast	O
,	O
the	O
fear	O
-	O
potentiated	O
startle	O
(	O
FPS	O
)	O
is	O
suggested	O
to	O
model	O
conditioned	O
fear	O
.	O

However	O
,	O
the	O
pharmacological	O
profiles	O
of	O
these	O
two	O
paradigms	O
are	O
very	O
similar	O
.	O

The	O
present	O
study	O
investigated	O
the	O
effects	O
of	O
putative	O
anxiogenic	O
drugs	O
on	O
LES	O
and	O
FPS	O
and	O
aimed	O
at	O
determining	O
the	O
sensitivity	O
of	O
LES	O
for	O
anxiogenic	O
drugs	O
and	O
to	O
potentially	O
showing	O
a	O
pharmacological	O
differentiation	O
between	O
these	O
two	O
paradigms	O
.	O

METHODS	O
:	O
Male	O
Wistar	O
rats	O
received	O
each	O
dose	O
of	O
the	O
alpha	O
(	O
2	O
)	O
-adrenoceptor	O
antagonist	O
yohimbine	B
(	O
0.25	O
-	O
1.0mg	O
/	O
kg	O
)	O
,	O
the	O
5-HT	B
(	O
2C	O
)	O
receptor	O
agonist	O
m	B
-	I
chlorophenylpiperazine	I
(	O
mCPP	B
,	O
0.5	O
-	O
2.0mg	O
/	O
kg	O
)	O
or	O
the	O
GABA	B
(	O
A	O
)	O
inverse	O
receptor	O
agonist	O
pentylenetetrazole	B
(	O
PTZ	B
,	O
3	O
-	O
30mg	O
/	O
kg	O
)	O
and	O
were	O
subsequently	O
tested	O
in	O
either	O
LES	O
or	O
FPS	O
.	O

RESULTS	O
:	O
None	O
of	O
the	O
drugs	O
enhanced	O
LES	O
,	O
whereas	O
mCPP	B
increased	O
percentage	O
FPS	O
and	O
yohimbine	B
increased	O
absolute	O
FPS	O
values	O
.	O

Furthermore	O
,	O
yohimbine	B
increased	O
baseline	O
startle	O
amplitude	O
in	O
the	O
LES	O
,	O
while	O
mCPP	B
suppressed	O
baseline	O
startle	O
in	O
both	O
the	O
LES	O
and	O
FPS	O
and	O
PTZ	B
suppressed	O
baseline	O
startle	O
in	O
the	O
FPS	O
.	O

CONCLUSIONS	O
:	O
In	O
contrast	O
to	O
findings	O
in	O
the	O
FPS	O
paradigm	O
,	O
none	O
of	O
the	O
drugs	O
were	O
able	O
to	O
exacerbate	O
the	O
LES	O
response	O
.	O

Thus	O
,	O
a	O
clear	O
pharmacological	O
differentiation	O
was	O
found	O
between	O
LES	O
and	O
FPS	O
.	O

The	O
ability	O
of	O
insulin	O
treatment	O
to	O
reverse	O
or	O
prevent	O
the	O
changes	O
in	O
urinary	O
bladder	O
function	O
caused	O
by	O
streptozotocin	B
-	O
induced	O
diabetes	O
mellitus	O
.	O

1	O
.	O

The	O
effects	O
of	O
insulin	O
treatment	O
on	O
in	O
vivo	O
and	O
in	O
vitro	O
urinary	O
bladder	O
function	O
in	O
streptozotocin	B
-	O
diabetic	O
rats	O
were	O
investigated	O
.	O

2	O
.	O
Diabetes	O
of	O
2	O
months	O
duration	O
resulted	O
in	O
decreases	O
in	O
body	O
weight	O
and	O
increases	O
in	O
fluid	O
consumption	O
,	O
urine	O
volume	O
,	O
frequency	O
of	O
micturition	O
,	O
and	O
average	O
volume	O
per	O
micturition	O
;	O
effects	O
which	O
were	O
prevented	O
by	O
insulin	O
treatment	O
.	O

3	O
.	O

Insulin	O
treatment	O
also	O
prevented	O
the	O
increases	O
in	O
contractile	O
responses	O
of	O
bladder	O
body	O
strips	O
from	O
diabetic	O
rats	O
to	O
nerve	O
stimulation	O
,	O
ATP	B
,	O
and	O
bethanechol	B
.	O

4	O
.	O
Diabetes	O
of	O
4	O
months	O
duration	O
also	O
resulted	O
in	O
decreases	O
in	O
body	O
weight	O
,	O
and	O
increases	O
in	O
fluid	O
consumption	O
,	O
urine	O
volume	O
,	O
frequency	O
of	O
micturition	O
,	O
and	O
average	O
volume	O
per	O
micturition	O
,	O
effects	O
which	O
were	O
reversed	O
by	O
insulin	O
treatment	O
for	O
the	O
final	O
2	O
months	O
of	O
the	O
study	O
.	O

5	O
.	O

Insulin	O
treatment	O
reversed	O
the	O
increases	O
in	O
contractile	O
responses	O
of	O
bladder	O
body	O
strips	O
from	O
diabetic	O
rats	O
to	O
nerve	O
stimulation	O
,	O
ATP	B
,	O
and	O
bethanechol	B
.	O

6	O
.	O

The	O
data	O
indicate	O
that	O
the	O
effects	O
of	O
streptozotocin	B
-	O
induced	O
diabetes	O
on	O
urinary	O
bladder	O
function	O
are	O
both	O
prevented	O
and	O
reversed	O
by	O
insulin	O
treatment	O
.	O

Severe	O
congestive	O
heart	O
failure	O
patient	O
on	O
amiodarone	B
presenting	O
with	O
myxedemic	O
coma	O
:	O
a	O
case	O
report	O
.	O

This	O
is	O
a	O
case	O
report	O
of	O
myxedema	O
coma	O
secondary	O
to	O
amiodarone	B
-	O
induced	O
hypothyroidism	O
in	O
a	O
patient	O
with	O
severe	O
congestive	O
heart	O
failure	O
(	O
CHF	O
)	O
.	O

To	O
our	O
knowledge	O
and	O
after	O
reviewing	O
the	O
literature	O
there	O
is	O
one	O
case	O
report	O
of	O
myxedema	O
coma	O
during	O
long	O
term	O
amiodarone	B
therapy	O
.	O

Myxedema	O
coma	O
is	O
a	O
life	O
threatening	O
condition	O
that	O
carries	O
a	O
mortality	O
reaching	O
as	O
high	O
as	O
20	O
%	O
with	O
treatment	O
.	O

The	O
condition	O
is	O
treated	O
with	O
intravenous	O
thyroxine	B
(	O
T4	B
)	O
or	O
intravenous	O
tri	B
-	I
iodo	I
-	I
thyronine	I
(	O
T3	B
)	O
.	O

Patients	O
with	O
CHF	O
on	O
amiodarone	B
may	O
suffer	O
serious	O
morbidity	O
and	O
mortality	O
from	O
hypothyroidism	O
,	O
and	O
thus	O
may	O
deserve	O
closer	O
follow	O
up	O
for	O
thyroid	O
stimulating	O
hormone	O
(	O
TSH	O
)	O
levels	O
.	O

This	O
case	O
report	O
carries	O
an	O
important	O
clinical	O
application	O
given	O
the	O
frequent	O
usage	O
of	O
amiodarone	B
among	O
CHF	O
patients	O
.	O

The	O
myriad	O
clinical	O
presentation	O
of	O
myxedema	O
coma	O
and	O
its	O
serious	O
morbidity	O
and	O
mortality	O
stresses	O
the	O
need	O
to	O
suspect	O
this	O
clinical	O
syndrome	O
among	O
CHF	O
patients	O
presenting	O
with	O
hypotension	O
,	O
weakness	O
or	O
other	O
unexplained	O
symptoms	O
.	O

Benzylacyclouridine	B
reverses	O
azidothymidine	B
-	O
induced	O
marrow	O
suppression	O
without	O
impairment	O
of	O
anti	O
-	O
human	O
immunodeficiency	O
virus	O
activity	O
.	O

Increased	O
extracellular	O
concentrations	O
of	O
uridine	B
(	O
Urd	B
)	O
have	O
been	O
reported	O
to	O
reduce	O
,	O
in	O
vitro	O
,	O
azidothymidine	B
(	O
AZT	B
)	O
-induced	O
inhibition	O
of	O
human	O
granulocyte	O
-	O
macrophage	O
progenitor	O
cells	O
without	O
impairment	O
of	O
its	O
antihuman	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
activity	O
.	O

Because	O
of	O
the	O
clinical	O
toxicities	O
associated	O
with	O
chronic	O
Urd	B
administration	O
,	O
the	O
ability	O
of	O
benzylacyclouridine	B
(	O
BAU	B
)	O
to	O
effect	O
,	O
in	O
vivo	O
,	O
AZT	B
-	O
induced	O
anemia	O
and	O
leukopenia	O
was	O
assessed	O
.	O

This	O
agent	O
inhibits	O
Urd	B
catabolism	O
and	O
,	O
in	O
vivo	O
,	O
increases	O
the	O
plasma	O
concentration	O
of	O
Urd	B
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
without	O
Urd	B
-	O
related	O
toxicity	O
.	O

In	O
mice	O
rendered	O
anemic	O
and	O
leukopenic	O
by	O
the	O
administration	O
of	O
AZT	B
for	O
28	O
days	O
in	O
drinking	O
water	O
(	O
1.5	O
mg	O
/	O
mL	O
)	O
,	O
the	O
continued	O
administration	O
of	O
AZT	B
plus	O
daily	O
BAU	B
(	O
300	O
mg	O
/	O
kg	O
,	O
orally	O
)	O
partially	O
reversed	O
AZT	B
-	O
induced	O
anemia	O
and	O
leukopenia	O
(	O
P	O
less	O
than	O
.05	O
)	O
,	O
increased	O
peripheral	O
reticulocytes	O
(	O
to	O
4.9	O
%	O
,	O
P	O
less	O
than	O
.01	O
)	O
,	O
increased	O
cellularity	O
in	O
the	O
marrow	O
,	O
and	O
improved	O
megaloblastosis	O
.	O

When	O
coadministered	O
with	O
AZT	B
from	O
the	O
onset	O
of	O
drug	O
administration	O
,	O
BAU	B
reduced	O
AZT	B
-	O
induced	O
marrow	O
toxicity	O
.	O

In	O
vitro	O
,	O
at	O
a	O
concentration	O
of	O
100	O
mumol	O
/	O
L	O
,	O
BAU	B
possesses	O
minimal	O
anti	O
-	O
HIV	O
activity	O
and	O
has	O
no	O
effect	O
on	O
the	O
ability	O
of	O
AZT	B
to	O
reverse	O
the	O
HIV	O
-	O
induced	O
cytopathic	O
effect	O
in	O
MT4	O
cells	O
.	O

The	O
clinical	O
and	O
biochemical	O
implications	O
of	O
these	O
findings	O
are	O
discussed	O
.	O

Late	O
-	O
onset	O
scleroderma	O
renal	O
crisis	O
induced	O
by	O
tacrolimus	B
and	O
prednisolone	B
:	O
a	O
case	O
report	O
.	O

Scleroderma	O
renal	O
crisis	O
(	O
SRC	O
)	O
is	O
a	O
rare	O
complication	O
of	O
systemic	O
sclerosis	O
(	O
SSc	O
)	O
but	O
can	O
be	O
severe	O
enough	O
to	O
require	O
temporary	O
or	O
permanent	O
renal	O
replacement	O
therapy	O
.	O

Moderate	O
to	O
high	O
dose	O
corticosteroid	B
use	O
is	O
recognized	O
as	O
a	O
major	O
risk	O
factor	O
for	O
SRC	O
.	O

Furthermore	O
,	O
there	O
have	O
been	O
reports	O
of	O
thrombotic	O
microangiopathy	O
precipitated	O
by	O
cyclosporine	B
in	O
patients	O
with	O
SSc	O
.	O

In	O
this	O
article	O
,	O
we	O
report	O
a	O
patient	O
with	O
SRC	O
induced	O
by	O
tacrolimus	B
and	O
corticosteroids	B
.	O

The	O
aim	O
of	O
this	O
work	O
is	O
to	O
call	O
attention	O
to	O
the	O
risk	O
of	O
tacrolimus	B
use	O
in	O
patients	O
with	O
SSc	O
.	O

The	O
risk	O
and	O
associated	O
factors	O
of	O
methamphetamine	B
psychosis	O
in	O
methamphetamine	B
-	O
dependent	O
patients	O
in	O
Malaysia	O
.	O

OBJECTIVE	O
:	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
risk	O
of	O
lifetime	O
and	O
current	O
methamphetamine	B
-	O
induced	O
psychosis	O
in	O
patients	O
with	O
methamphetamine	B
dependence	O
.	O

The	O
association	O
between	O
psychiatric	O
co	O
-	O
morbidity	O
and	O
methamphetamine	B
-	O
induced	O
psychosis	O
was	O
also	O
studied	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
cross	O
-	O
sectional	O
study	O
conducted	O
concurrently	O
at	O
a	O
teaching	O
hospital	O
and	O
a	O
drug	O
rehabilitation	O
center	O
in	O
Malaysia	O
.	O

Patients	O
with	O
the	O
diagnosis	O
of	O
methamphetamine	B
based	O
on	O
DSM	O
-	O
IV	O
were	O
interviewed	O
using	O
the	O
Mini	O
International	O
Neuropsychiatric	O
Interview	O
(	O
M.I.N.I.	O
)	O
for	O
methamphetamine	B
-	O
induced	O
psychosis	O
and	O
other	O
Axis	O
I	O
psychiatric	O
disorders	O
.	O

The	O
information	O
on	O
sociodemographic	O
background	O
and	O
drug	O
use	O
history	O
was	O
obtained	O
from	O
interview	O
or	O
medical	O
records	O
.	O

RESULTS	O
:	O
Of	O
292	O
subjects	O
,	O
47.9	O
%	O
of	O
the	O
subjects	O
had	O
a	O
past	O
history	O
of	O
psychotic	O
symptoms	O
and	O
13.0	O
%	O
of	O
the	O
patients	O
were	O
having	O
current	O
psychotic	O
symptoms	O
.	O

Co	O
-	O
morbid	O
major	O
depressive	O
disorder	O
(	O
OR=7.18	O
,	O
95	O
CI=2.612	O
-	O
19.708	O
)	O
,	O
bipolar	O
disorder	O
(	O
OR=13.807	O
,	O
95	O
CI=5.194	O
-	O
36.706	O
)	O
,	O
antisocial	O
personality	O
disorder	O
(	O
OR=12.619	O
,	O
95	O
CI=6.702	O
-	O
23.759	O
)	O
and	O
heavy	O
methamphetamine	B
uses	O
were	O
significantly	O
associated	O
with	O
lifetime	O
methamphetamine	B
-	O
induced	O
psychosis	O
after	O
adjusted	O
for	O
other	O
factors	O
.	O

Major	O
depressive	O
disorder	O
(	O
OR=2.870	O
,	O
CI=1.154	O
-	O
7.142	O
)	O
and	O
antisocial	O
personality	O
disorder	O
(	O
OR=3.299	O
,	O
95	O
CI=1.375	O
-	O
7.914	O
)	O
were	O
the	O
only	O
factors	O
associated	O
with	O
current	O
psychosis	O
.	O

CONCLUSION	O
:	O
There	O
was	O
a	O
high	O
risk	O
of	O
psychosis	O
in	O
patients	O
with	O
methamphetamine	B
dependence	O
.	O

It	O
was	O
associated	O
with	O
co	O
-	O
morbid	O
affective	O
disorder	O
,	O
antisocial	O
personality	O
,	O
and	O
heavy	O
methamphetamine	B
use	O
.	O

It	O
is	O
recommended	O
that	O
all	O
cases	O
of	O
methamphetamine	B
dependence	O
should	O
be	O
screened	O
for	O
psychotic	O
symptoms	O
.	O

Seizure	O
activity	O
with	O
imipenem	B
therapy	O
:	O
incidence	O
and	O
risk	O
factors	O
.	O

Two	O
elderly	O
patients	O
with	O
a	O
history	O
of	O
either	O
cerebral	O
vascular	O
accident	O
(	O
CVA	O
)	O
or	O
head	O
trauma	O
and	O
no	O
evidence	O
of	O
renal	O
disease	O
developed	O
seizures	O
while	O
receiving	O
maximum	O
doses	O
of	O
imipenem	B
/	I
cilastatin	I
.	O

Neither	O
patient	O
had	O
reported	O
previous	O
seizures	O
or	O
seizure	O
-	O
like	O
activity	O
nor	O
was	O
receiving	O
anticonvulsant	O
agents	O
.	O

All	O
seizures	O
were	O
controlled	O
with	O
therapeutic	O
doses	O
of	O
phenytoin	B
.	O

Both	O
patients	O
had	O
received	O
maximum	O
doses	O
of	O
other	O
beta	B
-	I
lactam	I
antibiotics	O
without	O
evidence	O
of	O
seizure	O
activity	O
.	O

Cerebellar	O
sensory	O
processing	O
alterations	O
impact	O
motor	O
cortical	O
plasticity	O
in	O
Parkinson	O
's	O
disease	O
:	O
clues	O
from	O
dyskinetic	O
patients	O
.	O

The	O
plasticity	O
of	O
primary	O
motor	O
cortex	O
(	O
M1	O
)	O
in	O
patients	O
with	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
and	O
levodopa	B
-	O
induced	O
dyskinesias	O
(	O
LIDs	O
)	O
is	O
severely	O
impaired	O
.	O

We	O
recently	O
reported	O
in	O
young	O
healthy	O
subjects	O
that	O
inhibitory	O
cerebellar	O
stimulation	O
enhanced	O
the	O
sensorimotor	O
plasticity	O
of	O
M1	O
that	O
was	O
induced	O
by	O
paired	O
associative	O
stimulation	O
(	O
PAS	O
)	O
.	O

This	O
study	O
demonstrates	O
that	O
the	O
deficient	O
sensorimotor	O
M1	O
plasticity	O
in	O
16	O
patients	O
with	O
LIDs	O
could	O
be	O
reinstated	O
by	O
a	O
single	O
session	O
of	O
real	O
inhibitory	O
cerebellar	O
stimulation	O
but	O
not	O
sham	O
stimulation	O
.	O

This	O
was	O
evident	O
only	O
when	O
a	O
sensory	O
component	O
was	O
involved	O
in	O
the	O
induction	O
of	O
plasticity	O
,	O
indicating	O
that	O
cerebellar	O
sensory	O
processing	O
function	O
is	O
involved	O
in	O
the	O
resurgence	O
of	O
M1	O
plasticity	O
.	O

The	O
benefit	O
of	O
inhibitory	O
cerebellar	O
stimulation	O
on	O
LIDs	O
is	O
known	O
.	O

To	O
explore	O
whether	O
this	O
benefit	O
is	O
linked	O
to	O
the	O
restoration	O
of	O
sensorimotor	O
plasticity	O
of	O
M1	O
,	O
we	O
conducted	O
an	O
additional	O
study	O
looking	O
at	O
changes	O
in	O
LIDs	O
and	O
PAS	O
-	O
induced	O
plasticity	O
after	O
10	O
sessions	O
of	O
either	O
bilateral	O
,	O
real	O
inhibitory	O
cerebellar	O
stimulation	O
or	O
sham	O
stimulation	O
.	O

Only	O
real	O
and	O
not	O
sham	O
stimulation	O
had	O
an	O
antidyskinetic	O
effect	O
and	O
it	O
was	O
paralleled	O
by	O
a	O
resurgence	O
in	O
the	O
sensorimotor	O
plasticity	O
of	O
M1	O
.	O

These	O
results	O
suggest	O
that	O
alterations	O
in	O
cerebellar	O
sensory	O
processing	O
function	O
,	O
occurring	O
secondary	O
to	O
abnormal	O
basal	O
ganglia	O
signals	O
reaching	O
it	O
,	O
may	O
be	O
an	O
important	O
element	O
contributing	O
to	O
the	O
maladaptive	O
sensorimotor	O
plasticity	O
of	O
M1	O
and	O
the	O
emergence	O
of	O
abnormal	O
involuntary	O
movements	O
.	O

The	O
function	O
of	O
P2X3	O
receptor	O
and	O
NK1	O
receptor	O
antagonists	O
on	O
cyclophosphamide	B
-	O
induced	O
cystitis	O
in	O
rats	O
.	O

PURPOSE	O
:	O
The	O
purpose	O
of	O
the	O
study	O
is	O
to	O
explore	O
the	O
function	O
of	O
P2X3	O
and	O
NK1	O
receptors	O
antagonists	O
on	O
cyclophosphamide	B
(	O
CYP	B
)	O
-induced	O
cystitis	O
in	O
rats	O
.	O

METHODS	O
:	O
Sixty	O
female	O
Sprague	O
-	O
Dawley	O
(	O
SD	O
)	O
rats	O
were	O
randomly	O
divided	O
into	O
three	O
groups	O
.	O

The	O
rats	O
in	O
the	O
control	O
group	O
were	O
intraperitoneally	O
(	O
i.p	O
.	O
)	O
injected	O
with	O
0.9	O
%	O
saline	O
(	O
4	O
ml	O
/	O
kg	O
)	O
;	O
the	O
rats	O
in	O
the	O
model	O
group	O
were	O
i.p	O
.	O

injected	O
with	O
CYP	B
(	O
150	O
mg	O
/	O
kg	O
)	O
;	O
and	O
the	O
rats	O
in	O
the	O
intervention	O
group	O
were	O
i.p	O
.	O
injected	O
with	O
CYP	B
with	O
subsequently	O
perfusion	O
of	O
bladder	O
with	O
P2X3	O
and	O
NK1	O
receptors	O
'	O
antagonists	O
,	O
Suramin	B
and	O
GR	B
82334	I
.	O

Spontaneous	O
pain	O
behaviors	O
following	O
the	O
administration	O
of	O
CYP	B
were	O
observed	O
.	O

Urodynamic	O
parameters	O
,	O
bladder	O
pressure	O
-	O
volume	O
curve	O
,	O
maximum	O
voiding	O
pressure	O
(	O
MVP	O
)	O
,	O
and	O
maximum	O
cystometric	O
capacity	O
(	O
MCC	O
)	O
,	O
were	O
recorded	O
.	O

Pathological	O
changes	O
in	O
bladder	O
tissue	O
were	O
observed	O
.	O

Immunofluorescence	O
was	O
used	O
to	O
detect	O
the	O
expression	O
of	O
P2X3	O
and	O
NK1	O
receptors	O
in	O
bladder	O
.	O

RESULTS	O
:	O
Cyclophosphamide	B
treatment	O
increased	O
the	O
spontaneous	O
pain	O
behaviors	O
scores	O
.	O

The	O
incidence	O
of	O
bladder	O
instability	O
during	O
urine	O
storage	O
period	O
of	O
model	O
group	O
was	O
significantly	O
higher	O
than	O
intervention	O
group	O
(	O
X	O
(	O
2	O
)	O
=	O
7.619	O
,	O
P	O
=	O
0.007	O
)	O
and	O
control	O
group	O
(	O
X	O
(	O
2	O
)	O
=	O
13.755	O
,	O
P	O
=	O
0.000	O
)	O
.	O

MCC	O
in	O
the	O
model	O
group	O
was	O
lower	O
than	O
the	O
control	O
and	O
intervention	O
groups	O
(	O
P	O
<	O
0.01	O
)	O
.	O

Histological	O
changes	O
evident	O
in	O
model	O
and	O
intervention	O
groups	O
rats	O
'	O
bladder	O
included	O
edema	O
,	O
vasodilation	O
,	O
and	O
infiltration	O
of	O
inflammatory	O
cells	O
.	O

In	O
model	O
group	O
,	O
the	O
expression	O
of	O
P2X3	O
receptor	O
increased	O
in	O
urothelium	O
and	O
suburothelium	O
,	O
and	O
NK1	O
receptor	O
increased	O
in	O
suburothelium	O
,	O
while	O
the	O
expression	O
of	O
them	O
in	O
intervention	O
group	O
was	O
lower	O
.	O

CONCLUSIONS	O
:	O
In	O
CYP	B
-	O
induced	O
cystitis	O
,	O
the	O
expression	O
of	O
P2X3	O
and	O
NK1	O
receptors	O
increased	O
in	O
urothelium	O
and/or	O
suburothelium	O
.	O

Perfusion	O
of	O
bladder	O
with	O
P2X3	O
and	O
NK1	O
receptors	O
antagonists	O
ameliorated	O
the	O
bladder	O
function	O
.	O

Acute	O
hepatitis	O
associated	O
with	O
clopidogrel	B
:	O
a	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O

Drug	O
-	O
induced	O
hepatotoxicity	O
is	O
a	O
common	O
cause	O
of	O
acute	O
hepatitis	O
,	O
and	O
the	O
recognition	O
of	O
the	O
responsible	O
drug	O
may	O
be	O
difficult	O
.	O

We	O
describe	O
a	O
case	O
of	O
clopidogrel	B
-	O
related	O
acute	O
hepatitis	O
.	O

The	O
diagnosis	O
is	O
strongly	O
suggested	O
by	O
an	O
accurate	O
medical	O
history	O
and	O
liver	O
biopsy	O
.	O

Reports	O
about	O
cases	O
of	O
hepatotoxicity	O
due	O
to	O
clopidogrel	B
are	O
increasing	O
in	O
the	O
last	O
few	O
years	O
,	O
after	O
the	O
increased	O
use	O
of	O
this	O
drug	O
.	O

In	O
conclusion	O
,	O
we	O
believe	O
that	O
physicians	O
should	O
carefully	O
consider	O
the	O
risk	O
of	O
drug	O
-	O
induced	O
hepatic	O
injury	O
when	O
clopidogrel	B
is	O
prescribed	O
.	O

Bortezomib	B
and	O
dexamethasone	B
as	O
salvage	O
therapy	O
in	O
patients	O
with	O
relapsed	O
/	O
refractory	O
multiple	O
myeloma	O
:	O
analysis	O
of	O
long	O
-	O
term	O
clinical	O
outcomes	O
.	O

Bortezomib	B
(	O
bort	B
)	O
-dexamethasone	O
(	O
dex	B
)	O
is	O
an	O
effective	O
therapy	O
for	O
relapsed	O
/	O
refractory	O
(	O
R	O
/	O
R	O
)	O
multiple	O
myeloma	O
(	O
MM	O
)	O
.	O

This	O
retrospective	O
study	O
investigated	O
the	O
combination	O
of	O
bort	B
(	O
1.3	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1	O
,	O
4	O
,	O
8	O
,	O
and	O
11	O
every	O
3	O
weeks	O
)	O
and	O
dex	B
(	O
20	O
mg	O
on	O
the	O
day	O
of	O
and	O
the	O
day	O
after	O
bort	B
)	O
as	O
salvage	O
treatment	O
in	O
85	O
patients	O
with	O
R	O
/	O
R	O
MM	O
after	O
prior	O
autologous	O
stem	O
cell	O
transplantation	O
or	O
conventional	O
chemotherapy	O
.	O

The	O
median	O
number	O
of	O
prior	O
lines	O
of	O
therapy	O
was	O
2	O
.	O

Eighty	O
-	O
seven	O
percent	O
of	O
the	O
patients	O
had	O
received	O
immunomodulatory	O
drugs	O
included	O
in	O
some	O
line	O
of	O
therapy	O
before	O
bort	B
-	O
dex	B
.	O

The	O
median	O
number	O
of	O
bort	B
-	O
dex	B
cycles	O
was	O
6	O
,	O
up	O
to	O
a	O
maximum	O
of	O
12	O
cycles	O
.	O

On	O
an	O
intention	O
-	O
to	O
-	O
treat	O
basis	O
,	O
55	O
%	O
of	O
the	O
patients	O
achieved	O
at	O
least	O
partial	O
response	O
,	O
including	O
19	O
%	O
CR	O
and	O
35	O
%	O
achieved	O
at	O
least	O
very	O
good	O
partial	O
response	O
.	O

Median	O
durations	O
of	O
response	O
,	O
time	O
to	O
next	O
therapy	O
and	O
treatment	O
-	O
free	O
interval	O
were	O
8	O
,	O
11.2	O
,	O
and	O
5.1	O
months	O
,	O
respectively	O
.	O

The	O
most	O
relevant	O
adverse	O
event	O
was	O
peripheral	O
neuropathy	O
,	O
which	O
occurred	O
in	O
78	O
%	O
of	O
the	O
patients	O
(	O
grade	O
II	O
,	O
38	O
%	O
;	O
grade	O
III	O
,	O
21	O
%	O
)	O
and	O
led	O
to	O
treatment	O
discontinuation	O
in	O
6	O
%	O
.	O

With	O
a	O
median	O
follow	O
up	O
of	O
22	O
months	O
,	O
median	O
time	O
to	O
progression	O
,	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
)	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
were	O
8.9	O
,	O
8.7	O
,	O
and	O
22	O
months	O
,	O
respectively	O
.	O

Prolonged	O
PFS	O
and	O
OS	O
were	O
observed	O
in	O
patients	O
achieving	O
CR	O
and	O
receiving	O
bort	B
-	O
dex	B
a	O
single	O
line	O
of	O
prior	O
therapy	O
.	O

Bort	B
-	O
dex	B
was	O
an	O
effective	O
salvage	O
treatment	O
for	O
MM	O
patients	O
,	O
particularly	O
for	O
those	O
in	O
first	O
relapse	O
.	O

Pubertal	O
exposure	O
to	O
Bisphenol	B
A	I
increases	O
anxiety	O
-	O
like	O
behavior	O
and	O
decreases	O
acetylcholinesterase	O
activity	O
of	O
hippocampus	O
in	O
adult	O
male	O
mice	O
.	O

The	O
negative	O
effects	O
of	O
Bisphenol	B
A	I
(	O
BPA	B
)	O
on	O
neurodevelopment	O
and	O
behaviors	O
have	O
been	O
well	O
established	O
.	O

Acetylcholinesterase	O
(	O
AChE	O
)	O
is	O
a	O
regulatory	O
enzyme	O
which	O
is	O
involved	O
in	O
anxiety	O
-	O
like	O
behavior	O
.	O

This	O
study	O
investigated	O
behavioral	O
phenotypes	O
and	O
AChE	O
activity	O
in	O
male	O
mice	O
following	O
BPA	B
exposure	O
during	O
puberty	O
.	O

On	O
postnatal	O
day	O
(	O
PND	O
)	O
35	O
,	O
male	O
mice	O
were	O
exposed	O
to	O
50	O
mg	O
BPA	B
/	O
kg	O
diet	O
per	O
day	O
for	O
a	O
period	O
of	O
35	O
days	O
.	O

On	O
PND71	O
,	O
a	O
behavioral	O
assay	O
was	O
performed	O
using	O
the	O
elevated	O
plus	O
maze	O
(	O
EPM	O
)	O
and	O
the	O
light	O
/	O
dark	O
test	O
.	O

In	O
addition	O
,	O
AChE	O
activity	O
was	O
measured	O
in	O
the	O
prefrontal	O
cortex	O
,	O
hypothalamus	O
,	O
cerebellum	O
and	O
hippocampus	O
.	O

Results	O
from	O
our	O
behavioral	O
phenotyping	O
indicated	O
that	O
anxiety	O
-	O
like	O
behavior	O
was	O
increased	O
in	O
mice	O
exposed	O
to	O
BPA	B
.	O

AChE	O
activity	O
was	O
significantly	O
decreased	O
in	O
the	O
hippocampus	O
of	O
mice	O
with	O
BPA	B
compared	O
to	O
control	O
mice	O
,	O
whereas	O
no	O
difference	O
was	O
found	O
in	O
the	O
prefrontal	O
cortex	O
,	O
hypothalamus	O
and	O
cerebellum	O
.	O

Our	O
findings	O
showed	O
that	O
pubertal	O
BPA	B
exposure	O
increased	O
anxiety	O
-	O
like	O
behavior	O
,	O
which	O
may	O
be	O
associated	O
with	O
decreased	O
AChE	O
activity	O
of	O
the	O
hippocampus	O
in	O
adult	O
male	O
mice	O
.	O

Further	O
studies	O
are	O
necessary	O
to	O
investigate	O
the	O
cholinergic	O
signaling	O
of	O
the	O
hippocampus	O
in	O
PBE	O
induced	O
anxiety	O
-	O
like	O
behaviors	O
.	O

Biochemical	O
effects	O
of	O
Solidago	O
virgaurea	O
extract	O
on	O
experimental	O
cardiotoxicity	O
.	O

Cardiovascular	O
diseases	O
(	O
CVDs	O
)	O
are	O
the	O
major	O
health	O
problem	O
of	O
advanced	O
as	O
well	O
as	O
developing	O
countries	O
of	O
the	O
world	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
protective	O
effect	O
of	O
the	O
Solidago	O
virgaurea	O
extract	O
on	O
isoproterenol	B
-	O
induced	O
cardiotoxicity	O
in	O
rats	O
.	O

The	O
subcutaneous	O
injection	O
of	O
isoproterenol	B
(	O
30	O
mg	O
/	O
kg	O
)	O
into	O
rats	O
twice	O
at	O
an	O
interval	O
of	O
24	O
h	O
,	O
for	O
two	O
consecutive	O
days	O
,	O
led	O
to	O
a	O
significant	O
increase	O
in	O
serum	O
lactate	B
dehydrogenase	O
,	O
creatine	B
phosphokinase	O
,	O
alanine	B
transaminase	O
,	O
aspartate	B
transaminase	O
,	O
and	O
angiotensin	B
-	O
converting	O
enzyme	O
activities	O
,	O
total	O
cholesterol	B
,	O
triglycerides	B
,	O
free	O
serum	O
fatty	B
acid	I
,	O
cardiac	O
tissue	O
malondialdehyde	B
(	O
MDA	B
)	O
,	O
and	O
nitric	B
oxide	I
levels	O
and	O
a	O
significant	O
decrease	O
in	O
levels	O
of	O
glutathione	B
and	O
superoxide	B
dismutase	O
in	O
cardiac	O
tissue	O
as	O
compared	O
to	O
the	O
normal	O
control	O
group	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Pretreatment	O
with	O
S.	O
virgaurea	O
extract	O
for	O
5	O
weeks	O
at	O
a	O
dose	O
of	O
250	O
mg	O
/	O
kg	O
followed	O
by	O
isoproterenol	B
injection	O
significantly	O
prevented	O
the	O
observed	O
alterations	O
.	O

Captopril	B
(	O
50	O
mg	O
/	O
kg	O
/	O
day	O
,	O
given	O
orally	O
)	O
,	O
an	O
inhibitor	O
of	O
angiotensin	B
-	O
converting	O
enzyme	O
used	O
as	O
a	O
standard	O
cardioprotective	O
drug	O
,	O
was	O
used	O
as	O
a	O
positive	O
control	O
in	O
this	O
study	O
.	O

The	O
data	O
of	O
the	O
present	O
study	O
suggest	O
that	O
S.	O
virgaurea	O
extract	O
exerts	O
its	O
protective	O
effect	O
by	O
decreasing	O
MDA	B
level	O
and	O
increasing	O
the	O
antioxidant	O
status	O
in	O
isoproterenol	B
-	O
treated	O
rats	O
.	O

The	O
study	O
emphasizes	O
the	O
beneficial	O
action	O
of	O
S.	O
virgaurea	O
extract	O
as	O
a	O
cardioprotective	O
agent	O
.	O

"	O
Real	O
-	O
world	O
"	O
data	O
on	O
the	O
efficacy	O
and	O
safety	O
of	O
lenalidomide	B
and	O
dexamethasone	B
in	O
patients	O
with	O
relapsed	O
/	O
refractory	O
multiple	O
myeloma	O
who	O
were	O
treated	O
according	O
to	O
the	O
standard	O
clinical	O
practice	O
:	O
a	O
study	O
of	O
the	O
Greek	O
Myeloma	O
Study	O
Group	O
.	O

Lenalidomide	B
and	O
dexamethasone	B
(	O
RD	B
)	O
is	O
a	O
standard	O
of	O
care	O
for	O
relapsed	O
/	O
refractory	O
multiple	O
myeloma	O
(	O
RRMM	O
)	O
,	O
but	O
there	O
is	O
limited	O
published	O
data	O
on	O
its	O
efficacy	O
and	O
safety	O
in	O
the	O
"	O
real	O
world	O
"	O
(	O
RW	O
)	O
,	O
according	O
to	O
the	O
International	O
Society	O
of	O
Pharmacoeconomics	O
and	O
Outcomes	O
Research	O
definition	O
.	O

We	O
studied	O
212	O
RRMM	O
patients	O
who	O
received	O
RD	B
in	O
RW	O
.	O

Objective	O
response	O
(	O
>	O
PR	O
(	O
partial	O
response	O
)	O
)	O
rate	O
was	O
77.4	O
%	O
(	O
complete	O
response	O
(	O
CR	O
)	O
,	O
20.2	O
%	O
)	O
.	O

Median	O
time	O
to	O
first	O
and	O
best	O
response	O
was	O
2	O
and	O
5	O
months	O
,	O
respectively	O
.	O

Median	O
time	O
to	O
CR	O
when	O
RD	B
was	O
given	O
as	O
2nd	O
or	O
>	O
2	O
(	O
nd	O
)	O
-line	O
treatment	O
at	O
4	O
and	O
11	O
months	O
,	O
respectively	O
.	O

Quality	O
of	O
response	O
was	O
independent	O
of	O
previous	O
lines	O
of	O
therapies	O
or	O
previous	O
exposure	O
to	O
thalidomide	B
or	O
bortezomib	B
.	O

Median	O
duration	O
of	O
response	O
was	O
34.4	O
months	O
,	O
and	O
it	O
was	O
higher	O
in	O
patients	O
who	O
received	O
RD	B
until	O
progression	O
(	O
not	O
reached	O
versus	O
19	O
months	O
,	O
p	O
<	O
0.001	O
)	O
.	O

Improvement	O
of	O
humoral	O
immunity	O
occurred	O
in	O
60	O
%	O
of	O
responders	O
(	O
p	O
<	O
0.001	O
)	O
and	O
in	O
the	O
majority	O
of	O
patients	O
who	O
achieved	O
stable	O
disease	O
.	O

Adverse	O
events	O
were	O
reported	O
in	O
68.9	O
%	O
of	O
patients	O
(	O
myelosuppression	O
in	O
49.4	O
%	O
)	O
and	O
12.7	O
%	O
of	O
patients	O
needed	O
hospitalization	O
.	O

Peripheral	O
neuropathy	O
was	O
observed	O
only	O
in	O
2.5	O
%	O
of	O
patients	O
and	O
deep	O
vein	O
thrombosis	O
in	O
5.7	O
%	O
.	O

Dose	O
reductions	O
were	O
needed	O
in	O
31	O
%	O
of	O
patients	O
and	O
permanent	O
discontinuation	O
in	O
38.9	O
%	O
.	O

Median	O
time	O
to	O
treatment	O
discontinuation	O
was	O
16.8	O
months	O
.	O

Performance	O
status	O
(	O
PS	O
)	O
and	O
initial	O
lenalidomide	B
dose	O
predicted	O
for	O
treatment	O
discontinuation	O
.	O

Extra	O
-	O
medullary	O
relapses	O
occurred	O
in	O
3.8	O
%	O
of	O
patients	O
.	O

Our	O
study	O
confirms	O
that	O
RD	B
is	O
effective	O
and	O
safe	O
in	O
RRMM	O
in	O
the	O
RW	O
;	O
it	O
produces	O
durable	O
responses	O
especially	O
in	O
patients	O
who	O
continue	O
on	O
treatment	O
till	O
progression	O
and	O
improves	O
humoral	O
immunity	O
even	O
in	O
patients	O
with	O
stable	O
disease	O
.	O

The	O
cytogenetic	O
action	O
of	O
ifosfamide	B
,	O
mesna	B
,	O
and	O
their	O
combination	O
on	O
peripheral	O
rabbit	O
lymphocytes	O
:	O
an	O
in	O
vivo	O
/	O
in	O
vitro	O
cytogenetic	O
study	O
.	O

Ifosfamide	B
(	O
IFO	B
)	O
is	O
an	O
alkylating	O
nitrogen	B
mustard	O
,	O
administrated	O
as	O
an	O
antineoplasmic	O
agent	O
.	O

It	O
is	O
characterized	O
by	O
its	O
intense	O
urotoxic	O
action	O
,	O
leading	O
to	O
hemorrhagic	O
cystitis	O
.	O

This	O
side	O
effect	O
of	O
IFO	B
raises	O
the	O
requirement	O
for	O
the	O
co	O
-	O
administration	O
with	O
sodium	B
2-sulfanylethanesulfonate	I
(	O
Mesna	B
)	O
aiming	O
to	O
avoid	O
or	O
minimize	O
this	O
effect	O
.	O

IFO	B
and	O
Mesna	B
were	O
administrated	O
separately	O
on	O
rabbit	O
's	O
lymphocytes	O
in	O
vivo	O
,	O
which	O
were	O
later	O
developed	O
in	O
vitro	O
.	O

Cytogenetic	O
markers	O
for	O
sister	O
chromatid	O
exchanges	O
(	O
SCEs	O
)	O
,	O
proliferation	O
rate	O
index	O
(	O
PRI	O
)	O
and	O
Mitotic	O
Index	O
were	O
recorded	O
.	O

Mesna	B
's	O
action	O
,	O
in	O
conjunction	O
with	O
IFO	B
reduces	O
the	O
frequency	O
of	O
SCEs	O
,	O
in	O
comparison	O
with	O
the	O
SCEs	O
recordings	O
obtained	O
when	O
IFO	B
is	O
administered	O
alone	O
.	O

In	O
addition	O
to	O
this	O
,	O
when	O
high	O
concentrations	O
of	O
Mesna	B
were	O
administered	O
alone	O
significant	O
reductions	O
of	O
the	O
PRI	O
were	O
noted	O
,	O
than	O
with	O
IFO	B
acting	O
at	O
the	O
same	O
concentration	O
on	O
the	O
lymphocytes	O
.	O

Mesna	B
significantly	O
reduces	O
IFO	B
's	O
genotoxicity	O
,	O
while	O
when	O
administered	O
in	O
high	O
concentrations	O
it	O
acts	O
in	O
an	O
inhibitory	O
fashion	O
on	O
the	O
cytostatic	O
action	O
of	O
the	O
drug	O
.	O

Risk	O
factors	O
and	O
predictors	O
of	O
levodopa	B
-	O
induced	O
dyskinesia	O
among	O
multiethnic	O
Malaysians	O
with	O
Parkinson	O
's	O
disease	O
.	O

Chronic	O
pulsatile	O
levodopa	B
therapy	O
for	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
leads	O
to	O
the	O
development	O
of	O
motor	O
fluctuations	O
and	O
dyskinesia	O
.	O

We	O
studied	O
the	O
prevalence	O
and	O
predictors	O
of	O
levodopa	B
-	O
induced	O
dyskinesia	O
among	O
multiethnic	O
Malaysian	O
patients	O
with	O
PD	O
.	O

METHODS	O
:	O
This	O
is	O
a	O
cross	O
-	O
sectional	O
study	O
involving	O
95	O
patients	O
with	O
PD	O
on	O
uninterrupted	O
levodopa	B
therapy	O
for	O
at	O
least	O
6	O
months	O
.	O

The	O
instrument	O
used	O
was	O
the	O
UPDRS	O
questionnaires	O
.	O

The	O
predictors	O
of	O
dyskinesia	O
were	O
determined	O
using	O
multivariate	O
logistic	O
regression	O
analysis	O
.	O

RESULTS	O
:	O
The	O
mean	O
age	O
was	O
65.6	O
+	O
8.5	O
years	O
.	O

The	O
mean	O
onset	O
age	O
was	O
58.5	O
+	O
9.8	O
years	O
.	O

The	O
median	O
disease	O
duration	O
was	O
6	O
(	O
7	O
)	O
years	O
.	O

Dyskinesia	O
was	O
present	O
in	O
44	O
%	O
(	O
n	O
=	O
42	O
)	O
with	O
median	O
levodopa	B
therapy	O
of	O
3	O
years	O
.	O

There	O
were	O
64.3	O
%	O
Chinese	O
,	O
31	O
%	O
Malays	O
,	O
and	O
3.7	O
%	O
Indians	O
and	O
other	O
ethnic	O
groups	O
.	O

Eighty	O
-	O
one	O
percent	O
of	O
patients	O
with	O
dyskinesia	O
had	O
clinical	O
fluctuations	O
.	O

Patients	O
with	O
dyskinesia	O
had	O
lower	O
onset	O
age	O
(	O
p	O
<	O
0.001	O
)	O
,	O
longer	O
duration	O
of	O
levodopa	B
therapy	O
(	O
p	O
<	O
0.001	O
)	O
,	O
longer	O
disease	O
duration	O
(	O
p	O
<	O
0.001	O
)	O
,	O
higher	O
total	O
daily	O
levodopa	B
dose	O
(	O
p	O
<	O
0.001	O
)	O
,	O
and	O
higher	O
total	O
UPDRS	O
scores	O
(	O
p	O
=	O
0.005	O
)	O
than	O
patients	O
without	O
dyskinesia	O
.	O

The	O
three	O
significant	O
predictors	O
of	O
dyskinesia	O
were	O
duration	O
of	O
levodopa	B
therapy	O
,	O
onset	O
age	O
,	O
and	O
total	O
daily	O
levodopa	B
dose	O
.	O

CONCLUSIONS	O
:	O
The	O
prevalence	O
of	O
levodopa	B
-	O
induced	O
dyskinesia	O
in	O
our	O
patients	O
was	O
44	O
%	O
.	O

The	O
most	O
significant	O
predictors	O
were	O
duration	O
of	O
levodopa	B
therapy	O
,	O
total	O
daily	O
levodopa	B
dose	O
,	O
and	O
onset	O
age	O
.	O

An	O
unexpected	O
diagnosis	O
in	O
a	O
renal	O
-	O
transplant	O
patient	O
with	O
proteinuria	O
treated	O
with	O
everolimus	B
:	O
AL	O
amyloidosis	O
.	O

Proteinuria	O
is	O
an	O
expected	O
complication	O
in	O
transplant	O
patients	O
treated	O
with	O
mammalian	O
target	O
of	O
rapamycin	B
inhibitors	O
(	O
mTOR	O
-	O
i	O
)	O
.	O

However	O
,	O
clinical	O
suspicion	O
should	O
always	O
be	O
supported	O
by	O
histological	O
evidence	O
in	O
order	O
to	O
investigate	O
potential	O
alternate	O
diagnoses	O
such	O
as	O
acute	O
or	O
chronic	O
rejection	O
,	O
interstitial	O
fibrosis	O
and	O
tubular	O
atrophy	O
,	O
or	O
recurrent	O
or	O
de	O
novo	O
glomerulopathy	O
.	O

In	O
this	O
case	O
we	O
report	O
the	O
unexpected	O
diagnosis	O
of	O
amyloidosis	O
in	O
a	O
renal	O
-	O
transplant	O
patient	O
with	O
pre	O
-	O
transplant	O
monoclonal	O
gammapathy	O
of	O
undetermined	O
significance	O
who	O
developed	O
proteinuria	O
after	O
conversion	O
from	O
tacrolimus	B
to	O
everolimus	B
.	O

An	O
investigation	O
of	O
the	O
pattern	O
of	O
kidney	O
injury	O
in	O
HIV	O
-	O
positive	O
persons	O
exposed	O
to	O
tenofovir	B
disoproxil	I
fumarate	I
:	O
an	O
examination	O
of	O
a	O
large	O
population	O
database	O
(	O
MHRA	O
database	O
)	O
.	O

The	O
potential	O
for	O
tenofovir	B
to	O
cause	O
a	O
range	O
of	O
kidney	O
syndromes	O
has	O
been	O
established	O
from	O
mechanistic	O
and	O
randomised	O
clinical	O
trials	O
.	O

However	O
,	O
the	O
exact	O
pattern	O
of	O
kidney	O
involvement	O
is	O
still	O
uncertain	O
.	O

We	O
undertook	O
a	O
descriptive	O
analysis	O
of	O
Yellow	O
Card	O
records	O
of	O
407	O
HIV	O
-	O
positive	O
persons	O
taking	O
tenofovir	B
disoproxil	I
fumarate	I
(	O
TDF	B
)	O
as	O
part	O
of	O
their	O
antiretroviral	O
therapy	O
regimen	O
and	O
submitted	O
to	O
the	O
Medicines	O
and	O
Healthcare	O
Products	O
Regulatory	O
Agency	O
(	O
MHRA	O
)	O
with	O
suspected	O
kidney	O
adverse	O
effects	O
.	O

Reports	O
that	O
satisfy	O
defined	O
criteria	O
were	O
classified	O
as	O
acute	O
kidney	O
injury	O
,	O
kidney	O
tubular	O
dysfunction	O
and	O
Fanconi	O
syndrome	O
.	O

Of	O
the	O
407	O
Yellow	O
Card	O
records	O
analysed	O
,	O
106	O
satisfied	O
criteria	O
for	O
TDF	B
-	O
related	O
kidney	O
disease	O
,	O
of	O
which	O
53	O
(	O
50	O
%	O
)	O
had	O
features	O
of	O
kidney	O
tubular	O
dysfunction	O
,	O
35	O
(	O
33	O
%	O
)	O
were	O
found	O
to	O
have	O
features	O
of	O
glomerular	O
dysfunction	O
and	O
18	O
(	O
17	O
%	O
)	O
had	O
Fanconi	O
syndrome	O
.	O

The	O
median	O
TDF	B
exposure	O
was	O
316	O
days	O
(	O
interquartile	O
range	O
120	O
-	O
740	O
)	O
.	O

The	O
incidence	O
of	O
hospitalisation	O
for	O
TDF	B
kidney	O
adverse	O
effects	O
was	O
high	O
,	O
particularly	O
amongst	O
patients	O
with	O
features	O
of	O
Fanconi	O
syndrome	O
.	O

The	O
pattern	O
of	O
kidney	O
syndromes	O
in	O
this	O
population	O
series	O
mirrors	O
that	O
reported	O
in	O
randomised	O
clinical	O
trials	O
.	O

Cessation	O
of	O
TDF	B
was	O
associated	O
with	O
complete	O
restoration	O
of	O
kidney	O
function	O
in	O
up	O
half	O
of	O
the	O
patients	O
in	O
this	O
report	O
.	O

Incidence	O
of	O
postoperative	O
delirium	O
is	O
high	O
even	O
in	O
a	O
population	O
without	O
known	O
risk	O
factors	O
.	O

PURPOSE	O
:	O
Postoperative	O
delirium	O
is	O
a	O
recognized	O
complication	O
in	O
populations	O
at	O
risk	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
assess	O
the	O
prevalence	O
of	O
early	O
postoperative	O
delirium	O
in	O
a	O
population	O
without	O
known	O
risk	O
factors	O
admitted	O
to	O
the	O
ICU	O
for	O
postoperative	O
monitoring	O
after	O
elective	O
major	O
surgery	O
.	O

The	O
secondary	O
outcome	O
investigated	O
is	O
to	O
identify	O
eventual	O
independent	O
risk	O
factors	O
among	O
demographic	O
data	O
and	O
anesthetic	O
drugs	O
used	O
.	O

METHODS	O
:	O
An	O
observational	O
,	O
prospective	O
study	O
was	O
conducted	O
on	O
a	O
consecutive	O
cohort	O
of	O
patients	O
admitted	O
to	O
our	O
ICU	O
within	O
and	O
for	O
at	O
least	O
24	O
h	O
after	O
major	O
surgical	O
procedures	O
.	O

Exclusion	O
criteria	O
were	O
any	O
preexisting	O
predisposing	O
factor	O
for	O
delirium	O
or	O
other	O
potentially	O
confounding	O
neurological	O
dysfunctions	O
.	O

Patients	O
were	O
assessed	O
daily	O
using	O
the	O
confusion	O
assessment	O
method	O
for	O
the	O
ICU	O
scale	O
for	O
3	O
days	O
after	O
the	O
surgical	O
procedure	O
.	O

Early	O
postoperative	O
delirium	O
incidence	O
risk	O
factors	O
were	O
then	O
assessed	O
through	O
three	O
different	O
multiple	O
regression	O
models	O
.	O

RESULTS	O
:	O
According	O
to	O
the	O
confusion	O
assessment	O
method	O
for	O
the	O
ICU	O
scale	O
,	O
28	O
%	O
of	O
patients	O
were	O
diagnosed	O
with	O
early	O
postoperative	O
delirium	O
.	O

The	O
use	O
of	O
thiopentone	B
was	O
significantly	O
associated	O
with	O
an	O
eight	O
-	O
fold	O
-	O
higher	O
risk	O
for	O
delirium	O
compared	O
to	O
propofol	B
(	O
57.1	O
%	O
vs.	O
7.1	O
%	O
,	O
RR	O
=	O
8.0	O
,	O
X2	O
=	O
4.256	O
;	O
df	O
=	O
1	O
;	O
0.05	O
<	O
p	O
<	O
0.02	O
)	O
.	O

CONCLUSION	O
:	O
In	O
this	O
study	O
early	O
postoperative	O
delirium	O
was	O
found	O
to	O
be	O
a	O
very	O
common	O
complication	O
after	O
major	O
surgery	O
,	O
even	O
in	O
a	O
population	O
without	O
known	O
risk	O
factors	O
.	O

Thiopentone	B
was	O
independently	O
associated	O
with	O
an	O
increase	O
in	O
its	O
relative	O
risk	O
.	O

A	O
single	O
neurotoxic	O
dose	O
of	O
methamphetamine	B
induces	O
a	O
long	O
-	O
lasting	O
depressive	O
-	O
like	O
behaviour	O
in	O
mice	O
.	O

Methamphetamine	B
(	O
METH	B
)	O
triggers	O
a	O
disruption	O
of	O
the	O
monoaminergic	O
system	O
and	O
METH	B
abuse	O
leads	O
to	O
negative	O
emotional	O
states	O
including	O
depressive	O
symptoms	O
during	O
drug	O
withdrawal	O
.	O

However	O
,	O
it	O
is	O
currently	O
unknown	O
if	O
the	O
acute	O
toxic	O
dosage	O
of	O
METH	B
also	O
causes	O
a	O
long	O
-	O
lasting	O
depressive	O
phenotype	O
and	O
persistent	O
monoaminergic	O
deficits	O
.	O

Thus	O
,	O
we	O
now	O
assessed	O
the	O
depressive	O
-	O
like	O
behaviour	O
in	O
mice	O
at	O
early	O
and	O
long	O
-	O
term	O
periods	O
following	O
a	O
single	O
high	O
METH	B
dose	O
(	O
30	O
mg	O
/	O
kg	O
,	O
i.p	O
.	O
)	O
.	O

METH	B
did	O
not	O
alter	O
the	O
motor	O
function	O
and	O
procedural	O
memory	O
of	O
mice	O
as	O
assessed	O
by	O
swimming	O
speed	O
and	O
escape	O
latency	O
to	O
find	O
the	O
platform	O
in	O
a	O
cued	O
version	O
of	O
the	O
water	O
maze	O
task	O
.	O

However	O
,	O
METH	B
significantly	O
increased	O
the	O
immobility	O
time	O
in	O
the	O
tail	O
suspension	O
test	O
at	O
3	O
and	O
49	O
days	O
post	O
-	O
administration	O
.	O

This	O
depressive	O
-	O
like	O
profile	O
induced	O
by	O
METH	B
was	O
accompanied	O
by	O
a	O
marked	O
depletion	O
of	O
frontostriatal	O
dopaminergic	O
and	O
serotonergic	O
neurotransmission	O
,	O
indicated	O
by	O
a	O
reduction	O
in	O
the	O
levels	O
of	O
dopamine	B
,	O
DOPAC	B
and	O
HVA	B
,	O
tyrosine	B
hydroxylase	O
and	O
serotonin	B
,	O
observed	O
at	O
both	O
3	O
and	O
49	O
days	O
post	O
-	O
administration	O
.	O

In	O
parallel	O
,	O
another	O
neurochemical	O
feature	O
of	O
depression	O
--	O
astroglial	O
dysfunction	O
--	O
was	O
unaffected	O
in	O
the	O
cortex	O
and	O
the	O
striatal	O
levels	O
of	O
the	O
astrocytic	O
protein	O
marker	O
,	O
glial	O
fibrillary	O
acidic	O
protein	O
,	O
were	O
only	O
transiently	O
increased	O
at	O
3	O
days	O
.	O

These	O
findings	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
a	O
single	O
high	O
dose	O
of	O
METH	B
induces	O
long	O
-	O
lasting	O
depressive	O
-	O
like	O
behaviour	O
in	O
mice	O
associated	O
with	O
a	O
persistent	O
disruption	O
of	O
frontostriatal	O
dopaminergic	O
and	O
serotonergic	O
homoeostasis	O
.	O

Linezolid	B
-	O
induced	O
optic	O
neuropathy	O
.	O

Many	O
systemic	O
antimicrobials	O
have	O
been	O
implicated	O
to	O
cause	O
ocular	O
adverse	O
effects	O
.	O

This	O
is	O
especially	O
relevant	O
in	O
multidrug	O
therapy	O
where	O
more	O
than	O
one	O
drug	O
can	O
cause	O
a	O
similar	O
ocular	O
adverse	O
effect	O
.	O

We	O
describe	O
a	O
case	O
of	O
progressive	O
loss	O
of	O
vision	O
associated	O
with	O
linezolid	B
therapy	O
.	O

A	O
45-year	O
-	O
old	O
male	O
patient	O
who	O
was	O
on	O
treatment	O
with	O
multiple	O
second	O
-	O
line	O
anti	O
-	O
tuberculous	O
drugs	O
including	O
linezolid	B
and	O
ethambutol	B
for	O
extensively	O
drug	O
-	O
resistant	O
tuberculosis	O
(	O
XDR	O
-	O
TB	O
)	O
presented	O
to	O
us	O
with	O
painless	O
progressive	O
loss	O
of	O
vision	O
in	O
both	O
eyes	O
.	O

Color	O
vision	O
was	O
defective	O
and	O
fundus	O
examination	O
revealed	O
optic	O
disc	O
edema	O
in	O
both	O
eyes	O
.	O

Ethambutol	B
-	O
induced	O
toxic	O
optic	O
neuropathy	O
was	O
suspected	O
and	O
tablet	O
ethambutol	B
was	O
withdrawn	O
.	O

Deterioration	O
of	O
vision	O
occurred	O
despite	O
withdrawal	O
of	O
ethambutol	B
.	O

Discontinuation	O
of	O
linezolid	B
resulted	O
in	O
marked	O
improvement	O
of	O
vision	O
.	O

Our	O
report	O
emphasizes	O
the	O
need	O
for	O
monitoring	O
of	O
visual	O
function	O
in	O
patients	O
on	O
long	O
-	O
term	O
linezolid	B
treatment	O
.	O

Resuscitation	O
with	O
lipid	O
,	O
epinephrine	B
,	O
or	O
both	O
in	O
levobupivacaine	B
-	O
induced	O
cardiac	O
toxicity	O
in	O
newborn	O
piglets	O
.	O

BACKGROUND	O
:	O
The	O
optimal	O
dosing	O
regimens	O
of	O
lipid	O
emulsion	O
,	O
epinephrine	B
,	O
or	O
both	O
are	O
not	O
yet	O
determined	O
in	O
neonates	O
in	O
cases	O
of	O
local	O
anaesthetic	O
systemic	O
toxicity	O
(	O
LAST	O
)	O
.	O

METHODS	O
:	O
Newborn	O
piglets	O
received	O
levobupivacaine	B
until	O
cardiovascular	O
collapse	O
occurred	O
.	O

Standard	O
cardiopulmonary	O
resuscitation	O
was	O
started	O
and	O
electrocardiogram	O
(	O
ECG	O
)	O
was	O
monitored	O
for	O
ventricular	O
tachycardia	O
,	O
fibrillation	O
,	O
or	O
QRS	O
prolongation	O
.	O

Piglets	O
were	O
then	O
randomly	O
allocated	O
to	O
four	O
groups	O
:	O
control	O
(	O
saline	O
)	O
,	O
Intralipid	O
(	O
)	O
alone	O
,	O
epinephrine	B
alone	O
,	O
or	O
a	O
combination	O
of	O
Intralipd	O
plus	O
epinephrine	B
.	O

Resuscitation	O
continued	O
for	O
30	O
min	O
or	O
until	O
there	O
was	O
a	O
return	O
of	O
spontaneous	O
circulation	O
(	O
ROSC	O
)	O
accompanied	O
by	O
a	O
mean	O
arterial	O
pressure	O
at	O
or	O
superior	O
to	O
the	O
baseline	O
pressure	O
and	O
normal	O
sinus	O
rhythm	O
for	O
a	O
period	O
of	O
30	O
min	O
.	O

RESULTS	O
:	O
ROSC	O
was	O
achieved	O
in	O
only	O
one	O
of	O
the	O
control	O
piglets	O
compared	O
with	O
most	O
of	O
the	O
treated	O
piglets	O
.	O

Mortality	O
was	O
not	O
significantly	O
different	O
between	O
the	O
three	O
treatment	O
groups	O
,	O
but	O
was	O
significantly	O
lower	O
in	O
all	O
the	O
treatment	O
groups	O
compared	O
with	O
control	O
.	O

The	O
number	O
of	O
ECG	O
abnormalities	O
was	O
zero	O
in	O
the	O
Intralipid	O
only	O
group	O
,	O
but	O
14	O
and	O
17	O
,	O
respectively	O
,	O
in	O
the	O
epinephrine	B
and	O
epinephrine	B
plus	O
lipid	O
groups	O
(	O
P<0.05	O
)	O
.	O

CONCLUSIONS	O
:	O
Lipid	O
emulsion	O
with	O
or	O
without	O
epinephrine	B
,	O
or	O
epinephrine	B
alone	O
were	O
equally	O
effective	O
in	O
achieving	O
a	O
return	O
to	O
spontaneous	O
circulation	O
in	O
this	O
model	O
of	O
LAST	O
.	O

Epinephrine	B
alone	O
or	O
in	O
combination	O
with	O
lipid	O
was	O
associated	O
with	O
an	O
increased	O
number	O
of	O
ECG	O
abnormalities	O
compared	O
with	O
lipid	O
emulsion	O
alone	O
.	O

Incidence	O
of	O
heparin	B
-	O
induced	O
thrombocytopenia	O
type	O
II	O
and	O
postoperative	O
recovery	O
of	O
platelet	O
count	O
in	O
liver	O
graft	O
recipients	O
:	O
a	O
retrospective	O
cohort	O
analysis	O
.	O

BACKGROUND	O
:	O
Thrombocytopenia	O
in	O
patients	O
with	O
end	O
-	O
stage	O
liver	O
disease	O
is	O
a	O
common	O
disorder	O
caused	O
mainly	O
by	O
portal	O
hypertension	O
,	O
low	O
levels	O
of	O
thrombopoetin	O
,	O
and	O
endotoxemia	O
.	O

The	O
impact	O
of	O
immune	O
-	O
mediated	O
heparin	B
-	O
induced	O
thrombocytopenia	O
type	O
II	O
(	O
HIT	O
type	O
II	O
)	O
as	O
a	O
cause	O
of	O
thrombocytopenia	O
after	O
liver	O
transplantation	O
is	O
not	O
yet	O
understood	O
,	O
with	O
few	O
literature	O
citations	O
reporting	O
contradictory	O
results	O
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
demonstrate	O
the	O
perioperative	O
course	O
of	O
thrombocytopenia	O
after	O
liver	O
transplantation	O
and	O
determine	O
the	O
occurrence	O
of	O
clinical	O
HIT	O
type	O
II	O
.	O

METHOD	O
:	O
We	O
retrospectively	O
evaluated	O
the	O
medical	O
records	O
of	O
205	O
consecutive	O
adult	O
patients	O
who	O
underwent	O
full	O
-	O
size	O
liver	O
transplantation	O
between	O
January	O
2006	O
and	O
December	O
2010	O
due	O
to	O
end	O
-	O
stage	O
or	O
malignant	O
liver	O
disease	O
.	O

Preoperative	O
platelet	O
count	O
,	O
postoperative	O
course	O
of	O
platelets	O
,	O
and	O
clinical	O
signs	O
of	O
HIT	O
type	O
II	O
were	O
analyzed	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
155	O
(	O
75.6	O
%	O
)	O
of	O
205	O
patients	O
had	O
thrombocytopenia	O
before	O
transplantation	O
,	O
significantly	O
influenced	O
by	O
Model	O
of	O
End	O
-	O
Stage	O
Liver	O
Disease	O
score	O
and	O
liver	O
cirrhosis	O
.	O

The	O
platelet	O
count	O
exceeded	O
100,000	O
/	O
uL	O
in	O
most	O
of	O
the	O
patients	O
(	O
n	O
=	O
193	O
)	O
at	O
a	O
medium	O
of	O
7	O
d.	O
Regarding	O
HIT	O
II	O
,	O
there	O
were	O
four	O
(	O
1.95	O
%	O
)	O
patients	O
with	O
a	O
background	O
of	O
HIT	O
type	O
II	O
.	O

CONCLUSIONS	O
:	O
The	O
incidence	O
of	O
HIT	O
in	O
patients	O
with	O
end	O
-	O
stage	O
hepatic	O
failure	O
is	O
,	O
with	O
about	O
1.95	O
%	O
,	O
rare	O
.	O

For	O
further	O
reduction	O
of	O
HIT	O
type	O
II	O
,	O
the	O
use	O
of	O
intravenous	O
heparin	B
should	O
be	O
avoided	O
and	O
the	O
prophylactic	O
anticoagulation	O
should	O
be	O
performed	O
with	O
low	O
-	O
molecular	O
-	O
weight	O
heparin	B
after	O
normalization	O
of	O
platelet	O
count	O
.	O

Takotsubo	O
syndrome	O
(	O
or	O
apical	O
ballooning	O
syndrome	O
)	O
secondary	O
to	O
Zolmitriptan	B
.	O

Takotsubo	O
syndrome	O
(	O
TS	O
)	O
,	O
also	O
known	O
as	O
broken	O
heart	O
syndrome	O
,	O
is	O
characterized	O
by	O
left	O
ventricle	O
apical	O
ballooning	O
with	O
elevated	O
cardiac	O
biomarkers	O
and	O
electrocardiographic	O
changes	O
suggestive	O
of	O
an	O
acute	O
coronary	O
syndrome	O
(	O
ie	O
,	O
ST	O
-	O
segment	O
elevation	O
,	O
T	O
wave	O
inversions	O
,	O
and	O
pathologic	O
Q	O
waves	O
)	O
.	O

We	O
report	O
a	O
case	O
of	O
54-year	O
-	O
old	O
woman	O
with	O
medical	O
history	O
of	O
mitral	O
valve	O
prolapse	O
and	O
migraines	O
,	O
who	O
was	O
admitted	O
to	O
the	O
hospital	O
for	O
substernal	O
chest	O
pain	O
and	O
electrocardiogram	O
demonstrated	O
1	O
/	O
2	O
mm	O
ST	O
-	O
segment	O
elevation	O
in	O
leads	O
II	O
,	O
III	O
,	O
aVF	O
,	O
V5	O
,	O
and	O
V6	O
and	O
positive	O
troponin	O
I.	O
Emergent	O
coronary	O
angiogram	O
revealed	O
normal	O
coronary	O
arteries	O
with	O
moderately	O
reduced	O
left	O
ventricular	O
ejection	O
fraction	O
with	O
wall	O
motion	O
abnormalities	O
consistent	O
with	O
TS	O
.	O

Detailed	O
history	O
obtained	O
retrospectively	O
revealed	O
that	O
the	O
patient	O
took	O
zolmitriptan	B
sparingly	O
only	O
when	O
she	O
had	O
migraines	O
.	O

But	O
before	O
this	O
event	O
,	O
she	O
was	O
taking	O
zolmitriptan	B
2	O
-	O
3	O
times	O
daily	O
for	O
several	O
days	O
because	O
of	O
a	O
persistent	O
migraine	O
headache	O
.	O

She	O
otherwise	O
reported	O
that	O
she	O
is	O
quite	O
active	O
,	O
rides	O
horses	O
,	O
and	O
does	O
show	O
jumping	O
without	O
any	O
limitations	O
in	O
her	O
physical	O
activity	O
.	O

There	O
was	O
no	O
evidence	O
of	O
any	O
recent	O
stress	O
or	O
status	O
migrainosus	O
.	O

Extensive	O
literature	O
search	O
revealed	O
multiple	O
cases	O
of	O
coronary	O
artery	O
vasospasm	O
secondary	O
to	O
zolmitriptan	B
,	O
but	O
none	O
of	O
the	O
cases	O
were	O
associated	O
with	O
TS	O
.	O

Depression	O
,	O
impulsiveness	O
,	O
sleep	O
,	O
and	O
memory	O
in	O
past	O
and	O
present	O
polydrug	O
users	O
of	O
3,4-methylenedioxymethamphetamine	B
(	O
MDMA	B
,	O
ecstasy	B
)	O
.	O

RATIONALE	O
:	O
Ecstasy	B
(	O
3,4-methylenedioxymethamphetamine	B
,	O
MDMA	B
)	O
is	O
a	O
worldwide	O
recreational	O
drug	O
of	O
abuse	O
.	O

Unfortunately	O
,	O
the	O
results	O
from	O
human	O
research	O
investigating	O
its	O
psychological	O
effects	O
have	O
been	O
inconsistent	O
.	O

OBJECTIVES	O
:	O
The	O
present	O
study	O
aimed	O
to	O
be	O
the	O
largest	O
to	O
date	O
in	O
sample	O
size	O
and	O
5HT	O
-	O
related	O
behaviors	O
;	O
the	O
first	O
to	O
compare	O
present	O
ecstasy	B
users	O
with	O
past	O
users	O
after	O
an	O
abstinence	O
of	O
4	O
or	O
more	O
years	O
,	O
and	O
the	O
first	O
to	O
include	O
robust	O
controls	O
for	O
other	O
recreational	O
substances	O
.	O

METHODS	O
:	O
A	O
sample	O
of	O
997	O
participants	O
(	O
52	O
%	O
male	O
)	O
was	O
recruited	O
to	O
four	O
control	O
groups	O
(	O
non	O
-	O
drug	O
(	O
ND	O
)	O
,	O
alcohol	B
/	O
nicotine	B
(	O
AN	B
)	O
,	O
cannabis	B
/	O
alcohol	B
/	O
nicotine	B
(	O
CAN	B
)	O
,	O
non	O
-	O
ecstasy	B
polydrug	O
(	O
PD	O
)	O
)	O
,	O
and	O
two	O
ecstasy	B
polydrug	O
groups	O
(	O
present	O
(	O
MDMA	B
)	O
and	O
past	O
users	O
(	O
EX	O
-	O
MDMA	B
)	O
.	O

Participants	O
completed	O
a	O
drug	O
history	O
questionnaire	O
,	O
Beck	O
Depression	O
Inventory	O
,	O
Barratt	O
Impulsiveness	O
Scale	O
,	O
Pittsburgh	O
Sleep	O
Quality	O
Index	O
,	O
and	O
Wechsler	O
Memory	O
Scale	O
-	O
Revised	O
which	O
,	O
in	O
total	O
,	O
provided	O
13	O
psychometric	O
measures	O
.	O

RESULTS	O
:	O
While	O
the	O
CAN	B
and	O
PD	O
groups	O
tended	O
to	O
record	O
greater	O
deficits	O
than	O
the	O
non	O
-	O
drug	O
controls	O
,	O
the	O
MDMA	B
and	O
EX	O
-	O
MDMA	B
groups	O
recorded	O
greater	O
deficits	O
than	O
all	O
the	O
control	O
groups	O
on	O
ten	O
of	O
the	O
13	O
psychometric	O
measures	O
.	O

Strikingly	O
,	O
despite	O
prolonged	O
abstinence	O
(	O
mean	O
,	O
4.98	O
;	O
range	O
,	O
4	O
-	O
9	O
years	O
)	O
,	O
past	O
ecstasy	B
users	O
showed	O
few	O
signs	O
of	O
recovery	O
.	O

Compared	O
with	O
present	O
ecstasy	B
users	O
,	O
the	O
past	O
users	O
showed	O
no	O
change	O
for	O
ten	O
measures	O
,	O
increased	O
impairment	O
for	O
two	O
measures	O
,	O
and	O
improvement	O
on	O
just	O
one	O
measure	O
.	O

CONCLUSIONS	O
:	O
Given	O
this	O
record	O
of	O
impaired	O
memory	O
and	O
clinically	O
significant	O
levels	O
of	O
depression	O
,	O
impulsiveness	O
,	O
and	O
sleep	O
disturbance	O
,	O
the	O
prognosis	O
for	O
the	O
current	O
generation	O
of	O
ecstasy	B
users	O
is	O
a	O
major	O
cause	O
for	O
concern	O
.	O

Association	O
of	O
common	O
genetic	O
variants	O
of	O
HOMER1	O
gene	O
with	O
levodopa	B
adverse	O
effects	O
in	O
Parkinson	O
's	O
disease	O
patients	O
.	O

Levodopa	B
is	O
the	O
most	O
effective	O
symptomatic	O
therapy	O
for	O
Parkinson	O
's	O
disease	O
,	O
but	O
its	O
chronic	O
use	O
could	O
lead	O
to	O
chronic	O
adverse	O
outcomes	O
,	O
such	O
as	O
motor	O
fluctuations	O
,	O
dyskinesia	O
and	O
visual	O
hallucinations	O
.	O

HOMER1	O
is	O
a	O
protein	O
with	O
pivotal	O
function	O
in	O
glutamate	B
transmission	O
,	O
which	O
has	O
been	O
related	O
to	O
the	O
pathogenesis	O
of	O
these	O
complications	O
.	O

This	O
study	O
investigates	O
whether	O
polymorphisms	O
in	O
the	O
HOMER1	O
gene	O
promoter	O
region	O
are	O
associated	O
with	O
the	O
occurrence	O
of	O
the	O
chronic	O
complications	O
of	O
levodopa	B
therapy	O
.	O

A	O
total	O
of	O
205	O
patients	O
with	O
idiopathic	O
Parkinson	O
's	O
disease	O
were	O
investigated	O
.	O

Patients	O
were	O
genotyped	O
for	O
rs4704559	O
,	O
rs10942891	O
and	O
rs4704560	O
by	O
allelic	O
discrimination	O
with	O
Taqman	O
assays	O
.	O

The	O
rs4704559	O
G	O
allele	O
was	O
associated	O
with	O
a	O
lower	O
prevalence	O
of	O
dyskinesia	O
(	O
prevalence	O
ratio	O
(	O
PR	O
)	O
=0.615	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
0.426	O
-	O
0.887	O
,	O
P=0.009	O
)	O
and	O
visual	O
hallucinations	O
(	O
PR=0.515	O
,	O
95	O
%	O
CI	O
0.295	O
-	O
0.899	O
,	O
P=0.020	O
)	O
.	O

Our	O
data	O
suggest	O
that	O
HOMER1	O
rs4704559	O
G	O
allele	O
has	O
a	O
protective	O
role	O
for	O
the	O
development	O
of	O
levodopa	B
adverse	O
effects	O
.	O

Crocin	B
improves	O
lipid	O
dysregulation	O
in	O
subacute	O
diazinon	B
exposure	O
through	O
ERK1	O
/	O
2	O
pathway	O
in	O
rat	O
liver	O
.	O

INTRODUCTION	O
:	O

Diazinon	B
Yis	O
one	O
of	O
the	O
most	O
broadly	O
used	O
organophosphorus	B
insecticides	O
in	O
agriculture	O
.	O

It	O
has	O
been	O
shown	O
that	O
exposure	O
to	O
diazinon	B
may	O
interfere	O
with	O
lipid	O
metabolism	O
.	O

Moreover	O
,	O
the	O
hypolipidemic	O
effect	O
of	O
crocin	B
has	O
been	O
established	O
.	O

Earlier	O
studies	O
revealed	O
the	O
major	O
role	O
of	O
Extracellular	O
signal	O
-	O
regulated	O
kinase	O
(	O
ERK	O
)	O
pathways	O
in	O
low	O
-	O
density	O
lipoprotein	O
receptor	O
(	O
LDLr	O
)	O
expression	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
changes	O
in	O
the	O
regulation	O
of	O
lipid	O
metabolism	O
,	O
ERK	O
and	O
LDLr	O
expression	O
in	O
the	O
liver	O
of	O
rats	O
exposed	O
to	O
subacute	O
diazinon	B
.	O

Furthermore	O
ameliorating	O
effect	O
of	O
crocin	B
on	O
diazinon	B
induced	O
disturbed	O
cholesterol	B
homeostasis	O
was	O
studied	O
.	O

METHODS	O
:	O
24	O
Rats	O
were	O
divided	O
into	O
4	O
groups	O
and	O
received	O
following	O
treatments	O
for	O
4	O
weeks	O
;	O
Corn	O
oil	O
(	O
control	O
)	O
,	O
diazinon	B
(	O
15mg	O
/	O
kg	O
per	O
day	O
,	O
orally	O
)	O
and	O
crocin	B
(	O
12.5	O
and	O
25mg	O
/	O
kg	O
per	O
day	O
,	O
intraperitoneally	O
)	O
in	O
combination	O
with	O
diazinon	B
(	O
15	O
mg	O
/	O
kg	O
)	O
.	O

The	O
levels	O
of	O
cholesterol	B
,	O
triglyceride	B
and	O
LDL	O
in	O
blood	O
of	O
rats	O
were	O
analyzed	O
.	O

Moreover	O
mRNA	O
levels	O
of	O
LDLr	O
and	O
ERK1	O
/	O
2	O
as	O
well	O
as	O
protein	O
levels	O
of	O
total	O
and	O
activated	O
forms	O
of	O
ERK1	O
/	O
2	O
in	O
rat	O
liver	O
were	O
evaluated	O
by	O
Western	O
blotting	O
and	O
quantitative	O
real	O
time	O
polymerase	O
chain	O
reaction	O
analysis	O
.	O

RESULTS	O
:	O
Our	O
data	O
showed	O
that	O
subacute	O
exposure	O
to	O
diazinon	B
significantly	O
increased	O
concentrations	O
of	O
cholesterol	B
,	O
triglyceride	B
and	O
LDL	O
.	O

Moreover	O
diazinon	B
decreased	O
ERK1	O
/	O
2	O
protein	O
phosphorylation	O
and	O
LDLr	O
transcript	O
.	O

Crocin	B
reduced	O
inhibition	O
of	O
ERK	O
activation	O
and	O
diazinon	B
-	O
induced	O
hyperlipemia	O
and	O
increased	O
levels	O
of	O
LDLr	O
transcript	O
.	O

CONCLUSIONS	O
:	O
Crocin	B
may	O
be	O
considered	O
as	O
a	O
novel	O
protective	O
agent	O
in	O
diazinon	B
-	O
induced	O
hyperlipemia	O
through	O
modulating	O
of	O
ERK	O
pathway	O
and	O
increase	O
of	O
LDLr	O
expression	O
.	O

GEM	B
-	O
P	O
chemotherapy	O
is	O
active	O
in	O
the	O
treatment	O
of	O
relapsed	O
Hodgkin	O
lymphoma	O
.	O

Hodgkin	O
lymphoma	O
(	O
HL	O
)	O
is	O
a	O
relatively	O
chemosensitive	O
malignancy	O
.	O

However	O
,	O
for	O
those	O
who	O
relapse	O
,	O
high	O
-	O
dose	O
chemotherapy	O
with	O
autologous	O
stem	O
cell	O
transplant	O
is	O
the	O
treatment	O
of	O
choice	O
which	O
relies	O
on	O
adequate	O
disease	O
control	O
with	O
salvage	O
chemotherapy	O
.	O

Regimens	O
commonly	O
used	O
often	O
require	O
inpatient	O
administration	O
and	O
can	O
be	O
difficult	O
to	O
deliver	O
due	O
to	O
toxicity	O
.	O

Gemcitabine	B
and	O
cisplatin	B
have	O
activity	O
in	O
HL	O
,	O
non	O
-	O
overlapping	O
toxicity	O
with	O
first	O
-	O
line	O
chemotherapeutics	O
,	O
and	O
may	O
be	O
delivered	O
in	O
an	O
outpatient	O
setting	O
.	O

In	O
this	O
retrospective	O
single	O
-	O
centre	O
analysis	O
,	O
patients	O
with	O
relapsed	O
or	O
refractory	O
HL	O
treated	O
with	O
gemcitabine	B
1,000	O
mg	O
/	O
m	O
(	O
2	O
)	O
day	O
(	O
D	O
)	O
1	O
,	O
D8	O
and	O
D15	O
;	O
methylprednisolone	B
1,000	O
mg	O
D1	O
-	O
5	O
;	O
and	O
cisplatin	B
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
D15	O
,	O
every	O
28	O
days	O
(	O
GEM	B
-	O
P	O
)	O
were	O
included	O
.	O

Demographic	O
,	O
survival	O
,	O
response	O
and	O
toxicity	O
data	O
were	O
recorded	O
.	O

Forty	O
-	O
one	O
eligible	O
patients	O
were	O
identified	O
:	O
median	O
age	O
27	O
.	O

One	O
hundred	O
and	O
twenty	O
-	O
two	O
cycles	O
of	O
GEM	B
-	O
P	O
were	O
administered	O
in	O
total	O
(	O
median	O
3	O
cycles	O
;	O
range	O
1	O
-	O
6	O
)	O
.	O

Twenty	O
of	O
41	O
(	O
48	O
%	O
)	O
patients	O
received	O
GEM	B
-	O
P	O
as	O
second	O
-	O
line	O
treatment	O
and	O
11	O
/	O
41	O
(	O
27	O
%	O
)	O
as	O
third	O
-	O
line	O
therapy	O
.	O

Overall	O
response	O
rate	O
(	O
ORR	O
)	O
to	O
GEM	B
-	O
P	O
in	O
the	O
entire	O
cohort	O
was	O
80	O
%	O
(	O
complete	O
response	O
(	O
CR	O
)	O
37	O
%	O
,	O
partial	O
response	O
44	O
%	O
)	O
with	O
14	O
/	O
15	O
CR	O
confirmed	O
as	O
a	O
metabolic	O
CR	O
on	O
PET	O
and	O
ORR	O
of	O
85	O
%	O
in	O
the	O
20	O
second	O
-	O
line	O
patients	O
.	O

The	O
most	O
common	O
grade	O
3	O
/	O
4	O
toxicities	O
were	O
haematological	O
:	O
neutropenia	O
54	O
%	O
and	O
thrombocytopenia	O
51	O
%	O
.	O

Median	O
follow	O
-	O
up	O
from	O
the	O
start	O
of	O
GEM	B
-	O
P	O
was	O
4.5	O
years	O
.	O

Following	O
GEM	B
-	O
P	O
,	O
5-year	O
progression	O
-	O
free	O
survival	O
was	O
46	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
,	O
30	O
-	O
62	O
%	O
)	O
and	O
5-year	O
overall	O
survival	O
was	O
59	O
%	O
(	O
95	O
%	O
CI	O
,	O
43	O
-	O
74	O
%	O
)	O
.	O

Fourteen	O
of	O
41	O
patients	O
proceeded	O
directly	O
to	O
autologous	O
transplant	O
.	O

GEM	B
-	O
P	O
is	O
a	O
salvage	O
chemotherapy	O
with	O
relatively	O
high	O
response	O
rates	O
,	O
leading	O
to	O
successful	O
transplantation	O
in	O
appropriate	O
patients	O
,	O
in	O
the	O
treatment	O
of	O
relapsed	O
or	O
refractory	O
HL	O
.	O

Basal	O
functioning	O
of	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
(	O
HPA	O
)	O
axis	O
and	O
psychological	O
distress	O
in	O
recreational	O
ecstasy	B
polydrug	O
users	O
.	O

RATIONALE	O
:	O
Ecstasy	B
(	O
MDMA	B
)	O
is	O
a	O
psychostimulant	O
drug	O
which	O
is	O
increasingly	O
associated	O
with	O
psychobiological	O
dysfunction	O
.	O

While	O
some	O
recent	O
studies	O
suggest	O
acute	O
changes	O
in	O
neuroendocrine	O
function	O
,	O
less	O
is	O
known	O
about	O
long	O
-	O
term	O
changes	O
in	O
HPA	O
functionality	O
in	O
recreational	O
users	O
.	O

OBJECTIVES	O
:	O
The	O
current	O
study	O
is	O
the	O
first	O
to	O
explore	O
the	O
effects	O
of	O
ecstasy	B
-	O
polydrug	O
use	O
on	O
psychological	O
distress	O
and	O
basal	O
functioning	O
of	O
the	O
HPA	O
axis	O
through	O
assessing	O
the	O
secretion	O
of	O
cortisol	B
across	O
the	O
diurnal	O
period	O
.	O

METHOD	O
:	O
Seventy	O
-	O
six	O
participants	O
(	O
21	O
nonusers	O
,	O
29	O
light	O
ecstasy	B
-	O
polydrug	O
users	O
,	O
26	O
heavy	O
ecstasy	B
-	O
polydrug	O
users	O
)	O
completed	O
a	O
substance	O
use	O
inventory	O
and	O
measures	O
of	O
psychological	O
distress	O
at	O
baseline	O
,	O
then	O
two	O
consecutive	O
days	O
of	O
cortisol	B
sampling	O
(	O
on	O
awakening	O
,	O
30	O
min	O
post	O
awakening	O
,	O
between	O
1400	O
and	O
1600	O
hours	O
and	O
pre	O
bedtime	O
)	O
.	O

On	O
day	O
2	O
,	O
participants	O
also	O
attended	O
the	O
laboratory	O
to	O
complete	O
a	O
20-min	O
multitasking	O
stressor	O
.	O

RESULTS	O
:	O
Both	O
user	O
groups	O
exhibited	O
significantly	O
greater	O
levels	O
of	O
anxiety	O
and	O
depression	O
than	O
nonusers	O
.	O

On	O
day	O
1	O
,	O
all	O
participants	O
exhibited	O
a	O
typical	O
cortisol	B
profile	O
,	O
though	O
light	O
users	O
had	O
significantly	O
elevated	O
levels	O
pre	O
-	O
bed	O
.	O

On	O
day	O
2	O
,	O
heavy	O
users	O
demonstrated	O
elevated	O
levels	O
upon	O
awakening	O
and	O
all	O
ecstasy	B
-	O
polydrug	O
users	O
demonstrated	O
elevated	O
pre	O
-	O
bed	O
levels	O
compared	O
to	O
non	O
-	O
users	O
.	O

Significant	O
between	O
group	O
differences	O
were	O
also	O
observed	O
in	O
afternoon	O
cortisol	B
levels	O
and	O
in	O
overall	O
cortisol	B
secretion	O
across	O
the	O
day	O
.	O

CONCLUSIONS	O
:	O
The	O
increases	O
in	O
anxiety	O
and	O
depression	O
are	O
in	O
line	O
with	O
previous	O
observations	O
in	O
recreational	O
ecstasy	B
-	O
polydrug	O
users	O
.	O

Dysregulated	O
diurnal	O
cortisol	B
may	O
be	O
indicative	O
of	O
inappropriate	O
anticipation	O
of	O
forthcoming	O
demands	O
and	O
hypersecretion	O
may	O
lead	O
to	O
the	O
increased	O
psychological	O
and	O
physical	O
morbidity	O
associated	O
with	O
heavy	O
recreational	O
use	O
of	O
ecstasy	B
.	O

Ifosfamide	B
related	O
encephalopathy	O
:	O
the	O
need	O
for	O
a	O
timely	O
EEG	O
evaluation	O
.	O

BACKGROUND	O
:	O
Ifosfamide	B
is	O
an	O
alkylating	O
agent	O
useful	O
in	O
the	O
treatment	O
of	O
a	O
wide	O
range	O
of	O
cancers	O
including	O
sarcomas	O
,	O
lymphoma	O
,	O
gynecologic	O
and	O
testicular	O
cancers	O
.	O

Encephalopathy	O
has	O
been	O
reported	O
in	O
10	O
-	O
40	O
%	O
of	O
patients	O
receiving	O
high	O
-	O
dose	O
IV	O
ifosfamide	B
.	O

OBJECTIVE	O
:	O
To	O
highlight	O
the	O
role	O
of	O
electroencephalogram	O
(	O
EEG	O
)	O
in	O
the	O
early	O
detection	O
and	O
management	O
of	O
ifosfamide	B
related	O
encephalopathy	O
.	O

METHODS	O
:	O
Retrospective	O
chart	O
review	O
including	O
clinical	O
data	O
and	O
EEG	O
recordings	O
was	O
done	O
on	O
five	O
patients	O
,	O
admitted	O
to	O
MD	O
Anderson	O
Cancer	O
Center	O
between	O
years	O
2009	O
and	O
2012	O
,	O
who	O
developed	O
ifosfamide	B
related	O
acute	O
encephalopathy	O
.	O

RESULTS	O
:	O
All	O
five	O
patients	O
experienced	O
symptoms	O
of	O
encephalopathy	O
soon	O
after	O
(	O
within	O
12	O
h-2	O
days	O
)	O
receiving	O
ifosfamide	B
.	O

Two	O
patients	O
developed	O
generalized	O
convulsions	O
while	O
one	O
patient	O
developed	O
continuous	O
non	O
-	O
convulsive	O
status	O
epilepticus	O
(	O
NCSE	O
)	O
that	O
required	O
ICU	O
admission	O
and	O
intubation	O
.	O

Initial	O
EEG	O
showed	O
epileptiform	O
discharges	O
in	O
three	O
patients	O
;	O
run	O
of	O
triphasic	O
waves	O
in	O
one	O
patient	O
and	O
moderate	O
degree	O
diffuse	O
generalized	O
slowing	O
.	O

Mixed	O
pattern	O
with	O
the	O
presence	O
of	O
both	O
sharps	O
and	O
triphasic	O
waves	O
were	O
also	O
noted	O
.	O

Repeat	O
EEGs	O
within	O
24_h	O
of	O
symptom	O
onset	O
showed	O
marked	O
improvement	O
that	O
was	O
correlated	O
with	O
clinical	O
improvement	O
.	O

CONCLUSIONS	O
:	O
Severity	O
of	O
ifosfamide	B
related	O
encephalopathy	O
correlates	O
with	O
EEG	O
changes	O
.	O

We	O
suggest	O
a	O
timely	O
EEG	O
evaluation	O
for	O
patients	O
receiving	O
ifosfamide	B
who	O
develop	O
features	O
of	O
encephalopathy	O
.	O

Incidence	O
of	O
contrast	B
-	O
induced	O
nephropathy	O
in	O
hospitalised	O
patients	O
with	O
cancer	O
.	O

OBJECTIVES	O
:	O
To	O
determine	O
the	O
frequency	O
of	O
and	O
possible	O
factors	O
related	O
to	O
contrast	B
-	O
induced	O
nephropathy	O
(	O
CIN	O
)	O
in	O
hospitalised	O
patients	O
with	O
cancer	O
.	O

METHODS	O
:	O
Ninety	O
adult	O
patients	O
were	O
enrolled	O
.	O

Patients	O
with	O
risk	O
factors	O
for	O
acute	O
renal	O
failure	O
were	O
excluded	O
.	O

Blood	O
samples	O
were	O
examined	O
the	O
day	O
before	O
contrast	B
-	O
enhanced	O
computed	O
tomography	O
(	O
CT	O
)	O
and	O
serially	O
for	O
3	O
days	O
thereafter	O
.	O

CIN	O
was	O
defined	O
as	O
an	O
increase	O
in	O
serum	O
creatinine	B
(	O
Cr	B
)	O
of	O
0.5	O
mg	O
/	O
dl	O
or	O
more	O
,	O
or	O
elevation	O
of	O
Cr	B
to	O
25	O
%	O
over	O
baseline	O
.	O

Relationships	O
between	O
CIN	O
and	O
possible	O
risk	O
factors	O
were	O
investigated	O
.	O

RESULTS	O
:	O
CIN	O
was	O
detected	O
in	O
18	O
/	O
90	O
(	O
20	O
%	O
)	O
patients	O
.	O

CIN	O
developed	O
in	O
25.5	O
%	O
patients	O
who	O
underwent	O
chemotherapy	O
and	O
in	O
11	O
%	O
patients	O
who	O
did	O
not	O
(	O
P	O
=	O
0.1	O
)	O
.	O

CIN	O
more	O
frequently	O
developed	O
in	O
patients	O
who	O
had	O
undergone	O
CT	O
within	O
45	O
days	O
after	O
the	O
last	O
chemotherapy	O
(	O
P	O
=	O
0.005	O
)	O
;	O
it	O
was	O
also	O
an	O
independent	O
risk	O
factor	O
(	O
P	O
=	O
0.017	O
)	O
.	O

CIN	O
was	O
significantly	O
more	O
after	O
treatment	O
with	O
bevacizumab	B
/	O
irinotecan	B
(	O
P	O
=	O
0.021	O
)	O
and	O
in	O
patients	O
with	O
hypertension	O
(	O
P	O
=	O
0.044	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
incidence	O
of	O
CIN	O
after	O
CT	O
in	O
hospitalised	O
oncological	O
patients	O
was	O
20	O
%	O
.	O

CIN	O
developed	O
4.5-times	O
more	O
frequently	O
in	O
patients	O
with	O
cancer	O
who	O
had	O
undergone	O
recent	O
chemotherapy	O
.	O

Hypertension	O
and	O
the	O
combination	O
of	O
bevacizumab	B
/	O
irinotecan	B
may	O
be	O
additional	O
risk	O
factors	O
for	O
CIN	O
development	O
.	O

KEY	O
POINTS	O
:	O
.	O

Contrast	B
-	O
induced	O
nephropathy	O
(	O
CIN	O
)	O
is	O
a	O
concern	O
for	O
oncological	O
patients	O
undergoing	O
CT	O
.	O
.	O

CIN	O
occurs	O
more	O
often	O
when	O
CT	O
is	O
performed	O
<	O
45	O
days	O
after	O
chemotherapy	O
.	O
.	O

Hypertension	O
and	O
treatment	O
with	O
bevacizumab	B
appear	O
to	O
be	O
additional	O
risk	O
factors	O
.	O

Syndrome	O
of	O
inappropriate	O
antidiuretic	O
hormone	O
secretion	O
associated	O
with	O
desvenlafaxine	B
.	O

OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
syndrome	O
of	O
inappropriate	O
anti	O
-	O
diuretic	O
hormone	O
(	O
SIADH	O
)	O
secretion	O
associated	O
with	O
desvenlafaxine	B
.	O

CASE	O
SUMMARY	O
:	O
A	O
57-year	O
old	O
female	O
with	O
hyponatraemia	O
.	O

Her	O
medications	O
included	O
desvenlafaxine	B
,	O
and	O
symptoms	O
included	O
nausea	O
,	O
anxiety	O
and	O
confusion	O
.	O

The	O
serum	O
sodium	B
at	O
this	O
time	O
was	O
120	O
mmol	O
/	O
L	O
,	O
serum	O
osmolality	O
was	O
263	O
mosmol	O
/	O
kg	O
,	O
urine	O
osmolality	O
410	O
mosmol	O
/	O
kg	O
and	O
urine	O
sodium	B
63	O
mmol	O
/	O
L	O
,	O
consistent	O
with	O
a	O
diagnosis	O
of	O
SIADH	O
.	O

Desvenlafaxine	B
was	O
ceased	O
and	O
fluid	O
restriction	O
implemented	O
.	O

After	O
4	O
days	O
the	O
sodium	B
increased	O
to	O
128	O
mmol	O
/	O
L	O
and	O
fluid	O
restriction	O
was	O
relaxed	O
.	O

During	O
her	O
further	O
3	O
weeks	O
inpatient	O
admission	O
the	O
serum	O
sodium	B
ranged	O
from	O
134	O
to	O
137	O
mmol	O
/	O
L	O
during	O
treatment	O
with	O
mirtazapine	B
.	O

DISCUSSION	O
:	O
SIADH	O
has	O
been	O
widely	O
reported	O
with	O
a	O
range	O
of	O
antidepressants	O
.	O

This	O
case	O
report	O
suggests	O
that	O
desvenlafaxine	B
might	O
cause	O
clinically	O
significant	O
hyponatremia	O
.	O

CONCLUSIONS	O
:	O
Clinicians	O
should	O
be	O
aware	O
of	O
the	O
potential	O
for	O
antidepressants	O
to	O
cause	O
hyponatremia	O
,	O
and	O
take	O
appropriate	O
corrective	O
action	O
where	O
necessary	O
.	O

Oxidative	O
stress	O
on	O
cardiotoxicity	O
after	O
treatment	O
with	O
single	O
and	O
multiple	O
doses	O
of	O
doxorubicin	B
.	O

The	O
mechanism	O
of	O
doxorubicin	B
(	O
DOX	B
)	O
-induced	O
cardiotoxicity	O
remains	O
controversial	O
.	O

Wistar	O
rats	O
(	O
n	O
=	O
66	O
)	O
received	O
DOX	B
injections	O
intraperitoneally	O
and	O
were	O
randomly	O
assigned	O
to	O
2	O
experimental	O
protocols	O
:	O
(	O
1	O
)	O
rats	O
were	O
killed	O
before	O
(	O
-24	O
h	O
,	O
n	O
=	O
8)	O
and	O
24	O
h	O
after	O
(	O
+	O
24	O
h	O
,	O
n	O
=	O
8)	O
a	O
single	O
dose	O
of	O
DOX	B
(	O
4	O
mg	O
/	O
kg	O
body	O
weight	O
)	O
to	O
determine	O
the	O
DOX	B
acute	O
effect	O
and	O
(	O
2	O
)	O
rats	O
(	O
n	O
=	O
58	O
)	O
received	O
4	O
injections	O
of	O
DOX	B
(	O
4	O
mg	O
/	O
kg	O
body	O
weight	O
/	O
week	O
)	O
and	O
were	O
killed	O
before	O
the	O
first	O
injection	O
(	O
M0	O
)	O
and	O
1	O
week	O
after	O
each	O
injection	O
(	O
M1	O
,	O
M2	O
,	O
M3	O
,	O
and	O
M4	O
)	O
to	O
determine	O
the	O
chronological	O
effects	O
.	O

Animals	O
used	O
at	O
M0	O
(	O
n	O
=	O
8)	O
were	O
also	O
used	O
at	O
moment	O
-24	O
h	O
of	O
acute	O
study	O
.	O

Cardiac	O
total	O
antioxidant	O
performance	O
(	O
TAP	O
)	O
,	O
DNA	O
damage	O
,	O
and	O
morphology	O
analyses	O
were	O
carried	O
out	O
at	O
each	O
time	O
point	O
.	O

Single	O
dose	O
of	O
DOX	B
was	O
associated	O
with	O
increased	O
cardiac	O
disarrangement	O
,	O
necrosis	O
,	O
and	O
DNA	O
damage	O
(	O
strand	O
breaks	O
(	O
SBs	O
)	O
and	O
oxidized	O
pyrimidines	O
)	O
and	O
decreased	O
TAP	O
.	O

The	O
chronological	O
study	O
showed	O
an	O
effect	O
of	O
a	O
cumulative	O
dose	O
on	O
body	O
weight	O
(	O
R	O
=	O
-0.99	O
,	O
p	O
=	O
0.011	O
)	O
,	O
necrosis	O
(	O
R	O
=	O
1.00	O
,	O
p	O
=	O
0.004	O
)	O
,	O
TAP	O
(	O
R	O
=	O
0.95	O
,	O
p	O
=	O
0.049	O
)	O
,	O
and	O
DNA	O
SBs	O
(	O
R	O
=	O
-0.95	O
,	O
p	O
=	O
0.049	O
)	O
.	O

DNA	O
SBs	O
damage	O
was	O
negatively	O
associated	O
with	O
TAP	O
(	O
R	O
=	O
-0.98	O
,	O
p	O
=	O
0.018	O
)	O
,	O
and	O
necrosis	O
(	O
R	O
=	O
-0.97	O
,	O
p	O
=	O
0.027	O
)	O
.	O

Our	O
results	O
suggest	O
that	O
oxidative	O
damage	O
is	O
associated	O
with	O
acute	O
cardiotoxicity	O
induced	O
by	O
a	O
single	O
dose	O
of	O
DOX	B
only	O
.	O

Increased	O
resistance	O
to	O
the	O
oxidative	O
stress	O
is	O
plausible	O
for	O
the	O
multiple	O
dose	O
of	O
DOX	B
.	O

Thus	O
,	O
different	O
mechanisms	O
may	O
be	O
involved	O
in	O
acute	O
toxicity	O
versus	O
chronic	O
toxicity	O
.	O

Tacrolimus	B
-	O
related	O
seizure	O
after	O
pediatric	O
liver	O
transplantation	O
--	O
a	O
single	O
-	O
center	O
experience	O
.	O

To	O
identify	O
the	O
risk	O
factors	O
for	O
new	O
-	O
onset	O
seizures	O
after	O
pediatric	O
LT	O
and	O
to	O
assess	O
their	O
clinical	O
implications	O
and	O
long	O
-	O
term	O
prognosis	O
.	O

The	O
clinical	O
and	O
laboratory	O
data	O
of	O
27	O
consecutive	O
children	O
who	O
underwent	O
LT	O
from	O
January	O
2007	O
to	O
December	O
2010	O
in	O
our	O
center	O
were	O
analyzed	O
retrospectively	O
.	O

Patients	O
were	O
divided	O
into	O
seizures	O
group	O
and	O
a	O
non	O
-	O
seizures	O
group	O
.	O

Pre	O
-	O
operative	O
,	O
intra	O
-	O
operative	O
,	O
and	O
post	O
-	O
operative	O
data	O
were	O
collected	O
.	O

Seizures	O
occurred	O
in	O
four	O
children	O
,	O
an	O
incidence	O
of	O
14.8	O
%	O
.	O

All	O
exhibited	O
generalized	O
tonic	O
-	O
clonic	O
seizures	O
within	O
the	O
first	O
two	O
wk	O
after	O
LT	O
.	O

Univariate	O
analysis	O
showed	O
that	O
the	O
risk	O
factors	O
associated	O
with	O
seizures	O
after	O
pediatric	O
LT	O
included	O
gender	O
,	O
pediatric	O
end	O
-	O
stage	O
liver	O
disease	O
score	O
before	O
surgery	O
,	O
Child	O
-	O
Pugh	O
score	O
before	O
surgery	O
,	O
serum	O
total	O
bilirubin	B
after	O
surgery	O
,	O
and	O
trough	O
TAC	B
level	O
.	O

Multivariate	O
analysis	O
showed	O
that	O
trough	O
TAC	B
level	O
was	O
the	O
only	O
independent	O
risk	O
factor	O
associated	O
with	O
the	O
seizures	O
.	O

All	O
children	O
who	O
experienced	O
seizures	O
survived	O
with	O
good	O
graft	O
function	O
and	O
remained	O
seizure	O
-	O
free	O
without	O
anti	O
-	O
epileptic	O
drugs	O
over	O
a	O
mean	O
follow	O
-	O
up	O
period	O
of	O
33.7	O
+	O
14.6	O
months	O
.	O

High	O
trough	O
TAC	B
level	O
was	O
the	O
predominant	O
factor	O
that	O
contributed	O
to	O
seizures	O
in	O
the	O
early	O
post	O
-	O
operative	O
period	O
after	O
pediatric	O
LT	O
.	O

High	O
PELD	O
and	O
Child	O
-	O
Pugh	O
scores	O
before	O
LT	O
and	O
high	O
post	O
-	O
operative	O
serum	O
Tbil	O
may	O
be	O
contributory	O
risk	O
factors	O
for	O
TAC	B
-	O
related	O
seizures	O
.	O

The	O
flavonoid	B
apigenin	B
delays	O
forgetting	O
of	O
passive	O
avoidance	O
conditioning	O
in	O
rats	O
.	O

The	O
present	O
experiments	O
were	O
performed	O
to	O
study	O
the	O
effect	O
of	O
the	O
flavonoid	B
apigenin	B
(	O
20	O
mg	O
/	O
kg	O
intraperitoneally	O
(	O
i.p	O
.	O
)	O
,	O
1	O
h	O
before	O
acquisition	O
)	O
,	O
on	O
24	O
h	O
retention	O
performance	O
and	O
forgetting	O
of	O
a	O
step	O
-	O
through	O
passive	O
avoidance	O
task	O
,	O
in	O
young	O
male	O
Wistar	O
rats	O
.	O

There	O
were	O
no	O
differences	O
between	O
saline-	O
and	O
apigenin	B
-	O
treated	O
groups	O
in	O
the	O
24	O
h	O
retention	O
trial	O
.	O

Furthermore	O
,	O
apigenin	B
did	O
not	O
prevent	O
the	O
amnesia	O
induced	O
by	O
scopolamine	B
(	O
1mg	O
/	O
kg	O
,	O
i.p	O
.	O
,	O
30	O
min	O
before	O
the	O
acquisition	O
)	O
.	O

The	O
saline-	O
and	O
apigenin	B
-	O
treated	O
rats	O
that	O
did	O
not	O
step	O
through	O
into	O
the	O
dark	O
compartment	O
during	O
the	O
cut	O
-	O
off	O
time	O
(	O
540	O
s	O
)	O
were	O
retested	O
weekly	O
for	O
up	O
to	O
eight	O
weeks	O
.	O

In	O
the	O
saline	O
treated	O
group	O
,	O
the	O
first	O
significant	O
decline	O
in	O
passive	O
avoidance	O
response	O
was	O
observed	O
at	O
four	O
weeks	O
,	O
and	O
complete	O
memory	O
loss	O
was	O
found	O
five	O
weeks	O
after	O
the	O
acquisition	O
of	O
the	O
passive	O
avoidance	O
task	O
.	O

At	O
the	O
end	O
of	O
the	O
experimental	O
period	O
,	O
60	O
%	O
of	O
the	O
animals	O
treated	O
with	O
apigenin	B
still	O
did	O
not	O
step	O
through	O
.	O

These	O
data	O
suggest	O
that	O
1	O
)	O
apigenin	B
delays	O
the	O
long	O
-	O
term	O
forgetting	O
but	O
did	O
not	O
modulate	O
the	O
24	O
h	O
retention	O
of	O
fear	O
memory	O
and	O
2	O
)	O
the	O
obtained	O
beneficial	O
effect	O
of	O
apigenin	B
on	O
the	O
passive	O
avoidance	O
conditioning	O
is	O
mediated	O
by	O
mechanisms	O
that	O
do	O
not	O
implicate	O
its	O
action	O
on	O
the	O
muscarinic	O
cholinergic	O
system	O
.	O

Cholecystokinin	B
-	I
octapeptide	I
restored	O
morphine	B
-	O
induced	O
hippocampal	O
long	O
-	O
term	O
potentiation	O
impairment	O
in	O
rats	O
.	O

Cholecystokinin	B
-	I
octapeptide	I
(	O
CCK-8	B
)	O
,	O
which	O
is	O
a	O
typical	O
brain	O
-	O
gut	O
peptide	O
,	O
exerts	O
a	O
wide	O
range	O
of	O
biological	O
activities	O
on	O
the	O
central	O
nervous	O
system	O
.	O

We	O
have	O
previously	O
reported	O
that	O
CCK-8	B
significantly	O
alleviated	O
morphine	B
-	O
induced	O
amnesia	O
and	O
reversed	O
spine	O
density	O
decreases	O
in	O
the	O
CA1	O
region	O
of	O
the	O
hippocampus	O
in	O
morphine	B
-	O
treated	O
animals	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
CCK-8	B
on	O
long	O
-	O
term	O
potentiation	O
(	O
LTP	O
)	O
in	O
the	O
lateral	O
perforant	O
path	O
(	O
LPP	O
)	O
-granule	O
cell	O
synapse	O
of	O
rat	O
dentate	O
gyrus	O
(	O
DG	O
)	O
in	O
acute	O
saline	O
or	O
morphine	B
-	O
treated	O
rats	O
.	O

Population	O
spikes	O
(	O
PS	O
)	O
,	O
which	O
were	O
evoked	O
by	O
stimulation	O
of	O
the	O
LPP	O
,	O
were	O
recorded	O
in	O
the	O
DG	O
region	O
.	O

Acute	O
morphine	B
(	O
30mg	O
/	O
kg	O
,	O
s.c	O
.	O
)	O
treatment	O
significantly	O
attenuated	O
hippocampal	O
LTP	O
and	O
CCK-8	B
(	O
1ug	O
,	O
i.c.v	O
.	O
)	O
restored	O
the	O
amplitude	O
of	O
PS	O
that	O
was	O
attenuated	O
by	O
morphine	B
injection	O
.	O

Furthermore	O
,	O
microinjection	O
of	O
CCK-8	B
(	O
0.1	O
and	O
1ug	O
,	O
i.c.v	O
.	O
)	O
also	O
significantly	O
augmented	O
hippocampal	O
LTP	O
in	O
saline	O
-	O
treated	O
(	O
1ml	O
/	O
kg	O
,	O
s.c	O
.	O
)	O
rats	O
.	O

Pre	O
-	O
treatment	O
of	O
the	O
CCK2	O
receptor	O
antagonist	O
L-365,260	O
(	O
10ug	O
,	O
i.c.v	O
)	O
reversed	O
the	O
effects	O
of	O
CCK-8	B
,	O
but	O
the	O
CCK1	O
receptor	O
antagonist	O
L-364,718	O
(	O
10ug	O
,	O
i.c.v	O
)	O
did	O
not	O
.	O

The	O
present	O
results	O
demonstrate	O
that	O
CCK-8	B
attenuates	O
the	O
effect	O
of	O
morphine	B
on	O
hippocampal	O
LTP	O
through	O
CCK2	O
receptors	O
and	O
suggest	O
an	O
ameliorative	O
function	O
of	O
CCK-8	B
on	O
morphine	B
-	O
induced	O
memory	O
impairment	O
.	O

Glial	O
activation	O
and	O
post	O
-	O
synaptic	O
neurotoxicity	O
:	O
the	O
key	O
events	O
in	O
Streptozotocin	B
(	O
ICV	O
)	O
induced	O
memory	O
impairment	O
in	O
rats	O
.	O

In	O
the	O
present	O
study	O
the	O
role	O
of	O
glial	O
activation	O
and	O
post	O
synaptic	O
toxicity	O
in	O
ICV	O
Streptozotocin	B
(	O
STZ	B
)	O
induced	O
memory	O
impaired	O
rats	O
was	O
explored	O
.	O

In	O
experiment	O
set	O
up	O
1	O
:	O
Memory	O
deficit	O
was	O
found	O
in	O
Morris	O
water	O
maze	O
test	O
on	O
14	O
-	O
16	O
days	O
after	O
STZ	B
(	O
ICV	O
;	O
3mg	O
/	O
Kg	O
)	O
administration	O
.	O

STZ	B
causes	O
increased	O
expression	O
of	O
GFAP	O
,	O
CD11b	O
and	O
TNF	O
-	O
a	O
indicating	O
glial	O
activation	O
and	O
neuroinflammation	O
.	O

STZ	B
also	O
significantly	O
increased	O
the	O
level	O
of	O
ROS	O
,	O
nitrite	B
,	O
Ca	B
(	O
2	O
+	O
)	O
and	O
reduced	O
the	O
mitochondrial	O
activity	O
in	O
synaptosomal	O
preparation	O
illustrating	O
free	O
radical	O
generation	O
and	O
excitotoxicity	O
.	O

Increased	O
expression	O
and	O
activity	O
of	O
Caspase-3	O
was	O
also	O
observed	O
in	O
STZ	B
treated	O
rat	O
which	O
specify	O
apoptotic	O
cell	O
death	O
in	O
hippocampus	O
and	O
cortex	O
.	O

STZ	B
treatment	O
showed	O
decrease	O
expression	O
of	O
post	O
synaptic	O
markers	O
CaMKIIa	O
and	O
PSD-95	O
,	O
while	O
,	O
expression	O
of	O
pre	O
synaptic	O
markers	O
(	O
synaptophysin	O
and	O
SNAP-25	O
)	O
remains	O
unaltered	O
indicating	O
selective	O
post	O
synaptic	O
neurotoxicity	O
.	O

Oral	O
treatment	O
with	O
Memantine	B
(	O
10mg	O
/	O
kg	O
)	O
and	O
Ibuprofen	B
(	O
50	O
mg	O
/	O
kg	O
)	O
daily	O
for	O
13	O
days	O
attenuated	O
STZ	B
induced	O
glial	O
activation	O
,	O
apoptotic	O
cell	O
death	O
and	O
post	O
synaptic	O
neurotoxicity	O
in	O
rat	O
brain	O
.	O

Further	O
,	O
in	O
experiment	O
set	O
up	O
2	O
:	O
where	O
memory	O
function	O
was	O
not	O
affected	O
i.e.	O
7	O
-	O
9	O
days	O
after	O
STZ	B
treatment	O
.	O

The	O
level	O
of	O
GFAP	O
,	O
CD11b	O
,	O
TNF	O
-	O
a	O
,	O
ROS	O
and	O
nitrite	B
levels	O
were	O
increased	O
.	O

On	O
the	O
other	O
hand	O
,	O
apoptotic	O
marker	O
,	O
synaptic	O
markers	O
,	O
mitochondrial	O
activity	O
and	O
Ca	B
(	O
2	O
+	O
)	O
levels	O
remained	O
unaffected	O
.	O

Collective	O
data	O
indicates	O
that	O
neuroinflammatory	O
process	O
and	O
oxidative	O
stress	O
occurs	O
earlier	O
to	O
apoptosis	O
and	O
does	O
not	O
affect	O
memory	O
function	O
.	O

Present	O
study	O
clearly	O
suggests	O
that	O
glial	O
activation	O
and	O
post	O
synaptic	O
neurotoxicity	O
are	O
the	O
key	O
factors	O
in	O
STZ	B
induced	O
memory	O
impairment	O
and	O
neuronal	O
cell	O
death	O
.	O

Comparison	O
of	O
effects	O
of	O
isotonic	O
sodium	B
chloride	I
with	O
diltiazem	B
in	O
prevention	O
of	O
contrast	B
-	O
induced	O
nephropathy	O
.	O

INTRODUCTION	O
AND	O
OBJECTIVE	O
:	O
Contrast	B
-	O
induced	O
nephropathy	O
(	O
CIN	O
)	O
significantly	O
increases	O
the	O
morbidity	O
and	O
mortality	O
of	O
patients	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
investigate	O
and	O
compare	O
the	O
protective	O
effects	O
of	O
isotonic	O
sodium	B
chloride	I
with	O
sodium	B
bicarbonate	I
infusion	O
and	O
isotonic	O
sodium	B
chloride	I
infusion	O
with	O
diltiazem	B
,	O
a	O
calcium	B
channel	O
blocker	O
,	O
in	O
preventing	O
CIN	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Our	O
study	O
included	O
patients	O
who	O
were	O
administered	O
30	O
-	O
60	O
mL	O
of	O
iodinated	O
contrast	B
agent	O
for	O
percutaneous	O
coronary	O
angiography	O
(	O
PCAG	O
)	O
,	O
all	O
with	O
creatinine	B
values	O
between	O
1.1	O
and	O
3.1	O
mg	O
/	O
dL.	O
Patients	O
were	O
divided	O
into	O
three	O
groups	O
and	O
each	O
group	O
had	O
20	O
patients	O
.	O

The	O
first	O
group	O
of	O
patients	O
was	O
administered	O
isotonic	O
sodium	B
chloride	I
;	O
the	O
second	O
group	O
was	O
administered	O
a	O
solution	O
that	O
of	O
5	O
%	O
dextrose	B
and	O
sodium	B
bicarbonate	I
,	O
while	O
the	O
third	O
group	O
was	O
administered	O
isotonic	O
sodium	B
chloride	I
before	O
and	O
after	O
the	O
contrast	B
injection	O
.	O

The	O
third	O
group	O
received	O
an	O
additional	O
injection	O
of	O
diltiazem	B
the	O
day	O
before	O
and	O
first	O
2	O
days	O
after	O
the	O
contrast	B
injection	O
.	O

All	O
of	O
the	O
patients	O
'	O
plasma	O
blood	B
urea	I
nitrogen	I
(	O
BUN	B
)	O
and	O
creatinine	B
levels	O
were	O
measured	O
on	O
the	O
second	O
and	O
seventh	O
day	O
after	O
the	O
administration	O
of	O
intravenous	O
contrast	B
material	O
.	O

RESULTS	O
:	O
The	O
basal	O
creatinine	B
levels	O
were	O
similar	O
for	O
all	O
three	O
groups	O
(	O
p	O
>	O
0.05	O
)	O
.	O

Among	O
a	O
total	O
of	O
60	O
patients	O
included	O
in	O
the	O
study	O
,	O
16	O
patients	O
developed	O
acute	O
renal	O
failure	O
(	O
ARF	O
)	O
on	O
the	O
second	O
day	O
after	O
contrast	B
material	O
was	O
injected	O
(	O
26.6	O
%	O
)	O
.	O

The	O
number	O
of	O
patients	O
who	O
developed	O
ARF	O
on	O
the	O
second	O
day	O
after	O
the	O
injection	O
in	O
the	O
first	O
group	O
was	O
five	O
(	O
25	O
%	O
)	O
,	O
in	O
the	O
second	O
group	O
was	O
six	O
(	O
30	O
%	O
)	O
and	O
the	O
third	O
group	O
was	O
five	O
(	O
25	O
%	O
)	O
(	O
p	O
>	O
0.05	O
)	O
.	O

CONCLUSION	O
:	O
There	O
was	O
no	O
significant	O
difference	O
between	O
isotonic	O
sodium	B
chloride	I
,	O
sodium	B
bicarbonate	I
and	O
isotonic	O
sodium	B
chloride	I
with	O
diltiazem	B
application	O
in	O
prevention	O
of	O
CIN	O
.	O

Neurocognitive	O
and	O
neuroradiologic	O
central	O
nervous	O
system	O
late	O
effects	O
in	O
children	O
treated	O
on	O
Pediatric	O
Oncology	O
Group	O
(	O
POG	O
)	O
P9605	O
(	O
standard	O
risk	O
)	O
and	O
P9201	O
(	O
lesser	O
risk	O
)	O
acute	O
lymphoblastic	O
leukemia	O
protocols	O
(	O
ACCL0131	O
)	O
:	O
a	O
methotrexate	B
consequence	O
?	O

A	O
report	O
from	O
the	O
Children	O
's	O
Oncology	O
Group	O
.	O

Concerns	O
about	O
long	O
-	O
term	O
methotrexate	B
(	O
MTX	B
)	O
neurotoxicity	O
in	O
the	O
1990s	O
led	O
to	O
modifications	O
in	O
intrathecal	O
(	O
IT	O
)	O
therapy	O
,	O
leucovorin	O
rescue	O
,	O
and	O
frequency	O
of	O
systemic	O
MTX	B
administration	O
in	O
children	O
with	O
acute	O
lymphoblastic	O
leukemia	O
.	O

In	O
this	O
study	O
,	O
neurocognitive	O
outcomes	O
and	O
neuroradiologic	O
evidence	O
of	O
leukoencephalopathy	O
were	O
compared	O
in	O
children	O
treated	O
with	O
intense	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
-directed	O
therapy	O
(	O
P9605	O
)	O
versus	O
those	O
receiving	O
fewer	O
CNS	O
-	O
directed	O
treatment	O
days	O
during	O
intensive	O
consolidation	O
(	O
P9201	O
)	O
.	O

A	O
total	O
of	O
66	O
children	O
from	O
16	O
Pediatric	O
Oncology	O
Group	O
institutions	O
with	O
"	O
standard	O
-	O
risk	O
"	O
acute	O
lymphoblastic	O
leukemia	O
,	O
1.00	O
to	O
9.99	O
years	O
at	O
diagnosis	O
,	O
without	O
evidence	O
of	O
CNS	O
leukemia	O
at	O
diagnosis	O
were	O
enrolled	O
on	O
ACCL0131	O
:	O
28	O
from	O
P9201	O
and	O
38	O
from	O
P9605	O
.	O

Magnetic	O
resonance	O
imaging	O
scans	O
and	O
standard	O
neuropsychological	O
tests	O
were	O
performed	O
>	O
2.6	O
years	O
after	O
the	O
end	O
of	O
treatment	O
.	O

Significantly	O
more	O
P9605	O
patients	O
developed	O
leukoencephalopathy	O
compared	O
with	O
P9201	O
patients	O
(	O
68	O
%	O
,	O
95	O
%	O
confidence	O
interval	O
49%-83	O
%	O
vs.	O
22	O
%	O
,	O
95	O
%	O
confidence	O
interval	O
5%-44	O
%	O
;	O
P=0.001	O
)	O
identified	O
as	O
late	O
as	O
7.7	O
years	O
after	O
the	O
end	O
of	O
treatment	O
.	O

Overall	O
,	O
40	O
%	O
of	O
patients	O
scored	O
<	O
85	O
on	O
either	O
Verbal	O
or	O
Performance	O
IQ	O
.	O

Children	O
on	O
both	O
studies	O
had	O
significant	O
attention	O
problems	O
,	O
but	O
P9605	O
children	O
scored	O
below	O
average	O
on	O
more	O
neurocognitive	O
measures	O
than	O
those	O
treated	O
on	O
P9201	O
(	O
82	O
%	O
,	O
14	O
/	O
17	O
measures	O
vs.	O
24	O
%	O
,	O
4	O
/	O
17	O
measures	O
)	O
.	O

This	O
supports	O
ongoing	O
concerns	O
about	O
intensive	O
MTX	B
exposure	O
as	O
a	O
major	O
contributor	O
to	O
CNS	O
late	O
effects	O
.	O

Tranexamic	B
acid	I
overdosage	O
-	O
induced	O
generalized	O
seizure	O
in	O
renal	O
failure	O
.	O

We	O
report	O
a	O
45-year	O
-	O
old	O
lady	O
with	O
chronic	O
kidney	O
disease	O
stage	O
4	O
due	O
to	O
chronic	O
tubulointerstial	O
disease	O
.	O

She	O
was	O
admitted	O
to	O
our	O
center	O
for	O
severe	O
anemia	O
due	O
to	O
menorrhagia	O
and	O
deterioration	O
of	O
renal	O
function	O
.	O

She	O
was	O
infused	O
three	O
units	O
of	O
packed	O
cells	O
during	O
a	O
session	O
of	O
hemodialysis	O
.	O

Tranexamic	B
acid	I
(	O
TNA	B
)	O
1	O
g	O
8-hourly	O
was	O
administered	O
to	O
her	O
to	O
control	O
bleeding	O
per	O
vaginum	O
.	O

Two	O
hours	O
after	O
the	O
sixth	O
dose	O
of	O
TNA	B
,	O
she	O
had	O
an	O
episode	O
of	O
generalized	O
tonic	O
clonic	O
convulsions	O
.	O

TNA	B
was	O
discontinued	O
.	O

Investigations	O
of	O
the	O
patient	O
revealed	O
no	O
biochemical	O
or	O
structural	O
central	O
nervous	O
system	O
abnormalities	O
that	O
could	O
have	O
provoked	O
the	O
convulsions	O
.	O

She	O
did	O
not	O
require	O
any	O
further	O
dialytic	O
support	O
.	O

She	O
had	O
no	O
further	O
episodes	O
of	O
convulsion	O
till	O
dis	O
-	O
charge	O
and	O
during	O
the	O
two	O
months	O
of	O
follow	O
-	O
up	O
.	O

Thus	O
,	O
the	O
precipitating	O
cause	O
of	O
convulsions	O
was	O
believed	O
to	O
be	O
an	O
overdose	O
of	O
TNA	B
.	O

Pre	O
-	O
treatment	O
of	O
bupivacaine	B
-	O
induced	O
cardiovascular	O
depression	O
using	O
different	O
lipid	O
formulations	O
of	O
propofol	B
.	O

BACKGROUND	O
:	O
Pre	O
-	O
treatment	O
with	O
lipid	O
emulsions	O
has	O
been	O
shown	O
to	O
increase	O
lethal	O
doses	O
of	O
bupivacaine	B
,	O
and	O
the	O
lipid	O
content	O
of	O
propofol	B
may	O
alleviate	O
bupivacaine	B
-	O
induced	O
cardiotoxicity	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
investigate	O
the	O
effects	O
of	O
propofol	B
in	O
intralipid	O
or	O
medialipid	O
emulsions	O
on	O
bupivacaine	B
-	O
induced	O
cardiotoxicity	O
.	O

METHODS	O
:	O
Rats	O
were	O
anaesthetised	O
with	O
ketamine	B
and	O
were	O
given	O
0.5	O
mg	O
/	O
kg	O
/	O
min	O
propofol	B
in	O
intralipid	O
(	O
Group	O
P	O
)	O
,	O
propofol	B
in	O
medialipid	O
(	O
Group	O
L	O
)	O
,	O
or	O
saline	O
(	O
Group	O
C	O
)	O
over	O
20	O
min	O
.	O

Thereafter	O
,	O
2	O
mg	O
/	O
kg	O
/	O
min	O
bupivacaine	B
0.5	O
%	O
was	O
infused	O
.	O

We	O
recorded	O
time	O
to	O
first	O
dysrhythmia	O
occurrence	O
,	O
respective	O
times	O
to	O
25	O
%	O
and	O
50	O
%	O
reduction	O
of	O
the	O
heart	O
rate	O
(	O
HR	O
)	O
and	O
mean	O
arterial	O
pressure	O
,	O
and	O
time	O
to	O
asystole	O
and	O
total	O
amount	O
of	O
bupivacaine	B
consumption	O
.	O

Blood	O
and	O
tissue	O
samples	O
were	O
collected	O
following	O
asystole	O
.	O

RESULTS	O
:	O
The	O
time	O
to	O
first	O
dysrhythmia	O
occurrence	O
,	O
time	O
to	O
25	O
%	O
and	O
50	O
%	O
reductions	O
in	O
HR	O
,	O
and	O
time	O
to	O
asystole	O
were	O
longer	O
in	O
Group	O
P	O
than	O
the	O
other	O
groups	O
.	O

The	O
cumulative	O
bupivacaine	B
dose	O
given	O
at	O
those	O
time	O
points	O
was	O
higher	O
in	O
Group	O
P.	O
Plasma	O
bupivacaine	B
levels	O
were	O
significantly	O
lower	O
in	O
Group	O
P	O
than	O
in	O
Group	O
C.	O
Bupivacaine	B
levels	O
in	O
the	O
brain	O
and	O
heart	O
were	O
significantly	O
lower	O
in	O
Group	O
P	O
and	O
Group	O
L	O
than	O
in	O
Group	O
C.	O
CONCLUSION	O
:	O
We	O
conclude	O
that	O
pre	O
-	O
treatment	O
with	O
propofol	B
in	O
intralipid	O
,	O
compared	O
with	O
propofol	B
in	O
medialipid	O
or	O
saline	O
,	O
delayed	O
the	O
onset	O
of	O
bupivacaine	B
-	O
induced	O
cardiotoxic	O
effects	O
as	O
well	O
as	O
reduced	O
plasma	O
bupivacaine	B
levels	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
explore	O
tissue	O
bupivacaine	B
levels	O
of	O
propofol	B
in	O
medialipid	O
and	O
adapt	O
these	O
results	O
to	O
clinical	O
practice	O
.	O

Drug	O
-	O
Induced	O
Acute	O
Liver	O
Injury	O

Within	O
12	O
Hours	O
After	O
Fluvastatin	B
Therapy	O
.	O

Although	O
statins	B
are	O
generally	O
well	O
-	O
tolerated	O
drugs	O
,	O
recent	O
cases	O
of	O
drug	O
-	O
induced	O
liver	O
injury	O
associated	O
with	O
their	O
use	O
have	O
been	O
reported	O
.	O

A	O
52-year	O
-	O
old	O
Chinese	O
man	O
reported	O
with	O
liver	O
damage	O
,	O
which	O
appeared	O
12	O
hours	O
after	O
beginning	O
treatment	O
with	O
fluvastatin	B
.	O

Patient	O
presented	O
with	O
complaints	O
of	O
increasing	O
nausea	O
,	O
anorexia	O
,	O
and	O
upper	O
abdominal	O
pain	O
.	O

His	O
laboratory	O
values	O
showed	O
elevated	O
creatine	B
kinase	O
and	O
transaminases	O
.	O

Testing	O
for	O
autoantibodies	O
was	O
also	O
negative	O
.	O

The	O
liver	O
biochemistries	O
eventually	O
normalized	O
within	O
3	O
weeks	O
of	O
stopping	O
the	O
fluvastatin	B
.	O

Therefore	O
,	O
when	O
prescribing	O
statins	O
,	O
the	O
possibility	O
of	O
hepatic	O
damage	O
should	O
be	O
taken	O
into	O
account	O
.	O

Fluconazole	B
associated	O
agranulocytosis	O
and	O
thrombocytopenia	O
.	O

CASE	O
:	O
We	O
describe	O
a	O
second	O
case	O
of	O
fluconazole	B
associated	O
agranulocytosis	O
with	O
thrombocytopenia	O
and	O
recovery	O
upon	O
discontinuation	O
of	O
therapy	O
.	O

The	O
patient	O
began	O
to	O
have	O
changes	O
in	O
white	O
blood	O
cells	O
and	O
platelets	O
within	O
48	O
h	O
of	O
administration	O
of	O
fluconazole	B
and	O
began	O
to	O
recover	O
with	O
48	O
h	O
of	O
discontinuation	O
.	O

This	O
case	O
highlights	O
that	O
drug	O
-	O
induced	O
blood	O
dyscrasias	O
can	O
occur	O
unexpectedly	O
as	O
a	O
result	O
of	O
treatment	O
with	O
a	O
commonly	O
used	O
drug	O
thought	O
to	O
be	O
"	O
safe	O
"	O
.	O

CONCLUSION	O
:	O
According	O
to	O
Naranjo	O
's	O
algorithm	O
the	O
likelihood	O
that	O
our	O
patient	O
's	O
agranulocytosis	O
and	O
thrombocytopenia	O
occurred	O
as	O
a	O
result	O
of	O
therapy	O
with	O
fluconazole	B
is	O
probable	O
,	O
with	O
a	O
total	O
of	O
six	O
points	O
.	O

We	O
feel	O
that	O
the	O
weight	O
of	O
the	O
overall	O
evidence	O
of	O
this	O
evidence	O
is	O
strong	O
.	O

In	O
particular	O
the	O
temporal	O
relationship	O
of	O
bone	O
marrow	O
suppression	O
to	O
the	O
initiation	O
of	O
fluconazole	B
and	O
the	O
abatement	O
of	O
symptoms	O
that	O
rapidly	O
reversed	O
immediately	O
following	O
discontinuation	O
.	O

Two	O
-	O
dimensional	O
speckle	O
tracking	O
echocardiography	O
combined	O
with	O
high	O
-	O
sensitive	O
cardiac	O
troponin	O
T	O
in	O
early	O
detection	O
and	O
prediction	O
of	O
cardiotoxicity	O
during	O
epirubicine	B
-	O
based	O
chemotherapy	O
.	O

AIMS	O
:	O
To	O
investigate	O
whether	O
alterations	O
of	O
myocardial	O
strain	O
and	O
high	O
-	O
sensitive	O
cardiac	O
troponin	O
T	O
(	O
cTnT	O
)	O
could	O
predict	O
future	O
cardiac	O
dysfunction	O
in	O
patients	O
after	O
epirubicin	B
exposure	O
.	O

METHODS	O
:	O
Seventy	O
-	O
five	O
patients	O
with	O
non	O
-	O
Hodgkin	O
lymphoma	O
treated	O
with	O
epirubicin	B
were	O
studied	O
.	O

Blood	O
collection	O
and	O
echocardiography	O
were	O
performed	O
at	O
baseline	O
,	O
1	O
day	O
after	O
the	O
third	O
cycle	O
,	O
and	O
1	O
day	O
after	O
completion	O
of	O
chemotherapy	O
.	O

Patients	O
were	O
studied	O
using	O
echocardiography	O
during	O
follow	O
-	O
up	O
.	O

Global	O
longitudinal	O
(	O
GLS	O
)	O
,	O
circumferential	O
(	O
GCS	O
)	O
,	O
and	O
radial	O
strain	O
(	O
GRS	O
)	O
were	O
calculated	O
using	O
speckle	O
tracking	O
echocardiography	O
.	O

Left	O
ventricular	O
ejection	O
fraction	O
was	O
analysed	O
by	O
real	O
-	O
time	O
3D	O
echocardiography	O
.	O

Cardiotoxicity	O
was	O
defined	O
as	O
a	O
reduction	O
of	O
the	O
LVEF	O
of	O
>	O
5	O
%	O
to	O
<	O
55	O
%	O
with	O
symptoms	O
of	O
heart	O
failure	O
or	O
an	O
asymptomatic	O
reduction	O
of	O
the	O
LVEF	O
of	O
>	O
10	O
%	O
to	O
<	O
55	O
%	O
.	O

RESULTS	O
:	O
Fourteen	O
patients	O
(	O
18.67	O
%	O
)	O
developed	O
cardiotoxicity	O
after	O
treatment	O
.	O

GLS	O
(	O
-18.48	O
+	O
1.72	O
%	O
vs.	O
-15.96	O
+	O
1.6	O
%	O
)	O
,	O
GCS	O
(	O
-20.93	O
+	O
2.86	O
%	O
vs.	O
-19.20	O
+	O
3.21	O
%	O
)	O
,	O
and	O
GRS	O
(	O
39.23	O
+	O
6.44	O
%	O
vs.	O
34.98	O
+	O
6.2	O
%	O
)	O
were	O
markedly	O
reduced	O
and	O
cTnT	O
was	O
elevated	O
from	O
0.0010	O
+	O
0.0020	O
to	O
0.0073	O
+	O
0.0038	O
ng	O
/	O
mL	O
(	O
P	O
all	O
<	O
0.01	O
)	O
at	O
the	O
completion	O
of	O
chemotherapy	O
compared	O
with	O
baseline	O
values	O
.	O

A	O
>	O
15.9	O
%	O
decrease	O
in	O
GLS	O
[	O
sensitivity	O
,	O
86	O
%	O
;	O
specificity	O
,	O
75	O
%	O
;	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
=	O
0.815	O
;	O
P	O
=	O
0.001	O
]	O
and	O
a	O
>	O
0.004	O
ng	O
/	O
mL	O
elevation	O
in	O
cTnT	O
(	O
sensitivity	O
,	O
79	O
%	O
;	O
specificity	O
,	O
64	O
%	O
;	O
AUC	O
=	O
0.757	O
;	O
P	O
=	O
0.005	O
)	O
from	O
baseline	O
to	O
the	O
third	O
cycle	O
of	O
chemotherapy	O
predicted	O
later	O
cardiotoxicity	O
.	O

The	O
decrease	O
in	O
GLS	O
remained	O
the	O
only	O
independent	O
predictor	O
of	O
cardiotoxicity	O
(	O
P	O
=	O
0.000	O
)	O
.	O

CONCLUSIONS	O
:	O
GLS	O
combined	O
with	O
cTnT	O
may	O
provide	O
a	O
reliable	O
and	O
non	O
-	O
invasive	O
method	O
to	O
predict	O
cardiac	O
dysfunction	O
in	O
patients	O
receiving	O
anthracycline	B
-	O
based	O
chemotherapy	O
.	O

Prevention	O
of	O
etomidate	B
-	O
induced	O
myoclonus	O
:	O
which	O
is	O
superior	O
:	O
Fentanyl	B
,	O
midazolam	B
,	O
or	O
a	O
combination	O
?	O

A	O
Retrospective	O
comparative	O
study	O
.	O

BACKGROUND	O
:	O
In	O
this	O
retrospective	O
comparative	O
study	O
,	O
we	O
aimed	O
to	O
compare	O
the	O
effectiveness	O
of	O
fentanyl	B
,	O
midazolam	B
,	O
and	O
a	O
combination	O
of	O
fentanyl	B
and	O
midazolam	B
to	O
prevent	O
etomidate	B
-	O
induced	O
myoclonus	O
.	O

MATERIAL	O
AND	O
METHODS	O
:	O
This	O
study	O
was	O
performed	O
based	O
on	O
anesthesia	O
records	O
.	O

Depending	O
on	O
the	O
drugs	O
that	O
would	O
be	O
given	O
before	O
the	O
induction	O
of	O
anesthesia	O
with	O
etomidate	B
,	O
the	O
patients	O
were	O
separated	O
into	O
4	O
groups	O
:	O
no	O
pretreatment	O
(	O
Group	O
NP	O
)	O
,	O
fentanyl	B
1	O
ug.kg-1	O
(	O
Group	O
F	O
)	O
,	O
midazolam	B
0.03	O
mg.kg-1	O
(	O
Group	O
M	O
)	O
,	O
and	O
midazolam	B
0.015	O
mg.kg-1	O
+	O
fentanyl	B
0.5	O
ug.kg-1	O
(	O
Group	O
FM	O
)	O
.	O

Patients	O
who	O
received	O
the	O
same	O
anesthetic	O
procedure	O
were	O
selected	O
:	O
2	O
minutes	O
after	O
intravenous	O
injections	O
of	O
the	O
pretreatment	O
drugs	O
,	O
anesthesia	O
is	O
induced	O
with	O
0.3	O
mg.kg-1	O
etomidate	B
injected	O
intravenously	O
over	O
a	O
period	O
of	O
20	O
-	O
30	O
seconds	O
.	O

Myoclonic	O
movements	O
are	O
evaluated	O
,	O
which	O
were	O
observed	O
and	O
graded	O
according	O
to	O
clinical	O
severity	O
during	O
the	O
2	O
minutes	O
after	O
etomidate	B
injection	O
.	O

The	O
severity	O
of	O
pain	O
due	O
to	O
etomidate	B
injection	O
,	O
mean	O
arterial	O
pressure	O
,	O
heart	O
rate	O
,	O
and	O
adverse	O
effects	O
were	O
also	O
evaluated	O
.	O

RESULTS	O
:	O
Study	O
results	O
showed	O
that	O
myoclonus	O
incidence	O
was	O
85	O
%	O
,	O
40	O
%	O
,	O
70	O
%	O
,	O
and	O
25	O
%	O
in	O
Group	O
NP	O
,	O
Group	O
F	O
,	O
Group	O
M	O
,	O
and	O
Group	O
FM	O
,	O
respectively	O
,	O
and	O
were	O
significantly	O
lower	O
in	O
Group	O
F	O
and	O
Group	O
FM	O
.	O

CONCLUSIONS	O
:	O
We	O
conclude	O
that	O
pretreatment	O
with	O
fentanyl	B
or	O
combination	O
of	O
fentanyl	B
and	O
midazolam	B
was	O
effective	O
in	O
preventing	O
etomidate	B
-	O
induced	O
myoclonus	O
.	O

Cholestatic	O
presentation	O
of	O
yellow	O
phosphorus	B
poisoning	O
.	O

Yellow	O
phosphorus	B
,	O
a	O
component	O
of	O
certain	O
pesticide	O
pastes	O
and	O
fireworks	O
,	O
is	O
well	O
known	O
to	O
cause	O
hepatotoxicity	O
.	O

Poisoning	O
with	O
yellow	O
phosphorus	B
classically	O
manifests	O
with	O
acute	O
hepatitis	O
leading	O
to	O
acute	O
liver	O
failure	O
which	O
may	O
need	O
liver	O
transplantation	O
.	O

We	O
present	O
a	O
case	O
of	O
yellow	O
phosphorus	B
poisoning	O
in	O
which	O
a	O
patient	O
presented	O
with	O
florid	O
clinical	O
features	O
of	O
cholestasis	O
highlighting	O
the	O
fact	O
that	O
cholestasis	O
can	O
rarely	O
be	O
a	O
presenting	O
feature	O
of	O
yellow	O
phosphorus	B
hepatotoxicity	O
.	O

Vasovagal	O
syncope	O
and	O
severe	O
bradycardia	O
following	O
intranasal	O
dexmedetomidine	B
for	O
pediatric	O
procedural	O
sedation	O
.	O

We	O
report	O
syncope	O
and	O
bradycardia	O
in	O
an	O
11-year	O
-	O
old	O
girl	O
following	O
administration	O
of	O
intranasal	O
dexmedetomidine	B
for	O
sedation	O
for	O
a	O
voiding	O
cystourethrogram	O
.	O

Following	O
successful	O
completion	O
of	O
VCUG	O
and	O
a	O
60-min	O
recovery	O
period	O
,	O
the	O
patient	O
's	O
level	O
of	O
consciousness	O
and	O
vital	O
signs	O
returned	O
to	O
presedation	O
levels	O
.	O

Upon	O
leaving	O
the	O
sedation	O
area	O
,	O
the	O
patient	O
collapsed	O
,	O
with	O
no	O
apparent	O
inciting	O
event	O
.	O

The	O
patient	O
quickly	O
regained	O
consciousness	O
and	O
no	O
injury	O
occurred	O
.	O

The	O
primary	O
abnormality	O
found	O
was	O
persistent	O
bradycardia	O
,	O
and	O
she	O
was	O
admitted	O
to	O
the	O
hospital	O
for	O
telemetric	O
observation	O
.	O

The	O
bradycardia	O
lasted	O
~2	O
h	O
,	O
and	O
further	O
cardiac	O
workup	O
revealed	O
no	O
underlying	O
abnormality	O
.	O

Unanticipated	O
and	O
previously	O
unreported	O
outcomes	O
may	O
be	O
witnessed	O
as	O
we	O
expand	O
the	O
use	O
of	O
certain	O
sedatives	O
to	O
alternative	O
routes	O
of	O
administration	O
.	O

Paradoxical	O
severe	O
agitation	O
induced	O
by	O
add	O
-	O
on	O
high	O
-	O
doses	O
quetiapine	B
in	O
schizo	O
-	O
affective	O
disorder	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
35-year	O
-	O
old	O
patient	O
suffering	O
from	O
schizo	O
-	O
affective	O
disorder	O
since	O
the	O
age	O
of	O
19	O
years	O
,	O
treated	O
by	O
a	O
combination	O
of	O
first	O
-	O
generation	O
antipsychotics	O
,	O
zuclopenthixol	B
(	O
100	O
mg	O
/	O
day	O
)	O
and	O
lithium	B
(	O
1200	O
mg	O
/	O
day	O
)	O
(	O
serum	O
lithium=0.85	B
mEq	O
/	O
l	O
)	O
.	O

This	O
patient	O
had	O
no	O
associated	O
personality	O
disorder	O
(	O
particularly	O
no	O
antisocial	O
disorder	O
)	O
and	O
no	O
substance	O
abuse	O
disorder	O
.	O

Within	O
the	O
48	O
h	O
following	O
the	O
gradual	O
introduction	O
of	O
quetiapine	B
(	O
up	O
to	O
600	O
mg	O
/	O
day	O
)	O
,	O
the	O
patient	O
presented	O
severe	O
agitation	O
without	O
an	O
environmental	O
explanation	O
,	O
contrasting	O
with	O
the	O
absence	O
of	O
a	O
history	O
of	O
aggressiveness	O
or	O
personality	O
disorder	O
.	O

The	O
diagnoses	O
of	O
manic	O
shift	O
and	O
akathisia	O
were	O
dismissed	O
.	O

The	O
withdrawal	O
and	O
the	O
gradual	O
reintroduction	O
of	O
quetiapine	B
2	O
weeks	O
later	O
,	O
which	O
led	O
to	O
another	O
severe	O
agitation	O
,	O
enabled	O
us	O
to	O
attribute	O
the	O
agitation	O
specifically	O
to	O
quetiapine	B
.	O

Antioxidant	O
effects	O
of	O
bovine	O
lactoferrin	O
on	O
dexamethasone	B
-	O
induced	O
hypertension	O
in	O
rat	O
.	O

Dexamethasone-	B
(	O
Dex-	B
)	O
induced	O
hypertension	O
is	O
associated	O
with	O
enhanced	O
oxidative	O
stress	O
.	O

Lactoferrin	O
(	O
LF	O
)	O
is	O
an	O
iron	B
-	O
binding	O
glycoprotein	O
with	O
antihypertensive	O
properties	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
chronic	O
administration	O
of	O
LF	O
on	O
oxidative	O
stress	O
and	O
hypertension	O
upon	O
Dex	B
administration	O
.	O

Male	O
Wistar	O
rats	O
were	O
treated	O
by	O
Dex	B
(	O
30	O
u	O
g	O
/	O
kg	O
/	O
day	O
subcutaneously	O
)	O
or	O
saline	O
for	O
14	O
days	O
.	O

Oral	O
bovine	O
LF	O
(	O
30	O
,	O
100	O
,	O
300	O
mg	O
/	O
kg	O
)	O
was	O
given	O
from	O
day	O
8	O
to	O
14	O
in	O
a	O
reversal	O
study	O
.	O

In	O
a	O
prevention	O
study	O
,	O
rats	O
received	O
4	O
days	O
of	O
LF	O
treatment	O
followed	O
by	O
Dex	B
and	O
continued	O
during	O
the	O
test	O
period	O
.	O

Systolic	O
blood	O
pressure	O
(	O
SBP	O
)	O
was	O
measured	O
using	O
tail	O
-	O
cuff	O
method	O
.	O

Thymus	O
weight	O
was	O
used	O
as	O
a	O
marker	O
of	O
glucocorticoid	O
activity	O
.	O

Plasma	O
hydrogen	B
peroxide	I
(	O
H2O2	B
)	O
concentration	O
and	O
ferric	O
reducing	O
antioxidant	O
power	O
(	O
FRAP	O
)	O
value	O
were	O
determined	O
.	O

Dexamethasone	B
significantly	O
increased	O
SBP	O
and	O
plasma	O
H2O2	B
level	O
and	O
decreased	O
thymus	O
and	O
body	O
weights	O
.	O

LF	O
lowered	O
(	O
P	O
<	O
0.01	O
)	O
and	O
dose	O
dependently	O
prevented	O
(	O
P	O
<	O
0.001	O
)	O
Dex	B
-	O
induced	O
hypertension	O
.	O

LF	O
prevented	O
body	O
weight	O
loss	O
and	O
significantly	O
reduced	O
the	O
elevated	O
plasma	O
H2O2	B
and	O
increased	O
FRAP	O
values	O
.	O

Chronic	O
administration	O
of	O
LF	O
strongly	O
reduced	O
the	O
blood	O
pressure	O
and	O
production	O
of	O
ROS	O
and	O
improved	O
antioxidant	O
capacity	O
in	O
Dex	B
-	O
induced	O
hypertension	O
,	O
suggesting	O
the	O
role	O
of	O
inhibition	O
of	O
oxidative	O
stress	O
as	O
another	O
mechanism	O
of	O
antihypertensive	O
action	O
of	O
LF	O
.	O

The	O
association	O
between	O
tranexamic	B
acid	I
and	O
convulsive	O
seizures	O
after	O
cardiac	O
surgery	O
:	O
a	O
multivariate	O
analysis	O
in	O
11	O
529	O
patients	O
.	O

Because	O
of	O
a	O
lack	O
of	O
contemporary	O
data	O
regarding	O
seizures	O
after	O
cardiac	O
surgery	O
,	O
we	O
undertook	O
a	O
retrospective	O
analysis	O
of	O
prospectively	O
collected	O
data	O
from	O
11	O
529	O
patients	O
in	O
whom	O
cardiopulmonary	O
bypass	O
was	O
used	O
from	O
January	O
2004	O
to	O
December	O
2010	O
.	O

A	O
convulsive	O
seizure	O
was	O
defined	O
as	O
a	O
transient	O
episode	O
of	O
disturbed	O
brain	O
function	O
characterised	O
by	O
abnormal	O
involuntary	O
motor	O
movements	O
.	O

Multivariate	O
regression	O
analysis	O
was	O
performed	O
to	O
identify	O
independent	O
predictors	O
of	O
postoperative	O
seizures	O
.	O

A	O
total	O
of	O
100	O
(	O
0.9	O
%	O
)	O
patients	O
developed	O
postoperative	O
convulsive	O
seizures	O
.	O

Generalised	O
and	O
focal	O
seizures	O
were	O
identified	O
in	O
68	O
and	O
32	O
patients	O
,	O
respectively	O
.	O

The	O
median	O
(	O
IQR	O
[	O
range	O
]	O
)	O
time	O
after	O
surgery	O
when	O
the	O
seizure	O
occurred	O
was	O
7	O
(	O
6	O
-	O
12	O
[	O
1	O
-	O
216	O
]	O
)	O
h	O
and	O
8	O
(	O
6	O
-	O
11	O
[	O
4	O
-	O
18	O
]	O
)	O
h	O
,	O
respectively	O
.	O

Epileptiform	O
findings	O
on	O
electroencephalography	O
were	O
seen	O
in	O
19	O
patients	O
.	O

Independent	O
predictors	O
of	O
postoperative	O
seizures	O
included	O
age	O
,	O
female	O
sex	O
,	O
redo	O
cardiac	O
surgery	O
,	O
calcification	O
of	O
ascending	O
aorta	O
,	O
congestive	O
heart	O
failure	O
,	O
deep	O
hypothermic	O
circulatory	O
arrest	O
,	O
duration	O
of	O
aortic	O
cross	O
-	O
clamp	O
and	O
tranexamic	B
acid	I
.	O

When	O
tested	O
in	O
a	O
multivariate	O
regression	O
analysis	O
,	O
tranexamic	B
acid	I
was	O
a	O
strong	O
independent	O
predictor	O
of	O
seizures	O
(	O
OR	O
14.3	O
,	O
95	O
%	O
CI	O
5.5	O
-	O
36.7	O
;	O
p	O
<	O
0.001	O
)	O
.	O

Patients	O
with	O
convulsive	O
seizures	O
had	O
2.5	O
times	O
higher	O
in	O
-	O
hospital	O
mortality	O
rates	O
and	O
twice	O
the	O
length	O
of	O
hospital	O
stay	O
compared	O
with	O
patients	O
without	O
convulsive	O
seizures	O
.	O

Mean	O
(	O
IQR	O
[	O
range	O
]	O
)	O
length	O
of	O
stay	O
in	O
the	O
intensive	O
care	O
unit	O
was	O
115	O
(	O
49	O
-	O
228	O
[	O
32	O
-	O
481	O
]	O
)	O
h	O
in	O
patients	O
with	O
convulsive	O
seizures	O
compared	O
with	O
26	O
(	O
22	O
-	O
69	O
[	O
14	O
-	O
1080	O
]	O
)	O
h	O
in	O
patients	O
without	O
seizures	O
(	O
p	O
<	O
0.001	O
)	O
.	O

Convulsive	O
seizures	O
are	O
a	O
serious	O
postoperative	O
complication	O
after	O
cardiac	O
surgery	O
.	O

As	O
tranexamic	B
acid	I
is	O
the	O
only	O
modifiable	O
factor	O
,	O
its	O
administration	O
,	O
particularly	O
in	O
doses	O
exceeding	O
80	O
mg.kg	O
(	O
-1	O
)	O
,	O
should	O
be	O
weighed	O
against	O
the	O
risk	O
of	O
postoperative	O
seizures	O
.	O

Dysfunctional	O
overnight	O
memory	O
consolidation	O
in	O
ecstasy	B
users	O
.	O

Sleep	O
plays	O
an	O
important	O
role	O
in	O
the	O
consolidation	O
and	O
integration	O
of	O
memory	O
in	O
a	O
process	O
called	O
overnight	O
memory	O
consolidation	O
.	O

Previous	O
studies	O
indicate	O
that	O
ecstasy	B
users	O
have	O
marked	O
and	O
persistent	O
neurocognitive	O
and	O
sleep	O
-	O
related	O
impairments	O
.	O

We	O
extend	O
past	O
research	O
by	O
examining	O
overnight	O
memory	O
consolidation	O
among	O
regular	O
ecstasy	B
users	O
(	O
n=12	O
)	O
and	O
drug	O
naive	O
healthy	O
controls	O
(	O
n=26	O
)	O
.	O

Memory	O
recall	O
of	O
word	O
pairs	O
was	O
evaluated	O
before	O
and	O
after	O
a	O
period	O
of	O
sleep	O
,	O
with	O
and	O
without	O
interference	O
prior	O
to	O
testing	O
.	O

In	O
addition	O
,	O
we	O
assessed	O
neurocognitive	O
performances	O
across	O
tasks	O
of	O
learning	O
,	O
memory	O
and	O
executive	O
functioning	O
.	O

Ecstasy	B
users	O
demonstrated	O
impaired	O
overnight	O
memory	O
consolidation	O
,	O
a	O
finding	O
that	O
was	O
more	O
pronounced	O
following	O
associative	O
interference	O
.	O

Additionally	O
,	O
ecstasy	B
users	O
demonstrated	O
impairments	O
on	O
tasks	O
recruiting	O
frontostriatal	O
and	O
hippocampal	O
neural	O
circuitry	O
,	O
in	O
the	O
domains	O
of	O
proactive	O
interference	O
memory	O
,	O
long	O
-	O
term	O
memory	O
,	O
encoding	O
,	O
working	O
memory	O
and	O
complex	O
planning	O
.	O

We	O
suggest	O
that	O
ecstasy	B
-	O
associated	O
dysfunction	O
in	O
fronto	O
-	O
temporal	O
circuitry	O
may	O
underlie	O
overnight	O
consolidation	O
memory	O
impairments	O
in	O
regular	O
ecstasy	B
users	O
.	O

Normoammonemic	O
encephalopathy	O
:	O
solely	O
valproate	B
induced	O
or	O
multiple	O
mechanisms	O
?	O

A	O
77-year	O
-	O
old	O
woman	O
presented	O
with	O
subacute	O
onset	O
progressive	O
confusion	O
,	O
aggression	O
,	O
auditory	O
hallucinations	O
and	O
delusions	O
.	O

In	O
the	O
preceding	O
months	O
,	O
the	O
patient	O
had	O
a	O
number	O
of	O
admissions	O
with	O
transient	O
unilateral	O
hemiparesis	O
with	O
facial	O
droop	O
,	O
and	O
had	O
been	O
started	O
on	O
valproate	B
for	O
presumed	O
hemiplegic	O
migraine	O
.	O

Valproate	B
was	O
withdrawn	O
soon	O
after	O
admission	O
and	O
her	O
cognitive	O
abilities	O
have	O
gradually	O
improved	O
over	O
3	O
months	O
of	O
follow	O
-	O
up	O
.	O

Valproate	B
levels	O
taken	O
prior	O
to	O
withdrawal	O
were	O
subtherapeutic	O
and	O
the	O
patient	O
was	O
normoammonaemic	O
.	O

EEG	O
undertaken	O
during	O
inpatient	O
stay	O
showed	O
changes	O
consistent	O
with	O
encephalopathy	O
,	O
and	O
low	O
titre	O
N	B
-	I
methyl	I
-	I
D	I
-	I
aspartate	I
(	O
NMDA	B
)	O
receptor	O
antibodies	O
were	O
present	O
in	O
this	O
patient	O
.	O

The	O
possible	O
aetiologies	O
of	O
valproate	B
-	O
induced	O
encephalopathy	O
and	O
NMDA	B
receptor	O
-	O
associated	O
encephalitis	O
present	O
a	O
diagnostic	O
dilemma	O
.	O

We	O
present	O
a	O
putative	O
combinatorial	O
hypothesis	O
to	O
explain	O
this	O
patient	O
's	O
symptoms	O
.	O

Dexmedetomidine	B
,	O
acting	O
through	O
central	O
alpha-2	O
adrenoceptors	O
,	O
prevents	O
opiate	O
-	O
induced	O
muscle	O
rigidity	O
in	O
the	O
rat	O
.	O

The	O
highly	O
-	O
selective	O
alpha-2	O
adrenergic	O
agonist	O
dexmedetomidine	B
(	O
D	B
-	I
MED	I
)	O
is	O
capable	O
of	O
inducing	O
muscle	O
flaccidity	O
and	O
anesthesia	O
in	O
rats	O
and	O
dogs	O
.	O

Intense	O
generalized	O
muscle	O
rigidity	O
is	O
an	O
undesirable	O
side	O
effect	O
of	O
potent	O
opiate	O
agonists	O
.	O

Although	O
the	O
neurochemistry	O
of	O
opiate	O
-	O
induced	O
rigidity	O
has	O
yet	O
to	O
be	O
fully	O
elucidated	O
,	O
recent	O
work	O
suggests	O
a	O
role	O
for	O
a	O
central	O
adrenergic	O
mechanism	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
authors	O
determined	O
if	O
treatment	O
with	O
D	B
-	I
MED	I
prevents	O
the	O
muscle	O
rigidity	O
caused	O
by	O
high	O
-	O
dose	O
alfentanil	B
anesthesia	O
in	O
the	O
rat	O
.	O

Animals	O
(	O
n	O
=	O
42	O
)	O
were	O
treated	O
intraperitoneally	O
with	O
one	O
of	O
the	O
following	O
six	O
regimens	O
:	O
1	O
)	O
L	O
-	O
MED	O
(	O
the	O
inactive	O
L	O
-	O
isomer	O
of	O
medetomidine	B
)	O
,	O
30	O
micrograms	O
/	O
kg	O
;	O
2	O
)	O
D	B
-	I
MED	I
,	O
10	O
micrograms	O
/	O
kg	O
;	O
3	O
)	O
D	B
-	I
MED	I
,	O
30	O
micrograms	O
/	O
kg	O
;	O
4	O
)	O
D	B
-	I
MED	I
[	O
30	O
micrograms	O
/	O
kg	O
]	O
and	O
the	O
central	O
-	O
acting	O
alpha-2	O
antagonist	O
,	O
idazoxan	B
[	O
10	O
mg	O
/	O
kg	O
]	O
;	O
5	O
)	O
D	B
-	I
MED	I
[	O
30	O
micrograms	O
/	O
kg	O
]	O
and	O
the	O
peripheral	O
-	O
acting	O
alpha-2	O
antagonist	O
DG-5128	B
[	O
10	O
mg	O
/	O
kg	O
]	O
,	O
or	O
;	O
6	O
)	O
saline	O
.	O

Baseline	O
electromyographic	O
activity	O
was	O
recorded	O
from	O
the	O
gastrocnemius	O
muscle	O
before	O
and	O
after	O
drug	O
treatment	O
.	O

Each	O
rat	O
was	O
then	O
injected	O
with	O
alfentanil	B
(	O
ALF	B
,	O
0.5	O
mg	O
/	O
kg	O
sc	O
)	O
.	O

ALF	B
injection	O
resulted	O
in	O
a	O
marked	O
increase	O
in	O
hindlimb	O
EMG	O
activity	O
in	O
the	O
L	O
-	O
MED	O
treatment	O
group	O
which	O
was	O
indistinguishable	O
from	O
that	O
seen	O
in	O
animals	O
treated	O
with	O
saline	O
.	O

In	O
contrast	O
,	O
D	B
-	I
MED	I
prevented	O
alfentanil	B
-	O
induced	O
muscle	O
rigidity	O
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
.	O

The	O
small	O
EMG	O
values	O
obtained	O
in	O
the	O
high	O
-	O
dose	O
D	B
-	I
MED	I
group	O
were	O
comparable	O
with	O
those	O
recorded	O
in	O
earlier	O
studies	O
from	O
control	O
animals	O
not	O
given	O
any	O
opiate	O
.	O

The	O
high	O
-	O
dose	O
D	B
-	I
MED	I
animals	O
were	O
flaccid	O
,	O
akinetic	O
,	O
and	O
lacked	O
a	O
startle	O
response	O
during	O
the	O
entire	O
experimental	O
period.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Some	O
central	O
effects	O
of	O
repeated	O
treatment	O
with	O
fluvoxamine	B
.	O

We	O
investigated	O
the	O
effect	O
of	O
repeated	O
treatment	O
with	O
fluvoxamine	B
,	O
a	O
selective	O
serotonin	B
uptake	O
inhibitor	O
,	O
on	O
behavioral	O
effects	O
of	O
dopaminomimetics	O
and	O
methoxamine	B
and	O
on	O
the	O
animal	O
behavior	O
in	O
the	O
"	O
behavioral	O
despair	O
"	O
test	O
.	O

A	O
repeated	O
treatment	O
with	O
fluvoxamine	B
(	O
twice	O
daily	O
for	O
14	O
days	O
)	O
potentiated	O
in	O
mice	O
and	O
in	O
rats	O
(	O
weaker	O
)	O
the	O
amphetamine	B
-	O
induced	O
hyperactivity	O
.	O

The	O
hyperactivity	O
induced	O
by	O
nomifensine	B
in	O
mice	O
remained	O
unaffected	O
by	O
fluvoxamine	B
.	O

The	O
stimulation	O
of	O
locomotor	O
activity	O
by	O
intracerebroventricularly	O
administered	O
methoxamine	B
was	O
not	O
affected	O
by	O
repeated	O
treatment	O
with	O
fluvoxamine	B
.	O

Given	O
three	O
times	O
fluvoxamine	B
had	O
no	O
effect	O
on	O
the	O
immobilization	O
time	O
in	O
the	O
"	O
behavioral	O
despair	O
"	O
test	O
in	O
rats	O
.	O

The	O
results	O
indicate	O
that	O
fluvoxamine	B
given	O
repeatedly	O
acts	O
differently	O
than	O
citalopram	B
,	O
another	O
selective	O
serotonin	B
uptake	O
inhibitor	O
,	O
and	O
differs	O
also	O
from	O
other	O
antidepressant	O
drugs	O
.	O

Protective	O
effect	O
of	O
a	O
specific	O
platelet	O
-	O
activating	O
factor	O
antagonist	O
,	O
BN	B
52021	I
,	O
on	O
bupivacaine	B
-	O
induced	O
cardiovascular	O
impairments	O
in	O
rats	O
.	O

Administration	O
of	O
the	O
local	O
anaesthetic	O
bupivacaine	B
(	O
1.5	O
or	O
2	O
mg	O
/	O
kg	O
,	O
i.v	O
.	O
)	O
to	O
rats	O
elicited	O
a	O
marked	O
decrease	O
of	O
mean	O
arterial	O
blood	O
pressure	O
(	O
MBP	O
)	O
and	O
heart	O
rate	O
(	O
HR	O
)	O
leading	O
to	O
death	O
(	O
in	O
67	O
%	O
or	O
90	O
%	O
of	O
animals	O
respectively	O
)	O
.	O

Intravenous	O
injection	O
of	O
the	O
specific	O
platelet	O
-	O
activating	O
factor	O
(	O
PAF	O
)	O
antagonist	O
BN	B
52021	I
(	O
10	O
mg	O
/	O
kg	O
)	O
,	O
30	O
min	O
before	O
bupivacaine	B
administration	O
(	O
2	O
mg	O
/	O
kg	O
i.v	O
.	O
)	O
suppressed	O
both	O
the	O
decrease	O
of	O
MBP	O
and	O
HR	O
.	O

In	O
contrast	O
,	O
doses	O
of	O
1	O
mg	O
/	O
kg	O
BN	B
52021	I
given	O
30	O
min	O
before	O
or	O
10	O
mg	O
/	O
kg	O
administered	O
5	O
min	O
before	O
i.v	O
.	O

injection	O
of	O
bupivacaine	B
were	O
ineffective	O
.	O

When	O
BN	B
52021	I
(	O
20	O
mg	O
/	O
kg	O
i.v	O
.	O
)	O
was	O
injected	O
immediately	O
after	O
bupivacaine	B
(	O
2	O
mg	O
/	O
kg	O
)	O
,	O
a	O
partial	O
reversion	O
of	O
the	O
decrease	O
of	O
MBP	O
and	O
HR	O
was	O
observed	O
,	O
whereas	O
the	O
dose	O
of	O
10	O
mg	O
/	O
kg	O
was	O
ineffective	O
.	O

A	O
partial	O
recovery	O
of	O
bupivacaine	B
-	O
induced	O
ECG	O
alterations	O
was	O
observed	O
after	O
pretreatment	O
of	O
the	O
rats	O
with	O
BN	B
52021	I
.	O

Since	O
the	O
administration	O
of	O
BN	B
52021	I
,	O
at	O
all	O
doses	O
studied	O
,	O
did	O
not	O
alter	O
MBP	O
and	O
HR	O
at	O
the	O
doses	O
used	O
,	O
the	O
bulk	O
of	O
these	O
results	O
clearly	O
demonstrate	O
a	O
protective	O
action	O
of	O
BN	B
52021	I
,	O
a	O
specific	O
antagonist	O
of	O
PAF	O
,	O
against	O
bupivacaine	B
-	O
induced	O
cardiovascular	O
toxicity	O
.	O

Thus	O
,	O
consistent	O
with	O
its	O
direct	O
effect	O
on	O
heart	O
,	O
PAF	O
appears	O
to	O
be	O
implicated	O
in	O
bupivacaine	B
-	O
induced	O
cardiovascular	O
alterations	O
.	O

The	O
epidemiology	O
of	O
the	O
acute	O
flank	O
pain	O
syndrome	O
from	O
suprofen	B
.	O

Suprofen	B
,	O
a	O
new	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drug	O
,	O
was	O
marketed	O
in	O
early	O
1986	O
as	O
an	O
analgesic	O
agent	O
.	O

Until	O
physicians	O
began	O
reporting	O
an	O
unusual	O
acute	O
flank	O
pain	O
syndrome	O
to	O
the	O
spontaneous	O
reporting	O
system	O
,	O
700,000	O
persons	O
used	O
the	O
drug	O
in	O
the	O
United	O
States	O
.	O

Through	O
August	O
1986	O
,	O
a	O
total	O
of	O
163	O
cases	O
of	O
this	O
syndrome	O
were	O
reported	O
.	O

To	O
elucidate	O
the	O
epidemiology	O
of	O
the	O
syndrome	O
,	O
a	O
case	O
-	O
control	O
study	O
was	O
performed	O
,	O
comparing	O
62	O
of	O
the	O
case	O
patients	O
who	O
had	O
been	O
reported	O
to	O
the	O
spontaneous	O
reporting	O
system	O
to	O
185	O
suprofen	B
-	O
exposed	O
control	O
subjects	O
who	O
did	O
not	O
have	O
the	O
syndrome	O
.	O

Case	O
patients	O
were	O
more	O
likely	O
to	O
be	O
men	O
(	O
odds	O
ratio	O
,	O
3.8	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1.2	O
-	O
12.1	O
)	O
,	O
suffer	O
from	O
hay	O
fever	O
and	O
asthma	O
(	O
odds	O
ratio	O
,	O
3.4	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1.0	O
-	O
11.9	O
)	O
;	O
to	O
participate	O
in	O
regular	O
exercise	O
(	O
odds	O
ratio	O
,	O
5.9	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1.1	O
-	O
30.7	O
)	O
,	O
especially	O
in	O
the	O
use	O
of	O
Nautilus	O
equipment	O
(	O
p	O
=	O
0.02	O
)	O
;	O
and	O
to	O
use	O
alcohol	B
(	O
odds	O
ratio	O
,	O
4.4	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1.1	O
-	O
17.5	O
)	O
.	O

Possible	O
risk	O
factors	O
included	O
young	O
age	O
,	O
concurrent	O
use	O
of	O
other	O
analgesic	O
agents	O
(	O
especially	O
ibuprofen	B
)	O
,	O
preexisting	O
renal	O
disease	O
,	O
a	O
history	O
of	O
kidney	O
stones	O
,	O
a	O
history	O
of	O
gout	O
,	O
a	O
recent	O
increase	O
in	O
activity	O
,	O
a	O
recent	O
increase	O
in	O
sun	O
exposure	O
,	O
and	O
residence	O
in	O
the	O
Sunbelt	O
.	O

These	O
were	O
findings	O
that	O
were	O
suggestive	O
but	O
did	O
not	O
reach	O
conventional	O
statistical	O
significance	O
.	O

These	O
findings	O
are	O
consistent	O
with	O
the	O
postulated	O
mechanism	O
for	O
this	O
unusual	O
syndrome	O
:	O
acute	O
diffuse	O
crystallization	O
of	O
uric	B
acid	I
in	O
renal	O
tubules	O
.	O

A	O
dystonia	O
-	O
like	O
syndrome	O
after	O
neuropeptide	O
(	O
MSH	B
/	O
ACTH	B
)	O
stimulation	O
of	O
the	O
rat	O
locus	O
ceruleus	O
.	O

The	O
movement	O
disorder	O
investigated	O
in	O
these	O
studies	O
has	O
some	O
features	O
in	O
common	O
with	O
human	O
idiopathic	O
dystonia	O
,	O
and	O
information	O
obtained	O
in	O
these	O
studies	O
may	O
be	O
of	O
potential	O
clinical	O
benefit	O
.	O

The	O
present	O
experimental	O
results	O
indicated	O
that	O
peptidergic	O
stimulation	O
of	O
the	O
LC	O
resulted	O
in	O
a	O
NE	O
-	O
mediated	O
inhibition	O
of	O
cerebellar	O
Purkinje	O
cells	O
located	O
at	O
terminals	O
of	O
the	O
ceruleo	O
-	O
cerebellar	O
pathway	O
.	O

However	O
,	O
it	O
is	O
not	O
certain	O
as	O
to	O
the	O
following	O
:	O
(	O
a	O
)	O
what	O
receptors	O
were	O
stimulated	O
by	O
the	O
ACTH	B
N	O
-	O
terminal	O
fragments	O
at	O
the	O
LC	O
that	O
resulted	O
in	O
this	O
disorder	O
;	O
(	O
b	O
)	O
whether	O
NE	O
,	O
released	O
onto	O
Purkinje	O
cell	O
synapses	O
located	O
at	O
terminals	O
of	O
the	O
ceruleo	O
-	O
cerebellar	O
pathway	O
,	O
did	O
indeed	O
cause	O
the	O
long	O
-	O
term	O
depression	O
at	O
Purkinje	O
cell	O
synapses	O
(	O
previously	O
described	O
by	O
others	O
)	O
that	O
resulted	O
in	O
the	O
long	O
duration	O
of	O
the	O
movement	O
disorder	O
;	O
(	O
c	O
)	O
whether	O
the	O
inhibition	O
of	O
inhibitory	O
Purkinje	O
cells	O
resulted	O
in	O
disinhibition	O
or	O
increased	O
excitability	O
of	O
the	O
unilateral	O
cerebellar	O
fastigial	O
or	O
interpositus	O
nuclei	O
,	O
the	O
output	O
targets	O
of	O
the	O
Purkinje	O
cell	O
axons	O
,	O
that	O
may	O
have	O
been	O
an	O
important	O
contributing	O
factor	O
to	O
this	O
disorder	O
.	O

These	O
questions	O
are	O
currently	O
being	O
investigated	O
.	O

Enhanced	O
stimulus	O
-	O
induced	O
neurotransmitter	O
overflow	O
in	O
epinephrine	B
-	O
induced	O
hypertensive	O
rats	O
is	O
not	O
mediated	O
by	O
prejunctional	O
beta	O
-	O
adrenoceptor	O
activation	O
.	O

The	O
present	O
study	O
examines	O
the	O
effect	O
of	O
6-day	O
epinephrine	B
treatment	O
(	O
100	O
micrograms	O
/	O
kg	O
per	O
h	O
,	O
s.c	O
.	O
)	O
on	O
stimulus	O
-	O
induced	O
(	O
1	O
Hz	O
)	O
endogenous	O
neurotransmitter	O
overflow	O
from	O
the	O
isolated	O
perfused	O
kidney	O
of	O
vehicle-	O
and	O
epinephrine	B
-	O
treated	O
rats	O
.	O

Renal	O
catecholamine	B
stores	O
and	O
stimulus	O
-	O
induced	O
overflow	O
in	O
the	O
vehicle	O
-	O
treated	O
group	O
consisted	O
of	O
norepinephrine	B
only	O
.	O

However	O
,	O
epinephrine	B
treatment	O
resulted	O
in	O
the	O
incorporation	O
of	O
epinephrine	B
into	O
renal	O
catecholamine	B
stores	O
such	O
that	O
approximately	O
40	O
%	O
of	O
the	O
catecholamine	B
present	O
was	O
epinephrine	B
while	O
the	O
norepinephrine	B
content	O
was	O
reduced	O
by	O
a	O
similar	O
degree	O
.	O

Total	O
tissue	O
catecholamine	B
content	O
of	O
the	O
kidney	O
on	O
a	O
molar	O
basis	O
was	O
unchanged	O
.	O

Stimulus	O
-	O
induced	O
fractional	O
overflow	O
of	O
neurotransmitter	O
from	O
the	O
epinephrine	B
-	O
treated	O
kidneys	O
was	O
approximately	O
twice	O
normal	O
and	O
consisted	O
of	O
both	O
norepinephrine	B
and	O
epinephrine	B
in	O
proportions	O
similar	O
to	O
those	O
found	O
in	O
the	O
kidney	O
.	O

This	O
difference	O
in	O
fractional	O
overflow	O
between	O
groups	O
was	O
not	O
affected	O
by	O
neuronal	O
and	O
extraneuronal	O
uptake	O
blockade	O
.	O

Propranolol	B
had	O
no	O
effect	O
on	O
stimulus	O
-	O
induced	O
overflow	O
in	O
either	O
group	O
.	O

Phentolamine	B
increased	O
stimulus	O
-	O
induced	O
overflow	O
in	O
both	O
groups	O
although	O
the	O
increment	O
in	O
overflow	O
was	O
greater	O
in	O
the	O
epinephrine	B
-	O
treated	O
group	O
.	O

In	O
conclusion	O
,	O
chronic	O
epinephrine	B
treatment	O
results	O
in	O
enhanced	O
fractional	O
neurotransmitter	O
overflow	O
.	O

However	O
,	O
neither	O
alterations	O
in	O
prejunctional	O
beta	O
-	O
adrenoceptor	O
influences	O
nor	O
alterations	O
in	O
neuronal	O
and	O
extraneuronal	O
uptake	O
mechanisms	O
appear	O
to	O
be	O
responsible	O
for	O
this	O
alteration	O
.	O

Furthermore	O
,	O
data	O
obtained	O
with	O
phentolamine	B
alone	O
do	O
not	O
suggest	O
alpha	O
-	O
adrenoceptor	O
desensitization	O
as	O
the	O
cause	O
of	O
the	O
enhanced	O
neurotransmitter	O
overflow	O
after	O
epinephrine	B
treatment	O
.	O

Initial	O
potassium	B
loss	O
and	O
hypokalaemia	O
during	O
chlorthalidone	B
administration	O
in	O
patients	O
with	O
essential	O
hypertension	O
:	O
the	O
influence	O
of	O
dietary	O
sodium	B
restriction	O
.	O

To	O
investigate	O
the	O
initial	O
potassium	B
loss	O
and	O
development	O
of	O
hypokalaemia	O
during	O
the	O
administration	O
of	O
an	O
oral	O
diuretic	O
,	O
metabolic	O
balance	O
studies	O
were	O
performed	O
in	O
ten	O
patients	O
with	O
essential	O
hypertension	O
who	O
had	O
shown	O
hypokalaemia	O
under	O
prior	O
oral	O
diuretic	O
treatment	O
.	O

Chlorthalidone	B
(	O
50	O
mg	O
daily	O
)	O
was	O
given	O
for	O
14	O
days	O
.	O

Six	O
patients	O
received	O
a	O
normal	O
-	O
sodium	B
diet	O
and	O
four	O
a	O
low	O
-	O
sodium	B
(	O
17	O
mmol	O
/	O
day	O
)	O
diet	O
.	O

All	O
patients	O
had	O
a	O
normal	O
initial	O
total	O
body	O
potassium	B
(	O
40	O
K	O
)	O
.	O

The	O
electrolyte	O
balances	O
,	O
weight	O
,	O
bromide	O
space	O
,	O
plasma	O
renin	O
activity	O
,	O
and	O
aldosterone	B
secretion	O
rate	O
were	O
measured	O
.	O

In	O
both	O
groups	O
a	O
potassium	B
deficit	O
developed	O
,	O
with	O
proportionally	O
larger	O
losses	O
from	O
the	O
extracellular	O
than	O
from	O
the	O
intracellular	O
compartment	O
.	O

In	O
the	O
normal	O
-	O
sodium	B
group	O
the	O
highest	O
mean	O
potassium	B
deficit	O
was	O
176	O
mmol	O
on	O
day	O
9	O
,	O
after	O
which	O
some	O
potassium	B
was	O
regained	O
;	O
in	O
the	O
low	O
-	O
sodium	B
group	O
the	O
highest	O
deficit	O
was	O
276	O
mmol	O
on	O
day	O
13	O
.	O

The	O
normal	O
-	O
sodium	B
group	O
showed	O
an	O
immediate	O
but	O
temporary	O
rise	O
of	O
the	O
renin	O
and	O
aldosterone	B
levels	O
;	O
in	O
the	O
low	O
-	O
sodium	B
group	O
renin	O
and	O
aldosterone	B
increased	O
more	O
slowly	O
but	O
remained	O
elevated	O
.	O

It	O
is	O
concluded	O
that	O
dietary	O
sodium	B
restriction	O
increases	O
diuretic	O
-	O
induced	O
potassium	B
loss	O
,	O
presumably	O
by	O
an	O
increased	O
activity	O
of	O
the	O
renin	O
-	O
angiotensin	B
-	O
aldosterone	B
system	O
,	O
while	O
sodium	B
delivery	O
to	O
the	O
distal	O
renal	O
tubules	O
remains	O
sufficiently	O
high	O
to	O
allow	O
increased	O
potassium	B
secretion	O
.	O

Toxicity	O
due	O
to	O
remission	O
inducing	O
drugs	O
in	O
rheumatoid	O
arthritis	O
.	O

Association	O
with	O
HLA	O
-	O
B35	O
and	O
Cw4	O
antigens	O
.	O

Twenty	O
-	O
five	O
patients	O
with	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
who	O
developed	O
toxicity	O
while	O
taking	O
remission	O
inducing	O
drugs	O
and	O
30	O
without	O
toxicity	O
were	O
studied	O
for	O
possible	O
associations	O
with	O
class	O
I	O
and	O
II	O
HLA	O
antigens	O
.	O

A	O
strong	O
association	O
has	O
been	O
found	O
between	O
nephritis	O
and	O
dermatitis	O
due	O
to	O
Tiopronin	B
(	O
a	O
D	B
-	I
Penicillamine	I
like	O
compound	O
)	O
and	O
class	O
I	O
antigens	O
B35-Cw4	O
,	O
and	O
between	O
dermatitis	O
due	O
to	O
gold	B
thiosulphate	B
and	O
B35	O
.	O

Compared	O
to	O
healthy	O
controls	O
a	O
lower	O
DR5	O
frequency	O
was	O
observed	O
in	O
patients	O
with	O
RA	O
except	O
for	O
the	O
Tiopronin	B
related	O
nephritis	O
group	O
.	O

Antagonism	O
of	O
diazepam	B
-	O
induced	O
sedative	O
effects	O
by	O
Ro15	B
-	I
1788	I
in	O
patients	O
after	O
surgery	O
under	O
lumbar	O
epidural	O
block	O
.	O

A	O
double	O
-	O
blind	O
placebo	O
-	O
controlled	O
investigation	O
of	O
efficacy	O
and	O
safety	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
efficacy	O
of	O
Ro15	B
-	I
1788	I
and	O
a	O
placebo	O
in	O
reversing	O
diazepam	B
-	O
induced	O
effects	O
after	O
surgery	O
under	O
epidural	O
block	O
,	O
and	O
to	O
evaluate	O
the	O
local	O
tolerance	O
and	O
general	O
safety	O
of	O
Ro15	B
-	I
1788	I
.	O

Fifty	O
-	O
seven	O
patients	O
were	O
sedated	O
with	O
diazepam	B
for	O
surgery	O
under	O
epidural	O
anaesthesia	O
.	O

Antagonism	O
of	O
diazepam	B
-	O
induced	O
effects	O
by	O
Ro15	B
-	I
1788	I
was	O
investigated	O
postoperatively	O
in	O
a	O
double	O
-	O
blind	O
placebo	O
-	O
controlled	O
trial	O
.	O

The	O
patient	O
's	O
subjective	O
assessment	O
of	O
mood	O
rating	O
,	O
an	O
objective	O
test	O
of	O
performance	O
,	O
a	O
test	O
for	O
amnesia	O
,	O
and	O
vital	O
signs	O
were	O
recorded	O
for	O
up	O
to	O
300	O
min	O
after	O
administration	O
of	O
the	O
trial	O
drug	O
.	O

No	O
significant	O
differences	O
between	O
the	O
two	O
groups	O
were	O
observed	O
for	O
mood	O
rating	O
,	O
amnesia	O
,	O
or	O
vital	O
signs	O
.	O

The	O
Ro15	B
-	I
1788	I
group	O
showed	O
a	O
significant	O
improvement	O
in	O
the	O
performance	O
test	O
up	O
to	O
120	O
min	O
after	O
administration	O
of	O
the	O
drug	O
.	O

There	O
was	O
no	O
evidence	O
of	O
reaction	O
at	O
the	O
injection	O
site	O
.	O

Reversible	O
cerebral	O
lesions	O
associated	O
with	O
tiazofurin	B
usage	O
:	O
MR	O
demonstration	O
.	O

Tiazofurin	B
is	O
an	O
experimental	O
chemotherapeutic	O
agent	O
currently	O
undergoing	O
clinical	O
evaluation	O
.	O

We	O
report	O
our	O
results	O
with	O
magnetic	O
resonance	O
(	O
MR	O
)	O
in	O
demonstrating	O
reversible	O
cerebral	O
abnormalities	O
concurrent	O
with	O
the	O
use	O
of	O
this	O
drug	O
.	O

The	O
abnormalities	O
on	O
MR	O
were	O
correlated	O
with	O
findings	O
on	O
CT	O
as	O
well	O
as	O
with	O
cerebral	O
angiography	O
.	O

The	O
utility	O
of	O
MR	O
in	O
the	O
evaluation	O
of	O
patients	O
receiving	O
this	O
new	O
agent	O
is	O
illustrated	O
.	O

Quinidine	B
phenylethylbarbiturate	I
-	O
induced	O
fulminant	O
hepatitis	O
in	O
a	O
pregnant	O
woman	O
.	O

A	O
case	O
report	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
19-year	O
-	O
old	O
Laotian	O
patient	O
affected	O
by	O
fulminant	O
hepatitis	O
during	O
the	O
third	O
trimester	O
of	O
her	O
pregnancy	O
after	O
a	O
1-month	O
administration	O
of	O
quinidine	B
phenylethylbarbiturate	I
.	O

After	O
delivery	O
,	O
the	O
patient	O
underwent	O
orthotopic	O
liver	O
transplantation	O
.	O

The	O
patient	O
was	O
in	O
good	O
condition	O
16	O
months	O
after	O
liver	O
transplantation	O
.	O

Quinidine	B
itself	O
or	O
phenylethylbarbiturate	B
may	O
be	O
responsible	O
for	O
fulminant	O
hepatitis	O
in	O
this	O
patient	O
.	O

Production	O
of	O
autochthonous	O
prostate	O
cancer	O
in	O
Lobund	O
-	O
Wistar	O
rats	O
by	O
treatments	O
with	O
N	B
-	I
nitroso	I
-	I
N	I
-	I
methylurea	I
and	O
testosterone	B
.	O

More	O
than	O
50	O
%	O
of	O
Lobund	O
-	O
Wistar	O
(	O
L	O
-	O
W	O
)	O
strain	O
rats	O
developed	O
large	O
,	O
palpable	O
prostate	O
adenocarcinomas	O
(	O
PAs	O
)	O
following	O
treatments	O
with	O
N	B
-	I
nitroso	I
-	I
N	I
-	I
methylurea	I
(	O
CAS	O
:	O
684	O
-	O
93	O
-	O
5	O
)	O
and	O
testosterone	B
propionate	I
[	O
(	O
TP	B
)	O
CAS	O
:	O
57	O
-	O
85	O
-	O
2	O
]	O
,	O
and	O
most	O
of	O
the	O
tumor	O
-	O
bearing	O
rats	O
manifested	O
metastatic	O
lesions	O
.	O

The	O
incubation	O
periods	O
averaged	O
10.6	O
months	O
.	O

Within	O
the	O
same	O
timeframe	O
,	O
no	O
L	O
-	O
W	O
rat	O
developed	O
a	O
similar	O
palpable	O
PA	O
when	O
treated	O
only	O
with	O
TP	B
.	O

In	O
L	O
-	O
W	O
rats	O
,	O
TP	B
acted	O
as	O
a	O
tumor	O
enhancement	O
agent	O
,	O
with	O
primary	O
emphasis	O
on	O
the	O
development	O
of	O
prostate	O
cancer	O
.	O

A	O
prospective	O
study	O
of	O
adverse	O
reactions	O
associated	O
with	O
vancomycin	B
therapy	O
.	O

A	O
prospective	O
evaluation	O
of	O
the	O
efficacy	O
and	O
safety	O
of	O
vancomycin	B
was	O
conducted	O
in	O
54	O
consecutive	O
patients	O
over	O
a	O
16-month	O
period	O
.	O

Vancomycin	B
was	O
curative	O
in	O
95	O
%	O
of	O
43	O
patients	O
with	O
proven	O
infection	O
.	O

Drugs	O
were	O
ceased	O
in	O
six	O
patients	O
because	O
of	O
adverse	O
reactions	O
;	O
in	O
three	O
of	O
these	O
vancomycin	B
was	O
considered	O
the	O
likely	O
cause	O
.	O

Reactions	O
included	O
thrombophlebitis	O
(	O
20	O
of	O
54	O
patients	O
)	O
,	O
rash	O
(	O
4	O
of	O
54	O
)	O
,	O
nephrotoxicity	O
(	O
4	O
of	O
50	O
)	O
,	O
proteinuria	O
(	O
1	O
of	O
50	O
)	O
and	O
ototoxicity	O
(	O
1	O
of	O
11	O
patients	O
tested	O
by	O
audiometry	O
)	O
.	O

Thrombophlebitis	O
occurred	O
only	O
with	O
infusion	O
through	O
peripheral	O
cannulae	O
;	O
nephrotoxicity	O
and	O
ototoxicity	O
were	O
confined	O
to	O
patients	O
receiving	O
an	O
aminoglycoside	B
plus	O
vancomycin	B
.	O

We	O
conclude	O
that	O
vancomycin	B
,	O
administered	O
appropriately	O
,	O
constitutes	O
safe	O
,	O
effective	O
therapy	O
for	O
infections	O
caused	O
by	O
susceptible	O
bacteria	O
.	O

Cardiac	O
toxicity	O
of	O
5-fluorouracil	B
.	O

Report	O
of	O
a	O
case	O
of	O
spontaneous	O
angina	O
.	O

We	O
report	O
a	O
case	O
of	O
a	O
patient	O
with	O
colon	O
carcinoma	O
and	O
liver	O
metastasis	O
who	O
presented	O
chest	O
pain	O
after	O
5-fluorouracil	B
(	O
5-FU	B
)	O
administration	O
.	O

Clinical	O
electrocardiographic	O
evolution	O
was	O
similar	O
to	O
that	O
observed	O
in	O
Prinzmetal	O
's	O
angina	O
,	O
and	O
chest	O
pain	O
promptly	O
resolved	O
with	O
nifedipine	B
.	O

These	O
data	O
suggest	O
that	O
coronary	O
spasm	O
may	O
be	O
the	O
cause	O
of	O
cardiotoxicity	O
due	O
to	O
5-FU	B
,	O
and	O
that	O
calcium	B
antagonists	O
may	O
probably	O
be	O
used	O
in	O
the	O
prevention	O
or	O
treatment	O
of	O
5-FU	B
cardiotoxicity	O
.	O

Time	O
course	O
alterations	O
of	O
QTC	O
interval	O
due	O
to	O
hypaque	B
76	I
.	O

Sequential	O
measurement	O
of	O
QT	O
interval	O
during	O
left	O
ventricular	O
angiography	O
was	O
made	O
30	O
seconds	O
and	O
one	O
,	O
three	O
,	O
five	O
and	O
ten	O
minutes	O
after	O
injection	O
of	O
hypaque	B
76	I
.	O

The	O
subjects	O
were	O
ten	O
patients	O
found	O
to	O
have	O
normal	O
left	O
ventricles	O
and	O
coronary	O
arteries	O
.	O

Significant	O
QTC	O
prolongation	O
occurred	O
in	O
30	O
seconds	O
to	O
one	O
minute	O
in	O
association	O
with	O
marked	O
hypotension	O
and	O
elevation	O
of	O
cardiac	O
output	O
.	O

Transient	O
hemiparesis	O
:	O
a	O
rare	O
manifestation	O
of	O
diphenylhydantoin	B
toxicity	O
.	O

Report	O
of	O
two	O
cases	O
.	O

Among	O
the	O
common	O
side	O
effects	O
of	O
diphenylhydantoin	B
(	O
DPH	B
)	O
overdose	O
,	O
the	O
most	O
frequently	O
encountered	O
neurological	O
signs	O
are	O
those	O
of	O
cerebellar	O
dysfunction	O
.	O

Very	O
rarely	O
,	O
the	O
toxic	O
neurological	O
manifestations	O
of	O
this	O
drug	O
are	O
of	O
cerebral	O
origin	O
.	O

Two	O
patients	O
are	O
presented	O
who	O
suffered	O
progressive	O
hemiparesis	O
due	O
to	O
DPH	B
overdose	O
.	O

Both	O
had	O
brain	O
surgery	O
before	O
DPH	B
treatment	O
.	O

It	O
is	O
assumed	O
that	O
patients	O
with	O
some	O
cerebral	O
damage	O
are	O
liable	O
to	O
manifest	O
DPH	B
toxicity	O
as	O
focal	O
neurological	O
signs	O
.	O

Indomethacin	B
induced	O
hypotension	O
in	O
sodium	B
and	O
volume	O
depleted	O
rats	O
.	O

After	O
a	O
single	O
oral	O
dose	O
of	O
4	O
mg	O
/	O
kg	O
indomethacin	B
(	O
IDM	B
)	O
to	O
sodium	B
and	O
volume	O
depleted	O
rats	O
plasma	O
renin	O
activity	O
(	O
PRA	O
)	O
and	O
systolic	O
blood	O
pressure	O
fell	O
significantly	O
within	O
four	O
hours	O
.	O

In	O
sodium	B
repleted	O
animals	O
indomethacin	B
did	O
not	O
change	O
systolic	O
blood	O
pressure	O
(	O
BP	O
)	O
although	O
plasma	O
renin	O
activity	O
was	O
decreased	O
.	O

Thus	O
,	O
indomethacin	B
by	O
inhibition	O
of	O
prostaglandin	B
synthesis	O
may	O
diminish	O
the	O
blood	O
pressure	O
maintaining	O
effect	O
of	O
the	O
stimulated	O
renin	O
-	O
angiotensin	B
system	O
in	O
sodium	B
and	O
volume	O
depletion	O
.	O

Quinidine	B
hepatitis	O
.	O

Long	O
-	O
term	O
administration	O
of	O
quinidine	B
was	O
associated	O
with	O
persistent	O
elevation	O
of	O
serum	O
concentrations	O
of	O
SGOT	O
,	O
lactic	B
acid	I
dehydrogenase	O
,	O
and	O
alkaline	O
phosphatase	O
.	O

Liver	O
biopsy	O
showed	O
active	O
hepatitis	O
.	O

Discontinuance	O
of	O
quinidine	B
therapy	O
led	O
to	O
normalization	O
of	O
liver	O
function	O
tests	O
.	O

A	O
challenge	O
dose	O
of	O
quinidine	B
caused	O
clinical	O
symptoms	O
and	O
abrupt	O
elevation	O
of	O
SGOT	O
,	O
alkaline	O
phosphatase	O
,	O
and	O
lactic	B
acid	I
dehydrogenase	O
values	O
.	O

We	O
concluded	O
that	O
this	O
patient	O
had	O
quinidine	B
hepatotoxicity	O
and	O
believe	O
that	O
this	O
is	O
the	O
first	O
case	O
reported	O
with	O
liver	O
biopsy	O
documentation	O
.	O

This	O
report	O
also	O
suggests	O
that	O
,	O
even	O
after	O
long	O
-	O
term	O
administration	O
,	O
the	O
hepatic	O
toxicity	O
is	O
reversible	O
.	O

Epileptogenic	O
properties	O
of	O
enflurane	B
and	O
their	O
clinical	O
interpretation	O
.	O

Three	O
cases	O
of	O
EEG	O
changes	O
induced	O
by	O
single	O
exposure	O
to	O
enflurane	B
anesthesia	O
are	O
reported	O
.	O

In	O
one	O
patient	O
,	O
enflurane	B
administered	O
during	O
a	O
donor	O
nephrectomy	O
resulted	O
in	O
unexpected	O
partial	O
motor	O
seizures	O
.	O

Until	O
the	O
cause	O
of	O
the	O
seizures	O
was	O
correctly	O
identified	O
,	O
the	O
patient	O
was	O
inappropriately	O
treated	O
with	O
anticonvulsants	O
.	O

Two	O
other	O
patients	O
suffered	O
from	O
partial	O
,	O
complex	O
and	O
generalized	O
seizures	O
uncontrolled	O
by	O
medication	O
.	O

Epileptic	O
foci	O
delineated	O
and	O
activated	O
by	O
enflurane	B
were	O
surgically	O
ablated	O
and	O
the	O
patients	O
are	O
now	O
seizure	O
-	O
free	O
.	O

Previous	O
exposures	O
to	O
enflurane	B
have	O
to	O
be	O
disclosed	O
to	O
avoid	O
mistakes	O
in	O
clinical	O
interpretation	O
of	O
the	O
EEG	O
.	O

On	O
the	O
other	O
hand	O
,	O
enflurane	B
may	O
prove	O
to	O
be	O
a	O
safe	O
fast	O
acting	O
activator	O
of	O
epileptic	O
foci	O
during	O
corticography	O
or	O
depth	O
electrode	O
intraoperative	O
recordings	O
.	O

Naloxazone	B
pretreatment	O
modifies	O
cardiorespiratory	O
,	O
temperature	O
,	O
and	O
behavioral	O
effects	O
of	O
morphine	B
.	O

Behavioral	O
and	O
cardiorespiratory	O
responses	O
to	O
a	O
lethal	O
dose	O
of	O
morphine	B
were	O
evaluated	O
in	O
rats	O
pretreated	O
with	O
saline	O
or	O
naloxazone	B
,	O
an	O
antagonist	O
of	O
high	O
-	O
affinity	O
mu	O
1	O
opioid	O
receptors	O
.	O

Pretreatment	O
with	O
naloxazone	B
significantly	O
blocked	O
morphine	B
analgesia	O
,	O
catalepsy	O
and	O
hypothermia	O
at	O
a	O
dose	O
which	O
completely	O
eliminated	O
high	O
-	O
affinity	O
binding	O
in	O
brain	O
membranes	O
.	O

Moreover	O
,	O
naloxazone	B
significantly	O
attenuated	O
the	O
morphine	B
-	O
induced	O
hypotension	O
and	O
respiratory	O
depression	O
,	O
whereas	O
morphine	B
-	O
induced	O
bradycardia	O
was	O
less	O
affected	O
.	O

Results	O
indicate	O
that	O
subpopulations	O
of	O
mu	O
receptors	O
may	O
mediate	O
selective	O
behavioral	O
and	O
cardiorespiratory	O
responses	O
to	O
morphine	B
.	O

Treatment	O
of	O
ifosfamide	B
-	O
induced	O
urothelial	O
toxicity	O
by	O
oral	O
administration	O
of	O
sodium	B
2-mercaptoethane	I
sulphonate	I
(	O
MESNA	B
)	O
to	O
patients	O
with	O
inoperable	O
lung	O
cancer	O
.	O

The	O
protective	O
effect	O
of	O
oral	O
administration	O
of	O
the	O
thiol	B
compound	O
sodium	B
2-mercaptoethane	I
sulphonate	I
(	O
MESNA	B
)	O
against	O
urothelial	O
toxicity	O
induced	O
by	O
ifosfamide	B
(	O
IF	B
)	O
was	O
tested	O
in	O
a	O
group	O
of	O
45	O
patients	O
with	O
inoperable	O
lung	O
cancer	O
under	O
treatment	O
with	O
IF	B
(	O
2250	O
mg	O
/	O
m2	O
on	O
days	O
2	O
-	O
5	O
)	O
as	O
part	O
of	O
a	O
polychemotherapy	O
regimen	O
repeated	O
in	O
a	O
4-week	O
cycle	O
.	O

MESNA	B
was	O
given	O
orally	O
on	O
the	O
days	O
of	O
treatment	O
with	O
IF	B
in	O
3	O
doses	O
of	O
840	O
mg	O
/	O
m2	O
,	O
each	O
administered	O
at	O
0	O
hr	O
(=	O
injection	O
of	O
IF	B
)	O
,	O
4	O
hr	O
and	O
8	O
hr	O
p.i	O
.	O

Out	O
of	O
a	O
total	O
of	O
88	O
courses	O
of	O
this	O
treatment	O
we	O
observed	O
10	O
episodes	O
of	O
asymptomatic	O
microscopic	O
haematuria	O
and	O
no	O
episodes	O
of	O
gross	O
haematuria	O
.	O

In	O
this	O
group	O
of	O
45	O
patients	O
under	O
protection	O
with	O
MESNA	B
there	O
were	O
5	O
complete	O
remissions	O
and	O
9	O
partial	O
remissions	O
(	O
total	O
31	O
%	O
)	O
.	O

A	O
further	O
group	O
of	O
25	O
patients	O
under	O
polychemotherapy	O
with	O
IF	B
were	O
treated	O
by	O
conventional	O
prophylactic	O
measures	O
(	O
raised	O
fluid	O
intake	O
and	O
forced	O
diuresis	O
)	O
.	O

In	O
this	O
group	O
there	O
were	O
1	O
complete	O
and	O
5	O
partial	O
remissions	O
(	O
total	O
24	O
%	O
)	O
,	O
but	O
nearly	O
all	O
patients	O
developed	O
either	O
gross	O
haematuria	O
and/or	O
symptoms	O
of	O
bladder	O
irritation	O
(	O
cystitis	O
and	O
pollakisuria	O
)	O
.	O

There	O
were	O
no	O
appreciable	O
differences	O
between	O
the	O
MESNA	B
series	O
and	O
the	O
conventional	O
prophylaxis	O
series	O
with	O
respect	O
to	O
either	O
haematological	O
or	O
systemic	O
toxicity	O
of	O
the	O
cytostatic	O
treatment	O
.	O

Our	O
results	O
support	O
the	O
view	O
that	O
MESNA	B
,	O
given	O
orally	O
in	O
conjunction	O
with	O
combined	O
cytostatic	O
regimens	O
which	O
include	O
IF	B
,	O
simplifies	O
the	O
treatment	O
and	O
provides	O
optimum	O
protection	O
for	O
the	O
urinary	O
epithelium	O
.	O

Protection	O
with	O
oral	O
MESNA	B
is	O
particularly	O
suitable	O
for	O
outpatients	O
.	O

Effect	O
of	O
captopril	B
on	O
pre	O
-	O
existing	O
and	O
aminonucleoside	B
-	O
induced	O
proteinuria	O
in	O
spontaneously	O
hypertensive	O
rats	O
.	O

Proteinuria	O
is	O
a	O
side	O
effect	O
of	O
captopril	B
treatment	O
in	O
hypertensive	O
patients	O
.	O

The	O
possibility	O
of	O
reproducing	O
the	O
same	O
renal	O
abnormality	O
with	O
captopril	B
was	O
examined	O
in	O
SHR	O
.	O

Oral	O
administration	O
of	O
captopril	B
at	O
100	O
mg	O
/	O
kg	O
for	O
14	O
days	O
failed	O
to	O
aggravate	O
proteinuria	O
pre	O
-	O
existing	O
in	O
SHR	O
.	O

Also	O
,	O
captopril	B
treatment	O
failed	O
to	O
potentiate	O
or	O
facilitate	O
development	O
of	O
massive	O
proteinuria	O
invoked	O
by	O
puromycin	B
aminonucleoside	I
in	O
SHR	O
.	O

Captopril	B
had	O
little	O
or	O
no	O
demonstrable	O
effects	O
on	O
serum	O
electrolyte	O
concentrations	O
,	O
excretion	O
of	O
urine	O
,	O
sodium	B
and	O
potassium	B
,	O
endogenous	O
creatinine	B
clearance	O
,	O
body	O
weight	O
,	O
and	O
food	O
and	O
water	O
consumption	O
.	O

However	O
,	O
ketone	B
bodies	O
were	O
consistently	O
present	O
in	O
urine	O
and	O
several	O
lethalities	O
occurred	O
during	O
multiple	O
dosing	O
of	O
captopril	B
in	O
SHR	O
.	O

Complete	O
heart	O
block	O
following	O
a	O
single	O
dose	O
of	O
trazodone	B
.	O

Forty	O
minutes	O
after	O
receiving	O
a	O
single	O
starting	O
dose	O
of	O
trazodone	B
,	O
a	O
patient	O
developed	O
complete	O
heart	O
block	O
.	O

The	O
case	O
illustrates	O
that	O
,	O
despite	O
the	O
results	O
of	O
earlier	O
studies	O
,	O
trazodone	B
's	O
effect	O
on	O
cardiac	O
conduction	O
may	O
be	O
severe	O
in	O
individuals	O
at	O
risk	O
for	O
conduction	O
delay	O
.	O

Heparin	B
-	O
induced	O
thrombocytopenia	O
,	O
thrombosis	O
,	O
and	O
hemorrhage	O
.	O

Sixty	O
-	O
two	O
patients	O
with	O
a	O
heparin	B
-	O
induced	O
thrombocytopenia	O
are	O
reported	O
.	O

Clinical	O
manifestations	O
of	O
this	O
disorder	O
include	O
hemorrhage	O
or	O
,	O
more	O
frequently	O
,	O
thromboembolic	O
events	O
in	O
patients	O
receiving	O
heparin	B
.	O

Laboratory	O
testing	O
has	O
revealed	O
a	O
falling	O
platelet	O
count	O
,	O
increased	O
resistance	O
to	O
heparin	B
,	O
and	O
aggregation	O
of	O
platelets	O
by	O
the	O
patient	O
's	O
plasma	O
when	O
heparin	B
is	O
added	O
.	O

Immunologic	O
testing	O
has	O
demonstrated	O
the	O
presence	O
of	O
a	O
heparin	B
-	O
dependent	O
platelet	O
membrane	O
antibody	O
.	O

The	O
20	O
deaths	O
,	O
52	O
hemorrhagic	O
and	O
thromboembolic	O
complications	O
,	O
and	O
21	O
surgical	O
procedures	O
to	O
manage	O
the	O
complications	O
confirm	O
the	O
seriousness	O
of	O
the	O
disorder	O
.	O

Specific	O
risk	O
factors	O
have	O
not	O
been	O
identified	O
;	O
therefore	O
,	O
all	O
patients	O
receiving	O
heparin	B
should	O
be	O
monitored	O
.	O

If	O
the	O
platelet	O
count	O
falls	O
to	O
less	O
than	O
100,000	O
/	O
mm3	O
,	O
while	O
the	O
patient	O
is	O
receiving	O
heparin	B
,	O
platelet	O
aggregation	O
testing	O
,	O
using	O
the	O
patient	O
's	O
plasma	O
,	O
is	O
indicated	O
.	O

Management	O
consists	O
of	O
cessation	O
of	O
heparin	B
,	O
platelet	O
anti	O
-	O
aggregating	O
agents	O
,	O
and	O
alternate	O
forms	O
of	O
anticoagulation	O
when	O
indicated	O
.	O

Induction	O
of	O
the	O
obstructive	O
sleep	O
apnea	O
syndrome	O
in	O
a	O
woman	O
by	O
exogenous	O
androgen	B
administration	O
.	O

We	O
documented	O
airway	O
occlusion	O
during	O
sleep	O
and	O
an	O
abnormally	O
high	O
supraglottic	O
resistance	O
while	O
awake	O
in	O
a	O
54-yr	O
-	O
old	O
woman	O
who	O
had	O
developed	O
physical	O
changes	O
and	O
the	O
syndrome	O
of	O
obstructive	O
sleep	O
apnea	O
while	O
being	O
administered	O
exogenous	O
androgens	B
.	O

When	O
the	O
androgens	B
were	O
withdrawn	O
,	O
the	O
patient	O
's	O
physical	O
changes	O
,	O
symptoms	O
,	O
sleep	O
study	O
,	O
and	O
supraglottic	O
resistance	O
all	O
returned	O
to	O
normal	O
.	O

A	O
rechallenge	O
with	O
androgen	B
produced	O
symptoms	O
of	O
obstructive	O
sleep	O
apnea	O
that	O
abated	O
upon	O
withdrawal	O
of	O
the	O
hormone	O
.	O

Previous	O
reports	O
have	O
favored	O
a	O
role	O
of	O
androgens	B
in	O
the	O
pathogenesis	O
of	O
sleep	O
apnea	O
.	O

Our	O
report	O
provides	O
direct	O
evidence	O
for	O
this	O
role	O
.	O

Structural	O
and	O
functional	O
measurements	O
indicate	O
that	O
androgens	B
exert	O
a	O
permissive	O
or	O
necessary	O
action	O
on	O
the	O
structural	O
configuration	O
of	O
the	O
oropharynx	O
that	O
predisposes	O
to	O
obstruction	O
during	O
sleep	O
.	O

Development	O
of	O
the	O
obstructive	O
sleep	O
apnea	O
syndrome	O
must	O
be	O
considered	O
a	O
possible	O
side	O
effect	O
of	O
androgen	B
therapy	O
.	O

Effects	O
of	O
the	O
novel	O
compound	O
aniracetam	B
(	O
Ro	B
13	I
-	I
5057	I
)	O
upon	O
impaired	O
learning	O
and	O
memory	O
in	O
rodents	O
.	O

The	O
effect	O
of	O
aniracetam	B
(	O
Ro	B
13	I
-	I
5057	I
,	O
1-anisoyl-2-pyrrolidinone	B
)	O
was	O
studied	O
on	O
various	O
forms	O
of	O
experimentally	O
impaired	O
cognitive	O
functions	O
(	O
learning	O
and	O
memory	O
)	O
in	O
rodents	O
and	O
produced	O
the	O
following	O
effects	O
:	O
(	O
1	O
)	O
almost	O
complete	O
prevention	O
of	O
the	O
incapacity	O
to	O
learn	O
a	O
discrete	O
escape	O
response	O
in	O
rats	O
exposed	O
to	O
sublethal	O
hypercapnia	O
immediately	O
before	O
the	O
acquisition	O
session	O
;	O
(	O
2	O
)	O
partial	O
(	O
rats	O
)	O
or	O
complete	O
(	O
mice	O
)	O
prevention	O
of	O
the	O
scopolamine	B
-	O
induced	O
short	O
-	O
term	O
amnesia	O
for	O
a	O
passive	O
avoidance	O
task	O
;	O
(	O
3	O
)	O
complete	O
protection	O
against	O
amnesia	O
for	O
a	O
passive	O
avoidance	O
task	O
in	O
rats	O
submitted	O
to	O
electroconvulsive	O
shock	O
immediately	O
after	O
avoidance	O
acquisition	O
;	O
(	O
4	O
)	O
prevention	O
of	O
the	O
long	O
-	O
term	O
retention-	O
or	O
retrieval	O
-	O
deficit	O
for	O
a	O
passive	O
avoidance	O
task	O
induced	O
in	O
rats	O
and	O
mice	O
by	O
chloramphenicol	B
or	O
cycloheximide	B
administered	O
immediately	O
after	O
acquisition	O
;	O
(	O
5	O
)	O
reversal	O
,	O
when	O
administered	O
as	O
late	O
as	O
1	O
h	O
before	O
the	O
retention	O
test	O
,	O
of	O
the	O
deficit	O
in	O
retention	O
or	O
retrieval	O
of	O
a	O
passive	O
avoidance	O
task	O
induced	O
by	O
cycloheximide	B
injected	O
2	O
days	O
previously	O
;	O
(	O
6	O
)	O
prevention	O
of	O
the	O
deficit	O
in	O
the	O
retrieval	O
of	O
an	O
active	O
avoidance	O
task	O
induced	O
in	O
mice	O
by	O
subconvulsant	O
electroshock	O
or	O
hypercapnia	O
applied	O
immediately	O
before	O
retrieval	O
testing	O
(	O
24	O
h	O
after	O
acquisition	O
)	O
.	O

These	O
improvements	O
or	O
normalizations	O
of	O
impaired	O
cognitive	O
functions	O
were	O
seen	O
at	O
oral	O
aniracetam	B
doses	O
of	O
10	O
-	O
100	O
mg	O
/	O
kg	O
.	O

Generally	O
,	O
the	O
dose	O
-	O
response	O
curves	O
were	O
bell	O
-	O
shaped	O
.	O

The	O
mechanisms	O
underlying	O
the	O
activity	O
of	O
aniracetam	B
and	O
its	O
'	O
therapeutic	O
window	O
'	O
are	O
unknown	O
.	O

Piracetam	B
,	O
another	O
pyrrolidinone	B
derivative	O
was	O
used	O
for	O
comparison	O
.	O

It	O
was	O
active	O
only	O
in	O
six	O
of	O
nine	O
tests	O
and	O
had	O
about	O
one	O
-	O
tenth	O
the	O
potency	O
of	O
aniracetam	B
.	O

The	O
results	O
indicate	O
that	O
aniracetam	B
improves	O
cognitive	O
functions	O
which	O
are	O
impaired	O
by	O
different	O
procedure	O
and	O
in	O
different	O
phases	O
of	O
the	O
learning	O
and	O
memory	O
process	O
.	O

Hepatic	O
veno	O
-	O
occlusive	O
disease	O
caused	O
by	O
6-thioguanine	B
.	O

Clinically	O
reversible	O
veno	O
-	O
occlusive	O
disease	O
of	O
the	O
liver	O
developed	O
in	O
a	O
23-year	O
-	O
old	O
man	O
with	O
acute	O
lymphocytic	O
leukemia	O
after	O
10	O
months	O
of	O
maintenance	O
therapy	O
with	O
6-thioguanine	B
.	O

Serial	O
liver	O
biopsies	O
showed	O
the	O
development	O
and	O
resolution	O
of	O
intense	O
sinusoidal	O
engorgement	O
.	O

Although	O
this	O
disease	O
was	O
clinically	O
reversible	O
,	O
some	O
subintimal	O
fibrosis	O
about	O
the	O
terminal	O
hepatic	O
veins	O
persisted	O
.	O

This	O
case	O
presented	O
a	O
unique	O
opportunity	O
to	O
observe	O
the	O
histologic	O
features	O
of	O
clinically	O
reversible	O
hepatic	O
veno	O
-	O
occlusive	O
disease	O
over	O
time	O
,	O
and	O
may	O
be	O
the	O
first	O
case	O
of	O
veno	O
-	O
occlusive	O
related	O
solely	O
to	O
6-thioguanine	B
.	O

Extrapyramidal	O
side	O
effects	O
and	O
oral	O
haloperidol	B
:	O
an	O
analysis	O
of	O
explanatory	O
patient	O
and	O
treatment	O
characteristics	O
.	O

The	O
incidence	O
of	O
extrapyramidal	O
side	O
effects	O
(	O
EPS	O
)	O
was	O
evaluated	O
in	O
98	O
patients	O
treated	O
with	O
haloperidol	B
.	O

The	O
incidence	O
of	O
parkinsonism	O
was	O
higher	O
at	O
higher	O
doses	O
of	O
haloperidol	B
and	O
in	O
younger	O
patients	O
.	O

Prophylactic	O
antiparkinsonian	O
medication	O
was	O
effective	O
in	O
younger	O
but	O
not	O
in	O
older	O
patients	O
.	O

However	O
,	O
these	O
medications	O
were	O
more	O
effective	O
in	O
both	O
young	O
and	O
old	O
patients	O
when	O
given	O
after	O
parkinsonism	O
developed	O
.	O

Akathisia	O
was	O
controlled	O
by	O
the	O
benzodiazepine	B
lorazepam	B
in	O
14	O
out	O
of	O
16	O
patients	O
,	O
while	O
prophylactic	O
antiparkinsonians	O
were	O
ineffective	O
.	O

The	O
present	O
study	O
points	O
to	O
patient	O
characteristics	O
that	O
may	O
be	O
of	O
significance	O
in	O
the	O
development	O
of	O
EPS	O
due	O
to	O
haloperidol	B
.	O

REM	O
sleep	O
deprivation	O
changes	O
behavioral	O
response	O
to	O
catecholaminergic	O
and	O
serotonergic	O
receptor	O
activation	O
in	O
rats	O
.	O

The	O
effects	O
of	O
REM	O
sleep	O
deprivation	O
(	O
REMD	O
)	O
on	O
apomorphine	B
-	O
induced	O
aggressiveness	O
and	O
quipazine	B
-	O
induced	O
head	O
twitches	O
in	O
rats	O
were	O
determined	O
.	O

Forty	O
-	O
eight	O
hr	O
of	O
REMD	O
increased	O
apomorphine	B
-	O
induced	O
aggressiveness	O
,	O
and	O
reduced	O
(	O
immediately	O
after	O
completing	O
of	O
REMD	O
)	O
or	O
increased	O
(	O
96	O
hr	O
after	O
completing	O
of	O
REMD	O
)	O
quipazine	B
-	O
induced	O
head	O
twitches	O
.	O

Results	O
are	O
discussed	O
in	O
terms	O
of	O
similarity	O
to	O
pharmacological	O
effects	O
of	O
other	O
antidepressive	O
treatments	O
.	O

Endometrial	O
carcinoma	O
after	O
Hodgkin	O
disease	O
in	O
childhood	O
.	O

A	O
34-year	O
-	O
old	O
patient	O
developed	O
metastic	O
endometrial	O
carcinoma	O
after	O
Hodgkin	O
disease	O
in	O
childhood	O
.	O

She	O
had	O
ovarian	O
failure	O
after	O
abdominal	O
irradiation	O
and	O
chemotherapy	O
for	O
Hodgkin	O
disease	O
,	O
and	O
received	O
exogenous	O
estrogens	B
,	O
a	O
treatment	O
implicated	O
in	O
the	O
development	O
of	O
endometrial	O
cancer	O
in	O
menopausal	O
women	O
.	O

Young	O
women	O
on	O
replacement	O
estrogens	B
for	O
ovarian	O
failure	O
after	O
cancer	O
therapy	O
may	O
also	O
have	O
increased	O
risk	O
of	O
endometrial	O
carcinoma	O
and	O
should	O
be	O
examined	O
periodically	O
.	O

Long	O
-	O
term	O
lithium	B
treatment	O
and	O
the	O
kidney	O
.	O

Interim	O
report	O
on	O
fifty	O
patients	O
.	O

This	O
is	O
a	O
report	O
on	O
the	O
first	O
part	O
of	O
our	O
study	O
of	O
the	O
effects	O
of	O
long	O
-	O
term	O
lithium	B
treatment	O
on	O
the	O
kidney	O
.	O

Creatinine	B
clearance	O
,	O
maximum	O
urinary	O
osmolality	O
and	O
24	O
hour	O
urine	O
volume	O
have	O
been	O
tested	O
in	O
50	O
affectively	O
ill	O
patients	O
who	O
have	O
been	O
on	O
long	O
-	O
term	O
lithium	B
for	O
more	O
than	O
one	O
year	O
.	O

These	O
findings	O
have	O
been	O
compared	O
with	O
norms	O
and	O
with	O
values	O
of	O
the	O
same	O
tests	O
from	O
screening	O
prior	O
to	O
lithium	B
,	O
available	O
for	O
most	O
of	O
our	O
patients	O
.	O

No	O
evidence	O
was	O
found	O
for	O
any	O
reduction	O
of	O
glomerular	O
filtration	O
during	O
lithium	B
treatment	O
.	O

Low	O
clearance	O
values	O
found	O
in	O
several	O
patients	O
could	O
be	O
accounted	O
for	O
by	O
their	O
age	O
and	O
their	O
pre	O
-	O
lithium	B
values	O
.	O

Urinary	O
concentration	O
defect	O
appeared	O
frequent	O
but	O
the	O
extent	O
of	O
the	O
impairment	O
is	O
difficult	O
to	O
assess	O
because	O
of	O
the	O
uncertainty	O
about	O
the	O
norms	O
applicable	O
to	O
this	O
group	O
of	O
patients	O
.	O

The	O
concentration	O
defect	O
appeared	O
reversible	O
,	O
at	O
least	O
in	O
part	O
.	O

Polyuria	O
above	O
3	O
litres	O
/	O
24	O
hours	O
was	O
found	O
in	O
10	O
%	O
of	O
patients	O
.	O

An	O
attempt	O
is	O
made	O
to	O
draw	O
practical	O
conclusions	O
from	O
the	O
preliminary	O
findings	O
.	O

Acute	O
renal	O
failure	O
in	O
high	O
dose	O
carboplatin	B
chemotherapy	O
.	O

Carboplatin	B
has	O
been	O
reported	O
to	O
cause	O
acute	O
renal	O
failure	O
when	O
administered	O
in	O
high	O
doses	O
to	O
adult	O
patients	O
.	O

We	O
report	O
a	O
4	O
1	O
/	O
2-year	O
-	O
old	O
girl	O
who	O
was	O
treated	O
with	O
high	O
-	O
dose	O
carboplatin	B
for	O
metastatic	O
parameningeal	O
embryonal	O
rhabdomyosarcoma	O
.	O

Acute	O
renal	O
failure	O
developed	O
followed	O
by	O
a	O
slow	O
partial	O
recovery	O
of	O
renal	O
function	O
.	O

Possible	O
contributing	O
factors	O
are	O
discussed	O
.	O

Cholinergic	O
toxicity	O
resulting	O
from	O
ocular	O
instillation	O
of	O
echothiophate	B
iodide	I
eye	O
drops	O
.	O

A	O
patient	O
developed	O
a	O
severe	O
cholinergic	O
syndrome	O
from	O
the	O
use	O
of	O
echothiophate	B
iodide	I
ophthalmic	O
drops	O
,	O
presented	O
with	O
profound	O
muscle	O
weakness	O
and	O
was	O
initially	O
given	O
the	O
diagnosis	O
of	O
myasthenia	O
gravis	O
.	O

Red	O
blood	O
cell	O
and	O
serum	O
cholinesterase	O
levels	O
were	O
severely	O
depressed	O
and	O
symptoms	O
resolved	O
spontaneously	O
following	O
discontinuation	O
of	O
the	O
eye	O
drops	O
.	O

Time	O
dependence	O
of	O
plasma	O
malondialdehyde	B
,	O
oxypurines	B
,	O
and	O
nucleosides	B
during	O
incomplete	O
cerebral	O
ischemia	O
in	O
the	O
rat	O
.	O

Incomplete	O
cerebral	O
ischemia	O
(	O
30	O
min	O
)	O
was	O
induced	O
in	O
the	O
rat	O
by	O
bilaterally	O
clamping	O
the	O
common	O
carotid	O
arteries	O
.	O

Peripheral	O
venous	O
blood	O
samples	O
were	O
withdrawn	O
from	O
the	O
femoral	O
vein	O
four	O
times	O
(	O
once	O
every	O
5	O
min	O
)	O
before	O
ischemia	O
(	O
0	O
time	O
)	O
and	O
5	O
,	O
15	O
,	O
and	O
30	O
min	O
after	O
ischemia	O
.	O

Plasma	O
extracts	O
were	O
analyzed	O
by	O
a	O
highly	O
sensitive	O
high	O
-	O
performance	O
liquid	O
chromatographic	O
method	O
for	O
the	O
direct	O
determination	O
of	O
malondialdehyde	B
,	O
oxypurines	B
,	O
and	O
nucleosides	B
.	O

During	O
ischemia	O
,	O
a	O
time	O
-	O
dependent	O
increase	O
of	O
plasma	O
oxypurines	B
and	O
nucleosides	B
was	O
observed	O
.	O

Plasma	O
malondialdehyde	B
,	O
which	O
was	O
present	O
in	O
minimal	O
amount	O
at	O
zero	O
time	O
(	O
0.058	O
mumol	O
/	O
liter	O
plasma	O
;	O
SD	O
0.015	O
)	O
,	O
increased	O
after	O
5	O
min	O
of	O
ischemia	O
,	O
resulting	O
in	O
a	O
fivefold	O
increase	O
after	O
30	O
min	O
of	O
carotid	O
occlusion	O
(	O
0.298	O
mumol	O
/	O
liter	O
plasma	O
;	O
SD	O
0.078	O
)	O
.	O

Increased	O
plasma	O
malondialdehyde	B
was	O
also	O
recorded	O
in	O
two	O
other	O
groups	O
of	O
animals	O
subjected	O
to	O
the	O
same	O
experimental	O
model	O
,	O
one	O
receiving	O
20	O
mg	O
/	O
kg	O
b.w	O
.	O

of	O
the	O
cyclooxygenase	O
inhibitor	O
acetylsalicylate	B
intravenously	O
immediately	O
before	O
ischemia	O
,	O
the	O
other	O
receiving	O
650	O
micrograms	O
/	O
kg	O
b.w	O
.	O
of	O
the	O
hypotensive	O
drug	O
nitroprusside	B
at	O
a	O
flow	O
rate	O
of	O
103	O
microliters	O
/	O
min	O
intravenously	O
during	O
ischemia	O
,	O
although	O
in	O
this	O
latter	O
group	O
malondialdehyde	B
was	O
significantly	O
higher	O
.	O

The	O
present	O
data	O
indicate	O
that	O
the	O
determination	O
of	O
malondialdehyde	B
,	O
oxypurines	B
,	O
and	O
nucleosides	B
in	O
peripheral	O
blood	O
,	O
may	O
be	O
used	O
to	O
monitor	O
the	O
metabolic	O
alterations	O
of	O
tissues	O
occurring	O
during	O
ischemic	O
phenomena.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Cognitive	O
deterioration	O
from	O
long	O
-	O
term	O
abuse	O
of	O
dextromethorphan	B
:	O
a	O
case	O
report	O
.	O

Dextromethorphan	B
(	O
DM	B
)	O
,	O
the	O
dextrorotatory	O
isomer	O
of	O
3-hydroxy	B
-	I
N	I
-	I
methylmorphinan	I
,	O
is	O
the	O
main	O
ingredient	O
in	O
a	O
number	O
of	O
widely	O
available	O
,	O
over	O
-	O
the	O
-	O
counter	O
antitussives	O
.	O

Initial	O
studies	O
(	O
Bornstein	O
1968	O
)	O
showed	O
that	O
it	O
possessed	O
no	O
respiratory	O
suppressant	O
effects	O
and	O
no	O
addiction	O
liability	O
.	O

Subsequently	O
,	O
however	O
,	O
several	O
articles	O
reporting	O
abuse	O
of	O
this	O
drug	O
have	O
appeared	O
in	O
the	O
literature	O
.	O

The	O
drug	O
is	O
known	O
to	O
cause	O
a	O
variety	O
of	O
acute	O
toxic	O
effects	O
,	O
ranging	O
from	O
nausea	O
,	O
restlessness	O
,	O
insomnia	O
,	O
ataxia	O
,	O
slurred	O
speech	O
and	O
nystagmus	O
to	O
mood	O
changes	O
,	O
perceptual	O
alterations	O
,	O
inattention	O
,	O
disorientation	O
and	O
aggressive	O
behavior	O
(	O
Rammer	O
et	O
al	O
1988	O
;	O
Katona	O
and	O
Watson	O
1986	O
;	O
Isbell	O
and	O
Fraser	O
1953	O
;	O
Devlin	O
et	O
al	O
1985	O
;	O
McCarthy	O
1971	O
;	O
Dodds	O
and	O
Revai	O
1967	O
;	O
Degkwitz	O
1964	O
;	O
Hildebrand	O
et	O
al	O
1989	O
)	O
.	O

There	O
have	O
also	O
been	O
two	O
reported	O
fatalities	O
from	O
DM	B
overdoses	O
(	O
Fleming	O
1986	O
)	O
.	O

However	O
,	O
there	O
are	O
no	O
reports	O
describing	O
the	O
effects	O
of	O
chronic	O
abuse	O
.	O

This	O
report	O
describes	O
a	O
case	O
of	O
cognitive	O
deterioration	O
resulting	O
from	O
prolonged	O
use	O
of	O
DM	B
.	O

Dexamethasone	B
-	O
induced	O
ocular	O
hypertension	O
in	O
perfusion	O
-	O
cultured	O
human	O
eyes	O
.	O

PURPOSE	O
:	O
Glucocorticoid	O
administration	O
can	O
lead	O
to	O
the	O
development	O
of	O
ocular	O
hypertension	O
and	O
corticosteroid	O
glaucoma	O
in	O
a	O
subset	O
of	O
the	O
population	O
through	O
a	O
decrease	O
in	O
the	O
aqueous	O
humor	O
outflow	O
facility	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
glucocorticoid	O
treatment	O
can	O
directly	O
affect	O
the	O
outflow	O
facility	O
of	O
isolated	O
,	O
perfusion	O
-	O
cultured	O
human	O
eyes	O
.	O

METHODS	O
:	O
The	O
anterior	O
segments	O
of	O
human	O
donor	O
eyes	O
from	O
regional	O
eye	O
banks	O
were	O
placed	O
in	O
a	O
constant	O
flow	O
,	O
variable	O
pressure	O
perfusion	O
culture	O
system	O
.	O

Paired	O
eyes	O
were	O
perfused	O
in	O
serum	O
-	O
free	O
media	O
with	O
or	O
without	O
10	O
(	O
-7	O
)	O
M	O
dexamethasone	B
for	O
12	O
days	O
.	O

Intraocular	O
pressure	O
was	O
monitored	O
daily	O
.	O

After	O
incubation	O
,	O
the	O
eyes	O
were	O
morphologically	O
characterized	O
by	O
light	O
microscopy	O
,	O
transmission	O
and	O
scanning	O
electron	O
microscopy	O
,	O
and	O
scanning	O
laser	O
confocal	O
microscopy	O
.	O

RESULTS	O
:	O
A	O
significant	O
increase	O
in	O
intraocular	O
pressure	O
developed	O
in	O
13	O
of	O
the	O
44	O
pairs	O
of	O
eyes	O
perfused	O
with	O
dexamethasone	B
with	O
an	O
average	O
pressure	O
rise	O
of	O
17.5	O
+	O
/-	O

3.8	O
mm	O
Hg	O
after	O
12	O
days	O
of	O
dexamethasone	B
exposure	O
.	O

The	O
contralateral	O
control	O
eyes	O
,	O
which	O
did	O
not	O
receive	O
dexamethasone	B
,	O
maintained	O
a	O
stable	O
intraocular	O
pressure	O
during	O
the	O
same	O
period	O
.	O

The	O
outflow	O
pathway	O
of	O
the	O
untreated	O
eyes	O
appeared	O
morphologically	O
normal	O
.	O

In	O
contrast	O
,	O
the	O
dexamethasone	B
-	O
treated	O
hypertensive	O
eyes	O
had	O
thickened	O
trabecular	O
beams	O
,	O
decreased	O
intertrabecular	O
spaces	O
,	O
thickened	O
juxtacanalicular	O
tissue	O
,	O
activated	O
trabecular	O
meshwork	O
cells	O
,	O
and	O
increased	O
amounts	O
of	O
amorphogranular	O
extracellular	O
material	O
,	O
especially	O
in	O
the	O
juxtacanalicular	O
tissue	O
and	O
beneath	O
the	O
endothelial	O
lining	O
of	O
the	O
canal	O
of	O
Schlemm	O
.	O

The	O
dexamethasone	B
-	O
treated	O
nonresponder	O
eyes	O
appeared	O
to	O
be	O
morphologically	O
similar	O
to	O
the	O
untreated	O
eyes	O
,	O
although	O
several	O
subtle	O
dexamethasone	B
-	O
induced	O
morphologic	O
changes	O
were	O
evident	O
.	O

CONCLUSION	O
:	O
Dexamethasone	B
treatment	O
of	O
isolated	O
,	O
perfusion	O
-	O
cultured	O
human	O
eyes	O
led	O
to	O
the	O
generation	O
of	O
ocular	O
hypertension	O
in	O
approximately	O
30	O
%	O
of	O
the	O
dexamethasone	B
-	O
treated	O
eyes	O
.	O

Steroid	B
treatment	O
resulted	O
in	O
morphologic	O
changes	O
in	O
the	O
trabecular	O
meshwork	O
similar	O
to	O
those	O
reported	O
for	O
corticosteroid	O
glaucoma	O
and	O
open	O
angle	O
glaucoma	O
.	O

This	O
system	O
may	O
provide	O
an	O
acute	O
model	O
in	O
which	O
to	O
study	O
the	O
pathogenic	O
mechanisms	O
involved	O
in	O
steroid	O
glaucoma	O
and	O
primary	O
open	O
angle	O
glaucoma	O
.	O

Water	O
intoxication	O
associated	O
with	O
oxytocin	B
administration	O
during	O
saline	O
-	O
induced	O
abortion	O
.	O

Four	O
cases	O
of	O
water	O
intoxication	O
in	O
connection	O
with	O
oxytocin	B
administration	O
during	O
saline	O
-	O
induced	O
abortions	O
are	O
described	O
.	O

The	O
mechanism	O
of	O
water	O
intoxication	O
is	O
discussed	O
in	O
regard	O
to	O
these	O
cases	O
.	O

Oxytocin	B
administration	O
during	O
midtrimester	O
-	O
induced	O
abortions	O
is	O
advocated	O
only	O
if	O
it	O
can	O
be	O
carried	O
out	O
under	O
careful	O
observations	O
of	O
an	O
alert	O
nursing	O
staff	O
,	O
aware	O
of	O
the	O
symptoms	O
of	O
water	O
intoxication	O
and	O
instructed	O
to	O
watch	O
the	O
diuresis	O
and	O
report	O
such	O
early	O
signs	O
of	O
the	O
syndrome	O
as	O
asthenia	O
,	O
muscular	O
irritability	O
,	O
or	O
headaches	O
.	O

The	O
oxytocin	B
should	O
be	O
given	O
only	O
in	O
Ringers	O
lactate	B
or	O
,	O
alternately	O
,	O
in	O
Ringers	O
lactate	B
and	O
a	O
5	O
per	O
cent	O
dextrose	B
and	O
water	O
solutions	O
.	O

The	O
urinary	O
output	O
should	O
be	O
monitored	O
and	O
the	O
oxytocin	B
administration	O
discontinued	O
and	O
the	O
serum	O
electrolytes	O
checked	O
if	O
the	O
urinary	O
output	O
decreases	O
.	O

The	O
oxytocin	B
should	O
not	O
be	O
administered	O
in	O
excess	O
of	O
36	O
hours	O
.	O

If	O
the	O
patient	O
has	O
not	O
aborted	O
by	O
then	O
the	O
oxytocin	B
should	O
be	O
discontinued	O
for	O
10	O
to	O
12	O
hours	O
in	O
order	O
to	O
perform	O
electrolyte	O
determinations	O
and	O
correct	O
any	O
electrolyte	O
imbalance	O
.	O

Light	O
chain	O
proteinuria	O
and	O
cellular	O
mediated	O
immunity	O
in	O
rifampin	B
treated	O
patients	O
with	O
tuberculosis	O
.	O

Light	O
chain	O
proteinuria	O
was	O
found	O
in	O
9	O
of	O
17	O
tuberculosis	O
patients	O
treated	O
with	O
rifampin	B
.	O

Concomitant	O
assay	O
of	O
cellular	O
mediated	O
immunity	O
in	O
these	O
patients	O
using	O
skin	O
test	O
antigen	O
and	O
a	O
lymphokine	O
in	O
vitro	O
test	O
provided	O
results	O
that	O
were	O
different	O
.	O

Response	O
to	O
Varidase	O
skin	O
test	O
antigen	O
was	O
negative	O
for	O
all	O
eight	O
tuberculosis	O
patients	O
tested	O
,	O
but	O
there	O
occurred	O
a	O
hyper	O
-	O
responsiveness	O
of	O
the	O
lymphocytes	O
of	O
these	O
eight	O
patients	O
to	O
phytomitogen	O
(	O
PHA	O
-	O
P	O
)	O
.	O

as	O
well	O
as	O
of	O
those	O
of	O
seven	O
other	O
tuberculous	O
patients	O
.	O

This	O
last	O
finding	O
may	O
be	O
related	O
to	O
time	O
of	O
testing	O
and/or	O
endogenous	O
serum	O
binding	O
of	O
rifampin	B
which	O
could	O
have	O
inhibited	O
mitogen	O
activity	O
for	O
the	O
lymphocyte	O
.	O

KF17837	B
:	O
a	O
novel	O
selective	O
adenosine	B
A2A	O
receptor	O
antagonist	O
with	O
anticataleptic	O
activity	O
.	O

KF17837	B
is	O
a	O
novel	O
selective	O
adenosine	B
A2A	O
receptor	O
antagonist	O
.	O

Oral	O
administration	O
of	O
KF17837	B
(	O
2.5	O
,	O
10.0	O
and	O
30.0	O
mg	O
/	O
kg	O
)	O
significantly	O
ameliorated	O
the	O
cataleptic	O
responses	O
induced	O
by	O
intracerebroventricular	O
administration	O
of	O
an	O
adenosine	B
A2A	O
receptor	O
agonist	O
,	O
CGS	B
21680	I
(	O
10	O
micrograms	O
)	O
,	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

KF17837	B
also	O
reduced	O
the	O
catalepsy	O
induced	O
by	O
haloperidol	B
(	O
1	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O
and	O
by	O
reserpine	B
(	O
5	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O
.	O

These	O
anticataleptic	O
effects	O
were	O
exhibited	O
dose	O
dependently	O
at	O
doses	O
from	O
0.625	O
and	O
2.5	O
mg	O
/	O
kg	O
p.o	O
.	O
,	O
respectively	O
.	O

Moreover	O
,	O
KF17837	B
(	O
0.625	O
mg	O
/	O
kg	O
p.o	O
.	O
)	O
potentiated	O
the	O
anticataleptic	O
effects	O
of	O
a	O
subthreshold	O
dose	O
of	O
L-3,4-dihydroxyphenylalanine	B
(	O
L	B
-	I
DOPA	I
;	O
25	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O
plus	O
benserazide	B
(	O
6.25	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O
.	O

These	O
results	O
suggested	O
that	O
KF17837	B
is	O
a	O
centrally	O
active	O
adenosine	B
A2A	O
receptor	O
antagonist	O
and	O
that	O
the	O
dopaminergic	O
function	O
of	O
the	O
nigrostriatal	O
pathway	O
is	O
potentiated	O
by	O
adenosine	B
A2A	O
receptor	O
antagonists	O
.	O

Furthermore	O
,	O
KF17837	B
may	O
be	O
a	O
useful	O
drug	O
in	O
the	O
treatment	O
of	O
parkinsonism	O
.	O

Hyperalgesia	O
and	O
myoclonus	O
in	O
terminal	O
cancer	O
patients	O
treated	O
with	O
continuous	O
intravenous	O
morphine	B
.	O

Eight	O
cancer	O
patients	O
in	O
the	O
terminal	O
stages	O
of	O
the	O
disease	O
treated	O
with	O
high	O
doses	O
of	O
intravenous	O
morphine	B
developed	O
hyperalgesia	O
.	O

All	O
cases	O
were	O
retrospectively	O
sampled	O
from	O
three	O
different	O
hospitals	O
in	O
Copenhagen	O
.	O

Five	O
patients	O
developed	O
universal	O
hyperalgesia	O
and	O
hyperesthesia	O
which	O
in	O
2	O
cases	O
were	O
accompanied	O
by	O
myoclonus	O
.	O

In	O
3	O
patients	O
a	O
pre	O
-	O
existing	O
neuralgia	O
increased	O
to	O
excruciating	O
intensity	O
and	O
in	O
2	O
of	O
these	O
cases	O
myoclonus	O
occurred	O
simultaneously	O
.	O

Although	O
only	O
few	O
clinical	O
descriptions	O
of	O
the	O
relationship	O
between	O
hyperalgesia	O
/	O
myoclonus	O
and	O
high	O
doses	O
of	O
morphine	B
are	O
available	O
,	O
experimental	O
support	O
from	O
animal	O
studies	O
indicates	O
that	O
morphine	B
,	O
or	O
its	O
metabolites	O
,	O
plays	O
a	O
causative	O
role	O
for	O
the	O
observed	O
behavioural	O
syndrome	O
.	O

The	O
possible	O
mechanisms	O
are	O
discussed	O
and	O
treatment	O
proposals	O
given	O
suggesting	O
the	O
use	O
of	O
more	O
efficacious	O
opioids	O
with	O
less	O
excitatory	O
potency	O
in	O
these	O
situations	O
.	O

Case	O
report	O
:	O
pentamidine	B
and	O
polymorphic	O
ventricular	O
tachycardia	O
revisited	O
.	O

Pentamidine	B
isethionate	I
has	O
been	O
associated	O
with	O
ventricular	O
tachyarrhythmias	O
,	O
including	O
torsade	O
de	O
pointes	O
.	O

This	O
article	O
reports	O
two	O
cases	O
of	O
this	O
complication	O
and	O
reviews	O
all	O
reported	O
cases	O
to	O
date	O
.	O

Pentamidine	B
-	O
induced	O
torsade	O
de	O
pointes	O
may	O
be	O
related	O
to	O
serum	O
magnesium	B
levels	O
and	O
hypomagnesemia	O
may	O
synergistically	O
induce	O
torsade	O
.	O

Torsade	O
de	O
pointes	O
occurred	O
after	O
an	O
average	O
of	O
10	O
days	O
of	O
treatment	O
with	O
pentamidine	B
.	O

In	O
these	O
patients	O
,	O
no	O
other	O
acute	O
side	O
effects	O
of	O
pentamidine	B
were	O
observed	O
.	O

Torsade	O
de	O
pointes	O
can	O
be	O
treated	O
when	O
recognized	O
early	O
,	O
possibly	O
without	O
discontinuation	O
of	O
pentamidine	B
.	O

When	O
QTc	O
interval	O
prolongation	O
is	O
observed	O
,	O
early	O
magnesium	B
supplementation	O
is	O
advocated	O
.	O

Efficacy	O
and	O
tolerability	O
of	O
lovastatin	B
in	O
3390	O
women	O
with	O
moderate	O
hypercholesterolemia	O
.	O

OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
lovastatin	B
in	O
women	O
with	O
moderate	O
hypercholesterolemia	O
.	O

DESIGN	O
:	O
The	O
Expanded	O
Clinical	O
Evaluation	O
of	O
Lovastatin	B
(	O
EXCEL	O
)	O
Study	O
,	O
a	O
multicenter	O
,	O
double	O
-	O
blind	O
,	O
diet-	O
and	O
placebo	O
-	O
controlled	O
trial	O
,	O
in	O
which	O
participants	O
were	O
randomly	O
assigned	O
to	O
receive	O
placebo	O
or	O
lovastatin	B
at	O
doses	O
of	O
20	O
or	O
40	O
mg	O
once	O
daily	O
,	O
or	O
20	O
or	O
40	O
mg	O
twice	O
daily	O
for	O
48	O
weeks	O
.	O

SETTING	O
:	O
Ambulatory	O
patients	O
recruited	O
by	O
362	O
participating	O
centers	O
throughout	O
the	O
United	O
States	O
.	O

PATIENTS	O
:	O
Women	O
(	O
n	O
=	O
3390	O
)	O
from	O
the	O
total	O
cohort	O
of	O
8245	O
volunteers	O
.	O

MEASUREMENTS	O
:	O
Plasma	O
total	O
,	O
low	O
-	O
density	O
lipoprotein	O
(	O
LDL	O
)	O
,	O
and	O
high	O
-	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
cholesterol	B
,	O
and	O
triglycerides	B
;	O
and	O
laboratory	O
and	O
clinical	O
evidence	O
of	O
adverse	O
events	O
monitored	O
periodically	O
throughout	O
the	O
study	O
.	O

RESULTS	O
:	O
Among	O
women	O
,	O
lovastatin	B
(	O
20	O
to	O
80	O
mg	O
/	O
d	O
)	O
produced	O
sustained	O
(	O
12-	O
to	O
48-week	O
)	O
,	O
dose	O
-	O
related	O
changes	O
(	O
P	O
<	O
0.001	O
)	O
:	O
decreases	O
in	O
LDL	O
cholesterol	B
(	O
24	O
%	O
to	O
40	O
%	O
)	O
and	O
triglycerides	B
(	O
9	O
%	O
to	O
18	O
%	O
)	O
,	O
and	O
increases	O
in	O
HDL	O
cholesterol	B
(	O
6.7	O
%	O
to	O
8.6	O
%	O
)	O
.	O

Depending	O
on	O
the	O
dose	O
,	O
from	O
82	O
%	O
to	O
95	O
%	O
of	O
lovastatin	B
-	O
treated	O
women	O
achieved	O
the	O
National	O
Cholesterol	B
Education	O
Program	O
goal	O
of	O
LDL	O
cholesterol	B
levels	O
less	O
than	O
4.14	O
mmol	O
/	O
L	O
(	O
160	O
mg	O
/	O
dL	O
)	O
,	O
and	O
40	O
%	O
to	O
87	O
%	O
achieved	O
the	O
goal	O
of	O
3.36	O
mmol	O
/	O
L	O
(	O
130	O
mg	O
/	O
dL	O
)	O
.	O

Successive	O
transaminase	O
elevations	O
greater	O
than	O
three	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
occurred	O
in	O
0.1	O
%	O
of	O
women	O
and	O
were	O
dose	O
dependent	O
above	O
the	O
20-mg	O
dose	O
.	O

Myopathy	O
,	O
defined	O
as	O
muscle	O
symptoms	O
with	O
creatine	B
kinase	O
elevations	O
greater	O
than	O
10	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
,	O
was	O
rare	O
and	O
associated	O
with	O
the	O
highest	O
recommended	O
daily	O
dose	O
of	O
lovastatin	B
(	O
80	O
mg	O
)	O
.	O

Estrogen	O
-	O
replacement	O
therapy	O
appeared	O
to	O
have	O
no	O
effect	O
on	O
either	O
the	O
efficacy	O
or	O
safety	O
profile	O
of	O
lovastatin	B
.	O

CONCLUSION	O
:	O
Lovastatin	B
is	O
highly	O
effective	O
and	O
generally	O
well	O
tolerated	O
as	O
therapy	O
for	O
primary	O
hypercholesterolemia	O
in	O
women	O
.	O

Ciprofloxacin	B
-	O
induced	O
nephrotoxicity	O
in	O
patients	O
with	O
cancer	O
.	O

Nephrotoxicity	O
associated	O
with	O
ciprofloxacin	B
is	O
uncommon	O
.	O

Five	O
patients	O
with	O
cancer	O
who	O
developed	O
acute	O
renal	O
failure	O
that	O
followed	O
treatment	O
with	O
ciprofloxacin	B
are	O
described	O
and	O
an	O
additional	O
15	O
cases	O
reported	O
in	O
the	O
literature	O
are	O
reviewed	O
.	O

Other	O
than	O
elevation	O
of	O
serum	O
creatinine	B
levels	O
,	O
characteristic	O
clinical	O
manifestations	O
and	O
abnormal	O
laboratory	O
findings	O
are	O
not	O
frequently	O
present	O
.	O

Allergic	O
interstitial	O
nephritis	O
is	O
believed	O
to	O
be	O
the	O
underlying	O
pathological	O
-	O
process	O
.	O

Definitive	O
diagnosis	O
requires	O
performance	O
of	O
renal	O
biopsy	O
,	O
although	O
this	O
is	O
not	O
always	O
feasible	O
.	O

An	O
improvement	O
in	O
renal	O
function	O
that	O
followed	O
the	O
discontinuation	O
of	O
the	O
offending	O
antibiotic	O
supports	O
the	O
presumptive	O
diagnosis	O
of	O
ciprofloxacin	B
-	O
induced	O
acute	O
renal	O
failure	O
.	O

Changes	O
in	O
peroxisomes	O
in	O
preneoplastic	O
liver	O
and	O
hepatoma	O
of	O
mice	O
induced	O
by	O
alpha	B
-	I
benzene	I
hexachloride	I
.	O

Peroxisomes	O
in	O
hepatomas	O
and	O
hyperplastic	O
preneoplastic	O
liver	O
lesions	O
induced	O
in	O
mice	O
by	O
500	O
ppm	O
alpha	B
-	I
benzene	I
hexachloride	I
were	O
examined	O
histochemically	O
and	O
electron	O
microscopically	O
.	O

Although	O
most	O
of	O
the	O
hepatomas	O
were	O
well	O
-	O
differentiated	O
tumors	O
and	O
contained	O
a	O
considerable	O
number	O
of	O
peroxisomes	O
,	O
the	O
tumor	O
cells	O
did	O
not	O
respond	O
to	O
ethyl	B
-	I
alpha	I
-	I
p	I
-	I
chlorophenoxyisobutyrate	I
with	O
proliferation	O
of	O
peroxisomes	O
.	O

At	O
the	O
16th	O
week	O
of	O
carcinogen	O
feeding	O
,	O
hyperplastic	O
nodules	O
appeared	O
and	O
advanced	O
to	O
further	O
stages	O
.	O

A	O
majority	O
of	O
the	O
nodules	O
showed	O
a	O
considerable	O
number	O
of	O
peroxisomes	O
and	O
the	O
inductive	O
proliferation	O
of	O
peroxisomes	O
.	O

Within	O
the	O
nodules	O
,	O
foci	O
of	O
proliferation	O
of	O
the	O
cells	O
that	O
showed	O
no	O
inducibility	O
of	O
proliferation	O
of	O
peroxisomes	O
appeared	O
.	O

These	O
cells	O
proliferated	O
further	O
,	O
replacing	O
the	O
most	O
part	O
of	O
the	O
nodules	O
,	O
and	O
with	O
this	O
process	O
hepatomas	O
appeared	O
to	O
have	O
been	O
formed	O
.	O

No	O
abnormal	O
matrical	O
inclusions	O
of	O
peroxisomes	O
were	O
formed	O
in	O
the	O
cells	O
of	O
hyperplastic	O
nodules	O
by	O
ethyl	B
-	I
alpha	I
-	I
p	I
-	I
chlorophenoxyisobutyrate	I
unlike	O
in	O
the	O
case	O
of	O
rats	O
.	O

Absence	O
of	O
effect	O
of	O
sertraline	B
on	O
time	O
-	O
based	O
sensitization	O
of	O
cognitive	O
impairment	O
with	O
haloperidol	B
.	O

This	O
double	O
-	O
blind	O
,	O
randomized	O
,	O
placebo	O
-	O
controlled	O
study	O
evaluated	O
the	O
effects	O
of	O
haloperidol	B
alone	O
and	O
haloperidol	B
plus	O
sertraline	B
on	O
cognitive	O
and	O
psychomotor	O
function	O
in	O
24	O
healthy	O
male	O
subjects	O
.	O

METHOD	O
:	O
All	O
subjects	O
received	O
placebo	O
on	O
Day	O
1	O
and	O
haloperidol	B
2	O
mg	O
on	O
Days	O
2	O
and	O
25	O
.	O

From	O
Days	O
9	O
to	O
25	O
,	O
subjects	O
were	O
randomly	O
assigned	O
to	O
either	O
sertraline	B
(	O
12	O
subjects	O
)	O
or	O
placebo	O
(	O
12	O
subjects	O
)	O
;	O
the	O
sertraline	B
dose	O
was	O
titrated	O
from	O
50	O
to	O
200	O
mg	O
/	O
day	O
from	O
Days	O
9	O
to	O
16	O
,	O
and	O
remained	O
at	O
200	O
mg	O
/	O
day	O
for	O
the	O
final	O
10	O
days	O
of	O
the	O
drug	O
administration	O
period	O
.	O

Cognitive	O
function	O
testing	O
was	O
performed	O
before	O
dosing	O
and	O
over	O
a	O
24-hour	O
period	O
after	O
dosing	O
on	O
Days	O
1	O
,	O
2	O
,	O
and	O
25	O
.	O

RESULTS	O
:	O
Impairment	O
of	O
cognitive	O
function	O
was	O
observed	O
6	O
to	O
8	O
hours	O
after	O
administration	O
of	O
haloperidol	B
on	O
Day	O
2	O
but	O
was	O
not	O
evident	O
23	O
hours	O
after	O
dosing	O
.	O

When	O
single	O
-	O
dose	O
haloperidol	B
was	O
given	O
again	O
25	O
days	O
later	O
,	O
greater	O
impairment	O
with	O
earlier	O
onset	O
was	O
noted	O
in	O
several	O
tests	O
in	O
both	O
treatment	O
groups	O
,	O
suggesting	O
enhancement	O
of	O
this	O
effect	O
.	O

There	O
was	O
no	O
indication	O
that	O
sertraline	B
exacerbated	O
the	O
impairment	O
produced	O
by	O
haloperidol	B
since	O
an	O
equivalent	O
effect	O
also	O
occurred	O
in	O
the	O
placebo	O
group	O
.	O

Three	O
subjects	O
(	O
2	O
on	O
sertraline	B
and	O
1	O
on	O
placebo	O
)	O
withdrew	O
from	O
the	O
study	O
because	O
of	O
side	O
effects	O
.	O

Ten	O
subjects	O
in	O
each	O
group	O
reported	O
side	O
effects	O
related	O
to	O
treatment	O
.	O

The	O
side	O
effect	O
profiles	O
of	O
sertraline	B
and	O
of	O
placebo	O
were	O
similar	O
.	O

CONCLUSION	O
:	O
Haloperidol	B
produced	O
a	O
clear	O
profile	O
of	O
cognitive	O
impairment	O
that	O
was	O
not	O
worsened	O
by	O
concomitant	O
sertraline	B
administration	O
.	O

Famotidine	B
-	O
associated	O
delirium	O
.	O

A	O
series	O
of	O
six	O
cases	O
.	O

Famotidine	B
is	O
a	O
histamine	O
H2-receptor	O
antagonist	O
used	O
in	O
inpatient	O
settings	O
for	O
prevention	O
of	O
stress	O
ulcers	O
and	O
is	O
showing	O
increasing	O
popularity	O
because	O
of	O
its	O
low	O
cost	O
.	O

Although	O
all	O
of	O
the	O
currently	O
available	O
H2-receptor	O
antagonists	O
have	O
shown	O
the	O
propensity	O
to	O
cause	O
delirium	O
,	O
only	O
two	O
previously	O
reported	O
cases	O
have	O
been	O
associated	O
with	O
famotidine	B
.	O

The	O
authors	O
report	O
on	O
six	O
cases	O
of	O
famotidine	B
-	O
associated	O
delirium	O
in	O
hospitalized	O
patients	O
who	O
cleared	O
completely	O
upon	O
removal	O
of	O
famotidine	B
.	O

The	O
pharmacokinetics	O
of	O
famotidine	B
are	O
reviewed	O
,	O
with	O
no	O
change	O
in	O
its	O
metabolism	O
in	O
the	O
elderly	O
population	O
seen	O
.	O

The	O
implications	O
of	O
using	O
famotidine	B
in	O
elderly	O
persons	O
are	O
discussed	O
.	O

Valsartan	B
,	O
a	O
new	O
angiotensin	B
II	I
antagonist	O
for	O
the	O
treatment	O
of	O
essential	O
hypertension	O
:	O
a	O
comparative	O
study	O
of	O
the	O
efficacy	O
and	O
safety	O
against	O
amlodipine	B
.	O

OBJECTIVE	O
:	O
To	O
compare	O
the	O
antihypertensive	O
efficacy	O
of	O
a	O
new	O
angiotensin	B
II	I
antagonist	O
,	O
valsartan	B
,	O
with	O
a	O
reference	O
therapy	O
,	O
amlodipine	B
.	O

METHODS	O
:	O
One	O
hundred	O
sixty	O
-	O
eight	O
adult	O
outpatients	O
with	O
mild	O
to	O
moderate	O
hypertension	O
were	O
randomly	O
allocated	O
in	O
double	O
-	O
blind	O
fashion	O
and	O
equal	O
number	O
to	O
receive	O
80	O
mg	O
valsartan	B
or	O
5	O
mg	O
amlodipine	B
for	O
12	O
weeks	O
.	O

After	O
8	O
weeks	O
of	O
therapy	O
,	O
in	O
patients	O
whose	O
blood	O
pressure	O
remained	O
uncontrolled	O
,	O
5	O
mg	O
amlodipine	B
was	O
added	O
to	O
the	O
initial	O
therapy	O
.	O

Patients	O
were	O
assessed	O
at	O
4	O
,	O
8	O
,	O
and	O
12	O
weeks	O
.	O

The	O
primary	O
efficacy	O
variable	O
was	O
change	O
from	O
baseline	O
in	O
mean	O
sitting	O
diastolic	O
blood	O
pressure	O
at	O
8	O
weeks	O
.	O

Secondary	O
variables	O
included	O
change	O
in	O
sitting	O
systolic	O
blood	O
pressure	O
and	O
responder	O
rates	O
.	O

RESULTS	O
:	O
Both	O
valsartan	B
and	O
amlodipine	B
were	O
effective	O
at	O
lowering	O
blood	O
pressure	O
at	O
4	O
,	O
8	O
,	O
and	O
12	O
weeks	O
.	O

Similar	O
decreases	O
were	O
observed	O
in	O
both	O
groups	O
,	O
with	O
no	O
statistically	O
significant	O
differences	O
between	O
the	O
groups	O
for	O
any	O
variable	O
analyzed	O
.	O

For	O
the	O
primary	O
variable	O
the	O
difference	O
was	O
0.5	O
mm	O
Hg	O
in	O
favor	O
of	O
valsartan	B
(	O
p	O
=	O
0.68	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
-2.7	O
to	O
1.7	O
)	O
.	O

Responder	O
rates	O
at	O
8	O
weeks	O
were	O
66.7	O
%	O
for	O
valsartan	B
and	O
60.2	O
%	O
for	O
amlodipine	B
(	O
p	O
=	O
0.39	O
)	O
.	O

Both	O
treatments	O
were	O
well	O
tolerated	O
.	O

The	O
incidence	O
of	O
drug	O
-	O
related	O
dependent	O
edema	O
was	O
somewhat	O
higher	O
in	O
the	O
amlodipine	B
group	O
,	O
particularly	O
at	O
a	O
dose	O
of	O
10	O
mg	O
per	O
day	O
(	O
2.4	O
%	O
for	O
80	O
mg	O
valsartan	B
;	O
3.6	O
%	O
for	O
5	O
mg	O
amlodipine	B
;	O
0	O
%	O
for	O
valsartan	B
plus	O
5	O
mg	O
amlodipine	B
;	O
14.3	O
%	O
for	O
10	O
mg	O
amlodipine	B
)	O
.	O

CONCLUSIONS	O
:	O
The	O
data	O
show	O
that	O
valsartan	B
is	O
at	O
least	O
as	O
effective	O
as	O
amlodipine	B
in	O
the	O
treatment	O
of	O
mild	O
to	O
moderate	O
hypertension	O
.	O

The	O
results	O
also	O
show	O
valsartan	B
to	O
be	O
well	O
tolerated	O
and	O
suggest	O
that	O
it	O
is	O
not	O
associated	O
with	O
side	O
effects	O
characteristic	O
of	O
this	O
comparator	O
class	O
,	O
dihydropyridine	B
calcium	B
antagonists	O
.	O

Fatal	O
excited	O
delirium	O
following	O
cocaine	B
use	O
:	O
epidemiologic	O
findings	O
provide	O
new	O
evidence	O
for	O
mechanisms	O
of	O
cocaine	B
toxicity	O
.	O

We	O
describe	O
an	O
outbreak	O
of	O
deaths	O
from	O
cocaine	B
-	O
induced	O
excited	O
delirium	O
(	O
EDDs	O
)	O
in	O
Dade	O
County	O
,	O
Florida	O
between	O
1979	O
and	O
1990	O
.	O

From	O
a	O
registry	O
of	O
all	O
cocaine	B
-	O
related	O
deaths	O
in	O
Dade	O
County	O
,	O
Florida	O
,	O
from	O
1969	O
-	O
1990	O
,	O
58	O
EDDs	O
were	O
compared	O
with	O
125	O
victims	O
of	O
accidental	O
cocaine	B
overdose	O
without	O
excited	O
delirium	O
.	O

Compared	O
with	O
controls	O
,	O
EDDs	O
were	O
more	O
frequently	O
black	O
,	O
male	O
,	O
and	O
younger	O
.	O

They	O
were	O
less	O
likely	O
to	O
have	O
a	O
low	O
body	O
mass	O
index	O
,	O
and	O
more	O
likely	O
to	O
have	O
died	O
in	O
police	O
custody	O
,	O
to	O
have	O
received	O
medical	O
treatment	O
immediately	O
before	O
death	O
,	O
to	O
have	O
survived	O
for	O
a	O
longer	O
period	O
,	O
to	O
have	O
developed	O
hyperthermia	O
,	O
and	O
to	O
have	O
died	O
in	O
summer	O
months	O
.	O

EDDs	O
had	O
concentrations	O
of	O
cocaine	B
and	O
benzoylecgonine	B
in	O
autopsy	O
blood	O
that	O
were	O
similar	O
to	O
those	O
for	O
controls	O
.	O

The	O
epidemiologic	O
findings	O
are	O
most	O
consistent	O
with	O
the	O
hypothesis	O
that	O
chronic	O
cocaine	B
use	O
disrupts	O
dopaminergic	O
function	O
and	O
,	O
when	O
coupled	O
with	O
recent	O
cocaine	B
use	O
,	O
may	O
precipitate	O
agitation	O
,	O
delirium	O
,	O
aberrant	O
thermoregulation	O
,	O
rhabdomyolysis	O
,	O
and	O
sudden	O
death	O
.	O

Neutrophil	O
superoxide	B
and	O
hydrogen	B
peroxide	I
production	O
in	O
patients	O
with	O
acute	O
liver	O
failure	O
.	O

Defects	O
in	O
superoxide	B
and	O
hydrogen	B
peroxide	I
production	O
may	O
be	O
implicated	O
in	O
the	O
high	O
incidence	O
of	O
bacterial	O
infections	O
in	O
patients	O
with	O
acute	O
liver	O
failure	O
(	O
ALF	O
)	O
.	O

In	O
the	O
present	O
study	O
,	O
oxygen	B
radical	O
production	O
in	O
patients	O
with	O
ALF	O
due	O
to	O
paracetamol	B
overdose	O
was	O
compared	O
with	O
that	O
of	O
healthy	O
volunteers	O
.	O

Neutrophils	O
from	O
14	O
ALF	O
patients	O
were	O
stimulated	O
via	O
the	O
complement	O
receptors	O
using	O
zymosan	O
opsonized	O
with	O
ALF	O
or	O
control	O
serum	O
.	O

Superoxide	B
and	O
hydrogen	B
peroxide	I
production	O
by	O
ALF	O
neutrophils	O
stimulated	O
with	O
zymosan	O
opsonized	O
with	O
ALF	O
serum	O
was	O
significantly	O
reduced	O
compared	O
with	O
the	O
control	O
subjects	O
(	O
P	O
<	O
0.01	O
)	O
.	O

This	O
defect	O
persisted	O
when	O
zymosan	O
opsonized	O
by	O
control	O
serum	O
was	O
used	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Superoxide	B
and	O
hydrogen	B
peroxide	I
production	O
in	O
neutrophils	O
stimulated	O
with	O
formyl	B
-	I
methionyl	I
-	I
leucyl	I
-	I
phenylalanine	I
(	O
fMLP	B
)	O
from	O
a	O
further	O
18	O
ALF	O
patients	O
was	O
unaffected	O
compared	O
with	O
control	O
neutrophils	O
.	O

Serum	O
C3	O
complement	O
levels	O
were	O
significantly	O
reduced	O
in	O
ALF	O
patients	O
compared	O
with	O
control	O
subjects	O
(	O
P	O
<	O
0.0005	O
)	O
.	O

These	O
results	O
demonstrate	O
a	O
neutrophil	O
defect	O
in	O
ALF	O
due	O
to	O
paracetamol	B
overdose	O
,	O
that	O
is	O
complement	O
dependent	O
but	O
independent	O
of	O
serum	O
complement	O
,	O
possibly	O
connected	O
to	O
the	O
complement	O
receptor	O
.	O

Cholesteryl	B
hemisuccinate	I
treatment	O
protects	O
rodents	O
from	O
the	O
toxic	O
effects	O
of	O
acetaminophen	B
,	O
adriamycin	B
,	O
carbon	B
tetrachloride	I
,	O
chloroform	B
and	O
galactosamine	B
.	O

In	O
addition	O
to	O
its	O
use	O
as	O
a	O
stabilizer	O
/	O
rigidifier	O
of	O
membranes	O
,	O
cholesteryl	B
hemisuccinate	I
,	O
tris	B
salt	I
(	O
CS	B
)	O
administration	O
has	O
also	O
been	O
shown	O
to	O
protect	O
rats	O
from	O
the	O
hepatotoxic	O
effects	O
of	O
carbon	B
tetrachloride	I
(	O
CCl4	B
)	O
.	O

To	O
further	O
our	O
understanding	O
of	O
the	O
mechanism	O
of	O
CS	B
cytoprotection	O
,	O
we	O
examined	O
in	O
rats	O
and	O
mice	O
the	O
protective	O
abilities	O
of	O
CS	B
and	O
the	O
non	O
-	O
hydrolyzable	O
ether	O
form	O
of	O
CS	B
,	O
gamma	B
-	I
cholesteryloxybutyric	I
acid	I
,	O
tris	B
salt	I
(	O
CSE	B
)	O
against	O
acetaminophen-	B
,	O
adriamycin-	B
,	O
carbon	B
tetrachloride-	I
,	O
chloroform-	B
and	O
galactosamine	B
-	O
induced	O
toxicity	O
.	O

The	O
results	O
of	O
these	O
studies	O
demonstrated	O
that	O
CS	B
-	O
mediated	O
protection	O
is	O
not	O
selective	O
for	O
a	O
particular	O
species	O
,	O
organ	O
system	O
or	O
toxic	O
chemical	O
.	O

A	O
24-h	O
pretreatment	O
of	O
both	O
rats	O
and	O
mice	O
with	O
a	O
single	O
dose	O
of	O
CS	B
(	O
100mg	O
/	O
kg	O
,	O
i.p	O
.	O
)	O
,	O
resulted	O
in	O
significant	O
protection	O
against	O
the	O
hepatotoxic	O
effects	O
of	O
CCl4	B
,	O
CHCl3	B
,	O
acetaminophen	B
and	O
galactosamine	B
and	O
against	O
the	O
lethal	O
(	O
and	O
presumably	O
cardiotoxic	O
)	O
effect	O
of	O
adriamycin	B
administration	O
.	O

Maximal	O
CS	B
-	O
mediated	O
protection	O
was	O
observed	O
in	O
experimental	O
animals	O
pretreated	O
24	O
h	O
prior	O
to	O
the	O
toxic	O
insult	O
.	O

These	O
data	O
suggest	O
that	O
CS	B
intervenes	O
in	O
a	O
critical	O
cellular	O
event	O
that	O
is	O
an	O
important	O
common	O
pathway	O
to	O
toxic	O
cell	O
death	O
.	O

The	O
mechanism	O
of	O
CS	B
protection	O
does	O
not	O
appear	O
to	O
be	O
dependent	O
on	O
the	O
inhibition	O
of	O
chemical	O
bioactivation	O
to	O
a	O
toxic	O
reactive	O
intermediate	O
(	O
in	O
light	O
of	O
the	O
protection	O
observed	O
against	O
galactosamine	B
hepatotoxicity	O
)	O
.	O

However	O
,	O
based	O
on	O
the	O
data	O
presented	O
,	O
we	O
can	O
not	O
exclude	O
the	O
possibility	O
that	O
CS	B
administration	O
inhibits	O
chemical	O
bioactivation	O
.	O

Our	O
findings	O
do	O
suggest	O
that	O
CS	B
-	O
mediated	O
protection	O
is	O
dependent	O
on	O
the	O
action	O
of	O
the	O
intact	O
anionic	O
CS	B
molecule	O
(	O
non	O
-	O
hydrolyzable	O
CSE	B
was	O
as	O
protective	O
as	O
CS	B
)	O
,	O
whose	O
mechanism	O
has	O
yet	O
to	O
be	O
defined	O
.	O

Contribution	O
of	O
the	O
glycine	B
site	O
of	O
NMDA	B
receptors	O
in	O
rostral	O
and	O
intermediate	O
-	O
caudal	O
parts	O
of	O
the	O
striatum	O
to	O
the	O
regulation	O
of	O
muscle	O
tone	O
in	O
rats	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
assess	O
the	O
contribution	O
of	O
the	O
glycine	B
site	O
of	O
NMDA	B
receptors	O
in	O
the	O
striatum	O
to	O
the	O
regulation	O
of	O
muscle	O
tone	O
.	O

Muscle	O
tone	O
was	O
examined	O
using	O
a	O
combined	O
mechanoand	O
electromyographic	O
method	O
,	O
which	O
measured	O
simultaneously	O
the	O
muscle	O
resistance	O
(	O
MMG	O
)	O
of	O
the	O
rat	O
's	O
hind	O
foot	O
to	O
passive	O
extension	O
and	O
flexion	O
in	O
the	O
ankle	O
joint	O
and	O
the	O
electromyographic	O
activity	O
(	O
EMG	O
)	O
of	O
the	O
antagonistic	O
muscles	O
of	O
that	O
joint	O
:	O
gastrocnemius	O
and	O
tibialis	O
anterior	O
.	O

Muscle	O
rigidity	O
was	O
induced	O
by	O
haloperidol	B
(	O
2.5	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O
.	O

5,7-dichlorokynurenic	B
acid	I
(	O
5,7-DCKA	B
)	O
,	O
a	O
selective	O
glycine	B
site	O
antagonist	O
,	O
injected	O
in	O
doses	O
of	O
2.5	O
and	O
4.5	O
microg	O
/	O
0.5	O
microl	O
bilaterally	O
,	O
into	O
the	O
rostral	O
region	O
of	O
the	O
striatum	O
,	O
decreased	O
both	O
the	O
haloperidol	B
-	O
induced	O
muscle	O
rigidity	O
(	O
MMG	O
)	O
and	O
the	O
enhanced	O
electromyographic	O
activity	O
(	O
EMG	O
)	O
.	O

5,7-DCKA	B
injected	O
bilaterally	O
in	O
a	O
dose	O
of	O
4.5	O
microg	O
/	O
0.5	O
microl	O
into	O
the	O
intermediate	O
-	O
caudal	O
region	O
of	O
the	O
striatum	O
of	O
rats	O
not	O
pretreated	O
with	O
haloperidol	B
had	O
no	O
effect	O
on	O
the	O
muscle	O
tone	O
.	O

The	O
present	O
results	O
suggest	O
that	O
blockade	O
of	O
the	O
glycine	B
site	O
of	O
NMDA	B
receptors	O
in	O
the	O
rostral	O
part	O
of	O
the	O
striatum	O
may	O
be	O
mainly	O
responsible	O
for	O
the	O
antiparkinsonian	O
action	O
of	O
this	O
drug	O
.	O

The	O
invention	O
relates	O
to	O
a	O
steroid	B
derivative	O
which	O
steroidal	O
skeleton	O
is	O
bound	O
at	O
carbon	O
atom	O
17	O
to	O
a	O
spiromethylene	B
ring	O
of	O
the	O
formula	O
:	O

<	O
See	O
formula	O
I	O
>	O
wherein	O
R	O
a	O
and	O
R	O
b	O
are	O
independently	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
hydrogen	B
,	O
methyl	B
,	O
and	O
halogen	B
;	O
m	O
is	O
1	O
or	O
2	O
;	O
and	O
the	O
asterisk	O
denotes	O
carbon	B
atom	O
2	O
of	O
the	O
spiromethylene	B
ring	O
which	O
is	O
carbon	B
atom	O
17	O
(	O
or	O
carbon	B
atom	O
17.alpha	O
.	O

of	O
a	O
homosteroid	O
skeleton	O
)	O
of	O
the	O
steroid	O
.	O

The	O
steroids	B
have	O
progestational	O
or	O
antiprogestational	O
activity	O
.	O

17-spiromethylene	B
steroids	I

The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
coumarins	B
such	O
as	O
esculoside	B
,	O
esculetin	B
,	O
extracts	O
containing	O
them	O
and	O
mixtures	O
thereof	O
,	O
in	O
combination	O
with	O
dimeric	O
and	O
oligomeric	O
proanthocyanidins	B
,	O
in	O
topical	O
formulations	O
for	O
the	O
treatment	O
of	O
peripheral	O
vasculopathies	O
,	O
including	O
the	O
complications	O
of	O
acute	O
venous	O
stasis	O
,	O
or	O
of	O
the	O
unesthetisms	O
related	O
to	O
capillary	O
alterations	O
,	O
or	O
to	O
improve	O
the	O
cicatrization	O
processes	O
.	O

These	O
coumarins	B
,	O
alone	O
or	O
in	O
combination	O
with	O
proanthocyanidins	B
,	O
are	O
also	O
useful	O
in	O
atopical	O
dermatitis	O
and	O
in	O
the	O
treatment	O
of	O
the	O
haematomas	O
.	O

Formulations	O
containing	O
coumarins	B
and	O
the	O
use	O
thereof	O
in	O
the	O
pharmaceutical	O
and	O
cosmetic	O
fields	O

Synthetic	O
melanins	O
suitable	O
for	O
cosmetic	O
uses	O
are	O
produced	O
through	O
oxidative	O
polymerization	O
of	O
monomeric	O
precursors	O
that	O
possess	O
aromatic	B
rings	O
with	O
ionizeable	O
side	O
groups	O
.	O

Agents	O
that	O
enhance	O
adherence	O
of	O
the	O
melanins	O
to	O
skin	O
and	O
hair	O
are	O
co	O
-	O
polymerized	O
with	O
the	O
precursors	O
to	O
become	O
part	O
of	O
the	O
melanin	O
molecules	O
.	O

Potential	O
new	O
precursors	O
and	O
adherence	O
-	O
enhancing	O
agents	O
are	O
screened	O
for	O
efficacy	O
by	O
subjecting	O
them	O
to	O
six	O
separate	O
synthetic	O
procedures	O
,	O
and	O
testing	O
the	O
resulting	O
melanins	O
for	O
color	O
,	O
ultraviolet	O
absorbance	O
charcteristics	O
,	O
and	O
substantivity	O
(	O
adherence	O
)	O
to	O
skin	O
and	O
hair	O
.	O

Melanins	O
of	O
different	O
colors	O
can	O
be	O
blended	O
together	O
in	O
cosmetic	O
creams	O
and	O
lotions	O
to	O
complement	O
the	O
natural	O
skin	O
,	O
eye	O
,	O
and	O
hair	O
colors	O
of	O
an	O
individual	O
.	O

The	O
synthetic	O
procedures	O
are	O
amendable	O
to	O
industrial	O
-	O
scale	O
production	O
of	O
cosmetic	O
melanins	O
.	O

The	O
materials	O
reduce	O
the	O
incidence	O
of	O
solar	O
damage	O
to	O
the	O
skin	O
.	O

Cosmetic	O
melanins	O

The	O
invention	O
describes	O
a	O
process	O
for	O
the	O
epimer	O
enrichment	O
of	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
by	O
silylation	O
,	O
fractionated	O
crystallization	O
and	O
acid	O
hydrolysis	O
.	O

Novel	O
silyl	B
compounds	O
and	O
their	O
use	O

Arylalkyl	B
diazinone	I
derivatives	O
of	O
the	O
formula	O

I	O
(	O
see	O
formula	O
I	O
)	O
and	O
their	O
physiologically	O
acceptable	O
salts	O
,	O
in	O
which	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
B	O
,	O
Q	O
and	O
X	O
have	O
the	O
meanings	O
indicated	O
in	O
Claim	O
1	O
,	O
exhibit	O
phosphodiesterase	O
IV	O
inhibition	O
and	O
can	O
be	O
employed	O
for	O
the	O
treatment	O
of	O
inflammatory	O
processes	O
and	O
also	O
of	O
allergies	O
,	O
asthma	O
and	O
autoimmune	O
disorders	O
.	O

Arylalkyl	B
-	I
diazinones	I

The	O
invention	O
relates	O
to	O
pharmaceutical	O
compositions	O
for	O
topical	O
administration	O
comprising	O
a	O
topically	O
acceptable	O
antiviral	O
substance	O
and	O
an	O
antiiflammatory	O
glucocorticoid	O
in	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O

The	O
pharmaceutical	O
composition	O
can	O
be	O
used	O
in	O
the	O
prophylactic	O
and	O
curative	O
treatment	O
of	O
herpesvirus	O
infections	O
in	O
mammals	O
including	O
man	O
.	O

The	O
invention	O
also	O
relates	O
to	O
the	O
use	O
of	O
a	O
combination	O
of	O
a	O
topically	O
acceptable	O
antiviral	O
substance	O
and	O
an	O
antiinflammatory	O
glucocorticoid	O
for	O
the	O
manufacture	O
of	O
a	O
midicament	O
for	O
said	O
prophylactic	O
and	O
curative	O
treatment	O
.	O

Novel	O
pharmaceutical	O
combination	O

Indanylidineacetylguanidines	B

I	O
(	O
see	O
formula	O
I	O
)	O
and	O
their	O
pharmaceutically	O
acceptable	O
salts	O
wherein	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
R6	O
,	O
R7	O
,	O
R8	O
,	O
R9	O
,	O
R10	O
and	O
X	O
have	O
the	O
meanings	O
given	O
in	O
the	O
claims	O
,	O
are	O
effective	O
inhibitors	O
of	O
the	O
cellular	O
sodium	B
/	O
proton	O
antiport	O
(	O
Na	B
+	I
/H	O
+	B
exchanger	O
)	O
,	O
which	O
,	O
in	O
numerous	O
diseases	O
(	O
essential	O
hypertension	O
,	O
atherosclerosis	O
,	O
diabetes	O
and	O
the	O
like	O
)	O
is	O
also	O
increased	O
in	O
those	O
cells	O
which	O
are	O
readily	O
accessible	O
for	O
measurements	O
,	O
such	O
as	O
,	O
for	O
example	O
,	O
in	O
erythrocytes	O
,	O
platelets	O
or	O
leukocytes	O
.	O

They	O
are	O
also	O
advantageous	O
for	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
the	O
treatment	O
or	O
prophylaxis	O
of	O
disorders	O
of	O
lipid	O
metabolism	O
.	O

Substituted	O
indanylidineacetylguanidines	B
,	O
process	O
for	O
their	O
preparation	O
,	O
their	O
use	O
as	O
medicaments	O
or	O
diagnostic	O
and	O
medicaments	O
containing	O
them	O

The	O
soporific	O
activity	O
of	O
cis-9,10-octadecenoamide	B
and	O
other	O
soporific	O
fatty	B
acid	I
primary	O
amides	B
is	O
neutralized	O
by	O
hydrolysis	O
in	O
the	O
presence	O
of	O
cis-9,10-octadecenoamidase	O
.	O

Hydrolysis	O
of	O
cis-9,10-octadecenoamide	B
leads	O
to	O
the	O
formation	O
of	O
oleic	B
acid	I
,	O
a	O
compound	O
without	O
soporific	O
activity	O
.	O

Inhibitors	O
of	O
cis-9,10-octadecenoamidase	O
are	O
disclosed	O
to	O
block	O
this	O
activity	O
.	O

Cis-9,10-octadecenoamidase	O

Methods	O
,	O
compounds	O
and	O
compositions	O
are	O
provided	O
for	O
inhibiting	O
the	O
growth	O
of	O
pathogenic	O
microbes	O
in	O
vitro	O
and	O
of	O
treatment	O
of	O
pathogenic	O
bacterial	O
infections	O
,	O
such	O
as	O
mycobacterial	O
,	O
Clostridium	O
,	O
Cryptosporidium	O
and	O
Helicobacter	O
infections	O
,	O
in	O
vivo	O
using	O
bicyclic	O
nitroimidazole	B
compounds	O
of	O
the	O
formula	O
(	O
II	O
)	O
:	O
(	O
see	O
formula	O
II	O
)	O

The	O
methods	O
,	O
compounds	O
and	O
compositions	O
are	O
particularly	O
useful	O
for	O
inhibiting	O
the	O
growth	O
of	O
Mycobacterium	O
tuberculosis	O
,	O
Clostridium	O
difficile	O
,	O
Cryptosporidium	O
parvum	O
,	O
and	O
Helicobacter	O
pylori	O
,	O
and	O
may	O
be	O
used	O
alone	O
,	O
or	O
in	O
combination	O
with	O
other	O
antimicrobial	O
agents	O
.	O

Nitroimidazole	B
antibacterial	O
compounds	O
and	O
methods	O
of	O
use	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
the	O
management	O
of	O
pain	O
without	O
requiring	O
or	O
allowing	O
for	O
reduction	O
in	O
the	O
level	O
of	O
administration	O
of	O
narcotics	O
,	O
and	O
to	O
self	O
-	O
management	O
of	O
pain	O
on	O
an	O
outpatient	O
basis	O
.	O

Accordingly	O
,	O
the	O
present	O
invention	O
is	O
broadly	O
directed	O
to	O
a	O
method	O
for	O
treating	O
pain	O
in	O
a	O
subject	O
comprising	O
administering	O
via	O
a	O
transmucosal	O
,	O
transdermal	O
,	O
or	O
oral	O
route	O
a	O
dose	O
of	O
ketamine	B
effective	O
to	O
alleviate	O
pain	O
to	O
a	O
subject	O
suffering	O
from	O
pain	O
.	O

The	O
invention	O
is	O
further	O
directed	O
to	O
a	O
method	O
for	O
synergistically	O
treating	O
pain	O
in	O
a	O
subject	O
comprising	O
administering	O
via	O
any	O
route	O
a	O
dose	O
of	O
ketamine	B
effective	O
to	O
allow	O
for	O
reduction	O
in	O
the	O
level	O
of	O
an	O
ongoing	O
pain	O
therapy	O
,	O
or	O
decrease	O
pain	O
(	O
improve	O
the	O
level	O
of	O
pain	O
relief	O
)	O
,	O
or	O
both	O
.	O

Transmucosal	O
,	O
transdermal	O
,	O
and	O
oral	O
administration	O
of	O
ketamine	B
advantageously	O
allows	O
for	O
patient	O
self	O
administration	O
of	O
the	O
drug	O
,	O
which	O
provides	O
for	O
pain	O
management	O
on	O
an	O
outpatient	O
basis	O
.	O

Moreover	O
,	O
ketamine	B
administration	O
in	O
transdermal	O
devices	O
(	O
suppositories	O
,	O
candies	O
,	O
buccal	O
patches	O
)	O
is	O
generally	O
socially	O
acceptable	O
.	O

In	O
a	O
specific	O
example	O
,	O
a	O
patient	O
suffering	O
from	O
intractable	O
bladder	O
pain	O
controlled	O
breakthrough	O
pain	O
by	O
transmucosal	O
(	O
nasal	O
)	O
administration	O
of	O
about	O
16	O
mg	O
to	O
about	O
32	O
mg	O
of	O
ketamine	B
per	O
dose	O
.	O

Administration	O
of	O
ketamine	B
to	O
manage	O
pain	O
and	O
to	O
reduce	O
drug	O
dependency	O

The	O
present	O
invention	O
concerns	O
a	O
G	O
-	O
coupled	O
receptor	O
which	O
has	O
an	O
amino	B
acid	I
sequence	O
having	O
more	O
than	O
50	O
%	O
homology	O
with	O
the	O
amino	B
acid	I
sequence	O
shown	O
in	O
Figure	O
1	O
.	O

G	O
-	O
coupled	O
receptor	O
showing	O
selective	O
affinity	O
for	O
atp	B

The	O
invention	O
provides	O
isolated	O
polynucleotide	O
molecules	O
,	O
including	O
plasmids	O
;	O
viral	O
vectors	O
;	O
and	O
transfected	O
host	O
cells	O
that	O
comprise	O
a	O
DNA	O
sequence	O
encoding	O
an	O
infectious	O
RNA	O
sequence	O
encoding	O
a	O
North	O
American	O
PRRS	O
virus	O
;	O
and	O
also	O
North	O
American	O
PRRS	O
viruses	O
encoded	O
thereby	O
.	O

The	O
invention	O
further	O
provides	O
isolated	O
infectious	O
RNA	O
molecules	O
encoding	O
a	O
North	O
American	O
PRRS	O
virus	O
.	O

The	O
invention	O
also	O
provides	O
isolated	O
polynucleotide	O
molecules	O
,	O
infectious	O
RNA	O
molecules	O
,	O
viral	O
vectors	O
,	O
and	O
transfected	O
host	O
cells	O
encoding	O
genetically	O
-	O
modified	O
North	O
American	O
PRRS	O
viruses	O
;	O
and	O
genetically	O
-	O
modified	O
North	O
American	O
PRRS	O
viruses	O
encoded	O
thereby	O
.	O

The	O
invention	O
also	O
provides	O
vaccines	O
comprising	O
such	O
plasmids	O
,	O
RNA	O
molecules	O
,	O
viral	O
vectors	O
,	O
and	O
North	O
American	O
PRRS	O
viruses	O
,	O
and	O
methods	O
of	O
using	O
these	O
vaccines	O
in	O
swine	O
and	O
in	O
other	O
animals	O
.	O

Also	O
provided	O
are	O
isolated	O
polynucleotide	O
molecules	O
,	O
viral	O
vectors	O
,	O
and	O
transfected	O
host	O
cells	O
that	O
comprise	O
a	O
nucleotide	O
sequence	O
encoding	O
a	O
peptide	O
of	O
a	O
North	O
American	O
PRRS	O
virus	O
.	O

These	O
viral	O
vectors	O
and	O
transfected	O
host	O
cell	O
lines	O
are	O
useful	O
in	O
providing	O
peptides	O
to	O
compensate	O
for	O
mutated	O
peptide	O
coding	O
sequences	O
of	O
DNA	O
sequences	O
encoding	O
genetically	O
-	O
modified	O
North	O
American	O
PRRS	O
viruses	O
so	O
that	O
functional	O
virions	O
can	O
be	O
generated	O
.	O

An	O
infectious	O
cdna	O
clone	O
of	O
north	O
american	O
porcine	O
reproductive	O
and	O
respiratory	O
syndrome	O
(	O
prrs	O
)	O
virus	O
and	O
uses	O
thereof	O

Compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
X	O
and	O
R1	O
to	O
R5	O
are	O
as	O
defined	O
in	O
the	O
description	O
,	O
are	O
useful	O
for	O
treating	O
disorders	O
mediated	O
full	O
or	O
in	O
part	O
by	O
mGluR5	O
.	O

Pyridine	B
derivatives	O

A	O
therapeutic	O
process	O
is	O
provided	O
for	O
the	O
inhibition	O
of	O
NF-.kappa	O
.	O

B	O
in	O
mammals	O
in	O
whose	O
cells	O
NF-.kappa	O
.	O

B	O
has	O
been	O
activated	O
by	O
an	O
agency	O
external	O
to	O
said	O
cell	O
.	O

Therapeutic	O
process	O
for	O
inhibiting	O
nf-.kappa.b	O

A	O
new	O
crystalline	O
form	O
of	O
1-methyl-5-p	B
-	I
toluoylpyrrole-2-acetamidoacetic	I
acid	I
guaiacyl	I
ester	I
,	O
a	O
process	O
for	O
its	O
preparation	O
and	O
pharmaceutical	O
compositions	O
endowed	O
of	O
antiinflammatory	O
,	O
analgesic	O
and	O
antipyretic	O
activity	O
containing	O
same	O
are	O
disclosed	O
.	O

New	O
crystalline	O
form	O
of	O
1-methyl-5-p	B
-	I
toluoylpyrrole-2-acetamidoacetic	I
acid	I
guaiacyl	I
ester	I

This	O
invention	O
relates	O
to	O
the	O
use	O
of	O
cyclic	O
guanosine	B
3	I
'	I
,	I
5'-monophosphate	I
phosphodiesterase	O
type	O
five	O
(	O
cGMP	O
PDE5	O
)	O
inhibitors	O
,	O
including	O
in	O
particular	O
the	O
compound	O
sildenafil	O
,	O
in	O
combination	O
with	O
gabapentin	B
or	O
pregabalin	B
,	O
which	O
may	O
be	O
used	O
for	O
the	O
treatment	O
of	O
neuropathy	O
,	O
including	O
in	O
particular	O
the	O
treatment	O
of	O
diabetic	O
neuropathy	O
.	O

Treatment	O
of	O
neuropathy	O

An	O
ascorbic	B
acid	I
(	O
Vitamin	B
C	I
)	O
composition	O
in	O
a	O
nonaqueous	O
or	O
substantially	O
anhydrous	O
silicone	B
vehicle	O
has	O
superior	O
stability	O
.	O

Particulate	O
ascorbic	O
acid	O
is	O
substantially	O
insoluble	O
in	O
the	O
disclosed	O
polyorganosiloxane	B
vehicles	O
,	O
and	O
the	O
vehicle	O
substantially	O
excludes	O
environmental	O
oxygen	B
.	O

The	O
ascorbic	B
acid	I
particles	O
have	O
surprisingly	O
been	O
found	O
to	O
have	O
a	O
high	O
degree	O
of	O
bioavailability	O
and	O
effectiveness	O
,	O
for	O
example	O
in	O
topical	O
applications	O
to	O
reduce	O
wrinkles	O
and	O
increase	O
collagen	O
growth	O
and	O
elasticity	O
.	O

Improved	O
stable	O
topical	O
ascorbic	B
acid	I
compositions	O

Compounds	O
that	O
inhibit	O
the	O
activity	O
of	O
NF	O
-	O
B	O
or	O
inhibit	O
the	O
activity	O
of	O
the	O
proteasome	O
or	O
both	O
promote	O
bone	O
formation	O
and	O
hair	O
growth	O
and	O
are	O
thus	O
useful	O
in	O
treating	O
osteoporosis	O
,	O
bone	O
fracture	O
or	O
deficiency	O
,	O
primary	O
or	O
secondary	O
hyperparathyroidism	O
,	O
periodontal	O
disease	O
or	O
defect	O
,	O
metastatic	O
bone	O
disease	O
,	O
osteolytic	O
bone	O
disease	O
,	O
post	O
-	O
plastic	O
surgery	O
,	O
post	O
-	O
prosthetic	O
joint	O
surgery	O
,	O
and	O
post	O
-	O
dental	O
implantation	O
;	O
they	O
also	O
stimulate	O
the	O
production	O
of	O
hair	O
follicles	O
and	O
are	O
thus	O
useful	O
in	O
stimulating	O
hair	O
growth	O
,	O
including	O
hair	O
density	O
,	O
in	O
subject	O
where	O
this	O
is	O
desirable	O
.	O

Inhibitors	O
of	O
proteasomal	O
activity	O
for	O
stimulating	O
bone	O
and	O
hair	O
growth	O

The	O
present	O
invention	O
relates	O
to	O
new	O
high	O
molecular	O
weight	O
salts	O
of	O
hyaluronic	B
acid	I
.	O

More	O
particularly	O
,	O
these	O
salts	O
are	O
characterized	O
in	O
that	O
they	O
have	O
as	O
a	O
counterion	O
a	O
natural	O
amino	B
acid	I
.	O

The	O
products	O
of	O
the	O
invention	O
can	O
be	O
prepared	O
starting	O
from	O
high	O
molecular	O
weight	O
hyaluronic	B
acid	I
or	O
salts	O
thereof	O
.	O

These	O
new	O
high	O
molecular	O
weights	O
salts	O
of	O
hyaluronic	B
acid	I
may	O
be	O
advantageously	O
employed	O
in	O
the	O
cosmetic	O
of	O
pharmaceutical	O
field	O
.	O

Reaction	O
products	O
of	O
hyaluronic	B
acid	I
and	O
natural	O
amino	B
acids	I
and	O
their	O
use	O
in	O
cosmetic	O
and	O
pharmaceutical	O
compositions	O

The	O
invention	O
discloses	O
novel	O
compounds	O
of	O
the	O
pyridinium	B
series	O
useful	O
for	O
the	O
management	O
of	O
diabetes	O
and	O
aging	O
-	O
related	O
vascular	O
complications	O
,	O
including	O
kidney	O
disease	O
,	O
nerve	O
damage	O
,	O
atherosclerosis	O
,	O
retinopathy	O
,	O
dermatological	O
disorders	O
and	O
discoloration	O
of	O
teeth	O
,	O
by	O
breaking	O
preformed	O
AGE	O
,	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O

The	O
invention	O
also	O
discloses	O
,	O
method	O
for	O
preparation	O
of	O
the	O
novel	O
compounds	O
of	O
the	O
series	O
and	O
pharmaceutical	O
composition	O
comprising	O
one	O
or	O
more	O
of	O
these	O
compounds	O
.	O

The	O
invention	O
further	O
discloses	O
a	O
method	O
of	O
treatment	O
of	O
a	O
diabetic	O
patient	O
by	O
administering	O
the	O
compounds	O
either	O
singly	O
or	O
in	O
combination	O
with	O
drugs	O
for	O
antidiabetic	O
therapy	O
.	O

Novel	O
compounds	O
for	O
the	O
management	O
of	O
aging	O
-	O
related	O
and	O
diabetic	O
vascular	O
complications	O
,	O
process	O
for	O
their	O
preparation	O
and	O
therapeutic	O
uses	O

Long	O
-	O
acting	O
antiparasitic	O
formulations	O
of	O
doramectin	O
,	O
suitable	O
for	O
injection	O
,	O
are	O
described	O
herein	O
.	O

Antiparasitic	O
formulations	O
comprising	O
doramectin	O

Modulators	O
of	O
PPAR.gamma	O
.	O

activity	O
are	O
provided	O
having	O
the	O
following	O
formula	O
,	O
which	O
modulators	O
are	O
useful	O
in	O
pharmaceutical	O
compositions	O
and	O
methods	O
for	O
the	O
treatment	O
of	O
conditions	O
such	O
as	O
type	O
II	O
diabetes	O
and	O
obesity	O
.	O

(	O
See	O
above	O
Formula	O
)	O
Compounds	O
for	O
the	O
modulation	O
of	O
ppar.gamma	O
.	O

activity	O

The	O
invention	O
relates	O
to	O
arylsulphonamide	B
-	I
substituted	I
benzimidazole	I
derivatives	O
of	O
general	O
formula	O
(	O
I	O
)	O
wherein	O
the	O
groups	O
R1	O
,	O
R2	O
,	O
R3	O
and	O
R4	O
may	O
have	O
the	O
meanings	O
given	O
in	O
the	O
claims	O
and	O
specification	O
,	O
processes	O
for	O
preparing	O
them	O
as	O
well	O
as	O
the	O
use	O
of	O
arylsulphonamide	B
-	I
substituted	I
benzimidazole	I
derivatives	O
as	O
pharmaceutical	O
compositions	O
,	O
particularly	O
as	O
pharmaceutical	O
compositions	O
with	O
a	O
tryptase	O
-	O
inhibiting	O
activity	O
.	O

Arylsulphonamide	B
-	I
substituted	I
benzimidazole	I
derivatives	O
,	O
processes	O
for	O
preparing	O
them	O
and	O
their	O
use	O
as	O
pharmaceutical	O
compositions	O

An	O
iron	B
chelator	O
delivery	O
system	O
is	O
disclosed	O
.	O

The	O
system	O
comprises	O
iron	B
chelator	O
and	O
a	O
lipid	O
carrier	O
,	O
e.g.	O
,	O
a	O
liposome	O
.	O

Methods	O
for	O
preparing	O
and	O
administering	O
the	O
iron	O
chelator	O
delivery	O
system	O
are	O
also	O
provided	O
.	O

Iron	B
chelator	O
delivery	O
system	O

The	O
invention	O
relates	O
to	O
a	O
method	O
for	O
the	O
antibiotic	O
coating	O
of	O
bodies	O
with	O
interconnecting	O
microcavities	O
as	O
well	O
as	O
bodies	O
coated	O
this	O
way	O
and	O
their	O
usage	O
.	O

The	O
invented	O
method	O
is	O
characterized	O
in	O
that	O
in	O
the	O
microcavities	O
of	O
non	O
-	O
metallic	O
bodies	O
an	O
aqueous	O
solution	O
1	O
,	O
which	O
contains	O
at	O
least	O
one	O
easily	O
water	O
-	O
soluble	O
antibiotic	O
component	O
from	O
the	O
groups	O
of	O
the	O
aminoglycoside	B
antibiotics	O
,	O
the	O
tetracycline	B
antibiotics	O
,	O
the	O
lincosamide	B
antibiotics	O
and	O
the	O
4-quinolone	B
antibiotics	O
,	O
and	O
an	O
aqueous	O
solution	O
2	O
,	O
which	O
contains	O
at	O
least	O
one	O
easily	O
water	O
-	O
soluble	O
amphiphilic	O
component	O
from	O
the	O
groups	O
of	O
the	O
alkyl	B
sulfates	I
,	O
alkyl	B
sulfonates	I
,	O
alkylaryl	B
sulfates	I
,	O
dialkylaryl	B
sulfates	I
,	O
alkylaryl	B
sulfonates	I
,	O
dialkylaryl	B
sulfonates	I
,	O
cycloalkyl	B
sulfates	I
,	O
cycloalkyl	B
sulfonates	I
,	O
alkylcycloalkyl	B
sulfates	I
,	O
are	O
introduced	O
,	O
wherein	O
between	O
the	O
introduction	O
of	O
solutions	O
1	O
and	O
2	O
the	O
water	O
is	O
basically	O
removed	O
through	O
vaporization	O
and/or	O
evaporation	O
,	O
and	O
whereby	O
from	O
the	O
components	O
of	O
solutions	O
1	O
and	O
2	O
in	O
the	O
microcavities	O
a	O
deposit	O
is	O
formed	O
,	O
which	O
is	O
sparingly	O
soluble	O
in	O
water	O
.	O

Method	O
for	O
the	O
antibiotic	O
coating	O
of	O
bodies	O
with	O
interconnecting	O
microcavities	O
as	O
well	O
as	O
coated	O
bodies	O
and	O
their	O
usage	O

An	O
ethanol	O
solvate	O
form	O
of	O
(	B
-	I
)	I
-cis-2-	I
(	I
2-chlorophenyl	I
)	I
-5,7-dihydroxy-8	I
[	I
4R-	I
(	I
3S	I
--	I
hydroxy-1-methyl	I
)	I
piperidinyl	I
]	I
-4H-1-benzopyran-4-one	I
(	O
Form	O
II	O
)	O
,	O
a	O
method	O
of	O
making	O
Form	O
II	O
and	O
a	O
pharmaceutical	O
composition	O
comprising	O
Form	O
II	O
for	O
treating	O
cancer	O
.	O

Ethanol	O
solvate	O
of	O
(	B
-	I
)	I
-cis-2-	I
(	I
2-chlorophenyl	I
)	I
-5,7-dihydroxy-8	I
[	I
4r-	I
(	I
3s	I
-	I
hydroxy-1-methyl	I
)	I
piperidinyl	I
]	I
-4h-1-benzopyran-4-one	I

The	O
identification	O
of	O
the	O
HYAL1	O
hyaluronidase	O
enzyme	O
as	O
a	O
human	O
plasma	O
-	O
derived	O
myeloid	O
colony	O
-	O
stimulating	O
factor	O
(	O
CSF	O
)	O
,	O
herein	O
designated	O
CSF5-hyaluronidase	O
,	O
its	O
recombinant	O
production	O
and	O
methods	O
of	O
use	O
are	O
described	O
.	O

This	O
protein	O
may	O
be	O
used	O
for	O
the	O
treatment	O
of	O
myelosuppression	O
as	O
may	O
occur	O
after	O
irradiation	O
,	O
chemotherapy	O
or	O
other	O
diseases	O
where	O
an	O
increase	O
in	O
leukocyte	O
levels	O
may	O
be	O
beneficial	O
.	O

For	O
example	O
,	O
CSF5	O
may	O
be	O
used	O
to	O
enhance	O
the	O
immune	O
response	O
to	O
viral	O
infection	O
or	O
other	O
diseases	O
associated	O
with	O
immune	O
suppression	O
.	O

Myeloid	O
colony	O
stimulating	O
factor	O
and	O
uses	O
thereof	O

A	O
method	O
of	O
producing	O
a	O
disinfectant	O
or	O
sterilizing	O
liquid	O
,	O
cream	O
,	O
ointment	O
,	O
paste	O
,	O
or	O
gel	O
by	O
dissolving	O
in	O
a	O
solvent	O
a	O
stable	O
ready	O
-	O
to	O
-	O
use	O
dosage	O
form	O
containing	O
coloring	O
matter	O
and	O
an	O
organic	O
chloroxidizer	O
acting	O
as	O
a	O
chlorine	B
donor	O
releasing	O
active	O
chlorine	B
.	O

The	O
coloring	O
matter	O
is	O
in	O
its	O
maximal	O
level	O
of	O
oxidation	O
.	O

The	O
chloroxidizer	O
with	O
coloring	O
matter	O
has	O
a	O
pH	O
of	O
4	O
-	O
8	O
and	O
is	O
present	O
in	O
a	O
sufficient	O
quantity	O
to	O
disinfect	O
or	O
sterilize	O
the	O
surface	O
,	O
vessel	O
,	O
or	O
tissue	O
as	O
required	O
while	O
the	O
colored	O
appearance	O
of	O
the	O
liquid	O
,	O
cream	O
,	O
ointment	O
,	O
paste	O
,	O
or	O
gel	O
is	O
stably	O
maintained	O
over	O
a	O
period	O
of	O
time	O
which	O
exceeds	O
the	O
period	O
of	O
time	O
that	O
the	O
disinfectant	O
would	O
be	O
normally	O
used	O
for	O
that	O
purpose	O
.	O

Stable	O
ready	O
-	O
to	O
-	O
use	O
dosage	O
forms	O
containing	O
coloring	O
matter	O
and	O
active	O
chlorine	O
,	O
and	O
methods	O
of	O
making	O
and	O
using	O
same	O
as	O
disinfectants	O

This	O
invention	O
relates	O
to	O
parenteral	O
preparations	O
of	O
antiestrogens	O
such	O
as	O
toremifene	B
,	O
desmethyl	B
toremifene	I
,	O
tamoxifen	B
or	O
desmethyltamoxifen	B
.	O

The	O
preparations	O
can	O
be	O
emulsions	O
,	O
liposomes	O
or	O
aqueous	O
solutions	O
of	O
cyclodextrin	O
-	O
drug	O
complexes	O
.	O

Particularly	O
the	O
invention	O
relates	O
to	O
a	O
parenteral	O
drug	O
formulation	O
comprising	O
a	O
complex	O
having	O
a	O
2-hydroxypropyl	O
cyclodextrin	O
component	O
and	O
including	O
an	O
active	O
drug	O
substance	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
toremifene	B
,	O
desmethyl	B
toremifene	I
,	O
tamoxifen	B
and	O
desmethyltamoxifen	B
or	O
a	O
pharmaceutically	O
acceptable	O
non	O
-	O
toxic	O
salt	O
thereof	O
,	O
said	O
complex	O
being	O
present	O
either	O
in	O
an	O
aqueous	O
solution	O
or	O
emulsion	O
or	O
loaded	O
into	O
a	O
liposome	O
.	O

Drug	O
formulations	O
for	O
parenteral	O
use	O

The	O
present	O
invention	O
relates	O
to	O
an	O
agent	O
for	O
inhibiting	O
decomposition	O
of	O
a	O
biologically	O
active	O
peptide	O
by	O
a	O
digestive	O
enzyme	O
,	O
which	O
is	O
aminoalkyl	B
methacrylate	I
copolymer	I
E	I
as	O
an	O
effective	O
ingredient	O
,	O
and	O
an	O
agent	O
for	O
reducing	O
viscosity	O
of	O
the	O
gastrointestinal	O
mucosa	O
and	O
mucous	O
layers	O
distributed	O
over	O
this	O
mucosa	O
.	O

The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
for	O
inhibiting	O
decomposition	O
of	O
a	O
biologically	O
active	O
peptide	O
by	O
a	O
digestive	O
enzyme	O
,	O
or	O
a	O
method	O
for	O
reducing	O
viscosity	O
of	O
the	O
gastrointestinal	O
mucosa	O
and/or	O
mucous	O
layers	O
distributed	O
over	O
the	O
mucosa	O
,	O
by	O
administration	O
of	O
aminoalkyl	B
methacrylate	I
copolymer	I
E.	I
Furthermore	O
,	O
the	O
present	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
for	O
oral	O
use	O
with	O
improved	O
absorption	O
,	O
which	O
comprises	O
a	O
biologically	O
active	O
peptide	O
and	O
aminoalkyl	B
methacrylate	I
copolymer	I
E.	I
Excellent	O
oral	O
absorption	O
of	O
a	O
biologically	O
active	O
peptide	O
that	O
were	O
considered	O
difficult	O
to	O
absorb	O
by	O
oral	O
administration	O
in	O
the	O
past	O
,	O
can	O
be	O
realized	O
based	O
on	O
the	O
ability	O
to	O
inhibit	O
decomposition	O
of	O
a	O
biologically	O
active	O
peptide	O
,	O
the	O
ability	O
to	O
reduce	O
viscosity	O
of	O
the	O
gastrointestinal	O
mucosa	O
and/or	O
mucous	O
layers	O
distributed	O
over	O
this	O
mucosa	O
,	O
and	O
the	O
ability	O
to	O
improve	O
permeability	O
of	O
a	O
biologically	O
active	O
peptide	O
in	O
the	O
gastrointestinal	O
mucosa	O
and/or	O
mucous	O
layers	O
of	O
the	O
pharmaceutical	O
composition	O
of	O
the	O
present	O
invention	O
.	O

Pharmaceutical	O
composition	O
for	O
oral	O
use	O
with	O
improved	O
absorption	O

Method	O
of	O
preventing	O
or	O
reducing	O
diarrhea	O
and	O
correcting	O
fat	O
malabsorption	O
(	O
steatorrhea	O
)	O
and	O
loss	O
of	O
body	O
mass	O
in	O
HIV	O
-	O
positive	O
patients	O
being	O
treated	O
with	O
High	O
Activity	O
Antiretroviral	O
drugs	O
(	O
HAART	O
)	O
containing	O
protease	O
inhibitors	O
,	O
nucleoside	O
reverse	O
transcriptase	O
inhibitors	O
or	O
non	O
-	O
nucleoside	O
reverse	O
transcriptase	O
inhibitors	O
and	O
by	O
co	O
-	O
administering	O
with	O
the	O
HAART	O
a	O
buffered	O
pancrelipase	O
composition	O
.	O

The	O
method	O
includes	O
the	O
steps	O
of	O
:	O
administering	O
to	O
the	O
HIV	O
-	O
positive	O
patient	O
a	O
High	O
Activity	O
Antiretroviral	O
drug	O
containing	O
a	O
protease	O
inhibitor	O
,	O
a	O
nucleoside	O
reverse	O
transcriptase	O
inhibitor	O
or	O
a	O
non	O
-	O
nucleoside	O
reverse	O
transcriptase	O
inhibitor	O
;	O
and	O
co	O
-	O
administering	O
with	O
the	O
HAART	O
drug	O
a	O
gastric	O
acid	O
-	O
resistant	O
polymer	O
-	O
coated	O
and	O
buffered	O
pancrelipase	O
enzyme	O
composition	O
containing	O
pancreatic	O
proteases	O
,	O
lipases	O
,	O
co	O
-	O
lipases	O
,	O
nucleases	O
,	O
amylases	O
and	O
other	O
bio	O
-	O
active	O
substances	O
produced	O
by	O
the	O
pancreatic	O
gland	O
.	O

Composition	O
and	O
method	O
to	O
prevent	O
or	O
reduce	O
diarrhea	O
and	O
steatorrhea	O
in	O
hiv	O
patients	O

Dimetalhydroxy	B
malate	I
compositions	O
as	O
well	O
as	O
methods	O
of	O
administering	O
and	O
making	O
such	O
bioavailable	O
compositions	O
are	O
provided	O
.	O

The	O
metal	O
used	O
can	O
be	O
any	O
nutritionally	O
relevant	O
divalent	O
metal	O
such	O
as	O
calcium	B
,	O
magnesium	B
,	O
zinc	B
,	O
copper	B
,	O
manganese	B
,	O
and	O
iron	B
.	O

The	O
composition	O
can	O
be	O
prepared	O
by	O
reacting	O
malic	B
acid	I
with	O
a	O
divalent	O
metal	O
oxide	B
or	O
hydroxide	B
at	O
a	O
1:2	O
molar	O
ratio	O
.	O

The	O
composition	O
can	O
be	O
administered	O
to	O
a	O
warm	O
-	O
blooded	O
animal	O
by	O
any	O
of	O
a	O
number	O
of	O
known	O
delivery	O
routes	O
,	O
including	O
oral	O
delivery	O
.	O

Dimetalhydroxy	B
malates	I

Carotenoids	B
are	O
provided	O
as	O
dietary	O
supplements	O
to	O
animal	O
feed	O
.	O

These	O
supplements	O
improve	O
the	O
bioavailability	O
of	O
carotenoids	O
by	O
providing	O
them	O
in	O
combination	O
with	O
phospholipids	B
.	O

The	O
invention	O
provides	O
animal	O
feeds	O
for	O
aquatic	O
and	O
terrestrial	O
animals	O
,	O
and	O
methods	O
for	O
making	O
the	O
feeds	O
.	O

Improved	O
absorption	O
of	O
fat	O
-	O
soluble	O
nutrients	O

It	O
is	O
intended	O
to	O
provide	O
medicinal	O
compositions	O
and	O
the	O
like	O
useful	O
in	O
treating	O
depression	O
which	O
contain	O
a	O
compound	O
having	O
an	O
antagonism	O
to	O
adenosine	B
A2A	O
receptor	O
(	O
for	O
example	O
,	O
(	B
E	I
)	I
-8-	I
(	I
3,4-dimethoxystyryl	I
)	I
-1,3-diethyl-7-methyl-3,7-dihydro-1H	I
-	I
purin-2,6-dione	I
)	O
or	O
a	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
together	O
with	O
an	O
antidepressant	O
(	O
for	O
example	O
,	O
a	O
tricyclic	O
antidepressant	O
,	O
a	O
tetracyclic	B
antidepressant	O
,	O
a	O
selective	O
serotonin	B
reuptake	O
inhibitor	O
,	O
a	O
selective	O
noradrenaline	B
reuptake	O
inhibitor	O
,	O
a	O
dopamine	B
reuptake	O
inhibitor	O
,	O
a	O
serotonin	B
/	O
noradrenaline	B
reuptake	O
inhibitor	O
,	O
a	O
monoamine	B
oxidase	O
inhibitor	O
or	O
a	O
serotonin	B
2	O
antagonist	O
)	O
.	O

Combinations	O
for	O
the	O
treatment	O
of	O
depression	O

The	O
present	O
invention	O
relates	O
to	O
a	O
composition	O
for	O
preventing	O
,	O
ameliorating	O
or	O
treating	O
a	O
bowel	O
disease	O
,	O
comprising	O
galactomannan	O
and/or	O
arabinogalactan	O
;	O
a	O
liquid	O
food	O
for	O
preventing	O
,	O
ameliorating	O
or	O
treating	O
a	O
bowel	O
disease	O
,	O
characterized	O
in	O
that	O
the	O
liquid	O
food	O
comprises	O
a	O
protein	O
and	O
galactomannan	O
and/or	O
arabinogalactan	B
;	O
and	O
a	O
composition	O
for	O
preventing	O
,	O
ameliorating	O
or	O
treating	O
an	O
irritable	O
bowel	O
syndrome	O
,	O
comprising	O
degraded	O
galactomannan	O
.	O

Compositions	O
of	O
galactomannan	O
for	O
the	O
treatment	O
of	O
bowel	O
diseases	O

This	O
application	O
describes	O
fluormated	O
(	O
+	O
)	O
PHNO	O
and	O
analogs	O
thereof	O
,	O
including	O
radiolabeled	O
analogs	O
,	O
of	O
Formula	O
(	O
I	O
)	O
,	O
wherein	O
R1	O
is	O
C1	B
-	I
6	I
alkyl	I
in	O
which	O
one	O
hydrogen	B
atom	O
on	O
the	O
alkyl	B
chain	O
is	O
replaced	O
with	O
fluoro	B
or	O
radioactive	O
fluoro	B
.	O

The	O
application	O
further	O
describes	O
compositions	O
comprising	O
these	O
compounds	O
and	O
methods	O
of	O
using	O
these	O
compounds	O
The	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
have	O
good	O
affinity	O
and	O
selectivity	O
for	O
the	O
dopamine	B
D2	O
receptors	O
and	O
are	O
therefore	O
useful	O
for	O
the	O
labelling	O
of	O
dopamine	B
D2	O
receptors	O
in	O
vivo	O
and	O
for	O
the	O
identification	O
and	O
quantification	O
of	O
the	O
extent	O
of	O
dopamine	B
supersensitivity	O
in	O
the	O
bram	O
in	O
various	O
stages	O
of	O
a	O
dopamine	B
-	O
related	O
disease	O
.	O

Fluorinated	O
phno	O
and	O
analogs	O
thereof	O

An	O
oral	O
care	O
composition	O
and	O
method	O
of	O
using	O
.	O
are	O
provided	O
for	O
treating	O
and	O
preventing	O
malodors	O
or	O
disease	O
conditions	O
of	O
the	O
oral	O
cavity	O
in	O
warm	O
-	O
blooded	O
animals	O
,	O
including	O
humans	O
.	O

When	O
applying	O
an	O
oral	O
care	O
effective	O
amount	O
of	O
the	O
oral	O
care	O
composition	O
of	O
the	O
present	O
invention	O
to	O
the	O
mucosal	O
tissue	O
of	O
the	O
oral	O
cavity	O
,	O
the	O
gingival	O
tissues	O
of	O
the	O
oral	O
cavity	O
,	O
and/or	O
surface	O
of	O
the	O
teeth	O
.	O

The	O
application	O
can	O
be	O
as	O
a	O
liquid	O
for	O
bathing	O
,	O
rinsing	O
or	O
gargling	O
,	O
or	O
lather	O
generated	O
by	O
brushing	O
the	O
teeth	O
for	O
a	O
sufficient	O
time	O
.	O

After	O
rinsing	O
,	O
gargling	O
or	O
brushing	O
,	O
the	O
composition	O
of	O
the	O
present	O
invention	O
should	O
be	O
swallowed	O
to	O
achieve	O
effective	O
reduction	O
of	O
various	O
organisms	O
,	O
diseases	O
and	O
malodors	O
.	O

An	O
oral	O
care	O
effective	O
amount	O
can	O
also	O
prevent	O
and	O
heal	O
mouth	O
sores	O
and	O
canker	O
sores	O
.	O

Oral	O
health	O
care	O
drink	O
and	O
method	O
for	O
reducing	O
malodors	O

The	O
invention	O
provides	O
cereal	O
plants	O
having	O
a	O
high	O
level	O
of	O
fructan	O
useful	O
for	O
the	O
production	O
of	O
a	O
range	O
of	O
food	O
,	O
beverage	O
,	O
nutraceutical	O
and	O
pharmaceutical	O
products	O
.	O

The	O
invention	O
provides	O
methods	O
of	O
producing	O
high	O
-	O
fructan	O
products	O
from	O
plants	O
modified	O
to	O
comprise	O
a	O
reduced	O
level	O
of	O
an	O
endogenous	O
polypeptide	O
with	O
starch	O
synthase	O
activity	O
,	O
and	O
products	O
so	O
produced	O
.	O

In	O
some	O
embodiments	O
,	O
plants	O
are	O
modified	O
by	O
introduction	O
of	O
an	O
agent	O
such	O
as	O
a	O
nucleic	O
acid	O
molecule	O
which	O
down	O
regulates	O
endogenous	O
starch	O
synthase	O
II	O
gene	O
expression	O
.	O

High	O
fructan	O
cereal	O
plants	O

An	O
adhesive	O
preparation	O
comprising	O
a	O
support	O
and	O
a	O
medicine	O
-	O
containing	O
layer	O
laminated	O
on	O
the	O
support	O
,	O
wherein	O
the	O
medicine	O
-	O
containing	O
layer	O
comprises	O
at	O
least	O
one	O
compound	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
fentanyl	O
and	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
and	O
an	O
adhesive	O
agent	O
comprising	O
polyisobutylene	B
and	O
a	O
silicon	B
-	O
containing	O
polymer	O
,	O
and	O
wherein	O
the	O
ratio	O
of	O
the	O
polyisobutylene	B
to	O
the	O
silicon	B
-	O
containing	O
polymer	O
in	O
the	O
adhesive	O
agent	O
is	O
20:1	O
to	O
7:3	O
by	O
mass	O
.	O

Adhesive	O
patch	O
containing	O
fentanyl	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O

This	O
invention	O
relates	O
to	O
compositions	O
and	O
methods	O
for	O
cancer	O
therapeutics	O
.	O

In	O
particular	O
,	O
the	O
present	O
invention	O
provides	O
compositions	O
and	O
methods	O
for	O
treating	O
tumors	O
by	O
inhibiting	O
the	O
activity	O
of	O
CPT1C	O
.	O

The	O
methods	O
and	O
compositions	O
can	O
additionally	O
include	O
inhibition	O
of	O
glycolysis	O
.	O

Induction	O
of	O
apoptosis	O
and	O
inhibition	O
of	O
cell	O
proliferation	O
through	O
modulation	O
of	O
carnitine	O
palmitoyltransferase	O
1c	O
activity	O

Provision	O
of	O
a	O
method	O
of	O
improving	O
preservation	O
stability	O
of	O
glutathione	B
in	O
a	O
solid	O
composition	O
containing	O
glutathione	B
and	O
arginine	B
,	O
or	O
a	O
solid	O
composition	O
containing	O
glutathione	B
and	O
arginine	B
,	O
which	O
shows	O
improved	O
preservation	O
stability	O
of	O
glutathione	B
.	O

In	O
the	O
production	O
of	O
a	O
solid	O
composition	O
containing	O
glutathione	B
and	O
arginine	B
,	O
glutathione	B
and	O
arginine	B
are	O
made	O
to	O
be	O
coexistent	O
with	O
an	O
organic	O
acid	O
.	O

Examples	O
of	O
the	O
organic	O
acid	O
include	O
citric	B
acid	I
,	O
tartaric	B
acid	I
,	O
ascorbic	B
acid	I
,	O
malic	B
acid	I
,	O
malonic	B
acid	I
,	O
succinic	B
acid	I
,	O
fumaric	B
acid	I
,	O
maleic	B
acid	I
and	O
the	O
like	O
.	O

The	O
amount	O
of	O
the	O
organic	O
acid	O
to	O
be	O
coexistent	O
with	O
glutathione	B
and	O
arginine	B
is	O
generally	O
0.1	O
-	O
2	O
parts	O
by	O
weight	O
relative	O
to	O
1	O
part	O
by	O
weight	O
of	O
arginine	B
.	O

Method	O
for	O
improving	O
storage	O
stability	O
of	O
glutathione	B

The	O
present	O
invention	O
provides	O
new	O
methods	O
of	O
treating	O
bowel	O
disease	O
(	O
BD	O
)	O
by	O
increasing	O
a	O
durability	O
of	O
response	O
;	O
treating	O
BD	O
in	O
males	O
;	O
treating	O
BD	O
in	O
adolescent	O
subjects	O
;	O
treating	O
bloating	O
due	O
to	O
BD	O
in	O
males	O
;	O
and	O
methods	O
of	O
maintaining	O
remission	O
of	O
BD	O
.	O

Methods	O
for	O
treating	O
bowel	O
diseases	O

The	O
present	O
invention	O
provides	O
a	O
dosage	O
form	O
comprising	O
at	O
least	O
one	O
form	O
of	O
tapentadol	B
,	O
with	O
or	O
without	O
a	O
second	O
analgesic	O
,	O
and	O
at	O
least	O
one	O
opioid	O
antagonist	O
,	O
wherein	O
tapentadol	B
is	O
present	O
in	O
an	O
optimal	O
or	O
suboptimal	O
amount	O
and	O
the	O
said	O
antagonist	O
is	O
present	O
in	O
an	O
amount	O
effective	O
to	O
improve	O
the	O
efficacy	O
and	O
or	O
reduce	O
the	O
side	O
effects	O
of	O
tapentadol	O
.	O

The	O
present	O
invention	O
further	O
provides	O
a	O
method	O
of	O
treating	O
pain	O
and	O
pain	O
related	O
conditions	O
by	O
administering	O
to	O
a	O
patient	O
in	O
need	O
thereof	O
,	O
a	O
dosage	O
form	O
comprising	O
at	O
least	O
one	O
form	O
of	O
tapentadol	B
,	O
with	O
or	O
without	O
a	O
second	O
analgesic	O
,	O
and	O
at	O
least	O
one	O
opioid	O
antagonist	O
,	O
wherein	O
tapentadol	B
is	O
present	O
in	O
an	O
optimal	O
or	O
suboptimal	O
amount	O
and	O
the	O
said	O
antagonist	O
is	O
present	O
in	O
an	O
amount	O
effective	O
to	O
improve	O
the	O
efficacy	O
and	O
or	O
reduce	O
the	O
side	O
effects	O
of	O
tapentadol	B
.	O

Novel	O
and	O
potent	O
tapentadol	B
dosage	O
forms	O

Compound	O
of	O
Formula	O
A	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
and	O
crystalline	O
Forms	O
I	O
and	O
ll	O
of	O
Compound	O
of	O
Formula	O
A.	O
(	O
see	O
formula	O
A	O
)	O
Also	O
,	O
methods	O
for	O
the	O
preparation	O
of	O
such	O
compounds	O
,	O
pharmaceutical	O
compositions	O
comprising	O
such	O
compounds	O
,	O
and	O
methods	O
for	O
their	O
uses	O
.	O

Compound	O
,	O
certain	O
novel	O
forms	O
thereof	O
,	O
pharmaceutical	O
compositions	O
thereof	O
and	O
methods	O
for	O
preparation	O
and	O
use	O

The	O
invention	O
relates	O
to	O
genetic	O
products	O
the	O
expression	O
of	O
which	O
is	O
associated	O
with	O
cancer	O
diseases	O
.	O

The	O
invention	O
also	O
relates	O
to	O
the	O
therapy	O
and	O
diagnosis	O
of	O
diseases	O
in	O
which	O
the	O
genetic	O
products	O
are	O
expressed	O
or	O
aberrantly	O
expressed	O
,	O
in	O
particular	O
cancer	O
diseases	O
.	O

Identification	O
of	O
tumor	O
-	O
associated	O
antigens	O
for	O
diagnosis	O
and	O
therapy	O

An	O
antibacterial	O
composition	O
is	O
provided	O
including	O
a	O
combination	O
of	O
a	O
	B
-	I
lactam	I
antibiotic	O
that	O
has	O
a	O
binding	O
affinity	O
for	O
bacterial	O
penicillin	B
-	O
binding	O
protein	O
2	O
;	O
and	O
a	O
non	O
-	O
antibiotic	O
compound	O
which	O
may	O
be	O
a	O
thienopyridine	B
or	O
a	O
non	O
-	O
thienopyridine	B
compound	O
.	O

A	O
method	O
of	O
treatment	O
using	O
the	O
composition	O
is	O
also	O
provided	O
.	O

Novel	O
antibacterial	O
combination	O
therapy	O

Compositions	O
and	O
methods	O
for	O
the	O
treatment	O
of	O
HIV	O
are	O
provided	O
.	O

Compositions	O
and	O
methods	O
for	O
the	O
treatment	O
of	O
hiv	O

This	O
invention	O
discloses	O
a	O
method	O
for	O
preparing	O
compounds	O
shown	O
in	O
formula	O
I	O
,	O
and	O
their	O
pharmaceutically	O
acceptable	O
salts	O
.	O

Method	O
for	O
producing	O
antifungal	O
drug	O
in	O
triazole	B
class	O

According	O
to	O
the	O
invention	O
,	O
there	O
is	O
provided	O
a	O
phosphate	B
derivative	O
of	O
a	O
compound	O
having	O
a	O
secondary	B
hydroxy	I
group	O
.	O

The	O
compound	O
having	O
a	O
secondary	B
hydroxyl	I
group	O
may	O
,	O
for	O
example	O
,	O
be	O
chosen	O
from	O
pravastatin	B
,	O
atorvastatin	B
venlafaxine	B
,	O
their	O
derivatives	O
and	O
mixtures	O
thereof	O
.	O

Phosphates	B
of	O
secondary	B
alcohols	I

This	O
invention	O
concerns	O
the	O
method	O
of	O
extracting	O
salvianolic	B
acid	I
A	I
from	O
Chinese	O
crude	O
drug	O
:	O
danshen	O
root	O
,	O
and	O
the	O
quality	O
control	O
methods	O
and	O
drug	O
combinations	O
,	O
and	O
the	O
application	O
of	O
this	O
drug	O
.	O

It	O
can	O
be	O
used	O
in	O
the	O
preparation	O
of	O
the	O
prevention	O
drugs	O
for	O
cardiovascular	O
disease	O
,	O
liver	O
damage	O
,	O
liver	O
fibrosis	O
,	O
pulmonary	O
fibrosis	O
and	O
other	O
.	O

Salvia	O
minium	O
phenolic	B
acid	I
A	O
and	O
process	O
of	O
preparing	O
preparation	O
and	O
use	O

The	O
invention	O
discloses	O
a	O
medicament	O
for	O
treating	O
hyperplasia	O
and	O
method	O
for	O
preparation	O
,	O
wherein	O
the	O
powdery	O
form	O
medicament	O
is	O
prepared	O
from	O
batryticated	O
silkworm	O
,	O
dahurian	O
angelica	O
root	O
,	O
buthus	O
martensi	O
karsch	O
,	O
centipede	O
,	O
pangolin	O
scales	O
,	O
vomiting	O
nut	O
and	O
musk	O
,	O
and	O
the	O
ointment	O
form	O
medicament	O
is	O
prepared	O
from	O
cibot	O
rhizome	O
,	O
eucommia	O
bark	O
,	O
spatholobus	O
stem	O
,	O
safflower	O
,	O
peach	O
kernels	O
,	O
ledebouriella	O
root	O
,	O
earthworm	O
,	O
agkistrodon	O
acutus	O
,	O
siberian	O
cocklebur	O
fruit	O
,	O
Chinese	O
starjasmine	O
,	O
homalomena	O
rhizoma	O
,	O
frankincense	O
,	O
myrrh	O
,	O
dragon	O
's	O
blood	O
resin	O
and	O
boneol	O
.	O

Powder	O
and	O
salve	O
for	O
hyperplasia	O
protrusion	O
rehabilitation	O
and	O
its	O
preparation	O
method	O

The	O
invention	O
relates	O
to	O
the	O
organic	O
amine	B
salt	O
or	O
hydrate	B
for	O
ceph	B
compound	O
used	O
for	O
treating	O
bacteria	O
infection	O
,	O
and	O
the	O
chemical	O
formula	O
is	O
demonstrated	O
in	O
(	O
I	O
)	O
.Said	O
organic	O
amine	B
can	O
be	O
lycine	B
,	O
arginine	B
,	O
tert	B
-	I
butylamine	I
,	O
diethanolamine	B
,	O
triethanolamine	B
,	O
diethylamine	B
or	O
meglumine	B
.	O

It	O
comprises	O
cefuroxime	B
organic	O
amine	B
salt	O
,	O
ceftriaxone	B
organic	O
amine	B
salt	O
,	O
ceftezole	B
organic	O
amine	B
salt	O
,	O
cefoperazone	B
organic	O
amine	B
salt	O
,	O
cephalothin	B
organic	O
amine	B
salt	O
,	O
cefotaxime	B
organic	O
amine	B
salt	O
,	O
cefradine	B
organic	O
amine	B
salt	O
,	O
cefonicid	B
organic	O
amine	B
salt	O
,	O
cefmetazole	B
organic	O
amine	B
salt	O
,	O
cefodizime	B
organic	O
amine	B
salt	O
,	O
cefmenoxime	B
organic	O
amine	B
salt	O
,	O
ceftizoxime	B
organic	O
amine	B
salt	O
,	O
cefpiramide	B
organic	O
amine	B
salt	O
,	O
cefazolin	B
organic	O
amine	B
salt	O
,	O
cefoxitinorganic	B
amine	B
salt	O
and	O
flomoxef	B
organic	O
amine	B
salr	O
.	O

The	O
invention	O
provides	O
the	O
medical	O
compound	O
taking	O
compound	O
in	O
formula	O
(	O
I	O
)	O
as	O
active	O
element	O
and	O
its	O
application	O
to	O
preparation	O
of	O
medicine	O
for	O
treating	O
bacteria	O
infection	O
.	O

Organic	O
amine	B
salt	O
of	O
cephalosporin	B
compound	O
and	O
its	O
preparation	O
method	O

The	O
invention	O
disclose	O
the	O
arginine	B
salt	O
of	O
1	B
,	I
6-	I
diphosphoric	I
acid-	I
D-	I
fructose	I
esters	I
in	O
hydrate	O
type	O
,	O
and	O
one	O
or	O
more	O
than	O
one	O
of	O
the	O
four	O
function	O
groups	O
is	O
salinized	O
by	O
arginine	B
.	O

The	O
salt	O
precipitation	O
with	O
1	B
,	I
6-	I
diphosphoric	I
acid-	I
D-	I
fructose	I
esters	I
and	O
arginine	B
solves	O
problems	O
of	O
strong	O
side	O
effect	O
of	O
sodium	B
fructose	I
diphosphate	I
,	O
and	O
starting	O
circuit	O
,	O
high	O
natremia	O
risk	O
.	O

It	O
is	O
demonstrated	O
through	O
pharmacological	O
test	O
that	O
arginine	B
salt	O
can	O
cooperate	O
with	O
drug	O
and	O
the	O
toxcity	O
is	O
low	O
.	O

1,6-diphospho	B
-	I
D	I
-	I
fructose	I
ester	I
arginine	I
salt	O
and	O
its	O
pharmaceutical	O
uses	O

The	O
invention	O
discloses	O
slow	O
release	O
tablets	O
of	O
Amoxicillin	B
and	O
process	O
for	O
preparation	O
,	O
wherein	O
the	O
raw	O
materials	O
of	O
the	O
preparation	O
include	O
Amoxicillin	B
of	O
a	O
predetermined	O
proportion	O
,	O
slow	O
release	O
matrix	O
material	O
and	O
medicinal	O
material	O
,	O
the	O
preparation	O
can	O
be	O
prepared	O
into	O
solid	O
dispersing	O
agent	O
,	O
wherein	O
the	O
medicament	O
can	O
be	O
released	O
slowly	O
and	O
continuously	O
after	O
being	O
administrated	O
,	O
the	O
effective	O
concentration	O
in	O
blood	O
can	O
be	O
maintained	O
,	O
and	O
long	O
action	O
can	O
be	O
achieved	O
.	O

The	O
advantages	O
of	O
the	O
invention	O
include	O
decreased	O
frequency	O
of	O
medicinal	O
administration	O
,	O
improved	O
patient	O
's	O
adaptability	O
,	O
lowered	O
blood	O
concentration	O
peak	O
-	O
valley	O
,	O
increased	O
medicinal	O
effect	O
and	O
safety	O
,	O
and	O
reduced	O
total	O
medicinal	O
dose	O
,	O
thereby	O
optimum	O
curative	O
effect	O
can	O
be	O
achieved	O
through	O
minimum	O
dose	O
,	O
thus	O
the	O
preparation	O
is	O
more	O
suitable	O
for	O
patients	O
.	O

Slow	O
release	O
tablet	O
of	O
amoxicillin	B

The	O
invention	O
discloses	O
a	O
making	O
method	O
of	O
RTN4BSR32	O
and	O
application	O
to	O
prepare	O
tumour	O
-	O
proof	O
drug	O
,	O
whose	O
sequence	O
contains	O
5'-AATGTCTCTCCAGTACAGG-3	O
'	O
or	O
5'-AAUGUCUCUCCAGUACAGG-3	O
'	O
.	O

The	O
molecular	O
can	O
inhibit	O
tumour	O
from	O
growing	O
obviously	O
,	O
which	O
provides	O
a	O
new	O
path	O
and	O
method	O
to	O
treat	O
and	O
release	O
tumour	O
.	O

Nucleic	O
acid	O
molecule	O
RTN4BSR62	O
and	O
application	O
in	O
preparation	O
of	O
anti	O
-	O
cancer	O
drugs	O

The	O
present	O
invention	O
relates	O
to	O
the	O
application	O
of	O
ferric	O
citrate	B
in	O
preparing	O
medicine	O
for	O
preventing	O
and	O
treating	O
calcification	O
of	O
blood	O
vessel	O
.	O

The	O
present	O
invention	O
has	O
determined	O
curative	O
effect	O
.	O

Experiment	O
proves	O
that	O
ferric	B
citrate	I
can	O
intervene	O
calcification	O
of	O
blood	O
vessel	O
and	O
inhibit	O
calcification	O
effectively	O
,	O
and	O
may	O
reverse	O
calcification	O
of	O
blood	O
vessel	O
.	O

Application	O
of	O
ferricitras	O
in	O
preparation	O
of	O
medicine	O
to	O
prevent	O
and	O
treat	O
angiosteosis	O

The	O
present	O
invention	O
is	O
serial	O
hydrophilic	O
polyglycol	B
supported	O
ursolic	B
acid	I
medicines	O
obtained	O
through	O
organic	O
synthesis	O
and	O
polymerization	O
to	O
grafting	O
hydrophilic	O
polyglycol	B
onto	O
cyclohydroxy	B
group	O
of	O
ursolic	B
acid	I
A.	O
The	O
structure	O
analysis	O
and	O
experiments	O
show	O
that	O
activated	O
polyglycol	B
is	O
grafted	O
successfully	O
onto	O
ursolic	B
acid	I
said	O
water	O
insoluble	O
ursolic	B
acid	I
becomes	O
water	O
soluble	O
polyglycol	B
-	I
ursolic	I
acid	I
.	O

Polyglycol	B
-	I
ursolic	I
acid	I
has	O
excellent	O
blood	O
compatibility	O
and	O
high	O
physiological	O
activity	O
,	O
so	O
that	O
polyglycol	B
supported	O
ursolic	B
acid	I
medicines	O
may	O
be	O
prepared	O
into	O
different	O
forms	O
,	O
including	O
injection	O
,	O
oral	O
liquid	O
,	O
capsule	O
,	O
tablet	O
,	O
etc	O
.	O

The	O
polyglycol	B
has	O
average	O
molecular	O
weight	O
of	O
200	O
-	O
60,000	O
.	O

Hydrophilic	O
polyglycol	B
supported	O
ursolic	B
acid	I
medicines	O
and	O
their	O
prepn	O
process	O

The	O
present	O
invention	O
discloses	O
ruthenium	B
porphyrin	I
complex	O
and	O
its	O
preparation	O
process	O
and	O
application	O
as	O
photosensitizer	O
for	O
photodynamic	O
therapy	O
.	O

The	O
ruthenium	B
porphyrin	I
complex	O
with	O
the	O
structure	O
as	O
shown	O
has	O
ruthenium	B
as	O
the	O
central	O
metal	O
ion	O
,	O
pyridyl	B
radical	O
containing	O
asymmetrical	O
porphyrin	B
and	O
its	O
metal	O
derivative	O
as	O
the	O
ligand	O
,	O
and	O
coordinate	O
bond	O
jointing	O
the	O
ruthenium	B
pyridyl	I
radical	O
and	O
the	O
porphyrin	B
ring	O
.	O

The	O
ruthenium	B
porphyrin	I
complex	O
of	O
the	O
present	O
invention	O
has	O
determined	O
composition	O
,	O
less	O
toxic	O
side	O
effect	O
and	O
good	O
absorption	O
and	O
metabolism	O
in	O
organism	O
,	O
and	O
is	O
suitable	O
for	O
use	O
as	O
photosensitizer	O
for	O
photodynamic	O
therapy	O
.	O

Ruthenium	B
porphyrin	I
complex	O
and	O
its	O
prepn	O
process	O
and	O
application	O
as	O
photosensitizer	O
for	O
photodynamic	O
therapy	O

The	O
present	O
invention	O
discloses	O
an	O
application	O
of	O
dihydromyricetin	B
in	O
preparation	O
of	O
medicine	O
for	O
preventing	O
or	O
curing	O
angiocardiopathy	O
.	O

The	O
animal	O
tests	O
show	O
that	O
the	O
dihydromyricetin	B
has	O
the	O
effect	O
for	O
resisting	O
internal	O
phlebothrombosis	O
,	O
can	O
be	O
used	O
for	O
effectively	O
preventing	O
angiocardiopathy	O
due	O
to	O
thrombosis	O
,	O
for	O
example	O
cardiac	O
disease	O
and	O
apoplexy	O
.	O

Said	O
invention	O
can	O
be	O
made	O
into	O
medicine	O
or	O
health	O
-	O
care	O
product	O
.	O

Use	O
of	O
dihydro	B
myricotin	I
element	O
for	O
treating	O
cardiac	O
blood	O
diseases	O

The	O
invention	O
relates	O
to	O
a	O
new	O
dihydrochalcone	B
compound	O
that	O
is	O
separated	O
and	O
purified	O
from	O
Long	O
Xuejie	O
and	O
the	O
manufacture	O
method	O
.	O

It	O
adopts	O
Long	O
Xuejie	O
as	O
raw	O
material	O
,	O
uses	O
light	O
petroleum	O
and	O
chloroform	B
solvent	O
to	O
distill	O
,	O
decreases	O
pressure	O
and	O
concentrating	O
chloroform	B
extractive	O
,	O
takes	O
silica	O
gel	O
column	O
or	O
rapid	O
silica	O
gel	O
chromatography	O
and	O
takes	O
Sephadex	O
LH-20	O
gelcolumn	O
chromatography	O
andseparating	O
,	O
purifies	O
chromatogram	O
,	O
and	O
finally	O
gains	O
dihydrochalcone	B
compound	O
.	O

The	O
chemical	O
name	O
is	O
4'-	B
hydroxyl-2	I
'	I
,	I
4-	I
dimethoxy-	I
dihydrochalcone	I
.	O

The	O
compound	O
has	O
good	O
effect	O
to	O
avoid	O
platelet	O
aggregation	O
.	O

Novel	O
dihydrochalcone	B
compound	O
separated	O
and	O
purified	O
from	O
drgon	O
blood	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
drug	O
compound	O
for	O
treating	O
disease	O
of	O
lower	O
urinary	O
tract	O
,	O
which	O
comprises	O
drug	O
active	O
component	O
,	O
drug	O
carrier	O
or	O
shaping	O
agent	O
,	O
wherein	O
the	O
drug	O
active	O
component	O
is	O
terraazoles	B
and	O
amiloripin	B
.	O

The	O
disease	O
of	O
lower	O
urinary	O
tract	O
relates	O
to	O
prostatitis	O
increment	O
,	O
lower	O
urinary	O
tract	O
syndrome	O
and	O
bladder	O
excessive	O
activities	O
,	O
in	O
particular	O
to	O
treat	O
lower	O
urinary	O
tract	O
syndrome	O
and	O
bladder	O
excessive	O
activities	O
induced	O
by	O
prostatitis	O
increment	O
.	O

And	O
the	O
inventive	O
drug	O
can	O
be	O
used	O
treat	O
the	O
high	O
blood	O
pressure	O
concomitant	O
with	O
lower	O
urinary	O
tract	O
,	O
to	O
effectively	O
control	O
blood	O
pressure	O
and	O
resolve	O
the	O
lower	O
urinary	O
tract	O
disease	O
,	O
compared	O
with	O
single	O
terraazoles	B
or	O
amiloripin	B
drug	O
,	O
to	O
improve	O
the	O
health	O
quality	O
of	O
patient	O
.	O

Pharmaceutical	O
composition	O
for	O
treatment	O
of	O
lower	O
urinary	O
tract	O
diseases	O

The	O
invention	O
discloses	O
a	O
method	O
for	O
preparing	O
nanometer	O
monomer	O
selenium	B
via	O
coupling	O
liquid	O
amino	B
acid	I
,	O
comprising	O
that	O
at	O
normal	O
temperature	O
and	O
normal	O
pressure	O
,	O
adding	O
vitamin	B
C	I
solution	O
into	O
amino	B
acid	I
solution	O
,	O
mixing	O
uniformly	O
and	O
adding	O
selenious	B
anhydride	I
or	O
selenite	B
solution	O
until	O
the	O
product	O
has	O
held	O
red	O
,	O
to	O
obtain	O
the	O
liquid	O
coupled	O
product	O
of	O
amino	B
acid	I
and	O
nanometer	O
selenium	B
.	O

The	O
nanometer	O
monomer	O
selenium	B
can	O
be	O
used	O
as	O
medical	O
health	O
-	O
care	O
product	O
to	O
display	O
the	O
cooperation	O
between	O
amino	B
acid	I
and	O
nanometer	O
selenium	B
,	O
while	O
the	O
nanometer	O
selenium	B
gel	O
has	O
small	O
diameter	O
,	O
narrow	O
distribution	O
and	O
liquid	O
storage	O
,	O
to	O
develop	O
oral	O
,	O
injection	O
or	O
the	O
like	O
.	O

Nanometer	O
elemental	O
selenium	B
coupled	O
with	O
liquid	O
amino	B
acid	I
and	O
the	O
method	O
for	O
preparing	O
and	O
preserving	O
the	O
same	O

The	O
invention	O
relates	O
to	O
an	O
anti	O
-	O
cancer	O
compound	O
as	O
a	O
slow	O
release	O
injection	O
which	O
contains	O
vessel	O
restrainer	O
and/or	O
alkyl	B
agent	O
,	O
formed	O
by	O
slow	O
release	O
micro	O
ball	O
and	O
solvent	O
.	O

The	O
slow	O
release	O
micro	O
ball	O
comprises	O
the	O
anti	O
-	O
cancer	O
effective	O
components	O
and	O
slow	O
release	O
findings	O
,	O
the	O
solvent	O
is	O
a	O
common	O
solvent	O
or	O
a	O
special	O
solvent	O
with	O
suspending	O
agent	O
,	O
while	O
the	O
viscosity	O
of	O
suspending	O
agent	O
is	O
100cp-3000cp	O
(	O
at	O
20	O
-	O
30Deg	O
.	O

C	O
)	O
,	O
selected	O
from	O
carboxymethyl	O
cellulose	O
,	O
the	O
anti	O
-	O
cancer	O
effective	O
component	O
is	O
the	O
combination	O
of	O
vessel	O
restrainer	O
and/or	O
the	O
alkyl	B
agent	O
selected	O
from	O
nimuxitin	O
,	O
or	O
the	O
like	O
,	O
the	O
slow	O
release	O
finding	O
is	O
selected	O
from	O
phosphate	B
polyester	I
as	O
p	B
(	I
LAEG	I
-	I
EOP	I
)	I
,	O
p	B
(	I
DAPG	I
-	I
EOP	I
)	I
,	O
or	O
the	O
polyester	B
or	O
mixture	O
of	O
phosphate	B
and	O
polylactic	B
acid	I
,	O
polyphenyl	B
,	O
2-aliphatic	B
acid	I
,	O
sebacic	B
acid	I
polyester	I
,	O
poly	B
(	I
erucic	I
acid	I
dimmer	I
-	I
sebacic	I
acid	I
)	I
or	O
poly	B
(	I
fumaric	I
acid	I
-	I
sebacic	I
acid	I
)	I
.	O

The	O
anti	O
-	O
cancer	O
compound	O
can	O
be	O
made	O
as	O
slow	O
release	O
plant	O
agent	O
,	O
to	O
inject	O
into	O
cancer	O
or	O
around	O
cancer	O
to	O
hold	O
the	O
effective	O
drug	O
density	O
for	O
more	O
than	O
40	O
days	O
,	O
while	O
it	O
can	O
significantly	O
reduce	O
the	O
general	O
reaction	O
of	O
drug	O
and	O
selectively	O
strengthen	O
the	O
effect	O
of	O
non	O
-	O
surgery	O
treatments	O
as	O
chemotherapy	O
or	O
the	O
like	O
.	O

Anticancer	O
compound	O
including	O
neoangiogenesis	O
inhibitors	O
and	O
alkylate	O
agent	O

A	O
medicinal	O
composition	O
is	O
prepared	O
from	O
gentamycin	B
,	O
amitriptyline	B
,	O
honey	O
,	O
and	O
11	O
Chinese	O
-	O
medicinal	O
materials	O
including	O
notoginseng	O
,	O
peach	O
kernel	O
,	O
fennel	O
,	O
borax	B
,	O
etc	O
.	O

Its	O
preparing	O
process	O
is	O
also	O
disclosed	O
.	O

Medicine	O
composition	O
and	O
its	O
preparing	O
method	O

An	O
improved	O
method	O
for	O
preparing	O
dimethylamino	B
-	I
methyl	I
-	I
carbazolone	I
and	O
ondansetron	B
base	O
.	O

A	O
recrystallization	O
process	O
for	O
preparing	O
pure	O
ondansetron	B
hydrochloride	I
dihydrate	I
with	O
a	O
purity	O
of	O
at	O
least	O
99.0	O
%	O
is	O
also	O
disclosed	O
.	O

An	O
improved	O
process	O
for	O
preparing	O
pure	O
ondansetron	B
hydrochloride	I
dihydrate	I

A	O
dripping	O
pill	O
of	O
anethol	B
trithione	I
for	O
treating	O
cholecystitis	O
,	O
cholelithiasis	O
and	O
acute	O
or	O
chronic	O
hepatitis	O
is	O
prepared	O
from	O
the	O
anethol	B
trithione	I
and	O
the	O
matrix	O
of	O
dripping	O
pill	O
.	O

Its	O
preparing	O
process	O
is	O
also	O
disclosed	O
.	O

Anethol	B
trithione	I
drop	O
pills	O
,	O
and	O
preparation	O
method	O

Disclosed	O
is	O
a	O
suppository	O
for	O
processing	O
wounds	O
in	O
the	O
treatment	O
of	O
uterine	O
neck	O
erosion	O
,	O
which	O
comprises	O
biologically	O
active	O
glass	O
,	O
collagen	O
and	O
activated	O
charcoal	O
fiber	O
by	O
a	O
weight	O
ratio	O
of	O
30	O
-	O
70:70	O
-	O
30	O
.	O

The	O
preparing	O
process	O
comprises	O
steps	O
of	O
coating	O
the	O
activated	O
charcoal	O
fiber	O
into	O
a	O
circular	O
form	O
,	O
crosslinking	O
the	O
collagen	O
solution	O
or	O
dried	O
powder	O
,	O
proportioning	O
collagen	O
and	O
biologically	O
active	O
glass	O
,	O
dissolving	O
and	O
stirring	O
20	O
-	O
50	O
minutes	O
,	O
freeze	O
drying	O
,	O
pressurizing	O
to	O
obtain	O
composite	O
film	O
,	O
adhering	O
the	O
composite	O
film	O
with	O
one	O
end	O
of	O
the	O
activated	O
charcoal	O
fiber	O
suppository	O
,	O
and	O
fixing	O
the	O
other	O
end	O
of	O
the	O
activated	O
charcoal	O
fiber	O
suppository	O
with	O
soft	O
wires	O
.	O

The	O
collagen	O
can	O
be	O
replaced	O
with	O
chitosan	O
.	O

Suppository	O
for	O
treating	O
wound	O
caused	O
by	O
cervical	O
erosion	O
treatment	O

The	O
invention	O
discloses	O
a	O
medicinal	O
component	O
of	O
substitute	O
nipa	O
glycosides	B
,	O
which	O
is	O
characterized	O
by	O
the	O
following	O
:	O
incorporating	O
substitute	O
nipa	O
glycosides	B
,	O
Tuwen	O
surface	O
activator	O
,	O
assisting	O
solvent	O
and	O
inorganic	O
salt	O
;	O
choosing	O
the	O
assisting	O
solvent	O
as	O
mixture	O
of	O
dimethyl	B
ethanolamine	I
and	O
carbowax	O
;	O
choosing	O
the	O
inorganic	O
salt	O
from	O
one	O
or	O
multiple	O
common	O
salt	B
,	O
potassium	B
chloride	I
,	O
sulphate	B
and	O
sulphate	B
;	O
setting	O
this	O
component	O
as	O
injection	O
or	O
freeze	O
dry	O
powder	O
needle	O
;	O
adding	O
into	O
Tuwen	O
and	O
the	O
assisting	O
dissolvent	O
;	O
adding	O
into	O
the	O
inorganic	O
salt	O
at	O
the	O
same	O
time	O
;	O
increasing	O
solubility	O
of	O
substitute	O
nipa	O
glycosides	B
.	O

This	O
invention	O
also	O
relates	O
to	O
the	O
preparing	O
method	O
and	O
usage	O
of	O
this	O
medicinal	O
component	O
.	O

Medical	O
combination	O
of	O
teniposide	B
,	O
the	O
preparing	O
method	O
and	O
the	O
function	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
novel	O
medicament	O
for	O
drug	O
abstinence	O
which	O
comprises	O
the	O
following	O
constituents	O
(	O
by	O
weight	O
ratio	O
)	O
:	O
acanthopanax	O
root	O
18	O
-	O
30	O
%	O
,	O
polygala	O
root	O
6	O
-	O
12	O
%	O
,	O
dendrobium	O
9	O
-	O
16	O
%	O
,	O
notoginseng	O
3	O
-	O
10	O
%	O
,	O
ginseng	O
10	O
-	O
24	O
%	O
,	O
ginkgo	O
leaves	O
24	O
-	O
34	O
%	O
,	O
atropine	B
sulfate	I
0	O
.	O

05	O
-	O
1	O
.	O
5	O
%	O
,	O
ansiolin	B
0	O
.	O
05	O
-	O
1	O
.	O
0	O
%	O
.	O

The	O
medicament	O
can	O
be	O
prepared	O
into	O
capsules	O
,	O
granules	O
and	O
tablets	O
through	O
conventional	O
processes	O
.	O

Novel	O
medicine	O
for	O
giving	O
up	O
drug	O

The	O
invention	O
is	O
concerned	O
with	O
the	O
method	O
to	O
produce	O
supply	O
of	O
iron	O
using	O
the	O
algin	O
and	O
compound	O
of	O
iron	B
.	O

Put	O
the	O
water	O
solution	O
or	O
degeneration	O
fluid	O
of	O
algin	O
into	O
a	O
container	O
,	O
add	O
assistant	O
stabilizer	O
and	O
inorganic	O
iron	B
salt	O
,	O
and	O
the	O
concentration	O
is	O
0.1	O
to	O
0.50	O
mol	O
/	O
L	O
,	O
adjust	O
the	O
pH	O
of	O
solution	O
is	O
4	O
to	O
8	O
,	O
refluence	O
for	O
2	O
to	O
5	O
hours	O
,	O
dialyse	O
,	O
concentrate	O
,	O
divide	O
with	O
alcohol	O
and	O
taking	O
centrifugal	O
processing	O
.	O

Wash	O
and	O
dry	O
the	O
sedimentation	O
to	O
get	O
algin	O
Fe	O
(	O
III	O
)	O
compound	O
.	O

The	O
method	O
has	O
reasonable	O
prcess	O
and	O
low	O
cost	O
,	O
the	O
produced	O
supply	O
of	O
iron	B
has	O
nice	O
stability	O
with	O
high	O
biology	O
utilization	O
ratio	O
,	O
the	O
revivification	O
and	O
dissolving	O
time	O
is	O
fit	O
to	O
absorb	O
for	O
body	O
.	O

The	O
algin	O
forms	O
into	O
gel	O
with	O
stomach	O
acid	O
and	O
protecting	O
film	O
on	O
the	O
surface	O
of	O
stomach	O
in	O
order	O
to	O
reduce	O
the	O
stimulating	O
to	O
stomach	O
.	O

It	O
is	O
fit	O
for	O
pregnant	O
woman	O
,	O
children	O
and	O
gastricism	O
sufferer	O
.	O

Method	O
for	O
preparing	O
iron	B
-	O
complementing	O
agent	O
by	O
complex	O
of	O
parafobrown	O
algin	O
and	O
iron	O

The	O
present	O
invention	O
provides	O
new	O
use	O
of	O
arctiin	B
,	O
and	O
is	O
especially	O
the	O
application	O
of	O
arctiin	B
in	O
preparing	O
medicine	O
for	O
preventing	O
and	O
treating	O
chronic	O
renal	O
failure	O
and	O
renal	O
fiberosis	O
.	O

Novel	O
use	O
of	O
medicine	O

The	O
improvement	O
in	O
the	O
process	O
of	O
preparing	O
Raltitrexed	B
as	O
antitumor	O
medicine	O
includes	O
the	O
reaction	O
between	O
N-	B
(	I
5-aminothienyl-2-formoxyl	I
)	I
-L	I
-	I
diethyl	I
glutarate	I
and	O
methyl	B
iodide	I
at	O
temperature	O
raised	O
to	O
100	O
deg.c	O
in	O
lucifugous	O
condition	O
with	O
yield	O
raised	O
to	O
91	O
%	O
;	O
the	O
replacement	O
of	O
sodium	B
sulfide	I
for	O
iron	B
powder	O
as	O
reductant	O
to	O
facilitate	O
post	O
-	O
treatment	O
and	O
raise	O
yield	O
;	O
the	O
replacement	O
of	O
re	O
-	O
crystallization	O
in	O
mixed	O
solvent	O
of	O
methanol	B
and	O
ether	O
for	O
column	O
separation	O
to	O
expand	O
the	O
production	O
capacity	O
;	O
and	O
oxidizing	O
5-nitrothienyl-2-formaldehyde	B
with	O
chromic	B
acid	I
,	O
rather	O
than	O
bromine	B
,	O
to	O
eliminate	O
toxicity	O
and	O
raise	O
safety	O
.	O

The	O
improved	O
preparation	O
process	O
of	O
Raltitrexed	B
has	O
high	O
yield	O
,	O
great	O
production	O
capacity	O
,	O
low	O
solvent	O
consumption	O
and	O
high	O
safety	O
.	O

Improved	O
process	O
of	O
preparing	O
Raltitrexed	B

The	O
invention	O
relates	O
to	O
a	O
kind	O
of	O
medicine	O
and	O
its	O
production	O
method	O
,	O
especially	O
relates	O
to	O
a	O
kind	O
of	O
rehabilitation	O
liquid	O
and	O
the	O
production	O
method	O
.	O

It	O
is	O
specialized	O
for	O
fiber	O
lung	O
treatment	O
.	O

The	O
anti	O
-	O
inflammation	O
effect	O
of	O
potato	O
is	O
strong	O
,	O
and	O
the	O
disinfection	O
effect	O
of	O
chromargyre	O
is	O
good	O
,	O
the	O
invention	O
combines	O
the	O
anti	O
-	O
inflammation	O
and	O
disinfection	O
effect	O
together	O
,	O
and	O
dissolves	O
them	O
in	O
spirit	O
to	O
treat	O
lung	O
disease	O
;	O
the	O
rehabilitation	O
liquid	O
can	O
be	O
discharged	O
through	O
manure	O
and	O
urine	O
,	O
so	O
it	O
can	O
disinfect	O
and	O
eliminate	O
inflammation	O
when	O
passing	O
through	O
other	O
organs	O
with	O
disease	O
.	O

The	O
production	O
method	O
comprises	O
two	O
technique	O
programs	O
:	O
one	O
is	O
immersion	O
and	O
another	O
is	O
blending	O
.	O

Potato	O
red	O
healing	O
liquid	O
and	O
method	O
for	O
preparing	O
the	O
same	O

The	O
invention	O
discloses	O
a	O
ruthenium	B
-	I
anthraquinone	I
conjugate	O
,	O
the	O
preparation	O
process	O
thereof	O
and	O
the	O
application	O
as	O
a	O
photo	O
-	O
dynamic	O
therapy	O
photosensitizer	O
.	O

The	O
general	O
formula	O
of	O
the	O
ruthenium	B
-	I
anthraquinone	I
conjugate	O
of	O
the	O
invention	O
is	O
[	B
Ru	I
(	I
L	I
)	I
2HAIP	I
]	I
.	I
(	I
PF6	I
)	I
2	I
,	O
the	O
general	O
formula	O
of	O
the	O
HAIP	B
is	O
1,8-	B
dihydroxy	I
-9,10-	I
anthraquinoneimidazole	I
[	I
4,5-f	I
]	I
[	I
1,10	I
]	I
phenanthroline	I
,	O
the	O
general	O
of	O
the	O
L	O
is	O
bpy	B
or	O
phen	B
.	O

The	O
preparation	O
process	O
for	O
the	O
ruthenium	B
-	I
anthraquinone	I
conjugate	O
comprises	O
the	O
following	O
procedures	O
:	O
1	O
.	O
the	O
synthesis	O
of	O
the	O
HAIP	B
:	O
1,8-	B
dihydroxy	I
-9,10-	I
anthraquinone-3-aldehyde	I
is	O
reacted	O
with	O
the	O
phenanthroline5,6-diketone	B
to	O
produce	O
the	O
HAIP	B
;	O
2	O
.	O

Ru	B
(	I
L	I
)	I
2Cl2	I
is	O
reacted	O
with	O
HAIP	B
and	O
NH4PF6	B
to	O
produce	O
the	O
[	B
Ru	I
(	I
L	I
)	I
2HAIP	I
]	I
.	I
(	I
PF6	I
)	I
2	I
.	O

The	O
invention	O
takes	O
the	O
aloe	O
-	O
emodin	B
as	O
the	O
raw	O
material	O
and	O
the	O
ruthenium	B
polypyridyl	I
complex	O
has	O
single	O
chemical	O
composition	O
;	O
the	O
synthesis	O
route	O
is	O
simple	O
and	O
the	O
yields	O
are	O
higher	O
;	O
during	O
the	O
experiment	O
,	O
the	O
compound	O
shows	O
the	O
light	O
suppression	O
to	O
the	O
growth	O
of	O
cancer	O
cells	O
.	O

Ruthenium	B
-	I
anthraquinone	I
conjugates	O
,	O
preparation	O
method	O
thereof	O
and	O
application	O
for	O
optical	O
power	O
therapeutic	O
photosensitizer	O

The	O
invention	O
relates	O
to	O
a	O
medicinal	O
and	O
dietary	O
composition	O
for	O
treating	O
bedsore	O
and	O
its	O
preparing	O
process	O
,	O
wherein	O
the	O
composition	O
is	O
prepared	O
mainly	O
from	O
frankincense	O
,	O
Chinese	O
angelica	O
root	O
,	O
dahurian	O
angelica	O
root	O
,	O
dried	O
rehmannia	O
root	O
,	O
goldthread	O
root	O
and	O
boneol	B
,	O
the	O
medicament	O
can	O
also	O
be	O
used	O
as	O
a	O
conventional	O
health	O
dietary	O
preparation	O
having	O
no	O
side	O
effects	O
easy	O
administering	O
.	O

Pistachio	O
galls	O
pressure	O
ulcer	O
powder	O

The	O
invention	O
discloses	O
a	O
medicinal	O
molecule	O
with	O
selective	O
anticancer	O
activity	O
with	O
structure	O
as	O
general	O
formula	O
(	O
I	O
)	O
,	O
which	O
uses	O
chiral	O
cyclohexamethylene	B
diamine	I
derivative	O
and	O
metal	O
ion	O
to	O
form	O
metal	O
complex	O
after	O
coordinating	O
and	O
provides	O
the	O
making	O
method	O
of	O
the	O
typical	O
compound	O
and	O
inhibition	O
and	O
mechanism	O
of	O
the	O
growth	O
of	O
human	O
breast	O
cancer	O
and	O
lung	O
cancer	O
,	O
wherein	O
R1	O
and	O
R2	O
contains	O
random	O
one	O
meaning	O
organic	O
group	O
or	O
hydrogen	B
atom	O
;	O
A1	O
and	O
A2	O
can	O
be	O
individually	O
selected	O
from	O
random	O
organic	O
group	O
;	O
M	O
is	O
random	O
one	O
transition	O
system	O
,	O
expensive	O
metal	O
or	O
rare	O
earth	O
metal	O
ion	O
or	O
radioactive	O
isotope	O
;	O
B1,B2,C1	O
and	O
C2	O
represent	O
random	O
one	O
complex	O
ion	O
,	O
molecular	O
or	O
vacant	O
site	O
individually	O
;	O
B1	O
and	O
B2	O
can	O
represent	O
a	O
couple	O
of	O
tooth	O
complex	O
together	O
;	O
R1,R2	O
,	O
A1,A2,B1,B2,C1	O
and	O
C2	O
can	O
link	O
biological	O
molecule	O
.	O

Anticancer	O
diaminocyclohexane	B
metallic	O
complex	O

The	O
present	O
invention	O
pertains	O
to	O
the	O
art	O
of	O
medical	O
technology	O
,	O
in	O
particular	O
to	O
an	O
application	O
of	O
an	O
alkaloid	B
compound	O
in	O
the	O
preparation	O
of	O
antitumor	O
drugs	O
.	O

The	O
alkaloid	B
compound	O
consists	O
of	O
a	O
Lycoris	O
lactone	O
,	O
a	O
narciprimine	B
and	O
a	O
7-dehydroxyl	B
narciprimine	I
and	O
the	O
molecular	O
formula	O
of	O
the	O
alkaloid	B
compound	O
is	O
C17H19NO5	B
,	O
C14H9NO5	B
,	O
C14H9NO4	B
.	O

Animal	O
experiments	O
prove	O
that	O
the	O
compounds	O
have	O
better	O
inhibited	O
activity	O
on	O
a	O
variety	O
of	O
tumors	O
.	O

The	O
invention	O
also	O
includes	O
one	O
or	O
more	O
than	O
one	O
types	O
of	O
three	O
compounds	O
with	O
effective	O
treatment	O
,	O
or	O
includes	O
medicine	O
combinations	O
of	O
the	O
pharmaceutical	O
acceptable	O
carrier	O
.	O

Application	O
of	O
alkaloids	B
compounds	O
in	O
the	O
preparation	O
of	O
antineoplastic	O
medicament	O

The	O
invention	O
relates	O
to	O
a	O
2-dihydroindolone	O
compound	O
as	O
formula	O
(	O
I	O
)	O
,	O
and	O
a	O
relative	O
application	O
of	O
the	O
compound	O
or	O
the	O
medical	O
acceptable	O
salt	O
of	O
the	O
compound	O
.	O

Pharmacological	O
experiment	O
proves	O
that	O
the	O
compound	O
or	O
relative	O
medical	O
acceptable	O
salt	O
can	O
restrain	O
various	O
cancer	O
cell	O
proliferations	O
.	O

The	O
invention	O
further	O
relates	O
to	O
a	O
preparation	O
method	O
of	O
the	O
compound	O
and	O
an	O
intermediate	O
formula	O
(	O
II	O
)	O
of	O
the	O
compound	O
.	O

2-dihydro	O
indolone	O
derivant	O
,	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
pain	O
ointmentl	O
,	O
which	O
is	O
characterized	O
in	O
that	O
:	O
the	O
major	O
components	O
of	O
the	O
drug	O
comprise	O
radix	O
saposhnikoviae	O
and	O
ginseng	O
,	O
the	O
mixture	O
ratio	O
is	O
55	O
-	O
65	O
precent:35	O
-	O
45	O
percent	O
.	O

The	O
invention	O
has	O
the	O
advantages	O
that	O
:	O
the	O
radix	O
saposhnikoviae	O
is	O
in	O
wild	O
nature	O
with	O
sweet	O
and	O
pungent	O
taste	O
,	O
which	O
has	O
the	O
efficacy	O
of	O
inducing	O
diaphoresis	O
to	O
dispel	O
wind	O
,	O
clearing	O
wind	O
-	O
damp	O
and	O
anti	O
-	O
spasticity	O
,	O
and	O
has	O
obvious	O
significant	O
efficacy	O
for	O
muscular	O
constricture	O
,	O
rheumatism	O
and	O
pruritus	O
;	O
the	O
ginseng	O
has	O
the	O
efficacy	O
of	O
expanding	O
coronary	O
artery	O
and	O
blood	O
vessels	O
;	O
the	O
product	O
has	O
no	O
additives	O
or	O
stroma	O
for	O
affecting	O
the	O
body	O
skin	O
;	O
the	O
use	O
is	O
convenient	O
and	O
the	O
effect	O
is	O
good	O
;	O
furthermore	O
,	O
the	O
preparation	O
method	O
is	O
simple	O
,	O
economical	O
and	O
practical	O
.	O

Pain	O
-	O
relieving	O
plaster	O
and	O
preparing	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
pharmaceutical	O
chemistry	O
,	O
in	O
particular	O
to	O
a	O
thiazole	B
[	I
5	I
,	I
4-b	I
]	I
pyrimidine	I
compounds	O
(	O
I	O
)	O
,	O
preparation	O
methods	O
thereof	O
and	O
also	O
to	O
pharmaceutical	O
composites	O
containing	O
the	O
compounds	O
and	O
medical	O
purposes	O
thereof	O
,	O
in	O
particular	O
to	O
telomerase	O
inhibitors	O
.	O

Telomerase	O
inhibitor	O
,	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
provides	O
a	O
matrix	O
-	O
typed	O
roxithromycin	B
sustained	O
release	O
micropill	O
capsule	O
which	O
is	O
prepared	O
by	O
60	O
-	O
75wt	O
percent	O
of	O
roxithromycin	B
,	O
2	O
-	O
5wt	O
percent	O
of	O
waxy	O
matrix	O
material	O
,	O
10	O
-	O
25wt	O
percent	O
of	O
microcrystalline	O
cellulose	O
,	O
lactose	B
,	O
cane	O
sugar	B
or	O
xylose	B
,	O
2	O
-	O
5wt	O
percent	O
of	O
hydrophilic	O
matrix	O
material	O
,	O
1	O
-	O
4wt	O
percent	O
of	O
anhydrous	O
sodium	B
carbonate	I
and	O
4	O
-	O
10wt	O
percent	O
of	O
mannite	O
according	O
to	O
the	O
normal	O
preparation	O
method	O
.	O

The	O
waxy	O
matrix	O
material	O
is	O
octodecyl	B
alcohol	I
,	O
cetyl	B
alcohol	I
,	O
octadecanoic	B
acid	I
,	O
glycerin	B
monostearate	I
or	O
hydrogenated	O
castor	O
oil	O
.	O

The	O
hydrophilic	O
matrix	O
material	O
is	O
xanthan	B
gum	O
,	O
alginic	B
acid	I
or	O
carbomer	O
974P	O
.	O

The	O
matrix	O
material	O
adopted	O
in	O
the	O
invention	O
delays	O
the	O
release	O
of	O
the	O
drug	O
,	O
reduces	O
the	O
density	O
of	O
sustained	O
release	O
micropill	O
,	O
prolongs	O
the	O
staying	O
time	O
of	O
the	O
sustained	O
release	O
micropill	O
in	O
the	O
stomach	O
and	O
intestinal	O
tract	O
and	O
improves	O
the	O
bioavailability	O
of	O
the	O
medicine	O
.	O

A	O
comparison	O
test	O
between	O
the	O
medicine	O
of	O
the	O
invention	O
and	O
the	O
roxithromycin	B
sustained	O
release	O
pill	O
is	O
carried	O
out	O
in	O
eighteen	O
testers	O
and	O
the	O
test	O
shows	O
that	O
the	O
matrix	O
-	O
typed	O
roxithromycin	B
slow	O
-	O
release	O
micropill	O
capsule	O
of	O
the	O
invention	O
and	O
the	O
roxithromycin	B
slow	O
-	O
release	O
pill	O
have	O
bioequiavailability	O
.	O

Skeleton	O
type	O
roxithromycin	B
sustained	O
release	O
pellet	O
capsule	O

The	O
invention	O
discloses	O
a	O
tinidazole	B
nano	O
-	O
composite	O
silver	O
micro	O
-	O
emulsified	O
antibiotics	O
,	O
0.10	O
to	O
1.50	O
units	O
of	O
tinidazole	B
and	O
0.008	O
to	O
0.020	O
units	O
of	O
nano	O
-	O
silver	O
being	O
regarded	O
as	O
medical	O
components	O
,	O
and	O
96.92	O
to	O
99.67	O
units	O
of	O
micro	O
-	O
emulsified	O
substrate	O
and	O
0.30	O
to	O
3.00	O
units	O
of	O
auxiliary	O
materials	O
are	O
evenly	O
mixed	O
together	O
with	O
a	O
certain	O
percentage	O
,	O
then	O
the	O
tinidazole	B
complex	O
nano	O
-	O
silver	O
micro	O
-	O
emulsified	O
antibiotics	O
can	O
be	O
got	O
which	O
has	O
a	O
yellow	O
outlook	O
,	O
the	O
diameter	O
of	O
grains	O
is	O
1	O
nm	O
to	O
100	O
nm	O
,	O
the	O
invention	O
is	O
stable	O
,	O
which	O
can	O
not	O
only	O
disturb	O
the	O
synthesis	O
of	O
DNA	O
,	O
but	O
also	O
be	O
able	O
to	O
combine	O
with	O
oxygen	B
metabolic	O
enzyme	O
(	O
-SH	O
)	O
to	O
interrupt	O
the	O
respiration	O
metabolism	O
process	O
,	O
so	O
as	O
to	O
kill	O
the	O
aerobic	O
and	O
anaerobic	O
pathogens	O
and	O
improve	O
the	O
recovery	O
of	O
wounds	O
,	O
and	O
diseases	O
such	O
as	O
vaginitis	O
,	O
endometritis	O
can	O
be	O
quickly	O
and	O
effectively	O
cured	O
,	O
and	O
the	O
preparation	O
method	O
of	O
the	O
invention	O
is	O
simple	O
and	O
safe	O
.	O

Tinidazole	B
compound	O
nano	O
silver	O
microemulsion	O
antibacterial	O
medicine	O

The	O
invention	O
discloses	O
a	O
new	O
application	O
in	O
a	O
preparation	O
using	O
asiaticoside	B
in	O
a	O
drug	O
against	O
delayed	O
lung	O
fibrosis	O
.	O

At	O
the	O
end	O
of	O
the	O
delayed	O
lung	O
fibrosis	O
,	O
the	O
asiaticoside	B
has	O
an	O
effect	O
against	O
the	O
lung	O
fibrosis	O
under	O
an	O
action	O
of	O
a	O
promoting	O
fibrosis	O
cytokine	O
in	O
vivo	O
.	O

The	O
invention	O
also	O
discloses	O
a	O
drug	O
composition	O
against	O
delayed	O
lung	O
fibrosis	O
,	O
which	O
active	O
component	O
comprises	O
the	O
asiaticoside	O
and	O
the	O
exogenous	O
promoting	O
fibrosis	O
cytokine	O
.	O

Application	O
of	O
asiaticoside	B
in	O
pulmonary	O
fibrosis	O
resistant	O
delayed	O
period	O

The	O
invention	O
discloses	O
a	O
drug	O
combination	O
as	O
iron	B
supplementary	O
agent	O
which	O
is	O
characterized	O
in	O
that	O
the	O
drug	O
combination	O
has	O
carbonyl	B
iron	I
and	O
natural	O
anti	O
-	O
oxidant	O
components	O
which	O
have	O
the	O
drug	O
activity	O
;	O
the	O
drug	O
combination	O
can	O
also	O
have	O
pharmaceutical	O
carrier	O
.	O

The	O
invention	O
also	O
disclosed	O
the	O
preparation	O
,	O
comprising	O
the	O
drug	O
combination	O
,	O
the	O
preparation	O
method	O
of	O
the	O
combination	O
and	O
the	O
preparation	O
,	O
and	O
the	O
function	O
of	O
preventing	O
and	O
curing	O
iron	O
deficiency	O
of	O
the	O
drug	O
combination	O
.	O

The	O
drug	O
combination	O
has	O
the	O
advantages	O
that	O
the	O
iron	O
deficiency	O
anemia	O
is	O
treated	O
effectively	O
;	O
the	O
production	O
of	O
free	O
radical	O
in	O
human	O
body	O
is	O
inhibited	O
;	O
the	O
oxygen	B
metabolism	O
balance	O
in	O
human	O
body	O
is	O
maintained	O
;	O
the	O
physical	O
quality	O
of	O
the	O
patient	O
is	O
enhanced	O
;	O
and	O
the	O
immunity	O
of	O
body	O
is	O
improved	O
.	O

Iron	B
supplement	O
composition	O
,	O
its	O
preparing	O
method	O
and	O
application	O
of	O
the	O
same	O

The	O
invention	O
relates	O
to	O
a	O
powder	O
for	O
treating	O
epilepsy	O
,	O
comprising	O
sheep	O
parasite	O
,	O
tussah	O
pupa	O
,	O
fennel	O
,	O
muscardine	O
cadaver	O
,	O
finch	O
brain	O
,	O
hawksbill	O
,	O
oryzanol	O
,	O
and	O
cow	O
-	O
bezoar	O
,	O
which	O
are	O
prepared	O
in	O
proportion	O
and	O
in	O
order	O
under	O
normal	O
temperature	O
.	O

The	O
powder	O
has	O
the	O
advantages	O
:	O
the	O
powder	O
has	O
the	O
advantages	O
of	O
easily	O
-	O
purchased	O
raw	O
materials	O
,	O
low	O
cost	O
,	O
simple	O
technology	O
,	O
easy	O
popularization	O
,	O
and	O
convenient	O
use	O
;	O
the	O
powder	O
can	O
make	O
the	O
percentage	O
of	O
epilepsy	O
-	O
treatment	O
reach	O
98.2	O
%	O
,	O
and	O
the	O
cure	O
rate	O
91.8	O
%	O
.	O

Sheep	O
insect	O
powder	O
for	O
treating	O
epilepsy	O

The	O
present	O
invention	O
provides	O
a	O
formulation	O
of	O
B12	O
extracted	O
from	O
the	O
gastric	O
of	O
lambs	O
.	O

The	O
material	O
extracted	O
from	O
the	O
gastric	O
of	O
lambs	O
is	O
the	O
total	O
extracts	O
from	O
the	O
forth	O
gastric	O
of	O
the	O
lambs	O
;	O
when	O
calculated	O
as	O
the	O
dried	O
material	O
,	O
the	O
rennet	O
activity	O
in	O
each	O
gram	O
is	O
not	O
less	O
than	O
800	O
units	O
,	O
and	O
the	O
stomach	O
enzyme	O
activity	O
is	O
not	O
less	O
than	O
230	O
units	O
;	O
the	O
ratio	O
of	O
rennet	O
activity	O
and	O
the	O
stomach	O
enzyme	O
activity	O
is	O
2.0	O
to	O
4.1	O
.	O

The	O
ratio	O
can	O
clinically	O
avoid	O
side	O
effects	O
caused	O
by	O
too	O
high	O
stomach	O
enzyme	O
activity	O
;	O
the	O
invention	O
can	O
be	O
used	O
for	O
patients	O
of	O
gastritis	O
with	O
erosion	O
,	O
hyperemia	O
and	O
ulcer	O
,	O
and	O
can	O
also	O
treat	O
anorexia	O
,	O
diarrhea	O
and	O
milk	O
vomiting	O
of	O
babies	O
.	O

The	O
formulation	O
of	O
B12	O
extracted	O
from	O
the	O
gastric	O
of	O
lambs	O
has	O
simple	O
manufacturing	O
process	O
and	O
does	O
not	O
use	O
organic	O
solvent	O
.	O

Lamb	O
stomach	O
extract	O
vitamin	B
B12	I
preparations	O
composing	O
prescription	O

The	O
invention	O
provides	O
a	O
Selegiline	B
hydrochloride	I
smell	O
covering	O
compound	O
,	O
which	O
contains	O
sugar	B
alcohol	B
,	O
corrective	O
agent	O
,	O
gelatin	B
,	O
and	O
xanthan	B
gum	O
,	O
and	O
is	O
treated	O
by	O
special	O
process	O
and	O
is	O
evenly	O
dispersed	O
with	O
Selegiline	B
hydrochloride	I
.	O

The	O
compound	O
covers	O
the	O
stimulating	O
taste	O
of	O
Selegiline	B
hydrochloride	I
,	O
is	O
used	O
for	O
preparing	O
the	O
orally	O
disintegrating	O
tablet	O
,	O
and	O
is	O
used	O
for	O
treating	O
Parkinsons	O
disease	O
.	O

Smell	O
concealing	O
composition	O
of	O
hydrochloric	B
selegiline	I
,	O
and	O
preparation	O
containing	O
the	O
composition	O

The	O
present	O
invention	O
provides	O
an	O
antisense	O
oligonucleotide	B
of	O
tissue	O
-	O
specific	O
regulation	O
POKEMON	O
gene	O
expression	O
and	O
its	O
application	O
.	O

The	O
antisense	O
oligonucleotide	B
is	O
one	O
of	O
the	O
following	O
formulas	O
:	O
CxCxAxCxGyCyCyGyCyCyGyGyCyCyAxTxCxTx	O
;	O
CxGxCxTxGxAyCyGyAyAyGyTyCyGyAxTxCxTx	O
;	O
GxGxCxCxCyGyGyCyCyCyAyTyAyGyAxAxGxTx	O
;	O
TxTxCxAxGxGyTyCyGyTyAyGyTyTyGxTxGxGx	O
;	O
TxTxCxAxGyGyTyCyGyTyAyGyTyTyGxTxGxGx	O
.	O

X	O
is	O
bond	O
between	O
thiophosphate	B
nucleoside	O
.	O

The	O
antisense	O
oligonucleotide	B
of	O
the	O
invention	O
is	O
used	O
for	O
preparing	O
gene	O
therapeutic	O
drug	O
for	O
curing	O
disease	O
caused	O
by	O
POKEMON	O
high	O
expression	O
.	O

Antisense	O
oligonucleotide	B
for	O
tissue	O
-	O
specific	O
regulation	O
of	O
POKEMON	O
gene	O
expression	O
and	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
an	O
in	O
-	O
situ	O
forming	O
eye	O
gel	O
preparation	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
in	O
-	O
situ	O
forming	O
eye	O
gel	O
preparation	O
can	O
be	O
prepared	O
by	O
mixing	O
a	O
Gelrite	O
Gellan	O
gum	O
as	O
a	O
matrix	O
base	O
.	O

Instant	O
type	O
gel	O
preparation	O
for	O
eye	O
and	O
method	O
of	O
producing	O
the	O
same	O

The	O
invention	O
relates	O
to	O
a	O
slow	O
-	O
released	O
injection	O
comprising	O
kanamycin	B
,	O
which	O
comprises	O
a	O
slow	O
-	O
released	O
microsphere	O
and	O
a	O
dissolvent	O
;	O
the	O
slow	O
-	O
released	O
microsphere	O
comprises	O
a	O
slow	O
-	O
release	O
adjuvant	O
and	O
the	O
aminoglycoside	B
antibiotic	O
;	O
the	O
dissolvent	O
is	O
the	O
special	O
dissolvent	O
which	O
comprises	O
a	O
suspending	O
agent	O
such	O
as	O
sodium	O
carboxymethylcellulose	O
,	O
etc	O
.	O
,	O
and	O
the	O
viscosity	O
of	O
which	O
is	O
100cp-3000cp	O
(	O
at	O
20	O
DEG	O
C-30	O
DEC	O
C	O
)	O
;	O
the	O
slow	O
-	O
release	O
adjuvant	O
can	O
be	O
selected	O
from	O
EVAc	O
,	O
polifeprosan	O
,	O
PLA	O
,	O
PLGA	O
,	O
sebacic	O
acid	O
copolymer	O
,	O
albumen	O
glue	O
and	O
gelatin	O
,	O
etc	O
.	O
;	O
the	O
slow	O
-	O
released	O
microsphere	O
also	O
can	O
be	O
made	O
into	O
a	O
slow	O
-	O
released	O
implant	O
and	O
an	O
ointment	O
.	O

The	O
slow	O
-	O
released	O
implant	O
and	O
the	O
slow	O
-	O
released	O
injection	O
can	O
be	O
partially	O
placed	O
or	O
injected	O
in	O
a	O
bacterial	O
focus	O
to	O
release	O
locally	O
and	O
slowly	O
for	O
more	O
than	O
5	O
-	O
30	O
days	O
,	O
thereby	O
obviously	O
reducing	O
the	O
toxicity	O
of	O
the	O
entire	O
body	O
while	O
getting	O
and	O
maintaining	O
a	O
valid	O
medicine	O
density	O
in	O
the	O
local	O
focus	O
effectively	O
.	O

The	O
slow	O
-	O
released	O
injection	O
comprising	O
the	O
kanamycin	B
of	O
the	O
invention	O
has	O
obvious	O
special	O
treatment	O
effect	O
for	O
focus	O
of	O
local	O
infection	O
such	O
as	O
chronic	O
osteomyelitis	O
,	O
severe	O
bedsore	O
,	O
refractory	O
skin	O
ulcer	O
,	O
diabetic	O
foot	O
,	O
osteonecrosis	O
of	O
femoral	O
head	O
and	O
various	O
abscesses	O
,	O
etc	O
.	O
,	O
caused	O
by	O
staphylococcus	O
,	O
streptococcus	O
,	O
peptostreptococcus	O
,	O
propionibacterium	O
acnes	O
,	O
enterobacter	O
,	O
tubercle	O
bacillus	O
,	O
gonococcus	O
and	O
meningococcus	O
,	O
etc	O
.	O

Sustained	O
-	O
release	O
injection	O
containing	O
kanamycin	B

The	O
invention	O
relates	O
to	O
a	O
health	O
care	O
product	O
which	O
is	O
Parbara	O
selenizing	O
VE	B
health	O
care	O
product	O
.	O

The	O
health	O
product	O
is	O
made	O
of	O
raw	O
materials	O
,	O
including	O
90	O
to	O
100	O
parts	O
of	O
balsam	O
pear	O
extract	O
,	O
0.5	O
to	O
1.0	O
part	O
of	O
selenium	B
,	O
0.1	O
to	O
0.5	O
part	O
of	O
Vitamin	B
E	I
and	O
90	O
to	O
110	O
parts	O
of	O
starch	O
.	O

Composing	O
prescription	O
is	O
simple	O
and	O
supplementary	O
trace	O
elements	O
are	O
reasonable	O
.	O

So	O
the	O
Parbara	O
selenizing	O
VE	B
health	O
care	O
product	O
can	O
serve	O
as	O
accessory	O
food	O
for	O
patients	O
with	O
diabetes	O
mellitus	O
.	O

The	O
Parbara	O
selenizing	O
VE	B
health	O
care	O
product	O
has	O
no	O
adverse	O
effect	O
and	O
is	O
suitable	O
for	O
long	O
-	O
term	O
administration	O
.	O

Pabala	O
selenizing	O
VE	B
health	O
products	O

The	O
invention	O
provides	O
oleanolic	B
acid	I
orally	O
disintegrating	O
tablets	O
with	O
high	O
dissolution	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
oleanolic	B
acid	I
orally	O
disintegrating	O
tablets	O
are	O
characterized	O
in	O
that	O
oleanolic	B
acid	I
is	O
prepared	O
into	O
solid	O
dispersion	O
via	O
hydrophilic	O
solid	O
dispersion	O
carrier	O
,	O
so	O
as	O
to	O
remarkably	O
improve	O
the	O
dissolution	O
,	O
promote	O
the	O
absorption	O
and	O
remarkably	O
improve	O
the	O
bioavailability	O
of	O
oleanolic	B
acid	I
.	O

The	O
weight	O
ratio	O
of	O
the	O
solid	O
dispersion	O
carrier	O
and	O
oleanolic	B
acid	I
is	O
0.5	O
-	O
5	O
.	O

Then	O
,	O
the	O
solid	O
dispersion	O
is	O
mixed	O
with	O
adjuvants	O
such	O
as	O
bulking	O
agent	O
,	O
corrective	O
and	O
lubricant	O
and	O
made	O
into	O
orally	O
disintegrating	O
tablets	O
by	O
using	O
conventional	O
tablet	O
production	O
equipment	O
via	O
directly	O
tabletting	O
or	O
wet	O
granulating	O
process	O
.	O

The	O
preparation	O
has	O
disintegrating	O
time	O
of	O
5	O
-	O
50s	O
,	O
and	O
dissolution	O
in	O
0.5	O
sodium	B
lauryl	I
sulfate	I
solution	O
in	O
1	O
hour	O
over	O
80	O
%	O
,	O
even	O
over	O
90	O
%	O
.	O

Oleanolic	B
acid	I
orally	O
disintegrating	O
tablet	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
series	O
of	O
novel	O
compounds	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
particularly	O
to	O
a	O
series	O
of	O
benzoxazolone	B
derivatives	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
and	O
solves	O
the	O
problem	O
that	O
the	O
prior	O
benzoxazolone	B
compounds	O
have	O
no	O
4-substituted	O
derivatives	O
and	O
have	O
anti	O
-	O
HBV	O
activity	O
and	O
anti	O
-	O
HIV	O
activity	O
.	O

The	O
general	O
structural	O
formula	O
of	O
the	O
derivatives	O
is	O
shown	O
in	O
the	O
figure	O
,	O
wherein	O
R	O
is	O
C3-C6	O
fatty	B
acid	I
ester	I
group	O
,	O
benzoate	B
group	O
/	O
substituted	O
benzoate	B
group	O
,	O
benzene	B
sulfonate	I
group	O
/	O
substituted	O
benzene	B
sulfonate	I
group	O
,	O
amino	B
acid	I
ester	I
group	O
,	O
or	O
heterocyclic	B
acid	I
ester	I
group	O
/	O
substituted	O
heterocyclic	B
acid	I
ester	I
group	O
.	O

The	O
invention	O
obtains	O
a	O
series	O
of	O
4-substituted	O
benzoxazolone	B
derivatives	O
with	O
proven	O
anti	O
-	O
HBV	O
activity	O
and	O
anti	O
-	O
HIV	O
activity	O
,	O
opens	O
new	O
preparation	O
paths	O
of	O
the	O
above	O
three	O
drugs	O
,	O
and	O
brings	O
new	O
breakthrough	O
in	O
pharmaceutical	O
and	O
pesticide	O
fields	O
.	O

In	O
addition	O
,	O
the	O
synthetic	O
method	O
has	O
the	O
advantages	O
of	O
easy	O
operation	O
,	O
mild	O
reaction	O
conditions	O
,	O
single	O
reaction	O
product	O
,	O
and	O
applicability	O
to	O
large	O
scale	O
production	O
.	O

Benzoxazole	B
ketones	I
derivative	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
preparation	O
method	O
of	O
a	O
chitosan	O
cachou	O
.	O

The	O
chitosan	O
cachou	O
is	O
prepared	O
by	O
chitosan	O
,	O
corn	O
starch	O
,	O
xylitol	B
,	O
maltodextrin	O
,	O
acesulfame	B
potassium	I
,	O
sodium	B
cyclamate	I
,	O
menthol	B
,	O
and	O
magnesium	B
stearate	I
,	O
and	O
the	O
preparation	O
method	O
includes	O
the	O
following	O
steps	O
:	O
embedding	O
processing	O
of	O
essence	O
,	O
mixing	O
,	O
damp	O
mass	O
making	O
,	O
wet	O
granule	O
making	O
,	O
drying	O
,	O
granule	O
finishing	O
,	O
final	O
mixing	O
,	O
sheeting	O
,	O
sterilization	O
,	O
and	O
packaging	O
,	O
thus	O
obtaining	O
the	O
chitosan	O
cachou	O
.	O

Chitosan	O
oral	O
scented	O
pieces	O
and	O
preparation	O
thereof	O

Compounds	O
and	O
methods	O
for	O
treating	O
diseases	O
mediated	O
by	O
a	O
P2X3	O
and/or	O
a	O
P2X2	O
/	O
3	O
receptor	O
antagonist	O
,	O
the	O
compounds	O
being	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
D	O
,	O
X	O
,	O
R<1	O
>	O
,	O
R<2	O
>	O
,	O
R<3	O
>	O
,	O
R<4	O
>	O
,	O
R<5	O
>	O
,	O
R<6	O
>	O
,	O
R<7	O
>	O
and	O
R<8	O
>	O
are	O
as	O
defined	O
herein	O
.	O

Diaminopyrimidines	B
as	O
P2X3	O
and	O
P2X2	O
/	O
3	O
modulators	O

The	O
invention	O
belongs	O
to	O
the	O
medicine	O
technical	O
field	O
,	O
in	O
particular	O
to	O
an	O
application	O
of	O
rutin	B
and	O
quercetin-7-rhamnose	B
in	O
preparation	O
of	O
anti	O
-	O
hepatitis	O
virus	O
agents	O
.	O

According	O
to	O
the	O
results	O
of	O
experiments	O
of	O
hepatitis	O
B	O
surface	O
antigen	O
(	O
HBsAg	O
)	O
and	O
hepatitis	O
B	O
e	O
antigen	O
(	O
HBeAg	O
)	O
detection	O
reagents	O
,	O
the	O
rutin	B
and	O
the	O
quercetin-7-rhamnose	B
can	O
suppress	O
HBsAg	O
and	O
HBeAg	O
obviously	O
and	O
can	O
prevent	O
and	O
cure	O
hepatitis	O
B	O
virus	O
.	O

Therefore	O
,	O
the	O
rutin	B
and	O
the	O
quercetin-7-rhamnose	B
can	O
be	O
used	O
for	O
preparing	O
anti	O
-	O
hepatitis	O
virus	O
agents	O
or	O
health	O
care	O
products	O
.	O

Uses	O
of	O
rutin	B
and	O
quercetin-7-rhamnose	B
in	O
preparing	O
anti	O
-	O
hepatitis	O
medicament	O

The	O
invention	O
relates	O
to	O
a	O
FAD	B
-	I
Na2	I
freeze	O
-	O
dried	O
acanthopanax	O
powder	O
spasmolytic	O
preparation	O
and	O
a	O
method	O
for	O
preparing	O
the	O
same	O
.	O

The	O
FAD	B
-	I
Na2	I
freeze	O
-	O
dried	O
acanthopanax	O
powder	O
spasmolytic	O
preparation	O
is	O
a	O
drug	O
composition	O
made	O
by	O
mixing	O
FAD	B
-	I
Na2	I
serving	O
as	O
medicinal	O
active	O
ingredients	O
and	O
pharmaceutically	O
acceptable	O
excipients	O
.	O

The	O
preparation	O
method	O
is	O
as	O
follows	O
:	O
the	O
FAD	B
-	I
Na2	I
is	O
used	O
as	O
raw	O
material	O
and	O
added	O
with	O
certain	O
spices	O
of	O
excipients	O
according	O
to	O
certain	O
proportions	O
;	O
the	O
mixture	O
is	O
prepared	O
and	O
developed	O
by	O
a	O
technical	O
means	O
provided	O
by	O
the	O
invention	O
into	O
freeze	O
-	O
dried	O
acanthopanax	O
powder	O
spasmolytic	O
agent	O
which	O
can	O
be	O
used	O
for	O
subcutaneous	O
injection	O
,	O
intramuscular	O
and	O
intravenous	O
injection	O
and	O
used	O
to	O
cure	O
a	O
variety	O
of	O
diseases	O
caused	O
by	O
lacks	O
of	O
vitamin	B
B2	I
.	O

Flavin	B
adenine	I
dinucleotide	I
disodium	I
salt	O
freeze	O
-	O
dried	O
powder	O
needle	O
preparation	O
and	O
preparation	O
thereof	O

The	O
present	O
invention	O
provides	O
a	O
detection	O
method	O
for	O
compound	O
Shedan	O
Chenpi	O
San	O
.	O

The	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
(	O
1	O
)	O
five	O
drugs	O
of	O
orange	O
peel	O
,	O
earthworm	O
,	O
stiff	O
silkworm	O
,	O
vermilion	O
and	O
amber	O
contained	O
in	O
the	O
compound	O
Shedan	O
Chenpi	O
San	O
are	O
identified	O
by	O
a	O
microscope	O
;	O
(	O
2	O
)	O
the	O
orange	O
peel	O
contained	O
in	O
the	O
compound	O
Shedan	O
Chenpi	O
San	O
is	O
identified	O
by	O
the	O
thin	O
layer	O
chromatography	O
;	O
(	O
3	O
)	O
the	O
content	O
of	O
hesperidin	B
in	O
the	O
compound	O
Shedan	O
Chenpi	O
San	O
is	O
measured	O
by	O
the	O
high	O
performance	O
liquid	O
chromatography	O
;	O
(	O
4	O
)	O
the	O
content	O
of	O
ethiopsite	O
in	O
the	O
vermilion	O
in	O
the	O
compound	O
Shedan	O
Chenpi	O
San	O
is	O
measured	O
by	O
thiocyanometry	O
.	O

The	O
detection	O
method	O
for	O
compound	O
Shedan	O
Chenpi	O
San	O
provided	O
by	O
the	O
present	O
invention	O
has	O
the	O
advantages	O
of	O
overcoming	O
a	O
defect	O
of	O
poor	O
specificity	O
existing	O
in	O
the	O
prior	O
chemical	O
identification	O
method	O
and	O
defects	O
of	O
complicated	O
operation	O
and	O
uncontrollable	O
product	O
quality	O
existing	O
in	O
the	O
prior	O
thin	O
layer	O
chromatography	O
,	O
improving	O
the	O
specificity	O
and	O
the	O
quality	O
stability	O
of	O
the	O
detection	O
method	O
for	O
compound	O
Shedan	O
Chenpi	O
San	O
and	O
ensuring	O
the	O
safety	O
and	O
effectiveness	O
of	O
medication	O
.	O

Detection	O
method	O
of	O
compound	O
preserved	O
snake	O
gall	O
orange	O
peel	O
powder	O

The	O
invention	O
discloses	O
an	O
oxazole	B
substituted	O
dihydro	B
-	I
pyrazole	I
miscellaneous	O
polycyclic	O
derivative	O
,	O
as	O
well	O
as	O
a	O
preparation	O
method	O
and	O
a	O
use	O
of	O
the	O
same	O
.	O

The	O
derivative	O
provided	O
by	O
the	O
invention	O
has	O
a	O
structure	O
as	O
shown	O
in	O
a	O
chemical	O
formula	O
D	O
and	O
is	O
prepared	O
through	O
the	O
following	O
method	O
that	O
:	O
substituted	O
isoquinoline	B
propiophenone	I
is	O
used	O
for	O
leading	O
,	O
expanded	O
and	O
converted	O
into	O
substituted	O
isoquinoline	B
alpha	O
and	O
beta	O
unsaturated	O
ketone	B
;	O
ring	O
closure	O
is	O
carried	O
out	O
to	O
form	O
5-substituted	O
isoquinoline	B
substituted	O
dihydro	B
-	I
pyrazole	I
ketone	I
;	O
by	O
inducing	O
an	O
oxime	B
structure	O
unit	O
and	O
adopting	O
a	O
microwave	O
auxiliary	O
synthesis	O
method	O
,	O
a	O
series	O
of	O
3-methyl	B
oxazole-5-isoquinoline	I
substituted	O
hydrogen	B
pyrazole	I
miscellaneous	O
polycyclic	O
compounds	O
is	O
designed	O
and	O
synthesized	O
.	O

Structure	O
modification	O
is	O
carried	O
out	O
according	O
to	O
the	O
principle	O
of	O
medicinal	O
chemistry	O
,	O
so	O
as	O
to	O
design	O
and	O
synthesize	O
a	O
high	O
-	O
activity	O
compound	O
with	O
the	O
effects	O
of	O
resisting	O
tumor	O
and	O
sterilizing	O
.	O

Oxazole	B
substituted	O
dihydro	B
pyrazol	I
multi	O
-	O
heterocyclic	B
ring	O
derivates	O
,	O
preparation	O
method	O
and	O
uses	O
thereof	O

The	O
invention	O
provides	O
a	O
novel	O
cephalosporin	B
compound	O
which	O
introduces	O
thioureido	B
onto	O
position	O
7	O
of	O
cephem	B
,	O
nontoxic	O
salt	O
of	O
the	O
cephalosporin	B
compound	O
acceptable	O
on	O
pharmacy	O
,	O
physiological	O
hydrolyzable	O
ester	B
of	O
the	O
cephalosporin	B
compound	O
,	O
acid	O
amide	B
of	O
the	O
cephalosporin	B
compound	O
,	O
hydrate	B
of	O
the	O
cephalosporin	B
compound	O
,	O
solvate	O
of	O
the	O
cephalosporin	B
compound	O
or	O
an	O
isomer	O
of	O
the	O
cephalosporin	B
compound	O
,	O
a	O
method	O
for	O
preparing	O
the	O
cephalosporin	B
compound	O
,	O
a	O
drug	O
composition	O
containing	O
the	O
cephalosporin	B
compound	O
and	O
an	O
application	O
of	O
the	O
cephalosporin	B
compound	O
.	O

Novel	O
cephalosporin	B
compounds	O
,	O
preparation	O
method	O
thereof	O
,	O
pharmaceutical	O
compositions	O
thereof	O
and	O
use	O

The	O
invention	O
discloses	O
a	O
red	O
yeast	O
rice	O
extract	O
and	O
a	O
preparation	O
method	O
and	O
a	O
quality	O
test	O
method	O
thereof	O
.	O

The	O
main	O
active	O
ingredient	O
of	O
the	O
extract	O
is	O
lovastatin	B
,	O
the	O
content	O
of	O
which	O
is	O
more	O
than	O
3	O
percent	O
.	O

The	O
extract	O
is	O
prepared	O
by	O
subjecting	O
a	O
medical	O
material	O
of	O
red	O
yeast	O
rice	O
to	O
extraction	O
with	O
an	O
organic	O
solvent	O
,	O
water	O
decoction	O
after	O
the	O
volatilization	O
of	O
the	O
solvent	O
,	O
precipitation	O
collection	O
by	O
siphonage	O
and	O
configuration	O
,	O
mixing	O
with	O
excipients	O
and	O
drying	O
.	O

The	O
preparation	O
method	O
improves	O
the	O
content	O
of	O
lovastatin	B
.	O

The	O
invention	O
also	O
provides	O
a	O
quality	O
control	O
method	O
for	O
identifying	O
the	O
ingredients	O
and	O
measuring	O
content	O
.	O

Rice	O
fermented	O
with	O
red	O
yeast	O
extract	O
,	O
preparation	O
method	O
and	O
quality	O
detection	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
medicine	O
for	O
treating	O
prolapse	O
of	O
lumbar	O
intervertebral	O
disc	O
.	O

The	O
preparation	O
method	O
for	O
the	O
medicine	O
comprises	O
the	O
following	O
steps	O
that	O
:	O
medicines	O
such	O
as	O
phrymaceae	O
,	O
buck	O
grass	O
,	O
slenderstyle	O
acanthopanax	O
barks	O
,	O
cortex	O
lycii	O
radicis	O
,	O
dittany	O
,	O
heracleum	O
hemsleyanum	O
,	O
common	O
monkshood	O
mother	O
root	O
,	O
kusnezoff	O
monkshood	O
,	O
safflower	O
,	O
Chinese	O
ephedra	O
,	O
dried	O
ginger	O
,	O
pollen	O
,	O
artemisia	O
leaves	O
,	O
cassia	O
barks	O
and	O
so	O
on	O
are	O
mixed	O
and	O
ground	O
into	O
powder	O
,	O
and	O
then	O
packaged	O
into	O
a	O
medicine	O
bag	O
.	O

When	O
the	O
medicine	O
is	O
used	O
,	O
the	O
medicine	O
bag	O
is	O
immersed	O
into	O
water	O
solution	O
of	O
hot	O
peppers	O
and	O
vinegar	O
,	O
placed	O
on	O
a	O
suffered	O
lumbar	O
part	O
of	O
a	O
patient	O
and	O
heated	O
,	O
and	O
then	O
absorbed	O
through	O
hot	O
application	O
.	O

The	O
medicine	O
can	O
disperse	O
stagnancy	O
and	O
dredge	O
channels	O
,	O
relieve	O
rigidity	O
of	O
muscles	O
and	O
promote	O
blood	O
circulation	O
,	O
reduce	O
swelling	O
and	O
alleviate	O
pain	O
,	O
and	O
stimulate	O
circulation	O
to	O
end	O
stasis	O
,	O
can	O
adjust	O
the	O
water	O
filling	O
level	O
of	O
nucleus	O
pulposus	O
and	O
make	O
the	O
protruded	O
nucleus	O
pulposus	O
retracted	O
,	O
eliminate	O
irritation	O
symptoms	O
of	O
edema	O
,	O
and	O
repair	O
damaged	O
anulus	O
fibrosus	O
,	O
is	O
quick	O
to	O
take	O
effect	O
,	O
has	O
no	O
side	O
effect	O
,	O
and	O
can	O
not	O
cause	O
recrudescence	O
after	O
cure	O
.	O

Medicament	O
for	O
treating	O
protrusion	O
of	O
lumber	O
intervertebral	O
disc	O

The	O
invention	O
discloses	O
a	O
preparation	O
technique	O
of	O
non	O
-	O
pegylation	O
docetaxel	B
long	O
-	O
circulating	O
liposome	O
which	O
meets	O
clinical	O
and	O
large	O
-	O
scale	O
production	O
requirements	O
and	O
a	O
freeze	O
-	O
dried	O
powder	O
-	O
injection	O
;	O
the	O
liposome	O
consists	O
of	O
docetaxel	B
,	O
neutral	O
phospholipid	O
,	O
charged	O
phospholipid	O
,	O
cholesterin	B
,	O
antioxidant	O
,	O
excipient	O
,	O
buffering	O
agent	O
and	O
water	O
for	O
injection	O
;	O
the	O
preparation	O
technique	O
includes	O
the	O
following	O
steps	O
:	O
preparing	O
multivesicular	O
liposome	O
,	O
homogenizing	O
the	O
liposome	O
,	O
fixing	O
volume	O
,	O
sterilizing	O
,	O
split	O
charging	O
,	O
freeze	O
drying	O
,	O
etc	O
.	O

The	O
liposome	O
increases	O
the	O
solubility	O
of	O
drugs	O
,	O
overcomes	O
poor	O
stability	O
of	O
docetaxel	B
injection	O
and	O
toxicity	O
caused	O
by	O
complex	O
solvent	O
and	O
prolongs	O
the	O
in	O
vivo	O
circulating	O
time	O
of	O
drugs	O
;	O
compared	O
with	O
pegylation	O
long	O
-	O
circulating	O
liposome	O
,	O
the	O
toxicity	O
is	O
decreased	O
and	O
the	O
inhibiting	O
effect	O
on	O
tumor	O
cells	O
is	O
strengthened	O
.	O

Preparation	O
of	O
docetaxel	B
long	O
-	O
circulating	O
liposome	O
and	O
freeze	O
-	O
dried	O
powder	O
injection	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
the	O
medical	O
technical	O
field	O
,	O
in	O
particular	O
to	O
a	O
lipid	O
microsphere	O
injection	O
medical	O
combination	O
containing	O
triamcinolone	B
palmitate	I
and	O
a	O
preparation	O
method	O
thereof	O
.	O

Medicine	O
composition	O
for	O
injecting	O
triamcinolone	B
acetonide	I
palmitate	I
lipid	O
microsphere	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
nootropic	O
capsule	O
used	O
for	O
strengthening	O
willpower	O
.	O

The	O
invention	O
is	O
characterized	O
in	O
that	O
the	O
nootropic	O
capsule	O
has	O
a	O
composing	O
prescription	O
which	O
comprises	O
gen	O
-	O
seng	O
,	O
glossy	O
ganoderma	O
,	O
milkwort	O
root	O
,	O
spine	O
date	O
seed	O
,	O
root	O
poria	O
,	O
grassleaf	O
sweetflag	O
rhizome	O
,	O
silktree	O
albizia	O
bark	O
,	O
the	O
tuber	O
of	O
multiflower	O
knot	O
weed	O
,	O
longan	O
aril	O
,	O
seabuckthorn	O
fruit	O
,	O
ginkgo	O
biloba	O
extract	O
,	O
wheat	O
-	O
germ	O
oil	O
,	O
pollen	O
,	O
tortoise	O
carapace	O
and	O
plastron	O
,	O
cape	O
jasmine	O
fruit	O
,	O
liquorice	O
,	O
royal	O
jelly	O
dry	O
-	O
freezing	O
powder	O
,	O
etc	O
.	O

The	O
extract	O
can	O
be	O
made	O
by	O
the	O
preparation	O
and	O
the	O
extract	O
is	O
mixed	O
with	O
the	O
powdery	O
raw	O
materials	O
and	O
the	O
nootropic	O
capsule	O
can	O
be	O
obtained	O
after	O
the	O
processes	O
of	O
drying	O
,	O
sterilizing	O
and	O
encapsulating	O
the	O
extract	O
in	O
a	O
capsule	O
.	O

'	O
Yizhi	O
'	O
capsule	O
for	O
enhancing	O
willpower	O

A	O
pharmaceutical	O
composition	O
is	O
an	O
organic	O
salt	O
formed	O
by	O
an	O
organic	O
acid	O
rosuvastatin	B
and	O
an	O
organic	O
base	O
azelnidipine	B
with	O
a	O
molar	O
ratio	O
of	O
1:1	O
.	O

The	O
pharmaceutical	O
composition	O
can	O
be	O
made	O
into	O
any	O
dosage	O
forms	O
together	O
with	O
a	O
pharmaceutically	O
-	O
acceptable	O
carrier	O
for	O
reducing	O
blood	O
pressure	O
and	O
blood	O
lipid	O
,	O
reducing	O
myocardial	O
infarction	O
and	O
treating	O
cerebral	O
apoplexy	O
.	O

The	O
inventive	O
pharmaceutical	O
composition	O
has	O
the	O
advantages	O
of	O
stable	O
physiochemical	O
indexes	O
,	O
controllable	O
product	O
quality	O
,	O
and	O
convenient	O
administration	O
.	O

Rosuvastatin	B
azelnidipine	B
composition	O

The	O
invention	O
discloses	O
a	O
pirenoxine	B
sodium	I
eye	O
gel	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
pirenoxine	B
sodium	I
eye	O
gel	O
contains	O
(	O
per	O
1,000	O
mL	O
)	O
pirenoxine	B
sodium	I
20	O
-	O
50	O
mg	O
,	O
antiseptic	O
0.05	O
-	O
1	O
g	O
,	O
osmotic	O
pressure	O
regulator	O
1.0	O
-	O
7.5	O
g	O
,	O
gel	O
matrix	O
30	O
-	O
150	O
g	O
,	O
and	O
acid	O
/	O
base	O
buffer	O
and	O
water	O
for	O
injection	O
in	O
balancing	O
amount	O
.	O

The	O
inventive	O
pirenoxine	B
sodium	I
eye	O
gel	O
optimizes	O
adjuvants	O
and	O
improves	O
production	O
process	O
,	O
so	O
as	O
to	O
enrich	O
the	O
compound	O
taurine	O
dosage	O
forms	O
,	O
remarkably	O
prolong	O
the	O
retention	O
time	O
of	O
the	O
compound	O
taurine	B
in	O
eyes	O
,	O
and	O
improve	O
the	O
therapeutic	O
effect	O
;	O
and	O
has	O
no	O
adverse	O
irritant	O
reactions	O
.	O

Eye	O
in	O
-	O
situ	O
gel	O
of	O
pirenoxine	B
sodium	I

The	O
present	O
invention	O
provides	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
,	O
or	O
a	O
stereoisomer	O
,	O
tautomer	O
,	O
pharmaceutically	O
acceptable	O
salt	O
or	O
solvate	O
form	O
thereof	O
,	O
wherein	O
the	O
variables	O
A	O
,	O
B	O
,	O
R<3	O
>	O
and	O
R<11	O
>	O
are	O
as	O
defined	O
herein	O
.	O

The	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
are	O
useful	O
as	O
selective	O
inhibitors	O
of	O
serine	O
protease	O
enzymes	O
of	O
the	O
coagulation	O
cascade	O
and/or	O
contact	O
activation	O
system	O
;	O
for	O
example	O
thrombin	O
,	O
factor	O
Xa	O
,	O
factor	O
XIa	O
,	O
factor	O
IXa	O
,	O
factor	O
VIIa	O
and/or	O
plasma	O
kallikrein	O
.	O

In	O
particular	O
,	O
it	O
relates	O
to	O
compounds	O
that	O
are	O
selective	O
factor	O
XIa	O
inhibitors	O
or	O
dual	O
inhibitors	O
of	O
fXIa	O
and	O
plasma	O
kallikrein	O
.	O

This	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
these	O
compounds	O
and	O
methods	O
of	O
treating	O
thromboembolic	O
and/or	O
inflammatory	O
disorders	O
using	O
the	O
same	O
.	O

Six	O
-	O
membered	O
heterocycles	B
useful	O
as	O
serine	O
protease	O
inhibitors	O

Disclosed	O
is	O
an	O
extract	O
of	O
flavonoid	B
of	O
ixeris	O
sonchifolia	O
hance	O
and	O
a	O
preparation	O
method	O
and	O
an	O
application	O
thereof	O
.	O

The	O
invention	O
discloses	O
a	O
novel	O
preparation	O
method	O
of	O
an	O
extract	O
of	O
flavonoid	B
of	O
ixeris	O
sonchifolia	O
hance	O
whose	O
content	O
of	O
luteolin-7-O	B
-	I
Beta	I
-	I
D	I
glucopyranose	I
aldehyde	I
acid	I
glycoside	I
is	O
25	O
percent	O
to	O
99.5	O
percent	O
,	O
discloses	O
a	O
novel	O
preparation	O
method	O
of	O
a	O
reference	O
substance	O
of	O
luteolin-7-O	B
-	I
Beta	I
-	I
D	I
glucopyranose	I
aldehyde	I
acid	I
glycoside	I
and	O
an	O
application	O
thereof	O
in	O
controlling	O
the	O
quality	O
of	O
the	O
ixeris	O
sonchifolia	O
hance	O
and	O
pharmaceutical	O
preparations	O
containing	O
the	O
extract	O
of	O
the	O
ixeris	O
sonchifolia	O
hance	O
,	O
and	O
also	O
discloses	O
an	O
application	O
of	O
the	O
extract	O
in	O
preparing	O
drugs	O
for	O
treating	O
the	O
coronary	O
heart	O
disease	O
,	O
the	O
cerebral	O
infarction	O
and	O
the	O
fracture	O
.	O

Lxeris	O
sonchifolia	O
(	O
bunge	O
)	O
hance	O
flavone	B
extract	O
,	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
discloses	O
an	O
ambroxol	B
hydrochloride	I
oral	O
solution	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
and	O
relates	O
to	O
a	O
preparation	O
method	O
of	O
western	O
medicine	O
,	O
in	O
particular	O
to	O
a	O
medical	O
production	O
formula	O
used	O
for	O
curing	O
bronchitis	O
and	O
a	O
preparation	O
method	O
thereof	O
;	O
the	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
sucrose	B
,	O
preservatives	O
and	O
purified	O
water	O
are	O
dissolved	O
in	O
a	O
mixing	O
mode	O
so	O
as	O
to	O
prepare	O
simple	O
syrup	O
;	O
the	O
ambroxol	B
hydrochloride	I
,	O
corrigents	O
and	O
preservatives	O
are	O
dissolved	O
by	O
the	O
purified	O
water	O
so	O
as	O
to	O
prepare	O
ambroxol	B
hydrochloride	I
solution	O
;	O
the	O
ambroxol	B
hydrochloride	I
solution	O
and	O
the	O
simple	O
syrup	O
are	O
stirred	O
and	O
mixed	O
evenly	O
,	O
the	O
corrigents	O
and	O
the	O
preservatives	O
are	O
added	O
successively	O
and	O
discontinuously	O
and	O
then	O
the	O
purified	O
water	O
is	O
added	O
to	O
adjust	O
the	O
concentration	O
.	O

The	O
invention	O
has	O
simple	O
and	O
reasonable	O
process	O
,	O
and	O
is	O
easy	O
to	O
operate	O
practically	O
and	O
the	O
produced	O
products	O
have	O
good	O
stability	O
;	O
the	O
products	O
can	O
used	O
as	O
common	O
phlegm	O
-	O
eliminating	O
drugs	O
,	O
has	O
functions	O
of	O
increasing	O
the	O
liquid	O
level	O
of	O
the	O
respiratory	O
tract	O
,	O
reducing	O
mucus	O
secretion	O
,	O
enhancing	O
the	O
secretion	O
of	O
pulmonary	O
surfactant	O
and	O
the	O
movement	O
of	O
cilium	O
and	O
preventing	O
cough	O
to	O
a	O
certain	O
extent	O
,	O
and	O
is	O
applicable	O
to	O
acute	O
respiratory	O
disease	O
and	O
chronic	O
respiratory	O
disease	O
,	O
such	O
as	O
ropy	O
sputum	O
and	O
difficult	O
cough	O
caused	O
by	O
acute	O
bronchitis	O
and	O
chronic	O
bronchitis	O
,	O
bronchial	O
asthma	O
and	O
pulmonary	O
tuberculosis	O
,	O
etc	O
.	O

Ambroxol	B
hydrochloride	I
oral	O
solution	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
composite	O
containing	O
tetrandrine	B
,	O
and	O
discloses	O
a	O
composite	O
injection	O
containing	O
the	O
tetrandrine	B
and	O
a	O
preparation	O
method	O
thereof	O
;	O
the	O
composite	O
injection	O
consists	O
of	O
the	O
tetrandrine	B
,	O
latent	O
solvent	O
,	O
stabilizing	O
agent	O
and	O
sodium	B
chloride	I
;	O
wherein	O
,	O
the	O
content	O
of	O
the	O
tetrandrine	B
is	O
2	O
-	O
60	O
%	O
,	O
the	O
content	O
of	O
the	O
latent	O
solvent	O
is	O
2	O
-	O
40	O
%	O
,	O
the	O
content	O
of	O
the	O
stabilizing	O
agent	O
is	O
1	O
-	O
8	O
%	O
,	O
and	O
the	O
content	O
of	O
the	O
sodium	B
chloride	I
is	O
9	O
-	O
90	O
%	O
;	O
the	O
proportion	O
among	O
the	O
tetrandrine	B
,	O
the	O
latent	O
solvent	O
and	O
the	O
stabilizing	O
agent	O
is	O
1:0.5:0.01	O
-	O
1:1:1	O
.	O

The	O
method	O
is	O
that	O
:	O
right	O
amount	O
of	O
water	O
used	O
for	O
injecting	O
is	O
added	O
with	O
2	O
-	O
60	O
%	O
of	O
latent	O
solvent	O
,	O
1	O
-	O
8	O
%	O
of	O
stabilizing	O
agent	O
and	O
9	O
-	O
90	O
%	O
of	O
sodium	B
chloride	I
for	O
dissolving	O
;	O
the	O
2	O
-	O
60	O
%	O
of	O
tetrandrine	B
is	O
added	O
to	O
be	O
stirred	O
and	O
dissolved	O
,	O
and	O
then	O
added	O
with	O
water	O
to	O
full	O
dose	O
;	O
after	O
being	O
mixed	O
,	O
the	O
content	O
and	O
pH	O
value	O
of	O
the	O
tetrandrine	B
is	O
measured	O
,	O
and	O
then	O
poured	O
into	O
a	O
bottle	O
after	O
being	O
filtered	O
;	O
after	O
sterilization	O
,	O
lamp	O
check	O
and	O
quality	O
control	O
are	O
carried	O
out	O
,	O
the	O
injection	O
is	O
prepared	O
.	O

The	O
composite	O
injection	O
is	O
easy	O
to	O
store	O
,	O
has	O
little	O
irritation	O
and	O
good	O
stability	O
,	O
can	O
overcome	O
the	O
problems	O
of	O
easy	O
precipitation	O
of	O
the	O
tetrandrine	B
and	O
clinical	O
pain	O
.	O

Composition	O
injection	O
containing	O
tetrandrine	B
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
benzo	B
sulfonamide	I
CA-4	I
analogues	O
,	O
a	O
synthetic	O
method	O
and	O
an	O
application	O
thereof	O
,	O
pertaining	O
to	O
the	O
field	O
of	O
chemical	O
drugs	O
.	O

The	O
compound	O
has	O
the	O
structure	O
shown	O
as	O
the	O
general	O
formula	O
(	O
IV	O
)	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
an	O
N	B
-	I
tert	I
butyl	I
-	I
benzene	I
sulfonamide	I
-	O
derivative	O
is	O
taken	O
as	O
raw	O
material	O
to	O
generate	O
corresponding	O
carbanion	B
under	O
the	O
function	O
of	O
a	O
metal	O
reagent	O
,	O
and	O
then	O
respectively	O
reacts	O
with	O
benzaldehydes	B
containing	O
methoxy	B
and	O
other	O
substituted	O
functional	O
groups	O
to	O
generate	O
secondary	O
alcohol	B
;	O
the	O
secondary	O
alcohol	B
is	O
oxidized	O
by	O
an	O
oxidant	O
;	O
a	O
series	O
of	O
conformational	O
restriction	O
CA-4	B
analogues	O
are	O
synthesized	O
by	O
making	O
use	O
of	O
a	O
novel	O
cyclization	O
reaction	O
induced	O
by	O
trimethylsilyl	B
chlorine	I
/	O
NaI	B
/	O
acetonitrile	B
reagent	O
.	O

The	O
result	O
of	O
a	O
vitro	O
cell	O
growth	O
inhibition	O
activity	O
test	O
of	O
the	O
target	O
compound	O
shows	O
that	O
the	O
CA-4	B
analogues	O
can	O
be	O
applied	O
as	O
anti	O
-	O
tumor	O
drugs	O
.	O

Benzenesulfonamides	B
Ca-4	I
analogue	O
,	O
synthesis	O
method	O
and	O
application	O

The	O
invention	O
provides	O
a	O
2-	B
(	I
4-substituted	I
phenyl-1	I
,	I
2	I
,	I
3-	I
thiadiazole-5-	I
mercapto	I
)	I
-N	I
-	I
substituted	I
phenyl	I
acetamide	I
derivative	O
with	O
the	O
structure	O
general	O
formula	O
shown	O
as	O
the	O
right	O
formula	O
,	O
wherein	O
,	O
R<1	O
>	O
is	O
H	B
,	O
F	B
or	O
Cl	B
;	O
R<2	O
>	O
is	O
H	B
,	O
F	B
,	O
Cl	B
or	O
OCH3	B
;	O
X	O
is	O
F	B
,	O
Cl	B
,	O
Br	B
or	O
NO2	B
;	O
and	O
Y	O
is	O
H	B
,	O
CH3	B
,	O
COOCH3	B
or	O
COOC2H5	B
.	O

The	O
derivative	O
is	O
a	O
novel	O
structure	O
framework	O
,	O
has	O
relatively	O
high	O
inhibition	O
activity	O
on	O
HIV	O
and	O
can	O
be	O
taken	O
as	O
a	O
lead	O
compound	O
to	O
be	O
applied	O
to	O
the	O
preparation	O
of	O
anti	O
-	O
HIV	O
agents	O
.	O

2-	B
(	I
4-substituted	I
phenyl-1,2,3-thiadiazole-5sulfhydryl	I
)	I
-N	I
-	I
substituted	I
phenyl	I
acetamides	I
derivates	O
,	O
preparation	O
thereof	O
and	O
application	O

The	O
invention	O
pertains	O
to	O
the	O
technical	O
field	O
of	O
medicine	O
and	O
particularly	O
relates	O
to	O
a	O
penem	O
compound	O
which	O
contains	O
sulfhydryl	O
piperidine	O
and	O
is	O
shown	O
as	O
general	O
formula	O
(	O
I	O
)	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
,	O
easily	O
hydrolysable	O
ester	O
and	O
isomers	O
of	O
the	O
compound	O
;	O
wherein	O
,	O
R<1	O
>	O
,	O
R<2	O
>	O
,	O
R<3	O
>	O
,	O
R<4	O
>	O
,	O
R<5	O
>	O
and	O
R<6	O
>	O
are	O
defined	O
as	O
the	O
specification	O
.	O

The	O
invention	O
also	O
relates	O
to	O
a	O
preparation	O
method	O
of	O
the	O
compounds	O
,	O
medicine	O
composition	O
containing	O
the	O
compounds	O
as	O
well	O
as	O
application	O
of	O
the	O
compounds	O
to	O
the	O
preparation	O
of	O
medicines	O
treating	O
and/or	O
preventing	O
infectious	O
diseases	O
.	O

Penem	O
compound	O
containing	O
sulfhydryl	O
piperidine	O

The	O
invention	O
pertains	O
to	O
the	O
technical	O
field	O
of	O
medicine	O
and	O
particularly	O
relates	O
to	O
a	O
carbon	O
penem	O
derivative	O
which	O
contains	O
sulfhydryl	B
pyrrolidine	I
and	O
is	O
shown	O
as	O
general	O
formula	O
(	O
I	O
)	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
,	O
easily	O
hydrolysable	O
ester	O
and	O
isomers	O
of	O
the	O
derivative	O
;	O
wherein	O
,	O
R<1	O
>	O
,	O
R<2	O
>	O
,	O
R<3	O
>	O
,	O
R<4	O
>	O
and	O
R<5	O
>	O
are	O
defined	O
as	O
the	O
specification	O
.	O

The	O
invention	O
also	O
relates	O
to	O
a	O
preparation	O
method	O
of	O
the	O
compounds	O
,	O
medicine	O
composition	O
containing	O
the	O
compounds	O
as	O
well	O
as	O
application	O
of	O
the	O
compounds	O
to	O
the	O
preparation	O
of	O
medicines	O
treating	O
and/or	O
preventing	O
infectious	O
diseases	O
.	O

Carbapenem	B
derivates	O
containing	O
sulfhydryl	B
pyrrolidine	I

The	O
invention	O
belongs	O
to	O
the	O
pharmaceutical	O
technical	O
field	O
,	O
and	O
particularly	O
relates	O
to	O
a	O
penem	O
derivative	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
easily	O
-	O
hydrolyzed	O
esters	O
thereof	O
,	O
isomers	O
thereof	O
,	O
hydrate	O
thereof	O
and	O
hydrates	O
of	O
esters	O
or	O
salts	O
thereof	O
shown	O
as	O
a	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
and	O
R5	O
are	O
defined	O
as	O
in	O
the	O
description	O
,	O
and	O
can	O
be	O
further	O
substituted	O
on	O
a	O
benzene	B
ring	O
.	O

The	O
invention	O
also	O
relates	O
to	O
the	O
preparation	O
method	O
of	O
the	O
compounds	O
and	O
the	O
pharmaceutical	O
compound	O
containing	O
the	O
same	O
,	O
and	O
the	O
application	O
thereof	O
on	O
the	O
preparation	O
of	O
pharmaceuticals	O
for	O
treating	O
and/or	O
preventing	O
infection	O
diseases	O
.	O

Penem	B
derivative	O

The	O
invention	O
relates	O
to	O
pyrrolidone	B
containing	O
hydroxymethyl	B
and	O
carboxyl	B
and	O
a	O
method	O
for	O
preparing	O
the	O
same	O
,	O
pharmaceutical	O
compositions	O
and	O
applications	O
thereof	O
,	O
in	O
particular	O
to	O
compounds	O
containing	O
sulfonyl	B
pyrrolidone	I
shown	O
in	O
the	O
general	O
formula	O
(	O
I	O
)	O
,	O
a	O
method	O
for	O
preparing	O
the	O
compounds	O
,	O
the	O
pharmaceutical	O
compositions	O
containing	O
the	O
compounds	O
,	O
as	O
well	O
as	O
pharmaceutical	O
applications	O
of	O
the	O
compounds	O
.	O

In	O
the	O
general	O
formula	O
,	O
R1	O
is	O
the	O
hydroxymethyl	B
and	O
the	O
carboxyl	B
.	O

Pyrrolidone	B
containing	O
hydroxymethyl	B
and	O
carboxyl	B
,	O
preparation	O
method	O
and	O
medicament	O
composition	O
and	O
use	O
thereof	O

The	O
invention	O
relates	O
to	O
an	O
androstane	B
azotic	O
glucocorticoid	O
receptor	O
stimulant	O
compound	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
invention	O
further	O
relates	O
to	O
the	O
pharmaceutical	O
preparations	O
comprising	O
the	O
compound	O
and	O
the	O
therapeutic	O
use	O
of	O
the	O
compound	O
,	O
in	O
particular	O
to	O
inflammatory	O
disease	O
,	O
allergic	O
disease	O
or	O
anaphylactic	O
disease	O
.	O

Novel	O
nitrogen	B
-	O
containing	O
medicament	O
with	O
anti	O
-	O
inflammatory	O
activity	O

The	O
invention	O
relates	O
to	O
a	O
drug	O
preparation	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
in	O
particular	O
to	O
a	O
compound	O
Alpha	B
-	I
ketonic	I
acid	I
chewable	O
tablet	O
used	O
for	O
curing	O
chronic	O
renal	O
failure	O
,	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
compound	O
Alpha	B
-	I
ketonic	I
acid	I
chewable	O
tablet	O
comprises	O
the	O
following	O
components	O
:	O
Alpha	B
-	I
ketophenylalanine	I
calcium	I
,	O
Alpha	B
-	I
hydroxymethionine	I
calcium	I
,	O
Alpha	B
-	I
ketoleucine	I
calcium	I
,	O
Alpha	B
-	I
ketoisoleucine	I
calcium	I
,	O
Alpha	B
-	I
ketovaline	I
calcium	I
,	O
tryptophan	B
,	O
histidine	B
,	O
tyrosine	B
,	O
threonine	B
,	O
lysine	B
,	O
acetate	B
,	O
a	O
filling	O
agent	O
,	O
a	O
bonding	O
agent	O
,	O
a	O
taste	O
-	O
masking	O
agent	O
,	O
a	O
lubricant	O
and	O
a	O
coating	O
agent	O
.	O

The	O
compound	O
Alpha	B
-	I
ketonic	I
acid	I
chewable	O
tablet	O
not	O
only	O
widens	O
the	O
dosage	O
form	O
range	O
of	O
the	O
compound	O
Alpha	B
-	I
ketonic	I
acid	I
chewable	O
tablets	O
,	O
but	O
also	O
has	O
the	O
advantages	O
of	O
having	O
good	O
dispersing	O
state	O
,	O
short	O
disintegration	O
time	O
,	O
fast	O
drug	O
dissolution	O
,	O
rapid	O
absorption	O
,	O
high	O
biological	O
availability	O
and	O
convenient	O
taking	O
,	O
being	O
capable	O
of	O
being	O
swallowed	O
,	O
chewed	O
and	O
sucked	O
and	O
being	O
especially	O
suitable	O
for	O
old	O
people	O
,	O
stroke	O
patients	O
,	O
patients	O
with	O
special	O
diseases	O
and	O
patients	O
having	O
swallowing	O
difficulty	O
.	O

Compound	O
alpha	B
-	I
ketoacid	I
chewing	O
tablet	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
curing	O
and	O
healing	O
ointment	O
used	O
for	O
curing	O
the	O
damage	O
of	O
big	O
muscle	O
,	O
muscle	O
fracture	O
,	O
pyogenic	O
infection	O
,	O
carbuncle	O
and	O
surgery	O
cut	O
,	O
in	O
particular	O
to	O
a	O
granulation	O
-	O
promoting	O
ointment	O
which	O
can	O
ensures	O
the	O
quick	O
growth	O
of	O
fester	O
soft	O
tissues	O
without	O
leaving	O
remarkable	O
sclerosis	O
and	O
scars	O
.	O

The	O
ointment	O
consists	O
of	O
xanthium	O
worm	O
(	O
1	O
)	O
,	O
rust	O
powder	O
(	O
2	O
)	O
,	O
vermilion	O
(	O
3	O
)	O
,	O
scorpion	O
(	O
4	O
)	O
,	O
calcined	O
alum	B
(	O
5	O
)	O
(	O
dewatered	O
alum	B
)	O
and	O
beeswax	O
(	O
6	O
)	O
.	O

The	O
curing	O
and	O
healing	O
ointment	O
has	O
the	O
main	O
functions	O
of	O
detumescence	O
and	O
toxin	O
drawing	O
-	O
out	O
as	O
well	O
as	O
pus	O
drainage	O
and	O
removal	O
of	O
necrotic	O
tissue	O
.	O

The	O
invention	O
relates	O
to	O
a	O
preparation	O
method	O
of	O
the	O
granulation	O
-	O
promoting	O
ointment	O
which	O
consists	O
of	O
20	O
fresh	O
xanthium	O
worms	O
(	O
1	O
)	O
,	O
2.4	O
g	O
of	O
the	O
rust	O
powder	O
(	O
2	O
)	O
,	O
2.4	O
g	O
of	O
the	O
vermilion	O
(	O
3	O
)	O
,	O
3	O
g	O
of	O
the	O
scorpion	O
(	O
4	O
)	O
,	O
6	O
g	O
of	O
the	O
calcined	O
alum	B
(	O
5	O
)	O
(	O
dewatered	O
alum	B
)	O
and	O
20	O
g	O
of	O
the	O
beeswax	O
(	O
6	O
)	O
.	O

In	O
the	O
method	O
,	O
the	O
xanthium	O
worms	O
are	O
dipped	O
in	O
benne	O
oil	O
for	O
7	O
days	O
and	O
the	O
scorpion	O
is	O
fried	O
.	O

The	O
rust	O
powder	O
,	O
the	O
scorpion	O
powder	O
,	O
the	O
calcined	O
alum	B
,	O
the	O
beeswax	O
and	O
the	O
vermilion	O
are	O
heated	O
and	O
mixed	O
uniformly	O
,	O
cooled	O
and	O
then	O
the	O
xanthium	O
worms	O
and	O
proper	O
amount	O
of	O
the	O
benne	O
oil	O
are	O
added	O
and	O
mashed	O
into	O
ointment	O
for	O
standby	O
.	O

The	O
curing	O
and	O
healing	O
ointment	O
has	O
the	O
main	O
functions	O
of	O
detumescence	O
and	O
toxin	O
drawing	O
-	O
out	O
as	O
well	O
as	O
pus	O
drainage	O
and	O
removal	O
of	O
necrotic	O
tissue	O
,	O
and	O
has	O
stronger	O
sterilization	O
and	O
infection	O
-	O
resistance	O
capacities	O
.	O

The	O
invention	O
also	O
has	O
the	O
advantages	O
of	O
easily	O
obtained	O
materials	O
,	O
novel	O
and	O
specific	O
prescription	O
,	O
simple	O
extraction	O
technique	O
and	O
convenient	O
medication	O
.	O

Putrefaction	O
-	O
removing	O
granulation	O
-	O
promoting	O
paste	O

The	O
invention	O
provides	O
an	O
external	O
use	O
scalding	O
drug	O
,	O
which	O
is	O
characterized	O
in	O
that	O
the	O
scalding	O
drug	O
is	O
prepared	O
from	O
the	O
following	O
raw	O
materials	O
by	O
weight	O
percentage	O
:	O
10	O
to	O
20	O
percent	O
of	O
gypsum	O
,	O
10	O
to	O
20	O
percent	O
of	O
rhubarb	O
,	O
10	O
to	O
20	O
percent	O
of	O
green	O
tea	O
,	O
10	O
to	O
20	O
percent	O
of	O
sesame	O
oil	O
,	O
10	O
to	O
20	O
percent	O
of	O
borneol	B
,	O
10	O
to	O
20	O
percent	O
of	O
soy	O
sauce	O
.	O

The	O
scalding	O
drug	O
has	O
the	O
efficacy	O
of	O
alleviating	O
the	O
pain	O
and	O
cooling	O
the	O
blood	O
,	O
and	O
effectively	O
avoids	O
blistering	O
on	O
the	O
scalded	O
part	O
,	O
thereby	O
preventing	O
the	O
wound	O
infection	O
;	O
moreover	O
,	O
the	O
scalding	O
drug	O
has	O
the	O
advantages	O
of	O
simple	O
and	O
reasonable	O
compatibility	O
of	O
medicaments	O
,	O
quick	O
onset	O
and	O
good	O
effect	O
.	O

External	O
-	O
use	O
medicament	O
for	O
scald	O

The	O
invention	O
discloses	O
Enterobacter	O
cloacae	O
Z0206	O
,	O
which	O
has	O
been	O
preserved	O
in	O
China	O
General	O
Microbiological	O
Culture	O
Collection	O
Center	O
on	O
December	O
3	O
,	O
2007	O
,	O
wherein	O
the	O
preserving	O
number	O
is	O
CGMCC	O
NO	O
:	O
2279	O
.	O

The	O
invention	O
also	O
discloses	O
a	O
method	O
for	O
preparing	O
Enterobacter	O
cloacae	O
Z0206	O
polysaccharide	O
and	O
application	O
thereof	O
.	O

The	O
method	O
has	O
the	O
advantages	O
that	O
the	O
production	O
process	O
of	O
extracting	O
the	O
polysaccharide	O
is	O
simple	O
,	O
and	O
the	O
yield	O
and	O
the	O
purity	O
of	O
products	O
are	O
higher	O
;	O
the	O
Enterobacter	O
cloacae	O
Z0206	O
polysaccharide	O
can	O
remarkably	O
improve	O
the	O
proliferation	O
capacity	O
of	O
lymph	O
cells	O
and	O
the	O
cytokine	O
level	O
of	O
a	O
small	O
mouse	O
with	O
low	O
immunity	O
and	O
has	O
remarkable	O
adjustment	O
effect	O
on	O
the	O
immunologic	O
function	O
of	O
the	O
small	O
mouse	O
with	O
low	O
immunity	O
;	O
and	O
the	O
Enterobacter	O
cloacae	O
Z0206	O
polysaccharide	O
has	O
apparent	O
antagonism	O
on	O
the	O
oxidative	O
damage	O
caused	O
by	O
cyclophosphamide	O
,	O
can	O
remarkably	O
improve	O
the	O
antioxidase	O
activity	O
of	O
an	O
organism	O
,	O
strengthen	O
the	O
function	O
of	O
an	O
antioxidant	O
defense	O
system	O
of	O
the	O
organism	O
,	O
and	O
prevent	O
harmful	O
free	O
radicals	O
from	O
damaging	O
biological	O
macromolecules	O
in	O
cells	O
.	O

Enterobacter	O
cloacae	O
,	O
and	O
use	O
of	O
polysaccharide	O
and	O
polysaccharide	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
novel	O
compound	O
separated	O
form	O
north	O
Juglans	O
regia	O
and	O
a	O
preparation	O
method	O
and	O
application	O
thereof	O
.	O

The	O
preparation	O
method	O
adopts	O
a	O
method	O
for	O
combining	O
alcohol	B
extraction	O
,	O
chromatographic	O
separation	O
and	O
purification	O
and	O
cytoactive	O
assay	O
to	O
separate	O
the	O
novel	O
compound	O
,	O
which	O
is	O
not	O
reported	O
before	O
and	O
has	O
anti	O
-	O
tumor	O
function	O
,	O
from	O
the	O
north	O
Juglans	O
regia	O
,	O
and	O
adopts	O
mass	O
spectrum	O
and	O
high	O
-	O
resolution	O
nuclear	O
magnetic	O
resonance	O
technique	O
to	O
determine	O
the	O
structure	O
of	O
the	O
compound	O
.	O

The	O
structural	O
formula	O
of	O
the	O
novel	O
compound	O
is	O
the	O
right	O
formula	O
(	O
I	O
)	O
.	O

The	O
novel	O
compound	O
is	O
applied	O
in	O
the	O
field	O
of	O
medicine	O
.	O

Novel	O
compound	O
separated	O
from	O
immature	O
exocarp	O
of	O
Juglans	O
mandshurica	O
Maxim	O
,	O
and	O
preparation	O
and	O
use	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
slow	O
-	O
release	O
tablet	O
prepared	O
from	O
cefixime	B
and	O
pharmaceutically	O
acceptable	O
auxiliary	O
materials	O
.	O

The	O
slow	O
-	O
release	O
tablet	O
is	O
characterized	O
in	O
that	O
:	O
the	O
slow	O
-	O
release	O
tablet	O
consists	O
of	O
the	O
following	O
raw	O
materials	O
and	O
auxiliary	O
materials	O
in	O
portion	O
by	O
weight	O
:	O
200	O
portions	O
of	O
cefixime	B
(	O
counted	O
as	O
an	O
anhydride	O
)	O
,	O
20	O
to	O
200	O
portions	O
of	O
at	O
least	O
one	O
pharmaceutically	O
acceptable	O
slow	O
-	O
release	O
material	O
which	O
can	O
control	O
the	O
drug	O
to	O
continuously	O
and	O
completely	O
release	O
,	O
20	O
and	O
400	O
portions	O
of	O
a	O
pharmaceutically	O
acceptable	O
excipient	O
and	O
5	O
to	O
100	O
portions	O
of	O
at	O
least	O
one	O
solubilizer	O
which	O
can	O
effectively	O
improve	O
the	O
release	O
rate	O
of	O
the	O
drug	O
.	O

The	O
slow	O
-	O
release	O
tablet	O
is	O
easy	O
to	O
prepare	O
and	O
facilitates	O
the	O
industrialized	O
production	O
.	O

Cefixime	B
sustained	O
-	O
release	O
tablets	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
the	O
radicals	O
Rto	O
R	O
,	O
L	O
,	O
Q	O
and	O
n	O
are	O
defined	O
as	O
indicated	O
in	O
claim	O
1	O
.	O

Said	O
compounds	O
are	O
suitable	O
for	O
treating	O
diseases	O
that	O
are	O
characterised	O
by	O
excessive	O
or	O
anomal	O
cell	O
proliferation	O
.	O

The	O
invention	O
also	O
relates	O
to	O
their	O
use	O
for	O
producing	O
a	O
medicament	O
having	O
the	O
above	O
-	O
mentioned	O
properties	O
.	O

Phenyl	B
substituted	I
heteroaryl	I
-	O
derivatives	O
and	O
use	O
thereof	O
as	O
anti	O
-	O
tumor	O
agents	O

The	O
invention	O
discloses	O
an	O
anti	O
-	O
infective	O
drug	O
combination	O
and	O
an	O
application	O
thereof	O
.	O

The	O
anti	O
-	O
infective	O
drug	O
combination	O
comprises	O
a	O
dryopteris	O
fragrans	O
extract	O
with	O
the	O
weight	O
percentage	O
being	O
1	O
%	O
to	O
99	O
%	O
of	O
the	O
drug	O
combination	O
,	O
and	O
pharmaceutically	O
conventional	O
auxiliary	O
materials	O
.	O

The	O
dryopteris	O
fragrans	O
extract	O
comprises	O
the	O
following	O
components	O
:	O
dryopteris	O
fragrans	O
essence	O
,	O
aspidin	B
AB	I
,	O
aspidin	B
PB	I
,	O
aspidin	B
BB	I
,	O
aspidinol	B
and	O
albicanol	B
.	O

The	O
anti	O
-	O
infective	O
drug	O
combination	O
is	O
applicable	O
in	O
the	O
preparation	O
of	O
drugs	O
for	O
curing	O
bacterial	O
,	O
fungal	O
or	O
viral	O
infection	O
diseases	O
;	O
and	O
the	O
anti	O
-	O
infective	O
drug	O
combination	O
has	O
the	O
advantages	O
that	O
the	O
anti	O
-	O
bacterial	O
spectrum	O
is	O
wide	O
,	O
the	O
anti	O
-	O
multidrug	O
resistance	O
is	O
good	O
and	O
the	O
safety	O
is	O
high	O
because	O
the	O
anti	O
-	O
infective	O
drug	O
combination	O
is	O
derived	O
from	O
the	O
natural	O
plant	O
resources	O
.	O

Anti	O
-	O
infective	O
medicament	O
composition	O
and	O
application	O

The	O
invention	O
discloses	O
a	O
polyhydroxyalkanoate	B
(	O
PHA	B
)	O
targeted	O
carrier	O
with	O
the	O
general	O
formula	O
being	O
FA	O
-	O
PEG	O
-	O
P	O
(	O
HBHO	O
)	O
and	O
a	O
targeted	O
drug	O
-	O
loading	O
nano	O
-	O
particle	O
prepared	O
by	O
encapsulating	O
anti	O
-	O
tumor	O
drugs	O
on	O
the	O
basis	O
of	O
ultrasonic	O
emulsification	O
method	O
with	O
the	O
carrier	O
being	O
FA	O
-	O
PEG	O
-	O
P	O
(	O
HBHO	O
)	O
.	O

The	O
drug	O
-	O
loading	O
nano	O
-	O
particle	O
is	O
characterized	O
in	O
that	O
the	O
particle	O
size	O
thereof	O
is	O
in	O
narrow	O
distribution	O
within	O
the	O
general	O
range	O
of	O
300	O
to	O
500	O
nm	O
and	O
the	O
morphological	O
feature	O
thereof	O
is	O
regular	O
,	O
has	O
the	O
advantages	O
of	O
high	O
biodegradability	O
and	O
biocompatibility	O
,	O
stable	O
structure	O
and	O
less	O
serious	O
toxic	O
andside	O
effects	O
,	O
and	O
has	O
better	O
effect	O
on	O
inhibiting	O
tumor	O
cells	O
according	O
to	O
the	O
in	O
vitro	O
cell	O
experiment	O
.	O

Polyhydroxyalkanoate	B
(	O
PHA	B
)	O
targeted	O
carrier	O
,	O
drug	O
-	O
loading	O
nano	O
-	O
particle	O
and	O
preparation	O
methods	O
and	O
application	O
thereof	O

The	O
invention	O
provides	O
a	O
liquiritin	B
preparation	O
with	O
the	O
molecular	O
formula	O
of	O
C26H30O13	B
and	O
the	O
molecular	O
weight	O
of	O
550	O
.	O

The	O
liquiritin	B
is	O
singly	O
prepared	O
or	O
by	O
matching	O
with	O
other	O
active	O
components	O
or	O
auxiliary	O
materials	O
,	O
and	O
the	O
preparation	O
composition	O
is	O
counted	O
in	O
such	O
a	O
way	O
that	O
1000	O
particles	O
contain	O
40	O
g	O
of	O
liquiritin	B
.	O

The	O
liquiritin	B
preparation	O
has	O
stronger	O
effect	O
for	O
relieving	O
cough	O
and	O
eliminating	O
phlegm	O
,	O
therefore	O
,	O
the	O
preparation	O
can	O
be	O
singly	O
prepared	O
by	O
liquiritin	B
or	O
by	O
the	O
liquiritin	B
matching	O
with	O
other	O
active	O
components	O
or	O
auxiliary	O
materials	O
,	O
can	O
be	O
used	O
for	O
improving	O
symptoms	O
of	O
cough	O
and	O
profuse	O
sputum	O
,	O
and	O
can	O
be	O
applied	O
to	O
the	O
preparation	O
of	O
medicine	O
for	O
curing	O
acute	O
cough	O
,	O
chronic	O
cough	O
and	O
profuse	O
sputum	O
.	O

The	O
liquiritin	B
preparation	O
originates	O
from	O
natural	O
plants	O
,	O
can	O
be	O
made	O
into	O
a	O
health	O
-	O
care	O
product	O
,	O
and	O
provides	O
the	O
natural	O
cough	O
-	O
relieving	O
medicine	O
with	O
less	O
toxic	O
side	O
effect	O
and	O
obvious	O
healing	O
effect	O
for	O
clinical	O
treatment	O
.	O

Liquiritin	B
preparation	O
and	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
compound	O
treating	O
diabetes	O
and	O
relevant	O
complicating	O
diseases	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O
.	O

The	O
invention	O
provides	O
the	O
compound	O
expressed	O
as	O
the	O
formula	O
X	O
:	O
shown	O
as	O
the	O
right	O
,	O
wherein	O
R	O
is	O
-OH	B
or	O
R1COO<-	B
>	I
,	O
R1	O
is	O
C2-C20	O
carbon	B
chain	O
.	O

The	O
invention	O
also	O
provides	O
the	O
method	O
for	O
preparing	O
the	O
compound	O
and	O
a	O
drug	O
compound	O
containing	O
the	O
compound	O
shown	O
as	O
the	O
formula	O
X.	O
The	O
invention	O
also	O
provides	O
the	O
application	O
of	O
the	O
compound	O
on	O
preparing	O
medicaments	O
for	O
treating	O
diabetes	O
and	O
relevant	O
complicating	O
diseases	O
.	O

Compound	O
treating	O
diabetes	O
and	O
relevant	O
complicating	O
diseases	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
discloses	O
a	O
method	O
from	O
extracting	O
amylase	O
from	O
liquorice	O
and	O
application	O
thereof	O
.	O

The	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
a.	O
dried	O
liquorice	O
is	O
ground	O
;	O
b.	O
the	O
ground	O
liquorice	O
is	O
put	O
into	O
an	O
extraction	O
tank	O
,	O
petroleum	O
ether	O
is	O
added	O
for	O
reflowing	O
and	O
degreasing	O
,	O
and	O
then	O
filtered	O
out	O
to	O
obtain	O
degreased	O
residue	O
;	O
c.	O
the	O
residue	O
is	O
added	O
with	O
distilled	O
water	O
for	O
extraction	O
in	O
normal	O
termperature	O
,	O
repeatedly	O
poached	O
and	O
extracted	O
for	O
three	O
times	O
,	O
and	O
triple	O
extraction	O
solutions	O
are	O
combined	O
;	O
d.	O
the	O
extraction	O
solution	O
is	O
decompressed	O
and	O
concentrated	O
to	O
cause	O
the	O
volume	O
of	O
the	O
solution	O
to	O
be	O
the	O
liquorice	O
powder	O
in	O
the	O
step	O
a	O
,	O
thus	O
obtaining	O
a	O
concentrated	O
solution	O
;	O
e.	O
a	O
concentrated	O
solution	O
is	O
added	O
into	O
the	O
concentrated	O
solution	O
in	O
the	O
step	O
d	O
,	O
and	O
then	O
the	O
concentrated	O
mixed	O
solution	O
stands	O
overnight	O
and	O
precipitates	O
;	O
f.	O
the	O
concentrated	O
mixed	O
solution	O
is	O
centrifugalized	O
to	O
obtain	O
the	O
precipitation	O
,	O
dried	O
,	O
and	O
then	O
washed	O
with	O
absolute	O
ethyl	B
alcohol	I
,	O
acetone	B
and	O
aether	O
after	O
is	O
extracted	O
by	O
a	O
Sevag	O
method	O
;	O
g.	O
semi	O
-	O
permeable	O
membrane	O
with	O
the	O
interception	O
molecular	O
weight	O
of	O
1000	O
-	O
10000	O
is	O
used	O
for	O
dialyzing	O
in	O
water	O
,	O
the	O
liquorice	O
amylase	O
is	O
obtained	O
by	O
freezing	O
and	O
drying	O
.	O

The	O
liquorice	O
amylase	O
is	O
applied	O
to	O
the	O
preparation	O
of	O
medicine	O
treating	O
or	O
preventing	O
osteoarthritis	O
.	O

The	O
liquorice	O
amylase	O
has	O
definite	O
active	O
ingredient	O
,	O
definite	O
healing	O
effect	O
and	O
no	O
toxic	O
side	O
effect	O
and	O
the	O
extraction	O
method	O
is	O
easy	O
to	O
be	O
implemented	O
.	O

Method	O
for	O
extracting	O
amylase	O
from	O
liquorice	O
and	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
method	O
for	O
preparing	O
a	O
tea	O
seed	O
oil	O
burn	O
wound	O
ointment	O
,	O
which	O
is	O
characterized	O
in	O
that	O
the	O
tea	O
seed	O
oil	O
burn	O
wound	O
ointment	O
comprises	O
the	O
following	O
components	O
in	O
percentage	O
by	O
weight	O
:	O
50	O
to	O
60	O
percent	O
of	O
tea	O
seed	O
oil	O
,	O
3	O
to	O
5	O
percent	O
of	O
borneol	B
,	O
3	O
to	O
5	O
percent	O
of	O
rhubarb	O
,	O
8	O
to	O
15	O
percent	O
of	O
dandelion	O
,	O
and	O
the	O
balance	O
of	O
bamboo	O
charcoal	O
powder	O
;	O
and	O
the	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
cleaning	O
,	O
drying	O
and	O
crushing	O
the	O
borneol	B
,	O
the	O
rhubarb	O
and	O
the	O
dandelion	O
;	O
stirring	O
the	O
materials	O
evenly	O
in	O
proportion	O
;	O
pouring	O
the	O
mixture	O
into	O
the	O
tea	O
seed	O
oil	O
and	O
stirring	O
the	O
mixture	O
;	O
and	O
finally	O
adding	O
the	O
bamboo	O
charcoal	O
powder	O
to	O
the	O
mixture	O
and	O
stirring	O
the	O
mixture	O
.	O

The	O
method	O
overcomes	O
the	O
defects	O
that	O
at	O
present	O
,	O
a	O
burn	O
medicine	O
has	O
less	O
medicinal	O
resources	O
and	O
high	O
price	O
so	O
that	O
the	O
economic	O
burden	O
of	O
a	O
patient	O
is	O
increased	O
,	O
and	O
is	O
easy	O
to	O
trickle	O
and	O
contaminate	O
clothes	O
and	O
beddings	O
.	O

The	O
tea	O
seed	O
oil	O
burn	O
wound	O
ointment	O
prepared	O
by	O
the	O
method	O
has	O
the	O
advantages	O
of	O
no	O
trickling	O
,	O
low	O
cost	O
,	O
extensive	O
medicinal	O
resources	O
,	O
remarkable	O
curative	O
effect	O
,	O
simple	O
production	O
process	O
,	O
less	O
equipment	O
investment	O
,	O
and	O
the	O
like	O
.	O

Method	O
for	O
preparing	O
tea	O
seed	O
oil	O
burn	O
wound	O
ointment	O

The	O
invention	O
relates	O
to	O
a	O
method	O
for	O
preparing	O
andrographolide	B
derivatives	O
,	O
and	O
a	O
preparation	O
thereof	O
.	O

The	O
preparation	O
is	O
a	O
salt	O
which	O
consists	O
of	O
Kalii	O
Dethydroandrographolidi	O
Succinas	O
and	O
Adamantanes	O
and	O
has	O
the	O
effect	O
of	O
synergistic	O
interaction	O
.	O

The	O
curative	O
effect	O
of	O
the	O
preparation	O
is	O
better	O
than	O
that	O
of	O
the	O
independent	O
use	O
of	O
Kalii	O
Dethydroandrographolidi	O
Succinas	O
and	O
Adamantanes	B
.	O

Method	O
for	O
preparing	O
andrographolide	B
derivatives	O
and	O
preparation	O
thereof	O

The	O
pharmaceutical	O
application	O
of	O
a	O
hesperetin	B
derivative	O
relates	O
to	O
the	O
application	O
thereof	O
in	O
the	O
preparation	O
of	O
anti	O
-	O
inflammatory	O
immune	O
medicaments	O
,	O
in	O
particular	O
to	O
the	O
application	O
in	O
treatment	O
of	O
autoimmune	O
diseases	O
such	O
as	O
rheumatic	O
,	O
rheumatoid	O
arthritis	O
and	O
osteoarthritis	O
,	O
and	O
the	O
like	O
.	O

The	O
hesperetin	B
derivative	O
is	O
the	O
derivative	O
which	O
is	O
prepared	O
by	O
a	O
non	O
-	O
carbohydrate	B
compound	O
obtained	O
by	O
hydrolyzing	O
hesperidin	B
and	O
removing	O
glycosyl	B
.	O

The	O
pharmacological	O
effect	O
of	O
the	O
hesperetin	B
derivative	O
is	O
significantly	O
higher	O
than	O
that	O
of	O
the	O
parent	O
hesperidin	B
;	O
and	O
compared	O
with	O
traditional	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
medicament	O
naproxen	B
and	O
a	O
medicament	O
tripterygium	O
treating	O
rheumatoid	O
arthritis	O
,	O
the	O
hesperetin	B
derivative	O
has	O
equivalent	O
activeness	O
,	O
is	O
safe	O
and	O
non	O
-	O
toxic	O
,	O
not	O
only	O
treats	O
the	O
symptom	O
,	O
but	O
also	O
treats	O
the	O
root	O
,	O
thus	O
having	O
very	O
good	O
medicinal	O
prospect	O
.	O

Application	O
of	O
7,3'-dimethoxy	B
hesperetin	I
in	O
preparation	O
of	O
anti	O
-	O
inflammatory	O
immune	O
medicaments	O

The	O
invention	O
provides	O
a	O
pharmaceutical	O
composition	O
containing	O
active	O
carbazochrome	B
sodium	I
sulfonate	I
and	O
prasugrel	O
or	O
the	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
.	O

The	O
invention	O
aims	O
to	O
invent	O
a	O
more	O
effective	O
and	O
low	O
adverse	O
-	O
reaction	O
method	O
for	O
curing	O
thrombotic	O
diseases	O
by	O
using	O
the	O
combined	O
medication	O
of	O
the	O
carbazochrome	B
sodium	I
sulfonate	I
and	O
the	O
prasugrel	B
.	O

After	O
conscientious	O
trail	O
of	O
the	O
patent	O
applicant	O
for	O
many	O
times	O
,	O
the	O
effect	O
of	O
applying	O
the	O
carbazochrome	B
sodium	I
sulfonate	I
to	O
inhibit	O
thrombosis	O
in	O
a	O
combined	O
manner	O
is	O
discovered	O
unexpected	O
in	O
the	O
process	O
of	O
applying	O
the	O
prasugrel	O
to	O
cure	O
the	O
thrombotic	O
diseases	O
,	O
the	O
anticoagulant	O
effect	O
of	O
the	O
prasugrel	O
is	O
not	O
abated	O
but	O
increased	O
,	O
and	O
the	O
very	O
good	O
synergistic	O
effects	O
are	O
achieved	O
after	O
the	O
combination	O
of	O
the	O
carbazochrome	B
sodium	I
sulfonate	I
and	O
the	O
prasugrel	B
,	O
therefore	O
,	O
the	O
risk	O
of	O
bleeding	O
is	O
greatly	O
reduced	O
when	O
the	O
advantages	O
of	O
good	O
anticoagulant	O
activity	O
and	O
fast	O
effect	O
of	O
the	O
prasugrel	B
during	O
the	O
antiplatelet	O
aggregation	O
are	O
fully	O
exerted	O
,	O
the	O
risk	O
of	O
bleeding	O
caused	O
by	O
the	O
prasugrel	B
is	O
effectively	O
reduced	O
and	O
the	O
compliance	O
of	O
patients	O
is	O
enhanced	O
.	O

Pharmaceutical	O
composition	O
containing	O
prasugrel	B
and	O
carbazochrome	B
sodium	I
sulfonate	I

The	O
invention	O
relates	O
to	O
a	O
method	O
for	O
preparing	O
zinc	O
supplementing	O
agent	O
carboxymethyl	B
chitosan	I
oligosaccharide	I
zinc	I
,	O
which	O
is	O
characterized	O
in	O
that	O
10	O
g	O
of	O
carboxymethyl	B
chitosan	I
is	O
taken	O
and	O
put	O
into	O
a	O
three	O
-	O
neck	O
flask	O
,	O
and	O
is	O
added	O
with	O
90ml	O
of	O
2	O
%	O
H2O2	B
in	O
batches	O
when	O
being	O
stirred	O
for	O
full	O
reaction	O
until	O
the	O
carboxymethyl	B
chitosan	I
is	O
completely	O
dissolved	O
;	O
pH	O
value	O
is	O
adjusted	O
to	O
be	O
7	O
,	O
the	O
precipitation	O
is	O
filtered	O
out	O
,	O
the	O
product	O
is	O
washed	O
,	O
and	O
filtrate	O
and	O
washing	O
liquid	O
are	O
collected	O
;	O
the	O
filtrate	O
and	O
the	O
washing	O
liquid	O
are	O
decompressed	O
and	O
concentrated	O
,	O
and	O
then	O
precipitated	O
,	O
filtered	O
and	O
washed	O
by	O
ethanol	O
;	O
finally	O
,	O
the	O
product	O
is	O
processed	O
by	O
vacuum	O
drying	O
with	O
the	O
drying	O
temperature	O
controlled	O
to	O
be	O
60	O
DEG	O
C.	O
The	O
invention	O
has	O
the	O
advantages	O
that	O
the	O
carboxymethyl	B
chitosan	I
is	O
prepared	O
after	O
chitosan	B
oligosaccharide	I
is	O
modified	O
,	O
so	O
as	O
to	O
have	O
the	O
pharmacological	O
actions	O
of	O
arrhythmia	O
resistance	O
,	O
anticoagulation	O
,	O
infection	O
resistance	O
and	O
the	O
like	O
;	O
the	O
carboxymethyl	B
chitosan	I
oligosaccharide	I
zinc	I
is	O
natural	O
modified	O
product	O
and	O
has	O
better	O
safety	O
and	O
biological	O
activity	O
compared	O
with	O
other	O
zinc	B
supplementing	O
agents	O
.	O

Method	O
for	O
preparing	O
zinc	B
supplementing	O
agent	O
carboxymethyl	B
chitosan	I
oligosaccharide	I
zinc	I

The	O
invention	O
discloses	O
two	O
sterol	B
derivatives	O
,	O
a	O
separation	O
and	O
extraction	O
method	O
thereof	O
and	O
an	O
application	O
thereof	O
in	O
preventing	O
and	O
treating	O
prostatoplasia	O
diseases	O
.	O

The	O
two	O
sterol	B
derivatives	O
arecompounds	O
24-methylene	B
cholesterol	I
linoleate	I
and	O
cycloeucalenol	B
linoleate	I
shown	O
as	O
formula	O
1	O
and	O
formula	O
2	O
.	O

The	O
compounds	O
which	O
are	O
not	O
reported	O
have	O
the	O
function	O
of	O
inhibiting	O
the	O
activity	O
of	O
aromatizing	O
enzyme	O
.	O

The	O
invention	O
also	O
discloses	O
an	O
application	O
of	O
the	O
two	O
sterol	B
derivatives	O
in	O
preparing	O
preparations	O
to	O
inhibit	O
the	O
activity	O
of	O
aromatizing	O
enzyme	O
and	O
in	O
preparing	O
pharmaceutical	O
compositions	O
to	O
prevent	O
or	O
treat	O
prostatoplasia	O
diseases	O
.	O

Two	O
sterol	B
derivatives	O
,	O
separation	O
and	O
extraction	O
method	O
thereof	O
and	O
application	O
thereof	O
in	O
preventing	O
and	O
treating	O
prostatoplasia	O
diseases	O

The	O
invention	O
discloses	O
a	O
Tibetan	O
medicine	O
aerosol	O
for	O
treating	O
acute	O
and	O
chronic	O
sprains	O
and	O
contusions	O
,	O
rheumatism	O
and	O
rheumatoid	O
disease	O
,	O
comprising	O
raw	O
medicines	O
of	O
Lamiophlomis	O
rotate	O
,	O
whin	O
,	O
curcuma	O
,	O
pricklyash	O
peel	O
,	O
comu	O
bubal	O
,	O
Myricaria	O
paniculata	O
,	O
safflower	O
,	O
camphol	O
and	O
the	O
like	O
.	O

The	O
pharmaceutical	O
composition	O
of	O
the	O
invention	O
has	O
the	O
functions	O
of	O
activating	O
blood	O
and	O
dissolving	O
stasis	O
,	O
and	O
relieving	O
swelling	O
and	O
pain	O
.	O

The	O
aerosol	O
of	O
the	O
invention	O
is	O
characterized	O
by	O
advanced	O
dosage	O
form	O
,	O
simple	O
process	O
,	O
rapid	O
effect	O
and	O
the	O
like	O
.	O

Tibetan	O
medicine	O
aerosol	O
for	O
treating	O
acute	O
and	O
chronic	O
sprains	O
and	O
contusions	O
,	O
rheumatism	O
and	O
rheumatoid	O
disease	O

The	O
invention	O
discloses	O
a	O
stomachic	O
hericium	O
erinaceum	O
polysaccharide	O
health	O
-	O
care	O
capsule	O
.	O

The	O
health	O
-	O
care	O
product	O
comprises	O
the	O
following	O
compositions	O
in	O
percentage	O
by	O
weight	O
:	O
10	O
to	O
30	O
percent	O
of	O
hericium	O
erinaceum	O
polysaccharide	O
,	O
70	O
to	O
90	O
percent	O
of	O
hericium	O
erinaceum	O
polysaccharide	O
byproduct	O
,	O
1	O
to	O
10	O
percent	O
of	O
glycopeptide	O
,	O
1	O
to	O
10	O
percent	O
of	O
oleanolic	B
acid	I
,	O
1	O
to	O
10	O
percent	O
of	O
ethylamine	B
sulfonic	I
acid	I
,	O
1	O
to	O
10	O
percent	O
of	O
alkaloid	B
and	O
1	O
to	O
10	O
percent	O
of	O
terpenoid	B
.	O

The	O
main	O
composition	O
of	O
the	O
stomachic	O
hericium	O
erinaceum	O
polysaccharide	O
health	O
-	O
care	O
capsule	O
is	O
the	O
hericium	O
erinaceum	O
polysaccharide	O
,	O
can	O
be	O
stored	O
at	O
normal	O
temperature	O
,	O
improve	O
the	O
immunity	O
level	O
of	O
cells	O
,	O
promote	O
the	O
repair	O
of	O
gastrointestinal	O
mucosa	O
,	O
relieve	O
the	O
gastrointestinal	O
spasm	O
,	O
inhibit	O
the	O
tumor	O
growth	O
,	O
promote	O
the	O
digestive	O
absorption	O
,	O
improve	O
the	O
inflammation	O
of	O
a	O
digestive	O
system	O
,	O
regulate	O
the	O
disorder	O
of	O
gastrointestinal	O
flora	O
and	O
has	O
the	O
functions	O
of	O
strengthening	O
spleen	O
,	O
harmonizing	O
stomach	O
,	O
replenishing	O
spleen	O
qi	O
and	O
relieving	O
pain	O
.	O

The	O
stomachic	O
hericium	O
erinaceum	O
polysaccharide	O
health	O
-	O
care	O
capsule	O
is	O
suitable	O
for	O
the	O
conditioning	O
and	O
health	O
care	O
of	O
diseases	O
of	O
the	O
digestive	O
system	O
.	O

Stomachic	O
hericium	O
erinaceum	O
polysaccharide	O
health	O
-	O
care	O
capsule	O

The	O
invention	O
discloses	O
a	O
medicament	O
composition	O
for	O
treating	O
climacteric	O
syndrome	O
of	O
women	O
.	O

The	O
medicament	O
composition	O
is	O
prepared	O
by	O
taking	O
medroxyprogesterone	B
,	O
nadestryl	O
,	O
amino	B
acid	I
chelated	O
calcium	B
,	O
vitamin	B
A	I
,	O
vitamin	B
D	I
and	O
vitamin	B
E	I
as	O
raw	O
materials	O
and	O
processing	O
the	O
raw	O
materials	O
according	O
to	O
a	O
conventional	O
preparation	O
.	O

By	O
complementing	O
estrogen	B
,	O
progestational	O
hormone	O
,	O
calcium	B
and	O
vitamin	B
,	O
the	O
invention	O
is	O
used	O
for	O
treating	O
the	O
climacteric	O
syndrome	O
of	O
women	O
.	O

Medicament	O
composition	O
for	O
treating	O
climacteric	O
syndrome	O
of	O
women	O

Compositions	O
and	O
methods	O
for	O
treating	O
wounds	O
to	O
significantly	O
reduce	O
the	O
healing	O
time	O
,	O
reduce	O
the	O
incidence	O
of	O
scar	O
formation	O
,	O
improve	O
the	O
success	O
of	O
skin	O
grafts	O
,	O
reduce	O
the	O
inflammatory	O
response	O
and	O
providing	O
anti	O
-	O
bacterial	O
treatments	O
to	O
a	O
patient	O
in	O
need	O
thereof	O
,	O
that	O
include	O
small	O
non	O
-	O
interlinked	O
particles	O
of	O
bioactive	O
glass	O
or	O
highly	O
porous	O
bioactive	O
glass	O
,	O
are	O
disclosed	O
.	O

Anti	O
-	O
bacterial	O
solutions	O
derived	O
from	O
bioactive	O
glass	O
,	O
and	O
methods	O
of	O
preparation	O
and	O
use	O
thereof	O
,	O
are	O
also	O
disclosed	O
.	O

The	O
compositions	O
include	O
non	O
-	O
interlinked	O
particles	O
of	O
bioactive	O
glass	O
,	O
alone	O
or	O
in	O
combination	O
with	O
anti	O
-	O
bacterial	O
agents	O
and/or	O
anti	O
-	O
inflammatory	O
agents	O
.	O

The	O
compositions	O
can	O
include	O
an	O
appropriate	O
carrier	O
for	O
topical	O
administration	O
.	O

Anti	O
-	O
bacterial	O
properties	O
can	O
be	O
imparted	O
to	O
implanted	O
materials	O
,	O
such	O
as	O
prosthetic	O
implants	O
,	O
sutures	O
,	O
stents	O
,	O
screws	O
,	O
plates	O
,	O
tubes	O
,	O
and	O
the	O
like	O
,	O
by	O
incorporating	O
small	O
bioactive	O
glass	O
particles	O
or	O
porous	O
bioactive	O
glass	O
into	O
or	O
onto	O
the	O
implanted	O
materials	O
.	O

Anti	O
-	O
bacterial	O
properties	O
can	O
also	O
be	O
imparted	O
to	O
devices	O
used	O
for	O
in	O
vitro	O
and	O
ex	O
vivo	O
cell	O
culture	O
by	O
incorporating	O
non	O
-	O
interlinked	O
particles	O
of	O
bioactive	O
glass	O
into	O
the	O
devices	O
.	O

Anti	O
-	O
bacterial	O
compositions	O
derived	O
from	O
aqueous	O
extracts	O
of	O
bioactive	O
glass	O
are	O
also	O
disclosed	O
.	O

These	O
compositions	O
can	O
be	O
used	O
,	O
for	O
example	O
,	O
in	O
food	O
preparation	O
,	O
solutions	O
used	O
for	O
cell	O
culture	O
,	O
and	O
buffer	O
solutions	O
,	O
such	O
as	O
i.v	O
.	O

solutions	O
.	O

Anti	O
-	O
inflammatory	O
and	O
antimicrobial	O
uses	O
for	O
bioactive	O
glass	O
compositions	O

The	O
invention	O
relates	O
to	O
a	O
lipidosome	O
medical	O
composition	O
which	O
uses	O
fluticasone	B
propionate	I
as	O
an	O
active	O
component	O
,	O
and	O
a	O
cyst	O
diameter	O
of	O
lipidosome	O
is	O
smaller	O
than	O
800	O
nm	O
.	O

The	O
composition	O
comprises	O
0.025	O
percent	O
to	O
0.2	O
percent	O
of	O
fluticasone	B
propionate	I
as	O
the	O
active	O
component	O
,	O
0.5	O
percent	O
to	O
6	O
percent	O
of	O
phospholipid	O
,	O
0	O
percent	O
to	O
1	O
percent	O
of	O
lipophilic	O
additive	O
,	O
0.01	O
percent	O
to	O
1	O
percent	O
of	O
antioxidant	O
which	O
is	O
used	O
for	O
preserving	O
the	O
medical	O
composition	O
,	O
a	O
pH	O
buffering	O
agent	O
which	O
is	O
used	O
for	O
retaining	O
the	O
pH	O
value	O
from	O
5	O
to	O
7.5	O
,	O
3	O
percent	O
to	O
15	O
percent	O
of	O
humectant	O
,	O
20	O
percent	O
to	O
30	O
percent	O
of	O
oil	O
phrase	O
component	O
,	O
0.01	O
percent	O
to	O
0.1	O
percent	O
of	O
antimicrobial	O
preservative	O
and	O
the	O
balanced	O
of	O
water	O
.	O

The	O
fluticasone	B
propionate	I
lipidosome	O
cream	O
is	O
used	O
for	O
treating	O
skin	O
diseases	O
of	O
human	O
beings	O
or	O
animals	O
.	O

Fluticasone	B
propionate	I
lipidosome	O
cream	O

The	O
invention	O
relates	O
to	O
a	O
solution	O
preparation	O
for	O
atomizing	O
and	O
inhaling	O
ambroxol	B
,	O
and	O
belongs	O
to	O
the	O
field	O
of	O
pharmaceutics	O
.	O

The	O
solution	O
preparation	O
for	O
atomizing	O
and	O
inhaling	O
the	O
ambroxol	B
comprises	O
(	O
1	O
)	O
ambroxol	B
or	O
medicinal	O
salt	O
thereof	O
with	O
single	O
medicinal	O
dosage	O
,	O
(	O
2	O
)	O
isotonic	O
agent	O
and	O
solvent	O
,	O
(	O
3	O
)	O
buffer	O
solution	O
and	O
(	O
4	O
)	O
medicinal	O
package	O
with	O
single	O
dosage	O
;	O
and	O
in	O
terms	O
of	O
the	O
ambroxol	B
,	O
the	O
mass	O
ratio	O
of	O
the	O
medicinal	O
components	O
to	O
the	O
isotonic	O
agent	O
is	O
1:1.1	O
-	O
1:3.3.The	O
invention	O
provides	O
the	O
solution	O
preparation	O
for	O
atomizing	O
and	O
inhaling	O
the	O
ambroxol	B
with	O
single	O
dosage	O
and	O
the	O
medicinal	O
package	O
adopting	O
blowing	O
-	O
filling	O
-	O
sealing	O
(	O
BFS	O
)	O
integrative	O
full	O
-	O
automatic	O
production	O
,	O
which	O
have	O
the	O
advantages	O
that	O
the	O
medicinal	O
package	O
is	O
designed	O
and	O
manufactured	O
for	O
patients	O
special	O
for	O
atomizing	O
and	O
inhaling	O
;	O
the	O
solution	O
preparation	O
does	O
not	O
contain	O
preservative	O
,	O
and	O
is	O
used	O
with	O
disposable	O
single	O
dosage	O
;	O
the	O
using	O
process	O
is	O
convenient	O
and	O
does	O
not	O
need	O
dilution	O
and	O
preparation	O
;	O
and	O
the	O
microbe	O
pollution	O
,	O
waste	O
and	O
the	O
like	O
during	O
using	O
can	O
be	O
greatly	O
reduced	O
.	O

The	O
medicinal	O
preparation	O
provides	O
a	O
treatment	O
medicament	O
and	O
a	O
treatment	O
proposal	O
with	O
accurate	O
medicinal	O
dosage	O
,	O
good	O
-	O
quality	O
and	O
stable	O
medicament	O
quality	O
,	O
and	O
safe	O
and	O
simple	O
clinical	O
application	O
lacking	O
in	O
the	O
prior	O
art	O
.	O

Solution	O
preparation	O
for	O
atomizing	O
and	O
inhaling	O
ambroxol	B
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
an	O
enrofloxacin	B
double	O
emulsion	O
for	O
livestock	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
wherein	O
the	O
enrofloxacin	B
double	O
emulsion	O
belongs	O
to	O
the	O
field	O
of	O
antibiotic	O
preparations	O
for	O
livestock	O
.	O

The	O
W	O
/	O
O	O
/	O
W	O
type	O
double	O
emulsion	O
is	O
prepared	O
by	O
using	O
enrofloxacin	B
as	O
active	O
ingredients	O
and	O
adding	O
oil	O
phase	O
,	O
emulsifier	O
,	O
stabilizer	O
and	O
the	O
like	O
.	O

The	O
enrofloxacin	B
double	O
emulsion	O
for	O
livestock	O
can	O
better	O
cover	O
the	O
bitter	O
taste	O
of	O
the	O
enrofloxacin	B
,	O
improves	O
the	O
adaptation	O
of	O
oral	O
drugs	O
for	O
livestock	O
,	O
can	O
better	O
control	O
the	O
diffusion	O
rate	O
of	O
the	O
drugs	O
to	O
play	O
a	O
role	O
of	O
slow	O
release	O
,	O
and	O
better	O
adapts	O
different	O
clinical	O
drugs	O
requirements	O
.	O

Clinical	O
tests	O
show	O
that	O
the	O
invention	O
can	O
overcome	O
phenomena	O
of	O
food	O
refusal	O
and	O
poor	O
appetite	O
of	O
taste	O
acuity	O
animals	O
of	O
pigs	O
and	O
the	O
like	O
,	O
therebyensuring	O
the	O
dosage	O
,	O
improving	O
the	O
medicine	O
effect	O
,	O
and	O
achieving	O
the	O
purpose	O
of	O
ideal	O
treatment	O
.	O

Meanwhile	O
,	O
because	O
of	O
a	O
certain	O
slow	O
release	O
function	O
,	O
the	O
frequency	O
for	O
medicine	O
administration	O
can	O
be	O
reduced	O
,	O
and	O
the	O
invention	O
provides	O
an	O
efficient	O
and	O
long	O
-	O
acting	O
enrofloxacin	B
preparation	O
for	O
clinical	O
veterinarian	O
.	O

Enrofloxacin	B
double	O
emulsion	O
for	O
livestock	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicine	O
,	O
particularly	O
relates	O
to	O
a	O
new	O
use	O
of	O
isosorbide	B
5-mononitrate	I
and	O
a	O
corresponding	O
new	O
dosage	O
form	O
suitable	O
for	O
the	O
new	O
use	O
,	O
and	O
concretely	O
relates	O
to	O
a	O
use	O
of	O
isosorbide	B
5-mononitrate	I
in	O
preparing	O
drug	O
for	O
improving	O
the	O
receptive	O
performance	O
of	O
endometrium	O
.	O

The	O
improvement	O
of	O
the	O
receptive	O
performance	O
of	O
endometrium	O
is	O
concretely	O
realized	O
through	O
repairing	O
and	O
improving	O
the	O
endometrium	O
,	O
or	O
through	O
prompting	O
the	O
development	O
of	O
uterus	O
glandular	O
organ	O
,	O
or	O
through	O
prompting	O
the	O
development	O
of	O
uterus	O
mesenchyma	O
.	O

In	O
order	O
to	O
adapt	O
to	O
the	O
four	O
new	O
uses	O
,	O
the	O
prepared	O
drug	O
is	O
vagina	O
local	O
drug	O
feeding	O
preparation	O
,	O
namely	O
,	O
preparation	O
which	O
takes	O
isosorbide	B
5-mononitrate	I
with	O
effective	O
amount	O
as	O
active	O
components	O
and	O
is	O
prepared	O
through	O
adding	O
accessories	O
which	O
are	O
allowable	O
in	O
pharmacy	O
.	O

The	O
isosorbide	B
5-mononitrate	I
not	O
only	O
can	O
exert	O
excellent	O
medical	O
effects	O
of	O
prompting	O
the	O
development	O
of	O
endometrium	O
tissues	O
and	O
improving	O
the	O
receptive	O
performance	O
of	O
endometrium	O
,	O
but	O
also	O
can	O
effectively	O
avoid	O
the	O
side	O
effect	O
that	O
isosorbide	B
5-mononitrate	I
lowers	O
blood	O
pressure	O
after	O
giving	O
drug	O
in	O
vagina	O
,	O
and	O
provides	O
a	O
new	O
choice	O
for	O
clinical	O
application	O
.	O

New	O
use	O
of	O
isosorbide	B
mononitrate	I
in	O
preparing	O
medicine	O
for	O
increasing	O
endometrial	O
thickness	O

The	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
for	O
treating	O
skin	O
(	O
A	O
)	O
disease	O
,	O
having	O
the	O
strong	O
eliminating	O
function	O
on	O
bacteria	O
,	O
epiphyte	O
and	O
viruses	O
and	O
has	O
the	O
obvious	O
effect	O
on	O
tinea	O
of	O
feet	O
and	O
hands	O
,	O
onychomycosis	O
,	O
tinea	O
cruris	O
,	O
scald	O
head	O
,	O
furuncle	O
,	O
mosquito	O
bite	O
and	O
acrohyperhidrosis	O
.	O

The	O
high	O
-	O
molecule	O
material	O
and	O
recipe	O
composition	O
of	O
the	O
pharmaceutical	O
composition	O
has	O
no	O
poison	O
and	O
little	O
stimulation	O
on	O
skin	O
,	O
has	O
long	O
action	O
time	O
and	O
presents	O
the	O
actions	O
of	O
controlled	O
release	O
and	O
stability	O
.	O

The	O
quality	O
can	O
be	O
kept	O
to	O
be	O
stable	O
when	O
the	O
composition	O
is	O
stored	O
at	O
normal	O
temperature	O
,	O
and	O
thereby	O
,	O
the	O
composition	O
is	O
safe	O
and	O
effective	O
.	O

The	O
composition	O
contains	O
the	O
main	O
constituents	O
of	O
povidone	B
iodine	I
,	O
acetylsalicylic	B
acid	I
,	O
polyethylene	B
glycol	I
,	O
potash	B
iodate	I
,	O
phenol	B
and	O
high	O
-	O
molecule	O
material	O
.	O

Pharmaceutical	O
composition	O
for	O
treating	O
skin	O
(	O
A	O
)	O
disease	O

The	O
invention	O
relates	O
to	O
the	O
technical	O
field	O
of	O
zinc	B
supplement	O
,	O
in	O
particular	O
to	O
a	O
transdermal	O
zinc	B
supplement	O
which	O
comprises	O
zinc	B
oxide	I
and	O
citric	B
acid	I
and	O
is	O
characterized	O
by	O
comprising	O
the	O
following	O
raw	O
material	O
components	O
by	O
weight	O
percent	O
:	O
10	O
-	O
40	O
%	O
of	O
zinc	B
oxide	I
,	O
30	O
-	O
70	O
%	O
of	O
citric	B
acid	I
and	O
10	O
-	O
50	O
%	O
of	O
sodium	B
hydroxide	I
.	O

A	O
method	O
for	O
manufacturing	O
the	O
transdermal	O
zinc	B
supplement	O
comprises	O
the	O
following	O
steps	O
:	O
weighing	O
the	O
raw	O
material	O
components	O
according	O
to	O
the	O
weight	O
percent	O
,	O
and	O
mixing	O
and	O
grinding	O
the	O
raw	O
material	O
components	O
until	O
being	O
evenly	O
mixed	O
;	O
heating	O
the	O
ground	O
material	O
to	O
the	O
temperature	O
of	O
120	O
-	O
150	O
DEG	O
C	O
and	O
then	O
carrying	O
out	O
heat	O
preservation	O
for	O
1	O
-	O
2h	O
to	O
lead	O
the	O
material	O
to	O
be	O
dried	O
;	O
and	O
finally	O
,	O
crushing	O
the	O
dried	O
material	O
,	O
screening	O
the	O
material	O
by	O
a	O
No.	O
5	O
sieve	O
,	O
obtaining	O
undersized	O
material	O
which	O
is	O
the	O
finished	O
product	O
of	O
the	O
transdermal	O
zinc	B
supplement	O
,	O
and	O
then	O
split	O
packaging	O
the	O
obtained	O
finished	O
product	O
of	O
the	O
transdermal	O
zinc	B
supplement	O
.	O

The	O
transdermal	O
zinc	B
supplement	O
can	O
avoid	O
the	O
interference	O
of	O
gastrointestinal	O
tract	O
as	O
well	O
as	O
the	O
influence	O
of	O
factors	O
such	O
as	O
the	O
pH	O
value	O
of	O
the	O
gastrointestinal	O
tract	O
,	O
food	O
,	O
digestive	O
juice	O
and	O
the	O
like	O
,	O
improves	O
the	O
bioavailability	O
of	O
the	O
zinc	B
supplement	O
,	O
has	O
wide	O
application	O
range	O
including	O
infants	O
children	O
,	O
pregnant	O
women	O
,	O
nursing	O
women	O
and	O
adults	O
,	O
and	O
improves	O
the	O
life	O
quality	O
of	O
the	O
whole	O
life	O
.	O

Transdermal	O
zinc	B
supplement	O

The	O
invention	O
relates	O
to	O
cyclopentenyl	B
fatty	I
acid	I
and	O
ester	B
or	O
a	O
solvate	O
thereof	O
.	O

The	O
cyclopentenyl	B
fatty	I
acid	I
consists	O
of	O
a	O
cyclopentenyl	B
structural	O
unit	O
and	O
a	O
long	O
-	O
chain	O
fatty	O
acid	O
or	O
the	O
ester	O
or	O
the	O
solvate	O
thereof	O
,	O
and	O
compounds	O
with	O
structural	O
formulas	O
A	O
and	O
B	O
are	O
preferable	O
.	O

The	O
invention	O
also	O
relates	O
to	O
a	O
preparation	O
method	O
of	O
the	O
compounds	O
and	O
application	O
thereof	O
in	O
preparing	O
anti	O
-	O
tuberculous	O
drugs	O
.	O

Cyclopentenyl	B
fatty	I
acid	I
,	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
discloses	O
an	O
ornidazole	B
medicinal	O
composition	O
.	O

Each	O
100	O
milliliters	O
of	O
ornidazole	B
medicinal	O
composition	O
contains	O
5	O
grams	O
of	O
ornidazole	B
,	O
35	O
to	O
60	O
milliliters	O
of	O
1,2-propylene	B
glycol	I
and	O
the	O
balance	O
of	O
water	O
for	O
injection	O
.	O

The	O
pH	O
value	O
of	O
the	O
ornidazole	B
medicinal	O
composition	O
is	O
2.5	O
to	O
4.5	O
.	O

The	O
composition	O
can	O
be	O
made	O
into	O
a	O
small	O
-	O
volume	O
injection	O
,	O
wherein	O
the	O
injection	O
can	O
be	O
a	O
5-milliliter	O
injection	O
containing	O
0.25	O
gram	O
of	O
the	O
composition	O
or	O
a	O
10-milliliter	O
injection	O
containing	O
0.5	O
gram	O
of	O
the	O
composition	O
.	O

The	O
invention	O
also	O
provides	O
a	O
preparation	O
method	O
of	O
the	O
ornidazole	B
medicinal	O
composition	O
,	O
which	O
comprises	O
:	O
adding	O
ornidazole	B
into	O
1,2-propylene	B
glycol	I
,	O
keeping	O
the	O
temperature	O
to	O
be	O
45	O
to	O
60	O
DEG	O
C	O
and	O
stirring	O
the	O
mixture	O
till	O
the	O
ornidazole	B
dissolves	O
completely	O
;	O
adding	O
disodium	B
ethylenediamintetraacetate	I
aqueous	O
solution	O
at	O
a	O
concentration	O
of	O
40	O
-	O
70mg	O
/	O
100ml	O
;	O
and	O
using	O
needle	O
active	O
carbon	B
for	O
absorption	O
and	O
microporous	O
filter	O
membrane	O
for	O
filtration	O
decarbonization	O
,	O
supplying	O
water	O
for	O
injection	O
and	O
adjusting	O
the	O
pH	O
value	O
to	O
2.5	O
to	O
4.5	O
to	O
obtain	O
the	O
ornidazole	B
medicinal	O
composition	O
.	O

The	O
method	O
provided	O
by	O
the	O
invention	O
has	O
simple	O
process	O
and	O
the	O
prepared	O
product	O
has	O
high	O
stability	O
.	O

Ornidazole	B
medicinal	O
composition	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
plaster	O
for	O
treating	O
facial	O
paralysis	O
,	O
which	O
comprises	O
rhizoma	O
typhonii	O
,	O
scorpio	O
,	O
stiff	O
silkworm	O
,	O
uncaria	O
,	O
rhizoma	O
gastrodiae	O
,	O
futokadsura	O
stem	O
,	O
notopterygium	O
root	O
,	O
asarum	O
,	O
herba	O
schizonepetae	O
,	O
radix	O
sileris	O
,	O
cicada	O
slough	O
,	O
angelica	O
root	O
,	O
centipede	O
,	O
zaocys	O
dhumnade	O
,	O
earthworm	O
,	O
mastic	O
,	O
myrrh	O
,	O
radix	O
salviae	O
miltiorrhizae	O
,	O
safflower	O
,	O
artemisia	O
anomala	O
,	O
cinnamon	O
,	O
rhizoma	O
ligustici	O
wallichii	O
,	O
red	O
peony	O
root	O
,	O
Chinese	O
ephedra	O
,	O
equisetum	O
,	O
tetrandra	O
root	O
,	O
rhizoma	O
atractylodis	O
,	O
pawpaw	O
,	O
pangolin	O
scales	O
,	O
speranskia	O
tuberculata	O
,	O
oyster	O
,	O
sea	O
-	O
ear	O
shell	O
,	O
strychnos	O
,	O
white	O
mustard	O
seed	O
,	O
musk	O
,	O
colophony	O
,	O
verdigris	O
,	O
draconis	O
sanguis	O
,	O
catechu	O
and	O
gleditsia	O
sinensis	O
lam	O
.	O

The	O
components	O
are	O
mutually	O
coordinated	O
to	O
achieve	O
the	O
functions	O
of	O
calming	O
the	O
endopathic	O
wind	O
,	O
relieving	O
convulsion	O
and	O
spasm	O
,	O
dispersing	O
pathogenic	O
wind	O
,	O
dispelling	O
cold	O
,	O
promoting	O
blood	O
circulation	O
,	O
relieving	O
the	O
stasis	O
of	O
blood	O
,	O
resolving	O
phlegm	O
,	O
reducing	O
the	O
stagnation	O
,	O
nourishing	O
the	O
blood	O
,	O
smoothing	O
collaterals	O
,	O
promoting	O
the	O
circulation	O
of	O
qi	O
and	O
alleviating	O
pain	O
.	O

Plaster	O
for	O
treating	O
facial	O
paralysis	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
method	O
for	O
preparing	O
oral	O
chondroitin	B
sulfate	I
nanoemulsion	O
,	O
belonging	O
to	O
the	O
field	O
of	O
the	O
pharmaceutical	O
preparation	O
.	O

The	O
oral	O
chondroitin	B
sulfate	I
nanoemulsion	O
is	O
clear	O
and	O
transparent	O
solution	O
which	O
comprises	O
oil	O
phase	O
,	O
surfactant	O
,	O
cosurfactant	O
and	O
water	O
phase	O
by	O
appropriate	O
proportion	O
,	O
wherein	O
the	O
proportion	O
of	O
the	O
oil	O
phase	O
to	O
the	O
surfactant	O
is	O
45:1	O
-	O
1:7	O
,	O
and	O
the	O
proportion	O
of	O
the	O
surfactant	O
to	O
the	O
cosurfactant	O
is	O
4:1	O
-	O
1:4	O
.	O

The	O
oral	O
chondroitin	B
sulfate	I
nanoemulsion	O
can	O
improve	O
the	O
bioavailability	O
of	O
the	O
chondroitin	B
sulfate	I
,	O
reduce	O
the	O
toxic	O
and	O
side	O
effect	O
of	O
the	O
chondroitin	B
sulfate	I
and	O
fully	O
exert	O
the	O
efficacy	O
of	O
the	O
chondroitin	B
sulfate	I
.	O

Method	O
for	O
preparing	O
oral	O
chondroitin	B
sulfate	I
nanoemulsion	O

The	O
invention	O
relates	O
to	O
a	O
raloxifene	B
emplastrum	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

Raloxifene	B
microemulsion	O
is	O
made	O
into	O
a	O
transdermal	O
emplastrum	O
which	O
is	O
divided	O
into	O
an	O
anti	O
-	O
adhesion	O
layer	O
,	O
a	O
viscose	O
layer	O
,	O
a	O
backlining	O
layer	O
and	O
a	O
medicine	O
storage	O
layer	O
.	O

The	O
raloxifene	B
microemulsion	O
taken	O
as	O
a	O
medical	O
ingredient	O
of	O
the	O
raloxifene	B
emplastrum	O
comprises	O
the	O
following	O
ingredients	O
:	O
raloxifene	B
taken	O
as	O
an	O
active	O
ingredient	O
,	O
polysorbate	B
taken	O
as	O
surfactant	O
,	O
propanediol	B
taken	O
as	O
cosurfactant	O
,	O
pure	O
water	O
or	O
distilled	O
water	O
,	O
and	O
the	O
like	O
.	O

Except	O
for	O
the	O
medical	O
ingredient	O
,	O
a	O
plurality	O
of	O
nonpolar	O
polymers	O
,	O
plasticizing	O
agent	O
,	O
caking	O
agent	O
,	O
transdermal	O
enhancing	O
agent	O
and	O
antioxidant	O
are	O
also	O
added	O
in	O
the	O
emplastrum	O
.	O

Compared	O
with	O
the	O
prior	O
dosage	O
forms	O
,	O
such	O
as	O
tablets	O
,	O
the	O
invention	O
has	O
the	O
remarkable	O
advantages	O
of	O
durable	O
medical	O
effect	O
,	O
safety	O
,	O
low	O
toxicity	O
,	O
simple	O
,	O
convenient	O
and	O
sanitary	O
,	O
and	O
accurate	O
medical	O
dosage	O
.	O

Raloxifene	B
emplastrum	O
preparation	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composite	O
for	O
reducing	O
blood	O
fat	O
,	O
which	O
comprises	O
sea	O
buckthorn	O
,	O
vitamin	B
B	I
complex	O
,	O
vitamin	B
E	I
and	O
trace	O
elements	O
of	O
zinc	B
,	O
selenium	B
,	O
chromium	B
and	O
molybdenum	B
.	O

The	O
pharmaceutical	O
composite	O
is	O
used	O
for	O
people	O
suffering	O
from	O
hyperlipaemia	O
,	O
has	O
very	O
good	O
effect	O
on	O
reducing	O
blood	O
fat	O
,	O
and	O
can	O
be	O
applied	O
to	O
a	O
long	O
time	O
or	O
in	O
course	O
of	O
treatment	O
.	O

Pharmaceutical	O
composite	O
for	O
reducing	O
blood	O
fat	O

The	O
invention	O
relates	O
to	O
a	O
cancer	O
pain	O
elimination	O
pill	O
which	O
is	O
a	O
medicament	O
for	O
treating	O
esophageal	O
cancer	O
,	O
esophagus	O
cancer	O
,	O
gastric	O
cancer	O
and	O
postoperation	O
metastasis	O
cancer	O
.	O

The	O
cancer	O
pain	O
elimination	O
pill	O
is	O
prepared	O
from	O
trogopterus	O
dung	O
,	O
akebia	O
trifoliata	O
koidz	O
.	O
,	O
long	O
-	O
noded	O
pit	O
viper	O
,	O
honeysuckle	O
flower	O
,	O
pangolin	O
,	O
fructus	O
amomi	O
,	O
lima	O
beans	O
,	O
borneol	O
,	O
radix	O
pseudostellariae	O
,	O
paris	O
polyphylla	O
,	O
radix	O
curcumae	O
,	O
white	O
paeony	O
roots	O
,	O
angelica	O
sinensis	O
,	O
peach	O
kernels	O
,	O
rabdosia	O
rubescens	O
,	O
curcuma	O
zedoary	O
,	O
rhizoma	O
zedoariae	O
,	O
malts	O
(	O
stirred	O
to	O
brown	O
)	O
,	O
hawthorns	O
(	O
stirred	O
to	O
brown	O
)	O
,	O
medicated	O
leaven	O
(	O
stirred	O
to	O
brown	O
)	O
,	O
agastache	O
rugosus	O
,	O
senecio	O
dianthus	O
franch	O
and	O
caulis	O
perllae	O
.	O

The	O
cancer	O
pain	O
elimination	O
pill	O
is	O
suitable	O
for	O
treating	O
the	O
esophageal	O
cancer	O
,	O
the	O
esophagus	O
cancer	O
,	O
the	O
gastric	O
cancer	O
and	O
the	O
postoperation	O
metastasis	O
cancer	O
,	O
has	O
good	O
curative	O
effect	O
and	O
quick	O
effect	O
,	O
treats	O
both	O
the	O
symptoms	O
and	O
root	O
causes	O
and	O
is	O
convenient	O
to	O
take	O
.	O

Proved	O
by	O
years	O
of	O
clinical	O
experiments	O
,	O
the	O
cancer	O
pain	O
elimination	O
pill	O
effectively	O
relieves	O
pains	O
of	O
patients	O
and	O
gets	O
the	O
praises	O
of	O
a	O
lot	O
of	O
patients	O
.	O

Cancer	O
pain	O
elimination	O
pill	O

The	O
invention	O
provides	O
a	O
preparation	O
method	O
and	O
products	O
of	O
danofloxacin	B
mesylate	I
liposome	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
(	O
1	O
)	O
adopting	O
the	O
ammonium	B
sulfate	I
gradient	O
method	O
to	O
prepare	O
blank	O
liposome	O
;	O
and	O
(	O
2	O
)	O
adding	O
danofloxacin	B
mesylate	I
liquor	O
in	O
the	O
blank	O
liposome	O
,	O
using	O
water	O
bath	O
for	O
incubation	O
,	O
filtrating	O
,	O
and	O
performing	O
repeated	O
freeze	O
thawing	O
to	O
the	O
filtrate	O
by	O
using	O
the	O
freeze	O
and	O
thawing	O
method	O
to	O
obtain	O
the	O
danofloxacin	B
mesylate	I
liposome	O
.	O

The	O
finished	O
liposome	O
prepared	O
by	O
the	O
preparation	O
method	O
of	O
the	O
invention	O
is	O
milky	O
semitransparent	O
mixed	O
suspension	O
which	O
appears	O
as	O
spherical	O
or	O
nearly	O
globose	O
small	O
vesicles	O
with	O
regular	O
shape	O
,	O
good	O
dispersity	O
and	O
uniform	O
grain	O
size	O
under	O
an	O
electron	O
microscope	O
;	O
the	O
entrapment	O
rate	O
of	O
the	O
liposome	O
is	O
above	O
90	O
%	O
and	O
the	O
liposome	O
has	O
good	O
stability	O
;	O
the	O
pharmacokinetic	O
and	O
pharmacodynamic	O
properties	O
of	O
the	O
liposome	O
are	O
better	O
than	O
that	O
of	O
conventional	O
dosage	O
forms	O
and	O
the	O
liposome	O
is	O
characterized	O
by	O
slow	O
release	O
,	O
long	O
acting	O
and	O
high	O
lung	O
-	O
targeting	O
.	O

Preparation	O
method	O
and	O
products	O
of	O
danofloxacin	B
mesylate	I
liposome	O

The	O
invention	O
relates	O
to	O
a	O
narcotic	O
-	O
abstaining	O
medicine	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
narcotic	O
-	O
abstaining	O
medicine	O
is	O
a	O
narcotic	O
-	O
abstaining	O
oral	O
medicine	O
prepared	O
from	O
the	O
raw	O
material	O
medicines	O
such	O
as	O
American	O
ginseng	O
,	O
astragalus	O
root	O
,	O
angelica	O
,	O
wild	O
or	O
spiny	O
jujuba	O
seed	O
,	O
schisandra	O
fruit	O
,	O
tuckahoe	O
,	O
corydalis	O
tuber	O
,	O
thymeleaf	O
sandwort	O
,	O
licorice	O
and	O
the	O
like	O
according	O
to	O
the	O
methods	O
of	O
grinding	O
,	O
decocting	O
,	O
distilling	O
,	O
concentrating	O
,	O
mixing	O
and	O
the	O
like	O
.	O

Clinical	O
observation	O
shows	O
that	O
the	O
medicine	O
has	O
good	O
functions	O
of	O
detoxication	O
and	O
addiction	O
abstaining	O
and	O
has	O
an	O
obvious	O
functionof	O
resisting	O
freak	O
-	O
out	O
recovery	O
,	O
and	O
the	O
narcotic	O
-	O
abstaining	O
rehabilitation	O
rate	O
of	O
resisting	O
freak	O
-	O
out	O
recovery	O
is	O
more	O
than	O
65	O
%	O
.	O

Anti	O
-	O
drug	O
medicine	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
new	O
phenolic	B
acid	I
compound	O
,	O
i.e.	O
danshinolic	B
acid	I
M	I
extracted	O
from	O
salvia	O
miltiorrhiza	O
bungered	O
sage	O
roots	O
,	O
the	O
compound	O
also	O
can	O
be	O
extracted	O
from	O
a	O
salvia	O
miltiorrhiza	O
bungered	O
sage	O
root	O
injection	O
,	O
and	O
the	O
invention	O
simultaneously	O
also	O
discloses	O
a	O
method	O
for	O
extracting	O
the	O
new	O
compound	O
respectively	O
from	O
the	O
salvia	O
miltiorrhiza	O
bungered	O
sage	O
roots	O
and	O
the	O
salvia	O
miltiorrhiza	O
bungered	O
sage	O
root	O
injection	O
.	O

Pharmacological	O
studies	O
indicate	O
that	O
the	O
danshinolic	B
acid	I
M	I
has	O
myocardial	O
preservation	O
and	O
oxidation	O
resistant	O
activity	O
,	O
thereby	O
the	O
compound	O
has	O
the	O
prospect	O
of	O
being	O
further	O
developed	O
into	O
an	O
effective	O
medicament	O
for	O
curing	O
treating	O
cardiovascular	O
diseases	O
and	O
can	O
be	O
used	O
in	O
the	O
quality	O
control	O
standard	O
of	O
the	O
salvia	O
miltiorrhiza	O
bunge	O
red	O
sage	O
root	O
injection	O
.	O

Compound	O
in	O
salvia	O
miltiorrhiza	O
bungered	O
sage	O
root	O
injection	O
and	O
application	O
thereof	O
in	O
curing	O
treating	O
cardiovascular	O
disease	O

The	O
invention	O
relates	O
to	O
substituted	O
pyridino-	B
[	I
2',1':2,3	I
]	I
imidazo	I
[	I
4,5-c	I
]	I
isoquinolone	I
compounds	O
,	O
a	O
method	O
for	O
synthesizing	O
the	O
same	O
,	O
use	O
of	O
the	O
same	O
and	O
a	O
medicinal	O
composition	O
having	O
the	O
same	O
,	O
in	O
particular	O
to	O
compounds	O
of	O
a	O
general	O
formula	O
(	O
I	O
)	O
or	O
stereoisomers	O
thereof	O
,	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
promedicaments	O
thereof	O
or	O
solvate	O
thereof	O
and	O
synthesis	O
method	O
thereof	O
.	O

With	O
specific	O
and	O
high	O
-	O
efficiency	O
mitosis	O
retarding	O
effect	O
,	O
the	O
compounds	O
can	O
be	O
used	O
as	O
mitosis	O
inhibitors	O
to	O
induce	O
the	O
apoptosis	O
of	O
cells	O
.	O

And	O
the	O
mechanism	O
of	O
action	O
of	O
the	O
compounds	O
is	O
different	O
from	O
those	O
of	O
known	O
mitosis	O
inhibitors	O
and	O
can	O
be	O
used	O
in	O
treating	O
leukemia	O
,	O
stomach	O
cancer	O
,	O
cervical	O
cancer	O
,	O
melanoma	O
,	O
colon	O
cancer	O
,	O
breast	O
cancer	O
,	O
ovarian	O
cancer	O
,	O
liver	O
cancer	O
and	O
lung	O
cancer	O
.	O

Substituted	O
pyridino-	B
[	I
2',1':2,3	I
]	I
imidazo	I
[	I
4,5-c	I
]	I
isoquinolone	I
compounds	O
,	O
method	O
for	O
synthesizing	O
same	O
,	O
use	O
of	O
same	O
and	O
medicinal	O
composition	O
having	O
same	O

The	O
invention	O
discloses	O
a	O
cefixime	B
oral	O
administration	O
mixed	O
suspension	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
in	O
order	O
to	O
meet	O
the	O
requirement	O
of	O
special	O
medicament	O
taking	O
crowds	O
on	O
the	O
taking	O
of	O
cefixime	B
.	O

The	O
cefixime	B
oral	O
administration	O
mixed	O
suspension	O
per	O
100ml	O
comprises	O
the	O
following	O
components	O
:	O
0.5	O
-	O
4.0	O
g	O
of	O
cefixime	B
,	O
larger	O
than	O
0	O
-	O
20.0	O
g	O
of	O
thickening	O
suspension	O
assistant	O
agent	O
,	O
a	O
cosolvent	O
,	O
a	O
flavoring	O
agent	O
,	O
a	O
preservative	O
and	O
the	O
balance	O
of	O
non	O
-	O
aqueous	O
liquid	O
medium	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
dissolving	O
the	O
preservative	O
into	O
the	O
cosolvent	O
;	O
adding	O
the	O
thickening	O
suspension	O
assistant	O
agent	O
into	O
the	O
non	O
-	O
aqueous	O
liquid	O
medium	O
,	O
stirring	O
and	O
dissolving	O
;	O
adding	O
solutions	O
of	O
the	O
flavoring	O
agent	O
,	O
the	O
preservative	O
and	O
the	O
cosolvent	O
uniformly	O
stirring	O
;	O
and	O
adding	O
cefixime	B
micropowder	O
and	O
uniformly	O
stirring	O
and	O
spreading	O
.	O

Compared	O
with	O
the	O
prior	O
art	O
,	O
the	O
unstable	O
cefixime	B
in	O
water	O
is	O
made	O
into	O
the	O
oral	O
administration	O
mixed	O
suspension	O
by	O
using	O
non	O
-	O
aqueous	O
liquid	O
as	O
a	O
dispersing	O
medium	O
,	O
and	O
the	O
invention	O
solves	O
the	O
problem	O
of	O
stability	O
,	O
has	O
good	O
taste	O
and	O
simple	O
preparation	O
method	O
,	O
is	O
convenient	O
for	O
children	O
,	O
old	O
people	O
and	O
a	O
dysphagia	O
patient	O
to	O
accept	O
and	O
is	O
suitable	O
for	O
industrialized	O
production	O
.	O

Cefixime	B
oral	O
administration	O
mixed	O
suspension	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
compound	O
of	O
N-	O
(	O
3-chloropyridine-4-group	O
)	O
-2-hydroxide	O
group-5-chlorbenzamide	O
,	O
the	O
first	O
preparation	O
method	O
comprises	O
the	O
steps	O
of	O
dissolving	O
2-	O
acetoxyl	O
group-5-lorobenzoyl	O
chloride	O
with	O
chloroform	O
,	O
adding	O
4-amino	O
group-3-chloropyridine	O
,	O
reacting	O
at	O
room	O
temperature	O
to	O
obtain	O
a	O
target	O
compound	O
,	O
wherein	O
triethylamine	O
is	O
used	O
an	O
acid	O
-	O
binding	O
agent	O
;	O
and	O
the	O
second	O
preparation	O
method	O
comprises	O
the	O
step	O
of	O
carrying	O
out	O
a	O
heating	O
reflow	O
reaction	O
on	O
2-acetoxyl	O
group-5-chlorobenzoic	O
methyl	O
formate	O
and	O
4-amino	O
group-3-chloropyridin	O
to	O
obtain	O
the	O
target	O
compound	O
.	O

The	O
compound	O
has	O
the	O
function	O
of	O
resisting	O
tubercule	O
bacillus	O
.	O

Preparation	O
and	O
application	O
of	O
N-	O
(	O
3-chloropyridine-4-group	O
)	O
-2-hydroxide	O
group-5-chlorbenzamide	O

The	O
invention	O
relates	O
to	O
a	O
docetaxel	B
nano	O
-	O
particle	O
composition	O
for	O
injection	O
administration	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
docetaxel	B
nano	O
-	O
particle	O
composition	O
contains	O
neutral	O
phospholipid	B
and	O
docetaxel	B
,	O
and	O
does	O
not	O
contain	O
negative	O
phospholipid	B
and	O
cholesterol	B
.	O

Docetaxel	B
nano	O
-	O
particle	O
composition	O

The	O
invention	O
discloses	O
a	O
method	O
for	O
preparing	O
a	O
block	O
polymer	O
micelle	O
freeze	O
-	O
drying	O
preparation	O
carrying	O
docetaxel	B
,	O
which	O
uses	O
a	O
PEO	B
-	O
PPO	B
-	O
PEO	B
block	O
polymer	O
as	O
a	O
micelle	O
carrier	O
to	O
wrap	O
the	O
docetaxel	B
inside	O
the	O
micelle	O
and	O
comprises	O
the	O
following	O
steps	O
:	O
(	O
1	O
)	O
dissolving	O
the	O
carrier	O
and	O
the	O
docetaxel	B
into	O
an	O
organic	O
solvent	O
to	O
make	O
the	O
PEO	B
-	O
PPO	B
-	O
PEO	B
block	O
polymer	O
and	O
the	O
docetaxel	B
fully	O
dissolved	O
in	O
the	O
organic	O
solvent	O
,	O
and	O
then	O
preparing	O
aqueous	O
solution	O
of	O
the	O
docetaxel	O
micelle	O
by	O
using	O
the	O
PEO	B
-	O
PPO	B
-	O
PEO	B
block	O
polymer	O
as	O
the	O
carrier	O
;	O
and	O
(	O
2	O
)	O
adding	O
a	O
freeze	O
-	O
drying	O
protective	O
agent	O
into	O
the	O
aqueous	O
solution	O
of	O
the	O
PEO	B
-	O
PPO	B
-	O
PEO	B
block	O
polymer	O
carrying	O
micelle	O
,	O
and	O
filtering	O
,	O
sterilizing	O
and	O
freeze	O
-	O
drying	O
the	O
mixture	O
to	O
obtain	O
freeze	O
-	O
drying	O
preparation	O
of	O
the	O
carrier	O
micelle	O
system	O
.	O

The	O
block	O
polymer	O
micelle	O
freeze	O
-	O
drying	O
preparation	O
carrying	O
the	O
docetaxel	B
can	O
increase	O
the	O
dissolubility	O
,	O
metabolic	O
stability	O
and	O
in	O
vivo	O
circulation	O
time	O
of	O
the	O
docetaxel	B
,	O
reduce	O
the	O
toxicity	O
and	O
improve	O
the	O
bioavailability	O
,	O
and	O
is	O
more	O
suitable	O
for	O
clinical	O
application	O
.	O

Method	O
for	O
preparing	O
block	O
polymer	O
micelle	O
freeze	O
-	O
drying	O
preparation	O
carrying	O
docetaxel	B

The	O
invention	O
provides	O
application	O
of	O
tetrahydrocurcumin	B
in	O
preparing	O
a	O
medicament	O
for	O
preventing	O
or	O
/	O
and	O
treating	O
a	O
set	O
of	O
clinical	O
syndromes	O
which	O
are	O
characterized	O
by	O
aggregating	O
a	O
variety	O
of	O
metabolic	O
disturbances	O
in	O
an	O
individual	O
,	O
such	O
as	O
obesity	O
,	O
hypertension	O
,	O
abnormal	O
blood	O
fat	O
,	O
abnormal	O
saccharometabolism	O
,	O
has	O
specific	O
medicinal	O
effect	O
,	O
and	O
is	O
a	O
new	O
treatment	O
medicament	O
which	O
can	O
simultaneously	O
and	O
effectively	O
correct	O
a	O
variety	O
of	O
clinical	O
disturbance	O
factors	O
of	O
MS	O
clinically	O
.	O

Novel	O
application	O
of	O
tetrahydrocurcumin	B

The	O
invention	O
provides	O
a	O
compound	O
preparation	O
prepared	O
from	O
lesser	O
galangal	O
rhizome	O
oil	O
,	O
nutgrass	O
galingale	O
rhizome	O
oil	O
and	O
clonidine	B
hydrochloride	I
,	O
which	O
is	O
an	O
external	O
preparation	O
for	O
treating	O
abdominal	O
pain	O
.	O

Clinical	O
tests	O
prove	O
that	O
the	O
prepared	O
emulsifiable	O
paste	O
preparation	O
has	O
good	O
treatment	O
effects	O
on	O
derangement	O
of	O
vitality	O
and	O
blood	O
,	O
and	O
irregular	O
cycles	O
,	O
abdominal	O
pain	O
during	O
menstruation	O
,	O
hypochondriac	O
pain	O
,	O
abdominal	O
distension	O
and	O
the	O
like	O
caused	O
by	O
the	O
derangement	O
of	O
vitality	O
and	O
blood	O
when	O
applied	O
to	O
abdomen	O
.	O

The	O
invention	O
also	O
carries	O
out	O
a	O
series	O
of	O
related	O
experiments	O
such	O
as	O
percutaneous	O
absorption	O
experiments	O
of	O
the	O
clonidine	B
hydrochloride	I
,	O
and	O
determination	O
tests	O
of	O
the	O
clonidine	B
hydrochloride	I
in	O
blood	O
concentration	O
,	O
which	O
further	O
affirms	O
medicinal	O
quality	O
control	O
and	O
clinical	O
effects	O
.	O

External	O
preparation	O
for	O
treating	O
abdominal	O
pain	O
and	O
women	O
's	O
menorrhalgia	O
,	O
preparation	O
method	O
thereof	O
,	O
and	O
quality	O
control	O
method	O
thereof	O

Disclosed	O
is	O
a	O
fat	O
emulsion	O
containing	O
a	O
compound	O
having	O
prostaglandin	B
E1	I
activity	O
,	O
which	O
fat	O
emulsion	O
is	O
hermetically	O
sealed	O
in	O
a	O
glass	O
container	O
and	O
then	O
heat	O
sterilized	O
.	O

The	O
residual	O
amount	O
of	O
prostaglandin	B
E1	I
activity	O
after	O
16-month	O
storage	O
at	O
5	O
DEG	O
C	O
is	O
not	O
less	O
than	O
65	O
%	O
but	O
not	O
more	O
than	O
100	O
%	O
of	O
the	O
prostaglandin	B
E1	I
activity	O
at	O
the	O
beginning	O
of	O
storage	O
.	O

Stable	O
fat	O
emulsion	O
containing	O
prostaglandin	B
e1	I

The	O
invention	O
provides	O
solid	O
dispersion	O
of	O
bromophenyl	B
-	I
substituted	I
thiazole	I
dihydropyrimidine	I
,	O
salts	O
thereof	O
or	O
hydrates	B
thereof	O
and	O
a	O
preparation	O
thereof	O
for	O
medical	O
purpose	O
.	O

Dissolutions	O
of	O
the	O
compound	O
of	O
bromophenyl	B
-	I
substituted	I
thiazole	I
dihydropyrimidine	I
,	O
the	O
salts	O
thereof	O
,	O
or	O
the	O
hydrates	B
thereof	O
in	O
various	O
mediums	O
are	O
improved	O
,	O
and	O
the	O
bioavailability	O
of	O
the	O
preparation	O
is	O
guaranteed	O
.	O

Solid	O
dispersion	O
of	O
dihydropyrimidine	B
compounds	O
and	O
preparation	O
thereof	O
for	O
medical	O
purpose	O

The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicines	O
and	O
relates	O
to	O
a	O
diaryl	B
pyrimidine	I
derivative	O
of	O
the	O
general	O
formula	O
I	O
,	O
medicinal	O
salts	O
thereof	O
,	O
hydrates	O
and	O
solvolytes	O
thereof	O
,	O
polycrystal	O
and	O
eutectic	O
thereof	O
,	O
and	O
precursors	O
and	O
derivatives	O
thereof	O
with	O
the	O
same	O
biological	O
functions	O
,	O
a	O
preparation	O
method	O
thereof	O
,	O
application	O
of	O
combination	O
containing	O
one	O
or	O
more	O
compounds	O
in	O
relative	O
medicines	O
for	O
treating	O
acquired	O
immune	O
deficiency	O
syndrome	O
and	O
the	O
like	O
,	O
a	O
preparation	O
method	O
and	O
use	O
of	O
the	O
combination	O
.	O

Experimental	O
results	O
show	O
that	O
the	O
compound	O
of	O
the	O
invention	O
not	O
only	O
has	O
excellent	O
biological	O
activity	O
of	O
resisting	O
HIV-1	O
virus	O
and	O
relatively	O
small	O
cytotoxicity	O
,	O
but	O
also	O
shows	O
relatively	O
good	O
inhibitory	O
action	O
to	O
a	O
drug	O
-	O
resistant	O
virus	O
strain	O
L103N+Y181C	O
,	O
can	O
be	O
used	O
as	O
medical	O
candidate	O
resisting	O
the	O
HIV	O
and	O
can	O
be	O
further	O
developed	O
as	O
a	O
medicine	O
resisting	O
AIDS	O
.	O

Diaryl	B
pyrimidine	I
derivative	O
,	O
preparation	O
method	O
and	O
use	O
thereof	O

The	O
invention	O
discloses	O
a	O
5-chloro	B
-	I
salicyloyl	I
hydrazine	I
tributyltin	I
chloride	I
coordination	O
compound	O
which	O
has	O
a	O
structural	O
formula	O
as	O
follows	O
.	O

A	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
sequentially	O
adding	O
1.5	O
-	O
2.0	O
mmol	O
of	O
N-1	O
,	O
8-naphthyl	B
diacyl-5-chloro	I
-	I
salicyloyl	I
hydrazine	I
,	O
3.0	O
-	O
4.0	O
mmol	O
of	O
sodium	B
methoxide	I
and	O
50	O
mL	O
of	O
absolute	O
methanol	B
,	O
stirring	O
for	O
0.5	O
hour	O
;	O
then	O
adding	O
2.0	O
-	O
3.0	O
mmol	O
of	O
tributyltin	B
chloride	I
,	O
stirring	O
for	O
6	O
-	O
8	O
hours	O
at	O
normal	O
temperature	O
;	O
filtering	O
,	O
rotationally	O
evaporating	O
filter	O
liquor	O
to	O
obtain	O
a	O
white	O
solid	O
;	O
and	O
then	O
recrystallizing	O
by	O
using	O
methylene	B
dichloride	I
-	O
absolute	O
methanol	B
to	O
obtain	O
a	O
light	O
yellow	O
crystal	O
,	O
i.e.	O
an	O
organotin	B
coordination	O
compound	O
which	O
has	O
higher	O
anticancer	O
activity	O
and	O
can	O
be	O
used	O
as	O
a	O
raw	O
material	O
for	O
preparing	O
drugs	O
treating	O
liver	O
cancer	O
and	O
cervical	O
cancer	O
.	O

Compared	O
with	O
the	O
traditional	O
commonly	O
-	O
used	O
platinum	B
anticancer	O
drug	O
,	O
the	O
organotin	B
coordination	O
compound	O
has	O
the	O
advantages	O
of	O
higher	O
anticancer	O
activity	O
,	O
good	O
lipid	O
solubility	O
,	O
low	O
cost	O
,	O
simple	O
preparation	O
method	O
,	O
and	O
the	O
like	O
.	O

5-chloro	B
-	I
salicyloyl	I
hydrazine	I
tributyltin	I
chloride	I
coordination	O
compound	O
as	O
well	O
as	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
preparation	O
formulations	O
of	O
a	O
sodium	B
pyruvate	I
freeze	O
-	O
dried	O
powder	O
injection	O
,	O
an	O
injection	O
and	O
a	O
solid	O
agent	O
and	O
production	O
processes	O
thereof	O
,	O
in	O
particular	O
to	O
a	O
method	O
and	O
a	O
technology	O
for	O
preparing	O
pyruvate	B
and	O
a	O
freeze	O
-	O
dried	O
powder	O
injection	O
,	O
an	O
injection	O
and	O
a	O
solid	O
agent	O
made	O
of	O
the	O
pyruvate	B
.	O

The	O
raw	O
materials	O
of	O
sodium	B
pyruvate	I
(	O
containing	O
calcium	B
and	O
potassium	B
)	O
is	O
synthesized	O
by	O
the	O
following	O
steps	O
of	O
:	O
reacting	O
pyruvic	O
acid	O
and	O
sodium	B
carbonate	I
(	O
salts	O
containing	O
organic	O
acid	O
)	O
produced	O
by	O
fermentation	O
and	O
chemical	O
synthesis	O
to	O
generate	O
sodium	B
pyruvate	I
(	O
and	O
corresponding	O
salts	O
)	O
at	O
a	O
reaction	O
temperature	O
of	O
20	O
-	O
90	O
DEG	O
C	O
for	O
60	O
-	O
70	O
min	O
;	O
filtering	O
in	O
vacuum	O
;	O
washing	O
the	O
crystal	O
with	O
ethyl	B
acetate	I
and	O
ethanol	B
for	O
3	O
-	O
5	O
times	O
;	O
drying	O
in	O
vacuum	O
to	O
obtain	O
a	O
product	O
with	O
the	O
purity	O
higher	O
than	O
99	O
percent	O
;	O
and	O
preparing	O
the	O
product	O
into	O
the	O
preparation	O
formulations	O
of	O
a	O
sodium	B
pyruvate	I
freeze	O
-	O
dried	O
powder	O
injection	O
,	O
an	O
injection	O
and	O
a	O
solid	O
agent	O
.	O

Preparation	O
formulations	O
of	O
sodium	B
pyruvate	I
freeze	O
-	O
dried	O
powder	O
injection	O
,	O
injection	O
and	O
solid	O
agent	O
and	O
production	O
processes	O
thereof	O

The	O
invention	O
provides	O
a	O
substance	O
with	O
a	O
structure	O
as	O
a	O
formula	O
I	O
,	O
wherein	O
R1	O
and	O
R2	O
in	O
the	O
formula	O
I	O
are	O
one	O
material	O
respectively	O
selected	O
from	O
alpha	B
-	I
arabinose	I
(	O
alpha	B
-	I
Ara	I
)	O
,	O
beta	B
-	I
arabinose	I
(	O
beta	B
-	I
Ara	I
)	O
and	O
beta	B
-	I
xylose	I
(	O
beta	B
-	I
Xyl	I
)	O
.	O

Dendrobii	O
extract	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
new	O
application	O
of	O
cimetidine	B
for	O
trauma	O
hemostasis	O
and	O
for	O
treating	O
periodontitis	O
.	O

The	O
method	O
for	O
trauma	O
hemostasis	O
comprises	O
the	O
following	O
steps	O
:	O
cimetidine	B
is	O
coated	O
on	O
the	O
bleeding	O
wound	O
surface	O
twice	O
each	O
day	O
with	O
dosage	O
thereof	O
being	O
approximately	O
200	O
mg	O
and	O
the	O
wound	O
can	O
be	O
cured	O
two	O
days	O
later	O
;	O
the	O
method	O
for	O
treating	O
periodontitis	O
:	O
one	O
tablet	O
of	O
cimetidine	B
weighing	O
200	O
mg	O
is	O
put	O
into	O
the	O
mouth	O
and	O
the	O
disease	O
can	O
be	O
cured	O
by	O
taking	O
the	O
medicine	O
once	O
a	O
day	O
.	O

The	O
medicine	O
of	O
the	O
invention	O
features	O
rapid	O
treatment	O
speed	O
,	O
good	O
curative	O
effect	O
and	O
radical	O
treatment	O
,	O
thus	O
being	O
widely	O
applied	O
to	O
various	O
groups	O
of	O
people	O
for	O
treating	O
trauma	O
hemostasis	O
and	O
periodontitis	O
.	O

New	O
application	O
of	O
cimetidine	B

The	O
invention	O
relates	O
to	O
propofol	B
phosphate	I
for	O
injection	O
,	O
pharmaceutical	O
salt	O
thereof	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
preparation	O
method	O
comprising	O
the	O
following	O
steps	O
:	O
adding	O
5	O
-	O
98	O
percent	O
of	O
water	O
for	O
injection	O
into	O
a	O
preparation	O
container	O
,	O
adding	O
propofol	B
phosphate	I
and	O
pharmaceutical	O
salt	O
thereof	O
of	O
90	O
-	O
110	O
percent	O
of	O
accurate	O
prescriptions	O
,	O
slowly	O
dropping	O
a	O
pH	O
value	O
regulator	O
while	O
stirring	O
so	O
as	O
to	O
adjust	O
the	O
pH	O
to	O
be	O
6.0	O
-	O
11	O
,	O
adding	O
water	O
to	O
the	O
full	O
volume	O
,	O
then	O
adding	O
medicinal	O
carbon	O
of	O
0.01	O
-	O
1.0	O
percent	O
(	O
W	O
/	O
V	O
)	O
,	O
stirring	O
for	O
15	O
-	O
60	O
minutes	O
,	O
roughly	O
filtering	O
with	O
a	O
sand	O
filter	O
rod	O
to	O
remove	O
the	O
carbon	O
,	O
and	O
finely	O
filtering	O
with	O
a	O
0.22mum	O
microporous	O
membrane	O
until	O
the	O
clarity	O
is	O
qualified	O
;	O
and	O
measuring	O
until	O
the	O
intermediate	O
content	O
is	O
acceptable	O
,	O
fixing	O
the	O
filling	O
amount	O
,	O
sub	O
-	O
packaging	O
into	O
cillin	O
bottles	O
,	O
plugging	O
in	O
plugs	O
by	O
half	O
,	O
freezing	O
and	O
drying	O
samples	O
to	O
control	O
the	O
moisture	O
content	O
being	O
0.1	O
-	O
8	O
percent	O
,	O
pressing	O
the	O
plugs	O
,	O
and	O
capping	O
.	O

Propofol	B
phosphate	I
for	O
injection	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
provides	O
lipoamide	B
series	O
derivates	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
derivates	O
are	O
characterized	O
in	O
that	O
the	O
molecular	O
structural	O
formula	O
of	O
the	O
compounds	O
are	O
represented	O
as	O
(	O
I	O
)	O
,	O
wherein	O
R1	O
is	O
one	O
of	O
substituted	O
phenyl	B
,	O
and	O
substituted	O
pyridyl	B
,	O
naphthyl	B
and	O
biphenyl	B
;	O
and	O
R2	O
is	O
one	O
of	O
hydrogen	B
,	O
C1	B
-	I
5	I
alkanoyl	I
and	I
aroyl	I
.	O

The	O
novel	O
derivates	O
have	O
low	O
toxicity	O
and	O
anti	O
-	O
tumor	O
activity	O
,	O
and	O
can	O
be	O
applied	O
to	O
preparation	O
of	O
functional	O
foods	O
or	O
medicament	O
for	O
preventing	O
or	O
curing	O
tumor	O
diseases	O
.	O

Lipoamide	B
series	O
derivates	O
,	O
preparation	O
method	O
and	O
pharmaceutical	O
application	O
thereof	O

The	O
invention	O
provides	O
a	O
compound	O
which	O
is	O
a	O
pyrimidine	B
of	O
formula	O
(	O
I	O
)	O
:	O
The	O
compounds	O
are	O
inhibitors	O
of	O
PI3	O
K	O
and	O
may	O
thus	O
be	O
used	O
to	O
treat	O
diseases	O
and	O
disorders	O
arising	O
from	O
abnormal	O
cell	O
growth	O
,	O
function	O
or	O
behaviour	O
associated	O
with	O
PI3	O
kinase	O
such	O
as	O
cancer	O
,	O
immune	O
disorders	O
,	O
cardiovascular	O
disease	O
,	O
viral	O
infection	O
,	O
inflammation	O
,	O
metabolism	O
/	O
endocrine	O
function	O
disorders	O
and	O
neurological	O
disorders	O
.	O

pharmaceutical	O
compounds	O

The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
antifungal	O
medicaments	O
and	O
provides	O
tolyltriazole	B
derivatives	O
having	O
a	O
structure	O
shown	O
as	O
a	O
general	O
formula	O
(	O
1	O
)	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O

In	O
the	O
general	O
formula	O
(	O
1	O
)	O
,	O
R1	O
,	O
R2	O
and	O
R3	O
are	O
defined	O
in	O
the	O
description	O
.	O

The	O
invention	O
also	O
relates	O
to	O
a	O
method	O
for	O
preparing	O
the	O
compounds	O
and	O
also	O
discloses	O
medicinal	O
compositions	O
using	O
thecompounds	O
or	O
the	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
as	O
active	O
ingredients	O
and	O
the	O
use	O
of	O
the	O
medicinal	O
compositions	O
as	O
antifungal	O
medicaments	O
.	O

Tolyltriazole	B
derivatives	O
,	O
preparation	O
method	O
thereof	O
and	O
use	O
thereof	O

The	O
invention	O
relates	O
to	O
the	O
technical	O
field	O
of	O
wine	O
,	O
in	O
particular	O
to	O
ant	O
and	O
ginseng	O
wine	O
.	O

The	O
invention	O
has	O
the	O
main	O
technical	O
scheme	O
that	O
1000	O
g	O
of	O
wine	O
comprises	O
1	O
to	O
5	O
g	O
of	O
ginseng	O
,	O
1	O
to	O
5	O
g	O
of	O
lucid	O
ganoderma	O
,	O
1	O
to	O
5	O
g	O
of	O
polyrhachis	O
vicina	O
,	O
0.01	O
to	O
0.1	O
g	O
of	O
stevioside	B
and	O
0.1	O
to	O
1	O
g	O
of	O
flavouring	O
agents	O
.	O

The	O
invention	O
gives	O
full	O
play	O
to	O
the	O
medical	O
value	O
of	O
the	O
ginseng	O
,	O
the	O
lucid	O
ganoderma	O
and	O
the	O
polyrhachis	O
vicina	O
per	O
se	O
,	O
so	O
the	O
ginseng	O
,	O
the	O
lucid	O
ganoderma	O
and	O
the	O
polyrhachis	O
vicina	O
have	O
the	O
pharmacodynamic	O
effects	O
,	O
and	O
in	O
addition	O
,	O
the	O
wine	O
has	O
the	O
effects	O
of	O
clearing	O
and	O
activating	O
the	O
channels	O
and	O
collaterals	O
,	O
nourishing	O
qi	O
,	O
activating	O
blood	O
and	O
regulating	O
the	O
immunity	O
in	O
two	O
ways	O
.	O

Particularly	O
,	O
the	O
wine	O
of	O
the	O
invention	O
is	O
sweet	O
,	O
contains	O
no	O
sugar	O
,	O
does	O
not	O
have	O
medicine	O
flavor	O
,	O
and	O
is	O
applicable	O
to	O
wide	O
range	O
of	O
people	O
.	O

Ant	O
and	O
ginseng	O
wine	O

The	O
invention	O
relates	O
to	O
Epothilone	B
derivatives	O
of	O
Formula	O
(	O
I	O
)	O
and	O
their	O
use	O
as	O
a	O
medicament	O
.	O

epothilone	B
derivatives	O

This	O
invention	O
relates	O
to	O
compounds	O
with	O
a	O
combination	O
of	O
cannabinoid	B
-	I
CB1antagonism	I
and	O
serotonin	O
reuptake	O
inhibition	O
to	O
pharmaceutical	O
compositions	O
containing	O
these	O
compounds	O
,	O
to	O
methods	O
for	O
preparing	O
the	O
compounds	O
,	O
methods	O
for	O
preparing	O
novel	O
intermediates	O
useful	O
for	O
their	O
synthesis	O
,	O
and	O
methods	O
for	O
preparing	O
compositions	O
.	O

The	O
invention	O
also	O
relates	O
to	O
the	O
uses	O
of	O
such	O
compounds	O
and	O
compositions	O
,	O
particularly	O
their	O
use	O
in	O
administering	O
them	O
to	O
patients	O
to	O
achieve	O
a	O
therapeutic	O
effect	O
in	O
psychosis	O
,	O
anxiety	O
,	O
depression	O
,	O
attention	O
deficits	O
,	O
cognitive	O
disorders	O
,	O
obesity	O
,	O
drug	O
dependence	O
,	O
Parkinson	O
's	O
disease	O
,	O
Alzheimer	O
's	O
disease	O
,	O
pain	O
disorders	O
,	O
neuropathic	O
pain	O
disorders	O
and	O
sexual	O
disorders	O
.	O

In	O
particular	O
the	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
the	O
symbols	O
have	O
the	O
meanings	O
given	O
in	O
the	O
specification	O
.	O

Compounds	O
with	O
a	O
combination	O
of	O
cannabinoid	B
-	I
CB1	I
antagonism	O
and	O
serotonin	B
reuptake	O
inhibition	O

The	O
invention	O
relates	O
to	O
a	O
salvianic	B
acid	I
A	I
pharmaceutical	O
composition	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

Salvianic	B
acid	I
A	I
can	O
be	O
dissolved	O
in	O
water	O
,	O
but	O
the	O
preparation	O
of	O
the	O
salvianic	B
acid	I
A	I
has	O
poor	O
stability	O
,	O
is	O
easy	O
for	O
oxidization	O
,	O
is	O
sensitive	O
to	O
light	O
and	O
heat	O
,	O
and	O
causes	O
content	O
reduction	O
and	O
impurity	O
increase	O
,	O
and	O
the	O
guarantee	O
on	O
the	O
stability	O
is	O
a	O
technical	O
problem	O
.	O

The	O
salvianic	B
acid	I
A	I
pharmaceutical	O
composition	O
comprises	O
the	O
salvianic	B
acid	I
A	I
,	O
a	O
pharmacological	O
allowable	O
pH	O
adjusting	O
substance	O
,	O
a	O
stabilizing	O
agent	O
and	O
an	O
excipient	O
.	O

The	O
salvianic	B
acid	I
A	I
in	O
the	O
salvianic	B
acid	I
A	I
pharmaceutical	O
composition	O
has	O
the	O
concentration	O
of	O
0.5	O
-	O
2,000	O
mg	O
.	O

The	O
weight	O
part	O
of	O
the	O
pH	O
adjusting	O
substance	O
is	O
the	O
adding	O
dosage	O
when	O
a	O
pH	O
value	O
is	O
adjusted	O
to	O
2.5	O
-	O
7.5	O
,	O
and	O
the	O
stabilizing	O
agent	O
in	O
the	O
salvianic	B
acid	I
A	I
pharmaceutical	O
composition	O
has	O
the	O
concentration	O
of	O
1mg-0.5	O
g	O
.	O

The	O
salvianic	B
acid	I
A	I
pharmaceutical	O
composition	O
is	O
used	O
as	O
an	O
injection	O
with	O
the	O
effects	O
of	O
protecting	O
the	O
cardiac	O
muscle	O
,	O
promoting	O
blood	O
circulation	O
,	O
removing	O
blood	O
stasis	O
,	O
resisting	O
bacteria	O
,	O
eliminating	O
inflammation	O
,	O
strengthening	O
body	O
immunity	O
,	O
resisting	O
atherosclerosis	O
,	O
reducing	O
blood	O
fat	O
,	O
resisting	O
platelet	O
aggregation	O
,	O
resisting	O
thrombosis	O
,	O
expanding	O
the	O
coronary	O
artery	O
,	O
treating	O
liver	O
injury	O
,	O
resisting	O
cerebral	O
ischemia	O
injury	O
,	O
resisting	O
tumors	O
,	O
and	O
the	O
like	O
and	O
a	O
therapeutical	O
effect	O
on	O
pulmonary	O
heart	O
disease	O
,	O
psoriasis	O
,	O
altitude	O
disease	O
,	O
and	O
the	O
like	O
.	O

Salvianic	B
acid	I
A	I
pharmaceutical	O
composition	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
composition	O
containing	O
potassium	B
sodium	I
dehydroandroan	I
drographolide	I
succinate	I
.	O

The	O
ratio	O
of	O
the	O
potassium	B
sodium	I
dehydroandroan	I
drographolide	I
succinate	I
to	O
methylmorphine	B
in	O
the	O
mixture	O
is	O
(	O
8	O
-	O
15	O
)	O
:1	O
,	O
based	O
on	O
the	O
weight	O
;	O
the	O
optimal	O
ratio	O
of	O
the	O
potassium	B
sodium	I
dehydroandroan	I
drographolide	I
succinate	I
to	O
the	O
methylmorphine	B
in	O
the	O
mixture	O
is	O
12:1	O
,	O
based	O
on	O
the	O
weight	O
;	O
and	O
the	O
ratio	O
of	O
the	O
mixture	O
of	O
the	O
potassium	B
sodium	I
dehydroandroan	I
drographolide	I
succinate	I
and	O
the	O
methylmorphine	B
to	O
poloxamer	O
is	O
25:1	O
,	O
based	O
on	O
the	O
weight	O
.	O

By	O
combining	O
potassium	B
sodium	I
dehydroandroan	I
drographolide	I
succinate	I
and	O
the	O
methylmorphin	B
,	O
the	O
invention	O
greatly	O
improves	O
the	O
antibacterial	O
activity	O
of	O
the	O
medicament	O
and	O
remarkably	O
reduces	O
the	O
side	O
effects	O
.	O

Composition	O
containing	O
potassium	B
sodium	I
dehydroandroan	I
drographolide	I
succinate	I

The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
pharmaceutical	O
chemistry	O
,	O
in	O
particular	O
to	O
a	O
preparation	O
method	O
of	O
new	O
flavonoids	B
compounds	O
and	O
application	O
of	O
the	O
new	O
flavonoids	B
compounds	O
as	O
an	O
alpha1	O
receptor	O
antagonist	O
,	O
wherein	O
R1	O
and	O
R2	O
are	O
defined	O
as	O
the	O
specifications	O
.	O

A	O
group	O
with	O
larger	O
polarity	O
is	O
introduced	O
in	O
a	O
flavones	B
structure	O
to	O
enable	O
the	O
polarity	O
of	O
an	O
integral	O
molecule	O
to	O
be	O
increased	O
;	O
meanwhile	O
,	O
the	O
compounds	O
have	O
a	O
certain	O
alkalinity	O
and	O
can	O
be	O
formed	O
into	O
salts	O
with	O
common	O
medicinal	O
acids	O
to	O
ensure	O
that	O
the	O
integral	O
molecule	O
has	O
a	O
certain	O
water	O
-	O
solubility	O
.	O

Preliminary	O
pharmacological	O
tests	O
indicate	O
that	O
the	O
compounds	O
have	O
an	O
alpha1	O
receptor	O
antagonizing	O
function	O
.	O

Flavones	B
derivative	O
as	O
well	O
as	O
preparation	O
method	O
and	O
application	O
thereof	O
as	O
alpha1	O
receptor	O
antagonist	O

The	O
invention	O
discloses	O
a	O
preparation	O
method	O
of	O
gossypol	B
acetate	I
intravenous	O
injection	O
fatty	O
emulsion	O
.	O

In	O
the	O
method	O
,	O
gossypol	B
acetate	I
is	O
used	O
as	O
an	O
active	O
constituent	O
,	O
ethyl	B
oleate	I
or	O
middle	O
-	O
chain	O
fatty	B
acid	I
triglyceride	I
is	O
used	O
as	O
an	O
oil	O
phase	O
,	O
soya	O
bean	O
lecithin	B
is	O
used	O
as	O
a	O
surface	O
active	O
agent	O
,	O
absolute	O
ethyl	B
alcohol	I
or	O
PEG	B
(	I
Polyethylene	I
Glycol	I
)	I
400	I
is	O
used	O
as	O
a	O
cosurfactant	O
,	O
and	O
sterilized	O
water	O
for	O
injection	O
is	O
used	O
as	O
a	O
water	O
phase	O
.	O

The	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
(	O
1	O
)	O
dissolving	O
the	O
gossypol	B
acetate	I
in	O
diethyl	B
ether	I
and	O
then	O
mixing	O
with	O
the	O
oil	O
phase	O
,	O
the	O
surface	O
active	O
agent	O
and	O
the	O
cosurfactant	O
;	O
decompressing	O
and	O
evaporating	O
to	O
remove	O
the	O
diethyl	B
ether	I
and	O
preserving	O
at	O
a	O
constant	O
temperature	O
for	O
later	O
use	O
;	O
(	O
2	O
)	O
heating	O
the	O
sterilized	O
water	O
for	O
injection	O
and	O
preserving	O
at	O
a	O
constant	O
temperature	O
for	O
later	O
use	O
;	O
(	O
3	O
)	O
mixing	O
liquids	O
obtained	O
in	O
the	O
steps	O
(	O
1	O
)	O
and	O
(	O
2	O
)	O
at	O
a	O
constant	O
temperature	O
of	O
60	O
or	O
70	O
DEG	O
C	O
and	O
stirring	O
until	O
a	O
transparent	O
and	O
homogeneous	O
solution	O
is	O
formed	O
;	O
making	O
the	O
volume	O
constant	O
and	O
then	O
repeatedly	O
homogenizing	O
by	O
using	O
a	O
homogenizer	O
;	O
and	O
filtering	O
by	O
using	O
a	O
millipore	O
filter	O
membrane	O
.	O

Proved	O
by	O
researches	O
,	O
the	O
gossypol	B
acetate	I
intravenousinjection	O
fatty	O
emulsion	O
prepared	O
by	O
using	O
the	O
method	O
has	O
good	O
slow	O
release	O
and	O
targeting	O
effects	O
and	O
good	O
stability	O
.	O

Preparation	O
method	O
of	O
gossypol	B
acetate	I
intravenous	O
injection	O
fatty	O
emulsion	O

The	O
invention	O
provides	O
a	O
magnetic	O
lipid	O
nano	O
particle	O
comprising	O
2.2%-5.9	O
%	O
of	O
ferroferric	B
oxide	I
nano	O
magnetic	O
powder	O
,	O
4.4%-28.6	O
%	O
of	O
oleic	B
acid	I
,	O
66.7%-93.4	O
%	O
of	O
glycerine	B
or	O
stearic	B
acid	I
and	O
0	O
-	O
28.2	O
%	O
of	O
hydrophobic	O
anti	O
-	O
tumor	O
medicaments	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
preparing	O
a	O
stable	O
ferroferric	B
oxide	I
nano	O
dispersing	O
solution	O
by	O
adopting	O
lipid	O
material	O
oleic	B
acid	I
in	O
a	O
liquid	O
state	O
at	O
room	O
temperature	O
as	O
a	O
surfactant	O
,	O
and	O
further	O
injecting	O
an	O
organic	O
solvent	O
dissolved	O
with	O
lipid	O
materials	O
to	O
the	O
ferroferric	B
oxide	I
nano	O
dispersing	O
solution	O
stabilized	O
by	O
the	O
oleic	O
to	O
prepare	O
the	O
magnetic	O
lipid	O
nano	O
particle	O
.	O

The	O
magnetic	O
lipid	O
nano	O
particle	O
containing	O
the	O
medicaments	O
can	O
be	O
prepared	O
by	O
adding	O
the	O
hydrophobic	O
medicament	O
in	O
the	O
organic	O
solvent	O
dissolved	O
with	O
the	O
lipidmaterials	O
.	O

The	O
magnetic	O
lipid	O
nano	O
particle	O
can	O
be	O
further	O
applied	O
to	O
magnetic	O
resonance	O
imaging	O
and	O
targeted	O
therapy	O
of	O
anti	O
-	O
tumor	O
medicaments	O
.	O

Magnetic	O
lipid	O
nano	O
particle	O
and	O
preparation	O
method	O

The	O
invention	O
discloses	O
application	O
of	O
baicalein	B
(	O
chemical	O
name	O
:	O
5,6,7-trihydroxyflavone	B
)	O
as	O
shown	O
in	O
a	O
general	O
formula	O
(	O
I	O
)	O
in	O
preparing	O
medicaments	O
for	O
preventing	O
and	O
treating	O
Parkinson	O
diseases	O
.	O

The	O
invention	O
relates	O
to	O
the	O
application	O
of	O
the	O
baicalein	B
capable	O
of	O
reducing	O
the	O
trembling	O
frequencies	O
and	O
amplitudes	O
of	O
the	O
Parkinson	O
diseases	O
and	O
improving	O
and	O
treating	O
the	O
symptoms	O
of	O
the	O
Parkinson	O
diseases	O
,	O
in	O
particular	O
to	O
the	O
application	O
of	O
the	O
baicalein	B
capable	O
of	O
protecting	O
dopaminergic	O
neurons	O
from	O
damage	O
so	O
that	O
the	O
pathological	O
changes	O
and	O
the	O
development	O
of	O
the	O
Parkinson	O
diseases	O
can	O
be	O
effectively	O
prevented	O
and	O
treated	O
;	O
and	O
the	O
baicalein	B
exerts	O
the	O
function	O
of	O
protecting	O
the	O
dopaminergic	O
neurons	O
through	O
apoptosis	O
resistance	O
,	O
inflammatory	O
resistance	O
and	O
antioxidation	O
and	O
exerts	O
the	O
function	O
of	O
inhibiting	O
Parkinson	O
symptoms	O
through	O
the	O
function	O
on	O
nervous	O
systems	O
.	O

Application	O
of	O
baicalein	B
in	O
preparing	O
medicaments	O
for	O
preventing	O
and	O
treating	O
Parkinson	O
diseases	O

The	O
invention	O
discloses	O
an	O
anti	O
-	O
aging	O
compound	O
which	O
comprises	O
spirulina	O
polysaccharide	O
and	O
folium	O
ginkgo	O
extract	O
,	O
and	O
the	O
mass	O
ratio	O
of	O
the	O
spirulina	O
polysaccharide	O
to	O
the	O
folium	O
ginkgo	O
extract	O
is	O
0.35	O
to	O
1.5:0.35	O
to	O
1.5	O
.	O

The	O
preferred	O
mass	O
ratio	O
of	O
the	O
spirulina	O
polysaccharide	O
to	O
the	O
folium	O
ginkgo	O
extract	O
is	O
2:1	O
.	O

The	O
spirulina	O
polysaccharide	O
is	O
water	O
-	O
soluble	O
heteropolysaccharide	O
,	O
and	O
the	O
content	O
of	O
the	O
polysaccharide	O
thereof	O
in	O
percentage	O
by	O
mass	O
is	O
more	O
than	O
or	O
equal	O
to	O
93	O
percent	O
.	O

The	O
content	O
of	O
general	O
flavone	B
of	O
the	O
folium	O
ginkgo	O
extract	O
in	O
percentage	O
by	O
mass	O
is	O
more	O
than	O
or	O
equal	O
to	O
24	O
percent	O
,	O
and	O
the	O
content	O
of	O
terpene	O
lactones	O
thereof	O
in	O
percentage	O
by	O
mass	O
is	O
more	O
than	O
or	O
equal	O
to	O
6	O
percent	O
.	O

The	O
anti	O
-	O
aging	O
compound	O
comprises	O
the	O
spirulina	O
polysaccharide	O
and	O
the	O
folium	O
ginkgo	O
extract	O
,	O
can	O
play	O
the	O
cooperative	O
and	O
synergistic	O
roles	O
by	O
combination	O
.	O

because	O
both	O
the	O
spirulina	O
polysaccharide	O
and	O
the	O
folium	O
ginkgo	O
extract	O
contain	O
hydroxyl	B
or	O
phenolic	B
hydroxyl	I
structures	O
,	O
thereby	O
significantly	O
improving	O
the	O
anti	O
-	O
aging	O
effect	O
.	O

Anti	O
-	O
aging	O
compound	O

The	O
invention	O
relates	O
to	O
a	O
medical	O
composition	O
and	O
a	O
mixture	O
for	O
treating	O
chicken	O
infectious	O
bursal	O
disease	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
medical	O
composition	O
(	O
100	O
grams	O
)	O
comprises	O
:	O
1	O
to	O
10	O
grams	O
of	O
astragalus	O
polysaccharides	O
,	O
3	O
to	O
12	O
grams	O
of	O
taurine	B
,	O
4	O
to	O
15	O
grams	O
of	O
aminopyrine	B
,	O
2	O
to	O
10	O
grams	O
of	O
vitamin	B
C	I
,	O
0.04	O
to	O
0.2	O
gram	O
of	O
interferon	O
inducer	O
,	O
5	O
to	O
20	O
grams	O
of	O
alcohol	B
,	O
0.1	O
to	O
0.4	O
gram	O
of	O
sodium	B
benzoate	I
,	O
and	O
the	O
balance	O
of	O
water	O
for	O
injection	O
.	O

The	O
product	O
is	O
characterized	O
by	O
reasonable	O
formula	O
composition	O
,	O
stable	O
physical	O
and	O
chemical	O
properties	O
,	O
accurate	O
dose	O
,	O
quick	O
effect	O
,	O
long	O
-	O
lasting	O
medicament	O
effect	O
,	O
high	O
bioavailability	O
,	O
safe	O
use	O
and	O
exact	O
treatment	O
effect	O
.	O

Medical	O
composition	O
and	O
mixture	O
for	O
treating	O
chicken	O
infectious	O
bursal	O
disease	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
an	O
aryl	B
ruthenium	I
(	I
II	I
)	I
composition	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O
.	O

In	O
the	O
structural	O
formula	O
(	O
I	O
)	O
of	O
the	O
aryl	B
ruthenium	I
(	I
II	I
)	I
composition	O
,	O
R	O
is	O
chosen	O
from	O
H	B
,	O
C1	B
to	I
C6	I
alkyl	I
or	O
alkyl	B
substituent	O
,	O
phenyl	B
or	O
phenyl	B
substituent	O
,	O
pyridyl	B
or	O
pyridyl	B
substituent	O
,	O
furyl	B
or	O
furyl	B
substituent	O
,	O
pyrrolyl	B
or	O
pyrrolyl	B
substituent	O
and	O
thiazole	B
or	O
thiazole	B
substituent	O
.	O

R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
and	O
R6	O
are	O
independently	O
chosen	O
from	O
H	B
,	O
C2	O
to	O
C6	O
alkenyl	B
,	O
C2	O
to	O
C6	O
alkynyl	B
,	O
oxhydryl	B
C1	O
to	O
C6	O
alkyl	B
,	O
amido	B
C1	O
to	O
C6	O
alkyl	B
,	O
halogen	B
,	O
CO2R7	B
,	O
CONR8R9	B
,	O
COR10	B
,	O
SO3H	B
,	O
SO2R11R12	B
,	O
aryloxy	B
,	O
C1	O
to	O
C6	O
alkoxy	B
,	O
C1	O
to	O
C6	O
alkylthio	B
,	O
-N	B
=	I
NR13,NR14R15	I
,	O
aryl	B
or	O
aralkyl	B
.	O

The	O
aryl	B
ruthenium	I
(	I
II	I
)	I
composition	O
can	O
be	O
used	O
to	O
prepare	O
tumor	O
medicine	O
,	O
has	O
good	O
inhibitory	O
action	O
particularly	O
on	O
lung	O
adenocarcinoma	O
and	O
has	O
potential	O
great	O
value	O
in	O
terms	O
of	O
tumor	O
disease	O
clinical	O
treatment	O
application	O
.	O

The	O
formula	O
(	O
I	O
)	O
.	O

Aryl	B
ruthenium	I
(	I
11	I
)	I
composition	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
two	O
open	O
loop	O
steroid	B
saponin	I
compounds	O
,	O
i.e.	O
Sinularoside	B
A	I
and	O
Sinularoside	B
B	I
with	O
antibacterial	O
activity	O
,	O
separated	O
from	O
sinularia	O
gyrosa	O
,	O
belonging	O
to	O
the	O
technical	O
field	O
of	O
medicines	O
.	O

The	O
compounds	O
have	O
the	O
chemical	O
structural	O
formulas	O
as	O
the	O
specification	O
,	O
wherein	O
the	O
R	O
group	O
is	O
FORMULA	O
.	O

The	O
in	O
-	O
vitro	O
antibacterial	O
test	O
on	O
the	O
Sinularoside	B
A	I
and	O
the	O
Sinularoside	B
B	I
shows	O
that	O
the	O
compounds	O
have	O
obvious	O
effect	O
for	O
inhibiting	O
fungus	O
,	O
bacteria	O
and	O
algae	O
for	O
test	O
,	O
thereby	O
the	O
two	O
open	O
loop	O
steroid	B
saponin	I
compounds	O
can	O
be	O
used	O
for	O
preparing	O
antibacterial	O
medicaments	O
.	O

The	O
invention	O
provides	O
a	O
new	O
lead	O
compound	O
for	O
developing	O
new	O
antibacterial	O
medicaments	O
and	O
has	O
great	O
significance	O
for	O
developing	O
ocean	O
medicine	O
biological	O
resources	O
in	O
China	O
.	O

Open	O
loop	O
steroid	B
saponin	I
compound	O
with	O
antibacterial	O
activity	O
in	O
sinularia	O
gyrosa	O

The	O
invention	O
relates	O
to	O
American	O
ginseng	O
saponin	B
F6	I
as	O
well	O
as	O
an	O
extraction	O
method	O
and	O
medical	O
application	O
thereof	O
,	O
which	O
belong	O
to	O
a	O
new	O
compound	O
as	O
well	O
as	O
an	O
extraction	O
method	O
and	O
medical	O
application	O
thereof	O
.	O

The	O
extraction	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
taking	O
American	O
ginseng	O
fruit	O
as	O
a	O
raw	O
material	O
,	O
obtaining	O
the	O
new	O
compound	O
through	O
macroporous	O
absorbent	O
resin	O
,	O
normal	O
and	O
reversed	O
-	O
phase	O
silica	B
gel	I
column	O
chromatography	O
and	O
a	O
recrystallization	O
method	O
of	O
fruit	O
juice	O
,	O
wherein	O
the	O
new	O
compound	O
has	O
the	O
chemical	O
name	O
of	O
6-O	B
-	I
beta	I
-	I
D	I
-	I
glucopyranesyl-20-O-	I
[	I
alpha	I
-	I
L	I
-	I
arabinofuranosyl-	I
(	I
1	I
-	I
6	I
)	I
-beta	I
-	I
D	I
-	I
glucopyranosyl	I
]	I
-dammar-24-ene-3beta	I
,	I
6alpha,12beta	I
,	I
20S	I
-	I
tetraol	I
and	O
is	O
abbreviated	O
as	O
the	O
American	O
ginseng	O
saponin	B
F6	I
,	O
and	O
the	O
yield	O
reaches	O
more	O
than	O
0.01	O
%	O
.	O

The	O
American	O
ginseng	O
saponin	B
F6	I
has	O
wide	O
application	O
in	O
preparing	O
antitumor	O
medicaments	O
.	O

American	O
ginseng	O
saponin	B
F6	I
as	O
well	O
as	O
extraction	O
method	O
and	O
medical	O
application	O
thereof	O

The	O
invention	O
provides	O
a	O
8,8-disubstituted-13,13a	B
-	I
dihyrdroberberine	I
derivative	O
with	O
a	O
structure	O
shown	O
as	O
the	O
following	O
general	O
formula	O
or	O
a	O
physiologically	O
acceptable	O
salt	O
and	O
application	O
thereof	O
and	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
derivative	O
.	O

The	O
8,8-disubstituted-13,13a	B
-	I
dihyrdroberberine	I
derivative	O
has	O
the	O
effect	O
of	O
promoting	O
the	O
glucose	B
absorption	O
on	O
muscle	O
cells	O
.	O

Proved	O
by	O
in	O
-	O
vivo	O
animal	O
experiments	O
,	O
the	O
compound	O
has	O
the	O
effects	O
on	O
improving	O
the	O
carbohydrate	B
tolerance	O
and	O
the	O
insulin	O
resistance	O
,	O
reducing	O
weight	O
,	O
relieving	O
fatty	O
livers	O
,	O
and	O
the	O
like	O
,	O
has	O
high	O
bioavailability	O
,	O
enhances	O
the	O
in	O
-	O
vivo	O
pesticide	O
effect	O
,	O
and	O
has	O
stable	O
structure	O
under	O
an	O
acidic	O
condition	O
.	O

The	O
compound	O
can	O
be	O
used	O
for	O
treating	O
type-2	O
diabetes	O
,	O
obesity	O
,	O
fatty	O
livers	O
or	O
complications	O
thereof	O
.	O

8,8-disubstituted-13,13a	B
-	I
dihyrdroberberine	I
derivative	O
as	O
well	O
as	O
pharmaceutical	O
composition	O
and	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
rosuvastatin	B
calcium	I
sustained	O
-	O
release	O
preparation	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
rosuvastatin	B
calcium	I
sustained	O
-	O
release	O
preparation	O
basically	O
contains	O
5	O
to	O
10	O
mg	O
of	O
rosuvastatin	B
calcium	I
,	O
and	O
the	O
balance	O
of	O
sustained	O
-	O
release	O
framework	O
material	O
and	O
other	O
pharmaceutical	O
excipients	O
.	O

The	O
preparation	O
method	O
is	O
simple	O
;	O
and	O
all	O
the	O
materials	O
are	O
proportioned	O
and	O
the	O
preparation	O
is	O
prepared	O
by	O
the	O
preparation	O
method	O
for	O
common	O
tablets	O
,	O
granules	O
or	O
capsules	O
.	O

The	O
rosuvastatin	B
calcium	I
sustained	O
-	O
release	O
preparation	O
prepared	O
by	O
the	O
method	O
avoids	O
adverse	O
reactions	O
such	O
as	O
rhabdomyolysis	O
,	O
proteinuria	O
,	O
nephrosis	O
,	O
kidney	O
failure	O
,	O
hepatotoxicity	O
and	O
the	O
like	O
caused	O
by	O
overdosage	O
of	O
medicaments	O
;	O
meanwhile	O
,	O
due	O
blood	O
concentration	O
and	O
time	O
for	O
treating	O
diseases	O
after	O
the	O
medicaments	O
are	O
taken	O
can	O
be	O
maintained	O
,	O
and	O
the	O
peak	O
valley	O
phenomenon	O
of	O
the	O
blood	O
concentration	O
is	O
effectively	O
avoided	O
.	O

Rosuvastatin	B
calcium	I
sustained	O
-	O
release	O
preparation	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
medicament	O
for	O
treating	O
mammary	O
gland	O
hyperplasia	O
.	O

The	O
medicament	O
is	O
characterized	O
by	O
being	O
prepared	O
from	O
the	O
following	O
raw	O
materials	O
in	O
part	O
by	O
weight	O
:	O
1	O
to	O
20	O
parts	O
of	O
rose	O
,	O
1	O
to	O
20	O
parts	O
of	O
Seville	O
orange	O
flower	O
,	O
1	O
to	O
20	O
parts	O
of	O
Paris	O
polyphylla	O
Sm	O
.	O
,	O
1	O
to	O
20	O
parts	O
of	O
common	O
selfheal	O
fruit	O
-	O
spike	O
,	O
1	O
to	O
20	O
parts	O
of	O
barbed	O
skullcap	O
herb	O
,	O
1	O
to	O
20	O
parts	O
of	O
snakegourd	O
fruit	O
,	O
1	O
to	O
20	O
parts	O
of	O
seaweed	O
,	O
1	O
to	O
20	O
parts	O
of	O
kelp	O
,	O
1	O
to	O
20	O
parts	O
of	O
frankincense	O
,	O
1	O
to	O
20	O
parts	O
of	O
myrrh	O
,	O
1	O
to	O
20	O
parts	O
of	O
tangerine	O
leaves	O
,	O
1	O
to	O
20	O
parts	O
of	O
green	O
tangerine	O
peel	O
,	O
1	O
to	O
20	O
parts	O
of	O
thunberg	O
fritillary	O
bulb	O
,	O
1	O
to	O
20	O
parts	O
of	O
common	O
burreed	O
rhizome	O
,	O
1	O
to	O
20	O
parts	O
of	O
zedoary	O
,	O
1	O
to	O
20	O
parts	O
of	O
Indian	O
iphigenia	O
bulb	O
,	O
1	O
to	O
20	O
parts	O
of	O
India	O
madder	O
root	O
,	O
1	O
to	O
20	O
parts	O
of	O
edible	O
alcohol	O
of	O
which	O
the	O
content	O
is	O
over	O
95	O
percent	O
.	O

The	O
medicament	O
can	O
be	O
absorbed	O
by	O
spleen	O
and	O
stomach	O
through	O
oral	O
administration	O
or	O
absorbed	O
by	O
skin	O
through	O
external	O
application	O
and	O
also	O
can	O
be	O
absorbed	O
through	O
the	O
combination	O
of	O
oral	O
administration	O
and	O
external	O
administration	O
.	O

The	O
medicament	O
of	O
the	O
invention	O
has	O
the	O
advantages	O
of	O
reasonable	O
formula	O
,	O
simple	O
compatibility	O
,	O
clear	O
treatment	O
effect	O
and	O
addressing	O
both	O
symptoms	O
and	O
root	O
causes	O
.	O

The	O
invention	O
also	O
provides	O
a	O
preparation	O
method	O
of	O
the	O
medicament	O
.	O

Medicament	O
for	O
treating	O
mammary	O
gland	O
hyperplasia	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
injection	O
of	O
piperazine	B
ferulate	I
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
novel	O
formulation	O
of	O
the	O
piperazine	B
ferulate	I
is	O
prepared	O
by	O
the	O
steps	O
of	O
dissolving	O
piperazine	B
ferulate	I
as	O
a	O
medicine	O
component	O
into	O
a	O
solvent	O
and	O
regulating	O
the	O
pH	O
value	O
to	O
be	O
5.0	O
-	O
8.0	O
with	O
a	O
pH	O
regulating	O
agent	O
so	O
that	O
the	O
piperazine	B
ferulate	I
is	O
fully	O
dissolved	O
to	O
prepare	O
an	O
injection	O
.	O

The	O
content	O
of	O
the	O
piperazine	B
ferulate	I
in	O
the	O
novel	O
formulation	O
is	O
27	O
-	O
200mg	O
/	O
ml	O
,	O
and	O
the	O
agent	O
is	O
the	O
water	O
of	O
injection	O
.	O

The	O
invention	O
broadens	O
the	O
clinical	O
application	O
range	O
of	O
the	O
piperazine	B
ferulate	I
,	O
has	O
the	O
characteristics	O
of	O
high	O
medicine	O
dissolubility	O
,	O
high	O
bioavailability	O
,	O
rapid	O
medicine	O
administration	O
,	O
more	O
quick	O
effect	O
-	O
taking	O
,	O
stronger	O
treatment	O
effect	O
,	O
and	O
the	O
like	O
,	O
is	O
especially	O
suitable	O
for	O
preventing	O
and	O
treating	O
patients	O
suffering	O
from	O
heavy	O
cerebral	O
infarction	O
,	O
nephroma	O
,	O
coronary	O
heart	O
disease	O
,	O
vascular	O
complication	O
in	O
diabetes	O
mellitus	O
and	O
dysphagia	O
,	O
overcomes	O
the	O
problem	O
of	O
low	O
dissolubility	O
of	O
the	O
piperazine	B
ferulate	I
in	O
the	O
prior	O
art	O
,	O
and	O
realizes	O
the	O
solubilization	O
of	O
the	O
piperazine	B
ferulate	I
by	O
regulating	O
the	O
pH	O
value	O
with	O
the	O
pH	O
regulating	O
agent	O
,	O
wherein	O
at	O
least	O
500	O
mg	O
of	O
piperazine	B
ferulate	I
can	O
be	O
dissolved	O
in	O
10mlof	O
water	O
solution	O
with	O
pH	O
value	O
of	O
5.5	O
.	O

Novel	O
formulation	O
of	O
piperazine	B
ferulate	I
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
high	O
-	O
release	O
erythrocin	B
enteric	O
-	O
coated	O
tablet	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
belonging	O
to	O
the	O
field	O
of	O
antibiotic	O
drugs	O
.	O

The	O
enteric	O
-	O
coated	O
tablet	O
contains	O
two	O
parts	O
:	O
a	O
substrate	O
and	O
an	O
enteric	O
coating	O
,	O
wherein	O
the	O
substrate	O
contains	O
the	O
following	O
components	O
:	O
12.5	O
(	O
BOU	O
)	O
of	O
erythrocin	B
,	O
2.5	O
-	O
3.0	O
kg	O
of	O
starch	O
,	O
0.21	O
-	O
0.25	O
kg	O
of	O
Tween-80	B
,	O
1	O
-	O
1.5	O
kg	O
of	O
hydroxy	O
propyl	O
cellulose	O
,	O
0.3	O
-	O
0.5	O
kg	O
of	O
magnesium	B
stearate	I
and	O
0.8	O
-	O
1.5	O
kg	O
of	O
talcum	O
powder	O
by	O
the	O
dosage	O
of	O
100	O
thousand	O
finished	O
erythrocin	B
enteric	O
-	O
coated	O
tablets	O
;	O
the	O
enteric	O
-	O
coated	O
tablet	O
contains	O
the	O
following	O
components	O
of	O
:	O
0.81	O
-	O
0.84	O
kg	O
of	O
polyacrylic	O
resin	O
(	O
II	O
)	O
,	O
15	O
-	O
16	O
kg	O
of	O
ethanol	B
the	O
concentration	O
of	O
more	O
than	O
90	O
percent	O
,	O
0.16	O
-	O
0.2	O
kg	O
of	O
Tween-80	B
,	O
0.16	O
-	O
0.20	O
kg	O
of	O
diethyl	B
phthalate	I
,	O
0.48	O
-	O
0.60	O
kg	O
of	O
castor	O
oil	O
and	O
0.59	O
-	O
0.70	O
kg	O
of	O
talcum	O
powder	O
by	O
the	O
dosage	O
of	O
100	O
thousand	O
finished	O
erythrocin	B
enteric	O
-	O
coated	O
tablets	O
.	O

The	O
average	O
release	O
of	O
the	O
enteric	O
-	O
coated	O
tablet	O
prepared	O
by	O
adopting	O
the	O
prescription	O
of	O
the	O
substrate	O
and	O
the	O
enteric	O
coating	O
is	O
not	O
less	O
than	O
90	O
percent	O
in	O
drug	O
effect	O
and	O
is	O
far	O
higher	O
than	O
the	O
national	O
pharmacopeia	O
standard	O
,	O
and	O
the	O
enteric	O
-	O
coated	O
tablet	O
can	O
be	O
stably	O
released	O
;	O
the	O
drug	O
action	O
of	O
the	O
enteric	O
-	O
coated	O
tablet	O
is	O
higher	O
than	O
the	O
national	O
pharmacopeia	O
standard	O
in	O
the	O
period	O
of	O
validity	O
;	O
the	O
surface	O
of	O
the	O
enteric	O
-	O
coated	O
tablet	O
is	O
fine	O
and	O
smooth	O
and	O
glossy	O
in	O
appearance	O
;	O
and	O
the	O
effectiveness	O
of	O
the	O
enteric	O
-	O
coated	O
tablet	O
is	O
not	O
influenced	O
after	O
being	O
stored	O
for	O
a	O
long	O
time	O
.	O

High	O
-	O
release	O
erythrocin	B
enteric	O
-	O
coated	O
tablet	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
plaster	O
for	O
treating	O
bone	O
fracture	O
,	O
mainly	O
comprising	O
the	O
following	O
drugs	O
in	O
parts	O
by	O
weight	O
:	O
20	O
-	O
40	O
parts	O
of	O
corydalis	O
tuber	O
,	O
20	O
-	O
30	O
parts	O
of	O
safflower	O
,	O
20	O
-	O
40	O
parts	O
of	O
frankincense	O
,	O
20	O
-	O
30	O
parts	O
of	O
myrrh	O
,	O
15	O
-	O
30	O
parts	O
of	O
scaly	O
anteater	O
,	O
20	O
-	O
40	O
parts	O
of	O
scorpio	O
,	O
20	O
-	O
40	O
parts	O
of	O
panax	O
notoginseng	O
,	O
10	O
-	O
20	O
parts	O
of	O
crinis	O
ustus	O
,	O
10	O
-	O
20	O
parts	O
of	O
eupolyphaga	O
,	O
20	O
-	O
40	O
parts	O
of	O
drgonsbone	O
,	O
20	O
-	O
40	O
parts	O
of	O
earthworm	O
,	O
20	O
-	O
40	O
parts	O
of	O
pyrite	O
,	O
20	O
-	O
40	O
parts	O
of	O
sapanwood	O
,	O
20	O
-	O
40	O
parts	O
of	O
rhizoma	O
drynariae	O
,	O
10	O
-	O
30	O
parts	O
of	O
dragon	O
's	O
blood	O
,	O
20	O
-	O
40	O
parts	O
of	O
peach	O
kernel	O
and	O
20	O
-	O
40	O
parts	O
of	O
angelica	O
.	O

The	O
plaster	O
for	O
treating	O
bone	O
fracture	O
has	O
the	O
effects	O
of	O
dredging	O
the	O
channel	O
,	O
stopping	O
bleeding	O
,	O
promoting	O
the	O
circulation	O
of	O
Qi	O
,	O
relieving	O
swelling	O
,	O
stopping	O
pain	O
,	O
removing	O
heat	O
from	O
the	O
heart	O
to	O
restore	O
to	O
consciousness	O
,	O
reuniting	O
bones	O
and	O
muscles	O
,	O
circulating	O
blood	O
and	O
promoting	O
the	O
quick	O
formation	O
of	O
poroma	O
and	O
has	O
obvious	O
treatment	O
effect	O
and	O
little	O
adverse	O
reaction	O
.	O

Plaster	O
for	O
treating	O
bone	O
fracture	O

The	O
invention	O
discloses	O
substituted	O
benzodihydropyran	B
derivatives	O
shown	O
in	O
a	O
general	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
R	O
is	O
hydrogen	B
atom	O
or	O
C1-C6	O
straight	O
chain	O
or	O
branched	O
alkane	B
,	O
methoxy	B
acyl	I
isopropyl	I
or	O
methoxy	B
acyl	I
oxy	I
isopropyl	I
,	O
methoxy	B
acyl	I
isobutyl	I
or	O
methoxy	B
acyl	I
oxy	I
isobutyl	I
,	O
methoxy	B
acyl	I
tertiary	I
butyl	I
or	O
methoxy	B
acyl	I
cyclobutyl	I
;	O
and	O
n	O
is	O
1	O
-	O
5	O
,	O
and	O
is	O
represented	O
as	O
a	O
single	O
bond	O
or	O
a	O
double	O
bond	O
.	O

The	O
invention	O
also	O
provides	O
a	O
method	O
for	O
inducing	O
apoptosis	O
in	O
cells	O
,	O
which	O
comprises	O
a	O
step	O
of	O
applying	O
a	O
composition	O
containing	O
the	O
compounds	O
.	O

The	O
compounds	O
designed	O
by	O
the	O
pharmacokinetics	O
have	O
improved	O
therapeutic	O
index	O
,	O
are	O
strong	O
inhibitors	O
for	O
cancer	O
cell	O
growth	O
,	O
and	O
have	O
high	O
anti	O
-	O
cancer	O
activity	O
and	O
extremely	O
small	O
side	O
effect	O
.	O

Substituted	O
benzodihydropyran	B
derivatives	O
and	O
anti	O
-	O
tumor	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
an	O
antibacterial	O
agent	O
,	O
belonging	O
to	O
the	O
field	O
of	O
hygiene	O
,	O
wherein	O
the	O
antibacterial	O
agent	O
comprises	O
the	O
following	O
active	O
components	O
:	O
tetracycline	B
and	O
bacillus	O
subtilis	O
;	O
the	O
ratio	O
of	O
the	O
tetracycline	B
to	O
the	O
bacillus	O
subtilis	O
in	O
the	O
antibacterial	O
agent	O
is	O
(	O
0.18	O
-	O
6.0	O
)	O
mu	O
g:	O
(	O
2.0	O
-	O
6.0	O
)	O
*10	O
to	O
the	O
power	O
of	O
[	O
6	O
]	O
cfu	O
;	O
and	O
the	O
antibacterial	O
agent	O
can	O
be	O
used	O
for	O
inhibiting	O
and	O
killing	O
staphylococcus	O
aurous	O
,	O
vibrio	O
,	O
escherichia	O
coli	O
,	O
salmonella	O
,	O
proteus	O
bacterial	O
and	O
fusarium	O
,	O
etc	O
.	O

The	O
antibacterial	O
agent	O
provided	O
by	O
the	O
invention	O
has	O
the	O
function	O
of	O
inhibiting	O
the	O
quorum	O
sensing	O
molecules	O
by	O
the	O
bacillus	O
subtilis	O
for	O
the	O
first	O
time	O
,	O
has	O
a	O
synergistic	O
effect	O
together	O
with	O
the	O
tetracycline	B
,	O
greatly	O
improves	O
the	O
performance	O
of	O
the	O
antibacterial	O
agent	O
for	O
killing	O
bacteria	O
,	O
obviously	O
lowers	O
the	O
threshold	O
value	O
of	O
the	O
efficient	O
dosage	O
of	O
the	O
tetracycline	B
and	O
prevents	O
the	O
tolerance	O
during	O
the	O
antibacterial	O
process	O
;	O
the	O
antibacterial	O
agent	O
also	O
has	O
effective	O
antibacterial	O
effect	O
,	O
less	O
side	O
effect	O
to	O
the	O
environment	O
and	O
less	O
toxic	O
side	O
effect	O
.	O

Antibacterial	O
agent	O

The	O
invention	O
provides	O
an	O
RGD	O
peptide	O
-	O
epimedium	O
flavone	B
combination	O
synthesized	O
by	O
combining	O
two	O
structural	O
units	O
of	O
RGD	O
peptides	O
and	O
epimedium	O
flavone	B
which	O
have	O
pharmacological	O
activities	O
of	O
different	O
action	O
mechanisms	O
on	O
osseous	O
metabolic	O
diseases	O
,	O
and	O
also	O
provides	O
a	O
synthesis	O
method	O
thereof	O
.	O

The	O
compound	O
of	O
the	O
invention	O
has	O
two	O
receptor	O
combining	O
sites	O
and	O
simultaneously	O
has	O
the	O
capability	O
of	O
combining	O
estrogen	B
receptors	O
of	O
icaritin	B
and	O
the	O
capability	O
of	O
combining	O
integrins	O
alphaVbeta3	O
of	O
RGD	O
,	O
and	O
the	O
capabilities	O
of	O
combining	O
the	O
two	O
different	O
receptors	O
can	O
produce	O
a	O
synergistic	O
effect	O
to	O
greatly	O
improve	O
the	O
curative	O
activity	O
of	O
the	O
medicament	O
on	O
osteoporosis	O
and	O
osseous	O
metabolic	O
diseases	O
.	O

The	O
synthesis	O
method	O
has	O
the	O
advantages	O
of	O
high	O
yield	O
,	O
high	O
synthesis	O
speed	O
and	O
easy	O
purification	O
of	O
products	O
.	O

RGD	O
peptide	O
-	O
epimedium	O
flavone	B
combination	O
,	O
preparation	O
method	O
and	O
application	O
thereof	O

Inhibitors	O
for	O
matrix	O
metalloproteinases	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
their	O
uses	O
.	O

The	O
inhibitors	O
for	O
matrix	O
metalloproteinases	O
have	O
the	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
W	O
,	O
X1	O
,	O
X2	O
,	O
R1	O
,	O
R2	O
are	O
as	O
defined	O
in	O
the	O
description	O
.	O

They	O
are	O
useful	O
for	O
the	O
prevention	O
or	O
treatment	O
of	O
diseases	O
regulated	O
by	O
matrix	O
metalloproteinases	O
,	O
in	O
particular	O
corneal	O
ulceration	O
,	O
pulmonary	O
emphysema	O
or	O
dermal	O
ulceration	O
resulted	O
from	O
chemical	O
injury	O
,	O
or	O
pulmonary	O
emphysema	O
caused	O
by	O
smoking	O
or	O
drowning	O
.	O

Inhibitors	O
for	O
matrix	O
metalloproteinases	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
their	O
uses	O

The	O
invention	O
relates	O
to	O
protecting	O
colloid	O
for	O
gastroenteric	O
mucosa	O
,	O
belonging	O
to	O
the	O
field	O
of	O
biomedical	O
preparation	O
and	O
comprising	O
a	O
collagenous	O
substance	O
,	O
an	O
acidifying	O
or	O
alkalizing	O
agent	O
,	O
a	O
cross	O
-	O
linking	O
agent	O
and	O
an	O
adhesive	O
based	O
on	O
the	O
weight	O
ratio	O
of	O
1:0.01	O
-	O
0.3:0.1	O
-	O
0.5	O
,	O
wherein	O
the	O
dosage	O
of	O
the	O
acidifying	O
or	O
alkalizing	O
agent	O
is	O
proper	O
when	O
the	O
pH	O
value	O
is	O
regulated	O
to	O
6.5	O
-	O
8.5	O
.	O

Under	O
the	O
action	O
of	O
gastric	O
acid	O
,	O
the	O
cross	O
-	O
linking	O
agent	O
in	O
the	O
protecting	O
colloid	O
can	O
be	O
released	O
so	O
as	O
to	O
form	O
a	O
colloid	O
membrane	O
on	O
the	O
surface	O
of	O
ulcer	O
,	O
avoid	O
the	O
gastroenteric	O
mucosa	O
from	O
being	O
digested	O
by	O
gastric	O
acid	O
and	O
pepsase	O
and	O
promote	O
healing	O
of	O
the	O
ulcer	O
.	O

Animal	O
tests	O
show	O
that	O
the	O
protecting	O
colloid	O
can	O
greatly	O
lower	O
the	O
ulcer	O
formation	O
caused	O
by	O
absolute	O
ethyl	B
alcohol	I
and	O
hydrochloric	B
acid	I
,	O
inhibit	O
ulcer	O
formation	O
and	O
have	O
a	O
protecting	O
effect	O
on	O
injury	O
of	O
the	O
mice	O
gastroenteric	O
mucosa	O
caused	O
by	O
absolute	O
ethyl	B
alcohol	I
and	O
hydrochloric	B
acid	I
.	O

Therefore	O
,	O
the	O
protecting	O
colloid	O
is	O
used	O
for	O
protecting	O
and	O
curing	O
gastroenteric	O
mucosa	O
ulcer	O
for	O
patients	O
.	O

Protecting	O
colloid	O
for	O
gastroenteric	O
mucosa	O

The	O
invention	O
relates	O
to	O
aloe	O
oculentum	O
and	O
a	O
preparation	O
method	O
,	O
and	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
eyedrops	O
.	O

The	O
aloe	O
oculentum	O
is	O
characterized	O
by	O
comprising	O
the	O
following	O
medicaments	O
and	O
raw	O
materials	O
in	O
part	O
by	O
weight	O
:	O
80	O
to	O
90	O
parts	O
of	O
aloe	O
gel	O
,	O
1	O
to	O
5	O
parts	O
of	O
aloin	B
,	O
0.1	O
to	O
1	O
part	O
of	O
alomycin	B
,	O
0.1	O
to	O
0.3	O
part	O
of	O
carbomer	O
,	O
0.1	O
to	O
0.2	O
part	O
of	O
sodium	O
hyaluronate	O
,	O
0.1	O
to	O
0.2	O
part	O
of	O
anthraquinone	B
compounds	O
,	O
0.1	O
to	O
0.2	O
part	O
of	O
cinnamate	B
and	O
0.2	O
to	O
0.5	O
part	O
of	O
free	O
amino	B
acid	I
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
extracting	O
the	O
aloe	O
gel	O
from	O
aloe	O
barbadensis	O
by	O
adopting	O
a	O
freezing	O
stabilization	O
method	O
,	O
and	O
converting	O
the	O
aloe	O
gel	O
into	O
aloe	O
gel	O
powder	O
;	O
and	O
mixing	O
the	O
aloe	O
gel	O
powder	O
and	O
water	O
for	O
injection	O
under	O
the	O
acidic	O
condition	O
or	O
neutral	O
condition	O
,	O
of	O
which	O
the	O
PH	O
is	O
between	O
5.5	O
and	O
7.5	O
,	O
mixing	O
the	O
mixture	O
and	O
the	O
aloin	B
,	O
the	O
alomycin	B
,	O
the	O
carbomer	O
,	O
the	O
sodium	O
hyaluronate	O
,	O
the	O
anthraquinone	B
compounds	O
,	O
the	O
cinnamate	B
and	O
the	O
free	O
amino	B
acid	I
,	O
stirring	O
uniformly	O
,	O
regulating	O
the	O
pH	O
value	O
to	O
be	O
neutral	O
,	O
and	O
subpackaging	O
and	O
disinfecting	O
.	O

The	O
aloe	O
oculentum	O
can	O
treat	O
eye	O
diseases	O
such	O
as	O
pterygium	O
,	O
conjunctivochalasis	O
,	O
corneal	O
nebula	O
,	O
chronic	O
dacryocystitis	O
,	O
eye	O
itching	O
,	O
xerophthalmia	O
and	O
the	O
like	O
.	O

Aloe	O
oculentum	O
and	O
preparation	O
method	O

The	O
invention	O
relates	O
to	O
synthesis	O
of	O
an	O
emodin	B
derivant	O
with	O
an	O
anti	O
-	O
tumor	O
function	O
,	O
in	O
particular	O
to	O
a	O
hydroxyl	B
whole	O
-	O
protection	O
didecyl	B
quaternary	I
ammonium	I
with	O
anti	O
-	O
tumor	O
activity	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
didecyl	B
quaternary	I
ammonium	I
is	O
decyldimethylchlorosilane-	B
[	I
2-	I
(	I
4,5,7-trimethoxy-9,10-anthraquinonyl	I
)	I
methyl	I
]	I
.	O

The	O
preparation	O
method	O
is	O
characterized	O
by	O
taking	O
emodin	B
as	O
a	O
raw	O
material	O
to	O
carry	O
out	O
a	O
series	O
of	O
synthetic	O
reaction	O
.	O

The	O
emodin	B
derivant	O
of	O
the	O
invention	O
has	O
proliferation	O
inhibition	O
action	O
of	O
different	O
degrees	O
on	O
liver	O
cancer	O
HepG2	O
,	O
gastric	O
cancer	O
BGC	O
,	O
neuroma	O
SH	O
-	O
SY5Y	O
,	O
gastric	O
cancer	O
AGS	O
,	O
cervical	O
cancer	O
Hela	O
and	O
the	O
like	O
as	O
well	O
as	O
normal	O
human	O
embryonic	O
lung	O
fibroblast	O
HELP	O
and	O
can	O
be	O
used	O
for	O
preparing	O
medicines	O
for	O
treating	O
cancers	O
.	O

Hydroxyl	B
whole	O
-	O
protection	O
didecyl	B
quaternary	I
ammonium	I
with	O
anti	O
-	O
tumor	O
activity	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
provides	O
a	O
novel	O
Irinotecan	B
carrier	O
which	O
is	O
circulating	O
nano	O
liposome	O
and	O
a	O
novel	O
preparation	O
method	O
thereof	O
which	O
is	O
an	O
ethanol	O
injection	O
-	O
ammonium	B
sulfate	I
active	O
medicament	O
-	O
loading	O
method	O
.	O

The	O
preparation	O
process	O
comprises	O
:	O
a	O
,	O
dissolving	O
a	O
lipid	O
material	O
for	O
forming	O
the	O
liposome	O
in	O
ethanol	O
to	O
prepare	O
solution	O
;	O
b	O
,	O
dissolving	O
a	O
polyethylene	B
glycol	I
compound	O
in	O
solution	O
of	O
ammonium	B
sulfate	I
to	O
prepare	O
a	O
hydration	O
medium	O
;	O
c	O
,	O
injecting	O
solution	O
obtained	O
by	O
the	O
step	O
a	O
into	O
the	O
hydration	O
medium	O
obtained	O
by	O
the	O
step	O
b	O
with	O
stirring	O
in	O
a	O
water	O
bath	O
,	O
stirring	O
at	O
a	O
constant	O
temperature	O
for	O
a	O
certain	O
period	O
under	O
a	O
condition	O
of	O
introducing	O
N2	B
to	O
form	O
circulating	O
blank	O
liposome	O
;	O
d	O
,	O
dialyzing	O
the	O
blank	O
liposome	O
obtained	O
by	O
the	O
step	O
c	O
in	O
physiological	O
saline	O
;	O
and	O
e	O
,	O
adding	O
solution	O
of	O
Irinotecan	B
into	O
the	O
blank	O
liposome	O
,	O
regulating	O
the	O
pH	O
value	O
of	O
an	O
external	O
phase	O
,	O
and	O
performing	O
incubation	O
and	O
medicament	O
loading	O
at	O
a	O
certain	O
temperature	O
to	O
obtain	O
the	O
Irinotecan	B
circulating	O
nano	O
liposome	O
.	O

The	O
process	O
is	O
simple	O
,	O
the	O
particle	O
size	O
is	O
80	O
to	O
150	O
nanometers	O
,	O
the	O
coating	O
rate	O
is	O
over	O
95	O
percent	O
,	O
the	O
sterile	O
preparation	O
can	O
be	O
obtained	O
easily	O
,	O
and	O
an	O
industrialization	O
requirement	O
is	O
met	O
.	O

Irinotecan	B
nano	O
circulating	O
liposome	O
and	O
preparation	O
method	O
thereof	O

A	O
micron	O
and	O
nanometer	O
encapsulated	O
technology	O
synthesized	O
by	O
step	O
-	O
by	O
-	O
step	O
shells	O
can	O
be	O
applied	O
for	O
intranasal	O
and	O
pulmonary	O
administration	O
.	O

Liquid	O
,	O
gas	O
or	O
solid	O
encapsulation	O
can	O
form	O
an	O
aerosol	O
in	O
spray	O
treatment	O
.	O

Different	O
shell	O
compositions	O
create	O
stability	O
,	O
compatibility	O
,	O
and	O
degradation	O
and	O
releasing	O
attributes	O
.	O

A	O
plurality	O
of	O
substances	O
comprising	O
the	O
compound	O
widely	O
used	O
for	O
intranasal	O
administration	O
can	O
be	O
encapsulated	O
,	O
or	O
are	O
administrated	O
through	O
spray	O
capsules	O
.	O

Intranasal	O
administration	O
encapsulated	O
based	O
on	O
polyelectrolyte	O
capsule	O

The	O
invention	O
discloses	O
a	O
medicament	O
for	O
oral	O
administration	O
for	O
treating	O
alcoholic	O
fatty	O
liver	O
and	O
a	O
preparation	O
method	O
thereof	O
and	O
belongs	O
to	O
the	O
field	O
of	O
medicaments	O
.	O

The	O
orally	O
taken	O
medicament	O
is	O
prepared	O
from	O
routine	O
auxiliary	O
materials	O
and	O
the	O
following	O
raw	O
medicinal	O
materials	O
in	O
part	O
by	O
weight	O
:	O
80	O
to	O
120	O
parts	O
of	O
scutellaria	O
total	O
flavonoid	B
,	O
60	O
to	O
100	O
parts	O
of	O
paeonia	O
saponins	B
,	O
60	O
to	O
120	O
parts	O
of	O
liquritin	B
and	O
proper	O
amount	O
of	O
auxiliary	O
materials	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
preparing	O
the	O
scutellaria	O
total	O
flavonoid	B
by	O
performing	O
water	O
extraction	O
on	O
scutellaria	O
;	O
preparing	O
the	O
paeonia	O
saponins	B
by	O
performing	O
water	O
extraction	O
on	O
paeonia	O
;	O
preparing	O
the	O
liquritin	B
by	O
performing	O
percolation	O
on	O
liquorice	O
;	O
and	O
preparing	O
the	O
general	O
formulation	O
by	O
blending	O
the	O
extracts	O
and	O
the	O
auxiliary	O
materials	O
,	O
and	O
obtaining	O
the	O
medicament	O
.	O

The	O
medicament	O
for	O
oral	O
administration	O
for	O
treating	O
alcoholic	O
fatty	O
liver	O
provided	O
by	O
the	O
invention	O
has	O
the	O
advantages	O
of	O
high	O
active	O
ingredient	O
content	O
,	O
stable	O
quality	O
,	O
safety	O
,	O
clear	O
treatment	O
effect	O
and	O
convenience	O
.	O

Compared	O
with	O
the	O
traditional	O
medicaments	O
,	O
the	O
orally	O
taken	O
medicament	O
greatly	O
reduces	O
the	O
toxic	O
and	O
side	O
effects	O
of	O
the	O
medicaments	O
and	O
obviously	O
improves	O
the	O
treatment	O
effect	O
.	O

Medicament	O
for	O
oral	O
administration	O
for	O
treating	O
alcoholic	O
fatty	O
liver	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
belongs	O
to	O
the	O
field	O
of	O
biomedicine	O
and	O
particularly	O
relates	O
to	O
a	O
method	O
for	O
establishing	O
an	O
experimental	O
model	O
for	O
subclinical	O
hepatic	O
encephalopathy	O
(	O
SHE	O
)	O
.	O

In	O
the	O
method	O
of	O
the	O
invention	O
,	O
an	O
experimental	O
rat	O
liver	O
cirrhosis	O
model	O
caused	O
by	O
composite	O
factors	O
such	O
as	O
high	O
fat	O
and	O
low	O
protein	O
of	O
carbon	B
tetrachloride	I
is	O
subjected	O
to	O
learning	O
,	O
recall	O
test	O
and	O
evoked	O
potential	O
test	O
of	O
a	O
nervous	O
system	O
and	O
a	O
brain	O
function	O
and	O
the	O
learning	O
,	O
memory	O
and	O
spatial	O
cognition	O
impairment	O
and	O
nerve	O
electrophysiology	O
test	O
abnormity	O
of	O
the	O
model	O
are	O
monitored	O
,	O
so	O
that	O
the	O
method	O
achieves	O
statistical	O
significance	O
compared	O
with	O
the	O
normal	O
comparison	O
group	O
and	O
a	O
relatively	O
ideal	O
SHE	O
animal	O
model	O
is	O
established	O
.	O

An	O
established	O
experiment	O
animal	O
model	O
provides	O
a	O
platform	O
for	O
the	O
research	O
,	O
diagnosis	O
and	O
treatment	O
of	O
SHE	O
and	O
has	O
high	O
clinically	O
practical	O
meaning	O
and	O
value	O
.	O

Method	O
for	O
establishing	O
experimental	O
model	O
for	O
subclinical	O
hepatic	O
encephalopathy	O
(	O
SHE	O
)	O

The	O
invention	O
discloses	O
a	O
compound	O
tincture	O
for	O
treating	O
external	O
acoustic	O
meatus	O
fungal	O
infection	O
.	O

The	O
compound	O
tincture	O
is	O
prepared	O
from	O
the	O
following	O
raw	O
materials	O
in	O
part	O
by	O
weight	O
:	O
1.5	O
to	O
5.5	O
parts	O
of	O
densefruit	O
pittany	O
root	O
-	O
bark	O
,	O
1.5	O
to	O
5.5	O
parts	O
of	O
bark	O
of	O
Chinese	O
redbud	O
,	O
1.0	O
to	O
3.5	O
parts	O
of	O
palemane	O
prunella	O
,	O
1.0	O
to	O
3.5	O
parts	O
of	O
Chinese	O
honeylocust	O
spine	O
,	O
2.5	O
to	O
5.0	O
parts	O
of	O
angelica	O
dahurica	O
,	O
2.5	O
to	O
5.0	O
parts	O
of	O
platycodon	O
root	O
,	O
1.0	O
to	O
3.5	O
parts	O
of	O
safflower	O
,	O
1.0	O
to	O
3.5	O
parts	O
of	O
szechuan	O
lovage	O
rhizome	O
,	O
1.5	O
to	O
5.5	O
parts	O
of	O
natural	O
indigo	O
,	O
2.5	O
to	O
5.0	O
parts	O
of	O
wild	O
chrysanthemum	O
,	O
2.5	O
to	O
5.0	O
parts	O
of	O
dandelion	O
,	O
1.5	O
to	O
5.5	O
parts	O
of	O
borax	B
,	O
1.5	O
to	O
5.5	O
parts	O
of	O
borneol	B
,	O
1.5	O
to	O
5.5	O
parts	O
of	O
peppermint	O
oil	O
and	O
100	O
parts	O
of	O
ethanol	B
.	O

The	O
inventor	O
studies	O
assiduously	O
under	O
the	O
condition	O
that	O
the	O
prior	O
art	O
is	O
not	O
perfect	O
.	O

The	O
compound	O
tincture	O
has	O
unique	O
therapeutic	O
effects	O
of	O
dispelling	O
wind	O
and	O
removing	O
dampness	O
,	O
detoxifying	O
and	O
relieving	O
itching	O
,	O
softening	O
and	O
dilating	O
blood	O
vessels	O
,	O
promoting	O
regeneration	O
of	O
necrotic	O
nerve	O
cells	O
and	O
treating	O
external	O
acoustic	O
meatus	O
mycosis	O
,	O
relieves	O
the	O
pain	O
of	O
patients	O
and	O
does	O
not	O
have	O
toxic	O
or	O
side	O
effect	O
.	O

Compound	O
tincture	O
for	O
treating	O
external	O
acoustic	O
meatus	O
fungal	O
infection	O

The	O
invention	O
discloses	O
a	O
microbial	O
feed	O
additive	O
for	O
treating	O
piglet	O
yellow	O
and	O
white	O
dysentery	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
additive	O
is	O
prepared	O
from	O
the	O
main	O
components	O
of	O
bacillus	O
subtilis	O
and	O
saccharomyces	O
cerevisiae	O
which	O
are	O
mixed	O
with	O
baking	B
soda	I
,	O
xylo	B
-	I
oligosaccharides	I
,	O
vitamins	O
,	O
vitamin	O
complex	O
,	O
glucose	B
and	O
the	O
like	O
according	O
to	O
certain	O
proportions	O
.	O

The	O
microbial	O
feed	O
additive	O
has	O
the	O
following	O
advantages	O
that	O
:	O
the	O
active	O
substances	O
such	O
as	O
subtilin	B
,	O
polymyxin	O
,	O
nystatin	B
,	O
gramicidin	B
and	O
the	O
like	O
generated	O
in	O
the	O
growing	O
process	O
of	O
the	O
bacillus	O
subtilis	O
have	O
obvious	O
inhibitionto	O
pathogens	O
or	O
conditioned	O
pathogens	O
of	O
endogenous	O
infection	O
;	O
cell	O
wall	O
polysaccharides	O
of	O
the	O
saccharomyces	O
cerevisiae	O
and	O
a	O
great	O
amount	O
of	O
nucleotides	O
and	O
bioactive	O
peptides	O
generated	O
in	O
the	O
growing	O
process	O
of	O
the	O
saccharomyces	O
cerevisiae	O
can	O
improve	O
the	O
immunity	O
of	O
animals	O
,	O
and	O
a	O
compound	O
taste	O
substance	O
is	O
also	O
generated	O
in	O
the	O
growing	O
process	O
of	O
the	O
saccharomyces	O
cerevisiae	O
to	O
promote	O
animal	O
feeding	O
;	O
the	O
baking	O
soda	O
replenishes	O
electrolyte	O
;	O
the	O
xylo	B
-	I
oligosaccharides	I
selectively	O
proliferate	O
beneficial	O
bacteria	O
such	O
as	O
bifidobacterium	O
and	O
the	O
like	O
;	O
the	O
vitamins	O
have	O
the	O
effects	O
of	O
resisting	O
stress	O
and	O
replenishing	O
nutrition	O
;	O
and	O
the	O
glucose	O
has	O
the	O
effects	O
of	O
supplying	O
energy	O
and	O
promoting	O
healing	O
.	O

Microbial	O
feed	O
additive	O
for	O
treating	O
piglet	O
yellow	O
and	O
white	O
dysentery	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
solution	O
with	O
effect	O
of	O
repairing	O
exercise	O
-	O
induced	O
skeletal	O
muscle	O
microdamage	O
and	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
preparation	O
and	O
application	O
of	O
health	O
care	O
products	O
.	O

One	O
liter	O
of	O
solution	O
comprises	O
200	O
to	O
250	O
g	O
of	O
purslane	O
herb	O
extract	O
and	O
50	O
g	O
of	O
brown	O
sugar	O
.	O

The	O
solution	O
is	O
prepared	O
by	O
the	O
following	O
steps	O
of	O
:	O
1	O
,	O
preparing	O
solution	O
matrix	O
:	O
adding	O
500	O
g	O
of	O
brown	O
sugar	O
into	O
one	O
liter	O
of	O
water	O
,	O
quickly	O
stirring	O
uniformly	O
and	O
heating	O
until	O
the	O
brown	O
sugar	O
is	O
completely	O
dissolved	O
to	O
obtain	O
the	O
matrix	O
solution	O
;	O
and	O
2	O
,	O
adding	O
200	O
to	O
250	O
g	O
of	O
purslane	O
herb	O
extract	O
into	O
the	O
one	O
liter	O
of	O
matrix	O
solution	O
,	O
quickly	O
stirring	O
uniformly	O
and	O
heating	O
until	O
the	O
mixture	O
is	O
boiling	O
to	O
ensure	O
that	O
the	O
purslane	O
herb	O
extract	O
is	O
completely	O
dissolved	O
to	O
obtain	O
solution	O
A	O
or	O
solution	O
B	O
,	O
and	O
cooling	O
,	O
filming	O
and	O
packaging	O
.	O

The	O
solution	O
is	O
edible	O
,	O
does	O
not	O
have	O
toxic	O
or	O
side	O
effect	O
,	O
has	O
the	O
effect	O
of	O
chills	O
and	O
fever	O
complementation	O
,	O
and	O
can	O
be	O
taken	O
for	O
a	O
long	O
time	O
.	O

The	O
solution	O
has	O
an	O
extremely	O
simple	O
formula	O
,	O
an	O
extremely	O
simple	O
preparation	O
method	O
,	O
low	O
cost	O
,	O
and	O
good	O
mouthfeel	O
,	O
has	O
the	O
exact	O
effect	O
of	O
repairing	O
exercise	O
-	O
induced	O
skeletal	O
muscle	O
microdamage	O
and	O
has	O
ideal	O
effect	O
of	O
treating	O
accompanied	O
delayed	O
muscle	O
soreness	O
and	O
wide	O
market	O
application	O
prospect	O
.	O

Solution	O
with	O
effect	O
of	O
repairing	O
exercise	O
-	O
induced	O
skeletal	O
muscle	O
microdamage	O

The	O
invention	O
relates	O
to	O
a	O
method	O
for	O
preparing	O
an	O
antibacterial	O
agent	O
suspension	O
,	O
in	O
particular	O
to	O
a	O
method	O
for	O
preparing	O
a	O
Cefquinome	B
sulfate	I
suspension	O
injection	O
.	O

Taking	O
5000ml	O
of	O
Cefquinome	B
sulfate	I
suspension	O
injection	O
as	O
reference	O
,	O
the	O
Cefquinome	B
sulfate	I
suspension	O
injection	O
contains	O
the	O
following	O
components	O
:	O
1	O
-	O
2.5	O
percent	O
(	O
W	O
/	O
V	O
)	O
of	O
Cefquinome	B
sulfate	I
micro	O
powder	O
,	O
0.15	O
-	O
0.3	O
percent	O
(	O
W	O
/	O
V	O
)	O
of	O
Vitamin	B
E	I
and	O
the	O
balance	O
of	O
esters	B
solvent	O
or	O
injection	O
oil	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
heating	O
the	O
esters	B
solvent	O
or	O
the	O
injection	O
oil	O
to	O
115	O
-	O
125	O
DEG	O
C	O
in	O
a	O
high	O
-	O
shear	O
homogenizer	O
;	O
carrying	O
out	O
heat	O
preservation	O
on	O
the	O
heated	O
esters	B
solvent	O
or	O
injection	O
oil	O
for	O
4	O
-	O
6	O
hours	O
;	O
cooling	O
to	O
below	O
40	O
DEG	O
C	O
;	O
adding	O
sterilized	O
Cefquinome	B
sulfate	I
raw	O
materials	O
;	O
dispersing	O
at	O
the	O
rotating	O
speed	O
of	O
5000	O
-	O
8000rpm	O
(	O
Revolutions	O
Per	O
Minute	O
)	O
;	O
homogenizing	O
by	O
using	O
a	O
high	O
-	O
pressure	O
homogenize	O
at	O
the	O
working	O
pressure	O
of	O
1200bar	O
after	O
the	O
Cefquinome	B
sulfate	I
raw	O
materials	O
are	O
evenly	O
dispersed	O
;	O
encapsuling	O
;	O
and	O
irradiating	O
with	O
cobalt60	O
for	O
sterilization	O
for	O
5	O
-	O
6	O
hours	O
.	O

The	O
Cefquinome	B
sulfate	I
suspension	O
injection	O
prepared	O
by	O
the	O
invention	O
has	O
high	O
safety	O
,	O
good	O
curative	O
effect	O
and	O
small	O
stimulation	O
in	O
intramuscular	O
injection	O
.	O

Method	O
for	O
preparing	O
Cefquinome	B
sulfate	I
suspension	O
injection	O

The	O
invention	O
relates	O
to	O
treating	O
fluid	O
for	O
culturing	O
a	O
Pinctada	O
martensii	O
seawater	O
pearl	O
and	O
a	O
method	O
for	O
culturing	O
the	O
seawater	O
pearl	O
.	O

The	O
treating	O
fluid	O
is	O
obtained	O
by	O
the	O
steps	O
of	O
weighing	O
raw	O
materials	O
including	O
aureomycin	B
,	O
polyvinylpyrrolidone	B
,	O
taurine	B
,	O
vitamin	B
C	I
and	O
the	O
like	O
and	O
then	O
dissolving	O
the	O
raw	O
materials	O
into	O
sodium	O
alga	O
acid	O
of	O
physiological	O
saline	O
solution	O
with	O
the	O
weight	O
contentof	O
0.7	O
-	O
1	O
%	O
.	O

In	O
the	O
process	O
of	O
culturing	O
the	O
seawater	O
pearls	O
,	O
flake	O
shells	O
and	O
shell	O
pearl	O
nuclei	O
are	O
sliced	O
from	O
selected	O
healthy	O
nacres	O
which	O
are	O
not	O
damaged	O
by	O
diseases	O
and	O
insects	O
and	O
are	O
soaked	O
inthe	O
treating	O
fluid	O
and	O
then	O
are	O
implanted	O
into	O
the	O
pearl	O
culturing	O
bags	O
of	O
the	O
nacres	O
.	O

The	O
nucleus	O
implanting	O
operation	O
procedure	O
is	O
carried	O
out	O
according	O
to	O
the	O
traditional	O
conventional	O
means	O
;	O
the	O
flake	O
shells	O
and	O
shell	O
pearl	O
nuclei	O
are	O
transferred	O
to	O
a	O
sea	O
area	O
for	O
hanging	O
culture	O
after	O
20	O
-	O
25	O
days	O
of	O
recreation	O
period	O
.	O

The	O
seawater	O
pearls	O
cultured	O
by	O
the	O
treating	O
fluid	O
have	O
thick	O
pearl	O
layers	O
,	O
high	O
survival	O
rate	O
and	O
high	O
high	O
-	O
quality	O
pearl	O
rate	O
.	O

The	O
invention	O
reduces	O
the	O
death	O
rate	O
and	O
the	O
nucleus	O
splitting	O
rate	O
of	O
the	O
cultured	O
pearl	O
and	O
greatly	O
improves	O
the	O
yield	O
and	O
the	O
nucleus	O
reservation	O
rate	O
of	O
the	O
cultured	O
pearl	O
and	O
the	O
economic	O
benefits	O
of	O
culture	O
production	O
.	O

Flake	O
and	O
pearl	O
nucleus	O
matching	O
treating	O
fluid	O
for	O
culturing	O
Pinctada	O
martensii	O
pearl	O

The	O
invention	O
relates	O
to	O
a	O
compound	O
apramycin	B
sulfate	I
injection	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
compound	O
apramycin	B
sulfate	I
injection	O
comprises	O
the	O
following	O
components	O
of	O
:	O
5	O
-	O
110kg	O
/	O
L	O
of	O
apramycin	B
sulfate	I
,	O
10	O
-	O
150kg	O
/	O
L	O
of	O
mequindox	B
,	O
10	O
-	O
400kg	O
/	O
L	O
of	O
soldium	B
salicylate	I
,	O
1	O
-	O
20kg	O
/	O
L	O
of	O
atropine	B
sulfate	I
and	O
1	O
-	O
20kg	O
/	O
L	O
of	O
chlortrimeton	B
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
(	O
1	O
)	O
adding	O
100	O
-	O
400kg	O
/	O
L	O
of	O
soldium	B
salicylate	I
into	O
a	O
part	O
of	O
water	O
for	O
injection	O
,	O
then	O
adding	O
10	O
-	O
150kg	O
/	O
L	O
of	O
mequindox	B
,	O
and	O
stirring	O
for	O
10	O
-	O
20min	O
until	O
a	O
solution	O
is	O
clarified	O
;	O
(	O
2	O
)	O
taking	O
a	O
part	O
of	O
water	O
for	O
injection	O
,	O
sequentially	O
adding	O
5	O
-	O
110kg	O
/	O
L	O
of	O
apramycin	B
sulfate	I
,	O
1	O
-	O
20kg	O
/	O
L	O
of	O
atropine	B
sulfate	I
and	O
1	O
-	O
20kg	O
/	O
L	O
of	O
chlortrimeton	B
,	O
stirring	O
and	O
dissolving	O
;	O
and	O
(	O
3	O
)	O
combining	O
the	O
solution	O
prepared	O
in	O
steps	O
(	O
1	O
)	O
and	O
(	O
2	O
)	O
,	O
then	O
adding	O
the	O
water	O
for	O
injection	O
to	O
a	O
marked	O
volume	O
,	O
uniformly	O
stirring	O
,	O
keeping	O
for	O
15	O
-	O
20min	O
,	O
and	O
clarifying	O
liquid	O
medicine	O
to	O
obtain	O
the	O
compound	O
apramycin	B
sulfate	I
injection	O
.	O

In	O
the	O
invention	O
,	O
the	O
compound	O
preparation	O
consisting	O
of	O
the	O
apramycin	B
sulfate	I
and	O
the	O
mequindox	B
has	O
very	O
obvious	O
treatment	O
effect	O
on	O
pig	O
bacterial	O
diarrhea	O
and	O
can	O
effectively	O
relieve	O
stress	O
reaction	O
of	O
a	O
suffering	O
animal	O
body	O
;	O
experiments	O
show	O
that	O
the	O
combination	O
use	O
of	O
the	O
apramycin	B
sulfate	I
,	O
the	O
mequindox	B
and	O
the	O
atropine	B
sulfate	I
can	O
remarkably	O
enhance	O
a	O
curative	O
effect	O
;	O
and	O
the	O
compound	O
has	O
wide	O
clinical	O
application	O
range	O
,	O
and	O
can	O
be	O
widely	O
used	O
for	O
treating	O
bacterial	O
diarrhea	O
of	O
livestock	O
,	O
such	O
as	O
pig	O
,	O
cattle	O
,	O
sheep	O
,	O
and	O
the	O
like	O
,	O
enhance	O
the	O
survival	O
rate	O
and	O
increase	O
the	O
body	O
weights	O
of	O
the	O
pig	O
,	O
the	O
cattle	O
and	O
the	O
sheep	O
.	O

Compound	O
apramycin	B
sulfate	I
injection	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
new	O
purpose	O
of	O
a	O
compound	O
.	O

In	O
the	O
invention	O
,	O
antrodia	O
camphorata	O
extract	O
is	O
separated	O
and	O
purified	O
to	O
obtain	O
4-hydroxy-2,3-dimethoxy-6-methy-5	B
(	I
3,7,11-trimethyl	I
-	I
dodeca-2,6,10-trienyl	I
)	I
-cyclohex-2-enone	I
.	O

The	O
cyclohexenone	B
compound	O
can	O
be	O
used	O
for	O
inhibiting	O
growth	O
of	O
pancreatic	O
cancer	O
tumor	O
cells	O
and	O
simultaneously	O
can	O
be	O
used	O
for	O
pharmaceutical	O
compositions	O
for	O
inhibiting	O
growth	O
of	O
pancreatic	O
cancer	O
tumor	O
cells	O
.	O

Application	O
of	O
antrodia	O
camphorata	O
cyclohexenone	B
compound	O
in	O
preparing	O
medicine	O
for	O
inhibiting	O
growth	O
of	O
pancreatic	O
cancer	O
tumor	O
cells	O

The	O
invention	O
discloses	O
a	O
2,6-dichloro-5-fluoronicotinoyl	B
fluorobenzene	I
salicylamide	I
compound	O
,	O
and	O
discloses	O
an	O
application	O
of	O
the	O
2,6-dichloro-5-fluoronicotinoyl	B
fluorobenzene	I
salicylamide	I
compound	O
in	O
preparing	O
anti	O
-	O
tumor	O
medicaments	O
,	O
in	O
particular	O
to	O
an	O
application	O
of	O
the	O
2,6-dichloro-5-fluoronicotinoyl	B
fluorobenzene	I
salicylamide	I
compound	O
in	O
preparing	O
anti	O
-	O
endometrial	O
cancer	O
or	O
anti	O
-	O
lung	O
cancermedicaments	O
.	O

The	O
invention	O
has	O
the	O
main	O
beneficial	O
effects	O
that	O
:	O
(	O
1	O
)	O
the	O
method	O
for	O
preparing	O
the	O
2,6-dichloro-5-fluoronicotinoyl	B
fluorobenzene	I
salicylamide	I
compound	O
is	O
provided	O
;	O
(	O
2	O
)	O
the	O
novel	O
anti	O
-	O
tumor	O
medicament	O
with	O
remarkable	O
anti	O
-	O
tumor	O
activity	O
is	O
provided	O
,	O
a	O
research	O
foundation	O
is	O
laid	O
for	O
novel	O
medicament	O
screening	O
,	O
and	O
the	O
compound	O
has	O
great	O
application	O
prospect	O
;	O
and	O
(	O
3	O
)	O
the	O
preparation	O
process	O
is	O
simple	O
,	O
and	O
is	O
advantageous	O
to	O
industrial	O
production	O
.	O

2,6-dichloro-5-fluoronicotinoyl	B
fluorobenzene	I
salicylamide	I
compound	O
as	O
well	O
as	O
preparation	O
and	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
postoperative	O
anti	O
-	O
adhesion	O
medicament	O
capable	O
of	O
effectively	O
preventing	O
postoperative	O
adhesion	O
,	O
lubricating	O
tissues	O
and	O
inhibiting	O
inflammation	O
.	O

The	O
technical	O
scheme	O
is	O
that	O
:	O
the	O
postoperative	O
anti	O
-	O
adhesion	O
medicament	O
consists	O
of	O
berberine	B
hydrochloride	I
,	O
dicynone	B
and	O
polyethylene	B
glycol	I
.	O

Postoperative	O
anti	O
-	O
adhesion	O
medicament	O

The	O
invention	O
relates	O
to	O
an	O
oral	O
hard	O
capsule	O
,	O
in	O
particular	O
to	O
a	O
tablet	O
capsule	O
with	O
roxithromycin	B
tablets	O
and	O
ambroxol	B
hydrochloride	I
tablets	O
.	O

The	O
tablet	O
capsule	O
consists	O
of	O
a	O
capsule	O
and	O
tablets	O
in	O
the	O
capsule	O
,	O
wherein	O
the	O
capsule	O
comprises	O
an	O
upper	O
capsule	O
body	O
and	O
a	O
lower	O
capsule	O
body	O
,	O
and	O
at	O
least	O
one	O
tablet	O
of	O
which	O
the	O
active	O
ingredient	O
is	O
roxithromycin	B
and	O
at	O
least	O
one	O
tablet	O
of	O
which	O
the	O
active	O
ingredient	O
is	O
ambroxol	B
hydrochloride	I
are	O
filled	O
in	O
the	O
capsule	O
.	O

Because	O
the	O
active	O
ingredients	O
in	O
the	O
capsule	O
do	O
not	O
contact	O
,	O
chemical	O
changes	O
can	O
not	O
be	O
generated	O
between	O
the	O
ingredients	O
,	O
side	O
products	O
can	O
not	O
be	O
generated	O
,	O
and	O
the	O
stability	O
of	O
the	O
product	O
is	O
improved	O
,	O
degradation	O
products	O
generated	O
after	O
the	O
roxithromycin	B
and	O
the	O
ambroxol	B
hydrochloride	I
contact	O
are	O
reduced	O
particularly	O
.	O

In	O
addition	O
,	O
the	O
designs	O
of	O
cylindrical	O
tablets	O
and	O
different	O
colors	O
and	O
the	O
application	O
of	O
transparent	O
capsule	O
shells	O
are	O
adopted	O
,	O
and	O
the	O
product	O
of	O
the	O
invention	O
is	O
particularly	O
suitable	O
for	O
industrial	O
production	O
,	O
thereby	O
the	O
compliance	O
of	O
patients	O
is	O
enhanced	O
.	O

Meanwhile	O
,	O
the	O
active	O
ingredients	O
are	O
respectively	O
tabletted	O
,	O
thus	O
the	O
drug	O
assay	O
and	O
the	O
quality	O
control	O
are	O
easier	O
.	O

Tablet	O
capsule	O
with	O
roxithromycin	B
tablets	O
and	O
ambroxol	B
hydrochloride	I
tablets	O

The	O
invention	O
discloses	O
a	O
chewable	O
tablet	O
of	O
calcium	B
carbonate	I
dimeticone	I
and	O
a	O
preparation	O
process	O
,	O
belonging	O
to	O
four	O
new	O
national	O
chemical	O
medicines	O
.	O

The	O
preparation	O
of	O
the	O
invention	O
is	O
prepared	O
from	O
the	O
following	O
main	O
components	O
:	O
calcium	B
carbonate	I
,	O
simethicone	O
,	O
siliciidoxydum	O
,	O
aspartame	B
,	O
essence	O
powder	O
,	O
mannite	B
,	O
corn	O
starch	O
,	O
low	O
-	O
substituted	O
hydroxypropyl	O
cellulose	O
and	O
magnesium	B
stearate	I
,	O
wherein	O
the	O
calcium	B
carbonate	I
as	O
the	O
main	O
content	O
has	O
stronger	O
acid	O
-	O
resisting	O
action	O
and	O
rapid	O
and	O
lasting	O
effects	O
,	O
and	O
the	O
simethicone	O
is	O
a	O
foam	O
suppressor	O
for	O
eliminating	O
gastrointestinal	O
tract	O
pneumatosis	O
.	O

The	O
preparation	O
is	O
used	O
for	O
treating	O
peptic	O
ulcers	O
including	O
stomach	O
and	O
duodenal	O
ulcer	O
and	O
easing	O
various	O
uncomfortable	O
symptoms	O
caused	O
by	O
hyperacidity	O
.	O

Chewable	O
tablet	O
of	O
calcium	B
carbonate	I
dimeticone	I
and	O
preparation	O
process	O

The	O
invention	O
relates	O
to	O
a	O
Chinese	O
and	O
Western	O
medicine	O
synthesized	O
preparation	O
,	O
in	O
particular	O
to	O
the	O
Chinese	O
and	O
Western	O
medicine	O
synthesized	O
preparation	O
for	O
treating	O
chronic	O
urticaria	O
.	O

The	O
preparation	O
is	O
characterized	O
by	O
consisting	O
of	O
the	O
following	O
raw	O
materials	O
in	O
part	O
by	O
weight	O
:	O
10	O
mg	O
of	O
antihistaminics	O
Loratadine	O
,	O
5	O
g	O
of	O
divaricate	O
saposhnikovia	O
root	O
,	O
8	O
g	O
of	O
belvedere	O
fruit	O
,	O
10	O
g	O
of	O
astragalus	O
mongholicus	O
,	O
5	O
g	O
of	O
Chinese	O
angelica	O
,	O
10	O
g	O
of	O
cocklebur	O
fruit	O
,	O
3	O
g	O
of	O
cassia	O
twig	O
,	O
and	O
1	O
part	O
of	O
musk	O
;	O
the	O
antihistaminics	O
Loratadine	O
,	O
the	O
musk	O
,	O
the	O
divaricate	O
saposhnikovia	O
root	O
,	O
the	O
belvedere	O
fruit	O
,	O
the	O
astragalus	O
mongholicus	O
,	O
the	O
Chinese	O
angelica	O
,	O
the	O
cocklebur	O
fruit	O
and	O
the	O
cassia	O
twig	O
are	O
ground	O
into	O
powder	O
and	O
mixed	O
uniformly	O
,	O
and	O
the	O
powder	O
in	O
which	O
musk	O
is	O
added	O
is	O
then	O
regulated	O
into	O
paste	O
with	O
yellow	O
wine	O
.	O

The	O
preparation	O
for	O
treating	O
the	O
chronic	O
urticaria	O
is	O
simple	O
and	O
practicable	O
in	O
method	O
,	O
has	O
small	O
toxic	O
or	O
side	O
effect	O
,	O
and	O
has	O
good	O
auxiliary	O
treatment	O
effect	O
on	O
the	O
chronic	O
urticaria	O
.	O

Chinese	O
and	O
Western	O
medicine	O
synthesized	O
preparation	O
for	O
treating	O
chronic	O
urticaria	O

The	O
invention	O
discloses	O
a	O
Chinese	O
materia	O
medica	O
preparation	O
for	O
treating	O
intense	O
heat	O
evil	O
rheumatic	O
fever	O
,	O
comprising	O
the	O
following	O
medicines	O
by	O
fixed	O
weight	O
ratio	O
:	O
gypsum	O
,	O
rhizoma	O
anemarrhenae	O
,	O
golden	O
cypress	O
,	O
polished	O
round	O
-	O
grained	O
rice	O
,	O
Cape	O
Jasmine	O
Fruit	O
and	O
the	O
like	O
.	O

The	O
raw	O
materials	O
of	O
the	O
medicine	O
are	O
easy	O
to	O
obtain	O
and	O
low	O
in	O
cost	O
;	O
and	O
the	O
medicine	O
has	O
the	O
advantages	O
of	O
short	O
course	O
of	O
treatment	O
,	O
excellent	O
curative	O
effect	O
and	O
no	O
side	O
effect	O
.	O

Medicine	O
for	O
treating	O
rheumatic	O
fever	O

The	O
invention	O
provides	O
Nimesulide	B
temperature	O
sensitive	O
gel	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
Nimesulide	B
temperature	O
sensitive	O
gel	O
comprises	O
Nimesulide	B
,	O
a	O
temperature	O
sensitive	O
gel	O
material	O
,	O
a	O
pH	O
regulator	O
,	O
a	O
preservative	O
and	O
the	O
like	O
and	O
is	O
characterized	O
in	O
that	O
:	O
the	O
temperature	O
sensitive	O
gel	O
material	O
is	O
poloxamer	O
,	O
and	O
the	O
weight	O
ratio	O
of	O
the	O
poloxamer	O
to	O
the	O
Nimesulide	B
is	O
9:1	O
;	O
and	O
the	O
optimized	O
temperature	O
sensitive	O
gel	O
material	O
is	O
poloxamer	O
407	O
.	O

The	O
temperature	O
sensitive	O
gel	O
is	O
sensitive	O
to	O
temperature	O
changes	O
,	O
and	O
rabbit	O
rectum	O
experimental	O
results	O
show	O
that	O
the	O
temperature	O
sensitive	O
gel	O
has	O
higher	O
medicament	O
release	O
rate	O
and	O
higher	O
bioavailability	O
which	O
are	O
obviously	O
better	O
than	O
those	O
of	O
the	O
conventional	O
Nimesulide	B
common	O
suppositories	O
.	O

The	O
Nimesulide	B
temperature	O
sensitive	O
gel	O
reserves	O
the	O
advantages	O
of	O
the	O
conventional	O
suppositories	O
,	O
overcomes	O
the	O
defects	O
of	O
the	O
conventional	O
suppositories	O
to	O
a	O
certain	O
extent	O
and	O
has	O
a	O
wide	O
clinical	O
application	O
prospect	O
.	O

The	O
Nimesulide	B
temperature	O
sensitive	O
gel	O
uses	O
common	O
safe	O
pharmaceutical	O
excipients	O
,	O
has	O
a	O
simple	O
production	O
process	O
,	O
stable	O
and	O
easily	O
-	O
controlled	O
quality	O
and	O
high	O
process	O
reproducibility	O
,	O
and	O
is	O
suitable	O
for	O
industrial	O
production	O
.	O

Nimesulide	B
temperature	O
sensitive	O
hydrogel	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
perfusate	O
for	O
treating	O
cow	O
recessive	O
mastitis	O
,	O
which	O
mainly	O
comprises	O
the	O
raw	O
materials	O
with	O
the	O
following	O
ratios	O
:	O
4000	O
-	O
5000	O
g	O
of	O
radix	O
astragali	O
,	O
4000	O
-	O
5000	O
g	O
of	O
herba	O
epimedii	O
,	O
300	O
-	O
500	O
g	O
of	O
levamisole	B
hydrochloride	I
,	O
300	O
-	O
400	O
g	O
of	O
antibacterial	O
pepetide	O
,	O
2000	O
-	O
3000ml	O
of	O
glycerol	B
,	O
400	O
-	O
500	O
g	O
of	O
gelatine	O
,	O
and	O
50	O
-	O
100	O
g	O
of	O
sodium	B
benzoate	I
,	O
wherein	O
pH	O
of	O
the	O
perfusate	O
is	O
5.5	O
-	O
7.5	O
.	O

The	O
perfusate	O
is	O
used	O
for	O
treating	O
cow	O
recessive	O
mastitis	O
with	O
determine	O
curative	O
effect	O
,	O
drug	O
concentration	O
for	O
local	O
application	O
is	O
high	O
,	O
absorption	O
ratio	O
is	O
high	O
,	O
the	O
direction	O
is	O
high	O
,	O
drug	O
application	O
is	O
convenient	O
and	O
safe	O
,	O
thereby	O
the	O
goal	O
of	O
fast	O
treating	O
cow	O
recessive	O
mastitis	O
is	O
achieved	O
,	O
and	O
the	O
perfusate	O
is	O
compound	O
perfusion	O
preparation	O
combining	O
antibiosis	O
,	O
antiphlogosis	O
and	O
improving	O
immunity	O
of	O
the	O
organism	O
.	O

Perfusate	O
and	O
preparation	O
method	O
thereof	O
for	O
treating	O
cow	O
recessive	O
mastitis	O

The	O
invention	O
relates	O
to	O
a	O
nano	O
selenium	B
-	I
germanium	I
snake	O
anion	O
far	O
infrared	O
body	O
-	O
building	O
life	O
-	O
prolonging	O
health	O
-	O
care	O
drink	O
and	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
drink	O
production	O
and	O
preparation	O
.	O

Snake	O
medicinal	O
material	O
has	O
rich	O
nutrients	O
.	O

The	O
snake	O
medicinal	O
material	O
not	O
only	O
contain	O
protein	O
,	O
fat	O
,	O
sugar	B
,	O
macro	O
and	O
trace	O
elements	O
and	O
vitamins	O
,	O
but	O
also	O
contains	O
eight	O
necessary	O
amino	B
acids	I
which	O
can	O
not	O
be	O
synthesized	O
in	O
human	O
bodies	O
or	O
are	O
synthesized	O
slowly	O
in	O
human	O
bodies	O
.	O

The	O
snake	O
medicinal	O
material	O
can	O
purify	O
water	O
source	O
.	O

The	O
snake	O
material	O
can	O
activate	O
,	O
purify	O
and	O
mineralize	O
65	O
percent	O
or	O
100	O
percent	O
of	O
water	O
in	O
human	O
bodies	O
and	O
therefore	O
can	O
promote	O
metabolism	O
element	O
balance	O
and	O
acid	O
-	O
base	O
balance	O
in	O
human	O
bodies	O
,	O
increase	O
oxygen	B
content	O
in	O
cells	O
of	O
human	O
bodies	O
and	O
strength	O
the	O
circulation	O
of	O
anions	O
in	O
the	O
drink	O
in	O
blood	O
;	O
and	O
at	O
the	O
same	O
time	O
,	O
the	O
anions	O
in	O
the	O
drink	O
and	O
the	O
far	O
infrared	O
electromagnetic	O
wave	O
resisting	O
materials	O
can	O
reach	O
a	O
3	O
to	O
5	O
millimeter	O
deep	O
place	O
in	O
skin	O
tissues	O
and	O
automatically	O
heats	O
to	O
improve	O
the	O
vitality	O
of	O
cells	O
,	O
promote	O
tissue	O
regeneration	O
,	O
supply	O
nutrients	O
to	O
cell	O
tissues	O
,	O
so	O
the	O
health	O
of	O
human	O
bodies	O
is	O
kept	O
and	O
life	O
is	O
prolonged	O
.	O

Nano	O
selenium	B
-	I
germanium	I
snake	O
anion	O
far	O
infrared	O
body	O
-	O
building	O
life	O
-	O
prolonging	O
health	O
-	O
care	O
drink	O

The	O
invention	O
relates	O
to	O
a	O
cold	O
-	O
system	O
preparation	O
method	O
of	O
south	O
calcite	B
as	O
a	O
Tibetan	O
medicine	O
.	O

The	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
(	O
1	O
)	O
collecting	O
mineral	O
south	O
calcite	B
,	O
cleaning	O
,	O
removing	O
impurities	O
,	O
scrapping	O
into	O
particles	O
with	O
the	O
granularity	O
of	O
10	O
-	O
30	O
mm	O
,	O
adding	O
auxiliaries	O
,	O
i.e.	O
,	O
Radix	O
Aconiti	O
and	O
potassium	O
nitrate	O
,	O
heating	O
and	O
continuously	O
boiling	O
for	O
2	O
-	O
16	O
h	O
to	O
obtain	O
the	O
boiled	O
south	O
calcite	B
;	O
(	O
2	O
)	O
rinsing	O
the	O
boiled	O
south	O
calcite	B
with	O
clear	O
water	O
until	O
the	O
rinsing	O
liquid	O
is	O
clear	O
as	O
crystal	O
,	O
and	O
drying	O
until	O
the	O
weight	O
is	O
consistent	O
to	O
obtain	O
the	O
dry	O
south	O
calcite	B
;	O
and	O
(	O
3	O
)	O
grinding	O
the	O
dry	O
south	O
calcite	B
,	O
sieving	O
with	O
a	O
screen	O
of	O
20	O
-	O
100	O
meshes	O
to	O
obtain	O
south	O
calcite	B
powder	O
,	O
uniformly	O
mixing	O
and	O
stirring	O
the	O
south	O
calcite	B
powder	O
with	O
fresh	O
milk	O
and	O
drying	O
in	O
shade	O
to	O
obtain	O
a	O
finished	O
product	O
.	O

The	O
cold	O
-	O
system	O
preparation	O
method	O
is	O
simple	O
and	O
convenient	O
to	O
operate	O
and	O
easy	O
to	O
implement	O
and	O
can	O
greatly	O
increase	O
the	O
content	O
of	O
effective	O
trace	O
elements	O
in	O
the	O
south	O
calcitewithout	B
remarkably	O
influencing	O
the	O
main	O
contents	O
,	O
thereby	O
the	O
method	O
can	O
be	O
used	O
as	O
a	O
reference	O
for	O
preparing	O
high	O
south	O
calcite	B
and	O
a	O
standard	O
preparation	O
method	O
of	O
the	O
south	O
calcite	B
as	O
the	O
Tibetan	O
medicine	O
.	O

Cold	O
-	O
system	O
preparation	O
method	O
of	O
south	O
calcite	B
as	O
a	O
Tibetan	O
medicine	O

The	O
invention	O
discloses	O
a	O
medicament	O
for	O
treating	O
pain	O
of	O
cervical	O
and	O
lumbar	O
vertebrae	O
,	O
which	O
is	O
prepared	O
according	O
to	O
the	O
following	O
steps	O
:	O
adding	O
raw	O
medicines	O
such	O
as	O
szechuan	O
aconite	O
,	O
wild	O
aconite	O
,	O
rhizoma	O
arisaematis	O
and	O
the	O
like	O
into	O
water	O
for	O
decocting	O
,	O
filtering	O
the	O
obtained	O
decoction	O
with	O
gauze	O
,	O
and	O
concentrating	O
the	O
decoction	O
into	O
fluid	O
extract	O
for	O
later	O
use	O
;	O
then	O
,	O
preparing	O
raw	O
medicines	O
such	O
as	O
mastic	O
,	O
myrrh	O
,	O
safflower	O
,	O
catechu	O
and	O
the	O
like	O
into	O
fine	O
powder	O
,	O
and	O
sieving	O
the	O
fine	O
powder	O
with	O
a	O
100-mesh	O
sieve	O
for	O
later	O
use	O
;	O
and	O
finally	O
,	O
mixing	O
and	O
heating	O
talcum	O
powder	O
,	O
zinc	B
oxide	I
,	O
sesame	O
oil	O
and	O
medical	O
solid	O
pressure	O
-	O
sensitive	O
hot	O
melt	O
adhesive	O
,	O
adding	O
the	O
fluid	O
extract	O
obtained	O
in	O
the	O
step	O
(	O
1	O
)	O
and	O
the	O
fine	O
powder	O
obtained	O
in	O
the	O
step	O
(	O
2	O
)	O
while	O
continuously	O
stirring	O
until	O
the	O
moisture	O
is	O
fully	O
evaporated	O
,	O
cooling	O
,	O
adding	O
certain	O
parts	O
by	O
weight	O
of	O
camphor	B
,	O
borneol	B
and	O
azone	B
,	O
stirring	O
uniformly	O
,	O
and	O
spreading	O
5	O
g	O
of	O
ointment	O
on	O
non	O
-	O
woven	O
fabric	O
to	O
obtain	O
the	O
plaster	O
disclosed	O
by	O
the	O
invention	O
.	O

Plaster	O
for	O
treating	O
pain	O
of	O
cervical	O
and	O
lumbar	O
vertebrae	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
geldanamycin	B
derivative	O
,	O
preparation	O
thereof	O
and	O
medicament	O
application	O
thereof	O
.	O

The	O
structural	O
formula	O
as	O
shown	O
in	O
the	O
following	O
formula	O
(	O
I	O
)	O
is	O
a	O
novel	O
structural	O
formula	O
formed	O
by	O
modifying	O
the	O
geldanamycin	B
,	O
and	O
the	O
pair	O
of	O
heat	O
shock	O
protein	O
90	O
is	O
good	O
in	O
activity	O
.	O

The	O
compound	O
as	O
shown	O
in	O
the	O
formula	O
(	O
I	O
)	O
,	O
or	O
the	O
medical	O
salt	O
of	O
the	O
compound	O
;	O
R1	O
group	O
is	O
phenyl	B
or	O
3-furyl	B
or	O
3-pyrryl	B
or	O
the	O
other	O
hexahydric	B
heteroaromatic	I
group	O
,	O
or	O
the	O
other	O
quinary	O
heteroaromatic	B
group	O
;	O
and	O
R2	O
group	O
is	O
carboxylic	B
acid	I
amide	O
or	O
acetyl	B
or	O
ethyl	B
or	O
the	O
fatty	B
hydrocarbon	I
group	O
of	O
the	O
other	O
C1-C5	B
carbon	I
straight	O
chain	O
or	O
the	O
carbonyl	B
group	O
of	O
the	O
other	O
C1-C5	B
carbon	I
straight	O
chain	O
fatty	B
hydrocarbon	I
.	O

The	O
compound	O
as	O
shown	O
in	O
the	O
formula	O
(	O
I	O
)	O
has	O
the	O
characteristic	O
of	O
the	O
high	O
-	O
efficiency	O
combined	O
heat	O
shock	O
protein	O
90	O
,	O
so	O
that	O
the	O
geldanamycin	B
derivative	O
can	O
be	O
used	O
for	O
curing	O
or	O
preventing	O
the	O
tumor	O
of	O
the	O
mammal	O
,	O
in	O
particular	O
to	O
the	O
solid	O
tumor	O
.	O

Geldanamycin	B
derivative	O
,	O
preparation	O
thereof	O
and	O
medicament	O
application	O
thereof	O

The	O
invention	O
discloses	O
an	O
Esculentoside	B
A	I
,	O
EsA	B
as	O
well	O
as	O
a	O
preparation	O
method	O
and	O
application	O
thereof	O
.	O

The	O
general	O
formula	O
of	O
the	O
Esculentoside	B
A	I
,	O
EsA	B
is	O
shown	O
in	O
the	O
specification	O
,	O
wherein	O
R	O
is	O
amino	B
acid	I
,	O
polypeptide	O
,	O
piperazine	B
base	O
,	O
substituted	O
piperazine	B
bases	O
or	O
substituted	O
amido	B
.	O

An	O
active	O
ester	O
intermediate	O
formed	O
by	O
the	O
Esculentoside	B
A	I
,	O
EsA	B
under	O
the	O
action	O
of	O
a	O
condensation	O
agent	O
reacts	O
with	O
amine	B
or	O
piperazine	B
or	O
substituted	O
piperazine	B
or	O
amino	B
acid	I
with	O
the	O
protected	O
carboxyl	B
or	O
polypeptide	O
;	O
and	O
the	O
Esculentoside	B
A	I
,	O
EsA	B
is	O
obtained	O
by	O
separation	O
and	O
purification	O
.	O

The	O
Esculentoside	B
A	I
,	O
EsA	B
,	O
as	O
well	O
as	O
pharmaceutical	O
salt	O
and	O
medical	O
composite	O
thereof	O
can	O
be	O
used	O
for	O
preparing	O
inflammatory	O
medicaments	O
.	O

Esculentoside	B
A	I
,	O
EsA	B
as	O
well	O
as	O
preparation	O
method	O
and	O
application	O
thereof	O

A	O
compound	O
of	O
Formula	O
(	O
I	O
)	O
or	O
Formula	O
(	O
II	O
)	O
and	O
enantiomers	O
,	O
diastereomers	O
and	O
pharmaceutically	O
-	O
acceptable	O
salts	O
thereof	O
.	O

Also	O
disclosed	O
are	O
pharmaceutical	O
compositions	O
containing	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
or	O
Formula	O
(	O
II	O
)	O
,	O
and	O
methods	O
of	O
treating	O
conditions	O
associated	O
with	O
the	O
activity	O
of	O
p38	O
kinase	O
.	O

Imidazopyridine	B
and	O
imidazopyrazine	B
compounds	O
useful	O
as	O
kinase	O
inhibitors	O

The	O
invention	O
relates	O
to	O
application	O
of	O
arachidonic	B
acid	I
as	O
a	O
xanthine	B
oxidase	O
inhibitor	O
and	O
in	O
the	O
preparation	O
of	O
medicines	O
for	O
treating	O
hyperuricemia	O
or	O
gout	O
.	O

Xanthine	B
oxidase	O
is	O
a	O
key	O
enzyme	O
for	O
the	O
generation	O
and	O
the	O
development	O
of	O
the	O
hyperuricemia	O
or	O
the	O
gout	O
,	O
most	O
substrates	O
of	O
the	O
xanthine	B
oxidase	O
are	O
cyclic	O
small	O
molecules	O
,	O
and	O
the	O
arachidonic	B
acid	I
is	O
long	O
chain	O
polyunsaturated	O
fatty	B
acid	I
;	O
a	O
three	O
dimensional	O
structure	O
of	O
the	O
xanthine	B
oxidase	O
is	O
downloaded	O
from	O
a	O
protein	O
data	O
bank	O
(	O
PDB	O
)	O
of	O
a	O
website	O
;	O
a	O
three	O
dimensional	O
structure	O
of	O
the	O
arachidonic	B
acid	I
is	O
downloaded	O
from	O
a	O
pubchem	O
;	O
molecular	O
docking	O
between	O
the	O
arachidonic	B
acid	I
and	O
the	O
xanthine	B
oxidase	O
is	O
performed	O
by	O
iGEMDOCK	O
software	O
and	O
docking	O
energy	O
is	O
computed	O
;	O
and	O
in	O
-	O
vitro	O
enzyme	O
activity	O
tests	O
prove	O
that	O
the	O
arachidonic	B
acid	I
has	O
an	O
inhibition	O
effect	O
on	O
the	O
xanthine	B
oxidase	O
.	O

By	O
the	O
application	O
,	O
another	O
important	O
physiological	O
function	O
of	O
the	O
arachidonic	B
acid	I
is	O
discovered	O
,	O
and	O
a	O
wider	O
way	O
is	O
provided	O
for	O
screening	O
the	O
xanthine	B
oxidase	O
inhibitor	O
from	O
a	O
natural	O
product	O
to	O
treat	O
the	O
hyperuricemia	O
or	O
the	O
gout	O
simultaneously	O
.	O

Application	O
of	O
arachidonic	B
acid	I
as	O
xanthine	B
oxidase	O
inhibitor	O
and	O
in	O
preparation	O
of	O
medicines	O
for	O
treating	O
hyperuricemia	O
or	O
gout	O

The	O
invention	O
relates	O
to	O
a	O
preparation	O
method	O
of	O
a	O
pulsatilla	O
saponin	O
matter	O
as	O
well	O
as	O
a	O
preparation	O
method	O
of	O
a	O
preparation	O
thereof	O
and	O
application	O
of	O
the	O
pulsatilla	B
saponin	I
matter	O
in	O
preparing	O
medicaments	O
for	O
treating	O
cancers	O
.	O

The	O
invention	O
relates	O
to	O
the	O
pulsatilla	O
saponin	B
matter	O
which	O
is	O
pulsatilla	B
saponin	I
A	I
or	O
pulsatilla	B
saponin	I
A	I
produced	O
by	O
hydrolysis	O
,	O
thereby	O
together	O
having	O
the	O
structural	O
units	O
of	O
23-hydroxy	B
oleanolic	I
acid-3-O	I
-	I
alpha	I
-	I
L	I
-	I
pyran	I
rhamnose-	I
(	I
1->2	I
)	I
-alpha	I
-	I
L	I
-	I
pyran	I
Arabic	I
glucoside	I
,	O
and	O
the	O
like	O
,	O
and	O
because	O
the	O
matter	O
is	O
easy	O
to	O
generate	O
the	O
pulsatilla	B
saponin	I
A	I
after	O
being	O
hydrolyzed	O
,	O
the	O
pulsatilla	B
saponin	I
matter	O
has	O
a	O
similar	O
treating	O
effect	O
in	O
human	O
bodies	O
.	O

Preparation	O
method	O
of	O
pulsatilla	O
saponin	B
matter	O
as	O
well	O
as	O
preparation	O
method	O
of	O
preparation	O
thereof	O
and	O
application	O
of	O
pulsatilla	B
saponin	I
matter	O
in	O
preparing	O
medicaments	O
for	O
treating	O
cancers	O

The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicines	O
,	O
and	O
particularly	O
relates	O
to	O
a	O
dirithromycin	B
medicinal	O
composition	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

By	O
the	O
dirithromycin	B
medicinal	O
composition	O
,	O
the	O
problem	O
of	O
the	O
flowability	O
of	O
granules	O
during	O
preparation	O
is	O
mainly	O
solved	O
,	O
and	O
the	O
stability	O
,	O
bioavailability	O
and	O
the	O
like	O
of	O
medicaments	O
are	O
improved	O
.	O

The	O
invention	O
also	O
provides	O
a	O
preparation	O
method	O
for	O
the	O
dirithromycin	B
medicinal	O
composition	O
,	O
namely	O
the	O
dirithromycin	B
medicinal	O
composition	O
is	O
filled	O
by	O
a	O
direct	O
method	O
,	O
so	O
by	O
the	O
preparation	O
method	O
,	O
the	O
problem	O
that	O
soft	O
materials	O
have	O
high	O
viscosity	O
and	O
are	O
difficult	O
to	O
pelletize	O
in	O
the	O
process	O
of	O
preparing	O
dirithromycin	B
medicinal	O
capsules	O
in	O
the	O
prior	O
art	O
is	O
solved	O
.	O

Dirithromycin	B
medicinal	O
composition	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
the	O
technical	O
field	O
of	O
medicines	O
,	O
in	O
particular	O
to	O
novel	O
application	O
of	O
a	O
feather	O
cockscomb	O
saponins	O
compound	O
,	O
such	O
as	O
Celosin	B
A	I
,	O
Celosin	B
B	I
,	O
Celosin	B
C1	I
,	O
Celosin	B
D1	I
,	O
Celosin	B
E	I
,	O
Celosin	B
F	I
,	O
Celosin	B
G	I
or	O
Cristatain	B
.	O

Proved	O
by	O
in	O
vitro	O
cell	O
experiments	O
,	O
the	O
feather	O
cockscomb	O
saponins	O
compound	O
,	O
such	O
as	O
the	O
Celosin	B
A	I
,	O
the	O
Celosin	B
B	I
,	O
the	O
Celosin	B
C1	I
,	O
the	O
Celosin	B
D1	I
,	O
the	O
Celosin	B
E	I
,	O
the	O
Celosin	B
F	I
,	O
Celosin	B
G	I
and	O
Cristatain	B
have	O
favorable	O
anti	O
-	O
inflammatory	O
activity	O
,	O
and	O
the	O
Celosin	B
A	I
,	O
the	O
Celosin	B
B	I
and	O
Cristatain	B
have	O
better	O
anti	O
-	O
inflammatory	O
effect	O
,	O
therefore	O
,	O
the	O
feather	O
cockscomb	O
saponins	B
compound	O
can	O
be	O
used	O
for	O
preparing	O
anti	O
-	O
inflammatory	O
or	O
antitumor	O
medicines	O
.	O

The	O
invention	O
provides	O
a	O
new	O
medicine	O
source	O
for	O
the	O
anti	O
-	O
inflammatory	O
medicines	O
.	O

Application	O
of	O
feather	O
cockscomb	O
saponins	B
compound	O
in	O
antitumor	O
or	O
anti	O
-	O
inflammatory	O
medicines	O

The	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
for	O
treating	O
small	O
cell	O
lung	O
cancer	O
and	O
application	O
,	O
a	O
kit	O
and	O
package	O
thereof	O
.	O

The	O
pharmaceutical	O
composition	O
,	O
kit	O
and	O
package	O
contain	O
a	O
treatment	O
effective	O
dose	O
of	O
lobaplatin	B
and	O
a	O
treatment	O
effective	O
dose	O
of	O
etoposide	B
as	O
a	O
combination	O
for	O
simultaneous	O
,	O
separated	O
or	O
sequential	O
use	O
.	O

When	O
used	O
for	O
treating	O
the	O
small	O
cell	O
lung	O
cancer	O
,	O
the	O
pharmaceutical	O
composition	O
,	O
kit	O
and	O
package	O
provided	O
by	O
the	O
invention	O
can	O
obtain	O
excellent	O
treatment	O
effect	O
and	O
have	O
small	O
toxic	O
side	O
effect	O
.	O

Pharmaceutical	O
composition	O
for	O
treating	O
small	O
cell	O
lung	O
cancer	O
and	O
application	O
,	O
kit	O
and	O
package	O
thereof	O

The	O
invention	O
discloses	O
a	O
preparation	O
method	O
of	O
a	O
pharmaceutical	O
composition	O
ointment	O
for	O
treating	O
skin	O
diseases	O
.	O

The	O
pharmaceutical	O
composition	O
contains	O
the	O
following	O
components	O
in	O
proportion	O
by	O
weight	O
:	O
0.05	O
-	O
0.08	O
%	O
of	O
betamethasone	B
valerate	I
,	O
0.08	O
-	O
0.12	O
%	O
of	O
chlorocresol	B
and	O
0.08	O
-	O
0.12	O
%	O
of	O
gentamicin	B
sulfate	I
.	O

The	O
pharmaceutical	O
composition	O
ointment	O
is	O
mainly	O
used	O
for	O
treating	O
dermatitis	O
,	O
eczema	O
,	O
contact	O
dermatitis	O
,	O
seborrheic	O
dermatitis	O
,	O
photodermatitis	O
,	O
neurodermatitis	O
,	O
intertrigo	O
,	O
exfoliative	O
dermatitis	O
,	O
skin	O
itch	O
,	O
psoriasis	O
,	O
first	O
-	O
degree	O
burn	O
and	O
the	O
like	O
.	O

The	O
pharmaceutical	O
composition	O
ointment	O
has	O
the	O
characteristics	O
of	O
jointly	O
applying	O
pharmaceutical	O
components	O
with	O
anti	O
-	O
inflammatory	O
,	O
antifungal	O
and	O
antibacterial	O
curative	O
effects	O
,	O
playing	O
the	O
curative	O
effects	O
in	O
multiple	O
aspects	O
,	O
overcoming	O
the	O
defect	O
that	O
an	O
individual	O
component	O
can	O
not	O
more	O
effectively	O
treat	O
skin	O
mycotic	O
infection	O
,	O
skin	O
allergy	O
,	O
dermatitis	O
,	O
eczema	O
and	O
the	O
like	O
,	O
or	O
concurrence	O
of	O
mycotic	O
infection	O
,	O
skin	O
allergy	O
,	O
dermatitis	O
,	O
eczema	O
and	O
the	O
like	O
,	O
and	O
relieving	O
the	O
serious	O
side	O
effects	O
caused	O
by	O
singly	O
using	O
a	O
big	O
amount	O
of	O
hormone	O
for	O
treating	O
dermatitis	O
,	O
eczema	O
and	O
the	O
like	O
;	O
and	O
a	O
component	O
for	O
promoting	O
percutaneous	O
absorption	O
is	O
added	O
to	O
auxiliary	O
materials	O
to	O
enhance	O
the	O
pharmaceutical	O
curative	O
effect	O
and	O
promote	O
absorption	O
.	O

The	O
ointment	O
disclosed	O
by	O
the	O
invention	O
has	O
the	O
advantages	O
of	O
exact	O
efficacy	O
,	O
strong	O
local	O
pertinence	O
,	O
no	O
irritation	O
on	O
skin	O
,	O
and	O
the	O
like	O
,	O
and	O
the	O
preparation	O
method	O
of	O
the	O
ointment	O
is	O
suitable	O
for	O
industrial	O
production	O
.	O

Absorption	O
-	O
promoting	O
pharmaceutical	O
composition	O
ointment	O
for	O
treating	O
skin	O
diseases	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
hyperosteogeny	O
plaster	O
used	O
for	O
treating	O
hyperosteogeny	O
and	O
functional	O
disorder	O
,	O
soft	O
tissue	O
injury	O
,	O
swell	O
,	O
sore	O
,	O
numbness	O
and	O
pain	O
caused	O
thereby	O
.	O

The	O
hyperosteogeny	O
plaster	O
takes	O
cotton	O
cloth	O
as	O
a	O
mounting	O
material	O
,	O
acrylic	B
ester	I
polymer	O
as	O
a	O
pressure	O
sensitive	O
adhesive	O
,	O
glycerol	B
as	O
a	O
cosolvent	O
and	O
azone	B
as	O
an	O
accelerator	O
,	O
and	O
the	O
main	O
medicines	O
comprise	O
80	O
-	O
97	O
%	O
of	O
micalex	O
in	O
weight	O
,	O
1	O
-	O
7	O
%	O
of	O
coptis	O
in	O
weight	O
and	O
2	O
-	O
13	O
%	O
of	O
dried	O
alum	O
in	O
weight	O
.	O

The	O
plaster	O
comprises	O
the	O
following	O
components	O
in	O
percentage	O
by	O
weight	O
:	O
0.1	O
-	O
30	O
%	O
of	O
main	O
medicines	O
,	O
50	O
-	O
90	O
%	O
of	O
pressure	O
sensitive	O
adhesive	O
acrylic	B
ester	I
polymer	O
,	O
2	O
-	O
20	O
%	O
of	O
cosolvent	O
glycerol	B
and	O
0.5	O
-	O
10	O
%	O
of	O
accelerator	O
azone	B
.	O

Hyperosteogeny	O
plaster	O

The	O
invention	O
discloses	O
a	O
method	O
for	O
preparing	O
an	O
infantile	O
lung	O
clearing	O
and	O
phlegm	O
eliminating	O
preparation	O
,	O
which	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
a	O
,	O
weighing	O
ephedra	O
,	O
gypsum	O
,	O
bitter	O
almond	O
,	O
whiteflower	O
hogfennel	O
root	O
,	O
baical	O
skullcap	O
root	O
,	O
perilla	O
fruit	O
powder	O
,	O
pepperweed	O
seed	O
and	O
bamboo	O
shavings	O
;	O
b	O
,	O
soaking	O
ephedra	O
coarse	O
powder	O
in	O
acidic	O
aqueous	O
solution	O
,	O
and	O
percolating	O
for	O
extracting	O
;	O
c	O
,	O
crushing	O
bitter	O
almond	O
,	O
inactivating	O
enzyme	O
,	O
and	O
extracting	O
by	O
low	O
-	O
degree	O
alcoholic	O
solution	O
;	O
d	O
,	O
decocting	O
gypsum	O
,	O
adding	O
other	O
components	O
,	O
extracting	O
in	O
water	O
,	O
mixing	O
with	O
ephedra	O
concentrating	O
solution	O
and	O
bitter	O
almond	O
concentrating	O
solution	O
,	O
and	O
concentrating	O
to	O
form	O
extract	O
;	O
and	O
e	O
,	O
adding	O
an	O
excipient	O
and	O
auxiliary	O
materials	O
,	O
and	O
preparing	O
by	O
the	O
conventional	O
method	O
of	O
preparations	O
to	O
obtain	O
a	O
pharmaceutically	O
-	O
acceptable	O
preparation	O
.	O

By	O
the	O
method	O
,	O
the	O
extraction	O
rate	O
of	O
ephedrine	B
and	O
amygdalin	B
can	O
be	O
improved	O
,	O
the	O
curative	O
effect	O
of	O
medicines	O
can	O
be	O
improved	O
,	O
and	O
the	O
quality	O
stability	O
ofproducts	O
can	O
be	O
improved	O
simultaneously	O
.	O

Method	O
for	O
preparing	O
infantile	O
lung	O
clearing	O
and	O
phlegm	O
eliminating	O
preparation	O

The	O
invention	O
discloses	O
Lansoprazole	B
medicinal	O
composition	O
tablets	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
Lansoprazole	B
medicinal	O
composition	O
tablets	O
comprise	O
the	O
following	O
components	O
in	O
part	O
by	O
mass	O
:	O
20	O
to	O
30	O
parts	O
of	O
Lansoprazole	B
medicinal	O
composition	O
tablets	O
,	O
400	O
to	O
450	O
parts	O
of	O
sodium	B
bicarbonate	I
,	O
100	O
to	O
150	O
parts	O
of	O
calcium	B
hydrophosphate	I
,	O
600	O
to	O
700	O
parts	O
of	O
magnesium	B
hydroxide	I
,	O
250	O
to	O
500	O
parts	O
of	O
filler	O
,	O
40	O
to	O
50	O
parts	O
of	O
disintegrating	O
agent	O
,	O
50	O
to	O
100	O
parts	O
of	O
flavoring	O
agent	O
,	O
80	O
to	O
100	O
parts	O
of	O
bonding	O
agent	O
and	O
20	O
to	O
25	O
parts	O
of	O
lubricating	O
agent	O
.	O

In	O
the	O
Lansoprazole	B
medicinal	O
composition	O
tablets	O
disclosed	O
by	O
the	O
invention	O
,	O
sodium	B
bicarbonate	I
,	O
calcium	B
hydrophosphate	I
and	O
magnesium	B
hydroxide	I
are	O
used	O
in	O
place	O
of	O
enteric	O
coating	O
,	O
the	O
secretion	O
of	O
gastric	O
acid	O
can	O
be	O
inhibited	O
,	O
the	O
Lansoprazole	B
can	O
be	O
prevented	O
from	O
being	O
decomposed	O
by	O
gastric	O
acid	O
,	O
the	O
medicines	O
can	O
be	O
absorbed	O
quickly	O
,	O
and	O
peak	O
concentration	O
can	O
be	O
reached	O
quickly	O
.	O

Lansoprazole	B
medicinal	O
composition	O
tablets	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicines	O
and	O
provides	O
a	O
3-O	B
-	I
alpha	I
-	I
L	I
-	I
pyran	I
rhamnose-	I
(	I
1->2	I
)	I
[	I
beta	I
-	I
D	I
-	I
glucopyranose-	I
(	I
1	I
-	I
4	I
)	I
]	I
-alpha	I
-	I
L	I
-	I
pyran	I
arabinose	I
hederasaponin	I
derivative	O
,	O
a	O
preparation	O
method	O
of	O
salts	O
thereof	O
and	O
application	O
thereof	O
to	O
resisting	O
tumor	O
.	O

The	O
structures	O
of	O
the	O
hederasaponin	B
3-O	I
-	I
alpha	I
-	I
L	I
-	I
pyran	I
rhamnose-	I
(	I
1->2	I
)	I
[	I
beta	I
-	I
D	I
-	I
glucopyranose-	I
(	I
1->4	I
)	I
]	I
-alpha	I
-	I
L	I
-	I
pyran	I
arabinose	I
hederasaponin	I
derivative	O
and	O
salts	O
thereof	O
are	O
shown	O
as	O
follows	O
.	O

The	O
hederasaponin	B
3-O	I
-	I
alpha	I
-	I
L	I
-	I
pyran	I
rhamnose-	I
(	I
1->2	I
)	I
[	I
beta	I
-	I
D	I
-	I
glucopyranose-	I
(	I
1->4	I
)	I
]	I
-alpha	I
-	I
L	I
-	I
pyran	I
arabinose	I
hederasaponin	I
derivative	O
and	O
the	O
salts	O
thereof	O
are	O
combined	O
with	O
a	O
pharmaceutical	O
acceptable	O
carrier	O
to	O
form	O
a	O
pharmaceutical	O
compound	O
which	O
is	O
used	O
for	O
preparing	O
tumor	O
-	O
resistant	O
medicines	O
.	O

Compared	O
with	O
the	O
prototype	O
medicine	O
,	O
a	O
medicine	O
containing	O
the	O
ingredient	O
derivative	O
and	O
the	O
salts	O
thereof	O
has	O
considerable	O
or	O
stronger	O
tumor	O
-	O
resistant	O
activity	O
;	O
and	O
meanwhile	O
,	O
the	O
activity	O
of	O
other	O
tumor	O
-	O
resistant	O
medicines	O
can	O
be	O
obviously	O
enhanced	O
and	O
the	O
side	O
effects	O
of	O
the	O
medicines	O
are	O
reduced	O
.	O

Hederasaponin	B
derivative	O
,	O
preparation	O
method	O
of	O
salts	O
thereof	O
and	O
application	O
thereof	O
to	O
resisting	O
tumor	O

The	O
invention	O
relates	O
to	O
a	O
slow	O
-	O
release	O
liquid	O
crystal	O
nanoparticle	O
containing	O
vinpocetine	B
prepared	O
by	O
a	O
supercritical	O
fluid	O
method	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
wherein	O
the	O
nanoparticle	O
comprises	O
active	O
ingredients	O
of	O
vinpocetine	B
,	O
glyceryl	B
monooleate	I
and	O
surfactant	O
.	O

The	O
slow	O
-	O
release	O
liquid	O
crystal	O
nanoparticle	O
of	O
the	O
invention	O
prepared	O
by	O
vinpocetine	B
has	O
an	O
obvious	O
slow	O
-	O
release	O
function	O
relative	O
to	O
a	O
vinpocetine	B
solution	O
and	O
has	O
a	O
remarkably	O
-	O
increased	O
oral	O
bioavailability	O
.	O

Slow	O
-	O
release	O
liquid	O
crystal	O
nanoparticle	O
containing	O
vinpocetine	B
prepared	O
by	O
supercritical	O
fluid	O
method	O

The	O
invention	O
provides	O
a	O
combined	O
medicament	O
,	O
in	O
particular	O
a	O
meropenem	B
sodium	I
and	O
sulbactam	B
sodium	I
combined	O
medicine	O
which	O
is	O
used	O
for	O
treating	O
infectious	O
diseases	O
caused	O
by	O
Acinetobacter	O
baumanii	O
.	O

The	O
meropenem	B
sodium	I
and	O
sulbactam	B
sodium	I
combined	O
medicine	O
has	O
synergistic	O
and	O
cumulative	O
antibacterial	O
effects	O
on	O
the	O
infectious	O
diseases	O
caused	O
by	O
the	O
Acinetobacter	O
baumanii	O
,	O
particularly	O
has	O
good	O
synergistic	O
and	O
cumulative	O
antibacterial	O
effects	O
on	O
multiple	O
medicine	O
-	O
resistant	O
Acinetobacter	O
baumanii	O
,	O
and	O
can	O
be	O
used	O
for	O
curing	O
the	O
clinical	O
infection	O
caused	O
by	O
the	O
multiple	O
medicine	O
-	O
resistant	O
Acinetobacter	O
baumanii	O
.	O

Meropenem	B
sodium	I
/	O
sulbactam	B
sodium	I
medicinal	O
composition	O

The	O
invention	O
relates	O
to	O
applications	O
of	O
epigallocatechin	B
gallate	I
(	O
EGCG	B
)	O
in	O
preparing	O
a	O
medicament	O
for	O
inducing	O
glioma	O
cell	O
apoptosis	O
and	O
preparing	O
a	O
medicament	O
for	O
inhibiting	O
glioma	O
cell	O
proliferation	O
.	O

Shown	O
by	O
experimental	O
results	O
,	O
the	O
EGCG	B
can	O
obviously	O
inhibit	O
the	O
glioma	O
cell	O
proliferation	O
(	O
P	O
(	O
0.001	O
)	O
,	O
with	O
the	O
increase	O
of	O
dosage	O
of	O
the	O
EGCG	B
and	O
extension	O
of	O
time	O
,	O
the	O
cyto	O
-	O
inhibition	O
is	O
more	O
obvious	O
;	O
and	O
shown	O
by	O
experimental	O
results	O
of	O
cell	O
apoptosis	O
,	O
48	O
hours	O
later	O
after	O
the	O
EGCG	B
is	O
added	O
,	O
with	O
the	O
increase	O
of	O
concentration	O
,	O
the	O
number	O
of	O
cell	O
apoptosis	O
is	O
markedly	O
increased	O
.	O

New	O
application	O
of	O
epigallocatechin	B
gallate	I
(	O
EGCG	B
)	O

The	O
invention	O
relates	O
to	O
a	O
motherwort	O
and	O
astragalus	O
capsule	O
used	O
for	O
treating	O
prostatic	O
hyperplasia	O
and	O
can	O
effectively	O
solve	O
the	O
treatment	O
problem	O
of	O
benign	O
prostatic	O
hyperplasia	O
.	O

The	O
technical	O
schemes	O
are	O
as	O
follows	O
:	O
the	O
motherwort	O
and	O
astragalus	O
capsule	O
is	O
prepared	O
from	O
motherwort	O
extract	O
,	O
astragalus	O
extract	O
,	O
starch	O
and	O
talcum	O
powder	O
,	O
wherein	O
the	O
weight	O
ratio	O
of	O
the	O
motherwort	O
extract	O
to	O
the	O
astragalus	O
extract	O
is	O
(	O
4	O
-	O
6	O
)	O
:	O
(	O
6	O
-	O
4	O
)	O
;	O
and	O
the	O
motherwort	O
and	O
astragalus	O
capsule	O
is	O
prepared	O
by	O
crushing	O
the	O
motherwort	O
extract	O
and	O
the	O
astragalus	O
extract	O
,	O
screening	O
with	O
a	O
100-mesh	O
sieve	O
,	O
mixing	O
uniformly	O
,	O
then	O
adding	O
starch	O
and	O
talcum	O
powder	O
,	O
uniformly	O
mixing	O
,	O
wherein	O
the	O
addition	O
amount	O
of	O
starch	O
and	O
talcum	O
powder	O
is	O
not	O
more	O
than	O
10	O
%	O
the	O
total	O
weight	O
of	O
the	O
motherwort	O
extract	O
,	O
astragalus	O
extract	O
,	O
starch	O
and	O
talcum	O
powder	O
and	O
the	O
weight	O
ratio	O
of	O
starch	O
to	O
talcum	O
powder	O
is	O
1:1	O
,	O
granulating	O
and	O
encapsulating	O
.	O

The	O
motherwort	O
and	O
astragalus	O
capsule	O
provided	O
by	O
the	O
invention	O
has	O
the	O
advantages	O
of	O
simple	O
preparation	O
method	O
,	O
proper	O
compatibility	O
,	O
good	O
efficacy	O
,	O
no	O
toxic	O
or	O
side	O
effect	O
and	O
significant	O
treatment	O
effect	O
on	O
benign	O
prostatic	O
hyperplasia	O
,	O
is	O
innovative	O
in	O
the	O
treatment	O
of	O
benign	O
prostatic	O
hyperplasia	O
,	O
and	O
has	O
huge	O
economic	O
and	O
social	O
benefits	O
.	O

Motherwort	O
and	O
astragalus	O
capsule	O
used	O
for	O
treating	O
prostatic	O
hyperplasia	O

Disclosed	O
is	O
a	O
cell	O
which	O
enables	O
the	O
reproduction	O
of	O
a	O
cartilage	O
tissue	O
and	O
has	O
a	O
proliferative	O
ability	O
.	O

Also	O
disclosed	O
is	O
a	O
technique	O
for	O
providing	O
a	O
cell	O
supply	O
source	O
which	O
can	O
be	O
used	O
in	O
a	O
definitive	O
treatment	O
of	O
osteochondrosis	O
deformans	O
.	O

A	O
chondrocyte	O
-	O
like	O
cell	O
which	O
has	O
the	O
same	O
properties	O
as	O
those	O
of	O
a	O
chondrocyte	O
and	O
can	O
proliferate	O
can	O
be	O
produced	O
by	O
selecting	O
a	O
combination	O
of	O
an	O
Myc	O
family	O
gene	O
and/or	O
a	O
Klf	O
family	O
gene	O
and	O
a	O
SOX9	O
gene	O
and	O
introducing	O
the	O
combination	O
into	O
a	O
somatic	O
cell	O
.	O

The	O
chondrocyte	O
-	O
like	O
cell	O
can	O
be	O
used	O
for	O
a	O
medical	O
purpose	O
of	O
cartilage	O
regeneration	O
.	O

Chondrocyte	O
-	O
like	O
cell	O
,	O
and	O
method	O
for	O
producing	O
same	O

The	O
invention	O
relates	O
to	O
a	O
medicinal	O
composition	O
for	O
preventing	O
or	O
treating	O
cystitis	O
caused	O
by	O
chemotherapy	O
.	O

The	O
medicinal	O
composition	O
consists	O
of	O
mesna	B
,	O
1,4,5,6-tetrahydro-2-methyl-4-pyrimidine	B
carbonic	I
acid	I
or	O
a	O
1,4,5,6-tetrahydro-2-methyl-4-pyrimidine	B
carbonic	I
acid	I
derivative	O
and	O
a	O
pharmaceutically	O
acceptable	O
medicinal	O
carrier	O
.	O

The	O
combined	O
medication	O
of	O
the	O
1,4,5,6-tetrahydro-2-methyl-4-pyrimidine	B
carbonic	I
acid	I
as	O
well	O
as	O
the	O
derivative	O
thereof	O
and	O
the	O
mesna	B
has	O
an	O
unexpected	O
therapeutic	O
effect	O
on	O
preventing	O
or	O
treating	O
the	O
cystitis	O
caused	O
by	O
a	O
chemotherapeutic	O
medicament	O
.	O

The	O
medicinal	O
composition	O
contributes	O
to	O
relieving	O
the	O
pain	O
of	O
a	O
chemotherapy	O
patient	O
;	O
and	O
the	O
tolerance	O
dose	O
of	O
the	O
patient	O
to	O
the	O
chemotherapeutic	O
medicament	O
is	O
improved	O
.	O

Compared	O
with	O
the	O
conventional	O
medicamentssuch	O
as	O
the	O
mesna	B
and	O
the	O
like	O
,	O
the	O
medicinal	O
composition	O
has	O
the	O
advantages	O
that	O
:	O
the	O
composition	O
of	O
the	O
1,4,5,6-tetrahydro-2-methyl-4-pyrimidine	B
carbonic	I
acid	I
as	O
well	O
as	O
the	O
derivative	O
thereof	O
and	O
the	O
mesna	O
has	O
a	O
wide	O
therapeutic	O
effect	O
on	O
the	O
cystitis	O
caused	O
by	O
the	O
chemotherapeutic	O
medicament	O
and	O
has	O
a	O
limited	O
prevention	O
effect	O
.	O

Medicinal	O
composition	O
for	O
preventing	O
or	O
treating	O
cystitis	O
caused	O
by	O
chemotherapy	O

The	O
invention	O
discloses	O
application	O
of	O
lycium	O
barbarum	O
polysaccharides	O
for	O
preparing	O
drugs	O
for	O
preventing	O
and	O
treating	O
chronic	O
stress	O
and	O
posttraumatic	O
stress	O
disorder	O
.	O

The	O
application	O
is	O
characterized	O
by	O
comprising	O
the	O
following	O
steps	O
of	O
:	O
filling	O
the	O
extracted	O
lycium	O
barbarum	O
polysaccharides	O
with	O
the	O
purity	O
of	O
more	O
than	O
or	O
equal	O
to	O
50	O
%	O
in	O
capsules	O
or	O
preparing	O
the	O
lycium	O
barbarum	O
polysaccharidesinto	O
tablets	O
,	O
wherein	O
each	O
capsule	O
contains	O
500	O
mg	O
of	O
the	O
lycium	O
barbarum	O
polysaccharides	O
,	O
or	O
each	O
tablet	O
contains	O
500	O
mg	O
of	O
the	O
lycium	O
barbarum	O
polysaccharides	O
;	O
uniformly	O
mixing	O
the	O
extracted	O
lyciumbarbarum	O
polysaccharides	O
with	O
the	O
purity	O
of	O
more	O
than	O
or	O
equal	O
to	O
50	O
%	O
and	O
corn	O
startch	O
;	O
and	O
filling	O
the	O
mixture	O
into	O
capsules	O
or	O
preparing	O
the	O
mixture	O
into	O
tablets	O
,	O
wherein	O
each	O
capsule	O
contains	O
500	O
mg	O
of	O
the	O
lycium	O
barbarum	O
polysaccharides	O
and	O
100	O
mg	O
of	O
the	O
corn	O
starch	O
,	O
or	O
each	O
tablet	O
contains	O
500	O
mg	O
of	O
the	O
lycium	O
barbarum	O
polysaccharides	O
and	O
100	O
mg	O
of	O
the	O
corn	O
starch	O
.	O

The	O
application	O
disclosed	O
by	O
the	O
invention	O
has	O
the	O
benefits	O
that	O
:	O
the	O
drugs	O
are	O
prescribed	O
preparations	O
composed	O
of	O
the	O
lycium	O
barbarum	O
polysaccharides	O
;	O
the	O
drugs	O
have	O
anti	O
-	O
stress	O
effect	O
and	O
are	O
capable	O
of	O
preventing	O
and	O
treating	O
chronic	O
stress	O
and/or	O
posttraumatic	O
stress	O
disorder	O
and	O
improving	O
cognitive	O
function	O
;	O
the	O
pharmaceutical	O
effect	O
is	O
clear	O
;	O
the	O
safety	O
is	O
high	O
;	O
and	O
the	O
novel	O
drug	O
application	O
selection	O
is	O
provided	O
in	O
clinical	O
.	O

Application	O
of	O
lycium	O
barbarum	O
polysaccharides	O
for	O
preparing	O
drugs	O
for	O
preventing	O
and	O
treating	O
chronic	O
stress	O
and	O
posttraumatic	O
stress	O
disorder	O

The	O
invention	O
relates	O
to	O
the	O
technical	O
field	O
of	O
medicine	O
,	O
and	O
in	O
particular	O
relates	O
to	O
a	O
cucoline	B
derivative	O
as	O
well	O
as	O
salts	O
,	O
a	O
preparation	O
method	O
and	O
application	O
thereof	O
.	O

According	O
to	O
the	O
invention	O
,	O
1	O
,	O
4	O
,	O
6	O
and	O
17	O
positions	O
in	O
a	O
cucoline	B
structure	O
are	O
modified	O
so	O
as	O
to	O
obtain	O
the	O
cucoline	B
derivative	O
the	O
structural	O
general	O
formula	O
of	O
which	O
is	O
as	O
follows	O
(	O
shown	O
in	O
the	O
specification	O
)	O
;	O
the	O
salts	O
of	O
the	O
cucoline	B
derivative	O
comprise	O
hydrochloride	B
,	O
sulfate	B
,	O
bisulfate	B
,	O
hydrobromide	B
,	O
oxalate	B
,	O
citrate	B
and	O
mesylate	B
;	O
and	O
the	O
inhibition	O
activity	O
of	O
partial	O
compounds	O
of	O
the	O
invention	O
on	O
NF	O
-	O
kappa	O
B	O
are	O
obviously	O
superior	O
to	O
that	O
of	O
cucoline	B
,	O
and	O
the	O
cucoline	B
derivative	O
and	O
salts	O
thereof	O
are	O
used	O
for	O
preparing	O
anti	O
-	O
inflammatory	O
medicaments	O
.	O

Cucoline	B
derivative	O
as	O
well	O
as	O
salts	O
,	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
provides	O
an	O
oral	O
aqueous	O
composition	O
,	O
which	O
comprises	O
0.1	O
to	O
1	O
percent	O
(	O
w	O
/	O
v	O
)	O
of	O
ambroxol	B
hydrochloride	I
,	O
0.05	O
to	O
0.2	O
percent	O
(	O
w	O
/	O
v	O
)	O
of	O
solution	O
thickener	O
,	O
0.005	O
to	O
0.05	O
percent	O
(	O
w	O
/	O
v	O
)	O
of	O
freshener	O
,	O
a	O
stabilizer	O
and	O
water	O
,	O
wherein	O
the	O
stabilizer	O
is	O
a	O
substance	O
for	O
forming	O
a	O
medicinal	O
solvent	O
system	O
by	O
combining	O
the	O
water	O
.	O

The	O
invention	O
also	O
provides	O
a	O
preparation	O
method	O
for	O
the	O
composition	O
.	O

The	O
oral	O
aqueous	O
composition	O
has	O
the	O
advantages	O
of	O
cool	O
and	O
refreshing	O
mouthfeel	O
,	O
wide	O
application	O
range	O
and	O
the	O
like	O
,	O
is	O
clear	O
and	O
stable	O
,	O
does	O
not	O
contain	O
any	O
natural	O
or	O
semi	O
-	O
synthetic	O
sweetener	O
,	O
and	O
is	O
suitable	O
for	O
patients	O
who	O
suffer	O
from	O
diabetes	O
and	O
people	O
who	O
are	O
allergic	O
to	O
the	O
semi	O
-	O
synthetic	O
sweetener	O
.	O

Ambroxol	B
hydrochloride	I
oral	O
aqueous	O
composition	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
drug	O
combination	O
containing	O
astragalus	O
and	O
a	O
use	O
thereof	O
.	O

The	O
drug	O
combination	O
contains	O
astragalus	O
or	O
an	O
astragalus	O
extractive	O
or	O
a	O
derivative	O
thereof	O
capable	O
of	O
being	O
received	O
chemically	O
.	O

The	O
drug	O
combination	O
comprises	O
the	O
following	O
components	O
:	O
100	O
parts	O
of	O
astragalus	O
and	O
1	O
-	O
50	O
of	O
levamisole	B
hydrochloride	I
.	O

On	O
the	O
basis	O
,	O
the	O
following	O
one	O
or	O
more	O
components	O
can	O
be	O
increased	O
,	O
but	O
not	O
limited	O
:	O
20	O
-	O
150	O
parts	O
of	O
vitamin	B
C.	I
The	O
use	O
method	O
and	O
the	O
dosage	O
of	O
the	O
combination	O
are	O
shown	O
as	O
follows	O
:	O
a	O
solid	O
preparation	O
is	O
used	O
after	O
being	O
mixed	O
by	O
0.1	O
-	O
10.0	O
percent	O
of	O
complete	O
feeds	O
;	O
and	O
a	O
liquid	O
preparation	O
is	O
drunk	O
after	O
the	O
water	O
of	O
250	O
-	O
500	O
kg	O
is	O
added	O
in	O
the	O
liquid	O
preparation	O
of	O
100	O
ml	O
.	O

The	O
combination	O
has	O
the	O
main	O
function	O
of	O
inducing	O
a	O
human	O
body	O
to	O
generate	O
the	O
interferon	O
,	O
promoting	O
the	O
antibody	O
formation	O
and	O
adjusting	O
the	O
immunologic	O
function	O
of	O
the	O
human	O
body	O
.	O

The	O
drug	O
combination	O
is	O
used	O
for	O
simulating	O
an	O
immune	O
system	O
of	O
an	O
animal	O
body	O
,	O
adjusting	O
the	O
immunity	O
,	O
enhancing	O
the	O
disease	O
resistance	O
,	O
reducing	O
the	O
disease	O
incidence	O
and	O
assisting	O
to	O
treat	O
the	O
virus	O
infection	O
.	O

Drug	O
combination	O
containing	O
astragalus	O
and	O
use	O
thereof	O

The	O
invention	O
provides	O
a	O
fenticonazole	B
nitrate	I
-	O
containing	O
medicinal	O
composition	O
.	O

The	O
fenticonazole	B
nitrate	I
-	O
containing	O
medicinal	O
composition	O
consists	O
of	O
fenticonazole	B
nitrate	I
,	O
36-type	O
mixed	O
fatty	B
acid	I
glyceride	B
and	O
silicon	B
dioxide	I
in	O
a	O
ratio	O
of	O
2:	O
(	O
10	O
-	O
14	O
)	O
:	O
(	O
0.05	O
-	O
0.10	O
)	O
.	O

By	O
the	O
formula	O
,	O
the	O
problem	O
that	O
in	O
the	O
prior	O
art	O
,	O
active	O
ingredients	O
can	O
not	O
be	O
dispersed	O
well	O
is	O
solved	O
.	O

Fenticonazole	B
nitrate	I
medicinal	O
composition	O

The	O
invention	O
relates	O
to	O
a	O
medicinal	O
composition	O
by	O
taking	O
amlodipine	B
and	O
atorvastatin	B
calcium	I
as	O
active	O
components	O
,	O
the	O
medicinal	O
composition	O
comprises	O
amlodipine	B
,	O
atorvastatin	B
calcium	I
,	O
a	O
filler	O
,	O
a	O
disintegrant	O
and	O
a	O
lubricant	O
;	O
the	O
active	O
components	O
are	O
composed	O
of	O
2	O
-	O
20	O
parts	O
of	O
amlodipine	B
and	O
5	O
-	O
120	O
parts	O
of	O
atorvastatin	B
calcium	I
;	O
the	O
amlodipine	B
is	O
a	O
maleic	B
acid	I
amlodipine	I
hydrate	I
crystal	O
.	O

The	O
molecular	O
formula	O
of	O
the	O
maleic	B
acid	I
amlodipine	I
hydrate	I
crystal	O
is	O
C24H29C1N2O9.1.5H2O	B
.	O

The	O
amlodipine	B
in	O
the	O
medicinal	O
composition	O
has	O
the	O
advantages	O
of	O
fast	O
effectiveness	O
and	O
stability	O
,	O
and	O
is	O
capable	O
of	O
steadily	O
releasing	O
the	O
drug	O
effect	O
in	O
24	O
hours	O
,	O
the	O
medicinal	O
composition	O
has	O
strong	O
synergy	O
,	O
accumulation	O
and	O
complementary	O
effects	O
,	O
and	O
the	O
bioavailability	O
is	O
high	O
.	O

Medicinal	O
composition	O
of	O
amlodipine	B
and	O
atorvastatin	B
calcium	I
and	O
its	O
preparation	O
method	O

The	O
invention	O
provides	O
application	O
of	O
an	O
atractylodin	B
alcohol	I
(	O
CZSC	B
)	O
compound	O
in	O
preparation	O
of	O
medicaments	O
for	O
treating	O
animal	O
virus	O
diseases	O
,	O
in	O
particular	O
application	O
in	O
preparation	O
of	O
a	O
medicament	O
for	O
treating	O
porcine	O
reproductive	O
and	O
respiratory	O
syndrome	O
virus	O
(	O
PRRSV	O
)	O
infection	O
and	O
a	O
medicament	O
for	O
treating	O
porcine	O
reproductive	O
and	O
respiratory	O
syndrome	O
(	O
PRRS	O
)	O
,	O
or	O
in	O
preparation	O
of	O
a	O
virus	O
gene	O
expression	O
inhibitor	O
and	O
an	O
anti	O
-	O
virus	O
medicament	O
and	O
in	O
preparation	O
of	O
a	O
medicament	O
for	O
inhibiting	O
blue	O
ear	O
disease	O
viruses	O
.	O

The	O
CZSC	O
has	O
remarkable	O
effects	O
of	O
regulating	O
nucleoprotein	O
gene	O
expression	O
of	O
the	O
PRRSV	O
down	O
and	O
inhibiting	O
virus	O
proliferation	O
;	O
and	O
in	O
vitro	O
cellular	O
pharmacological	O
tests	O
shows	O
that	O
the	O
CZSC	O
has	O
definite	O
anti	O
-	O
virus	O
effect	O
.	O

The	O
CZSC	O
has	O
wide	O
application	O
prospect	O
in	O
treatment	O
and	O
control	O
of	O
PRRSV	O
infection	O
.	O

Application	O
of	O
atractylodin	B
alcohol	I
in	O
medicament	O
preparation	O

The	O
invention	O
relates	O
to	O
wound	O
healing	O
gel	O
and	O
a	O
preparation	O
process	O
thereof	O
,	O
which	O
belong	O
to	O
the	O
field	O
of	O
medicine	O
preparations	O
and	O
clinic	O
applications	O
.	O

The	O
wound	O
healing	O
gel	O
is	O
prepared	O
from	O
the	O
following	O
components	O
in	O
percentage	O
by	O
weight	O
:	O
2	O
to	O
3	O
percent	O
of	O
paste	O
powder	O
,	O
0.5	O
to	O
2	O
percent	O
of	O
30-percent	O
borneol	B
solution	O
,	O
8	O
to	O
12	O
percent	O
of	O
glycerol	B
,	O
0.8	O
to	O
1.2	O
percent	O
of	O
carbomer	O
,	O
0.1	O
to	O
0.2	O
percent	O
of	O
NaHSO3	B
,	O
0.02	O
to	O
0.04	O
percent	O
of	O
ethylene	B
diamine	I
tetraacetic	I
acid	I
disodium	I
(	O
EDTA-2Na	B
)	O
,	O
8	O
to	O
12	O
percent	O
of	O
propylene	B
glycol	I
,	O
0.5	O
to	O
2	O
percent	O
of	O
10-percent	O
methylparaben	O
solution	O
,	O
1.4	O
to	O
1.8	O
percent	O
of	O
triethanolamine	B
and	O
50	O
to	O
80	O
percent	O
of	O
distilled	O
water	O
.	O

The	O
gel	O
can	O
be	O
used	O
for	O
treating	O
radiation	O
injury	O
,	O
cold	O
injury	O
and	O
burn	O
.	O

The	O
gel	O
can	O
be	O
used	O
for	O
II	O
degree	O
surface	O
of	O
burns	O
and	O
can	O
accelerate	O
the	O
healing	O
of	O
the	O
surface	O
of	O
burns	O
and	O
relieve	O
swelling	O
of	O
surface	O
of	O
burns	O
and	O
dehydration	O
of	O
the	O
wound	O
tissue	O
obviously	O
.	O

And	O
the	O
gel	O
has	O
the	O
characteristics	O
that	O
:	O
the	O
treatment	O
effect	O
is	O
exact	O
;	O
the	O
use	O
is	O
safe	O
;	O
the	O
quality	O
index	O
is	O
easy	O
to	O
control	O
;	O
the	O
price	O
is	O
low	O
;	O
and	O
the	O
like	O
.	O

Wound	O
healing	O
gel	O
and	O
preparation	O
process	O
thereof	O

The	O
invention	O
discloses	O
a	O
method	O
for	O
chemically	O
synthesizing	O
a	O
mangiferin	B
penta	I
-	I
esterified	I
derivative	O
and	O
a	O
pharmacological	O
effect	O
of	O
resisting	O
inflammation	O
and	O
reducing	O
blood	O
sugar	B
of	O
the	O
derivative	O
.	O

The	O
chemical	O
structural	O
formula	O
of	O
the	O
derivative	O
is	O
shown	O
in	O
the	O
specifications	O
.	O

The	O
derivative	O
has	O
a	O
remarkable	O
effect	O
of	O
inhibiting	O
mouse	O
auricle	O
tumefaction	O
caused	O
by	O
dimethylbenzene	B
;	O
and	O
the	O
derivative	O
has	O
a	O
remarkable	O
effect	O
of	O
treating	O
diabetic	O
mice	O
induced	O
by	O
alloxan	B
.	O

Mangiferin	B
penta	I
-	I
esterified	I
derivative	O

The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
microbial	O
engineering	O
,	O
and	O
specifically	O
relates	O
to	O
new	O
daldiniaeschscholzii	O
aromatic	B
polyketones	I
,	O
an	O
extraction	O
method	O
and	O
an	O
application	O
thereof	O
,	O
wherein	O
the	O
aromatic	B
polyketones	I
are	O
extracted	O
from	O
a	O
liquid	O
fermented	O
material	O
of	O
the	O
intestinal	O
bacteria	O
of	O
Tenoderaaridifolia	O
,	O
and	O
the	O
intestinal	O
bacteria	O
of	O
the	O
Tenoderaaridifolia	O
is	O
the	O
daldiniaeschscholzii	O
.	O

The	O
daldiniaeschscholzii	O
aromatic	B
polyketones	I
of	O
the	O
present	O
invention	O
have	O
the	O
following	O
structural	O
formula	O
.	O

The	O
daldiniaeschscholzii	O
aromatic	B
polyketone	I
1	O
has	O
strong	O
antioxidant	O
activity	O
,	O
and	O
the	O
daldiniaeschscholzii	O
aromatic	B
polyketones	I
of	O
2	O
-	O
5	O
have	O
strong	O
immunosuppression	O
activities	O
,	O
such	O
that	O
the	O
daldiniaeschscholzii	O
aromatic	B
polyketones	I
of	O
1	O
-	O
5	O
can	O
be	O
adopted	O
for	O
preparing	O
the	O
relevant	O
novel	O
drugs	O
,	O
wherein	O
the	O
daldiniaeschscholzii	O
aromatic	B
polyketones	I
of	O
1	O
-	O
5	O
are	O
adopted	O
as	O
the	O
compounds	O
with	O
the	O
antioxidant	O
effects	O
or	O
the	O
immunosuppression	O
effects	O
.	O

New	O
aromatic	B
polyketones	I
,	O
extraction	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
freeze	O
-	O
dried	O
powder	O
injection	O
with	O
omeprazole	B
sodium	I
as	O
its	O
active	O
component	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
freeze	O
-	O
dried	O
powder	O
injection	O
is	O
prepared	O
from	O
omeprazole	B
sodium	I
,	O
edetate	B
disodium	I
,	O
a	O
pH	O
value	O
conditioning	O
agent	O
and	O
injection	O
water	O
,	O
wherein	O
the	O
omeprazole	B
sodium	I
is	O
a	O
novel	O
omeprazole	B
sodium	I
crystalline	O
compound	O
with	O
a	O
molecular	O
formula	O
of	O
C17H18N3NaO3S.2H2O	B
.	O

The	O
omeprazole	B
sodium	I
in	O
the	O
freeze	O
-	O
dried	O
powder	O
injection	O
is	O
the	O
novel	O
omeprazole	B
sodium	I
crystalline	O
compound	O
,	O
and	O
the	O
freeze	O
-	O
dried	O
powder	O
injection	O
prepared	O
from	O
the	O
novel	O
omeprazole	B
sodium	I
crystalline	O
compound	O
has	O
excellent	O
stability	O
.	O

Freeze	O
-	O
dried	O
powder	O
injection	O
with	O
omeprazole	B
sodium	I
as	O
active	O
component	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
the	O
technical	O
field	O
of	O
pyrimidine	B
compounds	O
and	O
preparation	O
methods	O
thereof	O
.	O

The	O
novel	O
pyrimidine	B
derivatives	O
and	O
salts	O
thereof	O
are	O
compounds	O
shown	O
in	O
the	O
formula	O
(	O
1	O
)	O
in	O
the	O
specification	O
,	O
wherein	O
R1	O
represents	O
-CH2NHR4	B
or	O
cyano	O
group	O
;	O
R2	O
and	O
R3	O
independently	O
represent	O
aryl	O
and	O
substituted	O
aryl	B
;	O
X	O
represents	O
methylene	B
,	O
carbonyl	B
or	O
hydroxymethylene	B
;	O
R4	O
represents	O
H	B
,	O
acetyl	B
or	O
tosyl	B
;	O
and	O
n	O
is	O
an	O
integer	O
of	O
0	O
-	O
5	O
.	O

A	O
series	O
of	O
new	O
compounds	O
are	O
prepared	O
by	O
the	O
inventor	O
of	O
the	O
invention	O
;	O
pharmacological	O
results	O
show	O
that	O
the	O
dipeptidyl	O
peptidase	O
IV	O
(	O
DPPIV	O
)	O
inhibition	O
rate	O
is	O
close	O
to	O
or	O
superior	O
to	O
that	O
of	O
the	O
reference	O
substance	O
R-1579	O
;	O
and	O
some	O
pyrimidine	B
compounds	O
with	O
new	O
structures	O
have	O
excellent	O
DPP	O
-	O
IV	O
inhibitory	O
activity	O
and	O
wide	O
application	O
prospects	O
.	O

Novel	O
pyrimidine	B
derivatives	O
as	O
well	O
as	O
preparation	O
method	O
and	O
applications	O
thereof	O

Disclosed	O
are	O
a	O
kinase	O
inhibitor	O
and	O
N	B
-	I
oxide	I
form	O
and	O
pharmaceutically	O
acceptable	O
isomerous	O
form	O
thereof	O
as	O
represented	O
by	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
Z	O
is	O
NH	B
,	O
and	O
the	O
other	O
substituents	O
are	O
as	O
defined	O
herein	O
.	O

Macrocyclic	B
4-amino	I
-	I
quinazoline	I
derivatives	O
and	O
their	O
use	O
as	O
MTKI	O

The	O
invention	O
discloses	O
a	O
hypericin	O
albumin	O
nanoparticle	O
-	O
immune	O
globulin	O
G	O
antibody	O
conjugate	O
,	O
which	O
comprises	O
the	O
following	O
preparing	O
steps	O
:	O
step	O
(	O
1	O
)	O
,	O
dissolving	O
the	O
hypericin	O
albumin	O
nanoparticle	O
and	O
the	O
immune	O
globulin	O
G	O
antibody	O
conjugate	O
into	O
phosphate	O
buffer	O
solution	O
(	O
PBF	O
)	O
,	O
step	O
(	O
2	O
)	O
,	O
adding	O
glutaraldehyde	O
into	O
the	O
solution	O
obtained	O
by	O
the	O
step	O
(	O
1	O
)	O
,	O
and	O
obtaining	O
the	O
hypericin	O
albumin	O
nanoparticle	O
-	O
immune	O
globulin	O
G	O
antibody	O
conjugate	O
.	O

The	O
hypericin	O
albumin	O
nanoparticle	O
-	O
immune	O
globulin	O
G	O
antibody	O
conjugate	O
has	O
the	O
advantages	O
of	O
high	O
effective	O
utilization	O
;	O
simultaneously	O
,	O
the	O
preparation	O
method	O
of	O
the	O
hypericin	O
albumin	O
nanoparticle	O
-	O
immune	O
globulin	O
G	O
antibody	O
conjugate	O
has	O
the	O
advantages	O
of	O
being	O
simple	O
in	O
process	O
,	O
easy	O
to	O
operate	O
and	O
specially	O
suitable	O
for	O
industrial	O
production	O
.	O

Hypericin	O
albumin	O
nanoparticle	O
-	O
immune	O
globulin	O
G	O
antibody	O
conjugate	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
composition	O
for	O
protecting	O
lever	O
and	O
achieving	O
a	O
sobering	O
function	O
as	O
well	O
as	O
a	O
preparation	O
method	O
and	O
application	O
of	O
the	O
composition	O
.	O

The	O
composition	O
contains	O
30	O
-	O
180	O
parts	O
by	O
weight	O
of	O
sesamin	B
,	O
1	O
-	O
6	O
parts	O
by	O
weight	O
of	O
schisandrin	B
B	I
,	O
150	O
-	O
900	O
parts	O
by	O
weight	O
of	O
semen	O
hoveniae	O
extract	O
,	O
150	O
-	O
900	O
parts	O
by	O
weight	O
of	O
pueraria	O
lobata	O
extract	O
,	O
0.0012	O
-	O
0.0072	O
parts	O
by	O
weight	O
of	O
vitamin	B
B12	I
and	O
14	O
-	O
84	O
parts	O
by	O
weight	O
of	O
vitamin	B
E.	I
Composition	O
for	O
protecting	O
lever	O
and	O
achieving	O
sobering	O
function	O

The	O
invention	O
discloses	O
a	O
bisabolane	B
sesquiterpenoid	B
,	O
a	O
preparation	O
method	O
thereof	O
and	O
application	O
thereof	O
as	O
a	O
selective	O
antibacterial	O
agent	O
.	O

The	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
performing	O
strain	O
culturing	O
on	O
a	O
sponge	O
endophytic	O
fungi	O
,	O
i.e.	O
Asergillus	O
sp.	O
(	O
HM565949	O
)	O
in	O
a	O
strain	O
medium	O
;	O
cultivating	O
the	O
fungi	O
by	O
fermenting	O
in	O
a	O
fermentation	O
medium	O
;	O
filtering	O
the	O
obtained	O
fermentation	O
broth	O
to	O
remove	O
thallus	O
,	O
concentrating	O
the	O
filtrate	O
,	O
and	O
extracting	O
the	O
filtrate	O
with	O
ethyl	B
acetate	I
;	O
and	O
performing	O
chromatographic	O
separation	O
on	O
the	O
concentrate	O
and	O
respectively	O
concentrating	O
the	O
obtained	O
eluent	O
to	O
obtain	O
white	O
powder	O
,	O
i.e.	O
the	O
aspergterpeinoid	B
A	I
,	O
aspergiterpenoid	B
C	I
and	O
aspergiterpenoid	B
D.	I
The	O
bisabolane	B
sesquiterpenoid	B
obtained	O
from	O
a	O
marine	O
fungi	O
can	O
selectively	O
inhibit	O
the	O
activities	O
of	O
Staphylococcus	O
albus	O
,	O
Bacillus	O
subtilis	O
,	O
Bacillus	O
cereus	O
,	O
Sarcina	O
lutea	O
,	O
Escherichia	O
coli	O
,	O
Micrococcus	O
tetrgenus	O
,	O
marine	O
bacterial	O
Vibrio	O
parahaemolyticus	O
and	O
marine	O
bacterial	O
Vibrio	O
anguillarum	O
,	O
and	O
can	O
be	O
used	O
for	O
developing	O
the	O
selective	O
antibacterial	O
agent	O
.	O

In	O
addition	O
,	O
the	O
raw	O
materials	O
can	O
be	O
massively	O
produced	O
and	O
are	O
free	O
of	O
the	O
limitation	O
of	O
resources	O
.	O

Therefore	O
,	O
the	O
bisabolane	B
sesquiterpenoid	B
has	O
wide	O
application	O
prospect	O
.	O

Bisabolane	B
sesquiterpenoid	B
,	O
preparation	O
method	O
thereof	O
and	O
application	O
thereof	O
as	O
selective	O
antibacterial	O
agent	O

The	O
invention	O
discloses	O
an	O
injection	O
carbazochrome	B
sodium	I
sulfonate	I
suspension	O
and	O
a	O
preparation	O
method	O
thereof	O
,	O
relating	O
to	O
the	O
technical	O
field	O
of	O
medicines	O
.	O

The	O
injection	O
carbazochrome	B
sodium	I
sulfonate	I
suspension	O
is	O
a	O
powder	O
injection	O
and	O
comprises	O
the	O
following	O
components	O
in	O
parts	O
by	O
weight	O
:	O
1	O
part	O
of	O
carbazochrome	B
sodium	I
sulfonate	I
,	O
1.5	O
-	O
8.5	O
parts	O
of	O
pharmaceutically	O
acceptable	O
biological	O
carrier	O
,	O
0.1	O
-	O
1.8	O
parts	O
of	O
stabilizing	O
agent	O
and	O
2	O
-	O
5	O
parts	O
of	O
freezing	O
protective	O
agent	O
.	O

According	O
to	O
the	O
invention	O
,	O
the	O
stability	O
and	O
the	O
dissolvability	O
of	O
the	O
carbazochrome	B
sodium	I
sulfonate	I
are	O
improved	O
,	O
the	O
injection	O
carbazochrome	B
sodium	I
sulfonate	I
suspension	O
has	O
no	O
remarkable	O
change	O
of	O
various	O
indexes	O
through	O
detection	O
after	O
being	O
placed	O
for	O
a	O
long	O
time	O
,	O
the	O
quality	O
of	O
the	O
injection	O
carbazochrome	B
sodium	I
sulfonate	I
suspension	O
within	O
a	O
valid	O
period	O
is	O
ensured	O
to	O
be	O
qualified	O
;	O
and	O
the	O
injection	O
carbazochrome	B
sodium	I
sulfonate	I
suspension	O
can	O
be	O
slowly	O
administrated	O
for	O
a	O
long	O
time	O
,	O
thus	O
bioavailability	O
is	O
greatly	O
improved	O
.	O

The	O
pharmaceutically	O
acceptable	O
biological	O
carrier	O
,	O
i.e.	O
protein	O
,	O
is	O
degraded	O
in	O
vivo	O
without	O
toxicity	O
and	O
immunogenicity	O
;	O
and	O
meanwhile	O
,	O
medicine	O
therapeutic	O
indexes	O
can	O
be	O
effectively	O
increased	O
,	O
and	O
medicine	O
toxicity	O
is	O
lowered	O
and	O
medicine	O
side	O
effects	O
are	O
reduced	O
.	O

Injection	O
carbazochrome	B
sodium	I
sulfonate	I
suspension	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
an	O
adriamycin	O
lipid	O
pharmaceutical	O
composition	O
comprising	O
the	O
following	O
components	O
:	O
(	O
1	O
)	O
adriamycin	B
,	O
(	O
2	O
)	O
phospholipids	O
,	O
(	O
3	O
)	O
cholesterol	B
and	O
(	O
4	O
)	O
a	O
compound	O
shown	O
as	O
the	O
formula	O
I	O
or	O
the	O
formula	O
9	O
(	O
described	O
in	O
the	O
specification	O
)	O
or	O
physiologically	O
acceptable	O
salt	O
thereof	O
,	O
wherein	O
n	O
is	O
an	O
integral	O
number	O
of	O
5	O
-	O
500	O
,	O
m	O
is	O
an	O
integral	O
number	O
of	O
2	O
-	O
12	O
,	O
and	O
p	O
is	O
an	O
integral	O
number	O
of	O
1	O
-	O
8	O
.	O

The	O
invention	O
also	O
relates	O
to	O
a	O
method	O
and	O
application	O
of	O
the	O
lipid	O
pharmaceutical	O
composition	O
,	O
a	O
compound	O
shown	O
as	O
the	O
formula	O
I	O
or	O
the	O
formula	O
9	O
as	O
well	O
as	O
a	O
preparation	O
method	O
and	O
application	O
of	O
the	O
compound	O
.	O

The	O
lipid	O
pharmaceutical	O
composition	O
provided	O
by	O
the	O
invention	O
has	O
the	O
advantages	O
of	O
good	O
pH	O
sensitivity	O
and	O
optional	O
targeting	O
property	O
,	O
and	O
can	O
be	O
used	O
for	O
increasing	O
the	O
concentration	O
of	O
an	O
antitumour	O
medicament	O
at	O
a	O
target	O
part	O
and	O
also	O
reducing	O
the	O
toxic	O
and	O
side	O
effects	O
of	O
the	O
antitumour	O
medicament	O
at	O
a	O
non	O
-	O
target	O
part	O
when	O
being	O
taken	O
as	O
a	O
liposome	O
,	O
thus	O
improving	O
therapeutic	O
index	O
of	O
the	O
antitumour	O
medicament	O
.	O

Adriamycin	B
lipid	O
pharmaceutical	O
composition	O

The	O
invention	O
discloses	O
a	O
new	O
pharmaceutical	O
composition	O
for	O
treating	O
osteoporosis	O
.	O

The	O
pharmaceutical	O
composition	O
can	O
greatly	O
improve	O
the	O
efficacy	O
of	O
osteoporosis	O
treatment	O
,	O
and	O
reduce	O
the	O
health	O
risks	O
and	O
side	O
effects	O
associated	O
with	O
taking	O
of	O
commonly	O
used	O
drugs	O
(	O
parathyroid	O
hormone	O
,	O
thyroid	O
hormone	O
,	O
estrogen	B
,	O
and	O
calcium	B
supplements	O
)	O
for	O
treating	O
osteoporosis	O
.	O

The	O
invention	O
also	O
discloses	O
a	O
combined	O
treatment	O
method	O
of	O
osteoporosis	O
caused	O
by	O
cell	O
function	O
decline	O
.	O

The	O
method	O
includes	O
a	O
step	O
of	O
applying	O
an	O
effective	O
dose	O
of	O
to	O
the	O
new	O
pharmaceutical	O
composition	O
treating	O
osteoporosis	O
to	O
an	O
object	O
so	O
as	O
to	O
treat	O
osteoporosis	O
caused	O
by	O
cell	O
function	O
decline	O
of	O
the	O
object	O
.	O

Combined	O
treatment	O
of	O
osteoporosis	O
caused	O
by	O
cell	O
function	O
decline	O
and	O
pharmaceutical	O
composition	O

The	O
invention	O
discloses	O
a	O
health	O
-	O
care	O
lozenge	O
prepared	O
by	O
taking	O
an	O
acer	O
truncatum	O
extract	O
as	O
a	O
major	O
raw	O
material	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
health	O
-	O
care	O
lozenge	O
is	O
prepared	O
from	O
the	O
following	O
raw	O
materials	O
in	O
percentage	O
by	O
weight	O
:	O
20	O
-	O
40	O
percent	O
of	O
an	O
acer	O
truncatum	O
extract	O
,	O
15	O
-	O
25	O
percent	O
of	O
an	O
acer	O
truncatum	O
seed	O
extract	O
,	O
30	O
-	O
64	O
percent	O
of	O
a	O
seasoning	O
agent	O
and	O
1	O
-	O
5	O
percent	O
of	O
a	O
nutrition	O
fortifier	O
.	O

A	O
tablet	O
is	O
prepared	O
by	O
performing	O
deep	O
processing	O
on	O
terrestrial	O
plant	O
acer	O
truncatum	O
seeds	O
which	O
are	O
rich	O
in	O
nervonic	B
acid	I
and	O
terrestrial	O
plant	O
acer	O
truncatum	O
leaves	O
which	O
are	O
rich	O
in	O
flavone	B
,	O
and	O
has	O
the	O
effects	O
of	O
preventing	O
nerve	O
fiber	O
atrophy	O
,	O
promoting	O
brain	O
development	O
,	O
delaying	O
ageing	O
and	O
enhancing	O
the	O
immunity	O
and	O
digestive	O
function	O
of	O
a	O
human	O
body	O
;	O
and	O
over	O
-	O
high	O
blood	O
fat	O
concentration	O
in	O
blood	O
can	O
be	O
lowered	O
remarkably	O
,	O
and	O
the	O
occurrence	O
probability	O
of	O
diseases	O
such	O
as	O
certain	O
hypertension	O
and	O
cardiovascular	O
and	O
cerebrovascular	O
diseases	O
,	O
blood	O
circulation	O
disorder	O
,	O
and	O
the	O
like	O
is	O
lowered	O
.	O

Acer	O
truncatum	O
health	O
-	O
care	O
lozenge	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
provides	O
sinomenine	B
4-hydroxy	O
etherification	O
and	O
esterification	O
derivatives	O
and	O
a	O
preparation	O
method	O
and	O
application	O
thereof	O
,	O
relating	O
to	O
the	O
field	O
of	O
pharmaceutical	O
chemistry	O
.	O

Specifically	O
,	O
the	O
invention	O
relates	O
to	O
sinomenine	B
4-hydroxy	O
etherification	O
and	O
esterification	O
derivatives	O
and	O
discloses	O
a	O
preparation	O
method	O
of	O
the	O
sinomenine	B
4-OH	O
etherification	O
and	O
esterification	O
derivatives	O
.	O

An	O
ICR	O
(	O
Institute	O
of	O
Cancer	O
Research	O
)	O
mouse	O
model	O
and	O
an	O
SD	O
(	O
sprague	O
dawley	O
)	O
rat	O
model	O
are	O
applied	O
to	O
test	O
the	O
anti	O
-	O
inflammatory	O
and	O
immune	O
activity	O
293	O
cells	O
of	O
pNF	O
-	O
kB	O
-	O
luc	O
are	O
transfected	O
to	O
test	O
the	O
inhibition	O
of	O
the	O
compounds	O
to	O
an	O
NF	O
-	O
kB	O
signaling	O
channel	O
,	O
and	O
results	O
show	O
that	O
part	O
of	O
the	O
compounds	O
have	O
significant	O
anti	O
-	O
inflammatory	O
and	O
immune	O
activity	O
and	O
effects	O
on	O
inhibition	O
of	O
NF	O
-	O
kB.	O
The	O
derivatives	O
can	O
be	O
applied	O
in	O
preparation	O
of	O
anti	O
-	O
inflammatory	O
and	O
immune	O
medicine	O
.	O

Sinomenine	B
4-hydroxy	O
etherification	O
and	O
esterification	O
derivatives	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
an	O
active	O
bacteriostasis	O
capsule	O
,	O
comprising	O
the	O
following	O
ingredients	O
,	O
by	O
weight	O
,	O
lactobacillus	O
20	O
-	O
50	O
%	O
,	O
bifidobacterium	O
20	O
-	O
30	O
%	O
,	O
lactococcus	O
15	O
-	O
30	O
%	O
and	O
oliho	O
chitosan	O
15	O
-	O
30	O
%	O
.	O

The	O
Active	O
bacteriostasis	O
capsule	O
provided	O
in	O
the	O
invention	O
adopts	O
a	O
micro	O
ecological	O
theory	O
of	O
using	O
bacterium	O
to	O
kill	O
bacterium	O
and	O
inter	O
-	O
restriction	O
between	O
organisms	O
.	O

Large	O
amount	O
of	O
beneficial	O
bacterium	O
to	O
restrain	O
harmful	O
bacterium	O
is	O
supplied	O
and	O
the	O
beneficial	O
bacterium	O
is	O
planted	O
on	O
the	O
inner	O
wall	O
of	O
reproductive	O
tract	O
,	O
forming	O
a	O
beneficial	O
bacteria	O
barrier	O
.	O

The	O
capsule	O
can	O
repair	O
and	O
activate	O
a	O
self	O
clean	O
function	O
of	O
female	O
,	O
thereby	O
a	O
healthy	O
reproduction	O
tract	O
environment	O
is	O
formed	O
.	O

The	O
capsule	O
can	O
be	O
used	O
to	O
treat	O
various	O
vaginal	O
disease	O
caused	O
by	O
flora	O
disturbance	O
and	O
dysbacteriosis	O
.	O

Active	O
bacteriostasis	O
capsule	O

The	O
invention	O
relates	O
to	O
an	O
antipyrotic	O
powder	O
for	O
external	O
use	O
.	O

The	O
antipyrotic	O
powder	O
is	O
characterized	O
by	O
comprising	O
phellodendron	O
,	O
radix	O
sophorae	O
flavescentis	O
,	O
borneol	B
,	O
scorpio	O
,	O
alum	O
and	O
Senecio	O
scandens	O
with	O
auxiliary	O
materials	O
including	O
tea	O
oil	O
and	O
pig	O
bile	O
.	O

A	O
preparation	O
method	O
of	O
the	O
antipyrotic	O
powder	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
weighing	O
the	O
above	O
various	O
raw	O
materials	O
according	O
to	O
a	O
weight	O
ratio	O
,	O
placing	O
into	O
a	O
pulverizer	O
,	O
stirring	O
and	O
crushing	O
,	O
sieving	O
through	O
a	O
sieve	O
of	O
6	O
meshes	O
to	O
obtain	O
a	O
yellow	O
powder	O
,	O
and	O
packing	O
by	O
the	O
use	O
of	O
aluminium	B
foil	O
with	O
5	O
g	O
per	O
pack	O
.	O

The	O
invention	O
has	O
the	O
following	O
significant	O
effects	O
:	O
drug	O
properties	O
are	O
mild	O
;	O
there	O
is	O
no	O
side	O
effect	O
;	O
the	O
treatment	O
cost	O
is	O
low	O
;	O
the	O
curative	O
effect	O
is	O
fast	O
with	O
no	O
ache	O
;	O
and	O
the	O
total	O
efficiency	O
is	O
about	O
more	O
than	O
90	O
%	O
.	O

Antipyrotic	O
powder	O
for	O
external	O
use	O

The	O
invention	O
provides	O
a	O
novel	O
tamsulosin	B
hydrochloride	I
osmotic	O
pump	O
controlled	O
-	O
release	O
tablet	O
.	O

Ethyl	O
cellulose	O
and	O
povidone	B
are	O
used	O
as	O
membrane	O
forming	O
materials	O
of	O
a	O
semipermeable	O
membrane	O
,	O
and	O
the	O
asymmetric	O
tablet	O
form	O
is	O
preferably	O
selected	O
,	O
so	O
that	O
the	O
ageing	O
of	O
the	O
semipermeable	O
membrane	O
can	O
be	O
avoided	O
,	O
and	O
the	O
drug	O
residues	O
can	O
be	O
reduced	O
.	O

The	O
invention	O
also	O
provides	O
a	O
method	O
for	O
improving	O
the	O
ageing	O
resistance	O
of	O
the	O
tamsulosin	B
hydrochloride	I
osmotic	O
pump	O
controlled	O
-	O
release	O
tablet	O
,	O
wherein	O
the	O
method	O
is	O
characterized	O
in	O
that	O
the	O
ethyl	O
cellulose	O
-	O
povidone	O
are	O
used	O
as	O
the	O
membrane	O
forming	O
materials	O
of	O
the	O
semipermeable	O
membrane	O
.	O

In	O
addition	O
,	O
the	O
invention	O
also	O
provides	O
applications	O
of	O
the	O
ethyl	O
cellulose	O
-	O
povidone	O
composition	O
in	O
preparing	O
the	O
anti	O
-	O
ageing	O
tamsulosin	B
hydrochloride	I
osmotic	O
pump	O
controlled	O
-	O
release	O
tablet	O
.	O

Tamsulosin	B
hydrochloride	I
osmotic	O
pump	O
controlled	O
-	O
release	O
tablet	O

The	O
invention	O
discloses	O
an	O
ester	O
derivative	O
of	O
high	O
veratryl	B
alcohol	I
and	O
medical	O
treatment	O
application	O
,	O
and	O
belongs	O
to	O
the	O
field	O
of	O
medicines	O
.	O

A	O
compound	O
with	O
biological	O
activity	O
is	O
a	O
compound	O
in	O
a	O
general	O
formula	O
(	O
I	O
)	O
shown	O
in	O
the	O
specification	O
,	O
and	O
salt	O
,	O
a	O
solvate	O
or	O
a	O
hydrate	B
of	O
the	O
compound	O
,	O
wherein	O
X1	O
is	O
H	B
or	O
COR1	B
,	O
X2	O
is	O
H	B
or	O
COR2	B
,	O
X3	O
is	O
H	B
or	O
COR3	B
,	O
but	O
X1	O
,	O
X2	O
and	O
X3	O
are	O
not	O
H	B
and	O
3-pyridyl	B
simultaneously	O
;	O
R1	O
,	O
R2	O
and	O
R3	O
are	O
the	O
same	O
as	O
one	O
another	O
or	O
different	O
from	O
one	O
another	O
and	O
are	O
C1-C6	B
alkyl	I
substituted	O
by	O
R4	O
or	O
can	O
be	O
substituted	O
by	O
R9	O
at	O
random	O
and	O
can	O
contain	O
one	O
or	O
more	O
4	O
-	O
7-membered	O
rings	O
of	O
additional	O
heteroatom	B
of	O
O	B
,	O
S	B
(	I
O	I
)	I
n	I
and	O
NR9	B
;	O
R4	O
is	O
F	B
,	O
CF3	B
,	O
OR5	B
,	O
NR6R7	B
or	O
S	B
(	I
O	I
)	I
nR8	I
;	O
R5	O
,	O
R6	O
and	O
R7	O
are	O
the	O
same	O
as	O
one	O
another	O
or	O
different	O
from	O
one	O
another	O
and	O
are	O
H	B
or	O
C1-C6	B
alkyl	I
substituted	O
by	O
R4	O
at	O
random	O
,	O
or	O
NR6R7	B
is	O
one	O
or	O
more	O
C4-C6	B
heterocycle	I
alkyl	I
rings	O
of	O
the	O
heteroatom	B
of	O
O	B
,	O
NR9	B
and	O
S	B
(	I
O	I
)	I
n	I
;	O
each	O
n	O
is	O
0	O
to	O
2	O
;	O
R8	O
is	O
C1-C6	B
alkyl	I
;	O
R9	O
is	O
C1-C4	B
alkyl	I
which	O
is	O
defined	O
by	O
R4	O
or	O
substituted	O
by	O
R4	O
or	O
halogens	B
at	O
random	O
;	O
and	O
R9	O
is	O
H	B
or	O
C1-C6	B
alkyl	I
.	O

The	O
ester	O
derivative	O
has	O
the	O
effect	O
of	O
treating	O
liver	O
diseases	O
,	O
T	O
-	O
cell	O
proliferation	O
related	O
diseases	O
or	O
proinflammatory	O
cytokine	O
mediated	O
diseases	O
.	O

Ester	O
derivative	O
of	O
high	O
veratryl	B
alcohol	I
and	O
medical	O
treatment	O
application	O

The	O
invention	O
discloses	O
gemcitabine	B
hydrochloride	I
lyophilized	O
powder	O
for	O
injection	O
.	O

The	O
gemcitabine	B
hydrochloride	I
lyophilized	O
powder	O
consists	O
of	O
the	O
following	O
components	O
in	O
parts	O
by	O
mass	O
:	O
100	O
parts	O
of	O
gemcitabine	B
hydrochloride	I
,	O
160	O
-	O
180	O
parts	O
of	O
lactose	B
and	O
3	O
-	O
6	O
parts	O
of	O
sodium	B
citrate	I
.	O

As	O
proved	O
by	O
influencing	O
factor	O
testing	O
investigation	O
,	O
each	O
detection	O
index	O
the	O
gemcitabine	B
hydrochloride	I
lyophilized	O
powder	O
for	O
injection	O
prepared	O
by	O
adopting	O
a	O
formula	O
and	O
a	O
process	O
provided	O
by	O
the	O
invention	O
does	O
not	O
change	O
remarkably	O
in	O
a	O
high	O
-	O
temperature	O
,	O
high	O
-	O
humidity	O
and	O
strong	O
-	O
light	O
-	O
irradiation	O
environment	O
,	O
and	O
high	O
stability	O
is	O
achieved	O
.	O

Gemcitabine	B
hydrochloride	I
lyophilized	O
powder	O
for	O
injection	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
new	O
application	O
of	O
alpinetin	B
.	O

The	O
new	O
application	O
means	O
that	O
the	O
alpinetin	B
serving	O
as	O
an	O
active	O
ingredient	O
is	O
used	O
for	O
preparing	O
medicaments	O
or	O
health	O
-	O
care	O
food	O
for	O
treating	O
ulcerative	O
colitis	O
.	O

Experimental	O
results	O
show	O
that	O
the	O
alpinetin	B
can	O
obviously	O
improve	O
the	O
symptoms	O
such	O
as	O
weight	O
loss	O
,	O
bloody	O
stool	O
,	O
colon	O
shortening	O
,	O
inflammatory	O
cell	O
infiltration	O
and	O
pathological	O
tissue	O
damage	O
of	O
ulcerative	O
colitis	O
mice	O
,	O
and	O
can	O
inhibit	O
the	O
expression	O
of	O
proinflammatory	O
factors	O
TNF	O
-	O
alpha	O
and	O
IL-6	O
.	O

Therefore	O
,	O
the	O
alpinetin	B
serving	O
as	O
the	O
active	O
ingredient	O
is	O
expected	O
to	O
be	O
developed	O
into	O
a	O
medicament	O
or	O
health	O
-	O
care	O
food	O
for	O
treating	O
the	O
ulcerative	O
colitis	O
.	O

The	O
medicinal	O
value	O
of	O
the	O
alpinetin	B
can	O
be	O
fully	O
exerted	O
,	O
and	O
the	O
invention	O
has	O
significance	O
for	O
research	O
and	O
application	O
of	O
the	O
alpinetin	B
.	O

New	O
application	O
of	O
alpinetin	B

The	O
invention	O
provides	O
a	O
mecobalamin	B
tablet	O
which	O
has	O
very	O
low	O
content	O
of	O
related	O
substances	O
and	O
can	O
simultaneously	O
realize	O
rapid	O
disintegration	O
.	O

The	O
mecobalamin	B
tablet	O
is	O
prepared	O
by	O
mixing	O
mecobalamin	B
powder	O
with	O
a	O
coating	O
filling	O
agent	O
,	O
then	O
using	O
an	O
Opadry	O
coating	O
to	O
prepare	O
mecobalamin	B
coated	O
particles	O
under	O
the	O
conditions	O
of	O
protecting	O
from	O
light	O
,	O
further	O
adding	O
pharmaceutically	O
acceptable	O
tablet	O
excipients	O
,	O
and	O
tabletting	O
.	O

According	O
to	O
the	O
mecobalamin	B
tablet	O
provided	O
by	O
the	O
invention	O
,	O
the	O
process	O
flow	O
of	O
mecobalamin	B
which	O
is	O
very	O
sensitive	O
to	O
light	O
is	O
improved	O
from	O
the	O
way	O
of	O
firstly	O
tabletting	O
and	O
then	O
coating	O
to	O
the	O
way	O
of	O
firstly	O
coating	O
and	O
then	O
tabletting	O
..	O

Through	O
an	O
advanced	O
powder	O
coating	O
technology	O
,	O
the	O
treatment	O
of	O
protecting	O
from	O
the	O
light	O
is	O
performed	O
on	O
the	O
mecobalamin	B
in	O
the	O
first	O
process	O
step	O
to	O
complete	O
the	O
protection	O
of	O
the	O
mecobalamin	B
so	O
as	O
to	O
enable	O
the	O
follow	O
-	O
up	O
process	O
steps	O
to	O
get	O
rid	O
of	O
the	O
influence	O
of	O
a	O
light	O
source	O
on	O
the	O
mecobalamin	B
,	O
the	O
means	O
of	O
controlling	O
the	O
related	O
substances	O
is	O
better	O
than	O
the	O
traditional	O
full	O
-	O
process	O
operation	O
of	O
protecting	O
from	O
the	O
light	O
,	O
the	O
coating	O
time	O
is	O
saved	O
,	O
and	O
the	O
efficiency	O
is	O
improved	O
.	O

Mecobalamin	B
tablet	O
and	O
preparation	O
method	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
application	O
of	O
baicalin	B
to	O
preparation	O
of	O
a	O
medicament	O
for	O
treating	O
pneumonia	O
.	O

A	O
rabbit	O
erythrocyte	O
hemolysis	O
test	O
,	O
a	O
human	O
pulmonary	O
epithelial	O
cell	O
(	O
A549	O
)	O
injury	O
protection	O
test	O
and	O
a	O
mouse	O
Staphylococcus	O
aureus	O
pneumonia	O
model	O
are	O
employed	O
to	O
confirm	O
the	O
treatment	O
effect	O
of	O
the	O
baicalin	B
.	O

Compared	O
with	O
an	O
antibiotic	O
therapy	O
,	O
the	O
use	O
of	O
baicalin	B
has	O
characteristics	O
of	O
no	O
drug	O
resistance	O
and	O
high	O
cure	O
rate	O
.	O

Application	O
of	O
baicalin	B
to	O
preparation	O
of	O
medicament	O
for	O
treating	O
pneumonia	O

The	O
invention	O
provides	O
1-substituted-1H-1,2,4-triazole	B
-	I
formamide	I
derivatives	O
.	O

The	O
substitution	O
position	O
of	O
formamido	B
is	O
in	O
5-	O
or	O
3-	O
position	O
of	O
1H-1,2,4-triazole	B
,	O
rufinamide	B
is	O
a	O
lead	O
compound	O
,	O
the	O
parent	O
nucleus	O
1,2,3-triazole	B
is	O
replaced	O
by	O
1,2,4-triazole	B
,	O
the	O
structure	O
of	O
the	O
side	O
chain	O
formamide	B
is	O
maintained	O
,	O
different	O
substituted	O
aromatic	B
(	I
heterocyclic	I
)	I
rings	O
replace	O
2,6-difluorobenzene	B
structure	O
,	O
the	O
type	O
,	O
number	O
or	O
position	O
of	O
the	O
substituent	O
group	O
on	O
a	O
benzene	B
ring	O
is	O
changed	O
to	O
obtain	O
a	O
series	O
of	O
1-substituted-1H-1,2,4-triazole-5-formamide	B
/	O
1-substituted-1H-1,2,4-triazole-3-formamide	B
derivatives	O
.	O

Pharmaceutical	O
activity	O
screening	O
experiments	O
prove	O
that	O
the	O
compounds	O
have	O
good	O
anticonvulsant	O
activity	O
,	O
and	O
can	O
be	O
applied	O
to	O
preparation	O
of	O
anticonvulsant	O
medicaments	O
.	O

The	O
preparation	O
method	O
has	O
reasonable	O
design	O
,	O
simple	O
steps	O
and	O
practicality	O
;	O
and	O
the	O
derivatives	O
have	O
the	O
structural	O
general	O
formula	O
in	O
the	O
specification	O
.	O

1-substituted-1H-1,2,4-triazole	B
-	I
formamide	I
derivatives	O
,	O
preparation	O
and	O
application	O
thereof	O

The	O
invention	O
discloses	O
a	O
use	O
of	O
a	O
compound	O
or	O
its	O
pharmaceutically	O
acceptable	O
salt	O
in	O
prevention	O
and	O
treatment	O
on	O
senile	O
dementia	O
.	O

The	O
compound	O
is	O
N'-	B
{	I
5-	I
[	I
acetyl	I
(	I
hydroxyl	I
)	I
amido	I
]	I
pentyl	I
}	I
-N-	I
[	I
5-	I
(	I
{	I
4-	I
[	I
(	I
5-aminopentyl	I
)	I
(	I
hydroxyl	I
)	I
amido	I
]	I
-4-keto	I
-	I
butyryl	I
}	I
amido	I
)	I
pentyl	I
]	I
-N	I
-	I
hydroxysuccinic	I
acid	I
amide	I
.	O

The	O
compound	O
or	O
its	O
pharmaceutically	O
acceptable	O
salt	O
can	O
be	O
used	O
as	O
a	O
drug	O
for	O
preventing	O
and	O
treating	O
senile	O
dementia	O
.	O

The	O
compound	O
or	O
its	O
pharmaceutically	O
acceptable	O
salt	O
can	O
penetrate	O
a	O
blood	O
brain	O
barrier	O
and	O
then	O
bind	O
with	O
a	O
heavy	O
metal	O
to	O
form	O
a	O
chelate	O
thereby	O
inhibiting	O
production	O
of	O
amyloid	O
in	O
the	O
brain	O
,	O
preventing	O
polymerization	O
and	O
accumulation	O
of	O
amyloid	O
,	O
dissolving	O
produced	O
amyloid	O
plaques	O
and	O
promoting	O
amyloid	O
degradation	O
.	O

Use	O
of	O
compound	O
or	O
its	O
pharmaceutically	O
acceptable	O
salt	O
in	O
prevention	O
and	O
treatment	O
on	O
senile	O
dementia	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
pyridine	B
alkaloid	I
compounds	O
of	O
formula	O
(	O
I	O
)	O
:	O
or	O
a	O
pharmaceutically	O
acceptable	O
derivative	O
thereof	O
as	O
described	O
in	O
the	O
specification	O
,	O
the	O
process	O
for	O
the	O
preparation	O
of	O
the	O
same	O
,	O
and	O
the	O
composition	O
comprising	O
the	O
same	O
.	O

The	O
uses	O
of	O
a	O
pyridine	B
compound	O
for	O
increasing	O
the	O
activity	O
of	O
PPAR	O
[	O
gamma	O
]	O
,	O
for	O
the	O
prevention	O
and/or	O
treatment	O
of	O
a	O
disease	O
or	O
disorder	O
related	O
to	O
insulin	O
resistance	O
,	O
and	O
for	O
the	O
prevention	O
and/or	O
treatment	O
of	O
metabolic	O
syndrome	O
or	O
its	O
complication	O
are	O
also	O
provided	O
.	O

The	O
invention	O
also	O
provides	O
extracts	O
of	O
red	O
yeast	O
-	O
fermented	O
products	O
and	O
their	O
uses	O
for	O
prevention	O
and/or	O
treatment	O
of	O
a	O
disease	O
or	O
disorder	O
related	O
to	O
insulin	O
resistance	O
,	O
such	O
as	O
metabolic	O
syndrome	O
.	O

Novel	O
pyridine	B
alkaloids	I
,	O
preparation	O
process	O
thereof	O
,	O
and	O
the	O
uses	O
of	O
the	O
pyridine	B
alkaloids	I

The	O
invention	O
discloses	O
granulation	O
promoting	O
powder	O
for	O
treating	O
recurrent	O
aphthous	O
ulcer	O
.	O

The	O
granulation	O
promoting	O
powder	O
comprises	O
the	O
following	O
components	O
:	O
125	O
g	O
of	O
realgar	O
,	O
60	O
g	O
of	O
amber	O
,	O
15	O
g	O
of	O
borax	B
,	O
15	O
g	O
of	O
borneol	B
,	O
15	O
g	O
of	O
compound	O
of	O
glauber	B
-	I
salt	I
and	O
liquorice	O
and	O
250	O
g	O
of	O
talcum	O
powder	O
.	O

The	O
invention	O
also	O
discloses	O
a	O
preparation	O
method	O
of	O
the	O
granulation	O
promoting	O
powder	O
for	O
treating	O
recurrent	O
aphthous	O
ulcer	O
.	O

The	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
grinding	O
the	O
125	O
g	O
of	O
realgar	O
,	O
60	O
g	O
of	O
amber	O
,	O
15	O
g	O
of	O
borax	B
,	O
15	O
g	O
of	O
borneol	B
,	O
15	O
g	O
of	O
compound	O
of	O
glauber	B
-	I
salt	I
and	O
liquorice	O
and	O
250	O
g	O
of	O
talcum	O
powder	O
into	O
powder	O
;	O
uniformly	O
mixing	O
;	O
and	O
sub	O
-	O
packing	O
the	O
mixed	O
powder	O
.	O

Through	O
the	O
invention	O
,	O
the	O
medicine	O
can	O
be	O
directly	O
applied	O
to	O
the	O
lesion	O
to	O
completely	O
exert	O
the	O
efficacy	O
,	O
the	O
local	O
symptoms	O
of	O
red	O
,	O
swelling	O
,	O
itch	O
,	O
pain	O
and	O
the	O
like	O
can	O
be	O
relieved	O
,	O
the	O
exudation	O
and	O
incrustation	O
are	O
reduced	O
,	O
and	O
infection	O
is	O
eliminated	O
to	O
prompt	O
the	O
inflammation	O
absorption	O
and	O
quick	O
healing	O
of	O
wound	O
.	O

Granulation	O
promoting	O
powder	O
for	O
treating	O
recurrent	O
aphthous	O
ulcer	O
and	O
preparation	O
method	O
thereof	O

A	O
pull	O
-	O
apart	O
fragrance	O
sampler	O
laminate	O
is	O
constructed	O
by	O
dispersing	O
microcapsules	O
containing	O
fragrance	O
oil	O
into	O
a	O
quick	O
setting	O
adhesive	O
.	O

The	O
resulting	O
dispersion	O
is	O
applied	O
to	O
a	O
surface	O
of	O
a	O
substrate	O
and	O
then	O
covered	O
with	O
an	O
overlayer	O
.	O

The	O
substrate	O
and	O
overlayer	O
adhere	O
to	O
the	O
dispersion	O
until	O
they	O
are	O
pulled	O
apart	O
whereby	O
the	O
microcapsules	O
are	O
fractured	O
,	O
releasing	O
the	O
fragrance	O
.	O

The	O
substrate	O
may	O
be	O
a	O
continuous	O
web	O
of	O
two	O
-	O
layer	O
stock	O
having	O
a	O
silicone	B
coated	O
liner	O
and	O
a	O
release	O
layer	O
on	O
which	O
the	O
dispersion	O
is	O
coated	O
for	O
making	O
fragrance	O
samplers	O
in	O
the	O
form	O
of	O
die	O
cut	O
labels	O
.	O

The	O
dispersion	O
may	O
be	O
applied	O
to	O
the	O
substrate	O
by	O
a	O
relief	O
printing	O
plate	O
at	O
a	O
station	O
of	O
a	O
printing	O
press	O
through	O
which	O
the	O
substrate	O
and	O
cover	O
layer	O
are	O
transported	O
.	O

Dual	O
component	O
oral	O
care	O
product	O

The	O
invention	O
aims	O
to	O
provide	O
a	O
suction	O
therapy	O
for	O
repairing	O
brain	O
cells	O
,	O
containing	O
cerebral	O
hemorrhage	O
and	O
enhancing	O
an	O
immune	O
system	O
.	O

The	O
therapy	O
is	O
composed	O
of	O
curcumin	B
,	O
CNB-001	O
and	O
ornithine	B
and	O
is	O
characterized	O
by	O
the	O
utilization	O
of	O
a	O
suction	O
method	O
.	O

Active	O
ingredients	O
in	O
the	O
therapy	O
pass	O
through	O
a	O
respiratory	O
system	O
and	O
directly	O
penetrate	O
through	O
blood	O
cerebral	O
barrier	O
so	O
as	O
to	O
rapidly	O
reach	O
curative	O
effects	O
.	O

Suction	O
therapy	O
for	O
repairing	O
brain	O
cells	O
,	O
containing	O
cerebral	O
hemorrhage	O
and	O
enhancing	O
immune	O
system	O

The	O
invention	O
discloses	O
a	O
preparation	O
method	O
and	O
an	O
application	O
of	O
an	O
ecdysone	B
-	O
rich	O
plant	O
standardized	O
extract	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
steps	O
of	O
:	O
extracting	O
ecdysone	B
-	O
rich	O
plant	O
materials	O
using	O
ethanol	B
under	O
reflux	O
,	O
filtering	O
,	O
concentrating	O
and	O
centrifuing	O
;	O
decolorizing	O
the	O
centrifuged	O
supernatant	O
,	O
purifying	O
by	O
macroporous	O
resin	O
column	O
chromatography	O
,	O
concentrating	O
and	O
drying	O
to	O
obtain	O
the	O
standardized	O
extract	O
.	O

The	O
method	O
is	O
simple	O
and	O
feasible	O
,	O
short	O
in	O
production	O
period	O
,	O
and	O
stable	O
and	O
controllable	O
in	O
quality	O
,	O
and	O
is	O
easy	O
for	O
preparation	O
and	O
industrial	O
production	O
in	O
a	O
standardized	O
and	O
batch	O
manner	O
;	O
and	O
the	O
similarity	O
of	O
the	O
extract	O
obtained	O
by	O
the	O
method	O
is	O
more	O
than	O
99	O
%	O
by	O
HPLC	O
(	O
high	O
performance	O
liquid	O
chromatography	O
)	O
fingerprint	O
spectrum	O
detection	O
.	O

The	O
extract	O
can	O
be	O
applied	O
in	O
preparing	O
fixed	O
preparations	O
serving	O
as	O
drugs	O
for	O
reducing	O
blood	O
sugar	B
and	O
resisting	O
rheumatoid	O
arthritis	O
,	O
can	O
be	O
used	O
as	O
a	O
raw	O
material	O
for	O
natural	O
cosmetics	O
and	O
can	O
be	O
applied	O
in	O
animal	O
breeding	O
industry	O
.	O

Preparation	O
method	O
and	O
application	O
of	O
ecdysone	B
-	O
rich	O
plant	O
standardized	O
extract	O

The	O
invention	O
relates	O
to	O
application	O
of	O
isobavachalcone	B
displayed	O
in	O
formula	O
I	O
in	O
treating	O
microglial	O
cell	O
mediated	O
diseases	O
,	O
in	O
particular	O
to	O
application	O
of	O
isobavachalcone	B
in	O
preparing	O
medicines	O
for	O
treating	O
and/or	O
preventing	O
microglial	O
cell	O
mediated	O
diseases	O
especially	O
microglial	O
cell	O
mediated	O
neural	O
immune	O
inflammatory	O
diseases	O
caused	O
by	O
neurotoxic	O
effect	O
.	O

The	O
isobavachalcone	O
has	O
new	O
functions	O
of	O
being	O
capable	O
of	O
obviously	O
restraining	O
microglial	O
cellsfrom	O
activating	O
or	O
inducing	O
cells	O
to	O
die	O
,	O
restraining	O
generation	O
and	O
expression	O
of	O
inflammatory	O
media	O
NO	B
of	O
activated	O
microglial	O
cells	O
and	O
obviously	O
relieving	O
cytotoxicity	O
of	O
activated	O
microglial	O
cells	O
to	O
neurons	O
.	O

Therefore	O
,	O
isobavachalcone	B
can	O
be	O
applied	O
to	O
preventive	O
treatment	O
of	O
diseases	O
related	O
to	O
brain	O
immune	O
inflammatory	O
diseases	O
such	O
as	O
Parkinson	O
's	O
disease	O
.	O

Application	O
of	O
isobavachalcone	B
in	O
treating	O
nerve	O
inflammatory	O
diseases	O

The	O
invention	O
discloses	O
application	O
of	O
NSC23766	O
on	O
preparing	O
medicines	O
for	O
treating	O
mental	O
excitation	O
drug	O
addiction	O
.	O

The	O
NSC23766	O
is	O
used	O
for	O
treating	O
cocaine	B
induction	O
behaviouristics	O
plasticity	O
changes	O
,	O
and	O
the	O
NSC23766	O
is	O
proved	O
to	O
be	O
capable	O
of	O
effectively	O
restraining	O
behaviouristics	O
sensitization	O
action	O
and	O
conditioned	O
place	O
preference	O
induced	O
by	O
cocaine	B
,	O
the	O
NSC23766	O
is	O
basically	O
free	O
of	O
toxic	O
and	O
side	O
effects	O
,	O
and	O
the	O
medicine	O
has	O
developing	O
prospects	O
and	O
can	O
treat	O
the	O
mental	O
excitation	O
drug	O
addiction	O
,	O
in	O
particular	O
to	O
cocaine	B
addiction	O
.	O

Application	O
of	O
NSC23766	O
on	O
preparing	O
medicines	O
for	O
treating	O
mental	O
excitation	O
drug	O
addiction	O

The	O
invention	O
discloses	O
a	O
pharmaceutical	O
composition	O
for	O
treating	O
diabetes	O
associated	O
with	O
hyperlipemia	O
and	O
a	O
preparation	O
method	O
,	O
and	O
an	O
application	O
of	O
the	O
medicines	O
for	O
treating	O
diabetes	O
associated	O
with	O
hyperlipemia	O
.	O

The	O
pharmaceutical	O
composition	O
takes	O
a	O
mixture	O
of	O
at	O
least	O
one	O
or	O
more	O
of	O
Praeruptorin	B
A	I
,	O
Pb	O
-	O
Ia	O
and	O
its	O
isomeride	O
and	O
a	O
racemate	O
,	O
Praeruptorin	B
B	I
,	O
Pb	O
-	O
Ia	O
II	O
and	O
its	O
isomeride	O
and	O
a	O
racemate	O
,	O
and	O
Praeruptorin	B
C	I
according	O
to	O
certain	O
proportion	O
as	O
an	O
active	O
component	O
,	O
and	O
is	O
composed	O
of	O
the	O
mixture	O
and	O
a	O
conventional	O
drug	O
carrier	O
.	O

The	O
weight	O
percentage	O
content	O
of	O
the	O
active	O
component	O
is	O
0.1	O
-	O
99.5	O
%	O
.	O

The	O
pharmaceutical	O
composition	O
is	O
used	O
for	O
preparing	O
and	O
treating	O
diabetes	O
associated	O
with	O
hyperlipemia	O
.	O

The	O
pharmaceutical	O
composition	O
has	O
the	O
advantages	O
that	O
the	O
source	O
of	O
the	O
raw	O
materials	O
is	O
abundant	O
,	O
the	O
pharmaceutical	O
composition	O
has	O
substantial	O
prevention	O
and	O
treatment	O
effects	O
for	O
diabetes	O
associated	O
with	O
hyperlipemia	O
,	O
the	O
usage	O
is	O
convenient	O
,	O
and	O
provides	O
a	O
novel	O
treatment	O
candidate	O
medicine	O
for	O
patients	O
.	O

Pharmaceutical	O
composition	O
for	O
treating	O
diabetes	O
associated	O
with	O
hyperlipemia	O
and	O
preparation	O
method	O

The	O
invention	O
aims	O
to	O
provide	O
a	O
veterinary	O
compound	O
florfenicol	B
injection	O
,	O
which	O
is	O
used	O
for	O
efficiently	O
treating	O
porcine	O
respiratory	O
disease	O
complex	O
and	O
porcine	O
digestive	O
tract	O
disease	O
.	O

Each	O
100ml	O
of	O
veterinary	O
compound	O
florfenicol	B
injection	O
contains	O
10	O
-	O
30	O
g	O
of	O
florfenicol	B
,	O
1	O
-	O
5	O
g	O
of	O
andrographolide	B
,	O
1	O
-	O
3	O
g	O
of	O
TMP	O
(	O
Trimethoprim	B
)	O
,	O
0.1	O
-	O
0.2	O
g	O
of	O
antioxygen	O
,	O
0.01	O
-	O
0.02	O
g	O
of	O
ethylenediaminetetraacetic	B
acid	I
disodium	I
,	O
and	O
the	O
balance	O
of	O
solvent	O
for	O
injection	O
.	O

The	O
veterinary	O
compound	O
florfenicol	B
injection	O
is	O
a	O
composition	O
of	O
the	O
florfenicol	B
,	O
the	O
andrographolide	O
and	O
the	O
TMP	O
which	O
have	O
significant	O
effects	O
on	O
the	O
porcine	O
respiratory	O
disease	O
complex	O
,	O
and	O
is	O
administrated	O
through	O
an	O
injection	O
way	O
,	O
the	O
dosage	O
is	O
accurate	O
,	O
the	O
absorption	O
is	O
quick	O
,	O
the	O
blood	O
concentration	O
is	O
high	O
,	O
the	O
distribution	O
is	O
wide	O
,	O
the	O
half	O
-	O
life	O
period	O
is	O
long	O
,	O
the	O
effective	O
concentration	O
maintenance	O
time	O
is	O
long	O
,	O
and	O
compared	O
with	O
the	O
pesticide	O
effect	O
of	O
the	O
existing	O
florfenicol	B
injection	O
and	O
the	O
herba	O
andrographitis	O
injection	O
,	O
the	O
pesticide	O
effect	O
of	O
the	O
veterinary	O
compound	O
florfenicol	B
injection	O
is	O
obviously	O
enhanced	O
.	O

Veterinary	O
compound	O
florfenicol	B
injection	O

The	O
invention	O
provides	O
application	O
of	O
polysaccharide	O
sulphate	O
to	O
preparation	O
of	O
tumor	O
treatment	O
neovascularization	O
inhibitors	O
and	O
vascular	O
disrupting	O
agents	O
.	O

Experiments	O
prove	O
that	O
the	O
neovascularization	O
inhibiting	O
rate	O
,	O
the	O
maturation	O
blood	O
vessel	O
disrupting	O
rate	O
and	O
the	O
concentration	O
of	O
the	O
polysaccharide	O
sulphate	O
are	O
in	O
dosage	O
relying	O
relationship	O
in	O
a	O
certain	O
range	O
,	O
and	O
the	O
maturation	O
blood	O
vessel	O
disrupting	O
rate	O
and	O
the	O
polysaccharide	O
sulphate	O
acting	O
time	O
are	O
in	O
dosage	O
relying	O
relationship	O
.	O

The	O
application	O
provided	O
by	O
the	O
invention	O
has	O
the	O
advantages	O
that	O
the	O
effect	O
of	O
the	O
polysaccharide	O
sulphate	O
in	O
the	O
aspects	O
of	O
tumor	O
neovascularization	O
inhibiting	O
and	O
tumor	O
blood	O
vessel	O
generation	O
disrupting	O
can	O
be	O
proved	O
,	O
and	O
the	O
polysaccharide	O
sulphate	O
can	O
be	O
used	O
for	O
tumor	O
blood	O
vessel	O
generation	O
and	O
other	O
blood	O
vessel	O
generation	O
disease	O
treatment	O
,	O
and	O
can	O
also	O
be	O
used	O
in	O
aspects	O
of	O
tumor	O
chemotherapy	O
and/or	O
auxiliary	O
chemotherapy	O
.	O

Many	O
diseases	O
of	O
people	O
are	O
relevant	O
to	O
the	O
blood	O
vessel	O
generation	O
,	O
and	O
the	O
polysaccharide	O
sulphate	O
as	O
the	O
neovascularization	O
inhibitors	O
and	O
vascular	O
disrupting	O
agents	O
can	O
be	O
widely	O
applied	O
to	O
the	O
treatment	O
of	O
diseases	O
of	O
tumor	O
and	O
the	O
like	O
.	O

The	O
application	O
provided	O
by	O
the	O
invention	O
has	O
the	O
advantages	O
that	O
the	O
application	O
range	O
of	O
the	O
polysaccharide	O
sulphate	O
is	O
widened	O
,	O
and	O
the	O
scientific	O
basis	O
is	O
provided	O
for	O
the	O
purpose	O
development	O
of	O
the	O
polysaccharide	O
sulphate	O
in	O
the	O
anti	O
-	O
tumor	O
aspect	O
and	O
the	O
like	O
.	O

Application	O
of	O
polysaccharide	O
sulphate	O
to	O
preparation	O
of	O
tumor	O
treatment	O
neovascularization	O
inhibitors	O
and	O
vascular	O
disrupting	O
agents	O

The	O
invention	O
relates	O
to	O
a	O
vinflunine	B
liposome	O
preparation	O
and	O
the	O
preparation	O
method	O
thereof	O
.	O

The	O
vinflunine	B
liposome	O
preparation	O
mainly	O
comprises	O
vinflunine	B
or	O
salt	O
,	O
phospholipid	O
,	O
cholesterin	B
and	O
polyethylene	B
glycol	I
-	O
distearoyl	B
phosphatidyl	I
ethanolamine	I
of	O
the	O
vinflunine	B
,	O
wherein	O
salt	O
,	O
phospholipid	O
,	O
cholesterin	B
and	O
polyethylene	B
glycol	I
-	O
distearoyl	B
phosphatidyl	I
ethanolamine	I
are	O
pharmaceutically	O
acceptable	O
,	O
and	O
the	O
vinflunine	B
liposome	O
preparation	O
can	O
be	O
prepared	O
into	O
an	O
injection	O
or	O
a	O
lyophilized	O
preparation	O
.	O

The	O
preparation	O
method	O
is	O
simple	O
in	O
technology	O
,	O
easy	O
to	O
operate	O
and	O
suitable	O
for	O
industrial	O
production	O
,	O
and	O
long	O
-	O
circulating	O
vinflunine	B
liposomes	O
prepared	O
by	O
using	O
the	O
method	O
are	O
high	O
in	O
encapsulation	O
rate	O
and	O
good	O
in	O
stability	O
.	O

Vinflunine	B
liposome	O
preparation	O
and	O
preparation	O
method	O
of	O
vinflunine	B
liposome	O
preparation	O

The	O
invention	O
relates	O
to	O
an	O
iloperidone	B
composition	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

According	O
to	O
the	O
iloperidone	B
composition	O
,	O
iloperidone	B
which	O
is	O
taken	O
as	O
an	O
active	O
ingredient	O
is	O
pretreated	O
,	O
so	O
that	O
the	O
particle	O
size	O
of	O
the	O
iloperidone	B
is	O
minimized	O
;	O
and	O
therefore	O
,	O
the	O
dissolution	O
rate	O
of	O
the	O
iloperidone	B
is	O
effectively	O
increased	O
.	O

Iloperidone	B
composition	O
and	O
preparation	O
method	O
thereof	O

The	O
present	O
disclosure	O
generally	O
relates	O
to	O
lyophilized	O
pharmaceutical	O
compositions	O
comprising	O
polymeric	O
nanoparticles	O
which	O
,	O
upon	O
reconstitution	O
,	O
have	O
low	O
levels	O
of	O
greater	O
than	O
10	O
micron	O
size	O
particles	O
.	O

Other	O
aspects	O
of	O
the	O
invention	O
include	O
methods	O
of	O
making	O
such	O
nanoparticles	O
.	O

Stable	O
Formulations	O
For	O
Lyophilizing	O
Therapeutic	O
Particles	O

The	O
invention	O
relates	O
to	O
a	O
compound	O
neomycin	B
sulfate	I
composition	O
for	O
treating	O
pet	O
abscess	O
and	O
a	O
preparation	O
method	O
of	O
the	O
compound	O
neomycin	B
sulfate	I
composition	O
.	O

The	O
composition	O
is	O
prepared	O
by	O
uniformly	O
mixing	O
the	O
following	O
components	O
by	O
weight	O
:	O
1	O
-	O
3	O
parts	O
of	O
neomycin	B
sulfate	I
,	O
3	O
-	O
5	O
parts	O
of	O
erythromycin	B
thiocyanate	I
,	O
1	O
-	O
2	O
parts	O
of	O
trimethoprim	B
lactate	I
,	O
1	O
-	O
3	O
parts	O
of	O
cetrimonium	B
bromide	I
,	O
3	O
-	O
5	O
parts	O
of	O
piperitol	B
,	O
50	O
-	O
70	O
parts	O
of	O
liquid	O
paraffin	O
,	O
7	O
-	O
9	O
parts	O
of	O
glycerol	B
,	O
0.4	O
part	O
of	O
ethylparaben	B
,	O
1	O
-	O
3	O
parts	O
of	O
essence	O
,	O
80	O
-	O
113	O
parts	O
of	O
distilled	O
water	O
and	O
the	O
like	O
.	O

The	O
compound	O
neomycin	B
sulfate	I
composition	O
has	O
the	O
beneficial	O
effects	O
that	O
the	O
formula	O
is	O
reasonable	O
,	O
preparation	O
is	O
simple	O
,	O
curative	O
effects	O
are	O
very	O
remarkable	O
,	O
and	O
furthermore	O
,	O
clinical	O
application	O
show	O
that	O
the	O
compound	O
neomycin	B
sulfate	I
composition	O
has	O
special	O
effect	O
for	O
treating	O
pet	O
abscess	O
.	O

Compound	O
neomycin	B
sulfate	I
composition	O
for	O
treating	O
pet	O
abscess	O
and	O
preparation	O
method	O
of	O
compound	O
neomycin	B
sulfate	I
composition	O

The	O
invention	O
relates	O
to	O
an	O
application	O
of	O
dimethyldiguanide	B
in	O
drugs	O
taking	O
protective	O
effect	O
on	O
chemoradiotherapy	O
injury	O
.	O

As	O
an	O
optimal	O
implementation	O
scheme	O
,	O
the	O
invention	O
relates	O
to	O
the	O
application	O
of	O
the	O
dimethyldiguanide	B
in	O
preparing	O
drugs	O
taking	O
protective	O
effect	O
on	O
long	O
-	O
term	O
bone	O
marrow	O
suppression	O
caused	O
by	O
radiotherapy	O
.	O

As	O
an	O
optimal	O
implementation	O
scheme	O
,	O
the	O
invention	O
relates	O
to	O
the	O
application	O
of	O
the	O
dimethyldiguanide	B
in	O
preparing	O
drugs	O
taking	O
protective	O
effect	O
on	O
the	O
long	O
-	O
term	O
bone	O
marrow	O
suppression	O
caused	O
by	O
chemotherapeutics	O
.	O

Proved	O
by	O
the	O
invention	O
,	O
the	O
dimethyldiguanide	B
has	O
a	O
certain	O
protective	O
effect	O
on	O
hematopoietic	O
immune	O
cell	O
injury	O
caused	O
by	O
irradiation	O
and/or	O
the	O
chemotherapeutics	O
.	O

Application	O
of	O
dimethyldiguanide	B
in	O
drugs	O
taking	O
protective	O
effect	O
on	O
chemoradiotherapy	O
injury	O

The	O
invention	O
discloses	O
an	O
application	O
of	O
Houttuynoid	B
B	I
in	O
preparing	O
medicines	O
for	O
inhibiting	O
pulmonary	O
metastasis	O
,	O
and	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
new	O
applications	O
of	O
medicines	O
.	O

Houttuynoid	B
B	I
can	O
inhibit	O
tumor	O
cell	O
mobility	O
and	O
migration	O
ability	O
.	O

The	O
application	O
of	O
Houttuynoid	B
B	I
in	O
preparing	O
medicines	O
for	O
inhibiting	O
pulmonary	O
metastasis	O
is	O
disclosed	O
for	O
the	O
first	O
time	O
,	O
and	O
has	O
extremely	O
high	O
migration	O
inhibitory	O
activity	O
to	O
pulmonary	O
cells	O
.	O

Application	O
of	O
Houttuynoid	B
B	I
in	O
medicines	O
for	O
inhibiting	O
pulmonary	O
metastasis	O

The	O
invention	O
discloses	O
an	O
application	O
of	O
Houttuynoid	B
D	I
in	O
medicines	O
for	O
treating	O
nasopharyngeal	O
carcinoma	O
,	O
and	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
new	O
applications	O
of	O
medicines	O
.	O

In	O
vitro	O
MTT	B
(	O
Methyl	B
Thiazolyl	I
Tetrazolium	I
)	O
antineoplastic	O
activity	O
evaluation	O
finds	O
that	O
Houttuynoid	B
D	I
has	O
remarkable	O
inhibition	O
effect	O
on	O
the	O
growth	O
of	O
human	O
nasopharyngeal	O
carcinoma	O
cell	O
lines	O
HNE1	O
,	O
HNE1	O
,	O
HONE	O
and	O
CNE1	O
,	O
so	O
that	O
Houttuynoid	B
A	I
can	O
be	O
used	O
to	O
prepare	O
medicines	O
for	O
inhibiting	O
nasopharyngeal	O
carcinoma	O
and	O
has	O
good	O
development	O
application	O
prospect	O
.	O

The	O
application	O
of	O
Houttuynoid	B
D	I
in	O
medicines	O
for	O
treating	O
nasopharyngeal	O
carcinoma	O
is	O
disclosed	O
for	O
the	O
first	O
time	O
,	O
and	O
has	O
extremely	O
high	O
inhibitory	O
activity	O
to	O
breast	O
caner	O
cells	O
as	O
the	O
skeleton	O
type	O
belongs	O
to	O
a	O
completely	O
novel	O
skeleton	O
type	O
.	O

Application	O
of	O
Houttuynoid	B
D	I
in	O
medicines	O
for	O
treating	O
nasopharyngeal	O
carcinoma	O

The	O
invention	O
discloses	O
a	O
prulifloxacin	B
oral	O
solid	O
composition	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
prulifloxacin	B
oral	O
solid	O
composition	O
is	O
prepared	O
from	O
130	O
to	O
135	O
parts	O
by	O
weight	O
of	O
prulifloxacin	B
,	O
10	O
to	O
30	O
parts	O
by	O
weight	O
of	O
starch	O
,	O
30	O
to	O
50	O
parts	O
by	O
weight	O
of	O
microcrystalline	O
cellulose	O
,	O
20	O
to	O
40	O
parts	O
by	O
weight	O
of	O
lactose	B
,	O
0.05	O
to	O
10	O
parts	O
by	O
weight	O
of	O
one	O
or	O
more	O
binders	O
,	O
2	O
to	O
15	O
parts	O
by	O
weight	O
of	O
one	O
or	O
more	O
disintegrants	O
and	O
0.5	O
to	O
10	O
parts	O
by	O
weight	O
of	O
one	O
or	O
more	O
lubricants	O
.	O

The	O
one	O
or	O
more	O
binders	O
are	O
selected	O
from	O
polyvinylpyrrolidone	B
,	O
lauryl	B
sodium	I
sulfate	I
and	O
polyethylene	B
glycol	I
mixed	O
aqueous	O
solutions	O
or	O
alcoholic	O
solutions	O
.	O

The	O
one	O
or	O
more	O
disintegrants	O
are	O
selected	O
from	O
carboxymethyl	O
starch	O
sodium	O
,	O
polyvinylpolypyrrolidone	B
and	O
hydroxy	O
propyl	O
cellulose	O
.	O

The	O
one	O
or	O
more	O
lubricants	O
are	O
selected	O
from	O
magnesium	B
stearate	I
,	O
calcium	B
stearate	I
and	O
aerosil	O
.	O

The	O
prulifloxacin	B
oral	O
solid	O
composition	O
can	O
be	O
processed	O
into	O
tablets	O
,	O
capsules	O
or	O
granules	O
,	O
has	O
good	O
stability	O
,	O
can	O
effectively	O
improve	O
a	O
dissolution	O
rate	O
,	O
solves	O
the	O
problem	O
that	O
the	O
existing	O
prulifloxacin	B
oral	O
solid	O
preparation	O
has	O
a	O
slow	O
dissolution	O
speed	O
,	O
and	O
improves	O
bioavailability	O
.	O

Prulifloxacin	B
oral	O
solid	O
composition	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
cis	B
-	I
platinum	I
complex	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

Cis	B
-	I
platinum	I
and	O
a	O
polymer	O
with	O
the	O
structure	O
of	O
formula	O
(	O
I	O
)	O
are	O
used	O
as	O
raw	O
materials	O
for	O
preparing	O
the	O
cis	B
-	I
platinum	I
complex	O
,	O
wherein	O
a	O
polymer	O
molecule	O
with	O
the	O
structure	O
of	O
formula	O
(	O
I	O
)	O
contains	O
a	O
poly	B
(	I
L	I
-	I
glutamic	I
acid	I
-	I
co	I
-	I
L	I
-	I
lysine	I
)	I
segment	O
,	O
so	O
that	O
the	O
prepared	O
cis	B
-	I
platinum	I
complex	O
has	O
excellent	O
biocompatibility	O
and	O
is	O
degradable	O
;	O
meanwhile	O
,	O
the	O
poly	B
(	I
L	I
-	I
glutamic	I
acid	I
-	I
co	I
-	I
L	I
-	I
lysine	I
)	I
segment	O
can	O
further	O
prevent	O
the	O
cis	B
-	I
platinum	I
complex	O
from	O
being	O
influenced	O
by	O
a	O
blood	O
circulation	O
system	O
in	O
an	O
aqueous	O
medium	O
,	O
so	O
that	O
the	O
cis	B
-	I
platinum	I
complex	O
has	O
excellent	O
stability	O
;	O
and	O
the	O
terminal	O
of	O
the	O
branched	O
chain	O
of	O
the	O
cis	B
-	I
platinum	I
complex	O
provided	O
by	O
the	O
invention	O
contains	O
an	O
amino	O
group	O
,	O
so	O
that	O
the	O
cis	B
-	I
platinum	I
complex	O
has	O
excellent	O
solubility	O
.	O

In	O
addition	O
,	O
the	O
prepared	O
cis	B
-	I
platinum	I
complex	O
contains	O
a	O
carboxy	O
group	O
,	O
so	O
that	O
the	O
cis	B
-	I
platinum	I
complex	O
has	O
excellent	O
pH	O
value	O
sensitivity	O
,	O
the	O
carboxy	O
group	O
tends	O
to	O
deprotonation	O
in	O
the	O
environment	O
with	O
a	O
lower	O
pH	O
value	O
so	O
as	O
to	O
be	O
beneficial	O
to	O
promoting	O
the	O
drug	O
release	O
and	O
improve	O
the	O
efficacy	O
of	O
drugs	O
.	O

Cis	B
-	I
platinum	I
complex	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
meloxicam	B
injection	O
for	O
treating	O
chronic	O
infectious	O
arthritis	O
of	O
dogs	O
and	O
cats	O
.	O

The	O
meloxicam	B
injection	O
is	O
a	O
meloxicam	B
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drug	O
,	O
and	O
the	O
administration	O
route	O
is	O
intramuscular	O
injection	O
.	O

The	O
meloxicam	B
injection	O
for	O
treating	O
chronic	O
infectious	O
arthritis	O
of	O
dogs	O
and	O
cats	O
has	O
the	O
effect	O
of	O
dispelling	O
wind	O
and	O
eliminating	O
dampness	O
,	O
tonifying	O
kidney	O
and	O
repelling	O
cold	O
,	O
promoting	O
blood	O
circulation	O
to	O
remove	O
meridian	O
obstruction	O
and	O
strengthening	O
tendons	O
and	O
bones	O
,	O
and	O
achieves	O
remarkable	O
effect	O
in	O
treating	O
chronic	O
infectious	O
arthritis	O
.	O

Meloxicam	B
injection	O
for	O
treating	O
chronic	O
infectious	O
arthritis	O
of	O
dogs	O
and	O
cats	O

The	O
invention	O
provides	O
a	O
new	O
pharmaceutically	O
acceptable	O
salt	O
of	O
L	B
-	I
carnitine	I
,	O
namely	O
L	B
-	I
carnitine	I
calcium	I
citrate	I
,	O
and	O
a	O
preparation	O
method	O
and	O
application	O
of	O
the	O
salt	O
.	O

L	B
-	I
carnitine	I
calcium	I
citrate	I
not	O
only	O
has	O
the	O
characteristics	O
of	O
high	O
stability	O
and	O
difficult	O
moisture	O
absorption	O
as	O
compared	O
with	O
L	B
-	I
carnitine	I
inner	O
salt	O
,	O
but	O
also	O
is	O
easier	O
to	O
accept	O
by	O
human	O
bodies	O
and	O
easier	O
to	O
participate	O
in	O
physiologic	O
metabolism	O
of	O
the	O
human	O
bodies	O
as	O
compared	O
with	O
the	O
existing	O
pharmaceutically	O
acceptable	O
salts	O
of	O
L	B
-	I
carnitine	I
,	O
and	O
has	O
stronger	O
nutrition	O
and	O
treatment	O
effects	O
.	O

The	O
invention	O
also	O
provides	O
application	O
of	O
L	B
-	I
carnitine	I
calcium	I
citrate	I
to	O
preparing	O
a	O
slimming	O
medicament	O
or	O
health	O
food	O
,	O
application	O
to	O
preparing	O
a	O
diet	O
/	O
nutritional	O
supplement	O
,	O
and	O
application	O
to	O
preparing	O
veterinarian	O
products	O
or	O
feed	O
.	O

L	B
-	I
carnitine	I
calcium	I
citrate	I
and	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
provides	O
a	O
venlafaxine	B
hydrochloride	I
controlled	O
-	O
release	O
pellet	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
venlafaxine	B
hydrochloride	I
controlled	O
-	O
release	O
pellet	O
comprises	O
a	O
blank	O
pellet	O
core	O
,	O
a	O
venlafaxine	B
hydrochloride	I
-	O
containing	O
layer	O
and	O
a	O
controlled	O
-	O
release	O
film	O
,	O
wherein	O
the	O
venlafaxine	B
hydrochloride	I
-	O
containing	O
layer	O
comprises	O
active	O
components	O
including	O
venlafaxine	B
hydrochloride	I
and	O
talcum	O
powder	O
which	O
are	O
in	O
a	O
weight	O
ratio	O
of	O
12:1	O
-	O
8:1	O
,	O
and	O
the	O
weight	O
ratio	O
of	O
the	O
venlafaxine	B
hydrochloride	I
to	O
the	O
blank	O
pellet	O
core	O
is	O
4:10	O
-	O
8:10	O
.	O

The	O
venlafaxine	B
hydrochloride	I
controlled	O
-	O
release	O
pellet	O
is	O
prepared	O
by	O
adopting	O
a	O
fluidized	O
bed	O
bottom	O
-	O
spraying	O
venlafaxine	B
hydrochloride	I
applying	O
mode	O
;	O
by	O
using	O
75	O
percent	O
alcohol	B
as	O
a	O
solvent	O
,	O
the	O
viscosity	O
of	O
the	O
venlafaxine	B
hydrochloride	I
in	O
a	O
water	O
solution	O
is	O
remarkably	O
lowered	O
,	O
the	O
venlafaxine	B
hydrochloride	I
applying	O
speed	O
is	O
increased	O
;	O
and	O
the	O
prepared	O
venlafaxine	B
hydrochloride	I
containing	O
pellet	O
adopts	O
a	O
bottom	O
-	O
spraying	O
coating	O
process	O
,	O
thus	O
the	O
problem	O
of	O
static	O
electricity	O
generated	O
because	O
of	O
the	O
adoption	O
of	O
the	O
pure	O
organic	O
solvent	O
is	O
overcome	O
;	O
the	O
application	O
process	O
and	O
the	O
wrapping	O
process	O
can	O
be	O
continuously	O
operated	O
in	O
the	O
same	O
device	O
,	O
thus	O
the	O
production	O
efficiency	O
is	O
increased	O
and	O
the	O
production	O
cost	O
is	O
lowered	O
;	O
and	O
no	O
toxic	O
organic	O
solvent	O
is	O
adopted	O
in	O
the	O
whole	O
process	O
,	O
thus	O
the	O
venlafaxine	B
hydrochloride	I
controlled	O
-	O
release	O
pellet	O
is	O
environmental	O
-	O
friendly	O
and	O
is	O
good	O
in	O
stability	O
,	O
and	O
almost	O
no	O
broken	O
pellets	O
or	O
dust	O
is	O
produced	O
.	O

Venlafaxine	B
hydrochloride	I
controlled	O
-	O
release	O
pellet	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
provides	O
ginsenoside	B
M1	I
n	I
-	I
butyrate	I
which	O
is	O
a	O
new	O
compound	O
with	O
a	O
molecular	O
formula	O
of	O
C40H69O9	B
.	O

The	O
molecular	O
weight	O
of	O
the	O
ginsenoside	B
M1	I
n	I
-	I
butyrate	I
is	O
692	O
.	O

The	O
invention	O
further	O
discloses	O
a	O
preparation	O
method	O
of	O
the	O
compound	O
and	O
application	O
of	O
antidiabetic	O
medicines	O
of	O
the	O
compound	O
.	O

The	O
ginsenoside	B
M1	I
n	I
-	I
butyrate	I
can	O
resist	O
to	O
physiological	O
activity	O
of	O
diabetes	O
mellitus	O
and	O
can	O
be	O
used	O
for	O
preventing	O
and	O
treating	O
the	O
diabetes	O
mellitus	O
and	O
conducting	O
assistant	O
treating	O
the	O
diabetes	O
mellitus	O
.	O

Preparation	O
of	O
ginsenoside	B
M1	I
n	I
-	I
butyrate	I
and	O
application	O
of	O
antidiabetic	O
medicines	O
of	O
ginsenoside	B
M1	I
n	I
-	I
butyrate	I

The	O
invention	O
provides	O
a	O
compound	O
elvucitabine	B
medicine	O
composition	O
.	O

The	O
medicine	O
composition	O
comprises	O
elvucitabine	B
or	O
the	O
medicinal	O
salts	O
thereof	O
,	O
entecavir	O
or	O
the	O
medicinal	O
salts	O
thereof	O
and	O
an	O
anti	O
-	O
acid	O
stabilizer	O
.	O

The	O
invention	O
further	O
provides	O
a	O
method	O
for	O
preparing	O
the	O
medicine	O
composition	O
,	O
comprising	O
the	O
following	O
steps	O
of	O
:	O
(	O
1	O
)	O
mixing	O
elvucitabine	B
or	O
the	O
medicinal	O
salts	O
thereof	O
with	O
the	O
anti	O
-	O
acid	O
stabilizer	O
,	O
then	O
mixing	O
elvucitabine	B
or	O
the	O
medicinal	O
salts	O
thereof	O
with	O
one	O
or	O
more	O
adhesives	O
,	O
and	O
attaching	O
the	O
obtained	O
mixture	O
on	O
an	O
empty	O
carrier	O
to	O
prepare	O
a	O
medicated	O
carrier	O
;	O
and	O
(	O
2	O
)	O
mixing	O
the	O
medicated	O
carrier	O
obtained	O
in	O
the	O
step	O
(	O
1	O
)	O
with	O
entecavir	B
or	O
the	O
medicinal	O
salts	O
thereof	O
and	O
one	O
or	O
more	O
pharmaceutical	O
excipients	O
.	O

The	O
invention	O
further	O
provides	O
a	O
use	O
of	O
the	O
compound	O
elvucitabine	O
medicine	O
composition	O
for	O
preparing	O
a	O
medicine	O
for	O
treating	O
hepatitis	O
B	O
virus	O
.	O

Compound	O
elvucitabine	B
medicine	O
composition	O
as	O
well	O
as	O
preparation	O
method	O
and	O
use	O
for	O
same	O

The	O
invention	O
discloses	O
a	O
cough	O
-	O
treating	O
tendril	O
-	O
leaved	O
fritillary	O
bulb	O
and	O
loquat	O
sustained	O
release	O
tablet	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
(	O
1	O
)	O
weighting	O
raw	O
materials	O
;	O
(	O
2	O
)	O
adding	O
water	O
to	O
loquat	O
leaves	O
,	O
decocting	O
,	O
filtering	O
,	O
concentrating	O
to	O
obtain	O
clear	O
paste	O
,	O
adding	O
ethanol	O
,	O
stirring	O
sufficiently	O
,	O
standing	O
and	O
taking	O
supernate	O
for	O
later	O
use	O
;	O
(	O
3	O
)	O
crushing	O
tendril	O
-	O
leaved	O
fritillary	O
bulb	O
,	O
carrying	O
out	O
hot	O
reflux	O
extraction	O
on	O
the	O
crushed	O
tendril	O
-	O
leaved	O
fritillary	O
bulb	O
together	O
with	O
platycodon	O
root	O
and	O
perilla	O
fruit	O
by	O
using	O
ethanol	O
,	O
filtering	O
,	O
mixing	O
the	O
obtained	O
filtrate	O
with	O
the	O
supernate	O
obtained	O
in	O
(	O
2	O
)	O
,	O
recovering	O
the	O
ethanol	O
,	O
concentrating	O
to	O
obtain	O
clear	O
paste	O
,	O
cooling	O
to	O
room	O
temperature	O
,	O
adding	O
butanone	O
for	O
extraction	O
,	O
recovering	O
the	O
butanone	O
,	O
concentrating	O
to	O
obtain	O
thick	O
paste	O
,	O
and	O
drying	O
,	O
crushing	O
and	O
sieving	O
the	O
thick	O
paste	O
to	O
obtain	O
extractive	O
powder	O
;	O
and	O
(	O
4	O
)	O
adding	O
a	O
proper	O
amount	O
of	O
binding	O
agent	O
into	O
the	O
extractive	O
powder	O
,	O
a	O
filling	O
agent	O
,	O
hydroxypropyl	O
methylcellulose	O
and	O
a	O
release	O
rate	O
regulator	O
to	O
prepare	O
a	O
soft	O
material	O
,	O
granulating	O
,	O
drying	O
and	O
tabletting	O
.	O

The	O
sustained	O
release	O
tablet	O
disclosed	O
by	O
the	O
invention	O
has	O
the	O
effects	O
of	O
relieving	O
cough	O
,	O
eliminating	O
phlegm	O
and	O
relieving	O
asthma	O
,	O
and	O
the	O
sustained	O
release	O
tablet	O
prepared	O
from	O
the	O
raw	O
materials	O
extracted	O
by	O
using	O
an	O
extraction	O
method	O
disclosed	O
by	O
the	O
invention	O
is	O
low	O
in	O
drug	O
dose	O
,	O
high	O
in	O
content	O
,	O
convenient	O
to	O
take	O
and	O
carry	O
,	O
good	O
in	O
curative	O
effect	O
,	O
favorable	O
for	O
fixed	O
-	O
quantity	O
taking	O
,	O
and	O
beneficial	O
to	O
storage	O
and	O
transportation	O
.	O

Cough	O
-	O
treating	O
tendril	O
-	O
leaved	O
fritillary	O
bulb	O
and	O
loquat	O
sustained	O
release	O
tablet	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
6-	O
(	O
1-methyl	O
-	O
beta	O
-	O
carboline-3-carboxylic	O
acetyl	O
)	O
-6-deoxy	O
-	O
beta	O
-	O
cyclodextrin	O
prepared	O
by	O
connecting	O
harmine	B
onto	O
cyclodextrin	O
with	O
ethylenediamine	B
as	O
a	O
connection	O
arm	O
,	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
invention	O
also	O
discloses	O
a	O
supramolecular	O
inclusion	O
complex	O
of	O
6-	O
(	O
1-methyl	O
-	O
beta	O
-	O
carboline-3-carboxylic	O
acetyl	O
)	O
-6-deoxy	O
-	O
beta	O
-	O
cyclodextrin	O
and	O
adriamycin	B
,	O
and	O
a	O
preparation	O
method	O
and	O
an	O
application	O
thereof	O
.	O

The	O
invention	O
further	O
discloses	O
the	O
evaluation	O
of	O
anti	O
-	O
tumor	O
activity	O
and	O
survival	O
rate	O
of	O
the	O
supramolecular	O
inclusion	O
complex	O
provided	O
by	O
the	O
invention	O
on	O
a	O
S180	O
mouse	O
model	O
.	O

As	O
a	O
result	O
of	O
in	O
-	O
vivo	O
experiment	O
,	O
with	O
the	O
supramolecular	O
inclusion	O
complex	O
provided	O
by	O
the	O
invention	O
,	O
adriamycin	B
toxicity	O
is	O
reduced	O
.	O

Especially	O
,	O
under	O
high	O
dosage	O
,	O
on	O
a	O
basis	O
that	O
anti	O
-	O
tumor	O
activity	O
equivalent	O
with	O
that	O
of	O
adriamycin	B
is	O
maintained	O
,	O
mouse	O
survival	O
rate	O
is	O
improved	O
.	O

The	O
invention	O
assists	O
in	O
providing	O
a	O
novel	O
approach	O
for	O
clinical	O
applications	O
of	O
the	O
anticancer	O
medicine	O
adriamycin	B
.	O

Preparation	O
method	O
and	O
application	O
of	O
6-	O
(	O
1-methyl	O
-	O
beta	O
-	O
carboline-3-carboxylic	O
acetyl	O
)	O
-6-deoxy	O
-	O
beta	O
-	O
cyclodextrin	O
and	O
supramolecular	O
inclusion	O
complex	O
thereof	O
with	O
adriamycin	B

The	O
invention	O
discloses	O
a	O
health	O
-	O
care	O
foot	O
solution	O
.	O

The	O
health	O
-	O
care	O
foot	O
solution	O
consists	O
of	O
the	O
following	O
components	O
in	O
parts	O
by	O
weight	O
:	O
1	O
-	O
2	O
parts	O
of	O
ginger	O
,	O
6	O
-	O
8	O
parts	O
of	O
red	O
flower	O
,	O
2	O
-	O
5	O
parts	O
of	O
semen	O
armeniacae	O
amarae	O
,	O
3	O
-	O
8	O
parts	O
of	O
green	O
tea	O
,	O
2	O
-	O
3	O
parts	O
of	O
salt	O
and	O
the	O
balance	O
of	O
water	O
.	O

The	O
health	O
-	O
care	O
foot	O
solution	O
can	O
accelerate	O
leg	O
blood	O
circulation	O
,	O
so	O
that	O
venous	O
blood	O
in	O
the	O
legs	O
can	O
timely	O
flow	O
back	O
to	O
the	O
right	O
side	O
of	O
the	O
heart	O
,	O
and	O
the	O
health	O
-	O
care	O
foot	O
solution	O
contributes	O
to	O
lightening	O
venous	O
congestion	O
of	O
the	O
legs	O
and	O
preventing	O
varicose	O
vein	O
of	O
lower	O
limbs	O
and	O
contributes	O
to	O
soothing	O
the	O
nerves	O
and	O
removing	O
troubles	O
,	O
performing	O
hypnosis	O
and	O
falling	O
asleep	O
,	O
so	O
that	O
the	O
sleep	O
is	O
deep	O
and	O
sweet	O
.	O

Health	O
-	O
care	O
foot	O
solution	O

The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medical	O
engineering	O
and	O
provides	O
a	O
tumor	O
cavity	O
filler	O
for	O
treating	O
giant	O
cell	O
tumor	O
of	O
bone	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
mixture	O
is	O
formed	O
by	O
mixing	O
a	O
diphosphate	B
medicine	O
and	O
bone	O
cement	O
according	O
to	O
a	O
ratio	O
,	O
wherein	O
the	O
bone	O
cement	O
serves	O
as	O
a	O
controlled	O
release	O
carrier	O
of	O
the	O
diphosphate	B
medicine	O
,	O
so	O
that	O
a	O
topical	O
administration	O
system	O
is	O
formed	O
.	O

The	O
principle	O
is	O
that	O
the	O
bone	O
cement	O
serves	O
as	O
the	O
release	O
carrier	O
of	O
the	O
medicine	O
and	O
the	O
diphosphate	B
medicine	O
is	O
released	O
at	O
a	O
focus	O
,	O
so	O
that	O
the	O
aim	O
that	O
the	O
focus	O
is	O
positioned	O
in	O
a	O
long	O
-	O
term	O
high	O
-	O
concentration	O
medicine	O
environment	O
is	O
fulfilled	O
;	O
and	O
therefore	O
,	O
the	O
effects	O
of	O
suppressing	O
bone	O
destruction	O
and	O
preventing	O
bone	O
resorption	O
through	O
the	O
diphosphate	B
medicine	O
are	O
improved	O
,	O
and	O
the	O
function	O
of	O
repairing	O
the	O
bone	O
destruction	O
through	O
the	O
bone	O
cement	O
is	O
not	O
influenced	O
.	O

Tumor	O
cavity	O
filler	O
for	O
treating	O
giant	O
cell	O
tumor	O
of	O
bone	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
bath	O
powder	O
for	O
treating	O
neurasthenia	O
.	O

The	O
bath	O
powder	O
is	O
prepared	O
by	O
the	O
steps	O
of	O
mixing	O
50	O
parts	O
of	O
zizyphus	O
jujube	O
tree	O
roots	O
,	O
35	O
parts	O
of	O
salviae	O
miltiorrhizae	O
,	O
30	O
parts	O
of	O
longspur	O
epimedium	O
,	O
30	O
parts	O
of	O
lily	O
,	O
30	O
parts	O
of	O
tuber	O
fleeceflower	O
stem	O
,	O
20	O
parts	O
of	O
coptidis	O
rhizome	O
,	O
30	O
parts	O
of	O
rhizoma	O
sparganii	O
,	O
30	O
parts	O
of	O
earthworm	O
,	O
50	O
parts	O
of	O
agilawood	O
,	O
25	O
parts	O
of	O
mint	O
,	O
30	O
parts	O
of	O
cortex	O
albiziae	O
,	O
20	O
parts	O
of	O
radix	O
curcumae	O
,	O
45	O
parts	O
of	O
mirabilite	O
,	O
20	O
parts	O
of	O
liquorice	O
and	O
20	O
parts	O
of	O
polygala	O
tenuifolia	O
together	O
;	O
performing	O
heating	O
drying	O
the	O
above	O
drugs	O
with	O
an	O
intake	O
air	O
temperature	O
of	O
180	O
-	O
290	O
DEG	O
C	O
and	O
outlet	O
air	O
temperature	O
of	O
80	O
-	O
90	O
DEG	O
C	O
;	O
grinding	O
the	O
above	O
drugs	O
into	O
powder	O
;	O
and	O
subpackaging	O
quantitatively	O
.	O

In	O
the	O
above	O
composition	O
,	O
the	O
composition	O
can	O
be	O
made	O
into	O
80	O
-	O
100	O
g	O
per	O
bag	O
if	O
being	O
weighed	O
in	O
grams	O
.	O

When	O
the	O
bath	O
powder	O
is	O
in	O
use	O
,	O
the	O
drug	O
formula	O
is	O
put	O
in	O
bath	O
water	O
with	O
stirring	O
.	O

The	O
water	O
consumption	O
of	O
the	O
bath	O
is	O
between	O
80	O
L	O
and	O
100	O
L	O
;	O
an	O
immersing	O
time	O
is	O
1	O
-	O
2	O
hours	O
every	O
day	O
;	O
and	O
10	O
days	O
is	O
a	O
course	O
of	O
treatment	O
.	O

Usually	O
,	O
neurasthenia	O
is	O
healed	O
after	O
three	O
to	O
five	O
courses	O
.	O

The	O
effective	O
rate	O
is	O
97	O
%	O
.	O

The	O
usage	O
amount	O
can	O
be	O
adjusted	O
according	O
to	O
conditions	O
of	O
patients	O
.	O

The	O
bath	O
powder	O
has	O
the	O
main	O
functions	O
for	O
treating	O
neurasthenia	O
,	O
intractable	O
insomnia	O
,	O
disturbed	O
consciousness	O
and	O
dysphoria	O
and	O
impatience	O
.	O

Bath	O
powder	O
for	O
treating	O
neurasthenia	O

The	O
invention	O
discloses	O
an	O
expectorant	O
.	O

The	O
expectorant	O
comprises	O
the	O
following	O
active	O
pharmaceutical	O
ingredients	O
in	O
parts	O
by	O
weight	O
:	O
2	O
-	O
4	O
parts	O
of	O
sapium	O
sebiferum	O
,	O
1	O
-	O
3	O
parts	O
of	O
rhizoma	O
curcumae	O
longae	O
,	O
3	O
-	O
8	O
parts	O
of	O
realgar	O
,	O
1	O
-	O
3	O
parts	O
of	O
agkistrodon	O
,	O
2	O
-	O
5	O
parts	O
of	O
bulbus	O
allii	O
macrostemonis	O
,	O
3	O
-	O
6	O
parts	O
of	O
common	O
achyranthes	O
herb	O
,	O
1	O
-	O
2	O
parts	O
of	O
squama	O
manis	O
,	O
4	O
-	O
9	O
parts	O
of	O
plantago	O
asiatica	O
L.	O
and	O
1	O
-	O
4	O
parts	O
of	O
fructus	O
rosae	O
laevigatae	O
.	O

The	O
expectorant	O
not	O
only	O
has	O
the	O
effects	O
of	O
drying	O
dampness	O
,	O
eliminating	O
phlegm	O
,	O
clearing	O
heat	O
,	O
relieving	O
exterior	O
syndrome	O
,	O
alleviating	O
water	O
retention	O
,	O
activating	O
blood	O
,	O
relieving	O
cough	O
and	O
preventing	O
asthma	O
,	O
but	O
also	O
can	O
activate	O
blood	O
to	O
remove	O
stasis	O
,	O
break	O
blood	O
to	O
promote	O
qi	O
circulation	O
,	O
induce	O
menstruation	O
to	O
relieve	O
menalgia	O
,	O
draw	O
out	O
poison	O
to	O
astringe	O
and	O
dispel	O
wind	O
and	O
dampness	O
.	O

Expectorant	O

The	O
invention	O
discloses	O
a	O
long	O
-	O
term	O
suspension	O
uterine	O
perfusion	O
agent	O
for	O
treating	O
female	O
animal	O
postpartum	O
infection	O
and	O
a	O
preparation	O
process	O
.	O

The	O
long	O
-	O
term	O
suspension	O
uterine	O
perfusion	O
agent	O
comprises	O
,	O
by	O
weight	O
,	O
1.5	O
-	O
3.5	O
kg	O
of	O
ofloxacin	B
,	O
0.125	O
-	O
1	O
kg	O
of	O
flunixin	B
meglumine	I
,	O
0.125	O
-	O
0.75	O
kg	O
of	O
metronidazole	B
,	O
0.125	O
-	O
1	O
kg	O
of	O
leonurus	O
extract	O
(	O
injection	O
level	O
)	O
,	O
0.125	O
-	O
1	O
kg	O
of	O
angelica	O
sinensis	O
extract	O
(	O
injection	O
level	O
)	O
,	O
0.25	O
-	O
1.25	O
kg	O
of	O
polyvinyl	B
pyrrolidone	I
(	I
PVP	I
)	I
-K30	I
,	O
2	O
-	O
15	O
kg	O
of	O
polyethylene	B
glycol	I
(	I
PEG	I
)	I
-400	I
,	O
0.03	O
kg	O
of	O
ethylene	B
diamine	I
tetraacetic	I
acid	I
(	I
EDTA	I
)	I
-2Na	I
and	O
appropriate	O
water	O
for	O
injection	O
.	O

The	O
long	O
-	O
term	O
suspension	O
uterine	O
perfusion	O
agent	O
is	O
suitable	O
for	O
postpartum	O
health	O
care	O
,	O
is	O
used	O
for	O
postpartum	O
female	O
animal	O
preventive	O
perfusion	O
,	O
effectively	O
reduces	O
morbidity	O
of	O
endometritism	O
,	O
remarkably	O
shortens	O
female	O
animal	O
estrus	O
interval	O
,	O
and	O
improves	O
breeding	O
success	O
rate	O
and	O
farrowing	O
rate	O
of	O
female	O
animals	O
.	O

The	O
long	O
-	O
term	O
suspension	O
uterine	O
perfusion	O
agent	O
is	O
injected	O
in	O
uterus	O
by	O
using	O
an	O
irrigator	O
.	O

Long	O
-	O
term	O
suspension	O
uterine	O
perfusion	O
agent	O
for	O
treating	O
female	O
animal	O
postpartum	O
infection	O
and	O
preparation	O
process	O

The	O
invention	O
discloses	O
a	O
folium	O
mori	O
tablet	O
for	O
moistening	O
dryness	O
and	O
lungs	O
.	O

The	O
folium	O
mori	O
tablet	O
is	O
characterized	O
by	O
comprising	O
the	O
following	O
raw	O
materials	O
:	O
folium	O
mori	O
,	O
gypsum	O
fibrosum	O
,	O
unibract	O
fritillary	O
bulb	O
,	O
fructus	O
trichosanthis	O
,	O
liquorice	O
,	O
sang	O
,	O
linseed	O
,	O
donkey	O
-	O
hide	O
gelatin	O
,	O
radix	O
ophiopogonis	O
,	O
roasted	O
almond	O
and	O
folium	O
eriobotryae	O
.	O

Folium	O
mori	O
tablets	O
for	O
moistening	O
dryness	O
and	O
lungs	O

A	O
genistein	B
hydroxamic	I
acid	I
compound	O
has	O
the	O
following	O
structural	O
general	O
formula	O
.	O

The	O
genistein	B
hydroxamic	I
acid	I
compound	O
has	O
good	O
inhibitional	O
effect	O
on	O
urease	O
and	O
can	O
be	O
used	O
for	O
preparing	O
drugs	O
for	O
treating	O
gastritis	O
,	O
gastric	O
ulcer	O
,	O
lithangiuria	O
and	O
the	O
like	O
.	O

A	O
manufacturing	O
method	O
of	O
the	O
genistein	B
hydroxamic	I
acid	I
compound	O
is	O
disclosed	O
.	O

Urease	O
inhibitor	O
genistein	B
hydroxamic	I
acid	I
compound	O
and	O
synthesis	O
and	O
application	O
thereof	O

The	O
invention	O
provides	O
an	O
antitussive	O
and	O
expectorant	O
compound	O
chemical	O
drug	O
,	O
and	O
especially	O
relates	O
to	O
a	O
drug	O
composed	O
of	O
dimemorfan	B
and	O
carbocisteine	B
which	O
are	O
effective	O
components	O
,	O
as	O
well	O
as	O
pharmaceutically	O
acceptable	O
accessories	O
,	O
and	O
a	O
preparation	O
technology	O
.	O

The	O
dimemorfan	B
used	O
in	O
the	O
invention	O
is	O
a	O
non	O
-	O
narcotic	O
central	O
antitussive	O
drug	O
;	O
and	O
compared	O
with	O
central	O
antitussive	O
drugs	O
present	O
on	O
the	O
market	O
,	O
the	O
dimemorfan	B
is	O
equivalent	O
in	O
antitussive	O
effects	O
but	O
low	O
in	O
adverse	O
reaction	O
.	O

Compared	O
with	O
commercially	O
available	O
compound	O
antitussive	O
and	O
expectorant	O
drugs	O
,	O
the	O
compound	O
chemical	O
drug	O
provided	O
by	O
the	O
invention	O
has	O
advantages	O
of	O
relatively	O
good	O
efficacies	O
and	O
low	O
adverse	O
reaction	O
rate	O
,	O
and	O
has	O
quite	O
good	O
social	O
and	O
economic	O
benefits	O
.	O

Antitussive	O
and	O
expectorant	O
compound	O
chemical	O
drug	O

The	O
invention	O
provides	O
a	O
compound	O
chemical	O
medicament	O
containing	O
guaiacol	B
,	O
and	O
in	O
particular	O
relates	O
to	O
a	O
medicament	O
consisting	O
of	O
dimemorfan	O
and	O
guaifenesin	B
serving	O
as	O
effective	O
components	O
and	O
pharmaceutically	O
acceptable	O
auxiliary	O
materials	O
,	O
and	O
a	O
preparation	O
process	O
of	O
the	O
medicament	O
.	O

According	O
to	O
the	O
compound	O
chemical	O
medicament	O
,	O
guaiacol	B
serving	O
as	O
a	O
non	O
-	O
narcotic	O
central	O
antitussive	O
drug	O
has	O
equivalent	O
antitussive	O
effect	O
but	O
lower	O
adverse	O
reaction	O
compared	O
with	O
a	O
conventional	O
central	O
antitussive	O
drug	O
in	O
current	O
market	O
.	O

Compared	O
with	O
currently	O
commercial	O
compound	O
antitussive	O
expectorant	O
drug	O
,	O
the	O
composition	O
has	O
advantages	O
of	O
better	O
curative	O
effect	O
and	O
low	O
adverse	O
reaction	O
,	O
and	O
has	O
good	O
social	O
benefit	O
and	O
economic	O
benefit	O
.	O

Compound	O
chemical	O
medicament	O
containing	O
guaiacol	B

The	O
invention	O
discloses	O
an	O
application	O
of	O
tanshinone	B
IIA	I
or	O
pharmaceutically	O
acceptable	O
salt	O
in	O
preparation	O
of	O
medicament	O
for	O
treating	O
or	O
inhibiting	O
mucus	O
in	O
a	O
wind	O
pipe	O
.	O

The	O
tanshinone	B
IIA	I
or	O
pharmaceutically	O
acceptable	O
salt	O
can	O
obviously	O
inhibit	O
the	O
hypersecretion	O
of	O
mucoprotein	O
in	O
the	O
wind	O
pipe	O
of	O
the	O
lung	O
tissue	O
.	O

Compared	O
with	O
the	O
commonly	O
used	O
mucolytic	O
agents	O
,	O
the	O
tanshinone	B
IIA	I
or	O
pharmaceutically	O
acceptable	O
salt	O
can	O
obviously	O
inhibit	O
the	O
expression	O
and	O
the	O
secretion	O
of	O
mucoprotein	O
,	O
and	O
the	O
obvious	O
side	O
and	O
toxic	O
effects	O
can	O
not	O
be	O
found	O
.	O

Application	O
of	O
tanshinone	B
IIA	I
or	O
pharmaceutically	O
acceptable	O
salt	O
in	O
preparation	O
of	O
medicament	O
for	O
treating	O
or	O
inhibiting	O
mucus	O
in	O
wind	O
pipe	O

The	O
invention	O
relates	O
to	O
the	O
technical	O
field	O
of	O
medicines	O
,	O
and	O
in	O
particular	O
relates	O
to	O
a	O
novel	O
application	O
of	O
doxycycline	B
in	O
preparing	O
a	O
medicament	O
for	O
treating	O
epithelial	O
ovarian	O
cancer	O
.	O

Animal	O
experiments	O
and	O
in	O
-	O
vitro	O
cell	O
experiments	O
prove	O
that	O
doxycycline	B
can	O
inhibit	O
multiplication	O
and	O
invasion	O
of	O
ovarian	O
cancer	O
cells	O
,	O
can	O
prevent	O
epithelial	O
ovarian	O
cancer	O
cells	O
from	O
transferring	O
,	O
can	O
promote	O
apoptosis	O
of	O
epithelial	O
ovarian	O
cancer	O
cells	O
,	O
has	O
a	O
remarkable	O
inhibition	O
effect	O
to	O
ovarian	O
cancer	O
cells	O
,	O
in	O
particular	O
platinum	B
-	O
based	O
drug	O
-	O
resistance	O
ovarian	O
cancer	O
cells	O
,	O
and	O
can	O
inhibit	O
growth	O
of	O
ovarian	O
cancer	O
tissues	O
and	O
formation	O
of	O
ascites	O
,	O
so	O
that	O
doxycycline	B
can	O
be	O
used	O
for	O
preparing	O
a	O
medicament	O
for	O
treating	O
epithelial	O
ovarian	O
cancer	O
.	O

The	O
invention	O
provides	O
a	O
novel	O
application	O
to	O
doxycycline	B
,	O
and	O
compared	O
with	O
other	O
chemotherapeutic	O
drugs	O
,	O
doxycycline	B
has	O
the	O
advantages	O
of	O
convenient	O
administration	O
and	O
small	O
side	O
effect	O
in	O
the	O
field	O
of	O
treating	O
epithelial	O
ovarian	O
cancer	O
.	O

Application	O
of	O
doxycycline	B
in	O
preparing	O
medicament	O
for	O
treating	O
epithelial	O
ovarian	O
cancer	O

The	O
invention	O
relates	O
to	O
an	O
active	O
component	O
baicalin	B
of	O
a	O
Qingkailing	O
compound	O
,	O
which	O
has	O
an	O
inhibiting	O
effect	O
on	O
acinetobacter	O
calcoaceticus	O
,	O
acinetobacter	O
baumannii	O
,	O
A.baumannii	O
,	O
stenotrophomonas	O
maltophilia	O
and	O
escherichia	O
coli	O
containing	O
NDM-1	O
drug	O
resistance	O
gene	O
,	O
so	O
that	O
the	O
active	O
component	O
baicalin	B
can	O
be	O
used	O
for	O
inhibiting	O
these	O
bacterial	O
diseases	O
and	O
treating	O
and/or	O
preventing	O
diseases	O
caused	O
by	O
these	O
bacteria	O
.	O

Application	O
of	O
active	O
component	O
baicalin	B
of	O
Qingkailing	O
compound	O
in	O
preparation	O
of	O
medicines	O
resisting	O
multiple	O
drug	O
-	O
resistance	O
bacteria	O

The	O
invention	O
discloses	O
a	O
novel	O
amoxicillin	B
sodium	I
compound	O
.	O

The	O
purity	O
of	O
the	O
amoxicillin	B
sodium	I
compound	O
is	O
more	O
than	O
99	O
%	O
,	O
the	O
specific	O
rotation	O
of	O
the	O
amoxicillin	B
sodium	I
compound	O
is	O
between	O
+	O
260	O
degrees	O
and	O
+	O
280	O
degrees	O
.	O

The	O
invention	O
also	O
discloses	O
a	O
composition	O
of	O
the	O
amoxicillin	B
sodium	I
compound	O
and	O
the	O
sulbactam	B
sodium	I
compound	O
,	O
which	O
comprises	O
the	O
following	O
components	O
in	O
parts	O
by	O
weight	O
:	O
50	O
-	O
100	O
parts	O
of	O
amoxicillin	B
sodium	I
,	O
25	O
-	O
50	O
parts	O
of	O
sulbactam	B
sodium	I
,	O
3	O
-	O
9	O
parts	O
of	O
vitamin	B
C	I
,	O
1	O
-	O
6	O
parts	O
of	O
proline	B
,	O
and	O
2	O
-	O
8	O
parts	O
of	O
nicotinamide	B
.	O

According	O
to	O
the	O
composition	O
of	O
the	O
amoxicillin	B
sodium	I
compound	O
and	O
the	O
sulbactam	B
sodium	I
compound	O
,	O
the	O
vitamin	B
C	I
,	O
the	O
proline	B
and	O
the	O
nicotinamide	B
are	O
taken	O
as	O
stabilizers	O
and	O
play	O
synergistic	O
effect	O
so	O
as	O
to	O
improve	O
the	O
stability	O
of	O
the	O
composition	O
of	O
the	O
amoxicillin	B
sodium	I
compound	O
and	O
the	O
sulbactam	B
sodium	I
compound	O
effectively	O
,	O
the	O
composition	O
can	O
be	O
prepared	O
into	O
stable	O
injection	O
which	O
is	O
not	O
easy	O
to	O
deteriorate	O
due	O
to	O
oxygenolysis	O
after	O
being	O
laid	O
for	O
a	O
period	O
,	O
and	O
the	O
injection	O
does	O
not	O
need	O
to	O
be	O
prepared	O
when	O
being	O
used	O
,	O
thus	O
being	O
convenient	O
to	O
use	O
.	O

Novel	O
amoxicillin	B
sodium	I
compound	O
and	O
composition	O
of	O
amoxicillin	B
sodium	I
compound	O
and	O
sulbactam	B
sodium	I
compound	O

The	O
invention	O
discloses	O
a	O
resveratrol	B
nano	O
-	O
liposome	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
mixing	O
and	O
dissolving	O
resveratrol	B
,	O
a	O
film	O
material	O
,	O
an	O
antioxidant	O
and	O
an	O
organic	O
solvent	O
,	O
forming	O
a	O
film	O
and	O
removing	O
the	O
organic	O
solvent	O
at	O
the	O
same	O
time	O
,	O
and	O
then	O
adding	O
a	O
buffer	O
solution	O
to	O
hydrate	B
to	O
obtain	O
a	O
coarse	O
suspension	O
liquid	O
of	O
the	O
resveratrol	B
nano	O
-	O
liposome	O
,	O
and	O
carrying	O
out	O
high	O
-	O
pressure	O
microjet	O
treatment	O
on	O
the	O
coarse	O
suspension	O
liquid	O
to	O
obtain	O
the	O
resveratrol	B
nano	O
-	O
liposome	O
.	O

The	O
resveratrol	B
nano	O
-	O
liposome	O
is	O
prepared	O
through	O
the	O
steps	O
of	O
dissolving	O
,	O
lipid	O
forming	O
,	O
sufficient	O
hydrating	O
,	O
microjet	O
dispersing	O
and	O
other	O
steps	O
by	O
adopting	O
a	O
high	O
-	O
pressure	O
microjet	O
method	O
.	O

The	O
resveratrol	B
nano	O
-	O
liposome	O
is	O
uniform	O
and	O
consistent	O
,	O
small	O
in	O
grain	O
size	O
,	O
high	O
in	O
encapsulation	O
efficiency	O
,	O
and	O
good	O
in	O
stability	O
.	O

Resveratrol	B
nano	O
-	O
liposome	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
containing	O
a	O
granisetron	B
hydrochloride	I
compound	O
,	O
and	O
in	O
particular	O
to	O
a	O
freeze	O
-	O
dried	O
injection	O
preparation	O
of	O
granisetron	B
hydrochloride	I
and	O
a	O
preparation	O
method	O
thereof	O
.	O

For	O
every	O
1000	O
injections	O
,	O
the	O
pharmaceutical	O
composition	O
comprises	O
the	O
following	O
components	O
:	O
3	O
g	O
of	O
granisetron	B
hydrochloride	I
,	O
100	O
-	O
200	O
g	O
of	O
mannitol	B
,	O
1	O
-	O
3	O
g	O
of	O
sodium	B
hydroxide	I
,	O
1	O
-	O
2	O
g	O
of	O
vitamin	B
C	I
,	O
and	O
2000ml	O
of	O
sodium	B
hydrogencitrate	I
and	O
trisodium	B
citrate	I
buffer	O
liquor	O
with	O
molar	O
ratio	O
of	O
1:4	O
.	O

Pharmaceutical	O
composition	O
containing	O
granisetron	B
hydrochloride	I
compound	O

The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicine	O
,	O
and	O
particularly	O
relates	O
to	O
a	O
compound	O
Chinese	O
patent	O
drug	O
for	O
treating	O
a	O
primary	O
liver	O
cancer	O
,	O
and	O
an	O
administration	O
method	O
of	O
the	O
compound	O
Chinese	O
patent	O
drug	O
.	O

The	O
primary	O
liver	O
cancer	O
is	O
one	O
of	O
the	O
common	O
malignant	O
tumors	O
in	O
China	O
.	O

The	O
compound	O
Chinese	O
patent	O
drug	O
adopts	O
13	O
medicinal	O
materials	O
for	O
compounding	O
,	O
can	O
eliminate	O
pathogens	O
,	O
strengthen	O
body	O
resistance	O
,	O
promote	O
blood	O
circulation	O
,	O
stop	O
bleeding	O
and	O
treat	O
a	O
liver	O
and	O
a	O
spleen	O
,	O
and	O
treats	O
the	O
primary	O
liver	O
cancer	O
by	O
integrating	O
external	O
treatment	O
and	O
internal	O
treatment	O
.	O

The	O
compound	O
Chinese	O
patent	O
drug	O
adopts	O
the	O
technical	O
scheme	O
that	O
the	O
following	O
medicinal	O
materials	O
and	O
matching	O
ratio	O
are	O
adopted	O
,	O
and	O
the	O
13	O
medicinal	O
materials	O
are	O
porphyrized	O
and	O
uniformly	O
mixed	O
into	O
powder	O
according	O
to	O
the	O
matching	O
ratio	O
.	O

The	O
1.5	O
-	O
2	O
g	O
liver	O
benefiting	O
powder	O
is	O
taken	O
directly	O
with	O
warm	O
water	O
at	O
each	O
time	O
for	O
2	O
-	O
3	O
times	O
per	O
day	O
.	O

External	O
application	O
treatment	O
is	O
conducted	O
as	O
follows	O
:	O
realgar	O
is	O
placed	O
in	O
an	O
abdomen	O
of	O
a	O
live	O
toad	O
(	O
with	O
viscera	O
being	O
removed	O
)	O
,	O
warm	O
water	O
is	O
added	O
to	O
prepare	O
paste	O
,	O
and	O
then	O
the	O
toad	O
is	O
externally	O
applied	O
at	O
a	O
hepatic	O
region	O
for	O
twice	O
per	O
day	O
.	O

Liver	O
benefiting	O
powder	O

The	O
invention	O
relates	O
to	O
a	O
compound	O
solid	O
preparation	O
containing	O
tranexamic	B
acid	I
.	O

The	O
compound	O
oral	O
solid	O
preparation	O
containing	O
the	O
tranexamic	B
acid	I
is	O
prepared	O
from	O
the	O
tranexamic	B
acid	I
serving	O
as	O
a	O
main	O
active	O
ingredient	O
,	O
other	O
active	O
ingredients	O
and	O
pharmaceutically	O
acceptable	O
auxiliary	O
materials	O
by	O
a	O
preparation	O
technology	O
.	O

The	O
compound	O
solid	O
preparation	O
containing	O
the	O
tranexamic	B
acid	I
is	O
stable	O
and	O
controllable	O
in	O
quality	O
,	O
safe	O
and	O
effective	O
.	O

Compound	O
solid	O
preparation	O
containing	O
tranexamic	B
acid	I

The	O
invention	O
belongs	O
to	O
the	O
chemical	O
medicine	O
technical	O
field	O
,	O
and	O
especially	O
relates	O
to	O
a	O
bifendate	B
derivative	O
,	O
a	O
preparation	O
method	O
and	O
an	O
application	O
of	O
the	O
bifendate	B
derivative	O
for	O
treating	O
autoimmune	O
disease	O
.	O

A	O
structure	O
of	O
the	O
bifendate	B
derivative	O
is	O
shown	O
as	O
a	O
formula	O
I	O
,	O
and	O
has	O
good	O
effects	O
for	O
inhibiting	O
autoimmune	O
diseases	O
such	O
as	O
acute	O
hepatitis	O
,	O
chronic	O
hepatic	O
fibrosis	O
and	O
pulmonary	O
fibrosis	O
,	O
and	O
the	O
bifendate	B
derivative	O
provides	O
a	O
new	O
choice	O
for	O
medicines	O
exploitation	O
for	O
treating	O
the	O
diseases	O
.	O

Bifendate	B
derivative	O
,	O
preparation	O
method	O
and	O
application	O
of	O
bifendate	B
derivative	O
for	O
treating	O
autoimmune	O
disease	O

The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
medicinal	O
chemistry	O
and	O
in	O
particular	O
relates	O
to	O
an	O
imidazole	B
[	I
4,5-c	I
]	I
pyridine-7-methanamide	I
derivative	O
(	O
I	O
)	O
,	O
wherein	O
R	O
is	O
defined	O
in	O
the	O
specification	O
.	O

Pharmacodynamic	O
tests	O
proof	O
that	O
the	O
derivative	O
compound	O
provided	O
by	O
the	O
invention	O
can	O
serve	O
as	O
a	O
tumour	O
therapeutic	O
agent	O
and	O
especially	O
the	O
derivative	O
compound	O
has	O
extremely	O
strong	O
anti	O
-	O
tumour	O
effect	O
when	O
being	O
combined	O
with	O
cis	B
-	I
platinum	I
.	O

The	O
invention	O
also	O
discloses	O
a	O
preparation	O
method	O
of	O
the	O
derivative	O
compound	O
and	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
derivative	O
compound	O
.	O

Imidazole	B
[	I
4,5-c	I
]	I
pyridine-7-methanamide	I
derivative	O
as	O
well	O
as	O
preparation	O
method	O
and	O
medical	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
compound	O
of	O
an	O
inhibitor	O
for	O
hepatitis	O
C	O
virus	O
.	O

In	O
addition	O
,	O
the	O
invention	O
describes	O
a	O
pharmaceutical	O
composition	O
containing	O
the	O
compound	O
and	O
application	O
of	O
the	O
inhibitor	O
to	O
the	O
treatment	O
of	O
hepatitis	O
C	O
virus	O
infection	O
.	O

Thiophene	B
derivative	O
and	O
application	O
thereof	O
to	O
medicine	O

The	O
invention	O
provides	O
a	O
medicinal	O
composition	O
including	O
active	O
components	O
of	O
repaglinide	B
and	O
metformin	B
hydrochloride	I
,	O
and	O
its	O
preparation	O
method	O
.	O

The	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
carrying	O
out	O
hot	O
melting	O
granulation	O
of	O
metformin	B
hydrochloride	I
to	O
prepare	O
particles	O
,	O
directly	O
spraying	O
a	O
repaglinide	O
solution	O
on	O
the	O
metformin	B
hydrochloride	I
particles	O
through	O
a	O
one	O
-	O
step	O
granulation	O
technology	O
,	O
and	O
adding	O
parts	O
of	O
auxiliary	O
materials	O
to	O
prepare	O
a	O
tablet	O
.	O

Repaglinide	B
and	O
metformin	B
hydrochloride	I
medicinal	O
composition	O
and	O
its	O
preparation	O
method	O

A	O
medicine	O
composition	O
for	O
treating	O
mental	O
disorder	O
is	O
formed	O
by	O
combining	O
active	O
components	O
with	O
pharmaceutical	O
acceptable	O
auxiliary	O
materials	O
,	O
wherein	O
the	O
active	O
components	O
adopt	O
ecitalopram	B
(	O
salt	O
)	O
and	O
olanzapine	B
(	O
salt	O
)	O
.	O

Oral	O
preparations	O
,	O
such	O
as	O
tablets	O
,	O
capsules	O
,	O
soft	O
capsules	O
,	O
chewable	O
tablets	O
,	O
orally	O
disintegration	O
tablets	O
,	O
buccal	O
tablets	O
,	O
pill	O
and	O
the	O
like	O
,	O
can	O
be	O
produced	O
through	O
certain	O
preparation	O
techniques	O
.	O

The	O
composition	O
is	O
used	O
for	O
treating	O
the	O
mental	O
disorder	O
,	O
such	O
as	O
depression	O
,	O
insomnia	O
,	O
anxiety	O
,	O
schizophrenia	O
and	O
the	O
like	O
.	O

Medicine	O
composition	O
for	O
treating	O
mental	O
disorder	O

The	O
invention	O
discloses	O
compositions	O
with	O
anti	O
-	O
Japanese	O
-	O
encephalitis	O
-	O
virus	O
functions	O
,	O
and	O
applications	O
thereof	O
in	O
preparing	O
medicine	O
used	O
for	O
preventing	O
and/or	O
treating	O
Japanese	O
encephalitis	O
virus	O
infections	O
.	O

The	O
compositions	O
comprise	O
a	O
N-	B
(	I
2-thiazolyl	I
)	I
benzamide	I
compound	O
represented	O
by	O
the	O
formula	O
A	O
,	O
and	O
trehalose	B
or	O
Huangqi	O
Shengmai	O
Yin	O
.	O

R1	O
is	O
OH	B
,	O
OCOCH3	B
,	O
OCOC2H5	B
,	O
OCOCH2CH2CH3	B
or	O
OCOCH	B
(	I
CH3	I
)	I
2	I
;	O
R2	O
,	O
R3	O
,	O
and	O
R4	O
are	O
independently	O
H	B
or	O
C1-C3	B
alkyl	I
;	O
R5	O
is	O
halogen	B
,	O
nitro	B
,	O
or	O
C1-C3	O
of	O
the	O
alkylsulfonyl	B
;	O
and	O
R6	O
is	O
H	B
or	O
C1-C3	B
alkylsulfonyl	I
.	O

The	O
composition	O
provided	O
by	O
the	O
invention	O
can	O
effectively	O
inhibit	O
Japanese	O
encephalitis	O
virus	O
proliferation	O
.	O

Anti	O
-	O
Japanese	O
-	O
encephalitis	O
-	O
virus	O
-	O
infection	O
compositions	O
and	O
applications	O
thereof	O

The	O
invention	O
discloses	O
a	O
compound	O
preparation	O
for	O
reducing	O
the	O
concentration	O
of	O
uric	B
acid	I
in	O
the	O
blood	O
to	O
treat	O
gout	O
,	O
and	O
concretely	O
discloses	O
a	O
compound	O
Caulis	O
Sinomenii	O
tablet	O
.	O

The	O
tablet	O
is	O
characterized	O
in	O
that	O
the	O
components	O
of	O
the	O
tablet	O
and	O
the	O
proportions	O
of	O
the	O
components	O
are	O
shown	O
in	O
the	O
specification	O
,	O
and	O
eight	O
medicines	O
which	O
are	O
the	O
components	O
are	O
mixed	O
according	O
to	O
the	O
proportions	O
to	O
prepare	O
the	O
tablet	O
or	O
a	O
pill	O
.	O

0.5	O
-	O
1.0	O
g	O
of	O
the	O
tablet	O
or	O
the	O
pill	O
is	O
orally	O
taken	O
each	O
time	O
,	O
and	O
is	O
continuously	O
taken	O
three	O
times	O
a	O
day	O
after	O
each	O
meal	O
for	O
2	O
-	O
3	O
weeks	O
.	O

Compound	O
Caulis	O
Sinomenii	O
tablet	O

The	O
invention	O
discloses	O
a	O
medicinal	O
composite	O
for	O
treating	O
Alzheimer	O
's	O
disease	O
.	O

The	O
medicinal	O
composite	O
for	O
treating	O
the	O
Alzheimer	O
's	O
disease	O
comprises	O
procyanidine	B
and	O
cysteine	B
,	O
wherein	O
the	O
mass	O
ratio	O
of	O
the	O
procyanidine	B
to	O
the	O
cysteine	B
is	O
(	O
0.1	O
-	O
10	O
)	O
:1	O
,	O
preferably	O
(	O
1	O
-	O
3	O
)	O
:1	O
;	O
and	O
the	O
procyanidine	B
is	O
preferably	O
lotus	O
procyanidine	B
.	O

The	O
medicinal	O
composite	O
for	O
treating	O
the	O
Alzheimer	O
's	O
disease	O
can	O
improve	O
the	O
oxidation	O
resistance	O
of	O
brain	O
tissue	O
,	O
avoid	O
free	O
radical	O
injury	O
to	O
the	O
brain	O
tissue	O
,	O
inhibit	O
MAO	O
-	O
B	O
and	O
AchE	O
activity	O
and	O
enhance	O
the	O
oxidation	O
resistance	O
of	O
brain	O
and	O
hippocampal	O
anti	O
-	O
oxidation	O
system	O
and	O
serum	O
so	O
as	O
to	O
improve	O
the	O
learning	O
and	O
memory	O
function	O
.	O

According	O
to	O
animal	O
tests	O
,	O
the	O
medicinal	O
composite	O
for	O
treating	O
the	O
Alzheimer	O
's	O
disease	O
can	O
effectively	O
improve	O
mouse	O
learning	O
and	O
memory	O
injury	O
induced	O
by	O
ethanol	B
and	O
scopolamine	B
,	O
and	O
the	O
curative	O
effect	O
is	O
more	O
excellent	O
than	O
that	O
of	O
piracetam	O
and	O
procyanidine	B
.	O

Medicinal	O
composite	O
for	O
treating	O
Alzheimer	O
's	O
disease	O

The	O
invention	O
relates	O
to	O
a	O
slow	O
-	O
release	O
composition	O
containing	O
L	B
-	I
milnacipran	I
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
composition	O
contains	O
the	O
L	B
-	I
milnacipran	I
serving	O
as	O
an	O
active	O
ingredient	O
or	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O

The	O
composition	O
is	O
characterized	O
by	O
also	O
comprising	O
high	O
-	O
viscosity	O
hydroxypropyl	O
methylcellulose	O
serving	O
as	O
a	O
hydrophilic	O
gel	O
slow	O
-	O
release	O
skeleton	O
material	O
and	O
acrylic	B
resin	O
serving	O
as	O
a	O
pH	O
adjustor	O
,	O
wherein	O
the	O
composition	O
comprises	O
the	O
following	O
components	O
in	O
parts	O
by	O
weight	O
:	O
10	O
to	O
70	O
parts	O
of	O
L	B
-	I
milnacipran	I
or	O
pharmaceutically	O
acceptable	O
salt	O
,	O
5	O
to	O
30	O
parts	O
of	O
hydroxypropyl	O
methylcellulose	O
,	O
and	O
3.5	O
to	O
7.5	O
parts	O
of	O
acrylic	B
resin	O
;	O
and	O
during	O
preparation	O
,	O
the	O
L	B
-	I
milnacipran	I
,	O
the	O
hydroxypropyl	O
methylcellulose	O
and	O
the	O
acrylic	B
resin	O
are	O
bound	O
to	O
be	O
mixed	O
uniformly	O
.	O

The	O
composition	O
can	O
realize	O
consistency	O
of	O
release	O
behaviors	O
in	O
artificial	O
gastric	O
juice	O
and	O
artificial	O
intestinal	O
juice	O
and	O
keep	O
12-hour	O
continuous	O
release	O
effect	O
,	O
and	O
is	O
low	O
in	O
preparation	O
loss	O
,	O
high	O
in	O
efficiency	O
,	O
high	O
in	O
stability	O
,	O
easy	O
to	O
operate	O
and	O
easy	O
to	O
popularize	O
.	O

Slow	O
-	O
release	O
composition	O
containing	O
L	B
-	I
milnacipran	I
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
provides	O
a	O
carboxylic	B
acid	I
derivative	O
compound	O
.	O

The	O
compound	O
as	O
shown	O
in	O
the	O
formula	O
(	O
I	O
)	O
or	O
the	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
provided	O
by	O
the	O
invention	O
not	O
only	O
can	O
reduce	O
the	O
level	O
of	O
triglyceride	B
in	O
high	O
fat	O
model	O
animal	O
blood	O
,	O
but	O
also	O
has	O
the	O
good	O
function	O
of	O
reducing	O
cholesterol	B
and	O
low	O
-	O
density	O
lipoprotein	O
and	O
the	O
effects	O
of	O
promoting	O
biliation	O
,	O
reducing	O
content	O
of	O
cholesterol	B
in	O
bile	O
and	O
increasing	O
the	O
content	O
of	O
bile	B
acid	I
,	O
and	O
also	O
has	O
the	O
effect	O
of	O
preventing	O
and	O
treating	O
gallstone	O
when	O
being	O
applied	O
to	O
a	O
golden	O
gopher	O
gallstone	O
model	O
.	O

The	O
particular	O
importance	O
is	O
that	O
the	O
compound	O
or	O
the	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
provided	O
by	O
the	O
invention	O
is	O
low	O
in	O
toxicity	O
.	O

Carboxylic	B
acid	I
derivative	O
compound	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
belongs	O
to	O
the	O
fields	O
of	O
chemical	O
industry	O
and	O
medicine	O
,	O
and	O
relates	O
to	O
application	O
of	O
isosteviol	O
lactone	O
in	O
preparation	O
of	O
antitumor	O
medicaments	O
.	O

In	O
the	O
application	O
of	O
the	O
isosteviol	O
lactone	O
in	O
preparation	O
of	O
antitumor	O
medicaments	O
,	O
tumor	O
cells	O
include	O
liver	O
cancer	O
cells	O
,	O
leukemia	O
cells	O
and	O
pancreatic	O
cancer	O
cells	O
.	O

The	O
isosteviol	O
lactone	O
belongs	O
to	O
a	O
natural	O
product	O
,	O
is	O
low	O
in	O
toxic	O
and	O
side	O
effect	O
,	O
high	O
in	O
bioavailability	O
and	O
stable	O
in	O
property	O
,	O
and	O
has	O
clinical	O
use	O
value	O
.	O

The	O
small	O
-	O
molecule	O
compound	O
provided	O
by	O
the	O
invention	O
can	O
be	O
developed	O
as	O
a	O
new	O
antitumor	O
medicament	O
or	O
an	O
auxiliary	O
component	O
thereof	O
,	O
has	O
remarkable	O
tumor	O
inhibition	O
effect	O
,	O
and	O
is	O
green	O
and	O
environment	O
-	O
friendly	O
,	O
thereby	O
providing	O
a	O
new	O
way	O
and	O
means	O
for	O
treating	O
and	O
curing	O
tumors	O
.	O

Application	O
of	O
isosteviol	O
lactone	O
in	O
preparation	O
of	O
antitumor	O
medicaments	O

The	O
invention	O
discloses	O
a	O
method	O
for	O
preparing	O
a	O
farrerol	B
solid	O
dispersion	O
,	O
and	O
the	O
method	O
relates	O
to	O
the	O
technical	O
field	O
of	O
pharmaceutical	O
preparations	O
and	O
is	O
used	O
for	O
solving	O
the	O
problems	O
of	O
low	O
dissolution	O
rate	O
,	O
incomplete	O
dissolution	O
and	O
low	O
bioavailability	O
of	O
farrerol	B
.	O

The	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
dissolving	O
the	O
farrerol	B
and	O
a	O
carrier	O
material	O
into	O
a	O
medicinal	O
organic	O
solvent	O
according	O
to	O
a	O
mass	O
ratio	O
of	O
(	O
1:1	O
)	O
-	O
(	O
1:12	O
)	O
so	O
as	O
to	O
form	O
a	O
transparent	O
solution	O
;	O
heating	O
the	O
organic	O
solvent	O
in	O
a	O
water	O
bath	O
of	O
50	O
-	O
80	O
DEG	O
C	O
,	O
vaporizing	O
the	O
organic	O
solvent	O
to	O
be	O
sticky	O
and	O
then	O
quickly	O
putting	O
the	O
organic	O
solvent	O
in	O
a	O
refrigerator	O
of	O
-20	O
DEG	O
C	O
to	O
be	O
solidified	O
for	O
3	O
-	O
5	O
hours	O
;	O
taking	O
the	O
solidified	O
organic	O
solvent	O
out	O
,	O
and	O
grinding	O
the	O
solidified	O
organic	O
solvent	O
into	O
small	O
particles	O
of	O
20	O
meshes	O
;	O
putting	O
the	O
small	O
particles	O
in	O
a	O
vacuum	O
drying	O
oven	O
for	O
12	O
-	O
24	O
hours	O
so	O
as	O
to	O
thoroughly	O
remove	O
the	O
residual	O
organic	O
solvent	O
;	O
taking	O
the	O
small	O
particles	O
out	O
,	O
finely	O
grinding	O
and	O
screening	O
the	O
small	O
particles	O
through	O
a	O
screen	O
of	O
80	O
meshes	O
and	O
putting	O
the	O
small	O
particles	O
in	O
a	O
drying	O
device	O
to	O
be	O
kept	O
in	O
dark	O
places	O
.	O

In	O
a	O
process	O
of	O
preparing	O
the	O
solid	O
dispersion	O
,	O
the	O
farrerol	B
is	O
uniformly	O
dispersed	O
into	O
the	O
water	O
-	O
soluble	O
carrier	O
,	O
so	O
that	O
the	O
water	O
solubility	O
,	O
dissolution	O
rate	O
,	O
bioavailability	O
and	O
therapeutic	O
effect	O
of	O
the	O
farrerol	B
are	O
improved	O
.	O

Method	O
for	O
preparing	O
farrerol	B
solid	O
dispersion	O

The	O
invention	O
discloses	O
an	O
application	O
of	O
Aphanamixoid	B
A	I
in	O
preparation	O
of	O
a	O
medicine	O
for	O
treating	O
liver	O
cancer	O
,	O
and	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
new	O
application	O
of	O
the	O
medicine	O
.	O

The	O
Aphanamixoid	B
A	I
has	O
outstanding	O
inhibiting	O
effect	O
on	O
the	O
growth	O
of	O
human	O
liver	O
cancer	O
cell	O
strains	O
HepG2	O
,	O
MHCC	O
-	O
LM3	O
,	O
Bel-7402	O
and	O
HuH-7	O
through	O
in	O
-	O
vitro	O
MTT	B
(	O
Methyl	B
Thiazolyl	I
Tetrazolium	I
)	O
antineoplastic	O
activity	O
evaluation	O
.	O

Thus	O
,	O
the	O
Aphanamixoid	B
A	I
can	O
be	O
used	O
for	O
preparing	O
the	O
medicine	O
for	O
resisting	O
the	O
liver	O
cancer	O
and	O
has	O
good	O
development	O
and	O
application	O
prospect	O
;	O
and	O
the	O
application	O
of	O
the	O
Aphanamixoid	B
A	I
in	O
preparing	O
the	O
medicine	O
for	O
treating	O
the	O
liver	O
cancer	O
is	O
firstly	O
disclosed	O
because	O
a	O
skeleton	O
type	O
belongs	O
to	O
a	O
fire	O
-	O
new	O
skeleton	O
type	O
and	O
the	O
inhibitory	O
activity	O
of	O
the	O
Aphanamixoid	B
A	I
on	O
liver	O
cancer	O
cells	O
is	O
inconceivably	O
high	O
.	O

Application	O
of	O
Aphanamixoid	B
A	I
in	O
medicine	O
for	O
treating	O
liver	O
cancer	O

The	O
invention	O
relates	O
to	O
a	O
composition	O
containing	O
high	O
purity	O
bilobalide	B
B.	I
The	O
composition	O
is	O
a	O
bilobalide	B
B	I
injection	O
which	O
comprises	O
the	O
following	O
medical	O
active	O
components	O
in	O
parts	O
by	O
weight	O
:	O
20	O
parts	O
of	O
bilobalide	B
B	I
extract	O
,	O
580	O
-	O
630	O
parts	O
of	O
polyethylene	B
glycol-400	I
,	O
770	O
-	O
830	O
parts	O
of	O
glycerol	B
and	O
640	O
-	O
700	O
parts	O
of	O
ethanol	B
.	O

The	O
bilobalide	B
B	I
extract	O
is	O
extracted	O
from	O
ginkgo	O
leaves	O
and	O
contains	O
bilobalide	B
B	I
and	O
bilobalide	B
A	I
'	I
.	O

The	O
content	O
of	O
bilobalide	B
B	I
is	O
greater	O
than	O
99	O
%	O
,	O
and	O
the	O
content	O
of	O
the	O
bilobalide	B
A	I
'	I
is	O
less	O
than	O
0.4	O
%	O
.	O

In	O
the	O
bilobalide	B
B	I
composition	O
provided	O
by	O
the	O
invention	O
,	O
purity	O
of	O
bilobalide	B
B	I
in	O
the	O
bilobalide	B
B	I
extract	O
as	O
a	O
raw	O
material	O
medicine	O
is	O
high	O
,	O
and	O
the	O
content	O
of	O
the	O
bilobalide	B
A'is	I
extremely	O
low	O
,	O
so	O
that	O
the	O
demand	O
of	O
injection	O
to	O
the	O
raw	O
material	O
medicine	O
is	O
met	O
,	O
and	O
the	O
bioavailability	O
of	O
the	O
raw	O
material	O
medicine	O
and	O
the	O
medication	O
safety	O
of	O
patients	O
are	O
improved	O
.	O

Composition	O
containing	O
high	O
purity	O
bilobalide	B
B	I
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
composition	O
taking	O
high	O
-	O
purity	O
ginkgolide	B
B	I
as	O
an	O
active	O
ingredient	O
.	O

The	O
composition	O
is	O
a	O
ginkgolide	B
B	I
injection	O
.	O

The	O
ginkgolide	B
B	I
injection	O
comprises	O
the	O
following	O
pharmaceutical	O
active	O
ingredients	O
in	O
parts	O
by	O
weight	O
:	O
20	O
parts	O
of	O
ginkgolide	B
B	I
extract	O
,	O
580	O
-	O
630	O
parts	O
of	O
polyethylene	B
glycol-400	I
,	O
770	O
-	O
830	O
parts	O
of	O
glycerol	B
and	O
640	O
-	O
700	O
parts	O
of	O
ethanol	B
,	O
wherein	O
the	O
ginkgolide	B
B	I
extract	O
is	O
extracted	O
from	O
ginkgo	O
leaves	O
,	O
and	O
comprises	O
ginkgolide	B
B	I
and	O
ginkgolide	B
K	I
,	O
the	O
content	O
of	O
the	O
ginkgolide	B
B	I
is	O
more	O
than	O
99	O
%	O
,	O
and	O
the	O
content	O
of	O
the	O
ginkgolide	B
K	I
is	O
less	O
than	O
0.6	O
%	O
.	O

In	O
a	O
ginkgolide	B
B	I
composition	O
provided	O
by	O
the	O
invention	O
,	O
the	O
ginkgolide	B
B	I
in	O
the	O
ginkgolide	B
B	I
extract	O
as	O
a	O
raw	O
medicine	O
has	O
a	O
high	O
purity	O
,	O
and	O
the	O
content	O
of	O
the	O
ginkgolide	B
K	I
is	O
extremely	O
low	O
,	O
so	O
that	O
requirement	O
of	O
the	O
injection	O
on	O
the	O
raw	O
medicine	O
is	O
met	O
and	O
the	O
bioavailability	O
of	O
the	O
raw	O
medicine	O
and	O
the	O
medication	O
safety	O
of	O
patients	O
are	O
improved	O
.	O

Composition	O
taking	O
high	O
-	O
purity	O
ginkgolide	B
B	I
as	O
active	O
ingredient	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
calcitriol	B
powder	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
powder	O
is	O
prepared	O
from	O
the	O
following	O
ingredients	O
in	O
percentage	O
by	O
weight	O
:	O
0.0005	O
%	O
of	O
calcitriol	B
,	O
2.0	O
-	O
7.0	O
%	O
of	O
meglumine	B
,	O
2	O
-	O
4	O
%	O
of	O
polyethylene	B
glycol	I
400	I
,	O
20	O
-	O
30	O
%	O
of	O
polyethylene	B
glycol	I
6000	I
,	O
50.0	O
-	O
70.0	O
%	O
of	O
filler	O
and	O
an	O
appropriate	O
amount	O
of	O
lubricant	O
.	O

According	O
to	O
the	O
powder	O
,	O
the	O
content	O
of	O
calcitriol	B
is	O
remarkably	O
increased	O
,	O
so	O
that	O
the	O
drug	O
dosage	O
is	O
reduced	O
;	O
and	O
the	O
stability	O
of	O
calcitriol	B
to	O
light	O
and	O
air	O
is	O
improved	O
,	O
and	O
the	O
bioavailability	O
of	O
calcitriol	B
is	O
also	O
remarkably	O
improved	O
.	O

Calcitriol	B
powder	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
an	O
application	O
of	O
barbaloin	B
in	O
preparing	O
medicines	O
or	O
cosmetics	O
for	O
preventing	O
or	O
treating	O
acne	O
caused	O
by	O
propionibacterium	O
acne	O
breeding	O
.	O

The	O
invention	O
discloses	O
the	O
medicines	O
or	O
cosmetics	O
which	O
contain	O
the	O
barbaloin	B
which	O
can	O
effectively	O
treat	O
the	O
acne	O
generation	O
caused	O
by	O
propionibacterium	O
acne	O
breeding	O
.	O

Application	O
of	O
barbaloin	B

The	O
invention	O
discloses	O
an	O
ipecacuanha	O
effective	O
component	O
composition	O
,	O
its	O
preparation	O
method	O
and	O
application	O
.	O

The	O
composition	O
contains	O
cephaeline	B
and	O
emetine	B
that	O
are	O
in	O
a	O
weight	O
ratio	O
of	O
1	O
-	O
2:1	O
.	O

The	O
preparation	O
method	O
of	O
the	O
ipecacuanha	O
effective	O
component	O
composition	O
comprises	O
:	O
taking	O
ipecacuanha	O
medicinal	O
materials	O
with	O
different	O
producing	O
areas	O
and/or	O
different	O
batches	O
,	O
mixing	O
them	O
in	O
proportion	O
to	O
prepare	O
an	O
extract	O
,	O
a	O
fluid	O
extract	O
or	O
a	O
tincture	O
,	O
or	O
conducting	O
extraction	O
on	O
the	O
ipecacuanha	O
medicinal	O
materials	O
with	O
different	O
producing	O
areas	O
and/or	O
different	O
batches	O
to	O
prepare	O
extracts	O
,	O
performing	O
mixing	O
in	O
proportion	O
,	O
and	O
then	O
making	O
the	O
mixture	O
into	O
an	O
extract	O
,	O
a	O
fluid	O
extract	O
or	O
a	O
tincture	O
.	O

Based	O
on	O
the	O
pharmacological	O
and	O
pharmacokinetic	O
differences	O
of	O
emetine	B
and	O
cephaeline	B
,	O
screening	O
research	O
on	O
cough	O
relieving	O
and	O
sputum	O
reducing	O
effect	O
differences	O
caused	O
by	O
different	O
proportions	O
of	O
emetine	B
and	O
cephaeline	B
is	O
carried	O
out	O
,	O
and	O
a	O
good	O
emetine	B
and	O
cephaeline	B
combination	O
region	O
for	O
ideal	O
cough	O
relieving	O
and	O
sputum	O
reducing	O
effects	O
can	O
be	O
determined	O
.	O

Ipecacuanha	O
effective	O
component	O
composition	O
,	O
its	O
preparation	O
method	O
and	O
application	O

Provided	O
are	O
compounds	O
having	O
an	O
inhibitory	O
effect	O
on	O
kinases	O
including	O
Mixed	O
Lineage	O
Kinases	O
.	O

Also	O
provided	O
are	O
pharmaceutical	O
compositions	O
,	O
methods	O
of	O
preparing	O
the	O
compounds	O
,	O
synthetic	O
intermediates	O
,	O
and	O
methods	O
of	O
using	O
the	O
compounds	O
,	O
independently	O
or	O
in	O
combination	O
with	O
other	O
therapeutic	O
agents	O
,	O
for	O
treating	O
diseases	O
and	O
conditions	O
that	O
are	O
affected	O
by	O
Mixed	O
Lineage	O
Kinase	O
inhibition	O
.	O

Also	O
provided	O
are	O
methods	O
of	O
treatment	O
of	O
neuropsychiatric	O
disorders	O
that	O
comprise	O
the	O
inhibition	O
of	O
Mixed	O
Lineage	O
Kinases	O
.	O

Bicyclic	B
heteroaryl	I
kinase	O
inhibitors	O
and	O
methods	O
of	O
use	O

The	O
invention	O
discloses	O
kidney	O
bean	O
phytolectin	O
applications	O
in	O
preparation	O
of	O
human	O
drugs	O
and	O
a	O
drug	O
composition	O
,	O
and	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
drugs	O
.	O

Kidney	O
bean	O
phytolectins	O
are	O
used	O
as	O
active	O
components	O
for	O
preparing	O
drugs	O
used	O
for	O
adding	O
lactobacillus	O
amounts	O
in	O
woman	O
vaginas	O
.	O

The	O
drug	O
composition	O
adopts	O
the	O
kidney	O
bean	O
phytolectins	O
,	O
tremella	O
polysaccharide	O
,	O
stachyose	B
or	O
/	O
and	O
raffinose	B
and	O
bletilla	O
gum	O
,	O
or	O
added	O
scutellaria	O
,	O
Hollygreen	O
Barberry	O
and	O
matrine	O
extraction	O
as	O
the	O
active	O
components	O
.	O

The	O
drug	O
composition	O
comprises	O
relative	O
weight	O
parts	O
of	O
that	O
0.5	O
-	O
1.0	O
part	O
of	O
the	O
kidney	O
bean	O
phytolectins	O
,	O
1.5	O
-	O
3.0	O
parts	O
of	O
the	O
tremella	O
polysaccharide	O
,	O
0.2	O
-	O
2.0	O
parts	O
of	O
the	O
stachyose	B
or	O
/	O
and	O
raffinose	B
,	O
0.2	O
-	O
0.5	O
part	O
of	O
the	O
bletilla	O
gum	O
and	O
1.0	O
-	O
3.0	O
parts	O
of	O
the	O
extraction	O
of	O
one	O
kind	O
or	O
more	O
than	O
one	O
kind	O
of	O
scutellaria	O
dry	O
powder	O
,	O
Hollygreen	O
Barberry	O
dry	O
powder	O
and	O
matrine	O
dry	O
powder	O
.	O

The	O
kidney	O
bean	O
phytolectin	O
applications	O
in	O
preparation	O
of	O
people	O
use	O
drugs	O
and	O
the	O
drug	O
composition	O
can	O
be	O
water	O
-	O
soluble	O
complex	O
liquid	O
and	O
is	O
best	O
to	O
be	O
gel	O
,	O
and	O
also	O
can	O
be	O
solid	O
dosage	O
forms	O
such	O
as	O
suppository	O
,	O
disintegrating	O
tablets	O
and	O
the	O
like	O
which	O
are	O
drug	O
dosage	O
forms	O
suitable	O
for	O
external	O
uses	O
.	O

Compared	O
with	O
the	O
prior	O
art	O
,	O
obtained	O
products	O
do	O
not	O
need	O
to	O
be	O
preserved	O
in	O
a	O
low	O
temperature	O
and	O
is	O
long	O
in	O
storage	O
time	O
and	O
convenient	O
to	O
use	O
.	O

Kidney	O
bean	O
phytolectin	O
applications	O
in	O
preparation	O
of	O
human	O
drugs	O
and	O
drug	O
composition	O
thereof	O

The	O
invention	O
provides	O
a	O
vidarabine	B
monophosphate	I
injection	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
injection	O
is	O
prepared	O
from	O
the	O
following	O
raw	O
materials	O
by	O
weight	O
:	O
50	O
-	O
200	O
parts	O
of	O
vidarabine	B
monophosphate	I
,	O
0.015	O
-	O
0.05	O
part	O
of	O
a	O
pH	O
regulator	O
and	O
2000	O
parts	O
of	O
water	O
for	O
injection	O
.	O

A	O
finished	O
product	O
prepared	O
by	O
the	O
method	O
provided	O
by	O
the	O
invention	O
has	O
low	O
impurity	O
content	O
,	O
good	O
homogeneity	O
and	O
good	O
stability	O
.	O

A	O
water	O
injection	O
is	O
subjected	O
to	O
terminal	O
sterilization	O
to	O
ensure	O
the	O
safety	O
of	O
the	O
product	O
.	O

The	O
water	O
injection	O
is	O
convenient	O
to	O
use	O
,	O
and	O
does	O
not	O
need	O
to	O
be	O
prepared	O
before	O
clinical	O
application	O
,	O
so	O
as	O
to	O
reduce	O
the	O
potential	O
safety	O
hazard	O
caused	O
by	O
operation	O
and	O
provide	O
a	O
new	O
choice	O
of	O
medication	O
for	O
clinical	O
use	O
.	O

Vidarabine	B
monophosphate	I
injection	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
provides	O
an	O
application	O
of	O
a	O
terpenoid	B
to	O
preparation	O
of	O
an	O
anticoagulation	O
drug	O
.	O

The	O
terpenoid	B
has	O
a	O
structural	O
formula	O
I	O
which	O
is	O
as	O
shown	O
in	O
the	O
description	O
,	O
wherein	O
R1	O
represents	O
H	B
,	O
C1-C5	O
linear	O
alkyl	B
,	O
glycosyl	B
or	O
a	O
formula	O
which	O
is	O
as	O
shown	O
in	O
the	O
description	O
,	O
and	O
R2	O
is	O
selected	O
from	O
C1-C4	O
linear	O
alkyl	B
.	O

According	O
to	O
the	O
application	O
of	O
the	O
terpenoid	B
,	O
an	O
ionane	O
type	O
sesquiterpene	B
compound	O
separated	O
and	O
obtained	O
from	O
leonurus	O
for	O
the	O
first	O
time	O
can	O
obviously	O
inhibit	O
the	O
platelet	O
aggregation	O
in	O
vitro	O
and	O
has	O
extension	O
tendencies	O
to	O
prothrombin	O
time	O
(	O
PT	O
)	O
,	O
activated	O
partial	O
thromboplastin	O
time	O
(	O
APTT	O
)	O
and	O
thrombin	O
time	O
(	O
TT	O
)	O
and	O
has	O
a	O
certain	O
anticoagulation	O
activity	O
,	O
so	O
that	O
a	O
new	O
choice	O
is	O
provided	O
for	O
the	O
development	O
of	O
natural	O
anti	O
-	O
thrombus	O
drugs	O
.	O

Application	O
of	O
terpenoid	B

The	O
invention	O
discloses	O
an	O
imatinib	B
mesylate	I
tablet	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
imatinib	B
mesylate	I
tablet	O
comprises	O
8	O
-	O
30	O
%	O
of	O
crospovidone	B
and	O
8	O
to	O
40	O
%	O
of	O
silica	B
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
carrying	O
out	O
granulation	O
of	O
imatinib	B
mesylate	I
and	O
a	O
waterless	O
organic	O
solvent	O
,	O
drying	O
the	O
granules	O
,	O
uniformly	O
mixing	O
the	O
granules	O
,	O
crospovidone	B
,	O
silica	B
,	O
a	O
filler	O
and	O
a	O
lubricant	O
,	O
and	O
carrying	O
out	O
tabletting	O
.	O

The	O
preparation	O
method	O
solves	O
the	O
problem	O
of	O
a	O
slow	O
dissolution	O
rate	O
of	O
a	O
preparation	O
obtained	O
by	O
the	O
prior	O
art	O
.	O

Imatinib	B
mesylate	I
tablet	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
belongs	O
to	O
the	O
field	O
of	O
pharmaceutical	O
preparations	O
and	O
particularly	O
relates	O
to	O
a	O
compound	O
preparation	O
which	O
takes	O
ezetimibe	B
,	O
simvastatin	B
and	O
nicotinic	B
acid	I
as	O
effective	O
components	O
and	O
has	O
the	O
effects	O
of	O
reducing	O
blood	O
pressure	O
and	O
blood	O
lipid	O
and	O
a	O
preparation	O
method	O
of	O
the	O
compound	O
preparation	O
.	O

The	O
compound	O
preparation	O
is	O
a	O
sustained	O
release	O
tablet	O
.	O

Aiming	O
at	O
the	O
problems	O
of	O
poor	O
water	O
solubility	O
of	O
the	O
ezetimibe	B
,	O
unstability	O
of	O
the	O
simvastatin	B
to	O
acid	O
and	O
oxygen	B
,	O
and	O
the	O
like	O
,	O
the	O
preparation	O
method	O
of	O
the	O
compound	O
preparation	O
adopts	O
a	O
melt	O
extrusion	O
technology	O
for	O
improving	O
the	O
dissolution	O
rate	O
of	O
the	O
ezetimibe	B
,	O
and	O
adopts	O
a	O
cladding	O
membrane	O
technology	O
for	O
enhancing	O
the	O
stability	O
of	O
the	O
simvastatin	B
in	O
a	O
body	O
so	O
as	O
to	O
give	O
full	O
play	O
to	O
the	O
efficacy	O
of	O
all	O
components	O
of	O
the	O
compound	O
preparation	O
and	O
have	O
the	O
best	O
synergy	O
effect	O
.	O

The	O
specific	O
process	O
comprises	O
the	O
steps	O
of	O
preparing	O
the	O
nicotinic	B
acid	I
into	O
a	O
tablet	O
core	O
as	O
a	O
sustained	O
release	O
part	O
,	O
spraying	O
an	O
isolating	O
layer	O
on	O
the	O
tablet	O
core	O
,	O
then	O
spraying	O
the	O
simvastatin	B
and	O
the	O
ezetimibe	B
on	O
an	O
outer	O
layer	O
of	O
the	O
sustained	O
release	O
part	O
as	O
a	O
quick	O
release	O
layer	O
,	O
and	O
then	O
carrying	O
out	O
film	O
coating	O
on	O
the	O
quick	O
release	O
layer	O
.	O

The	O
compound	O
preparation	O
provided	O
by	O
the	O
invention	O
is	O
mainly	O
applied	O
to	O
the	O
treatment	O
or	O
prevention	O
of	O
diseases	O
and	O
indications	O
associated	O
with	O
heart	O
and	O
cerebral	O
vessels	O
.	O

Ezetimibe	B
,	O
simvastatin	B
and	O
nicotinic	B
acid	I
compound	O
preparation	O
and	O
preparation	O
method	O
of	O
ezetimibe	B
,	O
simvastatin	B
and	O
nicotinic	B
acid	I
compound	O
preparation	O

The	O
invention	O
discloses	O
an	O
enrofloxacin	B
clathrate	O
compound	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
enrofloxacin	B
clathrate	O
compound	O
is	O
prepared	O
by	O
taking	O
enrofloxacin	B
and	O
fenugreek	O
as	O
raw	O
materials	O
,	O
performing	O
clathration	B
treatment	O
on	O
auxiliary	O
materials	O
such	O
as	O
a	O
slow	O
release	O
formulation	O
,	O
a	O
flavoring	O
agent	O
,	O
a	O
plasticizer	O
,	O
a	O
curing	O
agent	O
and	O
a	O
flocculant	O
,	O
and	O
drying	O
the	O
materials	O
.	O

The	O
enrofloxacin	B
clathrate	O
compound	O
has	O
the	O
advantages	O
that	O
the	O
delay	O
medicines	O
are	O
released	O
,	O
the	O
clinical	O
administration	O
frequency	O
is	O
reduced	O
,	O
the	O
product	O
stability	O
is	O
improved	O
and	O
the	O
palatability	O
of	O
the	O
medicines	O
is	O
improved	O
.	O

Enrofloxacin	B
clathrate	O
compound	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
a	O
2,6-diketone	B
-	I
piperazine	I
(	I
piperidine	I
)	I
type	O
derivative	O
and	O
an	O
application	O
thereof	O
.	O

The	O
derivative	O
can	O
be	O
applied	O
to	O
preparation	O
of	O
medicines	O
for	O
preventing	O
or	O
treating	O
central	O
nervous	O
system	O
diseases	O
.	O

Animal	O
experiment	O
results	O
show	O
that	O
the	O
derivative	O
has	O
smaller	O
ED50	O
and	O
stronger	O
action	O
in	O
MK-801-induced	O
high	O
activity	O
and	O
apomorphine	B
-	O
induced	O
climbing	O
animal	O
models	O
as	O
well	O
as	O
has	O
larger	O
ED50	O
and	O
larger	O
therapeutic	O
indexes	O
in	O
an	O
animal	O
catalepsy	O
model	O
.	O

The	O
derivative	O
is	O
a	O
compound	O
or	O
salt	O
thereof	O
with	O
a	O
general	O
formula	O
(	O
I	O
)	O
.	O

2,6-diketone	B
-	I
piperazine	I
(	I
piperidine	I
)	I
type	O
derivative	O
and	O
application	O
thereof	O

The	O
present	O
invention	O
discloses	O
an	O
application	O
of	O
ampelopsin	B
in	O
preparation	O
of	O
mutation	O
resistance	O
health	O
food	O
or	O
drugs	O
,	O
wherein	O
purified	O
ampelopsin	B
or	O
an	O
unpurified	O
extract	O
containing	O
ampelopsin	B
can	O
be	O
adopted	O
to	O
prepare	O
into	O
a	O
pharmaceutically	O
acceptable	O
oral	O
formulation	O
,	O
a	O
pharmaceutically	O
acceptable	O
injection	O
formulation	O
or	O
a	O
pharmaceutically	O
acceptable	O
external	O
application	O
formulation	O
.	O

Application	O
of	O
ampelopsin	B
in	O
mutation	O
resistance	O
composition	O
preparation	O

The	O
invention	O
relates	O
to	O
drug	O
application	O
of	O
an	O
organic	O
compound	O
and	O
in	O
particular	O
relates	O
to	O
application	O
of	O
5,7,3',4',5'-pentamethoxyl	O
flavone	O
in	O
preparing	O
analgesic	O
and	O
anti	O
-	O
inflammatory	O
drugs	O
.	O

According	O
to	O
the	O
pharmacological	O
experiment	O
results	O
,	O
the	O
compound	O
has	O
better	O
inbibitional	O
effect	O
for	O
pains	O
and	O
inflammations	O
,	O
and	O
can	O
be	O
used	O
as	O
an	O
active	O
ingredient	O
for	O
preventing	O
and	O
treating	O
diseases	O
including	O
rheumatic	O
arthritis	O
,	O
rheumatoid	O
arthritis	O
and	O
the	O
like	O
.	O

Application	O
of	O
5,7,3',4',5'-pentamethoxyl	O
flavone	O
in	O
preparing	O
analgesic	O
and	O
anti	O
-	O
inflammatory	O
drugs	O

The	O
invention	O
relates	O
to	O
a	O
pleuromutilin	B
expansion	O
ring	O
derivative	O
shown	O
in	O
a	O
structural	O
general	O
formula	O
(	O
I	O
)	O
,	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O
.	O

A	O
novel	O
expansion	O
ring	O
pleuromutilin	B
compound	O
is	O
synthetized	O
by	O
rearrangement	O
reaction	O
.	O

The	O
compound	O
can	O
be	O
used	O
for	O
synthesizing	O
a	O
new	O
pleuromutilin	B
derivative	O
and	O
preparing	O
an	O
antibacterial	O
agent	O
.	O

Pleuromutilin	B
expansion	O
ring	O
derivative	O
,	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
topical	O
ointment	O
for	O
treating	O
furunculosis	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
topical	O
ointment	O
is	O
characterized	O
in	O
that	O
the	O
topical	O
ointment	O
is	O
made	O
from	O
the	O
following	O
raw	O
medicines	O
,	O
by	O
weight	O
,	O
17	O
-	O
23	O
parts	O
of	O
honeysuckles	O
,	O
8	O
-	O
12	O
parts	O
of	O
chrysanthemums	O
,	O
8	O
-	O
12	O
parts	O
of	O
scutellaria	O
baicalensis	O
,	O
8	O
-	O
12	O
parts	O
of	O
rheum	O
officinale	O
,	O
8	O
-	O
12	O
parts	O
of	O
fructus	O
forsythia	O
,	O
6	O
-	O
8	O
parts	O
of	O
Chinese	O
violets	O
,	O
6	O
-	O
8	O
parts	O
of	O
moutan	O
bark	O
,	O
6	O
-	O
8	O
parts	O
of	O
golden	O
cypress	O
,	O
6	O
-	O
8	O
parts	O
of	O
coptis	O
,	O
6	O
-	O
8	O
parts	O
of	O
radix	O
rehmanniae	O
,	O
6	O
-	O
8	O
parts	O
of	O
hematoxylon	O
,	O
6	O
-	O
8	O
parts	O
of	O
Chinese	O
angelica	O
,	O
4	O
-	O
6	O
parts	O
of	O
cape	O
jasmine	O
,	O
4	O
-	O
6	O
parts	O
of	O
notopterygium	O
roots	O
,	O
4	O
-	O
6	O
parts	O
of	O
flos	O
sophorae	O
,	O
4	O
-	O
6	O
parts	O
of	O
platycodon	O
grandiflorum	O
,	O
4	O
-	O
6	O
parts	O
of	O
Chinese	O
parsnip	O
roots	O
,	O
2	O
-	O
4	O
parts	O
of	O
smoked	O
plums	O
,	O
2	O
-	O
4	O
parts	O
of	O
plant	O
soot	O
and	O
0.8	O
-	O
1.2	O
parts	O
of	O
calomel	O
.	O

The	O
topical	O
ointment	O
is	O
advantaged	O
by	O
rapid	O
effects	O
,	O
significant	O
effects	O
and	O
simple	O
preparation	O
method	O
.	O

Through	O
clinical	O
verifications	O
,	O
the	O
cure	O
rate	O
of	O
the	O
topical	O
ointment	O
for	O
treating	O
furunculosis	O
is	O
100	O
%	O
.	O

[	O
0	O
]	O
Topical	O
ointment	O
for	O
treating	O
furunculosis	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
an	O
emulsifiable	O
paste	O
for	O
diminishing	O
inflammation	O
and	O
easing	O
pain	O
.	O

The	O
emulsifiable	O
paste	O
comprises	O
geniposide	B
,	O
isopropyl	B
myristate	I
,	O
caprylic	B
/	I
capric	I
triglyceride	I
and	O
polyoxyethylene	B
ether	I
40	I
hydrogenated	O
castor	O
oil	O
.	O

In	O
the	O
emulsifiable	O
paste	O
disclosed	O
by	O
the	O
invention	O
,	O
isopropyl	B
myristate	I
is	O
used	O
as	O
a	O
novel	O
percutaneous	O
permeation	O
agent	O
for	O
geniposide	B
,	O
thus	O
greatly	O
increasing	O
the	O
permeation	O
amount	O
for	O
geniposide	B
.	O

The	O
emulsifiable	O
paste	O
disclosed	O
by	O
the	O
invention	O
is	O
excellent	O
in	O
performance	O
,	O
low	O
in	O
greasy	O
feeling	O
,	O
easy	O
to	O
coat	O
and	O
clean	O
,	O
and	O
good	O
in	O
heat	O
stability	O
.	O

High	O
-	O
permeability	O
emulsifiable	O
paste	O
for	O
diminishing	O
inflammation	O
and	O
easing	O
pain	O

The	O
invention	O
discloses	O
a	O
method	O
for	O
preparing	O
long	O
-	O
acting	O
terramycin	B
injection	O
by	O
utilizing	O
carbamide	B
and	O
sodium	B
bisulfite	I
in	O
a	O
combined	O
way	O
.	O

The	O
long	O
-	O
acting	O
terramycin	B
injection	O
comprises	O
the	O
following	O
raw	O
materials	O
in	O
parts	O
by	O
weight	O
:	O
10	O
-	O
15	O
parts	O
of	O
tetramycin	B
hydrochloride	I
,	O
4	O
-	O
5	O
parts	O
of	O
magnesium	B
chloride	I
,	O
2	O
-	O
3	O
parts	O
of	O
carbamide	B
,	O
0.5	O
-	O
0.8	O
part	O
of	O
sodium	B
thiosulfate	I
,	O
4	O
-	O
6	O
parts	O
of	O
ethanolamine	B
,	O
1	O
-	O
1.5	O
parts	O
of	O
sodium	B
bisulfite	I
,	O
50	O
-	O
60	O
parts	O
of	O
alpha	B
-	I
pyrrolidone	I
,	O
0.01	O
-	O
0.03	O
part	O
of	O
disodium	B
EDTA	I
and	O
100	O
-	O
150	O
parts	O
of	O
water	O
for	O
injection	O
.	O

Compared	O
with	O
the	O
prior	O
art	O
,	O
the	O
long	O
-	O
acting	O
terramycin	O
injection	O
disclosed	O
by	O
the	O
invention	O
has	O
the	O
advantages	O
of	O
high	O
bioavailability	O
,	O
good	O
curative	O
effect	O
,	O
quick	O
effect	O
,	O
definite	O
curative	O
effect	O
and	O
stability	O
in	O
quality	O
and	O
can	O
keep	O
higher	O
biological	O
activity	O
for	O
a	O
longer	O
time	O
and	O
sufficiently	O
keep	O
the	O
stability	O
of	O
a	O
product	O
;	O
the	O
preparation	O
method	O
disclosed	O
by	O
the	O
invention	O
has	O
the	O
advantages	O
of	O
easiness	O
for	O
operation	O
of	O
product	O
preparation	O
,	O
low	O
cost	O
and	O
industrialized	O
large	O
-	O
scale	O
production	O
.	O

Method	O
for	O
preparing	O
long	O
-	O
acting	O
terramycin	B
injection	O
by	O
utilizing	O
carbamide	B
and	O
sodium	B
bisulfite	I
in	O
combined	O
way	O

The	O
invention	O
discloses	O
an	O
application	O
of	O
a	O
compound	O
in	O
preparation	O
of	O
medicaments	O
for	O
preventing	O
and	O
treating	O
liver	O
injury	O
.	O

According	O
to	O
the	O
application	O
disclosed	O
by	O
the	O
invention	O
,	O
pharmacological	O
research	O
performed	O
on	O
Polyflavanostilbene	B
A	I
,	O
Polyflavanostilbene	B
A	I
is	O
found	O
to	O
have	O
a	O
protective	O
effect	O
on	O
the	O
acute	O
liver	O
injury	O
induced	O
by	O
D	B
-	I
galactosamine	I
(	O
D	B
-	I
GalN	I
)	O
,	O
of	O
mice	O
,	O
and	O
a	O
protective	O
effect	O
on	O
the	O
acute	O
liver	O
injury	O
induced	O
by	O
CC14	O
,	O
of	O
mice	O
.	O

Therefore	O
,	O
the	O
Polyflavanostilbene	B
A	I
can	O
be	O
used	O
for	O
preparing	O
medicaments	O
for	O
preventing	O
and	O
treating	O
liver	O
injury	O
or	O
hepatitis	O
.	O

The	O
application	O
of	O
the	O
Polyflavanostilbene	B
A	I
in	O
preparation	O
of	O
medicaments	O
for	O
preventing	O
and	O
treating	O
liver	O
injury	O
is	O
disclosed	O
for	O
the	O
first	O
time	O
;	O
the	O
Polyflavanostilbene	B
A	I
has	O
a	O
new	O
framework	O
type	O
,	O
and	O
an	O
unexpectedly	O
high	O
activity	O
for	O
the	O
treatment	O
effect	O
on	O
liver	O
injury	O
,	O
so	O
that	O
the	O
possibility	O
of	O
giving	O
any	O
revelation	O
by	O
other	O
compounds	O
is	O
avoided	O
;	O
and	O
the	O
Polyflavanostilbene	B
A	I
has	O
prominent	O
substantive	O
features	O
and	O
has	O
an	O
obviously	O
remarkable	O
improvement	O
in	O
case	O
of	O
being	O
used	O
for	O
resisting	O
liver	O
injury	O
.	O

Application	O
of	O
compound	O
in	O
preparation	O
of	O
medicaments	O
for	O
preventing	O
and	O
treating	O
liver	O
injury	O

The	O
invention	O
discloses	O
cinnamic	B
amide	I
derivatives	O
,	O
their	O
preparation	O
methods	O
and	O
their	O
application	O
in	O
the	O
preparation	O
of	O
bleeding	O
stopping	O
and	O
stasis	O
dissolving	O
medicines	O
.	O

The	O
preparation	O
methods	O
adopting	O
hydroxycinnamic	B
acid	I
and	O
sulfanilamide	B
medicines	O
as	O
raw	O
materials	O
comprise	O
the	O
following	O
steps	O
:	O
dissolving	O
hydroxycinnamic	B
acid	I
in	O
acetic	B
anhydride	I
,	O
sequentially	O
adding	O
pyridine	B
and	O
tetrahydrofuran	B
for	O
reacting	O
with	O
the	O
sulfanilamide	B
medicines	O
to	O
obtain	O
crude	O
amide	O
compounds	O
,	O
filtering	O
,	O
washing	O
,	O
and	O
recrystallizing	O
to	O
obtain	O
the	O
novel	O
cinnamic	B
amide	I
derivatives	O
.	O

Researches	O
find	O
that	O
the	O
derivatives	O
can	O
activate	O
the	O
blood	O
coagulation	O
factor	O
in	O
an	O
endogenous	O
and	O
exogenous	O
blood	O
coagulation	O
way	O
,	O
reinforces	O
the	O
uterine	O
action	O
,	O
can	O
be	O
well	O
combined	O
with	O
the	O
human	O
serum	O
,	O
has	O
a	O
coagulation	O
promoting	O
activity	O
and	O
a	O
pain	O
easing	O
effect	O
,	O
and	O
also	O
has	O
a	O
two	O
-	O
way	O
regulation	O
effect	O
on	O
the	O
stasis	O
dissolving	O
.	O

Experiments	O
on	O
the	O
four	O
blood	O
coagulation	O
indexes	O
,	O
the	O
calcium	B
recovering	O
time	O
of	O
the	O
blood	O
plasma	O
and	O
the	O
mouse	O
in	O
-	O
vitro	O
uterus	O
confirm	O
that	O
the	O
derivatives	O
have	O
the	O
coagulation	O
promoting	O
,	O
coagulation	O
preventing	O
and	O
two	O
-	O
way	O
regulating	O
activities	O
,	O
have	O
a	O
use	O
in	O
the	O
bleeding	O
stopping	O
and	O
stasis	O
dissolving	O
medicines	O
,	O
and	O
can	O
be	O
used	O
for	O
preparing	O
blood	O
disease	O
medicines	O
.	O

Cinnamic	B
amide	I
derivatives	O
,	O
their	O
preparation	O
methods	O
and	O
their	O
application	O
in	O
preparation	O
of	O
bleeding	O
stopping	O
and	O
stasis	O
dissolving	O
medicines	O

The	O
invention	O
discloses	O
an	O
oxiracetam	B
medicinal	O
composition	O
having	O
a	O
high	O
safety	O
,	O
and	O
a	O
preparation	O
method	O
and	O
an	O
application	O
thereof	O
.	O

The	O
medicinal	O
composition	O
contains	O
oxiracetam	B
and	O
below	O
0.5	O
%	O
of	O
a	O
compound	O
having	O
a	O
structure	O
represented	O
by	O
formula	O
II	O
.	O

A	O
case	O
that	O
4-hydroxy-2-oxo-1-pyrrolidineaceticacid	B
is	O
the	O
largest	O
-	O
content	O
impurity	O
in	O
the	O
oxiracetam	B
compound	O
is	O
proved	O
for	O
the	O
first	O
time	O
,	O
purifying	O
characterization	O
and	O
relevant	O
researches	O
on	O
4-hydroxy-2-oxo-1-pyrrolidineaceticacid	B
are	O
carried	O
out	O
,	O
and	O
the	O
researches	O
find	O
that	O
4-hydroxy-2-oxo-1-pyrrolidineaceticacid	B
is	O
related	O
with	O
the	O
side	O
effects	O
of	O
the	O
oxiracetam	B
medicine	O
and	O
can	O
cause	O
a	O
series	O
of	O
untoward	O
effects	O
.	O

The	O
oxiracetam	B
medicinal	O
composition	O
has	O
a	O
high	O
safety	O
.	O

The	O
invention	O
further	O
provides	O
the	O
preparation	O
method	O
of	O
the	O
oxiracetam	B
medicinal	O
composition	O
.	O

Oxiracetam	B
medicinal	O
composition	O
,	O
and	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
natural	O
pharmaceutical	O
composition	O
.	O

The	O
natural	O
pharmaceutical	O
composition	O
comprises	O
a	O
katsumade	O
galangal	O
seed	O
and	O
baical	O
skullcap	O
root	O
water	O
decoction	O
concentrated	O
extract	O
,	O
a	O
katsumade	O
galangal	O
seed	O
ethyl	O
acetate	O
extract	O
,	O
total	O
flavonoids	O
of	O
baical	O
skullcap	O
root	O
and	O
baicalin	O
according	O
to	O
the	O
proportion	O
of	O
(	O
2	O
-	O
4	O
)	O
:	O
(	O
3	O
-	O
8	O
)	O
:	O
(	O
3	O
-	O
9	O
)	O
:	O
(	O
1	O
-	O
4	O
)	O
,	O
and	O
the	O
composition	O
has	O
an	O
excellent	O
curative	O
effect	O
against	O
diarrhea	O
which	O
is	O
related	O
to	O
cancer	O
chemotherapy	O
and	O
can	O
simultaneously	O
realize	O
a	O
synergistic	O
action	O
against	O
the	O
cancer	O
chemotherapy	O
.	O

Natural	O
pharmaceutical	O
composition	O

The	O
invention	O
discloses	O
N-3-arylamine-5-cyclopropane	B
spirohydantoin	I
and	O
a	O
preparation	O
method	O
and	O
application	O
thereof	O
.	O

The	O
structural	O
general	O
formula	O
of	O
the	O
N-3-arylamine	B
substituent-5-cyclopropane	I
spirohydantoin	I
is	O
shown	O
in	O
the	O
specification	O
,	O
wherein	O
R1	O
is	O
phenyl	B
,	O
substituted	O
phenyl	B
and	O
heterocyclic	B
arene	I
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
of	O
:	O
performing	O
a	O
reaction	O
between	O
1-carboxyl-2,2-dimethylcyclopropane	B
ethyl	I
carboxylate	I
and	O
ethyl	B
chloroformate	I
to	O
generate	O
1-acyl	B
azide-2,2-dimethylcyclopropane	I
ethyl	I
carboxylate	I
under	O
the	O
effect	O
of	O
NaN3	B
;	O
performing	O
Curtius	O
rearrangement	O
on	O
the	O
1-acyl	B
azide-2,2-dimethylcyclopropane	I
ethyl	I
carboxylate	I
to	O
generate	O
corresponding	O
isocyanate	B
;	O
performing	O
a	O
reaction	O
between	O
the	O
isocyanate	B
and	O
hydrazine	B
to	O
obtain	O
N'-arylamine	B
substituent	I
ureidocyclopropane	I
;	O
and	O
generating	O
N-3-arylamine	B
substituent-5-cyclopropane	I
spirohydantoin	I
from	O
the	O
N'-arylamine	B
substituent	I
ureidocyclopropane	I
.	O

The	O
preparation	O
method	O
disclosed	O
by	O
the	O
invention	O
is	O
simple	O
,	O
has	O
higher	O
yield	O
,	O
and	O
can	O
be	O
used	O
for	O
easily	O
preparing	O
the	O
N-3-arylamine	B
substituent-5-cyclopropane	I
spirohydantoin	I
.	O

N-3-arylamine-5-cyclopropane	B
spirohydantoin	I
and	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
6-	B
(	I
4-arylpiperazine-1-yl	I
)	I
pyridazine-3	I
(	I
2H	I
)	I
-ketone	I
,	O
which	O
has	O
a	O
chemical	O
structure	O
formula	O
shown	O
in	O
formula	O
(	O
I	O
)	O
.	O

The	O
6-	B
(	I
4-arylpiperazine-1-yl	I
)	I
pyridazine-3	I
(	I
2H	I
)	I
-ketone	I
disclosed	O
by	O
the	O
invention	O
can	O
be	O
obtained	O
by	O
reacting	O
phenylpiperazine	B
pyridazinone	I
and	O
1-	B
(	I
2-bromoethoxyl	I
)	I
-2-chlorobenzene	I
.	O

The	O
6-	B
(	I
4-arylpiperazine-1-yl	I
)	I
pyridazine-3	I
(	I
2H	I
)	I
-ketone	I
disclosed	O
by	O
the	O
invention	O
is	O
remarkable	O
in	O
effect	O
of	O
suppressing	O
an	O
alpha	O
1-adrenergic	O
receptor	O
.	O

6-	B
(	I
4-arylpiperazine-1-yl	I
)	I
pyridazine-3	I
(	I
2H	I
)	I
-ketone	I
and	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
feed	O
additive	O
for	O
preventing	O
dairy	O
cow	O
mastitis	O
.	O

The	O
feed	O
additive	O
is	O
prepared	O
from	O
the	O
following	O
components	O
in	O
parts	O
by	O
weight	O
:	O
5	O
-	O
10	O
parts	O
of	O
medlar	O
,	O
15	O
-	O
20	O
parts	O
of	O
Chinese	O
dates	O
,	O
5	O
-	O
8	O
parts	O
of	O
flowers	O
carthami	O
,	O
5	O
-	O
8	O
parts	O
of	O
chrysanthemum	O
,	O
2	O
-	O
4	O
parts	O
of	O
radix	O
paeoniae	O
alba	O
,	O
8	O
-	O
12	O
parts	O
of	O
polygonum	O
multiflorum	O
,	O
2	O
-	O
4	O
parts	O
of	O
smoked	O
plum	O
,	O
1	O
-	O
3	O
parts	O
of	O
yeast	O
culture	O
,	O
2	O
-	O
4	O
parts	O
of	O
medicinal	O
stones	O
and	O
3	O
-	O
5	O
parts	O
of	O
bentonite	O
.	O

The	O
feed	O
additive	O
disclosed	O
by	O
the	O
invention	O
can	O
be	O
used	O
for	O
preventing	O
the	O
dairy	O
cow	O
mastitis	O
effectively	O
,	O
so	O
that	O
the	O
health	O
condition	O
of	O
dairy	O
cow	O
is	O
improved	O
,	O
and	O
the	O
effects	O
on	O
the	O
milk	O
yield	O
and	O
the	O
quality	O
of	O
a	O
dairy	O
product	O
due	O
to	O
diseases	O
such	O
as	O
mastitis	O
are	O
avoided	O
.	O

By	O
virtue	O
of	O
the	O
feed	O
additive	O
disclosed	O
by	O
the	O
invention	O
,	O
the	O
economic	O
benefits	O
of	O
cow	O
cultivation	O
are	O
greatly	O
improved	O
,	O
and	O
the	O
adverse	O
effects	O
on	O
the	O
quality	O
of	O
the	O
dairy	O
product	O
and	O
the	O
health	O
of	O
the	O
dairy	O
cow	O
caused	O
by	O
antibiotics	O
can	O
be	O
avoided	O
.	O

Feed	O
additive	O
for	O
preventing	O
dairy	O
cow	O
mastitis	O

The	O
invention	O
relates	O
to	O
a	O
natural	O
pharmaceutical	O
extractive	O
which	O
comprises	O
concentrated	O
extractive	O
of	O
water	O
decocted	O
shizandra	O
berry	O
-	O
long	O
pepper	O
,	O
shizandra	O
berry	O
polyose	O
,	O
long	O
pepper	O
-	O
ethanol	B
extractive	O
,	O
and	O
piperine	B
according	O
to	O
the	O
proportion	O
of	O
(	O
3	O
-	O
6	O
)	O
:	O
(	O
3	O
-	O
7	O
)	O
:	O
(	O
1	O
-	O
3	O
)	O
:	O
(	O
4	O
-	O
9	O
)	O
.	O

The	O
natural	O
pharmaceutical	O
extractive	O
has	O
an	O
excellent	O
curative	O
effect	O
on	O
diarrhea	O
related	O
to	O
cancer	O
chemo	O
-	O
treatment	O
and	O
a	O
synergistic	O
effect	O
on	O
cancer	O
chemo	O
-	O
treatment	O
.	O

Natural	O
pharmaceutical	O
extractive	O

The	O
invention	O
discloses	O
a	O
pharmaceutical	O
composition	O
with	O
an	O
alimentary	O
anemia	O
improving	O
function	O
and	O
a	O
preparation	O
method	O
of	O
the	O
composition	O
.	O

The	O
composition	O
is	O
prepared	O
from	O
astragalus	O
membranaceus	O
,	O
codonopsis	O
pilosula	O
,	O
angelica	O
,	O
jujube	O
and	O
prepared	O
rehmannia	O
root	O
according	O
to	O
a	O
certain	O
weight	O
percentage	O
,	O
and	O
the	O
composition	O
can	O
be	O
prepared	O
into	O
any	O
commonly	O
used	O
preparation	O
,	O
preferably	O
an	O
oral	O
preparation	O
.	O

The	O
pharmaceutical	O
composition	O
has	O
a	O
function	O
of	O
improving	O
alimentary	O
anemia	O
.	O

Composition	O
with	O
alimentary	O
anemia	O
improving	O
function	O
and	O
preparation	O
method	O
of	O
composition	O

The	O
invention	O
discloses	O
a	O
new	O
application	O
of	O
Sarcaboside	B
B.	I
The	O
Sarcaboside	B
B	I
has	O
inhibitory	O
activity	O
on	O
acetylcholin	B
esterase	O
and	O
a	O
nerve	O
cell	O
protection	O
effect	O
.	O

As	O
a	O
multi	O
-	O
target	O
directed	O
compound	O
,	O
the	O
Sarcaboside	B
B	I
can	O
be	O
used	O
for	O
the	O
preparation	O
of	O
the	O
medicines	O
for	O
resisting	O
the	O
alzheimer	O
disease	O
.	O

The	O
application	O
of	O
the	O
Sarcaboside	B
B	I
in	O
the	O
preparation	O
of	O
medicines	O
for	O
treating	O
the	O
alzheimer	O
disease	O
is	O
disclosed	O
by	O
the	O
invention	O
for	O
the	O
first	O
time	O
.	O

As	O
the	O
skeleton	O
type	O
of	O
the	O
Sarcaboside	B
B	I
belongs	O
to	O
a	O
brand	O
-	O
new	O
skeleton	O
type	O
,	O
the	O
Sarcaboside	B
B	I
has	O
unexpected	O
strong	O
inhibitory	O
activity	O
on	O
the	O
acetylcholin	O
esterase	O
,	O
and	O
the	O
possibility	O
that	O
other	O
compounds	O
provide	O
revelation	O
does	O
not	O
exist	O
.	O

The	O
Sarcaboside	B
B	I
has	O
prominently	O
substantial	O
characteristics	O
and	O
meanwhile	O
has	O
remarkably	O
progressive	O
significance	O
when	O
being	O
used	O
for	O
preventing	O
and	O
treating	O
the	O
alzheimer	O
disease	O
.	O

Application	O
of	O
Sarcaboside	B
B	I
in	O
preparation	O
of	O
medicines	O
for	O
treating	O
alzheimer	O
disease	O

The	O
invention	O
discloses	O
an	O
application	O
of	O
Chukrasone	B
A	I
in	O
preparing	O
medicines	O
for	O
treating	O
or	O
preventing	O
yellow	O
fever	O
virus	O
infection	O
.	O

The	O
Chukrasone	B
A	I
can	O
effectively	O
inhibit	O
proliferation	O
of	O
yellow	O
fever	O
virus	O
but	O
is	O
small	O
in	O
cytotoxicity	O
,	O
so	O
that	O
the	O
Chukrasone	B
A	I
can	O
be	O
further	O
developed	O
to	O
medicines	O
for	O
treating	O
diseases	O
caused	O
by	O
the	O
virus	O
infection	O
,	O
and	O
has	O
a	O
wide	O
application	O
prospect	O
.	O

The	O
use	O
of	O
the	O
Chukrasone	B
A	I
for	O
preparing	O
medicines	O
for	O
treating	O
yellow	O
fever	O
virus	O
infection	O
provided	O
by	O
the	O
invention	O
is	O
disclosed	O
for	O
the	O
first	O
time	O
.	O

As	O
the	O
framework	O
type	O
belongs	O
to	O
a	O
brand	O
-	O
new	O
framework	O
type	O
,	O
and	O
the	O
inhibitory	O
activity	O
of	O
the	O
Chukrasone	B
A	I
to	O
yellow	O
fever	O
virus	O
infection	O
is	O
unimaginably	O
strong	O
,	O
the	O
probability	O
of	O
giving	O
any	O
enlightenment	O
by	O
other	O
compounds	O
does	O
not	O
exist	O
.	O

The	O
Chukrasone	B
A	I
has	O
remarkable	O
substantial	O
characteristics	O
and	O
meanwhile	O
has	O
remarkable	O
progress	O
for	O
preventing	O
and	O
treating	O
yellow	O
fever	O
virus	O
infection	O
.	O

Application	O
of	O
Chukrasone	B
A	I
in	O
preparing	O
medicines	O
for	O
treating	O
yellow	O
fever	O
virus	O
infection	O

The	O
invention	O
provides	O
a	O
crystal	O
form	O
,	O
a	O
preparation	O
method	O
and	O
an	O
application	O
of	O
agomelatine	B
,	O
as	O
well	O
as	O
a	O
medicine	O
composition	O
.	O

Compared	O
with	O
the	O
prior	O
art	O
,	O
the	O
crystal	O
form	O
provided	O
by	O
the	O
invention	O
has	O
the	O
following	O
advantages	O
and	O
positive	O
effects	O
that	O
the	O
new	O
crystal	O
form	O
of	O
the	O
agomelatine	B
obtained	O
by	O
the	O
preparation	O
method	O
provided	O
by	O
the	O
invention	O
is	O
high	O
in	O
purity	O
,	O
stable	O
,	O
good	O
in	O
repeatability	O
,	O
better	O
than	O
a	O
plurality	O
of	O
existing	O
crystal	O
forms	O
in	O
purity	O
and	O
stability	O
,	O
and	O
suitable	O
for	O
preparing	O
medicament	O
preparations	O
.	O

The	O
preparation	O
method	O
of	O
the	O
new	O
crystal	O
form	O
of	O
the	O
agomelatine	B
provided	O
by	O
the	O
invention	O
is	O
simpler	O
and	O
more	O
convenient	O
than	O
the	O
existing	O
crystal	O
form	O
,	O
is	O
also	O
moderate	O
in	O
condition	O
,	O
easy	O
to	O
be	O
applied	O
in	O
actual	O
production	O
and	O
low	O
in	O
cost	O
,	O
and	O
satisfies	O
the	O
requirements	O
of	O
industrial	O
production	O
.	O

Crystal	O
form	O
,	O
preparation	O
method	O
and	O
application	O
of	O
agomelatine	B
,	O
as	O
well	O
as	O
medicine	O
composition	O

The	O
invention	O
relates	O
to	O
chelidonine	B
,	O
fumarate	B
of	O
a	O
derivative	O
of	O
the	O
chelidonine	B
or	O
a	O
pharmaceutically	O
acceptable	O
solvate	O
of	O
the	O
chelidonine	B
and	O
applications	O
of	O
the	O
chelidonine	B
,	O
the	O
fumarate	B
and	O
the	O
solvate	O
in	O
preparation	O
of	O
medicaments	O
for	O
treating	O
hepatitis	O
B.	O
Salt	O
of	O
chelidonine	B
derivative	O

The	O
invention	O
discloses	O
an	O
ursodeoxycholic	B
acid	I
vitamin	O
composition	O
,	O
a	O
preparation	O
method	O
and	O
applications	O
thereof	O
.	O

The	O
composite	O
comprises	O
following	O
raw	O
materials	O
in	O
percentage	O
by	O
weight	O
:	O
1	O
to	O
30	O
%	O
of	O
ursodesoxycholic	B
acid	I
,	O
0.1	O
to	O
5	O
%	O
of	O
thiamine	B
mononitrate	I
,	O
0.05	O
to	O
2.5	O
%	O
of	O
riboflavin	B
and	O
the	O
balance	O
of	O
dispersion	O
supporter	O
.	O

The	O
invention	O
also	O
provides	O
a	O
preparation	O
method	O
of	O
a	O
capsule	O
preparation	O
of	O
the	O
composition	O
,	O
and	O
the	O
preparation	O
method	O
has	O
the	O
advantages	O
of	O
simple	O
operation	O
and	O
good	O
capsule	O
luster	O
and	O
homogeneity	O
.	O

The	O
ursodesoxycholic	B
acid	I
,	O
thiamine	B
mononitrate	I
and	O
riboflavin	B
are	O
used	O
together	O
to	O
have	O
the	O
functions	O
of	O
antagonizing	O
liver	O
hydrophobic	O
toxic	O
bile	O
acid	O
,	O
protecting	O
liver	O
cells	O
,	O
providing	O
enough	O
energy	O
to	O
liver	O
cells	O
,	O
and	O
helping	O
damaged	O
liver	O
cells	O
to	O
recover	O
,	O
the	O
ursodesoxycholic	B
acid	I
vitamin	O
composition	O
has	O
the	O
function	O
of	O
protecting	O
liver	O
and	O
gallbladder	O
,	O
and	O
is	O
capable	O
of	O
being	O
used	O
for	O
preparing	O
drugs	O
for	O
curing	O
liver	O
and	O
gallbladder	O
.	O

Ursodeoxycholic	B
acid	I
vitamin	O
composition	O
,	O
preparation	O
method	O
and	O
applications	O
thereof	O

The	O
invention	O
discloses	O
a	O
novel	O
application	O
of	O
a	O
ginseng	O
oligosaccharide	B
composition	O
in	O
preparation	O
of	O
an	O
anti	O
-	O
oxidation	O
medicine	O
and	O
a	O
health	O
-	O
care	O
food	O
.	O

The	O
ginseng	O
oligosaccharide	B
composition	O
is	O
extracted	O
from	O
ginseng	O
.	O

According	O
to	O
an	O
in	O
-	O
vitro	O
experiment	O
,	O
the	O
ginseng	O
oligosaccharide	B
composition	O
has	O
a	O
good	O
effect	O
of	O
clearing	O
away	O
hydroxyl	B
free	I
radicals	I
and	O
DPPH	B
(	O
1,1-Diphenyl-2-picrylhydrazyl	B
radical	I
2,2-Diphenyl-1-	I
(	I
2,4,6-trinitrophenyl	I
)	I
hydrazyl	I
)	O
,	O
and	O
also	O
has	O
the	O
good	O
effect	O
of	O
chelating	O
Fe<2+>.	B
According	O
to	O
an	O
animal	O
experiment	O
,	O
the	O
ginseng	O
oligosaccharide	B
composition	O
has	O
the	O
good	O
effect	O
of	O
enhancing	O
the	O
enzyme	O
activities	O
of	O
SOD	O
(	O
Superoxide	O
Dismutase	O
)	O
,	O
CAT	O
(	O
Catalase	O
)	O
,	O
GSH	O
-	O
Px	O
(	O
Glutathione	O
Peroxidase	O
)	O
and	O
T	O
-	O
AOC	O
(	O
Total	O
Antioxidative	O
Capacity	O
)	O
in	O
the	O
serum	O
and	O
the	O
liver	O
of	O
an	O
oxidative	O
stress	O
-	O
injured	O
mice	O
induced	O
by	O
D	B
-	I
Gal	I
(	O
Galactosamine	B
)	O
,	O
and	O
can	O
be	O
used	O
for	O
obviously	O
decreasing	O
the	O
MDA	B
(	O
Methane	B
Dicarboxylic	I
Aldehyde	I
)	O
level	O
of	O
the	O
oxidative	O
stress	O
-	O
injured	O
mice	O
.	O

Application	O
of	O
ginseng	O
oligosaccharide	B
composition	O
in	O
preparation	O
of	O
anti	O
-	O
oxidation	O
medicine	O
or	O
health	O
-	O
care	O
food	O

The	O
invention	O
provides	O
a	O
medicament	O
for	O
treating	O
insomnia	O
and	O
dreamful	O
sleep	O
.	O

The	O
medicament	O
comprises	O
the	O
following	O
components	O
in	O
parts	O
by	O
weight	O
:	O
6	O
-	O
12	O
parts	O
of	O
spina	O
date	O
seed	O
,	O
8	O
-	O
16	O
parts	O
of	O
tuber	O
fleeceflower	O
stem	O
,	O
8	O
-	O
12	O
parts	O
of	O
rhizoma	O
acori	O
graminei	O
,	O
8	O
-	O
12	O
parts	O
of	O
platycladi	O
seed	O
,	O
7	O
-	O
15	O
parts	O
of	O
polygala	O
tenuifolia	O
,	O
8	O
-	O
12	O
parts	O
of	O
nacre	O
mother	O
of	O
pearl	O
,	O
8	O
-	O
16	O
parts	O
of	O
amber	O
,	O
8	O
-	O
16	O
parts	O
of	O
magnet	O
,	O
9	O
-	O
15	O
parts	O
of	O
lily	O
,	O
7	O
-	O
14	O
parts	O
of	O
stamen	O
nelumbinis	O
,	O
and	O
8	O
-	O
15	O
parts	O
of	O
red	O
-	O
rooted	O
salvia	O
root	O
.	O

The	O
medicament	O
for	O
treating	O
insomnia	O
and	O
dreamful	O
sleep	O
has	O
the	O
advantages	O
and	O
positive	O
effects	O
of	O
good	O
treatment	O
effect	O
,	O
no	O
independence	O
and	O
small	O
toxic	O
and	O
side	O
effects	O
.	O

Medicament	O
for	O
treating	O
insomnia	O
and	O
dreamful	O
sleep	O

The	O
invention	O
relates	O
to	O
ten	O
amide	B
arylpiperazine	I
derivatives	O
,	O
their	O
preparation	O
method	O
,	O
and	O
their	O
use	O
in	O
the	O
preparation	O
of	O
benign	O
prostatic	O
hyperplasia	O
treatment	O
medicines	O
.	O

The	O
preparation	O
method	O
of	O
the	O
amide	B
arylpiperazine	I
derivatives	O
comprises	O
the	O
following	O
steps	O
:	O
reacting	O
free	O
alkali	O
of	O
3-bromopropylamine	B
hydrobromide	I
with	O
di	B
-	I
tert	I
-	I
butyl	I
dicarbonate	I
to	O
obtain	O
a	O
colorless	O
oily	O
liquid	O
,	O
reacting	O
the	O
colorless	O
oily	O
liquid	O
with	O
o	B
-	I
methoxyphenylpiperazine	I
to	O
obtain	O
a	O
light	O
yellow	O
oily	O
material	O
,	O
reacting	O
the	O
light	O
yellow	O
oily	O
material	O
with	O
trifluoroacetic	B
acid	I
to	O
obtain	O
a	O
product	O
,	O
and	O
reacting	O
the	O
product	O
with	O
N	B
,	I
N	I
-	I
diisopropylethylaine	I
,	O
2-	B
(	I
7-azobenzotriazol	I
)	I
-N	I
,	I
N	I
,	I
N',N'-tetramethylformamidinium	I
hexafluorophosphate	I
,	O
and	O
5-indoleacetic	B
acid	I
or	O
3-indoleacetic	B
acid	I
or	O
3-indolepropionic	B
acid	I
or	O
3-indolebutyric	B
acid	I
or	O
5-hydroxy-2-indoleacetic	B
acid	I
or	O
5-methoxy-2-indoleacetic	B
acid	I
or	O
1-methyl-3-indoleacetic	B
acid	I
or	O
6-bromo-2-indoleacetic	B
acid	I
or	O
5-chloro-2-indoleacetic	B
acid	I
or	O
7-nitro-2-indoleacetic	B
acid	I
to	O
obtain	O
final	O
products	O
.	O

Experiments	O
prove	O
that	O
the	O
benign	O
prostatic	O
hyperplasia	O
resistance	O
activities	O
of	O
eight	O
compounds	O
in	O
the	O
amide	B
arylpiperazine	I
derivatives	O
are	O
stronger	O
than	O
a	O
contrast	O
drug	O
prazosin	B
.	O

Amide	B
arylpiperazine	I
derivatives	O
,	O
their	O
preparation	O
method	O
,	O
and	O
their	O
application	O
in	O
benign	O
prostatic	O
hyperplasia	O
resistance	O

The	O
invention	O
relates	O
to	O
a	O
vagina	O
mold	O
containing	O
estriol	B
.	O

The	O
vagina	O
mold	O
is	O
composed	O
of	O
silicone	B
rubber	O
and	O
the	O
estriol	B
,	O
wherein	O
the	O
weight	O
ratio	O
of	O
the	O
silicone	B
rubber	O
and	O
the	O
estriol	B
is	O
20	O
:	O
(	O
5	O
-	O
8	O
)	O
.	O

The	O
vagina	O
mold	O
containing	O
the	O
estriol	B
has	O
the	O
advantages	O
that	O
the	O
vagina	O
mold	O
containing	O
estrogen	B
greatly	O
lowers	O
the	O
contracture	O
rate	O
of	O
a	O
man	O
-	O
made	O
vagina	O
.	O

The	O
silicone	B
rubber	O
and	O
the	O
estrogen	B
are	O
combined	O
to	O
manufacture	O
the	O
vagina	O
mold	O
with	O
the	O
estrogen	B
slow	O
releasing	O
ability	O
,	O
and	O
therefore	O
vagina	O
mold	O
treatment	O
and	O
estrogen	B
treatment	O
are	O
effectively	O
combined	O
,	O
and	O
the	O
vagina	O
mold	O
with	O
the	O
slow	O
releasing	O
function	O
has	O
great	O
potential	O
in	O
future	O
clinical	O
application	O
.	O

Vagina	O
mold	O
containing	O
estriol	B

The	O
invention	O
belongs	O
to	O
the	O
field	O
of	O
medicine	O
preparation	O
and	O
particularly	O
relates	O
to	O
an	O
application	O
of	O
berberine	B
in	O
a	O
medicine	O
for	O
treating	O
non	O
-	O
alcoholic	O
fatty	O
liver	O
disease	O
.	O

According	O
to	O
the	O
invention	O
,	O
db	O
/	O
db	O
mouse	O
with	O
diabetic	O
obesity	O
and	O
NAFLD	O
(	O
Non	O
-	O
Alcoholic	O
Fatty	O
Liver	O
Disease	O
)	O
is	O
employed	O
to	O
simulate	O
a	O
fat	O
NAFLD	O
patient	O
,	O
and	O
a	O
mouse	O
with	O
non	O
-	O
obese	O
fatty	O
liver	O
caused	O
by	O
methionine	B
-	O
choline	B
deficient	O
(	O
MCD	O
)	O
is	O
used	O
as	O
a	O
model	O
to	O
simulate	O
a	O
non	O
-	O
fat	O
NAFLD	O
patient	O
so	O
as	O
to	O
observe	O
the	O
effect	O
of	O
BBR	O
.	O

Shown	O
by	O
all	O
test	O
results	O
,	O
the	O
BBR	O
not	O
only	O
can	O
reduce	O
the	O
weight	O
of	O
the	O
obese	O
mouse	O
and	O
improve	O
the	O
glycometabolism	O
and	O
lipid	O
metabolism	O
,	O
but	O
also	O
can	O
treat	O
the	O
concurrent	O
fatty	O
liver	O
of	O
the	O
obese	O
mouse	O
,	O
and	O
also	O
has	O
obvious	O
treatment	O
effect	O
on	O
the	O
fatty	O
liver	O
of	O
the	O
non	O
-	O
obese	O
mouse	O
,	O
and	O
the	O
results	O
are	O
verified	O
in	O
a	O
cell	O
model	O
simulated	O
in	O
vitro	O
,	O
so	O
that	O
the	O
BBR	O
has	O
obvious	O
treatment	O
effect	O
on	O
the	O
obesity	O
and	O
the	O
non	O
-	O
obese	O
NAFLD	O
surely	O
and	O
can	O
be	O
used	O
in	O
preparation	O
of	O
the	O
medicine	O
for	O
treating	O
the	O
NAFLD	O
.	O

Application	O
of	O
berberine	B
in	O
medicine	O
for	O
treating	O
non	O
-	O
alcoholic	O
fatty	O
liver	O
disease	O

The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
anticancer	O
related	O
drugs	O
,	O
particularly	O
imidazolyl	B
-	I
substituted	I
thiazocyclohexane	I
derivatives	O
with	O
antitumor	O
activity	O
disclosed	O
as	O
Formula	O
I	O
,	O
and	O
a	O
preparation	O
method	O
,	O
pharmaceutical	O
composition	O
and	O
application	O
thereof	O
.	O

Imidazolyl	B
-	I
substituted	I
thiazocyclohexane	I
compounds	O
and	O
antitumor	O
application	O
thereof	O

The	O
invention	O
discloses	O
substituted	O
-	O
pyrrolidinyl	B
-	I
contained	I
thiomorpholine	I
compounds	O
,	O
a	O
preparation	O
method	O
thereof	O
and	O
applications	O
thereof	O
.	O

In	O
concrete	O
,	O
the	O
invention	O
relates	O
to	O
compounds	O
having	O
a	O
general	O
formula	O
(	O
I	O
)	O
,	O
stereoisomers	O
of	O
the	O
compounds	O
and	O
pharmaceutical	O
acceptable	O
salts	O
of	O
the	O
compounds	O
,	O
wherein	O
R	O
is	O
shown	O
in	O
the	O
specification	O
.	O

The	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds	O
,	O
and	O
the	O
applications	O
of	O
the	O
compounds	O
in	O
preparing	O
medicines	O
used	O
for	O
treating	O
and/or	O
preventing	O
a	O
disease	O
or	O
a	O
symptom	O
which	O
are	O
related	O
to	O
over	O
-	O
high	O
activity	O
of	O
DPP	O
-	O
IV	O
or	O
over	O
-	O
expression	O
of	O
the	O
DPP	O
-	O
IV	O
,	O
and	O
also	O
relates	O
to	O
a	O
method	O
of	O
using	O
the	O
compounds	O
for	O
treating	O
related	O
diseases	O
.	O

The	O
compounds	O
have	O
activity	O
for	O
effectively	O
inhibiting	O
the	O
DPP	O
-	O
IV	O
.	O

Substituted	O
-	O
pyrrolidinyl	B
-	I
contained	I
thiomorpholine	I
compounds	O

The	O
invention	O
relates	O
to	O
a	O
meclozine	B
oral	O
film	O
comprising	O
a	O
pharmaceutical	O
ingredient	O
meclozine	B
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
and	O
a	O
flavoring	O
agent	O
,	O
a	O
filling	O
agent	O
,	O
a	O
wetting	O
agent	O
,	O
a	O
coloring	O
agent	O
,	O
a	O
film	O
-	O
forming	O
material	O
and	O
an	O
essence	O
.	O

The	O
meclozine	B
oral	O
film	O
is	O
uniform	O
in	O
appearance	O
,	O
pleasant	O
in	O
mouth	O
feel	O
and	O
capable	O
of	O
reducing	O
medication	O
compliance	O
of	O
children	O
,	O
is	O
directly	O
swallowed	O
after	O
dissolution	O
in	O
the	O
mouth	O
without	O
drinking	O
water	O
,	O
is	O
quick	O
in	O
drug	O
release	O
and	O
especially	O
suitable	O
for	O
children	O
,	O
old	O
people	O
and	O
critical	O
patients	O
who	O
are	O
difficult	O
in	O
swallowing	O
.	O

The	O
meclozine	B
oral	O
film	O
also	O
has	O
the	O
advantages	O
of	O
few	O
auxiliary	O
materials	O
,	O
low	O
production	O
cost	O
and	O
simple	O
preparation	O
process	O
and	O
is	O
liable	O
to	O
industrial	O
production	O
.	O

Meclozine	B
oral	O
film	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicines	O
,	O
discloses	O
a	O
pharmaceutical	O
composition	O
of	O
paclitaxel	B
,	O
and	O
particularly	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
of	O
paclitaxel	B
,	O
polyoxyethylated	O
castor	O
oil	O
,	O
sodium	B
dihydrogen	I
phosphate	I
,	O
hexanedioic	B
acid	I
and	O
ethanol	B
.	O

The	O
pharmaceutical	O
composition	O
disclosed	O
by	O
the	O
invention	O
is	O
prepared	O
into	O
an	O
injection	O
;	O
the	O
single	O
impurity	O
and	O
total	O
impurities	O
accord	O
with	O
the	O
quality	O
requirements	O
by	O
virtue	O
of	O
a	O
high	O
-	O
temperature	O
and	O
highlight	O
test	O
.	O

The	O
preparation	O
prepared	O
from	O
the	O
pharmaceutical	O
composition	O
disclosed	O
by	O
the	O
invention	O
has	O
the	O
advantages	O
of	O
high	O
stability	O
and	O
low	O
impurity	O
content	O
.	O

Pharmaceutical	O
composition	O
of	O
paclitaxel	B

The	O
invention	O
relates	O
to	O
a	O
composition	O
containing	O
resveratrol	B
and	O
pterostilbene	B
,	O
which	O
contains	O
resveratrol	B
and	O
pterostilbene	B
.	O

As	O
shown	O
in	O
an	O
experimental	O
result	O
,	O
the	O
composition	O
containing	O
the	O
resveratrol	B
and	O
the	O
pterostilbene	B
has	O
a	O
synergistic	O
effect	O
of	O
inhibiting	O
the	O
growth	O
of	O
malignant	O
melanoma	O
grafts	O
.	O

Composition	O
containing	O
resveratrol	B
and	O
pterostilbene	B
and	O
preparation	O
containing	O
composition	O

The	O
invention	O
discloses	O
an	O
application	O
of	O
Incarviatone	B
A	I
in	O
preparation	O
of	O
medicaments	O
for	O
treating	O
bladder	O
cancer	O
,	O
and	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
a	O
new	O
application	O
of	O
medicaments	O
.	O

In	O
-	O
vitro	O
methyl	B
thiazolyl	I
tetrazolium	I
(	O
MTT	B
)	O
anti	O
-	O
tumor	O
activity	O
evaluation	O
discovers	O
that	O
the	O
Incarviatone	B
A	I
has	O
a	O
prominent	O
inhibiting	O
effect	O
on	O
growth	O
of	O
human	O
bladder	O
cancer	O
cell	O
strains	O
T-24	O
.	O

Therefore	O
,	O
the	O
Incarviatone	B
A	I
can	O
be	O
used	O
for	O
preparing	O
anti	O
-	O
bladder	O
cancer	O
medicaments	O
,	O
and	O
has	O
a	O
good	O
development	O
and	O
application	O
prospect	O
.	O

The	O
application	O
of	O
the	O
Incarviatone	B
A	I
in	O
preparation	O
of	O
the	O
medicaments	O
for	O
treating	O
bladder	O
cancer	O
is	O
made	O
public	O
for	O
the	O
first	O
time	O
,	O
the	O
skeleton	O
type	O
is	O
completely	O
novel	O
,	O
and	O
the	O
Incarviatone	B
A	I
has	O
an	O
unexpectedly	O
strong	O
bladder	O
cancer	O
cell	O
inhibiting	O
activity	O
.	O

Application	O
of	O
Incarviatone	B
A	I
in	O
medicaments	O
for	O
treating	O
bladder	O
cancer	O

The	O
invention	O
discloses	O
an	O
application	O
of	O
Incarviatone	B
A	I
in	O
preparation	O
of	O
medicaments	O
for	O
treating	O
human	O
bile	O
duct	O
cancer	O
,	O
and	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
a	O
new	O
application	O
of	O
medicaments	O
.	O

In	O
-	O
vitro	O
methyl	B
thiazolyl	I
tetrazolium	I
(	O
MTT	B
)	O
anti	O
-	O
tumor	O
activity	O
evaluation	O
discovers	O
that	O
the	O
Incarviatone	B
A	I
has	O
a	O
prominent	O
inhibiting	O
effect	O
on	O
growth	O
of	O
human	O
bile	O
duct	O
cancer	O
cell	O
strains	O
RBE	O
.	O

Therefore	O
,	O
the	O
Incarviatone	B
A	I
can	O
be	O
used	O
for	O
preparing	O
anti	O
-	O
bile	O
duct	O
cancer	O
medicaments	O
,	O
and	O
has	O
a	O
good	O
development	O
and	O
application	O
prospect	O
.	O

The	O
application	O
of	O
the	O
Incarviatone	B
A	I
in	O
preparation	O
of	O
the	O
medicaments	O
for	O
treating	O
human	O
bile	O
duct	O
cancer	O
is	O
made	O
public	O
for	O
the	O
first	O
time	O
,	O
the	O
skeleton	O
type	O
is	O
completely	O
novel	O
,	O
and	O
the	O
Incarviatone	B
A	I
has	O
an	O
unexpectedly	O
strong	O
human	O
bile	O
duct	O
cancer	O
cell	O
inhibiting	O
activity	O
.	O

Application	O
of	O
Incarviatone	B
A	I
in	O
medicaments	O
for	O
treating	O
bile	O
duct	O
cancer	O

The	O
invention	O
discloses	O
application	O
of	O
Lycojaponicumin	B
A	I
in	O
preparation	O
of	O
drugs	O
for	O
treating	O
tongue	O
cancer	O
and	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
new	O
application	O
of	O
drugs	O
.	O

In	O
vitro	O
MTT	O
anticancer	O
activity	O
evaluation	O
discovers	O
that	O
Lycojaponicumin	B
A	I
shows	O
remarkable	O
inhibitory	O
effects	O
on	O
growth	O
of	O
human	O
tongue	O
cancer	O
cell	O
lines	O
Tca8113	O
and	O
T6	O
.	O

Therefore	O
,	O
the	O
Lycojaponicumin	B
A	I
can	O
be	O
used	O
for	O
preparing	O
anti	O
-	O
tongue	O
cancer	O
drugs	O
,	O
and	O
has	O
good	O
development	O
and	O
application	O
prospects	O
.	O

Application	O
of	O
the	O
Lycojaponicumin	B
A	I
in	O
preparation	O
of	O
drugs	O
for	O
treating	O
tongue	O
cancer	O
is	O
disclosed	O
for	O
the	O
first	O
time	O
;	O
and	O
because	O
skeleton	O
type	O
is	O
completely	O
new	O
,	O
inhibitory	O
activity	O
on	O
tongue	O
cancer	O
cells	O
is	O
extraordinary	O
strong	O
.	O

Application	O
of	O
Lycojaponicumin	B
A	I
in	O
drugs	O
for	O
treating	O
tongue	O
cancer	O

The	O
invention	O
discloses	O
an	O
application	O
of	O
Lycojaponicumin	B
C	I
in	O
the	O
preparation	O
of	O
medicines	O
for	O
treating	O
ovarian	O
cancer	O
,	O
belonging	O
to	O
the	O
technical	O
field	O
of	O
new	O
applications	O
of	O
medicines	O
.	O

The	O
evaluation	O
on	O
an	O
in	O
vitro	O
MTT	B
(	O
3-	B
(	I
4,5-Dimethylthiazol-2-yl	I
)	I
-2,5-diphenyltetrazolium	I
bromide	I
)	O
anti	O
-	O
tumor	O
activity	O
shows	O
that	O
the	O
Lycojaponicumin	B
C	I
also	O
has	O
an	O
obvious	O
inhibiting	O
effect	O
on	O
the	O
growth	O
of	O
human	O
ovarian	O
cancer	O
cell	O
lines	O
HO-8910	O
,	O
HOC1	O
and	O
OVAC	O
.	O

Therefore	O
,	O
the	O
Lycojaponicumin	B
C	I
can	O
be	O
used	O
for	O
the	O
preparation	O
of	O
the	O
medicines	O
for	O
resisting	O
the	O
ovarian	O
cancer	O
and	O
has	O
good	O
development	O
and	O
application	O
prospects	O
.	O

The	O
application	O
of	O
the	O
Lycojaponicumin	B
C	I
in	O
the	O
preparation	O
of	O
the	O
medicines	O
for	O
treating	O
the	O
human	O
ovarian	O
cancer	O
is	O
disclosed	O
for	O
the	O
first	O
time	O
.	O

As	O
the	O
skeleton	O
type	O
of	O
the	O
Lycojaponicumin	B
C	I
belongs	O
to	O
a	O
brand	O
-	O
new	O
skeleton	O
type	O
,	O
the	O
Lycojaponicumin	B
C	I
has	O
unexpected	O
strong	O
inhibitory	O
activity	O
on	O
human	O
ovarian	O
cancer	O
cells	O
.	O

Application	O
of	O
Lycojaponicumin	B
C	I
in	O
preparation	O
of	O
medicines	O
for	O
treating	O
ovarian	O
cancer	O

The	O
invention	O
discloses	O
an	O
application	O
of	O
Lycojaponicumin	B
C	I
in	O
the	O
preparation	O
of	O
medicines	O
for	O
treating	O
or	O
preventing	O
yellow	O
fever	O
virus	O
infection	O
.	O

The	O
Lycojaponicumin	B
C	I
can	O
be	O
used	O
for	O
effectively	O
inhibiting	O
the	O
proliferation	O
of	O
yellow	O
fever	O
virus	O
,	O
has	O
very	O
low	O
toxicity	O
on	O
cells	O
,	O
can	O
be	O
further	O
developed	O
into	O
the	O
medicines	O
for	O
treating	O
diseases	O
caused	O
by	O
the	O
virus	O
infection	O
and	O
has	O
wide	O
application	O
prospects	O
.	O

The	O
application	O
of	O
the	O
Lycojaponicumin	B
C	I
in	O
the	O
preparation	O
of	O
medicines	O
for	O
treating	O
the	O
yellow	O
fever	O
virus	O
infection	O
is	O
disclosed	O
for	O
the	O
first	O
time	O
.	O

As	O
the	O
skeleton	O
type	O
of	O
the	O
Lycojaponicumin	B
C	I
belongs	O
to	O
a	O
brand	O
-	O
new	O
skeleton	O
type	O
,	O
the	O
Lycojaponicumin	B
C	I
has	O
unexpected	O
strong	O
inhibitory	O
activity	O
on	O
yellow	O
fever	O
virus	O
,	O
and	O
the	O
possibility	O
that	O
other	O
compounds	O
provide	O
revelation	O
does	O
not	O
exist	O
.	O

The	O
Lycojaponicumin	B
C	I
has	O
prominently	O
substantial	O
characteristics	O
and	O
meanwhile	O
has	O
remarkably	O
progressive	O
significance	O
when	O
being	O
used	O
for	O
preventing	O
or	O
treating	O
the	O
yellow	O
fever	O
virus	O
infection	O
.	O

Application	O
of	O
Lycojaponicumin	B
C	I
in	O
preparation	O
of	O
medicines	O
for	O
treating	O
yellow	O
fever	O
virus	O
infection	O

Provided	O
are	O
:	O
methods	O
for	O
treating	O
aging	O
or	O
an	O
age	O
-	O
related	O
condition	O
,	O
symptom	O
or	O
disease	O
;	O
methods	O
for	O
stimulating	O
hair	O
growth	O
,	O
regrowth	O
or	O
pigmentation	O
(	O
or	O
preventing	O
hair	O
loss	O
)	O
;	O
methods	O
for	O
increasing	O
the	O
expression	O
of	O
an	O
adenosine	O
receptor	O
in	O
dermal	O
cells	O
(	O
in	O
combination	O
with	O
hair	O
growth	O
)	O
;	O
methods	O
for	O
treating	O
a	O
condition	O
or	O
disease	O
of	O
the	O
skin	O
or	O
at	O
least	O
one	O
symptom	O
thereof	O
,	O
including	O
cosmetic	O
treatment	O
(	O
e.g.	O
,	O
wrinkles	O
,	O
hyperpigmentation	O
,	O
redness	O
,	O
rosacea	O
,	O
dryness	O
,	O
cracking	O
,	O
loss	O
of	O
firmness	O
,	O
loss	O
of	O
elasticity	O
,	O
thinning	O
,	O
and	O
loss	O
of	O
vibrance	O
)	O
.	O

The	O
methods	O
comprise	O
administering	O
a	O
sufficient	O
amount	O
of	O
a	O
CBP	O
/	O
catenin	O
(	O
e.g.	O
,	O
CBP	O
/	O
ss	O
-	O
catenin	O
)	O
antagonist	O
as	O
disclosed	O
,	O
and	O
particularly	O
wherein	O
administration	O
is	O
in	O
an	O
amount	O
and	O
manner	O
sufficient	O
to	O
provide	O
for	O
increasing	O
the	O
number	O
of	O
asymmetric	O
renewing	O
divisions	O
relative	O
to	O
,	O
or	O
at	O
the	O
expense	O
of	O
symmetric	O
divisions	O
in	O
relevant	O
somatic	O
stem	O
cell	O
population	O
.	O

In	O
particular	O
aspects	O
,	O
the	O
CBP	O
/	O
catenin	O
(	O
e.g.	O
,	O
CBP	O
/	O
ss	O
-	O
catenin	O
)	O
antagonist	O
comprises	O
an	O
alkyl	B
and/or	O
fatty	B
acid	I
ester	I
derivative	O
thereof	O
as	O
disclosed	O
herein	O
.	O

CBP	O
/	O
catenin	O
antagonists	O
for	O
enhancing	O
asymmetric	O
division	O
of	O
somatic	O
stem	O
cells	O

The	O
invention	O
provides	O
a	O
method	O
for	O
preparing	O
levofloxacin	B
hydrochloride	I
sodium	B
chloride	I
injection	O
.	O

By	O
researching	O
a	O
liquid	O
medicine	O
preparation	O
method	O
,	O
medicinal	O
charcoal	O
pretreatment	O
and	O
a	O
terminal	O
sterilization	O
process	O
,	O
product	O
quality	O
is	O
ensured	O
by	O
the	O
aid	O
of	O
technologies	O
of	O
a	O
concentrated	O
solution	O
and	O
diluted	O
solution	O
method	O
,	O
charcoal	O
slurry	O
preparation	O
from	O
medicinal	O
charcoal	O
,	O
water	O
bath	O
sterilization	O
and	O
the	O
like	O
,	O
production	O
is	O
facilitated	O
,	O
obtained	O
finished	O
products	O
have	O
higher	O
stability	O
,	O
so	O
that	O
the	O
storage	O
life	O
of	O
the	O
finished	O
products	O
can	O
be	O
prolonged	O
,	O
and	O
clinical	O
use	O
effects	O
are	O
better	O
.	O

Method	O
for	O
preparing	O
levofloxacin	B
hydrochloride	I
sodium	B
chloride	I
injection	O

The	O
invention	O
relates	O
to	O
a	O
compound	O
norfloxacin	B
nicotinate	I
soluble	O
powder	O
for	O
animals	O
.	O

A	O
formula	O
of	O
100	O
g	O
of	O
the	O
powder	O
comprises	O
5	O
-	O
10	O
g	O
of	O
norfloxacin	B
nicotinate	I
,	O
5	O
-	O
10	O
g	O
of	O
apramyein	B
sulfate	I
,	O
2	O
-	O
4	O
g	O
of	O
trimethoprim	B
lactate	I
,	O
and	O
the	O
balance	O
anhydrous	O
glucose	B
.	O

The	O
above	O
medicine	O
can	O
rapidly	O
kill	O
intestinal	O
pathogenic	O
microorganisms	O
to	O
timely	O
effectively	O
control	O
intestinal	O
bacterial	O
diseases	O
of	O
the	O
animals	O
,	O
and	O
alleviates	O
the	O
bacterial	O
drug	O
resistance	O
.	O

Compound	O
norfloxacin	B
nicotinate	I
soluble	O
powder	O
for	O
animals	O
,	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
discloses	O
burn	O
ointment	O
for	O
treating	O
burn	O
.	O

The	O
ointment	O
comprises	O
the	O
following	O
active	O
components	O
by	O
weight	O
:	O
60	O
-	O
80	O
g	O
of	O
indigo	O
naturalis	O
,	O
40	O
-	O
60	O
g	O
of	O
mint	O
,	O
40	O
-	O
60	O
g	O
of	O
astragalus	O
,	O
20	O
-	O
30	O
g	O
of	O
talcum	O
,	O
40	O
-	O
60	O
g	O
of	O
fresh	O
sunflower	O
,	O
50	O
-	O
70	O
g	O
of	O
polygonum	B
cuspidatum	I
,	O
40	O
-	O
60	O
g	O
of	O
ligusticum	O
wallichii	O
,	O
50	O
-	O
70	O
g	O
of	O
bamboo	O
leaves	O
,	O
50	O
-	O
70	O
g	O
of	O
common	O
jujube	O
bark	O
,	O
40	O
-	O
60	O
g	O
of	O
bile	O
arisaema	O
,	O
10	O
-	O
20	O
g	O
of	O
fructus	O
evodiae	O
,	O
40	O
-	O
60	O
g	O
of	O
beewax	O
,	O
40	O
-	O
60	O
g	O
of	O
borneol	O
,	O
and	O
30	O
-	O
50	O
g	O
of	O
angelica	O
root	O
.	O

The	O
ointment	O
can	O
be	O
used	O
for	O
solving	O
the	O
problems	O
of	O
local	O
blood	O
stasis	O
and	O
obstruction	O
,	O
meridian	O
stagnation	O
and	O
toxic	O
heat	O
flourishing	O
,	O
and	O
has	O
good	O
effects	O
in	O
activating	O
blood	O
circulation	O
,	O
removing	O
stasis	O
and	O
dredging	O
collaterals	O
,	O
clearing	O
heat	O
and	O
toxicity	O
and	O
cooling	O
blood	O
,	O
and	O
treating	O
burns	O
,	O
wherein	O
the	O
effective	O
rate	O
is	O
93.6	O
percent	O
,	O
and	O
the	O
rate	O
of	O
favorable	O
curative	O
effect	O
is	O
90.7	O
percent	O
.	O

Burn	O
ointment	O
for	O
treating	O
burn	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
resorcarenes	B
-	I
polysubstitution	I
pyrimidine	I
derivative	O
shown	O
in	O
a	O
general	O
formula	O
I	O
and	O
a	O
salt	O
,	O
ester	O
or	O
prodrug	O
acceptable	O
in	O
pharmacy	O
.	O

The	O
invention	O
also	O
provides	O
a	O
preparation	O
method	O
of	O
the	O
derivative	O
and	O
an	O
application	O
of	O
a	O
composition	O
containing	O
one	O
or	O
a	O
plurality	O
of	O
such	O
type	O
of	O
compounds	O
during	O
preparation	O
of	O
a	O
medicine	O
for	O
treating	O
and	O
preventing	O
infection	O
of	O
an	O
HIV	O
(	O
human	O
immunodeficiency	O
virus	O
)	O
.	O

Resorcarenes	B
-	I
polysubstitution	I
pyrimidine	I
derivative	O
as	O
well	O
as	O
preparation	O
method	O
and	O
application	O
of	O
derivative	O

The	O
invention	O
discloses	O
a	O
combined	O
medicine	O
for	O
treating	O
the	O
diarrhea	O
disease	O
in	O
livestock	O
.	O

The	O
combined	O
medicine	O
comprises	O
the	O
following	O
ingredients	O
in	O
parts	O
by	O
weight	O
:	O
8	O
-	O
12	O
parts	O
of	O
streptomycin	B
sulphate	I
or	O
derivative	O
,	O
4	O
-	O
8	O
parts	O
of	O
sulfamethoxazole	B
or	O
derivative	O
,	O
1	O
-	O
2	O
parts	O
of	O
trimethoprim	B
or	O
derivative	O
,	O
and	O
2	O
-	O
3	O
parts	O
of	O
Tranexamic	B
acid	I
or	O
derivative	O
.	O

The	O
combined	O
medicine	O
disclosed	O
by	O
the	O
invention	O
has	O
the	O
following	O
beneficial	O
effects	O
:	O
a	O
specific	O
antibiotic	O
,	O
a	O
specific	O
bacteriophage	O
and	O
a	O
specific	O
hemostatic	O
agent	O
are	O
used	O
in	O
combination	O
,	O
so	O
that	O
the	O
antibacterial	O
activity	O
and	O
antivirus	O
capacity	O
of	O
the	O
medicine	O
are	O
obviously	O
improved	O
and	O
the	O
curative	O
effect	O
is	O
improved	O
.	O

Combined	O
medicine	O
for	O
treating	O
diarrhea	O
disease	O
in	O
livestock	O

The	O
invention	O
relates	O
to	O
a	O
composition	O
containing	O
mushroom	O
mycelium	O
polysaccharides	O
and	O
applications	O
thereof	O
.	O

The	O
composition	O
comprises	O
following	O
components	O
in	O
percentage	O
by	O
weight	O
:	O
60	O
%	O
to	O
80	O
%	O
of	O
mushroom	O
mycelium	O
polysaccharides	O
,	O
10	O
%	O
to	O
20	O
%	O
of	O
black	O
rice	O
polypeptide	O
,	O
and	O
10	O
%	O
to	O
20	O
%	O
of	O
bird	O
cherry	O
anthocyanin	O
.	O

The	O
composition	O
containing	O
mushroom	O
mycelium	O
polysaccharides	O
can	O
be	O
used	O
to	O
produce	O
anti	O
-	O
fatigue	O
drugs	O
,	O
anti	O
-	O
fatigue	O
health	O
food	O
and	O
feed	O
.	O

Composition	O
containing	O
mushroom	O
mycelium	O
polysaccharides	O
and	O
applications	O
thereof	O

The	O
invention	O
provides	O
a	O
vitamin	B
A	I
nano	O
-	O
emulsion	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
vitamin	B
A	I
nano	O
-	O
emulsion	O
comprises	O
vitamin	B
A	I
and	O
tween-80	O
in	O
a	O
mass	O
ratio	O
of	O
1:	O
(	O
1.5	O
-	O
5	O
)	O
,	O
and	O
water	O
of	O
which	O
the	O
mass	O
is	O
0.5	O
-	O
3	O
times	O
of	O
the	O
total	O
mass	O
of	O
vitamin	B
A	I
and	O
tween-80	O
.	O

The	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
adding	O
vitamin	B
A	I
and	O
tween-80	O
into	O
a	O
container	O
,	O
uniformly	O
mixing	O
,	O
and	O
adding	O
water	O
to	O
obtain	O
a	O
mixed	O
solution	O
;	O
performing	O
ultrasonic	O
treatment	O
on	O
the	O
mixed	O
solution	O
until	O
the	O
mixed	O
solution	O
is	O
clear	O
and	O
transparent	O
,	O
thus	O
obtaining	O
the	O
vitamin	B
A	I
nano	O
-	O
emulsion	O
.	O

The	O
method	O
is	O
used	O
for	O
preparing	O
the	O
vitamin	B
A	I
nano	O
-	O
emulsion	O
by	O
adopting	O
an	O
ultrasonic	O
emulsification	O
method	O
,	O
is	O
simple	O
in	O
production	O
process	O
,	O
mild	O
in	O
condition	O
,	O
short	O
in	O
preparation	O
time	O
and	O
low	O
in	O
equipment	O
requirement	O
.	O

The	O
prepared	O
vitamin	B
A	I
nano	O
-	O
emulsion	O
is	O
of	O
an	O
oil	O
-	O
in	O
-	O
water	O
mode	O
,	O
is	O
clear	O
and	O
transparent	O
,	O
excellent	O
in	O
water	O
solution	O
and	O
good	O
in	O
stability	O
,	O
has	O
a	O
grain	O
distribution	O
range	O
of	O
23	O
-	O
62	O
nm	O
and	O
average	O
grain	O
diameter	O
of	O
38	O
nm	O
,	O
and	O
accords	O
with	O
the	O
basic	O
characteristics	O
of	O
a	O
nano	O
-	O
grade	O
material	O
.	O

Vitamin	B
A	I
nano	O
-	O
emulsion	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
compound	O
alpha	B
-	I
ketoacid	I
tablet	O
free	O
of	O
talcum	O
powder	O
and	O
a	O
preparation	O
process	O
thereof	O
.	O

The	O
conventional	O
preparation	O
process	O
is	O
changed	O
without	O
adding	O
the	O
talcum	O
powder	O
;	O
the	O
tablet	O
prepared	O
by	O
the	O
method	O
has	O
good	O
compressibility	O
,	O
attractive	O
appearance	O
,	O
high	O
disintegrating	O
speed	O
,	O
high	O
dissolution	O
rate	O
,	O
high	O
stability	O
in	O
long	O
-	O
term	O
placement	O
and	O
high	O
medicinal	O
safety	O
.	O

Wet	O
granulation	O
is	O
performed	O
separately	O
according	O
to	O
the	O
acidic	O
and	O
alkaline	O
ingredients	O
and	O
the	O
mass	O
balance	O
ratio	O
of	O
main	O
medicines	O
,	O
i.e.	O
,	O
a	O
meta	O
-	O
alkaline	O
ingredient	O
,	O
a	O
meta	O
-	O
acidic	O
ingredient	O
and	O
a	O
nearly	O
neutral	O
ingredient	O
are	O
subjected	O
to	O
wet	O
granulation	O
separately	O
,	O
and	O
then	O
mixing	O
,	O
tabletting	O
and	O
coating	O
are	O
performed	O
,	O
so	O
that	O
the	O
direct	O
contact	O
among	O
the	O
ingredients	O
is	O
avoided	O
,	O
long	O
-	O
term	O
stable	O
placement	O
can	O
be	O
realized	O
and	O
the	O
contents	O
of	O
the	O
active	O
ingredients	O
are	O
guaranteed	O
.	O

A	O
disintegrating	O
agent	O
internal	O
and	O
external	O
addition	O
method	O
is	O
adopted	O
in	O
the	O
formula	O
,	O
the	O
content	O
of	O
polyethylene	B
glycol	I
is	O
optimized	O
,	O
and	O
no	O
talcum	O
powder	O
or	O
analogs	O
with	O
ingredients	O
similar	O
to	O
the	O
talcum	O
powder	O
are	O
included	O
in	O
the	O
formula	O
,	O
so	O
that	O
the	O
problems	O
of	O
agglomeration	O
phenomenon	O
and	O
larger	O
viscosity	O
in	O
the	O
granulation	O
process	O
are	O
solved	O
,	O
and	O
the	O
safety	O
in	O
medication	O
is	O
guaranteed	O
.	O

Compound	O
alpha	B
-	I
ketoacid	I
tablet	O
free	O
of	O
talcum	O
powder	O
and	O
preparation	O
process	O
thereof	O

The	O
invention	O
discloses	O
application	O
of	O
a	O
tumor	O
inhibitor	O
MLN4924	O
to	O
preparation	O
of	O
an	O
antiviral	O
drug	O
.	O

Experiments	O
prove	O
that	O
the	O
small	O
-	O
molecule	O
inhibitor	O
MLN4924	O
with	O
good	O
performance	O
in	O
human	O
anti	O
-	O
tumor	O
clinical	O
trials	O
is	O
strong	O
in	O
antiviral	O
activity	O
and	O
can	O
inhibit	O
virus	O
replication	O
by	O
more	O
than	O
80	O
%	O
due	O
to	O
the	O
virus	O
inhibition	O
accessory	O
protein	O
function	O
.	O

With	O
long	O
preliminary	O
experimental	O
clinical	O
experience	O
and	O
a	O
strong	O
drug	O
action	O
effect	O
,	O
the	O
drug	O
can	O
be	O
produced	O
in	O
a	O
large	O
scale	O
and	O
has	O
great	O
potential	O
of	O
becoming	O
an	O
efficient	O
antiviral	O
drug	O
.	O

Through	O
an	O
ubiquitin	O
system	O
for	O
inhibiting	O
Neddylation	O
activation	O
dominated	O
by	O
virus	O
protein	O
by	O
small	O
molecule	O
drugs	O
,	O
the	O
application	O
value	O
of	O
the	O
tumor	O
inhibitor	O
MLN4924	O
for	O
preparing	O
the	O
antiviral	O
drug	O
is	O
detected	O
.	O

Application	O
of	O
tumor	O
inhibitor	O
MLN4924	O
to	O
preparation	O
of	O
antiviral	O
drug	O

The	O
invention	O
discloses	O
a	O
preparation	O
method	O
for	O
a	O
gel	O
,	O
belonging	O
to	O
the	O
field	O
of	O
preparation	O
of	O
medicines	O
.	O

The	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
extracting	O
common	O
cnidium	O
fruit	O
to	O
obtain	O
an	O
extract	O
containing	O
osthole	B
and	O
carrying	O
out	O
clathration	O
on	O
the	O
extract	O
by	O
using	O
beta	O
-	O
cyclodextrin	O
or	O
hydroxypropyl	O
-	O
beta	O
-	O
cyclodextrin	O
so	O
as	O
to	O
obtain	O
a	O
clathrate	O
of	O
the	O
extract	O
of	O
common	O
cnidium	O
fruit	O
;	O
treating	O
clindamycin	B
hydrochloride	I
and	O
adding	O
a	O
saturated	O
aqueous	O
solution	O
prepared	O
from	O
beta	O
-	O
cyclodextrin	O
so	O
as	O
to	O
obtain	O
a	O
clindamycin	B
hydrochloride	I
clathrate	O
;	O
and	O
mixing	O
the	O
clathrate	O
of	O
the	O
extract	O
of	O
common	O
cnidium	O
fruit	O
with	O
the	O
clindamycin	B
hydrochloride	I
clathrate	O
,	O
adding	O
hydroxypropyl	O
methylcellulose	O
,	O
water	O
,	O
glycerin	B
,	O
chitosan	O
,	O
a	O
10	O
%	O
ethylparaben	B
ethanol	B
solution	O
,	O
a	O
10	O
%	O
aqueous	O
sodium	B
hydrosulphite	I
solution	O
and	O
Tween-80	B
and	O
carrying	O
out	O
mixing	O
with	O
stirring	O
so	O
as	O
to	O
obtain	O
the	O
gel	O
.	O

With	O
the	O
preparation	O
method	O
provided	O
by	O
the	O
invention	O
,	O
the	O
gel	O
can	O
safely	O
and	O
effectively	O
perform	O
curative	O
effects	O
and	O
has	O
reduced	O
irritation	O
,	O
improved	O
solubility	O
,	O
an	O
accelerated	O
dissolution	O
speed	O
and	O
enhanced	O
bioavailability	O
.	O

Preparation	O
method	O
for	O
gel	O

The	O
invention	O
provides	O
a	O
preparation	O
method	O
for	O
a	O
Sanhuang	O
tablet	O
.	O

The	O
Sanhuang	O
tablet	O
is	O
prepared	O
from	O
the	O
bulk	O
drugs	O
consisting	O
of	O
300	O
g	O
of	O
rhubarb	O
root	O
and	O
rhizome	O
,	O
5	O
g	O
of	O
berberine	B
hydrochloride	I
and	O
80	O
g	O
of	O
baical	O
skullcap	O
root	O
extract	O
through	O
supercritical	O
extraction	O
,	O
so	O
the	O
content	O
of	O
Sanhuang	O
tablet	O
is	O
greatly	O
increased	O
,	O
and	O
the	O
dose	O
of	O
the	O
Sanhuang	O
tablet	O
is	O
reduced	O
.	O

The	O
invention	O
further	O
provides	O
application	O
of	O
the	O
Sanhuang	O
tablet	O
in	O
preparation	O
of	O
drugs	O
used	O
for	O
inhibiting	O
cell	O
proliferation	O
of	O
human	O
large	O
cell	O
carcinoma	O
NCI	O
-	O
H460	O
.	O

Preparation	O
method	O
for	O
Sanhuang	O
tablet	O

The	O
invention	O
relates	O
to	O
a	O
dextromethorphan	B
hydrobromide	I
injection	O
prepared	O
from	O
the	O
following	O
raw	O
materials	O
:	O
15	O
g	O
of	O
dextromethorphan	B
hydrobromide	I
,	O
13	O
g	O
of	O
lactic	B
acid	I
,	O
7	O
g	O
of	O
sorbic	B
acid	I
,	O
42	O
g	O
of	O
polyethylene	B
glycol	I
2000	I
and	O
2000ml	O
of	O
water	O
for	O
injection	O
through	O
adjusting	O
the	O
pH	O
value	O
to	O
3.4	O
-	O
3.5	O
.	O

Dextromethorphan	B
hydrobromide	I
injection	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
proanthocyanidin	B
sustained	O
release	O
nano	O
-	O
micro	O
spheres	O
.	O

The	O
proanthocyanidin	O
sustained	O
release	O
nano	O
-	O
micro	O
spheres	O
comprise	O
1	O
-	O
5	O
parts	O
of	O
proanthocyanidin	B
,	O
1	O
-	O
12	O
parts	O
of	O
chitosan	O
or	O
derivatives	O
thereof	O
,	O
1	O
-	O
12	O
parts	O
of	O
phospholipid	B
or	O
derivatives	O
thereof	O
and	O
1	O
-	O
10	O
parts	O
of	O
excipients	O
,	O
wherein	O
the	O
chitosan	O
and	O
the	O
derivatives	O
thereof	O
are	O
one	O
or	O
more	O
of	O
high	O
,	O
medium	O
and	O
low	O
-	O
molecular	O
weight	O
chitosan	O
,	O
chitosan	O
oligosaccharide	O
,	O
chitosan	O
quaternary	O
ammonium	O
salt	O
and	O
carboxymethyl	O
chitosan	O
.	O

The	O
particle	O
size	O
of	O
the	O
proanthocyanidin	B
sustained	O
release	O
nano	O
-	O
micro	O
spheres	O
is	O
10nm-0.3	O
mu	O
m	O
;	O
the	O
proanthocyanidin	B
is	O
prepared	O
into	O
the	O
powder	O
sustained	O
release	O
nano	O
-	O
micro	O
spheres	O
,	O
and	O
the	O
proanthocyanidin	B
sustained	O
release	O
nano	O
-	O
micro	O
spheres	O
can	O
directly	O
play	O
a	O
role	O
in	O
the	O
lung	O
as	O
a	O
pulmonary	O
inhalation	O
medicine	O
-	O
carrying	O
formulation	O
,	O
improve	O
the	O
bioavailability	O
of	O
the	O
proanthocyanidin	B
and	O
reduce	O
the	O
dosage	O
by	O
sustained	O
release	O
;	O
the	O
proanthocyanidin	B
nano	O
-	O
micro	O
spheres	O
can	O
also	O
be	O
applied	O
as	O
an	O
oral	O
sustained	O
release	O
formulation	O
;	O
the	O
proanthocyanidin	B
nano	O
-	O
micro	O
spheres	O
have	O
appropriate	O
particle	O
size	O
and	O
morphology	O
and	O
other	O
powder	O
properties	O
,	O
as	O
well	O
as	O
sustained	O
release	O
;	O
furthermore	O
,	O
the	O
preparation	O
method	O
has	O
the	O
advantages	O
of	O
simplicity	O
and	O
convenience	O
in	O
operation	O
,	O
stable	O
process	O
and	O
easiness	O
in	O
industrial	O
production	O
.	O

Proanthocyanidin	B
sustained	O
release	O
nano	O
-	O
micro	O
spheres	O
,	O
as	O
well	O
as	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
application	O
of	O
fisetin	B
in	O
preparation	O
of	O
a	O
drug	O
with	O
anticoagulation	O
,	O
anti	O
-	O
thrombosis	O
and	O
cardioprotective	O
effects	O
.	O

The	O
drug	O
can	O
reduce	O
ischemic	O
myocardial	O
cell	O
inflammatory	O
response	O
,	O
and	O
has	O
the	O
anticoagulation	O
,	O
anti	O
-	O
thrombosis	O
and	O
cardioprotective	O
effects	O
.	O

According	O
to	O
the	O
technical	O
scheme	O
provided	O
by	O
the	O
invention	O
,	O
application	O
of	O
the	O
fisetin	O
in	O
preparation	O
of	O
an	O
anticoagulation	O
drug	O
for	O
generating	O
anticoagulation	O
effects	O
is	O
for	O
inhibiting	O
ADP	B
-	O
induced	O
platelet	O
aggregation	O
,	O
inhibiting	O
thrombocyte	O
release	O
,	O
and	O
reducing	O
serum	O
Fg	O
and	O
vWF	O
content	O
to	O
achieve	O
anticoagulation	O
function	O
;	O
application	O
of	O
the	O
fisetin	O
in	O
preparation	O
of	O
an	O
anti	O
-	O
thrombosis	O
drug	O
is	O
also	O
for	O
significantly	O
prolonging	O
CT	O
,	O
PT	O
,	O
TT	O
and	O
APTT	O
to	O
indirectly	O
achieve	O
an	O
anti	O
-	O
thrombosis	O
effect	O
;	O
moreover	O
,	O
application	O
of	O
the	O
fisetin	O
in	O
preparation	O
of	O
a	O
drug	O
with	O
the	O
cardioprotective	O
effects	O
on	O
ischemia	O
/	O
reperfusion	O
myocardial	O
cells	O
is	O
for	O
reducing	O
the	O
ischemic	O
myocardial	O
cell	O
inflammatory	O
response	O
,	O
decreasing	O
the	O
infarct	O
area	O
of	O
injured	O
cardiac	O
muscle	O
and	O
achieving	O
a	O
protection	O
effect	O
on	O
the	O
ischemic	O
myocardial	O
cell	O
by	O
means	O
of	O
inhibiting	O
inflammatory	O
cells	O
invasion	O
,	O
MMP-9	O
and	O
NF	O
-	O
kB	O
expression	O
and	O
NF	O
-	O
kB	O
nuclear	O
migration	O
,	O
myocardial	O
apoptosis	O
and	O
the	O
like	O
.	O

Application	O
of	O
fisetin	B
in	O
preparation	O
of	O
drug	O
with	O
anticoagulation	O
,	O
anti	O
-	O
thrombosis	O
and	O
cardioprotective	O
effects	O

The	O
invention	O
discloses	O
a	O
haemorrhoid	O
treatment	O
lotion	O
,	O
which	O
is	O
used	O
for	O
positively	O
preventing	O
,	O
treating	O
and	O
performing	O
health	O
-	O
care	O
to	O
patients	O
with	O
three	O
human	O
common	O
diseases	O
,	O
namely	O
haemorrhoid	O
,	O
acnes	O
and	O
male	O
and	O
female	O
sexual	O
dysfunctions	O
,	O
as	O
well	O
as	O
frequently	O
-	O
occurring	O
diseases	O
radically	O
by	O
a	O
mode	O
of	O
self	O
-	O
healthcare	O
or	O
simple	O
self	O
-	O
therapy	O
in	O
daily	O
lives	O
.	O

The	O
lotion	O
is	O
characterized	O
by	O
being	O
prepared	O
from	O
15	O
elementary	O
components	O
according	O
to	O
a	O
scientific	O
proportional	O
prescription	O
and	O
compatibility	O
.	O

The	O
lotion	O
has	O
the	O
characteristics	O
of	O
wide	O
adaptability	O
,	O
high	O
popularization	O
and	O
application	O
values	O
,	O
safety	O
and	O
efficiency	O
,	O
and	O
no	O
toxic	O
or	O
side	O
effect	O
,	O
the	O
aim	O
that	O
the	O
three	O
diseases	O
severely	O
disturbing	O
human	O
beings	O
by	O
an	O
economical	O
and	O
simple	O
method	O
can	O
be	O
achieved	O
,	O
and	O
the	O
novel	O
product	O
has	O
three	O
dramatic	O
efficacies	O
and	O
applications	O
.	O

Haemorrhoid	O
treatment	O
lotion	O

The	O
invention	O
discloses	O
an	O
antibacterial	O
anti	O
-	O
inflammatory	O
medicament	O
.	O

The	O
antibacterial	O
anti	O
-	O
inflammatory	O
medicament	O
is	O
characterized	O
by	O
consisting	O
of	O
the	O
following	O
raw	O
materials	O
according	O
to	O
percentage	O
by	O
weight	O
:	O
5	O
-	O
15	O
%	O
of	O
folium	O
ginkgo	O
extract	O
,	O
10	O
-	O
15	O
%	O
of	O
dandelion	O
extract	O
,	O
8	O
-	O
10	O
%	O
of	O
borneol	B
,	O
10	O
-	O
20	O
%	O
of	O
folium	O
artemisiae	O
argyi	O
extract	O
,	O
10	O
-	O
15	O
%	O
of	O
honey	O
,	O
5	O
-	O
10	O
%	O
of	O
felwort	O
extract	O
,	O
5	O
-	O
15	O
%	O
of	O
seven	O
-	O
leaf	O
ginseng	O
extract	O
,	O
5	O
-	O
15	O
%	O
of	O
pueraria	O
extract	O
,	O
10	O
-	O
15	O
%	O
of	O
pseudo	O
-	O
ginseng	O
extract	O
and	O
15	O
-	O
30	O
%	O
of	O
medical	O
ethanol	B
.	O

The	O
antibacterial	O
anti	O
-	O
inflammatory	O
medicament	O
has	O
the	O
advantages	O
that	O
the	O
prepared	O
medicament	O
has	O
a	O
quick	O
anti	O
-	O
inflammation	O
effect	O
and	O
a	O
high	O
curative	O
effect	O
,	O
generates	O
no	O
resistance	O
to	O
medicaments	O
on	O
bacteria	O
and	O
has	O
a	O
remarkable	O
effect	O
on	O
such	O
diseases	O
caused	O
by	O
fungus	O
as	O
tinea	O
pedis	O
,	O
tinea	O
manuum	O
,	O
neurodermatitis	O
,	O
contact	O
dermatitis	O
and	O
onychomycosis	O
.	O

Antibacterial	O
anti	O
-	O
inflammatory	O
medicament	O

The	O
invention	O
discloses	O
a	O
capsule	O
and	O
a	O
tablet	O
containing	O
rich	O
hydroxytyrosol	B
,	O
lycium	O
barbarum	O
polysaccharide	O
and	O
apple	O
polyphenol	B
and	O
particularly	O
discloses	O
a	O
preparation	O
product	O
used	O
for	O
protecting	O
liver	O
.	O

The	O
preparation	O
product	O
,	O
namely	O
the	O
capsule	O
or	O
tablet	O
comprises	O
the	O
following	O
components	O
in	O
percentage	O
by	O
weight	O
:	O
0	O
-	O
60	O
%	O
of	O
hydroxytyrosol	B
,	O
0	O
-	O
30	O
%	O
of	O
lycium	O
barbarum	O
polysaccharide	O
,	O
0	O
-	O
50	O
%	O
of	O
apple	O
polyphenol	B
,	O
20	O
-	O
98	O
%	O
of	O
starch	O
,	O
0	O
-	O
20	O
%	O
of	O
xylitol	B
,	O
0	O
-	O
10	O
%	O
of	O
aspartame	B
and	O
0	O
-	O
2	O
%	O
of	O
magnesium	B
stearate	I
.	O

On	O
the	O
condition	O
of	O
satisfying	O
the	O
preparation	O
processing	O
and	O
producing	O
conditions	O
,	O
the	O
components	O
are	O
respectively	O
filtered	O
through	O
a	O
sieve	O
of	O
10	O
-	O
100	O
meshes	O
and	O
are	O
weighed	O
and	O
uniformly	O
mixed	O
according	O
to	O
prescriptions	O
,	O
the	O
mixed	O
components	O
are	O
pelletized	O
and	O
dried	O
,	O
and	O
products	O
with	O
proper	O
particle	O
sizes	O
are	O
selected	O
and	O
are	O
filled	O
to	O
capsules	O
or	O
tabletted	O
.	O

The	O
preparation	O
product	O
disclosed	O
by	O
the	O
invention	O
has	O
strong	O
oxidation	O
resistance	O
and	O
radiation	O
resistance	O
and	O
has	O
a	O
strong	O
effect	O
of	O
recovering	O
health	O
of	O
human	O
body	O
internal	O
organs	O
and	O
especially	O
protecting	O
the	O
liver	O
,	O
and	O
the	O
efficacy	O
is	O
better	O
than	O
the	O
single	O
component	O
effect	O
in	O
the	O
formulation	O
.	O

Since	O
the	O
dosage	O
of	O
a	O
single	O
component	O
in	O
the	O
composition	O
disclosed	O
by	O
the	O
invention	O
is	O
relatively	O
decreased	O
,	O
adverse	O
reactions	O
caused	O
by	O
single	O
use	O
of	O
the	O
single	O
component	O
is	O
alleviated	O
or	O
reduced	O
.	O

The	O
composition	O
disclosed	O
by	O
invention	O
has	O
the	O
advantages	O
of	O
being	O
clear	O
in	O
curative	O
effect	O
,	O
free	O
of	O
toxic	O
side	O
effect	O
,	O
convenient	O
to	O
take	O
and	O
low	O
in	O
price	O
.	O

Capsule	O
and	O
preparation	O
containing	O
rich	O
hydroxytyrosol	B
,	O
lycium	O
barbarum	O
polysaccharide	O
and	O
apple	O
polyphenol	B
and	O
used	O
for	O
protecting	O
liver	O

The	O
invention	O
relates	O
to	O
a	O
compound	O
vitamin	B
lyophilized	O
preparation	O
for	O
injection	O
and	O
its	O
preparation	O
method	O
.	O

According	O
to	O
the	O
invention	O
,	O
a	O
scientific	O
prescription	O
and	O
preparation	O
process	O
are	O
utilized	O
to	O
make	O
the	O
prepared	O
compound	O
vitamin	B
lyophilized	O
preparation	O
for	O
injection	O
have	O
the	O
advantages	O
of	O
high	O
stability	O
,	O
low	O
impurity	O
content	O
and	O
the	O
like	O
.	O

Compound	O
vitamin	B
lyophilized	O
preparation	O
for	O
injection	O
and	O
its	O
preparation	O
method	O

The	O
invention	O
provides	O
a	O
damp	O
clearing	O
decoction	O
which	O
is	O
a	O
medicament	O
prepared	O
from	O
the	O
following	O
raw	O
materials	O
in	O
parts	O
by	O
weight	O
:	O
5	O
-	O
7	O
parts	O
of	O
rhizoma	O
alismatis	O
,	O
8	O
-	O
12	O
parts	O
of	O
plantain	O
seed	O
,	O
8	O
-	O
12	O
parts	O
of	O
talc	O
,	O
5	O
-	O
7	O
parts	O
of	O
cortex	O
phellodendri	O
,	O
5	O
-	O
7	O
parts	O
of	O
white	O
poria	O
,	O
5	O
-	O
7	O
parts	O
of	O
caulis	O
akebiae	O
,	O
8	O
-	O
12	O
parts	O
of	O
christina	O
loosestrife	O
herb	O
,	O
8	O
-	O
12	O
parts	O
of	O
japanese	O
climbing	O
fern	O
spore	O
,	O
15	O
-	O
18	O
parts	O
of	O
herba	O
pyrrosiae	O
stephania	O
,	O
15	O
-	O
18	O
parts	O
of	O
rhizoma	O
atractylodis	O
sinensis	O
,	O
15	O
-	O
18	O
parts	O
of	O
cortex	O
eucommiae	O
,	O
15	O
-	O
18	O
parts	O
of	O
psoralea	O
corylifolia	O
,	O
5	O
-	O
7	O
parts	O
of	O
phaseolus	O
calcaratus	O
and	O
5	O
-	O
7	O
parts	O
of	O
euphorbia	O
helioscopia	O
.	O

By	O
taking	O
the	O
decoction	O
provided	O
by	O
the	O
invention	O
,	O
the	O
damp	O
in	O
a	O
body	O
can	O
be	O
effectively	O
cleared	O
,	O
and	O
the	O
immunity	O
of	O
the	O
body	O
is	O
enhanced	O
.	O

Damp	O
clearing	O
decoction	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
bufalin	O
derivative	O
having	O
a	O
structure	O
represented	O
as	O
a	O
general	O
formula	O
I	O
,	O
wherein	O
R	O
is	O
selected	O
from	O
one	O
of	O
the	O
following	O
structure	O
groups	O
as	O
shown	O
in	O
the	O
specification	O
,	O
or	O
pharmaceutically	O
acceptable	O
salt	O
,	O
as	O
well	O
as	O
a	O
preparation	O
method	O
,	O
a	O
pharmaceutical	O
composition	O
and	O
application	O
of	O
the	O
derivative	O
.	O

The	O
bufalin	O
derivative	O
has	O
an	O
activity	O
on	O
inhibiting	O
tumor	O
cell	O
lines	O
,	O
and	O
can	O
be	O
used	O
as	O
a	O
medicine	O
for	O
treating	O
malignant	O
tumors	O
.	O

Bufalin	O
derivative	O
as	O
well	O
as	O
preparation	O
method	O
,	O
pharmaceutical	O
composition	O
and	O
application	O
thereof	O

The	O
invention	O
discloses	O
a	O
preparation	O
capable	O
of	O
increasing	O
bone	O
mineral	O
density	O
.	O

The	O
preparation	O
is	O
prepared	O
with	O
the	O
main	O
raw	O
materials	O
including	O
American	O
ginseng	O
powder	O
,	O
walnut	O
powder	O
,	O
soy	O
isoflavone	B
and	O
calcium	B
phosphate	I
.	O

The	O
product	O
is	O
prepared	O
according	O
to	O
the	O
appropriate	O
ratio	O
,	O
so	O
as	O
to	O
generate	O
synergistic	O
effects	O
,	O
and	O
is	O
in	O
particular	O
suitable	O
for	O
having	O
by	O
the	O
middle	O
aged	O
and	O
elderly	O
people	O
.	O

Preparation	O
capable	O
of	O
increasing	O
bone	O
mineral	O
density	O

The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicines	O
and	O
relates	O
to	O
a	O
medical	O
application	O
of	O
2	B
,	I
2-dimethyl	I
thiochromanone	I
compounds	O
containing	O
piperazine	B
structures	O
and	O
analogues	O
thereof	O
.	O

The	O
structural	O
general	O
formula	O
of	O
the	O
2	B
,	I
2-dimethyl	I
thiochromanone	I
compounds	O
is	O
shown	O
in	O
the	O
specification	O
,	O
wherein	O
in	O
the	O
general	O
formula	O
,	O
X	O
is	O
independently	O
selected	O
from	O
CH2	B
or	O
C	B
=	I
O	I
;	O
when	O
Y	O
is	O
selected	O
from	O
CH2	B
,	O
Ar	B
is	O
independently	O
selected	O
from	O
methyl	B
,	O
hydroxy	B
,	O
methoxy	B
,	O
ethoxy	B
,	O
nitryl	B
,	O
fluorine	B
,	O
chlorine	B
,	O
bromine	B
substituted	O
or	O
unsubstituted	O
phenyl	B
;	O
n	O
is	O
defined	O
as	O
an	O
integer	O
from	O
0	O
to	O
3	O
;	O
and	O
X	O
is	O
independently	O
selected	O
from	O
CH2	B
or	O
C	B
=	I
O	I
;	O
when	O
Y	O
is	O
selected	O
from	O
C	B
=	I
O	I
,	O
Ar	O
is	O
independently	O
selected	O
from	O
methyl	B
,	O
hydroxy	B
,	O
methoxy	B
,	O
ethoxy	B
,	O
nitryl	B
,	O
fluorine	B
,	O
chlorine	B
,	O
bromine	B
substituted	O
or	O
unsubstituted	O
phenyl	B
;	O
and	O
n	O
is	O
defined	O
as	O
an	O
integer	O
from	O
1	O
to	O
3	O
.	O

The	O
novel	O
compounds	O
provided	O
by	O
the	O
invention	O
are	O
used	O
as	O
effective	O
antiplatelet	O
drugs	O
and	O
are	O
especially	O
used	O
for	O
preparing	O
drugs	O
for	O
preventing	O
or	O
treating	O
platelet	O
aggregation	O
caused	O
coronary	O
syndrome	O
,	O
myocardial	O
infarction	O
,	O
myocardial	O
ischemia	O
and	O
cardiovascular	O
and	O
cerebrovascular	O
diseases	O
for	O
clinical	O
use	O
.	O

Medical	O
application	O
of	O
2	B
,	I
2-dimethyl	I
thiochromanone	I
compounds	O
containing	O
piperazine	B
structures	O
and	O
analogues	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
pantoprazole	B
sodium	I
freeze	O
-	O
dried	O
powder	O
injection	O
used	O
for	O
injection	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

According	O
to	O
a	O
freeze	O
-	O
drying	O
method	O
for	O
the	O
pantoprazole	B
sodium	I
freeze	O
-	O
dried	O
powder	O
injection	O
used	O
for	O
injection	O
,	O
every	O
1000	O
bottles	O
of	O
the	O
pantoprazole	B
sodium	I
freeze	O
-	O
dried	O
powder	O
injection	O
are	O
prepared	O
by	O
dissolving	O
the	O
components	O
consisting	O
of	O
pantoprazole	B
sodium	I
,	O
mannitol	B
,	O
calcium	B
edentate	I
/	O
sodium	B
edentate	I
/	O
sodium	B
calcium	I
edentate	I
and	O
citric	B
acid	I
in	O
injection	O
water	O
to	O
obtain	O
drug	O
liquid	O
and	O
freeze	O
-	O
drying	O
the	O
drug	O
liquid	O
,	O
wherein	O
before	O
freeze	O
-	O
drying	O
of	O
the	O
drug	O
liquid	O
,	O
a	O
proper	O
amount	O
of	O
sodium	B
hydroxide	I
is	O
used	O
to	O
adjust	O
a	O
pH	O
value	O
to	O
9.5	O
to	O
10.5	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
1	O
)	O
weighing	O
;	O
2	O
)	O
preparation	O
;	O
3	O
)	O
degerming	O
and	O
filtering	O
;	O
4	O
)	O
bottle	O
washing	O
,	O
drying	O
and	O
disinfection	O
;	O
5	O
)	O
rubber	O
plug	O
cleaning	O
,	O
disinfection	O
and	O
drying	O
;	O
6	O
)	O
filling	O
;	O
7	O
)	O
freeze	O
-	O
drying	O
and	O
plug	O
pressing	O
;	O
and	O
8)	O
cover	O
rolling	O
.	O

With	O
such	O
a	O
technical	O
scheme	O
,	O
the	O
preparation	O
method	O
enables	O
sublimation	O
and	O
drying	O
time	O
to	O
be	O
saved	O
,	O
energy	O
consumption	O
to	O
be	O
reduced	O
and	O
product	O
quality	O
to	O
be	O
guaranteed	O
.	O

Pantoprazole	B
sodium	I
freeze	O
-	O
dried	O
powder	O
injection	O
used	O
for	O
injection	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
provides	O
a	O
drug	O
delivery	O
system	O
for	O
16-dehydropregnenolone	B
(	O
DHP	B
)	O
lipidosome	O
for	O
injection	O
and	O
a	O
preparation	O
method	O
.	O

The	O
drug	O
delivery	O
system	O
comprises	O
effective	O
amount	O
of	O
16-dehydropregnenolone	B
,	O
a	O
phospholipid	B
membrane	O
,	O
a	O
membrane	O
stabilization	O
material	O
and	O
pharmaceutically	O
-	O
acceptable	O
auxiliary	O
materials	O
,	O
wherein	O
the	O
weight	O
ratio	O
of	O
the	O
16-dehydropregnenolone	B
to	O
the	O
phospholipid	B
membrane	O
to	O
the	O
membrane	O
stabilization	O
material	O
is	O
1:5:0.2	O
-	O
1:50:50	O
.	O

The	O
preparation	O
technology	O
comprises	O
the	O
steps	O
of	O
preparing	O
multi	O
-	O
chamber	O
lipidosome	O
,	O
homogenizing	O
the	O
lipidosome	O
,	O
metering	O
volume	O
,	O
sterilizing	O
,	O
subpackaging	O
,	O
freeze	O
-	O
drying	O
and	O
the	O
like	O
.	O

The	O
lipidosome	O
prepared	O
by	O
the	O
method	O
is	O
small	O
in	O
average	O
grain	O
diameter	O
,	O
narrow	O
in	O
distribution	O
,	O
high	O
in	O
encapsulation	O
efficiency	O
,	O
high	O
in	O
drug	O
loading	O
capacity	O
,	O
good	O
in	O
repeatability	O
and	O
good	O
in	O
stability	O
,	O
and	O
can	O
satisfy	O
the	O
requirements	O
on	O
intravenous	O
injection	O
.	O

The	O
results	O
of	O
anti	O
-	O
tumor	O
in	O
vivo	O
experiments	O
show	O
that	O
16-DHP	B
lipidosome	O
prepared	O
by	O
the	O
invention	O
can	O
remarkably	O
inhibit	O
growth	O
of	O
a	O
transplantation	O
tumor	O
of	O
a	O
nude	O
mouse	O
bearing	O
the	O
tumor	O
and	O
has	O
a	O
relatively	O
good	O
anti	O
-	O
tumor	O
effect	O
.	O

An	O
experiment	O
result	O
of	O
rat	O
pharmacokinetics	O
shows	O
that	O
the	O
16-DHP	B
lipidosome	O
prepared	O
by	O
the	O
invention	O
can	O
prolong	O
the	O
time	O
that	O
a	O
medicine	O
stays	O
in	O
the	O
body	O
and	O
improve	O
the	O
amount	O
of	O
the	O
medicine	O
that	O
enters	O
systemic	O
circulation	O
of	O
a	O
rat	O
.	O

Drug	O
delivery	O
system	O
for	O
16-dehydropregnenolone	B
lipidosome	O
for	O
injection	O
and	O
preparation	O
method	O
of	O
same	O

The	O
invention	O
discloses	O
a	O
formula	O
and	O
a	O
preparation	O
method	O
for	O
an	O
externally	O
-	O
applied	O
medicine	O
capable	O
of	O
rapidly	O
diminishing	O
inflammation	O
and	O
relieving	O
pain	O
.	O

The	O
formula	O
comprises	O
,	O
by	O
mass	O
,	O
3.5	O
%	O
of	O
sorbitan	B
olivate	I
,	O
3	O
%	O
of	O
cetearyl	B
alcohol	I
,	O
2	O
%	O
of	O
squalane	B
,	O
2	O
%	O
of	O
iso	B
-	I
octyl	I
palmitate	I
,	O
2	O
%	O
of	O
caprylic	B
/	I
capric	I
triglyceride	I
,	O
0.5	O
%	O
of	O
xanthan	O
gum	O
,	O
4	O
%	O
of	O
glycerin	B
,	O
0.5	O
%	O
of	O
azelaic	B
acid	I
,	O
2	O
%	O
of	O
aloe	O
,	O
1	O
%	O
of	O
a	O
honeysuckle	O
flower	O
extract	O
,	O
1	O
%	O
of	O
a	O
chrysanthemum	O
extract	O
,	O
0.05	O
%	O
of	O
a	O
freshener	O
(	O
menthol	B
)	O
,	O
0.1	O
%	O
of	O
methyl	B
hydroxybenzoate	I
,	O
0.1	O
%	O
of	O
propyl	B
hydroxybenzoate	I
,	O
0.15	O
%	O
of	O
imidazolidinyl	B
urea	I
and	O
79.1	O
%	O
of	O
water	O
.	O

The	O
medicine	O
is	O
prepared	O
by	O
processing	O
the	O
above	O
-	O
mentioned	O
components	O
.	O

The	O
medicine	O
provided	O
by	O
the	O
invention	O
uses	O
herbaceous	O
plants	O
as	O
raw	O
materials	O
and	O
has	O
small	O
toxic	O
and	O
side	O
effects	O
;	O
the	O
medicine	O
can	O
be	O
directly	O
applied	O
on	O
the	O
surface	O
layer	O
of	O
the	O
skin	O
,	O
targetedly	O
reaches	O
a	O
desired	O
site	O
through	O
rapid	O
absorption	O
by	O
the	O
skin	O
,	O
exerts	O
good	O
anti	O
-	O
inflammation	O
and	O
sterilization	O
effects	O
and	O
has	O
fast	O
action	O
.	O

Formula	O
and	O
preparation	O
method	O
for	O
externally	O
-	O
applied	O
medicine	O
capable	O
of	O
rapidly	O
diminishing	O
inflammation	O
and	O
relieving	O
pain	O

The	O
invention	O
relates	O
to	O
veterinary	O
drugs	O
,	O
in	O
particular	O
to	O
a	O
scourge	O
-	O
clearing	O
toxin	O
-	O
vanquishing	O
drug	O
,	O
and	O
aims	O
to	O
provide	O
the	O
scourge	O
-	O
clearing	O
toxin	O
-	O
vanquishing	O
drug	O
which	O
has	O
small	O
side	O
effects	O
.	O

The	O
formula	O
of	O
the	O
scourge	O
-	O
clearing	O
toxin	O
-	O
vanquishing	O
drug	O
comprises	O
the	O
following	O
components	O
:	O
60	O
g	O
of	O
plaster	O
,	O
30	O
-	O
45	O
g	O
of	O
radix	O
rehmanniae	O
,	O
60	O
g	O
of	O
cornu	O
bubali	O
,	O
20	O
g	O
of	O
coptis	O
chinensis	O
,	O
35	O
-	O
45	O
g	O
of	O
cape	O
jasmine	O
,	O
20	O
g	O
of	O
cortex	O
moutan	O
,	O
25	O
g	O
of	O
scutellaria	O
baicalensis	O
,	O
30	O
g	O
of	O
radix	O
paeoniae	O
rubra	O
,	O
30	O
g	O
of	O
rhizoma	O
anemarrhenae	O
,	O
30	O
g	O
of	O
fructus	O
forsythia	O
,	O
25	O
g	O
of	O
platycodon	O
grandiflorum	O
,	O
15	O
g	O
of	O
liquorice	O
,	O
and	O
25	O
g	O
of	O
lophatherum	O
gracile	O
,	O
and	O
the	O
raw	O
materials	O
of	O
the	O
drug	O
are	O
smashed	O
and	O
further	O
smashed	O
superfinely	O
to	O
obtain	O
superfine	O
powder	O
.	O

According	O
to	O
the	O
scourge	O
-	O
clearing	O
toxin	O
-	O
vanquishing	O
drug	O
,	O
the	O
use	O
amount	O
of	O
plaster	O
is	O
remarkably	O
reduced	O
,	O
the	O
cold	O
property	O
of	O
the	O
drug	O
is	O
lowered	O
,	O
and	O
harm	O
and	O
side	O
effects	O
on	O
animal	O
bodies	O
are	O
alleviated	O
;	O
the	O
effects	O
of	O
an	O
original	O
drug	O
is	O
maintained	O
through	O
the	O
appropriate	O
adjustment	O
on	O
the	O
use	O
amount	O
of	O
other	O
components	O
;	O
the	O
curative	O
effect	O
is	O
exact	O
,	O
remarkable	O
,	O
and	O
the	O
drug	O
is	O
mild	O
in	O
property	O
;	O
radix	O
scrophulariae	O
is	O
eliminated	O
,	O
so	O
that	O
the	O
drug	O
formula	O
is	O
simplified	O
;	O
the	O
drug	O
raw	O
materials	O
and	O
processing	O
cost	O
are	O
reduced	O
.	O

Efficient	O
scourge	O
-	O
clearing	O
toxin	O
-	O
vanquishing	O
drug	O
for	O
livestock	O

The	O
invention	O
discloses	O
a	O
medicine	O
for	O
treating	O
cough	O
and	O
a	O
preparation	O
method	O
of	O
the	O
medicine	O
.	O

The	O
medicine	O
is	O
mainly	O
prepared	O
from	O
atractylodes	O
macrocephala	O
koidz	O
,	O
radix	O
polygonati	O
officinalis	O
,	O
herba	O
houttuyniae	O
,	O
spreading	O
hedyotis	O
herb	O
,	O
edible	O
tulip	O
,	O
honeysuckle	O
,	O
rhizoma	O
belamcandae	O
,	O
adenophora	O
tetraphylla	O
,	O
common	O
hogfenneI	O
root	O
,	O
flos	O
farfarae	O
,	O
radix	O
ophiopogonis	O
and	O
other	O
medicines	O
in	O
a	O
certain	O
weight	O
ratio	O
.	O

The	O
medicine	O
has	O
the	O
functions	O
of	O
dispelling	O
cold	O
and	O
warming	O
lung	O
,	O
eliminating	O
phlegm	O
and	O
stopping	O
cough	O
,	O
clearing	O
lung	O
and	O
harmonizing	O
stomach	O
,	O
and	O
is	O
quick	O
in	O
response	O
and	O
short	O
in	O
course	O
of	O
treatment	O
after	O
healing	O
when	O
used	O
for	O
treating	O
cough	O
,	O
and	O
prevents	O
relapse	O
.	O

Medicine	O
for	O
treating	O
cough	O
and	O
preparation	O
method	O
of	O
medicine	O

The	O
invention	O
discloses	O
a	O
medicine	O
for	O
treating	O
male	O
infertility	O
and	O
a	O
preparation	O
method	O
of	O
the	O
medicine	O
.	O

The	O
medicine	O
is	O
mainly	O
prepared	O
from	O
dendrobe	O
,	O
nidus	O
vespae	O
,	O
epimedium	O
,	O
tribulus	O
terrestris	O
,	O
bamboo	O
leaf	O
,	O
actinolite	O
,	O
raspberry	O
and	O
other	O
medicines	O
in	O
a	O
certain	O
weight	O
ratio	O
.	O

The	O
medicine	O
has	O
the	O
functions	O
of	O
invigorating	O
the	O
kidney	O
and	O
strengthening	O
Yang	O
,	O
activating	O
the	O
channels	O
and	O
strengthening	O
spleen	O
,	O
nourishing	O
blood	O
and	O
arresting	O
emission	O
,	O
and	O
is	O
quick	O
in	O
response	O
and	O
good	O
in	O
curative	O
effect	O
when	O
used	O
for	O
treating	O
male	O
infertility	O
,	O
and	O
prevents	O
relapse	O
.	O

Medicine	O
for	O
treating	O
male	O
infertility	O
and	O
preparation	O
method	O
of	O
medicine	O

The	O
invention	O
relates	O
to	O
a	O
drug	O
for	O
treating	O
infantile	O
cough	O
and	O
a	O
preparation	O
method	O
thereof	O
.	O

The	O
drug	O
contains	O
5	O
-	O
15	O
parts	O
of	O
honeysuckle	O
,	O
10	O
-	O
15	O
parts	O
of	O
platycodon	O
grandiflorum	O
,	O
10	O
-	O
15	O
parts	O
of	O
licorice	O
,	O
5	O
-	O
10	O
parts	O
of	O
white	O
radish	O
,	O
5	O
-	O
12	O
parts	O
of	O
tendril	O
-	O
leaved	O
fritillary	O
bulb	O
,	O
2	O
-	O
8	O
parts	O
of	O
towel	O
gourd	O
and	O
15	O
-	O
25	O
parts	O
of	O
brown	O
sugar	O
.	O

The	O
preparation	O
method	O
comprises	O
the	O
following	O
steps	O
:	O
(	O
1	O
)	O
weighing	O
honeysuckle	O
,	O
platycodon	O
grandiflorum	O
,	O
licorice	O
and	O
tendril	O
-	O
leaved	O
fritillary	O
bulb	O
according	O
to	O
a	O
proportion	O
,	O
adding	O
water	O
to	O
decoct	O
the	O
components	O
,	O
filtering	O
to	O
obtain	O
filtrate	O
I	O
after	O
the	O
decocting	O
treatment	O
;	O
(	O
2	O
)	O
weighing	O
white	O
radish	O
and	O
towel	O
gourd	O
according	O
to	O
a	O
proportion	O
,	O
adding	O
water	O
to	O
decoct	O
the	O
components	O
,	O
and	O
then	O
,	O
filtering	O
to	O
obtain	O
filtrate	O
II	O
;	O
(	O
3	O
)	O
mixing	O
the	O
filtrate	O
I	O
obtained	O
in	O
the	O
step	O
(	O
1	O
)	O
and	O
the	O
filtrate	O
II	O
obtained	O
in	O
the	O
step	O
(	O
2	O
)	O
,	O
and	O
decocting	O
the	O
mixture	O
to	O
obtain	O
a	O
mixed	O
concentrated	O
solution	O
III	O
;	O
and	O
(	O
4	O
)	O
adding	O
brown	O
sugar	B
in	O
the	O
mixed	O
concentrated	O
solution	O
III	O
,	O
and	O
slightly	O
heating	O
the	O
mixture	O
to	O
obtain	O
the	O
drug	O
.	O

The	O
drug	O
is	O
good	O
in	O
curative	O
effect	O
,	O
free	O
of	O
side	O
effect	O
and	O
capable	O
of	O
both	O
treating	O
infantile	O
cough	O
fundamentally	O
and	O
reinforcing	O
body	O
and	O
enhancing	O
immunity	O
of	O
children	O
on	O
chills	O
and	O
fever	O
and	O
the	O
like	O
.	O

Drug	O
for	O
treating	O
infantile	O
cough	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
an	O
antibacterial	O
finishing	O
agent	O
for	O
a	O
medical	O
dressing	O
.	O

The	O
antibacterial	O
finishing	O
agent	O
is	O
prepared	O
through	O
an	O
antibacterial	O
agent	O
,	O
a	O
hemostatic	O
,	O
and	O
an	O
astringent	O
capable	O
of	O
promoting	O
wound	O
healing	O
by	O
virtue	O
of	O
a	O
special	O
process	O
.	O

The	O
antibacterial	O
finishing	O
agent	O
is	O
used	O
for	O
finishing	O
gauze	O
,	O
a	O
bandage	O
,	O
sponge	O
and	O
other	O
medical	O
dressings	O
,	O
and	O
has	O
the	O
characteristics	O
of	O
broad	O
-	O
spectrum	O
antibacterial	O
property	O
,	O
blood	O
stopping	O
,	O
healing	O
promoting	O
,	O
safety	O
and	O
non	O
-	O
irritation	O
,	O
and	O
simple	O
preparation	O
process	O
.	O

The	O
finished	O
medical	O
dressing	O
has	O
the	O
effects	O
of	O
resisting	O
bacteria	O
,	O
stopping	O
blooding	O
,	O
diminishing	O
inflammation	O
,	O
and	O
promoting	O
wound	O
healing	O
.	O

Antibacterial	O
finishing	O
agent	O
for	O
medical	O
dressing	O

The	O
invention	O
discloses	O
mouth	O
wash	O
for	O
dental	O
diagnosis	O
and	O
treatment	O
,	O
and	O
is	O
applicable	O
to	O
diagnosis	O
and	O
treatment	O
in	O
dental	O
clinic	O
.	O

A	O
formula	O
of	O
the	O
mouth	O
wash	O
consists	O
of	O
the	O
following	O
components	O
in	O
percentage	O
by	O
weight	O
:	O
3	O
-	O
6	O
%	O
of	O
carboxymethyl	O
chitosan	O
,	O
2	O
-	O
6	O
%	O
of	O
marine	O
organism	O
lysozyme	O
and	O
reverse	O
osmosis	O
pure	O
water	O
to	O
100	O
%	O
.	O

The	O
mouth	O
wash	O
for	O
dental	O
diagnosis	O
and	O
treatment	O
containing	O
a	O
marine	O
organism	O
antibacterial	O
component	O
disclosed	O
by	O
the	O
invention	O
has	O
the	O
advantages	O
of	O
(	O
1	O
)	O
being	O
remarkable	O
in	O
antibacterial	O
effect	O
;	O
(	O
2	O
)	O
being	O
free	O
from	O
irritation	O
to	O
mucous	O
membrane	O
of	O
mouth	O
;	O
and	O
(	O
3	O
)	O
being	O
environmentally	O
friendly	O
and	O
non	O
-	O
toxic	O
due	O
to	O
the	O
marine	O
organism	O
component	O
.	O

Mouth	O
wash	O
for	O
dental	O
diagnosis	O
and	O
treatment	O

The	O
invention	O
belongs	O
to	O
the	O
technical	O
field	O
of	O
medicines	O
and	O
relates	O
to	O
a	O
pharmaceutical	O
use	O
of	O
a	O
2	B
,	I
2-dimethyl	I
chromanone	I
type	O
compound	O
and	O
analogs	O
thereof	O
.	O

The	O
structural	O
general	O
formula	O
is	O
as	O
follows	O
,	O
wherein	O
X	O
can	O
be	O
selected	O
from	O
CH2	B
or	O
C	B
=	I
O	I
;	O
and	O
R	O
and	O
R	O
'	O
are	O
as	O
described	O
in	O
the	O
description	O
.	O

The	O
new	O
compound	O
provided	O
by	O
the	O
invention	O
can	O
be	O
used	O
as	O
an	O
effective	O
anti	O
-	O
platelet	O
medicament	O
,	O
can	O
be	O
particularly	O
applied	O
to	O
the	O
preparation	O
of	O
medicaments	O
for	O
preventing	O
or	O
treating	O
coronary	O
syndrome	O
,	O
myocardial	O
infarction	O
,	O
myocardial	O
ischemia	O
and	O
cardiovascular	O
and	O
cerebrovascular	O
diseases	O
caused	O
by	O
platelet	O
aggregation	O
and	O
can	O
further	O
treat	O
thrombus	O
formation	O
,	O
ischemia	O
,	O
stroke	O
,	O
restenosis	O
or	O
inflammation	O
.	O

Pharmaceutical	O
use	O
of	O
2	B
,	I
2-dimethyl	I
chromanone	I
type	O
compound	O
and	O
analogs	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
I	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
:	O
wherein	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
A	O
,	O
Q	O
,	O
W	O
and	O
X	O
are	O
as	O
defined	O
in	O
the	O
description	O
.	O

These	O
compounds	O
selectively	O
modulate	O
,	O
regulate	O
,	O
and/or	O
inhibit	O
signal	O
transduction	O
mediated	O
by	O
certain	O
native	O
and/or	O
mutant	O
proteine	O
kinases	O
implicated	O
in	O
a	O
variety	O
of	O
human	O
and	O
animal	O
diseases	O
such	O
as	O
cell	O
proliferative	O
,	O
metabolic	O
,	O
allergic	O
,	O
and	O
degenerative	O
disorders	O
.	O

More	O
particularly	O
,	O
these	O
compounds	O
are	O
potent	O
and	O
selective	O
native	O
and/or	O
mutant	O
c	O
-	O
kit	O
inhibitors	O
.	O

Oxazole	B
and	O
thiazole	B
derivatives	O
as	O
selective	O
protein	O
kinase	O
inhibitors	O
(	O
c	O
-	O
kit	O
)	O

The	O
invention	O
relates	O
to	O
teasel	O
root	O
health	O
care	O
tea	O
for	O
stasis	O
ache	O
.	O

25	O
parts	O
of	O
teasel	O
roots	O
,	O
14	O
parts	O
of	O
sappan	O
wood	O
,	O
12	O
parts	O
of	O
peach	O
seeds	O
and	O
16	O
parts	O
of	O
borneol	O
are	O
washed	O
,	O
chopped	O
and	O
dried	O
;	O
16	O
parts	O
of	O
catechu	O
,	O
17	O
parts	O
of	O
green	O
tea	O
and	O
filiform	O
medicinal	O
material	O
are	O
uniformly	O
mixed	O
and	O
dried	O
,	O
and	O
are	O
packaged	O
into	O
packed	O
dipsacus	O
root	O
health	O
care	O
tea	O
for	O
stasis	O
ache	O
.	O

The	O
teasel	O
root	O
health	O
care	O
tea	O
for	O
stasis	O
ache	O
has	O
the	O
advantages	O
of	O
simple	O
preparation	O
method	O
and	O
convenient	O
carriage	O
with	O
good	O
effect	O
;	O
the	O
invention	O
has	O
the	O
blood	O
circulation	O
invigorating	O
,	O
stasis	O
dispersing	O
,	O
pain	O
relieving	O
and	O
hemostasis	O
efficacies	O
,	O
and	O
the	O
product	O
can	O
help	O
people	O
to	O
invigorate	O
blood	O
circulation	O
,	O
disperse	O
stasis	O
,	O
prevent	O
and	O
control	O
stasis	O
ache	O
symptoms	O
.	O

Teasel	O
root	O
health	O
care	O
tea	O
for	O
stasis	O
ache	O

The	O
invention	O
relates	O
to	O
fluoroquinolonesilver	B
,	O
and	O
a	O
preparation	O
method	O
and	O
medical	O
application	O
of	O
the	O
fluoroquinolonesilver	B
.	O

The	O
fluoroquinolonesilver	B
has	O
a	O
structure	O
shown	O
in	O
a	O
general	O
formula	O
(	O
I	O
)	O
(	O
refer	O
to	O
the	O
Specification	O
)	O
.	O

Silver	B
ions	I
and	O
fluoroquinolone	B
are	O
combined	O
together	O
,	O
and	O
through	O
the	O
synergistic	O
effect	O
of	O
the	O
silver	O
ions	O
and	O
fluoroquinolone	B
,	O
the	O
antibacterial	O
effect	O
is	O
further	O
enhanced	O
,	O
and	O
the	O
problem	O
of	O
the	O
drug	O
resistance	O
of	O
the	O
existing	O
fluoroquinolone	B
drugs	O
can	O
be	O
solved	O
to	O
a	O
certain	O
degree	O
.	O

The	O
fluoroquinolonesilver	B
is	O
simple	O
in	O
preparation	O
process	O
,	O
and	O
stable	O
in	O
productivity	O
(	O
refer	O
to	O
the	O
Specification	O
for	O
the	O
formula	O
I	O
)	O
.	O

Fluoroquinolonesilver	B
compound	O
as	O
well	O
as	O
preparation	O
method	O
and	O
application	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
substituted	O
imidazole-1-ethylene	B
compound	O
as	O
well	O
as	O
a	O
preparation	O
and	O
an	O
application	O
thereof	O
.	O

The	O
substituted	O
imidazole-1-ethylene	B
compound	O
is	O
a	O
compound	O
shown	O
as	O
a	O
formula	O
I	O
,	O
or	O
salts	O
thereof	O
formed	O
with	O
medicinal	O
acids	O
or	O
bases	O
.	O

According	O
to	O
the	O
antifungal	O
activity	O
test	O
performed	O
on	O
eight	O
clinical	O
fungi	O
by	O
the	O
compound	O
provided	O
in	O
the	O
invention	O
,	O
a	O
good	O
fungus	O
killing	O
effect	O
is	O
achieved	O
.	O

The	O
compound	O
can	O
serve	O
as	O
a	O
novel	O
broad	O
-	O
spectrum	O
antifungal	O
activity	O
compound	O
and	O
is	O
developed	O
into	O
antifungal	O
medicines	O
,	O
disinfectants	O
or	O
feed	O
additives	O
.	O

Substituted	O
imidazole-1-ethylene	B
compound	O
and	O
application	O
thereof	O

The	O
invention	O
provides	O
a	O
natural	O
medicinal	O
composition	O
beneficial	O
to	O
hypoxia	O
tolerance	O
.	O

The	O
composition	O
is	O
characterized	O
by	O
being	O
prepared	O
from	O
asiaticoside	B
and	O
paeoniflorin	B
with	O
effects	O
of	O
anti	O
-	O
inflammation	O
anti	O
-	O
exudation	O
,	O
and	O
ginseng	O
saponin	B
and	O
total	O
saponins	B
of	O
dried	O
tangerine	O
peel	O
with	O
anti	O
-	O
ischemia	O
and	O
anti	O
-	O
hypoxia	O
effects	O
.	O

The	O
natural	O
medicinal	O
composition	O
is	O
clear	O
in	O
substances	O
and	O
controllable	O
in	O
quality	O
,	O
and	O
sufficiently	O
utilizes	O
the	O
synergetic	O
effect	O
of	O
each	O
component	O
.	O

Besides	O
consideration	O
on	O
anti	O
-	O
ischemia	O
and	O
anti	O
-	O
hypoxia	O
substances	O
,	O
the	O
prescription	O
of	O
the	O
natural	O
medicinal	O
composition	O
is	O
contributed	O
to	O
prevention	O
and	O
treatment	O
of	O
emergent	O
inflammatory	O
exudation	O
caused	O
by	O
ischemia	O
and	O
hypoxia	O
to	O
tissues	O
of	O
heart	O
and	O
cerebral	O
vessels	O
.	O

The	O
composition	O
can	O
be	O
used	O
for	O
preparing	O
oral	O
preparations	O
,	O
such	O
as	O
hard	O
capsules	O
,	O
tablets	O
,	O
granules	O
,	O
powder	O
,	O
pills	O
,	O
teabags	O
and	O
oral	O
solutions	O
,	O
and	O
can	O
be	O
used	O
in	O
Chinese	O
patent	O
medicines	O
or	O
health	O
-	O
care	O
foods	O
for	O
improving	O
hypoxia	O
tolerance	O
.	O

Application	O
of	O
natural	O
medicinal	O
composition	O
in	O
preparing	O
anti	O
-	O
hypoxia	O
medicines	O
and	O
health	O
-	O
care	O
products	O

The	O
invention	O
provides	O
an	O
oidazole	B
paster	O
for	O
transluminal	O
administration	O
,	O
and	O
the	O
oidazole	B
paster	O
comprises	O
ornidazole	B
and	O
a	O
solid	O
water	O
-	O
soluble	O
matrix	O
.	O

The	O
solid	O
water	O
-	O
soluble	O
matrix	O
includes	O
carbopol	B
,	O
lactose	B
,	O
low	O
-	O
substituted	O
hydroxy	O
propyl	O
cellulose	O
and	O
carboxymethyl	O
cellulose	O
sodium	O
.	O

A	O
preparation	O
method	O
of	O
the	O
oidazole	B
patch	O
comprises	O
the	O
following	O
steps	O
:	O
respectively	O
sieving	O
secnidazole	B
,	O
lactose	B
,	O
low	O
-	O
substituted	O
hydroxy	O
propyl	O
cellulose	O
and	O
carboxymethyl	O
cellulose	O
sodium	O
in	O
the	O
prescription	O
dose	O
through	O
a	O
screen	O
of	O
80	O
mesh	O
,	O
mixing	O
well	O
,	O
adding	O
70	O
%	O
ethanol	B
for	O
granulation	O
,	O
drying	O
,	O
finishing	O
by	O
a	O
screen	O
of	O
30	O
mesh	O
,	O
adding	O
carbopol	B
,	O
magnesium	B
stearate	I
and	O
talcum	O
powder	O
,	O
which	O
are	O
sieved	O
through	O
a	O
screen	O
of	O
100	O
mesh	O
,	O
fully	O
mixing	O
and	O
tabletting	O
to	O
obtain	O
a	O
finished	O
product	O
.	O

The	O
invention	O
has	O
the	O
advantages	O
of	O
rapid	O
,	O
durable	O
and	O
reliable	O
effect	O
,	O
and	O
high	O
safety	O
;	O
at	O
the	O
same	O
time	O
,	O
the	O
local	O
administration	O
can	O
avoid	O
or	O
reduce	O
adverse	O
effects	O
of	O
systemic	O
administration	O
.	O

Ornidazole	B
paster	O
for	O
transluminal	O
administration	O

The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
drugs	O
,	O
and	O
particularly	O
relates	O
to	O
a	O
compound	O
capable	O
of	O
inhibiting	O
proteasomes	O
and	O
preventing	O
and	O
treating	O
rheumatoid	O
arthritis	O
.	O

The	O
compound	O
has	O
the	O
molecular	O
structure	O
of	O
3'-methoxy	B
benzyl-4-hydroxy-3,5-dimethoxy	I
-	I
benzoate	I
.	O

The	O
compound	O
has	O
the	O
beneficial	O
effects	O
that	O
the	O
compound	O
can	O
be	O
used	O
for	O
treating	O
rheumatoid	O
arthritis	O
,	O
and	O
has	O
potential	O
new	O
drug	O
development	O
value	O
.	O

Application	O
of	O
3'-methoxy	B
benzyl-4-hydroxy-3,5-dimethoxy	I
-	I
benzoate	I
in	O
preparation	O
of	O
drugs	O
for	O
treating	O
or	O
preventing	O
rheumatoid	O
arthritis	O

A	O
slowly	O
-	O
releasing	O
thiazmazole	B
tablet	O
for	O
treating	O
thyroidism	O
is	O
disclosed	O
.	O

It	O
is	O
prepared	O
by	O
unique	O
slow	O
-	O
releasing	O
technique	O
,	O
that	O
is	O
using	O
high	O
molecular	O
material	O
to	O
wrap	O
the	O
medicine	O
.	O

Preparation	O
containing	O
methimazole	B
and	O
its	O
preparing	O
method	O

The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
gossypol	B
and	O
its	O
derivative	O
in	O
preparation	O
of	O
drug	O
for	O
leukemia	O
/	O
bone	O
marrow	O
cancer	O
,	O
wherein	O
the	O
gossypol	B
has	O
the	O
constitutional	O
formula	O
disclosed	O
in	O
the	O
specification	O
,	O
the	O
gossypol	B
derivative	O
is	O
gossypol	B
acetate	I
or	O
formic	B
acid	I
gossypol	I
.	O

Use	O
of	O
gossypol	B
and	O
its	O
derivative	O
in	O
preparation	O
of	O
drug	O
for	O
leukemia	O
/	O
bone	O
marrow	O
cancer	O

The	O
invention	O
discloses	O
a	O
freeze	O
-	O
drying	O
fluconazole	B
injection	O
and	O
its	O
preparation	O
method	O
which	O
comprises	O
,	O
charging	O
a	O
definite	O
quantity	O
of	O
supporting	O
agent	O
into	O
reactive	O
medicinal	O
Fluconazole	B
(	O
50	O
-	O
200	O
mg	O
per	O
bottle	O
)	O
,	O
adding	O
pH	O
modifier	O
,	O
solubilizing	O
agent	O
so	O
as	O
to	O
prepare	O
solution	O
of	O
a	O
finite	O
concentration	O
,	O
and	O
loading	O
for	O
freeze	O
drying	O
.	O

Freeze	O
-	O
drying	O
fluconazole	B
injection	O
and	O
its	O
preparation	O
method	O

The	O
invention	O
provides	O
an	O
antiviral	O
activity	O
possessed	O
compound	O
,	O
in	O
particular	O
organic	O
ionic	O
compounds	O
with	O
antiviral	O
reactivity	O
,	O
pharmaceutical	O
compositions	O
containing	O
the	O
compound	O
,	O
and	O
the	O
external	O
antiviral	O
method	O
.	O

Antiviral	O
activity	O
possessed	O
compound	O

The	O
invention	O
relates	O
to	O
a	O
Nefopam	B
Hydrochloride	I
drop	O
pill	O
prepared	O
by	O
utilizing	O
ultramicro	O
disintegration	O
and	O
drop	O
pill	O
manufacturing	O
process	O
,	O
which	O
has	O
the	O
advantages	O
of	O
improving	O
collapse	O
and	O
dissolving	O
speed	O
,	O
quick	O
effect	O
,	O
increased	O
medicament	O
stability	O
,	O
reduced	O
adjuvant	O
consumption	O
,	O
lowered	O
production	O
costs	O
,	O
and	O
easiness	O
in	O
carrying	O
and	O
use	O
.	O

It	O
has	O
good	O
compliance	O
,	O
thus	O
is	O
especially	O
suitable	O
for	O
children	O
,	O
the	O
elderly	O
,	O
bedridden	O
patients	O
and	O
dysphagia	O
patients	O
.	O

Dripping	O
pills	O
of	O
nefopam	B
hydrochloride	I
and	O
its	O
preparation	O
method	O

The	O
invention	O
discloses	O
a	O
method	O
for	O
preparing	O
astragaloside	B
and	O
its	O
use	O
in	O
pharmacy	O
,	O
wherein	O
the	O
preparing	O
process	O
comprises	O
subjecting	O
the	O
astragalus	O
root	O
powder	O
to	O
ethanol	B
backflow	O
,	O
decompression	O
concentrating	O
with	O
the	O
inverse	O
flow	O
,	O
charging	O
NaOH	B
into	O
the	O
concentration	O
liquid	O
,	O
compressionalcohol	O
liquid	O
backflow	O
,	O
steaming	O
the	O
ethyl	B
alcohol	I
to	O
obtain	O
ethanol	B
hydrolysate	O
,	O
extracting	O
with	O
acetic	B
ester	I
,	O
washing	O
to	O
neutral	O
,	O
evaporating	O
to	O
dryness	O
,	O
obtaining	O
crude	O
saponin	B
,	O
charging	O
acetic	B
ester	I
,	O
stirring	O
in	O
water	O
-	O
bath	O
,	O
cooling	O
down	O
,	O
filtering	O
,	O
deposition	O
,	O
and	O
recrystallizing	O
with	O
methanol	B
.	O

Method	O
for	O
preparing	O
astragaloside	B
and	O
its	O
use	O
in	O
preparation	O
of	O
drug	O
for	O
preventing	O
and	O
treating	O
diabetic	O
nephropathy	O

The	O
present	O
invention	O
relates	O
to	O
soft	O
hydroxymethyl	B
coumarine	I
capsule	O
and	O
its	O
preparation	O
process	O
.	O

The	O
soft	O
hydroxymethyl	B
coumarine	I
capsule	O
is	O
prepared	O
with	O
hydroxymethyl	B
coumarine	I
as	O
active	O
component	O
in	O
20	O
-	O
75	O
wt%	O
,	O
preferably	O
35	O
-	O
55	O
wt%	O
;	O
solvent	O
and	O
diluent	O
in	O
20	O
-	O
75	O
wt%	O
,	O
preferably	O
40	O
-	O
55	O
wt%	O
;	O
emulsifier	O
in	O
2	O
-	O
12	O
wt%	O
,	O
preferably	O
5	O
-	O
8	O
wt%	O
to	O
increase	O
the	O
solubility	O
of	O
hydroxymethyl	B
coumarine	I
in	O
animal	O
and	O
vegetable	O
oil	O
and	O
raise	O
its	O
stability	O
;	O
and	O
antioxidant	O
in	O
0.2	O
-	O
5	O
wt%	O
,	O
preferably	O
0.5	O
-	O
3	O
wt%	O
,	O
to	O
raise	O
the	O
antioxidant	O
performance	O
.	O

The	O
soft	O
capsule	O
shell	O
is	O
prepared	O
with	O
gelatin	O
,	O
glycerin	B
,	O
sorbic	B
alcohol	I
,	O
etc	O
.	O
and	O
contains	O
titania	B
in	O
0.2	O
-	O
1.2	O
wt%	O
,	O
preferably	O
0.5	O
-	O
0.7	O
wt%	O
,	O
as	O
light	O
screening	O
agent	O
.	O

Hydroxymethyl	B
coumarine	I
soft	O
capsule	O
and	O
its	O
preparing	O
method	O

An	O
application	O
of	O
ursolic	B
acid	I
in	O
preparing	O
the	O
anticancer	O
medicine	O
for	O
treating	O
liver	O
cancer	O
,	O
breast	O
cancer	O
,	O
lymphomatosis	O
,	O
leukemia	O
,	O
etc	O
is	O
disclosed	O
.	O

Application	O
of	O
ursolic	B
acid	I
in	O
prepartation	O
of	O
anticancer	O
medicine	O

The	O
invention	O
relates	O
to	O
N	B
-	I
glycosyl	I
(	O
substituted	O
)	O
phthalimide	B
compounds	O
having	O
the	O
structural	O
formula	O
disclosed	O
in	O
the	O
specification	O
,	O
wherein	O
R1	O
separate	O
halogen	B
,	O
hydroxy	B
,	O
substituted	O
C1-C10	B
alkyl	I
,	O
C1-C10	B
aryl	I
,	O
C2-C8	B
alkene	I
,	O
C1-C10	B
alkoxy	I
,	O
C1-C10	B
acyl	I
,	O
C1-C10	B
ester	I
,	O
C1-C10	B
carboxyl	I
,	O
nitro	B
,	O
amido	B
,	O
monoalkyl	B
amino	I
,	O
dialkyl	B
amido	I
,	O
cyano	B
,	O
sulfonyl	B
,	O
alkyl	B
sulfonyl	I
,	O
alkyl	B
,	O
sulfhydryl	B
,	O
A	O
is	O
various	O
substituted	O
or	O
nonsubstituted	O
glycosyl	O
residue	O
.	O

The	O
invention	O
also	O
discloses	O
the	O
and	O
method	O
for	O
preparation	O
and	O
use	O
in	O
preparing	O
anti	O
-	O
inflammatory	O
medicament	O
.	O

Glycosyl	O
phthalic	O
imidine	B
compounds	O
with	O
anti	O
-	O
inflammatory	O
activity	O

An	O
application	O
of	O
dihydromyricetin	B
in	O
preparing	O
the	O
antalgic	O
and	O
apophlegmatic	O
medicine	O
or	O
health	O
-	O
care	O
food	O
is	O
disclosed	O
.	O

Application	O
of	O
dihydromyricetrin	B

The	O
present	O
invention	O
discloses	O
the	O
use	O
of	O
lycoramine	B
in	O
preparing	O
medicine	O
for	O
resisting	O
SARS	O
virus	O
,	O
total	O
lycoramine	B
extract	O
containing	O
lycoramine	B
and	O
its	O
preparation	O
process	O
,	O
use	O
in	O
preparing	O
medicine	O
for	O
resisting	O
SARS	O
virus	O
and	O
the	O
composition	O
therewith	O
.	O

Usage	O
of	O
glanthidine	B
,	O
total	O
alkali	O
extract	O
and	O
preparation	O
method	O
and	O
usage	O
thereof	O

An	O
anti	O
-	O
adhesion	O
protector	O
used	O
for	O
preparing	O
the	O
anti	O
-	O
adhesion	O
medicine	O
for	O
the	O
veterinary	O
operation	O
is	O
prepared	O
from	O
dihydrated	O
terramycin	B
,	O
acenocoumarol	B
,	O
erucic	B
acid	I
,	O
adrenine	B
and	O
carboxymethyl	O
cellulose	O
sodium	O
.	O

Antiadhesion	O
protective	O
preparation	O
and	O
its	O
application	O

A	O
powder	O
injection	O
of	O
sodium	B
neohouttuyfonate	I
is	O
prepared	O
from	O
the	O
sodium	B
neohouttuyfnoate	I
or	O
its	O
physiologically	O
acceptable	O
salt	O
and	O
the	O
phamacological	O
acceptable	O
auxiliary	O
for	O
injection	O
.	O

Powder	O
and	O
injection	O
preparation	O
of	O
new	O
houttuynine	B
sodium	I
bisulfite	I
and	O
preparation	O
method	O

An	O
oral	O
disintegrating	O
tablet	O
of	O
Shuangpuweima	O
is	O
prepared	O
from	O
acetylaminophenol	B
,	O
pseudoephedrine	B
hydrochloride	I
,	O
chlorpheniramine	B
,	O
disintegrant	O
,	O
filler	O
and	O
flavouring	O
.	O

Paracetamol	B
Pseudoephedrine	B
desintegration	O
piece	O
and	O
preparation	O
method	O

The	O
invention	O
relates	O
to	O
a	O
Chinese	O
angelica	O
polysaccharide	O
,	O
which	O
is	O
made	O
in	O
the	O
following	O
way	O
:	O
dissolve	O
alcohol	B
deposit	O
of	O
Chinese	O
angelica	O
into	O
distilled	O
water	O
,	O
use	O
savage	O
method	O
to	O
more	O
the	O
protein	O
away	O
until	O
there	O
is	O
no	O
protein	O
absorption	O
peak	O
of	O
280	O
nm	O
by	O
ultraviolet	O
test	O
,	O
centrifugation	O
to	O
clear	O
the	O
deposit	O
;	O
keep	O
the	O
water	O
-	O
phase	O
and	O
add	O
into	O
alcohol	B
for	O
depositing	O
polysaccharide	O
,	O
abandon	O
the	O
supernatant	O
liquid	O
,	O
wash	O
the	O
deposit	O
by	O
alcohol	B
,	O
then	O
freeze	O
and	O
dry	O
it	O
,	O
through	O
gel	O
molecular	O
chromatography	O
,	O
accumulate	O
the	O
separated	O
product	O
with	O
the	O
relative	O
molecule	O
mass	O
between	O
10,000	O
-	O
110,000	O
,	O
then	O
freeze	O
and	O
dry	O
it	O
again	O
to	O
acquire	O
the	O
Chinese	O
angelica	O
polysaccharide	O
.	O

The	O
invention	O
has	O
remarkable	O
analgesia	O
for	O
ache	O
caused	O
by	O
chemicals	O
and	O
hot	O
simulation	O
;	O
as	O
well	O
as	O
dysmenorrheal	O
caused	O
by	O
female	O
hormone	O
;	O
and	O
it	O
can	O
be	O
made	O
into	O
drug	O
for	O
analgesia	O
especially	O
that	O
for	O
curing	O
dysmenorrheal	O
.	O

Angelica	O
polysaccharide	O
and	O
its	O
preparation	O
and	O
use	O

The	O
invention	O
relates	O
to	O
the	O
application	O
of	O
rapamycin	B
(	O
RAPA	B
)	O
and	O
medicament	O
capable	O
of	O
self	O
-	O
degrading	O
in	O
preparing	O
eye	O
implantation	O
slow	O
release	O
medicament	O
,	O
the	O
medicament	O
can	O
keep	O
certain	O
reinforcement	O
and	O
shape	O
after	O
complete	O
release	O
,	O
and	O
can	O
be	O
naturally	O
degraded	O
under	O
internal	O
physiological	O
conditions	O
,	O
thus	O
can	O
be	O
absorbed	O
and	O
discharged	O
externally	O
through	O
metabolizing	O
,	O
and	O
no	O
secondary	O
surgery	O
is	O
needed	O
to	O
be	O
taken	O
out	O
.	O

The	O
invention	O
can	O
be	O
applied	O
to	O
the	O
repulsion	O
reaction	O
in	O
cornea	O
transplantation	O
for	O
treating	O
ophthalmology	O
diseases	O
.	O

Use	O
of	O
rapamycin	B
in	O
preparation	O
of	O
intraocularly	O
embedded	O
drug	O

The	O
liver	O
cancer	O
resisting	O
gene	O
medicine	O
composition	O
includes	O
antisense	O
fup1	O
gene	O
and/or	O
small	O
molecular	O
interfering	O
RNA	O
and	O
pharmaceutically	O
acceptable	O
supplementary	O
material	O
.	O

The	O
antisense	O
fup1	O
gene	O
has	O
the	O
DNA	O
sequence	O
of	O
SEQ	O
ID	O
No.	O
2	O
in	O
the	O
sequence	O
list	O
,	O
while	O
the	O
small	O
molecular	O
interfering	O
RNA	O
includes	O
the	O
RNA	O
sequence	O
of	O
SEQ	O
ID	O
No.	O
3	O
in	O
the	O
sequence	O
list	O
.	O

The	O
present	O
invention	O
also	O
provides	O
the	O
liver	O
cancer	O
resisting	O
gene	O
medicine	O
screening	O
method	O
to	O
design	O
small	O
molecular	O
interfering	O
RNA	O
based	O
on	O
fup1	O
encoding	O
area	O
via	O
adopting	O
ambion	O
web	O
site	O
provided	O
RNAi	O
design	O
software	O
.	O

The	O
present	O
invention	O
further	O
provides	O
liver	O
cancer	O
resisting	O
small	O
molecule	O
include	O
RNA	O
sequence	O
of	O
SEQ	O
ID	O
No.	O
3	O
in	O
the	O
sequence	O
list	O
.	O

The	O
present	O
invention	O
adopts	O
gene	O
fup1	O
high	O
expressed	O
in	O
liver	O
cancer	O
cell	O
as	O
medicine	O
target	O
to	O
design	O
the	O
antagonistic	O
molecule	O
to	O
provide	O
powerful	O
measure	O
for	O
the	O
gene	O
treatment	O
of	O
liver	O
cancer	O
and	O
excellent	O
platform	O
for	O
further	O
screening	O
liver	O
cancer	O
resisting	O
gene	O
medicine	O
.	O

Anti	O
cancer	O
gene	O
medicinal	O
composition	O
,	O
micromolecule	O
interfere	O
RNA	O
and	O
its	O
screening	O
method	O

The	O
invention	O
discloses	O
an	O
ethylamine	B
thiourea	I
injection	O
and	O
preparation	O
method	O
,	O
wherein	O
the	O
main	O
medicinal	O
constituent	O
is	O
diaminoethylisothiuramium	B
hydrobromate	I
.	O

By	O
employing	O
the	O
two	O
methods	O
of	O
cushioning	O
liquid	O
and	O
anti	O
-	O
oxidant	O
,	O
the	O
problem	O
of	O
unstable	O
ethylamine	B
thiocarbamide	I
can	O
be	O
solved	O
effectively	O
.	O

The	O
injection	O
has	O
the	O
advantages	O
of	O
simple	O
process	O
for	O
manufacturing	O
and	O
stabilized	O
product	O
quality	O
.	O

Ethylamine	B
thiourea	I
injection	O
and	O
preparation	O
method	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
the	O
new	O
action	O
application	O
of	O
methylene	B
blue	I
in	O
preventing	O
dental	O
caries	O
.	O

Methylene	B
blue	I
is	O
used	O
as	O
effective	O
component	O
in	O
preparing	O
dental	O
caries	O
preventing	O
preparation	O
.	O

New	O
action	O
and	O
application	O
of	O
methylene	B
blue	I
in	O
preventing	O
dental	O
caries	O

The	O
present	O
invention	O
relates	O
to	O
a	O
preparation	O
method	O
of	O
insoluble	O
medicine	O
gel	O
preparation	O
.	O

The	O
physiological	O
active	O
substance	O
of	O
said	O
gel	O
preparation	O
is	O
insoluble	O
medicine	O
.	O

Its	O
preparation	O
method	O
is	O
characterized	O
by	O
that	O
the	O
ink	O
course	O
of	O
preparation	O
of	O
gel	O
a	O
hydrophilic	O
substance	O
is	O
added	O
so	O
as	O
to	O
raise	O
the	O
solubility	O
of	O
main	O
medicine	O
in	O
water	O
,	O
and	O
can	O
make	O
the	O
main	O
medicine	O
be	O
uniformly	O
diffused	O
in	O
the	O
gel	O
,	O
and	O
the	O
gel	O
stability	O
is	O
good	O
.	O

Method	O
for	O
preparing	O
hard	O
-	O
soluble	O
gel	O
formulation	O

An	O
application	O
of	O
the	O
membrane	O
made	O
of	O
chitin	O
,	O
chitosan	O
,	O
or	O
their	O
derivatives	O
in	O
treating	O
vaginitis	O
and	O
cervicitis	O
is	O
disclosed	O
.	O

Said	O
membrane	O
may	O
be	O
replaced	O
by	O
fibrous	O
net	O
or	O
composite	O
material	O
.	O

Use	O
of	O
chitin	O
,	O
chitinous	O
glycan	O
and	O
its	O
derivative	O
biomembrane	O
in	O
medicinal	O
preparation	O
for	O
treaing	O
colpitis	O
and	O
cervicitis	O

The	O
anticancer	O
analgetic	O
preparation	O
has	O
lappaconitine	B
and	O
vincristine	B
as	O
main	O
active	O
anticancer	O
components	O
.	O

Lappaconitine	B
has	O
the	O
effect	O
of	O
increasing	O
the	O
sensitivity	O
of	O
vincristine	B
in	O
killing	O
cancer	O
cell	O
,	O
so	O
that	O
the	O
preparation	O
of	O
the	O
present	O
invention	O
can	O
reverse	O
the	O
drug	O
resistance	O
of	O
tumor	O
.	O

The	O
present	O
invention	O
has	O
obvious	O
functions	O
of	O
resisting	O
liver	O
cancer	O
,	O
lung	O
cancer	O
,	O
cancer	O
of	O
uterus	O
and	O
breast	O
cancer	O
,	O
stopping	O
pain	O
,	O
etc	O
.	O
and	O
has	O
the	O
feature	O
of	O
less	O
recovery	O
of	O
the	O
blood	O
supply	O
to	O
embolized	O
tumor	O
artery	O
.	O

Compared	O
with	O
similar	O
medicines	O
,	O
the	O
present	O
invention	O
has	O
the	O
advantages	O
of	O
less	O
side	O
effect	O
,	O
high	O
tumor	O
cell	O
killing	O
effect	O
,	O
high	O
stability	O
,	O
low	O
cost	O
,	O
etc	O
.	O

Anti	O
-	O
cancer	O
analgetic	O
preparation	O

The	O
present	O
invention	O
relates	O
to	O
application	O
of	O
pentacyclic	B
triterpene	I
compounds	O
in	O
preparing	O
glycogenic	O
phosphorylase	O
inhibitor	O
,	O
and	O
includes	O
the	O
application	O
of	O
medicine	O
composition	O
of	O
crataegolic	B
acid	I
,	O
Corosolic	B
acid	I
,	O
oleanolic	B
acid	I
,	O
ursolic	B
acid	I
,	O
betulin	B
,	O
betulic	B
acid	I
,	O
lupeol	B
or	O
their	O
pharmaceutically	O
acceptable	O
salt	O
or	O
ester	O
in	O
preparing	O
medicine	O
for	O
treating	O
diabetes	O
.	O

Use	O
of	O
pentacylic	B
triterpene	I
compounds	O
in	O
preparing	O
glycogenic	O
phosphorylase	O
inhibitor	O

An	O
orally	O
-	O
taken	O
composite	O
emulsion	O
of	O
Chuanhuning	O
is	O
prepared	O
from	O
Chuanhuning	O
,	O
surfactant	O
as	O
emulsifier	O
,	O
organic	O
solvent	O
as	O
coemulsifier	O
and	O
oil	O
.	O

It	O
has	O
higher	O
biologic	O
utilization	O
rate	O
.	O

Oral	O
emulsion	O
combination	O
of	O
'	O
Chuanhuning	O
'	O

The	O
invention	O
provides	O
a	O
silybin	B
nano	O
medicinal	O
preparation	O
,	O
which	O
comprises	O
liposome	O
nano	O
particles	O
of	O
silybin	B
,	O
the	O
liposome	O
material	O
is	O
the	O
mixture	O
of	O
soya	O
bean	O
lecithin	B
,	O
vitamin	B
E	I
and	O
soyabean	O
oil	O
by	O
the	O
mass	O
ratio	O
of	O
1:2.5:12.5	O
-	O
1:15:24	O
,	O
the	O
mass	O
ratio	O
of	O
silybin	B
and	O
lipsome	O
material	O
is	O
1:32	O
-	O
1:400	O
,	O
the	O
grain	O
diameter	O
of	O
the	O
liposome	O
nano	O
particles	O
is	O
less	O
than	O
500	O
nanometer	O
.	O

The	O
invention	O
also	O
discloses	O
the	O
preparing	O
process	O
of	O
the	O
preparation	O
.	O

Nanometer	O
preparation	O
of	O
silybin	B
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
vaginal	O
tablet	O
of	O
clindamycinum	B
and	O
metronidazole	B
,	O
which	O
uses	O
the	O
salts	O
or	O
esters	O
of	O
clindamycinum	B
and	O
metronidazole	B
as	O
the	O
active	O
constituents	O
,	O
and	O
the	O
conventional	O
tablets	O
as	O
the	O
auxiliary	O
material	O
.	O

Vaginal	O
tablet	O
with	O
clindamycin	B
and	O
metronidazole	B

The	O
invention	O
provides	O
a	O
Bergenini	B
penta	I
-	I
acetyl	I
,	O
whose	O
chemical	O
name	O
is	O
(	B
2R,3R,4R,4aS,10bS	I
)	I
-2-	I
(	I
acetoxymethyl	I
)	I
-9-methoxy-6-oxo-2,3,4,4a,6,10b	I
-	I
hexahydr	I
o	I
pyrano	I
[	I
3,2-c	I
]	I
isochromene-3,4,8,10-tetrayl	I
tetraacetate	I
,	O
and	O
is	O
prepared	O
from	O
Bergenini	O
as	O
lead	O
compound	O
through	O
butanoylation	O
reaction	O
,	O
the	O
hydroxyl	B
on	O
the	O
precursor	O
is	O
blocked	O
so	O
as	O
to	O
enhance	O
the	O
lipophilicity	O
.	O

The	O
Bergenini	O
penta	O
-	O
acetyl	O
can	O
be	O
used	O
for	O
preparing	O
medicine	O
for	O
relieving	O
cough	O
.	O

The	O
invention	O
further	O
provides	O
a	O
compound	O
preparation	O
containing	O
the	O
Bergenini	O
penta	O
-	O
acetyl	O
.	O

Purple	O
bergenia	O
element	O
pentaacetylate	B
and	O
its	O
uses	O

The	O
present	O
invention	O
relates	O
to	O
an	O
azithromycin	B
gel	O
.	O

Its	O
composition	O
includes	O
(	O
weight	O
portion	O
)	O
1	O
-	O
5	O
portions	O
of	O
azithromycin	B
,	O
0.5	O
-	O
10	O
portions	O
of	O
skeleton	O
materials	O
,	O
suchas	O
agar	O
and	O
arabic	O
gum	O
,	O
etc	O
.	O

capable	O
of	O
forming	O
gel	O
,	O
25	O
-	O
35	O
portions	O
of	O
sweetening	O
agent	O
and	O
80	O
-	O
120	O
portions	O
of	O
water	O
.	O

Azithromycin	B
gel	O

The	O
present	O
invention	O
discloses	O
an	O
ointment	O
medicine	O
preparation	O
for	O
curing	O
bed	O
sore	O
with	O
obvious	O
therapeutic	O
effect	O
.	O

Its	O
raw	O
material	O
composition	O
includes	O
(	O
by	O
weight	O
portion	O
)	O
0.1	O
-	O
5	O
portions	O
of	O
berberine	B
,	O
20	O
-	O
40	O
portions	O
of	O
fluocinonide	B
ointment	O
,	O
0.1	O
-	O
5	O
portions	O
of	O
Yunnan	O
white	O
medicine	O
and	O
0.1	O
-	O
5	O
portions	O
of	O
sulfonamides	B
anti	O
-	O
inflammatory	O
powder	O
.	O

Ointment	O
medicine	O
for	O
treating	O
bedsore	O

The	O
invention	O
discloses	O
a	O
soybean	O
isoflavone	B
soft	O
capsule	O
and	O
the	O
preparing	O
method	O
,	O
belonging	O
to	O
medical	O
field	O
,	O
with	O
the	O
technique	O
feature	O
being	O
:	O
the	O
material	O
in	O
the	O
capsule	O
comprising	O
soybean	O
isoflavone	B
,	O
phospholipid	O
,	O
calcium	B
salt	O
,	O
vitamin	O
,	O
anti	O
-	O
oxidant	O
,	O
capsule	O
stabilizing	O
agent	O
and	O
deflocculating	O
agent	O
,	O
the	O
capsule	O
shell	O
comprising	O
gelatine	O
,	O
plasticity	O
agent	O
,	O
conservative	O
,	O
hiding	O
agent	O
,	O
coloring	O
matter	O
,	O
corrective	O
and	O
water	O
.	O

The	O
soft	O
capsule	O
prepared	O
by	O
using	O
method	O
in	O
this	O
invention	O
is	O
characterized	O
by	O
the	O
stale	O
quality	O
,	O
safety	O
,	O
convenient	O
usage	O
,	O
ease	O
for	O
body	O
adsorption	O
,	O
and	O
high	O
bioavailability	O
,	O
and	O
particularly	O
be	O
used	O
for	O
regulating	O
the	O
estrogenic	O
hormones	O
for	O
menopausal	O
woman	O
,	O
and	O
for	O
preventing	O
and	O
treating	O
disease	O
relevant	O
with	O
estrogenic	O
hormones	O
.	O

Soybean	O
isoflavone	B
soft	O
capsule	O
and	O
its	O
preparation	O
process	O

The	O
invention	O
discloses	O
a	O
Breviscapine	B
oral	O
disintegrating	O
tablet	O
,	O
which	O
comprises	O
21.0	O
-	O
35.0	O
wt%	O
of	O
Breviscapine	B
,	O
11.0	O
-	O
15.0.0wt%	O
of	O
sodium	O
carboxymethylstarch	O
,	O
45.0	O
-	O
60.0	O
wt%	O
of	O
crystalline	O
cellulose	O
,	O
1.0	O
-	O
2.0	O
wt%	O
of	O
magnesium	B
stearate	I
,	O
5.0	O
-	O
10.0	O
wt%	O
of	O
miropowdered	O
silica	B
gel	I
,	O
and	O
0.1	O
-	O
0.5wt%	O
of	O
Aspartame	B
.	O

the	O
relative	O
weight	O
ratio	O
of	O
Breviscapine	B
and	O
sodium	O
carboxymethylstarch	O
is	O
1:0.3	O
-	O
1:0.7	O
.	O

Breviscapine	B
orally	O
disintegrating	O
tablet	O
and	O
preparation	O
method	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
non	O
-	O
metal	O
salt	O
compounds	O
of	O
glycididazole	B
,	O
including	O
ammonium	B
salt	I
of	I
glycididazole	I
,	O
diethylamine	B
double	I
salt	I
of	I
glycididazole	I
and	O
ethylene	B
diamine	I
double	I
salt	I
of	I
glycididazole	I
,	O
and	O
their	O
preparation	O
process	O
.	O

The	O
present	O
invention	O
provides	O
new	O
glycididazole	B
compounds	O
with	O
improved	O
water	O
solubility	O
and	O
stability	O
for	O
convenient	O
medicinal	O
application	O
.	O

In	O
addition	O
,	O
the	O
non	O
-	O
metal	O
salt	O
compounds	O
of	O
glycididazole	B
are	O
non	O
-	O
sodium	B
ion	I
salt	O
and	O
can	O
avoid	O
sodium	B
accumulation	O
and	O
other	O
bad	O
reaction	O
causing	O
electrolyte	O
metabolism	O
disorder	O
.	O

Non	O
-	O
metal	O
salt	O
of	O
Glicididazole	B
and	O
its	O
prepn	O

The	O
present	O
invention	O
is	O
new	O
preparation	O
form	O
of	O
Stepronin	B
,	O
especially	O
great	O
capacity	O
Stepronin	B
injection	O
,	O
and	O
its	O
preparation	O
process	O
.	O

The	O
injection	O
consists	O
of	O
Stepronin	B
or	O
its	O
metal	O
salt	O
or	O
amino	B
salt	O
as	O
active	O
component	O
and	O
medicinal	O
carrier	O
.	O

Compared	O
with	O
available	O
orally	O
taken	O
Stepronin	B
preparation	O
,	O
the	O
present	O
invention	O
has	O
the	O
advantages	O
of	O
high	O
bioavailability	O
,	O
good	O
medicine	O
absorption	O
,	O
fast	O
medicine	O
dispersion	O
,	O
fast	O
acting	O
,	O
etc	O
.	O

The	O
present	O
invention	O
expands	O
the	O
administration	O
range	O
of	O
Stepronin	B
and	O
raises	O
the	O
clinical	O
administration	O
level	O
of	O
Stepronin	B
.	O

Stepronin	B
injection	O
and	O
its	O
preparing	O
method	O

The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
formula	O
I	O
in	O
which	O
substituents	O
R<2	O
>	O
and	O
R<3	O
>	O
are	O
arranged	O
in	O
trans	O
-	O
configuration	O
,	O
Formula	O
(	O
I	O
)	O
,	O
wherein	O
:	O
R<1	O
>	O
is	O
H	B
or	O
C1-C6	B
alkyl	I
;	O
C3-C7	B
cycloalkyl	I
;	O
R<2	O
>	O
is	O
phenyl	B
,	O
optionally	O
substituted	O
with	O
1	O
to	O
5	O
substituents	O
independently	O
selected	O
from	O
the	O
group	O
comprising	O
OH	B
,	O
C1-C6	B
-alkyl	I
,	O
halogen	B
,	O
nitro	B
,	O
cyano	B
,	O
SH	B
,	O
SR<4	B
>	I
,	O
trihalo	B
-	I
C1-C6-alkyl	I
,	O
C1-C6	B
-alkoxy	I
and	O
phenyl	B
,	O
wherein	O
R<4	O
>	O
is	O
C1-C6	B
alkyl;R<3	I
>	O
is	O
phenyl	B
substituted	O
with	O
OR<5	B
>	I
wherein	O
R<5	O
>	O
has	O
the	O
Formula	O
(	O
II	O
)	O
,	O
(	O
III	O
)	O
or	O
(	O
IV	O
)	O
,	O
wherein	O
Y	O
is	O
chosen	O
from	O
NHR<4	B
>	I
,	O
NR<4>2	B
,	O
NHCOR<4	B
>	I
,	O
NHSO2R<4	B
>	I
,	O
CONHR<4	B
>	I
,	O
CONR<4	B
>	I
,	O
CONR<4>2	B
,	O
COOH	B
,	O
COOR<4	B
>	I
,	O
SO2R<4	B
>	I
,	O
SOR<4	B
>	I
,	O
SONHR<4	B
>	I
,	O
SONR<4>2	B
,	O
a	O
C3-C7	B
heterocyclic	I
ring	O
,	O
saturated	O
or	O
unsaturated	O
,	O
containing	O
one	O
or	O
two	O
heteroatoms	O
independently	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
O	B
,	O
S	B
and	O
N	B
,	O
optionally	O
being	O
substituted	O
with	O
1	O
to	O
3	O
substituents	O
independently	O
selected	O
from	O
the	O
group	O
comprising	O
H	B
,	O
OH	B
,	O
halogen	B
,	O
nitro	B
,	O
cyano	B
,	O
SH	B
,	O
SR<4	B
>	I
,	O
trihalo	B
-	I
C1-C6-	I
alkyl	I
,	O
C1-C6-alkyl	B
and	O
C1-C6	B
-alkoxy	I
,	O
preferably	O
NHR<4	B
>	I
,	O
NR2<4	B
>	I
,	O
or	O
a	O
nitrogen	B
heterocycle	I
,	O
wherein	O
R<4	O
>	O
is	O
as	O
defined	O
above	O
,	O
and	O
the	O
esters	B
,	O
ethers	B
,	O
and	O
salts	O
of	O
the	O
compounds	O
of	O
formula	O
I	O
,	O
optionally	O
along	O
pharmaceutically	O
acceptable	O
excipients	O
,	O
a	O
process	O
for	O
the	O
preparation	O
of	O
the	O
same	O
,	O
and	O
a	O
method	O
of	O
preventing	O
and/or	O
treating	O
estrogen	B
-	O
related	O
disease	O
conditions	O
in	O
a	O
subject	O
using	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
or	O
its	O
salts	O
,	O
optionally	O
along	O
with	O
pharmaceutically	O
acceptable	O
excipients	O
.	O

(	B
3R,4R	I
)	I
-trans-3,4-diarylchroman	I
derivatives	O
with	O
estrogenic	O
activity	O

The	O
present	O
invention	O
provides	O
a	O
tape	O
preparation	O
including	O
a	O
support	O
and	O
an	O
adhesive	O
layer	O
directly	O
or	O
indirectly	O
formed	O
on	O
at	O
least	O
one	O
surface	O
of	O
the	O
support	O
,	O
wherein	O
the	O
adhesive	O
layer	O
contains	O
a	O
rubber	O
adhesive	O
containing	O
at	O
least	O
one	O
kind	O
of	O
rubber	O
polymer	O
and	O
capsaicin	B
as	O
an	O
active	O
ingredient	O
.	O

Since	O
the	O
adhesive	O
layer	O
shows	O
extremely	O
fine	O
adhesive	O
property	O
and	O
superior	O
capsaicin	B
releaseability	O
,	O
a	O
rapid	O
pharmacological	O
effect	O
can	O
be	O
afforded	O
with	O
a	O
small	O
capsaicin	B
content	O
.	O

Tape	O
preparation	O

The	O
present	O
invention	O
relates	O
to	O
a	O
medicine	O
composition	O
with	O
domperidone	B
maleate	I
.	O

It	O
is	O
characterized	O
by	O
that	O
said	O
medicine	O
composition	O
is	O
micropowdered	O
,	O
and	O
can	O
be	O
used	O
for	O
invigorating	O
function	O
of	O
gastrointestinal	O
tract	O
and	O
curing	O
the	O
diseases	O
of	O
dyspepsia	O
and	O
nausea	O
-	O
vomiting	O
,	O
etc	O
.	O

Said	O
micropowdered	O
domperidone	B
maleate	I
preparation	O
can	O
raise	O
its	O
bioavailability	O
.	O

Besides	O
,	O
said	O
invention	O
also	O
provides	O
its	O
preparation	O
method	O
.	O

Micro	O
-	O
powder	O
dom	O
peridone	B
maleate	I
medicinal	O
composition	O
and	O
its	O
preparing	O
method	O

A	O
dripping	O
pill	O
of	O
compound	O
silymarinum	O
is	O
prepared	O
from	O
the	O
silymarinum	O
and	O
the	O
alcohol	B
extract	O
of	O
5	O
kernels	O
through	O
proportionally	O
mixing	O
it	O
with	O
matrix	O
(	O
polyoxyvinyl	B
monostearate	I
)	O
,	O
heating	O
until	O
the	O
mixture	O
is	O
fused	O
,	O
stirring	O
,	O
and	O
dripping	O
in	O
condensing	O
liquid	O
.	O

Compound	O
Silybum	O
drip	O
balls	O
and	O
preparation	O
thereof	O

An	O
eye	O
gel	O
of	O
Ganciclovir	B
for	O
treating	O
viral	O
keratitis	O
is	O
proportionally	O
prepared	O
from	O
ganciclovir	B
and	O
eye	O
gel	O
matrix	O
through	O
mixing	O
Ganciclovir	B
,	O
eye	O
gel	O
matrix	O
and	O
water	O
,	O
stirring	O
,	O
regulating	O
pH	O
value	O
,	O
adding	O
water	O
,	O
stirring	O
and	O
sterilizing	O
.	O

Ganciclovir	B
ophthalmic	O
gel	O
and	O
its	O
prepn	O
.	O

method	O

A	O
composite	O
medicine	O
in	O
the	O
form	O
of	O
softgel	O
is	O
prepared	O
from	O
domperidone	B
and	O
the	O
auxiliary	O
chosen	O
from	O
diluent	O
,	O
cosolvent	O
,	O
solubilizer	O
and	O
surfactant	O
.	O

It	O
has	O
high	O
stability	O
.	O

Its	O
preparing	O
process	O
is	O
also	O
disclosed	O
.	O

Soft	O
capsule	O
of	O
medication	O
composition	O
,	O
and	O
preparation	O
method	O

An	O
application	O
of	O
the	O
medicinal	O
composition	O
containing	O
paracetamol	B
,	O
propylphenazone	B
and	O
caffeine	B
in	O
treating	O
cerebral	O
ischemia	O
is	O
disclosed	O
.	O

Application	O
of	O
medication	O
composition	O
of	O
containing	O
acetamino	B
phenol	I
in	O
treating	O
insufficiency	O
of	O
blood	O
supply	O
for	O
brain	O

The	O
invention	O
relates	O
to	O
the	O
process	O
for	O
preparing	O
gelling	O
agent	O
of	O
rhubarb	O
horsetails	O
and	O
sulfur	B
by	O
using	O
free	O
anthraquinone	B
of	O
rhubarb	O
horsetails	O
extract	O
and	O
sulfur	B
as	O
the	O
main	O
constituents	O
,	O
using	O
carbomer	O
as	O
the	O
gel	O
matrix	O
,	O
and	O
using	O
methyl	B
ethylene	I
glycol	I
and	O
urea	B
as	O
the	O
mixed	O
transdermal	O
accelerating	O
agent	O
.	O

The	O
preparation	O
can	O
be	O
used	O
for	O
treating	O
acne	O
.	O

Method	O
for	O
preparing	O
rhubarb	O
sulfur	B
gel	O
agent	O

Disclosed	O
is	O
an	O
externally	O
used	O
medicament	O
for	O
treating	O
tragomaschalia	O
,	O
which	O
is	O
prepared	O
from	O
the	O
following	O
raw	O
materials	O
:	O
talcum	O
powder	O
,	O
goldthread	O
root	O
,	O
dandelion	O
,	O
gypsum	O
,	O
camphor	B
,	O
perfume	O
compound	O
and	O
ethanol	B
.	O

An	O
externally	O
applied	O
medicine	O
for	O
treating	O
hicismus	O
by	O
use	O
of	O
steatite	O

The	O
present	O
invention	O
relates	O
to	O
one	O
kind	O
of	O
veterinary	O
medicine	O
composition	O
for	O
eliminating	O
fever	O
,	O
relieving	O
pain	O
and	O
diminishing	O
inflammation	O
and	O
its	O
preparation	O
process	O
and	O
use	O
.	O

The	O
veterinary	O
medicine	O
composition	O
consists	O
of	O
diclofenac	B
sodium	I
and	O
naproxen	B
in	O
the	O
weight	O
ratio	O
of	O
0.1	O
-	O
10	O
,	O
preferably	O
0.2	O
-	O
5	O
;	O
or	O
consists	O
of	O
diclofenac	B
sodium	I
and	O
barbitone	B
in	O
the	O
weight	O
ratio	O
of	O
0.2	O
-	O
10	O
,	O
preferably1	O
-	O
7.5	O
.	O

The	O
veterinary	O
medicine	O
composition	O
is	O
used	O
in	O
preventing	O
and	O
treating	O
feverish	O
animal	O
diseases	O
and	O
has	O
synergistic	O
fever	O
eliminating	O
effect	O
,	O
fast	O
acting	O
and	O
less	O
recurrence	O
.	O

Compound	O
medicine	O
composition	O
and	O
its	O
prepn	O
and	O
use	O

A	O
sobering	O
-	O
up	O
beverage	O
is	O
proportionally	O
prepared	O
from	O
8	O
raw	O
materials	O
including	O
purified	O
water	O
,	O
pear	O
juice	O
,	O
pueraria	O
root	O
(	O
or	O
flower	O
)	O
,	O
ginsenoside	B
Rg3	I
,	O
rebescensine	O
A	O
,	O
isoliquiritigenin	B
,	O
etc	O
.	O

Sobering	O
-	O
up	O
beverage	O

The	O
invention	O
provides	O
a	O
Tranditerol	B
Hydrochloride	B
aerosol	O
,	O
which	O
comprises	O
(	O
by	O
weight	O
ratio	O
)	O

Tranditerol	B
Hydrochloride	B
0.005	O
-	O
0.01	O
part	O
,	O
double	O
solvent	O
5	O
-	O
10	O
parts	O
,	O
and	O
propellant	O
90	O
-	O
95	O
parts	O
.	O

Chlorhydric	B
acid	I
tranditerol	B
aerosol	O

The	O
invention	O
discloses	O
a	O
nalorphine	B
amino	I
compound	O
and	O
preparing	O
method	O
with	O
structural	O
formula	O
as	O
(	O
I	O
)	O
,	O
wherein	O
the	O
amino	B
can	O
be	O
Arg	B
,	O
Lys	B
or	O
His	B
;	O
the	O
molecular	O
rate	O
of	O
nalorphine	B
and	O
amino	B
is	O
1:1	O
-	O
1	O
:	O
5	O
or	O
5:1	O
-	O
1:1	O
.	O

Preparation	O
method	O
of	O
dexibuprofen	B
amino	I
acid	I
salt	I
and	O
application	O

The	O
invention	O
relates	O
to	O
a	O
nifungin	O
-	O
canstat	O
vagina	O
effervescent	O
tablet	O
.	O

Wherein	O
,	O
it	O
uses	O
nifungin	O
and	O
canstat	O
,	O
with	O
acid	O
-	O
alkali	O
adding	O
system	O
,	O
and	O
stuff	O
or	O
directly	O
being	O
compressed	O
into	O
tablet	O
or	O
particles	O
then	O
to	O
be	O
compressed	O
into	O
tablet	O
,	O
or	O
uses	O
macrogol	O
to	O
cover	O
the	O
alkali	O
,	O
then	O
to	O
be	O
compressed	O
into	O
tablet	O
.	O

The	O
invention	O
uses	O
the	O
acid	O
alkali	O
system	O
which	O
will	O
generate	O
carbon	B
dioxide	I
gas	O
when	O
meeting	O
water	O
as	O
slaking	O
agent	O
;	O
therefore	O
,	O
the	O
tablet	O
will	O
foam	O
and	O
slake	O
when	O
adsorbs	O
water	O
in	O
vagina	O
,	O
to	O
disperse	O
the	O
elements	O
into	O
vagina	O
completely	O
,	O
as	O
uterine	O
cervix	O
,	O
etc	O
.	O

Nifuratel	B
-	O
nystatin	B
vaginal	O
effervescent	O
-	O
tablets	O

The	O
present	O
invention	O
relates	O
to	O
geldanamycin	B
type	O
aromatic	B
reduced	O
benzoquinone	B
derivative	O
and	O
its	O
preparation	O
process	O
as	O
well	O
as	O
the	O
medicine	O
composition	O
with	O
the	O
compound	O
as	O
active	O
component	O
and	O
its	O
use	O
.	O

The	O
compound	O
is	O
prepared	O
through	O
fermentation	O
with	O
,	O
say	O
,	O
pseudostreptoverticillium	O
,	O
and	O
it	O
is	O
proved	O
experimentally	O
that	O
the	O
compound	O
may	O
be	O
used	O
in	O
preparing	O
cell	O
period	O
inhibitor	O
and	O
antitumor	O
preparation	O
.	O

Aromatic	B
reductive	O
derivative	O
of	O
geldanamycin	B
benzoquinone	I
,	O
preparation	O
method	O
and	O
use	O
thereof	O

The	O
stomatocase	O
treating	O
medicine	O
is	O
prepared	O
with	O
five	O
kinds	O
of	O
main	O
materials	O
,	O
including	O
gypsum	O
,	O
cape	O
jasmine	O
,	O
reed	O
rhizome	O
,	O
mint	O
and	O
anemarrhena	O
rhizome	O
,	O
and	O
six	O
kinds	O
of	O
supplementary	O
medicine	O
materials	O
,	O
including	O
rehmannia	O
root	O
,	O
skullcap	O
root	O
,	O
etc	O
.	O

The	O
present	O
invention	O
has	O
unique	O
recipe	O
,	O
obvious	O
treating	O
effect	O
and	O
fast	O
acting	O
.	O

Stomatocase	O
treating	O
medicine	O

The	O
present	O
invention	O
relates	O
to	O
a	O
Xiaoer	O
anfenhuangnamin	O
gel	O
preparation	O
for	O
children	O
and	O
its	O
preparation	O
method	O
.	O

Said	O
gel	O
preparation	O
composition	O
contains	O
(	O
by	O
wt%	O
)	O
0.05	O
-	O
30	O
%	O
of	O
acetaminophen	B
,	O
0.005	O
-	O
1	O
%	O
of	O
artificial	O
cow	O
-	O
bezoare	O
,	O
0.0005	O
-	O
0.08	O
%	O
of	O
chlorpheamine	B
maleate	I
,	O
0.2	O
-	O
10	O
%	O
of	O
agar	O
,	O
1	O
-	O
20	O
%	O
of	O
cane	O
sugar	B
,	O
1	O
-	O
10	O
%	O
of	O
cyclodextrin	O
and	O
45	O
-	O
90	O
%	O
of	O
water	O
.	O

Pediatric	O
paracetamol	B
artifical	O
low	O
-	O
bezoar	O
and	O
chlorphenzmine	B
maleategel	O
preparation	O
and	O
its	O
preparing	O
method	O

The	O
invention	O
relates	O
to	O
an	O
enantiomorphic	O
amine	B
alkyl	I
sesquiterpene	I
alcohol	I
and	O
glucoside	B
and	O
the	O
medicated	O
salt	O
or	O
solvent	O
thereof	O
,	O
as	O
well	O
as	O
the	O
effect	O
and	O
activity	O
of	O
the	O
composed	O
medicine	O
combination	O
,	O
mainly	O
relating	O
to	O
the	O
medical	O
use	O
in	O
reducing	O
HBV	O
-	O
DNA	O
replication	O
activity	O
.	O

And	O
it	O
has	O
considerably	O
strong	O
inhibiting	O
effect	O
on	O
HBsAG	O
screted	O
by	O
HepG2.2.15	O
and	O
HBV	O
-	O
DNA	O
replication	O
as	O
compared	O
with	O
positive	O
contrast	O
Lamivudine	B
;	O
and	O
it	O
has	O
obvious	O
inhibition	O
activity	O
to	O
HBV	O
-	O
DNA	O
replication	O
at	O
large	O
dosage	O
(	O
100	O
mug	O
/	O
mL	O
)	O
and	O
medium	O
dosage	O
(	O
20	O
mug	O
/	O
mL	O
)	O
as	O
contrasted	O
with	O
Lamivudine	B
,	O
and	O
can	O
be	O
expected	O
to	O
apply	O
to	O
preparing	O
medicines	O
for	O
curing	O
HB	O
virus	O
infection	O
disease	O
.	O

Pharmaceutical	O
use	O
of	O
ent	B
-	I
eudesmane	I
alcohol	I
type	O
sesquiterpene	B
for	O
inhibiting	O
hepatitis	O
virus	O

An	O
application	O
of	O
astragaloside	O
A	O
in	O
preventing	O
and	O
treating	O
acute	O
or	O
chronic	O
nephritis	O
and	O
acute	O
or	O
chronic	O
renal	O
failure	O
,	O
its	O
preparing	O
process	O
,	O
and	O
its	O
medical	O
composition	O
are	O
disclosed	O
.	O

Medical	O
usage	O
of	O
milkvetch	O
-	O
root	O
methcoside	O

The	O
invention	O
relates	O
to	O
an	O
intralipid	O
injection	O
which	O
contains	O
soya	O
oil	O
,	O
middle	O
chain	O
triglyceride	B
,	O
olive	O
oil	O
,	O
and	O
fish	O
oil	O
,	O
wherein	O
it	O
comprises	O
48	O
-	O
72	O
g	O
.	O

L	O
soya	O
oil	O
,	O
48	O
-	O
72g	O
/	O
L	O
middle	O
chain	O
triglyceride	B
,	O
40	O
-	O
60g	O
/	O
L	O
olive	O
oil	O
,	O
and	O
24	O
-	O
36g	O
/	O
L	O
fish	O
oil	O
,	O
108	O
-	O
162	O
mg	O
/	O
L	O
dl	B
-	I
alpha	I
-	I
tocofecol	I
,	O
9.6	O
-	O
14.4g	O
/	O
L	O
lipovitellin	B
,	O
22.5	O
-	O
27.5g	O
/	O
L	O
pure	O
glycerin	B
,	O
240	O
-	O
360mg	O
/	O
L	O
sodium	B
oleate	I
,	O
18	O
-	O
22mg	O
/	O
L	O
caustic	B
soda	I
,	O
and	O
1L	O
injection	O
water	O
.	O

The	O
ratio	O
between	O
w-6	O
and	O
w-3	O
aliphatic	B
acid	I
is	O
3.0	O
-	O
2.2:1	O
.	O

The	O
invention	O
optimizes	O
and	O
balances	O
the	O
aliphatic	O
acid	O
mode	O
.	O

Fat	O
emulsion	O
injection	O
liquid	O
containing	O
soybean	O
oil	O
,	O
medium	O
chain	O
triglyceride	B
,	O
olive	O
oil	O
and	O
fish	O
oil	O
and	O
method	O
for	O
preparing	O
the	O
same	O

The	O
invention	O
relates	O
to	O
a	O
medicament	O
for	O
spleen	O
-	O
reinforcing	O
and	O
digestion	O
-	O
promoting	O
and	O
process	O
for	O
preparation	O
,	O
wherein	O
the	O
medicament	O
comprises	O
(	O
by	O
weight	O
ratio	O
)	O
wrinkled	O
giant	O
hyssop	O
3	O
-	O
8	O
,	O
cape	O
jasmine	O
2	O
-	O
5	O
,	O
calcium	B
sulphate	I
3	O
-	O
8	O
,	O
licorice	O
root	O
5	O
-	O
10	O
,	O
ledebouriella	O
root	O
10	O
-	O
20	O
,	O
ginseng	O
3	O
-	O
8	O
,	O
poria	O
cocos	O
wolf	O
2	O
-	O
5	O
,	O
white	O
atractylodes	O
rhizome	O
2	O
-	O
5	O
,	O
dried	O
orange	O
peel	O
2	O
-	O
5	O
,	O
cardamorn	O
0.1	O
-	O
0.2	O
,	O
clove	O
0.1	O
-	O
0.2	O
,	O
sulfur	B
flour	O
0.1	O
-	O
0.2	O
and	O
talcum	O
powder	O
0.3	O
-	O
0.8	O
.	O

Medicament	O
for	O
harmonizing	O
middle	O
energizer	O
,	O
invigorating	O
spleen	O
and	O
regulating	O
stomach	O
function	O

The	O
medicine	O
composition	O
for	O
treating	O
laryngopharyngitis	O
is	O
prepared	O
with	O
rehmannia	O
root	O
5	O
-	O
100	O
weight	O
portions	O
,	O
date	O
coating	O
3	O
-	O
100	O
weight	O
portions	O
,	O
and	O
tortoise	O
plastron	O
5	O
-	O
200	O
weight	O
portions	O
.	O

The	O
preparation	O
process	O
includes	O
the	O
steps	O
of	O
decoction	O
,	O
filtering	O
,	O
concentrating	O
the	O
filtrate	O
to	O
obtain	O
paste	O
of	O
density	O
1.00	O
-	O
1.15	O
,	O
dissolving	O
the	O
paste	O
in	O
alcohol	B
,	O
filtering	O
,	O
concentrating	O
the	O
filtrate	O
toobtain	O
dense	O
paste	O
of	O
density	O
1.20	O
-	O
1.50	O
while	O
recovering	O
alcohol	B
,	O
and	O
drying	O
to	O
obtain	O
the	O
medicine	O
composition	O
.	O

The	O
medicine	O
composition	O
is	O
used	O
in	O
treating	O
laryngopharyngitis	O
,	O
and	O
has	O
high	O
safety	O
,	O
low	O
cost	O
,	O
high	O
effective	O
component	O
content	O
and	O
high	O
stability	O
.	O

Largngopharyngitis	O
treating	O
medicine	O
composition	O
and	O
its	O
preparation	O

A	O
medication	O
compound	O
,	O
which	O
include	O
cyclodextrin	O
and	O
cephalosporin	B
ester	O
's	O
clathrate	O
;	O
this	O
invention	O
alao	O
related	O
to	O
the	O
method	O
to	O
produce	O
it	O
.	O

Medicament	O
composition	O
of	O
cefpodoxime	B
proxetil	I
and	O
cyclodextrin	O
and	O
preparation	O
method	O
thereof	O

The	O
invention	O
relates	O
to	O
a	O
solvent	O
for	O
softening	O
ear	O
wax	O
,	O
which	O
is	O
prepared	O
from	O
compositions	O
of	O
sodium	B
hydrogen	I
carbonate	I
,	O
water	O
and	O
glycerine	O
through	O
specific	O
processes	O
.	O

The	O
medicament	O
provided	O
by	O
the	O
invention	O
has	O
good	O
effect	O
in	O
softening	O
ear	O
wax	O
,	O
and	O
easy	O
accessibility	O
of	O
raw	O
material	O
.	O

Cerumen	O
softening	O
agent	O

The	O
invention	O
discloses	O
an	O
application	O
of	O
4-methyl	B
cyclopentadecanone	I
in	O
the	O
drug	O
of	O
ischemic	O
cerebrovascular	O
disease	O
,	O
which	O
also	O
treats	O
antirheumatic	O
,	O
rheumatoid	O
disease	O
as	O
well	O
as	O
prevent	O
tumour	O
.	O

4-methyl	B
cyclopentadecanone	I
and	O
its	O
uses	O

The	O
utility	O
model	O
relates	O
to	O
a	O
bra	O
technical	O
structure	O
simple	O
in	O
structure	O
and	O
convenient	O
for	O
the	O
use	O
of	O
a	O
bra	O
or	O
bra	O
pads	O
filled	O
with	O
medicine	O
,	O
wherein	O
hollow	O
protection	O
layers	O
in	O
contact	O
with	O
the	O
breasts	O
are	O
arranged	O
on	O
the	O
bra	O
or	O
the	O
bra	O
pads	O
,	O
and	O
openings	O
corresponding	O
to	O
the	O
breasts	O
are	O
formed	O
on	O
the	O
two	O
protection	O
layers	O
;	O
medicine	O
materials	O
are	O
arranged	O
in	O
the	O
protective	O
layers	O
after	O
being	O
wrapped	O
by	O
soft	O
and	O
air	O
permeable	O
cloths	O
,	O
so	O
as	O
to	O
permeate	O
through	O
the	O
breasts	O
through	O
the	O
contact	O
between	O
the	O
openings	O
on	O
the	O
protective	O
layers	O
and	O
the	O
breast	O
skins	O
;	O
by	O
wearing	O
the	O
bra	O
,	O
the	O
skin	O
-	O
permeation	O
of	O
the	O
medicine	O
can	O
stimulate	O
the	O
hormone	O
to	O
secrete	O
,	O
and	O
can	O
preserve	O
the	O
excellent	O
shapes	O
of	O
the	O
breasts	O
;	O
in	O
addition	O
,	O
as	O
the	O
medicine	O
has	O
the	O
functions	O
of	O
anti	O
-	O
inflammatory	O
detumescence	O
and	O
blood	O
circulation	O
improvement	O
,	O
the	O
translucency	O
of	O
the	O
breasts	O
can	O
be	O
enhanced	O
,	O
the	O
lump	O
shadow	O
is	O
lessened	O
,	O
and	O
the	O
vascularity	O
gradually	O
becomes	O
normal	O
,	O
and	O
therefore	O
the	O
purposes	O
of	O
health	O
care	O
,	O
breast	O
enlarging	O
and	O
breast	O
rounding	O
and	O
firming	O
are	O
achieved	O
.	O

Bra	O
technical	O
structure	O

In	O
order	O
to	O
solve	O
the	O
technical	O
problem	O
existing	O
in	O
the	O
process	O
of	O
delivering	O
the	O
drug	O
to	O
the	O
skin	O
for	O
reduction	O
of	O
bleeding	O
amount	O
when	O
an	O
operation	O
is	O
performed	O
at	O
present	O
,	O
the	O
utility	O
model	O
relates	O
to	O
medical	O
supplies	O
,	O
and	O
provides	O
a	O
drug	O
delivery	O
plaster	O
for	O
reduction	O
of	O
the	O
bleeding	O
amount	O
in	O
an	O
operation	O
.	O

The	O
drug	O
delivery	O
plaster	O
comprises	O
a	O
plaster	O
body	O
,	O
and	O
is	O
characterized	O
in	O
that	O
the	O
plaster	O
body	O
is	O
formed	O
by	O
three	O
layers	O
,	O
wherein	O
the	O
surface	O
layer	O
is	O
a	O
bonding	O
layer	O
with	O
viscosity	O
,	O
and	O
a	O
plurality	O
of	O
drug	O
delivery	O
holes	O
are	O
formed	O
in	O
the	O
bonding	O
layer	O
,	O
the	O
intermediate	O
layer	O
is	O
a	O
drug	O
layer	O
,	O
the	O
bottom	O
layer	O
is	O
a	O
heating	O
layer	O
,	O
and	O
heater	O
strips	O
are	O
arranged	O
in	O
the	O
heating	O
layer	O
;	O
a	O
power	O
interface	O
connected	O
with	O
an	O
external	O
power	O
supply	O
is	O
arranged	O
in	O
the	O
bottom	O
surface	O
of	O
the	O
bottom	O
layer	O
.	O

The	O
drug	O
delivery	O
plaster	O
is	O
reasonable	O
in	O
structure	O
,	O
convenient	O
to	O
use	O
and	O
high	O
in	O
drug	O
delivery	O
efficiency	O
,	O
and	O
can	O
be	O
widely	O
applied	O
to	O
surgical	O
operations	O
.	O

Drug	O
delivery	O
plaster	O
for	O
reduction	O
of	O
bleeding	O
amount	O
in	O
operation	O

Piperazine	B
salt	O
(	O
I	O
)	O
of	O
omeprazole	B
or	O
its	O
enantiomer	O
is	O
new	O
.	O

An	O
independent	O
claim	O
is	O
also	O
included	O
for	O
the	O
preparation	O
of	O
(	O
I	O
)	O
.	O

-	O
ACTIVITY	O
:	O
Gastrointestinal	O
-	O
Gen	O
.	O
;	O
Antiulcer	O
;	O
Antiinflammatory	O
.	O

No	O
biological	O
data	O
given	O
.	O

-	O
MECHANISM	O
OF	O
ACTION	O
:	O
Proton	O
pump	O
inhibitor	O
.	O

No	O
biological	O
data	O
given	O
.	O

New	O
piperazine	B
salt	O
of	O
omeprazol	B
is	O
proton	O
pump	O
inhibitor	O
useful	O
to	O
prevent	O
/	O
treat	O
e.g.	O
peptic	O
ulcer	O
,	O
gastritis	O
,	O
gastroesophageal	O
reflux	O
,	O
acute	O
stress	O
ulcer	O
or	O
dyspepsia	O

Composition	O
for	O
topical	O
application	O
contains	O
barium	B
sulfate	I
with	O
a	O
particle	O
size	O
of	O
1	O
-	O
30	O
mu	O
m.	O
An	O
independent	O
claim	O
is	O
also	O
included	O
for	O
preparing	O
a	O
composition	O
as	O
above	O
by	O
adding	O
barium	B
sulfate	I
to	O
known	O
ingredients	O
of	O
conventional	O
cosmetic	O
products	O
.	O

Composition	O
for	O
topical	O
application	O
,	O
useful	O
as	O
a	O
cosmetic	O
or	O
dermatological	O
product	O
,	O
contains	O
finely	O
divided	O
barium	B
sulfate	I

Preparations	O
containing	O
one	O
or	O
more	O
apiogalacturonans	O
(	O
I	O
)	O
or	O
extract	O
(	O
s	O
)	O
of	O
(	O
I	O
)	O
from	O
Zostera	O
marina	O
and	O
also	O
one	O
or	O
more	O
emulsifiers	O
.	O

Cosmetic	O
or	O
dermatological	O
preparations	O
for	O
skin	O
care	O
and	O
cleaning	O
,	O
containing	O
apiogalacturonan	O
compounds	O
or	O
extracts	O
thereof	O
from	O
seaweed	O
,	O
together	O
with	O
emulsifiers	O

Preparations	O
containing	O
one	O
or	O
more	O
apiogalacturonans	B
(	O
I	O
)	O
or	O
extract	O
(	O
s	O
)	O
of	O
(	O
I	O
)	O
from	O
Zostera	O
marina	O
and	O
also	O
one	O
or	O
more	O
UV	O
light	O
absorbers	O
.	O

Cosmetic	O
or	O
dermatological	O
preparations	O
for	O
skin	O
care	O
,	O
protection	O
and	O
cleaning	O
,	O
containing	O
apiogalacturonan	B
compounds	O
or	O
extracts	O
thereof	O
from	O
seaweed	O
,	O
together	O
with	O
UV	O
light	O
absorbers	O

A	O
composition	O
for	O
the	O
treatment	O
of	O
livestock	O
suffering	O
from	O
disorders	O
such	O
as	O
fluid	O
depletion	O
,	O
acidosis	O
,	O
and	O
imbalances	O
or	O
loss	O
of	O
essential	O
electrolytes	O
,	O
same	O
to	O
be	O
made	O
up	O
in	O
water	O
at	O
point	O
of	O
use	O
as	O
an	O
oral	O
rehydration	O
formulation	O
,	O
comprises	O
an	O
intimate	O
mixture	O
of	O
an	O
energy	O
source	O
,	O
electrolytes	O
,	O
and	O
bicarbonate	B
precursors	O
,	O
which	O
precursors	O
are	O
provided	O
as	O
physiologically	O
acceptable	O
carboxylic	B
acid	I
anions	O
with	O
corresponding	O
physiologically	O
acceptable	O
cations	O
including	O
sodium	B
,	O
the	O
yield	O
of	O
bicarbonate	B
being	O
in	O
excess	O
of	O
30	O
millimole	O
/	O
litre	O
(	O
mmol	O
/	O
1	O
)	O
of	O
final	O
formulation	O
,	O
and	O
the	O
concentration	O
of	O
sodium	B
being	O
in	O
excess	O
of	O
80	O
mmol	O
/	O
1	O
of	O
final	O
formulation	O
.	O

Veterinary	O
rehydration	O
product	O

The	O
present	O
invention	O
concerns	O
heterocyclic	B
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
R1-R7	O
,	O
B	O
,	O
a	O
and	O
X	O
have	O
the	O
meanings	O
indicated	O
in	O
the	O
description	O
.	O

These	O
compounds	O
can	O
be	O
used	O
for	O
the	O
treatment	O
of	O
rheumatic	O
ailments	O
and	O
for	O
the	O
prevention	O
of	O
allergic	O
illnesses	O
.	O

[	O
a	O
]	O
-ANNELATED	O
PYRROLE	B
DERIVATIVES	O
AND	O
PHARMACEUTICAL	O
USES	O
THEREOF	O

An	O
in	O
vivo	O
method	O
for	O
depleting	O
mammalian	O
cells	O
of	O
adenosine	B
5'-monophosphate	I
(	O
AMP	B
)	O
useful	O
in	O
the	O
treatment	O
of	O
certain	O
cancers	O
is	O
provided	O
.	O

According	O
to	O
the	O
method	O
,	O
a	O
population	O
of	O
cells	O
is	O
obtained	O
from	O
a	O
host	O
and	O
assayed	O
for	O
loss	O
of	O
methylthioadenosine	B
phosphorylase	O
(	O
MTAse	O
)	O
activity	O
.	O

MTAse	O
catabolizes	O
methylthioadenosine	B
to	O
adenine	B
for	O
endogenous	O
salvage	O
incorporation	O
into	O
the	O
intracellular	O
AMP	O
pool	O
.	O

The	O
preferred	O
method	O
for	O
assaying	O
loss	O
of	O
MTAse	O
activity	O
is	O
a	O
hybridization	O
technique	O
for	O
detection	O
of	O
a	O
homozygous	O
loss	O
of	O
the	O
gene	O
which	O
encodes	O
with	O
a	O
therapeutically	O
effective	O
amount	O
of	O
an	O
agent	O
which	O
inhibits	O
the	O
activity	O
of	O
adenylsuccinate	B
synthetase	O
,	O
which	O
converts	O
inosine	O
5'-monophosphate	O
to	O
AMP	O
,	O
thus	O
depleting	O
the	O
tumor	O
cells	O
of	O
substrates	O
for	O
de	O
novo	O
AMP	O
production	O
.	O

L	B
-	I
alanosine	I
is	O
the	O
preferred	O
ASS	O
inhibitory	O
agent	O
for	O
use	O
in	O
the	O
method	O
of	O
the	O
invention	O
.	O

The	O
figure	O
is	O
a	O
nucleotide	O
sequence	O
for	O
genomic	O
MTAse	O
(	O
SEQ	O
.	O
ID	O
.	O

No.	O
1	O
)	O
wherein	O
the	O
exons	O
are	O
underlined	O
.	O

Method	O
for	O
inhibiting	O
adenylosuccinate	B
synthetase	O
activity	O
methylthioadenosine	B
phosphorylase	O
deficient	O
cells	O

The	O
present	O
invention	O
provides	O
the	O
use	O
of	O
an	O
orally	O
active	O
,	O
long	O
acting	O
,	O
CNS	O
-	O
penetrant	O
NK-1	O
receptor	O
antagonist	O
for	O
the	O
manufacture	O
of	O
a	O
medicament	O
adapted	O
for	O
oral	O
administration	O
for	O
the	O
treatment	O
or	O
prevention	O
of	O
major	O
depressive	O
disorder	O
with	O
anxiety	O
without	O
concomitant	O
therapy	O
with	O
other	O
anti	O
-	O
depressant	O
or	O
anti	O
-	O
anxiety	O
agents	O
,	O
methods	O
of	O
treatment	O
using	O
such	O
a	O
NK-1	O
receptor	O
antagonist	O
and	O
pharmaceutical	O
compositions	O
comprising	O
the	O
same	O
.	O

Use	O
of	O
nk-1	O
receptor	O
antagonists	O
for	O
treating	O
major	O
depressive	O
disorders	O
with	O
anxiety	O

The	O
invention	O
provides	O
a	O
method	O
of	O
inhibiting	O
cancer	O
cell	O
growth	O
,	O
and	O
thereby	O
of	O
treating	O
cancer	O
comprising	O
administering	O
to	O
a	O
mammal	O
afflicted	O
with	O
cancer	O
an	O
effective	O
amount	O
of	O
the	O
compound	O
of	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
the	O
variables	O
of	O
R1+and	O
R2	O
have	O
the	O
meanings	O
defined	O
in	O
the	O
specification	O
.	O

The	O
present	O
invention	O
also	O
provides	O
novel	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
as	O
well	O
as	O
novel	O
pharmaceutical	O
compositions	O
and	O
intermediates	O
useful	O
for	O
preparing	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
.	O

The	O
figure	O
illustrates	O
the	O
structure	O
and	O
binding	O
activity	O
of	O
compounds	O
of	O
the	O
invention	O
and	O
some	O
of	O
the	O
rifamycin	B
analogs	O
.	O

Method	O
for	O
antagonizing	O
HEREGUlin	O
or	O
its	O
receptor	O
and	O
use	O
for	O
the	O
inhibition	O
of	O
cancer	O
cells	O

Compounds	O
of	O
formulas	O
(	O
1	O
)	O
and	O
(	O
2	O
)	O
,	O
wherein	O
the	O
variables	O
of	O
X	O
,	O
Y	O
and	O
R	O
'	O
are	O
herein	O
defined	O
in	O
the	O
specification	O
,	O
promote	O
bone	O
information	O
and	O
are	O
thus	O
useful	O
in	O
treating	O
osteoporosis	O
,	O
bone	O
fracture	O
or	O
deficiency	O
,	O
primary	O
or	O
secondary	O
hyperparathyroidism	O
,	O
periodontal	O
disease	O
or	O
defect	O
,	O
metastatic	O
bone	O
disease	O
,	O
osteolytic	O
bone	O
disease	O
,	O
post	O
-	O
plastic	O
surgery	O
,	O
post	O
-	O
prosthetic	O
joint	O
surgery	O
,	O
and	O
post	O
-	O
dental	O
implantation	O
.	O

The	O
figure	O
shows	O
the	O
structure	O
and	O
activity	O
of	O
several	O
compounds	O
of	O
the	O
invention	O
namely	O
,	O
nevastatin	B
,	O
lovastatin	B
and	O
pravastatin	B
,	O
as	O
tested	O
in	O
the	O
in	O
vitro	O
BMP	O
-	O
promoter	O
based	O
assay	O
.	O

Compositions	O
and	O
methods	O
for	O
stimulating	O
bone	O
growth	O

Lipid	O
lowering	O
dosage	O
units	O
,	O
to	O
be	O
used	O
once	O
a	O
day	O
,	O
produce	O
minimal	O
side	O
effects	O
.	O

They	O
contain	O
a	O
combination	O
of	O
microspheres	O
formulated	O
to	O
co	O
-	O
deliver	O
a	O
HMG	O
-	O
CoA	O
reductase	O
inhibitor	O
component	O
and	O
a	O
niacin	B
component	O
.	O

Controlled	O
release	O
compositions	O
for	O
the	O
treatment	O
of	O
hyperlipidemia	O

The	O
APC	O
tumor	O
suppressor	O
protein	O
binds	O
to	O
beta	O
-catenin	O
,	O
a	O
protein	O
recently	O
shown	O
to	O
interact	O
with	O
Tcf	O
/	O
Lef	O
transcription	O
factors	O
.	O

Here	O
,	O
the	O
gene	O
encoding	O
a	O
Tcf	O
family	O
member	O
that	O
is	O
expressed	O
in	O
colonic	O
epithelium	O
(	O
hTcf-4	O
)	O
was	O
cloned	O
and	O
characterized	O
.	O

hTcf-4	O
transactivates	O
transcription	O
only	O
when	O
associated	O
with	O
beta	O
-catenin	O
.	O

Nuclei	O
of	O
APC<-	O
/	O
-	O
>	O
colon	O
carcinoma	O
cells	O
were	O
found	O
to	O
contain	O
a	O
stable	O
beta	O
-catenin	O
-	O
hTCF-4	O
complex	O
that	O
was	O
constitutively	O
active	O
,	O
as	O
measured	O
by	O
transcription	O
of	O
a	O
Tcf	O
reporter	O
gene	O
.	O

Reintroduction	O
of	O
APC	O
removed	O
beta	O
-catenin	O
from	O
hTcf4	O
and	O
abrogated	O
the	O
transcriptional	O
transactivation	O
.	O

Constitutive	O
transcription	O
of	O
TCF	O
target	O
genes	O
,	O
caused	O
by	O
loss	O
of	O
APC	O
function	O
,	O
may	O
be	O
a	O
crucial	O
event	O
in	O
the	O
early	O
transformation	O
of	O
colonic	O
epithelium	O
.	O

It	O
is	O
also	O
shown	O
here	O
that	O
the	O
products	O
of	O
mutant	O
APC	O
genes	O
found	O
in	O
colorectal	O
tumors	O
are	O
defective	O
in	O
regulating	O
beta	O
-catenin	O
/	O
Tcf-4	O
transcriptional	O
activation	O
.	O

Furthermore	O
,	O
colorectal	O
tumors	O
with	O
intact	O
APC	O
genes	O
were	O
shown	O
to	O
contain	O
subtle	O
activating	O
mutations	O
of	O
beta	O
-catenin	O
that	O
altered	O
functionally	O
significant	O
phosphorylation	O
sites	O
.	O

These	O
results	O
indicate	O
that	O
regulation	O
of	O
beta	O
-catenin	O
is	O
critical	O
to	O
APC	O
's	O
tumor	O
suppressive	O
effect	O
and	O
that	O
this	O
regulation	O
can	O
be	O
circumvented	O
by	O
mutations	O
in	O
either	O
APC	O
or	O
beta	O
-catenin	O
.	O

Beta	O
-	O
catenin	O
,	O
tcf-4	O
,	O
and	O
apc	O
interact	O
to	O
prevent	O
cancer	O

Methods	O
and	O
compositions	O
for	O
modulating	O
an	O
immune	O
response	O
in	O
a	O
mammal	O
infected	O
with	O
a	O
bacterium	O
,	O
a	O
virus	O
,	O
or	O
a	O
parasite	O
are	O
provided	O
.	O

The	O
methods	O
and	O
compositions	O
are	O
useful	O
in	O
mammals	O
experiencing	O
an	O
acute	O
infection	O
and	O
in	O
mammals	O
experiencing	O
a	O
chronic	O
infection	O
.	O

The	O
methods	O
and	O
compositions	O
may	O
be	O
used	O
in	O
conjunction	O
with	O
a	O
known	O
treatment	O
for	O
infection	O
of	O
a	O
mammal	O
by	O
an	O
infectious	O
agent	O
.	O

Methods	O
and	O
compositions	O
for	O
transmucosal	O
delivery	O
of	O
a	O
molecule	O
comprising	O
an	O
epitope	O
located	O
in	O
close	O
proximity	O
to	O
the	O
immune	O
response	O
are	O
provided	O
.	O

A	O
method	O
of	O
modulating	O
an	O
immune	O
response	O
in	O
an	O
infected	O
mammal	O
by	O
transmucosal	O
administration	O
of	O
modulating	O
agent	O

This	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
1	O
)	O
and	O
to	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O

The	O
compounds	O
of	O
formula	O
(	O
1	O
)	O
are	O
potent	O
antibacterial	O
agents	O
that	O
may	O
be	O
used	O
to	O
treat	O
various	O
bacterial	O
infections	O
and	O
disorders	O
related	O
to	O
such	O
infections	O
.	O

The	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
containing	O
the	O
compounds	O
of	O
formula	O
(	O
1	O
)	O
and	O
to	O
methods	O
of	O
treating	O
bacterial	O
infections	O
by	O
administering	O
the	O
compounds	O
of	O
formula	O
(	O
1	O
)	O
.	O

The	O
invention	O
also	O
relates	O
to	O
methods	O
of	O
preparing	O
the	O
compounds	O
of	O
formula	O
(	O
1	O
)	O
and	O
to	O
intermediates	O
useful	O
in	O
such	O
preparation	O
.	O

C-4''-substituted	B
macrolide	I
derivatives	O

33-Epichloro-33-desoxyascomycin	B
of	O
formula	O
(	O
I	O
)	O
and	O
various	O
tautomeric	O
or	O
solvated	O
forms	O
thereof	O
,	O
in	O
crystalline	O
form	O
,	O
such	O
as	O
Form	O
A	O
and	O
Form	O
B.	O
Their	O
preparation	O
involves	O
appropriately	O
converting	O
amorphous	O
compound	O
of	O
formula	O
(	O
I	O
)	O
,	O
or	O
compound	O
of	O
formula	O
(	O
I	O
)	O
in	O
other	O
than	O
Form	O
A	O
,	O
or	O
compound	O
of	O
formula	O
(	O
I	O
)	O
in	O
other	O
than	O
Form	O
B	O
,	O
respectively	O
,	O
from	O
a	O
solution	O
thereof	O
under	O
crystallization	O
-	O
inducing	O
conditions	O
or	O
conditions	O
inducing	O
preferential	O
crystallization	O
of	O
Form	O
A	O
or	O
B	O
,	O
respectively	O
.	O

Such	O
crystals	O
are	O
particularly	O
indicated	O
for	O
use	O
in	O
the	O
preparation	O
of	O
topical	O
galenical	O
forms	O
of	O
the	O
compound	O
for	O
pharmaceutical	O
use	O
,	O
e.g.	O
creams	O
,	O
emulsions	O
and	O
ointments	O
.	O

Crystalline	O
macrolides	B
and	O
process	O
for	O
their	O
preparation	O

The	O
invention	O
provides	O
the	O
use	O
of	O
taurolidine	B
or	O
taurultam	B
solutions	O
to	O
prevent	O
or	O
reduce	O
metastatic	O
growth	O
.	O

This	O
is	O
of	O
particular	O
application	O
in	O
preventing	O
or	O
reducing	O
the	O
incidence	O
of	O
metastatic	O
growth	O
following	O
surgery	O
,	O
particularly	O
following	O
the	O
use	O
of	O
trocars	O
during	O
minimal	O
invasive	O
laparoscopic	O
surgery	O
.	O

Use	O
of	O
taurolidine	B
or	O
taurultam	B
for	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
the	O
prevention	O
of	O
metastases	O

Invented	O
are	O
zinc	B
chelated	O
G	O
-	O
CSF	O
receptor	O
ligands	O
,	O
pharmaceutical	O
compositions	O
containing	O
these	O
compounds	O
,	O
and	O
methods	O
of	O
using	O
these	O
compounds	O
as	O
agonist	O
of	O
the	O
G	O
-	O
CSF	O
receptor	O
.	O

Also	O
invented	O
are	O
novel	O
processes	O
used	O
in	O
preparing	O
these	O
compounds	O
.	O

Also	O
invented	O
are	O
novel	O
G	O
-	O
CSF	O
receptor	O
binding	O
moieties	O
of	O
the	O
invented	O
zinc	B
chelated	O
G	O
-	O
CSF	O
receptor	O
ligands	O
.	O

metal	O
complexes	O
with	O
antibacterian	O
and	O
fungicidal	O
effects	O

Novel	O
compounds	O
involving	O
optically	O
pure	O
(	B
-	I
)	I
-1-	I
(	I
benzofuran-2-yl	I
)	I
-2-propylaminopentane	I
represented	O
by	O
formula	O
(	O
I	O
)	O
,	O
which	O
is	O
substantially	O
free	O
from	O
the	O
(	O
+	O
)	O
-isomer	O
and	O
pharmacologically	O
acceptable	O
acid	O
addition	O
salts	O
thereof	O
.	O

Because	O
of	O
being	O
excellent	O
in	O
the	O
effect	O
of	O
regulatively	O
enhancing	O
neurotransmitters	O
catecholamines	O
(	O
i.e.	O
,	O
CAE	O
(	O
Catecholaminergic	O
Activity	O
Enhancer	O
)	O
effect	O
)	O
,	O
these	O
compounds	O
are	O
useful	O
as	O
psychotropic	O
drugs	O
and	O
remedies	O
for	O
Parkinson	O
's	O
disease	O
,	O
depression	O
and	O
Alzheimer	O
's	O
disease	O
.	O

Novel	O
optically	O
active	O
aminopentane	B
derivative	O

Thyroid	O
hormone	O
analogues	O
are	O
disclosed	O
.	O

Methods	O
of	O
using	O
such	O
analogues	O
and	O
pharmaceutical	O
compositions	O
containing	O
them	O
are	O
also	O
disclosed	O
,	O
as	O
are	O
novel	O
procedures	O
for	O
their	O
preparation	O
.	O

Thyroid	O
hormone	O
analogues	O
and	O
methods	O
for	O
their	O
preparation	O

This	O
invention	O
relates	O
to	O
an	O
infusion	O
device	O
for	O
a	O
catheter	O
lock	O
solution	O
,	O
to	O
a	O
method	O
of	O
enhancing	O
the	O
patency	O
of	O
catheters	O
in	O
animals	O
and	O
to	O
a	O
catheter	O
lock	O
solution	O
.	O

The	O
device	O
includes	O
a	O
syringe	O
(	O
34	O
)	O
containing	O
a	O
lock	O
solution	O
comprising	O
a	O
citrate	B
salt	O
.	O

The	O
method	O
for	O
enhancing	O
the	O
patency	O
of	O
catheters	O
includes	O
infusing	O
a	O
lumen	O
(	O
14	O
,	O
16	O
)	O
of	O
an	O
indwelling	O
catheter	O
(	O
10	O
)	O
with	O
a	O
lock	O
solution	O
comprising	O
a	O
citrate	B
salt	O
.	O

In	O
one	O
aspect	O
of	O
the	O
invention	O
,	O
the	O
catheter	O
lock	O
solution	O
includes	O
a	O
citrate	B
salt	O
and	O
a	O
viscosifying	O
agent	O
.	O

The	O
lock	O
solution	O
is	O
prepared	O
to	O
have	O
sufficient	O
viscosity	O
and	O
density	O
to	O
remain	O
in	O
the	O
lumen	O
for	O
a	O
desired	O
amount	O
of	O
time	O
.	O

Use	O
of	O
citrate	B
in	O
a	O
catheter	O
lock	O
solution	O

Recombinant	O
nucleic	O
acid	O
molecules	O
are	O
described	O
.	O

The	O
molecules	O
have	O
a	O
first	O
sequence	O
encoding	O
a	O
Hepatitis	O
B	O
virus	O
core	O
antigen	O
and	O
a	O
second	O
sequence	O
encoding	O
at	O
least	O
one	O
T	O
cell	O
epitope	O
inserted	O
within	O
the	O
first	O
sequence	O
.	O

Vectors	O
and	O
compositions	O
containing	O
these	O
molecules	O
are	O
also	O
described	O
.	O

Methods	O
of	O
eliciting	O
an	O
immune	O
response	O
using	O
these	O
molecules	O
are	O
also	O
described	O
.	O

Nucleic	O
acid	O
constructs	O
for	O
genetic	O
immunisation	O

In	O
summary	O
of	O
this	O
disclosure	O
,	O
the	O
present	O
invention	O
provides	O
a	O
method	O
of	O
nucleic	O
acid	O
,	O
including	O
DNA	O
,	O
immunization	O
of	O
a	O
host	O
,	O
including	O
humans	O
,	O
against	O
disease	O
caused	O
by	O
infection	O
by	O
a	O
strain	O
of	O
Chlamydia	O
,	O
specifically	O
DOLLAR	O
I	O
(	O
C.	O
pneumoniae	O
)	O
,	O
employing	O
a	O
vector	O
,	O
containing	O
a	O
nucleotide	O
sequence	O
encoding	O
an	O
POMP91B	O
precursor	O
protein	O
of	O
a	O
strain	O
of	O
DOLLAR	O
I	O
(	O
Chlamydia	O
pneumoniae	O
)	O
and	O
a	O
promoter	O
to	O
effect	O
expression	O
of	O
the	O
POMP91B	O
precursor	O
gene	O
in	O
the	O
host	O
.	O

Modifications	O
are	O
possible	O
within	O
the	O
scope	O
of	O
this	O
invention	O
.	O

Chlamydia	O
antigen	O
and	O
corresponding	O
dna	O
fragments	O
and	O
uses	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
or	O
(	O
II	O
)	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
derivative	O
or	O
prodrug	O
thereof	O
;	O
wherein	O
Y	O
is	O
selected	O
from	O
-	B
(	I
CH2	I
)	I
-Q1	I
;	O
-	B
(	I
CO	I
)	I
-Q1	I
;	O
-	B
(	I
CO	I
)	I
NH	I
-	I
Q1	I
;	O
-	B
(	I
CO	I
)	I
-O	I
-	I
Q1	I
;	O
-	B
(	I
SO2	I
)	I
-Q1	I
or	O
-	B
(	I
SO2	I
)	I
NH	I
-	I
Q1	I
;	O
Q1	O
is	O
a	O
C1-C6	O
straight	O
chain	O
or	O
branched	O
alkyl	B
or	O
alkenyl	B
group	O
;	O
a	O
5	O
-	O
7	O
membered	O
aromatic	B
or	O
non	O
-	O
aromatic	B
carbocyclic	I
or	O
heterocyclic	B
ring	O
;	O
or	O
a	O
9	O
-	O
14	O
membered	O
bicyclic	B
or	O
tricyclic	B
aromatic	B
or	O
non	O
-	O
aromatic	B
carbocyclic	B
or	O
heterocyclic	B
ring	O
system	O
,	O
W	O
is	O
N	B
or	O
C	B
;	O
Z	O
is	O
CH	B
or	O
N	B
,	O
which	O
are	O
inhibitors	O
of	O
JNK	O
,	O
a	O
mammalian	O
protein	O
kinase	O
involved	O
cell	O
proliferation	O
,	O
cell	O
death	O
and	O
response	O
to	O
extracellular	O
stimuli	O
.	O

The	O
invention	O
also	O
relates	O
to	O
methods	O
for	O
producing	O
these	O
inhibitors	O
.	O

The	O
invention	O
also	O
provides	O
pharmaceutical	O
compositions	O
comprising	O
the	O
inhibitors	O
of	O
the	O
invention	O
and	O
methods	O
of	O
utilizing	O
those	O
compositions	O
in	O
the	O
treatment	O
and	O
prevention	O
of	O
various	O
disorders	O
.	O

Inhibitors	O
of	O
c	O
-	O
jun	O
n	O
-	O
terminal	O
kinases	O
(	O
jnk	O
)	O

Methods	O
of	O
screening	O
for	O
compounds	O
that	O
affect	O
melanogenesis	O
and	O
the	O
function	O
of	O
P	O
protein	O
in	O
organisms	O
,	O
cells	O
,	O
or	O
cell	O
-	O
free	O
systems	O
are	O
provided	O
.	O

The	O
invention	O
further	O
relates	O
to	O
the	O
pharmacologic	O
and	O
cosmetic	O
uses	O
of	O
such	O
compounds	O
to	O
reduce	O
or	O
increase	O
the	O
synthesis	O
of	O
melanin	O
in	O
animal	O
and	O
human	O
melanocytes	O
and	O
melanocyte	O
-	O
derived	O
cells	O
.	O

Screening	O
methods	O
for	O
compounds	O
which	O
affect	O
melanogenesis	O

Disclosed	O
are	O
compounds	O
of	O
the	O
formula	O
:	O
(	O
I	O
)	O
,	O
where	O
R?1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
R6	O
	O
,	O
and	O
X	O
are	O
defined	O
herein	O
.	O

These	O
compounds	O
are	O
selective	O
modulators	O
of	O
NPY1	O
receptors	O
.	O

These	O
compounds	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
a	O
number	O
of	O
CNS	O
disorders	O
,	O
metabolic	O
disorders	O
,	O
and	O
peripheral	O
disorders	O
,	O
particularly	O
eating	O
disorders	O
and	O
hypertension	O
.	O

Methods	O
of	O
treatment	O
of	O
such	O
disorders	O
as	O
well	O
as	O
packaged	O
pharmaceutical	O
compositions	O
are	O
also	O
provided	O
.	O

Compounds	O
of	O
the	O
invention	O
are	O
also	O
useful	O
as	O
probes	O
for	O
the	O
localization	O
of	O
NPY1	O
receptors	O
and	O
as	O
standards	O
in	O
assays	O
for	O
NPY1	O
receptor	O
binding	O
.	O

Methods	O
of	O
using	O
the	O
compounds	O
in	O
receptor	O
localization	O
studies	O
are	O
given	O
.	O

AMINO	B
SUBSTITUTED	I
PYRAZOLO1,5-a|-1,5-PYRIMIDINES	I
AND	O
PYRAZOLO1,5-a|-1,3,5-TRIAZINES	B

The	O
use	O
of	O
the	O
residues	O
from	O
wine	O
production	O
as	O
active	O
substance	O
preparations	O
in	O
the	O
production	O
of	O
cosmetic	O
and/or	O
pharmaceutical	O
preparations	O
is	O
disclosed	O
.	O

Use	O
of	O
the	O
residues	O
from	O
wine	O
production	O

The	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
preparation	O
containing	O
at	O
least	O
one	O
active	O
substance	O
that	O
is	O
cytostatically	O
active	O
,	O
at	O
least	O
one	O
biological	O
electron	O
acceptor	O
,	O
and	O
the	O
customary	O
pharmaceutical	O
additives	O
.	O

The	O
invention	O
also	O
relates	O
to	O
the	O
use	O
of	O
said	O
preparation	O
for	O
treating	O
tumor	O
diseases	O
,	O
in	O
particular	O
,	O
for	O
treating	O
cancer	O
.	O

Pharmaceutical	O
preparation	O
containing	O
cytostatic	O
agents	O
and	O
electron	O
acceptors	O
for	O
treating	O
tumor	O
diseases	O

The	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
which	O
are	O
suitable	O
for	O
the	O
production	O
of	O
medicaments	O
for	O
the	O
treatment	O
and	O
prophylaxis	O
of	O
diseases	O
,	O
in	O
which	O
an	O
increased	O
activity	O
of	O
matrix	O
-	O
degrading	O
enzymes	O
,	O
in	O
particular	O
,	O
stromelysin	O
,	O
are	O
implicated	O
.	O

Novel	O
stromelysin	O
inhibitors	O

New	O
RAR	O
selective	O
retinoid	B
agonists	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
the	O
symbols	O
are	O
as	O
defined	O
in	O
the	O
specification	O
,	O
and	O
pharmaceutically	O
active	O
salts	O
of	O
carboxylic	B
acids	I
of	O
formula	O
(	O
I	O
)	O
,	O
further	O
the	O
invention	O
relates	O
to	O
the	O
use	O
of	O
such	O
retinoic	B
acid	I
receptor	O
agonists	O
,	O
particularly	O
retinoic	B
acid	I
receptor	O
	O
(	O
RAR	O
)	O
selective	O
agonists	O
for	O
the	O
treatment	O
of	O
emphysema	O
and	O
associated	O
pulmonary	O
diseases	O
,	O
as	O
well	O
as	O
for	O
the	O
therapy	O
and	O
prophylaxis	O
of	O
dermatological	O
disorders	O
,	O
for	O
the	O
therapy	O
and	O
prophylaxis	O
of	O
malignant	O
and	O
premalignant	O
epithelial	O
lesions	O
,	O
tumours	O
and	O
precancerous	O
changes	O
of	O
the	O
mucous	O
membrane	O
in	O
the	O
mouth	O
,	O
tongue	O
,	O
larynx	O
,	O
oesophagus	O
,	O
bladder	O
,	O
cervix	O
and	O
colon	O
.	O

New	O
gamma	O
selective	O
retinoids	B

The	O
invention	O
concerns	O
a	O
method	O
for	O
preparing	O
a	O
fatty	O
substance	O
ester	B
,	O
characterised	O
in	O
that	O
it	O
consists	O
in	O
subjecting	O
to	O
an	O
esterification	O
reaction	O
at	O
least	O
a	O
fatty	O
substance	O
with	O
at	O
least	O
an	O
alcohol	B
compound	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
sterols	B
,	O
stanols	B
,	O
4-methylsterols	B
and	O
their	O
hydrogenated	O
homologues	O
,	O
triterpene	B
alcohols	I
and	O
their	O
hydrogenated	O
homologues	O
,	O
and	O
mixtures	O
thereof	O
,	O
in	O
the	O
presence	O
of	O
at	O
least	O
a	O
solid	O
catalyst	O
selected	O
in	O
the	O
group	O
consisting	O
of	O
lanthanide	B
oxides	I
and	O
the	O
mixtures	O
of	O
said	O
oxides	B
.	O

Said	O
method	O
enables	O
to	O
obtain	O
products	O
particularly	O
suited	O
for	O
use	O
in	O
the	O
field	O
of	O
pharmaceutics	O
,	O
in	O
particular	O
dermatology	O
,	O
cosmetics	O
and	O
special	O
food	O
production	O
(	O
functional	O
food	O
products	O
,	O
medicinal	O
food	O
products	O
and	O
dietetic	O
food	O
products	O
)	O
Method	O
for	O
preparing	O
a	O
fatty	O
substance	O
ester	B
and	O
use	O
thereof	O
in	O
pharmaceutics	O
,	O
cosmetics	O
or	O
food	O
industry	O

The	O
present	O
invention	O
is	O
concerned	O
with	O
2H	B
-	I
tetrazole-5-yl	I
-	I
amide	I
derivatives	O
of	O
general	O
formula	O
(	O
I	O
)	O
wherein	O
R1	O
signifies	O
hydrogen	B
,	O
lower	O
alkyl	B
,	O
-	B
(	I
CH2?	I
)	I
n	I
-	I
CF3	I
,	O
-	O
(	B
CH2	I
)	I
n	I
-	I
CHF2	I
,	O
-	B
(	I
CH2	I
)	I
n	I
-	I
CN	I
,	O
-	B
(	I
CH2	I
)	I
n	I
-	I
cycloalkyl	I
,	O
-	B
(	I
CH2	I
)	I
n	I
-	I
O	I
-	I
lower	I
alkyl	I
,	O
-	B
(	I
CH2	I
)	I
n	I
-	I
O	I
-	I
cycloalkyl	I
or	O
-	B
(	I
CH2	I
)	I
n	I
-	I
C	I
(	I
O	I
)	I
O	I
-	I
lower	I
alkyl	I
;	O
R?2	O
	O
signifies	O
hydrogen	B
,	O
lower	O
alkyl	B
,	O
lower	O
alkoxy	B
,	O
halogen	B
,	O
-C	B
(	I
O	I
)	I
-lower	I
alkyl	I
,	O
-C	B
(	I
O	I
)	I
OH	I
,	O
-C	B
(	I
O	I
)	I
O	I
-	I
lower	I
alkyl	I
,	O
-NR3R4	B
or	O
-C	B
(	I
O	I
)	I
-NR3R4	I
and	O
wherein	O
R?3	O
and	O
R4	O
	O
may	O
be	O
independently	O
from	O
each	O
other	O
hydrogen	B
or	O
lower	O
alkyl	B
;	O
X	O
signifies	O
-O-	B
,	O
-S-	B
,	O
-CH2	O
?	O
,	O
-OCH2-	B
or	O
two	O
hydrogen	B
atoms	O
not	O
forming	O
a	O
bridge	O
;	O
and	O
n	O
signifies	O
0	O
,	O
1	O
,	O
2	O
,	O
3	O
or	O
4	O
;	O
as	O
well	O
as	O
with	O
their	O
pharmaceutically	O
acceptable	O
salts	O
.	O

It	O
has	O
been	O
found	O
that	O
the	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
are	O
group	O
1	O
metabotropic	O
glutamate	B
receptor	O
agonists	O
(	O
mGluR	O
)	O
and	O
are	O
therefore	O
useful	O
in	O
the	O
treatment	O
of	O
corresponding	O
CNS	O
-	O
disorders	O
.	O

Tetrazole	B
derivatives	O

The	O
present	O
invention	O
relates	O
to	O
substantially	O
pure	O
mannin	O
-	O
binding	O
lectin	O
associated	O
serine	O
protease-2	O
(	O
MASP-2	O
)	O
polypeptides	O
and	O
fragments	O
thereof	O
as	O
well	O
as	O
nucleic	O
acids	O
encoding	O
such	O
polpeptides	O
.	O

Futhermone	O
,	O
the	O
present	O
invention	O
realates	O
to	O
uses	O
of	O
a	O
substantially	O
pure	O
polypeptide	O
comprising	O
amino	B
acid	I
sequences	O
derived	O
from	O
mannan	O
-	O
binding	O
lectin	O
associated	O
serine	O
protease-2	O
(	O
MASP2	O
)	O
or	O
a	O
functional	O
homologue	O
thereof	O
for	O
the	O
production	O
of	O
a	O
pharmaceutical	O
composition	O
as	O
well	O
as	O
pharmaceutical	O
compositons	O
comprising	O
MASP-2	O
and/or	O
MASP-2	O
fragments	O
.	O

In	O
addition	O
the	O
present	O
invetion	O
relates	O
to	O
inhibitors	O
of	O
MASP-2	O
and	O
pharmaceutical	O
compositiosn	O
compring	O
such	O
inhibitors	O
.	O

Methods	O
for	O
detecting	O
MASP-2	O
nucleic	O
acid	O
expression	O
are	O
included	O
in	O
the	O
invention	O
.	O

Masp-2	O
,	O
a	O
complement	O
-	O
fixing	O
enzyme	O
,	O
and	O
uses	O
for	O
it	O

Antisense	O
compounds	O
,	O
compositions	O
and	O
methods	O
are	O
provided	O
for	O
modulating	O
the	O
expression	O
of	O
clusterin	O
.	O

The	O
compositions	O
comprise	O
antisense	O
compounds	O
,	O
particularly	O
antisense	O
oligonucleotides	O
,	O
targeted	O
to	O
nucleic	O
acids	O
encoding	O
clusterin	O
.	O

Methods	O
of	O
using	O
these	O
compounds	O
for	O
modulation	O
of	O
clusterin	O
expression	O
and	O
for	O
treatment	O
of	O
diseases	O
associated	O
with	O
expression	O
of	O
clusterin	O
are	O
provided	O
.	O

Antisense	O
modulation	O
of	O
clusterin	O
expression	O

The	O
present	O
invention	O
relates	O
to	O
11,12	B
gamma	I
lactone	I
ketolides	I
of	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
R	O
,	O
R<1	O
>	O
,	O
R<2	O
>	O
and	O
R<3	O
>	O
are	O
as	O
defined	O
herein	O
and	O
pharmaceutically	O
acceptable	O
salts	O
and	O
solvates	O
thereof	O
,	O
to	O
process	O
for	O
their	O
preparation	O
and	O
their	O
use	O
in	O
therapy	O
or	O
prophylaxis	O
of	O
systemic	O
or	O
topical	O
bacterial	O
infections	O
in	O
a	O
human	O
or	O
animal	O
body	O
.	O

Macrolide	O
antibiotics	O

The	O
invention	O
concerns	O
the	O
use	O
of	O
a	O
combination	O
comprising	O
at	O
least	O
an	O
absorbent	O
and	O
at	O
least	O
a	O
compound	O
selected	O
among	O
the	O
group	O
consisting	O
of	O
non	O
-	O
metabolizable	O
sugars	B
and	O
polyols	O
for	O
preparing	O
a	O
composition	O
,	O
in	O
particular	O
medicinal	O
,	O
for	O
promoting	O
cell	O
regeneration	O
and/or	O
cell	O
differentiation	O
.	O

Promoting	O
cell	O
regeneration	O
and/or	O
cell	O
differentiation	O
with	O
non	O
-	O
metabolizable	O
sugar	O
and	O
a	O
polymeric	O
absorbent	O

The	O
present	O
invention	O
discloses	O
the	O
use	O
of	O
ERSS	O
-	O
selective	O
ligands	O
for	O
production	O
of	O
medicaments	O
for	O
regulating	O
fertility	O
without	O
additional	O
use	O
of	O
a	O
progestin	O
.	O

ERSS	O
-	O
agonists	O
are	O
used	O
for	O
treatment	O
of	O
infertility	O
and	O
ERSS	O
-	O
antagonists	O
for	O
contraception	O
.	O

Use	O
of	O
er	O
-	O
beta	O
selective	O
antagonists	O
as	O
contraceptives	O

The	O
invention	O
discloses	O
certain	O
steroidal	B
sapogenins	I
and	O
derivatives	O
thereof	O
,	O
and	O
their	O
use	O
in	O
the	O
treatment	O
of	O
cognitive	O
dysfunction	O
,	O
non	O
-	O
cognitive	O
neurodegeneration	O
,	O
non	O
-	O
cognitive	O
neuromuscular	O
degeneration	O
,	O
and	O
receptor	O
loss	O
in	O
the	O
absence	O
of	O
cognitive	O
,	O
neural	O
and	O
neuromuscular	O
impairment	O
.	O

Methods	O
of	O
synthesis	O
,	O
treatment	O
and	O
pharmaceutical	O
compositions	O
are	O
also	O
disclosed	O
.	O

Sapogenin	B
derivatives	O
,	O
their	O
synthesis	O
and	O
use	O

The	O
present	O
invention	O
is	O
directed	O
to	O
drug	O
dosage	O
forms	O
that	O
release	O
an	O
agent	O
that	O
raises	O
the	O
pH	O
of	O
a	O
patient	O
's	O
gastrointestinal	O
tract	O
,	O
followed	O
by	O
a	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drug	O
.	O

The	O
dosage	O
form	O
is	O
designed	O
so	O
that	O
the	O
NSAID	O
is	O
not	O
released	O
until	O
the	O
intragastric	O
pH	O
has	O
been	O
raised	O
to	O
a	O
safe	O
level	O
.	O

The	O
invention	O
also	O
encompasses	O
methods	O
of	O
trating	O
patients	O
by	O
administering	O
this	O
coordinated	O
release	O
,	O
gastroprotective	O
,	O
antiarthitic	O
/	O
analgesic	O
combination	O
unit	O
dosage	O
form	O
to	O
achieve	O
pain	O
and	O
symptom	O
relief	O
with	O
a	O
reduced	O
risk	O
of	O
developing	O
gastrointestinal	O
damage	O
such	O
as	O
ulcers	O
,	O
erosions	O
and	O
hemorrhages	O
.	O

PHARMACEUTICAL	O
COMPOSITIONS	O
FOR	O
THE	O
COORDINATED	O
DELIVERY	O
OF	O
NSAIDs	O

Oral	O
semi	O
-	O
solid	O
or	O
liquid	O
composition	O
for	O
treating	O
hyperlipidemia	O
or	O
hypercholesterolemia	O
in	O
humans	O
,	O
which	O
comprises	O
at	O
least	O
an	O
effective	O
amount	O
of	O
peroxisome	O
proliferator	O
activated	O
receptor	O
alpha	O
agent	O
(	O
PPARa	O
)	O
,	O
one	O
polyglycolized	O
glyceride	O
and	O
one	O
hydrophilic	O
disintegrating	O
agent	O
.	O

Improved	O
pharmaceutical	O
composition	O
containing	O
a	O
ppar	O
alpha	O
agent	O
and	O
a	O
process	O
for	O
preparing	O
it	O

The	O
invention	O
provides	O
a	O
controlled	O
-	O
release	O
pharmaceutical	O
formulation	O
for	O
oral	O
administration	O
comprising	O
4-amino-6,7-dimethoxy-2-	B
(	I
5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl	I
)	I
-5-	I
(	I
2-pyridyl	I
)	I
quinazoline	I
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
;	O
and	O
a	O
pharmaceutically	O
acceptable	O
adjuvant	O
,	O
diluent	O
or	O
carrier	O
;	O
characterized	O
in	O
that	O
the	O
formulation	O
is	O
adapted	O
to	O
release	O
at	O
least	O
50	O
%	O
by	O
weight	O
of	O
the	O
4-amino-6,7-dimethoxy-2-	B
(	I
5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl	I
)	I
-5-	I
(	I
2-pyridyl	I
)	I
-quinazoline	I
,	O
or	O
the	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
after	O
6	O
hours	O
in	O
Apparatus	O
1	O
described	O
in	O
the	O
United	O
States	O
Pharmacopoeia	O
24	O
(	O
2000	O
)	O
,	O
pp	O
1941	O
-	O
1943	O
,	O
having	O
1	O
litre	O
vessels	O
,	O
baskets	O
of	O
40	O
mesh	O
(	O
0.4	O
mm	O
apertures	O
)	O
,	O
a	O
rotation	O
speed	O
of	O
100	O
rpm	O
,	O
and	O
a	O
dissolution	O
medium	O
consisting	O
of	O
900	O
ml	O
of	O
0.01	O
M	O
hydrochloric	B
acid	I
containing	O
0.7	O
%	O
w	O
/	O
v	O
sodium	B
chloride	I
at	O
37	O
DEG	O
C.	O
Formulations	O
according	O
to	O
the	O
invention	O
are	O
suitable	O
for	O
the	O
treatment	O
of	O
BPH	O
.	O

Pharmaceutical	O
formulations	O
for	O
the	O
controlled	O
release	O
of	O
4-amino-6,7-dimethoxy-2-	B
(	I
5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl	I
)	I
-5-	I
(	I
2-pyridyl	I
)	I
quinazoline	I

Oxadiazole	B
derivatives	O
of	O
general	O
formula	O
(	O
1	O
)	O
in	O
which	O
X	O
,	O
Y	O
,	O
R	O
and	O
R2	O
have	O
the	O
meanings	O
defined	O
in	O
the	O
disclosure	O
.	O

The	O
compounds	O
have	O
antiproliferative	O
activity	O
against	O
a	O
number	O
of	O
human	O
tumors	O
cell	O
lines	O
and	O
can	O
therefore	O
be	O
used	O
for	O
the	O
preparation	O
of	O
antitumor	O
medicaments	O
.	O

Oxadiazoles	B
having	O
antiproliferative	O
activity	O

The	O
invention	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
active	O
glimepiride	B
and	O
metformin	B
substances	O
or	O
the	O
salts	O
thereof	O
,	O
such	O
as	O
hydrochloride	B
,	O
succinate	B
,	O
fumarate	B
,	O
etc	O
.	O
,	O
which	O
are	O
used	O
to	O
control	O
blood	O
glucose	B
in	O
patients	O
with	O
type	O
2	O
diabetes	O
.	O

Clinical	O
studies	O
,	O
which	O
were	O
carried	O
out	O
in	O
order	O
to	O
demonstrate	O
the	O
effectiveness	O
of	O
said	O
combination	O
,	O
have	O
shown	O
that	O
the	O
effect	O
produced	O
by	O
the	O
two	O
drugs	O
is	O
not	O
only	O
additive	O
but	O
also	O
synergetic	O
in	O
comparison	O
with	O
the	O
monotherapy	O
which	O
uses	O
only	O
one	O
of	O
the	O
drugs	O
from	O
the	O
combination	O
.	O

As	O
a	O
result	O
,	O
the	O
use	O
of	O
said	O
combination	O
is	O
suggested	O
as	O
an	O
effective	O
and	O
safe	O
therapy	O
for	O
the	O
control	O
of	O
blood	O
glucose	B
in	O
patients	O
with	O
type	O
2	O
diabetes	O
.	O

According	O
to	O
the	O
invention	O
,	O
different	O
proportions	O
of	O
the	O
active	O
substances	O
can	O
be	O
used	O
so	O
that	O
the	O
combination	O
suits	O
the	O
different	O
requirements	O
of	O
each	O
patient	O
.	O

Pharmaceutical	O
composition	O
that	O
is	O
used	O
to	O
control	O
blood	O
glucose	B
in	O
patients	O
with	O
type	O
2	O
diabetes	O

This	O
invention	O
relates	O
to	O
the	O
parenteral	O
administration	O
of	O
solid	O
drug	O
compositions	O
.	O

In	O
particular	O
,	O
this	O
invention	O
relates	O
to	O
a	O
syringe	O
-	O
like	O
device	O
for	O
delivering	O
solid	O
drug	O
cylinders	O
including	O
a	O
syringe	O
barrel	O
,	O
a	O
needle	O
,	O
and	O
a	O
microplunger	O
and	O
piston	O
assembly	O
,	O
wherein	O
said	O
microplunger	O
pushes	O
said	O
solid	O
drug	O
cylinder	O
out	O
of	O
said	O
needle	O
and	O
into	O
a	O
patient	O
and	O
said	O
piston	O
pushes	O
on	O
said	O
microplunger	O
.	O

Delivery	O
of	O
solid	O
drug	O
compositions	O

Cascade	O
esters	O
of	O
camptothecin	B
are	O
described	O
.	O

Processes	O
for	O
making	O
these	O
compounds	O
and	O
for	O
using	O
them	O
in	O
cancer	O
treatment	O
are	O
also	O
described	O
.	O

Cascade	O
esters	B
of	O
camptothecins	B
and	O
methods	O
of	O
treating	O
cancer	O
using	O
these	O
compounds	O

The	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
formulation	O
for	O
inwardly	O
transferring	O
nucleic	O
acids	O
into	O
eucaryotic	O
cells	O
,	O
characterized	O
in	O
that	O
the	O
formulation	O
has	O
a	O
pH	O
value	O
of	O
6.0	O
-	O
pH	O
7,4	O
,	O
and/or	O
an	O
anion	O
concentration	O
of	O
5	O
-	O
100	O
mmol	O
/	O
l	O
and/or	O
a	O
concentration	O
of	O
10	O
-	O
500	O
mol	O
/	O
l	O
of	O
nonsteroidal	O
antiphlogistics	O
.	O

Formulation	O
for	O
inwardly	O
transferring	O
nucleic	O
acids	O
into	O
eucaryotic	O
cells	O

A	O
peptide	O
that	O
inhibits	O
mucus	O
secretion	O
in	O
subjects	O
is	O
described	O
,	O
for	O
use	O
in	O
inhibiting	O
mucus	O
secretion	O
by	O
a	O
mucus	O
secreting	O
cell	O
.	O

A	O
pharmaceutical	O
composition	O
comprising	O
a	O
myristoylated	O
polypeptide	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
is	O
also	O
described	O
.	O

Compositions	O
for	O
altering	O
mucus	O
secretion	O

This	O
invention	O
relates	O
to	O
the	O
pyrazole	B
derivatives	O
of	O
formula	O
(	O
I	O
)	O
and	O
pharmaceutically	O
acceptable	O
salt	O
,	O
solvate	O
or	O
derivatives	O
thereof	O
,	O
to	O
their	O
use	O
in	O
medicine	O
,	O
to	O
compositions	O
containing	O
them	O
,	O
to	O
processes	O
for	O
their	O
preparation	O
and	O
to	O
intermediates	O
used	O
in	O
such	O
processes	O
.	O

The	O
compounds	O
of	O
the	O
invention	O
bind	O
to	O
the	O
enzyme	O
reverse	O
transcriptase	O
and	O
are	O
modulators	O
,	O
especially	O
inhibitors	O
,	O
thereof	O
.	O

Reverse	O
transcriptase	O
is	O
implicated	O
in	O
the	O
infectious	O
lifecycle	O
of	O
Human	O
Immunodeficiency	O
Virus	O
(	O
HIV	O
)	O
.	O

Compounds	O
which	O
interfere	O
with	O
the	O
function	O
of	O
this	O
enzyme	O
have	O
shown	O
utility	O
in	O
the	O
treatment	O
of	O
conditions	O
caused	O
by	O
HIV	O
and	O
genetically	O
related	O
retroviruses	O
,	O
such	O
as	O
Acquired	O
Immune	O
Deficiency	O
Syndrome	O
(	O
AIDS	O
)	O
.	O

4-	B
(	I
3,5-dicyanophenoxy	I
)	I
pyrazole	I
derivatives	O
for	O
use	O
as	O
transcriptase	O
modulators	O
in	O
the	O
treatment	O
of	O
i.a	O
.	O

hiv	O

The	O
compounds	O
of	O
the	O
instant	O
invention	O
are	O
bicyclic	B
or	I
tricyclic	I
amino	I
acids	I
useful	O
in	O
the	O
treatment	O
of	O
fibromylagia	O
.	O

Pharmaceutical	O
compositions	O
containing	O
one	O
or	O
more	O
of	O
the	O
compounds	O
for	O
use	O
in	O
the	O
treatment	O
of	O
fibromyalgia	O
are	O
also	O
included	O
.	O

Therapeutic	O
use	O
of	O
fused	B
bicyclic	I
or	I
tricyclic	I
amino	I
acids	I

The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
compounds	O
and	O
composition	O
of	O
compounds	O
that	O
modulate	O
norepinephrine	B
levels	O
for	O
the	O
treatment	O
of	O
vasomotor	O
symptoms	O
such	O
as	O
thermoregulatory	O
disorders	O
.	O

Furthermore	O
,	O
the	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
compounds	O
and	O
compositions	O
of	O
compounds	O
having	O
norepinephrine	B
reuptake	O
inhibitor	O
(	O
NRI	O
)	O
activity	O
alone	O
or	O
norepinephrine	B
reuptake	O
inhibitor	O
and	O
serotonin	B
reuptake	O
inhibitor	O
(	O
NRI	O
/	O
SRI	O
)	O
dual	O
activity	O
in	O
combination	O
with	O
5-HT2a	O
receptor	O
antagonist	O
activity	O
.	O

A	O
method	O
of	O
treating	O
vasomotor	O
symptoms	O
comprising	O
a	O
compound	O
having	O
norepinephrine	B
reuptake	O
inhibitor	O
activity	O
and	O
5-ht2a	O
antagonistic	O
activity	O

The	O
invention	O
concerns	O
methods	O
for	O
modulating	O
the	O
	O
-	O
adrenergic	O
pathway	O
.	O

In	O
particular	O
,	O
the	O
invention	O
concerns	O
methods	O
for	O
counteracting	O
a	O
pathologic	O
change	O
,	O
such	O
as	O
,	O
for	O
example	O
,	O
a	O
loss	O
in	O
	O
-	O
adrenergic	O
sensitivity	O
,	O
in	O
the	O
	O
-	O
adrenergic	O
signal	O
transduction	O
pathway	O
by	O
administering	O
an	O
effective	O
amount	O
of	O
a	O
compound	O
capable	O
of	O
inhibiting	O
TGF	O
-	O
	O
signaling	O
through	O
a	O
TGF	O
-	O
	O
receptor	O
.	O

Method	O
for	O
counteracting	O
a	O
pathologic	O
change	O
in	O
the	O
beta	O
-	O
adrenergic	O
pathway	O

A	O
food	O
supplement	O
of	O
therapeutic	O
composition	O
is	O
provided	O
suitable	O
for	O
the	O
treatment	O
or	O
prophylaxis	O
of	O
COPD	O
and	O
other	O
acute	O
or	O
chronic	O
diseases	O
in	O
a	O
mammal	O
,	O
especially	O
a	O
human	O
being	O
,	O
comprising	O
at	O
least	O
one	O
of	O
glutamate	B
,	O
other	O
than	O
mono	B
sodium	I
glutamate	I
,	O
and	O
a	O
precursor	O
of	O
glutamate	B
selected	O
from	O
the	O
group	O
consisting	O
of	O
leucine	B
,	O
valine	B
,	O
isoleucine	B
,	O
and	O
a	O
keto	B
acid	I
thereof	O
,	O
in	O
a	O
daily	O
dose	O
for	O
said	O
mammal	O
of	O
at	O
least	O
6	O
grams	O
,	O
preferably	O
between	O
9	O
and	O
20	O
grams	O
,	O
of	O
the	O
total	O
of	O
said	O
glutamate	B
and	O
precursor	O
forms	O
thereof	O
.	O

Compositions	O
and	O
methods	O
for	O
improving	O
the	O
condition	O
of	O
patients	O
suffering	O
from	O
copd	O
and	O
other	O
diseases	O

An	O
antibody	O
that	O
specifically	O
reacts	O
with	O
a	O
protein	O
comprising	O
an	O
amino	B
acid	I
sequence	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
:	O
(	O
a	O
)	O
the	O
amino	B
acid	I
sequence	O
of	O
SEQ	O
ID	O
NO:2	O
;	O
(	O
b	O
)	O
the	O
amino	B
acid	I
sequence	O
of	O
SEQ	O
ID	O
NO:2	O
from	O
amino	B
acids	I
11	O
to	O
163	O
;	O
(	O
c	O
)	O
the	O
amino	B
acid	I
sequence	O
of	O
SEQ	O
ID	O
NO:2	O
from	O
amino	B
acids	I
29	O
to	O
163	O
;	O
(	O
d	O
)	O
the	O
amino	B
acid	I
sequence	O
of	O
SEQ	O
ID	O
NO:2	O
from	O
amino	B
acids	I
31	O
to	O
163	O
;	O
and	O
(	O
e	O
)	O
a	O
fragment	O
of	O
the	O
amino	B
acid	I
sequence	O
of	O
SEQ	O
ID	O
NO:2	O
having	O
a	O
CTLA-8	O
activity	O
chosen	O
from	O
one	O
or	O
more	O
of	O
induction	O
of	O
expression	O
or	O
secretion	O
of	O
	O
-	O
IFN	O
,	O
IL-6	O
,	O
or	O
IL-8	O
,	O
or	O
inhibition	O
of	O
angiogenesis	O
.	O

Human	O
CLTA-8	O
and	O
uses	O
of	O
CTLA-8-related	O
proteins	O

The	O
invention	O
relates	O
to	O
methods	O
of	O
inhibiting	O
HCV	O
viral	O
replication	O
activityy	O
comprising	O
contacting	O
an	O
HCV	O
polymerase	O
with	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
hydroxamate	B
MMP	O
inhibitor	O
,	O
and	O
composition	O
comprising	O
the	O
same	O
.	O

Inhibitors	O
of	O
hepatitis	O
c	O
virus	O
,	O
compositions	O
and	O
treatments	O
using	O
the	O
same	O

Tricyclic	B
thiophene	I
,	O
furan	B
or	O
pyrrole	B
derivatives	O
(	O
I	O
)	O
are	O
new	O
.	O

Tricyclic	B
thiophene	I
,	O
furan	B
or	O
pyrrole	B
derivatives	O
(	O
I	O
)	O
of	O
formula	O
(	O
Ia	O
)	O
-	O
(	O
Id	O
)	O
and	O
their	O
salts	O
,	O
solvates	O
,	O
metabolites	O
,	O
tautomers	O
and	O
prodrugs	O
are	O
new	O
,	O
other	O
than	O
2-dimethylamino-4,7-diethoxy-8-cyano-9-p	B
henyl	I
-	I
pyrido	I
[	I
3',2':4,5	I
]	I
thieno	I
[	I
3,2-d	I
]	I
pyrimidine	I
,	O
1,4-dihydro-2,2-dimethyl-5-morpholino-10-propylthio-2H	B
-	I
pyrano	I
[	I
4",3":4	I
'	I
,	I
5'	I
]	I
pyrido	I
[	I
3',2':4',5'	I
]	I
thieno	I
[	I
3,2-d	I
]	I
pyrimidin-8	I
(	I
9H	I
)	I
-one	I
,	O
1	B
-	I
-butylthio-1,4-dihydro-2,2-dimethyl-5-morpholino-2H	I
-	I
pyrano	I
[	I
4",3":4	I
'	I
,	I
5'	I
]	I
pyrido	I
[	I
3',2':4',5'	I
]	I
thieno	I
[	I
3,2-d	I
]	I
pyrimidin-8	I
(	I
9H	I
)	I
-one	I
and	O
2-methyl-5-	B
(	I
2thienyl	I
)	I
-1,2,3,4-tetrahydro-11H-7-thia-2,6,9,11-tetraaza	I
-benzo	I
[	I
c	I
]	I
fluorene-8,10-dione	I
.	O

Y	O
'	O
:	O
S	B
,	O
O	B
or	O
N	B
;	O
R1	O
>	O
H	B
;	O
1	B
-	I
10C	I
(	I
cyclo	I
)	I
alkyl	I
,	O
2	B
-	I
12C	I
(	I
cyclo	I
)	I
alkenyl	I
or	O
2	B
-	I
12C	I
(	I
cyclo	I
)	I
alkynyl	I
,	O
(	B
6	I
-	I
12C	I
)	I
aryl	I
(	I
1	I
-	I
5C	I
)	I
alkyl	I
,	O
5-	O
to	O
14-membered	O
mono-	B
or	I
bicyclic	I
heterocyclyl	I
with	O
1	O
-	O
4	O
heteroatoms	O
,	O
1	B
-	I
10C	I
(	I
cyclo	I
)	I
alkoxy	I
,	O
(	B
6	I
-	I
12C	I
)	I
aryl	I
(	I
1	I
-	I
5C	I
)	I
alkoxy	I
,	O
2	B
-	I
12C	I
alkanoyl	I
,	O
benzoyl	B
or	O
1-	B
or	I
2-naphthoyl	I
,	O
alkylthio	B
,	O
alkylsulfinyl	B
,	O
alkoxysulfonyl	B
or	O
alkylsulfonyl	B
,	O
alkoxycarbonyl	B
,	O
alkylcarbamoyl	B
or	O
dialkylcarbamoyl	B
,	O
(	B
hetero	I
)	I
arylthio	I
,	O
(	B
hetero	I
)	I
arylsulfinyl	I
or	O
(	B
hetero	I
)	I
arylsulfonyl	I
,	O
aryloxycarbonyl	B
,	O
arylcarbamoyl	B
,	O
arylamido	B
,	O
N	B
-	I
aryl	I
-	I
N	I
-	I
alkylamido	I
,	O
N	B
-	I
aryl	I
-	I
N	I
-	I
alkylcarbamoyl	I
,	O
aralkoxycarbonyl	B
or	O
aralkylcarbamoyl	B
with	O
1	B
-	I
5C	I
alkyl	I
or	O
6	B
-	I
10C	I
aryl	I
,	O
heterocyclylcarbonyl	B
,	O
heterocyclylcarbamoyl	B
,	O
heterocyclylamido	B
,	O
N	B
-	I
heterocyclyl	I
-	I
N	I
-	I
alkylamino	I
,	O
heterocyclylalkoxycarbonyl	B
or	O
heterocyclylalkylcarbamoyl	B
,	O
arylhydrazino	B
or	O
phenyl	B
(	O
all	O
optionally	O
substituted	O
)	O
;	O
1-	B
or	I
2-naphthyl	I
;	O
OH	B
,	O
SH	B
,	O
CHO	B
,	O
COOH	B
,	O
CONH2	B
,	O
CN	B
,	O
SCN	B
,	O
NO2	B
,	O
SO3H	B
;	O
with	O
heterocyclyl	B
as	O
above	O
and	O
1	B
-	I
5C	I
alkyl	I
;	O
halo	B
;	O
NH2	B
,	O
1	B
-	I
6C	I
alkylamino	I
or	O
di	B
(	I
1	I
-	I
5C	I
alkyl	I
)	I
amino	I
,	O
optionally	O
substituted	O
;	O
heterocyclylamino	B
;	O
or	O
La	O
-	O
A	O
-	O
Lb	O
-	O
B	O
;	O
La	O
:	O
a	O
bond	O
,	O
NR	B
'	I
,	O
O	B
,	O
S	B
,	O
SO	B
,	O
SO2	B
;	O
A	O
:	O
phenyl	B
or	O
naphthyl	B
(	O
both	O
optionally	O
substituted	O
)	O
or	O
heterocyclyl	B
;	O
or	O
a	O
tricyclic	B
group	O
;	O
Lb	O
:	O
a	O
bond	O
,	O
NR	B
'	I
,	O
O	B
,	O
S	B
,	O
SO	B
,	O
SO2	B
,	O
CHR	B
,	O
CH2O	B
,	O
OCH2	B
,	O
NR'CO	B
,	O
NR'CS	B
,	O
NR'CONR	B
'	I
,	O
NR'CSNR	B
'	I
,	O
NR'C	B
(	I
NH	I
)	I
,	O
NR'SO	B
,	O
NR'SO2	B
,	O
N	B
(	I
R'	I
)	I
=S	I
(	I
O	I
)	I
(	I
R	I
'	I
)	I
,	O
NR'C	B
(	I
NHOH	I
)	I
,	O
NHNR	B
'	I
,	O
N	B
(	I
NHR'	I
)	I
CO	I
,	O
NHN=	B
,	O
N	B
(	I
OH	I
)	I
CS	I
,	O
NR'COO	B
,	O
NR'C	B
(	I
S	I
)	I
O	I
,	O
N	B
(	I
OH	I
)	I
CO	I
;	O
B	O
:	O
H	B
;	O
alkyl	B
(	O
optionally	O
substituted	O
)	O
;	O
CONH2	B
;	O
CONHQ	B
;	O
COOH	B
;	O
COOAlk	B
;	O
COQ	B
;	O
CH2CONH2	B
;	O
CH2CONHQ	B
;	O
CH2COOH	B
;	O
CH2COOAlk	B
;	O
CH2COQ	B
;	O
phenyl	B
or	O
naphthyl	B
or	O
4-	O
to	O
14-membered	O
mono-	B
or	I
bicyclic	I
heterocyclyl	I
with	O
1	O
-	O
5	O
heteroatoms	O
(	O
optionally	O
substituted	O
with	O
oxo	B
)	O
(	O
all	O
optionally	O
substituted	O
)	O
;	O
Alk	B
:	O
alkyl	B
(	O
optionally	O
substituted	O
)	O
;	O
Q	O
:	O
alkyl	B
,	O
aryl	B
or	O
heteroaryl	B
(	O
optionally	O
substituted	O
)	O
;	O
R	O
'	O
:	O
H	B
or	O
Alk	B
;	O
R2	O
>	O
H	B
,	O
1	B
-	I
12C	I
alkyl	I
,	O
2	B
-	I
12C	I
alkenyl	I
or	I
alkynyl	I
;	O
phenyl	B
(	I
1	I
-	I
6C	I
)	I
alkyl	I
(	O
optionally	O
substituted	O
)	O
;	O
phenacyl	B
(	O
optionally	O
substituted	O
)	O
;	O
COOH	B
,	O
1	B
-	I
4C	I
alkoxycarbonyl	I
,	O
CONH2	B
or	O
mono-	B
or	I
di	I
(	I
1	I
-	I
6C	I
alkyl	I
)	I
carbamoyl	I
;	O
COR	B
'	I
;	O
CN	B
,	O
NO2	B
,	O
NH2	B
,	O
mono-	B
or	I
di	I
(	I
1	I
-	I
6C	I
alkyl	I
)	I
amino	I
,	O
N	B
=	I
N	I
-	I
Ph	I
,	O
N	B
=	I
N	I
-	I
C6H4-R	I
,	O
1,3-diphenyl-4-pyrazolyl	B
,	O
2-thiazolinyl	B
,	O
2-imidazolinyl	B
or	O
3,4,5,6-tetrahydropyrimidinyl	B
;	O
R3	O
>	O
H	B
;	O
OH	B
,	O
SH	B
,	O
CHO	B
,	O
COOH	B
,	O
CONH2	B
,	O
CN	B
,	O
SCN	B
,	O
NO2	B
,	O
halo	B
;	O
NH2	B
,	O
or	O
SO3H	B
or	O
1	B
-	I
10C	I
(	I
cyclo	I
)	I
alkyl	I
,	O
2	B
-	I
12C	I
(	I
cyclo	I
)	I
alkenyl	I
,	O
2	B
-	I
12C	I
(	I
cyclo	I
)	I
alkynyl	I
,	O
(	B
6	I
-	I
12C	I
)	I
aryl	I
(	I
1	I
-	I
5C	I
)	I
alkyl	I
,	O
phenyl	B
,	O
1-	B
or	I
2-naphthyl	I
,	O
pyridyl	B
N	I
-	I
oxide	I
,	O
1	B
-	I
10C	I
(	I
cyclo	I
)	I
alkoxy	I
,	O
(	B
6	I
-	I
12C	I
)	I
aryl	I
(	I
1	I
-	I
5C	I
)	I
alkoxy	I
,	O
2	B
-	I
12C	I
alkanoyl	I
,	O
benzoyl	B
or	O
1-	B
or	I
2-naphthoyl	I
,	O
alkylthio	B
,	O
alkylsulfinyl	B
,	O
alkoxysulfonyl	B
or	O
alkylsulfonyl	B
,	O
(	B
hetero	I
)	I
arylthio	I
,	O
(	B
hetero	I
)	I
arylsulfinyl	I
or	O
(	B
hetero	I
)	I
arylsulfonyl	I
,	O
alkoxycarbonyl	B
,	O
alkylcarbamoyl	B
or	O
dialkylcarbamoyl	B
,	O
aryloxycarbonyl	B
,	O
arylcarbamoyl	B
,	O
arylamido	B
,	O
N	B
-	I
aryl	I
-	I
N	I
-	I
alkylamido	I
,	O
N	B
-	I
aryl	I
-	I
N	I
-	I
alkylcarbamoyl	I
,	O
aralkoxycarbonyl	B
or	O
aralkylcarbamoyl	B
with	O
1	B
-	I
5C	I
alkyl	I
or	O
6	B
-	I
10C	I
aryl	I
,	O
1	B
-	I
6C	I
alkylamino	I
or	O
di	B
(	I
1	I
-	I
5C	I
alkyl	I
)	I
amino	I
,	O
6	B
-	I
10C	I
arylamino	I
or	O
arylhydrazino	B
(	O
all	O
optionally	O
substituted	O
)	O
;	O
R4>2	O
-	B
14C	I
alkyl	I
,	O
3	B
-	I
14C	I
cycloalkyl	I
,	O
2	B
-	I
14C	I
alkenyl	I
,	O
3	B
-	I
14C	I
cycloalkenyl	I
,	O
2	B
-	I
14C	I
alkynyl	I
,	O
phenyl	B
or	O
1-	B
or	I
2-naphthyl	I
,	O
4-	O
to	O
14-membered	O
mono-	B
or	I
bicyclic	I
heterocyclyl	I
with	O
1	O
-	O
5	O
heteroatoms	O
(	O
all	O
optionally	O
substituted	O
)	O
;	O
SQ1	B
>	O
,	O
SOQ1	B
>	O
,	O
SO2Q1	B
>	O
;	O
OR6	B
>	O
or	O
NR7	B
>	O
R8	O
>	O
;	O
Q1>1	O
-	B
8C	I
alkyl	I
,	O
2	B
-	I
8C	I
alkenyl	I
or	O
2	B
-	I
8C	I
alkynyl	I
,	O
(	O
optionally	O
substituted	O
)	O
;	O
R6>1	O
-	B
4C	I
n	I
-	I
alkyl	I
,	O
t	B
-	I
Bu	I
,	O
CH2CH2OH	B
,	O
CH2CH2SH	B
,	O
CH2CH2SMe	B
,	O
CH2CF3	B
,	O
CH2CCl3	B
,	O
CH2CHF2	B
,	O
CH2CHCl2	B
,	O
CH2CH2F	B
,	O
CH2CH2Cl	B
,	O
CH2CH2Br	B
;	O
3	B
-	I
7C	I
cycloalkyl	I
,	O
2	B
-	I
5C	I
alkenyl	I
or	I
alkynyl	I
;	O
3	B
-	I
7C	I
cycloalkenyl	I
;	O
aryl	B
or	O
heteroaryl	B
;	O
1-	B
or	I
2-naphthyl	I
(	O
all	O
optionally	O
substituted	O
)	O
;	O
pyridyl	B
,	O
isoquinolinyl	B
Fused	O
pyrido	B
[	I
3',2':4,5	I
]	I
thieno	I
[	I
3,2-d	I
]	I
pyrimidines	I
and	O
pyrido	B
[	I
3',2':4,5	I
]	I
furo	I
[	I
3,2-d	I
]	I
pyrimidines	I

Pharmaceutical	O
compositions	O
(	O
A	O
)	O
for	O
local	O
application	O
to	O
stop	O
bleeding	O
,	O
close	O
wounds	O
and/or	O
stimulate	O
wound	O
healing	O
,	O
contain	O
fibrinogen	O
(	O
I	O
)	O
or	O
fibrin	O
(	O
Ia	O
)	O
,	O
thrombin	O
(	O
II	O
)	O
and	O
one	O
or	O
more	O
transglutaminases	O
(	O
III	O
)	O
,	O
also	O
at	O
least	O
one	O
serpin	O
-	O
type	O
protease	O
inhibitor	O
(	O
IV	O
)	O
that	O
has	O
no	O
inhibitory	O
action	O
on	O
collagenases	O
or	O
elastases	O
,	O
are	O
new	O
.	O

All	O
active	O
ingredients	O
are	O
of	O
allogenic	O
origin	O
(	O
isolated	O
from	O
plasma	O
or	O
tissue	O
,	O
or	O
recombinant	O
)	O
and	O
have	O
been	O
subjected	O
to	O
a	O
virus	O
removal	O
and/or	O
inactivation	O
step	O
,	O
provided	O
that	O
virus	O
inactivation	O
of	O
(	O
IV	O
)	O
is	O
not	O
done	O
in	O
presence	O
of	O
other	O
active	O
ingredients	O
.	O

Independent	O
claims	O
are	O
also	O
included	O
for	O
the	O
following	O
:	O
(	O
a	O
)	O
preparation	O
of	O
a	O
(	O
I	O
)	O
-containing	O
solution	O
,	O
as	O
such	O
or	O
as	O
part	O
of	O
(	O
A	O
)	O
,	O
that	O
can	O
be	O
stored	O
at	O
refrigerator	O
or	O
room	O
temperature	O
;	O
(	O
b	O
)	O
pharmaceutical	O
compositions	O
(	O
B	O
)	O
containing	O
a	O
highly	O
purified	O
(	O
I	O
)	O
-	O
or	O
(	O
I	O
)	O
plus	O
fibronectin	O
-	O
containing	O
composition	O
that	O
has	O
activated	O
prothrombin	O
time	O
and	O
Taipan	O
viper	O
venom	O
prothrombin	O
time	O
at	O
37	O
[	O
deg	O
]	O
C	O
of	O
at	O
least	O
200	O
and	O
300	O
sec	O
,	O
respectively	O
;	O
(	O
c	O
)	O
a	O
method	O
for	O
preparing	O
pathogen	O
-	O
free	O
(	O
A	O
)	O
;	O
(	O
d	O
)	O
a	O
method	O
for	O
covalent	O
binding	O
of	O
(	O
A	O
)	O
to	O
a	O
biological	O
matrix	O
;	O
(	O
e	O
)	O
a	O
method	O
for	O
preparing	O
a	O
(	O
Ia	O
)	O
-containing	O
gel	O
of	O
20	O
-	O
90	O
%	O
water	O
content	O
;	O
(	O
f	O
)	O
a	O
method	O
for	O
solidifying	O
a	O
(	O
Ia	O
)	O
-containing	O
gel	O
with	O
or	O
without	O
removal	O
of	O
water	O
;	O
(	O
g	O
)	O
a	O
freeze	O
-	O
dried	O
(	O
Ia	O
)	O
-containing	O
gel	O
to	O
which	O
a	O
plasticizer	O
,	O
particularly	O
glycol	B
,	O
has	O
been	O
added	O
before	O
solidification	O
and	O
freeze	O
-	O
drying	O
;	O
(	O
h	O
)	O
a	O
method	O
for	O
producing	O
a	O
high	O
viscosity	O
(	O
I	O
)	O
-containing	O
solution	O
;	O
and	O
(	O
i	O
)	O
a	O
method	O
for	O
determining	O
the	O
adhesive	O
capacity	O
of	O
a	O
fibrin	O
clot	O
to	O
a	O
wound	O
bed	O
.	O

Medicament	O
for	O
local	O
use	O

The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
medical	O
use	O
of	O
4,5-dihydro-1H	B
-	I
pyrazole	I
compounds	O
which	O
are	O
potent	O
antagonists	O
of	O
the	O
cannabis	O
CB1-receptor	O
.	O

Said	O
compounds	O
are	O
particularly	O
suitable	O
in	O
the	O
manufacture	O
of	O
medicaments	O
for	O
the	O
treatment	O
and/or	O
prophylaxis	O
of	O
CB1	O
receptor	O
related	O
diseases	O
in	O
juvenile	O
patients	O
and/or	O
for	O
the	O
treatment	O
and/or	O
prophylaxis	O
of	O
drug	O
induced	O
obesity	O
in	O
juvenile	O
as	O
well	O
as	O
in	O
adolescent	O
patients	O
.	O

The	O
compounds	O
have	O
the	O
general	O
formula	O
(	O
1	O
)	O
,	O
wherein	O
the	O
group	O
Bb	O
represents	O
sulfonyl	B
or	O
carbonyl	B
,	O
and	O
the	O
substituents	O
R	O
,	O
R1	O
,	O
R2and	O
R3	O
,	O
and	O
the	O
group	O
Aa	O
are	O
defined	O
as	O
shown	O
in	O
the	O
description	O
.	O

Use	O
of	O
4,5-dihydro-1h	B
-	I
pyrazole	I
derivatives	O
having	O
cb1-antagonistic	O
activity	O

Benzimidazole	B
compounds	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
and	O
pharmaceutically	O
acceptable	O
salts	O
or	O
esters	B
thereof	O
are	O
peptide	O
deformylase	O
inhibitors	O
useful	O
in	O
the	O
treatment	O
or	O
prevention	O
of	O
infections	O
and	O
other	O
diseases	O
in	O
which	O
peptide	O
deformylases	O
are	O
involved	O
,	O
especially	O
in	O
the	O
treatment	O
of	O
bacterial	O
and	O
parasitic	O
infections	O
,	O
for	O
example	O
infections	O
fully	O
or	O
partly	O
caused	O
by	O
microorganisms	O
belonging	O
to	O
Staphylococcus	O
,	O
Enterococcus	O
,	O
Streptococcus	O
,	O
Haemophilus	O
,	O
Moraxella	O
,	O
Escherichia	O
,	O
Mycobacterium	O
,	O
Mycoplasma	O
,	O
Pseudomonas	O
,	O
Chlamydia	O
,	O
Rickettsia	O
,	O
Klebsiella	O
,	O
Shigella	O
,	O
Salmonella	O
,	O
Bordetella	O
,	O
Clostridium	O
,	O
helicobacter	O
,	O
Campylobacter	O
,	O
Legionella	O
,	O
or	O
Neisseria	O
.	O

Benzimidazole	B
derivatives	O
and	O
use	O
thereof	O
as	O
peptide	O
deformylase	O
inhibitors	O

The	O
present	O
invention	O
relates	O
to	O
a	O
therapeutical	O
method	O
comprising	O
administration	O
of	O
a	O
composition	O
comprising	O
a	O
monoclonal	O
antibody	O
with	O
an	O
oligo	B
-	I
-	I
(	I
1,3	I
)	I
-glucan	I
and	O
.	O

a	O
pharmaceutically	O
acceptable	O
carrier	O
,	O
to	O
a	O
human	O
being	O
or	O
to	O
a	O
warm	O
-	O
blood	O
animal	O
suffering	O
from	O
cancer	O
in	O
an	O
amount	O
which	O
is	O
effective	O
to	O
treat	O
the	O
cancer	O
.	O

Oligo	B
-	I
beta-	I
(	I
1,3	I
)	I
-glucan	I
and	O
monoclonal	O
antibodies	O
against	O
cancer	O

Disclosed	O
are	O
methods	O
for	O
treating	O
a	O
patient	O
identified	O
as	O
having	O
a	O
hemoglobinopathy	O
that	O
is	O
characterized	O
by	O
a	O
reduced	O
affinity	O
of	O
hemoglobin	O
for	O
oxygen	B
.	O

The	O
methods	O
involve	O
providing	O
gaseous	O
nitric	B
oxide	I
and/or	O
carbon	B
monoxide	I
for	O
(	O
i	O
)	O
inhalation	O
by	O
the	O
patient	O
or	O
(	O
ii	O
)	O
ex	O
vivo	O
treatment	O
of	O
the	O
patient	O
's	O
erythrocytes	O
.	O

Alternatively	O
,	O
a	O
nitric	O
-	O
oxide	O
-	O
releasing	O
compound	O
can	O
be	O
administered	O
to	O
the	O
patient	O
.	O

Treatment	O
of	O
a	O
Hemoglobinopathy	O

In	O
the	O
case	O
where	O
the	O
sensitivity	O
of	O
a	O
cancer	O
cell	O
to	O
a	O
compound	O
can	O
be	O
understood	O
by	O
examining	O
molecules	O
expressed	O
in	O
the	O
cancer	O
cell	O
collected	O
from	O
a	O
cancer	O
patient	O
by	O
biopsy	O
or	O
the	O
like	O
,	O
it	O
is	O
possible	O
to	O
administer	O
the	O
compound	O
selectively	O
to	O
cancer	O
patients	O
on	O
whom	O
the	O
compound	O
can	O
exert	O
its	O
antitumor	O
effect	O
.	O

Thus	O
,	O
it	O
is	O
expected	O
that	O
the	O
therapeutic	O
effect	O
can	O
be	O
enhanced	O
while	O
relieving	O
unnecessary	O
side	O
effects	O
thereby	O
.	O

More	O
specifically	O
speaking	O
,	O
it	O
is	O
found	O
out	O
that	O
the	O
characteristics	O
"	O
low	O
pRB	O
-	O
expression	O
"	O
,	O
"	O
positive	O
to	O
p16	O
expression	O
"	O
and	O
"	O
high	O
cyclin	O
E	O
-	O
expression	O
"	O
are	O
usable	O
as	O
a	O
marker	O
for	O
the	O
high	O
sensitivity	O
of	O
cancer	O
cells	O
to	O
this	O
compound	O
.	O

Examination	O
of	O
these	O
characteristics	O
of	O
cancer	O
cells	O
,	O
therefore	O
,	O
the	O
sensitivity	O
of	O
the	O
cancer	O
cells	O
to	O
this	O
compound	O
can	O
be	O
preliminarily	O
understood	O
.	O

Method	O
of	O
examining	O
sensitivity	O
of	O
cancer	O
cell	O
to	O
anticancer	O
agent	O

The	O
present	O
invention	O
relates	O
to	O
pyridylpyrimidine	B
derivatives	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
R	O
represents	O
hydrogen	B
or	O
methyl	B
and	O
Z	O
represents	O
nitrogen	B
containing	O
functional	O
groups	O
,	O
the	O
use	O
of	O
the	O
pyridylpyrimidine	B
derivatives	O
as	O
pharmaceutically	O
active	O
agents	O
,	O
especially	O
for	O
the	O
prophylaxis	O
and/or	O
treatment	O
of	O
prion	O
infections	O
and	O
prion	O
diseases	O
,	O
as	O
well	O
as	O
compositions	O
containing	O
at	O
least	O
one	O
pyridylpyrimidine	B
derivative	O
and/or	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O

Furthermore	O
,	O
the	O
present	O
invention	O
is	O
directed	O
to	O
methods	O
for	O
preventing	O
and/or	O
treating	O
prion	O
infections	O
and	O
prion	O
diseases	O
using	O
said	O
pyridylpyrimidine	B
derivatives	O
.	O

Human	O
cellular	O
protein	O
kinases	O
,	O
phosphatases	O
and	O
cellular	O
signal	O
transduction	O
molecules	O
are	O
disclosed	O
as	O
targets	O
for	O
detecting	O
,	O
preventing	O
and/or	O
treating	O
prion	O
infections	O
and	O
diseases	O
,	O
especially	O
BSE	O
,	O
vCJD	O
,	O
or	O
CJD	O
which	O
can	O
be	O
inhibited	O
by	O
the	O
inventive	O
pyridylpyrimidine	B
derivatives	O
.	O

Pyridylpyrimidine	B
derivatives	O
as	O
effective	O
compounds	O
against	O
prion	O
infections	O
and	O
prion	O
diseases	O

The	O
present	O
invention	O
provides	O
aryl	B
nitrones	I
,	O
compositions	O
comprising	O
the	O
same	O
and	O
methods	O
of	O
their	O
use	O
for	O
the	O
treatment	O
or	O
prevention	O
of	O
oxidative	O
,	O
ischemic	O
,	O
ischemia	O
/	O
reperfusion	O
-	O
related	O
and	O
chemokine	O
mediated	O
conditions	O
.	O

2-substituted	O
and	O
4-substituted	O
aryl	B
nitrone	I
compouds	O

Formulations	O
and	O
methods	O
are	O
provided	O
for	O
the	O
treatment	O
of	O
pain	O
,	O
and	O
neuropathic	O
pain	O
in	O
particular	O
.	O

The	O
formulations	O
are	O
eutectic	O
mixtures	O
of	O
a	O
capsaicinoid	B
and	O
a	O
local	O
anesthetic	O
agent	O
and/or	O
anti	O
-	O
pruritic	O
agent	O
.	O

Formulations	O
comprising	O
a	O
capsaicinoid	B
,	O
a	O
local	O
anesthetic	O
and/or	O
an	O
antipruritic	O
agent	O
for	O
the	O
treatment	O
of	O
pain	O

A	O
compound	O
of	O
general	O
formula	O
(	O
1a	O
)	O
wherein	O
R1	O
,	O
R5	O
,	O
R6	O
,	O
A	O
,	O
B	O
,	O
Y	O
,	O
i	O
,	O
j	O
and	O
m	O
are	O
defined	O
as	O
in	O
the	O
description	O
and	O
claims	O
.	O

It	O
is	O
another	O
object	O
of	O
the	O
present	O
invention	O
to	O
provide	O
pharmaceutical	O
compositions	O
comprising	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
and	O
a	O
therapeutically	O
effective	O
amount	O
of	O
at	O
least	O
one	O
of	O
the	O
compounds	O
of	O
the	O
present	O
invention	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O

Alkyl	O
-	O
and	O
piperidine	O
-	O
substituted	O
benzimidazole	O
-	O
derivates	O

The	O
present	O
invention	O
discloses	O
novel	O
aryl	B
oxazole	I
compounds	O
of	O
Formula	O
I	O
(	O
I	O
)	O
,	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
which	O
have	O
histamine	B
-	O
H3	O
receptor	O
antagonist	O
or	O
inverse	O
agonist	O
activity	O
,	O
as	O
well	O
as	O
methods	O
for	O
preparing	O
and	O
using	O
such	O
compounds	O
.	O

In	O
another	O
embodiment	O
,	O
the	O
invention	O
discloses	O
pharmaceutical	O
compositions	O
comprising	O
compounds	O
of	O
Formula	O
I	O
as	O
well	O
as	O
methods	O
of	O
using	O
these	O
compositions	O
to	O
treat	O
obesity	O
,	O
cognitive	O
deficiencies	O
,	O
narcolepsy	O
,	O
and	O
other	O
histamine	B
H3	O
receptor	O
-	O
related	O
diseases	O
.	O

Formula	O
I	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
wherein	O
:	O
m	O
is	O
independenlly	O
at	O
each	O
occurrence	O
1	O
,	O
2	O
,	O
or	O
3	O
,	O
Z	O
independently	O
represents	O
carbon	B
(	O
substituted	O
with	O
hydrogen	B
or	O
the	O
optional	O
substituents	O
indicated	O
herein	O
)	O
or	O
nitrogen	B
,	O
provided	O
that	O
when	O
Z	O
is	O
nitrogen	B
then	O
R6	O
is	O
not	O
attached	O
to	O
Z	O
;	O
R1	O
and	O
R2	O
are	O
independently	O
-	B
(	I
C1-C7	I
)	I
alkyl	I
(	O
optionally	O
substituted	O
with	O
one	O
to	O
three	O
halogens	B
)	O
,	O
or	O
R1	O
and	O
R2	O
and	O
the	O
nitrogen	B
to	O
which	O
they	O
are	O
attached	O
form	O
an	O
azetidinyl	B
ring	O
,	O
a	O
pyrrolidinyl	B
ring	O
,	O
or	O
a	O
piperidinyl	B
ring	O
,	O
wherein	O
further	O
the	O
azetidinyl	B
,	O
pyrrolidinyl	B
,	O
or	O
piperidinyl	B
ring	O
so	O
formed	O
may	O
be	O
optionally	O
substituted	O
one	O
to	O
three	O
times	O
with	O
R5	O
;	O
R6	O
is	O
independently	O
at	O
each	O
occurrence	O
-H	B
,	O
-halogen	B
,	O
or	O
-CH3	B
.	O

Oxazole	B
derivatives	O
as	O
histamine	B
h3	O
receptor	O
agents	O
,	O
preparation	O
and	O
therapeutic	O
uses	O

Compounds	O
of	O
formula	O
(	O
I	O
)	O
possess	O
unexpectedly	O
high	O
affinity	O
for	O
Alk	O
5	O
and/or	O
Alk	O
4	O
,	O
and	O
can	O
be	O
useful	O
as	O
antagonists	O
thereof	O
for	O
preventing	O
and/or	O
treating	O
numerous	O
diseases	O
,	O
including	O
fibrotic	O
disorders	O
.	O

The	O
invention	O
features	O
a	O
compound	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
and	O
uses	O
thereof	O
.	O

Pyrimidinylimidazoles	B
as	O
tgf	O
-	O
beta	O
inhibitors	O

The	O
invention	O
relates	O
generally	O
to	O
novel	O
compositions	O
and	O
methods	O
comprising	O
at	O
least	O
one	O
Vitamin	B
B12	I
compound	O
,	O
at	O
least	O
one	O
IMPDH	O
inhibitor	O
,	O
and	O
optionally	O
an	O
interferon	O
.	O

The	O
compositions	O
and	O
methods	O
provide	O
beneficial	O
effects	O
in	O
the	O
treatment	O
of	O
viral	O
,	O
inflammatory	O
,	O
immunodeficiency	O
,	O
IMPDH	O
-	O
mediated	O
,	O
and	O
proliferative	O
diseases	O
.	O

Compositions	O
and	O
methods	O
comprising	O
vitamin	B
b12	I
and	O
an	O
impdh	O
inhibitor	O
for	O
treating	O
viral	O
,	O
inflammatory	O
and	O
proliferative	O
diseases	O

The	O
invention	O
generally	O
relates	O
to	O
compositions	O
and	O
methods	O
for	O
treatment	O
of	O
disease	O
caused	O
by	O
Yersinia	O
spp	O
.	O

infection	O
.	O

More	O
specifically	O
,	O
the	O
invention	O
relates	O
to	O
protein	O
tyrosine	B
phosphatase	O
inhibitors	O
and	O
derivatives	O
and	O
analogs	O
thereof	O
,	O
pharmaceutical	O
compositions	O
containing	O
the	O
protein	O
tyrosine	B
phosphatase	O
inhibitors	O
and	O
analogs	O
,	O
methods	O
of	O
making	O
the	O
protein	O
tyrosine	B
phosphatase	O
inhibitors	O
and	O
analogs	O
and	O
methods	O
of	O
use	O
thereof	O
.	O

Compositions	O
and	O
methods	O
for	O
treatment	O
of	O
disease	O
caused	O
by	O
yersinia	O
spp	O
infection	O

The	O
following	O
invention	O
is	O
directed	O
to	O
pharmaceutical	O
compounds	O
and	O
compositions	O
of	O
the	O
Formula	O
(	O
I	O
)	O
.	O

useful	O
for	O
treating	O
conditions	O
mediated	O
by	O
V3	O
and/or	O
V5	O
integrin	O
.	O

Biphenyl	B
integrin	O
antagonists	O

The	O
invention	O
relates	O
to	O
a	O
novel	O
multi	O
step	O
synthesis	O
of	O
3-	B
(	I
N	I
-	I
methyl	I
-	I
N	I
-	I
pentyl	I
)	I
amino	I
-	I
lhydroxypropane-1	I
,	I
1-diphosphonic	I
acid	I
,	I
monosodium	I
salt	I
,	I
monohydrate	I
,	O
of	O
Formula	O
(	O
I	O
)	O
.	O

Process	O
for	O
the	O
preparation	O
of	O
ibandronate	B

The	O
present	O
invention	O
relates	O
to	O
a	O
cosmetic	O
mixture	O
comprising	O
phytosterols	B
in	O
quantities	O
ranging	O
from	O
1	O
to	O
20	O
%	O
by	O
weight	O
,	O
isoflavones	B
from	O
0.1	O
to	O
4	O
%	O
by	O
weight	O
and	O
methylricinoleate	B
from	O
80	O
to	O
90	O
%	O
by	O
weight	O
.	O

Said	O
cosmetic	O
mixture	O
is	O
formulated	O
with	O
excipients	O
normally	O
used	O
in	O
the	O
cosmetic	O
sector	O
,	O
to	O
give	O
a	O
cosmetic	O
formulation	O
.	O

The	O
cosmetic	O
mixture	O
and	O
formulation	O
are	O
capable	O
of	O
inhibiting	O
the	O
enzyme	O
5-alpha	O
-	O
reductase	O
,	O
and	O
thus	O
have	O
inhibitory	O
or	O
retardatory	O
activity	O
towards	O
the	O
growth	O
of	O
body	O
hair	O
.	O

Cosmetic	O
composition	O
comprising	O
phytosterols	B
,	O
isoflavones	B
and	O
methylricinoleate	B
,	O
use	O
as	O
inhibitor	O
of	O
5-alpha	O
-	O
reductase	O
and	O
hair	O
growth	O

The	O
present	O
invention	O
relates	O
to	O
an	O
adjuvants	O
,	O
particularly	O
to	O
the	O
use	O
of	O
a	O
well	O
-	O
characterized	O
plant	O
based	O
iridoid	B
glycoside	I
adjuvant	O
from	O
plant	O
Picrorhiza	O
kurroa	O
,	O
acting	O
as	O
an	O
adjuvant	O
against	O
T	O
-dependent	O
antigen	O
and	O
specifically	O
against	O
HBsAg	O
and	O
typhoid	O
antigens	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
the	O
method	O
of	O
producing	O
the	O
iridoid	B
glycoside	I
adjuvant	O
and	O
the	O
products	O
utilizing	O
such	O
adjuvants	O
for	O
induction	O
of	O
cellular	O
immunity	O
.	O

The	O
adjuvants	O
may	O
be	O
used	O
alone	O
or	O
with	O
specific	O
antigens	O
.	O

The	O
two	O
antigens	O
used	O
in	O
the	O
study	O
represents	O
HBsAg	O
,	O
a	O
recombinant	O
antigen	O
expressed	O
in	O
Pichia	O
pastoris	O
,	O
and	O
typhoid	O
Vi	O
polysaccharide	O
purified	O
from	O
Salmonella	O
typhi	O
broth	O
.	O

These	O
antigens	O
are	O
studied	O
for	O
their	O
immunogenicity	O
with	O
the	O
adjuvant	O
iridoid	B
glycoside	I
adjuvant	O
.	O

Iridoid	B
glycoside	I
composition	O

The	O
invention	O
relates	O
to	O
an	O
improved	O
process	O
for	O
the	O
synthesis	O
of	O
13-	B
(	I
N	I
-	I
Boc	I
-	I
	I
-	I
isobutylserinyl	I
)	I
-14-	I
-	I
hydroxybaccatin	I
III-1,14-carbonate	I
(	O
I	O
)	O
,	O
wherein	O
carbonation	O
of	O
the	O
1,14-hydroxy	B
groups	O
of	O
the	O
baccatin	O
skeleton	O
is	O
carried	O
out	O
with	O
bis	B
(	I
trichloromethylcarbonate	I
and	O
the	O
7-hydroxy	B
group	O
is	O
protected	O
with	O
a	O
trichloroacetyl	B
group	O
.	O

Process	O
for	O
the	O
preparation	O
of	O
a	O
taxane	B
derivative	O

Use	O
of	O
a	O
3-acylated	B
pyridoxal	I
analogue	O
,	O
a	O
pharmaceutically	O
acceptable	O
acid	O
addition	O
salt	O
thereof	O
,	O
or	O
a	O
mixture	O
thereof	O
for	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
treating	O
insulin	O
-	O
dependent	O
or	O
non	O
-	O
insulin	O
-	O
dependent	O
diabetes	O
mellitus	O
,	O
related	O
conditions	O
,	O
symptoms	O
of	O
insulin	O
-	O
dependent	O
or	O
non	O
-	O
insulin	O
-	O
dependent	O
diabetes	O
mellitus	O
or	O
related	O
conditions	O
,	O
or	O
any	O
combination	O
thereof	O
in	O
a	O
mammal	O
.	O

Use	O
of	O
pyridoxal	B
phosphate	I
derivatives	O
for	O
the	O
treatment	O
of	O
diabetes	O
and	O
related	O
complications	O

The	O
present	O
invention	O
provides	O
alcohol	B
resistant	O
oral	O
dosage	O
pharmaceutical	O
forms	O
and	O
methods	O
of	O
using	O
such	O
oral	O
dosage	O
forms	O
to	O
avoid	O
dose	O
dumping	O
if	O
the	O
dosage	O
form	O
is	O
taken	O
together	O
with	O
alcohol	B
.	O

Alcohol	B
resistant	O
pharmaceutical	O
formulations	O

The	O
present	O
invention	O
relates	O
to	O
guanosine	B
-	O
rich	O
oligonucleotides	O
having	O
the	O
capacity	O
to	O
induce	O
cell	O
death	O
,	O
having	O
characteristics	O
of	O
programmed	O
cell	O
death	O
,	O
in	O
non	O
-	O
quiescent	O
cells	O
of	O
higher	O
eukaryotic	O
organisms	O
.	O

The	O
invention	O
also	O
relates	O
to	O
therapeutic	O
methods	O
involving	O
the	O
administration	O
of	O
these	O
nucleic	O
acid	O
molecules	O
to	O
subjects	O
suffering	O
from	O
,	O
or	O
being	O
predisposed	O
to	O
,	O
disorders	O
involving	O
abnormal	O
cell	O
proliferation	O
and	O
migration	O
.	O

The	O
invention	O
also	O
concerns	O
pharmaceutical	O
compositions	O
comprising	O
the	O
guanosine	B
-	O
rich	O
nucleic	O
acid	O
molecules	O
,	O
in	O
association	O
with	O
suitable	O
carriers	O
.	O

Guanosine	B
-	O
rich	O
oligonucleotides	O
as	O
agents	O
for	O
inducing	O
cell	O
death	O
in	O
eukaryotic	O
cells	O

The	O
invention	O
concerns	O
the	O
association	O
of	O
at	O
least	O
one	O
3	O
adrenergic	O
receptor	O
agonist	O
(	O
or	O
3	O
agonist	O
)	O
with	O
a	O
monoamine	B
reuptake	O
inhibitor	O
.	O

The	O
invention	O
also	O
concerns	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
inventive	O
association	O
and	O
its	O
therapeutic	O
use	O
.	O

ASSOCIATION	O
OF	O
3	O
RECEPTOR	O
AGONIST	O
AND	O
MONOAMINE	B
REUPTAKE	O
INHIBITORS	O
,	O
PHARMACEUTICAL	O
COMPOSITION	O
AND	O
THERAPEUTIC	O
USE	O
THEREOF	O

The	O
present	O
invention	O
relates	O
to	O
a	O
memory	O
CTL	O
induction	O
enhancer	O
comprising	O
a	O
combination	O
of	O
substance	O
(	O
b	O
)	O
with	O
substance	O
(	O
a	O
)	O
and/or	O
substance	O
(	O
c	O
)	O
,	O
wherein	O
substance	O
(	O
a	O
)	O
is	O
an	O
activator	O
of	O
antigen	O
-	O
presenting	O
cells	O
,	O
substance	O
(	O
b	O
)	O
is	O
an	O
inducer	O
of	O
homeostatic	O
proliferation	O
after	O
induction	O
of	O
lymphopenia	O
,	O
and	O
substance	O
(	O
c	O
)	O
is	O
a	O
suppressor	O
of	O
regulatory	O
T	O
cells	O
.	O

Novel	O
memory	O
ctl	O
induction	O
potentiator	O

Use	O
of	O
tenatoprazole	B
is	O
claimed	O
in	O
medicines	O
for	O
the	O
treatment	O
of	O
atypical	O
and	O
esophageal	O
symptoms	O
of	O
gastroesophageal	O
reflux	O
,	O
digestive	O
hemorrhages	O
and	O
dyspepsias	O
.	O

-	O
ACTIVITY	O
:	O
Gastrointestinal	O
-	O
Gen	O
;	O
Antiasthmatic	O
;	O
Antitussive	O
;	O
Respiratory	O
-	O
Gen	O
.	O
;	O
Antianginal	O
;	O
Hemostatic	O
.	O

In	O
a	O
test	O
,	O
fourteen	O
patients	O
suffering	O
from	O
gastroesophageal	O
reflux	O
were	O
given	O
a	O
daily	O
dose	O
of	O
tenatoprazole	B
(	O
20	O
mg	O
)	O
for	O
4	O
-	O
12	O
weeks	O
.	O

In	O
twelve	O
cases	O
,	O
the	O
dosage	O
was	O
tolerated	O
perfectly	O
and	O
in	O
the	O
other	O
two	O
cases	O
it	O
was	O
well	O
-	O
tolerated	O
.	O

The	O
effect	O
on	O
the	O
symptoms	O
was	O
very	O
good	O
.	O

-	O
MECHANISM	O
OF	O
ACTION	O
:	O
Proton	O
pump	O
inhibitor	O
.	O

Use	O
of	O
tenatoprazole	B
for	O
the	O
treatment	O
of	O
gastroesophageal	O
reflux	O
disease	O

The	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
their	O
derivatives	O
comprising	O
a	O
detectable	O
label	O
,	O
their	O
compositions	O
and	O
their	O
use	O
in	O
the	O
treatment	O
of	O
human	O
immunodeficiency	O
virus	O
(	O
HIV	O
)	O
infection	O
.	O

In	O
particular	O
,	O
the	O
invention	O
provides	O
novel	O
inhibitors	O
of	O
HIV	O
replication	O
,	O
pharmaceutical	O
compositions	O
containing	O
such	O
compounds	O
and	O
methods	O
for	O
using	O
these	O
compounds	O
in	O
the	O
treatment	O
of	O
HIV	O
infection	O
.	O

Inhibitors	O
of	O
human	O
immunodeficiency	O
virus	O
replication	O

The	O
present	O
invention	O
relates	O
to	O
the	O
field	O
of	O
regulating	O
the	O
activity	O
of	O
the	O
purinergic	O
receptors	O
for	O
the	O
modulation	O
of	O
the	O
vascular	O
tone	O
,	O
particularly	O
for	O
the	O
purpose	O
of	O
treatment	O
of	O
haemodynamic	O
conditions	O
by	O
overriding	O
of	O
vasoconstriction	O
activity	O
,	O
such	O
as	O
increases	O
in	O
sympathic	O
vasoconstriction	O
.	O

Modulators	O
,	O
such	O
as	O
UTP	O
analogues	O
as	O
described	O
herein	O
are	O
preferably	O
specific	O
for	O
P2Y2	O
.	O

Compounds	O
capable	O
of	O
stimulating	O
the	O
P2Y2	O
receptor	O
are	O
suitable	O
for	O
the	O
treatment	O
or	O
prevention	O
wherein	O
inhibition	O
of	O
vasoconstriction	O
activity	O
is	O
desirable	O
such	O
as	O
hypertension	O
and	O
hypertension	O
relates	O
disorders	O
or	O
diseases	O
,	O
whereas	O
compound	O
capable	O
of	O
counteracting	O
the	O
activity	O
of	O
the	O
P2Y2	O
receptor	O
are	O
suitable	O
for	O
the	O
treatment	O
of	O
or	O
prevention	O
wherein	O
inhibition	O
of	O
vasodilatation	O
is	O
desirable	O
.	O

Modulation	O
of	O
the	O
P2Y2	O
receptor	O
pathway	O

The	O
invention	O
relates	O
to	O
inhibitors	O
of	O
the	O
phosphodiesterase	O
4	O
(	O
PDE4	O
)	O
enzyme	O
.	O

More	O
particularly	O
,	O
the	O
invention	O
relates	O
to	O
compounds	O
that	O
are	O
derivatives	O
of	O
1-phenyl-2-pyridynyl	B
alkylene	I
alcohols	I
,	O
methods	O
of	O
preparing	O
such	O
compounds	O
,	O
compositions	O
containing	O
them	O
and	O
therapeutic	O
use	O
thereof	O
.	O

Derivatives	O
of	O
1-phenyl-2-pyridynyl	B
alkylene	I
alcohols	I
as	O
phosphodiesterase	O
inhibitors	O

A	O
composition	O
having	O
:	O
a	O
proanthocyanidin	B
:	O
and	O
a	O
macromolecule	O
,	O
an	O
assembly	O
of	O
macromolecules	O
,	O
a	O
semi	O
-	O
solid	O
,	O
or	O
a	O
solid	O
surface	O
to	O
which	O
the	O
proanthocyanidin	B
is	O
immobilized	O
.	O

A	O
composition	O
having	O
proanthocyanidin	B
compounds	O
having	O
an	O
average	O
degree	O
of	O
polymerization	O
of	O
at	O
least	O
about	O
6	O
.	O

A	O
method	O
of	O
administering	O
to	O
an	O
immunosuppressed	O
patient	O
or	O
a	O
patient	O
diagnosed	O
with	O
sepsis	O
or	O
septic	O
shock	O
a	O
composition	O
having	O
a	O
proanthocyanidin	B
.	O

A	O
method	O
of	O
administering	O
to	O
a	O
patient	O
diagnosed	O
with	O
a	O
gram	O
negative	O
bacterial	O
infection	O
a	O
composition	O
having	O
proanthocyanidin	B
compounds	O
having	O
an	O
average	O
degree	O
of	O
polymerization	O
of	O
at	O
least	O
about	O
6	O
.	O

Binding	O
interaction	O
of	O
proanthocyanidins	B
with	O
bacteria	O
and	O
bacterial	O
components	O

The	O
present	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
and	O
method	O
of	O
achieving	O
a	O
therapeutic	O
effect	O
including	O
,	O
but	O
not	O
limited	O
to	O
,	O
the	O
treatment	O
of	O
hypertension	O
,	O
kidney	O
or	O
heart	O
disease	O
in	O
an	O
animal	O
,	O
preferably	O
a	O
mammal	O
including	O
a	O
human	O
subject	O
,	O
using	O
(	O
i	O
)	O
SPP100	O
/	O
aliskiren	B
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
in	O
combination	O
with	O
(	O
ii	O
)	O
SPP301	O
/	O
avosentan	B
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
and	O
(	O
iii	O
)	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O

Pharmaceutical	O
composition	O
using	O
aliskiren	B
and	O
avosentan	B

The	O
invention	O
provides	O
4-IBBL	O
blocking	O
agents	O
,	O
as	O
well	O
as	O
pharmaceutical	O
compositions	O
and	O
articles	O
of	O
manufacture	O
comprising	O
such	O
blocking	O
agents	O
as	O
new	O
therapeutic	O
interventions	O
for	O
sustained	O
inflammation	O
.	O

Thus	O
,	O
the	O
invention	O
also	O
provides	O
methods	O
for	O
reducing	O
sustained	O
production	O
of	O
tumor	O
necrosis	O
factor	O
.	O

4	O
-	O
1	O
bb	O
ligand	O
in	O
inflammatory	O
diseases	O

A	O
compound	O
of	O
the	O
formula	O
I	O
:	O
wherein	O
R1	O
is	O
lower	O
alkyl	B
,	O
R2	O
is	O
hydrogen	B
or	O
lower	O
alkyl	B
,	O
Z	O
is	O
optionally	O
substituted	O
lower	O
alkyl	B
,	O
optionally	O
substituted	O
lower	O
alkenyl	B
,	O
optionally	O
substituted	O
amino	B
,	O
optionally	O
substituted	O
lower	O
alkoxy	B
,	O
optionally	O
substituted	O
carbocyclyl	B
or	O
optionally	O
substituted	O
heterocyclyl	B
can	O
stimulate	O
the	O
glucose	B
metabolism	O
independent	O
of	O
change	O
in	O
body	O
weight	O
.	O

The	O
compound	O
can	O
be	O
used	O
as	O
a	O
glucose	B
metabolism	O
stimulating	O
agent	O
.	O

Glucose	B
metabolism	O
ameliorating	O
agent	O

The	O
present	O
invention	O
relates	O
to	O
potentiation	O
of	O
the	O
analgesic	O
effect	O
of	O
opioids	O
as	O
well	O
as	O
to	O
attenuation	O
of	O
the	O
addiction	O
thereof	O
.	O

More	O
specifically	O
,	O
the	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
a	O
group	O
of	O
sigma	O
receptor	O
ligands	O
of	O
formula	O
I	O
for	O
the	O
potentiation	O
of	O
the	O
analgesic	O
effect	O
of	O
opioids	O
and	O
at	O
the	O
same	O
time	O
for	O
decreasing	O
of	O
the	O
dependency	O
induced	O
by	O
them	O
.	O

1-aryl-3-aminoalkoxy	B
-	I
pyrazoles	I
as	O
sigma	O
ligands	O
enhancing	O
analgesic	O
effects	O
of	O
opioids	O
and	O
attenuating	O
the	O
dependency	O
thereof	O

Disclosed	O
are	O
novel	O
oxylipins	B
,	O
referred	O
to	O
herein	O
as	O
docosanoids	B
and	O
eicosanoids	B
,	O
that	O
are	O
derived	O
from	O
C22	O
polyunsaturated	O
fatty	O
acids	O
and	O
from	O
C20	O
polyunsaturated	O
fatty	O
acids	O
,	O
respectively	O
,	O
and	O
methods	O
of	O
making	O
and	O
using	O
such	O
oxylipins	B
.	O

Also	O
disclosed	O
is	O
the	O
use	O
of	O
docosapentaenoic	B
acid	I
(	O
C22:5n-6	O
)	O
(	O
DPAn-6	O
)	O
,	O
docosapentaenoic	B
acid	I
(	O
C22:5n-3	O
)	O
(	O
DPAn-3	O
)	O
,	O
and	O
docosatetraenoic	B
acid	I
(	O
DTAn-6	O
:	O
C22:4n-6	O
)	O
,	O
docosatrienoic	B
acid	I
(	O
C22:3n-3	O
)	O
(	O
DTrAn-3	O
)	O
,	O
docosadienoic	B
acid	I
(	O
C22:2n-6	O
)	O
(	O
DDAn-6	O
)	O
,	O
eicosatrienoic	B
acid	I
(	O
C20:3n-3	O
)	O
(	O
ETrAn-3	O
)	O
eicosapentaenoic	B
acid	I
and	O
arachidonic	B
acid	I
as	O
substrates	O
for	O
the	O
production	O
of	O
novel	O
oxylipins	B
,	O
and	O
to	O
the	O
oxylipins	B
produced	O
thereby	O
.	O

Also	O
disclosed	O
is	O
the	O
use	O
of	O
DPAn-6	O
,	O
DPAn-3	O
,	O
DTAn-6	O
,	O
and/or	O
the	O
oxylipins	O
derived	O
therefrom	O
,	O
and/or	O
novel	O
docosanoids	O
derived	O
from	O
the	O
structures	O
of	O
C22	O
fatty	B
acids	I
in	O
therapeutic	O
and	O
nutritional	O
or	O
cosmetic	O
applications	O
,	O
and	O
particularly	O
as	O
anti	O
-	O
inflammatory	O
or	O
anti	O
-	O
neurodegenerative	O
compounds	O
.	O

The	O
invention	O
also	O
relates	O
to	O
novel	O
ways	O
of	O
producing	O
long	O
chain	O
polyunsaturated	O
acid	O
(	O
LCPUF	O
A	O
)	O
-rich	O
oils	O
and	O
compositions	O
that	O
contain	O
enhanced	O
and	O
effective	O
amounts	O
of	O
LCPUF	O
A	O
-	O
derived	O
oxylipins	B
,	O
and	O
particularly	O
,	O
docosanoids	B
.	O

Oxylipins	B
from	O
long	O
chain	O
polyunsaturated	O
fatty	B
acids	I
and	O
methods	O
of	O
making	O
and	O
using	O
the	O
same	O

The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
for	O
evaluating	O
patients	O
to	O
help	O
optimizing	O
the	O
treatment	O
of	O
chronic	O
myeloid	O
leukemia	O
(	O
CML	O
)	O
in	O
a	O
human	O
patient	O
population	O
.	O

More	O
specifically	O
,	O
the	O
method	O
comprises	O
the	O
steps	O
of	O
(	O
a	O
)	O
determining	O
the	O
OCT-1	O
Activity	O
in	O
pre	O
-	O
therapy	O
blood	O
of	O
a	O
warm	O
-	O
blooded	O
animal	O
suffering	O
from	O
CML	O
,	O
and	O
(	O
b	O
)	O
administering	O
a	O
daily	O
dose	O
between	O
about	O
500	O
and	O
1200	O
mg	O
of	O
Imatinib	B
mesylate	I
to	O
the	O
warm	O
-	O
blooded	O
animal	O
suffering	O
from	O
CML	O
showing	O
an	O
OCT-1	O
Activity	O
corresponding	O
to	O
Imatinib	B
intracellular	O
concentration	O
below	O
about	O
6.0	O
to	O
10.0	O
ng	O
/	O
200,000	O
cells	O
,	O
especially	O
about	O
8.0	O
to	O
8.5	O
ng	O
/	O
200,000	O
cells	O
.	O

Method	O
for	O
optimizing	O
the	O
treatment	O
of	O
chronic	O
myeloid	O
leukemia	O
with	O
abl	O
tyrosine	B
kinase	O
inhibitors	O

The	O
present	O
invention	O
pertains	O
to	O
the	O
use	O
of	O
a	O
composition	O
comprising	O
a	O
florfenicol	B
ester	I
and	O
a	O
pharmaceutically	O
acceptable	O
solvent	O
wherein	O
the	O
florfenicol	B
ester	I
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
florfenicol	B
acetate	I
,	O
florfenicol	B
propionate	I
,	O
florfenicol	B
butyrate	I
,	O
florfenicol	B
pentanoate	I
,	O
florfenicol	B
heptanoate	I
,	O
florfenicol	B
octanoate	I
,	O
florfenicol	B
nanoate	I
,	O
florfenicol	B
decanoate	I
,	O
florfenicol	B
undecanoate	I
,	O
and	O
florfenicol	B
dodecanoate	I
;	O
for	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
treating	O
a	O
bacterial	O
infection	O
that	O
is	O
susceptible	O
to	O
florfenicol	B
in	O
a	O
bovine	O
that	O
can	O
be	O
administered	O
as	O
a	O
single	O
injection	O
in	O
an	O
amount	O
sufficient	O
to	O
treat	O
the	O
infection	O
without	O
requiring	O
a	O
second	O
injection	O
Florfenicol	B
esters	I
for	O
treating	O
bacterial	O
infections	O

The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
the	O
use	O
of	O
compounds	O
from	O
Centella	O
Asiatica	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
Asiatic	B
acid	I
and	O
Madecassic	B
acid	I
,	O
and	O
plant	O
extracts	O
containing	O
both	O
acids	O
in	O
cosmetics	O
,	O
pharmaceuticals	O
and	O
food	O
supplements	O
for	O
preventing	O
the	O
glycation	O
phenomenon	O
and	O
the	O
glycation	O
consequences	O
in	O
tissues	O
,	O
more	O
paticularly	O
for	O
preventing	O
skin	O
aging	O
,	O
enhancing	O
wounds	O
treating	O
,	O
venous	O
insufficiency	O
etc	O
.	O

Anti	O
-	O
glycation	O
properties	O
of	O
asicatic	B
acid	I
and	O
madecassic	B
acid	I

Polyaromatic	B
sodium	I
channel	O
blockers	O
represented	O
by	O
the	O
formula	O
:	O
(	O
I	O
)	O
are	O
provided	O
where	O
the	O
structural	O
variables	O
are	O
defined	O
herein	O
.	O

The	O
invention	O
also	O
includes	O
a	O
variety	O
of	O
compositions	O
,	O
combinations	O
and	O
methods	O
of	O
treatment	O
using	O
these	O
inventive	O
sodium	B
channel	O
blockers	O
.	O

Poly	B
aromatic	I
sodium	I
channel	O
blockers	O

2-Aminopyridine	B
compounds	O
having	O
the	O
structure	O
of	O
Formula	O
I	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
of	O
these	O
compounds	O
.	O

Compounds	O
of	O
Formula	O
I	O
inhibit	O
the	O
activity	O
of	O
tyrosine	B
kinase	O
enzymes	O
in	O
animals	O
,	O
including	O
humans	O
,	O
and	O
are	O
useful	O
in	O
the	O
treatment	O
and/or	O
prevention	O
of	O
various	O
diseases	O
and	O
conditions	O
.	O

In	O
particular	O
,	O
compounds	O
disclosed	O
herein	O
are	O
inhibitors	O
of	O
kinases	O
,	O
in	O
particular	O
,	O
but	O
not	O
limited	O
to	O
,	O
KDR	O
,	O
Tie-2	O
,	O
F1t3	O
,	O
FGFR3	O
,	O
Ab1	O
,	O
Aurora	O
A	O
,	O
c	O
-	O
Src	O
,	O
IGF-	O
IR	O
,	O
ALK	O
,	O
c	O
-	O
MET	O
,	O
RON	O
,	O
PAK1	O
,	O
PAK2	O
,	O
and	O
TAK1	O
,	O
and	O
can	O
be	O
used	O
in	O
the	O
treatment	O
of	O
proliferative	O
diseases	O
,	O
such	O
as	O
,	O
but	O
not	O
limited	O
to	O
,	O
cancer	O
.	O

The	O
present	O
invention	O
is	O
also	O
directed	O
to	O
a	O
pharmaceutical	O
composition	O
comprising	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
compound	O
of	O
Formula	O
I	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O

The	O
present	O
invention	O
is	O
further	O
directed	O
to	O
a	O
method	O
of	O
treating	O
a	O
patient	O
having	O
a	O
condition	O
which	O
is	O
mediated	O
by	O
protein	O
kinase	O
activity	O
by	O
administering	O
to	O
the	O
patient	O
a	O
therapeutically	O
effective	O
amount	O
of	O
the	O
above	O
-	O
mentioned	O
pharmaceutical	O
composition	O
.	O

2-aminopyridine	B
kinase	O
inhibitors	O

Described	O
is	O
a	O
method	O
for	O
slowing	O
the	O
speed	O
of	O
the	O
isomerisation	O
of	O
petasin	B
and	O
neopetasin	B
to	O
isopetasin	B
,	O
and	O
the	O
isomerisation	O
of	O
S	B
-	I
petasin	I
and	O
neo	B
-	I
S	I
-	I
petasin	I
to	O
iso	B
-	I
S	I
-	I
petasin	I
,	O
especially	O
in	O
extracts	O
from	O
plants	O
of	O
the	O
genus	O
Petasites	O
,	O
preferably	O
Petasites	O
hybridus	O
,	O
by	O
the	O
addition	O
of	O
at	O
least	O
one	O
suitable	O
stabilizer	O
and/or	O
the	O
removal	O
of	O
at	O
least	O
one	O
destabilizing	O
substance	O
,	O
e.g.	O
a	O
fatty	B
acid	I
.	O

Stabilization	O
of	O
the	O
composition	O
of	O
a	O
mixture	O

The	O
application	O
is	O
directed	O
to	O
a	O
composition	O
and	O
its	O
use	O
for	O
treating	O
inflammation	O
comprising	O
a	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
active	O
agent	O
,	O
a	O
metasilicate	O
,	O
a	O
first	O
disintegrant	O
and	O
a	O
second	O
disintegrant	O
,	O
resulting	O
in	O
increased	O
absorption	O
of	O
said	O
active	O
in	O
mammals	O
with	O
suppressed	O
vagal	O
systems	O
The	O
preferred	O
composition	O
includes	O
a	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
active	O
,	O
sodium	B
bicarbonate	I
,	O
tartaric	B
acid	I
and	O
metasilicate	B
.	O

Enhanced	O
nsaid	O
formulations	O

Provided	O
are	O
a	O
tetracyclic	B
compound	O
represented	O
by	O
the	O
formula	O
(	O
I	O
)	O
:	O
[	O
in	O
the	O
formula	O
(	O
I	O
)	O
,the	O
formula	O
(	O
A	O
)	O
represents	O
a	O
benzene	B
ring	O
or	O
the	O
like	O
,	O
X	O
represents	O
CH	B
or	O
a	O
nitrogen	B
atom	O
,	O
Q	O
represents	O
-O-	B
or	O
the	O
like	O
,	O
R1	O
,	O
R2	O
,	O
and	O
R3	O
may	O
be	O
the	O
same	O
or	O
different	O
and	O
each	O
represent	O
a	O
hydrogen	B
atom	O
or	O
the	O
like	O
,	O
1	O
,	O
m	O
,	O
and	O
n	O
each	O
represent	O
an	O
integer	O
from	O
one	O
to	O
the	O
maximum	O
substitutable	O
number	O
of	O
substituents	O
,	O
and	O
R4	O
and	O
R5	O
may	O
be	O
the	O
same	O
or	O
different	O
and	O
each	O
represent	O
a	O
hydrogen	B
atom	O
or	O
the	O
like	O
]	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
and	O
the	O
like	O
.	O

Tetracyclic	B
compound	O

Cosmetic	O
composition	O
for	O
sensitive	O
skins	O
comprising	O
hyperoxygenated	O
fatty	O
acids	O
and	O
one	O
or	O
more	O
volatile	O
silicones	O
,	O
together	O
with	O
the	O
use	O
thereof	O
for	O
the	O
prevention	O
of	O
ulcers	O
and	O
the	O
preservation	O
of	O
perilesional	O
skin	O
.	O

Cosmetic	O
composition	O
for	O
sensitive	O
skins	O

The	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
combination	O
which	O
comprises	O
(	O
a	O
)	O
a	O
phosphoinositide	O
3-kinase	O
inhibitor	O
compound	O
of	O
formula	O
(	O
I	O
)	O
and	O
(	O
b	O
)	O
a	O
mTOR	O
inhibitor	O
for	O
the	O
treatment	O
of	O
a	O
target	O
of	O
raparnycin	B
(	O
mTOR	O
)	O
kinase	O
dependent	O
disease	O
,	O
especially	O
a	O
cancer	O
disease	O
;	O
a	O
pharmaceutical	O
composition	O
comprising	O
such	O
a	O
combination	O
;	O
the	O
use	O
of	O
such	O
a	O
combination	O
for	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
a	O
proliferative	O
disease	O
;	O
a	O
commercial	O
package	O
or	O
product	O
comprising	O
such	O
a	O
combination	O
as	O
a	O
combined	O
preparation	O
for	O
simultaneous	O
,	O
separate	O
or	O
sequential	O
use	O
;	O
and	O
to	O
a	O
method	O
of	O
treatment	O
of	O
a	O
warm	O
blooded	O
animal	O
,	O
especially	O
a	O
human	O
.	O

Combination	O
of	O
a	O
phosphatidylinositol-3-kinase	O
(	O
pi3k	O
)	O
inhibitor	O
and	O
a	O
mtor	O
inhibitor	O

The	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
in	O
which	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5,D	O
,	O
Z	O
,	O
X	O
,	O
Y	O
,	O
m	O
and	O
p	O
are	O
defined	O
as	O
cited	O
in	O
claim	O
1	O
.	O

Said	O
compounds	O
can	O
be	O
used	O
in	O
the	O
treatment	O
of	O
tumours	O
.	O

Benzonaphtyridine	B
compounds	O
used	O
as	O
inhibitors	O
of	O
autotaxin	O

A	O
topical	O
composition	O
which	O
is	O
suitable	O
for	O
treating	O
or	O
preventing	O
skin	O
or	O
mucosal	O
infectious	O
disorders	O
or	O
troubles	O
in	O
humans	O
,	O
in	O
particular	O
for	O
treating	O
or	O
preventing	O
urinary	O
tract	O
infections	O
and	O
lower	O
vaginal	O
tract	O
infections	O
in	O
females	O
comprises	O
an	O
oily	O
primary	O
phase	O
and	O
a	O
complementary	O
aqueous	O
phase	O
wherein	O
the	O
oily	O
primary	O
phase	O
consists	O
of	O
a	O
non	O
polar	O
mineral	O
or	O
silicone	B
comprising	O
an	O
efficient	O
amount	O
of	O
at	O
least	O
one	O
viable	O
probiotic	O
bacteria	O
strain	O
,	O
in	O
particular	O
a	O
lactobacillus	O
strain	O
.	O

The	O
composition	O
is	O
also	O
useful	O
for	O
suitable	O
for	O
balancing	O
or	O
restoring	O
skin	O
or	O
mucosal	O
indigenous	O
microflora	O
in	O
humans	O
,	O
in	O
particular	O
for	O
balancing	O
or	O
restoring	O
the	O
local	O
urinary	O
tract	O
and	O
lower	O
vaginal	O
tract	O
bacterial	O
flora	O
in	O
females	O
.	O

Topical	O
cosmetic	O
or	O
pharmaceutical	O
composition	O
comprising	O
probiotic	O
lactobacillus	O
strains	O
and	O
use	O
of	O
same	O

The	O
present	O
invention	O
provides	O
pyrazole	B
derived	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
useful	O
for	O
treating	O
p38	O
kinase	O
-	O
associated	O
conditions	O
,	O
where	O
W	O
,	O
X	O
,	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
R6	O
and	O
m	O
are	O
as	O
defined	O
herein	O
.	O

The	O
invention	O
further	O
pertains	O
to	O
pharmaceutical	O
compositions	O
containing	O
at	O
least	O
one	O
compound	O
according	O
to	O
the	O
invention	O
useful	O
for	O
treating	O
p38	O
kinase	O
-	O
associated	O
conditions	O
,	O
and	O
methods	O
of	O
inhibiting	O
the	O
activity	O
of	O
p38	O
kinase	O
in	O
a	O
mammal	O
.	O

Pyrazole	B
-	I
amine	I
compounds	O
useful	O
as	O
kinase	O
inhibitors	O

The	O
present	O
invention	O
is	O
directed	O
to	O
compounds	O
,	O
intermediates	O
and	O
methods	O
for	O
making	O
valerenic	B
acid	I
and	O
its	O
derivatives	O
as	O
well	O
as	O
the	O
use	O
of	O
such	O
compounds	O
as	O
GABAA	B
receptor	O
ligands	O
.	O

Methods	O
for	O
making	O
valerenic	B
acid	I
derivatives	O
and	O
their	O
use	O

New	O
pyridazin-3	B
(	I
2H	I
)	I
-one	I
derivatives	O
having	O
the	O
chemical	O
structure	O
of	O
formula	O
(	O
I	O
)	O
are	O
disclosed	O
;	O
as	O
well	O
as	O
process	O
for	O
their	O
preparation	O
,	O
pharmaceutical	O
compositions	O
comprising	O
them	O
and	O
their	O
use	O
in	O
therapy	O
as	O
inhibitors	O
of	O
the	O
phosphodiesterase	O
IV	O
(	O
PDE4	O
)	O
.	O

3-	B
(	I
5-Amino-6-oxo-1,6-dihydropyridazin-3-yl	I
)	I
-biphenyl	I
derivatives	O
as	O
PDE4	O
inhibitors	O

The	O
present	O
disclosure	O
in	O
a	O
broad	O
aspect	O
provides	O
for	O
diazeniumdiolated	O
phosphorylcholine	B
polymers	O
and	O
associated	O
methods	O
for	O
achieving	O
nitric	B
oxide	I
release	O
.	O

The	O
present	O
polymers	O
have	O
superior	O
biocompatibility	O
and	O
are	O
useful	O
for	O
coating	O
or	O
fabricating	O
medical	O
devices	O
such	O
as	O
a	O
vascular	O
stent	O
.	O

Diazeniumdiolated	O
phosphorylcholine	B
polymers	O
for	O
nitric	O
oxide	O
release	O

The	O
present	O
invention	O
provides	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
wherein	O
A	O
is	O
hydrogen	B
,	O
C1	B
-	I
4alkyl	I
,	O
C3	B
-	I
6cycloalkyl	I
,	O
C1	B
-	I
3alkoxy	I
,	O
C1	B
-	I
3alkoxy	I
C1	B
-	I
4alkyl	I
,	O
C1	B
-	I
2fluoroalkyl	I
,	O
halogen	B
,	O
NR6	B
R7	I
,	O
optionally	O
substituted	O
heteroaryl	B
(	O
Het	B
)	O
,	O
or	O
optionally	O
substituted	O
phenyl	B
,	O
and	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
R6	O
and	O
R7	O
are	O
as	O
defined	O
in	O
the	O
description	O
.	O

The	O
compounds	O
or	O
salts	O
are	O
thought	O
to	O
modulate	O
P2X7	O
receptor	O
function	O
and	O
to	O
be	O
capable	O
of	O
antagonizing	O
the	O
effects	O
of	O
ATP	B
at	O
the	O
P2X7	O
receptor	O
.	O

The	O
invention	O
also	O
provides	O
the	O
use	O
of	O
the	O
compound	O
or	O
salt	O
in	O
the	O
treatment	O
or	O
prophylaxis	O
of	O
,	O
for	O
example	O
,	O
inflammatory	O
pain	O
,	O
neuropathic	O
pain	O
,	O
visceral	O
pain	O
,	O
rheumatoid	O
arthritis	O
,	O
osteoarthritis	O
or	O
neurodegenerative	O
disorders	O
.	O

5,6,7,8-TETRAHYDRO	B
[	I
1,2,4	I
]	I
TRIAZOLO	I
[	I
4,3-a	I
]	I
PYRAZINE	I
DERIVATIVES	O
AS	O
P2X7	O
MODULATORS	O

We	O
describe	O
methods	O
and	O
compositions	O
for	O
treating	O
ophthalmic	O
conditions	O
associated	O
with	O
angiogenesis	O
,	O
vascular	O
leakage	O
,	O
and/or	O
damage	O
to	O
ganglia	O
.	O

Methods	O
and	O
compositions	O
for	O
treating	O
ophthalmic	O
conditions	O

The	O
present	O
invention	O
is	O
directed	O
to	O
a	O
method	O
of	O
treating	O
a	O
metabolic	O
disorder	O
or	O
key	O
elements	O
of	O
a	O
metabolic	O
disorder	O
such	O
method	O
comprising	O
the	O
use	O
of	O
an	O
agent	O
(	O
s	O
)	O
that	O
increases	O
central	O
dopaminergic	O
activity	O
plus	O
a	O
first	O
-	O
phase	O
insulin	O
secretagouge	O
.	O

Combination	O
of	O
dopamine	B
agonists	O
plus	O
first	O
phase	O
insulin	O
secretagouges	O
for	O
the	O
treatment	O
of	O
metabolic	O
disorders	O

The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
or	O
pharmaceutical	O
acceptable	O
salts	O
:	O
wherein	O
A1	O
,	O
A2	O
,	O
A3	O
,	O
A4	O
,	O
X	O
and	O
Y	O
are	O
defined	O
in	O
the	O
description	O
.	O

The	O
present	O
invention	O
relates	O
also	O
to	O
methods	O
of	O
making	O
said	O
compounds	O
,	O
and	O
compositions	O
containing	O
said	O
compounds	O
which	O
are	O
useful	O
for	O
inhibiting	O
kinases	O
such	O
as	O
aurora	O
and	O
KDR	O
.	O

2-	B
(	I
lh	I
-	I
pyrazol-4	I
-ylamino	I
)	I
-pyrimidine	I
as	O
kinase	O
inhibitors	O

The	O
objective	O
is	O
to	O
find	O
compounds	O
which	O
have	O
an	O
activity	O
to	O
improve	O
the	O
success	O
rate	O
of	O
pregnancy	O
and	O
implantation	O
in	O
blastocyst	O
transfer	O
in	O
mammals	O
,	O
to	O
provide	O
a	O
method	O
of	O
producing	O
and	O
using	O
the	O
compounds	O
,	O
and	O
to	O
provide	O
a	O
pregnancy	O
-	O
promoting	O
agent	O
.	O

Disclosed	O
is	O
a	O
pregnancy	O
-	O
promoting	O
agent	O
containing	O
one	O
or	O
more	O
lysophosphatidic	B
acids	I
selected	O
from	O
the	O
group	O
consisting	O
of	O
LPA	B
-	I
C16:0	I
,	O
LPA	B
-	I
C16:1	I
,	O
LPA	B
-	I
C18:0	I
,	O
LPA	B
-	I
C18:1	I
and	O
LPA	B
-	I
C18:2	I
.	O

The	O
use	O
of	O
lpa	B
for	O
encouraging	O
pregnancy	O
,	O
and	O
fertility	O
agent	O

The	O
present	O
invention	O
relates	O
to	O
medical	O
use	O
of	O
liposomes	O
,	O
more	O
particular	O
the	O
first	O
medical	O
use	O
of	O
sPLA2	O
hydrolysable	O
liposomes	O
.	O

Such	O
liposomes	O
may	O
be	O
used	O
for	O
targeted	O
delivery	O
of	O
therapeutic	O
agents	O
to	O
cancerous	O
tissue	O
and	O
in	O
such	O
embodiments	O
;	O
the	O
therapeutic	O
agents	O
are	O
typically	O
small	O
molecule	O
antitumor	O
agents	O
.	O

Other	O
aspects	O
of	O
the	O
inventions	O
relates	O
to	O
methods	O
of	O
reducing	O
the	O
side	O
effects	O
of	O
therapeutic	O
agents	O
,	O
e.g.	O
reducing	O
nephrotoxicity	O
,	O
neurotoxicity	O
and	O
gastrointestinal	O
toxicity	O
of	O
a	O
therapeutic	O
agent	O
.	O

Yet	O
another	O
aspect	O
of	O
the	O
present	O
invention	O
relate	O
to	O
methods	O
of	O
prolonging	O
the	O
therapeutic	O
effect	O
of	O
a	O
therapeutic	O
agent	O
.	O

Medical	O
use	O
of	O
spla2	O
hydrolysable	O
liposomes	O

The	O
present	O
invention	O
relates	O
to	O
a	O
solid	O
pharmaceutical	O
composition	O
for	O
oral	O
administration	O
,	O
containing	O
the	O
following	O
components	O
(	O
A	O
)	O
and	O
(	O
B	O
)	O
:	O
(	O
A	O
)	O
2-	B
[	I
4-	I
[	I
2-	I
(	I
benzimidazol-2-ylthio	I
)	I
ethyl	I
]	I
piperazin-1-yl	I
]	I
-N-	I
[	I
2,4	I
-bis	I
(	I
methylthio	I
)	I
-6-methyl-3-pyridyl	I
]	I
acetamide	I
(	O
compound	O
a	O
)	O
or	O
an	O
acid	O
addition	O
salt	O
thereof	O
,	O
and	O
(	O
B	O
)	O
organic	O
acid	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
tartaric	B
acid	I
,	O
malic	B
acid	I
,	O
ascorbic	B
acid	I
and	O
benzoic	B
acid	I
.	O

An	O
improvement	O
is	O
achieved	O
in	O
the	O
dissolubility	O
of	O
the	O
compound	O
a	O
,	O
which	O
is	O
useful	O
as	O
a	O
therapeutic	O
agent	O
for	O
hypercholesterolemia	O
,	O
arteriosclerosis	O
,	O
and	O
the	O
like	O
.	O

Solid	O
pharmaceutical	O
composition	O
for	O
oral	O
administration	O

The	O
present	O
invention	O
provides	O
methods	O
and	O
compounds	O
for	O
treating	O
viral	O
infections	O
using	O
modulators	O
of	O
host	O
cell	O
enzymes	O
relating	O
to	O
long	B
chain	I
fatty	I
acid	I
and	O
lipid	O
droplet	O
metabolism	O
.	O

It	O
includes	O
a	O
method	O
of	O
treating	O
viral	O
infections	O
using	O
triacsin	B
C	I
and	O
its	O
relatives	O
,	O
analogues	O
and	O
derivatives	O
as	O
well	O
as	O
other	O
inhibitors	O
of	O
long	B
chain	I
fatty	I
acid	I
metabolism	O
and	O
lipid	O
droplet	O
metabolism	O
.	O

Inhibitors	O
of	O
long	O
and	O
very	O
long	B
chain	I
fatty	I
acid	I
metabolism	O
as	O
broad	O
spectrum	O
anti	O
-	O
virals	O

A	O
composition	O
comprising	O
an	O
inhibitor	O
of	O
glucose	B
metabolism	O
for	O
use	O
in	O
the	O
treatment	O
of	O
Birt	O
-	O
Hogg	O
-	O
Dub	O
syndrome	O
.	O

The	O
inhibitor	O
of	O
glucose	B
metabolism	O
may	O
be	O
a	O
glycolytic	O
inhibitor	O
.	O

The	O
inhibitor	O
of	O
glucose	B
metabolism	O
may	O
be	O
an	O
inhibitor	O
of	O
pyruvate	B
metabolism	O
.	O

Suitable	O
inhibitors	O
of	O
glucose	B
metabolism	O
include	O
2-deoxy	O
-	O
D-	B
glucose	I
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
solvate	O
thereof	O
or	O
oxamate	B
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
solvate	O
thereof	O
.	O

Inhibitors	O
of	O
glucose	B
metabolism	O
for	O
use	O
in	O
the	O
treatment	O
of	O
birt	O
-	O
hogg	O
-	O
dub	O
syndrome	O

The	O
present	O
invention	O
relates	O
generally	O
to	O
benign	O
gynecological	O
diseases	O
and	O
in	O
particular	O
to	O
a	O
method	O
for	O
reducing	O
heavy	O
menstruation	O
associated	O
with	O
said	O
gynecological	O
diseases	O
following	O
treatment	O
with	O
vascular	O
occlusion	O
methods	O
or	O
thermal	O
related	O
treatment	O
methods	O
.	O

Treatment	O
of	O
excessive	O
menstrual	O
bleeding	O
associated	O
with	O
uterine	O
fibroids	O

The	O
present	O
invention	O
provides	O
a	O
pharmaceutical	O
composition	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
a	O
non	O
-	O
alcoholic	O
fatty	O
liver	O
disease	O
(	O
NAFLD	O
)	O
,	O
containing	O
an	O
active	O
ingredient	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
Compound	O
1	O
represented	O
by	O
formula	O
1	O
,	O
sitagliptin	B
,	O
vildagliptin	B
,	O
linagliptin	B
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O

Further	O
,	O
the	O
present	O
invention	O
provides	O
a	O
method	O
for	O
the	O
prevention	O
or	O
treatment	O
of	O
a	O
non	O
-	O
alcoholic	O
fatty	O
liver	O
disease	O
,	O
including	O
administering	O
an	O
effective	O
amount	O
of	O
an	O
active	O
ingredient	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
Compound	O
1	O
represented	O
by	O
formula	O
1	O
,	O
sitagliptin	B
,	O
vildagliptin	B
,	O
linagliptin	B
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
to	O
a	O
mammal	O
including	O
a	O
human	O
in	O
need	O
thereof	O
.	O

Further	O
,	O
the	O
present	O
invention	O
provides	O
use	O
of	O
Compound	O
1	O
represented	O
by	O
formula	O
1	O
,	O
sitagliptin	B
,	O
vildagliptin	B
,	O
linagliptin	B
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
for	O
manufacturing	O
a	O
pharmaceutical	O
composition	O
for	O
the	O
prevention	O
or	O
treatment	O
of	O
a	O
non	O
-	O
alcoholic	O
fatty	O
liver	O
disease	O
.	O

Pharmaceutical	O
composition	O
for	O
the	O
prevention	O
or	O
the	O
treatment	O
of	O
non	O
-	O
alcoholic	O
fatty	O
liver	O
disease	O
and	O
the	O
method	O
for	O
prevention	O
or	O
treatment	O
of	O
non	O
-	O
alcoholic	O
fatty	O
liver	O
disease	O
using	O
the	O
same	O

Provided	O
are	O
therapeutic	O
and/or	O
preventive	O
agents	O
for	O
migraine	O
which	O
comprise	O
,	O
as	O
an	O
active	O
ingredient	O
,	O
a	O
compound	O
having	O
a	O
selective	O
adenosine	O
A2A	O
receptor	O
antagonistic	O
activity	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
;	O
therapeutic	O
and/or	O
preventive	O
agents	O
for	O
migraine	O
which	O
comprises	O
,	O
as	O
an	O
active	O
ingredient	O
,	O
a	O
compound	O
having	O
a	O
selective	O
adenosine	B
A2A	O
receptor	O
antagonistic	O
activity	O
,	O
which	O
has	O
an	O
affinity	O
for	O
the	O
adenosine	B
A2A	O
receptor	O
10	O
times	O
or	O
higher	O
than	O
that	O
for	O
the	O
adenosine	B
A1	O
receptor	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
;	O
and	O
the	O
like	O
.	O

Therapeutic	O
Agent	O
for	O
Migraine	O

A	O
process	O
of	O
preparing	O
articles	O
having	O
gaseous	O
NO	B
sequestered	O
therein	O
is	O
disclosed	O
,	O
as	O
well	O
as	O
articles	O
prepared	O
thereby	O
.	O

Also	O
disclosed	O
are	O
articles	O
having	O
gaseous	O
NO	B
sequestered	O
therewithin	O
and	O
having	O
reduced	O
amount	O
of	O
oxygen	B
-	O
containing	O
and/or	O
nitrogen	B
-	O
containing	O
reactive	O
species	O
.	O

Also	O
disclosed	O
are	O
processes	O
of	O
preparing	O
packaged	O
articles	O
having	O
a	O
non	O
-	O
gas	O
permeable	O
package	O
that	O
comprises	O
gaseous	O
NO	B
therein	O
and	O
packaged	O
articles	O
made	O
therefrom	O
.	O

Also	O
disclosed	O
are	O
charging	O
devices	O
which	O
can	O
be	O
utilized	O
in	O
the	O
above	O
-	O
described	O
processes	O
.	O

The	O
articles	O
prepared	O
by	O
the	O
above	O
-	O
described	O
processes	O
are	O
preferably	O
medical	O
devices	O
such	O
as	O
indwelling	O
catheters	O
,	O
intubation	O
devices	O
and	O
tampons	O
.	O

Tampons	O
having	O
sequestered	O
therein	O
gaseous	O
NO	B
,	O
uses	O
thereof	O
and	O
processes	O
of	O
preparing	O
same	O
are	O
also	O
disclosed	O
.	O

Gaseous	O
nitric	B
oxide	I
-	O
sequestering	O
products	O
and	O
processes	O
of	O
preparing	O
same	O

Pharmaceutical	O
composition	O
comprises	O
enoximone	B
,	O
which	O
is	O
administered	O
intravenously	O
in	O
an	O
amount	O
of	O
not	O
>	O
300	O
mg	O
per	O
day	O
,	O
preferably	O
200	O
mg	O
per	O
day	O
.	O

An	O
independent	O
claim	O
is	O
also	O
included	O
for	O
a	O
kit	O
comprising	O
the	O
pharmaceutical	O
composition	O
and	O
a	O
drug	O
including	O
beta	O
-2	O
sympathomimetic	O
agent	O
,	O
catecholamines	B
,	O
aminophylline	B
,	O
corticosteroids	B
,	O
parasympatholytic	O
agent	O
,	O
magnesium	B
sulfate	I
,	O
ketamine	B
and/or	O
S	B
-	I
ketamine	I
for	O
treating	O
status	O
asthmaticus	O
.	O

ACTIVITY	O
:	O
Antiasthmatic	O
.	O

Test	O
details	O
are	O
described	O
but	O
no	O
results	O
given	O
.	O

MECHANISM	O
OF	O
ACTION	O
:	O
None	O
given	O
.	O

Pharmaceutical	O
compound	O
for	O
treating	O
status	O
asthmaticus	O

Compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
wherein	O
R2a	O
and	O
R2b	O
are	O
independently	O
H	B
,	O
halo	B
,	O
C1-C4alkyl	B
,	O
C1-C4haloalkyl	B
or	O
C1-C4alkoxy	B
,	O
or	O
R2a	O
and	O
R2b	O
together	O
with	O
the	O
carbon	B
atom	O
to	O
which	O
they	O
are	O
attached	O
form	O
a	O
C3-C6cycloalkyl	B
;	O
R3	O
is	O
a	O
C5-C10	B
alkyl	I
,	O
optionally	O
substituted	O
with	O
1	O
-	O
3	O
substituents	O
independently	O
selected	O
from	O
halo	B
,	O
C1-C4haloalkyl	B
,	O
C1-C4alkoxy	B
,	O
C1-C4haloalkoxy	B
;	O
or	O
R3	O
is	O
a	O
C2-C4alkyl	B
chain	O
with	O
at	O
least	O
2	O
chloro	B
or	O
3	O
fluoro	B
substituents	O
;	O
or	O
R3	O
is	O
C3-C7cycloalkylmethyl	B
,	O
optionally	O
substituted	O
with	O
1	O
-	O
3	O
substituents	O
independently	O
selected	O
from	O
C1-C4alkyl	B
,	O
halo	B
,	O
C1-C4haloalkyl	B
,	O
C1-C4alkoxy	B
,	O
C1-C4haloalkoxy	B
;	O
R4	O
is	O
C1-C6alkyl	B
,	O
C1-C6haloalkyl	B
,	O
C1-C6alkoxy	B
,	O
C1-C6haloalkoxy	B
,	O
C1-C6alkylamino	B
,	O
C1-	B
C6dialkylamino	I
or	O
;	O
R4	O
is	O
Het	B
or	O
Carbocyclyl	B
,	O
either	O
of	O
which	O
is	O
optionally	O
substituted	O
with	O
1	O
-	O
3	O
substituents	O
;	O
n	O
is	O
1	O
,	O
2	O
or	O
3	O
;	O
for	O
the	O
use	O
in	O
the	O
prophylaxis	O
or	O
treatment	O
of	O
a	O
disorder	O
characterised	O
by	O
inappropriate	O
expression	O
or	O
activation	O
of	O
cathepsin	O
S.	O
New	O
cathepsin	O
s	O
protease	O
inhibitors	O
,	O
useful	O
in	O
the	O
treatment	O
of	O
e.g.	O
autoimmune	O
disorders	O
,	O
allergy	O
and	O
chronic	O
pain	O
conditions	O

The	O
present	O
invention	O
is	O
directed	O
to	O
methods	O
for	O
treating	O
or	O
ameliorating	O
skin	O
conditions	O
,	O
diabetic	O
conditions	O
,	O
cardiovascular	O
conditions	O
,	O
cancer	O
,	O
infections	O
or	O
metal	O
poisoning	O
,	O
enhancing	O
performance	O
,	O
or	O
providing	O
nutritional	O
support	O
,	O
comprising	O
administering	O
to	O
a	O
subject	O
in	O
need	O
thereof	O
compositions	O
comprising	O
a	O
magnetic	O
dipole	O
stabilized	O
solution	O
(	O
MDSS	O
)	O
.	O

The	O
MDSS	O
solution	O
may	O
include	O
additional	O
components	O
and	O
can	O
be	O
provided	O
in	O
a	O
kit	O
.	O

Methods	O
of	O
treating	O
or	O
ameliorating	O
diseases	O
and	O
enhancing	O
performance	O
comprising	O
the	O
use	O
of	O
a	O
magnetic	O
dipole	O
stabilized	O
solution	O

A	O
stable	O
solid	O
dosage	O
form	O
comprising	O
a	O
non	O
-	O
toxic	O
base	O
and	O
an	O
amorphous	O
benzimidazole	B
compound	O
having	O
a	O
proton	O
pump	O
inhibitor	O
(	O
PPI	O
)	O
activity	O
.	O

Stable	O
solid	O
preparations	O

[	O
Problem	O
]	O
A	O
novel	O
and	O
excellent	O
compound	O
which	O
is	O
useful	O
as	O
an	O
agent	O
for	O
preventing	O
and/or	O
treating	O
rejection	O
reactions	O
in	O
various	O
organ	O
transplantations	O
,	O
allergy	O
diseases	O
,	O
autoimmune	O
diseases	O
,	O
and	O
hematologic	O
tumor	O
,	O
and	O
based	O
on	O
a	O
PI3K	O
selective	O
inhibitory	O
action	O
and/or	O
an	O
IL-2	O
production	O
inhibitory	O
action	O
and/or	O
a	O
B	O
cell	O
proliferation	O
inhibitory	O
action	O
(	O
including	O
an	O
activation	O
inhibitory	O
action	O
)	O
.	O

[	O
Means	O
for	O
Solution	O
]	O

The	O
present	O
inventors	O
have	O
investigated	O
a	O
compound	O
having	O
a	O
PI3K	O
selective	O
inhibitory	O
action	O
and/or	O
an	O
IL-2	O
production	O
inhibitory	O
action	O
and/or	O
a	O
B	O
cell	O
proliferation	O
inhibitory	O
action	O
(	O
including	O
an	O
activation	O
inhibitory	O
action	O
)	O
,	O
and	O
have	O
found	O
that	O
the	O
heterocyclic	B
compound	O
of	O
the	O
present	O
invention	O
has	O
a	O
PI3K	O
selective	O
inhibitory	O
action	O
and/or	O
and	O
IL-2	O
production	O
inhibitory	O
action	O
and/or	O
a	O
B	O
cell	O
proliferation	O
inhibitory	O
action	O
(	O
including	O
an	O
activation	O
inhibitory	O
action	O
)	O
,	O
thereby	O
completing	O
the	O
present	O
invention	O
.	O

Hetero	B
ring	O
compound	O

This	O
invention	O
relates	O
to	O
substituted	O
thiazoles	O
of	O
formula	O
I	O
:	O
wherein	O
:	O
L	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
-NHC	O
(	O
X	O
)	O
-	O
,	O
-C	O
(	O
X	O
)	O
NH-	O
,	O
-NHC	O
(	O
X	O
)	O
NH-	O
,	O
-C	O
(	O
X	O
)	O
-	O
,	O
-C	O
(	O
X	O
)	O
NH	O
-	O
alkylene-	O
and	O
-NHC	O
(	O
X	O
)	O
-alkylene-	O
,	O
where	O
X	O
is	O
oxygen	O
or	O
sulfur	O
;	O
and	O
Q	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
alkyl	O
,	O
substituted	O
alkyl	O
,	O
aryl	O
,	O
substituted	O
aryl	O
,	O
heteroaryl	O
,	O
substituted	O
heteroaryl	O
,	O
cycloalkyl	O
,	O
substituted	O
cycloalkyl	O
,	O
heterocyclic	O
and	O
substituted	O
heterocyclic	O
,	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
,	O
and	O
their	O
use	O
as	O
VEGFR2	O
(	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
2	O
)	O
kinase	O
inhibitors	O
and	O
in	O
the	O
treatment	O
of	O
diseases	O
capable	O
of	O
treatment	O
by	O
a	O
VEGFR2	O
kinase	O
inhibitor	O
,	O
particularly	O
cancer	O
.	O

Substituted	O
Thiazoles	O
as	O
VEGFR2	O
kinase	O
Inhibitors	O

This	O
invention	O
is	O
related	O
to	O
the	O
alkyl	B
-	I
piperazine	I
-	I
phenyl	I
4	I
(	I
3H	I
)	I
-quinazolinones	I
general	O
formula	O
(	O
I	O
)	O
compounds	O
,	O
pharmacologicaly	O
active	O
and	O
able	O
to	O
act	O
on	O
the	O
5-HT1A	O
and	O
5-HT2A	O
serotonin	O
receptors	O
in	O
a	O
manner	O
that	O
promotes	O
the	O
control	O
,	O
relief	O
or	O
cure	O
of	O
disorders	O
associated	O
with	O
these	O
receptors	O
,	O
and	O
pharmaceutical	O
compositions	O
containing	O
the	O
compounds	O
for	O
the	O
treatment	O
of	O
disorders	O
associated	O
with	O
these	O
receptors	O
.	O

These	O
compounds	O
and	O
their	O
pharmaceutical	O
compositions	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
conditions	O
such	O
as	O
depression	O
,	O
anxiety	O
,	O
phobias	O
,	O
addictions	O
,	O
aggressiveness	O
,	O
impulsiveness	O
,	O
panic	O
,	O
psychotic	O
,	O
eating	O
and	O
sleep	O
disorders	O
,	O
obsessive	O
-	O
compulsive	O
disorder	O
and	O
female	O
sexual	O
dysfunctions	O
,	O
among	O
other	O
disorders	O
associated	O
with	O
these	O
receptors	O
.	O

Compounds	O
and	O
pharmaceutical	O
compositions	O
for	O
treating	O
disorders	O
associated	O
with	O
the	O
5-ht1a	O
and	O
5-ht2a	O
receptors	O

The	O
present	O
invention	O
relates	O
to	O
a	O
pyrazole	B
amide	I
derivative	O
,	O
pharmaceutical	O
compositions	O
containing	O
this	O
compound	O
and	O
to	O
its	O
use	O
in	O
therapy	O
.	O

Pyrazole	B
compounds	O
acting	O
against	O
allergic	O
,	O
immune	O
and	O
inflammatory	O
conditions	O

Use	O
of	O
nitric	B
oxide	I
amino	I
acid	I
esters	I
for	O
improving	O
vascular	O
circulation	O
,	O
and	O
prophylaxis	O
or	O
treatment	O
of	O
a	O
condition	O
associated	O
with	O
impaired	O
blood	O
circulation	O
,	O
such	O
as	O
peripheral	O
vascular	O
disease	O
.	O

The	O
nitric	B
oxide	I
amino	I
acid	I
esters	I
may	O
be	O
co	O
-	O
administered	O
with	O
an	O
antimicrobial	O
in	O
topical	O
or	O
transdermal	O
compositions	O
for	O
improving	O
vascular	O
circulation	O
,	O
and	O
prophylaxis	O
or	O
treatment	O
of	O
a	O
condition	O
associated	O
with	O
impaired	O
blood	O
circulation	O
.	O

Nitric	B
oxide	I
amino	I
acid	I
esters	I
for	O
improving	O
vascular	O
circulation	O
,	O
and	O
prophylaxis	O
or	O
treatment	O
of	O
a	O
condition	O
associated	O
with	O
impaired	O
blood	O
circulation	O

This	O
invention	O
relates	O
to	O
bicyclic	O
ring	O
system	O
substituted	O
amide	B
functionalized	O
phenols	B
of	O
general	O
formula	O
1	O
,	O
their	O
use	O
as	O
inhibitors	O
of	O
CXCR2	O
activity	O
,	O
pharmaceutical	O
compositions	O
containing	O
the	O
same	O
,	O
and	O
methods	O
of	O
using	O
the	O
same	O
as	O
agents	O
for	O
treatment	O
and/or	O
prevention	O
of	O
respiratory	O
or	O
gastrointestinal	O
complaints	O
or	O
diseases	O
,	O
inflammatory	O
diseases	O
of	O
the	O
joints	O
,	O
skin	O
,	O
or	O
eyes	O
,	O
diseases	O
of	O
the	O
peripheral	O
or	O
central	O
nervous	O
system	O
or	O
cancers	O
,	O
as	O
well	O
as	O
pharmaceutical	O
compositions	O
which	O
contain	O
these	O
compounds	O
.	O

Bicyclic	O
ring	O
system	O
substituted	O
amide	O
functionalised	O
phenols	B
as	O
medicaments	O

A	O
topical	O
composition	O
for	O
the	O
treatment	O
of	O
skin	O
conditions	O
.	O

The	O
composition	O
comprises	O
an	O
antifungal	O
agent	O
,	O
an	O
anti	O
-	O
inflammatory	O
agent	O
and	O
an	O
antimicrobial	O
agent	O
together	O
with	O
a	O
pharmaceutically	O
acceptable	O
excipient	O
.	O

The	O
anti	O
-	O
inflammatory	O
is	O
present	O
at	O
a	O
concentration	O
of	O
less	O
than	O
0.01%wt	O
of	O
the	O
composition	O
and	O
the	O
antimicrobial	O
agent	O
has	O
the	O
general	O
formula	O
(	O
I	O
)	O
:	O
(	O
Formula	O
(	O
I	O
)	O
)	O
.	O

Composition	O
for	O
the	O
treatment	O
of	O
skin	O
conditions	O

Disclosed	O
herein	O
are	O
new	O
heterocyclic	B
compounds	O
and	O
compositions	O
and	O
their	O
application	O
as	O
pharmaceuticals	O
for	O
the	O
treatment	O
of	O
disease	O
.	O

Methods	O
of	O
inhibiting	O
PAS	O
Kinase	O
(	O
PASK	O
)	O
activity	O
in	O
a	O
human	O
or	O
animal	O
subject	O
are	O
also	O
provided	O
for	O
the	O
treatment	O
of	O
diseases	O
such	O
as	O
diabetes	O
mellitus	O
.	O

Heterocyclic	B
compounds	O
for	O
the	O
inhibition	O
of	O
pask	O

The	O
present	O
disclosure	O
provides	O
a	O
series	O
of	O
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
which	O
modulate	O
&	O
bgr	O
;-	O
amyloid	O
peptide	O
(	O
&	O
bgr	O
;-	O
AP	O
)	O
production	O
and	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
Alzheimer	O
's	O
Disease	O
and	O
other	O
conditions	O
affected	O
by	O
&	O
bgr	O
;-	O
amyloid	O
peptide	O
(	O
&	O
bgr	O
;-	O
AP	O
)	O
production	O
.	O

COMPOUNDS	O
FOR	O
THE	O
REDUCTION	O
OF	O
	O
-	O
AMYLOID	O
PRODUCTION	O

The	O
present	O
embodiments	O
provide	O
for	O
compositions	O
and	O
methods	O
that	O
regulate	O
microRNA	O
-	O
binding	O
protein	O
-	O
mediated	O
miRNA	O
biogenesis	O
;	O
for	O
example	O
Lin28-mediated	O
biogenesis	O
of	O
let-7	O
;	O
and	O
in	O
particular	O
Lin28A	O
-	O
recruited	O
3	O
'	O
terminal	O
uridylyl	O
transferase	O
(	O
TUTase	O
)	O
uridylation	O
of	O
pre	O
-	O
let-7	O
.	O

A	O
particular	O
embodiment	O
provides	O
compositions	O
and	O
methods	O
for	O
screening	O
for	O
agents	O
that	O
inhibit	O
TUTase	O
-	O
dependent	O
Lin28A	O
-	O
mediated	O
repression	O
of	O
let-7	O
miRNA	O
.	O

Lin28-mediated	O
control	O
of	O
let-7	O
biogenesis	O

The	O
present	O
invention	O
provides	O
new	O
pyridopyrazine	B
compounds	O
which	O
are	O
suitable	O
for	O
the	O
treatment	O
or	O
prevention	O
of	O
physiological	O
and/or	O
pathophysiological	O
states	O
mediated	O
and/or	O
modulated	O
by	O
signal	O
transduction	O
pathways	O
and/or	O
enzymes	O
in	O
mammals	O
and	O
in	O
particular	O
in	O
humans	O
.	O

Pyridopyrazine	B
derivatives	O
and	O
their	O
use	O

The	O
invention	O
provides	O
modulators	O
for	O
the	O
orphan	O
nuclear	O
receptor	O
RORy	O
and	O
methods	O
for	O
treating	O
RORy	O
mediated	O
diseases	O
by	O
administrating	O
these	O
novel	O
RORy	O
modulators	O
to	O
a	O
human	O
or	O
a	O
mammal	O
in	O
need	O
thereof	O
.	O

Specifically	O
,	O
the	O
present	O
invention	O
provides	O
pyrrolo	B
sulfonamide	I
compounds	O
of	O
Formula	O
(	O
1	O
)	O
and	O
the	O
enantiomers	O
,	O
diastereomers	O
,	O
tautomers	O
,	O
solvates	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O

Pyrrolo	B
sulfonamide	I
compounds	O
for	O
modulation	O
of	O
orphan	O
nuclear	O
receptor	O
rar	O
-	O
related	O
orphan	O
receptor	O
-	O
gamma	O
(	O
rorgamma	O
,	O
nr1f3	O
)	O
activity	O
and	O
for	O
the	O
treatment	O
of	O
chronic	O
inflammatory	O
and	O
autoimmune	O
diseases	O

The	O
present	O
invention	O
relates	O
to	O
a	O
combination	O
of	O
a	O
curcuminoid	B
and	O
a	O
taxane	B
for	O
use	O
in	O
the	O
treatment	O
of	O
a	O
hormone	O
-	O
refractory	O
prostate	O
cancer	O
(	O
HRPC	O
)	O
in	O
a	O
patient	O
in	O
need	O
thereof	O
.	O

Methods	O
and	O
pharmaceutical	O
compositions	O
for	O
the	O
treatment	O
of	O
hormone	O
-	O
refractory	O
prostate	O
cancers	O

The	O
present	O
invention	O
provides	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
wherein	O
R1	O
is	O
hydrogen	B
or	O
fluorine	B
,	O
one	O
of	O
A	O
and	O
B	O
is	O
R2	O
,	O
the	O
other	O
is	O
a	O
group	O
-X	O
-	O
Y	O
-	O
R3	O
.	O

R3	O
represents	O
a	O
carbocyclic	B
or	O
heterocyclic	B
ring	O
.	O

Further	O
variables	O
are	O
as	O
defined	O
in	O
the	O
specification	O
.	O

Also	O
claimed	O
are-	O
processes	O
for	O
their	O
preparation	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
their	O
use	O
in	O
therapy	O
of	O
diseases	O
such	O
as	O
schizophrenia	O
,	O
cognitive	O
disorders	O
and	O
pain	O
by	O
modulating	O
the	O
D	B
-	I
amino	I
acid	I
oxidase	O
enzyme	O
(	O
DAAO	O
)	O
.	O

5-	B
or	I
6	I
-	I
substituted	I
3	I
-	I
hydroxy	I
-	I
2	I
(	I
1h	I
)	I
-	I
pyridinones	I
as	O
d	B
-	I
amino	I
acid	I
oxidase	O
(	O
daao	O
)	O
inhibitors	O
in	O
therapy	O
of	O
diseases	O
such	O
as	O
schizophrenia	O
,	O
cognitive	O
disorder	O
and	O
pain	O

Suggested	O
is	O
a	O
pharmaceutical	O
composition	O
,	O
comprising	O
menthane	B
carboxylic	I
acid	I
-	I
N-	I
(	I
4-methoxy	I
-	I
phenyl	I
)	I
-amide	I
.	O

A	O
pharmaceutical	O
composition	O
comprising	O
a	O
menthane	B
carboxylic	I
acid	I
amide	I

The	O
present	O
invention	O
provides	O
an	O
agent	O
for	O
preventing	O
the	O
increase	O
in	O
a	O
body	O
weight	O
(	O
or	O
for	O
decreasing	O
a	O
body	O
weight	O
)	O
or	O
an	O
anti	O
-	O
obesity	O
agent	O
each	O
comprising	O
at	O
least	O
one	O
component	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
EPA	B
and	O
pharmaceutically	O
acceptable	O
salts	O
,	O
esters	O
and	O
derivatives	O
thereof	O
as	O
an	O
active	O
ingredient	O
for	O
obesity	O
in	O
which	O
the	O
increase	O
in	O
the	O
formation	O
of	O
hepatic	O
lipid	O
or	O
the	O
occurrence	O
of	O
fatty	O
liver	O
is	O
mild	O
,	O
preferably	O
the	O
increase	O
in	O
the	O
formation	O
of	O
hepatic	O
lipid	O
or	O
the	O
occurrence	O
of	O
fatty	O
liver	O
is	O
not	O
observed	O
.	O

Anti	O
-	O
obesity	O
agent	O
comprising	O
high	O
-	O
purity	O
epa	B

The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
galenic	O
form	O
of	O
cholesterol	B
derivative	O
.	O

More	O
particularly	O
,	O
the	O
invention	O
relates	O
to	O
liposomes	O
comprising	O
at	O
least	O
one	O
cholesterol	B
derivative	O
and	O
to	O
compositions	O
comprising	O
said	O
liposomes	O
.	O

Liposome	O
comprising	O
at	O
least	O
a	O
cholesterol	B
derivative	O

An	O
objective	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
:	O
a	O
cancer	O
stem	O
cell	O
isolated	O
using	O
a	O
cell	O
marker	O
;	O
a	O
substantively	O
homogeneous	O
cancer	O
stem	O
cell	O
population	O
including	O
said	O
cancer	O
stem	O
cell	O
;	O
and	O
a	O
method	O
of	O
preparing	O
said	O
cancer	O
stem	O
cell	O
population	O
.	O

Another	O
objective	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
:	O
a	O
method	O
for	O
separating	O
cancer	O
stem	O
cells	O
with	O
a	O
high	O
proliferative	O
potential	O
and	O
those	O
with	O
a	O
low	O
proliferative	O
potential	O
;	O
a	O
method	O
for	O
inducing	O
cancer	O
stem	O
cells	O
to	O
have	O
a	O
different	O
proliferative	O
potential	O
;	O
and	O
cancer	O
stem	O
cells	O
separated	O
or	O
induced	O
by	O
these	O
separation	O
or	O
induction	O
methods	O
.	O

A	O
further	O
objective	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
:	O
a	O
method	O
of	O
screening	O
for	O
pharmaceuticals	O
using	O
said	O
cancer	O
stem	O
cell	O
or	O
cancer	O
stem	O
cell	O
population	O
;	O
a	O
method	O
for	O
detecting	O
the	O
presence	O
of	O
said	O
cancer	O
stem	O
cell	O
or	O
cancer	O
stem	O
cell	O
population	O
and	O
for	O
identifying	O
or	O
quantifying	O
the	O
same	O
.	O

The	O
present	O
inventors	O
discovered	O
that	O
highly	O
pure	O
colon	O
cancer	O
stem	O
cells	O
(	O
CSC	O
)	O
can	O
be	O
obtained	O
in	O
a	O
large	O
quantity	O
,	O
and	O
identified	O
two	O
types	O
of	O
states	O
of	O
colon	O
CSCs	O
distinguishable	O
through	O
Lgr5	O
expression	O
.	O

Cancer	O
stem	O
cell	O
isolation	O

The	O
present	O
invention	O
relates	O
a	O
compound	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
solvate	O
thereof	O
for	O
use	O
in	O
inhibiting	O
HIV	O
capsid	O
assembly	O
,	O
wherein	O
the	O
compound	O
is	O
a	O
pyrimidine	B
being	O
at	O
least	O
substituted	O
in	O
two	O
positions	O
,	O
preferably	O
in	O
2	O
and	O
4	O
position	O
or	O
in	O
4	O
and	O
6	O
position	O
,	O
more	O
preferably	O
in	O
2	O
and	O
4	O
position	O
.	O

Compounds	O
for	O
use	O
in	O
inhibiting	O
HIV	O
capsid	O
assembly	O

A	O
compound	O
of	O
the	O
general	O
structure	O
(	O
I	O
)	O
is	O
capable	O
of	O
abrogating	O
the	O
deubiquitinating	O
(	O
DUB	O
)	O
activity	O
of	O
the	O
19S	O
RP	O
DUBs	O
.	O

The	O
compound	O
can	O
be	O
used	O
for	O
treating	O
cancer	O
,	O
in	O
particular	O
of	O
cancer	O
refractory	O
to	O
treatment	O
by	O
state	O
-	O
of	O
-	O
the	O
-	O
art	O
chemotherapy	O
.	O

Also	O
disclosed	O
are	O
corresponding	O
methods	O
of	O
treatment	O
and	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
compound	O
.	O

Method	O
for	O
inhibition	O
of	O
deubiquitinating	O
activity	O

The	O
present	O
invention	O
relates	O
to	O
new	O
anti	O
-	O
infectious	O
compounds	O
consisting	O
of	O
(	O
i	O
)	O
a	O
polar	O
head	O
having	O
from	O
one	O
to	O
three	O
mannose	O
,	O
dimannose	O
or	O
trimannose	O
moieties	O
,	O
which	O
is	O
coupled	O
through	O
an	O
appropriate	O
linker	O
to	O
(	O
ii	O
)	O
a	O
single	O
lipid	O
chain	O
of	O
at	O
least	O
17	O
carbon	O
atoms	O
of	O
length	O
.	O

Pharmaceutical	O
compositions	O
and	O
therapeutic	O
uses	O
thereof	O
are	O
also	O
provided	O
.	O

Mannosylated	O
compounds	O
useful	O
for	O
the	O
prevention	O
and	O
the	O
treatment	O
of	O
infectious	O
diseases	O

This	O
invention	O
relates	O
to	O
the	O
use	O
of	O
a	O
mutant	O
E2	O
polypeptide	O
to	O
induce	O
apoptosis	O
(	O
a	O
form	O
of	O
programmed	O
cell	O
death	O
)	O
in	O
cells	O
.	O

The	O
mutant	O
E2	O
derived	O
polypeptide	O
is	O
p53	O
binding	O
deficient	O
.	O

Preferably	O
it	O
is	O
unable	O
to	O
bind	O
p53	O
;	O
or	O
able	O
to	O
bind	O
p53	O
but	O
unable	O
to	O
induce	O
p53-dependent	O
apoptosis	O
.	O

Inducer	O
of	O
apoptosis	O

Use	O
of	O
endothelin	O
receptor	O
antagonists	O
for	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
tumour	O
diseases	O
.	O

Anticancer	O
agents	O
;	O
controlling	O
apoptosis	O

Compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
X	O
is	O
O	B
,	O
S	B
,	O
NH	B
,	O
OCO	B
,	O
NH	B
	I
CO	I
,	O
NH	B
	I
COO	I
,	O
NH	B
	I
CO	I
	I
NH	I
,	O
NH	B
	I
CS	I
or	O
NH	B
	I
CS	I
	I
NH	I
;	O
R4	O
is	O
H	B
,	O
(	B
C1-C3	I
)	I
-alkyl	I
optionally	O
substituted	O
by	O
halogen	B
,	O
or	O
a	O
C	O
-	O
linked	O
heterocyclic	B
radical	I
selected	O
from	O
several	O
possibilities	O
;	O
R1	O
and	O
R3	O
are	O
H	B
or	O
F	B
;	O
and	O
R2	O
is	O
an	O
N	O
-	O
linked	O
or	O
C	O
-	O
linked	O
heterocyclic	B
radical	I
,	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
microbial	O
infections	O
in	O
human	O
or	O
animal	O
body	O
.	O

Substituted	O
isoxazoles	B
and	O
their	O
use	O
as	O
antibiotics	O

The	O
present	O
invention	O
discloses	O
and	O
claims	O
benzimidazole	B
compounds	O
of	O
formula	O
(	O
I	O
)	O
:	O
in	O
which	O
A	O
is	O
aryl	B
or	O
heteroaryl	B
;	O
R1	O
is	O
sleceted	O
from	O
optionally	O
substituted	O
alkyl	B
,	O
alkoxy	B
,	O
aryl	B
or	O
heteroaryl	B
,	O
NH	B
-	I
lower	I
alkyl	I
or	O
NH	B
-	I
cycloalkyl	I
,	O
or	O
halogen	B
,	O
NH2	B
;	O
1-imidazolyl	B
or	O
SO2Me	B
;	O
R2	O
is	O
selected	O
from	O
optionally	O
substituted	O
CO	B
-	I
alkyl	I
,	O
CO	B
-	I
cycloalkyl	I
,	O
CO	B
-	I
aralkyl	I
,	O
CO	B
-	I
aryl	I
,	O
CO	B
-	I
alkoxy	I
,	O
aryl	B
or	O
aralkyl	B
,	O
or	O
O	B
-	I
amino	I
,	O
CO	B
	I
NHR3	I
or	O
CO	B
	I
R3R4	I
wherein	O
R3	O
and	O
R4	O
are	O
selecteded	O
independently	O
from	O
hydrogen	B
,	O
alkyl	B
,	O
hydroxyalkyl	B
,	O
alkoxyalkyl	B
,	O
fluoroalkyl	B
,	O
alkynyl	B
,	O
heteroalkyl	B
,	O
alkylheteroalkyl	B
,	O
aryl	B
,	O
aralkyl	B
or	O
together	O
form	O
an	O
alkylene	B
chain	O
optionally	O
containing	O
one	O
to	O
4	O
heteroatoms	O
;	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
a	O
prodrug	O
thereof	O
;	O
the	O
use	O
of	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
for	O
the	O
treatment	O
of	O
cancer	O
,	O
and	O
pharmaceutical	O
compositions	O
comprising	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
and	O
one	O
or	O
more	O
pharmaceutically	O
acceptable	O
adjuvants	O
or	O
diluents	O
.	O

Such	O
as	O
4-cyclopentylamino	B
-	I
benzenesulfonic	I
acid	I
2-	I
(	I
3,4-dimethoxy	I
-	I
phenylamino	I
)	I
-1H	I
-	I
benzoimidazol-5-yl	I
ester	I
;	O
cyclin	O
-	O
dependent	O
kinase	O
inhibitors	O
that	O
are	O
aimed	O
to	O
be	O
more	O
active	O
than	O
flavopiridol	B

Compounds	O
represented	O
by	O
the	O
general	O
formula	O
.	O

[	O
I	O
]	O
:	O
wherein	O
R1	O
and	O
R2	O
are	O
each	O
hydrogen	B
,	O
halogen	B
,	O
an	O
optionally	O
substituted	O
linear	O
hydrocarbon	B
group	O
,	O
or	O
hydroxyl	B
which	O
may	O
be	O
substituted	O
with	O
an	O
optionally	O
substituted	O
liner	O
hydrocarbon	B
group	O
,	O
or	O
R1	O
and	O
R2	O
together	O
with	O
the	O
carbon	B
atoms	O
adjacent	O
thereto	O
may	O
form	O
an	O
optionally	O
substituted	O
cyclic	B
hydrocarbon	I
or	O
a	O
dihydrofuran	B
ring	O
which	O
may	O
have	O
an	O
oxo	B
group	O
;	O
ring	O
A	O
is	O
a	O
benzene	B
ring	O
which	O
may	O
be	O
further	O
substituted	O
;	O
ring	O
B	O
is	O
an	O
aromatic	B
ring	O
which	O
may	O
be	O
substituted	O
;	O
X	O
is	O
a	O
bond	O
or	O
a	O
spacer	O
whose	O
main	O
chain	O
has	O
1	O
to	O
6	O
atoms	O
;	O
Y	O
is	O
carboxyl	B
which	O
may	O
be	O
esterified	O
,	O
carbamoyl	B
which	O
may	O
be	O
substituted	O
,	O
cyano	B
,	O
or	O
an	O
optionally	O
substituted	O
heterocyclic	B
group	O
bearing	O
a	O
hydrogen	B
atom	O
capable	O
of	O
being	O
deprotonated	O
,	O
or	O
salts	O
thereof	O
,	O
which	O
are	O
useful	O
as	O
lipid	O
-	O
rich	O
plaque	O
regressing	O
agents	O
and/or	O
ACAT	O
inhibitors	O
.	O

Acat	O
inhibitors	O
;	O
cardiovascular	O
disorders	O
;	O
restenosis	O
;	O
Alzheimer	O
's	O
disease	O

A	O
method	O
of	O
treating	O
a	O
human	O
being	O
suffering	O
from	O
a	O
hormone	O
-	O
dependent	O
disorder	O
characterized	O
by	O
the	O
overexpression	O
of	O
EGFR	O
,	O
comprising	O
administering	O
to	O
said	O
human	O
being	O
an	O
aromatase	O
inhibitor	O
and	O
an	O
EGFR	O
antagonist	O
or	O
EGFR	O
inhibitor	O
,	O
in	O
amounts	O
effective	O
to	O
produce	O
a	O
superadditive	O
or	O
synergistic	O
therapeutic	O
effect	O
.	O

administering	O
to	O
humans	O
synergystic	O
mixtures	O
of	O
aromatase	O
inhibitors	O
and	O
epidermal	O
growth	O
factor	O
receptor	O
antagonists	O
as	O
antitumor	O
agents	O

The	O
present	O
invention	O
provides	O
compounds	O
of	O
formula	O
I	O
:	O
or	O
a	O
pharmaceutically	O
acceptable	O
derivative	O
thereof	O
,	O
wherein	O
A	O
-	O
B	O
is	O
N	B
	I
O	I
or	O
O	B
	I
N	I
and	O
G	O
,	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
and	O
R4	O
are	O
as	O
described	O
in	O
the	O
specification	O
.	O

These	O
compounds	O
are	O
inhibitors	O
of	O
protein	O
kinase	O
,	O
particularly	O
inhibitors	O
of	O
Src	O
and	O
Lck	O
kinase	O
.	O

The	O
invention	O
also	O
provides	O
pharmaceutical	O
compositions	O
comprising	O
the	O
inhibitors	O
of	O
the	O
invention	O
and	O
methods	O
of	O
utilizing	O
those	O
compositions	O
in	O
the	O
treatment	O
and	O
prevention	O
of	O
various	O
disorders	O
.	O

Such	O
as	O
[	B
3-	I
(	I
2-Bromo	I
-	I
ethoxy	I
)	I
-phenyl	I
]	I
-	I
[	I
4-	I
(	I
3-cyclohexyl-5-methyl	I
-	I
isoxazol-4-yl	I
)	I
-pyrimidin-2-yl	I
]	I
-amine	I

Inhibitors	O
of	O
integrin	O
-	O
linked	O
kinase	O
(	O
ILK	O
)	O
are	O
used	O
in	O
the	O
treatment	O
of	O
various	O
eye	O
diseases	O
with	O
underlining	O
pathology	O
of	O
neovascularization	O
of	O
cornea	O
,	O
iris	O
,	O
retina	O
or	O
choroid	O
.	O

Treatment	O
of	O
neovascular	O
opthalmic	O
disease	O

A	O
condom	O
has	O
a	O
vasodilator	O
active	O
compound	O
applied	O
to	O
its	O
external	O
surface	O
,	O
preferably	O
disposed	O
towards	O
the	O
open	O
end	O
of	O
the	O
condom	O
whereby	O
,	O
in	O
use	O
during	O
intercourse	O
,	O
the	O
compound	O
makes	O
contact	O
with	O
the	O
vaginal	O
meatus	O
or	O
proximal	O
region	O
of	O
the	O
vagina	O
,	O
such	O
that	O
the	O
vasodilator	O
is	O
absorbed	O
though	O
the	O
lining	O
of	O
the	O
vagina	O
to	O
stimulate	O
and	O
increase	O
the	O
flow	O
of	O
blood	O
in	O
the	O
labia	O
and	O
through	O
the	O
clitoris	O
to	O
promote	O
engorgement	O
thereof	O
to	O
alleviate	O
symptoms	O
associated	O
with	O
female	O
inorgasmia	O
Condom	O

A	O
combination	O
of	O
therapeutic	O
agents	O
useful	O
in	O
the	O
treatment	O
of	O
obstructive	O
airways	O
and	O
other	O
inflammatory	O
diseases	O
comprising	O
(	O
i	O
)	O
an	O
adenosine	B
A2A	O
receptor	O
agonist	O
;	O
and	O
(	O
ii	O
)	O
an	O
anti	O
-	O
cholinergic	O
agent	O
,	O
preferably	O
comprising	O
a	O
member	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
tiotropium	B
and	O
derivatives	O
thereof	O
;	O
the	O
combination	O
being	O
therapeutically	O
effective	O
in	O
the	O
treatment	O
of	O
the	O
diseases	O
when	O
administered	O
by	O
inhalation	O
;	O
as	O
well	O
as	O
to	O
a	O
method	O
of	O
treating	O
the	O
obstructive	O
airways	O
and	O
other	O
inflammatory	O
diseases	O
comprising	O
administering	O
separately	O
,	O
simultaneously	O
or	O
sequentially	O
to	O
the	O
mammal	O
by	O
inhalation	O
a	O
therapeutically	O
effective	O
amount	O
of	O
the	O
combination	O
of	O
therapeutic	O
agents	O
;	O
as	O
well	O
as	O
to	O
a	O
pharmaceutical	O
composition	O
comprising	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
together	O
with	O
the	O
combination	O
of	O
therapeutic	O
agents	O
;	O
as	O
well	O
as	O
to	O
a	O
product	O
containing	O
the	O
compounds	O
of	O
the	O
combination	O
for	O
separate	O
,	O
simultaneous	O
or	O
sequential	O
administration	O
by	O
inhalation	O
to	O
a	O
mammal	O
for	O
the	O
treatment	O
of	O
obstructive	O
airways	O
and	O
other	O
inflammatory	O
diseases	O
.	O

It	O
is	O
preferred	O
that	O
the	O
anti	O
-	O
cholinergic	O
agent	O
component	O
be	O
tiotropium	O
bromide	O
.	O

Combination	O
of	O
an	O
adenosine	O
A2A	O
-	O
receptor	O
agonist	O
and	O
tiotropium	B
or	O
a	O
derivative	O
thereof	O
for	O
treating	O
obstructive	O
airways	O
and	O
other	O
inflammatory	O
diseases	O

The	O
present	O
invention	O
relates	O
to	O
compounds	O
that	O
are	O
capable	O
of	O
inhibiting	O
,	O
modulating	O
and/or	O
regulating	O
signal	O
transduction	O
of	O
both	O
receptor	O
-	O
type	O
and	O
non	O
-	O
receptor	O
type	O
tyrosine	B
kinases	O
.	O

The	O
compounds	O
of	O
the	O
instant	O
invention	O
possess	O
a	O
core	O
structure	O
that	O
comprises	O
a	O
sulfonyl	B
indole	I
moiety	O
.	O

The	O
present	O
invention	O
is	O
also	O
related	O
to	O
the	O
pharmaceutically	O
acceptable	O
salts	O
,	O
hydrates	B
and	O
stereoisomers	O
of	O
these	O
compounds	O
.	O

3-	O
(	O
Morpholin-4-ylsulfonyl	O
)	O
-5-	O
(	O
1,3-thiazol-2-yl	O
)	O
-1H	O
-	O
indole-2-carboxamide	O
;	O
inhibiting	O
,	O
modulating	O
and/or	O
regulating	O
signal	O
transduction	O
of	O
both	O
receptor	O
and	O
non	O
-	O
receptor	O
tyrosine	B
kinases	O
;	O
anticarcinogenic	O
,	O
-diabetic	O
,	O
-arhtritic	O
,	O
-inflammatory	O
agents	O
;	O
psoriasis	O
;	O
angiogenesisinhibitors	O
;	O
liver	O
cirrhosis	O

Sprayable	O
,	O
anhydrous	O
and	O
physically	O
/	O
chemically	O
stable	O
dermatological	O
/	O
pharmaceutical	O
compositions	O
,	O
well	O
suited	O
for	O
the	O
treatment	O
of	O
a	O
variety	O
of	O
dermatological	O
disorders	O
,	O
notably	O
psoriasis	O
,	O
contain	O
:	O
a	O
)	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
solubilized	O
corticoid	O
,	O
notably	O
dissolved	O
clobetasol	B
propionate	I
;	O
b	O
)	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
solubilized	O
vitamin	B
D	I
derivative	O
,	O
notably	O
dissolved	O
calcitriol	B
;	O
and	O
c	O
)	O
an	O
oily	O
phase	O
which	O
comprises	O
one	O
or	O
more	O
oils	O
;	O
formulated	O
into	O
d	O
)	O
,	O
a	O
sprayable	O
and	O
topically	O
applicable	O
,	O
dermatologically	O
/	O
pharmaceutically	O
acceptable	O
vehicle	O
therefor	O
.	O

Sprayable	O
compositions	O
comprising	O
a	O
combination	O
of	O
pharmaceutical	O
actives	O
and	O
an	O
oily	O
phase	O

Methods	O
are	O
disclosed	O
for	O
fast	O
and	O
accurate	O
readout	O
of	O
kidney	O
toxicity	O
before	O
it	O
occurs	O
and	O
before	O
it	O
is	O
demonstrated	O
by	O
histopathology	O
examination	O
.	O

Ultimately	O
,	O
this	O
approach	O
shall	O
allow	O
earlier	O
compound	O
selection	O
.	O

The	O
twelve	O
genes	O
identified	O
,	O
namely	O
Calbindin	O
-	O
D28k	O
,	O
KIM-1	O
,	O
OPN	O
,	O
EGF	O
,	O
Clusterin	O
,	O
VEGF	O
,	O
OAT	O
-	O
K1	O
,	O
Aldolase	O
A	O
,	O
Aldolase	O
B	O
,	O
Podocin	O
,	O
Alpha-2u	O
and	O
C4	O
,	O
were	O
grouped	O
and	O
ultimately	O
can	O
be	O
assessed	O
in	O
the	O
form	O
of	O
a	O
kit	O
using	O
PCR	O
,	O
a	O
high	O
throughput	O
technology	O
,	O
in	O
order	O
to	O
characterize	O
and	O
rank	O
new	O
compounds	O
according	O
to	O
their	O
anticipated	O
general	O
kidney	O
toxicity	O
.	O

Also	O
disclosed	O
are	O
methods	O
for	O
identifying	O
agents	O
useful	O
in	O
the	O
treatment	O
of	O
kidney	O
disease	O
,	O
methods	O
for	O
monitoring	O
the	O
efficacy	O
of	O
a	O
treatment	O
for	O
kidney	O
disease	O
and	O
kidney	O
-	O
specific	O
vectors	O
including	O
the	O
sequences	O
of	O
the	O
disclosed	O
genes	O
,	O
and	O
a	O
method	O
for	O
identifying	O
a	O
candidate	O
gene	O
associated	O
with	O
a	O
biological	O
process	O
including	O
kidney	O
function	O
.	O

Marker	O
genes	O

The	O
invention	O
relates	O
to	O
a	O
composition	O
having	O
antioxidant	O
properties	O
comprising	O
at	O
least	O
one	O
compound	O
of	O
the	O
formula	O
I	O
or	O
a	O
cosmetically	O
,	O
dermatologically	O
or	O
pharmacologically	O
tolerated	O
salt	O
or	O
derivative	O
thereof	O
where	O
R1	O
to	O
R4	O
can	O
be	O
identical	O
or	O
different	O
and	O
are	O
selected	O
from	O
H	O
C6	B
-	I
28-alkylcarboxylic	I
acid	I
radicals	O
C6	B
-	I
28-alkenylcarboxylic	I
acid	I
radicals	O
radicals	O
of	O
the	O
formula	O
II	O
where	O
R5-R8	O
,	O
independently	O
of	O
one	O
another	O
,	O
are	O
H	B
,	O
hydroxyl	B
or	O
C1	B
-	I
6-alkoxy	I
,	O
with	O
the	O
proviso	O
that	O
at	O
least	O
one	O
of	O
the	O
radicals	O
R1	O
to	O
R4	O
is	O
a	O
radical	O
of	O
the	O
formula	O
II	O
.	O

Composition	O
having	O
antioxidant	O
properties	O

The	O
present	O
invention	O
relates	O
generally	O
to	O
a	O
composition	O
for	O
use	O
in	O
the	O
prophylaxis	O
and/or	O
treatment	O
of	O
pain	O
.	O

More	O
particularly	O
,	O
the	O
present	O
invention	O
relates	O
to	O
a	O
composition	O
for	O
use	O
in	O
the	O
prophylaxis	O
and/or	O
treatment	O
of	O
chronic	O
neuromuscular	O
pain	O
.	O

The	O
composition	O
of	O
the	O
present	O
invention	O
is	O
particularly	O
useful	O
in	O
the	O
prophylaxis	O
and/or	O
treatment	O
of	O
chronic	O
neuromuscular	O
pain	O
such	O
as	O
,	O
for	O
example	O
,	O
fibromylagia	O
,	O
myofascial	O
pain	O
,	O
repetitive	O
strain	O
injury	O
or	O
overuse	O
syndromes	O
,	O
and	O
cytokine	O
-	O
mediated	O
cancer	O
and	O
chemotherapy	O
associated	O
pain	O
.	O

Composition	O
for	O
use	O
in	O
prophylaxis	O
and	O
or	O
treatment	O

This	O
invention	O
relates	O
to	O
the	O
fields	O
of	O
molecular	O
biology	O
and	O
oncology	O
.	O

More	O
particularly	O
,	O
this	O
invention	O
relates	O
to	O
the	O
sensitization	O
of	O
cancerous	O
cells	O
to	O
therapeutic	O
agents	O
.	O

The	O
invention	O
provides	O
methods	O
,	O
compositions	O
,	O
and	O
formulations	O
for	O
potentiating	O
or	O
enhancing	O
the	O
toxicity	O
of	O
various	O
cytotoxins	O
and	O
oxidizing	O
agents	O
,	O
and	O
of	O
reducing	O
the	O
resistance	O
and	O
proliferation	O
rate	O
of	O
cancer	O
cells	O
.	O

It	O
also	O
provides	O
various	O
compositions	O
and	O
therapeutic	O
formulations	O
useful	O
as	O
anticancer	O
agents	O
.	O

Sensitization	O
of	O
cells	O
to	O
cytotoxic	O
agents	O
using	O
oligonucleotides	B
directed	O
to	O
nucleotide	O
excision	O
repair	O
or	O
transcritpion	O
coupled	O
repair	O
genes	O

Compounds	O
of	O
formula	O
(	O
I	O
)	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
and	O
the	O
use	O
of	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
:	O
X	B
	I
CO	I
	I
CH2-Z	I
wherein	O
X	O
is	O
a	O
monocyclic	B
or	I
polycyclic	I
aromatic	I
group	O
,	O
Z	O
is	O
of	O
sub	O
-	O
formula	O
(	O
h	O
)	O
,	O
(	O
j	O
)	O
or	O
(	O
k	O
)	O
:	O
wherein	O
n1	O
is	O
1	O
,	O
2	O
,	O
3	O
or	O
4	O
;	O
n2	O
is	O
0	O
,	O
1	O
,	O
2	O
,	O
3	O
or	O
4	O
;	O
n3is	O
2	O
,	O
3	O
,	O
4	O
or	O
5	O
;	O
q	O
is	O
0	O
,	O
1	O
,	O
2	O
or	O
3	O
;	O
p	O
is	O
0	O
,	O
1	O
or	O
2	O
;	O
m	O
is	O
0	O
,	O
1	O
or	O
2	O
;	O
R5	O
is	O
hydrogen	B
,	O
C1	B
-	I
2	I
alkyl	I
,	O
aralkyl	B
or	O
R5	O
is	O
(	B
CH2	I
)	I
z	I
-	I
R10	I
wherein	O
z	O
is	O
2	O
or	O
3	O
and	O
R10	O
is	O
selected	O
from	O
cyano	B
,	O
hydroxyl	B
,	O
C1	B
-	I
6	I
alkoxy	I
,	O
phenoxy	B
,	O
C	B
(	I
O	I
)	I
C1	I
-	I
6	I
alkyl	I
,	O
COC6H5	B
,	O
CONR11R12	B
,	O
NR11COR12	B
,	O
SO2NR11R12	B
or	O
NR11SO2R12	B
wherein	O
R11	O
and	O
R12	O
are	O
hydrogen	B
or	O
C1	B
-	I
6	I
alkyl	I
;	O
or	O
R5	O
is	O
straight	O
or	O
branched	O
chain	O
alkylene	B
of	O
chain	O
length	O
1	O
-	O
6	O
carbon	B
atoms	O
terminally	O
substituted	O
by	O
aryl	B
,	O
3	O
to	O
8	O
membered	O
cycloalkyl	B
,	O
3	O
to	O
8	O
membered	O
heterocyclyl	B
,	O
5	O
or	O
6	O
membered	O
monocyclic	B
heteroaryl	I
or	O
9	O
or	O
10	O
membered	O
fused	O
bicyclic	B
heteroaryl	I
linked	O
through	O
carbon	B
,	O
C2	B
-	I
7	I
alkoxycarbonyl	I
,	O
or	O
secondary	O
or	O
tertiary	O
hydroxy	B
substituted	O
C1	B
-	I
6	I
alkyl	I
;	O
;	O
and	O
R6	O
,	O
R7	O
and	O
R8	O
are	O
independently	O
hydrogen	B
or	O
C1	B
-	I
6	I
alkyl	I
;	O
and	O
R9	O
is	O
hydrogen	B
or	O
C1	B
-	I
10alkyl	I
;	O
and	O
their	O
use	O
as	O
pharmaceuticals	O
in	O
the	O
treatment	O
of	O
gastrointestinal	O
disorders	O
,	O
cardiovascular	O
disorders	O
and	O
CNS	O
disorders	O
.	O

5-HT4	O
receptor	O
antagonists	O

A	O
method	O
of	O
manufacturing	O
ferromagnetic	O
particle	O
exothermic	O
elements	O
for	O
performing	O
a	O
deposition	O
treatment	O
for	O
causing	O
a	O
treating	O
aqueous	O
solution	O
containing	O
fluorine	B
and	O
iron	B
to	O
contact	O
nucleus	O
particles	O
,	O
to	O
deposit	O
iron	B
hydroxide	I
and	O
form	O
layers	O
around	O
the	O
nucleus	O
particles	O
,	O
and	O
an	O
after	O
-	O
treatment	O
for	O
heating	O
the	O
iron	B
hydroxide	I
layers	O
to	O
change	O
them	O
into	O
ferromagnetic	O
layers	O
,	O
thereby	O
producing	O
ferromagnetic	O
particle	O
exothermic	O
elements	O
with	O
outside	O
of	O
the	O
nucleus	O
particles	O
covered	O
by	O
the	O
ferromagnetic	O
layers	O
,	O
wherein	O
,	O
in	O
time	O
of	O
the	O
deposition	O
treatment	O
,	O
a	O
reaction	O
initiator	O
that	O
reacts	O
with	O
hydrogen	B
fluoride	I
is	O
added	O
to	O
said	O
treating	O
aqueous	O
solution	O
.	O

Method	O
of	O
manufacturing	O
ferromagnetic	O
particle	O
exothermic	O
elements	O

Disclosed	O
are	O
polymers	O
comprising	O
one	O
or	O
more	O
phenyl	B
boronate	I
ester	I
,	O
boronamide	B
or	O
boronate	B
thioester	I
groups	O
.	O

The	O
phenyl	B
boronate	I
ester	I
,	O
boronamide	B
and	O
boronate	B
thioester	I
groups	O
are	O
represented	O
by	O
one	O
of	O
the	O
following	O
structural	O
formulas	O
:	O
Ar	O
in	O
Structural	O
Formulas	O
(	O
I	O
)	O
and	O
(	O
II	O
)	O
is	O
substituted	O
or	O
unsubstituted	O
;	O
and	O
each	O
Z	O
is	O
O	B
,	O
NH	B
or	O
S	B
and	O
is	O
independently	O
selected	O
.	O

Pharmaceutically	O
acceptable	O
salts	O
of	O
the	O
polymer	O
are	O
also	O
included	O
.	O

The	O
aryl	B
boronate	I
ester	I
,	O
boronamide	B
or	O
boronate	B
thioester	I
can	O
be	O
cleaved	O
to	O
release	O
the	O
corresponding	O
aryl	B
boronic	I
acid	I
.	O

Also	O
disclosed	O
are	O
pharmaceutical	O
compositions	O
comprising	O
the	O
polymers	O
of	O
the	O
present	O
invention	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
or	O
diluent	O
;	O
and	O
methods	O
of	O
treating	O
a	O
subject	O
for	O
obesity	O
with	O
the	O
polymers	O
of	O
the	O
present	O
invention	O
.	O

Aryl	B
boronate	I
functionalized	O
polymers	O
for	O
treating	O
obesity	O

One	O
object	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
a	O
drug	O
that	O
is	O
effective	O
in	O
treatments	O
for	O
and	O
prevention	O
of	O
psychiatric	O
disorders	O
and	O
in	O
treatments	O
for	O
and	O
prevention	O
of	O
neurological	O
diseases	O
,	O
inhibiting	O
a	O
Group	O
II	O
metabotropic	O
glutamate	O
receptor	O
.	O

The	O
object	O
is	O
solved	O
by	O
a	O
2-amino	B
-	I
bicyclo	I
[	I
3.1.0	I
]	I
hexane-2,6-dicarboxylic	I
acid	I
derivative	O
represented	O
by	O
formula	O
[	O
I	O
]	O
:	O
(	O
wherein	O
R1	O
and	O
R2	O
are	O
the	O
same	O
or	O
different	O
,	O
and	O
each	O
represents	O
a	O
hydrogen	B
atom	O
,	O
C1	B
-	I
10alkyl	I
group	O
,	O
etc	O
;	O
X	O
represents	O
a	O
hydrogen	B
atom	O
or	O
a	O
fluorine	B
atom	O
;	O
and	O
Y	O
represents	O
an	O
amino	B
group	O
,	O
SR3	B
,	O
S	B
(	I
O	I
)	I
nR7	I
,	O
SCHR3R4	B
,	O
S	B
(	I
O	I
)	I
nCHR3R4	I
,	O
NHCHR3R4	B
,	O
N	B
(	I
CHR3R4	I
)	I
(	I
CHR5R6	I
)	I
,	O
NHCOR3	B
or	O
OCOR7	B
)	O
,	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
or	O
a	O
hydrate	O
thereof	O
and	O
so	O
on	O
.	O

2-Aminobicyclo	B
[	I
3.1.0	I
]	I
hexane-2,6-dicarboxylic	I
acid	I
derivative	O

A	O
pharmaceutical	O
product	O
containing	O
pamidronate	B
and	O
other	O
diphosphonate	B
solutions	O
in	O
an	O
appropriate	O
container	O
,	O
a	O
pH	O
of	O
between	O
5	O
and	O
8	O
and	O
without	O
organic	O
acid	O
buffer	O
or	O
polyethylen	B
glycol	I
.	O

The	O
container	O
may	O
be	O
treated	O
glass	O
or	O
made	O
of	O
other	O
appropriate	O
material	O
.	O

Coated	O
elastomeric	O
stoppers	O
are	O
also	O
included	O
.	O

A	O
method	O
of	O
producing	O
a	O
pharmaceutical	O
product	O
comprising	O
steps	O
of	O
making	O
a	O
suspension	O
of	O
pamadronic	B
acid	I
,	O
adding	O
sodium	B
hydroxide	I
,	O
to	O
form	O
a	O
solution	O
adjusting	O
the	O
pH	O
to	O
between	O
5	O
and	O
8	O
and	O
transferring	O
the	O
solution	O
to	O
a	O
container	O
.	O

Diphosphonate	B
solutions	O

This	O
invention	O
relates	O
to	O
a	O
method	O
for	O
inhibiting	O
the	O
reaction	O
of	O
an	O
	B
,	I
	I
-	I
unsaturated	I
aldehyde	I
with	O
a	O
biological	O
molecule	O
,	O
the	O
method	O
including	O
the	O
step	O
of	O
administering	O
hydralazine	O
and/or	O
dihydralazine	O
in	O
an	O
amount	O
that	O
is	O
effective	O
to	O
reduce	O
the	O
rate	O
of	O
reaction	O
of	O
the	O
	B
,	I
	I
-	I
unsaturated	I
aldehyde	I
with	O
the	O
biological	O
molecule	O
.	O

Method	O
of	O
controlling	O
damage	O
mediated	O
by	O
alpha	B
,	I
beta	I
-	I
unsaturated	I
aldehydes	I

Compounds	O
of	O
formula	O
I	O
wherein	O
R	O
and	O
R1	O
are	O
as	O
defined	O
in	O
the	O
description	O
.	O

The	O
compounds	O
of	O
formula	O
I	O
are	O
PDE	O
4	O
inhibitors	O
.	O

Phthalazine	B
derivatives	O
as	O
phosphodiesterase	O
4	O
inhibitors	O

The	O
invention	O
relates	O
to	O
anti	O
-	O
microbial	O
and	O
immunostimulatory	O
molecules	O
of	O
the	O
cathelicidin	B
family	O
derived	O
from	O
fish	O
.	O

The	O
invention	O
provides	O
a	O
novel	O
cathelicidin	B
molecule	O
,	O
fragments	O
,	O
derivatives	O
and	O
uses	O
thereof	O
,	O
and	O
nucleic	O
acids	O
encoding	O
the	O
same	O
.	O

Peptides	O
and	O
nucleic	O
acids	O
of	O
the	O
cathelicidin	B
family	O
,	O
derived	O
from	O
fish	O
,	O
and	O
uses	O
thereof	O

According	O
to	O
the	O
invention	O
there	O
is	O
provided	O
a	O
compound	O
the	O
formula	O
I	O
;	O
wherein	O
A	O
,	O
X	O
,	O
B	O
,	O
R1	O
,	O
R2	O
,	O
R3	O
and	O
R4	O
are	O
as	O
defined	O
in	O
the	O
specification	O
.	O

Having	O
antiinflammatory	O
,	O
anti	O
-	O
pyretic	O
and	O
anti	O
-	O
diarrheal	O
properties	O

The	O
present	O
invention	O
relates	O
to	O
2,3-bipyridines	B
of	O
formula	O
(	O
I	O
)	O
,	O
processes	O
for	O
their	O
preparation	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
,	O
and	O
their	O
medical	O
uses	O
.	O

2,3'-bipyridines	B
derivatives	O
as	O
selective	O
cox-2	O
inhibitors	O

A	O
method	O
of	O
inhibiting	O
cdc25	O
phosphatases	O
in	O
warm	O
-	O
blooded	O
animals	O
comprising	O
administering	O
to	O
warm	O
-	O
blooded	O
animals	O
in	O
need	O
thereof	O
an	O
effective	O
amount	O
of	O
a	O
compound	O
of	O
the	O
formula	O
wherein	O
the	O
substituents	O
are	O
defined	O
as	O
in	O
the	O
specification	O
.	O

Inhibitors	O
of	O
cdc25	O
phosphatases	O

This	O
therapeutic	O
agent	O
for	O
chronic	O
obstructive	O
pulmonary	O
disease	O
comprises	O
,	O
an	O
active	O
ingredient	O
,	O
at	O
least	O
one	O
of	O
a	O
7-aminoquinolinone	B
derivative	O
represented	O
by	O
the	O
general	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
R1	O
represents	O
a	O
hydrogen	B
atom	O
or	O
an	O
alkyl	B
group	O
;	O
R2	O
and	O
R3	O
each	O
represents	O
a	O
group	O
selected	O
from	O
a	O
hydrogen	B
atom	O
,	O
an	O
acyl	B
group	O
,	O
an	O
alkyl	B
group	O
and	O
an	O
alkenyl	B
group	O
;	O
and	O
R4	O
and	O
R5	O
each	O
represents	O
a	O
group	O
selected	O
from	O
a	O
hydrogen	B
atom	O
,	O
an	O
acyl	B
group	O
,	O
an	O
alkyl	B
group	O
,	O
an	O
alkenyl	B
group	O
and	O
an	O
aralkyl	B
group	O
,	O
and	O
its	O
physiologically	O
acceptable	O
salt	O
.	O

Therapeutic	O
agent	O
for	O
chronic	O
obstructive	O
pulmonary	O
disease	O
and	O
method	O
for	O
treatment	O
for	O
chronic	O
obstructive	O
pulmonary	O
disease	O
with	O
the	O
same	O

Methods	O
of	O
using	O
benzothiophenone	B
derivatives	O
to	O
treat	O
cancer	O
or	O
inflammation	O
in	O
a	O
mammal	O
and	O
pharmaceutical	O
compositions	O
containing	O
such	O
derivatives	O
are	O
disclosed	O
.	O

Methods	O
of	O
using	O
benzothiophenone	B
derivatives	O
to	O
treat	O
cancer	O
or	O
inflammation	O

The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
chemokines	O
and/or	O
nucleic	O
acids	O
encoding	O
a	O
chemokine	O
for	O
recruiting	O
mesenchymal	O
precursor	O
and/or	O
stem	O
cells	O
in	O
vivo	O
and	O
in	O
vitro	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
preparations	O
which	O
comprise	O
these	O
substances	O
and	O
which	O
are	O
preferably	O
intended	O
for	O
recruiting	O
mesenchymal	O
precursor	O
and/or	O
stem	O
cells	O
for	O
tissue	O
synthesis	O
.	O

Use	O
of	O
chemokines	O
,	O
and	O
pharmaceutical	O
preparations	O
containing	O
the	O
same	O

According	O
to	O
the	O
present	O
invention	O
,	O
there	O
is	O
provided	O
a	O
solid	O
dispersion	O
composition	O
which	O
can	O
maintain	O
amorphous	O
cefditoren	B
pivoxil	I
in	O
a	O
suspension	O
for	O
a	O
long	O
period	O
of	O
time	O
.	O

The	O
present	O
invention	O
is	O
a	O
solid	O
dispersion	O
composition	O
comprising	O
at	O
least	O
0.1	O
mg	O
of	O
a	O
sugar	B
ester	B
fatty	B
acid	I
on	O
the	O
basis	O
of	O
an	O
amount	O
equivalent	O
to	O
100	O
mg	O
efficacy	O
of	O
cefditoren	B
pivoxil	I
.	O

Amorphous	O
antibiotic	O
composition	O
comprising	O
cefditoren	B
pivoxil	I

Methods	O
of	O
using	O
substituted	O
3,5-dithio-	B
,	I
disulfinyl	I
-	I
or	I
disulfonyl	I
-	I
isothiazole	I
derivatives	O
to	O
treat	O
cancer	O
or	O
inflammation	O
in	O
a	O
mammal	O
and	O
pharmaceutical	O
compositions	O
containing	O
such	O
derivatives	O
are	O
disclosed	O
.	O

Methods	O
of	O
using	O
isothiazole	B
derivatives	O
to	O
treat	O
cancer	O
or	O
inflammation	O

The	O
hexuronic	B
acid	I
derivative	O
represented	O
by	O
the	O
following	O
formula	O
1	O
or	O
a	O
salt	O
thereof	O
is	O
used	O
as	O
an	O
active	O
ingredient	O
of	O
a	O
heparin	O
/	O
heparan	O
sulfate	O
sulfotransferase	O
inhibitor	O
.	O

In	O
the	O
formula	O
,	O
each	O
of	O
R1	O
,	O
R2	O
,	O
and	O
R3	O
independently	O
represent	O
(	O
s	O
)	O
SO3	B
	I
or	O
H	B
which	O
may	O
have	O
a	O
substituent	O
,	O
provided	O
that	O
at	O
least	O
one	O
thereof	O
represents	O
SO3	B
	I
;	O
X	O
represents	O
OR4	B
,	O
SR4	B
,	O
N	B
(	I
R4	I
)	I
2	I
,	O
or	O
C	B
(	I
R4	I
)	I
3	I
,	O
R4	O
independently	O
represents	O
H	B
,	O
alkyl	B
,	O
alkenyl	B
,	O
alkynyl	B
,	O
acyl	B
,	O
aryl	B
,	O
or	O
aralkyl	B
group	O
;	O
one	O
of	O
R5	O
and	O
R6	O
represents	O
COOH	B
while	O
the	O
other	O
represents	O
H	B
;	O
and	O
the	O
wavy	O
line	O
represents	O
	O
-	O
glycosidic	O
bond	O
or	O
	O
-	O
glycosidic	O
bond	O
.	O

Sulfotransferase	O
inhibitor	O

The	O
invention	O
concerns	O
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
ring	O
A	O
is	O
phenyl	B
or	O
a	O
5-	O
or	O
6-membered	O
heterocyclic	B
ring	O
as	O
defined	O
herein	O
;	O
Z	O
is	O
O	B
,	O
NH	B
or	O
S	B
;	O
m	O
is	O
an	O
integer	O
from	O
0	O
to	O
5	O
inclusive	O
;	O
R1	O
is	O
hydrogen	B
,	O
hydroxy	B
,	O
halogeno	B
,	O
nitro	B
,	O
trifluoromethyl	B
,	O
cyano	B
,	O
C1	B
-	I
3alkyl	I
,	O
C1	B
-	I
3alkoxy	I
,	O
C1	B
-	I
3alkylthio	I
,	O
or	O
NR5R6	B
(	O
wherein	O
R5	O
and	O
R6	O
,	O
which	O
may	O
be	O
the	O
same	O
or	O
different	O
,	O
are	O
hydrogen	O
or	O
C1	B
-	I
3alkyl	I
)	O
;	O
R2	O
is	O
hydrogen	B
,	O
hydroxy	B
,	O
halogeno	B
,	O
C1	B
-	I
3alkyl	I
,	O
C1	B
-	I
3alkoxy	I
,	O
trifluoromethyl	B
,	O
amino	B
or	O
nitro	B
;	O
R3	O
is	O
hydroxy	B
,	O
halogeno	B
,	O
C1	B
-	I
3alkyl	I
,	O
C1	O
-	O
3alkoxy	O
,	O
C1	O
-	O
3alkanoyloxy	O
,	O
trifluoromethyl	O
,	O
cyano	O
,	O
amino	O
or	O
nitro	O
;	O
provided	O
that	O
when	O
ring	O
A	O
is	O
a	O
5-	O
or	O
6-membered	O
heterocyclic	O
ring	O
,	O
at	O
least	O
one	O
R3	O
is	O
either	O
hydroxy	O
or	O
halogeno	B
;	O
X1	O
is	O
O	B
,	O
CH2	B
,	O
S	B
,	O
SO	B
,	O
SO2	B
,	O
NR7	B
,	O
NR7CO	B
,	O
CONR7	B
,	O
SO2NR7	B
or	O
NR7SO2	B
,	O
(	O
wherein	O
R7	O
is	O
hydrogen	B
,	O
C1	B
-	I
3alkyl	I
or	O
C1	B
-	I
3alkoxyC2	I
-	I
3alkyl	I
)	O
;	O
and	O
R4	O
is	O
selected	O
from	O
a	O
number	O
of	O
groups	O
defined	O
herein	O
comprising	O
an	O
C2	B
-	I
5alkylene	I
,	O
C3	B
-	I
5alkenylene	I
or	O
C3	B
-	I
5alkynylene	I
chain	O
wherein	O
each	O
methylene	B
group	O
(	O
other	O
than	O
that	O
of	O
the	O
	B
-	I
carbon	I
)	O
is	O
optionally	O
substituted	O
by	O
1	O
substituent	O
independently	O
selected	O
from	O
hydroxy	B
,	O
halogeno	B
,	O
amino	B
and	O
C1	B
-	I
4alkanoyloxy	I
;	O
provisos	O
are	O
as	O
defined	O
herein	O
.	O

The	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
,	O
to	O
the	O
use	O
of	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
in	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
use	O
in	O
the	O
production	O
of	O
an	O
antiangiogenic	O
and/or	O
vascular	O
permeability	O
reducing	O
effect	O
in	O
a	O
warm	O
-	O
blooded	O
animal	O
and	O
to	O
a	O
method	O
for	O
producing	O
an	O
antiangiogenic	O
and/or	O
vascular	O
permeability	O
reducing	O
effect	O
in	O
a	O
warm	O
-	O
blooded	O
animal	O
in	O
need	O
of	O
such	O
treatment	O
.	O

The	O
compounds	O
are	O
useful	O
in	O
disease	O
states	O
such	O
as	O
cancer	O
,	O
rheumatoid	O
arthritis	O
and	O
psoriasis	O
.	O

Angiogenesis	O
inhibitor	O
;	O
anticancer	O
agents	O
;	O
antiarthritic	O
agents	O
;	O
psoriasis	O

A	O
method	O
of	O
preventing	O
the	O
headache	O
phase	O
of	O
migraine	O
in	O
a	O
human	O
comprises	O
administration	O
of	O
a	O
5HT1	O
receptor	O
agonist	O
or	O
administration	O
of	O
an	O
over	O
-	O
the	O
-	O
counter	O
or	O
nonprescription	O
drug	O
to	O
said	O
human	O
exhibiting	O
prodrome	O
symptoms	O
of	O
migraine	O
.	O

Suitably	O
,	O
the	O
method	O
comprises	O
administration	O
of	O
a	O
migraine	O
headache	O
phase	O
-	O
preventing	O
effective	O
amount	O
of	O
the	O
5HT1	O
or	O
over	O
-	O
the	O
-	O
counter	O
or	O
nonprescription	O
drug	O
.	O

There	O
is	O
disclosed	O
a	O
preemptive	O
prophylaxis	O
migraine	O
method	O
using	O
the	O
following	O
cognitive	O
tests	O
:	O
Simple	O
Reaction	O
Time	O
;	O
Running	O
Memory	O
Continuous	O
Performance	O
Task	O
;	O
Matching	O
to	O
Sample	O
;	O
Mathematical	O
Processing	O
Task	O
;	O
and	O
interpreting	O
the	O
results	O
as	O
a	O
percent	O
of	O
baseline	O
indicator	O
of	O
need	O
for	O
prophylaxis	O
.	O

Preemptive	O
Prophylaxis	O
of	O
Migraine	O

The	O
present	O
invention	O
relates	O
to	O
an	O
active	O
substance	O
combination	O
comprising	O
at	O
least	O
one	O
substituted	O
carbinol	B
compound	O
and	O
at	O
least	O
one	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drug	O
(	O
NSAID	O
)	O
,	O
a	O
medicament	O
comprising	O
said	O
active	O
substance	O
combination	O
,	O
a	O
pharmaceutical	O
formulation	O
comprising	O
said	O
active	O
substance	O
combination	O
for	O
the	O
manufacture	O
of	O
a	O
medicament	O
.	O

Active	O
substance	O
combination	O
comprising	O
a	O
carbinol	B
combined	O
to	O
at	O
least	O
an	O
NSAID	O

Compounds	O
of	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
R	O
represents	O
a	O
substituted	O
benzyl	B
group	O
,	O
are	O
useful	O
as	O
inhibitors	O
of	O
glucosylceramide	B
synthase	O
.	O

2-Hydroxymethyl-3,4,5-trihydroxy-1-benzilpiperidine	B
derivatives	O
as	O
inhibitors	O
of	O
glucosylceramide	B

The	O
invention	O
is	O
related	O
to	O
novel	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
or	O
a	O
salt	O
,	O
solvate	O
or	O
prodrug	O
thereof	O
,	O
wherein	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
n	O
and	O
m	O
are	O
as	O
described	O
in	O
the	O
specification	O
,	O
useful	O
in	O
the	O
treatment	O
of	O
a	O
disease	O
or	O
condition	O
mediated	O
through	O
glucokinase	O
(	O
GLK	O
)	O
,	O
such	O
as	O
type	O
2	O
diabetes	O
.	O

The	O
invention	O
also	O
relates	O
to	O
methods	O
for	O
preparing	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
and	O
their	O
use	O
as	O
medicaments	O
in	O
the	O
treatment	O
of	O
diseases	O
mediated	O
by	O
glucokinase	O
.	O

Amino	B
nicotinate	I
derivatives	O
as	O
glucokinase	O
(	O
GLK	O
)	O
modulators	O

Inflammatory	O
skin	O
disorders	O
such	O
as	O
rosacea	O
,	O
including	O
a	O
variety	O
of	O
skin	O
diseases	O
,	O
whether	O
or	O
not	O
accompanied	O
by	O
dermatosis	O
,	O
are	O
treated	O
by	O
topically	O
applying	O
onto	O
the	O
affected	O
skin	O
area	O
,	O
a	O
thus	O
effective	O
amount	O
of	O
Ondansetron	B
,	O
or	O
salt	O
or	O
base	O
thereof	O
.	O

Treating	O
inflammation	O
with	O
ondansetron	B
and	O
pharmaceutical	O
compositions	O
comprised	O
thereof	O

An	O
antitumor	O
combination	O
comprising	O
a	O
stilbene	B
derivative	O
and	O
an	O
anticancer	O
compound	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
taxanes	B
,	O
alkylating	O
agents	O
,	O
antimetabolites	O
,	O
vinca	O
alkaloids	B
,	O
platinum	B
compounds	O
,	O
epidophylloptoxins	B
,	O
and	O
antibiotics	O
as	O
the	O
active	O
ingredients	O
is	O
provided	O
.	O

Methods	O
of	O
using	O
these	O
pharmaceutical	O
preparations	O
for	O
the	O
treatment	O
of	O
solid	O
carcinomas	O
and	O
the	O
like	O
are	O
also	O
provided	O
.	O

Combination	O
Comprising	O
Combretastatin	B
and	O
Anticancer	O
Agents	O

The	O
present	O
invention	O
provides	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
;	O
wherein	O
each	O
of	O
R1	O
to	O
R4	O
is	O
independently	O
selected	O
from	O
hydrogen	B
,	O
a	O
halogen	B
,	O
a	O
substituted	O
or	O
unsubstituted	O
cyclic	O
and	O
heterocyclic	B
moiety	O
,	O
substituted	O
or	O
unsubstituted	O
,	O
linear	O
or	O
branched	O
alkyl	B
,	O
alkyloxy	B
,	O
alkylcarbonyl	B
,	O
alkyloxycarbonyl	B
,	O
alkenyl	B
,	O
alkenyloxy	B
,	O
alkenylcarbonyl	B
,	O
alkenyloxycarbonyl	B
,	O
alkynyl	B
,	O
alkynyloxy	B
,	O
alkynylcarbonyl	B
,	O
alkynyloxycarbonyl	B
,	O
aryl	B
,	O
benzyl	B
,	O
arlyoxy	B
,	O
arylcarbonyl	B
,	O
aryloxycarbonyl	B
and	O
sulphur	B
equivalents	O
of	O
said	O
oxy	B
,	O
carbonyl	B
and	O
oxycarbonyl	B
moieties	O
,	O
and	O
A	O
is	O
NH	B
,	O
or	O
(	B
CH2	I
)	I
n	I
,	O
where	O
n	O
is	O
preferably	O
0	O
,	O
1	O
or	O
2	O
.	O

The	O
invention	O
also	O
relates	O
to	O
methods	O
for	O
preparing	O
the	O
compounds	O
and	O
their	O
uses	O
as	O
CCK	O
receptor	O
ligands	O
and	O
CCK	O
antagonists	O
.	O

Novel	O
ureido	B
-	I
and	I
amido	I
-	I
pyrazolone	I
derivatives	O

Compounds	O
complying	O
with	O
the	O
general	O
formula	O
in	O
which	O
R	O
either	O
represents	O
a	O
halogen	B
atom	O
or	O
a	O
phenyl	B
group	O
substituted	O
by	O
one	O
or	O
more	O
groups	O
chosen	O
from	O
halogen	B
atoms	O
and	O
(	B
C1-C6	I
)	I
alkyl	I
,	O
(	B
C1-C6	I
)	I
alkoxy	I
,	O
nitro	B
,	O
amino	B
,	O
trifluoromethyl	B
,	O
cyano	B
,	O
hydroxy	B
,	O
acetyl	B
or	O
methylenedioxy	B
groups	O
,	O
or	O
represents	O
a	O
pyridinyl	B
group	O
,	O
a	O
thienyl	B
group	O
,	O
an	O
indolyl	B
group	O
,	O
or	O
a	O
pyrimidinyl	B
group	O
optionally	O
substituted	O
by	O
one	O
or	O
more	O
(	B
C1-C6	I
)	I
alkoxy	I
groups	O
,	O
where	O
,	O
of	O
the	O
two	O
carbon	B
-	I
carbon	I
bonds	O
represented	O
by	O
Therapy	O
for	O
disease	O
caused	O
by	O
nicotinic	O
receptors	O
;	O
cognition	O
activatrors	O
;	O
central	O
nervous	O
system	O
disorders	O

Compounds	O
of	O
formula	O
(	O
I	O
)	O
which	O
are	O
useful	O
as	O
therapeutic	O
compounds	O
,	O
particularly	O
in	O
the	O
treatment	O
of	O
pain	O
and	O
other	O
conditions	O
ameliorated	O
by	O
the	O
modulation	O
of	O
the	O
function	O
of	O
the	O
vanilloid-1	B
receptor	O
(	O
VR1	O
)	O
.	O

Prodrugs	O
Of	O
Substituted	O
Amino	B
Heterobicycles	I
Which	O
Modulate	O
The	O
Function	O
Of	O
The	O
Vanilloid-1	B
Receptor	O
(	O
Vr1	O
)	O

The	O
invention	O
features	O
a	O
method	O
of	O
treating	O
an	O
inflammatory	O
condition	O
in	O
an	O
individual	O
,	O
comprising	O
administering	O
an	O
agent	O
inhibits	O
the	O
interaction	O
between	O
a	O
Toll	O
-	O
like	O
receptor	O
2	O
(	O
TLR2	O
)	O
and	O
a	O
high	O
mobility	O
group	O
B	O
(	O
HMGB	O
)	O
polypeptide	O
to	O
the	O
individual	O
.	O

The	O
invention	O
also	O
features	O
methods	O
for	O
identifying	O
agents	O
that	O
inhibit	O
the	O
interaction	O
between	O
TLR2	O
and	O
HMGB	O
.	O

Treating	O
an	O
inflammatory	O
condition	O
in	O
an	O
individual	O
by	O
administering	O
an	O
agent	O
which	O
inhibits	O
the	O
interaction	O
between	O
a	O
Toll	O
-	O
like	O
receptor	O
2	O
and	O
a	O
high	O
mobility	O
group	O
B	O
polypeptide	O
;	O
treating	O
Crohn	O
's	O
disease	O
,	O
sepsis	O
,	O
rheumatoid	O
arthritis	O
,	O
systemic	O
lupus	O
erythematosus	O
,	O
endotoxic	O
shock	O
,	O
allograft	O
rejection	O

The	O
present	O
invention	O
provides	O
methods	O
and	O
compositions	O
for	O
treating	O
tumorigenic	O
cells	O
(	O
e.g.	O
,	O
mammary	O
progenitor	O
cancer	O
cells	O
)	O
,	O
with	O
growth	O
hormone	O
receptor	O
antagonists	O
(	O
e.g.	O
,	O
Pegvisomant	B
)	O
,	O
as	O
well	O
as	O
methods	O
and	O
compositions	O
for	O
screening	O
growth	O
hormone	O
receptor	O
antagonists	O
for	O
their	O
ability	O
serve	O
as	O
anti	O
-	O
neoplastic	O
agents	O
capable	O
of	O
killing	O
tumorigenic	O
cells	O
.	O

The	O
present	O
invention	O
provides	O
methods	O
for	O
identifying	O
tumorigenic	O
cells	O
,	O
methods	O
of	O
obtaining	O
enriched	O
populations	O
of	O
tumorigenic	O
cells	O
,	O
and	O
methods	O
of	O
causing	O
mammary	O
progenitor	O
cells	O
to	O
proliferate	O
and/or	O
differentiate	O
.	O

Growth	O
hormone	O
receptor	O
antagonist	O
cancer	O
treatment	O

The	O
present	O
invention	O
provides	O
a	O
prophylactic	O
,	O
ameliorative	O
or	O
therapeutic	O
medicament	O
for	O
vascular	O
restenosis	O
,	O
ischemic	O
disease	O
,	O
allergic	O
disease	O
,	O
inflammatory	O
disease	O
,	O
autoimmune	O
disease	O
,	O
or	O
cancer	O
metastasis	O
,	O
invasion	O
(	O
cancer	O
metastasis	O
/	O
invasion	O
)	O
or	O
cachexia	O
based	O
on	O
the	O
inhibitory	O
action	O
on	O
a	O
plural	O
of	O
transcriptional	O
regulatory	O
factor	O
.	O

A	O
chimera	O
(	O
double	O
)	O
decoy	O
of	O
the	O
present	O
invention	O
has	O
plural	O
transcriptional	O
regulatory	O
factor	O
binding	O
sequences	O
in	O
a	O
single	O
molecule	O
thereof	O
.	O

Thus	O
,	O
it	O
is	O
able	O
to	O
inhibit	O
the	O
activity	O
of	O
plural	O
transcriptional	O
regulatory	O
factors	O
with	O
a	O
single	O
molecule	O
.	O

For	O
example	O
,	O
stenosis	O
of	O
an	O
anastomosed	O
site	O
of	O
an	O
artificial	O
blood	O
vessel	O
is	O
caused	O
by	O
thickening	O
of	O
the	O
vascular	O
intima	O
,	O
and	O
this	O
is	O
mainly	O
caused	O
by	O
activation	O
of	O
cell	O
proliferation	O
by	O
an	O
inflammatory	O
reaction	O
occurring	O
at	O
the	O
anastomosed	O
site	O
.	O

Thus	O
,	O
thickening	O
of	O
vessel	O
walls	O
can	O
be	O
inhibited	O
by	O
simultaneously	O
inhibiting	O
two	O
transcriptional	O
regulatory	O
factors	O
involved	O
in	O
inflammation	O
and	O
cell	O
proliferation	O
by	O
using	O
the	O
chimera	O
decoy	O
of	O
the	O
present	O
invention	O
.	O

Chimeric	O
(	O
Double	O
)	O
Decoy	O

[	O
Problem	O
]	O
There	O
is	O
provided	O
a	O
compound	O
which	O
can	O
be	O
used	O
for	O
therapy	O
of	O
diseases	O
in	O
which	O
11	B
-	I
hydroxysteroid	I
dehydrogenase	O
type	O
1	O
(	O
11	O
-	O
HSD1	O
)	O
participates	O
,	O
in	O
particular	O
diabetes	O
,	O
insulin	O
resistance	O
.	O

[	O
Means	O
for	O
Solution	O
]	O

It	O
has	O
been	O
found	O
that	O
a	O
triazole	B
derivative	O
wherein	O
the	O
triazole	B
ring	O
is	O
substituted	O
with	O
a	O
trisubstituted	O
methyl	B
group	O
in	O
the	O
2-position	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
has	O
a	O
strong	O
11	O
-	O
HSD1	O
inhibitory	O
activity	O
.	O

Moreover	O
,	O
the	O
triazole	B
derivative	O
of	O
the	O
invention	O
exhibits	O
an	O
excellent	O
blood	O
-	O
glucose	B
level	O
-	O
lowering	O
action	O
and	O
hence	O
can	O
be	O
used	O
for	O
therapy	O
of	O
diabetes	O
,	O
insulin	O
resistance	O
.	O

Triazole	B
Derivative	O
or	O
Salt	O
Thereof	O

The	O
present	O
invention	O
relates	O
to	O
an	O
amorphous	O
form	O
of	O
olanzapine	B
Formula	O
(	O
I	O
)	O
:	O
and	O
a	O
process	O
for	O
its	O
preparation	O
.	O

The	O
present	O
invention	O
further	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
comprising	O
an	O
amorphous	O
form	O
of	O
olanzapine	B
(	O
I	O
)	O
.	O

The	O
pharmaceutical	O
composition	O
may	O
be	O
used	O
,	O
in	O
particular	O
,	O
for	O
the	O
treatment	O
of	O
psychiatric	O
,	O
psychological	O
or	O
psychotic	O
disorders	O
,	O
anxiety	O
disorders	O
,	O
or	O
gastrointestinal	O
or	O
functional	O
bowel	O
disorders	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
a	O
method	O
of	O
treating	O
said	O
disorders	O
.	O

Amorphous	O
form	O
of	O
Olanzapine	B

The	O
disclosure	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
Y	O
,	O
Y1	O
,	O
Yo	O
,	O
R1	O
,	O
R2	O
,	O
R2	O
,	O
p	O
,	O
R3	O
,	O
R3	O
,	O
A	O
,	O
B	O
and	O
Y2	O
have	O
the	O
meanings	O
given	O
in	O
the	O
description	O
,	O
and	O
to	O
salts	O
thereof	O
,	O
pharmaceutical	O
compositions	O
comprising	O
said	O
compounds	O
and	O
use	O
thereof	O
as	O
protein	O
kinase	O
inhibitors	O
.	O

Heterocycle	B
-	I
Substituted	I
Cyclic	I
Urea	I
Derivatives	O
,	O
Preparation	O
Thereof	O
And	O
Pharmaceutical	O
Use	O

Thereof	O
As	O
Kinase	O
Inhibitors	O

A	O
method	O
of	O
delivery	O
of	O
a	O
combination	O
therapy	O
to	O
the	O
pulmonary	O
system	O
that	O
includes	O
providing	O
a	O
nebulizer	O
and	O
an	O
aqueous	O
solution	O
comprising	O
a	O
long	O
-	O
acting	O
corticosteroid	B
,	O
a	O
long	O
-	O
acting	O
beta	O
-	O
agonist	O
,	O
and	O
a	O
long	O
-	O
acting	O
anticholinergic	O
,	O
and	O
administering	O
the	O
solution	O
to	O
the	O
patient	O
using	O
the	O
nebulizer	O
.	O

The	O
corticosteroid	B
is	O
budesonide	B
,	O
the	O
beta	O
-	O
agonist	O
is	O
formoterol	B
and	O
the	O
anticholinergic	O
is	O
tiotropium	B
.	O

A	O
pharmaceutical	O
composition	O
is	O
also	O
described	O
for	O
the	O
treatment	O
of	O
respiratory	O
conditions	O
and	O
diseases	O
comprising	O
a	O
long	O
-	O
acting	O
corticosteroid	B
,	O
a	O
long	O
-	O
acting	O
beta	O
-	O
agonist	O
,	O
and	O
a	O
long	O
-	O
acting	O
anticholinergic	O
,	O
and	O
administering	O
the	O
solution	O
to	O
the	O
patient	O
using	O
the	O
nebulizer	O
.	O

Delivery	O
of	O
a	O
combination	O
therapy	O
for	O
asthma	O
and	O
chronic	O
obstructive	O
pulmonary	O
disease	O

The	O
use	O
of	O
a	O
compound	O
of	O
formula	O
I	O
in	O
free	O
form	O
or	O
in	O
the	O
form	O
of	O
a	O
pharmaceutically	O
acceptable	O
salt	O
for	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
a	O
functional	O
motility	O
disorder	O
of	O
the	O
viscera	O
.	O

Use	O
of	O
acylaminoalkenylene	B
-	I
amide	I
derivatives	O
in	O
functional	O
motility	O
disorders	O
of	O
the	O
viscera	O

The	O
present	O
invention	O
relates	O
to	O
polynucleotides	O
for	O
multigene	O
applications	O
comprising	O
a	O
novel	O
functional	O
arrangement	O
,	O
as	O
well	O
as	O
vectors	O
,	O
host	O
cells	O
,	O
and	O
recombinant	O
animals	O
comprising	O
said	O
polynucleotides	O
.	O

In	O
addition	O
,	O
the	O
present	O
invention	O
is	O
directed	O
to	O
methods	O
for	O
generating	O
multigene	O
expression	O
cassettes	O
,	O
methods	O
for	O
producing	O
multiprotein	O
complexes	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
and	O
methods	O
for	O
producing	O
a	O
vaccine	O
.	O

Furthermore	O
,	O
the	O
present	O
invention	O
encompasses	O
methods	O
for	O
screening	O
protein	O
complex	O
interactions	O
or	O
modifications	O
of	O
proteins	O
,	O
and	O
methods	O
for	O
the	O
in	O
vitro	O
or	O
in	O
vivo	O
screening	O
of	O
candidate	O
compounds	O
capable	O
of	O
protein	O
complex	O
interactions	O
or	O
modifications	O
of	O
proteins	O
or	O
capable	O
of	O
inhibiting	O
protein	O
complex	O
interactions	O
or	O
inhibiting	O
modifications	O
of	O
proteins	O
.	O

Also	O
,	O
the	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
the	O
polynucleotides	O
,	O
vectors	O
,	O
host	O
cells	O
or	O
recombinant	O
animals	O
of	O
the	O
invention	O
for	O
(	O
i	O
)	O
preparing	O
a	O
medicament	O
for	O
gene	O
therapy	O
,	O
for	O
(	O
ii	O
)	O
the	O
recombinant	O
production	O
of	O
multiprotein	O
complexes	O
,	O
(	O
iii	O
)	O
for	O
producing	O
a	O
vaccine	O
,	O
or	O
(	O
iv	O
)	O
for	O
screening	O
compounds	O
of	O
interest	O
.	O

Last	O
but	O
not	O
least	O
,	O
the	O
invention	O
is	O
directed	O
to	O
a	O
kit	O
of	O
parts	O
comprising	O
at	O
least	O
a	O
polynucleotide	O
,	O
a	O
vector	O
,	O
and/or	O
a	O
host	O
cell	O
according	O
to	O
the	O
invention	O
.	O

New	O
Expression	O
Tools	O
for	O
Multiprotein	O
Applications	O

The	O
present	O
invention	O
relates	O
to	O
metal	O
-	O
phthalocyanines	B
bearing	O
at	O
least	O
a	O
group	O
containing	O
boron	B
isotopes	O
11B	O
or	O
10B	O
,	O
covalently	O
bound	O
to	O
the	O
axial	O
positions	O
of	O
metal	O
-	O
phthalocyanine	B
nucleus	O
;	O
moreover	O
it	O
refers	O
to	O
the	O
process	O
for	O
their	O
preparation	O
,	O
the	O
pharmaceutical	O
compositions	O
comprising	O
them	O
and	O
their	O
use	O
for	O
the	O
treatment	O
of	O
neoplastic	O
and	O
dysplastic	O
pathologies	O
in	O
PDT	O
and/or	O
BNCT	O
.	O

Boronated	O
Metal	O
-	O
Phthalocyanines	O
,	O
Process	O
For	O
Their	O
Preparation	O
,	O
Pharmaceutical	O
Compositions	O
Comprising	O
Them	O

And	O
Use	O
Thereof	O

Compositions	O
and	O
methods	O
for	O
the	O
use	O
of	O
photoactivatable	O
antimicrobial	O
chalcogen	O
analogs	O
of	O
benzophenoxazinium	O
dyes	O
in	O
the	O
treatment	O
of	O
infections	O
are	O
provided	O
.	O

Antimicrobial	O
photoinactivation	O
using	O
chalcogen	O
analogs	O
of	O
benzo	O
(	O
A	O
)	O
phenoxazinium	O
dyes	O

The	O
present	O
invention	O
relates	O
to	O
combinations	O
of	O
serotonin	B
reuptake	O
inhibitors	O
and	O
imidazoline	B
I2	O
agonists	O
as	O
separate	O
chemical	O
units	O
or	O
both	O
properties	O
combined	O
in	O
a	O
single	O
molecule	O
and	O
to	O
the	O
use	O
thereof	O
for	O
the	O
preparation	O
of	O
medicaments	O
for	O
the	O
treatment	O
of	O
depression	O
,	O
obsessive	O
-	O
compulsive	O
disorders	O
(	O
OCDs	O
)	O
,	O
obsessive	O
-	O
compulsive	O
spectrum	O
disorders	O
(	O
OCSDs	O
)	O
and	O
other	O
anxiety	O
states	O
.	O

Combinations	O
of	O
Serotonin	B
Reuptake	O
Inhibitors	O
and	O
Imidazoline	B
I	O
2	O
Agonists	O

Though	O
copper	B
is	O
elevated	O
in	O
the	O
tumor	O
tissue	O
and	O
plasma	O
of	O
patients	O
with	O
various	O
malignancies	O
,	O
the	O
molecular	O
targets	O
for	O
copper	B
binding	O
agents	O
in	O
angiogenesis	O
and	O
tumor	O
progression	O
remain	O
poorly	O
understood	O
.	O

It	O
is	O
disclosed	O
that	O
one	O
anti	O
-	O
angiogenic	O
target	O
for	O
the	O
copper	B
binding	O
agent	O
tetrathiomolybdate	B
is	O
intracellular	O
CuZn	B
-	O
superoxide	B
dismutase	O
(	O
SOD1	O
)	O
.	O

A	O
second	O
generation	O
tetrathiomolybdate	B
analog	O
,	O
ATN-224	O
,	O
inhibits	O
endothelial	O
cell	O
(	O
EC	O
)	O
proliferation	O
in	O
vitro	O
,	O
binds	O
to	O
SOD1	O
and	O
inhibits	O
its	O
activity	O
without	O
displacing	O
bound	O
copper	B
ATN-224	I
can	O
accumulate	O
in	O
ECs	O
and	O
inhibit	O
CuZnSOD	O
activity	O
with	O
an	O
IC50	O
similar	O
to	O
the	O
IC50	O
for	O
EC	O
proliferation	O
,	O
resulting	O
in	O
increased	O
generation	O
of	O
intracellular	O
reactive	O
oxygen	B
species	O
.	O

Inhibition	O
of	O
EC	O
proliferation	O
by	O
ATN-224	O
in	O
vitro	O
is	O
substantially	O
reversed	O
by	O
a	O
synthetic	O
porphyrin	B
SOD	O
mimetic	O
.	O

Similar	O
results	O
were	O
observed	O
in	O
vivo	O
,	O
where	O
inhibition	O
of	O
angiogenesis	O
by	O
ATN-224	O
in	O
a	O
Matrigel	O
plug	O
model	O
was	O
also	O
reversed	O
by	O
MnTBAP	O
.	O

Thus	O
,	O
a	O
distinct	O
molecular	O
target	O
for	O
copper	B
depletion	O
therapy	O
has	O
been	O
identified	O
and	O
SOD1	O
is	O
now	O
validated	O
as	O
a	O
target	O
for	O
anti	O
-	O
angiogenesis	O
.	O

Methods	O
for	O
screening	O
,	O
or	O
designing	O
,	O
such	O
SOD1	O
inhibitors	O
for	O
use	O
as	O
angiogenesis	O
inhibitors	O
and	O
anti	O
-	O
cancer	O
agents	O
are	O
disclosed	O
.	O

Inhibition	O
Of	O
Superoxide	B
Dismutase	O
By	O
Tetrathiomolybdate	B
:	O
Identification	O
Of	O
New	O
Anti	O
-	O
Angiogenic	O
And	O
Antitumor	O
Agents	O

The	O
invention	O
relates	O
to	O
the	O
field	O
of	O
apoptosis	O
.	O

The	O
invention	O
provides	O
novel	O
therapies	O
,	O
for	O
example	O
,	O
novel	O
combinatorial	O
therapies	O
or	O
novel	O
therapeutic	O
compounds	O
that	O
can	O
work	O
alone	O
,	O
sequentially	O
to	O
,	O
or	O
jointly	O
with	O
Apoptin	O
,	O
especially	O
in	O
those	O
cases	O
wherein	O
p53	O
is	O
completely	O
or	O
partially	O
non	O
-	O
functional	O
.	O

Combinatorial	O
therapy	O
;	O
genetic	O
engineered	O
protein	O
;	O
therapy	O
for	O
autoimmune	O
diaeses	O
;	O
anticancer	O
agents	O

The	O
invention	O
is	O
related	O
to	O
polynucleotide	O
-	O
based	O
cytomegalovirus	O
vaccines	O
.	O

In	O
particular	O
,	O
the	O
invention	O
is	O
plasmids	O
operably	O
encoding	O
HCMV	O
antigens	O
,	O
in	O
which	O
the	O
naturally	O
-	O
occurring	O
coding	O
regions	O
for	O
the	O
HCMV	O
antigens	O
have	O
been	O
modified	O
for	O
improved	O
translation	O
in	O
human	O
or	O
other	O
mammalian	O
cells	O
through	O
codon	O
optimization	O
.	O

HCMV	O
antigens	O
which	O
are	O
useful	O
in	O
the	O
invention	O
include	O
,	O
but	O
are	O
not	O
limited	O
to	O
pp65	O
,	O
glycoprotein	O
B	O
(	O
gB	O
)	O
,	O
IE1	O
,	O
and	O
fragments	O
,	O
variants	O
or	O
derivatives	O
of	O
either	O
of	O
these	O
antigens	O
.	O

In	O
certain	O
embodiments	O
,	O
sequences	O
have	O
been	O
deleted	O
,	O
e.g.	O
,	O
the	O
Arg435-Lys438	O
putative	O
kinase	O
in	O
pp65	O
and	O
the	O
membrane	O
anchor	O
and	O
endocellular	O
domains	O
in	O
gB.	O
The	O
invention	O
is	O
further	O
directed	O
to	O
methods	O
to	O
induce	O
an	O
immune	O
response	O
to	O
HCMV	O
in	O
a	O
mammal	O
,	O
for	O
example	O
,	O
a	O
human	O
,	O
comprising	O
delivering	O
a	O
plasmid	O
encoding	O
a	O
codon	O
-	O
optimized	O
HCMV	O
antigen	O
as	O
described	O
above	O
.	O

The	O
invention	O
is	O
also	O
directed	O
to	O
pharmaceutical	O
compositions	O
comprising	O
plasmids	O
encoding	O
a	O
codon	O
-	O
optimized	O
HCMV	O
antigen	O
as	O
described	O
above	O
,	O
and	O
further	O
comprising	O
adjuvants	O
,	O
excipients	O
,	O
or	O
immune	O
modulators	O
.	O

Isolated	O
polynucleotides	O
comprising	O
a	O
nucleic	O
acid	O
which	O
operably	O
encodes	O
50	O
contiguous	O
amino	B
acids	I
,	O
nucleic	O
acids	O
are	O
fragments	O
of	O
a	O
codon	O
-	O
optimized	O
coding	O
region	O
;	O
a	O
carrier	O

The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
Formula	O
I	O
,	O
wherein	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
R6	O
,	O
and	O
R7	O
are	O
defined	O
in	O
the	O
specification	O
.	O

In	O
addition	O
,	O
the	O
present	O
invention	O
relates	O
to	O
methods	O
treating	O
disorders	O
related	O
to	O
matrix	O
metalloproteases	O
.	O

More	O
particularly	O
,	O
the	O
compounds	O
of	O
the	O
present	O
invention	O
are	O
useful	O
for	O
treating	O
stroke	O
.	O

N	B
-	I
Hydroxy	I
(	I
2S	I
)	I
-2-hydroxy	I
phenyl	I
or	I
heteroaryl	I
sulfonamide	I
derivatives	O
;	O
for	O
example	O
,	O
N	B
-	I
Hydroxy	I
(	I
2S	I
)	I
-2-hydroxy-3-	I
{	I
N-	I
[	I
4-	I
(	I
4-	I
chlorophenoxy	I
)	I
phenyl	I
]	I
,	I
N-	I
methanesulfonylamino	I
}	I
propionamide	I
;	O
for	O
treating	O
disorders	O
related	O
to	O
matrix	O
metalloproteases	O
,	O
particularly	O
useful	O
for	O
treating	O
strokes	O
;	O

The	O
present	O
invention	O
provides	O
a	O
polymerizable	O
antimicrobial	O
composition	O
and	O
a	O
method	O
for	O
using	O
the	O
same	O
.	O

The	O
polymerizable	O
antimicrobial	O
composition	O
of	O
the	O
invention	O
comprises	O
an	O
antimicrobial	O
compound	O
,	O
a	O
linker	O
,	O
and	O
a	O
polymerizable	O
function	O
group	O
.	O

Polymerizable	O
antimicrobial	O
composition	O

The	O
present	O
invention	O
provides	O
pharmaceutical	O
compositions	O
for	O
topical	O
delivery	O
comprising	O
a	O
suitable	O
carrier	O
and	O
a	O
codrug	O
capable	O
of	O
penetrating	O
,	O
or	O
being	O
transported	O
across	O
,	O
the	O
dermis	O
.	O

The	O
codrug	O
according	O
to	O
the	O
invention	O
comprises	O
a	O
first	O
constituent	O
moiety	O
linked	O
to	O
a	O
second	O
constituent	O
moiety	O
,	O
wherein	O
the	O
second	O
constituent	O
moiety	O
is	O
the	O
same	O
as	O
,	O
or	O
different	O
from	O
,	O
the	O
first	O
constituent	O
moiety	O
.	O

The	O
first	O
and	O
second	O
constituent	O
moieties	O
are	O
so	O
linked	O
that	O
they	O
are	O
easily	O
transported	O
into	O
or	O
across	O
the	O
dermis	O
,	O
into	O
the	O
skin	O
,	O
or	O
into	O
the	O
blood	O
or	O
lymphatic	O
system	O
,	O
and	O
are	O
reconstituted	O
in	O
vivo	O
to	O
form	O
the	O
first	O
and	O
second	O
constituent	O
moieties	O
.	O

Topical	O
delivery	O
of	O
codrugs	O

The	O
present	O
invention	O
provides	O
methods	O
and	O
compositions	O
for	O
the	O
treatment	O
of	O
ion	O
imbalances	O
.	O

In	O
particular	O
,	O
the	O
invention	O
provides	O
polymeric	O
and	O
pharmaceutical	O
compositions	O
comprising	O
crosslinked	O
amine	O
polymers	O
.	O

Methods	O
of	O
use	O
of	O
the	O
polymeric	O
and	O
pharmaceutical	O
compositions	O
for	O
therapeutic	O
and/or	O
prophylactic	O
benefits	O
are	O
disclosed	O
herein	O
.	O

Examples	O
of	O
these	O
methods	O
include	O
the	O
treatment	O
of	O
renal	O
diseases	O
and	O
hyperphosphatemia	O
.	O

Crosslinked	O
Amine	B
Polymers	O

The	O
present	O
invention	O
relates	O
to	O
liposomes	O
for	O
drug	O
delivery	O
,	O
wherein	O
a	O
liposome	O
includes	O
molecules	O
of	O
at	O
least	O
one	O
desired	O
drug	O
distributed	O
within	O
an	O
aqueous	O
phase	O
in	O
the	O
interior	O
of	O
the	O
liposome	O
and	O
wherein	O
the	O
liposome	O
further	O
includes	O
molecules	O
of	O
the	O
same	O
or	O
of	O
another	O
drug	O
attached	O
to	O
either	O
or	O
both	O
sides	O
of	O
the	O
liposomal	O
membrane	O
.	O

More	O
specifically	O
,	O
the	O
invention	O
relates	O
to	O
liposomes	O
,	O
wherein	O
at	O
least	O
a	O
part	O
of	O
the	O
molecules	O
of	O
a	O
desired	O
drug	O
bear	O
a	O
functional	O
group	O
that	O
is	O
reactive	O
with	O
a	O
functional	O
group	O
present	O
in	O
at	O
least	O
one	O
lipid	O
fraction	O
,	O
and	O
wherein	O
the	O
drug	O
is	O
covalently	O
linked	O
to	O
the	O
membrane	O
lipids	O
by	O
chemical	O
bonding	O
,	O
e.g.	O
by	O
ester	B
bonding	O
of	O
a	O
hydroxyl	B
group	O
of	O
a	O
lipid	O
molecule	O
and	O
an	O
acidic	O
residue	O
of	O
the	O
drug	O
.	O

In	O
a	O
preferred	O
embodiment	O
,	O
the	O
desired	O
drug	O
is	O
a	O
glycoprotein	O
such	O
as	O
erythropoietin	O
.	O

The	O
invention	O
further	O
relates	O
to	O
a	O
method	O
of	O
manufacture	O
of	O
said	O
liposomes	O
and	O
to	O
pharmaceutical	O
compositions	O
containing	O
them	O
.	O

drug	O
delivery	O
devices	O
comprising	O
capsules	O
containing	O
drugs	O
distributed	O
within	O
an	O
aqueous	O
phase	O
in	O
the	O
interior	O
of	O
the	O
capsule	O

The	O
present	O
invention	O
provides	O
methods	O
of	O
identifying	O
endocrine	O
stem	O
and	O
progenitor	O
cells	O
.	O

Hes6	O
as	O
a	O
marker	O
of	O
pancreatic	O
endocrine	O
cells	O

Compounds	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
X	O
is	O
a	O
fluorine	B
or	O
a	O
chlorine	B
atom	O
;	O
the	O
methyl	B
groups	O
located	O
at	O
the	O
2-	O
and	O
5-position	O
of	O
the	O
piperazine	B
ring	O
are	O
in	O
trans	O
-	O
configuration	O
to	O
each	O
other	O
;	O
Y	O
is	O
NH	B
or	O
O	B
;	O
R1	O
is	O
selected	O
from	O
hydrogen	B
,	O
chloro	B
,	O
bromo	B
,	O
nitro	B
,	O
methyl	B
or	O
trifluoromethyl	B
;	O
R2	O
is	O
selected	O
from	O
hydrogen	B
,	O
halo	B
,	O
methyl	B
,	O
trifluoromethyl	B
,	O
methoxy	B
or	O
trifluoromethoxy	B
;	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
solvate	O
thereof	O
;	O
The	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
containing	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
together	O
with	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O

Included	O
are	O
also	O
processes	O
for	O
the	O
preparation	O
of	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
as	O
well	O
as	O
methods	O
for	O
treating	O
mammals	O
suffering	O
from	O
inflammatory	O
,	O
autoimmune	O
,	O
proliferative	O
or	O
hyperproliferative	O
diseases	O
by	O
administering	O
a	O
compound	O
having	O
the	O
formula	O
(	O
I	O
)	O
to	O
said	O
mammal	O
.	O

Novel	O
Benzofurans	B
and	O
Indols	B

The	O
present	O
invention	O
provides	O
a	O
method	O
for	O
suppression	O
of	O
ultra	O
violet	O
-	O
induced	O
skin	O
pathologies	O
and	O
skin	O
abnormalities	O
,	O
such	O
as	O
abnormal	O
proliferation	O
and	O
mutagenesis	O
,	O
and	O
for	O
inducing	O
apoptosis	O
in	O
cells	O
having	O
Erbb2	O
or	O
HER2	O
receptors	O
.	O

The	O
method	O
involves	O
administration	O
of	O
Erbb2	O
/	O
HER2	O
inhibitors	O
,	O
either	O
before	O
or	O
after	O
exposure	O
to	O
UV	O
.	O

Topically	O
administrating	O
an	O
inhibitor	O
of	O
Erbb2	O
or	O
HER2	O
receptor	O
tyrosine	B
kinase	O
activity	O
because	O
of	O
a	O
novel	O
connection	O
between	O
HER2	O
and	O
a	O
DNA	O
damage	O
checkpoint	O
;	O
reducing	O
mutagenesis	O
and	O
apoptosis	O
;	O
antitumor	O
,	O
-carcinogenic	O
,	O
-proliferative	O
agents	O
and	O
-inflammatory	O
agents	O
;	O
sunburn	O
;	O
hyperplasia	O

The	O
present	O
invention	O
relates	O
to	O
a	O
substantially	O
pure	O
biologically	O
active	O
consecutive	O
anti	O
-	O
angiogenic	O
polypeptide	O
comprising	O
the	O
central	O
region	O
of	O
human	O
Histidine	B
Rich	O
Glycoprotein	O
(	O
HRGP	O
)	O
.	O

Said	O
polypeptide	O
is	O
shown	O
to	O
comprise	O
a	O
potential	O
endogenous	O
,	O
naturally	O
occurring	O
subfragment	O
of	O
human	O
HRGP	O
,	O
comprising	O
similar	O
anti	O
-	O
angiogenic	O
activities	O
as	O
the	O
mature	O
protein	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
one	O
or	O
more	O
new	O
biologically	O
active	O
subfragments	O
of	O
human	O
HRGP	O
,	O
derived	O
from	O
said	O
central	O
region	O
.	O

Said	O
subfragments	O
are	O
all	O
characterized	O
by	O
having	O
anti	O
-	O
angiogenic	O
activity	O
.	O

One	O
of	O
the	O
active	O
subfragments	O
is	O
referred	O
to	O
as	O
Pep2	O
.	O

Enscoped	O
by	O
the	O
present	O
invention	O
are	O
also	O
anti	O
-	O
angiogenic	O
subfragments	O
derived	O
from	O
Pep2	O
,	O
one	O
of	O
them	O
comprising	O
a	O
newly	O
identified	O
presently	O
minimal	O
functional	O
entity	O
.	O

Endogenous	O
Peptide	O
and	O
Active	O
Subfragments	O
Thereof	O

Disclosed	O
is	O
a	O
viral	O
vector	O
containing	O
a	O
nucleic	O
acid	O
sequence	O
encoding	O
erythropoietin	O
(	O
Epo	O
)	O
,	O
in	O
operable	O
linkage	O
with	O
an	O
HRE	O
expression	O
control	O
sequence	O
,	O
as	O
well	O
as	O
uses	O
of	O
the	O
vector	O
;	O
for	O
instance	O
,	O
in	O
preparing	O
a	O
medicament	O
.	O

Also	O
provided	O
are	O
methods	O
for	O
treating	O
anemia	O
,	O
can	O
involve	O
administering	O
the	O
vector	O
to	O
a	O
patient	O
,	O
wherein	O
expression	O
of	O
Epo	O
is	O
physiologically	O
regulated	O
such	O
that	O
hematocrit	O
levels	O
of	O
the	O
patient	O
are	O
corrected	O
and	O
maintained	O
.	O

Administering	O
vector	O
system	O
that	O
directs	O
regulated	O
erythropoietin	O
(	O
Epo	O
)	O
gene	O
therapy	O
in	O
a	O
manner	O
that	O
physiologically	O
corrects	O
the	O
hematocrit	O
levels	O
in	O
a	O
patient	O
in	O
need	O
of	O
anemia	O
treatment	O

The	O
present	O
invention	O
provides	O
a	O
method	O
for	O
screening	O
for	O
a	O
prophylactic	O
or	O
therapeutic	O
drug	O
for	O
apoptosis	O
or	O
an	O
inflammation	O
-	O
associated	O
disease	O
,	O
diabetes	O
and	O
complications	O
thereof	O
or	O
a	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
,	O
namely	O
,	O
a	O
method	O
for	O
screening	O
for	O
a	O
prophylactic	O
or	O
therapeutic	O
drug	O
for	O
apoptosis	O
or	O
an	O
inflammation	O
-	O
associated	O
disease	O
,	O
diabetes	O
and	O
complications	O
thereof	O
or	O
COPD	O
,	O
which	O
includes	O
(	O
1	O
)	O
comparing	O
the	O
activities	O
of	O
a	O
protein	O
having	O
an	O
amino	B
acid	I
sequence	O
the	O
same	O
as	O
or	O
substantially	O
the	O
same	O
as	O
the	O
amino	O
acid	O
sequence	O
shown	O
by	O
SEQ	O
ID	O
NO	O
:	O
2	O
or	O
a	O
partial	O
peptide	O
thereof	O
or	O
a	O
salt	O
thereof	O
,	O
between	O
in	O
the	O
presence	O
of	O
a	O
test	O
substance	O
and	O
in	O
the	O
absence	O
of	O
the	O
test	O
substance	O
,	O
or	O
(	O
2	O
)	O
comparing	O
the	O
expressions	O
of	O
a	O
protein	O
having	O
an	O
amino	B
acid	I
sequence	O
the	O
same	O
as	O
or	O
substantially	O
the	O
same	O
as	O
the	O
amino	B
acid	I
sequence	O
shown	O
by	O
SEQ	O
ID	O
NO	O
:	O
2	O
,	O
a	O
partial	O
peptide	O
thereof	O
and	O
a	O
salt	O
thereof	O
in	O
the	O
cells	O
having	O
the	O
ability	O
to	O
produce	O
the	O
protein	O
,	O
the	O
partial	O
peptide	O
thereof	O
and	O
the	O
salt	O
thereof	O
,	O
between	O
in	O
the	O
presence	O
of	O
a	O
test	O
substance	O
and	O
in	O
the	O
absence	O
of	O
the	O
test	O
substance	O
.	O

For	O
prophylaxis	O
or	O
treatment	O
of	O
apoptosis	O
or	O
inflammation	O
-	O
associated	O
disease	O
,	O
diabetes	O
,	O
or	O
chronic	O
obstructive	O
pulmonary	O
disease	O

The	O
application	O
discloses	O
a	O
role	O
of	O
p62	O
in	O
aging	O
-	O
related	O
disease	O
,	O
such	O
as	O
development	O
of	O
obesity	O
,	O
type	O
2	O
diabetes	O
mellitus	O
,	O
non	O
-	O
alcoholic	O
fatty	O
liver	O
,	O
various	O
tumors	O
,	O
increased	O
male	O
mortality	O
,	O
intracellular	O
inclusion	O
named	O
sequestosome	O
,	O
and	O
redox	O
regulation	O
.	O

In	O
particular	O
the	O
application	O
discloses	O
a	O
method	O
of	O
detecting	O
the	O
formation	O
of	O
inclusion	O
bodies	O
in	O
neurodegenerative	O
diseases	O
.	O

The	O
invention	O
further	O
relates	O
to	O
a	O
method	O
of	O
screening	O
for	O
therapeutic	O
agents	O
that	O
disperse	O
the	O
inclusions	O
.	O

Further	O
,	O
transgenic	O
mice	O
containing	O
a	O
mutation	O
in	O
the	O
p62	O
gene	O
and	O
having	O
a	O
functionally	O
disrupted	O
p62	O
gene	O
locus	O
are	O
also	O
disclosed	O
.	O

Screening	O
for	O
a	O
compound	O
which	O
inhibits	O
p62	O
/	O
ubiquitin	O
binding	O
;	O
detecting	O
the	O
formation	O
of	O
inclusion	O
bodies	O
in	O
neurodegenerative	O
diseases	O
;	O
screening	O
for	O
therapeutic	O
agents	O
that	O
disperse	O
the	O
inclusions	O

The	O
present	O
invention	O
provides	O
an	O
agent	O
for	O
preventing	O
or	O
treating	O
organ	O
functional	O
disorders	O
,	O
an	O
agent	O
for	O
preventing	O
or	O
treating	O
organ	O
dysfunction	O
and	O
an	O
agent	O
for	O
preventing	O
or	O
treating	O
obesity	O
and	O
deuteropathy	O
thereof	O
,	O
each	O
of	O
which	O
comprises	O
a	O
compound	O
having	O
an	O
effect	O
of	O
increasing	O
ubiquinone	B
or	O
a	O
salt	O
thereof	O
or	O
a	O
prodrug	O
thereof	O
;	O
as	O
well	O
as	O
a	O
ubiquinone	B
increasing	O
agent	O
comprising	O
a	O
compound	O
having	O
a	O
squalene	O
synthase	O
inhibitory	O
effect	O
or	O
a	O
salt	O
thereof	O
or	O
a	O
prodrug	O
thereof	O
.	O

Administering	O
(	B
3R,5S	I
)	I
-N	I
-	I
propanesulfonyl-7-chloro-5-	I
(	I
2,3-dimethoxyphenyl	I
)	I
-1-	I
(	I
3-hydroxy-2,2-dimethylpropyl	I
)	I
-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetamide	I
;	O
cerebral	O
infarction	O

A	O
compound	O
represented	O
by	O
the	O
following	O
general	O
formula	O
(	O
1	O
)	O
or	O
a	O
salt	O
thereof	O
or	O
a	O
hydrate	O
of	O
the	O
foregoing	O
is	O
safe	O
while	O
exhibiting	O
suitable	O
physicochemical	O
stability	O
,	O
and	O
is	O
useful	O
as	O
therapeutic	O
or	O
prophylactic	O
agents	O
for	O
diseases	O
associated	O
with	O
thrombus	O
formation	O
.	O

wherein	O
R1a	O
,	O
R1b	O
,	O
R1c	O
and	O
R1d	O
each	O
independently	O
represent	O
hydrogen	B
,	O
etc	O
.	O
,	O
R2	O
represents	O
optionally	O
substituted	O
phenyl	B
,	O
etc	O
.	O
,	O
R3	O
represents	O
optionally	O
substituted	O
C6	B
-	I
10	I
aryl	I
,	O
etc	O
.	O
,	O
Z1	O
,	O
Z2	O
and	O
Z3	O
each	O
independently	O
represent	O
hydrogen	B
,	O
etc	O
.	O
,	O
Z4	O
represents	O
hydrogen	B
,	O
etc	O
.	O
and	O
X	O
represents	O
a	O
single	O
bond	O
or	O
CO	B
,	O
etc	O
.	O

Hydrazide	B
Derivatives	O

The	O
invention	O
provides	O
a	O
method	O
of	O
reducing	O
flushing	O
induced	O
by	O
niacin	B
or	O
a	O
niacin	B
analog	O
in	O
a	O
subject	O
,	O
comprising	O
administering	O
to	O
said	O
subject	O
an	O
effective	O
flush	O
reducing	O
amount	O
of	O
a	O
niacin	B
receptor	O
partial	O
agonist	O
.	O

In	O
addition	O
,	O
the	O
invention	O
provides	O
a	O
method	O
of	O
reducing	O
flushing	O
induced	O
by	O
niacin	B
or	O
a	O
niacin	B
analog	O
in	O
a	O
subject	O
,	O
comprising	O
administering	O
to	O
said	O
subject	O
an	O
effective	O
flush	O
reducing	O
amount	O
of	O
a	O
niacin	B
receptor	O
partial	O
agonist	O
and	O
an	O
effective	O
lipid	O
altering	O
amount	O
of	O
niacin	B
or	O
a	O
niacin	B
analog	O
.	O

The	O
invention	O
further	O
provides	O
a	O
method	O
of	O
reducing	O
flushing	O
induced	O
by	O
niacin	B
or	O
a	O
niacin	B
analog	O
in	O
a	O
subject	O
,	O
comprising	O
administering	O
to	O
said	O
subject	O
an	O
effective	O
flush	O
reducing	O
amount	O
of	O
a	O
niacin	B
receptor	O
partial	O
agonist	O
and	O
subsequently	O
administering	O
to	O
said	O
subject	O
an	O
effective	O
lipid	O
altering	O
amount	O
of	O
niacin	B
or	O
a	O
niacin	B
analog	O
.	O

Compositions	O
For	O
Treating	O
Flushing	O
And	O
Lipid	O
-	O
Associated	O
Disorders	O
Comprising	O
Niacin	B
Receptor	O
Partial	O
Agonists	O

An	O
object	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
a	O
stable	O
aqueous	O
pharmaceutical	O
composition	O
which	O
suppresses	O
degradation	O
of	O
prostaglandin	B
F2	I
in	O
a	O
preparation	O
containing	O
prostaglandin	B
F2	I
.	O

The	O
object	O
was	O
attained	O
by	O
formulating	O
a	O
prostaglandin	B
F2	I
derivative	O
into	O
an	O
oil	O
-	O
in	O
-	O
water	O
emulsion	O
together	O
with	O
an	O
oil	O
,	O
for	O
example	O
,	O
medium	O
chain	O
fatty	B
acid	I
triglyceride	B
,	O
a	O
water	O
-	O
soluble	O
polymer	O
and	O
water	O
.	O

Pharmaceutical	O
Composition	O
Containing	O
Prostaglandin	B

The	O
present	O
invention	O
provides	O
injectable	O
formulations	O
of	O
water	O
-	O
soluble	O
salts	O
of	O
diclofenac	B
in	O
single	O
doses	O
of	O
less	O
than	O
2	O
ml	O
,	O
which	O
cause	O
significantly	O
less	O
pain	O
at	O
the	O
site	O
of	O
injection	O
and	O
can	O
be	O
administered	O
by	O
intradeltoid	O
route	O
,	O
in	O
addition	O
to	O
intragluteal	O
and	O
slow	O
intravenous	O
route	O
.	O

More	O
specifically	O
the	O
injectable	O
preparations	O
contain	O
75	O
mg	O
to	O
100	O
mg	O
of	O
water	O
-	O
soluble	O
salts	O
of	O
diclofenac	B
,	O
in	O
about	O
1	O
ml	O
injection	O
solution	O
without	O
significantly	O
raising	O
the	O
viscosity	O
of	O
the	O
injection	O
solution	O
without	O
the	O
use	O
surfactants	O
.	O

The	O
formulations	O
are	O
adjusted	O
to	O
pH	O
6	O
to	O
10	O
containing	O
up	O
to	O
100	O
mg	O
of	O
diclofenac	B
salt	O
in	O
a	O
medium	O
comprising	O
of	O
water	O
,	O
along	O
with	O
one	O
or	O
more	O
co	O
-	O
solvent	O
(	O
s	O
)	O
/	O
solubiliser	O
(	O
s	O
)	O
,	O
antioxidants	O
,	O
preservatives	O
,	O
buffers	O
,	O
alkali	O
and	O
stabilizers	O
.	O

Injectable	O
Preparations	O
Of	O
Diclofenac	B
And	O
Its	O
Pharmaceutically	O
Acceptable	O
Salts	O

The	O
present	O
disclosure	O
provides	O
a	O
composition	O
for	O
enhancing	O
effect	O
of	O
an	O
inhibitor	O
in	O
inhibiting	O
NAD+	B
/	O
NADP+	B
or	O
NADH	B
/	O
NADPH	B
dependent	O
enzymes	O
.	O

The	O
inhibition	O
of	O
the	O
NAD+	B
/	O
NADP+	B
or	O
NADH	B
/	O
NADPH	B
dependent	O
enzymes	O
such	O
as	O
Enoyl	O
-	O
ACP	O
reductase	O
(	O
ENR	O
)	O
by	O
the	O
composition	O
of	O
the	O
present	O
disclosure	O
serves	O
as	O
a	O
target	O
for	O
treating	O
malaria	O
and	O
other	O
infectious	O
diseases	O
.	O

The	O
present	O
disclosure	O
provides	O
composition	O
comprising	O
inhibitor	O
and	O
polyphenol	B
,	O
wherein	O
the	O
polyphenol	B
was	O
found	O
to	O
enhance	O
the	O
inhibitory	O
activity	O
of	O
the	O
inhibitor	O
.	O

The	O
present	O
disclosure	O
provides	O
method	O
for	O
treating	O
an	O
infectious	O
disease	O
comprising	O
administering	O
an	O
effective	O
amount	O
of	O
the	O
composition	O
of	O
the	O
present	O
disclosure	O
to	O
patients	O
in	O
need	O
thereof	O
.	O

The	O
present	O
disclosure	O
further	O
provides	O
a	O
method	O
for	O
identifying	O
a	O
compound	O
that	O
enhances	O
the	O
effect	O
of	O
the	O
inhibitor	O
,	O
a	O
method	O
of	O
determining	O
the	O
antimalarial	O
activity	O
of	O
a	O
compound	O
and	O
use	O
of	O
polyphenol	B
as	O
a	O
bioenhancer	O
that	O
enhances	O
effect	O
of	O
an	O
inhibitor	O
for	O
inhibiting	O
NAD+	B
/	O
NADP+	B
or	O
NADH	B
/	O
NADPH	B
dependent	O
enzymes	O
.	O

The	O
present	O
disclosure	O
provides	O
a	O
composition	O
comprising	O
inhibitor	O
and	O
a	O
polyphenol	B
wherein	O
the	O
polyphenol	B
enhances	O
effect	O
of	O
the	O
inhibitor	O
for	O
inhibiting	O
aldose	O
reductase	O
for	O
treating	O
complications	O
of	O
diabetes	O
that	O
include	O
diabetic	O
retinopathy	O
,	O
cataract	O
neuropathy	O
and	O
neural	O
complication	O
.	O

Synergistic	O
composition	O
for	O
modulating	O
activity	O
of	O
substrate	O
analogs	O
for	O
NAD+	O
,	O
NADP+	O
,	O
NADH	O
or	O
NADPH	O
dependent	O
enzymes	O
and	O
process	O
thereof	O

[	O
Object	O
]	O
Is	O
to	O
provide	O
a	O
novel	O
compound	O
having	O
an	O
anti	O
-	O
viral	O
activity	O
,	O
particularly	O
a	O
HIV	O
integrase	O
inhibitory	O
activity	O
,	O
and	O
an	O
agent	O
,	O
particularly	O
an	O
anti	O
-	O
HIV	O
agent	O
.	O

[	O
Solving	O
means	O
]	O
A	O
compound	O
represented	O
by	O
the	O
formula	O
:	O
(	O
wherein	O
Z1	O
is	O
NR4	B
(	O
R4	O
is	O
hydrogen	B
,	O
optionally	O
substituted	O
lower	O
alkyl	B
etc	O
.	O
)	O
,	O
O	B
or	O
CH2	B
;	O
Z2	O
is	O
optionally	O
substituted	O
lower	O
alkylene	O
or	O
optionally	O
substituted	O
lower	O
alkenylene	O
,	O
each	O
may	O
be	O
intervened	O
by	O
a	O
heteroatom	O
group	O
selected	O
from	O
group	O
consisting	O
O	O
,	O
S	O
,	O
SO	O
,	O
SO2	O
,	O
NR5	O
(	O
R5	O
is	O
selected	O
independently	O
from	O
the	O
same	O
substituent	O
group	O
of	O
R4	O
)	O
N	B
	I
and	O
	B
N	I
;	O
R1	O
is	O
hydrogen	B
or	O
lower	O
alkyl	B
;	O
X	O
is	O
a	O
single	O
bond	O
,	O
a	O
heteroatom	O
group	O
selected	O
from	O
O	B
,	O
S	B
,	O
SO	B
,	O
SO2	B
and	O
NH	B
,	O
or	O
lower	O
alkylene	B
or	O
lower	O
alkenylene	B
each	O
may	O
be	O
intervened	O
by	O
the	O
heteroatom	O
group	O
;	O
R2	O
is	O
optionally	O
substituted	O
aryl	B
;	O
R3	O
is	O
hydrogen	B
,	O
halogen	B
,	O
hydroxy	B
,	O
optionally	O
substituted	O
alkyl	O
group	O
etc	O
.	O
)	O
e.g.	O
9-Hydroxy-2-	B
(	I
2-methoxy	I
-	I
ethyl	I
)	I
-1,8-dioxo-1,8-dihydro-2H	I
-	I
pyrid	I
[	I
1,2-a	I
]	I
pyrazi	I
ne-7-carboxylic	I
acid	I
4-fluoro	I
-	I
banzylamide	I
;	O
Human	O
T	O
cell	O
leukemia	O
virus	O
,	O
Feline	O
and	O
Simian	O
immunodeficiency	O
virus	O
inhibitor	O
;	O
side	O
effects	O
reduction	O

Erlotinib	B
hydrochloride	I
hydrate	I
is	O
formed	O
from	O
an	O
aqueous	O
solution	O
and	O
is	O
useful	O
as	O
a	O
pharmaceutical	O
and	O
as	O
a	O
purification	O
intermediate	O
.	O

Crystalline	O
,	O
formed	O
by	O
crystallizing	O
from	O
an	O
aqueous	O
solution	O
without	O
agitation	O
;	O
treating	O
cancer	O

Compositions	O
are	O
provided	O
for	O
the	O
topical	O
treatment	O
of	O
cancer	O
consisting	O
of	O
lotions	O
,	O
creams	O
,	O
sprays	O
,	O
suppositories	O
or	O
slow	O
-	O
release	O
transdermal	O
patches	O
containing	O
lipid	O
-	O
soluble	O
,	O
skin	O
-	O
penetrating	O
organic	O
selenium	B
compounds	O
in	O
combination	O
with	O
inert	O
carriers	O
in	O
therapeutically	O
effective	O
amounts	O
of	O
selenium	B
compound	O
.	O

The	O
selenium	B
compounds	O
are	O
medium	O
linear	O
chain	O
dialkyl	B
diselenides	O
and	O
precursors	O
such	O
as	O
alkyl	B
selenols	I
.	O

Preferred	O
compositions	O
employ	O
R	B
	I
Se	I
	I
Se	I
	I
R	I
compounds	O
where	O
R	O
is	O
from	O
6	O
to	O
8	O
carbon	B
atoms	O
,	O
and	O
most	O
specifically	O
di	B
-	I
n	I
-	I
hexyl	I
diselenide	I
.	O

Commonly	O
used	O
carriers	O
may	O
be	O
purified	O
hydrocarbon	B
fractions	O
,	O
oils	O
,	O
with	O
or	O
without	O
added	O
fat	O
-	O
soluble	O
vitamins	O
,	O
water	O
and	O
emulsifying	O
agents	O
.	O

Compositions	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
cancer	O

The	O
present	O
invention	O
is	O
directed	O
to	O
small	O
interfering	O
RNA	O
molecules	O
(	O
siRNA	O
)	O
targeted	O
against	O
an	O
allele	O
of	O
interest	O
,	O
and	O
methods	O
of	O
using	O
these	O
siRNA	O
molecules	O
.	O

Allele	O
-	O
specific	O
silencing	O
of	O
disease	O
genes	O

The	O
present	O
invention	O
relates	O
to	O
a	O
stable	O
pharmaceutical	O
composition	O
comprising	O
sirolimus	O
.	O

The	O
pharmaceutical	O
composition	O
comprises	O
sirolimus	O
in	O
the	O
amorphous	O
form	O
,	O
a	O
fatty	B
acid	I
ester	I
and	O
a	O
pharmaceutically	O
acceptable	O
polymer	O
wherein	O
the	O
fatty	B
acid	I
ester	I
is	O
present	O
at	O
a	O
concentration	O
of	O
less	O
than	O
10	O
%	O
w	O
/	O
w	O
compared	O
to	O
the	O
total	O
weight	O
of	O
the	O
composition	O
.	O

Sirolimus	O
Formulation	O

The	O
invention	O
provides	O
N-	B
{	I
2-	I
[	I
(	I
(	I
2S	I
)	I
-3-	I
{	I
[	I
1-	I
(	I
4-chlorobenzyl	I
)	I
piperidin-4-yl	I
]	I
amino	I
}	I
-2-hydroxy-2-methyl	I
-	I
propyl	I
)	I
oxy	I
]	I
-4-hydroxyphenyl	I
}	I
acetamide	I
hemi	I
-	I
fumarate	I
or	O
a	O
solvate	O
thereof	O
,	O
pharmaceutical	O
compositions	O
containing	O
the	O
salt	O
or	O
solvate	O
and	O
use	O
of	O
the	O
salt	O
or	O
solvate	O
in	O
therapy	O
.	O

N-	B
{	I
2-	I
[	I
(	I
(	I
2S	I
)	I
-3-	I
{	I
[	I
1-	I
(	I
4-chlorobenzyl	I
)	I
piperidin-4-yl	I
]	I
amino	I
}	I
-2-hydroxy-2-methylpropyl	I
)	I
oxy	I
]	I
-4-hydroxyphenyl	I
}	I
acetamide	I
hemifumarate	I
;	O
chemokine	O
receptor	O
1	O
modulation	O
;	O
chronic	O
obstructive	O
pulmonary	O
disease	O
,	O
asthma	O
;	O
chemical	O
stability	O
;	O
easy	O
to	O
handle	O
;	O
inhalant	O
formulations	O

Disclosed	O
is	O
a	O
composition	O
and	O
method	O
,	O
for	O
various	O
conditions	O
,	O
including	O
body	O
weight	O
control	O
,	O
sexual	O
dysfunction	O
,	O
stomach	O
blotting	O
,	O
heartburn	O
,	O
body	O
pain	O
,	O
and	O
controlling	O
cholesterol	B
,	O
arginine	B
is	O
used	O
as	O
active	O
material	O
.	O

The	O
composition	O
is	O
in	O
the	O
form	O
of	O
lotion	O
/	O
cream	O
applicable	O
to	O
any	O
part	O
of	O
the	O
body	O
and	O
still	O
functional	O
.	O

It	O
does	O
not	O
need	O
to	O
be	O
applied	O
on	O
problematic	O
site	O
.	O

Weight	O
control	O
;	O
sexual	O
disorders	O
;	O
stomach	O
blotting	O
;	O
gastrointestinal	O
disorders	O
;	O
anticholesterol	O
agents	O

An	O
analgesic	O
composition	O
for	O
external	O
application	O
for	O
increasing	O
the	O
percutaneous	O
permeability	O
of	O
tramadol	B
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
and	O
for	O
achieving	O
a	O
quick	O
pharmacological	O
effect	O
.	O

The	O
analgesic	O
composition	O
includes	O
tramadol	B
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
a	O
menthol	B
substance	O
and	O
a	O
pyrrolidone	B
compound	O
.	O

External	O
pharmaceutical	O
composition	O
containing	O
tramadol	B

The	O
invention	O
provides	O
a	O
method	O
for	O
improving	O
the	O
bioavailability	O
,	O
preferably	O
,	O
oral	O
bioavailability	O
and/or	O
drug	O
disposition	O
,	O
e.g.	O
brain	O
penetration	O
,	O
of	O
an	O
iron	B
chelator	O
,	O
which	O
method	O
comprises	O
co	O
-	O
administering	O
to	O
a	O
mammal	O
,	O
especially	O
a	O
human	O
,	O
in	O
need	O
of	O
such	O
treatment	O
,	O
a	O
combination	O
of	O
an	O
iron	B
chelator	O
and	O
an	O
efflux	O
protein	O
inhibitor	O
.	O

Methods	O
for	O
Improving	O
Drug	O
Disposition	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
pharmaceutical	O
dosage	O
forms	O
with	O
controlled	O
release	O
of	O
active	O
ingredient	O
which	O
comprise	O
the	O
PDE	O
5	O
inhibitor	O
vardenafil	B
and/or	O
pharmaceutically	O
acceptable	O
salts	O
,	O
hydrates	B
,	O
solvates	O
and/or	O
polymorphic	O
forms	O
thereof	O
as	O
active	O
ingredient	O
,	O
and	O
to	O
the	O
production	O
thereof	O
.	O

The	O
invention	O
further	O
relates	O
to	O
the	O
use	O
of	O
these	O
novel	O
pharmaceutical	O
dosage	O
forms	O
as	O
medicaments	O
,	O
and	O
to	O
their	O
use	O
for	O
producing	O
medicaments	O
for	O
the	O
treatment	O
and/or	O
prevention	O
of	O
disorders	O
in	O
humans	O
and	O
animals	O
.	O

Containing	O
phosphodiesterase	O
inhibitor	O
vardensfil	B
;	O
erectile	O
dysfunction	O

Compounds	O
of	O
Formula	O
(	O
Ia	O
)	O
wherein	O
R	O
is	O
a	O
C6-C12	B
substituted	I
or	I
unsubstituted	I
aryl	I
,	O
a	O
C6-C12	B
substituted	I
or	I
unsubstituted	I
heteroaryl	I
,	O
a	O
C1-C6	B
substituted	I
or	I
unsubstituted	I
alkyl	I
or	I
NRR	I
,	O
Q	O
is	O
C	B
(	I
O	I
)	I
,	O
O	B
,	O
NR	B
,	O
S	B
,	O
S	B
(	I
O	I
)	I
2	I
,	O
C	B
(	I
O	I
)	I
2	I
(	B
CH2	I
)	I
p	I
Y	O
is	O
C	B
(	I
O	I
)	I
,	O
O	B
,	O
NR	B
,	O
S	B
,	O
S	B
(	I
O	I
)	I
2	I
,	O
C	B
(	I
O	I
)	I
2	I
(	I
CH2	I
)	I
p	I
Z	O
is	O
H	B
or	O
C1-C4	B
alkyl	I
,	O
R	O
is	O
H	B
,	O
C	B
(	I
O	I
)	I
,	O
S	B
(	I
O	I
)	I
2	I
,	O
C	B
(	I
O	I
)	I
2	I
,	O
a	O
C6-C12	B
substituted	I
or	I
unsubstituted	I
aryl	I
,	O
a	O
C6-C12	B
substituted	I
or	I
unsubstituted	I
heteroaryl	I
or	I
a	I
C1-C6	I
substituted	I
or	I
unsubstituted	I
alkyl	I
,	O
when	O
substituted	O
,	O
aryl	B
,	O
heteroaryl	B
and	O
alkyl	B
are	O
substituted	O
with	O
halogen	B
,	O
C6-C12	B
heteroaryl	I
,	O
NRR	B
or	O
COOZ	B
,	O
which	O
have	O
diagnostic	O
and	O
therapeutic	O
properties	O
,	O
such	O
as	O
the	O
treatment	O
and	O
management	O
of	O
prostate	O
cancer	O
and	O
other	O
diseases	O
related	O
to	O
NAALADase	O
inhibition	O
.	O

Radiolabels	O
can	O
be	O
incorporated	O
into	O
the	O
structure	O
through	O
a	O
variety	O
of	O
prosthetic	O
groups	O
attached	O
at	O
the	O
X	O
amino	B
acid	I
side	O
chain	O
via	O
a	O
carbon	B
or	O
hetero	B
atom	O
linkage	O
.	O

Heterodimers	O
of	O
glutamic	B
acid	I

Chemical	O
entities	O
that	O
modulate	O
smooth	O
muscle	O
myosin	O
and/or	O
non	O
-	O
muscle	O
myosin	O
,	O
pharmaceutical	O
compositions	O
and	O
methods	O
of	O
treatment	O
of	O
diseases	O
and	O
conditions	O
associated	O
with	O
smooth	O
muscle	O
myosin	O
and/or	O
non	O
-	O
muscle	O
myosin	O
are	O
described	O
.	O

E.g.	O
,	O
[	B
(	I
1-	I
(	I
2-aminoacetyl	I
)	I
-4-	I
{	I
N-	I
[	I
(	I
3-fluoro-2-methylphenyl	I
)	I
methyl	I
]	I
carbamoyl	I
}	I
(	I
4-piperidyl	I
)	I
)	I
methoxy	I
]	I
-N-	I
(	I
4-ethylphenyl	I
)	I
carboxamide	I
;	O
smooth	O
muscle	O
myosin	O
or	O
non	O
-	O
muscle	O
myosin	O
modulator	O
;	O
hypotensive	O
agent	O
;	O
asthma	O
,	O
COPD	O
,	O
bronchoconstrictive	O
disease	O
,	O
glaucoma	O
,	O
pre	O
-	O
menstrual	O
cramps	O
,	O
erectile	O
dysfunction	O

Compounds	O
of	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
,	O
solvate	O
or	O
prodrug	O
thereof	O
,	O
are	O
disclosed	O
:	O
wherein	O
R1	O
is	O
C1	B
-	I
6alkyl	I
,	O
haloC1	B
-	I
6alkyl	I
,	O
C2	B
-	I
6alkenyl	I
,	O
amino	B
,	O
monoC1	B
-	I
4alkylamino	I
or	O
diC1	B
-	I
4alkylamino	I
;	O
R2	O
and	O
R3	O
,	O
which	O
may	O
be	O
the	O
same	O
or	O
different	O
,	O
are	O
hydrogen	B
,	O
halogen	B
,	O
C1	B
-	I
6alkyl	I
,	O
haloC1	B
-	I
6alkyl	I
,	O
C1	B
-	I
4alkoxy	I
,	O
haloC1	B
-	I
4alkoxy	I
,	O
cyano	B
,	O
amino	B
,	O
monoC1	B
-	I
4alkylamino	I
or	O
diC1	B
-	I
4alkylamino	I
;	O
each	O
R4	O
,	O
which	O
may	O
be	O
the	O
same	O
or	O
different	O
,	O
is	O
C1	B
-	I
6alkyl	I
,	O
halogen	B
,	O
C1	B
-	I
6alkyl	I
,	O
haloC1	B
-	I
6alkyl	I
,	O
C1	B
-	I
4alkoxy	I
,	O
haloC1	B
-	I
4alkoxy	I
,	O
cyano	B
,	O
nitro	B
,	O
amino	B
,	O
monoC1	B
-	I
4alkylamino	I
or	O
diC1	B
-	I
4alkylamino	I
;	O
p	O
is	O
0	O
,	O
1	O
or	O
2	O
;	O
n	O
is	O
1	O
or	O
2	O
;	O
R5	O
and	O
R6	O
,	O
which	O
may	O
be	O
the	O
same	O
or	O
different	O
,	O
are	O
hydrogen	B
,	O
halogen	B
,	O
C1	B
-	I
6alkyl	I
,	O
haloC1	B
-	I
6alkyl	I
,	O
C1	B
-	I
4alkoxy	I
,	O
haloC1	B
-	I
4alkoxy	I
,	O
cyano	B
,	O
amino	B
,	O
monoC1	B
-	I
4alkylamino	I
or	O
diC1	B
-	I
4alkylamino	I
;	O
and	O
Het	O
is	O
thienyl	B
,	O
pyridyl	B
,	O
pyrimidinyl	B
,	O
pyridazinyl	B
,	O
pyrimidinyl	B
,	O
pyrazinyl	B
,	O
imidazolyl	B
,	O
pyrazolyl	B
,	O
pyrrolyl	B
,	O
quinolyl	B
,	O
thiazolyl	B
or	O
furyl	B
,	O
each	O
of	O
which	O
may	O
be	O
substituted	O
by	O
one	O
or	O
more	O
groups	O
independently	O
selected	O
from	O
the	O
list	O
consisting	O
of	O
C1	B
-	I
6alkyl	I
,	O
C1	B
-	I
6alkoxy	I
,	O
acetyl	B
,	O
halogen	B
,	O
haloC1	B
-	I
6alkyl	I
,	O
cyano	B
,	O
nitro	B
,	O
amino	B
,	O
monoC1	B
-	I
4alkylamino	I
and	O
diC1	B
-	I
4alkylamino	I
.	O

Methods	O
of	O
preparation	O
of	O
the	O
compounds	O
,	O
and	O
uses	O
thereof	O
in	O
medicine	O
,	O
for	O
example	O
treatment	O
of	O
schizophrenia	O
,	O
are	O
also	O
disclosed	O
.	O

glutamate	B
receptors	O
agonists	O
;	O
especially	O
to	O
treat	O
psychotic	O
conditions	O
,	O
including	O
schizophrenia	O
and	O
enhancement	O
of	O
cognition	O
;	O
N-	B
{	I
-2-	I
[	I
4-	I
(	I
6-fluoro-3-pyridinyl	I
)	I
phenyl	I
]	I
cyclopropyl	I
}	I
-2-propanesulfonamide	I

A	O
polymer	O
and	O
a	O
method	O
for	O
its	O
preparation	O
are	O
provided	O
.	O

The	O
polymer	O
comprises	O
poly	B
(	I
lactide	I
)	I
,	O
poly	B
(	I
lactide	I
/	I
glycolide	I
)	I
or	O
poly	B
(	I
lactic	I
acid	I
/	I
glycolic	I
acid	I
)	I
segments	O
bonded	O
by	O
ester	O
linkages	O
to	O
both	O
ends	O
of	O
an	O
alkanediol	B
core	O
unit	O
.	O

The	O
polymer	O
is	O
for	O
use	O
in	O
a	O
controlled	O
release	O
formulation	O
for	O
a	O
medicament	O
,	O
preferably	O
leuprolide	O
acetate	O
.	O

The	O
controlled	O
release	O
formulation	O
is	O
administered	O
to	O
a	O
patient	O
as	O
a	O
subcutaneous	O
depot	O
of	O
a	O
flowable	O
composition	O
comprising	O
the	O
polymer	O
,	O
a	O
biocompatible	O
solvent	O
,	O
and	O
the	O
medicament	O
.	O

Controlled	O
release	O
formulations	O
comprising	O
the	O
polymer	O
release	O
leuprolide	O
for	O
treatment	O
of	O
prostate	O
cancer	O
patients	O
over	O
periods	O
of	O
3	O
-	O
6	O
months	O
.	O

Novel	O
sustained	O
release	O
polymer	O

Methods	O
for	O
use	O
in	O
mobilizing	O
triacylglycerol	B
(	O
TAG	B
)	O
in	O
order	O
to	O
elevate	O
apoliprotein	B
B	I
and	O
Very	O
-	O
Low	O
-	O
Density	O
Lipoprotein	O
(	O
VLDL	O
)	O
are	O
described	O
.	O

In	O
some	O
embodiments	O
,	O
the	O
method	O
involves	O
providing	O
betaine	O
in	O
an	O
amount	O
of	O
about	O
3	O
gm	O
/	O
kg	O
of	O
body	O
weight	O
per	O
day	O
in	O
order	O
to	O
mobilize	O
TAG	O
.	O

In	O
some	O
embodiments	O
,	O
serum	O
VLDL	O
is	O
elevated	O
as	O
a	O
result	O
of	O
mobilizing	O
hepatic	O
TAG	O
.	O

In	O
some	O
embodiments	O
,	O
the	O
method	O
includes	O
restricting	O
methionine	B
intake	O
to	O
less	O
than	O
about	O
1	O
gm	O
/	O
kg	O
of	O
body	O
weight	O
per	O
day	O
.	O

In	O
some	O
embodiments	O
,	O
the	O
method	O
includes	O
feeding	O
L	B
-	I
cysteine	I
at	O
a	O
level	O
of	O
at	O
least	O
about	O
3	O
gm	O
/	O
kg	O
of	O
body	O
weight	O
per	O
day	O
.	O

In	O
some	O
embodiments	O
,	O
the	O
method	O
includes	O
feeding	O
choline	B
bitartrate	I
at	O
a	O
level	O
of	O
about	O
1.25	O
gm	O
/	O
kg	O
of	O
body	O
weight	O
per	O
day	O
.	O

Mobilizing	O
hepatic	O
TAG	B
is	O
effective	O
to	O
reduce	O
hepatic	O
steatosis	O
.	O

mobilizing	O
triacylglycerol	B
in	O
mammals	O
by	O
feeding	O
the	O
mammal	O
a	O
diet	O
that	O
includes	O
betaine	B
,	O
cysteine	B
and	O
choline	B
bitartrate	I
,	O
while	O
restricting	O
methionine	B
intake	O
;	O
reduction	O
of	O
liver	O
disorders	O
;	O
cirrhosis	O

Objective	O
methods	O
for	O
detecting	O
and	O
diagnosing	O
colorectal	O
cancer	O
(	O
CRC	O
)	O
are	O
described	O
herein	O
.	O

In	O
one	O
embodiment	O
,	O
the	O
diagnostic	O
method	O
involves	O
the	O
determining	O
an	O
expression	O
level	O
of	O
C10orf3	O
that	O
discriminate	O
between	O
CRC	O
and	O
normal	O
cell	O
.	O

The	O
present	O
invention	O
further	O
provides	O
methods	O
of	O
screening	O
for	O
therapeutic	O
agents	O
useful	O
in	O
the	O
treatment	O
of	O
CRC	O
,	O
methods	O
of	O
treating	O
CRC	O
and	O
method	O
of	O
vaccinating	O
a	O
subject	O
against	O
CRC	O
.	O

Method	O
For	O
Diagnosing	O
Colorectal	O
Cancers	O

The	O
present	O
invention	O
is	O
based	O
on	O
the	O
finding	O
that	O
the	O
artificial	O
induction	O
of	O
hepatic	O
stellate	O
cell	O
(	O
HSC	O
)	O
apoptosis	O
in	O
vivo	O
can	O
promote	O
the	O
resolution	O
of	O
liver	O
fibrosis	O
.	O

Thus	O
,	O
the	O
present	O
invention	O
provides	O
methods	O
for	O
treating	O
liver	O
disease	O
in	O
a	O
subject	O
involving	O
administration	O
of	O
an	O
inducer	O
of	O
apoptosis	O
which	O
is	O
capable	O
of	O
selectively	O
inducing	O
hepatic	O
stellate	O
cell	O
apoptosis	O
in	O
the	O
liver	O
of	O
the	O
subject	O
or	O
of	O
an	O
agent	O
which	O
is	O
capable	O
of	O
giving	O
rise	O
to	O
such	O
an	O
inducer	O
in	O
the	O
subject	O
.	O

In	O
addition	O
,	O
the	O
invention	O
provides	O
methods	O
for	O
treating	O
liver	O
fibrosis	O
in	O
a	O
subject	O
comprising	O
the	O
selective	O
delivery	O
of	O
an	O
inducer	O
of	O
apoptosis	O
specifically	O
to	O
the	O
hepatic	O
stellate	O
cells	O
of	O
the	O
subject	O
or	O
of	O
an	O
agent	O
which	O
is	O
capable	O
of	O
giving	O
rise	O
to	O
an	O
inducer	O
of	O
hepatic	O
stellate	O
cell	O
apoptosis	O
.	O

Treatment	O
for	O
liver	O
disease	O

We	O
have	O
developed	O
a	O
transcriptome	O
-	O
wide	O
approach	O
to	O
identify	O
genes	O
affected	O
by	O
promoter	O
CpG	O
island	O
hypermethylation	O
and	O
transcriptional	O
silencing	O
in	O
colorectal	O
cancer	O
(	O
CRC	O
)	O
.	O

By	O
screening	O
cell	O
lines	O
and	O
validating	O
tumor	O
specific	O
hypermethylation	O
in	O
a	O
panel	O
of	O
primary	O
human	O
CRC	O
samples	O
,	O
we	O
estimate	O
that	O
nearly	O
5	O
%	O
of	O
all	O
known	O
genes	O
may	O
be	O
promoter	O
methylated	O
in	O
an	O
individual	O
tumor	O
.	O

When	O
directly	O
compared	O
to	O
gene	O
mutations	O
,	O
we	O
find	O
a	O
much	O
larger	O
number	O
of	O
genes	O
hypermethylated	O
in	O
individual	O
tumors	O
,	O
and	O
much	O
higher	O
frequency	O
of	O
hypermethylation	O
within	O
individual	O
genes	O
harboring	O
either	O
genetic	O
or	O
epigenetic	O
changes	O
.	O

Thus	O
,	O
to	O
enumerate	O
the	O
full	O
spectrum	O
of	O
alterations	O
in	O
the	O
human	O
cancer	O
genome	O
,	O
and	O
facilitate	O
the	O
most	O
efficacious	O
grouping	O
of	O
tumors	O
to	O
identify	O
cancer	O
biomarkers	O
and	O
tailor	O
therapeutic	O
approaches	O
,	O
both	O
genetic	O
and	O
epigenetic	O
screens	O
should	O
be	O
undertaken	O
.	O

The	O
genes	O
we	O
identified	O
can	O
be	O
used	O
inter	O
alia	O
diagnostically	O
to	O
detect	O
cancer	O
,	O
pre	O
-	O
cancer	O
,	O
and	O
likelihood	O
of	O
developing	O
cancer	O
.	O

Early	O
Detection	O
and	O
Prognosis	O
of	O
Colon	O
Cancers	O

The	O
present	O
invention	O
discloses	O
and	O
claims	O
a	O
method	O
of	O
treating	O
cognition	O
deficits	O
in	O
a	O
patient	O
suffering	O
from	O
schizophrenia	O
by	O
administering	O
to	O
said	O
patient	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
CB1	O
receptor	O
antagonist	O
as	O
described	O
herein	O
.	O

In	O
another	O
aspect	O
,	O
this	O
invention	O
also	O
discloses	O
and	O
claims	O
a	O
combination	O
of	O
one	O
or	O
more	O
CB1	O
receptor	O
antagonists	O
and	O
of	O
one	O
or	O
more	O
antipsychotic	O
agents	O
useful	O
in	O
the	O
treatment	O
of	O
psychiatric	O
disorders	O
.	O

The	O
combination	O
of	O
this	O
invention	O
provides	O
synergistic	O
results	O
in	O
that	O
the	O
combination	O
improves	O
positive	O
and	O
negative	O
symptoms	O
of	O
schizophrenia	O
,	O
weight	O
gain	O
and	O
catalepsy	O
.	O

Use	O
of	O
a	O
CB1	O
Antagonist	O
for	O
Treating	O
Side	O
Effects	O
and	O
Negative	O
Symptoms	O
of	O
Schizophrenia	O

Compounds	O
,	O
compositions	O
,	O
and	O
methods	O
for	O
inhibiting	O
the	O
onset	O
of	O
metabolic	O
syndrome	O
and	O
treating	O
related	O
disorders	O
in	O
a	O
subject	O
in	O
need	O
of	O
such	O
therapy	O
are	O
disclosed	O
.	O

1-	B
[	I
1-	I
(	I
methylsulfonyl	I
)	I
piperidin-4-yl	I
]	I
-3-	I
(	I
adamant-1-yl	I
)	I
urea	I
,	I
1-	I
[	I
1-	I
(	I
acetyl	I
)	I
piperidin-4-yl	I
]	I
-3-	I
(	I
adamant-1-yl	I
)	I
urea	I
;	O
incipient	O
diabetes	O
,	O
glucose	B
intolerance	O
,	O
obesity	O
,	O
hypertension	O
,	O
high	O
blood	O
pressure	O
,	O
elevated	O
serum	O
cholesterol	B
,	O
reduced	O
high	O
-	O
density	O
lipoproteins	O
and	O
elevated	O
triglyceride	B
levels	O

The	O
present	O
invention	O
relates	O
to	O
controlled	O
release	O
transmucosal	O
formulations	O
which	O
mediate	O
absorption	O
and	O
methods	O
of	O
use	O
comprising	O
a	O
pharmaceutically	O
active	O
agent	O
,	O
preferably	O
morphine	B
,	O
and	O
a	O
water	O
soluble	O
polymer	O
,	O
chitosan	O
,	O
and	O
preferably	O
one	O
more	O
antioxidants	O
,	O
one	O
or	O
more	O
antimicrobial	O
agents	O
,	O
and	O
water	O
.	O

Controlled	O
Release	O
Formulations	O

A	O
method	O
of	O
effecting	O
a	O
treatment	O
response	O
in	O
a	O
target	O
tissue	O
of	O
a	O
subject	O
,	O
comprising	O
:	O
administering	O
to	O
the	O
subject	O
isolated	O
RNA	O
comprising	O
an	O
RNA	O
sequence	O
extractable	O
or	O
extracted	O
from	O
a	O
source	O
tissue	O
such	O
that	O
said	O
treatment	O
response	O
is	O
effected	O
;	O
wherein	O
the	O
RNA	O
is	O
isolated	O
polyA	O
positive	O
RNA	O
in	O
substantially	O
pure	O
form	O
.	O

Method	O
of	O
Treatment	O
by	O
Administration	O
of	O
Rna	O

A	O
cosmetic	O
makeup	O
product	O
comprising	O
at	O
least	O
two	O
compositions	O
,	O
the	O
first	O
composition	O
comprising	O
a	O
physiologically	O
acceptable	O
medium	O
and	O
the	O
second	O
composition	O
comprising	O
a	O
mixture	O
of	O
at	O
least	O
one	O
high	O
molecular	O
weight	O
polymer	O
having	O
a	O
weight	O
-	O
average	O
molecular	O
mass	O
of	O
greater	O
than	O
or	O
equal	O
to	O
200,000	O
g	O
/	O
mol	O
and	O
at	O
least	O
one	O
low	O
molecular	O
weight	O
non	O
-	O
volatile	O
liquid	O
silicone	B
compound	O
having	O
a	O
weight	O
-	O
average	O
molecular	O
mass	O
of	O
less	O
than	O
200,000	O
g	O
/	O
mol	O
,	O
wherein	O
the	O
at	O
least	O
one	O
high	O
molecular	O
weight	O
polymer	O
and	O
the	O
at	O
least	O
one	O
low	O
molecular	O
weight	O
non	O
-	O
volatile	O
liquid	O
silicone	B
compound	O
are	O
present	O
in	O
a	O
proportion	O
such	O
that	O
the	O
dynamic	O
viscosity	O
of	O
the	O
mixture	O
at	O
25	O
	O
C.	O
,	O
measured	O
with	O
a	O
Mettler	O
RM	O
180	O
rotational	O
viscometer	O
,	O
ranges	O
from	O
0.1	O
to	O
120	O
Pas	O
;	O
a	O
makeup	O
method	O
and	O
a	O
makeup	O
kit	O
comprising	O
the	O
cosmetic	O
makeup	O
product	O
.	O

The	O
cosmetic	O
makeup	O
product	O
may	O
,	O
for	O
example	O
,	O
be	O
a	O
lipstick	O
.	O

Two	O
-	O
coat	O
makeup	O
product	O
,	O
its	O
uses	O
,	O
and	O
makeup	O
kit	O
comprising	O
the	O
product	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
processes	O
for	O
their	O
preparation	O
,	O
compositions	O
comprising	O
them	O
and	O
their	O
use	O
in	O
the	O
treatment	O
or	O
prevention	O
of	O
diseases	O
capable	O
of	O
being	O
modulated	O
by	O
the	O
inhibition	O
of	O
cell	O
adhesion	O
.	O

Alpha-4	O
Integrin	O
Mediated	O
Cell	O
Adhesion	O
Inhibitors	O
for	O
the	O
Treatment	O
or	O
Prevention	O
of	O
Inflammatory	O
Diseases	O

Poly	B
(	I
beta	I
-	I
amino	I
esters	I
)	I
are	O
end	O
-	O
modified	O
to	O
form	O
materials	O
useful	O
in	O
the	O
medical	O
as	O
well	O
as	O
non	O
-	O
medical	O
field	O
.	O

An	O
amine	O
-	O
terminated	O
poly	B
(	I
beta	I
-	I
amino	I
ester	I
)	I
is	O
reacted	O
with	O
an	O
electrophile	O
,	O
or	O
an	O
acrylate	B
-	O
terminated	O
poly	B
(	I
beta	I
-	I
amino	I
ester	I
)	I
is	O
reacted	O
with	O
a	O
nucleophile	O
.	O

The	O
inventive	O
end	O
-	O
modified	O
polymers	O
may	O
be	O
used	O
in	O
any	O
field	O
where	O
polymers	O
have	O
been	O
found	O
useful	O
including	O
the	O
drug	O
delivery	O
arts	O
.	O

The	O
end	O
-	O
modified	O
polymers	O
are	O
particularly	O
useful	O
in	O
delivery	O
nucleic	O
acids	O
such	O
as	O
DNA	O
or	O
RNA	O
.	O

The	O
invention	O
also	O
provides	O
compositions	O
including	O
the	O
inventive	O
end	O
-	O
modified	O
polymers	O
,	O
methods	O
of	O
preparing	O
the	O
inventive	O
polymers	O
,	O
and	O
method	O
of	O
using	O
the	O
inventive	O
polymers	O
.	O

End	O
-	O
Modified	O
Poly	B
(	I
beta	I
-	I
amino	I
esters	I
)	I
and	O
Uses	O
Thereof	O

The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
GFR3	O
agonists	O
for	O
the	O
treatment	O
of	O
disorders	O
of	O
the	O
retina	O
.	O

A	O
preferred	O
GFR3	O
agonist	O
is	O
Neublastin	O
.	O

Neublastin	O
may	O
be	O
administered	O
to	O
the	O
eye	O
using	O
protein	O
formulations	O
,	O
in	O
vivo	O
or	O
ex	O
vivo	O
gene	O
therapy	O
,	O
or	O
implantation	O
of	O
encapsulated	O
cells	O
delivering	O
Neublastin	O
locally	O
to	O
the	O
retina	O
.	O

Using	O
vector	O
comprising	O
nucleotide	O
sequences	O
coding	O
neublastin	O
as	O
therapeutic	O
treatment	O
for	O
vision	O
defects	O

As	O
the	O
results	O
of	O
intensive	O
studies	O
aiming	O
at	O
providing	O
a	O
gene	O
targeting	O
a	O
cancer	O
cell	O
or	O
a	O
cancer	O
tissue	O
,	O
novel	O
nucleotide	O
sequences	O
showing	O
increased	O
expression	O
in	O
a	O
cancer	O
cell	O
or	O
a	O
cancer	O
tissue	O
compared	O
with	O
normal	O
tissues	O
are	O
identified	O
.	O

As	O
the	O
results	O
of	O
the	O
subsequent	O
studies	O
,	O
genes	O
showing	O
increased	O
expression	O
in	O
a	O
cancer	O
cell	O
or	O
a	O
cancer	O
tissue	O
which	O
are	O
useful	O
as	O
a	O
drug	O
discovery	O
target	O
are	O
found	O
out	O
.	O

Preventive	O
and/or	O
Therapeutic	O
Agent	O
for	O
Cancer	O

The	O
present	O
invention	O
relates	O
to	O
a	O
long	O
-	O
acting	O
sustained	O
-	O
release	O
dosage	O
form	O
for	O
treatment	O
of	O
Parkinson	O
Disease	O
,	O
comprising	O
a	O
dopamine	B
receptor	O
agonist	O
and	O
a	O
pharmaceutically	O
acceptable	O
biodegradable	O
polymer	O
accessories	O
,	O
wherein	O
the	O
content	O
of	O
the	O
dopamine	B
receptor	O
agonist	O
in	O
the	O
sustained	O
-	O
release	O
dosage	O
form	O
is	O
5	O
-	O
50	O
%	O
by	O
weight	O
,	O
and	O
the	O
content	O
of	O
the	O
pharmaceutically	O
acceptable	O
polymer	O
accessories	O
is	O
50	O
-	O
95	O
%	O
by	O
weight	O
.	O

Has	O
acceptable	O
biodegradable	O
polymer	O
;	O
polyglycolic	B
acid	I
,	O
polylactic	B
acid	I
;	O
Parkinson	O
's	O
Disease	O
;	O
injectable	O
microspheres	O
,	O
injectable	O
gels	O
and	O
implants	O
;	O
enhanced	O
bioavailability	O

Delivery	O
system	O
for	O
bioactive	O
agents	O
on	O
the	O
basis	O
of	O
a	O
polymeric	O
drug	O
carrier	O
formed	O
from	O
compositions	O
comprising	O
an	O
amphiphilic	O
block	O
copolymer	O
of	O
a	O
hydrophilic	O
block	O
and	O
a	O
hydrophobic	O
block	O
having	O
a	O
terminal	O
hydroxyl	B
group	O
substituted	O
with	O
a	O
tocopherol	B
or	O
cholesterol	B
group	O
,	O
and	O
a	O
polylactic	B
acide	I
derivative	O
wherein	O
one	O
end	O
of	O
the	O
polylactic	B
acid	I
is	O
covalently	O
bound	O
to	O
at	O
least	O
one	O
carboxyl	B
group	O
.	O

The	O
carboxyl	B
group	O
of	O
the	O
polylactic	B
acid	I
derivative	O
may	O
be	O
fixed	O
with	O
a	O
di-	O
or	O
trivalent	O
metal	O
ion	O
,	O
which	O
is	O
obtained	O
by	O
adding	O
the	O
di-	O
or	O
trivalent	O
metal	O
ion	O
to	O
the	O
polymeric	O
composition	O
.	O

Delivery	O
System	O
For	O
Bioactive	O
Agents	O
on	O
the	O
Basis	O
of	O
a	O
Polymeric	O
Drug	O
Carrier	O
Comprising	O
an	O
Amphiphilic	O
Block	O
Polymer	O
and	O
a	O
Polylacticacid	B
Derivative	O

A	O
composition	O
for	O
the	O
prevention	O
or	O
alleviation	O
of	O
pigmentation	O
which	O
can	O
produce	O
the	O
higher	O
effect	O
of	O
preventing	O
or	O
alleviating	O
pigmentation	O
.	O

The	O
composition	O
for	O
the	O
prevention	O
or	O
alleviation	O
of	O
pigmentation	O
comprises	O
a	O
combination	O
of	O
(	O
A	O
)	O
at	O
least	O
one	O
member	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
adenosine	B
5-monophosphate	I
and	O
salts	O
thereof	O
with	O
(	O
B	O
)	O
at	O
least	O
one	O
member	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
arbutin	B
,	O
ellagic	B
acid	I
,	O
4-alkylresorcinols	B
,	O
linoleic	B
acid	I
,	O
tranexamic	B
acid	I
,	O
salts	O
of	O
these	O
,	O
Chamomilla	O
recuita	O
extract	O
,	O
and	O
Ubiquinone	B
.	O

Topical	O
;	O
adenosine	B
5'-monophosphates	I
and	O
salts	O
thereof	O
;	O
arbutins	B
,	O
ellagic	B
acid	I
,	O
4-alkylresorcinols	B
,	O
linolic	B
acid	I
,	O
tranexamic	B
acid	I
,	O
chamomile	O
extracts	O
,	O
ubiquinones	B
;	O
chloasma	O
,	O
freckles	O

Reagents	O
which	O
regulate	O
human	O
RC	O
Kinase	O
activity	O
and	O
reagents	O
which	O
bind	O
to	O
human	O
RC	O
Kinase	O
gene	O
products	O
can	O
be	O
used	O
to	O
regulate	O
this	O
protein	O
for	O
therapeutic	O
effects	O
.	O

Such	O
regulation	O
is	O
particularly	O
useful	O
for	O
treating	O
chronic	O
obstructive	O
pulmonary	O
disease	O
,	O
asthma	O
,	O
cancer	O
,	O
and	O
diseases	O
in	O
which	O
cell	O
signaling	O
is	O
defective	O
.	O

Isolated	O
polynucleotide	O
encoding	O
a	O
Regulated	O
in	O
chronic	O
obstructive	O
pulmonary	O
disease	O
Kinase	O
polypeptide	O
;	O
host	O
cell	O
;	O
hybridization	O
;	O
screening	O
;	O
prediction	O
,	O
diagnosis	O
;	O
prognosis	O
;	O
chronic	O
obstructive	O
pulmonary	O
disease	O
,	O
asthma	O
,	O
cancer	O
,	O
diseases	O
of	O
defective	O
cell	O
signaling	O

The	O
present	O
invention	O
relates	O
to	O
Sphingosine	B
kinase	O
inhibitors	O
that	O
are	O
useful	O
for	O
treating	O
various	O
cancers	O
.	O

The	O
invention	O
further	O
relates	O
to	O
compositions	O
and	O
methods	O
of	O
SPK	O
inhibitors	O
,	O
including	O
siRNAs	O
,	O
which	O
specifically	O
block	O
gene	O
expression	O
of	O
SPK	O
and	O
potentiates	O
the	O
effect	O
of	O
radiation	O
in	O
the	O
treatment	O
of	O
various	O
cancers	O
.	O

siRNA	O
blocks	O
expression	O
of	O
sphingosine	B
kinase	O
,	O
potentiates	O
effect	O
of	O
radiation	O
in	O
cancer	O
cells	O
of	O
breast	O
,	O
prostate	O
,	O
colorectal	O
,	O
lung	O
,	O
bladder	O
,	O
head	O
and	O
neck	O
,	O
intestine	O
,	O
ovarian	O
,	O
skin	O
;	O
reduces	O
amount	O
of	O
radiation	O
needed	O
to	O
decrease	O
cancer	O
cell	O
viability	O
,	O
tumor	O
size	O
in	O
vivo	O

Ac	B
-	I
Phe	I
-	I
Tyr	I
-	I
phosphoSer	I
-	I
	I
[	I
CH	I
	I
C	I
]	I
-Pro	I
-	I
Arg	I
-	I
NH2AND	I
Fmoc	B
-	I
bis	I
(	I
pivaloylmethoxy	I
)	I
phosphoSer	I
-	I
	I
[	I
CH	I
	I
C	I
]	I
-Pro-2-aminoethyl-	I
(	I
3-indole	I
)	I
;	O
and	O
their	O
Phospho-	B
(	I
D	I
)	I
-serine	I
stereoisomers	O
are	O
novel	O
compounds	O
.	O

	O
refers	O
to	O
a	O
pseudo	O
amide	O
.	O

Such	O
novel	O
compounds	O
advantageously	O
may	O
be	O
used	O
as	O
alkene	B
mimics	O
.	O

Inhibitory	O
activity	O
against	O
Pin1	O
;	O
inhibit	O
peptidyl	O
-	O
prolyl	O
isomerase	O
activity	O
of	O
Pin1	O
;	O
inhibits	O
growth	O
of	O
cancer	O
cells	O
;	O
Ac	B
-	I
Phe	I
-	I
Tyr	I
-	I
phosphoSer-	I
pseudo	I
amide	I
-Pro	I
-	I
Arg	I
-	I
NH2	I
;	O
Fmoc	B
-	I
bis	I
(	I
POM	I
)	I
phosphoSer-	I
pseudo	I
amide	I
-Pro-2-aminoethyl-	I
(	I
3-indole	I
)	I
and	O
their	O
Phospho-	B
(	I
D	I
)	I
-serine	I
stereoisomers	O

Methods	O
of	O
preparing	O
,	O
and	O
compositions	O
comprising	O
,	O
derivatives	O
of	O
venlafaxine	B
are	O
disclosed	O
.	O

Also	O
disclosed	O
are	O
methods	O
of	O
treating	O
and	O
preventing	O
diseases	O
and	O
disorders	O
including	O
,	O
but	O
not	O
limited	O
to	O
,	O
affective	O
disorders	O
such	O
as	O
depression	O
,	O
bipolar	O
and	O
manic	O
disorders	O
,	O
attention	O
deficit	O
disorder	O
,	O
attention	O
deficit	O
disorder	O
with	O
hyperactivity	O
,	O
Parkinson	O
's	O
disease	O
,	O
epilepsy	O
,	O
cerebral	O
function	O
disorders	O
,	O
obesity	O
and	O
weight	O
gain	O
,	O
incontinence	O
,	O
dementia	O
and	O
related	O
disorders	O
.	O

O	B
-	I
desmethylvenlafaxine	I
succinate	I
;	O
tablet	O
,	O
capsule	O
;	O
sustained	O
release	O
;	O
hydroxypropylmethyl	O
cellulose	O
rate	O
controlling	O
polymer	O
;	O
microcrystalline	O
cellulose	O
binder	O
;	O
depression	O
,	O
bipolar	O
and	O
manic	O
disorders	O
,	O
attention	O
deficit	O
disorder	O
,	O
attention	O
deficit	O
disorder	O
with	O
hyperactivity	O
,	O
Parkinson	O
's	O
disease	O

Compounds	O
,	O
compositions	O
,	O
and	O
methods	O
of	O
avoiding	O
edema	O
while	O
treating	O
or	O
preventing	O
PPAR	O
-	O
mediated	O
diseases	O
,	O
including	O
cancer	O
,	O
using	O
derivatives	O
and	O
prodrugs	O
are	O
provided	O
.	O

Method	O
for	O
Avoiding	O
Edema	O
in	O
the	O
Treatment	O
or	O
Prevention	O
of	O
Ppary	O
-	O
Responsive	O
Diseases	O
,	O
Including	O
Cancer	O

This	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
:	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
wherein	O
:	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
A	O
and	O
m	O
are	O
each	O
as	O
described	O
herein	O
and	O
compositions	O
containing	O
such	O
compounds	O
and	O
the	O
use	O
of	O
such	O
compounds	O
in	O
the	O
treatment	O
of	O
a	O
condition	O
mediated	O
by	O
5-HT4	O
agonistic	O
activity	O
such	O
as	O
,	O
but	O
not	O
limited	O
to	O
,	O
gastroesophageal	O
reflux	O
disease	O
,	O
gastrointestinal	O
disease	O
,	O
gastric	O
motility	O
disorder	O
,	O
non	O
-	O
ulcer	O
dyspepsia	O
,	O
functional	O
dyspepsia	O
,	O
irritable	O
bowel	O
syndrome	O
(	O
IBS	O
)	O
,	O
constipation	O
,	O
dyspepsia	O
,	O
esophagitis	O
,	O
gastroesophageral	O
disease	O
,	O
nausea	O
,	O
central	O
nervous	O
system	O
disease	O
,	O
Alzheimer	O
's	O
disease	O
,	O
cognitive	O
disorder	O
,	O
emesis	O
,	O
migraine	O
,	O
neurological	O
disease	O
,	O
pain	O
,	O
cardiovascular	O
disorders	O
,	O
cardiac	O
failure	O
,	O
heart	O
arrhythmia	O
,	O
diabetes	O
and	O
apnea	O
syndrome	O
.	O

Antiserotonine	B
agents	O
;	O
gastrointestinal	O
disorders	O
;	O
irritable	O
bowel	O
syndrome	O
;	O
central	O
nervous	O
system	O
disorders	O
;	O
Alzheimer	O
's	O
disease	O
;	O
cognition	O
activators	O
;	O
analgesics	O
;	O
cardiovascular	O
disorders	O
;	O
antidiabetic	O
agents	O
;	O
sleep	O
disorders	O

The	O
present	O
invention	O
relates	O
to	O
substituted	O
spiro	B
compounds	O
,	O
to	O
processes	O
for	O
preparing	O
them	O
,	O
to	O
medicaments	O
comprising	O
these	O
compounds	O
and	O
to	O
the	O
use	O
of	O
these	O
compounds	O
for	O
producing	O
medicaments	O
.	O

Analgesics	O
;	O
antidepressants	O
;	O
neurodegenerative	O
diseases	O
;	O
antiepileptic	O
agents	O
;	O
cognition	O
activators	O
;	O
antitussive	O
agents	O
;	O
incotinence	O
;	O
irritable	O
bowel	O
syndrome	O
;	O
stroke	O
;	O
vision	O
defects	O
;	O
antiinflammatory	O
agents	O
;	O
skin	O
disorders	O
;	O
diarrhea	O
;	O
eating	O
disorders	O

The	O
invention	O
relates	O
to	O
antibacterial	O
amide	O
-	O
macrocycles	O
of	O
formula	O
(	O
I	O
)	O
,	O
in	O
which	O
R26	O
represents	O
hydrogen	B
,	O
halogen	B
,	O
amino	B
or	O
methyl	B
,	O
R7	O
represents	O
a	O
group	O
of	O
formula	O
(	O
II	O
)	O
,	O
(	O
III	O
)	O
,	O
(	O
IV	O
)	O
or	O
(	O
V	O
)	O
,	O
whereby	O
R1	O
represents	O
hydrogen	B
or	O
hydroxy	B
and	O
*	O
is	O
the	O
linkage	O
site	O
to	O
the	O
carbon	B
atom	O
,	O
R2	O
represents	O
hydrogen	B
or	O
methyl	B
and	O
methods	O
for	O
their	O
production	O
,	O
their	O
use	O
for	O
the	O
treatment	O
and/or	O
prophylaxis	O
of	O
diseases	O
as	O
well	O
as	O
their	O
use	O
for	O
the	O
production	O
of	O
medicaments	O
for	O
the	O
treatment	O
and/or	O
prophylaxis	O
of	O
diseases	O
,	O
in	O
particular	O
of	O
bacterial	O
infections	O
.	O

Antibacterial	O
amide	O
-	O
macrocycles	O
v	O

The	O
present	O
invention	O
relates	O
to	O
a	O
use	O
of	O
a	O
specific	O
alpha	B
-	I
arylmethoxyacrylate	I
derivative	O
,	O
or	O
its	O
pharmacologically	O
acceptable	O
salt	O
or	O
solvate	O
for	O
preventing	O
and	O
treating	O
metabolic	O
bone	O
diseases	O
.	O

Pharmaceutical	O
Composition	O
for	O
Preventing	O
and	O
Treating	O
Metabolic	O
Bone	O
Diseases	O
Containing	O
Alpha	B
-	I
Arylmethoxyacrylate	I
Derivatives	O

Inhibitors	O
of	O
plasminogen	O
activator	O
inhibitor-1	O
(	O
PAI	O
-	O
I	O
)	O
are	O
provided	O
,	O
which	O
may	O
also	O
act	O
as	O
anti	O
cancer	O
agents	O
,	O
of	O
formulae	O
(	O
I	O
-	O
V	O
)	O
.	O

Plasminogen	O
Activator	O
Inhibitor-1	O
Inhibitors	O

This	O
invention	O
describes	O
the	O
principles	O
and	O
procedures	O
suitable	O
for	O
developing	O
,	O
testing	O
,	O
manufacturing	O
,	O
and	O
using	O
combinations	O
of	O
various	O
amphipatic	O
,	O
if	O
necessary	O
modified	O
,	O
macromolecules	O
(	O
such	O
as	O
polypeptides	O
,	O
proteins	O
,	O
etc	O
.	O
)	O
or	O
other	O
chain	O
molecules	O
(	O
such	O
as	O
suitable	O
,	O
e.g.	O
partly	O
hydrophobised	O
,	O
polynucleotides	O
or	O
polysaccharides	O
)	O
with	O
the	O
aggregates	O
which	O
comprise	O
a	O
mixture	O
of	O
polar	O
and/or	O
charged	O
amphipats	O
and	O
form	O
extended	O
surfaces	O
that	O
can	O
be	O
freely	O
suspended	O
or	O
supported	O
.	O

The	O
described	O
methods	O
can	O
be	O
utilised	O
for	O
the	O
optimisation	O
of	O
aggregates	O
that	O
,	O
after	O
association	O
with	O
chain	O
molecules	O
exerting	O
some	O
activity	O
or	O
a	O
useful	O
function	O
,	O
are	O
suitable	O
for	O
the	O
application	O
in	O
vitro	O
or	O
in	O
vivo	O
,	O
for	O
example	O
,	O
in	O
the	O
fields	O
of	O
drug	O
delivery	O
,	O
diagnostics	O
or	O
bio	O
/	O
catalysis	O
.	O

As	O
special	O
examples	O
,	O
mixtures	O
of	O
vesicular	O
droplets	O
consisting	O
of	O
lipids	O
loaded	O
(	O
associated	O
)	O
with	O
insulin	O
,	O
interferon	O
,	O
interleukin	O
,	O
nerve	O
growth	O
factor	O
,	O
calcitonin	O
,	O
and	O
an	O
immunoglobulin	O
,	O
etc	O
.	O
,	O
are	O
described	O
.	O

Method	O
for	O
developing	O
,	O
testing	O
,	O
and	O
using	O
associates	O
of	O
macromolecules	O
and	O
complex	O
aggregates	O
for	O
improved	O
payload	O
and	O
controllable	O
de	O
/	O
association	O
rates	O

Preservative	O
compositions	O
containing	O
emollient	O
solvents	O
such	O
as	O
octanediol	B
or	O
Symdiol	B
	O
or	O
octoxyglycerine	B
monoesters	I
in	O
combination	O
with	O
organic	O
acids	O
such	O
as	O
alpha	B
hydroxyl	I
acids	I
can	O
be	O
used	O
for	O
preventing	O
microbial	O
growth	O
and	O
spoilage	O
in	O
cosmetic	O
and	O
topical	O
skin	O
formulations	O
with	O
the	O
added	O
benefit	O
of	O
providing	O
silky	O
smooth	O
texture	O
to	O
skin	O
.	O

The	O
compositions	O
may	O
optionally	O
contain	O
an	O
essential	O
oil	O
/	O
component	O
.	O

These	O
preservative	O
compositions	O
are	O
odorless	O
and	O
colorless	O
and	O
small	O
concentrations	O
can	O
be	O
added	O
to	O
cosmetic	O
/	O
topical	O
formulations	O
to	O
prevent	O
bacterial	O
,	O
yeast	O
and	O
fungal	O
growth	O
within	O
24	O
to	O
48	O
hours	O
after	O
contamination	O
.	O

Broad	O
Spectrum	O
Non	O
-	O
Traditional	O
Preservative	O
System	O

Methods	O
of	O
detecting	O
and	O
treating	O
rapidly	O
growing	O
exogenous	O
cells	O
,	O
such	O
as	O
Protista	O
,	O
or	O
parasites	O
,	O
that	O
preferentially	O
accumulate	O
a	O
photoactivatable	O
porphyrin	B
in	O
which	O
5-aminolevulinic	B
acid	I
or	O
precursor	O
thereof	O
is	O
administered	O
to	O
the	O
patient	O
,	O
or	O
contacted	O
to	O
the	O
exogenous	O
cells	O
,	O
in	O
an	O
amount	O
sufficient	O
to	O
induce	O
synthesis	O
fluorescence	O
and/or	O
photosensitizing	O
concentrations	O
of	O
a	O
protoporphyrin	O
IX	O
in	O
the	O
exogenous	O
cells	O
,	O
followed	O
by	O
exposure	O
of	O
the	O
exogenous	O
cells	O
to	O
light	O
of	O
photoactivating	O
wavelengths	O
.	O

Photochemotherapeutic	O
method	O
using	O
5-aminolevulinic	B
acid	I
and	O
other	O
precursors	O
of	O
endogenous	O
porphyrins	O

The	O
present	O
invention	O
has	O
its	O
object	O
to	O
provide	O
an	O
agent	O
for	O
preventing	O
and/or	O
ameliorating	O
life	O
style	O
-	O
related	O
diseases	O
which	O
contains	O
,	O
as	O
an	O
active	O
ingredient	O
,	O
a	O
substance	O
derived	O
from	O
a	O
safe	O
food	O
material	O
having	O
a	O
long	O
history	O
of	O
being	O
eaten	O
as	O
a	O
food	O
and	O
which	O
is	O
capable	O
of	O
being	O
utilized	O
as	O
functional	O
foods	O
such	O
as	O
health	O
foods	O
or	O
functional	O
health	O
foods	O
(	O
specific	O
health	O
foods	O
,	O
functional	O
nutritive	O
foods	O
)	O
.	O

The	O
agent	O
for	O
preventing	O
and/or	O
ameliorating	O
life	O
style	O
-	O
related	O
diseases	O
according	O
to	O
the	O
invention	O
contains	O
,	O
as	O
an	O
active	O
ingredient	O
,	O
at	O
least	O
one	O
compound	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
ar	B
-	I
turmerone	I
,	O
	B
-	I
turmerone	I
,	O
	B
-	I
turmerone	I
,	O
curlone	B
,	O
bisacumol	B
and	O
	B
-	I
sesquiphellandrene	I
,	O
or	O
at	O
least	O
one	O
compound	O
selected	O
from	O
among	O
the	O
bisabolane	B
type	O
sesquiterpenoids	B
derived	O
from	O
Curcuma	O
longa	O
L.	O
,	O
and	O
therefore	O
is	O
useful	O
for	O
preventing	O
and/or	O
ameliorating	O
diabetes	O
,	O
visceral	O
fat	O
obesity	O
,	O
metabolic	O
syndrome	O
and	O
obesity	O
,	O
among	O
others	O
.	O

Agent	O
for	O
Preventing	O
/	O
Ameliorating	O
Life	O
Style	O
-	O
Related	O
Diseases	O
Containing	O
Turmeric	O
Essential	O
Oil	O
Component	O

The	O
invention	O
describes	O
the	O
use	O
of	O
surfactant	O
comprising	O
phospholipids	B
and	O
pulmonary	O
surfactant	O
proteins	O
for	O
the	O
treatment	O
of	O
surgical	O
adhesions	O
.	O

Use	O
of	O
Surfactant	O
Preparations	O
for	O
the	O
Treatment	O
of	O
Surgical	O
Adhesions	O

Human	O
ALDO	O
genes	O
are	O
identified	O
as	O
modulators	O
of	O
the	O
IGF	O
pathway	O
,	O
and	O
thus	O
are	O
therapeutic	O
targets	O
for	O
disorders	O
associated	O
with	O
defective	O
IGF	O
function	O
.	O

Methods	O
for	O
identifying	O
modulators	O
of	O
IGF	O
,	O
comprising	O
screening	O
for	O
agents	O
that	O
modulate	O
the	O
activity	O
of	O
ALDO	O
are	O
provided	O
.	O

Aldos	O
as	O
modifiers	O
of	O
the	O
igf	O
pathway	O
and	O
methods	O
of	O
use	O

A	O
patch	O
pump	O
device	O
generally	O
includes	O
at	O
least	O
one	O
fluid	O
source	O
,	O
a	O
fluid	O
communicator	O
,	O
and	O
an	O
electrochemical	O
actuator	O
.	O

The	O
fluid	O
communicator	O
is	O
in	O
fluid	O
communication	O
with	O
the	O
fluid	O
source	O
.	O

The	O
electrochemical	O
actuator	O
is	O
operative	O
to	O
cause	O
fluid	O
to	O
be	O
delivered	O
from	O
the	O
fluid	O
source	O
into	O
the	O
fluid	O
communicator	O
.	O

Systems	O
and	O
methods	O
for	O
delivering	O
drugs	O

This	O
invention	O
relates	O
to	O
a	O
novel	O
human	O
deoxyribonuclease	O
,	O
referred	O
to	O
as	O
human	O
DNase	O
II	O
.	O

The	O
invention	O
provides	O
nucleic	O
acid	O
sequences	O
encoding	O
human	O
DNase	O
II	O
,	O
thereby	O
enabling	O
the	O
production	O
of	O
human	O
DNase	O
II	O
by	O
recombinant	O
DNA	O
methods	O
in	O
quantities	O
sufficient	O
for	O
clinical	O
use	O
.	O

The	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
and	O
diagnostic	O
and	O
therapeutic	O
uses	O
of	O
human	O
DNase	O
II	O
.	O

Human	O
dnase	O
ii	O

Polyglycerol	B
anti	O
-	O
microbial	O
agents	O
and	O
compositions	O
are	O
provided	O
.	O

The	O
agents	O
are	O
effective	O
against	O
a	O
variety	O
of	O
pathogens	O
including	O
fungi	O
,	O
Gram	O
positive	O
bacteria	O
and	O
Gram	O
negative	O
bacteria	O
yet	O
are	O
expected	O
to	O
have	O
low	O
human	O
toxicity	O
due	O
in	O
part	O
to	O
their	O
polymeric	O
nature	O
.	O

Applications	O
for	O
the	O
polyglycerol	B
anti	O
-	O
microbial	O
agents	O
and	O
compositions	O
include	O
those	O
involving	O
human	O
and	O
plant	O
contact	O
,	O
such	O
as	O
cosmetics	O
,	O
hair	O
care	O
products	O
,	O
textiles	O
and	O
plant	O
protections	O
,	O
as	O
well	O
as	O
in	O
applications	O
with	O
much	O
less	O
human	O
contact	O
,	O
such	O
as	O
plastics	O
,	O
coatings	O
,	O
wood	O
,	O
paper	O
and	O
other	O
materials	O
of	O
construction	O
.	O

Polyglycerol	B
anti	O
-	O
microbial	O
agents	O
and	O
compositions	O

The	O
present	O
invention	O
relates	O
to	O
substituted	O
nitrogen	O
-	O
containing	O
heteroaryl	O
derivatives	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
,	O
and	O
methods	O
of	O
using	O
any	O
of	O
these	O
derivatives	O
and	O
compositions	O
for	O
H4	O
receptor	O
activity	O
modulation	O
and	O
the	O
treatment	O
of	O
states	O
mediated	O
by	O
histamine	O
H4	O
receptor	O
activity	O
.	O

Substituted	O
nitrogen	O
-	O
containing	O
heteroaryl	O
derivatives	O
useful	O
as	O
modulators	O
of	O
the	O
histamine	O
H4	O
receptor	O

The	O
present	O
invention	O
is	O
directed	O
to	O
novel	O
spiro	B
-	I
benzo	I
[	I
C	I
]	I
chromene	I
derivatives	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
their	O
use	O
in	O
the	O
treatment	O
of	O
disorders	O
mediated	O
by	O
one	O
or	O
more	O
estrogen	B
receptors	O
.	O

The	O
compounds	O
of	O
the	O
invention	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
disorders	O
associated	O
with	O
the	O
depletion	O
of	O
estrogen	B
such	O
as	O
hot	O
flashes	O
,	O
vaginal	O
dryness	O
,	O
osteopenia	O
and	O
osteoporosis	O
;	O
hormone	O
sensitive	O
cancers	O
and	O
hyperplasia	O
of	O
the	O
breast	O
,	O
endometrium	O
,	O
cervix	O
and	O
prostate	O
;	O
endometriosis	O
,	O
uterine	O
fibroids	O
,	O
osteoarthritis	O
and	O
as	O
contraceptive	O
agents	O
,	O
alone	O
or	O
in	O
combination	O
with	O
a	O
progestogen	B
or	O
progestogen	B
antagonist	O
.	O

Novel	O
Spiro	B
-	I
benzo	I
[	I
c	I
]	I
chromene	I
derivatives	O
useful	O
as	O
modulators	O
of	O
the	O
estrogen	B
receptors	O

The	O
present	O
application	O
describes	O
deuterium	B
-	I
enriched	I
miglustat	I
,	O
pharmaceutically	O
acceptable	O
salt	O
forms	O
thereof	O
,	O
and	O
methods	O
of	O
treating	O
using	O
the	O
same	O
.	O

Deuterium	B
-	I
enriched	I
miglustat	I

Substituted	O
N	B
[	I
N-	I
(	I
sulphonylphenyl	I
)	I
sulfonyl	I
-	I
prolyl	I
]	I
-phenylalanine	I
derivatives	O
of	O
the	O
present	O
invention	O
are	O
antagonists	O
of	O
the	O
VLA-4	O
integrin	O
and	O
are	O
useful	O
in	O
the	O
treatment	O
,	O
prevention	O
and	O
suppression	O
of	O
diseases	O
mediated	O
by	O
VLA-4-binding	O
and	O
cell	O
adhesion	O
and	O
activation	O
.	O

Moreover	O
,	O
the	O
compounds	O
of	O
the	O
present	O
invention	O
demonstrate	O
significant	O
receptor	O
occupancy	O
of	O
VLA-4	O
bearing	O
cells	O
after	O
oral	O
administration	O
and	O
are	O
suitable	O
for	O
once-	O
,	O
twice-	O
,	O
or	O
thrice	O
-	O
a	O
-	O
day	O
oral	O
administration	O
.	O

This	O
invention	O
also	O
relates	O
to	O
compositions	O
containing	O
such	O
compounds	O
and	O
methods	O
of	O
treatment	O
using	O
such	O
compounds	O
.	O

Substituted	O
N	B
[	I
N-	I
(	I
sulphonylphenyl	I
)	I
sulfonyl	I
-	I
prolyl	I
]	I
-phenylalanine	I
derivatives	O
are	O
antagonists	O
of	O
the	O
very	O
late	O
antigen-4	O
integrin	O
;	O
ulcerative	O
colitis	O
,	O
Crohn	O
's	O
disease	O
,	O
asthma	O
,	O
multiple	O
sclerosis	O
,	O
rheumatoid	O
arthritis	O

The	O
subject	O
invention	O
provides	O
dipeptides	O
useful	O
in	O
promoting	O
healthy	O
muscle	O
tissues	O
as	O
well	O
as	O
effective	O
immune	O
responses	O
.	O

The	O
dipeptides	O
of	O
the	O
subject	O
invention	O
are	O
particularly	O
advantageous	O
because	O
they	O
are	O
stable	O
,	O
bioavailable	O
,	O
and	O
can	O
be	O
formulated	O
in	O
an	O
aqueous	O
solution	O
.	O

Dipeptides	O
for	O
Prevention	O
of	O
Muscle	O
Breakdown	O
and	O
Microbial	O
Infection	O

Provided	O
herein	O
are	O
compounds	O
,	O
compositions	O
and	O
methods	O
for	O
decreasing	O
NFB	O
DNA	O
-	O
binding	O
activity	O
in	O
a	O
patient	O
comprising	O
administering	O
of	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
compound	O
or	O
composition	O
of	O
the	O
application	O
to	O
the	O
patient	O
to	O
reduce	O
,	O
alleviate	O
or	O
treat	O
various	O
gastrointestinal	O
diseases	O
,	O
such	O
as	O
inflammatory	O
bowel	O
disease	O
(	O
IBD	O
)	O
.	O

Targeting	O
Prodrugs	O
for	O
the	O
Treatment	O
of	O
Gastrointestinal	O
Diseases	O

The	O
present	O
invention	O
is	O
directed	O
to	O
metal	O
chelating	O
conjugates	O
for	O
use	O
as	O
metallopharmaceutical	O
diagnostic	O
or	O
therapeutic	O
agents	O
.	O

Specifically	O
,	O
conjugates	O
of	O
the	O
present	O
invention	O
include	O
one	O
or	O
more	O
carriers	O
,	O
a	O
linker	O
,	O
and	O
metal	O
coordinating	O
moiety	O
comprising	O
a	O
resorcinol	B
,	O
thioresorcinol	B
,	O
or	O
dithioresorcinol	B
derivative	O
through	O
which	O
the	O
metal	O
coordinating	O
moiety	O
is	O
bonded	O
to	O
the	O
linker	O
.	O

Bifunctional	O
Resorcinol	B
,	O
Thioresorcinol	B
,	O
and	O
Dithioresorcinol	B
Derivative	O
Metal	O
Chelating	O
Conjugates	O

[	O
Problem	O
]	O
To	O
provide	O
a	O
compound	O
which	O
may	O
be	O
used	O
in	O
treating	O
diseases	O
in	O
which	O
11	B
-	I
hydroxysteroid	I
dehydrogenase	O
type	O
1	O
(	O
11	O
-	O
HSD1	O
)	O
is	O
concerned	O
,	O
especially	O
diabetes	O
and	O
insulin	O
resistance	O
.	O

[	O
Means	O
for	O
Solution	O
]	O

It	O
was	O
found	O
that	O
a	O
triazole	B
derivative	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
in	O
which	O
the	O
3-position	O
of	O
triazole	B
ring	O
is	O
substituted	O
with	O
a	O
trisubstituted	B
methyl	I
group	O
and	O
the	O
5-position	O
is	O
substituted	O
with	O
a	O
lower	O
alkyl	B
,	O
cycloalkyl	B
or	O
the	O
like	O
,	O
has	O
a	O
strong	O
11	O
-	O
HSD1-inhibitory	O
activity	O
.	O

In	O
addition	O
,	O
since	O
the	O
triazole	B
derivative	O
of	O
the	O
present	O
invention	O
shows	O
excellent	O
blood	O
glucose	B
-	O
lowering	O
action	O
,	O
it	O
may	O
be	O
used	O
in	O
the	O
treatment	O
of	O
diabetes	O
and	O
insulin	O
resistance	O
.	O

Triazole	B
derivative	O
or	O
a	O
salt	O
thereof	O

Compounds	O
of	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
Ra	O
,	O
Rb	O
,	O
R	O
,	O
X1	O
and	O
X2	O
are	O
as	O
defined	O
in	O
the	O
disclosure	O
,	O
pharmaceutical	O
compositions	O
comprising	O
said	O
compounds	O
,	O
processes	O
for	O
making	O
and	O
methods	O
of	O
using	O
the	O
same	O
are	O
provided	O
.	O

Novel	O
Cyclic	O
Urea	B
Derivatives	O
,	O
Preparation	O
Thereof	O
and	O
Pharmaceutical	O
Use	O

Thereof	O
as	O
Kinase	O
Inhibitors	O

The	O
present	O
application	O
describes	O
deuterium	B
-	I
enriched	I
pioglitazone	I
,	O
pharmaceutically	O
acceptable	O
salt	O
forms	O
thereof	O
,	O
and	O
methods	O
of	O
treating	O
using	O
the	O
same	O
.	O

Deuterium	B
-	I
enriched	I
pioglitazone	I

A	O
composition	O
for	O
treating	O
cancer	O
cells	O
and	O
a	O
preparation	O
method	O
therefore	O
is	O
provided	O
.	O

The	O
composition	O
includes	O
novel	O
withanolide	B
compounds	O
derived	O
from	O
a	O
Solanaceae	O
plant	O
,	O
which	O
the	O
novel	O
withanolide	B
compounds	O
have	O
the	O
cytotoxicity	O
to	O
the	O
cancer	O
cells	O
.	O

withanolide	B
compounds	O
extracted	O
from	O
a	O
Solanaceae	O
plant	O
as	O
anticancer	O
agents	O
;	O
solvent	O
extraction	O
from	O
Tubocapsicum	O
anomalum	O

The	O
present	O
invention	O
is	O
directed	O
to	O
pharmaceutical	O
compositions	O
and	O
nutritional	O
supplements	O
that	O
contain	O
large	O
amount	O
of	O
ginkgolides	B
,	O
particularly	O
ginkgolide	B
A	I
or	I
B	I
,	O
and	O
for	O
which	O
,	O
the	O
other	O
components	O
normally	O
found	O
in	O
Ginkgo	O
biloba	O
extracts	O
have	O
been	O
removed	O
.	O

The	O
compositions	O
may	O
be	O
administered	O
to	O
women	O
to	O
prevent	O
or	O
treat	O
ovarian	O
cancer	O
,	O
particularly	O
non	O
-	O
mucinous	O
ovarian	O
cancer	O
.	O

Ginkgolides	B
in	O
the	O
Treatment	O
and	O
Prevention	O
of	O
Ovarian	O
Cancer	O

Hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
is	O
a	O
major	O
cause	O
of	O
chronic	O
liver	O
disease	O
and	O
affects	O
over	O
270	O
million	O
individuals	O
worldwide	O
.	O

The	O
HCV	O
genome	O
is	O
a	O
single	O
-	O
stranded	O
RNA	O
that	O
functions	O
as	O
both	O
a	O
messenger	O
RNA	O
and	O
replication	O
template	O
,	O
making	O
it	O
an	O
attractive	O
target	O
for	O
the	O
study	O
of	O
RNA	O
interference	O
.	O

Double	O
-	O
stranded	O
short	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
molecules	O
designed	O
to	O
target	O
the	O
HCV	O
genome	O
are	O
disclosed	O
herein	O
.	O

Short	O
interfering	O
rna	O
as	O
an	O
antiviral	O
agent	O
for	O
hepatitis	O
c	O

The	O
invention	O
provides	O
20-alkyl	B
Gemini	O
vitamin	B
D3	I
compounds	O
,	O
methods	O
for	O
using	O
the	O
compounds	O
to	O
treat	O
vitamin	B
D3	I
associated	O
states	O
and	O
pharmaceutical	O
compositions	O
containing	O
the	O
compounds	O
.	O

20-Alkyl	B
,	O
Gemini	O
Vitamin	B
D3	I
Compounds	O
and	O
Methods	O
of	O
Use	O
Thereof	O

The	O
invention	O
described	O
herein	O
relates	O
to	O
diagnostic	O
and	O
treatment	O
methods	O
and	O
compositions	O
useful	O
in	O
the	O
management	O
of	O
disorders	O
,	O
for	O
example	O
cancers	O
,	O
involving	O
cells	O
that	O
overexpress	O
MDR-1	O
,	O
and	O
methods	O
of	O
decreasing	O
the	O
incidence	O
of	O
CNS	O
complications	O
that	O
are	O
often	O
associated	O
with	O
CML	O
patients	O
that	O
have	O
been	O
administered	O
imatinib	B
or	O
other	O
protein	O
tyrosine	B
kinase	O
inhibitors	O
.	O

Methods	O
of	O
Identifying	O
and	O
Treating	O
Individuals	O
Exhibiting	O
MDR-1	O
Overexpression	O
With	O
Protein	O
Tyrosine	B
Kinase	O
Inhibitors	O
and	O
Combinations	O
Thereof	O

This	O
invention	O
provides	O
methods	O
of	O
inducing	O
cell	O
death	O
with	O
Flavivirus	O
or	O
Pestivirus	O
capsid	O
protein	O
,	O
such	O
as	O
West	O
Nile	O
virus	O
(	O
WNV	O
)	O
capsid	O
protein	O
,	O
and	O
functional	O
fragments	O
thereof	O
.	O

The	O
invention	O
also	O
provides	O
methods	O
of	O
treating	O
patients	O
suffering	O
from	O
diseases	O
characterized	O
by	O
hyperproliferating	O
cells	O
by	O
administering	O
pharmaceutical	O
compositions	O
comprising	O
WNV	O
or	O
other	O
virus	O
including	O
Flavivirus	O
or	O
Pestivirus	O
capsid	O
or	O
other	O
protein	O
or	O
a	O
nucleic	O
acid	O
molecule	O
encoding	O
the	O
same	O
.	O

Methods	O
of	O
identifying	O
compounds	O
which	O
have	O
anti	O
-	O
viral	O
and/or	O
anti	O
-	O
WNV	O
and/or	O
anti	O
-	O
Flavivirus	O
and/or	O
anti	O
-	O
Pestivirus	O
capsid	O
or	O
other	O
protein	O
activity	O
are	O
disclosed	O
.	O

The	O
invention	O
also	O
provides	O
vaccine	O
compositions	O
comprising	O
capsid	O
or	O
other	O
proteins	O
,	O
or	O
fragments	O
thereof	O
,	O
or	O
nucleic	O
acids	O
encoding	O
same	O
,	O
from	O
WNV	O
or	O
other	O
virus	O
including	O
Flavivirus	O
or	O
Pestivirus	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O

The	O
invention	O
also	O
provides	O
diagnostic	O
methods	O
and	O
kits	O
for	O
identifying	O
individuals	O
exposed	O
to	O
WNV	O
or	O
other	O
viruses	O
including	O
Flavivirus	O
or	O
Pestivirus	O
.	O

Compositions	O
and	O
methods	O
of	O
using	O
capsid	O
protein	O
from	O
flaviviruses	O
and	O
pestiviruses	O

The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
herbal	O
composition	O
comprising	O
extract	O
of	O
roots	O
of	O
the	O
plant	O
Murraya	O
koenigii	O
for	O
the	O
treatment	O
of	O
infections	O
caused	O
by	O
dermatophytes	O
,	O
particularly	O
tinea	O
infections	O
,	O
and	O
method	O
of	O
manufacture	O
of	O
said	O
composition	O
.	O

The	O
said	O
herbal	O
composition	O
comprises	O
2-methoxy-3-methyl-9H	B
-	I
carbazole	I
(	O
compound	O
1	O
)	O
as	O
a	O
bioactive	O
ingredient	O
.	O

Invention	O
also	O
discloses	O
methods	O
for	O
topical	O
application	O
of	O
the	O
said	O
herbal	O
composition	O
for	O
the	O
treatment	O
of	O
infections	O
caused	O
by	O
dermatophytes	O
.	O

Herbal	O
composition	O
for	O
treatment	O
of	O
infections	O
caused	O
by	O
dermatophytes	O

The	O
present	O
invention	O
provides	O
methods	O
for	O
inhibiting	O
VEGF	O
production	O
or	O
secretion	O
in	O
a	O
subject	O
comprising	O
administering	O
to	O
the	O
subject	O
an	O
effective	O
amount	O
of	O
a	O
compound	O
of	O
Formula	O
I.	O
The	O
invention	O
also	O
provides	O
methods	O
for	O
the	O
treatment	O
or	O
prevention	O
of	O
conditions	O
associated	O
with	O
abnormal	O
levels	O
of	O
VEGF	O
production	O
or	O
secretion	O
.	O

VEGF	O
Inhibition	O

Embodiments	O
of	O
the	O
invention	O
provide	O
a	O
stretchable	O
sleeve	O
having	O
a	O
medicinal	O
section	O
that	O
can	O
be	O
loaded	O
with	O
a	O
medicinal	O
composition	O
and	O
a	O
perforated	O
section	O
comprising	O
a	O
plurality	O
of	O
openings	O
,	O
wherein	O
the	O
medicinal	O
section	O
and	O
the	O
perforated	O
section	O
overlap	O
,	O
and	O
wherein	O
the	O
sleeve	O
is	O
sized	O
so	O
that	O
the	O
interior	O
surface	O
of	O
the	O
medicinal	O
section	O
comfortably	O
fits	O
a	O
body	O
portion	O
and	O
the	O
medicinal	O
section	O
contacts	O
the	O
body	O
portion	O
at	O
the	O
site	O
of	O
pain	O
.	O

Embodiments	O
of	O
the	O
invention	O
also	O
provide	O
methods	O
for	O
preparing	O
a	O
sleeve	O
by	O
applying	O
a	O
medicinal	O
composition	O
to	O
the	O
inner	O
surface	O
of	O
the	O
medicinal	O
section	O
through	O
the	O
openings	O
at	O
the	O
perforated	O
section	O
.	O

Embodiments	O
of	O
the	O
invention	O
also	O
provide	O
methods	O
for	O
relieving	O
pain	O
in	O
a	O
body	O
portion	O
by	O
pulling	O
the	O
sleeve	O
in	O
an	O
outside	O
-	O
out	O
configuration	O
straight	O
up	O
a	O
body	O
portion	O
without	O
having	O
to	O
roll	O
and	O
flip	O
its	O
exterior	O
surface	O
outside	O
.	O

Medicated	O
sleeve	O

The	O
present	O
invention	O
provides	O
compositions	O
and	O
methods	O
for	O
modulating	O
smooth	O
muscle	O
cells	O
.	O

The	O
present	O
invention	O
also	O
provides	O
methods	O
of	O
identifying	O
small	O
molecule	O
candidate	O
therapeutic	O
agents	O
for	O
modulating	O
smooth	O
muscle	O
.	O

Non	O
-	O
peptidyl	O
agents	O
with	O
pHSP20-like	O
activity	O
,	O
and	O
uses	O
thereof	O

This	O
invention	O
provides	O
a	O
method	O
for	O
regulating	O
migration	O
of	O
neuronal	O
progenitor	O
cells	O
in	O
the	O
nervous	O
system	O
of	O
a	O
mammal	O
.	O

The	O
method	O
comprises	O
providing	O
a	O
mammal	O
with	O
TNR	O
,	O
a	O
biologically	O
active	O
fragment	O
of	O
TNR	O
,	O
or	O
a	O
TNR	O
agonist	O
in	O
an	O
amount	O
sufficient	O
to	O
direct	O
migration	O
of	O
the	O
neuronal	O
progenitor	O
cells	O
.	O

The	O
invention	O
provides	O
a	O
method	O
of	O
treating	O
neurological	O
diseases	O
by	O
replenishing	O
diseased	O
,	O
damaged	O
,	O
or	O
destroyed	O
neural	O
cells	O
in	O
the	O
central	O
nervous	O
system	O
or	O
in	O
the	O
peripheral	O
nervous	O
system	O
.	O

Methods	O
of	O
treating	O
neurological	O
diseases	O
by	O
regulating	O
migration	O
of	O
neuroblasts	O
in	O
the	O
adult	O
nervous	O
system	O
with	O
tenascin	O
-	O
R	O

The	O
present	O
invention	O
provides	O
methods	O
for	O
making	O
,	O
delivering	O
and	O
using	O
formulations	O
that	O
combine	O
a	O
therapeutically	O
active	O
agent	O
(	O
s	O
)	O
(	O
such	O
as	O
for	O
example	O
a	O
Rho	O
antagonist	O
(	O
s	O
)	O
)	O
and	O
a	O
flowable	O
carrier	O
component	O
capable	O
of	O
forming	O
a	O
therapeutically	O
acceptable	O
matrix	O
in	O
vivo	O
(	O
such	O
as	O
for	O
example	O
tissue	O
adhesives	O
)	O
,	O
to	O
injured	O
nerves	O
to	O
promote	O
repair	O
and	O
regeneration	O
and	O
regrowth	O
of	O
injured	O
(	O
mammalian	O
)	O
neuronal	O
cells	O
,	O
e.g.	O
for	O
facilitating	O
axon	O
growth	O
at	O
a	O
desired	O
lesion	O
site	O
.	O

Preferred	O
active	O
agents	O
are	O
known	O
Rho	O
antagonists	O
such	O
as	O
for	O
example	O
C3	O
,	O
chimeric	O
C3	O
proteins	O
,	O
etc	O
.	O
or	O
substances	O
selected	O
from	O
among	O
known	O
trans-4-amino	B
(	I
alkyl	I
)	I
-1-pyridylcarbamoylcyclohexane	I
compounds	O
or	O
Rho	O
kinase	O
inhibitors	O
.	O

The	O
system	O
for	O
example	O
may	O
deliver	O
an	O
antagonist	O
(	O
s	O
)	O
in	O
a	O
tissue	O
adhesive	O
such	O
as	O
,	O
for	O
example	O
,	O
a	O
fibrin	O
glue	O
or	O
a	O
collagen	O
gel	O
to	O
create	O
a	O
delivery	O
matrix	O
in	O
situ	O
.	O

A	O
kit	O
and	O
methods	O
of	O
stimulating	O
neuronal	O
regeneration	O
are	O
also	O
included	O
.	O

Methods	O
for	O
Making	O
and	O
Delivering	O
Rho	O
-	O
Antagonist	O
Tissue	O
Adhesive	O
Formulations	O
to	O
the	O
Injured	O
Mammalian	O
Central	O
and	O
Peripheral	O
Nervous	O
Systems	O
and	O
uses	O
Thereof	O

Rate	O
-	O
controlled	O
particles	O
,	O
comprising	O
compounds	O
of	O
the	O
formula	O
as	O
a	O
solid	O
dispersion	O
.	O

Rate	O
-	O
controlled	O
particles	O

The	O
present	O
invention	O
relates	O
to	O
new	O
substituted	O
nitrogen	B
-	O
containing	O
heterobicyclic	B
compounds	O
of	O
general	O
formula	O
wherein	O
B	O
,	O
X1	O
to	O
X3	O
and	O
R1	O
to	O
R5	O
are	O
defined	O
as	O
in	O
claim	O
1	O
,	O
the	O
tautomers	O
,	O
the	O
enantiomers	O
,	O
the	O
diastereomers	O
,	O
the	O
mixtures	O
thereof	O
and	O
the	O
salts	O
thereof	O
,	O
particularly	O
the	O
physiologically	O
acceptable	O
salts	O
thereof	O
with	O
inorganic	O
or	O
organic	O
acids	O
or	O
bases	O
,	O
which	O
have	O
valuable	O
properties	O
.	O

The	O
compounds	O
of	O
the	O
above	O
general	O
formula	O
I	O
as	O
well	O
as	O
the	O
tautomers	O
,	O
the	O
enantiomers	O
,	O
the	O
diastereomers	O
,	O
the	O
mixtures	O
thereof	O
and	O
the	O
salts	O
thereof	O
,	O
particularly	O
the	O
physiologically	O
acceptable	O
salts	O
thereof	O
with	O
inorganic	O
or	O
organic	O
acids	O
or	O
bases	O
,	O
and	O
their	O
stereoisomers	O
have	O
valuable	O
pharmacological	O
properties	O
,	O
particularly	O
an	O
antithrombotic	O
activity	O
and	O
a	O
factor	O
Xa	O
-	O
inhibiting	O
activity	O
.	O

Substituted	O
nitrogen	B
-	O
containing	O
heterobicycles	B
,	O
the	O
preparation	O
thereof	O
and	O
their	O
use	O
as	O
pharmaceutical	O
compositions	O

The	O
present	O
invention	O
provides	O
methods	O
of	O
treating	O
sexual	O
dysfunction	O
.	O

The	O
methods	O
include	O
administering	O
an	O
effective	O
amount	O
of	O
nebivolol	B
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
alone	O
or	O
in	O
combination	O
with	O
a	O
second	O
active	O
agent	O
e.g.	O
a	O
PDE-5	O
inhibitor	O
,	O
such	O
as	O
sildenafil	B
citrate	I
.	O

The	O
methods	O
of	O
the	O
present	O
invention	O
are	O
particularly	O
suited	O
to	O
the	O
treatment	O
of	O
erectile	O
dysfunction	O
and	O
female	O
sexual	O
arousal	O
disorder	O
.	O

Nebivolol	B
in	O
the	O
treatment	O
of	O
sexual	O
dysfunction	O

Biomacromolecules	O
such	O
as	O
proteins	O
are	O
inactivated	O
by	O
hydrophobic	O
ANSA	O
derivatives	O
of	O
the	O
formula	O
:	O
wherein	O
R1	O
and	O
R2	O
are	O
hydrophobic	O
or	O
affinity	O
groups	O
and	O
R3	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
aminoacyl	B
groups	O
and	O
peptidyl	O
groups	O
upon	O
nitrosation	O
.	O

ANSA	O
derivatives	O
can	O
be	O
designed	O
to	O
selectively	O
kill	O
tumor	O
cells	O
and	O
various	O
pathogens	O
,	O
including	O
bacteria	O
,	O
viruses	O
,	O
and	O
fungi	O
.	O

Nitrosation	O
-	O
Inducible	O
Inhibitors	O
Biological	O
Macromolecules	O

The	O
present	O
invention	O
discloses	O
oxygenic	O
oxygenic	O
oxysterols	B
.	O

Also	O
disclosed	O
,	O
agents	O
and	O
methods	O
for	O
protecting	O
,	O
blocking	O
or	O
rescuing	O
marrow	O
stromal	O
cells	O
from	O
the	O
inhibitory	O
effects	O
of	O
oxidative	O
stress	O
on	O
their	O
osteoblastic	O
cellular	O
differentiation	O
.	O

Exemplary	O
agents	O
include	O
oxysterols	B
,	O
rhBMP2	O
,	O
alone	O
or	O
in	O
combination	O
which	O
are	O
demonstrated	O
to	O
specifically	O
combat	O
oxidative	O
stress	O
caused	O
by	O
inflammatory	O
oxidized	O
lipids	O
,	O
such	O
as	O
xanthine	B
/	O
xanthine	B
oxidase	O
and	O
minimally	O
oxidized	O
LDL	O
.	O

The	O
synergistic	O
effects	O
of	O
oxysterols	B
and	O
bone	O
morphogenic	O
proteins	O
are	O
disclosed	O
.	O

Agents	O
and	O
Methods	O
for	O
Osteogenic	O
Oxysterols	B
Inhibition	O
of	O
Oxidative	O
Stress	O
on	O
Osteogenic	O
Cellular	O
Differentiation	O

The	O
invention	O
relates	O
to	O
methods	O
of	O
screening	O
for	O
binding	O
partners	O
,	O
especially	O
binding	O
partners	O
essential	O
for	O
the	O
biological	O
activity	O
of	O
erastin	O
(	O
e.g.	O
VDACs	O
such	O
as	O
VDAC3	O
)	O
.	O

The	O
invention	O
also	O
provides	O
reagents	O
and	O
methods	O
for	O
effective	O
killing	O
of	O
cancer	O
cells	O
with	O
erastin	O
and	O
related	O
compounds	O
or	O
derivatives	O
.	O

Quinoxaline	O
Derivatives	O
as	O
Antitumor	O
Agents	O

This	O
invention	O
relates	O
to	O
the	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
shown	O
below	O
.	O

Each	O
variable	O
in	O
formula	O
(	O
I	O
)	O
is	O
defined	O
in	O
the	O
specification	O
.	O

These	O
compounds	O
can	O
be	O
used	O
to	O
treat	O
a	O
kinesin	O
Eg5	O
protein	O
-	O
mediated	O
disorder	O
.	O

Kinesin	O
inhibitors	O

This	O
invention	O
is	O
in	O
the	O
field	O
of	O
cancer	O
-	O
associated	O
genes	O
.	O

Specifically	O
it	O
relates	O
to	O
methods	O
for	O
detecting	O
cancer	O
or	O
the	O
likelihood	O
of	O
developing	O
cancer	O
based	O
on	O
the	O
presence	O
or	O
absence	O
of	O
expression	O
of	O
a	O
PRLR	O
gene	O
or	O
protein	O
.	O

The	O
invention	O
also	O
provides	O
methods	O
and	O
molecules	O
for	O
upregulating	O
or	O
downregulating	O
PRLR	O
gene	O
expression	O
and	O
PRLR	O
protein	O
activity	O
.	O

Cancer	O
Related	O
Genes	O
(	O
PRLR	O
)	O

Topical	O
compositions	O
comprising	O
:	O
a	O
physiologically	O
acceptable	O
alkanediol	B
,	O
ether	B
diol	I
or	O
diether	B
alcohol	I
containing	O
up	O
to	O
(	O
8)	O
carbon	B
atoms	O
;	O
water	O
;	O
and	O
	O
optionally	O
an	O
unsaturated	O
fatty	B
alcohol	I
;	O
and	O
optionally	O
further	O
conventional	O
excipients	O
,	O
for	O
use	O
as	O
a	O
cosmeceutical	O
,	O
in	O
particular	O
for	O
use	O
in	O
the	O
repair	O
or	O
maintenance	O
of	O
skin	O
barrier	O
function	O
.	O

They	O
are	O
indicated	O
for	O
use	O
in	O
e.g.	O
moisturizing	O
skin	O
,	O
nail	O
and	O
mucosa	O
and	O
,	O
when	O
an	O
optional	O
pharmaceutically	O
active	O
agent	O
is	O
present	O
,	O
additionally	O
in	O
the	O
treatment	O
of	O
various	O
skin	O
,	O
nail	O
and	O
mucosal	O
diseases	O
.	O

Also	O
disclosed	O
are	O
compositions	O
suitable	O
for	O
topical	O
application	O
to	O
infants	O
and	O
babies	O
for	O
treating	O
dry	O
skin	O
,	O
and	O
soothing	O
skin	O
irritated	O
from	O
diaper	O
rash	O
and	O
scrapes	O
.	O

Cosmeceutical	O
composition	O

Methods	O
of	O
antagonizing	O
MIF	O
activity	O
using	O
ibudilast	B
are	O
described	O
.	O

Also	O
described	O
are	O
methods	O
of	O
screening	O
for	O
MIF	O
antagonists	O
.	O

These	O
agents	O
can	O
be	O
used	O
for	O
treating	O
addictions	O
,	O
including	O
drug	O
and	O
behavioral	O
addictions	O
,	O
as	O
well	O
as	O
for	O
treating	O
neuropathic	O
pain	O
.	O

Drug	O
screening	O
;	O
antagonizing	O
macrophage	O
migration	O
inhibitory	O
factor	O
(	O
MIF	O
)	O
using	O
ibudilast	B
;	O
neuropathic	O
pain	O
;	O
identifying	O
agents	O
useful	O
for	O
opiate	O
withdrawal	O
and	O
for	O
treating	O
other	O
addictions	O
and	O
dependence	O

The	O
present	O
invention	O
relates	O
to	O
compositions	O
and	O
uses	O
of	O
novel	O
high	O
penetration	O
compositions	O
or	O
high	O
penetration	O
prodrugs	O
(	O
HPP	O
)	O
,	O
in	O
particular	O
HPPs	O
for	O
4-aminophenol	B
derivatives	O
,	O
which	O
are	O
capable	O
of	O
crossing	O
biological	O
barriers	O
with	O
high	O
penetration	O
efficiency	O
.	O

The	O
HPPs	O
herein	O
are	O
capable	O
of	O
being	O
converted	O
to	O
parent	O
active	O
drugs	O
or	O
drug	O
metabolites	O
after	O
crossing	O
the	O
biological	O
barrier	O
and	O
thus	O
can	O
render	O
treatments	O
for	O
the	O
conditions	O
that	O
the	O
parent	O
drugs	O
or	O
metabolites	O
can	O
.	O

Additionally	O
,	O
due	O
to	O
the	O
ability	O
of	O
penetrating	O
biological	O
barriers	O
,	O
the	O
HPPs	O
herein	O
are	O
capable	O
of	O
reaching	O
areas	O
that	O
parent	O
drugs	O
may	O
not	O
be	O
able	O
to	O
access	O
or	O
to	O
render	O
a	O
sufficient	O
concentration	O
at	O
the	O
target	O
areas	O
and	O
therefore	O
render	O
novel	O
treatments	O
.	O

The	O
HPPs	O
herein	O
can	O
be	O
administered	O
to	O
a	O
subject	O
through	O
various	O
administration	O
routes	O
.	O

For	O
example	O
,	O
the	O
HPPs	O
can	O
be	O
locally	O
delivered	O
to	O
an	O
action	O
site	O
of	O
a	O
condition	O
with	O
a	O
high	O
concentration	O
due	O
to	O
their	O
ability	O
of	O
penetrating	O
biological	O
barriers	O
and	O
thus	O
obviate	O
the	O
need	O
for	O
a	O
systematic	O
administration	O
.	O

For	O
another	O
example	O
,	O
the	O
HPPs	O
herein	O
can	O
be	O
systematically	O
administer	O
to	O
a	O
biological	O
subject	O
and	O
enter	O
the	O
general	O
circulation	O
with	O
a	O
faster	O
rate	O
.	O

High	O
penetration	O
composition	O
and	O
uses	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
delivery	O
systems	O
.	O

In	O
particular	O
,	O
the	O
present	O
invention	O
provides	O
microporous	O
scaffolds	O
having	O
thereon	O
agents	O
(	O
e.g.	O
,	O
extracellular	O
matrix	O
proteins	O
,	O
exendin-4	O
)	O
and	O
biological	O
material	O
(	O
e.g.	O
,	O
pancreatic	O
islet	O
cells	O
)	O
.	O

In	O
some	O
embodiments	O
,	O
the	O
scaffolds	O
are	O
used	O
for	O
transplanting	O
biological	O
material	O
into	O
a	O
subject	O
.	O

In	O
some	O
embodiments	O
,	O
the	O
scaffolds	O
are	O
used	O
in	O
the	O
treatment	O
of	O
diseases	O
(	O
e.g.	O
,	O
type	O
1	O
diabetes	O
)	O
,	O
and	O
related	O
methods	O
(	O
e.g.	O
,	O
diagnostic	O
methods	O
,	O
research	O
methods	O
,	O
drug	O
screening	O
)	O
.	O

Delivery	O
scaffolds	O
and	O
related	O
methods	O
of	O
use	O

A	O
compound	O
of	O
Formula	O
(	O
I	O
)	O
and	O
pharmaceutically	O
and/or	O
veterinarily	O
acceptable	O
derivatives	O
thereof	O
,	O
wherein	O
:	O
R1	O
is	O
H	B
,	O
C1	B
-	I
6alkyl	I
,	O
C	O
(	O
A	O
)	O
D	O
,	O
C3	B
-	I
8cycloalkyl	I
,	O
aryl	B
,	O
het	O
,	O
aryl	B
-	I
C1	I
-	I
4alkyl	I
or	O
het	B
-	I
C1	I
-	I
4alkyl	I
,	O
wherein	O
the	O
cycloalkyl	B
,	O
aryl	B
or	O
het	O
groups	O
are	O
optionally	O
substituted	O
;	O
A	O
is	O
S	B
or	O
O	B
;	O
D	O
is	O
H	B
,	O
C1	B
-	I
6alkyl	I
,	O
aryl	B
,	O
het	B
,	O
aryl	B
-	I
C1	I
-	I
4alkyl	I
or	O
het	B
-	I
C1	I
-	I
4alkyl	I
;	O
aryl	B
represents	O
phenyl	B
,	O
naphthyl	B
,	O
anthracyl	B
or	O
phenanthryl	B
;	O
het	O
represents	O
an	O
aromatic	B
or	O
non	O
-	O
aromatic	B
4-	O
,	O
5-	O
or	O
6-membered	O
heterocycle	B
which	O
contains	O
at	O
least	O
one	O
N	B
,	O
O	B
or	O
S	B
heteroatom	O
,	O
optionally	O
fused	O
to	O
a	O
5-	O
or	O
6-membered	O
carbocyclic	B
group	O
or	O
a	O
second	O
4-	O
,	O
5-	O
or	O
6-membered	O
heterocycle	B
which	O
contains	O
at	O
least	O
one	O
N	B
,	O
O	B
or	O
S	B
heteroatom	O
;	O
R2	O
is	O
aryl1	B
or	O
het1	O
,	O
each	O
optionally	O
substituted	O
;	O
n	O
is	O
1	O
or	O
2	O
,	O
provided	O
that	O
when	O
n	O
is	O
1	O
,	O
m	O
is	O
0	O
or	O
1	O
and	O
when	O
n	O
is	O
2	O
,	O
m	O
is	O
0	O
,	O
wherein	O
if	O
m	O
is	O
0	O
,	O
then	O
*	O
represents	O
a	O
chiral	O
centre	O
;	O
R3	O
is	O
(	B
CH2	I
)	I
aE	I
,	O
wherein	O
a	O
is	O
0	O
,	O
1	O
or	O
2	O
and	O
E	O
is	O
a	O
group	O
selected	O
from	O
:	O
Formula	O
(	O
i	O
)	O
wherein	O
:	O
X	O
is	O
O	B
,	O
S	B
,	O
NR12	B
,	O
(	B
CH2	I
)	I
v	I
or	O
a	O
bond	O
;	O
b	O
is	O
1	O
,	O
2	O
,	O
3	O
or	O
4	O
;	O
c	O
is	O
1	O
,	O
2	O
or	O
3	O
;	O
v	O
is	O
1	O
or	O
2	O
;	O
R10	O
and	O
11	O
are	O
each	O
independently	O
H	B
or	O
C1	B
-	I
4	I
alkyl	I
;	O
and	O
R12	O
is	O
H	B
,	O
1	B
-	I
6	I
alkyl	I
,	O
C	B
(	I
O	I
)	I
C1	I
-	I
6	I
alkyl	I
,	O
SO2C1	B
-	I
6alkyl	I
;	O
and	O
wherein	O
one	O
or	O
more	O
pairs	O
of	O
hydrogen	B
atoms	O
on	O
adjacent	O
carbon	B
or	O
nitrogen	B
atoms	O
may	O
be	O
replaced	O
by	O
a	O
corresponding	O
number	O
of	O
double	O
bonds	O
,	O
provided	O
the	O
ring	O
system	O
is	O
not	O
aromatic	B
;	O
Formula	O
(	O
ii	O
)	O
a	O
carbocyclic	B
spiro	O
group	O
containing	O
6	O
to	O
12	O
carbon	B
atoms	O
;	O
Formula	O
(	O
iii	O
)	O
wherein	O
:	O
d	O
is	O
1	O
,	O
2	O
,	O
3	O
or	O
4	O
;	O
a	O
is	O
1	O
,	O
2	O
or	O
3	O
;	O
f	O
is	O
1	O
or	O
2	O
;	O
and	O
R30	O
is	O
H	B
or	O
C1	B
-	I
4alkyl	I
;	O
and	O
wherein	O
one	O
or	O
more	O
pairs	O
of	O
hydrogen	B
atoms	O
on	O
adjacent	O
carbon	B
atoms	O
may	O
be	O
replaced	O
by	O
a	O
corresponding	O
number	O
of	O
double	O
bonds	O
,	O
provided	O
the	O
ring	O
system	O
is	O
not	O
aromatic	B
;	O
Formula	O
(	O
iv	O
)	O
wherein	O
:	O
g	O
is	O
0	O
,	O
1	O
,	O
2	O
or	O
3	O
;	O
J	O
is	O
NR40	O
;	O
and	O
R40	O
is	O
C	B
(	I
O	I
)	I
C1	I
-	I
6	I
alkyl	I
,	O
S02-C1	B
-	I
6alkyl	I
;	O
Formula	O
(	O
v	O
)	O
wherein	O
:	O
h	O
is	O
0	O
,	O
1	O
,	O
2	O
or	O
3	O
;	O
and	O
R50	O
is	O
H	B
,	O
C1	B
-	I
8alkyl	I
,	O
C1	B
-	I
8alkoxy	I
,	O
OH	B
,	O
halo	B
,	O
CF3	B
,	O
OCF3	B
,	O
SCF3	B
,	O
hydroxy	B
-	I
C1	I
-	I
6alkyl	I
,	O
C1	B
-	I
4alkoxy	I
-	I
C1	B
-	I
6alkyl	I
and	O
C1	B
-	I
4alkyl	I
-	I
S	I
	I
C1	I
-	I
4alkyl	I
;	O
Formula	O
(	O
vi	O
)	O
CH	B
(	I
cyclopropane	I
)	I
2	I
;	O
Formula	O
(	O
vii	O
)	O
C1	B
-	I
6alkyl	I
,	O
substituted	O
by	O
at	O
least	O
one	O
substituent	O
;	O
and	O
Formula	O
(	O
viii	O
)	O
C3	B
-	I
8cycloalkyl	I
-	I
C1	I
-	I
6alkyl	I
;	O
wherein	O
the	O
C1	B
-	I
6alkyl	I
moiety	O
is	O
substituted	O
at	O
any	O
point	O
other	O
than	O
at	O
the	O
junction	O
with	O
the	O
C3	B
-	I
8cycloalkyl	I
moiety	O
,	O
by	O
at	O
least	O
one	O
substituent	O
.	O

The	O
compounds	O
exhibit	O
activity	O
as	O
both	O
serotonin	B
and/or	O
noradrenaline	B
re	O
-	O
uptake	O
inhibitors	O
and	O
therefore	O
have	O
utility	O
in	O
a	O
variety	O
of	O
therapeutic	O
areas	O
,	O
for	O
example	O
urinary	O
incontinence	O
.	O

N	B
-	I
Pyrrolidin-3-YL	I
-	I
Amide	I
Derivatives	O
As	O
Serotonin	B
and	O
Noradrenalin	B
Re	O
-	O
Uptake	O
Inhibitors	O

A	O
safer	O
,	O
more	O
effective	O
treatment	O
of	O
many	O
medical	O
diseases	O
may	O
be	O
approached	O
by	O
a	O
method	O
utilizing	O
modified	O
viruses	O
as	O
vehicles	O
to	O
transport	O
medically	O
therapeutic	O
drug	O
molecules	O
to	O
specific	O
cells	O
in	O
the	O
body	O
with	O
the	O
intent	O
to	O
have	O
the	O
drug	O
exert	O
an	O
effect	O
only	O
on	O
those	O
cells	O
to	O
which	O
the	O
modified	O
virus	O
delivers	O
the	O
drug	O
.	O

The	O
modified	O
virus	O
or	O
virus	O
-	O
like	O
structures	O
make	O
contact	O
with	O
specific	O
target	O
cells	O
by	O
means	O
of	O
the	O
modified	O
virus	O
's	O
exterior	O
probes	O
or	O
virus	O
-	O
like	O
structures	O
'	O
exterior	O
probes	O
.	O

Once	O
the	O
exterior	O
probes	O
engage	O
a	O
target	O
cell	O
's	O
receptors	O
,	O
the	O
modified	O
virus	O
or	O
virus	O
-	O
like	O
structure	O
inserts	O
into	O
the	O
target	O
cell	O
the	O
quantity	O
of	O
medically	O
therapeutic	O
drug	O
molecules	O
it	O
is	O
carrying	O
.	O

By	O
delivering	O
the	O
medically	O
therapeutic	O
drug	O
only	O
to	O
specific	O
cells	O
in	O
the	O
body	O
it	O
is	O
assured	O
the	O
drug	O
reaches	O
the	O
site	O
in	O
the	O
body	O
it	O
will	O
be	O
most	O
beneficial	O
and	O
the	O
occurrence	O
of	O
unwanted	O
side	O
effects	O
due	O
the	O
drug	O
are	O
significantly	O
minimized	O
.	O

Method	O
for	O
treating	O
cancer	O
,	O
rheumatoid	O
arthritis	O
and	O
other	O
medical	O
diseases	O
by	O
utilizing	O
modified	O
virus	O
virions	O
to	O
insert	O
medications	O
into	O
targeted	O
cells	O

The	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
formula	O
I	O
,	O
which	O
are	O
appropriate	O
for	O
the	O
treatment	O
of	O
kinase	O
,	O
e.g.	O
PI3K	O
-	O
related	O
,	O
diseases	O
,	O
such	O
as	O
proliferative	O
diseases	O
,	O
inflammatory	O
diseases	O
,	O
obstructive	O
airways	O
disorders	O
and	O
transplantation	O
related	O
diseases	O
.	O

2,4-Substituted	B
Quinazolines	I
as	O
Lipid	O
Kinase	O
Inhibitors	O

This	O
invention	O
is	O
directed	O
generally	O
to	O
a	O
liquid	O
pharmaceutical	O
composition	O
comprising	O
at	O
least	O
one	O
thyroid	O
hormone	O
(	O
particularly	O
a	O
composition	O
further	O
comprising	O
at	O
least	O
one	O
cyclodextrin	O
compound	O
)	O
,	O
a	O
process	O
for	O
making	O
such	O
a	O
composition	O
and	O
a	O
method	O
of	O
using	O
such	O
a	O
composition	O
to	O
treat	O
a	O
condition	O
associated	O
with	O
impaired	O
thyroid	O
hormone	O
function	O
.	O

Concentrated	O
Liquid	O
Thyroid	O
Hormone	O
Composition	O

A	O
device	O
and	O
method	O
for	O
removing	O
facial	O
blemishes	O
,	O
including	O
sebum	O
that	O
blocks	O
facial	O
pores	O
.	O

The	O
device	O
includes	O
a	O
substantially	O
flat	O
,	O
elongated	O
and	O
rigid	O
element	O
having	O
a	O
first	O
surface	O
and	O
a	O
second	O
surface	O
,	O
and	O
a	O
distal	O
end	O
and	O
a	O
proximal	O
end	O
.	O

The	O
device	O
also	O
includes	O
a	O
base	O
member	O
to	O
which	O
the	O
rigid	O
element	O
is	O
attached	O
such	O
that	O
a	O
collection	O
area	O
is	O
formed	O
between	O
the	O
second	O
surface	O
of	O
the	O
distal	O
end	O
of	O
the	O
rigid	O
element	O
and	O
a	O
portion	O
of	O
the	O
base	O
member	O
.	O

Facial	O
blemish	O
removing	O
device	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
lactose	B
-	O
derived	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
and	O
to	O
their	O
use	O
as	O
agents	O
for	O
stimulating	O
the	O
immune	O
system	O
of	O
the	O
skin	O
and/or	O
as	O
immunoregulators	O
,	O
and	O
for	O
preparing	O
a	O
composition	O
containing	O
a	O
cosmetically	O
or	O
pharmaceutically	O
acceptable	O
medium	O
,	O
intended	O
in	O
particular	O
to	O
prevent	O
and/or	O
limit	O
the	O
appearance	O
of	O
cutaneous	O
immune	O
imbalances	O
,	O
in	O
particular	O
related	O
to	O
environmental	O
stresses	O
.	O

Use	O
of	O
a	O
lactose	B
-	O
derived	O
c	O
-	O
glycoside	O
compound	O
as	O
an	O
agent	O
for	O
activating	O
and	O
regulating	O
cutaneous	O
immunity	O

The	O
invention	O
relates	O
to	O
novel	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
and	O
to	O
their	O
pharmaceutical	O
compositions	O
and	O
to	O
their	O
methods	O
of	O
use	O
.	O

These	O
novel	O
compounds	O
possess	O
CHK1	O
kinase	O
inhibitory	O
activity	O
,	O
PDK1	O
inhibitory	O
activity	O
and	O
Pak	O
kinase	O
inhibitory	O
activity	O
and	O
are	O
accordingly	O
useful	O
in	O
the	O
treatment	O
and/or	O
prophylaxis	O
of	O
cancer	O
.	O

Substituted	O
heterocycles	O
and	O
their	O
use	O
as	O
chk1	O
,	O
pdk1	O
and	O
pak	O
inhibitors	O

Muscarinic	O
Acetylcholine	B
receptor	O
antagonists	O
and	O
methods	O
of	O
using	O
them	O
are	O
provided	O
.	O

M3	O
Muscarinic	O
Acetylcholine	B
Receptor	O
Antagonists	O

Disclosed	O
herein	O
are	O
compounds	O
,	O
compositions	O
and	O
methods	O
for	O
modulating	O
the	O
expression	O
of	O
IL-4R	O
alpha	O
in	O
a	O
cell	O
,	O
tissue	O
or	O
animal	O
.	O

Also	O
provided	O
are	O
methods	O
of	O
target	O
validation	O
.	O

Also	O
provided	O
are	O
uses	O
of	O
disclosed	O
compounds	O
and	O
compositions	O
in	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
treatment	O
of	O
diseases	O
and	O
disorders	O
related	O
to	O
expression	O
of	O
IL	O
4R	O
-	O
	O
,	O
airway	O
hyperresponsiveness	O
,	O
and/or	O
pulmonary	O
inflammation	O
.	O

Compositions	O
and	O
Their	O
Uses	O
Directed	O
to	O
IL-4R	O
Alpha	O

The	O
present	O
invention	O
relates	O
to	O
33	O
novel	O
human	O
secreted	O
proteins	O
and	O
isolated	O
nucleic	O
acids	O
containing	O
the	O
coding	O
regions	O
of	O
the	O
genes	O
encoding	O
such	O
proteins	O
.	O

Also	O
provided	O
are	O
vectors	O
,	O
host	O
cells	O
,	O
antibodies	O
,	O
and	O
recombinant	O
methods	O
for	O
producing	O
human	O
secreted	O
proteins	O
.	O

The	O
invention	O
further	O
relates	O
to	O
diagnostic	O
and	O
therapeutic	O
methods	O
useful	O
for	O
diagnosing	O
and	O
treating	O
diseases	O
,	O
disorders	O
,	O
and/or	O
conditions	O
related	O
to	O
these	O
novel	O
human	O
secreted	O
proteins	O
.	O

33	O
Human	O
Secreted	O
Proteins	O

A	O
controlled	O
release	O
combination	O
formulation	O
for	O
oral	O
administration	O
comprising	O
a	O
)	O
a	O
controlled	O
release	O
portion	O
containing	O
metformin	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
as	O
an	O
active	O
ingredient	O
,	O
and	O
a	O
combination	O
of	O
a	O
polyethylene	B
oxide	I
and	O
a	O
natural	O
gum	O
as	O
a	O
carrier	O
for	O
controlled	O
release	O
;	O
and	O
b	O
)	O
a	O
rapid	O
-	O
release	O
portion	O
containing	O
a	O
sulfonylurea	B
-	O
based	O
medicine	O
for	O
treating	O
diabetes	O
as	O
an	O
active	O
ingredient	O
coated	O
on	O
the	O
controlled	O
release	O
portion	O
is	O
useful	O
for	O
the	O
treatment	O
of	O
diabetes	O
,	O
for	O
it	O
is	O
capable	O
of	O
maintaining	O
an	O
effective	O
concentration	O
of	O
the	O
medicines	O
in	O
blood	O
at	O
a	O
constant	O
level	O
.	O

Controlled	O
Release	O
Complex	O
Formulation	O
For	O
Oral	O
Administration	O
of	O
Medicine	O
For	O
Diabetes	O
and	O
Method	O

For	O
The	O
Preparation	O
Thereof	O

There	O
are	O
provided	O
disclosures	O
relating	O
to	O
a	O
conjugate	O
of	O
a	O
perfluorocarbon	B
compound	O
and	O
a	O
cationic	O
polymer	O
wherein	O
the	O
conjugate	O
is	O
a	O
blood	O
substitute	O
.	O

Perfluorocarbon	B
conjugate	O
as	O
a	O
blood	O
substitute	O

Compositions	O
containing	O
one	O
or	O
more	O
early	O
polypeptide	O
(	O
s	O
)	O
of	O
human	O
papillomavirus	O
(	O
HPV	O
)	O
-18	O
or	O
a	O
nucleic	O
acid	O
encoding	O
one	O
or	O
more	O
early	O
polypeptide	O
(	O
s	O
)	O
of	O
HPV-18	O
are	O
useful	O
for	O
preventing	O
or	O
treating	O
an	O
infection	O
or	O
a	O
pathological	O
condition	O
caused	O
by	O
at	O
least	O
one	O
papillomavirus	O
other	O
than	O
HPV-18	O
;	O
the	O
subject	O
compositions	O
are	O
of	O
very	O
special	O
interest	O
in	O
immunotherapy	O
,	O
in	O
particular	O
for	O
preventing	O
or	O
treating	O
HPV	O
persistent	O
infections	O
that	O
might	O
promote	O
cervical	O
intraepithelial	O
neoplasia	O
(	O
CIN	O
)	O
and	O
ultimately	O
cervical	O
cancer	O
.	O

Hpv-18-based	O
papillomavirus	O
vaccines	O

The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
at	O
least	O
one	O
interleukin-17	O
inhibitor	O
and/or	O
of	O
at	O
least	O
one	O
IL-17	O
receptor	O
inhibitor	O
,	O
for	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
inhibiting	O
,	O
preventing	O
or	O
treating	O
gastric	O
cancer	O
.	O

Drug	O
for	O
treating	O
gastric	O
cancer	O

It	O
has	O
been	O
discovered	O
that	O
the	O
uptake	O
of	O
anionic	O
charged	O
species	O
into	O
cells	O
can	O
be	O
enhanced	O
by	O
noncovalently	O
associating	O
such	O
species	O
with	O
specifically	O
modified	O
forms	O
of	O
cyclodextrin	O
.	O

The	O
invention	O
modified	O
forms	O
of	O
cyclodextrin	O
form	O
well	O
defined	O
stoichiometric	O
complexes	O
with	O
anionic	O
charged	O
molecules	O
.	O

This	O
discovery	O
enables	O
one	O
to	O
produce	O
various	O
compositions	O
containing	O
anionic	O
charged	O
molecules	O
and	O
facilitates	O
methods	O
for	O
enhancing	O
the	O
cellular	O
uptake	O
of	O
double	O
-	O
stranded	O
or	O
hairpin	O
nucleic	O
acid	O
.	O

Cyclodextrin	O
conjugates	O

The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
solvate	O
thereof	O
,	O
wherein	O
:	O
R1	O
,	O
R2	O
,	O
Z1	O
,	O
t	O
,	O
and	O
ring	O
A	O
are	O
as	O
defined	O
in	O
the	O
specification	O
.	O

The	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
and	O
methods	O
of	O
treating	O
a	O
condition	O
that	O
is	O
mediated	O
by	O
the	O
modulation	O
of	O
JNK	O
,	O
such	O
as	O
diabetes	O
,	O
the	O
method	O
comprising	O
administering	O
to	O
a	O
mammal	O
an	O
effective	O
amount	O
of	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
.	O

Substituted	O
2-amino	B
-	I
fused	I
heterocyclic	I
compounds	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
indazole	B
derivatives	O
having	O
pharmacological	O
activity	O
,	O
processes	O
for	O
their	O
preparation	O
,	O
compositions	O
containing	O
them	O
and	O
uses	O
of	O
these	O
compounds	O
in	O
the	O
treatment	O
of	O
estrogen	O
receptor	O
beta	O
mediated	O
diseases	O
.	O

Indazoles	B
Used	O
To	O
Treat	O
Estrogen	B
Receptor	O
Beta	O
Mediated	O
Disorders	O

Site	O
-	O
specific	O
modifications	O
of	O
proteins	O
at	O
their	O
N	O
-	O
termini	O
are	O
provided	O
.	O

In	O
particular	O
,	O
a	O
chemical	O
modification	O
of	O
proteins	O
at	O
their	O
N	O
-	O
termini	O
via	O
a	O
transamination	O
reaction	O
to	O
form	O
homogeneous	O
adducts	O
such	O
as	O
,	O
the	O
corresponding	O
oxime	O
derivatives	O
is	O
provided	O
.	O

Methods	O
of	O
making	O
and	O
using	O
the	O
adducts	O
in	O
radio	O
-	O
labelling	O
,	O
molecular	O
imaging	O
applications	O
,	O
and	O
treatment	O
of	O
disorders	O
such	O
as	O
cancer	O
,	O
Crohn	O
's	O
disease	O
,	O
arthritis	O
,	O
atherothrombosis	O
and	O
plaque	O
rupture	O
are	O
also	O
provided	O
.	O

Site	O
-	O
specific	O
chemical	O
modification	O
of	O
proteins	O
at	O
their	O
n	O
-	O
termini	O
,	O
enabling	O
the	O
formation	O
of	O
homogeneous	O
adducts	O

Symptoms	O
of	O
viral	O
infection	O
are	O
mitigated	O
by	O
administering	O
to	O
a	O
subject	O
exposed	O
to	O
a	O
virus	O
a	O
protective	O
or	O
symptom	O
-	O
mitigating	O
amount	O
of	O
a	O
dsRNA	O
and	O
continuing	O
administration	O
until	O
the	O
subject	O
's	O
symptoms	O
have	O
improved	O
.	O

Early	O
intervention	O
of	O
viral	O
infection	O
with	O
immune	O
activators	O

The	O
present	O
invention	O
relates	O
to	O
antibiotic	O
synergism	O
of	O
pharmaceutical	O
compositions	O
comprising	O
a	O
defensin	O
and	O
a	O
beta	B
-	I
lactam	I
antibiotic	O
.	O

Antibiotic	O
synergism	O

The	O
invention	O
is	O
directed	O
to	O
a	O
method	O
for	O
oral	O
administration	O
of	O
a	O
liquid	O
containing	O
an	O
active	O
substance	O
to	O
a	O
subject	O
for	O
improved	O
absorption	O
into	O
the	O
subject	O
's	O
bloodstream	O
includes	O
the	O
steps	O
of	O
providing	O
a	O
delivery	O
device	O
containing	O
the	O
liquid	O
and	O
having	O
a	O
mouthpiece	O
for	O
directing	O
the	O
liquid	O
in	O
a	O
defined	O
direction	O
during	O
delivery	O
;	O
directing	O
the	O
mouthpiece	O
toward	O
a	O
localized	O
area	O
of	O
the	O
subject	O
's	O
mouth	O
being	O
especially	O
suitable	O
for	O
increased	O
uptake	O
and	O
faster	O
onset	O
of	O
action	O
of	O
the	O
active	O
substance	O
relative	O
to	O
other	O
areas	O
of	O
and/or	O
the	O
whole	O
mouth	O
;	O
and	O
delivering	O
a	O
measured	O
amount	O
of	O
the	O
liquid	O
directly	O
to	O
the	O
localized	O
area	O
using	O
the	O
delivery	O
device	O
,	O
and	O
a	O
spray	O
device	O
for	O
administering	O
an	O
active	O
substance	O
to	O
the	O
oral	O
cavity	O
of	O
a	O
subject	O
that	O
includes	O
a	O
container	O
capable	O
of	O
holding	O
a	O
liquid	O
containing	O
an	O
active	O
substance	O
,	O
and	O
a	O
mouthpiece	O
being	O
constructed	O
to	O
dispense	O
the	O
liquid	O
containing	O
the	O
substance	O
in	O
a	O
defined	O
direction	O
and	O
directly	O
to	O
a	O
localized	O
area	O
of	O
a	O
subject	O
's	O
mouth	O
,	O
the	O
localized	O
area	O
being	O
the	O
oral	O
vestibule	O
.	O

Directional	O
use	O

Compounds	O
of	O
the	O
present	O
invention	O
find	O
utility	O
in	O
the	O
treatment	O
of	O
mammalian	O
cancers	O
and	O
especially	O
human	O
cancers	O
including	O
,	O
but	O
not	O
limited	O
to	O
,	O
malignant	O
melanomas	O
,	O
solid	O
tumors	O
,	O
glioblastomas	O
,	O
ovarian	O
cancer	O
,	O
pancreatic	O
cancer	O
,	O
prostate	O
cancer	O
,	O
lung	O
cancers	O
,	O
breast	O
cancers	O
,	O
kidney	O
cancers	O
,	O
hepatic	O
cancers	O
,	O
cervical	O
carcinomas	O
,	O
metastasis	O
of	O
primary	O
tumor	O
sites	O
,	O
myeloproliferative	O
diseases	O
,	O
chronic	O
myelogenous	O
leukemia	O
,	O
leukemias	O
,	O
papillary	O
thyroid	O
carcinoma	O
,	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
,	O
mesothelioma	O
,	O
hypereosinophilic	O
syndrome	O
,	O
gastrointestinal	O
stromal	O
tumors	O
,	O
colonic	O
cancers	O
,	O
ocular	O
diseases	O
characterized	O
by	O
hyperproliferation	O
leading	O
to	O
blindness	O
including	O
various	O
retinopathies	O
,	O
diabetic	O
retinopathy	O
,	O
rheumatoid	O
arthritis	O
,	O
asthma	O
,	O
chronic	O
obstructive	O
pulmonary	O
disease	O
,	O
mastocytosis	O
,	O
mast	O
cell	O
leukemia	O
,	O
and	O
diseases	O
caused	O
by	O
PDGFR	O
-	O
	O
kinase	O
,	O
PDGFR	O
-	O
	O
kinase	O
,	O
c	O
-	O
KIT	O
kinase	O
,	O
cFMS	O
kinase	O
,	O
c	O
-	O
MET	O
kinase	O
,	O
and	O
oncogenic	O
forms	O
,	O
aberrant	O
fusion	O
proteins	O
and	O
polymorphs	O
of	O
any	O
of	O
the	O
foregoing	O
kinases	O
.	O

Cyclopropane	B
amides	I
and	O
analogs	O
exhibiting	O
anti	O
-	O
cancer	O
and	O
anti	O
-	O
proliferative	O
activities	O

The	O
present	O
invention	O
relates	O
to	O
low	O
-	O
dose	O
formulations	O
of	O
melatonin	B
,	O
and	O
methods	O
of	O
use	O
thereof	O
,	O
which	O
provide	O
a	O
sustained	O
release	O
of	O
melatonin	B
so	O
as	O
to	O
rapidly	O
increase	O
plasma	O
levels	O
of	O
melatonin	B
,	O
maintain	O
a	O
relatively	O
high	O
level	O
(	O
which	O
mimics	O
the	O
endogenous	O
level	O
of	O
a	O
young	O
subject	O
)	O
for	O
approximately	O
5	O
-	O
6	O
hours	O
,	O
and	O
then	O
decrease	O
so	O
as	O
to	O
achieve	O
low	O
levels	O
by	O
early	O
morning	O
(	O
rapid	O
washout	O
)	O
,	O
thereby	O
avoiding	O
a	O
"	O
hangover	O
effect	O
"	O
.	O

The	O
sustained	O
release	O
formulations	O
of	O
the	O
invention	O
may	O
be	O
used	O
to	O
treat	O
a	O
variety	O
of	O
sleep	O
-	O
related	O
disorders	O
,	O
including	O
,	O
but	O
not	O
limited	O
to	O
,	O
delayed	O
onset	O
and	O
maintenance	O
forms	O
of	O
insomnia	O
.	O

Sustained	O
release	O
formulation	O
of	O
melatonin	B

Methods	O
of	O
treating	O
glioblastoma	O
and	O
pancreatic	O
cancer	O
are	O
provided	O
by	O
the	O
administration	O
of	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
iodo	B
-	I
hexose	I
compound	O
to	O
a	O
subject	O
in	O
need	O
thereof	O
.	O

The	O
subject	O
disclosure	O
includes	O
methods	O
of	O
treating	O
glioblastoma	O
and	O
pancreatic	O
cancer	O
comprising	O
the	O
administration	O
of	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
2-deoxy-2-iodo	B
-	I
D	I
-	I
hexose	I
compound	O
including	O
2-deoxy-2-iodo	B
-	I
D	I
-	I
mannose	I
,	O
2-deoxy-2-iodo	B
-	I
D	I
-	I
glucose	I
,	O
2-deoxy-2-iodo	B
-	I
D	I
-	I
galactose	I
,	O
and/or	O
2-deoxy-2-iodo	B
-	I
D	I
-	I
talose	I
to	O
a	O
subject	O
in	O
need	O
thereof	O
.	O

Iodo	B
-	I
Hexose	I
Compounds	O
Useful	O
to	O
Treat	O
Cancer	O

The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
polymorphic	O
form	O
and	O
the	O
amorphous	O
form	O
of	O
5-chloro	B
-	I
N-	I
(	I
{	I
(	I
5S	I
)	I
-2-oxo-3-	I
[	I
4-	I
(	I
3-oxo-4-morpholinyl	I
)	I
-phenyl	I
]	I
-1,3-oxazolidin-5-yl	I
}	I
-methyl	I
)	I
-2-thiophene	I
-	I
carboxamide	I
,	O
processes	O
for	O
their	O
preparation	O
,	O
medicaments	O
comprising	O
these	O
forms	O
,	O
and	O
their	O
use	O
in	O
the	O
control	O
of	O
diseases	O
.	O

Novel	O
polymorphous	O
form	O
and	O
the	O
amorphous	O
form	O
of	O
5-chloro	B
-	I
n-	I
(	I
{	I
(	I
5s	I
)	I
-2-oxo-3	I
[	I
4-	I
(	I
3-oxo-4-morpholinyl	I
(	I
-phenyl	I
]	I
-1,3-oxazolidine-5-yl	I
}	I
-methyl	I
)	I
-2-thiophene	I
carboxamide	I

The	O
invention	O
provides	O
an	O
assay	O
for	O
determining	O
whether	O
a	O
test	O
agent	O
is	O
a	O
COX	O
modulator	O
.	O

In	O
general	O
terms	O
,	O
the	O
assay	O
includes	O
:	O
determining	O
whether	O
a	O
test	O
agent	O
modulates	O
binding	O
of	O
a	O
PDZ	O
-	O
containing	O
polypeptide	O
to	O
a	O
COX	O
PL	O
-	O
containing	O
polypeptide	O
.	O

The	O
PDZ	O
-	O
containing	O
polypeptide	O
may	O
contain	O
the	O
PDZ	O
domain	O
of	O
PDZ	O
domain	O
of	O
MAGI1	O
,	O
TIP-1	O
,	O
MAST2	O
,	O
PSD95	O
,	O
or	O
SHANK	O
.	O

The	O
assays	O
may	O
be	O
done	O
in	O
a	O
cell	O
-	O
free	O
environment	O
or	O
in	O
a	O
cellular	O
environment	O
,	O
particularly	O
using	O
a	O
neuronal	O
cell	O
.	O

The	O
invention	O
finds	O
use	O
in	O
a	O
variety	O
of	O
therapeutic	O
applications	O
,	O
including	O
for	O
identifying	O
agents	O
for	O
use	O
in	O
treating	O
cancer	O
,	O
pain	O
,	O
inflammation	O
and	O
neuronal	O
conditions	O
caused	O
by	O
acute	O
insult	O
,	O
e.g.	O
,	O
stroke	O
.	O

Assays	O
For	O
Detecting	O
Inhibitors	O
Of	O
Binding	O
Between	O
COX-2	O
And	O
PDZ	O
Proteins	O

Provided	O
herein	O
is	O
a	O
method	O
of	O
screening	O
a	O
tumour	O
cell	O
for	O
resistance	O
to	O
a	O
tubulin	O
-	O
binding	O
agent	O
,	O
the	O
method	O
comprising	O
detecting	O
the	O
expression	O
of	O
any	O
one	O
or	O
more	O
of	O
class	O
II	O
,	O
class	O
III	O
and	O
class	O
IVb	O
	O
-	O
tubulin	O
by	O
the	O
tumour	O
cell	O
,	O
wherein	O
the	O
expression	O
of	O
any	O
one	O
or	O
more	O
of	O
class	O
II	O
,	O
class	O
III	O
and	O
class	O
IVb	O
	O
-	O
tubulin	O
indicates	O
that	O
the	O
tumour	O
cell	O
has	O
resistance	O
or	O
potential	O
resistance	O
to	O
the	O
tubulin	O
-	O
binding	O
agent	O
.	O

Also	O
provided	O
are	O
methods	O
of	O
modulating	O
the	O
sensitivity	O
of	O
a	O
tumour	O
cell	O
.	O

Also	O
provided	O
is	O
a	O
method	O
of	O
modulating	O
the	O
tumorigenesis	O
of	O
a	O
tumour	O
cell	O
.	O

Methods	O
for	O
detecting	O
and	O
modulating	O
the	O
sensitivity	O
of	O
tumor	O
cells	O
to	O
anti	O
-	O
mitotic	O
agents	O
and	O
for	O
modulating	O
turmorgenicity	O

Disclosed	O
are	O
methods	O
involving	O
the	O
administration	O
of	O
an	O
extracellular	O
matrix	O
(	O
ECM	O
)	O
/	O
metastasis	O
modifier	O
gene	O
,	O
e.g.	O
,	O
Anakin	O
,	O
Necdin	O
,	O
CentaurinD3	O
(	O
CentD3	O
)	O
,	O
Csf1r	O
,	O
Brd4	O
,	O
Pi16	O
,	O
and	O
Luc7l	O
,	O
for	O
the	O
prevention	O
or	O
inhibition	O
of	O
metastasis	O
or	O
of	O
tumor	O
growth	O
.	O

Further	O
disclosed	O
are	O
methods	O
of	O
characterizing	O
a	O
tumor	O
or	O
cancer	O
in	O
a	O
subject	O
comprising	O
detecting	O
(	O
i	O
)	O
a	O
single	O
nucleotide	B
polymorphism	O
(	O
SNP	O
)	O
in	O
an	O
Anakin	O
gene	O
or	O
a	O
Brd4	O
gene	O
of	O
the	O
subject	O
,	O
(	O
ii	O
)	O
an	O
amino	B
acid	I
substitution	O
in	O
an	O
Anakin	O
protein	O
in	O
the	O
subject	O
,	O
or	O
(	O
iii	O
)	O
a	O
level	O
of	O
expression	O
of	O
an	O
Anakin	O
gene	O
or	O
a	O
Brd4	O
gene	O
in	O
the	O
subject	O
.	O

Methods	O
of	O
screening	O
a	O
compound	O
for	O
anti	O
-	O
cancer	O
activity	O
and	O
use	O
of	O
a	O
compound	O
with	O
anti	O
-	O
cancer	O
activity	O
for	O
the	O
preparation	O
of	O
a	O
medicament	O
to	O
treat	O
or	O
prevent	O
cancer	O
in	O
a	O
subject	O
are	O
also	O
disclosed	O
.	O

Also	O
disclosed	O
is	O
a	O
method	O
of	O
inhibiting	O
Sipa-1	O
in	O
a	O
subject	O
.	O

Extracellular	O
matrix	O
/	O
metastasis	O
modifier	O
genes	O
for	O
the	O
prevention	O
or	O
inhibition	O
of	O
metastasis	O
or	O
growth	O
of	O
tumor	O
and	O
for	O
characterization	O
of	O
tumor	O

The	O
present	O
invention	O
relates	O
to	O
a	O
composition	O
comprising	O
an	O
egg	O
white	O
-	O
chalcanthite	O
component	O
for	O
preventing	O
or	O
treating	O
cancer	O
,	O
and	O
more	O
particularly	O
,	O
to	O
a	O
composition	O
for	O
preventing	O
or	O
treating	O
cancer	O
,	O
which	O
comprises	O
egg	O
white	O
-	O
chalcanthite	O
prepared	O
by	O
mixing	O
a	O
roasted	O
chalcanthite	O
with	O
egg	O
white	O
to	O
reduce	O
the	O
toxicity	O
of	O
the	O
chalcanthite	O
or	O
comprises	O
a	O
mixture	O
of	O
the	O
egg	O
white	O
-	O
chalcanthite	O
and	O
a	O
bamboo	O
salt	O
,	O
and	O
a	O
method	O
for	O
preparing	O
the	O
same	O
.	O

The	O
composition	O
comprising	O
the	O
egg	O
white	O
-	O
chalcanthite	O
exhibits	O
excellent	O
anti	O
-	O
cancer	O
activity	O
,	O
and	O
thus	O
is	O
usefully	O
applicable	O
to	O
pharmaceutical	O
preparations	O
for	O
preventing	O
or	O
treating	O
cancer	O
or	O
the	O
manufacture	O
of	O
health	O
functional	O
foods	O
.	O

Composition	O
comprising	O
egg	O
white	O
-	O
chalcanthite	O
for	O
preventing	O
or	O
treating	O
cancer	O

This	O
invention	O
is	O
directed	O
to	O
methods	O
of	O
using	O
spiro	B
-	I
oxindole	I
compounds	O
of	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
k	O
,	O
j	O
,	O
Q	O
,	O
R1	O
,	O
R2a	O
,	O
R2b	O
,	O
R2c	O
,	O
R2d	O
,	O
R3a	O
,	O
R3b	O
,	O
R3c	O
,	O
and	O
R3d	O
are	O
as	O
defined	O
herein	O
,	O
as	O
a	O
stereoisomer	O
,	O
enantiomer	O
,	O
tautomer	O
thereof	O
or	O
mixtures	O
thereof	O
;	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
,	O
solvate	O
or	O
prodrug	O
thereof	O
,	O
for	O
the	O
treatment	O
and/or	O
prevention	O
of	O
hypercholesterolemia	O
,	O
benign	O
prostatic	O
hyperplasia	O
,	O
pruritis	O
and	O
cancer	O
.	O

Use	O
of	O
spiro	B
-	I
oxindole	I
compounds	O
as	O
therapeutic	O
agents	O

Patients	O
are	O
subject	O
to	O
a	O
post	O
-	O
seizure	O
treatment	O
regime	O
to	O
separately	O
inhibitor	O
consecutive	O
targets	O
of	O
an	O
epileptogenic	O
cascade	O
comprising	O
neurotransmitter	O
receptor	O
signaling	O
,	O
kinase	O
/	O
phosphatase	O
activity	O
,	O
protein	O
translation	O
,	O
and	O
apoptosis	O
or	O
inflammation	O
.	O

Treating	O
post	O
-	O
seizure	O
patients	O

The	O
invention	O
relates	O
generally	O
to	O
treatment	O
of	O
muscle	O
pain	O
and/or	O
fatigue	O
and	O
to	O
methods	O
of	O
treatment	O
of	O
side	O
effects	O
of	O
statin	O
therapy	O
which	O
involve	O
the	O
administration	O
of	O
uridine	B
,	O
biological	O
precursors	O
or	O
derivatives	O
or	O
uridine	O
or	O
salts	O
,	O
esters	O
,	O
tautomers	O
or	O
analogues	O
thereof	O
,	O
which	O
are	O
collectively	O
referred	O
to	O
as	O
uridine	B
related	O
compounds	O
.	O

The	O
invention	O
is	O
also	O
directed	O
to	O
compositions	O
,	O
uses	O
and	O
combination	O
packs	O
or	O
kits	O
related	O
to	O
the	O
treatment	O
method	O
.	O

Treatment	O
of	O
Statin	O
Side	O
Effects	O
Using	O
Uridine	B
Derivatives	O

The	O
invention	O
provides	O
compounds	O
and	O
pharmaceutical	O
compositions	O
thereof	O
,	O
which	O
are	O
useful	O
as	O
protein	O
kinase	O
inhibitors	O
,	O
and	O
methods	O
for	O
using	O
such	O
compounds	O
to	O
treat	O
,	O
ameliorate	B
or	O
prevent	O
a	O
condition	O
associated	O
with	O
abnormal	O
or	O
deregulated	O
kinase	O
activity	O
.	O

In	O
some	O
embodiments	O
,	O
the	O
invention	O
provides	O
methods	O
for	O
using	O
such	O
compounds	O
to	O
treat	O
,	O
ameliorate	B
or	O
prevent	O
diseases	O
or	O
disorders	O
that	O
involve	O
abnormal	O
activation	O
of	O
Alk	O
,	O
Abl	O
,	O
Aurora	O
-	O
A	O
,	O
B	O
-	O
Raf	O
,	O
C	O
-	O
Raf	O
,	O
Bcr	O
-	O
Abl	O
,	O
BRK	O
,	O
Blk	O
,	O
Bmx	O
,	O
BTK	O
,	O
C	O
-	O
Kit	O
,	O
CSK	O
,	O
C	O
-	O
Src	O
,	O
EphB1	O
,	O
EphB2	O
,	O
EphB4	O
,	O
FLT1	O
,	O
Fms	O
,	O
Flt3	O
,	O
Fyn	O
,	O
FRK3	O
,	O
JAK2	O
,	O
KDR	O
,	O
Lck	O
,	O
Lyn	O
,	O
PDGFR	O
,	O
PDGFR	O
,	O
PKC	O
,	O
SAPK2	O
,	O
Src	O
,	O
SIK	O
,	O
Syk	O
,	O
Tie2	O
and	O
TrkB	O
kinases	O
.	O

Protein	O
Kinase	O
Inhibitors	O
and	O
Methods	O
for	O
Using	O
Thereof	O

The	O
present	O
invention	O
provides	O
an	O
ophthalmic	O
solution	O
without	O
an	O
antimicrobial	O
preservative	O
.	O

The	O
solution	O
includes	O
as	O
an	O
active	O
substance	O
at	O
least	O
one	O
prostaglandin	B
and	O
as	O
a	O
solubilizing	O
agent	O
,	O
a	O
surfactant	O
,	O
where	O
the	O
solubilizing	O
agent	O
is	O
polyoxyl-15-hydroxystearate	B
.	O

Preservative	O
-	O
free	O
prostaglandin	B
-	O
based	O
ophthalmic	O
solution	O

The	O
present	O
invention	O
is	O
directed	O
to	O
pharmaceutical	O
compositions	O
and	O
the	O
use	O
thereof	O
for	O
preventing	O
or	O
minimizing	O
the	O
intensity	O
of	O
the	O
serotonin	B
syndrome	O
.	O

The	O
present	O
invention	O
is	O
directed	O
at	O
a	O
method	O
of	O
preventing	O
or	O
minimizing	O
the	O
intensity	O
of	O
the	O
serotonin	B
syndrome	O
in	O
humans	O
which	O
comprises	O
administering	O
proserotonergic	O
agents	O
and	O
serotonin	B
surge	O
protectors	O
,	O
wherein	O
said	O
concurrent	O
administration	O
reduces	O
or	O
prevents	O
serotonin	B
excess	O
,	O
which	O
is	O
the	O
cause	O
of	O
the	O
serotonin	B
syndrome	O
.	O

The	O
present	O
invention	O
is	O
also	O
directed	O
to	O
pharmaceutical	O
compositions	O
comprising	O
proserotonergic	O
agents	O
and	O
serotonin	B
surge	O
protectors	O
useful	O
for	O
carrying	O
out	O
the	O
method	O
of	O
the	O
present	O
invention	O
.	O

Methods	O
of	O
Preventing	O
the	O
Serotonin	B
Syndrome	O
and	O
Compositions	O
for	O
Use	O
Therefor	O

Embodiments	O
of	O
the	O
present	O
invention	O
include	O
the	O
use	O
of	O
heterocyclic	B
trialkyl	I
ammonium	I
-	O
containing	O
compounds	O
alone	O
or	O
in	O
combination	O
with	O
alkaline	O
phosphatase	O
or	O
other	O
weight	O
loss	O
-	O
inducing	O
drugs	O
or	O
methods	O
to	O
reduce	O
or	O
reverse	O
excess	O
weight	O
gain	O
and	O
obesity	O
as	O
well	O
as	O
reduce	O
the	O
risk	O
of	O
development	O
and	O
help	O
treatment	O
of	O
diseases	O
and	O
unhealthy	O
conditions	O
related	O
to	O
overweight	O
and	O
obesity	O
.	O

Small	O
molecules	O
to	O
induce	O
weight	O
loss	O
or	O
to	O
reduce	O
weight	O
gain	O

The	O
invention	O
provides	O
a	O
palindromic	O
immune	O
modulatory	O
nucleic	O
acid	O
.	O

The	O
invention	O
also	O
provides	O
methods	O
for	O
generating	O
,	O
enhancing	O
and	O
modifying	O
the	O
immune	O
response	O
caused	O
by	O
palindromic	O
immune	O
modulatory	O
compounds	O
used	O
for	O
immunotherapy	O
applications	O
Immunostimulatory	O
activity	O
of	O
palindromic	O
immune	O
modulatory	O
oligonucleotides	O
(	O
imo	O
)	O
containing	O
different	O
lengths	O
of	O
palindromic	O
segments	O

The	O
present	O
invention	O
is	O
directed	O
to	O
compositions	O
containing	O
a	O
combination	O
of	O
a	O
herb	O
from	O
the	O
genus	O
Equisetum	O
together	O
with	O
one	O
film	O
forming	O
agent	O
and	O
its	O
use	O
as	O
a	O
nail	O
topical	O
formulation	O
,	O
like	O
nail	O
varnish	O
,	O
cream	O
,	O
gel	O
,	O
lotion	O
or	O
foam	O
.	O

The	O
present	O
invention	O
is	O
further	O
directed	O
to	O
the	O
use	O
of	O
a	O
water	O
soluble	O
film	O
forming	O
agent	O
as	O
an	O
additive	O
in	O
a	O
nail	O
topical	O
formulation	O
.	O

These	O
compositions	O
can	O
be	O
used	O
to	O
treat	O
specific	O
alterations	O
of	O
the	O
ungual	O
structure	O
,	O
with	O
onychoschizia	O
which	O
is	O
a	O
specific	O
alteration	O
of	O
the	O
ungual	O
structure	O
,	O
characterized	O
by	O
lamellar	O
splitting	O
of	O
the	O
nail	O
plate	O
.	O

Method	O
for	O
treating	O
onychoschizia	O

A	O
warming	O
vapor	O
pad	O
to	O
treat	O
respiratory	O
syncytial	O
virus	O
infections	O
in	O
babies	O
,	O
children	O
and	O
adults	O
includes	O
a	O
fabric	O
impregnated	O
with	O
a	O
topical	O
ointment	O
providing	O
medicated	O
vapors	O
to	O
relieve	O
a	O
user	O
's	O
cough	O
,	O
with	O
the	O
fabric	O
being	O
superimposed	O
on	O
an	O
elastic	O
thermal	O
wrap	O
for	O
application	O
as	O
a	O
single	O
layer	O
on	O
the	O
user	O
's	O
chest	O
.	O

Warming	O
vapor	O
pad	O

Alveolar	O
bone	O
resorption	O
,	O
periodontal	O
membrane	O
loss	O
,	O
and	O
gingival	O
recession	O
can	O
be	O
inhibited	O
by	O
administering	O
500	O
mg	O
to	O
2000	O
mg	O
per	O
day	O
of	O
calcium	B
,	O
10	O
mg	O
to	O
40	O
mg	O
per	O
day	O
of	O
soy	O
isoflavone	B
aglycone	I
,	O
and	O
vitamin	B
D3	I
to	O
persons	O
having	O
a	O
tendency	O
for	O
decreased	O
bone	O
density	O
,	O
postmenopausal	O
women	O
,	O
and	O
periodontal	O
disease	O
patients	O
in	O
a	O
maintenance	O
phase	O
;	O
and	O
even	O
an	O
extended	O
period	O
of	O
administration	O
provides	O
a	O
high	O
degree	O
of	O
safety	O
.	O

Method	O
of	O
inhibiting	O
alveolar	O
bone	O
resorption	O
and	O
periodontal	O
membrane	O
loss	O
and	O
composition	O
for	O
internal	O
use	O
to	O
be	O
used	O
therein	O

A	O
compound	O
of	O
Formula	O
(	O
I	O
)	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
solvate	O
thereof	O
,	O
wherein	O
,	O
R1	O
and	O
R2	O
each	O
independently	O
represent	O
H	B
,	O
halogen	B
,	O
CF3	B
,	O
C1	B
-	I
3	I
alkyl	I
or	O
C1	B
-	I
3	I
alkoxy	I
;	O
R3	O
represents	O
C1	B
-	I
6	I
alkyl	I
,	O
C3	B
-	I
6	I
cycloalkyl	I
,	O
phenyl	B
(	O
optionally	O
substituted	O
by	O
one	O
or	O
more	O
substituents	O
each	O
independently	O
selected	O
from	O
Ra	O
)	O
or	O
Het	B
(	O
optionally	O
substituted	O
by	O
one	O
or	O
more	O
substituents	O
each	O
independently	O
selected	O
from	O
OH	B
,	O
oxo	B
,	O
or	O
C1	B
-	I
4	I
alkyl	I
)	O
;	O
R4	O
represents	O
H	B
or	O
C1	B
-	I
3	I
alkyl	I
;	O
R5	O
represents	O
C1	B
-	I
6	I
alkyl	I
(	O
optionally	O
substituted	O
by	O
one	O
or	O
more	O
substituents	O
each	O
independently	O
selected	O
from	O
Rb	O
)	O
,	O
C3	B
-	I
6	I
cycloalkyl	I
(	O
optionally	O
substituted	O
by	O
one	O
or	O
more	O
substituents	O
each	O
independently	O
selected	O
from	O
oxo	B
or	O
OH	B
)	O
,	O
or	O
Het2	O
(	O
optionally	O
substituted	O
by	O
one	O
or	O
more	O
substituents	O
each	O
independently	O
selected	O
from	O
Rd	O
)	O
;	O
oxygen	B
atom	O
or	O
1	O
sulphur	B
atom	O
,	O
or	O
(	O
c	O
)	O
1	O
oxygen	B
atom	O
or	O
1	O
sulphur	B
atom	O
,	O
(	O
optionally	O
substituted	O
by	O
one	O
or	O
more	O
substituents	O
each	O
independently	O
selected	O
from	O
OH	B
,	O
oxo	B
or	O
C1	B
-	I
4	I
alkyl	I
)	O
;	O
and	O
R6	O
represents	O
C1	B
-	I
3	I
alkyl	I
(	O
optionally	O
substituted	O
by	O
one	O
or	O
more	O
substituents	O
each	O
independently	O
selected	O
from	O
Rf	O
)	O
,	O
C3	B
-	I
5	I
cycloalkyl	I
(	O
optionally	O
substituted	O
by	O
one	O
or	O
more	O
halogen	B
)	O
,	O
CN	B
or	O
halogen	B
;	O
where	O
Rf	O
represents	O
halogen	B
or	O
phenyl	B
:	O
and	O
compositions	O
,	O
processes	O
for	O
the	O
preparation	O
,	O
and	O
uses	O
thereof	O
,	O
e.g.	O
in	O
the	O
treatment	O
of	O
endometriosis	O
or	O
uterine	O
fibroids	O
Amide	B
Compounds	O
Useful	O
in	O
Therapy	O

The	O
present	O
invention	O
relates	O
to	O
substituted	O
heteroarylpiperidine	B
derivatives	O
as	O
melanocortin-4	O
receptor	O
modulators	O
.	O

Depending	O
on	O
the	O
structure	O
and	O
the	O
stereochemistry	O
the	O
compounds	O
of	O
the	O
invention	O
are	O
either	O
selective	O
agonists	O
or	O
selective	O
antagonists	O
of	O
the	O
human	O
melanocortin-4	O
receptor	O
(	O
MC-4R	O
)	O
.	O

The	O
agonists	O
can	O
be	O
used	O
for	O
the	O
treatment	O
of	O
disorders	O
and	O
diseases	O
such	O
as	O
obesity	O
,	O
diabetes	O
and	O
sexual	O
dysfunction	O
,	O
whereas	O
the	O
antagonists	O
are	O
useful	O
for	O
the	O
treatment	O
of	O
disorders	O
and	O
diseases	O
such	O
as	O
cancer	O
cachexia	O
,	O
muscle	O
wasting	O
,	O
anorexia	O
,	O
amyotrophic	O
lateral	O
sclerosis	O
(	O
ALS	O
)	O
,	O
anxiety	O
and	O
depression	O
.	O

Generally	O
all	O
diseases	O
and	O
disorders	O
where	O
the	O
regulation	O
of	O
the	O
MC-4R	O
is	O
involved	O
can	O
be	O
treated	O
with	O
the	O
compounds	O
of	O
the	O
invention	O
.	O

Substituted	O
Heteroarylpiperidine	B
Derivatives	O

As	O
Melanocortin-4	O
Receptor	O
Modulators	O

This	O
invention	O
provides	O
certain	O
compounds	O
,	O
methods	O
of	O
their	O
preparation	O
,	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds	O
,	O
and	O
their	O
use	O
in	O
treating	O
human	O
or	O
animal	O
disorders	O
.	O

The	O
compounds	O
of	O
the	O
invention	O
are	O
useful	O
as	O
modulators	O
of	O
the	O
interaction	O
between	O
the	O
receptor	O
for	O
advanced	O
glycated	O
end	O
products	O
(	O
RAGE	O
)	O
and	O
its	O
ligands	O
,	O
such	O
as	O
advanced	O
glycated	O
end	O
products	O
(	O
AGEs	O
)	O
,	O
S100	O
/	O
calgranulin	O
/	O
EN	O
-	O
RAGE	O
,	O
	O
-	O
amyloid	O
and	O
amphoterin	O
,	O
and	O
for	O
the	O
management	O
,	O
treatment	O
,	O
control	O
,	O
or	O
as	O
an	O
adjunct	O
treatment	O
for	O
diseases	O
in	O
humans	O
caused	O
by	O
RAGE	O
.	O

Such	O
diseases	O
or	O
disease	O
states	O
include	O
acute	O
and	O
chronic	O
inflammation	O
,	O
the	O
development	O
of	O
diabetic	O
late	O
complications	O
such	O
as	O
increased	O
vascular	O
permeability	O
,	O
nephrdpathy	O
,	O
atherosclerosis	O
,	O
and	O
retinopathy	O
,	O
the	O
development	O
of	O
Alzheimer	O
's	O
disease	O
,	O
erectile	O
dysfunction	O
,	O
and	O
tumor	O
invasion	O
and	O
metastasis	O
.	O

Azole	O
derivatives	O
and	O
fused	O
bicyclic	O
azole	O
derivatives	O
as	O
therapeutic	O
agents	O

This	O
invention	O
relates	O
to	O
the	O
use	O
of	O
a	O
sulfonamide	B
substituted	I
diphenyl	I
urea	I
compound	O
to	O
treat	O
cystic	O
fibrosis	O
,	O
or	O
the	O
symptoms	O
associated	O
with	O
cystic	O
fibrosis	O
.	O

Method	O
of	O
treatment	O

This	O
invention	O
relates	O
generally	O
to	O
methods	O
and	O
materials	O
for	O
rapid	O
detection	O
of	O
mutations	O
for	O
tumor	O
genotyping	O
.	O

Methods	O
and	O
materials	O
for	O
genetic	O
analysis	O
of	O
tumors	O

Disclosed	O
herein	O
are	O
indolo	B
[	I
3,2-c	I
]	I
quinoline	I
compounds	O
of	O
formula	O
(	O
I	O
)	O
:	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
wherein	O
R	O
and	O
m	O
are	O
given	O
the	O
definitions	O
as	O
set	O
forth	O
in	O
the	O
Specification	O
and	O
Claims	O
.	O

These	O
compounds	O
can	O
be	O
used	O
to	O
inhibit	O
both	O
growth	O
of	O
cancer	O
cells	O
and	O
activity	O
of	O
telomerase	O
.	O

Indolo	B
[	I
3,2-c	I
]	I
quinoline	I
compounds	O

A	O
means	O
for	O
improving	O
cognitive	O
functions	O
and	O
memory	O
based	O
on	O
hydrogenated	O
pyrido	B
(	I
4,3-b	I
)	I
indoles	I
(	O
variants	O
)	O
,	O
a	O
pharmacological	O
means	O
based	O
thereon	O
and	O
a	O
method	O
for	O
the	O
use	O
thereof	O
relate	O
to	O
the	O
use	O
of	O
chemical	O
compounds	O
in	O
the	O
field	O
of	O
medicine	O
and	O
may	O
be	O
used	O
to	O
extend	O
the	O
arsenal	O
of	O
means	O
which	O
can	O
be	O
utilized	O
for	O
substantial	O
enhancement	O
of	O
memory	O
and	O
activation	O
of	O
the	O
learning	O
process	O
,	O
for	O
the	O
treatment	O
of	O
impaired	O
cognitive	O
functions	O
and	O
memory	O
in	O
the	O
elderly	O
and	O
in	O
mild	O
cognitive	O
impairment	O
,	O
in	O
brain	O
trauma	O
,	O
in	O
chronic	O
cerebrovascular	O
insufficiency	O
,	O
in	O
hypoxic	O
encephalopathies	O
,	O
resulting	O
from	O
chronic	O
alcoholism	O
and	O
in	O
delayed	O
development	O
in	O
children	O
.	O

Said	O
task	O
is	O
resolved	O
by	O
the	O
use	O
of	O
hydrogenated	O
pyrido	B
(	I
[	I
4	I
,	I
3-b	I
]	I
)	I
indoles	I
of	O
formula	O
(	O
1	O
)	O
or	O
formula	O
(	O
2	O
)	O
as	O
means	O
for	O
improving	O
cognitive	O
functions	O
and	O
memory	O
.	O

Means	O
for	O
improving	O
cognitive	O
functions	O
and	O
memory	O
based	O
on	O
hydrogenated	O
pyrido	B
(	I
4,3-b	I
)	I
indoles	I
(	O
variants	O
)	O
,	O
pharmacological	O
means	O
based	O
thereon	O
and	O
method	O
for	O
the	O
use	O
thereof	O

The	O
invention	O
provides	O
compositions	O
and	O
methods	O
for	O
delivery	O
of	O
a	O
bioactive	O
agent	O
to	O
an	O
individual	O
.	O

Delivery	O
vehicles	O
are	O
provided	O
that	O
include	O
a	O
bioactive	O
agent	O
in	O
disc	O
shaped	O
particles	O
that	O
include	O
one	O
or	O
more	O
lipid	O
binding	O
polypeptides	O
circumscribing	O
the	O
perimeter	O
of	O
a	O
lipid	O
bilayer	O
in	O
which	O
the	O
bioactive	O
agent	O
is	O
localized	O
.	O

Chimeric	O
lipid	O
binding	O
polypeptides	O
are	O
also	O
provided	O
and	O
may	O
be	O
used	O
to	O
add	O
additional	O
functional	O
properties	O
to	O
the	O
delivery	O
particles	O
.	O

Lipophilic	O
drug	O
delivery	O
vehicle	O
and	O
methods	O
of	O
use	O
thereof	O

This	O
invention	O
features	O
methods	O
and	O
compositions	O
for	O
treating	O
cancer	O
and	O
modulating	O
signal	O
transduction	O
and	O
metabolism	O
pathways	O
.	O

For	O
example	O
,	O
the	O
methods	O
and	O
compositions	O
of	O
the	O
invention	O
can	O
be	O
used	O
to	O
kill	O
or	O
inhibit	O
the	O
growth	O
or	O
spread	O
of	O
cancer	O
cells	O
.	O

The	O
invention	O
also	O
features	O
a	O
method	O
of	O
identifying	O
a	O
compound	O
that	O
modulates	O
a	O
signal	O
transduction	O
or	O
metabolic	O
pathway	O
.	O

Methods	O
and	O
compositions	O
for	O
treating	O
cancer	O
and	O
modulating	O
signal	O
transduction	O
and	O
metabolism	O
pathways	O

Disclosed	O
are	O
extracts	O
,	O
compositions	O
,	O
and	O
methods	O
for	O
treating	O
cancer	O
and	O
inflammatory	O
disorders	O
.	O

Also	O
disclosed	O
are	O
methods	O
for	O
preparing	O
extracts	O
or	O
compounds	O
for	O
treating	O
the	O
disorders	O
.	O

Treatment	O
of	O
Cancer	O
and	O
Inflammatory	O
Disorder	O

Provided	O
is	O
a	O
compound	O
having	O
a	O
serotonin	B
5-HT2C	O
receptor	O
activating	O
action	O
.	O

A	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
I0	O
)	O
:	O
wherein	O
each	O
symbol	O
is	O
as	O
defined	O
in	O
the	O
specification	O
,	O
or	O
a	O
salt	O
thereof	O
.	O

Pyrazinooxazepine	B
derivatives	O

The	O
invention	O
relates	O
to	O
compounds	O
,	O
in	O
particular	O
2-amino-3,4,5,-trisubstituted	B
thiophenes	I
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
the	O
uses	O
of	O
said	O
compounds	O
and	O
compositions	O
for	O
diseases	O
related	O
to	O
sphingosine-1-phosphate	B
(	O
S1P	B
)	O
receptors	O
,	O
predominantly	O
S1P3	O
receptors	O
.	O

The	O
diseases	O
include	O
cardiovascular	O
diseases	O
,	O
atherosclerosis	O
,	O
cancer	O
,	O
pulmonary	O
oedema	O
,	O
autoimmune	O
disorders	O
and	O
Adult	O
Respiratory	O
Distress	O
Syndrome	O
.	O

Sphingosine-1-phosphate	B
(	O
s1p	O
)	O
receptor	O
compounds	O

This	O
invention	O
relates	O
to	O
compounds	O
,	O
compositions	O
,	O
and	O
methods	O
useful	O
for	O
modulating	O
platelet	O
derived	O
growth	O
factor	O
(	O
PDGF	O
)	O
and/or	O
platelet	O
derived	O
growth	O
factor	O
receptor	O
(	O
PDGFr	O
)	O
gene	O
expression	O
using	O
short	O
interfering	O
nucleic	O
acid	O
(	O
siNA	O
)	O
molecules	O
.	O

This	O
invention	O
also	O
relates	O
to	O
compounds	O
,	O
compositions	O
,	O
and	O
methods	O
useful	O
for	O
modulating	O
the	O
expression	O
and	O
activity	O
of	O
other	O
genes	O
involved	O
in	O
pathways	O
of	O
platelet	O
derived	O
growth	O
factor	O
(	O
PDGF	O
)	O
and/or	O
platelet	O
derived	O
growth	O
factor	O
receptor	O
(	O
PDGFr	O
)	O
gene	O
expression	O
and/or	O
activity	O
by	O
RNA	O
interference	O
(	O
RNAi	O
)	O
using	O
small	O
nucleic	O
acid	O
molecules	O
.	O

In	O
particular	O
,	O
the	O
instant	O
invention	O
features	O
small	O
nucleic	O
acid	O
molecules	O
,	O
such	O
as	O
short	O
interfering	O
nucleic	O
acid	O
(	O
siNA	O
)	O
,	O
short	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
,	O
double	O
-	O
stranded	O
RNA	O
(	O
dsRNA	O
)	O
,	O
micro	O
-	O
RNA	O
(	O
miRNA	O
)	O
,	O
and	O
short	O
hairpin	O
RNA	O
(	O
shRNA	O
)	O
molecules	O
and	O
methods	O
used	O
to	O
modulate	O
the	O
expression	O
of	O
platelet	O
derived	O
growth	O
factor	O
(	O
PDGF	O
)	O
and/or	O
platelet	O
derived	O
growth	O
factor	O
receptor	O
(	O
PDGFr	O
)	O
genes	O
,	O
such	O
as	O
PDGF	O
and/or	O
PDGFr	O
.	O

RNA	O
INTERFERENCE	O
MEDIATED	O
INHIBITION	O
OF	O
PLATELET	O
DERIVED	O
GROWTH	O
FACTOR	O
(	O
PDGF	O
)	O
AND	O
PLATELET	O
DERIVED	O
GROWTH	O
FACTOR	O
RECEPTOR	O
(	O
PDGFR	O
)	O
GENE	O
EXPRESSION	O
USING	O
SHORT	O
INTERFERING	O
NUCLEIC	O
ACID	O
(	O
siNA	O
)	O

The	O
present	O
invention	O
refers	O
to	O
rosemary	O
extracts	O
for	O
use	O
as	O
medicament	O
for	O
the	O
treatment	O
of	O
a	O
disorder	O
connected	O
to	O
reduced	O
neurotransmission	O
,	O
as	O
well	O
as	O
to	O
dietary	O
and	O
pharmaceutical	O
compositions	O
containing	O
such	O
rosemary	O
extracts	O
and	O
their	O
uses	O
.	O

Rosemary	O
extracts	O
,	O
dietary	O
and	O
pharmaceutical	O
compostions	O
containing	O
them	O
and	O
their	O
uses	O

Disclosed	O
is	O
a	O
medicinal	O
composition	O
and	O
method	O
of	O
use	O
conspiring	O
topiramate	B
for	O
treating	O
drug	O
-	O
induced	O
excessive	O
sweating	O
(	O
hyperhidrosis	O
)	O
.	O

As	O
a	O
further	O
embodiment	O
of	O
this	O
invention	O
,	O
topiramate	B
may	O
be	O
administered	O
along	O
with	O
another	O
medicament	O
that	O
causes	O
excessive	O
sweating	O
to	O
prevent	O
such	O
excessive	O
sweating	O
.	O

As	O
still	O
a	O
further	O
embodiment	O
of	O
this	O
invention	O
,	O
topiramate	B
may	O
be	O
administered	O
along	O
with	O
another	O
medicament	O
that	O
treats	O
excessive	O
sweating	O
,	O
such	O
that	O
the	O
synergy	O
of	O
the	O
drugs	O
effectively	O
treats	O
the	O
sweating	O
.	O

Hyperhidrosis	O
treatment	O

The	O
present	O
invention	O
provides	O
a	O
method	O
for	O
increasing	O
metabolism	O
and/or	O
energy	O
expenditure	O
in	O
a	O
subject	O
,	O
e.g.	O
,	O
to	O
treat	O
or	O
prevent	O
obesity	O
and/or	O
a	O
related	O
condition	O
and/or	O
to	O
reduce	O
adiposity	O
,	O
the	O
method	O
comprising	O
increasing	O
the	O
level	O
and/or	O
activity	O
of	O
Hypoxia	O
Induced	O
Factor	O
1	O
(	O
HIF-1	O
)	O
in	O
a	O
cell	O
,	O
tissue	O
or	O
organ	O
of	O
the	O
subject	O
,	O
thereby	O
increasing	O
metabolism	O
in	O
the	O
subject	O
.	O

The	O
present	O
invention	O
also	O
provides	O
a	O
method	O
for	O
increasing	O
metabolism	O
in	O
a	O
subject	O
,	O
the	O
method	O
comprising	O
administering	O
an	O
iron	O
chelating	O
agent	O
to	O
the	O
subject	O
,	O
thereby	O
increasing	O
metabolism	O
in	O
the	O
subject	O
.	O

Method	O
of	O
increasing	O
metabolism	O

The	O
invention	O
provides	O
methods	O
for	O
treating	O
diabetes	O
and	O
related	O
disorders	O
,	O
such	O
as	O
metabolic	O
syndromes	O
(	O
which	O
includes	O
insulin	O
resistance	O
)	O
,	O
by	O
administering	O
an	O
inhibitor	O
of	O
osteopontin	O
(	O
OPN	O
)	O
,	O
which	O
includes	O
an	O
antibody	O
,	O
antibody	O
fragment	O
,	O
siRNA	O
,	O
and	O
aptamer	O
.	O

Also	O
disclosed	O
are	O
methods	O
for	O
increasing	O
glucose	O
uptake	O
by	O
cells	O
in	O
a	O
subject	O
,	O
by	O
administering	O
an	O
inhibitor	O
of	O
OPN	O
.	O

Method	O
for	O
controlling	O
glucose	B
uptake	O
and	O
insulin	O
sensitivity	O

The	O
present	O
invention	O
provides	O
a	O
novel	O
pharmaceutical	O
use	O
of	O
2-phenyl-1,2-benzisoselenazol-3	B
(	I
2H	I
)	I
-one	I
or	O
a	O
salt	O
thereof	O
.	O

2-Phenyl-1,2-benzisoselenazol-3	B
(	I
2H	I
)	I
-one	I
or	O
a	O
salt	O
thereof	O
exhibits	O
an	O
excellent	O
suppressive	O
effect	O
on	O
retinal	O
ganglion	O
cell	O
death	O
in	O
a	O
pharmacological	O
test	O
using	O
rats	O
,	O
and	O
is	O
therefore	O
useful	O
as	O
a	O
prophylactic	O
or	O
therapeutic	O
agent	O
for	O
an	O
eye	O
disease	O
accompanied	O
by	O
optic	O
nerve	O
disorder	O
.	O

Prophylactic	O
or	O
therapeutic	O
agent	O
for	O
eye	O
disease	O
accompanied	O
by	O
optic	O
nerve	O
disorder	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
quinoline	B
compounds	O
.	O

The	O
compounds	O
possess	O
valuable	O
therapeutic	O
properties	O
and	O
are	O
particularly	O
suitable	O
,	O
for	O
treating	O
diseases	O
that	O
respond	O
to	O
modulation	O
of	O
the	O
serotonin	B
5-HT6	O
receptor	O
.	O

wherein	O
R	O
is	O
a	O
moiety	O
of	O
the	O
formula	O
wherein	O
A	O
,	O
R1	O
to	O
R4	O
are	O
as	O
defined	O
in	O
the	O
claims	O
and	O
the	O
specification	O
,	O
n	O
is	O
0	O
,	O
1	O
or	O
2	O
;	O
m	O
is	O
0	O
,	O
1	O
,	O
2	O
or	O
3	O
;	O
Ra	O
,	O
Rb	O
are	O
independently	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
halogen	B
,	O
CN	B
,	O
C1-C4-alkyl	B
,	O
C1-C4-haloalkyl	B
,	O
C1-C4-alkoxy	B
,	O
C1-C4-haloalkoxy	B
,	O
C	B
(	I
O	I
)	I
Raa	I
,	O
C	B
(	I
O	I
)	I
NRccRbb	I
and	O
NRccRbb	B
;	O
X	O
is	O
CH2	B
,	O
C	B
(	I
O	I
)	I
,	O
S	B
,	O
S	B
(	I
O	I
)	I
or	O
S	B
(	I
O	I
)	I
2	I
;	O
which	O
is	O
located	O
in	O
the	O
3-	O
or	O
4-position	O
of	O
the	O
quinoline	B
ring	O
;	O
Ar	B
is	O
a	O
radical	O
Ar1	B
,	O
Ar2Ar3	B
or	O
Ar2O	B
	I
Ar3	I
,	O
wherein	O
Ar1	B
,	O
Ar2	B
and	O
Ar3	B
are	O
each	O
independently	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
aryl	B
or	O
hetaryl	O
wherein	O
aryl	B
or	O
hetaryl	B
moieties	O
may	O
be	O
unsubstituted	O
or	O
may	O
carry	O
1	O
,	O
2	O
,	O
3	O
substituents	O
Rx	O
,	O
wherein	O
and	O
physiologically	O
tolerated	O
acid	O
addition	O
salts	O
and	O
the	O
N	B
-	I
oxides	I
thereof	O
.	O

Quinoline	B
compounds	O
suitable	O
for	O
treating	O
disorders	O
that	O
respond	O
to	O
modulation	O
of	O
the	O
serotonin	B
5-ht6	O
receptor	O

Provided	O
herein	O
are	O
novel	O
sirtuin	O
-	O
modulating	O
compounds	O
Structural	O
Formula	O
(	O
I	O
)	O
:	O
and	O
methods	O
of	O
use	O
thereof	O
.	O

The	O
sirtuin	O
-	O
modulating	O
compounds	O
may	O
be	O
used	O
for	O
increasing	O
the	O
lifespan	O
of	O
a	O
cell	O
,	O
and	O
treating	O
and/or	O
preventing	O
a	O
wide	O
variety	O
of	O
diseases	O
and	O
disorders	O
including	O
,	O
for	O
example	O
,	O
diseases	O
or	O
disorders	O
related	O
to	O
aging	O
or	O
stress	O
,	O
diabetes	O
,	O
obesity	O
,	O
neurodegenerative	O
diseases	O
,	O
cardiovascular	O
disease	O
,	O
blood	O
clotting	O
disorders	O
,	O
inflammation	O
,	O
cancer	O
,	O
and/or	O
flushing	O
as	O
well	O
as	O
diseases	O
or	O
disorders	O
that	O
would	O
benefit	O
from	O
increased	O
mitochondrial	O
activity	O
.	O

Also	O
provided	O
are	O
compositions	O
comprising	O
a	O
sirtuin	O
-	O
modulating	O
compound	O
in	O
combination	O
with	O
another	O
therapeutic	O
agent	O
.	O

Solubilized	O
thiazolopyridines	B

The	O
present	O
invention	O
is	O
directed	O
to	O
compositions	O
and	O
methods	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
cephalotaxines	B
,	O
for	O
example	O
,	O
homoharringtonine	B
.	O

The	O
invention	O
is	O
also	O
directed	O
to	O
improvements	O
in	O
the	O
purity	O
,	O
manufacturing	O
process	O
,	O
formulation	O
and	O
administration	O
of	O
homoharringtonine	B
for	O
the	O
treatment	O
of	O
cancer	O
and	O
other	O
aberrant	O
cellular	O
diseases	O
.	O

The	O
invention	O
also	O
provides	O
methods	O
and	O
compositions	O
for	O
antiparasitic	O
,	O
antifungal	O
,	O
antiviral	O
and	O
antibacterial	O
treatments	O
.	O

Formulations	O
and	O
Methods	O
of	O
Administration	O
of	O
Cephalotaxines	B
,	O
Including	O
Homoharringtonine	B

The	O
present	O
invention	O
provides	O
compounds	O
represented	O
by	O
formula	O
1	O
:	O
wherein	O
,	O
R1	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
R6	O
,	O
R7	O
,	O
R8	O
,	O
R9	O
,	O
R10	O
,	O
R11	O
,	O
R12	O
,	O
R13	O
and	O
X	O
are	O
as	O
defined	O
in	O
the	O
specification	O
,	O
in	O
all	O
its	O
stereoisomeric	O
and	O
tautomeric	O
forms	O
and	O
mixtures	O
thereof	O
in	O
all	O
ratios	O
,	O
and	O
its	O
pharmaceutically	O
acceptable	O
salts	O
,	O
pharmaceutically	O
acceptable	O
solvates	O
,	O
pharmaceutically	O
acceptable	O
polymorphs	O
and	O
prodrugs	O
.	O

These	O
compounds	O
are	O
useful	O
for	O
treatment	O
of	O
inflammatory	O
disorders	O
including	O
those	O
caused	O
by	O
elevated	O
levels	O
of	O
proinflammatory	O
cytokines	O
such	O
as	O
Tumor	O
Necrosis	O
Factor	O
(	O
TNF	O
-	O
	O
and/or	O
interleukins	O
(	O
IL-1	O
,	O
IL-6	O
,	O
IL-8	O
)	O
.	O

The	O
invention	O
also	O
relates	O
to	O
processes	O
for	O
the	O
manufacture	O
of	O
compounds	O
of	O
formula	O
1	O
and	O
pharmaceutical	O
compositions	O
containing	O
them	O
.	O

Tricyclic	O
compounds	O
for	O
the	O
treatment	O
of	O
inflammatory	O
disorders	O

Disclosed	O
herein	O
are	O
methods	O
for	O
treating	O
pre	O
-	O
eclampsia	O
and	O
eclampsia	O
using	O
compounds	O
that	O
increase	O
VEGF	O
or	O
PlGF	O
levels	O
or	O
compounds	O
that	O
decrease	O
sFlt-1	O
levels	O
.	O

Compounds	O
that	O
inhibit	O
the	O
binding	O
of	O
VEGF	O
or	O
PlGF	O
to	O
sFlt1are	O
also	O
disclosed	O
herein	O
for	O
the	O
treatment	O
of	O
pre	O
-	O
eclampsia	O
or	O
eclampsia	O
.	O

Methods	O
of	O
treating	O
pre	O
-	O
eclampsia	O
or	O
eclampsia	O

The	O
compositions	O
and	O
methods	O
of	O
the	O
invention	O
described	O
herein	O
provide	O
pre-	O
or	O
post	O
-	O
exposure	O
treatments	O
against	O
filovirus	O
or	O
arenavirus	O
infection	O
by	O
expressing	O
one	O
or	O
more	O
genes	O
(	O
e.g.	O
,	O
two	O
ore	O
more	O
genes	O
)	O
from	O
filoviruses	O
or	O
arenaviruses	O
in	O
a	O
delivery	O
vehicle	O
(	O
e.g.	O
,	O
a	O
recombinant	O
viral	O
vector	O
or	O
a	O
liposome	O
)	O
.	O

Pre	O
-	O
or	O
post	O
-	O
exposure	O
treatment	O
for	O
filovirus	O
or	O
arenavirus	O
infection	O

The	O
invention	O
relates	O
to	O
formulations	O
of	O
hygroscopic	O
solids	O
with	O
a	O
lipophilic	O
coating	O
layer	O
,	O
and	O
a	O
method	O
of	O
production	O
thereof	O
.	O

Formulation	O
with	O
reduced	O
hygroscopicity	O

The	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
according	O
to	O
the	O
claim	O
1	O
comprising	O
an	O
SGLT2	O
inhibitor	O
,	O
a	O
DPPIV	O
inhibitor	O
and	O
a	O
third	O
antidiabetic	O
agent	O
which	O
is	O
suitable	O
in	O
the	O
treatment	O
or	O
prevention	O
of	O
one	O
or	O
more	O
conditions	O
selected	O
from	O
type	O
1	O
diabetes	O
mellitus	O
,	O
type	O
2	O
diabetes	O
mellitus	O
,	O
impaired	O
glucose	B
tolerance	O
and	O
hyperglycemia	O
.	O

In	O
addition	O
the	O
present	O
invention	O
relates	O
to	O
methods	O
for	O
preventing	O
or	O
treating	O
of	O
metabolic	O
disorders	O
and	O
related	O
conditions	O
.	O

Pharmaceutical	O
composition	O
,	O
methods	O
for	O
treating	O
and	O
uses	O
thereof	O

Briefly	O
described	O
,	O
embodiments	O
of	O
this	O
disclosure	O
include	O
compositions	O
,	O
pharmaceutical	O
compositions	O
,	O
methods	O
of	O
treating	O
a	O
host	O
infected	O
with	O
a	O
virus	O
from	O
the	O
Flaviviridae	O
family	O
of	O
viruses	O
,	O
methods	O
of	O
treating	O
HCV	O
replication	O
in	O
a	O
host	O
,	O
methods	O
of	O
inhibiting	O
the	O
binding	O
of	O
NS4B	O
polypeptide	O
to	O
the	O
3UTR	O
of	O
HCV	O
negative	O
strand	O
RNA	O
in	O
a	O
host	O
,	O
methods	O
of	O
treating	O
liver	O
fibrosis	O
in	O
a	O
host	O
,	O
and	O
the	O
like	O
.	O

Methods	O
of	O
treating	O
a	O
flaviviridae	O
family	O
viral	O
infection	O
and	O
compositions	O
for	O
treating	O
a	O
flaviviridae	O
family	O
viral	O
infection	O

This	O
invention	O
relates	O
to	O
certain	O
complexes	O
of	O
ascorbic	B
acid	I
and	O
its	O
derivatives	O
with	O
certain	O
natural	O
antioxidant	O
and	O
anti	O
-	O
inflammatory	O
ketones	B
for	O
topical	O
or	O
oral	O
application	O
;	O
said	O
complexes	O
having	O
general	O
chemical	O
formula	O
(	O
I	O
)	O
,	O
its	O
isomers	O
,	O
and	O
salts	O
thereof	O
,	O
including	O
their	O
optically	O
active	O
or	O
racemic	O
forms	O
.	O

This	O
invention	O
also	O
relates	O
to	O
a	O
method	O
of	O
treatment	O
of	O
skin	O
condition	O
,	O
including	O
dark	O
skin	O
,	O
age	O
spots	O
,	O
acne	O
,	O
inflammation	O
,	O
loss	O
of	O
cellular	O
antioxidants	O
,	O
collagen	O
loss	O
with	O
aging	O
,	O
loss	O
of	O
skin	O
pliability	O
,	O
loss	O
of	O
skin	O
suppleness	O
,	O
skin	O
wrinkles	O
,	O
oxidation	O
,	O
damage	O
from	O
radiation	O
,	O
malfunction	O
of	O
matrix	O
metalloproteases	O
,	O
malfunction	O
of	O
tyrosinases	O
,	O
damage	O
from	O
free	O
radicals	O
,	O
photo	O
-	O
damage	O
,	O
nutritional	O
deficiency	O
,	O
and	O
combinations	O
thereof	O
;	O
Chiral	O
Complexes	O
of	O
Ascorbic	B
Acid	I
with	O
Natural	O
Antioxidant	O
and	O
Anti	O
-	O
Inflammatory	O
Ketones	B
Including	O
Aloe	O
,	O
Citrus	O
,	O
Ginger	O
,	O
and	O
Mango	O
for	O
Skin	O
and	O
Hair	O
Care	O

A	O
pharmaceutical	O
composition	O
comprising	O
in	O
admixture	O
a	O
hyaluronic	B
acid	I
related	O
component	O
(	O
HARC	O
)	O
and	O
a	O
pharmaceutically	O
effective	O
amount	O
of	O
triamcinolone	B
hexacetonide	I
(	O
TAH	O
)	O
.	O

The	O
composition	O
is	O
stable	O
in	O
an	O
accelerated	O
shelf	O
life	O
test	O
in	O
which	O
the	O
composition	O
is	O
heated	O
to	O
80	O
	O
C.	O
for	O
24	O
hours	O
.	O

Stable	O
Hyaluronan	O
/	O
Steroid	O
Formulation	O

The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
{	B
4-	I
[	I
2-	I
(	I
dimethylamino	I
)	I
-1-	I
(	I
1-hydroxycyclohexyl	I
)	I
ethyl	I
]	I
phenoxy	I
}	I
phosphate	I
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
a	O
production	O
method	O
therefor	O
and	O
a	O
pharmaceutical	O
composition	O
for	O
preventing	O
and	O
treating	O
central	O
nervous	O
system	O
disorders	O
which	O
contains	O
the	O
same	O
as	O
an	O
active	O
component	O
.	O

The	O
novel	O
{	B
4-	I
[	I
2-	I
(	I
dimethylamino	I
)	I
-1-	I
(	I
1-hydroxycyclohexyl	I
)	I
ethyl	I
]	I
phenoxy	I
}	I
phosphate	I
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
according	O
to	O
the	O
present	O
invention	O
can	O
beneficially	O
be	O
used	O
to	O
prevent	O
and	O
treat	O
central	O
nervous	O
system	O
disorders	O
since	O
it	O
exhibits	O
an	O
equivalent	O
biological	O
and	O
pharmacological	O
activity	O
to	O
venlafaxine	O
and	O
salts	O
thereof	O
which	O
are	O
known	O
in	O
the	O
field	O
,	O
it	O
has	O
very	O
little	O
toxicity	O
,	O
and	O
,	O
in	O
particular	O
,	O
it	O
is	O
outstandingly	O
soluble	O
in	O
water	O
as	O
compared	O
with	O
prior	O
-	O
art	O
venlafaxine	B
derivatives	O
.	O

Novel	O
phosphate	B
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
a	O
production	O
method	O
therefor	O
and	O
a	O
pharmaceutical	O
composition	O
for	O
preventing	O
and	O
treating	O
central	O
nervous	O
system	O
disorders	O
containing	O
the	O
same	O
as	O
an	O
active	O
component	O

The	O
invention	O
provides	O
a	O
class	O
of	O
compounds	O
,	O
pharmaceutical	O
compositions	O
comprising	O
such	O
compounds	O
and	O
methods	O
of	O
using	O
such	O
compounds	O
to	O
treat	O
or	O
prevent	O
malaria	O
.	O

Compounds	O
and	O
compositions	O
useful	O
for	O
the	O
treatment	O
of	O
parasitic	O
diseases	O

The	O
disclosure	O
provides	O
compounds	O
of	O
Formula	O
I	O
,	O
including	O
pharmaceutically	O
acceptable	O
salts	O
,	O
their	O
pharmaceutical	O
compositions	O
,	O
and	O
their	O
uses	O
in	O
inhibiting	O
	O
-	O
amyloid	O
peptide	O
(	O
	O
-	O
AP	O
)	O
production	O
.	O

2-Aryl	B
Glycinamide	I
Derivatives	O

A	O
xanthophyll	O
composition	O
that	O
contains	O
macular	O
pigments	O
including	O
trans	B
-	I
lutein	I
and	O
zeaxanthin	B
isomers	O
,	O
namely	O
,	O
(	B
R	I
,	I
R	I
)	I
-zeaxanthin	I
and	O
(	B
R	I
,	I
S	I
)	I
-zeaxanthin	I
,	O
derived	O
from	O
the	O
plant	O
extract	O
/	O
oleoresin	O
containing	O
xanthophylls	B
/	O
xanthophylls	B
esters	I
which	O
is	O
safe	O
for	O
human	O
consumption	O
and	O
useful	O
for	O
nutrition	O
and	O
health	O
care	O
.	O

The	O
composition	O
has	O
at	O
least	O
80	O
%	O
by	O
weight	O
that	O
is	O
total	O
xanthophylls	B
,	O
of	O
which	O
the	O
ratio	O
of	O
trans	B
-	I
lutein	I
and	O
zeaxanthin	B
isomers	O
being	O
in	O
the	O
range	O
of	O
about	O
4:1	O
to	O
about	O
6:1	O
and	O
the	O
ratio	O
of	O
the	O
isomers	O
of	O
zeaxanthin	B
being	O
in	O
the	O
range	O
of	O
about	O
80	O
to	O
20:20	O
to	O
80	O
.	O

Xanthophyll	B
composition	O
containing	O
macular	O
pigments	O
and	O
a	O
process	O
for	O
its	O
preparation	O

A	O
synergistic	O
composition	O
,	O
or	O
the	O
use	O
of	O
that	O
composition	O
in	O
the	O
manufacture	O
of	O
a	O
medicament	O
,	O
or	O
a	O
method	O
of	O
treatment	O
including	O
the	O
use	O
of	O
that	O
composition	O
,	O
for	O
the	O
treatment	O
of	O
hair	O
loss	O
and	O
baldness	O
,	O
for	O
combined	O
,	O
sequential	O
or	O
simultaneous	O
administration	O
,	O
in	O
any	O
form	O
,	O
via	O
any	O
biological	O
route	O
.	O

In	O
its	O
optimal	O
embodiment	O
the	O
composition	O
consists	O
,	O
in	O
the	O
form	O
of	O
a	O
lotion	O
:	O
1600	O
-	O
2400	O
IU	O
/	O
mL	O
Vitamin	B
A	I
Palmitate	I
,	O
0.64%-0.96	O
%	O
Thiamine	B
Hydrochloride	I
,	O
0.64%-0.96	O
%	O
Pyridoxine	B
Hydrochloride	I
,	O
4.8%-7.2	O
%	O
Niacinamide	B
,	O
2.85%-5.2	O
%	O
D	B
-	I
Panthenol	I
,	O
1.6%-2.4	O
%	O
L	B
-	I
Arginine	I
,	O
3.6%-4.4	O
%	O
Methyl	B
Sulphonyl	I
Methane	I
(	O
MSM	B
)	O
,	O
0.08%-0.12	O
%	O
Ginger	O
Oil	O
,	O
0.08%-0.12	O
%	O
Cinnamon	O
Oil	O
,	O
0.0996%-0.1494	O
%	O
Oleoresin	O
Capsicum	O
,	O
1.3%-1.95	O
%	O
Magnesium	B
,	O
2.4%-3.6	O
%	O
Zinc	B
,	O
0.192%-0.288	O
%	O
Manganese	B
,	O
2.6%-3.9	O
%	O
Urea	B
,	O
2.4%-3.6	O
%	O
Sodium	B
Glycerophosphate	I
,	O
4.8%-7.2	O
%	O
L	B
-	I
Lysine	I
HCl	I
,	O
plus	O
Preservatives	O
,	O
Co	O
-	O
solvent	O
(	O
Propylene	B
Glycol	I
)	O
,	O
Fragrances	O
,	O
Anti	O
-	O
Oxidant	O
,	O
Cooling	O
agent	O
(	O
Menthol	B
)	O
,	O
Emulsifier	O
,	O
and	O
Vehicle	O
(	O
Purified	O
water	O
)	O
.	O

Composition	O
for	O
the	O
treatment	O
of	O
hair	O
loss	O
and	O
baldness	O

The	O
invention	O
provides	O
compounds	O
that	O
inhibit	O
CK2	O
and/or	O
Pim	O
kinases	O
and	O
compositions	O
containing	O
such	O
compounds	O
.	O

These	O
compounds	O
and	O
compositions	O
are	O
useful	O
for	O
treating	O
proliferative	O
disorders	O
such	O
as	O
cancer	O
,	O
as	O
well	O
as	O
other	O
kinase	O
-	O
associated	O
conditions	O
including	O
inflammation	O
,	O
pain	O
,	O
infections	O
,	O
and	O
certain	O
immunological	O
disorders	O
.	O

Pharmaceutically	O
useful	O
heterocycle	B
-	I
substituted	I
lactams	I

This	O
invention	O
relates	O
to	O
the	O
discovery	O
of	O
substituted	O
analogues	O
of	O
the	O
selective	O
platelet	O
lowering	O
agent	O
anagrelide	O
with	O
reduced	O
potential	O
for	O
cardiovascular	O
side	O
-	O
effects	O
which	O
should	O
lead	O
to	O
improved	O
patient	O
compliance	O
and	O
safety	O
in	O
the	O
treatment	O
of	O
myeloproliferative	O
diseases	O
.	O

More	O
specifically	O
,	O
the	O
present	O
invention	O
relates	O
to	O
certain	O
imidazoquinazoline	B
derivatives	O
which	O
have	O
the	O
general	O
formula	O
shown	O
below	O
wherein	O
the	O
substituents	O
have	O
the	O
meanings	O
defined	O
in	O
claim	O
(	O
I	O
)	O
:	O
and	O
which	O
have	O
utility	O
as	O
platelet	O
lowering	O
agents	O
in	O
humans	O
.	O

The	O
compounds	O
of	O
the	O
present	O
invention	O
function	O
by	O
inhibiting	O
megakaryocytopoeisis	O
and	O
hence	O
the	O
formation	O
of	O
blood	O
platelets	O
.	O

Substituted	O
quinazolines	B
as	O
blood	O
platelet	O
lowering	O
agents	O

There	O
is	O
provided	O
a	O
series	O
of	O
novel	O
-	B
(	I
N	I
-	I
sulfonamido	I
)	I
acetamide	I
compounds	O
of	O
the	O
Formula	O
(	O
I	O
)	O
wherein	O
R1	O
,	O
R2	O
and	O
n	O
are	O
defined	O
herein	O
,	O
which	O
are	O
inhibitors	O
of	O
	O
-	O
amyloid	O
peptide	O
(	O
	O
-	O
AP	O
)	O
production	O
and	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
Alzheimer	O
's	O
Disease	O
and	O
other	O
conditions	O
affected	O
by	O
anti	O
-	O
amyloid	O
activity	O
.	O

Thiophenyl	B
Sulfonamides	I
for	O
the	O
Treatment	O
of	O
Alzheimer	O
's	O
Disease	O

The	O
present	O
invention	O
relates	O
to	O
methods	O
and	O
assays	O
for	O
identifying	O
agents	O
capable	O
of	O
inhibiting	O
the	O
mutant	O
huntingtin	O
protein	O
,	O
inhibiting	O
or	O
reducing	O
polyglutamine	B
-	O
induced	O
protein	O
aggregation	O
,	O
and/or	O
altering	O
huntingtin	O
protein	O
conformation	O
,	O
which	O
inhibition	O
is	O
useful	O
in	O
the	O
prevention	O
,	O
amelioration	O
and/or	O
treatment	O
of	O
neurodegenerative	O
diseases	O
,	O
and	O
protein	O
aggregation	O
diseases	O
more	O
generally	O
.	O

In	O
particular	O
,	O
the	O
present	O
invention	O
provides	O
methods	O
and	O
assays	O
for	O
identifying	O
agents	O
for	O
use	O
in	O
the	O
prevention	O
and/or	O
treatment	O
of	O
Huntington	O
's	O
disease	O
.	O

The	O
invention	O
provides	O
polypeptide	O
and	O
nucleic	O
acid	O
TARGETs	O
and	O
siRNA	O
sequences	O
based	O
on	O
these	O
Molecular	O
targets	O
and	O
compounds	O
,	O
and	O
methods	O
to	O
identify	O
the	O
same	O
,	O
useful	O
in	O
the	O
treatment	O
of	O
neurodegenerative	O
diseases	O

A	O
composition	O
and	O
method	O
for	O
the	O
treatment	O
of	O
Alzheimer	O
's	O
disease	O
and	O
related	O
amyloid	O
plaque	O
development	O
and	O
reduction	O
of	O
amyloid	O
plaque	O
,	O
amyloidosis	O
and	O
amyotrophic	O
lateral	O
sclerosis	O
,	O
as	O
well	O
as	O
neuro	O
-	O
degenerative	O
diseases	O
and	O
protein	O
aggregation	O
diseases	O
,	O
includes	O
an	O
effective	O
amount	O
of	O
a	O
compound	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
phytic	B
acid	I
(	O
inositol	B
hexakisphosphate	I
)	O
,	O
a	O
phytate	B
salt	I
,	O
an	O
isomer	O
or	O
hydrolysate	O
of	O
phytic	B
acid	I
or	O
a	O
phytate	B
salt	I
,	O
or	O
a	O
mixture	O
of	O
any	O
combination	O
thereof	O
,	O
being	O
administered	O
to	O
a	O
person	O
in	O
an	O
amount	O
from	O
about	O
0.5	O
grams	O
to	O
about	O
18.75	O
grams	O
per	O
day	O
,	O
with	O
or	O
without	O
a	O
dephosphorylating	O
enzyme	O
.	O

Prophylactic	O
and	O
therapeutic	O
treatment	O
of	O
neuro	O
-	O
degenerative	O
diseases	O
and	O
protein	O
aggregation	O
diseases	O

The	O
invention	O
relates	O
to	O
a	O
composite	O
material	O
,	O
a	O
precursor	O
for	O
forming	O
the	O
composite	O
material	O
and	O
a	O
method	O
of	O
forming	O
the	O
composite	O
material	O
from	O
the	O
precursor	O
.	O

The	O
invention	O
also	O
relates	O
to	O
the	O
use	O
of	O
said	O
composite	O
material	O
and	O
in	O
particular	O
to	O
its	O
use	O
as	O
an	O
antibacterial	O
or	O
antimicrobial	O
agent	O
.	O

Composite	O
material	O

Disclosed	O
herein	O
are	O
compositions	O
of	O
nanoparticles	O
.	O

In	O
some	O
embodiments	O
,	O
the	O
nanoparticles	O
are	O
Janus	O
particles	O
,	O
where	O
each	O
particle	O
includes	O
a	O
first	O
component	O
and	O
second	O
component	O
that	O
are	O
exposed	O
to	O
the	O
surface	O
of	O
the	O
particle	O
.	O

Also	O
,	O
disclosed	O
are	O
methods	O
and	O
systems	O
for	O
making	O
a	O
composition	O
of	O
nanoparticles	O
.	O

Finally	O
,	O
a	O
method	O
of	O
treating	O
a	O
mammal	O
by	O
administering	O
a	O
composition	O
of	O
nanoparticles	O
is	O
disclosed	O
.	O

Compositions	O
of	O
nanoparticles	O
and	O
methods	O
of	O
making	O
the	O
same	O

The	O
present	O
invention	O
relates	O
to	O
a	O
cell	O
-	O
targeting	O
complex	O
comprising	O
a	O
targeting	O
moiety	O
and	O
a	O
deliverable	O
compound	O
,	O
wherein	O
said	O
targeting	O
moiety	O
and	O
said	O
deliverable	O
compound	O
are	O
joined	O
by	O
means	O
of	O
a	O
(	O
transition	O
)	O
metal	O
ion	O
complex	O
having	O
at	O
least	O
a	O
first	O
reactive	O
moiety	O
for	O
forming	O
a	O
coordination	O
bond	O
with	O
a	O
reactive	O
site	O
of	O
said	O
targeting	O
moiety	O
and	O
having	O
at	O
least	O
a	O
second	O
reactive	O
moiety	O
for	O
forming	O
a	O
coordination	O
bond	O
with	O
a	O
reactive	O
site	O
of	O
said	O
deliverable	O
compound	O
,	O
and	O
wherein	O
said	O
deliverable	O
compound	O
is	O
a	O
therapeutic	O
compound	O
.	O

Method	O
of	O
conjugating	O
therapeutic	O
compounds	O
to	O
cell	O
targeting	O
devices	O
via	O
metal	O
complexes	O

This	O
application	O
relates	O
to	O
a	O
method	O
of	O
inhibiting	O
the	O
degradation	O
of	O
an	O
extracellular	O
matrix	O
associated	O
with	O
islet	O
beta	O
cells	O
,	O
said	O
method	O
comprising	O
contacting	O
said	O
extracellular	O
matrix	O
with	O
an	O
effective	O
amount	O
of	O
a	O
heparanase	O
inhibitor	O
.	O

Inhibition	O
of	O
degradation	O
of	O
extracellular	O
matrix	O

The	O
present	O
invention	O
provides	O
novel	O
tricyclic	B
spiro	I
-	I
oxathiine	I
naphthoquinone	I
derivatives	O
,	O
a	O
synthetic	O
method	O
for	O
making	O
the	O
derivatives	O
,	O
and	O
the	O
use	O
of	O
the	O
derivatives	O
to	O
induce	O
cell	O
death	O
and/or	O
to	O
inhibit	O
proliferation	O
of	O
cancer	O
or	O
precancerous	O
cells	O
.	O

The	O
naphthoquinone	B
derivatives	O
of	O
the	O
present	O
invention	O
are	O
related	O
to	O
the	O
compound	O
known	O
as	O
	B
-	I
lapachone	I
(	O
3,4-dihydro-2,2-dimethyl-2H	B
-	I
naphtho	I
(	I
1,2-b	I
)	I
pyran-5,6-dione	I
)	O
.	O

Novel	O
Lapachone	B
Compounds	O
And	O
Methods	O
of	O
Use	O
Thereof	O

This	O
invention	O
relates	O
to	O
a	O
novel	O
arylindenopyrimidine	B
,	O
A	O
,	O
and	O
its	O
therapeutic	O
and	O
prophylactic	O
uses	O
.	O

Disorders	O
treated	O
and/or	O
prevented	O
include	O
Parkinson	O
's	O
Disease	O
.	O

2-AMINO-9-	B
[	I
4-	I
(	I
4-METHOXY	I
-	I
PHENOXY	I
)	I
-PIPERIDIN-1-YL	I
]	I
-4-PHENYL	I
-	I
INDENO	I
[	I
1,2-D	I
]	I
PYRIMIDIN-5-ONE	I
AND	O
ITS	O
USE	O
AS	O
A	O
HIGHLY	O
SELECTIVE	O
ADENOSINE	O
A2a	O
RECEPTOR	O
ANTAGONIST	O

The	O
present	O
specification	O
provides	O
drug	O
delivery	O
platforms	O
useful	O
for	O
the	O
controlled	O
release	O
of	O
a	O
compound	O
over	O
time	O
in	O
an	O
individual	O
.	O

Drug	O
Delivery	O
Platforms	O
Comprising	O
Silk	O
Fibroin	O
Hydrogels	O
and	O
Uses	O
Thereof	O

This	O
disclosure	O
concerns	O
the	O
use	O
of	O
agonists	O
of	O
AMP	O
-	O
activated	O
protein	O
kinase	O
(	O
AMPK	O
)	O
for	O
improving	O
exercise	O
and	O
modifying	O
energy	O
metabolism	O
in	O
a	O
subject	O
.	O

The	O
disclosure	O
also	O
relates	O
to	O
a	O
combination	O
of	O
AMPK	O
and	O
peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
(	O
PPAR	O
)	O
	O
agonists	O
for	O
improving	O
exercise	O
performance	O
in	O
a	O
subject	O
,	O
methods	O
for	O
identifying	O
substance	O
-	O
enhanced	O
exercise	O
performance	O
in	O
a	O
subject	O
,	O
and	O
methods	O
for	O
identifying	O
compounds	O
that	O
affect	O
the	O
interaction	O
of	O
PPAR	O
with	O
exercise	O
-	O
induced	O
kinases	O
.	O

Methods	O
for	O
enhancing	O
muscle	O
performance	O
and	O
tone	O

The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
tranilast	B
and	O
derivatives	O
thereof	O
for	O
the	O
preparation	O
of	O
a	O
pharmaceutical	O
composition	O
for	O
treating	O
and/or	O
preventing	O
a	O
neuronal	O
condition	O
where	O
there	O
is	O
a	O
need	O
of	O
neuroprotection	O
and	O
neuroregeneration	O
.	O

The	O
invention	O
furthermore	O
relates	O
to	O
the	O
use	O
of	O
tranilast	B
and	O
derivatives	O
thereof	O
for	O
the	O
in	O
vitro	O
differentiation	O
of	O
neuronal	O
stem	O
cells	O
and	O
the	O
use	O
of	O
such	O
pre	O
-	O
treated	O
cells	O
for	O
stem	O
cell	O
therapy	O
von	O
neurological	O
conditions	O
.	O

Use	O
Of	O
Tranilast	B
And	O
Derivatives	O
Thereof	O

For	O
The	O
Therapy	O
Of	O
Neurological	O
Conditions	O

A	O
novel	O
scalable	O
synthesis	O
for	O
the	O
preparation	O
of	O
7-	B
(	I
3-pyridinyI	I
)	I
-1,7-diazaspiro	I
[	I
4.4	I
)	I
nonane	I
has	O
been	O
developed	O
,	O
and	O
7-	B
(	I
3-pyridinyl	I
)	I
-1,7-diazaspiro	I
[	I
4.4	I
]	I
nonane	I
salts	O
have	O
been	O
formed	O
with	O
succinic	B
acid	I
and	O
oxalic	B
acid	I
.	O

Additionally	O
,	O
7-	B
(	I
3-pyridinyl	I
)	I
-1,7-diaza	I
-	I
spiro	I
[	I
4.4	I
]	I
nonane	I
has	O
been	O
separated	O
into	O
its	O
stereoisomers	O
via	O
resolution	O
with	O
L	B
and	I
D	I
di	I
-	I
p	I
-	I
toluoyltartaric	I
acids	I
,	O
giving	O
(	B
R	I
)	I
-	I
and	I
(	I
S	I
)	I
-7-	I
(	I
3-pyridinyl	I
)	I
-1,7-diazaspiro	I
[	I
4.4	I
]	I
nonane	I
of	O
high	O
enantiomeric	O
purity	O
.	O

Numerous	O
solid	O
salts	O
of	O
the	O
resulting	O
(	B
R	I
)	I
-	I
and	I
(	I
S	I
)	I
-7-	I
(	I
3-pyridinyl	I
)	I
-1,7-diazaspiro	I
[	I
4.4	I
}	I
nonane	I
have	O
been	O
prepared	O
.	O

Methods	O
for	O
the	O
preparation	O
of	O
the	O
racemic	O
and	O
enantiomeric	O
salts	O
,	O
pharmaceutical	O
compositions	O
comprising	O
such	O
salts	O
,	O
and	O
uses	O
thereof	O
are	O
disclosed	O
.	O

The	O
salts	O
can	O
be	O
administered	O
to	O
patients	O
susceptible	O
to	O
or	O
suffering	O
from	O
conditions	O
and	O
disorders	O
,	O
such	O
as	O
central	O
nervous	O
system	O
disorders	O
,	O
to	O
treat	O
and/or	O
prevent	O
such	O
disorders	O
.	O

Preparation	O
and	O
enantiomeric	O
separation	O
of	O
7-	B
(	I
3-pyridinyl	I
)	I
-1,7-diazaspiro	I
[	I
4.4	I
]	I
nonane	I
and	O
novel	O
salt	O
forms	O
of	O
the	O
racemate	O
and	O
enantiomers	O

The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
useful	O
as	O
selective	O
inhibitors	O
of	O
JAK2	O
kinase	O
.	O

The	O
invention	O
also	O
provides	O
pharmaceutical	O
acceptable	O
compositions	O
comprising	O
said	O
compounds	O
and	O
methods	O
of	O
using	O
the	O
compositions	O
in	O
the	O
treatment	O
of	O
various	O
diseases	O
,	O
conditions	O
or	O
disorders	O
.	O

The	O
invention	O
also	O
provides	O
processes	O
for	O
preparing	O
the	O
compounds	O
of	O
the	O
invention	O
.	O

PYRAZOLO	B
[	I
1,5-a	I
]	I
PYRIMIDINES	I
USEFUL	O
AS	O
JAK2	O
INHIBITORS	O

Compounds	O
of	O
formula	O
(	O
I	O
)	O
are	O
A2B	O
receptor	O
antagonists	O
,	O
wherein	O
R1	O
is	O
optionally	O
substituted	O
aryl	B
or	O
an	O
optionally	O
substituted	O
5-	O
or	O
6-membered	O
heteroaryl	B
ring	O
;	O
R2	O
and	O
R3	O
are	O
independently	O
selected	O
from	O
hydrogen	B
,	O
C1-C6	B
alkyl	I
,	O
C3-C8	B
cycloalkyl	I
,	O
C3-C8	B
cycloalkyl-	I
(	B
C1-C6	I
)	I
-alkyl	I
,	O
aryl-	B
(	I
C1-C6	I
)	I
-alkyl	I
optionally	O
substituted	O
in	O
the	O
ring	O
part	O
thereof	O
,	O
a	O
5-	O
or	O
6-membered	O
monocyclic	B
heterocyclic	I
group	O
optionally	O
linked	O
via	O
a	O
C1-C6	B
alkylene	I
chain	O
and	O
optionally	O
substituted	O
in	O
the	O
ring	O
part	O
thereof	O
,	O
benzimidazol-2-yl	B
-	I
methyl	I
,	O
pyrid-3-yl	B
-	I
carbonyl	I
,	O
or	O
(	B
1-methyl	I
-	I
piperidin-4-yl	I
)	I
-carbonyl	I
-	I
methyl	I
;	O
or	O
R2	O
and	O
R3	O
taken	O
together	O
with	O
the	O
nitrogen	B
atom	O
to	O
which	O
they	O
are	O
attached	O
form	O
an	O
optionally	O
substituted	O
5-	O
or	O
6-membered	O
ring	O
;	O
R4	O
is	O
C1-C3	B
alkyl	I
,	O
C2-C3	B
alkenyl	I
,	O
N	B
(	I
R5	I
)	I
R6	I
,	O
or	O
optionally	O
substituted	O
heteroarylmethylamino	B
;	O
and	O
R5	O
and	O
R6	O
are	O
independently	O
selected	O
from	O
hydrogen	B
or	O
C1-C3	B
alkyl	I
;	O
or	O
R5	O
and	O
R6	O
taken	O
together	O
with	O
the	O
nitrogen	B
atom	O
to	O
which	O
they	O
are	O
attached	O
form	O
an	O
optionally	O
substituted	O
4-	O
to	O
6-membered	O
saturated	O
ring	O
.	O

Thienopyrimidine	B
compounds	O

The	O
present	O
invention	O
is	O
directed	O
to	O
6-	B
(	I
1H	I
-	I
imidazo-1-yl	I
)	I
-2-aryl	I
and	O
2-heteroaryl	B
quinazoline	I
and	O
quinolines	B
derivatives	O
,	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
their	O
pharmaceutical	O
acceptable	O
salts	O
and	O
solvates	O
and	O
corresponding	O
pharmaceutical	O
compositions	O
,	O
that	O
acts	O
as	O
Monoamine	B
Oxidase	O
(	O
MAO	O
)	O
inhibitors	O
and	O
Imidazoline	B
Receptor	O
ligands	O
:	O
wherein	O
:	O
X	O
is	O
independently	O
selected	O
from	O
CH	B
group	O
or	O
a	O
nitrogen	B
atom	O
(	O
N	B
)	O
,	O
W	O
is	O
independently	O
selected	O
from	O
an	O
aryl	B
group	O
,	O
an	O
heteroaryl	B
group	O
,	O
or	O
a	O
benzocondensed	O
heteroaryl	B
group	O
such	O
as	O
1,3-benzodioxole	B
,	O
benzofuran	B
,	O
2,3-dihydrobenzofuran	B
,	O
benzothiophene	B
,	O
2,3-dihydrobenzothiophene	B
,	O
indole	B
,	O
2,3-dihydroindole	B
,	O
benzimidazole	B
,	O
benzoxazole	B
,	O
benzothiazole	B
,	O
2H-3,4-dihydrobenzopyran	B
,	O
[	B
1,4	I
]	I
-benzodioxine	I
,	I
2,3-dihydro-	I
[	I
1,4	I
]	I
-benzodioxine	I
(	I
1,4-benzodioxan	I
)	I
.	O

R1	O
is	O
independently	O
selected	O
from	O
hydrogen	B
(	O
H	B
)	O
,	O
C1-C4	B
alkyl	I
,	O
hydroxymethyl	B
(	O
CH2OH	B
)	O
,	O
aminomethyl	B
(	O
CH2NH2	B
)	O
,	O
alkylaminomethyl	B
[	O
CH2NH	B
(	I
R2	I
)	I
]	O
,	O
or	O
di	B
-	I
alkylaminomethyl	I
[	O
CH2N	B
(	I
R2	I
)	I
2	I
]	O
,	O
trifluoromethyl	B
(	O
CF3	B
)	O
.	O

Compounds	O
of	O
formula	O
(	O
I	O
)	O
elicited	O
a	O
pharmacological	O
profile	O
suitable	O
for	O
the	O
clinical	O
treatment	O
of	O
depression	O
and	O
related	O
disorders	O
,	O
Parkinson	O
disease	O
,	O
drug	O
abuse	O
,	O
and	O
morphine	B
tolerance	O
and	O
dependence	O
.	O

6	B
-	I
1h	I
-	I
imidazo	I
-	I
quinazoline	I
and	O
quinolines	B
derivatives	O
,	O
new	O
mao	O
inhibitors	O
and	O
imidazoline	B
receptor	O
ligands	O

The	O
multiphase	O
preparation	O
having	O
higher	O
contraceptive	O
safety	O
and	O
reduced	O
side	O
effects	O
is	O
based	O
on	O
a	O
combination	O
of	O
a	O
natural	O
oestrogen	B
with	O
dienogest	O
or	O
drospirenon	O
.	O

The	O
multiphase	O
prepration	O
is	O
characterized	O
by	O
a	O
first	O
phase	O
consisting	O
of	O
2	O
daily	O
dose	O
dose	O
units	O
of	O
3	O
mg	O
of	O
oestradiol	B
valerate	I
,	O
a	O
second	O
phase	O
consisting	O
of	O
2	O
groups	O
of	O
daily	O
dose	O
units	O
,	O
wherein	O
a	O
first	O
group	O
is	O
formed	O
by	O
5	O
daily	O
dose	O
units	O
each	O
containing	O
a	O
combination	O
of	O
2	O
mg	O
of	O
oestradiol	B
valerate	I
and	O
at	O
least	O
two	O
or	O
three	O
times	O
an	O
ovulation	O
-	O
inhibitory	O
dose	O
of	O
dienogest	O
or	O
drospirenon	O
and	O
a	O
second	O
group	O
is	O
formed	O
by	O
17	O
daily	O
dose	O
units	O
each	O
containing	O
a	O
combination	O
of	O
2	O
mg	O
of	O
oestradiol	B
valerate	I
and	O
at	O
least	O
three	O
or	O
four	O
times	O
the	O
ovulation	O
-	O
inhibitory	O
dose	O
of	O
dienogest	O
or	O
drospirenon	O
,	O
a	O
third	O
phase	O
consisting	O
of	O
2	O
daily	O
dose	O
units	O
of	O
1	O
mg	O
of	O
oestradiol	B
valerate	I
,	O
and	O
a	O
further	O
phase	O
consisting	O
of	O
2	O
daily	O
dose	O
units	O
of	O
pharmaceutically	O
acceptable	O
placebo	O
.	O

Multi	O
-	O
phase	O
contraceptive	O
preparation	O
based	O
on	O
a	O
natural	O
estrogen	B

The	O
disclosure	O
provides	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
including	O
their	O
salts	O
,	O
as	O
well	O
as	O
compositions	O
and	O
methods	O
of	O
using	O
the	O
compounds	O
.	O

The	O
compounds	O
are	O
CRF	O
receptor	O
antagonists	O
and	O
may	O
be	O
useful	O
for	O
treating	O
disorders	O
associated	O
with	O
abnormal	O
CRF	O
levels	O
or	O
aberrant	O
functioning	O
of	O
CRF	O
receptors	O
.	O

Substituted	O
Carbamate	B
Derivatives	O
as	O
Modulators	O
of	O
Corticotropin	O
-	O
Releasing	O
Factor	O
Receptor	O
Activity	O

Disclosed	O
are	O
terpolymer	O
compositions	O
of	O
lactide	B
,	O
glycolide	B
,	O
and	O
caprolactone	B
and	O
methods	O
of	O
making	O
such	O
polymers	O
with	O
an	O
initiator	O
.	O

Methods	O
of	O
using	O
the	O
terpolymers	O
as	O
a	O
drug	O
delivery	O
platform	O
are	O
also	O
disclosed	O
.	O

Viscous	O
Terpolymers	O
as	O
Drug	O
Delivery	O
Platform	O

A	O
platelet	O
adhesion	O
-	O
resistant	O
material	O
is	O
provided	O
,	O
which	O
includes	O
polytriuret	B
-	I
urethane	I
consisting	O
essentially	O
of	O
repeating	O
structural	O
units	O
of	O
formulae	O
(	O
I	O
)	O
to	O
(	O
III	O
)	O
in	O
a	O
random	O
order	O
,	O
in	O
which	O
when	O
the	O
total	O
number	O
of	O
the	O
three	O
repeating	O
structural	O
units	O
in	O
the	O
polytriuret	B
-	I
urethane	I
is	O
100	O
,	O
the	O
number	O
of	O
the	O
repeating	O
structural	O
units	O
(	O
I	O
)	O
is	O
about	O
5	O
to	O
about	O
50	O
:	O
in	O
which	O
each	O
R	O
independently	O
represents	O
a	O
C2-C16	B
alkylene	I
group	O
,	O
a	O
C6-C30	B
aromatic	I
group	O
,	O
a	O
C6-C30	B
alicyclic	I
group	O
;	O
n	O
is	O
an	O
integer	O
of	O
2	O
to	O
16	O
;	O
and	O
R1	O
represents	O
	B
(	I
OCmH2m	I
)	I
p	I
,	O
in	O
which	O
m	O
is	O
an	O
integer	O
of	O
2	O
to	O
5	O
,	O
and	O
p	O
is	O
an	O
integer	O
of	O
3	O
to	O
150	O
.	O

Platelet	O
adhesion	O
-	O
resistant	O
material	O

The	O
marginal	O
zone	O
(	O
MZ	O
)	O
and	O
B1	O
subsets	O
of	O
B	O
cells	O
,	O
which	O
differ	O
from	O
conventional	O
follicular	O
(	O
FO	O
)	O
B	O
cells	O
both	O
developmentally	O
and	O
functionally	O
,	O
are	O
involved	O
in	O
early	O
responses	O
to	O
infectious	O
pathogens	O
and	O
the	O
production	O
of	O
self	O
-	O
reactive	O
antibodies	O
.	O

A	O
novel	O
gene	O
,	O
mzb1	O
,	O
is	O
expressed	O
at	O
high	O
levels	O
in	O
MZ	O
and	O
B1	O
B	O
cells	O
but	O
at	O
low	O
level	O
,	O
if	O
at	O
all	O
,	O
in	O
FOB	O
cells	O
.	O

MZB1	O
is	O
involved	O
in	O
the	O
regulation	O
of	O
proliferation	O
,	O
BCR	O
-	O
mediated	O
signal	O
transduction	O
,	O
and	O
antibody	O
production	O
in	O
B	O
cells	O
.	O

Inhibitors	O
,	O
activators	O
and	O
enhancers	O
of	O
MZB1	O
expression	O
or	O
activity	O
can	O
be	O
used	O
as	O
immune	O
modulators	O
for	O
research	O
and	O
therapeutic	O
purposes	O
.	O

Mzb1	O
,	O
a	O
novel	O
b	O
cell	O
factor	O
,	O
and	O
uses	O
thereof	O

Methods	O
and	O
compositions	O
for	O
the	O
treating	O
chronic	O
renal	O
hypertension	O
in	O
a	O
subject	O
comprising	O
administering	O
a	O
therapeutically	O
effective	O
amount	O
of	O
at	O
least	O
one	O
nitroxide	B
-	O
containing	O
composition	O
to	O
the	O
subject	O
,	O
particularly	O
4-hydroxy-2,2,6,6-tetramethyl-1-piperidine-1-oxyl	B
(	O
Tempol	B
)	O
.	O

Methods	O
and	O
Compositions	O
for	O
the	O
Treatment	O
of	O
Chronic	O
Renal	O
Hypertension	O

Embodiments	O
of	O
the	O
present	O
invention	O
relate	O
to	O
methods	O
and	O
compositions	O
for	O
tissue-	O
specific	O
delivery	O
of	O
a	O
gene	O
therapeutic	O
,	O
transgenic	O
nucleic	O
acid	O
in	O
mammals	O
.	O

Methods	O
and	O
compositions	O
of	O
the	O
invention	O
include	O
the	O
steps	O
of	O
providing	O
a	O
nucleic	O
acid	O
comprising	O
a	O
transgene	O
flanked	O
by	O
two	O
terminal	O
repeats	O
and	O
,	O
within	O
the	O
same	O
or	O
on	O
a	O
separate	O
nucleic	O
acid	O
,	O
a	O
nucleotide	O
sequence	O
encoding	O
a	O
transposase	O
,	O
wherein	O
the	O
transgene	O
comprises	O
a	O
biotherapeutic	O
gene	O
,	O
contacting	O
the	O
nucleic	O
acid	O
with	O
perfluorocarbon	O
gas	O
-	O
filled	O
microbubbles	O
to	O
form	O
a	O
mixture	O
,	O
introducing	O
the	O
mixture	O
into	O
the	O
bloodstream	O
of	O
a	O
mammal	O
,	O
and	O
focusing	O
ultrasound	O
pulses	O
on	O
a	O
specific	O
tissue	O
of	O
said	O
mammal	O
,	O
wherein	O
said	O
pulses	O
disrupt	O
said	O
microbubbles	O
of	O
said	O
mixture	O
and	O
release	O
said	O
nucleic	O
acid	O
into	O
the	O
bloodstream	O
within	O
the	O
target	O
tissue	O
,	O
thereby	O
enabling	O
uptake	O
of	O
the	O
transgenic	O
nucleic	O
acid	O
into	O
the	O
cells	O
of	O
said	O
target	O
tissue	O
.	O

Methods	O
and	O
compositions	O
for	O
targeted	O
delivery	O
of	O
gene	O
therapeutic	O
vectors	O

Stable	O
,	O
extracellular	O
microRNAs	O
and	O
methods	O
for	O
isolating	O
and	O
identifying	O
such	O
microRNAs	O
from	O
a	O
body	O
fluid	O
are	O
provided	O
.	O

The	O
extracellular	O
microRNAs	O
isolated	O
from	O
a	O
bodily	O
fluid	O
of	O
a	O
subject	O
can	O
be	O
used	O
to	O
measure	O
disease	O
and	O
provide	O
sensitive	O
,	O
efficient	O
,	O
and	O
non	O
invasive	O
methods	O
for	O
the	O
detection	O
of	O
disease	O
,	O
including	O
cancer	O
.	O

The	O
extracellular	O
microRNAs	O
can	O
be	O
used	O
to	O
develop	O
new	O
therapeutics	O
for	O
the	O
treatment	O
of	O
disease	O
,	O
including	O
cancer	O
.	O

The	O
examples	O
illustrate	O
diagnosis	O
of	O
prostate	O
and	O
ovarian	O
cancer	O
and	O
differential	O
expression	O
of	O
miR-100	O
,	O
miR-135b	O
,	O
miR-141	O
,	O
miR-148a	O
,	O
miR-200a	O
,	O
miR-200c	O
,	O
miR-210	O
,	O
miR-222	O
,	O
miR-375	O
,	O
miR-425-Sp	O
and	O
miR-429	O
.	O

Use	O
of	O
extracellular	O
rna	O
to	O
measure	O
disease	O

The	O
present	O
invention	O
relates	O
to	O
treatment	O
and	O
prevention	O
devices	O
and	O
regimens	O
for	O
tendon	O
injury	O
and	O
damage	O
.	O

The	O
invention	O
further	O
provides	O
compositions	O
comprising	O
therapeutic	O
agents	O
and	O
the	O
use	O
of	O
such	O
compositions	O
in	O
methods	O
of	O
treating	O
disorders	O
,	O
injuries	O
and	O
conditions	O
beneficially	O
treated	O
by	O
these	O
agents	O
,	O
particularly	O
those	O
relating	O
to	O
the	O
management	O
of	O
tendon	O
damage	O
.	O

Device	O
and	O
methods	O
for	O
treatment	O
and	O
prevention	O
of	O
tendon	O
injuries	O

There	O
is	O
provided	O
a	O
method	O
of	O
treating	O
or	O
preventing	O
a	O
neurodegenerative	O
disease	O
,	O
which	O
includes	O
administration	O
of	O
a	O
composition	O
that	O
includes	O
a	O
reagent	O
capable	O
of	O
modulating	O
expression	O
of	O
ribonucleic	O
acid	O
(	O
RNA	O
)	O
encoded	O
by	O
a	O
nucleic	O
acid	O
,	O
wherein	O
the	O
nucleic	O
acid	O
is	O
selected	O
from	O
a	O
group	O
that	O
includes	O
a	O
contiguous	O
nucleotide	B
sequence	O
being	O
at	O
least	O
90	O
%	O
homologous	O
to	O
at	O
least	O
20	O
nucleotides	B
of	O
:	O
SEQ	O
ID	O
NO	O
:	O
1	O
,	O
SEQ	O
ID	O
NO	O
:	O
3	O
,	O
SEQ	O
ID	O
NO	O
:	O
5	O
,	O
SEQ	O
ID	O
NO	O
:	O
7	O
,	O
or	O
any	O
combination	O
thereof	O
.	O

There	O
is	O
further	O
provided	O
a	O
method	O
of	O
treating	O
or	O
preventing	O
a	O
neurodegenerative	O
disease	O
,	O
which	O
includes	O
administration	O
of	O
a	O
composition	O
that	O
includes	O
a	O
reagent	O
capable	O
of	O
modulating	O
expression	O
and/or	O
activity	O
of	O
a	O
polypeptide	O
,	O
wherein	O
the	O
sequence	O
of	O
the	O
polypeptide	O
is	O
selected	O
from	O
a	O
group	O
that	O
includes	O
a	O
contiguous	O
amino	B
acid	I
sequence	O
being	O
at	O
least	O
90	O
%	O
homologous	O
to	O
at	O
least	O
10	O
amino	B
acid	I
of	O
:	O
SEQ	O
ID	O
NO	O
:	O
2	O
,	O
SEQ	O
ID	O
NO	O
:	O
4	O
,	O
SEQ	O
ID	O
NO	O
:	O
6	O
,	O
SEQ	O
ID	O
NO	O
:	O
8	O
,	O
or	O
any	O
combination	O
thereof	O
.	O

Cd44	O
splice	O
variants	O
in	O
neurodegenerative	O
diseases	O

The	O
present	O
invention	O
relates	O
to	O
the	O
discovery	O
of	O
an	O
effective	O
treatment	O
for	O
a	O
variety	O
of	O
gain	O
-	O
of	O
-	O
function	O
diseases	O
,	O
in	O
particular	O
,	O
Huntington	O
's	O
disease	O
(	O
HD	O
)	O
.	O

The	O
present	O
invention	O
utilizes	O
RNA	O
Interference	O
technology	O
(	O
RNAi	O
)	O
against	O
polymorphic	O
regions	O
in	O
the	O
genes	O
encoding	O
various	O
gain	O
-	O
of	O
-	O
function	O
mutant	O
proteins	O
resulting	O
in	O
an	O
effective	O
treatment	O
for	O
the	O
gain	O
-	O
of	O
-	O
function	O
disease	O
.	O

Rna	O
interference	O
for	O
the	O
treatment	O
of	O
gain	O
-	O
of	O
-	O
function	O
disorders	O

Immunogenic	O
HCV	O
E1E2809	O
DNA	O
compositions	O
and	O
methods	O
of	O
using	O
the	O
same	O
are	O
described	O
.	O

The	O
compositions	O
comprise	O
HCV	O
E1E2809	O
DNA	O
adsorbed	O
to	O
cationic	O
microparticles	O
,	O
such	O
as	O
poly	B
(	I
lactide	I
-	I
co	I
-	I
glycolide	I
)	I
(	O
PLG	B
)	O
microparticles	O
.	O

Compositions	O
comprising	O
cationic	O
microparticles	O
and	O
hcv	O
e1e2	O
dna	O
and	O
methods	O
of	O
use	O
thereof	O

Pharmaceutical	O
compositions	O
comprising	O
bortezomib	B
for	O
oral	O
or	O
parenteral	O
administration	O
.	O

Specific	O
aspects	O
relate	O
to	O
stable	O
,	O
sugar	B
free	O
pharmaceutical	O
compositions	O
of	O
bortezomib	B
,	O
including	O
its	O
pharmaceutically	O
acceptable	O
salts	O
or	O
solvates	O
,	O
in	O
the	O
form	O
of	O
ready	O
-	O
to	O
-	O
use	O
solutions	O
,	O
lyophilized	O
forms	O
,	O
or	O
physical	O
admixtures	O
,	O
and	O
the	O
preparation	O
thereof	O
.	O

Other	O
aspects	O
include	O
processes	O
for	O
preparing	O
compositions	O
and	O
methods	O
of	O
using	O
compositions	O
for	O
treating	O
various	O
types	O
of	O
cancers	O
in	O
mammals	O
.	O

Pharmaceutical	O
compositions	O
comprising	O
boronic	B
acid	I
compounds	O

A	O
foamable	O
composition	O
is	O
described	O
that	O
contains	O
one	O
or	O
more	O
of	O
:	O
minoxidil	B
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
an	O
aqueous	O
-	O
alcoholic	O
solvent	O
medium	O
which	O
enables	O
said	O
minoxidil	B
or	O
said	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
to	O
be	O
solubilized	O
,	O
a	O
surfactant	O
,	O
such	O
as	O
oleth-20	O
,	O
a	O
foam	O
stabilizer	O
,	O
such	O
as	O
lauryl	B
glucoside	I
,	O
and	O
a	O
sunscreen	O
.	O

The	O
foamable	O
minoxidil	B
composition	O
is	O
optionally	O
delivered	O
in	O
a	O
measured	O
dosage	O
as	O
a	O
foam	O
using	O
a	O
non	O
-	O
pressurized	O
container	O
,	O
where	O
the	O
foam	O
is	O
produced	O
within	O
the	O
container	O
without	O
use	O
of	O
a	O
propellant	O
.	O

minoxidil	B
composition	O
and	O
non	O
-	O
aerosol	O
,	O
non	O
-	O
spray	O
foam	O
method	O
of	O
delivery	O
therefor	O

The	O
present	O
invention	O
relates	O
to	O
Tricyclic	B
Indole	I
Derivatives	O
,	O
compositions	O
comprising	O
at	O
least	O
one	O
Tricyclic	B
Indole	I
Derivatives	O
,	O
and	O
methods	O
of	O
using	O
the	O
Tricyclic	B
Indole	I
Derivatives	O
for	O
treating	O
or	O
preventing	O
a	O
viral	O
infection	O
or	O
a	O
virus	O
-	O
related	O
disorder	O
in	O
a	O
patient	O
.	O

Tricyclic	B
indole	I
derivatives	O
and	O
methods	O
of	O
use	O
thereof	O

Rapidly	O
dispersing	O
solid	O
dry	O
therapeutic	O
dosage	O
form	O
comprised	O
of	O
a	O
water	O
insoluble	O
compound	O
existing	O
as	O
a	O
nanometer	O
or	O
micrometer	O
particulate	O
solid	O
which	O
is	O
surface	O
stabilized	O
by	O
the	O
presence	O
of	O
at	O
least	O
one	O
phospholipid	B
,	O
the	O
particulate	O
solid	O
being	O
dispersed	O
throughout	O
a	O
bulking	O
matrix	O
.	O

When	O
the	O
dosage	O
form	O
is	O
introduced	O
into	O
an	O
aqueous	O
environment	O
the	O
bulking	O
matrix	O
is	O
substantially	O
completely	O
dissolves	O
within	O
less	O
than	O
2	O
minutes	O
thereby	O
releasing	O
the	O
water	O
insoluble	O
particulate	O
solid	O
in	O
an	O
unaggregated	O
and/or	O
unagglomerated	O
state	O
.	O

The	O
matrix	O
is	O
composed	O
of	O
a	O
water	O
insoluble	O
substance	O
or	O
therapeutically	O
useful	O
water	O
insoluble	O
or	O
poorly	O
water	O
soluble	O
compound	O
,	O
a	O
phospholipid	B
and	O
optionally	O
also	O
at	O
least	O
one	O
non	O
-	O
ionic	O
,	O
anionic	O
,	O
cationic	O
,	O
or	O
amphipathic	O
surfactant	O
,	O
together	O
with	O
a	O
matrix	O
or	O
bulking	O
agent	O
and	O
if	O
needed	O
a	O
release	O
agent	O
.	O

The	O
volume	O
weighted	O
mean	O
particle	O
size	O
of	O
the	O
water	O
insoluble	O
particle	O
is	O
5	O
micrometers	O
or	O
less	O
.	O

Dispersible	O
phospholipid	B
stabilized	O
microparticles	O

This	O
present	O
invention	O
provides	O
methods	O
and	O
kits	O
for	O
identifying	O
patients	O
at	O
risk	O
of	O
suffering	O
from	O
a	O
drug	O
induced	O
liver	O
injury	O
,	O
particularly	O
for	O
an	O
antioxidant	O
drug	O
,	O
or	O
for	O
identifying	O
patients	O
who	O
are	O
suffering	O
from	O
early	O
stages	O
of	O
a	O
liver	O
disorder	O
by	O
assessing	O
the	O
levels	O
of	O
apolipoprotein	O
in	O
a	O
sample	O
of	O
the	O
patient	O
and	O
comparing	O
that	O
to	O
a	O
reference	O
value	O
.	O

The	O
reference	O
value	O
is	O
predetermined	O
by	O
identifying	O
a	O
population	O
sample	O
and	O
determining	O
an	O
upper	O
limit	O
of	O
normal	O
value	O
.	O

This	O
value	O
is	O
then	O
used	O
as	O
a	O
reference	O
point	O
for	O
comparison	O
of	O
apolipoprotein	O
levels	O
from	O
patient	O
samples	O
.	O

In	O
one	O
embodiment	O
,	O
apolipoprotein	O
levels	O
are	O
combined	O
with	O
ATL	O
and/or	O
total	O
bilirubin	O
levels	O
for	O
predicting	O
liver	O
damage	O
,	O
hepatotoxicity	O
or	O
hepatic	O
events	O
after	O
drug	O
administration	O
.	O

Screening	O
Method	O
for	O
Identifying	O
Patients	O
at	O
Risk	O
of	O
Adverse	O
Hepatologic	O
Events	O

The	O
disclosure	O
provides	O
modified	O
chloroquine	B
compounds	O
having	O
single	O
ring	O
or	O
fused	O
ring	O
moieties	O
.	O

Also	O
provided	O
are	O
pharmaceutical	O
compositions	O
comprising	O
such	O
compounds	O
,	O
methods	O
of	O
using	O
such	O
compounds	O
to	O
inhibit	O
or	O
treat	O
diseases	O
or	O
conditions	O
caused	O
by	O
chloroquine	B
-	O
resistant	O
(	O
CQR	O
)	O
and	O
chloroquine	B
-	O
sensitive	O
(	O
CqS	O
)	O
malaria	O
parasites	O
and	O
other	O
CQ	O
-	O
susceptible	O
microorganisms	O
,	O
and	O
processes	O
and	O
intermediates	O
useful	O
for	O
preparing	O
such	O
compounds	O
.	O

Modified	O
chloroquines	B
with	O
single	O
ring	O
moiety	O
or	O
fused	O
ring	O
moiety	O

A	O
method	O
of	O
determining	O
a	O
personalised	O
therapeutic	O
regime	O
,	O
comprising	O
:	O
receiving	O
genetic	O
information	O
relating	O
to	O
a	O
patient	O
;	O
determining	O
genetic	O
criteria	O
relevant	O
to	O
a	O
personalised	O
therapeutic	O
regime	O
for	O
the	O
patient	O
using	O
the	O
genetic	O
information	O
;	O
receiving	O
personal	O
information	O
relating	O
to	O
the	O
patient	O
;	O
determining	O
personal	O
criteria	O
relevant	O
to	O
the	O
personalised	O
therapeutic	O
regime	O
using	O
the	O
personal	O
information	O
;	O
and	O
combining	O
the	O
genetic	O
criteria	O
and	O
the	O
personal	O
criteria	O
to	O
determine	O
the	O
personalised	O
therapeutic	O
regime	O
for	O
the	O
patient	O
.	O

Method	O
and	O
Kit	O
for	O
Assessing	O
a	O
Patient	O
's	O
Genetic	O
Information	O
,	O
Lifestyle	O
and	O
Environment	O
Conditions	O
,	O
and	O
Providing	O
a	O
Tailored	O
Therapeutic	O
Regime	O

This	O
disclosure	O
demonstrates	O
a	O
novel	O
therapy	O
immunological	O
approach	O
using	O
polyamine	B
-	O
based	O
therapy	O
(	O
PBT	O
)	O
for	O
relieving	O
tumor	O
-	O
induced	O
suppression	O
of	O
the	O
patient	O
's	O
immune	O
system	O
.	O

The	O
demonstration	O
of	O
the	O
pharmacological	O
release	O
from	O
the	O
naturally	O
occurring	O
polyamine	B
-	O
mediated	O
immune	O
suppression	O
offers	O
profound	O
impact	O
on	O
the	O
immunotherapy	O
of	O
cancer	O
together	O
with	O
a	O
variety	O
of	O
diseases	O
caused	O
by	O
the	O
disease	O
-	O
causing	O
vector	O
's	O
ability	O
to	O
evade	O
an	O
immune	O
reaction	O
.	O

This	O
therapeutic	O
approach	O
is	O
equally	O
applicable	O
to	O
disease	O
states	O
whereby	O
immune	O
system	O
suppression	O
by	O
polyamines	B
has	O
been	O
demonstrated	O
including	O
;	O
bacterial	O
infections	O
,	O
parasitic	O
infections	O
including	O
malaria	O
and	O
typanosomiasis	O
,	O
viral	O
infections	O
,	O
peptic	O
ulcers	O
and	O
gastric	O
cancer	O
due	O
to	O
H.	O
Pylori	O
infection	O
together	O
with	O
prevention	O
of	O
pregnancy	O
.	O

With	O
a	O
small	O
molecule	O
drug	O
,	O
used	O
in	O
combination	O
with	O
DFMO	O
,	O
the	O
pharmacological	O
manipulation	O
of	O
polyamine	B
levels	O
for	O
therapeutic	O
benefit	O
in	O
various	O
disease	O
states	O
is	O
possible	O
.	O

Methods	O
for	O
enhancing	O
immune	O
response	O

Provided	O
herein	O
is	O
a	O
prenatal	O
and	O
postpartum	O
multivitamin	O
and	O
mineral	O
supplement	O
package	O
provided	O
in	O
the	O
form	O
of	O
a	O
plurality	O
of	O
solid	O
oral	O
dosage	O
units	O
individually	O
contained	O
in	O
blister	O
packs	O
wherein	O
a	O
portion	O
of	O
the	O
dosage	O
forms	O
are	O
iron	B
-	O
containing	O
while	O
at	O
least	O
half	O
of	O
the	O
dosage	O
units	O
are	O
essentially	O
iron	B
-	O
free	O
and	O
wherein	O
the	O
total	O
amount	O
of	O
iron	B
in	O
the	O
package	O
as	O
sold	O
to	O
purchasers	O
is	O
less	O
than	O
about	O
1300	O
mg	O
of	O
elemental	O
iron	O
.	O

Micronutrient	O
Supplement	O
Dispensing	O
Package	O

The	O
present	O
invention	O
relates	O
to	O
alkaloid	B
aminoester	I
compounds	O
which	O
act	O
as	O
muscarinic	O
receptor	O
antagonists	O
,	O
processes	O
for	O
their	O
preparation	O
,	O
compositions	O
comprising	O
them	O
,	O
and	O
therapeutic	O
uses	O
thereof	O
.	O

Alkaloid	B
aminoester	I
derivatives	O
and	O
medicinal	O
composition	O
thereof	O

The	O
instant	O
invention	O
provides	O
methods	O
of	O
using	O
a	O
class	O
of	O
compounds	O
known	O
as	O
cardenolides	B
in	O
the	O
treatment	O
of	O
proliferative	O
diseases	O
such	O
as	O
cancer	O
.	O

In	O
particular	O
,	O
the	O
instant	O
invention	O
provides	O
methods	O
of	O
treating	O
ocular	O
cancer	O
{	O
e.g.	O
,	O
retinoblastoma	O
)	O
using	O
intraarterial	O
infusion	O
to	O
administer	O
cardenolides	B
locally	O
to	O
the	O
eye	O
of	O
a	O
subject	O
with	O
an	O
ocular	O
cancer	O
.	O

Cardenolides	B
for	O
the	O
treatment	O
of	O
ocular	O
cancer	O

This	O
invention	O
relates	O
to	O
novel	O
saponin	B
compounds	O
of	O
formula	O
II	O
wherein	O
MBz	B
denotes	O
p	B
-	I
methoxybenzoyl	I
,	O
and	O
R	O
is	O
selected	O
from	O
the	O
group	O
comprising	O
C6	B
-	I
10	I
aryl	I
,	O
C6	B
-	I
10	I
aryl	I
-	O
C1	B
-	I
4	I
alkyl-	I
,	O
C1	B
-	I
18	I
alkanoyl	I
,	O
C3	B
-	I
18	I
alkenyl	I
,	O
C6	B
-	I
10	I
aryl	I
-	I
C	I
(	I
O	I
)	I
	I
,	O
C6	B
-	I
10	I
aryl	I
-	O
C1	B
-	I
4	I
alkyl	I
-	I
C	I
(	I
O	I
)	I
	I
,	O
wherein	O
each	O
of	O
the	O
groups	O
can	O
optionally	O
be	O
substituted	O
.	O

These	O
compounds	O
possess	O
a	O
selective	O
cytostatic	O
activity	O
,	O
useful	O
,	O
e.g.	O
,	O
in	O
the	O
treatment	O
of	O
proliferative	O
diseases	O
.	O

The	O
invention	O
further	O
relates	O
to	O
methods	O
of	O
preparation	O
of	O
the	O
novel	O
compounds	O
and	O
to	O
a	O
pharmaceutical	O
composition	O
containing	O
these	O
compounds	O
.	O

Novel	O
Saponin	B
Compounds	O
,	O
Methods	O
of	O
Preparation	O
Thereof	O
,	O
Use	O
Thereof	O
and	O
Pharmaceutical	O
Compositions	O

The	O
invention	O
relates	O
to	O
substituted	O
(	B
2-aryloxyacetylamino	I
)	I
phenylpropionic	I
acid	I
derivatives	O
,	O
and	O
to	O
the	O
physiologically	O
acceptable	O
salts	O
thereof	O
.	O

The	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
formula	O
I	O
in	O
which	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
R6	O
,	O
R7	O
,	O
R8	O
,	O
R9	O
and	O
A	O
are	O
each	O
defined	O
as	O
specified	O
,	O
and	O
the	O
physiologically	O
compatible	O
salts	O
thereof	O
.	O

The	O
compounds	O
are	O
suitable	O
,	O
for	O
example	O
,	O
for	O
treatment	O
of	O
diabetes	O
.	O

(	B
2-aryloxyacetylamino	I
)	I
phenylpropionic	I
acid	I
derivatives	O
,	O
processes	O
for	O
preparation	O
thereof	O
and	O
use	O
thereof	O
as	O
medicaments	O

The	O
present	O
invention	O
relates	O
to	O
a	O
process	O
for	O
the	O
preparation	O
of	O
compounds	O
which	O
are	O
therapeutically	O
active	O
in	O
the	O
central	O
nervous	O
system	O
.	O

In	O
one	O
aspect	O
,	O
the	O
invention	O
relates	O
to	O
a	O
process	O
for	O
the	O
preparation	O
of	O
compounds	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
HA	O
is	O
a	O
pharmaceutically	O
acceptable	O
acid	O
and	O
R1-R4	O
are	O
each	O
independently	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
hydrogen	B
,	O
halogen	B
,	O
C1-C6-alkyl	B
,	O
C1-C6-alkoxy	B
,	O
and	O
di	B
-	I
C1-C6-alkylamino	I
-	I
C2-C6-alkoxy	I
.	O

The	O
invention	O
also	O
relates	O
to	O
the	O
use	O
of	O
said	O
compound	O
to	O
manufacture	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
a	O
serotonin	B
-	O
related	O
disorder	O
.	O

Succinate	B
salt	O
of	O
(	B
2r	I
)	I
-methyl-1-piperazine	I

The	O
invention	O
relates	O
to	O
(	O
among	O
other	O
things	O
)	O
oligomer	B
-	I
diarylpiperazine	I
conjugates	O
and	O
related	O
compounds	O
.	O

A	O
conjugate	O
of	O
the	O
invention	O
,	O
when	O
administered	O
by	O
any	O
of	O
a	O
number	O
of	O
administration	O
routes	O
,	O
exhibits	O
advantages	O
over	O
previously	O
administered	O
un	O
-	O
conjugated	O
diarylpiperazine	B
compounds	O
.	O

Oligomer	B
-	I
Diarylpiperazine	I
Conjugates	O

The	O
present	O
invention	O
relates	O
to	O
oligomer	O
compounds	O
(	O
oligomers	O
)	O
,	O
which	O
target	O
mtGPAT1mRNA	O
in	O
a	O
cell	O
,	O
leading	O
to	O
reduced	O
expression	O
of	O
mtGPAT1	O
.	O

Reduction	O
of	O
mtGPAT1	O
expression	O
is	O
beneficial	O
for	O
the	O
treatment	O
of	O
certain	O
medical	O
disorders	O
,	O
such	O
as	O
overweight	O
,	O
obesity	O
,	O
fatty	O
liver	O
,	O
hepatosteatosis	O
,	O
non	O
alcoholic	O
fatty	O
liver	O
disease	O
(	O
NAFLD	O
)	O
,	O
non	O
alcoholic	O
steatohepatitis	O
(	O
NASH	O
)	O
,	O
insulin	O
resistance	O
,	O
and	O
non	O
insulin	O
dependent	O
diabetes	O
mellitus	O
(	O
NIDDM	O
)	O
.	O

Rna	O
antagonist	O
compounds	O
for	O
the	O
inhibition	O
of	O
expression	O
of	O
mitochondrial	O
glycerol-3	B
phosphate	I
acyltransferase	O
1	O
(	O
mtgpat1	O
)	O

The	O
present	O
invention	O
relates	O
to	O
antisense	O
oligonucleotides	B
that	O
modulate	O
the	O
expression	O
of	O
and/or	O
function	O
of	O
Delta	O
-	O
like	O
(	O
1	O
)	O
homolog	O
(	O
DLK1	O
)	O
,	O
in	O
particular	O
,	O
by	O
targeting	O
natural	O
antisense	O
polynucleotides	B
of	O
Delta	O
-	O
like	O
(	O
1	O
)	O
homolog	O
(	O
DLK1	O
)	O
.	O

The	O
invention	O
also	O
relates	O
to	O
the	O
identification	O
of	O
these	O
antisense	O
oligonucleotides	B
and	O
their	O
use	O
in	O
treating	O
diseases	O
and	O
disorders	O
associated	O
with	O
the	O
expression	O
of	O
(	O
DLK1	O
)	O
.	O

Treatment	O
of	O
delta	O
-	O
like	O
1	O
homolog	O
(	O
dlk1	O
)	O
related	O
diseases	O
by	O
inhibition	O
of	O
natural	O
antisense	O
transcript	O
to	O
dlk1	O

Methods	O
,	O
compounds	O
and	O
compositions	O
for	O
promoting	O
motor	O
neuron	O
survival	O
and	O
the	O
treatment	O
of	O
a	O
neurodegenerative	O
disorders	O
such	O
as	O
Spinal	O
Muscular	O
Atrophy	O
(	O
SMA	O
)	O
are	O
described	O
herein	O
.	O

Methods	O
and	O
compounds	O
for	O
treatment	O
of	O
neurodegenerative	O
disorders	O

A	O
method	O
of	O
parenterally	O
administering	O
a	O
composition	O
,	O
the	O
method	O
including	O
parenterally	O
administering	O
to	O
a	O
person	O
a	O
composition	O
including	O
at	O
least	O
one	O
omega-3	B
fatty	I
acid	I
and	O
at	O
least	O
one	O
drug	O
,	O
wherein	O
the	O
at	O
least	O
one	O
omega-3	B
fatty	I
acid	I
source	O
and	O
the	O
at	O
least	O
one	O
drug	O
are	O
administered	O
simultaneously	O
.	O

Method	O
of	O
mitigating	O
adverse	O
drug	O
events	O
using	O
omega-3	B
fatty	I
acids	I
as	O
a	O
parenteral	O
therapeutic	O
drug	O
vehicle	O

The	O
present	O
invention	O
is	O
directed	O
to	O
crystalline	O
forms	O
of	O
oxymorphone	B
hydrochloride	I
.	O

Crystalline	O
forms	O
of	O
oxymorphone	B
hydrochloride	I

There	O
is	O
disclosed	O
a	O
technique	O
for	O
imparting	O
an	O
appropriate	O
rupture	O
strength	O
and	O
high	O
drug	O
-	O
release	O
properties	O
to	O
a	O
jelly	O
formulation	O
comprising	O
pectin	O
.	O

The	O
jelly	O
formulation	O
of	O
the	O
present	O
invention	O
comprises	O
a	O
drug	O
,	O
pectin	O
,	O
and	O
divalent	O
metal	O
ion	O
,	O
and	O
further	O
comprises	O
a	O
component	O
selected	O
from	O
sucrose	B
,	O
maltitol	B
and	O
C3-C4	B
alditols	I
,	O
and	O
a	O
component	O
selected	O
from	O
C5-C6	B
alditols	I
in	O
combination	O
.	O

Pectin	O
-	O
containing	O
jelly	O
formulation	O

A	O
pharmaceutical	O
depot	O
comprising	O
(	O
i	O
)	O
5-fluoro-2-	B
[	I
[	I
(	I
1S	I
)	I
-1-	I
(	I
5-fluoro-2-pyridyl	I
)	I
ethyl	I
]	I
amino	I
]	I
-6-	I
[	I
(	I
5-isopropoxy-1H	I
-	I
pyrazol-3-yl	I
)	I
amino	I
]	I
pyridine-3-carbonitrile	I
,	O
or	O
a	O
pharmaceutically	O
-	O
acceptable	O
salt	O
thereof	O
,	O
as	O
a	O
pharmaceutical	O
agent	O
(	O
PA	O
)	O
and	O
(	O
ii	O
)	O
a	O
polymer	O
which	O
degrades	O
to	O
create	O
an	O
acidic	O
microclimate	O
,	O
wherein	O
the	O
PA	O
is	O
released	O
from	O
the	O
polymer	O
upon	O
polymer	O
degradation	O
.	O

Pharmaceutical	O
depot	O
for	O
5-fluoro-2-	B
[	I
[	I
(	I
1s	I
)	I
-1-	I
(	I
5-fluoro-2-pyridyl	I
)	I
ethyl	I
]	I
amino	I
]	I
-6-	I
[	I
(	I
5-isopropoxy-1h	I
-	I
pyrazol-3-yl	I
)	I
amino	I
]	I
pyridine-3-carbonitrile	I

A	O
composition	O
for	O
administration	O
to	O
the	O
nasal	O
mucosa	O
of	O
a	O
subject	O
comprises	O
a	O
solution	O
of	O
nicotine	B
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
in	O
a	O
pharmaceutically	O
acceptable	O
solvent	O
.	O

The	O
composition	O
has	O
a	O
nicotine	B
concentration	O
less	O
than	O
0.08	O
mg	O
/	O
ml	O
.	O

The	O
composition	O
used	O
alone	O
assists	O
in	O
reduction	O
of	O
the	O
desire	O
of	O
a	O
subject	O
to	O
smoke	O
tobacco	O
.	O

It	O
also	O
reduces	O
the	O
nasal	O
symptoms	O
associated	O
with	O
administration	O
of	O
higher	O
concentrations	O
of	O
nicotine	B
to	O
the	O
nasal	O
mucosa	O
.	O

Low	O
-	O
dose	O
,	O
non	O
-	O
irritating	O
nicotine	O
nasal	O
composition	O
to	O
reduce	O
the	O
desire	O
to	O
smoke	O

Provided	O
is	O
a	O
GIP	O
-	O
increase	O
inhibitor	O
,	O
which	O
is	O
customary	O
used	O
for	O
food	O
production	O
,	O
is	O
excellent	O
in	O
safety	O
,	O
and	O
is	O
useful	O
for	O
,	O
for	O
example	O
,	O
a	O
medicine	O
or	O
a	O
food	O
.	O

The	O
GIP	O
-	O
increase	O
inhibitor	O
contains	O
catechins	B
as	O
active	O
ingredient	O
.	O

Inhibitor	O
for	O
elevation	O
of	O
gip	O
level	O

The	O
subject	O
application	O
relates	O
to	O
methods	O
of	O
treatment	O
of	O
peripheral	O
vascular	O
disease	O
(	O
PVD	O
)	O
as	O
well	O
as	O
ischemic	O
osteonecrosis	O
,	O
peritoneal	O
ischemia	O
,	O
chronic	O
ocular	O
disease	O
,	O
macular	O
degeneration	O
,	O
or	O
diabetic	O
retinopathy	O
,	O
comprising	O
administering	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
trans	B
carotenoid	I
.	O

The	O
invention	O
also	O
relates	O
to	O
the	O
use	O
of	O
such	O
carotenoids	B
as	O
pretreatments	O
for	O
mammals	O
at	O
risk	O
of	O
an	O
ischemic	O
event	O
.	O

Use	O
of	O
bipolar	O
trans	B
carotenoids	I
as	O
a	O
pretreatment	O
and	O
in	O
the	O
treatment	O
of	O
peripheral	O
vascular	O
disease	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
crystalline	O
form	O
(	O
s	O
)	O
of	O
water	O
-	O
soluble	O
salts	O
and	O
of	O
free	O
base	O
of	O
a	O
cdk	O
inhibitor	O
.	O

Such	O
crystal	O
salts	O
are	O
for	O
example	O
fumarate	B
,	O
L	B
-	I
malate	I
,	O
maleate	B
,	O
succinate	B
,	O
adipate	B
,	O
malonate	B
,	O
glycolate	B
,	O
phosphate	B
,	O
mesylate	B
,	O
L	B
-	I
lactate	I
,	O
hydrochloride	B
,	O
di	B
-	I
hydrochloride	I
,	O
tri	B
-	I
hydrochloride	I
.	O

Hydrates	B
and	O
polymorphs	O
of	O
such	O
new	O
salt	O
forms	O
,	O
a	O
process	O
for	O
their	O
preparation	O
,	O
their	O
utility	O
in	O
therapy	O
and	O
to	O
the	O
pharmaceutical	O
compositions	O
containing	O
them	O
are	O
also	O
claimed	O
and	O
described	O
in	O
the	O
present	O
application	O
.	O

Cdk	O
inhibitor	O
salts	O

Substituted	O
spirocyclic	B
amines	I
of	O
structural	O
formula	O
I	O
are	O
selective	O
antagonists	O
of	O
the	O
somatostatin	O
sub	O
-	O
type	O
receptor	O
5	O
(	O
SSTR5	O
)	O
and	O
are	O
useful	O
for	O
the	O
treatment	O
,	O
control	O
or	O
prevention	O
of	O
disorders	O
responsive	O
to	O
antagonism	O
of	O
SSTR5	O
,	O
such	O
as	O
Type	O
2	O
diabetes	O
,	O
insulin	O
resistance	O
,	O
lipid	O
disorders	O
,	O
obesity	O
,	O
atherosclerosis	O
,	O
metabolic	O
syndrome	O
,	O
depression	O
,	O
and	O
anxiety	O
.	O

Substituted	O
spirocyclic	B
amines	I
useful	O
as	O
antidiabetic	O
compounds	O

The	O
use	O
of	O
tapentadol	B
for	O
treating	O
pain	O
due	O
to	O
osteoarthritis	O
.	O

Tapentadol	B
for	O
treating	O
pain	O
due	O
to	O
osteoarthritis	O

The	O
present	O
invention	O
provides	O
a	O
novel	O
method	O
for	O
preventing	O
and	O
treating	O
memory	O
and	O
cognitive	O
impairment	O
resulting	O
from	O
oxidative	O
stress	O
,	O
inflammation	O
and	O
the	O
process	O
of	O
aging	O
,	O
as	O
well	O
as	O
,	O
neurodegenerative	O
conditions	O
.	O

The	O
method	O
is	O
comprised	O
of	O
administering	O
a	O
composition	O
comprising	O
a	O
mixture	O
of	O
Free	O
-	O
B	O
-	O
Ring	O
flavonoids	B
and	O
flavans	B
synthesized	O
and/or	O
isolated	O
from	O
a	O
single	O
plant	O
or	O
multiple	O
plants	O
to	O
a	O
host	O
in	O
need	O
thereof	O
.	O

The	O
present	O
also	O
includes	O
a	O
novel	O
method	O
for	O
simultaneously	O
inhibiting	O
expression	O
of	O
pro	O
-	O
inflammatory	O
cytokines	O
,	O
preventing	O
ROS	O
generation	O
and	O
augmenting	O
anti	O
-	O
oxidant	O
defenses	O
.	O

The	O
activity	O
of	O
this	O
composition	O
is	O
conducive	O
to	O
ultimately	O
preserving	O
cognitive	O
function	O
and	O
providing	O
a	O
level	O
of	O
neuroprotection	O
.	O

Formulation	O
of	O
a	O
mixture	O
of	O
free	O
-	O
b	O
-	O
ring	O
flavonoids	B
and	O
flavans	B
for	O
use	O
in	O
the	O
prevention	O
and	O
treatment	O
of	O
cognitive	O
decline	O
and	O
age	O
-	O
related	O
memory	O
impairments	O

Provided	O
herein	O
is	O
an	O
optically	O
active	O
pyrozolylaminoquinazaline	B
,	O
and	O
pharmaceutical	O
compositions	O
thereof	O
.	O

Also	O
provided	O
herein	O
is	O
a	O
method	O
for	O
treating	O
,	O
preventing	O
,	O
or	O
ameliorating	O
one	O
or	O
more	O
symptoms	O
of	O
a	O
JAK	O
-	O
mediated	O
condition	O
,	O
disorder	O
,	O
or	O
disease	O
.	O

Further	O
provided	O
herein	O
is	O
a	O
method	O
for	O
treating	O
,	O
preventing	O
,	O
or	O
ameliorating	O
one	O
or	O
more	O
symptoms	O
of	O
a	O
proliferative	O
disease	O
,	O
inflammatory	O
disease	O
,	O
or	O
renal	O
disease	O
.	O

Optically	O
active	O
pyrazolylaminoquinazoline	B
,	O
and	O
pharmaceutical	O
compositions	O
and	O
methods	O
of	O
use	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
N-1-Benzyl-2-hydroxy-3-	O
(	O
hetero	O
)	O
arylamino	O
-	O
propyl	O
)	O
-isophthalamides	O
of	O
formula	O
I	O
having	O
BACE2	O
inhibitory	O
activity	O
and	O
their	O
use	O
as	O
therapeutically	O
active	O
substances	O
,	O
their	O
manufacture	O
and	O
pharmaceutical	O
compositions	O
.	O

The	O
active	O
compounds	O
of	O
the	O
present	O
invention	O
are	O
useful	O
in	O
the	O
therapeutic	O
and/or	O
prophylactic	O
treatment	O
of	O
e.g.	O
type	O
2	O
diabetes	O
.	O

Bace	O
2	O
inhibitors	O

The	O
invention	O
provides	O
polymers	O
and	O
methods	O
for	O
their	O
use	O
.	O

Certain	O
embodiments	O
of	O
the	O
invention	O
provide	O
slow	O
degrading	O
microspheres	O
for	O
undelayed	O
and	O
sustained	O
drug	O
delivery	O
.	O

Slow	O
-	O
degrading	O
polymers	O
for	O
undelayed	O
and	O
sustained	O
drug	O
delivery	O

The	O
present	O
invention	O
provides	O
biomarkers	O
which	O
are	O
predictive	O
for	O
the	O
clinical	O
benefit	O
of	O
erlotinib	B
hydrochloride	I
treatment	O
in	O
cancer	O
patients	O
.	O

Ipp	O
complex	O
as	O
marker	O
for	O
erlotinib	B
treatment	O

Methods	O
and	O
compositions	O
of	O
inhibitors	O
of	O
MAPK	O
kinases	O
1	O
and	O
2	O
(	O
MEK1	O
and	O
MEK2	O
,	O
or	O
together	O
,	O
MEK1	O
/	O
2	O
)	O
,	O
such	O
as	O
ARRY142886	O
,	O
and	O
their	O
use	O
in	O
inhibiting	O
MEK1	O
/	O
2	O
kinase	O
activity	O
in	O
mammals	O
for	O
the	O
treatment	O
and/or	O
reversal	O
of	O
the	O
symptoms	O
of	O
pulmonary	O
fibrosis	O
.	O

MEK1	O
/	O
2	O
inhibitors	O
can	O
selectively	O
inhibit	O
the	O
MAPK	O
/	O
ERK	O
pathway	O
in	O
vivo	O
and	O
prevent	O
TGF	O
-	O
	O
mediated	O
fibrosis	O
.	O

There	O
are	O
several	O
distinct	O
MAPK	O
pathways	O
that	O
are	O
important	O
in	O
the	O
regulation	O
of	O
cell	O
proliferation	O
,	O
differentiation	O
,	O
development	O
,	O
inflammation	O
,	O
survival	O
,	O
and	O
migration	O
.	O

The	O
Ras	O
-	O
Raf	O
-	O
MEK	O
-	O
ERK	O
pathway	O
(	O
a	O
key	O
component	O
of	O
the	O
MAPK	O
pathway	O
)	O
via	O
inhibition	O
of	O
MEK1	O
/	O
2	O
is	O
an	O
attractive	O
strategy	O
for	O
therapeutic	O
intervention	O
in	O
idiopathic	O
pulmonary	O
fibrosis	O
,	O
because	O
inhibition	O
of	O
MEK1	O
/	O
2	O
has	O
the	O
potential	O
to	O
block	O
inappropriate	O
signal	O
transduction	O
leading	O
to	O
pulmonary	O
fibrosis	O
,	O
regardless	O
of	O
the	O
upstream	O
position	O
of	O
the	O
aberration	O
causing	O
it	O
.	O

Methods	O
and	O
compositions	O
of	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
mapk	O
)	O
pathway	O
inhibitors	O
for	O
treating	O
pulmonary	O
fibrosis	O

The	O
present	O
invention	O
is	O
directed	O
to	O
compounds	O
of	O
Formula	O
I	O
:	O
or	O
salt	O
thereof	O
,	O
which	O
are	O
modulators	O
of	O
the	O
glucocorticoid	B
receptor	O
.	O

The	O
compounds	O
and	O
salts	O
of	O
the	O
invention	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
conditions	O
mediated	O
by	O
glucocorticoid	B
receptor	O
activity	O
.	O

Tricyclic	O
compounds	O
,	O
compositions	O
,	O
and	O
methods	O

This	O
invention	O
relates	O
to	O
the	O
manufacture	O
of	O
novel	O
chemical	O
compounds	O
which	O
have	O
biological	O
activity	O
,	O
particularly	O
to	O
novel	O
chemical	O
compounds	O
that	O
are	O
cytotoxic	O
against	O
colon	O
cancer	O
cells	O
and	O
colon	O
cancer	O
cell	O
lines	O
.	O

The	O
manufacturing	O
of	O
said	O
chemical	O
compounds	O
displaying	O
anti	O
-	O
cancer	O
properties	O
employs	O
the	O
use	O
of	O
multi	O
-	O
component	O
chemical	O
reactions	O
.	O

The	O
object	O
of	O
this	O
invention	O
is	O
to	O
manufacture	O
and	O
isolate	O
analogues	O
of	O
imidazo	O
[	O
1,2-a	O
]	O
pyridine	O
,	O
namely	O
compounds	O
of	O
Formula	O
1	O
,	O
which	O
are	O
cytotoxic	O
against	O
colon	O
cancer	O
cells	O
,	O
while	O
concomitantly	O
being	O
relatively	O
inactive	O
against	O
white	O
blood	O
cells	O
.	O

wherein	O
,	O
R	O
is	O
bromo	O
,	O
methyl	O
,	O
phenyl	O
,	O
nitro	O
,	O
hydrogen	O
or	O
an	O
amide	O
functional	O
group	O
;	O
R1	O
is	O
benzyl	O
,	O
2,6-dimethylphenyl	O
or	O
cyclohexyl	O
;	O
and	O
R2	O
is	O
methoxy	O
,	O
benzyloxy	O
or	O
hydroxy	O
.	O

Imidazo	O
[	O
1,2	O
a	O
]	O
pyridine	O
6	O
carboxamide	O
derivatives	O
,	O
their	O
use	O
for	O
the	O
treatment	O
of	O
colon	O
cancer	O
and	O
their	O
method	O
of	O
manufacture	O

The	O
invention	O
is	O
concerned	O
with	O
the	O
compounds	O
of	O
formula	O
I	O
:	O
and	O
pharmaceutically	O
acceptable	O
salts	O
and	O
esters	O
thereof	O
,	O
wherein	O
Q	O
,	O
W	O
,	O
X	O
,	O
R1-R5	O
and	O
n	O
are	O
defined	O
in	O
the	O
detailed	O
description	O
and	O
claims	O
.	O

In	O
addition	O
,	O
the	O
present	O
invention	O
relates	O
to	O
methods	O
of	O
manufacturing	O
and	O
using	O
the	O
compounds	O
of	O
formula	O
I	O
as	O
well	O
as	O
pharmaceutical	O
compositions	O
containing	O
such	O
compounds	O
.	O

The	O
compounds	O
of	O
formula	O
I	O
are	O
antagonists	O
at	O
the	O
CRTH2	O
receptor	O
and	O
may	O
be	O
useful	O
in	O
treating	O
diseases	O
and	O
disorders	O
associated	O
with	O
that	O
receptor	O
such	O
as	O
asthma	O
.	O

Aminotetrahydroindazoloacetic	B
Acids	I

5-membered	B
heteroaryl	I
derivatives	O
of	O
formula	O
(	O
I	O
)	O
or	O
salts	O
thereof	O
,	O
processes	O
for	O
their	O
preparation	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
their	O
uses	O
in	O
the	O
treatment	O
of	O
various	O
disorders	O
mediated	O
by	O
S1P1	O
receptors	O
are	O
disclosed	O
.	O

5-membered	B
heteroaryl	I
derivatives	O
used	O
as	O
sphingosine	B
1-	I
phosphate	I
receptor	O
agonists	O

Disclosed	O
in	O
certain	O
embodiments	O
is	O
a	O
pharmaceutical	O
composition	O
for	O
parenteral	O
administration	O
comprising	O
:	O
an	O
aqueous	O
solution	O
comprising	O
ketorolac	B
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
in	O
an	O
amount	O
from	O
about	O
0.1	O
mg	O
/	O
mL	O
to	O
about	O
10	O
mg	O
/	O
mL	O
;	O
and	O
a	O
pharmaceutically	O
acceptable	O
excipient	O
;	O
wherein	O
the	O
formulation	O
is	O
substantially	O
free	O
of	O
alcohol	B
.	O

Ready	O
to	O
Use	O
Ketorolac	B
Formulations	O

The	O
invention	O
relates	O
to	O
the	O
therapeutic	O
use	O
of	O
immunostimulatory	O
oligonucleotides	B
and/or	O
immunomers	O
in	O
combination	O
with	O
chemotherapeutic	O
agents	O
to	O
provide	O
a	O
synergistic	O
therapeutic	O
effect	O
.	O

Synergistic	O
treatment	O
of	O
cancer	O
using	O
immunomers	O
in	O
conjunction	O
with	O
chemotherapeutic	O
agents	O

The	O
invention	O
provides	O
compositions	O
and	O
methods	O
for	O
identifying	O
a	O
cancer	O
patient	O
suitable	O
for	O
anti	O
-	O
VEGF	O
therapy	O
.	O

After	O
determining	O
if	O
a	O
patient	O
is	O
likely	O
to	O
be	O
successfully	O
treated	O
,	O
the	O
invention	O
also	O
provides	O
methods	O
for	O
treating	O
the	O
patients	O
.	O

Gene	O
expression	O
levels	O
of	O
egfr	O
,	O
vegfr2	O
,	O
and	O
ercc1	O
associated	O
with	O
clinical	O
outcomes	O
of	O
chemotherapy	O

The	O
present	O
invention	O
relates	O
to	O
a	O
product	O
obtained	O
from	O
gastropod	O
spawn	O
,	O
to	O
be	O
used	O
to	O
prepare	O
dermatological	O
,	O
cosmetic	O
or	O
cosmeceutical	O
compositions	O
designed	O
for	O
skin	O
care	O
;	O
said	O
product	O
has	O
the	O
capacity	O
to	O
activate	O
and	O
mobilise	O
skin	O
stem	O
cells	O
,	O
as	O
well	O
as	O
prevent	O
the	O
loss	O
thereof	O
that	O
takes	O
place	O
as	O
a	O
consequence	O
of	O
chronological	O
and	O
premature	O
ageing	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
the	O
process	O
followed	O
in	O
order	O
to	O
obtain	O
said	O
product	O
.	O

Product	O
for	O
the	O
preparation	O
of	O
dermatological	O
,	O
cosmetic	O
or	O
cosmeceutical	O
compositions	O
intended	O
for	O
skin	O
treatment	O

ET-743	O
is	O
used	O
in	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
an	O
effective	O
treatment	O
of	O
a	O
tumour	O
by	O
combination	O
therapy	O
employing	O
ET-743	O
with	O
another	O
drug	O
.	O

Effective	O
Antitumor	O
Treatments	O

The	O
present	O
invention	O
generally	O
relates	O
to	O
the	O
transdermal	O
delivery	O
of	O
substances	O
In	O
one	O
aspect	O
,	O
various	O
methods	O
for	O
the	O
transdermal	O
delivery	O
of	O
beneficial	O
substances	O
are	O
disclosed	O
.	O

By	O
creating	O
a	O
hostile	O
biophysical	O
environment	O
,	O
beneficial	O
substances	O
may	O
be	O
delivered	O
,	O
according	O
to	O
certain	O
embodiments	O
,	O
through	O
the	O
stratum	O
corneum	O
of	O
the	O
skin	O
into	O
the	O
body	O
.	O

Beneficial	O
substances	O
include	O
,	O
but	O
are	O
not	O
limited	O
to	O
,	O
pharmaceutical	O
agents	O
,	O
drugs	O
,	O
vitamins	O
,	O
co	O
-	O
factors	O
,	O
peptides	O
,	O
dietary	O
supplements	O
,	O
and	O
others	O
.	O

The	O
beneficial	O
effects	O
disclosed	O
include	O
,	O
for	O
instance	O
,	O
relief	O
of	O
pain	O
and	O
inflammation	O
,	O
prevention	O
and	O
healing	O
of	O
ulcers	O
of	O
the	O
skin	O
,	O
relief	O
of	O
headache	O
,	O
improved	O
sexual	O
function	O
and	O
enjoyment	O
,	O
growth	O
of	O
hair	O
on	O
the	O
scalp	O
,	O
improving	O
muscle	O
size	O
and/or	O
function	O
,	O
removing	O
body	O
fat	O
and/or	O
cellulite	O
,	O
treating	O
cancer	O
,	O
treating	O
viral	O
infections	O
and	O
others	O
.	O

A	O
hostile	O
biophysical	O
environment	O
may	O
also	O
be	O
used	O
in	O
conjunction	O
with	O
systems	O
and	O
methods	O
for	O
increasing	O
local	O
blood	O
flow	O
,	O
according	O
to	O
one	O
set	O
of	O
embodiments	O
.	O

Transdermal	O
delivery	O
of	O
beneficial	O
substances	O
effected	O
by	O
a	O
hostile	O
biophysical	O
environment	O

Methods	O
are	O
disclosed	O
for	O
predicting	O
a	O
patient	O
response	O
to	O
anti	O
-	O
Her2	O
therapy	O
or	O
anti	O
-	O
aromatase	O
therapy	O
.	O

In	O
certain	O
embodiments	O
,	O
the	O
methods	O
involve	O
the	O
identification	O
of	O
low	O
molecular	O
weight	O
cyclin	O
E	O
(	O
LMW	O
-	O
E	O
)	O
in	O
cancers	O
,	O
such	O
as	O
breast	O
cancer	O
cells	O
,	O
as	O
a	O
predictive	O
and	O
prognostic	O
marker	O
.	O

In	O
further	O
embodiments	O
,	O
LMW	O
-	O
E	O
expression	O
by	O
a	O
cancerous	O
or	O
pre	O
-	O
cancerous	O
cell	O
may	O
be	O
used	O
to	O
predict	O
response	O
to	O
an	O
aromatase	O
inhibitor	O
and/or	O
CDK2	O
inhibitor	O
,	O
and	O
determination	O
of	O
LMW	O
-	O
E	O
expression	O
may	O
be	O
used	O
in	O
the	O
personalization	O
of	O
cancer	O
therapies	O
.	O

Low	O
molecular	O
weight	O
cyclin	O
e	O
(	O
lmw	O
-	O
e	O
)	O
as	O
a	O
biomarker	O
for	O
personalization	O
of	O
cancer	O
therapies	O

An	O
objective	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
compounds	O
that	O
can	O
effectively	O
suppress	O
the	O
concentration	O
of	O
phosphorus	B
in	O
serum	O
to	O
effectively	O
prevent	O
or	O
treat	O
diseases	O
induced	O
by	O
an	O
increase	O
in	O
concentration	O
of	O
phosphate	B
in	O
serum	O
.	O

The	O
compounds	O
according	O
to	O
the	O
present	O
invention	O
are	O
compounds	O
represented	O
by	O
formula	O
(	O
I	O
)	O
and	O
pharmaceutically	O
acceptable	O
salts	O
and	O
solvates	O
thereof	O
:	O
wherein	O
A	O
represents	O
an	O
optionally	O
substituted	O
five-	O
to	O
nine	O
-	O
membered	O
unsaturated	O
carbocyclic	B
moiety	O
or	O
a	O
five-	O
to	O
nine	O
-	O
membered	O
unsaturated	O
heterocyclic	B
moiety	O
,	O
and	O
represents	O
a	O
single	O
bond	O
or	O
a	O
double	O
bond	O
,	O
R5	O
represents	O
optionally	O
substituted	O
aryl	O
or	O
the	O
like	O
,	O
Z	O
represents	O
N	B
	I
CHR6R7	I
or	O
the	O
like	O
,	O
R6	O
and	O
R7	O
represent	O
H	B
,	O
optionally	O
substituted	O
alkyl	B
,	O
optionally	O
substituted	O
aryl	B
or	O
the	O
like	O
,	O
R101	O
and	O
R102	O
together	O
form	O
	B
O	I
,	O
and	O
R103	O
and	O
R104	O
represent	O
H	B
,	O
or	O
R101	O
and	O
R104	O
together	O
from	O
a	O
bond	O
,	O
and	O
R102	O
and	O
R103	O
together	O
form	O
a	O
bond	O
.	O

Compound	O
inhibiting	O
in	O
vivo	O
phosphorus	O
transport	O
and	O
medicine	O
containing	O
the	O
same	O

The	O
present	O
invention	O
discloses	O
compositions	O
of	O
facially	O
amphiphilic	O
compounds	O
and	O
their	O
use	O
in	O
methods	O
for	O
treating	O
or	O
reducing	O
cancers	O
in	O
animals	O
,	O
such	O
as	O
humans	O
.	O

Facially	O
Amphiphilic	O
Compounds	O
,	O
Compositions	O
,	O
And	O
Uses	O
Thereof	O
In	O
Treating	O
Cancer	O

The	O
present	O
invention	O
is	O
directed	O
to	O
quinolinone	B
compounds	O
which	O
are	O
useful	O
as	O
therapeutic	O
agents	O
for	O
the	O
treatment	O
of	O
central	O
nervous	O
system	O
disorders	O
associated	O
with	O
phosphodiesterase	O
2	O
(	O
PDE2	O
)	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
the	O
use	O
of	O
such	O
compounds	O
for	O
treating	O
neurological	O
and	O
psychiatric	O
disorders	O
,	O
such	O
as	O
schizophrenia	O
,	O
psychosis	O
or	O
Huntington	O
's	O
disease	O
,	O
and	O
those	O
associated	O
with	O
striatal	O
hypofunction	O
or	O
basal	O
ganglia	O
dysfunction	O
.	O

Quinolinone	B
PDE2	O
Inhibitors	O

Isogenic	O
human	O
cell	O
lines	O
comprising	O
at	O
least	O
one	O
mutated	O
cancer	O
allele	O
under	O
the	O
control	O
of	O
the	O
cell	O
line	O
endogenous	O
promoter	O
,	O
which	O
corresponds	O
to	O
the	O
wild	O
-	O
type	O
cancer	O
allele	O
promoter	O
are	O
disclosed	O
,	O
as	O
well	O
as	O
an	O
in	O
vitro	O
process	O
for	O
determining	O
sensitivity	O
/	O
resistance	O
of	O
a	O
patient	O
suffering	O
from	O
a	O
tumor	O
to	O
a	O
pharmacological	O
agent	O
comprising	O
the	O
following	O
steps	O
:	O
a	O
)	O
identifying	O
at	O
least	O
one	O
mutated	O
cancer	O
allele	O
in	O
a	O
tissue	O
affected	O
by	O
a	O
tumor	O
of	O
said	O
patient	O
;	O
b	O
)	O
providing	O
an	O
isogenic	O
human	O
cell	O
line	O
representative	O
of	O
the	O
tissue	O
,	O
wherein	O
the	O
cell	O
line	O
comprises	O
at	O
least	O
the	O
identified	O
mutated	O
cancer	O
allele	O
,	O
which	O
is	O
under	O
the	O
control	O
of	O
the	O
cell	O
line	O
endogenous	O
promoter	O
corresponding	O
to	O
the	O
wild	O
-	O
type	O
cancer	O
allele	O
promoter	O
;	O
c	O
)	O
putting	O
in	O
contact	O
said	O
cell	O
line	O
with	O
the	O
pharmacological	O
agent	O
;	O
d	O
)	O
determining	O
a	O
variation	O
of	O
proliferation	O
,	O
apoptosis	O
or	O
cytotoxicity	O
of	O
the	O
cell	O
line	O
in	O
presence	O
of	O
the	O
pharmacological	O
agent	O
;	O
wherein	O
the	O
variation	O
of	O
proliferation	O
,	O
apoptosis	O
car	O
cytotoxicity	O
indicative	O
of	O
the	O
sensitivity	O
/	O
resistance	O
of	O
the	O
patient	O
tumor	O
to	O
the	O
pharmacological	O
agent	O
.	O

Isogenic	O
human	O
cell	O
lines	O
comprising	O
mutated	O
cancer	O
alleles	O
and	O
process	O
using	O
the	O
cell	O
lines	O

Matrix	O
metalloproteases	O
(	O
MMPs	O
)	O
play	O
many	O
important	O
roles	O
in	O
normal	O
and	O
pathological	O
remodeling	O
processes	O
including	O
atherothrombotic	O
disease	O
,	O
inflammation	O
,	O
angiogenesis	O
and	O
cancer	O
.	O

This	O
invention	O
relates	O
to	O
the	O
activation	O
of	O
protease	O
-	O
activated	O
receptor-1	O
(	O
PAR-1	O
)	O
by	O
endogenous	O
platelet	O
MMP-1	O
collagenase	O
on	O
the	O
surface	O
of	O
platelets	O
.	O

Exposure	O
of	O
platelets	O
to	O
fibrillar	O
collagen	O
converts	O
the	O
surface	O
-	O
bound	O
pro	O
-	O
MMP-1	O
zymogen	O
to	O
active	O
MMP-1	O
,	O
which	O
promotes	O
aggregation	O
through	O
PAR-1	O
,	O
MMP-1	O
is	O
shown	O
to	O
cleave	O
the	O
PAR-1	O
extracellular	O
domain	O
at	O
a	O
novel	O
site	O
,	O
which	O
then	O
strongly	O
activates	O
Rho	O
-	O
GTP	O
signaling	O
pathways	O
,	O
cell	O
shape	O
change	O
and	O
motility	O
,	O
and	O
MAPK	O
signaling	O
.	O

Blockade	O
of	O
MMP	O
-	O
PAR	O
1	O
suppresses	O
thrombogenesis	O
under	O
arterial	O
flow	O
conditions	O
and	O
inhibited	O
thrombosis	O
in	O
animals	O
.	O

These	O
studies	O
provide	O
a	O
link	O
between	O
matrix	O
-	O
dependent	O
activation	O
of	O
metalloproteases	O
and	O
platelet	O
-	O
G	O
protein	O
signaling	O
and	O
identify	O
MMP-1	O
/	O
PAR-1	O
as	O
a	O
new	O
target	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
arterial	O
thrombosis	O
and	O
other	O
thrombotic	O
diseases	O
.	O

PAR-1	O
Activation	O
by	O
Metalloproteinase-1	O
(	O
MMP-1	O
)	O

Biomarkers	O
relating	O
to	O
glucose	O
disposal	O
rate	O
,	O
insulin	O
resistance	O
,	O
and/or	O
insulin	O
resistance	O
-	O
related	O
disorders	O
are	O
provided	O
.	O

Methods	O
based	O
on	O
the	O
same	O
biomarkers	O
are	O
also	O
provided	O
.	O

Biomarkers	O
Related	O
to	O
Insulin	O
Resistance	O
and	O
Methods	O
using	O
the	O
Same	O

The	O
present	O
invention	O
provides	O
for	O
prevention	O
and/or	O
treatment	O
of	O
neurological	O
or	O
neuropsychiatric	O
disorders	O
involving	O
abnormal	O
D1-D2	O
dopamine	O
receptor	O
coupling	O
and/or	O
activation	O
.	O

Methods	O
and	O
agents	O
are	O
provided	O
for	O
modulating	O
dopamine	O
receptor	O
function	O
arising	O
from	O
D1-D2	O
coupling	O
and/or	O
activation	O
.	O

Agents	O
of	O
the	O
present	O
invention	O
include	O
fragments	O
of	O
D2	O
receptor	O
or	O
D1	O
receptor	O
that	O
can	O
disrupt	O
D1-D2	O
coupling	O
.	O

Compositions	O
and	O
methods	O
for	O
modulating	O
d1-d2	O
dopamine	B
receptor	O
interaction	O
and	O
function	O

This	O
invention	O
relates	O
to	O
S	B
-	I
MNTX	I
,	O
methods	O
of	O
producing	O
S	B
-	I
MNTX	I
,	O
pharmaceutical	O
preparations	O
comprising	O
S	B
-	I
MNTX	I
and	O
methods	O
for	O
their	O
use	O
.	O

(	B
s	I
)	I
-n	I
-	I
methylnaltrexone	I

Disclosed	O
are	O
a	O
new	O
class	O
of	O
non	O
-	O
lipid	O
small	O
molecule	O
inhibitors	O
which	O
interfere	O
with	O
the	O
interaction	O
between	O
PIP3	B
and	O
pleckstrin	O
homology	O
domains	O
.	O

These	O
molecules	O
target	O
a	O
broad	O
range	O
of	O
PIP3-dependent	B
signaling	O
events	O
in	O
vitro	O
and	O
exert	O
significant	O
anti	O
-	O
tumor	O
activity	O
in	O
vivo	O
.	O

The	O
small	O
molecule	O
inhibitors	O
of	O
the	O
invention	O
can	O
be	O
used	O
alone	O
or	O
together	O
with	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
-related	O
apoptosis	O
-	O
inducing	O
ligand	O
(	O
TRAIL	O
)	O
or	O
other	O
cancer	O
medicament	O
to	O
treat	O
cancer	O
.	O

Small	O
molecule	O
inhibitors	O
of	O
the	O
invention	O
act	O
synergistically	O
in	O
combination	O
with	O
TRAIL	O
in	O
treating	O
cancer	O
.	O

Pharmaceutical	O
compositions	O
and	O
methods	O
for	O
treating	O
cancer	O
are	O
provided	O
.	O

Small	O
Molecule	O
Antagonists	O
of	O
Phosphatidylinositol-3,4,5-Triphosphate	B
(	O
PIP3	B
)	O
and	O
Uses	O
Thereof	O

A	O
method	O
for	O
preventing	O
,	O
reducing	O
,	O
ameliorating	O
or	O
treating	O
ophthalmic	O
disorders	O
associated	O
with	O
neurodegenerative	O
diseases	O
or	O
trauma	O
,	O
comprising	O
the	O
topical	O
,	O
periocular	O
,	O
or	O
intraocular	O
application	O
of	O
an	O
ophthalmic	O
formulation	O
comprising	O
a	O
therapeutically	O
effective	O
amount	O
of	O
one	O
or	O
more	O
ophthalmic	O
agents	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
alpha	B
-	I
tocotrienol	I
,	O
beta	B
-	I
tocotrienol	I
,	O
gamma	B
-	I
tocotrienol	I
,	O
delta	B
-	I
tocotrienol	I
,	O
or	O
esters	O
or	O
mixtures	O
thereof	O
is	O
disclosed	O
.	O

Use	O
of	O
tocotrienols	B
for	O
the	O
prevention	O
,	O
reduction	O
,	O
amelioration	O
or	O
treatment	O
of	O
ophthalmic	O
disorders	O
that	O
are	O
,	O
or	O
that	O
are	O
associated	O
with	O
,	O
mitochondrial	O
diseases	O
is	O
also	O
discussed	O
.	O

Topical	O
ophthalmic	O
formulations	O
comprising	O
tocotrienols	B
are	O
also	O
discussed	O
.	O

Topical	O
,	O
periocular	O
,	O
or	O
intraocular	O
use	O
of	O
tocotrienols	B
for	O
the	O
treatment	O
of	O
ophthalmic	O
diseases	O

The	O
invention	O
relates	O
to	O
compounds	O
which	O
activate	O
the	O
BASIGIN	O
signaling	O
pathway	O
,	O
preferably	O
agonists	O
of	O
BASIGIN	O
,	O
for	O
the	O
treatment	O
of	O
neurodegenerative	O
disorders	O
.	O

Method	O
and	O
Pharmaceutical	O
Composition	O
for	O
Use	O
in	O
the	O
Treatment	O
of	O
Neurodegenerative	O
Disorders	O

A	O
composition	O
for	O
delivering	O
edible	O
salts	O
into	O
food	O
products	O
via	O
microcapsules	O
having	O
a	O
protein	O
-	O
polysaccharide	O
shell	O
matrix	O
and	O
an	O
edible	O
salt	O
-	O
containing	O
active	O
material	O
.	O

A	O
method	O
of	O
treating	O
osteoporosis	O
is	O
also	O
disclosed	O
.	O

Microcapsules	O
containing	O
salts	O
for	O
food	O
products	O

The	O
present	O
invention	O
is	O
a	O
biomarker	O
of	O
chemotherapeutic	O
drug	O
-	O
resistant	O
cancer	O
stem	O
cells	O
and	O
a	O
method	O
of	O
inhibiting	O
the	O
growth	O
of	O
drug	O
-	O
resistant	O
cancer	O
stem	O
cells	O
.	O

In	O
one	O
embodiment	O
the	O
cancer	O
stem	O
cells	O
are	O
testicular	O
cancer	O
germ	O
cells	O
.	O

In	O
another	O
embodiment	O
the	O
present	O
invention	O
is	O
a	O
method	O
of	O
overcoming	O
drug	O
resistance	O
in	O
cancer	O
treatment	O
where	O
the	O
combination	O
of	O
low	O
dose	O
decitabine	O
and	O
administration	O
of	O
a	O
chemotherapeutic	O
drug	O
to	O
which	O
cancer	O
cells	O
were	O
resistant	O
results	O
in	O
successful	O
cancer	O
treatment	O
.	O

Compositions	O
for	O
Inhibiting	O
Growth	O
of	O
Cancer	O
Stem	O
Cells	O

Compositions	O
and	O
methods	O
of	O
preparing	O
and	O
using	O
such	O
compositions	O
to	O
treat	O
the	O
symptoms	O
of	O
herpes	O
virus	O
.	O

Homeopathic	O
Formulations	O
For	O
Treatment	O
Of	O
Herpes	O
Virus	O
Symptoms	O

Compounds	O
that	O
selectively	O
inhibit	O
pathological	O
production	O
of	O
human	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
and	O
compositions	O
comprising	O
such	O
Compounds	O
are	O
described	O
.	O

Compounds	O
that	O
inhibit	O
viral	O
replication	O
or	O
the	O
production	O
of	O
viral	O
RNA	O
or	O
DNA	O
or	O
viral	O
protein	O
and	O
compositions	O
comprising	O
such	O
Compounds	O
are	O
described	O
.	O

Also	O
described	O
are	O
methods	O
of	O
reducing	O
VEGF	O
using	O
such	O
Compounds	O
and	O
methods	O
for	O
treating	O
cancer	O
and	O
non	O
-	O
neoplastic	O
conditions	O
involving	O
the	O
administration	O
of	O
such	O
Compounds	O
.	O

Further	O
described	O
are	O
methods	O
of	O
inhibiting	O
viral	O
replication	O
or	O
the	O
production	O
of	O
viral	O
RNA	O
or	O
DNA	O
or	O
viral	O
protein	O
using	O
such	O
Compounds	O
and	O
methods	O
for	O
treating	O
viral	O
infections	O
involving	O
the	O
administration	O
of	O
such	O
Compounds	O
.	O

The	O
Compounds	O
may	O
be	O
administered	O
as	O
a	O
single	O
agent	O
therapy	O
or	O
in	O
combination	O
with	O
one	O
or	O
more	O
additional	O
therapies	O
to	O
a	O
human	O
in	O
need	O
of	O
such	O
treatments	O
.	O

Methods	O
for	O
treating	O
cancer	O
and	O
non	O
-	O
neoplastic	O
conditions	O

The	O
present	O
invention	O
relates	O
to	O
chemistry	O
and	O
pharmacy	O
and	O
,	O
in	O
particular	O
,	O
to	O
the	O
production	O
of	O
novel	O
molecular	O
entities	O
,	O
tricyclic	B
and	O
tetracyclic	B
derivatives	O
of	O
benzodiazepine	B
,	O
pyridodiazepine	B
and	O
pyrimidodiazepine	B
type	O
fused	O
with	O
1,4-dihydropyridine	B
derivatives	O
,	O
having	O
an	O
effect	O
on	O
the	O
central	O
-	O
nervous	O
and	O
vascular	O
systems	O
.	O

Derivatives	O
containing	O
a	O
dihydropyridine	B
ring	O
are	O
used	O
,	O
by	O
means	O
of	O
reactions	O
with	O
compounds	O
of	O
the	O
ortho	B
-	I
phenylenediamine	I
,	O
ortho	B
-	I
diaminopyridine	I
and	O
ortho	B
-	I
diaminopyrimidine	I
type	O
,	O
and	O
also	O
subsequent	O
conversions	O
to	O
some	O
thereof	O
,	O
to	O
obtain	O
tricyclic	B
and	O
tetracyclic	B
derivatives	O
of	O
general	O
formula	O
I	O
-	O
XII	O
that	O
contain	O
a	O
diazepine	B
or	O
diazepinone	B
nucleus	O
fused	O
to	O
a	O
1,4-dihydropyridine	B
nucleus	O
,	O
in	O
which	O
the	O
A	O
ring	O
is	O
a	O
substituted	O
or	O
unsubstituted	O
benzene	B
,	O
pyridine	B
or	O
pyrimidine	B
ring	O
.	O

These	O
molecular	O
entities	O
exhibit	O
GABAergica	O
and	O
modulating	O
action	O
in	O
the	O
case	O
of	O
calcium	B
channels	O
which	O
can	O
be	O
used	O
in	O
the	O
treatment	O
of	O
cardiovascular	O
,	O
cerebrovascular	O
,	O
neurodegenerative	O
,	O
neuropsychiatric	O
and	O
neurological	O
disorders	O
.	O

Tricyclic	B
and	O
Tetracyclic	B
Systems	O
with	O
Activity	O
on	O
the	O
Central	O
Nervous	O
and	O
Vascular	O
Systems	O

Described	O
herein	O
is	O
an	O
improved	O
method	O
of	O
treating	O
overactive	O
bladder	O
,	O
wherein	O
the	O
method	O
comprises	O
administering	O
to	O
a	O
patient	O
in	O
need	O
thereof	O
a	O
beta	O
3	O
adrenergic	O
receptor	O
agonist	O
,	O
an	O
antimuscarinic	O
agent	O
,	O
and	O
an	O
optional	O
selective	O
M2	O
antagonist	O
.	O

Such	O
combination	O
therapy	O
provides	O
improved	O
efficacy	O
and/or	O
reduced	O
side	O
effects	O
.	O

Combination	O
therapy	O
using	O
a	O
beta	O
3	O
adrenergic	O
receptor	O
agonists	O
and	O
an	O
antimuscarinic	O
agent	O

The	O
present	O
invention	O
relates	O
to	O
a	O
compound	O
or	O
a	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
having	O
an	O
excellent	O
DGAT	O
inhibitory	O
effect	O
and	O
feeding	O
suppressant	O
effect	O
.	O

The	O
present	O
invention	O
provides	O
trans-6-	B
[	I
3-	I
(	I
2,4-difluoro	I
-	I
phenyl	I
)	I
-ureido	I
]	I
-3,4-dihydro-1H	I
-	I
isoquinoline-2-carboxylic	I
acid	I
4-carboxymethyl	I
-	I
cyclohexyl	I
ester	I
,	O
trans-6-	B
[	I
3-	I
(	I
2-chloro	I
-	I
phenyl	I
)	I
-ureido	I
]	I
-3,4-dihydro-1H	I
-	I
isoquinoline-2-carboxylic	I
acid	I
4-carboxymethyl	I
-	I
cyclohexyl	I
ester	I
,	O
trans-6-	B
[	I
3-	I
(	I
2,3-difluoro	I
-	I
phenyl	I
)	I
-ureido	I
]	I
-3,4-dihydro-1H	I
-	I
isoquinoline-2-carboxylic	I
acid	I
4-carboxymethyl	I
-	I
cyclohexyl	I
ester	I
,	I
trans-6-	I
[	I
3-	I
(	I
2,5-difluoro	I
-	I
phenyl	I
)	I
-ureido	I
]	I
-3,4-dihydro-1H	I
-	I
isoquinoline-2-carboxylic	I
acid	I
4-carboxymethyl	I
-	I
cyclohexyl	I
ester	I
,	I
trans-6-	B
[	I
3-	I
(	I
2,6-difluoro	I
-	I
phenyl	I
)	I
-ureido	I
]	I
-3,4-dihydro-1H	I
-	I
isoquinoline-2-carboxylic	I
acid	I
4-carboxymethyl	I
-	I
cyclohexyl	I
ester	I
,	O
or	O
the	O
like	O
,	O
or	O
a	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
.	O

Novel	O
Tetrahydroisoquinoline	O
Compounds	O

Novel	O
methods	O
for	O
biological	O
effective	O
,	O
stable	O
amorphous	O
and	O
monoclinic	O
selenium	B
nanoparticles	O
are	O
disclosed	O
.	O

They	O
are	O
prepared	O
by	O
reacting	O
selenium	B
source	O
with	O
a	O
reducing	O
agent	O
or	O
an	O
oxidative	O
agent	O
in	O
an	O
aqueous	O
media	O
at	O
a	O
temperature	O
between	O
0	O
-	O
100	O
	O
C.	O
in	O
the	O
presence	O
of	O
selenium	B
binding	O
polymer	O
molecules	O
such	O
as	O
poly	O
/	O
oligopeptide	O
acids	O
or	O
peptone	O
or	O
nucleic	O
acids	O
or	O
poly	O
/	O
oligosaccharide	O
or	O
their	O
mixtures	O
.	O

Selenium	B
Nanoparticles	O
with	O
Improvded	O
Biological	O
Effects	O

The	O
present	O
invention	O
provides	O
methods	O
of	O
treating	O
,	O
reducing	O
,	O
and/or	O
preventing	O
the	O
incidence	O
of	O
an	O
influenza	O
related	O
viral	O
infection	O
in	O
a	O
patient	O
comprising	O
administering	O
a	O
therapeutically	O
effective	O
amount	O
of	O
an	O
oxidative	O
reductive	O
potential	O
(	O
ORP	O
)	O
water	O
solution	O
.	O

The	O
present	O
invention	O
also	O
provides	O
methods	O
of	O
reducing	O
or	O
preventing	O
the	O
incidence	O
of	O
an	O
influenza	O
related	O
viral	O
infection	O
in	O
a	O
patient	O
associated	O
with	O
a	O
medical	O
device	O
comprising	O
contacting	O
the	O
medical	O
device	O
with	O
an	O
effective	O
amount	O
of	O
an	O
ORP	O
water	O
solution	O
.	O

Methods	O
of	O
treating	O
or	O
preventing	O
influenza	O
associated	O
illness	O
with	O
oxidative	O
reductive	O
potential	O
water	O
solutions	O

The	O
invention	O
provides	O
compositions	O
for	O
controlled	O
delivery	O
and/or	O
containment	O
of	O
therapeutic	O
and/or	O
diagnostic	O
agents	O
comprising	O
the	O
agent	O
or	O
agents	O
encapsulated	O
by	O
a	O
matrix	O
containing	O
chitosan	O
,	O
polyethylene	B
glycol	I
(	O
PEG	B
)	O
and/or	O
polyvinyl	B
alcohol	I
(	O
PVA	B
)	O
,	O
and	O
tetra	B
-	I
methoxy	I
-	I
ortho	I
-	I
silicate	I
(	O
TMOS	B
)	O
or	O
tetra	B
-	I
ethoxy	I
-	I
ortho	I
-	I
silicate	I
(	O
TEOS	B
)	O
,	O
as	O
well	O
as	O
methods	O
for	O
preparing	O
the	O
compositions	O
,	O
and	O
uses	O
of	O
the	O
compositions	O
for	O
therapy	O
and	O
imaging	O
.	O

Versatile	O
nanoparticulate	O
biomaterial	O
for	O
controlled	O
delivery	O
and/or	O
containment	O
of	O
therapeutic	O
and	O
diagnostic	O
material	O

The	O
present	O
invention	O
discloses	O
compositions	O
of	O
omega	O
polyunsaturated	O
fatty	B
acids	I
for	O
controlling	O
and	O
preventing	O
dental	O
caries	O
resulting	O
from	O
oral	O
infections	O
.	O

The	O
compositions	O
of	O
fatty	B
acids	I
include	O
omega-3	B
fatty	I
acids	I
,	O
omega-6	B
fatty	I
acids	I
,	O
and	O
other	O
fatty	B
acids	I
,	O
for	O
their	O
synergistic	O
bioactivity	O
against	O
cariogenic	O
pathogens	O
.	O

The	O
application	O
of	O
this	O
composition	O
can	O
be	O
used	O
for	O
the	O
preparation	O
of	O
drugs	O
,	O
nutritional	O
supplements	O
,	O
food	O
and	O
daily	O
necessities	O
with	O
oral	O
health	O
care	O
and	O
therapeutic	O
effects	O
.	O

Compositions	O
of	O
omega	O
fatty	B
acids	I
for	O
the	O
prevention	O
and	O
treatment	O
of	O
dental	O
caries	O
resulting	O
from	O
oral	O
infections	O

The	O
present	O
invention	O
is	O
directed	O
to	O
compounds	O
of	O
Formulae	O
(	O
I	O
)	O
,	O
(	O
II	O
)	O
,	O
(	O
III	O
)	O
,	O
(	O
IV	O
)	O
,	O
(	O
V	O
)	O
,	O
(	O
VI	O
)	O
,	O
(	O
VII	O
)	O
,	O
and	O
(	O
VIII	O
)	O
,	O
pharmaceutical	O
compositions	O
thereof	O
and	O
methods	O
of	O
use	O
thereof	O
in	O
the	O
treatment	O
of	O
conditions	O
associated	O
with	O
a	O
dysfunction	O
in	O
proteostasis	O
.	O

Proteostasis	O
regulators	O

Herein	O
is	O
described	O
the	O
use	O
of	O
a	O
collection	O
of	O
50	O
breast	O
cancer	O
cell	O
lines	O
to	O
match	O
responses	O
to	O
77	O
conventional	O
and	O
experimental	O
therapeutic	O
agents	O
with	O
transcriptional	O
,	O
proteomic	O
and	O
genomic	O
subtypes	O
found	O
in	O
primary	O
tumors	O
.	O

Almost	O
all	O
compounds	O
produced	O
strong	O
differential	O
responses	O
across	O
the	O
cell	O
lines	O
produced	O
responses	O
that	O
were	O
associated	O
with	O
transcriptional	O
and	O
proteomic	O
subtypes	O
and	O
produced	O
responses	O
that	O
were	O
associated	O
with	O
recurrent	O
genome	O
copy	O
number	O
abnormalities	O
.	O

These	O
associations	O
can	O
now	O
be	O
incorporated	O
into	O
clinical	O
trials	O
that	O
test	O
subtype	O
markers	O
and	O
clinical	O
responses	O
simultaneously	O
.	O

Molecular	O
Predictors	O
of	O
Therapeutic	O
Response	O
to	O
Specific	O
Anti	O
-	O
Cancer	O
Agents	O

The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
of	O
regulating	O
the	O
expression	O
level	O
of	O
survival	O
of	O
motor	O
neuron	O
1	O
(	O
SMN1	O
)	O
comprising	O
administering	O
to	O
a	O
subject	O
in	O
need	O
thereof	O
a	O
therapeutically	O
effective	O
amount	O
of	O
ubiquitin	O
carboxyl	B
-	O
terminal	O
hydrolase	O
L1	O
(	O
UCHL1	O
)	O
regulator	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
a	O
method	O
of	O
detecting	O
enzyme	O
activity	O
of	O
ubiquitin	O
carboxyl	B
-	O
terminal	O
hydrolase	O
L1	O
(	O
UCHL1	O
)	O
in	O
human	O
fibroblasts	O
comprising	O
detecting	O
protein	O
expression	O
level	O
of	O
survival	O
of	O
motor	O
neuron	O
1	O
(	O
SMN1	O
)	O
.	O

Method	O
of	O
regulating	O
the	O
expression	O
level	O
of	O
survival	O
of	O
motor	O
neuron	O
1	O
(	O
smn1	O
)	O
and	O
detecting	O
enzyme	O
activity	O
of	O
ubiquitin	O
carboxyl	B
-	O
terminal	O
hydrolase	O
l1	O
(	O
uchl1	O
)	O

Methods	O
for	O
modulating	O
gene	O
expression	O
in	O
a	O
skin	O
cell	O
by	O
administering	O
to	O
the	O
cell	O
an	O
amount	O
of	O
a	O
therapeutic	O
composition	O
in	O
an	O
amount	O
sufficient	O
to	O
modulate	O
the	O
expression	O
of	O
miR-1	O
,	O
and	O
therapeutic	O
compositions	O
and	O
uses	O
thereof	O
are	O
disclosed	O
.	O

Anti	O
-	O
miR-1	O
Therapy	O
for	O
Wound	O
Healing	O

The	O
present	O
invention	O
provides	O
a	O
stable	O
composition	O
of	O
rasagiline	B
comprising	O
an	O
effective	O
dosage	O
of	O
rasagiline	B
or	O
its	O
pharmaceutically	O
acceptable	O
salts	O
and	O
an	O
antioxidant	O
used	O
as	O
a	O
stabilizer	O
.	O

The	O
dosage	O
forms	O
of	O
the	O
composition	O
are	O
pharmaceutically	O
common	O
transdermal	O
-	O
drug	O
delivery	O
dosage	O
form	O
and	O
mucoadhesive	O
delivery	O
dosage	O
form	O
,	O
such	O
as	O
patch	O
,	O
gel	O
,	O
ointment	O
,	O
cream	O
,	O
cataplasm	O
,	O
film	O
,	O
spray	O
and	O
solution	O
,	O
etc	O
.	O

The	O
composition	O
can	O
be	O
used	O
to	O
prevent	O
or	O
treat	O
mental	O
disorders	O
.	O

Stable	O
rasagiline	B
composition	O

The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
of	O
reducing	O
the	O
production	O
of	O
glutamate	B
from	O
glutamine	B
by	O
glutaminase	O
C	O
in	O
a	O
cell	O
or	O
tissue	O
.	O

The	O
method	O
involves	O
inhibiting	O
glutaminase	O
C	O
activity	O
in	O
the	O
cell	O
or	O
tissue	O
under	O
conditions	O
effective	O
to	O
reduce	O
production	O
of	O
glutamate	B
from	O
glutamine	B
.	O

Compounds	O
for	O
carrying	O
out	O
this	O
method	O
are	O
also	O
disclosed	O
.	O

Inhibitions	O
of	O
glutaminase	O
c	O

The	O
invention	O
consists	O
of	O
a	O
rapidly	O
crosslinkable	O
,	O
two	O
-	O
component	O
silicone	B
elastomer	O
together	O
with	O
a	O
specially	O
designed	O
tray	O
that	O
serves	O
as	O
a	O
form	O
for	O
the	O
silicone	B
resin	O
and	O
forms	O
an	O
integral	O
portion	O
of	O
a	O
dental	O
appliance	O
.	O

Novel	O
dental	O
appliances	O
and	O
methods	O
for	O
their	O
fabrication	O

The	O
present	O
invention	O
provides	O
polymers	O
,	O
compositions	O
thereof	O
,	O
and	O
polyplexes	O
comprising	O
said	O
polymers	O
.	O

In	O
particular	O
,	O
cationic	O
polymers	O
,	O
pegylated	O
versions	O
thereof	O
,	O
and	O
polynucleotide	O
containing	O
polyplexes	O
comprising	O
such	O
polymers	O
are	O
provided	O
.	O

The	O
invention	O
further	O
provides	O
methods	O
of	O
using	O
said	O
polymers	O
and	O
polyplexes	O
.	O

Pegylated	O
polyplexes	O
containing	O
two	O
or	O
more	O
different	O
polymers	O
for	O
polynucleotide	O
delivery	O

Methods	O
of	O
preparing	O
bioactive	O
composites	O
are	O
described	O
.	O

Also	O
described	O
are	O
methods	O
of	O
molding	O
such	O
composites	O
.	O

Shaped	O
bodies	O
comprising	O
bioactive	O
composites	O
are	O
further	O
described	O
.	O

Bioactive	O
Load	O
-	O
Bearing	O
Composites	O

The	O
method	O
of	O
treating	O
a	O
person	O
having	O
a	O
cancer	O
selected	O
from	O
carcinoma	O
,	O
sarcoma	O
or	O
hematopoietic	O
cancer	O
by	O
administering	O
(	O
a	O
)	O
an	O
effective	O
amount	O
of	O
at	O
least	O
one	O
anti	O
-	O
cancer	O
drug	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
an	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
inhibitor	O
,	O
a	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
(	O
VEGFR	O
)	O
inhibitor	O
and	O
a	O
Raf	O
kinase	O
inhibitor	O
and	O
(	O
b	O
)	O
an	O
effective	O
amount	O
of	O
5-	B
(	I
4-	I
(	I
6-	I
(	I
4-amino-3,5-dimethyl	I
-	I
phenoxy	I
)	I
-1-methyl-1H	I
-	I
benzimidazol-2-ylmethoxy	I
)	I
-benzyl	I
)	I
-thiazolidine-2,4-dione.dihydrochloride	I
provided	O
that	O
said	O
carcinoma	O
is	O
not	O
lung	O
cancer	O
when	O
an	O
EGFR	O
inhibitor	O
is	O
erlotinib	O
.	O

The	O
invention	O
also	O
provides	O
a	O
pharmaceutical	O
composition	O
that	O
may	O
be	O
used	O
in	O
practicing	O
said	O
method	O
.	O

Method	O
of	O
treating	O
cancers	O
and	O
a	O
pharmaceutical	O
composition	O
that	O
may	O
be	O
used	O
in	O
practicing	O
said	O
method	O

Provided	O
are	O
compounds	O
that	O
are	O
capable	O
of	O
modulating	O
the	O
activity	O
of	O
the	O
influenza	O
A	O
virus	O
via	O
interaction	O
with	O
the	O
M2	O
transmembrane	O
protein	O
.	O

Also	O
provided	O
are	O
methods	O
for	O
treating	O
an	O
influenza	O
A	O
-	O
affected	O
disease	O
state	O
or	O
infection	O
comprising	O
administering	O
a	O
composition	O
comprising	O
one	O
or	O
more	O
compounds	O
that	O
have	O
been	O
identified	O
as	O
being	O
capable	O
of	O
interaction	O
with	O
the	O
M2	O
protein	O
.	O

Adamantane	B
analogs	O

The	O
present	O
invention	O
provides	O
a	O
method	O
of	O
suppressing	O
the	O
bitter	O
taste	O
of	O
a	O
drug	O
when	O
a	O
rapidly	O
disintegrating	O
tablet	O
in	O
an	O
oral	O
cavity	O
is	O
produced	O
.	O

When	O
a	O
rapidly	O
disintegrating	O
tablet	O
in	O
an	O
oral	O
cavity	O
is	O
produced	O
,	O
the	O
bitter	O
taste	O
of	O
a	O
drug	O
is	O
suppressed	O
by	O
utilizing	O
(	O
a	O
)	O
a	O
granule	O
which	O
contains	O
a	O
drug	O
having	O
a	O
bitter	O
taste	O
and	O
an	O
excipient	O
and	O
in	O
which	O
the	O
bitter	O
taste	O
has	O
not	O
been	O
suppressed	O
and	O
(	O
b	O
)	O
a	O
granule	O
containing	O
a	O
water	O
soluble	O
saccharide	O
.	O

Rapidly	O
disintegrating	O
tablet	O
in	O
oral	O
cavity	O

This	O
invention	O
relates	O
to	O
microgel	O
compositions	O
,	O
and	O
in	O
particular	O
,	O
to	O
gel	O
compositions	O
formed	O
by	O
binding	O
a	O
plurality	O
of	O
individual	O
microgel	O
particles	O
together	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
processes	O
for	O
the	O
preparation	O
of	O
these	O
compositions	O
and	O
their	O
use	O
for	O
particular	O
applications	O
,	O
especially	O
medical	O
applications	O
such	O
as	O
the	O
repair	O
of	O
damaged	O
,	O
degenerated	O
or	O
inappropriately	O
formed	O
load	O
-	O
bearing	O
tissue	O
(	O
such	O
as	O
,	O
for	O
example	O
,	O
intervertebral	O
discs	O
)	O
.	O

Microgel	O
compositions	O

Compositions	O
of	O
apatite	O
derivative	O
crystals	O
are	O
disclosed	O
herein	O
.	O

Also	O
disclosed	O
are	O
methods	O
of	O
using	O
these	O
compositions	O
to	O
treat	O
tooth	O
sensitivity	O
,	O
to	O
use	O
as	O
an	O
anticaries	O
treatment	O
,	O
to	O
use	O
as	O
a	O
restorative	O
material	O
,	O
to	O
use	O
as	O
a	O
tooth	O
surface	O
whitener	O
,	O
and	O
to	O
combat	O
or	O
lessen	O
the	O
side	O
effects	O
of	O
tooth	O
whitening	O
.	O

Compositions	O
of	O
Apatite	O
and	O
Methods	O
of	O
Use	O

Compositions	O
are	O
disclosed	O
of	O
combinations	O
of	O
small	O
interfering	O
RNAs	O
(	O
siRNA	O
)	O
that	O
can	O
inhibit	O
the	O
replication	O
of	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
in	O
liver	O
cells	O
,	O
along	O
with	O
methods	O
of	O
co	O
-	O
administering	O
the	O
siRNAs	O
to	O
subjects	O
.	O

Further	O
,	O
methods	O
are	O
disclosed	O
for	O
improving	O
the	O
delivery	O
of	O
nucleic	O
acids	O
to	O
the	O
liver	O
.	O

Inhibiting	O
hepatitis	O
c	O
viral	O
replication	O
with	O
sirna	O
combinations	O

Disclosed	O
are	O
a	O
novel	O
5-membered	B
heterocycle	I
derivatives	O
of	O
Formula	O
I	O
,	O
a	O
tautomer	O
,	O
pharmaceutically	O
acceptable	O
salt	O
,	O
prodrug	O
thereof	O
and	O
a	O
pharmaceutical	O
use	O
thereof	O
.	O

The	O
5-membered	B
heterocycle	I
derivatives	O
of	O
Formula	O
I	O
,	O
a	O
tautomer	O
,	O
pharmaceutically	O
acceptable	O
salt	O
,	O
prodrug	O
thereof	O
and	O
compositions	O
containing	O
them	O
are	O
useful	O
for	O
treating	O
a	O
tumor	O
.	O

5-membered	B
heterocycle	I
derivatives	O
and	O
manufacturing	O
process	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
for	O
preventing	O
or	O
treating	O
obesity	O
,	O
diabetes	O
,	O
dyslipidemia	O
,	O
fatty	O
liver	O
or	O
insulin	O
resistance	O
syndrome	O
,	O
comprising	O
:	O
administering	O
to	O
a	O
mammalian	O
subject	O
in	O
need	O
thereof	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
composition	O
comprising	O
adipic	B
acid	I
.	O

The	O
present	O
composition	O
containing	O
adipic	B
acid	I
as	O
an	O
active	O
ingredient	O
is	O
very	O
effective	O
in	O
preventing	O
or	O
treating	O
obesity	O
,	O
diabetes	O
,	O
dyslipidemia	O
,	O
fatty	O
liver	O
(	O
preferably	O
,	O
non	O
-	O
alcoholic	O
fatty	O
liver	O
)	O
or	O
insulin	O
resistance	O
syndrome	O
.	O

The	O
composition	O
of	O
the	O
present	O
invention	O
useful	O
as	O
pharmaceuticals	O
compositions	O
or	O
functional	O
food	O
compositions	O
has	O
therapeutic	O
efficacies	O
for	O
obesity	O
,	O
dyslipidemia	O
or	O
fatty	O
liver	O
,	O
and	O
also	O
induces	O
significant	O
decrease	O
in	O
fasting	O
glucose	B
level	O
and	O
blood	O
insulin	O
level	O
to	O
improve	O
type	O
2	O
diabetes	O
,	O
insulin	O
resistance	O
and	O
related	O
metabolic	O
diseases	O
.	O

Novel	O
uses	O
of	O
adipic	B
acid	I

A	O
pharmaceutical	O
composition	O
comprising	O
a	O
vitamin	B
D	I
derivative	O
or	O
analogue	O
as	O
the	O
active	O
ingredient	O
dissolved	O
in	O
a	O
three	O
-	O
component	O
surfactant	O
-	O
solvent	O
mixture	O
is	O
useful	O
in	O
the	O
treatment	O
of	O
dermal	O
disorders	O
or	O
conditions	O
.	O

Cutaneous	O
composition	O
comprising	O
vitamin	B
d	I
analogue	O
and	O
a	O
mixture	O
of	O
solvent	O
and	O
surfactants	O

A	O
pharmaceutical	O
kit	O
for	O
treating	O
neuronal	O
damages	O
is	O
disclosed	O
.	O

The	O
pharmaceutical	O
composition	O
of	O
the	O
present	O
invention	O
comprises	O
:	O
a	O
first	O
pharmaceutical	O
composition	O
comprising	O
a	O
first	O
effective	O
amount	O
of	O
a	O
Mg2	B
+	I
-containing	O
compound	O
;	O
and	O
a	O
second	O
pharmaceutical	O
composition	O
comprising	O
a	O
second	O
effective	O
amount	O
of	O
a	O
COX-2	O
inhibitor	O
.	O

Pharmaceutical	O
kit	O
for	O
treating	O
neuronal	O
damages	O

The	O
present	O
invention	O
relates	O
to	O
a	O
new	O
splice	O
variant	O
of	O
BANK1	O
,	O
the	O
use	O
of	O
SNPs	O
in	O
BANK1	O
for	O
diagnostics	O
and	O
the	O
use	O
of	O
antagonists	O
to	O
modulate	O
BANK1	O
and/or	O
the	O
BANK1	O
pathway	O
.	O

Nucleic	O
acid	O
molecules	O
encoding	O
bank1	O
splice	O
variants	O

A	O
hydrogel	O
polymer	O
includes	O
a	O
ceragenin	B
compound	O
.	O

The	O
ceragenin	B
compound	O
has	O
a	O
hydrophobicity	O
/	O
hydrophilicity	O
that	O
produces	O
a	O
release	O
rate	O
in	O
a	O
range	O
of	O
0.1	O
-	O
100	O
g	O
/	O
ml	O
for	O
at	O
least	O
3	O
days	O
.	O

Hydrogel	O
materials	O
incorporating	O
eluting	O
ceragenin	B
compound	O

An	O
aqueous	O
pharmaceutical	O
composition	O
containing	O
tapentadol	B
or	O
a	O
physiologically	O
acceptable	O
salt	O
thereof	O
and	O
being	O
adapted	O
for	O
oral	O
administration	O
.	O

The	O
composition	O
has	O
excellent	O
storage	O
stability	O
without	O
relying	O
on	O
the	O
presence	O
of	O
high	O
amounts	O
of	O
preservatives	O
.	O

Aqueous	O
Pharmaceutical	O
Formulation	O
of	O
Tapentadol	B
for	O
Oral	O
Administration	O

The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
for	O
determining	O
the	O
redox	O
status	O
of	O
a	O
cell	O
or	O
tissue	O
comprising	O
a	O
step	O
consisting	O
of	O
determining	O
the	O
level	O
of	O
PML	O
nuclear	O
bodies	O
in	O
said	O
cell	O
or	O
tissue	O
.	O

Promyelocytic	O
leukemia	O
protein	O
as	O
a	O
redox	O
sensor	O

An	O
intravascular	O
stent	O
and	O
method	O
for	O
inhibiting	O
restenosis	O
,	O
following	O
vascular	O
injury	O
,	O
is	O
disclosed	O
.	O

The	O
stent	O
has	O
an	O
expandable	O
,	O
linked	O
-	O
filament	O
body	O
and	O
a	O
drug	O
-	O
release	O
coating	O
formed	O
on	O
the	O
stent	O
-	O
body	O
filaments	O
,	O
for	O
contacting	O
the	O
vessel	O
injury	O
site	O
when	O
the	O
stent	O
is	O
placed	O
in	O
-	O
situ	O
in	O
an	O
expanded	O
condition	O
.	O

The	O
coating	O
releases	O
,	O
for	O
a	O
period	O
of	O
at	O
least	O
4	O
weeks	O
,	O
a	O
restenosis	O
-	O
inhibiting	O
amount	O
of	O
a	O
monocyclic	B
triene	I
immunosuppressive	O
compound	O
having	O
an	O
alkyl	B
group	O
substituent	O
at	O
carbon	B
position	O
40	O
in	O
the	O
compound	O
.	O

The	O
stent	O
,	O
when	O
used	O
to	O
treat	O
a	O
vascular	O
injury	O
,	O
gives	O
good	O
protection	O
against	O
clinical	O
restenosis	O
,	O
even	O
when	O
the	O
extent	O
of	O
vascular	O
injury	O
involves	O
vessel	O
overstretching	O
by	O
more	O
than	O
30	O
%	O
diameter	O
.	O

Also	O
disclosed	O
is	O
a	O
stent	O
having	O
a	O
drug	O
-	O
release	O
coating	O
composed	O
of	O
(	O
i	O
)	O
10	O
and	O
60	O
weight	O
percent	O
poly	B
-	I
dl	I
-	I
Iactide	I
polymer	O
substrate	O
and	O
(	O
ii	O
)	O
40	O
-	O
90	O
weight	O
percent	O
of	O
an	O
anti	O
-	O
restenosis	O
compound	O
,	O
and	O
a	O
polymer	O
undercoat	O
having	O
a	O
thickness	O
of	O
between	O
1	O
-	O
5	O
microns	O
.	O

Drug	O
-	O
delivery	O
endovascular	O
stent	O
and	O
method	O
of	O
forming	O
the	O
same	O

The	O
present	O
invention	O
provides	O
compositions	O
and	O
methods	O
for	O
treating	O
pain	O
in	O
mammals	O
.	O

A	O
composition	O
of	O
the	O
invention	O
comprises	O
one	O
or	O
more	O
anti	O
-	O
inflammatory	O
agents	O
and	O
optionally	O
contains	O
one	O
or	O
more	O
anti	O
-	O
oxidants	O
and	O
immune	O
system	O
boosting	O
agents	O
.	O

Compositions	O
and	O
Methods	O
for	O
Treating	O
Pain	O

The	O
present	O
invention	O
refers	O
to	O
a	O
modified	O
release	O
pharmaceutical	O
composition	O
comprising	O
desvenlafaxine	B
or	O
salts	O
thereof	O
,	O
a	O
release	O
rate	O
modifying	O
system	O
that	O
controls	O
the	O
release	O
of	O
active	O
agent	O
(	O
s	O
)	O
in	O
both	O
acidic	O
and	O
basic	O
environments	O
.	O

A	O
process	O
of	O
making	O
and	O
method	O
of	O
using	O
the	O
above	O
-	O
described	O
composition	O
is	O
also	O
disclosed	O
.	O

Modified	O
release	O
dosage	O
form	O
comprising	O
desvenlafaxine	B
or	O
salts	O
thereof	O

Provided	O
herein	O
are	O
compounds	O
,	O
compositions	O
and	O
methods	O
for	O
the	O
treatment	O
of	O
liver	O
disorders	O
,	O
including	O
HCV	O
infections	O
.	O

In	O
certain	O
embodiments	O
,	O
compounds	O
and	O
compositions	O
of	O
nucleoside	O
derivatives	O
are	O
disclosed	O
,	O
which	O
can	O
be	O
administered	O
either	O
alone	O
or	O
in	O
combination	O
with	O
other	O
anti	O
-	O
viral	O
agents	O
.	O

Substituted	O
Carbonyloxymethylphosphoramidate	B
Compounds	O
and	O
Pharmaceutical	O
Compositions	O
for	O
the	O
Treatment	O
of	O
Viral	O
Infections	O

Heterocyclic	B
compounds	O
,	O
and	O
pharmaceutical	O
compositions	O
thereof	O
,	O
are	O
disclosed	O
as	O
RORt	O
modulators	O
that	O
have	O
a	O
formula	O
represented	O
by	O
the	O
following	O
:	O
and	O
wherein	O
n1	O
,	O
n2	O
,	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
and	O
R4	O
are	O
as	O
described	O
herein	O
.	O

These	O
compounds	O
may	O
be	O
used	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
a	O
variety	O
of	O
conditions	O
in	O
mammals	O
including	O
humans	O
,	O
including	O
by	O
way	O
of	O
non	O
-	O
limiting	O
example	O
,	O
inflammatory	O
conditions	O
,	O
autoimmune	O
disorders	O
,	O
cancer	O
,	O
and	O
graft	O
-	O
versus	O
-	O
host	O
disease	O
.	O

COMPOUNDS	O
AS	O
RORyT	O
MODULATORS	O
AND	O
USES	O
THEREOF	O

A	O
method	O
of	O
achieving	O
improved	O
hair	O
feel	O
.	O

The	O
method	O
comprises	O
applying	O
to	O
hair	O
a	O
composition	O
comprising	O
:	O
(	O
a	O
)	O
a	O
specific	O
cationic	O
guar	O
polymer	O
;	O
(	O
b	O
)	O
a	O
specific	O
cationic	O
copolymer	O
;	O
(	O
c	O
)	O
an	O
anti	O
-	O
dandruff	O
active	O
;	O
(	O
d	O
)	O
a	O
cosmetically	O
acceptable	O
carrier	O
;	O
(	O
e	O
)	O
a	O
surfactant	O
;	O
wherein	O
the	O
weight	O
ratio	O
of	O
(	O
a	O
)	O
:	O
(	O
b	O
)	O
is	O
from	O
about	O
1000:1	O
to	O
about	O
3.5:1	O
;	O
and	O
wherein	O
the	O
sum	O
of	O
(	O
a	O
)	O
+	O
(	O
b	O
)	O
is	O
an	O
amount	O
of	O
from	O
about	O
0.0001	O
%	O
to	O
about	O
0.7	O
%	O
,	O
by	O
total	O
weight	O
of	O
the	O
composition	O
.	O

The	O
composition	O
forms	O
coacervate	O
particles	O
upon	O
dilution	O
of	O
the	O
composition	O
with	O
water	O
and	O
the	O
coacervate	O
particles	O
have	O
a	O
squeeze	O
flow	O
viscosity	O
of	O
from	O
about	O
1	O
cP	O
to	O
about	O
100	O
cP.	O
The	O
percentage	O
of	O
coacervate	O
particles	O
with	O
a	O
floc	O
size	O
of	O
greater	O
than	O
about	O
20	O
micron	O
is	O
from	O
about	O
1	O
%	O
to	O
about	O
60	O
%	O
and	O
the	O
on	O
-	O
scalp	O
deposition	O
of	O
the	O
anti	O
-	O
dandruff	O
active	O
is	O
at	O
least	O
about	O
1	O
microgram	O
/	O
cm2	O
.	O

Method	O
of	O
Achieving	O

Improved	O
Hair	O
Feel	O

The	O
invention	O
provides	O
compositions	O
comprising	O
carboline	B
compounds	O
for	O
treating	O
infections	O
such	O
as	O
viral	O
conjunctivitis	O
.	O

The	O
invention	O
also	O
provides	O
methods	O
for	O
treating	O
of	O
other	O
infections	O
,	O
including	O
ocular	O
infections	O
.	O

More	O
particularly	O
,	O
the	O
present	O
invention	O
relates	O
to	O
compositions	O
comprising	O
carboline	B
compounds	O
for	O
the	O
treatment	O
of	O
ocular	O
infections	O
such	O
as	O
viral	O
conjunctivitis	O
,	O
particularly	O
those	O
caused	O
by	O
adenovirus	O
Antimicrobial	O
carboline	B
compounds	O

Provided	O
herein	O
are	O
novel	O
iso	O
-	O
ergoline	O
derivatives	O
and	O
compositions	O
thereof	O
.	O

In	O
other	O
embodiments	O
,	O
provided	O
herein	O
are	O
methods	O
of	O
treatment	O
,	O
prevention	O
,	O
or	O
amelioration	O
of	O
a	O
variety	O
of	O
medical	O
disorders	O
such	O
as	O
,	O
for	O
example	O
,	O
migraine	O
using	O
the	O
compounds	O
and	O
compositions	O
disclosed	O
herein	O
.	O

In	O
still	O
other	O
embodiments	O
,	O
provided	O
herein	O
are	O
methods	O
of	O
agonizing	O
receptors	O
such	O
as	O
,	O
for	O
example	O
,	O
the	O
5-HT1D	O
and/or	O
the	O
5-HT1Breceptor	O
,	O
without	O
agonizing	O
the	O
5-HT2B	O
receptor	O
using	O
the	O
compounds	O
and	O
compositions	O
disclosed	O
herein	O
.	O

In	O
still	O
other	O
embodiments	O
,	O
provided	O
herein	O
are	O
methods	O
of	O
antagonizing	O
or	O
inhibiting	O
activity	O
at	O
receptors	O
such	O
as	O
,	O
for	O
example	O
,	O
the	O
adrenergic	O
alpha2A	O
and/or	O
the	O
alpha2Breceptors	O
using	O
the	O
compounds	O
and	O
compositions	O
disclosed	O
herein	O
.	O

Novel	O
iso	O
-	O
ergoline	O
derivatives	O

A	O
method	O
for	O
treating	O
human	O
patients	O
who	O
require	O
hospitalization	O
for	O
a	O
trauma	O
injury	O
wherein	O
the	O
patients	O
are	O
intravenously	O
administered	O
a	O
first	O
dose	O
of	O
a	O
therapeutically	O
effective	O
dose	O
of	O
ibuprofen	B
intravenously	O
as	O
soon	O
as	O
possible	O
after	O
hospitalization	O
is	O
disclosed	O
.	O

The	O
patients	O
are	O
further	O
treated	O
with	O
intravenous	O
ibuprofen	B
at	O
suitable	O
dosing	O
intervals	O
to	O
the	O
human	O
patient	O
until	O
(	O
a	O
)	O
the	O
patient	O
no	O
longer	O
requires	O
intravenous	O
dosing	O
of	O
ibuprofen	B
.	O

Administration	O
of	O
intravenous	O
ibuprofen	B
to	O
trauma	O
patients	O

Radiation	O
-	O
oxidative	O
exposure	O
treatment	O
compositions	O
may	O
include	O
a	O
mixture	O
of	O
micronutrient	O
multivitamin	O
and	O
trace	O
elements	O
,	O
a	O
mixture	O
of	O
antioxidants	O
and	O
chemopreventative	O
agents	O
,	O
and	O
optionally	O
a	O
mixture	O
of	O
fatty	B
acids	I
.	O

Methods	O
of	O
treatment	O
of	O
a	O
subject	O
exposed	O
to	O
a	O
radiation	O
source	O
or	O
an	O
oxidative	O
stress	O
with	O
the	O
radiation	O
-	O
oxidative	O
exposure	O
treatment	O
composition	O
may	O
include	O
the	O
step	O
of	O
administering	O
to	O
the	O
subject	O
a	O
daily	O
dose	O
of	O
the	O
radiation	O
-	O
oxidative	O
exposure	O
treatment	O
composition	O
such	O
that	O
the	O
life	O
shortening	O
effects	O
induced	O
by	O
the	O
radiation	O
source	O
or	O
the	O
oxidative	O
stress	O
are	O
ameliorated	O
.	O

Method	O
and	O
composition	O
for	O
ameliorating	O
the	O
effects	O
for	O
a	O
subject	O
exposed	O
to	O
radiation	O
or	O
other	O
sources	O
of	O
oxidative	O
stress	O

The	O
disclosure	O
is	O
directed	O
to	O
a	O
nanoparticle	O
comprising	O
a	O
porous	O
framework	O
core	O
including	O
a	O
porous	O
framework	O
material	O
and	O
a	O
compound	O
,	O
and	O
a	O
lipid	O
layer	O
disposed	O
on	O
the	O
surface	O
of	O
the	O
porous	O
framework	O
core	O
.	O

Nanoparticles	O
,	O
Compositions	O
Thereof	O
,	O
and	O
Methods	O
of	O
Use	O
,	O
and	O
Methods	O
of	O
Making	O
the	O
Same	O

A	O
solid	O
oral	O
controlled	O
-	O
release	O
dosage	O
form	O
of	O
hydrocodone	B
is	O
disclosed	O
,	O
the	O
dosage	O
form	O
comprising	O
an	O
analgesically	O
effective	O
amount	O
of	O
hydrocodone	B
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
and	O
controlled	O
release	O
material	O
.	O

Controlled	O
release	O
hydrocodone	B

A	O
fullerene	O
derivative	O
represented	O
by	O
the	O
formula	O
(	O
I	O
)	O
:	O
[	O
wherein	O
,	O
A	O
is	O
a	O
residue	O
of	O
monosaccharides	B
or	O
disaccharides	B
,	O
and	O
Alk	B
is	O
a	O
lower	O
alkylene	B
group	O
,	O
the	O
group	O
represented	O
by	O
the	O
formula	O
(	O
X	O
)	O
:	O
is	O
a	O
fullerene	O
residual	O
skeleton	O
,	O
and	O
n	O
is	O
an	O
integral	O
number	O
of	O
1	O
or	O
2	O
]	O
or	O
its	O
salt	O
produces	O
a	O
formulation	O
usable	O
for	O
PDT	O
which	O
has	O
more	O
hydrophilicity	O
and	O
lipophilicity	O
,	O
is	O
expected	O
to	O
have	O
selectivity	O
to	O
tumor	O
cells	O
by	O
cell	O
recognition	O
,	O
shows	O
no	O
toxicity	O
to	O
the	O
cells	O
in	O
a	O
dark	O
place	O
and	O
has	O
a	O
cytocidal	O
effect	O
by	O
light	O
irradiation	O
.	O

Fullerene	O
derivative	O
and	O
composition	O
comprising	O
the	O
same	O

The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
of	O
producing	O
an	O
improved	O
compressed	O
product	O
,	O
wherein	O
agglomeration	O
of	O
the	O
ingredients	O
is	O
induced	O
.	O

This	O
invention	O
also	O
relates	O
to	O
a	O
compressed	O
product	O
produced	O
by	O
this	O
method	O
.	O

Method	O
for	O
producing	O
a	O
tablet	O
made	O
of	O
isomaltulose	B
,	O
isomalt	B
or	O
isomalt	B
variants	O

Compounds	O
which	O
are	O
2-ureido-1,3-thiazole	O
derivatives	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
R	O
is	O
a	O
halogen	O
atom	O
,	O
a	O
nitro	O
group	O
,	O
an	O
optionally	O
substituted	O
amino	O
group	O
or	O
it	O
is	O
a	O
group	O
optionally	O
further	O
substituted	O
,	O
selected	O
from	O
:	O
i	O
)	O
straight	O
or	O
branched	O
C1-C6	O
alkyl	O
;	O
ii	O
)	O
C3-C6	O
cycloalkyl	O
;	O
iii	O
)	O
aryl	O
or	O
arylalkyl	O
with	O
from	O
1	O
to	O
6	O
carbon	O
atoms	O
within	O
the	O
straight	O
or	O
branched	O
alkyl	O
chain	O
;	O
R1	O
is	O
an	O
optionally	O
substituted	O
group	O
selected	O
from	O
:	O
i	O
)	O
straight	O
or	O
branched	O
C1-C6	O
alkyl	O
;	O
ii	O
)	O
3	O
to	O
6	O
membered	O
carbocycle	O
or	O
5	O
to	O
7	O
membered	O
heterocycle	O
ring	O
;	O
iii	O
)	O
aryl	O
or	O
arylcarbonyl	O
;	O
iv	O
)	O
arylalkyl	O
with	O
from	O
1	O
to	O
6	O
carbon	O
atoms	O
within	O
the	O
straight	O
or	O
branched	O
alkyl	O
chain	O
;	O
R2	O
is	O
hydrogen	O
,	O
a	O
straight	O
or	O
branched	O
C1-C6	O
alkyl	O
or	O
C2-C4	O
alkenyl	O
or	O
alkynyl	O
group	O
;	O
or	O
,	O
taken	O
together	O
with	O
the	O
nitrogen	O
atom	O
so	O
which	O
they	O
are	O
bonded	O
,	O
R1	O
and	O
R2	O
form	O
a	O
substituted	O
or	O
unsubstituted	O
group	O
selected	O
from	O
:	O
i	O
)	O
an	O
optionally	O
benzocondensed	O
or	O
bridged	O
5	O
to	O
7	O
membered	O
heterocycle	O
;	O
or	O
ii	O
)	O
a	O
9	O
to	O
11	O
membered	O
spiro	O
-	O
heterocyclic	O
compound	O
;	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
;	O
are	O
useful	O
for	O
treating	O
cell	O
proliferative	O
disorders	O
associated	O
with	O
an	O
altered	O
cell	O
dependent	O
kinase	O
activity	O
.	O

2-Ureido	O
-	O
thiazole	O
derivatives	O
,	O
process	O
for	O
their	O
preparation	O
,	O
and	O
their	O
use	O
as	O
antitumor	O
agents	O

Flexible	O
impervious	O
bag	O
for	O
medical	O
use	O
containing	O
a	O
pharmaceutical	O
preparation	O
of	O
liquid	O
oxaliplatinum	B
said	O
flexible	O
bag	O
is	O
constructed	O
from	O
plastic	O
materials	O
,	O
with	O
the	O
proviso	O
that	O
any	O
portion	O
to	O
the	O
bag	O
in	O
direct	O
contact	O
with	O
said	O
pharmaceutical	O
preparation	O
of	O
liquid	O
oxaliplatinum	B
does	O
not	O
contain	O
polyvinylchloride	B
-	O
based	O
plastic	O
material	O
.	O

Oxalipatinum	B
preparation	O
packaging	O

Certain	O
novel	O
sterol	O
derivatives	O
can	O
be	O
used	O
for	O
regulating	O
the	O
meiosis	O
in	O
oocytes	O
and	O
in	O
male	O
germ	O
cells	O
.	O

Useful	O
for	O
relieving	O
infertility	O
in	O
females	O
and	O
males	O

Compounds	O
of	O
the	O
formula	O
I	O
:	O
where	O
;	O
R1	O
is	O
O	B
,	O
S	B
;	O
R2	O
is	O
an	O
optionally	O
substituted	O
nitrogen	B
-	O
containing	O
heterocycle	B
,	O
wherein	O
the	O
nitrogen	B
is	O
located	O
at	O
the	O
2	O
position	O
relative	O
to	O
the	O
(	B
thio	I
)	I
urea	I
bond	O
;	O
R3	O
is	O
H	B
,	O
C1-C3	B
alkyl	I
,	O
R4-R7	O
are	O
independently	O
selected	O
from	O
H	B
,	O
C1-C6	B
alkyl	I
,	O
C2-C6	B
alkenyl	I
,	O
C2-C6	B
alkynyl	I
,	O
haloC1-C6	B
alkyl	I
,	O
C1-C6	B
alkanoyl	I
,	O
haloC1-C6	B
alkanoyl	I
,	O
C1-C6	B
alkoxy	I
,	O
haloC1-C6	B
alkoxy	I
,	O
C1-C6	B
alkyloxy	I
-	I
C1-C6	I
alkyl	I
,	O
haloC1-C6	B
alkyloxy	I
-	I
C1-C6	I
alkyl	I
hydroxy	I
-	I
C1-C6	I
alkyl	I
,	O
amino	B
-	I
C1-C6	I
alkyl	I
,	O
carboxy	B
-	I
C1-C6	I
alkyl	I
,	O
cyano	B
-	I
C1-C6	I
alkyl	I
,	O
amino	B
,	O
carboxy	B
,	O
carbamoyl	B
,	O
cyano	B
,	O
halo	B
,	O
hydroxy	B
,	O
keto	B
;	O
X	O
is	O
	B
(	I
CH2	I
)	I
nD	I
(	I
CH2	I
)	I
m	I
;	O
D	O
is	O
O	B
,	O
S	B
;	O
n	O
and	O
m	O
are	O
independently	O
0	O
or	O
1	O
;	O
and	O
prodrugs	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
have	O
utility	O
as	O
inhibitors	O
of	O
HIV-1	O
reverse	O
transcriptase	O
,	O
particularly	O
drug	O
escape	O
mutants	O
.	O

Viricides	O
;	O
human	O
immunodeficiency	O
virus	O

Compounds	O
of	O
the	O
formula	O
I	O
,	O
in	O
which	O
B1	O
,	O
B2	O
,	O
R1	O
,	O
R2	O
,	O
R6	O
,	O
R7	O
,	O
K1	O
and	O
K2	O
are	O
as	O
defined	O
in	O
the	O
description	O
are	O
novel	O
effective	O
tryp	O
-	O
tase	O
inhibitors	O
.	O

Diazocine	B
derivatives	O
and	O
their	O
use	O
as	O
tryptase	O
inhibitors	O

The	O
present	O
invention	O
provides	O
a	O
group	O
of	O
tobacco	O
alkaloids	B
,	O
tobacco	O
extract	O
,	O
Yerbamat	O
extract	O
,	O
and	O
an	O
extract	O
of	O
chewing	O
gum	O
and	O
lozenges	O
which	O
are	O
modulators	O
of	O
monoamine	B
oxidase	O
(	O
MAO	O
)	O
activity	O
(	O
i.e.	O
,	O
compounds	O
and	O
substances	O
which	O
inhibit	O
MAO	O
enzyme	O
and	O
prevent	O
its	O
biological	O
activity	O
)	O
.	O

The	O
MAO	O
inhibitors	O
of	O
the	O
present	O
invention	O
can	O
cause	O
an	O
increase	O
in	O
the	O
level	O
of	O
norepinephrine	B
,	O
dopamine	B
,	O
and	O
serotonin	B
in	O
the	O
brain	O
and	O
other	O
tissues	O
,	O
and	O
thus	O
can	O
cause	O
a	O
wide	O
variety	O
of	O
pharmacological	O
effects	O
mediated	O
by	O
their	O
effects	O
on	O
these	O
compounds	O
.	O

The	O
MAO	O
inhibitors	O
of	O
the	O
present	O
invention	O
are	O
useful	O
for	O
a	O
variety	O
of	O
therapeutic	O
applications	O
,	O
such	O
as	O
the	O
treatment	O
of	O
depression	O
,	O
disorders	O
of	O
attention	O
and	O
focus	O
,	O
mood	O
and	O
emotional	O
disorders	O
,	O
Parkinson	O
's	O
disease	O
,	O
extrapyramidal	O
disorders	O
,	O
hypertension	O
,	O
substance	O
abuse	O
,	O
smoking	O
substitution	O
,	O
anti	O
-	O
depression	O
therapy	O
,	O
eating	O
disorders	O
,	O
withdrawal	O
syndromes	O
,	O
and	O
the	O
cessation	O
of	O
smoking	O
.	O

Active	O
agent	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
anabasine	B
,	O
anatabine	B
,	O
nomicotine	B
,	O
Yerbamate	O
(	O
Ilex	O
paraguariensis	O
)	O
extract	O
,	O
and	O
a	O
liquid	O
extract	O
of	O
tobacco	O
;	O
especially	O
for	O
treating	O
psychological	O
disorders	O

The	O
present	O
invention	O
provides	O
novel	O
phosphate	B
derivatives	O
having	O

the	O
general	O
Formula	O
I	O
wherein	O
the	O
wavy	O
bond	O
(	O
)	O
represents	O
the	O
racemate	O
,	O
the	O
(	O
R	O
)	O
-enantiomer	O
or	O
the	O
(	O
S	O
)	O
-enantiomer	O
and	O
A	O
,	O
B	O
,	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
m	O
and	O
n	O
are	O
as	O
defined	O
herein	O
,	O
or	O
a	O
nontoxic	O
pharmaceutically	O
acceptable	O
salt	O
or	O
solvate	O
thereof	O
and	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
disorders	O
which	O
are	O
responsive	O
to	O
the	O
opening	O
of	O
potassium	B
channels	O
.	O

Phosphate	B
prodrugs	O
of	O
fluoroxindoles	B

Novel	O
fused	B
indazoles	I
and	I
indoles	I
are	O
disclosed	O
.	O

Also	O
disclosed	O
are	O
methods	O
for	O
the	O
lowering	O
and	O
controlling	O
of	O
normal	O
or	O
elevated	O
intraocular	O
pressure	O
as	O
well	O
as	O
a	O
method	O
for	O
the	O
treatment	O
of	O
glaucoma	O
using	O
compositions	O
containing	O
one	O
or	O
more	O
of	O
the	O
compounds	O
of	O
the	O
present	O
invention	O
.	O

Fused	B
indazoles	I
and	I
indoles	I
and	O
their	O
use	O
for	O
the	O
treatment	O
of	O
glaucoma	O

Cosmetic	O
or	O
dermatological	O
composition	O
characterized	O
in	O
that	O
it	O
comprises	O
a	O
combination	O
of	O
an	O
elastase	O
inhibitor	O
of	O
the	O
N	B
-	I
acylaminoamide	I
family	O
and	O
at	O
least	O
one	O
antifungal	O
agent	O
or	O
at	O
least	O
one	O
antibacterial	O
agent	O
.	O

Cosmetic	O
or	O
dermatological	O
composition	O
comprising	O
of	O
a	O
combination	O
of	O
an	O
elastase	O
inhibitor	O
of	O
the	O
N	B
-	I
acylaminoamide	I
family	O
and	O
at	O
least	O
one	O
antifungal	O
agent	O
or	O
at	O
least	O
one	O
antibacterial	O
agent	O

This	O
invention	O
provides	O
a	O
heterocyclic	B
compound	O
having	O
potent	O
tyrosine	B
kinase	O
-	O
inhibiting	O
activity	O
represented	O
by	O
the	O
formula	O
:	O
wherein	O
m	O
is	O
an	O
integer	O
of	O
1	O
to	O
3	O
;	O
n	O
is	O
an	O
integer	O
of	O
1	O
or	O
2	O
;	O
R1	O
is	O
a	O
halogen	B
atom	O
or	O
an	O
optionally	O
halogenated	O
C1	B
-	I
2	I
alkyl	I
group	O
;	O
each	O
of	O
R2	O
and	O
R3	O
is	O
,	O
same	O
or	O
different	O
,	O
a	O
hydrogen	B
atom	O
,	O
a	O
halogen	B
atom	O
,	O
a	O
lower	O
alkyl	B
group	O
or	O
a	O
lower	O
alkoxy	B
group	O
;	O
R4	O
is	O
a	O
group	O
represented	O
by	O
the	O
formula	O
:	O
wherein	O
p	O
is	O
an	O
integer	O
of	O
2	O
to	O
5	O
;	O
R5	O
is	O
a	O
C1	B
-	I
4	I
alkyl	I
group	O
substituted	O
by	O
alkoxycarbonyl	B
group	O
,	O
carbamoyl	B
group	O
,	O
carbamoyloxy	B
group	O
,	O
alkylsulfonyl	B
group	O
,	O
alkylsulfinyl	B
group	O
,	O
sulfamoyl	B
group	O
,	O
carbamoylamino	B
group	O
,	O
alkylsulfonylamino	B
group	O
,	O
acylamino	B
group	O
,	O
and	O
the	O
like	O
;	O
or	O
a	O
salt	O
thereof	O
and	O
a	O
pharmaceutical	O
composition	O
comprising	O
thereof	O
.	O

useful	O
as	O
a	O
growth	O
factor	O
receptor	O
tyrosine	B
kinase	O
HER2	O
(	O
Human	O
epidermal	O
growth	O
factor	O
receptor-2	O
)	O
inhibitor	O
;	O
for	O
treating	O
cancer	O

The	O
invention	O
relates	O
to	O
p	B
-	I
thienylbenzylamides	I
of	O
formula	O
(	O
I	O
)	O
:	O
in	O
which	O
R	O
(	O
1	O
)	O
,	O
R	O
(	O
2	O
)	O
,	O
R	O
(	O
3	O
)	O
,	O
R	O
(	O
4	O
)	O
,	O
R	O
(	O
5	O
)	O
,	O
R	O
(	O
6	O
)	O
and	O
X	O
have	O
the	O
meanings	O
given	O
in	O
the	O
description	O
.	O

The	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
are	O
potent	O
agonists	O
of	O
angiotensin-	O
(	O
1	O
-	O
7	O
)	O
receptors	O
and	O
are	O
useful	O
as	O
pharmaceutically	O
active	O
compounds	O
to	O
treat	O
and/or	O
prevent	O
hypertension	O
;	O
cardiac	O
hypertrophy	O
;	O
cardiac	O
insufficiency	O
;	O
coronary	O
heart	O
diseases	O
,	O
such	O
as	O
angina	O
pectoris	O
;	O
and	O
endothelial	O
dysfunction	O
or	O
endothelial	O
damage	O
as	O
a	O
consequence	O
,	O
for	O
example	O
,	O
of	O
atherosclerotic	O
processes	O
or	O
in	O
association	O
with	O
diabetes	O
mellitus	O
.	O

To	O
treat	O
and/or	O
prevent	O
hypertension	O
,	O
cardiac	O
hypertrophy	O
,	O
cardiac	O
insufficiency	O
,	O
coronary	O
heart	O
diseases	O
such	O
as	O
angina	O
pectoris	O
,	O
and	O
endothelial	O
dysfunction	O
or	O
endothelial	O
damage	O
as	O
a	O
consequence	O
of	O
atherosclerotic	O
processes	O
or	O
diabetes	O

A	O
conjugated	O
prodrug	O
of	O
an	O
estradiol	B
compound	O
conjugated	O
to	O
a	O
biological	O
activity	O
modifying	O
agent	O
.	O

Prodrug	O
of	O
an	O
estradiol	B
conjugated	O
to	O
a	O
glucuronide	B
sugar	I
;	O
6-oxo-2-methoxyestradiol	B
;	O
3-acetyl-6-oxo-2-methoxyestradiol	B
;	O
and	O
2-methoxyestradiol-6-hydrazone	B
;	O
angiogenesis	O
inhibitor	O
;	O
antiinflammatory	O
for	O
asthma	O
or	O
rheumatoid	O
arthritis	O

Combinations	O
of	O
hydrophilic	O
and	O
hydrophobic	O
entities	O
in	O
a	O
biodegradable	O
sustained	O
release	O
implant	O
are	O
shown	O
to	O
modulate	O
each	O
other	O
's	O
rate	O
of	O
release	O
.	O

Formulations	O
of	O
a	O
therapeutically	O
active	O
agent	O
and	O
modulator	O
provide	O
controlled	O
,	O
sustained	O
release	O
for	O
an	O
extended	O
period	O
of	O
time	O
.	O

Formulation	O
for	O
controlled	O
release	O
of	O
drugs	O
by	O
combining	O
hyrophilic	O
and	O
hydrophobic	O
agents	O

Disclosed	O
are	O
compounds	O
of	O
the	O
formula	O
:	O
and	O
the	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
wherein	O
W	O
,	O
Q	O
,	O
X	O
,	O
X1	O
,	O
Y	O
and	O
Z	O
are	O
as	O
defined	O
herein	O
.	O

These	O
compounds	O
bind	O
with	O
high	O
selectivity	O
and/or	O
high	O
affinity	O
to	O
the	O
benzodiazepine	B
site	O
of	O
GABAA	O
receptors	O
and	O
are	O
therefore	O
useful	O
in	O
the	O
treatment	O
of	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
diseases	O
and	O
as	O
probes	O
for	O
the	O
localization	O
of	O
GABAA	O
receptors	O
in	O
tissue	O
samples	O
.	O

Also	O
disclosed	O
are	O
intermediates	O
useful	O
in	O
the	O
preparation	O
of	O
these	O
compounds	O
.	O

Nitrogen	O
compounds	O
such	O
as	O
1-	B
(	I
(	I
3-	I
Phenylimidazo	I
(	I
5,1-a	I
)	I
-isoquinolin-6-yl	I
)	I
carbonyl	I
)	I
piperidine	I
,	O
that	O
bind	O
preferentially	O
to	O
gamma	B
-	I
aminobutyric	I
acid	I
(	O
GABAA	O
)	O
receptors	O
;	O
prophylaxis	O
of	O
nervous	O
system	O
disorders	O

The	O
present	O
invention	O
is	O
directed	O
to	O
novel	O
1,3,8-triazaspiro	B
[	I
4.5	I
]	I
decan-4-one	I
derivatives	O
of	O
the	O
general	O
formula	O
wherein	O
all	O
variables	O
are	O
as	O
defined	O
herein	O
,	O
useful	O
in	O
the	O
treatment	O
of	O
disorders	O
and	O
conditions	O
mediated	O
by	O
the	O
ORL-1	O
G	O
-	O
protein	O
coupled	O
receptor	O
.	O

More	O
particularly	O
,	O
the	O
compounds	O
of	O
the	O
present	O
invention	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
disorders	O
and	O
conditions	O
such	O
as	O
anxiety	O
,	O
depression	O
,	O
substance	O
abuse	O
,	O
neuropathic	O
pain	O
,	O
acute	O
pain	O
,	O
migraine	O
,	O
asthma	O
,	O
cough	O
and	O
for	O
improved	O
cognition	O
.	O

Orphan	O
opioid	O
receptor	O
(	O
orl-1	O
)	O
ligands	O
;	O
anxiety	O
,	O
depression	O
,	O
neuropathic	O
and	O
acute	O
pain	O
,	O
migraines	O
,	O
asthma	O
,	O
improved	O
cognition	O

This	O
invention	O
relates	O
to	O
N	B
-	I
acylamino	I
aryl	I
derivatives	O
of	O
the	O
formula	O
where	O
R1	O
,	O
R21	O
,	O
R22	O
,	O
R23	O
,	O
R24	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
R6	O
,	O
R7	O
,	O
R8	O
,	O
R	O
,	O
and	O
n	O
are	O
as	O
defined	O
herein	O
and	O
where	O
X	O
is	O
CHRO	B
,	O
OCHR	B
,	O
CH2S	B
,	O
SCH2	B
,	O
CH2CH2	B
,	O
CH	B
	I
CH	I
or	O
CC.	B
The	O
compounds	O
of	O
the	O
invention	O
are	O
selective	O
monoamine	B
oxidase	O
B	O
inhibitors	O
,	O
and	O
they	O
are	O
therefore	O
useful	O
in	O
the	O
treatment	O
of	O
diseases	O
mediated	O
by	O
monoamine	B
oxidase	O
B	O
,	O
for	O
example	O
,	O
for	O
the	O
treatment	O
of	O
Alzheimer	O
's	O
disease	O
or	O
senile	O
dementia	O
.	O

N	B
-	I
acylamino	I
benzyl	I
ether	I
derivatives	O

The	O
invention	O
is	O
concerned	O
with	O
novel	O
N-	O
(	O
4-carbamimidoyl	O
-	O
phenyl	O
)	O
-glycine	O
derivatives	O
of	O
the	O
formula	O
:	O
wherein	O
R1	O
,	O
E	O
,	O
X1	O
to	O
X4	O
and	O
G1	O
and	O
G2	O
are	O
as	O
defined	O
in	O
the	O
description	O
and	O
the	O
claims	O
,	O
as	O
well	O
as	O
hydrates	O
or	O
solvates	O
and	O
physiologically	O
usable	O
salts	O
thereof	O
.	O

N-	O
(	O
4-carbamimidoyl	O
-	O
phenyl	O
)	O
-glycine	O
derivatives	O

The	O
present	O
invention	O
relates	O
to	O
methods	O
for	O
inducing	O
cell	O
death	O
via	O
activation	O
of	O
the	O
caspase	O
,	O
SAPK	O
,	O
and	O
apoptotic	O
signaling	O
cascades	O
in	O
a	O
cell	O
comprising	O
administering	O
to	O
a	O
cell	O
a	O
composition	O
comprising	O
tempo	O
in	O
a	O
amount	O
sufficient	O
to	O
induce	O
death	O
of	O
said	O
cell	O
.	O

Compositions	O
and	O
methods	O
for	O
inducing	O
cell	O
death	O

A	O
method	O
for	O
treating	O
or	O
preventing	O
a	O
disorder	O
or	O
a	O
condition	O
by	O
double	O
inhibition	O
of	O
serotonin	B
(	O
5-HT	B
)	O
and	O
noradrenaline	B
(	O
NA	B
)	O
reuptake	O
in	O
a	O
subject	O
in	O
need	O
thereof	O
,	O
while	O
limiting	O
the	O
risks	O
of	O
cardiovascular	O
disturbances	O
and/or	O
organ	O
and/or	O
tissue	O
toxicity	O
,	O
comprising	O
the	O
step	O
of	O
administering	O
to	O
said	O
subject	O
a	O
mixture	O
of	O
enantiomers	O
of	O
milnacipran	O
enriched	O
in	O
the	O
(	B
1S,2R	I
)	I
enantiomer	I
of	I
milnacipran	I
and/or	O
of	O
at	O
least	O
one	O
of	O
its	O
metabolites	O
,	O
as	O
well	O
as	O
their	O
pharmaceutically	O
-	O
acceptable	O
salts	O
.	O

Use	O
of	O
the	O
(	B
1S,2R	I
)	I
enantiomer	I
of	I
milnacipran	I
for	O
the	O
preparation	O
of	O
a	O
drug	O

Methods	O
and	O
compositions	O
of	O
antidepressants	O
and	O
analogs	O
thereof	O
for	O
inducing	O
local	O
long	O
-	O
lasting	O
anesthesia	O
and	O
analgesia	O
are	O
provided	O
.	O

The	O
methods	O
and	O
compositions	O
are	O
useful	O
for	O
alleviating	O
acute	O
and	O
chronic	O
pain	O
,	O
particularly	O
useful	O
for	O
treating	O
a	O
localized	O
pain	O
.	O

Antidepressants	O
and	O
their	O
analogues	O
as	O
long	O
-	O
acting	O
local	O
anesthetics	O
and	O
analgesics	O

This	O
invention	O
provides	O
isolated	O
nucleic	O
acids	O
encoding	O
mammalian	O
galanin	O
receptors	O
,	O
isolated	O
galanin	O
receptor	O
proteins	O
,	O
vectors	O
comprising	O
isolated	O
nucleic	O
acid	O
encoding	O
a	O
mammalian	O
galanin	O
receptor	O
,	O
cells	O
comprising	O
such	O
vectors	O
,	O
antibodies	O
directed	O
to	O
a	O
mammalian	O
galanin	O
receptor	O
,	O
nucleic	O
acid	O
probes	O
useful	O
for	O
detecting	O
nucleic	O
acid	O
encoding	O
a	O
mammalian	O
galanin	O
receptor	O
,	O
antisense	O
oligonucleotides	O
complementary	O
to	O
unique	O
sequences	O
of	O
nucleic	O
acid	O
encoding	O
a	O
mammalian	O
galanin	O
receptor	O
,	O
nonhuman	O
transgenic	O
animals	O
which	O
express	O
DNA	O
encoding	O
a	O
normal	O
or	O
a	O
mutant	O
mammalian	O
galanin	O
receptor	O
,	O
as	O
well	O
as	O
methods	O
of	O
determining	O
binding	O
of	O
compounds	O
to	O
mammalian	O
galanin	O
receptors	O
.	O

Uses	O
of	O
galanin	O
GALR2	O
receptors	O

Novel	O
carbohydrate	O
-	O
based	O
compounds	O
with	O
an	O
attached	O
ring	O
system	O
that	O
have	O
antimicrobial	O
or	O
cytostatic	O
activity	O
.	O

The	O
compounds	O
are	O
administered	O
to	O
humans	O
and	O
animals	O
for	O
the	O
treatment	O
or	O
amelioration	O
of	O
bacterial	O
,	O
fungal	O
,	O
viral	O
or	O
protozoal	O
infections	O
or	O
tumors	O
.	O

The	O
compounds	O
are	O
of	O
the	O
general	O
formula	O
:	O
Preparation	O
and	O
use	O
of	O
carbohydrate	O
-	O
based	O
bicyclic	B
ring	O
structures	O
with	O
antimicrobial	O
and	O
cytostatic	O
activity	O

The	O
invention	O
discloses	O
an	O
injection	O
made	O
from	O
Chinese	O
herb	O
Ixeris	O
Sonchifolia	O
Hance	O
for	O
treatment	O
of	O
cardio	O
-	O
cerebral	O
vascular	O
diseases	O
and	O
fundus	O
diseases	O
and	O
method	O
of	O
producing	O
thereof	O
.	O

The	O
injection	O
is	O
in	O
a	O
form	O
of	O
lyophilized	O
powder	O
in	O
which	O
the	O
rate	O
of	O
flavone	B
to	O
adenosine	B
is	O
5	O
mg:15	O
g	O
or	O
5	O
mg:30	O
g	O
.	O

The	O
flavone	B
and	O
adenosine	B
from	O
Ixeris	O
Sonchifolia	O
Hance	O
is	O
more	O
stable	O
in	O
the	O
lyophilized	O
powder	O
form	O
than	O
in	O
liquid	O
form	O
for	O
injection	O
so	O
that	O
it	O
is	O
easy	O
to	O
control	O
the	O
quality	O
of	O
the	O
product	O
so	O
as	O
to	O
make	O
the	O
medicament	O
safe	O
and	O
effective	O
.	O

It	O
has	O
benefit	O
in	O
store	O
.	O

Injection	O
made	O
from	O
Ixeris	O
Sonchifolia	O
Hance	O
for	O
treatment	O
of	O
cardio	O
-	O
cerebral	O
vascular	O
diseases	O
and	O
fundus	O
diseases	O
and	O
method	O
of	O
producing	O
thereof	O

The	O
invention	O
encompasses	O
novel	O
compounds	O
of	O
Formula	O
I	O
,	O
which	O
are	O
nitric	B
oxide	I
-	O
releasing	O
prodrugs	O
of	O
diaryl-2-	B
(	I
5H	I
)	I
furanones	I
useful	O
in	O
the	O
treatment	O
of	O
cyclooxygenase-2	O
mediated	O
diseases	O
.	O

The	O
invention	O
also	O
encompasses	O
certain	O
pharmaceutical	O
compositions	O
and	O
methods	O
for	O
treating	O
cyclooxygenase-2	O
mediated	O
diseases	O
comprising	O
the	O
use	O
of	O
compounds	O
of	O
Formula	O
I.	O
The	O
above	O
compounds	O
may	O
be	O
used	O
as	O
a	O
combination	O
therapy	O
with	O
low	O
-	O
dose	O
aspirin	B
to	O
treat	O
chronic	O
cyclooxygenase-2	O
mediated	O
diseases	O
or	O
conditions	O
while	O
also	O
reducing	O
the	O
risk	O
of	O
thrombotic	O
cardiovascular	O
events	O
.	O

Reducing	O
risk	O
of	O
thrombotic	O
cardiovascular	O
events	O
such	O
as	O
stroke	O
,	O
myocardial	O
ischemia	O
,	O
myocardial	O
infarction	O
,	O
angina	O
pectoris	O
,	O
and	O
transient	O
ischemic	O
attack	O
;	O
side	O
effect	O
reduction	O

The	O
present	O
invention	O
relates	O
to	O
a	O
composition	O
for	O
topical	O
use	O
for	O
treating	O
and	O
improving	O
the	O
aesthetic	O
conditions	O
of	O
the	O
skin	O
,	O
which	O
comprises	O
,	O
as	O
an	O
active	O
ingredient	O
,	O
a	O
mixture	O
of	O
ethyllinoleate	B
and	O
triethylcitrate	B
.	O

This	O
composition	O
is	O
active	O
in	O
the	O
treatment	O
of	O
seborrhea	O
and	O
acne	O
.	O

Composition	O
based	O
on	O
ethyl	B
ester	I
of	O
linoleic	B
acid	I
and	O
triethyl	B
ester	I
of	O
citric	B
acid	I
for	O
topical	O
use	O
in	O
the	O
treatment	O
of	O
seborrhea	O
and	O
acne	O

Compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
the	O
symbol	O
aa	O
means	O
a	O
residue	O
of	O
an	O
	B
-	I
amino	I
acid	I
.	O

The	O
invention	O
is	O
also	O
directed	O
to	O
a	O
method	O
for	O
the	O
preparation	O
of	O
the	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
as	O
well	O
as	O
their	O
use	O
as	O
prolyl	O
oligopeptide	O
inhibitors	O
,	O
for	O
example	O
for	O
the	O
treatment	O
of	O
Alzheimer	O
's	O
disease	O
.	O

Compounds	O
having	O
prolyl	O
oligopeptidase	O
inhibitory	O
activity	O
,	O
methods	O
for	O
their	O
preparation	O
and	O
their	O
use	O

A	O
method	O
of	O
treating	O
gum	O
disease	O
,	O
includes	O
directing	O
a	O
stream	O
of	O
oxidizing	O
gas	O
onto	O
a	O
diseased	O
gum	O
for	O
a	O
period	O
of	O
time	O
sufficient	O
to	O
kill	O
microorganisms	O
.	O

Use	O
of	O
ozone	O
for	O
the	O
treatment	O
of	O
gum	O
disease	O

A	O
melanin	O
-	O
concentrating	O
hormone	O
antagonist	O
comprising	O
a	O
compound	O
of	O
the	O
formula	O
:	O
wherein	O
R	O
is	O
hydrogen	B
atom	O
or	O
a	O
cyclic	O
group	O
which	O
may	O
be	O
substituted	O
;	O
X	O
is	O
a	O
bond	O
or	O
a	O
spacer	O
having	O
a	O
main	O
chain	O
of	O
1	O
to	O
10	O
atoms	O
;	O
Y	O
is	O
a	O
spacer	O
having	O
a	O
main	O
chain	O
of	O
1	O
to	O
6	O
atoms	O
;	O
ring	O
A	O
is	O
benzene	B
ring	O
which	O
may	O
be	O
further	O
substituted	O
;	O
ring	O
B	O
is	O
a	O
5-	O
to	O
9-membered	B
nitrogen	I
-	I
containing	I
non	I
-	I
aromatic	I
heterocyclic	I
ring	O
which	O
may	O
be	O
further	O
substituted	O
;	O
R1	O
and	O
R2	O
are	O
the	O
same	O
or	O
different	O
and	O
are	O
hydrogen	B
atom	O
,	O
a	O
hydrocarbon	B
group	O
which	O
may	O
be	O
substituted	O
or	O
a	O
heterocyclic	B
group	O
which	O
may	O
be	O
substituted	O
;	O
or	O
R1	O
and	O
R2	O
,	O
together	O
with	O
the	O
adjacent	O
nitrogen	B
atom	O
,	O
may	O
form	O
a	O
nitrogen	B
-	O
containing	O
heterocyclic	B
ring	O
which	O
may	O
be	O
substituted	O
;	O
or	O
R2	O
,	O
together	O
with	O
the	O
adjacent	O
nitrogen	B
atom	O
and	O
Y	O
,	O
may	O
form	O
a	O
nitrogen	B
-	O
containing	O
heterocyclic	B
ring	O
which	O
may	O
be	O
substituted	O
;	O
or	O
a	O
salt	O
thereof	O
is	O
useful	O
as	O
a	O
preventive	O
or	O
therapeutic	O
agent	O
for	O
obesity	O
,	O
etc	O
.	O

Melanin	O
-	O
concentrating	O
hormone	O
antagonist	O

The	O
present	O
invention	O
provides	O
a	O
polynucleotide	O
comprising	O
a	O
RNA	O
polymerase	O
III	O
promoter	O
,	O
a	O
region	O
encoding	O
a	O
siRNA	O
,	O
and	O
a	O
transcriptional	O
termination	O
element	O
comprising	O
five	O
consecutive	O
thymine	B
residues	O
.	O

The	O
invention	O
also	O
provides	O
for	O
vectors	O
,	O
cells	O
and	O
non	O
-	O
human	O
transgenic	O
animal	O
comprising	O
the	O
polynucleotides	O
of	O
the	O
invention	O
as	O
well	O
as	O
their	O
use	O
in	O
medicaments	O
for	O
various	O
conditions	O
.	O

A	O
polynucleotide	O
comprising	O
a	O
RNA	O
polymerase	O
promoter	O
,	O
able	O
encoding	O
a	O
siRNA	O
;	O
treating	O
cancer	O
and	O
genetic	O
disorders	O
;	O
genetic	O
engineering	O
,	O
inhibit	O
gene	O
expression	O
of	O
a	O
target	O
gene	O

An	O
isolated	O
,	O
purified	O
or	O
recombinant	O
nucleic	O
acid	O
sequence	O
is	O
disclosed	O
,	O
comprising	O
:	O
(	O
a	O
)	O
a	O
sequence	O
that	O
encodes	O
both	O
an	O
angiogenic	O
factor	O
antagonist	O
and	O
a	O
vascular	O
endothelial	O
structure	O
regulator	O
;	O
(	O
b	O
)	O
a	O
sequence	O
substantially	O
homologous	O
to	O
or	O
that	O
hybridizes	O
to	O
sequence	O
(	O
a	O
)	O
under	O
stringent	O
conditions	O
;	O
or	O
(	O
c	O
)	O
a	O
sequence	O
substantially	O
homologous	O
to	O
or	O
that	O
hybridizes	O
under	O
stringent	O
conditions	O
to	O
the	O
sequence	O
(	O
a	O
)	O
or	O
(	O
b	O
)	O
but	O
for	O
the	O
degeneracy	O
of	O
the	O
genetic	O
code	O
;	O
or	O
(	O
g	O
)	O
an	O
oligonucleotide	B
specific	O
for	O
any	O
of	O
the	O
sequences	O
(	O
a	O
)	O
,	O
(	O
b	O
)	O
or	O
(	O
c	O
)	O
.	O

Particular	O
oligonucleotides	B
(	O
d	O
)	O
are	O
those	O
encoding	O
the	O
vascular	O
endothelial	O
structure	O
regulator	O
.	O

Also	O
described	O
are	O
methods	O
for	O
preparing	O
the	O
recombinant	O
polynucleotide	O
,	O
proteins	O
encoded	O
by	O
such	O
polynucleotides	O
and	O
their	O
use	O
in	O
gene	O
or	O
protein	O
therapy	O
for	O
the	O
treatment	O
of	O
conditions	O
such	O
as	O
cancer	O
.	O

Recombinant	O
sequence	O
,	O
its	O
preparation	O
and	O
use	O

Compounds	O
of	O
Formula	O
I	O
are	O
useful	O
for	O
inhibiting	O
serine	O
protease	O
enzymes	O
,	O
such	O
as	O
TF	O
/	O
factor	O
VIIa	O
,	O
factor	O
Xa	O
,	O
thrombin	O
and	O
kallikrein	O
and	O
have	O
improved	O
pharmacokinetic	O
properties	O
.	O

These	O
compounds	O
may	O
be	O
used	O
in	O
methods	O
of	O
preventing	O
and/or	O
treating	O
clotting	O
disorders	O
.	O

Benzofuran	O
inhibitors	O
of	O
factor	O
VIIa	O

The	O
invention	O
relates	O
to	O
novel	O
tetrahydroisoquinoline	B
derivatives	O
of	O
general	O
formula	O
I	O
and	O
theirs	O
use	O
as	O
active	O
ingredients	O
in	O
the	O
preparation	O
of	O
pharmaceutical	O
compositions	O
.	O

The	O
invention	O
also	O
concerns	O
related	O
aspects	O
including	O
processes	O
for	O
the	O
preparation	O
of	O
the	O
compounds	O
,	O
pharmaceutical	O
compositions	O
containing	O
one	O
or	O
more	O
of	O
those	O
compounds	O
and	O
their	O
use	O
as	O
anti	O
-	O
infectives	O
,	O
wherein	O
R1	O
,	O
R2	O
and	O
R3	O
are	O
as	O
defined	O
in	O
claim	O
1	O
.	O

Infections	O
caused	O
by	O
Gram	O
positive	O
and/or	O
negative	O
pathogens	O

New	O
methods	O
for	O
the	O
treatment	O
of	O
human	O
disease	O
are	O
provided	O
.	O

IGFBP-3	O
is	O
administered	O
together	O
with	O
a	O
co	O
-	O
administered	O
agent	O
to	O
subjects	O
having	O
disease	O
,	O
thereby	O
alleviating	O
the	O
symptoms	O
of	O
the	O
disease	O
,	O
under	O
conditions	O
where	O
administration	O
of	O
IGFBP-3	O
alone	O
at	O
the	O
maximum	O
practicable	O
dose	O
has	O
no	O
measurable	O
beneficial	O
effect	O
on	O
the	O
disease	O
condition	O
.	O

Method	O
for	O
use	O
of	O
IGF	O
-	O
binding	O
protein	O
for	O
selective	O
sensitization	O
of	O
target	O
cells	O
in	O
vivo	O

The	O
present	O
invention	O
is	O
directed	O
to	O
acyl	B
and	O
sulfonyl	B
derivatives	O
of	O
6,9-disubstituted	B
2-	I
(	I
trans-1,4	I
-diaminocyclohexyl	I
)	I
-purines	I
of	O
the	O
formula	O
where	O
Z	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
S	B
(	I
O	I
)	I
2	I
,	O
and	O
C	B
(	I
O	I
)	I
.	I
Inhibiting	O
cyclin	O
-	O
dependent	O
kinase	O
complexes	O
including	O
cdk1	O
/	O
cyclin	O
B	O
,	O
cdk2	O
/	O
cyclin	O
E	O
and	O
cdk4	O
/	O
cyclin	O
D1	O
;	O
preventing	O
apoptosis	O

This	O
invention	O
generally	O
relates	O
to	O
methods	O
for	O
treating	O
or	O
preventing	O
a	O
condition	O
responsive	O
to	O
JNK	O
inhibition	O
,	O
such	O
as	O
a	O
metabolic	O
condition	O
,	O
comprising	O
administering	O
to	O
a	O
patient	O
in	O
need	O
thereof	O
an	O
effective	O
amount	O
of	O
an	O
Anilinopyrimidine	B
Derivative	O
having	O
the	O
following	O
structure	O
:	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
wherein	O
R1	O
through	O
R6	O
are	O
as	O
defined	O
herein	O
.	O

Methods	O
for	O
treating	O
or	O
preventing	O
an	O
inflammatory	O
or	O
metabolic	O
condition	O
or	O
inhibiting	O
JNK	O

The	O
use	O
of	O
a	O
dietary	O
fiber	O
or	O
a	O
mixture	O
of	O
dietary	O
fibers	O
for	O
the	O
manufacture	O
of	O
a	O
composition	O
,	O
being	O
a	O
pharmaceutical	O
composition	O
or	O
a	O
functional	O
food	O
or	O
a	O
functional	O
feed	O
,	O
for	O
the	O
prevention	O
,	O
the	O
inhibition	O
and/or	O
the	O
treatment	O
of	O
systemic	O
infections	O
in	O
humans	O
and	O
in	O
vertebrates	O
caused	O
by	O
pathogenic	O
bacteria	O
is	O
disclosed	O
.	O

A	O
method	O
for	O
the	O
prevention	O
,	O
the	O
inhibition	O
and/or	O
the	O
treatment	O
of	O
systemic	O
infections	O
in	O
humans	O
and	O
in	O
vertebrates	O
caused	O
by	O
pathogenic	O
bacteria	O
,	O
comprising	O
administration	O
to	O
said	O
beings	O
,	O
orally	O
,	O
through	O
tube	O
feeding	O
or	O
rectally	O
,	O
a	O
composition	O
containing	O
an	O
effective	O
amount	O
of	O
a	O
dietary	O
fiber	O
or	O
mixture	O
of	O
dietary	O
fibers	O
is	O
also	O
disclosed	O
.	O

The	O
dietary	O
fiber	O
is	O
preferably	O
a	O
fructan	O
,	O
typically	O
inulin	O
and/or	O
oligofructose	O
,	O
most	O
preferably	O
chicory	O
inulin	O
with	O
an	O
average	O
degree	O
of	O
polymerization	O
(	O
DP	O
)	O
of	O
at	O
least	O
20	O
.	O

Inhibition	O
of	O
systemic	O
infections	O
in	O
humans	O
and	O
vertebrates	O
by	O
dietary	O
fibers	O

There	O
is	O
provided	O
novel	O
diazepines	B
that	O
function	O
as	O
agonists	O
at	O
the	O
melanocortin	O
4	O
receptor	O
and	O
as	O
agonists	O
at	O
the	O
melanocortin	O
1	O
receptor	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
,	O
methods	O
for	O
their	O
use	O
in	O
treatment	O
,	O
and	O
processes	O
for	O
their	O
preparation	O
.	O

Diazepine	B
compounds	O
as	O
ligands	O
of	O
the	O
melanocortin	O
1	O
and/or	O
4	O
receptors	O

Compounds	O
having	O
activity	O
as	O
inhibitors	O
of	O
IKK	O
are	O
disclosed	O
,	O
particularly	O
IKK-2	O
.	O

The	O
compounds	O
of	O
this	O
invention	O
are	O
anilinopyrimidine	B
derivatives	O
having	O
the	O
following	O
structure	O
:	O
wherein	O
R1	O
and	O
R6	O
are	O
as	O
defined	O
herein	O
.	O

Such	O
compounds	O
have	O
utility	O
in	O
the	O
treatment	O
of	O
a	O
wide	O
range	O
of	O
conditions	O
that	O
are	O
responsive	O
to	O
IKK	O
inhibition	O
.	O

Thus	O
,	O
methods	O
of	O
treating	O
such	O
conditions	O
are	O
also	O
disclosed	O
,	O
as	O
are	O
pharmaceutical	O
compositions	O
containing	O
one	O
or	O
more	O
compounds	O
of	O
the	O
above	O
compounds	O
.	O

For	O
treatment	O
of	O
rheumatoid	O
arthritis	O
,	O
inflammatory	O
or	O
autoimmune	O
condition	O
,	O
viral	O
infection	O
,	O
cancer	O
;	O
4-	B
{	I
[	I
4-	I
(	I
4-chlorophenyl	I
)	I
pyrimidin-2-yl	I
]	I
amino	I
}	I
benzamide	I

This	O
invention	O
provides	O
methods	O
and	O
compositions	O
for	O
inducing	O
weight	O
loss	O
and	O
maintaining	O
optimum	O
weight	O
comprising	O
administering	O
an	O
agent	O
that	O
stimulates	O
carnitine	B
palmitoyl	I
transferase-1	O
(	O
CPT-1	O
)	O
activity	O
to	O
the	O
patient	O
in	O
need	O
,	O
including	O
human	O
patients	O
.	O

These	O
methods	O
do	O
not	O
require	O
inhibition	O
of	O
fatty	B
acid	I
synthesis	O
.	O

In	O
particular	O
,	O
this	O
invention	O
provides	O
methods	O
for	O
development	O
of	O
therapeutics	O
that	O
selectively	O
enhance	O
fatty	B
acid	I
oxidation	O
,	O
increase	O
energy	O
production	O
,	O
and	O
reduce	O
adiposity	O
while	O
preserving	O
lean	O
mass	O
,	O
through	O
the	O
pharmacological	O
stimulation	O
of	O
CPT-1	O
activity	O
.	O

In	O
a	O
preferred	O
mode	O
,	O
the	O
agent	O
is	O
administered	O
in	O
an	O
amount	O
sufficient	O
to	O
increase	O
fatty	B
acid	I
oxidation	O
.	O

In	O
another	O
preferred	O
mode	O
,	O
the	O
agent	O
is	O
administered	O
in	O
an	O
amount	O
sufficient	O
to	O
antagonize	O
malonyl	O
CoA	O
inhibition	O
of	O
CPT-1	O
.	O

In	O
yet	O
another	O
preferred	O
mode	O
,	O
the	O
agent	O
is	O
administered	O
in	O
an	O
amount	O
sufficient	O
to	O
increase	O
malonyl	O
CoA	O
level	O
.	O

Adust	O
fatty	B
acid	I
oxidation	O
;	O
stimulant	O
of	O
carnitine	B
plamitoyl	I
treansferrase	O

The	O
present	O
invention	O
provides	O
a	O
purified	O
polynucleotide	O
encoding	O
a	O
novel	O
polypeptide	O
,	O
designated	O
Fhm	O
,	O
which	O
belongs	O
to	O
the	O
TNF	O
gene	O
superfamily	O
;	O
to	O
purified	O
Fhm	O
polypeptide	O
molecules	O
;	O
to	O
antibodies	O
that	O
bind	O
Fhm	O
;	O
to	O
materials	O
comprising	O
such	O
molecules	O
;	O
and	O
to	O
methods	O
of	O
using	O
such	O
molecules	O
.	O

Identifying	O
modulators	O
for	O
prevention	O
and	O
treatment	O
of	O
infection	O
,	O
blood	O
,	O
metabolic	O
,	O
cell	O
proliferative	O
and	O
respiratory	O
system	O
disorders	O

The	O
present	O
invention	O
provides	O
a	O
novel	O
a	O
condensed	O
polycyclic	O
compound	O
useful	O
as	O
a	O
phosphodiesterase	O
4	O
inhibitor	O
,	O
which	O
is	O
shown	O
by	O
the	O
formula	O
[	O
I	O
]	O
:	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
and	O
a	O
pharmaceutical	O
composition	O
containing	O
the	O
same	O
.	O

Use	O
of	O
phosphodiesterase	O
4	O
inhibitors	O
such	O
as	O
6,7-dimethoxy-1-	B
[	I
2-	I
(	I
1,3-dioxocyclohexan-2-yl	I
)	I
pyridin-4-yl	I
]	I
-2,3-bis	I
(	I
hydroxymethyl	I
)	I
naphthalene	I
to	O
treat	O
asthma	O
,	O
chronic	O
obstructive	O
pulmonary	O
disease	O
,	O
atopic	O
dermatitis	O
,	O
allergic	O
rhinitis	O
,	O
psoriasis	O
,	O
rheumatoid	O
arthritis	O
,	O
septic	O
shock	O
,	O
ulcerative	O
colitis	O

A	O
prodrug	O
comprising	O
a	O
heparin	B
and	O
a	O
drug	O
is	O
provided	O
.	O

The	O
prodrug	O
can	O
be	O
used	O
to	O
form	O
a	O
coating	O
on	O
a	O
medical	O
device	O
.	O

The	O
prodrug	O
can	O
also	O
be	O
used	O
with	O
a	O
polymeric	O
material	O
to	O
form	O
a	O
coating	O
on	O
a	O
medical	O
device	O
.	O

The	O
polymeric	O
material	O
can	O
be	O
a	O
hydrophobic	O
polymer	O
,	O
a	O
hydrophilic	O
polymer	O
,	O
a	O
non	O
-	O
fouling	O
polymer	O
,	O
or	O
combinations	O
thereof	O
.	O

The	O
medical	O
device	O
can	O
be	O
implanted	O
in	O
a	O
human	O
being	O
for	O
the	O
treatment	O
of	O
a	O
disease	O
such	O
as	O
atherosclerosis	O
,	O
thrombosis	O
,	O
restenosis	O
,	O
hemorrhage	O
,	O
vascular	O
dissection	O
or	O
perforation	O
,	O
vascular	O
aneurysm	O
,	O
vulnerable	O
plaque	O
,	O
chronic	O
total	O
occlusion	O
,	O
claudication	O
,	O
anastomotic	O
proliferation	O
for	O
vein	O
and	O
artificial	O
grafts	O
,	O
bile	O
duct	O
obstruction	O
,	O
ureter	O
obstruction	O
,	O
tumor	O
obstruction	O
,	O
or	O
combinations	O
thereof	O
.	O

Heparin	B
prodrugs	O
and	O
drug	O
delivery	O
stents	O
formed	O
therefrom	O

The	O
invention	O
describes	O
novel	O
methods	O
for	O
treating	O
and	O
preventing	O
dementia	O
caused	O
by	O
vascular	O
diseases	O
;	O
dementia	O
associated	O
with	O
Parkinson	O
's	O
disease	O
;	O
Lewy	O
Body	O
dementia	O
;	O
AIDS	O
dementia	O
;	O
mild	O
cognitive	O
impairments	O
;	O
age	O
-	O
associated	O
memory	O
impairments	O
;	O
cognitive	O
impairments	O
and/or	O
dementia	O
associated	O
with	O
neurologic	O
and/or	O
psychiatric	O
conditions	O
,	O
including	O
epilepsy	O
,	O
brain	O
tumors	O
,	O
brain	O
lesions	O
,	O
multiple	O
sclerosis	O
,	O
Down	O
's	O
syndrome	O
,	O
Rett	O
's	O
syndrome	O
,	O
progressive	O
supranuclear	O
palsy	O
,	O
frontal	O
lobe	O
syndrome	O
,	O
and	O
schizophrenia	O
and	O
related	O
psychiatric	O
disorders	O
;	O
cognitive	O
impairments	O
caused	O
by	O
traumatic	O
brain	O
injury	O
,	O
post	O
coronary	O
artery	O
by	O
-	O
pass	O
graft	O
surgery	O
,	O
electroconvulsive	O
shock	O
therapy	O
,	O
and	O
chemotherapy	O
,	O
administering	O
a	O
therapeutically	O
effective	O
amount	O
of	O
at	O
least	O
one	O
of	O
the	O
cholinesterase	O
inhibitor	O
compounds	O
described	O
herein	O
.	O

The	O
invention	O
also	O
describes	O
novel	O
methods	O
for	O
treating	O
and	O
preventing	O
delirium	O
,	O
Tourette	O
's	O
syndrome	O
,	O
myasthenia	O
gravis	O
,	O
attention	O
deficit	O
hyperactivity	O
disorder	O
,	O
autism	O
,	O
dyslexia	O
,	O
mania	O
,	O
depression	O
,	O
apathy	O
,	O
and	O
myopathy	O
associated	O
with	O
diabetes	O
by	O
administering	O
a	O
therapeutically	O
effective	O
amount	O
of	O
at	O
least	O
one	O
of	O
the	O
cholinesterase	O
inhibitor	O
compounds	O
described	O
herein	O
.	O

The	O
invention	O
also	O
describes	O
novel	O
methods	O
for	O
delaying	O
the	O
onset	O
of	O
Alzheimer	O
's	O
disease	O
,	O
for	O
enhancing	O
cognitive	O
functions	O
,	O
for	O
treating	O
and	O
preventing	O
sleep	O
apnea	O
,	O
for	O
alleviating	O
tobacco	O
withdrawal	O
syndrome	O
,	O
and	O
for	O
treating	O
the	O
dysfunctions	O
of	O
Huntington	O
's	O
Disease	O
by	O
administering	O
a	O
therapeutically	O
effective	O
amount	O
of	O
at	O
least	O
one	O
of	O
the	O
cholinesterase	O
inhibitor	O
compounds	O
described	O
herein	O
.	O

A	O
preferred	O
cholinesterase	O
inhibitor	O
for	O
use	O
in	O
the	O
methods	O
of	O
the	O
invention	O
is	O
donepezil	B
hydrochloride	I
or	O
ARICEPT	B
	O
.	O

administering	O
a	O
cholinesterase	O
inhibitor	O
(	O
a	O
dimethoxyindanone	B
derivative	O
)	O
to	O
treat	O
dementia	O
associated	O
with	O
or	O
caused	O
by	O
vascular	O
diseases	O

The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
N	B
-	I
substituted	I
indole-3-glyoxylamides	I
of	O
the	O
general	O
formula	O
I	O
as	O
antitumor	O
agents	O
and	O
to	O
a	O
pharmaceutical	O
composition	O
having	O
antitumor	O
action	O
,	O
characterized	O
in	O
that	O
it	O
contains	O
at	O
least	O
one	O
of	O
the	O
compounds	O
of	O
the	O
general	O
formula	O
1	O
,	O
if	O
appropriate	O
also	O
in	O
the	O
form	O
of	O
the	O
physiologically	O
tolerable	O
acid	O
addition	O
salts	O
or	O
N	B
-	I
oxides	I
.	O

Furthermore	O
,	O
the	O
invention	O
also	O
includes	O
antitumor	O
agents	O
comprising	O
as	O
active	O
compound	O
one	O
or	O
more	O
N	B
-	I
substituted	I
indole-3-glyoxylamides	I
according	O
to	O
the	O
general	O
formula	O
1	O
and	O
,	O
if	O
appropriate	O
,	O
their	O
physiologically	O
tolerable	O
acid	O
addition	O
salts	O
and	O
,	O
if	O
possible	O
,	O
N	B
-	I
oxides	I
and	O
a	O
pharmaceutically	O
utilizable	O
carrier	O
and/or	O
diluent	O
or	O
auxiliary	O
substance	O
in	O
the	O
form	O
of	O
tablets	O
,	O
coated	O
tablets	O
,	O
capsules	O
,	O
solutions	O
for	O
infusion	O
or	O
ampoules	O
,	O
suppositories	O
,	O
patches	O
,	O
powder	O
preparations	O
which	O
can	O
be	O
employed	O
by	O
inhalation	O
,	O
suspensions	O
,	O
creams	O
and	O
ointments	O
.	O

For	O
therapy	O
of	O
oncoses	O

The	O
invention	O
relates	O
to	O
epothilone	B
analog	O
represented	O
by	O
the	O
formula	O
I	O
wherein	O
(	O
i	O
)	O
R2	O
is	O
absent	O
or	O
oxygen	B
;	O
"	O
a	O
"	O
can	O
be	O
either	O
a	O
single	O
or	O
double	O
bond	O
;	O
"	O
b	O
"	O
can	O
be	O
either	O
absent	O
or	O
a	O
single	O
bond	O
;	O
and	O
"	O
c	O
"	O
can	O
be	O
either	O
absent	O
or	O
a	O
single	O
bond	O
,	O
with	O
the	O
proviso	O
that	O
if	O
R2	O
is	O
oxygen	B
then	O
"	O
b	O
"	O
and	O
"	O
c	O
"	O
are	O
both	O
a	O
single	O
bond	O
and	O
"	O
a	O
"	O
is	O
a	O
single	O
bond	O
;	O
if	O
R2	O
is	O
absent	O
then	O
"	O
b	O
"	O
and	O
"	O
c	O
"	O
are	O
absent	O
and	O
"	O
a	O
"	O
is	O
a	O
double	O
bond	O
;	O
and	O
if	O
"	O
a	O
"	O
is	O
a	O
double	O
bond	O
,	O
then	O
R2	O
,	O
"	O
b	O
"	O
and	O
"	O
c	O
"	O
are	O
absent	O
;	O
R3	O
is	O
a	O
radical	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
hydrogen	B
;	O
lower	O
alkyl	B
;	O
CH	B
	I
CH2	I
;	O
CCH	B
;	O
CH2F	B
;	O
CH2Cl	B
;	O
CH2OH	B
;	O
CH2O	B
(	I
C1-C6-alkyl	I
)	I
;	O
and	O
CH2S	B
(	I
C1-C6-alkyl	I
)	I
;	O
R4	O
and	O
R5	O
are	O
independently	O
selected	O
from	O
hydrogen	B
,	O
methyl	B
or	O
a	O
protecting	O
group	O
;	O
and	O
R1	O
is	O
as	O
defined	O
in	O
the	O
specification	O
,	O
or	O
a	O
salt	O
of	O
a	O
compound	O
of	O
the	O
formula	O
I	O
where	O
a	O
salt	O
-	O
forming	O
group	O
is	O
present	O
.	O

A	O
further	O
aspect	O
of	O
the	O
invention	O
is	O
related	O
to	O
the	O
synthesis	O
of	O
epothilone	B
E.	I
These	O
compounds	O
have	O
inter	O
alia	O
microtubuli	O
depolymerisation	O
inhibiting	O
activity	O
and	O
are	O
e.g.	O
useful	O
against	O
proliferative	O
diseases	O
.	O

Epothilone	B
derivatives	O
and	O
their	O
synthesis	O
and	O
use	O

Compounds	O
are	O
provided	O
which	O
have	O
the	O
structure	O
wherein	O
Q	O
is	O
C	B
or	O
N	B
,	O
A	O
is	O
O	B
or	O
S	B
,	O
Z	O
is	O
O	B
or	O
a	O
bond	O
,	O
X	O
is	O
CH	B
or	O
N	B
and	O
R1	O
,	O
R2	O
,	O
R2a	O
,	O
R2b	O
,	O
R2c	O
,	O
R3	O
,	O
Y	O
,	O
x	O
,	O
m	O
,	O
and	O
n	O
are	O
as	O
defined	O
herein	O
,	O
which	O
compounds	O
are	O
useful	O
as	O
antidiabetic	O
,	O
hypolipidemic	O
,	O
and	O
antiobesity	O
agents	O
.	O

Modulators	O
of	O
blood	O
glucose	B
levels	O
,	O
triglyceride	B
levels	O
,	O
insulin	O
levels	O
and	O
non	B
-	I
esterified	I
fatty	I
acid	I
(	O
NEFA	B
)	O
levels	O
;	O
hypoglycemia	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
antidiabetic	O
,	O
hypolipidemic	O
,	O
antiobesity	O
and	O
hypocholesterolemic	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
their	O
derivatives	O
,	O
their	O
analogs	O
,	O
their	O
tautomeric	O
forms	O
,	O
their	O
stereoisomers	O
,	O
their	O
polymorphs	O
,	O
their	O
pharmaceutically	O
acceptable	O
salts	O
,	O
their	O
pharmaceutically	O
acceptable	O
solvates	O
and	O
pharmaceutically	O
acceptable	O
compositions	O
containing	O
them	O
.	O

Antidiabetic	O
agents	O
,	O
antilipemic	O
agents	O
,	O
dietetics	O
,	O
anticholesterol	O
agents	O
,	O
hypotensive	O
agents	O
,	O
cardiovascular	O
disorders	O
;	O
(	B
S	I
)	I
-Ethyl	I
2-methoxy-3-	I
[	I
4-	I
{	I
3-	I
(	I
4-methanesulfonyloxyphenyl	I
)	I
propylamino	I
}	I
phenyl	I
]	I
propionate	I

The	O
present	O
invention	O
pertains	O
to	O
the	O
use	O
of	O
a	O
compounds	O
for	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
use	O
in	O
the	O
treatment	O
of	O
a	O
proliferative	O
condition	O
,	O
wherein	O
the	O
compounds	O
have	O
the	O
following	O
formula	O
:	O
wherein	O
:	O
each	O
of	O
RB2	O
,	O
RB3	O
,	O
RB4	O
,	O
and	O
RB5	O
is	O
independently	O
H	B
,	O
OH	B
,	O
or	O
OMe	B
;	O
each	O
of	O
R1	O
and	O
R2	O
is	O
independently	O
:	O
H	B
,	O
optionally	O
substituted	O
C1	B
-	I
4alkyl	I
,	O
or	O
optionally	O
substituted	O
C5	B
-	I
20aryl	I
;	O
RA3	O
is	O
H	B
,	O
OH	B
,	O
OC	B
(	I
	I
O	I
)	I
RE	I
,	O
OS	B
(	I
	I
O	I
)	I
2OH	I
,	O
or	O
OP	B
(	I
	I
O	I
)	I
(	I
OH	I
)	I
2	I
;	O
RE	O
is	O
:	O
H	B
,	O
optionally	O
substituted	O
C1	B
-	I
6alkyl	I
,	O
optionally	O
substituted	O
C3	B
-	I
20	I
heterocyclyl	I
,	O
or	O
optionally	O
substituted	O
C5	B
-	I
20aryl	I
;	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
,	O
solvate	O
,	O
amide	B
,	O
ester	B
,	O
ether	B
,	O
chemically	O
protected	O
form	O
,	O
or	O
prodrug	O
thereof	O
.	O

The	O
present	O
invention	O
also	O
pertains	O
to	O
such	O
compounds	O
,	O
pharmaceutical	O
compositions	O
comprising	O
such	O
compounds	O
,	O
and	O
the	O
use	O
of	O
such	O
compounds	O
and	O
compositions	O
,	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
for	O
both	O
diagnosis	O
and	O
treatment	O
of	O
,	O
for	O
example	O
,	O
proliferative	O
conditions	O
,	O
such	O
as	O
cancer	O
,	O
and	O
inflammatory	O
conditions	O
.	O

Antiproliferative	O
agents	O
;	O
antiinflammatory	O
agents	O
;	O
anticancer	O
agents	O
;	O
diagnosis	O
,	O
therapy	O

The	O
invention	O
features	O
methods	O
for	O
increasing	O
or	O
maintaining	O
the	O
number	O
of	O
functional	O
cells	O
of	O
a	O
predetermined	O
type	O
,	O
for	O
example	O
,	O
insulin	O
producing	O
cells	O
of	O
the	O
pancreas	O
,	O
blood	O
cells	O
,	O
spleen	O
cells	O
,	O
brain	O
cells	O
,	O
heart	O
cells	O
,	O
vascular	O
tissue	O
cells	O
,	O
cells	O
of	O
the	O
bile	O
duct	O
,	O
or	O
skin	O
cells	O
,	O
in	O
a	O
mammal	O
(	O
e.g.	O
,	O
a	O
human	O
patient	O
)	O
that	O
has	O
injured	O
or	O
damaged	O
cells	O
of	O
the	O
predetermined	O
type	O
.	O

Induce	O
cell	O
differentiation	O
;	O
process	O
control	O

A	O
process	O
for	O
the	O
preparation	O
of	O
an	O
orally	O
administrable	O
calcium	B
composition	O
comprising	O
the	O
steps	O
of	O
:	O
(	O
i	O
)	O
obtaining	O
a	O
physiologically	O
tolerable	O
particulate	O
calcium	B
compound	O
having	O
a	O
mean	O
particle	O
size	O
in	O
the	O
range	O
3	O
to	O
40	O
m	O
,	O
having	O
a	O
crystalline	O
structure	O
and	O
having	O
a	O
surface	O
area	O
of	O
0.1	O
to	O
1.2	O
m2	O
/	O
g	O
;	O
(	O
ii	O
)	O
mixing	O
the	O
calcium	B
compound	O
with	O
a	O
water	O
-	O
soluble	O
diluent	O
and	O
an	O
aqueous	O
solution	O
of	O
a	O
water	O
soluble	O
binder	O
in	O
a	O
fluid	O
bed	O
granulation	O
apparatus	O
and	O
drying	O
the	O
resulting	O
mixture	O
to	O
produce	O
a	O
first	O
granulate	O
;	O
(	O
iii	O
)	O
optionally	O
mixing	O
the	O
first	O
granulate	O
with	O
one	O
or	O
more	O
further	O
components	O
to	O
produce	O
a	O
second	O
granulate	O
;	O
and	O
(	O
iv	O
)	O
optionally	O
compressing	O
the	O
first	O
or	O
second	O
granulate	O
to	O
form	O
tablets	O
.	O

Fluidized	O
bed	O
granulation	O
,	O
compression	O
to	O
form	O
tablets	O

Methods	O
and	O
compositions	O
for	O
prophylaxis	O
and/or	O
treatment	O
of	O
diseases	O
of	O
the	O
eye	O
of	O
a	O
patient	O
resulting	O
angiogenesis	O
in	O
the	O
eye	O
using	O
antagonists	O
of	O
the	O
integrin	O
receptors	O
v	O
3	O
and/or	O
v	O
5	O
.	O

The	O
compositions	O
can	O
be	O
nanoparticles	O
and	O
are	O
administered	O
to	O
the	O
eye	O
by	O
injection	O
into	O
the	O
sclera	O
of	O
the	O
eye	O
.	O

Methods	O
and	O
compositions	O
for	O
the	O
treatment	O
of	O
diseases	O
of	O
the	O
eye	O

Substituted	O
rifamycin	B
derivatives	O
in	O
which	O
a	O
nitroimidazole	B
,	O
nitrothiazole	B
or	O
nitrofuran	B
pharmacophore	O
is	O
covalently	O
bonded	O
to	O
a	O
rifamycin	B
,	O
methods	O
of	O
using	O
the	O
rifamycin	B
derivatives	O
,	O
and	O
pharmaceutical	O
compositions	O
containing	O
the	O
rifamycin	B
derivatives	O
are	O
disclosed	O
.	O

Methods	O
of	O
synthesizing	O
these	O
substituted	O
rifamycin	B
derivatives	O
are	O
also	O
disclosed	O
.	O

The	O
rifamycin	B
derivatives	O
possess	O
antibacterial	O
activity	O
,	O
and	O
are	O
effective	O
against	O
a	O
number	O
of	O
human	O
and	O
veterinary	O
pathogens	O
in	O
the	O
treatment	O
of	O
bacterial	O
diseases	O
.	O

4-Deoxy-3,4-	B
[	I
2-spiro-	I
[	I
1-	I
[	I
2-	I
(	I
2-methyl-5-nitro	I
-	I
imidazol-1-yl	I
)	I
ethyl	I
]	I
-piperidin-4-yl	I
]	I
]	I
-	I
(	I
1H	I
)	I
-imidazo-	I
(	I
2,5-dihydro	I
)	I
rifamycin	I
;	O
antibiotic	O
resistance	O
;	O
synergistic	O
effects	O
of	O
covalently	O
linking	O
antibacterial	O
pharmacophores	O
together	O
;	O
pharmacokinetics	O
;	O
aerobic	O
,	O
anaerobic	O
gram	O
-	O
positive	O
and	O
gram	O
-	O
negative	O
bacteria	O

Disclosed	O
herein	O
are	O
a	O
cephalosporin	B
compound	O
of	O
formula	O
I	O
,	O
wherein	O
R1	O
is	O
selected	O
from	O
the	O
following	O
groups	O
:	O
wherein	O
R2	O
is	O
selected	O
from	O
the	O
following	O
groups	O
:	O
the	O
preparation	O
and	O
uses	O
thereof	O
.	O

A	O
method	O
of	O
preparing	O
the	O
cephalosporin	B
compound	O
as	O
disclosed	O
herein	O
comprises	O
reacting	O
a	O
starting	O
cephalosporin	B
comprising	O
a	O
C7	B
amino	I
group	O
and	O
a	O
C3	B
thio	I
-	I
methyl	I
moiety	O
substituted	O
with	O
an	O
N	O
-	O
containing	O
heterocyclic	B
group	O
with	O
bromoacetyl	B
bromide	I
and	O
then	O
with	O
a	O
N	B
,	I
N-bissubstituted	I
thiourea	I
.	O

Methods	O
of	O
treating	O
an	O
infectious	O
disease	O
are	O
also	O
disclosed	O
,	O
comprising	O
administering	O
to	O
a	O
patient	O
in	O
need	O
thereof	O
the	O
pharmaceutical	O
composition	O
disclosed	O
herein	O
.	O

3-	B
(	I
(	I
1,2,5,6-tetrahydro-2-methyl-5,6-d	I
ioxo-1,2,4-triazine-3-yl	I
)	I
thio	I
)	I
methyl	I
)	I
-7-	I
[	I
[	I
[	I
[	I
[	I
(	I
1-methyl	I
ethyl	I
)	I
amino	I
]	I
[	I
(	I
1-methylethyl	I
)	I
imino	I
]	I
methyl	I
]	I
thio	I
]	I
acetyl	I
]	I
amino	I
]	I
-8-oxo-5-thia-1-aza	I
-	I
bicyclo	I
[	I
4.2.0	I
]	I
oct-2-ene-2-carboxylic	I
acid	I
;	O
bioavailibility	O
;	O
stability	O
;	O
pharmacokinetics	O
;	O
antibiotics	O
;	O
infections	O

The	O
present	O
invention	O
provides	O
illudin	B
analogs	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
:	O
where	O
R1	O
is	O
(	B
CH2	I
)	I
n	I
	I
X	I
	I
Y	I
or	O
H	B
;	O
n	O
is	O
0	O
to	O
4	O
;	O
X	O
is	O
O	B
or	O
S	B
or	O
N	B
or	O
absent	O
;	O
and	O
Y	O
is	O
an	O
optionally	O
substituted	O
(	B
C1-C8	I
)	I
alkyl	I
,	O
(	B
C6-C10	I
)	I
aryl	I
,	O
(	B
C6-C10	I
)	I
aryl	I
(	I
C1-C4	I
)	I
alkyl	I
or	O
cyclo	B
(	I
C3-C6	I
)	I
alkyl	I
optionally	O
comprising	O
one	O
or	O
more	O
heteroatoms	O
;	O
a	O
monosaccharide	B
,	O
an	O
amino	B
acid	I
residue	O
,	O
or	O
H	B
when	O
n	O
is	O
2	O
-	O
4	O
;	O
R2	O
is	O
absent	O
;	O
or	O
R1	O
and	O
R2	O
together	O
comprise	O
a	O
5	O
-	O
7	O
membered	O
cyclic	O
ring	O
;	O
R3	O
is	O
(	B
C1-C4	I
)	I
alkyl	I
or	O
H	B
;	O
R4	O
is	O
H	B
,	O
SCH2CO2	B
(	I
C1-C4	I
)	I
alkyl	I
,	O
O	B
(	I
C5-C12	I
)	I
aryl	I
or	O
S	B
(	I
C5-C12	I
)	I
aryl	I
;	O
R5	O
is	O
H	B
,	O
OH	B
or	O
absent	O
;	O
R6	O
is	O
(	B
C1-C4	I
)	I
alkyl	I
or	O
absent	O
;	O
R7	O
is	O
OH	B
or	O
OSi	B
(	I
(	I
C1-C4	I
)	I
alkyl	I
)	I
3	I
;	O
or	O
R6	O
and	O
R7	O
together	O
are	O
ethylenedioxy	B
;	O
R8	O
is	O
optionally	O
substituted	O
(	B
C1-C4	I
)	I
alkyl	I
;	O
and	O
the	O
bonds	O
represented	O
by	O
-----	O
are	O
individually	O
present	O
or	O
absent	O
.	O

The	O
invention	O
further	O
provides	O
dimers	O
comprising	O
analogs	O
of	O
formula	O
(	O
I	O
)	O
.	O

1-Substituted-	B
[	I
1H	I
-	I
indene-6,1'-cyclopropane	I
]	I
-4-one	I
derivatives	O
:	O
solid	O
tumors	O
and	O
multi	O
-	O
drug	O
resistant	O
tumors	O
;	O
-cell	O
leukemia	O
,	O
B	O
-	O
cell	O
lymphoma	O
,	O
myeloma	O
,	O
T	O
-	O
cell	O
leukemia	O
,	O
T	O
-	O
cell	O
lymphoma	O
,	O
small	O
leukemia	O
,	O
and	O
small	O
cell	O
lymphoma	O

Compounds	O
of	O
the	O
formula	O
(	O
1	O
)	O
in	O
which	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
and	O
X	O
have	O
the	O
meanings	O
indicated	O
in	O
the	O
description	O
,	O
are	O
novel	O
effective	O
compounds	O
with	O
Eg5	O
inhibitory	O
,	O
anti	O
-	O
proliferative	O
and/or	O
apoptosis	O
inducing	O
activity	O
.	O

10-	B
(	I
o	I
-	I
Hydroxyphenyl	I
)	I
--3a,4,9,10-tetrahydro-2-alkyl-2,9,10a	I
-	I
triazacyclopenty	I
[	I
b	I
]	I
fluorene-1,3-diones	I
or	O
the	O
corresponding	O
2,10a	B
-	I
diaza-9	I
oxafluorenediones	I
or	I
1,10a	I
-	I
diaza-9-thiafluorenediones	I
;	O
antiproliferative	O
,	O
apoptosis	O
-	O
inducing	O
agents	O
;	O
treating	O
color	O
cancer	O

Fasudil	B
-	O
containing	O
preparations	O
that	O
despite	O
the	O
us	O
of	O
a	O
container	O
excelling	O
in	O
the	O
visibility	O
of	O
contents	O
without	O
particularly	O
blocking	O
of	O
light	O
,	O
exhibit	O
high	O
stability	O
against	O
light	O
;	O
and	O
a	O
method	O
of	O
improving	O
the	O
stability	O
of	O
the	O
preparations	O
against	O
light	O
of	O
storing	O
the	O
same	O
.	O

By	O
regulating	O
the	O
pH	O
value	O
of	O
aqueous	O
solution	O
of	O
fasudil	B
charged	O
in	O
a	O
colorless	O
transparent	O
container	O
to	O
5.5	O
,	O
there	O
can	O
be	O
provided	O
fasudil	B
-	O
containing	O
preparations	O
excelling	O
in	O
stability	O
against	O
light	O
;	O
and	O
can	O
be	O
provided	O
a	O
method	O
of	O
improving	O
the	O
stability	O
of	O
the	O
aqueous	O
solution	O
of	O
fasudil	O
against	O
light	O
,	O
or	O
storing	O
the	O
same	O
.	O

Fasudil	B
-	O
containing	O
preparation	O
and	O
method	O
of	O
improving	O
stability	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
NS1	O
proteins	O
or	O
parts	O
thereof	O
of	O
Flaviviruses	O
,	O
in	O
particular	O
of	O
Dengue	O
viruses	O
useful	O
for	O
vaccination	O
against	O
said	O
Flavivirus	O
and	O
against	O
one	O
or	O
more	O
other	O
Flaviviruses	O
.	O

The	O
invention	O
further	O
concerns	O
the	O
NS1	O
protein	O
or	O
parts	O
thereof	O
of	O
one	O
Dengue	O
virus	O
serotype	O
,	O
in	O
particular	O
serotype	O
2	O
,	O
useful	O
for	O
vaccination	O
against	O
Dengue	O
viruses	O
from	O
all	O
serotypes	O
.	O

The	O
invention	O
further	O
concerns	O
DNA	O
comprising	O
an	O
expression	O
cassette	O
coding	O
for	O
a	O
Flavivirus	O
NS1	O
or	O
parts	O
thereof	O
,	O
vectors	O
comprising	O
said	O
DNA	O
and	O
vaccines	O
containing	O
or	O
expressing	O
a	O
Flavivirus	O
NS1	O
.	O

Dengue	O
viruses	O
useful	O
for	O
vaccination	O
against	O
Flavivirus	O
;	O
Modified	O
Vaccinia	O
Virus	O
Ankara	O
(	O
MVA	O
)	O
;	O
stable	O
,	O
can	O
easily	O
be	O
produced	O

The	O
present	O
invention	O
provides	O
Hsp90	O
family	O
protein	O
inhibitors	O
comprising	O
,	O
as	O
an	O
active	O
ingredient	O
,	O
a	O
benzoyl	B
compound	O
represented	O
by	O
general	O
formula	O
(	O
I	O
)	O
:	O
(	O
wherein	O
n	O
represents	O
an	O
integer	O
of	O
0	O
to	O
10	O
;	O
R1	O
represents	O
substituted	O
or	O
unsubstituted	O
lower	O
alkoxy	B
,	O
substituted	O
or	O
unsubstituted	O
lower	O
alkoxycarbonyl	B
,	O
CONR7R8	B
or	O
the	O
like	O
;	O
R2	O
represents	O
substituted	O
or	O
unsubstituted	O
aryl	B
,	O
a	O
substituted	O
or	O
unsubstituted	O
aromatic	B
heterocyclic	I
group	O
or	O
the	O
like	O
;	O
R3	O
and	O
R5	O
,	O
which	O
may	O
be	O
the	O
same	O
or	O
different	O
,	O
each	O
represent	O
a	O
hydrogen	B
atom	O
,	O
substituted	O
or	O
unsubstituted	O
lower	O
alkyl	B
,	O
substituted	O
or	O
unsubstituted	O
lower	O
alkenyl	B
or	O
the	O
like	O
;	O
and	O
R4	O
and	O
R6	O
,	O
which	O
may	O
be	O
the	O
same	O
or	O
different	O
,	O
each	O
represent	O
a	O
hydrogen	B
atom	O
,	O
halogen	B
,	O
substituted	O
or	O
unsubstituted	O
lower	O
alkyl	B
,	O
substituted	O
or	O
unsubstituted	O
aryl	B
or	O
the	O
like	O
)	O
or	O
a	O
prodrug	O
thereof	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
of	O
said	O
benzoyl	B
compound	O
or	O
said	O
prodrug	O
.	O

inhibition	O
of	O
heat	O
shock	O
protein	O
90	O
(	O
HSP90	O
)	O
comprising	O
administering	O
benzoyl	B
compounds	O
or	O
prodrugs	O
,	O
as	O
antitumor	O
agents	O

Isomaltooligosaccharides	B
(	O
IMOs	B
)	O
produced	O
by	O
Leuconostoc	O
mesenteroides	O
ATCC	O
13146	O
fermentation	O
with	O
a	O
sucrose	B
:	O
maltose	B
ratio	O
of	O
2:1	O
have	O
been	O
discovered	O
to	O
be	O
effective	O
prebiotics	O
in	O
mixed	O
cultures	O
of	O
microbial	O
populations	O
,	O
including	O
cultures	O
from	O
chicken	O
ceca	O
.	O

Surprisingly	O
in	O
mixed	O
microbial	O
cultures	O
this	O
IMO	B
composition	O
proved	O
as	O
effective	O
as	O
FOS	O
.	O

Thus	O
,	O
these	O
IMOs	B
can	O
be	O
used	O
as	O
effective	O
prebiotics	O
for	O
both	O
birds	O
and	O
mammals	O
.	O

Moreover	O
,	O
the	O
IMOs	B
were	O
discovered	O
to	O
be	O
effective	O
non	O
-	O
competitive	O
inhibitors	O
of	O
	O
-	O
glucosidase	O
.	O

These	O
IMOs	B
also	O
will	O
be	O
useful	O
,	O
as	O
an	O
	O
-	O
glucosidase	O
inhibitor	O
,	O
in	O
a	O
therapeutic	O
application	O
for	O
several	O
diseases	O
,	O
including	O
obesity	O
,	O
diabetes	O
mellitus	O
,	O
pre	O
-	O
diabetes	O
,	O
gastritis	O
,	O
gastric	O
ulcer	O
,	O
duodenal	O
ulcer	O
,	O
caries	O
,	O
cancer	O
,	O
viral	O
disease	O
such	O
as	O
hepatitis	O
B	O
and	O
C	O
,	O
HIV	O
,	O
and	O
AIDS	O
.	O

A	O
diet	O
with	O
5	O
-	O
20	O
%	O
IMOs	B
was	O
also	O
shown	O
to	O
reduce	O
the	O
abdominal	O
fat	O
tissue	O
in	O
mammals	O
.	O

Isomaltooligosaccharides	B
to	O
inhibit	O
avian	O
pathogenic	O
intestinal	O
bacteria	O

A	O
method	O
of	O
identifying	O
epigenetically	O
silenced	O
genes	O
,	O
e.g.	O
,	O
methylation	O
silenced	O
genes	O
,	O
in	O
cancer	O
cells	O
is	O
provided	O
.	O

In	O
addition	O
,	O
methods	O
of	O
identifying	O
a	O
cancer	O
by	O
detecting	O
epigenetic	O
silencing	O
of	O
gene	O
expression	O
are	O
provided	O
,	O
as	O
are	O
methods	O
of	O
treating	O
a	O
subject	O
having	O
such	O
a	O
cancer	O
,	O
for	O
example	O
,	O
a	O
colorectal	O
cancer	O
and/or	O
gastric	O
cancer	O
.	O

Reagents	O
for	O
practicing	O
such	O
methods	O
also	O
are	O
provided	O
.	O

Detecting	O
a	O
colorectal	O
cancer	O
and/or	O
gastric	O
cancer	O
,	O
detecting	O
selective	O
hybridization	O
of	O
nucleic	O
acid	O
,	O
therapeutic	O
treatment	O
of	O
a	O
cancer	O
,	O
a	O
kit	O
contains	O
oligonucleotide	B

The	O
present	O
invention	O
relates	O
to	O
cinnamic	B
acid	I
dimers	I
,	O
their	O
preparation	O
and	O
the	O
use	O
thereof	O
for	O
treating	O
neurodegenerative	O
disease	O
,	O
which	O
have	O
excellent	O
effect	O
on	O
enhancing	O
the	O
learning	O
and	O
memory	O
-	O
retention	O
ability	O
in	O
vivo	O
and	O
have	O
fewer	O
side	O
-	O
effects	O
by	O
showing	O
no	O
hormone	O
properties	O
,	O
even	O
when	O
administered	O
for	O
a	O
long	O
period	O
of	O
time	O
,	O
and	O
thus	O
which	O
can	O
be	O
used	O
for	O
neurodegenerative	O
disease	O
including	O
dementia	O
.	O

fewer	O
side	O
-	O
effects	O
by	O
showing	O
no	O
hormone	O
properties	O
;	O
enhancing	O
the	O
learning	O
and	O
memory	O
-	O
retention	O
,	O
treat	O
dementia	O

Liposarcomas	O
are	O
treated	O
using	O
HIV	O
protease	O
inhibitors	O
,	O
particularly	O
nelfinavir	B
.	O

The	O
protease	O
inhibitors	O
may	O
be	O
used	O
alone	O
or	O
in	O
combination	O
with	O
traditional	O
cancer	O
treatments	O
,	O
such	O
as	O
chemotherapy	O
,	O
radiotherapy	O
,	O
or	O
surgery	O
.	O

Using	O
HIV	O
protease	O
inhibitors	O
(	O
indinavir	B
,	O
nelfinavir	B
,	O
ritonavir	B
,	O
or	O
saquinavir	B
)	O
alone	O
or	O
in	O
combination	O
with	O
chemotherapy	O
,	O
radiotherapy	O
,	O
or	O
surgery	O

Disclosed	O
herein	O
are	O
pharmaceutical	O
compositions	O
comprising	O
an	O
inverse	O
serotonin	B
receptor	O
agonist	O
or	O
a	O
serotonin	B
receptor	O
antagonist	O
and	O
an	O
anti	O
-	O
psychotic	O
agent	O
.	O

Disclosed	O
herein	O
are	O
also	O
methods	O
of	O
treating	O
psychotic	O
disorders	O
using	O
the	O
disclosed	O
pharmaceutical	O
compositions	O
.	O

combination	O
of	O
N-	B
(	I
1-methylpiperidin-4-yl	I
)	I
-N-	I
(	I
4-fluorophenylmethyl	I
)	I
-N'-	I
(	I
4-	I
(	I
2-methylpropyloxy	I
)	I
phenylmethyl	I
)	I
carbamide	I
andmonoamine	O
oxidase	O
inhibitor	O
(	O
MAO	O
-	O
I	O
)	O
selected	O
from	O
tranylcypromine	B
(	O
Parnate	B
)	O
,	O
phenelzine	B
(	O
Nardil	B
)	O
,	O
maprotiline	B
,	O
and	O
isocarboxazid	B
(	O
Marplan	B
)	O
;	O
anti	O
-	O
psychotic	O
agent	O
;	O
dosage	O
form	O
;	O
capsule	O

Compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
,	O
in	O
which	O
R1	O
,	O
R2	O
,	O
m	O
,	O
Q	O
and	O
B	O
have	O
the	O
meanings	O
indicated	O
in	O
Claim	O
1	O
,	O
are	O
inhibitors	O
of	O
tyrosine	B
kinases	O
,	O
in	O
particular	O
Met	B
kinase	O
,	O
and	O
can	O
be	O
employed	O
,	O
inter	O
alia	O
,	O
for	O
the	O
treatment	O
of	O
tumours	O
.	O

Substituted	O
5-phenyl-3,6-dihydro-2-oxo-6H-1,3,4-thiadiazines	B

This	O
invention	O
relates	O
to	O
vitamin	O
-	O
mitomycin	O
conjugates	O
,	O
to	O
a	O
method	O
of	O
using	O
the	O
conjugates	O
to	O
selectively	O
eliminate	O
a	O
population	O
of	O
pathogenic	O
cells	O
in	O
a	O
host	O
animal	O
harboring	O
the	O
pathogenic	O
cells	O
,	O
and	O
to	O
a	O
method	O
of	O
preparation	O
of	O
the	O
conjugates	O
.	O

The	O
conjugate	O
is	O
of	O
the	O
general	O
formula	O
B	O
-	O
L	O
-	O
X	O
wherein	O
the	O
group	O
B	O
is	O
a	O
vitamin	O
,	O
or	O
an	O
analog	O
or	O
a	O
derivative	O
thereof	O
,	O
that	O
binds	O
to	O
a	O
surface	O
accessible	O
vitamin	O
receptor	O
that	O
is	O
uniquely	O
expressed	O
,	O
overexpressed	O
,	O
or	O
preferentially	O
expressed	O
by	O
a	O
population	O
of	O
pathogenic	O
cells	O
,	O
wherein	O
the	O
group	O
L	O
comprises	O
a	O
cleavable	O
linker	O
,	O
and	O
wherein	O
the	O
group	O
X	O
comprises	O
a	O
mitomycin	B
compound	O
,	O
or	O
an	O
analog	O
or	O
a	O
derivative	O
thereof	O
.	O

An	O
additional	O
therapeutic	O
agent	O
,	O
such	O
as	O
a	O
chemotherapeutic	O
agent	O
,	O
can	O
be	O
administered	O
in	O
combination	O
with	O
the	O
conjugate	O
.	O

Antiproliferative	O
agents	O
;	O
gene	O
overexpression	O

The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
P	O
is	O
sulfone	O
or	O
sulfonamide	B
;	O
and	O
A	O
,	O
B	O
,	O
W	O
,	O
X	O
,	O
Y	O
and	O
R3	O
are	O
as	O
defined	O
in	O
the	O
description	O
;	O
to	O
pharmaceutical	O
compositions	O
comprising	O
these	O
compounds	O
,	O
and	O
to	O
the	O
use	O
of	O
the	O
compounds	O
for	O
the	O
prophylaxis	O
and	O
treatment	O
of	O
medical	O
conditions	O
relating	O
to	O
obesity	O
,	O
type	O
II	O
diabetes	O
,	O
and/or	O
CNS	O
disorders	O
,	O
to	O
achieve	O
reduction	O
of	O
body	O
weight	O
and	O
of	O
body	O
weight	O
gain	O
.	O

Such	O
as	O
6-benzenesulfonyl-4-piperazin-1-yl	B
-	I
quinoline	I
hydrochloride	I
;	O
for	O
treatment	O
of	O
central	O
nervous	O
system	O
and/or	O
5-	O
HT6	O
receptor	O
related	O
disorders	O
;	O
for	O
weight	O
gain	O
/	O
loss	O

Methods	O
of	O
modifying	O
,	O
repairing	O
,	O
attenuating	O
and	O
inactivating	O
a	O
gene	O
or	O
other	O
chromosomal	O
DNA	O
in	O
a	O
cell	O
are	O
disclosed	O
.	O

Also	O
disclosed	O
are	O
methods	O
of	O
treating	O
or	O
prophylaxis	O
of	O
a	O
genetic	O
disease	O
in	O
an	O
individual	O
in	O
need	O
thereof	O
.	O

Gene	O
repair	O
involving	O
in	O
vivo	O
excision	O
of	O
targeting	O
DNA	O

The	O
invention	O
relates	O
to	O
a	O
novel	O
pharmaceutical	O
modified	O
release	O
formulation	O
of	O
guaifenesin	B
and	O
dextromethorphan	B
.	O

The	O
formulation	O
may	O
comprise	O
a	O
hydrophilic	O
polymer	O
,	O
preferably	O
a	O
hydroxypropyl	O
methylcellulose	O
,	O
and	O
a	O
water	O
-	O
insoluble	O
polymer	O
,	O
preferably	O
an	O
acrylic	O
resin	O
,	O
in	O
a	O
ratio	O
range	O
of	O
about	O
one	O
-	O
to	O
-	O
one	O
(	O
1:1	O
)	O
to	O
about	O
nine	O
-	O
to	O
-	O
one	O
(	O
9:1	O
)	O
,	O
more	O
preferably	O
a	O
range	O
of	O
about	O
three	O
-	O
to	O
-	O
two	O
(	O
3:2	O
)	O
to	O
about	O
six	O
-	O
to	O
-	O
one	O
(	O
6:1	O
)	O
,	O
and	O
most	O
preferably	O
in	O
a	O
range	O
of	O
about	O
two	O
-	O
to	O
-	O
one	O
(	O
2:1	O
)	O
to	O
about	O
four	O
-	O
to	O
-	O
one	O
(	O
4:1	O
)	O
by	O
weight	O
.	O

This	O
formulation	O
capable	O
of	O
providing	O
therapeutically	O
effective	O
bioavailability	O
of	O
guaifenesin	B
for	O
at	O
least	O
twelve	O
hours	O
after	O
dosing	O
in	O
a	O
human	O
subject	O
.	O

The	O
invention	O
also	O
relates	O
to	O
a	O
modified	O
release	O
product	O
which	O
has	O
two	O
portions	O
:	O
a	O
first	O
portion	O
having	O
an	O
immediate	O
release	O
formulation	O
of	O
guaifenesin	B
and	O
a	O
second	O
portion	O
having	O
a	O
sustained	O
release	O
formulation	O
of	O
guaifenesin	O
,	O
wherein	O
one	O
or	O
both	O
portions	O
further	O
comprises	O
dextromethorphan	B
.	O

The	O
modified	O
release	O
product	O
has	O
a	O
maximum	O
guaifenesin	B
serum	O
concentration	O
equivalent	O
to	O
that	O
of	O
an	O
immediate	O
release	O
guaifenesin	B
tablet	O
,	O
and	O
is	O
capable	O
of	O
providing	O
therapeutically	O
effective	O
bioavailability	O
of	O
guaifenesin	B
for	O
at	O
least	O
twelve	O
hours	O
after	O
dosing	O
in	O
a	O
human	O
subject	O
.	O

Sustained	O
release	O
portion	O
of	O
unit	O
dose	O
containing	O
guaifenesin	B
,	O
dextromethorphan	B
and	O
a	O
release	O
-	O
delaying	O
matrix	O
contains	O
a	O
hydrophilic	O
polymer	O
and	O
a	O
water	O
insoluble	O
polymer	O
,	O
immediate	O
release	O
portion	O
containing	O
guaifenesin	B

Provided	O
is	O
a	O
rapamycin	B
analog	O
composition	O
including	O
a	O
crystalline	O
form	O
of	O
a	O
rapamycin	B
analog	O
.	O

The	O
crystal	O
can	O
be	O
a	O
hydrate	B
.	O

dehydrate	B
,	O
solvate	O
,	O
or	O
desolvate	O
.	O

The	O
rampamycin	B
analog	O
can	O
have	O
a	O
structure	O
of	O
Formula	O
1	O
,	O
which	O
is	O
optionally	O
a	O
prodrug	O
,	O
salt	O
,	O
derivative	O
,	O
or	O
combination	O
thereof	O
:	O
Crystalline	O
forms	O
of	O
rapamycin	B
analogs	O

A	O
novel	O
adenine	B
compound	O
represented	O
by	O
the	O
formula	O
(	O
1	O
)	O
:	O
[	O
wherein	O
R1	O
is	O
substituted	O
or	O
unsubstituted	O
alkyl	B
,	O
etc	O
.	O
,	O
X	O
is	O
oxygen	B
,	O
etc	O
.	O
,	O
A1	O
is	O
4-	O
to	O
8-membered	O
substituted	O
or	O
unsubstituted	O
saturated	O
nitrogen	B
-	O
containing	O
heterocycle	B
containing	O
1	O
to	O
2	O
hetero	B
atom	O
(	O
s	O
)	O
selected	O
from	O
1	O
to	O
2	O
nitrogen	B
(	O
s	O
)	O
,	O
0	O
to	O
1	O
oxygen	B
and	O
0	O
to	O
1	O
sulfur	B
,	O
etc	O
.	O
,	O
A2	O
is	O
substituted	O
or	O
unsubstituted	O
6-	O
to	O
10-membered	O
aryl	B
,	O
etc	O
.	O
,	O
L1	O
and	O
L2	O
are	O
independently	O
a	O
straight	O
chain	O
or	O
branched	O
chain	O
alkylene	B
,	O
etc	O
.	O
]	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
which	O
is	O
useful	O
as	O
a	O
medicament	O
.	O

Adenine	B
compound	O

The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
Formula	O
I	O
below	O
and	O
their	O
tautomers	O
or	O
pharmaceutically	O
acceptable	O
salts	O
,	O
compositions	O
and	O
methods	O
of	O
uses	O
thereof	O
:	O
An	O
enzyme	O
in	O
the	O
tryptophan	B
degradation	O
pathway	O
,	O
used	O
to	O
treat	O
neurodegenerative	O
disorders	O
,	O
certain	O
cancers	O
,	O
drug	O
addiction	O
;	O
arylsulfonamides	B
such	O
as	O
3,4-dimethoxy	B
-	I
N-	I
[	I
5-	I
(	I
4-chlorophenyl	I
)	I
-1,2,4-thiadiazole-3-yl	I
]	I
benzenesulfonamide	I

The	O
present	O
invention	O
relates	O
to	O
a	O
composition	O
comprising	O
prebiotic	O
(	O
prebiotic	O
adjuvant	O
)	O
for	O
decreasing	O
inflammatory	O
process	O
by	O
improving	O
the	O
homeostasis	O
of	O
non	O
-	O
specific	O
immune	O
parameters	O
and	O
of	O
lymphocyte	O
subpopulations	O
.	O

It	O
also	O
relates	O
to	O
the	O
use	O
of	O
a	O
prebiotic	O
formulation	O
in	O
the	O
manufacture	O
of	O
a	O
medicament	O
or	O
a	O
food	O
or	O
petfood	O
composition	O
for	O
decreasing	O
inflammatory	O
process	O
and/or	O
abnormal	O
activation	O
of	O
non	O
-	O
specific	O
immune	O
parameters	O
,	O
such	O
as	O
phagocytes	O
.	O

Administering	O
oligosaccharides	B

Fused	O
cyclic	O
pyrimidine	B
compounds	O
,	O
including	O
tautomers	O
thereof	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
,	O
prodrugs	O
,	O
solvates	O
and	O
hydrates	B
thereof	O
,	O
are	O
disclosed	O
having	O
the	O
general	O
Formula	O
I	O
:	O

These	O
compounds	O
are	O
useful	O
in	O
methods	O
for	O
treating	O
cancer	O
,	O
selectively	O
targeting	O
cancerous	O
cells	O
via	O
the	O
proton	O
coupled	O
folate	O
transporter	O
,	O
folate	O
receptor	O
alpha	O
,	O
and/or	O
folate	O
receptor	O
beta	O
pathways	O
,	O
inhibiting	O
GARFTase	O
in	O
cancerous	O
cells	O
,	O
and	O
selectively	O
targeting	O
activated	O
macrophages	O
in	O
a	O
patient	O
having	O
an	O
autoimmune	O
disease	O
,	O
such	O
as	O
rheumatoid	O
arthritis	O
.	O

Selective	O
proton	O
coupled	O
folate	O
transporter	O
and	O
folate	O
receptor	O
,	O
and	O
GARFTase	O
inhibitor	O
compounds	O
and	O
methods	O
of	O
using	O
the	O
same	O

A	O
method	O
for	O
restructuring	O
the	O
epidermis	O
with	O
a	O
composition	O
,	O
wherein	O
said	O
composition	O
includes	O
a	O
polyol	B
-	I
glycoside	I
and	O
said	O
polyol	B
-	I
glycoside	I
is	O
obtained	O
by	O
the	O
acetalization	O
of	O
a	O
polyol	B
with	O
a	O
reducing	O
sugar	B
.	O

Method	O
for	O
restructuring	O
the	O
epidermis	O
using	O
a	O
polyol	B
-	I
glycoside	I
composition	O

The	O
present	O
invention	O
relates	O
to	O
HSP90	O
inhibitors	O
containing	O
fused	O
amino	B
pyridine	I
core	O
that	O
are	O
useful	O
as	O
inhibitors	O
of	O
HSP90	O
and	O
their	O
use	O
in	O
the	O
treatment	O
of	O
HSP90	O
related	O
diseases	O
and	O
disorders	O
such	O
as	O
cancer	O
,	O
an	O
autoimmune	O
disease	O
,	O
or	O
a	O
neurodegenerative	O
disease	O
.	O

Fused	O
amino	B
pyridine	I
as	O
HSP90	O
inhibitors	O

The	O
invention	O
relates	O
to	O
compounds	O
and	O
composition	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
cancer	O
.	O

The	O
invention	O
also	O
covers	O
all	O
diseases	O
that	O
may	O
be	O
treated	O
by	O
selective	O
modulation	O
of	O
levels	O
of	O
reactive	O
oxygen	O
species	O
in	O
diseased	O
cells	O
versus	O
normal	O
cells	O
.	O

Methods	O
for	O
the	O
preparation	O
and	O
administration	O
of	O
such	O
compositions	O
are	O
also	O
disclosed	O
.	O

Compounds	O
and	O
compositions	O
for	O
treating	O
cancer	O

The	O
presently	O
disclosed	O
subject	O
matter	O
discloses	O
characterization	O
of	O
interactions	O
between	O
ligands	O
and	O
Hsp90	O
proteins	O
,	O
including	O
GRP94	O
,	O
wherein	O
ligand	O
binding	O
to	O
the	O
N	B
-	O
terminal	O
nucleotide	O
binding	O
domain	O
of	O
GRP94	O
elicits	O
a	O
conformational	O
change	O
that	O
converts	O
the	O
GRP94	O
from	O
an	O
inactive	O
to	O
an	O
active	O
conformation	O
,	O
and	O
wherein	O
the	O
chaperone	O
and	O
peptide	O
-	O
binding	O
activities	O
of	O
the	O
GRP94	O
are	O
markedly	O
stimulated	O
.	O

Also	O
disclosed	O
are	O
purification	O
,	O
screening	O
,	O
and	O
therapeutic	O
methods	O
pertaining	O
to	O
the	O
biological	O
activity	O
of	O
GRP94	O
,	O
and	O
in	O
some	O
instances	O
HSP90	O
,	O
based	O
upon	O
the	O
characterization	O
of	O
ligand	O
interactions	O
of	O
Hsp90	O
peptide	O
-	O
binding	O
proteins	O
,	O
including	O
GRP94	O
.	O

Characterization	O
of	O
GRP94-ligand	O
interactions	O
and	O
purification	O
,	O
screening	O
,	O
and	O
therapeutic	O
methods	O
relating	O
thereto	O

A	O
wound	O
care	O
device	O
for	O
local	O
treatment	O
of	O
pain	O
in	O
a	O
wound	O
,	O
said	O
device	O
comprising	O
an	O
active	O
pain	O
relieving	O
composition	O
,	O
the	O
device	O
being	O
constructed	O
in	O
such	O
a	O
manner	O
that	O
the	O
pain	O
killing	O
agent	O
is	O
released	O
to	O
the	O
wound	O
in	O
such	O
a	O
way	O
that	O
substantially	O
no	O
effective	O
systemic	O
plasma	O
concentration	O
of	O
the	O
pain	O
killing	O
agent	O
can	O
be	O
found	O
and	O
wherein	O
a	O
majority	O
of	O
said	O
pain	O
killing	O
agent	O
is	O
in	O
direct	O
contact	O
with	O
the	O
wound	O
.	O

Wound	O
care	O
device	O

Thieno-	B
and	O
furo	B
-	I
pyrimidine	I
compounds	O
are	O
described	O
,	O
which	O
are	O
useful	O
as	O
H4	O
receptor	O
modulators	O
.	O

Such	O
compounds	O
may	O
be	O
used	O
in	O
pharmaceutical	O
compositions	O
and	O
methods	O
for	O
the	O
modulation	O
of	O
histamine	B
H4	O
receptor	O
activity	O
and	O
for	O
the	O
treatment	O
of	O
disease	O
states	O
,	O
disorders	O
,	O
and	O
conditions	O
mediated	O
by	O
H4	O
receptor	O
activity	O
,	O
such	O
as	O
inflammation	O
.	O

Thieno-	B
and	O
furo	B
-	I
pyrimidine	I
modulators	O
of	O
the	O
histamine	B
H4	O
receptor	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
synthetic	O
polysaccharides	O
with	O
antithrombotic	O
activity	O
,	O
having	O
at	O
least	O
one	O
covalent	O
bond	O
with	O
an	O
amino	B
chain	O
,	O
and	O
to	O
the	O
preparation	O
method	O
thereof	O
and	O
to	O
the	O
therapeutic	O
use	O
thereof	O
.	O

Polysaccharides	O
with	O
antithrombotic	O
activity	O
,	O
including	O
a	O
covalent	O
bond	O
and	O
an	O
amino	O
chain	O

The	O
invention	O
provides	O
dietary	O
fiber	O
formulation	O
and	O
related	O
methods	O
for	O
its	O
administration	O
.	O

In	O
one	O
embodiment	O
,	O
the	O
invention	O
provides	O
a	O
dietary	O
fiber	O
formulation	O
comprising	O
:	O
partially	O
-	O
hydrolyzed	O
guar	O
gum	O
(	O
PHGG	O
)	O
;	O
and	O
fructooligosaccharides	O
(	O
FOS	O
)	O
,	O
wherein	O
the	O
dietary	O
fiber	O
formulation	O
exhibits	O
a	O
prebiotic	O
potential	O
greater	O
than	O
a	O
prebiotic	O
potential	O
of	O
PHGG	O
and	O
FOS	O
individually	O
.	O

Dietary	O
fiber	O
formulation	O
and	O
method	O
of	O
administration	O

A	O
novel	O
class	O
of	O
hydroxylases	O
is	O
described	O
having	O
the	O
amino	O
acid	O
sequence	O
of	O
SEQ	O
ID	O
NO	O
:	O
2	O
,	O
4	O
,	O
6	O
and	O
8	O
,	O
and	O
variants	O
and	O
fragments	O
thereof	O
having	O
HIF	O
hydroxylation	O
activity	O
.	O

The	O
polypeptides	O
of	O
the	O
invention	O
have	O
in	O
particular	O
prolyl	O
hydroxylase	O
activity	O
.	O

An	O
assay	O
method	O
monitors	O
the	O
interaction	O
of	O
the	O
HIF	O
hydroxylase	O
with	O
a	O
substrate	O
.	O

Modulators	O
of	O
HIF	O
hydroxylase	O
are	O
provided	O
for	O
use	O
in	O
the	O
treatment	O
of	O
a	O
condition	O
associated	O
with	O
increased	O
or	O
decreased	O
HIF	O
levels	O
or	O
activity	O
or	O
for	O
the	O
treatment	O
of	O
a	O
condition	O
where	O
it	O
is	O
desirable	O
to	O
modulate	O
HIF	O
levels	O
or	O
activity	O
.	O

Assay	O
for	O
identifying	O
a	O
modulator	O
of	O
HIF	O
hydroxylase	O

The	O
present	O
invention	O
provides	O
heteroaryl	B
substituted	I
pyrrolo	I
[	I
2,3-b	I
]	I
pyridines	I
and	O
heteroaryl	B
substituted	I
pyrrolo	I
[	I
2,3-b	I
]	I
pyrimidines	I
that	O
modulate	O
the	O
activity	O
of	O
Janus	O
kinases	O
and	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
diseases	O
related	O
to	O
activity	O
of	O
Janus	O
kinases	O
including	O
,	O
for	O
example	O
,	O
immune	O
-	O
related	O
diseases	O
,	O
skin	O
disorders	O
,	O
myeloid	O
proliferative	O
disorders	O
,	O
cancer	O
,	O
and	O
other	O
diseases	O
.	O

Heteroaryl	B
substituted	I
pyrrolo	I
[	I
2,3-b	I
]	I
pyridines	I
and	O
pyrrolo	B
[	I
2,3-b	I
]	I
pyrimidines	I
as	O
Janus	O
kinase	O
inhibitors	O

A	O
composition	O
of	O
three	O
compounds	O
each	O
selected	O
from	O
a	O
selective	O
re	O
-	O
uptake	O
inhibitor	O
of	O
serotonin	B
,	O
a	O
monoamine	B
oxidase	O
inhibitor	O
,	O
and	O
a	O
phosphodiesterase	O
inhibitor	O
,	O
such	O
that	O
all	O
three	O
compounds	O
are	O
different	O
and	O
are	O
naturally	O
occurring	O
.	O

Composition	O
for	O
treating	O
mental	O
health	O
disorders	O

Neurophysiologic	O
information	O
such	O
as	O
quantitative	O
electroencephalography	O
(	O
QEEG	O
)	O
is	O
used	O
in	O
a	O
method	O
for	O
classifying	O
,	O
diagnosing	O
,	O
and	O
treating	O
physiologic	O
brain	O
imbalances	O
.	O

Neurophysiologic	O
information	O
is	O
also	O
used	O
to	O
guide	O
sample	O
selection	O
in	O
clinical	O
tests	O
for	O
psychopharmacologic	O
drug	O
candidates	O
.	O

Finally	O
,	O
neurophysiologic	O
information	O
is	O
used	O
for	O
remotely	O
assessing	O
and	O
treating	O
patients	O
with	O
physiologic	O
brain	O
imbalances	O
.	O

Methods	O
for	O
recommending	O
neurophysiological	O
disorder	O
therapy	O

Desensitizing	O
drug	O
products	O
,	O
methods	O
of	O
making	O
desensitizing	O
drug	O
products	O
,	O
and	O
methods	O
of	O
using	O
desensitizing	O
drug	O
products	O
including	O
delivery	O
of	O
desensitizing	O
drug	O
products	O
.	O

In	O
one	O
embodiment	O
,	O
the	O
desensitizing	O
drug	O
products	O
are	O
male	O
genital	O
desensitizers	O
that	O
comprise	O
one	O
or	O
anesthetic	O
agents	O
and	O
one	O
or	O
more	O
melting	O
point	O
depressing	O
agents	O
.	O

Desensitizing	O
drug	O
product	O

(	B
R	I
)	I
-2-	I
(	I
2-aminothiazol-4-yl	I
)	I
-4-	I
[	I
2-	I
[	I
(	I
2-hydroxy-2-phenylethyl	I
)	I
amino	I
]	I
ethyl	I
]	I
acetic	I
acid	I
anilide	I
or	O
its	O
salt	O
shows	O
a	O
potent	O
bladder	O
relaxation	O
effect	O
in	O
"	O
isolated	O
rat	O
bladder	O
smooth	O
muscle	O
relaxation	O
test	O
"	O
,	O
dose	O
-	O
dependently	O
lowers	O
the	O
contraction	O
frequency	O
of	O
rhythmic	O
bladder	O
contractions	O
in	O
"	O
rat	O
rhythmic	O
bladder	O
contraction	O
measurement	O
test	O
"	O
and	O
,	O
moreover	O
,	O
prolongs	O
the	O
urination	O
intervals	O
in	O
"	O
urination	O
functions	O
measurement	O
test	O
on	O
cyclophosphamide	B
-	O
induced	O
overactive	O
bladder	O
model	O
rat	O
"	O
.	O

Owing	O
to	O
these	O
effects	O
,	O
the	O
above	O
compound	O
is	O
useful	O
as	O
a	O
remedy	O
for	O
overactive	O
bladder	O
.	O

Remedy	O
for	O
overactive	O
bladder	O
comprising	O
acetic	B
acid	I
anilide	I
derivative	O
as	O
the	O
active	O
ingredient	O

Racemates	O
,	O
diastereoisomers	O
and	O
optical	O
isomers	O
of	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
B	O
is	O
H	B
,	O
a	O
C6	O
or	O
C10	O
aryl	B
,	O
C7	B
-	I
16	I
aralkyl	I
;	O
Het	O
or	O
(	O
lower	O
alkyl	B
)	O
-Het	O
,	O
all	O
of	O
which	O
optionally	O
substituted	O
with	O
C1	B
-	I
6	I
alkyl	I
;	O
C1	B
-	I
6	I
alkoxy	I
;	O
C1	B
-	I
6	I
alkanoyl	I
;	O
hydroxy	B
;	O
hydroxyalkyl	B
;	O
halo	B
;	O
haloalkyl	B
;	O
nitro	B
;	O
cyano	B
;	O
cyanoalkyl	B
;	I
amino	B
optionally	O
substituted	O
with	O
C1	B
-	I
6	I
alkyl	I
;	O
amido	B
;	O
or	O
(	O
lower	O
alkyl	B
)	O
amide	B
;	O
or	O
B	O
is	O
an	O
acyl	B
derivative	O
of	O
formula	O
R4C	B
(	I
O	I
)	I
	I
;	O
a	O
carboxyl	B
of	O
formula	O
R4O	B
	I
C	I
(	I
O	I
)	I
	I
;	O
an	O
amide	B
of	O
formula	O
R4N	B
(	I
R5	I
)	I
C	I
(	I
O	I
)	I
	I
;	O
a	O
thioamide	B
of	O
formula	O
R4N	B
(	I
R5	I
)	I
C	I
(	I
S	I
)	I
	I
;	O
or	O
a	O
sulfonyl	B
of	O
formula	O
R4SO2	B
;	O
R5	O
is	O
H	B
or	O
C1	B
-	I
6	I
alkyl	I
;	O
and	O
Y	O
is	O
H	B
or	O
C1	B
-	I
6	I
alkyl	I
;	O
R3	O
is	O
C1	B
-	I
8	I
alkyl	I
,	O
C3	B
-	I
7	I
cycloalkyl	I
,	O
or	O
C4	B
-	I
10	I
alkylcycloalkyl	I
,	O
all	O
optionally	O
substituted	O
with	O
hydroxy	B
,	O
C1	B
-	I
6	I
alkoxy	I
,	O
C1	B
-	I
6	I
thioalkyl	I
,	O
amido	B
,	O
(	O
lower	O
alkyl	B
)	O
amido	B
,	O
C6	O
or	O
C10	O
aryl	B
,	O
or	O
C7	O
-	O
16	O
aralkyl	B
;	O
R2	O
is	O
CH2R20	B
,	O
NH	B
	I
R20	I
,	O
O	B
	I
R20	I
or	O
S	B
	I
R20	I
,	O
wherein	O
R20	O
is	O
a	O
saturated	O
or	O
unsaturated	O
C3	B
-	I
7	I
cycloalkyl	I
or	O
C4	O
-	O
10	O
(	O
alkylcycloalkyl	O
)	O
,	O
all	O
of	O
which	O
being	O
optionally	O
mono-	O
,	O
di-	O
or	O
tri	O
-	O
substituted	O
with	O
R21	O
,	O
or	O
R20	O
is	O
a	O
C6	O
or	O
C10	B
aryl	I
or	O
C7	B
-	I
14	I
aralkyl	I
optionally	O
substituted	O
,	O
or	O
R20	O
is	O
Het	O
or	O
(	O
lower	O
alkyl	B
)	O
-Het	O
,	O
both	O
optionally	O
substituted	O
,	O
Het	O
or	O
(	O
lower	O
alkyl	B
)	O
-Het	O
;	O
carboxyl	B
;	O
carboxy	B
(	O
lower	O
alkyl	B
)	O
;	O
C6	O
or	O
C10	O
aryl	B
,	O
C7	O
-	O
14	O
aralkyl	B
or	O
Het	O
,	O
said	O
aryl	B
,	O
aralkyl	B
or	O
Het	O
being	O
optionally	O
substituted	O
;	O
and	O
R1	O
is	O
H	B
;	O
C1	B
-	I
6	I
alkyl	I
,	O
C3	B
-	I
7	I
cycloalkyl	I
,	O
C2	B
-	I
6	I
alkenyl	I
,	O
or	O
C2	B
-	I
6	I
alkynyl	I
,	O
all	O
optionally	O
substituted	O
with	O
halogen	B
;	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
ester	O
thereof	O
.	O

Hepatitis	O
C	O
inhibitor	O
tri	O
-	O
peptides	O

Methods	O
and	O
compositions	O
for	O
treating	O
or	O
preventing	O
,	O
the	O
occurrence	O
of	O
senile	O
dementia	O
of	O
the	O
Alzheimer	O
's	O
type	O
,	O
or	O
other	O
conditions	O
arising	O
from	O
reduced	O
neuronal	O
metabolism	O
and	O
leading	O
to	O
lessened	O
cognitive	O
function	O
are	O
described	O
.	O

In	O
a	O
preferred	O
embodiment	O
the	O
administration	O
of	O
triglicerides	B
or	O
fatty	B
acids	I
with	O
chain	O
lengths	O
between	O
5	O
and	O
12	O
,	O
to	O
said	O
patient	O
at	O
a	O
level	O
produce	O
an	O
improvement	O
in	O
cognitive	O
ability	O
.	O

Use	O
of	O
medium	O
chain	O
triglycerides	B
for	O
the	O
treatment	O
and	O
prevention	O
of	O
alzheimer	O
's	O
disease	O
and	O
other	O
diseases	O
resulting	O
from	O
reduced	O
neuronal	O
metabolism	O

The	O
invention	O
concerns	O
substituted	O
tricyclic	B
isoxazoline	I
derivatives	O
,	O
more	O
in	O
particular	O
tricyclic	B
dihydrobenzopyranoisoxazoline	I
,	O
dihydroquinolinoisoxazoline	B
,	O
dihydronaphthalenoisoxazoline	B
and	O
dihydrobenzothiopyranoisoxazoline	B
derivatives	O
substituted	O
on	O
at	O
least	O
one	O
of	O
the	O
C6-	O
and	O
C9-positions	O
of	O
the	O
phenylpart	O
of	O
the	O
tricyclic	O
moiety	O
with	O
a	O
selected	O
radical	O
,	O
according	O
to	O
Formula	O
(	O
I	O
)	O
wherein	O
X	O
=	O
CH2	B
,	O
N	B
-	I
R7	I
,	O
S	B
or	O
O	B
,	O
R1	O
,	O
R2	O
,	O
R14	O
and	O
R15	O
are	O
certain	O
specific	O
substituents	O
,	O
with	O
the	O
proviso	O
that	O
at	O
least	O
one	O
of	O
R14	O
and	O
R15	O
is	O
not	O
hydrogen	B
,	O
Pir	O
is	O
preferably	O
an	O
optionally	O
substituted	O
piperidinyl	B
or	O
piperazinyl	B
radical	O
and	O
R3	O
represents	O
an	O
optionally	O
substituted	O
aromatic	B
homocyclic	I
or	I
heterocyclic	I
ring	O
system	O
including	O
a	O
partially	O
or	O
completely	O
hydrogenated	O
hydrocarbon	B
chain	O
of	O
maximum	O
6	O
atoms	O
long	O
with	O
which	O
the	O
ring	O
system	O
is	O
attached	O
to	O
the	O
Pir	O
radical	O
and	O
which	O
may	O
contain	O
one	O
or	O
more	O
heteroatoms	O
selected	O
from	O
the	O
group	O
of	O
O	B
,	O
N	B
and	O
S	B
;	O
a	O
process	O
for	O
their	O
preparation	O
,	O
pharmaceutical	O
compositions	O
comprising	O
them	O
and	O
their	O
use	O
as	O
a	O
medicine	O
,	O
in	O
particular	O
for	O
the	O
treatment	O
of	O
depression	O
,	O
anxiety	O
,	O
movement	O
disorders	O
,	O
psychosis	O
,	O
Parkinson	O
's	O
disease	O
and	O
body	O
weight	O
disorders	O
..	O

The	O
compounds	O
according	O
to	O
the	O
invention	O
have	O
surprisingly	O
been	O
shown	O
to	O
have	O
a	O
serotonine	B
(	O
5-HT	B
)	O
reuptake	O
inhibitor	O
activity	O
in	O
combination	O
with	O
additional	O
2-adrenoceptor	O
antagonist	O
activity	O
and	O
show	O
a	O
strong	O
anti	O
-	O
depressant	O
activity	O
without	O
being	O
sedative	O
.	O

The	O
invention	O
also	O
relates	O
to	O
novel	O
combination	O
of	O
isoxazoline	B
derivatives	O
according	O
to	O
the	O
invention	O
with	O
one	O
or	O
more	O
other	O
compounds	O
selected	O
from	O
the	O
group	O
of	O
antidepressants	O
,	O
anxiolytics	O
,	O
anti	O
-	O
psychotics	O
and	O
anti	O
-	O
Parkinson	O
's	O
disease	O
drugs	O
to	O
improve	O
efficacy	O
and/or	O
onset	O
of	O
action	O
.	O

C6-	O
and	O
c9-substituted	O
chromeno	B
[	I
4	I
,	I
3-c	I
]	I
isoxazoline	I
derivatives	O
and	O
their	O
use	O
as	O
anti	O
-	O
depressants	O

A	O
preparation	O
for	O
external	O
percutaneous	O
administration	O
which	O
comprises	O
a	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drug	O
,	O
an	O
alkyl	B
gallate	I
,	O
and	O
a	O
phenolic	O
radial	O
scavenger	O
having	O
a	O
branched	O
lower	O
alkyl	B
group	O
.	O

Also	O
provided	O
is	O
an	O
interleukin-1	O
production	O
inhibitor	O
which	O
comprises	O
a	O
phenolic	O
radial	O
scavenger	O
having	O
a	O
branched	O
lower	O
alkyl	B
group	O
and/or	O
an	O
alkyl	B
gallate	I
.	O

PREPARATION	O
FOR	O
EXTERNAL	O
PERCUTANEOUS	O
ADMINISTRATION	O
CONTAINING	O
NON	O
-	O
STEROIDAL	O
ANTI	O
-	O
INFLAMMATORY	O
DRUG	O
AND	O
INTERLEUKIN-1	O
PRODUCTION	O
INHIBITOR	O

This	O
invention	O
relates	O
to	O
methods	O
for	O
treating	O
or	O
preventing	O
hepatitis	O
C	O
virus	O
infections	O
in	O
mammals	O
using	O
Toll	O
-	O
Like	O
Receptor	O
(	O
TLR	O
)	O
7	O
ligands	O
and	O
prodrugs	O
thereof	O
.	O

More	O
particularly	O
,	O
this	O
invention	O
relates	O
to	O
methods	O
of	O
orally	O
administering	O
a	O
therapeutically	O
effective	O
amount	O
of	O
one	O
or	O
more	O
prodrugs	O
of	O
TLR7	O
ligands	O
for	O
the	O
treatment	O
or	O
prevention	O
of	O
hepatitis	O
C	O
viral	O
infection	O
.	O

Oral	O
administration	O
of	O
these	O
TLR7	O
immunomodulating	O
ligands	O
and	O
prodrugs	O
thereof	O
to	O
a	O
mammal	O
provides	O
therapeutically	O
effective	O
amounts	O
and	O
reduced	O
undesirable	O
side	O
effects	O
.	O

Tlr7	O
ligands	O
for	O
the	O
treatment	O
of	O
hepatitis	O
c	O

The	O
invention	O
relates	O
to	O
a	O
composition	O
comprising	O
(	O
A	O
)	O
a	O
pharmaceutically	O
effective	O
compound	O
from	O
the	O
compound	O
class	O
of	O
antimycotic	O
substituted	O
2-aminothiazoles	B
,	O
and	O
(	O
B	O
)	O
a	O
nail	O
polish	O
formulation	O
of	O
said	O
compound	O
.	O

The	O
invention	O
further	O
relates	O
to	O
antimycotic	O
nail	O
polish	O
formulations	O
for	O
treating	O
onychomycoses	O
and	O
other	O
diseases	O
of	O
the	O
fingernails	O
or	O
toenails	O
caused	O
by	O
fungal	O
infections	O
.	O

The	O
invention	O
particularly	O
relates	O
to	O
antimycotic	O
nail	O
polish	O
formulations	O
that	O
are	O
applied	O
to	O
nails	O
and	O
form	O
a	O
coating	O
from	O
which	O
the	O
antimycotic	O
agent	O
is	O
released	O
and	O
can	O
penetrate	O
into	O
the	O
nail	O
.	O

Said	O
method	O
allows	O
nails	O
of	O
humans	O
and	O
animals	O
to	O
be	O
treated	O
against	O
fungal	O
infections	O
or	O
fungal	O
infections	O
to	O
be	O
prevented	O
.	O

Antimycotic	O
nail	O
polish	O
formulations	O
comprising	O
substituted	O
2-aminothiazoles	B
as	O
an	O
active	O
substance	O

The	O
use	O
of	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
variable	O
groups	O
are	O
defined	O
within	O
;	O
in	O
the	O
manufacture	O
of	O
medicaments	O
for	O
use	O
in	O
the	O
inhibition	O
of	O
11HSD1	O
,	O
processes	O
for	O
making	O
them	O
,	O
certain	O
compounds	O
within	O
the	O
definition	O
of	O
the	O
formula	O
(	O
I	O
)	O
and	O
pharmaceutical	O
compositions	O
comprising	O
them	O
are	O
described	O
.	O

N	B
-	I
acylated-3-	I
(	I
benzoyl	I
)	I
-	I
pyrrolidines	I
as	O
11-beta	O
-	O
hsd1	O
inhibitors	O
useful	O
for	O
the	O
treatment	O
of	O
metabolic	O
disorders	O
.	O

An	O
agent	O
or	O
method	O
for	O
treatments	O
for	O
severe	O
aphasia	O
in	O
chronic	O
-	O
stage	O
cerebrovascular	O
disorders	O
which	O
contains	O
or	O
employs	O
2-oxo-1-pyrrolidineacetamide	B
as	O
an	O
active	O
ingredient	O
.	O

Agent	O
or	O
method	O
for	O
treatment	O
for	O
severe	O
aphasia	O
in	O
chronic	O
-	O
stage	O
cerebrovascular	O
disorder	O

The	O
present	O
invention	O
discloses	O
the	O
use	O
of	O
conjugated	O
linolenic	B
acids	I
selected	O
from	O
the	O
groups	O
consisting	O
of	O
Cl	B
8:3	I
(	B
9cis	I
,	I
11	I
trans	I
,	I
15	I
cis	I
)	I
octadecatrienoic	I
acid	I
,	O
C18:3	B
(	B
9cis,13trans,15cis	I
)	I
octadecatrienoic	I
acid	I
and	O
mixtures	O
thereof	O
in	O
the	O
reduction	O
of	O
body	O
fat	O
mass	O
and	O
in	O
the	O
treatment	O
and/or	O
prevention	O
of	O
obesity	O
.	O

These	O
conjugated	O
linolenic	B
acids	I
may	O
be	O
provided	O
in	O
the	O
form	O
of	O
a	O
food	O
supplement	O
or	O
as	O
a	O
component	O
of	O
a	O
prepared	O
food	O
product	O
.	O

Use	O
of	O
conjugated	O
linolenic	B
acids	I
for	O
reducing	O
body	O
fat	O
mass	O

An	O
active	O
oxygen	B
eliminator	O
originating	O
in	O
a	O
natural	O
material	O
which	O
comprises	O
water	O
,	O
an	O
organic	O
solvent	O
,	O
an	O
emulsifier	O
and	O
,	O
as	O
the	O
main	O
active	O
ingredients	O
,	O
p	B
-	I
coumalic	I
acid	I
,	O
3,4-di	B
-	I
O	I
-	I
caffeoylquinic	I
acid	I
,	O
3,5-di	B
-	I
O	I
-	I
caffeoylquinic	I
acid	I
,	O
4-hydroxy-3-prenylcinnamic	B
acid	I
and	O
3,5,7-trihydroxy-4'-methoxyflavonol	B
;	O
and	O
a	O
food	O
and	O
a	O
cosmetic	O
containing	O
this	O
active	O
oxygen	B
eliminator	O
.	O

Active	O
oxygen	B
eliminator	O
originating	O
in	O
natural	O
material	O
and	O
use	O
of	O
the	O
same	O

The	O
present	O
invention	O
relates	O
to	O
pharmaceutical	O
compositions	O
having	O
antiviral	O
activity	O
against	O
Coronavirus	O
,	O
and	O
more	O
particularly	O
against	O
those	O
viruses	O
responsible	O
for	O
Severe	O
Acute	O
Respiratory	O
Syndrome	O
(	O
SARS	O
)	O
.	O

In	O
a	O
preferred	O
embodiment	O
it	O
comprises	O
a	O
total	O
standardised	O
extract	O
of	O
a	O
Scutellariae	O
spp	O
.	O

Extracts	O
of	O
scutellaria	O
for	O
the	O
treatment	O
of	O
sars	O

It	O
is	O
intended	O
to	O
provide	O
a	O
remedy	O
for	O
urinary	O
disorder	O
.	O

Namely	O
,	O
a	O
remedy	O
for	O
urinary	O
disorder	O
containing	O
a	O
compound	O
which	O
suppresses	O
the	O
GIRK	O
channel	O
activated	O
current	O
while	O
showing	O
no	O
suppressive	O
effect	O
on	O
the	O
glycine	B
receptor	O
activated	O
current	O
or	O
NMDA	B
receptor	O
activated	O
current	O
.	O

Remedy	O
for	O
urinary	O
disorder	O

Compositions	O
and	O
methods	O
for	O
treating	O
or	O
preventing	O
sepsis	O
in	O
an	O
animal	O
are	O
disclosed	O
.	O

The	O
method	O
comprises	O
administering	O
an	O
electrolyzed	O
saline	O
solution	O
to	O
the	O
animal	O
.	O

In	O
one	O
embodiment	O
,	O
the	O
electrolyzed	O
saline	O
solution	O
comprises	O
ozone	O
and	O
at	O
least	O
one	O
active	O
chlorine	B
species	O
.	O

The	O
electrolyzed	O
saline	O
can	O
further	O
comprise	O
at	O
least	O
one	O
active	O
hydrogen	B
species	O
.	O

Method	O
of	O
treating	O
sepsis	O

An	O
antiviral	O
composition	O
having	O
an	O
effect	O
of	O
selectively	O
inactivating	O
virus	O
-	O
infected	O
cells	O
which	O
comprises	O
,	O
as	O
the	O
active	O
ingredient	O
,	O
iodine	B
ion	I
or	O
a	O
compound	O
forming	O
iodine	B
ion	I
;	O
a	O
functional	O
food	O
containing	O
the	O
antiviral	O
composition	O
as	O
described	O
above	O
and	O
thus	O
having	O
an	O
antiviral	O
function	O
imparted	O
thereto	O
;	O
and	O
an	O
antiviral	O
drug	O
comprising	O
the	O
antiviral	O
composition	O
as	O
described	O
above	O
and	O
having	O
an	O
effect	O
of	O
selectively	O
inactivating	O
virus	O
-	O
infected	O
cells	O
.	O

Thus	O
,	O
it	O
is	O
intended	O
to	O
provide	O
a	O
novel	O
antiviral	O
composition	O
and	O
so	O
on	O
having	O
a	O
function	O
of	O
selectively	O
inactivating	O
AIDS	O
virus	O
-	O
infected	O
cells	O
,	O
viral	O
cancer	O
cells	O
,	O
etc	O
.	O

Composition	O
against	O
aids	O
virus	O
and	O
method	O
of	O
selectively	O
inactivating	O
virus	O
-	O
infected	O
cells	O

A	O
medicine	O
having	O
prostaglandin	B
D2	I
(	O
PGD2	B
)	O
production	O
inhibitory	O
activity	O
and	O
having	O
as	O
an	O
active	O
ingredient	O
a	O
substance	O
selected	O
from	O
compounds	O
represented	O
by	O
the	O
general	O
formula	O
(	O
I	O
)	O
:	O
A	O
-	O
Y	O
-	O
B	O
{	O
wherein	O
A	O
and	O
B	O
each	O
independently	O
represents	O
an	O
optionally	O
substituted	O
,	O
cyclic	B
hydrocarbon	I
or	O
heterocyclic	B
group	O
;	O
and	O
Y	O
represents	O
-CH	B
=	I
N-	I
,	O
-N	B
=	I
CH-	I
,	O
-CONH-	B
,	O
or	O
-NHCO-	B
,	O
provided	O
that	O
the	O
compounds	O
represented	O
by	O
the	O
following	O
formula	O
(	O
I-1	O
)	O
[	O
wherein	O
X	O
represents	O
the	O
formula	O
-N	B
=	I
C	I
(	I
R5	I
)	I
-	I
(	O
wherein	O
the	O
left	O
-	O
side	O
bond	O
is	O
bonded	O
to	O
the	O
benzene	B
ring	O
and	O
the	O
right	O
-	O
side	O
bond	O
is	O
bonded	O
to	O
the	O
nitrogen	B
atom	O
)	O
or	O
the	O
formula	O
-NH	B
-	I
CH	I
(	I
R5	I
)	I
-	I
(	O
wherein	O
the	O
left	O
-	O
side	O
bond	O
is	O
bonded	O
to	O
the	O
benzene	B
ring	O
and	O
the	O
right	O
-	O
side	O
bond	O
is	O
bonded	O
to	O
the	O
nitrogen	B
atom	O
)	O
;	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
and	O
R4	O
each	O
independently	O
represents	O
hydrogen	B
,	O
halogeno	B
,	O
or	O
optionally	O
substituted	O
C1	B
-	I
6	I
alkyl	I
or	O
hydroxy	B
;	O
R5	O
represents	O
an	O
optionally	O
substituted	O
C1	B
-	I
6	I
alkyl	I
or	O
C6	B
-	I
10	I
aryl	I
group	O
;	O
and	O
R	O
represents	O
optionally	O
substituted	O
amino	B
]	O
are	O
excluded	O
}	O
,	O
salts	O
,	O
hydrates	O
,	O
and	O
solvates	O
.	O

Imine	B
derivative	O
and	O
amide	B
derivative	O

The	O
present	O
invention	O
provides	O
compositions	O
including	O
a	O
macrolide	O
compound	O
that	O
inhibits	O
MHC	O
class	O
II	O
expression	O
.	O

The	O
compositions	O
of	O
the	O
invention	O
are	O
used	O
as	O
an	O
immunosuppressive	O
agent	O
in	O
the	O
treatment	O
prior	O
to	O
,	O
during	O
and/or	O
after	O
organ	O
or	O
tissue	O
transplantation	O
,	O
as	O
well	O
as	O
in	O
the	O
treatment	O
of	O
immune	O
-	O
related	O
disorders	O
.	O

Macrolide	O
compositions	O
as	O
therapeutic	O
agent	O

The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
Abnormal	O
Cannabidiols	B
as	O
potent	O
ocular	O
hypotensives	O
,	O
and	O
are	O
particular	O
suitable	O
for	O
the	O
management	O
of	O
glaucoma	O
.	O

In	O
particular	O
said	O
compounds	O
are	O
represented	O
by	O
formula	O
(	O
I	O
)	O
or	O
formula	O
(	O
II	O
)	O
or	O
formula	O
(	O
III	O
)	O
.	O

These	O
compounds	O
have	O
also	O
been	O
found	O
to	O
be	O
useful	O
in	O
providing	O
neuroprotective	O
effect	O
to	O
the	O
eye	O
.	O

Abnormal	O
cannabidiols	B
for	O
lowering	O
intraocular	O
pressure	O

The	O
invention	O
concerns	O
amino	B
-	I
tropane	I
derivatives	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
:	O
Ra	O
R	O
a	O
'	O
et	O
R5	O
represent	O
hydrogen	B
atoms	O
or	O
alkyl	B
groups	O
;	O
R1	O
represents	O
a	O
hydrogen	B
atom	O
or	O
an	O
alkyl	B
,	O
cycloalkyl	B
,	O
heterocycloalkyl	B
or	O
aryl	B
group	O
;	O
R2	O
represents	O
a	O
group	O
of	O
formula	O
-	B
(	I
CH2	I
)	I
x-	I
(	I
CO	I
)	I
y	I
-	I
Y	I
or	O
-	B
(	I
CO	I
)	I
y-	I
(	I
CH2	I
)	I
x	I
-	I
Y	I
,	O
wherein	O
Y	O
represents	O
a	O
hydrogen	B
atom	O
or	O
a	O
hydroxy	B
,	O
alkyl	B
,	O
cycloalkyl	B
,	O
alkoxy	B
,	O
aryl	B
,	O
heteroaryl	B
group	O
or	O
NR11R12	B
;	O
R3	O
represents	O
1	O
to	O
3	O
groups	O
selected	O
among	O
halogen	B
atoms	O
and	O
alkyl	B
,	O
cycloalkyl	B
OR	I
,	O
-NRR	B
'	I
,	O
-CO	B
-	I
NRR	I
'	I
,	O
-NR	B
-	I
CO	I
-	I
R	I
'	I
,	O
-NR	B
-	I
CO	I
-	I
NRR	I
'	I
,	O
-NR	B
-	I
COOR	I
'	I
,	O
-NO2	B
,	O
-CN	B
and	O
-COOR	B
groups	O
;	O
R4	O
is	O
selected	O
among	O
a	O
group	O
of	O
formula	O
(	O
a	O
)	O
,	O
(	O
b	O
)	O
,	O
(	O
c	O
)	O
or	O
(	O
d	O
)	O
:	O
or	O
a	O
group	O
of	O
formula	O
-A	B
-	I
R18	I
,	O
-A	B
-	I
CH	I
=	I
N	I
-	I
R19	I
,	O
-A	B
-	I
N	I
(	I
R20	I
)	I
-A'-R19	I
,	O
-A	B
-	I
CO	I
-	I
N	I
(	I
R2O	I
)	I
-A'-R19	I
,	O
-A	B
-	I
CH	I
(	I
NH2	I
)	I
-R19	I
,	O
-A	B
-	I
N	I
(	I
R20	I
)	I
-COO	I
-	I
A	I
'	I
or	O
-	B
(	I
CH2	I
)	I
r	I
-	I
heteroaryl	I
.	O

The	O
invention	O
also	O
concerns	O
a	O
method	O
for	O
preparing	O
said	O
derivatives	O
and	O
the	O
therapeutic	O
use	O
thereof	O
.	O

Amino	B
-	I
tropane	I
derivatives	O
,	O
preparation	O
thereof	O
and	O
therapeutic	O
use	O
thereof	O

The	O
invention	O
relates	O
to	O
crystalline	O
acid	O
addition	O
salts	O
of	O
donepezil	B
with	O
an	O
organic	O
acid	O
.	O

The	O
acid	O
addition	O
salts	O
have	O
a	O
lower	O
corrosivity	O
compared	O
to	O
the	O
previously	O
known	O
donepezil	B
hydrochloride	I
.	O

The	O
salts	O
can	O
be	O
used	O
for	O
the	O
production	O
of	O
pharmaceutical	O
compositions	O
for	O
the	O
treatment	O
of	O
dementia	O
.	O

Donepezyl	B
salts	O

The	O
invention	O
relates	O
to	O
the	O
preparation	O
of	O
compounds	O
comprising	O
at	O
least	O
one	O
phenol	B
function	O
and	O
one	O
amide	B
function	O
derived	O
from	O
amino-2	B
alkanol-1	I
having	O
formula	O
(	O
I	O
)	O
and	O
(	O
II	O
)	O
,	O
which	O
have	O
antioxidant	O
and	O
antiradical	O
properties	O
and	O
which	O
are	O
soluble	O
in	O
lipid	O
media	O
.	O

The	O
inventive	O
compounds	O
can	O
be	O
used	O
as	O
cosmetic	O
or	O
pharmaceutical	O
preparations	O
for	O
the	O
prevention	O
of	O
biological	O
degradation	O
caused	O
by	O
free	O
radicals	O
.	O

Preparation	O
of	O
phenol	B
-	I
amide	I
compounds	O
with	O
antioxidant	O
properties	O

A	O
medicine	O
for	O
the	O
prevention	O
,	O
treatment	O
,	O
and/or	O
symptom	O
progress	O
inhibition	O
of	O
Parkinson	O
's	O
disease	O
and/or	O
Parkinson	O
's	O
syndrome	O
.	O

It	O
comprises	O
a	O
combination	O
of	O
(	B
2R	I
)	I
-2-propyloctanoic	I
acid	I
,	O
a	O
salt	O
or	O
solvate	O
thereof	O
,	O
or	O
a	O
prodrug	O
of	O
either	O
with	O
an	O
agent	O
for	O
the	O
prevention	O
,	O
treatment	O
,	O
and/or	O
symptom	O
progress	O
inhibition	O
of	O
Parkinson	O
's	O
disease	O
and/or	O
Parkinson	O
's	O
syndrome	O
.	O

The	O
medicine	O
is	O
highly	O
effective	O
in	O
the	O
prevention	O
,	O
treatment	O
,	O
and/or	O
symptom	O
progress	O
inhibition	O
of	O
Parkinson	O
's	O
disease	O
and/or	O
Parkinson	O
's	O
syndrome	O
.	O

In	O
particular	O
,	O
when	O
the	O
medicinal	O
composition	O
which	O
is	O
for	O
oral	O
administration	O
,	O
which	O
contains	O
(	B
2R	I
)	I
-2-propyloctanoic	I
acid	I
,	O
a	O
salt	O
or	O
solvate	O
thereof	O
,	O
or	O
a	O
prodrug	O
of	O
either	O
as	O
an	O
active	O
ingredient	O
,	O
is	O
administered	O
in	O
combination	O
with	O
a	O
levodopa	B
preparation	O
,	O
levodopa	B
/	O
benserazide	O
preparation	O
,	O
levodopa	B
/	O
carbidopa	B
preparation	O
,	O
and/or	O
bromocriptine	B
mesilate	I
in	O
the	O
manner	O
and	O
dose	O
shown	O
in	O
the	O
description	O
,	O
then	O
effects	O
unobtainable	O
with	O
conventional	O
treatments	O
can	O
be	O
produced	O
,	O
such	O
as	O
a	O
dose	O
reduction	O
,	O
alleviation	O
of	O
side	O
effects	O
,	O
and	O
therapeutic	O
-	O
effect	O
enhancement	O
.	O

Therapeutic	O
agent	O
for	O
parkinson	O
's	O
disease	O

This	O
invention	O
provides	O
anti	O
-	O
inflammatory	O
agents	O
of	O
formula	O
(	O
I	O
)	O
,	O
having	O
the	O
structure	O
:	O
formula	O
(	O
I	O
)	O
,	O
formula	O
(	O
II	O
)	O
,	O
wherein	O
A	O
and	O
R1-R10	O
are	O
as	O
defined	O
in	O
the	O
specification	O
,	O
or	O
a	O
N	B
-	I
oxide	I
thereof	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
or	O
a	O
prodrug	O
thereof	O
.	O

(	B
(	I
1h	I
-	I
indazol-3-yl	I
)	I
methyl	I
)	I
phenols	I
and	O
(	B
hydroxyphenyl	I
)	I
(	I
1h	I
-	I
indazol-3-yl	I
)	I
methanones	I
as	O
ligands	O
of	O
the	O
estrogen	O
receptor	O

An	O
URAT1	O
activity	O
inhibitor	O
which	O
contains	O
a	O
nitrogen	B
-	O
containing	O
fused	O
ring	O
compound	O
represented	O
by	O
the	O
following	O
general	O
formula	O
[	O
1	O
]	O
:	O
[	O
1	O
]	O
wherein	O
each	O
symbol	O
is	O
as	O
defined	O
in	O
the	O
description	O
.	O

This	O
URAT1	O
activity	O
inhibitor	O
is	O
useful	O
in	O
,	O
for	O
example	O
,	O
treating	O
pathological	O
conditions	O
in	O
which	O
uric	B
acid	I
participates	O
such	O
as	O
hyperuricemia	O
,	O
gouty	O
node	O
,	O
acute	O
gouty	O
arthritis	O
,	O
chronic	O
gouty	O
arthritis	O
,	O
gouty	O
kidney	O
,	O
urinary	O
calcus	O
,	O
renal	O
dysfunction	O
,	O
coronary	O
artery	O
disease	O
and	O
ischemic	O
heart	O
disease	O
.	O

Nitrogen	B
-	O
containing	O
fused	O
ring	O
compound	O
and	O
use	O
thereof	O

Compounds	O
are	O
described	O
that	O
are	O
active	O
on	O
at	O
least	O
one	O
of	O
PPAR	O
,	O
PPAR	O
,	O
and	O
PPAR	O
,	O
which	O
are	O
useful	O
for	O
therapeutic	O
and/or	O
prophylactic	O
methods	O
involving	O
modulation	O
of	O
at	O
least	O
one	O
of	O
PPAR	O
,	O
PPAR	O
,	O
and	O
PPAR.	O
Indole	B
derivatives	O
for	O
use	O
as	O
ppar	O
active	O
compounds	O

The	O
topical	O
use	O
of	O
13	B
(	I
S	I
)	I
-HODE	I
and	O
analogs	O
are	O
disclosed	O
for	O
the	O
treatment	O
of	O
dry	O
eye	O
disorders	O
.	O

Method	O
of	O
treating	O
dry	O
eye	O
disorders	O
using	O
13	B
(	I
s	I
)	I
-hode	I
and	O
its	O
analogs	O

Therapeutic	O
compositions	O
,	O
particularly	O
sprayable	O
aqueous	O
compositions	O
,	O
comprise	O
ketorolac	B
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
,	O
in	O
combination	O
with	O
a	O
local	O
anesthetic	O
,	O
such	O
as	O
lidocaine	B
hydrochloride	I
.	O

The	O
compositions	O
are	O
nasally	O
administered	O
to	O
a	O
subject	O
in	O
need	O
thereof	O
to	O
treat	O
pain	O
or	O
inflammation	O
and	O
have	O
the	O
benefit	O
of	O
reduced	O
stinging	O
and	O
improved	O
efficacy	O
,	O
compared	O
to	O
known	O
nasally	O
administered	O
compositions	O
.	O

Therapeutic	O
compositions	O
for	O
intranasal	O
administration	O
of	O
ketorolac	B

The	O
present	O
invention	O
is	O
a	O
solid	O
dosage	O
form	O
of	O
a	O
metal	O
complex	O
of	O
tetracycline	B
of	O
Formula	O
(	O
I	O
)	O
for	O
pharmaceutical	O
administration	O
,	O
(	O
I	O
)	O
wherein	O
R1	O
=	O
Cl	B
,	O
N	B
(	I
CH3	I
)	I
2	I
,	O
or	O
H	B
;	O
R2	O
=	O
CH3	B
,	O
H	B
,	O
or	O
CH2=	B
;	O
R3	O
=	O
CH3	B
,	O
H	B
,	O
OH	B
,	O
or	O
absent	O
;	O
and	O
R4	O
=	O
OH	B
or	O
H	B
,	O
with	O
the	O
proviso	O
that	O
if	O
R2	O
is	O
CH3	B
and	O
R3	O
is	O
H	B
,	O
then	O
R4	O
is	O
not	O
OH	B
.	O

A	O
tetracycline	B
metal	O
complex	O
in	O
a	O
solid	O
dosage	O
form	O

The	O
present	O
invention	O
provides	O
novel	O
solid	O
pharmaceutical	O
dosage	O
forms	O
for	O
oral	O
administration	O
comprising	O
a	O
therapeutically	O
active	O
amount	O
of	O
bambuterol	B
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
a	O
therapeutically	O
effective	O
amount	O
of	O
N-	B
(	I
2-chloro-6-methylbenzoyl	I
)	I
-4-	I
[	I
(	I
2,6-dichlorobenzoyl	I
)	I
amino	I
]	I
-L	I
-	I
phenylalanine-2-	I
(	I
diethylamino	I
)	I
ethyl	I
ester	I
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
and	O
one	O
or	O
more	O
pharmaceutically	O
acceptable	O
excipients	O
.	O

These	O
novel	O
solid	O
pharmaceutical	O
dosage	O
forms	O
are	O
useful	O
in	O
the	O
treatment	O
or	O
control	O
of	O
asthma	O
.	O

Bambuterol	B
and	O
integrin	O
inhibitor	O
combination	O

The	O
present	O
invention	O
relates	O
to	O
a	O
human	O
monoclonal	O
antibody	O
specific	O
for	O
the	O
serotype	O
IATS	O
O11	O
of	O
P.	O
aeruginosa	O
,	O
a	O
hybridoma	O
producing	O
it	O
,	O
nucleic	O
acids	O
encoding	O
it	O
,	O
and	O
host	O
cells	O
transfected	O
therewith	O
.	O

Further	O
,	O
the	O
present	O
invention	O
relates	O
to	O
methods	O
for	O
producing	O
said	O
monoclonal	O
antibody	O
.	O

In	O
addition	O
,	O
the	O
present	O
invention	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
at	O
least	O
one	O
antibody	O
or	O
at	O
least	O
one	O
nucleic	O
acid	O
encoding	O
said	O
antibody	O
.	O

Human	O
monoclonal	O
antibody	O
specific	O
for	O
lipopolysaccharides	O
(	O
lps	O
)	O
of	O
the	O
pseudomonas	O
aeruginosa	O
iats	O
o11	O
serotype	O

It	O
is	O
intended	O
to	O
conveniently	O
and	O
efficiently	O
provide	O
a	O
specific	O
compound	O
originating	O
in	O
a	O
natural	O
material	O
and	O
a	O
composition	O
for	O
preventing	O
and/or	O
treating	O
metabolic	O
syndrome	O
and	O
insulin	O
resistance	O
syndrome	O
characterized	O
by	O
containing	O
the	O
above	O
compound	O
as	O
the	O
active	O
ingredient	O
.	O

Namely	O
,	O
a	O
composition	O
for	O
preventing	O
and/or	O
treating	O
metabolic	O
syndrome	O
and	O
insulin	O
resistance	O
syndrome	O
which	O
contains	O
,	O
as	O
the	O
active	O
ingredient	O
,	O
at	O
least	O
one	O
compound	O
selected	O
from	O
among	O
the	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
1	O
)	O
,	O
the	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
4	O
)	O
and	O
the	O
compound	O
represented	O
by	O
the	O
formula	O
(	O
5	O
)	O
or	O
a	O
salt	O
or	O
an	O
ester	O
of	O
the	O
same	O
.	O

Composition	O
for	O
preventing	O
and/or	O
treating	O
metabolic	O
syndrome	O
and	O
insulin	O
resistance	O
syndrome	O

The	O
present	O
invention	O
provides	O
4-hydroxy	B
pentanamides	I
having	O
the	O
following	O
formula	O
(	O
1	O
)	O
,	O
preparation	O
and	O
use	O
thereof	O
.	O

The	O
said	O
compounds	O
show	O
effective	O
activity	O
of	O
inhibiting	O
BACE	O
and	O
preclude	O
the	O
formation	O
of	O
A	O
.	O

Thus	O
the	O
said	O
compounds	O
are	O
useful	O
in	O
the	O
manufacture	O
of	O
medicines	O
for	O
treating	O
Alzheimer	O
's	O
Disease	O
.	O

4-hydroxy	B
pentanamides	I
,	O
the	O
preparation	O
and	O
use	O
thereof	O

The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
deuterated	O
N-	B
[	I
2-	I
(	I
5-methoxy-1H	I
-	I
indol-3-yl	I
)	I
ethyl	I
]	I
acetamides	I
or	O
the	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
for	O
preventing	O
,	O
treating	O
,	O
or	O
controlling	O
a	O
disorder	O
,	O
disease	O
,	O
or	O
biological	O
function	O
that	O
is	O
related	O
to	O
a	O
relative	O
melatonin	B
deficiency	O
and/or	O
can	O
be	O
treated	O
or	O
influenced	O
by	O
administering	O
melatonin	B
provided	O
that	O
the	O
disease	O
or	O
disorder	O
is	O
not	O
a	O
disorder	O
in	O
the	O
framework	O
of	O
manic	O
depression	O
.	O

The	O
invention	O
further	O
relates	O
to	O
the	O
use	O
of	O
deuterated	O
N-	B
[	I
2-	I
(	I
5-methoxy-1H	I
-	I
indol-3-yl	I
)	I
ethyl	I
]	I
acetamides	I
or	O
the	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
for	O
producing	O
a	O
medicament	O
.	O

Also	O
disclosed	O
is	O
a	O
medicament	O
containing	O
deuterated	O
N-	B
[	I
2-	I
(	I
5-methoxy-1H	I
-	I
indol-3-yl	I
)	I
ethyl	I
]	I
acetamides	I
or	O
the	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O

Use	O
of	O
deuterated	O
n-	B
[	I
2-	I
(	I
5-methoxy-1h	I
-	I
indol-3-yl	I
)	I
-ethyl	I
]	I
acetamides	I
and	O
the	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
and	O
medicaments	O
containing	O
said	O
compounds	O

There	O
is	O
provided	O
according	O
to	O
the	O
invention	O
novel	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
or	O
pharmaceutically	O
acceptable	O
solvates	O
thereof	O
.	O

2-quinolone	B
compounds	O
as	O
inhibitors	O
of	O
phosphodiesterases	O

[	O
PROBLEMS	O
]	O
To	O
provide	O
a	O
preventive	O
or	O
remedy	O
having	O
improved	O
efficacy	O
against	O
lipid	O
metabolism	O
disorder	O
,	O
obesity	O
and	O
diabetes	O
and	O
a	O
method	O
of	O
using	O
the	O
same	O
.	O

[	O
MEANS	O
FOR	O
SOLVING	O
PROBLEMS	O
]	O
Focusing	O
on	O
the	O
multidrug	O
therapy	O
,	O
a	O
medicine	O
is	O
designed	O
by	O
using	O
a	O
novel	O
phenylpropionic	B
acid	I
derivative	O
serving	O
as	O
a	O
PPAR	O
activator	O
(	O
for	O
example	O
,	O
(	B
S	I
)	I
-2-ethyl-3-	I
[	I
4-methoxy-3-	I
[	I
N-	I
[	I
[	I
4-	I
(	I
4-fluorophenoxy	I
)	I
phenyl	I
]	I
methyl	I
]	I
carbamoyl	I
]	I
phenyl	I
]	I
propionic	I
acid	I
(	O
KRP-101	O
)	O
)	O
together	O
with	O
a	O
statin	O
drug	O
serving	O
as	O
an	O
antihyperlipidemic	O
or	O
blending	O
them	O
to	O
synergistically	O
or	O
additionally	O
enhance	O
the	O
lipid	O
-	O
lowering	O
effect	O
,	O
thereby	O
providing	O
a	O
novel	O
preventive	O
or	O
remedy	O
having	O
improved	O
efficacy	O
against	O
lipid	O
metabolism	O
disorder	O
,	O
obesity	O
and	O
diabetes	O
and	O
a	O
method	O
of	O
using	O
the	O
same	O
.	O

Novel	O
preventive	O
or	O
remedy	O
for	O
lipid	O
metabolism	O
disorder	O
,	O
obesity	O
and	O
diabetes	O
and	O
use	O
therefor	O

The	O
invention	O
relates	O
to	O
novel	O
oxindol	B
derivative	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
substituents	O
R1	O
,	O
R2	O
,	O
A	O
,	O
B	O
and	O
Y	O
are	O
such	O
as	O
defined	O
in	O
a	O
claim	O
1	O
.	O

Drugs	O
containing	O
said	O
derivatives	O
and	O
the	O
use	O
thereof	O
for	O
preventing	O
and/or	O
treating	O
vassopress	O
-	O
and	O
/	O
or	O
oxytocin	B
-	O
dependent	O
-	O
diseases	O
are	O
also	O
disclosed	O
.	O

Substituted	O
oxindol	B
derivatives	O
,	O
drugs	O
containing	O
said	O
derivatives	O
and	O
the	O
use	O
thereof	O

The	O
inventive	O
antineoplastic	O
preparation	O
is	O
based	O
on	O
a	O
gluconic	O
acid	O
and	O
exhibits	O
an	O
apoptotic	O
and	O
anti	O
-	O
proliferative	O
effect	O
preserving	O
healthy	O
cells	O
.	O

In	O
the	O
first	O
variant	O
,	O
said	O
preparation	O
is	O
embodied	O
in	O
the	O
form	O
of	O
at	O
least	O
one	O
type	O
of	O
gluconate	O
,	O
wherein	O
a	O
salt	O
-	O
forming	O
agent	O
is	O
selected	O
from	O
a	O
group	O
comprising	O
magnesium	O
,	O
sodium	O
,	O
potassium	O
,	O
	O
-	O
aminobutyric	O
acid	O
,	O
ethylenediamine	O
or	O
the	O
mixture	O
thereof	O
.	O

In	O
the	O
second	O
variant	O
,	O
the	O
perpetration	O
is	O
embodied	O
in	O
the	O
form	O
of	O
a	O
co	O
-	O
ordination	O
compound	O
which	O
is	O
based	O
on	O
a	O
magnesium	O
gluconate	O
in	O
which	O
ligands	O
are	O
selected	O
from	O
a	O
group	O
consisting	O
of	O
a	O
	O
-	O
aminobutyric	O
acid	O
,	O
3-hydroxy	O
-	O
	O
-	O
aminobutyric	O
acid	O
,	O
ethylene	O
diamine	O
tetraacetic	O
acid	O
and	O
an	O
ethylene	O
glycol	O
tetraacetic	O
acid	O
.	O

In	O
the	O
third	O
variant	O
,	O
the	O
composition	O
is	O
embodied	O
in	O
the	O
form	O
of	O
a	O
binary	O
salt	O
selected	O
from	O
a	O
group	O
consisting	O
of	O
a	O
magnesium	O
butyrate	O
-	O
gluconate	O
,	O
magnesium	O
oxybutyrate	O
-	O
gluconate	O
,	O
magnesium	O
glucarate	O
-	O
gluconate	O
,	O
calcium	O
butyrate	O
-	O
gluconate	O
,	O
butyrate	O
-	O
gluconate	O
oxybutyrate	O
-	O
gluconate	O
,	O
calcium	O
glucarate	O
-	O
gluconate	O
and	O
the	O
combination	O
thereof	O
.	O

Antineoplastic	O
preparation	O

As	O
a	O
result	O
of	O
a	O
large	O
scale	O
SNP	O
analysis	O
on	O
a	O
group	O
of	O
Perkinson	O
disease	O
patients	O
and	O
a	O
control	O
group	O
of	O
normal	O
persons	O
,	O
it	O
has	O
succeeded	O
in	O
the	O
identification	O
of	O
a	O
gene	O
involved	O
in	O
Perkinson	O
disease	O
(	O
GRK5	O
)	O
.	O

It	O
is	O
now	O
found	O
that	O
the	O
increase	O
in	O
the	O
expression	O
of	O
the	O
GRK5	O
gene	O
induces	O
the	O
enhancement	O
of	O
the	O
phosphorylation	O
of	O
	O
-	O
synuclein	O
,	O
which	O
in	O
turn	O
induces	O
the	O
enhancement	O
of	O
the	O
formation	O
of	O
a	O
soluble	O
	O
-	O
synuclein	O
oligomer	O
,	O
leading	O
to	O
the	O
development	O
of	O
Perkinson	O
disease	O
.	O

It	O
becomes	O
possible	O
to	O
diagnose	O
Perkinson	O
disease	O
and	O
screen	O
a	O
therapeutic	O
agent	O
for	O
Perkinson	O
disease	O
by	O
using	O
the	O
expression	O
of	O
the	O
GRK5	O
gene	O
.	O

Perkinson	O
disease	O
-	O
related	O
gene	O
grk5	O
and	O
use	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
the	O
stable	O
pharmaceutical	O
dosage	O
forms	O
of	O
combination	O
of	O
antiretroviral	O
agents	O
.	O

More	O
particularly	O
,	O
the	O
present	O
invention	O
relates	O
to	O
stable	O
pharmaceutical	O
dosage	O
forms	O
of	O
Lamivudine	B
,	O
Zidovudine	B
and	O
Nevirapine	B
,	O
prepared	O
by	O
granulation	O
technology	O
.	O

Pharmaceutical	O
compositions	O
of	O
antiretrovirals	O

The	O
invention	O
relates	O
to	O
novel	O
heterocyclic	B
N	I
-	I
oxides	I
which	O
are	O
useful	O
as	O
hypoxic	O
selective	O
cytotoxic	O
agents	O
that	O
mediate	O
and/or	O
inhibit	O
cell	O
proliferation	O
,	O
for	O
example	O
,	O
through	O
the	O
activity	O
of	O
protein	O
kinases	O
.	O

The	O
invention	O
is	O
further	O
related	O
to	O
pharmaceutical	O
compositions	O
containing	O
such	O
compounds	O
and	O
compositions	O
,	O
and	O
to	O
methods	O
of	O
treating	O
cancer	O
as	O
well	O
as	O
other	O
disease	O
states	O
associated	O
with	O
unwanted	O
ahgiogenesis	O
and/or	O
cellular	O
proliferation	O
by	O
administering	O
effective	O
amounts	O
of	O
such	O
compounds	O
.	O

Heterocyclic	B
n	I
-	I
oxides	I
as	O
hypoxic	O
selective	O
protein	O
kinase	O
inhibitors	O

Various	O
injectable	O
or	O
insertable	O
uterine	O
fibroid	O
treatment	O
formulations	O
are	O
provided	O
,	O
which	O
comprise	O
a	O
uterine	O
fibroid	O
treatment	O
agent	O
in	O
an	O
amount	O
effective	O
to	O
cause	O
shrinkage	O
or	O
elimination	O
of	O
uterine	O
fibroids	O
.	O

The	O
injectable	O
or	O
insertable	O
formulations	O
are	O
typically	O
solids	O
,	O
semi	O
-	O
solids	O
or	O
high	O
-	O
viscosity	O
fluids	O
.	O

Other	O
aspects	O
of	O
the	O
invention	O
are	O
directed	O
to	O
systems	O
and	O
methods	O
for	O
treatment	O
of	O
uterine	O
fibroids	O
.	O

Method	O
for	O
treatment	O
of	O
uterine	O
fibroid	O
tumors	O

Disclosed	O
are	O
substituted	O
benzo	B
[	I
d	I
]	I
isoxazol-3-yl	I
amine	I
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
which	O
are	O
suitable	O
for	O
the	O
treatment	O
of	O
pain	O
while	O
being	O
provided	O
with	O
an	O
excellent	O
affinity	O
to	O
the	O
KCNQ2	O
/	O
3	O
K+	O
channel	O
and	O
thus	O
being	O
suitable	O
for	O
the	O
treatment	O
of	O
disorders	O
or	O
diseases	O
that	O
are	O
transmitted	O
at	O
least	O
in	O
part	O
through	O
KCNQ2	O
/	O
3	O
K+	B
channels	O
.	O

Substituted	O
benzo	B
(	I
d	I
)	I
isoxazol-3-yl	I
amine	I
compounds	O
as	O
analgesics	O

The	O
present	O
invention	O
provides	O
compounds	O
useful	O
,	O
for	O
example	O
,	O
for	O
modulating	O
insulin	O
levels	O
in	O
a	O
subject	O
,	O
having	O
the	O
general	O
formula	O
I	O
:	O
wherein	O
Q	O
is	O
an	O
optionally	O
substituted	O
phenyl	B
;	O
L	O
is	O
a	O
bond	O
or	O
O	B
;	O
P	B
is	O
a	O
benzene	B
or	O
an	O
optionally	O
substituted	O
thiazole	B
ring	O
;	O
and	O
R1	O
has	O
the	O
values	O
provided	O
herein	O
.	O

The	O
present	O
invention	O
also	O
provides	O
compositions	O
,	O
uses	O
,	O
and	O
methods	O
for	O
use	O
of	O
the	O
compounds	O
,	O
for	O
instance	O
,	O
for	O
treatment	O
of	O
type	O
II	O
diabetes	O
.	O

Compounds	O
,	O
pharmaceutical	O
compositions	O
and	O
methods	O
for	O
their	O
use	O
in	O
treating	O
metabolic	O
disorders	O

This	O
invention	O
relates	O
to	O
a	O
method	O
of	O
treatment	O
of	O
cancer	O
with	O
a	O
combination	O
of	O
an	O
additional	O
therapeutic	O
agent	O
in	O
mammals	O
.	O

This	O
invention	O
also	O
relates	O
to	O
a	O
kit	O
useful	O
in	O
the	O
treatment	O
of	O
abnormal	O
cell	O
growth	O
in	O
mammals	O
,	O
especially	O
humans	O
.	O

Combinations	O
of	O
erbb2	O
inhibitors	O
with	O
other	O
therapeutic	O
agents	O
in	O
the	O
treatment	O
of	O
cancer	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
non	O
steroidal	O
anti	O
-	O
inflammatory	O
compounds	O
(	O
NSAIDs	O
)	O
derivatives	O
of	O
sulindac	B
,	O
for	O
the	O
treatment	O
/	O
prevention	O
,	O
alone	O
or	O
in	O
combination	O
,	O
of	O
cancer	O
.	O

Sulindac	B
derivatives	O
for	O
treatment	O
of	O
cancer	O

The	O
invention	O
provides	O
a	O
compound	O
of	O
the	O
formula	O
(	O
I	O
)	O
or	O
a	O
salt	O
,	O
solvate	O
,	O
tautomer	O
or	O
N	B
-	I
oxide	I
thereof	O
;	O
for	O
use	O
as	O
a	O
PKB	O
kinase	O
inhibitor	O
or	O
PKA	O
kinase	O
inhibitor	O
.	O

In	O
formula	O
(	O
I	O
)	O
,	O
A	O
is	O
a	O
saturated	O
hydrocarbon	B
linker	O
group	O
;	O
E	O
is	O
a	O
monocyclic	B
or	O
bicyclic	B
carbocyclic	I
or	O
heterocyclic	B
group	O
;	O
HET	B
is	O
a	O
monocyclic	B
heterocyclic	I
group	O
;	O
R1	O
is	O
an	O
aryl	B
or	O
heteroaryl	B
group	O
;	O
n	O
is	O
0	O
to	O
4	O
;	O
and	O
R2	O
,	O
R3	O
and	O
R4	O
are	O
as	O
defined	O
in	O
the	O
claims	O
,	O
provided	O
that	O
HET	B
is	O
other	O
than	O
an	O
unsubstituted	O
or	O
substituted	O
pyrazole-4-yl	B
group	O
.	O

Heterocyclic	B
containing	I
amines	I
as	O
kinase	O
b	O
inhibitors	O

The	O
present	O
invention	O
discloses	O
sulfonamide	B
CA	O
IX	O
-	O
selective	O
inhibitors	O
,	O
which	O
selectively	O
bind	O
to	O
the	O
enzyme	O
under	O
hypoxic	O
conditions	O
and	O
are	O
able	O
to	O
reverse	O
the	O
tumor	O
acidification	O
mediated	O
by	O
the	O
enzyme	O
.	O

These	O
compounds	O
are	O
useful	O
in	O
anticancer	O
therapies	O
based	O
on	O
tumor	O
-	O
associated	O
CA	O
isozyme	O
inhibition	O
as	O
well	O
as	O
for	O
hypoxic	O
tumor	O
imaging	O
.	O

The	O
inhibitors	O
contain	O
a	O
fluorescent	O
moiety	O
,	O
preferably	O
fluorescein	O
.	O

Fluorescent	O
sulfonamide	B
derivatives	O
having	O
carbonic	O
anhydrase	O
inhibiting	O
activity	O
and	O
their	O
use	O
as	O
theapeutic	O
and	O
diagnostic	O
agents	O

Disclosed	O
is	O
a	O
tablet	O
containing	O
about	O
3	O
-	O
50	O
%	O
by	O
weight	O
(	O
w	O
/	O
w	O
)	O
of	O
a	O
poorly	O
soluble	O
active	O
ingredient	O
relative	O
to	O
the	O
total	O
tablet	O
weight	O
,	O
magnesium	B
stearate	I
and	O
a	O
hydroxypropylcellulose	O
having	O
a	O
viscosity	O
of	O
about	O
1	O
-	O
4	O
mPas	O
.	O

This	O
tablet	O
is	O
suppressed	O
in	O
dissolution	O
variation	O
between	O
lots	O
.	O

Tablet	O
containing	O
poorly	O
soluble	O
active	O
ingredient	O

Provided	O
is	O
a	O
pharmaceutical	O
composition	O
including	O
clopidogrel	B
bisulfate	I
and	O
a	O
pregelatinized	O
starch	O
.	O

The	O
pharmaceutical	O
composition	O
in	O
which	O
the	O
stability	O
of	O
clopido	B
grel	I
bisulfate	I
is	O
significantly	O
enhanced	O
can	O
be	O
obtained	O
by	O
mixing	O
clopidogrel	B
bisulfate	I
w	O
ith	O
the	O
pregelatinized	O
starch	O
.	O

Pharmaceutical	O
compositions	O
containing	O
clopidogrel	B
bisulfate	I

Therefore	O
the	O
present	O
invention	O
relates	O
specifically	O
to	O
the	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
in	O
which	O
R1	O
and	O
R2	O
,	O
which	O
may	O
be	O
identical	O
or	O
different	O
,	O
are	O
selected	O
from	O
the	O
group	O
comprising	O
H	B
,	O
-CnH2n-1	B
,	O
a	O
linear	O
or	O
branched	O
alkyl	B
group	O
having	O
from	O
1	O
to	O
6	O
carbon	B
atoms	O
,	O
or	O
together	O
form	O
an	O
aromatic	B
or	O
aliphatic	B
ring	O
with	O
5	O
or	O
6	O
atoms	O
;	O
R3	O
is	O
selected	O
from	O
-CO	B
-	I
CH3	I
,	O
-NHOH	B
,	O
-OH	B
,	O
-OR6	B
in	O
which	O
R6	O
is	O
a	O
linear	O
or	O
branched	O
alkyl	B
group	O
having	O
from	O
1	O
to	O
6	O
carbon	B
atoms	O
;	O
R4	O
is	O
selected	O
from	O
H	B
,	O
a	O
linear	O
or	O
branched	O
alkyl	B
group	O
having	O
from	O
1	O
to	O
6	O
carbon	B
atoms	O
,	O
phenyl	B
,	O
benzyl	B
,	O
-CF3	B
or	O
-CF2CF3	B
,	O
vinyl	B
or	O
allyl	B
;	O
R5	O
,	O
R7	O
,	O
R8	O
are	O
hydrogen	B
atoms	O
;	O
or	O
R3	O
and	O
R4	O
,	O
R4	O
and	O
R5	O
,	O
or	O
R7	O
and	O
R8	O
together	O
form	O
a	O
ring	O
,	O
fused	O
to	O
the	O
benzene	B
,	O
aromatic	B
or	O
aliphatic	B
ring	O
with	O
5	O
or	O
6	O
atoms	O
comprising	O
from	O
1	O
to	O
2	O
heteroatoms	O
selected	O
independently	O
from	O
the	O
group	O
comprising	O
N	B
,	O
O.	B
and	O
use	O
thereof	O
in	O
the	O
medical	O
field	O
.	O

Compounds	O
and	O
their	O
salts	O
specific	O
to	O
the	O
ppar	O
receptors	O
and	O
the	O
egf	O
receptors	O
and	O
their	O
use	O
in	O
the	O
medical	O
field	O

[	O
PROBLEMS	O
]	O
To	O
provide	O
a	O
process	O
for	O
producing	O
a	O
glycolipid	O
-	O
containing	O
Simon	O
potato	O
extract	O
or	O
a	O
glycosphingolipid	O
from	O
a	O
Simon	O
potato	O
for	O
the	O
purpose	O
of	O
providing	O
an	O
alternative	O
to	O
a	O
livestock	O
brain	O
ganglioside	O
which	O
is	O
free	O
from	O
the	O
risk	O
of	O
BSE	O
or	O
the	O
like	O
,	O
is	O
safe	O
to	O
a	O
human	O
body	O
and	O
can	O
be	O
ingested	O
on	O
a	O
daily	O
basis	O
,	O
and	O
to	O
provide	O
a	O
nerve	O
cell	O
activator	O
comprising	O
a	O
glycolipid	O
or	O
glycosphingolipid	O
derived	O
from	O
a	O
Simon	O
potato	O
and	O
a	O
health	O
food	O
prepared	O
by	O
using	O
the	O
glycolipid	O
or	O
glycosphingolipid	O
.	O

[	O
MEANS	O
FOR	O
SOLVING	O
PROBLEMS	O
]	O

A	O
Simon	O
potato	O
extract	O
can	O
be	O
produced	O
by	O
immersing	O
a	O
Simon	O
potato	O
in	O
a	O
polar	O
solvent	O
to	O
extract	O
a	O
glycolipid	O
or	O
glycosphingolipid	O
into	O
the	O
polar	O
solvent	O
and	O
then	O
concentrating	O
the	O
resulting	O
immersion	O
fluid	O
.	O

The	O
nerve	O
cell	O
activation	O
effect	O
of	O
the	O
glycolipid	O
or	O
glycosphingolipid	O
is	O
confirmed	O
using	O
an	O
established	O
neuroblast	O
.	O

Simon	O
potato	O
extract	O
,	O
glycosphingolipid	O
derived	O
from	O
simon	O
potato	O
,	O
and	O
process	O
for	O
production	O
of	O
the	O
extract	O
or	O
glycosphingolipid	O

The	O
present	O
invention	O
provides	O
novel	O
compounds	O
which	O
mimic	O
peptides	O
with	O
a	O
C	B
-	O
terminal	O
penultimate	O
proline	O
,	O
such	O
compounds	O
being	O
useful	O
as	O
protease	O
inhibitors	O
,	O
particularly	O
as	O
inhibitors	O
of	O
serine	B
proteases	O
,	O
and	O
more	O
particularly	O
as	O
inhibitors	O
of	O
the	O
NS3	O
serine	B
protease	O
from	O
hepatitis	O
C.	O
The	O
compounds	O
find	O
utility	O
as	O
antiviral	O
agents	O
directed	O
at	O
hepatitis	O
C.	O
The	O
invention	O
further	O
provides	O
methods	O
of	O
employing	O
such	O
inhibitors	O
,	O
alone	O
or	O
in	O
combination	O
with	O
other	O
therapeutic	O
agents	O
,	O
to	O
treat	O
hepatitis	O
C	O
infection	O
in	O
a	O
subject	O
in	O
need	O
of	O
such	O
treatment	O
.	O

Hepatitis	O
c	O
serine	B
protease	O
inhibitors	O
and	O
uses	O
therefor	O

A	O
vaginal	O
treatment	O
composition	O
that	O
rapidly	O
forms	O
a	O
gel	O
when	O
placed	O
into	O
contact	O
with	O
monovalent	O
or	O
polyvalent	O
cations	O
,	O
such	O
as	O
sodium	B
(	O
Na+	B
)	O
and	O
calcium	B
(	O
Ca2	B
+	I
)	O
cations	O
naturally	O
found	O
in	O
vaginal	O
mucosa	O
,	O
is	O
provided	O
.	O

The	O
gel	O
may	O
form	O
in	O
less	O
than	O
about	O
1	O
hour	O
,	O
in	O
some	O
embodiments	O
less	O
than	O
about	O
1	O
minute	O
,	O
and	O
in	O
some	O
embodiments	O
,	O
less	O
than	O
about	O
30	O
seconds	O
.	O

Among	O
other	O
things	O
,	O
such	O
rapid	O
gelation	O
reduces	O
the	O
likelihood	O
of	O
leakage	O
during	O
use	O
.	O

In	O
addition	O
,	O
because	O
the	O
gel	O
may	O
form	O
intravaginally	O
,	O
it	O
is	O
more	O
likely	O
to	O
retain	O
its	O
structure	O
and	O
shape	O
over	O
an	O
extended	O
period	O
of	O
time	O
.	O

In	O
this	O
manner	O
,	O
the	O
gel	O
may	O
provide	O
the	O
prolonged	O
release	O
of	O
a	O
therapeutic	O
agent	O
that	O
inhibits	O
and/or	O
treats	O
vaginal	O
infection	O
.	O

For	O
instance	O
,	O
the	O
gel	O
may	O
remain	O
within	O
the	O
vagina	O
for	O
about	O
2	O
to	O
about	O
48	O
hours	O
to	O
provide	O
the	O
desired	O
effect	O
.	O

Vaginal	O
treatment	O
composition	O

This	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
:	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
wherein	O
:	O
A	O
,	O
B	O
,	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
R6	O
and	O
R7	O
are	O
each	O
as	O
described	O
herein	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
,	O
and	O
compositions	O
containing	O
such	O
compounds	O
and	O
the	O
method	O
and	O
use	O
of	O
such	O
compounds	O
in	O
the	O
treatment	O
of	O
a	O
condition	O
mediated	O
by	O
acid	O
pump	O
antagonistic	O
activity	O
such	O
as	O
,	O
but	O
not	O
limited	O
to	O
,	O
as	O
gastrointestinal	O
disease	O
,	O
gastroesophageal	O
disease	O
,	O
gastroesophageal	O
reflux	O
disease	O
(	O
GERD	O
)	O
,	O
peptic	O
ulcer	O
,	O
gastric	O
ulcer	O
,	O
duodenal	O
ulcer	O
,	O
NSAID	O
-	O
induced	O
ulcers	O
,	O
gastritis	O
,	O
infection	O
of	O
Helicobacter	O
pylori	O
,	O
dyspepsia	O
,	O
functional	O
dyspepsia	O
,	O
Zollinger	O
-	O
Ellison	O
syndrome	O
,	O
non	O
-	O
erosive	O
reflux	O
disease	O
(	O
NERD	O
)	O
,	O
visceral	O
pain	O
,	O
heartburn	O
,	O
nausea	O
,	O
esophagitis	O
,	O
dysphagia	O
,	O
hypersalivation	O
,	O
airway	O
disorders	O
or	O
asthma	O
.	O

Chromane	B
substituted	I
2-alkyl	I
imidazopyridine	I
derivatives	O
and	O
use	O
thereof	O
as	O
acid	O
pump	O
antagonists	O

There	O
are	O
provided	O
sunscreen	O
and	O
cosmetics	O
compositions	O
containing	O
non	O
-	O
steroidal	O
anti-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
in	O
the	O
form	O
of	O
metal	O
complexes	O
for	O
the	O
prophylaxis	O
or	O
treatment	O
of	O
cancers	O
of	O
the	O
skin	O
.	O

The	O
ligand	O
(	O
s	O
)	O
of	O
the	O
complex	O
typically	O
independently	O
comprise	O
a	O
carboxylate	B
,	O
or	O
a	O
derivative	O
of	O
a	O
carboxylate	B
,	O
having	O
anti	O
-	O
inflammatory	O
activity	O
.	O

Carboxylate	B
derivatives	O
having	O
anti	O
-	O
inflammatory	O
activity	O
that	O
may	O
be	O
used	O
include	O
hydroxamates	B
,	O
hydroximates	B
,	O
amides	B
and	O
esters	B
.	O

Copper	B
and	O
zinc	B
metal	O
complexes	O
including	O
the	O
NSAIDs	O
indomethacin	B
and	O
acematacin	B
are	O
particularly	O
preferred	O
.	O

Sunscreen	O
and	O
cosmetic	O
compositions	O
for	O
prophylaxis	O
or	O
treatment	O
of	O
skin	O
cancers	O

The	O
compound	O
having	O
the	O
structural	O
formula	O
I	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
is	O
disclosed	O
,	O
as	O
well	O
as	O
its	O
use	O
in	O
the	O
treatment	O
of	O
central	O
nervous	O
system	O
diseases	O
,	O
in	O
particular	O
Parkinson	O
's	O
disease	O
,	O
Extra	O
Pyramidal	O
Syndrome	O
,	O
restless	O
legs	O
syndrome	O
and	O
attention	O
deficit	O
hyperactivity	O
disorder	O
,	O
pharmaceutical	O
compositions	O
comprising	O
it	O
,	O
and	O
combinations	O
with	O
other	O
agents	O
.	O

7-	B
[	I
2-	I
[	I
4-	I
(	I
6-FLUORO-3-METHYL-1,2-BENZISOXAZOL-5-YL	I
)	I
-1-PIPERAZINYL	I
]	I
ETHYL	I
]	I
-2-	I
(	I
1-PROPYNYL	I
)	I
-7H	I
-	I
PYRAZOLO-	I
[	I
4,3-e	I
]	I
-	I
[	I
1,2,4	I
]	I
-TRIAZOLO-	I
[	I
1,5-c	I
]	I
-PYRIMIDIN-5	I
AMINE	I

Disclosed	O
is	O
a	O
compound	O
represented	O
by	O
the	O
general	O
formula	O
(	O
I	O
)	O
below	O
or	O
a	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
.	O

(	O
In	O
the	O
formula	O
,	O
R1	O
represents	O
a	O
hydrogen	B
atom	O
or	O
a	O
C1-C6	B
alkyl	I
group	O
,	O
and	O
R2	O
represents	O
a	O
substituted	O
cyclic	B
amino	I
.	O
)	O

Thienopyridine-2-carboxamide	B
derivative	O

The	O
invention	O
is	O
directed	O
to	O
Compounds	O
of	O
Formula	O
I	O
and	O
pharmaceutically	O
acceptable	O
salts	O
or	O
solvates	O
thereof	O
,	O
as	O
well	O
as	O
methods	O
of	O
making	O
and	O
using	O
the	O
compounds	O
.	O

PYRIDOPYRIMIDINONE	B
INHIBITORS	O
OF	O
PI3K	O

An	O
oral	O
formulation	O
compring	O
hyaluronid	B
acid-	I
phospholipid	O
complexes	O
as	O
active	O
ingredient	O
and	O
the	O
application	O
of	O
hyaluronic	B
acid-	I
phosphlipid	O
complexes	O
in	O
preparation	O
of	O
the	O
product	O
for	O
improving	O
and	O
protecting	O
the	O
function	O
of	O
joint	O
.	O

The	O
oral	O
agent	O
for	O
improving	O
and	O
protecting	O
the	O
function	O
of	O
joint	O
comprising	O
hyaluronic	B
acid	I
-	O
phospholipid	O
complexes	O

The	O
present	O
invention	O
relates	O
to	O
new	O
adjuvants	O
and	O
the	O
uses	O
in	O
pharmaceutical	O
compositions	O
,	O
like	O
in	O
vaccines	O
.	O

In	O
particular	O
,	O
the	O
present	O
invention	O
provides	O
new	O
compounds	O
useful	O
as	O
adjuvants	O
and/or	O
immunomodulators	O
for	O
prophylactic	O
and/or	O
therapeutic	O
vaccination	O
in	O
the	O
treatment	O
of	O
infectious	O
diseases	O
,	O
inflammatory	O
diseases	O
,	O
autoimmune	O
diseases	O
,	O
tumours	O
,	O
allergies	O
as	O
well	O
as	O
for	O
the	O
control	O
of	O
fertility	O
in	O
human	O
or	O
animal	O
populations	O
.	O

The	O
compounds	O
are	O
particularly	O
useful	O
not	O
only	O
as	O
systemic	O
,	O
but	O
preferably	O
as	O
mucosal	O
adjuvants	O
.	O

In	O
addition	O
,	O
the	O
invention	O
relates	O
to	O
its	O
uses	O
as	O
active	O
ingredients	O
in	O
pharmaceutical	O
compositions	O
.	O

Pqs	O
and	O
its	O
conjugates	O
as	O
adjuvants	O
and	O
their	O
uses	O
in	O
pharmaceutical	O
compositions	O

A	O
compound	O
of	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
derivative	O
thereof	O
,	O
having	O
antimicrobial	O
activity	O
,	O
processes	O
for	O
their	O
preparation	O
,	O
compositions	O
containing	O
them	O
and	O
to	O
their	O
use	O
in	O
medicine	O
.	O

Macrolones	B

This	O
invention	O
provides	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
,	O
wherein	O
B	O
,	O
G	O
,	O
A	O
,	O
E	O
,	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
m	O
and	O
n	O
are	O
as	O
defined	O
herein	O
,	O
which	O
are	O
useful	O
as	O
type	O
I	O
receptor	O
tyrosine	B
kinase	O
inhibitors	O
,	O
and	O
methods	O
of	O
use	O
thereof	O
in	O
the	O
treatment	O
of	O
hyperproliferative	O
disorders	O
in	O
mammals	O
.	O

N4-phenyl	B
-	I
quinaz0line-4	I
-amine	I
derivatives	O
and	O
related	O
compounds	O
as	O
erbb	O
type	O
i	O
receptor	O
tyrosine	O
kinase	O
inhibitors	O
for	O
the	O
treatment	O
of	O
hyperproliferative	O
diseases	O

The	O
present	O
invention	O
relates	O
to	O
the	O
necessities	O
of	O
life	O
,	O
and	O
more	O
particularly	O
to	O
the	O
field	O
of	O
cosmetology	O
and	O
dermatology	O
.	O

It	O
relates	O
more	O
particularly	O
to	O
novel	O
cosmetological	O
and/or	O
dermatological	O
compositions	O
which	O
bring	O
about	O
a	O
very	O
significant	O
increase	O
in	O
the	O
deposition	O
of	O
collagen	O
type	O
(	O
III	O
)	O
in	O
the	O
extracellular	O
matrix	O
,	O
characterized	O
in	O
that	O
they	O
contain	O
,	O
as	O
active	O
ingredient	O
,	O
a	O
combination	O
of	O
a	O
4-hydroxyproline	B
fatty	I
acid	I
amido	I
ester	I
,	O
of	O
formula	O
(	O
I	O
)	O
:	O
in	O
which	O
R1	O
and	O
R'1	O
are	O
identical	O
or	O
different	O
aliphatic	B
chains	I
containing	O
from	O
10	O
to	O
24	O
carbon	B
atoms	O
that	O
are	O
in	O
a	O
straight	O
line	O
or	O
branched	O
,	O
and	O
of	O
an	O
extract	O
of	O
the	O
epicarp	O
of	O
the	O
Opuntia	O
ficus	O
-	O
indica	O
(	O
Barbary	O
fig	O
)	O
fruit	O
in	O
an	O
inert	O
,	O
nontoxic	O
excipient	O
or	O
carrier	O
suitable	O
for	O
topical	O
use	O
.	O

Use	O
in	O
the	O
form	O
of	O
a	O
fatty	O
cream	O
or	O
gel	O
for	O
the	O
increased	O
production	O
of	O
collagen	O
,	O
without	O
amplifying	O
that	O
of	O
procollagen	O
(	O
III	O
)	O
or	O
of	O
enzymes	O
of	O
the	O
metalloproteinase	O
family	O
.	O

Novel	O
proline	B
-	O
derivative	O
based	O
cosmetological	O
and/or	O
dermatological	O
compositions	O
and	O
uses	O
thereof	O

A	O
method	O
of	O
screening	O
reagents	O
for	O
preventing	O
or	O
treating	O
Alzheimer	O
's	O
disease	O
or	O
related	O
neurodegenerative	O
disease	O
is	O
provided	O
.	O

The	O
method	O
comprises	O
:	O
(	O
a	O
)	O
stimulating	O
a	O
receptor	O
and	O
identifying	O
its	O
degree	O
of	O
internalization	O
,	O
wherein	O
the	O
receptor	O
is	O
a	O
G	O
protein	O
-	O
coupled	O
receptor	O
combining	O
with	O
PS1	O
;	O
(	O
b	O
)	O
stimulating	O
the	O
receptor	O
as	O
step	O
(	O
a	O
)	O
in	O
the	O
presence	O
of	O
a	O
reagent	O
,	O
and	O
identifying	O
its	O
degree	O
of	O
internalization	O
again	O
;	O
(	O
c	O
)	O
comparing	O
the	O
difference	O
between	O
the	O
internalizing	O
degrees	O
of	O
(	O
a	O
)	O
and	O
(	O
b	O
)	O
;	O
(	O
d	O
)	O
repeating	O
steps	O
(	O
a	O
)	O
-	O
(	O
c	O
)	O
if	O
the	O
difference	O
is	O
less	O
than	O
the	O
least	O
value	O
.	O

And	O
use	O
of	O
the	O
receptor	O
antagonist	O
for	O
preparing	O
a	O
drug	O
for	O
preventing	O
or	O
treating	O
Alzheimer	O
's	O
disease	O
or	O
related	O
neurodegenerative	O
disease	O
is	O
provided	O
.	O

The	O
receptor	O
antagonist	O
can	O
be	O
used	O
to	O
inhibit	O
the	O
internalization	O
of	O
the	O
G	O
protein	O
-	O
coupled	O
receptor	O
combing	O
with	O
PS1	O
.	O

A	O
g	O
protein	O
-	O
coupled	O
receptor	O
antagonist	O
and	O
its	O
use	O
for	O
preventing	O
and	O
treating	O
alzheimer	O
's	O
disease	O

14	B
-	I
0-	I
[	I
(	I
(	I
(	I
C1.6	I
)	I
Alkoxy-	I
(	I
C1.6	I
)	I
alkyl	I
)	I
-phenylsulfanyl	I
)	I
-acetyl	I
]	I
-mutilins	I
,	O
14-O-	B
[	I
(	I
(	I
(	I
C1	I
-	I
6	I
)	I
Mono-	I
or	I
dialkylamino-	I
(	I
C1.6	I
)	I
alkyl	I
)	I
-phenylsulfanyl	I
)	I
-acetyl	I
]	I
-mutilins	I
,	O
14-O-	B
[	I
(	I
(	I
Hydroxy-	I
(	I
C1	I
-	I
6	I
)	I
-alkyl	I
)	I
-phenylsulfanyl	I
)	I
-acetyl	I
]	I
-mutilins	I
,	O
14-O-	B
[	I
(	I
(	I
Formyl-	I
(	I
C0.5	I
)	I
-alkyl	I
)	I
-phenylsulfanyl	I
)	I
-acetyl	I
]	I
-mutilins	I
,	O
14-O-	B
[	I
(	I
(	I
Guanidino	I
-	I
imino-	I
(	I
C1	I
-	I
6	I
)	I
alkyl	I
)	I
-phenylsulfanyl	I
)	I
-acetyl	I
]	I
-mutilins	I
,	O
14-O-	B
[	I
(	I
(	I
Ureido	I
-	I
imino-	I
(	I
C1	I
-	I
6	I
)	I
alky	I
)	I
-phenylsulfany	I
]	I
-acety	I
]	I
-mutilins	I
,	O
14-O-	B
[	I
(	I
(	I
Thioureido	I
-	I
imino-	I
(	I
C1	I
-	I
6	I
)	I
alkyl	I
)	I
-phenylsulfanyl	I
)	I
-acetyl	I
]	I
-mutilins	I
,	O
14-O-	B
[	I
(	I
(	I
lsothioureido	I
-	I
imino-	I
(	I
C1	I
-	I
6	I
)	I
alkyl	I
)	I
-phenylsulfanyl	I
)	I
-acetyl	I
]	I
-mutilins	I
and	O
their	O
use	O
as	O
pharmaceuticals	O
.	O

Mutilin	B
derivatives	O
and	O
their	O
use	O
as	O
pharmaceutical	O

The	O
present	O
invention	O
relates	O
to	O
sulphonamide	B
derivatives	O
corresponding	O
to	O
the	O
general	O
formula	O
(	O
I	O
)	O
,	O
in	O
which	O
Ar1	O
represents	O
an	O
aryl	O
optionally	O
substituted	O
with	O
one	O
or	O
more	O
groups	O
,	O
or	O
an	O
optionally	O
substituted	O
heterocyclyl	B
group	O
;	O
T	O
represents	O
a	O
-	B
(	I
CH2	I
)	I
n-	I
or	O
a	O
group	O
(	O
II	O
)	O
,	O
Ar2	O
represents	O
an	O
aryl	B
as	O
optionally	O
substituted	O
with	O
one	O
or	O
more	O
groups	O
,	O
or	O
an	O
optionally	O
substituted	O
heterocyclyl	B
group	O
;	O
Ar3	O
represents	O
an	O
aryl	B
optionally	O
substituted	O
with	O
one	O
or	O
more	O
groups	O
,	O
or	O
else	O
an	O
optionally	O
substituted	O
heterocyclyl	B
,	O
R1	O
represents	O
a	O
group	O
of	O
formula	O
(	O
A	O
)	O
or	O
(	O
B	O
)	O
:	O
(	O
A	O
)	O
(	O
B	O
)	O
in	O
the	O
form	O
of	O
a	O
base	O
,	O
an	O
addition	O
salt	O
with	O
an	O
acid	O
,	O
a	O
hydrate	O
or	O
a	O
solvate	O
,	O
in	O
the	O
form	O
of	O
enantiomers	O
,	O
diastereoisomers	O
,	O
rotamers	O
or	O
atropoisomers	O
,	O
or	O
mixtures	O
thereof	O
.	O

It	O
also	O
relates	O
to	O
the	O
process	O
for	O
the	O
preparation	O
and	O
also	O
the	O
therapeutic	O
use	O
of	O
the	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
.	O

Sulfonamide	B
derivatives	O
,	O
preparation	O
thereof	O
and	O
therapeutic	O
use	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
a	O
topical	O
composition	O
comprising	O
a	O
thiourea	B
derivative	O
,	O
which	O
is	O
a	O
vanilloid	O
receptor	O
antagonist	O
,	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
and	O
a	O
pharmaceutical	O
use	O
of	O
the	O
same	O
.	O

The	O
topical	O
composition	O
according	O
to	O
the	O
present	O
invention	O
is	O
excellent	O
in	O
skin	O
permeation	O
and	O
stability	O
and	O
effective	O
in	O
treatment	O
of	O
pruritic	O
or	O
irritant	O
skin	O
diseases	O
.	O

Topical	O
preparation	O
composition	O
containing	O
a	O
thiourea	B
derivative	O
for	O
preventing	O
or	O
treating	O
pruritic	O
or	O
irritant	O
skin	O
diseases	O

A	O
composition	O
comprises	O
plasmin	O
or	O
an	O
enzymatically	O
equivalent	O
derivative	O
thereof	O
and	O
at	O
least	O
an	O
anti	O
-	O
inflammatory	O
medicament	O
,	O
such	O
as	O
triamcinolone	B
acetonide	B
.	O

The	O
composition	O
can	O
be	O
used	O
to	O
effect	O
or	O
induce	O
a	O
controlled	O
posterior	O
vitreous	O
detachment	O
(	O
'	O
PVD	O
'	O
)	O
to	O
prevent	O
,	O
treat	O
,	O
or	O
ameliorate	O
a	O
potential	O
complication	O
of	O
a	O
pathological	O
ocular	O
condition	O
.	O

Such	O
a	O
composition	O
can	O
be	O
administered	O
intravitreally	O
.	O

Compositions	O
and	O
methods	O
for	O
effecting	O
controlled	O
posterior	O
vitreous	O
detachment	O

The	O
invention	O
provides	O
a	O
hair	O
grower	O
having	O
a	O
hair	O
-	O
glowing	O
effect	O
and	O
useful	O
application	O
forms	O
of	O
the	O
hair	O
grower	O
.	O

The	O
invention	O
relates	O
to	O
a	O
hair	O
grower	O
containing	O
as	O
the	O
active	O
ingredient	O
a	O
lithospermic	B
acid	I
derivative	O
represented	O
by	O
the	O
general	O
formula	O
(	O
I	O
)	O
or	O
a	O
salt	O
thereof	O
;	O
and	O
oral	O
preparations	O
,	O
external	O
preparations	O
,	O
and	O
foods	O
,	O
containing	O
the	O
hair	O
grower	O
:	O
(	O
I	O
)	O
wherein	O
R1	O
and	O
R2	O
may	O
be	O
the	O
same	O
or	O
different	O
and	O
are	O
each	O
hydrogen	B
or	O
optionally	O
substituted	O
C1	B
-	I
4	I
alkyl	I
;	O
and	O
R3	O
is	O
hydrogen	B
,	O
optionally	O
substituted	O
C1	B
-	I
4	I
alkyl	I
,	O
or	O
a	O
group	O
represented	O
by	O
the	O
general	O
formula	O
(	O
II	O
)	O
.	O

Hair	O
grower	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
diphenylurea	B
derivatives	O
of	O
formula	O
(	O
I	O
)	O
useful	O
as	O
chloride	B
channel	O
blockers	O
or	O
BKCa	O
channel	O
modulators	O
.	O

In	O
other	O
aspects	O
the	O
invention	O
relates	O
to	O
the	O
use	O
of	O
these	O
compounds	O
in	O
a	O
method	O
for	O
therapy	O
,	O
and	O
to	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds	O
of	O
the	O
invention	O
.	O

Diphenylurea	B
derivatives	O
and	O
their	O
use	O
as	O
chloride	B
channel	O
blockers	O
or	O
bkca	O
channel	O
modulators	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
thiazolyldihydroindazoles	B
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
where	O
the	O
R1	O
,	O
R2	O
and	O
R3	O
radicals	O
are	O
each	O
as	O
defined	O
in	O
the	O
claims	O
and	O
the	O
description	O
,	O
to	O
their	O
tautomers	O
,	O
racemates	O
,	O
enantiomers	O
,	O
diastereomers	O
and	O
mixtures	O
thereof	O
,	O
and	O
where	O
appropriate	O
to	O
their	O
pharmacologically	O
safe	O
acid	O
addition	O
salts	O
,	O
solvates	O
and	O
hydrates	B
,	O
and	O
to	O
processes	O
for	O
preparing	O
these	O
thiazolyldihydroindazoles	B
and	O
to	O
their	O
use	O
as	O
medicaments	O
.	O

Thiazolyldihydroindazoles	B

The	O
present	O
invention	O
provides	O
a	O
compound	O
of	O
the	O
formula	O
(	O
I	O
)	O
or	O
pharmaceutically	O
acceptable	O
salts	O
,	O
solvates	O
or	O
prodrugs	O
thereof	O
,	O
wherein	O
Y	O
,	O
Ar	B
,	O
R1	O
and	O
R2	O
are	O
defined	O
herein	O
.	O

Also	O
provided	O
are	O
pharmaceutical	O
compositions	O
,	O
their	O
use	O
and	O
methods	O
of	O
preparing	O
the	O
compounds	O
.	O

Heterocyclic	B
gaba	O
alpha	O
subtype	O
selective	O
receptor	O
modulators	O

The	O
invention	O
relates	O
,	O
amongst	O
other	O
things	O
,	O
to	O
the	O
use	O
of	O
1,4:3,6-dianhydromannitol	B
derivatives	O
of	O
formulae	O
(	O
Ia	O
)	O
-	O
(	O
I	O
d	O
)	O
as	O
therapeutic	O
agents	O
.	O

1,4:3,6-dianhydromannitol	B
derivatives	O
and	O
use	O
thereof	O

The	O
invention	O
relates	O
to	O
novel	O
3-tetrazolyl	B
indazole	I
derivatives	O
and	O
3-tetrazolyl	B
pyrazolo	I
[	I
3,4-b	I
]	I
-pyridine	I
derivatives	O
,	O
methods	O
for	O
producing	O
the	O
same	O
,	O
the	O
exclusive	O
or	O
combined	O
use	O
thereof	O
for	O
treating	O
and/or	O
preventing	O
diseases	O
,	O
and	O
the	O
use	O
thereof	O
for	O
producing	O
medicaments	O
utilized	O
for	O
the	O
treatment	O
and/or	O
prevention	O
of	O
diseases	O
,	O
particularly	O
cardiovascular	O
diseases	O
.	O

3-tetrazolyl	B
indazoles	I
,	O
3-tetrazolyl	B
pyrazolopyridines	I
,	O
and	O
use	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
2,3-dioxoindole	B
derivatives	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
for	O
use	O
as	O
a	O
medicament	O
,	O
and	O
particularly	O
for	O
use	O
in	O
the	O
prevention	O
or	O
treatment	O
of	O
fever	O
,	O
inflammation	O
or	O
pain	O
,	O
wherein	O
in	O
the	O
general	O
formula	O
(	O
I	O
)	O
;	O
R1	O
is	O
hydrogen	B
,	O
or	O
(	O
C1-C10	B
)	O
linear	O
or	O
branched	O
alkyl	B
or	O
hydroxyalkyl	B
group	O
or	O
acyl	B
group	O
containing	O
(	O
C1-C10	B
)	O
linear	O
or	O
branched	O
alkyl	B
group	O
,	O
R2-R5	O
are	O
independently	O
hydrogen	B
,	O
halogen	B
,	O
amino	B
group	O
,	O
nitro	B
group	O
,	O
optionally	O
halogen	B
substituted	O
(	B
C1-C10	I
)	I
alkyl	I
group	O
,	O
(	B
C1-C10	I
)	I
alkoxy	I
group	O
or	O
hydroxyl	B
group	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
methods	O
for	O
the	O
prevention	O
or	O
treatment	O
of	O
fever	O
,	O
inflammation	O
or	O
pain	O
,	O
wherein	O
a	O
medicament	O
incorporating	O
a	O
pharmacologically	O
effective	O
dose	O
of	O
the	O
above	O
described	O
active	O
ingredient	O
is	O
administered	O
to	O
patients	O
in	O
need	O
of	O
such	O
treatment	O
.	O

Isatin	B
and	O
its	O
derivatives	O
for	O
use	O
as	O
a	O
medicament	O

The	O
invention	O
provides	O
antiperiodontitis	O
agents	O
which	O
originate	O
in	O
plant	O
components	O
free	O
from	O
the	O
anxiety	O
about	O
safety	O
and	O
have	O
no	O
peculiar	O
spice	O
-	O
like	O
aroma	O
or	O
taste	O
and	O
which	O
have	O
high	O
antibacterial	O
effects	O
on	O
bacteria	O
causative	O
of	O
periodontal	O
diseases	O
and	O
can	O
prevent	O
or	O
cure	O
periodontal	O
diseases	O
;	O
and	O
drinks	O
,	O
foods	O
,	O
or	O
oral	O
hygiene	O
products	O
,	O
containing	O
the	O
agents	O
.	O

Antiperiodontitis	O
agents	O
,	O
characterized	O
by	O
containing	O
one	O
or	O
more	O
isothiocyanate	B
compounds	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
	B
-	I
alkenyl	I
isothiocyanate	I
compounds	O
represented	O
by	O
the	O
general	O
formula	O
[	O
1	O
]	O
,	O
	B
-	I
alkylthioalkyl	I
isothiocyanate	I
compounds	O
represented	O
by	O
the	O
general	O
formula	O
[	O
2	O
]	O
,	O
and	O
	B
-	I
phenylalkyl	I
isothiocyanate	I
compounds	O
represented	O
by	O
the	O
general	O
formula	O
[	O
3	O
]	O
and	O
mint	O
essential	O
oil	O
or	O
a	O
mint	O
essential	O
oil	O
component	O
;	O
and	O
drinks	O
,	O
foods	O
,	O
or	O
oral	O
hygiene	O
products	O
,	O
containing	O
the	O
agents	O
:	O
General	O
formula	O
[	O
1	O
]	O
:	O
CH2	B
=	I
CH-	I
(	I
CH2	I
)	I
m	I
-	I
NCS	I
(	O
wherein	O
m	O
is	O
an	O
integer	O
of	O
1	O
to	O
10	O
)	O
General	O
formula	O
[	O
2	O
]	O
:	O
R	B
-	I
S-	I
(	I
CH2	I
)	I
n	I
-	I
NCS	I
(	O
wherein	O
n	O
is	O
an	O
integer	O
of	O
1	O
to	O
10	O
and	O
R	O
is	O
straight-	O
or	O
branched	O
-	O
chain	O
alkyl	B
of	O
1	O
to	O
4	O
carbon	B
atoms	O
)	O
,	O
and	O
General	O
formula	O
[	O
3	O
]	O
:	O
Ph-	B
(	I
CH2	I
)	I
p	I
-	I
NCS	I
(	O
wherein	O
Ph	B
is	O
phenyl	B
and	O
p	O
is	O
an	O
integer	O
of	O
1	O
to	O
10	O
)	O
.	O

Antiperiodontitis	O
agents	O
,	O
and	O
drinks	O
,	O
foods	O
or	O
oral	O
hygiene	O
products	O
containing	O
the	O
agents	O

A	O
compound	O
of	O
formula	O
(	O
I	O
)	O
or	O
(	O
II	O
)	O
for	O
use	O
as	O
a	O
medicament	O
.	O

A	O
pharmaceutical	O
composition	O
the	O
compound	O
.	O

Use	O
of	O
the	O
compound	O
for	O
preparing	O
a	O
medicament	O
for	O
the	O
treatment	O
of	O
a	O
disorder	O
selected	O
from	O
hyperproliferative	O
diseases	O
,	O
autoimmune	O
diseases	O
,	O
and	O
heart	O
diseases	O
.	O

Compounds	O
for	O
use	O
as	O
a	O
medicament	O

The	O
invention	O
provides	O
methods	O
and	O
compositions	O
for	O
modulating	O
hepsin	O
activity	O
and	O
the	O
uPA	O
/	O
plasmin	O
pathway	O
,	O
in	O
particular	O
by	O
regulating	O
pro	O
-	O
uPA	O
activation	O
by	O
hepsin	O
.	O

Methods	O
and	O
compositions	O
for	O
modulating	O
hepsin	O
activation	O
of	O
urokinase	O
-	O
type	O
plasminogen	O
activator	O

This	O
invention	O
provides	O
the	O
treatment	O
of	O
viral	O
infections	O
with	O
a	O
4,6-	B
disubstituted	I
or	I
2,4,6-trisubstituted	I
quinazoline	I
derivative	O
represented	O
by	O
the	O
structural	O
formula	O
[	O
(	O
I	O
)	O
]	O
wherein	O
:	O
R2	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
hydrogen	B
,	O
NR'R	B
'	I
and	O
C1	B
-	I
7	I
alkyl	I
;	O
-	O
A	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
a	O
bond	O
,	O
O	B
,	O
S	B
(	I
O	I
)	I
n	I
,	O
C1	B
-	I
7	I
alkylene	I
,	O
C2	B
-	I
7	I
alkenylene	I
and	O
C2	B
-	I
7	I
alkynylene	I
;	O
R4	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
C1	B
-	I
7	I
alkyl	I
,	O
C2	B
-	I
7	I
alkenyl	I
,	O
C3	B
-	I
10	I
cycloalkyl	I
,	O
C3	B
-	I
10	I
cycloalkenyl	I
,	O
aryl	B
,	O
heterocyclic	B
,	O
arylalkyl	B
,	O
heterocyclic	B
-	I
substituted	I
alkyl	I
and	O
cycloalkyl	B
-	I
alkyl	I
;	O
-	O
Y	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
a	O
single	O
bond	O
,	O
C1	B
-	I
7	I
alkylene	I
,	O
C2	B
-	I
7	I
alkenylene	I
,	O
and	O
C2	B
-	I
7	I
alkynylene	I
;	O
n	O
is	O
0	O
,	O
1	O
or	O
2	O
;	O
and	O
R6	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
halogen	B
,	O
heteroaryl	B
and	O
aryl	B
;	O
a	O
pharmaceutically	O
acceptable	O
addition	O
salt	O
,	O
a	O
stereoisomer	O
,	O
a	O
mono-	O
or	O
a	O
di	B
-	I
	I
/	I
-oxide	I
,	O
a	O
solvate	O
or	O
a	O
pro	O
-	O
drug	O
thereof	O
.	O

4,6-dl-	B
and	I
2,4,6-trisubstituted	I
quinazoline	I
derivatives	O
and	O
pharmaceutical	O
compositions	O
useful	O
for	O
treating	O
viral	O
infections	O

This	O
invention	O
provides	O
quinazoline	B
derivatives	O
represented	O
by	O
the	O
structural	O
formula	O
:	O
(	O
I	O
)	O
;	O
wherein	O
:	O
R2	O
is	O
hydrogen	B
,	O
NR'R	B
'	I
,	O
C1	B
-	I
7	I
alkyl	I
,	O
arylC1	B
-	I
7	I
alkyl	I
or	O
C3	B
-	I
10	I
cycloalkyl	I
;	O
R4	O
is	O
amino	B
,	O
C1	B
-	I
7	I
alkyl	I
,	O
C2	B
-	I
7	I
alkenyl	I
,	O
C3	B
-	I
10	I
cycloalkyl	I
,	O
C3	B
-	I
10	I
cycloalkenyl	I
,	O
aryl	B
,	O
heterocyclic	B
,	O
arylalkyl	B
,	O
heterocyclic	B
-	I
substituted	I
C1	I
-	I
7	I
alkyl	I
or	O
C3	B
-	I
10	I
cycloalkyl	I
-	I
C1	I
-	I
7	I
alkyl	I
;	O
R5	O
is	O
hydrogen	B
or	O
C1	B
-	I
7	I
alkyl	I
,	O
or	O
R5	O
and	O
R4	O
together	O
with	O
the	O
nitrogen	B
atom	O
to	O
which	O
they	O
are	O
attached	O
form	O
a	O
heterocyclic	B
ring	O
;	O
Y	O
is	O
a	O
single	O
bond	O
,	O
C1	B
-	I
7alkylene	I
,	O
C2	B
-	I
7	I
alkenylene	I
or	O
C2	B
-	I
7	I
alkynylene	I
;	O
R6	O
is	O
halogen	B
,	O
heteroaryl	B
or	O
aryl	B
;	O
R	O
'	O
and	O
R	O
'	O
are	O
each	O
independently	O
hydrogen	B
,	O
C1	B
-	I
7	I
alkyl	I
-	I
carbonyl	I
or	O
C1	B
-	I
7	I
alkyl	I
;	O
provided	O
that	O
R4	O
is	O
not	O
phenyl	B
substituted	O
with	O
morpholino	B
when	O
R2	O
is	O
H	B
and	O
R5	O
is	O
H	B
,	O
and	O
provided	O
that	O
when	O
NR4R5	B
is	O
piperazinyl	B
,	O
said	O
NR4R5	B
is	O
either	O
non	O
-	O
substituted	O
or	O
substituted	O
with	O
methyl	B
or	O
acetyl	B
;	O
a	O
pharmaceutically	O
acceptable	O
addition	O
salt	O
,	O
a	O
stereoisomer	O
,	O
a	O
mono-	O
or	O
a	O
di	B
-	I
N	I
-	I
oxide	I
,	O
a	O
solvate	O
or	O
a	O
pro	O
-	O
drug	O
thereof	O
,	O
for	O
the	O
treatment	O
of	O
viral	O
infections	O
.	O

4,6-dl-	B
and	I
2,4,6-trisubstituted	I
quinazoline	I
derivatives	O
useful	O
for	O
treating	O
viral	O
infections	O

The	O
invention	O
relates	O
to	O
novel	O
drug	O
combinations	O
,	O
comprising	O
,	O
in	O
addition	O
to	O
one	O
or	O
more	O
,	O
preferably	O
one	O
,	O
compound	O
of	O
general	O
formula	O
(	O
1	O
)	O
,	O
where	O
the	O
groups	O
R1	O
,	O
R2	O
and	O
R3	O
can	O
have	O
the	O
meanings	O
given	O
in	O
the	O
claims	O
and	O
description	O
,	O
at	O
least	O
one	O
further	O
active	O
ingredient	O
2	O
,	O
a	O
method	O
for	O
production	O
and	O
use	O
thereof	O
as	O
a	O
drug	O
.	O

Drug	O
combinations	O
for	O
treating	O
airway	O
diseases	O

The	O
invention	O
relates	O
to	O
an	O
inhibitor	O
of	O
pulmonary	O
emphysematous	O
lesions	O
containing	O
as	O
an	O
active	O
ingredient	O
a	O
substance	O
having	O
an	O
action	O
of	O
promoting	O
the	O
degradation	O
of	O
CSPG	O
,	O
an	O
action	O
of	O
inhibiting	O
the	O
synthesis	O
of	O
CSPG	O
,	O
or	O
an	O
action	O
of	O
inhibiting	O
the	O
sulfation	O
of	O
CSPG	O
,	O
for	O
example	O
,	O
chondroitinase	O
ABC	O
,	O
a	O
C6ST	O
antisense	O
agent	O
,	O
a	O
GalNAc	O
antisense	O
agent	O
or	O
the	O
like	O
,	O
an	O
inhibitor	O
of	O
emphysematous	O
lesions	O
suitable	O
for	O
treating	O
or	O
preventing	O
COPD	O
,	O
a	O
therapeutic	O
or	O
preventive	O
agent	O
for	O
COPD	O
,	O
and	O
also	O
relates	O
to	O
a	O
method	O
of	O
inhibiting	O
emphysematous	O
lesions	O
and	O
a	O
method	O
of	O
treating	O
or	O
preventing	O
COPD	O
.	O

Remedy	O
for	O
chronic	O
obstructive	O
pulmonary	O
disease	O

The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
wherein	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
and	O
R6	O
are	O
as	O
defined	O
in	O
the	O
specification	O
,	O
to	O
intermediates	O
for	O
their	O
preparation	O
,	O
to	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
to	O
their	O
medicinal	O
use	O
as	O
modulators	O
of	O
the	O
dopamine	B
D3	O
receptor	O
,	O
particularly	O
as	O
psychotherapeutic	O
agents	O
.	O

Morpholine	B
d3	O
dopamine	B
antagonists	O

[	O
PROBLEMS	O
]	O
To	O
provide	O
a	O
2-alkyl-6-	B
(	I
pyrazolopyridin-	I
4-yl	I
)	I
pyridazinone	I
derivative	O
which	O
is	O
useful	O
as	O
a	O
pharmaceutical	O
agent	O
having	O
a	O
phosphodiesterase	O
-	O
inhibiting	O
activity	O
.	O

[	O
MEANS	O
FOR	O
SOLVING	O
PROBLEMS	O
]	O
A	O
2-alkyl-6-	B
(	I
pyrazolopyridin-4-yl	I
)	I
pyridazinone	I
derivative	O
represented	O
by	O
the	O
general	O
formula	O
(	O
1	O
)	O
(	O
a	O
specific	O
example	O
:	O
6-	B
(	I
7-methoxy-2-	I
trifluoromethylpyrazolo	I
[	I
1,5-a	I
]	I
pyridin-4-yl	I
)	I
-5-methyl-2-	I
[	I
3-	I
[	I
4-	I
(	I
4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-	I
yl	I
)	I
phenoxy	I
]	I
propyl	I
]	I
-4,5-dihydro-2H-	I
pyridazin-3-one	I
)	I
.	O

2-alkyl-6-	B
(	I
pyrazolopyridin-4-yl	I
)	I
pyridazinone	I
derivative	O
,	O
addition	O
salt	O
thereof	O
,	O
and	O
pde	O
inhibitor	O
comprising	O
the	O
derivative	O
or	O
the	O
salt	O
as	O
active	O
ingredient	O

The	O
present	O
invention	O
relates	O
to	O
modulators	O
of	O
IRAK	O
kinases	O
of	O
formula	O
(	O
I	O
)	O
and	O
provides	O
compositions	O
comprising	O
such	O
modulators	O
,	O
as	O
well	O
as	O
methods	O
therewith	O
for	O
treating	O
IRAK-	O
mediated	O
or	O
IRAK	O
-associated	O
conditions	O
or	O
diseases	O
.	O

Indazole	B
derivatives	O
as	O
modulators	O
of	O
interleukin-	O
1	O
receptor	O
-	O
associated	O
kinase	O

A	O
therapeutic	O
formulation	O
comprising	O
of	O
Thiazolidinediones	B
as	O
active	O
agents	O
namely	O
,	O
Pioglitazone	B
and	O
Rosiglitazone	B
,	O
characterized	O
in	O
that	O
said	O
Thiazolidinediones	B
are	O
combined	O
or	O
complexated	O
with	O
NO	B
Scavenger	O
to	O
prevent	O
Diabetic	O
Complications	O
arising	O
out	O
of	O
Nitrosative	O
stress	O
.	O

Therapeutical	O
formulation	O
comprising	O
a	O
thiazolidinedione	B
and	O
a	O
nitric	B
oxide	I
scavenger	O
.	O

The	O
present	O
invention	O
relates	O
to	O
methods	O
and	O
compositions	O
for	O
treating	O
fibrosis	O
.	O

In	O
one	O
aspect	O
the	O
invention	O
provides	O
the	O
use	O
of	O
an	O
agent	O
capable	O
of	O
increasing	O
the	O
number	O
of	O
stem	O
cells	O
and/or	O
progenitor	O
cells	O
available	O
to	O
and/or	O
engraftment	O
at	O
a	O
site	O
of	O
fibrosis	O
in	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
use	O
in	O
conjunction	O
with	O
an	O
anti-	O
fibrotic	O
agent	O
for	O
the	O
treatment	O
of	O
fibrosis	O
.	O

The	O
anti	O
-	O
fibrotic	O
agent	O
can	O
be	O
supplied	O
to	O
the	O
subject	O
before	O
,	O
at	O
the	O
same	O
time	O
,	O
or	O
after	O
the	O
agent	O
capable	O
of	O
increasing	O
the	O
number	O
of	O
stem	O
cells	O
and/or	O
progenitor	O
cells	O
available	O
to	O
and/or	O
engraftment	O
at	O
a	O
site	O
of	O
fibrosis	O
.	O

The	O
fibrosis	O
may	O
be	O
idiopathic	O
pulmonary	O
fibrosis	O
.	O

The	O
anti	O
-	O
fibrotic	O
agent	O
can	O
be	O
a	O
modulator	O
of	O
RhoA	O
,	O
RhoA	O
GTPases	O
,	O
TGF	O
-	O
l	O
or	O
CTGF	O
,	O
or	O
any	O
other	O
member	O
of	O
the	O
RhoA	O
signalling	O
pathway	O
;	O
or	O
can	O
modulate	O
the	O
effect	O
of	O
suppressor	O
of	O
cytokine	O
signalling	O
1	O
(	O
SOCS	O
1	O
)	O
,	O
suppressor	O
of	O
cytokine	O
signalling	O
3	O
(	O
SOCS	O
3	O
)	O
or	O
TLR9	O
;	O
or	O
can	O
be	O
a	O
statin	O
compound	O
or	O
derivative	O
thereof	O
.	O

Treatment	O
of	O
fibrosis	O

3-phosphoindole	B
compounds	O
substantially	O
in	O
the	O
form	O
of	O
a	O
single	O
enantiomer	O
useful	O
for	O
the	O
treatment	O
of	O
Flaviviridae	O
virus	O
infections	O
,	O
and	O
particularly	O
for	O
HLV	O
infections	O
are	O
provided	O
.	O

Also	O
provided	O
are	O
pharmaceutical	O
compositions	O
comprising	O
the	O
3-phosphoindole	B
compounds	O
alone	O
or	O
in	O
combination	O
with	O
one	O
or	O
more	O
other	O
antiviral	O
agents	O
,	O
processes	O
for	O
their	O
preparation	O
,	O
and	O
methods	O
of	O
manufacturing	O
a	O
medicament	O
incorporating	O
these	O
compounds	O
.	O

The	O
3-phosphoindole	B
compounds	O
are	O
of	O
the	O
formula	O
(	O
A	O
)	O
or	O
(	O
B	O
)	O
and	O
the	O
pharmaceutically	O
acceptable	O
salts	O
,	O
solvates	O
,	O
hydrates	B
,	O
or	O
esters	B
thereof	O
.	O

In	O
the	O
formulae	O
X	O
is	O
hydrogen	B
;	O
aryl	B
or	O
heterocyclyl	B
;	O
C2	B
-	I
6	I
alkenyl	I
,	O
C2	B
-	I
6	I
alkynyl	I
or	O
alkyl	B
;	O
Y	O
is	O
hydrogen	B
,	O
-R	O
,	O
-O	B
-	I
R	I
,	O
-NH	B
-	I
R	I
,	O
or	O
-NRR	B
;	O
Z	O
is	O
-OR	B
,	O
-NHR	B
,	O
-NRR	B
,	O
carboxamido	B
,	O
arnido	B
,	O
carboxyl	B
,	O
carbonyl	B
,	O
or	O
an	O
amino	B
acid	I
residue	O
;	O
R1	O
is	O
hydrogen	B
,	O
acyl	B
,	O
-S	B
(	I
O	I
)	I
n	I
-	I
R	I
,	O
carboxyl	B
,	O
carbonyl	B
,	O
or	O
an	O
amino	B
acid	I
residue	O
;	O
each	O
R4	O
'	O
,	O
R5	O
'	O
,	O
R6	O
'	O
and	O
R7	O
'	O
is	O
independently	O
hydrogen	B
,	O
C2	B
-	I
6	I
alkenyl	I
,	O
C2	B
-	I
6	I
alkynyl	I
,	O
aryl	B
,	O
heterocyclyl	B
,	O
halogen	B
,	O
-CN	B
,	O
-CF3	B
,	O
-OR	B
,	O
-NHR	B
,	O
-NRR	B
,	O
or	O
-NO2	B
;	O
n	O
is	O
0	O
,	O
1	O
,	O
or	O
2	O
;	O
and	O
each	O
R	O
is	O
independently	O
hydrogen	B
,	O
alkyl	B
,	O
C2	B
-	I
6	I
alkenyl	I
,	O
C2	B
-	I
6	I
alkynyl	I
,	O
aryl	B
,	O
or	O
heterocyclyl	B
.	O

Enantiomerically	O
pure	O
phosphoindoles	B
as	O
hiv	O
inhibitors	O

The	O
invention	O
provides	O
crystalline	O
substances	O
each	O
consisting	O
of	O
the	O
carbapenem	B
compound	O
represented	O
by	O
formula	O
(	O
I	O
)	O
or	O
a	O
solvate	O
of	O
the	O
compound	O
.	O

The	O
crystalline	O
substances	O
are	O
excellent	O
in	O
handleability	O
and	O
storage	O
stability	O
.	O

Further	O
,	O
the	O
invention	O
also	O
provides	O
solid	O
compositions	O
each	O
containing	O
both	O
the	O
compound	O
of	O
formula	O
(	O
I	O
)	O
and	O
an	O
alkali	O
metal	O
halide	B
.	O

The	O
crystalline	O
substances	O
and	O
the	O
solid	O
compositions	O
exhibit	O
excellent	O
antimicrobial	O
activity	O
.	O

Crystalline	O
carbapenem	B
compounds	O

5-	B
[	I
(	I
2R	I
)	I
-	I
[	I
2-	I
[	I
2-	I
[	I
2-	I
(	I
2,2,2-trifluoroethoxy	I
)	I
phenoxy	I
]	I
ethyl	I
]	I
amino	I
]	I
propyl	I
]	I
-2-methoxybenzenesulfonamide	I
,	O
a	O
pharmaceutical	O
composition	O
containing	O
the	O
compound	O
,	O
and	O
the	O
synthesis	O
method	O
thereof	O
.	O

The	O
compound	O
has	O
strong	O
antagonism	O
toward	O
1-adrenoceptor	O
and	O
has	O
high	O
selectivity	O
toward	O
smooth	O
muscle	O
of	O
urethra	O
.	O

5-	B
[	I
(	I
2r	I
)	I
-	I
[	I
2-	I
[	I
2-	I
[	I
2-	I
(	I
2,2,2-trifluoroethoxy	I
)	I
phenoxy	I
]	I
ethyl	I
]	I
amino	I
]	I
propyl	I
]	I
-2-methoxybenzenesulfonamide	I

The	O
invention	O
is	O
directed	O
to	O
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
described	O
herein	O
,	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
or	O
a	O
prodrug	O
thereof	O
,	O
and	O
pharmaceutical	O
compositions	O
and	O
methods	O
of	O
treatment	O
.	O

Thienyl	B
-	I
containing	I
glycopyranosyl	I
derivatives	O
as	O
antidiabetics	O

This	O
invention	O
relates	O
to	O
a	O
novel	O
antibiotic	O
compounds	O
,	O
pharmaceutically	O
acceptable	O
salts	O
and	O
to	O
methods	O
for	O
obtaining	O
such	O
compounds	O
.	O

Aminothiazole	B
macrocycles	O
,	O
their	O
use	O
as	O
antibacterial	O
compounds	O
and	O
processes	O
for	O
their	O
production	O

The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
a	O
glucopyranosyloxy	B
-	I
pyrazole	I
as	O
defined	O
in	O
claim	O
1	O
for	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
treating	O
,	O
preventing	O
or	O
slowing	O
,	O
delaying	O
or	O
reversing	O
progression	O
of	O
one	O
or	O
more	O
neurodegenerative	O
disorders	O
in	O
a	O
patient	O
in	O
need	O
thereof	O
.	O

Use	O
of	O
glucopyranosyloxy-	B
pyrazoles	I
for	O
preventing	O
and	O
treating	O
neurodegenerative	O
disorders	O

Disclosed	O
are	O
:	O
an	O
agent	O
for	O
activating	O
,	O
improving	O
or	O
protecting	O
a	O
neuronal	O
cell	O
;	O
an	O
agent	O
for	O
activating	O
,	O
improving	O
or	O
protecting	O
the	O
brain	O
function	O
;	O
and	O
a	O
prophylactic	O
,	O
ameliorating	O
or	O
therapeutic	O
agent	O
for	O
a	O
central	O
or	O
peripheral	O
nerve	O
disease	O
,	O
each	O
of	O
which	O
comprises	O
reduced	O
coenzyme	O
A	O
as	O
an	O
active	O
ingredient	O
.	O

Specifically	O
disclosed	O
are	O
:	O
a	O
prophylactic	O
,	O
ameliorating	O
or	O
therapeutic	O
agent	O
for	O
a	O
central	O
or	O
peripheral	O
nerve	O
disease	O
,	O
which	O
has	O
less	O
adverse	O
side	O
effects	O
and	O
is	O
highly	O
safe	O
;	O
and	O
a	O
method	O
for	O
treating	O
a	O
central	O
or	O
peripheral	O
nerve	O
disease	O
,	O
which	O
is	O
characterized	O
by	O
administering	O
the	O
agent	O
.	O

Agent	O
for	O
activating	O
or	O
improving	O
neuronal	O
cell	O
or	O
brain	O
function	O

The	O
present	O
invention	O
relates	O
to	O
the	O
diagnosis	O
,	O
risk	O
assessment	O
,	O
prevention	O
,	O
and	O
treatment	O
of	O
Senile	O
Dementia	O
of	O
the	O
Alzheimer	O
's	O
Type	O
(	O
SDAT	O
)	O
.	O

More	O
specifically	O
the	O
present	O
invention	O
relates	O
to	O
the	O
measurement	O
of	O
ethanolamine	B
phospholipids	B
in	O
human	O
serum	O
.	O

Subsets	O
of	O
these	O
molecules	O
are	O
significantly	O
altered	O
in	O
subjects	O
with	O
pathologically	O
confirmed	O
deposits	O
of	O
	O
-	O
amyloid	O
versus	O
subjects	O
without	O
	O
-	O
amyloid	O
deposits	O
and	O
in	O
subjects	O
with	O
a	O
clinical	O
manifestation	O
of	O
dementia	O
consistent	O
with	O
a	O
diagnosis	O
of	O
SDAT	O
versus	O
non	O
-	O
demented	O
controls	O
.	O

Further	O
,	O
the	O
invention	O
relates	O
to	O
the	O
diagnosis	O
of	O
various	O
stages	O
of	O
SDAT	O
,	O
the	O
early	O
detection	O
and	O
prevention	O
of	O
SDAT	O
symptoms	O
,	O
the	O
treatment	O
of	O
SDAT	O
,	O
the	O
differential	O
diagnosis	O
of	O
non	O
-	O
SDAT	O
dementia	O
,	O
and	O
the	O
identification	O
of	O
molecular	O
targets	O
for	O
which	O
chemical	O
or	O
biological	O
treatments	O
can	O
be	O
designed	O
for	O
the	O
therapeutic	O
intervention	O
of	O
SDAT	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
methods	O
of	O
using	O
a	O
molecular	O
diagnostic	O
assay	O
to	O
direct	O
and	O
select	O
the	O
appropriate	O
therapeutic	O
intervention	O
for	O
subjects	O
suffering	O
from	O
dementia	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
small	O
molecules	O
or	O
metabolites	O
that	O
are	O
found	O
to	O
have	O
significantly	O
different	O
abundances	O
between	O
persons	O
with	O
a	O
clinical	O
manifestation	O
of	O
SDAT	O
and	O
normal	O
,	O
non	O
-	O
demented	O
patients	O
.	O

Methods	O
for	O
the	O
treatment	O
of	O
senile	O
dementia	O
of	O
the	O
alzheimer	O
's	O
type	O

The	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
wherein	O
R1	O
to	O
R8	O
and	O
R11	O
have	O
the	O
meanings	O
as	O
given	O
in	O
the	O
description	O
,	O
the	O
salts	O
thereof	O
,	O
the	O
N	B
-	I
oxides	I
of	O
the	O
compounds	O
and	O
the	O
salts	O
thereof	O
,	O
and	O
the	O
stereoisomers	O
of	O
the	O
compounds	O
,	O
the	O
salts	O
,	O
the	O
N	B
-	I
oxides	I
of	O
the	O
compounds	O
and	O
the	O
N	B
-	I
oxides	I
of	O
the	O
salts	O
thereof	O
are	O
effective	O
inhibitors	O
of	O
the	O
type	O
5	O
phosphodiesterase	O
.	O

6-benzyl-2,3,4,7-tetrahydro	B
-	I
indolo	I
[	I
2	I
,	I
3-c	I
]	I
quinoline	I
compounds	O
useful	O
as	O
pde5	O
inhibitors	O

The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
of	O
treating	O
irritable	O
bowel	O
syndrome	O
with	O
constipation	O
(	O
IBS	O
-	O
c	O
)	O
or	O
irritable	O
bowel	O
syndrome	O
with	O
alternating	O
constipation	O
and	O
diarrhea	O
(	O
IBS	O
-	O
a	O
)	O
in	O
a	O
subject	O
in	O
need	O
of	O
treatment	O
.	O

The	O
method	O
comprises	O
administering	O
to	O
said	O
subject	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
thieno	B
[	I
3,2-b	I
]	I
pyridine	I
compound	O
of	O
Structural	O
Formula	O
I	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
or	O
N	B
-	I
oxide	I
derivative	O
thereof	O
.	O

Compositions	O
comprising	O
mkc-733	O
(	O
pumosetrag	O
)	O
useful	O
for	O
treating	O
irritable	O
bowel	O
syndrome	O

The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
for	O
the	O
treatment	O
of	O
an	O
amyloidosis	O
such	O
as	O
Alzheimer	O
's	O
disease	O
in	O
a	O
subject	O
in	O
need	O
thereof	O
,	O
characterized	O
in	O
that	O
it	O
comprises	O
administering	O
an	O
agonist	O
of	O
the	O
P	O
/	O
Q	O
type	O
voltage	O
-	O
gated	O
presynaptic	O
calcium	B
channel	O
to	O
said	O
subject	O
.	O

Method	O
for	O
the	O
treatment	O
of	O
amyloidoses	O

This	O
invention	O
describes	O
compounds	O
and	O
pharmaceutical	O
compositions	O
useful	O
as	O
ubiquitin	O
agent	O
inhibitors	O
,	O
particularly	O
ubiquitin	O
ligase	O
inhibitors	O
.	O

The	O
compounds	O
and	O
pharmaceutical	O
compositions	O
of	O
the	O
invention	O
are	O
useful	O
as	O
inhibitors	O
of	O
the	O
biochemical	O
pathways	O
of	O
organisms	O
in	O
which	O
ubiquitination	O
is	O
involved	O
,	O
such	O
as	O
signal	O
transduction	O
pathways	O
.	O

The	O
invention	O
also	O
comprises	O
the	O
use	O
of	O
the	O
compounds	O
and	O
pharmaceutical	O
compositions	O
of	O
the	O
invention	O
for	O
the	O
treatment	O
of	O
conditions	O
that	O
require	O
inhibition	O
of	O
ubiquitination	O
.	O

Furthermore	O
,	O
the	O
invention	O
comprises	O
methods	O
of	O
inhibiting	O
ubiquitination	O
in	O
a	O
cell	O
comprising	O
contacting	O
a	O
cell	O
in	O
which	O
inhibition	O
of	O
ubiquitination	O
is	O
desired	O
with	O
a	O
compound	O
or	O
pharmaceutical	O
composition	O
according	O
to	O
the	O
invention	O
.	O

Particularly	O
,	O
the	O
compounds	O
and	O
pharmaceutical	O
compositions	O
are	O
useful	O
to	O
inhibit	O
the	O
ubiquitin	O
ligase	O
activity	O
of	O
TRAF6	O
.	O

Derivatives	O
of	O
benzoxadiazole	B
suitable	O
for	O
the	O
treatment	O
of	O
cell	O
proliferative	O
diseases	O

Embodiments	O
of	O
the	O
present	O
invention	O
include	O
the	O
use	O
of	O
heterocyclic	B
trialkyl	I
ammonium	I
-	O
containing	O
compounds	O
to	O
promote	O
regeneration	O
of	O
bone	O
marrow	O
from	O
endogenous	O
or	O
exogenous	O
stem	O
/	O
progenitor	O
cells	O
and	O
to	O
normalize	O
blood	O
cell	O
and	O
platelet	O
counts	O
.	O

Compounds	O
to	O
promote	O
regeneration	O
of	O
bone	O
marrow	O

The	O
present	O
invention	O
relates	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
which	O
are	O
believed	O
to	O
possess	O
antibacterial	O
activity	O
.	O

Substituted	O
piperidines	B
for	O
use	O
in	O
the	O
treatment	O
of	O
bacterial	O
infections	O

Provided	O
is	O
a	O
pharmaceutical	O
and	O
nutraceutical	O
composition	O
for	O
oral	O
delivery	O
which	O
contains	O
at	O
least	O
60	O
wt%	O
of	O
glycerophospholipids	O
(	O
GPLs	O
)	O
,	O
in	O
which	O
the	O
ratio	O
of	O
esterified	O
to	O
free	O
phosphatidic	B
acid	I
is	O
between	O
6	O
and	O
7	O
,	O
and	O
wherein	O
phosphatidylserine	B
constitutes	O
more	O
than	O
50	O
wt%	O
of	O
the	O
phosphatidic	B
esters	I
.	O

The	O
composition	O
mitigates	O
diabetes	O
-	O
like	O
conditions	O
and	O
boosts	O
mental	O
and	O
bodily	O
vigor	O
.	O

Compositions	O
containing	O
phosphatidylserine	B
in	O
treating	O
diabetes	O
associated	O
conditions	O

Small	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
molecules	O
that	O
target	O
a	O
mammalian	O
thymidylate	B
synthase	O
gene	O
(	O
TS	O
)	O
,	O
and	O
which	O
are	O
capable	O
of	O
inhibiting	O
the	O
expression	O
of	O
their	O
target	O
gene	O
,	O
are	O
provided	O
The	O
siRNA	O
molecules	O
are	O
also	O
capable	O
of	O
sensitizing	O
cells	O
to	O
the	O
effects	O
of	O
other	O
anti	O
-	O
cancer	O
agents	O
,	O
particularly	O
chemotherapeutic	O
agents	O
that	O
target	O
TS	O
Methods	O
of	O
treating	O
cancer	O
using	O
the	O
TS	O
siRNA	O
in	O
combination	O
with	O
another	O
anti	O
-	O
cancer	O
agent	O
are	O
also	O
provided	O
Methods	O
of	O
enhancing	O
the	O
effect	O
of	O
a	O
TS	O
siRNA	O
on	O
cancer	O
cell	O
proliferation	O
by	O
combining	O
the	O
TS	O
siRNA	O
with	O
a	O
siRNA	O
targeting	O
a	O
cell	O
survival	O
gene	O
such	O
as	O
Bcl-2	O
are	O
further	O
provided	O
.	O

Sirna	O
against	O
thymidylate	B
synthase	O
and	O
uses	O
thereof	O
in	O
cancer	O
treatment	O
regimens	O

The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
and	O
to	O
their	O
pharmaceutical	O
compositions	O
,	O
and	O
to	O
their	O
methods	O
of	O
use	O
.	O

These	O
novel	O
compounds	O
provide	O
a	O
treatment	O
for	O
myeloproliferative	O
disorders	O
and	O
cancer	O
.	O

5-aminopyrazol-3-yl-3h	B
-	I
imidazo	I
[	I
4,5-b	I
]	I
pyridine	I
derivatives	O
and	O
their	O
use	O
for	O
the	O
treatment	O
of	O
cancer	O

Disclosed	O
are	O
an	O
external	O
preparation	O
for	O
skin	O
for	O
improving	O
wrinkles	O
and	O
sagging	O
,	O
an	O
external	O
preparation	O
for	O
skin	O
for	O
moisture	O
retention	O
,	O
an	O
external	O
preparation	O
for	O
skin	O
for	O
promoting	O
wound	O
healing	O
and	O
an	O
external	O
preparation	O
for	O
lips	O
,	O
each	O
of	O
which	O
contains	O
raspberry	O
ketone	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
as	O
an	O
active	O
ingredient	O
.	O

External	O
preparation	O
for	O
skin	O
and	O
external	O
preparation	O
for	O
lips	O

Disclosed	O
herein	O
are	O
methods	O
and	O
compositions	O
for	O
the	O
treatment	O
of	O
diseases	O
or	O
disorders	O
involving	O
disturbances	O
in	O
glutathione	B
(	O
GSH	B
)	O
metabolism	O
and	O
oxidative	O
stress	O
,	O
especially	O
respiratory	O
diseases	O
or	O
disorders	O
,	O
and	O
most	O
especially	O
asthma	O
.	O

In	O
particular	O
embodiments	O
,	O
methods	O
are	O
disclosed	O
for	O
the	O
treatment	O
of	O
respiratory	O
diseases	O
or	O
disorders	O
,	O
involving	O
the	O
step	O
of	O
administering	O
an	O
agent	O
that	O
inhibits	O
gamma	O
glutamyl	O
transpeptidase	O
(	O
GGT	O
)	O
activity	O
in	O
lung	O
and	O
airway	O
lining	O
fluid	O
.	O

Methods	O
and	O
compositions	O
for	O
the	O
treatment	O
of	O
respiratory	O
disease	O

The	O
invention	O
relates	O
to	O
oligonucleotides	B
including	O
at	O
least	O
one	O
backbone	O
modification	O
and	O
a	O
pyrimidine	B
-	I
purine	I
dinucleotide	B
.	O

The	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
and	O
methods	O
of	O
use	O
thereof	O
.	O

Phosphate	B
-	O
modified	O
oligonucleotide	B
analogs	O
with	O
immunostimulatory	O
activity	O

The	O
present	O
invention	O
is	O
directed	O
to	O
compositions	O
methods	O
and	O
kits	O
for	O
regulation	O
of	O
gene	O
therapies	O
,	O
including	O
,	O
without	O
limitation	O
,	O
reversible	O
gene	O
therapies	O
and	O
allele-	O
specific	O
therapies	O
.	O

Compositions	O
and	O
methods	O
for	O
making	O
therapies	O
delivered	O
by	O
viral	O
vectors	O
reversible	O
for	O
safety	O
or	O
allele	O
-	O
specificity	O

The	O
present	O
invention	O
provides	O
triazolyl	B
aminopyrimidine	I
compounds	O
useful	O
in	O
the	O
treatment	O
of	O
cancer	O
.	O

Triazolyl	B
aminopyrimidine	I
compounds	O

Compounds	O
of	O
general	O
formula	O
(	O
1	O
)	O
and	O
pharmacologically	O
acceptable	O
salts	O
and	O
pro	O
-	O
drugs	O
thereof	O
:	O
wherein	O
A	O
and	O
B	O
are	O
CH2	B
or	O
CH2CH2	B
,	O
R1	O
is	O
hydrogen	B
,	O
alkyl	B
,	O
cycloalkyl	B
,	O
aryl	B
,	O
aralkyl	B
or	O
heteroaralkyl	B
,	O
D	O
,	O
E	O
and	O
G	O
are	O
CR2	O
or	O
nitrogen	B
,	O
with	O
the	O
proviso	O
that	O
at	O
least	O
one	O
of	O
D	O
,	O
E	O
and	O
G	O
is	O
nitrogen	B
,	O
R2	O
,	O
R3	O
and	O
R4	O
are	O
hydrogen	B
,	O
alkyl	B
,	O
halogen	B
,	O
haloalkyl	B
,	O
alkoxy	B
,	O
alkoxycarbonyl	B
,	O
carboxyl	B
,	O
hydroxyl	B
or	O
cyano	B
,	O
X	O
is	O
R5SO2	B
,	O
R5R7NCO	B
,	O
R5R7NSO2or	B
R5SO2NR7CO	B
,	O
Y	O
is	O
R6CO	B
,	O
R6SO2	B
,	O
R6R7NCO	B
,	O
R6R7NSO2	B
,	O
R6SO2NR7CO	B
or	O
CO2R8	B
,	O
R5	O
and	O
R6	O
are	O
hydrogen	B
,	O
alkyl	B
,	O
aryl	B
,	O
aralkyl	B
,	O
heteroaryl	B
or	O
heteroaralkyl	B
,	O
R7	O
is	O
hydrogen	B
,	O
alkyl	B
,	O
aryl	B
or	O
aralkyl	B
,	O
and	O
R8	O
is	O
alkyl	B
,	O
aryl	B
,	O
aralkyl	B
,	O
alkoxyalkyl	B
,	O
heteroaryl	B
or	O
heteroarylalkyl	B
,	O
are	O
of	O
use	O
inthe	O
prophylaxis	O
or	O
treatment	O
of	O
diseases	O
and	O
conditions	O
in	O
which	O
Kv1.x	O
channels	O
are	O
involved	O
,	O
such	O
as	O
lower	O
urinary	O
tract	O
disorders	O
,	O
cardiovascular	O
diseases	O
,	O
inflammatory	O
and	O
immunological	O
diseases	O
and	O
pain	O
.	O

Potassium	B
ion	I
channel	O
modulators	O
and	O
uses	O
thereof	O

Disclosed	O
is	O
a	O
novel	O
pyrazolone	B
derivative	O
represented	O
by	O
the	O
general	O
formula	O
(	O
1	O
)	O
below	O
,	O
which	O
is	O
useful	O
as	O
a	O
pharmaceutical	O
product	O
having	O
phosphodiesterase	O
inhibitory	O
activity	O
.	O

(	O
1	O
)	O
R1	O
,	O
R2	O
:	O
C1	B
-	I
6	I
alkyl	I
R3	O
,	O
R4	O
:	O
H	B
,	O
X	O
,	O
C1	B
-	I
6	I
alkoxy	I
Z	O
:	O
O	B
,	O
S	B
A	O
:	O
AA	O
,	O
BB	O
(	O
R5	O
:	O
H	B
,	O
C1	B
-	I
6	I
alkyl	I
;	O
R6	O
,	O
R7	O
:	O
C1	B
-	I
6	I
alkyl	I
)	O
Pyrazolone	B
derivative	O
and	O
pde	O
inhibitor	O
containing	O
the	O
same	O
as	O
active	O
ingredient	O

Invented	O
is	O
a	O
method	O
of	O
inhibiting	O
the	O
activity	O
/	O
function	O
of	O
P13	O
kinases	O
using	O
quinazoline	B
derivatives	O
.	O

Also	O
invented	O
is	O
a	O
method	O
of	O
treating	O
one	O
or	O
more	O
disease	O
states	O
selected	O
from	O
:	O
autoimmune	O
disorders	O
,	O
inflammatory	O
diseases	O
,	O
cardiovascular	O
diseases	O
,	O
neurodegenerative	O
diseases	O
,	O
allergy	O
,	O
asthma	O
,	O
pancreatitis	O
,	O
multiorgan	O
failure	O
,	O
kidney	O
diseases	O
,	O
platelet	O
aggregation	O
,	O
cancer	O
,	O
sperm	O
motility	O
,	O
transplantation	O
rejection	O
,	O
graft	O
rejection	O
and	O
lung	O
injuries	O
by	O
the	O
administration	O
of	O
quinazoline	B
derivatives	O
.	O

Quinazoline	B
derivatives	O
as	O
pi3	O
kinase	O
inhibitors	O

The	O
present	O
invention	O
provides	O
novel	O
methods	O
of	O
making	O
a	O
non	O
-	O
corrosive	O
base	O
solution	O
for	O
use	O
as	O
an	O
alkalinity	O
increasing	O
agent	O
and/or	O
antioxidant	O
.	O

The	O
present	O
invention	O
further	O
provides	O
novel	O
compositions	O
and	O
methods	O
which	O
can	O
be	O
used	O
to	O
provide	O
relief	O
from	O
disorders	O
related	O
to	O
or	O
complicated	O
by	O
acidosis	O
or	O
excessive	O
free	O
radical	O
or	O
other	O
reactive	O
oxygen	B
species	O
production	O
including	O
,	O
but	O
not	O
limited	O
to	O
,	O
gout	O
,	O
Lesch	O
-	O
Nyhan	O
syndrome	O
,	O
hemochromatosis	O
,	O
Alzheimer	O
's	O
,	O
amyotropic	O
lateral	O
sclerosis	O
,	O
arthritis	O
,	O
atherosclerosis	O
,	O
cancer	O
,	O
cataracts	O
,	O
chronic	O
obstructive	O
pulmonary	O
disease	O
,	O
diabetes	O
,	O
cellulitis	O
,	O
coronary	O
artery	O
disease	O
,	O
heart	O
failure	O
,	O
hypertension	O
,	O
inflammatory	O
bowel	O
disease	O
,	O
macular	O
degeneration	O
,	O
multiple	O
sclerosis	O
,	O
Parkinson	O
's	O
,	O
Reynaud	O
's	O
phenomenon	O
,	O
reperfusion	O
injury	O
,	O
pancreatic	O
impairment	O
,	O
skin	O
infections	O
,	O
Hepatitis	O
C	O
,	O
methicillin-	O
resistant	O
Staphylococcus	O
aureus	O
and	O
infection	O
.	O

The	O
compositions	O
and	O
methods	O
of	O
the	O
present	O
invention	O
additionally	O
supply	O
relief	O
from	O
microbial	O
infections	O
including	O
fungal	O
infections	O
as	O
well	O
as	O
prevent	O
secondary	O
infections	O
.	O

Additional	O
compositions	O
and	O
methods	O
are	O
provided	O
which	O
employ	O
a	O
non	O
-	O
corrosive	O
base	O
solution	O
in	O
combination	O
with	O
a	O
second	O
alkalinity	O
increasing	O
agent	O
and/or	O
antioxidant	O
,	O
or	O
other	O
therapeutic	O
agent	O
to	O
yield	O
a	O
more	O
effective	O
treatment	O
tool	O
against	O
acidosis	O
and/or	O
excessive	O
ROS	O
production	O
including	O
free	O
radical	O
production	O
useful	O
to	O
prevent	O
or	O
reduce	O
acidosis	O
and/or	O
excessive	O
ROS	O
production	O
or	O
related	O
symptoms	O
or	O
conditions	O
associated	O
with	O
acidosis	O
and/or	O
excessive	O
free	O
radical	O
production	O
in	O
mammalian	O
subjects	O
.	O

Process	O
for	O
the	O
preparation	O
of	O
a	O
non	O
-	O
corrosive	O
base	O
solution	O
and	O
methods	O
of	O
using	O
same	O

The	O
present	O
invention	O
relates	O
to	O
PPAR	O
agonists	O
,	O
and	O
their	O
use	O
in	O
therapy	O
including	O
the	O
treatment	O
of	O
disease	O
.	O

In	O
particular	O
,	O
the	O
invention	O
relates	O
to	O
flavonoid	B
compounds	O
which	O
are	O
PPAR	O
-	O
gamma	O
agonists	O
and/or	O
PPAR	O
alpha	O
/	O
gamma	O
dual	O
agonists	O
.	O

Flavonoid	B
ppar	O
agonists	O

The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
and	O
to	O
their	O
salts	O
,	O
pharmaceutical	O
compositions	O
,	O
methods	O
of	O
use	O
,	O
and	O
methods	O
for	O
their	O
preparation	O
.	O

These	O
compounds	O
provide	O
a	O
treatment	O
for	O
myeloproliferative	O
disorders	O
and	O
cancer	O
.	O

2,4	B
diaminopyrimid'lnes	I
for	O
the	O
treatment	O
of	O
myeloproliferative	O
disorders	O
and	O
cancer	O

A	O
therapeutic	O
agent	O
for	O
cancers	O
having	O
resistance	O
to	O
protease	O
inhibitors	O
which	O
contains	O
,	O
as	O
a	O
heat	O
shock	O
protein	O
90	O
(	O
Hsp90	O
)	O
family	O
protein	O
inhibitor	O
,	O
either	O
a	O
benzoyl	B
compound	O
represented	O
by	O
the	O
formula	O
(	O
I	O
)	O
[	O
wherein	O
n	O
is	O
an	O
integer	O
of	O
1	O
-	O
5	O
;	O
R1	O
represents	O
(	O
un	O
)	O
substituted	O
lower	O
alkyl	B
,	O
CONR7R8	B
(	O
wherein	O
R7	O
and	O
R8	O
are	O
the	O
same	O
or	O
different	O
and	O
each	O
represents	O
hydrogen	B
,	O
(	O
un	O
)	O
substituted	O
lower	O
alkyl	B
,	O
etc	O
.	O
)	O
,	O
etc	O
.	O
;	O
R2	O
represents	O
(	O
un	O
)	O
substituted	O
aryl	B
,	O
etc	O
.	O
;	O
R3	O
and	O
R5	O
are	O
the	O
same	O
or	O
different	O
and	O
each	O
represents	O
hydrogen	B
,	O
(	O
un	O
)	O
substituted	O
lower	O
alkyl	B
,	O
etc	O
.	O
;	O
R4	O
represents	O
hydrogen	B
,	O
etc	O
.	O
;	O
and	O
R6	O
represents	O
hydrogen	B
,	O
halogeno	B
,	O
(	O
un	O
)	O
substituted	O
lower	O
alkyl	B
,	O
etc	O
.	O
]	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
of	O
the	O
compound	O
.	O

Therapeutic	O
agent	O
for	O
cancer	O
with	O
resistance	O
to	O
protease	O
inhibitor	O

The	O
invention	O
relates	O
to	O
novel	O
acylphloroglucinols	B
which	O
have	O
strong	O
growth	O
inhibitory	O
effects	O
on	O
multi	O
-	O
drug	O
resistant	O
strains	O
of	O
bacteria	O
,	O
particularly	O
MRSA	O
.	O

Typically	O
the	O
compounds	O
have	O
a	O
terpene	B
substituent	O
,	O
or	O
a	O
terpene-	B
derived	O
substituent	O
.	O

Methods	O
of	O
isolating	O
the	O
compounds	O
from	O
natural	O
sources	O
,	O
and	O
synthetic	O
methods	O
for	O
forming	O
the	O
compounds	O
are	O
also	O
provided	O
.	O

Anti	O
-	O
bacterial	O
agents	O

This	O
invention	O
relates	O
to	O
a	O
combination	O
product	O
,	O
as	O
defined	O
herein	O
,	O
comprising	O
a	O
MEK	O
inhibitor	O
and	O
a	O
mTOR	O
-	O
selective	O
inhibitor	O
,	O
and	O
to	O
methods	O
for	O
the	O
production	O
of	O
an	O
anti	O
-	O
cancer	O
effect	O
in	O
a	O
patient	O
,	O
which	O
is	O
accordingly	O
useful	O
in	O
the	O
treatment	O
of	O
cancer	O
in	O
a	O
patient	O
.	O

More	O
specifically	O
the	O
present	O
invention	O
relates	O
to	O
;	O
a	O
combination	O
product	O
,	O
as	O
defined	O
herein	O
,	O
comprising	O
a	O
MEK	O
inhibitor	O
and	O
a	O
mTOR	O
-	O
selective	O
inhibitor	O
;	O
a	O
combination	O
product	O
,	O
as	O
defined	O
herein	O
,	O
comprising	O
a	O
kit	O
of	O
parts	O
comprising	O
a	O
MEK	O
inhibitor	O
and	O
a	O
mTOR	O
-	O
selective	O
inhibitor	O
;	O
use	O
of	O
the	O
combination	O
product	O
,	O
as	O
defined	O
herein	O
,	O
in	O
the	O
treatment	O
of	O
cancer	O
;	O
a	O
method	O
of	O
treating	O
cancer	O
comprising	O
administering	O
the	O
combination	O
product	O
,	O
as	O
defined	O
herein	O
,	O
to	O
a	O
patient	O
.	O

The	O
combination	O
product	O
,	O
as	O
defined	O
herein	O
,	O
and	O
methods	O
of	O
the	O
invention	O
are	O
also	O
useful	O
in	O
the	O
treatment	O
of	O
other	O
diseases	O
associated	O
with	O
the	O
activity	O
of	O
MEK	O
,	O
and/or	O
mTOR	O
.	O

Combination	O
059	O

The	O
present	O
invention	O
provides	O
methods	O
of	O
using	O
modulators	O
of	O
the	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
pathway	O
for	O
treatment	O
or	O
prevention	O
of	O
substance	O
abuse	O
such	O
as	O
alcohol	O
abuse	O
.	O

The	O
modulators	O
include	O
small	O
molecule	O
inhibitors	O
such	O
as	O
Erlotinib	B
(	O
TARCEVA	B
	I
,	O
N-	B
(	I
3-ethynylphenyl	I
)	I
-6,7-bis	I
(	I
2-methoxyethoxy	I
)	I
-4-	I
quinazolineamine	I
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
,	O
hydrate	O
or	O
prodrug	O
thereof	O
and	O
Gefitinib	B
[	O
IRES	B
S	I
A	I
	I
,	O
N-	B
(	I
3	I
-chloro-4-fluoro	I
-	I
phenyl	I
)	I
-7-methoxy-6-	I
(	I
3	I
-morpholin-4-	I
ylpropoxy	I
)	I
quinazolin-4-amine	I
]	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
,	O
hydrate	B
or	O
prodrug	O
thereof	O
and	O
various	O
macromolecular	O
inhibitors	O
of	O
the	O
EGFR	O
pathway	O
such	O
as	O
siRNAs	O
and	O
antibodies	O
that	O
target	O
genes	O
or	O
proteins	O
in	O
the	O
EGFR	O
/	O
ERK	O
pathway	O
such	O
as	O
one	O
of	O
the	O
EGFR	O
/	O
ErbB	O
protein	O
or	O
a	O
homolog	O
thereof	O
.	O

Modulators	O
of	O
the	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
egfr	O
)	O
pathway	O
for	O
use	O
in	O
the	O
treatment	O
or	O
prevention	O
of	O
substance	O
abuse	O

A	O
composition	O
comprises	O
a	O
material	O
capable	O
of	O
controlling	O
a	O
level	O
of	O
cortisol	O
in	O
an	O
ocular	O
environment	O
for	O
effecting	O
ocular	O
neuroprotection	O
in	O
subjects	O
in	O
risk	O
of	O
developing	O
or	O
worsening	O
an	O
ocular	O
neurodegenerative	O
condition	O
.	O

Such	O
a	O
composition	O
is	O
injected	O
into	O
or	O
implanted	O
in	O
the	O
subject	O
's	O
posterior	O
segment	O
to	O
provide	O
such	O
neuroprotection	O
.	O

Inhibition	O
of	O
11	B
beta	I
-	I
hydroxysteroid	I
dehydrogenase	O
type	O
1	O
for	O
ocular	O
neuroprotection	O

Chemokine	O
receptor	O
antagonists	O
,	O
in	O
particular	O
,	O
compounds	O
of	O
Formula	O
(	O
I-	O
A	O
)	O
that	O
act	O
as	O
antagonists	O
of	O
the	O
chemokine	O
CCR2	O
receptor	O
,	O
including	O
pharmaceutical	O
compositions	O
and	O
uses	O
thereof	O
to	O
treat	O
or	O
prevent	O
diseases	O
associated	O
with	O
monocyte	O
accumulation	O
,	O
lymphocyte	O
accumulation	O
or	O
leukocyte	O
accumulation	O
are	O
described	O
herein	O
.	O

Carboxamid	B
compounds	O
and	O
their	O
use	O
as	O
chemokine	O
receptor	O
agonists	O

The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
a	O
mutant	O
TRAIL	O
protein	O
to	O
treat	O
various	O
cancers	O
in	O
mammals	O
.	O

The	O
invention	O
provides	O
a	O
variant	O
TRAIL	O
protein	O
,	O
which	O
has	O
superior	O
selectivity	O
for	O
the	O
death	O
receptor	O
5	O
,	O
for	O
treating	O
a	O
mammal	O
diagnosed	O
with	O
cancer	O
.	O

Trail	O
variants	O
for	O
treating	O
cancer	O

The	O
present	O
invention	O
relates	O
to	O
the	O
pharmaceutical	O
field	O
and	O
discloses	O
cucurbitane	B
triterpenoid	I
saponins	I
extracted	O
from	O
Momordica	O
charantia	O
,	O
a	O
pharmaceutical	O
composition	O
containing	O
them	O
and	O
their	O
preparation	O
.	O

The	O
invention	O
also	O
discloses	O
the	O
use	O
of	O
such	O
compounds	O
in	O
preparation	O
of	O
medicaments	O
for	O
the	O
treatment	O
of	O
diabetes	O
,	O
obesity	O
and	O
hyperlipaemia	O
.	O

The	O
saponins	B
disclosed	O
in	O
the	O
invention	O
are	O
represented	O
by	O
formula	O
I.	O
Cucurbitane	B
triterpenoid	I
saponins	I
,	O
pharmaceutical	O
composition	O
thereof	O
,	O
preparation	O
and	O
use	O
thereof	O

Composition	O
comprising	O
an	O
anti	O
-	O
inflammatory	O
plant	O
extract	O
from	O
rosehips	O
together	O
with	O
a	O
cartilage	O
-	O
protective	O
substance	O
,	O
and	O
a	O
method	O
of	O
producing	O
the	O
rosehip	O
extract	O
.	O

Preparations	O
with	O
rosehip	O
extracts	O
,	O
and	O
method	O
of	O
producing	O
rosehip	O
extracts	O

Disclosed	O
are	O
methods	O
for	O
treating	O
asthma	O
,	O
inflammatory	O
gastrointestinal	O
tract	O
disorders	O
,	O
cancer	O
,	O
cardiovascular	O
diseases	O
,	O
neurological	O
disorders	O
,	O
and	O
diseases	O
related	O
to	O
undesirable	O
angiogenesis	O
using	O
A2B	O
adenosine	B
receptor	O
antagonists	O
having	O
the	O
structure	O
of	O
Formula	O
(	O
I	O
)	O
or	O
Formula	O
(	O
II	O
)	O
.	O

A2b	O
adenosine	B
receptor	O
antagonists	O
for	O
the	O
treatment	O
of	O
cancer	O

The	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
the	O
groups	O
R	O
and	O
R	O
'	O
A	O
,	O
D	O
,	O
E	O
,	O
G	O
,	O
L	O
,	O
p	O
and	O
Rl	O
to	O
R1O	O
have	O
the	O
stated	O
meanings	O
and	O
to	O
their	O
physiologically	O
compatible	O
salts	O
.	O

Said	O
compounds	O
are	O
suitable	O
,	O
for	O
example	O
,	O
as	O
anti	O
-	O
obesity	O
drugs	O
.	O

Aryl	B
-	I
substituted	I
imidazolidine-2,4-diones	I
,	O
method	O
for	O
the	O
production	O
thereof	O
,	O
medicaments	O
containing	O
said	O
compounds	O
and	O
use	O
thereof	O

The	O
present	O
invention	O
provides	O
imidazopyridines	B
of	O
formula	O
(	O
I	O
)	O
.	O

The	O
compounds	O
show	O
inhibitory	O
activity	O
against	O
protein	O
kinase	O
,	O
especially	O
VEGFR2	O
,	O
FLT3	O
,	O
and	O
C	O
-	O
KIT	O
receptors	O
and	O
so	O
on	O
,	O
and	O
can	O
be	O
used	O
for	O
the	O
preparation	O
of	O
the	O
medicament	O
for	O
treating	O
diseases	O
associated	O
with	O
abnormal	O
high	O
level	O
of	O
kinase	O
activity	O
,	O
such	O
as	O
cancer	O
.	O

Imidazopyridine	B
compounds	O

Provided	O
herein	O
are	O
novel	O
,	O
commercially	O
viable	O
and	O
industrially	O
advantageous	O
processes	O
for	O
the	O
preparation	O
of	O
substantially	O
pure	O
ethylene	B
glycol	I
sulfonamide	I
compounds	O
such	O
as	O
bosentan	B
.	O

Processes	O
for	O
the	O
preparation	O
of	O
bosentan	B
and	O
related	O
compounds	O

This	O
disclosure	O
relates	O
to	O
new	O
heterocyclic	B
compounds	O
that	O
may	O
be	O
used	O
to	O
modulate	O
a	O
histamine	O
receptor	O
in	O
an	O
individual	O
.	O

Pyrido	B
[	I
3,4-b	I
]	I
indoles	I
are	O
described	O
,	O
as	O
are	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds	O
and	O
methods	O
of	O
using	O
the	O
compounds	O
in	O
a	O
variety	O
of	O
therapeutic	O
applications	O
,	O
including	O
the	O
treatment	O
of	O
a	O
cognitive	O
disorder	O
,	O
psychotic	O
disorder	O
,	O
neurotransmitter	O
-	O
mediated	O
disorder	O
and/or	O
a	O
neuronal	O
disorder	O
.	O

Pyrido	B
[	I
3	I
,	I
4-b	I
]	I
indoles	I
and	O
methods	O
of	O
use	O

The	O
present	O
invention	O
discloses	O
fused	O
bicyclic	B
2-aryl-	I
or	I
2-heteroarylthiazolyl	I
compounds	O
and	O
their	O
pharmaceutically	O
acceptable	O
salts	O
and	O
esters	O
thereof	O
,	O
which	O
are	O
useful	O
for	O
inhibiting	O
the	O
growth	O
of	O
cancerous	O
cells	O
,	O
inhibiting	O
human	O
breast	O
carcinoma	O
tumor	O
growth	O
in	O
particular	O
and	O
to	O
treat	O
diseases	O
or	O
disorders	O
associated	O
with	O
securin	O
,	O
including	O
elevated	O
securin	O
levels	O
.	O

2-aryl-	B
and	O
2-heteroarylthiazolyl	B
compounds	O
,	O
methods	O
for	O
their	O
preparation	O
and	O
use	O
thereof	O

Compounds	O
,	O
pharmaceutical	O
compositions	O
and	O
methods	O
are	O
provided	O
that	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
CDK4-mediated	O
disorders	O
,	O
such	O
as	O
cancer	O
.	O

The	O
subject	O
compounds	O
are	O
gem	O
-	O
disubstituted	O
or	O
spirocyclic	B
pyridine	I
,	I
pyrimidine	I
and	I
triazine	I
derivatives	O
.	O

Gem	O
-	O
disubstituted	O
and	O
spirocyclic	B
amino	I
pyridines	I
/	I
pyrimidines	I
as	O
cell	O
cycle	O
inhibitors	O

Disclosed	O
are	O
:	O
a	O
therapeutic	O
agent	O
for	O
intermittent	O
claudication	O
,	O
which	O
comprises	O
a	O
tricyclic	O
compound	O
represented	O
by	O
formula	O
(	O
I	O
)	O
[	O
wherein	O
R1	O
represents	O
a	O
substituted	O
or	O
unsubstituted	O
lower	O
alkyl	B
]	O
or	O
a	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
as	O
an	O
active	O
ingredient	O
;	O
a	O
therapeutic	O
agent	O
for	O
arterial	O
occlusive	O
intermittent	O
claudication	O
,	O
which	O
comprises	O
a	O
tricyclic	O
compound	O
represented	O
by	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
as	O
an	O
active	O
ingredient	O
;	O
a	O
therapeutic	O
agent	O
for	O
intermittent	O
claudication	O
,	O
which	O
comprises	O
a	O
tricyclic	O
compound	O
represented	O
by	O
formula	O
(	O
IA	O
)	O
or	O
a	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
as	O
an	O
active	O
ingredient	O
;	O
a	O
therapeutic	O
agent	O
for	O
arterial	O
occlusive	O
intermittent	O
claudication	O
,	O
which	O
comprises	O
a	O
tricyclic	O
compound	O
represented	O
by	O
formula	O
(	O
IA	O
)	O
or	O
a	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
as	O
an	O
active	O
ingredient	O
;	O
and	O
others	O
.	O

Therapeutic	O
agent	O
for	O
intermittent	O
claudication	O

Compounds	O
of	O
formula	O
(	O
I	O
)	O
are	O
of	O
use	O
in	O
treating	O
a	O
range	O
of	O
conditions	O
,	O
including	O
pain	O
.	O

Indole-	B
3	I
-glyoxylamide	I
derivatives	O
for	O
use	O
as	O
calcium	B
ion	O
channel	O
modulators	O

The	O
invention	O
is	O
directed	O
to	O
using	O
4-	B
{	I
(	I
3-aminophenyl	I
)	I
[	I
4-	I
(	I
4-fluorobenzyl	I
)	I
piperazin-1-yl	I
]	I
methyl	I
}	I
-N	I
,	I
N	I
-	I
diethylbenzamide	I
,	O
or	O
enantiomer	O
thereof	O
,	O
or	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
and/or	O
mixture	O
thereof	O
to	O
treat	O
anxious	O
major	O
depressive	O
disorder	O
(	O
AMDD	O
)	O
.	O

Method	O
of	O
treating	O
anxious	O
major	O
depressive	O
disorder	O

A	O
single	O
nucleotide	O
G	O
>	O
A	O
polymorphism	O
at	O
position	O
-126	O
in	O
the	O
promoter	O
of	O
the	O
human	O
myeloid	O
cell	O
leukemia-1	O
gene	O
is	O
associated	O
with	O
a	O
reduced	O
predisposition	O
to	O
cancer	O
and	O
an	O
increased	O
responsiveness	O
to	O
pro	O
-	O
apoptotic	O
cancer	O
therapeutic	O
agents	O
.	O

The	O
G>;A	O
polymorphism	O
is	O
in	O
an	O
ELK4	O
transcription	O
factor	O
binding	O
site	O
,	O
which	O
results	O
in	O
reduced	O
myeloid	O
cell	O
leukemia-1	O
gene	O
expression	O
.	O

Elevated	O
levels	O
of	O
ELK4	O
and	O
Mcl-1	O
protein	O
and	O
nucleic	O
acids	O
are	O
associated	O
with	O
an	O
increased	O
predisposition	O
to	O
cancer	O
and	O
an	O
decreased	O
responsiveness	O
to	O
pro	O
-	O
apoptotic	O
agents	O
.	O

Reduced	O
levels	O
of	O
ELK4	O
and	O
Mcl-1	O
protein	O
and	O
nucleic	O
acids	O
are	O
associated	O
with	O
less	O
of	O
a	O
predisposition	O
to	O
cancer	O
and	O
an	O
increased	O
responsiveness	O
to	O
pro	O
-	O
apoptotic	O
cancer	O
therapeutic	O
agents	O
.	O

Methods	O
of	O
cancer	O
diagnosis	O
and/or	O
therapy	O
which	O
target	O
ELK4	O
and/or	O
Mcl-1	O
protein	O
and/or	O
nucleic	O
acids	O
are	O
particularly	O
applicable	O
to	O
cancers	O
such	O
as	O
glioma	O
,	O
colon	O
cancer	O
,	O
lung	O
cancer	O
,	O
thyroid	O
cancer	O
,	O
kidney	O
cancer	O
and/or	O
melanoma	O
.	O

Such	O
methods	O
and	O
compositions	O
may	O
sensitize	O
or	O
improve	O
responsiveness	O
of	O
cancer	O
cells	O
to	O
pro	O
-	O
apoptotic	O
agents	O
.	O

Cancer	O
drug	O
target	O
and	O
methods	O
of	O
diagnosis	O
and	O
therapy	O

It	O
is	O
intended	O
to	O
provide	O
a	O
benzodiazepine	B
compound	O
useful	O
in	O
the	O
production	O
of	O
an	O
antidepressant	O
drug	O
that	O
has	O
a	O
wider	O
therapeutic	O
spectrum	O
and	O
can	O
exert	O
sufficient	O
therapeutic	O
effects	O
in	O
a	O
short	O
period	O
.	O

The	O
benzodiazepine	B
compound	O
of	O
the	O
present	O
invention	O
is	O
represented	O
by	O
the	O
general	O
formula	O
(	O
1	O
)	O
:	O
wherein	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
and	O
R7	O
respectively	O
represent	O
a	O
hydrogen	B
atom	O
or	O
the	O
like	O
;	O
and	O
R6	O
represents	O
a	O
substituted	O
phenyl	B
group	O
or	O
the	O
like	O
.	O

Benzo	B
[	I
1	I
,	I
4	I
]	I
diazepines	I
substituted	O
at	O
the	O
1-position	O
by	O
a	O
ring	O
,	O
for	O
use	O
as	O
antidepressants	O

A	O
compound	O
for	O
use	O
in	O
the	O
treatment	O
of	O
proliferative	O
disorders	O
,	O
such	O
as	O
cancer	O
,	O
having	O
the	O
following	O
formula	O
:	O
z	O
wherein	O
:	O
R1	O
,	O
R2	O
and	O
R3	O
are	O
independently	O
H	B
or	O
lower	O
alkyl	B
;	O
R4	O
,	O
R5	O
,	O
R6	O
,	O
R7	O
and	O
R8	O
are	O
independently	O
H	B
,	O
halo	B
,	O
lower	O
alkyl	B
or	O
-O	B
-	I
lower	I
alkyl	I
,	O
provided	O
that	O
at	O
least	O
one	O
is	O
-O	B
-	I
lower	I
alkyl	I
;	O
or	O
at	O
least	O
one	O
pair	O
of	O
R4	O
to	O
R8	O
,	O
the	O
members	O
of	O
which	O
pair	O
are	O
adjacent	O
to	O
one	O
another	O
on	O
the	O
ring	O
,	O
are	O
conjoined	O
to	O
form-0-	O
(	B
CR14R15	I
)	I
n	I
-	I
O-	I
,	O
where	O
n	O
is	O
1	O
or	O
2	O
and	O
R14	O
and	O
R15	O
are	O
independently	O
H	B
or	O
lower	O
alkyl	B
,	O
and	O
the	O
remainder	O
of	O
R4	O
to	O
R8	O
are	O
independently	O
H	B
,	O
halo	B
,	O
lower	O
alkyl	B
or	O
-O	B
-	I
lower	I
alkyl	I
;	O
and	O
R9	O
,	O
R10	O
,	O
R11	O
,	O
R12	O
and	O
R13	O
are	O
independently	O
H	B
,	O
halo	B
,	O
lower	O
alkyl	B
or	O
-O	B
-	I
lower	I
alkyl	I
,	O
provided	O
that	O
at	O
least	O
one	O
is	O
-O	B
-	I
lower	I
alkyl	I
;	O
or	O
at	O
least	O
one	O
pair	O
of	O
R9	O
to	O
R13	O
,	O
the	O
members	O
of	O
which	O
pair	O
are	O
adjacent	O
to	O
one	O
another	O
on	O
the	O
ring	O
,	O
are	O
conjoined	O
to	O
form	O
-	B
O-	I
(	I
CR16R17	I
)	I
m	I
-	I
O-	I
,	O
where	O
m	O
is	O
1	O
or	O
2	O
and	O
R16	O
and	O
R17	O
are	O
independently	O
H	B
or	O
lower	O
alkyl	B
,	O
and	O
the	O
remainder	O
of	O
R9	O
to	O
R13	O
are	O
independently	O
H	B
,	O
halo	B
,	O
lower	O
alkyl	B
or	O
-O	B
-	I
lower	I
alkyl	I
.	O

4	B
,	I
6-diphenylpyrid-2	I
-	I
0nes	I
against	O
cancer	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
heterocyclic	B
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
which	O
are	O
phosphodiesterase	O
inhibitors	O
(	O
PDEs	O
)	O
,	O
in	O
particular	O
phosphodiesterase	O
type	O
4	O
inhibitors	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
,	O
and	O
processes	O
for	O
their	O
preparation	O
.	O

These	O
novel	O
PDEs	O
are	O
useful	O
in	O
treating	O
allergic	O
and	O
inflammatory	O
diseases	O
(	O
such	O
as	O
asthma	O
,	O
COPD	O
,	O
allergic	O
rhinitis	O
,	O
allergic	O
conjunctivitis	O
,	O
respiratory	O
distress	O
syndrome	O
,	O
chronic	O
bronchitis	O
,	O
nephritis	O
,	O
rheumatoid	O
spondylitis	O
,	O
osteoarthritis	O
,	O
atopic	O
dermatitis	O
,	O
eosinophilic	O
granuloma	O
,	O
psoriasis	O
,	O
rheumatoid	O
septic	O
shock	O
,	O
ulcerative	O
colitis	O
,	O
multiple	O
sclerosis	O
,	O
chronic	O
inflammation	O
,	O
Crohn	O
's	O
syndrome	O
and	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
disorders	O
)	O
and	O
for	O
inhibiting	O
the	O
production	O
of	O
Tumor	O
Necrosis	O
Factor	O
(	O
TNF	O
-	O
	O
)	O
.	O

Novel	O
pde	O
inhibitors	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
processes	O
for	O
their	O
preparation	O

A	O
pharmaceutical	O
combination	O
product	O
is	O
disclosed	O
that	O
comprises	O
a	O
receptor	O
tyrosine	B
kinase	O
inhibitor	O
and	O
a	O
fatty	B
acid	I
synthase	O
inhibitor	O
,	O
and	O
to	O
the	O
use	O
thereof	O
in	O
the	O
manufacture	O
of	O
a	O
medicament	O
for	O
use	O
in	O
the	O
treatment	O
or	O
prophylaxis	O
of	O
cancer	O
.	O

Combination	O
product	O
of	O
receptor	O
tyrosine	B
kinase	O
inhibitor	O
and	O
fatty	B
acid	I
synthase	O
inhibitor	O
for	O
treating	O
cancer	O

Compounds	O
active	O
on	O
Fms	O
and/or	O
Kit	O
protein	O
kinases	O
are	O
described	O
,	O
as	O
well	O
as	O
methods	O
of	O
using	O
such	O
compounds	O
to	O
treat	O
diseases	O
and	O
conditions	O
associated	O
with	O
aberrant	O
activity	O
of	O
Fms	O
and/or	O
Kit	O
protein	O
kinases	O
.	O

5h	B
-	I
pyrr0l0	I
[	I
2,3-b	I
]	I
pyrazine	I
derivatives	O
for	O
kinase	O
modulation	O
,	O
and	O
indications	O
therefor	O

A	O
method	O
of	O
treating	O
a	O
proliferative	O
disease	O
in	O
a	O
vertebrate	O
,	O
the	O
method	O
comprising	O
administering	O
to	O
the	O
vertebrate	O
a	O
therapeutically	O
effective	O
amount	O
of	O
at	O
least	O
one	O
compound	O
of	O
formula	O
(	O
I	O
)	O
(	O
I	O
)	O
wherein	O
R1	O
is	O
selected	O
from	O
H	B
,	O
C1	B
-	I
6	I
alkyl	I
,	O
C2	B
-	I
6	I
alkenyl	I
and	O
phenyl	B
;	O
R2	O
is	O
selected	O
from	O
H	B
,	O
C1	B
-	I
6	I
alkyl	I
,	O
C2	B
-	I
6	I
alkenyl	I
and	O
phenyl	B
;	O
wherein	O
R1	O
and	O
R2	O
are	O
the	O
same	O
or	O
different	O
,	O
or	O
a	O
salt	O
,	O
hydrate	O
,	O
or	O
iron	B
complex	O
thereof	O
,	O
or	O
a	O
pharmaceutical	O
composition	O
comprising	O
said	O
compound	O
,	O
salt	O
,	O
hydrate	O
or	O
iron	B
complex	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
,	O
diluent	O
or	O
excipient	O
.	O

Thiosemicarbazone	B
compounds	O
and	O
use	O
thereof	O

This	O
invention	O
relates	O
to	O
novel	O
compounds	O
that	O
are	O
2-alkyl-3-acylpyrazolo	B
[	I
l,5-	I
a	I
]	I
pyridines	I
,	O
their	O
derivatives	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O

More	O
specifically	O
,	O
the	O
invention	O
relates	O
to	O
2-alkyl-3-acylpyrazolo	B
[	I
l,5-a	I
]	I
pyridine	I
compounds	O
that	O
are	O
derivatives	O
of	O
ibudilast	B
.	O

This	O
invention	O
also	O
provides	O
compositions	O
comprising	O
a	O
compound	O
of	O
this	O
invention	O
and	O
the	O
use	O
of	O
such	O
compositions	O
in	O
methods	O
of	O
treating	O
diseases	O
and	O
conditions	O
that	O
are	O
beneficially	O
treated	O
by	O
administering	O
a	O
phosphodiesterase	O
(	O
PDE	O
)	O
inhibitor	O
,	O
a	O
leukotriene	O
CysLTl	O
(	O
LTD4	O
)	O
antagonist	O
,	O
an	O
inhibitor	O
of	O
nitric	B
oxide	I
synthase	O
,	O
and/or	O
a	O
glial	O
cell	O
activation	O
suppressant	O
,	O
such	O
as	O
ibudilast	B
.	O

Deuterated	B
ibudilast	I

The	O
present	O
invention	O
relates	O
to	O
novel	O
Tricyclic	B
Heterocylce	I
Derivatives	O
,	O
pharmaceutical	O
compositions	O
comprising	O
the	O
Tricyclic	B
Heterocycle	I
Derivatives	O
and	O
the	O
use	O
of	O
these	O
compounds	O
for	O
treating	O
or	O
preventing	O
allergy	O
,	O
an	O
allergy	O
-	O
induced	O
airway	O
response	O
,	O
congestion	O
,	O
a	O
cardiovascular	O
disease	O
,	O
an	O
inflammatory	O
disease	O
,	O
a	O
gastrointestinal	O
disorder	O
,	O
a	O
neurological	O
disorder	O
,	O
a	O
metabolic	O
disorder	O
,	O
obesity	O
or	O
an	O
obesity	O
-	O
related	O
disorder	O
,	O
diabetes	O
,	O
a	O
diabetic	O
complication	O
,	O
impaired	O
glucose	B
tolerance	O
or	O
impaired	O
fasting	O
glucose	B
.	O

R1	O
is	O
formula	O
(	O
Ia	O
)	O
,	O
(	O
Ib	O
)	O
or	O
(	O
Ic	O
)	O
;	O
R2	O
is	O
alkvl	B
,	O
alkenyl	B
,	O
alkynyl	B
,	O
aryl	B
,	O
heteroaryl	B
,	O
cycloalkyl	B
or	O
heterocycloalkyl	B
.	O

any	O
of	O
which	O
can	O
be	O
optionally	O
substituted	O
with	O
R11	O
;	O
M1	O
is	O
-CH-	B
.	O

-C	B
(	I
halo	I
)	I
-	I
or	O
-N-	B
;	O
Y	O
is	O
-C	B
(	I
O	I
)	I
-	I
,	O
-S-	B
.	O
-S	B
(	I
O	I
)	I
-	I
,	O
-S	B
(	I
O	I
)	I
2-	I
,	O
-CH2-	B
or	O
-O-	B
,	O
such	O
that	O
Y	O
is	O
not	O
-O-	B
when	O
an	O
adjacent	O
atom	O
is	O
N.	B
Tricyclic	B
heterocycle	I
derivatives	O
as	O
histamine	B
h3	O
antagonists	O

Disclosed	O
is	O
a	O
polyglutamine	B
aggregation	O
inhibitor	O
including	O
a	O
chemical	O
compound	O
represented	O
by	O
any	O
of	O
the	O
following	O
general	O
formulae	O
(	O
1	O
)	O
-	O
(	O
13	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O

(	O
1	O
)	O
R3-	O
[	O
-X	O
-	O
B	O
(	O
ZR1	O
)	O
-Y	O
-	O
B	O
(	O
ZR2	O
)	O
-W-	O
]	O
n	O
-	O
R4	O
;	O
(	O
2	O
)	O
R3-	O
[	O
-X	O
-	O
B	O
(	O
ZR1	O
)	O
-Y-	O
]	O
n	O
-	O
R4	O
;	O
(	O
3	O
)	O
R3-	O
[	O
-B	O
(	O
ZR1	O
)	O
-Y	O
-	O
B	O
(	O
ZR2	O
)	O
-W-	O
]	O
n	O
-	O
R4	O
;	O
(	O
4	O
)	O
R3-	O
[	O
-X	O
-	O
B	O
(	O
ZR1	O
)	O
-	O
]	O
n	O
-	O
R4	O
;	O
(	O
5	O
)	O
R3-	O
[	O
-B	O
(	O
ZR2	O
)	O
-W-	O
]	O
n	O
-	O
R4	O
;	O
(	O
6	O
)	O
R3-X	O
-	O
B	O
(	O
ZR1	O
)	O
-T	O
[	O
B	O
(	O
ZR2	O
)	O
-W	O
-	O
R4	O
]	O
2	O
;	O
(	O
7	O
)	O
R3-B	O
(	O
OH	O
)	O
2	O
;	O
(	O
8)	O
R3-B	O
(	O
ZR1	O
)	O
-X	O
-	O
B	O
(	O
ZR2	O
)	O
-R4	O
;	O
(	O
9	O
)	O
R3-B	O
(	O
R1	O
)	O
-O	O
-	O
B	O
(	O
R2	O
)	O
-R4	O
;	O
(	O
10	O
)	O
R3-	O
[	O
-X	O
-	O
B	O
(	O
ZR1	O
)	O
-Y	O
-	O
B	O
(	O
ZR2	O
)	O
-	O
]	O
n	O
-	O
R4	O
;	O
(	O
11	O
)	O
R3-	O
[	O
-X	O
-	O
B	O
(	O
ZR1	O
)	O
-Y	O
-	O
B	O
(	O
ZR2	O
)	O
-W	O
-	O
Q-	O
]	O
n	O
-	O
R4	O
;	O
(	O
12	O
)	O
R3-	O
[	O
-P	O
-	O
X	O
-	O
B	O
(	O
ZR1	O
)	O
-Y	O
-	O
B	O
(	O
ZR2	O
)	O
-W-	O
]	O
n	O
-	O
R4	O
;	O
and	O
(	O
13	O
)	O
[	O
R3-X	O
-	O
B	O
(	O
ZR1	O
)	O
-Y	O
]	O
2B	O
(	O
ZR2	O
)	O
(	O
wherein	O
the	O
symbols	O
in	O
each	O
formula	O
carry	O
the	O
same	O
definitions	O
as	O
those	O
used	O
in	O
the	O
Specification	O
)	O
.	O

Polyglutamine	B
aggregation	O
inhibitor	O

The	O
invention	O
relates	O
to	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
wherein	O
W	O
,	O
D	O
,	O
E	O
,	O
G	O
,	O
J	O
,	O
L	O
,	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
and	O
Y	O
are	O
as	O
defined	O
herein	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
,	O
hydrates	O
,	O
or	O
solvates	O
thereof	O
,	O
for	O
use	O
-alone	O
or	O
in	O
combination	O
with	O
one	O
or	O
more	O
other	O
pharmaceutically	O
active	O
compounds-	O
in	O
therapy	O
,	O
for	O
treating	O
diseases	O
associated	O
with	O
deregulated	O
angiogenesis	O
,	O
such	O
as	O
cancer	O
and	O
skin	O
and	O
eye	O
diseases	O
.	O

Pyridine	B
derivatives	O
as	O
vegfr-2	O
receptor	O
and	O
protein	O
tyrosine	B
kinase	O
inhibitors	O

Hybrid	O
tripyrrole	B
-	I
octaarginine	I
compounds	O
.	O

Hybrids	O
formed	O
of	O
a	O
tripyrrole	B
group	O
linked	O
to	O
a	O
polyarginine	B
peptide	O
which	O
permit	O
efficient	O
cellular	O
internalisation	O
and	O
promotes	O
greater	O
affinity	O
for	O
DNA	O
.	O

The	O
method	O
of	O
obtainment	O
and	O
uses	O
thereof	O
.	O

Hybrid	O
tripyrrole	B
-	I
octaarginine	I
compounds	O
and	O
their	O
use	O
as	O
medicament	O
in	O
the	O
treatment	O
of	O
cancer	O
and	O
microbial	O
illnesses	O

The	O
present	O
invention	O
relates	O
to	O
methods	O
and	O
compounds	O
useful	O
for	O
increasing	O
neurogenesis	O
.	O

Methods	O
and	O
compounds	O
for	O
increasing	O
dopaminergic	O
differentiation	O
are	O
also	O
provided	O
.	O

Methods	O
for	O
treating	O
neurological	O
disorders	O
by	O
increasing	O
neurogenesis	O
are	O
also	O
provided	O
.	O

Methods	O
for	O
increasing	O
neurogenesis	O

Macrocyclic	B
derivative	O
compounds	O
that	O
inhibit	O
protein	O
kinase	O
enzymes	O
are	O
disclosed	O
along	O
with	O
pharmaceutical	O
compositions	O
comprising	O
these	O
compounds	O
and	O
methods	O
for	O
synthesizing	O
the	O
same	O
.	O

Such	O
compounds	O
have	O
utility	O
in	O
the	O
treatment	O
of	O
proliferative	O
diseases	O
resulting	O
from	O
unregulated	O
and/or	O
disturbed	O
kinase	O
activity	O
such	O
as	O
cancers	O
,	O
psoriasis	O
,	O
viral	O
and	O
bacterial	O
infections	O
,	O
inflammatory	O
and	O
autoimmune	O
diseases	O
.	O

Macrocyclics	O
pyrimidines	B
as	O
aurora	O
kinase	O
inhibitors	O

Antibacterial	O
and/or	O
anti	O
-	O
acne	O
formulation	O
containing	O
(	O
a	O
)	O
salicylic	B
acid	I
or	O
a	O
derivative	O
thereof	O
and	O
(	O
b	O
)	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
or	O
derivative	O
thereof	O
:	O
formula	O
(	O
I	O
)	O
wherein	O
each	O
of	O
R1	O
and	O
R2	O
is	O
independently	O
selected	O
from	O
methyl	B
and	O
ethyl	B
and	O
R3	O
is	O
hydrogen	B
.	O

The	O
formulation	O
is	O
particularly	O
active	O
against	O
propionibacteria	O
,	O
and	O
may	O
therefore	O
be	O
used	O
to	O
treat	O
acne	O
.	O

Antibacterial	O
and/or	O
anti	O
-	O
acne	O
formulations	O
containing	O
salicylic	B
acid	I
or	O
a	O
derivative	O
thereof	O

The	O
invention	O
relates	O
to	O
methods	O
of	O
treatment	O
of	O
hepatitis	O
C	O
,	O
dyslipidemia	O
,	O
insulin	O
resistance	O
,	O
and	O
inflammation	O
,	O
with	O
flavonoid-	B
sugar	B
complexes	O
.	O

Naringenin	B
complexes	O
and	O
methods	O
of	O
use	O
thereof	O

The	O
invention	O
is	O
based	O
on	O
the	O
finding	O
that	O
the	O
enzyme	O
AKR1C3	O
is	O
capable	O
of	O
exhibiting	O
nitroreductase	O
activity	O
and	O
activating	O
nitroaromatic	O
prodrugs	O
to	O
release	O
the	O
cytotoxic	O
effector	O
.	O

AKR1C3-activated	O
nitroaromatic	B
prodrugs	O
include	O
dinitrobenzamide	B
mustards	O
such	O
as	O
2-	B
(	I
(	I
2-bromoethyl	I
)	I
-2-	I
{	I
[	I
(	I
2-hydroxyethyl	I
)	I
amino	I
]	I
carbonyl	I
}	I
-4,6-dinitroanilino	I
)	I
ethyl	I
methanesulfonate	I
(	O
PR-104A	O
)	O
,	O
and	O
the	O
corresponding	O
pre	O
-	O
prodrug	O
2-	B
[	I
(	I
2-	I
(	I
bromoethyl	I
)	I
-2,4-dinitro-6-	I
[	I
[	I
[	I
2-	I
(	I
phosphonooxy	I
)	I
ethyl	I
]	I
amino	I
]	I
carbonyl	I
]	I
anilino	I
]	I
ethyl	I
methanesulfonate	I
(	O
PR-104	O
)	O
.	O

The	O
invention	O
provides	O
methods	O
and	O
procedures	O
to	O
determine	O
drug	O
sensitivity	O
in	O
patients	O
to	O
allow	O
the	O
identification	O
of	O
individualized	O
patient	O
profiles	O
which	O
will	O
aid	O
in	O
treating	O
diseases	O
and	O
disorders	O
,	O
such	O
as	O
cancer	O
.	O

The	O
invention	O
also	O
provides	O
methods	O
of	O
treatment	O
which	O
are	O
based	O
upon	O
such	O
biomarker	O
-	O
related	O
profiles	O
,	O
as	O
well	O
as	O
compounds	O
suitable	O
for	O
use	O
in	O
such	O
methods	O
and	O
compositions	O
comprising	O
"	O
such	O
compounds	O
.	O

Akr1c3	O
as	O
a	O
biomarker	O
,	O
methods	O
of	O
selecting	O
and	O
treating	O
patients	O
based	O
upon	O
an	O
akr1c3	O
profile	O
and	O
compounds	O
for	O
use	O
therein	O

Disclosed	O
are	O
compounds	O
and	O
compositions	O
of	O
the	O
formula	O
I	O
as	O
described	O
herein	O
which	O
are	O
inhibitors	O
of	O
MMP-13	O
.	O

Also	O
disclosed	O
are	O
methods	O
of	O
using	O
and	O
making	O
compounds	O
of	O
the	O
formula	O
I.	O
Fused	O
heteroaryl	B
diamide	I
compounds	O
useful	O
as	O
mmp-13	O
inhibitors	O

A	O
pyrimidine	B
derivative	O
or	O
a	O
pyridine	B
derivative	O
represented	O
by	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
of	O
the	O
pyrimidine	B
derivative	O
or	O
the	O
pyridine	B
derivative	O
,	O
which	O
can	O
inhibit	O
the	O
activity	O
of	O
PI3	O
K	O
to	O
control	O
many	O
biological	O
processes	O
including	O
growth	O
,	O
differentiation	O
,	O
survival	O
,	O
proliferation	O
,	O
migration	O
and	O
metabolism	O
of	O
cells	O
and	O
is	O
therefore	O
useful	O
for	O
the	O
prevention	O
/	O
treatment	O
of	O
diseases	O
including	O
inflammatory	O
diseases	O
,	O
arteriosclerosis	O
,	O
vascular	O
/	O
cardiovascular	O
diseases	O
,	O
cancer	O
/	O
tumors	O
,	O
immune	O
diseases	O
,	O
cell	O
proliferative	O
diseases	O
and	O
infectious	O
diseases	O
.	O

Pyrimidine	B
derivative	O
and	O
pyridine	B
derivative	O
both	O
having	O
pi3k	O
inhibitory	O
activity	O

The	O
present	O
invention	O
relates	O
to	O
the	O
treatment	O
of	O
attention	O
deficit	O
disorder	O
(	O
ADD	O
)	O
,	O
attention	O
deficit	O
hyperactivity	O
disorder	O
(	O
ADHD	O
)	O
,	O
to	O
the	O
treatment	O
of	O
cognitive	O
impairment	O
associated	O
with	O
ADD	O
or	O
ADHD	O
,	O
and	O
to	O
sabcomeline	B
,	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
and	O
compositions	O
comprising	O
sabcomeline	B
for	O
use	O
in	O
said	O
treatments	O
.	O

Use	O
of	O
sabcomeline	B
for	O
the	O
treatment	O
of	O
add	O
or	O
adhd	O

Low	O
levels	O
of	O
antibodies	O
reactive	O
with	O
oxidised	O
Cardiolipin	B
(	O
oxCL	O
)	O
in	O
mammals	O
are	O
related	O
to	O
an	O
increased	O
risk	O
of	O
developing	O
cardivacular	O
diseases	O
,	O
auto	O
-	O
immune	O
diseases	O
or	O
inflammatory	O
conditions	O
.	O

High	O
levels	O
can	O
have	O
a	O
protective	O
function	O
and	O
in	O
general	O
there	O
is	O
a	O
negative	O
association	O
between	O
manifestations	O
of	O
these	O
conditions	O
and	O
antibodies	O
against	O
oxCL	O
.	O

Thus	O
,	O
based	O
on	O
their	O
relations	O
methods	O
of	O
monitoring	O
,	O
determining	O
and	O
diagnosing	O
as	O
well	O
as	O
methods	O
of	O
immunisation	O
and	O
therapy	O
of	O
these	O
diseases	O
and	O
conditions	O
are	O
provided	O
.	O

Oxidized	O
cardiolipin	B
as	O
a	O
novel	O
pro	O
-	O
inflammatory	O
factor	O

The	O
invention	O
relates	O
to	O
chiral	O
compounds	O
with	O
monoterpene	B
skeleton	O
of	O
general	O
formula	O
(	O
I	O
)	O
-	O
where	O
in	O
the	O
formula	O
X	O
stands	O
for	O
O	B
or	O
H2	B
;	O
W	O
stands	O
for	O
O	B
,	O
S	B
,	O
N	B
-	I
R2	I
or	O
Ph	B
-	I
R3	I
;	O
Y	O
stands	O
for	O
O	B
or	O
N	B
-	I
R4	I
;	O
R1	O
stands	O
for	O
H	B
,	O
C1	B
-	I
4Alk	I
or	O
(	B
C2	I
)	I
1	I
-	I
4-Ph	I
;	O
R2	O
stands	O
for	O
C1	B
-	I
4Alk	I
or	O
Ph	B
-	I
R3	I
;	O
R3	O
stands	O
for	O
H	B
,	O
C1	B
-	I
4Alk	I
,	O
C1	B
-	I
4Alk	I
-	I
O	I
or	O
Hlg	O
;	O
R4	O
stands	O
for	O
H	B
or	O
Ph	B
;	O
and	O
one	O
of	O
the	O
signs	O
---	O
means	O
the	O
presence	O
of	O
a	O
double	O
bond	O
and	O
the	O
other	O
means	O
the	O
absense	O
of	O
a	O
double	O
bond	O
,	O
with	O
the	O
proviso	O
that	O
only	O
one	O
of	O
W	O
and	O
Y	O
may	O
simultaneously	O
stand	O
for	O
oxygen	B
-	O
as	O
well	O
as	O
to	O
their	O
prodrugs	O
and	O
salts	O
formed	O
with	O
pharmaceutically	O
acceptable	O
acids	O
.	O

Furthermore	O
,	O
the	O
invention	O
relates	O
to	O
cytostatic	O
pharmaceutical	O
compositions	O
comprising	O
one	O
or	O
more	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
and	O
usual	O
inert	O
pharmaceutical	O
carriers	O
and/or	O
auxiliary	O
agents	O
,	O
to	O
the	O
use	O
of	O
the	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
for	O
preparing	O
cytostatic	O
pharmaceutical	O
compositions	O
as	O
well	O
as	O
to	O
the	O
treatment	O
and/or	O
curing	O
of	O
cancerous	O
illnesses	O
.	O

1,3-heterocycles	B
condensed	O
with	O
monoterpene	B
skeleton	O
,	O
their	O
use	O
and	O
pharmaceutical	O
compositions	O
comprising	O
such	O
compounds	O

The	O
present	O
invention	O
provides	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
or	O
a	O
salt	O
form	O
thereof	O
,	O
wherein	O
Q1	O
,	O
Q2	O
,	O
Q3	O
,	O
and	O
Q4	O
are	O
as	O
defined	O
herein	O
.	O

The	O
compound	O
of	O
formula	O
(	O
I	O
)	O
has	O
ALK	O
and/or	O
JAK2	O
inhibitory	O
activity	O
,	O
and	O
may	O
be	O
used	O
to	O
treat	O
proliferative	O
disorders	O
.	O

Pyrrolotriazines	B
as	O
alk	O
and	O
jak2	O
inhibitors	O

The	O
present	O
invention	O
relates	O
to	O
a	O
new	O
process	O
for	O
the	O
preparation	O
of	O
rosuvastatin	B
[	O
7-	B
[	I
4-	I
(	I
4-Fluorophenyl	I
)	I
-6-isopropyl-2-	I
(	I
methanesulphonyl	I
-	I
methyl	I
-	I
amino	I
)	I
-pyrimidin-5-yl	I
]	I
-	I
(	I
3R,51S	I
)	I
-	I
dihydroxy	I
-	I
hept-6-enoic	I
acid	I
]	O
of	O
the	O
formula	O
(	O
I	O
)	O
salts	O
formed	O
with	O
bivalent	O
cations	O
,	O
preferably	O
with	O
calcium	B
or	I
zinc	I
ions	I
,	O
characterized	O
in	O
that	O
rosuvastatin	B
tert	I
.-	I
butylammonium	I
salt	O
is	O
reacted	O
with	O
the	O
appropriate	O
bivalent	O
cation	O
,	O
preferably	O
with	O
calcium	B
or	I
zinc	I
ions	I
in	O
a	O
mixture	O
of	O
a	O
water	O
immiscible	O
or	O
slightly	O
miscible	O
organic	O
solvent	O
and	O
water	O
and	O
the	O
formed	O
salt	O
is	O
isolated	O
.	O

Process	O
for	O
the	O
preparation	O
of	O
rosuvastatin	B
salts	O

The	O
invention	O
relates	O
to	O
the	O
prevention	O
and	O
treatment	O
of	O
metabolic	O
abnormalities	O
characterized	O
by	O
abnormal	O
glucose	O
metabolism	O
,	O
including	O
diabetes	O
mellitus	O
and	O
new	O
onset	O
diabetes	O
mellitus	O
through	O
the	O
use	O
of	O
fibroblast	O
activation	O
protein	O
(	O
FAP	O
)	O
selective	O
inhibitors	O
.	O

Novel	O
metabolic	O
disease	O
therapy	O

The	O
present	O
invention	O
provides	O
bumetanide	B
,	O
furosemide	B
,	O
piretanide	B
,	O
azosemide	B
,	O
and	O
torsemide	B
analogs	O
and	O
compositions	O
comprising	O
such	O
analogs	O
.	O

The	O
present	O
invention	O
also	O
provides	O
pharmaceutical	O
compositions	O
containing	O
these	O
bumetanide	B
,	O
furosemide	B
,	O
piretanide	B
,	O
azosemide	B
,	O
and	O
torsemide	B
analogs	O
and	O
methods	O
for	O
their	O
use	O
.	O

All	O
of	O
these	O
analogs	O
are	O
particularly	O
useful	O
for	O
the	O
treatment	O
and/or	O
prophylaxis	O
of	O
conditions	O
that	O
involve	O
the	O
Na+K+Cl-	O
co	O
-	O
transporter	O
or	O
GABAA	B
receptor	O
including	O
but	O
not	O
limited	O
to	O
addictive	O
disorders	O
,	O
Alzheimer	O
's	O
Disease	O
,	O
anxiety	O
disorders	O
,	O
ascites	O
,	O
autism	O
,	O
bipolar	O
disorder	O
,	O
cancer	O
,	O
depression	O
,	O
endothelial	O
corneal	O
dystrophy	O
,	O
edema	O
,	O
epilepsy	O
,	O
glaucoma	O
,	O
Huntington	O
's	O
Disease	O
,	O
insomnia	O
,	O
ischemia	O
,	O
migraine	O
,	O
migraine	O
with	O
aura	O
,	O
neuropathic	O
pain	O
,	O
nociceptive	O
neuralgia	O
,	O
nociceptive	O
pain	O
,	O
ocular	O
diseases	O
,	O
pain	O
,	O
Parkinson	O
's	O
disease	O
,	O
personality	O
disorders	O
,	O
postherpetic	O
neuralgia	O
,	O
psychosis	O
,	O
schizophrenia	O
,	O
seizure	O
disorders	O
,	O
tinnitus	O
,	O
and	O
withdrawal	O
syndromes	O
.	O

Bumetanide	B
,	O
furosemide	B
,	O
piretanide	B
,	O
azosemide	B
,	O
and	O
torsemide	B
analogs	O
,	O
compositions	O
and	O
methods	O
of	O
use	O

The	O
present	O
invention	O
relates	O
to	O
C-7	B
isoxazolyl	I
quinoline	I
/	O
naphthyridine	B
derivatives	O
useful	O
as	O
antimicrobial	O
compounds	O
,	O
pharmaceutical	O
compositions	O
comprising	O
said	O
derivatives	O
and	O
the	O
use	O
of	O
said	O
derivatives	O
and	O
pharmaceutical	O
compositions	O
as	O
antimicrobial	O
agents	O
against	O
pathogenic	O
microorganisms	O
,	O
particularly	O
against	O
resistant	O
microbes	O
.	O

C-7	B
isoxazolinyl	I
quinolone	I
/	O
naphthyridine	B
derivatives	O
useful	O
as	O
antibacterial	O
agents	O

Methods	O
are	O
disclosed	O
for	O
improving	O
treatment	O
of	O
various	O
medical	O
conditions	O
via	O
administration	O
of	O
D	B
-	I
cycloserine	I
to	O
facilitate	O
learning	O
.	O

Specifically	O
,	O
by	O
administering	O
D-	B
cycloserine	I
to	O
a	O
patient	O
at	O
a	O
time	O
that	O
is	O
both	O
subsequent	O
to	O
extinction	O
training	O
during	O
the	O
day	O
and	O
within	O
two	O
hours	O
prior	O
to	O
the	O
patient	O
's	O
initial	O
nightly	O
sleep	O
period	O
following	O
the	O
extinction	O
training	O
,	O
the	O
known	O
ability	O
of	O
D	B
-	I
cycloserine	I
to	O
facilitate	O
extinction	O
learning	O
can	O
be	O
enhanced	O
.	O

Method	O
for	O
facilitating	O
extinction	O
training	O
using	O
d	B
-	I
cycloserine	I

The	O
invention	O
relates	O
to	O
pharmaceutical	O
compositions	O
and	O
formulations	O
comprising	O
polymeric	B
myrcene	I
.	O

More	O
particularly	O
,	O
the	O
invention	O
relates	O
to	O
compositions	O
comprising	O
an	O
isolated	O
fraction	O
of	O
polymeric	B
myrcene	I
in	O
a	O
hydrophobic	O
carrier	O
and	O
formulations	O
which	O
maintain	O
the	O
biological	O
activity	O
of	O
the	O
active	O
polymer	O
.	O

Therapeutic	O
uses	O
of	O
mastic	O
gum	O
fractions	O

2-Indolyl	B
imidazo	I
[	I
4,5-d	I
]	I
phenanthroline	I
compounds	O
of	O
Formula	O
(	O
I	O
)	O
that	O
are	O
capable	O
of	O
inhibiting	O
angiogenesis	O
are	O
provided	O
Methods	O
of	O
inhibiting	O
angiogenesis	O
using	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
,	O
as	O
well	O
as	O
methods	O
and	O
uses	O
of	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
in	O
the	O
treatment	O
of	O
angiogenesis	O
-	O
associated	O
diseases	O
and	O
disorders	O
such	O
as	O
cancer	O
,	O
age-	O
related	O
macular	O
degeneration	O
(	O
AMD	O
)	O
,	O
diabetic	O
retinopathy	O
and	O
retinal	O
vein	O
occlusion	O
are	O
also	O
provided	O
.	O

2-indolyl	B
imidazo	I
[	I
4,5-d	I
]	I
phenanthroline	I
derivatives	O
and	O
their	O
use	O
to	O
inhibit	O
angiogenesis	O

This	O
invention	O
relates	O
to	O
novel	O
tetrazole	B
derivatives	O
of	O
formula	O
(	O
I	O
)	O
,	O
which	O
are	O
found	O
to	O
be	O
modulators	O
of	O
the	O
nicotinic	O
acetylcholine	B
receptors	O
.	O

Due	O
to	O
their	O
pharmacological	O
profile	O
the	O
compounds	O
of	O
the	O
invention	O
may	O
be	O
useful	O
for	O
the	O
treatment	O
of	O
diseases	O
or	O
disorders	O
as	O
diverse	O
as	O
those	O
related	O
to	O
the	O
cholinergic	O
system	O
of	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
,	O
the	O
peripheral	O
nervous	O
system	O
(	O
PNS	O
)	O
,	O
diseases	O
or	O
disorders	O
related	O
to	O
smooth	O
muscle	O
contraction	O
,	O
endocrine	O
diseases	O
or	O
disorders	O
,	O
diseases	O
or	O
disorders	O
related	O
to	O
neuro-	O
degeneration	O
,	O
diseases	O
or	O
disorders	O
related	O
to	O
inflammation	O
,	O
pain	O
,	O
and	O
withdrawal	O
symptoms	O
caused	O
by	O
the	O
termination	O
of	O
abuse	O
of	O
chemical	O
substances	O
.	O

2	B
,	I
5-disubstituted	I
tetrazole	I
derivatives	O
and	O
their	O
use	O
as	O
nicotinic	O
acetylcholine	B
receptor	O
modulators	O

The	O
invention	O
relates	O
to	O
the	O
use	O
of	O
kynurenic	B
acid	I
derivatives	O
of	O
general	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
R1	O
is	O
hydroxy	B
,	O
NHR2	B
,	O
NR2R2	B
or	O
C1	O
-	O
10	O
straight	O
or	O
branched	O
alkoxy	B
or	O
glyceryl	B
group	O
;	O
R2	O
is	O
hydrogen	B
atom	O
or	O
C1	O
-	O
10	O
straight	O
or	O
branched	O
alkyl	B
group	O
;	O
R3-R6	O
are	O
independently	O
of	O
each	O
other	O
hydrogen	B
atom	O
,	O
halogen	B
atom	O
,	O
C1	B
-	I
10	I
alkyl	I
,	O
C2	B
-	I
10	I
alkenyl	I
or	O
alkynyl	B
group	O
optionally	O
substituted	O
with	O
a	O
halogen	B
atom	O
,	O
and	O
a	O
pharmaceutically	O
acceptable	O
salt	O
,	O
ester	B
or	O
amide	B
thereof	O
in	O
manufacturing	O
of	O
a	O
drug	O
used	O
in	O
prevention	O
and	O
therapy	O
of	O
pancreas	O
disorders	O
characterized	O
by	O
edema	O
and/or	O
vacuolization	O
and/or	O
destruction	O
of	O
pancreatic	O
tissue	O
and/or	O
pancreas	O
necrosis	O
leading	O
to	O
release	O
of	O
pancreatic	O
	O
-	O
amylase	O
.	O

Prefereably	O
,	O
in	O
the	O
compound	O
represented	O
by	O
formula	O
(	O
I	O
)	O
R1	O
is	O
a	O
hydroxy	B
,	O
NH2	B
,	O
NH-	B
(	I
C1	I
-	I
5	I
straight	I
or	I
branched	I
alkyl	I
)	I
or	O
C1	O
-	O
5	O
straight	O
or	O
branched-	O
alkoxy	B
or	O
glyceryl	B
group	O
;	O
R2	O
is	O
a	O
hydrogen	B
atom	O
;	O
R3-R6	O
are	O
independently	O
of	O
each	O
other	O
a	O
hydrogen	B
atom	O
,	O
halogen	B
atom	O
or	O
CF3	B
group	O
.	O

In	O
the	O
most	O
preferred	O
embodiment	O
,	O
the	O
invention	O
concerns	O
the	O
use	O
of	O
kynurenic	B
acid	I
or	O
its	O
pharmaceutically	O
acceptable	O
salt	O
in	O
manufacturing	O
of	O
a	O
drug	O
used	O
in	O
prevention	O
and	O
therapy	O
of	O
pancreas	O
disorders	O
characterized	O
by	O
edema	O
and/or	O
vacuolization	O
and/or	O
destruction	O
of	O
pancreatic	O
tissue	O
and/or	O
pancreas	O
necrosis	O
leading	O
to	O
release	O
of	O
pancreatic	O
	O
-	O
amylase	O
.	O

A	O
novel	O
medical	O
use	O
of	O
kynurenic	B
acid	I
,	O
its	O
precursors	O
and	O
derivatives	O

Compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
X	O
and	O
n	O
are	O
as	O
defined	O
herein	O
,	O
are	O
useful	O
for	O
the	O
treatment	O
or	O
prophylaxis	O
of	O
conditions	O
such	O
as	O
Duchenne	O
muscular	O
dystrophy	O
,	O
Becker	O
muscular	O
dystrophy	O
,	O
and	O
cachexia	O
.	O

Benzoxazoles	B
for	O
the	O
treatment	O
of	O
duchenne	O
muscular	O
dystrophy	O

A	O
process	O
for	O
preparation	O
of	O
1-	B
[	I
[	I
[	I
3-	I
[	I
2-	I
(	I
dimethylamino	I
)	I
ethyl	I
]	I
-1H	I
-	I
indol-5-yl	I
]	I
methyl	I
]	I
sulfonyl	I
]	I
pyrrolidine	I
of	O
Formula	O
(	O
1	O
)	O
,	O
which	O
is	O
commonly	O
known	O
as	O
Almotriptan	B
,	O
and	O
its	O
pharmaceutically	O
acceptable	O
salts	O
is	O
provided	O
.	O

The	O
required	O
purity	O
of	O
almotriptan	B
malate	I
free	O
of	O
impurities	O
is	O
attained	O
in	O
three	O
different	O
ways	O
,	O
including	O
by	O
preparing	O
the	O
acid	O
addition	O
salts	O
of	O
amino	B
indole	I
compound	O
,	O
by	O
proceeding	O
through	O
the	O
almotriptan	B
succinate	I
and	O
by	O
specific	O
purification	O
of	O
almotriptan	B
malate	I
from	O
a	O
suitable	O
solvent	O
.	O

Process	O
for	O
the	O
preparation	O
of	O
1-	B
[	I
[	I
[	I
3-	I
[	I
2-	I
(	I
dimethylamino	I
)	I
ethyl	I
]	I
-1h	I
-	I
indol-5-yl	I
]	I
methyl	I
]	I
sulfonyl	I
]	I
pyrrolidine	I
and	O
its	O
pharmaceutically	O
acceptable	O
salts	O

As	O
a	O
tumor	O
-	O
specific	O
promoter	O
,	O
a	O
polynucleotide	O
is	O
used	O
which	O
comprises	O
the	O
nucleotide	O
sequence	O
depicted	O
in	O
SEQ	O
ID	O
NO:1	O
or	O
a	O
nucleotide	O
sequence	O
capable	O
of	O
hybridizing	O
to	O
a	O
nucleotide	O
sequence	O
complementary	O
to	O
the	O
nucleotide	O
sequence	O
depicted	O
in	O
SEQ	O
ID	O
NO:1	O
under	O
stringent	O
conditions	O
and	O
which	O
has	O
a	O
tumor	O
-	O
specific	O
promoter	O
activity	O
.	O

Tumor	O
-	O
specific	O
promoter	O
and	O
use	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
a	O
strontium	B
compound	O
alone	O
or	O
in	O
combination	O
with	O
vitamin	B
D	I
which	O
is	O
used	O
for	O
the	O
treatment	O
and/or	O
prophylaxis	O
of	O
diseases	O
and	O
conditions	O
associated	O
with	O
abnormal	O
bone	O
resorption	O
and/or	O
effective	O
as	O
a	O
supplement	O
.	O

Stable	O
pharmaceutical	O
compositions	O
with	O
high	O
bioavailability	O

Provided	O
is	O
a	O
new	O
external	O
preparation	O
of	O
a	O
tertiary	B
amine	I
compound	O
that	O
exhibits	O
a	O
CXCR4-antagonizing	O
action	O
,	O
said	O
preparation	O
being	O
a	O
nonaqueous	O
preparation	O
containing	O
a	O
tertiary	B
amine	I
compound	O
indicated	O
by	O
general	O
formula	O
(	O
1	O
)	O
,	O
in	O
solution	O
in	O
a	O
fatty	B
acid	I
ionic	O
liquid	O
.	O

(	O
1	O
)	O
(	O
In	O
general	O
formula	O
(	O
1	O
)	O
,	O
R1	O
through	O
R6	O
each	O
independently	O
represent	O
either	O
a	O
hydrogen	B
atom	O
or	O
a	O
C14	B
lower	I
alkyl	I
group	O
;	O
n	O
1	O
through	O
n	O
3	O
are	O
integers	O
from	O
1	O
to	O
4	O
,	O
inclusive	O
;	O
A1	O
and	O
A2	O
represent	O
substituted	O
or	O
unsubstituted	O
heteroaromatic	B
ring	O
groups	O
;	O
W	O
represents	O
a	O
substituted	O
or	O
unsubstituted	O
phenylene	B
group	O
;	O
X	O
represents	O
an	O
N-	B
(	I
carboxymethyl	I
)	I
methylene	I
group	O
;	O
and	O
D	O
represents	O
a	O
C15	B
lower	I
alkylene	I
group	O
substituted	O
with	O
a	O
secondary	O
amino	B
group	O
having	O
a	O
C14	B
lower	I
alkyl	I
group	O
.	O
)	O

Preparation	O
for	O
external	O
use	O

Disclosed	O
is	O
a	O
fused	O
pyrrolopyridine	B
derivative	O
which	O
is	O
useful	O
as	O
an	O
active	O
ingredient	O
for	O
a	O
pharmaceutical	O
composition	O
,	O
in	O
particular	O
a	O
pharmaceutical	O
composition	O
for	O
prevention	O
or	O
treatment	O
of	O
diseases	O
that	O
are	O
caused	O
by	O
undesirable	O
cytokine	O
signaling	O
or	O
diseases	O
that	O
are	O
caused	O
by	O
abnormal	O
cytokine	O
signaling	O
.	O

The	O
inventors	O
have	O
intensively	O
studied	O
on	O
compounds	O
having	O
JAK	O
inhibitory	O
activity	O
,	O
and	O
found	O
that	O
the	O
compound	O
of	O
the	O
present	O
invention	O
,	O
namely	O
a	O
fused	O
pyrrolopyridine	B
derivative	O
has	O
excellent	O
JAK	O
inhibitory	O
activity	O
and	O
is	O
thus	O
useful	O
as	O
an	O
agent	O
for	O
prevention	O
or	O
treatment	O
of	O
diseases	O
that	O
are	O
caused	O
by	O
undesirable	O
cytokine	O
signaling	O
or	O
diseases	O
that	O
are	O
caused	O
by	O
abnormal	O
cytokine	O
signaling	O
.	O

Fused	O
pyrrolopyridine	B
derivative	O

Described	O
herein	O
are	O
compositions	O
and	O
methods	O
for	O
treating	O
a	O
subject	O
suffering	O
from	O
a	O
non	O
-	O
localized	O
inflammatory	O
condition	O
(	O
or	O
any	O
symptoms	O
associated	O
with	O
such	O
inflammation	O
)	O
,	O
including	O
systemic	O
inflammation	O
,	O
and	O
inflammatory	O
conditions	O
affecting	O
the	O
large	O
portions	O
of	O
or	O
the	O
whole	O
body	O
,	O
or	O
sepsis	O
by	O
administering	O
to	O
the	O
subject	O
a	O
pharmaceutical	O
composition	O
comprising	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
compound	O
that	O
is	O
a	O
pan	O
-	O
HDAC	O
inhibitor	O
.	O

Also	O
described	O
herein	O
are	O
methods	O
for	O
decreasing	O
iNOS	O
and	O
cytokine	O
expression	O
by	O
administering	O
to	O
the	O
subject	O
a	O
pharmaceutical	O
composition	O
comprising	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
compound	O
that	O
is	O
a	O
pan	O
-	O
HDAC	O
inhibitor	O
.	O

Treatment	O
of	O
non	O
-	O
localized	O
inflammation	O
with	O
pan	O
-	O
hdac	O
inhibitors	O

Compounds	O
are	O
provided	O
according	O
to	O
formula	O
(	O
1	O
)	O
,	O
wherein	O
W	O
,	O
X	O
,	O
Z	O
,	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
and	O
ml	O
are	O
as	O
defined	O
herein	O
.	O

Provided	O
compounds	O
and	O
pharmaceutical	O
compositions	O
thereof	O
are	O
useful	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
a	O
variety	O
of	O
conditions	O
in	O
mammals	O
including	O
humans	O
,	O
including	O
by	O
way	O
of	O
non-	O
limiting	O
example	O
,	O
pain	O
,	O
inflammation	O
,	O
cognitive	O
disorders	O
,	O
anxiety	O
,	O
depression	O
,	O
and	O
others	O
.	O

Provided	O
compounds	O
and	O
pharmaceutical	O
compositions	O
thereof	O
are	O
also	O
useful	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
a	O
variety	O
of	O
conditions	O
in	O
mammals	O
including	O
humans	O
,	O
including	O
by	O
way	O
of	O
non-	O
limiting	O
example	O
immune	O
-	O
mediated	O
disorders	O
and	O
autoimmune	O
diseases	O
,	O
including	O
multiple	O
sclerosis	O
,	O
type-1	O
diabetes	O
mellitus	O
,	O
type-2	O
diabetes	O
mellitus	O
,	O
rheumatoid	O
arthritis	O
,	O
psoriasis	O
,	O
contact	O
dermatitis	O
,	O
obesity	O
,	O
systemic	O
lupus	O
erythematosus	O
,	O
graft	O
-	O
versus	O
host	O
disease	O
,	O
transplant	O
rejection	O
,	O
and	O
others	O
.	O

Sulfonamide	B
compounds	O
,	O
pharmaceutical	O
compositions	O
and	O
uses	O
thereof	O

Disclosed	O
is	O
a	O
sphingomyelin	B
-	O
containing	O
material	O
which	O
can	O
be	O
produced	O
in	O
a	O
large	O
quantity	O
at	O
low	O
cost	O
.	O

Also	O
disclosed	O
is	O
an	O
useful	O
use	O
application	O
of	O
a	O
sphingomyelin	B
-	O
containing	O
material	O
.	O

Specifically	O
disclosed	O
is	O
an	O
anti	O
-	O
hyperglycemic	O
and/or	O
anti	O
-	O
hyperlipidemic	O
agent	O
comprising	O
a	O
material	O
containing	O
a	O
sphingomyelin	B
derived	O
from	O
an	O
avain	O
skin	O
as	O
an	O
active	O
ingredient	O
.	O

Anti	O
-	O
hyperglycemic	O
and/or	O
anti	O
-	O
hyperlipidemic	O
agent	O
comprising	O
material	O
containing	O
avian	O
skin	O
-	O
derived	O
sphingomyelin	B
as	O
active	O
ingredient	O

The	O
invention	O
relates	O
to	O
imidazo	B
[	I
1,5-a	I
]	I
quinoxaline	I
derivatives	O
which	O
are	O
inhibitors	O
of	O
phosphodiesterase	O
10	O
(	O
PDE10	O
)	O
useful	O
in	O
treating	O
central	O
nervous	O
system	O
diseases	O
such	O
as	O
psychosis	O
and	O
also	O
in	O
treating	O
,	O
for	O
example	O
,	O
obesity	O
,	O
type	O
2	O
diabetes	O
,	O
metabolic	O
syndrome	O
,	O
glucose	B
intolerance	O
,	O
and	O
pain	O
.	O

SUBSTITUTED	B
IMIDAZO	I
[	I
1,5-a	I
]	I
QUINOXALINES	I
AS	O
INHIBITORS	O
OF	O
PHOSPHODIESTERASE	O
10	O

The	O
invention	O
provides	O
a	O
4-methylbenzenesulphonate	B
salt	O
of	O
the	O
muscarinic	O
antagonist	O
(	B
R	I
)	I
-	I
1-	I
(	I
4-fluorophenethyl	I
)	I
-3-	I
(	I
(	I
S	I
)	I
-2-phenyl-2-	I
(	I
piperidin-1	I
-yl	I
)	I
propanoyloxy	I
)	I
-1-	I
azoniabicyclo	I
[	I
2.2.2	I
]	I
octane	I
and	O
its	O
use	O
in	O
therapy	O
,	O
as	O
well	O
as	O
a	O
process	O
for	O
preparing	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
salt	O
and	O
its	O
use	O
in	O
therapy	O
.	O

A	O
novel	O
4-methylbenzenesulphonate	B
salt	O
and	O
a	O
process	O
for	O
preparing	O
a	O
pharmaceutical	O
composition	O
comprising	O
the	O
salt	O

Liquiritigenin	B
derivatives	O
,	O
preparation	O
methods	O
and	O
uses	O
thereof	O
are	O
disclosed	O
.	O

More	O
specifically	O
,	O
the	O
compounds	O
of	O
formula	O
I	O
,	O
isomers	O
,	O
racemates	O
,	O
enantiomers	O
,	O
diastereomers	O
,	O
enantiomer	O
enrichments	O
,	O
solvates	O
,	O
prodrugs	O
,	O
and	O
esters	O
thereof	O
are	O
disclosed	O
,	O
in	O
which	O
n	O
is	O
0	O
or	O
1	O
,	O
R1	O
is	O
C3	B
-	I
8	I
cycloalkyl	I
and	O
R2	O
is	O
H.	B
The	O
preparation	O
methods	O
for	O
the	O
compounds	O
of	O
formula	O
I	O
,	O

the	O
pharmaceutical	O
compositions	O
comprising	O
the	O
compounds	O
of	O
formula	O
I	O
,	O
and	O
the	O
uses	O
of	O
the	O
compounds	O
of	O
formula	O
I	O
in	O
the	O
manufacture	O
of	O
medicaments	O
for	O
treating	O
and/or	O
preventing	O
cerebral	O
ischemic	O
diseases	O
,	O
neurodegenerative	O
diseases	O
and	O
inflammatory	O
diseases	O
are	O
also	O
disclosed	O
.	O

Liquiritigenin	B
derivatives	O
,	O
preparation	O
methods	O
and	O
uses	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
conjugates	O
of	O
anticancer	O
chemotherapeutic	O
agent	O
-	O
chlorine	B
derivatives	O
,	O
photosensitizer	O
containing	O
the	O
same	O
and	O
composition	O
for	O
treating	O
cancer	O
containing	O
the	O
same	O
.	O

The	O
conjugates	O
,	O
photosensitizer	O
and	O
composition	O
suppress	O
cancer	O
cell	O
proliferation	O
and	O
enables	O
photodynamic	O
therapy	O
at	O
the	O
same	O
time	O
by	O
conjugating	O
chlorine	B
derivatives	O
with	O
photodynamic	O
activity	O
and	O
an	O
anticancer	O
chemotherapeutic	O
agent	O
with	O
activity	O
of	O
suppressing	O
cell	O
proliferation	O
,	O
as	O
well	O
as	O
being	O
useful	O
in	O
cancer	O
therapy	O
by	O
reducing	O
the	O
toxicity	O
of	O
anticancer	O
chemotherapeutic	O
agent	O
and	O
avoiding	O
chemotherapeutic	O
agent	O
-	O
resistance	O
.	O

Conjugates	O
of	O
anticancer	O
chemotherapeutic	O
agent	O
-	O
chlorine	B
derivatives	O
,	O
photosensitizer	O
containing	O
same	O
and	O
composition	O
for	O
treating	O
cancer	O
containing	O
same	O

A	O
decapeptide	O
derivative	O
of	O
formula	O
(	O
I	O
)	O
possessing	O
hydantoin	O
structure	O
,	O
a	O
preparation	O
method	O
thereof	O
,	O
a	O
pharmaceutical	O
composition	O
containing	O
said	O
decapeptide	O
derivative	O
and	O
applications	O
thereof	O
in	O
preparing	O
medications	O
are	O
provided	O
.	O

The	O
decapeptide	O
derivative	O
is	O
a	O
luteinising	O
hormone	O
releasing	O
hormone	O
(	O
LHRH	O
)	O
antagonist	O
,	O
having	O
LHRH	O
receptor	O
antagonist	O
activity	O
and	O
inhibiting	O
pituitary	O
gonadotropin	O
secretion	O
and	O
steroid	O
hormone	O
secretion	O
of	O
sexual	O
glands	O
.	O

Formula	O
(	O
I	O
)	O
,	O
R	O
-	O
Xaa3-Ser	O
-	O
Xaa5-	O
Xaa6-	O
Xaa7-	O
Xaa8-Pro	O
-	O
D	O
-	O
Ala	O
-	O
B	O
Luteinising	O
hormone	O
releasing	O
hormone	O
antagonist	O
with	O
hydantoin	O
structure	O

Disclosed	O
are	O
creatine	O
	B
-	I
alaninate	I
,	O
compositions	O
and	O
formulations	O
containing	O
same	O
,	O
and	O
methods	O
of	O
use	O
therefor	O
.	O

CREATINE	O
	B
-	I
ALANINATE	I
:	O
A	O
NOVEL	O
SALT	O
FOR	O
INCREASING	O
ATHLETIC	O
PERFORMANCE	O

Disclosed	O
is	O
a	O
compound	O
having	O
an	O
activity	O
of	O
modulating	O
a	O
histamine	B
-	O
H4	O
receptor	O
.	O

Specifically	O
disclosed	O
is	O
a	O
compound	O
represented	O
by	O
formula	O
(	O
I	O
)	O
[	O
wherein	O
Ra	O
and	O
Rb	O
independently	O
represent	O
a	O
hydrogen	B
atom	O
,	O
a	O
substituted	O
or	O
unsubstituted	O
alkyl	B
group	O
,	O
or	O
the	O
like	O
;	O
X	O
represents	O
-O-	B
or	O
-S	B
(	I
O	I
)	I
p-	I
;	O
p	O
represents	O
an	O
integer	O
of	O
0	O
to	O
2	O
;	O
Y	O
represents	O
=	B
O	I
or	O
=	B
S	I
;	O
R1	O
represents	O
a	O
halogen	B
atom	O
,	O
a	O
substituted	O
or	O
unsubstituted	O
alkyl	B
group	O
,	O
or	O
the	O
like	O
;	O
n	O
represents	O
an	O
integer	O
of	O
0	O
to	O
4	O
;	O
and	O
R2	O
represents	O
a	O
hydrogen	B
atom	O
,	O
a	O
substituted	O
or	O
unsubstituted	O
alkyl	B
group	O
,	O
or	O
the	O
like	O
]	O
,	O
a	O
pharmaceutically	O
acceptable	O
salt	O
of	O
the	O
compound	O
,	O
or	O
a	O
solvate	O
of	O
the	O
compound	O
or	O
the	O
pharmaceutically	O
acceptable	O
salt	O
.	O

Aromatic	B
fused	O
heterocyclic	B
derivative	O
and	O
pharmaceutical	O
composition	O
containing	O
same	O

The	O
invention	O
features	O
compositions	O
comprising	O
microRNAs	O
that	O
are	O
capable	O
of	O
repressing	O
vIL6	O
or	O
hIL6	O
,	O
and	O
related	O
methods	O
of	O
using	O
the	O
microRNAs	O
for	O
treating	O
Kaposi	O
's	O
sarcoma-	O
associated	O
herpes	O
virus	O
(	O
KSHV	O
)	O
infections	O
or	O
diseases	O
caused	O
by	O
KSHV	O
.	O

Inhibitors	O
of	O
kshv	O
vil6	O
and	O
human	O
il6	O

The	O
present	O
invention	O
relates	O
to	O
therapeutic	O
uses	O
of	O
pharmaceutical	O
compositions	O
or	O
combinations	O
of	O
a	O
DPP-4	O
inhibitor	O
with	O
metformin	B
.	O

Pharmaceutical	O
compositions	O
comprising	O
bi-1356	O
and	O
metformin	B

Provided	O
are	O
methods	O
for	O
treating	O
a	O
hematological	O
malignancy	O
comprising	O
administering	O
an	O
effective	O
amount	O
of	O
flubendazole	B
alone	O
or	O
in	O
combination	O
with	O
a	O
vinca	B
alkaloid	I
.	O

Also	O
provided	O
are	O
compositions	O
and	O
kits	O
comprising	O
an	O
effective	O
amount	O
of	O
flubendazole	B
and/or	O
a	O
vinca	B
alkaloid	I
for	O
use	O
in	O
the	O
methods	O
of	O
the	O
disclosure	O
.	O

Use	O
of	O
flubendazole	B
and	O
vinca	B
alkaloids	I
for	O
treatment	O
of	O
hematological	O
diseases	O

A	O
process	O
for	O
preparation	O
of	O
propargylated	O
aminoindans	B
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
comprises	O
:	O
a	O
)	O
reacting	O
an	O
indanone	B
derivative	O
or	O
a	O
salt	O
thereof	O
with	O
propargyl	B
amine	I
or	O
a	O
salt	O
thereof	O
in	O
the	O
presence	O
of	O
a	O
Lewis	B
acid	I
;	O
b	O
)	O
subjecting	O
the	O
resultant	O
reaction	O
mixture	O
to	O
reduction	O
.	O

Process	O
for	O
preparation	O
of	O
propargylated	O
aminoindans	B
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O

The	O
invention	O
provides	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
wherein	O
:	O
R1	O
is	O
C1	B
-	I
3alkyl	I
or	O
C1fluoroalkyl	B
-	I
CH2	I
;	O
R2	O
is	O
hydrogen	B
,	O
C1	B
-	I
4alkyl	I
,	O
C1fluoroalkyl	B
-	I
CH2-	I
,	O
C3	B
-	I
6cycloalkyl	I
,	O
C3	B
-	I
6cycloalkyl	I
-	I
methyl-	I
,	O
optionally	O
substituted	O
benzyl	B
,	O
or	O
optionally	O
substituted	O
heteroaryl-	B
(	I
CH2	I
)	I
n-	I
,	O
wherein	O
n	O
is	O
0	O
or	O
1	O
,	O
wherein	O
in	O
R2	O
the	O
benzyl	B
is	O
optionally	O
substituted	O
on	O
the	O
ring	O
with	O
one	O
or	O
two	O
substituents	O
independently	O
being	O
methyl	B
,	O
methoxy	B
,	O
fluorine	B
or	O
chlorine	B
,	O
and	O
wherein	O
in	O
R2	O
the	O
heteroaryl-	B
(	I
CH2	I
)	I
n-	I
optionally	O
substituted	O
on	O
the	O
heteroaryl	B
ring	O
with	O
one	O
or	O
two	O
substituents	O
independently	O
being	O
C1	B
-	I
3alkyl	I
,	O
CF3	B
,	O
methoxy	B
,	O
a	O
halogen	B
atom	O
,	O
or	O
cyano	B
;	O
and	O
wherein	O
:	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
R6	O
and	O
R7	O
independently	O
are	O
hydrogen	B
,	O
a	O
halogen	B
atom	O
,	O
C1	B
-	I
4alkyl	I
,	O
trifluoromethyl	B
,	O
or	O
cyano	B
,	O
such	O
that	O
one	O
or	O
both	O
of	O
R3	O
and	O
R7	O
is	O
or	O
are	O
a	O
group	O
other	O
than	O
hydrogen	B
.	O

Thiadiazolidinedioxide	B
p2x7	O
receptor	O
antagonists	O

The	O
present	O
invention	O
provides	O
anti	O
-	O
inflammatory	O
extracts	O
derived	O
from	O
plants	O
of	O
the	O
Dodonaeoideae	O
subfamily	O
.	O

The	O
present	O
invention	O
also	O
provides	O
a	O
method	O
for	O
preparing	O
an	O
anti	O
-	O
inflammatory	O
extracts	O
.	O

Other	O
aspects	O
of	O
the	O
present	O
invention	O
also	O
relate	O
to	O
pharmaceutical	O
compositions	O
comprising	O
anti	O
-	O
inflammatory	O
extracts	O
and	O
methods	O
of	O
treating	O
or	O
preventing	O
inflammation	O
in	O
a	O
subject	O
.	O

Anti	O
-	O
inflammatory	O
extract	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
derivatives	O
of	O
the	O
general	O
formula	O
(	O
I	O
)	O
,	O
their	O
tautomeric	O
forms	O
,	O
their	O
stereoisomers	O
,	O
their	O
pharmaceutically	O
acceptable	O
salts	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
,	O
methods	O
for	O
their	O
preparation	O
,	O
use	O
of	O
these	O
compounds	O
in	O
medicine	O
and	O
the	O
intermediates	O
involved	O
in	O
their	O
preparation	O
.	O

Novel	O
antithrombotic	O
agents	O

The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
wherein	O
R1,R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
and	O
R6	O
,	O
X	O
and	O
n	O
are	O
as	O
defined	O
herein	O
.	O

Preferred	O
compounds	O
are	O
inositol	B
phosphate	I
derivatives	O
wherein	O
R1	O
is	O
a	O
substituted	O
or	O
unsubstituted	O
phenyl	B
and	O
at	O
least	O
one	O
of	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
and	O
R6	O
is	O
PO3	O
2-	O
Alternative	O
compounds	O
are	O
inositol	B
phosphate	I
derivatives	O
of	O
the	O
formula	O
(	O
I	O
)	O
wherein	O
R1	O
is	O
a	O
fiuorophore	O
moiety	O
The	O
compounds	O
are	O
useful	O
alone	O
or	O
in	O
combination	O
with	O
known	O
therapeutic	O
agents	O
for	O
the	O
treatment	O
of	O
diseases	O
,	O
especially	O
cancer	O
.	O

Novel	O
inositol	B
phosphate	I
derivatives	O

Methods	O
and	O
kits	O
for	O
treating	O
or	O
preventing	O
psoriasis	O
or	O
a	O
symptom	O
associated	O
with	O
psoriasis	O
in	O
a	O
subject	O
are	O
described	O
.	O

The	O
methods	O
involve	O
topical	O
applications	O
to	O
the	O
subject	O
a	O
therapeutically	O
effective	O
amount	O
of	O
an	O
2	O
adrenergic	O
receptor	O
agonist	O
,	O
such	O
as	O
brimonidine	O
.	O

Use	O
of	O
alpha	O
2	O
adrenergic	O
receptor	O
agonists	O
for	O
treating	O
or	O
preventing	O
psoriasis	O

The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
cromoglicic	B
acid	I
and/or	O
nedocromil	B
salts	O
in	O
pharmaceutically	O
effective	O
amounts	O
in	O
a	O
pharmaceutical	O
composition	O
containing	O
salmeterol	B
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
as	O
a	O
2-agonisti	O
combined	O
with	O
fluticasone	B
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
as	O
a	O
corticosteroid	B
for	O
the	O
treatment	O
of	O
the	O
respiratory	O
diseases	O
.	O

Compositions	O
containing	O
salmeterol	B
,	O
fluticasone	B
and	O
cromoglicic	B
acid	I

Compounds	O
which	O
effectively	O
remove	O
tumor	O
or	O
cancer	O
cell	O
and	O
their	O
use	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
tumor	O
or	O
cancer	O
by	O
making	O
immune	O
system	O
find	O
tumor	O
or	O
cancer	O
cell	O
are	O
provided	O
.	O

In	O
detail	O
,	O
by	O
immune	O
identifier	O
of	O
tumor	O
or	O
cancer	O
cell	O
the	O
immune	O
system	O
of	O
organism	O
can	O
find	O
and	O
remove	O
them	O
in	O
time	O
.	O

The	O
substances	O
used	O
for	O
immune	O
identifier	O
are	O
organic	O
molecules	O
(	O
including	O
organometallic	O
compounds	O
)	O
which	O
are	O
adhered	O
to	O
on	O
the	O
surface	O
of	O
the	O
cell	O
.	O

These	O
organic	O
molecules	O
are	O
linked	O
with	O
sugar	B
molecule	O
.	O

Compounds	O
which	O
effecttively	O
remove	O
tumor	O
or	O
cancer	O
cell	O

The	O
present	O
invention	O
relates	O
to	O
a	O
composition	O
containing	O
DHA	B
ethyl	I
esters	I
with	O
over	O
80	O
%	O
by	O
weight	O
purity	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
age	O
related	O
macular	O
degeneration	O
,	O
that	O
uses	O
peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
gamma	O
(	O
PPAR	O
)	O
as	O
target	O
.	O

Docosahexaenoic	B
acid	I
ethyl	I
esters	I
and/or	O
its	O
derivatives	O
for	O
prevention	O
and/or	O
treatment	O
of	O
age	O
-	O
related	O
macular	O
degeneration	O

The	O
present	O
invention	O
discloses	O
a	O
controlled	O
(	O
sustained	O
)	O
release	O
preparation	O
and	O
preparation	O
method	O
as	O
well	O
as	O
the	O
use	O
thereof	O
.	O

Said	O
preparation	O
contains	O
quetiapine	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
,	O
5	O
-	O
50	O
%	O
of	O
polyoxyethylene	B
in	O
amount	O
of	O
total	O
weight	O
of	O
said	O
controlled	O
(	O
sustained	O
)	O
release	O
preparation	O
,	O
and	O
remaining	O
amount	O
of	O
pharmaceutically	O
acceptable	O
excipients	O
.	O

Controlled	O
(	O
sustained	O
)	O
release	O
preparation	O
containing	O
quetiapine	O
and	O
preparation	O
method	O
and	O
use	O
thereof	O

The	O
topical	O
ophthalmic	O
use	O
of	O
5,6,7-trihydroxyheptanoic	B
acid	I
and	O
analogs	O
for	O
the	O
acceleration	O
of	O
corneal	O
wound	O
healing	O
in	O
humans	O
,	O
is	O
disclosed	O
.	O

Method	O
of	O
accelerating	O
corneal	O
wound	O
healing	O

The	O
compositions	O
and	O
methods	O
disclosed	O
herein	O
are	O
of	O
use	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
weight	O
gain	O
and	O
obesity	O
.	O

In	O
particular	O
,	O
the	O
compositions	O
and	O
methods	O
include	O
treatment	O
of	O
weight	O
gain	O
and	O
obesity	O
with	O
berberine	B
and/or	O
berberine	B
analogs	O
alone	O
or	O
in	O
combination	O
thereof	O
to	O
cause	O
a	O
reduction	O
in	O
an	O
individual	O
's	O
weight	O
or	O
prevent	O
weight	O
gain	O
or	O
obesity	O
.	O

In	O
certain	O
embodiments	O
,	O
the	O
weight	O
gain	O
and	O
obesity	O
are	O
associated	O
with	O
administration	O
of	O
anti	O
-	O
psychotic	O
drugs	O
.	O

In	O
an	O
alternative	O
embodiment	O
,	O
the	O
compositions	O
and	O
methods	O
provide	O
berberine	O
or	O
berberine	B
analogs	O
alone	O
or	O
for	O
coadministration	O
with	O
an	O
anti	O
-	O
psychotic	O
agent	O
.	O

In	O
an	O
additional	O
embodiment	O
,	O
the	O
compositions	O
and	O
methods	O
further	O
include	O
a	O
natural	O
product	O
.	O

The	O
usefulness	O
of	O
the	O
present	O
invention	O
is	O
that	O
berberine	B
and	O
berberine	B
analogs	O
do	O
not	O
have	O
synergistic	O
effects	O
with	O
other	O
drugs	O
and	O
administration	O
results	O
in	O
few	O
side	O
effects	O
.	O

Such	O
characteristics	O
of	O
berberine	B
or	O
berberine	B
analogs	O
are	O
a	O
great	O
improvement	O
able	O
to	O
support	O
the	O
widespread	O
use	O
of	O
the	O
compositions	O
and	O
methods	O
of	O
the	O
present	O
invention	O
as	O
therapeutics	O
for	O
the	O
treatment	O
and	O
prevention	O
of	O
weight	O
gain	O
and	O
obesity	O
.	O

Pharmaceutical	O
compositions	O
containing	O
berberine	B
for	O
treatment	O
or	O
prevention	O
of	O
weight	O
gain	O
and	O
obesity	O
associated	O
with	O
anti	O
-	O
psychotic	O
drugs	O

The	O
present	O
invention	O
relates	O
to	O
new	O
macrolide	B
inhibitors	O
of	O
mTOR	O
,	O
pharmaceutical	O
compositions	O
thereof	O
,	O
and	O
methods	O
of	O
use	O
thereof	O
(	O
Formula	O
I	O
)	O
.	O

Macrolide	B
inhibitors	O
of	O
mtor	O

Treatment	O
regimens	O
comprising	O
co	O
-	O
treatment	O
of	O
cancer	O
with	O
perifosine	B
and	O
capecitabine	B
are	O
disclosed	O
herein	O
,	O
as	O
well	O
as	O
pharmaceutical	O
compositions	O
and	O
unit	O
dosage	O
forms	O
thereof	O
formulated	O
to	O
be	O
suitable	O
for	O
use	O
in	O
said	O
treatment	O
regimens	O
.	O

Perifosine	B
and	O
capecitabine	B
as	O
a	O
combined	O
treatment	O
for	O
cancer	O

Substituted	O
bicyclic	O
heteroaryls	B
and	O
compositions	O
containing	O
them	O
,	O
for	O
the	O
treatment	O
of	O
general	O
inflammation	O
,	O
arthritis	O
,	O
rheumatic	O
diseases	O
,	O
osteoarthritis	O
,	O
inflammatory	O
bowel	O
disorders	O
,	O
inflammatory	O
eye	O
disorders	O
,	O
inflammatory	O
or	O
unstable	O
bladder	O
disorders	O
,	O
psoriasis	O
,	O
skin	O
complaints	O
with	O
inflammatory	O
components	O
,	O
chronic	O
inflammatory	O
conditions	O
,	O
including	O
but	O
not	O
restricted	O
to	O
autoimmune	O
diseases	O
such	O
as	O
systemic	O
lupus	O
erythematosis	O
(	O
SLE	O
)	O
,	O
myestenia	O
gravis	O
,	O
rheumatoid	O
arthritis	O
,	O
acute	O
disseminated	O
encephalomyelitis	O
,	O
idiopathic	O
thrombocytopenic	O
purpura	O
,	O
multiples	O
sclerosis	O
,	O
Sjoegren	O
's	O
syndrome	O
and	O
autoimmune	O
hemolytic	O
anemia	O
,	O
allergic	O
conditions	O
including	O
all	O
forms	O
of	O
hypersensitivity	O
,	O
The	O
present	O
invention	O
also	O
enables	O
methods	O
for	O
treating	O
cancers	O
that	O
are	O
mediated	O
,	O
dependent	O
on	O
or	O
associated	O
with	O
p110	O
activity	O
,	O
including	O
but	O
not	O
restricted	O
to	O
leukemias	O
,	O
such	O
as	O
Acute	O
Myeloid	O
leukaemia	O
(	O
AML	O
)	O
Myelo	O
-	O
dysplastic	O
syndrome	O
(	O
MDS	O
)	O
myelo	O
-	O
proliferative	O
diseases	O
(	O
MPD	O
)	O
Chronic	O
Myeloid	O
Leukemia	O
(	O
CML	O
)	O
T	O
-	O
cell	O
Acute	O
Lymphoblastic	O
leukaemia	O
(	O
T	O
-	O
ALL	O
)	O
B	O
-	O
cell	O
Acute	O
Lymphoblastic	O
leukaemia	O
(	O
B	O
-	O
ALL	O
)	O
Non	O
Hodgkins	O
Lymphoma	O
(	O
NHL	O
)	O
B	O
-	O
cell	O
lymphoma	O
and	O
solid	O
tumors	O
,	O
such	O
as	O
breast	O
cancer	O
.	O

Heterocyclic	B
compounds	O
and	O
their	O
use	O
as	O
pi3k	O
inhibitors	O

The	O
present	O
invention	O
describes	O
a	O
washing	O
machine	O
(	O
1	O
)	O
comprising	O
an	O
external	O
chassis	O
(	O
11	O
)	O
,	O
on	O
the	O
front	O
panel	O
(	O
12	O
)	O
of	O
which	O
are	O
accessible	O
at	O
least	O
one	O
aperture	O
(	O
13	O
)	O
,	O
equipped	O
with	O
a	O
door	O
(	O
14	O
)	O
,	O
for	O
the	O
loading	O
and/or	O
unloading	O
of	O
garments	O
into	O
or	O
from	O
the	O
rotary	O
drum	O
inside	O
said	O
chassis	O
(	O
11	O
)	O
,	O
a	O
soap	O
dispenser	O
(	O
2	O
)	O
of	O
washing	O
agents	O
assembled	O
on	O
the	O
slidable	O
drawer	O
support	O
structure	O
(	O
21	O
)	O
able	O
to	O
additionally	O
contain	O
,	O
adjacent	O
to	O
compartments	O
(	O
22	O
;	O
221	O
,	O
222	O
,	O
223	O
,	O
224	O
)	O
,	O
one	O
or	O
more	O
receptacles	O
(	O
23	O
)	O
,	O
able	O
to	O
contain	O
and	O
house	O
various	O
types	O
of	O
useful	O
objects	O
and	O
accessories	O
,	O
and	O
a	O
control	O
panel	O
(	O
26	O
;	O
261	O
,	O
262	O
)	O
.	O

Fully	O
openable	O
multifunction	O
drawer	O
for	O
household	O
appliances	O

This	O
invention	O
relates	O
to	O
piperidine	B
derivatives	O
,	O
to	O
processes	O
for	O
their	O
preparation	O
,	O
to	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
to	O
their	O
use	O
in	O
medicine	O
.	O

Microsomal	O
prostaglandin	B
e	I
syntase-1	O
inhibitors	O

Provided	O
are	O
compounds	O
shown	O
by	O
formula	O
I	O
,	O
optical	O
isomers	O
,	O
racemes	O
,	O
diastereoisomers	O
,	O
pharmaceutically	O
acceptable	O
salts	O
or	O
solvates	O
thereof	O
,	O
wherein	O
each	O
substituent	O
has	O
the	O
meaning	O
as	O
defined	O
in	O
the	O
specification	O
.	O

Also	O
provided	O
are	O
their	O
preparation	O
methods	O
,	O
pharmaceutical	O
compositions	O
containing	O
them	O
and	O
uses	O
of	O
said	O
compounds	O
for	O
preparation	O
of	O
drugs	O
useful	O
for	O
the	O
treatment	O
and/or	O
prophylaxis	O
of	O
diseases	O
or	O
disorders	O
caused	O
by	O
the	O
infection	O
of	O
mycobacterium	O
tuberculosis	O
.	O

Aromatic	B
butan-2-ol	I
compounds	O
,	O
preparation	O
methods	O
and	O
uses	O
thereof	O

Therapeutic	O
compounds	O
are	O
disclosed	O
having	O
the	O
general	O
formula	O
(	O
I	O
)	O
that	O
are	O
useful	O
for	O
the	O
treatment	O
of	O
metabolic	O
disorders	O
,	O
including	O
type	O
II	O
diabetes	O
.	O

The	O
compounds	O
have	O
activity	O
as	O
agonists	O
of	O
GPR119	O
.	O

Compounds	O
having	O
the	O
stereochemistry	O
of	O
formula	O
(	O
la	O
)	O
may	O
also	O
demonstrate	O
DPP	O
-	O
IV	O
inhibitory	O
activity	O
.	O

Cycloamino	B
derivatives	O
as	O
gpr119	O
agonists	O

The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
,	O
methods	O
for	O
preparing	O
these	O
compounds	O
,	O
compositions	O
,	O
intermediates	O
and	O
derivatives	O
thereof	O
and	O
for	O
treating	O
a	O
condition	O
including	O
but	O
not	O
limited	O
to	O
ankylosing	O
spondylitis	O
,	O
artherosclerosis	O
,	O
arthritis	O
(	O
such	O
as	O
rheumatoid	O
arthritis	O
,	O
infectious	O
arthritis	O
,	O
childhood	O
arthritis	O
,	O
psoriatic	O
arthritis	O
,	O
reactive	O
arthritis	O
)	O
,	O
bone	O
-	O
related	O
diseases	O
(	O
including	O
those	O
related	O
to	O
bone	O
formation	O
)	O
,	O
breast	O
cancer	O
(	O
including	O
those	O
unresponsive	O
to	O
anti	O
-	O
estrogen	O
therapy	O
)	O
,	O
cardiovascular	O
disorders	O
,	O
cartilage	O
-	O
related	O
disease	O
(	O
such	O
as	O
cartilage	O
injury	O
/	O
loss	O
,	O
cartilage	O
degeneration	O
,	O
and	O
those	O
related	O
to	O
cartilage	O
formation	O
)	O
,	O
chondrodysplasia	O
,	O
chondrosarcoma	O
,	O
chronic	O
back	O
injury	O
,	O
chronic	O
bronchitis	O
,	O
chronic	O
inflammatory	O
airway	O
disease	O
,	O
chronic	O
obstructive	O
pulmonary	O
disease	O
,	O
diabetes	O
,	O
disorders	O
of	O
energy	O
homeostasis	O
,	O
gout	O
,	O
pseudogout	O
,	O
lipid	O
disorders	O
,	O
metabolic	O
syndrome	O
,	O
multiple	O
myeloma	O
,	O
obesity	O
,	O
osteoarthritis	O
,	O
osteogenesis	O
imperfecta	O
,	O
osteolytic	O
bone	O
metastasis	O
,	O
osteomalacia	O
,	O
osteoporosis	O
,	O
Paget	O
's	O
disease	O
,	O
periodontal	O
disease	O
,	O
polymyalgia	O
rheumatica	O
,	O
Reiter	O
's	O
syndrome	O
,	O
repetitive	O
stress	O
injury	O
,	O
hyperglycemia	O
,	O
elevated	O
blood	O
glucose	O
level	O
,	O
and	O
insulin	O
resistance	O
.	O

SUBSTITUTED	O
THIAZOLIDINEDIONE	O
INDAZOLES	O
,	O
INDOLES	O
AND	O
BENZOTRIAZOLES	O
AS	O
ESTROGEN	O
-	O
RELATED	O
RECEPTOR	O
-	O
	O
MODULATORS	O

The	O
invention	O
relates	O
to	O
a	O
gas	O
composition	O
containing	O
xenon	B
gas	I
for	O
use	O
in	O
preventing	O
the	O
relapse	O
of	O
a	O
patient	O
who	O
has	O
been	O
weaned	O
from	O
at	O
least	O
one	O
psychotropic	O
product	O
which	O
resulted	O
in	O
said	O
patient	O
becoming	O
habituated	O
,	O
the	O
xenon	B
being	O
administered	O
to	O
the	O
patient	O
by	O
inhalation	O
.	O

The	O
composition	O
of	O
the	O
invention	O
contains	O
an	O
effective	O
volume	O
proportion	O
of	O
xenon	B
,	O
in	O
particular	O
from	O
5	O
to	O
70	O
%	O
by	O
volume	O
of	O
xenon	B
.	O

DRAWING	O
:	O
FIG	O
.	O

5	O
:	O
Nombres	O
de	O
pression	O
sur	O
le	O
levier	O
/	O
session	O
Number	O
of	O
presses	O
on	O
the	O
lever	O
/	O
session	O
Levier	O
respectif	O
inactif	O
Respective	O
inactive	O
lever	O
rechute	O
relapse	O
Xenon	O
-	O
based	O
inhalable	O
drug	O
for	O
preventing	O
addiction	O
relapses	O
in	O
humans	O

The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
of	O
treating	O
and/or	O
preventing	O
gynecological	O
diseases	O
,	O
by	O
modulating	O
a	O
receptor	O
which	O
is	O
specifically	O
and	O
highly	O
expressed	O
in	O
granulosa	O
cells	O
and	O
oocytes	O
of	O
primates	O
.	O

A	O
role	O
for	O
somatostatin	B
to	O
modulate	O
initiation	O
of	O
follicular	O
growth	O
in	O
the	O
human	O
ovary	O

The	O
invention	O
relates	O
to	O
the	O
pharmaceutical	O
industry	O
,	O
and	O
specifically	O
to	O
a	O
composition	O
based	O
on	O
6-decaprenyl-2,3-dimethoxy-5-methyl-1,4-benzoquinone	B
(	O
ubinone	B
,	O
ubiquinone	B
,	O
coenzyme	B
Q10	I
)	O
in	O
liquid	O
form	O
,	O
which	O
can	O
be	O
used	O
for	O
the	O
prophylaxis	O
and	O
treatment	O
of	O
various	O
illnesses	O
,	O
for	O
restoring	O
fitness	O
for	O
work	O
,	O
and	O
also	O
as	O
a	O
food	O
additive	O
.	O

In	O
addition	O
to	O
the	O
active	O
substance	O
,	O
the	O
composition	O
comprises	O
a	O
nonionic	O
surface	O
-	O
active	O
substance	O
,	O
an	O
antioxidant	O
,	O
a	O
preservative	O
,	O
a	O
fat	O
-	O
soluble	O
emulsion	O
stabilizer	O
,	O
water	O
-	O
soluble	O
cellulose	O
derivatives	O
,	O
a	O
water	O
-	O
soluble	O
emulsion	O
stabilizer	O
and	O
water	O
.	O

The	O
composition	O
is	O
characterized	O
by	O
high	O
bioaccessibility	O
and	O
an	O
extended	O
storage	O
life	O
.	O

The	O
method	O
for	O
producing	O
the	O
composition	O
consists	O
in	O
that	O
the	O
nonionic	O
surface	O
-	O
active	O
substance	O
and	O
the	O
antioxidant	O
are	O
mixed	O
and	O
heated	O
to	O
40	O
-	O
120	O
	O
C	O
,	O
the	O
fat	O
-	O
soluble	O
emulsion	O
stabilizer	O
and	O
6-decaprenyl-2,3-dimethoxy-5-methyl-1,4-benzoquinone	B
are	O
dissolved	O
in	O
the	O
solution	O
produced	O
,	O
the	O
resultant	O
mixture	O
is	O
cooled	O
to	O
30	O
-	O
60	O
	O
	O
and	O
poured	O
under	O
intensive	O
stirring	O
into	O
a	O
mixed	O
solution	O
,	O
preheated	O
to	O
30	O
-	O
100	O
	O
	O
,	O
of	O
the	O
water	O
-	O
soluble	O
cellulose	O
derivatives	O
,	O
water	O
-	O
soluble	O
emulsion	O
stabilizer	O
and	O
preservative	O
in	O
water	O
.	O

6-decaprenyl-2,3-dimethoxy-5-methyl-1,4-benzoquinone	B
-	O
based	O
composition	O
and	O
method	O
for	O
the	O
production	O
thereof	O

Provided	O
herein	O
are	O
PAK	O
inhibitors	O
and	O
methods	O
of	O
utilizing	O
PAK	O
inhibitors	O
for	O
the	O
treatment	O
of	O
CNS	O
disorders	O
such	O
as	O
neuropsychiatric	O
disoders	O
.	O

6-	B
(	I
sulfonylaryl	I
)	I
pyrido	I
[	I
2,3-d	I
]	I
pyrimidin-7	I
(	I
8h	I
)	I
-ones	I
for	O
the	O
treatment	O
of	O
cns	O
disorders	O

An	O
anti	O
-	O
WSSV	O
and/or	O
TSV	O
nucleic	O
acid	O
drug	O
,	O
the	O
active	O
ingredients	O
of	O
which	O
are	O
five	O
nucleic	O
acids	O
whose	O
nucleotide	O
sequences	O
are	O
respectively	O
sequence	O
1	O
,	O
sequence	O
2	O
,	O
sequence	O
3	O
,	O
sequence	O
4	O
and	O
sequence	O
5	O
in	O
the	O
sequence	O
list	O
.	O

Anti	O
-	O
wssv	O
and/or	O
tsv	O
nucleic	O
acid	O
drug	O

Amide	B
substituted	I
indazoles	I
and	O
benzotriazoles	B
as	O
inhibitors	O
of	O
the	O
enzyme	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
(	O
PARP	O
)	O
.	O

The	O
compounds	O
of	O
the	O
present	O
invention	O
are	O
useful	O
as	O
mono	O
-	O
therapies	O
in	O
tumors	O
with	O
specific	O
defects	O
in	O
DNA	O
-	O
repair	O
pathways	O
,	O
as	O
enhancers	O
of	O
certain	O
DNA	O
-	O
damaging	O
agents	O
such	O
as	O
anticancer	O
agents	O
and	O
radiotherapy	O
,	O
for	O
reducing	O
cell	O
necrosis	O
(	O
in	O
stroke	O
and	O
myocardial	O
infarction	O
)	O
,	O
regulating	O
inflammation	O
and	O
tissue	O
injury	O
,	O
treating	O
retroviral	O
infections	O
,	O
and	O
protecting	O
against	O
the	O
toxicity	O
of	O
chemotherapy	O
.	O

Amids	B
substituted	I
indazole	I
derivativees	O
as	O
ploy	O
(	O
adp	O
-	O
ribose	O
)	O
polymerase	O
inhibitors	O

A	O
nitrogenated	B
aromatic	I
heterocyclic	I
ring	O
derivative	O
represented	O
by	O
formula	O
(	O
I	O
)	O
[	O
wherein	O
R1	O
and	O
R2	O
independently	O
represent	O
a	O
hydrogen	B
atom	O
or	O
the	O
like	O
;	O
W	O
represents	O
CR3	O
(	O
wherein	O
R3	O
represents	O
a	O
hydrogen	B
atom	O
or	O
the	O
like	O
)	O
or	O
the	O
like	O
;	O
R4	O
and	O
R5	O
independently	O
represent	O
a	O
hydrogen	B
atom	O
or	O
the	O
like	O
;	O
R9	O
represents	O
a	O
pyrazolyl	B
group	O
which	O
may	O
have	O
a	O
substituent	O
,	O
or	O
the	O
like	O
;	O
and	O
R12	O
and	O
R13	O
independently	O
represent	O
a	O
hydrogen	B
atom	O
or	O
the	O
like	O
]	O
(	O
wherein	O
N-	B
[	I
2-chloro-4-	I
(	I
6,7-dimethoxy-4-	I
quinolyloxy	I
)	I
phenyl	I
]	I
-N'-	I
(	I
5-methyl-3-isooxazolyl	I
)	I
urea	I
is	O
excluded	O
from	O
the	O
derivative	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
;	O
and	O
a	O
FGFR	O
inhibitor	O
or	O
the	O
like	O
which	O
comprises	O
the	O
derivative	O
or	O
the	O
pharmaceutically	O
acceptable	O
salt	O
as	O
an	O
active	O
ingredient	O
.	O

Nitrogenated	B
aromatic	I
heterocyclic	I
ring	O
derivative	O

The	O
use	O
of	O
polydeoxyribonucleotides	O
(	O
PDRNs	O
)	O
in	O
the	O
treatment	O
of	O
metabolic	O
and/or	O
lactic	O
acidosis	O
conditions	O
is	O
described	O
.	O

Compositions	O
comprising	O
the	O
synergistic	O
combination	O
of	O
polydeoxyribonucleotides	O
and	O
one	O
methyl	B
amide	I
,	O
such	O
as	O
carnitine	B
,	O
are	O
also	O
described	O
,	O
which	O
are	O
particularly	O
effective	O
in	O
the	O
treatment	O
of	O
metabolic	O
and/or	O
lactic	O
acidosis	O
conditions	O
.	O

The	O
compositions	O
of	O
the	O
invention	O
may	O
include	O
further	O
optional	O
active	O
ingredients	O
,	O
such	O
as	O
a	O
calcium	B
salt	O
,	O
vitamins	B
of	I
the	I
D	I
or	I
B	I
groups	O
,	O
a	O
sodium	B
salt	O
and	O
a	O
potassium	B
salt	O
,	O
preferably	O
used	O
in	O
combination	O
.	O

Polydeoxyribonucleotides	O
(	O
pdrns	O
)	O
for	O
use	O
in	O
the	O
treatment	O
of	O
metabolic	O
and/or	O
lactic	O
acidosis	O
and	O
polydeoxyribonucleotide	O
-	O
based	O
compositions	O
for	O
the	O
aforesaid	O
use	O

Disclosed	O
are	O
novel	O
polymorphic	O
forms	O
of	O
bis	B
[	I
(	I
E	I
)	I
-7-	I
[	I
4-	I
(	I
4-fluorophenyl	I
)	I
-6-iso	I
-	I
propyl-2-	I
[	I
methyl	I
(	I
methylsulfonyl	I
)	I
amino	I
]	I
pyrimidin-5-yl	I
]	I
(	I
3R,5S	I
)	I
-3,5-dihydroxyhept-6-enoic	I
acid	I
]	I
calcium	I
.	O

Novel	O
polymorph	O
of	O
bis	B
[	I
(	I
e	I
)	I
-7-	I
[	I
4-	I
(	I
4-fluorophenyl	I
)	I
-6-iso	I
-	I
propyl-2-	I
[	I
methyl	I
(	I
methylsulfonyl	I
)	I
amino	I
]	I
pyrimidin-5-yl	I
]	I
(	I
3r,5s	I
)	I
-3,5-dihydroxyhept-6-enoic	I
acid	I
]	I
calcium	I
salt	I

The	O
purpose	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
a	O
composition	O
that	O
has	O
the	O
effect	O
of	O
suppressing	O
matrix	O
-	O
metalloproteinase	O
activity	O
.	O

Specifically	O
,	O
the	O
present	O
invention	O
pertains	O
to	O
a	O
composition	O
which	O
suppresses	O
matrix	O
-	O
metalloproteinase	O
activity	O
and	O
contains	O
,	O
as	O
an	O
active	O
ingredient	O
,	O
a	O
glucose	B
-	O
metabolism	O
inhibitor	O
.	O

Composition	O
suppressing	O
matrix	O
-	O
metalloproteinase	O
activity	O

The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
antibiotically	O
active	O
compound	O
and	O
to	O
an	O
antibiotic	O
composition	O
comprising	O
the	O
compound	O
,	O
and	O
more	O
specifically	O
relates	O
to	O
a	O
compound	O
that	O
inhibits	O
microorganism	O
protein	O
synthesis	O
and	O
to	O
a	O
use	O
for	O
the	O
compound	O
.	O

Novel	O
antibiotically	O
active	O
compound	O
and	O
an	O
antibiotic	O
composition	O
comprising	O
the	O
compound	O

Provided	O
is	O
a	O
medicinal	O
tablet	O
,	O
particularly	O
an	O
orally	O
disintegrating	O
tablet	O
,	O
in	O
which	O
unpleasant	O
taste	O
of	O
atorbastatin	B
in	O
the	O
oral	O
cavity	O
is	O
reduced	O
(	O
drug	O
compliance	O
)	O
,	O
and	O
which	O
can	O
be	O
dispersed	O
or	O
eluted	O
rapidly	O
in	O
the	O
digestive	O
tract	O
.	O

This	O
medicinal	O
tablet	O
comprises	O
atorbastatin	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
and	O
glycyrrhetinic	B
acid	I
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O

Atorbastatin	B
-	O
containing	O
medicinal	O
tablet	O

A	O
compound	O
of	O
formula	O
(	O
I	O
)	O
:	O
wherein	O
R1	O
is	O
hydrogen	B
;	O
R2	O
is	O
C1-C10	B
alkyl	I
,	O
which	O
C1-C10	B
alkyl	I
comprises	O
0	O
,	O
1	O
,	O
2	O
,	O
3	O
or	O
4	O
heteroatoms	O
,	O
selected	O
from	O
O	B
and	O
N	B
,	O
or	O
0	O
,	O
1	O
or	O
2	O
acid	O
,	O
ester	O
or	O
amide	O
functionalities	O
,	O
and	O
said	O
C1-C10	B
alkyl	I
is	O
substituted	O
by	O
0	O
,	O
1	O
,	O
2	O
,	O
3	O
or	O
4	O
CH3	B
,	O
halogen	B
or	O
CF3	B
,	O
or	O
-XR20	O
,	O
wherein	O
X	O
is	O
a	O
bond	O
or	O
_	O
-CH2-	B
,	O
and	O
R20	O
is	O
a	O
4	O
to	O
10	O
membered	O
,	O
monocyclic	B
or	O
bicyclic	B
heterocyclic	B
aromatic	B
or	O
non	O
-	O
aromatic	B
ring	O
containing	O
1	O
,	O
2	O
,	O
3	O
or	O
4	O
heteroatoms	O
selected	O
from	O
O	B
and	O
N	B
,	O
and	O
R20	O
is	O
substituted	O
by	O
0	O
,	O
1	O
,	O
2	O
,	O
3	O
or	O
4	O
CH3	B
,	O
halogen	O
or	O
CF3	B
,	O
pharmaceutical	O
compositions	O
,	O
medical	O
uses	O
and	O
treatment	O
or	O
prophylaxis	O
of	O
a	O
disease	O
or	O
condition	O
in	O
which	O
modulation	O
of	O
fibrinolysisis	O
is	O
beneficial	O
.	O

Isoxazol-3	B
(	I
2h	I
)	I
-one	I
analogs	O
as	O
plasminogen	O
inhibitors	O
and	O
their	O
use	O
in	O
the	O
treatment	O
of	O
fibrinolysis	O
related	O
diseases	O

The	O
present	O
invention	O
regards	O
the	O
use	O
of	O
phosphatidylcholine	B
in	O
the	O
treatment	O
of	O
tumoral	O
pathologies	O
.	O

In	O
particular	O
,	O
the	O
phosphatidylcholine	B
according	O
to	O
the	O
present	O
invention	O
is	O
polyunsaturated	O
phosphatidylcholine	B
.	O

The	O
phosphatidylcholine	B
suitable	O
for	O
the	O
invention	O
can	O
be	O
obtained	O
by	O
extraction	O
from	O
egg	O
-	O
yolk	O
or	O
from	O
soybean	O
seeds	O
.	O

The	O
tumoral	O
pathologies	O
that	O
can	O
be	O
treated	O
according	O
to	O
the	O
invention	O
are	O
in	O
particular	O
hepatoma	O
and	O
mammary	O
tumour	O
.	O

Phosphatidylcholine	B
in	O
the	O
treatment	O
ophosphatidylcholinef	O
tumours	O

The	O
subject	O
of	O
the	O
present	O
invention	O
are	O
novel	O
esters	B
of	I
(	I
acyloxymethyl	I
)	I
acrylamide	I
,	O
a	O
pharmaceutical	O
composition	O
containing	O
them	O
and	O
their	O
use	O
in	O
the	O
production	O
of	O
drugs	O
for	O
the	O
prophylaxis	O
or	O
treatment	O
of	O
oncogenic	O
diseases	O
and	O
diseases	O
connected	O
with	O
increased	O
cell	O
proliferation	O
.	O

Novel	O
esters	B
of	I
(	I
acyloxymethyl	I
)	I
acrylamide	I
,	O
a	O
pharmaceutical	O
composition	O
containing	O
them	O
,	O
and	O
their	O
use	O
as	O
inhibitors	O
of	O
the	O
thioredoxin	O
-	O
thioredoxin	O
reductase	O
system	O

The	O
invention	O
relates	O
to	O
medicine	O
and	O
can	O
be	O
used	O
for	O
treating	O
a	O
range	O
of	O
diseases	O
in	O
the	O
treatment	O
of	O
which	O
interferon	O
is	O
used	O
.	O

The	O
agent	O
for	O
inducing	O
endogenous	O
interferon	O
is	O
comprised	O
of	O
the	O
compound	O
6-	B
(	I
3-methoxycarbonyl	I
phenyl	I
)	I
amino-2,4	I
(	I
1	I
,	I
	I
)	I
-pyrimidinedione	I
C12H11N34	B
of	O
general	O
formula	O
:	O
(	O
I	O
)	O
.	O

The	O
preparation	O
exhibits	O
greater	O
activity	O
both	O
when	O
injected	O
and	O
when	O
administered	O
orally	O
.	O

Agent	O
for	O
inducing	O
endogenous	O
interferon	O

Provided	O
herein	O
are	O
compositions	O
and	O
related	O
methods	O
useful	O
for	O
prevention	O
or	O
mitigation	O
of	O
ionizing	O
radiation	O
-	O
induced	O
esophagitis	O
.	O

The	O
compositions	O
comprise	O
compounds	O
comprising	O
a	O
nitroxide	B
-	O
containing	O
group	O
attached	O
to	O
a	O
mitochondria	O
-	O
targeting	O
group	O
.	O

The	O
compounds	O
can	O
be	O
cross	O
-	O
linked	O
into	O
dimers	O
without	O
loss	O
of	O
activity	O
.	O

The	O
method	O
comprises	O
delivering	O
a	O
compound	O
,	O
as	O
described	O
herein	O
,	O
to	O
a	O
patient	O
in	O
an	O
amount	O
and	O
dosage	O
regimen	O
effective	O
to	O
prevent	O
or	O
mitigate	O
esophageal	O
damage	O
caused	O
by	O
radiation	O
.	O

Intraesophageal	O
administration	O
of	O
targeted	O
nitroxide	B
agents	O
for	O
protection	O
against	O
ionizing	O
irradiation	O
-	O
induced	O
esophagatis	O

The	O
invention	O
provides	O
multilayer	O
tablets	O
that	O
contain	O
rilpivirine	B
hydrochloride	I
,	O
emtricitabine	B
,	O
and	O
tenofivir	B
disoproxil	I
fumarate	I
.	O

The	O
tablets	O
are	O
useful	O
for	O
the	O
treatment	O
of	O
HIV	O
.	O

Therapeutic	O
compositions	O
comprising	O
rilpivirine	B
hcl	I
and	O
tenofovir	B
disoproxil	I
fumarate	I

The	O
invention	O
relates	O
to	O
a	O
composition	O
for	O
the	O
treatment	O
of	O
nail	O
infections	O
.	O

The	O
invention	O
also	O
relates	O
to	O
the	O
use	O
of	O
olive	O
leaf	O
product	O
,	O
and	O
oleuropein	B
and	O
derivatives	O
thereof	O
,	O
for	O
the	O
preparation	O
of	O
a	O
product	O
for	O
the	O
treatment	O
of	O
infections	O
,	O
in	O
particular	O
nail	O
infections	O
,	O
more	O
in	O
particular	O
bacterial	O
and/or	O
fungal	O
nail	O
infections	O
.	O

The	O
compositions	O
according	O
to	O
the	O
invention	O
are	O
based	O
on	O
natural	O
products	O
and	O
have	O
a	O
lower	O
chance	O
to	O
induce	O
allergies	O
in	O
users	O
than	O
conventional	O
products	O
.	O

Composition	O
and	O
use	O
of	O
a	O
fermented	O
olive	O
leaf	O
product	O
for	O
the	O
treatment	O
of	O
nail	O
and	O
skin	O
infections	O
.	O

The	O
present	O
invention	O
provides	O
an	O
antifungal	O
composition	O
including	O
as	O
an	O
active	O
ingredient	O
a	O
AN1542	O
strain	O
(	O
accession	O
number	O
:	O
KCTC	O
12113BP	O
)	O
in	O
a	O
Streptomyces	O
sp.	O
having	O
antifungal	O
activity	O
,	O
an	O
antifungal	O
composition	O
including	O
a	O
compound	O
represented	O
by	O
Formula	O
1	O
or	O
Formula	O
2	O
or	O
a	O
strain	O
producing	O
same	O
as	O
an	O
active	O
ingredient	O
,	O
and	O
a	O
method	O
for	O
preparing	O
the	O
compound	O
.	O

The	O
compound	O
or	O
the	O
strain	O
of	O
the	O
present	O
invention	O
exhibits	O
strong	O
antifungal	O
activity	O
to	O
pathogenic	O
microorganisms	O
and	O
antibiotics	O
-	O
tolerant	O
bacteria	O
,	O
and	O
in	O
particular	O
,	O
can	O
be	O
useful	O
in	O
treating	O
contagious	O
diseases	O
due	O
to	O
super	O
bacteria	O
by	O
exhibiting	O
strong	O
antifungal	O
activity	O
to	O
MRSA	O
,	O
QRSA	O
,	O
VRSA	O
,	O
and	O
VRE	O
.	O

Antifungal	O
composition	O
including	O
polycyclic	O
peptide	O
compound	O
and	O
method	O
for	O
producing	O
same	O

This	O
invention	O
describes	O
substituted	O
pyrazole	B
derivatives	O
of	O
Formula	O
I	O
,	O
and	O
methods	O
of	O
making	O
and	O
using	O
the	O
compounds	O
.	O

These	O
compounds	O
have	O
utility	O
in	O
the	O
treatment	O
of	O
conditions	O
or	O
diseases	O
in	O
which	O
modification	O
of	O
the	O
activity	O
of	O
ERK	O
would	O
have	O
a	O
positive	O
therapeutic	O
outcome	O
,	O
for	O
instance	O
various	O
cancers	O
,	O
psoriasis	O
and	O
actinic	O
keratosis	O
.	O

Pyrazole	B
derivatives	O
as	O
erk	O
inhibitors	O

The	O
present	O
invention	O
provides	O
stable	O
aqueous	O
doxycycline	B
aqueous	O
solutions	O
suitable	O
for	O
pharmaceutical	O
,	O
especially	O
ophthalmic	O
,	O
use	O
.	O

The	O
doxycycline	B
aqueous	O
solutions	O
have	O
a	O
pH	O
ranging	O
from	O
4.5	O
-	O
8	O
,	O
and	O
contain	O
an	O
antioxidant	O
and	O
a	O
stabilizer	O
such	O
as	O
caffeine	B
,	O
creatine	O
or	O
mixtures	O
thereof	O
.	O

The	O
solutions	O
have	O
improved	O
lifetimes	O
and	O
can	O
be	O
used	O
topically	O
.	O

Therapeutic	O
eye	O
drop	O
comprising	O
doxycycline	B
and	O
a	O
stabilizer	O

A	O
dextrin	O
inclusion	O
complex	O
of	O
total	O
ginsenoside	B
and	O
total	O
flavone	B
of	O
epimedium	O
and	O
the	O
preparation	O
method	O
thereof	O
are	O
disclosed	O
.	O

A	O
pharmaceutical	O
formulation	O
comprising	O
the	O
dextrin	O
inclusion	O
complex	O
and	O
the	O
use	O
of	O
the	O
dextrin	O
inclusion	O
complex	O
in	O
preparing	O
a	O
pharmaceutical	O
formulation	O
are	O
also	O
disclosed	O
.	O

Dextrin	O
inclusion	O
complex	O
,	O
preparation	O
method	O
thereof	O
and	O
pharmaceutical	O
formulation	O
comprising	O
said	O
inclusion	O
complex	O

To	O
study	O
different	O
types	O
of	O
thrombolytic	O
agents	O
,	O
both	O
thrombolysis	O
and	O
stimulation	O
of	O
fucoidan	O
were	O
studied	O
in	O
a	O
mouse	O
model	O
of	O
ferric	B
chloride	I
-	O
induced	O
arterial	O
thrombosis	O
and	O
were	O
compared	O
with	O
those	O
of	O
a	O
heparin	O
and	O
tissue	O
plasminogen	O
activator	O
(	O
t	O
-	O
PA	O
)	O
.	O

Thrombosis	O
was	O
induced	O
by	O
applying	O
a	O
filter	O
paper	O
saturated	O
with	O
5	O
%	O
FeCl3	B
to	O
the	O
left	O
carotid	O
artery	O
.	O

20	O
minutes	O
after	O
complete	O
occlusion	O
,	O
several	O
test	O
preparations	O
including	O
a	O
fucoidan	O
source	O
from	O
Undaria	O
pinnatifida	O
sporophylls	O
were	O
intravenously	O
injected	O
to	O
each	O
mouse	O
group	O
by	O
various	O
dosages	O
of	O
10	O
-	O
200	O
mg	O
/	O
kg-1	O
.	O

To	O
study	O
the	O
stimulation	O
effect	O
of	O
fucoidan	O
with	O
respect	O
to	O
t	O
-	O
PA	O
,	O
fucoidan	O
added	O
in	O
a	O
predetermined	O
amount	O
of	O
t	O
-	O
PA	O
was	O
injected	O
by	O
a	O
dose	O
of	O
1	O
-	O
10	O
mg	O
/	O
kg	O
.	O

Then	O
,	O
the	O
time	O
to	O
reperfusion	O
was	O
measured	O
.	O

As	O
a	O
result	O
,	O
an	O
occluded	O
aorta	O
was	O
dose	O
-	O
dependently	O
reperfused	O
,	O
and	O
the	O
reperfusion	O
was	O
observed	O
at	O
37.512.4	O
minutes	O
after	O
the	O
administration	O
of	O
100	O
mg	O
/	O
kg-1	O
of	O
unfractionated	O
fucoidan	O
.	O

The	O
time	O
to	O
reperfusion	O
was	O
retarded	O
to	O
55.08.0	O
minutes	O
when	O
a	O
large	O
amount	O
of	O
fucoidan	O
such	O
as	O
1	O
g	O
/	O
kg-1	O
was	O
administered	O
to	O
a	O
mouse	O
provided	O
with	O
low	O
molecular	O
weight	O
fucoidan	O
(	O
LMWF	O
)	O
.	O

Reperfusion	O
occurred	O
at	O
16.67	O
minutes	O
after	O
administration	O
in	O
a	O
mouse	O
of	O
a	O
control	O
group	O
provided	O
with	O
20	O
mg	O
/	O
kg-1	O
of	O
t	O
-	O
PA	O
.	O

On	O
the	O
contrary	O
,	O
reperfusion	O
was	O
not	O
observed	O
in	O
an	O
occluded	O
mouse	O
provided	O
with	O
heparin	O
(	O
p<0.01	O
)	O
.	O

The	O
occluded	O
artery	O
was	O
recovered	O
without	O
reperfusion	O
at	O
17.2	O
minutes	O
after	O
injection	O
if	O
the	O
least	O
amount	O
of	O
fucoidan	O
added	O
in	O
a	O
predetermined	O
amount	O
of	O
t	O
-	O
PA	O
was	O
provided	O
.	O

All	O
the	O
data	O
show	O
that	O
fucoidan	O
can	O
serve	O
as	O
both	O
a	O
thrombolytic	O
agent	O
and	O
a	O
stimulant	O
with	O
respect	O
to	O
thrombolysis	O
activation	O
of	O
t	O
-	O
PA	O
in	O
a	O
thrombosis	O
model	O
,	O
differently	O
from	O
heparin	O
.	O

Fucoidan	O
for	O
thrombolysis	O
,	O
derived	O
from	O
seaweed	O

The	O
present	O
invention	O
relates	O
to	O
the	O
treatment	O
of	O
severe	O
persistent	O
asthma	O
,	O
and	O
in	O
particular	O
severe	O
persistent	O
corticosteroid	B
-	O
dependent	O
or	O
corticosteroid	B
-	O
resistant	O
asthma	O
,	O
comprising	O
administration	O
a	O
tyrosine	B
kinase	O
inhibitor	O
or	O
a	O
mast	O
cell	O
inhibitor	O
,	O
especially	O
masitinib	B
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O

Treatment	O
of	O
severe	O
persitent	O
asthma	O
with	O
masitinib	B

The	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
A	O
)	O
having	O
an	O
anti	O
-	O
angiogenic	O
and/or	O
anti	O
-	O
tumoral	O
activity	O
,	O
to	O
pharmaceutical	O
compositions	O
comprising	O
same	O
,	O
and	O
to	O
the	O
use	O
thereof	O
for	O
treating	O
cancer	O
.	O

(	O
substituted	O
)	O
N-	B
(	I
CH2	I
)	I
m	I
-	I
A	I
-	I
Rc	I
where	O
A	O
is	O
a	O
bond	O
,	O
Het-	B
(	I
CH2	I
)	I
1	I
-	I
6	I
or	O
NH-	B
(	I
CH2	I
)	I
1	I
-	I
6	I
and	O
Rc	O
is	O
O	B
-	O
substituted	O
or	O
N	B
-	O
substituted	O
.	O

Anti	O
-	O
angiogenic	O
compounds	O
,	O
pharmaceutical	O
compositions	O
containing	O
same	O
,	O
and	O
use	O
thereof	O

The	O
present	O
invention	O
is	O
intended	O
to	O
provide	O
new	O
antimalarial	O
compounds	O
with	O
a	O
strong	O
antimalarial	O
activity	O
as	O
well	O
as	O
antibacterial	O
activity	O
with	O
few	O
neurological	O
side	O
effects	O
and	O
a	O
new	O
enantioselective	O
pathway	O
to	O
mefloquine	B
amino	O
-	O
analogs	O
allowing	O
the	O
access	O
of	O
such	O
compounds	O
.	O

The	O
present	O
invention	O
relates	O
to	O
new	O
4	B
-aminoalcohol	I
quinoline	I
derivatives	O
of	O
formula	O
(	O
I	O
)	O
,	O
as	O
well	O
as	O
the	O
synthesis	O
methods	O
and	O
the	O
uses	O
of	O
such	O
derivatives	O
.	O

In	O
which	O
Y	O
is	O
one	O
selected	O
from	O
formulae	O
(	O
II	O
)	O
to	O
(	O
III	O
)	O
.	O

In	O
which	O
Z	O
is	O
selected	O
from	O
formulae	O
(	O
IV	O
)	O
to	O
(	O
VI	O
)	O
,	O
and	O
wherein	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
R4	O
,	O
R5	O
,	O
R6	O
,	O
R7	O
and	O
n	O
are	O
as	O
defined	O
in	O
the	O
claims	O
.	O

4-aminoalcoholquinoline	B
derivatives	O
,	O
enantioselective	O
synthesis	O
methods	O
and	O
the	O
use	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
a	O
cell	O
therapy	O
composition	O
for	O
preventing	O
or	O
treating	O
immune	O
disease	O
comprising	O
mesenchymal	O
stem	O
cells	O
and	O
immunoregulatory	O
T	O
-	O
cells	O
as	O
an	O
active	O
ingredient	O
.	O

By	O
infusing	O
mesenchymal	O
stem	O
cells	O
and	O
immunoregulatory	O
T	O
-	O
cells	O
,	O
which	O
are	O
the	O
cellular	O
therapeutic	O
agent	O
of	O
the	O
present	O
invention	O
,	O
into	O
bone	O
marrow	O
transplant	O
animals	O
,	O
rejection	O
to	O
the	O
host	O
is	O
suppressed	O
after	O
the	O
engraftment	O
of	O
transplanted	O
bone	O
-	O
marrow	O
to	O
thus	O
obtain	O
the	O
effect	O
of	O
reducing	O
graft	O
-	O
versus	O
-	O
host	O
disease	O
and	O
immune	O
disease	O
.	O

Moreover	O
,	O
the	O
effect	O
of	O
such	O
GVHD	O
reduction	O
is	O
much	O
greater	O
than	O
the	O
one	O
obtained	O
when	O
only	O
mesenchymal	O
stem	O
cells	O
are	O
infused	O
.	O

Accordingly	O
,	O
the	O
cell	O
therapy	O
composition	O
of	O
the	O
present	O
invention	O
having	O
the	O
above	O
-	O
mentioned	O
effects	O
can	O
be	O
useful	O
in	O
the	O
prevention	O
or	O
treatment	O
of	O
immune	O
disease	O
.	O

Cell	O
therapy	O
composition	O
for	O
preventing	O
or	O
treating	O
immune	O
disease	O
comprising	O
mesenchymal	O
stem	O
cells	O
and	O
immunoregulatory	O
t	O
-	O
cells	O
as	O
active	O
ingredient	O

In	O
alternative	O
embodiments	O
the	O
invention	O
provides	O
compositions	O
,	O
e.g.	O
,	O
pharmaceutical	O
compositions	O
and	O
preparations	O
,	O
formulations	O
,	O
kits	O
and	O
other	O
products	O
of	O
manufacture	O
,	O
e.g.	O
,	O
exemplary	O
drug	O
combinations	O
packaged	O
together	O
or	O
separately	O
in	O
blister	O
packs	O
,	O
lidded	O
blisters	O
or	O
blister	O
cards	O
,	O
or	O
wrapped	O
in	O
paper	O
,	O
plastic	O
or	O
cellophane	O
wrappers	O
(	O
e.g.	O
,	O
a	O
shrink	O
wrap	O
)	O
,	O
comprising	O
a	O
combination	O
regimen	O
of	O
at	O
least	O
two	O
active	O
ingredients	O
designed	O
to	O
diminish	O
systemic	O
inflammation	O
by	O
targeting	O
(	O
inhibiting	O
)	O
two	O
different	O
,	O
but	O
convergent	O
,	O
signaling	O
pathways	O
,	O
i.e.	O
,	O
the	O
sympathetic	O
nervous	O
system	O
and	O
the	O
lipid-	O
derived	O
autacoid	O
system	O
;	O
and	O
methods	O
for	O
making	O
and	O
using	O
these	O
compositions	O
.	O

In	O
alternative	O
embodiments	O
,	O
the	O
compositions	O
of	O
the	O
invention	O
(	O
e.g.	O
,	O
the	O
combination	O
of	O
drugs	O
)	O
are	O
used	O
to	O
ameliorate	O
,	O
diminish	O
,	O
treat	O
,	O
block	O
or	O
prevent	O
an	O
inflammatory	O
response	O
secondary	O
to	O
an	O
infection	O
,	O
e.g.	O
,	O
a	O
viral	O
infection	O
and/or	O
a	O
reactivation	O
.	O

Compositions	O
for	O
ameliorating	O
systemic	O
inflammation	O
and	O
methods	O
for	O
making	O
and	O
using	O
them	O

Use	O
of	O
poly	B
(	I
4-styrene	I
sulfonic	I
acid	I
-	I
copoly	I
-	I
maleic	I
acid	I
)	I
sodium	I
salt	I
in	O
the	O
preparation	O
of	O
pharmaceutical	O
inhibiting	O
infection	O
of	O
HIV-1	O
and	O
pharmaceutical	O
composition	O
thereof	O
.	O

Said	O
pharmaceutical	O
composition	O
comprises	O
poly	O
(	O
4-styrene	O
sulfonic	O
acid	O
-	O
copoly	O
-	O
maleic	O
acid	O
)	O
sodium	O
salt	O
as	O
active	O
ingredient	O
and	O
conventional	O
pharmaceutical	O
carrier	O
.	O

Use	O
of	O
poly	B
(	I
4-styrene	I
sulfonic	I
acid	I
-	I
copoly	I
-	I
maleic	I
acid	I
)	I
sodium	I
salt	I
and	O
pharmaceutical	O
composition	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
compound	O
,	O
or	O
a	O
stereoisomer	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
and	O
a	O
pharmaceutical	O
composition	O
for	O
human-11-beta	O
-	B
hydroxysteroid	I
dehydrogenase	O
type	O
1	O
(	O
11	O
-	O
HSD1	O
)	O
comprising	O
the	O
same	O
.	O

The	O
invention	O
provides	O
a	O
compound	O
,	O
which	O
has	O
excellent	O
activity	O
and	O
solubility	O
and	O
is	O
more	O
efficiently	O
formulated	O
and	O
delivered	O
,	O
and	O
a	O
pharmaceutical	O
composition	O
for	O
human-11-beta	O
-	B
hydroxysteroid	I
dehydrogenase	O
type	O
1	O
comprising	O
the	O
same	O
.	O

A	O
COMPOUND	O
FOR	O
INHIBITING	O
HUMAN	O
11-	B
-	I
HYDROXY	I
STEROID	I
DEHYDROGENASE	O
TYPE	O
1	O
,	O
AND	O
A	O
PHARMACEUTICAL	O
COMPOSITION	O
COMPRISING	O
THE	O
SAME	O

This	O
invention	O
relates	O
to	O
a	O
method	O
of	O
treating	O
xeroderma	O
pigmentosum	O
and	O
related	O
symptoms	O
in	O
patients	O
by	O
administering	O
a	O
MC1R	O
before	O
or	O
after	O
exposing	O
them	O
to	O
visible	O
light	O
.	O

Method	O
for	O
treatment	O
of	O
xeroderma	O
pigmentosum	O

The	O
present	O
invention	O
provides	O
a	O
pharmaceutical	O
product	O
which	O
has	O
a	O
sufficient	O
curative	O
effect	O
on	O
multiple	O
sclerosis	O
and	O
has	O
excellent	O
autoimmune	O
inhibitory	O
activity	O
,	O
while	O
being	O
reduced	O
in	O
the	O
side	O
effects	O
which	O
steroidal	O
agents	O
and	O
interferon	O
	O
have	O
.	O

The	O
present	O
invention	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
for	O
the	O
treatment	O
or	O
prophylaxis	O
of	O
multiple	O
sclerosis	O
,	O
which	O
contains	O
,	O
as	O
an	O
active	O
ingredient	O
,	O
4-	B
(	I
2-aminopyridin-4-yl	I
)	I
-3-	I
(	I
4-fluorophenyl	I
)	I
-1-	I
(	I
1,4,5,6-tetrahydro-6-oxopyridazin-3-yl	I
)	I
-1H	I
-	I
pyrazole	I
or	O
a	O
pharmacologically	O
acceptable	O
salt	O
thereof	O
.	O

Pharmaceutical	O
composition	O
for	O
treatment	O
or	O
prophylaxis	O
of	O
neurogenic	O
diseases	O

The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
cephalosporin	B
derivative	O
indicated	O
in	O
chemical	O
formula	O
1	O
of	O
the	O
description	O
.	O

In	O
the	O
chemical	O
formula	O
1	O
,	O
X	O
,	O
Y	O
,	O
L	O
,	O
R1	O
,	O
R2	O
are	O
identical	O
as	O
defined	O
in	O
the	O
detailed	O
explanation	O
.	O

In	O
addition	O
,	O
the	O
present	O
invention	O
relates	O
an	O
antibiotic	O
medical	O
composition	O
containing	O
the	O
novel	O
cephalosporin	B
derivative	O
of	O
the	O
chemical	O
formula	O
1	O
,	O
a	O
prodrug	O
thereof	O
,	O
a	O
hydrate	O
thereof	O
,	O
a	O
solvate	O
thereof	O
,	O
an	O
isomer	O
thereof	O
,	O
and	O
a	O
pharmaceutically	O
permitted	O
salt	O
thereof	O
,	O
as	O
active	O
ingredients	O
.	O

The	O
novel	O
cephalosporin	B
derivative	O
of	O
the	O
chemical	O
formula	O
1	O
,	O
the	O
prodrug	O
thereof	O
,	O
the	O
hydrate	O
thereof	O
,	O
the	O
solvate	O
thereof	O
,	O
the	O
isomer	O
thereof	O
,	O
and	O
the	O
pharmaceutically	O
permitted	O
salt	O
thereof	O
have	O
a	O
wide	O
antibacterial	O
spectrum	O
for	O
resistant	O
bacteria	O
,	O
have	O
low	O
toxicity	O
,	O
and	O
in	O
particular	O
,	O
show	O
strong	O
antibacterial	O
effect	O
on	O
gram	O
negative	O
bacteria	O
,	O
and	O
is	O
thus	O
useful	O
as	O
an	O
antibiotic	O
.	O

Novel	O
cephalosporin	B
derivative	O
and	O
medical	O
composition	O
containing	O
same	O

The	O
present	O
invention	O
relates	O
to	O
methods	O
of	O
treating	O
heartburn	O
in	O
a	O
patient	O
receiving	O
clopidogrel	B
therapy	O
.	O

In	O
another	O
aspect	O
,	O
the	O
present	O
invention	O
relates	O
to	O
methods	O
of	O
preventing	O
gastric	O
bleeding	O
or	O
hemorrhage	O
in	O
patients	O
receiving	O
clopidogrel	B
therapy	O
.	O

Methods	O
for	O
treating	O
heartburn	O
and/or	O
preventing	O
gastric	O
bleeding	O
or	O
hemorrhage	O
in	O
patients	O
receiving	O
clopidogrel	B
therapy	O

Disclosed	O
are	O
solid	O
forms	O
of	O
antiretroviral	O
compounds	O
and	O
anti	O
-	O
oxidative	O
acids	O
,	O
and	O
processes	O
for	O
their	O
preparation	O
.	O

Pharmaceutical	O
compositions	O
using	O
the	O
solid	O
forms	O
are	O
also	O
disclosed	O
.	O

Solid	O
forms	O
of	O
antiretroviral	O
compounds	O
and	O
anti	O
-	O
oxidative	O
acids	O
,	O
processes	O
for	O
preparation	O
and	O
pharmaceutical	O
compositions	O
thereof	O

The	O
invention	O
relates	O
to	O
acadesine	B
derivatives	O
as	O
a	O
drug	O
,	O
as	O
well	O
as	O
to	O
said	O
derivatives	O
for	O
the	O
treatment	O
of	O
cancer	O
and	O
particularly	O
for	O
the	O
treatment	O
of	O
chronic	O
myeloid	O
leukemia	O
(	O
CML	O
)	O
.	O

The	O
invention	O
further	O
relates	O
to	O
a	O
product	O
containing	O
said	O
derivatives	O
and	O
at	O
least	O
one	O
second	O
active	O
ingredient	O
as	O
a	O
combination	O
product	O
to	O
be	O
simultaneously	O
or	O
separately	O
administered	O
,	O
or	O
administered	O
over	O
time	O
,	O
in	O
the	O
treatment	O
of	O
cancer	O
,	O
as	O
well	O
as	O
to	O
a	O
pharmaceutical	O
composition	O
including	O
said	O
derivatives	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
.	O

Finally	O
,	O
the	O
invention	O
relates	O
to	O
a	O
method	O
for	O
the	O
in	O
vitro	O
inhibition	O
of	O
the	O
proliferation	O
of	O
cells	O
,	O
including	O
contacting	O
a	O
cell	O
with	O
said	O
derivatives	O
in	O
vitro	O
,	O
and	O
to	O
methods	O
for	O
synthesizing	O
said	O
derivatives	O
.	O

Acadesine	B
derivatives	O
,	O
products	O
and	O
compositions	O
including	O
same	O
,	O
therapeutic	O
uses	O
thereof	O
,	O
and	O
methods	O
for	O
synthesizing	O
same	O

This	O
invention	O
discloses	O
2	B
-	I
methyl	I
and	O
2	B
-	I
methyl	I
analogs	O
of	O
19,26-dinor-1,25-dihydroxyvitamin	B
D3	I
and	O
pharmaceutical	O
uses	O
therefor	O
.	O

These	O
compounds	O
exhibit	O
in	O
vitro	O
biological	O
activities	O
evidencing	O
use	O
as	O
an	O
anti	O
-	O
cancer	O
agent	O
and	O
for	O
the	O
treatment	O
of	O
skin	O
diseases	O
such	O
as	O
psoriasis	O
as	O
well	O
as	O
skin	O
conditions	O
such	O
as	O
wrinkles	O
,	O
slack	O
skin	O
,	O
dry	O
skin	O
and	O
insufficient	O
sebum	O
secretion	O
.	O

These	O
compounds	O
have	O
little	O
,	O
if	O
any	O
,	O
in	O
vivo	O
calcemic	O
activity	O
and	O
therefore	O
may	O
be	O
used	O
to	O
treat	O
autoimmune	O
disorders	O
in	O
humans	O
as	O
well	O
as	O
secondary	O
hyperparathyroidism	O
and	O
renal	O
osteodystrophy	O
.	O

2	B
-	I
METHYL	I
AND	O
2	B
-	I
METHYL	I
ANALOGS	O
OF	O
19,26-DINOR-1	B
,	I
25-DIHYDROXYVITAMIN	I
D3	I
AND	O
THEIR	O
USES	O

The	O
purpose	O
of	O
the	O
invention	O
is	O
to	O
provide	O
a	O
novel	O
and	O
effective	O
anti	O
-	O
wrinkle	O
agent	O
.	O

The	O
invention	O
relates	O
to	O
a	O
matrix	O
metalloproteinase	O
(	O
MMP	O
)	O
inhibitor	O
and/or	O
laminin	O
5	O
production	O
promoter	O
,	O
as	O
well	O
as	O
an	O
anti	O
-	O
wrinkle	O
agent	O
,	O
each	O
of	O
which	O
comprises	O
1-piperidine	B
propionate	I
and/or	O
a	O
salt	O
thereof	O
.	O

Anti	O
-	O
wrinkle	O
agent	O
,	O
matrix	O
metalloproteinase	O
(	O
mmp	O
)	O
inhibitor	O
and/or	O
laminin	O
5	O
production	O
promoter	O
,	O
each	O
comprising	O
1-piperidine	B
propionate	I

Disclosed	O
herein	O
are	O
KCNQ	O
potassium	B
channels	O
modulators	O
of	O
formula	O
(	O
I	O
)	O
wherein	O
ring	O
G1	O
,	O
R1	O
,	O
and	O
R2	O
are	O
as	O
defined	O
in	O
the	O
specification	O
.	O

Compositions	O
comprising	O
such	O
compounds	O
;	O
and	O
methods	O
for	O
treating	O
conditions	O
and	O
disorders	O
using	O
such	O
compounds	O
and	O
compositions	O
are	O
also	O
described	O
.	O

Condensed	O
2	B
-	I
carbamoylpyridazinones	I
as	O
potassium	B
channel	O
modulators	O

The	O
present	O
invention	O
relates	O
to	O
a	O
method	O
for	O
treating	O
spinal	O
muscular	O
atrophy	O
and	O
other	O
related	O
neuromuscular	O
disorders	O
in	O
a	O
subject	O
in	O
need	O
thereof	O
,	O
said	O
method	O
comprising	O
administering	O
a	O
therapeutically	O
effective	O
amount	O
of	O
an	O
ERK	O
inhibitor	O
,	O
such	O
as	O
Selumetinib	B
to	O
said	O
subject	O
.	O

Erk	O
inhibitors	O
for	O
use	O
in	O
treating	O
spinal	O
muscular	O
atrophy	O

River	O
rocks	O
are	O
used	O
in	O
a	O
therapy	O
regime	O
whereby	O
the	O
river	O
rocks	O
are	O
used	O
to	O
absorb	O
excess	O
oils	O
from	O
the	O
skin	O
of	O
a	O
user	O
.	O

In	O
one	O
method	O
,	O
river	O
rocks	O
arc	O
collected	O
from	O
a	O
source	O
(	O
e.g	O
..	O
river	O
or	O
supplier	O
)	O
,	O
sorted	O
for	O
size	O
and	O
color	O
,	O
engraved	O
with	O
logo	O
or	O
other	O
content	O
,	O
packaged	O
and	O
shipped	O
to	O
customers	O
or	O
retailers	O
with	O
instructions	O
on	O
use	O
.	O

Use	O
comprises	O
placement	O
of	O
the	O
river	O
rocks	O
on	O
oily	O
portions	O
of	O
the	O
user	O
's	O
skin	O
for	O
an	O
appropriate	O
time	O
period	O
allowing	O
the	O
river	O
rock	O
to	O
absorb	O
the	O
excess	O
oils	O
.	O

The	O
river	O
rocks	O
are	O
reusable	O
after	O
being	O
washed	O
with	O
mild	O
soap	O
and	O
water	O
.	O

Skin	O
treatment	O
method	O

This	O
disclosure	O
relates	O
to	O
pharmaceutical	O
compositions	O
useful	O
for	O
inhibiting	O
insulin	O
-	O
degrading	O
enzyme	O
(	O
IDE	O
)	O
and	O
methods	O
of	O
treating	O
disorders	O
involving	O
the	O
same	O
or	O
peptide	O
substrates	O
of	O
the	O
same	O
.	O

For	O
example	O
,	O
provided	O
herein	O
are	O
methods	O
of	O
treating	O
diabetes	O
,	O
promotion	O
of	O
wound	O
healing	O
,	O
and	O
improvement	O
of	O
memory	O
.	O

Thiocarbamate	B
and	O
sulfonamide	B
hydroxamate	I
inhibitors	O
of	O
insulin	O
-	O
degrading	O
enzyme	O

The	O
present	O
patent	O
application	O
relates	O
to	O
a	O
pharmaceutical	O
composition	O
comprising	O
a	O
transient	O
receptor	O
potential	O
ankyrin-1	O
receptor	O
(	O
"	O
TRPA1	O
"	O
)	O
antagonist	O
and	O
a	O
leukotriene	O
receptor	O
antagonist	O
.	O

Pharmaceutical	O
composition	O
comprising	O
a	O
trpa1	O
antagonist	O
and	O
a	O
leukotriene	O
receptor	O
antagonist	O

The	O
present	O
invention	O
provides	O
an	O
antifungal	O
composition	O
comprising	O
cis	B
-	I
cyclo	I
(	I
L	I
-	I
Phe	I
-	I
L	I
-	I
Pro	I
)	I
as	O
an	O
active	O
ingredient	O
and	O
having	O
Genus	O
Ganoderma	O
fungus	O
-	O
specific	O
antifungal	O
activity	O
,	O
an	O
insecticide	O
composition	O
,	O
and	O
a	O
method	O
for	O
producing	O
an	O
antifungal	O
agent	O
for	O
Genus	O
Ganoderma	O
fungi	O
.	O

The	O
present	O
invention	O
exhibits	O
superior	O
antifungal	O
activity	O
to	O
the	O
Genus	O
Ganoderma	O
fungi	O
(	O
especially	O
,	O
to	O
Ganoderma	O
boninense	O
fungi	O
)	O
and	O
thus	O
can	O
be	O
applied	O
to	O
various	O
industrial	O
fields	O
requiring	O
removal	O
and	O
prevention	O
of	O
Genus	O
Ganoderma	O
fungi	O
,	O
and	O
is	O
economically	O
advantageous	O
in	O
terms	O
of	O
usage	O
due	O
to	O
the	O
antifungal	O
activity	O
even	O
with	O
a	O
small	O
amount	O
.	O

In	O
addition	O
,	O
the	O
present	O
invention	O
provides	O
basic	O
material	O
as	O
a	O
biological	O
agent	O
regarding	O
cis	B
-	I
cyclo	I
(	I
L	I
-	I
Phe	I
-	I
L	I
-	I
Pro	I
)	I
to	O
the	O
insecticide	O
industry	O
which	O
uses	O
biological	O
agents	O
.	O

Antifungal	O
composition	O
comprising	O
cis	B
-	I
cyclo	I
(	I
l	I
-	I
phe	I
-	I
l	I
-	I
pro	I
)	I
having	O
genus	O
ganoderma	O
fungus	O
-	O
specific	O
antifungal	O
activity	O

There	O
is	O
provided	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
wherein	O
R1	O
,	O
R2	O
,	O
X	O
,	O
R3	O
and	O
R4	O
have	O
meanings	O
given	O
in	O
the	O
description	O
(	O
and	O
which	O
compounds	O
are	O
optionally	O
substituted	O
as	O
indicated	O
in	O
the	O
description	O
)	O
,	O
and	O
pharmaceutically	O
-	O
acceptable	O
esters	O
,	O
amides	O
,	O
solvates	O
or	O
salts	O
thereof	O
,	O
which	O
compounds	O
are	O
useful	O
in	O
the	O
treatment	O
of	O
diseases	O
in	O
which	O
inhibition	O
of	O
a	O
protein	O
or	O
lipid	O
kinase	O
(	O
e.g.	O
a	O
PIM	O
family	O
kinase	O
,	O
such	O
as	O
PIM-1	O
,	O
PIM-2	O
and/or	O
PIM-3	O
)	O
is	O
desired	O
and/or	O
required	O
,	O
and	O
particularly	O
in	O
the	O
treatment	O
of	O
cancer	O
or	O
a	O
proliferative	O
disease	O
.	O

There	O
is	O
also	O
provided	O
combinations	O
comprising	O
the	O
compounds	O
of	O
formula	O
I.	O
Tricyclic	B
heterocyclic	I
compounds	O
as	O
kinase	O
inhibitors	O

The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
or	O
pharmaceutical	O
acceptable	O
salts	O
,	O
wherein	O
R1	O
,	O
R2	O
,	O
R3	O
,	O
A	O
,	O
B	O
,	O
and	O
n	O
are	O
defined	O
in	O
the	O
description	O
.	O

The	O
present	O
invention	O
relates	O
also	O
to	O
compositions	O
containing	O
said	O
compounds	O
which	O
are	O
useful	O
for	O
inhibiting	O
kinases	O
such	O
as	O
wee-1	O
and	O
methods	O
of	O
treating	O
diseases	O
such	O
as	O
cancer	O
.	O

Tricyclic	B
inhibitors	O
of	O
kinases	O
useful	O
for	O
the	O
treatment	O
of	O
proliferative	O
diseases	O

The	O
present	O
invention	O
relates	O
to	O
spirocyclic	O
compounds	O
of	O
formula	O
I	O
,	O
namely	O
spirocyclic	O
(	B
1H	I
-	I
pyrazol-4-yl	I
)	I
-3-	I
(	I
1-	I
(	I
2,6-dichloro-3-	I
fiuorophenyl	I
)	I
ethoxy	I
)	I
pyridin-2-amines	I
having	O
protein	O
kinase	O
inhibitory	O
activity	O
,	O
and	O
methods	O
of	O
synthesizing	O
and	O
using	O
such	O
compounds	O
.	O

Preferred	O
compounds	O
are	O
c	O
-	O
Met	O
and/or	O
ALK	O
inhibitors	O
useful	O
for	O
the	O
treatment	O
of	O
abnormal	O
cell	O
growth	O
,	O
such	O
as	O
cancers	O
.	O

Spirocyclic	O
molecules	O
as	O
protein	O
kinase	O
inhibitors	O

The	O
present	O
invention	O
relates	O
to	O
a	O
composition	O
containing	O
5-hydroxyindole	B
compounds	O
or	O
sponge	O
Scalarispongia	O
sp.	O
extracts	O
as	O
active	O
ingredients	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
cancer	O
diseases	O
,	O
and	O
more	O
specifically	O
,	O
the	O
novel	O
compound	O
or	O
the	O
Scalarispongia	O
sp.	O
extract	O
and	O
more	O
specifically	O
,	O
the	O
novel	O
compound	O
or	O
the	O
Scalarispongia	O
sp.	O
extract	O
of	O
the	O
present	O
invention	O
exhibits	O
growth	O
inhibitory	O
activities	O
against	O
various	O
cancer	O
cell	O
lines	O
and	O
is	O
thus	O
useful	O
as	O
a	O
pharmaceutical	O
composition	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
cancer	O
diseases	O
.	O

Composition	O
containing	O
5-hydroxyindole	B
compounds	O
or	O
sponge	O
scalarispongia	O
sp.	O
extracts	O
as	O
active	O
ingredients	O
for	O
prevention	O
and	O
treatment	O
of	O
cancer	O
diseases	O

Pyridazine	B
derivatives	O
that	O
activate	O
the	O
excitatory	O
amino	B
acid	I
transporter	O
2	O
(	O
EAAT2	O
)	O
,	O
and	O
methods	O
of	O
use	O
thereof	O
for	O
treating	O
or	O
preventing	O
diseases	O
,	O
disorders	O
,	O
and	O
conditions	O
associated	O
with	O
glutamate	B
excitotoxicity	O
.	O

Pyridazine	B
derivatives	O
as	O
eaat2	O
activators	O

Provided	O
are	O
urea	B
compounds	O
of	O
formula	O
(	O
I	O
)	O
as	O
Tec	O
kinase	O
inhibitors	O
,	O
in	O
particular	O
ITK	O
(	O
interleukin-2	O
inducible	O
tyrosine	B
kinase	O
)	O
inhibitors	O
.	O

Also	O
provided	O
herein	O
are	O
processes	O
for	O
preparing	O
compounds	O
described	O
herein	O
,	O
intermediates	O
used	O
in	O
their	O
synthesis	O
,	O
pharmaceutical	O
compositions	O
thereof	O
,	O
and	O
methods	O
for	O
treating	O
or	O
preventing	O
diseases	O
,	O
conditions	O
and/or	O
disorders	O
mediated	O
by	O
ITK	O
.	O

Novel	O
urea	B
derivatives	O
as	O
tec	O
kinase	O
inhibitors	O
and	O
uses	O
thereof	O

Embodiments	O
of	O
the	O
invention	O
include	O
methods	O
of	O
using	O
vitamin	B
B12	I
to	O
influence	O
amyloid	O
-	O
beta	O
peptide	O
aggregation	O
.	O

A	O
preferred	O
method	O
comprises	O
contacting	O
at	O
least	O
one	O
amyloid	O
-	O
beta	O
peptide	O
oligomer	O
formed	O
from	O
a	O
plurality	O
of	O
amyloid	O
-	O
beta	O
peptide	O
monomers	O
with	O
an	O
effective	O
amount	O
of	O
vitamin	B
B12	I
,	O
the	O
effective	O
amount	O
being	O
sufficient	O
to	O
stimulate	O
dissociation	O
of	O
the	O
amyloid	O
-	O
beta	O
peptide	O
monomers	O
from	O
the	O
amyloid	O
-	O
beta	O
peptide	O
oligomer	O
or	O
fibril	O
.	O

Also	O
provided	O
are	O
methods	O
of	O
treating	O
Alzheimer	O
's	O
disease	O
and	O
diagnostic	O
tests	O
for	O
detecting	O
the	O
presence	O
of	O
amyloid	O
-	O
beta	O
peptides	O
.	O

Methods	O
of	O
treating	O
amyloidoses	O
with	O
vitamin	B
b12	I
and	O
test	O
for	O
detecting	O
amyloid	O
-	O
beta	O
peptides	O

The	O
invention	O
is	O
directed	O
to	O
T	O
cells	O
and	O
other	O
cells	O
that	O
express	O
chimeric	O
NKp30	O
receptors	O
(	O
"	O
chimeric	O
NKp30	O
T	O
cells	O
"	O
)	O
,	O
methods	O
of	O
making	O
and	O
using	O
chimeric	O
NKp30	O
T	O
cells	O
,	O
and	O
methods	O
of	O
using	O
these	O
chimeric	O
NKp30	O
T	O
cells	O
to	O
address	O
diseases	O
and	O
disorders	O
.	O

In	O
one	O
aspect	O
,	O
the	O
disclosure	O
broadly	O
relates	O
to	O
chimeric	O
NKp30	O
T	O
cells	O
,	O
isolated	O
populations	O
thereof	O
,	O
and	O
compositions	O
comprising	O
the	O
same	O
.	O

In	O
another	O
aspect	O
,	O
said	O
chimeric	O
NKp30	O
T	O
cells	O
are	O
further	O
designed	O
to	O
express	O
a	O
functional	O
non	O
-	O
TCR	O
receptor	O
.	O

The	O
disclosure	O
also	O
pertains	O
to	O
methods	O
of	O
making	O
said	O
chimeric	O
NKp30	O
T	O
cells	O
,	O
and	O
methods	O
of	O
reducing	O
or	O
ameliorating	O
,	O
or	O
preventing	O
or	O
treating	O
,	O
diseases	O
and	O
disorders	O
using	O
said	O
chimeric	O
NKp30	O
T	O
cells	O
,	O
populations	O
thereof	O
,	O
or	O
compositions	O
comprising	O
the	O
same	O
.	O

Nkp30	O
receptor	O
targeted	O
therapeutics	O

The	O
present	O
invention	O
provides	O
a	O
method	O
for	O
treating	O
osteoporosis	O
by	O
co-	O
administration	O
of	O
a	O
vitamin	B
D	I
and	O
a	O
3-hydroxy-3-methyl	O
-	O
glutaryl	O
-	O
Co	O
A	O
reductase	O
(	O
HMG	O
Co	O
A	O
reductase	O
)	O
inhibitor	O
.	O

Also	O
provided	O
are	O
compositions	O
and	O
kits	O
useful	O
for	O
treating	O
osteoporosis	O
comprising	O
a	O
vitamin	B
D	I
and	O
an	O
HMG	O
Co	O
A	O
reductase	O
inhibitor	O
.	O

Combination	O
use	O
of	O
vitamin	B
d	I
and	O
hmg	O
coa	O
reductase	O
inhibitor	O
for	O
treating	O
osteoporosis	O

The	O
present	O
invention	O
discloses	O
certain	O
polyene	O
cyclodextrin	O
acetals	O
and	O
hemiacetals	O
that	O
are	O
effective	O
in	O
providing	O
skin	O
clarification	O
,	O
which	O
is	O
useful	O
for	O
the	O
treatment	O
of	O
acne	O
,	O
and	O
skin	O
disfigurements	O
and	O
skin	O
darkening	O
resulting	O
from	O
acne	O
;	O
skin	O
darkening	O
from	O
cancer	O
,	O
diabetes	O
,	O
radiation	O
treatments	O
,	O
chemotherapy	O
,	O
and	O
sun	O
-	O
burn	O
;	O
mitochondrial	O
and	O
DNA	O
dysfunction	O
;	O
age	O
spots	O
;	O
loss	O
of	O
cellular	O
antioxidants	O
;	O
skin	O
changes	O
associated	O
with	O
aging	O
including	O
collagen	O
loss	O
,	O
loss	O
of	O
skin	O
pliability	O
,	O
loss	O
of	O
skin	O
suppleness	O
,	O
skin	O
wrinkles	O
and	O
fine	O
lines	O
,	O
oxidation	O
,	O
damage	O
from	O
radiation	O
,	O
damage	O
from	O
free	O
radicals	O
,	O
and	O
damage	O
from	O
UV	O
;	O
dry	O
skin	O
;	O
xerosis	O
;	O
ichthyosis	O
;	O
dandruff	O
;	O
brownish	O
spots	O
;	O
keratoses	O
;	O
melasma	O
;	O
lentigines	O
;	O
liver	O
spots	O
;	O
skin	O
pigmentation	O
including	O
pigmented	O
spots	O
,	O
dark	O
circles	O
under	O
the	O
eyes	O
,	O
darkened	O
skin	O
,	O
and	O
blemishes	O
;	O
oily	O
skin	O
;	O
warts	O
;	O
eczema	O
;	O
pruritic	O
skin	O
;	O
psoriasis	O
;	O
inflammatory	O
dermatoses	O
;	O
topical	O
inflammation	O
;	O
disturbed	O
keratinization	O
;	O
scalp	O
dryness	O
,	O
and	O
combinations	O
thereof	O
.	O

Retinal	O
cyclodextrin	O
acetals	O
and	O
hemiacetals	O
for	O
clarifying	O
skin	O
complexion	O

Disclosed	O
are	O
compounds	O
with	O
the	O
formula	O
(	O
I	O
)	O
,	O
where	O
R1	O
and	O
R2	O
are	O
as	O
disclosed	O
herein	O
,	O
which	O
are	O
eIF4E	O
inhibitors	O
useful	O
in	O
the	O
treatment	O
of	O
cancers	O
.	O

Also	O
disclosed	O
are	O
compositions	O
comprising	O
the	O
compounds	O
,	O
as	O
well	O
as	O
methods	O
of	O
treating	O
cancer	O
using	O
the	O
compounds	O
.	O

Benzoic	B
acid	I
derivatives	O
as	O
eif4e	O
inhibitors	O

The	O
present	O
disclosure	O
relates	O
to	O
substituted	O
amide	B
compounds	O
that	O
are	O
inhibitors	O
of	O
Fatty	O
Acid	O
Amide	O
Hydrolase	O
(	O
FAAH	O
)	O
,	O
their	O
stereoisomers	O
,	O
tautomers	O
,	O
prodrugs	O
,	O
polymorphs	O
,	O
solvates	O
,	O
pharmaceutically	O
acceptable	O
salts	O
,	O
and	O
pharmaceutical	O
compositions	O
containing	O
them	O
.	O

These	O
compounds	O
are	O
useful	O
in	O
the	O
treatment	O
,	O
prevention	O
,	O
prophylaxis	O
,	O
management	O
,	O
or	O
adjunct	O
treatment	O
of	O
all	O
medical	O
conditions	O
related	O
to	O
inhibition	O
of	O
Fatty	O
Acid	O
Amide	O
Hydrolase	O
(	O
FAAH	O
)	O
,	O
such	O
as	O
pain	O
including	O
acute	O
and	O
post	O
operative	O
pain	O
,	O
chronic	O
pain	O
,	O
cancer	O
pain	O
,	O
cancer	O
chemotherapy	O
induced	O
pain	O
,	O
neuropathic	O
pain	O
,	O
nociceptive	O
pain	O
,	O
inflammatory	O
pain	O
,	O
back	O
pain	O
,	O
pain	O
due	O
to	O
disease	O
of	O
various	O
origin	O
such	O
as	O
:	O
diabetic	O
neuropathy	O
,	O
neurotropic	O
viral	O
disease	O
including	O
human	O
immunodeficient	O
virus	O
(	O
HIV	O
)	O
,	O
herpes	O
zoster	O
such	O
as	O
post	O
herpetic	O
neuralgia	O
;	O
polyneuropathy	O
,	O
neurotoxicity	O
,	O
mechanical	O
nerve	O
injury	O
,	O
carpal	O
tunnel	O
syndrome	O
,	O
immunologic	O
mechanisms	O
like	O
multiple	O
sclerosis	O
;	O
sleep	O
disorders	O
,	O
anxiety	O
and	O
depression	O
disorders	O
,	O
inflammatory	O
disorders	O
,	O
weight	O
and	O
eating	O
disorders	O
,	O
Parkinson	O
's	O
disease	O
,	O
addiction	O
,	O
spasticity	O
,	O
hypertension	O
or	O
other	O
disorders	O
.	O

The	O
disclosure	O
also	O
relates	O
to	O
the	O
process	O
of	O
preparation	O
of	O
the	O
amide	B
compounds	O
.	O

Formula	O
(	O
1	O
)	O
.	O

The	O
present	O
disclosure	O
also	O
relates	O
to	O
methods	O
for	O
the	O
preparation	O
of	O
such	O
compounds	O
,	O
and	O
to	O
pharmaceutical	O
compositions	O
containing	O
them	O
.	O

Amide	B
compounds	O
,	O
compositions	O
and	O
applications	O
thereof	O

The	O
present	O
invention	O
provides	O
a	O
compound	O
comprising	O
a	O
helminth	O
-	O
derived	O
glycan	O
and/or	O
glycoconjugate	O
thereof	O
(	O
e.g.	O
,	O
a	O
compound	O
comprising	O
a	O
Lewisx	O
antigen	O
(	O
e.g.	O
,	O
LNFPIII	O
)	O
,	O
a	O
non	O
-	O
Lewisx	O
antigen	O
(	O
e.g.	O
,	O
LNnT	O
,	O
LDN	O
,	O
and	O
LDN	O
derivatives	O
)	O
,	O
or	O
a	O
mixture	O
of	O
Lewisx	O
and	O
non	O
-	O
Lewisx	O
antigens	O
(	O
e.g.	O
,	O
SEA	O
)	O
)	O
,	O
useful	O
as	O
a	O
therapeutic	O
compound	O
for	O
treating	O
or	O
preventing	O
diseases	O
associated	O
with	O
fat	O
accumulation	O
in	O
the	O
liver	O
.	O

The	O
compounds	O
of	O
the	O
invention	O
are	O
useful	O
for	O
treating	O
or	O
preventing	O
the	O
development	O
of	O
a	O
fatty	O
liver	O
disease	O
in	O
a	O
subject	O
that	O
has	O
the	O
disease	O
or	O
is	O
at	O
risk	O
of	O
developing	O
the	O
disease	O
,	O
and	O
inhibiting	O
lipogenesis	O
in	O
hepatocytes	O
.	O

The	O
invention	O
also	O
provides	O
methods	O
of	O
regulating	O
the	O
Erk	O
-	O
c	O
-	O
fos	O
/	O
AP-1-FXR	O
signalling	O
pathway	O
by	O
administering	O
a	O
compound	O
comprising	O
a	O
helminth	O
-	O
derived	O
glycan	O
and/or	O
glycoconjugate	O
thereof	O
to	O
a	O
subject	O
with	O
a	O
fatty	O
liver	O
disease	O
,	O
or	O
contacting	O
a	O
hepatocyte	O
with	O
a	O
compound	O
comprising	O
a	O
helminth	O
-	O
derived	O
glycan	O
and/or	O
glycoconjugate	O
thereof	O
.	O

Methods	O
of	O
treating	O
fatty	O
liver	O
disease	O
with	O
helminth	O
-	O
derived	O
glycan	O
-	O
containing	O
compounds	O

The	O
present	O
invention	O
relates	O
to	O
a	O
novel	O
chalcone	B
derivative	O
and	O
to	O
an	O
anticancer	O
composition	O
comprising	O
same	O
as	O
an	O
active	O
ingredient	O
.	O

Novel	O
chalcone	B
derivative	O
and	O
anticancer	O
composition	O
comprising	O
same	O
as	O
active	O
ingredient	O

Disclosed	O
is	O
an	O
oral	O
liquid	O
for	O
treating	O
a	O
hepatitis	O
B	O
virus	O
infection	O
,	O
and	O
composed	O
of	O
entecavir	B
,	O
sodium	B
diacetate	I
and	O
water	O
.	O

The	O
content	O
of	O
entecavir	B
is	O
0.001	O
-	O
0.2mg	O
/	O
ml	O
,	O
and	O
the	O
content	O
of	O
sodium	B
diacetate	I
is	O
0.1	O
-	O
10mg	O
/	O
ml	O
.	O

Liquid	O
composition	O
of	O
anti	O
-	O
hepatitis	O
b	O
virus	O

The	O
present	O
invention	O
relates	O
to	O
the	O
use	O
of	O
compounds	O
derived	O
from	O
1,2,3,5-tetrasubstituted	B
pyroles	I
in	O
conjunction	O
with	O
pharmaceutically	O
acceptable	O
excipients	O
in	O
the	O
production	O
of	O
a	O
drug	O
that	O
can	O
be	O
used	O
to	O
treat	O
inflammatory	O
diseases	O
involving	O
processes	O
of	O
cellular	O
apoptosis	O
,	O
preferably	O
diseases	O
arising	O
through	O
sepsis	O
caused	O
by	O
Gramnegative	O
bacteria	O
.	O

Said	O
diseases	O
include	O
acute	O
sepsisinduced	O
pulmonary	O
diseases	O
,	O
acute	O
sepsisinduced	O
respiratory	O
distress	O
syndrome	O
,	O
endotoxic	O
or	O
endotoxemic	O
shock	O
,	O
septic	O
peritonitis	O
or	O
trauma	O
.	O

The	O
invention	O
also	O
comprises	O
the	O
pharmaceutical	O
composition	O
for	O
treating	O
said	O
diseases	O
.	O

Use	O
of	O
a	O
chemical	O
compound	O
derived	O
from	O
a	O
1,2,3,5-tetrasubstituted	B
pyrole	I
in	O
the	O
preparation	O
of	O
a	O
drug	O
for	O
use	O
in	O
treating	O
inflammatory	O
diseases	O
involving	O
processes	O
of	O
cellular	O
apoptosis	O

The	O
present	O
invention	O
relates	O
to	O
a	O
new	O
16-tetrazolyl	B
-	I
eburnamenine	I
of	O
formula	O
(	O
I	O
)	O
or	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
and/or	O
hydrates	O
and/or	O
solvates	O
thereof	O
.	O

The	O
invention	O
also	O
relates	O
to	O
the	O
pharmaceutical	O
compositions	O
containing	O
the	O
compound	O
of	O
formula	O
(	O
I	O
)	O
or	O
hydrates	B
or	O
solvates	O
thereof	O
as	O
active	O
ingredient	O
.	O

The	O
invention	O
also	O
relates	O
to	O
the	O
synthesis	O
of	O
compounds	O
of	O
formula	O
(	O
I	O
)	O
,	O
and	O
the	O
chemical	O
and	O
pharmaceutical	O
manufacture	O
of	O
medicaments	O
containing	O
these	O
compounds	O
,	O
as	O
well	O
as	O
the	O
methods	O
of	O
treatment	O
of	O
mammals	O
-	O
including	O
human	O
-	O
with	O
these	O
compounds	O
.	O

There	O
is	O
still	O
further	O
provided	O
methods	O
for	O
the	O
treatment	O
of	O
neurological	O
,	O
neurodegenerative	O
and	O
psychiatric	O
diseases	O
or	O
conditions	O
as	O
well	O
as	O
comprising	O
the	O
step	O
of	O
administering	O
to	O
human	O
,	O
in	O
need	O
of	O
such	O
treatment	O
and/or	O
prophylaxis	O
a	O
pharmaceutical	O
composition	O
comprising	O
a	O
therapeutically	O
effective	O
amount	O
of	O
compound	O
of	O
formula	O
(	O
I	O
)	O
or	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
alone	O
or	O
together	O
with	O
at	O
least	O
one	O
and	O
a	O
pharmaceutically	O
acceptable	O
carrier	O
and/or	O
diluent	O
.	O

A	O
new	O
diaza	B
-	I
benzofluoranthene	I
derivative	O
as	O
drug	O

A	O
hydroxymethylfurfural	B
derivative	O
represented	O
by	O
general	O
formula	O
(	O
A	O
)	O
.	O

In	O
the	O
formula	O
,	O
R	O
is	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
formula	O
(	O
I	O
)	O
,	O
(	O
II	O
)	O
HOOCCH2COCO-	B
,	O
(	O
III	O
)	O
HOOCCH2CH2COCO-	B
,	O
and	O
(	O
IV	O
)	O
a	O
hydrogen	B
atom	O
.	O

Hydroxymethylfurfural	B
derivative	O

Embodiments	O
of	O
the	O
present	O
disclosure	O
related	O
to	O
compounds	O
and	O
compositions	O
derived	O
from	O
G.	O
buchananii	O
baker	O
and	O
methods	O
thereof	O
.	O

Garcinia	O
buchananii	O
baker	O
compounds	O
,	O
compositions	O
and	O
related	O
methods	O

Pharmaceutical	O
compositions	O
and	O
single	O
unit	O
dosage	O
forms	O
of	O
(	B
+	I
)	I
-2-	I
[	I
l-	I
(	I
3-ethox	I
4-mcthoxy	I
-	I
phcnyl	I
)	I
-2-mcthancsulfonyl	I
-	I
cthyl	I
]	I
-4-acctylaminoisoindolinc	I
-	I
l,3-dionc	I
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
stereoisomer	O
,	O
prodrug	O
,	O
salt	O
,	O
solvate	O
,	O
hydrate	B
,	O
or	O
clathrate	O
5	O
thereof	O
,	O
are	O
provided	O
herein	O
.	O

Also	O
provided	O
are	O
methods	O
of	O
treating	O
,	O
managing	O
,	O
or	O
preventing	O
various	O
diseases	O
or	O
disorders	O
.	O

The	O
compound	O
is	O
known	O
as	O
Apremilast	O
and	O
has	O
the	O
following	O
structural	O
formula	O
:	O
Formulations	O
of	O
(	B
+	I
)	I
-2-	I
[	I
1-	I
(	I
3-ethoxy-4-methoxy	I
-	I
phenyl	I
)	I
-2-methanesulfonyl	I
-	I
ethyl	I
]	I
-4-acetyl	I
aminoisoindoline-1,3-dione	I

Topical	O
formulations	O
comprising	O
an	O
effective	O
amount	O
of	O
menthol	B
in	O
combination	O
with	O
an	O
acidifier	O
,	O
wherein	O
the	O
topical	O
formulation	O
has	O
a	O
pH	O
of	O
about	O
1	O
to	O
3	O
,	O
and	O
methods	O
comprising	O
administration	O
of	O
the	O
same	O
,	O
and	O
use	O
of	O
the	O
topical	O
formulations	O
to	O
treat	O
pain	O
and/or	O
inflammation	O
associated	O
with	O
a	O
skin	O
condition	O
are	O
described	O
.	O

For	O
example	O
,	O
the	O
topical	O
formulation	O
relieves	O
pain	O
,	O
redness	O
,	O
swelling	O
,	O
reduces	O
rash	O
and/or	O
itching	O
relating	O
to	O
skin	O
conditions	O
,	O
such	O
as	O
,	O
but	O
not	O
limited	O
to	O
,	O
any	O
kind	O
of	O
envenomation	O
from	O
stings	O
and/or	O
bites	O
from	O
animals	O
,	O
insects	O
and	O
plants	O
in	O
addition	O
to	O
contact	O
dermatitis	O
,	O
burns	O
,	O
urticaria	O
,	O
rash	O
and	O
other	O
forms	O
of	O
dermatitis	O
.	O

Treatment	O
of	O
pain	O
and/or	O
inflammation	O
including	O
activation	O
and/or	O
stimulation	O
and/or	O
blocking	O
and/or	O
reducing	O
the	O
activity	O
of	O
one	O
or	O
more	O
pain	O
receptors	O
to	O
thereby	O
treat	O
the	O
pain	O
and/or	O
inflammation	O
is	O
described	O
.	O

Formulation	O
and	O
method	O
for	O
treatment	O
of	O
pain	O
and/or	O
inflammation	O
associated	O
with	O
a	O
skin	O
condition	O

A	O
Chinese	O
herbal	O
medicine	O
composition	O
for	O
treating	O
diabetic	O
foot	O
,	O
consisting	O
of	O
the	O
following	O
raw	O
material	O
medicines	O
in	O
parts	O
by	O
weight	O
:	O
1	O
-	O
30	O
parts	O
of	O
scorpion	O
,	O
1	O
-	O
30	O
parts	O
of	O
lithargite	O
,	O
1	O
-	O
30	O
parts	O
of	O
centipede	O
,	O
1	O
-	O
20	O
parts	O
of	O
borneol	B
,	O
1	O
-	O
20	O
parts	O
of	O
cirsium	O
japonicum	O
,	O
1	O
-	O
20	O
parts	O
of	O
pangolin	O
,	O
1	O
-	O
20	O
parts	O
of	O
castor	O
beans	O
,	O
1	O
-	O
20	O
parts	O
of	O
garden	O
burnet	O
,	O
and	O
1	O
-	O
20	O
parts	O
of	O
safflower	O
.	O

The	O
composition	O
has	O
the	O
effects	O
of	O
clearing	O
heat	O
and	O
detoxicating	O
,	O
eliminating	O
necrotic	O
tissue	O
and	O
promoting	O
granulation	O
,	O
stimulating	O
blood	O
circulation	O
and	O
removing	O
blood	O
stasis	O
,	O
warming	O
and	O
activating	O
arteries	O
and	O
veins	O
,	O
and	O
reducing	O
swelling	O
and	O
stopping	O
pain	O
,	O
and	O
is	O
used	O
to	O
treat	O
nerve	O
patho	O
-	O
type	O
,	O
artery	O
ischemia	O
-	O
type	O
and	O
mixed	O
-	O
type	O
diabetic	O
foot	O
with	O
the	O
symptoms	O
of	O
foot	O
muscular	O
atrophy	O
,	O
deformity	O
,	O
skin	O
infection	O
,	O
purulence	O
,	O
rhagades	O
and	O
ulcers	O
,	O
and	O
toe	O
tip	O
ulcers	O
and	O
gangrene	O
.	O

Chinese	O
herbal	O
medicine	O
composition	O
for	O
treating	O
diabetic	O
foot	O

The	O
present	O
invention	O
relates	O
to	O
an	O
effervescent	O
pharmaceutical	O
formulation	O
comprising	O
a	O
combination	O
of	O
pregabalin	B
and	O
vitamin	B
B12	I
and	O
use	O
of	O
this	O
formulation	O
in	O
the	O
treatment	O
of	O
epilepsy	O
,	O
central	O
nervous	O
system	O
disorders	O
,	O
Parkinson	O
's	O
disease	O
;	O
Huntington	O
's	O
disease	O
;	O
tardive	O
dyskinesia	O
;	O
spasticity	O
;	O
cerebral	O
ischemia	O
;	O
postherpetic	O
neuralgia	O
;	O
social	O
phobia	O
;	O
fibromyalgia	O
and	O
spinal	O
cord	O
injury	O
induced	O
chronic	O
pains	O
;	O
neuropathic	O
pains	O
associated	O
with	O
diabetic	O
peripheral	O
neuropathy	O
and	O
common	O
anxiety	O
disorder	O
and	O
in	O
treatment	O
and/or	O
prevention	O
of	O
anemia	O
diseases	O
such	O
as	O
macrocytic	O
anemia	O
,	O
megaloblastic	O
anemia	O
and	O
pernicious	O
anemia	O
.	O

Effervescent	O
pharmaceutical	O
formulations	O
comprising	O
pregabalin	B
and	O
vitamin	B
b12	I

A	O
class	O
of	O
enzymatically	O
generated	O
electrophilic	O
fatty	B
acid	I
derivatives	O
(	O
EFADs	O
)	O
,	O
or	O
their	O
enzymatically	O
generated	O
metabolites	O
.	O

The	O
EFAD	O
's	O
and	O
their	O
metabolites	O
have	O
beneficial	O
effects	O
human	O
health	O
.	O

According	O
to	O
the	O
inventors	O
the	O
inventive	O
keto	B
fatty	I
acids	I
or	O
their	O
enzymatically	O
generated	O
metabolites	O
,	O
can	O
inhibit	O
inflammation	O
by	O
giving	O
rise	O
to	O
adaptive	O
signaling	O
molecules	O
in	O
vivo	O
.	O

Fatty	B
acids	I
as	O
anti	O
-	O
inflammatory	O
agents	O

An	O
alcohol	B
based	O
suspension	O
formulation	O
including	O
a	O
therapeutically	O
effective	O
amount	O
of	O
at	O
least	O
one	O
ionophore	O
antibiotic	O
in	O
an	O
organic	O
liquid	O
phase	O
including	O
at	O
least	O
one	O
polyol	O
and	O
benzyl	B
alcohol	I
and	O
at	O
least	O
one	O
or	O
more	O
of	O
at	O
least	O
one	O
anionic	O
and/or	O
non	O
-	O
ionic	O
surfactant	O
;	O
at	O
least	O
one	O
stabilising	O
agent	O
or	O
water	O
in	O
an	O
amount	O
of	O
less	O
than	O
or	O
equal	O
to	O
15	O
%	O
v	O
/	O
v	O
of	O
the	O
total	O
formulation	O
.	O

Methods	O
of	O
manufacture	O
of	O
the	O
formulation	O
are	O
also	O
described	O
along	O
with	O
methods	O
of	O
use	O
for	O
selected	O
treatments	O
.	O

Ionophore	O
antibiotic	O
suspension	O

The	O
present	O
invention	O
relates	O
to	O
certain	O
compounds	O
(	O
e.g.	O
,	O
imidazopyrazine	B
,	O
imidazopyridine	B
,	O
imidazopyridazine	B
and	O
imidazpyrimidine	B
compounds	O
)	O
that	O
act	O
as	O
inhibitors	O
of	O
the	O
MAP	O
kinase	O
interacting	O
kinases	O
MNK2a	O
,	O
MNK2b	O
,	O
MNK1a	O
,	O
and	O
MNK1b	O
.	O

The	O
present	O
invention	O
further	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
these	O
compounds	O
,	O
and	O
to	O
the	O
use	O
of	O
the	O
compounds	O
for	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
the	O
prophylaxis	O
and	O
treatment	O
of	O
diseases	O
(	O
e.g.	O
,	O
proliferative	O
diseases	O
(	O
e.g.	O
,	O
cancer	O
)	O
,	O
inflammatory	O
diseases	O
,	O
Alzheimer	O
's	O
disease	O
)	O
,	O
as	O
well	O
as	O
methods	O
of	O
treating	O
these	O
diseases	O
.	O

Bicyclic	B
heterocyclic	I
derivatives	O
as	O
mnk1	O
and	O
mnk2	O
modulators	O
and	O
uses	O
thereof	O

Invented	O
is	O
a	O
method	O
of	O
treating	O
steroid	B
responsive	O
dermatoses	O
in	O
a	O
mammal	O
,	O
including	O
a	O
human	O
,	O
in	O
need	O
thereof	O
which	O
comprises	O
the	O
administration	O
of	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
compound	O
selected	O
from	O
the	O
group	O
consisting	O
of	O
:	O
N-	B
{	I
(	I
1S	I
)	I
-2-Amino-1-	I
[	I
(	I
3-fluorophenyl	I
)	I
methyl	I
]	I
ethyl	I
}	I
-5-chloro-4-	I
(	I
4-chloro-1-methyl-1H	I
-	I
pyrazol-5-yl	I
)	I
-2-thiophenecarboxamide	I
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
and	O
the	O
compound	O
N-	O
{	B
(	I
1S	I
)	I
-2-amino-1-	I
[	I
(	I
3,4-difluorophenyl	I
)	I
methyl	I
]	I
ethyl	I
}	I
-5-chloro-4-	I
(	I
4-chloro-1-methyl-1H	I
-	I
pyrazol-5-yl	I
)	I
-2-	I
furancarboxamide	I
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
to	O
such	O
mammal	O
.	O

Treatment	O
method	O
for	O
steroid	B
responsive	O
dermatoses	O

The	O
present	O
invention	O
relates	O
to	O
pyrrolopyridinone	B
derivatives	O
which	O
have	O
blocking	O
activities	O
of	O
voltage	O
gated	O
sodium	B
channels	O
as	O
the	O
TTX	O
-	O
S	O
channels	O
,	O
and	O
which	O
are	O
useful	O
in	O
the	O
treatment	O
or	O
prevention	O
of	O
disorders	O
and	O
diseases	O
in	O
which	O
voltage	O
gated	O
sodium	O
channels	O
are	O
involved	O
.	O

The	O
invention	O
also	O
relates	O
to	O
pharmaceutical	O
compositions	O
comprising	O
these	O
compounds	O
and	O
the	O
use	O
of	O
these	O
compounds	O
and	O
compositions	O
in	O
the	O
prevention	O
or	O
treatment	O
of	O
such	O
diseases	O
in	O
which	O
voltage	O
gated	O
sodium	B
channels	O
are	O
involved	O
.	O

Pyrrolopyridinone	B
derivatives	O
as	O
ttx	O
-	O
s	O
blockers	O

The	O
current	O
disclosure	O
describes	O
materials	O
and	O
methods	O
for	O
identifying	O
subjects	O
that	O
would	O
benefit	O
from	O
treatment	O
with	O
a	O
DNA	O
topoisomerase	O
1	O
inhibitor	O
,	O
based	O
on	O
the	O
levels	O
of	O
cullin	O
4B	O
gene	O
,	O
RNA	O
and	O
protein	O
levels	O
in	O
the	O
subject	O
.	O

The	O
disclosure	O
identifies	O
CUL4B	O
as	O
a	O
predictive	O
biomarker	O
for	O
cancer	O
diagnosis	O
and	O
the	O
subsequent	O
treatment	O
with	O
directed	O
therapeutic	O
agents	O
.	O

The	O
current	O
disclosure	O
also	O
identifies	O
novel	O
therapeutic	O
agents	O
that	O
modulate	O
the	O
level	O
of	O
CUL4B	O
expression	O
,	O
and	O
sensitize	O
a	O
subject	O
to	O
treatment	O
with	O
a	O
second	O
therapeutic	O
agent	O
.	O

Cul4b	O
as	O
predictive	O
biomarker	O
for	O
cancer	O
treatment	O

The	O
problem	O
to	O
be	O
solved	O
by	O
the	O
present	O
invention	O
is	O
to	O
provide	O
an	O
excellent	O
prophylactic	O
agent	O
and/or	O
an	O
excellent	O
therapeutic	O
agent	O
for	O
stress	O
urinary	O
incontinence	O
.	O

The	O
present	O
invention	O
provides	O
a	O
prophylactic	O
agent	O
and/or	O
a	O
therapeutic	O
agent	O
for	O
stress	O
urinary	O
incontinence	O
,	O
which	O
comprises	O
an	O
effective	O
amount	O
of	O
4-piperidyldiphenylpropoxyacetate	B
or	O
a	O
salt	O
thereof	O
and	O
a	O
pharmaceutical	O
carrier	O
.	O

Prophylactic	O
agent	O
and/or	O
therapeutic	O
agent	O
for	O
stress	O
urinary	O
incontinence	O

Aspects	O
of	O
the	O
invention	O
provide	O
single	O
stranded	O
oligonucleotides	B
for	O
activating	O
or	O
enhancing	O
expression	O
of	O
hemoglobin	O
genes	O
(	O
HBB	O
,	O
HBD	O
,	O
HBEl	O
,	O
HBG1	O
or	O
HBG2	O
)	O
.	O

Further	O
aspects	O
provide	O
compositions	O
and	O
kits	O
comprising	O
single	O
stranded	O
oligonucleotides	B
for	O
activating	O
or	O
enhancing	O
expression	O
of	O
hemoglobin	O
genes	O
.	O

Methods	O
for	O
modulating	O
expression	O
of	O
hemoglobin	O
genes	O
using	O
the	O
single	O
stranded	O
oligonucleotides	B
are	O
also	O
provided	O
.	O

Further	O
aspects	O
of	O
the	O
invention	O
provide	O
methods	O
for	O
selecting	O
a	O
candidate	O
oligonucleotide	B
for	O
activating	O
or	O
enhancing	O
expression	O
of	O
hemoglobin	O
genes	O
.	O

Compositions	O
and	O
methods	O
for	O
modulating	O
hemoglobin	O
gene	O
family	O
expression	O

Disclosed	O
are	O
the	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
or	O
its	O
pharmaceutically	O
acceptable	O
salts	O
.	O

The	O
pharmaceutical	O
compositions	O
comprising	O
an	O
effective	O
amount	O
of	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
useful	O
for	O
the	O
treatment	O
of	O
periodontitis	O
and	O
rheumatoid	O
arthritis	O
may	O
be	O
formulated	O
for	O
oral	O
,	O
buccal	O
,	O
rectal	O
,	O
topical	O
,	O
transdermal	O
,	O
transmucosal	O
,	O
intravenous	O
,	O
parenteral	O
administration	O
,	O
syrup	O
or	O
injection	O
.	O

Compositions	O
and	O
methods	O
for	O
treatment	O
of	O
peridontitis	O
and	O
rheumatoid	O
arthritis	O

Disclosed	O
are	O
polyoxopregnane	B
compounds	O
and	O
the	O
use	O
of	O
the	O
compounds	O
for	O
the	O
manufacture	O
of	O
medicaments	O
reversing	O
or	O
inhibiting	O
mutidrug	O
resistance	O
of	O
tumor	O
cells	O
.	O

Polyoxopregnane	B
compounds	O
and	O
use	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
uses	O
for	O
:	O
restricting	O
apoptosis	O
of	O
miRNA	O
of	O
Epstein	O
-	O
Barr	O
virus	O
,	O
especially	O
miR	O
-	O
BART3	O
-	O
5p	O
,	O
miR	O
-	O
BART3	O
-	O
3p	O
,	O
miR	O
-	O
BART21	O
-	O
5p	O
,	O
miR	O
-	O
BART21	O
-	O
3p	O
,	O
miR	O
-	O
BART18	O
-	O
5p	O
,	O
miR	O
-	O
BART18	O
-	O
3p	O
,	O
miR	O
-	O
BART7	O
-	O
5p	O
,	O
miR	O
-	O
BART7	O
-	O
3p	O
,	O
miR	O
-	O
BART8	O
-	O
5p	O
,	O
miR	O
-	O
BART8	O
-	O
3p	O
,	O
miR	O
-	O
BART9	O
-	O
5p	O
,	O
miR	O
-	O
BART22	O
-	O
5p	O
,	O
miR	O
-	O
BART22	O
-	O
3p	O
,	O
miR	O
-	O
BART19	O
-	O
5p	O
,	O
miR	O
-	O
BART19	O
-	O
3p	O
,	O
miR	O
-	O
BART13	O
-	O
5p	O
,	O
miR	O
-	O
BART13	O
-	O
3p	O
,	O
miR	O
-	O
BART14	O
-	O
5p	O
,	O
miR	O
-	O
BART2	O
-	O
3p	O
,	O
miR	O
-	O
BART1	O
-	O
3p	O
,	O
miR	O
-	O
BART9	O
-	O
3p	O
,	O
miR	O
-	O
BART10	O
-	O
5p	O
,	O
miR	O
-	O
BART10	O
-	O
3p	O
,	O
miR	O
-	O
BART14	O
-	O
3p	O
and	O
their	O
mimics	O
;	O
and	O
promoting	O
cell	O
proliferation	O
.	O

Composition	O
for	O
restricting	O
apoptosis	O
,	O
including	O
mirna	O
of	O
epstein	O
-	O
barr	O
virus	O
,	O
or	O
promoting	O
cell	O
proliferation	O

Provided	O
herein	O
are	O
novel	O
compositions	O
and	O
methods	O
to	O
inhibit	O
Olig2	O
activity	O
.	O

The	O
Olig2	O
inhibitors	O
and	O
methods	O
of	O
using	O
the	O
same	O
are	O
useful	O
,	O
inter	O
alia	O
,	O
for	O
treating	O
cancer	O
.	O

In	O
particular	O
the	O
Olig2	O
inhibitors	O
may	O
be	O
used	O
to	O
treat	O
glioblastoma	O
.	O

Further	O
,	O
provided	O
are	O
peptide	O
compositions	O
capable	O
of	O
inhibiting	O
Olig	O
2	O
.	O

Novel	O
therapeutics	O
for	O
brain	O
cancer	O

A	O
method	O
for	O
treating	O
a	O
neuroendocrine	O
tumor	O
,	O
particularly	O
pancreatic	O
neuroendocrine	O
tumor	O
,	O
comprising	O
administering	O
to	O
a	O
subject	O
in	O
need	O
thereof	O
a	O
therapeutically	O
effective	O
amount	O
of	O
a	O
compound	O
of	O
formula	O
(	O
I	O
)	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
alone	O
or	O
in	O
combination	O
with	O
at	O
least	O
one	O
therapeutic	O
agent	O
,	O
wherein	O
said	O
neuroendocrine	O
tumor	O
is	O
resistant	O
or	O
refractory	O
to	O
treatment	O
with	O
at	O
least	O
one	O
mTOR	O
inhibitor	O
;	O
uses	O
of	O
said	O
compounds	O
for	O
the	O
preparation	O
of	O
a	O
medicament	O
for	O
use	O
in	O
the	O
treatment	O
of	O
a	O
neuroendocrine	O
tumor	O
resistant	O
or	O
refractory	O
to	O
treatment	O
with	O
at	O
least	O
one	O
mTOR	O
inhibitor	O
;	O
uses	O
of	O
said	O
compound	O
for	O
treating	O
said	O
disease	O
;	O
and	O
related	O
pharmaceutical	O
compositions	O
and	O
pharmaceutical	O
package	O
thereof	O
.	O

Neuroendocrine	O
tumor	O
treatment	O

The	O
method	O
which	O
is	O
the	O
subject	O
matter	O
of	O
the	O
present	O
invention	O
provides	O
a	O
quantitative	O
and	O
qualitative	O
production	O
method	O
for	O
the	O
chemical	O
compound	O
known	O
as	O
trans	B
-	I
pinocarvyl	I
acetate	I
.	O

This	O
compound	O
has	O
relevant	O
applications	O
in	O
the	O
chemical	O
and	O
cosmetic	O
industries	O
for	O
producing	O
perfumes	O
and	O
fragrances	O
.	O

The	O
method	O
which	O
is	O
the	O
subject	O
matter	O
of	O
the	O
present	O
invention	O
also	O
provides	O
nanoemulsions	O
containing	O
essential	O
oil	O
of	O
Microlicia	O
graveolens	O
,	O
thus	O
making	O
its	O
use	O
possible	O
.	O

Method	O
for	O
obtaining	O
high	O
concentrations	O
of	O
the	O
chemical	O
constituent	O
trans	B
-	I
pinocarvyl	I
acetate	I
by	O
hydrodistillation	O
of	O
the	O
aerial	O
parts	O
of	O
microlicia	O
graveolens	O
and	O
obtaining	O
nano	O
-	O
emulsified	O
formulations	O

The	O
invention	O
provides	O
compositions	O
and	O
methods	O
for	O
treating	O
or	O
preventing	O
cancer	O
with	O
an	O
inventive	O
composition	O
.	O
'	O

The	O
invention	O
relates	O
to	O
the	O
fields	O
of	O
biomedicine	O
,	O
pharmacology	O
,	O
and	O
molecular	O
biology	O
.	O

Novel	O
fatty	B
acid	I
-	I
salicylate	I
conjugates	O
with	O
enhanced	O
therapeutic	O
properties	O

Disclosed	O
are	O
novel	O
heteroaryl	B
and	O
heterocycle	B
compounds	O
of	O
formula	O
I-1	O
,	O
I-2	O
or	O
I-3	O
and	O
pharmaceutical	O
compositions	O
comprising	O
them	O
,	O
uses	O
and	O
methods	O
thereof	O
for	O
inhibiting	O
the	O
activity	O
of	O
PI3	O
K	O
and	O
for	O
treating	O
inflammatory	O
and	O
autoimmune	O
diseases	O
and	O
cancer	O
.	O

Novel	O
heteroaryl	B
and	O
heterocycle	B
compounds	O
,	O
composition	O
and	O
methods	O
thereof	O

The	O
present	O
invention	O
relates	O
to	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
wherein	O
Ar1	O
/	O
Ar2	O
are	O
phenyl	B
or	O
a	O
5	O
or	O
6-membered	O
heteroaryl	B
;	O
R1	O
/	O
R2	O
is	O
hydrogen	B
,	O
halogen	B
,	O
lower	O
alkyl	B
,	O
CF3	B
or	O
lower	O
alkoxy	B
;	O
n	O
,	O
m	O
are	O
1	O
or	O
2	O
;	O
or	O
to	O
a	O
pharmaceutically	O
acceptable	O
acid	O
addition	O
salt	O
,	O
to	O
a	O
racemic	O
mixture	O
or	O
to	O
its	O
corresponding	O
enantiomer	O
and/or	O
optical	O
isomers	O
thereof	O
,	O
with	O
the	O
exception	O
of	O
the	O
compound	O
2,1-benzisoxazole,3-	O
(	B
4-chlorophenyl	I
)	I
-5-	I
(	I
1-phenyl-1H	I
-	I
pyrazol-5-yl	I
)	I
-	I
.	O

The	O
compounds	O
may	O
be	O
used	O
for	O
the	O
treatment	O
of	O
schizophrenia	O
,	O
obsessive	O
-	O
compulsive	O
personality	O
disorder	O
,	O
major	O
depression	O
,	O
bipolar	O
disorders	O
,	O
anxiety	O
disorders	O
,	O
normal	O
aging	O
,	O
epilepsy	O
,	O
retinal	O
degeneration	O
,	O
traumatic	O
brain	O
injury	O
,	O
spinal	O
cord	O
injury	O
,	O
post	O
-	O
traumatic	O
stress	O
disorder	O
,	O
panic	O
disorder	O
,	O
Parkinson	O
's	O
disease	O
,	O
dementia	O
,	O
Alzheimer	O
's	O
disease	O
,	O
mild	O
cognitive	O
impairment	O
,	O
chemotherapy	O
-	O
induced	O
cognitive	O
dysfunction	O
,	O
Down	O
syndrome	O
,	O
autism	O
spectrum	O
disorders	O
,	O
hearing	O
loss	O
,	O
tinnitus	O
,	O
spinocerebellar	O
ataxia	O
,	O
amyotrophic	O
lateral	O
sclerosis	O
,	O
multiple	O
sclerosis	O
,	O
Huntington	O
's	O
disease	O
,	O
stroke	O
,	O
radiation	O
therapy	O
,	O
chronic	O
stress	O
,	O
abuse	O
of	O
neuro	O
-	O
active	O
drugs	O
,	O
such	O
as	O
alcohol	B
,	O
opiates	O
,	O
methamphetamine	B
,	O
phencyclidine	B
and	O
cocaine	B
.	O

Benzisoxazole	B
modulators	O
of	O
neurogenesis	O

The	O
present	O
invention	O
relates	O
to	O
Substituted	O
Naphthyridinedione	B
Derivatives	O
and	O
pharmaceutically	O
acceptable	O
salts	O
thereof	O
.	O

The	O
present	O
invention	O
also	O
relates	O
to	O
compositions	O
comprising	O
at	O
least	O
one	O
Substituted	O
Naphthyridinedione	B
Derivative	O
,	O
and	O
methods	O
of	O
using	O
the	O
Substituted	O
Naphthyridinedione	B
Derivatives	O
for	O
treating	O
or	O
preventing	O
HIV	O
infection	O
in	O
a	O
subject	O
.	O

Substituted	O
naphthyridinedione	B
derivatives	O
as	O
hiv	O
integrase	O
inhibitors	O

Provided	O
is	O
a	O
piperazinotrizole	B
compound	O
represented	O
by	O
general	O
formula	O
I	O
or	O
an	O
isomer	O
,	O
a	O
pharmaceutically	O
acceptable	O
salt	O
,	O
ester	O
,	O
prodrug	O
or	O
hydrate	O
thereof	O
.	O

Also	O
provided	O
are	O
a	O
method	O
for	O
preparing	O
the	O
compound	O
,	O
a	O
drug	O
composition	O
containing	O
the	O
compound	O
,	O
and	O
a	O
use	O
thereof	O
as	O
a	O
high	O
-	O
selectivity	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase-1	O
(	O
PARP1	O
)	O
inhibitor	O
in	O
the	O
preparation	O
of	O
drugs	O
for	O
the	O
prevention	O
and/or	O
treatment	O
of	O
PARP	O
-	O
related	O
diseases	O
.	O

Piperazinotrizole	B
compound	O
,	O
preparation	O
method	O
therefor	O
,	O
and	O
use	O
thereof	O
in	O
drug	O
preparation	O

The	O
use	O
of	O
ORL-1	O
receptor	O
antagonists	O
of	O
the	O
formula	O
(	O
I	O
)	O
for	O
the	O
treatment	O
of	O
anxiety	O
disorders	O
is	O
described	O
.	O

Orl-1	O
receptor	O
antagonists	O
for	O
the	O
treatment	O
of	O
anxiety	O

Compounds	O
of	O
the	O
formula	O
(	O
I	O
)	O
,	O
in	O
which	O
R1	O
,	O
X	O
,	O
Y	O
and	O
n	O
have	O
the	O
meanings	O
indicated	O
in	O
Claim	O
1	O
,	O
are	O
inhibitors	O
of	O
Tankyrase	O
,	O
and	O
can	O
be	O
employed	O
,	O
inter	O
alia	O
,	O
for	O
the	O
treatment	O
of	O
diseases	O
such	O
as	O
cancer	O
,	O
cardiovascular	O
diseases	O
,	O
central	O
nervous	O
system	O
injury	O
and	O
different	O
forms	O
of	O
inflammation	O
.	O

(	B
aza-	I
)	I
isoquinolinone	I
derivatives	O

The	O
invention	O
relates	O
to	O
buffer	O
substances	O
for	O
the	O
phase	O
-	O
appropriate	O
treatment	O
of	O
wounds	O
,	O
said	O
treatment	O
comprising	O
the	O
suppression	O
of	O
fibrin	O
formation	O
and/or	O
fibrin	O
cross	O
-	O
linking	O
.	O

The	O
invention	O
further	O
relates	O
to	O
a	O
wound	O
dressing	O
product	O
containing	O
said	O
buffer	O
substances	O
to	O
suppress	O
fibrin	O
formation	O
and/or	O
fibrin	O
cross	O
-	O
linking	O
.	O

Buffer	O
substance	O
for	O
the	O
treatment	O
of	O
wounds	O

The	O
present	O
invention	O
discloses	O
a	O
method	O
of	O
diagnosing	O
glomerular	O
kidney	O
disease	O
or	O
the	O
risk	O
of	O
glomerular	O
kidney	O
disease	O
comprising	O
determining	O
the	O
expression	O
level	O
of	O
miRNA	O
miR-193a	O
,	O
wherein	O
said	O
glomerular	O
kidney	O
disease	O
or	O
risk	O
thereof	O
is	O
detected	O
if	O
miR-193a	O
expression	O
levels	O
are	O
increased	O
as	O
compared	O
to	O
a	O
healthy	O
control	O
,	O
method	O
of	O
prophylactically	O
treating	O
a	O
glomerular	O
kidney	O
disease	O
or	O
of	O
reducing	O
the	O
risk	O
of	O
glomerular	O
kidney	O
disease	O
progression	O
in	O
a	O
patient	O
comprising	O
inhibiting	O
miR-193a	O
in	O
a	O
podocyte	O
cell	O
in	O
said	O
patient	O
and	O
suitable	O
means	O
for	O
said	O
methods	O
.	O

Therapeutic	O
and	O
diagnostic	O
mirna	O
regulator	O
in	O
kidney	O
disease	O

The	O
subject	O
of	O
the	O
invention	O
is	O
a	O
group	O
of	O
preventive	O
products	O
to	O
be	O
used	O
against	O
pathogenic	O
germs	O
,	O
and	O
the	O
method	O
for	O
using	O
these	O
products	O
,	O
each	O
product	O
is	O
being	O
a	O
special	O
combined	O
additive	O
for	O
preventive	O
purposes	O
,	O
which	O
could	O
be	O
used	O
as	O
additive	O
or	O
supplementary	O
material	O
in	O
animal	O
feed	O
to	O
produce	O
products	O
primarily	O
for	O
preventing	O
and	O
treating	O
bacterial	O
infection	O
of	O
poultry	O
,	O
which	O
selectively	O
inhibit	O
the	O
propagation	O
of	O
pathogenic	O
germs	O
that	O
generate	O
endo	O
and	O
exo	O
toxins	O
.	O

The	O
product	O
according	O
to	O
the	O
invention	O
suitable	O
primarily	O
for	O
preventing	O
and	O
treating	O
bacterial	O
contamination	O
of	O
poultry	O
.	O

It	O
is	O
charactrised	O
by	O
that	O
,	O
the	O
product	O
is	O
prepared	O
by	O
homogenizing	O
or	O
blending	O
methylglyoxal	B
or	O
its	O
diacetate	B
,	O
i.e.	O
methylglyoxal	B
diacetate	I
with	O
some	O
organic	O
acids	O
and/or	O
in	O
combination	O
with	O
Na	B
salts	O
of	O
organic	O
acids	O
.	O

During	O
the	O
method	O
according	O
to	O
the	O
invention	O
the	O
product	O
is	O
added	O
to	O
the	O
drinking	O
water	O
of	O
the	O
animals	O
and/or	O
mixed	O
in	O
the	O
feed	O
,	O
and	O
in	O
this	O
way	O
it	O
is	O
administered	O
to	O
the	O
animals	O
,	O
and/or	O
used	O
for	O
disinfecting	O
the	O
bedding	O
materials	O
.	O

Preventive	O
products	O
against	O
pathogenic	O
germs	O
,	O
and	O
method	O
for	O
use	O
thereof	O

Compounds	O
of	O
Formula	O
(	O
I	O
)	O
,	O
their	O
preparation	O
and	O
use	O
in	O
preventing	O
or	O
treating	O
bacterial	O
infections	O
are	O
disclosed	O
.	O

1,6-	B
diazabicyclo	I
[	I
3,2,1	I
]	I
octan-	I
7-	I
one	I
derivatives	O
and	O
their	O
use	O
in	O
the	O
treatment	O
of	O
bacterial	O
infections	O

Compounds	O
of	O
Formula	O
I	O
are	O
useful	O
inhibitors	O
of	O
tankyrase	O
.	O

Compounds	O
of	O
Formula	O
I	O
have	O
the	O
following	O
structure	O
:	O
where	O
the	O
definitions	O
of	O
the	O
variables	O
are	O
provided	O
herein	O
.	O

Quinazolinone	B
compounds	O
and	O
derivatives	O
thereof	O

The	O
invention	O
relates	O
to	O
compositions	O
and	O
methods	O
for	O
improving	O
memory	O
and	O
related	O
functions	O
as	O
alertness	O
,	O
attention	O
,	O
concentration	O
,	O
learning	O
,	O
and	O
language	O
processing	O
.	O

More	O
particularly	O
,	O
the	O
invention	O
relates	O
to	O
compositions	O
comprising	O
at	O
least	O
two	O
drugs	O
selected	O
from	O
cinacalcet	B
,	O
baclofen	B
,	O
acamprosate	O
,	O
mexiletine	O
,	O
sulfisoxazole	B
and	O
torasemide	B
useful	O
to	O
enhance	O
memory	O
and	O
related	O
functions	O
in	O
healthy	O
subjects	O
or	O
subjects	O
suffering	O
from	O
conditions	O
or	O
disorders	O
having	O
a	O
negative	O
impact	O
on	O
their	O
memory	O
.	O

Nootropic	O
compositions	O
for	O
improving	O
memory	O
performance	O

An	O
object	O
is	O
to	O
provide	O
means	O
for	O
improving	O
the	O
solubility	O
of	O
luliconazole	B
.	O

Disclosed	O
is	O
a	O
crystal	O
of	O
luliconazole	B
wherein	O
the	O
crystal	O
has	O
such	O
a	O
crystal	O
habit	O
that	O
(	O
021	O
)	O
plane	O
is	O
a	O
specific	O
crystal	O
growth	O
plane	O
.	O

Crystal	O
having	O
crystal	O
habits	O
and	O
pharmaceutical	O
composition	O
obtained	O
by	O
processing	O
the	O
crystal	O

The	O
present	O
invention	O
relates	O
to	O
novel	O
cross	O
-	O
linkers	O
for	O
hydrogels	O
,	O
in	O
particular	O
for	O
hyaluronan	O
hydrogels	O
,	O
corresponding	O
hydrogels	O
including	O
said	O
cross	O
-	O
linkers	O
and	O
various	O
applications	O
thereof	O
.	O

The	O
cross	O
linker	O
of	O
the	O
invention	O
is	O
a	O
bi-	O
or	O
multifunctional	O
cross	O
-	O
linker	O
comprising	O
or	O
consisting	O
of	O
an	O
aromatic	B
or	O
heteroaromatic	B
ring	O
system	O
with	O
3	O
-	O
6	O
C	B
atoms	O
which	O
is	O
coupled	O
via	O
functional	O
groups	O
on	O
at	O
least	O
2	O
ring	O
positions	O
with	O
at	O
least	O
2	O
terminal	O
groups	O
capable	O
to	O
form	O
a	O
covalent	O
bond	O
with	O
thiol	B
or	O
amino	B
groups	O
,	O
in	O
particular	O
with	O
thiol	B
groups	O
in	O
a	O
thiol	B
-	I
en	I
reaction	O
.	O

The	O
cross	O
-	O
linker	O
may	O
be	O
charged	O
or	O
uncharged	O
.	O

In	O
a	O
specific	O
embodiment	O
,	O
the	O
terminal	O
groups	O
are	O
coupled	O
to	O
carboxy	B
groups	O
of	O
the	O
aromatic	B
or	O
heteroaromatic	B
ring	O
system	O
via	O
an	O
ester	B
or	O
amide	B
bond	O
.	O

More	O
specifically	O
,	O
the	O
cross	O
-	O
linker	O
of	O
the	O
invention	O
is	O
a	O
derivative	O
of	O
pyridine-3	B
,	I
5-dicarboxylic	I
acid	I
or	O
a	O
corresponding	O
pyridinium	B
salt	O
thereof	O
wherein	O
2	O
terminal	O
groups	O
are	O
coupled	O
to	O
the	O
carboxy	O
groups	O
of	O
the	O
pyridine	B
or	O
pyridinium	B
core	O
via	O
an	O
ester	B
or	O
amide	B
bond	O
.	O

In	O
a	O
preferred	O
embodiment	O
,	O
the	O
cross	O
-	O
linker	O
is	O
N3,N5-bis	B
(	I
2-acrylamidoethyl	I
)	I
pyridine-3	I
,	I
5-dicarboxamide	I
or	O
a	O
3,5-bis	B
(	I
(	I
2-acrylamidoethyl	I
)	I
carbamoyl	I
)	I
-1-methylpyridin	I
-	I
l	I
-	I
ium	I
-	I
halogenide	I
.	O

"	O
novel	O
cross	O
-	O
linkers	O
for	O
hydrogels	O
,	O
hydrogels	O
including	O
these	O
cross	O
-	O
linkers	O
and	O
applications	O
thereof	O
"	O

The	O
present	O
invention	O
relates	O
to	O
a	O
composition	O
comprising	O
a	O
compound	O
of	O
the	O
formula	O
I	O
for	O
use	O
as	O
a	O
medicament	O
,	O
wherein	O
R1	O
is	O
methyl	B
or	O
hydrogen	B
,	O
and	O
wherein	O
R2	O
is	O
methyl	B
or	O
hydrogen	B
.	O

The	O
invention	O
furthermore	O
relates	O
to	O
food	O
ingredients	O
and	O
food	O
products	O
comprising	O
a	O
compound	O
of	O
the	O
formula	O
I.	O
The	O
invention	O
also	O
relates	O
to	O
processes	O
for	O
producing	O
compounds	O
of	O
the	O
formula	O
I.	O
Dihydroferulic	B
acid	I
and/or	O
dihydrocaffeic	B
acid	I
for	O
use	O
in	O
the	O
treatment	O
of	O
metabolic	O
diseases	O

The	O
subject	O
of	O
the	O
present	O
invention	O
is	O
n	O
-	B
acyl	I
derivatives	O
of	O
aminoacyl-2-cyanopyrrolidine	O
-	O
inhibitors	O
of	O
prolyl	O
endopeptidase	O
and	O
dipeptidyl	O
peptidase	O
-	O
iv	O
,	O
having	O
hypoglycemic	O
,	O
antihypoxic	O
,	O
neuroprotective	O
action	O
and	O
action	O
of	O
cognitive	O
function	O
improvement	O
.	O

Na	O
-	B
acyl	I
derivatives	O
of	O
aminoacyl-2-cyanopyrrolidine	O
-	B
inhibitors	O
of	O
prolyl	O
endopeptidase	O
and	O
dipeptidyl	O
peptidase	O
-	O
iv	O
,	O
having	O
hypoglycemic	O
,	O
antihypoxic	O
,	O
neuroprotective	O
action	O
and	O
action	O
of	O
cognitive	O
function	O
improvement	O

Disclosed	O
is	O
an	O
application	O
of	O
a	O
phenyl	B
1,2-isoxazolyl	I
or	I
1,2-pyrazole	I
compound	O
of	O
the	O
following	O
structure	O
formula	O
(	O
I	O
)	O
.	O

It	O
is	O
proved	O
through	O
a	O
biological	O
activity	O
test	O
,	O
the	O
compound	O
has	O
an	O
obvious	O
activity	O
of	O
inhibiting	O
the	O
heat	O
shock	O
protein	O
90	O
.	O

Therefore	O
,	O
the	O
phenyl	B
1,2-isoxazolyl	I
or	I
1,2-pyrazole	I
compound	O
of	O
the	O
present	O
invention	O
can	O
be	O
used	O
as	O
an	O
inhibitor	O
of	O
the	O
heat	O
shock	O
protein	O
90	O
for	O
curing	O
cancers	O
.	O

Phenyl	B
1,2-isoxazolyl	I
or	O
phenyl	B
1,2-pyrazole	I
compound	O
and	O
application	O
thereof	O

A	O
pharmaceutical	O
composition	O
comprising	O
:	O
3-	O
(	O
1-	O
{	O
3-	O
[	O
5-	O
(	O
1-methyl	O
-	O
piperidin-4-ylmethoxy	O
)	O
-pyrimidin-2-yl	O
]	O
-benzyl	O
}	O
-6-oxo-1,6-dihydro	O
-	O
pyridazin-3-yl	O
)	O
-	O
benzonitrile	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
and/or	O
solvate	O
thereof	O
and	O
N-	O
(	O
(	O
S	O
)	O
-2,3-dihydroxy	O
-	O
propyl	O
)	O
-3-	O
(	O
2-fluoro-4-iodo	O
-	O
phenylamino	O
)	O
-isonicotinamide	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
and/or	O
solvate	O
thereof	O
.	O

Combination	O
of	O
a	O
6-oxo-1,6-dihydro	O
-	O
pyridazine	O
derivative	O
having	O
anti	O
-	O
cancer	O
activity	O
with	O
a	O
mek	O
inhibitor	O

The	O
present	O
invention	O
relates	O
to	O
5-fluoro	B
-	I
N-	I
(	I
pyridin-2-yl	I
)	I
pyridin-2-amine	I
derivatives	O
containing	O
a	O
sulfone	B
group	O
of	O
general	O
formula	O
(	O
I	O
)	O
as	O
described	O
and	O
defined	O
herein	O
,	O
and	O
methods	O
for	O
their	O
preparation	O
,	O
their	O
use	O
for	O
the	O
treatment	O
and/or	O
prophylaxis	O
of	O
disorders	O
,	O
in	O
particular	O
of	O
hyper	O
-	O
proliferative	O
disorders	O
and/or	O
virally	O
induced	O
infectious	O
diseases	O
and/or	O
of	O
cardiovascular	O
diseases	O
.	O

The	O
invention	O
further	O
relates	O
to	O
intermediate	O
compounds	O
useful	O
in	O
the	O
preparation	O
of	O
said	O
compounds	O
of	O
general	O
formula	O
(	O
I	O
)	O
.	O

5-fluoro	B
-	I
n-	I
(	I
pyridin-2-yl	I
)	I
pyridin-2-amine	I
derivatives	O
containing	O
a	O
sulfone	B
group	O

The	O
subject	O
matter	O
of	O
the	O
invention	O
is	O
a	O
complex	O
of	O
delphinidin	B
and	O
a	O
sulfoalkyl	O
ether	O
	O
-	O
cyclodextrin	O
for	O
use	O
as	O
a	O
medicinal	O
drug	O
,	O
in	O
particular	O
in	O
the	O
treatment	O
of	O
multiple	O
myeloma	O
.	O

Anthocyanidin	B
complex	O
for	O
the	O
treatment	O
of	O
multiple	O
myeloma	O

The	O
present	O
invention	O
provides	O
novel	O
compounds	O
of	O
Formula	O
(	O
I	O
)	O
,	O
and	O
pharmaceutically	O
acceptable	O
salts	O
,	O
solvates	O
,	O
hydrates	B
,	O
polymorphs	O
,	O
co	O
-	O
crystals	O
,	O
tautomers	O
,	O
stereoisomers	O
,	O
isotopically	O
labeled	O
derivatives	O
,	O
prodrugs	O
,	O
and	O
compositions	O
thereof	O
.	O

Also	O
provided	O
are	O
methods	O
and	O
kits	O
involving	O
the	O
inventive	O
compounds	O
or	O
compositions	O
for	O
treating	O
or	O
preventing	O
proliferative	O
diseases	O
(	O
e.g.	O
,	O
cancers	O
(	O
e.g.	O
,	O
leukemia	O
,	O
lymphoma	O
,	O
melanoma	O
,	O
multiple	O
myeloma	O
,	O
breast	O
cancer	O
,	O
Ewing	O
's	O
sarcoma	O
,	O
osteosarcoma	O
,	O
brain	O
cancer	O
,	O
neuroblastoma	O
,	O
lung	O
cancer	O
)	O
,	O
benign	O
neoplasms	O
,	O
angiogenesis	O
,	O
inflammatory	O
diseases	O
,	O
autoinflammatory	O
diseases	O
,	O
and	O
autoimmune	O
diseases	O
)	O
in	O
a	O
subject	O
.	O

Treatment	O
of	O
a	O
subject	O
with	O
a	O
proliferative	O
disease	O
using	O
a	O
compound	O
or	O
composition	O
of	O
the	O
invention	O
may	O
inhibit	O
the	O
aberrant	O
activity	O
of	O
a	O
kinase	O
,	O
such	O
as	O
cyclin	O
-	O
dependent	O
kinase	O
(	O
CDK	O
)	O
(	O
e.g.	O
,	O
cyclin	O
-	O
dependent	O
kinase	O
7	O
(	O
CDK7	O
)	O
)	O
,	O
and	O
therefore	O
,	O
induce	O
cellular	O
apoptosis	O
and/or	O
inhibit	O
transcription	O
in	O
the	O
subject	O
.	O

Inhibitors	O
of	O
cyclin	O
-	O
dependent	O
kinase	O
7	O
(	O
cdk7	O
)	O

The	O
present	O
invention	O
relates	O
to	O
substituted	O
pyrimidinyl-	O
and	O
pyridinylpyrrolopyridinone	O
compounds	O
which	O
modulate	O
the	O
activity	O
of	O
protein	O
kinases	O
and	O
are	O
therefore	O
useful	O
in	O
treating	O
diseases	O
caused	O
by	O
dysregulated	O
protein	O
kinase	O
activity	O
,	O
in	O
particular	O
RET	O
family	O
kinases	O
.	O

The	O
present	O
invention	O
also	O
provides	O
methods	O
for	O
preparing	O
these	O
compounds	O
,	O
pharmaceutical	O
compositions	O
comprising	O
these	O
compounds	O
,	O
and	O
methods	O
of	O
treating	O
diseases	O
utilizing	O
pharmaceutical	O
compositions	O
containing	O
these	O
compounds	O
.	O

Substituted	O
pyrimidinyl	O
and	O
pyridinyl	O
-	O
pyrrolopyridinones	O
,	O
process	O
for	O
their	O
preparation	O
and	O
their	O
use	O
as	O
kinase	O
inhibitors	O

The	O
present	O
invention	O
provides	O
compositions	O
,	O
uses	O
and	O
methods	O
thereof	O
,	O
for	O
inhibiting	O
the	O
growth	O
of	O
caries	O
-	O
causing	O
bacteria	O
.	O

The	O
composition	O
comprises	O
xylitol	B
,	O
sodium	B
citrate	I
,	O
sodium	B
bicarbonate	I
,	O
anionic	O
polymers	O
and	O
acceptable	O
carrier	O
materials	O
.	O

The	O
compositions	O
can	O
tend	O
to	O
be	O
used	O
for	O
treating	O
or	O
preventing	O
a	O
condition	O
caused	O
by	O
caries	O
-	O
causing	O
bacteria	O
The	O
compositions	O
can	O
further	O
tend	O
to	O
be	O
used	O
in	O
patients	O
such	O
as	O
children	O
,	O
adolescents	O
or	O
patients	O
suffering	O
from	O
a	O
heightened	O
susceptibility	O
to	O
toxic	O
substances	O
.	O

Compositions	O
,	O
uses	O
and	O
methods	O
for	O
treating	O
or	O
preventing	O
dental	O
caries	O

HIV-1	O
latency	O
is	O
a	O
major	O
obstacle	O
in	O
HIV-1	O
eradication	O
.	O

Although	O
current	O
highly	O
active	O
antiretroviral	O
therapy	O
(	O
HAART	O
)	O
has	O
efficiently	O
decreased	O
the	O
viral	O
load	O
in	O
patients	O
,	O
latently	O
infected	O
cells	O
are	O
permanent	O
reservoirs	O
and	O
inevitably	O
lead	O
to	O
viral	O
rebound	O
upon	O
discontinuation	O
of	O
HAART	O
.	O

Therefore	O
,	O
extensive	O
efforts	O
are	O
being	O
directed	O
toward	O
the	O
reactivation	O
of	O
latent	O
HIV	O
reservoirs	O
with	O
the	O
hope	O
that	O
latently	O
infected	O
cells	O
will	O
be	O
eliminated	O
by	O
the	O
host	O
immune	O
system	O
and/or	O
virus	O
-	O
mediated	O
cell	O
lysis	O
.	O

We	O
are	O
currently	O
working	O
on	O
developing	O
strategies	O
to	O
reactivate	O
the	O
latent	O
viral	O
reservoir	O
in	O
order	O
to	O
eliminate	O
them	O
.	O

Through	O
high	O
-	O
throughput	O
screening	O
,	O
an	O
anti-	O
cancer	O
molecule	O
PKC412	O
that	O
is	O
able	O
to	O
reactivate	O
HIV-1	O
expression	O
from	O
a	O
HIV-1	O
latently	O
infected	O
ACH2	O
cell	O
line	O
and	O
latently	O
infected	O
CD4	O
+	O
T	O
cells	O
has	O
been	O
identified	O
.	O

Use	O
of	O
pkc412	O
in	O
the	O
reactivation	O
of	O
latent	O
hiv-1	O

[	O
Problem	O
]	O
To	O
provide	O
a	O
medical	O
patch	O
with	O
an	O
adhesive	O
layer	O
formed	O
thereon	O
,	O
said	O
medical	O
patch	O
containing	O
a	O
large	O
amount	O
of	O
a	O
drug	O
and	O
a	O
dissolution	O
auxiliary	O
,	O
being	O
flexible	O
without	O
losing	O
shape	O
and	O
leaving	O
behind	O
adhesive	O
residue	O
,	O
and	O
exhibiting	O
excellent	O
drug	O
release	O
from	O
the	O
adhesive	O
layer	O
.	O

[	O
Solution	O
]	O
A	O
medical	O
patch	O
comprising	O
:	O
a	O
drug	O
having	O
a	O
secondary	O
or	O
tertiary	B
amine	I
structure	O
in	O
the	O
molecules	O
thereof	O
;	O
a	O
liquid	O
auxiliary	O
for	O
the	O
drug	O
;	O
and	O
a	O
resin	O
composition	O
formed	O
by	O
cross	O
-	O
linking	O
a	O
copolymerized	O
acrylic	O
resin	O
with	O
an	O
isocyanate	O
group	O
-	O
containing	O
cross	O
-	O
linking	O
agent	O
that	O
has	O
been	O
blocked	O
,	O
said	O
copolymerized	O
acrylic	O
resin	O
having	O
a	O
(	O
meth	O
)	O
acrylate	B
monomer	O
as	O
a	O
main	O
monomer	O
component	O
and	O
having	O
a	O
functional	O
group	O
capable	O
of	O
reacting	O
with	O
the	O
aforementioned	O
isocyanate	B
group	O
-	O
containing	O
cross	O
-	O
linking	O
agent	O
to	O
thereby	O
form	O
a	O
cross	O
-	O
linked	O
structure	O
.	O

The	O
solubility	O
of	O
the	O
drug	O
in	O
a	O
phosphate	B
buffer	O
solution	O
(	O
pH6.4	O
)	O
is	O
at	O
least	O
0.5wt%	O
.	O

Medical	O
patch	O

Provided	O
herein	O
are	O
compounds	O
that	O
modulate	O
the	O
activity	O
of	O
inhibitor	O
of	O
apoptosis	O
proteins	O
(	O
IAPs	O
)	O
,	O
compositions	O
comprising	O
the	O
compounds	O
,	O
and	O
methods	O
of	O
using	O
the	O
compounds	O
and	O
compositions	O
comprising	O
the	O
compounds	O
.	O

Inhibitor	O
of	O
apoptosis	O
protein	O
(	O
iap	O
)	O
antagonists	O

In	O
the	O
present	O
invention	O
,	O
a	O
CBP	O
/	O
	O
-	O
catenin	O
inhibitor	O
exhibits	O
a	O
superior	O
defibrinating	O
effect	O
with	O
respect	O
to	O
Cre	O
/	O
loxP	O
/	O
HCV	O
-	O
MxCre	O
transgenic	O
mice	O
,	O
which	O
are	O
an	O
experimental	O
animal	O
model	O
for	O
hepatic	O
fibrosis	O
,	O
and	O
is	O
useful	O
as	O
a	O
prevention	O
or	O
treatment	O
drug	O
for	O
hepatic	O
fibrosis	O
.	O

Prevention	O
or	O
treatment	O
agent	O
for	O
hepatic	O
fibrosis	O

Provided	O
is	O
a	O
prophylactic	O
/	O
therapeutic	O
agent	O
for	O
dry	O
eye	O
,	O
which	O
comprises	O
a	O
novel	O
component	O
capable	O
of	O
preventing	O
the	O
deterioration	O
of	O
a	O
tear	O
fluid	O
secretion	O
ability	O
and	O
also	O
capable	O
of	O
inhibiting	O
the	O
generation	O
of	O
active	O
oxygen	B
in	O
tear	O
gland	O
tissues	O
.	O

The	O
prophylactic	O
/	O
therapeutic	O
agent	O
for	O
dry	O
eye	O
according	O
to	O
the	O
present	O
invention	O
contains	O
a	O
maqui	O
berry	O
extract	O
as	O
an	O
active	O
ingredient	O
.	O

The	O
prophylactic	O
/	O
therapeutic	O
agent	O
for	O
dry	O
eye	O
according	O
to	O
the	O
present	O
invention	O
may	O
contain	O
,	O
as	O
an	O
active	O
ingredient	O
,	O
a	O
delphinidin	B
glycoside	I
that	O
is	O
extracted	O
from	O
maqui	O
berry	O
.	O

The	O
prophylactic	O
/	O
therapeutic	O
agent	O
for	O
dry	O
eye	O
according	O
to	O
the	O
present	O
invention	O
may	O
contain	O
at	O
least	O
one	O
component	O
selected	O
from	O
delphinidin-3-sambubioside-5-glucoside	B
,	O
delphinidin-3,5-diglucoside	B
,	O
delphinidin-3-sambubioside	B
and	O
delphinidin-3-glucoside	B
,	O
desirably	O
delphinidin-3,5-diglucoside	B
,	O
as	O
an	O
active	O
ingredient	O
.	O

Prophylactic	O
/	O
therapeutic	O
agent	O
for	O
dry	O
eye	O

The	O
Invention	O
relates	O
to	O
pyrazolyl	B
-	O
based	O
carboxamide	B
compounds	O
of	O
formula	O
(	O
l	O
)	O
useful	O
as	O
ICRAC	O
inhibitors	O
,	O
to	O
pharmaceutical	O
compositions	O
containing	O
these	O
compounds	O
and	O
to	O
these	O
compounds	O
for	O
the	O
use	O
in	O
the	O
treatment	O
and/or	O
prophylaxis	O
of	O
diseases	O
and/or	O
disorders	O
,	O
in	O
particular	O
inflammatory	O
diseases	O
and/or	O
inflammatory	O
disorders	O
.	O

Pyrazolyl	B
-	O
based	O
carboxamides	B
i	O
as	O
crac	O
channel	O
inhibitors	O

New	O
pyrrolotriazine	B
derivatives	O
having	O
the	O
chemical	O
structure	O
of	O
formula	O
(	O
I	O
)	O
are	O
disclosed	O
;	O
as	O
well	O
as	O
process	O
for	O
their	O
preparation	O
,	O
pharmaceutical	O
compositions	O
comprising	O
them	O
and	O
their	O
use	O
in	O
therapy	O
as	O
inhibitors	O
of	O
Phosphoinositide	O
3-Kinases	O
(	O
PI3Ks	O
)	O
Pyrrolotriazine	B
derivatives	O
as	O
pi3k	O
inhibitors	O

This	O
invention	O
provides	O
compounds	O
,	O
methods	O
and	O
compositions	O
for	O
the	O
treatment	O
of	O
inflammatory	O
diseases	O
,	O
comprising	O
the	O
timely	O
administration	O
of	O
a	O
provided	O
compound	O
,	O
which	O
has	O
a	O
structure	O
related	O
to	O
an	O
endogenously	O
formed	O
lipid	O
mediator	O
.	O

One	O
embodiment	O
of	O
the	O
present	O
invention	O
is	O
directed	O
to	O
a	O
compound	O
selected	O
from	O
a	O
group	O
having	O
the	O
general	O
formula	O
A.	O
Compositions	O
for	O
the	O
treatment	O
of	O
inflammatory	O
diseases	O

This	O
invention	O
relates	O
to	O
2-Aza	B
-	I
bicyclo	I
[	I
2.2.1	I
]	I
heptane-3-carboxylic	I
acid	I
(	I
cyano	I
-	I
methyl	I
)	I
-amides	I
of	O
formula	O
(	O
1	O
)	O
and	O
their	O
use	O
as	O
inhibitors	O
of	O
Cathepsin	O
C	O
,	O
pharmaceutical	O
compositions	O
containing	O
the	O
same	O
,	O
and	O
methods	O
of	O
using	O
the	O
same	O
as	O
agents	O
for	O
treatment	O
and/or	O
prevention	O
of	O
diseases	O
connected	O
with	O
dipeptidyl	O
peptidase	O
I	O
activity	O
,	O
e.g.	O
respiratory	O
diseases	O
.	O

Substituted	O
2-aza	B
-	I
bicyclo	I
[	I
2.2.1	I
]	I
heptane-3-carboxylic	I
acid	I
(	I
cyano	I
-	I
methyl	I
)	I
-amides	I
inhibitors	O
of	O
cathepsin	O
c	O

Provided	O
is	O
a	O
compound	O
as	O
represented	O
by	O
formula	O
[	O
I	O
]	O
[	O
in	O
which	O
n	O
indicates	O
1	O
or	O
2	O
]	O
,	O
formula	O
[	O
II	O
]	O
or	O
[	O
IIh	O
]	O
,	O
or	O
formula	O
[	O
III	O
]	O
,	O
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
.	O

Also	O
provided	O
are	O
medicinal	O
uses	O
for	O
the	O
compound	O
or	O
the	O
salt	O
thereof	O
.	O

Pyrazole	O
-	O
amide	O
compound	O
and	O
medicinal	O
uses	O
therefor	O

Methods	O
of	O
treating	O
,	O
reducing	O
the	O
incidence	O
of	O
,	O
and/or	O
preventing	O
an	O
ischemic	O
event	O
in	O
a	O
patient	O
undergoing	O
percutaneous	O
coronary	O
intervention	O
(	O
PCI	O
)	O
,	O
comprising	O
administering	O
to	O
the	O
patient	O
a	O
pharmaceutical	O
composition	O
comprising	O
cangrelor	O
.	O

The	O
method	O
may	O
further	O
comprise	O
administering	O
an	O
additional	O
therapeutic	O
agent	O
to	O
the	O
patient	O
,	O
the	O
additional	O
therapeutic	O
agent	O
comprising	O
a	O
P2Yi2	O
inhibitor	O
.	O

Pharmaceutical	O
compositions	O
useful	O
for	O
treating	O
,	O
reducing	O
the	O
incidence	O
of	O
,	O
and/or	O
preventing	O
an	O
ischemic	O
event	O
in	O
a	O
patient	O
undergoing	O
PCI	O
.	O

The	O
pharmaceutical	O
compositions	O
comprise	O
cangrelor	O
.	O

Methods	O
of	O
preparing	O
a	O
pharmaceutical	O
composition	O
for	O
treating	O
,	O
reducing	O
the	O
incidence	O
of	O
,	O
and/or	O
preventing	O
an	O
ischemic	O
event	O
in	O
a	O
patient	O
undergoing	O
PCI	O
,	O
comprising	O
admixing	O
cangrelor	O
with	O
one	O
or	O
more	O
pharmaceutically	O
acceptable	O
excipients	O
.	O

An	O
ischemic	O
event	O
may	O
include	O
stent	O
thrombosis	O
,	O
myocardial	O
infarction	O
,	O
ischemia	O
-	O
driven	O
revascularization	O
,	O
and	O
mortality	O
.	O

Methods	O
of	O
treating	O
,	O
reducing	O
the	O
incidence	O
of	O
,	O
and/or	O
preventing	O
ischemic	O
events	O

The	O
present	O
invention	O
relates	O
to	O
the	O
method	O
of	O
treating	O
heavy	O
menstrual	O
bleeding	O
in	O
a	O
subject	O
with	O
or	O
without	O
uterine	O
fibroids	O
and	O
in	O
need	O
of	O
treatment	O
by	O
administering	O
an	O
effective	O
amount	O
of	O
4-	B
(	I
(	I
R	I
)	I
-2-	I
[	I
5-	I
(	I
2-fluoro-3-methoxy	I
-	I
phenyl	I
)	I
-3-	I
(	I
2-fluoro-6-trifluoromethyl	I
-	I
benzyl	I
)	I
-4-	I
methyl-2,6-dioxo-3,6-dihydro-2H	I
-	I
pyrimidin	I
-	I
l	I
-	I
yl	I
]	I
-l	I
-	I
phenyl	I
-	I
ethylamino	I
)	I
-butyric	I
acid	I
or	O
a	O
pharmaceutically	O
acceptable	O
salt	O
thereof	O
,	O
in	O
combination	O
with	O
estrogens	O
and	O
progestogens	O
.	O

Compositions	O
for	O
use	O
in	O
treating	O
heavy	O
menstrual	O
bleeding	O
and	O
uterine	O
fibroids	O

Compounds	O
of	O
formula	O
(	O
I	O
)	O
which	O
are	O
inhibitors	O
of	O
Bub1	O
kinase	O
,	O
processes	O
for	O
their	O
production	O
and	O
their	O
use	O
as	O
pharmaceuticals	O
.	O

3-heteroaryl	B
substituted	I
indazoles	I

The	O
purpose	O
of	O
the	O
present	O
invention	O
is	O
to	O
provide	O
a	O
pharmaceutical	O
composition	O
for	O
the	O
treatment	O
of	O
inflammatory	O
bowel	O
disease	O
and	O
a	O
treatment	O
method	O
therefor	O
.	O

A	O
pharmaceutical	O
composition	O
containing	O
siRNA	O
inhibiting	O
the	O
expression	O
of	O
a	O
CD98	O
heavy	O
chain	O
was	O
found	O
to	O
be	O
useful	O
in	O
the	O
treatment	O
of	O
inflammatory	O
bowel	O
disease	O
.	O

As	O
a	O
result	O
,	O
a	O
novel	O
treatment	O
method	O
can	O
be	O
provided	O
that	O
uses	O
the	O
siRNA	O
for	O
inflammatory	O
bowel	O
disease	O
for	O
which	O
there	O
has	O
conventionally	O
been	O
no	O
appropriate	O
treatment	O
method	O
.	O

Pharmaceutical	O
composition	O
for	O
treatment	O
of	O
inflammatory	O
bowel	O
disease	O

The	O
present	O
invention	O
relates	O
to	O
a	O
therapeutic	O
agent	O
for	O
neurodegenerative	O
diseases	O
,	O
which	O
contains	O
a	O
compound	O
represented	O
by	O
formula	O
(	O
I	O
)	O
or	O
a	O
salt	O
thereof	O
.	O

(	O
In	O
the	O
formula	O
,	O
Ar1	O
represents	O
an	O
aromatic	B
group	O
;	O
X	O
represents	O
a	O
single	O
bond	O
or	O
a	O
linking	O
group	O
;	O
R1	O
represents	O
a	O
hydrogen	B
atom	O
,	O
an	O
aromatic	B
group	O
or	O
an	O
aralkyl	B
group	O
;	O
Y	O
represents	O
CH	B
(	I
R2	I
)	I
(	O
wherein	O
R2	O
represents	O
a	O
hydrogen	B
atom	O
,	O
a	O
carbamoyl	B
group	O
,	O
an	O
acyl	B
group	O
or	O
an	O
alkyl	B
group	O
)	O
;	O
Z	O
represents	O
a	O
carbonyl	B
group	O
or	O
CH	B
(	I
R3	I
)	I
(	O
wherein	O
R3	O
represents	O
a	O
hydrogen	B
atom	O
,	O
an	O
aromatic	B
group	O
or	O
an	O
aralkyl	B
group	O
)	O
;	O
and	O
Y	O
and	O
Z	O
may	O
combine	O
together	O
and	O
represent	O
C	B
(	I
R2	I
)	I
=C	I
(	I
R4	I
)	I
(	O
wherein	O
R2	O
represents	O
a	O
hydrogen	B
atom	O
,	O
a	O
carbamoyl	B
group	O
,	O
an	O
acyl	B
group	O
or	O
an	O
alkyl	B
group	O
,	O
and	O
R4	O
represents	O
a	O
hydrogen	B
atom	O
,	O
a	O
hydroxyl	B
group	O
,	O
an	O
aromatic	B
group	O
or	O
an	O
aralkyl	B
group	O
)	O
.	O
)	O

Therapeutic	O
agent	O
for	O
neurodegenerative	O
diseases	O

The	O
present	O
invention	O
provides	O
an	O
instantaneous	O
intestinal	O
regulator	O
,	O
which	O
:	O
contains	O
a	O
Propionibacteriaceae	O
culture	O
,	O
DHNA	B
or	O
an	O
analog	O
thereof	O
as	O
an	O
active	O
ingredient	O
;	O
manifests	O
intestine	O
-	O
regulating	O
effects	O
within	O
one	O
day	O
after	O
being	O
taken	O
;	O
and	O
manifests	O
more	O
pronounced	O
intestine	O
-	O
regulating	O
effects	O
within	O
two	O
days	O
after	O
being	O
taken	O
.	O

The	O
present	O
invention	O
also	O
provides	O
an	O
instantaneous	O
intestinal	O
regulator	O
,	O
which	O
contains	O
a	O
Propionibacteriaceae	O
culture	O
,	O
DHNA	B
or	O
an	O
analog	O
thereof	O
as	O
an	O
active	O
ingredient	O
and	O
maintains	O
the	O
intestine	O
-	O
regulating	O
effects	O
for	O
two	O
weeks	O
after	O
being	O
taken	O
.	O

Instantaneous	O
intestinal	O
regulator	O

Extracts	O
of	O
the	O
creosote	O
bush	O
(	O
Larrea	O
tridentata	O
,	O
family	O
Zygophyllaceae	O
)	O
have	O
long	O
been	O
used	O
as	O
a	O
folk	O
remedy	O
for	O
Type	O
II	O
(	O
non	O
-	O
insulin	O
-	O
dependent	O
)	O
diabetes	O
by	O
native	O
Americans	O
in	O
southwestern	O
North	O
America	O
.	O

In	O
this	O
study	O
we	O
have	O
evaluated	O
the	O
metabolic	O
effects	O
of	O
masoprocol	B
,	O
a	O
pure	O
compound	O
isolated	O
from	O
the	O
creosote	O
bush	O
,	O
in	O
a	O
rat	O
model	O
of	O
Type	O
II	O
diabetes	O
.	O

Animals	O
were	O
fed	O
a	O
20	O
%	O
fat	O
(	O
by	O
weight	O
)	O
diet	O
for	O
2	O
weeks	O
prior	O
to	O
intravenous	O
injection	O
with	O
streptozotocin	B
(	O
STZ	B
,	O
0.19	O
mmol	O
/	O
kg	O
)	O
.	O

Diabetic	O
animals	O
(	O
glucose	B
16	O
-	O
33	O
mmol	O
/	O
l	O
)	O
were	O
treated	O
with	O
vehicle	O
,	O
metformin	B
(	O
0.83	O
mmol	O
/	O
kg	O
body	O
weight	O
)	O
or	O
masoprocol	B
(	O
0.83	O
mmol	O
/	O
kg	O
body	O
weight	O
)	O
twice	O
a	O
day	O
for	O
4	O
days	O
.	O

Masoprocol	B
treatment	O
lowered	O
glucose	B
concentrations	O
an	O
average	O
of	O
35	O
%	O
compared	O
with	O
vehicle	O
(	O
14.2+	O
/	O
-1.1	O
vs	O
21.7+	O
/	O
-1.0	O
mmol	O
/	O
l	O
,	O
p	O
<	O
0.001	O
)	O
,	O
a	O
reduction	O
similar	O
to	O
metformin	B
treatment	O
(	O
12.8+	O
/	O
-0.9	O
mmol	O
/	O
l	O
)	O
,	O
without	O
any	O
change	O
in	O
insulin	O
concentration	O
.	O

Masoprocol	B
treatment	O
also	O
lowered	O
triglyceride	B
concentrations	O
80	O
%	O
compared	O
with	O
vehicle	O
(	O
1.0+	O
/	O
-0.1	O
vs	O
4.8+	O
/	O
-0.3	O
mmol	O
/	O
l	O
,	O
p	O
<	O
0.001	O
)	O
,	O
a	O
reduction	O
far	O
greater	O
than	O
following	O
metformin	B
treatment	O
(	O
3.6+	O
/	O
-0.3	O
mmol	O
/	O
l	O
)	O
.	O

Non	O
-	O
esterified	O
fatty	B
acid	I
and	O
glycerol	B
concentration	O
were	O
decreased	O
by	O
approximately	O
65	O
%	O
by	O
masoprocol	B
compared	O
with	O
vehicle	O
,	O
a	O
reduction	O
approximately	O
twice	O
as	O
great	O
as	O
seen	O
with	O
metformin	B
(	O
p	O
<	O
0.001	O
)	O
.	O

The	O
effect	O
of	O
masoprocol	B
on	O
in	O
vivo	O
insulin	O
-	O
mediated	O
glucose	B
disposal	O
was	O
evaluated	O
by	O
infusing	O
fat	O
-	O
fed	O
/	O
STZ	B
rats	O
with	O
glucose	B
(	O
0.22	O
mmol	O
kg	O
x	O
min	O
(	O
-1	O
)	O
)	O
and	O
insulin	O
(	O
30	O
pmol	O
x	O
kg	O
x	O
min	O
(	O
-1	O
)	O
)	O
for	O
5	O
h.	O
In	O
response	O
to	O
the	O
infusion	O
,	O
steady	O
-	O
state	O
plasma	O
glucose	B
concentrations	O
were	O
reduced	O
30	O
%	O
in	O
masoprocol	B
-	O
treated	O
animals	O
compared	O
with	O
vehicle	O
controls	O
(	O
p	O
<	O
0.05	O
)	O
with	O
no	O
change	O
noted	O
in	O
rats	O
treated	O
with	O
metformin	B
.	O

The	O
effect	O
of	O
masoprocol	B
treatment	O
was	O
also	O
tested	O
in	O
primary	O
adipocytes	O
isolated	O
from	O
normal	O
animals	O
.	O

Adipocytes	O
treated	O
with	O
masoprocol	B
(	O
30	O
micromol	O
/	O
l	O
)	O
had	O
higher	O
basal	O
and	O
insulin	O
-	O
stimulated	O
glucose	B
clearance	O
than	O
did	O
adipocytes	O
treated	O
with	O
vehicle	O
(	O
p	O
<	O
0.05	O
)	O
.	O

These	O
data	O
show	O
that	O
masoprocol	B
decreases	O
both	O
plasma	O
glucose	B
and	O
triglyceride	B
concentrations	O
in	O
fat	O
-	O
fed	O
/	O
STZ	B
rats	O
,	O
presumably	O
as	O
a	O
result	O
of	O
its	O
ability	O
to	O
both	O
increase	O
glucose	B
disposal	O
and	O
decrease	O
lipolysis	O
.	O

The	O
induction	O
of	O
micronucleated	O
erythrocytes	O
by	O
diisopropylcarbodiimide	B
(	O
DIC	B
)	O
and	O
dicyclohexylcarbodiimide	B
(	O
DCC	B
)	O
was	O
investigated	O
as	O
part	O
of	O
a	O
U.S.	O
National	O
Toxicology	O
Program	O
(	O
NTP	O
)	O
evaluation	O
of	O
the	O
subchronic	O
toxicity	O
of	O
these	O
chemicals	O
.	O

Analysis	O
of	O
peripheral	O
blood	O
smears	O
from	O
male	O
and	O
female	O
B6C3F1	O
mice	O
exposed	O
to	O
17.5	O
-	O
140.0	O
mg	O
DIC	B
/	O
kg	O
/	O
day	O
by	O
skin	O
painting	O
for	O
13	O
weeks	O
revealed	O
dose	O
-	O
related	O
increases	O
in	O
the	O
frequency	O
of	O
micronucleated	O
normochromatic	O
erythrocytes	O
(	O
MN	O
-	O
NCE	O
)	O
in	O
both	O
sexes	O
.	O

Results	O
of	O
a	O
similar	O
13-week	O
peripheral	O
blood	O
micronucleus	O
(	O
MN	O
)	O
test	O
with	O
DCC	B
(	O
1.5	O
-	O
12.0	O
mg	O
/	O
kg	O
/	O
day	O
)	O
were	O
also	O
positive	O
,	O
although	O
the	O
increases	O
in	O
MN	O
-	O
NCE	O
were	O
not	O
as	O
great	O
as	O
those	O
observed	O
with	O
DIC	B
.	O

In	O
contrast	O
to	O
the	O
positive	O
results	O
of	O
the	O
subchronic	O
skin	O
-	O
painting	O
studies	O
in	O
mice	O
,	O
acute	O
bone	O
marrow	O
MN	O
studies	O
with	O
DIC	B
and	O
DCC	B
in	O
male	O
F344	O
rats	O
,	O
using	O
intraperitoneal	O
(	O
i.p	O
.	O
)	O
injection	O
,	O
yielded	O
negative	O
results	O
.	O

Both	O
the	O
acute	O
and	O
the	O
subchronic	O
exposures	O
included	O
doses	O
that	O
produced	O
clinical	O
signs	O
of	O
toxicity	O
.	O

Acute	O
mouse	O
bone	O
marrow	O
MN	O
tests	O
with	O
DIC	B
administered	O
in	O
single	O
or	O
triple	O
i.p	O
.	O

injection	O
protocols	O
were	O
subsequently	O
conducted	O
to	O
determine	O
if	O
the	O
differing	O
responses	O
between	O
mice	O
and	O
rats	O
were	O
due	O
to	O
species	O
or	O
protocol	O
differences	O
.	O

The	O
results	O
of	O
these	O
acute	O
tests	O
were	O
negative	O
or	O
equivocal	O
.	O

Because	O
the	O
subchronic	O
studies	O
produced	O
positive	O
results	O
,	O
it	O
was	O
hypothesized	O
that	O
these	O
carbodiimides	B
required	O
multiple	O
treatments	O
over	O
an	O
extended	O
period	O
of	O
time	O
to	O
produce	O
an	O
increase	O
in	O
MN	O
-	O
erythrocytes	O
.	O

To	O
confirm	O
the	O
original	O
response	O
,	O
a	O
second	O
dermal	O
subchronic	O
study	O
was	O
conducted	O
with	O
DIC	B
;	O
the	O
protocol	O
was	O
modified	O
to	O
include	O
sequential	O
blood	O
samplings	O
to	O
permit	O
monitoring	O
MN	O
frequencies	O
over	O
time	O
.	O

The	O
data	O
demonstrated	O
a	O
small	O
but	O
consistent	O
induction	O
of	O
micronucleated	O
erythrocytes	O
in	O
mice	O
treated	O
with	O
DIC	B
by	O
skin	O
painting	O
.	O

Antibacterial	O
antibiotics	O
,	O
diperamycin	B
(	O
1	O
)	O
was	O
produced	O
in	O
the	O
culture	O
broth	O
of	O
Streptomyces	O
griseoaurantiacus	O
MK393-AF2	O
.	O

Various	O
spectroscopic	O
analyses	O
of	O
1	O
suggested	O
that	O
1	O
belonged	O
to	O
a	O
member	O
of	O
cyclic	B
hexadepsipeptide	I
antibiotic	O
.	O

Antibiotic	B
1	I
had	O
potent	O
inhibitory	O
activity	O
against	O
various	O
Gram	O
-	O
positive	O
bacteria	O
including	O
Enterococcus	O
seriolicida	O
and	O
methicillin	O
-	O
resistant	O
Staphylococcus	O
aureus	O
.	O

Subcutaneous	O
tumor	O
induction	O
with	O
three	O
dose	O
levels	O
of	O
3-methylcholanthrene	B
(	O
MCA	B
)	O
,	O
benzo	B
[	I
a	I
]	I
pyrene	I
(	O
BP	B
)	O
,	O
and	O
7,12-dimethylbenz	B
[	I
a	I
]	I
anthracene	I
(	O
DMBA	B
)	O
in	O
two	O
vehicles	O
was	O
studied	O
in	O
C3H	O
/	O
Anf	O
Cum	O
,	O
C57BL	O
/	O
6	O
Cum	O
,	O
DBA	O
/	O
2J	O
,	O
and	O
(	O
C57BLXC3H	O
/	O
Anf	O
)	O
F1	O
(	O
BC3F1	O
/	O
Cum	O
)	O
mice	O
.	O

Median	O
tumor	O
dose	O
levels	O
were	O
significantly	O
lower	O
when	O
the	O
three	O
carcinogens	O
were	O
suspended	O
in	O
trioctanoin	B
.	O

When	O
beeswax	B
:	I
trioctanoin	I
(	O
B	B
:	I
T	I
)	O
was	O
used	O
as	O
a	O
vehicle	O
,	O
the	O
three	O
carcinogens	O
differed	O
in	O
their	O
abilities	O
to	O
be	O
absorbed	O
or	O
solubilized	O
from	O
the	O
vehicle	O
by	O
the	O
three	O
strains	O
of	O
mice	O
and	O
the	O
hybrid	O
.	O

In	O
C3H	O
/	O
Anf	O
mice	O
,	O
BP	B
in	O
B	B
:	I
T	I
failed	O
to	O
produce	O
tumors	O
.	O

In	O
BC3F1	O
mice	O
,	O
no	O
tumors	O
were	O
produced	O
by	O
MCA	B
,	O
BP	B
,	O
or	O
DMBA	B
in	O
B	B
:	I
T.	I
In	O
C57BL	O
/	O
6	O
mice	O
,	O
no	O
tumors	O
were	O
produced	O
with	O
DMBA	B
or	O
MCA	B
in	O
B	B
:	I
T.	I
In	O
DBA	O
/	O
2	O
mice	O
,	O
no	O
tumors	O
were	O
produced	O
by	O
BP	B
or	O
MCA	B
in	O
B	B
:	I
T.	I
These	O
results	O
indicated	O
that	O
the	O
interpretation	O
of	O
tumor	O
induction	O
results	O
obtained	O
with	O
B	B
:	I
T	I
vehicle	O
may	O
be	O
related	O
to	O
the	O
conditions	O
of	O
bioassay	O
rather	O
than	O
to	O
the	O
carcinogenic	O
potential	O
of	O
a	O
compound	O
.	O

DNA	O
-	O
dependent	O
protein	O
kinase	O
(	O
DNA	O
-	O
PK	O
)	O
and	O
poly	B
(	I
ADP	I
-	I
ribose	I
)	I
polymerase	O
(	O
PARP	O
)	O
are	O
activated	O
by	O
DNA	O
strand	O
breaks	O
and	O
participate	O
in	O
DNA	O
repair	O
.	O

We	O
investigated	O
the	O
interactive	O
effects	O
of	O
inhibitors	O
of	O
these	O
enzymes	O
[	O
wortmannin	B
(	O
WM	B
)	O
,	O
which	O
inhibits	O
DNA	O
-	O
PK	O
,	O
and	O
8-hydroxy-2-methylquinazolin-4-one	B
(	O
NU1025	B
)	O
,	O
a	O
PARP	O
inhibitor	O
]	O
on	O
cell	O
survival	O
and	O
DNA	O
double	O
-	O
strand	O
break	O
(	O
DSB	O
)	O
and	O
single	O
-	O
strand	O
break	O
(	O
SSB	O
)	O
rejoining	O
in	O
Chinese	O
hamster	O
ovary	O
-	O
K1	O
cells	O
following	O
exposure	O
to	O
ionizing	O
radiation	O
(	O
IR	O
)	O
or	O
temozolomide	B
.	O

WM	B
(	O
20	O
microM	O
)	O
or	O
NU1025	B
(	O
300	O
microM	O
)	O
potentiated	O
the	O
cytotoxicity	O
of	O
IR	O
with	O
dose	O
enhancement	O
factors	O
at	O
10	O
%	O
survival	O
(	O
DEF10	O
)	O
values	O
of	O
4.5	O
+	O
/-	O

0.6	O
and	O
1.7	O
+	O
/-	O

0.2	O
,	O
respectively	O
.	O

When	O
used	O
in	O
combination	O
,	O
a	O
DEF10	O
of	O
7.8	O
+	O
/-	O

1.5	O
was	O
obtained	O
.	O

WM	B
or	O
NU1025	B
potentiated	O
the	O
cytotoxicity	O
of	O
temozolomide	B
,	O
and	O
an	O
additive	O
effect	O
on	O
the	O
DEF10	O
value	O
was	O
obtained	O
with	O
the	O
combined	O
inhibitors	O
.	O

Using	O
the	O
same	O
inhibitor	O
concentrations	O
,	O
their	O
single	O
and	O
combined	O
effects	O
on	O
DSB	O
and	O
SSB	O
levels	O
following	O
IR	O
were	O
assessed	O
by	O
neutral	O
and	O
alkaline	O
elution	O
.	O

Cells	O
exposed	O
to	O
IR	O
were	O
post	O
-	O
incubated	O
for	O
30	O
min	O
to	O
allow	O
repair	O
to	O
occur	O
.	O

WM	B
or	O
NU1025	B
increased	O
net	O
DSB	O
levels	O
relative	O
to	O
IR	O
alone	O
(	O
DSB	O
levels	O
of	O
1.29	O
+	O
/-	O

0.04	O
and	O
1.20	O
+	O
/-	O

0.05	O
,	O
respectively	O
,	O
compared	O
with	O
1.01	O
+	O
/-	O

0.03	O
for	O
IR	O
alone	O
)	O
and	O
the	O
combination	O
had	O
an	O
additive	O
effect	O
.	O

WM	B
had	O
no	O
effect	O
on	O
SSB	O
levels	O
,	O
either	O
alone	O
or	O
in	O
combination	O
with	O
NU1025	B
.	O

SSB	O
levels	O
were	O
increased	O
to	O
1.27	O
+	O
/-	O

0.05	O
with	O
NU1025	B
compared	O
with	O
IR	O
alone	O
,	O
1.02	O
+	O
/-	O

0.04	O
.	O

The	O
dose	O
-	O
dependent	O
effects	O
of	O
the	O
inhibitors	O
on	O
DSB	O
levels	O
showed	O
that	O
they	O
were	O
near	O
maximal	O
by	O
20	O
microM	O
WM	O
and	O
300	O
microM	O
NU1025	O
.	O

DSB	O
repair	O
kinetics	O
were	O
studied	O
.	O

Both	O
inhibitors	O
increased	O
net	O
DSB	O
levels	O
over	O
a	O
3	O
h	O
time	O
period	O
;	O
when	O
they	O
were	O
combined	O
,	O
net	O
DSB	O
levels	O
at	O
3	O
h	O
were	O
identical	O
to	O
DSB	O
levels	O
immediately	O
post	O
-	O
IR	O
.	O

The	O
combined	O
use	O
of	O
DNA	O
repair	O
inhibitors	O
may	O
have	O
therapeutic	O
potential	O
.	O

Chemical	O
investigation	O
of	O
the	O
sponge	O
Spongia	O
matamata	O
collected	O
in	O
Yap	O
,	O
Micronesia	O
,	O
has	O
resulted	O
in	O
the	O
isolation	O
of	O
six	O
new	O
spongian	O
diterpenoids	B
,	O
2	O
-	O
7	O
,	O
along	O
with	O
the	O
known	O
compound	O
,	O
spongia-13	B
(	I
16	I
)	I
,	I
14-dien-19-oic	I
acid	I
(	O
1	O
)	O
.	O

The	O
structures	O
were	O
determined	O
by	O
spectroscopic	O
methods	O
.	O

Meloxicam	B
[	O
4-hydroxy-2-methyl	B
-	I
N-	I
(	I
5-methyl-2-thiazolyl	I
)	I
-2H-1,2-benzothiazine	I
-3-carboxamide-1	I
,	I
1-dioxide	I
]	O
is	O
a	O
nonsteroidal	B
anti	I
-	I
inflammatory	I
drug	I
(	O
NSAID	B
)	O
of	O
the	O
oxicam	B
class	O
which	O
shows	O
preferential	O
inhibition	O
of	O
cyclo	O
-	O
oxygenase-2	O
.	O

Meloxicam	B
has	O
a	O
plasma	O
half	O
-	O
life	O
of	O
approximately	O
20	O
hours	O
,	O
making	O
it	O
convenient	O
for	O
once	O
-	O
daily	O
administration	O
.	O

Meloxicam	B
is	O
eliminated	O
after	O
biotransformation	O
to	O
4	O
pharmacologically	O
inactive	O
metabolites	O
,	O
which	O
are	O
excreted	O
in	O
urine	O
and	O
faeces	O
.	O

Meloxicam	B
and	O
its	O
metabolites	B
bind	O
extensively	O
to	O
plasma	O
albumin	O
.	O

Substantial	O
concentrations	O
of	O
meloxicam	B
are	O
attained	O
in	O
synovial	O
fluid	O
,	O
the	O
proposed	O
site	O
of	O
action	O
in	O
chronic	O
inflammatory	O
arthropathies	O
.	O

Neither	O
moderate	O
renal	O
nor	O
hepatic	O
insufficiency	O
significantly	O
alter	O
the	O
pharmacokinetics	O
of	O
meloxicam	B
.	O

Dosage	O
adjustment	O
is	O
not	O
required	O
in	O
the	O
elderly	O
.	O

Drug	O
-	O
drug	O
interaction	O
studies	O
are	O
available	O
for	O
some	O
commonly	O
co	O
-	O
prescribed	O
medications	O
.	O

Concentration	O
-	O
dependent	O
therapeutic	O
and	O
toxicological	O
effects	O
have	O
yet	O
to	O
be	O
extensively	O
elucidated	O
for	O
this	O
NSAID	B
.	O

Recent	O
work	O
within	O
our	O
laboratory	O
has	O
focused	O
on	O
the	O
enzymes	O
we	O
hypothesize	O
are	O
involved	O
in	O
the	O
biosynthesis	O
of	O
bis	B
(	I
monoacylglycerol	I
)	I
phosphate	I
from	O
phosphatidylglycerol	B
.	O

Here	O
we	O
describe	O
a	O
transacylase	O
,	O
active	O
at	O
acidic	O
pH	O
values	O
,	O
isolated	O
from	O
a	O
macrophage	O
-	O
like	O
cell	O
line	O
,	O
RAW	O
264.7	O
.	O

This	O
enzyme	O
acylates	O
the	O
head	O
group	O
glycerol	B
of	O
sn-3	B
:	I
sn-1	I
'	I
lysophosphatidylglycerol	I
to	O
form	O
sn-3	B
:	I
sn-1	I
'	I
bis	I
(	I
monoacylglycerol	I
)	I
phosphate	I
.	O

Here	O
we	O
demonstrate	O
that	O
this	O
enzyme	O
uses	O
two	O
lysophosphatidylglycerol	B
molecules	O
,	O
one	O
as	O
an	O
acyl	O
donor	O
and	O
another	O
as	O
an	O
acyl	O
acceptor	O
,	O
and	O
that	O
the	O
acyl	O
contributions	O
from	O
all	O
other	O
lipids	B
tested	O
are	O
comparatively	O
minor	O
.	O

This	O
enzyme	O
prefers	O
saturated	O
acyl	O
chains	O
to	O
monounsaturates	B
,	O
16	B
and	O
18	B
carbon	I
fatty	I
acids	I
over	O
14	B
carbon	I
fatty	I
acids	I
,	O
and	O
saturated	O
acyl	B
chains	I
at	O
the	O
sn-1	O
position	O
to	O
monounsaturated	O
acyl	B
chains	I
on	O
the	O
sn-2	O
carbon	B
of	O
lysophosphatidylglycerol	O
.	O

We	O
present	O
data	O
which	O
show	O
the	O
transacylase	O
activity	O
depends	O
on	O
the	O
presence	O
of	O
a	O
lipid	B
-	O
water	B
interface	O
and	O
the	O
lipid	B
polymorphic	O
state	O
.	O

INTRODUCTION	O
We	O
have	O
recently	O
shown	O
that	O
rabbit	O
antibodies	O
to	O
the	O
p	B
-	I
azophenylphosphorylcholine	I
(	O
APPC	B
)	O
determinant	O
,	O
which	O
bears	O
2	O
charges	O
of	O
opposite	O
sign	O
,	O
have	O
both	O
positively	O
and	O
negatively	O
charged	O
groups	O
in	O
their	O
binding	O
sites	O
(	O
Krausz	O
et	O
al.	O
,	O
1976	O
)	O
.	O

The	O
positive	O
charge	O
is	O
contributed	O
by	O
the	O
guanidinium	B
group	I
of	O
arginine	B
and	O
the	O
negative	O
charge	O
is	O
contributed	O
by	O
the	O
carboxylate	B
group	I
of	B
either	O
a	B
glutamyl	B
or	O
aspartyl	B
residue	I
.	O

We	O
have	O
also	O
previously	O
shown	O
(	O
Grossberg	O
et	O
al.	O
,	O
1974	O
)	O
that	O
the	O
phosphorylcholine	B
-	O
binding	O
mouse	O
myeloma	O
protein	O
,	O
HOPC-8	O
,	O
similarly	O
contains	O
gaunidinium	B
and	O
carboxylate	B
groups	I
in	O
its	O
binding	O
site	O
.	O

In	O
an	O
attempt	O
to	O
gain	O
further	O
insight	O
into	O
the	O
nature	O
of	O
these	O
binding	O
sites	O
we	O
have	O
measured	O
the	O
relative	O
binding	O
constants	O
of	O
several	O
structurally	O
related	O
small	O
molecules	O
with	O
anti	O
-	O
APPC	B
antibodies	O
and	O
with	O
HOPC-8	O
.	O

The	O
Krel	O
values	O
for	O
hapten	B
binding	O
to	O
the	O
rabbit	O
anti	O
-	O
APPC	B
antibodies	O
and	O
to	O
the	O
myeloma	O
protein	O
,	O
together	O
with	O
our	O
evidence	O
for	O
specific	O
functional	O
groups	O
in	O
the	O
binding	O
sites	O
,	O
have	O
allowed	O
us	O
to	O
draw	O
inferences	O
regarding	O
the	O
topography	O
of	O
the	O
binding	O
sites	O
of	O
anti	O
-	O
APPC	B
antibodies	O
and	O
HOPC-8	O
.	O

*	O
This	O
work	O
was	O
supported	O
in	O
part	O
by	O
U.S.	O
Public	O
Health	O
Service	O
Research	O
Grants	O
CA-11656	O
and	O
AI-03962	O
from	O
the	O
National	O
Cancer	O
Institute	O
.	O

t	O
A	O
unit	O
of	O
the	O
New	O
York	O
State	O
Department	O
of	O
Health	O
.	O

$	O
Abbreviations	O
used	O
:	O
APPC	B
,	O
p	B
-	I
azophenylphosphorylcholine	I
;	O
NPPC	B
,	O
p	B
-	I
nitrophenylphosphorylcholine	I
;	O
PC	B
,	O
phosphorylcholine	B
;	O
GPC	B
,	O
L	B
-	I
a	I
-	I
glycerophosphorylcholine	I
;	O
AcC	B
,	O
acetylcholine	B
;	O
I	B
-	I
Ap	I
,	O
p	B
-	I
iodophenyltrimethylammonium	I
;	O
PO3	B
,	O
phenylphosphate	B
;	O
03	B
,	O
phenylphosphonate	B
;	O
BBS	B
,	O
borate	B
buffered	I
saline	I
.	O

901	O
MATERIALS	O
AND	O
METHODS	O
p	B
-	I
Diazonium	I
phenylphosphorylcholine	I
chloride	I
(	O
DPPC	B
)	O
This	O
was	O
prepared	O
according	O
to	O
Chesebro	O
&	O
Metzger	O
(	O
1972	O
)	O
with	O
the	O
exception	O
that	O
in	O
the	O
diazotization	O
step	O
1.0	O
N	O
HCl	B
rather	O
than	O
0.1	O
N	O
HCl	B
was	O
used	O
(	O
Grossberg	O
et	O
al.	O
,	O
1974	O
)	O
.	O

Haptens	B
Haptens	B
tested	O
were	O
reagent	O
grade	O
commercial	O
products	O
,	O
used	O
without	O
further	O
purification	O
.	O

Goat	O
anti	O
-	O
rabbit	O
IgG	O
This	O
serum	O
was	O
a	O
preparation	O
previously	O
described	O
(	O
Hoffman	O
et	O
al.	O
,	O
1971	O
)	O
.	O

Rabbit	O
anti	O
-	O
mouse	O
IgA	O
This	O
serum	O
was	O
obtained	O
from	O
Dr.	O
Oliver	O
A.	O
Roholt	O
of	O
our	O
Department	O
.	O

It	O
was	O
prepared	O
by	O
hyperimmunization	O
of	O
rabbits	O
with	O
MOPC-315	O
myeloma	O
protein	O
.	O

Anti	O
-	O
APPC	B
antibodies	O
The	O
preparation	O
of	O
rabbit	O
antisera	O
to	O
the	O
APPC	B
determinant	O
and	O
the	O
subsequent	O
isolation	O
and	O
purification	O
of	O
the	O
antibodies	O
from	O
individual	O
rabbits	O
by	O
specific	O
immunoadsorption	O
has	O
been	O
described	O
previously	O
(	O
Krausz	O
et	O
al.	O
,	O
1976	O
)	O
.	O

In	O
the	O
present	O
work	O
preparations	O
from	O
rabbits	O
6055	O
and	O
6057	O
were	O
specifically	O
purified	O
anti	O
-	O
APPC	B
antibodies	O
and	O
the	O
preparation	O
from	O
rabbit	O
5920	O
was	O
a	O
gamma	O
globulin	O
fraction	O
of	O
anti	O
-	O
APPC	B
serum	O
.	O

HOPC-8	O
myeloma	O
protein	O
This	O
was	O
obtained	O
from	O
the	O
serum	O
of	O
tumor	O
-	O
bearing	O
mice	O
as	O
previously	O
described	O
(	O
Grossberg	O
et	O
al.	O
,	O
1974	O
)	O
.	O

The	O
myeloma	O
tumor	O
was	O
obtained	O
through	O
the	O
courtesy	O
of	O
Dr.	O
Michael	O
Potter	O
,	O
National	O
Cancer	O
Institute	O
,	O
Bethesda	O
,	O
MD	O
.	O

L.	O
M.	O
KRAUSZ	O
,	O
A.	O
L.	O
GROSSBERG	O
and	O
D.	O
PRESSMAN	O
Rabbit	O
serum	O
albumin	O
(	O
RSA	O
)	O
This	O
was	O
Fraction	O
V	O
obtained	O
from	O
Pentex	O
,	O
Inc.	O
,	O
Kankakee	O
,	O
IL	O
.	O

RSA	O
-	O
APPC	B
This	O
was	O
prepared	O
by	O
reacting	O
160	O
mg	O
of	O
RSA	O
in	O
about	O
10	O
ml	O
of	O
pH	O
9.5	O
borate	B
buffer	I
with	O
90	O
umoles	O
of	O
DPPC	B
for	O
18	O
hr	O
.	O

The	O
solution	O
was	O
then	O
dialyzed	O
against	O
pH	O
8	O
z	O
BBS	B
,	O
stored	O
frozen	O
and	O
used	O
as	O
needed	O
.	O

The	O
entire	O
prep-	O
ae	O
aration	O
was	O
carried	O
out	O
at	O
4	O
.	O

Radioiodination	O
of	O
RSA	O
-	O
APPC	B
RSA	O
-	O
APPC	B
was	O
trace	O
labeled	O
with	O
'	B
251	I
by	O
a	O
modification	O
of	O
the	O
method	O
of	O
Greenwood	O
et	O
al.	O
(	O
1963	O
)	O
.	O

Iodination	O
was	O
carried	O
out	O
in	O
0.45	O
ml	O
of	O
pH	O
8	O
BBS	B
containing	O
200	O
Ug	O
(	O
ca	O
.	O

3	O
n	O
-	O
mole	O
)	O
RSA	O
-	O
APPC	B
,	O
1	O
n	O
-	O
mole	O
of	O
KI	B
,	O
0.4	O
mCi	O
of	O
'	B
ZSI	I
and	O
300	O
n	O
-	O
mole	O
of	O
chloromine	B
T.	I
The	O
reaction	O
was	O
allowed	O
to	O
proceed	O
for	O
30	O
min	O
,	O
stopped	O
with	O
300	O
n	O
-	O
mole	O
of	O
bisulfite	B
and	O
the	O
product	O
dialyzed	O
to	O
remove	O
free	O
"	O
'	O
I	O
and	O
reagents	B
.	O

Measurement	O
of	O
K	O
,	O
e	O
,	O
The	O
method	O
used	O
to	O
obtain	O
the	O
relative	O
binding	O
constants	O
for	O
the	O
various	O
haptens	B
is	O
based	O
on	O
the	O
technique	O
originally	O
developed	O
by	O
Skom	O
&	O
Talmadge	O
(	O
1958	O
)	O
for	O
precipitating	O
antigen	O
-	O
antibody	O
complexes	O
with	O
antiglobulin	O
.	O

In	O
our	O
assay	O
the	O
primary	O
haptenic	O
determinant	O
,	O
p	B
-	I
azophenylphosphory1choline	I
,	O
was	O
coupled	O
to	O
rabbit	O
serum	O
albumin	O
which	O
was	O
then	O
trace	O
labeled	O
with	O
1251	B
.	O

Labeled	B
antigen	I
was	O
mixed	O
with	O
varying	O
amounts	O
of	O
antibody	O
and	O
the	O
amount	O
of	O
antigen	B
bound	O
was	O
determined	O
by	O
precipitating	O
all	O
the	O
gamma	O
globulin	O
(	O
i.e.	O
bound	O
and	O
unbound	O
antibody	O
as	O
well	O
as	O
non	O
-	O
specific	O
y	O
globulin	O
)	O
with	O
goat	O
antiglobulin	O
antibody	O
and	O
measuring	O
the	O
radioactivity	O
associated	O
with	O
the	O
precipitate	O
.	O

Relative	O
binding	O
constants	O
(	O
K	O
,	O
e	O
,	O
)	O
for	O
the	O
different	O
haptens	B
were	O
determined	O
by	O
measuring	O
their	O
ability	O
to	O
inhibit	O
the	O
reaction	O
of	O
labeled	O
antigen	B
with	O
antibody	O
.	O

The	O
amount	O
of	O
antibody	O
was	O
chosen	O
so	O
that	O
about	O
60	O
%	O
of	O
the	O
labeled	O
antigen	B
was	O
bound	O
by	O
antibody	O
in	O
the	O
absence	O
of	O
hapten	B
.	O

In	O
a	O
typical	O
determination	O
the	O
antigen	B
solution	O
was	O
made	O
to	O
contain	O
100	O
ng	O
per	O
ml	O
of	O
1251-RSA	O
-	O
APPC	B
and	O
1	O
mg	O
/	O
ml	O
of	O
RSA	O
in	O
pH	O
8	O
BBS	B
.	O

The	O
required	O
concentration	O
of	O
antibody	O
was	O
made	O
up	O
in	O
normal	O
rabbit	O
serum	O
diluted	O
1:5	O
with	O
pH	O
8	O
BBS	B
.	O

HOPC-8	O
myeloma	O
protein	O
was	O
made	O
up	O
in	O
normal	O
mouse	O
serum	O
diluted	O
1:5	O
.	O

To	O
0.1	O
ml	O
of	O
antibody	O
(	O
or	O
HOPC-8	O
)	O
solution	O
were	O
added	O
,	O
0.1	O
ml	O
'	O
251-RSA	O
-	O
APPC	O
solution	O
and	O
0.1	O
ml	O
hapten	B
solution	O
in	O
pH	O
8	O
BBS	B
.	O

Hapten	B
concentrations	O
ranged	O
from	O
10	O
'	O
to	O
10-'M.	O
In	O
one	O
sample	O
(	O
uninhibited	O
)	O
,	O
hapten	B
solution	O
was	O
replaced	O
by	O
buffer	B
to	O
determine	O
the	O
amount	O
of	O
antigen	B
precipitated	O
in	O
the	O
absence	O
of	O
hapten	B
.	O

Another	O
mixture	O
(	O
non	O
-	O
specific	O
control	O
)	O
contained	O
0.1	O
ml	O
1:5	O
diluted	O
normal	O
rabbit	O
(	O
or	O
mouse	O
)	O
serum	O
in	O
place	O
of	O
antibody	O
,	O
0.1	O
ml	O
of	O
antigen	B
and	O
0.1	O
ml	O
of	O
buffer	B
.	O

All	O
tubes	O
were	O
incubated	O
at	O
37	O
for	O
30	O
min	O
.	O

Then	O
0.2	O
ml	O
of	O
anti	O
-	O
globulin	O
antiserum	O
was	O
added	O
to	O
all	O
tubes	O
.	O

The	O
amount	O
added	O
was	O
that	O
determined	O
to	O
be	O
sufficient	O
to	O
precipitate	O
all	O
the	O
globulin	O
in	O
the	O
mixture	O
.	O

Goat	O
anti	O
-	O
rabbit	O
y	O
-	O
globulin	O
was	O
used	O
to	O
precipitate	O
the	O
rabbit	O
antibodies	O
and	O
rabbit	O
anti	O
-	O
mouse	O
IgA	O
was	O
used	O
to	O
precipitate	O
the	O
HOPC-8	O
myeloma	O
protein	O
.	O

The	O
reaction	O
mixtures	O
were	O
allowed	O
to	O
stand	O
at	O
room	O
temperature	O
for	O
1	O
hr	O
,	O
and	O
then	O
stored	O
at	O
5	O
overnight	O
.	O

The	O
tubes	O
were	O
centrifuged	O
,	O
the	O
supernatants	O
discarded	O
and	O
the	O
precipitates	O
washed	O
twice	O
with	O
saline	B
.	O

Radioactivity	O
in	O
the	O
precipitates	O
was	O
determined	O
.	O

All	O
determinations	O
were	O
done	O
in	O
duplicate	O
.	O

Per	O
cent	O
inhibition	O
is	O
given	O
by	O
:	O
Inhibition	O
=	O
f	O
1	O
ANTI	O
-	O
APPC	O
#	O
6055	O
loo	O
50	O
01	O
10	O
-	O
6	O
10	O
-	O
5	O
NPPC	B
GPC	B
,	O
Pc	O
P03	O
I_AD	O
CHOLINE	O
10	O
4	O
10	O
-	O
3	O
10-z	O
10	O
I	O
INHIBITOR	O
CONC	O
.	O

(	O
M	O
)	O
Fig.	O
1	O
.	O

Plots	O
of	O
the	O
inhibition	O
by	O
haptens	B
of	O
the	O
binding	O
of	O
RSA	O
-	O
APPC	B
antigen	B
to	O
anti	O
-	O
APPC	O
antibody	O
from	O
rabbit	O
6055	O
.	O

Values	O
determined	O
in	O
this	O
manner	O
were	O
reproducible	O
to	O
within	O
%	O
.	O

RESULTS	O
Plots	O
of	O
effect	O
of	O
hapten	B
on	O
antigen	B
binding	O
are	O
given	O
in	O
Fig.	O
1	O
for	O
anti	O
-	O
APPC	O
from	O
rabbit	O
6055	O
and	O
in	O
Fig.	O
2	O
for	O
anti	O
-	O
APPC	O
from	O
rabbit	O
5920	O
.	O

The	O
plots	O
for	O
anti	O
-	O
APPC	O
from	O
rabbit	O
6057	O
,	O
were	O
essentially	O
identical	O
to	O
those	O
in	O
Fig.	O
1	O
.	O

From	O
these	O
data	O
,	O
K	O
,	O
el	O
values	O
were	O
calculated	O
relative	O
to	O
the	O
most	O
inhibitory	O
hapten	B
,	O
NPPC	B
,	O
according	O
to	O
the	O
formula	O
:	O
_	O
(	O
NPPC	B
)	O
at	O
50	O
%	O
inhibition	O
K	O
"	O
'	O
(	O
HAPTEN	B
)	O
at	O
50	O
%	O
inhibition	O
The	O
values	O
of	O
K	O
,	O
e	O
,	O
are	O
given	O
in	O
Table	O
1	O
.	O

The	O
only	O
effective	O
inhibitors	O
observed	O
are	O
those	O
listed	O
in	O
Table	O
1	O
,	O
having	O
K	O
,	O
e	O
,	O
values	O
>	O
0.0001	O
.	O

It	O
is	O
interesting	O
that	O
the	O
p	B
-	I
iodophenyltrimethylammonium	I
ion	I
gave	O
detectable	O
inhibition	O
in	O
2	O
instances	O
.	O

Twentyfive	O
other	O
haptens	B
were	O
tested	O
.	O

None	O
showed	O
appreciable	O
binding	O
to	O
anti	O
-	O
APPC	B
antibodies	O
.	O

Among	O
those	O
tested	O
were	O
negatively	O
and	O
positively	O
chargen	O
haptens	B
,	O
including	O
other	O
phenyltrimethylammonium	B
ions	I
and	O
ANTI	O
-	O
APPC	O
#	O
5920	O
loo	O
50	O
z	O
x	O
NPPC	B
,	O
GPC	O
I	O
-	O
AP	O
PC	O
CHOLINE	B
0	O
10	O
-	O
6	O
10	O
-	O
5	O
10	O
4	O
10	O
-	O
3	O
10-z	O
10-I	O
INHIBITOR	O
CONC.	O
(	O
M	O
)	O
Fig.	O
2	O
.	O

Plots	O
of	O
the	O
inhibition	O
by	O
haptens	O
of	O
the	O
binding	O
of	O
RSA	O
-	O
APPC	B
antigen	O
to	O
anti	O
-	O
APPC	B
antibody	O
from	O
rabbit	O
5920	O
.	O

inhibited	O
sample	O
counts	O
/	O
min	O
-	O
non	O
-	O
specific	O
control	O
counts	O
/	O
min	O
uninhibited	O
sample	O
counts	O
/	O
min	O
-	O
non	O
-	O
specific	O
control	O
counts	O
/	O
min	O
x	O
100	O
.	O

Specificity	O
of	O
Anti	O
-	O
p	O
-	O
Azophenylphosphorylcholine	B
Antibodies	O
Table	O
1	O
.	O

Relative	O
binding	O
constants	O
of	O
haptens	B
for	O
anti	O
APPC	B
antibodies	O
Hapten	O
NPPC	O
t	I
.-	I
a	I
-	I
glycerophosphorylcholine	I
Phosphorylcholine	B
I	B
-	I
Ap	I
Choline	I
Phenylphosphonate	B
Phenylphosphate	B
Rabbit	O
No.	O
5920	O
6055	O
6057	O
K	O
1.0	O
0.015	O
0.0003	O
0.004	O
0.0007	O
0.0001	O
0.0001	O
1.0	O
1.0	O
0.019	O
0.016	O
0.0004	O
0.0005	O
0.0001	O
<	O
0.0001	O
0.00006	O
0.00006	O
0.0002	O
<	O
0.0001	O
0.0001	O
<	O
0.0001	O
several	O
phenylarsonates	B
and	O
sulfonates	B
.	O

A	O
representative	O
list	O
of	O
some	O
of	O
these	O
non	O
-	O
inhibitory	O
haptens	B
is	O
given	O
in	O
Table	O
2	O
.	O

The	O
results	O
of	O
inhibition	O
studies	O
with	O
the	O
mouse	O
myeloma	O
protein	O
HOPC-8	O
are	O
given	O
in	O
Fig.	O
3	O
where	O
the	O
inhibition	O
curves	O
are	O
drawn	O
only	O
for	O
those	O
haptens	B
showing	O
significant	O
ability	O
to	O
inhibit	O
.	O

K	O
,	O
e	O
,	O
values	O
were	O
calculated	O
as	O
described	O
above	O
and	O
are	O
listed	O
in	O
Table	O
3	O
.	O

For	O
comparison	O
,	O
Table	O
3	O
also	O
lists	O
values	O
of	O
K	O
,	O
el	O
calculated	O
from	O
the	O
data	O
of	O
Leon	O
&	O
Young	O
(	O
1971	O
)	O
for	O
TEPC-15	B
in	O
a	O
system	O
using	O
the	O
C	B
-	I
polysaccharide	I
of	O
pneumococcus	O
as	O
an	O
antigen	B
.	O

There	O
is	O
adequate	O
serological	O
and	O
chemical	O
evidence	O
showing	O
that	O
HOPC-8	O
and	O
TEPC-15	O
are	O
nearly	O
identical	O
proteins	O
(	O
Potter	O
&	O
Lieberman	O
,	O
1970	O
;	O
Hood	O
et	O
al.	O
,	O
1970	O
)	O
.	O

The	O
values	O
in	O
Table	O
3	O
show	O
the	O
close	O
correspondence	O
between	O
our	O
values	O
of	O
K	O
,	O
e	O
,	O
for	O
HOPC-8	O
and	O
those	O
calculated	O
from	O
the	O
data	O
of	O
Leon	O
&	O
Young	O
for	O
TECP-15	O
.	O

The	O
K	O
,	O
e	O
,	O
values	O
for	O
anti	O
-	O
APPC	B
from	O
rabbit	O
6055	O
are	O
also	O
listed	O
in	O
Table	O
3	O
to	O
facilitate	O
comparisons	O
with	O
HOPC-8	O
.	O

In	O
order	O
to	O
assess	O
further	O
the	O
validity	O
of	O
the	O
inhibition	O
method	O
as	O
used	O
here	O
for	O
obtaining	O
Kre	O
,	O
values	O
,	O
we	O
have	O
compared	O
the	O
value	O
of	O
K	O
,	O
e	O
,	O
calculated	O
from	O
the	O
individual	O
binding	O
constants	O
of	O
HOPC-8	O
for	O
phosphory1choline	B
(	O
PC	B
)	O
and	O
p	B
-	I
nitrophenylphosphorylcholine	I
(	O
NPPC	B
)	O
as	O
determined	O
by	O
equilibrium	O
dialysis	O
,	O
to	O
the	O
Kre	O
,	O
values	O
calculated	O
from	O
the	O
inhibition	O
data	O
.	O

As	O
measured	O
by	O
equilibrium	O
dialysis	O
with	O
HOPC-8	O
the	O
binding	O
constant	O
for	O
PC	B
(	O
KPc	O
)	O
was	O
found	O
to	O
be	O
1.2	O
x	O
106	O
M-1	O
and	O
for	O
NPPC	B
the	O
KNPPC	O
was	O
0.43	O
x	O
106	O
M-1	O
(	O
Krausz	O
et	O
al.	O
,	O
1976	O
)	O
.	O

The	O
ratio	O
of	O
the	O
two	O
is	O
:	O
1.20	O
x	O
106	O
_	O
KPCIKNPPC	O
-	O
0.43	O
x	O
106	O
-	O
2.8	O
.	O

Table	O
2	O
.	O

Haptens	B
unable	O
to	O
inhibit	O
binding	O
of	O
RSA	O
-	O
APPC	B
to	O
anti	O
-	O
APPC	B
antibodies	O
"	O
Acetylcholine	B
Phenyltrimethylammonium	B
p	B
-	I
Aminophenyltrimethylammonium	I
chloride	I
Phenylarsonate	B
p	B
-	I
Nitrophenylarsonate	I
p	B
-	I
lodophenylarsonate	I
Hydroxyphenylazo	B
)	I
phenylarsonate	I
p	B
-	I
lodobenzenesulfonate	I
Naphthalene	B
-	I
l	I
-	I
sulfonate	I
5-Nitro-3-iodo-4-hydroxyphenylacetate	B
5-Nitro-4-hydroxyphenylacetate	B
Kre	O
,	O
<	O
0.0001	O
,	O
relative	O
to	O
NPPC	B
,	O
which	O
is	O
equivalent	O
to	O
<	O
50	O
%	O
inhibition	O
at	O
0.1	O
M	O
hapten	B
concentration	O
.	O

903	O
HOPC-8	O
100	O
PC	O
WPC	O
I	O
-	O
Ap	O
GPC	O
AcC	O
m	O
50	O
z	O
_	O
<	O
60P	O
Y	O
,	O
OOPO=3	O
~	O
OP	O
03	O
0	O
ITS	O
I	O
I	O
INHIBITOR	O
CONC	O
.	O

(	O
M	O
)	O
IT	O
2	O
IT	O
l	O
Fig.	O
3	O
.	O

Plots	O
of	O
the	O
inhibition	O
by	O
haptens	B
of	O
the	O
binding	O
of	O
RSA	O
-	O
APPC	B
antigen	B
to	O
mouse	O
myeloma	O
protein	O
HOPC-8	O
.	O

The	O
ratio	O
obtained	O
using	O
K	O
,	O
e	O
,	O
values	O
obtained	O
by	O
hapten	B
inhibition	O
(	O
Table	O
3	O
)	O
is	O
2.9	O
,	O
a	O
satisfactory	O
agreement	O
.	O

DISCUSSION	O
The	O
relative	O
binding	O
constants	O
(	O
K	O
,	O
,	O
,	O
)	O
for	O
haptens	B
to	O
anti	O
-	O
APPC	B
antibodies	O
were	O
determined	O
by	O
hapten	B
inhibition	O
.	O

About	O
30	O
potential	O
ligands	B
were	O
tested	O
and	O
only	O
5	O
of	O
these	O
were	O
shown	O
to	O
bind	O
significantly	O
(	O
NPPC	B
,	O
glycerophosphorylcholine	B
,	O
I	B
-	I
Ap	I
,	O
choline	B
and	O
phosphorylcholine	B
)	O
.	O

The	O
values	O
of	O
K	O
,	O
,	O
,	O
obtained	O
with	O
the	O
several	O
haptens	B
allow	O
inferences	O
as	O
to	O
the	O
relative	O
importance	O
of	O
the	O
particular	O
structural	O
features	O
of	O
each	O
hapten	B
in	O
contributing	O
to	O
the	O
binding	O
energy	O
.	O

The	O
rabbit	O
anti	O
-	O
APPC	B
antibodies	O
studied	O
here	O
were	O
raised	O
against	O
a	O
hapten	B
having	O
3	O
distinct	O
structural	O
features	O
-	O
a	O
p	B
-	I
azophenyl	I
group	I
,	O
a	O
negatively	O
charged	O
phosphoryl	B
ester	I
group	I
,	O
and	O
a	O
positively	O
charged	O
quarternary	B
ammonium	I
group	I
.	O

Of	O
these	O
,	O
the	O
one	O
apparently	O
very	O
important	O
for	O
binding	O
is	O
the	O
positively	B
charged	I
group	I
,	O
since	O
haptens	B
which	O
were	O
most	O
effective	O
in	O
inhibiting	O
the	O
binding	O
of	O
the	O
APPC	B
-	B
containing	I
antigen	I
to	O
antibody	O
contained	O
this	O
group	O
(	O
Table	O
1	O
)	O
and	O
those	O
least	O
effective	O
did	O
not	O
.	O

Thus	O
,	O
removal	O
of	O
the	O
choline	B
group	I
from	O
phenylphosphorylcholine	B
decreases	O
its	O
binding	O
strength	O
by	O
a	O
factor	O
of	O
about	O
Table	O
3	O
.	O

Comparison	O
of	O
K	O
,	O
e	O
,	O
values	O
for	O
HOPC-8	O
,	O
TEPC-15	O
and	O
a	O
rabbit	O
anti	O
-	O
APPC	B
antibody	O
Hapten	B
HOPC-8	O
2.9	O
1.0	O
0.5	O
0.033	O
0.015	O
0.01	O
"	O
0.001	O
<	O
0.0001	O
Rabbit	O
anti	O
APPC	B
-	O
No	O
.	O

6055	O
K	O
,	O
TEPC-15	O
Phosphorylcholine	B
NPPC	B
-a	O
-	B
glycerophosphorylchole	I
I	B
-	I
Ap	I
Acetylcholine	B
Choline	B
Phenylphosphate	B
Phenylphosphonate	B
2.9	O
0.0004	O
1.0	O
0.019	O
0.0001	O
0.0001	O
0.008	O
0.00006	O
0.005	O
0.0001	O
-	O
0.0002	O
-	O
0.27	O
Calculated	O
from	O
the	O
data	O
of	O
Leon	O
&	O
Young	O
(	O
1971	O
)	O
for	O
the	O
inhibition	O
of	O
binding	O
of	O
c	B
-	I
polysaccharide	I
of	O
Pneumococcus	O
.	O

The	O
values	O
were	O
obtained	O
by	O
setting	O
the	O
Kre	O
,	O
value	O
for	O
phosphorylchole	B
at	O
2.9	O
and	O
calculating	O
the	O
other	O
values	O
relative	O
to	O
this	O
.	O

"	O
Estimated	O
from	O
the	O
value	O
of	O
Kre	O
,	O
for	O
choline	B
with	O
TEPC-15	O
.	O

904	O
L.	O
M.	O
KRAUSZ	O
,	O
A.	O
L.	O
GROSSBERG	O
and	O
D.	O
PRESSMAN	O
10,000	O
since	O
K	O
,	O
e	O
,	O
for	O
phenylphosphate	B
was	O
at	O
least	O
this	O
much	O
smaller	O
than	O
the	O
K	O
,	O
e	O
,	O
for	O
NPPC	B
(	O
Table	O
1	O
)	O
.	O

Moreover	O
,	O
p	B
-	I
iodophenyltrimethylammonium	I
gave	O
detectable	O
inhibition	O
with	O
one	O
anti	O
-	O
APPC	B
preparation	O
,	O
although	O
its	O
structure	O
is	O
otherwise	O
rather	O
different	O
from	O
the	O
choline	B
inhibitors	O
.	O

The	O
p	B
-	I
nitrophenyl	I
group	I
of	O
NPPC	B
contributes	O
very	O
effectively	O
to	O
the	O
specific	O
interaction	O
,	O
since	O
replacing	O
it	O
by	O
the	O
glycerol	B
group	I
decreases	O
the	O
binding	O
by	O
a	O
factor	O
of	O
50	O
(	O
Table	O
1	O
)	O
.	O

Similarly	O
,	O
removing	O
the	O
p	B
-	I
nitrophenyl	I
group	I
,	O
to	O
give	O
phosphorylcholine	B
,	O
decreases	O
the	O
binding	O
by	O
another	O
factor	O
of	O
50	O
(	O
Table	O
1	O
)	O
so	O
that	O
phosphorylcholine	B
binds	O
2500	O
times	O
more	O
weakly	O
than	O
NPPC	B
.	O

The	O
negatively	O
charged	O
phosphoryl	B
group	I
apparently	O
interacts	O
only	O
to	O
a	O
small	O
extent	O
with	O
the	O
antibody	O
site	O
.	O

This	O
is	O
evident	O
from	O
the	O
fact	O
that	O
K	O
,	O
,	O
,	O
for	O
phosphorylcholine	B
is	O
only	O
6	O
-	O
8	O
times	O
greater	O
than	O
Kre	O
,	O
for	O
choline	B
for	O
2	O
antibody	O
preparations	O
studied	O
and	O
is	O
actually	O
smaller	O
than	O
that	O
for	O
choline	B
for	O
the	O
third	O
antibody	O
preparation	O
(	O
Table	O
1	O
)	O
.	O

In	O
addition	O
,	O
phenylphosphate	B
(	O
Table	O
2	O
)	O
and	O
phenylphosphonate	B
(	O
Table	O
1	O
)	O
show	O
only	O
weak	O
binding	O
to	O
the	O
antibodies	O
.	O

Thus	O
the	O
contribution	O
of	O
the	O
negative	O
charge	O
to	O
binding	O
is	O
not	O
great	O
,	O
in	O
spite	O
of	O
the	O
fact	O
that	O
we	O
have	O
previously	O
shown	O
(	O
Krausz	O
et	O
al.	O
,	O
1976	O
)	O
that	O
a	O
positively	O
charged	O
arginyl	B
residue	I
is	O
present	O
in	O
the	O
anti	O
-	O
APPC	B
antibody	O
site	O
,	O
providing	O
a	O
basis	O
for	O
electrostatic	O
interaction	O
with	O
the	O
phosphoryl	B
group	I
.	O

When	O
the	O
rabbit	O
anti	O
-	O
APPC	B
antibodies	O
are	O
compared	O
to	O
the	O
mouse	O
myeloma	O
protein	O
,	O
HOPC-8	O
,	O
some	O
very	O
obvious	O
differences	O
in	O
specificity	O
are	O
apparent	O
.	O

In	O
general	O
HOPC-8	O
shows	O
broader	O
cross	O
-	O
reactivity	O
than	O
the	O
induced	O
rabbit	O
antibody	O
.	O

The	O
representative	O
comparison	O
of	O
K	O
,	O
e	O
,	O
values	O
(	O
relative	O
to	O
NPPC	B
)	O
given	O
in	O
Table	O
3	O
,	O
indicates	O
that	O
many	O
more	O
of	O
the	O
compounds	O
listed	O
show	O
appreciable	O
binding	O
(	O
K	O
,	O
e	O
,	O
>	O
0.005	O
)	O
to	O
HOPC-8	O
than	O
to	O
rabbit	O
anti	O
-	O
APPC	B
.	O

In	O
addition	O
,	O
the	O
fine	O
specificity	O
of	O
HOPC-8	O
is	O
quite	O
different	O
from	O
that	O
of	O
the	O
rabbit	O
antibody	O
,	O
since	O
the	O
relative	O
binding	O
constant	O
for	O
phosphorylcholine	B
is	O
10	O
'	O
greater	O
with	O
HOPC-8	O
than	O
with	O
rabbit	O
anti	O
-	O
APPC	B
.	O

The	O
binding	O
to	O
the	O
2	O
proteins	O
differs	O
for	O
glycerophosphorylcholine	B
by	O
a	O
factor	O
of	O
25	O
,	O
for	O
chohne	B
by	O
a	O
factor	O
of	O
100	O
and	O
for	O
acetylcholine	B
by	O
a	O
factor	O
greater	O
than	O
100	O
.	O

The	O
negatively	O
charged	O
phosphoryl	B
group	I
appears	O
to	O
be	O
much	O
more	O
important	O
for	O
binding	O
to	O
HOPC-8	O
than	O
to	O
the	O
rabbit	O
antibody	O
,	O
since	O
the	O
K-	O
,	O
value	O
for	O
phosphorylcholine	B
is	O
greater	O
than	O
that	O
for	O
choline	B
by	O
a	O
factor	O
of	O
about	O
300	O
in	O
the	O
case	O
of	O
HOPC-8	O
.	O

For	O
rabbit	O
antibody	O
this	O
factor	O
is	O
only	O
about	O
10	O
(	O
Table	O
3	O
)	O
.	O

Moreover	O
,	O
phenylphosphate	B
binds	O
more	O
than	O
10	O
times	O
more	O
strongly	O
to	O
HOPC-8	O
than	O
to	O
anti	O
-	O
APPC	B
antibody	O
.	O

This	O
is	O
in	O
spite	O
of	O
the	O
fact	O
that	O
the	O
addition	O
of	O
the	O
p	B
-	I
nitrophenyl	I
group	I
to	O
phosphorylcholine	B
neither	O
adds	O
to	O
nor	O
subtracts	O
from	O
the	O
binding	O
energy	O
with	O
HOPC-8	O
,	O
whereas	O
it	O
adds	O
a	O
great	O
deal	O
to	O
the	O
binding	O
energy	O
with	O
anti	O
-	O
APPC	B
antibody	O
.	O

The	O
fact	O
that	O
the	O
HOPC-8	O
site	O
is	O
large	O
enough	O
to	O
accommodate	O
the	O
p	B
-	I
nitrophenyl	I
group	I
of	O
NPPC	B
with	O
little	O
steric	O
hindrance	O
is	O
of	O
interest	O
,	O
since	O
the	O
site	O
of	O
McPC-603	O
protein	O
,	O
which	O
also	O
binds	O
phosphorylcholine	B
analogues	I
with	O
similar	O
although	O
not	O
identical	O
specificity	O
(	O
Leon	O
&	O
Young	O
,	O
1971	O
)	O
also	O
can	O
accommodate	O
a	O
large	O
substituent	O
on	O
phosphorylcholine	B
.	O

Thus	O
,	O
the	O
X	O
-	O
ray	O
crystallographic	O
structure	O
studies	O
of	O
the	O
Fab	O
fragment	O
of	O
McPC-603	O
as	O
summarized	O
by	O
Segal	O
et	O
al.	O
(	O
1974	O
)	O
indicate	O
that	O
there	O
is	O
a	O
large	O
region	O
of	O
the	O
cleft	O
in	O
which	O
phosphorylcholine	B
is	O
bound	O
which	O
is	O
available	O
for	O
binding	O
additional	O
structure	O
.	O

Indeed	O
,	O
one	O
of	O
the	O
compounds	O
used	O
in	O
defining	O
the	O
site	O
region	O
was	O
2-	B
(	I
5'-acetoxy	I
-	I
mercury-2'-thiemyl	I
)	I
-ethylphosphory1choline	I
(	O
Padlan	O
et	O
al.	O
,	O
1973	O
)	O
.	O

Our	O
studies	O
suggest	O
that	O
this	O
large	O
compound	O
might	O
bind	O
equally	O
as	O
well	O
to	O
the	O
HOPC-8	O
site	O
as	O
to	O
the	O
McPC-603	O
site	O
.	O

The	O
differences	O
between	O
HOPC-8	O
sites	O
and	O
rabbit	O
anti	O
-	O
APPC	B
sites	O
are	O
interesting	O
in	O
view	O
of	O
the	O
fact	O
that	O
when	O
APPC	B
conjugated	O
to	O
protein	O
is	O
used	O
as	O
an	O
immunogen	O
in	O
the	O
BALB	O
/	O
c	O
mouse	O
,	O
the	O
IgM	O
antibodies	O
elicited	O
are	O
largely	O
of	O
the	O
HOPC-8-TEPC-15	O
idiotype	O
and	O
show	O
the	O
same	O
binding	O
characteristics	O
as	O
the	O
myeloma	O
proteins	O
(	O
Lee	O
it	O
al.	O
,	O
1974	O
)	O
.	O

Thus	O
it	O
appears	O
that	O
the	O
receptor	O
sites	O
on	O
cells	O
responding	O
to	O
APPC	B
in	O
the	O
rabbits	O
we	O
used	O
are	O
quite	O
different	O
in	O
structure	O
from	O
sites	O
on	O
cells	O
which	O
respond	O
in	O
the	O
mouse	O
.	O

Furthermore	O
,	O
we	O
have	O
previously	O
observed	O
that	O
the	O
rabbit	O
antibodies	O
are	O
rather	O
heterogeneous	O
,	O
as	O
evidenced	O
by	O
their	O
non	O
-	O
linear	O
binding	O
curves	O
(	O
Krausz	O
et	O
al.	O
,	O
1976	O
)	O
,	O
and	O
their	O
complex	O
isoelectric	O
focusing	O
patterns	O
(	O
Nutt	O
et	O
al.	O
,	O
1976	O
)	O
.	O

Populations	O
of	O
anti	O
-	O
APPC	B
antibodies	O
produced	O
also	O
differ	O
from	O
rabbit	O
to	O
rabbit	O
as	O
evidenced	O
by	O
the	O
differences	O
in	O
binding	O
strength	O
for	O
p	B
-	I
iodophenyltrimethylammonium	I
and	O
for	O
choline	B
shown	O
by	O
antibodies	O
from	O
rabbits	O
6055	O
and	O
5920	O
(	O
Table	O
1	O
)	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
induced	O
mouse	O
antibodies	O
appear	O
to	O
be	O
essentially	O
monoclonal	O
products	O
(	O
Lee	O
et	O
al.	O
,	O
1974	O
)	O
.	O

There	O
are	O
,	O
of	O
course	O
,	O
some	O
similarities	O
between	O
the	O
rabbit	O
antibodies	O
and	O
HOPC-8	O
.	O

The	O
major	O
of	O
these	O
is	O
that	O
for	O
both	O
binding	O
sites	O
the	O
positively	O
charged	O
quarternary	B
ammonium	I
group	I
appears	O
to	O
be	O
the	O
immunodominant	O
group	O
,	O
since	O
those	O
haptens	B
not	O
containing	O
this	O
group	O
are	O
bound	O
very	O
poorly	O
in	O
both	O
cases	O
(	O
Table	O
3	O
)	O
.	O

Thus	O
a	O
negatively	O
charged	O
carboxylate	B
group	I
which	O
would	O
interact	O
with	O
this	O
group	O
,	O
and	O
which	O
we	O
have	O
shown	O
to	O
be	O
present	O
in	O
the	O
combining	O
site	O
of	O
both	O
HOPC-8	O
and	O
anti	O
-	O
APPC	B
antibodies	O
,	O
is	O
probably	O
the	O
most	O
important	O
common	O
feature	O
of	O
both	O
sites	O
.	O

The	O
above	O
considerations	O
allow	O
us	O
to	O
make	O
the	O
following	O
inferences	O
about	O
the	O
topography	O
of	O
the	O
antiAPPC	O
and	O
HOPC-8	O
binding	O
sites	O
:	O
(	O
1	O
)	O
The	O
anti	O
-	O
APPC	B
site	O
contains	O
a	O
region	O
closely	O
complementary	O
to	O
the	O
phenyl	B
group	I
of	O
APPC	B
,	O
so	O
that	O
an	O
appreciable	O
part	O
ofAhe	O
binding	O
interaction	O
occurs	O
in	O
this	O
region	O
.	O

The	O
HOPC-8	O
site	O
accommodates	O
the	O
phenyl	B
group	I
with	O
little	O
interaction	O
energy	O
.	O

(	O
2	O
)	O
An	O
arginyl	B
residue	I
in	O
the	O
HOPC-8	O
site	O
contributes	O
a	O
positive	O
charge	O
which	O
interacts	O
strongly	O
with	O
the	O
negative	O
charge	O
on	O
the	O
phosphoryl	B
group	I
.	O

In	O
the	O
anti	O
-	O
APPC	B
site	O
,	O
which	O
also	O
contains	O
an	O
arginyl	B
residue	I
,	O
the	O
interaction	O
with	O
the	O
phosphoryl	B
group	I
is	O
much	O
weaker	O
,	O
and	O
therefore	O
the	O
2	O
groups	O
are	O
probably	O
farther	O
apart	O
than	O
in	O
the	O
HOPC-8	O
site	O
.	O

(	O
3	O
)	O
Both	O
sites	O
interact	O
strongly	O
with	O
the	O
quaternary	B
ammonium	I
group	I
of	O
choline	B
and	O
thus	O
this	O
group	O
probably	O
closely	O
approaches	O
a	O
carboxylate	B
group	I
present	O
in	O
both	O
sites	O
.	O

Acknowledgements	O
-	O
We	O
thank	O
Messrs.	O
Robert	O
Hewson	O
,	O
Leonard	O
Rendina	O
and	O
Arthur	O
Trott	O
for	O
expert	O
technical	O
assistance	O
.	O

Specificity	O
of	O
Anti	O
-	O
p	B
-	I
Azophenylphosphorylcholine	I
Antibodies	O

Manganous	B
chloride	I
and	O
Congo	B
red	I
incorporated	O
into	O
blotting	O
paper	O
discs	O
have	O
been	O
used	O
to	O
differentiate	O
gonococci	O
from	O
meningococci	O
.	O

The	O
new	O
technique	O
is	O
simple	O
and	O
reliable	O
;	O
the	O
materials	O
for	O
the	O
test	O
are	O
inexpensive	O
.	O

The	O
method	O
will	O
increase	O
the	O
efficiency	O
of	O
distinguishing	O
between	O
the	O
pathogenic	O
Neisseria	O
in	O
any	O
clinical	O
bacteriology	O
laboratory	O
and	O
especially	O
in	O
those	O
in	O
the	O
tropical	O
areas	O
.	O

A	O
methodology	O
to	O
determine	O
the	O
intrinsic	O
capacities	O
of	O
a	O
microflora	O
to	O
degrade	O
gasoline	B
was	O
developed	O
,	O
in	O
particular	O
for	O
assessing	O
the	O
potential	O
of	O
autochtonous	O
populations	O
of	O
polluted	O
and	O
non	O
polluted	O
soils	O
for	O
natural	O
attenuation	O
and	O
engineered	O
bioremediation	O
.	O

A	O
model	O
mixture	O
(	O
GM23	B
)	O
constituted	O
of	O
the	O
23	O
most	O
representative	O
hydrocarbons	B
of	O
a	O
commercial	O
gasoline	B
was	O
used	O
.	O

The	O
capacities	O
of	O
the	O
microflorae	O
(	O
kinetics	O
and	O
extent	O
of	O
biodegradation	O
)	O
were	O
assessed	O
by	O
chromatographic	O
analysis	O
of	O
hydrocarbon	B
consumption	O
and	O
of	O
CO2	B
production	O
.	O

The	O
degradation	O
of	O
the	O
components	O
of	O
GM23	B
was	O
assayed	O
in	O
separate	O
incubations	O
of	O
each	O
component	O
and	O
in	O
the	O
complete	O
mixture	O
.	O

For	O
the	O
microflora	O
of	O
an	O
unpolluted	O
spruce	O
forest	O
soil	O
,	O
all	O
hydrocarbons	B
of	O
GM23	B
except	O
cyclohexane	B
,	O
2,2,4-	B
and	O
2,3,4-trimethylpentane	B
isomers	O
were	O
degraded	O
to	O
below	O
detection	O
limit	O
in	O
28	O
days	O
.	O

This	O
microflora	O
was	O
reinforced	O
with	O
two	O
mixed	O
microbial	O
communities	O
selected	O
from	O
gasoline	B
-	O
polluted	O
sites	O
and	O
shown	O
to	O
degrade	O
cyclohexane	B
and	O
2,2,4-trimethylpentane	B
.	O

With	O
the	O
reinforced	O
microflora	O
,	O
complete	O
degradation	O
of	O
GM23	B
was	O
observed	O
.	O

The	O
degradation	O
patterns	O
of	O
individual	O
components	O
of	O
GM23	B
were	O
similar	O
when	O
the	O
compounds	O
were	O
present	O
individually	O
or	O
in	O
the	O
GM23	B
mixture	O
,	O
as	O
long	O
as	O
the	O
concentrations	O
of	O
2-ethyltoluene	B
and	O
trimethylbenzene	B
isomers	I
were	O
kept	O
sufficiently	O
low	O
(	O
<	O
or	O
=	O
35	O
mg.l-1	O
)	O
to	O
remain	O
below	O
their	O
inhibitory	O
level	O
.	O

The	O
first	O
acyclonucleosides	B
based	O
on	O
the	O
benzothiadiazine	B
dioxide	I
system	O
were	O
synthesized	O
following	O
the	O
silylation	O
procedure	O
.	O

Several	O
acyclic	B
moieties	I
,	O
including	O
acetoxyethoxymethyl	B
,	O
benzyloxymethyl	B
,	O
and	O
propargyloxymethyl	B
groups	I
,	O
were	O
introduced	O
.	O

Two	O
synthetic	O
strategies	O
were	O
designed	O
to	O
selectively	O
obtain	O
the	O
N-1	B
or	O
N-3	B
derivatives	I
.	O

Lipase	O
-	O
mediated	O
deacylation	O
was	O
used	O
for	O
the	O
deprotection	O
of	O
the	O
acyclonucleosides	B
.	O

Some	O
of	O
the	O
benzothiadiazine	B
dioxide	I
acyclonucleosides	I
,	O
in	O
particular	O
16	B
,	O
proved	O
active	O
against	O
human	O
cytomegalovirus	O
(	O
CMV	O
)	O
at	O
concentrations	O
slightly	O
higher	O
than	O
that	O
found	O
for	O
ganciclovir	B
[	O
50	O
%	O
inhibitory	O
concentration	O
(	O
IC50	O
)	O
=	O
3	O
.	O
5	O
-	O
3.7	O
micrograms	O
/	O
mL	O
,	O
cytotoxicity	O
(	O
CC50	O
)	O
>	O
/=	O
40	O
micrograms	O
/	O
mL	O
,	O
MCC	O
=	O
20	O
micrograms	O
/	O
mL	O
]	O
.	O

Additionally	O
,	O
compound	B
16	I
inhibited	O
the	O
replication	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
and	O
HIV-2	O
in	O
CEM	O
cells	O
at	O
concentrations	O
that	O
were	O
5-fold	O
lower	O
than	O
its	O
cytotoxic	O
concentration	O
.	O

To	O
examine	O
the	O
stereospecific	O
effects	O
of	O
lipoic	B
compounds	I
on	O
pyruvate	B
metabolism	O
,	O
the	O
effects	O
of	O
R	B
-	I
lipoic	I
acid	I
(	O
R	B
-	I
LA	I
)	O
,	O
S	B
-	I
lipoic	I
acid	I
(	O
S	B
-	I
LA	I
)	I
and	O
1,2-diselenolane-3-pentanoic	B
acid	I
(	O
Se	B
-	I
LA	I
)	O
on	O
the	O
activities	O
of	O
the	O
mammalian	O
pyruvate	O
dehydrogenase	O
complex	O
(	O
PDC	O
)	O
and	O
its	O
catalytic	O
components	O
were	O
investigated	O
.	O

Both	O
S	B
-	I
LA	I
and	O
R	B
-	I
LA	I
markedly	O
inhibited	O
PDC	O
activity	O
;	O
whereas	O
Se	B
-	I
LA	I
displayed	O
inhibition	O
only	O
at	O
higher	O
concentrations	O
.	O

Examination	O
of	O
the	O
effects	O
on	O
the	O
individual	O
catalytic	O
components	O
indicated	O
that	O
Se	B
-	I
LA	I
inhibited	O
the	O
pyruvate	O
dehydrogenase	O
component	O
;	O
whereas	O
R	B
-	I
LA	I
and	O
S	B
-	I
LA	I
inhibited	O
the	O
dihydrolipoamide	O
acetyltransferase	O
component	O
.	O

The	O
three	O
lipoic	B
compounds	I
lowered	O
dihydrolipoamide	O
dehydrogrenase	O
(	O
E3	O
)	O
activity	O
in	O
the	O
forward	O
reaction	O
by	O
about	O
30	O
to	O
45	O
%	O
.	O

The	O
kinetic	O
data	O
of	O
E3	O
showed	O
that	O
both	O
R	B
-	I
LA	I
and	O
Se	B
-	I
LA	I
are	O
used	O
as	O
substrates	O
by	O
E3	O
for	O
the	O
reverse	O
reaction	O
.	O

Decarboxylation	O
of	O
[	B
1	I
-	I
14C	I
]	I
pyruvate	I
via	O
PDC	O
by	O
cultured	O
HepG2	O
cells	O
was	O
not	O
affected	O
by	O
R	B
-	I
LA	I
,	O
but	O
moderately	O
decreased	O
with	O
S	B
-	I
LA	I
and	O
Se	B
-	I
LA	I
.	O

These	O
findings	O
indicate	O
that	O
(	O
i	O
)	O
purified	O
PDC	O
and	O
its	O
catalytic	O
components	O
are	O
affected	O
by	O
lipoic	B
compounds	I
based	O
on	O
their	O
stereoselectivity	O
;	O
and	O
(	O
ii	O
)	O
the	O
oxidation	O
of	O
pyruvate	B
by	O
intact	O
HepG2	O
cells	O
is	O
not	O
inhibited	O
by	O
R	B
-	I
LA	I
.	O

The	O
later	O
finding	O
with	O
the	O
intact	O
cells	O
is	O
in	O
support	O
of	O
therapeutic	O
role	O
of	O
R	B
-	I
LA	I
as	O
an	O
antioxidant	O
.	O

A	O
highly	O
sensitive	O
pre	O
-	O
column	O
HPLC	O
method	O
for	O
simultaneous	O
determination	O
of	O
prolyl	B
dipeptides	I
,	O
Pro	B
and	O
Hyp	B
in	O
urine	O
was	O
developed	O
.	O

The	O
analytes	O
were	O
labelled	O
with	O
4-	B
(	I
5,6-dimethoxy-2-phthalimidinyl	I
)	I
-2-methoxyphenylsulfonyl	I
chloride	I
at	O
70	O
degrees	O
C	O
for	O
20	O
min	O
.	O

The	O
derivatives	O
separated	O
on	O
tandem	O
reversed	O
-	O
phase	O
columns	O
by	O
a	O
gradient	O
elution	O
and	O
were	O
monitored	O
with	O
fluorescence	O
detection	O
at	O
318	O
nm	O
(	O
excitation	O
)	O
and	O
392	O
nm	O
(	O
emission	O
)	O
.	O

The	O
detection	O
limits	O
for	O
prolyl	B
dipeptides	I
,	O
Pro	B
and	O
Hyp	B
were	O
1	O
-	O
5	O
fmol	O
/	O
injection	O
(	O
S	O
/	O
N	O
=	O
3	O
)	O
.	O

Urine	O
samples	O
were	O
treated	O
with	O
o	B
-	I
phthalaldehyde	I
,	O
followed	O
by	O
purification	O
on	O
a	O
Bond	O
Elut	O
C18	O
column	O
before	O
conducting	O
the	O
labelling	O
reaction	O
.	O

Pro	B
-	I
Hyp	I
,	O
Pro	B
-	I
Gly	I
and	O
Pro	B
-	I
Pro	I
were	O
identified	O
as	O
prolyl	B
dipeptides	I
in	O
urine	O
.	O

The	O
within	O
-	O
day	O
and	O
between	O
-	O
day	O
relative	O
standard	O
deviations	O
were	O
1.5	O
-	O
4.8	O
and	O
1.7	O
-	O
5.8	O
%	O
,	O
respectively	O
.	O

The	O
concentrations	O
of	O
Pro	B
-	I
Hyp	I
,	O
Pro	B
-	I
Gly	I
,	O
Pro	B
-	I
Pro	I
,	O
Pro	B
and	O
Hyp	B
in	O
normal	O
human	O
urine	O
were	O
97.6	O
+	O
/-	O

28.2	O
,	O
2.74	O
+	O
/-	O

1.48	O
,	O
2.08	O
+	O
/-	O

1.13	O
,	O
6.71	O
+	O
/-	O

3.34	O
and	O
2.30	O
+	O
/-	O

1.59	O
nmol	O
/	O
mg	O
creatinine	B
,	O
respectively	O
.	O

An	O
enzyme	O
with	O
lipase	O
and	O
esterase	O
activity	O
was	O
purified	O
from	O
bovine	O
pancreas	O
.	O

Furthermore	O
,	O
a	O
non	O
-	O
radioactive	O
lipase	O
assay	O
was	O
developed	O
which	O
is	O
100	O
times	O
more	O
sensitive	O
than	O
the	O
conventional	O
methods	O
and	O
allowed	O
the	O
characterization	O
of	O
the	O
lipase	O
activity	O
of	O
the	O
enzyme	O
.	O

The	O
lipase	O
activity	O
increased	O
42	O
times	O
in	O
the	O
presence	O
of	O
10	O
mM	O
sodium	B
taurocholate	I
,	O
which	O
for	O
the	O
first	O
time	O
provides	O
direct	O
evidence	O
that	O
a	O
bile	O
salt	O
-	O
activated	O
lipase	O
(	O
bp	O
-	O
BAL	O
)	O
was	O
isolated	O
from	O
bovine	O
pancreas	O
.	O

This	O
conclusion	O
is	O
further	O
supported	O
by	O
the	O
fact	O
that	O
the	O
N	B
-	I
terminal	I
amino	I
acid	I
sequence	O
of	O
this	O
lipase	O
/	O
esterase	O
is	O
88	O
%	O
homologous	O
to	O
human	O
milk	O
BAL	O
and	O
human	O
pancreatic	O
BAL	O
.	O

Staining	O
with	O
various	O
lectins	O
showed	O
that	O
bp	O
-	O
BAL	O
is	O
a	O
glycoprotein	O
which	O
contains	O
fucose	B
residues	O
.	O

Previously	O
from	O
bovine	O
pancreas	O
a	O
lysophospholipase	O
has	O
been	O
purified	O
and	O
a	O
gene	O
was	O
cloned	O
and	O
sequenced	O
encoding	O
an	O
enzyme	O
with	O
cholesterol	O
esterase	O
/	O
lysophospholipase	O
activity	O
.	O

Comparison	O
of	O
the	O
N	B
-	I
terminal	I
amino	I
acid	I
sequence	O
of	O
bp	O
-	O
BAL	O
with	O
the	O
deduced	O
amino	B
acid	I
sequence	O
of	O
the	O
latter	O
revealed	O
that	O
they	O
are	O
identical	O
.	O

Furthermore	O
,	O
the	O
molecular	O
weight	O
of	O
the	O
purified	O
bp	O
-	O
BAL	O
of	O
63,000	O
,	O
as	O
estimated	O
by	O
SDS	O
-	O
PAGE	O
,	O
is	O
very	O
similar	O
to	O
that	O
of	O
the	O
purified	O
lysophospholipase	O
(	O
65,000	O
)	O
and	O
to	O
the	O
theoretical	O
molecular	O
weight	O
of	O
65,147	O
of	O
the	O
cholesterol	O
esterase	O
/	O
lysophospholipase	O
.	O

These	O
data	O
suggest	O
that	O
these	O
three	O
enzymes	O
are	O
one	O
and	O
the	O
same	O
.	O

The	O
antioxidant	O
activity	O
of	O
Eriobotrya	O
japonica	O
was	O
determined	O
by	O
measuring	O
the	O
radical	O
scavenging	O
effect	O
on	O
DPPH	B
(	O
1,1-diphenyl-2-picrylhydrazyl	B
)	O
radical	B
and	O
lipid	B
peroxidation	O
produced	O
when	O
mouse	O
liver	O
homogenate	O
was	O
exposed	O
to	O
the	O
air	O
at	O
37	O
degrees	O
C	O
,	O
using	O
2-thiobarbituric	B
acid	I
(	O
TBA	B
)	O
.	O

The	O
methanol	B
extract	O
and	O
its	O
fractions	O
of	O
Eriobotrya	O
japonica	O
leaves	O
showed	O
strong	O
antioxidant	O
activity	O
.	O

The	O
antioxidant	O
activity	O
of	O
EtOAc	B
and	O
n	B
-	I
BuOH	I
soluble	O
fractions	O
were	O
stronger	O
than	O
the	O
others	O
,	O
and	O
were	O
further	O
purified	O
by	O
repeated	O
silica	B
gel	I
,	O
MCl	B
gel	I
CHP-20P	I
,	O
and	O
Sephadex	B
LH-20	I
column	O
chromatography	O
.	O

Antioxidant	O
chlorogenic	B
acid	I
,	O
quercetin-3-sambubioside	B
from	O
n	B
-	I
BuOH	I
fraction	O
,	O
and	O
methyl	B
chlorogenate	I
,	O
kaempferol-	B
and	O
quercetin-3-rhamnosides	B
,	O
together	O
with	O
the	O
inactive	O
ursolic	B
acid	I
and	O
2	B
alpha	I
-	I
hydroxyursolic	I
acid	I
from	O
EtOAc	B
fraction	O
were	O
isolated	O
.	O

Antioxidant	O
flavonoids	B
and	O
chlorogenic	B
acid	I
also	O
showed	O
prominent	O
inhibitory	O
activity	O
against	O
free	O
radical	O
generation	O
in	O
dichlorofluorescein	B
(	O
DCF	B
)	O
method	O
.	O

The	O
synthesis	O
and	O
the	O
antimicrobial	O
properties	O
of	O
a	O
new	O
series	O
of	O
cephalosporinic	B
beta	I
-	I
lactam	I
antibiotics	I
is	O
described	O
.	O

The	O
data	O
reported	O
in	O
the	O
present	O
paper	O
show	O
the	O
potential	O
of	O
this	O
type	O
of	O
substituted	B
cephalosporins	I
as	O
new	O
anti	B
Gram	I
-	I
positive	I
antibiotic	I
drugs	I
.	O

In	O
fact	O
,	O
all	O
compounds	B
tested	O
showed	O
a	O
good	O
in	O
vitro	O
antibacterial	O
activity	O
against	O
the	O
most	O
relevant	O
Gram	O
-	O
positive	O
pathogens	O
including	O
resistant	O
species	O
that	O
currently	O
represent	O
unmet	O
medical	O
need	O
.	O

On	O
the	O
contrary	O
,	O
the	O
new	O
synthesized	O
compounds	B
were	O
found	O
to	O
be	O
completely	O
devoid	O
of	O
any	O
activity	O
on	O
Gram	O
-	O
negative	O
bacteria	O
up	O
to	O
a	O
concentration	O
of	O
the	O
single	O
agent	O
of	O
128	O
microg	O
/	O
ml	O
.	O

The	O
hydroxylation	O
at	O
C-2	O
of	O
testosterone	B
and	O
5alpha	B
-	I
dihydrotestosterone	I
is	O
measured	O
by	O
isolation	O
of	O
HTO	B
after	O
incubating	O
"	O
metabolically	O
labile	O
"	O
tritium	B
labeled	I
steroids	I
with	O
the	O
enzymes	O
.	O

After	O
hydroxylation	O
of	O
testosterone	B
in	O
rat	O
liver	O
2alpha	B
-	I
hydroxytestosterone	I
was	O
isolated	O
and	O
identified	O
by	O
gaschromatography	O
and	O
mass	O
spectra	O
.	O

Oxamniquine	B
(	O
1,2,3,4-tetrahydro-2-	B
[	I
(	I
isopropylamino	I
)	I
methyl	I
]	I
-7-nitro-6-quinoline	I
methanol	I
)	I
is	O
an	O
antischistosomal	B
agent	I
that	O
is	O
indicated	O
for	O
the	O
treatment	O
of	O
S.	O
mansoni	O
(	O
intestinal	O
schistosomiasis	O
)	O
infection	O
.	O

It	O
has	O
been	O
shown	O
to	O
inhibit	O
DNA	B
,	O
RNA	B
and	O
protein	O
synthesis	O
in	O
schistosomes	O
.	O

The	O
oral	O
bioavailability	O
of	O
oxamniquine	B
is	O
good	O
,	O
effective	O
plasma	O
levels	O
are	O
achieved	O
in	O
11.5	O
h	O
[	O
1	O
]	O
.	O

Oxamniquine	B
is	O
the	O
subject	O
of	O
a	O
monograph	O
in	O
the	O
US	O
Pharmacopoeia	O
(	O
USP	O
XXIII	O
)	O
[	O
2	O
]	O
whereby	O
a	O
spectrophotometric	O
method	O
is	O
recommended	O
for	O
its	O
determination	O
,	O
whether	O
in	O
its	O
pure	O
form	O
or	O
in	O
capsules	O
.	O

Other	O
reported	O
methods	O
include	O
spectrophotometry	O
[	O
3,4	O
]	O
,	O
non	O
-	O
aqueous	O
titration	O
[	O
5	O
]	O
,	O
gas	O
chromatography	O
[	O
6	O
]	O
,	O
high	O
-	O
performance	O
liquid	O
chromatography	O
[	O
711	O
]	O
,	O
polarography	O
[	O
12	O
]	O
,	O
capillary	O
electrophoresis	O
[	O
9	O
]	O
,	O
flow	O
-	O
injection	O
analysis	O
[	O
13	O
]	O
and	O
cyclic	O
voltammetry	O
[	O
14	O
]	O
.	O

The	O
above	O
-	O
mentioned	O
methods	O
are	O
either	O
not	O
sufficiently	O
sensitive	O
or	O
are	O
tedious	O
and	O
require	O
highly	O
sophisticated	O
instrumentation	O
.	O

Therefore	O
,	O
there	O
is	O
still	O
a	O
need	O
for	O
a	O
much	O
more	O
sensitive	O
and	O
simple	O
method	O
for	O
the	O
determination	O
of	O
oxamniquine	B
,	O
especially	O
in	O
biological	O
fluids	O
.	O

Fluorimetry	O
,	O
by	O
virtue	O
of	O
its	O
high	O
sensitivity	O
,	O
meets	O
this	O
requirement	O
.	O

Reviewing	O
the	O
literature	O
revealed	O
that	O
no	O
fluorimetric	O
methods	O
were	O
reported	O
for	O
oxamniquine	B
.	O

As	O
for	O
2-cyanoacetamide	B
,	O
it	O
has	O
been	O
recently	O
used	O
for	O
the	O
determination	O
of	O
aminoglycosides	B
[	O
15	O
]	O
,	O
reducing	O
carbohydrates	B
[	O
1618	O
]	O
,	O
enzymatic	O
degradation	O
products	O
of	O
reducing	O
polysaccharides	B
[	O
19	O
]	O
and	O
catecholamines	B
[	O
20,21	O
]	O
.	O

The	O
aim	O
of	O
the	O
present	O
work	O
is	O
to	O
study	O
the	O
reaction	O
of	O
the	O
reduced	O
derivative	B
(	O
nitroso	B
)	O
of	B
oxamniquine	I
with	O
2-cyanoacetamide	B
in	O
an	O
attempt	O
to	O
develop	O
a	O
sensitive	O
fluorimetric	O
method	O
to	O
be	O
used	O
for	O
its	O
determination	O
in	O
biological	O
fluids	O
.	O

2	O
Experimental	O
2.1	O
Apparatus	O
An	O
Aminco	O
-	O
Bowman	O
Model	O
J4	O
-9860	O
spectrofluorometer	O
was	O
used	O
with	O
the	O
excitation	O
and	O
emission	O
slits	O
set	O
at	O
5	O
mm	O
.	O

A	O
1-cm	O
quartz	O
cell	O
was	O
used	O
for	O
all	O
measurements	O
.	O

2.2	O
Materials	O
and	O
reagents	O
All	O
the	O
chemicals	O
used	O
were	O
of	O
analytical	O
reagent	O
grade	O
,	O
while	O
the	O
solvents	B
were	O
of	O
the	O
spectroscopic	O
grade	O
.	O

A	O
pure	O
drug	B
sample	O
of	O
oxamniquine	B
was	O
kindly	O
supplied	O
by	O
Pfizer	O
(	O
Sandwich	O
,	O
UK	O
)	O
and	O
was	O
used	O
as	O
received	O
.	O

2-Cyanoacetamide	B
was	O
purchased	O
from	O
Aldrich	O
Chemical	O
Co.	O
Plasma	O
was	O
obtained	O
from	O
Mansoura	O
University	O
Hospital	O
,	O
Mansoura	O
(	O
Egypt	O
)	O
and	O
urine	O
was	O
obtained	O
from	O
healthy	O
volunteers	O
.	O

Freshly	O
prepared	O
10	O
%	O
aqueous	O
solution	O
of	O
calcium	B
chloride	I
and	O
4	O
%	O
aqueous	O
solution	O
of	O
2-cyanoacetamide	B
were	O
prepared	O
and	O
used	O
throughout	O
the	O
study	O
.	O

2.2.1	O
Stock	O
solution	O
Dissolve	O
20	O
mg	O
of	O
oxamniquine	B
in	O
100	O
of	O
methanol	B
.	O

Make	O
serial	O
dilutions	O
with	O
water	B
to	O
obtain	O
a	O
final	O
concentration	O
of	O
20	O
g	O
/	O
ml	O
.	O

2.3	O
Procedure	O
2.3.1	O
Preparation	O
of	O
the	O
calibration	O
curve	O
Transfer	O
aliquots	O
of	O
oxamniquine	B
final	O
stock	O
solution	O
into	O
a	O
series	O
of	O
25	O
ml	O
standard	O
flasks	O
so	O
that	O
the	O
final	O
drug	B
concentration	O
is	O
in	O
the	O
range	O
0.080.88	O
g	O
/	O
ml	O
.	O

Add	O
to	O
each	O
flask	O
1205	O
mg	O
of	O
zinc	O
dust	O
and	O
12	O
ml	O
of	O
calcium	B
chloride	I
solution	O
.	O

Shake	O
well	O
and	O
leave	O
to	O
stand	O
for	O
20	O
min	O
.	O

Filter	O
the	O
excess	O
zinc	B
powder	O
.	O

Add	O
1	O
ml	O
of	O
2-cyanoacetamide	B
solution	O
to	O
the	O
filtrate	O
,	O
then	O
heat	O
on	O
a	O
boiling	O
water	B
bath	O
for	O
1	O
h.	O
Cool	O
and	O
fill	O
to	O
the	O
mark	O
in	O
25	O
ml	O
standard	O
flask	O
with	O
water	B
.	O

Measure	O
the	O
fluorescence	O
of	O
the	O
filtrate	O
using	O
370	O
nm	O
as	O
the	O
excitation	O
wavelength	O
and	O
450	O
nm	O
as	O
the	O
emission	O
wavelength	O
.	O

A	O
blank	O
reagent	B
is	O
prepared	O
simultaneously	O
.	O

Plot	O
the	O
values	O
of	O
the	O
%	O
relative	O
intensity	O
against	O
the	O
final	O
concentration	O
in	O
g	O
/	O
ml	O
to	O
get	O
the	O
calibration	O
graph	O
.	O

Alternatively	O
,	O
the	O
regression	O
equation	O
is	O
derived	O
.	O

2.3.2	O
Determination	O
of	O
oxamniquine	B
in	O
spiked	O
human	O
plasma	O
and	O
urine	O
A	O
standard	O
calibration	O
curve	O
was	O
prepared	O
daily	O
by	O
spiking	O
blank	O
plasma	O
or	O
urine	O
with	O
varying	O
amounts	O
of	O
oxamniquine	B
.	O

A	O
stock	O
solution	O
containing	O
10	O
g	O
/	O
ml	O
of	O
oxamniquine	B
was	O
freshly	O
prepared	O
.	O

Control	O
samples	O
of	O
plasma	O
or	O
urine	O
were	O
spiked	O
with	O
different	O
quantities	O
of	O
oxamniquine	B
to	O
give	O
a	O
final	O
drug	B
concentration	O
of	O
0.20.8	O
g	O
/	O
ml	O
.	O

Add	O
0.8	O
ml	O
of	O
1	O
M	O
NaOH	B
with	O
gentle	O
shaking	O
to	O
1.0	O
ml	O
of	O
the	O
spiked	O
urine	O
or	O
plasma	O
.	O

The	O
solution	O
was	O
then	O
vortexed	O
with	O
3	O
	O
5	O
ml	O
of	O
ether	O
for	O
2	O
min	O
then	O
centrifuged	O
at	O
2500	O
rpm	O
for	O
5	O
min	O
.	O

The	O
resulting	O
supernatant	O
was	O
then	O
evaporated	O
to	O
dryness	O
under	O
nitrogen	B
at	O
ambient	O
temperature	O
.	O

The	O
resulting	O
residue	O
was	O
dissolved	O
in	O
5	O
ml	O
of	O
methanol	B
and	O
then	O
made	O
up	O
to	O
10	O
ml	O
with	O
water	B
in	O
a	O
volumetric	O
flask	O
.	O

The	O
procedure	O
described	O
in	O
Section	O
2.3.1	O
was	O
then	O
applied	O
.	O

A	O
blank	O
experiment	O
using	O
plasma	O
or	O
urine	O
without	O
the	O
drug	B
was	O
carried	O
out	O
simultaneously	O
.	O

The	O
content	O
of	O
oxamniquine	B
was	O
then	O
determined	O
from	O
the	O
previously	O
plotted	O
calibration	O
graphs	O
.	O

3	O
Results	O
and	O
discussion	O
The	O
nitro	B
group	I
is	O
reported	O
to	O
be	O
reduced	O
into	O
the	O
corresponding	O
nitroso	B
group	I
upon	O
reduction	O
with	O
Zn	B
/	O
CaCl2	B
[	O
22	O
]	O
.	O

This	O
process	O
was	O
confirmed	O
by	O
testing	O
for	O
the	O
nitroso	B
group	I
using	O
sodium	B
nitroprusside	I
[	O
23	O
]	O
.	O

The	O
nitroso	B
compounds	I
were	O
reported	O
to	O
react	O
with	O
active	O
methylene	B
containing	I
compounds	I
with	O
the	O
production	O
of	O
the	O
corresponding	O
imines	B
[	O
24	O
]	O
.	O

The	O
latter	O
is	O
proposed	O
to	O
undergo	O
a	O
ring	O
-	O
closing	O
reaction	O
with	O
the	O
elimination	O
of	O
one	O
molecule	O
of	O
ammonia	B
and	O
the	O
production	O
of	O
the	O
3-cyanooxazazepin-2-one	B
derivative	I
,	O
which	O
is	O
the	O
fluorescent	B
product	I
.	O

A	O
proposal	O
of	O
reaction	O
pathway	O
is	O
suggested	O
in	O
Scheme	O
1	O
.	O

A	O
highly	O
fluorescent	B
product	I
with	O
max	O
excitation	O
at	O
370	O
nm	O
and	O
max	O
emission	O
of	O
450	O
nm	O
was	O
obtained	O
(	O
Fig.	O
1	O
)	O
.	O

3.1	O
Study	O
of	O
the	O
experimental	O
conditions	O
The	O
factors	O
affecting	O
the	O
production	O
of	O
nitroso	B
derivative	I
were	O
first	O
studied	O
.	O

All	O
factors	O
were	O
kept	O
constant	O
except	O
one	O
,	O
which	O
was	O
changed	O
in	O
turn	O
to	O
study	O
its	O
effect	O
.	O

Any	O
amount	O
of	O
zinc	B
powder	O
in	O
the	O
range	O
100300	O
mg	O
was	O
found	O
to	O
give	O
the	O
same	O
results	O
;	O
therefore	O
1205	O
mg	O
were	O
used	O
throughout	O
the	O
work	O
.	O

As	O
for	O
calcium	B
chloride	I
solution	O
121	O
ml	O
of	O
10	O
%	O
(	O
wt.	O
/	O
vol	O
.	O
)	O

aqueous	O
solution	O
was	O
found	O
to	O
give	O
maximum	O
fluorescence	O
.	O

Larger	O
volumes	O
caused	O
slight	O
decrease	O
in	O
fluorescence	O
.	O

Increasing	O
the	O
reduction	O
time	O
(	O
at	O
room	O
temperature	O
)	O
was	O
found	O
to	O
increase	O
the	O
fluorescence	O
up	O
to	O
20	O
min	O
,	O
after	O
which	O
time	O
the	O
fluorescence	O
intensity	O
remained	O
unchanged	O
.	O

3.2	O
Factors	O
affecting	O
the	O
development	O
of	O
the	O
fluorophore	B
The	O
effect	O
of	O
the	O
concentration	O
of	O
2-cyanoacetamide	B
was	O
studied	O
by	O
using	O
increasing	O
volumes	O
of	O
4	O
%	O
aqueous	O
solution	O
.	O

It	O
was	O
found	O
that	O
1.00.1	O
ml	O
is	O
appropriate	O
for	O
maximum	O
fluorescence	O
intensity	O
;	O
larger	O
volumes	O
caused	O
no	O
further	O
increase	O
in	O
fluorescence	O
.	O

The	O
temperature	O
and	O
time	O
of	O
heating	O
were	O
also	O
studied	O
.	O

It	O
was	O
concluded	O
that	O
heating	O
in	O
a	O
boiling	O
water	B
-	I
bath	O
for	O
1	O
h	O
gave	O
the	O
highest	O
fluorescence	O
readings	O
.	O

Longer	O
heating	O
time	O
caused	O
a	O
decrease	O
in	O
fluorescence	O
as	O
shown	O
in	O
Fig.	O
2	O
.	O

After	O
optimizing	O
the	O
conditions	O
,	O
it	O
was	O
found	O
that	O
the	O
relation	O
between	O
the	O
%	O
relative	O
intensity	O
(	O
%	O
RI	O
)	O
and	O
final	O
concentration	O
of	O
oxamniquine	B
was	O
rectilinear	O
over	O
the	O
range	O
0.080.88	O
g	O
/	O
ml	O
with	O
a	O
minimum	O
detectability	O
(	O
S	O
/N	O
=	O
2	O
)	O
of	O
8	O
ng	O
/	O
ml	O
(	O
Fig.	O
3	O
)	O
.	O

The	O
linear	O
regression	O
analysis	O
of	O
the	O
results	O
gave	O
the	O
following	O
equation:%	O
RI	O
=	O
0.0358	O
+	O
107.4C	O
(	O
r=0.9999	O
)	O
where	O
C	O
=	O
final	O
concentration	O
in	O
g	O
/	O
ml	O
,	O
%	O
RI	O
=	O
relative	O
fluorescence	O
intensity	O
and	O
r	O
=	O
correlation	O
coefficient	O
.	O

Statistical	O
analysis	O
of	O
the	O
results	O
of	O
analysis	O
of	O
authentic	O
sample	O
of	O
oxamniquine	B
obtained	O
by	O
both	O
the	O
proposed	O
method	O
and	O
the	O
official	O
method	O
[	O
2	O
]	O
revealed	O
no	O
significant	O
difference	O
between	O
the	O
two	O
methods	O
regarding	O
the	O
accuracy	O
and	O
precision	O
,	O
as	O
indicated	O
by	O
the	O
F	O
-test	O
and	O
Student	O
's	O
t	O
-test	O
,	O
respectively	O
[	O
25	O
]	O
.	O

Oxamniquine	B
is	O
readily	O
absorbed	O
following	O
oral	O
ingestion	O
,	O
and	O
a	O
peak	O
concentration	O
in	O
plasma	O
occurs	O
within	O
about	O
3	O
h.	O
The	O
presence	O
of	O
food	O
significantly	O
delays	O
absorption	O
and	O
limits	O
the	O
concentration	O
achieved	O
in	O
plasma	O
during	O
the	O
first	O
several	O
hours	O
after	O
administration	O
.	O

Urinary	O
excretion	O
is	O
the	O
major	O
route	O
of	O
elimination	O
in	O
humans	O
[	O
26	O
]	O
.	O

Oxamniquine	B
is	O
given	O
orally	O
in	O
a	O
dose	O
of	O
250	O
mg	O
three	O
times	O
daily	O
;	O
this	O
leads	O
to	O
a	O
final	O
blood	O
level	O
concentration	O
of	O
about	O
5	O
g	O
/	O
ml	O
,	O
i.e.	O
higher	O
than	O
the	O
upper	O
limit	O
of	O
the	O
working	O
range	O
of	O
the	O
proposed	O
method	O
.	O

Thus	O
,	O
the	O
high	O
sensitivity	O
of	O
the	O
proposed	O
method	O
allowed	O
the	O
determination	O
of	O
oxamniquine	B
in	O
biological	O
fluids	O
.	O

Table	O
1	O
shows	O
the	O
results	O
for	O
the	O
fluorimetric	O
determination	O
of	O
a	O
pure	O
sample	O
of	O
oxamniquine	B
,	O
while	O
Table	O
2	O
shows	O
the	O
results	O
of	O
the	O
fluorometric	O
determination	O
of	O
oxamniquine	B
in	O
spiked	O
urine	O
and	O
plasma	O
samples	O
,	O
respectively	O
.	O

The	O
extraction	O
procedure	O
described	O
by	O
Woolhouse	O
and	O
Wood	O
[	O
6	O
]	O
was	O
adopted	O
here	O
.	O

The	O
results	O
are	O
satisfactorily	O
accurate	O
and	O
precise	O
.	O

In	O
conclusion	O
,	O
a	O
highly	O
sensitive	O
and	O
accurate	O
method	O
was	O
developed	O
for	O
the	O
determination	O
of	O
oxamniquine	B
in	O
urine	O
and	O
plasma	O
.	O

Although	O
the	O
previously	O
reported	O
methods	O
[	O
6,7	O
]	O
for	O
its	O
determination	O
in	O
biological	O
fluids	O
may	O
be	O
less	O
time	O
-	O
consuming	O
,	O
the	O
proposed	O
method	O
is	O
,	O
however	O
,	O
more	O
sensitive	O
and	O
does	O
not	O
need	O
complicated	O
instrumentation	O
.	O

The	O
relationship	O
between	O
taurine	B
and	O
aging	O
of	O
brain	O
neural	O
cells	O
was	O
studied	O
by	O
using	O
primary	O
human	O
fetal	O
brain	O
neural	O
cells	O
cultured	O
in	O
serum	O
-	O
free	O
medium	O
.	O

The	O
results	O
indicated	O
that	O
the	O
activity	O
of	O
superoxide	O
dismutase	O
(	O
SOD	O
)	O
was	O
significantly	O
higher	O
in	O
taurine	B
added	O
group	O
than	O
the	O
control	O
group	O
cultured	O
for	O
6	O
,	O
9	O
and	O
15	O
days	O
(	O
P	O
<	O
0.05	O
)	O
.	O

With	O
different	O
taurine	B
levels	O
,	O
the	O
SOD	O
activities	O
of	O
50	O
mg	O
/	O
L	O
and	O
200	O
mg	O
/	O
L	O
taurine	B
groups	O
were	O
significantly	O
higher	O
than	O
the	O
control	O
group	O
cultured	O
for	O
6	O
days	O
(	O
P	O
<	O
0.05	O
)	O
.	O

After	O
3-day	O
culture	O
,	O
the	O
activity	O
of	O
glutathione	O
peroxidase	O
(	O
GSH	O
-	O
Px	O
)	O
in	O
the	O
taurine	O
added	O
group	O
was	O
significantly	O
higher	O
than	O
the	O
control	O
group	O
(	O
P	O
<	O
0.05	O
)	O
.	O

The	O
membrane	O
lipid	B
fluidity	O
of	O
neural	O
cells	O
decreased	O
with	O
time	O
in	O
control	O
group	O
,	O
but	O
was	O
stable	O
in	O
the	O
group	O
treated	O
with	O
taurine	B
.	O

The	O
fluidity	O
was	O
more	O
stable	O
in	O
the	O
groups	O
treated	O
with	O
50	O
,	O
200	O
and	O
400	O
mg	O
/	O
L	O
groups	O
cultured	O
for	O
6	O
days	O
,	O
compared	O
with	O
the	O
control	O
group	O
(	O
P	O
<	O
0.05	O
or	O
0.01	O
)	O
.	O

The	O
present	O
study	O
showed	O
that	O
taurine	B
is	O
necessary	O
for	O
maintaining	O
membrane	O
lipid	O
fluidity	O
of	O
neural	O
cells	O
in	O
proper	O
levels	O
,	O
and	O
plays	O
an	O
important	O
role	O
in	O
postponing	O
the	O
aging	O
process	O
of	O
brain	O
neural	O
cells	O
.	O

A	O
combination	O
of	O
atovaquone	B
and	O
proguanil	B
has	O
been	O
found	O
to	O
be	O
quite	O
effective	O
in	O
treating	O
malaria	O
,	O
with	O
little	O
evidence	O
of	O
the	O
emergence	O
of	O
resistance	O
when	O
atovaquone	B
was	O
used	O
as	O
a	O
single	O
agent	O
.	O

We	O
have	O
examined	O
possible	O
mechanisms	O
for	O
the	O
synergy	O
between	O
these	O
two	O
drugs	B
.	O

While	O
proguanil	B
by	O
itself	O
had	O
no	O
effect	O
on	O
electron	O
transport	O
or	O
mitochondrial	O
membrane	O
potential	O
(	O
DeltaPsim	O
)	O
,	O
it	O
significantly	O
enhanced	O
the	O
ability	O
of	O
atovaquone	B
to	O
collapse	O
DeltaPsim	O
when	O
used	O
in	O
combination	O
.	O

This	O
enhancement	O
was	O
observed	O
at	O
pharmacologically	O
achievable	O
doses	O
.	O

Proguanil	B
acted	O
as	O
a	O
biguanide	B
rather	O
than	O
as	O
its	O
metabolite	B
cycloguanil	B
(	O
a	O
parasite	O
dihydrofolate	O
reductase	O
[	O
DHFR	O
]	O
inhibitor	O
)	O
to	O
enhance	O
the	O
atovaquone	B
effect	O
;	O
another	O
DHFR	O
inhibitor	O
,	O
pyrimethamine	B
,	O
also	O
had	O
no	O
enhancing	O
effect	O
.	O

Proguanil	B
-	O
mediated	O
enhancement	O
was	O
specific	O
for	O
atovaquone	B
,	O
since	O
the	O
effects	O
of	O
other	O
mitochondrial	O
electron	O
transport	O
inhibitors	O
,	O
such	O
as	O
myxothiazole	B
and	O
antimycin	B
,	O
were	O
not	O
altered	O
by	O
inclusion	O
of	O
proguanil	B
.	I

Surprisingly	O
,	O
proguanil	B
did	O
not	O
enhance	O
the	O
ability	O
of	O
atovaquone	B
to	O
inhibit	O
mitochondrial	O
electron	O
transport	O
in	O
malaria	O
parasites	O
.	O

These	O
results	O
suggest	O
that	O
proguanil	B
in	O
its	O
prodrug	O
form	O
acts	O
in	O
synergy	O
with	O
atovaquone	B
by	O
lowering	O
the	O
effective	O
concentration	O
at	O
which	O
atovaquone	B
collapses	O
DeltaPsim	O
in	O
malaria	O
parasites	O
.	O

This	O
could	O
explain	O
the	O
paradoxical	O
success	O
of	O
the	O
atovaquone	B
-	O
proguanil	B
combination	O
even	O
in	O
regions	O
where	O
proguanil	B
alone	O
is	O
ineffective	O
due	O
to	O
resistance	O
.	O

The	O
results	O
also	O
suggest	O
that	O
the	O
atovaquone	B
-	O
proguanil	B
combination	O
may	O
act	O
as	O
a	O
site	O
-	O
specific	O
uncoupler	O
of	O
parasite	O
mitochondria	O
in	O
a	O
selective	O
manner	O
.	O

To	O
develop	O
positron	O
-	O
emitting	O
tracers	O
for	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
studies	O
,	O
ex	O
vivo	O
autoradiography	O
(	O
ARG	O
)	O
is	O
a	O
useful	O
technique	O
to	O
demonstrate	O
the	O
distribution	O
of	O
the	O
tracer	O
in	O
the	O
brain	O
as	O
well	O
as	O
in	O
the	O
whole	O
body	O
.	O

A	O
recent	O
advent	O
of	O
radioluminography	O
using	O
phosphor	O
-	O
imaging	O
plates	O
(	O
12	O
,	O
14	O
)	O
has	O
enabled	O
the	O
ex	O
vivo	O
ARG	O
to	O
be	O
applied	O
to	O
ultrashort	O
-	O
lived	O
11	O
C	O
-	O
labeled	O
tracers	O
.	O

Yanai	O
et	O
al.	O
reported	O
a	O
potential	O
of	O
the	O
imaging	O
plates	O
for	O
receptor	O
ARG	O
with	O
11	B
C	I
-	O
labeled	O
ligands	O
compared	O
with	O
tritiated	O
ligands	O
(	O
25	O
)	O
.	O

Planas	O
et	O
al.	O
(	O
18	O
)	O
characterized	O
a	O
cholinesterase	O
inhibitor	O
[	B
11	I
C	I
]	I
physostigmine	I
using	O
a	O
similar	O
type	O
storage	O
phosphor	O
plates	O
.	O

We	O
also	O
used	O
imaging	O
plates	O
to	O
characterize	O
newly	O
developed	O
11	B
C	I
-	O
labeled	O
receptor	O
ligands	O
(	O
3	O
,	O
10	O
,	O
16	O
)	O
.	O

Because	O
the	O
intensity	O
of	O
photo	O
-	O
stimulated	O
-	O
luminescence	O
(	O
PSL	O
)	O
is	O
linearly	O
proportional	O
to	O
the	O
radioactivity	O
in	O
a	O
wide	O
range	O
,	O
ARG	O
images	O
expressed	O
as	O
PSL	O
is	O
considered	O
to	O
reflect	O
the	O
quantitative	O
distribution	O
of	O
radioactivity	O
.	O

Recently	O
,	O
Sihver	O
et	O
al.	O
(	O
21	O
)	O
have	O
quantitatively	O
evaluated	O
in	O
vitro	O
ARG	O
with	O
storage	O
phosphor	O
plates	O
and	O
11	B
C	I
-	I
flumazenil	I
.	O

In	O
the	O
present	O
paper	O
,	O
we	O
describe	O
quantitative	O
evaluation	O
of	O
ex	O
vivo	O
and	O
in	O
vitro	O
ARG	O
using	O
an	O
imaging	O
plate	O
and	O
a	O
11	B
C	I
-	O
labeled	O
dopamine	B
D2	O
-like	O
receptor	O
ligand	O
,	O
[	B
11	I
C	I
]	I
nemonapride	I
(	O
[	B
11	I
C	I
]	I
YM-09151	I
-	I
2	I
)	O
(	O
5	O
,	O
6	O
,	O
8	O
,	O
9	O
,	O
11	O
)	O
.	O

Its	O
tritiated	O
compound	O
has	O
been	O
used	O
widely	O
for	O
pharmacological	O
studies	O
as	O
one	O
of	O
representative	O
dopamine	B
D2	O
-like	O
receptor	O
ligands	O
.	O

We	O
report	O
the	O
presence	O
of	O
saturable	O
binding	O
sites	O
for	O
[	B
11	I
C	I
]	I
nemonapride	I
in	O
the	O
cortex	O
beside	O
the	O
dopamine	B
D2	O
-like	O
receptors	O
in	O
the	O
striatum	O
both	O
ex	O
vivo	O
and	O
in	O
vitro	O
.	O

Materials	O
and	O
methods	O
[	B
11	I
C	I
]	I
Nemonapride	I
(	O
9	B
)	O
and	O
[	B
11	I
C	I
]	I
SCH	I
23390	I
(	O
4	B
)	O
were	O
synthesized	O
by	O
11	B
C	I
-	I
methylation	O
of	O
the	O
corresponding	O
desmethyl	B
compound	I
with	O
[	B
11	I
C	I
]	I
methyl	I
iodide	I
by	O
the	O
method	O
previously	O
described	O
.	O

The	O
specific	O
activity	O
of	O
the	O
compounds	O
was	O
measured	O
as	O
follows	O
.	O

The	O
radioactivity	O
(	O
MBq	O
)	O
of	O
an	O
appropriate	O
volume	O
of	O
tracer	O
solution	O
was	O
measured	O
by	O
a	O
radioisotope	O
calibrator	O
(	O
type	O
CRC-712	O
,	O
Capintec	O
Inc.	O
,	O
Ramsey	O
,	O
NJ	O
)	O
,	O
and	O
a	O
part	O
of	O
the	O
solution	O
was	O
applied	O
to	O
high	O
-	O
performance	O
liquid	O
chromatography	O
(	O
HPLC	O
)	O
to	O
determine	O
the	O
mass	O
(	O
nmol	O
)	O
of	O
the	O
compounds	O
based	O
on	O
the	O
ultraviolet	O
(	O
UV	O
)	O
response	O
to	O
the	O
authentic	O
sample	O
.	O

Male	O
Wistar	O
rats	O
(	O
810	O
weeks	O
old	O
)	O
were	O
obtained	O
from	O
Tokyo	O
Laboratory	O
Animals	O
Company	O
(	O
Tokyo	O
,	O
Japan	O
)	O
.	O

The	O
animal	O
studies	O
were	O
approved	O
by	O
the	O
Animal	O
Care	O
and	O
Use	O
Committee	O
of	O
Tokyo	O
Metropolitan	O
Institute	O
of	O
Gerontology	O
.	O

Calibration	O
of	O
PSL	O
Relationship	O
between	O
PSL	O
and	O
radioactivity	O
on	O
filter	O
paper	O
A	O
solution	O
of	O
11	O
C	O
-	O
tracer	O
was	O
prepared	O
at	O
the	O
concentration	O
of	O
100	O
MBq	O
/	O
mL	O
measured	O
with	O
a	O
radioisotope	O
calibrator	O
(	O
t	O
=	O
0	O
min	O
,	O
26	O
min	O
after	O
end	O
of	O
bombardment	O
[	O
EOB	O
]	O
)	O
.	O

The	O
solution	O
was	O
diluted	O
to	O
0.0310	O
MBq	O
/	O
mL	O
,	O
and	O
10	O
L	O
of	O
each	O
diluted	O
solution	O
(	O
0.3100	O
kBq	O
)	O
was	O
loaded	O
on	O
six	O
pieces	O
of	O
filter	O
paper	O
(	O
5	O
mm	O
	O
5	O
mm	O
,	O
0.23	O
	O
0.05	O
mm	O
thickness	O
,	O
Toyo	O
Roshi	O
Kaisha	O
,	O
Tokyo	O
,	O
Japan	O
)	O
.	O

Three	O
pieces	O
of	O
the	O
filter	O
paper	O
were	O
exposed	O
on	O
an	O
imaging	O
plate	O
of	O
type	O
IP	O
BAS	O
SR	O
(	O
FUJIX	O
Fuji	O
Photo	O
Film	O
Co.	O
,	O
Tokyo	O
,	O
Japan	O
)	O
until	O
the	O
decay	O
-	O
out	O
of	O
11	B
C	I
(	O
t	O
=	O
20	O
h	O
)	O
.	O

The	O
activity	O
at	O
the	O
start	O
of	O
contact	O
ranged	O
from	O
1.05	O
to	O
2990	O
Bq	O
(	O
t	O
=	O
35.5	O
min	O
)	O
.	O

At	O
the	O
same	O
time	O
,	O
the	O
radioactivity	O
(	O
cpm	O
)	O
of	O
the	O
other	O
three	O
pieces	O
of	O
the	O
filter	O
paper	O
was	O
measured	O
with	O
a	O
well	O
-	O
type	O
auto	O
-	O
gamma	O
counter	O
(	O
type	O
1282	O
Compugamma	O
CS	O
,	O
Wallac	O
Oy	O
,	O
Turku	O
,	O
Finland	O
)	O
for	O
15	O
s	O
,	O
and	O
the	O
cpm	O
/	O
Bq	O
was	O
computed	O
with	O
decay	O
correction	O
.	O

The	O
PSL	O
values	O
over	O
the	O
entire	O
piece	O
of	O
filter	O
paper	O
(	O
25	O
mm2	O
)	O
were	O
measured	O
with	O
a	O
bioimaging	O
analyzer	O
of	O
type	O
BAS	O
2500	O
(	O
FUJIX	O
Fuji	O
Photo	O
Film	O
Co.	O
,	O
Tokyo	O
,	O
Japan	O
)	O
,	O
to	O
compute	O
the	O
PSL	O
per	O
Bq	O
at	O
the	O
start	O
of	O
contact	O
.	O

Reproducibility	O
between	O
imaging	O
plates	O
The	O
filter	O
paper	O
provided	O
with	O
the	O
11	O
C	O
-	O
radioactivity	O
as	O
described	O
above	O
and	O
the	O
autoradiographic	O
[	O
14	O
C	O
]	O
micro	O
-	O
scales	O
(	O
1.1131.73	O
kBq	O
/	O
g	O
)	O
(	O
Amersham	O
International	O
plc	O
.	O
,	O
Buckinghamshire	O
,	O
England	O
)	O
were	O
exposed	O
to	O
five	O
imaging	O
plates	O
of	O
the	O
same	O
type	O
for	O
4	O
h	O
to	O
examine	O
the	O
reproducibility	O
between	O
imaging	O
plates	O
;	O
the	O
PSL	O
of	O
the	O
micro	O
-	O
scales	O
were	O
measured	O
as	O
PSL	O
/	O
mm2	O
.	O

Ex	O
vivo	O
autoradiography	O
Effect	O
of	O
section	O
thickness	O
[	B
11	I
C	I
]	I
Nemonapride	I
(	O
143	O
MBq	O
/	O
4.3	O
nmol	O
)	O
was	O
injected	O
intravenously	O
into	O
a	O
rat	O
(	O
235	O
g	O
)	O
(	O
t	O
=	O
0	O
min	O
,	O
29	O
min	O
after	O
EOB	O
)	O
.	O

Fifteen	O
minutes	O
later	O
,	O
the	O
rat	O
was	O
killed	O
and	O
the	O
brain	O
was	O
removed	O
.	O

The	O
brain	O
at	O
the	O
bregma	O
(	O
17	O
)	O
was	O
cut	O
into	O
10-	O
,	O
15-	O
,	O
20-	O
,	O
30-	O
,	O
75-	O
,	O
100-	O
,	O
and	O
150-m	O
thick	O
coronal	O
sections	O
using	O
a	O
cryotome	O
(	O
Bright	O
Instruments	O
Co.	O
Ltd.	O
,	O
UK	O
)	O
at	O
15	O
	O
C	O
.	O

The	O
brain	O
sections	O
were	O
thaw	O
-	O
mounted	O
on	O
glass	O
plates	O
(	O
20	O
	O
32	O
mm2	O
)	O
that	O
were	O
precoated	O
with	O
3	O
%	O
3-aminopropyltriethoxysilane	B
in	O
acetone	B
.	O

The	O
sections	O
were	O
dried	O
on	O
a	O
hot	O
plate	O
at	O
60	O
	O
C	O
and	O
apposed	O
placed	O
on	O
an	O
imaging	O
plate	O
(	O
t	O
=	O
110	O
min	O
)	O
.	O

The	O
tracer	O
uptake	O
was	O
visualized	O
as	O
described	O
above	O
.	O

Regions	O
of	O
interest	O
(	O
ROIs	O
)	O
were	O
placed	O
on	O
the	O
striatum	O
(	O
68	O
mm2	O
)	O
and	O
on	O
the	O
cerebral	O
cortex	O
(	O
68	O
mm2	O
)	O
,	O
and	O
the	O
PSL	O
/	O
mm2	O
values	O
were	O
measured	O
.	O

From	O
the	O
other	O
rat	O
(	O
230	O
g	O
)	O
given	O
[	B
11	I
C	I
]	I
nemonapride	I
(	O
136	O
MBq	O
/	O
4.4	O
nmol	O
)	O
,	O
the	O
coronal	O
brain	O
sections	O
with	O
10-	O
,	O
15-	O
,	O
20-	O
,	O
30-	O
,	O
75-	O
,	O
100-	O
,	O
and	O
150-m	O
thickness	O
were	O
also	O
obtained	O
as	O
described	O
above	O
.	O

The	O
whole	O
section	O
was	O
measured	O
for	O
the	O
radioactivity	O
(	O
cpm	O
)	O
with	O
an	O
auto	O
-	O
gamma	O
counter	O
for	O
15	O
s.	O

The	O
effect	O
of	O
section	O
thickness	O
was	O
evaluated	O
,	O
assuming	O
equal	O
radioactivity	O
concentration	O
between	O
corresponding	O
regions	O
or	O
whole	O
brains	O
in	O
neighboring	O
sections	O
at	O
the	O
bregma	O
.	O

Relationship	O
between	O
PSL	O
and	O
radioactivity	O
on	O
the	O
brain	O
section	O
To	O
obtain	O
coronal	O
brain	O
sections	O
having	O
a	O
wider	O
range	O
of	O
radioactivity	O
,	O
ex	O
vivo	O
ARG	O
was	O
performed	O
with	O
[	B
11	I
C	I
]	I
SCH	I
23390	I
,	O
which	O
is	O
more	O
concentrated	O
in	O
the	O
striatum	O
than	O
[	B
11	I
C	I
]	I
nemonapride	I
.	O

[	B
11	I
C	I
]	I
SCH	I
23390	I
(	O
236	O
MBq	O
/	O
11.1	O
nmol	O
and	O
47	O
MBq	O
/	O
2.2	O
nmol	O
)	O
was	O
injected	O
intravenously	O
into	O
two	O
rats	O
(	O
t	O
=	O
0	O
min	O
,	O
30	O
min	O
after	O
EOB	O
)	O
.	O

The	O
rats	O
were	O
killed	O
15	O
min	O
later	O
,	O
and	O
25	O
pairs	O
of	O
the	O
adjacent	O
coronal	O
brain	O
sections	O
with	O
20-m	O
thickness	O
were	O
prepared	O
throughout	O
the	O
brain	O
as	O
described	O
above	O
.	O

One	O
set	O
of	O
the	O
brain	O
sections	O
was	O
applied	O
to	O
an	O
imaging	O
plate	O
until	O
decay	O
-	O
out	O
to	O
measure	O
the	O
PSL	O
for	O
the	O
whole	O
section	O
,	O
and	O
the	O
other	O
set	O
was	O
measured	O
for	O
the	O
radioactivity	O
(	O
cpm	O
)	O
with	O
an	O
auto	O
-	O
gamma	O
counter	O
(	O
t	O
=	O
102	O
min	O
)	O
.	O

Then	O
the	O
PSL	O
/	O
cpm	O
was	O
calculated	O
for	O
each	O
brain	O
section	O
.	O

Regional	O
brain	O
uptake	O
of	O
[	B
11	I
C	I
]	I
nemonapride	I
measured	O
by	O
ex	O
vivo	O
ARG	O
and	O
tissue	O
sampling	O
method	O
[	B
11	I
C	I
]	I
Nemonapride	I
(	O
82.696.7	O
MBq	O
/	O
2.15.7	O
nmol	O
)	O
was	O
injected	O
intravenously	O
into	O
four	O
rats	O
(	O
260290	O
g	O
)	O
.	O

They	O
were	O
killed	O
30	O
min	O
later	O
and	O
the	O
brains	O
were	O
removed	O
.	O

From	O
a	O
half	O
brain	O
hemisphere	O
,	O
three	O
pairs	O
of	O
adjacent	O
coronal	O
brain	O
sections	O
with	O
20-m	O
thickness	O
were	O
cut	O
near	O
bregma	O
.	O

The	O
radioactivity	O
(	O
cpm	O
)	O
of	O
one	O
set	O
of	O
section	O
was	O
measured	O
with	O
an	O
auto	O
-	O
gamma	O
counter	O
and	O
converted	O
to	O
Bq	O
.	O

The	O
other	O
section	O
was	O
exposed	O
to	O
an	O
imaging	O
plate	O
to	O
measure	O
the	O
PSL	O
for	O
the	O
whole	O
section	O
as	O
described	O
above	O
,	O
and	O
the	O
PSL	O
/	O
Bq	O
was	O
calculated	O
assuming	O
that	O
the	O
pair	O
of	O
adjacent	O
brain	O
sections	O
had	O
the	O
same	O
radioactivity	O
.	O

ROIs	O
were	O
placed	O
on	O
the	O
striatum	O
and	O
on	O
the	O
cortex	O
to	O
measure	O
the	O
PSL	O
for	O
the	O
regional	O
brain	O
section	O
volume	O
(	O
mm2	O
	O
0.02	O
mm	O
)	O
,	O
which	O
was	O
converted	O
to	O
Bq	O
/	O
mL.	O
Then	O
,	O
the	O
uptake	O
of	O
[	B
11	I
C	I
]	I
nemonapride	I
by	O
the	O
striatum	O
or	O
cortex	O
was	O
assessed	O
as	O
the	O
percent	O
of	O
the	O
injected	O
dose	O
per	O
milliliter	O
of	O
tissue	O
(	O
%	O
ID	O
/	O
mL	O
)	O
.	O

From	O
the	O
other	O
hemisphere	O
the	O
striatum	O
and	O
cortex	O
were	O
dissected	O
and	O
weighed	O
,	O
and	O
the	O
radioactivity	O
of	O
the	O
tissues	O
was	O
measured	O
with	O
an	O
auto	O
-	O
gamma	O
counter	O
.	O

The	O
uptake	O
was	O
expressed	O
as	O
the	O
percent	O
of	O
the	O
injected	O
dose	O
per	O
gram	O
of	O
tissue	O
(	O
%	O
ID	O
/	O
g	O
)	O
.	O

Effect	O
of	O
carrier	O
dose	O
To	O
measure	O
the	O
receptor	O
binding	O
capacity	O
quantitatively	O
in	O
ex	O
vivo	O
ARG	O
,	O
the	O
amount	O
of	O
injected	O
carrier	O
ligand	O
must	O
be	O
sufficiently	O
small	O
to	O
avoid	O
saturation	O
effect	O
.	O

To	O
determine	O
if	O
the	O
carrier	O
amount	O
of	O
nemonapride	B
meets	O
this	O
requirement	O
under	O
the	O
specific	O
activity	O
of	O
current	O
experimental	O
condition	O
,	O
the	O
effect	O
of	O
carrier	O
dose	O
on	O
the	O
regional	O
uptake	O
of	O
[	B
11	I
C	I
]	I
nemonapride	I
was	O
evaluated	O
by	O
tissue	O
sampling	O
.	O

[	B
11	I
C	I
]	I
Nemonapride	I
with	O
various	O
amount	O
of	O
carrier	O
(	O
10	O
MBq	O
/	O
0.027500	O
nmol	O
)	O
was	O
injected	O
into	O
rats	O
(	O
227	O
	O
12	O
g	O
)	O
,	O
and	O
the	O
uptake	O
(	O
%	O
ID	O
/	O
g	O
)	O
by	O
the	O
striatum	O
,	O
cortex	O
,	O
and	O
cerebellum	O
was	O
measured	O
at	O
30	O
min	O
after	O
the	O
injection	O
by	O
the	O
tissue	O
sampling	O
method	O
as	O
described	O
above	O
.	O

In	O
vitro	O
autoradiography	O
Effect	O
of	O
section	O
thickness	O
In	O
vitro	O
ARG	O
with	O
[	B
11	I
C	I
]	I
nemonapride	I
was	O
performed	O
according	O
to	O
the	O
method	O
of	O
Przedborski	O
et	O
al.	O
(	O
19	O
)	O
with	O
a	O
slight	O
modification	O
.	O

Coronal	O
rat	O
brain	O
sections	O
with	O
10-	O
,	O
20-	O
,	O
30-	O
,	O
75-	O
,	O
100-	O
,	O
and	O
150-m	O
thickness	O
near	O
the	O
bregma	O
(	O
17	O
)	O
were	O
prepared	O
.	O

The	O
brain	O
sections	O
were	O
pre	O
-	O
incubated	O
in	O
100	O
mL	O
50	O
mM	O
Tris	O
-	O
HCl	O
,	O
pH	O
7.4	O
,	O
containing	O
120	O
mM	O
NaCl	B
for	O
30	O
min	O
at	O
room	O
temperature	O
.	O

Then	O
,	O
the	O
same	O
buffer	O
containing	O
100	O
kBq	O
/	O
mL	O
(	O
25	O
TBq	O
/	O
mmol	O
)	O
[	B
11	I
C	I
]	I
nemonapride	I
was	O
prepared	O
(	O
t	O
=	O
0	O
min	O
,	O
29	O
min	O
after	O
EOB	O
)	O
,	O
in	O
which	O
all	O
the	O
sections	O
were	O
incubated	O
for	O
30	O
min	O
at	O
37	O
	O
C	O
.	O

After	O
being	O
washed	O
with	O
ice	B
-	O
cold	O
50	O
mM	O
Tris	B
-	I
HCl	I
(	O
pH	O
7.4	O
)	O
containing	O
120	O
mM	O
NaCl	B
,	O
the	O
brain	O
sections	O
were	O
dried	O
on	O
a	O
hot	O
plate	O
at	O
60	O
	O
C	O
,	O
and	O
then	O
contacted	O
on	O
an	O
imaging	O
plate	O
(	O
t	O
=	O
58	O
min	O
)	O
until	O
the	O
activity	O
decayed	O
out	O
(	O
t	O
=	O
20	O
h	O
)	O
.	O

The	O
binding	O
of	O
11	B
C	I
was	O
measured	O
as	O
the	O
PSL	O
/	O
mm2	O
over	O
the	O
ROIs	O
placed	O
in	O
the	O
same	O
manner	O
as	O
in	O
the	O
ex	O
vivo	O
ARG	O
,	O
and	O
the	O
effect	O
of	O
section	O
thickness	O
was	O
evaluated	O
.	O

The	O
other	O
set	O
of	O
the	O
brain	O
section	O
was	O
also	O
assayed	O
as	O
described	O
above	O
and	O
the	O
radioactivity	O
(	O
cpm	O
)	O
of	O
the	O
whole	O
section	O
was	O
measured	O
with	O
a	O
gamma	O
counter	O
.	O

Saturation	O
of	O
[	B
11	I
C	I
]	I
nemonapride	I
binding	O
The	O
buffer	O
containing	O
various	O
concentrations	O
(	O
0.156	O
,	O
0.313	O
,	O
0.625	O
,	O
1.25	O
,	O
and	O
2.50	O
nM	O
)	O
of	O
[	B
11	I
C	I
]	I
nemonapride	I
(	O
21	O
TBq	O
/	O
mmol	O
)	O
was	O
prepared	O
(	O
t	O
=	O
0	O
min	O
,	O
40	O
min	O
after	O
EOB	O
)	O
,	O
and	O
six	O
brain	O
sections	O
with	O
20-m	O
thickness	O
were	O
incubated	O
for	O
30	O
min	O
at	O
37	O
	O
C	O
in	O
each	O
buffer	O
as	O
described	O
above	O
.	O

Nonspecific	O
binding	O
was	O
determined	O
by	O
incubating	O
adjacent	O
six	O
sections	O
in	O
the	O
medium	O
to	O
which	O
haloperidol	B
was	O
added	O
to	O
a	O
final	O
concentration	O
of	O
20	O
M.	O
Three	O
brain	O
sections	O
in	O
each	O
assay	O
were	O
exposed	O
on	O
an	O
imaging	O
plate	O
(	O
t	O
=	O
85	O
min	O
)	O
to	O
measure	O
the	O
PSL	O
values	O
,	O
and	O
the	O
adjacent	O
three	O
sections	O
were	O
measured	O
for	O
radioactivity	O
(	O
cpm	O
)	O
.	O

Then	O
,	O
the	O
PSL	O
/	O
Bq	O
calculated	O
as	O
described	O
above	O
was	O
converted	O
to	O
concentration	O
of	O
receptor	O
-	O
bound	O
ligand	O
(	O
nmol	O
/	O
mL	O
tissue	O
)	O
using	O
the	O
specific	O
activity	O
of	O
the	O
ligand	O
.	O

Scatchard	O
plot	O
,	O
bound	O
ligand	O
(	O
nmol	O
/	O
mL	O
tissue	O
)	O
versus	O
bound	O
ligand	O
/	O
free	O
ligand	O
(	O
nmol	O
/	O
mL	O
tissue	O
/	O
nM	O
)	O
,	O
was	O
carried	O
out	O
.	O

Results	O
and	O
discussion	O
Relationship	O
between	O
PSL	O
and	O
radioactivity	O
on	O
filter	O
paper	O
Figure	O
1	O
shows	O
the	O
PSL	O
values	O
of	O
the	O
standard	O
sample	O
on	O
filter	O
paper	O
.	O

The	O
PSL	O
values	O
were	O
linearly	O
proportional	O
to	O
the	O
11	B
C	I
radioactivity	O
(	O
Bq	O
)	O
measured	O
with	O
a	O
radioisotope	O
calibrator	O
(	O
Fig.	O
1A	O
)	O
,	O
and	O
the	O
ratio	O
was	O
10.7	O
PSL	O
/	O
Bq	O
at	O
the	O
start	O
of	O
contact	O
.	O

Because	O
each	O
sample	O
presented	O
uniform	O
activity	O
distribution	O
within	O
the	O
piece	O
of	O
filter	O
paper	O
,	O
the	O
PSL	O
of	O
the	O
standard	O
sample	O
on	O
the	O
filter	O
paper	O
was	O
expressed	O
as	O
a	O
linear	O
function	O
of	O
radioactivity	O
in	O
the	O
range	O
from	O
0.4	O
to	O
1110	O
PSL	O
/	O
mm2	O
(	O
0.04104	O
Bq	O
/	O
mm2	O
)	O
in	O
the	O
present	O
study	O
.	O

The	O
linearity	O
between	O
the	O
radioisotope	O
calibrator	O
and	O
the	O
well	O
-	O
type	O
gamma	O
counter	O
was	O
also	O
confirmed	O
,	O
the	O
ratio	O
being	O
40.1	O
cpm	O
/	O
Bq	O
.	O

Reproducibility	O
between	O
imaging	O
plates	O
When	O
the	O
11	O
C	O
-	O
samples	O
on	O
filter	O
paper	O
and	O
standard	O
[	O
14	O
C	O
]	O
micro	O
-	O
scales	O
were	O
exposed	O
to	O
five	O
imaging	O
plates	O
,	O
the	O
coefficient	O
variation	O
(	O
SD	O
/	O
mean	O
)	O
of	O
the	O
five	O
plates	O
for	O
11	B
C	I
-	O
sensitivity	O
and	O
14	B
C	I
-	O
sensitivity	O
was	O
2.43.2	O
%	O
at	O
17.4164	O
PSL	O
/	O
mm2	O
and	O
2.66.9	O
%	O
at	O
5.236.6	O
PSL	O
/	O
mm2	O
,	O
respectively	O
.	O

The	O
variation	O
for	O
11	B
C	I
was	O
comparable	O
to	O
that	O
for	O
14	B
C	I
,	O
which	O
confirmed	O
the	O
reliability	O
of	O
our	O
homemade	O
standard	O
source	O
on	O
filter	O
paper	O
.	O

Effect	O
of	O
section	O
thickness	O
Figure	O
2	O
shows	O
representative	O
autoradiograms	O
of	O
[	B
11	I
C	I
]	I
nemonapride	I
by	O
ex	O
vivo	O
and	O
in	O
vitro	O
ARG	O
.	O

High	O
11	B
C	I
density	O
was	O
observed	O
in	O
the	O
caudate	O
putamen	O
,	O
nucleus	O
accumbens	O
,	O
and	O
olfactory	O
tubercle	O
,	O
consistent	O
with	O
the	O
well	O
-	O
known	O
distribution	O
of	O
dopamine	B
D2	O
receptors	O
.	O

Figure	O
3	O
illustrates	O
the	O
relationship	O
between	O
brain	O
section	O
thickness	O
and	O
PSL	O
values	O
measured	O
by	O
ex	O
vivo	O
and	O
in	O
vitro	O
ARG	O
.	O

The	O
PSL	O
/	O
mm2	O
value	O
for	O
ex	O
vivo	O
ARG	O
was	O
not	O
linearly	O
proportional	O
to	O
the	O
slice	O
thickness	O
(	O
Fig.	O
3A	O
)	O
,	O
suggesting	O
that	O
the	O
absorption	O
of	O
radiation	O
increases	O
as	O
the	O
section	O
thickness	O
increases	O
,	O
because	O
it	O
is	O
reasonably	O
assumed	O
that	O
the	O
radioactivity	O
of	O
[	B
11	I
C	I
]	I
nemonapride	I
was	O
uniformly	O
distributed	O
throughout	O
the	O
thickness	O
in	O
the	O
striatum	O
and	O
cortex	O
near	O
the	O
bregma	O
.	O

On	O
the	O
other	O
hand	O
,	O
a	O
deviation	O
from	O
the	O
linear	O
function	O
was	O
much	O
larger	O
for	O
the	O
in	O
vitro	O
ARG	O
than	O
for	O
the	O
ex	O
vivo	O
ARG	O
,	O
and	O
the	O
PSL	O
/	O
mm2	O
values	O
reached	O
a	O
plateau	O
both	O
in	O
the	O
striatum	O
and	O
cortex	O
for	O
over	O
100-m	O
thick	O
sections	O
.	O

This	O
finding	O
is	O
probably	O
because	O
diffusion	O
of	O
the	O
11	B
C	I
-	O
tracer	O
into	O
the	O
brain	O
tissue	O
was	O
not	O
completed	O
in	O
thick	O
brain	O
sections	O
during	O
the	O
incubation	O
period	O
,	O
and	O
the	O
binding	O
did	O
not	O
reach	O
an	O
equilibrium	O
state	O
.	O

The	O
explanation	O
was	O
approved	O
by	O
measurement	O
of	O
radioactivity	O
of	O
the	O
whole	O
brain	O
sections	O
with	O
a	O
gamma	O
counter	O
(	O
Fig.	O
3C	O
)	O
.	O

The	O
radioactivity	O
was	O
linearly	O
proportional	O
to	O
the	O
slice	O
thickness	O
in	O
ex	O
vivo	O
ARG	O
,	O
but	O
not	O
in	O
in	O
vitro	O
ARG	O
.	O

Relationship	O
between	O
PSL	O
and	O
radioactivity	O
on	O
the	O
brain	O
section	O
Figure	O
4	O
shows	O
relationship	O
between	O
the	O
PSL	O
value	O
and	O
the	O
radioactivity	O
of	O
11	B
C	I
on	O
the	O
whole	O
section	O
with	O
20-m	O
thickness	O
and	O
for	O
the	O
entire	O
piece	O
of	O
25-mm2	O
filter	O
paper	O
with	O
230-m	O
thickness	O
.	O

The	O
PSL	O
was	O
found	O
to	O
be	O
linearly	O
proportional	O
to	O
the	O
radioactivity	O
within	O
the	O
brain	O
sections	O
or	O
filter	O
paper	O
,	O
although	O
the	O
coefficient	O
was	O
different	O
between	O
the	O
two	O
materials	O
because	O
of	O
different	O
thickness	O
as	O
suggested	O
from	O
Figure	O
2	O
.	O

Therefore	O
,	O
the	O
PSL	O
value	O
can	O
be	O
converted	O
to	O
the	O
radioactivity	O
expressed	O
as	O
Bq	O
unit	O
,	O
if	O
the	O
radioactivity	O
of	O
the	O
adjacent	O
brain	O
sections	O
with	O
the	O
same	O
thickness	O
is	O
measured	O
with	O
a	O
gamma	O
-	O
counter	O
.	O

Table	O
1	O
summarizes	O
the	O
uptake	O
of	O
[	B
11	I
C	I
]	I
nemonapride	I
by	O
the	O
striatum	O
and	O
cortex	O
measured	O
by	O
ex	O
vivo	O
ARG	O
and	O
by	O
the	O
tissue	O
sampling	O
.	O

Comparable	O
values	O
of	O
the	O
striatal	O
and	O
cortical	O
uptake	O
were	O
obtained	O
by	O
the	O
two	O
methods	O
,	O
nevertheless	O
the	O
technical	O
problem	O
that	O
the	O
nonstriatal	O
region	O
might	O
be	O
contaminated	O
with	O
the	O
striatal	O
sample	O
in	O
the	O
tissue	O
sampling	O
,	O
and	O
the	O
fact	O
that	O
the	O
uptake	O
of	O
[	B
11	I
C	I
]	I
nemonapride	I
is	O
less	O
homogeneous	O
in	O
the	O
striatum	O
than	O
in	O
the	O
cortex	O
.	O

Therefore	O
,	O
ex	O
vivo	O
ARG	O
may	O
be	O
a	O
suitable	O
method	O
to	O
quantitatively	O
evaluate	O
small	O
regions	O
such	O
as	O
nucleus	O
accumbens	O
and	O
olfactory	O
tubercles	O
.	O

Effect	O
of	O
carrier	O
dose	O
To	O
evaluate	O
the	O
carrier	O
dose	O
on	O
the	O
regional	O
brain	O
uptake	O
of	O
[	B
11	I
C	I
]	I
nemonapride	I
,	O
the	O
uptake	O
was	O
measured	O
by	O
tissue	O
sampling	O
method	O
.	O

As	O
shown	O
in	O
Figure	O
5	O
,	O
at	O
the	O
dose	O
of	O
22	O
nmol	O
/	O
kg	O
the	O
uptake	O
was	O
slightly	O
decreased	O
,	O
though	O
not	O
statistically	O
significant	O
.	O

In	O
the	O
regional	O
brain	O
distribution	O
study	O
with	O
ex	O
vivo	O
ARG	O
and	O
tissue	O
sampling	O
(	O
Table	O
1	O
)	O
,	O
the	O
injected	O
doses	O
were	O
320330	O
MBq	O
/	O
kg	O
as	O
radioactivity	O
and	O
8.120	O
nmol	O
/	O
kg	O
as	O
carrier	O
amounts	O
.	O

Therefore	O
,	O
the	O
injected	O
carrier	O
dose	O
of	O
[	B
11	I
C	I
]	I
nemonapride	I
slightly	O
exceeded	O
to	O
the	O
optimum	O
condition	O
.	O

However	O
,	O
because	O
the	O
PSL	O
/	O
mm2	O
values	O
measured	O
in	O
the	O
cortex	O
were	O
1214	O
at	O
6570	O
min	O
after	O
the	O
tracer	O
injection	O
(	O
at	O
3540	O
min	O
after	O
the	O
exposing	O
time	O
)	O
in	O
the	O
study	O
described	O
in	O
Table	O
1	O
,	O
the	O
injected	O
dose	O
for	O
the	O
[	B
11	I
C	I
]	I
nemonapride	I
can	O
be	O
reasonably	O
reduced	O
to	O
approximately	O
one	O
-	O
tenth	O
within	O
the	O
linearity	O
range	O
for	O
the	O
PSL	O
/	O
mm2	O
(	O
>	O
0.4	O
in	O
Fig.	O
1	O
)	O
,	O
although	O
statistical	O
noise	O
is	O
increased	O
.	O

Therefore	O
,	O
the	O
quantitative	O
ex	O
vivo	O
ARG	O
method	O
using	O
imaging	O
plates	O
presented	O
in	O
this	O
study	O
is	O
applicable	O
to	O
quantitative	O
measurement	O
of	O
the	O
receptor	O
binding	O
capacity	O
with	O
[	B
11	I
C	I
]	I
nemonapride	I
.	O

It	O
can	O
also	O
be	O
applied	O
to	O
other	O
dopamine	O
receptor	O
ligands	O
such	O
as	O
[	B
11	I
C	I
]	I
raclopride	I
,	O
[	B
11	I
C	I
]	I
N	I
-methylspiperone	I
,	O
and	O
[	B
11	I
C	I
]	I
SCH	I
23390	I
(	O
data	O
not	O
shown	O
)	O
,	O
although	O
the	O
uptake	O
depends	O
in	O
the	O
ligand	O
.	O

Figure	O
5	O
also	O
showed	O
that	O
a	O
saturable	O
uptake	O
of	O
[	B
11	I
C	I
]	I
nemonapride	I
was	O
observed	O
in	O
the	O
cortex	O
and	O
cerebellum	O
besides	O
in	O
the	O
striatum	O
,	O
which	O
was	O
preliminarily	O
suggested	O
by	O
a	O
previous	O
report	O
(	O
5	O
)	O
.	O

In	O
vitro	O
[	B
11	I
C	I
]	I
Nemonapride	I
binding	O
to	O
the	O
striatum	O
and	O
cortex	O
In	O
previous	O
studies	O
on	O
in	O
vitro	O
binding	O
of	O
radiolabeled	O
nemonapride	B
(	B
[	I
3	I
H	I
]	I
YM-09151	I
-	I
2	I
)	O
at	O
room	O
temperature	O
,	O
the	O
tracer	O
binding	O
reached	O
equilibrium	O
after	O
90	O
min	O
(	O
2	O
,	O
15	O
,	O
24	O
)	O
.	O

In	O
our	O
preliminary	O
experiment	O
,	O
when	O
the	O
incubation	O
was	O
carried	O
out	O
at	O
37	O
	O
C	O
to	O
accelerate	O
the	O
equilibration	O
,	O
the	O
[	B
11	I
C	I
]	I
nemonapride	I
binding	O
reached	O
a	O
maximal	O
level	O
at	O
30	O
min	O
(	O
data	O
not	O
shown	O
)	O
,	O
which	O
enabled	O
the	O
use	O
of	O
the	O
short	O
-	O
lived	O
11	B
C	I
-	O
ligand	O
.	O

The	O
specific	O
activity	O
of	O
[	B
11	I
C	I
]	I
nemonapride	I
was	O
reasonably	O
high	O
(	O
25	O
TBq	O
/	O
mmol	O
at	O
the	O
start	O
of	O
assay	O
in	O
the	O
present	O
study	O
)	O
compared	O
with	O
conventional	O
in	O
vitro	O
ARG	O
using	O
3	B
H	I
-	O
labeled	O
compounds	O
.	O

Thus	O
the	O
in	O
vitro	O
ARG	O
with	O
[	B
11	I
C	I
]	I
nemonapride	I
is	O
a	O
practicable	O
technique	O
.	O

The	O
period	O
required	O
from	O
the	O
end	O
of	O
radiosynthesis	O
to	O
the	O
exposing	O
the	O
brain	O
slice	O
to	O
imaging	O
plate	O
was	O
approximately	O
90	O
min	O
.	O

A	O
saturation	O
binding	O
experiment	O
showed	O
a	O
specific	O
binding	O
of	O
[	B
11	I
C	I
]	I
nemonapride	I
to	O
the	O
striatum	O
and	O
cortex	O
(	O
Fig.	O
6A	O
)	O
.	O

Scatchard	O
analysis	O
indicated	O
a	O
Kd	O
of	O
730	O
pM	O
and	O
an	O
apparent	O
Bmax	O
of	O
160	O
nmol	O
/	O
mL	O
tissue	O
in	O
the	O
striatum	O
and	O
a	O
Kd	O
of	O
1.5	O
nM	O
and	O
a	O
Bmax	O
of	O
29	O
nmol	O
/	O
mL	O
tissue	O
in	O
the	O
cortex	O
.	O

The	O
Kd	O
value	O
of	O
730	O
pM	O
for	O
the	O
striatum	O
is	O
in	O
the	O
same	O
order	O
as	O
those	O
obtained	O
with	O
in	O
vitro	O
ARG	O
by	O
Unis	O
et	O
al.	O
(	O
626	O
pM	O
)	O
(	O
24	O
)	O
and	O
Yokoyama	O
et	O
al.	O
(	O
315	O
pM	O
)	O
(	O
26	O
)	O
,	O
but	O
is	O
larger	O
than	O
those	O
(	O
2182	O
pM	O
)	O
measured	O
by	O
the	O
membrane	O
binding	O
assay	O
(	O
1	O
,	O
13	O
,	O
15	O
,	O
23	O
)	O
or	O
with	O
in	O
vitro	O
ARG	O
(	O
2	O
)	O
.	O

These	O
differences	O
may	O
be	O
caused	O
by	O
the	O
assay	O
conditions	O
such	O
as	O
incubation	O
time	O
,	O
temperature	O
,	O
blockers	O
used	O
to	O
evaluate	O
the	O
nonspecific	O
binding	O
,	O
other	O
medium	O
components	O
,	O
and	O
slice	O
thickness	O
in	O
ARG	O
.	O

The	O
saturation	O
kinetics	O
may	O
also	O
be	O
different	O
between	O
the	O
membrane	O
homogenate	O
and	O
the	O
brain	O
slice	O
.	O

An	O
in	O
vivo	O
saturation	O
binding	O
experiment	O
in	O
Figure	O
6	O
revealed	O
the	O
presence	O
of	O
saturable	O
binding	O
sites	O
for	O
[	B
11	I
C	I
]	I
nemonapride	I
in	O
the	O
cortex	O
and	O
striatum	O
.	O

This	O
finding	O
was	O
also	O
revealed	O
by	O
an	O
ex	O
vivo	O
study	O
(	O
Fig.	O
5	O
)	O
,	O
which	O
also	O
suggested	O
the	O
presence	O
of	O
saturable	O
binding	O
sites	O
in	O
the	O
cerebellum	O
.	O

The	O
specific	O
binding	O
evaluated	O
with	O
a	O
haloperidol	B
-	O
blockade	O
was	O
lower	O
than	O
the	O
nonspecific	O
binding	O
in	O
the	O
cortex	O
(	O
Fig.	O
6A	O
-2	O
)	O
.	O

Kazawa	O
et	O
al.	O
(	O
13	O
)	O
demonstrated	O
that	O
[	B
3	I
H	I
]	I
nemonapride	I
binding	O
in	O
the	O
cortical	O
membrane	O
was	O
displaced	O
by	O
sulpiride	B
or	O
by	O
haloperidol	B
.	O

They	O
also	O
showed	O
that	O
these	O
binding	O
sites	O
were	O
apparently	O
different	O
from	O
serotonin-2	O
receptors	O
.	O

The	O
unknown	O
binding	O
sites	O
may	O
be	O
dopamine	B
D4	O
receptors	O
,	O
because	O
haloperidol	B
,	O
but	O
not	O
raclopride	B
,	O
displaced	O
the	O
uptake	O
(	O
20	O
)	O
.	O

Sigma	O
receptors	O
may	O
be	O
another	O
candidate	O
for	O
the	O
unknown	O
binding	O
sites	O
.	O

Helmeste	O
et	O
al.	O
(	O
7	O
)	O
suggested	O
that	O
nemonapride	B
also	O
has	O
an	O
affinity	O
for	O
sigma	O
receptors	O
,	O
which	O
was	O
evaluated	O
by	O
a	O
blocking	O
study	O
with	O
a	O
selective	O
sigma	O
receptor	O
ligand	O
,	O
R	B
(	I
	I
)	I
-N	I
-	I
(	I
3-phenyl	I
-	I
n	I
-propyl	I
)	I
-1-phenyl-2-aminopropane	I
(	O
PPAP	B
)	O
.	O

Preliminary	O
findings	O
indicated	O
that	O
the	O
[	B
11	I
C	I
]	I
nemonapride	I
uptake	O
was	O
reduced	O
by	O
carrier	O
nemonapride	B
or	O
by	O
haloperidol	B
in	O
the	O
striatum	O
,	O
cortex	O
,	O
and	O
cerebellum	O
of	O
the	O
mouse	O
brain	O
,	O
but	O
that	O
other	O
sigma	O
receptor	O
ligands	O
such	O
as	O
PPAP	B
,	O
(	B
+	I
)	I
-SKF10047	I
,	O
R	B
(	I
+	I
)	I
-3-	I
(	I
3-hydroxyphenyl	I
)	I
-N	I
-propylpiperidine	I
hydrochloride	I
(	O
R	B
[	I
+	I
]	I
-3-PPP	I
)	O
and	O
NE-100	B
(	O
22	O
)	O
did	O
not	O
reduce	O
the	O
[	B
11	I
C	I
]	I
nemonapride	I
uptake	O
by	O
the	O
striatum	O
(	O
unpublished	O
data	O
)	O
.	O

The	O
in	O
vivo	O
affinity	O
of	O
the	O
[	B
11	I
C	I
]	I
nemonapride	I
for	O
sigma	O
receptors	O
is	O
under	O
investigation	O
.	O

So	O
far	O
,	O
we	O
confirmed	O
in	O
ex	O
vivo	O
and	O
in	O
vitro	O
experiments	O
that	O
the	O
saturable	O
binding	O
sites	O
of	O
[	B
11	I
C	I
]	I
nemonapride	I
are	O
present	O
in	O
the	O
cortex	O
(	O
and	O
probably	O
in	O
the	O
cerebellum	O
)	O
although	O
their	O
characteristics	O
remain	O
unknown	O
.	O

Acknowledgements	O
This	O
work	O
was	O
supported	O
by	O
a	O
Grant	O
-	O
in	O
-	O
Aid	O
for	O
Scientific	O
Research	O
(	O
B	O
)	O
No.	O
10558115	O
from	O
the	O
Ministry	O
of	O
Education	O
,	O
Science	O
,	O
Sports	O
and	O
Culture	O
,	O
Japan	O
.	O

Perillyl	B
alcohol	I
is	O
a	O
hydroxylated	B
metabolite	I
of	O
d	B
-limonene	I
[	O
13	O
]	O
,	O
which	O
is	O
the	O
major	O
,	O
naturally	O
occurring	O
monoterpene	B
present	O
in	O
orange	O
peel	O
oil	O
.	O

Perillyl	B
alcohol	I
is	O
also	O
found	O
in	O
lavender	O
,	O
mints	O
,	O
and	O
celery	O
seeds	O
.	O

It	O
has	O
been	O
shown	O
that	O
d	B
-limonene	I
and	O
metabolites	B
possess	O
chemopreventative	O
and	O
chemotherapeutic	O
activity	O
against	O
human	O
malignancies	O
with	O
low	O
toxicity	O
[	O
48	O
]	O
.	O

d	B
-Limonene	I
is	O
extensively	O
metabolized	O
(	O
Scheme	O
1	O
)	O
in	O
animals	O
[	O
15	O
]	O
and	O
in	O
humans	O
[	O
9,10	O
]	O
and	O
perillic	B
acid	I
and	O
dihydroperillic	B
acid	I
were	O
found	O
to	O
be	O
the	O
major	O
circulating	O
metabolites	B
[	O
13,5,6	O
]	O
and	O
for	O
perillyl	B
alcohol	I
[	O
11	O
]	O
.	O

Metabolites	B
of	O
limonene	B
with	O
intermediate	O
polarity	O
such	O
as	O
perillyl	B
alcohol	I
,	O
perillic	B
acid	I
methyl	I
ester	I
and	O
perillaldehyde	B
were	O
found	O
to	O
be	O
more	O
potent	O
inhibitors	O
of	O
isoprenylation	O
of	O
the	O
p2126	O
kDa	O
protein	O
,	O
which	O
is	O
involved	O
in	O
cell	O
growth	O
and	O
proliferation	O
[	O
7	O
]	O
,	O
than	O
limonene	B
itself	O
.	O

In	O
vivo	O
,	O
perillyl	B
alcohol	I
was	O
also	O
found	O
to	O
be	O
more	O
active	O
than	O
d	B
-limonene	I
[	O
47,1214	O
]	O
.	O

Phillips	O
et	O
al.	O
[	O
11	O
]	O
conducted	O
a	O
pharmacokinetic	O
study	O
of	O
perillyl	B
alcohol	I
in	O
dogs	O
using	O
a	O
GC	O
	O
MS	O
method	O
with	O
a	O
sensitivity	O
limit	O
of	O
0.25	O
g	O
/	O
ml	O
,	O
but	O
were	O
unable	O
to	O
detect	O
the	O
parent	O
drug	B
in	O
circulation	O
.	O

In	O
order	O
to	O
understand	O
the	O
pharmacokinetic	O
and	O
disposition	O
characteristics	O
of	O
perillyl	B
alcohol	I
,	O
the	O
development	O
of	O
a	O
more	O
sensitive	O
quantitation	O
assay	O
method	O
is	O
necessary	O
.	O

The	O
present	O
report	O
describes	O
a	O
sensitive	O
GC	O
	O
MS	O
method	O
for	O
the	O
measurement	O
of	O
perillyl	B
alcohol	I
and	O
its	O
metabolites	B
in	O
plasma	O
using	O
the	O
stable	O
isotope	B
-	I
labelled	I
analogs	I
as	O
the	O
internal	O
standards	O
.	O

A	O
derivatization	O
procedure	O
is	O
also	O
used	O
to	O
facilitate	O
the	O
GC	O
separation	O
and	O
mass	O
spectrometric	O
detection	O
.	O

2	O
Materials	O
and	O
methods	O
2.1	O
Chemicals	O
and	O
reagents	O
(	B
S	I
)	I
-	I
(	I
	I
)	I
-Perillyl	I
alcohol	I
(	O
POH	B
)	O
was	O
purchased	O
from	O
Aldrich	O
(	O
Milwaukee	O
,	O
WI	O
,	O
USA	O
)	O
.	O

Perillic	B
acid	I
(	O
PA	B
)	O
,	O
cis-	B
/trans-	I
dihydroperillic	I
acid	I
(	O
cis-	B
/trans-	I
DHPA	I
,	O
cis-	B
/trans-	I
4	I
(	I
1-methylethenyl	I
)	I
cyclohexane-1-carboxylic	I
acid	I
)	O
,	O
perillyl	B
alcohol	I
-	I
d3	I
(	O
POH	B
-	I
d3	I
)	O
and	O
perillic	B
acid	I
-	I
d2	I
-13	I
C	I
(	O
13	B
C	I
-	I
PA	I
-	I
d2	I
)	O
(	O
Fig.	O
1	O
)	O
were	O
synthesized	O
according	O
to	O
the	O
literature	O
method	O
[	O
15	O
]	O
.	O

POH	B
-	I
d3	I
was	O
used	O
as	O
the	O
internal	O
standard	O
for	O
POH	B
,	O
whereas	O
13	B
C	I
-	I
PA	I
-	I
d2	I
was	O
used	O
as	O
the	O
internal	O
standard	O
for	O
PA	B
and	O
cis-	B
/	I
trans	I
-DHPA	I
.	O

Cis-	B
and	O
trans-	B
1-carboxy-4-methylcyclohexane	I
were	O
purchased	O
from	O
Aldrich	O
.	O

The	O
chemical	O
purity	O
of	O
all	O
these	O
synthetic	B
compounds	I
as	O
well	O
as	O
the	O
isotope	O
purity	O
of	O
labeled	B
compounds	I
was	O
99	O
%	O
.	O

N	B
,-	I
O	I
-Bis-	I
(	I
trimethylsilyl	I
)	I
silyltrifluoroacetamide	I
(	O
BSTFA	B
)	O
was	O
obtained	O
from	O
Pierce	O
(	O
Rockford	O
,	O
IL	O
,	O
USA	O
)	O
.	O

Acetonitrile	B
(	O
HPLC	O
grade	O
)	O
was	O
purchased	O
from	O
Fisher	O
Scientific	O
(	O
Pittsburgh	O
,	O
PA	O
,	O
USA	O
)	O
.	O

All	O
other	O
organic	B
solvents	I
and	O
reagents	B
purchased	O
from	O
Fisher	O
Scientific	O
were	O
of	O
reagent	O
grade	O
.	O

2.2	O
Sample	O
extraction	O
To	O
each	O
of	O
a	O
set	O
of	O
16	O
	O
125-mm	O
disposable	O
tubes	O
was	O
added	O
appropriate	O
amounts	O
of	O
the	O
internal	O
standards	O
in	O
acetonitrile	B
followed	O
by	O
gentle	O
evaporation	O
of	O
the	O
solvent	O
with	O
a	O
stream	O
of	O
nitrogen	B
.	O

A	O
plasma	O
sample	O
(	O
0.5	O
ml	O
or	O
less	O
)	O
was	O
then	O
added	O
and	O
the	O
content	O
mixed	O
.	O

The	O
sample	O
volume	O
of	O
less	O
than	O
0.5	O
ml	O
was	O
made	O
up	O
to	O
0.5	O
ml	O
by	O
addition	O
of	O
blank	O
mouse	O
or	O
human	O
plasma	O
.	O

Acetonitrile	B
(	O
1.0	O
ml	O
)	O
was	O
added	O
to	O
precipitate	O
the	O
protein	O
.	O

The	O
mixture	O
was	O
centrifuged	O
at	O
500	O
g	O
for	O
3	O
min	O
.	O

The	O
supernatant	O
was	O
transferred	O
to	O
a	O
new	O
set	O
of	O
disposable	O
tubes	O
and	O
was	O
acidified	O
by	O
addition	O
of	O
10	O
l	O
of	O
3	O
M	O
HCl	B
.	I

The	O
extraction	O
was	O
accomplished	O
with	O
3	O
	O
2	O
ml	O
methylene	B
chloride	I
by	O
vigorously	O
mixing	O
on	O
a	O
vortex	O
-	O
mixer	O
for	O
10	O
s	O
,	O
followed	O
by	O
centrifugation	O
at	O
500	O
g	O
for	O
3	O
min	O
.	O

The	O
methylene	B
chloride	I
extracts	O
were	O
combined	O
and	O
evaporated	O
to	O
dryness	O
by	O
a	O
stream	O
of	O
N2	O
.	O

Forty	O
l	O
of	O
60	O
%	O
BSTFA	B
in	O
acetonitrile	B
was	O
then	O
added	O
.	O

The	O
content	O
was	O
allowed	O
to	O
stand	O
at	O
room	O
temperature	O
for	O
5	O
min	O
before	O
analysis	O
by	O
GC	O
	O
MS	O
.	O

2.3	O
GC	O
	O
MS	O
analysis	O
GC	O
	O
MS	O
analysis	O
of	O
the	O
analytes	O
was	O
performed	O
on	O
a	O
Finnigan	O
MAT	O
ITS40	O
(	O
Finnigan	O
MAT	O
,	O
San	O
Jose	O
,	O
CA	O
,	O
USA	O
)	O
coupled	O
to	O
a	O
3300	O
/	O
3400	O
Model	O
Varian	O
gas	O
chromatograph	O
(	O
Walnut	O
Creek	O
,	O
CA	O
,	O
USA	O
)	O
.	O

The	O
gas	O
chromatograph	O
was	O
equipped	O
with	O
a	O
DB-5	O
fused	O
-	O
silica	B
capillary	O
column	O
(	O
30	O
m	O
	O
0.25	O
mm	O
)	O
wall	O
-	O
coated	O
with	O
0.25	O
mm	O
of	O
cross	O
-	O
linked	O
95	O
%	O
methyl-	B
and	O
5	O
%	O
phenyl	B
-	I
polysiloxane	I
(	O
J&W	O
Scientific	O
,	O
Folsom	O
,	O
CA	O
,	O
USA	O
)	O
and	O
an	O
autosampler	O
(	O
Finnigan	O
MAT	O
)	O
.	O

Ultra	O
-	O
high	O
purity	O
helium	B
was	O
used	O
as	O
the	O
carrier	O
gas	O
with	O
a	O
head	O
pressure	O
of	O
15	O
psi	O
(	O
ca	O
.	O

105	O
Pa	O
)	O
.	O

The	O
injection	O
port	O
and	O
the	O
transfer	O
line	O
were	O
set	O
at	O
270	O
	O
C	O
.	O

The	O
oven	O
temperature	O
was	O
initiated	O
at	O
100	O
	O
C	O
for	O
1	O
min	O
,	O
and	O
was	O
ramped	O
to	O
250	O
	O
C	O
at	O
15	O
	O
C	O
/	O
min	O
,	O
then	O
increased	O
to	O
280	O
	O
C	O
at	O
30	O
	O
C	O
/	O
min	O
.	O

The	O
column	O
was	O
held	O
at	O
250	O
	O
C	O
for	O
1	O
min	O
.	O

Analysis	O
was	O
performed	O
using	O
chemical	O
ionization	O
mode	O
and	O
ammonia	B
was	O
used	O
as	O
the	O
reagent	B
gas	O
.	O

Quantitation	O
was	O
performed	O
in	O
the	O
selected	O
ion	O
monitor	O
mode	O
by	O
measuring	O
the	O
base	O
peak	O
of	O
either	O
MH+	O
or	O
the	O
fragment	O
ions	O
characteristic	O
of	O
the	O
trimethylsilylated	B
derivatives	I
of	O
the	O
analytes	O
and	O
their	O
respective	O
internal	O
standards	O
.	O

The	O
peak	O
area	O
ratio	O
method	O
was	O
used	O
in	O
construction	O
of	O
the	O
calibration	O
curves	O
.	O

2.4	O
13	O
C	O
-	O
NMR	O
analysis	O
13	O
C	O
-	O
NMR	O
spectra	O
were	O
recorded	O
on	O
either	O
a	O
Brucker	O
NR-250	O
spectrometer	O
at	O
a	O
radio	O
frequency	O
of	O
62.89	O
MHz	O
or	O
a	O
Brucker	O
AM-500	O
spectrometer	O
at	O
a	O
radio	O
frequency	O
of	O
125.77	O
MHz	O
with	O
tetramethylsilane	B
as	O
the	O
internal	O
standard	O
and	O
CDCl3	B
as	O
the	O
solvent	B
.	O

2.5	O
Separation	O
of	O
cis-	B
and	O
trans-	B
dihydroperillic	I
acid	I
A	O
mixture	O
of	O
synthetic	O
cis-	B
and	O
trans-	B
dihydroperillic	I
acids	I
was	O
separated	O
by	O
thin	O
-	O
layer	O
chromatography	O
.	O

The	O
mixture	O
(	O
10	O
mg	O
)	O
was	O
dissolved	O
in	O
a	O
small	O
volume	O
of	O
CH2	B
Cl2	I
and	O
the	O
solution	O
was	O
applied	O
onto	O
a	O
precoated	O
silica	B
gel	I
G	O
60	O
thin	O
-	O
layer	O
plate	O
(	O
EM	O
Merck	O
,	O
thickness	O
0.2	O
mm	O
,	O
20	O
	O
20	O
cm	O
)	O
.	O

This	O
plate	O
was	O
developed	O
ascendingly	O
with	O
50:1	O
CH2	B
Cl2	I
MeOH	O
on	O
a	O
lined	O
tank	O
for	O
one	O
full	O
-	O
length	O
.	O

Under	O
UV	O
light	O
visualization	O
,	O
two	O
overlapping	O
spots	O
(	O
ca	O
.	O
50	O
%	O
)	O
(	O
R	O
f	O
0.550.76	O
)	O
were	O
seen	O
and	O
the	O
upper	O
portion	O
of	O
the	O
faster	O
-	O
running	O
spot	O
(	O
R	O
f	O
0.720.76	O
)	O
was	O
scrapped	O
off	O
and	O
eluted	O
with	O
CH2	B
Cl2	I
.	O

The	O
collected	O
compound	O
(	O
ca	O
.	O

2	O
mg	O
)	O
was	O
found	O
to	O
be	O
the	O
pure	O
component	O
corresponding	O
to	O
a	O
retention	O
time	O
of	O
6.3	O
min	O
on	O
GC	O
	O
MS	O
using	O
the	O
condition	O
as	O
described	O
above	O
.	O

The	O
lower	O
portion	O
of	O
the	O
spot	O
was	O
also	O
collected	O
and	O
GC	O
	O
MS	O
still	O
showed	O
a	O
mixture	O
of	O
cis	B
/	I
trans	I
-DHPA	I
with	O
retention	O
times	O
of	O
6.3	O
and	O
6.7	O
min	O
.	O

Attempts	O
to	O
further	O
resolve	O
these	O
components	O
were	O
unsuccessful	O
.	O

2.6	O
Assay	O
characterization	O
and	O
validation	O
Detection	O
limit	O
was	O
measured	O
by	O
reducing	O
the	O
amount	O
of	O
each	O
analyte	O
until	O
the	O
signal	O
-	O
to	O
-	O
noise	O
equaled	O
to	O
four	O
,	O
which	O
is	O
defined	O
as	O
the	O
detection	O
limit	O
.	O

The	O
recovery	O
was	O
estimated	O
by	O
comparing	O
the	O
ratio	O
of	O
the	O
extracted	O
analytes	O
to	O
the	O
unextracted	O
internal	O
standard	O
with	O
that	O
of	O
the	O
unextracted	O
pairs	O
.	O

Within	O
-	O
run	O
precision	O
for	O
POH	B
,	O
PA	B
,	O
cis-	B
and	O
trans-	B
DHPA	I
was	O
determined	O
by	O
analyzing	O
six	O
replicates	O
at	O
each	O
concentration	O
on	O
the	O
same	O
day	O
.	O

The	O
concentrations	O
used	O
were	O
:	O
for	O
POH	B
at	O
2	O
,	O
4	O
,	O
20	O
,	O
200	O
and	O
2000	O
ng	O
/	O
ml	O
,	O
for	O
PA	O
at	O
40	O
,	O
200	O
,	O
and	O
2000	O
ng	O
/	O
ml	O
,	O
and	O
for	O
cis-	B
and	O
trans-	B
DHPA	I
each	O
at	O
20	O
,	O
100	O
,	O
and	O
1000	O
ng	O
/	O
ml	O
.	O

Between	O
-	O
run	O
precision	O
was	O
evaluated	O
by	O
analyzing	O
the	O
variation	O
of	O
the	O
slopes	O
of	O
six	O
standard	O
curves	O
for	O
each	O
analyte	O
obtained	O
on	O
six	O
different	O
days	O
.	O

2.7	O
Pilot	O
animal	O
study	O
The	O
femoral	O
and	O
jugular	O
veins	O
of	O
a	O
Sprague	O
-	O
Dawley	O
rat	O
weighing	O
350	O
g	O
were	O
cannulated	O
under	O
ether	O
anesthesia	O
.	O

Three	O
hours	O
after	O
recovery	O
,	O
the	O
animal	O
was	O
given	O
neat	O
perillyl	B
alcohol	I
(	O
ca	O
.	O

22	O
l	O
)	O
at	O
23	O
mg	O
/	O
kg	O
i.v	O
.	O

via	O
the	O
femoral	O
cannula	O
over	O
30	O
s	O
followed	O
by	O
a	O
rinse	O
of	O
0.5	O
ml	O
normal	O
saline	B
.	O

At	O
the	O
time	O
schedule	O
of	O
0	O
,	O
3	O
,	O
5	O
,	O
10	O
,	O
30	O
,	O
60	O
,	O
120	O
,	O
180	O
,	O
240	O
,	O
300	O
,	O
360	O
,	O
480	O
,	O
720	O
,	O
960	O
,	O
1200	O
,	O
and	O
1440	O
min	O
following	O
dosing	O
,	O
approximately	O
0.2	O
ml	O
of	O
heparinized	O
blood	O
each	O
was	O
withdrawn	O
from	O
the	O
jugular	O
vein	O
cannula	O
.	O

Plasma	O
was	O
separated	O
by	O
centrifugation	O
.	O

An	O
aliquot	O
of	O
each	O
plasma	O
sample	O
was	O
appropriately	O
diluted	O
with	O
blank	O
rat	O
plasma	O
to	O
make	O
up	O
to	O
0.5	O
ml	O
.	O

Under	O
this	O
condition	O
,	O
the	O
measured	O
concentrations	O
were	O
in	O
the	O
range	O
of	O
the	O
calibration	O
-	O
curve	O
.	O

To	O
each	O
plasma	O
sample	O
was	O
added	O
200	O
ng	O
of	O
the	O
internal	O
standard	O
followed	O
by	O
an	O
addition	O
of	O
1.0	O
ml	O
acetonitrile	B
to	O
precipitate	O
the	O
protein	O
.	O

The	O
mixture	O
was	O
centrifuged	O
at	O
2000	O
g	O
for	O
5	O
m.	O
The	O
supernatant	O
was	O
removed	O
and	O
frozen	O
at	O
20	O
	O
C	O
until	O
analysis	O
.	O

2.8	O
Preliminary	O
clinical	O
study	O
The	O
clinical	O
study	O
is	O
a	O
part	O
of	O
an	O
ongoing	O
Phase	O
I	O
evaluation	O
of	O
POH	B
as	O
a	O
chemopreventative	B
agent	I
at	O
the	O
Cleveland	O
Clinic	O
Foundation	O
.	O

The	O
Phase	O
I	O
protocol	O
was	O
approved	O
by	O
the	O
Institution	O
Review	O
Board	O
(	O
IRB	O
)	O
at	O
the	O
Cleveland	O
Clinic	O
Foundation	O
.	O

Subjects	O
with	O
a	O
personal	O
history	O
of	O
AJCC	O
Stage	O
I	O
	O
IIIa	O
breast	O
cancer	O
who	O
have	O
undergone	O
definitive	O
resection	O
with	O
curative	O
intent	O
and	O
who	O
have	O
completed	O
all	O
adjuvant	O
radiation	O
therapy	O
,	O
chemotherapy	O
,	O
and	O
reversible	O
hormone	O
therapy	O
are	O
eligible	O
to	O
enroll	O
in	O
this	O
study	O
.	O

All	O
subjects	O
were	O
in	O
good	O
general	O
health	O
with	O
adequate	O
major	O
organ	O
functions	O
and	O
ECOG	O
Performance	O
Status	O
of	O
01	O
.	O

Patients	O
were	O
treated	O
at	O
the	O
Cleveland	O
Clinic	O
Foundation	O
,	O
Cleveland	O
,	O
Ohio	O
.	O

The	O
current	O
study	O
was	O
limited	O
to	O
patients	O
at	O
the	O
first	O
of	O
the	O
five	O
dose	O
levels	O
.	O

Dose	O
at	O
0.5	O
g	O
/	O
m2	O
was	O
given	O
as	O
capsules	O
,	O
which	O
were	O
supplied	O
by	O
the	O
National	O
Cancer	O
Institute	O
.	O

Following	O
dosing	O
,	O
blood	O
samples	O
were	O
drawn	O
at	O
0	O
(	O
predose	O
)	O
,	O
0.25	O
,	O
0.5	O
,	O
0.75	O
,	O
1.0	O
,	O
1.5	O
,	O
2.0	O
,	O
3.0	O
,	O
4.0	O
,	O
6.0	O
,	O
8.0	O
,	O
10.0	O
,	O
and	O
24	O
h.	O
Plasma	O
was	O
separated	O
from	O
red	O
blood	O
cells	O
by	O
centrifugation	O
and	O
kept	O
frozen	O
at	O
20	O
	O
C	O
until	O
shipment	O
.	O

All	O
frozen	O
specimens	O
were	O
then	O
shipped	O
in	O
a	O
dry	B
-	I
ice	I
container	O
(	O
overnight	O
)	O
to	O
Dr.	O
Chan	O
's	O
Laboratory	O
at	O
the	O
Ohio	O
State	O
University	O
.	O

Plasma	O
samples	O
were	O
analyzed	O
in	O
the	O
same	O
manner	O
as	O
the	O
rat	O
plasma	O
samples	O
.	O

2.9	O
Quality	O
control	O
and	O
stability	O
Two	O
sets	O
of	O
spiked	O
plasma	O
samples	O
consisting	O
of	O
three	O
concentration	O
levels	O
,	O
20	O
,	O
50	O
,	O
and	O
100	O
ng	O
/	O
ml	O
of	O
POH	B
,	O
PA	B
,	I
cis-	B
/trans-	I
DHPA	I
were	O
prepared	O
and	O
frozen	O
at	O
20	O
	O
C	O
.	O

One	O
frozen	O
set	O
was	O
sent	O
to	O
the	O
Laboratory	O
at	O
the	O
Cleveland	O
Clinic	O
Foundation	O
by	O
overnight	O
courier	O
service	O
in	O
dry	B
-	I
ice	I
.	O

After	O
storage	O
for	O
approximately	O
one	O
week	O
at	O
20	O
	O
C	O
,	O
the	O
same	O
samples	O
were	O
returned	O
by	O
courier	O
service	O
to	O
the	O
Ohio	O
State	O
University	O
Laboratory	O
.	O

Another	O
set	O
of	O
samples	O
were	O
maintained	O
frozen	O
at	O
the	O
Ohio	O
State	O
University	O
Laboratory	O
for	O
the	O
same	O
duration	O
until	O
analysis	O
.	O

Drug	B
and	O
metabolite	B
levels	O
were	O
analyzed	O
in	O
these	O
two	O
sets	O
of	O
samples	O
at	O
the	O
same	O
time	O
and	O
the	O
results	O
were	O
compared	O
.	O

3	O
Results	O
3.1	O
Analysis	O
of	O
perillyl	B
alcohol	I
and	O
its	O
metabolites	B
The	O
GC	O
	O
MS	O
mass	O
spectra	O
of	O
POH	B
,	O
PA	B
and	O
cis-	B
/trans-	I
DHPA	I
and	O
their	O
internal	O
standards	O
,	O
POH	B
-	I
d3	I
and	O
13	B
C	I
-	I
PA	I
-	I
d2	I
are	O
shown	O
in	O
Fig.	O
1	O
.	O

As	O
shown	O
,	O
silylated	B
POH	I
and	O
its	O
internal	O
standard	O
each	O
showed	O
the	O
base	O
peak	O
at	O
m	O
/	O
z	O
135	O
and	O
138	O
corresponding	O
to	O
their	O
C	O
	O
O	O
cleavages	O
.	O

MH+	O
ions	O
as	O
their	O
TMS	B
derivatives	I
at	O
m	O
/	O
z	O
239	O
and	O
m	O
/	O
z	O
242	O
,	O
respectively	O
,	O
were	O
detected	O
for	O
PA	B
and	O
13	B
C	I
-	I
PA	I
-	I
d2	I
as	O
the	O
base	O
peak	O
,	O
and	O
also	O
for	O
cis-	B
/trans-	I
DHPA	I
at	O
m	O
/	O
z	O
241	O
at	O
55	O
%	O
relative	O
abundance	O
.	O

These	O
ions	O
were	O
used	O
for	O
subsequent	O
quantitation	O
.	O

On	O
this	O
basis	O
,	O
a	O
typical	O
set	O
of	O
GC	O
mass	O
chromatograms	O
of	O
human	O
and	O
rat	O
plasma	O
extracts	O
is	O
shown	O
in	O
Fig.	O
2	O
.	O

As	O
shown	O
,	O
all	O
analytes	O
were	O
detected	O
as	O
symmetrical	O
peaks	O
and	O
cis-	B
and	O
trans-	B
DHPA	I
were	O
well	O
resolved	O
.	O

The	O
retention	O
times	O
of	O
the	O
analytes	O
were	O
:	O
POH	B
/	O
POH	B
-	I
d3	I
at	O
6.2	O
min	O
,	O
PA	B
/	O
13	B
C	I
-	I
PA	I
-	I
d2	I
at	O
7.3	O
min	O
,	O
cis-	B
DHPA	I
at	O
6.3	O
min	O
,	O
and	O
trans-	B
DHPA	I
at	O
6.7	O
min	O
.	O

The	O
assignments	O
of	O
cis-	B
and	O
trans-	B
DHPA	I
are	O
described	O
below	O
and	O
coincided	O
with	O
those	O
of	O
Phillips	O
et	O
al.	O
[	O
11	O
]	O
.	O

No	O
interference	O
peaks	O
at	O
the	O
selected	O
ion	O
regions	O
were	O
found	O
in	O
the	O
human	O
or	O
rat	O
plasma	O
blank	O
,	O
except	O
for	O
low	O
levels	O
of	O
signal	O
contributed	O
by	O
the	O
internal	O
standards	O
.	O

These	O
interference	O
contributions	O
were	O
due	O
to	O
incomplete	O
isotope	O
labeling	O
and	O
were	O
all	O
<	O
2	O
%	O
.	O

Thus	O
,	O
the	O
ions	O
monitored	O
at	O
m	O
/	O
z	O
135	O
,	O
138	O
,	O
239	O
,	O
242	O
and	O
241	O
were	O
considered	O
to	O
be	O
highly	O
specific	O
and	O
sensitive	O
for	O
detecting	O
POH	B
and	O
its	O
metabolites	B
.	O

3.2	O
Assignments	O
of	O
cis-	B
and	O
trans-	O
DHPA	B
Phillips	O
et	O
al.	O
[	O
11	O
]	O
using	O
GC	O
	O
MS	O
method	O
with	O
electron	O
-	O
impact	O
ionization	O
partially	O
resolved	O
the	O
underivatized	O
cis-	B
and	O
trans-	B
DHPA	I
.	O

On	O
the	O
basis	O
of	O
the	O
different	O
mass	O
spectral	O
fragmentation	O
patterns	O
of	O
these	O
two	O
isomers	B
augmented	O
by	O
a	O
quantum	O
mechanical	O
calculation	O
to	O
correlate	O
the	O
configuration	O
and	O
mass	O
fragmentation	O
preference	O
,	O
they	O
assigned	O
the	O
smaller	O
component	O
with	O
a	O
shorter	O
retention	O
time	O
as	O
the	O
cis-	B
isomer	I
and	O
the	O
larger	O
slower	O
-	O
eluting	O
component	O
as	O
the	O
trans-	B
isomer	I
.	O

Since	O
we	O
employed	O
derivatization	O
in	O
our	O
GC	O
	O
MS	O
assay	O
,	O
direct	O
correlation	O
of	O
our	O
system	O
with	O
those	O
of	O
Philips	O
et	O
al.	O
was	O
difficult	O
.	O

Therefore	O
,	O
we	O
resorted	O
to	O
use	O
an	O
alternative	O
method	O
for	O
the	O
assignment	O
of	O
these	O
isomers	B
.	O

Using	O
thin	O
layer	O
chromatographic	O
separation	O
,	O
we	O
were	O
able	O
to	O
partially	O
resolve	O
the	O
two	O
isomers	B
.	O

The	O
faster	O
running	O
spot	O
was	O
enriched	O
and	O
accumulated	O
.	O

The	O
GC	O
	O
MS	O
showed	O
that	O
the	O
enriched	O
component	O
had	O
a	O
retention	O
time	O
of	O
6.3	O
min	O
.	O

The	O
H	O
-	O
decoupled	O
13	O
C	O
-	O
NMR	O
spectrum	O
of	O
the	O
synthetic	O
mixture	O
of	O
cis-	B
and	O
trans-	B
DHPA	I
showed	O
sets	O
of	O
doublets	O
at	O
180.97	O
and	O
181.65	O
ppm	O
corresponding	O
to	O
the	O
-COOH	O
signals	O
,	O
at	O
149.76	O
and	O
149.96	O
ppm	O
corresponding	O
to	O
C-1	O
,	O
at	O
108.54	O
and	O
108.75	O
ppm	O
corresponding	O
to	O
C-2	O
,	O
at	O
44.15	O
and	O
44.55	O
ppm	O
corresponding	O
to	O
C-4	O
,	O
at	O
39.37	O
and	O
42.98	O
ppm	O
corresponding	O
to	O
C-1	O
,	O
and	O
at	O
above	O
40	O
ppm	O
for	O
the	O
remaining	O
carbons	B
and	O
the	O
side	O
chain	O
methyl	B
.	O

The	O
carbon	B
chemical	O
shift	O
assignments	O
were	O
based	O
on	O
the	O
H	O
-	O
coupling	O
,	O
H	O
-	O
decoupling	O
data	O
,	O
and	O
comparison	O
with	O
known	O
assignments	O
of	O
several	O
monoterpenes	B
and	O
cyclohexane	B
systems	O
[	O
1618	O
]	O
.	O

However	O
,	O
the	O
H	O
-	O
decoupled	O
13	O
C	O
-	O
NMR	O
spectrum	O
of	O
the	O
above	O
described	O
enriched	O
component	O
failed	O
to	O
show	O
signals	O
with	O
adequate	O
intensity	O
at	O
the	O
downfield	O
region	O
(	O
180	O
ppm	O
)	O
but	O
signals	O
above	O
120	O
ppm	O
were	O
clearly	O
discernible	O
with	O
unequal	O
intensity	O
,	O
consistent	O
with	O
the	O
enrichment	O
.	O

Based	O
on	O
the	O
cyclohexanol	B
system	O
,	O
chemical	O
shift	O
of	O
C-1	O
appears	O
to	O
be	O
most	O
sensitive	O
to	O
cis-	O
/trans-	O
isomerism	O
[	O
18	O
]	O
.	O

Thus	O
,	O
13	O
C	O
-	O
NMR	O
spectra	O
of	O
cis-	B
and	O
trans-	B
1,4-methyl	I
cyclohexanol	I
show	O
C-1	O
at	O
66.2	O
and	O
70.0	O
ppm	O
,	O
respectively	O
,	O
and	O
cis-	B
and	O
trans-	B
1,4-t	I
-	I
butylcyclohexanol	I
show	O
C-1	O
at	O
65.0	O
and	O
70.4	O
ppm	O
,	O
respectively	O
.	O

In	O
both	O
cases	O
C-1s	O
for	O
the	O
cis-	B
isomer	I
are	O
several	O
ppm	O
upfield	O
from	O
the	O
trans-	B
isomer	I
.	O

The	O
enriched	O
DHPA	B
isomer	I
showed	O
only	O
a	O
singlet	O
at	O
39.36	O
ppm	O
of	O
C-1	O
with	O
the	O
more	O
downfield	O
signal	O
missing	O
.	O

This	O
suggests	O
that	O
the	O
enriched	O
DHPA	B
isomer	I
may	O
be	O
the	O
cis-	B
isomer	I
.	O

This	O
possibility	O
was	O
further	O
supported	O
by	O
examination	O
of	O
the	O
13	O
C	O
-	O
NMR	O
spectra	O
of	O
synthetic	O
cis-	B
and	O
trans-	B
1-carboxyl-4-methylcyclohexanes	I
which	O
showed	O
C-1	O
chemical	O
shifts	O
at	O
31.32	O
and	O
34.21	O
ppm	O
,	O
respectively	O
.	O

Again	O
,	O
the	O
C-1	O
of	O
cis-	B
isomer	I
shows	O
nearly	O
3	O
ppm	O
upfield	O
from	O
that	O
of	O
the	O
trans-	B
isomer	I
.	O

In	O
order	O
to	O
correlate	O
the	O
GC	O
	O
MS	O
retention	O
times	O
of	O
the	O
silyl	B
derivatives	I
of	I
these	O
cyclohexane	B
isomers	I
with	O
their	O
stereochemistry	O
,	O
cis-	B
and	O
trans-	B
1-carboxyl-4-methylcyclohexane	I
were	O
silylated	O
with	O
BSTFA	B
.	I

The	O
GC	O
	O
MS	O
showed	O
that	O
the	O
cis-	B
isomer	I
gave	O
a	O
retention	O
time	O
of	O
4.12	O
min	O
while	O
the	O
trans-	B
isomer	I
gave	O
a	O
retention	O
time	O
of	O
4.28	O
min	O
using	O
the	O
similar	O
temperature	O
programming	O
and	O
column	O
as	O
those	O
of	O
DHPA	B
.	O

On	O
this	O
basis	O
,	O
it	O
was	O
concluded	O
that	O
the	O
DHPA	B
isomer	I
with	O
the	O
shorter	O
retention	O
time	O
was	O
the	O
cis-	B
isomer	I
and	O
that	O
with	O
the	O
longer	O
retention	O
time	O
was	O
the	O
isomer	B
with	I
trans-	I
configuration	I
.	O

Interestingly	O
,	O
the	O
assignment	O
appeared	O
to	O
be	O
the	O
same	O
as	O
those	O
of	O
Philips	O
et	O
al.	O
[	O
11	O
]	O
,	O
based	O
on	O
the	O
relative	O
retention	O
times	O
of	O
the	O
underivatized	O
compounds	O
and	O
the	O
relative	O
amount	O
of	O
the	O
DHPA	B
found	O
as	O
metabolite	B
in	O
vivo	O
.	O

3.3	O
Within	O
-	O
run	O
validation	O
When	O
plotting	O
the	O
peak	O
area	O
ratios	O
between	O
the	O
analyte	O
and	O
the	O
internal	O
standard	O
against	O
the	O
added	O
concentrations	O
of	O
the	O
analytes	O
a	O
linear	O
relationship	O
was	O
obtained	O
within	O
the	O
concentration	O
ranges	O
monitored	O
for	O
all	O
analytes	O
.	O

In	O
both	O
human	O
and	O
rat	O
plasma	O
,	O
for	O
POH	B
linearity	O
was	O
demonstrated	O
from	O
2	O
to	O
2000	O
ng	O
/	O
ml	O
,	O
for	O
PA	B
and	O
trans-	B
DHPA	I
from	O
10	O
to	O
1000	O
ng	O
/	O
ml	O
,	O
and	O
for	O
cis-	B
DHPA	I
20	O
to1000	O
ng	O
/	O
ml	O
.	O

The	O
routine	O
sensitivity	O
limit	O
was	O
found	O
to	O
be	O
2	O
ng	O
/	O
ml	O
for	O
POH	B
,	O
10	O
ng	O
/	O
ml	O
for	O
PA	O
and	O
trans-	B
DHPA	I
,	O
and	O
20	O
ng	O
/	O
ml	O
for	O
cis-	B
DHPA	I
.	O

The	O
within	O
-	O
run	O
validation	O
data	O
for	O
POH	B
and	O
metabolites	B
in	O
rat	O
and	O
human	O
plasma	O
are	O
shown	O
in	O
Table	O
1	O
.	O

Also	O
shown	O
in	O
the	O
same	O
table	O
are	O
the	O
accuracy	O
data	O
.	O

As	O
shown	O
,	O
the	O
%	O
C.V.	O
values	O
ranged	O
from	O
0.5	O
to	O
8	O
%	O
with	O
the	O
majority	O
falling	O
below	O
5	O
%	O
and	O
a	O
mean	O
accuracy	O
value	O
of	O
98.6	O
%	O
.	O

3.4	O
Between	O
-	O
run	O
validation	O
The	O
between	O
-	O
run	O
variation	O
for	O
POH	B
in	O
human	O
plasma	O
was	O
5.5	O
%	O
and	O
6.3	O
%	O
in	O
rat	O
plasma	O
as	O
measured	O
by	O
the	O
slopes	O
of	O
six	O
calibration	O
curves	O
in	O
each	O
medium	O
at	O
six	O
different	O
occasions	O
(	O
Table	O
2	O
)	O
.	O

At	O
each	O
case	O
,	O
the	O
mean	O
intercept	O
is	O
less	O
than	O
2	O
ng	O
/	O
ml	O
equivalent	O
.	O

The	O
between	O
-	O
run	O
C.V.s	O
for	O
PA	B
by	O
similar	O
measurements	O
were	O
5.5	O
%	O
in	O
human	O
plasma	O
and	O
3.4	O
%	O
in	O
rat	O
plasma	O
,	O
all	O
n	O
=	O
6	O
.	O

The	O
between	O
-	O
run	O
C.V.s	O
for	O
cis-	B
DHPA	I
in	O
human	O
and	O
rat	O
plasma	O
were	O
6.9	O
%	O
and	O
5.1	O
%	O
,	O
respectively	O
(	O
n	O
=	O
6	O
)	O
.	O

The	O
between	O
-	O
run	O
C.V.s	O
for	O
trans-	B
DHPA	I
were	O
5.0	O
and	O
6.3	O
%	O
,	O
respectively	O
(	O
n	O
=	O
6	O
)	O
(	O
Table	O
2	O
)	O
.	O

In	O
these	O
cases	O
,	O
the	O
mean	O
intercepts	O
for	O
the	O
calibration	O
curves	O
of	O
the	O
metabolites	B
were	O
less	O
than	O
5	O
ng	O
/	O
ml	O
analyte	O
equivalent	O
.	O

3.5	O
Recovery	O
and	O
quality	O
control	O
The	O
recovery	O
values	O
of	O
POH	B
,	O
PA	B
,	O
cis-	B
and	O
trans-	B
DHPA	I
from	O
the	O
entire	O
procedure	O
were	O
:	O
98	O
%	O
,	O
59	O
%	O
,	O
64	O
%	O
and	O
72	O
%	O
in	O
human	O
plasma	O
and	O
90	O
%	O
,	O
77	O
%	O
,	O
69	O
%	O
and	O
76	O
%	O
in	O
rat	O
plasma	O
,	O
respectively	O
.	O

There	O
was	O
less	O
than	O
3	O
%	O
variation	O
for	O
POH	B
and	O
metabolite	B
levels	O
in	O
plasma	O
samples	O
kept	O
at	O
20	O
	O
C	O
over	O
the	O
course	O
of	O
four	O
weeks	O
and	O
there	O
was	O
no	O
appreciable	O
difference	O
in	O
the	O
samples	O
tested	O
through	O
mailing	O
via	O
the	O
courier	O
service	O
.	O

3.6	O
Preliminary	O
pharmacokinetics	O
of	O
perillyl	B
alcohol	I
and	O
its	O
metabolites	B
in	O
a	O
rat	O
Fig.	O
3	O
shows	O
a	O
plasma	O
concentration	O
	O
time	O
profile	O
of	O
POH	B
and	O
metabolites	B
in	O
the	O
rat	O
given	O
POH	B
at	O
23	O
mg	O
/	O
kg	O
i.v	O
.	O

As	O
shown	O
,	O
POH	B
was	O
detected	O
in	O
circulation	O
up	O
to	O
360	O
min	O
with	O
the	O
initial	O
concentration	O
at	O
2089	O
ng	O
/	O
ml	O
.	O

The	O
concentrations	O
declined	O
biexponentially	O
with	O
a	O
terminal	O
half	O
-	O
life	O
of	O
approximately	O
135	O
min	O
.	O

PA	B
appeared	O
in	O
plasma	O
in	O
the	O
first	O
sample	O
at	O
3	O
min	O
and	O
peaked	O
at	O
10	O
at	O
8893	O
ng	O
/	O
ml	O
and	O
declined	O
approximately	O
monoexponentially	O
to	O
about	O
35	O
ng	O
/	O
ml	O
at	O
720	O
min	O
.	O

Cis	B
-	I
and	O
trans-	B
DHPA	I
appeared	O
in	O
plasma	O
at	O
about	O
10	O
min	O
and	O
peaked	O
at	O
about	O
60	O
min	O
and	O
also	O
declined	O
monoexponentially	O
.	O

The	O
plasma	O
levels	O
of	O
the	O
trans-	B
metabolite	I
were	O
significantly	O
higher	O
than	O
those	O
of	O
the	O
cis-	B
isomer	I
.	I

An	O
unknown	O
metabolite	B
,	O
labeled	O
as	O
M2	B
,	O
was	O
also	O
detected	O
in	O
plasma	O
at	O
high	O
levels	O
and	O
this	O
metabolite	B
has	O
the	O
same	O
m	O
/	O
z	O
value	O
as	O
PA	B
but	O
with	O
a	O
retention	O
time	O
of	O
8.3	O
min	O
.	O

M2	B
appeared	O
in	O
plasma	O
at	O
3	O
min	O
at	O
2070	O
ng	O
/	O
ml	O
PA	B
equivalent	O
and	O
peaked	O
at	O
10	O
min	O
at	O
levels	O
over	O
6000	O
ng	O
/	O
ml	O
.	O

Although	O
the	O
initial	O
levels	O
of	O
this	O
metabolite	B
were	O
slightly	O
lower	O
than	O
those	O
of	O
PA	B
,	O
the	O
levels	O
after	O
2	O
h	O
exceeded	O
those	O
of	O
PA	B
after	O
and	O
were	O
detectable	O
even	O
at	O
1440	O
min	O
.	O

The	O
plasma	O
half	O
-	O
life	O
was	O
approximately	O
3	O
h.	O
3.7	O
Preliminary	O
pharmacokinetics	O
of	O
perillyl	B
alcohol	I
and	O
its	O
metabolites	B
in	O
a	O
patient	O
The	O
plasma	O
concentration	O
	O
time	O
profiles	O
of	O
POH	B
and	O
its	O
metabolites	B
were	O
measured	O
in	O
a	O
patient	O
who	O
received	O
a	O
p.o	O
.	O

dose	O
at	O
500	O
mg	O
/	O
m2	O
and	O
the	O
results	O
are	O
shown	O
in	O
Fig.	O
4	O
.	O

As	O
shown	O
,	O
POH	B
,	O
PA	B
,	O
cis-	B
and	O
trans-	B
DHPA	I
were	O
all	O
detectable	O
in	O
plasma	O
.	O

POH	B
was	O
detectable	O
at	O
3.5	O
ng	O
/	O
ml	O
at	O
0.75	O
h	O
and	O
peaked	O
at	O
5.0	O
ng	O
/	O
ml	O
at	O
1.5	O
h.	O
The	O
levels	O
then	O
declined	O
monoexponentially	O
with	O
a	O
half	O
-	O
life	O
of	O
approximately	O
2.3	O
h.	O
The	O
AUC	O
value	O
was	O
22	O
ng	O
/	O
ml	O
h.	O
The	O
most	O
abundant	O
metabolite	B
in	O
circulation	O
was	O
PA	B
which	O
peaked	O
slowly	O
at	O
11400	O
ng	O
/	O
ml	O
at	O
about	O
1.5	O
h.	O
PA	B
was	O
formed	O
rapidly	O
following	O
the	O
POH	B
administration	O
,	O
and	O
remained	O
at	O
a	O
steady	O
-	O
state	O
for	O
12	O
h	O
before	O
declining	O
.	O

The	O
level	O
then	O
declined	O
monoexponentially	O
to	O
about	O
40	O
ng	O
/	O
ml	O
at	O
8	O
h	O
and	O
became	O
undetectable	O
thereafter	O
.	O

Similar	O
to	O
the	O
case	O
in	O
the	O
rat	O
,	O
cis-	B
DHPA	I
levels	O
were	O
lower	O
than	O
those	O
of	O
trans	O
.	O

Two	O
previously	O
undescribed	O
metabolites	B
were	O
detected	O
in	O
circulation	O
.	O

M1	B
gave	O
a	O
retention	O
time	O
of	O
7.7	O
min	O
and	O
M2	B
gave	O
a	O
retention	O
of	O
8.3	O
min	O
,	O
which	O
appears	O
identical	O
to	O
the	O
one	O
described	O
in	O
the	O
rat	O
.	O

Both	O
of	O
these	O
metabolites	O
gave	O
the	O
MH+	O
ion	O
identical	O
to	O
that	O
of	O
PA	B
.	O

Levels	O
of	O
M2	B
were	O
lower	O
than	O
those	O
of	O
PA	B
but	O
higher	O
than	O
those	O
of	O
M1	B
.	O

M2	B
peaked	O
at	O
over	O
1000	O
ng	O
/	O
ml	O
at	O
3	O
h	O
,	O
and	O
M1	B
peaked	O
at	O
76	O
ng	O
/	O
ml	O
at	O
1	O
h.	O
4	O
Discussion	O
Previous	O
GC	O
and	O
GC	O
	O
MS	O
methods	O
failed	O
to	O
detect	O
POH	B
in	O
plasma	O
presumably	O
because	O
of	O
inadequate	O
sensitivity	O
[	O
11	O
]	O
.	O

The	O
reason	O
for	O
the	O
low	O
sensitivity	O
may	O
be	O
due	O
to	O
the	O
use	O
of	O
electron	O
impact	O
mass	O
spectrometry	O
for	O
detection	O
.	O

Excess	O
fragmentation	O
under	O
the	O
EI	O
condition	O
significantly	O
reduced	O
the	O
assay	O
sensitivity	O
.	O

Moreover	O
,	O
POH	B
and	O
its	O
metabolites	B
such	O
as	O
PA	B
are	O
still	O
rather	O
polar	O
.	O

Tailing	O
of	O
their	O
GC	O
peaks	O
may	O
also	O
reduce	O
the	O
assay	O
sensitivity	O
.	O

The	O
present	O
method	O
used	O
a	O
soft	O
ammonia	B
chemical	O
ionization	O
,	O
which	O
could	O
reduce	O
fragmentation	O
and	O
increase	O
the	O
relative	O
abundance	O
of	O
the	O
ion	O
.	O

Additionally	O
,	O
we	O
also	O
found	O
that	O
BSTFA	B
derivatization	O
of	O
POH	B
and	O
its	O
metabolites	B
reduced	O
tailing	O
and	O
further	O
reduced	O
fragmentation	O
and	O
enhanced	O
sensitivity	O
.	O

Another	O
improvement	O
of	O
our	O
analytical	O
method	O
was	O
to	O
use	O
the	O
stable	O
isotopically	O
labeled	O
POH	B
and	O
PA	B
as	O
the	O
internal	O
standard	O
that	O
provided	O
the	O
excellent	O
C.V.s	O
obtained	O
.	O

Thus	O
,	O
the	O
current	O
assay	O
provided	O
more	O
than	O
a	O
hundred	O
-	O
fold	O
improvement	O
in	O
sensitivity	O
over	O
the	O
previous	O
GC	O
	O
MS	O
method	O
,	O
and	O
made	O
it	O
possible	O
to	O
detect	O
circulating	O
POH	B
following	O
POH	B
administration	O
.	O

The	O
use	O
of	O
derivatization	O
and	O
a	O
capillary	O
column	O
in	O
this	O
method	O
also	O
permitted	O
the	O
complete	O
separation	O
of	O
cis-	B
and	O
trans-	B
DHPA	I
(	O
Fig.	O
3	O
)	O
.	O

The	O
earlier	O
eluting	O
peak	O
(	O
6.3	O
min	O
)	O
was	O
assigned	O
to	O
be	O
the	O
cis-	B
isomer	I
,	O
based	O
on	O
the	O
NMR	O
method	O
and	O
this	O
assignment	O
is	O
identical	O
to	O
those	O
of	O
Philip	O
et	O
al.	O
[	O
11	O
]	O
who	O
assigned	O
their	O
earlier	O
eluting	O
component	O
in	O
the	O
partially	O
resolved	O
pair	O
as	O
the	O
cis-	B
isomer	I
.	O

Both	O
the	O
preliminary	O
rat	O
and	O
human	O
pharmacokinetic	O
data	O
show	O
that	O
POH	B
was	O
detectable	O
in	O
circulation	O
for	O
the	O
first	O
time	O
following	O
POH	B
administration	O
.	O

Metabolites	B
of	O
POH	B
were	O
detected	O
in	O
high	O
levels	O
in	O
both	O
rat	O
and	O
human	O
plasma	O
.	O

PA	B
appeared	O
very	O
rapidly	O
in	O
circulation	O
and	O
rose	O
to	O
high	O
concentrations	O
,	O
suggesting	O
that	O
POH	B
underwent	O
rapid	O
metabolism	O
.	O

Both	O
cis-	B
and	O
trans-	B
DHPA	I
were	O
unequivocally	O
detected	O
in	O
the	O
human	O
and	O
in	O
the	O
rat	O
and	O
their	O
formation	O
as	O
a	O
mixture	O
was	O
previously	O
under	O
debate	O
[	O
11	O
]	O
.	O

Two	O
previously	O
undescribed	O
metabolites	B
were	O
detected	O
in	O
significant	O
levels	O
in	O
human	O
plasma	O
and	O
one	O
also	O
in	O
the	O
rat	O
.	O

These	O
two	O
metabolites	B
as	O
their	O
silylated	B
derivatives	I
gave	O
the	O
parent	O
ion	O
(	O
MH+	O
)	O
at	O
m	O
/	O
z	O
239	O
identical	O
to	O
that	O
of	O
silylated	B
PA	I
but	O
with	O
different	O
retention	O
times	O
.	O

Characterization	O
of	O
these	O
metabolites	B
is	O
currently	O
underway	O
.	O

Thus	O
,	O
the	O
current	O
method	O
is	O
useful	O
to	O
support	O
preclinical	O
and	O
clinical	O
investigations	O
of	O
disposition	O
of	O
perillyl	B
alcohol	I
.	O

5	O
Conclusion	O
A	O
GC	O
	O
MS	O
stable	O
isotope	O
-	O
dilution	O
method	O
has	O
been	O
developed	O
for	O
the	O
analysis	O
of	O
perillyl	B
alcohol	I
and	O
its	O
metabolites	B
in	O
human	O
and	O
animal	O
plasma	O
and	O
the	O
method	O
has	O
been	O
validated	O
.	O

Unchanged	O
perillyl	B
alcohol	I
in	O
plasma	O
was	O
detected	O
in	O
human	O
and	O
animal	O
circulation	O
for	O
the	O
first	O
time	O
.	O

Isomers	O
of	O
a	O
reduced	O
metabolite	B
DHPA	B
have	O
been	O
total	O
resolved	O
and	O
detected	O
and	O
their	O
previous	O
cis-	O
and	O
trans-	O
assignments	O
verified	O
by	O
alternate	O
techniques	O
.	O

Two	O
new	O
metabolites	B
were	O
also	O
detected	O
.	O

This	O
GC	O
	O
MS	O
can	O
be	O
applied	O
to	O
investigate	O
preclinical	O
and	O
clinical	O
pharmacokinetics	O
of	O
perillyl	B
alcohol	I
both	O
as	O
a	O
chemopreventative	B
and	O
chemotherapeutical	B
agent	I
.	O

Acknowledgments	O
This	O
study	O
was	O
in	O
part	O
supported	O
by	O
PHS	O
Contract	O
NCI	O
-	O
CN-55083070	O
,	O
Task	O
22	O
,	O
awarded	O
to	O
the	O
Cleveland	O
Clinic	O
Foundation	O
subcontracted	O
to	O
the	O
Ohio	O
State	O
University	O
and	O
by	O
P30	O
CA16058	O
by	O
the	O
National	O
Cancer	O
Institute	O
.	O

Eosinophils	O
may	O
play	O
important	O
roles	O
in	O
allergic	O
diseases	O
such	O
as	O
asthma	O
and	O
atopic	O
dermatitis	O
)	O
'	O
2	O
In	O
such	O
diseases	O
,	O
eosinophiis	O
migrate	O
to	O
inflammatory	O
sites	O
and	O
degranulate	O
eytotoxic	O
proteins	O
such	O
as	O
major	O
basic	O
protein	O
and	O
eosinophil	O
-	O
derived	O
neurotoxin	O
(	O
EDN	O
)	O
.	O

The	O
cytotoxic	O
proteins	O
damage	O
tissues	O
and	O
cause	O
physiologic	O
abnormalities	O
in	O
patients	O
with	O
allergic	O
diseases	O
.	O

Therefore	O
,	O
cosinophil	O
degranulation	O
inhibitors	O
may	O
be	O
anti	O
-	O
allergic	O
drugs	B
.	O

Recently	O
,	O
we	O
found	O
that	O
sulochrin	B
(	O
6	B
)	O
,	O
a	O
metabolite	B
of	O
fungi	O
,	O
was	O
a	O
specific	O
inhibitor	O
of	O
eosinophil	O
degranulation3	O
and	O
also	O
inhibited	O
eosinophll	O
activation	O
and	O
chemotaxis	O
.	O

*	O
We	O
report	O
here	O
the	O
effects	O
of	O
ortho-	O
substituent	O
groups	O
on	O
inhibitory	O
activity	O
to	O
eosinophil	O
degranulation	O
.	O

Chemistry	O
Sulochrin	B
(	O
6	B
)	O
was	O
synthesized	O
as	O
shown	O
in	O
scheme	O
1	O
.	O

Benzoic	B
acid	I
benzyl	I
ester	I
(	O
5	B
)	O
was	O
obtained	O
by	O
the	O
condensation	O
of	O
2-bromo	B
benzyl	I
alcohol	I
(	O
2	B
)	O
and	O
benzoic	B
acid	I
(	O
4	O
)	O
.	O

Anion	O
induced	O
rearrangement	O
of	O
(	O
5	B
)	O
gave	O
1-	B
benzoyl	I
benzyl	I
alcohol	I
,	O
which	O
was	O
oxidized	O
to	O
benzoyl	B
benzoic	I
acid	I
without	O
isolation.5	O
'	O
6	O
Esterification	O
of	O
the	O
benzoyl	B
benzoic	I
acid	I
followed	O
by	O
debenzylatinn	O
afforded	O
sulochrin	B
(	O
6	B
)	O
.7	O
All	O
other	O
sulochrin	B
derivatives	B
except	O
for	O
(	O
9	B
)	O
were	O
obtained	O
through	O
a	O
modified	O
methodology	O
.	O

Compound	B
9	I
was	O
prepared	O
as	O
shown	O
in	O
scheme	O
2	O
.	O

Results	O
and	O
Discussion	O
The	O
derivatives	B
of	I
sulochrin	I
(	O
6	B
)	O
were	O
examined	O
for	O
their	O
inba"oitory	O
activity	O
against	O
eosinophil	O
degranulation	O
as	O
descn'bed	O
previously.3	O
At	O
first	O
,	O
ester	B
derivatives	B
were	O
synthesized	O
to	O
examine	O
the	O
structure	O
-	O
activity	O
relationship	O
.	O

As	O
shown	O
in	O
Table	O
la	O
,	O
alkyl	B
esters	I
(	O
11	O
-	O
15	O
)	O
retained	O
activity	O
,	O
and	O
in	O
particular	O
,	O
n	B
-	I
butyl	I
and	O
see	B
-	I
butyl	I
esters	I
0960	O
-	O
894X	O
/	O
99	O
/	O
$	O
-	O
see	O
front	O
matter	O
1999	O
Elsevier	O
Science	O
Ltd.	O
All	O
rights	O
reserved	O
.	O

Pll	O
:	O
S0960	O
-	O
894X	O
(	O
99	O
)	O
00305	O
-	O
4	O
1946	O
H.	O
Ohashi	O
et	O
al.	O
/	O
Bioorg	O
.	O

Med	O
.	O

Chem	O
.	O

Lett	O
.	O

9	O
(	O
1999	O
)	O
1945	O
-	O
1948	O

Scheme	O
I	O
OH	O
OBn	O
a	O
,	O
b	O
,	O
c	O
,	O
d	O
Br	O
Me	O
"	O
<	O
~	O
OH	O
Me	O
"	O
"	O
~	O
OBn	O
COOMe	O
"	O
~OH	O
e	O
,	O
f	O
1	O
2	O
3	O
4	O
O	O
OBn	O
7	O
~	O
-~	O
OMe	O
QH13	O
!	O

r	O
2	O
+	O
4	O
P	O
5~	O
15	O
T	O
"	O
Br	O
BnO	O
"	O
-	O
..	O

:	O
I	O
"	O
Me	O
h	O
,	O
i	O
,	O
j	O
,	O
k	O
,	O
I	O
I	O
"	O
~1	O
-	O
1	O
"	O
g	O
OMe	O
MeOOC	O
O	O
OH	O
9	O
8	O
5	O
6	O
(	O
Sulochrln	B
)	O
(	O
a	O
)	O
BnBr	B
,	O
K	O
~	O
O~	O
/	O
CH3CN	B
/	O
reflux,33	O
%	O
;	O
(	O
b	O
)	O
Me	O
zSO4,K	O
~	O
CO3	O
/	O
CHaCN	O
/	O
reflux,96	O
%	O
;	O
(	O
c	O
)	O
UAIH4	O
/	O
I'HF,96	O
%	O
;	O
(	O
d	O
)	O
NBS	B
/	O
CCI4,43	B
%	O
;	O
(	O
e	O
)	O
BnBr	B
,	O
l	O
~	O
COa	O
/	O
DMF	B
/	O
reflux,74	O
%	O
;	O
(	O
f	O
)	O
t	O
-	O
BuOWiPr	O
=	O
O	O
/	O
reflux,93	O
%	O
;	O
(	O
g	O
)	O
DEAD	B
/	O
PPh	O
.	O

VrHF,82	O
%	O
;	O
(	O
h	O
)	O
n	B
-	I
BuLi	I
/	O
1"HF,-78"C,45	O
%	O
;	O
(	O
i	O
)	O
PDC	B
/	O
DMF,54	B
%	O
;	O
(	O
j	O
)	O
BudNH4	O
)	O
KMnO,~=yddlne,81	O
%	O
;	O
(	O
k	O
)	O
Mel	B
K2CO	O
~	O
JDMF	O
;	O
(	O
I	O
)	O
Pd	B
(	I
OH	I
)	I
rCarbon	O
/	B
EtOH	B
/	O
Cyclohexene	B
/	O
refiux	O
81	O
%	O
Scheme	O
2	O
Me	O
~	O
OMe	O
o~	O
OMe	O
OH	O
MeO	O
~	O
OMe	O
~	O
MeO'~OMe	O
.	O

HO	O
~	O
Me	O
"	O
COOH	O
m	O
"	O
~	O
"	O
COCI	O
n	O
,	O
p	O
7	O
8	O
O	O
OH	O
(	O
m	O
)	O
SOCle	O
;	O
(	O
n	O
)	O
n	B
-	I
BuLi	I
/	O
THF	B
,	O
-4YC,15	O
%	O
;	O
(	O
P	O
)	O
BBrdCH	O
=	O
Cle,64	O
%	O
(	O
13	O
and	O
14	O
)	O
showed	O
more	O
potent	O
activity	O
than	O
sulochrin	B
(	O
6	B
)	O
.	O

On	O
thc	O
other	O
hand	O
,	O
decarboxyl	O
and	O
flee	O
carboxylic	B
acid	I
derivatives	O
(	O
9	O
and	O
10	O
)	O
did	O
not	O
show	O
any	O
activity	O
even	O
at	O
10	O
pM.	O
These	O
results	O
suggest	O
that	O
the	O
existence	O
of	O
H.	O
Ohashi	O
et	O
al.	O
/	O
Bioorg	O
.	O

Med	O
.	O

Chem	O
.	O

Lett	O
.	O

9	O
(	O
1999	O
)	O
1945	O
-	O
1948	O
1947	O
Table	O
la	O
Effects	O
of	O
alkylester	B
on	O
eoslnophll	O
degranulation	O
OMe	O
OH	O
R1	O
O	O
OH	O
Compound	O
R	O
,	O
ICso	O
(	O
mlcroM	O
)	O
Sulochrin	B
(	O
6	B
)	O
9	O
10	O
11	O
12	O
13	O
14	O
15	O
COOCHa	O
H	O
COOH	O
COOCH2CHa	O
COOCH	O
=	O
CH	O
=	O
CHa	O
COOCH	O
=	O
CH2CH	O
=	O
CHa	O
COO	O
(	O
CH	O
)	O
CHaCH	O
=	O
CHa	O
COO	O
(	O
CH=	O
)	O
sCH.~	O
0.1	O
>	O
10	O
>	O
10	O
0.1	O
0.1	O
0.04	O
0.03	O
0.3	O
Table	O
lb	O
Effects	O
of	O
phenolic	B
hydroxyl	B
groups	I
on	O
eoslnophil	O
degranulation	O
Sulochdn	B
(	O
6	B
)	O
HO-,~zFtz	O
12~	O
16	O
17	O
MeOOC	O
O	O
OR	O
,	O
19	O
2O	O
Compound	O
R2	O
FL~	O
P~	O
ICs0	O
(	O
microM	O
)	O
H	O
Me	O
H	O
Me	O
H	O
H	O
Me	O
H	O
Me	O
Me	O
Me	O
H	O
(	O
CH2	O
)	O
2OH	O
H	O
H	O
Me	O
H	O
(	O
CH=	O
)	O
=OH	O
0.1	O
0.4	O
0.3	O
>	O
10	O
>	O
10	O
>	O
10	O
alkyl	B
ester	I
at	O
C-6	O
position	O
is	O
essential	O
and	O
see	B
-	I
butyl	I
ester	I
is	O
most	O
suitable	O
for	O
activity	O
.	O

Next	O
,	O
we	O
examined	O
the	O
importance	O
of	O
methoxy	B
and	O
hydroxyl	B
groups	I
at	O
C-2	O
,	O
C-12	O
and	O
C-16	O
positions	O
(	O
Table	O
lb	O
)	O
.	O

Compared	O
to	O
sulochrin	B
(	O
6	B
)	O
,	O
19	B
showed	O
much	O
less	O
activity	O
.	O

Activity	O
of	O
16	B
approached	O
that	O
of	O
sulochrin	B
(	O
6	B
)	O
after	O
methylation	O
of	O
hydroxyl	B
group	I
at	O
C-12	O
position	O
in	O
19	B
.	O

Furthermore	O
,	O
compound	O
17	B
also	O
showed	O
activity	O
.	O

These	O
results	O
indicate	O
that	O
at	O
least	O
one	O
methoxy	B
group	I
at	O
C-2	O
or	O
(	O
2	O
-	O
12	O
position	O
is	O
required	O
for	O
activity	O
.	O

Compound	B
18	I
,	O
in	O
which	O
two	O
methoxy	B
groups	I
at	O
C-12	O
and	O
(	O
2	O
-	O
16	O
positions	O
on	O
the	O
ring	O
B	O
were	O
introduced	O
,	O
showed	O
much	O
less	O
activity	O
than	O
16	B
or	O
17	B
.	O

Furthermore	O
,	O
compound	B
20	I
also	O
lost	O
activity	O
.	O

These	O
results	O
indicate	O
that	O
at	O
least	O
one	O
free	O
hydroxyl	B
group	I
at	O
ortho	O
-	O
position	O
on	O
the	O
ring	O
B	O
is	O
required	O
for	O
activity	O
,	O
suggesting	O
that	O
hydrogen	B
bond	O
between	O
16-OH	O
and	O
carbunyl	O
at	O
(	O
2	O
-	O
10	O
might	O
contn'bute	O
to	O
activity	O
.	O

We	O
have	O
recently	O
shown	O
that	O
substituents	O
at	O
ortho	O
-	O
positions	O
showed	O
effect	O
on	O
the	O
conformation	O
from	O
the	O
analysis	O
of	O
crystal	O
structures	O
of	O
suiochrin	B
derivatives	B
,	O
a	O
The	O
hydrogen	B
bond	O
between	O
16-OH	O
and	O
earbonyl	O
at	O
C-10	O
may	O
contribute	O
to	O
the	O
conformation	O
where	O
the	O
ring	O
B	O
and	O
the	O
central	O
carbunyl	O
planes	O
are	O
co	O
-	O
planner	O
and	O
cross	O
at	O
a	O
right	O
angle	O
to	O
the	O
1948	O
1	O
t	O
.	O

Ohashi	O
et	O
al.	O
/	O
Bioorg	O
.	O

Med	O
.	O

Chem	O
.	O

Lett	O
.	O

9	O
(	O
1999	O
)	O
1945	O
-	O
1948	O
ring	O
A.	O
This	O
conformation	O
would	O
be	O
inaccess	O
~	O
le	O
to	O
the	O
less	O
active	O
compounds	O
that	O
lack	O
the	O
hydrogen	B
bond	O
,	O
supporting	O
the	O
speculation	O
.	O

Compounds	B
10	B
and	O
19	B
,	O
which	O
have	O
more	O
hydrophilic	O
substitution	O
at	O
ortho	O
-	O
positions	O
,	O
lost	O
activity	O
.	O

Therefore	O
,	O
hydrophobicity	O
is	O
also	O
important	O
for	O
activity	O
.	O

In	O
conclusion	O
,	O
we	O
found	O
that	O
i	O
)	O
alkylester	B
at	O
C-6	O
position	O
is	O
required	O
;	O
ii	O
)	O
see	B
-	I
butyl	I
ester	I
at	O
C-6	O
position	O
is	O
optimal	O
for	O
activity	O
;	O
ill	O
)	O
optimal	O
hydrophobicity	O
of	O
the	O
ortho	O
-	O
substituents	O
may	O
exist	O
;	O
and	O
iv	O
)	O
the	O
conformation	O
of	O
sulochrin	B
may	O
influence	O
to	O
the	O
inlu'bitory	O
activity	O
against	O
eosinophil	O
degranulation	O
.	O

Acknowledgements	O

We	O
thank	O
to	O
Dr.	O
Masakazu	O
Sakalo'bara	O
for	O
critical	O
reading	O
of	O
this	O
manuscript	O
.	O

An	O
accurate	O
estimation	O
of	O
the	O
onset	O
of	O
oestrus	O
in	O
cows	O
is	O
vital	O
to	O
the	O
cost	O
-	O
efficient	O
application	O
of	O
artificial	O
insemination	O
(	O
AI	O
)	O
procedures	O
(	O
Ball	O
,	O
1982	O
)	O
.	O

The	O
steroid	B
hormone	O
progesterone	B
,	O
which	O
is	O
secreted	O
by	O
the	O
corpus	O
luteum	O
,	O
functions	O
to	O
prepare	O
the	O
uterus	O
for	O
pregnancy	O
and	O
to	O
maintain	O
pregnancy	O
following	O
conception	O
.	O

Fluctuations	O
in	O
the	O
level	O
of	O
secreted	O
progesterone	B
are	O
reflected	O
throughout	O
the	O
oestrus	O
cycle	O
by	O
the	O
concentration	O
of	O
the	O
hormone	O
present	O
in	O
cows	O
'	O
milk	O
.	O

It	O
follows	O
that	O
by	O
monitoring	O
milk	O
progesterone	B
concentration	O
it	O
has	O
been	O
possible	O
accurately	O
to	O
predict	O
the	O
onset	O
of	O
oestrus	O
;	O
using	O
enzyme	O
immunoassay	O
methodology	O
(	O
Foulkes	O
et	O
al.	O
,	O
1982a	O
)	O
,	O
it	O
has	O
been	O
demonstrated	O
that	O
optimum	O
fertility	O
rates	O
can	O
be	O
achieved	O
when	O
AI	O
is	O
performed	O
on	O
the	O
third	O
day	O
of	O
sustained	O
low	O
milk	O
progesterone	B
concentration	O
(	O
Foulkes	O
et	O
al.	O
,	O
1982b	O
;	O
Foulkes	O
and	O
Goodey	O
,	O
1988	O
)	O
.	O

The	O
search	O
for	O
a	O
rapid	O
,	O
convenient	O
and	O
inexpensive	O
means	O
of	O
frequently	O
monitoring	O
milk	O
progesterone	B
levels	O
in	O
a	O
herd	O
of	O
animals	O
has	O
led	O
into	O
research	O
toward	O
a	O
user	O
-	O
friendly	O
on	O
-	O
the	O
-	O
farm	O
device	O
.	O

One	O
such	O
approach	O
is	O
a	O
disposable	O
screen	O
-	O
printed	O
amperometric	O
biosensor	O
.	O

Previously	O
,	O
we	O
described	O
the	O
development	O
of	O
a	O
prototype	O
progesterone	B
biosensor	O
comprising	O
mAb	O
immobilised	O
on	O
the	O
working	O
surface	O
of	O
a	O
screen	O
-	O
printed	O
carbon	B
electrode	O
(	O
SPCE	O
)	O
.	O

It	O
operated	O
in	O
a	O
competitive	O
immunoassay	O
format	O
,	O
relying	O
upon	O
a	O
reduction	O
in	O
the	O
binding	O
of	O
enzyme	O
-	O
labelled	O
progesterone	B
in	O
the	O
presence	O
of	O
endogenous	O
milk	O
progesterone	B
.	O

Initial	O
proof	O
-	O
of	O
-	O
principle	O
was	O
provided	O
from	O
experiments	O
conducted	O
in	O
aqueous	O
buffer	O
solution	O
using	O
phenyl	B
phosphate	I
as	O
substrate	O
for	O
the	O
enzyme	O
alkaline	O
phosphatase	O
,	O
with	O
a	O
chronoamperometric	O
readout	O
dependent	O
on	O
the	O
oxidation	O
of	O
phenol	B
at	O
a	O
potential	O
of	O
+	O
700	O
mV	O
versus	O
SCE	O
(	O
Hart	O
et	O
al.	O
,	O
1997	O
)	O
.	O

Operating	O
at	O
this	O
relatively	O
high	O
electrode	O
potential	O
,	O
however	O
,	O
it	O
was	O
not	O
possible	O
to	O
obtain	O
a	O
calibration	O
in	O
milk	O
,	O
due	O
to	O
variable	O
adsorption	O
,	O
at	O
the	O
electrode	O
surface	O
,	O
of	O
electroactive	O
species	O
present	O
within	O
this	O
complex	O
matrix	O
(	O
Pemberton	O
et	O
al.	O
,	O
1998	O
)	O
;	O
even	O
washing	O
with	O
solvents	O
of	O
varying	O
polarity	O
did	O
not	O
remove	O
the	O
interferent	O
.	O

For	O
this	O
reason	O
,	O
it	O
is	O
desirable	O
to	O
reduce	O
the	O
operating	O
potential	O
to	O
below	O
that	O
required	O
to	O
oxidise	O
the	O
interferent	O
.	O

In	O
order	O
to	O
achieve	O
this	O
objective	O
,	O
two	O
potentially	O
useful	O
enzyme	O
substrates	O
,	O
1-naphthyl	B
phosphate	I
(	O
1-NP	B
)	O
and	O
4-aminophenyl	B
phosphate	I
(	O
4-APP	B
)	O
,	O
may	O
be	O
considered	O
.	O

These	O
are	O
hydrolysed	O
to	O
their	O
corresponding	O
phenols	B
,	O
1-naphthol	B
and	O
4-aminophenol	B
,	O
on	O
reaction	O
with	O
alkaline	B
phosphatase	I
.	O

Both	O
4-APP	B
(	O
Tang	O
et	O
al.	O
,	O
1988	O
;	O
Pemberton	O
et	O
al.	O
,	O
1998	O
;	O
Schreiber	O
et	O
al.	O
,	O
1997	O
)	O
and	O
1-NP	B
(	O
Athey	O
et	O
al.	O
,	O
1993	O
;	O
Fernandez	O
-	O
Sanchez	O
and	O
Costa	O
-	O
Garcia	O
,	O
1997	O
)	O
have	O
been	O
investigated	O
previously	O
in	O
immunoassay	O
systems	O
,	O
but	O
no	O
detailed	O
comparative	O
studies	O
of	O
their	O
performance	O
have	O
been	O
reported	O
at	O
SPCEs	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
compare	O
the	O
electrochemical	O
behaviour	O
of	O
1-naphthol	B
and	O
4-aminophenol	B
at	O
bare	O
and	O
antibody	O
-	O
coated	O
SPCEs	O
and	O
to	O
determine	O
which	O
phenol	B
would	O
be	O
the	O
more	O
compatible	O
with	O
biosensor	O
operation	O
.	O

Their	O
phosphorylated	B
derivatives	I
were	O
then	O
evaluated	O
as	O
substrates	O
for	O
use	O
with	O
a	O
milk	O
progesterone	B
immunosensor	O
.	O

This	O
paper	O
describes	O
the	O
results	O
of	O
these	O
studies	O
.	O

2	O
Experimental	O
2.1	O
Chemicals	O
and	O
reagents	O
Chemicals	O
used	O
were	O
of	O
AR	O
-	O
grade	O
and	O
were	O
purchased	O
from	O
Merck	O
(	O
Poole	O
,	O
Dorset	O
,	O
UK	O
)	O
.	O

Water	B
for	O
the	O
preparation	O
of	O
buffer	O
solutions	O
was	O
drawn	O
from	O
a	O
Milli	O
-	O
Q	O
Water	O
Purification	O
System	O
(	O
Millipore	O
UK	O
,	O
Watford	O
,	O
UK	O
)	O
.	O

Carbonate	B
coating	O
buffer	O
(	O
CB	O
)	O
comprised	O
0.015	O
mol	O
/	O
dm	O
Na2	B
CO3	I
and	O
0.035	O
mol	O
/	O
dm3	O
NaHCO3	B
at	O
a	O
pH	O
of	O
9.6	O
.	O

Diethanolamine	B
-	I
HCl	I
buffer	O
(	O
DB	O
;	O
0.1	O
mol	O
/	O
dm3	O
)	O
was	O
adjusted	O
to	O
a	O
final	O
pH	O
of	O
7.2	O
or	O
9.8	O
.	O

MgCl2	B
at	O
a	O
concentration	O
of	O
0.01	O
mol	O
/	O
dm3	O
was	O
included	O
in	O
pH9.8	O
DB	O
as	O
a	O
cofactor	O
for	O
alkaline	O
phosphatase	O
.	O

Before	O
final	O
dilution	O
in	O
DB	O
,	O
4-aminophenol	B
(	O
Sigma	O
-	O
Aldrich	O
Company	O
,	O
Poole	O
,	O
Dorset	O
,	O
UK	O
)	O
was	O
dissolved	O
in	O
0.1	O
mol	O
/	O
dm3	O
NaOH	B
;	O
1-naphthol	B
(	O
Acros	O
Organics	O
,	O
Loughborough	O
,	O
Leics	O
,	O
UK	O
)	O
was	O
dissolved	O
directly	O
in	O
DB	O
.	O

A	O
polyclonal	O
rabbit	O
antibody	O
(	O
IgG	O
fraction	O
)	O
against	O
sheep	O
IgG	O
was	O
purchased	O
from	O
Sigma	O
-	O
Aldrich	O
(	O
rIg	O
)	O
.	O

Sheep	O
monoclonal	O
antibody	O
(	O
mAb	O
)	O
against	O
progesterone	B
(	O
Groves	O
et	O
al.	O
,	O
1990	O
)	O
was	O
kindly	O
provided	O
by	O
Ridgeway	O
Science	O
Ltd.	O
in	O
the	O
form	O
of	O
culture	O
supernatant	O
.	O

A	O
solution	O
containing	O
alkaline	O
-	O
phosphatase	O
-	O
labelled	O
progesterone	B
(	O
AP	O
-	O
prog	O
)	O
was	O
obtained	O
from	O
the	O
same	O
source	O
.	O

Unlabelled	O
progesterone	B
(	O
f.wt.=314.5	O
)	O
was	O
purchased	O
from	O
Sigma	O
-	O
Aldrich	O
.	O

4-APP	B
(	O
monosodium	B
salt	I
)	O
and	O
1-NP	B
were	O
purchased	O
from	O
ICN	O
Biomedicals	O
Ltd.	O
,	O
Thame	O
,	O
Oxon	O
,	O
UK	O
and	O
Acros	O
Organics	O
,	O
respectively	O
.	O

Whole	O
milk	O
test	O
samples	O
from	O
six	O
different	O
Fresian	O
Holstein	O
dairy	O
cows	O
at	O
various	O
stages	O
of	O
their	O
oestrus	O
cycles	O
were	O
obtained	O
from	O
Ridgeway	O
Science	O
Ltd.	O
These	O
samples	O
were	O
collected	O
following	O
agitation	O
of	O
the	O
complete	O
milking	O
jar	O
after	O
morning	O
milking	O
of	O
cows	O
.	O

One	O
Lactab	O
MkIII	O
tablet	O
(	O
Thompson	O
and	O
Capper	O
Ltd.	O
,	O
Runcorn	O
,	O
Cheshire	O
,	O
UK	O
)	O
containing	O
30	O
mg	O
potassium	B
dichromate	I
was	O
added	O
to	O
every	O
25	O
ml	O
milk	O
as	O
a	O
preservative	O
.	O

Samples	O
were	O
then	O
stored	O
at	O
4	O
	O
C	O
where	O
they	O
were	O
stable	O
for	O
up	O
to	O
3	O
months	O
.	O

In	O
the	O
present	O
study	O
,	O
assays	O
were	O
performed	O
after	O
21	O
days	O
of	O
storage	O
.	O

Standards	O
containing	O
known	O
concentrations	O
of	O
progesterone	B
were	O
prepared	O
by	O
dissolving	O
progesterone	B
in	O
methanol	B
at	O
1	O
mg	O
/	O
ml	O
,	O
aliquoting	O
a	O
known	O
volume	O
into	O
a	O
glass	O
tube	O
and	O
evaporating	O
the	O
methanol	B
under	O
N2	B
before	O
adding	O
to	O
whole	O
milk	O
(	O
sampled	O
and	O
preserved	O
as	O
above	O
)	O
from	O
an	O
oestrus	O
cow	O
(	O
containing	O
<	O
1	O
ng	O
/	O
ml	O
progesterone	B
)	O
.	O

Serial	O
dilutions	O
were	O
then	O
performed	O
in	O
the	O
same	O
milk	O
over	O
the	O
desired	O
concentration	O
range	O
.	O

2.2	O
Biosensor	O
preparation	O
Carbon	B
electrodes	O
(	O
3	O
	O
3	O
mm	O
working	O
area	O
)	O
were	O
screen	O
-	O
printed	O
using	O
code	O
D14	O
ink	O
formulation	O
onto	O
PVC	B
backing	O
card	O
at	O
Gwent	O
Electronic	O
Materials	O
Ltd.	O
(	O
Mamhilad	O
,	O
Gwent	O
,	O
UK	O
)	O
as	O
described	O
elsewhere	O
(	O
Sprules	O
et	O
al.	O
,	O
1996	O
)	O
.	O

Individual	O
screen	O
-	O
printed	O
electrodes	O
(	O
SPCEs	O
)	O
were	O
coated	O
with	O
rIg	O
(	O
to	O
capture	O
and	O
orientate	O
the	O
mAb	O
)	O
and	O
mAb	O
as	O
described	O
previously	O
(	O
Hart	O
et	O
al.	O
,	O
1997	O
)	O
.	O

For	O
these	O
studies	O
,	O
a	O
1	O
/	O
20	O
dilution	O
of	O
mAb	O
was	O
applied	O
to	O
the	O
electrodes	O
,	O
being	O
chosen	O
empirically	O
as	O
the	O
highest	O
dilution	O
giving	O
an	O
optimum	O
sigmoidal	O
calibration	O
plot	O
for	O
progesterone	B
measured	O
colorimetrically	O
(	O
see	O
Pemberton	O
et	O
al.	O
,	O
1998	O
)	O
.	O

These	O
are	O
referred	O
to	O
as	O
mAb	O
-	O
SPCEs	O
.	O

2.3	O
Instrumentation	O
Electrochemical	O
procedures	O
were	O
carried	O
out	O
using	O
an	O
E612	O
VA	O
Scanner	O
and	O
an	O
E611	O
VA	O
Detector	O
(	O
Metrohm	O
,	O
Herisau	O
,	O
Switzerland	O
)	O
attached	O
to	O
a	O
Linseis	O
LY18100	O
x	O
y	O
plotter	O
(	O
Recorder	O
Laboratory	O
Services	O
,	O
Sutton	O
,	O
Surrey	O
,	O
UK	O
)	O
.	O

A	O
Viglen	O
486	O
Sx	O
computer	O
was	O
used	O
for	O
simulation	O
of	O
cyclic	O
voltammograms	O
using	O
the	O
simulation	O
program	O
CVSIM	O
(	O
Gosser	O
,	O
1993	O
)	O
.	O

The	O
simple	O
'	O
E	O
r	O
'	O
,	O
mechanism	O
for	O
a	O
one	O
-	O
electron	O
oxidation	O
of	O
a	O
solution	O
species	O
at	O
the	O
working	O
electrode	O
was	O
used	O
to	O
estimate	O
values	O
for	O
k	O
het	O
from	O
simulations	O
of	O
the	O
oxidation	O
of	O
4-aminophenol	B
at	O
bare	O
and	O
mAb	O
-	O
coated	O
SPCEs	O
.	O

Common	O
electroactive	O
species	O
parameters	O
were	O
:	O
C	O
red	O
=	O
1	O
mM	O
,	O
C	O
ox	O
=	O
0.0	O
mM	O
,	O
D	O
=	O
5	O
	O
106	O
cm2	O
/s	O
;	O
and	O
common	O
experimental	O
settings	O
were	O
:	O
number	O
of	O
half	O
cycles=2	O
,	O
A	O
=	O
0.09	O
cm2	O
,	O
E	O
i	O
=	O
0.3	O
V	O
,	O
E	O
s	O
=	O
+	O
1.0	O
V	O
,	O
E	O
f	O
=	O
0.3	O
V	O
,	O
v	O
=	O
0.05	O
vs1	O
.	O

Parameters	O
specific	O
for	O
reaction	O
at	O
a	O
bare	O
SPCE	O
were	O
:	O
E	O
0	O
/	O
=	O
0.050	O
V	O
,	O
	O
=	O
0.533	O
and	O
for	O
reaction	O
at	O
a	O
mAb	O
-	O
coated	O
SPCE	O
were	O
:	O
E	O
0	O
/	O
=	O
0.037	O
V	O
,	O
	O
=	O
0.400	O
.	O

2.4	O
Cyclic	O
voltammetry	O
and	O
chronoamperometry	O
Cyclic	O
voltammetric	O
studies	O
were	O
conducted	O
using	O
10	O
ml	O
analyte	O
volumes	O
in	O
a	O
glass	O
voltammetric	O
cell	O
.	O

Individual	O
working	O
SPCEs	O
or	O
mAb	O
-	O
SPCEs	O
were	O
used	O
in	O
a	O
3-electrode	O
configuration	O
in	O
conjunction	O
with	O
a	O
saturated	O
calomel	B
reference	O
and	O
platinum	B
counter	O
electrode	O
.	O

Chronoamperometric	O
measurements	O
were	O
made	O
by	O
using	O
individual	O
working	O
mAb	O
-	O
SPCEs	O
,	O
together	O
with	O
a	O
saturated	O
calomel	B
electrode	O
functioning	O
as	O
a	O
combined	O
counter	O
/	O
reference	O
electrode	O
in	O
a	O
two	O
electrode	O
configuration	O
.	O

In	O
this	O
way	O
it	O
was	O
possible	O
to	O
perform	O
measurements	O
using	O
a	O
small	O
(	O
0.5	O
ml	O
)	O
volume	O
of	O
enzyme	O
substrate	O
solution	O
in	O
a	O
conical	O
polypropylene	B
cell	O
.	O

2.5	O
Electrochemical	O
immunoassay	O
procedure	O
Milk	O
samples	O
were	O
mixed	O
with	O
AP	O
-	O
prog	O
solution	O
in	O
the	O
ratio	O
3:5	O
(	O
this	O
combination	O
gave	O
a	O
maximum	O
signal	O
:	O
noise	O
ratio	O
)	O
.	O

Eight	O
microlitre	O
volumes	O
of	O
these	O
mixtures	O
were	O
added	O
to	O
the	O
surface	O
of	O
individual	O
mAb	O
-	O
SPCEs	O
.	O

After	O
30	O
min	O
at	O
room	O
temperature	O
(	O
1825	O
	O
C	O
;	O
RT	O
)	O
,	O
the	O
electrodes	O
were	O
washed	O
three	O
times	O
in	O
DB	O
,	O
pH	O
9.8	O
,	O
then	O
placed	O
in	O
0.5	O
ml	O
DB	O
,	O
pH	O
9.8	O
or	O
the	O
same	O
buffer	O
containing	O
5	O
mmol	O
/	O
dm3	O
4-APP	B
or	O
1-NP	B
.	O

After	O
5	O
min	O
(	O
a	O
compromise	O
between	O
maximum	O
enzyme	O
activity	O
and	O
speed	O
of	O
assay	O
for	O
multiple	O
samples	O
)	O
,	O
the	O
working	O
electrode	O
potential	O
was	O
stepped	O
from	O
open	O
circuit	O
to	O
+	O
200	O
or	O
+	O
300	O
mV	O
versus	O
SCE	O
,	O
respectively	O
and	O
the	O
peak	O
current	O
(	O
i	O
p	O
)	O
response	O
was	O
recorded	O
.	O

Calibration	O
graphs	O
were	O
obtained	O
by	O
plotting	O
i	O
p	O
values	O
in	O
the	O
presence	O
of	O
an	O
enzyme	O
substrate	O
minus	O
background	O
i	O
p	O
values	O
in	O
buffer	O
only	O
for	O
each	O
known	O
standard	O
progesterone	B
concentration	O
(	O
y	O
-axis	O
)	O
against	O
progesterone	B
concentration	O
(	O
x	O
-axis	O
)	O
.	O

For	O
each	O
unknown	O
cow	O
sample	O
,	O
a	O
similar	O
subtraction	O
of	O
the	O
buffer	O
blank	O
i	O
p	O
value	O
was	O
performed	O
before	O
using	O
the	O
calibration	O
plot	O
by	O
interpolation	O
to	O
obtain	O
an	O
estimate	O
of	O
progesterone	B
concentration	O
.	O

The	O
relationship	O
between	O
readings	O
obtained	O
by	O
EIA	O
and	O
electrochemical	O
assays	O
was	O
investigated	O
using	O
linear	O
regression	O
analysis	O
.	O

3	O
Results	O
and	O
discussion	O
3.1	O
Electrochemistry	O
of	O
4-aminophenol	B
,	O
1-naphthol	B
and	O
corresponding	O
monophosphates	B
The	O
electrochemical	O
behaviour	O
of	O
the	O
enzyme	O
substrates	O
4-APP	B
and	O
1-NP	B
,	O
and	O
their	O
hydrolysis	O
products	O
,	O
4-aminophenol	B
and	O
1-naphthol	B
,	O
was	O
examined	O
by	O
cyclic	O
voltammetry	O
at	O
unmodified	O
SPCEs	O
(	O
Fig.	O
1	O
)	O
.	O

4-Aminophenol	B
showed	O
well	O
-	O
defined	O
oxidation	O
and	O
reduction	O
peaks	O
and	O
the	O
E	O
p	O
value	O
indicated	O
that	O
the	O
electrode	O
reaction	O
was	O
quasi	O
-	O
reversible	O
(	O
Fig.	O
1	O
(	O
a	O
)	O
)	O
.	O

The	O
anodic	O
potential	O
(	O
E	O
pa	O
)	O
was	O
well	O
below	O
that	O
required	O
for	O
the	O
oxidation	O
of	O
the	O
corresponding	O
monophosphate	B
,	O
4-APP	B
(	O
Fig.	O
1	O
(	O
b	O
)	O
)	O
.	O

In	O
contrast	O
,	O
1-naphthol	B
gave	O
only	O
an	O
oxidation	O
peak	O
at	O
+	O
230	O
mV	O
(	O
Fig.	O
1	O
(	O
c	O
)	O
)	O
,	O
which	O
could	O
be	O
due	O
to	O
the	O
electrode	O
reaction	O
itself	O
giving	O
an	O
electro	O
-	O
inactive	O
product	O
,	O
or	O
to	O
the	O
oxidised	O
naphthol	B
product	O
undergoing	O
an	O
irreversible	O
chemical	O
reaction	O
.	O

1-NP	B
(	O
Fig.	O
1	O
(	O
d	O
)	O
)	O
was	O
not	O
electrochemically	O
active	O
over	O
the	O
potential	O
range	O
studied	O
.	O

At	O
this	O
stage	O
,	O
it	O
appeared	O
that	O
the	O
anodic	O
signals	O
for	O
either	O
4-aminophenol	B
or	O
1-naphthol	B
could	O
be	O
used	O
as	O
the	O
basis	O
for	O
an	O
immunoassay	O
for	O
progesterone	B
.	O

Further	O
studies	O
were	O
therefore	O
performed	O
to	O
gain	O
a	O
better	O
understanding	O
of	O
the	O
voltammetric	O
behaviour	O
of	O
these	O
two	O
phenols	B
.	O

The	O
cyclic	O
voltammetric	O
behaviour	O
of	O
4-aminophenol	B
and	O
1-naphthol	B
was	O
next	O
compared	O
at	O
naked	O
and	O
mAb	O
-	O
SPCEs	O
(	O
Fig.	O
2	O
)	O
.	O

For	O
both	O
analytes	O
,	O
the	O
presence	O
of	O
the	O
antibodies	O
increased	O
the	O
background	O
oxidation	O
signal	O
at	O
potentials	O
above	O
+	O
0.5	O
V	O
(	O
Fig.	O
2	O
(	O
b	O
,	O
d	O
)	O
)	O
,	O
but	O
the	O
magnitude	O
of	O
the	O
overall	O
peak	O
currents	O
were	O
the	O
same	O
as	O
obtained	O
at	O
naked	O
SPCEs	O
(	O
Fig.	O
2	O
(	O
a	O
,	O
c	O
)	O
)	O
.	O

However	O
,	O
in	O
the	O
case	O
of	O
4aminophenol	B
,	O
the	O
oxidation	O
peak	O
became	O
broader	O
in	O
the	O
presence	O
of	O
the	O
antibodies	O
and	O
showed	O
a	O
small	O
positive	O
E	O
p	O
shift	O
(	O
30	O
mV	O
,	O
Fig.	O
2	O
(	O
a	O
,	O
b	O
)	O
)	O
.	O

In	O
the	O
case	O
of	O
1-naphthol	B
,	O
there	O
was	O
also	O
a	O
small	O
positive	O
E	O
p	O
shift	O
(	O
10	O
mV	O
)	O
in	O
the	O
presence	O
of	O
the	O
antibodies	O
(	O
Fig.	O
2	O
(	O
c	O
,	O
d	O
)	O
)	O
.	O

Further	O
comparison	O
of	O
the	O
electrochemistry	O
of	O
4-aminophenol	B
and	O
1-naphthol	B
,	O
at	O
naked	O
and	O
mAb	O
-	O
coated	O
SPCEs	O
,	O
was	O
obtained	O
by	O
performing	O
cyclic	O
voltammetry	O
at	O
various	O
scan	O
rates	O
.	O

The	O
relationship	O
produced	O
during	O
cyclic	O
voltammetry	O
between	O
peak	O
current	O
(	O
i	O
p	O
)	O
and	O
v	O
1	O
/	O
2	O
is	O
described	O
by	O
the	O
Randles	O
-	O
Sevcik	O
equation	O
,	O
modified	O
for	O
irreversible	O
systems	O
:	O

Cv	O
1	O
/	O
2	O
ip	O
=	O
(	O
2.99	O
	O
10	O
5	O
)	O
	O
n	O
(	O
na	O
)	O
1	O
/	O
2	O
AD1	O
/	O
2	O
(	O
Heineman	O
and	O
Kissinger	O
,	O
1984	O
)	O
where	O
i	O
p	O
=	O
peak	O
current	O
(	O
A	O
)	O
,	O
n	O
=	O
number	O
of	O
electrons	O
,	O
n	O
a	O
=	O
electron	O
transfer	O
coefficient	O
,	O
A	O
=	O
working	O
electrode	O
area	O
(	O
cm2	O
)	O
,	O
D	O
=	O
diffusion	O
coefficient	O
(	O
cm2	O
/s	O
)	O
,	O
C=	O
bulk	O
concentration	O
of	O
analyte	O
(	O
mmoles	O
/	O
ml	O
)	O
and	O
v	O
=	O
scan	O
rate	O
(	O
mV	O
/	O
s	O
)	O
.	O

Plots	O
of	O
i	O
p	O
versus	O
v	O
1	O
/	O
2	O
for	O
both	O
analytes	O
at	O
naked	O
and	O
mAb	O
-	O
SPCEs	O
are	O
shown	O
in	O
Fig.	O
3	O
.	O

In	O
the	O
case	O
of	O
4-aminophenol	B
,	O
there	O
is	O
evidence	O
that	O
the	O
presence	O
of	O
the	O
mAb	O
results	O
in	O
lower	O
i	O
p	O
values	O
at	O
all	O
scan	O
rates	O
compared	O
with	O
naked	O
SPCEs	O
(	O
Fig.	O
3	O
(	O
a	O
)	O
)	O
.	O

These	O
observations	O
suggest	O
that	O
the	O
mAb	O
may	O
slow	O
the	O
diffusion	O
of	O
4-AP	B
towards	O
the	O
electrode	O
surface	O
,	O
and	O
may	O
combine	O
with	O
polyphenols	B
to	O
reduce	O
the	O
working	O
area	O
available	O
for	O
the	O
oxidation	O
of	O
4-AP	B
.	O

In	O
contrast	O
,	O
ip	O
values	O
obtained	O
for	O
1-naphthol	B
at	O
naked	O
and	O
mAb	O
-	O
SPCEs	O
are	O
almost	O
superimposed	O
for	O
scan	O
rates	O
up	O
to	O
200	O
mVs1	O
(	O
Fig.	O
3	O
(	O
b	O
)	O
)	O
.	O

This	O
suggests	O
that	O
the	O
antibody	O
coating	O
has	O
little	O
effect	O
on	O
the	O
diffusional	O
characteristics	O
of	O
1-naphthol	B
.	O

Electron	O
transfer	O
coefficients	O
(	O
n	O
a	O
)	O
were	O
calculated	O
for	O
naked	O
and	O
mAb	O
-	O
SPCEs	O
as	O
described	O
previously	O
(	O
Galus	O
,	O
1976	O
)	O
.	O

For	O
4-aminophenol	B
,	O
these	O
values	O
were	O
0.533	O
and	O
0.400	O
,	O
respectively	O
;	O
this	O
decrease	O
indicates	O
that	O
the	O
antibody	O
layer	O
partially	O
inhibits	O
the	O
electron	O
transfer	O
step	O
,	O
possibly	O
due	O
to	O
steric	O
hindrance	O
.	O

A	O
computer	O
simulation	O
program	O
(	O
CVSIM	O
,	O
Gosser	O
,	O
1993	O
)	O
was	O
used	O
to	O
simulate	O
cyclic	O
voltammograms	O
for	O
4-aminophenol	B
in	O
order	O
to	O
obtain	O
values	O
for	O
the	O
electrochemical	O
rate	O
constant	O
.	O

Using	O
the	O
above	O
n	O
a	O
values	O
,	O
it	O
was	O
found	O
that	O
the	O
heterogeneous	O
rate	O
constant	O
(	O
k	O
het	O
)	O
for	O
the	O
mAb	O
-	O
SPCEs	O
was	O
3.0	O
	O
104	O
/cm	O
s1	O
,	O
whereas	O
k	O
het	O
for	O
a	O
naked	O
SPCE	O
was	O
calculated	O
to	O
be	O
6.5	O
	O
104	O
cm	O
s1	O
.	O

The	O
slower	O
rate	O
constant	O
obtained	O
with	O
the	O
mAb	O
-	O
SPCEs	O
supports	O
the	O
suggestion	O
of	O
partial	O
inhibition	O
discussed	O
above	O
.	O

Finally	O
,	O
the	O
n	O
a	O
values	O
were	O
calculated	O
for	O
1-naphthol	B
at	O
naked-	O
and	O
mAb	O
-	O
SPCEs	O
,	O
to	O
be	O
0.53	O
and	O
0.60	O
,	O
respectively	O
.	O

These	O
values	O
suggest	O
that	O
the	O
antibody	O
coating	O
does	O
not	O
inhibit	O
the	O
rate	O
of	O
electron	O
transfer	O
during	O
the	O
oxidation	O
of	O
this	O
phenol	B
.	O

Fig.	O
4	O
(	O
a	O
)	O
shows	O
the	O
effect	O
of	O
scan	O
rate	O
on	O
the	O
anodic	O
peak	O
potential	O
for	O
4-aminophenol	B
,	O
at	O
naked	O
and	O
antibody	O
-	O
coated	O
SPCEs	O
.	O

True	O
reversible	O
reactions	O
do	O
not	O
show	O
shifts	O
of	O
E	O
p	O
with	O
scan	O
rate	O
,	O
inferring	O
that	O
the	O
oxidation	O
reactions	O
at	O
both	O
types	O
of	O
SPCE	O
appear	O
to	O
be	O
quasi	O
-	O
reversible	O
over	O
the	O
range	O
studied	O
.	O

In	O
contrast	O
,	O
at	O
scan	O
rates	O
above	O
100	O
mVs1	O
,	O
1-naphthol	B
appears	O
to	O
show	O
more	O
reversible	O
behaviour	O
at	O
both	O
SPCEs	O
than	O
4-aminophenol	B
.	O

This	O
may	O
be	O
explained	O
by	O
a	O
slow	O
chemical	O
follow	O
-	O
up	O
reaction	O
(	O
possibly	O
polymerisation	O
)	O
for	O
1-naphthol	B
after	O
the	O
initial	O
electron	O
transfer	O
step	O
.	O

It	O
should	O
also	O
be	O
noted	O
that	O
the	O
peak	O
potential	O
for	O
the	O
oxidation	O
of	O
1-naphthol	B
obtained	O
at	O
the	O
mAb	O
-	O
SPCE	O
at	O
200	O
mVs1	O
is	O
+	O
0.38	O
V	O
;	O
for	O
4-aminophenol	B
at	O
this	O
electrode	O
the	O
E	O
p	O
value	O
was	O
+	O
0.28	O
V.	O
All	O
of	O
the	O
above	O
observations	O
using	O
cyclic	O
voltammetry	O
suggested	O
that	O
1-NP	B
would	O
be	O
a	O
suitable	O
candidate	O
for	O
the	O
chronoamperometric	O
immunoassay	O
.	O

Although	O
the	O
magnitude	O
of	O
the	O
anodic	O
response	O
was	O
lower	O
than	O
that	O
seen	O
for	O
4-aminophenol	B
at	O
equivalent	O
concentration	O
,	O
the	O
hydrolysis	O
product	O
,	O
1-naphthol	B
,	O
appeared	O
capable	O
of	O
producing	O
a	O
significant	O
and	O
unimpeded	O
oxidation	O
signal	O
at	O
mAb	O
-	O
SPCEs	O
.	O

3.2	O
Establishing	O
the	O
operating	O
potential	O
for	O
chronoamperometric	O
detection	O
of	O
l	B
-	I
naphthol	I
Previous	O
cyclic	O
voltammograms	O
with	O
SPCEs	O
(	O
Pemberton	O
et	O
al.	O
,	O
1998	O
)	O
have	O
demonstrated	O
the	O
presence	O
,	O
in	O
milk	O
,	O
of	O
electroactive	O
species	O
capable	O
of	O
adsorbing	O
onto	O
the	O
electrode	O
surface	O
and	O
being	O
oxidised	O
to	O
produce	O
anodic	O
signals	O
capable	O
of	O
interfering	O
with	O
the	O
operation	O
of	O
the	O
immunosensor	O
by	O
chronoamperometry	O
.	O

Using	O
4-APP	B
as	O
enzyme	O
substrate	O
it	O
was	O
possible	O
to	O
select	O
an	O
operating	O
potential	O
of	O
+	O
200	O
mV	O
,	O
well	O
below	O
the	O
potential	O
required	O
to	O
oxidise	O
adsorbed	O
milk	O
species	O
(	O
Pemberton	O
et	O
al.	O
,	O
1998	O
)	O
.	O

In	O
order	O
to	O
confirm	O
that	O
1-naphthol	B
could	O
be	O
detected	O
amperometrically	O
and	O
to	O
establish	O
an	O
operating	O
potential	O
for	O
use	O
in	O
the	O
assay	O
,	O
chronoamperometric	O
measurement	O
of	O
a	O
1	O
mM	O
1-naphthol	B
solution	O
was	O
performed	O
over	O
a	O
range	O
of	O
operating	O
potentials	O
at	O
mAb	O
-	O
SPCEs	O
which	O
had	O
been	O
incubated	O
with	O
enzyme	O
-	O
labelled	O
progesterone	B
either	O
in	O
buffer	O
solution	O
or	O
in	O
milk	O
.	O

Fig.	O
5	O
shows	O
that	O
in	O
order	O
to	O
avoid	O
signals	O
due	O
to	O
the	O
oxidation	O
of	O
electroactive	O
species	O
within	O
milk	O
,	O
it	O
would	O
be	O
necessary	O
to	O
operate	O
below	O
+	O
400	O
mV.	O
It	O
was	O
necessary	O
to	O
operate	O
at	O
+	O
600	O
mV	O
to	O
achieve	O
the	O
maximum	O
current	O
signal	O
from	O
chronoamperometry	O
of	O
1-naphthol	B
.	O

However	O
,	O
it	O
was	O
still	O
possible	O
to	O
obtain	O
over	O
50	O
%	O
of	O
this	O
response	O
at	O
+	O
300	O
mV	O
which	O
was	O
therefore	O
chosen	O
as	O
the	O
operating	O
potential	O
for	O
the	O
biosensor	O
.	O

3.3	O
Analysis	O
of	O
cows	O
'	O
milk	O
-	O
comparison	O
of	O
enzyme	O
substrates	O
4-APP	B
and	O
1-NP	B
In	O
order	O
to	O
compare	O
the	O
performance	O
of	O
the	O
immunosensor	O
using	O
1-NP	B
as	O
an	O
enzyme	O
substrate	O
with	O
its	O
performance	O
using	O
4-APP	B
,	O
milk	O
samples	O
obtained	O
from	O
a	O
number	O
of	O
different	O
cows	O
were	O
analysed	O
for	O
progesterone	B
content	O
using	O
both	O
approaches	O
.	O

The	O
results	O
were	O
then	O
compared	O
with	O
those	O
obtained	O
using	O
a	O
commercial	O
EIA	O
(	O
Ridgeway	O
Science	O
Ltd.	O
;	O
accuracy=8	O
%	O
inter	O
-	O
assay	O
C.V.	O
,	O
sensitivity=0.6	O
ng	O
/	O
ml	O
)	O
by	O
reference	O
to	O
a	O
standard	O
curve	O
of	O
absorbance	O
reading	O
versus	O
progesterone	O
concentration	O
(	O
Sauer	O
et	O
al.	O
,	O
1986	O
)	O
.	O

Fig.	O
6	O
(	O
a	O
)	O
shows	O
the	O
calibration	O
curve	O
obtained	O
using	O
4-APP	B
as	O
substrate	O
to	O
measure	O
progesterone	B
milk	O
standards	O
over	O
the	O
concentration	O
range	O
,	O
050	O
ng	O
/	O
ml	O
,	O
before	O
and	O
after	O
background	O
subtraction	O
.	O

Precision	O
for	O
triplicate	O
sensors	O
at	O
each	O
concentration	O
ranged	O
from	O
5.3	O
to	O
18.3	O
%	O
.	O

The	O
readings	O
obtained	O
for	O
six	O
cows	O
'	O
milk	O
samples	O
,	O
together	O
with	O
those	O
obtained	O
using	O
the	O
standard	O
EIA	O
are	O
shown	O
on	O
a	O
correlation	O
plot	O
for	O
the	O
two	O
sets	O
of	O
values	O
(	O
Fig.	O
6	O
(	O
b	O
)	O
)	O
.	O

Reasonable	O
agreement	O
(	O
r	O
=	O
0.840	O
)	O
was	O
obtained	O
between	O
the	O
two	O
methods	O
.	O

One	O
calibration	O
curve	O
obtained	O
using	O
1-NP	B
is	O
shown	O
in	O
Fig.	O
7	O
(	O
a	O
)	O
,	O
before	O
and	O
after	O
adjustment	O
for	O
background	O
current	O
.	O

Precision	O
for	O
triplicate	O
sensors	O
at	O
each	O
concentration	O
was	O
improved	O
compared	O
with	O
the	O
4-APP	B
assay	O
and	O
ranged	O
from	O
4.1	O
to	O
12.4	O
%	O
;	O
this	O
may	O
have	O
been	O
due	O
to	O
the	O
improved	O
solubility	O
of	O
the	O
1-naphthyl	B
phosphate	I
over	O
the	O
4-APP	B
.	O

Readings	O
obtained	O
for	O
the	O
same	O
six	O
cows	O
'	O
milk	O
samples	O
tested	O
above	O
are	O
shown	O
on	O
a	O
correlation	O
plot	O
comparing	O
these	O
values	O
with	O
those	O
obtained	O
by	O
EIA	O
(	O
Fig.	O
7	O
(	O
b	O
)	O
)	O
.	O

The	O
result	O
was	O
a	O
close	O
agreement	O
between	O
the	O
two	O
sets	O
of	O
readings	O
and	O
an	O
improved	O
correlation	O
(	O
r	O
=	O
0.946	O
)	O
over	O
the	O
4-APP	B
assay	O
.	O

4	O
Conclusion	O
In	O
summary	O
,	O
the	O
above	O
results	O
have	O
demonstrated	O
that	O
by	O
using	O
1-naphthyl	B
phosphate	I
(	O
1-NP	B
)	O
as	O
enzyme	O
substrate	O
,	O
it	O
is	O
possible	O
to	O
develop	O
an	O
amperometric	O
screen	O
-	O
printed	O
immunosensor	O
for	O
milk	O
progesterone	B
based	O
on	O
the	O
detection	O
of	O
the	O
product	O
,	O
1-naphthol	B
at	O
an	O
operating	O
potential	O
of	O
+	O
300	O
mV.	O
The	O
required	O
detection	O
limit	O
of	O
25	O
ng	O
/	O
ml	O
(	O
Bulman	O
,	O
1979	O
;	O
Sauer	O
et	O
al.	O
,	O
1986	O
)	O
was	O
achieved	O
using	O
this	O
approach	O
.	O

Examination	O
of	O
the	O
electrochemistry	O
of	O
1-naphthol	B
itself	O
indicated	O
that	O
it	O
was	O
readily	O
oxidisable	O
at	O
the	O
surface	O
of	O
an	O
SPCE	O
in	O
the	O
presence	O
or	O
absence	O
of	O
immobilised	O
antibody	O
.	O

This	O
was	O
a	O
potential	O
advantage	O
over	O
4-aminophenol	B
which	O
appeared	O
to	O
suffer	O
from	O
a	O
diffusional	O
barrier	O
,	O
most	O
probably	O
as	O
a	O
result	O
of	O
the	O
formation	O
of	O
polyphenols	B
at	O
the	O
electrode	O
surface	O
.	O

Although	O
the	O
operating	O
potential	O
required	O
for	O
oxidation	O
of	O
1-naphthol	B
was	O
100	O
mV	O
higher	O
than	O
that	O
used	O
for	O
the	O
detection	O
of	O
4-aminophenol	B
,	O
the	O
1-naphthol	B
assay	O
operated	O
below	O
the	O
oxidation	O
potential	O
of	O
milkborne	O
interferents	O
and	O
did	O
not	O
suffer	O
from	O
a	O
loss	O
of	O
sensitivity	O
.	O

Indeed	O
,	O
a	O
closer	O
agreement	O
than	O
that	O
achieved	O
using	O
4-APP	B
was	O
obtained	O
with	O
an	O
established	O
EIA	O
method	O
for	O
milk	O
samples	O
taken	O
from	O
different	O
cows	O
having	O
varying	O
background	O
responses	O
.	O

Furthermore	O
,	O
this	O
correlation	O
was	O
also	O
better	O
than	O
that	O
obtained	O
using	O
4-APP	B
in	O
a	O
previous	O
study	O
on	O
milk	O
samples	O
taken	O
from	O
a	O
single	O
animal	O
(	O
Pemberton	O
et	O
al.	O
,	O
1998	O
)	O
.	O

Since	O
1-NP	B
is	O
inexpensive	O
,	O
readily	O
soluble	O
and	O
easy	O
to	O
obtain	O
,	O
the	O
screenprinted	O
immunosensor	O
when	O
used	O
in	O
combination	O
with	O
this	O
substrate	O
may	O
hold	O
promise	O
for	O
future	O
development	O
into	O
a	O
device	O
for	O
large	O
-	O
scale	O
milk	O
monitoring	O
.	O

Acknowledgements	O
The	O
authors	O
wish	O
to	O
thank	O
R.	O
Pittson	O
and	O
his	O
staff	O
at	O
Gwent	O
Electronic	O
Materials	O
Ltd.	O
(	O
GEM	O
)	O
,	O
Mamhilad	O
,	O
Gwent	O
for	O
supplying	O
the	O
SPCEs	O
.	O

Drs	O
D.J.	O
Groves	O
and	O
B.A.	O
Morris	O
from	O
the	O
Heterohybridoma	O
Antibody	O
Group	O
,	O
Department	O
of	O
Biochemistry	O
,	O
University	O
of	O
Surrey	O
are	O
gratefully	O
acknowledged	O
as	O
the	O
originators	O
of	O
the	O
mAb	O
.	O

Financial	O
support	O
for	O
this	O
project	O
was	O
provided	O
by	O
the	O
HEFCE	O
.	O

Ferbam	B
[	O
iron	B
(	I
III	I
)	I
dimethyldithiocarbamate	I
]	O
is	O
a	O
well	O
known	O
dithiocarbamate	B
effective	O
fungicide	B
widely	O
used	O
against	O
a	O
variety	O
of	O
plant	O
pathogenic	O
fungi	O
.	O

Ferbam	B
is	O
generally	O
determined	O
by	O
the	O
carbon	B
disulphide	I
evolution	O
method	O
based	O
on	O
its	O
decomposition	O
by	O
hot	O
mineral	O
acids	B
to	O
amine	B
and	O
carbon	B
disulfide	I
using	O
different	O
approaches	O
[	O
1	O
]	O
.	O

Ferbam	B
is	O
also	O
determined	O
by	O
converting	O
it	O
into	O
moybdenum	B
[	O
2	O
]	O
,	O
copper	B
[	O
3	O
]	O
and	O
1,10-phenanthroline	B
[	O
4	O
]	O
complexes	B
.	O

McLeod	O
and	O
McCulley	O
[	O
5	O
]	O
determined	O
dithiocarbamate	B
fungicides	B
by	O
headspace	O
gas	O
chromatography	O
of	O
the	O
carbon	B
disulphide	I
evolved	O
in	O
controlled	O
conditions	O
from	O
foodstuffs	O
and	O
similar	O
methods	O
were	O
also	O
given	O
by	O
the	O
Committee	O
for	O
Analytical	O
Methods	O
[	O
6	O
]	O
.	O

However	O
,	O
all	O
these	O
methods	O
suffer	O
from	O
the	O
following	O
disadvantages	O
:	O
(	O
a	O
)	O
Methods	O
other	O
than	O
gas	O
chromatography	O
are	O
indirect	O
,	O
time	O
consuming	O
and	O
sensitivity	O
is	O
low	O
.	O

(	O
b	O
)	O
Gas	O
chromatographic	O
methods	O
are	O
sensitive	O
but	O
suffer	O
from	O
lack	O
of	O
the	O
selectivity	O
since	O
all	O
dithiocarbamate	B
fungicides	B
evolve	O
carbon	B
disulphide	I
on	O
acid	B
hydrolysis	O
.	O

(	O
c	O
)	O
Spectrophotometric	O
methods	O
suffer	O
the	O
interference	O
of	O
various	O
ions	O
.	O

Capillary	O
electrophoresis	O
[	O
7,8	O
]	O
,	O
is	O
a	O
microvolume	O
separation	O
technique	O
increasingly	O
achieving	O
recognition	O
for	O
its	O
use	O
in	O
the	O
separation	O
of	O
inorganic	B
and	O
organic	B
compounds	I
.	O

The	O
key	O
features	O
of	O
this	O
technique	O
are	O
its	O
very	O
short	O
analysis	O
time	O
and	O
small	O
sample	O
volumes	O
in	O
the	O
nanoliter	O
and	O
picoliter	O
range	O
.	O

Capillary	O
electrophoresis	O
has	O
been	O
used	O
for	O
the	O
determination	O
of	O
sodium	B
dimethyldithiocarbamate	I
using	O
sulphonic	B
acid	I
polymer	B
coated	O
capillary	O
columns	O
at	O
pH	O
6.5	O
using	O
sodium	B
phosphate	I
buffer	O
[	O
9	O
]	O
.	O

Liang	O
et	O
al.	O
used	O
diode	O
array	O
detection	O
and	O
factor	O
analysis	O
for	O
the	O
determination	O
of	O
dithiocarbamates	B
[	O
10	O
]	O
.	O

In	O
another	O
approach	O
,	O
solid	O
-	O
phase	O
extraction	O
was	O
used	O
to	O
separate	O
dithiocarbamates	B
with	O
other	O
pesticides	B
[	O
11	O
]	O
.	O

The	O
extensive	O
studies	O
of	O
metal	B
	I
aminopolycarboxylate	I
complexes	I
are	O
reviewed	O
by	O
Timerbaev	O
[	O
12	O
]	O
.	O

This	O
report	O
is	O
concerned	O
with	O
the	O
investigation	O
of	O
the	O
potential	O
of	O
capillary	O
electrophoresis	O
in	O
the	O
determination	O
of	O
Ferbam	B
.	O

As	O
will	O
be	O
demonstrated	O
in	O
this	O
report	O
,	O
capillary	O
electrophoresis	O
with	O
its	O
precision	O
instrumentation	O
and	O
small	O
sample	O
requirements	O
is	O
well	O
suited	O
for	O
the	O
determination	O
of	O
Ferbam	B
.	O

Here	O
,	O
we	O
present	O
a	O
relatively	O
simple	O
and	O
selective	O
capillary	O
electrophoretic	O
method	O
by	O
converting	O
Fe	B
(	I
III	I
)	I
present	O
in	O
Ferbam	B
into	O
Fe	B
(	I
III	I
)	I
EDTA	I
complex	I
.	O

The	O
chemical	O
structure	O
of	O
Ferbam	B
is	O
as	O
follows	O
:	O
[	O
(	O
CH3	O
)	O
2	O
NC	O
(	O
S	O
)	O
2	O
]	O
3	O
Fe	O
.	O

2	O
Experimental	O
2.1	O
Instrumentation	O
Separations	O
were	O
performed	O
on	O
a	O
Thermo	O
Separation	O
Products	O
100	O
CE	O
-	O
system	O
equipped	O
with	O
an	O
UV	O
absorbance	O
detector	O
.	O

Fused	O
silica	B
capillaries	O
of	O
75	O
cm	O
long	O
(	O
45	O
cm	O
to	O
the	O
detector	O
)	O
	O
100	O
m	O
I.D.	O
were	O
used	O
.	O

The	O
solutes	O
were	O
injected	O
in	O
the	O
hydrodynamic	O
mode	O
by	O
vacuum	O
injection	O
for	O
2	O
s.	O
TSP	O
1000	O
software	O
was	O
used	O
for	O
the	O
data	O
acquisition	O
.	O

Detection	O
was	O
performed	O
by	O
direct	O
UV	O
absorbance	O
at	O
254	O
nm	O
.	O

All	O
experiments	O
were	O
conducted	O
at	O
251	O
	O
C	O
.	O

2.2	O
Reagents	B
and	O
solutions	O
All	O
chemicals	B
used	O
were	O
of	O
analytical	O
-	O
reagent	B
grade	O
and	O
doubly	O
distilled	B
water	I
was	O
used	O
for	O
the	O
preparation	O
of	O
solutions	O
and	O
all	O
dilutions	O
.	O

2.2.1	O
Ferbam	B
solution	O
Ferbam	B
was	O
obtained	O
from	O
Riedel	O
-	O
de	O
Han	O
(	O
Germany	O
)	O
and	O
used	O
as	O
received	O
.	O

Ferbam	B
solution	O
was	O
prepared	O
by	O
decomposing	O
its	O
20	O
mg	O
with	O
concentrated	O
nitric	B
acid	I
(	O
510	O
ml	O
)	O
and	O
heated	O
till	O
all	O
the	O
fumes	O
were	O
ceased	O
(	O
almost	O
to	O
dryness	O
)	O
and	O
dissolved	O
the	O
residue	O
in	O
12	O
ml	O
of	O
concentrated	O
HCl	B
and	O
diluted	O
upto	O
3040	O
ml	O
and	O
pH	O
adjusted	O
in	O
the	O
range	O
23	O
using	O
dilute	O
NaOH	B
and	O
finally	O
diluted	O
to	O
100	O
ml	O
in	O
a	O
calibrated	O
flask	O
.	O

The	O
recovery	O
of	O
iron	B
(	I
III	I
)	I
from	O
Ferbam	B
was	O
checked	O
by	O
titrating	O
it	O
using	O
Variamine	B
Blue	I
B	I
as	O
indicator	O
[	O
13	O
]	O
.	O

Working	O
solutions	O
of	O
lower	O
concentrations	O
were	O
prepared	O
by	O
appropriate	O
dilutions	O
with	O
distilled	B
water	I
.	O

2.2.2	O
EDTA	B
solution	O
Stock	O
solution	O
of	O
EDTA	B
(	O
0.5	O
mM	O
)	O
as	O
disodium	B
salt	I
was	O
prepared	O
in	O
distilled	B
water	I
.	O

2.2.3	O
Buffer	O
solution	O
Electrophoretic	O
buffer	O
solution	O
was	O
prepared	O
from	O
boric	B
acid	I
50	O
mM	O
and	O
adjusting	O
the	O
desired	O
pH	O
by	O
adding	O
0.1	O
M	O
NaOH	B
solution	O
.	O

2.3	O
Procedures	O
2.3.1	O
Basic	O
procedure	O
The	O
capillary	O
was	O
rinsed	O
with	O
1	O
M	O
NaOH	B
,	O
0.1	O
M	O
NaOH	B
and	O
water	B
for	O
2	O
min	O
,	O
respectively	O
,	O
then	O
equilibrated	O
with	O
the	O
carrier	O
electrolyte	O
for	O
2	O
min	O
.	O

Between	O
all	O
electrophoretic	O
separations	O
the	O
capillary	O
was	O
rinsed	O
for	O
2	O
min	O
with	O
carrier	O
electrolyte	B
.	O

All	O
electrolyte	B
solutions	O
were	O
filtered	O
through	O
a	O
0.45	O
m	O
membrane	O
filter	O
.	O

2.3.2	O
Preparation	O
of	O
standard	O
calibration	O
graph	O
A	O
series	O
of	O
standard	O
solutions	O
of	O
Ferbam	B
were	O
mixed	O
with	O
EDTA	B
(	O
1	O
ml	O
)	O
and	O
diluted	O
to	O
2	O
ml	O
with	O
distilled	B
water	I
and	O
injected	O
into	O
the	O
capillary	O
under	O
the	O
optimised	O
conditions	O
to	O
test	O
the	O
linearity	O
of	O
the	O
calibration	O
graph	O
.	O

2.3.3	O
Determination	O
of	O
Ferbam	B
in	O
grains	O
The	O
method	O
was	O
applied	O
for	O
the	O
determination	O
of	O
Ferbam	B
from	O
wheat	O
grains	O
.	O

A	O
known	O
amount	O
of	O
Ferbam	B
in	O
acetonitrile	B
was	O
crushed	O
with	O
10	O
g	O
of	O
wheat	B
grains	O
and	O
shaken	O
mechanically	O
with	O
chloroform	B
(	O
100	O
ml	O
)	O
for	O
1	O
h.	O
The	O
mixture	O
was	O
filtered	O
and	O
the	O
residue	O
in	O
the	O
funnel	O
was	O
washed	O
with	O
chloroform	B
(	O
3	O
	O
10	O
ml	O
)	O
.	O

The	O
extracts	O
were	O
evaporated	O
to	O
dryness	O
and	O
solution	O
was	O
prepared	O
as	O
discussed	O
above	O
and	O
determined	O
by	O
the	O
general	O
procedure	O
.	O

Untreated	O
samples	O
were	O
taken	O
as	O
reference	O
and	O
the	O
results	O
indicated	O
good	O
recoveries	O
in	O
all	O
cases	O
.	O

The	O
results	O
of	O
the	O
determinations	O
are	O
given	O
in	O
Table	O
1	O
.	O

3	O
Results	O
and	O
discussion	O
A	O
typical	O
capillary	O
electropherogram	O
of	O
Ferbam	B
at	O
pH	O
9.0	O
is	O
shown	O
in	O
Fig.	O
1	O
.	O

It	O
shows	O
a	O
sharp	O
peak	O
with	O
baseline	O
resolution	O
.	O

In	O
order	O
to	O
determine	O
the	O
best	O
experimental	O
conditions	O
(	O
peak	O
efficiency	O
,	O
analysis	O
time	O
)	O
borate	B
,	O
phosphate	B
and	O
acetate	B
buffer	O
of	O
pH	O
9.0	O
,	O
7.0	O
and	O
4.5	O
,	O
respectively	O
of	O
1.2550	O
mM	O
were	O
investigated	O
and	O
compared	O
.	O

It	O
was	O
observed	O
that	O
below	O
pH	O
7.0	O
in	O
phosphate	B
and	O
acetate	B
buffer	O
good	O
peak	O
were	O
not	O
observed	O
.	O

A	O
well	O
defined	O
peak	O
was	O
obtained	O
in	O
between	O
25	O
and	O
50	O
mM	O
borate	B
buffer	O
of	O
pH	O
9.0	O
.	O

It	O
was	O
observed	O
that	O
the	O
migration	O
time	O
was	O
more	O
at	O
the	O
higher	O
concentrations	O
of	O
the	O
borate	B
buffer	O
.	O

Above	O
25	O
mM	O
concentration	O
of	O
borate	B
buffer	O
there	O
was	O
a	O
considerable	O
increase	O
in	O
the	O
migration	O
time	O
of	O
the	O
both	O
analytes	O
,	O
resulting	O
in	O
an	O
increase	O
in	O
the	O
analysis	O
time	O
.	O

Therefore	O
,	O
25	O
mM	O
of	O
borate	B
buffer	O
concentration	O
was	O
preferred	O
.	O

The	O
influence	O
of	O
the	O
applied	O
voltage	O
was	O
also	O
studied	O
by	O
increasing	O
the	O
applied	O
voltage	O
.	O

The	O
retention	O
time	O
decreases	O
with	O
increasing	O
voltage	O
.	O

Therefore	O
,	O
+	O
30	O
kV	O
was	O
applied	O
to	O
get	O
the	O
shortest	O
time	O
.	O

A	O
linear	O
relationship	O
between	O
peak	O
height	O
and	O
concentrations	O
were	O
obtained	O
in	O
the	O
range	O
3.5500	O
g	O
/	O
ml	O
with	O
an	O
correlation	O
coefficient	O
of	O
0.9994	O
.	O

The	O
linear	O
regression	O
equation	O
for	O
the	O
calibration	O
curve	O
is	O
y	O
=	O
0.0001x	O
+	O
0.0003	O
.	O

Aliquots	O
containing	O
50	O
g	O
/	O
ml	O
of	O
give	O
a	O
relative	O
standard	O
deviation	O
of	O
2.9	O
%	O
in	O
analysis	O
.	O

Ferbam	B
,	O
if	O
present	O
with	O
other	O
water	B
soluble	O
dithiocarbamates	B
such	O
as	O
nabam	B
,	O
metham	B
,	O
sodium	B
diethyldithiocarbamate	I
,	O
etc	O
.	O
,	O
can	O
easily	O
be	O
separated	O
by	O
extraction	O
with	O
chloroform	B
;	O
Nabam	B
and	O
others	O
will	O
remain	O
in	O
the	O
aqueous	O
phase	O
which	O
can	O
then	O
be	O
analysed	O
by	O
the	O
basic	O
procedure	O
[	O
14	O
]	O
.	O

Furthermore	O
,	O
our	O
experiments	O
have	O
shown	O
that	O
Ferbam	B
can	O
be	O
determined	O
directly	O
in	O
the	O
presence	O
of	O
metal	B
ions	I
like	O
Co	B
(	I
II	I
)	I
,	O
Zn	B
(	I
II	I
)	I
,	O
Cu	B
(	I
II	I
)	I
and	O
Ni	B
(	I
II	I
)	I
without	O
any	O
interference	O
,	O
whereas	O
,	O
these	O
metal	B
ions	I
strongly	O
interfere	O
in	O
the	O
spectrophotometric	O
methods	O
[	O
2,3	O
]	O
.	O

These	O
results	O
are	O
similar	O
to	O
as	O
reported	O
by	O
earlier	O
workers	O
[	O
12,15	O
]	O
.	O

4	O
Conclusions	O
Capillary	O
electrophoresis	O
provides	O
an	O
important	O
tool	O
in	O
the	O
hands	O
of	O
the	O
analytical	O
chemists	O
for	O
the	O
determination	O
of	O
Ferbam	B
.	O

The	O
detection	O
limit	O
(	O
S	O
/N	O
=3	O
)	O
using	O
this	O
method	O
is	O
0.7	O
g	O
/	O
ml	O
(	O
0.7	O
mg	O
/	O
kg	O
)	O
of	O
Ferbam	B
which	O
is	O
better	O
than	O
1	O
g	O
/	O
ml	O
of	O
Nitowski	O
et	O
al.	O
's	O
[	O
9	O
]	O
method	O
reported	O
for	O
dimethyldithiocarbamate	B
using	O
sulphonic	B
acid	I
polymer	B
-	O
coated	O
capillary	O
columns	O
.	O

As	O
most	O
of	O
the	O
cations	B
and	O
anions	B
do	O
not	O
interfere	O
in	O
the	O
determination	O
of	O
Ferbam	B
,	O
moreover	O
,	O
the	O
simplicity	O
and	O
small	O
sample	O
volume	O
requirements	O
makes	O
it	O
advantageous	O
to	O
other	O
chromatographic	O
techniques	O
.	O

Thus	O
,	O
the	O
usefulness	O
of	O
capillary	O
electrophoresis	O
as	O
a	O
tool	O
for	O
checking	O
the	O
amount	O
of	O
Ferbam	B
is	O
successfully	O
demonstrated	O
.	O

Acknowledgements	O
One	O
of	O
the	O
authors	O
(	O
A.K.M.	O
)	O
thanks	O
the	O
AvH	O
Foundation	O
,	O
Bonn	O
,	O
Germany	O
for	O
financial	O
assistance	O
.	O

l	B
-cis	I
Diltiazem	I
,	O
the	O
enantiomer	O
of	O
diltiazem	B
(	O
d	B
-cis	I
diltiazem	I
)	O
,	O
has	O
100	O
times	O
less	O
Ca2	B
+	I
channel	O
blocking	O
activity	O
than	O
diltiazem	B
(	O
Ikeda	O
et	O
al.	O
,	O
1991	O
)	O
.	O

l	B
-cis	I
Diltiazem	I
is	O
not	O
a	O
simple	O
inactive	O
stereoisomer	O
but	O
has	O
been	O
established	O
as	O
a	O
unique	O
pharmacological	O
tool	O
(	O
Caretta	O
et	O
al.	O
,	O
1979	O
)	O
.	O

For	O
example	O
,	O
l	B
-cis	I
diltiazem	I
,	O
but	O
not	O
diltiazem	B
,	O
inhibits	O
the	O
cGMP	O
-	O
gated	O
cation	O
channel	O
in	O
rod	O
cells	O
(	O
Stern	O
et	O
al.	O
,	O
1986	O
;	O
Quandt	O
et	O
al.	O
,	O
1991	O
)	O
.	O

Interestingly	O
,	O
there	O
have	O
been	O
several	O
reports	O
indicating	O
that	O
l	B
-cis	I
diltiazem	I
protects	O
against	O
ischemic	O
cardiac	O
injury	O
.	O

For	O
example	O
,	O
l	B
-cis	I
diltiazem	I
produces	O
a	O
high	O
recovery	O
of	O
cardiac	O
function	O
after	O
ischemia	O
/	O
reperfusion	O
and	O
inhibits	O
the	O
increase	O
of	O
non	O
-	O
esterified	O
fatty	B
acids	I
during	O
ischemia	O
in	O
isolated	O
,	O
perfused	O
working	O
rat	O
heart	O
(	O
Nasa	O
et	O
al.	O
,	O
1990	O
;	O
Xiao	O
et	O
al.	O
,	O
1997	O
)	O
.	O

Recently	O
,	O
our	O
laboratory	O
has	O
reported	O
that	O
treatment	O
with	O
l	B
-cis	I
diltiazem	I
reduced	O
infarct	O
size	O
without	O
affecting	O
any	O
hemodynamic	O
parameter	O
in	O
rabbit	O
heart	O
in	O
vivo	O
(	O
Nishida	O
et	O
al.	O
,	O
1999	O
)	O
.	O

Since	O
l	B
-cis	I
diltiazem	I
has	O
a	O
much	O
less	O
potent	O
Ca2	O
+	O
channel	O
blocking	O
action	O
than	O
diltiazem	B
,	O
it	O
has	O
been	O
suggested	O
that	O
l	B
-cis	I
diltiazem	I
protects	O
against	O
ischemia	O
/	O
reperfusion	O
injury	O
with	O
a	O
mechanism	O
other	O
than	O
Ca2	O
+	O
channel	O
blockade	O
.	O

We	O
have	O
also	O
demonstrated	O
that	O
treatment	O
with	O
l	B
-cis	I
diltiazem	I
before	O
reperfusion	O
also	O
reduced	O
infarct	O
size	O
in	O
ischemic	O
rabbit	O
heart	O
(	O
Nishida	O
et	O
al.	O
,	O
1999	O
)	O
.	O

Ca2	B
+	I
overload	O
at	O
reperfusion	O
after	O
ischemia	O
(	O
Allen	O
and	O
Orchard	O
,	O
1983	O
)	O
and	O
reoxygenation	O
after	O
hypoxia	O
(	O
Poole	O
-	O
Wilson	O
et	O
al.	O
,	O
1984	O
)	O
have	O
been	O
considered	O
to	O
be	O
involved	O
in	O
the	O
final	O
stage	O
of	O
ischemia	O
/	O
reperfusion	O
injury	O
of	O
cardiac	O
myocytes	O
(	O
Nayler	O
,	O
1981	O
;	O
Farber	O
,	O
1982	O
;	O
Steenbergen	O
et	O
al.	O
,	O
1990	O
)	O
.	O

Thus	O
,	O
it	O
is	O
postulated	O
that	O
l	B
-cis	I
diltiazem	I
elicits	O
a	O
cardioprotective	O
action	O
via	O
the	O
attenuation	O
of	O
Ca2	O
+	O
overload	O
after	O
reperfusion	O
.	O

In	O
terms	O
of	O
energy	O
metabolism	O
,	O
ischemic	O
insults	O
can	O
be	O
simulated	O
,	O
in	O
part	O
,	O
by	O
controlled	O
metabolic	O
inhibition	O
.	O

Li	O
et	O
al.	O
(	O
1989	O
)	O
has	O
reported	O
that	O
the	O
myocytes	O
were	O
reversibly	O
ATP	B
-	O
depleted	O
by	O
metabolic	O
inhibitors	O
.	O

Thus	O
,	O
myocardial	O
Ca2	B
+	I
overload	O
induced	O
by	O
ischemia	O
and	O
reperfusion	O
is	O
considered	O
to	O
be	O
simply	O
mimicked	O
,	O
in	O
part	O
,	O
by	O
treatment	O
with	O
carbonyl	B
cyanide	I
m	I
-chrolophenylhydrazone	I
(	O
CCCP	B
)	O
,	O
a	O
mitochondrial	O
uncoupler	O
,	O
followed	O
by	O
washout	O
of	O
CCCP	B
.	O

In	O
order	O
to	O
assess	O
the	O
effect	O
of	O
l	B
-cis	I
diltiazem	I
on	O
reperfusion	O
-	O
induced	O
Ca2	B
+	I
overload	O
,	O
we	O
used	O
a	O
model	O
for	O
Ca2	B
+	I
overload	O
by	O
metabolic	O
inhibition	O
and	O
energy	O
repletion	O
in	O
isolated	O
guinea	O
pig	O
cardiomyocytes	O
.	O

We	O
also	O
assessed	O
the	O
effect	O
of	O
other	O
drugs	O
,	O
Ca2	O
+	O
channel	O
blockers	O
and	O
Na+	B
/Ca2	O
+	B
exchanger	O
blockers	O
,	O
to	O
clarify	O
the	O
mechanism	O
for	O
Ca2	B
+	I
overload	O
in	O
this	O
model	O
.	O

2	O
Materials	O
and	O
methods	O
2.1	O
Preparation	O
of	O
single	O
cells	O
Ventricular	O
myocytes	O
were	O
isolated	O
enzymatically	O
from	O
the	O
hearts	O
of	O
male	O
Hartley	O
guinea	O
pigs	O
(	O
weight	O
250500	O
g	O
)	O
according	O
to	O
the	O
method	O
described	O
(	O
Kurokawa	O
et	O
al.	O
,	O
1997	O
)	O
.	O

The	O
animals	O
were	O
anaesthetized	O
with	O
sodium	B
pentobarbital	I
(	O
50	O
mg	O
/	O
kg	O
,	O
i.p	O
.	O
)	O
and	O
the	O
ascending	O
aorta	O
was	O
cannulated	O
in	O
situ	O
under	O
artificial	O
respiration	O
.	O

The	O
heart	O
was	O
perfused	O
with	O
Ca2	B
+	I
-free	O
Tyrode	B
solution	I
for	O
10	O
min	O
,	O
followed	O
by	O
the	O
same	O
solution	O
containing	O
collagenase	O
for	O
714	O
min	O
at	O
a	O
perfusion	O
rate	O
of	O
810	O
ml	O
/	O
min	O
via	O
a	O
Langendorff	O
apparatus	O
at	O
37	O
	O
C	O
.	O

Subsequently	O
,	O
the	O
enzyme	O
solution	O
was	O
washed	O
out	O
with	O
a	O
high	O
K+	B
,	O
Ca2	B
+	I
-free	O
solution	O
(	O
Kraftbrhe	B
(	O
KB	B
)	O
solution	B
,	O
Isenberg	O
and	O
Klckner	O
,	O
1982	O
)	O
.	O

The	O
ventricular	O
myocytes	O
were	O
dissociated	O
by	O
gentle	O
stirring	O
of	O
the	O
tissue	O
fragments	O
at	O
37	O
	O
C	O
.	O

The	O
dissociated	O
cells	O
were	O
stored	O
in	O
KB	B
solution	I
at	O
4	O
	O
C	O
,	O
and	O
were	O
used	O
up	O
to	O
10	O
h	O
after	O
isolation	O
.	O

Nominally	O
Ca2	B
+	I
-free	O
solution	O
had	O
the	O
following	O
composition	O
(	O
mM	O
)	O
:	O
NaCl	B
135	O
,	O
KCl	B
5.4	O
,	O
MgCl2	B
1	O
,	O
glucose	B
5.8	O
,	O
HEPES	B
5	O
(	O
pH	O
7.4	O
,	O
adjusted	O
with	O
tris	B
)	O
.	O

Normal	O
Tyrode	B
solution	I
was	O
made	O
by	O
adding	O
1.8	O
mM	O
CaCl2	B
to	O
nominally	O
Ca2	B
+	I
-free	O
solution	O
.	O

The	O
collagenase	O
solutions	O
were	O
prepared	O
by	O
adding	O
collagenase	O
(	O
110	O
units	O
/	O
ml	O
Collagenase	O
S-1	O
,	O
Nitta	O
Gelatin	O
,	O
Osaka	O
,	O
Japan	O
;	O
200220	O
units	O
/	O
ml	O
collagenase	O
,	O
Yakult	O
,	O
Tokyo	O
.	O

Japan	O
)	O
and	O
10.8	O
nM	O
CaCl2	B
to	O
Ca2	B
+	I
-free	O
Tyrode	B
solution	I
,	O
or	O
by	O
combining	O
collagenase	O
(	O
0.145	O
U	O
/	O
ml	O
collagenase	O
A	O
,	O
Boehringer	O
Mannheim	O
,	O
Japan	O
)	O
and	O
protease	O
(	O
0.156	O
units	O
/	O
ml	O
protease	O
type	O
IX	O
,	O
Sigma	O
,	O
St.	O
Louis	O
,	O
MO	O
,	O
USA	O
)	O
to	O
Ca2	B
+	I
-free	O
Tyrode	B
solution	I
.	O

The	O
KB	B
solution	I
contained	O
(	O
mM	O
)	O
:	O
potassium	B
glutamate	I
70	O
,	O
KCl	B
20	O
,	O
oxalic	B
acid	I
10	O
,	O
KH2	B
PO4	I
10	O
,	O
taurine	B
10	O
,	O
glucose	B
5.8	O
,	O
HEPES	B
5	O
,	O
EGTA	B
0.5	O
(	O
pH	O
7.4	O
,	O
adjusted	O
with	O
KOH	B
)	O
.	O

2.2	O
Measurement	O
of	O
fluorescence	O
ratio	O
of	O
fura-2	B
in	O
cardiac	O
myocytes	O
For	O
measurement	O
of	O
a	O
change	O
in	O
[	O
Ca2	B
+	I
]	O
i	O
of	O
cardiac	O
myocytes	O
,	O
a	O
Ca2	B
+	I
-sensitive	O
fluorescent	O
dye	O
,	O
fura-2	B
/	I
acetoxymethylester	I
(	O
fura-2	B
/	I
AM	I
)	O
,	O
was	O
used	O
.	O

Fura-2	B
/	I
AM	I
(	O
1	O
mM	O
,	O
dissolved	O
in	O
dimethylsulfoxide	B
,	O
DMSO	B
)	O
was	O
prepared	O
in	O
KB	B
solution	I
and	O
applied	O
to	O
isolated	O
myocytes	O
at	O
a	O
final	O
concentration	O
of	O
10	O
M.	O
After	O
the	O
cell	O
suspension	O
had	O
been	O
incubated	O
for	O
10	O
min	O
at	O
37	O
	O
C	O
,	O
the	O
cells	O
settled	O
out	O
and	O
became	O
loosely	O
attached	O
to	O
the	O
bottom	O
of	O
the	O
chamber	O
.	O

Then	O
the	O
fura-2-loaded	B
myocytes	O
were	O
washed	O
and	O
superfused	O
(	O
45	O
ml	O
/	O
min	O
,	O
37	O
	O
C	O
)	O
with	O
normal	O
Tyrode	B
solution	I
containing	O
1.8	O
mM	O
Ca2	B
+	I
for	O
30	O
min	O
.	O

The	O
myocytes	O
were	O
illuminated	O
with	O
a	O
dual	O
wavelength	O
fluorometer	O
(	O
CAM-230	O
,	O
Japan	O
Spectroscopic	O
,	O
Tokyo	O
,	O
Japan	O
)	O
.	O

Video	O
images	O
were	O
digitized	O
,	O
using	O
an	O
Argus-50	O
/	O
Ca	O
system	O
(	O
Hamamatsu	O
Photonics	O
)	O
.	O

The	O
fluorescence	O
ratio	O
was	O
calculated	O
from	O
the	O
value	O
of	O
the	O
fluorescence	O
intensity	O
at	O
500	O
nm	O
with	O
340-	O
and	O
380-nm	O
excitation	O
.	O

The	O
digital	O
images	O
were	O
obtained	O
every	O
5	O
min	O
from	O
just	O
before	O
treatment	O
with	O
CCCP	B
till	O
the	O
end	O
of	O
the	O
experiment	O
.	O

2.3	O
Evaluation	O
of	O
morphological	O
changes	O
of	O
cardiac	O
myocytes	O
Cells	O
lightly	O
attached	O
to	O
the	O
perfusion	O
chamber	O
were	O
superfused	O
with	O
normal	O
Tyrode	B
solution	I
at	O
37	O
	O
C	O
.	O

After	O
30	O
min	O
of	O
stabilization	O
,	O
a	O
rod	O
-	O
shaped	O
cell	O
was	O
selected	O
randomly	O
from	O
those	O
within	O
the	O
microscopic	O
field	O
of	O
the	O
chamber	O
.	O

Caffeine	B
(	O
5	O
mM	O
)	O
was	O
added	O
for	O
1	O
min	O
to	O
the	O
chamber	O
in	O
order	O
to	O
confirm	O
that	O
the	O
function	O
of	O
the	O
intracellular	O
Ca2	B
+	I
store	O
of	O
the	O
myocyte	O
was	O
maintained	O
.	O

After	O
washing	O
out	O
of	O
the	O
caffeine	B
for	O
5	O
min	O
,	O
the	O
morphology	O
of	O
the	O
myocyte	O
was	O
recorded	O
as	O
a	O
digital	O
image	O
using	O
the	O
Argus-50	O
/	O
Ca	O
system	O
.	O

To	O
examine	O
the	O
morphological	O
change	O
of	O
the	O
myocyte	O
,	O
the	O
morphology	O
of	O
the	O
same	O
cell	O
was	O
also	O
recorded	O
at	O
the	O
end	O
of	O
chemical	O
ischemia	O
and	O
also	O
at	O
the	O
end	O
of	O
30-min	O
reperfusion	O
.	O

After	O
Ca2	B
+	I
measurement	O
,	O
the	O
morphological	O
change	O
was	O
analyzed	O
by	O
measuring	O
the	O
area	O
of	O
the	O
myocyte	O
.	O

The	O
cell	O
surface	O
area	O
was	O
calculated	O
from	O
the	O
digitized	O
image	O
of	O
the	O
cell	O
and	O
the	O
post	O
-	O
ischemic	O
value	O
was	O
expressed	O
as	O
percentage	O
of	O
the	O
pre	O
-	O
ischemic	O
value	O
.	O

2.4	O
Experimental	O
protocols	O
In	O
order	O
to	O
determine	O
the	O
optimal	O
condition	O
of	O
the	O
Ca2	B
+	I
overload	O
model	O
by	O
metabolic	O
inhibition	O
and	O
energy	O
repletion	O
,	O
we	O
performed	O
some	O
preliminary	O
experiments	O
.	O

We	O
first	O
followed	O
a	O
protocol	O
for	O
metabolic	O
inhibition	O
,	O
using	O
Tyrode	B
solution	I
containing	O
normal	O
Ca2	B
+	I
and	O
1	O
M	O
of	O
CCCP	B
.	O

However	O
,	O
the	O
myocytes	O
exposed	O
to	O
CCCP	B
for	O
1015	O
min	O
showed	O
a	O
rigor	O
contraction	O
with	O
an	O
increase	O
in	O
[	O
Ca2	O
+	O
]	O
i	O
,	O
but	O
failed	O
to	O
show	O
Ca2	O
+	O
overload	O
on	O
washout	O
of	O
CCCP	B
(	O
energy	O
repletion	O
)	O
after	O
the	O
transition	O
to	O
rigor	O
contraction	O
(	O
the	O
sign	O
of	O
ATP	B
depletion	O
)	O
.	O

These	O
cells	O
showed	O
neither	O
further	O
[	O
Ca2	B
+	I
]	O
i	O
increase	O
nor	O
morphological	O
changes	O
after	O
energy	O
repletion	O
.	O

To	O
improve	O
the	O
efficacy	O
of	O
the	O
assessment	O
of	O
reperfusion	O
injury	O
,	O
we	O
used	O
Ca2	B
+	I
-free	O
Tyrode	B
solution	I
for	O
metabolic	O
inhibition	O
,	O
since	O
it	O
was	O
reported	O
that	O
cells	O
in	O
the	O
low	O
Ca2	B
+	I
solution	O
remain	O
rod	O
-	O
shaped	O
for	O
a	O
longer	O
period	O
against	O
metabolic	O
inhibition	O
(	O
Li	O
et	O
al.	O
,	O
1988	O
)	O
.	O

We	O
also	O
examined	O
the	O
dose	O
-	O
dependent	O
effects	O
of	O
CCCP	B
(	O
100	O
nM	O
,	O
1	O
and	O
3	O
M	O
)	O
,	O
and	O
confirmed	O
that	O
1	O
M	O
of	O
CCCP	B
was	O
the	O
most	O
stable	O
to	O
induce	O
Ca2	B
+	I
overload	O
after	O
energy	O
repletion	O
.	O

Based	O
on	O
these	O
experiments	O
,	O
we	O
established	O
the	O
standard	O
procedure	O
as	O
follows	O
.	O

After	O
confirmation	O
of	O
the	O
integrity	O
of	O
the	O
myocardial	O
store	O
functions	O
described	O
in	O
the	O
previous	O
section	O
,	O
Ca2	B
+	I
-free	O
Tyrode	O
containing	O
CCCP	B
(	O
1	O
M	O
)	O
was	O
perfused	O
for	O
40	O
min	O
at	O
a	O
perfusion	O
rate	O
of	O
23	O
ml	O
/	O
min	O
.	O

Ca2	B
+	I
overload	O
was	O
induced	O
by	O
washout	O
of	O
CCCP	B
with	O
normal	O
Tyrode	B
solution	I
for	O
30	O
min	O
at	O
a	O
perfusion	O
rate	O
of	O
45	O
ml	O
/	O
min	O
.	O

In	O
this	O
study	O
,	O
we	O
employed	O
the	O
following	O
two	O
protocols	O
:	O
(	O
A	O
)	O
before	O
metabolic	O
inhibition	O
,	O
in	O
which	O
drugs	O
were	O
included	O
throughout	O
the	O
experiment	O
,	O
and	O
(	O
B	O
)	O
before	O
energy	O
repletion	O
,	O
in	O
which	O
drugs	O
were	O
included	O
from	O
5	O
min	O
before	O
energy	O
repletion	O
to	O
the	O
end	O
of	O
the	O
experiment	O
.	O

2.5	O
Calibration	O
for	O
Ca2	B
+	I
concentration	O
The	O
maximum	O
ratio	O
(	O
R	O
max	O
)	O
unique	O
to	O
individual	O
cells	O
was	O
obtained	O
at	O
the	O
end	O
of	O
each	O
experiment	O
by	O
applying	O
ionomycin	B
(	O
2	O
M	O
)	O
to	O
the	O
normal	O
Tyrode	B
solution	I
.	O

The	O
minimum	O
ratio	O
(	O
R	O
min	O
)	O
was	O
obtained	O
by	O
applying	O
EGTA	B
(	O
10	O
mM	O
)	O
to	O
the	O
ionomycin	B
containing	O
Tyrode	B
solution	I
.	O

Both	O
R	O
max	O
and	O
R	O
min	O
values	O
were	O
obtained	O
under	O
steady	O
state	O
conditions	O
.	O

[	O
Ca2	B
+	I
]	O
i	O
was	O
calculated	O
from	O
the	O
following	O
formula	O
:	O
[	O
Ca2	B
+	I
]	O
i	O
(	O
nM	O
)	O
=	O
(	O
R	O
R	O
min	O
)	O
K	O
d	O
F	O
min	O
/	O
(	O
(	O
R	O
max	O
R	O
)	O
F	O
max	O
)	O
)	O
,	O
where	O
R	O
is	O
the	O
ratio	O
obtained	O
from	O
the	O
experiment	O
,	O
F	O
means	O
the	O
fluorescence	O
intensity	O
at	O
380-nm	O
excitation	O
,	O
and	O
K	O
d	O
is	O
the	O
dissociation	O
constant	O
defined	O
as	O
224	O
nM.	O
2.6	O
Chemicals	O
l	B
-cis	I
Diltiazem	I
and	O
diltiazem	B
were	O
kind	O
gifts	O
from	O
Tanabe	O
Seiyaku	O
(	O
Osaka	O
,	O
Japan	O
)	O
.	O

A	O
specific	O
inhibitor	O
of	O
Na+	B
/Ca2	O
+	B
exchanger	O
,	O
2-	B
[	I
2-	I
[	I
4-	I
(	I
4-nitrobenzyloxy	I
)	I
phenyl	I
]	I
ethyl	I
]	I
isothiourea	I
methanesulphonate	I
(	O
KB	B
-	I
R7943	I
)	O
,	O
was	O
a	O
kind	O
gift	O
from	O
Kanebo	O
(	O
Osaka	O
,	O
Japan	O
)	O
.	O

CCCP	B
was	O
purchased	O
from	O
Sigma	O
.	O

2.7	O
Statistical	O
analysis	O
All	O
data	O
were	O
expressed	O
as	O
meansS.E.M.	O
The	O
time	O
course	O
data	O
(	O
Ca2	B
+	I
measurement	O
)	O
were	O
divided	O
into	O
two	O
events	O
,	O
during	O
40	O
min	O
of	O
metabolic	O
inhibition	O
and	O
during	O
30-min	O
energy	O
repletion	O
,	O
and	O
repeated	O
measures	O
two	O
-	O
way	O
analysis	O
of	O
variance	O
was	O
used	O
.	O

If	O
there	O
was	O
no	O
interaction	O
between	O
the	O
drug	O
factor	O
and	O
the	O
time	O
factor	O
,	O
Bonferroni	O
/	O
Dunn	O
(	O
Dunn	O
's	O
Procedure	O
for	O
Comparing	O
a	O
Control	O
to	O
All	O
other	O
Means	O
)	O
post	O
-	O
hoc	O
test	O
was	O
done	O
thereafter	O
.	O

One	O
-	O
way	O
analysis	O
of	O
variance	O
(	O
ANOVA	O
)	O
followed	O
by	O
the	O
Bonferroni	O
/	O
Dunn	O
post	O
-	O
hoc	O
test	O
was	O
used	O
for	O
the	O
cell	O
size	O
data	O
.	O

All	O
statistical	O
analyses	O
were	O
performed	O
using	O
Super	O
ANOVA	O
	O
(	O
Abacus	O
Concepts	O
,	O
Berkeley	O
,	O
CA	O
)	O
.	O

Differences	O
were	O
considered	O
to	O
be	O
statistically	O
significant	O
when	O
the	O
P	O
value	O
was	O
less	O
than	O
0.05	O
.	O

3	O
Results	O
3.1	O
Cell	O
selection	O
In	O
all	O
the	O
experiments	O
,	O
rod	O
-	O
shaped	O
myocytes	O
as	O
shown	O
in	O
Fig.	O
1A	O
were	O
selected	O
.	O

A	O
single	O
myocyte	O
was	O
further	O
selected	O
for	O
the	O
ischemia	O
experiment	O
,	O
based	O
on	O
the	O
criterion	O
that	O
it	O
showed	O
a	O
transient	O
[	O
Ca2	B
+	I
]	O
i	O
increase	O
on	O
treatment	O
with	O
5	O
mM	O
caffeine	B
(	O
Fig.	O
1B	O
)	O
.	O

The	O
cells	O
,	O
which	O
did	O
not	O
satisfy	O
these	O
criteria	O
,	O
or	O
which	O
changed	O
morphologically	O
after	O
the	O
treatment	O
with	O
caffeine	B
,	O
were	O
excluded	O
.	O

3.2	O
Changes	O
in	O
[	O
Ca2	B
+	I
]	O
i	O
by	O
metabolic	O
inhibition	O
and	O
energy	O
repletion	O
Fig.	O
2	O
represents	O
the	O
change	O
in	O
time	O
course	O
of	O
[	O
Ca2	B
+	I
]	O

i	O
in	O
the	O
absence	O
and	O
the	O
presence	O
of	O
drugs	O
.	O

Before	O
CCCP	B
treatment	O
,	O
the	O
[	O
Ca2	B
+	I
]	O
i	O
of	O
all	O
cells	O
used	O
were	O
almost	O
identical	O
in	O
level	O
(	O
about	O
100	O
nM	O
)	O
.	O

In	O
the	O
control	O
myocytes	O
,	O
[	O
Ca2	B
+	I
]	O
i	O
did	O
not	O
change	O
during	O
40	O
min	O
of	O
CCCP	B
treatment	O
.	O

After	O
washout	O
of	O
CCCP	B
,	O
[	O
Ca2	B
+	I
]	O
i	O
increased	O
dramatically	O
within	O
5	O
min	O
and	O
continued	O
to	O
increase	O
until	O
the	O
end	O
of	O
energy	O
repletion	O
.	O

In	O
order	O
to	O
confirm	O
that	O
this	O
[	O
Ca2	B
+	I
]	O
i	O
increase	O
was	O
not	O
due	O
to	O
the	O
simple	O
entry	O
of	O
extracellular	O
Ca2	B
+	I
when	O
Ca2	B
+	I
-free	O
Tyrode	B
was	O
replaced	O
by	O
normal	O
Tyrode	B
,	O
we	O
performed	O
the	O
same	O
perfusion	O
protocol	O
without	O
CCCP	B
treatment	O
.	O

We	O
observed	O
that	O
the	O
[	O
Ca2	B
+	I
]	O
i	O
showed	O
a	O
small	O
(	O
2030	O
nM	O
)	O
,	O
but	O
not	O
significant	O
,	O
increase	O
at	O
5	O
min	O
after	O
energy	O
repletion	O
.	O

Therefore	O
,	O
the	O
Ca2	B
+	I
overload	O
observed	O
here	O
is	O
considered	O
to	O
be	O
induced	O
by	O
the	O
injury	O
due	O
to	O
metabolic	O
inhibition	O
and	O
energy	O
repletion	O
.	O

Furthermore	O
,	O
Ni2	B
+	I
(	O
5	O
mM	O
)	O
and	O
KB	B
-	I
R7943	I
(	O
10	O
M	O
)	O
,	O
known	O
as	O
inhibitors	O
of	O
the	O
Na+	B
/Ca2	B
+	I
exchanger	O
,	O
completely	O
blocked	O
the	O
initial	O
rise	O
of	O
[	O
Ca2	B
+	I
]	O
i	O
after	O
washout	O
of	O
CCCP	B
(	O
P	O
<	O
0.01	O
vs.	O
control	O
)	O
and	O
continued	O
to	O
attenuate	O
the	O
[	O
Ca2	B
+	I
]	O
i	O
increase	O
during	O
30	O
min	O
of	O
energy	O
repletion	O
.	O

However	O
,	O
nitrendipine	B
(	O
10	O
M	O
)	O
,	O
a	O
dihydropyridine	B
Ca2	B
+	I
channel	O
blocker	O
,	O
failed	O
to	O
attenuate	O
the	O
[	O
Ca2	B
+	I
]	O
i	O
increase	O
after	O
washout	O
of	O
CCCP	B
.	O

Nicardipine	B
(	O
10	O
M	O
)	O
,	O
another	O
dihydropyridine	B
Ca2	B
+	I
channel	O
blocker	O
,	O
also	O
failed	O
to	O
attenuate	O
the	O
[	O
Ca2	B
+	I
]	O
i	O
increase	O
(	O
see	O
Table	O
1	O
)	O
.	O

Thus	O
,	O
the	O
[	O
Ca2	B
+	I
]	O
i	O
increase	O
in	O
this	O
model	O
was	O
suggested	O
to	O
be	O
mediated	O
,	O
not	O
by	O
L	O
-	O
type	O
Ca2	B
+	I
channels	O
but	O
by	O
the	O
Na+	B
/Ca2	O
+	B
exchanger	O
.	O

As	O
for	O
the	O
treatment	O
with	O
drugs	O
before	O
metabolic	O
inhibition	O
(	O
protocol	O
(	O
A	O
)	O
)	O
,	O
diltiazem	B
(	O
3	O
M	O
)	O
and	O
l	B
-cis	I
diltiazem	I
(	O
10	O
M	O
)	O
,	O
but	O
not	O
l	B
-cis	I
diltiazem	I
(	O
3	O
M	O
)	O
significantly	O
attenuated	O
the	O
[	B
Ca2	I
+	I
]	O
i	O
increase	O
during	O
energy	O
repletion	O
(	O
Fig.	O
3A	O
)	O
.	O

As	O
for	O
the	O
treatment	O
with	O
drugs	O
5	O
min	O
before	O
washout	O
of	O
CCCP	B
(	O
protocol	O
(	O
B	O
)	O
)	O
,	O
3	O
M	O
of	O
diltiazem	B
,	O
which	O
was	O
effective	O
in	O
protocol	O
(	O
A	O
)	O
,	O
failed	O
to	O
attenuate	O
the	O
[	O
Ca2	B
+	I
]	O
i	O
increase	O
.	O

However	O
,	O
a	O
higher	O
concentration	O
of	O
diltiazem	B
(	O
10	O
M	O
)	O
could	O
significantly	O
attenuate	O
the	O
[	O
Ca2	B
+	I
]	O
i	O
increase	O
after	O
energy	O
repletion	O
(	O
Fig.	O
3B	O
)	O
.	O

l	B
-cis	I
Diltiazem	I
(	O
10	O
M	O
)	O
also	O
attenuated	O
the	O
[	O
Ca2	B
+	I
]	O
i	O
increase	O
(	O
P	O
<	O
0.01	O
vs.	O
control	O
)	O
.	O

3.3	O
Morphological	O
change	O
of	O
the	O
cell	O
after	O
energy	O
repletion	O
Cells	O
,	O
which	O
showed	O
a	O
rigor	O
contraction	O
during	O
CCCP	B
treatment	O
,	O
were	O
all	O
excluded	O
from	O
the	O
experiments	O
.	O

Table	O
1	O
represents	O
the	O
morphological	O
change	O
in	O
cell	O
size	O
caused	O
by	O
metabolic	O
inhibition	O
and	O
energy	O
repletion	O
in	O
the	O
absence	O
and	O
the	O
presence	O
of	O
drugs	O
,	O
accompanied	O
by	O
[	O
Ca2	B
+	I
]	O
i	O
.	O

Compared	O
with	O
the	O
control	O
,	O
l	B
-cis	I
diltiazem	I
(	O
10	O
M	O
)	O
,	O
diltiazem	B
(	O
10	O
M	O
)	O
,	O
Ni2	B
+	I
(	O
5	O
mM	O
)	O
and	O
KB	B
-	I
R7943	I
(	O
10	O
M	O
)	O
,	O
added	O
5	O
min	O
before	O
washout	O
of	O
CCCP	B
,	O
all	O
reduced	O
the	O
cell	O
shortening	O
(	O
P	O
<	O
0.05	O
)	O
,	O
and	O
these	O
effects	O
correlated	O
well	O
with	O
the	O
attenuation	O
in	O
[	O
Ca2	B
+	I
]	O
i	O
increase	O
.	O

Treatment	O
with	O
diltiazem	B
(	O
3	O
M	O
)	O
failed	O
to	O
reduce	O
the	O
contraction	O
,	O
which	O
correlated	O
with	O
the	O
increase	O
in	O
[	O
Ca2	B
+	I
]	O
i	O
.	O

Neither	O
nitrendipine	B
(	O
10	O
M	O
)	O
nor	O
nicardipine	B
(	O
10	O
M	O
)	O
attenuated	O
the	O
contraction	O
or	O
the	O
[	O
Ca2	B
+	I
]	O
i	O
increase	O
after	O
energy	O
repletion	O
.	O

4	O
Discussion	O
4.1	O
Increase	O
in	O
[	O
Ca2	B
+	I
]	O
i	O
by	O
metabolic	O
inhibition	O
and	O
energy	O
repletion	O
in	O
guinea	O
pig	O
isolated	O
myocytes	O
Isolated	O
cardiomyocytes	O
are	O
reversibly	O
made	O
ATP	B
-	O
depleted	O
by	O
CCCP	B
,	O
a	O
reversible	O
inhibitor	O
of	O
mitochondrial	O
oxidative	O
phosphorylation	O
(	O
Li	O
et	O
al.	O
,	O
1989	O
)	O
.	O

The	O
myocytes	O
,	O
which	O
show	O
a	O
rigor	O
contraction	O
on	O
metabolic	O
inhibition	O
are	O
reported	O
to	O
have	O
depressed	O
Ca2	B
+	I
overload	O
,	O
because	O
the	O
activity	O
of	O
the	O
Na+	B
/Ca2	O
+	B
exchanger	O
is	O
inhibited	O
by	O
energy	O
depletion	O
(	O
Li	O
et	O
al.	O
,	O
1988	O
;	O
Collins	O
et	O
al.	O
,	O
1992	O
)	O
.	O

Li	O
et	O
al.	O
(	O
1988	O
)	O
have	O
also	O
reported	O
that	O
cells	O
maintaining	O
a	O
low	O
[	O
Ca2	B
+	I
]	O
i	O
level	O
remain	O
rod	O
-	O
shaped	O
for	O
a	O
longer	O
period	O
against	O
metabolic	O
inhibition	O
.	O

Since	O
our	O
aim	O
was	O
to	O
assess	O
the	O
effect	O
of	O
l	B
-cis	I
diltiazem	I
on	O
reperfusion	O
-	O
induced	O
Ca2	B
+	I
overload	O
in	O
vitro	O
,	O
we	O
followed	O
a	O
protocol	O
with	O
Ca2	B
+	I
-free	O
Tyrode	B
solution	I
,	O
which	O
improves	O
the	O
efficacy	O
of	O
the	O
assessment	O
of	O
reperfusion	O
injury	O
.	O

Using	O
this	O
type	O
of	O
model	O
,	O
we	O
could	O
partially	O
simulate	O
the	O
ischemia	O
/	O
reperfusion	O
-	O
induced	O
Ca2	B
+	I
overload	O
in	O
vitro	O
by	O
metabolic	O
inhibition	O
and	O
energy	O
repletion	O
.	O

A	O
marked	O
[	O
Ca2	B
+	I
]	O
i	O
increase	O
was	O
observed	O
after	O
washout	O
of	O
CCCP	B
with	O
Ca2	B
+	I
-containing	O
Tyrode	B
solution	I
.	O

This	O
[	O
Ca2	B
+	I
]	O
i	O
increase	O
was	O
suppressed	O
by	O
Ni2	B
+	I
or	O
KB	B
-	I
R7943	I
,	O
a	O
specific	O
inhibitor	O
of	O
the	O
Na+	B
/Ca2	O
+	B
exchanger	O
,	O
but	O
was	O
not	O
suppressed	O
by	O
nitrendipine	B
or	O
nicardipine	B
(	O
Fig.	O
2	O
)	O
.	O

These	O
results	O
indicate	O
that	O
the	O
[	O
Ca2	B
+	I
]	O
i	O
increase	O
by	O
energy	O
repletion	O
occurred	O
via	O
the	O
Na+	B
/Ca2	O
+	B
exchanger	O
,	O
but	O
not	O
through	O
the	O
dihydropyridine	B
-	O
sensitive	O
Ca2	B
+	I
channel	O
in	O
this	O
model	O
.	O

4.2	O
Cardioprotective	O
effect	O
of	O
l	B
-cis	I
diltiazem	I
on	O
Ca2	B
+	I
overload	O
in	O
guinea	O
pig	O
myocytes	O
In	O
the	O
present	O
study	O
,	O
l	B
-cis	I
diltiazem	I
and	O
diltiazem	B
attenuated	O
both	O
the	O
[	O
Ca2	B
+	I
]	O
i	O
increase	O
and	O
the	O
cell	O
shortening	O
induced	O
by	O
CCCP	B
.	O

Itogawa	O
et	O
al.	O
(	O
1996	O
)	O
demonstrated	O
that	O
both	O
l	B
-cis	I
diltiazem	I
and	O
diltiazem	B
attenuated	O
veratridine	B
-	O
induced	O
Ca2	B
+	I
overload	O
and	O
hypercontracture	O
in	O
isolated	O
rat	O
hearts	O
.	O

However	O
,	O
this	O
is	O
not	O
direct	O
evidence	O
that	O
l	B
-cis	I
diltiazem	I
actually	O
protects	O
against	O
ischemia	O
/	O
reperfusion	O
injury	O
by	O
inhibiting	O
Ca2	B
+	I
overload	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
mimicked	O
the	O
phenomenon	O
of	O
ischemia	O
/	O
reperfusion	O
injury	O
in	O
the	O
chamber	O
and	O
our	O
data	O
are	O
the	O
first	O
demonstration	O
that	O
both	O
l	B
-cis	I
diltiazem	I
and	O
diltiazem	B
protect	O
against	O
the	O
Ca2	B
+	I
overload	O
induced	O
by	O
metabolic	O
inhibition	O
and	O
energy	O
repletion	O
in	O
the	O
same	O
concentration	O
range	O
.	O

This	O
observation	O
,	O
together	O
with	O
the	O
observation	O
that	O
nitrendipine	B
and	O
nicardipine	B
were	O
without	O
effect	O
,	O
suggests	O
that	O
their	O
effects	O
are	O
independent	O
of	O
L	O
-	O
type	O
Ca2	B
+	I
channel	O
blocking	O
.	O

This	O
possibility	O
is	O
also	O
supported	O
by	O
the	O
results	O
of	O
a	O
previous	O
study	O
in	O
our	O
laboratory	O
showing	O
that	O
l	B
-cis	I
diltiazem	I
(	O
10	O
M	O
)	O
as	O
well	O
as	O
diltiazem	B
(	O
3	O
M	O
)	O
worked	O
to	O
preserve	O
high	O
-	O
energy	O
phosphates	B
in	O
the	O
ischemia	O
	O
reperfusion	O
model	O
of	O
isolated	O
guinea	O
pig	O
hearts	O
(	O
submitted	O
for	O
publication	O
)	O
.	O

In	O
the	O
present	O
study	O
,	O
inclusion	O
of	O
diltiazem	B
(	O
3	O
M	O
)	O
throughout	O
the	O
experiment	O
attenuated	O
the	O
[	O
Ca2	B
+	I
]	O
i	O
increase	O
during	O
reperfusion	O
(	O
Fig.	O
3A	O
)	O
.	O

However	O
,	O
the	O
addition	O
of	O
diltiazem	B
(	O
3	O
M	O
)	O
,	O
started	O
5	O
min	O
before	O
reperfusion	O
,	O
failed	O
to	O
attenuate	O
the	O
[	O
Ca2	B
+	I
]	O
i	O
increase	O
(	O
Fig.	O
3B	O
)	O
.	O

Thus	O
,	O
we	O
suggest	O
that	O
some	O
events	O
during	O
chemical	O
ischemia	O
,	O
which	O
could	O
be	O
affected	O
by	O
diltiazem	B
,	O
might	O
be	O
involved	O
in	O
the	O
Ca2	B
+	I
overload	O
during	O
reperfusion	O
(	O
Watts	O
et	O
al.	O
,	O
1990	O
;	O
Sakamoto	O
et	O
al.	O
,	O
1997	O
)	O
.	O

4.3	O
Cardioprotective	O
mechanism	O
by	O
l	B
-cis	I
diltiazem	I
on	O
Ca2	B
+	I
overload	O
by	O
metabolic	O
inhibition	O
and	O
energy	O
repletion	O
In	O
the	O
present	O
model	O
,	O
the	O
[	O
Ca2	O
+	O
]	O
i	O
increase	O
after	O
energy	O
repletion	O
was	O
inhibited	O
by	O
both	O
Ni2	B
+	I
and	O
KB	B
-	I
R7943	I
(	O
Fig.	O
2	O
)	O
.	O

Concerning	O
the	O
[	O
Ca2	B
+	I
]	O
i	O
increase	O
in	O
this	O
model	O
,	O
the	O
L	O
-	O
type	O
Ca2	B
+	I
channel	O
does	O
not	O
seem	O
to	O
be	O
involved	O
.	O

This	O
is	O
because	O
the	O
dihydropyridine	B
Ca2	B
+	I
channel	O
blockers	O
,	O
nitrendipine	B
and	O
nicardipine	B
,	O
affected	O
neither	O
[	O
Ca2	B
+	I
]	O
i	O
increase	O
nor	O
cell	O
shortening	O
(	O
Table	O
1	O
)	O
.	O

The	O
inhibition	O
of	O
the	O
Na+	B
/Ca2	O
+	B
exchanger	O
may	O
afford	O
protection	O
from	O
metabolic	O
inhibition	O
and	O
energy	O
repletion	O
.	O

A	O
previous	O
report	O
has	O
demonstrated	O
that	O
the	O
intracellular	O
Na+	B
concentration	O
(	O
[	O
Na+	B
]	O
i	O
)	O
is	O
increased	O
by	O
metabolic	O
inhibition	O
in	O
guinea	O
pig	O
myocytes	O
(	O
Satoh	O
et	O
al.	O
,	O
1995	O
)	O
.	O

This	O
indicates	O
that	O
Na+	B
overload	O
caused	O
during	O
metabolic	O
inhibition	O
is	O
important	O
in	O
this	O
model	O
.	O

Itogawa	O
et	O
al.	O
(	O
1996	O
)	O
previously	O
reported	O
that	O
l	B
-cis	I
diltiazem	I
inhibited	O
veratridine	B
-	O
induced	O
Na+	B
overload	O
in	O
rat	O
cardiac	O
myocytes	O
.	O

Haigney	O
et	O
al.	O
(	O
1992	O
)	O
reported	O
that	O
the	O
[	O
Na+	B
]	O
i	O
increase	O
seen	O
during	O
hypoxia	O
is	O
potentiated	O
after	O
rigor	O
contraction	O
in	O
isolated	O
rat	O
myocytes	O
.	O

They	O
also	O
suggested	O
that	O
inactivation	O
-	O
resistant	O
Na+	B
channels	O
were	O
involved	O
in	O
this	O
[	O
Na+	B
]	O
i	O
increase	O
.	O

We	O
demonstrated	O
in	O
the	O
present	O
study	O
that	O
both	O
l	B
-cis	I
diltiazem	I
and	O
diltiazem	B
at	O
10	O
M	O
,	O
when	O
introduced	O
5	O
min	O
before	O
washout	O
of	O
CCCP	B
,	O
attenuated	O
cell	O
shortening	O
after	O
energy	O
repletion	O
(	O
Fig.	O
3B	O
)	O
.	O

Thus	O
,	O
it	O
is	O
speculated	O
that	O
both	O
l	B
-cis	I
diltiazem	I
and	O
diltiazem	B
attenuate	O
Ca2	B
+	I
overload	O
by	O
inhibiting	O
the	O
[	O
Na+	B
]	O
i	O
accumulation	O
early	O
after	O
energy	O
repletion	O
.	O

In	O
conclusion	O
,	O
we	O
first	O
demonstrated	O
that	O
l	B
-cis	I
diltiazem	I
attenuated	O
the	O
Ca2	B
+	I
overload	O
caused	O
by	O
metabolic	O
inhibition	O
and	O
energy	O
repletion	O
in	O
guinea	O
pig	O
myocytes	O
.	O

The	O
cardioprotective	O
action	O
of	O
l	B
-cis	I
diltiazem	I
evidenced	O
in	O
the	O
present	O
work	O
merits	O
further	O
research	O
,	O
since	O
l	B
-cis	I
diltiazem	I
could	O
become	O
a	O
lead	O
compound	O
for	O
investigating	O
protection	O
against	O
ischemia	O
/	O
reperfusion	O
injury	O
.	O

Acknowledgements	O
The	O
authors	O
wish	O
to	O
thank	O
Dr.	O
Satomi	O
Adachi	O
-	O
Akahane	O
(	O
University	O
of	O
Tokyo	O
)	O
for	O
the	O
helpful	O
discussions	O
and	O
Mr.	O
Shoichi	O
Kanda	O
,	O
Ms.	O
Maki	O
Urata	O
,	O
and	O
Mr.	O
Taichiro	O
Tomida	O
(	O
University	O
of	O
Tokyo	O
)	O
for	O
the	O
kind	O
assistance	O
with	O
cell	O
preparation	O
.	O

We	O
thank	O
Tanabe	O
Seiyaku	O
for	O
the	O
kind	O
gift	O
of	O
l	B
-cis	I
diltiazem	I
and	O
diltiazem	B
.	O

We	O
thank	O
Kanebo	O
for	O
the	O
kind	O
gift	O
of	O
KB	B
-	I
R	I
7943	I
.	O

This	O
work	O
was	O
supported	O
by	O
a	O
Grant	O
-	O
in	O
-	O
Aid	O
for	O
Scientific	O
Research	O
from	O
the	O
Ministry	O
of	O
Education	O
,	O
Science	O
,	O
Sports	O
and	O
Culture	O
,	O
Japan	O
.	O

Dopamine	B
(	O
DA	B
)	O
is	O
a	O
neurotransmitter	O
that	O
plays	O
a	O
fundamental	O
role	O
in	O
the	O
control	O
of	O
a	O
variety	O
of	O
physiological	O
functions	O
including	O
locomotor	O
movement	O
,	O
learning	O
,	O
reward	O
behavior	O
,	O
and	O
hormone	O
synthesis	O
and	O
release	O
[	O
40	O
]	O
.	O

However	O
,	O
overflow	O
of	O
DA	B
in	O
the	O
brain	O
has	O
been	O
suggested	O
to	O
participate	O
in	O
certain	O
neurodegenerative	O
processes	O
.	O

These	O
include	O
ischemia	O
[	O
6	O
]	O
,	O
hypoxia	O
[	O
2	O
]	O
,	O
and	O
neurotoxicities	O
induced	O
by	O
excitatory	O
amino	B
acids	I
[	O
16	O
]	O
and	O
methamphetamine	B
[	O
38	O
]	O
.	O

In	O
all	O
of	O
the	O
above	O
cases	O
,	O
striatal	O
DA	B
availability	O
in	O
the	O
brain	O
is	O
significantly	O
increased	O
.	O

For	O
example	O
,	O
the	O
striatal	O
DA	B
concentration	O
rapidly	O
reaches	O
concentrations	O
as	O
high	O
as	O
0.2	O
mM	O
after	O
ligation	O
of	O
the	O
cervical	O
artery	O
in	O
the	O
gerbil	O
ischemic	O
model	O
[	O
45	O
]	O
.	O

Depletion	O
of	O
endogenous	O
DA	B
by	O
chemical	O
lesion	O
of	O
the	O
nigrostriatal	O
dopaminergic	O
pathway	O
reduces	O
ischemic	O
insult	O
to	O
the	O
striatum	O
[	O
17	O
]	O
.	O

Direct	O
intrastriatal	O
injections	O
of	O
DA	B
result	O
in	O
apoptosis	O
and	O
neurodegeneration	O
[	O
18	O
,	O
19	O
]	O
.	O

This	O
DA	B
neurotoxicity	O
is	O
believed	O
to	O
be	O
mediated	O
through	O
a	O
DA	B
-	O
oxidation	O
-	O
associated	O
pathway	O
.	O

DA	B
oxidative	O
stress	O
is	O
also	O
assumed	O
to	O
be	O
a	O
major	O
pathological	O
factor	O
that	O
contributes	O
to	O
dopaminergic	O
neuronal	O
degeneration	O
in	O
Parkinson	O
's	O
disease	O
[	O
14	O
]	O
.	O

We	O
have	O
recently	O
demonstrated	O
that	O
DA	B
induces	O
apoptosis	O
involving	O
the	O
oxidation	O
	O
JNK	O
	O
c	O
-	O
Jun	O
activation	O
pathway	O
in	O
in	O
vitro	O
cell	O
cultures	O
[	O
32	O
]	O
and	O
activation	O
of	O
transcription	O
factors	O
AP-1	O
and	O
NF	O
-	O
B	O
in	O
an	O
in	O
vivo	O
rat	O
model	O
[	O
29	O
]	O
.	O

Direct	O
intrastriatal	O
injections	O
of	O
high	O
concentrations	O
of	O
DA	B
in	O
rats	O
also	O
result	O
in	O
activation	O
of	O
astrocytes	O
as	O
indicated	O
by	O
an	O
increase	O
of	O
glial	O
fibrillary	O
acidic	O
protein	O
(	O
GFAP	O
)	O
immunocytochemical	O
staining	O
and	O
astrocyte	O
proliferation	O
determined	O
by	O
[	B
3	I
H	I
]	I
R05	I
-	I
4864	I
binding	O
to	O
peripheral	O
benzodiazepine	O
receptors	O
on	O
astrocytes	O
[	O
15	O
]	O
.	O

Astrocytes	O
are	O
the	O
intimate	O
partners	O
of	O
neurons	O
and	O
play	O
important	O
physiological	O
roles	O
in	O
the	O
maintenance	O
of	O
the	O
microenvironment	O
of	O
neurons	O
,	O
including	O
sequestration	O
and	O
metabolism	O
of	O
various	O
neurotransmitters	O
,	O
and	O
production	O
of	O
proinflammatory	O
and	O
immunomodulatory	O
cytokines	O
and	O
neuropeptides	B
[	O
50	O
]	O
.	O

In	O
the	O
rat	O
ischemic	O
model	O
,	O
activated	O
striatal	O
astrocytes	O
appear	O
to	O
play	O
a	O
protective	O
role	O
for	O
DA	O
-	O
innervated	O
neurons	O
[	O
51	O
]	O
.	O

In	O
a	O
cell	O
culture	O
system	O
,	O
striatal	O
astrocytes	O
were	O
also	O
shown	O
to	O
have	O
a	O
protective	O
effect	O
against	O
hydrogen	B
peroxide	I
toxicity	O
in	O
dopaminergic	O
neurons	O
[	O
24	O
]	O
.	O

Nevertheless	O
,	O
the	O
mechanism	O
by	O
which	O
DA	B
activates	O
astrocytes	O
is	O
unknown	O
.	O

To	O
investigate	O
potential	O
signaling	O
of	O
activation	O
of	O
astrocytes	O
by	O
DA	B
,	O
we	O
have	O
chosen	O
a	O
rat	O
C6	O
glioma	O
cell	O
line	O
stably	O
expressing	O
DA	O
D2L	O
receptors	O
based	O
on	O
the	O
following	O
reasons	O
.	O

(	O
1	O
)	O
C6	O
glioma	O
cells	O
have	O
been	O
widely	O
used	O
as	O
a	O
model	O
of	O
glial	O
phenotype	O
[	O
5	O
,	O
39	O
]	O
.	O

(	O
2	O
)	O
Recent	O
evidence	O
suggests	O
that	O
D2	O
receptors	O
are	O
expressed	O
in	O
striatal	O
astrocytes	O
.	O

Physiologically	O
,	O
DA	B
can	O
induce	O
membrane	O
hyperpolarization	O
in	O
the	O
majority	O
of	O
astrocytes	O
from	O
the	O
striatum	O
,	O
which	O
can	O
be	O
inhibited	O
by	O
application	O
of	O
domperidone	B
,	O
a	O
D2	O
receptor	O
antagonist	O
[	O
21	O
]	O
.	O

D2	O
antagonists	O
,	O
[	B
3	I
H	I
]	I
domperidone	I
and	O
[	B
3	I
H	I
]	I
spiperone	I
,	O
can	O
specifically	O
label	O
striatal	O
astrocytes	O
[	O
20	O
]	O
.	O

D2	O
receptor	O
mRNA	O
can	O
be	O
detected	O
by	O
either	O
in	O
situ	O
hybridization	O
or	O
polymerase	O
chain	O
reaction	O
from	O
astrocytes	O
in	O
striatum	O
,	O
an	O
area	O
enriched	O
with	O
dopaminergic	O
termini	O
,	O
but	O
not	O
astrocytes	O
in	O
cerebellum	O
,	O
which	O
receives	O
little	O
dopaminergic	O
innervation	O
[	O
4	O
]	O
.	O

This	O
region	O
-	O
specific	O
expression	O
of	O
D2	O
receptors	O
suggests	O
that	O
dopaminergic	O
neurons	O
may	O
physiologically	O
influence	O
astrocyte	O
functions	O
.	O

(	O
3	O
)	O
C6-D2L	O
cells	O
stably	O
express	O
recombinant	O
D2L	O
DA	O
receptors	O
[	O
36	O
]	O
.	O

The	O
expression	O
level	O
of	O
D2	O
receptors	O
in	O
C6-D2L	O
cells	O
is	O
about	O
188	O
fmol	O
/	O
mg	O
protein	O
,	O
which	O
is	O
close	O
to	O
that	O
in	O
striatal	O
membranes	O
(	O
400	O
fmol	O
/	O
mg	O
protein	O
)	O
[	O
30	O
,	O
37	O
]	O
.	O

(	O
4	O
)	O
Like	O
native	O
neuronal	O
D2	O
receptors	O
,	O
the	O
binding	O
of	O
agonist	O
to	O
D2	O
receptors	O
in	O
the	O
C6-D2L	O
cells	O
is	O
functionally	O
coupled	O
to	O
pertussis	O
-	O
toxin	O
-	O
sensitive	O
G	O
proteins	O
,	O
resulting	O
in	O
inhibition	O
of	O
adenylate	O
cyclase	O
[	O
49	O
]	O
and	O
activation	O
of	O
both	O
extracellular	O
signal	O
-	O
regulated	O
kinases	O
(	O
ERKs	O
)	O
and	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
(	O
JNK	O
)	O
[	O
30	O
]	O
.	O

Given	O
the	O
fact	O
of	O
C6	O
glial	O
phenotype	O
and	O
D2	O
receptors	O
in	O
striatal	O
astrocytes	O
,	O
the	O
biological	O
functions	O
stimulated	O
by	O
D2	O
receptors	O
observed	O
in	O
C6-D2L	O
cells	O
may	O
mimic	O
those	O
produced	O
in	O
vivo	O
.	O

Thus	O
,	O
this	O
C6-D2L	O
cell	O
line	O
may	O
serve	O
as	O
a	O
good	O
in	O
vitro	O
cell	O
culture	O
model	O
for	O
studies	O
of	O
DA	B
regulation	O
of	O
glial	O
response	O
.	O

Using	O
this	O
C6-D2L	O
cell	O
line	O
,	O
we	O
have	O
previously	O
reported	O
that	O
nanomolar	O
levels	O
of	O
DA	B
stimulate	O
cell	O
proliferation	O
through	O
activation	O
of	O
both	O
ERKs	O
and	O
JNK	O
[	O
30	O
]	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
found	O
that	O
high	O
concentrations	O
(	O
micromolar	O
levels	O
)	O
of	O
DA	B
stimulate	O
a	O
delayed	O
mitogenesis	O
compared	O
to	O
that	O
induced	O
by	O
the	O
nanomolar	O
levels	O
of	O
DA	B
.	O

This	O
DA	B
-	O
stimulated	O
mitogenesis	O
requires	O
D2-receptor	O
-	O
mediated	O
intracellular	O
redox	O
	O
tyrosine	O
kinase	O
cascade	O
,	O
but	O
does	O
not	O
need	O
ERK	O
activation	O
.	O

In	O
addition	O
,	O
micromolar	O
levels	O
of	O
DA	B
also	O
increase	O
GFAP	O
expression	O
,	O
which	O
is	O
linked	O
to	O
a	O
D2-receptor	O
-	O
independent	O
p38	O
MAPK	O
activation	O
.	O

2	O
Materials	O
and	O
methods	O
2.1	O
Materials	O
Antibodies	O
against	O
phosphorylated	B
tyrosine	I
(	O
PY99	B
)	O
and	O
ERK2	O
were	O
purchased	O
from	O
Santa	O
Cruz	O
Biotechnology	O
(	O
Santa	O
Cruz	O
,	O
CA	O
)	O
.	O

Antibodies	O
against	O
phospho	O
-	O
specific	O
ERK	O
and	O
phospho	O
-	O
specific	O
p38	O
MAPK	O
were	O
from	O
New	O
England	O
Biolabs	O
(	O
Beverly	O
,	O
MA	O
)	O
.	O

DA	B
,	O
(	B
+	I
)	I
-	I
and	O
(	B
	I
)	I
-butaclamol	I
hydrochloride	I
,	O
and	O
(	B
	I
)	I
-quinpirole	I
hydrochloride	I
were	O
from	O
Research	O
Biochemicals	O
International	O
(	O
Natick	O
,	O
MA	O
)	O
.	O

PD098059	B
,	O
p38	O
inhibitor	O
SB	B
203580	I
,	O
diphenyleneiodonium	B
chloride	I
(	O
DPI	B
)	O
,	O
Herbimycin	B
A	I
,	O
Wortmannin	B
,	O
H7	B
,	O
and	O
staurosporine	B
were	O
from	O
Calbiochem	O
(	O
San	O
Diego	O
,	O
CA	O
)	O
.	O

Pertussis	O
toxin	O
(	O
PTX	O
)	O
and	O
N	B
-acetyl	I
-	I
l	I
-cysteine	I
(	O
NAC	B
)	O
were	O
from	O
Sigma	O
(	O
St.	O
Louis	O
,	O
MO	O
)	O
.	O

[	B
3	I
H	I
]	I
Thymidine	I
was	O
purchased	O
form	O
Amersham	O
(	O
Arlington	O
Heights	O
,	O
IL	O
)	O
.	O

Genistein	B
was	O
from	O
Gibco	O
BRL	O
(	O
Gaithersburg	O
,	O
MD	O
)	O
.	O

Hoechst	B
33342	I
was	O
from	O
Molecular	O
Probes	O
(	O
Eugene	O
,	O
OR	O
)	O
.	O

2.2	O
Cell	O
culture	O
and	O
treatments	O
Stably	O
transfected	O
C6-D2L	O
cells	O
were	O
prepared	O
as	O
described	O
[	O
46	O
]	O
and	O
maintained	O
in	O
Dulbecco	B
's	I
modified	I
Eagle	I
's	I
medium	I
(	O
DMEM	B
)	O
supplemented	O
with	O
5	O
%	O
fetal	O
bovine	O
serum	O
and	O
5	O
%	O
donor	O
calf	O
serum	O
with	O
penicillin	B
/	O
streptomycin	B
and	O
puromycin	B
(	O
2	O
g	O
/	O
ml	O
)	O
.	O

The	O
wild	O
-	O
type	O
C6	O
cells	O
were	O
maintained	O
in	O
the	O
above	O
medium	O
without	O
puromycin	B
.	O

For	O
tyrosine	B
phosphorylation	O
and	O
GFAP	O
studies	O
,	O
the	O
cells	O
were	O
starved	O
with	O
serum	O
-	O
free	O
medium	O
containing	O
0.025	O
%	O
ascorbic	B
acid	I
for	O
68	O
h	O
and	O
then	O
stimulated	O
with	O
indicated	O
reagents	O
.	O

All	O
reagents	O
were	O
prepared	O
or	O
diluted	O
with	O
DMEM	B
plus	O
0.025	O
%	O
ascorbic	B
acid	I
.	O

For	O
inhibitory	O
experiments	O
,	O
all	O
inhibitory	O
reagents	O
except	O
PTX	O
were	O
added	O
0.5	O
h	O
(	O
PTX	O
for	O
6	O
h	O
)	O
prior	O
to	O
stimulation	O
with	O
DA	B
.	O

2.3	O
Lysate	O
preparation	O
After	O
stimulation	O
,	O
the	O
cells	O
were	O
immediately	O
washed	O
twice	O
using	O
cold	O
PBS	B
and	O
then	O
solubilized	O
with	O
ice	O
-	O
cold	O
buffer	O
consisting	O
of	O
25	O
mM	O
Hepes	B
,	O
pH	O
7.5	O
,	O
300	O
mM	O
NaCl	B
,	O
1.5	O
mM	O
MgCl2	B
,	O
0.2	O
mM	O
EDTA	B
,	O
0.1	O
%	O
Triton	B
X-100	I
,	O
20	O
mM	O
	B
-	I
glycerophosphate	I
,	O
0.1	O
mM	O
sodium	B
orthovanadate	I
,	O
0.5	O
mM	O
DTT	B
,	O
100	O
g	O
/	O
ml	O
PMSF	B
,	O
and	O
2	O
g	O
/	O
ml	O
leupeptin	B
.	O

Cellular	O
extracts	O
were	O
cleared	O
by	O
centrifugation	O
for	O
30	O
min	O
at	O
14,000	O
rpm	O
at	O
4	O
	O
C	O
.	O

The	O
supernatants	O
were	O
saved	O
and	O
the	O
protein	O
concentration	O
was	O
determined	O
using	O
Bio	B
-	I
Rad	I
protein	I
reagent	I
.	O

For	O
determination	O
of	O
GFAP	O
,	O
the	O
cell	O
lysates	O
were	O
prepared	O
as	O
follows	O
.	O

Stimulated	O
cells	O
were	O
scraped	O
and	O
collected	O
by	O
centrifugation	O
for	O
5	O
min	O
at	O
3000	O
rpm	O
.	O

The	O
cell	O
pellets	O
were	O
washed	O
once	O
with	O
cold	O
PBS	B
,	O
pH	O
7.4	O
,	O
solubilized	O
with	O
hot	O
lysis	O
buffer	O
(	O
8090	O
	O
C	O
)	O
containing	O
10	O
mM	O
Tris	B
	I
HCl	I
,	O
pH	O
7.6	O
,	O
150	O
mM	O
NaCl	B
,	O
0.5	O
mm	O
EDTA	B
,	O
1	O
mM	O
EGTA	B
,	O
1	O
%	O
sodium	B
dodecyl	I
sulfate	I
(	O
SDS	B
)	O
,	O
1	O
mM	O
sodium	O
orthovanadate	O
,	O
1	O
mM	O
PMSF	B
,	O
1	O
g	O
/	O
ml	O
pepstatin	B
A	I
,	O
and	O
2	O
g	O
/	O
ml	O
aprotinin	O
,	O
and	O
heated	O
for	O
20	O
min	O
at	O
90	O
	O
C	O
.	O

The	O
protein	O
concentration	O
of	O
the	O
lysates	O
was	O
determined	O
by	O
using	O
Micro	B
BCA	I
(	O
Pierce	O
,	O
Rockford	O
,	O
IL	O
)	O
.	O

All	O
lysates	O
were	O
used	O
immediately	O
or	O
aliquoted	O
and	O
stored	O
at	O
70	O
	O
C	O
for	O
further	O
use	O
.	O

2.4	O
Immunoblotting	O
Equal	O
amounts	O
of	O
lysate	O
protein	O
(	O
40	O
g	O
/	O
lane	O
)	O
were	O
run	O
on	O
816	O
%	O
SDS	O
-	O
PAGE	O
and	O
electrophoretically	O
transferred	O
to	O
nitrocellulose	B
.	O

The	O
nitrocellulose	B
blot	O
was	O
blocked	O
with	O
10	O
%	O
non	O
-	O
fat	O
dry	O
milk	O
in	O
TBST	B
buffer	I
(	O
20	O
mM	O
Tris	B
	I
HCl	I
,	O
pH	O
7.4	O
,	O
500	O
mM	O
NaCl	B
,	O
and	O
0.01	O
%	O
Tween-20	B
)	O
and	O
then	O
incubated	O
with	O
primary	O
antibodies	O
(	O
phospho	O
-	O
specific	O
ERK	O
,	O
ERK2	O
,	O
phospho	O
-	O
specific	O
p38	O
MAPK	O
,	O
or	O
PY99	O
,	O
1:1000	O
)	O
in	O
TBST	B
containing	O
5	O
%	O
BSA	O
overnight	O
at	O
4	O
	O
C	O
.	O

The	O
immunoreactive	O
bands	O
were	O
detected	O
by	O
sequential	O
incubation	O
with	O
horseradish	O
-	O
peroxidase	O
-	O
conjugated	O
secondary	O
antibody	O
(	O
1:5000	O
,	O
Jackson	O
ImmunoResearch	O
Laboratories	O
,	O
West	O
Grove	O
,	O
PA	O
)	O
and	O
Renaissance	O
substrate	O
(	O
DuPont	O
;	O
Boston	O
,	O
MA	O
)	O
.	O

For	O
control	O
of	O
protein	O
loading	O
,	O
immunoblotting	O
with	O
ERK2	O
was	O
performed	O
using	O
either	O
a	O
sister	O
gel	O
or	O
a	O
stripped	O
blot	O
.	O

For	O
quantitative	O
studies	O
,	O
the	O
band	O
was	O
quantified	O
with	O
the	O
NIH	O
Image	O
1.55	O
Program	O
.	O

The	O
results	O
were	O
normalized	O
to	O
fold	O
of	O
control	O
and	O
presented	O
as	O
meansS.E.M.	O
2.5	O
Measurement	O
of	O
mitogenesis	O
The	O
procedures	O
were	O
described	O
elsewhere	O
[	O
31	O
]	O
.	O

C6-D2L	O
cells	O
(	O
1	O
	O
105	O
/ml	O
,	O
0.2	O
ml	O
/	O
well	O
)	O
were	O
plated	O
in	O
a	O
96-well	O
plate	O
and	O
grown	O
for	O
24	O
h.	O
The	O
cells	O
were	O
rinsed	O
twice	O
with	O
serum	O
-	O
free	O
DMEM	B
and	O
starved	O
for	O
8	O
h	O
in	O
serum	O
-	O
free	O
medium	O
containing	O
0.025	O
%	O
ascorbic	B
acid	I
.	O

After	O
that	O
,	O
the	O
cells	O
were	O
incubated	O
with	O
DA	B
for	O
23	O
h	O
and	O
pulsed	O
with	O
2	O
Ci	O
[	B
3	I
H	I
]	I
thymidine	I
per	O
well	O
for	O
an	O
additional	O
6	O
h.	O
The	O
cells	O
in	O
each	O
well	O
were	O
fixed	O
with	O
ice	O
-	O
cold	O
5	O
%	O
trichloroacetic	B
acid	I
,	O
washed	O
three	O
times	O
with	O
cold	O
STE	B
buffer	I
(	O
150	O
mM	O
NaCl	B
,	O
50	O
mM	O
Tris	B
	I
HCl	I
,	O
pH	O
7.2	O
,	O
1	O
mM	O
EDTA	B
)	O
,	O
and	O
solubilized	O
with	O
0.1	O
ml	O
of	O
a	O
mixture	O
of	O
0.1	O
%	O
SDS	B
and	O
0.01	O
N	O
NaOH	B
.	O

Incorporated	O
[	B
3	I
H	I
]	I
thymidine	I
was	O
counted	O
with	O
a	O
Beckman	O
liquid	O
scintillation	O
counter	O
and	O
expressed	O
as	O
counts	O
per	O
minute	O
per	O
well	O
(	O
cpm	O
/	O
well	O
)	O
.	O

2.6	O
Cell	O
cycle	O
analysis	O
by	O
flow	O
cytometry	O
Cell	O
cycle	O
analysis	O
was	O
performed	O
according	O
to	O
the	O
method	O
by	O
Chrest	O
et	O
al.	O
[	O
9	O
]	O
.	O

Briefly	O
,	O
C6-D2L	O
cells	O
were	O
plated	O
in	O
35	O
mm	O
dishes	O
,	O
and	O
seeded	O
overnight	O
.	O

The	O
cells	O
were	O
starved	O
for	O
8	O
h	O
by	O
replacing	O
the	O
mixture	O
of	O
DMEM	B
plus	O
0.025	O
%	O
ascorbic	B
acid	I
and	O
stimulated	O
for	O
29	O
h.	O
The	O
cells	O
were	O
then	O
collected	O
and	O
suspended	O
in	O
complete	O
cell	O
culture	O
medium	O
.	O

The	O
cells	O
(	O
1	O
	O
106	O
cells	O
/	O
ml	O
)	O
were	O
treated	O
with	O
1	O
M	O
Hoechst	B
33342	I
for	O
30	O
min	O
at	O
37	O
	O
C	O
.	O

Cells	O
were	O
analyzed	O
for	O
DNA	O
content	O
using	O
a	O
FACStarplus	O
flow	O
cytometer	O
(	O
Becton	O
Dickinson	O
Immunocytometry	O
System	O
,	O
San	O
Jose	O
,	O
CA	O
)	O
equipped	O
with	O
argon	B
and	O
krypton	B
lasers	O
.	O

Hoechst	B
33342	I
stained	O
cells	O
were	O
excited	O
with	O
350356	O
nm	O
wavelength	O
UV	O
light	O
from	O
the	O
krypton	B
laser	O
and	O
the	O
fluorescence	O
emission	O
was	O
collected	O
with	O
a	O
424-nm	O
filter	O
.	O

DNA	O
histograms	O
were	O
acquired	O
by	O
collecting	O
a	O
total	O
of	O
10,000	O
events	O
.	O

Cell	O
compartments	O
,	O
including	O
G1	O
,	O
S	O
,	O
and	O
G2	O
/M	O
phases	O
,	O
were	O
determined	O
using	O
the	O
Multicycle	O
software	O
(	O
Phoenix	O
Flow	O
Systems	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
.	O

3	O
Results	O
3.1	O
DA	B
stimulates	O
mitogenesis	O
We	O
have	O
previously	O
reported	O
that	O
nanomolar	O
levels	O
of	O
DA	B
stimulated	O
mitogenesis	O
in	O
C6-D2L	O
cells	O
[	O
30	O
]	O
.	O

The	O
maximal	O
[	B
3	I
H	I
]	I
thymidine	I
incorporation	O
into	O
DNA	O
occurs	O
at	O
17	O
h	O
after	O
exposure	O
to	O
100	O
nM	O
DA	B
concentration	O
.	O

We	O
extended	O
this	O
study	O
by	O
observing	O
the	O
cell	O
response	O
at	O
high	O
DA	B
concentrations	O
and	O
longer	O
exposure	O
.	O

Interestingly	O
,	O
micromolar	O
levels	O
of	O
DA	B
also	O
stimulate	O
DNA	O
synthesis	O
but	O
with	O
a	O
slower	O
time	O
course	O
(	O
about	O
29	O
h	O
after	O
DA	B
stimulation	O
,	O
data	O
not	O
shown	O
)	O
.	O

Under	O
these	O
conditions	O
,	O
DA	B
stimulated	O
[	B
3	I
H	I
]	I
thymidine	I
incorporation	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
(	O
Fig.	O
1	O
a	O
)	O
.	O

The	O
[	B
3	I
H	I
]	I
thymidine	I
incorporation	O
into	O
DNA	O
was	O
linearly	O
increased	O
from	O
0.1	O
to	O
500	O
M	O
DA	B
.	O

The	O
mitogenic	O
activity	O
at	O
500	O
M	O
DA	B
was	O
about	O
3.20.2	O
times	O
higher	O
than	O
that	O
of	O
control	O
group	O
.	O

This	O
DA	B
-	O
induced	O
mitogenesis	O
could	O
be	O
completely	O
inhibited	O
in	O
the	O
presence	O
of	O
aphidicoline	B
(	O
20	O
g	O
/	O
ml	O
,	O
data	O
not	O
shown	O
)	O
,	O
a	O
potent	O
DNA	O
polymerase	O
a	O
inhibitor	O
.	O

To	O
confirm	O
the	O
DA	B
mitogenic	O
activation	O
,	O
we	O
also	O
determined	O
the	O
cell	O
cycle	O
distribution	O
.	O

As	O
shown	O
in	O
Table	O
1	O
,	O
200	O
M	O
DA	B
increased	O
the	O
percentage	O
of	O
the	O
cells	O
in	O
S	O
phase	O
and	O
decreased	O
the	O
percentage	O
of	O
cells	O
in	O
G1	O
phase	O
,	O
suggesting	O
that	O
DA	B
promotes	O
progression	O
through	O
the	O
cell	O
cycle	O
.	O

Next	O
,	O
we	O
tested	O
whether	O
this	O
DA	B
-	O
stimulated	O
mitogenesis	O
requires	O
activation	O
of	O
D2	O
receptors	O
.	O

Pretreatment	O
of	O
the	O
C6-D2L	O
cells	O
with	O
10	O
M	O
(	B
+	I
)	I
-butaclamol	I
,	O
a	O
potent	O
D2	O
receptor	O
antagonist	O
,	O
completely	O
inhibited	O
DA	B
-	O
induced	O
DNA	O
[	B
3	I
H	I
]	I
thymidine	I
incorporation	O
,	O
while	O
10	O
M	O
(	B
	I
)	I
-butaclamol	I
,	O
an	O
inactive	O
form	O
of	O
(	B
+	I
)	I
-butaclamol	I
,	O
had	O
no	O
effect	O
on	O
the	O
DA	B
-	O
stimulated	O
mitogenesis	O
(	O
Fig.	O
1	O
b	O
)	O
.	O

To	O
confirm	O
these	O
results	O
,	O
we	O
determined	O
the	O
effect	O
of	O
quinpirole	B
,	O
a	O
specific	O
D2	O
receptor	O
agonist	O
,	O
on	O
cell	O
cycling	O
.	O

Like	O
the	O
effect	O
of	O
micromolar	O
levels	O
of	O
DA	B
,	O
micromolar	O
levels	O
of	O
quinpirole	B
promoted	O
cell	O
proliferation	O
.	O

Quinpirole	B
increased	O
the	O
percentage	O
of	O
cells	O
in	O
S	O
phase	O
and	O
decreased	O
the	O
percentage	O
in	O
G1	O
phase	O
(	O
Table	O
1	O
)	O
.	O

Furthermore	O
,	O
we	O
did	O
not	O
observe	O
any	O
mitogenic	O
effect	O
within	O
a	O
DA	B
concentration	O
range	O
of	O
0500	O
M	O
in	O
wild	O
-	O
type	O
C6	O
cells	O
without	O
expression	O
of	O
D2L	O
receptors	O
(	O
Fig.	O
1	O
a	O
)	O
.	O

Instead	O
,	O
[	B
3	I
H	I
]	I
thymidine	I
incorporation	O
into	O
DNA	O
of	O
wild	O
-	O
type	O
C6	O
cells	O
was	O
decreased	O
about	O
2026	O
%	O
at	O
DA	B
concentrations	O
from	O
10	O
to	O
500	O
M	O
(	O
Fig.	O
1	O
a	O
)	O
.	O

Pretreatment	O
of	O
the	O
C6-D2L	O
cells	O
with	O
100	O
ng	O
/	O
ml	O
PTX	O
,	O
a	O
G	O
protein	O
-	O
receptor	O
uncoupler	O
,	O
partially	O
blocked	O
DA	B
-	O
stimulated	O
[	B
3	I
H	I
]	I
thymidine	I
incorporation	O
into	O
DNA	O
(	O
Fig.	O
1	O
b	O
)	O
.	O

Thus	O
,	O
it	O
appears	O
that	O
this	O
DA	B
-	O
stimulated	O
mitogenesis	O
requires	O
DA	B
D2	O
receptor	O
activation	O
.	O

3.2	O
Effects	O
of	O
kinase	O
inhibitors	O
on	O
DA	B
-	O
induced	O
mitogenesis	O
In	O
order	O
to	O
examine	O
the	O
signaling	O
that	O
mediates	O
the	O
DA	B
-	O
stimulated	O
mitogenesis	O
,	O
we	O
first	O
tested	O
the	O
effect	O
of	O
DA	B
on	O
the	O
activity	O
of	O
ERK	O
,	O
a	O
protein	O
serine	O
kinase	O
that	O
is	O
linked	O
to	O
cell	O
proliferation	O
stimulated	O
by	O
growth	O
factors	O
,	O
cytokines	O
and	O
neurotransmitters	O
[	O
11	O
,	O
34	O
]	O
.	O

As	O
shown	O
in	O
the	O
phospho	O
-	O
specific	O
ERK	O
immunoblot	O
of	O
Fig.	O
2	O
a	O
,	O
DA	B
had	O
little	O
or	O
no	O
effect	O
on	O
ERK	O
phosphorylation	O
at	O
concentrations	O
corresponding	O
to	O
its	O
mitogenic	O
effect	O
(	O
10500	O
M	O
)	O
,	O
although	O
DA	B
at	O
lower	O
concentrations	O
did	O
stimulate	O
ERK	O
phosphorylation	O
and	O
activity	O
[	O
30	O
]	O
.	O

The	O
bottom	O
panel	O
in	O
Fig.	O
2	O
a	O
shows	O
ERK2	O
immunoblot	O
of	O
a	O
sister	O
gel	O
,	O
indicating	O
that	O
a	O
similar	O
amount	O
of	O
protein	O
was	O
loaded	O
.	O

To	O
confirm	O
that	O
ERK	O
was	O
not	O
involved	O
in	O
DA	B
-	O
induced	O
mitogenesis	O
,	O
we	O
also	O
examined	O
the	O
effect	O
of	O
PD098059	B
,	O
a	O
selective	O
MEK1	O
inhibitor	O
[	O
3	O
]	O
,	O
on	O
DA	B
-	O
induced	O
mitogenesis	O
.	O

As	O
shown	O
in	O
Fig.	O
2	O
b	O
,	O
the	O
DA	B
-	O
stimulated	O
DNA	O
synthesis	O
was	O
only	O
partially	O
inhibited	O
by	O
pretreatment	O
of	O
the	O
cells	O
with	O
PD	B
098059	I
(	O
1050	O
M	O
)	O
(	O
Fig.	O
2	O
b	O
)	O
.	O

With	O
application	O
of	O
either	O
10	O
or	O
50	O
M	O
PD	B
098059	I
,	O
bFGF	O
-	O
stimulated	O
ERK	O
activity	O
,	O
as	O
indicated	O
by	O
ERK	O
phosphorylation	O
,	O
was	O
greatly	O
or	O
completely	O
inhibited	O
,	O
respectively	O
(	O
Fig.	O
2	O
c	O
)	O
,	O
which	O
serves	O
as	O
a	O
positive	O
control	O
of	O
the	O
inhibitory	O
effect	O
of	O
PD098059	B
on	O
MEK1ERK	O
pathway	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
the	O
mitogenesis	O
induced	O
by	O
micromolar	O
levels	O
of	O
DA	B
is	O
not	O
mediated	O
by	O
a	O
MEK	O
	O
ERK	O
activation	O
pathway	O
.	O

We	O
have	O
also	O
tested	O
other	O
kinase	O
inhibitors	O
on	O
DA	B
-	O
stimulated	O
mitogenesis	O
.	O

These	O
inhibitors	O
included	O
Wortmannin	B
for	O
PI3	O
kinase	O
,	O
rapamycin	B
for	O
S6	O
kinase	O
,	O
and	O
SB203580	B
for	O
p38	O
MAP	O
kinase	O
.	O

Staurosporine	O
and	O
H7	O
are	O
inhibitors	O
for	O
a	O
broad	O
spectrum	O
of	O
protein	O
kinases	O
,	O
which	O
include	O
protein	O
kinase	O
A	O
,	O
protein	O
kinase	O
C	O
,	O
protein	O
kinase	O
G	O
,	O
CaM	O
kinase	O
,	O
and	O
myosin	O
light	O
chain	O
kinase	O
.	O

The	O
effect	O
of	O
depletion	O
of	O
PKC	O
on	O
DA	B
-	O
stimulated	O
[	B
3	I
H	I
]	I
thymidine	I
incorporation	O
into	O
DNA	O
was	O
also	O
examined	O
by	O
prolonged	O
treatment	O
of	O
the	O
cells	O
with	O
PMA	O
.	O

The	O
data	O
are	O
summarized	O
on	O
Table	O
2	O
.	O

All	O
these	O
treatments	O
had	O
no	O
effect	O
on	O
DA	B
-	O
induced	O
DNA	O
synthesis	O
.	O

3.3	O
DA	B
stimulates	O
mitogenesis	O
-	O
associated	O
protein	O
tyrosine	B
phosphorylation	O
DA	B
stimulated	O
protein	O
tyrosine	B
phosphorylation	O
in	O
a	O
time-	O
and	O
concentration	O
-	O
dependent	O
manner	O
(	O
Fig.	O
3	O
a	O
and	O
b	O
)	O
.	O

The	O
phosphorylated	B
tyrosine	I
-	O
containing	O
proteins	O
were	O
easily	O
immunodetected	O
with	O
monoclonal	O
anti	O
-	O
phosphotyrosine	O
IgG	O
(	O
PY99	O
)	O
.	O

When	O
C6-D2L	O
cells	O
were	O
treated	O
with	O
200	O
M	O
DA	B
,	O
protein	O
tyrosine	B
phosphorylation	O
rapidly	O
increased	O
within	O
5	O
min	O
,	O
reached	O
a	O
maximum	O
between	O
15	O
and	O
30	O
min	O
,	O
then	O
decreased	O
by	O
1	O
h	O
(	O
Fig.	O
3	O
a	O
)	O
.	O

A	O
majority	O
of	O
tyrosine	B
-	O
phosphorylated	O
proteins	O
were	O
located	O
within	O
the	O
molecular	O
size	O
range	O
of	O
50200	O
kDa	O
,	O
some	O
of	O
which	O
are	O
indicated	O
by	O
arrows	O
in	O
Fig.	O
3	O
a.	O
DA	B
-	O
stimulated	O
tyrosine	B
phosphorylation	O
was	O
evident	O
within	O
DA	B
concentrations	O
ranging	O
from	O
10	O
to	O
500	O
M	O
(	O
Fig.	O
3	O
b	O
)	O
,	O
which	O
paralleled	O
the	O
DA	B
concentrations	O
for	O
stimulation	O
of	O
mitogenesis	O
(	O
Fig.	O
1	O
a	O
)	O
.	O

To	O
monitor	O
the	O
amounts	O
of	O
protein	O
loaded	O
,	O
all	O
blots	O
were	O
stripped	O
and	O
then	O
immunoblotted	O
with	O
anti	O
-	O
ERK2	O
.	O

The	O
lower	O
anti	O
-	O
ERK2	O
immunoblottings	O
in	O
Fig.	O
3	O
a	O
and	O
b	O
show	O
that	O
a	O
similar	O
amount	O
of	O
protein	O
was	O
loaded	O
.	O

This	O
protein	O
tyrosine	B
phosphorylation	O
,	O
mostly	O
at	O
molecular	O
sizes	O
between	O
50	O
and	O
150	O
kDa	O
,	O
required	O
D2	O
receptor	O
activation	O
.	O

Preincubation	O
of	O
C6-D2L	O
cells	O
30	O
min	O
with	O
(	B
+	I
)	I
-butaclamol	I
,	O
a	O
specific	O
D2	O
receptor	O
antagonist	O
,	O
could	O
block	O
DA	B
-	O
induced	O
protein	O
tyrosine	B
phosphorylation	O
(	O
Fig.	O
3	O
c	O
)	O
.	O

This	O
antagonistic	O
effect	O
was	O
concentration	O
-	O
dependent	O
.	O

Increasing	O
(	B
+	I
)	I
-butaclamol	I
from	O
1	O
to	O
100	O
M	O
resulted	O
in	O
significant	O
inhibition	O
of	O
protein	O
tyrosine	B
phosphorylation	O
.	O

Especially	O
in	O
the	O
presence	O
of	O
100	O
M	O
(	B
+	I
)	I
-butaclamol	I
,	O
the	O
cells	O
failed	O
to	O
respond	O
to	O
200	O
M	O
DA	B
stimulation	O
(	O
upper	O
left	O
panel	O
,	O
Fig.	O
3	O
c	O
)	O
.	O

This	O
blocking	O
effect	O
was	O
specific	O
to	O
D2	O
receptors	O
since	O
application	O
of	O
the	O
same	O
amount	O
of	O
(	B
	I
)	I
-butaclamol	I
,	O
an	O
inactive	O
form	O
of	O
(	B
+	I
)	I
-butaclamol	I
,	O
did	O
not	O
show	O
any	O
effect	O
on	O
DA	B
-	O
stimulated	O
tyrosine	B
phosphorylation	O
.	O

We	O
have	O
also	O
directly	O
tested	O
the	O
effect	O
of	O
quinpirole	B
,	O
a	O
D2	O
receptor	O
agonist	O
,	O
on	O
protein	O
tyrosine	B
phosphorylation	O
.	O

As	O
shown	O
in	O
the	O
right	O
panel	O
of	O
Fig.	O
3	O
c	O
,	O
increasing	O
quinpirole	B
from	O
10	O
to	O
200	O
M	O
resulted	O
in	O
a	O
great	O
increase	O
in	O
the	O
amount	O
of	O
tyrosine	B
-	O
phosphorylated	O
proteins	O
.	O

Furthermore	O
,	O
we	O
could	O
not	O
observe	O
significant	O
changes	O
in	O
tyrosine	B
-	O
phosphorylated	O
proteins	O
in	O
wild	O
-	O
type	O
C6	O
cells	O
treated	O
with	O
DA	B
concentrations	O
from	O
10	O
to	O
500	O
M	O
(	O
data	O
not	O
shown	O
)	O
.	O

Inactivation	O
of	O
cellular	O
PTX	O
-	O
sensitive	O
G	O
proteins	O
by	O
PTX	O
partially	O
blocked	O
DA	B
-	O
induced	O
protein	O
tyrosine	B
phosphorylation	O
.	O

We	O
have	O
quantified	O
tyrosine	B
-	O
phosphorylated	O
proteins	O
between	O
50	O
and	O
150	O
kDa	O
by	O
using	O
the	O
NIH	O
Image	O
1.55	O
Program	O
.	O

Pretreatment	O
of	O
the	O
cells	O
with	O
500	O
ng	O
/	O
ml	O
PTX	O
inhibited	O
DA	B
(	O
200	O
M	O
)	O
-stimulated	O
tyrosine	B
phosphorylation	O
by	O
5715	O
%	O
(	O
n	O
=	O
3	O
)	O
.	O

PTX	O
at	O
a	O
concentration	O
of	O
100	O
ng	O
/	O
ml	O
also	O
reduced	O
the	O
tyrosine	B
-	O
phosphorylated	O
proteins	O
by	O
2413	O
%	O
(	O
n	O
=	O
3	O
)	O
.	O

Coincidentally	O
,	O
this	O
percentage	O
of	O
reduction	O
of	O
tyrosine	B
phosphorylation	O
by	O
100	O
ng	O
/	O
ml	O
PTX	O
is	O
close	O
to	O
its	O
inhibitory	O
ability	O
(	O
3210	O
%	O
,	O
n	O
=3	O
,	O
Fig.	O
1	O
b	O
)	O
to	O
DA	B
-	O
stimulated	O
mitogenesis	O
.	O

Thus	O
,	O
these	O
results	O
suggest	O
that	O
D2	O
receptor	O
activation	O
is	O
associated	O
with	O
protein	O
tyrosine	O
kinase	O
activity	O
.	O

In	O
order	O
to	O
test	O
the	O
idea	O
that	O
tyrosine	O
kinase	O
is	O
involved	O
in	O
DA	B
-	O
stimulated	O
mitogenesis	O
,	O
we	O
examined	O
the	O
effect	O
of	O
genistein	B
,	O
a	O
potent	O
tyrosine	O
kinase	O
inhibitor	O
,	O
on	O
DA	B
-	O
induced	O
tyrosine	B
phosphorylation	O
and	O
mitogenesis	O
.	O

As	O
shown	O
in	O
Fig.	O
4	O
a	O
,	O
preincubation	O
of	O
either	O
genistein	B
or	O
herbimycin	B
(	O
another	O
tyrosine	O
kinase	O
inhibitor	O
)	O
significantly	O
blocked	O
the	O
protein	O
tyrosine	B
phosphorylation	O
stimulated	O
by	O
200	O
M	O
DA	B
.	O

Application	O
of	O
10	O
M	O
genistein	B
completely	O
inhibited	O
the	O
DNA	O
synthesis	O
induced	O
by	O
DA	B
(	O
Fig.	O
4	O
b	O
)	O
.	O

These	O
observations	O
indicate	O
that	O
the	O
activation	O
of	O
protein	O
tyrosine	O
kinase	O
is	O
required	O
for	O
the	O
promotion	O
of	O
mitogenesis	O
induced	O
by	O
DA	B
.	O

3.4	O
DA	B
-	O
induced	O
mitogenesis	O
is	O
involved	O
in	O
an	O
intracellular	O
redox	O
	O
tyrosine	B
phosphorylation	O
pathway	O
Although	O
reactive	B
oxygen	I
species	I
(	O
ROS	B
)	O
are	O
implicated	O
in	O
pathological	O
cellular	O
processes	O
,	O
including	O
oxidative	O
stress	O
damage	O
[	O
47	O
]	O
and	O
ischemic	O
neuronal	O
injury	O
[	O
10	O
]	O
,	O
recent	O
evidence	O
suggests	O
that	O
ROS	B
are	O
involved	O
in	O
cell	O
signaling	O
that	O
regulates	O
proliferation	O
and	O
DNA	O
synthesis	O
[	O
22	O
]	O
.	O

To	O
test	O
the	O
idea	O
that	O
D2	O
receptors	O
stimulate	O
mitogenesis	O
through	O
regulation	O
of	O
an	O
intracellular	O
redox	O
	O
tyrosine	O
kinase	O
cascade	O
,	O
we	O
examined	O
the	O
effect	O
of	O
diphenylene	B
iodonium	I
(	O
DPI	B
)	O
and	O
N	B
-acetyl	I
cysteine	I
(	O
NAC	B
)	O
on	O
DA	B
-	O
induced	O
tyrosine	B
phosphorylation	O
and	O
mitogenesis	O
.	O

DPI	B
is	O
an	O
inhibitor	O
of	O
flavonoid	B
-	O
containing	O
oxidases	O
that	O
can	O
catalyze	O
the	O
formation	O
of	O
superoxide	B
from	O
oxygen	B
with	O
NADH	B
/	O
NADPH	B
as	O
an	O
electron	O
donor	O
[	O
28	O
,	O
43	O
]	O
.	O

Some	O
flavonoid	B
-	O
containing	O
oxidases	O
,	O
such	O
as	O
NADPH	B
-	O
dependent	O
oxidase	O
,	O
have	O
been	O
shown	O
to	O
be	O
regulated	O
by	O
a	O
variety	O
of	O
membrane	O
receptors	O
,	O
such	O
as	O
intrinsic	O
tyrosine	O
-	O
kinase	O
-	O
containing	O
receptors	O
and	O
G	O
-	O
protein	O
-	O
coupled	O
receptors	O
[	O
22	O
,	O
23	O
]	O
.	O

NAC	B
is	O
an	O
antioxidant	O
that	O
can	O
scavenge	O
free	B
radicals	I
.	O

Pretreatment	O
of	O
C6-D2L	O
cells	O
with	O
either	O
1	O
M	O
DPI	B
or	O
20	O
mM	O
NAC	B
greatly	O
reduced	O
tyrosine	B
phosphorylation	O
and	O
consequent	O
mitogenesis	O
induced	O
by	O
DA	B
(	O
Fig.	O
5	O
a	O
and	O
b	O
)	O
.	O

Either	O
DPI	B
or	O
NAC	B
itself	O
has	O
no	O
effect	O
on	O
tyrosine	B
phosphorylation	O
of	O
proteins	O
(	O
Fig.	O
5	O
)	O
.	O

The	O
anti	O
-	O
ERK2	O
immunoblotting	O
of	O
same	O
stripped	O
blot	O
shows	O
that	O
a	O
similar	O
amount	O
of	O
protein	O
was	O
loaded	O
in	O
each	O
lane	O
(	O
lower	O
panel	O
,	O
Fig.	O
5	O
a	O
)	O
.	O

Thus	O
,	O
these	O
results	O
suggest	O
that	O
the	O
protein	O
tyrosine	O
kinase	O
and	O
consequent	O
mitogenesis	O
may	O
be	O
regulated	O
by	O
intracellular	O
ROS	B
,	O
which	O
are	O
assumed	O
to	O
be	O
produced	O
by	O
flavonoid	B
-	O
containing	O
oxidases	O
.	O

Next	O
,	O
we	O
tested	O
the	O
roles	O
of	O
ROS	B
in	O
DA	B
-	O
induced	O
tyrosine	B
phosphorylation	O
and	O
mitogenesis	O
by	O
application	O
of	O
exogenous	O
H2	B
O2	I
.	O

We	O
assumed	O
that	O
the	O
protein	O
tyrosine	O
kinase	O
could	O
be	O
activated	O
by	O
DA	B
-	O
stimulated	O
increase	O
of	O
intracellular	O
ROS	B
.	O

If	O
this	O
is	O
the	O
case	O
,	O
exogenous	O
application	O
of	O
low	O
concentrations	O
of	O
H2	B
O2	I
may	O
enhance	O
protein	O
kinase	O
activity	O
and	O
subsequent	O
mitogenesis	O
induced	O
by	O
DA	B
.	O

As	O
shown	O
in	O
Fig.	O
6	O
a	O
,	O
increasing	O
extracellular	O
H2	B
O2	I
concentrations	O
did	O
result	O
in	O
increase	O
of	O
DA	B
-	O
induced	O
tyrosine	B
-	O
phosphorylated	O
proteins	O
.	O

The	O
upper	O
panel	O
shows	O
anti	O
-	O
phosphotyrosine	O
immunoblotting	O
,	O
while	O
the	O
lower	O
panel	O
is	O
a	O
quantified	O
data	O
(	O
from	O
50	O
to	O
150	O
kDa	O
)	O
of	O
at	O
least	O
three	O
experiments	O
using	O
the	O
NIH	O
Image	O
1.55	O
Program	O
.	O

The	O
sister	O
gel	O
was	O
run	O
and	O
immunostained	O
with	O
anti	O
-	O
ERK2	O
to	O
monitor	O
protein	O
loading	O
.	O

The	O
nanomolar	O
levels	O
of	O
H2	B
O2	I
enhanced	O
by	O
about	O
2.7-fold	O
amounts	O
of	O
tyrosine	B
-	O
phosphorylated	O
proteins	O
stimulated	O
by	O
10	O
M	O
DA	B
,	O
although	O
H2	B
O2	I
levels	O
below	O
1	O
nM	O
show	O
only	O
a	O
small	O
effect	O
(	O
Fig.	O
6	O
a	O
)	O
.	O

Furthermore	O
,	O
an	O
enhancement	O
effect	O
of	O
H2	B
O2	I
on	O
DA	B
-	O
stimulated	O
mitogenesis	O
was	O
also	O
observed	O
(	O
Fig.	O
6	O
b	O
)	O
.	O

However	O
,	O
the	O
capability	O
of	O
increasing	O
DA	B
-	O
induced	O
mitogenesis	O
at	O
nanomolar	O
levels	O
of	O
H2	B
O2	I
was	O
reduced	O
when	O
compared	O
with	O
that	O
at	O
0.1	O
pM	O
H2	B
O2	I
(	O
Fig.	O
6	O
b	O
)	O
.	O

This	O
may	O
be	O
due	O
to	O
a	O
dual	O
effect	O
of	O
ROS	O
in	O
cell	O
proliferation	O
:	O
a	O
stimulatory	O
effect	O
at	O
low	O
concentrations	O
and	O
a	O
toxic	O
effect	O
at	O
high	O
concentrations	O
[	O
22	O
]	O
.	O

With	O
the	O
application	O
of	O
H2	B
O2	I
alone	O
without	O
DA	B
,	O
C6-D2L	O
cells	O
did	O
exhibit	O
such	O
a	O
dual	O
mitogenic	O
effect	O
(	O
data	O
not	O
shown	O
)	O
.	O

3.5	O
DA	B
increases	O
GFAP	O
expression	O
In	O
addition	O
to	O
stimulating	O
DNA	O
synthesis	O
,	O
DA	B
at	O
micromolar	O
levels	O
also	O
significantly	O
increased	O
the	O
expression	O
of	O
GFAP	O
,	O
a	O
sensitive	O
parameter	O
serving	O
as	O
another	O
criterion	O
of	O
reactive	O
astrocytes	O
[	O
33	O
]	O
.	O

As	O
shown	O
in	O
Fig.	O
7	O
a	O
,	O
C6-D2L	O
cells	O
responded	O
to	O
DA	B
(	O
200	O
M	O
)	O
treatment	O
with	O
an	O
increase	O
in	O
GFAP	O
expression	O
in	O
a	O
time	O
-	O
dependent	O
manner	O
.	O

Between	O
0	O
and	O
48	O
h	O
after	O
stimulation	O
,	O
the	O
amount	O
of	O
GFAP	O
was	O
increased	O
about	O
2.10.1-fold	O
(	O
Fig.	O
7	O
a	O
)	O
.	O

Concentration	O
dependence	O
studies	O
carried	O
out	O
at	O
24	O
h	O
showed	O
that	O
maximal	O
stimulation	O
of	O
GFAP	O
expression	O
occurred	O
at	O
200	O
M	O
DA	B
(	O
Fig.	O
7	O
b	O
)	O
.	O

Interestingly	O
,	O
GFAP	O
production	O
was	O
decreased	O
when	O
the	O
cells	O
were	O
exposed	O
to	O
500	O
M	O
DA	B
for	O
24	O
h	O
(	O
Fig.	O
7	O
b	O
)	O
,	O
which	O
differs	O
from	O
the	O
dose	O
	O
response	O
data	O
of	O
DA	B
-	O
induced	O
mitogenesis	O
(	O
Fig.	O
1	O
)	O
.	O

This	O
observation	O
suggests	O
that	O
DA	B
stimulatory	O
GFAP	O
synthesis	O
may	O
be	O
regulated	O
by	O
a	O
different	O
pathway	O
from	O
mitogenesis	O
.	O

Alternatively	O
,	O
this	O
decrease	O
of	O
GFAP	O
expression	O
at	O
500	O
M	O
DA	B
may	O
be	O
due	O
to	O
widespread	O
mitogenesis	O
since	O
immature	O
astrocytes	O
have	O
a	O
less	O
amount	O
of	O
GFAP	O
expression	O
.	O

3.6	O
DA	B
-	O
induced	O
GFAP	O
generation	O
involves	O
activation	O
of	O
p38	O
MAPK	O
It	O
became	O
important	O
to	O
determine	O
whether	O
DA	B
-	O
stimulated	O
GFAP	O
production	O
might	O
also	O
be	O
required	O
to	O
activate	O
the	O
D2	O
receptor	O
	O
tyrosine	O
kinase	O
pathway	O
.	O

To	O
test	O
this	O
idea	O
,	O
we	O
used	O
a	O
paradigm	O
similar	O
to	O
that	O
for	O
DA	B
-	O
stimulated	O
mitogenesis	O
in	O
C6-D2L	O
cells	O
(	O
Fig.	O
1	O
)	O
.	O

Surprisingly	O
,	O
the	O
GFAP	O
stimulation	O
did	O
not	O
appear	O
to	O
be	O
regulated	O
by	O
D2	O
receptors	O
since	O
it	O
was	O
not	O
influenced	O
by	O
the	O
D2	O
receptor	O
antagonist	O
,	O
(	B
+	I
)	I
-butaclamol	I
(	O
Fig.	O
8	O
a	O
)	O
.	O

Application	O
of	O
DA	B
to	O
wild	O
-	O
type	O
C6	O
cells	O
also	O
resulted	O
in	O
a	O
similar	O
increase	O
in	O
GFAP	O
expression	O
as	O
that	O
in	O
C6-D2L	O
cells	O
(	O
data	O
not	O
shown	O
)	O
.	O

Moreover	O
,	O
direct	O
application	O
of	O
quinpirole	B
(	O
200	O
M	O
)	O
,	O
a	O
D2	O
receptor	O
agonist	O
,	O
had	O
no	O
effect	O
on	O
GFAP	O
expression	O
(	O
Fig.	O
8	O
a	O
)	O
.	O

Pretreatment	O
of	O
the	O
C6-D2L	O
cells	O
with	O
PTX	O
for	O
6	O
h	O
had	O
no	O
effect	O
on	O
DA	B
-	O
stimulated	O
GFAP	O
generation	O
(	O
Fig.	O
8	O
a	O
)	O
,	O
suggesting	O
that	O
PTX	O
-	O
sensitive	O
G	O
proteins	O
might	O
also	O
not	O
be	O
involved	O
.	O

Pretreatment	O
of	O
the	O
cells	O
with	O
either	O
10	O
M	O
genistein	B
or	O
20	O
mM	O
NAC	B
also	O
had	O
no	O
effect	O
on	O
GFAP	O
expression	O
due	O
to	O
DA	B
(	O
Fig.	O
8	O
a	O
)	O
,	O
while	O
the	O
identical	O
treatments	O
resulted	O
in	O
the	O
blocking	O
of	O
DA	B
-	O
induced	O
mitogenesis	O
(	O
Fig.	O
4	O
b	O
,	O
Fig.	O
5	O
b	O
)	O
.	O

PD098059	B
also	O
had	O
no	O
effect	O
on	O
DA	B
-	O
stimulated	O
GFAP	O
expression	O
(	O
Fig.	O
8	O
a	O
)	O
.	O

Thus	O
,	O
unlike	O
DA	B
-	O
induced	O
mitogenesis	O
,	O
GFAP	O
stimulation	O
does	O
not	O
seem	O
to	O
involve	O
the	O
D2	O
receptor	O
	O
tyrosine	O
kinase	O
pathway	O
.	O

However	O
,	O
we	O
have	O
found	O
that	O
GFAP	O
expression	O
stimulated	O
by	O
DA	B
could	O
be	O
inhibited	O
by	O
pretreatment	O
of	O
the	O
cells	O
with	O
SB203580	B
,	O
a	O
selective	O
p38	O
MAPK	O
inhibitor	O
[	O
13	O
,	O
27	O
]	O
.	O

As	O
shown	O
in	O
Fig.	O
8	O
b	O
,	O
application	O
of	O
10	O
M	O
SB	B
203580	I
completely	O
blocked	O
the	O
increases	O
in	O
GFAP	O
generation	O
stimulated	O
by	O
DA	B
at	O
concentrations	O
ranging	O
from	O
10	O
to	O
200	O
M	O
,	O
suggesting	O
that	O
activation	O
of	O
p38	O
MAPK	O
might	O
be	O
required	O
for	O
the	O
regulation	O
of	O
GFAP	O
generation	O
.	O

By	O
using	O
anti	O
-	O
phospho	O
-	O
specific	O
p38	O
MAPK	O
immunoblotting	O
,	O
we	O
examined	O
the	O
effect	O
of	O
DA	B
on	O
p38	O
MAPK	O
phosphorylation	O
,	O
a	O
requirement	O
for	O
p38	O
MAPK	O
activity	O
[	O
42	O
]	O
.	O

With	O
the	O
application	O
of	O
100	O
M	O
DA	B
to	O
C6-D2L	O
cells	O
,	O
p38	O
MAPK	O
was	O
rapidly	O
phosphorylated	O
within	O
5	O
min	O
,	O
reached	O
a	O
maximum	O
at	O
15	O
min	O
,	O
then	O
gradually	O
decreased	O
to	O
basal	O
level	O
by	O
about	O
1	O
h	O
(	O
Fig.	O
9	O
a	O
)	O
.	O

The	O
p38	O
MAPK	O
phosphorylation	O
was	O
greatly	O
increased	O
when	O
the	O
cells	O
were	O
exposed	O
to	O
DA	B
concentrations	O
ranging	O
from	O
10	O
to	O
200	O
M	O
for	O
15	O
min	O
(	O
Fig.	O
9	O
b	O
)	O
.	O

Pretreatment	O
of	O
the	O
cells	O
with	O
(	B
+	I
)	I
-butaclamol	I
had	O
no	O
effect	O
on	O
DA	B
-	O
stimulated	O
phosphorylation	O
of	O
p38	O
MAPK	O
(	O
Fig.	O
9	O
c	O
)	O
.	O

These	O
data	O
suggest	O
that	O
DA	B
-	O
activated	O
p38	O
MAPK	O
may	O
not	O
be	O
mediated	O
by	O
D2	O
receptors	O
.	O

4	O
Discussion	O
In	O
this	O
paper	O
,	O
we	O
report	O
that	O
micromolar	O
levels	O
of	O
DA	B
stimulate	O
mitogenesis	O
in	O
C6-D2L	O
cells	O
.	O

In	O
contrast	O
with	O
our	O
previous	O
report	O
for	O
earlier	O
mitogenesis	O
(	O
peaking	O
at	O
17	O
h	O
)	O
induced	O
by	O
nanomolar	O
levels	O
of	O
DA	B
[	O
30	O
]	O
,	O
this	O
mitogenesis	O
stimulated	O
by	O
micromolar	O
levels	O
of	O
DA	B
occurs	O
at	O
about	O
29	O
h.	O
Biochemically	O
,	O
the	O
earlier	O
phase	O
of	O
mitogenesis	O
requires	O
D2	O
receptor	O
	O
MAPK	O
signaling	O
,	O
while	O
the	O
later	O
phase	O
requires	O
the	O
D2-receptor	O
	O
tyrosine	O
kinase	O
pathway	O
.	O

Although	O
relationship	O
of	O
the	O
two	O
phases	O
of	O
DA	B
-	O
induced	O
mitogenesis	O
is	O
not	O
clear	O
,	O
the	O
different	O
signaling	O
mechanisms	O
suggest	O
that	O
they	O
are	O
not	O
likely	O
to	O
be	O
dependent	O
on	O
each	O
other	O
.	O

For	O
example	O
,	O
nanomolar	O
levels	O
of	O
DA	B
strongly	O
stimulate	O
MAPK	O
without	O
significant	O
protein	O
tyrosine	B
phosphorylation	O
and	O
the	O
mitogenesis	O
can	O
be	O
inhibited	O
by	O
blockers	O
of	O
MAPK	O
pathway	O
.	O

Micromolar	O
levels	O
of	O
DA	B
strongly	O
stimulate	O
protein	O
tyrosine	O
kinase	O
without	O
effect	O
on	O
MAPK	O
,	O
and	O
the	O
consequent	O
mitogenesis	O
can	O
be	O
blocked	O
by	O
tyrosine	B
kinase	I
inhibitors	I
but	O
not	O
by	O
blockers	O
of	O
the	O
MAPK	O
pathway	O
.	O

Under	O
normal	O
physiological	O
conditions	O
,	O
striatal	O
astrocytes	O
surround	O
dopaminergic	O
neurons	O
.	O

Although	O
the	O
astrocytes	O
do	O
not	O
have	O
synaptic	O
contact	O
with	O
dopaminergic	O
neurons	O
,	O
D2	O
receptors	O
in	O
astrocytes	O
may	O
sense	O
DA	B
(	O
low	O
concentrations	O
)	O
that	O
might	O
escape	O
from	O
the	O
synapse	O
and	O
play	O
a	O
physiological	O
role	O
via	O
the	O
MAPK	O
pathway	O
.	O

In	O
pathologic	O
conditions	O
,	O
such	O
as	O
ischemia	O
,	O
hypoxia	O
and	O
excitatory	B
amino	I
acid	I
-	O
induced	O
neurotoxicity	O
,	O
the	O
extracellular	O
DA	B
concentration	O
in	O
striata	O
is	O
significantly	O
increased	O
to	O
micromolar	O
levels	O
[	O
2	O
,	O
6	O
,	O
45	O
]	O
.	O

Although	O
the	O
length	O
of	O
DA	B
exposure	O
in	O
our	O
cell	O
culture	O
was	O
relatively	O
long	O
,	O
the	O
signaling	O
responses	O
,	O
such	O
as	O
protein	O
tyrosine	B
phosphorylation	O
and	O
p38	O
MAPK	O
phosphorylation	O
,	O
were	O
rapid	O
,	O
within	O
a	O
few	O
minutes	O
(	O
Fig.	O
3	O
a	O
,	O
Fig.	O
9	O
a	O
)	O
.	O

Thus	O
,	O
the	O
micromolar	O
level	O
DA	B
-	O
induced	O
activation	O
of	O
astrocytes	O
may	O
be	O
implicated	O
in	O
these	O
pathologic	O
conditions	O
.	O

Our	O
results	O
suggest	O
that	O
micromolar	O
levels	O
of	O
DA	B
activate	O
C6-D2L	O
cells	O
through	O
an	O
interaction	O
with	O
receptors	O
.	O

This	O
is	O
evident	O
since	O
DA	B
-	O
stimulated	O
mitogenesis	O
can	O
be	O
blocked	O
by	O
(	B
+	I
)	I
-butaclamol	I
,	O
a	O
selective	O
D2	O
DA	B
receptor	O
antagonist	O
,	O
with	O
no	O
effect	O
of	O
(	B
	I
)	I
-butaclamol	I
,	O
an	O
inactive	O
isoform	O
of	O
(	B
+	I
)	I
-butaclamol	I
.	O

Quinpirole	B
,	O
a	O
specific	O
D2	O
receptor	O
agonist	O
,	O
also	O
promotes	O
cell	O
cycle	O
progression	O
.	O

Furthermore	O
,	O
wild	O
-	O
type	O
C6	O
cells	O
,	O
lacking	O
the	O
expression	O
of	O
D2	O
receptors	O
,	O
exhibit	O
no	O
mitogenic	O
response	O
to	O
stimulation	O
by	O
DA	B
.	O

This	O
also	O
ruled	O
out	O
the	O
possibility	O
that	O
the	O
mitogenesis	O
might	O
be	O
mediated	O
by	O
ROS	B
produced	O
by	O
DA	B
autoxidation	O
.	O

However	O
,	O
considering	O
the	O
fact	O
that	O
C6	O
cells	O
contain	O
other	O
monoamine	B
receptors	O
,	O
such	O
as	O
	O
adrenergic	O
receptors	O
[	O
35	O
]	O
,	O
we	O
can	O
not	O
exclude	O
the	O
possibility	O
that	O
micromolar	O
levels	O
of	O
DA	B
may	O
also	O
non	O
-	O
specifically	O
stimulate	O
these	O
receptors	O
and	O
may	O
cooperate	O
with	O
DA	B
receptors	O
.	O

A	O
receptor	O
-	O
mediated	O
mechanism	O
may	O
also	O
be	O
involved	O
in	O
GFAP	O
upregulation	O
stimulated	O
by	O
DA	B
since	O
GFAP	O
synthesis	O
could	O
not	O
be	O
prevented	O
by	O
preincubation	O
with	O
20	O
mM	O
NAC	B
,	O
which	O
can	O
scavenge	O
ROS	B
generated	O
either	O
by	O
DA	B
oxidation	O
or	O
through	O
a	O
D2-receptor	O
-	O
mediated	O
redox	O
system	O
.	O

Although	O
the	O
type	O
of	O
receptor	O
involved	O
in	O
DA	B
-	O
stimulated	O
GFAP	O
expression	O
is	O
currently	O
unknown	O
,	O
it	O
would	O
appear	O
not	O
to	O
be	O
D2	O
receptors	O
since	O
both	O
wild	O
-	O
type	O
C6	O
and	O
C6-D2L	O
cells	O
gave	O
a	O
similar	O
GFAP	O
regulatory	O
response	O
to	O
DA	B
stimulation	O
.	O

One	O
potential	O
candidate	O
would	O
be	O
	O
adrenergic	O
receptors	O
,	O
shown	O
to	O
stimulate	O
GFAP	O
expression	O
through	O
cAMP	O
[	O
44	O
]	O
.	O

High	O
-	O
concentration	O
DA	B
-	O
stimulated	O
mitogenesis	O
appears	O
to	O
involve	O
the	O
intracellular	O
production	O
of	O
ROS	B
as	O
supported	O
by	O
the	O
following	O
evidence	O
.	O

First	O
,	O
DA	B
-	O
stimulated	O
mitogenesis	O
can	O
be	O
inhibited	O
by	O
DPI	B
.	O

DPI	B
has	O
been	O
demonstrated	O
to	O
be	O
a	O
potent	O
and	O
selective	O
inhibitor	O
for	O
membrane	O
-	O
bound	O
NADPH	B
-	O
dependent	O
oxidase	O
through	O
a	O
binding	O
to	O
the	O
flavoprotein	O
component	O
of	O
the	O
oxidase	O
[	O
12	O
,	O
28	O
,	O
43	O
]	O
.	O

This	O
intracellular	O
NADPH	B
-	O
dependent	O
oxidase	O
can	O
directly	O
catalyze	O
substrate	B
oxygen	I
conversion	O
to	O
the	O
superoxide	B
anion	I
,	O
which	O
can	O
in	O
turn	O
generate	O
other	O
reactive	B
oxygen	I
intermediates	I
.	O

Secondly	O
,	O
DA	B
-	O
induced	O
mitogenesis	O
is	O
prevented	O
by	O
the	O
membrane	O
-	O
permeable	O
antioxidant	O
,	O
NAC	B
.	O

Finally	O
,	O
application	O
of	O
very	O
low	O
concentrations	O
of	O
H2	B
O2	I
can	O
enhance	O
both	O
DA	B
-	O
induced	O
protein	O
tyrosine	B
phosphorylation	O
and	O
mitogenesis	O
.	O

These	O
observations	O
suggest	O
that	O
ROS	B
may	O
serve	O
as	O
a	O
second	O
messenger	O
in	O
the	O
signaling	O
of	O
DA	B
-	O
stimulated	O
mitogenesis	O
,	O
adding	O
evidence	O
in	O
support	O
of	O
the	O
recent	O
notion	O
that	O
ROS	B
act	O
as	O
intracellular	O
messengers	O
of	O
cell	O
proliferation	O
[	O
22	O
]	O
.	O

Like	O
other	O
astrocyte	O
mitogens	B
,	O
such	O
as	O
endothelin	B
[	O
7	O
,	O
26	O
]	O
,	O
micromolar	O
level	O
DA	B
-	O
induced	O
mitogenesis	O
requires	O
tyrosine	B
phosphorylation	O
.	O

Application	O
of	O
DA	B
to	O
C6-D2L	O
cells	O
rapidly	O
increases	O
protein	O
tyrosine	B
phosphorylation	O
.	O

Concentration	O
-	O
dependent	O
tyrosine	B
phosphorylation	O
studies	O
show	O
a	O
similar	O
profile	O
to	O
that	O
of	O
DA	B
-	O
induced	O
DNA	O
synthesis	O
.	O

Both	O
protein	O
tyrosine	B
phosphorylation	O
and	O
mitogenesis	O
can	O
be	O
effectively	O
blocked	O
by	O
preincubation	O
of	O
the	O
cells	O
with	O
genistein	B
,	O
a	O
potent	O
protein	O
tyrosine	O
kinase	O
inhibitor	O
[	O
1	O
]	O
.	O

However	O
,	O
unlike	O
for	O
the	O
mitogen	B
endothelin	B
,	O
DA	B
-	O
stimulated	O
mitogenesis	O
is	O
not	O
linked	O
to	O
the	O
tyrosine	O
kinase	O
	O
ERK	O
pathway	O
since	O
DA	B
at	O
micromolar	O
levels	O
has	O
no	O
stimulatory	O
effect	O
on	O
ERK	O
activation	O
.	O

Furthermore	O
,	O
PD098095	B
,	O
the	O
MEK1	O
inhibitor	O
,	O
has	O
little	O
,	O
if	O
any	O
,	O
effect	O
on	O
high	O
concentration	O
of	O
DA	B
-	O
induced	O
mitogenesis	O
although	O
it	O
does	O
have	O
some	O
inhibitory	O
effects	O
on	O
basal	O
DNA	O
synthesis	O
.	O

DA	B
-	O
stimulated	O
mitogenesis	O
at	O
micromolar	O
levels	O
is	O
partially	O
mediated	O
by	O
PTX	O
-	O
sensitive	O
G	O
proteins	O
.	O

This	O
is	O
supported	O
by	O
the	O
following	O
evidence	O
.	O

(	O
1	O
)	O
Pretreatment	O
of	O
the	O
cells	O
with	O
100	O
ng	O
/	O
ml	O
PTX	O
only	O
inhibits	O
DA	B
-	O
stimulated	O
mitogenesis	O
by	O
about	O
2450	O
%	O
,	O
depending	O
on	O
concentrations	O
of	O
DA	B
(	O
Fig.	O
1	O
b	O
)	O
.	O

(	O
2	O
)	O
Application	O
of	O
PTX	O
,	O
even	O
in	O
a	O
very	O
high	O
concentration	O
(	O
500	O
ng	O
/	O
ml	O
)	O
,	O
only	O
partially	O
blocks	O
DA	B
-	O
induced	O
tyrosine	B
phosphorylation	O
.	O

(	O
3	O
)	O
The	O
ability	O
of	O
PTX	O
to	O
inhibit	O
protein	O
tyrosine	B
phosphorylation	O
is	O
correlated	O
with	O
that	O
to	O
inhibit	O
DA	B
-	O
induced	O
mitogenesis	O
(	O
Fig.	O
1	O
b	O
)	O
.	O

These	O
observations	O
raise	O
the	O
possibility	O
that	O
PTX	O
-	O
resistant	O
G	O
proteins	O
may	O
participate	O
in	O
the	O
signaling	O
of	O
high	O
concentration	O
of	O
DA	B
-	O
induced	O
mitogenesis	O
,	O
although	O
further	O
studies	O
are	O
required	O
.	O

Some	O
literature	O
reports	O
suggest	O
that	O
receptors	O
coupled	O
to	O
PTX	O
-	O
insensitive	O
G	O
proteins	O
or	O
the	O
small	O
G	O
protein	O
Ras	O
can	O
regulate	O
cell	O
proliferation	O
.	O

For	O
example	O
,	O
thrombin	O
,	O
an	O
astrocytic	O
mitogen	O
,	O
has	O
been	O
shown	O
to	O
stimulate	O
DNA	O
synthesis	O
in	O
1321N1	O
astrocytoma	O
cells	O
through	O
coupling	O
with	O
G12	O
,	O
a	O
Gq	O
subtype	O
of	O
GTP	O
binding	O
proteins	O
[	O
41	O
]	O
.	O

Recently	O
,	O
D2	O
receptors	O
were	O
also	O
reported	O
to	O
stimulate	O
prolactin	O
release	O
via	O
coupling	O
of	O
a	O
PTX	O
-	O
insensitive	O
G	O
protein	O
pathway	O
[	O
8	O
]	O
.	O

Whether	O
or	O
not	O
D2	O
receptors	O
might	O
be	O
coupled	O
to	O
PTX	O
-	O
insensitive	O
G	O
proteins	O
or	O
Ras	O
small	O
G	O
proteins	O
in	O
response	O
to	O
high	O
concentrations	O
of	O
DA	B
needs	O
further	O
study	O
.	O

Our	O
data	O
suggest	O
that	O
activation	O
of	O
p38	O
MAPK	O
is	O
required	O
for	O
upregulation	O
of	O
GFAP	O
synthesis	O
following	O
high	O
concentrations	O
of	O
DA	B
stimulation	O
.	O

This	O
is	O
based	O
on	O
the	O
following	O
observations	O
.	O

(	O
1	O
)	O
Micromolar	O
level	O
DA	B
-	O
stimulated	O
GFAP	O
production	O
can	O
be	O
completely	O
inhibited	O
by	O
pretreatment	O
of	O
the	O
cells	O
with	O
SB203580	B
,	O
a	O
highly	O
selective	O
inhibitor	O
of	O
p38	O
MAPK	O
[	O
13	O
,	O
27	O
]	O
.	O

Inhibition	O
of	O
a	O
parallel	O
MAPK	O
pathway	O
by	O
PD098059	B
has	O
no	O
effect	O
on	O
DA	B
-	O
induced	O
GFAP	O
expression	O
,	O
suggesting	O
that	O
a	O
relative	O
specificity	O
of	O
p38	O
MAPK	O
may	O
play	O
a	O
role	O
in	O
GFAP	O
generation	O
.	O

(	O
2	O
)	O
DA	B
activates	O
p38	O
MAPK	O
activity	O
at	O
concentrations	O
similar	O
to	O
those	O
of	O
DA	B
-	O
induced	O
GFAP	O
expression	O
.	O

(	O
3	O
)	O
Both	O
activation	O
of	O
p38	O
MAPK	O
and	O
GFAP	O
synthesis	O
are	O
not	O
regulated	O
by	O
D2	O
receptors	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
regarding	O
the	O
regulation	O
of	O
GFAP	O
by	O
p38	O
MAPK	O
.	O

In	O
C6	O
cells	O
,	O
an	O
increase	O
in	O
intracellular	O
cAMP	B
,	O
either	O
by	O
stimulation	O
of	O
	O
-	O
adrenergic	O
receptors	O
[	O
44	O
]	O
or	O
by	O
stimulation	O
of	O
adenylate	O
cyclase	O
by	O
forskolin	B
[	O
44	O
]	O
,	O
is	O
capable	O
of	O
stimulating	O
GFAP	O
.	O

The	O
relationship	O
of	O
cAMP	B
to	O
p38	O
MAPK	O
deserves	O
further	O
investigation	O
.	O

In	O
our	O
cell	O
culture	O
studies	O
,	O
at	O
least	O
two	O
pathways	O
have	O
been	O
demonstrated	O
to	O
activate	O
C6-D2L	O
glioma	O
cells	O
.	O

One	O
is	O
the	O
D2-receptor	O
-	O
required	O
intracellular	O
redox	O
	O
protein	O
tyrosine	O
kinase	O
pathway	O
,	O
which	O
is	O
involved	O
in	O
stimulation	O
of	O
cell	O
mitogenesis	O
.	O

Another	O
is	O
the	O
D2	O
receptor	O
-	O
independent	O
p38	O
MAPK	O
cascade	O
,	O
which	O
is	O
involved	O
in	O
stimulation	O
of	O
GFAP	O
synthesis	O
.	O

Interestingly	O
,	O
in	O
an	O
in	O
vivo	O
rat	O
model	O
,	O
reactive	O
astrocytes	O
in	O
the	O
brain	O
respond	O
differently	O
to	O
brain	O
injury	O
.	O

Some	O
astrocytes	O
undergo	O
proliferation	O
as	O
indicated	O
only	O
by	O
[	B
3	I
H	I
]	I
thymidine	I
incorporation	O
;	O
some	O
exhibit	O
hypertrophy	O
labeled	O
only	O
by	O
GFAP	O
;	O
some	O
are	O
labeled	O
by	O
both	O
GFAP	O
and	O
[	B
3	I
H	I
]	I
thymidine	I
[	O
25	O
,	O
48	O
]	O
.	O

This	O
observation	O
suggests	O
that	O
these	O
two	O
separate	O
pathways	O
may	O
operate	O
in	O
the	O
in	O
vivo	O
situation	O
.	O

Taken	O
together	O
,	O
the	O
information	O
from	O
our	O
in	O
vitro	O
cell	O
culture	O
studies	O
may	O
provide	O
insight	O
into	O
the	O
mechanisms	O
of	O
in	O
vivo	O
striatal	O
astrocytic	O
response	O
and	O
help	O
to	O
elucidate	O
potential	O
roles	O
of	O
astrocytes	O
in	O
neurodegeneration	O
.	O

Acknowledgements	O

We	O
thank	O
Dr.	O
K.A.	O
Neve	O
for	O
providing	O
C6-D2L	O
cells	O
.	O

Malaria	O
is	O
still	O
the	O
most	O
important	O
parasitic	O
disease	O
in	O
the	O
world	O
,	O
causing	O
23	O
million	O
deaths	O
every	O
year	O
(	O
WHO	O
,	O
1997	O
)	O
.	O

The	O
rising	O
resistance	O
of	O
Plasmodium	O
spp	O
.	O
,	O
especially	O
Plasmodium	O
falciparum	O
,	O
to	O
known	O
antimalarials	O
such	O
as	O
chloroquine	B
makes	O
the	O
search	O
for	O
new	O
antimalarial	B
drugs	I
increasingly	O
important	O
.	O

Therefore	O
,	O
we	O
investigated	O
several	O
medicinal	O
plants	O
,	O
which	O
are	O
traditionally	O
used	O
as	O
antimalarial	O
or	O
antipyretic	O
remedies	O
by	O
the	O
indigenous	O
population	O
in	O
Latin	O
America	O
(	O
Duke	O
,	O
1975	O
;	O
Hirschhorn	O
,	O
1981	O
;	O
Joly	O
et	O
al.	O
,	O
1987	O
;	O
Gupta	O
et	O
al.	O
,	O
1993	O
)	O
.	O

During	O
a	O
screening	O
program	O
,	O
we	O
obtained	O
lipophilic	O
and	O
hydrophilic	O
extracts	O
of	O
these	O
plants	O
with	O
antiplasmodial	O
activity	O
and	O
we	O
selected	O
the	O
most	O
active	O
ones	O
for	O
further	O
investigation	O
(	O
Jenett	O
-	O
Siems	O
et	O
al.	O
,	O
1999	O
)	O
.	O

Andira	O
inermis	O
(	O
W.	O
Wright	O
)	O
H.B.K.	O
(	O
Fabaceae	O
)	O
is	O
a	O
tall	O
tree	O
characterised	O
by	O
a	O
thick	O
trunk	O
and	O
red	O
-	O
purple	O
flowers	O
,	O
native	O
from	O
southern	O
Mexico	O
to	O
northern	O
South	O
America	O
.	O

As	O
a	O
febrifuge	O
,	O
the	O
bark	O
is	O
boiled	O
in	O
milk	O
,	O
sweetened	O
water	B
or	O
performed	O
in	O
pills	O
.	O

It	O
is	O
also	O
used	O
as	O
a	O
purgative	O
,	O
vermifuge	O
,	O
or	O
for	O
dermal	O
irritations	O
.	O

The	O
seeds	O
have	O
similar	O
uses	O
.	O

Large	O
doses	O
of	O
the	O
stem	O
bark	O
or	O
seeds	O
caused	O
vomiting	O
and	O
violent	O
diarrhoea	O
;	O
in	O
some	O
cases	O
they	O
were	O
even	O
fatal	O
(	O
Hirschhorn	O
,	O
1981	O
;	O
Morton	O
,	O
1981	O
)	O
.	O

From	O
this	O
species	O
,	O
several	O
isoflavones	B
and	O
related	O
structures	O
have	O
been	O
reported	O
(	O
Cocker	O
et	O
al.	O
,	O
1962	O
;	O
Lock	O
de	O
Ugaz	O
et	O
al.	O
,	O
1991	O
)	O
.	O

The	O
lipophilic	O
extracts	O
of	O
stems	O
and	O
leaves	O
showed	O
moderate	O
in	O
vitro	O
activity	O
against	O
P.	O
falciparum	O
in	O
this	O
screening	O
program	O
and	O
were	O
further	O
analysed	O
by	O
bioassay	O
-	O
guided	O
fractionation	O
to	O
isolate	O
the	O
active	O
compounds	O
.	O

2	O
Material	O
and	O
methods	O
2.1	O
General	O
For	O
fractionation	O
,	O
silica	B
gel	I
60	I
(	O
70230	O
mesh	O
)	O
was	O
utilised	O
.	O

Preparative	O
high	O
performance	O
liquid	O
chromatography	O
(	O
HPLC	O
)	O
was	O
performed	O
on	O
a	O
Knauer	O
Eurochrom	O
2000	O
equipped	O
with	O
a	O
Nucleosil	B
P	I
300	I
C-18	I
(	O
10	O
m	O
)	O
column	O
.	O

Mass	O
spectra	O
were	O
determined	O
with	O
a	O
Finnigan	O
MAT	O
CH7A	O
(	O
220	O
	O
C	O
,	O
ionisation	O
70	O
eV	O
)	O
and	O
1	O
H	O
-	O
NMR	O
spectra	O
were	O
obtained	O
using	O
acetone	B
-	I
D6	I
as	O
a	O
solvent	O
with	O
a	O
Bruker	O
AVANCE	O
DPX	O
400	O
(	O
400	O
MHz	O
,	O
TMS	B
as	O
internal	O
standard	O
)	O
.	O

The	O
erythrocytes	O
were	O
harvested	O
with	O
an	O
Inotech	O
cell	O
harvester	O
and	O
the	O
	O
-	O
radiation	O
of	O
the	O
incorporated	O
[	B
3	I
H	I
]	I
hypoxanthine	I
was	O
measured	O
with	O
a	O
Wallac	O
1450	O
MicroBeta	O
plus	O
liquid	O
scintillation	O
counter	O
.	O

2.2	O
Plant	O
material	O
Leaves	O
and	O
stems	O
of	O
A.	O
inermis	O
were	O
collected	O
in	O
the	O
area	O
of	O
Panama	O
City	O
(	O
at	O
the	O
road	O
El	O
Llano	O
-	O
Carti	O
)	O
,	O
Panama	O
,	O
during	O
March	O
1997	O
.	O

Voucher	O
specimens	O
(	O
FLORPAN	O
2758	O
)	O
were	O
identified	O
by	O
Professor	O
M.D.	O
Correa	O
A.	O
and	O
deposited	O
at	O
the	O
Herbarium	O
of	O
the	O
University	O
of	O
Panama	O
.	O

2.3	O
Extraction	O
and	O
isolation	O
In	O
the	O
screening	O
program	O
,	O
the	O
air	O
-	O
dried	O
stem	O
bark	O
and	O
leaves	O
(	O
20	O
g	O
)	O
were	O
extracted	O
three	O
times	O
for	O
2	O
h	O
with	O
150	O
ml	O
petroleum	B
ether	I
/	O
ethyl	B
acetate	I
(	O
1:1	O
)	O
at	O
room	O
temperature	O
.	O

Then	O
the	O
plant	O
material	O
was	O
air	O
dried	O
again	O
and	O
treated	O
three	O
times	O
with	O
150	O
ml	O
methanol	B
/	O
water	B
(	O
8:2	O
)	O
to	O
yield	O
the	O
hydrophilic	O
extracts	O
.	O

The	O
solvents	O
were	O
evaporated	O
under	O
reduced	O
pressure	O
at	O
40	O
	O
C	O
.	O

For	O
further	O
investigations	O
,	O
the	O
crushed	O
stems	O
(	O
600	O
g	O
)	O
were	O
air	O
dried	O
and	O
extracted	O
three	O
times	O
with	O
2	O
l	O
of	O
petroleum	B
ether	I
/	O
ethyl	B
acetate	I
(	O
1:1	O
)	O
for	O
24	O
h	O
at	O
room	O
temperature	O
.	O

The	O
solvents	O
were	O
evaporated	O
under	O
reduced	O
pressure	O
at	O
40	O
	O
C	O
.	O

The	O
oily	O
residue	O
(	O
3.3	O
g	O
)	O
was	O
subjected	O
to	O
column	O
chromatography	O
on	O
silica	B
gel	I
60	I
(	O
45	O
g	O
)	O
and	O
eluted	O
with	O
cyclohexane	B
,	O
cyclohexane	B
/	O
ethyl	B
acetate	I
mixtures	O
,	O
and	O
methanol	B
to	O
yield	O
seven	O
fractions	O
,	O
which	O
were	O
tested	O
against	O
P.	O
falciparum	O
.	O

Fraction	O
5	O
and	O
6	O
,	O
which	O
were	O
eluted	O
with	O
cyclohexane	B
/	O
ethyl	B
acetate	I
(	O
8:2	O
and	O
7:3	O
,	O
respectively	O
)	O
,	O
proved	O
to	O
be	O
most	O
active	O
.	O

Further	O
separation	O
of	O
fraction	O
5	O
(	O
150	O
mg	O
)	O
by	O
HPLC	O
at	O
a	O
5	O
ml	O
/	O
min	O
flow	O
rate	O
of	O
methanol	B
/	O
water	B
(	O
55:45	O
)	O
yielded	O
the	O
compounds	O
1	O
(	O
2.4	O
mg	O
)	O
,	O
2	O
(	O
6.1	O
mg	O
)	O
,	O
and	O
3	O
(	O
6.6	O
mg	O
)	O
.	O

Fraction	O
6	O
was	O
separated	O
with	O
methanol	B
/	O
water	B
(	O
45:55	O
)	O
to	O
give	O
the	O
compounds	O
4	O
(	O
8.3	O
mg	O
)	O
,	O
5	O
(	O
8.5	O
mg	O
)	O
,	O
and	O
6	O
(	O
1.6	O
mg	O
)	O
.	O

Compound	O
2	O
(	O
prunetin	B
)	O
:	O
EI	O
-	O
MS	O
:	O
m	O
/z	O
(	O
rel	O
.	O

int.	O
)	O
=284	O
(	O
M+	O
,	O
100	O
)	O
,	O
166	O
(	O
35	O
)	O
,	O
138	O
(	O
22	O
)	O
,	O
118	O
(	O
15	O
)	O
,	O
110	O
(	O
10	O
)	O
,	O
95	O
(	O
13	O
)	O
;	O
1	O
H	O
-	O
NMR	O
(	O
400	O
MHz	O
,	O
acetone	O
-	O
D6	O
):	O
	O
(	O
ppm	O
)	O
=3.93	O
(	O
3	O
H	O
,	O
s	O
,	O
CH3	O
O-7	O
)	O
,	O
6.36	O
(	O
1	O
H	O
,	O
d	O
,	O
J	O
=	O
2.3	O
Hz	O
,	O
H-6	O
)	O
,	O
6.55	O
(	O
1	O
H	O
,	O
d	O
,	O
J	O
=	O
2.4	O
Hz	O
,	O
H-8	O
)	O
,	O
6.91	O
(	O
2	O
H	O
,	O
d	O
,	O
J	O
=	O
8.5	O
Hz	O
,	O
H-3,5	O
)	O
,	O
7.47	O
(	O
2	O
H	O
,	O
d	O
,	O
J	O
=	O
8.5	O
Hz	O
,	O
H-2,6	O
)	O
,	O
8.22	O
(	O
1	O
H	O
,	O
s	O
,	O
H-2	O
)	O
,	O
13.4	O
(	O
1	O
H	O
,	O
s	O
,	O
OH-5	O
)	O
.	O

2.4	O
Antiplasmodial	O
bioassay	O
In	O
this	O
study	O
,	O
the	O
chloroquine	B
-	O
sensitive	O
strain	O
of	O
P.	O
falciparum	O
poW	O
(	O
IC50	O
=	O
0.015	O
M	O
)	O
and	O
the	O
chloroquine	B
-	O
resistant	O
clone	O
Dd2	O
(	O
IC50	O
=	O
0.14	O
M	O
)	O
were	O
used	O
.	O

They	O
were	O
maintained	O
in	O
continuous	O
culture	O
in	O
human	O
red	O
blood	O
cells	O
(	O
A+	O
)	O
diluted	O
to	O
5	O
%	O
haematocrit	O
in	O
RPMI	B
1640	I
medium	I
supplemented	O
with	O
25	O
mM	O
Hepes	B
,	O
30	O
mM	O
NaHCO3	B
,	O
and	O
10	O
%	O
human	O
A+	O
serum	O
.	O

Crude	O
extracts	O
and	O
isolated	O
compounds	O
were	O
dissolved	O
in	O
DMSO	B
(	O
1	O
mg	O
/	O
50	O
l	O
)	O
and	O
diluted	O
in	O
RPMI	B
1640	I
medium	I
(	O
Trager	O
and	O
Jensen	O
,	O
1976	O
)	O
.	O

The	O
tests	O
were	O
performed	O
in	O
96-well	O
microtiter	O
plates	O
(	O
Desjardins	O
et	O
al.	O
,	O
1979	O
)	O
which	O
contained	O
150	O
l	O
of	O
a	O
parasitized	O
red	O
blood	O
suspension	O
(	O
A+	O
,	O
2.5	O
%	O
haematocrit	O
,	O
0.5	O
%	O
parasitaemia	O
)	O
.	O

The	O
samples	O
were	O
added	O
to	O
give	O
final	O
concentrations	O
between	O
1.56	O
and	O
100	O
g	O
/	O
ml	O
.	O

After	O
incubation	O
in	O
a	O
candle	O
jar	O
for	O
24	O
h	O
,	O
0.5	O
Ci	O
[	B
3	I
H	I
]	I
hypoxanthine	I
(	O
1	O
mCi	O
/	O
ml	O
,	O
ICN	O
)	O
was	O
added	O
to	O
each	O
well	O
and	O
the	O
plate	O
was	O
incubated	O
for	O
another	O
18	O
h.	O
Incorporation	O
of	O
[	B
3	I
H	I
]	I
hypoxanthine	I
was	O
measured	O
by	O
liquid	O
scintillation	O
after	O
harvesting	O
the	O
cells	O
on	O
glass	O
fibre	O
filters	O
with	O
the	O
cell	O
harvester	O
.	O

All	O
tests	O
were	O
performed	O
in	O
triplicate	O
.	O

The	O
percentage	O
of	O
growth	O
inhibition	O
was	O
calculated	O
as	O
follows	O
:	O
(	O
1	O
[	O
cpm	O
in	O
drug	O
treated	O
cultures	O
/	O
cpm	O
in	O
untreated	O
cultures	O
]	O
)	O
	O
100	O
.	O

The	O
concentration	O
at	O
which	O
growth	O
was	O
inhibited	O
by	O
50	O
%	O
(	O
IC50	O
)	O
was	O
estimated	O
by	O
interpolation	O
.	O

Extracts	O
with	O
IC50	O
values	O
above	O
50	O
g	O
/	O
ml	O
were	O
considered	O
to	O
be	O
inactive	O
(	O
O'Neill	O
et	O
al.	O
,	O
1985	O
)	O
.	O

3	O
Results	O
The	O
isolated	O
compounds	O
16	O
(	O
Fig.	O
1	O
)	O
turned	O
out	O
to	O
be	O
isoflavones	B
.	O

Compound	O
1	O
,	O
isolated	O
from	O
both	O
stems	O
and	O
leaves	O
was	O
identified	O
as	O
formononetin	B
by	O
comparison	O
with	O
an	O
authentic	O
sample	O
.	O

According	O
to	O
the	O
spectral	O
data	O
(	O
1	O
H	O
-	O
NMR	O
,	O
EI	O
-	O
MS	O
)	O
,	O
compound	O
2	O
proved	O
to	O
be	O
prunetin	B
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
no	O
1	O
H	O
-	O
NMR	O
values	O
for	O
prunetin	B
have	O
been	O
published	O
so	O
far	O
,	O
therefore	O
they	O
are	O
given	O
in	O
Section	O
2.3	O
.	O

The	O
isoflavones	O
3	O
,	O
4	O
,	O
5	O
,	O
and	O
6	O
were	O
identified	O
as	O
biochanin	B
A	I
,	O
calycosin	B
,	O
genistein	B
,	O
and	O
pratensein	B
,	O
respectively	O
,	O
by	O
comparison	O
of	O
1	O
H	O
-	O
NMR	O
and	O
EI	O
-	O
MS	O
with	O
published	O
data	O
(	O
Asres	O
et	O
al.	O
,	O
1985	O
;	O
Kobayashi	O
et	O
al.	O
,	O
1985	O
)	O
.	O

Prunetin	B
(	O
2	O
)	O
,	O
calycosin	B
(	O
4	O
)	O
,	O
and	O
pratensein	B
(	O
6	O
)	O
were	O
detected	O
for	O
the	O
first	O
time	O
from	O
the	O
genus	O
Andira	O
.	O

The	O
lipophilic	O
extracts	O
of	O
A.	O
inermis	O
exhibited	O
IC50	O
values	O
from	O
56.0	O
g	O
/	O
ml	O
(	O
leaves	O
)	O
to	O
108.7	O
g	O
/	O
ml	O
(	O
stems	O
)	O
against	O
P.	O
falciparum	O
in	O
vitro	O
(	O
Table	O
1	O
)	O
.	O

The	O
hydrophilic	O
extracts	O
proved	O
to	O
be	O
inactive	O
.	O

For	O
all	O
tested	O
substances	O
the	O
antiparasitic	O
activity	O
against	O
the	O
chloroquine	B
-	O
sensitive	O
strain	O
poW	O
was	O
higher	O
(	O
factor	O
two	O
)	O
than	O
against	O
the	O
chloroquine	B
-	O
resistant	O
clone	O
Dd2	O
.	O

Calycosin	B
(	O
IC50	O
4.2	O
g	O
/	O
ml	O
for	O
poW	O
;	O
9.8	O
g	O
/	O
ml	O
for	O
Dd2	O
)	O
and	O
genistein	B
(	O
IC50	O
2.0	O
g	O
/	O
ml	O
for	O
poW	O
;	O
4.1	O
g	O
/	O
ml	O
for	O
Dd2	O
)	O
proved	O
to	O
be	O
most	O
active	O
.	O

The	O
other	O
four	O
compounds	O
were	O
considered	O
to	O
be	O
inactive	O
.	O

4	O
Discussion	O
Although	O
the	O
lipophilic	O
extracts	O
of	O
A.	O
inermis	O
showed	O
only	O
moderate	O
antiplasmodial	O
activity	O
compared	O
to	O
those	O
known	O
for	O
other	O
plant	O
remedies	O
(	O
O'Neill	O
et	O
al.	O
,	O
1985	O
;	O
Jenett	O
-	O
Siems	O
et	O
al.	O
,	O
1999	O
)	O
they	O
afforded	O
two	O
active	O
isoflavones	B
.	O

This	O
is	O
the	O
first	O
report	O
on	O
antiplasmodial	O
activity	O
of	O
isoflavones	B
against	O
P.	O
falciparum	O
.	O

The	O
low	O
concentration	O
of	O
calycosin	B
and	O
genistein	B
(	O
<	O
0.01	O
%	O
w	O
/	O
w	O
)	O
may	O
be	O
the	O
explanation	O
for	O
the	O
low	O
antiplasmodial	O
activity	O
of	O
the	O
crude	O
extract	O
.	O

It	O
is	O
known	O
that	O
calycosin	B
also	O
proved	O
to	O
be	O
active	O
against	O
Giardia	O
intestinalis	O
,	O
a	O
potent	O
protozoan	O
agent	O
for	O
enteric	O
diseases	O
(	O
ElSohly	O
et	O
al.	O
,	O
1999	O
)	O
.	O

During	O
the	O
preparation	O
of	O
this	O
paper	O
a	O
patent	O
application	O
was	O
published	O
(	O
Khan	O
et	O
al.	O
,	O
1999	O
)	O
,	O
which	O
claimed	O
a	O
method	O
of	O
treating	O
giardiasis	O
and/or	O
malaria	O
comprising	O
the	O
use	O
of	O
isoflavones	B
,	O
but	O
mentioning	O
no	O
data	O
,	O
proving	O
their	O
antiplasmodial	O
activity	O
against	O
P.	O
falciparum	O
.	O

In	O
our	O
study	O
,	O
we	O
have	O
focused	O
on	O
the	O
investigation	O
of	O
the	O
lipophilic	O
extract	O
.	O

The	O
indigenous	O
population	O
,	O
e.g.	O
in	O
Brazil	O
(	O
Morton	O
,	O
1981	O
)	O
,	O
prefer	O
to	O
boil	O
the	O
stem	O
bark	O
with	O
milk	O
.	O

This	O
procedure	O
covers	O
the	O
bitter	O
taste	O
and	O
probably	O
causes	O
the	O
extraction	O
of	O
lipophilic	O
constituents	O
.	O

Interestingly	O
,	O
hydrophilic	O
extracts	O
(	O
methanol	B
/	O
water	B
8:2	O
)	O
from	O
A.	O
inermis	O
did	O
not	O
show	O
antiplasmodial	O
activity	O
in	O
our	O
test	O
system	O
.	O

The	O
evaluation	O
of	O
extracts	O
obtained	O
with	O
water	B
or	O
milk	O
is	O
still	O
in	O
progress	O
and	O
might	O
be	O
interesting	O
with	O
regard	O
to	O
the	O
ethnobotanical	O
use	O
of	O
this	O
species	O
.	O

Acknowledgements	O
The	O
authors	O
are	O
indebted	O
to	O
C.	O
Guerra	O
,	O
for	O
his	O
support	O
in	O
collecting	O
the	O
plant	O
material	O
,	O
and	O
to	O
Professor	O
M.D.	O
Correa	O
A.	O
,	O
Herbarium	O
of	O
the	O
University	O
of	O
Panama	O
,	O
Republic	O
of	O
Panama	O
,	O
for	O
her	O
identification	O
of	O
the	O
species	O
.	O

We	O
thank	O
Drs	O
D.S.	O
Kim	O
and	O
B.	O
Kleuser	O
,	O
Institut	O
fr	O
Pharmazie	O
,	O
Freie	O
Universitt	O
Berlin	O
,	O
Germany	O
,	O
for	O
their	O
advice	O
concerning	O
determination	O
of	O
radioactivity	O
.	O

This	O
study	O
was	O
supported	O
by	O
a	O
grant	O
from	O
the	O
Deutsche	O
Pharmazeutische	O
Gesellschaft	O
to	O
K.	O
Jenett	O
-	O
Siems	O
and	O
by	O
Charit	O
Grant	O
Nr	O
.	O

98	O
-	O
700	O
.	O

CIFLORPAN	O
acknowledges	O
the	O
Fundation	O
Natura	O
and	O
the	O
Organization	O
of	O
American	O
States	O
(	O
OAS	O
)	O
for	O
financial	O
support	O
.	O

Models	O
to	O
predict	O
intestinal	O
absorption	O
of	O
therapeutic	O
peptides	O
and	O
proteins	O
.	O

Prediction	O
of	O
human	O
intestinal	O
absorption	O
is	O
a	O
major	O
goal	O
in	O
the	O
design	O
,	O
optimization	O
,	O
and	O
selection	O
of	O
drugs	O
intended	O
for	O
oral	O
delivery	O
,	O
in	O
particular	O
proteins	O
,	O
which	O
possess	O
intrinsic	O
poor	O
transport	O
across	O
intestinal	O
epithelium	O
.	O

There	O
are	O
various	O
techniques	O
currently	O
employed	O
to	O
evaluate	O
the	O
extension	O
of	O
protein	O
absorption	O
in	O
the	O
different	O
phases	O
of	O
drug	O
discovery	O
and	O
development	O
.	O

Screening	O
protocols	O
to	O
evaluate	O
protein	O
absorption	O
include	O
a	O
range	O
of	O
preclinical	O
methodologies	O
like	O
in	O
silico	O
,	O
in	O
vitro	O
,	O
in	O
situ	O
,	O
ex	O
vivo	O
and	O
in	O
vivo	O
.	O

It	O
is	O
the	O
careful	O
and	O
critical	O
use	O
of	O
these	O
techniques	O
that	O
can	O
help	O
to	O
identify	O
drug	O
candidates	O
,	O
which	O
most	O
probably	O
will	O
be	O
well	O
absorbed	O
from	O
the	O
human	O
intestinal	O
tract	O
.	O

It	O
is	O
well	O
recognized	O
that	O
the	O
human	O
intestinal	O
permeability	O
can	O
not	O
be	O
accurately	O
predicted	O
based	O
on	O
a	O
single	O
preclinical	O
method	O
.	O

However	O
,	O
the	O
present	O
social	O
and	O
scientific	O
concerns	O
about	O
the	O
animal	O
well	O
care	O
as	O
well	O
as	O
the	O
pharmaceutical	O
industries	O
need	O
for	O
rapid	O
,	O
cheap	O
and	O
reliable	O
models	O
predicting	O
bioavailability	O
give	O
reasons	O
for	O
using	O
methods	O
providing	O
an	O
appropriate	O
correlation	O
between	O
results	O
of	O
in	O
vivo	O
and	O
in	O
vitro	O
drug	O
absorption	O
.	O

The	O
aim	O
of	O
this	O
review	O
is	O
to	O
describe	O
and	O
compare	O
in	O
silico	O
,	O
in	O
vitro	O
,	O
in	O
situ	O
,	O
ex	O
vivo	O
and	O
in	O
vivo	O
methods	O
used	O
to	O
predict	O
human	O
intestinal	O
absorption	O
,	O
giving	O
a	O
special	O
attention	O
to	O
the	O
intestinal	O
absorption	O
of	O
therapeutic	O
peptides	O
and	O
proteins	O
.	O

Fish	O
consumption	O
during	O
child	O
bearing	O
age	O
:	O
a	O
quantitative	O
risk	O
-	O
benefit	O
analysis	O
on	O
neurodevelopment	O
.	O

The	O
fish	O
ingredient	O
N3-docosahexaenoic	B
acid	I
22:6	O
n-3	O
(	O
DHA	B
)	O
stimulates	O
brain	O
development	O
.	O

On	O
the	O
other	O
hand	O
methylmercury	B
(	O
MeHg	B
)	O
in	O
fish	O
disturbs	O
the	O
developing	O
central	O
nervous	O
system	O
.	O

In	O
this	O
Context	O
the	O
IQ	O
score	O
in	O
children	O
is	O
considered	O
as	O
an	O
aggregate	O
measure	O
of	O
in	O
utero	O
brain	O
development	O
.	O

To	O
determine	O
the	O
effect	O
of	O
DHA	B
exposure	O
on	O
prenatal	O
neurodevelopment	O
the	O
maternal	O
DHA	B
intake	O
during	O
pregnancy	O
was	O
compared	O
with	O
its	O
epidemiologically	O
observed	O
effect	O
on	O
the	O
IQ	O
score	O
of	O
children	O
.	O

For	O
MeHg	B
the	O
maternal	O
intake	O
was	O
converted	O
into	O
its	O
accumulation	O
in	O
the	O
maternal	O
body	O
.	O

The	O
maternal	O
body	O
burden	O
then	O
was	O
compared	O
with	O
its	O
epidemiologically	O
observed	O
relationship	O
with	O
the	O
IQ	O
score	O
.	O

Taking	O
the	O
MeHg	B
and	O
DHA	B
content	O
of	O
33	O
fish	O
species	O
the	O
net	O
effect	O
of	O
these	O
compounds	O
on	O
the	O
IQ	O
score	O
was	O
quantified	O
.	O

For	O
most	O
fish	O
species	O
the	O
adverse	O
effect	O
of	O
MeHg	B
on	O
the	O
IQ	O
score	O
exceeded	O
the	O
beneficial	O
effect	O
of	O
DHA	B
.	O

In	O
the	O
case	O
of	O
long	O
-	O
living	O
predators	O
a	O
negative	O
effect	O
up	O
to	O
10	O
points	O
on	O
the	O
IQ	O
score	O
was	O
found	O
.	O

The	O
results	O
of	O
this	O
study	O
indicate	O
that	O
food	O
interventions	O
aiming	O
at	O
the	O
beneficial	O
effects	O
of	O
fish	O
consumption	O
should	O
focus	O
on	O
fish	O
species	O
with	O
a	O
high	O
DHA	B
content	O
,	O
while	O
avoiding	O
fish	O
species	O
with	O
a	O
high	O
MeHg	B
content	O
.	O

Tissues	O
distribution	O
of	O
heavy	O
metals	O
and	O
erythrocytes	O
antioxidant	O
status	O
in	O
rats	O
exposed	O
to	O
Nigerian	O
bonny	O
light	O
crude	O
oil	O
.	O

The	O
harmful	O
effects	O
of	O
folkloric	O
uses	O
of	O
Nigerian	O
bonny	O
light	O
crude	O
oil	O
(	O
BLCO	O
)	O
in	O
ailments	O
management	O
may	O
outweigh	O
the	O
expected	O
beneficial	O
effects	O
.	O

We	O
investigated	O
the	O
levels	O
of	O
heavy	O
metal	O
concentrations	O
in	O
the	O
tissues	O
as	O
well	O
as	O
the	O
effect	O
of	O
BLCO	O
on	O
the	O
antioxidant	O
status	O
of	O
erythrocytes	O
of	O
rats	O
after	O
oral	O
exposure	O
to	O
0	O
,	O
200	O
and	O
800	O
mg	O
/	O
kg	O
BLCO	O
for	O
7	O
days	O
.	O

Analysis	O
of	O
heavy	O
metal	O
concentrations	O
in	O
BLCO	O
showed	O
that	O
Zn	B
>	O
Fe	B
>	O
Pb	B
>	O
Cu	B
>	O
Ni	B
.	O

The	O
trend	O
of	O
accumulation	O
of	O
the	O
metals	O
in	O
the	O
tissues	O
is	O
blood	O
-	O
Fe	B
>	O
Pb	B
>	O
Zn	B
whereas	O
Cu	B
and	O
Ni	B
levels	O
were	O
not	O
affected	O
;	O
Liver	O
-	O
Ni	B
>	O
Zn	B
>	O
Fe	B
>	O
Cu	B
>	O
Pb	B
and	O
Testes	O
-	O
Ni	B
>	O
Cu	B
>	O
Pb	B
>	O
Zn	B
>	O
Fe	B
.	O

The	O
order	O
of	O
concentration	O
of	O
the	O
metals	O
in	O
the	O
tissues	O
is	O
as	O
follows	O
:	O
iron	B
-	O
blood	O
>	O
liver	O
>	O
testes	O
;	O
zinc	B
-	O
liver	O
>	O
blood	O
>	O
testes	O
;	O
lead	O
-	O
blood	O
>	O
liver	O
>	O
testes	O
;	O
copper	B
-	O
testes	O
>	O
liver	O
>	O
blood	O
;	O
nickel	B
-	O
liver	O
>	O
testes	O
>	O
blood	O
.	O

Activities	O
of	O
the	O
antioxidant	O
enzymes	O
of	O
erythrocytes	O
such	O
as	O
superoxide	B
dismutase	O
,	O
catalase	O
,	O
glutathione	B
S	O
-	O
transferase	O
and	O
glutathione	B
peroxidase	O
increased	O
significantly	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
with	O
significant	O
elevation	O
in	O
hydrogen	B
peroxide	I
and	O
malondialdehyde	B
levels	O
,	O
whereas	O
glutathione	B
level	O
was	O
not	O
significantly	O
decreased	O
in	O
BLCO	O
-	O
treated	O
animals	O
.	O

Collectively	O
,	O
the	O
results	O
showed	O
that	O
BLCO	O
induces	O
oxidative	O
damage	O
to	O
erythrocytes	O
of	O
rats	O
.	O

Green	O
tea	O
extract	O
alleviates	O
arsenic	B
-	O
induced	O
biochemical	O
toxicity	O
and	O
lipid	O
peroxidation	O
in	O
rats	O
.	O

The	O
present	O
work	O
was	O
undertaken	O
to	O
evaluate	O
the	O
protective	O
effect	O
of	O
an	O
aqueous	O
extract	O
of	O
green	O
tea	O
(	O
GT	O
,	O
Camellia	O
sinensis	O
)	O
leaves	O
against	O
arsenic	B
(	O
NaAsO2	B
)	O
-induced	O
biochemical	O
toxicity	O
and	O
lipid	O
peroxidation	O
production	O
in	O
experimental	O
rats	O
.	O

The	O
treatment	O
with	O
arsenic	B
exhibited	O
a	O
significant	O
increase	O
in	O
some	O
serum	O
hepatic	O
and	O
renal	O
biochemical	O
parameters	O
(	O
alanine	B
aminotransferase	O
,	O
aspartate	B
aminotransferase	O
,	O
alkaline	O
phosphatase	O
,	O
total	O
protein	O
,	O
albumin	O
,	O
bilirubin	B
,	O
cholesterol	B
,	O
urea	B
and	O
creatinine	B
)	O
.	O

But	O
the	O
co	O
-	O
administration	O
of	O
GT	O
has	O
increased	O
the	O
level	O
of	O
plasmatic	O
concentration	O
of	O
biochemical	O
parameters	O
.	O

Exposure	O
of	O
rats	O
to	O
arsenic	B
caused	O
also	O
a	O
significant	O
increase	O
in	O
liver	O
,	O
kidney	O
and	O
testicular	O
thiobarbituric	B
acid	I
reactive	O
substances	O
compared	O
to	O
control	O
.	O

However	O
,	O
the	O
co	O
-	O
administration	O
of	O
GT	O
was	O
effective	O
in	O
reducing	O
its	O
level	O
.	O

To	O
conclude	O
,	O
our	O
data	O
suggest	O
that	O
arsenic	B
exposure	O
enhanced	O
an	O
oxidative	O
stress	O
by	O
disturbing	O
the	O
tissue	O
antioxidant	O
defense	O
system	O
,	O
but	O
the	O
GT	O
co	O
-	O
administration	O
alleviates	O
the	O
toxicity	O
induced	O
by	O
arsenic	B
exposure	O
.	O

Changes	O
in	O
carbohydrate	B
metabolism	O
,	O
oxidative	O
stress	O
and	O
loss	O
of	O
cortisol	B
secretion	O
in	O
adrenocortica	O
l	O
cells	O
of	O
Oreochromis	O
niloticus	O
exposed	O
in	O
vitro	O
to	O
endosulfan	B
.	O

The	O
effects	O
of	O
endosulfan	B
,	O
an	O
organochlorine	B
pesticide	O
regularly	O
used	O
in	O
Niger	O
Delta	O
ecological	O
zone	O
,	O
were	O
examined	O
and	O
also	O
its	O
effects	O
on	O
various	O
biochemical	O
parameters	O
in	O
the	O
serum	O
of	O
Oreochromis	O
niloticus	O
,	O
a	O
dominant	O
fish	O
species	O
in	O
Nigeria	O
.	O

One	O
hundred	O
and	O
fifty	O
juveniles	O
of	O
O.	O
niloticus	O
were	O
used	O
for	O
the	O
toxicity	O
study	O
.	O

Lethal	O
concentration	O
of	O
50	O
%	O
mortality	O
of	O
sample	O
(	O
LC50	O
)	O
was	O
determined	O
using	O
semi	O
-	O
static	O
method	O
.	O

From	O
the	O
result	O
of	O
the	O
LC50	O
determination	O
,	O
lower	O
concentrations	O
of	O
endosulfan	B
were	O
prepared	O
for	O
sublethal	O
test	O
.	O

Five	O
fish	O
per	O
test	O
concentration	O
in	O
three	O
replicates	O
were	O
exposed	O
to	O
varying	O
concentrations	O
of	O
endosulfan	B
.	O

Glucose	B
level	O
and	O
the	O
enzyme	O
activities	O
were	O
measured	O
spectrophotometrically	O
at	O
the	O
end	O
of	O
28	O
days	O
of	O
exposure	O
.	O

Glucose	B
levels	O
and	O
glutathione	B
-	B
S	O
-	O
transferase	O
activities	O
were	O
significantly	O
(	O
p	O
<	O
0.05	O
)	O
higher	O
than	O
the	O
control	O
and	O
the	O
concentrations	O
increased	O
with	O
increasing	O
concentration	O
of	O
the	O
toxicant	O
and	O
exposure	O
duration	O
.	O

Cortisol	B
secretion	O
was	O
significantly	O
(	O
p	O
=	O
0.05	O
)	O
lower	O
in	O
the	O
treated	O
fish	O
than	O
the	O
control	O
.	O

These	O
findings	O
indicated	O
that	O
endosulfan	B
altered	O
all	O
the	O
investigated	O
parameters	O
,	O
which	O
is	O
an	O
indication	O
of	O
their	O
suitability	O
as	O
markers	O
for	O
fish	O
and	O
other	O
aquatic	O
organism	O
toxicity	O
study	O
.	O

Serratin	B
a	O
new	O
metabolite	O
obtained	O
from	O
Serratia	O
marcescens	O
,	O
a	O
bacterium	O
isolated	O
from	O
the	O
microflora	O
associated	O
with	O
banana	O
plantations	O
.	O

When	O
cultures	O
of	O
Serratia	O
marcescens	O
,	O
an	O
enterobacteria	O
isolated	O
from	O
the	O
microflora	O
associated	O
with	O
banana	O
plantations	O
incubated	O
at	O
27	O
	O
C	O
in	O
a	O
yeast	O
-	O
calcium	B
carbonate	I
-	O
dextrose	B
solid	O
medium	O
(	O
10	O
g	O
of	O
yeast	O
extract	O
,	O
20	O
g	O
dextrose	B
,	O
15	O
g	O
bacteriological	O
agar	O
,	O
20	O
g	O
calcium	B
carbonate	I
and	O
1000	O
mL	O
distilled	O
water	O
)	O
were	O
extracted	O
with	O
chloroform	B
and	O
purified	O
by	O
column	O
chromatography	O
,	O
we	O
obtained	O
a	O
new	O
colourless	O
bacterial	O
metabolite	O
which	O
according	O
to	O
spectroscopic	O
data	O
proved	O
to	O
be	O
serratin	B
.	O

Development	O
and	O
characterization	O
of	O
coated	O
-	O
microparticles	O
based	O
on	O
whey	O
protein	O
/	O
alginate	O
using	O
the	O
Encapsulator	O
device	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
prepare	O
whey	O
protein	O
(	O
WP	O
)	O
-based	O
microparticles	O
(	O
MP	O
)	O
using	O
the	O
Encapsulator	O
(	O
	O
)	O
device	O
.	O

The	O
viscosity	O
dependence	O
of	O
the	O
extrusion	O
device	O
required	O
to	O
mix	O
WP	O
with	O
a	O
food	O
-	O
grade	O
and	O
less	O
viscous	O
polymer	O
.	O

Mixed	O
WP	O
/	O
ALG	O
MP	O
were	O
obtained	O
with	O
the	O
optimized	O
WP	O
/	O
alginate	O
(	O
ALG	O
)	O
ratio	O
(	O
62	O
/	O
38	O
)	O
.	O

These	O
particles	O
were	O
further	O
coated	O
with	O
WP	O
or	O
ALG	O
using	O
non	O
-	O
traumatic	O
and	O
solvent	O
-	O
free	O
coating	O
process	O
developed	O
in	O
this	O
study	O
.	O

Size	O
and	O
morphology	O
of	O
coated	O
and	O
uncoated	O
MP	O
were	O
determined	O
.	O

Then	O
,	O
swelling	O
and	O
degradation	O
(	O
WP	O
release	O
)	O
of	O
formulations	O
were	O
investigated	O
in	O
pH	O
1.2	O
and	O
7.5	O
buffers	O
and	O
in	O
simulated	O
gastric	O
and	O
intestinal	O
fluids	O
(	O
SGF	O
,	O
SIF	O
)	O
and	O
compared	O
to	O
pure	O
ALG	O
and	O
pure	O
WP	O
particle	O
behaviours	O
.	O

At	O
pH	O
1.2	O
,	O
pure	O
ALG	O
shrank	O
and	O
pure	O
WP	O
swelled	O
,	O
whereas	O
the	O
sizes	O
of	O
mixed	O
WP	O
/	O
ALG	O
matrix	O
were	O
stable	O
.	O

In	O
SGF	O
,	O
WP	O
/	O
ALG	O
MP	O
resisted	O
to	O
pepsin	O
degradation	O
compare	O
to	O
pure	O
WP	O
particles	O
due	O
to	O
ALG	O
shrinkage	O
which	O
limited	O
pepsin	O
diffusion	O
within	O
particles	O
.	O

Coating	O
addition	O
with	O
WP	O
or	O
ALG	O
slowed	O
down	O
pepsin	O
degradation	O
.	O

At	O
pH	O
7.5	O
,	O
WP	O
/	O
ALG	O
particles	O
were	O
rapidly	O
degraded	O
due	O
to	O
ALG	O
sensitivity	O
but	O
the	O
addition	O
of	O
a	O
WP	O
coating	O
limited	O
effectively	O
the	O
swelling	O
and	O
the	O
degradation	O
of	O
MP	O
.	O

In	O
SIF	O
,	O
pancreatin	O
accelerated	O
MP	O
degradation	O
but	O
ALG	O
-	O
coated	O
MP	O
exhibited	O
interesting	O
robustness	O
.	O

These	O
results	O
confirmed	O
the	O
interest	O
and	O
the	O
feasibility	O
to	O
produce	O
coated	O
WP	O
-	O
based	O
MP	O
which	O
could	O
be	O
a	O
potential	O
orally	O
controlled	O
release	O
drug	O
delivery	O
system	O
.	O

New	O
immunosuppressive	O
cyclomyrsinol	B
diterpenes	I
from	O
Euphorbia	O
kopetdaghi	O
Prokh	O
.	O

Aceton	B
:	O
chloroform	B
(	O
1:2	O
)	O
extracts	O
of	O
the	O
aerial	O
parts	O
of	O
Euphorbia	O
kopetdaghi	O
Prokh	O
.	O

(	O
Euphorbiaceae	O
)	O
were	O
investigated	O
for	O
its	O
diterpenoids	B
and	O
afforded	O
three	O
new	O
five	O
-	O
membered	O
ring	O
,	O
pentacyclic	B
myrisinane	I
polyester	I
comprised	O
of	O
3,5,10-O	B
-	I
triacetyl-8-O	I
-	I
isobutanoyl-14-O	I
-	I
benzoylcyclomyrsinol	I
(	O
1	O
)	O
,	O
3,5,10,14-O	B
-	I
tetraacetyl-8-O-	I
(	I
2'-methyl	I
butanoyl	I
)	I
-cyclomyrsinol	I
(	O
2	O
)	O
and	O
3,5,10,14-O	B
-	I
tetracetyl-8-O	I
-	I
isobutanoylcyclomyrsinol	I
(	O
3	O
)	O
.	O

The	O
structures	O
were	O
elucidated	O
based	O
on	O
(	B
13	I
)	I
C-	I
and	O
(	B
1	I
)	I
H	I
-	O
NMR	O
as	O
well	O
as	O
2D	O
-	O
NMR	O
,	O
IR	O
and	O
different	O
MS	O
spectra	O
and	O
the	O
immunomodulation	O
activity	O
for	O
compound	O
1	O
was	O
evaluated	O
through	O
lymphocyte	O
proliferation	O
assay	O
,	O
IL-2	O
assay	O
,	O
oxidative	O
burst	O
of	O
phagocytic	O
leukocytes	O
and	O
through	O
their	O
cytotoxicity	O
on	O
two	O
cell	O
lines	O
.	O

Compound	O
1	O
showed	O
significant	O
suppressive	O
activity	O
against	O
phytohemagglutinin	O
-	O
activated	O
T	O
-	O
cell	O
proliferation	O
with	O
an	O
IC	O
(	O
50	O
)	O
of	O
1.83	O
g	O
mL	O
(	O
-1	O
)	O
,	O
IL-2	O
suppressive	O
activity	O
with	O
an	O
IC	O
(	O
50	O
)	O
of	O
19.0	O
g	O
mL	O
(	O
-1	O
)	O
and	O
oxidative	O
burst	O
suppressive	O
activity	O
with	O
an	O
IC	O
(	O
50	O
)	O
of	O
1.6	O
g	O
mL	O
(	O
-1	O
)	O
and	O
ignorable	O
cytotoxic	O
effect	O
on	O
the	O
CC-1	O
rat	O
hepatocyte	O
and	O
3T3-L1	O
mouse	O
fibroblast	O
cell	O
-	O
lines	O
.	O

Molecular	O
crosstalk	O
between	O
a	O
chemical	O
and	O
a	O
biological	O
stressor	O
and	O
consequences	O
on	O
disease	O
manifestation	O
in	O
rainbow	O
trout	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
examine	O
the	O
molecular	O
and	O
organism	O
reaction	O
of	O
rainbow	O
trout	O
,	O
Oncorhynchus	O
mykiss	O
,	O
to	O
the	O
combined	O
impact	O
of	O
two	O
environmental	O
stressors	O
.	O

The	O
two	O
stressors	O
were	O
the	O
myxozoan	O
parasite	O
,	O
Tetracapsuloides	O
bryosalmonae	O
,	O
which	O
is	O
the	O
etiological	O
agent	O
of	O
proliferative	O
kidney	O
disease	O
(	O
PKD	O
)	O
and	O
a	O
natural	O
stressor	O
to	O
salmonid	O
populations	O
,	O
and	O
17	B
-	I
estradiol	I
(	O
E2	O
)	O
as	O
prototype	O
of	O
estrogen	B
-	O
active	O
chemical	O
stressors	O
in	O
the	O
aquatic	O
environment	O
.	O

Both	O
stressors	O
,	O
the	O
parasite	O
and	O
estrogenic	O
contaminants	O
,	O
co	O
-	O
exist	O
in	O
Swiss	O
rivers	O
and	O
are	O
discussed	O
as	O
factors	O
contributing	O
to	O
the	O
decline	O
of	O
Swiss	O
brown	O
trout	O
populations	O
over	O
the	O
last	O
decades	O
.	O

Using	O
a	O
microarray	O
approach	O
contrasting	O
parasite	O
-	O
infected	O
and	O
non	O
-	O
infected	O
rainbow	O
trout	O
at	O
low	O
or	O
high	O
estrogen	B
levels	O
,	O
it	O
was	O
observed	O
that	O
molecular	O
response	O
patterns	O
under	O
joint	O
exposure	O
differed	O
from	O
those	O
to	O
the	O
single	O
stressors	O
.	O

More	O
specifically	O
,	O
three	O
major	O
response	O
patterns	O
were	O
present	O
:	O
(	O
i	O
)	O
expression	O
responses	O
of	O
gene	O
transcripts	O
to	O
one	O
stressor	O
are	O
weakened	O
by	O
the	O
presence	O
of	O
the	O
second	O
stressor	O
;	O
(	O
ii	O
)	O
expression	O
responses	O
of	O
gene	O
transcripts	O
to	O
one	O
stressor	O
are	O
enhanced	O
by	O
the	O
presence	O
of	O
the	O
second	O
stressor	O
;	O
(	O
iii	O
)	O
expression	O
responses	O
of	O
gene	O
transcripts	O
at	O
joint	O
treatment	O
are	O
dominated	O
by	O
one	O
of	O
the	O
two	O
stressors	O
.	O

Organism	O
-	O
level	O
responses	O
to	O
concurrent	O
E2	O
and	O
parasite	O
treatment	O
-	O
assessed	O
through	O
measuring	O
parasite	O
loads	O
in	O
the	O
fish	O
host	O
and	O
cumulative	O
mortalities	O
of	O
trout	O
-	O
were	O
dominated	O
by	O
the	O
pathogen	O
,	O
with	O
no	O
modulating	O
influence	O
of	O
E2	O
.	O

The	O
findings	O
reveal	O
function-	O
and	O
level	O
-	O
specific	O
responses	O
of	O
rainbow	O
trout	O
to	O
stressor	O
combinations	O
,	O
which	O
are	O
only	O
partly	O
predictable	O
from	O
the	O
response	O
to	O
the	O
single	O
stressors	O
.	O

Intraspecific	O
chemical	O
variability	O
of	O
essential	O
oil	O
from	O
leaves	O
of	O
Cupressus	O
atlantica	O
Gaussen	O
,	O
an	O
endemic	O
and	O
endangered	O
coniferous	O
species	O
in	O
Morocco	O
.	O

The	O
composition	O
of	O
essential	O
oils	O
isolated	O
from	O
leaves	O
of	O
11	O
natural	O
populations	O
of	O
Cupressus	O
atlantica	O
,	O
an	O
endemic	O
and	O
endangered	O
coniferous	O
species	O
from	O
Morocco	O
,	O
was	O
investigated	O
by	O
GC	O
-	O
MS	O
.	O

In	O
total	O
,	O
42	O
essential	O
oil	O
components	O
were	O
identified	O
,	O
accounting	O
for	O
73.1	O
-	O
97.7	O
%	O
of	O
the	O
total	O
oil	O
.	O

Monoterpene	B
(	O
25.2	O
-	O
84.9	O
%	O
)	O
and	O
sesquiterpene	B
hydrocarbons	I
(	O
12.2	O
-	O
46.8	O
%	O
)	O
were	O
the	O
principal	O
subclasses	O
of	O
compounds	O
,	O
with	O
	B
-	I
pinene	I
(	O
15	O
-	O
65.4	O
%	O
)	O
,	O
germacrene	B
D	I
(	O
5.9	O
-	O
30.5	O
%	O
)	O
,	O
-3-carene	B
(	O
2	O
-	O
16.6	O
%	O
)	O
and	O
	B
-	I
cadinene	I
(	O
1.3	O
-	O
9.8	O
%	O
)	O
as	O
the	O
main	O
constituents	O
.	O

The	O
results	O
of	O
the	O
oil	O
composition	O
were	O
analysed	O
by	O
hierarchical	O
cluster	O
and	O
principal	O
component	O
analysis	O
that	O
established	O
three	O
main	O
groups	O
of	O
essential	O
oils	O
.	O

These	O
oils	O
were	O
differentiated	O
by	O
the	O
content	O
of	O
the	O
major	O
constituents	O
(	O
	B
-	I
pinene	I
,	O
germacrene	B
D	I
,	O
-3-carene	B
and	O
	B
-	I
cadinene	I
)	O
,	O
geographical	O
location	O
and	O
climatic	O
characteristics	O
.	O

Effects	O
of	O
Bixa	O
orellana	O
L.	O
seeds	O
on	O
hyperlipidemia	O
.	O

Bixa	O
orellana	O
L.	O
,	O
urucum	O
,	O
or	O
urucu	O
,	O
a	O
native	O
tropical	O
tree	O
of	O
Central	O
and	O
South	O
American	O
rain	O
forests	O
is	O
used	O
to	O
treat	O
various	O
diseases	O
in	O
popular	O
medicine	O
.	O

In	O
Cear	O
,	O
Northeast	O
of	O
Brazil	O
,	O
the	O
seeds	O
of	O
urucum	O
have	O
been	O
used	O
for	O
the	O
treatment	O
of	O
high	O
lipid	O
blood	O
levels	O
.	O

The	O
present	O
study	O
investigated	O
the	O
effects	O
of	O
the	O
aqueous	O
extract	O
from	O
Bixa	O
orellana	O
seeds	O
(	O
AEBO	O
)	O
in	O
mice	O
with	O
hyperlipidemia	O
induced	O
by	O
tyloxapol	B
,	O
fructose	B
and	O
ethanol	B
.	O

In	O
hyperlipidemia	O
induced	O
by	O
Triton	B
WR1339	I
,	O
400	O
and	O
800	O
mg	O
/	O
kg	O
AEBO	O
reduced	O
triglycerides	B
(	O
TG	O
)	O
serum	O
levels	O
at	O
24	O
h	O
and	O
48	O
h.	O
In	O
the	O
study	O
of	O
hypertriglyceridemia	O
induced	O
by	O
fructose	B
,	O
AEBO	O
in	O
doses	O
of	O
400	O
mg	O
/	O
kg	O
and	O
800	O
mg	O
/	O
kg	O
reduced	O
TG	O
levels	O
by	O
48.2	O
%	O
and	O
48.7	O
%	O
,	O
respectively	O
.	O

Finally	O
,	O
the	O
ethanol	B
experimental	O
model	O
with	O
400	O
mg	O
/	O
kg	O
AEBO	O
promoted	O
a	O
reduction	O
of	O
33.6	O
%	O
of	O
TG	O
levels	O
,	O
while	O
the	O
800	O
mg	O
/	O
kg	O
concentration	O
reduced	O
hypertriglyceridemia	O
in	O
62.2	O
%	O
.	O

In	O
conclusion	O
,	O
the	O
aqueous	O
extract	O
of	O
the	O
seeds	O
of	O
Bixa	O
orellana	O
was	O
capable	O
of	O
reversing	O
the	O
hypertriglyceridemia	O
induced	O
by	O
Triton	B
,	O
fructose	B
and	O
ethanol	B
,	O
demonstrating	O
a	O
hypolipidemic	O
effect	O
.	O

However	O
,	O
further	O
studies	O
are	O
necessary	O
to	O
discover	O
the	O
precise	O
mechanism	O
of	O
action	O
.	O

Sarmentosamide	B
,	O
a	O
novel	O
hexadienamide	B
from	O
Thai	O
soil	O
actinomycetes	O
.	O

A	O
new	O
hexadienamide	O
derivative	O
named	O
sarmentosamide	B
(	O
1	O
)	O
was	O
identified	O
from	O
the	O
culture	O
of	O
Streptomyces	O
sp.	O
SBI108	O
isolated	O
from	O
Thai	O
soil	O
under	O
an	O
herb	O
.	O

The	O
structure	O
was	O
elucidated	O
on	O
the	O
basis	O
of	O
spectroscopic	O
data	O
,	O
and	O
the	O
absolute	O
configuration	O
was	O
determined	O
by	O
chemical	O
degradation	O
.	O

Electroporation	O
-	O
mediated	O
gene	O
transfer	O
directly	O
to	O
the	O
swine	O
heart	O
.	O

In	O
vivo	O
gene	O
transfer	O
to	O
the	O
ischemic	O
heart	O
via	O
electroporation	O
holds	O
promise	O
as	O
a	O
potential	O
therapeutic	O
approach	O
for	O
the	O
treatment	O
of	O
heart	O
disease	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
investigated	O
the	O
use	O
of	O
in	O
vivo	O
electroporation	O
for	O
gene	O
transfer	O
using	O
three	O
different	O
penetrating	O
electrodes	O
and	O
one	O
non	O
-	O
penetrating	O
electrode	O
.	O

The	O
hearts	O
of	O
adult	O
male	O
swine	O
were	O
exposed	O
through	O
a	O
sternotomy	O
.	O

Eight	O
electric	O
pulses	O
synchronized	O
to	O
the	O
rising	O
phase	O
of	O
the	O
R	O
wave	O
of	O
the	O
electrocardiogram	O
were	O
administered	O
at	O
varying	O
pulse	O
widths	O
and	O
field	O
strengths	O
following	O
an	O
injection	O
of	O
either	O
a	O
plasmid	O
encoding	O
luciferase	O
or	O
one	O
encoding	O
green	O
fluorescent	O
protein	O
.	O

Four	O
sites	O
on	O
the	O
anterior	O
wall	O
of	O
the	O
left	O
ventricle	O
were	O
treated	O
.	O

Animals	O
were	O
killed	O
48	O
h	O
after	O
injection	O
and	O
electroporation	O
and	O
gene	O
expression	O
was	O
determined	O
.	O

Results	O
were	O
compared	O
with	O
sites	O
in	O
the	O
heart	O
that	O
received	O
plasmid	O
injection	O
but	O
no	O
electric	O
pulses	O
or	O
were	O
not	O
treated	O
.	O

Gene	O
expression	O
was	O
higher	O
in	O
all	O
electroporated	O
sites	O
when	O
compared	O
with	O
injection	O
only	O
sites	O
demonstrating	O
the	O
robustness	O
of	O
this	O
approach	O
.	O

Our	O
results	O
provide	O
evidence	O
that	O
in	O
vivo	O
electroporation	O
can	O
be	O
a	O
safe	O
and	O
effective	O
non	O
-	O
viral	O
method	O
for	O
delivering	O
genes	O
to	O
the	O
heart	O
,	O
in	O
vivo	O
.	O

Continuous	O
infusion	O
of	O
20-hydroxyecdysone	B
increased	O
mass	O
of	O
triceps	O
brachii	O
in	O
C57BL	O
/	O
6	O
mice	O
.	O

Phytoecdysteroids	B
have	O
been	O
attributed	O
with	O
numerous	O
pharmacological	O
properties	O
in	O
animals	O
,	O
including	O
increasing	O
muscle	O
mass	O
,	O
and	O
20-hydroxyecdysone	B
(	O
20E	O
)	O
is	O
one	O
of	O
the	O
most	O
abundant	O
phytoecdysteroids	B
produced	O
by	O
plants	O
.	O

In	O
this	O
study	O
,	O
the	O
physiological	O
and	O
gene	O
expression	O
effects	O
of	O
20E	O
were	O
analyzed	O
in	O
C57BL	O
/	O
6	O
mice	O
given	O
a	O
continuous	O
infusion	O
of	O
saline	O
or	O
20E	O
(	O
5	O
mg	O
/	O
kg	O
/	O
day	O
)	O
for	O
5	O
or	O
15	O
days	O
using	O
subcutaneously	O
implanted	O
Alzet	O
	O
osmotic	O
pumps	O
.	O

The	O
masses	O
of	O
the	O
total	O
body	O
,	O
muscle	O
groups	O
and	O
organs	O
were	O
determined	O
.	O

There	O
was	O
a	O
significant	O
increase	O
(	O
p	O
=	O
0.01	O
)	O
in	O
the	O
mass	O
of	O
triceps	O
brachii	O
in	O
mice	O
treated	O
with	O
20E	O
for	O
5	O
days	O
(	O
115	O
	O
8	O
mg	O
)	O
compared	O
with	O
mice	O
treated	O
with	O
saline	O
for	O
5	O
days	O
(	O
88	O
	O
3	O
mg	O
)	O
,	O
however	O
,	O
there	O
were	O
no	O
differences	O
in	O
the	O
other	O
measured	O
parameters	O
.	O

To	O
determine	O
potential	O
mechanisms	O
of	O
20E	O
in	O
skeletal	O
muscle	O
,	O
Illumina	O
's	O
Mouse	O
Whole	O
Genome-6	O
v2.0	O
Expression	O
BeadChips	O
were	O
used	O
to	O
evaluate	O
changes	O
in	O
gene	O
expression	O
of	O
the	O
triceps	O
brachii	O
after	O
20E	O
infusion	O
.	O

Ingenuity	O
Pathways	O
Analysis	O
was	O
used	O
to	O
identify	O
genes	O
with	O
the	O
most	O
evidence	O
for	O
differential	O
expression	O
,	O
of	O
which	O
,	O
16	O
genes	O
involved	O
in	O
the	O
skeletal	O
and	O
muscular	O
system	O
were	O
identified	O
.	O

Overall	O
,	O
the	O
data	O
suggest	O
that	O
20E	O
does	O
not	O
have	O
potent	O
anabolic	O
properties	O
,	O
however	O
,	O
a	O
muscle	O
-	O
specific	O
increase	O
was	O
observed	O
and	O
genes	O
were	O
identified	O
to	O
provide	O
an	O
explanation	O
for	O
the	O
muscle	O
accretion	O
.	O

Continuous	O
production	O
of	O
drug	O
nanoparticle	O
suspensions	O
via	O
wet	O
stirred	O
media	O
milling	O
:	O
a	O
fresh	O
look	O
at	O
the	O
Rehbinder	O
effect	O
.	O

Nanoparticles	O
of	O
BCS	O
Class	O
II	O
drugs	O
are	O
produced	O
in	O
wet	O
stirred	O
media	O
mills	O
operating	O
in	O
batch	O
or	O
recirculation	O
mode	O
with	O
the	O
goal	O
of	O
resolving	O
the	O
poor	O
water	O
-	O
solubility	O
issue	O
.	O

Scant	O
information	O
is	O
available	O
regarding	O
the	O
continuous	O
production	O
of	O
drug	O
nanoparticles	O
via	O
wet	O
media	O
milling	O
.	O

Griseofulvin	B
and	O
Naproxen	B
were	O
milled	O
in	O
both	O
recirculation	O
mode	O
and	O
multi	O
-	O
pass	O
continuous	O
mode	O
to	O
study	O
the	O
breakage	O
dynamics	O
and	O
to	O
determine	O
the	O
effects	O
of	O
suspension	O
flow	O
rate	O
.	O

The	O
evolution	O
of	O
the	O
median	O
particle	O
size	O
was	O
measured	O
and	O
described	O
by	O
an	O
empirical	O
breakage	O
model	O
.	O

We	O
found	O
that	O
these	O
two	O
operation	O
modes	O
could	O
produce	O
drug	O
nanosuspensions	O
with	O
similar	O
particle	O
size	O
distributions	O
(	O
PSDs	O
)	O
.	O

A	O
reduced	O
suspension	O
flow	O
rate	O
slowed	O
the	O
breakage	O
rate	O
and	O
led	O
to	O
a	O
wider	O
PSD	O
and	O
more	O
differentiation	O
between	O
the	O
two	O
operation	O
modes	O
.	O

The	O
latter	O
part	O
of	O
this	O
study	O
focused	O
on	O
the	O
roles	O
of	O
stabilizers	O
(	O
hydroxypropyl	B
cellulose	O
and	O
sodium	B
lauryl	I
sulfate	I
)	O
and	O
elucidation	O
of	O
the	O
so	O
-	O
called	O
Rehbinder	O
effect	O
(	O
reduction	O
in	O
particle	O
strength	O
due	O
to	O
adsorbed	O
stabilizers	O
such	O
as	O
polymers	O
and	O
surfactants	O
)	O
.	O

Milling	O
the	O
drugs	O
in	O
the	O
absence	O
of	O
the	O
stabilizers	O
produced	O
primary	O
nanoparticles	O
and	O
their	O
aggregates	O
,	O
while	O
milling	O
with	O
the	O
stabilizers	O
produced	O
smaller	O
primary	O
nanoparticles	O
with	O
minimal	O
aggregation	O
.	O

Using	O
laser	O
diffraction	O
,	O
BET	O
nitrogen	B
adsorption	O
,	O
scanning	O
electron	O
microscopy	O
imaging	O
,	O
and	O
a	O
microhydrodynamic	O
analysis	O
of	O
milling	O
,	O
this	O
study	O
,	O
for	O
the	O
first	O
time	O
,	O
provides	O
sufficient	O
evidence	O
for	O
the	O
existence	O
of	O
the	O
Rehbinder	O
effect	O
during	O
the	O
milling	O
of	O
drugs	O
.	O

Not	O
only	O
do	O
the	O
polymers	O
and	O
surfactants	O
allow	O
proper	O
stabilization	O
of	O
the	O
nanoparticles	O
in	O
the	O
suspensions	O
,	O
but	O
they	O
also	O
do	O
facilitate	O
drug	O
particle	O
breakage	O
.	O

PTPN14	O
interacts	O
with	O
and	O
negatively	O
regulates	O
the	O
oncogenic	O
function	O
of	O
YAP	O
.	O

The	O
Hippo	O
signaling	O
pathway	O
regulates	O
cellular	O
proliferation	O
and	O
survival	O
,	O
thus	O
exerting	O
profound	O
effects	O
on	O
normal	O
cell	O
fate	O
and	O
tumorigenesis	O
.	O

The	O
pivotal	O
effector	O
of	O
this	O
pathway	O
is	O
YAP	O
,	O
a	O
transcriptional	O
co	O
-	O
activator	O
amplified	O
in	O
mouse	O
and	O
human	O
cancers	O
where	O
it	O
promotes	O
epithelial	O
-	O
to	O
-	O
mesenchymal	O
transition	O
and	O
malignant	O
transformation	O
.	O

Here	O
,	O
we	O
report	O
a	O
novel	O
regulatory	O
mechanism	O
for	O
the	O
YAP	O
oncogenic	O
function	O
via	O
direct	O
interaction	O
with	O
non	O
-	O
receptor	O
tyrosine	B
phosphatase	O
14	O
(	O
PTPN14	O
)	O
through	O
the	O
WW	O
domain	O
of	O
YAP	O
and	O
the	O
PPxY	O
domain	O
of	O
PTPN14	O
.	O

We	O
also	O
found	O
that	O
YAP	O
is	O
a	O
direct	O
substrate	O
of	O
PTPN14	O
.	O

In	O
addition	O
,	O
luciferase	O
reporter	O
assay	O
showed	O
that	O
the	O
inhibition	O
of	O
the	O
YAP	O
transcriptional	O
co	O
-	O
activator	O
function	O
by	O
PTPN14	O
is	O
mediated	O
through	O
their	O
protein	O
interactions	O
and	O
may	O
result	O
from	O
an	O
increase	O
in	O
the	O
inactive	O
cytoplasmic	O
form	O
of	O
YAP	O
.	O

Last	O
,	O
knockdown	O
of	O
PTPN14	O
induces	O
the	O
nuclear	O
retention	O
of	O
YAP	O
and	O
increases	O
the	O
YAP	O
-	O
dependent	O
cell	O
migration	O
.	O

In	O
summary	O
,	O
our	O
results	O
indicate	O
a	O
potential	O
regulatory	O
role	O
of	O
PTPN14	O
on	O
YAP	O
and	O
demonstrate	O
a	O
novel	O
mechanism	O
in	O
YAP	O
regulation	O
.	O

The	O
autophagy	O
-	O
associated	O
factors	O
DRAM1	O
and	O
p62	O
regulate	O
cell	O
migration	O
and	O
invasion	O
in	O
glioblastoma	O
stem	O
cells	O
.	O

The	O
aggressiveness	O
of	O
glioblastoma	O
multiforme	O
(	O
GBM	O
)	O
is	O
defined	O
by	O
local	O
invasion	O
and	O
resistance	O
to	O
therapy	O
.	O

Within	O
established	O
GBM	O
,	O
a	O
subpopulation	O
of	O
tumor	O
-	O
initiating	O
cells	O
with	O
stem	O
-	O
like	O
properties	O
(	O
GBM	O
stem	O
cells	O
,	O
GSCs	O
)	O
is	O
believed	O
to	O
underlie	O
resistance	O
to	O
therapy	O
.	O

The	O
metabolic	O
pathway	O
autophagy	O
has	O
been	O
implicated	O
in	O
the	O
regulation	O
of	O
survival	O
in	O
GBM	O
.	O

However	O
,	O
the	O
status	O
of	O
autophagy	O
in	O
GBM	O
and	O
its	O
role	O
in	O
the	O
cancer	O
stem	O
cell	O
fraction	O
is	O
currently	O
unclear	O
.	O

We	O
found	O
that	O
a	O
number	O
of	O
autophagy	O
regulators	O
are	O
highly	O
expressed	O
in	O
GBM	O
tumors	O
carrying	O
a	O
mesenchymal	O
signature	O
,	O
which	O
defines	O
aggressiveness	O
and	O
invasion	O
,	O
and	O
are	O
associated	O
with	O
components	O
of	O
the	O
MAPK	O
pathway	O
.	O

This	O
autophagy	O
signature	O
included	O
the	O
autophagy	O
-	O
associated	O
genes	O
DRAM1	O
and	O
SQSTM1	O
,	O
which	O
encode	O
a	O
key	O
regulator	O
of	O
selective	O
autophagy	O
,	O
p62	O
.	O

High	O
levels	O
of	O
DRAM1	O
were	O
associated	O
with	O
shorter	O
overall	O
survival	O
in	O
GBM	O
patients	O
.	O

In	O
GSCs	O
,	O
DRAM1	O
and	O
SQSTM1	O
expression	O
correlated	O
with	O
activation	O
of	O
MAPK	O
and	O
expression	O
of	O
the	O
mesenchymal	O
marker	O
c	O
-	O
MET	O
.	O

DRAM1	O
knockdown	O
decreased	O
p62	O
localization	O
to	O
autophagosomes	O
and	O
its	O
autophagy	O
-	O
mediated	O
degradation	O
,	O
thus	O
suggesting	O
a	O
role	O
for	O
DRAM1	O
in	O
p62-mediated	O
autophagy	O
.	O

In	O
contrast	O
,	O
autophagy	O
induced	O
by	O
starvation	O
or	O
inhibition	O
of	O
mTOR	O
/	O
PI-3	O
K	O
was	O
not	O
affected	O
by	O
either	O
DRAM1	O
or	O
p62	O
downregulation	O
.	O

Functionally	O
,	O
DRAM1	O
and	O
p62	O
regulate	O
cell	O
motility	O
and	O
invasion	O
in	O
GSCs	O
.	O

This	O
was	O
associated	O
with	O
alterations	O
of	O
energy	O
metabolism	O
,	O
in	O
particular	O
reduced	O
ATP	B
and	O
lactate	B
levels	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
shed	O
new	O
light	O
on	O
the	O
role	O
of	O
autophagy	O
in	O
GBM	O
and	O
reveal	O
a	O
novel	O
function	O
of	O
the	O
autophagy	O
regulators	O
DRAM1	O
and	O
p62	O
in	O
control	O
of	O
migration	O
/	O
invasion	O
in	O
cancer	O
stem	O
cells	O
.	O

Effect	O
of	O
water	O
extracts	O
from	O
edible	O
myrtaceae	O
plants	O
on	O
uptake	O
of	O
2-	B
(	I
n-	I
(	I
7-nitrobenz-2-oxa-1,3-diazol-4-yl	I
)	I
amino	I
)	I
-2-deoxyglucose	I
in	O
TNF	O
-	O
	O
-	O
treated	O
FL83B	O
mouse	O
hepatocytes	O
.	O

This	O
study	O
investigated	O
the	O
glucose	B
uptake	O
activity	O
of	O
the	O
water	O
extracts	O
from	O
the	O
leaves	O
and	O
fruit	O
of	O
edible	O
Myrtaceae	O
plants	O
,	O
including	O
guava	O
(	O
Psidium	O
guajava	O
Linn	O
.	O
)	O
,	O
wax	O
apples	O
[	O
Syzygium	O
samarangense	O
(	O
Blume	O
)	O
Merr	O
.	O

and	O
L.M.	O
Perry	O
]	O
,	O
Pu	O
-	O
Tau	O
[	O
Syzygium	O
jambo	O
(	O
L.	O
)	O
Alston	O
]	O
,	O
and	O
Kan	O
-	O
Shi	O
Pu	O
-	O
Tau	O
(	O
Syzygium	O
cumini	O
Linn	O
.	O
)	O
in	O
FL83B	O
mouse	O
hepatocytes	O
.	O

The	O
fluorescent	O
dye	O
2-	B
(	I
n-	I
(	I
7-nitrobenz-2-oxa-1,3-diazol-4-yl	I
)	I
amino	I
)	I
-2-deoxyglucose	I
was	O
used	O
to	O
estimate	O
the	O
uptake	O
ability	O
of	O
the	O
cells	O
.	O

Glucose	B
uptake	O
test	O
showed	O
that	O
pink	O
wax	O
apple	O
fruit	O
extract	O
(	O
PWFE	O
)	O
exhibits	O
the	O
highest	O
glucose	B
uptake	O
activity	O
,	O
at	O
an	O
increment	O
of	O
21	O
%	O
in	O
the	O
insulin	O
-	O
resistant	O
FL83B	O
mouse	O
hepatocytes	O
as	O
compared	O
with	O
the	O
TNF	O
-	O
	O
-	O
treated	O
control	O
group	O
.	O

Vescalagin	B
was	O
isolated	O
using	O
column	O
chromatography	O
of	O
PWFE	O
.	O

This	O
compound	O
,	O
at	O
the	O
concentration	O
of	O
6.25	O
g	O
/	O
mL	O
,	O
exhibits	O
the	O
same	O
glucose	B
uptake	O
improvement	O
in	O
insulin	O
-	O
resistant	O
cells	O
as	O
PWFE	O
at	O
a	O
100-g	O
/	O
mL	O
dose	O
.	O

We	O
postulate	O
that	O
vescalagin	B
is	O
an	O
active	O
component	O
in	O
PWFE	O
that	O
may	O
alleviate	O
the	O
insulin	O
resistance	O
in	O
mouse	O
hepatocytes	O
.	O

TRAPPC9-related	O
autosomal	O
recessive	O
intellectual	O
disability	O
:	O
report	O
of	O
a	O
new	O
mutation	O
and	O
clinical	O
phenotype	O
.	O

Intellectual	O
disability	O
(	O
ID	O
)	O
with	O
autosomal	O
recessive	O
(	O
AR	O
)	O
inheritance	O
is	O
believed	O
to	O
be	O
common	O
;	O
however	O
,	O
very	O
little	O
is	O
known	O
about	O
causative	O
genes	O
and	O
genotype	O
-	O
phenotype	O
correlations	O
.	O

The	O
broad	O
genetic	O
heterogeneity	O
of	O
AR	O
-	O
ID	O
,	O
and	O
its	O
usually	O
nonsyndromic	O
nature	O
make	O
it	O
difficult	O
to	O
pool	O
multiple	O
pedigrees	O
with	O
the	O
same	O
underlying	O
genetic	O
defect	O
to	O
achieve	O
consistent	O
nosology	O
.	O

Nearly	O
all	O
autosomal	O
genes	O
responsible	O
for	O
recessive	O
cognitive	O
disorders	O
have	O
been	O
identified	O
in	O
large	O
consanguineous	O
families	O
from	O
the	O
Middle	O
East	O
,	O
and	O
nonsense	O
mutations	O
in	O
TRAPPC9	O
have	O
been	O
reported	O
in	O
a	O
total	O
of	O
5	O
.	O

Although	O
several	O
recurrent	O
phenotypic	O
abnormalities	O
are	O
described	O
in	O
some	O
of	O
these	O
patients	O
,	O
the	O
associated	O
phenotype	O
is	O
usually	O
referred	O
to	O
as	O
nonsyndromic	O
.	O

By	O
means	O
of	O
single	O
-	O
nucleotide	O
polymorphism	O
-	O
array	O
first	O
and	O
then	O
by	O
exome	O
sequencing	O
,	O
we	O
identified	O
a	O
new	O
pathogenic	O
mutation	O
in	O
TRAPPC9	O
in	O
two	O
Italian	O
sisters	O
born	O
to	O
healthy	O
and	O
apparently	O
nonconsanguineous	O
parents	O
.	O

It	O
consists	O
of	O
a	O
homozygous	O
splice	O
site	O
mutation	O
causing	O
exon	O
skipping	O
with	O
frameshift	O
and	O
premature	O
termination	O
,	O
as	O
confirmed	O
by	O
mRNA	O
sequencing	O
.	O

By	O
detailed	O
phenotypic	O
analysis	O
of	O
our	O
patients	O
,	O
and	O
by	O
critical	O
literature	O
review	O
,	O
we	O
found	O
that	O
homozygous	O
TRAPPC9	O
loss	O
-	O
of	O
-	O
function	O
mutations	O
cause	O
a	O
distinctive	O
phenotype	O
,	O
characterized	O
by	O
peculiar	O
facial	O
appearance	O
,	O
obesity	O
,	O
hypotonia	O
(	O
all	O
signs	O
resembling	O
a	O
Prader	O
-	O
Willi	O
-	O
like	O
phenotype	O
)	O
,	O
moderate	O
-	O
to	O
-	O
severe	O
ID	O
,	O
and	O
consistent	O
brain	O
abnormalities	O
.	O

The	O
effect	O
of	O
process	O
parameters	O
on	O
audible	O
acoustic	O
emissions	O
from	O
high	O
-	O
shear	O
granulation	O
.	O

Product	O
quality	O
in	O
high	O
-	O
shear	O
granulation	O
is	O
easily	O
compromised	O
by	O
minor	O
changes	O
in	O
raw	O
material	O
properties	O
or	O
process	O
conditions	O
.	O

It	O
is	O
desired	O
to	O
develop	O
a	O
process	O
analytical	O
technology	O
(	O
PAT	O
)	O
that	O
can	O
monitor	O
the	O
process	O
in	O
real	O
-	O
time	O
and	O
provide	O
feedback	O
for	O
quality	O
control	O
.	O

In	O
this	O
work	O
,	O
the	O
application	O
of	O
audible	O
acoustic	O
emissions	O
(	O
AAEs	O
)	O
as	O
a	O
PAT	O
tool	O
was	O
investigated	O
.	O

A	O
condenser	O
microphone	O
was	O
placed	O
at	O
the	O
top	O
of	O
the	O
air	O
exhaust	O
on	O
a	O
PMA-10	O
high	O
-	O
shear	O
granulator	O
to	O
collect	O
AAEs	O
for	O
a	O
design	O
of	O
experiment	O
(	O
DOE	O
)	O
varying	O
impeller	O
speed	O
,	O
total	O
binder	O
volume	O
and	O
spray	O
rate	O
.	O

The	O
results	O
showed	O
the	O
10	O
Hz	O
total	O
power	O
spectral	O
densities	O
(	O
TPSDs	O
)	O
between	O
20	O
and	O
250	O
Hz	O
were	O
significantly	O
affected	O
by	O
the	O
changes	O
in	O
process	O
conditions	O
.	O

Impeller	O
speed	O
and	O
spray	O
rate	O
were	O
shown	O
to	O
have	O
statistically	O
significant	O
effects	O
on	O
granulation	O
wetting	O
,	O
and	O
impeller	O
speed	O
and	O
total	O
binder	O
volume	O
were	O
significant	O
in	O
terms	O
of	O
process	O
end	O
-	O
point	O
.	O

The	O
DOE	O
results	O
were	O
confirmed	O
by	O
a	O
multivariate	O
PLS	O
model	O
of	O
the	O
TPSDs	O
.	O

The	O
scores	O
plot	O
showed	O
separation	O
based	O
on	O
impeller	O
speed	O
in	O
the	O
first	O
component	O
and	O
spray	O
rate	O
in	O
the	O
second	O
component	O
.	O

The	O
findings	O
support	O
the	O
use	O
of	O
AAEs	O
to	O
monitor	O
changes	O
in	O
process	O
conditions	O
in	O
real	O
-	O
time	O
and	O
achieve	O
consistent	O
product	O
quality	O
.	O

Discovery	O
and	O
structural	O
characterization	O
of	O
a	O
phospholamban	O
-	O
binding	O
cyclic	O
peptide	O
and	O
design	O
of	O
novel	O
inhibitors	O
of	O
phospholamban	O
.	O

The	O
interplay	O
between	O
cardiac	O
sarcoplasmic	O
Ca	B
(	I
2+	I
)	I
ATPase	O
and	O
phospholamban	O
is	O
a	O
key	O
regulating	O
factor	O
of	O
contraction	O
and	O
relaxation	O
in	O
the	O
cardiac	O
muscle	O
.	O

In	O
heart	O
failure	O
,	O
aberrations	O
in	O
the	O
inhibition	O
of	O
sarcoplasmic	O
Ca	B
(	I
2+	I
)	I
ATPase	O
by	O
phospholamban	O
are	O
associated	O
with	O
anomalies	O
in	O
cardiac	O
functions	O
.	O

In	O
experimental	O
heart	O
failure	O
models	O
,	O
modulation	O
of	O
the	O
interaction	O
between	O
these	O
two	O
proteins	O
has	O
been	O
shown	O
to	O
be	O
a	O
potential	O
therapeutic	O
approach	O
.	O

The	O
aim	O
of	O
our	O
research	O
was	O
to	O
find	O
molecules	O
able	O
to	O
interfere	O
with	O
the	O
inhibitory	O
activity	O
of	O
phospholamban	O
on	O
sarcoplasmic	O
Ca	B
(	I
2+	I
)	I
ATPase	O
.	O

For	O
this	O
purpose	O
,	O
a	O
portion	O
of	O
phospholamban	O
was	O
synthesized	O
and	O
used	O
as	O
target	O
for	O
a	O
phage	O
-	O
display	O
peptide	O
library	O
screening	O
.	O

The	O
cyclic	O
peptide	O
C	O
-	O
Y	O
-	O
W	O
-	O
E	O
-	O
L	O
-	O
E	O
-	O
W	O
-	O
L	O
-	O
P	O
-	O
C	O
-	O
A	O
was	O
found	O
to	O
bind	O
to	O
phospholamban	O
(	O
1	O
-	O
36	O
)	O
with	O
high	O
specificity	O
.	O

Its	O
functional	O
activity	O
was	O
tested	O
in	O
Ca	B
(	I
2+	I
)	I
uptake	O
assays	O
utilizing	O
preparations	O
from	O
cardiac	O
sarcoplasmic	O
reticulum	O
.	O

By	O
synthesizing	O
and	O
testing	O
a	O
series	O
of	O
alanine	B
point	O
-	O
mutated	O
cyclic	O
peptides	O
,	O
we	O
identified	O
which	O
amino	B
acid	I
was	O
important	O
for	O
the	O
inhibition	O
of	O
the	O
phospholamban	O
function	O
.	O

The	O
structures	O
of	O
active	O
and	O
inactive	O
alanine	B
-	O
mutated	O
cyclic	O
peptides	O
,	O
and	O
of	O
phospholamban	O
(	O
1	O
-	O
36	O
)	O
,	O
were	O
determined	O
by	O
NMR	O
.	O

This	O
structure	O
-	O
activity	O
analysis	O
allowed	O
building	O
a	O
model	O
of	O
phospholamban	O
-cyclic	O
peptide	O
complex	O
.	O

Thereafter	O
,	O
a	O
simple	O
pharmacophore	O
was	O
defined	O
and	O
used	O
for	O
the	O
design	O
of	O
small	O
molecules	O
.	O

Finally	O
,	O
examples	O
of	O
such	O
molecules	O
were	O
synthesized	O
and	O
characterized	O
as	O
phospholamban	O
inhibitors	O
.	O

Organ	O
accumulation	O
in	O
mice	O
after	O
inhalation	O
of	O
single	O
or	O
mixed	O
essential	O
oil	O
compounds	O
.	O

Essential	O
oils	O
are	O
composed	O
of	O
multiple	O
components	O
.	O

It	O
is	O
thought	O
that	O
the	O
effect	O
of	O
essential	O
oils	O
is	O
due	O
to	O
specific	O
component	O
ratios	O
,	O
which	O
may	O
differ	O
from	O
the	O
original	O
ratio	O
when	O
the	O
essential	O
oil	O
is	O
absorbed	O
.	O

However	O
,	O
very	O
little	O
detailed	O
research	O
exists	O
in	O
this	O
area	O
.	O

We	O
studied	O
the	O
distribution	O
of	O
essential	O
oil	O
components	O
after	O
inhalation	O
of	O
single	O
and	O
mixed	O
components	O
in	O
mice	O
.	O

This	O
research	O
was	O
done	O
using	O
four	O
main	O
components	O
of	O
Alpinia	O
zerumbet	O
(	O
Pers	O
.	O
)	O

B.	O
L.	O
Burtt	O
.	O

and	O
R.	O
M.	O
Sm	O
.	O

:	O
	B
-	I
pinene	I
,	O
p	B
-	I
cymene	I
,	O
1,8-cineole	B
,	O
and	O
limonene	B
.	O

After	O
inhalation	O
of	O
single	O
or	O
mixed	O
components	O
for	O
90	O
min	O
,	O
component	O
levels	O
in	O
the	O
brain	O
and	O
liver	O
of	O
mice	O
were	O
measured	O
.	O

The	O
results	O
indicated	O
that	O
the	O
amount	O
of	O
	B
-	I
pinene	I
in	O
the	O
brain	O
and	O
liver	O
was	O
twofold	O
greater	O
after	O
mixed	O
-	O
component	O
inhalation	O
than	O
that	O
after	O
single	O
-	O
component	O
inhalation	O
.	O

In	O
a	O
comparison	O
of	O
the	O
components	O
of	O
the	O
mixed	O
inhalation	O
,	O
the	O
ratio	O
of	O
	B
-	I
pinene	I
increased	O
to	O
about	O
three	O
times	O
that	O
of	O
1,8-cineole	B
.	O

It	O
is	O
thought	O
that	O
the	O
absorption	O
via	O
the	O
nasal	O
mucus	O
greatly	O
influences	O
this	O
phenomenon	O
.	O

The	O
results	O
of	O
this	O
investigation	O
of	O
the	O
bodily	O
distribution	O
of	O
essential	O
oil	O
volatile	O
components	O
may	O
provide	O
clues	O
for	O
elucidating	O
their	O
action	O
.	O

Mitochondrial	O
activation	O
by	O
inhibition	O
of	O
PDKII	O
suppresses	O
HIF1a	O
signaling	O
and	O
angiogenesis	O
in	O
cancer	O
.	O

Most	O
solid	O
tumors	O
are	O
characterized	O
by	O
a	O
metabolic	O
shift	O
from	O
glucose	B
oxidation	O
to	O
glycolysis	O
,	O
in	O
part	O
due	O
to	O
actively	O
suppressed	O
mitochondrial	O
function	O
,	O
a	O
state	O
that	O
favors	O
resistance	O
to	O
apoptosis	O
.	O

Suppressed	O
mitochondrial	O
function	O
may	O
also	O
contribute	O
to	O
the	O
activation	O
of	O
hypoxia	O
-	O
inducible	O
factor	O
1	O
(	O
HIF1	O
)	O
and	O
angiogenesis	O
.	O

We	O
have	O
previously	O
shown	O
that	O
the	O
inhibitor	O
of	O
pyruvate	B
dehydrogenase	O
kinase	O
(	O
PDK	O
)	O
dichloroacetate	B
(	O
DCA	B
)	O
activates	O
glucose	B
oxidation	O
and	O
induces	O
apoptosis	O
in	O
cancer	O
cells	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

We	O
hypothesized	O
that	O
DCA	B
will	O
also	O
reverse	O
the	O
'	O
pseudohypoxic	O
'	O
mitochondrial	O
signals	O
that	O
lead	O
to	O
HIF1	O
activation	O
in	O
cancer	O
,	O
even	O
in	O
the	O
absence	O
of	O
hypoxia	O
and	O
inhibit	O
cancer	O
angiogenesis	O
.	O

We	O
show	O
that	O
inhibition	O
of	O
PDKII	O
inhibits	O
HIF1	O
in	O
cancer	O
cells	O
using	O
several	O
techniques	O
,	O
including	O
HIF1	O
luciferase	O
reporter	O
assays	O
.	O

Using	O
pharmacologic	O
and	O
molecular	O
approaches	O
that	O
suppress	O
the	O
prolyl	B
-	O
hydroxylase	O
(	O
PHD	O
)	O
-mediated	O
inhibition	O
of	O
HIF1	O
,	O
we	O
show	O
that	O
DCA	B
inhibits	O
HIF1	O
by	O
both	O
a	O
PHD	O
-	O
dependent	O
mechanism	O
(	O
that	O
involves	O
a	O
DCA	B
-	O
induced	O
increase	O
in	O
the	O
production	O
of	O
mitochondria	O
-	O
derived	O
	B
-	I
ketoglutarate	I
)	O
and	O
a	O
PHD	O
-	O
independent	O
mechanism	O
,	O
involving	O
activation	O
of	O
p53	O
via	O
mitochondrial	O
-	O
derived	O
H	B
(	I
2	I
)	I
O	I
(	I
2	I
)	I
,	O
as	O
well	O
as	O
activation	O
of	O
GSK3	O
.	O

Effective	O
inhibition	O
of	O
HIF1	O
is	O
shown	O
by	O
a	O
decrease	O
in	O
the	O
expression	O
of	O
several	O
HIF1	O
regulated	O
gene	O
products	O
as	O
well	O
as	O
inhibition	O
of	O
angiogenesis	O
in	O
vitro	O
in	O
matrigel	O
assays	O
.	O

More	O
importantly	O
,	O
in	O
rat	O
xenotransplant	O
models	O
of	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
and	O
breast	O
cancer	O
,	O
we	O
show	O
effective	O
inhibition	O
of	O
angiogenesis	O
and	O
tumor	O
perfusion	O
in	O
vivo	O
,	O
assessed	O
by	O
contrast	O
-	O
enhanced	O
ultrasonography	O
,	O
nuclear	O
imaging	O
techniques	O
and	O
histology	O
.	O

This	O
work	O
suggests	O
that	O
mitochondria	O
-	O
targeting	O
metabolic	O
modulators	O
that	O
increase	O
pyruvate	B
dehydrogenase	O
activity	O
,	O
in	O
addition	O
to	O
the	O
recently	O
described	O
pro	O
-	O
apoptotic	O
and	O
anti	O
-	O
proliferative	O
effects	O
,	O
suppress	O
angiogenesis	O
as	O
well	O
,	O
normalizing	O
the	O
pseudo	O
-	O
hypoxic	O
signals	O
that	O
lead	O
to	O
normoxic	O
HIF1	O
activation	O
in	O
solid	O
tumors	O
.	O

Macrophage	O
cathepsin	O
K	O
promotes	O
prostate	O
tumor	O
progression	O
in	O
bone	O
.	O

Bone	O
marrow	O
macrophages	O
(	O
BMMs	O
)	O
share	O
common	O
progenitors	O
with	O
osteoclasts	O
and	O
are	O
critical	O
components	O
of	O
bone	O
-	O
tumor	O
microenvironment	O
;	O
however	O
,	O
their	O
function	O
in	O
prostate	O
tumor	O
growth	O
in	O
the	O
skeleton	O
has	O
not	O
been	O
explored	O
.	O

BMMs	O
are	O
the	O
major	O
source	O
of	O
inflammatory	O
factors	O
and	O
proteases	O
,	O
including	O
cysteine	B
protease	O
cathepsin	O
K	O
(	O
CTSK	O
)	O
.	O

In	O
this	O
study	O
,	O
utilizing	O
mice	O
deficient	O
in	O
CTSK	O
,	O
we	O
demonstrate	O
the	O
critical	O
involvement	O
of	O
this	O
potent	O
collagenase	O
in	O
tumor	O
progression	O
in	O
bone	O
.	O

We	O
present	O
the	O
evidence	O
that	O
tumor	O
growth	O
and	O
progression	O
in	O
the	O
bone	O
are	O
impaired	O
in	O
the	O
absence	O
of	O
CTSK	O
.	O

Most	O
importantly	O
,	O
we	O
show	O
for	O
the	O
first	O
time	O
that	O
BMM	O
-	O
supplied	O
CTSK	O
may	O
be	O
involved	O
in	O
CCL2-	O
and	O
COX-2-driven	O
pathways	O
that	O
contribute	O
to	O
tumor	O
progression	O
in	O
bone	O
.	O

Together	O
,	O
our	O
data	O
unravel	O
novel	O
roles	O
for	O
CTSK	O
in	O
macrophage	O
-	O
regulated	O
processes	O
,	O
and	O
provide	O
evidence	O
for	O
close	O
interplay	O
between	O
inflammatory	O
,	O
osteolytic	O
and	O
tumor	O
cell	O
-	O
driven	O
events	O
in	O
the	O
bone	O
-	O
tumor	O
microenvironment	O
.	O

Silibinin	B
triggers	O
apoptosis	O
and	O
cell	O
-	O
cycle	O
arrest	O
of	O
SGC7901	O
cells	O
.	O

Silibinin	B
,	O
a	O
flavonoid	B
compound	O
,	O
has	O
shown	O
to	O
be	O
of	O
chemopreventive	O
potential	O
against	O
many	O
cancers	O
.	O

However	O
,	O
its	O
efficacy	O
against	O
gastric	O
cancer	O
has	O
not	O
been	O
well	O
elucidated	O
.	O

Here	O
,	O
we	O
assessed	O
the	O
activity	O
of	O
Silibinin	B
on	O
apoptosis	O
and	O
cell	O
-	O
cycle	O
arrest	O
in	O
human	O
gastric	O
cells	O
culture	O
system	O
using	O
SGC-7901	O
as	O
the	O
model	O
.	O

Silibinin	B
treatment	O
could	O
inhibit	O
the	O
cell	O
growth	O
and	O
cause	O
a	O
prominent	O
G2	O
phase	O
arrest	O
and	O
apoptosis	O
in	O
dose-	O
and	O
time	O
-	O
dependent	O
manner	O
.	O

In	O
mechanistic	O
studies	O
,	O
Silibinin	B
decreased	O
the	O
protein	O
level	O
of	O
p34cdc2	O
,	O
which	O
might	O
be	O
the	O
possible	O
molecular	O
mechanism	O
of	O
Silibinin	B
efficacy	O
on	O
the	O
growth	O
inhibition	O
in	O
SGC-7901	O
cells	O
.	O

In	O
addition	O
,	O
Silibinin	B
caused	O
an	O
increase	O
in	O
p53	O
and	O
p21	O
protein	O
level	O
as	O
well	O
as	O
mRNA	O
levels	O
.	O

Interestingly	O
,	O
Silibinin	B
-	O
induced	O
apoptosis	O
in	O
SGC-7901	O
cells	O
was	O
independent	O
of	O
caspases	O
activation	O
.	O

These	O
results	O
indicated	O
that	O
Silibinin	B
is	O
a	O
cell	O
-	O
cycle	O
regulator	O
and	O
apoptosis	O
inducer	O
in	O
human	O
gastric	O
carcinoma	O
SGC-7901	O
cells	O
and	O
might	O
be	O
used	O
as	O
a	O
candidate	O
chemopreventive	O
agent	O
for	O
gastric	O
carcinoma	O
prevention	O
and	O
intervention	O
.	O

Copyright	O
	O
2012	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd.	O

Acetylation	O
and	O
deacetylation	O
--	O
novel	O
factors	O
in	O
muscle	O
wasting	O
.	O

We	O
review	O
recent	O
evidence	O
that	O
acetylation	O
and	O
deacetylation	O
of	O
cellular	O
proteins	O
,	O
including	O
transcription	O
factors	O
and	O
nuclear	O
cofactors	O
,	O
may	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
muscle	O
mass	O
.	O

The	O
level	O
of	O
protein	O
acetylation	O
is	O
balanced	O
by	O
histone	O
acetyltransferases	O
(	O
HATs	O
)	O
and	O
histone	O
deacetylases	O
(	O
HDACs	O
)	O
and	O
studies	O
suggest	O
that	O
this	O
balance	O
is	O
perturbed	O
in	O
muscle	O
wasting	O
.	O

Hyperacetylation	O
of	O
transcription	O
factors	O
and	O
nuclear	O
cofactors	O
regulating	O
gene	O
transcription	O
in	O
muscle	O
wasting	O
may	O
influence	O
muscle	O
mass	O
.	O

In	O
addition	O
,	O
hyperacetylation	O
may	O
render	O
proteins	O
susceptible	O
to	O
degradation	O
by	O
different	O
mechanisms	O
,	O
including	O
intrinsic	O
ubiquitin	O
ligase	O
activity	O
exerted	O
by	O
HATs	O
and	O
by	O
dissociation	O
of	O
proteins	O
from	O
cellular	O
chaperones	O
.	O

In	O
recent	O
studies	O
,	O
inhibition	O
of	O
p300	O
/	O
HAT	O
expression	O
and	O
activity	O
and	O
stimulation	O
of	O
SIRT1-dependent	O
HDAC	O
activity	O
reduced	O
glucocorticoid	O
-	O
induced	O
catabolic	O
response	O
in	O
skeletal	O
muscle	O
,	O
providing	O
further	O
evidence	O
that	O
hyperacetylation	O
plays	O
a	O
role	O
in	O
muscle	O
wasting	O
.	O

It	O
should	O
be	O
noted	O
,	O
however	O
,	O
that	O
although	O
several	O
studies	O
advocate	O
a	O
role	O
of	O
hyperacetylation	O
in	O
muscle	O
wasting	O
,	O
apparently	O
contradictory	O
results	O
have	O
also	O
been	O
reported	O
.	O

For	O
example	O
,	O
muscle	O
atrophy	O
caused	O
by	O
denervation	O
or	O
immobilization	O
may	O
be	O
associated	O
with	O
reduced	O
,	O
rather	O
than	O
increased	O
,	O
protein	O
acetylation	O
.	O

In	O
addition	O
,	O
whereas	O
hyperacetylation	O
results	O
in	O
increased	O
degradation	O
of	O
certain	O
proteins	O
,	O
other	O
proteins	O
may	O
be	O
stabilized	O
by	O
increased	O
acetylation	O
.	O

Thus	O
,	O
the	O
role	O
of	O
acetylation	O
and	O
deacetylation	O
in	O
the	O
regulation	O
of	O
muscle	O
mass	O
may	O
be	O
both	O
condition-	O
and	O
protein	O
-	O
specific	O
.	O

The	O
influence	O
of	O
HATs	O
and	O
HDACs	O
on	O
the	O
regulation	O
of	O
muscle	O
mass	O
,	O
as	O
well	O
as	O
methods	O
to	O
modulate	O
protein	O
acetylation	O
,	O
is	O
an	O
important	O
area	O
for	O
continued	O
research	O
aimed	O
at	O
preventing	O
and	O
treating	O
muscle	O
wasting	O
.	O

Combining	O
GLP-1	O
receptor	O
agonists	O
with	O
insulin	O
:	O
therapeutic	O
rationales	O
and	O
clinical	O
findings	O
.	O

Due	O
to	O
the	O
increasing	O
prevalence	O
of	O
type	O
2	O
diabetes	O
mellitus	O
(	O
T2DM	O
)	O
,	O
the	O
emergent	O
trend	O
towards	O
diagnosis	O
in	O
younger	O
patients	O
and	O
the	O
progressive	O
nature	O
of	O
this	O
disease	O
,	O
many	O
more	O
patients	O
than	O
before	O
now	O
require	O
insulin	O
to	O
maintain	O
glycaemic	O
control	O
.	O

However	O
,	O
there	O
is	O
a	O
degree	O
of	O
inertia	O
among	O
physicians	O
and	O
patients	O
regarding	O
the	O
initiation	O
and	O
intensification	O
of	O
insulin	O
therapy	O
,	O
in	O
part	O
due	O
to	O
concerns	O
about	O
the	O
associated	O
weight	O
gain	O
and	O
increased	O
risk	O
of	O
hypoglycaemia	O
.	O

Glucagon	O
-	O
like	O
peptide-1	O
receptor	O
agonists	O
(	O
GLP-1RAs	O
)	O
increase	O
insulin	O
release	O
and	O
suppress	O
glucagon	O
secretion	O
in	O
a	O
glucose	B
-	O
dependent	O
manner	O
,	O
thus	O
conferring	O
glycaemic	O
control	O
with	O
a	O
low	O
incidence	O
of	O
hypoglycaemia	O
.	O

GLP-1RAs	O
also	O
promote	O
weight	O
loss	O
,	O
and	O
have	O
beneficial	O
effects	O
on	O
markers	O
of	O
	O
cell	O
function	O
,	O
lipid	O
levels	O
,	O
blood	O
pressure	O
and	O
cardiovascular	O
risk	O
markers	O
.	O

However	O
,	O
the	O
durability	O
of	O
their	O
effectiveness	O
is	O
unknown	O
and	O
,	O
compared	O
with	O
insulin	O
,	O
the	O
antihyperglycaemic	O
efficacy	O
of	O
GLP-1RAs	O
is	O
limited	O
.	O

The	O
combination	O
of	O
a	O
GLP-1RA	O
and	O
insulin	O
might	O
thus	O
be	O
highly	O
effective	O
for	O
optimal	O
glucose	B
control	O
,	O
ameliorating	O
the	O
adverse	O
effects	O
typically	O
associated	O
with	O
insulin	O
.	O

Data	O
from	O
clinical	O
studies	O
support	O
the	O
therapeutic	O
potential	O
of	O
GLP-1RA	O
-	O
insulin	O
combination	O
therapy	O
,	O
typically	O
showing	O
beneficial	O
effects	O
on	O
glycaemic	O
control	O
and	O
body	O
weight	O
,	O
with	O
a	O
low	O
incidence	O
of	O
hypoglycaemia	O
and	O
,	O
in	O
established	O
insulin	O
therapy	O
,	O
facilitating	O
reductions	O
in	O
insulin	O
dose	O
.	O

In	O
this	O
review	O
,	O
the	O
physiological	O
and	O
pharmacological	O
rationale	O
for	O
using	O
GLP-1RA	O
and	O
insulin	O
therapies	O
in	O
combination	O
is	O
discussed	O
,	O
and	O
data	O
from	O
clinical	O
studies	O
that	O
have	O
assessed	O
the	O
efficacy	O
and	O
safety	O
of	O
this	O
treatment	O
strategy	O
are	O
outlined	O
.	O

Group	O
III	O
and	O
subtype	O
4	O
metabotropic	O
glutamate	B
receptor	O
agonists	O
:	O
discovery	O
and	O
pathophysiological	O
applications	O
in	O
Parkinson	O
's	O
disease	O
.	O

Restoring	O
the	O
balance	O
between	O
excitatory	O
and	O
inhibitory	O
circuits	O
in	O
the	O
basal	O
ganglia	O
,	O
following	O
the	O
loss	O
of	O
dopaminergic	O
(	O
DA	O
)	O
neurons	O
of	O
the	O
substantia	O
nigra	O
pars	O
compacta	O
,	O
represents	O
a	O
major	O
challenge	O
to	O
treat	O
patients	O
affected	O
by	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
.	O

The	O
imbalanced	O
situation	O
in	O
favor	O
of	O
excitation	O
in	O
the	O
disease	O
state	O
may	O
also	O
accelerate	O
excitotoxic	O
processes	O
,	O
thereby	O
representing	O
a	O
potential	O
target	O
for	O
neuroprotective	O
therapies	O
.	O

Reducing	O
the	O
excitatory	O
action	O
of	O
glutamate	B
,	O
the	O
major	O
excitatory	O
neurotransmitter	O
in	O
the	O
basal	O
ganglia	O
,	O
should	O
lead	O
to	O
symptomatic	O
improvement	O
for	O
PD	O
patients	O
and	O
may	O
promote	O
the	O
survival	O
of	O
DA	O
neurons	O
.	O

Recent	O
studies	O
have	O
focused	O
on	O
the	O
modulatory	O
action	O
of	O
metabotropic	O
glutamate	B
(	O
mGlu	O
)	O
receptors	O
on	O
neurodegenerative	O
diseases	O
including	O
PD	O
.	O

Group	O
III	O
mGlu	O
receptors	O
,	O
including	O
subtypes	O
4	O
,	O
7	O
and	O
8	O
,	O
are	O
largely	O
expressed	O
in	O
the	O
basal	O
ganglia	O
.	O

Recent	O
studies	O
highlight	O
the	O
use	O
of	O
selective	O
mGlu4	O
receptor	O
positive	O
allosteric	O
modulators	O
(	O
PAMs	O
)	O
for	O
the	O
treatment	O
of	O
PD	O
.	O

Here	O
we	O
review	O
the	O
effects	O
of	O
newly	O
-	O
designed	O
group	O
-	O
III	O
orthosteric	O
agonists	O
on	O
neuroprotection	O
,	O
neurorestoration	O
and	O
reduction	O
of	O
l	B
-	I
DOPA	I
induced	O
dyskinesia	O
in	O
animal	O
models	O
of	O
PD	O
.	O

The	O
combination	O
of	O
orthosteric	O
mGlu4	O
receptor	O
selective	O
agonists	O
with	O
PAMs	O
may	O
open	O
new	O
avenues	O
for	O
the	O
symptomatic	O
treatment	O
of	O
PD	O
.	O

This	O
article	O
is	O
part	O
of	O
a	O
Special	O
Issue	O
entitled	O
'	O
Metabotropic	O
Glutamate	B
Receptors	O
'	O
.	O

A	O
new	O
bromobenzyl	B
methyl	I
sulphoxide	I
from	O
marine	O
red	O
alga	O
Symphyocladia	O
latiuscula	O
.	O

A	O
new	O
bromophenol	B
,	O
2,3,6-tribromo-4,5-dihydroxybenzyl	B
methyl	I
sulphoxide	I
,	O
was	O
isolated	O
from	O
the	O
EtOH	B
extract	O
of	O
the	O
marine	O
alga	O
Symphyocladia	O
latiuscula	O
.	O

Its	O
structure	O
was	O
confirmed	O
by	O
spectroscopic	O
methods	O
(	O
1D-	O
and	O
2D	O
-	O
NMR	O
,	O
HR	O
-	O
ESI	O
-	O
MS	O
)	O
.	O

This	O
new	O
bromophenol	B
showed	O
moderate	O
antifungal	O
activity	O
against	O
Candida	O
albicans	O
with	O
MIC	O
value	O
of	O
37.5	O
g	O
mL	O
(	O
-1	O
)	O
.	O

Aromadendrine	B
,	O
a	O
new	O
component	O
of	O
the	O
flavonoid	B
pattern	O
of	O
Olea	O
europaea	O
L.	O
and	O
its	O
anti	O
-	O
inflammatory	O
activity	O
.	O

Leaves	O
of	O
Olea	O
europaea	O
,	O
cultivar	O
Nocellara	O
del	O
Belice	O
,	O
were	O
examined	O
with	O
respect	O
to	O
the	O
medium	O
-	O
polar	O
fraction	O
,	O
obtained	O
by	O
an	O
ethyl	B
acetate	I
extraction	O
of	O
the	O
whole	O
extract	O
.	O

In	O
the	O
medium	O
polar	O
fraction	O
,	O
we	O
isolated	O
the	O
two	O
hydroxy	B
-	I
phenyl	I
-	I
ethyl	I
alcohols	I
(	O
hydroxyl	B
-	I
tyrosol	I
and	O
tyrosol	B
)	O
that	O
are	O
the	O
main	O
component	O
of	O
olives	O
.	O

In	O
addition	O
,	O
we	O
isolated	O
a	O
flavonoidic	B
compound	O
,	O
aromadendrine	B
,	O
a	O
dihydroflavonol	B
yet	O
known	O
but	O
quite	O
rare	O
in	O
nature	O
.	O

It	O
is	O
the	O
first	O
time	O
that	O
aromadendrine	B
is	O
isolated	O
in	O
O.	O
europaea	O
and	O
we	O
studied	O
the	O
aromadendrine	B
biological	O
activity	O
.	O

In	O
particular	O
,	O
the	O
ability	O
of	O
aromadendrine	B
to	O
reduce	O
the	O
inflammation	O
induced	O
in	O
normal	O
keratinocytes	O
using	O
an	O
in	O
vitro	O
cell	O
model	O
was	O
evaluated	O
.	O

The	O
results	O
of	O
the	O
present	O
research	O
indicate	O
aromadendrine	B
as	O
a	O
novel	O
component	O
in	O
O.	O
europaea	O
with	O
effective	O
activity	O
against	O
skin	O
inflammation	O
.	O

Ibuprofen	B
ion	O
-	O
exchange	O
fiber	O
complex	O
:	O
improved	O
dissolution	O
and	O
gastric	O
tolerance	O
based	O
on	O
ion	O
exchange	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
is	O
to	O
develop	O
a	O
novel	O
method	O
to	O
improve	O
the	O
dissolution	O
of	O
water	O
-	O
insoluble	O
drug	O
ibuprofen	B
and	O
the	O
gastric	O
tolerance	O
of	O
this	O
non	O
-	O
steroidal	O
anti	O
-	O
inflammatory	O
drug	O
which	O
has	O
potentially	O
serious	O
gastrointestinal	O
side	O
effects	O
.	O

This	O
method	O
is	O
based	O
on	O
ion	O
exchange	O
of	O
ion	O
-	O
exchange	O
fibers	O
.	O

Water	O
-	O
insoluble	O
drug	O
ibuprofen	B
was	O
dispersed	O
in	O
deionized	O
water	O
,	O
and	O
then	O
the	O
ion	O
-	O
exchange	O
fibers	O
in	O
OH	B
(	I
-	I
)	I
type	O
was	O
immersed	O
in	O
it	O
.	O

Ibuprofen	B
and	O
the	O
active	O
groups	O
of	O
the	O
ion	O
-	O
exchange	O
fibers	O
combined	O
into	O
ion	O
pairs	O
based	O
on	O
the	O
acid	O
-	O
base	O
reaction	O
.	O

This	O
drug	O
carrier	O
did	O
not	O
release	O
drugs	O
in	O
deionized	O
water	O
,	O
but	O
in	O
water	O
solution	O
containing	O
other	O
ions	O
it	O
would	O
release	O
the	O
drugs	O
into	O
the	O
solution	O
by	O
ion	O
exchange	O
.	O

Confirmed	O
by	O
the	O
X	O
-	O
ray	O
diffraction	O
and	O
the	O
scanning	O
electron	O
microscopy	O
,	O
the	O
ibuprofen	B
combined	O
onto	O
the	O
ion	O
-	O
exchange	O
fibers	O
was	O
in	O
a	O
highly	O
molecular	O
level	O
dispersed	O
state	O
.	O

The	O
improved	O
dissolution	O
of	O
ibuprofen	B
ion	O
-	O
exchange	O
fiber	O
complexes	O
is	O
likely	O
to	O
originate	O
from	O
this	O
ibuprofen	B
's	O
highly	O
dispersed	O
state	O
.	O

Due	O
to	O
this	O
,	O
ibuprofen	B
's	O
highly	O
dispersed	O
state	O
,	O
ibuprofen	B
ion	O
-	O
exchange	O
fiber	O
complexes	O
significantly	O
decreases	O
the	O
gastrointestinal	O
side	O
effects	O
of	O
ibuprofen	B
by	O
avoiding	O
the	O
solid	O
ibuprofen	B
's	O
educing	O
.	O

The	O
present	O
study	O
showed	O
that	O
ibuprofen	B
ion	O
-	O
exchange	O
fiber	O
complexes	O
have	O
the	O
two	O
-	O
fold	O
advantages	O
.	O

One	O
is	O
to	O
improve	O
the	O
dissolution	O
of	O
ibuprofen	B
.	O

The	O
other	O
is	O
to	O
decrease	O
the	O
ibuprofen	B
's	O
gastrointestinal	O
toxicity	O
.	O

A	O
modern	O
approach	O
for	O
controlled	O
transdermal	O
delivery	O
of	O
diflunisal	B
:	O
optimization	O
and	O
in	O
vivo	O
evaluation	O
.	O

The	O
purpose	O
of	O
the	O
present	O
work	O
was	O
to	O
elaborate	O
an	O
optimized	O
transdermal	O
therapeutic	O
system	O
for	O
diflunisal	B
.	O

Selection	O
of	O
suitable	O
ingredients	O
was	O
done	O
via	O
solubility	O
and	O
phase	O
behavior	O
studies	O
.	O

Composition	O
of	O
microemulsion	O
(	O
ME	O
)	O
systems	O
consisting	O
of	O
butyl	B
lactate	I
,	O
Brij	B
(	O
	O
)	O
97	O
,	O
Transcutol	B
(	O
	O
)	O
and	O
water	O
was	O
optimized	O
using	O
augmented	O
simplex	O
lattice	O
mixture	O
design	O
.	O

The	O
independent	O
variables	O
selected	O
were	O
the	O
percentages	O
of	O
butyl	B
lactate	I
,	O
surfactant	O
mixture	O
and	O
water	O
.	O

The	O
dependent	O
variables	O
were	O
refractive	O
index	O
,	O
pH	O
,	O
conductivity	O
,	O
viscosity	O
,	O
drug	O
solubility	O
in	O
the	O
ME	O
formulation	O
and	O
the	O
ex	O
vivo	O
skin	O
permeation	O
flux	O
.	O

Mathematical	O
equations	O
and	O
response	O
surface	O
plots	O
were	O
used	O
to	O
relate	O
the	O
dependent	O
and	O
independent	O
variables	O
.	O

The	O
statistical	O
validity	O
of	O
the	O
polynomials	O
was	O
established	O
.	O

Optimized	O
formulation	O
factors	O
were	O
selected	O
by	O
desirability	O
approach	O
.	O

The	O
optimized	O
ME	O
formulation	O
was	O
converted	O
into	O
gel	O
using	O
Carbomer	B
(	O
	O
)	O
934	O
.	O

The	O
microemulsion	O
based	O
gel	O
(	O
MBG	O
)	O
showed	O
better	O
spreadability	O
and	O
5.07-fold	O
increase	O
in	O
the	O
transdermal	O
flux	O
than	O
Carbomer	B
(	O
	O
)	O
934	O
gel	O
.	O

The	O
in	O
vivo	O
antihyperalgesia	O
assay	O
performed	O
on	O
mice	O
showed	O
significant	O
reduction	O
of	O
the	O
licking	O
time	O
in	O
the	O
treated	O
group	O
compared	O
to	O
the	O
control	O
group	O
.	O

This	O
demonstrated	O
the	O
reliability	O
of	O
the	O
simplex	O
lattice	O
statistical	O
design	O
for	O
predicting	O
optimum	O
ME	O
formulation	O
.	O

The	O
developed	O
MBG	O
proved	O
its	O
in	O
vivo	O
efficiency	O
for	O
transdermal	O
delivery	O
of	O
diflunisal	B
.	O

Nanostructural	O
difference	O
of	O
water	O
-	O
soluble	O
pectin	O
and	O
chelate	O
-	O
soluble	O
pectin	O
among	O
ripening	O
stages	O
and	O
cultivars	O
of	O
Chinese	O
cherry	O
.	O

Nanostructure	O
of	O
water	O
-	O
soluble	O
pectin	O
(	O
WSP	O
)	O
and	O
chelate	O
-	O
soluble	O
pectin	O
(	O
CSP	O
)	O
of	O
two	O
Chinese	O
cherry	O
(	O
Prunus	O
pseudocerasus	O
L.	O
)	O
cultivars	O
(	O
soft	O
cultivar	O
'	O
Caode	O
'	O
and	O
crisp	O
cultivar	O
'	O
Bende	O
'	O
)	O
with	O
two	O
different	O
ripening	O
stages	O
were	O
characterised	O
using	O
atomic	O
force	O
microscopy	O
.	O

Both	O
cultivars	O
shared	O
some	O
common	O
values	O
of	O
chain	O
widths	O
for	O
WSP	O
or	O
CSP	O
,	O
and	O
both	O
pectins	O
shared	O
several	O
values	O
of	O
chain	O
widths	O
including	O
37	O
,	O
55	O
and	O
61	O
nm	O
.	O

The	O
results	O
indicate	O
that	O
different	O
cultivars	O
shared	O
similar	O
components	O
of	O
pectin	O
,	O
and	O
cultivar	O
textural	O
difference	O
might	O
be	O
related	O
to	O
the	O
interaction	O
between	O
pectin	O
and	O
other	O
cherry	O
components	O
or	O
the	O
dissociation	O
of	O
pectin	O
.	O

During	O
ripening	O
,	O
the	O
wide	O
WSP	O
and	O
CSP	O
gradually	O
dissociate	O
in	O
width	O
.	O

The	O
results	O
demonstrated	O
that	O
the	O
changes	O
of	O
WSP	O
and	O
CSP	O
of	O
Chinese	O
cherry	O
in	O
widths	O
were	O
a	O
dissociation	O
process	O
.	O

Cation	O
-	O
chloride	B
cotransporters	O
NKCC1	O
and	O
KCC2	O
as	O
potential	O
targets	O
for	O
novel	O
antiepileptic	O
and	O
antiepileptogenic	O
treatments	O
.	O

In	O
cortical	O
and	O
hippocampal	O
neurons	O
,	O
cation	O
-	O
chloride	B
cotransporters	O
(	O
CCCs	O
)	O
control	O
the	O
reversal	O
potential	O
(	O
EGABA	O
)	O
of	O
GABAA	O
receptor	O
-	O
mediated	O
current	O
and	O
voltage	O
responses	O
and	O
,	O
consequently	O
,	O
they	O
modulate	O
the	O
efficacy	O
of	O
GABAergic	O
inhibition	O
.	O

Two	O
members	O
of	O
the	O
CCC	O
family	O
,	O
KCC2	O
(	O
the	O
major	O
neuron	O
-	O
specific	O
K	O
-	O
Cl	O
cotransporter	O
;	O
KCC	O
isoform	O
2	O
)	O
and	O
NKCC1	O
(	O
the	O
Na	O
-	O
K-2Cl	O
cotransporter	O
isoform	O
1	O
which	O
is	O
expressed	O
in	O
both	O
neurons	O
and	O
glial	O
cells	O
)	O
have	O
attracted	O
much	O
interest	O
in	O
studies	O
on	O
GABAergic	O
signaling	O
under	O
both	O
normal	O
and	O
pathophysiological	O
conditions	O
,	O
such	O
as	O
epilepsy	O
.	O

There	O
is	O
tentative	O
evidence	O
that	O
loop	O
diuretic	O
compounds	O
such	O
as	O
furosemide	O
and	O
bumetanide	O
may	O
have	O
clinically	O
relevant	O
antiepileptic	O
actions	O
,	O
especially	O
when	O
administered	O
in	O
combination	O
with	O
conventional	O
GABA	O
-	O
mimetic	O
drugs	O
such	O
as	O
phenobarbital	O
.	O

Furosemide	O
is	O
a	O
non	O
-	O
selective	O
inhibitor	O
of	O
CCCs	O
while	O
at	O
low	O
concentrations	O
bumetanide	O
is	O
selective	O
for	O
NKCCs	O
.	O

Search	O
for	O
novel	O
antiepileptic	O
drugs	O
(	O
AEDs	O
)	O
is	O
highly	O
motivated	O
especially	O
for	O
the	O
treatment	O
of	O
neonatal	O
seizures	O
which	O
are	O
often	O
resistant	O
to	O
,	O
or	O
even	O
aggravated	O
by	O
conventional	O
AEDs	O
.	O

This	O
review	O
shows	O
that	O
the	O
antiepileptic	O
effects	O
of	O
loop	O
diuretics	O
described	O
in	O
the	O
pertinent	O
literature	O
are	O
based	O
on	O
widely	O
heterogeneous	O
mechanisms	O
ranging	O
from	O
actions	O
on	O
both	O
neuronal	O
NKCC1	O
and	O
KCC2	O
to	O
modulation	O
of	O
the	O
brain	O
extracellular	O
volume	O
fraction	O
.	O

A	O
promising	O
strategy	O
for	O
the	O
development	O
of	O
novel	O
CCC	O
-	O
blocking	O
AEDs	O
is	O
based	O
on	O
prodrugs	O
that	O
are	O
activated	O
following	O
their	O
passage	O
across	O
the	O
blood	O
-	O
brain	O
barrier	O
.	O

This	O
article	O
is	O
part	O
of	O
the	O
Special	O
Issue	O
entitled	O
'	O
New	O
Targets	O
and	O
Approaches	O
to	O
the	O
Treatment	O
of	O
Epilepsy	O
'	O
.	O

Isolation	O
and	O
structure	O
determination	O
of	O
new	O
siderophore	O
tsukubachelin	B
B	I
from	O
Streptomyces	O
sp.	O
TM-74	O
.	O

The	O
new	O
siderophore	O
tsukubachelin	B
B	I
(	O
1	O
)	O
was	O
isolated	O
from	O
the	O
iron	B
-	O
deficient	O
culture	O
medium	O
of	O
the	O
newly	O
isolated	O
strain	O
Streptomyces	O
sp.	O
TM-74	O
.	O

The	O
chemical	O
structure	O
of	O
tsukubachelin	B
B	I
(	O
1	O
)	O
was	O
established	O
via	O
interpretation	O
of	O
2D	O
nuclear	O
magnetic	O
resonance	O
and	O
electrospray	O
ionization	O
-	O
mass	O
spectroscopic	O
data	O
.	O

The	O
structure	O
of	O
tsukubachelin	B
B	I
(	O
1	O
)	O
comprises	O
6	O
mol	O
of	O
amino	B
acids	I
,	O
including	O
2	O
mol	O
of	O
serine	B
and	O
1	O
mol	O
each	O
of	O
ornithine	B
,	O
N	B
-	I
	I
-	I
methyl	I
-	I
N	I
-	I
	I
-	I
hydroxy	I
-	I
N	I
-	I
	I
-	I
formylornithine	I
,	O
N	B
-	I
	I
-	I
methyl	I
-	I
N	I
-	I
	I
-	I
hydroxyornithine	I
,	O
and	O
cyclic	B
N	I
-	I
hydroxyornithine	I
.	O

Hierarchical	O
clustering	O
analysis	O
of	O
blood	O
plasma	O
lipidomics	O
profiles	O
from	O
mono-	O
and	O
dizygotic	O
twin	O
families	O
.	O

Twin	O
and	O
family	O
studies	O
are	O
typically	O
used	O
to	O
elucidate	O
the	O
relative	O
contribution	O
of	O
genetic	O
and	O
environmental	O
variation	O
to	O
phenotypic	O
variation	O
.	O

Here	O
,	O
we	O
apply	O
a	O
quantitative	O
genetic	O
method	O
based	O
on	O
hierarchical	O
clustering	O
,	O
to	O
blood	O
plasma	O
lipidomics	O
data	O
obtained	O
in	O
a	O
healthy	O
cohort	O
consisting	O
of	O
37	O
monozygotic	O
and	O
28	O
dizygotic	O
twin	O
pairs	O
,	O
and	O
52	O
of	O
their	O
biological	O
nontwin	O
siblings	O
.	O

Such	O
data	O
are	O
informative	O
of	O
the	O
concentrations	O
of	O
a	O
wide	O
range	O
of	O
lipids	O
in	O
the	O
studied	O
blood	O
samples	O
.	O

An	O
important	O
advantage	O
of	O
hierarchical	O
clustering	O
is	O
that	O
it	O
can	O
be	O
applied	O
to	O
a	O
high	O
-	O
dimensional	O
'	O
omics	O
'	O
type	O
data	O
,	O
whereas	O
the	O
use	O
of	O
many	O
other	O
quantitative	O
genetic	O
methods	O
for	O
analysis	O
of	O
such	O
data	O
is	O
hampered	O
by	O
the	O
large	O
number	O
of	O
correlated	O
variables	O
.	O

For	O
this	O
study	O
we	O
combined	O
two	O
lipidomics	O
data	O
sets	O
,	O
originating	O
from	O
two	O
different	O
measurement	O
blocks	O
,	O
which	O
we	O
corrected	O
for	O
block	O
effects	O
by	O
'	O
quantile	O
equating	O
'	O
.	O

In	O
the	O
analysis	O
of	O
the	O
combined	O
data	O
,	O
average	O
similarities	O
of	O
lipidomics	O
profiles	O
were	O
highest	O
between	O
monozygotic	O
(	O
MZ	O
)	O
cotwins	O
,	O
and	O
became	O
progressively	O
lower	O
between	O
dizygotic	O
(	O
DZ	O
)	O
cotwins	O
,	O
among	O
sex	O
-	O
matched	O
nontwin	O
siblings	O
and	O
among	O
sex	O
-	O
matched	O
unrelated	O
participants	O
,	O
respectively	O
.	O

Our	O
results	O
suggest	O
that	O
(	O
1	O
)	O
shared	O
genetic	O
background	O
,	O
shared	O
environment	O
,	O
and	O
similar	O
age	O
contribute	O
to	O
similarities	O
in	O
blood	O
plasma	O
lipidomics	O
profiles	O
among	O
individuals	O
;	O
and	O
(	O
2	O
)	O
that	O
the	O
power	O
of	O
quantitative	O
genetic	O
analyses	O
is	O
enhanced	O
by	O
quantile	O
equating	O
and	O
combination	O
of	O
data	O
sets	O
obtained	O
in	O
different	O
measurement	O
blocks	O
.	O

Anti	O
-	O
diabetic	O
Activity	O
of	O
Swertiamarin	B
is	O
due	O
to	O
an	O
Active	O
Metabolite	O
,	O
Gentianine	B
,	O
that	O
Upregulates	O
PPAR	O
-	O
	O
Gene	O
Expression	O
in	O
3T3-L1	O
cells	O
.	O

We	O
have	O
previously	O
shown	O
the	O
anti	O
-	O
diabetic	O
effects	O
of	O
swertiamarin	B
;	O
however	O
,	O
pharmacokinetic	O
analysis	O
showed	O
that	O
swertiamarin	B
had	O
a	O
plasma	O
half	O
-	O
life	O
of	O
1.3	O
h.	O
Gentianine	B
is	O
an	O
active	O
metabolite	O
of	O
swertiamarin	B
that	O
possesses	O
a	O
pharmacophoric	O
moiety	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
explore	O
the	O
possibility	O
whether	O
the	O
anti	O
-	O
diabetic	O
effect	O
of	O
swertiamarin	B
is	O
due	O
to	O
gentianine	B
.	O

Swertiamarin	B
treatment	O
had	O
no	O
significant	O
effect	O
on	O
adipogenesis	O
,	O
or	O
the	O
mRNA	O
expression	O
of	O
PPAR	O
-	O
	O
and	O
GLUT-4	O
;	O
however	O
,	O
there	O
was	O
a	O
significant	O
increase	O
in	O
the	O
mRNA	O
expression	O
of	O
adiponectin	O
.	O

On	O
the	O
other	O
hand	O
,	O
treatment	O
with	O
gentianine	B
significantly	O
increased	O
adipogenesis	O
,	O
which	O
was	O
associated	O
with	O
a	O
significant	O
increase	O
in	O
the	O
mRNA	O
expression	O
of	O
PPAR	O
-	O
	O
,	O
GLUT-4	O
and	O
adiponectin	O
.	O

These	O
findings	O
suggest	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
the	O
anti	O
-	O
diabetic	O
effect	O
of	O
swertiamarin	B
is	O
due	O
to	O
gentianine	B
,	O
an	O
active	O
metabolite	O
of	O
swertiamarin	B
.	O

Copyright	O
	O
2012	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd.	O

Chronic	O
treatment	O
with	O
selective	O
I2-imidazoline	O
receptor	O
ligands	O
decreases	O
the	O
content	O
of	O
pro	O
-	O
apoptotic	O
markers	O
in	O
rat	O
brain	O
.	O

Selective	O
I	O
(	O
2	O
)	O
-imidazoline	O
receptor	O
ligands	O
induce	O
neuroprotection	O
through	O
various	O
molecular	O
mechanisms	O
including	O
blockade	O
of	O
N	B
-	I
methyl	I
-	I
D	I
-	I
aspartate	I
(	O
NMDA	B
)	O
receptors	O
.	O

To	O
investigate	O
new	O
neuroprotective	O
mechanisms	O
associated	O
with	O
I	O
(	O
2	O
)	O
-imidazoline	O
receptors	O
,	O
the	O
effects	O
of	O
selective	O
(	O
2-styryl-2-imidazoline	B
(	O
LSL	B
61122	I
)	O
,	O
2-	B
(	I
2-benzofuranyl	I
)	I
-2-imidazoline	I
(	O
2-BFI	B
)	O
,	O
2-	B
(	I
4,5-dihydroimidazol-2-yl	I
)	I
quinoline	I
hydrochloride	I
(	O
BU-224	B
)	O
)	O
and	O
non	O
-	O
selective	O
(	O
idazoxan	B
)	O
I	O
(	O
2	O
)	O
-drugs	O
on	O
canonical	O
apoptotic	O
pathways	O
were	O
assessed	O
in	O
rat	O
brain	O
cortex	O
.	O

The	O
acute	O
treatment	O
with	O
LSL	B
61122	I
(	O
10	O
mg	O
/	O
kg	O
)	O
reduced	O
the	O
content	O
of	O
mitochondrial	O
(	O
pro	O
-	O
apoptotic	O
)	O
Bax	O
(	O
-33	O
%	O
)	O
and	O
cytochrome	O
c	O
(	O
-31	O
%	O
)	O
,	O
which	O
was	O
prevented	O
by	O
idazoxan	B
,	O
an	O
I	O
(	O
2	O
)	O
-receptor	O
antagonist	O
.	O

The	O
sustained	O
stimulation	O
of	O
I	O
(	O
2	O
)	O
-imidazoline	O
receptors	O
with	O
selective	O
drugs	O
(	O
10	O
mg	O
/	O
kg	O
,	O
every	O
12	O
h	O
for	O
seven	O
days	O
)	O
was	O
associated	O
with	O
down	O
-	O
regulation	O
of	O
key	O
components	O
of	O
the	O
extrinsic	O
(	O
Fas	O
receptor	O
:	O
-20	O
%	O
;	O
Fas	O
associated	O
protein	O
with	O
death	O
domain	O
(	O
FADD	O
)	O
adaptor	O
:	O
-47	O
-	O
54	O
%	O
)	O
and/or	O
intrinsic	O
(	O
Bax	O
:	O
-20	O
-	O
23	O
%	O
;	O
cytochrome	O
c	O
:	O
-22	O
-	O
28	O
%	O
)	O
apoptotic	O
signalling	O
and/or	O
up	O
-	O
regulation	O
of	O
survival	O
anti	O
-	O
apoptotic	O
factors	O
(	O
p	O
-	O
Ser194	B
FADD	O
/	O
FADD	O
ratio	O
:	O
+	O
1.6	O
-	O
2.5-fold	O
;	O
and/or	O
Bcl-2	O
/	O
Bax	O
ratio	O
:	O
+	O
1.5-fold	O
)	O
,	O
which	O
in	O
the	O
long	O
-	O
term	O
could	O
dampen	O
cell	O
death	O
in	O
the	O
brain	O
.	O

Similar	O
chronic	O
treatments	O
with	O
LSL	B
60101	I
(	O
the	O
imidazole	B
analogue	O
of	O
2-BFI	B
)	O
and	O
idazoxan	B
(	O
a	O
mixed	O
I	O
(	O
2	O
)	O
/	O
	O
(	O
2	O
)	O
-ligand	O
)	O
did	O
not	O
induce	O
significant	O
alterations	O
of	O
pro-	O
or	O
anti	O
-	O
apoptotic	O
proteins	O
.	O

The	O
disclosed	O
anti	O
-	O
apoptotic	O
mechanisms	O
of	O
selective	O
I	O
(	O
2	O
)	O
-imidazoline	O
drugs	O
may	O
work	O
in	O
concert	O
with	O
other	O
molecular	O
mechanisms	O
of	O
neuroprotection	O
(	O
e.g.	O
blockade	O
of	O
NMDA	O
receptors	O
)	O
that	O
are	O
engaged	O
by	O
I	O
(	O
2	O
)	O
-ligands	O
.	O

Alleviation	O
of	O
high	O
salt	O
toxicity	O
-	O
induced	O
oxidative	O
damage	O
by	O
salicylic	B
acid	I
pretreatment	O
in	O
two	O
wheat	O
cultivars	O
.	O

Role	O
of	O
exogenous	O
salicylic	B
acid	I
(	O
SA	O
)	O
in	O
the	O
antioxidative	O
response	O
to	O
salt	O
toxicity	O
of	O
two	O
wheat	O
(	O
Triticum	O
aestivum	O
)	O
cultivars	O
(	O
Gerek-79	O
and	O
Bezostaya	O
)	O
was	O
investigated	O
.	O

Hydroponic	O
growth	O
environment	O
of	O
10-day	O
wheat	O
seedlings	O
grown	O
under	O
normal	O
conditions	O
(	O
22	O
/	O
20	O
	O
C	O
)	O
was	O
adjusted	O
to	O
0.0	O
,	O
0.25	O
,	O
0.50	O
and	O
0.75	O
M	O
of	O
salt	O
(	O
NaCl	B
)	O
,	O
and	O
then	O
freshly	O
prepared	O
SA	O
solutions	O
(	O
0.0	O
,	O
0.01	O
and	O
0.1	O
mM	O
)	O
were	O
once	O
sprayed	O
on	O
leaves	O
of	O
the	O
same	O
seedlings	O
.	O

Activities	O
of	O
superoxide	B
dismutase	O
(	O
SOD	O
)	O
,	O
peroxidase	O
(	O
POX	O
)	O
and	O
catalase	O
(	O
CAT	O
)	O
were	O
determined	O
in	O
fresh	O
leaves	O
obtained	O
from	O
15-day	O
seedlings	O
.	O

Treatment	O
with	O
SA	O
alone	O
increased	O
all	O
the	O
antioxidant	O
activities	O
in	O
Gerek-79	O
.	O

However	O
,	O
the	O
same	O
treatments	O
with	O
SA	O
decreased	O
the	O
activities	O
of	O
CAT	O
and	O
SOD	O
in	O
Bezostaya	O
,	O
while	O
increased	O
that	O
of	O
POX	O
.	O

Salt	O
applications	O
alone	O
increased	O
the	O
activities	O
of	O
POX	O
and	O
SOD	O
,	O
while	O
decreased	O
that	O
of	O
CAT	O
in	O
Bezostaya	O
.	O

The	O
same	O
salt	O
applications	O
increased	O
the	O
POX	O
activity	O
,	O
while	O
decreased	O
the	O
activities	O
of	O
CAT	O
and	O
SOD	O
in	O
Gerek-79	O
.	O

In	O
plants	O
under	O
saline	O
conditions	O
,	O
except	O
0.75	O
M	O
NaCl	B
,	O
treatments	O
with	O
SA	O
increased	O
the	O
activities	O
of	O
CAT	O
,	O
POX	O
and	O
SOD	O
in	O
both	O
the	O
varieties	O
compared	O
with	O
plants	O
applied	O
salt	O
alone	O
.	O

In	O
plants	O
applied	O
with	O
0.75	O
M	O
NaCl	B
,	O
however	O
,	O
treatments	O
with	O
SA	O
decreased	O
CAT	O
activity	O
.	O

Results	O
showed	O
that	O
salt	O
toxicity	O
caused	O
a	O
derangement	O
in	O
the	O
regulation	O
of	O
antioxidant	O
enzyme	O
activities	O
by	O
decreasing	O
CAT	O
activity	O
especially	O
in	O
both	O
the	O
varieties	O
,	O
but	O
treatments	O
with	O
SA	O
could	O
turn	O
back	O
the	O
derangement	O
in	O
the	O
antioxidative	O
enzymes	O
caused	O
by	O
salt	O
toxicity	O
.	O

SA	O
can	O
involve	O
in	O
increasing	O
salt	O
tolerance	O
by	O
regulating	O
the	O
activities	O
of	O
antioxidant	O
enzymes	O
in	O
wheat	O
cultivars	O
exposed	O
to	O
salt	O
toxicity	O
.	O

Melamine	B
in	O
prenatal	O
and	O
postnatal	O
organs	O
in	O
rats	O
.	O

Melamine	B
can	O
be	O
transferred	O
to	O
fetus	O
in	O
utero	O
through	O
placenta	O
and	O
to	O
infant	O
ex	O
utero	O
by	O
breast	O
feeding	O
.	O

In	O
this	O
study	O
,	O
we	O
characterized	O
the	O
pharmacokinetics	O
of	O
melamine	B
in	O
prenatal	O
and	O
postnatal	O
organs	O
in	O
rats	O
.	O

Single	O
bolus	O
of	O
melamine	B
was	O
administered	O
to	O
pregnant	O
rats	O
at	O
different	O
gestational	O
stages	O
and	O
to	O
infants	O
at	O
different	O
postnatal	O
stages	O
.	O

Distribution	O
of	O
melamine	B
in	O
maternal	O
serum	O
was	O
about	O
30	O
%	O
higher	O
in	O
late	O
pregnancy	O
than	O
that	O
in	O
early	O
pregnancy	O
;	O
and	O
it	O
was	O
2	O
folds	O
higher	O
in	O
postnatal	O
serum	O
in	O
early	O
infants	O
in	O
young	O
adulthood	O
.	O

Distribution	O
of	O
melamine	B
in	O
all	O
postnatal	O
organs	O
was	O
higher	O
than	O
that	O
in	O
prenatal	O
organs	O
.	O

Postnatal	O
kidneys	O
in	O
early	O
infants	O
had	O
the	O
highest	O
maximum	O
concentration	O
and	O
the	O
lowest	O
clearance	O
of	O
melamine	B
than	O
the	O
other	O
postnatal	O
organs	O
.	O

It	O
may	O
relate	O
to	O
the	O
high	O
vulnerability	O
to	O
the	O
toxicity	O
of	O
melamine	B
in	O
this	O
population	O
.	O

Allosteric	O
alpha-7	O
nicotinic	O
receptor	O
modulation	O
and	O
P50	O
sensory	O
gating	O
in	O
schizophrenia	O
:	O
a	O
proof	O
-	O
of	O
-	O
mechanism	O
study	O
.	O

In	O
this	O
multicenter	O
,	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
randomized	O
,	O
four	O
way	O
cross	O
-	O
over	O
proof	O
-	O
of	O
-	O
mechanism	O
study	O
,	O
we	O
tested	O
the	O
effect	O
of	O
the	O
positive	O
allosteric	O
7	O
nicotinic	O
acetylcholine	B
receptor	O
(	O
nAChR	O
)	O
modulator	O
JNJ-39393406	B
in	O
a	O
key	O
translational	O
assay	O
(	O
sensory	O
P50	O
gating	O
)	O
in	O
39	O
regularly	O
smoking	O
male	O
patients	O
with	O
schizophrenia	O
.	O

All	O
patients	O
were	O
clinically	O
stable	O
and	O
JNJ-39393406	B
was	O
administered	O
as	O
an	O
adjunct	O
treatment	O
to	O
antipsychotics	O
.	O

No	O
indication	O
was	O
found	O
that	O
JNJ-39393406	B
has	O
the	O
potential	O
to	O
reverse	O
basic	O
deficits	O
of	O
information	O
processing	O
in	O
schizophrenia	O
(	O
sensory	O
P50	O
gating	O
)	O
or	O
has	O
a	O
significant	O
effect	O
on	O
other	O
tested	O
electrophysiological	O
markers	O
(	O
MMN	O
,	O
P300	O
and	O
quantitative	O
resting	O
EEG	O
)	O
.	O

Sensitivity	O
analyses	O
including	O
severity	O
of	O
disease	O
,	O
baseline	O
P50	O
gating	O
,	O
medication	O
and	O
gene	O
variants	O
of	O
the	O
CHRNA7	O
gene	O
did	O
not	O
reveal	O
any	O
subgroups	O
with	O
consistent	O
significant	O
effects	O
.	O

It	O
is	O
discussed	O
that	O
potential	O
positive	O
effects	O
in	O
subgroups	O
not	O
present	O
or	O
not	O
large	O
enough	O
in	O
the	O
current	O
study	O
or	O
upon	O
chronic	O
dosing	O
are	O
possible	O
,	O
but	O
unlikely	O
to	O
be	O
developed	O
.	O

This	O
article	O
is	O
part	O
of	O
a	O
Special	O
Issue	O
entitled	O
'	O
Cognitive	O
Enhancers	O
'	O
.	O

Metastability	O
in	O
Pressure	O
-	O
Induced	O
Structural	O
Transformations	O
of	O
CdSe	B
/	O
ZnS	B
Core	O
/	O
Shell	O
Nanocrystals	O
.	O

The	O
kinetics	O
and	O
thermodynamics	O
of	O
structural	O
transformations	O
under	O
pressure	O
depend	O
strongly	O
on	O
particle	O
size	O
due	O
to	O
the	O
influence	O
of	O
surface	O
free	O
energy	O
.	O

By	O
suitable	O
design	O
of	O
surface	O
structure	O
,	O
composition	O
,	O
and	O
passivation	O
it	O
is	O
possible	O
,	O
in	O
principle	O
,	O
to	O
prepare	O
nanocrystals	O
in	O
structures	O
inaccessible	O
to	O
bulk	O
materials	O
.	O

However	O
,	O
few	O
realizations	O
of	O
such	O
extreme	O
size	O
-	O
dependent	O
behavior	O
exist	O
.	O

Here	O
,	O
we	O
show	O
with	O
molecular	O
dynamics	O
computer	O
simulation	O
that	O
in	O
a	O
model	O
of	O
CdSe	B
/	O
ZnS	B
core	O
/	O
shell	O
nanocrystals	O
the	O
core	O
high	O
-	O
pressure	O
structure	O
can	O
be	O
made	O
metastable	O
under	O
ambient	O
conditions	O
by	O
tuning	O
the	O
thickness	O
of	O
the	O
shell	O
.	O

In	O
nanocrystals	O
with	O
thick	O
shells	O
,	O
we	O
furthermore	O
observe	O
a	O
wurtzite	B
to	O
NiAs	B
transformation	O
,	O
which	O
does	O
not	O
occur	O
in	O
the	O
pure	O
bulk	O
materials	O
.	O

These	O
phenomena	O
are	O
linked	O
to	O
a	O
fundamental	O
change	O
in	O
the	O
atomistic	O
transformation	O
mechanism	O
from	O
heterogeneous	O
nucleation	O
at	O
the	O
surface	O
to	O
homogeneous	O
nucleation	O
in	O
the	O
crystal	O
core	O
.	O

Serotonergic	O
involvement	O
in	O
the	O
amelioration	O
of	O
behavioral	O
abnormalities	O
in	O
dopamine	B
transporter	O
knockout	O
mice	O
by	O
nicotine	B
.	O

Dopamine	B
transporter	O
knockout	O
(	O
DAT	O
KO	O
)	O
mice	O
exhibit	O
elevated	O
extracellular	O
dopamine	B
levels	O
in	O
brain	O
regions	O
that	O
include	O
the	O
striatum	O
and	O
the	O
nucleus	O
accumbens	O
,	O
but	O
not	O
the	O
prefrontal	O
cortex	O
.	O

DAT	O
KO	O
mice	O
model	O
some	O
aspects	O
of	O
psychiatric	O
disorders	O
,	O
including	O
schizophrenia	O
.	O

Smoking	O
is	O
more	O
common	O
in	O
patients	O
with	O
schizophrenia	O
,	O
suggesting	O
that	O
nicotine	O
might	O
ameliorate	O
aspects	O
of	O
the	O
behavioral	O
abnormalities	O
and/or	O
treatment	O
side	O
effects	O
seen	O
in	O
these	O
individuals	O
.	O

We	O
report	O
nicotine	B
-	O
induced	O
normalization	O
of	O
effects	O
on	O
locomotion	O
and	O
prepulse	O
inhibition	O
of	O
acoustic	O
startle	O
(	O
PPI	O
)	O
in	O
DAT	O
KO	O
mice	O
that	O
require	O
intact	O
serotonin	B
5-HT1A	O
systems	O
.	O

First	O
,	O
we	O
observed	O
that	O
the	O
marked	O
hyperactivity	O
displayed	O
by	O
DAT	O
KO	O
mice	O
was	O
reduced	O
by	O
administration	O
of	O
nicotine	B
.	O

This	O
nicotine	B
effect	O
was	O
blocked	O
by	O
pretreatment	O
with	O
the	O
non	O
-	O
specific	O
nicotinic	O
acetylcholine	B
(	O
nACh	O
)	O
receptor	O
antagonist	O
mecamylamine	B
,	O
or	O
the	O
5-HT1A	O
antagonist	O
WAY100635	B
.	O

Secondly	O
,	O
we	O
examined	O
the	O
effects	O
of	O
nicotine	B
on	O
PPI	O
in	O
DAT	O
KO	O
mice	O
.	O

Treatment	O
with	O
nicotine	B
significantly	O
ameliorated	O
the	O
PPI	O
deficits	O
observed	O
in	O
DAT	O
KO	O
mice	O
.	O

The	O
ameliorating	O
action	O
of	O
nicotine	B
on	O
PPI	O
deficits	O
in	O
DAT	O
KO	O
mice	O
was	O
blocked	O
by	O
mecamylamine	B
,	O
the	O
	O
nACh	O
receptor	O
antagonist	O
methyllycaconitine	B
or	O
WAY100635	B
,	O
while	O
the	O
	O
nACh	O
receptor	O
antagonist	O
dihydro	B
-	I
	I
-	I
erythroidinehydrobromide	I
(	O
DHE	B
)	O
produced	O
only	O
a	O
non	O
-	O
significant	O
trend	O
toward	O
attenuation	O
of	O
nicotine	B
effects	O
.	O

Finally	O
,	O
we	O
observed	O
that	O
administration	O
of	O
the	O
5-HT1A	O
receptor	O
agonist	O
8-OH	B
-	I
DPAT	I
also	O
ameliorated	O
the	O
deficit	O
in	O
PPI	O
observed	O
in	O
DAT	O
KO	O
mice	O
.	O

This	O
amelioration	O
was	O
antagonized	O
by	O
pretreatment	O
with	O
WAY100635	B
.	O

These	O
data	O
support	O
the	O
idea	O
that	O
nicotine	B
might	O
ameliorate	O
some	O
of	O
the	O
cognitive	O
dysfunctions	O
found	O
in	O
schizophrenia	O
in	O
a	O
5-HT1A	O
-	O
dependent	O
fashion	O
.	O

This	O
article	O
is	O
part	O
of	O
a	O
Special	O
Issue	O
entitled	O
'	O
Cognitive	O
Enhancers	O
'	O
.	O

Disposition	O
of	O
diiosononyl	B
phthalate	I
and	O
its	O
effects	O
on	O
sexual	O
development	O
of	O
the	O
male	O
fetus	O
following	O
repeated	O
dosing	O
in	O
pregnant	O
rats	O
.	O

Pregnant	O
Sprague	O
-	O
Dawley	O
rats	O
received	O
50	O
,	O
250	O
,	O
and	O
500	O
mg	O
/	O
kg	O
/	O
day	O
diisononyl	B
phthalate	I
(	O
DiNP	B
)	O
from	O
GD	O
12	O
to	O
19	O
via	O
corn	O
oil	O
gavage	O
to	O
study	O
the	O
dose	O
response	O
for	O
effects	O
on	O
fetal	O
male	O
rat	O
sexual	O
development	O
as	O
well	O
as	O
metabolite	O
disposition	O
in	O
the	O
dam	O
and	O
fetus	O
.	O

Monoisononyl	B
phthalate	I
(	O
MiNP	B
)	O
,	O
mono	B
(	I
carboxy	I
-	I
isooctyl	I
)	I
phthalate	I
(	O
MCiOP	B
)	O
,	O
mono	B
(	I
hydroxyl	I
-	I
isononyl	I
)	I
phthalate	I
(	O
MHiNP	B
)	O
,	O
mono	B
(	I
oxo	I
-	I
isononyl	I
)	I
phthalate	I
(	O
MOiNP	B
)	O
,	O
and	O
monoisononyl	B
phthalate	I
glucuronide	I
(	O
MiNP	B
-	I
G	I
)	O
were	O
found	O
in	O
all	O
measured	O
tissues	O
.	O

MCiOP	B
was	O
the	O
major	O
metabolite	O
,	O
followed	O
in	O
decreasing	O
order	O
by	O
MiNP	B
,	O
MHiNP	B
,	O
MOiNP	B
,	O
and	O
MiNP	B
-	I
G.	I
Percentage	O
of	O
dose	O
absorbed	O
decreased	O
at	O
750	O
mg	O
/	O
kg	O
/	O
day	O
.	O

Testosterone	B
concentration	O
in	O
the	O
fetal	O
testes	O
was	O
reduced	O
at	O
250	O
and	O
750	O
mg	O
/	O
kg	O
/	O
day	O
.	O

Multinucleated	O
germ	O
cells	O
were	O
increased	O
in	O
the	O
testes	O
of	O
rats	O
at	O
250	O
and	O
750	O
mg	O
/	O
kg	O
/	O
day	O
.	O

The	O
no	O
observed	O
effect	O
level	O
(	O
NOEL	O
)	O
for	O
this	O
study	O
was	O
50	O
mg	O
/	O
kg	O
/	O
day	O
based	O
on	O
increased	O
MNGs	O
and	O
reduced	O
testes	O
testosterone	B
concentration	O
in	O
the	O
fetal	O
rat	O
.	O

Effects	O
of	O
clopidogrel	B
and	O
clarithromycin	B
on	O
the	O
disposition	O
of	O
sibutramine	B
and	O
its	O
active	O
metabolites	O
M1	O
and	O
M2	O
in	O
relation	O
to	O
CYP2B6	O
*	O
6	O
polymorphism	O
.	O

Plasma	O
concentrations	O
of	O
sibutramine	B
and	O
its	O
two	O
active	O
metabolites	O
after	O
single	O
oral	O
dose	O
of	O
sibutramine	B
were	O
determined	O
in	O
Korean	O
healthy	O
male	O
subjects	O
with	O
different	O
CYP2B6	O
genotypes	O
(	O
CYP2B6	O
*	O
1	O
/	O
*1	O
,	O
*	O
1	O
/	O
*6	O
and	O
*	O
6	O
/	O
*6	O
)	O
,	O
either	O
alone	O
or	O
after	O
four	O
-	O
day	O
pretreatment	O
with	O
clopidogrel	B
or	O
clarithromycin	B
.	O

The	O
pretreatment	O
with	O
clopidogrel	B
and	O
clarithromycin	B
raised	O
the	O
mean	O
area	O
under	O
the	O
concentration	O
-	O
time	O
curve	O
(	O
AUC	O
)	O
of	O
sibutramine	B
by	O
163	O
%	O
and	O
255	O
%	O
,	O
respectively	O
.	O

Co	O
-	O
administration	O
of	O
clarithromycin	B
,	O
combined	O
with	O
CYP2B6	O
*	O
6	O
/	O
*6	O
genotype	O
,	O
led	O
to	O
highest	O
concentration	O
of	O
sibutramine	B
.	O

The	O
molar	O
sum	O
AUC	O
(	O
M1	O
+	O
M2	O
)	O
was	O
raised	O
by	O
35	O
%	O
in	O
the	O
clopidogrel	B
phase	O
but	O
not	O
significantly	O
affected	O
by	O
clarithromycin	B
or	O
CYP2B6	O
genotype	O
.	O

The	O
CYP2B6	O
*	O
6	O
/	O
*6	O
subjects	O
in	O
the	O
clopidogrel	B
phase	O
showed	O
the	O
highest	O
molar	O
AUC	O
(	O
M1	O
+	O
M2	O
)	O
among	O
three	O
genotype	O
groups	O
throughout	O
the	O
three	O
phases	O
.	O

The	O
exposure	O
of	O
sibutramine	B
and	O
its	O
metabolites	O
seemed	O
to	O
be	O
associated	O
with	O
the	O
CYP2B6	O
genotype	O
.	O

The	O
treatment	O
of	O
clopidogrel	B
significantly	O
altered	O
the	O
disposition	O
of	O
active	O
metabolites	O
as	O
well	O
as	O
sibutramine	B
,	O
but	O
clarithromycin	B
only	O
affects	O
the	O
disposition	O
of	O
sibutramine	B
.	O

These	O
results	O
suggest	O
that	O
the	O
perturbation	O
of	O
CYP2B6	O
activity	O
may	O
contribute	O
to	O
the	O
inter	O
-	O
individual	O
variation	O
of	O
sibutramine	B
drug	O
responses	O
although	O
the	O
clinical	O
relevance	O
is	O
remained	O
to	O
be	O
established	O
.	O

Naringin	B
induces	O
death	O
receptor	O
and	O
mitochondria	O
-	O
mediated	O
apoptosis	O
in	O
human	O
cervical	O
cancer	O
(	O
SiHa	O
)	O
cells	O
.	O

Cervical	O
cancer	O
is	O
the	O
second	O
most	O
common	O
female	O
cancer	O
worldwide	O
,	O
and	O
it	O
remains	O
a	O
challenge	O
to	O
manage	O
preinvasive	O
and	O
invasive	O
lesions	O
.	O

Fruit	O
-	O
based	O
cancer	O
prevention	O
entities	O
,	O
such	O
as	O
flavonoid	B
and	O
their	O
derivatives	O
,	O
have	O
demonstrated	O
a	O
marked	O
ability	O
to	O
inhibit	O
preclinical	O
models	O
of	O
epithelial	O
cancer	O
cell	O
growth	O
and	O
tumor	O
formation	O
.	O

Here	O
,	O
we	O
extend	O
the	O
role	O
of	O
naringin	B
-	O
mediated	O
chemoprevention	O
to	O
that	O
of	O
cervical	O
carcinogenesis	O
.	O

The	O
present	O
study	O
sought	O
to	O
investigate	O
the	O
therapeutic	O
potential	O
effect	O
of	O
naringin	B
on	O
apoptosis	O
in	O
human	O
cervical	O
SiHa	O
cancer	O
cells	O
.	O

Viability	O
of	O
SiHa	O
cells	O
was	O
evaluated	O
by	O
the	O
MTT	B
assay	O
,	O
apoptosis	O
and	O
mitochondrial	O
transmembrane	O
potential	O
by	O
flow	O
cytometry	O
,	O
and	O
pro	O
-	O
apoptotic	O
related	O
genes	O
by	O
Real	O
-	O
time	O
quantitative	O
PCR	O
.	O

Naringin	B
showed	O
a	O
50	O
%	O
inhibition	O
of	O
SiHa	O
human	O
cervical	O
cancer	O
cells	O
at	O
a	O
concentration	O
of	O
750M.	O
SiHa	O
cells	O
exhibited	O
apoptotic	O
cell	O
death	O
,	O
intranucleosomal	O
DNA	O
fragmentation	O
,	O
morphological	O
changes	O
and	O
decline	O
in	O
the	O
mitochondrial	O
transmembrane	O
potential	O
.	O

In	O
addition	O
,	O
administration	O
of	O
naringin	B
increased	O
the	O
expression	O
of	O
caspases	O
,	O
p53	O
and	O
Bax	O
,	O
Fas	O
death	O
receptor	O
and	O
its	O
adaptor	O
protein	O
FADD	O
.	O

These	O
results	O
suggest	O
that	O
the	O
induction	O
of	O
apoptosis	O
by	O
naringin	B
is	O
through	O
both	O
death	O
-	O
receptor	O
and	O
mitochondrial	O
pathways	O
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
naringin	B
might	O
be	O
an	O
effective	O
agent	O
to	O
treat	O
human	O
cervical	O
cancer	O
.	O

Powering	O
the	O
future	O
of	O
molecular	O
artificial	O
photosynthesis	O
with	O
light	O
-	O
harvesting	O
metallosupramolecular	O
dye	O
assemblies	O
.	O

Chemical	O
ingenuity	O
will	O
play	O
a	O
significant	O
role	O
in	O
solving	O
the	O
greatest	O
challenge	O
currently	O
facing	O
society	O
:	O
providing	O
clean	O
and	O
carbon	O
neutral	O
energy	O
for	O
all	O
of	O
humanity	O
.	O

Molecular	O
artificial	O
photosynthesis	O
is	O
an	O
emerging	O
technology	O
based	O
on	O
principles	O
learned	O
from	O
Nature	O
where	O
individual	O
components	O
perform	O
the	O
essential	O
light	O
-	O
harvesting	O
,	O
charge	O
-	O
separation	O
,	O
and	O
water	O
splitting	O
functions	O
to	O
store	O
solar	O
energy	O
in	O
the	O
form	O
of	O
chemical	O
bonds	O
.	O

This	O
tutorial	O
review	O
focuses	O
specifically	O
on	O
the	O
application	O
of	O
metallosupramolecular	O
self	O
-	O
assembly	O
strategies	O
to	O
interface	O
solar	O
fuel	O
catalysts	O
with	O
photosensitizers	O
and	O
construct	O
light	O
-	O
harvesting	O
antennae	O
capable	O
of	O
achieving	O
panchromatic	O
absorption	O
and	O
directional	O
energy	O
concentration	O
.	O

Inhibitory	O
function	O
of	O
the	O
dorsomedial	O
hypothalamic	O
nucleus	O
on	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
axis	O
response	O
to	O
an	O
emotional	O
stressor	O
but	O
not	O
immune	O
challenge	O
.	O

Accumulating	O
evidence	O
implicates	O
the	O
dorsomedial	O
hypothalamic	O
nucleus	O
(	O
DMH	O
)	O
in	O
the	O
regulation	O
of	O
autonomic	O
and	O
neuroendocrine	O
stress	O
responses	O
.	O

However	O
,	O
although	O
projections	O
from	O
the	O
DMH	O
to	O
the	O
paraventricular	O
hypothalamic	O
nucleus	O
(	O
PVN	O
)	O
,	O
which	O
is	O
the	O
critical	O
site	O
of	O
the	O
neuroendocrine	O
stress	O
axis	O
,	O
have	O
been	O
described	O
,	O
the	O
impact	O
of	O
DMH	O
neurones	O
in	O
the	O
modulation	O
of	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
(	O
HPA	O
)	O
axis	O
activation	O
during	O
stress	O
is	O
not	O
fully	O
understood	O
.	O

The	O
present	O
study	O
aimed	O
to	O
investigate	O
the	O
role	O
of	O
the	O
DMH	O
in	O
HPA	O
axis	O
responses	O
to	O
different	O
types	O
of	O
stimuli	O
.	O

Male	O
Sprague	O
-	O
Dawley	O
rats	O
fitted	O
with	O
a	O
chronic	O
jugular	O
venous	O
catheter	O
were	O
exposed	O
to	O
either	O
an	O
emotional	O
stressor	O
(	O
elevated	O
platform	O
-	O
exposure	O
)	O
or	O
immune	O
challenge	O
(	O
systemic	O
interleukin-1	O
administration	O
)	O
.	O

Bilateral	O
electrolytic	O
lesions	O
of	O
the	O
DMH	O
disinhibited	O
HPA	O
axis	O
responses	O
to	O
the	O
emotional	O
stressor	O
,	O
as	O
indicated	O
by	O
higher	O
plasma	O
adrenocorticotrophic	O
hormone	O
levels	O
during	O
and	O
after	O
elevated	O
platform	O
exposure	O
in	O
lesioned	O
animals	O
compared	O
to	O
sham	O
-	O
lesioned	O
controls	O
.	O

Moreover	O
,	O
DMH	O
-	O
lesioned	O
animals	O
showed	O
increased	O
neuronal	O
activation	O
in	O
the	O
PVN	O
,	O
as	O
indicated	O
by	O
a	O
higher	O
c	O
-	O
Fos	O
expression	O
after	O
elevated	O
-	O
platform	O
exposure	O
compared	O
to	O
controls	O
.	O

By	O
contrast	O
,	O
DMH	O
-	O
lesions	O
had	O
no	O
effects	O
on	O
HPA	O
axis	O
responses	O
to	O
immune	O
challenge	O
.	O

Taken	O
together	O
,	O
our	O
data	O
suggest	O
an	O
inhibitory	O
role	O
of	O
DMH	O
neurones	O
on	O
stress	O
-	O
induced	O
HPA	O
axis	O
activation	O
that	O
is	O
dependent	O
upon	O
the	O
nature	O
of	O
the	O
stimulus	O
being	O
important	O
in	O
response	O
to	O
an	O
emotional	O
stressor	O
but	O
not	O
to	O
immune	O
challenge	O
.	O

Genotoxic	O
damage	O
in	O
the	O
oral	O
mucosa	O
cells	O
of	O
subjects	O
carrying	O
restorative	O
dental	O
fillings	O
.	O

A	O
large	O
proportion	O
of	O
the	O
population	O
carries	O
restorative	O
dental	O
fillings	O
containing	O
either	O
classic	O
Hg	B
-	O
based	O
amalgams	B
and/or	O
the	O
more	O
frequently	O
used	O
methacrylates	B
.	O

Both	O
Hg-	B
and	O
resin	O
-	O
based	O
materials	O
have	O
been	O
shown	O
to	O
be	O
released	O
into	O
the	O
buccal	O
cavity	O
and	O
to	O
be	O
spread	O
systemically	O
.	O

In	O
addition	O
,	O
they	O
induce	O
toxic	O
and	O
genotoxic	O
alterations	O
in	O
experimental	O
test	O
systems	O
.	O

Using	O
the	O
comet	O
assay	O
,	O
we	O
previously	O
demonstrated	O
that	O
circulating	O
lymphocytes	O
of	O
subjects	O
with	O
dental	O
fillings	O
have	O
an	O
increased	O
DNA	O
damage	O
.	O

Here	O
,	O
we	O
analyzed	O
the	O
oral	O
mucosa	O
cells	O
of	O
63	O
young	O
subjects	O
of	O
both	O
genders	O
,	O
by	O
using	O
both	O
the	O
comet	O
assay	O
and	O
the	O
micronucleus	O
(	O
MN	O
)	O
test	O
and	O
by	O
monitoring	O
cell	O
death	O
markers	O
.	O

The	O
results	O
obtained	O
show	O
that	O
both	O
amalgams	B
and	O
resin	O
-	O
based	O
composite	O
fillings	O
can	O
induce	O
genotoxic	O
damage	O
in	O
human	O
oral	O
mucosa	O
cells	O
,	O
as	O
convincingly	O
and	O
dose	O
-	O
dependently	O
inferred	O
from	O
the	O
results	O
of	O
the	O
MN	O
test	O
and	O
,	O
more	O
marginally	O
,	O
from	O
comet	O
assay	O
data	O
.	O

Lifestyle	O
variables	O
,	O
also	O
including	O
alcohol	B
intake	O
and	O
smoking	O
habits	O
,	O
did	O
not	O
affect	O
the	O
genotoxic	O
response	O
and	O
did	O
not	O
act	O
as	O
confounding	O
factors	O
.	O

Thus	O
,	O
we	O
provide	O
unequivocal	O
evidence	O
for	O
the	O
genotoxicity	O
of	O
both	O
amalgams	B
and	O
resin	O
-	O
based	O
dental	O
fillings	O
in	O
humans	O
not	O
only	O
by	O
testing	O
circulating	O
lymphocytes	O
but	O
also	O
by	O
analyzing	O
oral	O
mucosa	O
cells	O
.	O

These	O
findings	O
are	O
of	O
particular	O
relevance	O
due	O
to	O
the	O
circumstance	O
that	O
subjects	O
with	O
restorative	O
materials	O
are	O
exposed	O
continuously	O
and	O
for	O
long	O
periods	O
of	O
time	O
.	O

Thiazolidinediones	B
(	O
TZDs	B
)	O
affect	O
osteoblast	O
viability	O
and	O
biomarkers	O
independently	O
of	O
the	O
TZD	B
effects	O
on	O
aromatase	O
.	O

Thiazolidinediones	B
(	O
TZDs	B
)	O
are	O
insulin	O
sensitizers	O
used	O
for	O
treatment	O
of	O
diabetes	O
.	O

We	O
have	O
previously	O
reported	O
that	O
TZDs	B
reduce	O
estrogen	B
synthesis	O
by	O
inhibiting	O
aromatase	O
activity	O
in	O
human	O
granulosa	O
cells	O
(	O
HGC	O
)	O
.	O

Multiple	O
clinical	O
trials	O
demonstrated	O
that	O
TZDs	B
increase	O
the	O
risk	O
of	O
fractures	O
in	O
postmenopausal	O
women	O
with	O
type	O
2	O
diabetes	O
.	O

We	O
studied	O
mouse	O
osteoblasts	O
alone	O
or	O
in	O
a	O
co	O
-	O
culture	O
with	O
HGC	O
to	O
determine	O
whether	O
TZD	B
inhibition	O
of	O
aromatase	O
plays	O
a	O
role	O
in	O
their	O
effects	O
on	O
bone	O
metabolism	O
.	O

Mouse	O
osteoblasts	O
were	O
cultured	O
with	O
and	O
without	O
HGC	O
,	O
and	O
incubated	O
in	O
a	O
medium	O
with	O
or	O
without	O
testosterone	B
,	O
pioglitazone	B
or	O
rosiglitazone	B
.	O

Cell	O
growth	O
,	O
oleic	O
acid	O
uptake	O
,	O
alkaline	O
phosphatase	O
activity	O
,	O
and	O
osteocalcin	O
production	O
were	O
measured	O
.	O

TZDs	B
inhibited	O
estradiol	B
production	O
by	O
up	O
to	O
84	O
%	O
in	O
HGC	O
/	O
mouse	O
osteoblast	O
co	O
-	O
cultures	O
.	O

TZDs	B
induced	O
mouse	O
osteoblast	O
death	O
and	O
increased	O
oleic	B
acid	I
uptake	O
.	O

TZDs	B
also	O
inhibited	O
alkaline	O
phosphatase	O
activity	O
(	O
58	O
-	O
75	O
%	O
,	O
p<0.046	O
)	O
and	O
osteocalcin	O
production	O
(	O
52	O
-	O
75	O
%	O
,	O
p<0.031	O
)	O
.	O

For	O
all	O
the	O
parameters	O
,	O
there	O
were	O
no	O
significant	O
differences	O
between	O
the	O
osteoblast	O
cultures	O
alone	O
and	O
the	O
HCG	O
/	O
osteoblast	O
co	O
-	O
cultures	O
.	O

TZD	B
effects	O
on	O
osteoblast	O
viability	O
,	O
oleic	O
acid	O
uptake	O
,	O
alkaline	O
phosphatase	O
and	O
osteocalcin	O
production	O
are	O
independent	O
of	O
their	O
effects	O
on	O
aromatase	O
.	O

Sonochemical	O
synthesis	O
of	O
hierarchical	O
ZnO	B
nanostructures	O
.	O

This	O
work	O
is	O
about	O
fabrication	O
of	O
ZnO	B
nanostructures	O
(	O
ZnO	B
-	O
NS	O
)	O
via	O
a	O
simple	O
sonochemical	O
method	O
.	O

The	O
chemicals	O
used	O
for	O
the	O
synthesis	O
of	O
various	O
shaped	O
ZnO	B
are	O
Zn	B
salt	O
,	O
sodium	B
hydroxide	I
and	O
ammonia	B
solution	I
without	O
other	O
structure	O
directing	O
agent	O
or	O
surfactant	O
needed	O
.	O

This	O
method	O
is	O
feasible	O
and	O
green	O
,	O
as	O
it	O
does	O
not	O
require	O
high	O
temperature	O
and/or	O
highly	O
toxic	O
chemicals	O
.	O

The	O
shape	O
of	O
the	O
ZnO	B
-	O
NS	O
can	O
be	O
tuned	O
by	O
adjusting	O
the	O
ultrasound	O
energy	O
dissipated	O
via	O
varying	O
the	O
ultrasonication	O
time	O
from	O
5	O
to	O
60	O
min	O
.	O

It	O
was	O
found	O
that	O
uniform	O
ZnO	B
nanorods	O
with	O
diameter	O
around	O
50	O
nm	O
were	O
formed	O
after	O
15	O
min	O
of	O
ultrasonication	O
while	O
flowerlike	O
ZnO	B
-	O
NS	O
was	O
formed	O
after	O
30	O
min	O
.	O

This	O
method	O
produces	O
high	O
quality	O
ZnO	B
-	O
NS	O
with	O
controllable	O
shapes	O
,	O
uniformity	O
,	O
and	O
purity	O
.	O

The	O
development	O
of	O
better	O
photocatalysts	O
through	O
composition-	O
and	O
structure	O
-	O
engineering	O
.	O

Semiconductor	O
photocatalysts	O
that	O
can	O
effectively	O
utilize	O
solar	O
irradiation	O
hold	O
great	O
potential	O
for	O
harnessing	O
renewable	O
-	O
energy	O
sources	O
,	O
as	O
well	O
as	O
for	O
environmental	O
protection	O
and	O
-remediation	O
.	O

Exploring	O
advanced	O
photocatalysts	O
that	O
have	O
improved	O
performance	O
has	O
been	O
a	O
central	O
theme	O
in	O
photocatalysis	O
research	O
.	O

Herein	O
,	O
we	O
review	O
the	O
recent	O
developments	O
in	O
the	O
design-	O
and	O
fabrication	O
of	O
photocatalysts	O
with	O
an	O
emphasis	O
on	O
composition-	O
and	O
structural	O
control	O
over	O
multiple	O
length	O
scales	O
.	O

This	O
Focus	O
Review	O
will	O
be	O
of	O
value	O
for	O
researchers	O
in	O
the	O
area	O
of	O
photocatalysis	O
,	O
in	O
particular	O
,	O
in	O
the	O
aspects	O
of	O
material	O
design	O
that	O
lead	O
to	O
the	O
synthesis	O
of	O
better	O
photocatalysts	O
.	O

Multidrug	O
resistance	O
-	O
associated	O
proteins	O
are	O
involved	O
in	O
the	O
transport	O
of	O
the	O
glutathione	B
conjugates	O
of	O
the	O
ultimate	O
carcinogen	O
of	O
benzo	B
[	I
a	I
]	I
pyrene	I
in	O
human	O
Caco-2	O
cells	O
.	O

A	O
wide	O
variety	O
of	O
contaminants	O
are	O
ingested	O
through	O
food	O
,	O
among	O
them	O
the	O
pro	O
-	O
carcinogenic	O
polycyclic	O
aromatic	O
hydrocarbon	O
benzo	B
[	I
a	I
]	I
pyrene	I
(	O
BP	O
)	O
that	O
is	O
resorbed	O
and	O
partially	O
metabolized	O
in	O
the	O
enterocytes	O
of	O
the	O
small	O
intestine	O
.	O

Previous	O
in	O
vitro	O
studies	O
have	O
revealed	O
that	O
BP	B
phenols	I
are	O
excreted	O
as	O
Phase	O
II	O
metabolites	O
including	O
glucuronides	O
and	O
sulfates	B
.	O

This	O
export	O
is	O
mediated	O
by	O
the	O
breast	O
cancer	O
resistance	O
protein	O
(	O
ABCG2	O
)	O
.	O

The	O
ultimate	O
carcinogenic	O
Phase	O
I	O
BP	O
metabolite	O
anti	O
-	O
BP-7,8-dihydrodiol-9,10-epoxide	B
(	O
BPDE	B
)	O
can	O
be	O
detoxified	O
by	O
glutathione	B
conjugate	O
formation	O
catalyzed	O
by	O
glutathione	B
S	O
-	O
transferases	O
.	O

In	O
the	O
present	O
study	O
,	O
differentiated	O
human	O
intestinal	O
Caco-2	O
cells	O
were	O
used	O
as	O
a	O
model	O
for	O
the	O
human	O
small	O
intestine	O
to	O
investigate	O
the	O
detoxification	O
of	O
BPDE	B
and	O
excretion	O
of	O
stereoisomeric	O
glutathione	B
conjugates	O
in	O
the	O
presence	O
of	O
an	O
inhibitor	O
of	O
the	O
glutathione	B
-	O
cleaving	O
enzyme	O
	O
-	O
glutamyl	O
transpeptidase	O
at	O
the	O
cell	O
surface	O
.	O

The	O
results	O
indicate	O
that	O
the	O
glutathione	B
conjugates	O
of	O
BPDE	B
are	O
formed	O
and	O
excreted	O
mainly	O
to	O
the	O
apical	O
and	O
to	O
a	O
minor	O
extent	O
to	O
the	O
basolateral	O
side	O
of	O
polarized	O
Caco-2	O
monolayers	O
.	O

Inhibition	O
studies	O
revealed	O
that	O
the	O
multidrug	O
resistance	O
-	O
associated	O
proteins	O
(	O
ABCCs	O
)	O
are	O
involved	O
in	O
the	O
transport	O
of	O
BPDE	B
glutathione	I
conjugates	O
.	O

Stable	O
ABCC1	O
,	O
ABCC2	O
and	O
ABCC3	O
knockdown	O
cell	O
lines	O
were	O
generated	O
,	O
thus	O
making	O
it	O
possible	O
to	O
demonstrate	O
that	O
ABCC1	O
mediates	O
the	O
basolateral	O
and	O
ABCC2	O
the	O
apical	O
excretion	O
of	O
BPDE	B
glutathione	I
conjugates	O
.	O

In	O
conclusion	O
,	O
the	O
ultimate	O
carcinogen	O
BPDE	B
is	O
detoxified	O
via	O
glutathione	B
conjugation	O
and	O
subsequently	O
excreted	O
by	O
Caco-2	O
cells	O
in	O
both	O
apical	O
and	O
basolateral	O
directions	O
.	O

This	O
finding	O
is	O
equivalent	O
to	O
a	O
transport	O
into	O
feces	O
as	O
well	O
as	O
blood	O
system	O
in	O
the	O
in	O
vivo	O
situation	O
.	O

The	O
influence	O
of	O
the	O
choice	O
of	O
digestion	O
enzyme	O
used	O
to	O
prepare	O
rat	O
hepatocytes	O
on	O
xenobiotic	O
uptake	O
and	O
efflux	O
.	O

Isolated	O
rat	O
hepatocytes	O
are	O
widely	O
used	O
to	O
assess	O
the	O
metabolism	O
and	O
toxicity	O
of	O
xenobiotics	O
.	O

The	O
choice	O
of	O
digestion	O
enzyme	O
used	O
to	O
prepare	O
the	O
cells	O
has	O
been	O
shown	O
previously	O
to	O
influence	O
their	O
metabolic	O
capability	O
.	O

This	O
study	O
investigates	O
the	O
effect	O
of	O
the	O
digestion	O
enzyme	O
(	O
collagenase	O
II	O
,	O
collagenase	O
A	O
/	O
trypsin	O
inhibitor	O
,	O
or	O
collagenase	O
plus	O
dispase	O
)	O
on	O
the	O
uptake	O
of	O
xenobiotics	O
into	O
,	O
and	O
efflux	O
from	O
,	O
hepatocytes	O
.	O

The	O
choice	O
of	O
digestion	O
enzymes	O
used	O
in	O
this	O
study	O
does	O
not	O
affect	O
uptake	O
of	O
either	O
pravastatin	B
(	O
an	O
organic	O
anion	O
probe	O
substrate	O
for	O
Oatp	O
transporter	O
)	O
or	O
metformin	B
(	O
an	O
organic	O
cation	O
probe	O
substrate	O
for	O
Oct	O
transporter	O
)	O
.	O

With	O
regard	O
to	O
efflux	O
transporters	O
,	O
hepatocyte	O
differentiation	O
was	O
better	O
maintained	O
when	O
cells	O
were	O
isolated	O
using	O
collagenase	O
II	O
alone	O
.	O

Impact	O
of	O
lead	O
and	O
mercuric	B
ions	O
on	O
the	O
interleukin-2-dependent	O
proliferation	O
and	O
survival	O
of	O
T	O
cells	O
.	O

Mercury	B
and	O
lead	O
are	O
widespread	O
in	O
the	O
environment	O
,	O
causing	O
chronic	O
exposure	O
of	O
a	O
large	O
population	O
to	O
low	O
concentrations	O
of	O
these	O
metals	O
.	O

While	O
several	O
studies	O
demonstrated	O
that	O
low	O
levels	O
of	O
both	O
metals	O
affect	O
the	O
immune	O
system	O
,	O
little	O
is	O
known	O
about	O
underlying	O
molecular	O
mechanisms	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
impact	O
of	O
mercuric	B
(	O
Hg	B
(	I
2	I
+	I
)	I
)	O
and	O
lead	O
(	O
Pb	B
(	I
2	I
+	I
)	I
)	O
ions	O
on	O
T	O
cells	O
.	O

Up	O
to	O
100	O
M	O
Pb	B
(	I
NO	I
(	I
3	I
)	I
)	I
(	I
2	I
)	I
had	O
no	O
effect	O
on	O
cellular	O
viability	O
and	O
proliferation	O
.	O

In	O
contrast	O
,	O
HgCl	B
(	I
2	I
)	I
caused	O
a	O
concentration	O
-	O
dependent	O
decline	O
of	O
viable	O
leukocytes	O
and	O
especially	O
of	O
activated	O
T	O
cells	O
.	O

Additionally	O
,	O
Hg	B
(	I
2	I
+	I
)	I
induced	O
reactive	O
oxygen	B
species	O
(	O
ROS	O
)	O
generation	O
accompanied	O
by	O
the	O
loss	O
of	O
mitochondrial	O
transmembrane	O
potential	O
,	O
measured	O
by	O
Dihydrorhodamine	B
and	O
Rhodamine-123	B
,	O
respectively	O
.	O

The	O
antioxidant	O
N	B
-	I
acetylcysteine	I
partially	O
reversed	O
the	O
toxic	O
effects	O
of	O
Hg	B
(	I
2	I
+	I
)	I
,	O
pointing	O
to	O
an	O
involvement	O
of	O
ROS	O
.	O

The	O
major	O
cytokine	O
controlling	O
T	O
-	O
cell	O
survival	O
and	O
proliferation	O
is	O
interleukin	O
(	O
IL	O
)	O
-2	O
.	O

Hg	B
(	I
2	I
+	I
)	I
had	O
no	O
effect	O
on	O
the	O
secretion	O
of	O
IL-2	O
,	O
but	O
on	O
IL-2	O
mediated	O
signal	O
transduction	O
pathways	O
,	O
reducing	O
phosphorylation	O
of	O
the	O
downstream	O
kinases	O
ERK1	O
/	O
2	O
and	O
AKT	O
.	O

Moreover	O
,	O
Hg	B
(	I
2	I
+	I
)	I
led	O
to	O
an	O
arrest	O
of	O
the	O
cells	O
in	O
the	O
S	O
phase	O
of	O
the	O
cell	O
cycle	O
.	O

Taken	O
together	O
,	O
these	O
data	O
fit	O
a	O
model	O
in	O
which	O
Hg	B
(	I
2	I
+	I
)	I
disrupts	O
mitochondria	O
,	O
and	O
the	O
resulting	O
release	O
of	O
ROS	O
inhibits	O
IL-2-dependent	O
signal	O
transduction	O
,	O
reducing	O
proliferation	O
and	O
survival	O
of	O
T	O
cells	O
.	O

Analysis	O
of	O
cytotoxic	O
T	O
lymphocyte	O
antigen-4	O
(	O
CTLA-4	O
)	O
promoter	O
-318C	O
/	O
T	O
and	O
+	O
49A	O
/	O
G	O
gene	O
polymorphisms	O
in	O
Turkish	O
patients	O
with	O
familial	O
Mediterranean	O
fever	O
.	O

Either	O
the	O
role	O
of	O
the	O
adaptive	O
immune	O
system	O
or	O
the	O
interaction	O
between	O
innate	O
and	O
adaptive	O
immune	O
systems	O
in	O
familial	O
Mediterranean	O
fever	O
(	O
FMF	O
)	O
is	O
not	O
clear	O
so	O
far	O
.	O

So	O
,	O
we	O
planned	O
to	O
search	O
for	O
the	O
interaction	O
between	O
the	O
innate	O
and	O
adaptive	O
immune	O
systems	O
in	O
the	O
pathogenesis	O
of	O
FMF	O
by	O
investigating	O
polymorphism	O
for	O
CTLA-4	O
gene	O
,	O
which	O
plays	O
a	O
role	O
in	O
controlling	O
antigen	O
presentation	O
to	O
T	O
cells	O
.	O

We	O
also	O
aimed	O
to	O
investigate	O
whether	O
there	O
is	O
an	O
association	O
between	O
-318C	O
/	O
T	O
and	O
+	O
49A	O
/	O
G	O
polymorphisms	O
in	O
the	O
CTLA-4	O
gene	O
and	O
the	O
main	O
clinical	O
features	O
of	O
the	O
disease	O
.	O

75	O
FMF	O
patients	O
and	O
179	O
controls	O
were	O
studied	O
.	O

Polymorphism	O
was	O
detected	O
by	O
the	O
PCR	O
-	O
RFLP	O
technique	O
.	O

The	O
CT	O
genotype	O
and	O
T	O
allele	O
frequencies	O
of	O
the	O
-318C	O
/	O
T	O
polymorphism	O
and	O
the	O
haplotype	O
frequency	O
for	O
the	O
-318T	O
/	O
+49A	O
in	O
the	O
CTLA-4	O
gene	O
were	O
higher	O
in	O
the	O
FMF	O
(	O
21.3	O
,	O
21.3	O
,	O
and	O
10.7	O
%	O
)	O
when	O
compared	O
with	O
the	O
controls	O
(	O
10.6	O
,	O
10.6	O
,	O
and	O
5.3	O
%	O
;	O
P	O
=	O
0.029	O
,	O
0.044	O
,	O
and	O
0.029	O
)	O
.	O

However	O
,	O
these	O
differences	O
did	O
not	O
reach	O
a	O
statistically	O
significant	O
level	O
after	O
the	O
Bonferroni	O
correction	O
.	O

A	O
significant	O
linkage	O
disequilibrium	O
was	O
found	O
between	O
the	O
-318C	O
/	O
T	O
and	O
+	O
49A	O
/	O
G	O
polymorphisms	O
in	O
the	O
CTLA-4	O
gene	O
(	O
D	O
'	O
=	O
0.997	O
,	O
r	O
(	O
2	O
)	O
=	O
0.027	O
,	O
P	O
=	O
0.0002	O
)	O
.	O

Genotype	O
and	O
carrier	O
frequencies	O
of	O
the	O
CTLA-4	O
gene	O
+	O
49A	O
/	O
G	O
polymorphism	O
were	O
not	O
significantly	O
different	O
between	O
FMF	O
patients	O
and	O
healthy	O
controls	O
.	O

No	O
association	O
was	O
found	O
between	O
the	O
studied	O
polymorphisms	O
and	O
the	O
main	O
clinical	O
features	O
of	O
the	O
disease	O
.	O

Our	O
findings	O
suggest	O
that	O
although	O
not	O
statistically	O
significant	O
,	O
higher	O
frequencies	O
of	O
CTLA-4	O
gene	O
-318CT	O
genotype	O
,	O
T	O
allele	O
,	O
and	O
-318T	O
/	O
+49A	O
haplotype	O
in	O
FMF	O
patients	O
may	O
be	O
related	O
to	O
the	O
non	O
-	O
autoimmune	O
pathogenesis	O
of	O
FMF	O
.	O

Cost	O
-	O
effectiveness	O
of	O
hepatitis	O
B	O
vaccination	O
in	O
adults	O
with	O
diagnosed	O
diabetes	O
.	O

OBJECTIVE	O
To	O
examine	O
the	O
cost	O
-	O
effectiveness	O
of	O
a	O
hepatitis	O
B	O
vaccination	O
program	O
for	O
unvaccinated	O
adults	O
with	O
diagnosed	O
diabetes	O
in	O
the	O
U.S.	O
RESEARCH	O
DESIGN	O
AND	O
METHODS	O
We	O
used	O
a	O
cost	O
-	O
effectiveness	O
simulation	O
model	O
to	O
estimate	O
the	O
cost	O
-	O
effectiveness	O
of	O
vaccinating	O
adults	O
20	O
-	O
59	O
years	O
of	O
age	O
with	O
diagnosed	O
diabetes	O
not	O
previously	O
vaccinated	O
for	O
or	O
infected	O
by	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
.	O

The	O
model	O
estimated	O
acute	O
and	O
chronic	O
HBV	O
infections	O
,	O
complications	O
,	O
quality	O
-	O
adjusted	O
life	O
-	O
years	O
(	O
QALYs	O
)	O
,	O
and	O
incremental	O
cost	O
-	O
effectiveness	O
ratios	O
.	O

Data	O
sources	O
included	O
surveillance	O
data	O
,	O
epidemiological	O
studies	O
,	O
and	O
vaccine	O
prices	O
.	O

RESULTS	O
With	O
a	O
10	O
%	O
uptake	O
rate	O
,	O
the	O
intervention	O
will	O
vaccinate	O
528,047	O
people	O
and	O
prevent	O
4,271	O
acute	O
and	O
256	O
chronic	O
hepatitis	O
B	O
infections	O
.	O

Net	O
health	O
care	O
costs	O
will	O
increase	O
by	O
$	O
91.4	O
million	O
,	O
and	O
1,218	O
QALYs	O
will	O
be	O
gained	O
,	O
producing	O
a	O
cost	O
-	O
effectiveness	O
ratio	O
of	O
$	O
75,094	O
per	O
QALY	O
gained	O
.	O

Results	O
are	O
most	O
sensitive	O
to	O
age	O
,	O
the	O
discount	O
rate	O
,	O
the	O
hepatitis	O
B	O
incidence	O
ratio	O
for	O
people	O
with	O
diabetes	O
,	O
and	O
hepatitis	O
B	O
infection	O
rates	O
.	O

Cost	O
-	O
effectiveness	O
ratios	O
rise	O
with	O
age	O
at	O
vaccination	O
;	O
an	O
alternative	O
intervention	O
that	O
vaccinates	O
adults	O
with	O
diabetes	O
60	O
years	O
of	O
age	O
or	O
older	O
had	O
a	O
cost	O
-	O
effectiveness	O
ratio	O
of	O
$	O
2.7	O
million	O
per	O
QALY	O
.	O

CONCLUSIONS	O
Hepatitis	O
B	O
vaccination	O
for	O
adults	O
with	O
diabetes	O
20	O
-	O
59	O
years	O
of	O
age	O
is	O
modestly	O
cost	O
-	O
effective	O
.	O

Vaccinating	O
older	O
adults	O
with	O
diabetes	O
is	O
not	O
cost	O
-	O
effective	O
.	O

The	O
study	O
did	O
not	O
consider	O
hepatitis	O
outbreak	O
investigation	O
costs	O
,	O
and	O
limited	O
information	O
exists	O
on	O
hepatitis	O
progression	O
among	O
older	O
adults	O
with	O
diabetes	O
.	O

Partly	O
based	O
on	O
these	O
results	O
,	O
the	O
Advisory	O
Committee	O
on	O
Immunization	O
Practices	O
recently	O
recommended	O
hepatitis	O
B	O
vaccination	O
for	O
people	O
20	O
-	O
59	O
years	O
of	O
age	O
with	O
diagnosed	O
diabetes	O
.	O

Evaluation	O
of	O
aggregating	O
brain	O
cell	O
cultures	O
for	O
the	O
detection	O
of	O
acute	O
organ	O
-	O
specific	O
toxicity	O
.	O

As	O
part	O
of	O
the	O
ACuteTox	O
project	O
aimed	O
at	O
the	O
development	O
of	O
non	O
-	O
animal	O
testing	O
strategies	O
for	O
predicting	O
human	O
acute	O
oral	O
toxicity	O
,	O
aggregating	O
brain	O
cell	O
cultures	O
(	O
AGGR	O
)	O
were	O
examined	O
for	O
their	O
capability	O
to	O
detect	O
organ	O
-	O
specific	O
toxicity	O
.	O

Previous	O
multicenter	O
evaluations	O
of	O
in	O
vitro	O
cytotoxicity	O
showed	O
that	O
some	O
20	O
%	O
of	O
the	O
tested	O
chemicals	O
exhibited	O
significantly	O
lower	O
in	O
vitro	O
toxicity	O
as	O
expected	O
from	O
in	O
vivo	O
toxicity	O
data	O
.	O

This	O
was	O
supposed	O
to	O
be	O
due	O
to	O
toxicity	O
at	O
supracellular	O
(	O
organ	O
or	O
system	O
)	O
levels	O
.	O

To	O
examine	O
the	O
capability	O
of	O
AGGR	O
to	O
alert	O
for	O
potential	O
organ	O
-	O
specific	O
toxicants	O
,	O
concentration	O
-	O
response	O
studies	O
were	O
carried	O
out	O
in	O
AGGR	O
for	O
86	O
chemicals	O
,	O
taking	O
as	O
endpoints	O
the	O
mRNA	O
expression	O
levels	O
of	O
four	O
selected	O
genes	O
.	O

The	O
lowest	O
observed	O
effect	O
concentration	O
(	O
LOEC	O
)	O
determined	O
for	O
each	O
chemical	O
was	O
compared	O
with	O
the	O
IC20	O
reported	O
for	O
the	O
3T3	O
/	O
NRU	O
cytotoxicity	O
assay	O
.	O

A	O
LOEC	O
lower	O
than	O
IC20	O
by	O
at	O
least	O
a	O
factor	O
of	O
5	O
was	O
taken	O
to	O
alert	O
for	O
organ	O
-	O
specific	O
toxicity	O
.	O

The	O
results	O
showed	O
that	O
the	O
frequency	O
of	O
alerts	O
increased	O
with	O
the	O
level	O
of	O
toxicity	O
observed	O
in	O
AGGR	O
.	O

Among	O
the	O
chemicals	O
identified	O
as	O
alert	O
were	O
many	O
compounds	O
known	O
for	O
their	O
organ	O
-	O
specific	O
toxicity	O
.	O

These	O
findings	O
suggest	O
that	O
AGGR	O
are	O
suitable	O
for	O
the	O
detection	O
of	O
organ	O
-	O
specific	O
toxicity	O
and	O
that	O
they	O
could	O
,	O
in	O
conjunction	O
with	O
the	O
3T3	O
/	O
NRU	O
cytotoxicity	O
assay	O
,	O
improve	O
the	O
predictive	O
capacity	O
of	O
in	O
vitro	O
toxicity	O
testing	O
.	O

Silver	B
nanoparticle	O
-	O
induced	O
cytotoxicity	O
in	O
rat	O
brain	O
endothelial	O
cell	O
culture	O
.	O

Silver	B
nanoparticles	O
(	O
AgNPs	O
)	O
are	O
among	O
the	O
most	O
widely	O
commercialised	O
engineered	O
nanomaterials	O
,	O
because	O
of	O
their	O
antimicrobial	O
properties	O
.	O

They	O
are	O
already	O
commonly	O
used	O
in	O
medical	O
devices	O
,	O
household	O
products	O
and	O
industry	O
.	O

Concerns	O
have	O
been	O
raised	O
about	O
potential	O
adverse	O
health	O
effects	O
due	O
to	O
increasing	O
dispersion	O
of	O
AgNPs	O
in	O
the	O
environment	O
.	O

The	O
present	O
study	O
examined	O
the	O
cytotoxic	O
effects	O
of	O
spherical	O
,	O
citrate	B
-	O
coated	O
AgNPs	O
(	O
10	O
,	O
50	O
and	O
100	O
nm	O
)	O
in	O
rat	O
brain	O
endothelial	O
(	O
RBE4	O
)	O
cells	O
and	O
investigated	O
whether	O
the	O
observed	O
effects	O
can	O
be	O
explained	O
by	O
the	O
intrinsic	O
toxicity	O
of	O
the	O
particles	O
or	O
the	O
silver	B
ions	O
released	O
from	O
the	O
particles	O
.	O

The	O
results	O
indicated	O
that	O
exposure	O
of	O
RBE4	O
cells	O
to	O
AgNPs	O
lead	O
to	O
significant	O
reduction	O
in	O
dye	O
uptake	O
as	O
measured	O
with	O
the	O
Neutral	B
red	I
(	O
NR	O
)	O
assay	O
.	O

The	O
effect	O
was	O
found	O
to	O
be	O
related	O
to	O
particle	O
size	O
,	O
surface	O
area	O
,	O
dose	O
and	O
exposure	O
time	O
.	O

In	O
contrast	O
,	O
silver	B
ions	O
increased	O
NR	O
uptake	O
(	O
ca	O
.	O
10	O
%	O
)	O
in	O
RBE4	O
cells	O
after	O
1h	O
,	O
while	O
a	O
reduction	O
in	O
NR	O
uptake	O
was	O
observed	O
after	O
24h	O
exposure	O
at	O
high	O
concentrations	O
(	O
20	O
-	O
30	O
M	O
)	O
.	O

Colony	O
formation	O
,	O
as	O
an	O
indicator	O
of	O
proliferation	O
ability	O
,	O
was	O
completely	O
inhibited	O
by	O
AgNPs	O
at	O
concentrations	O
higher	O
than	O
1	O
g	O
/	O
ml	O
.	O

Silver	B
ions	O
had	O
less	O
effect	O
on	O
the	O
colony	O
formation	O
of	O
RBE4	O
cells	O
than	O
AgNPs	O
.	O

Green	O
tomato	O
extract	O
attenuates	O
high	O
-	O
fat	O
-	O
diet	O
-	O
induced	O
obesity	O
through	O
activation	O
of	O
the	O
AMPK	O
pathway	O
in	O
C57BL	O
/	O
6	O
mice	O
.	O

Obesity	O
is	O
a	O
risk	O
factor	O
for	O
numerous	O
metabolic	O
disorders	O
.	O

Recently	O
,	O
natural	O
compounds	O
that	O
may	O
be	O
beneficial	O
for	O
improving	O
obesity	O
have	O
received	O
increasing	O
attention	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
whether	O
red	O
and	O
green	O
tomato	O
extracts	O
attenuate	O
high	O
-	O
fat	O
-	O
diet	O
-	O
induced	O
obesity	O
in	O
C57BL	O
/	O
6	O
mice	O
.	O

The	O
mice	O
were	O
maintained	O
on	O
a	O
normal	O
diet	O
(	O
ND	O
)	O
or	O
high	O
-	O
fat	O
diet	O
(	O
HFD	O
)	O
for	O
4	O
weeks	O
and	O
then	O
fed	O
ND	O
,	O
HFD	O
,	O
HFD	O
plus	O
2	O
%	O
red	O
tomato	O
extract	O
(	O
RTE	O
)	O
or	O
HFD	O
plus	O
2	O
%	O
green	O
tomato	O
extract	O
(	O
GTE	O
)	O
for	O
13	O
weeks	O
.	O

The	O
weekly	O
food	O
intakes	O
among	O
the	O
groups	O
were	O
not	O
significantly	O
different	O
.	O

Body	O
weight	O
of	O
mice	O
fed	O
HFD	O
plus	O
GTE	O
was	O
significantly	O
decreased	O
to	O
the	O
level	O
of	O
mice	O
fed	O
ND	O
,	O
but	O
the	O
body	O
weight	O
was	O
only	O
slightly	O
reduced	O
in	O
mice	O
fed	O
HFD	O
plus	O
RTE	O
.	O

Epididymal	O
adipose	O
tissue	O
and	O
liver	O
weights	O
were	O
significantly	O
decreased	O
in	O
mice	O
fed	O
HFD	O
plus	O
GTE	O
compared	O
to	O
those	O
in	O
HFD	O
.	O

Serum	O
total	O
cholesterol	B
and	O
low	O
-	O
density	O
lipoprotein	O
cholesterol	B
levels	O
in	O
mice	O
fed	O
GTE	O
were	O
modestly	O
reduced	O
,	O
and	O
liver	O
total	O
cholesterol	B
level	O
was	O
strongly	O
decreased	O
in	O
HFD	O
plus	O
GTE	O
-	O
fed	O
mice	O
compared	O
to	O
that	O
in	O
HFD	O
-	O
fed	O
mice	O
.	O

Adenosine	B
-	I
monophosphate	I
-	O
activated	O
protein	O
kinase	O
(	O
AMPK	O
)	O
and	O
acetyl	B
-	I
CoA	I
carboxylase	O
phosphorylation	O
in	O
liver	O
from	O
HFD	O
plus	O
GTE	O
-	O
fed	O
mice	O
was	O
significantly	O
elevated	O
,	O
and	O
HMG	B
-	I
CoA	I
reductase	O
expression	O
was	O
also	O
significantly	O
decreased	O
.	O

GTE	O
strongly	O
decreased	O
the	O
expression	O
of	O
peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
gamma	O
,	O
CCAAT	O
/	O
enhancer	O
-	O
binding	O
protein	O
alpha	O
and	O
perilipin	O
in	O
the	O
adipose	O
tissue	O
of	O
mice	O
fed	O
HFD	O
plus	O
GTE	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
antiobesity	O
effects	O
of	O
GTE	O
may	O
be	O
associated	O
with	O
activation	O
of	O
the	O
AMPK	O
pathway	O
.	O

Opportunities	O
for	O
functional	O
selectivity	O
in	O
GPCR	O
antibodies	O
.	O

Monoclonal	O
antibodies	O
(	O
mAbs	O
)	O
have	O
been	O
used	O
for	O
decades	O
as	O
tools	O
to	O
probe	O
the	O
biology	O
and	O
pharmacology	O
of	O
receptors	O
in	O
cells	O
and	O
tissues	O
.	O

They	O
are	O
also	O
increasingly	O
being	O
developed	O
for	O
clinical	O
purposes	O
against	O
a	O
broad	O
range	O
of	O
targets	O
,	O
albeit	O
to	O
a	O
lesser	O
extent	O
for	O
G	O
-	O
protein	O
-	O
coupled	O
receptors	O
(	O
GPCRs	O
)	O
relative	O
to	O
other	O
therapeutic	O
targets	O
.	O

Recent	O
pharmacological	O
,	O
structural	O
and	O
biophysical	O
data	O
have	O
provided	O
a	O
great	O
deal	O
of	O
new	O
insight	O
into	O
the	O
molecular	O
details	O
,	O
complexity	O
and	O
regulation	O
of	O
GPCR	O
function	O
.	O

Whereas	O
GPCRs	O
used	O
to	O
be	O
viewed	O
as	O
having	O
either	O
"	O
on	O
"	O
or	O
"	O
off	O
"	O
conformational	O
states	O
,	O
it	O
is	O
now	O
recognized	O
that	O
their	O
structures	O
may	O
be	O
finely	O
tuned	O
by	O
ligands	O
and	O
other	O
interacting	O
proteins	O
,	O
leading	O
to	O
the	O
selective	O
activation	O
of	O
specific	O
signaling	O
pathways	O
.	O

This	O
information	O
coupled	O
with	O
new	O
technologies	O
for	O
the	O
selection	O
of	O
mAbs	O
targeting	O
GPCRs	O
will	O
be	O
increasingly	O
deployed	O
for	O
the	O
development	O
of	O
highly	O
selective	O
mAbs	O
that	O
recognize	O
conformational	O
determinants	O
leading	O
to	O
novel	O
therapeutics	O
.	O

Nephrogenic	O
systemic	O
fibrosis	O
-	O
like	O
effects	O
of	O
magnetic	O
resonance	O
imaging	O
contrast	O
agents	O
in	O
rats	O
with	O
adenine	B
-	O
induced	O
renal	O
failure	O
.	O

Nephrogenic	O
systemic	O
fibrosis	O
(	O
NSF	O
)	O
is	O
a	O
scleroderma	O
-	O
like	O
disease	O
associated	O
with	O
prior	O
administration	O
of	O
certain	O
gadolinium	B
chelates	O
(	O
GCs	O
)	O
.	O

NSF	O
occurs	O
in	O
patients	O
with	O
severe	O
renal	O
failure	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
set	O
up	O
a	O
rat	O
model	O
of	O
GC	O
-	O
associated	O
NSF	O
to	O
elucidate	O
the	O
mechanism	O
of	O
this	O
devastating	O
disease	O
.	O

Firstly	O
,	O
after	O
characterization	O
of	O
the	O
model	O
,	O
male	O
Wistar	O
rats	O
received	O
a	O
0.75	O
%	O
adenine	B
-	O
enriched	O
diet	O
for	O
8	O
,	O
14	O
,	O
or	O
16	O
days	O
to	O
obtain	O
various	O
degrees	O
of	O
renal	O
failure	O
.	O

Rats	O
received	O
five	O
consecutive	O
daily	O
iv	O
injections	O
of	O
saline	O
or	O
gadodiamide	B
(	O
2.5	O
mmol	O
/	O
kg	O
/	O
day	O
)	O
.	O

Secondly	O
,	O
the	O
safety	O
profile	O
and	O
in	O
vivo	O
propensity	O
to	O
dissociate	O
of	O
all	O
categories	O
of	O
marketed	O
GCs	O
(	O
gadoterate	B
,	O
gadobutrol	B
,	O
gadobenate	B
,	O
gadopentetate	B
,	O
and	O
gadodiamide	B
)	O
were	O
compared	O
in	O
rats	O
receiving	O
adenine	B
-	O
enriched	O
diet	O
for	O
16	O
days	O
.	O

Serial	O
skin	O
biopsies	O
were	O
performed	O
for	O
blinded	O
histopathological	O
study	O
.	O

Total	O
Gd	B
concentration	O
in	O
tissues	O
was	O
measured	O
by	O
Inductively	O
Coupled	O
Plasma	O
Mass	O
Spectrometry	O
.	O

Relaxometry	O
was	O
used	O
to	O
evaluate	O
the	O
presence	O
of	O
dissociated	O
Gd	B
in	O
skin	O
and	O
bone	O
.	O

Gadodiamide	B
-	O
induced	O
high	O
mortality	O
and	O
skin	O
lesions	O
(	O
dermal	O
fibrosis	O
,	O
calcification	O
,	O
and	O
inflammation	O
)	O
were	O
related	O
to	O
adenine	B
diet	O
duration	O
.	O

No	O
skin	O
lesions	O
were	O
observed	O
with	O
other	O
molecules	O
.	O

Unlike	O
macrocyclic	O
GCs	O
,	O
gadodiamide	B
,	O
gadopentetate	B
,	O
and	O
gadobenate	B
gradually	O
increased	O
the	O
r	O
(	O
1	O
)	O
relaxivity	O
value	O
,	O
consistent	O
with	O
in	O
vivo	O
dissociation	O
and	O
release	O
of	O
soluble	O
Gd	B
(	O
or	O
,	O
in	O
the	O
case	O
of	O
gadobenate	B
,	O
the	O
consequence	O
of	O
protein	O
binding	O
)	O
.	O

Gadodiamide	B
-	O
induced	O
cutaneous	O
and	O
systemic	O
toxicity	O
depended	O
on	O
baseline	O
renal	O
function	O
.	O

We	O
demonstrate	O
in	O
vivo	O
dissociation	O
of	O
linear	O
GCs	O
,	O
gadodiamide	B
,	O
and	O
gadopentetate	B
,	O
whereas	O
macrocyclic	O
agents	O
remained	O
stable	O
over	O
the	O
study	O
period	O
.	O

Effects	O
of	O
ozone	B
and	O
particulate	O
matter	O
on	O
cardiac	O
mechanics	O
:	O
role	O
of	O
the	O
atrial	O
natriuretic	O
peptide	O
gene	O
.	O

A	O
positive	O
association	O
between	O
air	O
pollution	O
exposure	O
and	O
increased	O
human	O
risk	O
of	O
chronic	O
heart	O
disease	O
progression	O
is	O
well	O
established	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
test	O
two	O
hypotheses	O
:	O
(	O
1	O
)	O
the	O
cardiac	O
compensatory	O
changes	O
in	O
response	O
to	O
air	O
pollution	O
are	O
dependent	O
on	O
its	O
composition	O
and	O
(	O
2	O
)	O
specific	O
cardiac	O
adaptations	O
are	O
regulated	O
by	O
atrial	O
natriuretic	O
peptide	O
(	O
ANP	O
)	O
.	O

We	O
address	O
these	O
hypotheses	O
by	O
initially	O
examining	O
the	O
exposure	O
effects	O
of	O
ozone	B
(	O
O	B
(	I
3	I
)	I
)	O
and/or	O
particulate	O
matter	O
(	O
PM	O
)	O
on	O
cardiac	O
function	O
in	O
C57Bl	O
/	O
6J	O
(	O
B6	O
)	O
mice	O
.	O

Subsequently	O
,	O
the	O
results	O
are	O
compared	O
with	O
cardiac	O
functional	O
changes	O
to	O
the	O
same	O
exposures	O
in	O
Nppa	O
(	O
the	O
precursor	O
gene	O
for	O
ANP	O
)	O
knockout	O
(	O
KO	O
)	O
mice	O
.	O

Separate	O
groups	O
of	O
mice	O
underwent	O
3	O
consecutive	O
days	O
of	O
the	O
same	O
exposure	O
sequence	O
for	O
3h	O
each	O
consisting	O
of	O
the	O
following	O
:	O
(	O
1	O
)	O
6h	O
of	O
filtered	O
air	O
(	O
FAFA	O
)	O
,	O
(	O
2	O
)	O
O	B
(	I
3	I
)	I
then	O
FA	O
(	O
O	B
(	I
3	I
)	I
FA	O
)	O
,	O
(	O
3	O
)	O
FA	O
then	O
carbon	B
black	I
(	O
FACB	O
)	O
,	O
or	O
(	O
4	O
)	O
O	B
(	I
3	I
)	I
then	O
CB	O
.	O

Cardiac	O
function	O
was	O
assessed	O
using	O
a	O
conductance	O
catheter	O
to	O
generate	O
cardiac	O
pressure	O
-	O
volume	O
loops	O
8	O
-	O
10h	O
following	O
each	O
exposure	O
sequence	O
.	O

As	O
compared	O
with	O
FAFA	O
,	O
each	O
sequence	O
led	O
to	O
a	O
substantial	O
drop	O
(	O
as	O
much	O
as	O
33	O
%	O
)	O
in	O
stroke	O
volume	O
and	O
cardiac	O
output	O
.	O

However	O
,	O
these	O
losses	O
of	O
cardiac	O
function	O
occurred	O
by	O
different	O
compensatory	O
mechanisms	O
dependent	O
on	O
the	O
pollutant	O
composition	O
.	O

For	O
example	O
,	O
O	B
(	I
3	I
)	I
FA	O
exposure	O
led	O
to	O
reductions	O
in	O
both	O
end	O
-	O
systolic	O
and	O
end	O
-	O
diastolic	O
left	O
ventricular	O
(	O
LV	O
)	O
volumes	O
,	O
whereas	O
FACB	O
exposure	O
led	O
an	O
increase	O
in	O
end	O
-	O
diastolic	O
LV	O
volume	O
.	O

These	O
same	O
cardiac	O
compensatory	O
changes	O
were	O
largely	O
abolished	O
in	O
Nppa	O
KO	O
mice	O
following	O
O	B
(	I
3	I
)	I
FA	O
or	O
FACB	O
exposure	O
.	O

These	O
results	O
suggest	O
that	O
cardiac	O
functional	O
changes	O
in	O
response	O
to	O
air	O
pollution	O
exposure	O
are	O
strongly	O
dependent	O
on	O
the	O
pollutant	O
constituents	O
,	O
especially	O
related	O
to	O
O	B
(	I
3	I
)	I
and/or	O
PM	O
.	O

Furthermore	O
,	O
ANP	O
regulation	O
appears	O
to	O
be	O
crucial	O
to	O
these	O
cardiac	O
compensatory	O
mechanisms	O
induced	O
by	O
air	O
pollution	O
.	O

Solving	O
the	O
lost	O
in	O
translation	O
problem	O
:	O
improving	O
the	O
effectiveness	O
of	O
translational	O
research	O
.	O

Translational	O
research	O
frequently	O
fails	O
to	O
replicate	O
in	O
the	O
clinic	O
what	O
has	O
been	O
demonstrated	O
in	O
the	O
laboratory	O
.	O

This	O
has	O
been	O
true	O
for	O
neuroprotection	O
in	O
the	O
central	O
nervous	O
system	O
,	O
neuroprotection	O
in	O
glaucoma	O
,	O
as	O
well	O
as	O
many	O
other	O
areas	O
of	O
medicine	O
.	O

Two	O
fundamental	O
reasons	O
for	O
this	O
'	O
Lost	O
in	O
Translation	O
'	O
problem	O
are	O
the	O
'	O
Butterfly	O
Effect	O
'	O
(	O
chaotic	O
behavior	O
of	O
many	O
animal	O
models	O
)	O
and	O
the	O
'	O
Two	O
Cultures	O
'	O
problem	O
(	O
differences	O
between	O
the	O
methodologies	O
for	O
preclinical	O
and	O
clinical	O
research	O
)	O
.	O

We	O
propose	O
several	O
strategies	O
to	O
deal	O
with	O
these	O
issues	O
,	O
including	O
the	O
use	O
of	O
ensembles	O
of	O
animal	O
models	O
,	O
adding	O
intraocular	O
pressure	O
lowering	O
to	O
preclinical	O
neuroprotection	O
studies	O
,	O
changing	O
the	O
way	O
in	O
which	O
preclinical	O
research	O
is	O
done	O
,	O
and	O
increasing	O
interactions	O
between	O
the	O
preclinical	O
and	O
clinical	O
teams	O
.	O

The	O
involvement	O
of	O
Reelin	O
in	O
neurodevelopmental	O
disorders	O
.	O

Reelin	O
is	O
a	O
glycoprotein	O
that	O
serves	O
important	O
roles	O
both	O
during	O
development	O
(	O
regulation	O
of	O
neuronal	O
migration	O
and	O
brain	O
lamination	O
)	O
and	O
in	O
adulthood	O
(	O
maintenance	O
of	O
synaptic	O
function	O
)	O
.	O

A	O
number	O
of	O
neuropsychiatric	O
disorders	O
including	O
autism	O
,	O
schizophrenia	O
,	O
bipolar	O
disorder	O
,	O
major	O
depression	O
,	O
Alzheimer	O
's	O
disease	O
and	O
lissencephaly	O
share	O
a	O
common	O
feature	O
of	O
abnormal	O
Reelin	O
expression	O
in	O
the	O
brain	O
.	O

Altered	O
Reelin	O
expression	O
has	O
been	O
hypothesized	O
to	O
impair	O
neuronal	O
connectivity	O
and	O
synaptic	O
plasticity	O
,	O
leading	O
ultimately	O
to	O
the	O
cognitive	O
deficits	O
present	O
in	O
these	O
disorders	O
.	O

The	O
mechanisms	O
for	O
abnormal	O
Reelin	O
expression	O
in	O
some	O
of	O
these	O
disorders	O
are	O
currently	O
unknown	O
although	O
possible	O
explanations	O
include	O
early	O
developmental	O
insults	O
,	O
mutations	O
,	O
hypermethylation	O
of	O
the	O
promoter	O
for	O
the	O
Reelin	O
gene	O
(	O
RELN	O
)	O
,	O
miRNA	O
silencing	O
of	O
Reelin	O
mRNA	O
,	O
FMRP	O
underexpression	O
and	O
Reelin	O
processing	O
abnormalities	O
.	O

Increasing	O
Reelin	O
expression	O
through	O
pharmacological	O
therapies	O
may	O
help	O
ameliorate	O
symptoms	O
resulting	O
from	O
Reelin	O
deficits	O
.	O

This	O
article	O
is	O
part	O
of	O
the	O
Special	O
Issue	O
entitled	O
'	O
Neurodevelopmental	O
Disorders	O
'	O
.	O

Antidepressant	O
-	O
like	O
properties	O
of	O
three	O
new	O
2-adrenoceptor	O
antagonists	O
.	O

Evidence	O
suggests	O
that	O
depression	O
is	O
associated	O
with	O
an	O
increase	O
in	O
the	O
high	O
-	O
affinity	O
conformation	O
of	O
the	O
2-adrenoceptors	O
in	O
human	O
brain	O
.	O

Such	O
enhanced	O
2-adrenoceptor	O
activity	O
could	O
explain	O
the	O
deficit	O
in	O
central	O
noradrenergic	O
transmission	O
described	O
in	O
the	O
aetiology	O
of	O
depression	O
.	O

Thus	O
,	O
administration	O
of	O
2-adrenoceptor	O
antagonists	O
augments	O
noradrenaline	B
levels	O
and	O
provides	O
an	O
effective	O
therapeutic	O
approach	O
for	O
the	O
treatment	O
of	O
depressive	O
disorders	O
.	O

In	O
previous	O
studies	O
,	O
we	O
have	O
characterized	O
three	O
new	O
synthesized	O
guanidine	B
and	O
2-aminoimidazoline	B
aromatic	O
derivatives	O
(	O
8b	O
,	O
17b	O
and	O
20b	O
)	O
as	O
2-adrenoceptor	O
antagonists	O
that	O
are	O
able	O
to	O
increase	O
extracellular	O
concentration	O
of	O
noradrenaline	B
in	O
rat	O
brain	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
the	O
in	O
vivo	O
antidepressant	O
-	O
like	O
properties	O
of	O
these	O
three	O
new	O
2-adrenoceptor	O
antagonists	O
.	O

For	O
that	O
aim	O
,	O
compounds	O
were	O
tested	O
on	O
the	O
tail	O
suspension	O
test	O
(	O
TST	O
)	O
and	O
forced	O
swim	O
test	O
(	O
FST	O
)	O
,	O
two	O
classically	O
widely	O
-	O
used	O
behavioural	O
paradigms	O
for	O
the	O
evaluation	O
of	O
antidepressant	O
-	O
like	O
activity	O
.	O

Compound	O
8b	O
significantly	O
reduced	O
the	O
immobility	O
time	O
at	O
10	O
,	O
20	O
and	O
40	O
mg	O
/	O
kg	O
doses	O
in	O
both	O
TST	O
and	O
FST	O
.	O

Compound	O
17b	O
reduced	O
the	O
immobility	O
time	O
at	O
40	O
mg	O
/	O
kg	O
in	O
both	O
TST	O
and	O
FST	O
.	O

Compound	O
20b	O
showed	O
a	O
significant	O
decrease	O
in	O
the	O
immobility	O
time	O
at	O
20	O
mg	O
/	O
kg	O
in	O
the	O
TST	O
.	O

As	O
drugs	O
of	O
reference	O
,	O
fluoxetine	B
induced	O
a	O
significant	O
antidepressant	O
-	O
like	O
effect	O
in	O
both	O
TST	O
and	O
FST	O
,	O
while	O
mirtazapine	B
induced	O
a	O
significant	O
antidepressant	O
-	O
like	O
effect	O
only	O
in	O
the	O
FST	O
.	O

Additionally	O
,	O
none	O
of	O
the	O
tested	O
compounds	O
increased	O
locomotor	O
activity	O
or	O
displayed	O
anxiolytic	O
-	O
like	O
properties	O
.	O

These	O
results	O
suggest	O
that	O
these	O
new	O
synthesized	O
2-adrenoceptor	O
antagonists	O
may	O
be	O
useful	O
as	O
potential	O
antidepressant	O
drugs	O
.	O

Leptin	O
overexpression	O
in	O
VTA	O
trans	O
-	O
activates	O
the	O
hypothalamus	O
whereas	O
prolonged	O
leptin	O
action	O
in	O
either	O
region	O
cross	O
-	O
desensitizes	O
.	O

High	O
-	O
fat	O
feeding	O
or	O
CNS	O
leptin	O
overexpression	O
in	O
chow	O
-	O
fed	O
rats	O
results	O
in	O
a	O
region	O
-	O
specific	O
cellular	O
leptin	O
resistance	O
in	O
medial	O
basal	O
hypothalamic	O
regions	O
and	O
the	O
ventral	O
tegmental	O
area	O
(	O
VTA	O
)	O
.	O

The	O
present	O
investigation	O
examined	O
the	O
effects	O
of	O
targeted	O
chronic	O
leptin	O
overexpression	O
in	O
the	O
VTA	O
as	O
compared	O
with	O
the	O
medial	O
basal	O
hypothalamus	O
on	O
long	O
-	O
term	O
body	O
weight	O
homeostasis	O
.	O

The	O
study	O
also	O
examined	O
if	O
this	O
targeted	O
intervention	O
conserves	O
regional	O
leptin	O
sensitivity	O
or	O
results	O
in	O
localized	O
leptin	O
resistance	O
.	O

Cellular	O
leptin	O
resistance	O
was	O
assessed	O
by	O
leptin	O
-	O
stimulated	O
phosphorylation	O
of	O
signal	O
transducers	O
and	O
activators	O
of	O
transcription	O
3	O
(	O
STAT3	O
)	O
.	O

Tyrosine	B
hydroxylase	O
was	O
measured	O
in	O
hypothalamus	O
and	O
VTA	O
along	O
with	O
brown	O
adipose	O
tissue	O
uncoupling	O
protein	O
1	O
.	O

Leptin	O
overexpression	O
in	O
VTA	O
tempered	O
HF	O
-	O
induced	O
obesity	O
,	O
but	O
to	O
a	O
slightly	O
lesser	O
extent	O
than	O
that	O
with	O
leptin	O
overexpression	O
in	O
the	O
hypothalamus	O
.	O

Moreover	O
,	O
the	O
overexpression	O
of	O
leptin	O
in	O
the	O
VTA	O
stimulated	O
cellular	O
STAT3	O
phosphorylation	O
in	O
several	O
regions	O
of	O
the	O
medial	O
basal	O
hypothalamus	O
,	O
whereas	O
verexpression	O
in	O
the	O
hypothalamus	O
did	O
not	O
activate	O
STAT3	O
signaling	O
in	O
the	O
VTA	O
.	O

This	O
unidirectional	O
trans	O
-	O
stimulation	O
did	O
not	O
appear	O
to	O
involve	O
migration	O
of	O
either	O
the	O
vector	O
or	O
the	O
gene	O
product	O
.	O

Long	O
-	O
term	O
leptin	O
overexpression	O
in	O
either	O
the	O
medial	O
basal	O
hypothalamus	O
or	O
VTA	O
caused	O
desensitization	O
of	O
leptin	O
signaling	O
in	O
the	O
treated	O
region	O
and	O
cross	O
-	O
desensitization	O
of	O
leptin	O
signaling	O
in	O
the	O
untreated	O
region	O
.	O

These	O
results	O
demonstrate	O
a	O
role	O
of	O
leptin	O
receptors	O
in	O
the	O
VTA	O
in	O
long	O
-	O
term	O
body	O
weight	O
regulation	O
,	O
but	O
the	O
trans	O
-	O
activation	O
of	O
the	O
hypothalamus	O
following	O
VTA	O
leptin	O
stimulation	O
suggests	O
that	O
an	O
integrative	O
response	O
involving	O
both	O
brain	O
regions	O
may	O
account	O
for	O
the	O
observed	O
physiological	O
outcomes	O
.	O

Experiences	O
of	O
microsurgical	O
reconstruction	O
for	O
variant	O
hepatic	O
artery	O
in	O
living	O
donor	O
liver	O
transplantation	O
.	O

There	O
is	O
an	O
emergent	O
need	O
for	O
improving	O
the	O
microsurgical	O
technique	O
of	O
variant	O
arterial	O
anastomosis	O
to	O
reduce	O
the	O
often	O
seen	O
surgery	O
-	O
related	O
complications	O
.	O

We	O
describe	O
in	O
this	O
article	O
our	O
experience	O
in	O
improving	O
this	O
technique	O
,	O
in	O
73	O
living	O
donor	O
liver	O
grafts	O
(	O
64	O
right	O
lobes	O
,	O
9	O
left	O
lobes	O
)	O
in	O
patients	O
with	O
end	O
-	O
stage	O
liver	O
disease	O
during	O
living	O
donor	O
liver	O
transplantation	O
.	O

The	O
hepatic	O
arteries	O
were	O
evaluated	O
preoperatively	O
with	O
computed	O
tomography	O
and	O
magnetic	O
resonance	O
angiography	O
.	O

In	O
this	O
series	O
,	O
13	O
grafts	O
(	O
17.80	O
%	O
)	O
with	O
variant	O
hepatic	O
artery	O
were	O
conducted	O
arterioplasty	O
on	O
a	O
back	O
-	O
table	O
under	O
a	O
loupe	O
or	O
a	O
high	O
-	O
power	O
microscope	O
,	O
which	O
included	O
one	O
recipient	O
in	O
situ	O
interposition	O
vessel	O
graft	O
of	O
recipient	O
proper	O
hepatic	O
artery	O
for	O
artery	O
reconstruction	O
.	O

The	O
back	O
-	O
table	O
reconstruction	O
time	O
was	O
16	O
	O
5.6	O
min	O
.	O

No	O
arterial	O
thrombosis	O
was	O
found	O
in	O
these	O
cases	O
during	O
the	O
6-month	O
postoperative	O
follow	O
-	O
up	O
.	O

On	O
the	O
basis	O
of	O
our	O
experience	O
,	O
we	O
suggest	O
that	O
back	O
-	O
table	O
microsurgical	O
plasty	O
for	O
graft	O
with	O
arterial	O
variation	O
should	O
be	O
applied	O
to	O
minimize	O
operative	O
difficulties	O
and	O
to	O
avoid	O
arterial	O
complications	O
in	O
living	O
donor	O
liver	O
transplantation	O
.	O

Purinergic	O
receptor	O
antagonist	O
a438079	O
protects	O
against	O
acetaminophen	B
-	O
induced	O
liver	O
injury	O
by	O
inhibiting	O
p450	O
isoenzymes	O
,	O
not	O
by	O
inflammasome	O
activation	O
.	O

Acetaminophen	B
(	O
APAP	B
)	O
overdose	O
is	O
the	O
most	O
frequent	O
cause	O
of	O
acute	O
liver	O
failure	O
in	O
the	O
western	O
world	O
.	O

Controversy	O
exists	O
regarding	O
the	O
hypothesis	O
that	O
the	O
hepatocyte	O
injury	O
is	O
amplified	O
by	O
a	O
sterile	O
inflammatory	O
response	O
,	O
rather	O
than	O
being	O
the	O
result	O
of	O
intracellular	O
mechanisms	O
alone	O
.	O

A	O
recent	O
study	O
suggested	O
that	O
the	O
purinergic	O
receptor	O
antagonist	O
A438079	B
protects	O
against	O
APAP	B
-	O
induced	O
liver	O
injury	O
by	O
preventing	O
the	O
activation	O
of	O
the	O
Nalp3	O
inflammasome	O
in	O
Kupffer	O
cells	O
and	O
thereby	O
preventing	O
inflammatory	O
injury	O
.	O

To	O
test	O
the	O
hypothesis	O
that	O
A438079	B
actually	O
affects	O
the	O
intracellular	O
signaling	O
events	O
in	O
hepatocytes	O
,	O
C57Bl	O
/	O
6	O
mice	O
were	O
treated	O
with	O
APAP	B
(	O
300	O
mg	O
/	O
kg	O
)	O
and	O
A438079	B
(	O
80	O
mg	O
/	O
kg	O
)	O
or	O
saline	O
and	O
GSH	B
depletion	O
,	O
protein	O
adduct	O
formation	O
,	O
c	O
-	O
jun	O
-	B
N	O
-	O
terminal	O
kinase	O
(	O
JNK	O
)	O
activation	O
,	O
oxidant	O
stress	O
,	O
and	O
liver	O
cell	O
necrosis	O
were	O
determined	O
between	O
0	O
and	O
6	O
h	O
after	O
APAP	B
administration	O
.	O

APAP	B
caused	O
rapid	O
GSH	B
depletion	O
,	O
extensive	O
protein	O
adduct	O
formation	O
in	O
liver	O
homogenates	O
and	O
in	O
mitochondria	O
,	O
JNK	O
phosphorylation	O
and	O
mitochondrial	O
translocation	O
of	O
phospho	O
-	O
JNK	O
within	O
2	O
h	O
,	O
oxidant	O
stress	O
,	O
and	O
extensive	O
centrilobular	O
necrosis	O
at	O
6	O
h.	O
A438079	B
significantly	O
attenuated	O
GSH	B
depletion	O
,	O
which	O
resulted	O
in	O
a	O
50	O
%	O
reduction	O
of	O
total	O
liver	O
and	O
mitochondrial	O
protein	O
adducts	O
and	O
substantial	O
reduction	O
of	O
JNK	O
activation	O
,	O
mitochondrial	O
P	O
-	O
JNK	O
translocation	O
,	O
oxidant	O
stress	O
,	O
and	O
liver	O
injury	O
.	O

The	O
same	O
results	O
were	O
obtained	O
using	O
primary	O
mouse	O
hepatocytes	O
.	O

A438079	B
did	O
not	O
directly	O
affect	O
JNK	O
activation	O
induced	O
by	O
tert	B
-	I
butyl	I
hydroperoxide	I
and	O
GSH	B
depletion	O
.	O

However	O
,	O
A438079	B
dose	O
-	O
dependently	O
inhibited	O
hepatic	O
P450	O
enzyme	O
activity	O
.	O

Thus	O
,	O
the	O
protective	O
effect	O
of	O
A438079	B
against	O
APAP	B
hepatotoxicity	O
in	O
vivo	O
can	O
be	O
explained	O
by	O
its	O
effect	O
on	O
metabolic	O
activation	O
and	O
cell	O
death	O
pathways	O
in	O
hepatocytes	O
without	O
involvement	O
of	O
the	O
Nalp3	O
inflammasome	O
.	O

Aryl	B
methylcarbamates	I
:	O
Potency	O
and	O
selectivity	O
towards	O
wild	O
-	O
type	O
and	O
carbamate	B
-	O
insensitive	O
(	O
G119S	O
)	O
Anopheles	O
gambiae	O
acetylcholinesterase	O
,	O
and	O
toxicity	O
to	O
G3	O
strain	O
An	O
.	O

gambiae	O
.	O

New	O
carbamates	B
that	O
are	O
highly	O
selective	O
for	O
inhibition	O
of	O
Anopheles	O
gambiae	O
acetylcholinesterase	O
(	O
AChE	O
)	O
over	O
the	O
human	O
enzyme	O
might	O
be	O
useful	O
in	O
continuing	O
efforts	O
to	O
limit	O
malaria	O
transmission	O
.	O

In	O
this	O
report	O
we	O
assessed	O
34	O
synthesized	O
and	O
commercial	O
carbamates	B
for	O
their	O
selectivity	O
to	O
inhibit	O
the	O
AChEs	O
found	O
in	O
carbamate	B
-	O
susceptible	O
(	O
G3	O
)	O
and	O
carbamate	B
-	O
resistant	O
(	O
Akron	O
)	O
An	O
.	O

gambiae	O
,	O
relative	O
to	O
human	O
AChE.	O
Excellent	O
correspondence	O
is	O
seen	O
between	O
inhibition	O
potencies	O
measured	O
with	O
carbamate	B
-	O
susceptible	O
mosquito	O
homogenate	O
and	O
purified	O
recombinant	O
wild	O
-	O
type	O
(	O
WT	O
)	O
An	O
.	O

gambiae	O
AChE	O
(	O
AgAChE	O
)	O
.	O

Similarly	O
,	O
excellent	O
correspondence	O
is	O
seen	O
between	O
inhibition	O
potencies	O
measured	O
with	O
carbamate	B
-	O
resistant	O
mosquito	O
homogenate	O
and	O
purified	O
recombinant	O
G119S	O
AgAChE	O
,	O
consistent	O
with	O
our	O
earlier	O
finding	O
that	O
the	O
Akron	O
strain	O
carries	O
the	O
G119S	O
mutation	O
.	O

Although	O
high	O
(	O
100-	O
to	O
500-fold	O
)	O
WT	O
An	O
.	O

gambiae	O
vs	O
human	O
selectivity	O
is	O
observed	O
for	O
several	O
compounds	O
,	O
none	O
of	O
the	O
carbamates	B
tested	O
potently	O
inhibits	O
the	O
G119S	O
mutant	O
enzyme	O
.	O

Finally	O
,	O
we	O
describe	O
a	O
predictive	O
model	O
for	O
WT	O
An	O
.	O

gambiae	O
tarsal	O
contact	O
toxicity	O
of	O
the	O
carbamates	B
that	O
relies	O
on	O
inhibition	O
potency	O
,	O
molecular	O
volume	O
,	O
and	O
polar	O
surface	O
area	O
.	O

Single	O
molecule	O
sensing	O
with	O
solid	O
-	O
state	O
nanopores	O
:	O
novel	O
materials	O
,	O
methods	O
,	O
and	O
applications	O
.	O

This	O
tutorial	O
review	O
will	O
introduce	O
and	O
explore	O
the	O
fundamental	O
aspects	O
of	O
nanopore	O
(	O
bio	O
)	O
sensing	O
,	O
fabrication	O
,	O
modification	O
,	O
and	O
the	O
emerging	O
technologies	O
and	O
applications	O
that	O
both	O
intrigue	O
and	O
inspire	O
those	O
working	O
in	O
and	O
around	O
the	O
field	O
.	O

Although	O
nanopores	O
can	O
be	O
classified	O
into	O
two	O
categories	O
,	O
solid	O
-	O
state	O
and	O
biological	O
,	O
they	O
are	O
essentially	O
two	O
sides	O
of	O
the	O
same	O
coin	O
.	O

For	O
instance	O
,	O
both	O
garner	O
popularity	O
due	O
to	O
their	O
ability	O
to	O
confine	O
analytes	O
of	O
interest	O
to	O
a	O
nanoscale	O
volume	O
.	O

Due	O
to	O
the	O
vast	O
diversity	O
of	O
nanopore	O
platforms	O
and	O
applications	O
,	O
no	O
single	O
review	O
can	O
cover	O
the	O
entire	O
landscape	O
of	O
published	O
work	O
in	O
the	O
field	O
.	O

Therefore	O
,	O
in	O
this	O
article	O
focus	O
will	O
be	O
placed	O
on	O
recent	O
advancements	O
and	O
developments	O
taking	O
place	O
in	O
the	O
field	O
of	O
solid	O
-	O
state	O
nanopores	O
.	O

It	O
should	O
be	O
stated	O
that	O
the	O
intention	O
of	O
this	O
tutorial	O
review	O
is	O
not	O
to	O
cite	O
all	O
articles	O
relating	O
to	O
solid	O
-	O
state	O
nanopores	O
,	O
but	O
rather	O
to	O
highlight	O
recent	O
,	O
select	O
developments	O
that	O
will	O
hopefully	O
benefit	O
the	O
new	O
and	O
seasoned	O
scientist	O
alike	O
.	O

Initially	O
we	O
begin	O
with	O
the	O
fundamentals	O
of	O
solid	O
-	O
state	O
nanopore	O
sensing	O
.	O

Then	O
the	O
spotlight	O
is	O
shone	O
on	O
the	O
sophisticated	O
fabrication	O
methods	O
that	O
have	O
their	O
origins	O
in	O
the	O
semiconductor	O
industry	O
.	O

One	O
inherent	O
advantage	O
of	O
solid	O
-	O
state	O
nanopores	O
is	O
in	O
the	O
ease	O
of	O
functionalizing	O
the	O
surface	O
with	O
a	O
range	O
of	O
molecules	O
carrying	O
functional	O
groups	O
.	O

Therefore	O
,	O
an	O
entire	O
section	O
is	O
devoted	O
to	O
highlighting	O
various	O
chemical	O
and	O
bio	O
-	O
molecular	O
modifications	O
and	O
explores	O
how	O
these	O
permit	O
the	O
development	O
of	O
novel	O
sensors	O
with	O
specific	O
targets	O
and	O
functions	O
.	O

The	O
review	O
is	O
completed	O
with	O
a	O
discussion	O
on	O
novel	O
detection	O
strategies	O
using	O
nanopores	O
.	O

Although	O
the	O
most	O
popular	O
mode	O
of	O
nanopore	O
sensing	O
is	O
based	O
upon	O
what	O
has	O
come	O
to	O
be	O
known	O
as	O
ionic	O
-	O
current	O
blockade	O
sensing	O
,	O
there	O
is	O
a	O
vast	O
,	O
growing	O
literature	O
based	O
around	O
exploring	O
alternative	O
detection	O
techniques	O
to	O
further	O
expand	O
on	O
the	O
versatility	O
of	O
the	O
sensors	O
.	O

Such	O
techniques	O
include	O
optical	O
,	O
electronic	O
,	O
and	O
force	O
based	O
methods	O
.	O

It	O
is	O
perhaps	O
fair	O
to	O
say	O
that	O
these	O
new	O
frontiers	O
have	O
caused	O
further	O
excitement	O
within	O
the	O
sensing	O
community	O
.	O

Wogonoside	B
induces	O
autophagy	O
in	O
MDA	O
-	O
MB-231	O
cells	O
by	O
regulating	O
MAPK	O
-	O
mTOR	O
pathway	O
.	O

Previous	O
studies	O
have	O
demonstrated	O
that	O
wogonoside	B
,	O
a	O
bioactive	O
flavonoid	B
extracted	O
from	O
the	O
root	O
of	O
Scutellaria	O
baicalensis	O
Gerogi	O
,	O
has	O
anti	O
-	O
inflammatory	O
and	O
anti	O
-	O
angiogenic	O
activities	O
.	O

In	O
this	O
study	O
,	O
we	O
evaluated	O
wogonoside	B
-	O
induced	O
autophagy	O
on	O
human	O
breast	O
MDA	O
-	O
MB-231	O
cells	O
.	O

We	O
report	O
that	O
wogonoside	B
triggered	O
the	O
formation	O
of	O
microtubule	O
-	O
associated	O
protein	O
-	O
light	O
chain	O
3	O
(	O
MAP	O
-	O
LC3	O
)	O
positive	O
autophagosomes	O
and	O
the	O
accumulation	O
of	O
acidic	O
vesicular	O
and	O
autolysosomes	O
in	O
MDA	O
-	O
MB-231	O
cells	O
.	O

In	O
addition	O
,	O
cells	O
treated	O
by	O
wogonoside	B
developed	O
autophagosome	O
-	O
like	O
characteristics	O
,	O
including	O
single	O
and	O
double	O
membrane	O
vacuoles	O
containing	O
intact	O
and	O
degraded	O
cellular	O
debris	O
.	O

The	O
results	O
showed	O
that	O
wogonoside	B
promotes	O
the	O
expression	O
of	O
LC3-II	O
and	O
Beclin-1	O
.	O

Furthermore	O
,	O
wogonoside	B
inhibited	O
cell	O
growth	O
of	O
MDA	O
-	O
MB-231	O
cells	O
in	O
a	O
concentration-	O
and	O
time	O
-	O
dependent	O
manner	O
,	O
which	O
was	O
associated	O
with	O
wogonoside	B
-	O
induced	O
autophagy	O
.	O

Wogonoside	B
also	O
suppressed	O
the	O
activation	O
of	O
mammalian	O
target	O
of	O
rapamycin	B
(	O
mTOR	O
)	O
and	O
p70-S6	O
kinase	O
(	O
p70S6	O
K	O
)	O
by	O
regulating	O
the	O
expression	O
of	O
the	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
(	O
ERK1	O
/	O
2	O
)	O
and	O
p38	O
involved	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
signaling	O
pathway	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
wogonoside	B
partially	O
inhibits	O
MDA	O
-	O
MB-231	O
cell	O
growth	O
by	O
inducing	O
autophagy	O
through	O
the	O
MAPK	O
-	O
mTOR	O
pathway	O
and	O
may	O
be	O
a	O
promising	O
anti	O
-	O
tumor	O
agent	O
.	O

Water	O
extracts	O
of	O
tree	O
Hypericum	O
sps	O
.	O

protect	O
DNA	O
from	O
oxidative	O
and	O
alkylating	O
damage	O
and	O
enhance	O
DNA	O
repair	O
in	O
colon	O
cells	O
.	O

Diet	O
may	O
induce	O
colon	O
carcinogenesis	O
through	O
oxidative	O
or	O
alkylating	O
DNA	O
damage	O
.	O

However	O
,	O
diet	O
may	O
also	O
contain	O
anticarcinogenic	O
compounds	O
that	O
contribute	O
to	O
cancer	O
prevention	O
.	O

DNA	O
damage	O
prevention	O
and/or	O
induction	O
of	O
repair	O
are	O
two	O
important	O
mechanisms	O
involved	O
in	O
cancer	O
chemoprevention	O
by	O
dietary	O
compounds	O
.	O

Hypericum	O
sps	O
.	O
are	O
widely	O
used	O
in	O
traditional	O
medicine	O
to	O
prepare	O
infusions	O
due	O
to	O
their	O
beneficial	O
digestive	O
and	O
neurologic	O
effects	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
potential	O
of	O
water	O
extracts	O
from	O
three	O
Hypericum	O
sps	O
.	O

and	O
some	O
of	O
their	O
main	O
phenolic	B
compounds	O
to	O
prevent	O
and	O
repair	O
oxidative	O
and	O
alkylating	O
DNA	O
damage	O
in	O
colon	O
cells	O
.	O

The	O
results	O
showed	O
that	O
water	O
extracts	O
of	O
Hypericum	O
perforatum	O
,	O
Hypericum	O
androsaemum	O
,	O
Hypericum	O
undulatum	O
,	O
quercetin	B
and	O
rutin	B
have	O
protective	O
effect	O
against	O
oxidative	O
DNA	O
damage	O
in	O
HT29	O
cells	O
.	O

Protective	O
effect	O
was	O
also	O
observed	O
against	O
alkylating	O
DNA	O
damage	O
induced	O
by	O
methyl	B
-	I
methanesulfonate	I
,	O
except	O
for	O
H.	O
androsaemum	O
.	O

With	O
regard	O
to	O
alkylating	O
damage	O
repair	O
H.	O
perforatum	O
,	O
H.	O
androsaemum	O
and	O
chlorogenic	B
acid	I
increased	O
repair	O
of	O
alkylating	O
DNA	O
damage	O
by	O
base	O
excision	O
repair	O
pathway	O
.	O

No	O
effect	O
was	O
observed	O
on	O
nucleotide	B
excision	O
repair	O
pathway	O
.	O

Antigenotoxic	O
effects	O
of	O
Hypericum	O
sps	O
.	O

may	O
contribute	O
to	O
colon	O
cancer	O
prevention	O
and	O
the	O
high	O
amount	O
of	O
phenolic	B
compounds	O
present	O
in	O
Hypericum	O
sps	O
.	O

play	O
an	O
important	O
role	O
in	O
DNA	O
protective	O
effects	O
.	O

Lattice	O
Microbes	O
:	O
high	O
-	O
performance	O
stochastic	O
simulation	O
method	O
for	O
the	O
reaction	O
-	O
diffusion	O
master	O
equation	O
.	O

Spatial	O
stochastic	O
simulation	O
is	O
a	O
valuable	O
technique	O
for	O
studying	O
reactions	O
in	O
biological	O
systems	O
.	O

With	O
the	O
availability	O
of	O
high	O
-	O
performance	O
computing	O
(	O
HPC	O
)	O
,	O
the	O
method	O
is	O
poised	O
to	O
allow	O
integration	O
of	O
data	O
from	O
structural	O
,	O
single	O
-	O
molecule	O
and	O
biochemical	O
studies	O
into	O
coherent	O
computational	O
models	O
of	O
cells	O
.	O

Here	O
,	O
we	O
introduce	O
the	O
Lattice	O
Microbes	O
software	O
package	O
for	O
simulating	O
such	O
cell	O
models	O
on	O
HPC	O
systems	O
.	O

The	O
software	O
performs	O
either	O
well	O
-	O
stirred	O
or	O
spatially	O
resolved	O
stochastic	O
simulations	O
with	O
approximated	O
cytoplasmic	O
crowding	O
in	O
a	O
fast	O
and	O
efficient	O
manner	O
.	O

Our	O
new	O
algorithm	O
efficiently	O
samples	O
the	O
reaction	O
-	O
diffusion	O
master	O
equation	O
using	O
NVIDIA	O
graphics	O
processing	O
units	O
and	O
is	O
shown	O
to	O
be	O
two	O
orders	O
of	O
magnitude	O
faster	O
than	O
exact	O
sampling	O
for	O
large	O
systems	O
while	O
maintaining	O
an	O
accuracy	O
of	O
!	O

0.1	O
%	O
.	O

Display	O
of	O
cell	O
models	O
and	O
animation	O
of	O
reaction	O
trajectories	O
involving	O
millions	O
of	O
molecules	O
is	O
facilitated	O
using	O
a	O
plug	O
-	O
in	O
to	O
the	O
popular	O
VMD	O
visualization	O
platform	O
.	O

The	O
Lattice	O
Microbes	O
software	O
is	O
open	O
source	O
and	O
available	O
for	O
download	O
at	O
http://www.scs.illinois.edu/schulten/lm	O

Toxicological	O
and	O
mutagenic	O
analysis	O
of	O
Artemisia	O
dracunculus	O
(	O
tarragon	O
)	O
extract	O
.	O

Mutagenicity	O
and	O
liver	O
toxicity	O
of	O
the	O
herb	O
tarragon	O
(	O
Artemisia	O
dracunculus	O
)	O
were	O
evaluated	O
using	O
single	O
cell	O
gel	O
(	O
comet	O
)	O
electrophoresis	O
.	O

Ten	O
microlitres	O
aliquots	O
of	O
peripheral	O
venous	O
human	O
blood	O
were	O
incubated	O
with	O
tarragon	O
extract	O
,	O
saline	O
,	O
or	O
the	O
mutagen	O
sodium	B
dichromate	I
.	O

Cell	O
suspensions	O
dispersed	O
in	O
low	O
-	O
melting	O
agarose	O
were	O
electrophoresed	O
in	O
ethidium	B
bromide	I
.	O

The	O
resulting	O
DNA	O
migration	O
trails	O
were	O
obtained	O
using	O
fluorescent	O
microscopy	O
at	O
400	O
	O
magnification	O
,	O
and	O
graded	O
according	O
to	O
the	O
mutagenicity	O
index	O
(	O
MI	O
)	O
for	O
each	O
cell	O
incubation	O
condition	O
.	O

The	O
in	O
vivo	O
liver	O
toxicity	O
of	O
Artemisia	O
dracunculus	O
was	O
assessed	O
in	O
the	O
blood	O
of	O
mice	O
treated	O
orally	O
with	O
the	O
extract	O
of	O
the	O
herb	O
,	O
using	O
alanine	B
aminotransferase	O
(	O
ALT	O
)	O
and	O
aspartate	B
aminotransferase	O
(	O
AST	O
)	O
as	O
liver	O
function	O
indicators	O
.	O

Liver	O
morphology	O
was	O
assessed	O
using	O
hematoxylin	B
and	O
eosin	B
(	O
HE	O
)	O
staining	O
of	O
liver	O
tissue	O
.	O

The	O
present	O
study	O
demonstrated	O
a	O
direct	O
correlation	O
between	O
tarragon	O
extract	O
dosage	O
and	O
three	O
major	O
outcome	O
variables	O
:	O
MI	O
;	O
serum	O
liver	O
enzyme	O
activity	O
;	O
and	O
liver	O
histopathology	O
.	O

These	O
outcomes	O
are	O
possibly	O
due	O
to	O
the	O
presence	O
in	O
tarragon	O
of	O
methylchavicol	B
and	O
other	O
genotoxic	O
compounds	O
.	O

These	O
findings	O
provide	O
a	O
preliminary	O
guide	O
for	O
risk	O
assessment	O
of	O
tarragon	O
in	O
diet	O
and	O
in	O
possible	O
therapeutic	O
applications	O
.	O

Phenolics	B
profiles	O
of	O
olive	O
fruits	O
(	O
Olea	O
europaea	O
L.	O
)	O
and	O
oils	O
from	O
Ayvalk	O
,	O
Domat	O
and	O
Gemlik	O
varieties	O
at	O
different	O
ripening	O
stages	O
.	O

Phenolic	B
compounds	O
in	O
olive	O
fruit	O
and	O
oils	O
obtained	O
from	O
Ayvalk	O
,	O
Domat	O
and	O
Gemlik	O
olive	O
varieties	O
collected	O
at	O
different	O
ripening	O
periods	O
were	O
evaluated	O
by	O
High	O
Performance	O
Liquid	O
Chromatography	O
(	O
HPLC	O
)	O
.	O

Gallic	B
acid	I
and	O
p	B
-	I
cumaric	I
acid	I
were	O
identified	O
for	O
Ayvalk	O
and	O
Domat	O
at	O
each	O
period	O
of	O
ripening	O
,	O
respectively	O
.	O

In	O
addition	O
,	O
gallic	B
acid	I
,	O
p	B
-	I
cumaric	I
acid	I
,	O
sinapinic	B
and	I
apigenin	I
acids	I
were	O
detected	O
in	O
Gemlik	O
olive	O
fruit	O
.	O

Hydroxytyrosol	B
,	O
rutin	B
,	O
oleoropein	B
,	O
luteolin	B
,	O
tyrosol	B
,	O
vanilic	B
acid	I
and	O
gallic	B
acid	I
in	O
Ayvalk	O
olive	O
fruit	O
in	O
all	O
ripening	O
periods	O
were	O
determined	O
.	O

The	O
tyrasol	B
contents	O
varied	O
between	O
0.18	O
to	O
1.57mg	O
/	O
kg	O
.	O

Luteolin	B
contents	O
of	O
olive	O
oils	O
ranged	O
at	O
the	O
levels	O
between	O
0.12	O
to	O
2.28mg	O
/	O
kg	O
.	O

In	O
contrast	O
,	O
oils	O
had	O
the	O
lowest	O
syringic	B
,	I
p	I
-	I
cumaric	I
,	I
chlorogenic	I
and	I
ferulic	I
acids	I
.	O

Vanillic	B
acid	I
contents	O
of	O
oils	O
ranged	O
between	O
0.08	O
to	O
2.38mg	O
/	O
kg	O
.	O

Optimization	O
of	O
frozen	O
sour	O
cherries	O
vacuum	O
drying	O
process	O
.	O

The	O
objective	O
of	O
this	O
research	O
was	O
to	O
optimize	O
the	O
vacuum	O
-	O
drying	O
of	O
frozen	O
sour	O
cherries	O
in	O
order	O
to	O
preserve	O
health	O
-	O
beneficial	O
phytochemicals	O
,	O
as	O
well	O
as	O
textural	O
characteristics	O
.	O

Investigated	O
range	O
of	O
temperature	O
was	O
46	O
-	O
74	O
	O
C	O
and	O
,	O
of	O
pressure	O
,	O
17	O
-	O
583	O
mbar	O
,	O
in	O
a	O
new	O
design	O
of	O
vacuum	O
-	O
dryer	O
equipment	O
.	O

The	O
total	O
solids	O
,	O
a	O
(	O
w	O
)	O
value	O
,	O
total	O
phenolics	B
,	O
vitamin	B
C	I
,	O
antioxidant	O
activity	O
,	O
anthocyanin	B
content	O
,	O
total	O
colour	O
change	O
and	O
firmness	O
were	O
used	O
as	O
quality	O
indicators	O
of	O
dried	O
sour	O
cherry	O
.	O

Within	O
the	O
experimental	O
range	O
of	O
studied	O
variables	O
,	O
the	O
optimum	O
conditions	O
of	O
54.03	O
	O
C	O
and	O
148.16	O
mbar	O
were	O
established	O
for	O
vacuum	O
drying	O
of	O
sour	O
cherry	O
.	O

Separate	O
validation	O
experiments	O
were	O
conducted	O
,	O
under	O
optimum	O
conditions	O
,	O
to	O
verify	O
predictions	O
and	O
adequacy	O
of	O
the	O
second	O
-	O
order	O
polynomial	O
models	O
.	O

Under	O
these	O
optimal	O
conditions	O
,	O
the	O
predicted	O
amount	O
of	O
total	O
phenolics	B
was	O
744	O
mg	O
CAE	O
/	O
100	O
dw	O
,	O
vitamin	B
C	I
1.44mg	O
/	O
100	O
g	O
per	O
dry	O
weight	O
(	O
g	O
dw	O
)	O
,	O
anthocyanin	B
content	O
125mg	O
/	O
100	O
g	O
dw	O
,	O
IC	O
(	O
50	O
)	O
3.23mg	O
/	O
ml	O
,	O
total	O
solids	O
70.72	O
%	O
,	O
a	O
(	O
w	O
)	O
value	O
0.646	O
,	O
total	O
colour	O
change	O
52.61	O
and	O
firmness	O
3395.4	O
g	O
.	O

The	O
investigated	O
parameters	O
had	O
a	O
significant	O
effect	O
on	O
the	O
quality	O
of	O
the	O
dried	O
sour	O
cherries	O
.	O

Occurrence	O
of	O
ochratoxin	B
A	I
in	O
cocoa	O
by	O
-	O
products	O
and	O
determination	O
of	O
its	O
reduction	O
during	O
chocolate	O
manufacture	O
.	O

This	O
work	O
reports	O
an	O
investigation	O
carried	O
out	O
to	O
assess	O
the	O
natural	O
occurrence	O
of	O
ochratoxin	B
A	I
in	O
168	O
samples	O
from	O
different	O
fractions	O
obtained	O
during	O
the	O
technological	O
processing	O
of	O
cocoa	O
(	O
shell	O
,	O
nibs	O
,	O
liquor	O
,	O
butter	O
,	O
cake	O
and	O
cocoa	O
powder	O
)	O
and	O
the	O
reduction	O
of	O
ochratoxin	B
A	I
during	O
chocolate	O
manufacture	O
.	O

Ochratoxin	B
A	I
analyses	O
were	O
performed	O
with	O
immunoaffinity	O
columns	O
and	O
detection	O
by	O
high	O
performance	O
liquid	O
chromatography	O
.	O

Concerning	O
the	O
natural	O
ochratoxin	B
A	I
contamination	O
in	O
cocoa	O
by	O
-	O
products	O
,	O
the	O
highest	O
levels	O
of	O
ochratoxin	B
A	I
were	O
found	O
in	O
the	O
shell	O
,	O
cocoa	O
powder	O
and	O
cocoa	O
cake	O
.	O

The	O
cocoa	O
butter	O
was	O
the	O
least	O
contaminated	O
,	O
showing	O
that	O
ochratoxin	B
A	I
seems	O
to	O
remain	O
in	O
the	O
defatted	O
cocoa	O
solids	O
.	O

Under	O
the	O
technological	O
conditions	O
applied	O
during	O
the	O
manufacture	O
of	O
chocolate	O
in	O
this	O
study	O
and	O
the	O
level	O
of	O
contamination	O
present	O
in	O
the	O
cocoa	O
beans	O
,	O
this	O
experiment	O
demonstrated	O
that	O
93.6	O
%	O
of	O
ochratoxin	B
A	I
present	O
in	O
the	O
beans	O
was	O
reduced	O
during	O
the	O
chocolate	O
producing	O
.	O

Diuretic	O
effects	O
of	O
cannabinoids	O
.	O

In	O
vivo	O
effects	O
of	O
cannabinoid	O
(	O
CB	O
)	O
agonists	O
are	O
often	O
assessed	O
using	O
four	O
well	O
-	O
established	O
measures	O
:	O
locomotor	O
activity	O
,	O
hypothermia	O
,	O
cataleptic	O
-	O
like	O
effects	O
,	O
and	O
analgesia	O
.	O

The	O
present	O
studies	O
demonstrate	O
that	O
doses	O
of	O
CB	O
agonists	O
that	O
produce	O
these	O
effects	O
also	O
reliably	O
increase	O
diuresis	O
.	O

Diuretic	O
effects	O
of	O
several	O
CB	O
agonists	O
were	O
measured	O
in	O
female	O
rats	O
over	O
2	O
hours	O
immediately	O
after	O
drug	O
injection	O
,	O
and	O
results	O
were	O
compared	O
with	O
hypothermic	O
effects	O
.	O

Direct	O
-	O
acting	O
CB1	O
agonists	O
,	O
including	O
	B
(	I
9	I
)	I
-tetrahydrocannabinol	I
,	O
WIN	B
55,212	I
[	O
R-	B
(	I
1	I
)	I
-	I
[	I
2,3-dihydro-5-methyl-3-	I
[	I
(	I
morpholinyl	I
)	I
methyl	I
]	I
pyrrolo	I
[	I
1,2,3-de	I
]	I
-1,4-benzoxazinyl	I
]	I
-	I
(	I
1-naphthalenyl	I
)	I
methanone	I
mesylate	I
]	O
,	O
AM2389	B
[	O
9	B
-	I
hydroxy-3-	I
(	I
1-hexyl	I
-	I
cyclobut-1-yl	I
)	I
-hexahydrocannabinol	I
]	O
,	O
and	O
AM4054	B
[	O
9-	B
(	I
hydroxymethyl	I
)	I
-3-	I
(	I
1-adamantyl	I
)	I
-hexahydrocannabinol	I
]	O
,	O
produced	O
dose	O
-	O
dependent	O
increases	O
in	O
diuresis	O
and	O
decreases	O
in	O
colonic	O
temperature	O
,	O
with	O
slightly	O
lower	O
ED	O
(	O
50	O
)	O
values	O
for	O
diuresis	O
than	O
for	O
hypothermia	O
.	O

The	O
highest	O
doses	O
of	O
cannabinoid	O
drugs	O
yielded	O
,	O
on	O
average	O
,	O
26	O
-	O
32	O
g	O
/	O
kg	O
urine	O
;	O
comparable	O
effects	O
were	O
obtained	O
with	O
10	O
mg	O
/	O
kg	O
furosemide	B
and	O
3.0	O
mg	O
/	O
kg	O
trans-	B
(	I
-	I
)	I
-3,4-dichloro	I
-	I
N	I
-	I
methyl	I
-	I
N-	I
[	I
2-	I
(	I
1-pyrrolidinyl	I
)	I
cyclohexyl	I
]	I
benzeneacetamide	I
(	O
U50	B
-	I
488	I
)	O
.	O

Methanandamide	B
(	O
10.0	O
mg	O
/	O
kg	O
)	O
had	O
lesser	O
effect	O
than	O
other	O
CB	O
agonists	O
,	O
and	O
the	O
CB2	O
agonist	O
AM1241	B
[	O
1-	B
(	I
methylpiperidin-2-ylmethyl	I
)	I
-3-	I
(	I
2-iodo-5-nitrobenzoyl	I
)	I
indole	I
]	O
,	O
the	O
anandamide	B
transport	O
inhibitor	O
AM404	B
,	O
and	O
the	O
CB	O
antagonist	O
rimonabant	B
did	O
not	O
have	O
diuretic	O
effects	O
.	O

In	O
further	O
studies	O
,	O
the	O
diuretic	O
effects	O
of	O
the	O
CB1	O
agonist	O
AM4054	B
were	O
similar	O
in	O
male	O
and	O
female	O
rats	O
,	O
displayed	O
a	O
relatively	O
rapid	O
onset	O
to	O
action	O
,	O
and	O
were	O
dose	O
-	O
dependently	O
antagonized	O
by	O
30	O
minutes	O
pretreatment	O
with	O
rimonabant	B
,	O
but	O
not	O
by	O
the	O
vanilloid	B
receptor	O
type	O
I	O
antagonist	O
capsazepine	B
,	O
nor	O
were	O
the	O
effects	O
of	O
WIN	B
55,212	I
antagonized	O
by	O
the	O
CB2	O
antagonist	O
AM630	B
[	O
(	B
6-iodo-2-methyl-1-	I
[	I
2-	I
(	I
4-morpholinyl	I
)	I
ethyl	I
]	I
-1H	I
-	I
indol-3-yl	I
]	I
(	I
4-methoxyphenyl	I
)	I
methanone	I
)	I
]	O
.	O

These	O
data	O
indicate	O
that	O
cannabinoids	O
have	O
robust	O
diuretic	O
effects	O
in	O
rats	O
that	O
are	O
mediated	O
via	O
CB1	O
receptor	O
mechanisms	O
.	O

The	O
PNarec	O
method	O
for	O
detection	O
of	O
ancient	O
recombinations	O
through	O
phylogenetic	O
network	O
analysis	O
.	O

Recombinations	O
are	O
known	O
to	O
disrupt	O
bifurcating	O
tree	O
structure	O
of	O
gene	O
genealogies	O
.	O

Although	O
recently	O
occurred	O
recombinations	O
are	O
easily	O
detectable	O
by	O
using	O
conventional	O
methods	O
,	O
recombinations	O
may	O
have	O
occurred	O
at	O
any	O
time	O
.	O

We	O
devised	O
a	O
new	O
method	O
for	O
detecting	O
ancient	O
recombinations	O
through	O
phylogenetic	O
network	O
analysis	O
,	O
and	O
detected	O
five	O
ancient	O
recombinations	O
in	O
gibbon	O
ABO	O
blood	O
group	O
genes	O
[	O
Kitano	O
et	O
al.	O
,	O
2009	O
.	O

Mol	O
.	O

Phylogenet	O
.	O

Evol	O
.	O
,	O
51	O
,	O
465	O
-	O
471	O
]	O
.	O

We	O
present	O
applications	O
of	O
this	O
method	O
,	O
now	O
named	O
as	O
"	O
PNarec	O
"	O
,	O
to	O
various	O
virus	O
sequences	O
as	O
well	O
as	O
HLA	O
genes	O
.	O

Association	O
analysis	O
between	O
K	O
and	O
-116A	O
variants	O
of	O
butyrylcholinesterase	O
and	O
Alzheimer	O
's	O
disease	O
in	O
a	O
Brazilian	O
population	O
.	O

In	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
a	O
reduction	O
in	O
acetylcholinesterase	O
(	O
AChE	O
)	O
and	O
an	O
increase	O
in	O
butyrylcholinesterase	O
(	O
BChE	O
)	O
activity	O
are	O
observed	O
.	O

K	O
variant	O
(	O
539	O
T	O
)	O
is	O
the	O
most	O
common	O
variant	O
of	O
the	O
BCHE	O
gene	O
and	O
,	O
although	O
controversial	O
,	O
several	O
studies	O
reported	O
association	O
between	O
K	O
variant	O
and	O
AD	O
.	O

Previous	O
results	O
showed	O
that	O
the	O
K	O
variant	O
alone	O
is	O
not	O
capable	O
of	O
diminishing	O
BChE	O
activity	O
,	O
depending	O
on	O
the	O
presence	O
of	O
the	O
-116A	O
variant	O
.	O

Considering	O
that	O
,	O
we	O
conducted	O
a	O
case	O
-	O
control	O
association	O
study	O
using	O
a	O
clinically	O
well	O
defined	O
group	O
of	O
AD	O
patients	O
(	O
n=82	O
)	O
and	O
age	O
and	O
sex	O
matched	O
control	O
subjects	O
(	O
EC	O
;	O
n=78	O
)	O
in	O
order	O
to	O
test	O
the	O
association	O
with	O
these	O
variations	O
of	O
BCHE	O
gene	O
in	O
a	O
Brazilian	O
population	O
.	O

The	O
allele	O
,	O
genotype	O
and	O
haplotype	O
frequencies	O
of	O
the	O
K	O
and	O
the	O
-116A	O
variants	O
of	O
BCHE	O
gene	O
were	O
not	O
significantly	O
different	O
between	O
cases	O
and	O
controls	O
.	O

Although	O
not	O
reaching	O
statistical	O
significance	O
,	O
the	O
results	O
suggested	O
that	O
the	O
presence	O
of	O
-116A	O
variant	O
may	O
have	O
a	O
protective	O
effect	O
against	O
AD	O
.	O

The	O
association	O
of	O
the	O
K	O
variant	O
with	O
AD	O
in	O
a	O
controversial	O
manner	O
in	O
different	O
surveys	O
is	O
probably	O
caused	O
by	O
its	O
linkage	O
disequilibrium	O
with	O
-116A	O
that	O
,	O
by	O
reducing	O
BChE	O
activity	O
,	O
potentially	O
increases	O
cholinergic	O
transmission	O
in	O
comparison	O
with	O
usual	O
genotypes	O
.	O

Methamphetamine	B
regulation	O
of	O
sulfotransferase	O
1A1	O
and	O
2A1	O
expression	O
in	O
rat	O
brain	O
sections	O
.	O

Sulfotransferase	O
catalyzed	O
sulfation	O
regulates	O
the	O
biological	O
activities	O
of	O
various	O
neurotransmitters	O
/	O
hormones	O
and	O
detoxifies	O
xenobiotics	O
.	O

Rat	O
sulfotransferase	O
rSULT1A1	O
catalyzes	O
the	O
sulfation	O
of	O
neurotransmitters	O
and	O
xenobiotic	O
phenolic	B
compounds	O
.	O

rSULT2A1	O
catalyzes	O
the	O
sulfation	O
of	O
hydroxysteroids	B
and	O
xenobiotic	O
alcoholic	B
compounds	O
.	O

In	O
this	O
work	O
,	O
Western	O
blot	O
and	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
were	O
used	O
to	O
investigate	O
the	O
effect	O
of	O
methamphetamine	B
on	O
rSULT1A1	O
and	O
rSULT2A1	O
protein	O
and	O
mRNA	O
expression	O
in	O
rat	O
cerebellum	O
,	O
frontal	O
cortex	O
,	O
hippocampus	O
,	O
and	O
striatum	O
.	O

After	O
1-day	O
treatment	O
,	O
significant	O
induction	O
of	O
rSULT1A1	O
was	O
observed	O
only	O
in	O
the	O
cerebellum	O
;	O
rSULT2A1	O
was	O
induced	O
significantly	O
in	O
the	O
cerebellum	O
,	O
frontal	O
cortex	O
,	O
and	O
hippocampus	O
.	O

After	O
7	O
days	O
of	O
exposure	O
,	O
rSULT1A1	O
was	O
induced	O
in	O
the	O
cerebellum	O
,	O
frontal	O
cortex	O
,	O
and	O
hippocampus	O
,	O
while	O
rSULT2A1	O
was	O
induced	O
significantly	O
in	O
all	O
four	O
regions	O
.	O

Western	O
blot	O
results	O
agreed	O
with	O
the	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
results	O
,	O
suggesting	O
that	O
the	O
induction	O
occurred	O
at	O
the	O
gene	O
transcriptional	O
level	O
.	O

Results	O
indicate	O
that	O
rSULT1A1	O
and	O
rSULT2A1	O
are	O
expressed	O
in	O
rat	O
frontal	O
cortex	O
,	O
cerebellum	O
,	O
striatum	O
,	O
and	O
hippocampus	O
.	O

rSULT1A1	O
and	O
rSULT2A1are	O
inducible	O
by	O
methamphetamine	B
in	O
rat	O
brain	O
sections	O
in	O
a	O
time	O
dependable	O
manner	O
.	O

rSULT2A1	O
is	O
more	O
inducible	O
than	O
rSULT1A1	O
by	O
methamphetamine	B
in	O
rat	O
brain	O
sections	O
.	O

Induction	O
activity	O
of	O
methamphetamine	B
is	O
in	O
the	O
order	O
of	O
cerebellum	O
>	O
frontal	O
cortex	O
,	O
hippocampus	O
>	O
striatum	O
.	O

These	O
results	O
suggest	O
that	O
the	O
physiological	O
functions	O
of	O
rSULT1A1	O
and	O
rSULT2A1	O
in	O
different	O
brain	O
regions	O
can	O
be	O
affected	O
by	O
methamphetamine	B
.	O

Nanostructured	O
superhydrophobic	O
substrates	O
trigger	O
the	O
development	O
of	O
3D	O
neuronal	O
networks	O
.	O

The	O
generation	O
of	O
3D	O
networks	O
of	O
primary	O
neurons	O
is	O
a	O
big	O
challenge	O
in	O
neuroscience	O
.	O

Here	O
,	O
a	O
novel	O
method	O
is	O
presented	O
for	O
a	O
3D	O
neuronal	O
culture	O
on	O
superhydrophobic	O
(	O
SH	O
)	O
substrates	O
.	O

How	O
nano	O
-	O
patterned	O
SH	O
devices	O
stimulate	O
neurons	O
to	O
build	O
3D	O
networks	O
is	O
investigated	O
.	O

Scanning	O
electron	O
microscopy	O
and	O
confocal	O
imaging	O
show	O
that	O
soon	O
after	O
plating	O
neurites	O
adhere	O
to	O
the	O
nanopatterned	O
pillar	O
sidewalls	O
and	O
they	O
are	O
subsequently	O
pulled	O
between	O
pillars	O
in	O
a	O
suspended	O
position	O
.	O

These	O
neurons	O
display	O
an	O
enhanced	O
survival	O
rate	O
compared	O
to	O
standard	O
cultures	O
and	O
develop	O
mature	O
networks	O
with	O
physiological	O
excitability	O
.	O

These	O
findings	O
underline	O
the	O
importance	O
of	O
using	O
nanostructured	O
SH	O
surfaces	O
for	O
directing	O
3D	O
neuronal	O
growth	O
,	O
as	O
well	O
as	O
for	O
the	O
design	O
of	O
biomaterials	O
for	O
neuronal	O
regeneration	O
.	O

The	O
GARD	O
assay	O
for	O
assessment	O
of	O
chemical	O
skin	O
sensitizers	O
.	O

Allergic	O
contact	O
dermatitis	O
is	O
a	O
skin	O
disease	O
caused	O
by	O
an	O
immunologic	O
reaction	O
to	O
low	O
molecular	O
weight	O
compounds	O
,	O
so	O
called	O
haptens	O
.	O

These	O
substances	O
are	O
commonly	O
present	O
in	O
products	O
used	O
by	O
humans	O
in	O
daily	O
life	O
,	O
such	O
as	O
in	O
cosmetics	O
and	O
fragrances	O
,	O
as	O
well	O
as	O
within	O
chemical	O
industry	O
and	O
in	O
pharmaceuticals	O
.	O

The	O
frequent	O
usage	O
of	O
these	O
compounds	O
in	O
different	O
applications	O
has	O
led	O
to	O
increasing	O
incidences	O
of	O
allergic	O
contact	O
dermatitis	O
,	O
which	O
has	O
become	O
a	O
substantial	O
economic	O
burden	O
for	O
society	O
.	O

As	O
a	O
consequence	O
,	O
chemicals	O
are	O
routinely	O
tested	O
for	O
their	O
ability	O
to	O
induce	O
skin	O
sensitization	O
,	O
using	O
animal	O
models	O
such	O
as	O
the	O
murine	O
Local	O
Lymph	O
Node	O
Assay	O
.	O

However	O
,	O
recent	O
legislations	O
regulate	O
the	O
use	O
of	O
animal	O
models	O
within	O
chemical	O
testing	O
.	O

Thus	O
,	O
there	O
is	O
an	O
urgent	O
need	O
for	O
in	O
vitro	O
alternatives	O
to	O
replace	O
these	O
assays	O
for	O
safety	O
assessment	O
of	O
chemicals	O
.	O

Recently	O
,	O
we	O
identified	O
a	O
signature	O
of	O
predictive	O
genes	O
,	O
which	O
are	O
differentially	O
regulated	O
in	O
the	O
human	O
myeloid	O
cell	O
-	O
line	O
MUTZ-3	O
when	O
stimulated	O
with	O
sensitizing	O
compounds	O
compared	O
to	O
non	O
-	O
sensitizing	O
compounds	O
.	O

Based	O
on	O
these	O
findings	O
,	O
we	O
have	O
formulated	O
a	O
test	O
strategy	O
for	O
assessment	O
of	O
sensitizing	O
compounds	O
,	O
called	O
Genomic	O
Allergen	O
Rapid	O
Detection	O
,	O
GARD	O
.	O

In	O
this	O
paper	O
,	O
we	O
present	O
a	O
detailed	O
method	O
description	O
of	O
how	O
the	O
assay	O
should	O
be	O
performed	O
.	O

Rational	O
design	O
of	O
apoptosis	O
signal	O
-	O
regulating	O
kinase	O
1	O
inhibitors	O
:	O
discovering	O
novel	O
structural	O
scaffold	O
.	O

Increased	O
activity	O
of	O
apoptosis	O
signal	O
-	O
regulating	O
kinase	O
1	O
(	O
ASK1	O
)	O
is	O
associated	O
with	O
a	O
number	O
of	O
human	O
disorders	O
and	O
the	O
inhibitors	O
of	O
ASK1	O
may	O
become	O
important	O
compounds	O
for	O
pharmaceutical	O
application	O
.	O

Here	O
we	O
report	O
novel	O
ASK1	O
inhibitor	O
scaffold	O
,	O
namely	O
5-	B
(	I
5-Phenyl	I
-	I
furan-2-ylmethylene	I
)	I
-2-thioxo	I
-	I
thiazolidin-4-one	I
,	O
that	O
has	O
been	O
identified	O
using	O
virtual	O
screening	O
and	O
biochemical	O
tests	O
.	O

A	O
series	O
of	O
derivatives	O
has	O
been	O
synthesized	O
and	O
evaluated	O
in	O
vitro	O
towards	O
human	O
protein	O
kinase	O
ASK1	O
.	O

It	O
was	O
revealed	O
that	O
the	O
most	O
active	O
compounds	O
4-	B
(	I
(	I
5Z	I
)	I
-5-	I
{	I
[	I
5-	I
(	I
4-bromophenyl	I
)	I
-2-furyl	I
]	I
methylene	I
}	I
-4-oxo-2-thioxo-1,3-thiazolidin-3-yl	I
)	I
butanoic	I
acid	I
and	O
6-	B
(	I
(	I
5Z	I
)	I
-5-	I
{	I
[	I
5-	I
(	I
4-bromophenyl	I
)	I
-2-furyl	I
]	I
methylene	I
}	I
-4-oxo-2-thioxo-1,3-thiazolidin-3-yl	I
)	I
hexanoic	I
acid	I
inhibit	O
ASK1	O
with	O
IC50	O
of	O
0.2	O
M.	O
Structure	O
-	O
activity	O
relationships	O
of	O
33	O
derivatives	O
of	O
5-	B
(	I
5-Phenyl	I
-	I
furan-2-ylmethylene	I
)	I
-2-thioxo	I
-	I
thiazolidin-4-one	I
have	O
been	O
studied	O
and	O
binding	O
mode	O
of	O
this	O
chemical	O
class	O
has	O
been	O
predicted	O
.	O

Identification	O
and	O
characterization	O
of	O
novel	O
catalytic	O
bioscavengers	O
of	O
organophosphorus	B
nerve	O
agents	O
.	O

In	O
an	O
effort	O
to	O
discover	O
novel	O
catalytic	O
bioscavengers	O
of	O
organophosphorus	B
(	O
OP	O
)	O
nerve	O
agents	O
,	O
cell	O
lysates	O
from	O
a	O
diverse	O
set	O
of	O
bacterial	O
strains	O
were	O
screened	O
for	O
their	O
capacity	O
to	O
hydrolyze	O
the	O
OP	O
nerve	O
agents	O
VX	O
,	O
VR	O
,	O
and	O
soman	B
(	O
GD	O
)	O
.	O

The	O
library	O
of	O
bacterial	O
strains	O
was	O
identified	O
using	O
both	O
random	O
and	O
rational	O
approaches	O
.	O

Specifically	O
,	O
two	O
representative	O
strains	O
from	O
eight	O
categories	O
of	O
extremophiles	O
were	O
chosen	O
at	O
random	O
.	O

For	O
the	O
rational	O
approach	O
,	O
the	O
protein	O
sequence	O
of	O
organophosphorus	B
hydrolase	O
(	O
OPH	O
)	O
from	O
Brevundimonas	O
diminuta	O
was	O
searched	O
against	O
a	O
non	O
-	O
redundant	O
protein	O
database	O
using	O
the	O
Basic	O
Local	O
Alignment	O
Search	O
Tool	O
to	O
find	O
regions	O
of	O
local	O
similarity	O
between	O
sequences	O
.	O

Over	O
15	O
protein	O
sequences	O
with	O
significant	O
sequence	O
similarity	O
to	O
OPH	O
were	O
identified	O
from	O
a	O
variety	O
of	O
bacterial	O
strains	O
.	O

Some	O
of	O
these	O
matches	O
were	O
based	O
on	O
predicted	O
protein	O
structures	O
derived	O
from	O
bacterial	O
genome	O
sequences	O
rather	O
than	O
from	O
bona	O
fide	O
proteins	O
isolated	O
from	O
bacteria	O
.	O

Of	O
the	O
25	O
strains	O
selected	O
for	O
nerve	O
agent	O
testing	O
,	O
three	O
bacterial	O
strains	O
had	O
measurable	O
levels	O
of	O
OP	O
hydrolase	O
activity	O
.	O

These	O
strains	O
are	O
Ammoniphilus	O
oxalaticus	O
,	O
Haloarcula	O
sp.	O
,	O
and	O
Micromonospora	O
aurantiaca	O
.	O

Lysates	O
from	O
A.	O
oxalaticus	O
had	O
detectable	O
hydrolysis	O
of	O
VR	O
;	O
Haloarcula	O
sp.	O
had	O
appreciable	O
hydrolysis	O
of	O
VX	O
and	O
VR	O
,	O
whereas	O
lysates	O
from	O
M.	O
aurantiaca	O
had	O
detectable	O
hydrolysis	O
of	O
VR	O
and	O
GD	O
.	O

Establishment	O
of	O
an	O
in	O
vitro	O
photoallergy	O
test	O
using	O
NCTC2544	O
cells	O
and	O
IL-18	O
production	O
.	O

Differentiation	O
between	O
photoallergenic	O
and	O
phototoxic	O
reactions	O
induced	O
by	O
low	O
molecular	O
weight	O
compounds	O
represents	O
a	O
current	O
problem	O
.	O

The	O
use	O
of	O
keratinocytes	O
as	O
a	O
potential	O
tool	O
for	O
the	O
detection	O
of	O
photoallergens	O
as	O
opposed	O
to	O
photoirritants	O
is	O
considered	O
an	O
interesting	O
strategy	O
for	O
developing	O
in	O
vitro	O
methods	O
.	O

We	O
have	O
previously	O
demonstrated	O
the	O
possibility	O
to	O
use	O
the	O
human	O
keratinocyte	O
cell	O
line	O
NCTC2455	O
and	O
the	O
production	O
of	O
interleukin-18	O
(	O
IL-18	O
)	O
to	O
screen	O
low	O
molecular	O
weight	O
sensitizers	O
.	O

The	O
purpose	O
of	O
this	O
work	O
was	O
to	O
explore	O
the	O
possibility	O
to	O
use	O
the	O
NCTC2544	O
assay	O
to	O
identify	O
photoallergens	O
and	O
discriminate	O
from	O
phototoxic	O
chemicals	O
.	O

First	O
,	O
we	O
identified	O
suitable	O
condition	O
of	O
UV	O
-	O
irradiation	O
(	O
3.5	O
J	O
/	O
cm	O
(	O
2	O
)	O
)	O
by	O
investigating	O
the	O
effect	O
of	O
UVA	O
irradiation	O
on	O
intracellular	O
IL-18	O
on	O
untreated	O
or	O
chloropromazine	B
(	O
a	O
representative	O
phototoxic	O
compound	O
)	O
-treated	O
NCTC2544	O
cells	O
.	O

Then	O
,	O
the	O
effect	O
of	O
UVA	O
-	O
irradiation	O
over	O
NCTC2544	O
cells	O
treated	O
with	O
increasing	O
concentrations	O
of	O
15	O
compounds	O
including	O
photoallergens	O
(	O
benzophenone	B
,	O
4-ter	B
-	I
butyl-4-methoxy	I
-	I
dibenzoylmethane	I
,	I
2-ethylexyl	I
-	I
p	I
-	I
methoxycinnamate	I
,	O
ketoprofen	B
,	O
6-methylcumarin	B
)	O
;	O
photoirritant	O
and	O
photoallergen	O
(	O
4-aminobenzoic	B
acid	I
,	O
chlorpromazine	B
,	O
promethazine	B
)	O
;	O
photoirritants	O
(	O
acridine	B
,	O
ibuprofen	B
,	O
8-methoxypsoralen	B
,	O
retinoic	B
acid	I
)	O
;	O
and	O
negative	O
compounds	O
(	O
lactic	B
acid	I
,	O
SDS	B
and	O
p	B
-	I
phenilendiamine	I
)	O
was	O
investigated	O
.	O

Twenty	O
-	O
four	O
hours	O
after	O
exposure	O
,	O
cytotoxicity	O
was	O
evaluated	O
by	O
the	O
MTT	B
assay	O
or	O
LDH	O
leakage	O
,	O
while	O
ELISA	O
was	O
used	O
to	O
measure	O
the	O
production	O
of	O
IL-18	O
.	O

At	O
the	O
maximal	O
concentration	O
assayed	O
with	O
non	O
-	O
cytotoxic	O
effects	O
(	O
CV80	O
under	O
irradiated	O
condition	O
)	O
,	O
all	O
tested	O
photoallergens	O
induced	O
a	O
significant	O
and	O
a	O
dose	O
-	O
dependent	O
increase	O
of	O
intracellular	O
IL-18	O
following	O
UVA	O
irratiation	O
,	O
whereas	O
photoirritants	O
failed	O
.	O

We	O
suggest	O
that	O
this	O
system	O
may	O
be	O
useful	O
for	O
the	O
in	O
vitro	O
evaluation	O
of	O
the	O
photoallergic	O
potential	O
of	O
chemicals	O
.	O

Differing	O
effects	O
of	O
PTH	O
1	O
-	O
34	O
,	O
PTH	O
1	O
-	O
84	O
,	O
and	O
zoledronic	B
acid	I
on	O
bone	O
microarchitecture	O
and	O
estimated	O
strength	O
in	O
postmenopausal	O
women	O
with	O
osteoporosis	O
:	O
an	O
18-month	O
open	O
-	O
labeled	O
observational	O
study	O
using	O
HR	O
-	O
pQCT	O
.	O

Whereas	O
the	O
beneficial	O
effects	O
of	O
intermittent	O
treatment	O
with	O
parathyroid	O
hormone	O
(	O
PTH	O
)	O
(	O
intact	O
PTH	O
1	O
-	O
84	O
or	O
fragment	O
PTH	O
1	O
-	O
34	O
,	O
teriparatide	O
)	O
on	O
vertebral	O
strength	O
is	O
well	O
documented	O
,	O
treatment	O
may	O
not	O
be	O
equally	O
effective	O
in	O
the	O
peripheral	O
skeleton	O
.	O

We	O
used	O
high	O
-	O
resolution	O
peripheral	O
quantitative	O
computed	O
tomography	O
(	O
HR	O
-	O
pQCT	O
)	O
to	O
detail	O
effects	O
on	O
compartmental	O
geometry	O
,	O
density	O
,	O
and	O
microarchitecture	O
as	O
well	O
as	O
finite	O
element	O
(	O
FE	O
)	O
estimated	O
integral	O
strength	O
at	O
the	O
distal	O
radius	O
and	O
tibia	O
in	O
postmenopausal	O
osteoporotic	O
women	O
treated	O
with	O
PTH	O
1	O
-	O
34	O
(	O
20	O
g	O
sc	O
daily	O
,	O
n	O
=	O
18	O
)	O
or	O
PTH	O
1	O
-	O
84	O
(	O
100	O
g	O
sc	O
daily	O
,	O
n	O
=	O
20	O
)	O
for	O
18	O
months	O
in	O
an	O
open	O
-	O
label	O
,	O
nonrandomized	O
study	O
.	O

A	O
group	O
of	O
postmenopausal	O
osteoporotic	O
women	O
receiving	O
zoledronic	B
acid	I
(	O
5	O
mg	O
infusion	O
once	O
yearly	O
,	O
n	O
=	O
33	O
)	O
was	O
also	O
included	O
.	O

Anabolic	O
therapy	O
increased	O
cortical	O
porosity	O
in	O
radius	O
(	O
PTH	O
1	O
-	O
34	O
32	O
	O
37	O
%	O
,	O
PTH	O
1	O
-	O
84	O
39	O
	O
32	O
%	O
,	O
both	O
p	O
<	O
0.001	O
)	O
and	O
tibia	O
(	O
PTH	O
1	O
-	O
34	O
13	O
	O
27	O
%	O
,	O
PTH	O
1	O
-	O
84	O
15	O
	O
22	O
%	O
,	O
both	O
p	O
<	O
0.001	O
)	O
with	O
corresponding	O
declines	O
in	O
cortical	O
density	O
.	O

With	O
PTH	O
1	O
-	O
34	O
,	O
increases	O
in	O
cortical	O
thickness	O
in	O
radius	O
(	O
2.0	O
	O
3.8	O
%	O
,	O
p	O
<	O
0.05	O
)	O
and	O
tibia	O
(	O
3.8	O
	O
10.4	O
%	O
,	O
p	O
<	O
0.01	O
)	O
were	O
found	O
.	O

Trabecular	O
number	O
increased	O
in	O
tibia	O
with	O
both	O
PTH	O
1	O
-	O
34	O
(	O
4.2	O
	O
7.1	O
%	O
,	O
p	O
<	O
0.05	O
)	O
and	O
PTH	O
1	O
-	O
84	O
(	O
5.3	O
	O
8.3	O
%	O
,	O
p	O
<	O
0.01	O
)	O
.	O

Zoledronic	B
acid	I
did	O
not	O
impact	O
cortical	O
porosity	O
at	O
either	O
site	O
but	O
increased	O
cortical	O
thickness	O
(	O
3.0	O
	O
3.5	O
%	O
,	O
p	O
<	O
0.01	O
)	O
,	O
total	O
(	O
2.7	O
	O
2.5	O
%	O
,	O
p	O
<	O
0.001	O
)	O
and	O
cortical	O
density	O
(	O
1.5	O
	O
2.0	O
%	O
,	O
p	O
<	O
0.01	O
)	O
in	O
tibia	O
as	O
well	O
as	O
trabecular	O
volume	O
fraction	O
in	O
radius	O
(	O
2.5	O
	O
5.1	O
%	O
,	O
p	O
<	O
0.05	O
)	O
and	O
tibia	O
(	O
2.2	O
	O
2.2	O
%	O
,	O
p	O
<	O
0.01	O
)	O
.	O

FE	O
estimated	O
bone	O
strength	O
was	O
preserved	O
,	O
but	O
not	O
increased	O
,	O
with	O
PTH	O
1	O
-	O
34	O
and	O
zoledronic	B
acid	I
at	O
both	O
sites	O
,	O
whereas	O
it	O
decreased	O
with	O
PTH	O
1	O
-	O
84	O
in	O
radius	O
(	O
-2.8	O
	O
5.8	O
%	O
,	O
p	O
<	O
0.05	O
)	O
and	O
tibia	O
(	O
-3.9	O
	O
4.8	O
%	O
,	O
p	O
<	O
0.001	O
)	O
.	O

Conclusively	O
,	O
divergent	O
treatment	O
-	O
specific	O
effects	O
in	O
cortical	O
and	O
trabecular	O
bone	O
were	O
observed	O
with	O
anabolic	O
and	O
zoledronic	B
acid	I
therapy	O
.	O

The	O
finding	O
of	O
decreased	O
estimated	O
strength	O
with	O
PTH	O
1	O
-	O
84	O
treatment	O
was	O
surprising	O
and	O
warrants	O
confirmation	O
.	O

Deletion	O
of	O
CD74	O
,	O
a	O
putative	O
MIF	O
receptor	O
,	O
in	O
mice	O
enhances	O
osteoclastogenesis	O
and	O
decreases	O
bone	O
mass	O
.	O

CD74	O
is	O
a	O
type	O
II	O
transmembrane	O
protein	O
that	O
can	O
act	O
as	O
a	O
receptor	O
for	O
macrophage	O
migration	O
inhibitory	O
factor	O
(	O
MIF	O
)	O
and	O
plays	O
a	O
role	O
in	O
MIF	O
-	O
regulated	O
responses	O
.	O

We	O
reported	O
that	O
MIF	O
inhibited	O
osteoclast	O
formation	O
and	O
MIF	O
knockout	O
(	O
KO	O
)	O
mice	O
had	O
decreased	O
bone	O
mass	O
.	O

We	O
therefore	O
examined	O
if	O
CD74	O
was	O
involved	O
in	O
the	O
ability	O
of	O
MIF	O
to	O
alter	O
osteoclastogenesis	O
in	O
cultured	O
bone	O
marrow	O
(	O
BM	O
)	O
from	O
wild	O
-	O
type	O
(	O
WT	O
)	O
and	O
CD74-deficient	O
(	O
KO	O
)	O
male	O
mice	O
.	O

We	O
also	O
measured	O
the	O
bone	O
phenotype	O
of	O
CD74	O
KO	O
male	O
mice	O
.	O

Bone	O
mass	O
in	O
the	O
femur	O
of	O
8-week	O
-	O
old	O
mice	O
was	O
measured	O
by	O
micro	O
-	O
computed	O
tomography	O
and	O
histomorphometry	O
.	O

Bone	O
marrow	O
cells	O
from	O
CD74	O
KO	O
mice	O
formed	O
15	O
%	O
more	O
osteoclast	O
-	O
like	O
cells	O
(	O
OCLs	O
)	O
with	O
macrophage	O
colony	O
-	O
stimulating	O
factor	O
(	O
M	O
-	O
CSF	O
)	O
and	O
receptor	O
activator	O
of	O
NF	O
-	O
B	O
ligand	O
(	O
RANKL	O
)	O
(	O
both	O
at	O
30	O
ng	O
/	O
mL	O
)	O
compared	O
to	O
WT	O
.	O

Addition	O
of	O
MIF	O
to	O
WT	O
cultures	O
inhibited	O
OCL	O
formation	O
by	O
16	O
%	O
but	O
had	O
no	O
effect	O
on	O
CD74KO	O
cultures	O
.	O

The	O
number	O
of	O
colony	O
forming	O
unit	O
granulocyte	O
-	O
macrophage	O
(	O
CFU	O
-	O
GM	O
)	O
in	O
the	O
bone	O
marrow	O
of	O
CD74	O
KO	O
mice	O
was	O
26	O
%	O
greater	O
than	O
in	O
WT	O
controls	O
.	O

Trabecular	O
bone	O
volume	O
(	O
TBV	O
)	O
in	O
the	O
femurs	O
of	O
CD74	O
KO	O
male	O
mice	O
was	O
decreased	O
by	O
26	O
%	O
compared	O
to	O
WT	O
.	O

In	O
addition	O
,	O
cortical	O
area	O
and	O
thickness	O
were	O
decreased	O
by	O
14	O
%	O
and	O
11	O
%	O
,	O
respectively	O
.	O

Histomorphometric	O
analysis	O
demonstrated	O
that	O
tartrate	B
-	O
resistant	O
acid	O
phosphatase	O
(	O
TRAP	O
)	O
(	O
+	O
)	O
osteoclast	O
number	O
and	O
area	O
were	O
significantly	O
increased	O
in	O
CD74	O
KO	O
by	O
35	O
%	O
and	O
43	O
%	O
,	O
respectively	O
compared	O
to	O
WT	O
.	O

Finally	O
,	O
we	O
examined	O
the	O
effect	O
of	O
MIF	O
on	O
RANKL	O
-	O
induced	O
-	O
signaling	O
pathways	O
in	O
bone	O
marrow	O
macrophage	O
(	O
BMM	O
)	O
cultures	O
.	O

MIF	O
treatment	O
decreased	O
RANKL	O
-	O
induced	O
nuclear	O
factor	O
of	O
activated	O
T	O
cells	O
,	O
cytoplasmic	O
1	O
(	O
NFATc1	O
)	O
and	O
c	O
-	O
Fos	O
protein	O
in	O
BMM	O
cultures	O
by	O
70	O
%	O
and	O
41	O
%	O
,	O
respectively	O
.	O

Our	O
data	O
demonstrate	O
that	O
CD74	O
is	O
required	O
for	O
MIF	O
to	O
affect	O
in	O
vitro	O
osteoclastogenesis	O
.	O

Further	O
,	O
the	O
bone	O
phenotype	O
of	O
CD74	O
KO	O
mice	O
is	O
similar	O
to	O
that	O
of	O
MIF	O
KO	O
mice	O
.	O

MIF	O
treatment	O
of	O
WT	O
cultures	O
suppressed	O
RANKL	O
-	O
induced	O
activator	O
protein	O
1	O
(	O
AP-1	O
)	O
expression	O
,	O
which	O
resulted	O
in	O
decreased	O
osteoclast	O
differentiation	O
in	O
vitro	O
.	O

We	O
propose	O
that	O
CD74	O
plays	O
a	O
critical	O
role	O
in	O
the	O
MIF	O
inhibition	O
of	O
osteoclastogenesis	O
.	O

Hierarchical	O
rutile	O
TiO2	B
flower	O
cluster	O
-	O
based	O
high	O
efficiency	O
dye	O
-	O
sensitized	O
solar	O
cells	O
via	O
direct	O
hydrothermal	O
growth	O
on	O
conducting	O
substrates	O
.	O

Dye	O
-	O
sensitized	O
solar	O
cells	O
(	O
DSSCs	O
)	O
based	O
on	O
hierarchical	O
rutile	O
TiO	B
(	I
2	I
)	I
flower	O
clusters	O
prepared	O
by	O
a	O
facile	O
,	O
one	O
-	O
pot	O
hydrothermal	O
process	O
exhibit	O
a	O
high	O
efficiency	O
.	O

Complex	O
yet	O
appealing	O
rutile	O
TiO	B
(	I
2	I
)	I
flower	O
films	O
are	O
,	O
for	O
the	O
first	O
time	O
,	O
directly	O
hydrothermally	O
grown	O
on	O
a	O
transparent	O
conducting	O
fluorine	B
-	I
doped	I
tin	I
oxide	I
(	O
FTO	B
)	O
substrate	O
.	O

The	O
thickness	O
and	O
density	O
of	O
as	O
-	O
grown	O
flower	O
clusters	O
can	O
be	O
readily	O
tuned	O
by	O
tailoring	O
growth	O
parameters	O
,	O
such	O
as	O
growth	O
time	O
,	O
the	O
addition	O
of	O
cations	O
of	O
different	O
valence	O
and	O
size	O
,	O
initial	O
concentrations	O
of	O
precursor	O
and	O
cation	O
,	O
growth	O
temperature	O
,	O
and	O
acidity	O
.	O

Notably	O
,	O
the	O
small	O
lattice	O
mismatch	O
between	O
the	O
FTO	B
substrate	O
and	O
rutile	O
TiO	B
(	I
2	I
)	I
renders	O
the	O
epitaxial	O
growth	O
of	O
a	O
compact	O
rutile	O
TiO	B
(	I
2	I
)	I
layer	O
on	O
the	O
FTO	B
glass	O
.	O

Intriguingly	O
,	O
these	O
TiO	B
(	I
2	I
)	I
flower	O
clusters	O
can	O
then	O
be	O
exploited	O
as	O
photoanodes	O
to	O
produce	O
DSSCs	O
,	O
yielding	O
a	O
power	O
conversion	O
efficiency	O
of	O
2.94	O
%	O
despite	O
their	O
rutile	O
nature	O
,	O
which	O
is	O
further	O
increased	O
to	O
4.07	O
%	O
upon	O
the	O
TiCl	B
(	I
4	I
)	I
treatment	O
.	O

INO-8875	B
,	O
a	O
highly	O
selective	O
A1	O
adenosine	B
receptor	O
agonist	O
:	O
evaluation	O
of	O
chronotropic	O
,	O
dromotropic	O
,	O
and	O
hemodynamic	O
effects	O
in	O
rats	O
.	O

Selective	O
pharmacological	O
activation	O
of	O
the	O
adenosine	B
1	O
receptor	O
(	O
A	O
(	O
1	O
)	O
R	O
)	O
is	O
a	O
promising	O
new	O
approach	O
to	O
achieve	O
a	O
potent	O
block	O
of	O
atrioventricular	O
(	O
A	O
-	O
V	O
)	O
-nodal	O
conduction	O
without	O
significant	O
cardiovascular	O
side	O
effects	O
.	O

The	O
purpose	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
the	O
cardiovascular	O
profile	O
of	O
INO-8875	B
,	O
a	O
highly	O
selective	O
A	O
(	O
1	O
)	O
R	O
agonist	O
,	O
and	O
to	O
compare	O
its	O
properties	O
with	O
N-	B
[	I
3	I
(	I
R	I
)	I
-tetrahydrofuranyl	I
]	I
-6-aminopurine	I
riboside	I
(	O
CVT-510	B
)	O
,	O
which	O
has	O
already	O
been	O
shown	O
to	O
induce	O
negative	O
dromotropic	O
effects	O
with	O
minimal	O
cardiovascular	O
side	O
effects	O
in	O
animals	O
and	O
in	O
clinical	O
studies	O
.	O

Dose	O
-	O
response	O
experiments	O
in	O
the	O
isolated	O
hearts	O
of	O
rats	O
were	O
used	O
to	O
evaluate	O
the	O
functional	O
selectivity	O
of	O
INO-8875	B
for	O
the	O
slowing	O
of	O
A	O
-	O
V	O
-	O
nodal	O
conduction	O
.	O

Ventilated	O
adult	O
rats	O
were	O
used	O
to	O
study	O
the	O
effects	O
of	O
INO-8875	B
,	O
in	O
vivo	O
,	O
on	O
arterial	O
blood	O
pressure	O
as	O
well	O
as	O
on	O
supraventricular	O
electrophysiology	O
.	O

Ex	O
vivo	O
,	O
INO-8875	B
(	O
100	O
nM	O
to	O
3	O
M	O
)	O
progressively	O
prolonged	O
A	O
-	O
V	O
-	O
nodal	O
conduction	O
without	O
reducing	O
left	O
ventricular	O
function	O
or	O
coronary	O
resistance	O
.	O

In	O
vivo	O
,	O
INO-8875	B
up	O
to	O
a	O
dose	O
of	O
50	O
g	O
/	O
kg	O
did	O
not	O
reduce	O
the	O
carotid	O
arterial	O
blood	O
pressure	O
(	O
n	O
=	O
4	O
)	O
.	O

INO-8875	B
(	O
1	O
-	O
50	O
g	O
/	O
kg	O
)	O
and	O
CVT-510	B
(	O
20	O
and	O
50	O
g	O
/	O
kg	O
)	O
both	O
induced	O
a	O
dose	O
-	O
dependent	O
decrease	O
in	O
heart	O
rate	O
and	O
atrial	O
refractoriness	O
,	O
as	O
well	O
as	O
slowing	O
of	O
A	O
-	O
V	O
-	O
nodal	O
conduction	O
.	O

However	O
,	O
compared	O
with	O
CVT-510	B
,	O
the	O
activity	O
of	O
INO-8875	B
was	O
more	O
pronounced	O
in	O
A	O
-	O
V	O
-	O
nodal	O
function	O
.	O

INO-8875	B
exhibited	O
a	O
greater	O
duration	O
of	O
action	O
,	O
lasting	O
up	O
to	O
2.5	O
hours	O
post	O
dosing	O
,	O
whereas	O
the	O
effects	O
of	O
CVT-510	B
dissipated	O
over	O
1	O
hour	O
.	O

INO-8875	B
demonstrates	O
functional	O
properties	O
of	O
a	O
highly	O
selective	O
A	O
(	O
1	O
)	O
R	O
agonist	O
.	O

INO-8875	B
exhibits	O
an	O
increased	O
dromotropic	O
effect	O
and	O
greater	O
duration	O
of	O
action	O
compared	O
with	O
CVT-510	B
.	O

Exposures	O
to	O
1,3-dimethylamylamine	B
-	O
containing	O
products	O
reported	O
to	O
Texas	O
poison	O
centers	O
.	O

1,3-Dimethylamylamine	B
(	O
DMAA	B
)	O
is	O
an	O
ingredient	O
in	O
a	O
number	O
of	O
weight	O
loss	O
and	O
exercise	O
performance	O
enhancing	O
products	O
.	O

However	O
,	O
information	O
on	O
the	O
safety	O
of	O
DMAA	B
-	O
containing	O
products	O
is	O
limited	O
.	O

Exposures	O
to	O
DMAA	B
-	O
containing	O
products	O
reported	O
to	O
Texas	O
poison	O
centers	O
during	O
2010	O
-	O
2011	O
were	O
identified	O
and	O
selected	O
factors	O
were	O
examined	O
.	O

A	O
total	O
of	O
56	O
exposures	O
were	O
found	O
,	O
of	O
which	O
75.0	O
%	O
were	O
reported	O
during	O
2011	O
.	O

OxyElite	O
Pro	O
	O
was	O
the	O
reported	O
product	O
in	O
80.4	O
%	O
of	O
the	O
exposures	O
.	O

The	O
patients	O
were	O
51.8	O
%	O
male	O
and	O
55.4	O
%	O
age	O
5	O
years	O
.	O

The	O
patient	O
was	O
managed	O
on	O
site	O
(	O
such	O
as	O
at	O
home	O
)	O
in	O
57.1	O
%	O
of	O
the	O
cases	O
,	O
and	O
the	O
exposure	O
was	O
known	O
or	O
expected	O
to	O
result	O
in	O
an	O
outcome	O
that	O
was	O
classified	O
as	O
not	O
serious	O
in	O
80.4	O
%	O
.	O

The	O
most	O
frequently	O
reported	O
clinical	O
effects	O
were	O
tachycardia	O
(	O
28.6	O
%	O
)	O
,	O
nausea	O
(	O
16.1	O
%	O
)	O
,	O
and	O
vomiting	O
(	O
12.5	O
%	O
)	O
.	O

The	O
most	O
common	O
treatments	O
were	O
dilution	O
(	O
41.1	O
%	O
)	O
,	O
food	O
(	O
19.6	O
%	O
)	O
,	O
and	O
activated	O
charcoal	B
(	O
14.3	O
%	O
)	O
.	O

It	O
should	O
be	O
noted	O
that	O
the	O
adverse	O
clinical	O
effects	O
may	O
be	O
due	O
to	O
other	O
ingredients	O
in	O
the	O
DMAA	B
-	O
containing	O
products	O
,	O
such	O
as	O
caffeine	B
.	O

Emergency	O
do	O
not	O
consume	O
/	O
do	O
not	O
use	O
concentrations	O
for	O
blended	O
phosphates	B
in	O
drinking	O
water	O
.	O

The	O
U.S.	O
Congress	O
[	O
PL	O
107	O
-	O
188	O
]	O
amended	O
the	O
Safe	O
Drinking	O
Water	O
Act	O
and	O
required	O
each	O
community	O
water	O
system	O
serving	O
more	O
than	O
3,000	O
people	O
to	O
conduct	O
vulnerability	O
assessments	O
.	O

These	O
assessments	O
address	O
potential	O
circumstances	O
that	O
could	O
compromise	O
the	O
safety	O
and	O
reliability	O
of	O
municipal	O
water	O
.	O

The	O
present	O
evaluation	O
concerns	O
the	O
concentrations	O
of	O
the	O
blended	O
phosphates	B
(	O
also	O
known	O
as	O
polyphosphates	B
,	O
condensed	O
complex	O
phosphates	B
,	O
polyphosphate	O
glassy	O
balls	O
,	O
and	O
pyrophosphates	B
)	O
intended	O
to	O
aid	O
regulatory	O
agencies	O
in	O
decisions	O
to	O
avoid	O
contact	O
with	O
affected	O
water	O
.	O

Polyphosphates	B
are	O
direct	O
food	O
additives	O
and	O
they	O
are	O
used	O
to	O
treat	O
municipal	O
drinking	O
water	O
,	O
but	O
depending	O
upon	O
the	O
concentration	O
and	O
duration	O
of	O
exposure	O
these	O
substances	O
can	O
induce	O
chemical	O
burns	O
.	O

Ingested	O
polyphosphates	B
are	O
degraded	O
by	O
phosphatase	O
enzymes	O
to	O
monophosphates	B
,	O
substances	O
that	O
are	O
over	O
-	O
the	O
-	O
counter	O
bowel	O
purgatives	O
.	O

High	O
oral	O
doses	O
of	O
the	O
monophosphates	B
can	O
induce	O
transient	O
hyperphosphatemia	O
in	O
older	O
and	O
susceptible	O
young	O
people	O
,	O
which	O
can	O
lead	O
to	O
acute	O
phosphate	B
nephropathy	O
.	O

In	O
some	O
patients	O
,	O
the	O
condition	O
is	O
fatal	O
.	O

Based	O
on	O
the	O
acute	O
diarrhea	O
after	O
the	O
ingestion	O
of	O
a	O
single	O
oral	O
dose	O
of	O
monobasic	O
(	O
NaH2PO	B
(	I
4	I
)	I
)	O
and	O
dibasic	O
(	O
Na2HPO	B
(	I
4	I
)	I
)	O
monophosphates	B
in	O
adults	O
,	O
a	O
do	O
not	O
consume	O
concentration	O
of	O
600	O
mg	O
PO	B
(	I
4	I
)	I
/	O
L	O
can	O
be	O
derived	O
.	O

Based	O
on	O
mild	O
local	O
irritation	O
after	O
topical	O
application	O
of	O
1.0	O
%	O
sodium	B
metaphosphate	I
[	O
(	B
NaPO	I
(	I
3	I
)	I
)	I
6	I
	I
H2O	I
]	O
to	O
intact	O
skin	O
of	O
sensitive	O
volunteers	O
,	O
a	O
do	O
not	O
use	O
concentration	O
of	O
8,000	O
mg	O
PO4	B
/	O
L	O
can	O
be	O
assigned	O
.	O

Given	O
the	O
lack	O
of	O
eye	O
irritation	O
in	O
rabbits	O
after	O
direct	O
instillation	O
of	O
0.2	O
%	O
(	B
NaPO	I
(	I
3	I
)	I
)	I
6	I
	I
H2O	I
,	O
an	O
acute	O
ocular	O
contact	O
limit	O
of	O
50	O
mg	O
PO4	B
/	O
L	O
serves	O
as	O
the	O
overall	O
do	O
not	O
use	O
level	O
.	O

Anti	O
-	O
tumor	O
necrosis	O
factor	O
treatment	O
in	O
cherubism	O
--	O
clinical	O
,	O
radiological	O
and	O
histological	O
findings	O
in	O
two	O
children	O
.	O

Cherubism	O
is	O
a	O
rare	O
and	O
disfiguring	O
genetic	O
disorder	O
with	O
excessive	O
bone	O
resorption	O
and	O
multilocular	O
lesions	O
in	O
the	O
mandible	O
and/or	O
maxilla	O
.	O

The	O
disease	O
-	O
causing	O
gain	O
-	O
of	O
-	O
function	O
mutations	O
in	O
the	O
SH3-binding	O
protein	O
2	O
(	O
SH3BP2	O
)	O
gene	O
result	O
in	O
increased	O
myeloid	O
cell	O
responses	O
to	O
macrophage	O
colony	O
stimulating	O
factor	O
and	O
RANK	O
ligand	O
,	O
formation	O
of	O
hyperactive	O
osteoclasts	O
(	O
giant	O
cells	O
)	O
,	O
and	O
hyper	O
-	O
reactive	O
macrophages	O
that	O
produce	O
excessive	O
amounts	O
of	O
the	O
inflammatory	O
cytokine	O
tumor	O
necrosis	O
factor	O
	O
(	O
TNF	O
-	O
	O
)	O
.	O

Recent	O
findings	O
in	O
the	O
cherubism	O
mouse	O
model	O
suggest	O
that	O
TNF	O
-	O
	O
plays	O
a	O
major	O
role	O
in	O
disease	O
pathogenesis	O
and	O
that	O
removal	O
of	O
TNF	O
-	O
	O
prevents	O
development	O
of	O
the	O
bone	O
phenotype	O
.	O

We	O
treated	O
two	O
children	O
with	O
cherubism	O
with	O
the	O
TNF	O
-	O
	O
antagonist	O
adalimumab	O
for	O
approximately	O
2.5	O
years	O
and	O
collected	O
extensive	O
clinical	O
,	O
radiological	O
and	O
histological	O
follow	O
-	O
up	O
data	O
during	O
the	O
treatment	O
.	O

Histologically	O
the	O
treatment	O
resulted	O
in	O
a	O
significant	O
reduction	O
in	O
the	O
number	O
of	O
multinucleated	O
giant	O
cells	O
and	O
TNF	O
-	O
	O
staining	O
positivity	O
in	O
both	O
patients	O
.	O

As	O
evaluated	O
by	O
computed	O
tomography	O
and	O
magnetic	O
resonance	O
imaging	O
,	O
the	O
lesions	O
in	O
Patient	O
1	O
showed	O
either	O
moderate	O
enlargement	O
(	O
mandibular	O
symphysis	O
)	O
or	O
remained	O
stable	O
(	O
mandibular	O
rami	O
and	O
body	O
,	O
the	O
maxilla	O
)	O
.	O

In	O
Patient	O
2	O
,	O
the	O
lesions	O
in	O
mandibular	O
symphysis	O
showed	O
enlargement	O
during	O
the	O
first	O
8	O
months	O
of	O
treatment	O
,	O
and	O
thereafter	O
the	O
lesions	O
remained	O
unchanged	O
.	O

Bone	O
formation	O
and	O
resorption	O
markers	O
remained	O
unaffected	O
.	O

The	O
treatment	O
was	O
well	O
tolerated	O
.	O

Based	O
on	O
our	O
findings	O
,	O
TNF	O
-	O
	O
antagonist	O
may	O
decrease	O
the	O
formation	O
of	O
pathogenic	O
giant	O
cells	O
,	O
but	O
does	O
not	O
result	O
in	O
lesion	O
regression	O
or	O
prevent	O
lesion	O
expansion	O
in	O
active	O
cherubism	O
.	O

TNF	O
-	O
	O
modulator	O
treatment	O
thus	O
does	O
not	O
appear	O
to	O
provide	O
sufficient	O
amelioration	O
for	O
patients	O
suffering	O
from	O
cherubism	O
.	O

Design	O
,	O
synthesis	O
,	O
and	O
in	O
vitro	O
evaluation	O
of	O
new	O
amphiphilic	O
cyclodextrin	O
-	O
based	O
nanoparticles	O
for	O
the	O
incorporation	O
and	O
controlled	O
release	O
of	O
acyclovir	B
.	O

Acyclovir	B
possesses	O
low	O
solubility	O
in	O
water	O
and	O
in	O
lipid	O
bilayers	O
,	O
so	O
that	O
its	O
dosage	O
forms	O
do	O
not	O
allow	O
suitable	O
drug	O
levels	O
at	O
target	O
sites	O
following	O
oral	O
,	O
local	O
,	O
or	O
parenteral	O
administration	O
.	O

In	O
order	O
to	O
improve	O
this	O
lack	O
of	O
solubility	O
,	O
new	O
cyclodextrin	O
-	O
based	O
amphiphilic	O
derivatives	O
have	O
been	O
designed	O
to	O
form	O
nanoparticles	O
,	O
allowing	O
the	O
efficient	O
encapsulation	O
of	O
this	O
hydrophobic	O
antiviral	O
agent	O
.	O

The	O
present	O
work	O
first	O
describes	O
the	O
synthesis	O
and	O
characterization	O
of	O
five	O
new	O
O-2,O-3	B
permethylated	I
O-6	I
alkylthio-	I
and	I
perfluoroalkyl	I
-	I
propanethio	I
-	I
amphiphilic	I
	I
-	I
cyclodextrins	I
.	O

These	O
derivatives	O
have	O
been	O
obtained	O
with	O
good	O
overall	O
yields	O
.	O

The	O
capacity	O
of	O
these	O
molecules	O
to	O
form	O
nanoparticles	O
in	O
water	O
and	O
to	O
encapsulate	O
acyclovir	B
has	O
then	O
been	O
studied	O
.	O

The	O
nanoparticles	O
prepared	O
from	O
the	O
new	O
	B
-	I
cyclodextrin	I
derivatives	O
have	O
been	O
characterized	O
by	O
dynamic	O
light	O
scattering	O
and	O
have	O
an	O
average	O
size	O
of	O
120	O
nm	O
for	O
the	O
fluorinated	O
derivatives	O
and	O
220	O
nm	O
for	O
the	O
hydrogenated	O
analogs	O
.	O

They	O
all	O
allowed	O
high	O
loading	O
and	O
sustained	O
release	O
of	O
acyclovir	B
.	O

The	O
arginine	B
and	O
GHRP-2	O
tests	O
as	O
alternatives	O
to	O
the	O
insulin	O
tolerance	O
test	O
for	O
the	O
diagnosis	O
of	O
adult	O
GH	O
deficiency	O
in	O
Japanese	O
patients	O
:	O
a	O
comparison	O
.	O

The	O
arginine	B
+	O
GHRH	O
test	O
has	O
been	O
established	O
as	O
an	O
alternative	O
to	O
the	O
insulin	O
tolerance	O
test	O
(	O
ITT	O
)	O
for	O
the	O
diagnosis	O
of	O
adult	O
GH	O
deficiency	O
(	O
AGHD	O
)	O
.	O

However	O
,	O
the	O
glucagon	O
,	O
arginine	B
,	O
and	O
GH	O
releasing	O
peptide-2	O
(	O
GHRP-2	O
)	O
test	O
are	O
recommended	O
as	O
alternatives	O
in	O
Japan	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
arginine	B
and	O
GHRP-2	O
tests	O
as	O
alternatives	O
to	O
the	O
ITT	O
for	O
the	O
diagnosis	O
of	O
AGHD	O
in	O
a	O
Japanese	O
population	O
.	O

Three	O
stimulation	O
tests	O
(	O
ITT	O
,	O
arginine	B
test	O
,	O
and	O
GHRP-2	O
test	O
)	O
were	O
conducted	O
in	O
71	O
pre	O
-	O
operative	O
adult	O
patients	O
with	O
pituitary	O
tumors	O
(	O
age	O
,	O
18	O
-	O
65	O
years	O
)	O
.	O

The	O
peak	O
GH	O
responses	O
to	O
each	O
test	O
were	O
examined	O
.	O

The	O
peak	O
GH	O
responses	O
were	O
significantly	O
lower	O
with	O
the	O
ARG	B
test	O
(	O
median	O
4.43	O
g	O
/	O
L	O
)	O
(	O
p	O
<	O
0.0001	O
)	O
than	O
with	O
the	O
ITT	O
(	O
median	O
9.38	O
g	O
/	O
L	O
)	O
,	O
and	O
the	O
peak	O
GH	O
responses	O
with	O
the	O
GHRP-2	O
test	O
(	O
median	O
28.88	O
g	O
/	O
L	O
)	O
were	O
higher	O
(	O
p	O
<	O
0.0001	O
)	O
.	O

However	O
,	O
among	O
the	O
AGHD	O
patients	O
,	O
there	O
was	O
no	O
significant	O
difference	O
between	O
the	O
peak	O
GH	O
responses	O
to	O
the	O
ARG	B
test	O
and	O
the	O
ITT	O
.	O

The	O
sensitivities	O
and	O
specificities	O
of	O
the	O
ARG	B
/	O
GHRP-2	O
tests	O
compared	O
to	O
the	O
ITT	O
for	O
the	O
diagnosis	O
of	O
severe	O
AGHD	O
(	O
peak	O
GH	O
responses	O
to	O
ITT	O
	O
1.8	O
g	O
/	O
L	O
)	O
were	O
93.8	O
%	O
/	O
81.3	O
%	O
and	O
85.5	O
%	O
/	O
94.5	O
%	O
,	O
respectively	O
.	O

The	O
arginine	B
and	O
GHRP-2	O
stimulation	O
tests	O
are	O
acceptable	O
alternatives	O
to	O
the	O
ITT	O
for	O
the	O
diagnosis	O
of	O
AGHD	O
in	O
Japanese	O
patients	O
.	O

The	O
method	O
and	O
criterion	O
for	O
the	O
diagnosis	O
of	O
AGHD	O
should	O
be	O
reconsidered	O
and	O
adjusted	O
to	O
each	O
population	O
.	O

H	B
-	O
TiO	B
(	I
2	I
)	I
@MnO	O
(	B
2	I
)	I
/	O
/	O
H	B
-	O
TiO	B
(	I
2	I
)	I
@C	O
core	O
-	O
shell	O
nanowires	O
for	O
high	O
performance	O
and	O
flexible	O
asymmetric	O
supercapacitors	O
.	O

A	O
flexible	O
solid	O
-	O
state	O
asymmetric	O
supercapacitor	O
device	O
with	O
H	O
-	O
TiO	B
(	I
2	I
)	I
@MnO	O
(	B
2	I
)	I
core	O
-	O
shell	O
NWs	O
as	O
the	O
positive	O
electrode	O
and	O
H	O
-	O
TiO	B
(	I
2	I
)	I
@C	B
core	O
-	O
shell	O
NWs	O
as	O
the	O
negative	O
electrode	O
is	O
developed	O
.	O

This	O
device	O
operates	O
in	O
a	O
1.8	O
V	O
voltage	O
window	O
and	O
is	O
able	O
to	O
deliver	O
a	O
high	O
specific	O
capacitance	O
of	O
139.6	O
F	O
g	O
(	O
-1	O
)	O
and	O
maximum	O
volumetric	O
energy	O
density	O
of	O
0.30	O
mWh	O
cm	O
(	O
-3	O
)	O
with	O
excellent	O
cycling	O
performance	O
and	O
good	O
flexibility	O
.	O

Sub	O
-	O
lethal	O
effects	O
of	O
titanium	B
dioxide	I
nanoparticles	O
on	O
the	O
physiology	O
and	O
reproduction	O
of	O
zebrafish	O
.	O

There	O
are	O
limited	O
data	O
on	O
the	O
sub	O
-	O
lethal	O
physiological	O
effects	O
of	O
titanium	B
dioxide	I
nanoparticles	O
(	O
TiO	B
(	I
2	I
)	I
NPs	O
)	O
in	O
adult	O
fishes	O
,	O
and	O
the	O
consequences	O
of	O
TiO	B
(	I
2	I
)	I
NP	O
exposure	O
on	O
reproductive	O
success	O
are	O
also	O
unclear	O
.	O

This	O
study	O
aimed	O
to	O
examine	O
the	O
sub	O
-	O
lethal	O
effects	O
of	O
a	O
14-d	O
aqueous	O
TiO	B
(	I
2	I
)	I
(	O
TiO	B
(	I
2	I
)	I
NP	O
,	O
0.1	O
or	O
1.0	O
mg	O
l	O
(	O
-1	O
)	O
;	O
TiO	B
(	I
2	I
)	I
bulk	O
,	O
1.0	O
mg	O
l	O
(	O
-1	O
)	O
)	O
exposure	O
on	O
the	O
physiology	O
and	O
reproductive	O
health	O
of	O
zebrafish	O
.	O

After	O
the	O
14-d	O
exposure	O
,	O
fish	O
were	O
examined	O
for	O
haematology	O
,	O
whole	O
body	O
electrolyte	O
and	O
trace	O
metal	O
profiles	O
,	O
biochemistry	O
,	O
and	O
histopathology	O
.	O

Then	O
,	O
during	O
a	O
21-d	O
post	O
exposure	O
recovery	O
period	O
,	O
effects	O
of	O
the	O
TiO	B
(	I
2	I
)	I
exposure	O
on	O
reproductive	O
success	O
were	O
evaluated	O
.	O

Whole	O
body	O
Ti	B
concentrations	O
increased	O
significantly	O
in	O
fish	O
exposed	O
to	O
both	O
the	O
1.0	O
mg	O
l	O
(	O
-1	O
)	O
TiO	B
(	I
2	I
)	I
NP	O
and	O
bulk	O
TiO	B
(	I
2	I
)	I
compared	O
to	O
controls	O
,	O
but	O
concentrations	O
returned	O
to	O
control	O
levels	O
by	O
the	O
end	O
of	O
the	O
recovery	O
period	O
.	O

No	O
change	O
in	O
erythrocyte	O
counts	O
were	O
observed	O
,	O
but	O
there	O
was	O
a	O
two	O
-	O
fold	O
decline	O
in	O
leukocyte	O
counts	O
in	O
all	O
TiO	B
(	I
2	I
)	I
treatment	O
groups	O
relative	O
to	O
time	O
-	O
matched	O
controls	O
.	O

Whole	O
body	O
electrolyte	O
and	O
trace	O
metal	O
profiles	O
were	O
not	O
affected	O
by	O
exposure	O
to	O
TiO	B
(	I
2	I
)	I
,	O
and	O
there	O
were	O
no	O
changes	O
in	O
Na	B
(	I
+	I
)	I
K	B
(	I
+	I
)	I
-ATPase	O
activity	O
in	O
brain	O
,	O
gill	O
or	O
liver	O
tissues	O
.	O

Total	O
glutathione	B
(	O
GSH	B
)	O
levels	O
in	O
brain	O
,	O
gill	O
and	O
liver	O
tissues	O
were	O
higher	O
in	O
fish	O
exposed	O
to	O
TiO	B
(	I
2	I
)	I
NP	O
(	O
both	O
0.1	O
and	O
1.0	O
mg	O
l	O
(	O
-1	O
)	O
)	O
compared	O
to	O
bulk	O
TiO	B
(	I
2	I
)	I
and	O
control	O
fish	O
.	O

Histological	O
examination	O
of	O
gill	O
,	O
liver	O
,	O
brain	O
and	O
gonad	O
tissues	O
showed	O
little	O
evidence	O
of	O
treatment	O
-	O
related	O
morphological	O
change	O
.	O

At	O
the	O
end	O
of	O
the	O
14-d	O
exposure	O
adult	O
zebrafish	O
were	O
able	O
to	O
reproduce	O
;	O
however	O
,	O
the	O
cumulative	O
number	O
of	O
viable	O
embryos	O
produced	O
was	O
lower	O
in	O
fish	O
exposed	O
to	O
1.0	O
mg	O
l	O
(	O
-1	O
)	O
TiO	B
(	I
2	I
)	I
(	O
both	O
NP	O
and	O
bulk	O
)	O
by	O
the	O
end	O
of	O
the	O
21-d	O
recovery	O
period	O
.	O

Overall	O
,	O
this	O
study	O
showed	O
limited	O
toxicity	O
of	O
bulk	O
or	O
nano	O
scale	O
TiO	B
(	I
2	I
)	I
during	O
the	O
exposure	O
;	O
however	O
reproduction	O
was	O
affected	O
in	O
both	O
bulk	O
and	O
NP	O
1.0	O
mg	O
l	O
(	O
-1	O
)	O
groups	O
.	O

Toxic	O
effects	O
of	O
microcystin	B
-	I
LR	I
on	O
the	O
reproductive	O
system	O
of	O
male	O
Rana	O
nigromaculata	O
in	O
vitro	O
.	O

This	O
study	O
aims	O
to	O
demonstrate	O
that	O
microcystin	B
-	I
LR	I
(	O
MC	B
-	I
LR	I
)	O
has	O
toxic	O
effects	O
on	O
the	O
reproductive	O
system	O
of	O
male	O
Rana	O
nigromaculata	O
in	O
vitro	O
.	O

R.	O
nigromaculata	O
were	O
treated	O
with	O
0	O
,	O
0.1	O
,	O
1	O
,	O
10	O
,	O
and	O
100	O
nmol	O
/	O
L	O
of	O
MC	O
-	O
LR	O
for	O
6	O
h.	O
Results	O
show	O
that	O
exposure	O
to	O
1	O
nmol	O
/	O
L	O
to	O
100	O
nmol	O
/	O
L	O
of	O
MC	B
-	I
LR	I
decreased	O
sperm	O
motility	O
and	O
number	O
of	O
sperm	O
cells	O
and	O
increased	O
the	O
sperm	O
abnormality	O
rate	O
,	O
whose	O
values	O
were	O
significantly	O
different	O
from	O
those	O
of	O
the	O
control	O
(	O
P<0.01	O
)	O
.	O

Moreover	O
,	O
the	O
same	O
dosage	O
of	O
MC	B
-	I
LR	I
increased	O
reactive	O
oxygen	B
species	O
production	O
and	O
malondialdehyde	B
content	O
.	O

At	O
the	O
same	O
time	O
,	O
antioxidant	O
enzyme	O
(	O
catalase	O
and	O
glutathione	B
S	O
-	O
transferase	O
)	O
activity	O
and	O
glutathione	B
reduced	O
content	O
rapidly	O
increased	O
,	O
whereas	O
antioxidant	O
enzyme	O
superoxide	B
dismutase	O
activity	O
significantly	O
decreased	O
.	O

These	O
results	O
imply	O
that	O
the	O
defense	O
system	O
of	O
the	O
testes	O
quickly	O
responds	O
to	O
oxidative	O
stress	O
.	O

Ultrastructural	O
observation	O
shows	O
distention	O
of	O
the	O
mitochondria	O
,	O
endoplasmic	O
reticulum	O
,	O
and	O
Golgi	O
apparatus	O
and	O
changes	O
in	O
the	O
mitochondrial	O
matrix	O
color	O
,	O
cristae	O
number	O
,	O
and	O
morphology	O
.	O

Moreover	O
,	O
using	O
real	O
-	O
time	O
PCR	O
,	O
increased	O
relative	O
expressions	O
of	O
P450	O
aromatase	O
and	O
SF-1	O
genes	O
were	O
observed	O
.	O

The	O
results	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
MC	B
-	I
LR	I
could	O
induce	O
toxicity	O
in	O
the	O
male	O
reproductive	O
system	O
of	O
R.	O
nigromaculata	O
.	O

The	O
findings	O
in	O
this	O
research	O
will	O
provide	O
more	O
insights	O
into	O
the	O
relationships	O
between	O
aquatic	O
microcystins	B
and	O
amphibians	O
.	O

Ultrasound	O
-	O
promoted	O
coating	O
of	O
silk	O
yarn	O
with	O
different	O
morphology	O
of	O
magnesium	B
hydroxide	I
nanostructures	O
.	O

The	O
growth	O
of	O
magnesium	B
hydroxide	I
nanostructures	O
on	O
silk	O
yarn	O
was	O
achieved	O
by	O
sequential	O
dipping	O
steps	O
in	O
alternating	O
bath	O
of	O
magnesium	B
nitrate	I
and	O
potassium	B
hydroxide	I
under	O
ultrasound	O
irradiation	O
.	O

The	O
effects	O
of	O
ultrasound	O
irradiation	O
,	O
concentration	O
,	O
pH	O
and	O
sequential	O
dipping	O
steps	O
on	O
growth	O
of	O
the	O
Mg	B
(	I
OH	I
)	I
(	I
2	I
)	I
nanostructures	O
have	O
been	O
studied	O
.	O

Morphology	O
of	O
the	O
nanostructures	O
,	O
depending	O
on	O
pH	O
and	O
with	O
decreasing	O
pH	O
from	O
13	O
to	O
8	O
,	O
changed	O
from	O
nanoparticle	O
to	O
nanoneedle	O
.	O

Results	O
show	O
a	O
decrease	O
in	O
the	O
particles	O
size	O
as	O
the	O
concentration	O
and	O
sequential	O
dipping	O
steps	O
increased	O
.	O

The	O
physicochemical	O
properties	O
of	O
the	O
nanostructures	O
were	O
determined	O
by	O
powder	O
X	O
-	O
ray	O
diffraction	O
(	O
XRD	O
)	O
,	O
scanning	O
electron	O
microscopy	O
(	O
SEM	O
)	O
and	O
wavelength	O
dispersive	O
X	O
-	O
ray	O
(	O
WDX	O
)	O
.	O

Effect	O
of	O
amorphization	O
method	O
on	O
telmisartan	B
solubility	O
and	O
the	O
tableting	O
process	O
.	O

Telmisartan	B
(	O
TLM	B
)	O
,	O
a	O
poorly	O
water	O
-	O
soluble	O
angiotensin	O
II	O
receptor	O
antagonist	O
in	O
crystalline	O
form	O
,	O
was	O
transformed	O
into	O
the	O
amorphous	O
state	O
by	O
the	O
melt	O
quench	O
technique	O
,	O
as	O
well	O
as	O
a	O
cryogenic	O
grinding	O
method	O
,	O
in	O
order	O
to	O
improve	O
its	O
physiochemical	O
properties	O
.	O

The	O
chemical	O
stability	O
of	O
TLM	B
,	O
that	O
is	O
,	O
the	O
tendency	O
of	O
the	O
material	O
to	O
resist	O
change	O
or	O
decomposition	O
due	O
to	O
internal	O
reaction	O
,	O
or	O
due	O
to	O
the	O
effects	O
of	O
air	O
,	O
heat	O
,	O
light	O
,	O
pressure	O
,	O
etc	O
.	O
,	O
during	O
formation	O
of	O
the	O
amorphous	O
phase	O
was	O
assessed	O
by	O
monitoring	O
high	O
performance	O
liquid	O
chromatography	O
.	O

The	O
existence	O
of	O
the	O
amorphous	O
state	O
was	O
confirmed	O
by	O
differential	O
scanning	O
calorimetry	O
and	O
X	O
-	O
ray	O
powder	O
diffraction	O
.	O

The	O
glass	O
transition	O
occurred	O
at	O
T	O
(	O
g	O
)	O
=401	O
K	O
.	O

In	O
the	O
next	O
stage	O
,	O
the	O
solubility	O
of	O
TLM	B
in	O
0.1	O
M	O
HCl	B
,	O
phosphate	O
buffer	O
,	O
pH=6.8	O
,	O
and	O
water	O
(	O
25	O
	O
C	O
and	O
37	O
	O
C	O
)	O
was	O
determined	O
.	O

Both	O
amorphous	O
forms	O
of	O
TLM	B
(	O
vitrified	O
and	O
cryogrinded	O
)	O
had	O
a	O
higher	O
solubility	O
(	O
g	O
/	O
ml	O
)	O
than	O
their	O
crystalline	O
counterpart	O
.	O

An	O
important	O
and	O
interesting	O
problem	O
of	O
the	O
study	O
was	O
to	O
evaluate	O
how	O
the	O
tableting	O
process	O
was	O
affected	O
by	O
the	O
choice	O
of	O
either	O
a	O
crystalline	O
or	O
an	O
amorphous	O
form	O
of	O
TLM	B
.	O

Eight	O
different	O
tablet	O
formulations	O
were	O
evaluated	O
using	O
both	O
the	O
crystalline	O
and	O
the	O
amorphous	O
form	O
of	O
TLM	B
.	O

Measurements	O
of	O
the	O
physical	O
properties	O
and	O
dissolution	O
tests	O
of	O
G4	O
formulations	O
tablets	O
with	O
telmisartan	B
in	O
crystalline	O
and	O
amorphous	O
form	O
after	O
different	O
storage	O
periods	O
were	O
also	O
performed	O
.	O

Binding	O
of	O
Gq	O
protein	O
stabilizes	O
the	O
activated	O
state	O
of	O
the	O
muscarinic	O
receptor	O
type	O
1	O
.	O

Activation	O
of	O
G	O
protein	O
coupled	O
receptors	O
(	O
GPCRs	O
)	O
induces	O
various	O
cellular	O
responses	O
through	O
interactions	O
with	O
G	O
proteins	O
.	O

The	O
key	O
trigger	O
of	O
GPCR	O
activation	O
is	O
agonist	O
binding	O
.	O

It	O
is	O
reportedly	O
known	O
that	O
the	O
agonist	O
-	O
bound	O
active	O
conformation	O
of	O
the	O
GPCRs	O
,	O
such	O
as	O
the	O
muscarinic	O
acetylcholine	O
receptor	O
type	O
1	O
(	O
M	O
(	O
1	O
)	O
R	O
)	O
,	O
can	O
be	O
affected	O
by	O
the	O
coupling	O
of	O
G	O
proteins	O
and	O
by	O
depolarization	O
of	O
the	O
membrane	O
potential	O
.	O

Here	O
we	O
aimed	O
at	O
investigating	O
their	O
effects	O
on	O
the	O
structural	O
rearrangements	O
of	O
the	O
M	O
(	O
1	O
)	O
Rs	O
between	O
the	O
active	O
and	O
quiescent	O
states	O
,	O
using	O
the	O
fluorescence	O
resonance	O
energy	O
transfer	O
(	O
FRET	O
)	O
technique	O
.	O

For	O
this	O
purpose	O
,	O
fluorescent	O
M	O
(	O
1	O
)	O
R	O
constructs	O
that	O
maintained	O
intact	O
activation	O
of	O
the	O
Gq	O
pathway	O
and	O
interaction	O
with	O
Gq	O
were	O
used	O
.	O

We	O
captured	O
the	O
agonist	O
-	O
induced	O
conformational	O
changes	O
of	O
the	O
M	O
(	O
1	O
)	O
R	O
as	O
the	O
FRET	O
decreases	O
and	O
found	O
that	O
the	O
FRET	O
decreases	O
were	O
enhanced	O
by	O
co	O
-	O
expression	O
of	O
the	O
Gq	O
subunits	O
.	O

In	O
addition	O
,	O
co	O
-	O
expression	O
of	O
the	O
Gq	O
subunits	O
decelerated	O
the	O
recovery	O
of	O
the	O
declined	O
FRET	O
upon	O
removal	O
of	O
the	O
agonists	O
,	O
which	O
was	O
slower	O
than	O
the	O
dissociation	O
of	O
the	O
Gq	O
subunits	O
from	O
the	O
receptor	O
.	O

These	O
results	O
suggested	O
that	O
Gq	O
binding	O
stabilizes	O
the	O
agonist	O
-	O
induced	O
activated	O
conformation	O
of	O
the	O
M	O
(	O
1	O
)	O
R.	O
We	O
also	O
found	O
that	O
depolarization	O
of	O
the	O
membrane	O
potential	O
slightly	O
but	O
significantly	O
enhanced	O
the	O
agonist	O
-	O
induced	O
FRET	O
decrease	O
,	O
by	O
accelerating	O
the	O
agonist	O
-	O
induced	O
conformational	O
changes	O
.	O

Thus	O
,	O
structural	O
rearrangement	O
analyses	O
by	O
FRET	O
revealed	O
that	O
Gq	O
coupling	O
stabilizes	O
the	O
active	O
conformation	O
of	O
the	O
M	O
(	O
1	O
)	O
R	O
and	O
also	O
suggested	O
that	O
depolarization	O
accelerates	O
the	O
transition	O
from	O
quiescent	O
to	O
activation	O
conformation	O
.	O

What	O
is	O
behind	O
the	O
non	O
-	O
antibiotic	O
properties	O
of	O
minocycline	B
?	O

Minocycline	B
is	O
a	O
second	O
-	O
generation	O
,	O
semi	O
-	O
synthetic	O
tetracycline	B
that	O
has	O
been	O
in	O
use	O
in	O
therapy	O
for	O
over	O
30	O
years	O
for	O
its	O
antibiotic	O
properties	O
against	O
both	O
Gram	O
-	O
positive	O
and	O
Gram	O
-	O
negative	O
bacteria	O
.	O

It	O
displays	O
antibiotic	O
activity	O
due	O
to	O
its	O
ability	O
to	O
bind	O
to	O
the	O
30S	O
ribosomal	O
subunit	O
of	O
bacteria	O
and	O
thus	O
inhibit	O
protein	O
synthesis	O
.	O

More	O
recently	O
,	O
it	O
has	O
been	O
described	O
to	O
exert	O
a	O
variety	O
of	O
biological	O
actions	O
beyond	O
its	O
antimicrobial	O
activity	O
,	O
including	O
anti	O
-	O
inflammatory	O
and	O
anti	O
-	O
apoptotic	O
activities	O
,	O
inhibition	O
of	O
proteolysis	O
,	O
as	O
well	O
as	O
suppression	O
of	O
angiogenesis	O
and	O
tumor	O
metastasis	O
,	O
which	O
have	O
been	O
confirmed	O
in	O
different	O
experimental	O
models	O
of	O
non	O
-	O
infectious	O
diseases	O
.	O

There	O
are	O
also	O
many	O
studies	O
that	O
have	O
focused	O
on	O
the	O
mechanisms	O
involved	O
in	O
these	O
non	O
-	O
antibiotic	O
properties	O
of	O
minocycline	B
,	O
including	O
anti	O
-	O
oxidant	O
activity	O
,	O
inhibition	O
of	O
several	O
enzyme	O
activities	O
,	O
inhibition	O
of	O
apoptosis	O
and	O
regulation	O
of	O
immune	O
cell	O
activation	O
and	O
proliferation	O
.	O

This	O
review	O
summarizes	O
the	O
current	O
findings	O
in	O
this	O
topic	O
,	O
mainly	O
focusing	O
on	O
the	O
mechanisms	O
underlying	O
the	O
immunomodulatory	O
and	O
anti	O
-	O
inflammatory	O
activities	O
of	O
minocycline	B
.	O

Target	O
promiscuity	O
and	O
physicochemical	O
properties	O
contribute	O
to	O
pharmacologically	O
induced	O
ER	O
-	O
stress	O
.	O

In	O
vivo	O
toxicity	O
of	O
drug	O
candidates	O
remains	O
a	O
major	O
problem	O
in	O
the	O
pharmaceutical	O
industry	O
,	O
and	O
is	O
a	O
significant	O
cause	O
of	O
late	O
stage	O
attrition	O
.	O

As	O
a	O
consequence	O
predictive	O
in	O
vitro	O
assays	O
are	O
developed	O
and	O
put	O
in	O
place	O
early	O
in	O
the	O
discovery	O
pipeline	O
to	O
aid	O
compound	O
selection	O
.	O

Endoplasmic	O
reticulum	O
stress	O
(	O
ER	O
-	O
stress	O
)	O
has	O
been	O
implicated	O
in	O
many	O
disease	O
states	O
,	O
as	O
well	O
as	O
compound	O
-	O
induced	O
organ	O
toxicities	O
.	O

We	O
explored	O
the	O
role	O
of	O
ER	O
-	O
stress	O
as	O
a	O
general	O
mechanism	O
of	O
toxicity	O
by	O
utilizing	O
a	O
high	O
-	O
throughput	O
in	O
vitro	O
assay	O
to	O
screen	O
316	O
chemically	O
diverse	O
Pfizer	O
proprietary	O
compounds	O
with	O
known	O
in	O
vivo	O
toxicity	O
outcome	O
for	O
nuclear	O
accumulation	O
of	O
spliced	O
x	O
-	O
box	O
binding	O
protein	O
1	O
(	O
XBP1s	O
)	O
,	O
a	O
key	O
transcription	O
factor	O
of	O
the	O
unfolded	O
protein	O
response	O
(	O
UPR	O
)	O
.	O

We	O
examined	O
the	O
correlation	O
between	O
physicochemical	O
properties	O
,	O
such	O
as	O
molecular	O
weight	O
,	O
pKA	O
,	O
lipophilicity	O
,	O
topological	O
polar	O
surface	O
area	O
,	O
and	O
passive	O
permeability	O
,	O
as	O
well	O
as	O
target	O
promiscuity	O
,	O
between	O
XBP1s	O
hits	O
and	O
non	O
-	O
hits	O
and	O
found	O
that	O
lipophilicity	O
,	O
target	O
promiscuity	O
and	O
low	O
passive	O
permeability	O
significantly	O
contributed	O
to	O
ER	O
-	O
stress	O
.	O

In	O
addition	O
,	O
we	O
have	O
shown	O
that	O
compounds	O
which	O
cause	O
ER	O
-	O
stress	O
in	O
the	O
form	O
of	O
XBP1s	O
activation	O
at	O
concentrations	O
below	O
40	O
M	O
have	O
a	O
more	O
than	O
four	O
times	O
greater	O
chance	O
of	O
causing	O
in	O
vivo	O
toxicity	O
at	O
10	O
M	O
plasma	O
exposure	O
.	O

Chemical	O
cholecystokinin	O
receptor	O
activation	O
protects	O
against	O
obesity	O
-	O
diabetes	O
in	O
high	O
fat	O
fed	O
mice	O
and	O
has	O
sustainable	O
beneficial	O
effects	O
in	O
genetic	O
ob	O
/	O
ob	O
mice	O
.	O

The	O
current	O
study	O
has	O
determined	O
the	O
ability	O
of	O
(	O
pGlu	O
-	O
Gln	O
)	O
-CCK-8	O
to	O
counter	O
the	O
development	O
of	O
diet	O
-	O
induced	O
obesity	O
-	O
diabetes	O
and	O
examined	O
persistence	O
of	O
beneficial	O
metabolic	O
effects	O
in	O
high	O
fat	O
and	O
ob	O
/	O
ob	O
mice	O
,	O
respectively	O
.	O

Twice	O
daily	O
injection	O
of	O
(	O
pGlu	O
-	O
Gln	O
)	O
-CCK-8	O
in	O
normal	O
mice	O
transferred	O
to	O
a	O
high	O
fat	O
diet	O
reduced	O
energy	O
intake	O
(	O
p	O
<	O
0.001	O
)	O
,	O
body	O
weight	O
(	O
p	O
<	O
0.01	O
)	O
,	O
circulating	O
insulin	O
and	O
LDL	O
-	O
cholesterol	B
(	O
p	O
<	O
0.001	O
)	O
and	O
improved	O
insulin	O
sensitivity	O
(	O
p	O
<	O
0.001	O
)	O
as	O
well	O
as	O
oral	O
and	O
intraperitoneal	O
(	O
p	O
<	O
0.001	O
)	O
glucose	B
tolerance	O
.	O

Energy	O
intake	O
,	O
body	O
weight	O
,	O
circulating	O
insulin	O
and	O
glucose	B
tolerance	O
of	O
(	O
pGlu	O
-	O
Gln	O
)	O
-CCK-8	O
mice	O
were	O
similar	O
to	O
lean	O
controls	O
.	O

In	O
addition	O
,	O
(	O
pGlu	O
-	O
Gln	O
)	O
-CCK-8	O
prevented	O
the	O
effect	O
of	O
high	O
fat	O
feeding	O
on	O
triacylglycerol	B
accumulation	O
in	O
liver	O
and	O
muscle	O
.	O

Interestingly	O
,	O
(	O
pGlu	O
-	O
Gln	O
)	O
-CCK-8	O
significantly	O
(	O
p	O
<	O
0.001	O
)	O
elevated	O
pancreatic	O
glucagon	O
content	O
.	O

Histological	O
examination	O
of	O
the	O
pancreata	O
of	O
(	O
pGlu	O
-	O
Gln	O
)	O
-CCK-8	O
mice	O
revealed	O
no	O
changes	O
in	O
islet	O
number	O
or	O
size	O
,	O
but	O
there	O
was	O
increased	O
turnover	O
of	O
beta	O
-	O
cells	O
with	O
significantly	O
(	O
p	O
<	O
0.001	O
)	O
increased	O
numbers	O
of	O
peripherally	O
located	O
alpha	O
-	O
cells	O
,	O
co	O
-	O
expressing	O
both	O
glucagon	O
and	O
GLP-1	O
.	O

Beneficial	O
metabolic	O
effects	O
were	O
observed	O
similarly	O
in	O
ob	O
/	O
ob	O
mice	O
treated	O
twice	O
daily	O
with	O
(	O
pGlu	O
-	O
Gln	O
)	O
-CCK-8	O
for	O
18	O
days	O
,	O
including	O
significantly	O
reduced	O
energy	O
intake	O
(	O
p	O
<	O
0.05	O
)	O
,	O
body	O
weight	O
(	O
p	O
<	O
0.05	O
to	O
p	O
<	O
0.01	O
)	O
,	O
circulating	O
glucose	B
(	O
p	O
<	O
0.05	O
to	O
p	O
<	O
0.01	O
)	O
and	O
insulin	O
(	O
p	O
<	O
0.05	O
to	O
p	O
<	O
0.001	O
)	O
and	O
improved	O
glucose	B
tolerance	O
(	O
p	O
<	O
0.05	O
)	O
and	O
insulin	O
sensitivity	O
(	O
p	O
<	O
0.001	O
)	O
.	O

Notably	O
,	O
these	O
beneficial	O
effects	O
were	O
still	O
evident	O
18	O
days	O
following	O
cessation	O
of	O
treatment	O
.	O

These	O
studies	O
emphasize	O
the	O
potential	O
of	O
(	O
pGlu	O
-	O
Gln	O
)	O
-CCK-8	O
for	O
the	O
treatment	O
of	O
obesity	O
-	O
diabetes	O
.	O

Effects	O
of	O
DMSA	B
-	O
coated	O
Fe3O4	B
nanoparticles	O
on	O
the	O
transcription	O
of	O
genes	O
related	O
to	O
iron	B
and	O
osmosis	O
homeostasis	O
.	O

In	O
this	O
article	O
,	O
we	O
checked	O
the	O
effect	O
of	O
2,3-dimercaptosuccinic	B
acid	I
-	O
coated	O
Fe	B
(	I
3	I
)	I
O	I
(	I
4	I
)	I
nanoparticles	O
on	O
gene	O
expression	O
of	O
mouse	O
macrophage	O
RAW264.7	O
cells	O
and	O
found	O
that	O
the	O
transcription	O
of	O
several	O
important	O
genes	O
related	O
to	O
intracellular	O
iron	B
homeostasis	O
were	O
significantly	O
changed	O
.	O

We	O
thus	O
speculated	O
that	O
the	O
cellular	O
iron	B
homeostasis	O
might	O
be	O
disturbed	O
by	O
this	O
nanoparticle	O
through	O
releasing	O
iron	B
ion	O
in	O
cells	O
.	O

To	O
verify	O
this	O
speculation	O
,	O
we	O
first	O
confirmed	O
the	O
transcriptional	O
changes	O
of	O
several	O
key	O
iron	B
homeostasis-	O
related	O
genes	O
,	O
such	O
as	O
Tfrc	O
,	O
Trf	O
,	O
and	O
Lcn2	O
,	O
using	O
quantitative	O
PCR	O
,	O
and	O
found	O
that	O
an	O
iron	B
ion	O
chelator	O
,	O
desferrioxamine	B
,	O
could	O
alleviate	O
the	O
transcriptional	O
alterations	O
of	O
two	O
typical	O
genes	O
,	O
Tfrc	O
and	O
Lcn2	O
.	O

Then	O
,	O
we	O
designed	O
and	O
validated	O
a	O
method	O
based	O
on	O
centrifugation	O
for	O
assaying	O
intracellular	O
irons	B
in	O
ion	O
and	O
nanoparticle	O
state	O
.	O

After	O
extensive	O
measures	O
of	O
intracellular	O
iron	B
in	O
two	O
forms	O
and	O
total	O
iron	B
,	O
we	O
found	O
that	O
the	O
intracellular	O
iron	B
ion	O
significantly	O
increased	O
with	O
intracellular	O
total	O
iron	B
and	O
nanoparticle	O
iron	B
,	O
demonstrating	O
degradation	O
of	O
this	O
nanoparticle	O
into	O
iron	B
ion	O
in	O
cells	O
.	O

We	O
next	O
mimicked	O
the	O
intralysosomal	O
environment	O
in	O
vitro	O
and	O
verified	O
that	O
the	O
internalized	O
iron	O
nanoparticle	O
could	O
release	O
iron	B
ion	O
in	O
lysosome	O
.	O

We	O
found	O
that	O
as	O
another	O
important	O
compensatory	O
response	O
to	O
intracellular	O
overload	O
of	O
iron	B
ion	O
,	O
cells	O
significantly	O
downregulated	O
the	O
expressions	O
of	O
genes	O
belonging	O
to	O
solute	O
carrier	O
family	O
which	O
are	O
responsible	O
for	O
transferring	O
many	O
organic	O
solutes	O
into	O
cells	O
,	O
such	O
as	O
Slc5a3	O
and	O
Slc44a1	O
,	O
in	O
order	O
to	O
prevent	O
more	O
organic	O
solutes	O
into	O
cells	O
and	O
thus	O
lower	O
the	O
intracellular	O
osmosis	O
.	O

Based	O
on	O
these	O
findings	O
,	O
we	O
profiled	O
a	O
map	O
of	O
gene	O
effects	O
after	O
cells	O
were	O
treated	O
with	O
this	O
iron	B
nanoparticle	O
and	O
concluded	O
that	O
the	O
iron	B
nanoparticles	O
might	O
be	O
more	O
detrimental	O
to	O
cell	O
than	O
iron	B
ion	O
due	O
to	O
its	O
intracellular	O
internalization	O
fashion	O
,	O
nonspecific	O
endocytosis	O
.	O

Developmental	O
consequences	O
of	O
the	O
ColQ	O
/	O
MuSK	O
interactions	O
.	O

CollagenQ	O
(	O
ColQ	O
)	O
is	O
a	O
specific	O
collagen	O
that	O
anchors	O
acetylcholinesterase	O
(	O
AChE	O
)	O
in	O
the	O
synaptic	O
basal	O
lamina	O
of	O
the	O
neuromuscular	O
junction	O
(	O
NMJ	O
)	O
.	O

Over	O
30	O
mutations	O
in	O
the	O
COLQ	O
gene	O
have	O
been	O
identified	O
that	O
are	O
responsible	O
for	O
a	O
congenital	O
myasthenic	O
syndrome	O
with	O
AChE	O
deficiency	O
,	O
highlighting	O
the	O
importance	O
of	O
this	O
collagen	O
in	O
the	O
physiology	O
of	O
the	O
NMJ	O
.	O

The	O
anchoring	O
of	O
AChE	O
at	O
the	O
synapse	O
requires	O
the	O
interaction	O
of	O
ColQ	O
with	O
MuSK	O
(	O
Muscle	O
-	O
Specific	O
Kinase	O
)	O
,	O
a	O
tyrosine	B
kinase	O
expressed	O
on	O
the	O
muscle	O
membrane	O
that	O
is	O
necessary	O
for	O
the	O
formation	O
and	O
the	O
maintenance	O
of	O
the	O
NMJ	O
.	O

MuSK	O
forms	O
with	O
its	O
co	O
-	O
receptor	O
LRP4	O
,	O
a	O
member	O
of	O
the	O
Low	O
-	O
density	O
Related	O
Protein	O
family	O
,	O
a	O
receptor	O
complex	O
for	O
agrin	O
and	O
Wnts	O
,	O
representing	O
the	O
core	O
system	O
from	O
which	O
the	O
postsynaptic	O
domain	O
is	O
built	O
,	O
the	O
growth	O
cone	O
attracted	O
and	O
the	O
presynaptic	O
element	O
instructed	O
for	O
some	O
aspects	O
of	O
its	O
differentiation	O
.	O

Therefore	O
,	O
the	O
discovery	O
that	O
ColQ	O
binds	O
to	O
MuSK	O
prompted	O
us	O
to	O
study	O
a	O
possible	O
regulatory	O
function	O
of	O
ColQ	O
during	O
NMJ	O
development	O
.	O

In	O
this	O
review	O
,	O
after	O
a	O
brief	O
survey	O
on	O
ColQ	O
,	O
we	O
summarize	O
our	O
recent	O
data	O
demonstrating	O
that	O
ColQ	O
,	O
in	O
addition	O
to	O
its	O
anchoring	O
role	O
,	O
exerts	O
signaling	O
functions	O
and	O
controls	O
some	O
aspects	O
of	O
postsynaptic	O
differentiation	O
such	O
as	O
the	O
clustering	O
of	O
acetylcholine	O
receptors	O
.	O

Our	O
results	O
also	O
strengthen	O
the	O
hypothesis	O
that	O
the	O
defects	O
observed	O
in	O
synaptic	O
congenital	O
myasthenic	O
syndromes	O
might	O
be	O
linked	O
,	O
at	O
least	O
in	O
part	O
,	O
to	O
alterations	O
of	O
ColQ	O
signaling	O
functions	O
and	O
not	O
only	O
to	O
AChE	O
deficiency	O
.	O

Finally	O
,	O
we	O
discuss	O
future	O
research	O
directions	O
to	O
understand	O
how	O
ColQ	O
may	O
modulate	O
the	O
action	O
of	O
the	O
other	O
ligands	O
of	O
the	O
MuSK	O
/	O
LRP4	O
complex	O
and	O
cooperate	O
with	O
them	O
to	O
coordinate	O
the	O
different	O
steps	O
of	O
NMJ	O
formation	O
and	O
maintenance	O
.	O

Enhanced	O
charge	O
carrier	O
mobility	O
in	O
two	O
-	O
dimensional	O
high	O
dielectric	O
molybdenum	B
oxide	I
.	O

We	O
demonstrate	O
that	O
the	O
energy	O
bandgap	O
of	O
layered	O
,	O
high	O
-	O
dielectric	O
	B
-	I
MoO	I
(	I
3	I
)	I
can	O
be	O
reduced	O
to	O
values	O
viable	O
for	O
the	O
fabrication	O
of	O
2D	O
electronic	O
devices	O
.	O

This	O
is	O
achieved	O
through	O
embedding	O
Coulomb	O
charges	O
within	O
the	O
high	O
dielectric	O
media	O
,	O
advantageously	O
limiting	O
charge	O
scattering	O
.	O

As	O
a	O
result	O
,	O
devices	O
with	O
	B
-	I
MoO	I
(	I
3	I
)	I
of	O
11	O
nm	O
thickness	O
and	O
carrier	O
mobilities	O
larger	O
than	O
1100	O
cm	O
(	O
2	O
)	O
V	O
(	O
-1	O
)	O
s	O
(	O
-1	O
)	O
are	O
obtained	O
.	O

Adsorption	O
of	O
multimeric	O
T	O
cell	O
antigens	O
on	O
carbon	B
nanotubes	O
:	O
effect	O
on	O
protein	O
structure	O
and	O
antigen	O
-	O
specific	O
T	O
cell	O
stimulation	O
.	O

Antigen	O
-	O
specific	O
activation	O
of	O
cytotoxic	O
T	O
cells	O
can	O
be	O
enhanced	O
up	O
to	O
three	O
-	O
fold	O
more	O
than	O
soluble	O
controls	O
when	O
using	O
functionalized	O
bundled	O
carbon	B
nanotube	O
substrates	O
(	O
(	O
b	O
)	O
CNTs	O
)	O
.	O

To	O
overcome	O
the	O
denaturing	O
effects	O
of	O
direct	O
adsorption	O
on	O
(	O
b	O
)	O
CNTs	O
,	O
a	O
simple	O
but	O
robust	O
method	O
is	O
demonstrated	O
to	O
stabilize	O
the	O
T	O
cell	O
stimulus	O
on	O
carbon	B
nanotube	O
substrates	O
through	O
non	O
-	O
covalent	O
attachment	O
of	O
the	O
linker	O
neutravidin	O
.	O

Combination	O
lopinavir	B
and	O
ritonavir	B
alter	O
exogenous	O
and	O
endogenous	O
bile	B
acid	I
disposition	O
in	O
sandwich	O
-	O
cultured	O
rat	O
hepatocytes	O
.	O

Inhibition	O
of	O
the	O
bile	B
salt	I
export	O
pump	O
(	O
BSEP	O
)	O
can	O
cause	O
intracellular	O
accumulation	O
of	O
bile	B
acids	I
and	O
is	O
a	O
risk	O
factor	O
for	O
drug	O
-	O
induced	O
liver	O
injury	O
in	O
humans	O
.	O

Antiretroviral	O
protease	O
inhibitors	O
lopinavir	B
(	O
LPV	B
)	O
and	O
ritonavir	B
(	O
RTV	B
)	O
are	O
reported	O
BSEP	O
inhibitors	O
.	O

However	O
,	O
the	O
consequences	O
of	O
LPV	B
and	O
RTV	B
,	O
alone	O
and	O
combined	O
(	O
LPV	B
/	O
r	O
)	O
,	O
on	O
hepatocyte	O
viability	O
,	O
bile	B
acid	I
transport	O
,	O
and	O
endogenous	O
bile	B
acid	I
disposition	O
in	O
rat	O
hepatocytes	O
have	O
not	O
been	O
examined	O
.	O

The	O
effect	O
of	O
LPV	B
,	O
RTV	B
,	O
and	O
LPV	B
/	O
r	O
on	O
cellular	O
viability	O
and	O
the	O
disposition	O
of	O
[	B
(	I
3	I
)	I
H	I
]	I
taurocholic	I
acid	I
(	O
TCA	B
)	O
and	O
[	B
(	I
14	I
)	I
C	I
]	I
chenodeoxycholic	I
acid	I
(	O
CDCA	B
)	O
was	O
determined	O
in	O
sandwich	O
-	O
cultured	O
rat	O
hepatocytes	O
(	O
SCRH	O
)	O
and	O
suspended	O
rat	O
hepatocytes	O
.	O

Lactate	B
dehydrogenase	O
and	O
ATP	B
assays	O
revealed	O
a	O
concentration	O
-	O
dependent	O
effect	O
of	O
LPV	B
and	O
RTV	B
on	O
cellular	O
viability	O
.	O

LPV	B
(	O
5	O
M	O
)	O
,	O
alone	O
and	O
combined	O
with	O
5	O
M	O
RTV	B
,	O
significantly	O
decreased	O
[	B
(	I
3	I
)	I
H	I
]	I
TCA	I
accumulation	O
in	O
cells	O
+	O
bile	O
of	O
SCRHs	O
compared	O
with	O
control	O
.	O

LPV	B
/	O
r	O
significantly	O
increased	O
[	B
(	I
3	I
)	I
H	I
]	I
TCA	I
cellular	O
accumulation	O
(	O
7.7	O
	O
0.1	O
pmol	O
/	O
mg	O
of	O
protein	O
)	O
compared	O
with	O
vehicle	O
and	O
5	O
M	O
LPV	B
alone	O
(	O
5.1	O
	O
0.7	O
and	O
5.0	O
	O
0.5	O
pmol	O
/	O
mg	O
of	O
protein	O
)	O
.	O

The	O
[	B
(	I
3	I
)	I
H	I
]	I
TCA	I
biliary	O
clearance	O
was	O
reduced	O
significantly	O
by	O
LPV	B
and	O
RTV	B
and	O
further	O
reduced	O
by	O
LPV	B
/	O
r	O
.	O

LPV	B
and	O
RTV	B
did	O
not	O
affect	O
the	O
initial	O
uptake	O
rates	O
of	O
[	B
(	I
3	I
)	I
H	I
]	I
TCA	I
or	O
[	B
(	I
14	I
)	I
C	I
]	I
CDCA	I
in	O
suspended	O
rat	O
hepatocytes	O
.	O

LPV	B
(	O
50	O
M	O
)	O
,	O
RTV	B
(	O
5	O
M	O
)	O
,	O
and	O
LPV	B
/	O
r	O
(	O
5	O
and	O
50	O
M	O
/	O
5	O
M	O
)	O
significantly	O
decreased	O
the	O
accumulation	O
of	O
total	O
measured	O
endogenous	O
bile	B
acids	I
(	O
TCA	B
,	O
glycocholic	B
acid	I
,	O
taurochenodeoxycholic	B
acid	I
,	O
glycochenodeoxycholic	B
acid	I
,	O
and	O
	B
/	I
	I
-	I
tauromuricholic	I
acid	I
)	O
in	O
SCRH	O
.	O

Quantification	O
of	O
endogenous	O
bile	B
acids	I
in	O
SCRH	O
may	O
reveal	O
important	O
adaptive	O
responses	O
associated	O
with	O
exposure	O
to	O
known	O
BSEP	O
inhibitors	O
.	O

Phosphoinositide	O
-	O
dependent	O
kinase-1	O
and	O
protein	O
kinase	O
C	O
contribute	O
to	O
endothelin-1	O
constriction	O
and	O
elevated	O
blood	O
pressure	O
in	O
intermittent	O
hypoxia	O
.	O

Obstructive	O
sleep	O
apnea	O
(	O
OSA	O
)	O
is	O
associated	O
with	O
cardiovascular	O
complications	O
including	O
hypertension	O
.	O

Previous	O
findings	O
from	O
our	O
laboratory	O
indicate	O
that	O
exposure	O
to	O
intermittent	O
hypoxia	O
(	O
IH	O
)	O
,	O
to	O
mimic	O
sleep	O
apnea	O
,	O
increases	O
blood	O
pressure	O
in	O
rats	O
.	O

IH	O
also	O
increases	O
endothelin-1	O
(	O
ET-1	O
)	O
constrictor	O
sensitivity	O
in	O
a	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
	O
-	O
dependent	O
manner	O
in	O
mesenteric	O
arteries	O
.	O

Because	O
phosphoinositide	O
-	O
dependent	O
kinase-1	O
(	O
PDK-1	O
)	O
regulates	O
PKC	O
activity	O
,	O
we	O
hypothesized	O
that	O
PDK-1	O
contributes	O
to	O
the	O
augmented	O
ET-1	O
constrictor	O
sensitivity	O
and	O
elevated	O
blood	O
pressure	O
following	O
IH	O
.	O

Male	O
Sprague	O
-	O
Dawley	O
rats	O
were	O
exposed	O
to	O
either	O
sham	O
or	O
IH	O
(	O
cycles	O
between	O
21	O
%	O
O	B
(	I
2	I
)	I
/	O
0	O
%	O
CO	B
(	I
2	I
)	I
and	O
5	O
%	O
O	B
(	I
2	I
)	I
/	O
5	O
%	O
CO	B
(	I
2	I
)	I
)	O
conditions	O
for	O
7	O
h	O
/	O
day	O
for	O
14	O
or	O
21	O
days	O
.	O

The	O
contribution	O
of	O
PKC	O
and	O
PDK-1	O
to	O
ET-1-mediated	O
vasoconstriction	O
was	O
assessed	O
in	O
mesenteric	O
arteries	O
using	O
pharmacological	O
inhibitors	O
.	O

Constrictor	O
sensitivity	O
to	O
ET-1	O
was	O
enhanced	O
in	O
arteries	O
from	O
IH	O
-	O
exposed	O
rats	O
.	O

Inhibition	O
of	O
PKC	O
or	O
PDK-1	O
blunted	O
ET-1	O
constriction	O
in	O
arteries	O
from	O
IH	O
but	O
not	O
sham	O
group	O
rats	O
.	O

Western	O
analysis	O
revealed	O
similar	O
levels	O
of	O
total	O
and	O
phosphorylated	O
PDK-1	O
in	O
arteries	O
from	O
sham	O
and	O
IH	O
group	O
rats	O
but	O
decreased	O
protein	O
-	O
protein	O
interaction	O
between	O
PKC	O
and	O
PDK-1	O
in	O
arteries	O
from	O
IH-	O
compared	O
with	O
sham	O
-	O
exposed	O
rats	O
.	O

Blood	O
pressure	O
was	O
increased	O
in	O
rats	O
exposed	O
to	O
IH	O
,	O
and	O
treatment	O
with	O
the	O
PDK-1	O
inhibitor	O
OSU-03012	B
[	O
2-amino	B
-	I
N-	I
{	I
4-	I
[	I
5-	I
(	I
2-phenanthrenyl	I
)	I
-3-	I
(	I
trifluoromethyl	I
)	I
-1H	I
-	I
pyrazol-1-yl	I
]	I
-phenyl	I
}	I
-acetamide	I
]	O
(	O
33	O
mg	O
/	O
day	O
)	O
lowered	O
blood	O
pressure	O
in	O
IH	O
but	O
not	O
sham	O
group	O
rats	O
.	O

Our	O
results	O
suggest	O
that	O
exposure	O
to	O
IH	O
unmasks	O
a	O
role	O
for	O
PDK-1	O
in	O
regulating	O
ET-1	O
constrictor	O
sensitivity	O
and	O
blood	O
pressure	O
that	O
is	O
not	O
present	O
under	O
normal	O
conditions	O
.	O

These	O
novel	O
findings	O
suggest	O
that	O
PDK-1	O
may	O
be	O
a	O
uniquely	O
effective	O
antihypertensive	O
therapy	O
for	O
OSA	O
patients	O
.	O

Mouse	O
liver	O
protein	O
sulfhydryl	B
depletion	O
after	O
acetaminophen	B
exposure	O
.	O

Acetaminophen	B
(	O
APAP	B
)	O
-induced	O
liver	O
injury	O
is	O
the	O
leading	O
cause	O
of	O
acute	O
liver	O
failure	O
in	O
many	O
countries	O
.	O

This	O
study	O
determined	O
the	O
extent	O
of	O
liver	O
protein	O
sulfhydryl	B
depletion	O
not	O
only	O
in	O
whole	O
liver	O
homogenate	O
but	O
also	O
in	O
the	O
zonal	O
pattern	O
of	O
sulfhydryl	B
depletion	O
within	O
the	O
liver	O
lobule	O
.	O

A	O
single	O
oral	O
gavage	O
dose	O
of	O
150	O
or	O
300	O
mg	O
/	O
kg	O
APAP	B
in	O
B6C3F1	O
mice	O
produced	O
increased	O
serum	O
alanine	B
aminotransferase	O
levels	O
,	O
liver	O
necrosis	O
,	O
and	O
glutathione	B
depletion	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Free	O
protein	O
sulfhydryls	B
were	O
measured	O
in	O
liver	O
protein	O
homogenates	O
by	O
labeling	O
with	O
maleimide	B
linked	O
to	O
a	O
near	O
infrared	O
fluorescent	O
dye	O
followed	O
by	O
SDS	B
-	O
polyacrylamide	B
gel	O
electrophoresis	O
.	O

Global	O
protein	O
sulfhydryl	B
levels	O
were	O
decreased	O
significantly	O
(	O
48.4	O
%	O
)	O
starting	O
at	O
1	O
hour	O
after	O
the	O
APAP	B
dose	O
and	O
maintained	O
at	O
this	O
reduced	O
level	O
through	O
24	O
hours	O
.	O

To	O
visualize	O
the	O
specific	O
hepatocytes	O
that	O
had	O
reduced	O
protein	O
sulfhydryl	B
levels	O
,	O
frozen	O
liver	O
sections	O
were	O
labeled	O
with	O
maleimide	B
linked	O
to	O
horseradish	O
peroxidase	O
.	O

The	O
centrilobular	O
areas	O
exhibited	O
dramatic	O
decreases	O
in	O
free	O
protein	O
sulfhydryls	B
while	O
the	O
periportal	O
regions	O
were	O
essentially	O
spared	O
.	O

These	O
protein	O
sulfhydryl	B
-	O
depleted	O
regions	O
correlated	O
with	O
areas	O
exhibiting	O
histopathologic	O
injury	O
and	O
APAP	B
binding	O
to	O
protein	O
.	O

The	O
majority	O
of	O
protein	O
sulfhydryl	B
depletion	O
was	O
due	O
to	O
reversible	O
oxidation	O
since	O
the	O
global-	O
and	O
lobule	O
-	O
specific	O
effects	O
were	O
essentially	O
reversed	O
when	O
the	O
samples	O
were	O
reduced	O
with	O
tris	B
(	I
2-carboxyethy	I
)	I
phosphine	I
before	O
maleimide	B
labeling	O
.	O

These	O
temporal	O
and	O
zonal	O
pattern	O
changes	O
in	O
protein	O
sulfhydryl	B
oxidation	O
shed	O
new	O
light	O
on	O
the	O
importance	O
that	O
changes	O
in	O
protein	O
redox	O
status	O
might	O
play	O
in	O
the	O
pathogenesis	O
of	O
APAP	B
hepatotoxicity	O
.	O

Dietary	O
exposure	O
to	O
inorganic	O
arsenic	B
of	O
the	O
Hong	O
Kong	O
population	O
:	O
results	O
of	O
the	O
first	O
Hong	O
Kong	O
total	O
diet	O
study	O
.	O

Inorganic	O
arsenic	B
,	O
a	O
human	O
carcinogen	O
,	O
can	O
be	O
found	O
in	O
the	O
environment	O
and	O
food	O
.	O

In	O
the	O
first	O
Hong	O
Kong	O
Total	O
Diet	O
Study	O
,	O
the	O
dietary	O
exposure	O
of	O
the	O
Hong	O
Kong	O
people	O
,	O
including	O
various	O
age	O
-	O
gender	O
subgroups	O
,	O
to	O
inorganic	O
arsenic	B
was	O
estimated	O
for	O
assessing	O
the	O
associated	O
health	O
risk	O
.	O

Food	O
samples	O
,	O
which	O
represented	O
the	O
Hong	O
Kong	O
people	O
's	O
diet	O
,	O
were	O
collected	O
and	O
prepared	O
"	O
as	O
consumed	O
"	O
for	O
analysis	O
.	O

Concentrations	O
of	O
inorganic	O
arsenic	B
,	O
as	O
sum	O
of	O
arsenite	B
(	O
As	B
(	I
III	I
)	I
)	O
and	O
arsenate	B
(	O
As	B
(	I
V	I
)	I
)	O
were	O
determined	O
in	O
600	O
composite	O
samples	O
by	O
using	O
inductively	O
coupled	O
plasma	O
mass	O
spectrometry	O
.	O

The	O
dietary	O
exposures	O
were	O
estimated	O
by	O
combining	O
the	O
analytical	O
results	O
with	O
the	O
local	O
food	O
consumption	O
data	O
of	O
the	O
adult	O
population	O
.	O

The	O
mean	O
and	O
95th	O
percentile	O
of	O
inorganic	O
arsenic	B
exposures	O
of	O
the	O
Hong	O
Kong	O
people	O
were	O
0.22	O
and	O
0.38g	O
/	O
kg	O
body	O
weight	O
(	O
bw	O
)	O
/	O
day	O
,	O
respectively	O
.	O

Among	O
the	O
12	O
age	O
-	O
gender	O
subgroups	O
,	O
the	O
respective	O
exposures	O
ranged	O
from	O
0.19	O
to	O
0.26g	O
/	O
kg	O
bw	O
/	O
day	O
and	O
from	O
0.33	O
to	O
0.46g	O
/	O
kg	O
bw	O
/	O
day	O
.	O

The	O
main	O
food	O
category	O
that	O
contributed	O
inorganic	O
arsenic	B
was	O
"	O
cereals	O
and	O
their	O
products	O
"	O
(	O
53.5	O
%	O
of	O
the	O
total	O
exposure	O
)	O
,	O
particularly	O
rice	O
.	O

Having	O
considered	O
the	O
carcinogenic	O
risk	O
of	O
inorganic	O
arsenic	B
to	O
humans	O
,	O
it	O
is	O
suggested	O
that	O
efforts	O
should	O
be	O
made	O
to	O
reduce	O
the	O
inorganic	O
arsenic	B
exposure	O
of	O
the	O
Hong	O
Kong	O
population	O
.	O

Reelin	O
supplementation	O
recovers	O
sensorimotor	O
gating	O
,	O
synaptic	O
plasticity	O
and	O
associative	O
learning	O
deficits	O
in	O
the	O
heterozygous	O
reeler	O
mouse	O
.	O

The	O
lipoprotein	O
receptor	O
ligand	O
Reelin	O
is	O
important	O
for	O
the	O
processes	O
of	O
normal	O
synaptic	O
plasticity	O
,	O
dendritic	O
morphogenesis	O
,	O
and	O
learning	O
and	O
memory	O
.	O

Heterozygous	O
reeler	O
mice	O
(	O
HRM	O
)	O
show	O
many	O
neuroanatomical	O
,	O
biochemical	O
,	O
and	O
behavioral	O
features	O
that	O
are	O
associated	O
with	O
schizophrenia	O
.	O

HRM	O
show	O
subtle	O
morphological	O
defects	O
including	O
reductions	O
in	O
dendritic	O
spine	O
density	O
,	O
altered	O
synaptic	O
plasticity	O
and	O
behavioral	O
deficits	O
in	O
associative	O
learning	O
and	O
memory	O
and	O
pre	O
-	O
pulse	O
inhibition	O
.	O

The	O
present	O
studies	O
test	O
the	O
hypothesis	O
that	O
in	O
vivo	O
elevation	O
of	O
Reelin	O
levels	O
can	O
rescue	O
synaptic	O
and	O
behavioral	O
phenotypes	O
associated	O
with	O
HRM	O
.	O

We	O
demonstrate	O
that	O
a	O
single	O
in	O
vivo	O
injection	O
of	O
Reelin	O
increases	O
GAD67	O
expression	O
and	O
alters	O
dendritic	O
spine	O
morphology	O
.	O

In	O
parallel	O
we	O
observed	O
enhancement	O
of	O
hippocampal	O
synaptic	O
function	O
and	O
associative	O
learning	O
and	O
memory	O
.	O

Reelin	O
supplementation	O
also	O
increases	O
pre	O
-	O
pulse	O
inhibition	O
.	O

These	O
results	O
suggest	O
that	O
characteristics	O
of	O
HRM	O
,	O
similar	O
to	O
those	O
observed	O
in	O
schizophrenia	O
,	O
are	O
sensitive	O
to	O
Reelin	O
levels	O
and	O
can	O
be	O
modified	O
with	O
Reelin	O
supplementation	O
in	O
male	O
and	O
female	O
adults	O
.	O

Identification	O
of	O
two	O
-	O
component	O
system	O
AfsQ1	O
/	O
Q2	O
regulon	O
and	O
its	O
cross	O
-	O
regulation	O
with	O
GlnR	O
in	O
Streptomyces	O
coelicolor	O
.	O

The	O
two	O
-	O
component	O
system	O
AfsQ1	O
/	O
Q2	O
of	O
Streptomyces	O
coelicolor	O
was	O
identified	O
in	O
our	O
previous	O
work	O
as	O
a	O
pleiotropic	O
regulator	O
for	O
antibiotic	O
biosynthesis	O
and	O
morphological	O
differentiation	O
under	O
the	O
condition	O
of	O
a	O
minimal	O
medium	O
supplemented	O
with	O
75	O
mM	O
glutamate	B
.	O

In	O
this	O
work	O
,	O
we	O
report	O
the	O
dissection	O
of	O
the	O
mechanism	O
underlying	O
the	O
function	O
of	O
AfsQ1	O
/	O
Q2	O
on	O
antibiotic	O
production	O
and	O
also	O
the	O
identification	O
of	O
the	O
AfsQ1	O
/	O
Q2	O
regulon	O
.	O

The	O
results	O
showed	O
that	O
AfsQ1	O
/	O
Q2	O
stimulated	O
antibiotic	O
ACT	O
,	O
RED	O
and	O
CDA	O
production	O
directly	O
through	O
the	O
pathway	O
-	O
specific	O
activator	O
genes	O
actII	O
-	O
ORF4	O
,	O
redZ	O
and	O
cdaR	O
respectively	O
.	O

In	O
addition	O
,	O
expression	O
of	O
sigQ	O
that	O
encodes	O
a	O
sigma	O
factor	O
and	O
is	O
divergently	O
transcribed	O
from	O
afsQ1	O
was	O
also	O
subject	O
to	O
direct	O
regulation	O
by	O
AfsQ1	O
/	O
Q2	O
.	O

The	O
precise	O
AfsQ1	O
binding	O
sites	O
in	O
the	O
upstream	O
regions	O
of	O
these	O
target	O
genes	O
were	O
determined	O
by	O
DNase	O
I	O
footprinting	O
assays	O
coupled	O
with	O
site	O
-	O
directed	O
DNA	O
mutagenesis	O
.	O

By	O
computational	O
prediction	O
and	O
functional	O
analysis	O
,	O
at	O
least	O
17	O
new	O
AfsQ1	O
targets	O
were	O
identified	O
,	O
including	O
pstS	O
gene	O
encoding	O
a	O
high	O
-	O
affinity	O
phosphate	B
-	O
binding	O
protein	O
and	O
two	O
developmental	O
genes	O
whiD	O
,	O
bldM.	O
For	O
the	O
AfsQ1	O
/	O
Q2	O
regulon	O
,	O
an	O
AfsQ1	O
binding	O
motif	O
comprising	O
the	O
sequence	O
GTnAC	O
-	O
n	O
(	O
6	O
)	O
-GTnAC	O
has	O
been	O
defined	O
.	O

Interestingly	O
,	O
we	O
found	O
from	O
electrophoretic	O
mobility	O
shift	O
assays	O
and	O
transcriptional	O
analysis	O
that	O
AfsQ1	O
/	O
Q2	O
can	O
also	O
function	O
as	O
a	O
repressor	O
for	O
nitrogen	B
assimilation	O
,	O
and	O
AfsQ1	O
can	O
compete	O
with	O
GlnR	O
for	O
the	O
promoter	O
regions	O
of	O
glnA	O
and	O
nirB	O
,	O
suggesting	O
the	O
cross	O
-	O
regulation	O
between	O
AfsQ1	O
/	O
Q2	O
and	O
GlnR	O
in	O
nitrogen	B
metabolism	O
.	O

These	O
findings	O
suggested	O
that	O
AfsQ1	O
/	O
Q2	O
is	O
important	O
not	O
only	O
for	O
antibiotic	O
biosynthesis	O
but	O
also	O
in	O
maintaining	O
the	O
metabolic	O
homeostasis	O
of	O
nutrient	O
utilization	O
under	O
the	O
stress	O
of	O
high	O
concentration	O
of	O
glutamate	B
in	O
S.	O
coelicolor	O
.	O

Synthesis	O
and	O
chiral	O
recognition	O
of	O
nickel	B
(	I
II	I
)	I
macrocyclic	O
complex	O
with	O
(	B
R	I
)	I
-naphthylethyleneamine	I
pendant	O
groups	O
and	O
its	O
self	O
-	O
assembled	O
framework	O
.	O

A	O
novel	O
nickel	B
(	I
II	I
)	I
hexaaza	I
macrocyclic	O
complex	O
,	O
[	B
Ni	I
(	I
L	I
(	I
R	I
,	I
R	I
)	I
)	I
]	I
(	I
ClO	I
(	I
4	I
)	I
)	I
(	I
2	I
)	I
(	O
1	O
)	O
,	O
containing	O
chiral	O
pendant	O
groups	O
was	O
synthesized	O
by	O
an	O
efficient	O
one	O
-	O
pot	O
template	O
condensation	O
and	O
characterized	O
(	O
L	O
(	O
R	O
,	O
R	O
)	O
	O
1,8-di	B
(	I
(	I
R	I
)	I
-	I
-	I
methylnaphthyl	I
)	I
-1,3,6,8,10,13-hexaazacyclotetradecane	I
)	O
.	O

The	O
crystal	O
structure	O
of	O
compound	O
1	O
was	O
determined	O
by	O
single	O
-	O
crystal	O
X	O
-	O
ray	O
analysis	O
.	O

The	O
complex	O
was	O
found	O
to	O
have	O
a	O
square	O
-	O
planar	O
coordination	O
environment	O
for	O
the	O
nickel	B
(	I
II	I
)	I
ion	O
.	O

Open	O
framework	O
[	B
Ni	I
(	I
L	I
(	I
R	I
,	I
R	I
)	I
)	I
]	I
(	I
3	I
)	I
[	I
C	I
(	I
6	I
)	I
H	I
(	I
3	I
)	I
(	I
COO	I
)	I
(	I
3	I
)	I
]	I
(	I
2	I
)	I
(	O
2	O
)	O
was	O
constructed	O
from	O
the	O
self	O
-	O
assembly	O
of	O
compound	O
1	O
with	O
deprotonated	O
1,3,5-benzenetricarboxylic	B
acid	I
,	O
BTC	B
(	I
3-	I
)	I
.	O

Chiral	O
discrimination	O
of	O
rac-1,1'-bi-2-naphthol	B
and	O
rac-2,2,2-trifluoro-1-	B
(	I
9-anthryl	I
)	I
ethanol	I
was	O
performed	O
to	O
determine	O
the	O
chiral	O
recognition	O
ability	O
of	O
the	O
chiral	O
complex	O
(	O
1	O
)	O
and	O
its	O
self	O
-	O
assembled	O
framework	O
(	O
2	O
)	O
.	O

Binaphthol	B
showed	O
a	O
good	O
chiral	O
discrimination	O
on	O
the	O
framework	O
(	O
2	O
)	O
.	O

The	O
optimum	O
experimental	O
conditions	O
for	O
the	O
chiral	O
discrimination	O
were	O
examined	O
by	O
changing	O
the	O
weight	O
ratio	O
between	O
the	O
macrocyclic	O
complex	O
1	O
or	O
self	O
-	O
assembled	O
framework	O
2	O
and	O
racemates	O
.	O

The	O
detailed	O
synthetic	O
procedures	O
,	O
spectroscopic	O
data	O
including	O
single	O
-	O
crystal	O
X	O
-	O
ray	O
analysis	O
,	O
and	O
the	O
results	O
of	O
the	O
chiral	O
recognition	O
for	O
the	O
compounds	O
are	O
described	O
.	O

Sclerostin	O
antibody	O
treatment	O
improves	O
bone	O
mass	O
,	O
bone	O
strength	O
,	O
and	O
bone	O
defect	O
regeneration	O
in	O
rats	O
with	O
type	O
2	O
diabetes	O
mellitus	O
.	O

Type	O
2	O
diabetes	O
mellitus	O
results	O
in	O
increased	O
risk	O
of	O
fracture	O
and	O
delayed	O
fracture	O
healing	O
.	O

ZDF	O
fa	O
/	O
fa	O
rats	O
are	O
an	O
established	O
model	O
of	O
type	O
2	O
diabetes	O
mellitus	O
with	O
low	O
bone	O
mass	O
and	O
delayed	O
bone	O
healing	O
.	O

We	O
tested	O
whether	O
a	O
sclerostin	O
-	O
neutralizing	O
antibody	O
(	O
Scl	O
-	O
AbVI	O
)	O
would	O
reverse	O
the	O
skeletal	O
deficits	O
of	O
diabetic	O
ZDF	O
rats	O
.	O

Femoral	O
defects	O
of	O
3	O
mm	O
were	O
created	O
in	O
11-week	O
-	O
old	O
diabetic	O
ZDF	O
fa	O
/	O
fa	O
and	O
nondiabetic	O
ZDF	O
+	O
/+	O
rats	O
and	O
stabilized	O
by	O
an	O
internal	O
plate	O
.	O

Saline	O
or	O
25	O
mg	O
/	O
kg	O
Scl	O
-	O
AbVI	O
was	O
administered	O
subcutaneously	O
(	O
s.c	O
.	O
)	O
twice	O
weekly	O
for	O
12	O
weeks	O
(	O
n	O
=	O
9	O
-	O
10	O
/	O
group	O
)	O
.	O

Bone	O
mass	O
and	O
strength	O
were	O
assessed	O
using	O
pQCT	O
,	O
micro	O
-	O
computed	O
tomography	O
(	O
CT	O
)	O
,	O
and	O
biomechanical	O
testing	O
.	O

Bone	O
histomorphometry	O
was	O
used	O
to	O
assess	O
bone	O
formation	O
,	O
and	O
the	O
filling	O
of	O
the	O
bone	O
defect	O
was	O
analyzed	O
by	O
CT	O
.	O

Diabetic	O
rats	O
displayed	O
lower	O
spinal	O
and	O
femoral	O
bone	O
mass	O
compared	O
to	O
nondiabetic	O
rats	O
,	O
and	O
Scl	O
-	O
AbVI	O
treatment	O
significantly	O
enhanced	O
bone	O
mass	O
of	O
the	O
femur	O
and	O
the	O
spine	O
of	O
diabetic	O
rats	O
(	O
p	O
<	O
0.0001	O
)	O
.	O

Scl	O
-	O
AbVI	O
also	O
reversed	O
the	O
deficit	O
in	O
bone	O
strength	O
in	O
the	O
diabetic	O
rats	O
,	O
with	O
65	O
%	O
and	O
89	O
%	O
increases	O
in	O
maximum	O
load	O
at	O
the	O
femoral	O
shaft	O
and	O
neck	O
,	O
respectively	O
(	O
p	O
<	O
0.0001	O
)	O
.	O

The	O
lower	O
bone	O
mass	O
in	O
diabetic	O
rats	O
was	O
associated	O
with	O
a	O
65	O
%	O
decrease	O
in	O
vertebral	O
bone	O
formation	O
rate	O
,	O
which	O
Scl	O
-	O
AbVI	O
increased	O
by	O
sixfold	O
,	O
consistent	O
with	O
a	O
pronounced	O
anabolic	O
effect	O
.	O

Nondiabetic	O
rats	O
filled	O
57	O
%	O
of	O
the	O
femoral	O
defect	O
,	O
whereas	O
diabetic	O
rats	O
filled	O
only	O
21	O
%	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Scl	O
-	O
AbVI	O
treatment	O
increased	O
defect	O
regeneration	O
by	O
47	O
%	O
and	O
74	O
%	O
,	O
respectively	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Sclerostin	O
antibody	O
treatment	O
reverses	O
the	O
adverse	O
effects	O
of	O
type	O
2	O
diabetes	O
mellitus	O
on	O
bone	O
mass	O
and	O
strength	O
,	O
and	O
improves	O
bone	O
defect	O
regeneration	O
in	O
rats	O
.	O

SPIDIA	O
-	O
RNA	O
:	O
first	O
external	O
quality	O
assessment	O
for	O
the	O
pre	O
-	O
analytical	O
phase	O
of	O
blood	O
samples	O
used	O
for	O
RNA	O
based	O
analyses	O
.	O

The	O
diagnostic	O
use	O
of	O
in	O
vitro	O
molecular	O
assays	O
can	O
be	O
limited	O
by	O
the	O
lack	O
of	O
guidelines	O
for	O
collection	O
,	O
handling	O
,	O
stabilization	O
and	O
storage	O
of	O
patient	O
specimens	O
.	O

One	O
of	O
the	O
major	O
goals	O
of	O
the	O
EC	O
funded	O
project	O
SPIDIA	O
(	O
www.spidia.eu	O
)	O
is	O
to	O
develop	O
evidence	O
-	O
based	O
quality	O
guidelines	O
for	O
the	O
pre	O
-	O
analytical	O
phase	O
of	O
blood	O
samples	O
used	O
for	O
molecular	O
testing	O
which	O
requires	O
intracellular	O
RNA	O
analytes	O
.	O

To	O
this	O
end	O
,	O
a	O
survey	O
and	O
a	O
pan	O
-	O
European	O
external	O
quality	O
assessment	O
(	O
EQA	O
)	O
were	O
implemented	O
.	O

This	O
report	O
is	O
the	O
summary	O
of	O
the	O
results	O
of	O
that	O
trial	O
.	O

With	O
the	O
European	O
Federation	O
of	O
Laboratory	O
Medicine	O
(	O
EFLM	O
)	O
support	O
,	O
124	O
applications	O
for	O
participation	O
in	O
the	O
trial	O
were	O
received	O
from	O
27	O
different	O
European	O
countries	O
,	O
and	O
102	O
laboratories	O
actually	O
participated	O
in	O
the	O
trial	O
.	O

Each	O
participating	O
laboratory	O
described	O
their	O
respective	O
laboratory	O
policies	O
and	O
practices	O
as	O
well	O
as	O
blood	O
collection	O
tubes	O
typically	O
used	O
in	O
performing	O
this	O
type	O
of	O
testing	O
.	O

The	O
participating	O
laboratories	O
received	O
two	O
identical	O
blood	O
specimens	O
:	O
in	O
an	O
EDTA	B
tubes	O
(	O
unstabilized	O
blood	O
;	O
n=67	O
)	O
or	O
in	O
tubes	O
designed	O
specifically	O
for	O
the	O
stabilization	O
of	O
intracellular	O
RNA	O
in	O
blood	O
(	O
PAXgene	O
	O
Blood	O
RNA	O
tubes	O
;	O
n=35	O
)	O
.	O

Laboratories	O
were	O
requested	O
to	O
perform	O
RNA	O
extraction	O
according	O
to	O
the	O
laboratory	O
's	O
own	O
procedure	O
as	O
soon	O
as	O
possible	O
upon	O
receipt	O
of	O
the	O
tubes	O
for	O
one	O
tube	O
and	O
24h	O
after	O
the	O
first	O
extraction	O
for	O
the	O
second	O
tube	O
.	O

Participants	O
(	O
n=93	O
)	O
returned	O
the	O
two	O
extracted	O
RNAs	O
to	O
SPIDIA	O
facility	O
for	O
analysis	O
,	O
and	O
provided	O
details	O
about	O
the	O
reagents	O
and	O
protocols	O
they	O
used	O
for	O
the	O
extraction	O
.	O

At	O
the	O
SPIDIA	O
facility	O
responsible	O
for	O
coordinating	O
the	O
study	O
,	O
the	O
survey	O
data	O
were	O
classified	O
,	O
and	O
the	O
extracted	O
RNA	O
samples	O
were	O
evaluated	O
for	O
purity	O
,	O
yield	O
,	O
integrity	O
,	O
stability	O
,	O
and	O
the	O
presence	O
of	O
interfering	O
substances	O
affecting	O
RT	O
-	O
qPCR	O
assays	O
.	O

All	O
participants	O
received	O
a	O
report	O
comparing	O
the	O
performance	O
of	O
the	O
RNA	O
they	O
submitted	O
to	O
that	O
of	O
the	O
other	O
participants	O
.	O

All	O
the	O
results	O
obtained	O
by	O
participants	O
for	O
each	O
RNA	O
quality	O
parameter	O
were	O
classified	O
as	O
"	O
in	O
control	O
"	O
,	O
"	O
warning	O
"	O
,	O
"	O
out	O
of	O
control	O
"	O
and	O
"	O
missing	O
"	O
by	O
consensus	O
mean	O
analysis	O
.	O

From	O
the	O
survey	O
data	O
,	O
the	O
most	O
variable	O
parameters	O
were	O
the	O
volume	O
of	O
blood	O
collected	O
and	O
the	O
time	O
and	O
storage	O
temperature	O
between	O
blood	O
collection	O
and	O
RNA	O
extraction	O
.	O

Analyzing	O
the	O
results	O
of	O
quality	O
testing	O
of	O
submitted	O
RNA	O
samples	O
we	O
observed	O
a	O
data	O
distribution	O
of	O
purity	O
,	O
yield	O
,	O
and	O
presence	O
of	O
assay	O
interference	O
in	O
agreement	O
with	O
expected	O
values	O
.	O

The	O
RNA	O
Integrity	O
Number	O
(	O
RIN	O
)	O
values	O
distribution	O
was	O
,	O
on	O
the	O
other	O
hand	O
,	O
much	O
wider	O
than	O
the	O
optimal	O
expected	O
value	O
,	O
which	O
led	O
to	O
an	O
"	O
in	O
control	O
"	O
classification	O
,	O
even	O
for	O
partly	O
degraded	O
RNA	O
samples	O
.	O

On	O
the	O
other	O
hand	O
,	O
RIN	O
values	O
below	O
5	O
significantly	O
correlated	O
with	O
a	O
reduction	O
of	O
GAPDH	O
expression	O
levels	O
.	O

Furthermore	O
,	O
the	O
distribution	O
of	O
the	O
values	O
of	O
the	O
four	O
transcripts	O
investigated	O
(	O
c	O
-	O
fos	O
,	O
IL-1	O
,	O
IL-8	O
,	O
and	O
GAPDH	O
)	O
was	O
wide	O
and	O
the	O
RNA	O
instability	O
between	O
samples	O
separated	O
by	O
24h	O
were	O
similar	O
.	O

Assuming	O
the	O
presence	O
of	O
at	O
least	O
two	O
quality	O
parameters	O
"	O
out	O
of	O
control	O
"	O
as	O
an	O
indication	O
of	O
a	O
critical	O
performance	O
of	O
the	O
laboratory	O
,	O
33	O
%	O
of	O
the	O
laboratories	O
were	O
included	O
in	O
this	O
group	O
.	O

The	O
results	O
of	O
this	O
study	O
will	O
be	O
the	O
basis	O
for	O
implementing	O
a	O
second	O
pan	O
-	O
European	O
EQA	O
and	O
the	O
results	O
of	O
both	O
EQAs	O
will	O
be	O
pooled	O
and	O
will	O
provide	O
the	O
basis	O
for	O
the	O
implementation	O
of	O
evidence	O
-	O
based	O
guidelines	O
for	O
the	O
pre	O
-	O
analytical	O
phase	O
of	O
RNA	O
analysis	O
of	O
blood	O
samples	O
.	O

Reversal	O
of	O
efflux	O
mediated	O
antifungal	O
resistance	O
underlies	O
synergistic	O
activity	O
of	O
two	O
monoterpenes	B
with	O
fluconazole	B
.	O

Thymol	B
(	O
THY	B
)	O
and	O
carvacrol	B
(	O
CARV	B
)	O
,	O
the	O
principal	O
chemical	O
components	O
of	O
thyme	O
oil	O
have	O
long	O
been	O
known	O
for	O
their	O
wide	O
use	O
in	O
medicine	O
due	O
to	O
antimicrobial	O
and	O
disinfectant	O
properties	O
.	O

This	O
study	O
,	O
however	O
,	O
draws	O
attention	O
to	O
a	O
possible	O
synergistic	O
antifungal	O
effect	O
of	O
these	O
monoterpenes	B
with	O
azole	B
antimycotic	O
-	O
fluconazole	B
.	O

Resistance	O
to	O
azoles	B
in	O
Candida	O
albicans	O
involves	O
over	O
-	O
expression	O
of	O
efflux	O
-	O
pump	O
genes	O
MDR1	O
,	O
CDR1	O
,	O
CDR2	O
or	O
mutations	O
and	O
over	O
-	O
expression	O
of	O
target	O
gene	O
ERG11	O
.	O

The	O
inhibition	O
of	O
drug	O
efflux	O
pumps	O
is	O
considered	O
a	O
feasible	O
strategy	O
to	O
overcome	O
clinical	O
antifungal	O
resistance	O
.	O

To	O
put	O
forward	O
this	O
approach	O
,	O
we	O
investigated	O
the	O
combination	O
effects	O
of	O
these	O
monoterpenes	B
and	O
FLC	B
against	O
38	O
clinically	O
obtained	O
FLC	B
-	O
sensitive	O
,	O
and	O
eleven	O
FLC	B
-	O
resistant	O
Candida	O
isolates	O
.	O

Synergism	O
was	O
observed	O
with	O
combinations	O
of	O
THY	B
-	O
FLC	B
and	O
CARV	B
-	O
FLC	B
evaluated	O
by	O
checkerboard	O
microdilution	O
method	O
and	O
nature	O
of	O
the	O
interactions	O
was	O
calculated	O
by	O
FICI	O
.	O

In	O
addition	O
,	O
antifungal	O
activity	O
was	O
assessed	O
using	O
agar	O
-	O
diffusion	O
and	O
time	O
-	O
kill	O
curves	O
.	O

The	O
drug	O
efflux	O
activity	O
was	O
determined	O
using	O
two	O
dyes	O
,	O
Rhodamine6	B
G	I
(	O
R6	B
G	I
)	O
and	O
fluorescent	O
Hoechst	B
33342	I
.	O

No	O
significant	O
differences	O
were	O
observed	O
in	O
dye	O
uptakes	O
between	O
FLC	O
-	O
susceptible	O
and	O
resistant	O
isolates	O
,	O
incubated	O
in	O
glucose	B
free	O
buffer	O
.	O

However	O
,	O
a	O
significantly	O
higher	O
efflux	O
was	O
recorded	O
in	O
FLC	B
-	O
resistant	O
isolates	O
when	O
glucose	B
was	O
added	O
.	O

Both	O
monoterpenes	B
inhibited	O
efflux	O
by	O
70	O
-	O
90	O
%	O
,	O
showing	O
their	O
high	O
potency	O
to	O
block	O
drug	O
transporter	O
pumps	O
.	O

Significant	O
differences	O
,	O
in	O
the	O
expression	O
levels	O
of	O
CDR1	O
and	O
MDR1	O
,	O
induced	O
by	O
monoterpenes	B
revealed	O
reversal	O
of	O
FLC	B
-	O
resistance	O
.	O

The	O
selectively	O
fungicidal	O
characteristics	O
and	O
ability	O
to	O
restore	O
FLC	B
susceptibility	O
in	O
resistant	O
isolates	O
signify	O
a	O
promising	O
candidature	O
of	O
THY	B
and	O
CARV	B
as	O
antifungal	O
agents	O
in	O
combinational	O
treatments	O
for	O
candidiasis	O
.	O

Adaptive	O
radiation	O
-	O
induced	O
epigenetic	O
alterations	O
mitigated	O
by	O
antioxidants	O
.	O

Humans	O
are	O
exposed	O
to	O
low	O
-	O
dose	O
ionizing	O
radiation	O
(	O
LDIR	O
)	O
from	O
a	O
number	O
of	O
environmental	O
and	O
medical	O
sources	O
.	O

In	O
addition	O
to	O
inducing	O
genetic	O
mutations	O
,	O
there	O
is	O
concern	O
that	O
LDIR	O
may	O
also	O
alter	O
the	O
epigenome	O
.	O

Such	O
heritable	O
effects	O
early	O
in	O
life	O
can	O
either	O
be	O
positively	O
adaptive	O
or	O
result	O
in	O
the	O
enhanced	O
formation	O
of	O
diseases	O
,	O
including	O
cancer	O
,	O
diabetes	O
,	O
and	O
obesity	O
.	O

Herein	O
,	O
we	O
show	O
that	O
LDIR	O
significantly	O
increased	O
DNA	O
methylation	O
at	O
the	O
viable	O
yellow	O
agouti	O
(	O
A	O
(	O
vy	O
)	O
)	O
locus	O
in	O
a	O
sex	O
-	O
specific	O
manner	O
(	O
P=0.004	O
)	O
.	O

Average	O
DNA	O
methylation	O
was	O
significantly	O
increased	O
in	O
male	O
offspring	O
exposed	O
to	O
doses	O
between	O
0.7	O
and	O
7.6	O
cGy	O
,	O
with	O
maximum	O
effects	O
at	O
1.4	O
and	O
3.0	O
cGy	O
(	O
P<0.01	O
)	O
.	O

Offspring	O
coat	O
color	O
was	O
concomitantly	O
shifted	O
toward	O
pseudoagouti	O
(	O
P<0.01	O
)	O
.	O

Maternal	O
dietary	O
antioxidant	O
supplementation	O
mitigated	O
both	O
the	O
DNA	O
methylation	O
changes	O
and	O
coat	O
color	O
shift	O
in	O
the	O
irradiated	O
offspring	O
.	O

Thus	O
,	O
LDIR	O
exposure	O
during	O
gestation	O
elicits	O
epigenetic	O
alterations	O
that	O
lead	O
to	O
positive	O
adaptive	O
phenotypic	O
changes	O
that	O
are	O
negated	O
with	O
antioxidants	O
,	O
indicating	O
they	O
are	O
mediated	O
in	O
part	O
by	O
oxidative	O
stress	O
.	O

These	O
findings	O
provide	O
evidence	O
that	O
in	O
the	O
isogenic	O
A	O
(	O
vy	O
)	O
mouse	O
model	O
,	O
epigenetic	O
alterations	O
resulting	O
from	O
LDIR	O
play	O
a	O
role	O
in	O
radiation	O
hormesis	O
,	O
bringing	O
into	O
question	O
the	O
assumption	O
that	O
every	O
dose	O
of	O
radiation	O
is	O
harmful	O
.	O

Inhibitory	O
effect	O
of	O
aqueous	O
spinach	O
extract	O
on	O
degranulation	O
of	O
RBL-2H3	O
cells	O
.	O

The	O
inhibitory	O
effect	O
of	O
an	O
aqueous	O
extract	O
from	O
spinach	O
on	O
degranulation	O
of	O
RBL-2H3	O
cells	O
is	O
herein	O
reported	O
.	O

The	O
extract	O
significantly	O
suppressed	O
antigen	O
-	O
induced	O
degranulation	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
without	O
affecting	O
cell	O
viability	O
.	O

Active	O
substances	O
in	O
the	O
extract	O
were	O
heat	O
-	O
stable	O
and	O
trypsin	O
-	O
resistant	O
with	O
molecular	O
weights	O
ranging	O
from	O
500	O
Da	O
to	O
14	O
kDa	O
.	O

The	O
extract	O
inhibited	O
elevation	O
of	O
the	O
intracellular	O
Ca	B
(	I
2	I
+	I
)	I
concentration	O
caused	O
by	O
stimulation	O
by	O
antigen	O
,	O
while	O
not	O
suppressing	O
degranulation	O
induced	O
by	O
a	O
calcium	B
ionophore	O
A23187	B
.	O

Immunoblot	O
analysis	O
revealed	O
that	O
the	O
inhibitory	O
effect	O
results	O
from	O
downregulation	O
of	O
phosphorylation	O
of	O
both	O
Syk	O
kinase	O
and	O
phosphatidylinositol	B
3-kinase	O
in	O
the	O
signalling	O
pathways	O
involved	O
in	O
degranulation	O
caused	O
by	O
the	O
antigen	O
-	O
antibody	O
interaction	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
suggest	O
that	O
aqueous	O
spinach	O
extract	O
has	O
an	O
anti	O
-	O
allergic	O
activity	O
that	O
controls	O
degranulation	O
.	O

Anthraquinone	B
profile	O
,	O
antioxidant	O
and	O
antimicrobial	O
activity	O
of	O
bark	O
extracts	O
of	O
Rhamnus	O
alaternus	O
,	O
R.	O
fallax	O
,	O
R.	O
intermedia	O
and	O
R.	O
pumila	O
.	O

The	O
quantity	O
of	O
phenols	B
,	O
as	O
well	O
as	O
antioxidant	O
and	O
antimicrobial	O
activities	O
,	O
were	O
investigated	O
in	O
bark	O
of	O
Rhamnus	O
alaternus	O
L.	O
,	O
R.	O
fallax	O
Boiss	O
.	O

,	O
R.	O
intermedia	O
Steud	O
.	O

et	O
Hochst	O
.	O
,	O
and	O
R.	O
pumila	O
Turra	O
from	O
natural	O
stands	O
in	O
Croatia	O
.	O

The	O
most	O
abundant	O
anthraquinones	B
in	O
the	O
investigated	O
extracts	O
were	O
chrysophanol	B
in	O
R.	O
alaternus	O
(	O
3.14	O
mg	O
/	O
g	O
)	O
,	O
emodin	B
in	O
R.	O
pumila	O
(	O
0.339	O
mg	O
/	O
g	O
)	O
,	O
and	O
physcion	B
in	O
R.	O
fallax	O
(	O
2.70	O
mg	O
/	O
g	O
)	O
and	O
R.	O
intermedia	O
(	O
0.285	O
mg	O
/	O
g	O
)	O
.	O

The	O
species	O
exhibiting	O
the	O
highest	O
antioxidant	O
activity	O
were	O
R.	O
fallax	O
and	O
R.	O
pumila	O
.	O

A	O
positive	O
correlation	O
was	O
observed	O
between	O
total	O
phenolic	B
and	O
flavonoid	B
levels	O
of	O
the	O
extracts	O
and	O
antioxidant	O
activity	O
in	O
some	O
of	O
the	O
assays	O
.	O

All	O
species	O
showed	O
antimicrobial	O
activity	O
against	O
Staphylococcus	O
aureus	O
,	O
Pseudomonas	O
aeruginosa	O
,	O
Escherichia	O
coli	O
,	O
Candida	O
albicans	O
,	O
Aspergillus	O
niger	O
and	O
Microsporum	O
gypseum	O
with	O
minimal	O
inhibitory	O
concentrations	O
equal	O
to	O
or	O
below	O
2.500	O
mg	O
/	O
mL.	O
The	O
results	O
indicate	O
that	O
the	O
investigated	O
Rhamnus	O
species	O
are	O
a	O
source	O
of	O
anthraquinones	B
and	O
other	O
phenols	B
,	O
which	O
act	O
as	O
multifunctional	O
antioxidants	O
with	O
antimicrobial	O
activity	O
.	O

Syzygium	O
aqueum	O
leaf	O
extract	O
and	O
its	O
bioactive	O
compounds	O
enhances	O
pre	O
-	O
adipocyte	O
differentiation	O
and	O
2-NBDG	B
uptake	O
in	O
3T3-L1	O
cells	O
.	O

The	O
insulin	O
-	O
like	O
and/or	O
insulin	O
-	O
sensitising	O
effects	O
of	O
Syzygium	O
aqueum	O
leaf	O
extract	O
and	O
its	O
six	O
bioactive	O
compounds	O
;	O
4-hydroxybenzaldehyde	B
,	O
myricetin-3-O	B
-	I
rhamnoside	I
,	O
europetin-3-O	B
-	I
rhamnoside	I
,	O
phloretin	B
,	O
myrigalone	B
-	I
G	I
and	O
myrigalone	B
-	I
B	I
were	O
investigated	O
in	O
3T3-L1	O
adipocytes	O
.	O

We	O
observed	O
that	O
,	O
S.	O
aqueum	O
leaf	O
extract	O
(	O
0.04	O
-	O
5	O
g	O
/	O
ml	O
)	O
and	O
its	O
six	O
bioactive	O
compounds	O
(	O
0.08	O
-	O
10	O
M	O
)	O
at	O
non	O
-	O
cytotoxic	O
concentrations	O
were	O
effectively	O
enhance	O
adipogenesis	O
,	O
stimulate	O
glucose	B
uptake	O
and	O
increase	O
adiponectin	O
secretion	O
in	O
3T3-L1	O
adipocytes	O
.	O

Clearly	O
,	O
the	O
compounds	O
myricetin-3-O	B
-	I
rhamnoside	I
and	O
europetin-3-O	B
-	I
rhamnoside	I
showed	O
insulin	O
-	O
like	O
and	O
insulin	O
-	O
sensitising	O
effects	O
on	O
adipocytes	O
from	O
a	O
concentration	O
of	O
0.08	O
M.	O
These	O
compounds	O
were	O
far	O
better	O
than	O
rosiglitazone	B
and	O
the	O
other	O
isolated	O
compounds	O
in	O
enhancing	O
adipogenesis	O
,	O
stimulating	O
2-NBDG	B
uptake	O
and	O
increasing	O
adiponectin	O
secretion	O
at	O
all	O
the	O
concentrations	O
tested	O
.	O

These	O
suggest	O
the	O
antidiabetic	O
potential	O
of	O
S.	O
aqueum	O
leaf	O
extract	O
and	O
its	O
six	O
bioactive	O
compounds	O
.	O

However	O
,	O
further	O
molecular	O
interaction	O
studies	O
to	O
explain	O
the	O
mechanisms	O
of	O
action	O
are	O
highly	O
warranted	O
.	O

An	O
improved	O
mass	O
spectrometric	O
method	O
for	O
identification	O
and	O
quantification	O
of	O
phenolic	B
compounds	O
in	O
apple	O
fruits	O
.	O

Thirty	O
-	O
nine	O
phenolic	B
compounds	O
were	O
analysed	O
using	O
ultra	O
high	O
performance	O
liquid	O
chromatography	O
(	O
UHPLC	O
)	O
coupled	O
with	O
diode	O
array	O
and	O
accurate	O
mass	O
spectrometry	O
detection	O
using	O
electrospray	O
ionisation	O
(	O
DAD	O
/	O
ESI	O
-	O
am	O
-	O
MS	O
)	O
.	O

Instrumental	O
parameters	O
such	O
as	O
scan	O
speed	O
,	O
resolution	O
,	O
and	O
mass	O
accuracy	O
were	O
optimised	O
to	O
establish	O
accurate	O
mass	O
measurements	O
.	O

The	O
method	O
was	O
fully	O
validated	O
in	O
terms	O
of	O
model	O
deviation	O
(	O
r	O
(	O
2	O
)	O
>0.9990	O
)	O
,	O
range	O
(	O
typically	O
10	O
-	O
3500	O
ngg	O
(	O
-1	O
)	O
)	O
,	O
intra	O
/	O
inter	O
-	O
day	O
precision	O
(	O
<	O
6	O
%	O
and	O
<	O
8	O
%	O
,	O
respectively	O
)	O
and	O
accuracy	O
(	O
typically	O
100	O
	O
10	O
%	O
)	O
.	O

The	O
mass	O
accuracy	O
of	O
each	O
selected	O
phenolic	B
compound	O
was	O
below	O
1.5	O
ppm	O
.	O

The	O
results	O
confirmed	O
that	O
the	O
UHPLC	O
-	O
DAD	O
/	O
ESI	O
-	O
am	O
-	O
MS	O
method	O
developed	O
here	O
was	O
convenient	O
and	O
reliable	O
for	O
the	O
determination	O
of	O
phenolic	B
compounds	O
in	O
apple	O
extracts	O
.	O

Identification	O
of	O
active	O
compounds	O
in	O
vegetal	O
extracts	O
based	O
on	O
correlation	O
between	O
activity	O
and	O
HPLC	O
-	O
MS	O
data	O
.	O

We	O
propose	O
a	O
method	O
identifying	O
candidates	O
for	O
active	O
compounds	O
in	O
vegetal	O
extracts	O
.	O

From	O
a	O
collection	O
of	O
samples	O
,	O
the	O
method	O
requires	O
,	O
for	O
each	O
sample	O
,	O
a	O
HPLC	O
-	O
MS	O
analysis	O
and	O
a	O
measurement	O
of	O
the	O
activity	O
.	O

By	O
applying	O
a	O
correlation	O
analysis	O
between	O
the	O
activity	O
and	O
the	O
chromatographic	O
area	O
for	O
each	O
interval	O
of	O
elution	O
time	O
and	O
m	O
/	O
z	O
ratio	O
,	O
the	O
peaks	O
corresponding	O
to	O
candidates	O
for	O
active	O
compounds	O
can	O
be	O
identified	O
.	O

Additionally	O
,	O
when	O
peaks	O
are	O
identified	O
,	O
a	O
model	O
can	O
be	O
estimated	O
to	O
predict	O
the	O
activity	O
in	O
new	O
samples	O
.	O

Both	O
methods	O
are	O
evaluated	O
in	O
one	O
experiment	O
involving	O
the	O
phenolic	O
extract	O
(	O
PE	O
)	O
from	O
22	O
samples	O
of	O
extra	O
virgin	O
olive	O
oil	O
(	O
EVOO	O
)	O
where	O
the	O
activity	O
is	O
a	O
cytotoxicity	O
index	O
against	O
JIMT-1	O
breast	O
cancer	O
cells	O
.	O

In	O
this	O
experiment	O
,	O
the	O
samples	O
were	O
separated	O
into	O
two	O
disjunct	O
partitions	O
:	O
one	O
was	O
used	O
for	O
training	O
(	O
identification	O
of	O
candidates	O
and	O
estimation	O
of	O
prediction	O
model	O
)	O
,	O
while	O
the	O
other	O
was	O
used	O
for	O
validation	O
(	O
by	O
comparing	O
the	O
predicted	O
and	O
the	O
measured	O
activities	O
)	O
.	O

Three	O
compounds	O
were	O
identified	O
as	O
candidates	O
to	O
be	O
responsible	O
for	O
the	O
cytotoxicity	O
of	O
the	O
EVOO	O
-	O
PE	O
against	O
JIMT-1	O
cells	O
.	O

The	O
prediction	O
model	O
provided	O
an	O
accurate	O
estimation	O
of	O
the	O
activity	O
.	O

Phillyrin	B
attenuates	O
high	O
glucose	B
-	O
induced	O
lipid	O
accumulation	O
in	O
human	O
HepG2	O
hepatocytes	O
through	O
the	O
activation	O
of	O
LKB1	O
/	O
AMP	B
-	O
activated	O
protein	O
kinase	O
-	O
dependent	O
signalling	O
.	O

Phillyrin	B
,	O
an	O
active	O
constituent	O
found	O
in	O
many	O
medicinal	O
plants	O
and	O
certain	O
functional	O
foods	O
,	O
has	O
anti	O
-	O
obesity	O
activity	O
in	O
vivo	O
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
provide	O
new	O
data	O
on	O
the	O
molecular	O
mechanism	O
(	O
s	O
)	O
underlying	O
the	O
role	O
of	O
phillyrin	B
in	O
the	O
prevention	O
of	O
high	O
glucose	B
-	O
induced	O
lipid	O
accumulation	O
in	O
human	O
HepG2	O
hepatocytes	O
.	O

We	O
found	O
that	O
phillyrin	B
suppressed	O
high	O
glucose	B
-	O
induced	O
lipid	O
accumulation	O
in	O
HepG2	O
cells	O
.	O

Phillyrin	B
strongly	O
inhibited	O
high	O
glucose	B
-	O
induced	O
fatty	B
acid	I
synthase	O
(	O
FAS	O
)	O
expression	O
by	O
modulating	O
sterol	B
regulatory	O
element	O
-	O
binding	O
protein-1c	O
(	O
SREBP-1c	O
)	O
activation	O
.	O

Moreover	O
,	O
use	O
of	O
the	O
pharmacological	O
AMP	B
-	O
activated	O
protein	O
kinase	O
(	O
AMPK	O
)	O
inhibitor	O
compound	B
C	I
revealed	O
that	O
AMPK	O
is	O
essential	O
for	O
suppressing	O
SREBP-1c	O
expression	O
in	O
phillyrin	B
-	O
treated	O
cells	O
.	O

Finally	O
,	O
we	O
found	O
that	O
liver	O
kinase	O
B1	O
(	O
LKB1	O
)	O
phosphorylation	O
is	O
required	O
for	O
the	O
phillyrin	B
-	O
enhanced	O
activation	O
of	O
AMPK	O
in	O
HepG2	O
hepatocytes	O
.	O

These	O
results	O
indicate	O
that	O
phillyrin	B
prevents	O
lipid	O
accumulation	O
in	O
HepG2	O
cells	O
by	O
blocking	O
the	O
expression	O
of	O
SREBP-1c	O
and	O
FAS	O
through	O
LKB1	O
/	O
AMPK	O
activation	O
,	O
suggesting	O
that	O
phillyrin	B
is	O
a	O
novel	O
AMPK	O
activator	O
with	O
a	O
role	O
in	O
the	O
prevention	O
and	O
treatment	O
of	O
obesity	O
.	O

Physicochemical	O
parameters	O
that	O
influence	O
carotenoids	O
bioaccessibility	O
from	O
a	O
tomato	O
juice	O
.	O

In	O
vitro	O
digestion	O
models	O
have	O
been	O
developed	O
to	O
estimate	O
carotenoid	O
bioavailability	O
but	O
most	O
do	O
not	O
consider	O
that	O
their	O
diffusion	O
from	O
fruit	O
matrix	O
to	O
the	O
lipid	O
phase	O
of	O
the	O
bolus	O
could	O
be	O
a	O
limiting	O
step	O
.	O

Therefore	O
we	O
designed	O
a	O
model	O
in	O
which	O
tomato	O
juice	O
is	O
mixed	O
with	O
oil	O
or	O
oil	O
/	O
water	O
emulsions	O
,	O
and	O
the	O
carotenoids	O
diffusing	O
to	O
oil	O
are	O
measured	O
by	O
spectrometry	O
.	O

Temperature	O
,	O
pH	O
and	O
tomato	O
juice	O
/	O
peanut	O
oil	O
ratio	O
were	O
evaluated	O
for	O
their	O
influence	O
on	O
carotenoid	O
diffusion	O
.	O

When	O
oil	O
/	O
tomato	O
ratio	O
was	O
between	O
0.11	O
and	O
1	O
,	O
extraction	O
of	O
lycopene	B
was	O
limited	O
by	O
the	O
saturation	O
of	O
the	O
oil	O
phase	O
.	O

With	O
a	O
large	O
excess	O
of	O
oil	O
,	O
diffusion	O
was	O
also	O
limited	O
,	O
as	O
only	O
31	O
	O
1	O
%	O
of	O
lycopene	B
could	O
be	O
extracted	O
from	O
the	O
juice	O
.	O

Diffusion	O
did	O
not	O
vary	O
significantly	O
with	O
pH	O
but	O
doubled	O
when	O
temperature	O
rose	O
from	O
10	O
	O
C	O
to	O
37	O
	O
C	O
.	O

When	O
the	O
juice	O
was	O
mixed	O
in	O
an	O
emulsion	O
stabilised	O
with	O
bovine	O
serum	O
albumin	O
or	O
phospholipids	O
the	O
maximum	O
extraction	O
decreased	O
to	O
14.5	O
	O
0.2	O
%	O
and	O
18.5	O
	O
1.5	O
%	O
respectively	O
,	O
indicating	O
that	O
in	O
addition	O
to	O
the	O
saturation	O
of	O
the	O
oil	O
phase	O
at	O
low	O
oil	O
/	O
tomato	O
ratio	O
and	O
in	O
addition	O
to	O
intrinsic	O
properties	O
of	O
the	O
tomato	O
juice	O
in	O
non	O
-	O
saturating	O
conditions	O
,	O
lycopene	B
diffusion	O
was	O
limited	O
by	O
the	O
structure	O
of	O
the	O
interface	O
in	O
emulsions	O
.	O

Effect	O
of	O
heat	O
treatments	O
on	O
the	O
essential	O
oils	O
of	O
kumquat	O
(	O
Fortunella	O
margarita	O
Swingle	O
)	O
.	O

Kumquats	O
(	O
Fortunella	O
margarita	O
Swingle	O
)	O
cultivated	O
in	O
Taiwan	O
are	O
eaten	O
raw	O
or	O
made	O
into	O
candied	O
fruit	O
or	O
fruit	O
tea	O
.	O

For	O
the	O
experiments	O
described	O
in	O
this	O
paper	O
,	O
essential	O
oils	O
were	O
obtained	O
from	O
kumquat	O
peels	O
or	O
whole	O
fruit	O
by	O
cold	O
pressing	O
,	O
steam	O
distillation	O
or	O
heating	O
in	O
water	O
at	O
90	O
	O
C	O
for	O
15	O
min	O
followed	O
by	O
steam	O
distillation	O
.	O

The	O
volatile	O
components	O
contained	O
in	O
the	O
essential	O
oils	O
were	O
identified	O
by	O
direct	O
injection	O
(	O
DI	O
)	O
or	O
headspace	O
-	O
solid	O
phase	O
microextraction	O
(	O
HS	O
-	O
SPME	O
)	O
coupled	O
with	O
gas	O
chromatography	O
(	O
GC	O
)	O
.	O

A	O
total	O
of	O
43	O
compounds	O
were	O
identified	O
,	O
of	O
which	O
37	O
were	O
verified	O
by	O
DI	O
/	O
GC	O
and	O
31	O
by	O
HS	O
-	O
SPME	O
/	O
GC	O
.	O

Hot	O
water	O
heating	O
increased	O
the	O
yields	O
of	O
essential	O
oils	O
from	O
both	O
peels	O
and	O
whole	O
fruit	O
.	O

The	O
principal	O
constituents	O
of	O
the	O
oils	O
were	O
similar	O
except	O
for	O
the	O
minor	O
compounds	O
,	O
including	O
linalool	B
,	O
terpinen-4-ol	B
and	O
	B
-	I
terpineol	I
,	O
the	O
levels	O
of	O
which	O
increased	O
after	O
steam	O
distillation	O
.	O

The	O
whole	O
fruit	O
also	O
contained	O
higher	O
levels	O
of	O
terpene	B
alcohols	I
.	O

Salicylic	B
acid	I
-	O
induced	O
elicitation	O
of	O
folates	O
in	O
coriander	O
(	O
Coriandrum	O
sativum	O
L.	O
)	O
improves	O
bioaccessibility	O
and	O
reduces	O
pro	O
-	O
oxidant	O
status	O
.	O

Foliage	O
of	O
Coriandrum	O
sativum	O
is	O
a	O
rich	O
source	O
of	O
natural	O
folates	O
amenable	O
for	O
enhancement	O
through	O
salicylic	B
acid	I
-	O
mediated	O
elicitation	O
,	O
thereby	O
holding	O
a	O
great	O
promise	O
for	O
natural	O
-	O
mode	O
alleviation	O
of	O
this	O
vitamin	B
(	I
B	I
(	I
9	I
)	I
)	I
deficiency	O
.	O

In	O
the	O
present	O
study	O
we	O
report	O
salicylic	B
acid	I
-	O
mediated	O
differential	O
elicitation	O
of	O
different	O
forms	O
of	O
folates	B
-	O
5-methyltetrahydrofolate	B
,	O
5-formyltetrahydrofolate	B
and	O
10-formyltetrahydrofolate	B
-	O
their	O
stabilities	O
during	O
microwave	O
-	O
drying	O
and	O
bioaccessibilities	O
from	O
fresh	O
and	O
dried	O
foliage	O
.	O

The	O
first	O
two	O
compounds	O
nearly	O
doubled	O
and	O
the	O
third	O
increased	O
sixfold	O
post	O
-	O
elicitation	O
,	O
with	O
all	O
three	O
showing	O
concomitant	O
increase	O
in	O
bioaccessibilities	O
.	O

Although	O
a	O
slight	O
decrease	O
in	O
bioaccessibility	O
was	O
observed	O
in	O
dried	O
foliage	O
,	O
over	O
twofold	O
increase	O
of	O
each	O
form	O
of	O
folate	O
upon	O
elicitation	O
would	O
deliver	O
much	O
higher	O
levels	O
of	O
natural	O
folates	O
from	O
this	O
traditional	O
culinary	O
foliage	O
,	O
which	O
is	O
widely	O
used	O
in	O
many	O
cuisines	O
.	O

Elicitor	O
-	O
mediated	O
folate	O
enhancement	O
also	O
imparted	O
reduction	O
of	O
oxidative	O
status	O
and	O
the	O
enhancement	O
of	O
antioxidant	O
enzyme	O
activities	O
in	O
coriander	O
foliage	O
.	O

Short	O
-	O
term	O
comparative	O
study	O
of	O
the	O
influence	O
of	O
fried	O
edible	O
oils	O
intake	O
on	O
the	O
metabolism	O
of	O
essential	O
fatty	B
acids	I
in	O
obese	O
individuals	O
.	O

The	O
effect	O
of	O
breakfast	O
intake	O
of	O
fried	O
oils	O
containing	O
natural	O
antioxidants	O
or	O
a	O
synthetic	O
autooxidation	O
inhibitor	O
on	O
the	O
metabolism	O
of	O
essential	O
fatty	B
acids	I
focused	O
on	O
obese	O
individuals	O
.	O

Serum	O
levels	O
of	O
eicosanoids	B
were	O
compared	O
in	O
individuals	O
before	O
and	O
after	O
intake	O
of	O
different	O
breakfasts	O
.	O

Univariate	O
descriptive	O
analysis	O
was	O
used	O
to	O
characterise	O
the	O
cohort	O
selected	O
for	O
this	O
study	O
and	O
multivariate	O
analysis	O
to	O
reveal	O
statistical	O
differences	O
of	O
normalised	O
eicosanoids	B
concentrations	O
(	O
determined	O
by	O
solid	O
-	O
phase	O
extraction	O
coupled	O
to	O
LC	O
-	O
MS	O
/	O
MS	O
)	O
depending	O
on	O
the	O
edible	O
oil	O
used	O
for	O
breakfast	O
preparation	O
.	O

The	O
results	O
showed	O
that	O
the	O
intake	O
of	O
breakfast	O
prepared	O
with	O
pure	O
sunflower	O
oil	O
subjected	O
to	O
deep	O
frying	O
causes	O
an	O
effect	O
over	O
the	O
eicosanoids	B
profile	O
that	O
enables	O
discrimination	O
versus	O
the	O
rest	O
of	O
individuals	O
.	O

The	O
effect	O
was	O
a	O
significant	O
increase	O
in	O
the	O
concentration	O
of	O
hydroxyoctadecadienoic	B
acid	I
(	O
HODE	B
)	O
metabolites	O
,	O
indicative	O
markers	O
of	O
the	O
intake	O
of	O
fried	O
oils	O
.	O

The	O
concentration	O
of	O
HODE	B
metabolites	O
was	O
lower	O
when	O
the	O
oil	O
contained	O
either	O
natural	O
antioxidants	O
from	O
olive	O
-	O
oil	O
pomace	O
or	O
a	O
synthetic	O
autooxidation	O
inhibitor	O
as	O
dimethylsiloxane	B
.	O

The	O
comparison	O
of	O
the	O
effect	O
of	O
fried	O
sunflower	O
oils	O
with	O
fried	O
extra	O
virgin	O
olive	O
oil	O
shows	O
the	O
benefits	O
associated	O
to	O
the	O
consumption	O
of	O
the	O
latter	O
.	O

Comprehensive	O
analysis	O
of	O
Phyteuma	O
orbiculare	O
L.	O
,	O
a	O
wild	O
Alpine	O
food	O
plant	O
.	O

Plants	O
which	O
have	O
been	O
traditionally	O
eaten	O
by	O
the	O
alpine	O
population	O
may	O
provide	O
new	O
opportunities	O
for	O
agricultural	O
development	O
in	O
mountain	O
regions	O
.	O

In	O
this	O
context	O
we	O
have	O
investigated	O
the	O
chemical	O
composition	O
of	O
Phyteuma	O
orbiculare	O
(	O
Campanulaceae	O
)	O
,	O
a	O
perennial	O
herb	O
whose	O
leaves	O
have	O
been	O
eaten	O
as	O
salad	O
by	O
rural	O
populations	O
in	O
Valais	O
(	O
Switzerland	O
)	O
.	O

Extracts	O
of	O
different	O
polarities	O
were	O
subjected	O
to	O
comprehensive	O
metabolite	O
profiling	O
using	O
a	O
dereplication	O
platform	O
combining	O
HPLC	O
-	O
PDA	O
-	O
MS	O
,	O
and	O
offline	O
NMR	O
analysis	O
.	O

Twenty	O
-	O
three	O
compounds	O
,	O
including	O
various	O
phenolic	B
glycosides	I
,	O
a	O
new	O
dimeric	O
phenylpropanoid	B
glucoside	I
,	O
saponins	B
,	O
and	O
fatty	B
acids	I
were	O
identified	O
online	O
,	O
or	O
after	O
targeted	O
isolation	O
.	O

Selected	O
phenolic	O
constituents	O
were	O
quantitatively	O
assessed	O
by	O
HPLC	O
-	O
PDA	O
analysis	O
.	O

In	O
addition	O
,	O
substances	O
relevant	O
for	O
nutrition	O
,	O
such	O
as	O
	B
-	I
carotene	I
,	O
fatty	B
acids	I
,	O
ascorbic	B
acid	I
and	O
minerals	O
were	O
quantified	O
in	O
leaves	O
and	O
flowers	O
.	O

The	O
antioxidant	O
capacity	O
was	O
determined	O
with	O
an	O
ORAC	O
assay	O
,	O
and	O
total	O
phenolic	B
compounds	O
were	O
quantified	O
.	O

Finally	O
,	O
the	O
phytochemical	O
profile	O
was	O
compared	O
to	O
that	O
of	O
the	O
related	O
species	O
P.	O
spicatum	O
,	O
P.	O
hemisphaericum	O
and	O
P.	O
ovatum	O
.	O

Neferine	B
induces	O
reactive	O
oxygen	B
species	O
mediated	O
intrinsic	O
pathway	O
of	O
apoptosis	O
in	O
HepG2	O
cells	O
.	O

Evidence	O
has	O
accumulated	O
concerning	O
the	O
medicinal	O
application	O
of	O
Nelumbo	O
nucifera	O
in	O
the	O
treatment	O
of	O
various	O
diseases	O
.	O

Neferine	B
,	O
an	O
alkaloid	O
from	O
N.	O
nucifera	O
was	O
found	O
to	O
exert	O
cytotoxicity	O
on	O
liver	O
cancer	O
cells	O
HepG2	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

We	O
evaluated	O
its	O
anticancer	O
potential	O
by	O
studying	O
its	O
effect	O
on	O
mitochondrial	O
membrane	O
potential	O
,	O
intracellular	O
calcium	B
levels	O
[	O
Ca	B
(	I
2+	I
)	I
]	O
(	O
i	O
)	O
,	O
cell	O
membrane	O
integrity	O
,	O
apoptotic	O
body	O
formation	O
and	O
DNA	O
fragmentation	O
in	O
cultured	O
HepG2	O
cells	O
.	O

The	O
reactive	O
oxygen	B
species	O
level	O
has	O
been	O
increased	O
upon	O
neferine	B
treatment	O
with	O
concomitant	O
decrease	O
in	O
reduced	O
glutathione	B
.	O

Our	O
data	O
further	O
indicate	O
reduction	O
of	O
M	O
and	O
increased	O
[	O
Ca	B
(	I
2+	I
)	I
]	O
(	O
i	O
)	O
during	O
apoptosis	O
induction	O
by	O
neferine	B
with	O
increased	O
expression	O
of	O
apoptotic	O
proteins	O
such	O
as	O
Bax	O
,	O
Bad	O
,	O
cleaved	O
forms	O
of	O
caspase	O
3	O
,	O
caspase	O
9	O
and	O
PARP	O
,	O
with	O
the	O
downregulation	O
of	O
anti	O
-	O
apoptotic	O
protein	O
Bcl2	O
in	O
HepG2	O
cells	O
.	O

Moreover	O
,	O
the	O
expressions	O
of	O
tumour	O
suppressor	O
proteins	O
p53	O
and	O
PTEN	O
were	O
upregulated	O
along	O
with	O
the	O
downregulation	O
of	O
P	O
-	O
Akt	O
.	O

In	O
addition	O
,	O
expression	O
levels	O
of	O
TNF	O
-	O
	O
,	O
p38	O
and	O
ERK1	O
/	O
2	O
MAP	O
kinases	O
were	O
increased	O
upon	O
neferine	B
treatment	O
.	O

These	O
results	O
imply	O
that	O
mitochondrial	O
-	O
mediated	O
ROS	O
generation	O
induced	O
by	O
neferine	B
leads	O
to	O
caspase	O
-	O
dependent	O
apoptosis	O
in	O
HepG2	O
cells	O
.	O

A	O
sensitive	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
for	O
the	O
determination	O
of	O
fish	O
protein	O
in	O
processed	O
foods	O
.	O

Fish	O
is	O
one	O
of	O
the	O
most	O
common	O
causes	O
of	O
food	O
allergy	O
and	O
its	O
major	O
allergen	O
is	O
parvalbumin	O
,	O
a	O
12	O
kDa	O
muscular	O
protein	O
.	O

In	O
this	O
study	O
,	O
a	O
sandwich	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
for	O
the	O
determination	O
of	O
fish	O
protein	O
in	O
processed	O
foods	O
was	O
developed	O
using	O
a	O
polyclonal	O
antibody	O
raised	O
against	O
Pacific	O
mackerel	O
parvalbumin	O
.	O

The	O
developed	O
sandwich	O
ELISA	O
showed	O
22.6	O
-	O
99.0	O
%	O
reactivity	O
(	O
based	O
on	O
the	O
reactivity	O
to	O
Pacific	O
mackerel	O
parvalbumin	O
)	O
to	O
parvalbumins	O
from	O
various	O
species	O
of	O
fish	O
.	O

The	O
limits	O
of	O
detection	O
and	O
quantitation	O
were	O
estimated	O
to	O
be	O
0.23	O
and	O
0.70	O
g	O
protein	O
per	O
g	O
of	O
food	O
,	O
respectively	O
.	O

When	O
the	O
sandwich	O
ELISA	O
was	O
subjected	O
to	O
inter	O
-	O
laboratory	O
validation	O
,	O
spiked	O
fish	O
protein	O
was	O
recovered	O
from	O
five	O
model	O
processed	O
foods	O
in	O
the	O
range	O
of	O
69.4	O
-	O
84.8	O
%	O
and	O
the	O
repeatability	O
and	O
reproducibility	O
relative	O
standard	O
deviations	O
were	O
satisfactorily	O
low	O
(	O
	O
10.5	O
%	O
)	O
.	O

Thus	O
,	O
the	O
sandwich	O
ELISA	O
was	O
judged	O
to	O
be	O
a	O
useful	O
tool	O
to	O
determine	O
fish	O
protein	O
in	O
processed	O
foods	O
.	O

Batch	O
and	O
continuous	O
synthesis	O
of	O
lactulose	B
from	O
whey	O
lactose	B
by	O
immobilized	O
	O
-	O
galactosidase	O
.	O

In	O
this	O
study	O
,	O
lactulose	B
synthesis	O
from	O
whey	O
lactose	B
was	O
investigated	O
in	O
batch	O
and	O
continuous	O
systems	O
using	O
immobilized	O
	O
-	O
galactosidase	O
.	O

In	O
the	O
batch	O
system	O
,	O
the	O
optimal	O
concentration	O
of	O
fructose	B
for	O
lactulose	B
synthesis	O
was	O
20	O
%	O
,	O
and	O
the	O
effect	O
of	O
galactose	B
,	O
glucose	B
and	O
fructose	B
on	O
	O
-	O
galactosidase	O
activity	O
was	O
determined	O
for	O
hydrolysis	O
of	O
whey	O
lactose	B
and	O
the	O
transgalactosylation	O
reaction	O
for	O
lactulose	B
synthesis	O
.	O

Galactose	B
and	O
fructose	B
were	O
competitive	O
inhibitors	O
,	O
and	O
glucose	B
acted	O
as	O
a	O
noncompetitive	O
inhibitor	O
.	O

The	O
inhibitory	O
effects	O
of	O
galactose	B
and	O
glucose	B
were	O
stronger	O
in	O
the	O
transgalactosylation	O
reaction	O
than	O
they	O
were	O
in	O
the	O
hydrolysis	O
reaction	O
.	O

In	O
addition	O
,	O
when	O
immobilized	O
	O
-	O
galactosidase	O
was	O
reused	O
for	O
lactulose	B
synthesis	O
,	O
its	O
catalytic	O
activity	O
was	O
retained	O
to	O
the	O
extent	O
of	O
52.9	O
%	O
after	O
10	O
reuses	O
.	O

Lactulose	B
was	O
synthesized	O
continuously	O
in	O
a	O
packed	O
-	O
bed	O
reactor	O
.	O

We	O
synthesized	O
19.1g	O
/	O
l	O
lactulose	B
during	O
the	O
continuous	O
flow	O
reaction	O
at	O
a	O
flow	O
rate	O
of	O
0.5	O
ml	O
/	O
min	O
.	O

Gangliosides	O
and	O
sialic	B
acid	I
effects	O
upon	O
newborn	O
pathogenic	O
bacteria	O
adhesion	O
:	O
an	O
in	O
vitro	O
study	O
.	O

The	O
effect	O
of	O
the	O
main	O
gangliosides	O
(	O
GM	O
(	O
1	O
)	O
,	O
GM	O
(	O
3	O
)	O
,	O
GD	O
(	O
3	O
)	O
)	O
and	O
free	O
sialic	B
acid	I
(	O
Neu5Ac	B
)	O
upon	O
the	O
adhesion	O
of	O
pathogenic	O
bacteria	O
implicated	O
in	O
infant	O
diarrhoea	O
is	O
assessed	O
in	O
vitro	O
using	O
the	O
Caco-2	O
cell	O
line	O
.	O

Concentrations	O
of	O
the	O
bioactive	O
compounds	O
found	O
in	O
the	O
bioaccessible	O
(	O
soluble	O
)	O
fraction	O
of	O
infant	O
formula	O
and	O
human	O
milk	O
are	O
employed	O
.	O

Bacterial	O
adhesion	O
behaviour	O
included	O
enterotoxigenic	O
Escherichia	O
coli	O
(	O
ETEC	O
)	O
,	O
enteropathogenic	O
E.coli	O
(	O
EPEC	O
)	O
,	O
Listeria	O
monocytogenes	O
,	O
Salmonella	O
entericaserovartyphi	O
,	O
Shigella	O
sonnei	O
,	O
Campylobacter	O
jejuni	O
and	O
Helicobacter	O
pylori	O
.	O

Three	O
different	O
approaches	O
were	O
assayed	O
:	O
pre	O
-	O
incubation	O
of	O
bacteria	O
and	O
compounds	O
before	O
addition	O
to	O
cells	O
(	O
competition	O
)	O
;	O
pre	O
-	O
incubation	O
of	O
the	O
cells	O
with	O
compounds	O
(	O
exclusion	O
)	O
;	O
and	O
pre	O
-	O
incubation	O
of	O
cells	O
with	O
bacteria	O
(	O
displacement	O
)	O
.	O

Furthermore	O
,	O
the	O
spatial	O
localization	O
of	O
the	O
most	O
abundant	O
gangliosides	O
,	O
GM	O
(	O
3	O
)	O
and	O
GD	O
(	O
3	O
)	O
,	O
in	O
Caco-2	O
cells	O
has	O
been	O
determined	O
using	O
confocal	O
microscopy	O
.	O

Results	O
show	O
that	O
GM	O
(	O
3	O
)	O
,	O
GD	O
(	O
3	O
)	O
,	O
GM	O
(	O
1	O
)	O
and	O
Neu5Ac	B
at	O
the	O
assayed	O
concentrations	O
are	O
able	O
to	O
interfere	O
with	O
the	O
adhesion	O
of	O
several	O
pathogenic	O
bacteria	O
involved	O
in	O
neonatal	O
diseases	O
-	O
the	O
greatest	O
effect	O
corresponding	O
to	O
Neu5Ac	B
,	O
followed	O
by	O
GD	O
(	O
3	O
)	O
,	O
GM	O
(	O
1	O
)	O
and	O
GM	O
(	O
3	O
)	O
.	O

Gangliosides	O
GM	O
(	O
3	O
)	O
and	O
GD	O
(	O
3	O
)	O
are	O
located	O
in	O
the	O
apical	O
and	O
basolateral	O
membranes	O
of	O
the	O
Caco-2	O
cells	O
.	O

A	O
simple	O
GC	O
-	O
MS	O
method	O
for	O
the	O
screening	O
of	O
betulinic	B
,	I
corosolic	I
,	I
maslinic	I
,	I
oleanolic	I
and	I
ursolic	I
acid	I
contents	O
in	O
commercial	O
botanicals	O
used	O
as	O
food	O
supplement	O
ingredients	O
.	O

The	O
occurrence	O
of	O
triterpene	B
pentacyclic	I
acids	I
in	O
plants	O
is	O
extensive	O
,	O
but	O
little	O
is	O
known	O
about	O
their	O
availability	O
in	O
commercial	O
extracts	O
.	O

A	O
simple	O
GC	O
-	O
MS	O
method	O
for	O
the	O
simultaneous	O
determination	O
of	O
betulinic	B
,	I
corosolic	I
,	I
maslinic	I
,	I
oleanolic	I
and	I
ursolic	I
acids	I
was	O
developed	O
and	O
applied	O
to	O
38	O
different	O
commercial	O
plant	O
extracts	O
sold	O
as	O
ingredients	O
for	O
dietary	O
supplements	O
.	O

A	O
suitable	O
protocol	O
was	O
set	O
up	O
to	O
perform	O
routine	O
control	O
of	O
a	O
diverse	O
array	O
of	O
samples	O
with	O
different	O
botanical	O
,	O
chemical	O
and	O
physical	O
characteristics	O
.	O

Remarkable	O
quantities	O
of	O
corosolic	B
acid	I
were	O
found	O
in	O
dried	O
extracts	O
from	O
aerial	O
parts	O
of	O
Lagerstroemia	O
speciosa	O
and	O
Ortosiphon	O
stamineus	O
(	O
14233	O
and	O
1132	O
mg	O
/	O
kg	O
,	O
respectively	O
)	O
,	O
while	O
oleanolic	B
acid	I
was	O
abundant	O
in	O
O.	O
stamineus	O
and	O
Crataegus	O
monogyna	O
flowers	O
(	O
2774	O
and	O
2339	O
mg	O
/	O
kg	O
)	O
;	O
ursolic	B
was	O
identified	O
in	O
O.	O
stamineus	O
,	O
C.	O
monogyna	O
,	O
L.	O
speciosa	O
and	O
Arctostaphylos	O
uva	O
-	O
ursi	O
leaves	O
(	O
7773	O
,	O
4165	O
,	O
2108	O
and	O
1034	O
mg	O
/	O
kg	O
)	O
.	O

Only	O
L.	O
speciosa	O
was	O
rich	O
in	O
maslinic	B
acid	I
(	O
4958	O
mg	O
/	O
kg	O
)	O
,	O
while	O
minor	O
amounts	O
of	O
betulinic	B
acid	I
(	O
257	O
and	O
80	O
mg	O
/	O
kg	O
)	O
were	O
detected	O
in	O
L.	O
speciosa	O
and	O
C.	O
monogyna	O
extracts	O
.	O

Lower	O
quantities	O
of	O
triterpenic	B
acids	I
were	O
identified	O
in	O
dried	O
extracts	O
of	O
Harpagophyton	O
procumbens	O
root	O
,	O
propolis	O
,	O
Punica	O
granatum	O
root	O
,	O
Styrax	O
benzoin	O
,	O
Vaccinium	O
myrtillus	O
fruits	O
and	O
Vitis	O
vinifera	O
seeds	O
.	O

Decoctions	O
and	O
fluid	O
extracts	O
lacked	O
or	O
contained	O
very	O
low	O
amounts	O
of	O
triterpenic	B
acids	I
.	O

Results	O
are	O
discussed	O
in	O
terms	O
of	O
quality	O
and	O
safety	O
of	O
these	O
ingredients	O
.	O

The	O
importance	O
of	O
amylose	O
and	O
amylopectin	O
fine	O
structures	O
for	O
starch	O
digestibility	O
in	O
cooked	O
rice	O
grains	O
.	O

Statistically	O
and	O
causally	O
meaningful	O
relationships	O
are	O
established	O
between	O
starch	O
molecular	O
structures	O
(	O
obtained	O
by	O
size	O
-	O
exclusion	O
chromatography	O
,	O
proton	O
NMR	O
and	O
multiple	O
-	O
angle	O
laser	O
light	O
scattering	O
)	O
and	O
digestibility	O
of	O
cooked	O
rice	O
grains	O
(	O
measured	O
by	O
in	O
vitro	O
digestion	O
)	O
.	O

Significant	O
correlations	O
are	O
observed	O
between	O
starch	O
digestion	O
rate	O
and	O
molecular	O
structural	O
characteristics	O
,	O
including	O
fine	O
structures	O
of	O
the	O
distributions	O
of	O
branch	O
(	O
chain	O
)	O
lengths	O
in	O
both	O
amylose	O
and	O
amylopectin	O
.	O

The	O
in	O
vitro	O
digestion	O
rate	O
tends	O
to	O
increase	O
with	O
longer	O
amylose	O
branches	O
and	O
smaller	O
ratios	O
of	O
long	O
amylopectin	O
and	O
long	O
amylose	O
branches	O
to	O
short	O
amylopectin	O
branches	O
,	O
although	O
the	O
statistical	O
analyses	O
show	O
that	O
further	O
data	O
are	O
needed	O
to	O
establish	O
this	O
unambiguously	O
.	O

These	O
new	O
relationships	O
between	O
fine	O
starch	O
structural	O
features	O
and	O
digestibility	O
of	O
cooked	O
rice	O
grains	O
are	O
mechanistically	O
reasonable	O
,	O
but	O
suggestive	O
rather	O
than	O
statistically	O
definitive	O
.	O

Immunoreactivity	O
of	O
hen	O
egg	O
allergens	O
:	O
influence	O
on	O
in	O
vitro	O
gastrointestinal	O
digestion	O
of	O
the	O
presence	O
of	O
other	O
egg	O
white	O
proteins	O
and	O
of	O
egg	O
yolk	O
.	O

Hen	O
egg	O
white	O
comprises	O
of	O
a	O
complex	O
mixture	O
of	O
proteins	O
,	O
which	O
greatly	O
differ	O
in	O
their	O
physicochemical	O
characteristics	O
and	O
relative	O
abundance	O
.	O

We	O
aimed	O
to	O
identify	O
potential	O
undiscovered	O
egg	O
allergens	O
within	O
the	O
egg	O
white	O
proteome	O
and	O
investigated	O
the	O
existence	O
of	O
matrix	O
effects	O
on	O
the	O
proteolytic	O
stability	O
and	O
resultant	O
IgE	O
-	O
binding	O
of	O
the	O
allergenic	O
proteins	O
.	O

In	O
addition	O
to	O
the	O
main	O
egg	O
allergens	O
:	O
ovalbumin	O
(	O
OVA	O
)	O
,	O
ovomucoid	O
(	O
OM	O
)	O
and	O
lysozyme	O
(	O
LYS	O
)	O
,	O
two	O
minor	O
egg	O
white	O
proteins	O
,	O
tentatively	O
identified	O
as	O
ovoinhibitor	O
and	O
clusterin	O
,	O
were	O
found	O
to	O
react	O
with	O
serum	O
IgE	O
from	O
egg	O
-	O
allergic	O
patients	O
.	O

Egg	O
white	O
exhibited	O
residual	O
immunoreactivity	O
after	O
gastrointestinal	O
digestion	O
due	O
to	O
the	O
presence	O
of	O
intact	O
OVA	O
and	O
LYS	O
,	O
as	O
well	O
as	O
of	O
several	O
IgE	O
-	O
binding	O
peptides	O
derived	O
from	O
OVA	O
.	O

The	O
presence	O
of	O
egg	O
yolk	O
slightly	O
increased	O
the	O
susceptibility	O
to	O
hydrolysis	O
of	O
egg	O
white	O
proteins	O
and	O
abrogated	O
bile	B
salt	I
-	O
induced	O
precipitation	O
of	O
LYS	O
in	O
the	O
duodenal	O
medium	O
.	O

However	O
,	O
the	O
resultant	O
immunoreactivity	O
against	O
IgE	O
of	O
egg	O
white	O
proteins	O
after	O
in	O
vitro	O
digestion	O
was	O
not	O
significantly	O
modified	O
by	O
the	O
presence	O
of	O
yolk	O
components	O
.	O

Comparison	O
the	O
neuropreotective	O
effect	O
of	O
Cortex	O
Phellodendri	O
chinensis	O
and	O
Cortex	O
Phellodendri	O
amurensis	O
against	O
beta	O
-	O
amyloid	O
-	O
induced	O
neurotoxicity	O
in	O
PC12	O
cells	O
.	O

Cortex	O
Phellodendron	O
chinensis	O
(	O
CPC	O
)	O
and	O
Cortex	O
Phellodendron	O
amurensis	O
(	O
CPA	O
)	O
derived	O
from	O
the	O
dried	O
bark	O
of	O
Phellodendron	O
chinense	O
Schneid	O
.	O
or	O
Phellodendron	O
amurense	O
Rupr	O
.	O
,	O
respectively	O
,	O
are	O
used	O
interchangeably	O
in	O
clinical	O
practice	O
under	O
the	O
name	O
"	O
Huang	O
Bai	O
"	O
for	O
centuries	O
in	O
Chinese	O
medicine	O
for	O
the	O
treatment	O
of	O
various	O
inflammatory	O
conditions	O
.	O

Previous	O
study	O
in	O
our	O
laboratory	O
demonstrated	O
that	O
CPC	O
and	O
CPA	O
had	O
different	O
anti	O
-	O
diarrheal	O
,	O
anti	O
-	O
bacterial	O
and	O
anti	O
-	O
inflammatory	O
effects	O
.	O

In	O
this	O
present	O
study	O
,	O
we	O
aimed	O
to	O
compare	O
the	O
protective	O
effect	O
of	O
ethanol	B
extract	O
of	O
Cortex	O
Phellodendri	O
chinensis	O
(	O
ECPC	O
)	O
and	O
Cortex	O
Phellodendri	O
Amurensis	O
(	O
ECPA	O
)	O
against	O
beta	O
-	O
amyloid	O
(	O
A	O
)	O
-induced	O
neurotoxicity	O
in	O
PC12	O
cells	O
,	O
a	O
typical	O
model	O
of	O
Alzheimer	O
's	O
disease	O
.	O

The	O
results	O
showed	O
that	O
ECPC	O
and	O
ECPA	O
contain	O
four	O
common	O
chemical	O
markers	O
such	O
as	O
berberine	B
,	O
but	O
palmatine	B
and	O
jatrorrhizin	B
were	O
not	O
found	O
in	O
CPC	O
in	O
contrast	O
to	O
the	O
presence	O
in	O
CPA	O
.	O

In	O
addition	O
,	O
both	O
ECPC	O
and	O
ECPA	O
can	O
significantly	O
increase	O
the	O
cell	O
viability	O
in	O
A	O
-	O
treated	O
PC12	O
cells	O
.	O

Moreover	O
,	O
ECPC	O
and	O
ECPA	O
can	O
markedly	O
elevate	O
the	O
ratio	O
of	O
the	O
protein	O
and	O
mRNA	O
levels	O
of	O
Bcl-2	O
/	O
Bax	O
,	O
while	O
remarkably	O
decrease	O
the	O
release	O
of	O
cytochrome	O
c	O
,	O
and	O
the	O
protein	O
and	O
mRNA	O
expression	O
of	O
caspase-3	O
.	O

Interestingly	O
,	O
ECPA	O
has	O
better	O
protective	O
effect	O
than	O
ECPC	O
against	O
A	O
-	O
induced	O
neurotoxicity	O
in	O
PC12	O
cells	O
.	O

These	O
results	O
indicate	O
that	O
both	O
ECPC	O
and	O
ECPA	O
have	O
potential	O
protective	O
effect	O
against	O
A	O
-	O
induced	O
neurotoxicity	O
in	O
PC12	O
cells	O
,	O
and	O
ECPA	O
is	O
more	O
potential	O
of	O
the	O
two	O
species	O
to	O
be	O
used	O
in	O
traditional	O
medicine	O
as	O
a	O
neuroprotective	O
agent	O
for	O
the	O
treatment	O
of	O
AD	O
.	O

The	O
neuroprotective	O
effect	O
of	O
the	O
two	O
species	O
may	O
be	O
mediated	O
,	O
at	O
least	O
in	O
part	O
,	O
via	O
suppressing	O
of	O
the	O
cellular	O
apoptosis	O
.	O

	B
-	I
Asarone	I
,	O
an	O
active	O
principle	O
of	O
Acorus	O
calamus	O
rhizome	O
,	O
inhibits	O
morphogenesis	O
,	O
biofilm	O
formation	O
and	O
ergosterol	B
biosynthesis	O
in	O
Candida	O
albicans	O
.	O

Anti	O
-	O
Candida	O
potential	O
of	O
Acorus	O
calamus	O
rhizome	O
and	O
its	O
active	O
principle	O
,	O
	B
-	I
asarone	I
,	O
was	O
evaluated	O
against	O
the	O
human	O
fungal	O
pathogen	O
,	O
Candida	O
albicans	O
.	O

	B
-	I
Asarone	I
exhibited	O
promising	O
growth	O
inhibitory	O
activity	O
at	O
0.5mg	O
/	O
ml	O
and	O
it	O
was	O
fungicidal	O
at	O
8	O
mg	O
/	O
ml	O
.	O

Time	O
dependant	O
kill	O
curve	O
assay	O
showed	O
that	O
MFC	O
of	O
	B
-	I
asarone	I
was	O
highly	O
toxic	O
to	O
C.	O
albicans	O
,	O
killing	O
99.9	O
%	O
inoculum	O
within	O
120	O
min	O
of	O
exposure	O
.	O

	B
-	I
Asarone	I
caused	O
significant	O
inhibition	O
of	O
C.	O
albicans	O
morphogenesis	O
and	O
biofilm	O
development	O
at	O
sub	O
-	O
inhibitory	O
concentrations	O
.	O

Our	O
data	O
indicate	O
that	O
the	O
growth	O
inhibitory	O
activity	O
of	O
	B
-	I
asarone	I
might	O
be	O
through	O
inhibition	O
of	O
ergosterol	B
biosynthesis	O
.	O

Hemolytic	O
assay	O
showed	O
that	O
	B
-	I
asarone	I
is	O
non	O
-	O
toxic	O
,	O
even	O
at	O
concentrations	O
approaching	O
MIC	O
value	O
.	O

Our	O
results	O
suggest	O
that	O
	B
-	I
asarone	I
may	O
be	O
safe	O
as	O
a	O
topical	O
antifungal	O
agent	O
.	O

Testing	O
of	O
novel	O
brain	O
-	O
penetrating	O
oxime	B
reactivators	O
of	O
acetylcholinesterase	O
inhibited	O
by	O
nerve	O
agent	O
surrogates	O
.	O

A	O
critical	O
need	O
for	O
combating	O
the	O
effects	O
of	O
organophosphate	B
(	O
OP	O
)	O
anticholinesterases	O
,	O
such	O
as	O
nerve	O
agents	O
,	O
is	O
the	O
current	O
lack	O
of	O
an	O
effective	O
oxime	B
reactivator	O
which	O
can	O
penetrate	O
the	O
blood	O
-	O
brain	O
barrier	O
(	O
BBB	O
)	O
,	O
and	O
therefore	O
reactivate	O
inhibited	O
acetylcholinesterase	O
(	O
AChE	O
)	O
in	O
the	O
brain	O
.	O

Our	O
laboratories	O
have	O
synthesized	O
and	O
have	O
initiated	O
testing	O
of	O
novel	O
phenoxyalkyl	B
pyridinium	I
oximes	I
(	O
patent	O
pending	O
)	O
that	O
are	O
more	O
lipophilic	O
than	O
currently	O
approved	O
oximes	B
.	O

This	O
is	O
a	O
preliminary	O
report	O
on	O
these	O
novel	O
oximes	B
which	O
have	O
been	O
tested	O
in	O
vitro	O
in	O
rat	O
brain	O
homogenates	O
with	O
highly	O
relevant	O
surrogates	O
for	O
sarin	B
(	O
phthalimidyl	B
isopropyl	I
methylphosphonate	I
;	O
PIMP	B
)	O
and	O
VX	O
(	O
nitrophenyl	B
ethyl	I
methylphosphonate	I
;	O
NEMP	B
)	O
.	O

The	O
oximes	B
demonstrated	O
a	O
range	O
of	O
14	O
-	O
76	O
%	O
reactivation	O
of	O
rat	O
brain	O
AChE	O
in	O
vitro	O
.	O

An	O
in	O
vivo	O
testing	O
paradigm	O
was	O
developed	O
in	O
which	O
the	O
novel	O
oxime	B
was	O
administered	O
at	O
the	O
time	O
of	O
maximal	O
brain	O
AChE	O
inhibition	O
(	O
about	O
80	O
%	O
)	O
(	O
1h	O
)	O
elicited	O
by	O
nitrophenyl	B
isopropyl	I
methylphosphonate	I
(	O
NIMP	B
;	O
sarin	B
surrogate	O
)	O
.	O

This	O
paradigm	O
,	O
with	O
delayed	O
administration	O
of	O
oxime	B
to	O
a	O
time	O
when	O
brain	O
AChE	O
was	O
starting	O
to	O
recover	O
,	O
was	O
designed	O
to	O
minimize	O
reactivation	O
/	O
reinhibition	O
of	O
peripheral	O
AChE	O
during	O
the	O
reactivation	O
period	O
which	O
would	O
decrease	O
the	O
availability	O
of	O
the	O
surrogate	O
for	O
entry	O
into	O
the	O
brain	O
;	O
this	O
paradigm	O
will	O
allow	O
proof	O
of	O
concept	O
of	O
BBB	O
penetrability	O
.	O

The	O
initial	O
studies	O
of	O
these	O
oximes	B
in	O
vivo	O
with	O
the	O
sarin	B
surrogate	O
NIMP	B
have	O
indicated	O
reactivation	O
of	O
up	O
to	O
about	O
25	O
%	O
at	O
30min	O
after	O
oxime	B
administration	O
and	O
substantial	O
attenuation	O
of	O
seizure	O
behavior	O
from	O
some	O
of	O
the	O
oximes	B
.	O

Therefore	O
these	O
novel	O
oximes	B
have	O
considerable	O
potential	O
as	O
brain	O
-	O
protecting	O
therapeutics	O
for	O
anticholinesterases	O
.	O

Absolute	O
quantitation	O
of	O
stevioside	B
and	O
rebaudioside	B
A	I
in	O
commercial	O
standards	O
by	O
quantitative	O
NMR	O
.	O

The	O
extract	O
prepared	O
from	O
the	O
leaves	O
of	O
Stevia	O
rebaudiana	O
BERTONI	O
(	O
Asteraceae	O
)	O
contains	O
sweet	O
steviol	B
glycosides	I
,	O
mainly	O
stevioside	B
and	O
rebaudioside	B
A.	I
Highly	O
purified	O
stevia	O
extracts	O
have	O
become	O
popular	O
worldwide	O
as	O
a	O
natural	O
,	O
low	O
-	O
calorie	O
sweetener	O
.	O

They	O
contain	O
various	O
types	O
of	O
steviol	B
glycosides	I
,	O
and	O
their	O
main	O
components	O
are	O
stevioside	B
and	O
rebaudioside	B
A.	I
The	O
content	O
of	O
each	O
steviol	B
glycoside	I
is	O
quantified	O
by	O
comparing	O
the	O
ratios	O
of	O
the	O
molecular	O
weights	O
and	O
the	O
chromatographic	O
peak	O
areas	O
of	O
the	O
samples	O
to	O
those	O
of	O
stevioside	B
or	O
rebaudioside	B
A	I
standards	O
of	O
the	O
Food	O
and	O
Agriculture	O
Organization	O
of	O
the	O
United	O
Nations	O
(	O
FAO	O
)	O
/	O
World	O
Health	O
Organization	O
(	O
WHO	O
)	O
Joint	O
Expert	O
Committee	O
on	O
Food	O
Additives	O
(	O
JECFA	O
)	O
and	O
other	O
specifications	O
.	O

However	O
,	O
various	O
commercial	O
standard	O
reagents	O
of	O
stevioside	B
and	O
rebaudioside	B
A	I
are	O
available	O
.	O

Their	O
purities	O
are	O
different	O
and	O
their	O
exact	O
purities	O
are	O
not	O
indicated	O
.	O

Therefore	O
,	O
the	O
measured	O
values	O
of	O
stevioside	B
and	O
rebaudioside	B
A	I
contained	O
in	O
a	O
sample	O
vary	O
according	O
to	O
the	O
standard	O
used	O
for	O
the	O
quantification	O
.	O

In	O
this	O
study	O
,	O
we	O
utilized	O
an	O
accurate	O
method	O
,	O
quantitative	O
NMR	O
(	O
qNMR	O
)	O
,	O
for	O
determining	O
the	O
contents	O
of	O
stevioside	B
and	O
rebaudioside	B
A	I
in	O
standards	O
,	O
with	O
traceability	O
to	O
the	O
International	O
System	O
of	O
Units	O
(	O
SI	O
units	O
)	O
.	O

The	O
purities	O
of	O
several	O
commercial	O
standards	O
were	O
determined	O
to	O
confirm	O
their	O
actual	O
values	O
.	O

2-Amino-4-arylthiazole	B
compounds	O
as	O
TRPA1	O
antagonists	O
(	O
WO	O
2012085662	O
)	O
:	O
a	O
patent	O
evaluation	O
.	O

The	O
patent	O
claims	O
2-amino-4-arylthiazole	B
derivative	O
compounds	O
as	O
inhibitors	O
of	O
the	O
TRPA1	O
(	O
transient	O
receptor	O
potential	O
ankyrin	O
,	O
member	O
1	O
)	O
receptor	O
.	O

These	O
compounds	O
are	O
potent	O
antagonists	O
on	O
the	O
basis	O
of	O
the	O
results	O
of	O
in	O
vitro	O
assays	O
,	O
and	O
are	O
expected	O
to	O
be	O
useful	O
for	O
treating	O
conditions	O
and	O
disorders	O
associated	O
with	O
TRPA1	O
function	O
such	O
as	O
pain	O
,	O
chronic	O
pain	O
,	O
neuropathic	O
pain	O
,	O
rheumatoid	O
arthritic	O
pain	O
,	O
osteoarthritic	O
pain	O
,	O
diabetic	O
neuropathy	O
and	O
inflammatory	O
disorders	O
.	O

Bioactive	O
constituents	O
of	O
Salvia	O
chrysophylla	O
Stapf	O
.	O

The	O
dichloromethane	B
extract	O
of	O
the	O
aerial	O
parts	O
of	O
Salvia	O
chrysophylla	O
Stapf	O
(	O
Lamiaceae	O
)	O
,	O
which	O
is	O
an	O
endemic	O
species	O
to	O
south	O
-	O
western	O
Anatolia	O
,	O
was	O
studied	O
for	O
non	O
-	O
volatile	O
secondary	O
metabolites	O
for	O
the	O
first	O
time	O
in	O
this	O
study	O
.	O

Structures	O
of	O
the	O
isolated	O
compounds	O
were	O
elucidated	O
as	O
sclareol	B
,	O
	B
-	I
sitosterol	I
,	O
salvigenin	B
,	O
oleanolic	B
acid	I
and	O
ursolic	B
acid	I
.	O

The	O
lipid	O
peroxidation	O
inhibitory	O
activity	O
and	O
the	O
DPPH	B
free	O
radical	O
scavenging	O
activity	O
of	O
the	O
pure	O
isolates	O
were	O
investigated	O
to	O
establish	O
their	O
antioxidant	O
potential	O
.	O

Their	O
anticholinesterase	O
activity	O
was	O
carried	O
out	O
by	O
the	O
Ellman	O
assay	O
against	O
both	O
enzymes	O
,	O
acetylcholinesterase	O
(	O
AChE	O
)	O
and	O
butyrylcholinesterase	O
,	O
and	O
diterpene	O
sclareol	B
exhibited	O
fairly	O
good	O
activity	O
against	O
both	O
the	O
enzymes	O
while	O
the	O
two	O
triterpenoids	O
oleanolic	B
and	I
ursolic	I
acids	I
exhibited	O
selective	O
activity	O
against	O
AChE.	O

Protective	O
effect	O
of	O
cinnamon	O
polyphenols	B
against	O
STZ	B
-	O
diabetic	O
mice	O
fed	O
high	O
-	O
sugar	O
,	O
high	O
-	O
fat	O
diet	O
and	O
its	O
underlying	O
mechanism	O
.	O

This	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
potential	O
effects	O
of	O
14days	O
'	O
intragastrically	O
given	O
of	O
cinnamon	O
polyphenols	B
(	O
CPS	O
)	O
in	O
treating	O
diabetic	O
mice	O
induced	O
by	O
intraperitoneal	O
injection	O
of	O
streptozotocin	B
(	O
150mgkg	O
(	O
-1	O
)	O
)	O
and	O
fed	O
high	O
-	O
sugar	B
,	O
high	O
-	O
fat	O
diet	O
.	O

The	O
diabetic	O
mice	O
model	O
was	O
successfully	O
established	O
through	O
determining	O
on	O
fasting	O
blood	O
-	O
glucose	B
(	O
FBG	O
)	O
test	O
.	O

As	O
revealed	O
by	O
glucose	B
oxidase	O
(	O
GOD	O
)	O
and	O
radioimmunoassay	O
(	O
RIA	O
)	O
,	O
both	O
dimethyldiguanide	B
(	O
DC	O
,	O
0.6gkg	O
(	O
-1	O
)	O
d	O
(	O
-1	O
)	O
)	O
and	O
CPS	O
(	O
0.3	O
,	O
0.6	O
,	O
1.2gkg	O
(	O
-1	O
)	O
d	O
(	O
-1	O
)	O
)	O
treatments	O
significantly	O
resulted	O
in	O
down	O
-	O
regulation	O
of	O
blood	O
glucose	B
and	O
insulin	O
levels	O
in	O
serum	O
,	O
while	O
the	O
levels	O
of	O
oxidative	O
stress	O
markers	O
were	O
markedly	O
lowered	O
through	O
ELISA	O
assay	O
.	O

Meanwhile	O
,	O
the	O
pathological	O
damage	O
in	O
islet	O
with	O
pancreatic	O
beta	O
cells	O
was	O
ameliorated	O
by	O
treatment	O
of	O
CPS	O
at	O
different	O
doses	O
,	O
as	O
shown	O
in	O
HE	O
stain	O
.	O

At	O
the	O
same	O
time	O
,	O
the	O
treatments	O
also	O
caused	O
notable	O
reduction	O
of	O
iNOS	O
,	O
NF	O
-	O
B	O
expressions	O
showing	O
in	O
Western	O
blot	O
analysis	O
.	O

These	O
findings	O
demonstrate	O
that	O
cinnamon	O
polyphenols	B
can	O
exert	O
the	O
hypoglycemic	O
and	O
hypolipidemic	O
effects	O
through	O
the	O
mechanisms	O
that	O
may	O
be	O
associated	O
with	O
repairing	O
pancreatic	O
beta	O
cells	O
in	O
diabetic	O
mice	O
and	O
improving	O
its	O
anti	O
-	O
oxidative	O
capacity	O
,	O
as	O
well	O
as	O
attenuating	O
cytotoxicity	O
via	O
inhibition	O
of	O
iNOS	O
,	O
NF	O
-	O
B	O
activation	O
.	O

Postexposure	O
application	O
of	O
Fas	O
receptor	O
small	O
-	O
interfering	O
RNA	O
to	O
suppress	O
sulfur	B
mustard	O
-	O
induced	O
apoptosis	O
in	O
human	O
airway	O
epithelial	O
cells	O
:	O
implication	O
for	O
a	O
therapeutic	O
approach	O
.	O

Sulfur	B
mustard	O
(	O
SM	O
)	O
is	O
a	O
vesicant	O
chemical	O
warfare	O
and	O
terrorism	O
agent	O
.	O

Besides	O
skin	O
and	O
eye	O
injury	O
,	O
respiratory	O
damage	O
has	O
been	O
mainly	O
responsible	O
for	O
morbidity	O
and	O
mortality	O
after	O
SM	O
exposure	O
.	O

Previously	O
,	O
it	O
was	O
shown	O
that	O
suppressing	O
the	O
death	O
receptor	O
(	O
DR	O
)	O
response	O
by	O
the	O
dominant	O
-	O
negative	O
Fas	O
-	O
associated	O
death	O
domain	O
protein	O
prior	O
to	O
SM	O
exposure	O
blocked	O
apoptosis	O
and	O
microvesication	O
in	O
skin	O
.	O

Here	O
,	O
we	O
studied	O
whether	O
antagonizing	O
the	O
Fas	O
receptor	O
(	O
FasR	O
)	O
pathway	O
by	O
small	O
-	O
interfering	O
RNA	O
(	O
siRNA	O
)	O
applied	O
after	O
SM	O
exposure	O
would	O
prevent	O
apoptosis	O
and	O
,	O
thus	O
,	O
airway	O
injury	O
.	O

Normal	O
human	O
bronchial	O
/	O
tracheal	O
epithelial	O
(	O
NHBE	O
)	O
cells	O
were	O
used	O
as	O
an	O
in	O
vitro	O
model	O
with	O
FasR	O
siRNA	O
,	O
FasR	O
agonistic	O
antibody	O
CH11	O
,	O
and	O
FasR	O
antagonistic	O
antibody	O
ZB4	O
as	O
investigative	O
tools	O
.	O

In	O
NHBE	O
cells	O
,	O
both	O
SM	O
(	O
300	O
M	O
)	O
and	O
CH11	O
(	O
100	O
ng	O
/	O
ml	O
)	O
induced	O
caspase-3	O
activation	O
,	O
which	O
was	O
inhibited	O
by	O
FasR	O
siRNA	O
and	O
ZB4	O
,	O
indicating	O
that	O
SM	O
-	O
induced	O
apoptosis	O
was	O
via	O
the	O
Fas	O
response	O
.	O

FasR	O
siRNA	O
inhibited	O
SM	O
-	O
induced	O
caspase-3	O
activation	O
when	O
added	O
to	O
NHBE	O
cultures	O
up	O
to	O
8	O
hours	O
after	O
SM	O
.	O

Results	O
using	O
annexin	O
V	O
/	O
propidium	B
iodide	I
-	O
stained	O
cells	O
showed	O
that	O
both	O
apoptosis	O
and	O
necrosis	O
were	O
involved	O
in	O
cell	O
death	O
due	O
to	O
SM	O
;	O
FasR	O
siRNA	O
decreased	O
both	O
apoptotic	O
and	O
necrotic	O
cell	O
populations	O
.	O

Bronchoalveolar	O
lavage	O
fluid	O
(	O
BALF	O
)	O
of	O
rats	O
exposed	O
to	O
SM	O
(	O
1	O
mg	O
/	O
kg	O
,	O
50	O
minutes	O
)	O
revealed	O
a	O
significant	O
(	O
P	O
<	O
0.05	O
)	O
increase	O
in	O
soluble	O
Fas	O
ligand	O
and	O
active	O
caspase-3	O
in	O
BALF	O
cells	O
.	O

These	O
findings	O
suggest	O
an	O
intervention	O
of	O
Fas	O
-	O
mediated	O
apoptosis	O
as	O
a	O
postexposure	O
therapeutic	O
strategy	O
with	O
a	O
therapeutic	O
window	O
for	O
SM	O
inhalation	O
injury	O
and	O
possibly	O
other	O
respiratory	O
diseases	O
involving	O
the	O
Fas	O
response	O
.	O

Investigating	O
the	O
roles	O
of	O
different	O
monoamine	B
transmitters	O
and	O
impulse	O
control	O
using	O
the	O
5-choice	O
serial	O
reaction	O
time	O
task	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
drugs	O
which	O
block	O
the	O
reuptake	O
of	O
catecholamine	B
neurotransmitters	O
improve	O
impulse	O
control	O
in	O
diseases	O
such	O
as	O
attention	O
deficit	O
hyperactivity	O
disorder	O
(	O
ADHD	O
)	O
.	O

Serotonin	B
-	O
specific	O
reuptake	O
inhibitors	O
(	O
SSRI	O
)	O
lack	O
efficacy	O
in	O
ADHD	O
and	O
have	O
been	O
linked	O
to	O
increased	O
suicide	O
risk	O
.	O

The	O
present	O
study	O
investigated	O
drugs	O
with	O
affinity	O
for	O
one	O
or	O
more	O
of	O
the	O
monoamine	B
reuptake	O
transporters	O
using	O
the	O
5-choice	O
serial	O
reaction	O
time	O
task	O
,	O
a	O
model	O
of	O
attention	O
and	O
impulsivity	O
in	O
rodents	O
.	O

We	O
also	O
tested	O
the	O
effects	O
of	O
the	O
alpha	O
(	O
2	O
)	O
-adreoceptor	O
antagonist	O
,	O
idazoxan	B
and	O
novel	O
antidepressant	O
,	O
agomelatine	B
,	O
which	O
both	O
increase	O
cortical	O
noradrenaline	B
concentrations	O
through	O
non	O
-	O
reuptake	O
mechanisms	O
.	O

Improvements	O
in	O
impulse	O
control	O
were	O
observed	O
with	O
venlafaxine	B
,	O
a	O
serotonin	B
and	O
noradrenaline	B
re	O
-	O
uptake	O
inhibitor	O
(	O
SNRI	O
)	O
but	O
not	O
bupropion	B
(	O
dopamine	B
and	O
noradrenaline	B
re	O
-	O
uptake	O
inhibitor	O
)	O
.	O

Sibutramine	B
(	O
SNRI	O
)	O
reduced	O
premature	O
responses	O
by	O
~50	O
%	O
at	O
the	O
highest	O
dose	O
tested	O
but	O
this	O
was	O
not	O
significant	O
.	O

All	O
three	O
of	O
the	O
SSRIs	O
tested	O
reduced	O
premature	O
responding	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
although	O
also	O
slowed	O
response	O
and	O
collection	O
latencies	O
.	O

Neither	O
idazoxan	B
nor	O
agomelatine	B
significantly	O
reduced	O
premature	O
responding	O
,	O
suggesting	O
a	O
lack	O
of	O
efficacy	O
at	O
the	O
doses	O
tested	O
.	O

None	O
of	O
the	O
drugs	O
tested	O
improved	O
attention	O
in	O
this	O
task	O
but	O
sibutramine	B
(	O
SNRI	O
)	O
,	O
fluoxetine	B
(	O
SSRI	O
)	O
and	O
paroxetine	B
(	O
SSRI	O
)	O
all	O
increased	O
omissions	O
at	O
the	O
highest	O
dose	O
tested	O
.	O

These	O
data	O
suggest	O
that	O
the	O
SNRIs	O
and	O
SSRIs	O
reduce	O
premature	O
responding	O
but	O
tend	O
to	O
be	O
less	O
specific	O
than	O
noradrenaline	B
specific	O
reuptake	O
inhibitors	O
in	O
this	O
model	O
.	O

SSRIs	O
did	O
not	O
induce	O
any	O
specific	O
impairment	O
in	O
impulse	O
control	O
in	O
this	O
model	O
.	O

Interactions	O
between	O
chemical	O
and	O
climate	O
stressors	O
:	O
a	O
role	O
for	O
mechanistic	O
toxicology	O
in	O
assessing	O
climate	O
change	O
risks	O
.	O

Incorporation	O
of	O
global	O
climate	O
change	O
(	O
GCC	O
)	O
effects	O
into	O
assessments	O
of	O
chemical	O
risk	O
and	O
injury	O
requires	O
integrated	O
examinations	O
of	O
chemical	O
and	O
nonchemical	O
stressors	O
.	O

Environmental	O
variables	O
altered	O
by	O
GCC	O
(	O
temperature	O
,	O
precipitation	O
,	O
salinity	O
,	O
pH	O
)	O
can	O
influence	O
the	O
toxicokinetics	O
of	O
chemical	O
absorption	O
,	O
distribution	O
,	O
metabolism	O
,	O
and	O
excretion	O
as	O
well	O
as	O
toxicodynamic	O
interactions	O
between	O
chemicals	O
and	O
target	O
molecules	O
.	O

In	O
addition	O
,	O
GCC	O
challenges	O
processes	O
critical	O
for	O
coping	O
with	O
the	O
external	O
environment	O
(	O
water	O
balance	O
,	O
thermoregulation	O
,	O
nutrition	O
,	O
and	O
the	O
immune	O
,	O
endocrine	O
,	O
and	O
neurological	O
systems	O
)	O
,	O
leaving	O
organisms	O
sensitive	O
to	O
even	O
slight	O
perturbations	O
by	O
chemicals	O
when	O
pushed	O
to	O
the	O
limits	O
of	O
their	O
physiological	O
tolerance	O
range	O
.	O

In	O
simplest	O
terms	O
,	O
GCC	O
can	O
make	O
organisms	O
more	O
sensitive	O
to	O
chemical	O
stressors	O
,	O
while	O
alternatively	O
,	O
exposure	O
to	O
chemicals	O
can	O
make	O
organisms	O
more	O
sensitive	O
to	O
GCC	O
stressors	O
.	O

One	O
challenge	O
is	O
to	O
identify	O
potential	O
interactions	O
between	O
nonchemical	O
and	O
chemical	O
stressors	O
affecting	O
key	O
physiological	O
processes	O
in	O
an	O
organism	O
.	O

We	O
employed	O
adverse	O
outcome	O
pathways	O
,	O
constructs	O
depicting	O
linkages	O
between	O
mechanism	O
-	O
based	O
molecular	O
initiating	O
events	O
and	O
impacts	O
on	O
individuals	O
or	O
populations	O
,	O
to	O
assess	O
how	O
chemical-	O
and	O
climate	O
-	O
specific	O
variables	O
interact	O
to	O
lead	O
to	O
adverse	O
outcomes	O
.	O

Case	O
examples	O
are	O
presented	O
for	O
prospective	O
scenarios	O
,	O
hypothesizing	O
potential	O
chemical	O
-	O
GCC	O
interactions	O
,	O
and	O
retrospective	O
scenarios	O
,	O
proposing	O
mechanisms	O
for	O
demonstrated	O
chemical	O
-	O
climate	O
interactions	O
in	O
natural	O
populations	O
.	O

Understanding	O
GCC	O
interactions	O
along	O
adverse	O
outcome	O
pathways	O
facilitates	O
extrapolation	O
between	O
species	O
or	O
other	O
levels	O
of	O
organization	O
,	O
development	O
of	O
hypotheses	O
and	O
focal	O
areas	O
for	O
further	O
research	O
,	O
and	O
improved	O
inputs	O
for	O
risk	O
and	O
resource	O
injury	O
assessments	O
.	O

How	O
is	O
(	B
68	I
)	I
Ga	I
labeling	O
of	O
macrocyclic	O
chelators	O
influenced	O
by	O
metal	O
ion	O
contaminants	O
in	O
(	B
68	I
)	I
Ge	I
/	O
(	B
68	I
)	I
Ga	I
generator	O
eluates	O
?	O

To	O
assess	O
the	O
influence	O
of	O
Zn	B
(	I
2	I
+	I
)	I
,	O
Cu	B
(	I
2	I
+	I
)	I
,	O
Fe	B
(	I
3	I
+	I
)	I
,	O
Al	B
(	I
3	I
+	I
)	I
,	O
Ti	B
(	I
IV	I
)	I
,	O
and	O
Sn	B
(	I
IV	I
)	I
on	O
incorporation	O
of	O
(	B
68	I
)	I
Ga	I
(	I
3	I
+	I
)	I
into	O
pendant	O
-	O
arm	O
macrocyclic	O
chelators	O
,	O
the	O
(	B
68	I
)	I
Ga	I
labeling	O
of	O
1,4,7-triazacyclononane-1,4,7-triacetic	B
acid	I
(	O
NOTA	B
)	O
,	O
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic	B
acid	I
(	O
DOTA	B
)	O
,	O
1,4,7-triazacyclononane-1,4,7-tris	B
[	I
methyl	I
(	I
2-carboxyethyl	I
)	I
phosphinic	I
acid	I
]	I
)	I
(	O
TRAP	B
)	O
,	O
and	O
1,4,7-triazacyclononane-1-	B
[	I
methyl	I
(	I
2-carboxyethyl	I
)	I
phosphinic	I
acid	I
]	I
-4,7-bis	I
[	I
methyl	I
(	I
2-hydroxymethyl	I
)	I
phosphinic	I
acid	I
]	I
(	O
NOPO	B
)	O
,	O
as	O
well	O
as	O
their	O
peptide	O
conjugates	O
,	O
was	O
investigated	O
in	O
the	O
presence	O
of	O
varying	O
concentrations	O
of	O
these	O
metal	O
ions	O
.	O

The	O
(	B
68	I
)	I
Ga	I
labeling	O
yield	O
for	O
carboxylate	B
-	O
type	O
chelators	O
NOTA	B
and	O
DOTA	B
is	O
decreased	O
at	O
lower	O
metal	O
ion	O
contaminant	O
concentrations	O
compared	O
with	O
phosphinate	B
-	O
type	O
chelators	O
TRAP	B
and	O
NOPO	B
.	O

The	O
latter	O
are	O
able	O
to	O
rapidly	O
exchange	O
coordinated	O
Zn	B
(	I
II	I
)	I
with	O
(	B
68	I
)	I
Ga	I
(	I
3	I
+	I
)	I
,	O
as	O
confirmed	O
by	O
mass	O
spectrometry	O
and	O
(	B
31	I
)	I
P	I
NMR	O
spectroscopy	O
.	O

(	B
68	I
)	I
Ga	I
labeling	O
of	O
Zn	B
(	I
II	I
)	I
complexes	O
of	O
TRAP	B
and	O
NOPO	B
proceeds	O
as	O
efficient	O
as	O
labeling	O
of	O
neat	O
NOTA	B
;	O
this	O
applies	O
also	O
to	O
the	O
corresponding	O
peptide	O
conjugates	O
of	O
these	O
chelators	O
.	O

This	O
behavior	O
results	O
in	O
substantially	O
improved	O
selectivity	O
for	O
Ga	B
(	I
3	I
+	I
)	I
and	O
,	O
therefore	O
,	O
in	O
more	O
robust	O
and	O
reliable	O
(	B
68	I
)	I
Ga	I
labeling	O
procedures	O
.	O

In	O
addition	O
,	O
none	O
of	O
the	O
investigated	O
chelators	O
binds	O
(	B
68	I
)	I
Ge	I
,	O
rendering	O
post	O
-	O
labeling	O
purification	O
protocols	O
,	O
for	O
example	O
,	O
solid	O
-	O
phase	O
extraction	O
,	O
a	O
reliable	O
means	O
of	O
removal	O
of	O
(	B
68	I
)	I
Ge	I
contamination	O
from	O
(	B
68	I
)	I
Ga	I
radiopharmaceuticals	O
.	O

Influence	O
of	O
global	O
climate	O
change	O
on	O
chemical	O
fate	O
and	O
bioaccumulation	O
:	O
the	O
role	O
of	O
multimedia	O
models	O
.	O

Multimedia	O
environmental	O
fate	O
models	O
are	O
valuable	O
tools	O
for	O
investigating	O
potential	O
changes	O
associated	O
with	O
global	O
climate	O
change	O
,	O
particularly	O
because	O
thermodynamic	O
forcing	O
on	O
partitioning	O
behavior	O
as	O
well	O
as	O
diffusive	O
and	O
nondiffusive	O
exchange	O
processes	O
are	O
implicitly	O
considered	O
.	O

Similarly	O
,	O
food	O
-	O
web	O
bioaccumulation	O
models	O
are	O
capable	O
of	O
integrating	O
the	O
net	O
effect	O
of	O
changes	O
associated	O
with	O
factors	O
such	O
as	O
temperature	O
,	O
growth	O
rates	O
,	O
feeding	O
preferences	O
,	O
and	O
partitioning	O
behavior	O
on	O
bioaccumulation	O
potential	O
.	O

For	O
the	O
climate	O
change	O
scenarios	O
considered	O
in	O
the	O
present	O
study	O
,	O
such	O
tools	O
indicate	O
that	O
alterations	O
to	O
exposure	O
concentrations	O
are	O
typically	O
within	O
a	O
factor	O
of	O
2	O
of	O
the	O
baseline	O
output	O
.	O

Based	O
on	O
an	O
appreciation	O
for	O
the	O
uncertainty	O
in	O
model	O
parameters	O
and	O
baseline	O
output	O
,	O
the	O
authors	O
recommend	O
caution	O
when	O
interpreting	O
or	O
speculating	O
on	O
the	O
relative	O
importance	O
of	O
global	O
climate	O
change	O
with	O
respect	O
to	O
how	O
changes	O
caused	O
by	O
it	O
will	O
influence	O
chemical	O
fate	O
and	O
bioavailability	O
.	O

High	O
-	O
dose	O
sodium	B
selenite	I
toxicity	O
can	O
not	O
be	O
prevented	O
by	O
the	O
co	O
-	O
administration	O
of	O
pharmacological	O
levels	O
of	O
epigallocatechin-3-gallate	B
which	O
in	O
turn	O
aggravates	O
the	O
toxicity	O
.	O

Selenium	B
,	O
an	O
essential	O
trace	O
element	O
,	O
can	O
also	O
be	O
toxic	O
at	O
higher	O
levels	O
of	O
exposure	O
.	O

Several	O
lines	O
of	O
evidence	O
show	O
epigallocatechin-3-gallate	B
(	O
EGCG	B
)	O
,	O
a	O
predominant	O
component	O
of	O
green	O
tea	O
catechins	B
with	O
numerous	O
health	O
benefits	O
,	O
can	O
ameliorate	O
the	O
toxicity	O
of	O
many	O
agents	O
.	O

A	O
proof	O
-	O
in	O
-	O
principle	O
experiment	O
was	O
conducted	O
to	O
determine	O
if	O
EGCG	B
would	O
ameliorate	O
sodium	B
selenite	I
-	O
induced	O
growth	O
suppression	O
.	O

Mice	O
were	O
intraperitioneally	O
injected	O
with	O
selenite	B
once	O
daily	O
for	O
five	O
days	O
at	O
a	O
dose	O
of	O
3	O
mg	O
Se	B
/	O
kg	O
,	O
which	O
fully	O
suppressed	O
animal	O
growth	O
but	O
did	O
not	O
cause	O
death	O
.	O

Surprisingly	O
the	O
co	O
-	O
administration	O
of	O
the	O
selenite	B
and	O
nontoxic	O
doses	O
of	O
EGCG	B
(	O
10	O
,	O
20	O
and	O
40	O
mg	O
/	O
kg	O
,	O
intraperitioneally	O
)	O
resulted	O
in	O
the	O
mortality	O
of	O
treated	O
mice	O
in	O
a	O
dose	O
and	O
time	O
-	O
dependent	O
manner	O
(	O
33.3	O
%	O
,	O
100	O
%	O
and	O
100	O
%	O
,	O
respectively	O
)	O
.	O

EGCG	B
-	O
selenite	B
induced	O
lethality	O
did	O
not	O
result	O
from	O
enhanced	O
selenium	B
accumulation	O
but	O
appeared	O
to	O
involve	O
the	O
suppression	O
of	O
a	O
selenite	B
-	O
induced	O
adaptive	O
response	O
as	O
evidenced	O
by	O
hepatic	O
glutathione	B
S	O
-	O
transferase	O
activity	O
.	O

While	O
EGCG	B
has	O
been	O
reported	O
to	O
ameliorate	O
the	O
toxicity	O
of	O
some	O
agents	O
,	O
the	O
induction	O
of	O
mortality	O
by	O
combined	O
treatment	O
with	O
pharmacological	O
doses	O
of	O
selenium	B
and	O
EGCG	B
is	O
a	O
previously	O
unrecognized	O
synergism	O
that	O
must	O
be	O
considered	O
not	O
only	O
in	O
the	O
remediation	O
of	O
high	O
environmental	O
selenium	B
exposures	O
but	O
also	O
in	O
the	O
development	O
of	O
pharmaceuticals	O
and	O
nutriceuticals	O
.	O

Chinese	O
medicine	O
formula	O
"	O
Weikang	O
Keli	O
"	O
induces	O
autophagic	O
cell	O
death	O
on	O
human	O
gastric	O
cancer	O
cell	O
line	O
SGC-7901	O
.	O

Weikang	O
Keli	O
(	O
constitutes	O
of	O
Root	O
of	O
Codonopsis	O
pilosula	O
,	O
Rhizoma	O
Atractylodis	O
Macrocephalae	O
,	O
Rhizoma	O
Curcumae	O
Aeruginosae	O
,	O
Rhizoma	O
Pinelliae	O
,	O
Actinidia	O
chinensis	O
Planch	O
,	O
and	O
Rhodiola	O
rosea	O
)	O
is	O
a	O
well	O
known	O
Chinese	O
herbal	O
formula	O
for	O
gastric	O
cancer	O
therapy	O
in	O
clinical	O
treatment	O
.	O

However	O
,	O
the	O
detailed	O
molecular	O
mechanisms	O
involved	O
are	O
still	O
not	O
fully	O
understood	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
that	O
Weikang	O
Keli	O
could	O
induce	O
patterns	O
of	O
autophagy	O
in	O
SGC-7901	O
cells	O
,	O
including	O
intracellular	O
vacuole	O
formation	O
,	O
microtubule	O
-	O
associated	O
protein	O
1	O
light	O
chain	O
3	O
(	O
LC3	O
)	O
conversion	O
.	O

Hoechst	B
33258	I
staining	O
and	O
Western	O
blot	O
analysis	O
of	O
apoptosis	O
-	O
related	O
proteins	O
showed	O
that	O
WK	O
induced	O
SGC-7901	O
cell	O
death	O
was	O
not	O
through	O
apoptosis	O
.	O

In	O
vivo	O
study	O
also	O
revealed	O
that	O
i.g	O
.	O

administration	O
of	O
Weikang	O
Keli	O
once	O
a	O
day	O
for	O
25	O
days	O
could	O
significantly	O
reduce	O
tumor	O
volumes	O
by	O
about	O
50	O
%	O
.	O

Collectively	O
,	O
the	O
current	O
data	O
indicated	O
that	O
Weikang	O
Keli	O
induced	O
gastric	O
cancer	O
cell	O
death	O
by	O
autophagy	O
effects	O
.	O

Relieving	O
visceral	O
hyperalgesia	O
effect	O
of	O
Kangtai	O
capsule	O
and	O
its	O
potential	O
mechanisms	O
via	O
modulating	O
the	O
5-HT	B
and	O
NO	B
level	O
in	O
vivo	O
.	O

Kangtai	O
capsule	O
(	O
KT	O
)	O
is	O
one	O
type	O
of	O
traditional	O
Chinese	O
medicine	O
preparation	O
derived	O
from	O
the	O
proved	O
recipe	O
,	O
which	O
was	O
frequently	O
applied	O
as	O
an	O
effective	O
clinical	O
treatment	O
of	O
IBS	O
.	O

However	O
,	O
there	O
still	O
lack	O
the	O
reasonable	O
and	O
all	O
-	O
round	O
analytical	O
approach	O
and	O
the	O
scientific	O
studies	O
on	O
its	O
underlying	O
mechanisms	O
.	O

Therefore	O
,	O
our	O
study	O
aimed	O
to	O
develop	O
the	O
novel	O
method	O
for	O
evaluating	O
its	O
quality	O
as	O
well	O
as	O
to	O
interpret	O
the	O
potential	O
mechanisms	O
.	O

In	O
our	O
study	O
,	O
high	O
performance	O
liquid	O
chromatography	O
(	O
HPLC	O
)	O
fingerprint	O
was	O
applied	O
to	O
provide	O
a	O
chemical	O
profile	O
of	O
KT	O
.	O

The	O
neonatal	O
maternal	O
separation	O
(	O
NMS	O
)	O
on	O
Sprague	O
-	O
Dawley	O
pups	O
was	O
employed	O
to	O
evaluate	O
the	O
therapeutic	O
effect	O
of	O
KT	O
by	O
virtue	O
of	O
various	O
parameters	O
including	O
visceral	O
hyperalgesia	O
,	O
serum	O
nitric	B
oxide	I
(	O
NO	B
)	O
level	O
,	O
and	O
tissue	O
5-hydroxytryptamine	B
(	O
5-HT	B
)	O
level	O
.	O

Consequently	O
,	O
a	O
chromatographic	O
condition	O
,	O
which	O
was	O
carried	O
at	O
30	O
	O
C	O
with	O
a	O
flow	O
rate	O
of	O
0.5	O
ml	O
/	O
min	O
on	O
AQUA	O
3	O
C18	O
column	O
with	O
mobile	O
phase	O
of	O
acetonitrile	B
and	O
water	O
-	O
phosphoric	B
acid	I
(	O
100:0.1	O
,	O
v	O
/	O
v	O
)	O
,	O
was	O
established	O
to	O
give	O
a	O
common	O
fingerprint	O
chromatography	O
under	O
254	O
nm	O
with	O
a	O
similarity	O
index	O
of	O
0.963	O
within	O
ten	O
batches	O
of	O
KT	O
samples	O
.	O

On	O
the	O
NMS	O
model	O
,	O
KT	O
markedly	O
elevated	O
the	O
pain	O
threshold	O
of	O
NMS	O
rats	O
.	O

Furthermore	O
,	O
KT	O
at	O
three	O
doses	O
significantly	O
decreased	O
5-HT	B
content	O
from	O
distal	O
colon	O
of	O
visceral	O
hyperalgesia	O
rats	O
induced	O
by	O
NMS	O
,	O
while	O
the	O
significant	O
decrease	O
of	O
5-HT	B
content	O
in	O
serum	O
was	O
only	O
observed	O
in	O
the	O
group	O
with	O
KT	O
at	O
high	O
dose	O
.	O

However	O
,	O
compared	O
with	O
that	O
in	O
NMS	O
rats	O
without	O
KT	O
,	O
there	O
was	O
no	O
apparent	O
difference	O
of	O
5-HT	B
level	O
from	O
brain	O
issue	O
in	O
the	O
rats	O
with	O
various	O
doses	O
.	O

Besides	O
,	O
KT	O
could	O
substantially	O
elevate	O
the	O
concentration	O
of	O
NO	B
in	O
the	O
serum	O
.	O

The	O
results	O
showed	O
our	O
study	O
developed	O
the	O
simple	O
,	O
rapid	O
,	O
accurate	O
,	O
reproducible	O
qualitative	O
and	O
quantitative	O
analysis	O
by	O
HPLC	O
fingerprint	O
for	O
the	O
quality	O
control	O
for	O
KT	O
.	O

Data	O
from	O
the	O
pharmacological	O
investigation	O
suggested	O
that	O
the	O
curative	O
effect	O
of	O
KT	O
to	O
the	O
visceral	O
hypersensitivity	O
may	O
be	O
concerned	O
with	O
the	O
level	O
of	O
5-HT	B
and	O
NO	B
in	O
vivo	O
,	O
promising	O
its	O
potential	O
in	O
irritable	O
bowel	O
syndrome	O
treatment	O
.	O

Effects	O
of	O
phospholipase	O
A2	O
and	O
metalloprotease	O
fractions	O
of	O
Russell	O
's	O
viper	O
venom	O
on	O
cytokines	O
and	O
renal	O
hemodynamics	O
in	O
dogs	O
.	O

Several	O
enzymes	O
in	O
Russell	O
's	O
viper	O
(	O
Daboia	O
siamensis	O
)	O
venom	O
are	O
involved	O
in	O
the	O
venom	O
effects	O
and	O
renal	O
injury	O
.	O

The	O
effects	O
of	O
fractional	O
components	O
of	O
Russell	O
's	O
viper	O
venom	O
,	O
phospholipase	O
A	O
(	O
2	O
)	O
and	O
metalloprotease	O
fractions	O
,	O
were	O
examined	O
in	O
two	O
groups	O
of	O
four	O
experimental	O
dogs	O
each	O
.	O

Animals	O
received	O
an	O
intravenous	O
injection	O
of	O
140	O
g	O
/	O
kg	O
of	O
each	O
venom	O
fraction	O
.	O

The	O
inflammatory	O
effects	O
and	O
renal	O
hemodynamic	O
changes	O
were	O
assessed	O
.	O

Plasma	O
concentrations	O
of	O
interleukin-6	O
(	O
IL-6	O
)	O
,	O
tumor	O
necrosis	O
factor	O
-	O
	O
(	O
TNF	O
-	O
	O
)	O
and	O
PGE2	B
were	O
elevated	O
by	O
both	O
phospholipase	O
A	O
(	O
2	O
)	O
(	O
PLA	O
(	O
2	O
)	O
)	O
and	O
metalloprotease	O
(	O
MP	O
)	O
fractions	O
.	O

The	O
plasma	O
level	O
of	O
nitric	B
oxide	I
was	O
increased	O
after	O
PLA	O
(	O
2	O
)	O
fraction	O
injection	O
but	O
not	O
with	O
MP	O
fraction	O
injection	O
.	O

Leukocytosis	O
with	O
increase	O
in	O
lymphocytes	O
,	O
monocytes	O
and	O
granulocytes	O
was	O
observed	O
after	O
both	O
PLA	O
(	O
2	O
)	O
and	O
MP	O
injections	O
.	O

Results	O
from	O
this	O
study	O
suggested	O
that	O
both	O
PLA	O
(	O
2	O
)	O
and	O
MP	O
were	O
inflammatory	O
.	O

Increased	O
red	O
blood	O
cell	O
count	O
,	O
hematocrit	O
and	O
hemoglobin	O
concentration	O
were	O
observed	O
in	O
animals	O
injected	O
with	O
PLA	O
(	O
2	O
)	O
fraction	O
,	O
but	O
not	O
with	O
MP	O
fraction	O
.	O

Hemodynamically	O
,	O
PLA	O
(	O
2	O
)	O
fraction	O
induced	O
marked	O
decrease	O
in	O
mean	O
arterial	O
pressure	O
with	O
decreased	O
renal	O
vascular	O
resistance	O
initially	O
followed	O
later	O
by	O
increased	O
renal	O
vascular	O
resistance	O
.	O

MP	O
fraction	O
caused	O
less	O
decrease	O
of	O
mean	O
arterial	O
pressure	O
but	O
increased	O
renal	O
vascular	O
resistance	O
throughout	O
the	O
experiment	O
.	O

Both	O
enzymes	O
decreased	O
renal	O
blood	O
flow	O
,	O
glomerular	O
filtration	O
rate	O
and	O
urine	O
flow	O
.	O

The	O
findings	O
indicate	O
vasodilating	O
effect	O
of	O
PLA	O
(	O
2	O
)	O
fraction	O
and	O
vasoconstricting	O
effect	O
and	O
decreased	O
cardiac	O
function	O
of	O
MP	O
fraction	O
.	O

Heteromtoxin	O
(	O
HmTx	O
)	O
,	O
a	O
novel	O
heterodimeric	O
phospholipase	O
A	O
(	O
2	O
)	O
from	O
Heterometrus	O
laoticus	O
scorpion	O
venom	O
.	O

Heteromtoxin	O
(	O
HmTx	O
)	O
is	O
a	O
group	O
III	O
phospholipase	O
A	O
(	O
2	O
)	O
produced	O
in	O
Heterometrus	O
laoticus	O
,	O
in	O
Thailand	O
.	O

In	O
this	O
study	O
,	O
HmTx	O
was	O
purified	O
from	O
venom	O
by	O
separation	O
chromatography	O
,	O
and	O
the	O
PLA	O
(	O
2	O
)	O
activity	O
of	O
the	O
fractions	O
was	O
determined	O
by	O
lecithin	O
agar	O
assay	O
.	O

The	O
enzyme	O
is	O
an	O
acidic	O
protein	O
with	O
a	O
pI	O
of	O
5.6	O
and	O
an	O
apparent	O
molecular	O
weight	O
of	O
14018.4	O
Da	O
.	O

The	O
nucleotide	B
sequence	O
of	O
HmTx	O
contains	O
649	O
bp	O
,	O
and	O
the	O
mature	O
protein	O
is	O
predicted	O
to	O
have	O
131	O
amino	B
acid	I
residues-104	O
of	O
which	O
make	O
up	O
the	O
large	O
subunit	O
,	O
and	O
27	O
of	O
which	O
make	O
up	O
the	O
small	O
subunit	O
.	O

The	O
subunit	O
structure	O
of	O
HmTx	O
is	O
highly	O
similar	O
to	O
that	O
of	O
the	O
other	O
toxin	O
,	O
Pandinus	O
imperator	O
imperatoxin	O
I	O
(	O
IpTx	O
(	O
i	O
)	O
)	O
and	O
to	O
Mesobuthus	O
tamulus	O
phospholipase	O
A	O
(	O
2	O
)	O
(	O
MtPLA	O
(	O
2	O
)	O
)	O
.	O

The	O
3D	O
-	O
structure	O
of	O
HmTx	O
consists	O
of	O
three	O
conserved	O
alpha	O
-	O
helices	O
:	O
h1	O
(	O
Lys24-His34	B
)	O
,	O
h2	O
(	O
Cys59-Asp71	B
)	O
,	O
and	O
h3	O
(	O
Ala80-Phe89	B
)	O
.	O

The	O
beta	O
-	O
sheet	O
consisted	O
of	O
a	O
single	O
stranded	O
anti	O
-	O
parallel	O
beta	O
-	O
sheet	O
(	O
b1.1	O
at	O
Glu43-Lys45	B
and	O
b1.2	O
at	O
Lys48-Asn50	B
)	O
that	O
was	O
highly	O
similar	O
to	O
the	O
conserved	O
sequences	O
(	O
-CGXG-	O
,	O
-CCXXHDXC-	O
and	O
CXCEXXXXXC-	O
)	O
of	O
Apis	O
mellifera	O
(	O
bee	O
)	O
phospholipases	O
.	O

A	O
non	O
-	O
catalytic	O
function	O
of	O
Rev1	O
in	O
translesion	O
DNA	O
synthesis	O
and	O
mutagenesis	O
is	O
mediated	O
by	O
its	O
stable	O
interaction	O
with	O
Rad5	O
.	O

DNA	O
damage	O
tolerance	O
consisting	O
of	O
template	O
switching	O
and	O
translesion	O
synthesis	O
is	O
a	O
major	O
cellular	O
mechanism	O
in	O
response	O
to	O
unrepaired	O
DNA	O
lesions	O
during	O
replication	O
.	O

The	O
Rev1	O
pathway	O
constitutes	O
the	O
major	O
mechanism	O
of	O
translesion	O
synthesis	O
and	O
base	O
damage	O
-	O
induced	O
mutagenesis	O
in	O
model	O
cell	O
systems	O
.	O

Rev1	O
is	O
a	O
dCMP	B
transferase	O
,	O
but	O
additionally	O
plays	O
non	O
-	O
catalytic	O
functions	O
in	O
translesion	O
synthesis	O
.	O

Using	O
the	O
yeast	O
model	O
system	O
,	O
we	O
attempted	O
to	O
gain	O
further	O
insights	O
into	O
the	O
non	O
-	O
catalytic	O
functions	O
of	O
Rev1	O
.	O

Rev1	O
stably	O
interacts	O
with	O
Rad5	O
(	O
a	O
central	O
component	O
of	O
the	O
template	O
switching	O
pathway	O
)	O
via	O
the	O
C	O
-	O
terminal	O
region	O
of	O
Rev1	O
and	O
the	O
N	O
-	O
terminal	O
region	O
of	O
Rad5	O
.	O

Supporting	O
functional	O
significance	O
of	O
this	O
interaction	O
,	O
both	O
the	O
Rev1	O
pathway	O
and	O
Rad5	O
are	O
required	O
for	O
translesion	O
synthesis	O
and	O
mutagenesis	O
of	O
1,N	B
(	I
6	I
)	I
-ethenoadenine	I
.	O

Furthermore	O
,	O
disrupting	O
the	O
Rev1-Rad5	O
interaction	O
by	O
mutating	O
Rev1	O
did	O
not	O
affect	O
its	O
dCMP	B
transferase	O
,	O
but	O
led	O
to	O
inactivation	O
of	O
the	O
Rev1	O
non	O
-	O
catalytic	O
function	O
in	O
translesion	O
synthesis	O
of	O
UV	O
-	O
induced	O
DNA	O
damage	O
.	O

Deletion	O
analysis	O
revealed	O
that	O
the	O
C	O
-	O
terminal	O
21-amino	O
acid	B
sequence	O
of	O
Rev1	O
is	O
uniquely	O
required	O
for	O
its	O
interaction	O
with	O
Rad5	O
and	O
is	O
essential	O
for	O
its	O
non	O
-	O
catalytic	O
function	O
.	O

Deletion	O
analysis	O
additionally	O
implicated	O
a	O
C	O
-	O
terminal	O
region	O
of	O
Rev1	O
in	O
its	O
negative	O
regulation	O
.	O

These	O
results	O
show	O
that	O
a	O
non	O
-	O
catalytic	O
function	O
of	O
Rev1	O
in	O
translesion	O
synthesis	O
and	O
mutagenesis	O
is	O
mediated	O
by	O
its	O
interaction	O
with	O
Rad5	O
.	O

TNF	O
-	O
	O
-	O
induced	O
CXCL8	O
production	O
by	O
A549	O
cells	O
:	O
involvement	O
of	O
the	O
non	O
-	O
neuronal	O
cholinergic	O
system	O
.	O

It	O
was	O
recently	O
suggested	O
that	O
the	O
non	O
-	O
neuronal	O
cholinergic	O
system	O
has	O
a	O
regulatory	O
role	O
in	O
pulmonary	O
inflammation	O
.	O

We	O
investigated	O
this	O
system	O
's	O
involvement	O
in	O
the	O
control	O
of	O
cytokine	O
production	O
by	O
the	O
A549	O
human	O
alveolar	O
epithelial	O
cell	O
line	O
.	O

CXCL8	O
and	O
acetylcholine	B
(	O
ACh	B
)	O
concentrations	O
were	O
measured	O
using	O
ELISA	O
and	O
LC	O
-	O
MS	O
/	O
MS	O
,	O
respectively	O
.	O

The	O
mRNA	O
expression	O
of	O
muscarinic	O
receptor	O
(	O
MR	O
)	O
subtypes	O
was	O
determined	O
using	O
RT	O
-	O
PCR	O
.	O

In	O
A549	O
cells	O
,	O
TNF	O
-	O
	O
increased	O
the	O
release	O
of	O
CXCL8	O
and	O
ACh	B
and	O
the	O
expression	O
of	O
the	O
subtype	O
3	O
MR	O
(	O
M3R	O
)	O
.	O

Furthermore	O
,	O
TNF	O
-	O
	O
-	O
induced	O
CXCL8	O
secretion	O
was	O
(	O
i	O
)	O
inhibited	O
by	O
the	O
MR	O
antagonist	O
tiotropium	B
and	O
the	O
M3R	O
antagonist	O
4-DAMP	B
and	O
(	O
ii	O
)	O
enhanced	O
by	O
the	O
M1	O
/	O
M3R	O
agonist	O
pilocarpine	B
and	O
the	O
cholinesterase	O
inhibitor	O
physostigmine	B
.	O

Taken	O
as	O
a	O
whole	O
,	O
these	O
results	O
suggest	O
that	O
ACh	B
release	O
by	O
A549	O
cells	O
enhances	O
TNF	O
-	O
	O
-	O
induced	O
CXCL8	O
secretion	O
through	O
activation	O
of	O
the	O
M3R	O
.	O

Western	O
blot	O
analysis	O
revealed	O
that	O
pilocarpine	B
and	O
physostigmine	B
enhanced	O
the	O
TNF	O
-	O
	O
-	O
induced	O
phosphorylation	O
of	O
ERK1	O
/	O
2	O
and	O
p38	O
MAPK	O
and	O
the	O
degradation	O
of	O
IB	O
.	O

Inhibition	O
of	O
these	O
pathways	O
with	O
specific	O
inhibitors	O
abrogated	O
the	O
pilocarpine	B
-	O
induced	O
CXCL8	O
release	O
.	O

Our	O
results	O
suggest	O
that	O
the	O
TNF	O
-	O
	O
-	O
induced	O
secretion	O
of	O
CXCL8	O
in	O
A549	O
cells	O
is	O
regulated	O
by	O
the	O
release	O
of	O
ACh	B
,	O
the	O
latter	O
's	O
binding	O
to	O
the	O
M3R	O
and	O
the	O
downstream	O
activation	O
of	O
NF	O
-	O
B	O
and	O
the	O
ERK1	O
/	O
2	O
and	O
p38	O
MAPK	O
signaling	O
pathways	O
.	O

Our	O
findings	O
suggest	O
that	O
MR	O
antagonists	O
may	O
have	O
anti	O
-	O
inflammatory	O
effects	O
by	O
preventing	O
pro	O
-	O
inflammatory	O
events	O
driven	O
by	O
endogenous	O
,	O
non	O
-	O
neuronal	O
ACh	B
.	O

Inhibition	O
of	O
vitellogenin	O
gene	O
induction	O
by	O
2,3,7,8-tetrachlorodibenzo	B
-	I
p	I
-	I
dioxin	I
is	O
mediated	O
by	O
aryl	B
hydrocarbon	I
receptor	O
2	O
(	O
AHR2	O
)	O
in	O
zebrafish	O
(	O
Danio	O
rerio	O
)	O
.	O

Vitellogenins	O
are	O
hepatically	O
derived	O
yolk	O
-	O
protein	O
precursors	O
required	O
for	O
oogenesis	O
in	O
all	O
oviparous	O
teleosts	O
.	O

Altered	O
gene	O
-	O
regulation	O
of	O
vitellogenesis	O
by	O
environmental	O
contaminants	O
can	O
have	O
profound	O
effects	O
on	O
reproductive	O
success	O
,	O
and	O
ultimately	O
population	O
sustainability	O
.	O

To	O
better	O
understand	O
chemical	O
effects	O
on	O
vitellogenin	O
gene	O
regulation	O
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
activation	O
of	O
the	O
aryl	B
hydrocarbon	I
receptor	O
2	O
(	O
AHR2	O
)	O
by	O
dioxin	B
inhibits	O
the	O
estrogen	B
receptor	O
pathway	O
regulation	O
of	O
3	O
vitellogenin	O
genes	O
(	O
vtg1	O
-	O
3	O
)	O
in	O
vivo	O
,	O
using	O
zebrafish	O
(	O
Danio	O
rerio	O
)	O
as	O
a	O
model	O
teleost	O
.	O

Using	O
an	O
embryo	O
-	O
larval	O
bioassay	O
,	O
embryos	O
were	O
either	O
treated	O
with	O
1000	O
pptr	O
(	O
parts	O
-	O
per	O
-	O
trillion	O
,	O
pg	O
/	O
mL	O
)	O
17	B
-	I
ethynylestradiol	I
(	O
EE2	B
)	O
alone	O
from	O
6h	O
post	O
fertilization	O
(	O
hpf	O
)	O
to	O
4	O
days	O
post	O
fertilization	O
(	O
dpf	O
)	O
,	O
or	O
pre	O
-	O
treated	O
with	O
dioxin	O
(	O
4	O
-	O
5	O
hpf	O
)	O
prior	O
to	O
EE2	B
.	O

Pre	O
-	O
treatment	O
with	O
400	O
pptr	O
2,3,7,8-tetrachlorodibenzo	B
-	I
p	I
-	I
dioxin	I
(	O
2,3,7,8-TCDD	B
)	O
or	O
1,2,3,7,8-pentachlorodibenzo	B
-	I
p	I
-	I
dioxin	I
inhibited	O
the	O
EE2	B
induction	O
of	O
vtg1	O
,	O
vtg2	O
and	O
vtg3	O
by	O
>	O
95	O
%	O
(	O
p0.05	O
)	O
.	O

In	O
comparison	O
,	O
a	O
splice	O
-	O
blocking	O
AHR2	O
morpholino	O
used	O
to	O
down	O
-	O
regulate	O
ahr2	O
expression	O
significantly	O
reduced	O
the	O
inhibition	O
of	O
vtg1	O
,	O
vtg2	O
and	O
vtg3	O
by	O
400	O
pptr	O
2,3,7,8-TCDD	B
(	O
20.7	O
-	O
27.4	O
%	O
rescue	O
)	O
.	O

These	O
studies	O
demonstrate	O
that	O
2,3,7,8-TCDD	B
directly	O
inhibits	O
the	O
vitellogenin	O
pathway	O
in	O
vivo	O
through	O
activation	O
of	O
the	O
AHR2	O
.	O

This	O
work	O
provides	O
evidence	O
for	O
AHR2	O
dependent	O
cross	O
-	O
talk	O
inhibition	O
of	O
vitellogenin	O
genes	O
and	O
offers	O
insight	O
into	O
anti	O
-	O
estrogenic	O
reproductive	O
effects	O
observed	O
in	O
oviparous	O
species	O
exposed	O
to	O
AHR	O
agonist	O
contaminants	O
.	O

Gene	O
transcription	O
and	O
biomarker	O
responses	O
in	O
the	O
clam	O
Ruditapes	O
philippinarum	O
after	O
exposure	O
to	O
ibuprofen	B
.	O

Pharmaceuticals	O
are	O
a	O
class	O
of	O
emerging	O
environmental	O
contaminants	O
that	O
continuously	O
enter	O
aquatic	O
environments	O
.	O

Presently	O
,	O
little	O
information	O
is	O
available	O
about	O
the	O
effects	O
of	O
these	O
substances	O
on	O
non	O
-	O
target	O
organisms	O
,	O
such	O
as	O
bivalves	O
.	O

We	O
investigated	O
the	O
effects	O
of	O
ibuprofen	B
(	O
IBU	B
)	O
on	O
the	O
clam	O
Ruditapes	O
philippinarum	O
.	O

Clams	O
were	O
exposed	O
for	O
1	O
,	O
3	O
,	O
5	O
and	O
7	O
days	O
to	O
0	O
,	O
100	O
and	O
1000	O
gIBU	O
/	O
L	O
,	O
and	O
established	O
biomarker	O
responses	O
(	O
haemolymph	O
lysozyme	O
,	O
gill	O
acetylcholinesterase	O
and	O
digestive	O
gland	O
superoxide	B
dismutase	O
activities	O
)	O
as	O
well	O
as	O
digestive	O
gland	O
transcriptome	O
were	O
evaluated	O
.	O

A	O
two	O
-	O
way	O
ANOVA	O
revealed	O
significant	O
effects	O
of	O
both	O
"	O
IBU	B
concentration	O
"	O
and	O
"	O
exposure	O
duration	O
"	O
on	O
biomarker	O
responses	O
.	O

Overall	O
,	O
the	O
enzyme	O
activities	O
were	O
generally	O
lower	O
in	O
IBU	B
-	O
exposed	O
clams	O
than	O
in	O
controls	O
.	O

Although	O
limited	O
knowledge	O
of	O
the	O
mollusc	O
transcriptome	O
makes	O
it	O
difficult	O
to	O
interpret	O
the	O
effects	O
of	O
IBU	B
on	O
clams	O
,	O
the	O
gene	O
transcription	O
analysis	O
using	O
DNA	O
microarrays	O
enabled	O
the	O
identification	O
of	O
the	O
putative	O
molecular	O
mode	O
of	O
action	O
of	O
the	O
IBU	B
.	O

The	O
functional	O
analysis	O
of	O
differentially	O
transcribed	O
genes	O
suggests	O
that	O
IBU	B
can	O
interfere	O
with	O
various	O
signalling	O
pathways	O
in	O
clams	O
,	O
such	O
as	O
arachidonic	B
acid	I
metabolism	O
,	O
apoptosis	O
,	O
peroxisomal	O
proliferator	O
-	O
activated	O
receptors	O
,	O
and	O
nuclear	O
factor	O
-	O
kappa	O
B.	O
In	O
addition	O
,	O
several	O
genes	O
involved	O
in	O
the	O
metabolism	O
of	O
xenobiotics	O
(	O
e.g.	O
,	O
glutathione	B
S	O
-	O
transferase	O
,	O
sulfotransferase	O
,	O
cytochrome	O
P450	O
)	O
were	O
also	O
found	O
to	O
be	O
significantly	O
affected	O
by	O
IBU	B
exposure	O
.	O

In	O
summary	O
,	O
the	O
integrated	O
approach	O
of	O
gene	O
transcription	O
analysis	O
and	O
biomarker	O
responses	O
facilitated	O
the	O
elucidation	O
of	O
the	O
putative	O
mechanisms	O
of	O
action	O
of	O
IBU	B
in	O
non	O
-	O
target	O
species	O
.	O

Thyroid	O
disruption	O
in	O
the	O
lizard	O
Podarcis	O
bocagei	O
exposed	O
to	O
a	O
mixture	O
of	O
herbicides	O
:	O
a	O
field	O
study	O
.	O

Pesticide	O
exposure	O
has	O
been	O
related	O
with	O
thyroid	O
disrupting	O
effects	O
in	O
different	O
vertebrate	O
species	O
.	O

However	O
,	O
very	O
little	O
is	O
known	O
about	O
the	O
effects	O
of	O
these	O
compounds	O
in	O
reptiles	O
.	O

In	O
the	O
Mediterranean	O
area	O
,	O
lacertid	O
lizards	O
are	O
the	O
most	O
abundant	O
vertebrate	O
group	O
in	O
agroecosystems	O
,	O
and	O
have	O
been	O
identified	O
as	O
potential	O
model	O
species	O
for	O
reptile	O
ecotoxicology	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
understand	O
if	O
the	O
herbicides	O
applied	O
in	O
corn	O
fields	O
have	O
thyroid	O
disruptive	O
effects	O
in	O
the	O
lizard	O
Podarcis	O
bocagei	O
.	O

Adult	O
male	O
lizards	O
were	O
captured	O
in	O
north	O
-	O
western	O
Portugal	O
in	O
corn	O
fields	O
treated	O
with	O
herbicides	O
(	O
exposed	O
sites	O
)	O
,	O
and	O
in	O
organic	O
agricultural	O
fields	O
(	O
reference	O
sites	O
)	O
.	O

Thyroid	O
and	O
male	O
gonad	O
morphology	O
and	O
functionality	O
,	O
and	O
testosterone	B
levels	O
were	O
investigated	O
through	O
histological	O
,	O
immunohistochemical	O
and	O
biochemical	O
techniques	O
.	O

Lizards	O
from	O
exposed	O
locations	O
displayed	O
thyroid	O
follicular	O
lumens	O
with	O
more	O
reabsorption	O
vacuoles	O
and	O
significantly	O
larger	O
follicular	O
area	O
than	O
those	O
from	O
reference	O
fields	O
.	O

Furthermore	O
,	O
testes	O
of	O
lizards	O
from	O
exposed	O
locations	O
had	O
significantly	O
larger	O
seminiferous	O
tubule	O
diameters	O
,	O
significantly	O
higher	O
number	O
of	O
spermatogenic	O
layers	O
and	O
displayed	O
an	O
up	O
-	O
regulation	O
of	O
thyroid	O
hormone	O
receptors	O
when	O
compared	O
with	O
lizards	O
from	O
reference	O
areas	O
.	O

These	O
findings	O
strongly	O
suggest	O
that	O
the	O
complex	O
mixture	O
of	O
herbicides	O
that	O
lizards	O
are	O
exposed	O
to	O
in	O
agricultural	O
areas	O
have	O
thyroid	O
disrupting	O
effects	O
which	O
ultimately	O
affect	O
the	O
male	O
reproductive	O
system	O
.	O

Alachlor	B
,	O
which	O
has	O
demonstrated	O
thyroid	O
effects	O
in	O
mammals	O
,	O
may	O
be	O
largely	O
responsible	O
for	O
the	O
observed	O
effects	O
.	O

Effects	O
of	O
pyrene	B
exposure	O
and	O
temperature	O
on	O
early	O
development	O
of	O
two	O
co	O
-	O
existing	O
Arctic	O
copepods	O
.	O

Oil	O
exploration	O
is	O
expected	O
to	O
increase	O
in	O
the	O
near	O
future	O
in	O
Western	O
Greenland	O
.	O

At	O
present	O
,	O
effects	O
of	O
exposure	O
to	O
oil	O
compounds	O
on	O
early	O
life	O
-	O
stages	O
of	O
the	O
ecologically	O
important	O
Calanus	O
spp	O
.	O
are	O
unknown	O
.	O

We	O
investigated	O
the	O
effects	O
of	O
the	O
oil	O
compound	O
pyrene	B
,	O
on	O
egg	O
hatching	O
and	O
naupliar	O
development	O
of	O
the	O
calanoid	O
copepods	O
Calanus	O
glacialis	O
and	O
C.	O
finmarchicus	O
,	O
two	O
key	O
species	O
in	O
the	O
Disko	O
Bay	O
,	O
Western	O
Greenland	O
.	O

At	O
low	O
temperature	O
the	O
nauplii	O
of	O
C.	O
glacialis	O
experienced	O
reduced	O
growth	O
when	O
exposed	O
to	O
pyrene	B
,	O
and	O
survival	O
in	O
both	O
species	O
decreased	O
.	O

Naupliar	O
mortality	O
increased	O
with	O
temperature	O
at	O
high	O
pyrene	B
concentration	O
in	O
C.	O
finmarchicus	O
.	O

Both	O
Calanus	O
species	O
were	O
affected	O
by	O
pyrene	B
exposure	O
but	O
C.	O
finmarchicus	O
was	O
more	O
sensitive	O
compared	O
to	O
C.	O
glacialis	O
.	O

Lowered	O
growth	O
rate	O
and	O
increased	O
mortality	O
of	O
the	O
naupliar	O
stages	O
entail	O
reduced	O
recruitment	O
to	O
copepod	O
populations	O
.	O

Exposure	O
to	O
pyrene	B
from	O
an	O
oil	O
spill	O
may	O
reduce	O
the	O
standing	O
stock	O
of	O
Calanus	O
,	O
which	O
can	O
lead	O
to	O
less	O
energy	O
available	O
to	O
higher	O
trophic	O
levels	O
in	O
the	O
Arctic	O
marine	O
food	O
web	O
.	O

A	O
perspective	O
on	O
the	O
contribution	O
of	O
metabolites	O
to	O
drug	O
-	O
drug	O
interaction	O
potential	O
:	O
the	O
need	O
to	O
consider	O
both	O
circulating	O
levels	O
and	O
inhibition	O
potency	O
.	O

The	O
2012	O
drug	O
-	O
drug	O
interaction	O
(	O
DDI	O
)	O
guidance	O
from	O
the	O
European	O
Medicines	O
Agency	O
(	O
EMA	O
)	O
and	O
the	O
draft	O
DDI	O
guidance	O
from	O
the	O
Food	O
and	O
Drug	O
Administration	O
(	O
FDA	O
)	O
have	O
proposed	O
that	O
metabolites	O
present	O
at	O
>	O
25	O
%	O
of	O
the	O
parent	O
area	O
under	O
the	O
time	O
-	O
concentration	O
curve	O
(	O
AUC	O
)	O
(	O
EMA	O
and	O
FDA	O
)	O
and	O
>	O
10	O
%	O
of	O
the	O
total	O
drug	O
-	O
related	O
exposure	O
(	O
EMA	O
)	O
should	O
be	O
investigated	O
in	O
vitro	O
for	O
their	O
DDI	O
potential	O
.	O

This	O
commentary	O
attempts	O
to	O
rationalize	O
the	O
clinically	O
relevant	O
levels	O
of	O
metabolite	O
(	O
s	O
)	O
that	O
contribute	O
to	O
DDI	O
by	O
considering	O
not	O
only	O
the	O
abundance	O
but	O
also	O
inhibition	O
potency	O
,	O
physicochemical	O
properties	O
,	O
and	O
structural	O
alerts	O
of	O
the	O
metabolite	O
.	O

A	O
decision	O
tree	O
is	O
proposed	O
for	O
levels	O
of	O
metabolites	O
that	O
could	O
trigger	O
in	O
vitro	O
DDI	O
assessment	O
.	O

When	O
the	O
parent	O
is	O
an	O
inhibitor	O
of	O
cytochrome	O
P450s	O
(	O
P450s	O
)	O
,	O
clinical	O
DDI	O
studies	O
will	O
assess	O
the	O
in	O
vivo	O
DDI	O
effect	O
of	O
the	O
combination	O
of	O
parent	O
and	O
metabolite	O
(	O
s	O
)	O
.	O

When	O
the	O
parent	O
is	O
not	O
a	O
P450	O
inhibitor	O
,	O
it	O
is	O
important	O
to	O
assess	O
the	O
inhibition	O
potential	O
of	O
abundant	O
metabolites	O
in	O
vitro	O
.	O

The	O
proposal	O
is	O
to	O
apply	O
a	O
default	O
cutoff	O
value	O
of	O
metabolite	O
level	O
which	O
is	O
100	O
%	O
of	O
the	O
parent	O
AUC	O
.	O

It	O
is	O
important	O
to	O
note	O
that	O
exceptions	O
can	O
occur	O
,	O
and	O
different	O
metabolite	O
levels	O
may	O
be	O
considered	O
depending	O
on	O
the	O
physiochemical	O
properties	O
of	O
metabolites	O
(	O
e.g.	O
,	O
increased	O
lipophilicity	O
)	O
and	O
whether	O
the	O
metabolite	O
contains	O
structural	O
alerts	O
for	O
DDI	O
(	O
e.g.	O
,	O
mechanism	O
-	O
based	O
inhibition	O
)	O
.	O

A	O
key	O
objective	O
of	O
this	O
commentary	O
is	O
to	O
stimulate	O
discussions	O
among	O
the	O
scientific	O
community	O
on	O
this	O
important	O
topic	O
,	O
so	O
that	O
appropriate	O
in	O
vitro	O
metabolism	O
studies	O
are	O
conducted	O
on	O
metabolites	O
,	O
to	O
ensure	O
the	O
safety	O
of	O
drugs	O
in	O
development	O
balanced	O
with	O
the	O
desire	O
to	O
avoid	O
creating	O
unnecessary	O
studies	O
that	O
will	O
add	O
little	O
to	O
no	O
value	O
in	O
ensuring	O
patient	O
safety	O
.	O

Male	O
mating	O
behaviour	O
in	O
relation	O
to	O
female	O
sexual	O
swellings	O
,	O
socio	O
-	O
sexual	O
behaviour	O
and	O
hormonal	O
changes	O
in	O
wild	O
Barbary	O
macaques	O
.	O

In	O
many	O
cercopithecine	O
primates	O
females	O
display	O
probabilistic	O
cues	O
of	O
fertility	O
to	O
indicate	O
the	O
periovulatory	O
period	O
to	O
males	O
.	O

These	O
cues	O
may	O
include	O
female	O
behaviour	O
,	O
acoustic	O
signals	O
,	O
and	O
morphological	O
signs	O
such	O
as	O
the	O
anogenital	O
swelling	O
.	O

However	O
,	O
the	O
extent	O
to	O
which	O
males	O
can	O
utilise	O
this	O
information	O
varies	O
between	O
species	O
.	O

We	O
describe	O
male	O
sexual	O
behaviour	O
in	O
relation	O
to	O
changes	O
in	O
anogenital	O
swelling	O
size	O
,	O
timing	O
of	O
ovulation	O
and	O
female	O
socio	O
-	O
sexual	O
behaviour	O
in	O
wild	O
Barbary	O
macaques	O
(	O
Macaca	O
sylvanus	O
)	O
.	O

We	O
further	O
compare	O
male	O
sexual	O
behaviour	O
during	O
conception	O
and	O
post	O
-	O
conception	O
cycles	O
to	O
evaluate	O
if	O
males	O
differentiate	O
between	O
these	O
qualitatively	O
different	O
cycle	O
types	O
.	O

Our	O
results	O
show	O
that	O
during	O
conception	O
cycles	O
male	O
mating	O
behaviour	O
was	O
concentrated	O
around	O
the	O
fertile	O
phase	O
implying	O
that	O
males	O
inferred	O
information	O
from	O
more	O
than	O
swelling	O
size	O
alone	O
.	O

Male	O
mating	O
frequency	O
increased	O
in	O
line	O
with	O
female	O
socio	O
-	O
sexual	O
behaviour	O
,	O
namely	O
female	O
presenting	O
and	O
the	O
frequency	O
of	O
copulations	O
with	O
copulation	O
calls	O
.	O

Most	O
strikingly	O
our	O
results	O
show	O
that	O
males	O
invested	O
equally	O
in	O
mating	O
during	O
fertile	O
and	O
non	O
-	O
fertile	O
,	O
i.e.	O
post	O
-	O
conception	O
,	O
maximum	O
swelling	O
phases	O
.	O

Whether	O
post	O
-	O
conception	O
swellings	O
were	O
merely	O
a	O
result	O
of	O
changes	O
in	O
hormone	O
concentrations	O
during	O
pregnancy	O
or	O
part	O
of	O
a	O
female	O
reproductive	O
strategy	O
remains	O
elusive	O
.	O

In	O
sum	O
,	O
this	O
study	O
adds	O
to	O
the	O
body	O
of	O
research	O
on	O
the	O
evolution	O
of	O
female	O
sexual	O
signals	O
and	O
how	O
males	O
may	O
infer	O
information	O
from	O
these	O
cues	O
.	O

Metabolically	O
competent	O
human	O
skin	O
models	O
:	O
activation	O
and	O
genotoxicity	O
of	O
benzo	B
[	I
a	I
]	I
pyrene	I
.	O

The	O
polycyclic	B
aromatic	I
hydrocarbon	I
(	O
PAH	B
)	O
benzo	B
[	I
a	I
]	I
pyrene	I
(	O
BP	O
)	O
is	O
metabolized	O
into	O
a	O
complex	O
pattern	O
of	O
BP	O
derivatives	O
,	O
among	O
which	O
the	O
ultimate	O
carcinogen	O
(	B
+	I
)	I
-anti	I
-	I
BP-7,8-diol-9,10-epoxide	I
(	O
BPDE	B
)	O
is	O
formed	O
to	O
certain	O
extents	O
.	O

Skin	O
is	O
frequently	O
in	O
contact	O
with	O
PAHs	B
and	O
data	O
on	O
the	O
metabolic	O
capacity	O
of	O
skin	O
tissue	O
toward	O
these	O
compounds	O
are	O
inconclusive	O
.	O

We	O
compared	O
BP	O
metabolism	O
in	O
excised	O
human	O
skin	O
,	O
commercially	O
available	O
in	O
vitro	O
3D	O
skin	O
models	O
and	O
primary	O
2D	O
skin	O
cell	O
cultures	O
,	O
and	O
analyzed	O
the	O
metabolically	O
catalyzed	O
occurrence	O
of	O
seven	O
different	O
BP	O
follow	O
-	O
up	O
products	O
by	O
means	O
of	O
liquid	O
chromatography	O
coupled	O
to	O
tandem	O
mass	O
spectrometry	O
(	O
LC	O
-	O
MS	O
/	O
MS	O
)	O
.	O

All	O
models	O
investigated	O
were	O
competent	O
to	O
metabolize	O
BP	O
,	O
and	O
the	O
metabolic	O
profiles	O
generated	O
by	O
ex	O
vivo	O
human	O
skin	O
and	O
skin	O
models	O
were	O
remarkably	O
similar	O
.	O

Furthermore	O
,	O
the	O
genotoxicity	O
of	O
BP	O
and	O
its	O
derivatives	O
was	O
monitored	O
in	O
these	O
models	O
via	O
comet	O
assays	O
.	O

In	O
a	O
full	O
-	O
thickness	O
skin	O
,	O
equivalent	O
BP	O
-	O
mediated	O
genotoxic	O
stress	O
was	O
generated	O
via	O
keratinocytes	O
.	O

Cultured	O
primary	O
keratinocytes	O
revealed	O
a	O
level	O
of	O
genotoxicity	O
comparable	O
with	O
that	O
of	O
direct	O
exposure	O
to	O
50	O
-	O
100	O
nM	O
of	O
BPDE	B
.	O

Our	O
data	O
demonstrate	O
that	O
the	O
metabolic	O
capacity	O
of	O
human	O
skin	O
ex	O
vivo	O
,	O
as	O
well	O
as	O
organotypic	O
human	O
3D	O
skin	O
models	O
toward	O
BP	O
,	O
is	O
sufficient	O
to	O
cause	O
significant	O
genotoxic	O
stress	O
and	O
thus	O
cutaneous	O
bioactivation	O
may	O
potentially	O
contribute	O
to	O
mutations	O
that	O
ultimately	O
lead	O
to	O
skin	O
cancer	O
.	O

Response	O
to	O
variable	O
light	O
intensity	O
in	O
photoacclimated	O
algae	O
and	O
cyanobacteria	O
exposed	O
to	O
atrazine	B
.	O

Atrazine	B
is	O
frequently	O
detected	O
in	O
freshwater	O
ecosystems	O
exposed	O
to	O
agricultural	O
waste	O
waters	O
and	O
runoffs	O
worldwide	O
and	O
it	O
can	O
affect	O
non	O
-	O
target	O
organisms	O
(	O
mainly	O
photoautotrophic	O
)	O
and	O
modify	O
community	O
structure	O
.	O

Meanwhile	O
,	O
light	O
environment	O
is	O
known	O
to	O
vary	O
between	O
aquatic	O
ecosystems	O
,	O
but	O
also	O
before	O
and	O
during	O
the	O
exposure	O
to	O
atrazine	B
and	O
these	O
variations	O
may	O
modify	O
the	O
sensitivity	O
to	O
atrazine	B
of	O
photoautotroph	O
organisms	O
.	O

In	O
this	O
study	O
,	O
10	O
species	O
of	O
phytoplankton	O
(	O
chlorophytes	O
,	O
baccilariophytes	O
and	O
cyanophytes	O
)	O
acclimated	O
to	O
low	O
or	O
high	O
light	O
intensities	O
were	O
exposed	O
to	O
atrazine	B
and	O
light	O
of	O
different	O
intensities	O
to	O
compare	O
their	O
combined	O
effect	O
.	O

Our	O
data	O
showed	O
that	O
chlorophytes	O
and	O
baccilariophytes	O
were	O
more	O
resistant	O
to	O
atrazine	B
compared	O
to	O
cyanophytes	O
for	O
all	O
light	O
conditions	O
.	O

Atrazine	B
was	O
found	O
to	O
inhibit	O
'	O
(	O
M	O
)	O
,	O
	O
(	O
0	O
)	O
,	O
P	O
(	O
M	O
)	O
and	O
non	O
-	O
photochemical	O
quenching	O
for	O
all	O
species	O
indicating	O
an	O
effect	O
on	O
electron	O
transport	O
,	O
primary	O
production	O
and	O
photoregulation	O
processes	O
.	O

These	O
data	O
also	O
indicate	O
a	O
higher	O
sensitivity	O
of	O
	O
(	O
0	O
)	O
(	O
average	O
	O
(	O
0	O
)	O
-EC	O
(	O
50	O
)	O
of	O
91	O
	O
11	O
nM	O
or	O
19.6	O
	O
0.9	O
gL	O
(	O
-1	O
)	O
)	O
compared	O
to	O
'	O
(	O
M	O
)	O
(	O
average	O
'	O
(	O
M	O
)	O
-EC	O
(	O
50	O
)	O
of	O
217	O
	O
19	O
nM	O
or	O
46.8	O
	O
4.1	O
gL	O
(	O
-1	O
)	O
)	O
and	O
suggest	O
that	O
photoregulation	O
processes	O
activated	O
in	O
presence	O
of	O
light	O
decrease	O
the	O
effect	O
of	O
atrazine	B
.	O

We	O
also	O
showed	O
that	O
increasing	O
light	O
intensity	O
decreased	O
'	O
(	O
M	O
)	O
-EC	O
(	O
50	O
)	O
in	O
both	O
low	O
(	O
except	O
baccilariophytes	O
)	O
and	O
high	O
light	O
acclimated	O
conditions	O
.	O

Despite	O
this	O
similarity	O
,	O
most	O
species	O
acclimated	O
to	O
high	O
light	O
were	O
found	O
to	O
have	O
higher	O
or	O
similar	O
'	O
(	O
M	O
)	O
-EC	O
(	O
50	O
)	O
compared	O
to	O
low	O
light	O
acclimated	O
cells	O
and	O
thus	O
,	O
were	O
less	O
sensitive	O
to	O
atrazine	B
in	O
low	O
light	O
and	O
high	O
light	O
environments	O
.	O

We	O
concluded	O
that	O
an	O
increase	O
in	O
the	O
plastoquinone	B
pool	O
induced	O
by	O
acclimation	O
to	O
high	O
light	O
decreased	O
the	O
sensitivity	O
to	O
atrazine	B
in	O
phytoplankton	O
and	O
we	O
hypothesized	O
that	O
the	O
effect	O
observed	O
was	O
the	O
result	O
of	O
a	O
dilution	O
of	O
atrazine	B
toxicity	O
through	O
increased	O
binding	O
site	O
availability	O
(	O
quinones	B
)	O
combined	O
with	O
increased	O
photoregulation	O
processes	O
capacity	O
.	O

RBFOX2	O
is	O
an	O
important	O
regulator	O
of	O
mesenchymal	O
tissue	O
-	O
specific	O
splicing	O
in	O
both	O
normal	O
and	O
cancer	O
tissues	O
.	O

Alternative	O
splicing	O
provides	O
a	O
critical	O
and	O
flexible	O
layer	O
of	O
regulation	O
intervening	O
in	O
many	O
biological	O
processes	O
to	O
regulate	O
the	O
diversity	O
of	O
proteins	O
and	O
impact	O
cell	O
phenotype	O
.	O

To	O
identify	O
alternative	O
splicing	O
differences	O
that	O
distinguish	O
epithelial	O
from	O
mesenchymal	O
tissues	O
,	O
we	O
have	O
investigated	O
hundreds	O
of	O
cassette	O
exons	O
using	O
a	O
high	O
-	O
throughput	O
reverse	O
transcription	O
-	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
platform	O
.	O

Extensive	O
changes	O
in	O
splicing	O
were	O
noted	O
between	O
epithelial	O
and	O
mesenchymal	O
tissues	O
in	O
both	O
human	O
colon	O
and	O
ovarian	O
tissues	O
,	O
with	O
many	O
changes	O
from	O
mostly	O
one	O
splice	O
variant	O
to	O
predominantly	O
the	O
other	O
.	O

Remarkably	O
,	O
many	O
of	O
the	O
splicing	O
differences	O
that	O
distinguish	O
normal	O
mesenchymal	O
from	O
normal	O
epithelial	O
tissues	O
matched	O
those	O
that	O
differentiate	O
normal	O
ovarian	O
tissues	O
from	O
ovarian	O
cancer	O
.	O

Furthermore	O
,	O
because	O
splicing	O
profiling	O
could	O
classify	O
cancer	O
cell	O
lines	O
according	O
to	O
their	O
epithelial	O
/	O
mesenchymal	O
characteristics	O
,	O
we	O
used	O
these	O
cancer	O
cell	O
lines	O
to	O
identify	O
regulators	O
for	O
these	O
specific	O
splicing	O
signatures	O
.	O

By	O
knocking	O
down	O
78	O
potential	O
splicing	O
factors	O
in	O
five	O
cell	O
lines	O
,	O
we	O
provide	O
an	O
extensive	O
view	O
of	O
the	O
complex	O
regulatory	O
landscape	O
associated	O
with	O
the	O
epithelial	O
and	O
mesenchymal	O
states	O
,	O
thus	O
revealing	O
that	O
RBFOX2	O
is	O
an	O
important	O
driver	O
of	O
mesenchymal	O
tissue	O
-	O
specific	O
splicing	O
.	O

Design	O
,	O
synthesis	O
and	O
anticancer	O
activity	O
of	O
N	B
(	I
3	I
)	I
,N	I
(	I
11	I
)	I
-bis	I
(	I
2-hydroxyethyl	I
)	I
-14-aryl-14H	I
-	I
dibenzo	I
[	I
a	I
,	I
j	I
]	I
xanthenes-3,11-dicarboxamide	I
.	O

A	O
series	O
of	O
novel	O
N	B
(	I
3	I
)	I
,N	I
(	I
11	I
)	I
-bis	I
(	I
2-hydroxyethyl	I
)	I
-14-aryl-14H	I
-	I
dibenzo	I
[	I
a	I
,	I
j	I
]	I
xanthenes-3,11-dicarboxamide	I
,	O
three	O
N	B
(	I
3	I
)	I
,N	I
(	I
11	I
)	I
-bis	I
(	I
2-hydroxyethyl	I
)	I
-14-aryl-14H	I
-	I
dibenzo	I
[	I
a	I
,	I
j	I
]	I
xanthene-3,11-dimethanamine	I
derivatives	O
and	O
their	O
intermediates	O
14-aryl-14H	B
-	I
dibenzo	I
[	I
a	I
,	I
j	I
]	I
xanthenes-3,11-dicarboxylic	I
acid	I
,	O
were	O
synthesized	O
,	O
and	O
the	O
structures	O
of	O
which	O
were	O
characterized	O
by	O
(	B
1	I
)	I
H	I
-	O
NMR	O
,	O
(	B
13	I
)	I
C	I
-	O
NMR	O
,	O
high	O
resolution	O
(	O
HR	O
)	O
-MS	O
,	O
and	O
IR	O
spectra	O
.	O

The	O
antitumor	O
activities	O
of	O
these	O
molecules	O
were	O
evaluated	O
on	O
five	O
cancer	O
cell	O
lines	O
.	O

The	O
results	O
of	O
in	O
vitro	O
assay	O
against	O
human	O
hepatocellular	O
carcinoma	O
cell	O
lines	O
(	O
SK	O
-	O
HEP-1	O
and	O
HepG2	O
and	O
SMMC-7721	O
cells	O
)	O
,	O
acute	O
promyelocytic	O
leukemia	O
NB4	O
cells	O
and	O
uterine	O
cervix	O
cancer	O
HeLa	O
cells	O
,	O
show	O
several	O
compounds	O
to	O
be	O
endowed	O
with	O
cytotoxicity	O
in	O
micromolar	O
to	O
submicromolar	O
range	O
.	O

The	O
carboxamide	B
derivatives	O
6c	O
and	O
6e	O
exhibitted	O
good	O
inhibition	O
on	O
NB4	O
cancer	O
cells	O
,	O
and	O
the	O
IC	O
(	O
50	O
)	O
values	O
of	O
which	O
were	O
0.82	O
M	O
and	O
0.96	O
M	O
,	O
respectively	O
,	O
much	O
lower	O
than	O
5.01	O
M	O
of	O
the	O
positive	O
control	O
As	B
(	I
2	I
)	I
O	I
(	I
3	I
)	I
.	O

Flow	O
cytometric	O
analysis	O
results	O
revealed	O
that	O
compounds	O
6e	O
and	O
6f	O
may	O
induce	O
tumor	O
cell	O
apoptosis	O
.	O

Membrane	O
domains	O
and	O
the	O
"	O
lipid	O
raft	O
"	O
concept	O
.	O

The	O
bulk	O
structure	O
of	O
biological	O
membranes	O
consists	O
of	O
a	O
bilayer	O
of	O
amphipathic	O
lipids	O
.	O

According	O
to	O
the	O
fluid	O
mosaic	O
model	O
proposed	O
by	O
Singer	O
and	O
Nicholson	O
,	O
the	O
glycerophospholipid	B
bilayer	O
is	O
a	O
two	O
-	O
dimensional	O
fluid	O
construct	O
that	O
allows	O
the	O
lateral	O
movement	O
of	O
membrane	O
components	O
.	O

Different	O
types	O
of	O
lateral	O
interactions	O
among	O
membrane	O
components	O
can	O
take	O
place	O
,	O
giving	O
rise	O
to	O
multiple	O
levels	O
of	O
lateral	O
order	O
that	O
lead	O
to	O
highly	O
organized	O
structures	O
.	O

Early	O
observations	O
suggested	O
that	O
some	O
of	O
the	O
lipid	O
components	O
of	O
biological	O
membranes	O
may	O
play	O
active	O
roles	O
in	O
the	O
creation	O
of	O
these	O
levels	O
of	O
order	O
.	O

In	O
the	O
late	O
1980s	O
,	O
a	O
diverse	O
series	O
of	O
experimental	O
findings	O
collectively	O
gave	O
rise	O
to	O
the	O
lipid	O
raft	O
hypothesis	O
.	O

Lipid	O
rafts	O
were	O
originally	O
defined	O
as	O
membrane	O
domains	O
,	O
i.e.	O
,	O
ordered	O
structures	O
created	O
as	O
a	O
consequence	O
of	O
the	O
lateral	O
segregation	O
of	O
sphingolipids	B
and	O
differing	O
from	O
the	O
surrounding	O
membrane	O
in	O
their	O
molecular	O
composition	O
and	O
properties	O
.	O

This	O
definition	O
was	O
subsequently	O
modified	O
to	O
introduce	O
the	O
notion	O
that	O
lipid	O
rafts	O
correspond	O
to	O
membrane	O
areas	O
stabilized	O
by	O
the	O
presence	O
of	O
cholesterol	B
within	O
a	O
liquid	O
-	O
ordered	O
phase	O
.	O

During	O
the	O
past	O
two	O
decades	O
,	O
the	O
concept	O
of	O
lipid	O
rafts	O
has	O
become	O
extremely	O
popular	O
among	O
cell	O
biologists	O
,	O
and	O
these	O
structures	O
have	O
been	O
suggested	O
to	O
be	O
involved	O
in	O
a	O
great	O
variety	O
of	O
cellular	O
functions	O
and	O
biological	O
events	O
.	O

During	O
the	O
same	O
period	O
,	O
however	O
,	O
some	O
groups	O
presented	O
experimental	O
evidence	O
that	O
appeared	O
to	O
contradict	O
the	O
basic	O
tenets	O
that	O
underlie	O
the	O
lipid	O
raft	O
concept	O
.	O

The	O
concept	O
is	O
currently	O
being	O
re	O
-	O
defined	O
,	O
with	O
greater	O
consistency	O
regarding	O
the	O
true	O
nature	O
and	O
role	O
of	O
lipid	O
rafts	O
.	O

In	O
this	O
article	O
we	O
will	O
review	O
the	O
concepts	O
,	O
criticisms	O
,	O
and	O
the	O
novel	O
confirmatory	O
findings	O
relating	O
to	O
the	O
lipid	O
raft	O
hypothesis	O
.	O

The	O
onset	O
of	O
antineutrophil	O
cytoplasmic	O
antibody	O
-	O
associated	O
vasculitis	O
immediately	O
after	O
methimazole	B
was	O
switched	O
to	O
propylthiouracil	B
in	O
a	O
woman	O
with	O
Graves	O
'	O
disease	O
who	O
wished	O
to	O
become	O
pregnant	O
.	O

Propylthiouracil	B
(	O
PTU	B
)	O
is	O
recommended	O
as	O
a	O
first	O
-	O
line	O
antithyroid	O
drug	O
(	O
ATD	O
)	O
during	O
first	O
trimester	O
organogenesis	O
in	O
pregnancy	O
because	O
recent	O
evidence	O
suggests	O
that	O
methimazole	B
(	O
MMI	B
)	O
may	O
be	O
associated	O
with	O
congenital	O
anomalies	O
.	O

However	O
,	O
PTU	B
more	O
commonly	O
causes	O
myeloperoxidase	O
(	O
MPO	O
)	O
-antineutrophil	O
cytoplasmic	O
antibody	O
(	O
ANCA	O
)	O
-associated	O
vasculitis	O
,	O
which	O
usually	O
occurs	O
during	O
prolonged	O
treatment	O
,	O
compared	O
with	O
MMI	B
.	O

We	O
report	O
a	O
case	O
of	O
MPO	O
-	O
ANCA	O
-	O
associated	O
vasculitis	O
in	O
a	O
35-year	O
-	O
old	O
woman	O
with	O
Graves'disease	O
.	O

Although	O
her	O
thyroid	O
function	O
could	O
be	O
maintained	O
euthyroid	O
by	O
MMI	O
,	O
her	O
ATD	O
was	O
switched	O
to	O
PTU	B
because	O
she	O
wished	O
to	O
become	O
pregnant	O
.	O

The	O
patient	O
presented	O
with	O
flu	O
-	O
like	O
symptoms	O
8	O
days	O
after	O
starting	O
PTU	B
and	O
developed	O
hemoptysis	O
and	O
dyspnea	O
at	O
22	O
days	O
.	O

Her	O
MPO	O
-	O
ANCA	O
titer	O
was	O
21	O
ELISA	O
units	O
(	O
EUs	O
)	O
before	O
PTU	B
treatment	O
but	O
increased	O
to	O
259	O
EUs	O
at	O
22	O
days	O
after	O
PTU	B
treatment	O
.	O

Her	O
clinical	O
condition	O
improved	O
with	O
the	O
discontinuation	O
of	O
PTU	B
and	O
with	O
immunosuppressive	O
therapy	O
.	O

This	O
case	O
indicated	O
that	O
MPO	O
-	O
ANCA	O
vasculitis	O
occurred	O
within	O
several	O
weeks	O
after	O
the	O
initiation	O
of	O
PTU	B
and	O
that	O
this	O
side	O
effect	O
could	O
be	O
caused	O
by	O
the	O
change	O
from	O
MMI	B
to	O
PTU	B
.	O

Thus	O
,	O
our	O
clinical	O
observation	O
suggests	O
that	O
patients	O
treated	O
with	O
PTU	B
should	O
be	O
carefully	O
monitored	O
for	O
MPO	O
-	O
ANCA	O
titers	O
and	O
variable	O
manifestations	O
of	O
MPO	O
-	O
ANCA	O
-	O
associated	O
vasculitis	O
regardless	O
of	O
the	O
period	O
of	O
administration	O
.	O

Effects	O
of	O
antipsychotics	O
on	O
the	O
BDNF	O
in	O
schizophrenia	O
.	O

Brain	O
-	O
derived	O
neurotropic	O
factor	O
(	O
BDNF	O
)	O
is	O
involved	O
in	O
the	O
development	O
of	O
the	O
brain	O
,	O
and	O
likely	O
influences	O
the	O
neuroplasticity	O
in	O
schizophrenia	O
.	O

BDNF	O
is	O
also	O
believed	O
to	O
interact	O
with	O
other	O
neurotransmitter	O
systems	O
implicated	O
in	O
schizophrenia	O
,	O
such	O
as	O
dopamine	B
,	O
glutamate	B
,	O
serotonin	B
and	O
GABA	B
.	O

Therefore	O
,	O
BDNF	O
is	O
a	O
candidate	O
gene	O
for	O
schizophrenia	O
.	O

In	O
past	O
decades	O
,	O
the	O
blood	O
(	O
serum	O
or	O
plasma	O
)	O

BDNF	O
protein	O
levels	O
and	O
BDNF	O
gene	O
alleles	O
and	O
genotypes	O
to	O
the	O
clinical	O
features	O
of	O
schizophrenia	O
,	O
such	O
as	O
age	O
of	O
onset	O
,	O
clinical	O
subtypes	O
,	O
symptom	O
severity	O
,	O
and	O
drug	O
response	O
,	O
have	O
been	O
evaluated	O
among	O
different	O
populations	O
.	O

However	O
,	O
the	O
results	O
are	O
still	O
inconsistent	O
.	O

Further	O
,	O
different	O
drugs	O
have	O
been	O
reported	O
to	O
have	O
different	O
effects	O
on	O
BDNF	O
protein	O
levels	O
.	O

A	O
cross	O
-	O
sectional	O
survey	O
revealed	O
that	O
serum	O
BDNF	O
levels	O
in	O
chronic	O
schizophrenic	O
patients	O
treated	O
with	O
clozapine	B
exceeded	O
those	O
of	O
patients	O
treated	O
with	O
risperidone	B
or	O
with	O
typical	O
antipsychotics	O
.	O

In	O
recent	O
times	O
,	O
BDNF	O
epigenetic	O
studies	O
have	O
also	O
been	O
conducted	O
in	O
clinical	O
studies	O
of	O
schizophrenia	O
to	O
address	O
the	O
question	O
of	O
why	O
patients	O
with	O
the	O
same	O
gene	O
genotype	O
and	O
alleles	O
have	O
different	O
clinical	O
presentations	O
.	O

In	O
addition	O
,	O
the	O
effects	O
of	O
different	O
antipsychotic	O
drugs	O
on	O
gene	O
methylation	O
and	O
protein	O
acetylation	O
have	O
also	O
been	O
reported	O
.	O

In	O
conclusion	O
,	O
more	O
data	O
are	O
needed	O
regarding	O
BDNF	O
in	O
the	O
brain	O
and	O
in	O
peripheral	O
blood	O
,	O
including	O
protein	O
levels	O
,	O
single	O
nucleotide	O
polymorphisms	O
,	O
epigenetic	O
regulation	O
,	O
and	O
clinical	O
data	O
in	O
order	O
to	O
understand	O
the	O
role	O
of	O
BDNF	O
in	O
schizophrenia	O
.	O

Facilitative	O
effect	O
of	O
serotonin	B
(	O
1A	O
)	O
receptor	O
agonists	O
on	O
cognition	O
in	O
patients	O
with	O
schizophrenia	O
.	O

Disturbances	O
of	O
cognitive	O
function	O
are	O
considered	O
to	O
largely	O
affect	O
the	O
outcome	O
in	O
patients	O
with	O
schizophrenia	O
.	O

There	O
is	O
much	O
attention	O
to	O
the	O
role	O
of	O
psychotropic	O
compounds	O
acting	O
on	O
serotonin	B
(	O
5-HT	B
)	O
receptors	O
in	O
ameliorating	O
cognitive	O
deficits	O
of	O
the	O
disease	O
.	O

Among	O
the	O
5-HT	B
receptor	O
subtypes	O
,	O
the	O
5-HT	B
(	O
1A	O
)	O
receptor	O
is	O
attracting	O
particular	O
interests	O
as	O
a	O
potential	O
target	O
for	O
enhancing	O
cognition	O
,	O
based	O
on	O
preclinical	O
and	O
clinical	O
evidence	O
.	O

The	O
neural	O
network	O
underlying	O
the	O
ability	O
of	O
5-HT	B
(	O
1A	O
)	O
agonists	O
to	O
treat	O
cognitive	O
impairments	O
of	O
schizophrenia	O
likely	O
includes	O
dopamine	B
,	O
glutamate	B
,	O
and	O
gamma	B
-	I
aminobutyric	I
acid	I
neurons	O
.	O

Recent	O
advances	O
of	O
electrophysiological	O
measures	O
,	O
such	O
as	O
event	O
-	O
related	O
potentials	O
,	O
have	O
provided	O
insights	O
into	O
facilitative	O
effects	O
on	O
cognition	O
of	O
some	O
atypical	O
antipsychotic	O
drugs	O
or	O
related	O
compounds	O
acting	O
directly	O
or	O
indirectly	O
on	O
5-HT	B
(	O
1A	O
)	O
receptors	O
.	O

These	O
considerations	O
are	O
expected	O
to	O
promote	O
the	O
development	O
of	O
novel	O
therapeutics	O
for	O
the	O
betterment	O
of	O
functional	O
outcome	O
in	O
people	O
suffering	O
from	O
schizophrenia	O
.	O

Neurobiological	O
basis	O
of	O
dyskinetic	O
effects	O
induced	O
by	O
antipsychotics	O
:	O
the	O
contribution	O
of	O
animal	O
models	O
.	O

Tardive	O
dyskinesia	O
(	O
TD	O
)	O
is	O
a	O
movement	O
disorder	O
characterized	O
by	O
abnormal	O
involuntary	O
facial	O
movements	O
induced	O
by	O
chronic	O
therapy	O
with	O
classical	O
antipsychotic	O
medications	O
.	O

Currently	O
,	O
there	O
is	O
no	O
satisfactory	O
pharmacotherapy	O
for	O
TD	O
,	O
which	O
represents	O
a	O
major	O
limitation	O
to	O
therapy	O
with	O
classical	O
antipsychotics	O
.	O

In	O
order	O
to	O
develop	O
or	O
optimize	O
therapies	O
for	O
TD	O
,	O
and	O
to	O
develop	O
new	O
APDs	O
with	O
lower	O
indices	O
of	O
motor	O
side	O
effects	O
,	O
the	O
pathology	O
underlying	O
TD	O
must	O
first	O
be	O
understood	O
.	O

The	O
use	O
of	O
animal	O
models	O
has	O
been	O
used	O
to	O
further	O
this	O
objective	O
.	O

Here	O
,	O
we	O
review	O
different	O
preparations	O
that	O
have	O
been	O
used	O
to	O
model	O
TD	O
and	O
discuss	O
the	O
contribution	O
of	O
neuroimaging	O
studies	O
conducted	O
in	O
these	O
models	O
.	O

Studies	O
in	O
animal	O
models	O
have	O
lead	O
to	O
several	O
hypotheses	O
of	O
TD	O
pathology	O
,	O
although	O
none	O
has	O
yet	O
emerged	O
as	O
the	O
ultimate	O
underlying	O
cause	O
of	O
this	O
syndrome	O
.	O

We	O
discuss	O
alterations	O
in	O
functional	O
indices	O
,	O
neuron	O
and	O
synapse	O
morphology	O
and	O
changes	O
in	O
specific	O
neurotransmitter	O
systems	O
that	O
have	O
been	O
described	O
in	O
animal	O
models	O
of	O
TD	O
,	O
and	O
outline	O
how	O
these	O
findings	O
have	O
contributed	O
to	O
our	O
understanding	O
of	O
antipsychotic	O
-	O
induced	O
dyskinesias	O
.	O

We	O
conclude	O
that	O
several	O
non	O
-	O
mutually	O
exclusive	O
theories	O
of	O
TD	O
are	O
supported	O
by	O
animal	O
studies	O
,	O
including	O
increases	O
in	O
oxidative	O
stress	O
leading	O
to	O
structural	O
and	O
functional	O
changes	O
in	O
specific	O
neurotransmitter	O
systems	O
.	O

Elucidating	O
the	O
mechanisms	O
underlying	O
TD	O
neuropathology	O
partly	O
through	O
the	O
use	O
of	O
animal	O
models	O
will	O
lead	O
to	O
the	O
development	O
of	O
APDs	O
with	O
superior	O
side	O
effect	O
profiles	O
or	O
more	O
effective	O
therapies	O
for	O
TD	O
.	O

Abnormal	O
striatal	O
dopamine	B
transmission	O
in	O
schizophrenia	O
.	O

Despite	O
numerous	O
revisions	O
and	O
reformulations	O
,	O
dopamine	B
(	O
DA	O
)	O
hypothesis	O
of	O
schizophrenia	O
remains	O
a	O
pivotal	O
neurochemical	O
hypothesis	O
of	O
this	O
illness	O
.	O

The	O
aim	O
of	O
this	O
review	O
is	O
to	O
expose	O
and	O
discuss	O
findings	O
from	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
or	O
single	O
-	O
photon-	O
emission	O
computed	O
tomography	O
(	O
SPECT	O
)	O
studies	O
investigating	O
DA	O
function	O
in	O
the	O
striatum	O
of	O
medicated	O
,	O
drug	O
-	O
naive	O
or	O
drug	O
-	O
free	O
patients	O
with	O
schizophrenia	O
and	O
in	O
individuals	O
at	O
risk	O
compared	O
with	O
healthy	O
volunteers	O
.	O

DA	O
function	O
was	O
studied	O
at	O
several	O
levels	O
:	O
i	O
)	O
at	O
a	O
presynaptic	O
level	O
where	O
neuroimaging	O
studies	O
investigating	O
DOPA	B
uptake	O
capacity	O
clearly	O
show	O
an	O
increase	O
of	O
DA	O
synthesis	O
in	O
patients	O
with	O
schizophrenia	O
;	O
ii	O
)	O
at	O
a	O
synaptic	O
level	O
where	O
neuroimaging	O
studies	O
investigating	O
dopamine	B
transporter	O
availability	O
(	O
DAT	O
)	O
does	O
not	O
bring	O
any	O
evidence	O
of	O
dysfunction	O
;	O
iii	O
)	O
and	O
finally	O
,	O
neuroimaging	O
studies	O
investigating	O
DA	O
receptor	O
density	O
show	O
a	O
mild	O
increase	O
of	O
D2	O
receptor	O
density	O
in	O
basic	O
condition	O
and	O
,	O
an	O
hyperreactivity	O
of	O
DA	O
system	O
in	O
dynamic	O
condition	O
.	O

These	O
results	O
are	O
discussed	O
regarding	O
laterality	O
,	O
sub	O
-	O
regions	O
of	O
striatum	O
and	O
implications	O
for	O
the	O
at	O
-	O
risk	O
population	O
.	O

Striatal	O
DA	O
abnormalities	O
are	O
now	O
clearly	O
demonstrated	O
in	O
patients	O
with	O
schizophrenia	O
and	O
at	O
risk	O
population	O
and	O
could	O
constitute	O
an	O
endophenotype	O
of	O
schizophrenia	O
.	O

Subtle	O
sub	O
-	O
clinical	O
striatal	O
DA	O
abnormalities	O
in	O
at	O
risk	O
population	O
could	O
be	O
a	O
biomarker	O
of	O
transition	O
from	O
a	O
vulnerability	O
state	O
to	O
the	O
expression	O
of	O
frank	O
psychosis	O
.	O

Proton	O
magnetic	O
resonance	O
spectroscopy	O
changes	O
after	O
antipsychotic	O
treatment	O
.	O

Proton	O
magnetic	O
resonance	O
spectroscopy	O
(	O
(	B
1	I
)	I
H	I
MRS	O
)	O
enables	O
the	O
observation	O
of	O
brain	O
function	O
in	O
vivo	O
.	O

Several	O
brain	O
metabolites	O
can	O
be	O
measured	O
by	O
the	O
means	O
of	O
(	O
1	O
)	O
H	O
MRS	O
:	O
N	B
-	I
acetylaspartate	I
(	O
NAA	B
)	O
,	O
choline	B
containing	O
compounds	O
(	O
Cho	O
)	O
,	O
myo	B
-	I
inositol	I
(	O
mI	O
)	O
and	O
glutamate	B
(	O
Glu	B
)	O
,	O
glutamine	B
(	O
Gln	B
)	O
and	O
GABA	B
(	O
together	O
as	O
Glx	O
complex	O
or	O
separately	O
)	O
.	O

(	B
1	I
)	I
H	I
MRS	O
measures	O
have	O
been	O
found	O
to	O
be	O
abnormal	O
in	O
psychotic	O
disorders	O
such	O
as	O
schizophrenia	O
.	O

Here	O
we	O
specifically	O
review	O
the	O
influence	O
exerted	O
by	O
antipsychotic	O
drugs	O
on	O
brain	O
metabolism	O
,	O
as	O
detected	O
by	O
(	B
1	I
)	I
H	I
MRS	O
.	O

We	O
systematically	O
reviewed	O
the	O
available	O
literature	O
and	O
uncovered	O
27	O
studies	O
,	O
16	O
before	O
-	O
after	O
treatment	O
and	O
11	O
cross	O
-	O
sectional	O
.	O

Most	O
of	O
them	O
addressed	O
the	O
effects	O
of	O
antipsychotics	O
in	O
schizophrenia	O
and	O
mainly	O
focusing	O
on	O
NAA	B
alterations	O
.	O

Follow	O
up	O
studies	O
indicated	O
antipsychotic	O
drugs	O
may	O
act	O
by	O
increasing	O
NAA	B
levels	O
in	O
selected	O
brain	O
areas	O
(	O
the	O
frontal	O
lobe	O
and	O
thalamus	O
)	O
,	O
especially	O
during	O
the	O
short	O
-	O
time	O
observation	O
.	O

This	O
phenomenon	O
seems	O
to	O
vanish	O
after	O
longer	O
observation	O
.	O

Other	O
studies	O
indicated	O
that	O
glutamate	B
measures	O
are	O
decreasing	O
along	O
with	O
the	O
duration	O
of	O
the	O
disease	O
,	O
suggesting	O
both	O
a	O
neurodegenerative	O
process	O
present	O
in	O
schizophrenic	O
brain	O
as	O
well	O
as	O
an	O
influence	O
of	O
antipsychotics	O
.	O

The	O
above	O
results	O
were	O
reviewed	O
according	O
to	O
the	O
most	O
recent	O
theories	O
in	O
the	O
field	O
accounting	O
for	O
the	O
impact	O
of	O
antipsychotics	O
(	B
1	I
)	I
HMRS	I
measures	O
.	O

The	O
next	O
frontier	O
in	O
composite	O
tissue	O
allotransplantation	O
.	O

Solid	O
organ	O
transplantations	O
became	O
a	O
clinical	O
option	O
in	O
the	O
1950s	O
.	O

The	O
hand	O
allograft	O
was	O
the	O
pioneer	O
of	O
composite	O
tissue	O
allotransplantation	O
(	O
CTA	O
)	O
,	O
successfully	O
started	O
near	O
the	O
end	O
of	O
the	O
last	O
century	O
despite	O
arguments	O
over	O
the	O
practicality	O
and	O
methods	O
.	O

Since	O
then	O
,	O
CTA	O
such	O
as	O
hand	O
and	O
face	O
has	O
continued	O
to	O
progress	O
from	O
the	O
theoretical	O
to	O
clinical	O
reality	O
.	O

The	O
treatment	O
principles	O
,	O
drug	O
combinations	O
,	O
and	O
mechanisms	O
of	O
the	O
immunosuppression	O
medications	O
on	O
which	O
contemporary	O
transplant	O
surgeries	O
have	O
been	O
based	O
continue	O
to	O
develop	O
as	O
researchers	O
and	O
physicians	O
gain	O
more	O
experience	O
in	O
the	O
CTA	O
field	O
.	O

It	O
could	O
be	O
argued	O
that	O
the	O
ethical	O
issues	O
associated	O
with	O
CTA	O
have	O
prevented	O
evolution	O
of	O
the	O
field	O
rather	O
than	O
surgical	O
or	O
technical	O
skill	O
.	O

This	O
is	O
particularly	O
true	O
for	O
allo	O
-	O
head	O
and	O
body	O
reconstruction	O
(	O
AHBR	O
)	O
.	O

How	O
can	O
leaders	O
in	O
the	O
field	O
of	O
CTA	O
develop	O
a	O
model	O
that	O
would	O
satisfy	O
ethical	O
concerns	O
?	O

Bolstered	O
by	O
recent	O
successes	O
in	O
the	O
field	O
,	O
is	O
it	O
time	O
to	O
traverse	O
the	O
next	O
frontier	O
?	O

Can	O
AHBR	O
ever	O
be	O
a	O
feasible	O
option	O
in	O
the	O
clinical	O
setting	O
?	O

The	O
reader	O
will	O
be	O
provided	O
with	O
a	O
brief	O
history	O
of	O
CTA	O
from	O
theory	O
to	O
research	O
to	O
clinical	O
practice	O
.	O

A	O
concise	O
description	O
of	O
AHBR	O
as	O
it	O
pertains	O
to	O
the	O
critical	O
procedure	O
(	O
i.e.	O
,	O
surgery	O
design	O
)	O
will	O
also	O
be	O
discussed	O
.	O

Behavioural	O
and	O
EEG	O
effects	O
of	O
chronic	O
rapamycin	B
treatment	O
in	O
a	O
mouse	O
model	O
of	O
Tuberous	O
Sclerosis	O
Complex	O
.	O

Tuberous	O
Sclerosis	O
Complex	O
(	O
TSC	O
)	O
is	O
a	O
multisystem	O
genetic	O
disorder	O
caused	O
by	O
mutation	O
in	O
either	O
Tsc1	O
or	O
Tsc2	O
genes	O
that	O
leads	O
to	O
the	O
hyper	O
activation	O
of	O
the	O
mTOR	O
pathway	O
,	O
a	O
key	O
signalling	O
pathway	O
for	O
synaptic	O
plasticity	O
.	O

TSC	O
is	O
characterized	O
by	O
benign	O
tumors	O
arising	O
in	O
different	O
organs	O
and	O
severe	O
neuropsychiatric	O
symptoms	O
,	O
such	O
as	O
epilepsy	O
,	O
intellectual	O
disability	O
,	O
autism	O
,	O
anxiety	O
and	O
depressive	O
behaviour	O
.	O

Rapamycin	B
is	O
a	O
potent	O
inhibitor	O
of	O
mTOR	O
and	O
its	O
efficacy	O
in	O
treating	O
epilepsy	O
and	O
neurological	O
symptoms	O
remains	O
elusive	O
.	O

In	O
a	O
mouse	O
model	O
in	O
which	O
Tsc1	O
has	O
been	O
deleted	O
in	O
embryonic	O
telencephalic	O
neural	O
stem	O
cells	O
,	O
we	O
analyzed	O
anxiety-	O
and	O
depression	O
-	O
like	O
behaviour	O
by	O
elevated	O
-	O
plus	O
maze	O
(	O
EPM	O
)	O
,	O
open	O
-	O
field	O
test	O
(	O
OFT	O
)	O
,	O
forced	O
-	O
swim	O
test	O
(	O
FST	O
)	O
and	O
tail	O
-	O
suspension	O
test	O
(	O
TST	O
)	O
,	O
after	O
chronic	O
administration	O
of	O
rapamycin	B
.	O

In	O
addition	O
,	O
spectral	O
analysis	O
of	O
background	O
EEG	O
was	O
performed	O
.	O

Rapamycin	B
-	O
treated	O
mutant	O
mice	O
displayed	O
a	O
reduction	O
in	O
anxiety-	O
and	O
depression	O
-	O
like	O
phenotype	O
,	O
as	O
shown	O
by	O
the	O
EPM	O
/	O
OFT	O
and	O
FST	O
,	O
respectively	O
.	O

These	O
results	O
were	O
inline	O
with	O
EEG	O
power	O
spectra	O
outcomes	O
.	O

The	O
same	O
effects	O
of	O
rapamycin	B
were	O
observed	O
in	O
wild	O
-	O
type	O
mice	O
.	O

Notably	O
,	O
in	O
heterozygous	O
animals	O
we	O
did	O
not	O
observe	O
any	O
EEG	O
and/or	O
behavioural	O
variation	O
after	O
rapamycin	B
treatment	O
.	O

Together	O
these	O
results	O
suggest	O
that	O
both	O
TSC1	O
deletion	O
and	O
chronic	O
rapamycin	B
treatment	O
might	O
have	O
a	O
role	O
in	O
modulating	O
behaviour	O
and	O
brain	O
activity	O
,	O
and	O
point	O
out	O
to	O
the	O
potential	O
usefulness	O
of	O
background	O
EEG	O
analysis	O
in	O
tracking	O
brain	O
dysfunction	O
in	O
parallel	O
with	O
behavioural	O
testing	O
.	O

Novel	O
antitussive	O
strategies	O
.	O

Acute	O
and	O
chronic	O
cough	O
represent	O
one	O
of	O
the	O
most	O
common	O
symptoms	O
of	O
medical	O
importance	O
but	O
effective	O
pharmacotherapy	O
is	O
,	O
to	O
all	O
intents	O
and	O
purposes	O
,	O
absent	O
.	O

Numerous	O
initiatives	O
targeting	O
the	O
recently	O
discovered	O
tussive	O
pathways	O
are	O
in	O
progress	O
.	O

Here	O
,	O
we	O
review	O
the	O
current	O
antitussive	O
armamentarium	O
and	O
provide	O
an	O
update	O
on	O
the	O
novel	O
strategies	O
and	O
compounds	O
in	O
development	O
.	O

A	O
method	O
for	O
assessing	O
the	O
potential	O
for	O
confounding	O
applied	O
to	O
ionic	O
strength	O
in	O
central	O
Appalachian	O
streams	O
.	O

Causal	O
relationships	O
derived	O
from	O
field	O
data	O
are	O
potentially	O
confounded	O
by	O
variables	O
that	O
are	O
correlated	O
with	O
both	O
the	O
cause	O
and	O
its	O
effect	O
.	O

The	O
present	O
study	O
presents	O
a	O
method	O
for	O
assessing	O
the	O
potential	O
for	O
confounding	O
and	O
applies	O
it	O
to	O
the	O
relationship	O
between	O
ionic	O
strength	O
and	O
impairment	O
of	O
benthic	O
invertebrate	O
assemblages	O
in	O
central	O
Appalachian	O
streams	O
.	O

The	O
method	O
weighs	O
all	O
available	O
evidence	O
for	O
and	O
against	O
confounding	O
by	O
each	O
potential	O
confounder	O
.	O

It	O
identifies	O
10	O
types	O
of	O
evidence	O
for	O
confounding	O
,	O
presents	O
a	O
qualitative	O
scoring	O
system	O
,	O
and	O
provides	O
rules	O
for	O
applying	O
the	O
scores	O
.	O

Twelve	O
potential	O
confounders	O
were	O
evaluated	O
:	O
habitat	O
,	O
organic	O
enrichment	O
,	O
nutrients	O
,	O
deposited	O
sediments	O
,	O
pH	O
,	O
selenium	B
,	O
temperature	O
,	O
lack	O
of	O
headwaters	O
,	O
catchment	O
area	O
,	O
settling	O
ponds	O
,	O
dissolved	O
oxygen	B
,	O
and	O
metals	O
.	O

One	O
potential	O
confounder	O
,	O
low	O
pH	O
,	O
was	O
found	O
to	O
be	O
biologically	O
significant	O
and	O
eliminated	O
by	O
removing	O
sites	O
with	O
pH	O
<	O
6	O
.	O

Other	O
potential	O
confounders	O
were	O
eliminated	O
based	O
on	O
the	O
weight	O
of	O
evidence	O
.	O

This	O
method	O
was	O
found	O
to	O
be	O
useful	O
and	O
defensible	O
.	O

It	O
could	O
be	O
applied	O
to	O
other	O
environmental	O
assessments	O
that	O
use	O
field	O
data	O
to	O
develop	O
causal	O
relationships	O
,	O
including	O
contaminated	O
site	O
remediation	O
or	O
management	O
of	O
natural	O
resources	O
.	O

Substituent	O
variation	O
drives	O
metal	O
/	O
monolayer	O
/	O
semiconductor	O
junctions	O
from	O
strongly	O
rectifying	O
to	O
ohmic	O
behavior	O
.	O

An	O
eight	O
-	O
orders	O
of	O
magnitude	O
enhancement	O
in	O
current	O
across	O
Hg	B
/	O
X	O
-	O
styrene	B
-	O
Si	B
junctions	O
is	O
caused	O
by	O
merely	O
altering	O
a	O
substituent	O
,	O
X.	O
Interface	O
states	O
are	O
passivated	O
and	O
,	O
depending	O
on	O
X	O
,	O
the	O
Si	B
Schottky	O
junction	O
encompasses	O
the	O
full	O
range	O
from	O
Ohmic	O
to	O
strongly	O
rectifying	O
.	O

This	O
powerful	O
electrostatic	O
molecular	O
effect	O
has	O
immediate	O
implications	O
for	O
interface	O
band	O
alignment	O
and	O
sensing	O
.	O

Influence	O
of	O
silver	B
doping	O
on	O
electron	O
transport	O
in	O
thin	O
films	O
of	O
PbSe	B
nanocrystals	O
.	O

Field	O
-	O
effect	O
transistors	O
are	O
fabricated	O
from	O
thin	O
films	O
of	O
Ag	B
-	I
doped	I
PbSe	I
nanocrystals	O
to	O
analyze	O
the	O
influence	O
of	O
electronically	O
active	O
impurities	O
on	O
electrical	O
transport	O
in	O
this	O
important	O
material	O
for	O
nanocrystal	O
applications	O
.	O

Data	O
is	O
collected	O
as	O
a	O
function	O
of	O
nanocrystal	O
size	O
,	O
dopant	O
concentration	O
,	O
and	O
temperature	O
.	O

Changes	O
in	O
the	O
Fermi	O
level	O
and	O
transport	O
parameters	O
indicate	O
that	O
Ag	B
is	O
acting	O
as	O
a	O
p	O
-	O
type	O
dopant	O
(	O
acceptor	O
)	O
.	O

New	O
horizons	O
for	O
diagnostics	O
and	O
therapeutic	O
applications	O
of	O
graphene	B
and	O
graphene	B
oxide	I
.	O

Graphene	B
,	O
a	O
one	O
-	O
atom	O
-	O
thick	O
two	O
-	O
dimensional	O
(	O
2D	O
)	O
layer	O
of	O
sp	O
(	O
2	O
)	O
-bonded	O
carbon	B
,	O
has	O
received	O
worldwide	O
attention	O
owing	O
to	O
its	O
extraordinary	O
physical	O
and	O
chemical	O
properties	O
.	O

Recently	O
,	O
great	O
efforts	O
have	O
been	O
devoted	O
to	O
explore	O
potential	O
applications	O
of	O
graphene	B
and	O
its	O
oxide	O
in	O
life	O
science	O
,	O
especially	O
in	O
disease	O
-	O
related	O
diagnostics	O
,	O
near	O
-	O
Infrared	O
(	O
NIR	O
)	O
phototherapy	O
and	O
imaging	O
.	O

Here	O
we	O
will	O
introduce	O
recent	O
advances	O
and	O
new	O
horizons	O
in	O
this	O
area	O
,	O
and	O
focus	O
on	O
the	O
rising	O
progress	O
on	O
NIR	O
photothermal	O
therapy	O
for	O
cancer	O
and	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
,	O
human	O
telomerase	O
detection	O
,	O
stem	O
cell	O
proliferation	O
and	O
differentiation	O
on	O
graphene	B
substrate	O
,	O
diagnosis	O
of	O
cancer	O
cell	O
and	O
related	O
biomarkers	O
,	O
drug	O
/	O
nucleotide	B
/	O
peptide	O
delivery	O
and	O
cell	O
imaging	O
,	O
which	O
have	O
not	O
been	O
comprehensively	O
reviewed	O
.	O

We	O
hope	O
to	O
provide	O
an	O
outlook	O
to	O
the	O
applications	O
of	O
graphene	B
and	O
its	O
oxide	O
,	O
especially	O
on	O
the	O
new	O
horizons	O
in	O
this	O
field	O
,	O
and	O
inspire	O
broader	O
interests	O
across	O
various	O
disciplines	O
.	O

SchistoDB	O
:	O
an	O
updated	O
genome	O
resource	O
for	O
the	O
three	O
key	O
schistosomes	O
of	O
humans	O
.	O

The	O
new	O
release	O
of	O
SchistoDB	O
(	O
http://SchistoDB.net	O
)	O
provides	O
a	O
rich	O
resource	O
of	O
genomic	O
data	O
for	O
key	O
blood	O
flukes	O
(	O
genus	O
Schistosoma	O
)	O
which	O
cause	O
disease	O
in	O
hundreds	O
of	O
millions	O
of	O
people	O
worldwide	O
.	O

SchistoDB	O
integrates	O
whole	O
-	O
genome	O
sequence	O
and	O
annotation	O
of	O
three	O
species	O
of	O
the	O
genus	O
and	O
provides	O
enhanced	O
bioinformatics	O
analyses	O
and	O
data	O
-	O
mining	O
tools	O
.	O

A	O
simple	O
,	O
yet	O
comprehensive	O
web	O
interface	O
provided	O
through	O
the	O
Strategies	O
Web	O
Development	O
Kit	O
is	O
available	O
for	O
the	O
mining	O
and	O
visualization	O
of	O
the	O
data	O
.	O

Genomic	O
scale	O
data	O
can	O
be	O
queried	O
based	O
on	O
BLAST	O
searches	O
,	O
annotation	O
keywords	O
and	O
gene	O
ID	O
searches	O
,	O
gene	O
ontology	O
terms	O
,	O
sequence	O
motifs	O
,	O
protein	O
characteristics	O
and	O
phylogenetic	O
relationships	O
.	O

Search	O
strategies	O
can	O
be	O
saved	O
within	O
a	O
user	O
's	O
profile	O
for	O
future	O
retrieval	O
and	O
may	O
also	O
be	O
shared	O
with	O
other	O
researchers	O
using	O
a	O
unique	O
web	O
address	O
.	O

Genetic	O
requirements	O
for	O
Moraxella	O
catarrhalis	O
growth	O
under	O
iron	B
-	O
limiting	O
conditions	O
.	O

Iron	B
sequestration	O
by	O
the	O
human	O
host	O
is	O
a	O
first	O
line	O
defence	O
against	O
respiratory	O
pathogens	O
like	O
Moraxella	O
catarrhalis	O
,	O
which	O
consequently	O
experiences	O
a	O
period	O
of	O
iron	B
starvation	O
during	O
colonization	O
.	O

We	O
determined	O
the	O
genetic	O
requirements	O
for	O
M.	O
catarrhalis	O
BBH18	O
growth	O
during	O
iron	B
starvation	O
using	O
the	O
high	O
-	O
throughput	O
genome	O
-	O
wide	O
screening	O
technology	O
genomic	O
array	O
footprinting	O
(	O
GAF	O
)	O
.	O

By	O
subjecting	O
a	O
large	O
random	O
transposon	O
mutant	O
library	O
to	O
growth	O
under	O
iron	B
-	O
limiting	O
conditions	O
,	O
mutants	O
of	O
the	O
MCR_0996-rhlB	O
-	O
yggW	O
operon	O
,	O
rnd	O
,	O
and	O
MCR_0457	O
were	O
negatively	O
selected	O
.	O

Growth	O
experiments	O
using	O
directed	O
mutants	O
confirmed	O
the	O
GAF	O
phenotypes	O
with	O
yggW	O
(	O
putative	O
haem	O
-	O
shuttling	O
protein	O
)	O
and	O
MCR_0457	O
(	O
hypothetical	O
protein	O
)	O
most	O
severely	O
attenuated	O
during	O
iron	B
starvation	O
,	O
phenotypes	O
which	O
were	O
restored	O
upon	O
genetic	O
complementation	O
of	O
the	O
deleted	O
genes	O
.	O

Deletion	O
of	O
yggW	O
resulted	O
in	O
similar	O
attenuated	O
phenotypes	O
in	O
three	O
additional	O
strains	O
.	O

Transcriptional	O
profiles	O
of	O
yggW	O
and	O
MCR_0457	O
were	O
highly	O
altered	O
with	O
393	O
and	O
192	O
differentially	O
expressed	O
genes	O
respectively	O
.	O

In	O
all	O
five	O
mutants	O
,	O
expression	O
of	O
nitrate	B
reductase	O
genes	O
was	O
increased	O
and	O
of	O
nitrite	B
reductase	O
decreased	O
,	O
suggesting	O
an	O
impaired	O
aerobic	O
respiration	O
.	O

Alteration	O
of	O
iron	B
metabolism	O
may	O
affect	O
nasopharyngeal	O
colonization	O
as	O
adherence	O
of	O
all	O
mutants	O
to	O
respiratory	O
tract	O
epithelial	O
cells	O
was	O
attenuated	O
.	O

In	O
conclusion	O
,	O
we	O
elucidated	O
the	O
genetic	O
requirements	O
for	O
M.	O
catarrhalis	O
growth	O
during	O
iron	B
starvation	O
and	O
characterized	O
the	O
roles	O
of	O
the	O
identified	O
genes	O
in	O
bacterial	O
growth	O
and	O
host	O
interaction	O
.	O

Synaptic	O
plasticity	O
in	O
the	O
hippocampus	O
shows	O
resistance	O
to	O
acute	O
ethanol	B
exposure	O
in	O
transgenic	O
mice	O
with	O
astrocyte	O
-	O
targeted	O
enhanced	O
CCL2	O
expression	O
.	O

It	O
has	O
been	O
shown	O
that	O
ethanol	O
exposure	O
can	O
activate	O
astrocytes	O
and	O
microglia	O
resulting	O
in	O
the	O
production	O
of	O
neuroimmune	O
factors	O
,	O
including	O
the	O
chemokine	O
CCL2	O
.	O

The	O
role	O
of	O
these	O
neuroimmune	O
factors	O
in	O
the	O
effects	O
of	O
ethanol	B
on	O
the	O
central	O
nervous	O
system	O
has	O
yet	O
to	O
be	O
elucidated	O
.	O

To	O
address	O
this	O
question	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
ethanol	B
on	O
synaptic	O
transmission	O
and	O
plasticity	O
in	O
the	O
hippocampus	O
from	O
mice	O
that	O
express	O
elevated	O
levels	O
of	O
CCL2	O
in	O
the	O
brain	O
and	O
their	O
non	O
-	O
transgenic	O
littermate	O
controls	O
.	O

The	O
brains	O
of	O
the	O
transgenic	O
mice	O
simulate	O
one	O
aspect	O
of	O
the	O
alcoholic	O
brain	O
,	O
chronically	O
increased	O
levels	O
of	O
CCL2	O
.	O

We	O
used	O
extracellular	O
field	O
potential	O
recordings	O
in	O
acutely	O
isolated	O
hippocampal	O
slices	O
to	O
identify	O
neuroadaptive	O
changes	O
produced	O
by	O
elevated	O
levels	O
of	O
CCL2	O
and	O
how	O
these	O
neuroadaptive	O
changes	O
affect	O
the	O
actions	O
of	O
acute	O
ethanol	B
.	O

Results	O
showed	O
that	O
synaptic	O
transmission	O
and	O
the	O
effects	O
of	O
ethanol	B
on	O
synaptic	O
transmission	O
were	O
similar	O
in	O
the	O
CCL2-transgenic	O
and	O
non	O
-	O
transgenic	O
hippocampus	O
.	O

However	O
,	O
long	O
-	O
term	O
potentiation	O
(	O
LTP	O
)	O
,	O
a	O
cellular	O
mechanism	O
thought	O
to	O
underlie	O
learning	O
and	O
memory	O
,	O
in	O
the	O
CCL2-transgenic	O
hippocampus	O
was	O
resistant	O
to	O
the	O
ethanol	B
-	O
induced	O
depression	O
of	O
LTP	O
observed	O
in	O
the	O
non	O
-	O
transgenic	O
hippocampus	O
.	O

Consistent	O
with	O
these	O
results	O
,	O
ethanol	B
pretreatment	O
significantly	O
impaired	O
cued	O
and	O
contextual	O
fear	O
conditioning	O
in	O
non	O
-	O
transgenic	O
mice	O
,	O
but	O
had	O
no	O
effect	O
in	O
CCL2-transgenic	O
mice	O
.	O

These	O
data	O
show	O
that	O
chronically	O
elevated	O
levels	O
of	O
CCL2	O
in	O
the	O
hippocampus	O
produce	O
neuroadaptive	O
changes	O
that	O
block	O
the	O
depressing	O
effects	O
of	O
ethanol	B
on	O
hippocampal	O
synaptic	O
plasticity	O
and	O
support	O
the	O
hypothesis	O
that	O
CCL2	O
may	O
provide	O
a	O
neuroprotective	O
effect	O
against	O
the	O
devastating	O
actions	O
of	O
ethanol	B
on	O
hippocampal	O
function	O
.	O

Supra	O
-	O
normal	O
stimulation	O
of	O
dopamine	B
D1	O
receptors	O
in	O
the	O
prelimbic	O
cortex	O
blocks	O
behavioral	O
expression	O
of	O
both	O
aversive	O
and	O
rewarding	O
associative	O
memories	O
through	O
a	O
cyclic	B
-	I
AMP	I
-	O
dependent	O
signaling	O
pathway	O
.	O

Dopamine	B
(	O
DA	O
)	O
receptor	O
transmission	O
through	O
either	O
D	O
(	O
1	O
)	O
or	O
D	O
(	O
2	O
)	O
-like	O
subtypes	O
is	O
involved	O
critically	O
in	O
the	O
processing	O
of	O
emotional	O
information	O
within	O
the	O
medial	O
prefrontal	O
cortex	O
(	O
mPFC	O
)	O
.	O

However	O
the	O
functional	O
role	O
of	O
specific	O
DA	O
D	O
(	O
1	O
)	O
-like	O
receptor	O
transmission	O
in	O
the	O
expression	O
of	O
emotionally	O
salient	O
associative	O
memories	O
(	O
either	O
aversive	O
or	O
rewarding	O
)	O
is	O
not	O
currently	O
understood	O
.	O

Here	O
we	O
demonstrate	O
that	O
specific	O
activation	O
of	O
DA	O
D	O
(	O
1	O
)	O
receptors	O
in	O
the	O
prelimbic	O
(	O
PLC	O
)	O
division	O
of	O
the	O
mPFC	O
causes	O
a	O
transient	O
block	O
in	O
the	O
behavioral	O
expression	O
of	O
both	O
aversive	O
and	O
rewarding	O
associative	O
memories	O
.	O

We	O
report	O
that	O
intra	O
-	O
PLC	O
microinfusions	O
of	O
a	O
selective	O
D	O
(	O
1	O
)	O
receptor	O
agonist	O
block	O
the	O
spontaneous	O
expression	O
of	O
an	O
associative	O
olfactory	O
fear	O
memory	O
,	O
without	O
altering	O
the	O
stability	O
of	O
the	O
original	O
memory	O
trace	O
.	O

Furthermore	O
,	O
using	O
an	O
unbiased	O
place	O
conditioning	O
procedure	O
(	O
CPP	O
)	O
,	O
intra	O
-	O
PLC	O
D	O
(	O
1	O
)	O
receptor	O
activation	O
blocks	O
the	O
spontaneous	O
expression	O
of	O
an	O
associative	O
morphine	B
(	O
5	O
mg	O
/	O
kg	O
;	O
i.p	O
.	O
)	O
reward	O
memory	O
,	O
while	O
leaving	O
morphine	B
-	O
primed	O
memory	O
expression	O
intact	O
.	O

Interestingly	O
,	O
both	O
intra	O
-	O
PLC	O
D	O
(	O
1	O
)	O
-receptor	O
mediated	O
block	O
of	O
either	O
fear	O
-	O
related	O
or	O
reward	O
-	O
related	O
associative	O
memories	O
were	O
dependent	O
upon	O
downstream	O
cyclic	B
-	I
AMP	I
(	O
cAMP	B
)	O
signaling	O
as	O
both	O
effects	O
were	O
rescued	O
by	O
co	O
-	O
administration	O
of	O
a	O
cAMP	B
signaling	O
inhibitor	O
.	O

The	O
blockade	O
of	O
both	O
rewarding	O
and	O
aversive	O
associative	O
memories	O
is	O
mediated	O
through	O
a	O
D	O
(	O
1	O
)	O
-specific	O
signaling	O
pathway	O
,	O
as	O
neither	O
forms	O
of	O
spontaneous	O
memory	O
expression	O
were	O
blocked	O
by	O
intra	O
-	O
PLC	O
microinfusions	O
of	O
a	O
D	O
(	O
2	O
)	O
-like	O
receptor	O
agonist	O
.	O

Our	O
results	O
demonstrate	O
that	O
the	O
spontaneous	O
expression	O
of	O
either	O
rewarding	O
or	O
aversive	O
emotionally	O
salient	O
memories	O
shares	O
a	O
common	O
,	O
D	O
(	O
1	O
)	O
-receptor	O
mediated	O
substrate	O
within	O
the	O
mPFC	O
.	O

Glucose	B
attenuates	O
impairments	O
in	O
memory	O
and	O
CREB	O
activation	O
produced	O
by	O
an	O
42	O
but	O
not	O
an	O
7	O
nicotinic	O
receptor	O
antagonist	O
.	O

Glucose	B
improves	O
memory	O
for	O
a	O
variety	O
of	O
tasks	O
when	O
administered	O
to	O
rats	O
and	O
mice	O
near	O
the	O
time	O
of	O
training	O
.	O

Prior	O
work	O
indicates	O
glucose	B
may	O
enhance	O
memory	O
by	O
increasing	O
the	O
synthesis	O
and	O
release	O
of	O
the	O
neurotransmitter	O
acetylcholine	B
in	O
the	O
brain	O
.	O

To	O
investigate	O
if	O
specific	O
acetylcholine	B
receptor	O
subtypes	O
may	O
mediate	O
some	O
of	O
the	O
memory	O
-	O
enhancing	O
actions	O
of	O
glucose	B
,	O
we	O
examined	O
the	O
effects	O
of	O
subtype	O
-	O
specific	O
nicotinic	O
acetylcholine	B
receptor	O
antagonists	O
on	O
memory	O
in	O
Fischer-344	O
rats	O
and	O
also	O
examined	O
the	O
ability	O
of	O
glucose	B
to	O
reverse	O
drug	O
-	O
induced	O
impairments	O
.	O

Pre	O
-	O
training	O
peripheral	O
injections	O
of	O
methyllycaconitine	B
(	O
MLA	B
)	O
or	O
dihydro	B
-	I
beta	I
-	I
erythroidine	I
(	O
DHE	B
)	O
,	O
which	O
are	O
specific	O
7	O
and	O
42	O
nicotinic	O
receptor	O
antagonists	O
,	O
respectively	O
,	O
dose	O
-	O
dependently	O
impaired	O
retention	O
latencies	O
in	O
an	O
inhibitory	O
avoidance	O
task	O
when	O
tested	O
7-days	O
but	O
not	O
1	O
h	O
after	O
training	O
.	O

Immediate	O
post	O
-	O
training	O
glucose	B
injections	O
attenuated	O
the	O
impairments	O
,	O
but	O
were	O
more	O
effective	O
in	O
attenuating	O
the	O
DHE	B
-	O
induced	O
impairments	O
.	O

Likewise	O
,	O
peripheral	O
or	O
direct	O
intrahippocampal	O
injections	O
of	O
MLA	B
or	O
DHE	B
dose	O
-	O
dependently	O
impaired	O
spatial	O
working	O
memory	O
scores	O
on	O
a	O
spontaneous	O
alternation	O
task	O
.	O

Concurrent	O
administration	O
of	O
glucose	B
reversed	O
DHE-	B
but	O
not	O
MLA	B
-	O
induced	O
impairments	O
.	O

CREB	O
phosphorylation	O
downstream	O
of	O
cholinergic	O
signaling	O
was	O
assessed	O
30	O
min	O
after	O
spontaneous	O
alternation	O
testing	O
and	O
intrahippocampal	O
drug	O
infusions	O
.	O

Both	O
MLA	B
and	O
DHE	B
impaired	O
hippocampal	O
CREB	O
phosphorylation	O
;	O
glucose	B
reversed	O
DHE-	B
but	O
not	O
MLA	B
-	O
induced	O
deficits	O
.	O

The	O
effectiveness	O
of	O
glucose	B
in	O
reversing	O
DHE-	B
but	O
not	O
MLA	B
-	O
induced	O
impairments	O
in	O
behavioral	O
performance	O
and	O
CREB	O
phosphorylation	O
suggests	O
that	O
activation	O
of	O
7	O
receptors	O
may	O
play	O
an	O
important	O
role	O
in	O
memory	O
enhancement	O
by	O
glucose	B
.	O

Enantioselective	O
synthesis	O
of	O
derivatives	O
and	O
structure	O
-	O
activity	O
relationship	O
study	O
in	O
the	O
development	O
of	O
NA255	B
as	O
a	O
novel	O
host	O
-	O
targeting	O
anti	O
-	O
HCV	O
agent	O
.	O

Hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
infection	O
represents	O
a	O
serious	O
health	O
-	O
care	O
problem	O
.	O

Previously	O
we	O
reported	O
the	O
identification	O
of	O
NA255	B
from	O
our	O
natural	O
products	O
library	O
using	O
a	O
HCV	O
sub	O
-	O
genomic	O
replicon	O
cell	O
culture	O
system	O
.	O

Herein	O
,	O
we	O
report	O
how	O
the	O
absolute	O
stereochemistry	O
of	O
NA255	B
was	O
determined	O
and	O
an	O
enantioselective	O
synthetic	O
method	O
for	O
NA255	B
derivatives	O
was	O
developed	O
.	O

The	O
structure	O
-	O
activity	O
relationship	O
of	O
the	O
NA255	B
derivatives	O
and	O
rat	O
pharmacokinetic	O
profiles	O
of	O
the	O
representative	O
compounds	O
are	O
disclosed	O
.	O

Reproductive	O
and	O
developmental	O
toxicity	O
screening	O
test	O
of	O
3-cyanopyridine	B
in	O
rats	O
.	O

Crl	O
:	O
CD	O
(	O
SD	O
)	O
rats	O
were	O
given	O
3-cyanopyridine	B
by	O
gavage	O
at	O
0	O
,	O
5	O
,	O
30	O
or	O
180	O
mg	O
/	O
kg	O
/	O
day	O
.	O

Males	O
were	O
dosed	O
for	O
42	O
days	O
beginning	O
14	O
days	O
before	O
mating	O
,	O
and	O
females	O
for	O
40	O
-	O
53	O
days	O
beginning	O
14	O
days	O
before	O
mating	O
to	O
day	O
3	O
of	O
lactation	O
,	O
including	O
throughout	O
the	O
mating	O
and	O
gestation	O
periods	O
.	O

General	O
toxicity	O
,	O
mainly	O
liver	O
damage	O
,	O
was	O
observed	O
in	O
males	O
at	O
30	O
mg	O
/	O
kg	O
/	O
day	O
and	O
in	O
females	O
at	O
5	O
mg	O
/	O
kg	O
/	O
day	O
.	O

Sertoli	O
cell	O
vacuolation	O
was	O
observed	O
at	O
180	O
mg	O
/	O
kg	O
/	O
day	O
,	O
and	O
spermatocyte	O
damages	O
were	O
observed	O
at	O
30	O
mg	O
/	O
kg	O
/	O
day	O
.	O

Effects	O
on	O
estrous	O
cycles	O
,	O
corpora	O
lutea	O
and	O
implantations	O
,	O
and	O
unsuccessfully	O
mated	O
females	O
,	O
despite	O
additional	O
mating	O
,	O
were	O
observed	O
at	O
180	O
mg	O
/	O
kg	O
/	O
day	O
.	O

Delayed	O
initiation	O
of	O
delivery	O
,	O
dystocia	O
,	O
and	O
deaths	O
or	O
moribundities	O
of	O
pregnant	O
females	O
were	O
observed	O
at	O
180	O
mg	O
/	O
kg	O
/	O
day	O
,	O
and	O
only	O
two	O
pregnant	O
rats	O
delivered	O
live	O
pups	O
at	O
that	O
dose	O
.	O

The	O
NOAEL	O
for	O
reproductive	O
/	O
developmental	O
toxicity	O
was	O
concluded	O
to	O
be	O
30	O
mg	O
/	O
kg	O
/	O
day	O
.	O

Three	O
-	O
month	O
subchronic	O
intramuscular	O
toxicity	O
study	O
of	O
rotigotine	B
-	O
loaded	O
microspheres	O
in	O
Cynomolgus	O
monkeys	O
.	O

Continuous	O
dopaminergic	O
stimulation	O
(	O
CDS	O
)	O
is	O
an	O
important	O
drug	O
development	O
strategy	O
in	O
the	O
treatment	O
of	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
.	O

Rotigotine	B
is	O
a	O
non	O
-	O
ergoline	B
D	O
(	O
3	O
)	O
/	O
D	O
(	O
2	O
)	O
/	O
D	O
(	O
1	O
)	O
dopamine	B
receptor	O
agonist	O
for	O
treating	O
PD	O
.	O

As	O
a	O
new	O
treatment	O
option	O
for	O
CDS	O
,	O
rotigotine	B
-	O
loaded	O
microspheres	O
(	O
RoMS	O
)	O
,	O
long	O
-	O
acting	O
sustained	O
-	O
release	O
microspheres	O
with	O
poly	B
(	I
lactide	I
-	I
co	I
-	I
glycolide	I
)	I
as	O
drug	O
carrier	O
,	O
are	O
now	O
being	O
evaluated	O
in	O
clinical	O
trial	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
subchronic	O
toxicity	O
in	O
Cynomolgus	O
monkeys	O
has	O
been	O
characterized	O
via	O
intramuscular	O
administration	O
with	O
RoMS	O
at	O
0	O
,	O
10	O
,	O
40	O
and	O
160	O
mg	O
/	O
kg	O
,	O
weekly	O
for	O
3	O
months	O
with	O
a	O
1-month	O
recovery	O
period	O
.	O

The	O
NOAEL	O
was	O
10	O
mg	O
/	O
kg	O
/	O
week	O
.	O

One	O
male	O
at	O
160	O
mg	O
/	O
kg	O
died	O
from	O
an	O
extensive	O
pulmonary	O
embolism	O
.	O

The	O
major	O
toxicological	O
effects	O
were	O
associated	O
with	O
dopamine	B
agonist	O
-	O
related	O
pharmacodynamic	O
properties	O
of	O
rotigotine	B
(	O
e.g.	O
,	O
hyperactivity	O
and	O
stereotype	O
,	O
decreased	O
serum	O
prolactin	O
level	O
)	O
and	O
foreign	O
body	O
removal	O
reaction	O
induced	O
by	O
poly	B
(	I
lactide	I
-	I
co	I
-	I
glycolide	I
)	I
and	O
carboxymethycellulose	O
sodium	B
(	O
e.g.	O
,	O
increased	O
mononuclear	O
cells	O
and	O
neutrophils	O
,	O
thymus	O
atrophy	O
and	O
vacuolar	O
degeneration	O
of	O
adrenal	O
cortex	O
,	O
foreign	O
body	O
granuloma	O
with	O
foam	O
cells	O
accumulation	O
at	O
injection	O
sites	O
and	O
foam	O
cells	O
accumulation	O
in	O
spleen	O
and	O
multiple	O
lymph	O
sinuses	O
)	O
.	O

At	O
the	O
end	O
of	O
recovery	O
period	O
,	O
above	O
findings	O
recovered	O
to	O
a	O
normal	O
level	O
or	O
to	O
a	O
certain	O
degree	O
except	O
vacuolar	O
degeneration	O
of	O
adrenal	O
gland	O
.	O

RoMS	O
has	O
exhibited	O
high	O
safety	O
on	O
monkeys	O
.	O

In	O
vitro	O
combined	O
cytotoxic	O
effects	O
of	O
pesticide	O
cocktails	O
simultaneously	O
found	O
in	O
the	O
French	O
diet	O
.	O

Although	O
human	O
populations	O
may	O
be	O
constantly	O
exposed	O
to	O
complex	O
pesticide	O
mixtures	O
through	O
their	O
diet	O
,	O
the	O
human	O
health	O
risk	O
of	O
pesticide	O
exposure	O
is	O
currently	O
assessed	O
on	O
the	O
basis	O
of	O
toxicity	O
data	O
on	O
individual	O
compounds	O
.	O

To	O
investigate	O
the	O
combined	O
toxic	O
effects	O
of	O
pesticide	O
cocktails	O
previously	O
identified	O
in	O
the	O
French	O
diet	O
,	O
we	O
first	O
studied	O
the	O
cytotoxicity	O
induced	O
by	O
seven	O
cocktails	O
composed	O
of	O
two	O
to	O
six	O
pesticides	O
on	O
human	O
hepatic	O
(	O
HepG2	O
)	O
and	O
colon	O
(	O
Caco-2	O
)	O
cell	O
lines	O
using	O
the	O
MTT	B
and	O
neutral	B
red	I
uptake	O
assays	O
.	O

Secondly	O
,	O
we	O
challenged	O
to	O
assess	O
the	O
combined	O
effects	O
of	O
the	O
two	O
most	O
cytotoxic	O
cocktails	O
by	O
comparing	O
the	O
measured	O
effects	O
of	O
the	O
mixtures	O
with	O
the	O
predictions	O
based	O
on	O
additive	O
effects	O
on	O
two	O
concepts	O
-	O
independent	O
action	O
(	O
IA	O
)	O
and	O
concentration	O
addition	O
(	O
CA	O
)	O
.	O

For	O
the	O
cocktail	O
composed	O
of	O
dichlorodiphenyltrichloroethane	B
(	O
DDT	B
)	O
and	O
dieldrin	B
,	O
the	O
cytotoxicity	O
of	O
the	O
equimolar	O
cocktail	O
proved	O
greater	O
than	O
the	O
additive	O
effect	O
estimated	O
by	O
the	O
two	O
concepts	O
.	O

Furthermore	O
,	O
apoptosis	O
induction	O
was	O
higher	O
in	O
equimolar	O
cocktail	O
than	O
predicted	O
by	O
summing	O
the	O
effects	O
of	O
DDT	B
and	O
dieldrin	B
.	O

Thus	O
,	O
some	O
supra	O
-	O
additive	O
toxicity	O
was	O
found	O
in	O
the	O
DDT	B
-	O
dieldrin	B
cocktail	O
.	O

Nevertheless	O
,	O
if	O
IA	O
and	O
CA	O
models	O
could	O
reveal	O
combined	O
effects	O
of	O
pesticide	O
cocktails	O
,	O
an	O
accurate	O
evaluation	O
remains	O
challenging	O
.	O

Identification	O
,	O
characterization	O
,	O
and	O
isolation	O
of	O
a	O
common	O
progenitor	O
for	O
osteoclasts	O
,	O
macrophages	O
,	O
and	O
dendritic	O
cells	O
from	O
murine	O
bone	O
marrow	O
and	O
periphery	O
.	O

Osteoclasts	O
are	O
specialized	O
bone	O
-	O
resorbing	O
cells	O
that	O
derive	O
from	O
monocyte	O
precursors	O
.	O

We	O
have	O
identified	O
three	O
populations	O
of	O
cells	O
with	O
high	O
osteoclastogenic	O
potential	O
in	O
murine	O
bone	O
marrow	O
,	O
which	O
expressed	O
the	O
phenotype	O
B220	O
(	O
-	O
)	O
CD3	O
(	O
-	O
)	O
CD11b	O
(	O
-	O
/	O
low	O
)	O
CD115	O
(	O
+	O
)	O
and	O
either	O
CD117	O
(	O
hi	O
)	O
,	O
CD117	O
(	O
intermediate	O
)	O
,	O
or	O
CD117	O
(	O
low	O
)	O
.	O

We	O
have	O
evaluated	O
these	O
populations	O
for	O
their	O
ability	O
to	O
also	O
generate	O
macrophages	O
and	O
dendritic	O
cells	O
.	O

At	O
a	O
single	O
-	O
cell	O
level	O
,	O
the	O
population	O
expressing	O
higher	O
CD117	O
levels	O
was	O
able	O
to	O
generate	O
bone	O
-	O
resorbing	O
osteoclasts	O
,	O
phagocytic	O
macrophages	O
,	O
and	O
antigen	O
-	O
presenting	O
dendritic	O
cells	O
in	O
vitro	O
with	O
efficiencies	O
of	O
more	O
than	O
90	O
%	O
,	O
indicating	O
that	O
there	O
exists	O
a	O
common	O
developmental	O
pathway	O
for	O
these	O
cell	O
types	O
.	O

Cells	O
with	O
osteoclastogenic	O
potential	O
also	O
exist	O
in	O
blood	O
and	O
peripheral	O
hematopoietic	O
organs	O
.	O

Their	O
functional	O
meaning	O
and/or	O
their	O
relationship	O
with	O
bone	O
marrow	O
progenitors	O
is	O
not	O
well	O
established	O
.	O

Hence	O
,	O
we	O
characterized	O
murine	O
peripheral	O
cell	O
populations	O
for	O
their	O
ability	O
to	O
form	O
osteoclasts	O
,	O
macrophages	O
,	O
and	O
dendritic	O
cells	O
in	O
vitro	O
.	O

The	O
spleen	O
and	O
peripheral	O
blood	O
monocyte	O
progenitors	O
share	O
phenotypic	O
markers	O
with	O
bone	O
marrow	O
progenitors	O
but	O
differ	O
in	O
their	O
expression	O
of	O
CD11b	O
,	O
which	O
was	O
low	O
in	O
bone	O
marrow	O
but	O
high	O
in	O
periphery	O
.	O

We	O
propose	O
that	O
circulating	O
monocyte	O
progenitors	O
are	O
derived	O
from	O
a	O
common	O
bone	O
marrow	O
osteoclasts	O
/	O
macrophage	O
/	O
dendritic	O
cell	O
progenitor	O
(	O
OcMDC	O
)	O
,	O
which	O
we	O
have	O
now	O
characterized	O
at	O
a	O
clonal	O
level	O
.	O

However	O
,	O
the	O
lineage	O
relationship	O
between	O
the	O
bone	O
marrow	O
and	O
peripheral	O
monocyte	O
progenitors	O
has	O
yet	O
to	O
be	O
defined	O
.	O

	O
2013	O
American	O
Society	O
for	O
Bone	O
and	O
Mineral	O
Research	O
.	O

Fabrication	O
of	O
3-dimensional	O
cellular	O
constructs	O
via	O
microstereolithography	O
using	O
a	O
simple	O
,	O
three	O
-	O
component	O
,	O
poly	B
(	I
ethylene	I
glycol	I
)	I
acrylate	I
-	O
based	O
system	O
.	O

A	O
novel	O
method	O
for	O
the	O
production	O
of	O
inhibitor-	O
and	O
solvent	O
-	O
free	O
resins	O
suitable	O
for	O
three	O
-	O
dimensional	O
(	O
3D	O
)	O
microstereolithography	O
is	O
reported	O
.	O

Using	O
an	O
exemplar	O
poly	B
(	I
ethylene	I
glycol	I
)	I
-based	O
resin	O
,	O
the	O
control	O
of	O
features	O
in	O
the	O
X	O
,	O
Y	O
,	O
and	O
Z	O
planes	O
is	O
demonstrated	O
such	O
that	O
complex	O
structures	O
can	O
be	O
manufactured	O
.	O

Human	O
mesenchymal	O
stem	O
cells	O
cultured	O
on	O
the	O
manufactured	O
scaffolds	O
remained	O
viable	O
during	O
the	O
7	O
day	O
assessment	O
period	O
,	O
with	O
proliferation	O
rates	O
comparable	O
to	O
those	O
observed	O
on	O
tissue	O
culture	O
polystyrene	B
.	O

These	O
data	O
suggest	O
that	O
this	O
novel	O
,	O
yet	O
simple	O
,	O
method	O
is	O
suitable	O
for	O
the	O
production	O
of	O
3D	O
scaffolds	O
for	O
tissue	O
engineering	O
and	O
regenerative	O
medicine	O
applications	O
.	O

8,8-dialkyldihydroberberines	B
with	O
potent	O
antiprotozoal	O
activity	O
.	O

Semisynthetic	O
8,8-dialkyldihydroberberines	B
(	O
8,8-DDBs	B
)	O
were	O
found	O
to	O
possess	O
mid-	O
to	O
low	O
-	O
nanomolar	O
potency	O
against	O
Plasmodium	O
falciparum	O
blood	O
-	O
stage	O
parasites	O
,	O
Leishmania	O
donovani	O
intracellular	O
amastigotes	O
,	O
and	O
Trypanosoma	O
brucei	O
brucei	O
bloodstream	O
forms	O
.	O

For	O
example	O
,	O
8,8-diethyldihydroberberine	B
chloride	I
(	O
5b	O
)	O
exhibited	O
in	O
vitro	O
IC50	O
values	O
of	O
77	O
,	O
100	O
,	O
and	O
5.3	O
nM	O
against	O
these	O
three	O
parasites	O
,	O
respectively	O
.	O

In	O
turn	O
,	O
two	O
8,8-dialkylcanadines	B
,	O
obtained	O
by	O
reduction	O
of	O
the	O
corresponding	O
8,8-DDBs	B
,	O
were	O
much	O
less	O
potent	O
against	O
these	O
parasites	O
in	O
vitro	O
.	O

While	O
the	O
natural	O
product	O
berberine	O
is	O
a	O
weak	O
DNA	O
binder	O
,	O
the	O
8,8-DDBs	B
displayed	O
no	O
affinity	O
for	O
DNA	O
,	O
as	O
assessed	O
by	O
changes	O
in	O
the	O
melting	O
temperature	O
of	O
poly	B
(	I
dAdT	I
)	I
DNA	O
.	O

Selected	O
8,8-DDBs	B
showed	O
efficacy	O
in	O
mouse	O
models	O
of	O
visceral	O
leishmaniasis	O
and	O
African	O
trypanosomiasis	O
,	O
with	O
8,8-dimethyldihydroberberine	B
chloride	I
(	O
5a	O
)	O
reducing	O
liver	O
parasitemia	O
by	O
46	O
%	O
in	O
L.	O
donovani	O
-	O
infected	O
BALB	O
/	O
c	O
mice	O
when	O
given	O
at	O
an	O
intraperitoneal	O
dose	O
of	O
10	O
mg	O
/	O
kg	O
/	O
day	O
for	O
five	O
days	O
.	O

The	O
8,8-DDBs	O
may	O
thus	O
serve	O
as	O
leads	O
for	O
discovering	O
new	O
antimalarial	O
,	O
antileishmanial	O
,	O
and	O
antitrypanosomal	O
drug	O
candidates	O
.	O

Stiripentol	B
is	O
anticonvulsant	O
by	O
potentiating	O
GABAergic	O
transmission	O
in	O
a	O
model	O
of	O
benzodiazepine	B
-	O
refractory	O
status	O
epilepticus	O
.	O

Benzodiazepines	B
(	O
BZDs	B
)	O
are	O
first	O
-	O
line	O
therapy	O
for	O
treatment	O
of	O
status	O
epilepticus	O
(	O
SE	O
)	O
.	O

However	O
,	O
BZD	B
treatment	O
is	O
negatively	O
affected	O
by	O
seizure	O
duration	O
due	O
to	O
decreases	O
in	O
BZD	B
-	O
sensitive	O
GABA	O
(	O
A	O
)	O
receptors	O
during	O
prolonged	O
SE	O
.	O

Stiripentol	B
(	O
STP	B
)	O
is	O
an	O
anticonvulsant	O
that	O
is	O
used	O
as	O
add	O
-	O
on	O
treatment	O
for	O
Dravet	O
Syndrome	O
.	O

Recent	O
studies	O
have	O
shown	O
that	O
STP	B
is	O
a	O
positive	O
allosteric	O
modulator	O
of	O
the	O
GABA	O
(	O
A	O
)	O
receptor	O
.	O

The	O
subunit	O
selectivity	O
of	O
STP	B
at	O
this	O
receptor	O
suggests	O
that	O
it	O
would	O
be	O
anticonvulsant	O
in	O
both	O
brief	O
as	O
well	O
as	O
prolonged	O
SE	O
.	O

We	O
tested	O
this	O
possibility	O
by	O
comparing	O
the	O
ability	O
of	O
STP	B
and	O
diazepam	B
(	O
DZP	B
)	O
,	O
a	O
commonly	O
used	O
BZD	B
,	O
to	O
terminate	O
behavioral	O
convulsions	O
in	O
a	O
rodent	O
model	O
of	O
pharmacoresistant	O
SE	O
.	O

We	O
found	O
that	O
STP	B
was	O
anticonvulsant	O
in	O
this	O
model	O
and	O
remained	O
effective	O
during	O
prolonged	O
SE	O
,	O
unlike	O
DZP	B
which	O
exhibited	O
a	O
14	O
fold	O
increase	O
in	O
its	O
ED	O
(	O
50	O
)	O
.	O

Whole	O
cell	O
recording	O
from	O
hippocampal	O
slices	O
from	O
these	O
animals	O
revealed	O
that	O
STP	B
potentiated	O
GABAergic	O
IPSCs	O
,	O
as	O
well	O
as	O
tonic	O
GABAergic	O
current	O
by	O
acting	O
at	O
a	O
site	O
on	O
the	O
GABA	O
(	O
A	O
)	O
receptor	O
separate	O
from	O
the	O
BDZ	B
binding	O
site	O
.	O

Potentiation	O
of	O
GABAergic	O
currents	O
by	O
STP	B
remained	O
intact	O
during	O
prolonged	O
SE	O
,	O
while	O
potentiation	O
by	O
DZP	B
was	O
lost	O
.	O

Both	O
IPSC	O
potentiation	O
and	O
anticonvulsant	O
activity	O
of	O
STP	B
were	O
greater	O
in	O
younger	O
animals	O
than	O
in	O
adults	O
.	O

These	O
findings	O
suggest	O
that	O
at	O
doses	O
that	O
yield	O
therapeutically	O
relevant	O
concentrations	O
,	O
STP	B
is	O
anticonvulsant	O
by	O
potentiating	O
GABAergic	O
inhibition	O
and	O
that	O
the	O
subunit	O
selectivity	O
profile	O
of	O
STP	B
enables	O
it	O
to	O
remain	O
effective	O
despite	O
GABA	O
(	O
A	O
)	O
receptor	O
subunit	O
changes	O
during	O
prolonged	O
SE	O
.	O

Regulation	O
of	O
serotonin	B
(	O
5-HT	B
)	O
function	O
by	O
a	O
VGLUT1	O
dependent	O
glutamate	B
pathway	O
.	O

Unraveling	O
the	O
mechanisms	O
of	O
5-HT	B
neuron	O
control	O
might	O
provide	O
new	O
insights	O
into	O
depression	O
pathophysiology	O
.	O

In	O
addition	O
to	O
the	O
inhibitory	O
5-HT1A	O
autoreceptors	O
,	O
cortico	O
-	O
raphe	O
glutamatergic	O
descending	O
pathways	O
are	O
suggested	O
to	O
modulate	O
5-HT	B
activity	O
in	O
the	O
DRN	O
.	O

Here	O
we	O
studied	O
how	O
decreased	O
VGLUT1	O
levels	O
in	O
the	O
brain	O
stem	O
affect	O
glutamate	B
regulation	O
of	O
5-HT	B
function	O
.	O

VGLUT1+	O
/	O
-	O
mice	O
(	O
C57BL	O
/	O
6	O
)	O
and	O
wild	O
type	O
(	O
WT	O
)	O
littermates	O
were	O
used	O
.	O

VGLUT1	O
expression	O
in	O
the	O
DRN	O
,	O
5-HT	B
turnover	O
and	O
immuno	O
histochemical	O
analysis	O
of	O
neuronal	O
activity	O
in	O
different	O
areas	O
was	O
studied	O
.	O

Moreover	O
,	O
the	O
functionality	O
of	O
the	O
inhibitory	O
5-HT1A	O
autoreceptor	O
was	O
assessed	O
using	O
electrophysiological	O
,	O
biochemical	O
and	O
pharmacological	O
approaches	O
.	O

VGLUT1	O
immunoreactivity	O
was	O
markedly	O
lower	O
in	O
the	O
DRN	O
of	O
the	O
VGLUT1+	O
/	O
-	O
mice	O
and	O
specifically	O
,	O
in	O
the	O
surroundings	O
of	O
GABA	B
and	O
5-HT	B
cell	O
bodies	O
.	O

These	O
mice	O
showed	O
decreased	O
induced	O
neuronal	O
activity	O
in	O
5-HT	B
cells	O
bodies	O
and	O
in	O
different	O
forebrain	O
areas	O
,	O
as	O
well	O
as	O
decreased	O
hippocampal	O
cell	O
proliferation	O
and	O
5-HT	B
turnover	O
.	O

Further	O
,	O
5-HT1A	O
autoreceptor	O
desensitization	O
was	O
evidenced	O
by	O
electrophysiological	O
studies	O
,	O
GTP	B
-	I
	I
-	I
S	I
coupling	O
to	O
5-HT1A	O
autoreceptor	O
and	O
a	O
lower	O
hypothermic	O
response	O
to	O
5-HT1A	O
activation	O
.	O

This	O
study	O
shows	O
first	O
time	O
that	O
VGLUT1	O
dependent	O
glutamate	B
innervation	O
of	O
the	O
DRN	O
could	O
modulate	O
5-HT	B
function	O
.	O

Solid	O
-	O
state	O
NMR	O
studies	O
of	O
micelle	O
-	O
templated	O
mesoporous	O
solids	O
.	O

In	O
this	O
tutorial	O
review	O
we	O
intend	O
to	O
give	O
an	O
overview	O
of	O
the	O
potential	O
of	O
NMR	O
spectroscopy	O
,	O
and	O
in	O
particular	O
solid	O
-	O
state	O
NMR	O
,	O
in	O
characterising	O
micelle	O
-	O
templated	O
mesoporous	O
materials	O
.	O

Different	O
topics	O
are	O
covered	O
including	O
the	O
study	O
of	O
formation	O
mechanisms	O
,	O
the	O
characterisation	O
of	O
structures	O
,	O
textures	O
,	O
surfaces	O
and	O
interfaces	O
,	O
functionalisation	O
,	O
dynamic	O
properties	O
and	O
structure	O
-	O
reactivity	O
correlations	O
.	O

Some	O
selected	O
examples	O
illustrate	O
the	O
variety	O
of	O
information	O
provided	O
by	O
this	O
spectroscopy	O
.	O

Particular	O
attention	O
is	O
paid	O
to	O
recent	O
technological	O
and/or	O
methodological	O
developments	O
.	O

Metabolism	O
and	O
pharmacokinetics	O
of	O
3-n	B
-	I
butylphthalide	I
(	O
NBP	B
)	O
in	O
humans	O
:	O
the	O
role	O
of	O
cytochrome	O
P450s	O
and	O
alcohol	B
dehydrogenase	O
in	O
biotransformation	O
.	O

3-n	B
-	I
Butylphthalide	I
(	O
NBP	B
)	O
is	O
a	O
cardiovascular	O
drug	O
currently	O
used	O
for	O
the	O
treatment	O
of	O
cerebral	O
ischemia	O
.	O

The	O
present	O
study	O
aims	O
to	O
investigate	O
the	O
metabolism	O
,	O
pharmacokinetics	O
,	O
and	O
excretion	O
of	O
NBP	B
in	O
humans	O
and	O
identify	O
the	O
enzymes	O
responsible	O
for	O
the	O
formation	O
of	O
major	O
metabolites	O
.	O

NBP	B
underwent	O
extensive	O
metabolism	O
after	O
an	O
oral	O
administration	O
of	O
200	O
mg	O
NBP	B
and	O
23	O
metabolites	O
were	O
identified	O
in	O
human	O
plasma	O
and	O
urine	O
.	O

Principal	O
metabolic	O
pathways	O
included	O
hydroxylation	O
on	O
alkyl	B
side	O
chain	O
,	O
particularly	O
at	O
3-	B
,	I
-1-	I
,	I
and	I
	I
-	I
carbons	I
,	O
and	O
further	O
oxidation	O
and	O
conjugation	O
.	O

Approximately	O
81.6	O
%	O
of	O
the	O
dose	O
was	O
recovered	O
in	O
urine	O
,	O
mainly	O
as	O
NBP-11-oic	B
acid	I
(	O
M5	O
-	O
2	O
)	O
and	O
glucuronide	O
conjugates	O
of	O
M5	O
-	O
2	O
and	O
mono	O
-	O
hydroxylated	O
products	O
.	O

10-Keto	B
-	I
NBP	I
(	O
M2	O
)	O
,	O
3-hydroxy	B
-	I
NBP	I
(	O
M3	O
-	O
1	O
)	O
,	O
10-hydroxy	B
-	I
NBP	I
(	O
M3	O
-	O
2	O
)	O
,	O
and	O
M5	O
-	O
2	O
were	O
the	O
major	O
circulating	O
metabolites	O
,	O
wherein	O
the	O
areas	O
under	O
the	O
curve	O
values	O
were	O
1.6-	O
,	O
2.9-	O
,	O
10.3-	O
,	O
and	O
4.1-fold	O
higher	O
than	O
that	O
of	O
NBP	B
.	O

Reference	O
standards	O
of	O
these	O
four	O
metabolites	O
were	O
obtained	O
through	O
microbial	O
biotransformation	O
by	O
Cunninghamella	O
blakesleana	O
.	O

In	O
vitro	O
phenotyping	O
studies	O
demonstrated	O
that	O
multiple	O
cytochrome	O
P450	O
(	O
P450	O
)	O
isoforms	O
,	O
especially	O
CYP3A4	O
,	O
2E1	O
,	O
and	O
1A2	O
,	O
were	O
involved	O
in	O
the	O
formation	O
of	O
M3	O
-	O
1	O
,	O
M3	O
-	O
2	O
,	O
and	O
11-hydroxy	B
-	I
NBP	I
.	O

Using	O
M3	O
-	O
2	O
and	O
11-hydroxy	B
-	I
NBP	I
as	O
substrates	O
,	O
human	O
subcellular	O
fractions	O
experiments	O
revealed	O
that	O
P450	O
,	O
alcohol	B
dehydrogenase	O
,	O
and	O
aldehyde	B
dehydrogenase	O
catalyzed	O
the	O
generation	O
of	O
M2	O
and	O
M5	O
-	O
2	O
.	O

Formation	O
of	O
M5	O
-	O
2	O
was	O
much	O
faster	O
than	O
that	O
of	O
M2	O
,	O
and	O
M5	O
-	O
2	O
can	O
undergo	O
	O
-	O
oxidation	O
to	O
yield	O
phthalide-3-acetic	B
acid	I
in	O
rat	O
liver	O
homogenate	O
.	O

Overall	O
,	O
our	O
study	O
demonstrated	O
that	O
NBP	B
was	O
well	O
absorbed	O
and	O
extensively	O
metabolized	O
by	O
multiple	O
enzymes	O
to	O
various	O
metabolites	O
prior	O
to	O
urinary	O
excretion	O
.	O

Pharmacokinetics	O
,	O
metabolism	O
,	O
and	O
excretion	O
of	O
the	O
antidiabetic	O
agent	O
ertugliflozin	B
(	O
PF-04971729	B
)	O
in	O
healthy	O
male	O
subjects	O
.	O

The	O
disposition	O
of	O
ertugliflozin	B
(	O
PF-04971729	B
)	O
,	O
an	O
orally	O
active	O
selective	O
inhibitor	O
of	O
the	O
sodium	B
-	O
dependent	O
glucose	B
cotransporter	O
2	O
,	O
was	O
studied	O
after	O
a	O
single	O
25-mg	O
oral	O
dose	O
of	O
[	B
(	I
14	I
)	I
C	I
]	I
-ertugliflozin	I
to	O
healthy	O
human	O
subjects	O
.	O

Mass	O
balance	O
was	O
achieved	O
with	O
approximately	O
91	O
%	O
of	O
the	O
administered	O
dose	O
recovered	O
in	O
urine	O
and	O
feces	O
.	O

The	O
total	O
administered	O
radioactivity	O
excreted	O
in	O
feces	O
and	O
urine	O
was	O
40.9	O
%	O
and	O
50.2	O
%	O
,	O
respectively	O
.	O

The	O
absorption	O
of	O
ertugliflozin	B
in	O
humans	O
was	O
rapid	O
with	O
a	O
T	O
(	O
max	O
)	O
at	O
1.0	O
hour	O
.	O

Of	O
the	O
total	O
radioactivity	O
excreted	O
in	O
feces	O
and	O
urine	O
,	O
unchanged	O
ertugliflozin	B
collectively	O
accounted	O
for	O
35.3	O
%	O
of	O
the	O
dose	O
,	O
suggestive	O
of	O
moderate	O
metabolic	O
elimination	O
in	O
humans	O
.	O

The	O
principal	O
biotransformation	O
pathway	O
involved	O
glucuronidation	O
of	O
the	O
glycoside	O
hydroxyl	B
groups	O
to	O
yield	O
three	O
regioisomeric	O
metabolites	O
,	O
M4a	O
,	O
M4b	O
,	O
and	O
M4c	O
(	O
39.3	O
%	O
of	O
the	O
dose	O
in	O
urine	O
)	O
,	O
of	O
which	O
M4c	O
was	O
the	O
major	O
regioisomer	O
(	O
31.7	O
%	O
of	O
the	O
dose	O
)	O
.	O

The	O
structure	O
of	O
M4a	O
and	O
M4c	O
were	O
confirmed	O
to	O
be	O
ertugliflozin	B
-4-O	I
-	I
-	I
and	I
-3-O	I
-	I
	I
-	I
glucuronide	I
,	O
respectively	O
,	O
via	O
comparison	O
of	O
the	O
HPLC	O
retention	O
time	O
and	O
mass	O
spectra	O
with	O
authentic	O
standards	O
.	O

A	O
minor	O
metabolic	O
fate	O
involved	O
oxidation	O
by	O
cytochrome	O
P450	O
to	O
yield	O
monohydroxylated	O
metabolites	O
M1	O
and	O
M3	O
and	O
des	B
-	I
ethyl	I
ertugliflozin	I
(	O
M2	O
)	O
,	O
which	O
accounted	O
for	O
5.2	O
%	O
of	O
the	O
dose	O
in	O
excreta	O
.	O

In	O
plasma	O
,	O
unchanged	O
ertugliflozin	B
and	O
the	O
corresponding	O
4-O	O
-	O
-	O
(	O
M4a	O
)	O
and	O
3-O	O
-	O
-	O
(	O
M4c	O
)	O
glucuronides	O
were	O
the	O
principal	O
components	O
,	O
which	O
accounted	O
for	O
49.9	O
,	O
12.2	O
,	O
and	O
24.1	O
%	O
of	O
the	O
circulating	O
radioactivity	O
.	O

Overall	O
,	O
these	O
data	O
suggest	O
that	O
ertugliflozin	O
is	O
well	O
absorbed	O
in	O
humans	O
,	O
and	O
eliminated	O
largely	O
via	O
glucuronidation	O
.	O

The	O
role	O
of	O
cytochrome	O
P450-dependent	O
metabolism	O
in	O
the	O
regulation	O
of	O
mouse	O
hepatic	O
growth	O
hormone	O
signaling	O
components	O
and	O
target	O
genes	O
by	O
3-methylcholanthrene	B
.	O

3-Methylcholanthrene	B
(	O
MC	O
)	O
is	O
a	O
readily	O
metabolized	O
aryl	B
hydrocarbon	I
receptor	O
(	O
AHR	O
)	O
agonist	O
.	O

MC	O
disrupts	O
expression	O
of	O
mouse	O
hepatic	O
growth	O
hormone	O
(	O
GH	O
)	O
signaling	O
components	O
and	O
suppresses	O
cytochrome	O
P450	O
2D9	O
(	O
Cyp2d9	O
)	O
,	O
a	O
male	O
-	O
specific	O
gene	O
controlled	O
by	O
pulsatile	O
GH	O
via	O
signal	O
transducer	O
and	O
activator	O
of	O
transcription	O
5b	O
(	O
STAT5b	O
)	O
.	O

To	O
determine	O
if	O
these	O
effects	O
of	O
MC	O
depend	O
on	O
hepatic	O
microsomal	O
P450-mediated	O
activity	O
,	O
we	O
examined	O
biologic	O
responses	O
to	O
MC	O
treatment	O
in	O
liver	O
Cpr	O
-	O
null	O
(	O
LCN	O
)	O
mice	O
with	O
hepatocyte	O
-	O
specific	O
conditional	O
deletion	O
of	O
NADPH	B
-	O
cytochrome	O
P450	O
oxidoreductase	O
(	O
POR	O
)	O
.	O

MC	O
caused	O
mild	O
induction	O
of	O
Por	O
and	O
a	O
hepatic	O
inflammatory	O
marker	O
in	O
wild	O
-	O
type	O
mice	O
,	O
whereas	O
MC	O
caused	O
strong	O
induction	O
of	O
AHR	O
target	O
genes	O
,	O
Cyp1a1	O
,	O
Cyp1a2	O
,	O
and	O
Cyp1b1	O
in	O
wild	O
-	O
type	O
and	O
LCN	O
mice	O
.	O

Two	O
mouse	O
hepatic	O
STAT5b	O
target	O
genes	O
,	O
Cyp2d9	O
and	O
major	O
urinary	O
protein	O
2	O
(	O
Mup2	O
)	O
,	O
were	O
suppressed	O
by	O
MC	O
in	O
wild	O
-	O
type	O
mice	O
,	O
and	O
the	O
CYP2D9	O
mRNA	O
response	O
was	O
maintained	O
in	O
LCN	O
mice	O
.	O

In	O
wild	O
-	O
type	O
mice	O
only	O
,	O
MC	O
decreased	O
hepatic	O
GH	O
receptor	O
(	O
GHR	O
)	O
mRNA	O
but	O
increased	O
GHR	O
protein	O
levels	O
.	O

There	O
was	O
an	O
apparent	O
impairment	O
of	O
STAT5	O
phosphorylation	O
by	O
MC	O
in	O
wild	O
-	O
type	O
and	O
LCN	O
mice	O
,	O
but	O
large	O
interanimal	O
variation	O
prevented	O
achievement	O
of	O
statistical	O
significance	O
.	O

In	O
vehicle	O
-	O
treated	O
mice	O
,	O
basal	O
levels	O
of	O
MUP2	O
mRNA	O
,	O
GHR	O
mRNA	O
,	O
GHR	O
protein	O
,	O
and	O
the	O
activation	O
status	O
of	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
2	O
and	O
Akt	O
were	O
influenced	O
by	O
hepatic	O
Por	O
genetic	O
status	O
.	O

These	O
results	O
indicate	O
that	O
the	O
effects	O
of	O
MC	O
on	O
hepatic	O
GH	O
signaling	O
components	O
and	O
target	O
genes	O
are	O
complex	O
,	O
involving	O
aspects	O
that	O
are	O
both	O
dependent	O
and	O
independent	O
of	O
hepatic	O
microsomal	O
P450-mediated	O
activity	O
.	O

High	O
electrochemical	O
performance	O
based	O
on	O
ultrathin	O
porous	O
CuO	B
nanobelts	O
grown	O
on	O
Cu	B
substrate	O
as	O
integrated	O
electrode	O
.	O

A	O
facile	O
and	O
low	O
-	O
cost	O
approach	O
has	O
been	O
developed	O
to	O
fabricate	O
porous	O
CuO	B
nanobelts	O
directly	O
grown	O
on	O
a	O
Cu	B
substrate	O
.	O

The	O
as	O
-	O
prepared	O
CuO	B
samples	O
can	O
be	O
directly	O
used	O
as	O
integrated	O
electrodes	O
for	O
lithium	B
-	O
ion	O
batteries	O
and	O
pseudo	O
-	O
supercapacitors	O
without	O
the	O
addition	O
of	O
other	O
ancillary	O
materials	O
such	O
as	O
carbon	B
black	I
or	O
a	O
binder	O
to	O
enhance	O
electrode	O
conductivity	O
and	O
cycling	O
stability	O
.	O

The	O
unique	O
nanostructural	O
features	O
endow	O
them	O
with	O
excellent	O
electrochemical	O
performance	O
as	O
demonstrated	O
by	O
high	O
capacities	O
of	O
640	O
mA	O
h	O
g	O
(	O
-1	O
)	O
after	O
100	O
cycles	O
at	O
0.2	O
C	O
rate	O
and	O
an	O
excellent	O
specific	O
capacitance	O
of	O
340	O
F	O
g	O
(	O
-1	O
)	O
,	O
which	O
corresponds	O
to	O
the	O
energy	O
density	O
of	O
45	O
W	O
h	O
kg	O
(	O
-1	O
)	O
.	O

The	O
cyclability	O
of	O
the	O
electrode	O
demonstrates	O
only	O
a	O
10	O
-	O
15	O
%	O
loss	O
in	O
capacitance	O
over	O
5000	O
cycles	O
.	O

Xenobiotic	O
receptor	O
humanized	O
mice	O
and	O
their	O
utility	O
.	O

The	O
nuclear	O
receptors	O
pregnane	O
X	O
receptor	O
,	O
constitutive	O
androstane	B
receptor	O
,	O
and	O
peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
alpha	O
have	O
important	O
endogenous	O
functions	O
and	O
are	O
also	O
involved	O
in	O
the	O
induction	O
of	O
drug	O
-	O
metabolizing	O
enzymes	O
and	O
transporters	O
in	O
response	O
to	O
exogenous	O
xenobiotics	O
.	O

Though	O
not	O
belonging	O
to	O
the	O
same	O
protein	O
family	O
,	O
the	O
Per	O
-	O
Sim	O
-	O
ARNT	O
domain	O
receptor	O
aryl	B
hydrocarbon	I
receptor	O
functionally	O
overlaps	O
with	O
the	O
three	O
nuclear	O
receptors	O
in	O
many	O
aspects	O
and	O
is	O
therefore	O
included	O
in	O
this	O
review	O
.	O

Significant	O
species	O
differences	O
in	O
ligand	O
affinity	O
and	O
biological	O
responses	O
as	O
a	O
result	O
of	O
activation	O
of	O
these	O
receptors	O
have	O
been	O
described	O
.	O

Several	O
xenobiotic	O
receptor	O
humanized	O
mice	O
have	O
been	O
created	O
to	O
overcome	O
these	O
species	O
differences	O
and	O
to	O
provide	O
in	O
vivo	O
models	O
that	O
are	O
more	O
predictive	O
for	O
human	O
responses	O
.	O

This	O
review	O
provides	O
an	O
overview	O
of	O
the	O
different	O
xenobiotic	O
receptor	O
humanized	O
mouse	O
models	O
described	O
to	O
date	O
and	O
will	O
summarize	O
how	O
these	O
models	O
can	O
be	O
applied	O
in	O
basic	O
research	O
and	O
improve	O
drug	O
discovery	O
and	O
development	O
.	O

Some	O
of	O
the	O
key	O
applications	O
in	O
the	O
evaluation	O
of	O
drug	O
induction	O
,	O
drug	O
-	O
drug	O
interactions	O
,	O
nongenotoxic	O
carcinogenicity	O
,	O
other	O
toxicity	O
,	O
or	O
efficacy	O
studies	O
are	O
described	O
.	O

We	O
also	O
discuss	O
relevant	O
considerations	O
in	O
the	O
interpretation	O
of	O
such	O
data	O
and	O
potential	O
future	O
directions	O
for	O
the	O
use	O
of	O
xenobiotic	O
receptor	O
humanized	O
mice	O
.	O

The	O
relationship	O
between	O
carotid	O
intima	O
-	O
media	O
thickness	O
and	O
endogenous	O
androgens	B
in	O
young	O
women	O
with	O
polycystic	O
ovary	O
syndrome	O
in	O
Taiwan	O
.	O

Polycystic	O
ovary	O
syndrome	O
(	O
PCOS	O
)	O
is	O
a	O
common	O
and	O
complex	O
female	O
endocrinopathy	O
that	O
is	O
associated	O
with	O
multiple	O
vascular	O
risk	O
factors	O
.	O

Our	O
objective	O
was	O
to	O
investigate	O
the	O
relationship	O
between	O
carotid	O
intima	O
-	O
media	O
thickness	O
(	O
CIMT	O
)	O
and	O
endogenous	O
androgens	B
in	O
young	O
Taiwanese	O
-	O
Chinese	O
women	O
with	O
PCOS	O
.	O

We	O
measured	O
CIMT	O
with	O
B	O
-	O
mode	O
ultrasound	O
in	O
42	O
young	O
PCOS	O
patients	O
and	O
43	O
controls	O
.	O

Atherosclerosis	O
-	O
associated	O
profiles	O
and	O
endocrinological	O
parameters	O
were	O
also	O
measured	O
.	O

The	O
results	O
showed	O
that	O
although	O
Taiwanese	O
-	O
Chinese	O
PCOS	O
patients	O
tend	O
to	O
possess	O
more	O
risk	O
factors	O
for	O
atherosclerosis	O
than	O
controls	O
,	O
there	O
was	O
no	O
evidence	O
to	O
support	O
that	O
they	O
have	O
a	O
greater	O
CIMT	O
at	O
this	O
age	O
.	O

Furthermore	O
,	O
androstenedione	B
appears	O
to	O
be	O
inversely	O
associated	O
with	O
CIMT	O
.	O

Histopathological	O
effects	O
of	O
waterborne	O
copper	B
nanoparticles	O
and	O
copper	B
sulphate	I
on	O
the	O
organs	O
of	O
rainbow	O
trout	O
(	O
Oncorhynchus	O
mykiss	O
)	O
.	O

It	O
is	O
unclear	O
whether	O
copper	B
nanoparticles	O
are	O
more	O
toxic	O
than	O
traditional	O
forms	O
of	O
dissolved	O
copper	B
.	O

This	O
study	O
aimed	O
to	O
describe	O
the	O
pathologies	O
in	O
gill	O
,	O
gut	O
,	O
liver	O
,	O
kidney	O
,	O
brain	O
and	O
muscle	O
of	O
juvenile	O
rainbow	O
trout	O
,	O
Oncorhynchus	O
mykiss	O
,	O
exposed	O
in	O
triplicate	O
to	O
either	O
a	O
control	O
(	O
no	O
added	O
Cu	B
)	O
,	O
20	O
or	O
100	O
g	O
l	O
(	O
-1	O
)	O
of	O
either	O
dissolved	O
Cu	B
(	O
as	O
CuSO	B
(	I
4	I
)	I
)	O
or	O
Cu	B
-	O
NPs	O
(	O
mean	O
primary	O
particle	O
size	O
of	O
87	O
	O
27	O
nm	O
)	O
in	O
a	O
semi	O
-	O
static	O
waterborne	O
exposure	O
regime	O
.	O

Fish	O
were	O
sampled	O
at	O
days	O
0	O
,	O
4	O
,	O
and	O
10	O
for	O
histology	O
.	O

All	O
treatments	O
caused	O
organ	O
injuries	O
,	O
and	O
the	O
kinds	O
of	O
pathologies	O
observed	O
with	O
Cu	B
-	O
NPs	O
were	O
broadly	O
of	O
the	O
same	O
type	O
as	O
CuSO	B
(	I
4	I
)	I
including	O
:	O
hyperplasia	O
,	O
aneurisms	O
,	O
and	O
necrosis	O
in	O
the	O
secondary	O
lamellae	O
of	O
the	O
gills	O
;	O
swelling	O
of	O
goblet	O
cells	O
,	O
necrosis	O
in	O
the	O
mucosa	O
layer	O
and	O
vacuole	O
formation	O
in	O
the	O
gut	O
;	O
hepatitis	O
-	O
like	O
injury	O
and	O
cells	O
with	O
pyknotic	O
nuclei	O
in	O
the	O
liver	O
;	O
damage	O
to	O
the	O
epithelium	O
of	O
some	O
renal	O
tubules	O
and	O
increased	O
Bowman	O
's	O
space	O
in	O
the	O
kidney	O
.	O

In	O
the	O
brain	O
,	O
some	O
mild	O
changes	O
were	O
observed	O
in	O
the	O
nerve	O
cell	O
bodies	O
in	O
the	O
telencephalon	O
,	O
alteration	O
in	O
the	O
thickness	O
of	O
the	O
mesencephalon	O
layers	O
,	O
and	O
enlargement	O
of	O
blood	O
vessel	O
on	O
the	O
ventral	O
surface	O
of	O
the	O
cerebellum	O
.	O

Changes	O
in	O
the	O
proportional	O
area	O
of	O
muscle	O
fibres	O
were	O
observed	O
in	O
skeletal	O
muscle	O
.	O

Overall	O
the	O
data	O
showed	O
that	O
pathology	O
from	O
CuSO	B
(	I
4	I
)	I
and	O
Cu	B
-	O
NPs	O
were	O
of	O
similar	O
types	O
,	O
but	O
there	O
were	O
some	O
material	O
-	O
type	O
effects	O
in	O
the	O
severity	O
or	O
incidence	O
of	O
injuries	O
with	O
Cu	B
-	O
NPs	O
causing	O
more	O
injury	O
in	O
the	O
intestine	O
,	O
liver	O
and	O
brain	O
than	O
the	O
equivalent	O
concentration	O
of	O
CuSO	B
(	I
4	I
)	I
by	O
the	O
end	O
of	O
the	O
experiment	O
,	O
but	O
in	O
the	O
gill	O
and	O
muscle	O
CuSO	B
(	I
4	I
)	I
caused	O
more	O
pathology	O
.	O

Pharmacological	O
and	O
behavioral	O
characterization	O
of	O
the	O
novel	O
CRF	O
(	O
1	O
)	O
antagonist	O
BMS-763534	B
.	O

BMS-763534	B
is	O
a	O
potent	O
(	O
CRF	O
(	O
1	O
)	O
IC	O
(	O
50	O
)	O
=	O
0.4	O
nM	O
)	O
and	O
selective	O
(	O
>	O
1000-fold	O
selectivity	O
vs.	O
all	O
other	O
sites	O
tested	O
)	O
CRF	O
(	O
1	O
)	O
receptor	O
antagonist	O
(	O
pA2	O
=	O
9.47	O
vs.	O
CRF	O
(	O
1	O
)	O
-mediated	O
cAMP	B
production	O
in	O
Y79	O
cells	O
)	O
.	O

BMS-763534	B
accelerated	O
the	O
dissociation	O
of	O
(	B
125	I
)	I
I	I
-	O
o	O
-	O
CRF	O
from	O
rat	O
frontal	O
cortex	O
membrane	O
CRF	O
(	O
1	O
)	O
receptors	O
consistent	O
with	O
a	O
negative	O
allosteric	O
modulation	O
of	O
CRF	O
binding	O
.	O

BMS-763534	B
produced	O
dose	O
-	O
dependent	O
increases	O
in	O
CRF	O
(	O
1	O
)	O
receptor	O
occupancy	O
and	O
anxiolytic	O
efficacy	O
;	O
lowest	O
effective	O
anxiolytic	O
dose	O
=	O
0.56	O
mg	O
/	O
kg	O
,	O
PO	O
,	O
which	O
was	O
associated	O
with	O
71	O
	O
5	O
%	O
CRF	O
(	O
1	O
)	O
receptor	O
occupancy	O
of	O
frontoparietal	O
CRF	O
(	O
1	O
)	O
receptors	O
.	O

Sedative	O
/	O
ataxic	O
effects	O
of	O
BMS-763534	B
were	O
only	O
observed	O
at	O
high	O
dose	O
multiples	O
(	O
54	O
-	O
179	O
	O
)	O
relative	O
to	O
the	O
lowest	O
dose	O
required	O
for	O
anxiolytic	O
efficacy	O
.	O

At	O
doses	O
of	O
5-	O
to	O
18-fold	O
higher	O
than	O
the	O
lowest	O
efficacious	O
dose	O
in	O
the	O
anxiety	O
assay	O
,	O
BMS-763534	B
shared	O
subjective	O
effects	O
with	O
the	O
benzodiazepine	O
chlordiazepoxide	B
.	O

Interestingly	O
BMS-790318	B
,	O
the	O
O	O
-	O
demethylated	O
metabolite	O
of	O
BMS-763534	B
,	O
showed	O
weak	O
affinity	O
for	O
the	O
TBOB	B
site	O
of	O
the	O
GABA	B
(	O
A	O
)	O
receptor	O
(	O
67	O
%	O
inhibition	O
at	O
10	O
M	O
)	O
and	O
augmented	O
GABA	B
evoked	O
currents	O
(	O
EC	O
(	O
50	O
)	O
=	O
1.6	O
M	O
)	O
.	O

Thus	O
,	O
the	O
unanticipated	O
signal	O
in	O
the	O
drug	O
discrimination	O
assay	O
may	O
have	O
resulted	O
from	O
an	O
interaction	O
of	O
the	O
metabolite	O
BMS-790318	B
with	O
the	O
TBOB	B
site	O
on	O
the	O
GABA	B
(	O
A	O
)	O
channel	O
where	O
it	O
appears	O
to	O
behave	O
as	O
an	O
allosteric	O
potentiator	O
of	O
GABA	B
evoked	O
currents	O
.	O

Ginkgo	O
biloba	O
extract	O
attenuates	O
hippocampal	O
neuronal	O
loss	O
and	O
cognitive	O
dysfunction	O
resulting	O
from	O
trimethyltin	B
in	O
mice	O
.	O

The	O
present	O
study	O
was	O
an	O
attempt	O
to	O
investigate	O
the	O
neuromodulatory	O
potential	O
of	O
Ginkgo	O
biloba	O
extract	O
(	O
GBE	O
)	O
against	O
hippocamapal	O
structural	O
and	O
functional	O
damages	O
induced	O
by	O
trimethyltin	B
(	O
TMT	B
)	O
a	O
potent	O
neurotoxicant	O
.	O

Male	O
Balb	O
/	O
C	O
mice	O
were	O
administered	O
with	O
Ginkgo	O
biloba	O
extract	O
for	O
14	O
days	O
at	O
a	O
dose	O
of	O
70	O
mg	O
/	O
kg	O
body	O
weight	O
interperitoneally	O
and	O
on	O
11-day	O
of	O
treatment	O
animals	O
were	O
exposed	O
to	O
Trimethyltin	B
(	O
2.5	O
mg	O
/	O
kg	O
b.w	O
)	O
single	O
intraperitoneal	O
injection	O
.	O

The	O
co	O
-	O
administered	O
of	O
TMT	B
with	O
GBE	O
showed	O
marked	O
improvement	O
in	O
memory	O
and	O
aggressive	O
behavior	O
.	O

Which	O
were	O
in	O
turn	O
reflected	O
in	O
the	O
levels	O
of	O
serotonin	B
and	O
acetylcholine	B
esterase	O
.	O

The	O
conjunctive	O
treatment	O
also	O
showed	O
significant	O
decrease	O
in	O
oxidative	O
stress	O
as	O
assessed	O
by	O
MDA	B
levels	O
and	O
the	O
antioxidant	O
enzymes	O
(	O
GSH	B
,	O
GSSH	B
,	O
GPX	O
,	O
total	O
glutathione	B
,	O
Catalase	O
and	O
Superoxide	B
dismutase	O
)	O
which	O
were	O
depressed	O
by	O
TMT	B
treatment	O
was	O
significantly	O
improved	O
by	O
GBE	O
.	O

Correspondingly	O
,	O
induction	O
of	O
Bcl-2	O
mitochondrial	O
apoptotic	O
pathway	O
by	O
trimethyltin	B
was	O
down	O
regulated	O
by	O
Ginkgo	O
biloba	O
treatment	O
.	O

The	O
structural	O
analysis	O
of	O
dentate	O
gyrus	O
revealed	O
improvement	O
in	O
degenerating	O
neurons	O
by	O
treatment	O
with	O
GBE	O
.	O

Therefore	O
,	O
it	O
is	O
suggested	O
that	O
prophylactic	O
treatment	O
of	O
Ginkgo	O
biloba	O
extract	O
protects	O
against	O
the	O
trimethyltin	B
induced	O
neurodegenration	O
by	O
multiple	O
mechanism	O
involved	O
in	O
its	O
antioxidant	O
effects	O
and	O
may	O
be	O
useful	O
in	O
developing	O
therapies	O
against	O
neurodegenration	O
.	O

Solubility	O
-	O
pH	O
profiles	O
of	O
some	O
acidic	O
,	O
basic	O
and	O
amphoteric	O
drugs	O
.	O

The	O
solubility	O
vs.	O
pH	O
profiles	O
of	O
five	O
ionizable	O
drugs	O
of	O
different	O
nature	O
(	O
a	O
monoprotic	O
acid	O
,	O
a	O
monoprotic	O
base	O
,	O
a	O
diprotic	O
base	O
and	O
two	O
amphoteric	O
compounds	O
showing	O
a	O
zwitterionic	O
species	O
each	O
one	O
)	O
have	O
been	O
determined	O
through	O
two	O
different	O
methodologies	O
:	O
the	O
classical	O
shake	O
-	O
flask	O
(	O
S	O
-	O
F	O
)	O
and	O
the	O
potentiometric	O
Cheqsol	O
methods	O
using	O
in	O
both	O
instances	O
the	O
appropriate	O
Henderson	O
-	O
Hasselbalch	O
(	O
H	O
-	O
H	O
)	O
or	O
derived	O
relationships	O
.	O

The	O
results	O
obtained	O
independently	O
from	O
both	O
approaches	O
are	O
consistent	O
.	O

A	O
critical	O
revision	O
about	O
the	O
influence	O
of	O
the	O
electrolyte	O
used	O
as	O
buffering	O
agent	O
in	O
the	O
S	O
-	O
F	O
method	O
on	O
the	O
obtained	O
solubility	O
values	O
is	O
also	O
performed	O
.	O

Thus	O
,	O
some	O
deviations	O
of	O
the	O
experimental	O
points	O
with	O
respect	O
the	O
H	O
-	O
H	O
profiles	O
can	O
be	O
attributed	O
to	O
specific	O
interactions	O
between	O
the	O
buffering	O
electrolyte	O
and	O
the	O
drug	O
due	O
to	O
the	O
hydrotrophic	O
character	O
of	O
citric	B
and	I
lactic	I
acids	I
.	O

In	O
other	O
cases	O
,	O
the	O
observed	O
deviations	O
are	O
independent	O
of	O
the	O
buffers	O
used	O
since	O
they	O
are	O
caused	O
by	O
the	O
formation	O
of	O
new	O
species	O
such	O
as	O
drug	O
aggregates	O
(	O
cefadroxil	B
)	O
or	O
the	O
precipitation	O
of	O
a	O
salt	O
from	O
a	O
cationic	O
species	O
of	O
the	O
analyzed	O
compound	O
(	O
quetiapine	B
)	O
.	O

APLF	O
promotes	O
the	O
assembly	O
and	O
activity	O
of	O
non	O
-	O
homologous	O
end	O
joining	O
protein	O
complexes	O
.	O

Non	O
-	O
homologous	O
end	O
joining	O
(	O
NHEJ	O
)	O
is	O
critical	O
for	O
the	O
maintenance	O
of	O
genetic	O
integrity	O
and	O
DNA	O
double	O
-	O
strand	O
break	O
(	O
DSB	O
)	O
repair	O
.	O

NHEJ	O
is	O
regulated	O
by	O
a	O
series	O
of	O
interactions	O
between	O
core	O
components	O
of	O
the	O
pathway	O
,	O
including	O
Ku	O
heterodimer	O
,	O
XLF	O
/	O
Cernunnos	O
,	O
and	O
XRCC4	O
/	O
DNA	O
Ligase	O
4	O
(	O
Lig4	O
)	O
.	O

However	O
,	O
the	O
mechanisms	O
by	O
which	O
these	O
proteins	O
assemble	O
into	O
functional	O
protein	O
-	O
DNA	O
complexes	O
are	O
not	O
fully	O
understood	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
von	O
Willebrand	O
(	O
vWA	O
)	O
domain	O
of	O
Ku80	O
fulfills	O
a	O
critical	O
role	O
in	O
this	O
process	O
by	O
recruiting	O
Aprataxin	O
-	O
and	O
-	O
PNK	O
-	O
Like	O
Factor	O
(	O
APLF	O
)	O
into	O
Ku	O
-	O
DNA	O
complexes	O
.	O

APLF	O
,	O
in	O
turn	O
,	O
functions	O
as	O
a	O
scaffold	O
protein	O
and	O
promotes	O
the	O
recruitment	O
and/or	O
retention	O
of	O
XRCC4-Lig4	O
and	O
XLF	O
,	O
thereby	O
assembling	O
multi	O
-	O
protein	O
Ku	O
complexes	O
capable	O
of	O
efficient	O
DNA	O
ligation	O
in	O
vitro	O
and	O
in	O
cells	O
.	O

Disruption	O
of	O
the	O
interactions	O
between	O
APLF	O
and	O
either	O
Ku80	O
or	O
XRCC4-Lig4	O
disrupts	O
the	O
assembly	O
and	O
activity	O
of	O
Ku	O
complexes	O
,	O
and	O
confers	O
cellular	O
hypersensitivity	O
and	O
reduced	O
rates	O
of	O
chromosomal	O
DSB	O
repair	O
in	O
avian	O
and	O
human	O
cells	O
,	O
respectively	O
.	O

Collectively	O
,	O
these	O
data	O
identify	O
a	O
role	O
for	O
the	O
vWA	O
domain	O
of	O
Ku80	O
and	O
a	O
molecular	O
mechanism	O
by	O
which	O
DNA	O
ligase	O
proficient	O
complexes	O
are	O
assembled	O
during	O
NHEJ	O
in	O
mammalian	O
cells	O
,	O
and	O
reveal	O
APLF	O
to	O
be	O
a	O
structural	O
component	O
of	O
this	O
critical	O
DSB	O
repair	O
pathway	O
.	O

Human	O
embryonic	O
stem	O
cell	O
-	O
derived	O
test	O
systems	O
for	O
developmental	O
neurotoxicity	O
:	O
a	O
transcriptomics	O
approach	O
.	O

Developmental	O
neurotoxicity	O
(	O
DNT	O
)	O
and	O
many	O
forms	O
of	O
reproductive	O
toxicity	O
(	O
RT	O
)	O
often	O
manifest	O
themselves	O
in	O
functional	O
deficits	O
that	O
are	O
not	O
necessarily	O
based	O
on	O
cell	O
death	O
,	O
but	O
rather	O
on	O
minor	O
changes	O
relating	O
to	O
cell	O
differentiation	O
or	O
communication	O
.	O

The	O
fields	O
of	O
DNT	O
/	O
RT	O
would	O
greatly	O
benefit	O
from	O
in	O
vitro	O
tests	O
that	O
allow	O
the	O
identification	O
of	O
toxicant	O
-	O
induced	O
changes	O
of	O
the	O
cellular	O
proteostasis	O
,	O
or	O
of	O
its	O
underlying	O
transcriptome	O
network	O
.	O

Therefore	O
,	O
the	O
'	O
human	O
embryonic	O
stem	O
cell	O
(	O
hESC	O
)	O
-derived	O
novel	O
alternative	O
test	O
systems	O
(	O
ESNATS	O
)	O
'	O
European	O
commission	O
research	O
project	O
established	O
RT	O
tests	O
based	O
on	O
defined	O
differentiation	O
protocols	O
of	O
hESC	O
and	O
their	O
progeny	O
.	O

Valproic	B
acid	I
(	O
VPA	B
)	O
and	O
methylmercury	B
(	O
MeHg	B
)	O
were	O
used	O
as	O
positive	O
control	O
compounds	O
to	O
address	O
the	O
following	O
fundamental	O
questions	O
:	O
(	O
1	O
)	O
Does	O
transcriptome	O
analysis	O
allow	O
discrimination	O
of	O
the	O
two	O
compounds	O
?	O

(	O
2	O
)	O
How	O
does	O
analysis	O
of	O
enriched	O
transcription	O
factor	O
binding	O
sites	O
(	O
TFBS	O
)	O
and	O
of	O
individual	O
probe	O
sets	O
(	O
PS	O
)	O
distinguish	O
between	O
test	O
systems	O
?	O

(	O
3	O
)	O
Can	O
batch	O
effects	O
be	O
controlled	O
?	O

(	O
4	O
)	O
How	O
many	O
DNA	O
microarrays	O
are	O
needed	O
?	O

(	O
5	O
)	O
Is	O
the	O
highest	O
non	O
-	O
cytotoxic	O
concentration	O
optimal	O
and	O
relevant	O
for	O
the	O
study	O
of	O
transcriptome	O
changes	O
?	O

VPA	O
triggered	O
vast	O
transcriptional	O
changes	O
,	O
whereas	O
MeHg	B
altered	O
fewer	O
transcripts	O
.	O

To	O
attenuate	O
batch	O
effects	O
,	O
analysis	O
has	O
been	O
focused	O
on	O
the	O
500	O
PS	O
with	O
highest	O
variability	O
.	O

The	O
test	O
systems	O
differed	O
significantly	O
in	O
their	O
responses	O
(	O
<	O
20	O
%	O
overlap	O
)	O
.	O

Moreover	O
,	O
within	O
one	O
test	O
system	O
,	O
little	O
overlap	O
between	O
the	O
PS	O
changed	O
by	O
the	O
two	O
compounds	O
has	O
been	O
observed	O
.	O

However	O
,	O
using	O
TFBS	O
enrichment	O
,	O
a	O
relatively	O
large	O
'	O
common	O
response	O
'	O
to	O
VPA	B
and	O
MeHg	B
could	O
be	O
distinguished	O
from	O
'	O
compound	O
-	O
specific	O
'	O
responses	O
.	O

In	O
conclusion	O
,	O
the	O
ESNATS	O
assay	O
battery	O
allows	O
classification	O
of	O
human	O
DNT	O
/	O
RT	O
toxicants	O
on	O
the	O
basis	O
of	O
their	O
transcriptome	O
profiles	O
.	O

Therapy	O
of	O
adrenal	O
insufficiency	O
:	O
an	O
update	O
.	O

Adrenal	O
insufficiency	O
may	O
be	O
caused	O
by	O
the	O
destruction	O
or	O
altered	O
function	O
of	O
the	O
adrenal	O
gland	O
with	O
a	O
primary	O
deficit	O
in	O
cortisol	B
secretion	O
(	O
primary	O
adrenal	O
insufficiency	O
)	O
or	O
by	O
hypothalamic	O
-	O
pituitary	O
pathologies	O
determining	O
a	O
deficit	O
of	O
ACTH	O
(	O
secondary	O
adrenal	O
insufficiency	O
)	O
.	O

The	O
clinical	O
picture	O
is	O
determined	O
by	O
the	O
glucocorticoid	O
deficit	O
,	O
which	O
may	O
in	O
some	O
conditions	O
be	O
accompanied	O
by	O
a	O
deficit	O
of	O
mineralcorticoids	O
and	O
adrenal	O
androgens	B
.	O

The	O
substitutive	O
treatment	O
is	O
aimed	O
at	O
reducing	O
the	O
signs	O
and	O
symptoms	O
of	O
the	O
disease	O
as	O
well	O
as	O
at	O
preventing	O
the	O
development	O
of	O
an	O
addisonian	O
crisis	O
,	O
a	O
clinical	O
emergency	O
characterized	O
by	O
hypovolemic	O
shock	O
.	O

The	O
oral	O
substitutive	O
treatment	O
should	O
attempt	O
at	O
mimicking	O
the	O
normal	O
circadian	O
profile	O
of	O
cortisol	B
secretion	O
,	O
by	O
using	O
the	O
lower	O
possible	O
doses	O
able	O
to	O
guarantee	O
an	O
adequate	O
quality	O
of	O
life	O
to	O
patients	O
.	O

The	O
currently	O
available	O
hydrocortisone	B
or	O
cortisone	B
acetate	I
preparations	O
do	O
not	O
allow	O
an	O
accurate	O
reproduction	O
of	O
the	O
physiological	O
secretion	O
pattern	O
of	O
cortisol	B
.	O

A	O
novel	O
dual	O
-	O
release	O
formulation	O
of	O
hydrocortisone	B
,	O
recently	O
approved	O
by	O
EMEA	O
,	O
represents	O
an	O
advancement	O
in	O
the	O
optimization	O
of	O
the	O
clinical	O
management	O
of	O
patients	O
with	O
adrenal	O
insufficiency	O
.	O

Future	O
clinical	O
trials	O
of	O
immunomodulation	O
or	O
immunoprevention	O
will	O
test	O
the	O
possibility	O
to	O
delay	O
(	O
or	O
prevent	O
)	O
the	O
autoimmune	O
destruction	O
of	O
the	O
adrenal	O
gland	O
in	O
autoimmune	O
Addison	O
's	O
disease	O
.	O

DDBJ	O
new	O
system	O
and	O
service	O
refactoring	O
.	O

The	O
DNA	O
data	O
bank	O
of	O
Japan	O
(	O
DDBJ	O
,	O
http://www.ddbj.nig.ac.jp	O
)	O
maintains	O
a	O
primary	O
nucleotide	O
sequence	O
database	O
and	O
provides	O
analytical	O
resources	O
for	O
biological	O
information	O
to	O
researchers	O
.	O

This	O
database	O
content	O
is	O
exchanged	O
with	O
the	O
US	O
National	O
Center	O
for	O
Biotechnology	O
Information	O
(	O
NCBI	O
)	O
and	O
the	O
European	O
Bioinformatics	O
Institute	O
(	O
EBI	O
)	O
within	O
the	O
framework	O
of	O
the	O
International	O
Nucleotide	O
Sequence	O
Database	O
Collaboration	O
(	O
INSDC	O
)	O
.	O

Resources	O
provided	O
by	O
the	O
DDBJ	O
include	O
traditional	O
nucleotide	O
sequence	O
data	O
released	O
in	O
the	O
form	O
of	O
27	O
316	O
452	O
entries	O
or	O
16	O
876	O
791	O
557	O
base	O
pairs	O
(	O
as	O
of	O
June	O
2012	O
)	O
,	O
and	O
raw	O
reads	O
of	O
new	O
generation	O
sequencers	O
in	O
the	O
sequence	O
read	O
archive	O
(	O
SRA	O
)	O
.	O

A	O
Japanese	O
researcher	O
published	O
his	O
own	O
genome	O
sequence	O
via	O
DDBJ	O
-	O
SRA	O
on	O
31	O
July	O
2012	O
.	O

To	O
cope	O
with	O
the	O
ongoing	O
genomic	O
data	O
deluge	O
,	O
in	O
March	O
2012	O
,	O
our	O
computer	O
previous	O
system	O
was	O
totally	O
replaced	O
by	O
a	O
commodity	O
cluster	O
-	O
based	O
system	O
that	O
boasts	O
122.5	O
TFlops	O
of	O
CPU	O
capacity	O
and	O
5	O
PB	O
of	O
storage	O
space	O
.	O

During	O
this	O
upgrade	O
,	O
it	O
was	O
considered	O
crucial	O
to	O
replace	O
and	O
refactor	O
substantial	O
portions	O
of	O
the	O
DDBJ	O
software	O
systems	O
as	O
well	O
.	O

As	O
a	O
result	O
of	O
the	O
replacement	O
process	O
,	O
which	O
took	O
more	O
than	O
2	O
years	O
to	O
perform	O
,	O
we	O
have	O
achieved	O
significant	O
improvements	O
in	O
system	O
performance	O
.	O

Genomic	O
deletions	O
and	O
point	O
mutations	O
induced	O
in	O
Saccharomyces	O
cerevisiae	O
by	O
the	O
trinucleotide	O
repeats	O
(	O
GAATTC	O
)	O
associated	O
with	O
Friedreich	O
's	O
ataxia	O
.	O

Expansion	O
of	O
certain	O
trinucleotide	O
repeats	O
causes	O
several	O
types	O
of	O
human	O
diseases	O
,	O
and	O
such	O
tracts	O
are	O
associated	O
with	O
the	O
formation	O
of	O
deletions	O
and	O
other	O
types	O
of	O
genetic	O
rearrangements	O
in	O
Escherichia	O
coli	O
,	O
yeast	O
,	O
and	O
mammalian	O
cells	O
.	O

Below	O
,	O
we	O
show	O
that	O
long	O
(	O
230	O
repeats	O
)	O
tracts	O
of	O
the	O
trinucleotide	O
associated	O
with	O
Friedreich	O
's	O
ataxia	O
(	O
GAATTC	O
)	O
stimulate	O
both	O
large	O
(	O
>	O
50	O
bp	O
)	O
deletions	O
and	O
point	O
mutations	O
in	O
a	O
reporter	O
gene	O
located	O
more	O
than	O
1	O
kb	O
from	O
the	O
repetitive	O
tract	O
.	O

Sequence	O
analysis	O
of	O
deletion	O
breakpoints	O
indicates	O
that	O
the	O
deletions	O
reflect	O
non	O
-	O
homologous	O
end	O
joining	O
of	O
double	O
-	O
stranded	O
DNA	O
breaks	O
(	O
DSBs	O
)	O
initiated	O
in	O
the	O
tract	O
.	O

The	O
tract	O
-	O
induced	O
point	O
mutations	O
appear	O
to	O
reflect	O
a	O
different	O
mechanism	O
involving	O
single	O
-	O
strand	O
annealing	O
of	O
DNA	O
molecules	O
generated	O
by	O
DSBs	O
within	O
the	O
tract	O
,	O
followed	O
by	O
filling	O
-	O
in	O
of	O
single	O
-	O
stranded	O
gaps	O
by	O
the	O
error	O
-	O
prone	O
DNA	O
polymerase	O
zeta	O
.	O

An	O
artificial	O
neural	O
network	O
approach	O
to	O
improving	O
the	O
correlation	O
between	O
protein	O
energetics	O
and	O
the	O
backbone	O
structure	O
.	O

Computational	O
approaches	O
to	O
modeling	O
protein	O
structures	O
have	O
made	O
significant	O
advances	O
over	O
the	O
past	O
decade	O
.	O

However	O
,	O
the	O
current	O
limitation	O
in	O
modeling	O
protein	O
structures	O
is	O
to	O
produce	O
protein	O
structures	O
consistently	O
below	O
the	O
limit	O
of	O
6	O
	O
compared	O
to	O
their	O
native	O
structure	O
.	O

Therefore	O
,	O
improvement	O
of	O
protein	O
structures	O
consistently	O
below	O
the	O
6	O
	O
limit	O
using	O
simulation	O
of	O
biophysical	O
forces	O
is	O
of	O
significant	O
interest	O
.	O

Current	O
protein	O
force	O
fields	O
such	O
as	O
those	O
implemented	O
in	O
CHARMM	O
,	O
AMBER	O
,	O
and	O
NAMD	O
have	O
been	O
deemed	O
complete	O
,	O
yet	O
their	O
use	O
in	O
ab	O
initio	O
approaches	O
to	O
protein	O
structure	O
determination	O
has	O
been	O
unsuccessful	O
.	O

Here	O
,	O
we	O
introduce	O
a	O
new	O
approach	O
in	O
evaluation	O
of	O
protein	O
structures	O
based	O
on	O
analysis	O
of	O
energy	O
profiles	O
produced	O
by	O
the	O
SCOPE	O
software	O
package	O
.	O

The	O
latest	O
version	O
of	O
SCOPE	O
produces	O
a	O
hydrogen	B
bond	O
profile	O
that	O
is	O
substantially	O
more	O
informative	O
than	O
a	O
single	O
hydrogen	B
bond	O
energy	O
value	O
.	O

We	O
demonstrate	O
how	O
analysis	O
of	O
SCOPE	O
's	O
energy	O
profile	O
by	O
an	O
artificial	O
neural	O
network	O
shows	O
a	O
significant	O
improvement	O
compared	O
to	O
the	O
traditional	O
force	O
-	O
based	O
approaches	O
to	O
evaluation	O
of	O
structures	O
.	O

The	O
artificial	O
neural	O
network	O
based	O
analysis	O
of	O
SCOPE	O
's	O
energy	O
profile	O
showed	O
identification	O
of	O
structures	O
to	O
within	O
the	O
range	O
of	O
1.5	O
-	O
3.0	O
	O
of	O
the	O
native	O
structure	O
.	O

These	O
results	O
have	O
been	O
obtained	O
by	O
testing	O
structures	O
in	O
the	O
same	O
Homology	O
,	O
Topology	O
,	O
Architecture	O
,	O
or	O
Class	O
of	O
the	O
CATH	O
family	O
.	O

Evaluation	O
of	O
romidepsin	B
for	O
clinical	O
activity	O
and	O
radioactive	B
iodine	I
reuptake	O
in	O
radioactive	B
iodine	I
-	O
refractory	O
thyroid	O
carcinoma	O
.	O

Background	O
:	O
Historically	O
,	O
systemic	O
therapy	O
for	O
radioactive	B
iodine	I
(	O
RAI	B
)	O
-refractory	O
thyroid	O
cancer	O
has	O
been	O
understudied	O
.	O

Available	O
drugs	O
have	O
modest	O
efficacy	O
.	O

Romidepsin	B
is	O
a	O
histone	O
deacetylase	O
inhibitor	O
with	O
potent	O
antitumor	O
effects	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

In	O
thyroid	O
cancer	O
cell	O
lines	O
,	O
romidepsin	O
increases	O
expression	O
of	O
both	O
thyroglobulin	O
and	O
the	O
sodium	B
iodide	I
symporter	O
messenger	O
RNAs	O
,	O
suggesting	O
the	O
possibility	O
of	O
improved	O
iodine	B
concentrating	O
ability	O
of	O
RAI	B
-	O
resistant	O
tumors	O
.	O

Methods	O
:	O
This	O
was	O
a	O
single	O
-	O
institution	O
Simon	O
2-stage	O
phase	O
II	O
clinical	O
study	O
.	O

Eligible	O
patients	O
had	O
progressive	O
,	O
RAI	B
-	O
refractory	O
,	O
recurrent	O
/	O
metastatic	O
,	O
nonmedullary	O
,	O
nonanaplastic	O
thyroid	O
cancer	O
.	O

Response	O
Evaluation	O
Criteria	O
in	O
Solid	O
Tumors	O
(	O
RECIST	O
)	O
1.0	O
measurable	O
disease	O
and	O
adequate	O
organ	O
/	O
marrow	O
function	O
were	O
required	O
.	O

Romidepsin	B
13	O
mg	O
/	O
m	O
(	O
2	O
)	O
was	O
administered	O
intravenously	O
on	O
days	O
1	O
,	O
8	O
,	O
and	O
15	O
,	O
in	O
cycles	O
of	O
28	O
days	O
.	O

The	O
primary	O
endpoint	O
was	O
the	O
response	O
rate	O
by	O
RECIST	O
;	O
change	O
in	O
RAI	B
avidity	O
was	O
a	O
secondary	O
endpoint	O
.	O

The	O
study	O
closed	O
after	O
the	O
first	O
stage	O
due	O
to	O
the	O
lack	O
of	O
response	O
.	O

Results	O
:	O
Twenty	O
patients	O
were	O
enrolled	O
:	O
female	O
,	O
50	O
%	O
;	O
median	O
age	O
,	O
64	O
years	O
;	O
histology	O
,	O
8	O
papillary	O
/	O
1	O
follicular	O
/	O
11	O
Hrthle	O
.	O

Grade	O
4	O
-	O
5	O
adverse	O
events	O
(	O
AEs	O
)	O
possibly	O
related	O
to	O
the	O
drug	O
:	O
grade	O
5	O
,	O
1	O
sudden	O
death	O
;	O
grade	O
4	O
,	O
1	O
pulmonary	O
embolus	O
.	O

Twelve	O
of	O
20	O
subjects	O
had	O
a	O
reported	O
adverse	O
event	O
.	O

No	O
RECIST	O
major	O
responses	O
have	O
been	O
seen	O
.	O

Response	O
per	O
protocol	O
:	O
stable	O
disease	O
,	O
13	O
;	O
disease	O
progression	O
,	O
7	O
.	O

Restoration	O
of	O
RAI	B
avidity	O
was	O
documented	O
in	O
two	O
patients	O
.	O

Median	O
overall	O
survival	O
and	O
time	O
on	O
study	O
was	O
33.2	O
(	O
1	O
-	O
71	O
+	O
)	O
and	O
1.7	O
(	O
0.46	O
-	O
12	O
)	O
months	O
,	O
respectively	O
.	O

Conclusions	O

:	O
We	O
observed	O
preliminary	O
signs	O
of	O
in	O
vivo	O
reversal	O
of	O
RAI	B
resistance	O
after	O
treatment	O
with	O
romidepsin	B
.	O

However	O
,	O
no	O
major	O
responses	O
were	O
observed	O
and	O
accrual	O
was	O
poor	O
after	O
the	O
grade	O
5	O
AE	O
.	O

Quantification	O
of	O
silanol	B
sites	O
for	O
the	O
most	O
common	O
mesoporous	O
ordered	O
silicas	B
and	O
organosilicas	B
:	O
total	O
versus	O
accessible	O
silanols	B
.	O

IR	O
and	O
NMR	O
spectroscopy	O
were	O
used	O
to	O
determine	O
the	O
silanol	B
content	O
in	O
the	O
most	O
common	O
mesoporous	O
ordered	O
silicas	B
:	O
MCM-41	B
,	O
MCM-48	B
,	O
SBA-15	B
and	O
SBA-16	B
.	O

In	O
addition	O
,	O
a	O
spray	O
dried	O
MCM-41	B
and	O
an	O
ethene	B
bridged	O
PMO	B
are	O
investigated	O
.	O

The	O
results	O
are	O
compared	O
with	O
a	O
commercial	O
chromatographic	O
silica	B
(	O
Nucleosil	B
)	O
.	O

The	O
complete	O
distribution	O
of	O
surface	O
and	O
bulk	O
silanols	B
,	O
and	O
of	O
isolated	O
,	O
geminal	B
and	I
vicinal	I
silanols	I
for	O
all	O
these	O
materials	O
is	O
presented	O
.	O

A	O
distinction	O
is	O
made	O
between	O
the	O
total	O
silanol	B
number	O
and	O
the	O
reachable	O
or	O
surface	O
silanol	B
content	O
.	O

The	O
latter	O
is	O
determined	O
by	O
controlled	O
reactions	O
with	O
simple	O
silanes	B
.	O

All	O
mesoporous	O
ordered	O
silicas	B
,	O
and	O
especially	O
the	O
thick	O
walled	O
SBA	O
-	O
type	O
materials	O
and	O
the	O
PMO	B
contain	O
a	O
surprisingly	O
high	O
amount	O
of	O
total	O
silanol	B
sites	O
,	O
albeit	O
that	O
up	O
to	O
90	O
%	O
of	O
these	O
silanols	B
are	O
buried	O
inside	O
the	O
walls	O
and	O
are	O
not	O
reachable	O
for	O
small	O
silanes	B
.	I

Mechanism	O
of	O
the	O
antiproliferative	O
activity	O
of	O
some	O
naphthalene	B
diimide	I
G	O
-	O
quadruplex	O
ligands	O
.	O

G	O
-	O
quadruplexes	O
are	O
higher	O
-	O
order	O
nucleic	O
acid	O
structures	O
that	O
can	O
form	O
in	O
G	O
-	O
rich	O
telomeres	O
and	O
promoter	O
regions	O
of	O
oncogenes	O
.	O

Telomeric	O
quadruplex	O
stabilization	O
by	O
small	O
molecules	O
can	O
lead	O
to	O
telomere	O
uncapping	O
,	O
followed	O
by	O
DNA	O
damage	O
response	O
and	O
senescence	O
,	O
as	O
well	O
as	O
chromosomal	O
fusions	O
leading	O
to	O
deregulation	O
of	O
mitosis	O
,	O
followed	O
by	O
apoptosis	O
and	O
downregulation	O
of	O
oncogene	O
expression	O
.	O

We	O
report	O
here	O
on	O
investigations	O
into	O
the	O
mechanism	O
of	O
action	O
of	O
tetra	O
-	O
substituted	O
naphthalene	B
diimide	I
ligands	O
on	O
the	O
basis	O
of	O
cell	O
biologic	O
data	O
together	O
with	O
a	O
National	O
Cancer	O
Institute	O
COMPARE	O
study	O
.	O

We	O
conclude	O
that	O
four	O
principal	O
mechanisms	O
of	O
action	O
are	O
implicated	O
for	O
these	O
compounds	O
:	O
1	O
)	O
telomere	O
uncapping	O
with	O
subsequent	O
DNA	O
damage	O
response	O
and	O
senescence	O
;	O
2	O
)	O
inhibition	O
of	O
transcription	O
/	O
translation	O
of	O
oncogenes	O
;	O
3	O
)	O
genomic	O
instability	O
through	O
telomeric	O
DNA	O
end	O
fusions	O
,	O
resulting	O
in	O
mitotic	O
catastrophe	O
and	O
apoptosis	O
;	O
and	O
4	O
)	O
induction	O
of	O
chromosomal	O
instability	O
by	O
telomere	O
aggregate	O
formation	O
.	O

Mangiferin	B
-	O
a	O
bioactive	O
xanthonoid	B
,	O
not	O
only	O
from	O
mango	O
and	O
not	O
just	O
antioxidant	O
.	O

Mangiferin	B
is	O
a	O
plant	O
natural	O
polyphenol	B
of	O
C	B
-	I
glycosylxanthone	I
structure	O
and	O
various	O
pharmacological	O
activities	O
.	O

It	O
can	O
be	O
found	O
in	O
many	O
plant	O
species	O
,	O
among	O
which	O
the	O
mango	O
tree	O
(	O
Mangifera	O
indica	O
)	O
is	O
one	O
of	O
the	O
primary	O
sources	O
.	O

Mangiferin	B
is	O
also	O
present	O
in	O
some	O
medicinal	O
herbs	O
,	O
influencing	O
their	O
therapeutic	O
and	O
preventive	O
properties	O
,	O
and	O
in	O
honeybush	O
(	O
Cyclopia	O
sp.	O
)	O
,	O
a	O
popular	O
South	O
African	O
herbal	O
tea	O
.	O

Mangiferin	B
dissolves	O
well	O
in	O
water	O
,	O
so	O
it	O
can	O
be	O
easily	O
extracted	O
into	O
infusions	O
and	O
decoctions	O
.	O

In	O
the	O
mangiferin	B
molecule	O
,	O
four	O
aromatic	B
hydroxyl	I
groups	O
determine	O
its	O
strong	O
antiradical	O
and	O
antioxidant	O
properties	O
.	O

Mangiferin	B
is	O
also	O
an	O
efficient	O
iron	B
chelator	O
,	O
therefore	O
preventing	O
the	O
generation	O
of	O
hydroxyl	B
radical	O
in	O
Fenton	O
-	O
type	O
reactions	O
.	O

Numerous	O
published	O
in	O
vitro	O
and	O
in	O
vivo	O
pharmacological	O
studies	O
,	O
demonstrated	O
many	O
other	O
activities	O
of	O
mangiferin	B
:	O
analgesic	O
,	O
antidiabetic	O
,	O
antisclerotic	O
,	O
atimicrobial	O
and	O
antiviral	O
,	O
cardio-	O
,	O
hepato-	O
,	O
and	O
neuroprotective	O
,	O
antiinflammatory	O
,	O
antiallergic	O
,	O
MAO	O
inhibiting	O
and	O
memory	O
improving	O
,	O
as	O
well	O
as	O
radioprotective	O
against	O
X	O
-	O
ray	O
,	O
gamma	O
,	O
and	O
UV	O
radiation	O
.	O

Several	O
studies	O
indicated	O
also	O
its	O
ability	O
to	O
inhibit	O
cancerogenesis	O
and	O
cancer	O
cells	O
growth	O
by	O
apoptosis	O
induction	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

It	O
is	O
also	O
used	O
in	O
cosmetics	O
,	O
due	O
to	O
antioxidant	O
and	O
UV	O
-	O
protecting	O
properties	O
.	O

Phenolic	B
compounds	O
as	O
antioxidants	O
:	O
carbonic	O
anhydrase	O
isoenzymes	O
inhibitors	O
.	O

Antioxidant	O
compounds	O
can	O
scavenge	O
free	O
radicals	O
and	O
increase	O
shelf	O
life	O
by	O
retarding	O
the	O
process	O
of	O
lipid	O
peroxidation	O
,	O
which	O
is	O
one	O
of	O
the	O
major	O
reasons	O
for	O
deterioration	O
of	O
food	O
,	O
medicine	O
and	O
pharmaceutical	O
products	O
during	O
processing	O
and	O
storage	O
.	O

An	O
antioxidant	O
molecule	O
has	O
been	O
defined	O
as	O
any	O
substance	O
when	O
found	O
in	O
low	O
concentrations	O
compared	O
to	O
that	O
of	O
an	O
oxidizable	O
substrate	O
significantly	O
delays	O
or	O
inhibits	O
the	O
oxidation	O
.	O

The	O
major	O
antioxidant	O
compounds	O
are	O
especially	O
phenolics	B
and	O
flavonoids	B
,	O
which	O
are	O
responsible	O
for	O
their	O
health	O
benefits	O
.	O

Carbonic	O
anhydrase	O
(	O
EC	O
4.2.1.1	O
.	O
,	O
CA	O
)	O
is	O
a	O
pH	O
regulatory	O
/	O
metabolic	O
enzyme	O
in	O
all	O
life	O
kingdoms	O
,	O
being	O
found	O
in	O
organisms	O
all	O
over	O
the	O
phylogenetic	O
tree	O
.	O

It	O
catalyzes	O
the	O
hydration	O
of	O
carbon	B
dioxide	I
(	O
CO	B
(	I
2	I
)	I
)	O
to	O
bicarbonate	B
(	O
HCO	B
(	I
3	I
)	I
-	I
)	O
and	O
the	O
corresponding	O
dehydration	O
of	O
HCO	B
(	I
3	I
)	I
-in	I
acidic	O
medium	O
with	O
regeneration	O
of	O
CO	B
(	I
2	I
)	I
.	O

Also	O
,	O
CA	O
isoforms	O
are	O
found	O
in	O
a	O
variety	O
of	O
tissues	O
where	O
they	O
participate	O
in	O
several	O
important	O
biological	O
processes	O
such	O
as	O
acid	O
-	O
base	O
balance	O
,	O
respiration	O
,	O
carbon	B
dioxide	I
and	O
ion	O
transport	O
,	O
bone	O
resorption	O
,	O
ureagenesis	O
,	O
gluconeogenesis	O
,	O
lipogenesis	O
and	O
electrolyte	O
secretion	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
phenyl	B
moiety	O
of	O
phenol	B
was	O
found	O
to	O
lay	O
in	O
the	O
hydrophobic	O
part	O
of	O
the	O
CA	O
active	O
site	O
,	O
where	O
CO	B
(	I
2	I
)	I
,	O
the	O
physiologic	O
substrate	O
of	O
the	O
CAs	O
,	O
binds	O
in	O
the	O
precatalytic	O
complex	O
,	O
explaining	O
thus	O
the	O
behavior	O
of	O
phenol	B
as	O
a	O
unique	O
CO	B
(	I
2	I
)	I
competitive	O
inhibitor	O
.	O

This	O
review	O
consists	O
of	O
two	O
main	O
sections	O
.	O

The	O
first	O
section	O
is	O
devoted	O
to	O
main	O
phenolic	B
antioxidant	O
compounds	O
in	O
the	O
foodstuffs	O
and	O
beverages	O
.	O

The	O
second	O
general	O
section	O
is	O
about	O
some	O
definitions	O
of	O
CA	O
inhibitory	O
effects	O
of	O
the	O
main	O
phenolic	B
compounds	O
used	O
for	O
antioxidant	O
activity	O
.	O

The	O
phenolic	B
compounds	O
and	O
acids	O
had	O
marked	O
especially	O
CA	O
I	O
and	O
CA	O
II	O
inhibitory	O
effects	O
and	O
might	O
be	O
used	O
as	O
leads	O
for	O
generating	O
CA	O
isoenzyme	O
inhibitors	O
.	O

This	O
class	O
of	O
compounds	O
may	O
lead	O
to	O
isoform	O
-	O
selective	O
inhibitors	O
targeting	O
just	O
one	O
or	O
few	O
of	O
the	O
medicinally	O
relevant	O
CAs	O
.	O

In	O
addition	O
,	O
there	O
are	O
given	O
some	O
chemical	O
and	O
kinetic	O
basis	O
and	O
technical	O
details	O
related	O
to	O
phenolic	B
antioxidant	O
compounds	O
and	O
carbonic	O
anhydrase	O
isoenzymes	O
.	O

Recent	O
studies	O
of	O
antioxidant	O
quinoline	B
derivatives	O
.	O

Quinoline	B
derivatives	O
constitute	O
an	O
important	O
class	O
of	O
compounds	O
for	O
new	O
drug	O
development	O
.	O

As	O
a	O
large	O
number	O
of	O
experimental	O
and	O
theoretical	O
studies	O
have	O
shown	O
that	O
the	O
quinoline	B
ring	O
system	O
is	O
an	O
important	O
structural	O
unit	O
widely	O
existing	O
in	O
alkaloids	O
,	O
therapeutics	O
and	O
synthetic	O
analogues	O
with	O
exciting	O
biological	O
activities	O
.	O

The	O
present	O
review	O
provides	O
recent	O
antioxidant	O
activities	O
covering	O
in	O
vivo	O
and	O
in	O
vitro	O
studies	O
of	O
natural	O
and	O
synthetic	O
analogues	O
,	O
as	O
well	O
as	O
the	O
proposed	O
mechanisms	O
of	O
action	O
and	O
structure	O
-	O
activity	O
relationships	O
.	O

Supramolecular	O
hydrogels	O
with	O
reverse	O
thermal	O
gelation	O
properties	O
from	O
(	B
oligo	I
)	I
tyrosine	I
containing	O
block	O
copolymers	O
.	O

Novel	O
block	O
copolymers	O
comprising	O
poly	B
(	I
ethylene	I
glycol	I
)	I
(	O
PEG	B
)	O
and	O
an	O
oligo	B
(	I
tyrosine	I
)	I
block	O
were	O
synthesized	O
in	O
different	O
compositions	O
by	O
N	B
-	I
carboxyanhydride	I
(	O
NCA	B
)	O
polymerization	O
.	O

It	O
was	O
shown	O
that	O
PEG2000-Tyr	B
(	I
6	I
)	I
undergoes	O
thermoresponsive	O
hydrogelation	O
at	O
a	O
low	O
concentration	O
range	O
of	O
0.25	O
-	O
3.0	O
wt	O
%	O
within	O
a	O
temperature	O
range	O
of	O
25	O
-	O
50	O
	O
C	O
.	O

Cryogenic	O
transmission	O
electron	O
microscopy	O
(	O
Cryo	O
-	O
TEM	O
)	O
revealed	O
a	O
continuous	O
network	O
of	O
fibers	O
throughout	O
the	O
hydrogel	O
sample	O
,	O
even	O
at	O
concentrations	O
as	O
low	O
as	O
0.25	O
wt	O
%	O
.	O

Circular	O
dichroism	O
(	O
CD	O
)	O
results	O
suggest	O
that	O
better	O
packing	O
of	O
the	O
	O
-	O
sheet	O
tyrosine	B
block	O
at	O
increasing	O
temperature	O
induces	O
the	O
reverse	O
thermogelation	O
.	O

A	O
preliminary	O
assessment	O
of	O
the	O
potential	O
of	O
the	O
hydrogel	O
for	O
in	O
vitro	O
application	O
confirmed	O
the	O
hydrogel	O
is	O
not	O
cytotoxic	O
,	O
is	O
biodegradable	O
,	O
and	O
produced	O
a	O
sustained	O
release	O
of	O
a	O
small	O
-	O
molecule	O
drug	O
.	O

Green	O
asymmetric	O
synthesis	O
:	O
	B
-	I
amino	I
alcohol	I
-	O
catalyzed	O
direct	O
asymmetric	O
aldol	B
reactions	O
in	O
aqueous	O
micelles	O
.	O

The	O
ability	O
of	O
chiral	B
	I
-	I
amino	I
alcohols	I
to	O
catalyze	O
the	O
direct	O
asymmetric	O
aldol	B
reaction	O
was	O
evaluated	O
for	O
the	O
first	O
time	O
in	O
aqueous	O
micellar	O
media	O
.	O

A	O
family	O
of	O
cheap	O
and	O
easily	O
accessible	O
	B
-	I
amino	I
alcohols	I
,	O
obtained	O
in	O
one	O
step	O
from	O
naturally	O
occurring	O
amino	B
acids	I
,	O
was	O
shown	O
to	O
successfully	O
catalyze	O
the	O
asymmetric	O
aldol	B
reaction	O
between	O
a	O
series	O
of	O
ketones	B
and	O
aromatic	B
aldehydes	I
.	O

These	O
aldol	B
reactions	O
furnished	O
the	O
corresponding	O
	B
-	I
hydroxy	I
ketones	I
with	O
up	O
to	O
93	O
%	O
isolated	O
yield	O
and	O
89	O
%	O
ee	O
.	O

(	B
S	I
)	I
-2-phenylglycinol	I
and	O
Triton	B
X-100	I
proved	O
to	O
be	O
the	O
best	O
organocatalyst	O
and	O
surfactant	O
,	O
respectively	O
.	O

Allen	O
Brain	O
Atlas	O
:	O
an	O
integrated	O
spatio	O
-	O
temporal	O
portal	O
for	O
exploring	O
the	O
central	O
nervous	O
system	O
.	O

The	O
Allen	O
Brain	O
Atlas	O
(	O
http://www.brain-map.org	O
)	O
provides	O
a	O
unique	O
online	O
public	O
resource	O
integrating	O
extensive	O
gene	O
expression	O
data	O
,	O
connectivity	O
data	O
and	O
neuroanatomical	O
information	O
with	O
powerful	O
search	O
and	O
viewing	O
tools	O
for	O
the	O
adult	O
and	O
developing	O
brain	O
in	O
mouse	O
,	O
human	O
and	O
non	O
-	O
human	O
primate	O
.	O

Here	O
,	O
we	O
review	O
the	O
resources	O
available	O
at	O
the	O
Allen	O
Brain	O
Atlas	O
,	O
describing	O
each	O
product	O
and	O
data	O
type	O
[	O
such	O
as	O
in	O
situ	O
hybridization	O
(	O
ISH	O
)	O
and	O
supporting	O
histology	O
,	O
microarray	O
,	O
RNA	O
sequencing	O
,	O
reference	O
atlases	O
,	O
projection	O
mapping	O
and	O
magnetic	O
resonance	O
imaging	O
]	O
.	O

In	O
addition	O
,	O
standardized	O
and	O
unique	O
features	O
in	O
the	O
web	O
applications	O
are	O
described	O
that	O
enable	O
users	O
to	O
search	O
and	O
mine	O
the	O
various	O
data	O
sets	O
.	O

Features	O
include	O
both	O
simple	O
and	O
sophisticated	O
methods	O
for	O
gene	O
searches	O
,	O
colorimetric	O
and	O
fluorescent	O
ISH	O
image	O
viewers	O
,	O
graphical	O
displays	O
of	O
ISH	O
,	O
microarray	O
and	O
RNA	O
sequencing	O
data	O
,	O
Brain	O
Explorer	O
software	O
for	O
3D	O
navigation	O
of	O
anatomy	O
and	O
gene	O
expression	O
,	O
and	O
an	O
interactive	O
reference	O
atlas	O
viewer	O
.	O

In	O
addition	O
,	O
cross	O
data	O
set	O
searches	O
enable	O
users	O
to	O
query	O
multiple	O
Allen	O
Brain	O
Atlas	O
data	O
sets	O
simultaneously	O
.	O

All	O
of	O
the	O
Allen	O
Brain	O
Atlas	O
resources	O
can	O
be	O
accessed	O
through	O
the	O
Allen	O
Brain	O
Atlas	O
data	O
portal	O
.	O

Arcuate	O
nucleus	O
homeostatic	O
systems	O
are	O
not	O
altered	O
immediately	O
prior	O
to	O
the	O
scheduled	O
consumption	O
of	O
large	O
,	O
binge	O
-	O
type	O
meals	O
of	O
palatable	O
solid	O
or	O
liquid	O
diet	O
in	O
rats	O
and	O
Mice	O
.	O

Meal	O
feeding	O
is	O
a	O
critical	O
issue	O
in	O
the	O
over	O
-	O
consumption	O
of	O
calories	O
leading	O
to	O
human	O
obesity	O
.	O

To	O
investigate	O
the	O
mechanisms	O
involved	O
in	O
the	O
regulation	O
of	O
meal	O
feeding	O
in	O
rodents	O
,	O
we	O
studied	O
a	O
scheduled	O
feeding	O
regime	O
that	O
induces	O
substantial	O
food	O
intake	O
over	O
short	O
periods	O
of	O
time	O
.	O

Male	O
Sprague	O
-	O
Dawley	O
rats	O
and	O
C57BL6	O
mice	O
were	O
fed	O
one	O
of	O
four	O
palatable	O
diets	O
[	O
45	O
%	O
fat	O
pellet	O
,	O
60	O
%	O
fat	O
pellet	O
or	O
standard	O
pellet	O
supplemented	O
with	O
Ensure	O
(	O
EN	O
;	O
Abbott	O
Laboratories	O
,	O
Maidenhead	O
,	O
UK	O
)	O
or	O
12.5	O
%	O
sucrose	O
(	O
SUC	O
)	O
]	O
either	O
ad	O
lib	O
.	O
or	O
with	O
daily	O
2-h	O
scheduled	O
access	O
and	O
standard	O
pellet	O
available	O
for	O
22	O
h.	O
Energy	O
balance	O
gene	O
expression	O
in	O
the	O
hypothalamic	O
arcuate	O
nucleus	O
(	O
ARC	O
)	O
and	O
nucleus	O
accumbens	O
(	O
NAcc	O
)	O
reward	O
gene	O
expression	O
were	O
assessed	O
by	O
in	O
situ	O
hybridisation	O
.	O

Rats	O
fed	O
ad	O
lib	O
.	O

on	O
45	O
%	O
or	O
60	O
%	O
fat	O
diet	O
were	O
heavier	O
and	O
fatter	O
than	O
controls	O
,	O
and	O
had	O
reduced	O
neuropeptide	O
Y	O
(	O
NPY	O
)	O
gene	O
expression	O
in	O
the	O
ARC	O
.	O

Mice	O
fed	O
ad	O
lib	O
.	O

on	O
any	O
of	O
the	O
palatable	O
diets	O
were	O
heavier	O
,	O
fatter	O
and	O
had	O
higher	O
blood	O
leptin	O
than	O
controls	O
,	O
and	O
had	O
reduced	O
NPY	O
and	O
increased	O
cocaine-	B
and	O
-	O
amphetamine	B
-	O
regulated	O
transcript	O
mRNA	O
in	O
the	O
ARC	O
.	O

Schedule	O
-	O
fed	O
rats	O
and	O
mice	O
quickly	O
adapted	O
their	O
feeding	O
behaviour	O
to	O
2-h	O
access	O
on	O
palatable	O
food	O
.	O

Three	O
schedule	O
-	O
fed	O
groups	O
binged	O
:	O
the	O
percentage	O
of	O
daily	O
calories	O
consumed	O
in	O
2	O
h	O
on	O
45	O
%	O
fat	O
diet	O
,	O
60	O
%	O
fat	O
diet	O
or	O
EN	O
,	O
respectively	O
,	O
was	O
55	O
%	O
,	O
63	O
%	O
and	O
49	O
%	O
in	O
rats	O
,	O
and	O
86	O
%	O
,	O
86	O
%	O
and	O
45	O
%	O
in	O
mice	O
.	O

However	O
,	O
changed	O
feeding	O
behaviour	O
was	O
not	O
reflected	O
in	O
an	O
induction	O
of	O
orexigenic	O
neuropeptide	O
or	O
suppression	O
of	O
anorexigenic	O
neuropeptide	O
gene	O
expression	O
in	O
the	O
ARC	O
,	O
in	O
the	O
2-h	O
period	O
prior	O
to	O
scheduled	O
feeding	O
.	O

The	O
mechanisms	O
underlying	O
large	O
meal	O
/	O
binge	O
-	O
type	O
eating	O
may	O
be	O
regulated	O
by	O
nonhomeostatic	O
processes	O
involving	O
other	O
genes	O
in	O
the	O
hypothalamus	O
or	O
other	O
brain	O
areas	O
.	O

However	O
,	O
assessment	O
of	O
opioid	O
and	O
dopamine	B
receptor	O
gene	O
expression	O
in	O
the	O
NAcc	O
did	O
not	O
reveal	O
evidence	O
of	O
the	O
involvement	O
of	O
these	O
genes	O
in	O
driving	O
large	O
meals	O
,	O
at	O
least	O
at	O
the	O
investigated	O
time	O
point	O
.	O

A	O
potential	O
practical	O
approach	O
to	O
reduce	O
Ara	O
h	O
6	O
allergenicity	O
by	O
gamma	O
irradiation	O
.	O

Peanut	O
allergen	O
Ara	O
h	O
6	O
was	O
isolated	O
and	O
irradiated	O
at	O
1	O
,	O
3	O
,	O
5	O
,	O
or	O
10	O
kGy	O
,	O
and	O
a	O
whole	O
peanut	O
protein	O
extract	O
(	O
WPPE	O
)	O
was	O
also	O
treated	O
by	O
irradiation	O
.	O

Alteration	O
in	O
structure	O
of	O
Ara	O
h	O
6	O
was	O
characterised	O
by	O
circular	O
dichroism	O
(	O
CD	O
)	O
spectroscopy	O
,	O
ultraviolet	O
(	O
UV	O
)	O
absorption	O
spectroscopy	O
,	O
fluorescence	O
spectroscopy	O
and	O
SDS	B
-	O
PAGE	O
,	O
and	O
antigenicity	O
was	O
evaluated	O
by	O
immunoblotting	O
and	O
indirect	O
ELISA	O
with	O
anti	O
-	O
Ara	O
h	O
6	O
polyclonal	O
antibody	O
.	O

Irradiation	O
induced	O
significant	O
changes	O
in	O
the	O
secondary	O
and	O
tertiary	O
structures	O
of	O
Ara	O
h	O
6	O
,	O
and	O
the	O
antigenicity	O
of	O
both	O
purified	O
Ara	O
h	O
6	O
and	O
WPPE	O
were	O
reduced	O
upon	O
increasing	O
the	O
irradiation	O
doses	O
.	O

Moreover	O
,	O
a	O
good	O
correlation	O
between	O
the	O
loss	O
in	O
	O
-	O
helix	O
and	O
IgG	O
binding	O
to	O
Ara	O
h	O
6	O
was	O
observed	O
.	O

This	O
indicated	O
that	O
irradiation	O
might	O
be	O
an	O
efficient	O
approach	O
to	O
reduce	O
or	O
eliminate	O
peanut	O
allergenicity	O
.	O

Analysis	O
of	O
total	O
polyphenols	B
in	O
wines	O
by	O
FIA	O
with	O
highly	O
stable	O
amperometric	O
detection	O
using	O
carbon	B
nanotube	O
-	O
modified	O
electrodes	O
.	O

The	O
use	O
of	O
glassy	O
carbon	B
electrodes	O
(	O
GCEs	O
)	O
modified	O
with	O
multi	O
-	O
walled	O
carbon	B
nanotube	O
(	O
CNT	O
)	O
films	O
for	O
the	O
continuous	O
monitoring	O
of	O
polyphenols	B
in	O
flow	O
systems	O
has	O
been	O
examined	O
.	O

The	O
performance	O
of	O
these	O
modified	O
electrodes	O
was	O
evaluated	O
and	O
compared	O
to	O
bare	O
GCE	O
by	O
cyclic	O
voltammetry	O
experiments	O
and	O
by	O
flow	O
injection	O
analysis	O
(	O
FIA	O
)	O
with	O
amperometric	O
detection	O
monitoring	O
the	O
response	O
of	O
gallic	B
,	I
caffeic	I
,	I
ferulic	I
and	I
p	I
-	I
coumaric	I
acids	I
in	O
0.050	O
M	O
acetate	B
buffer	O
pH	O
4.5	O
containing	O
100	O
mM	O
NaCl	B
.	O

The	O
GCE	O
modified	O
with	O
CNT	O
dispersions	O
in	O
polyethyleneimine	B
(	O
PEI	B
)	O
provided	O
lower	O
overpotentials	O
,	O
higher	O
sensitivity	O
and	O
much	O
higher	O
signal	O
stability	O
under	O
a	O
dynamic	O
regime	O
than	O
bare	O
GCEs	O
.	O

These	O
properties	O
allowed	O
the	O
estimation	O
of	O
the	O
total	O
polyphenol	B
content	O
in	O
red	O
and	O
white	O
wines	O
with	O
a	O
remarkable	O
long	O
-	O
term	O
stability	O
in	O
the	O
measurements	O
despite	O
the	O
presence	O
of	O
potential	O
fouling	O
substances	O
in	O
the	O
wine	O
matrix	O
.	O

In	O
addition	O
,	O
the	O
versatility	O
of	O
the	O
electrochemical	O
methodology	O
allowed	O
the	O
selective	O
estimation	O
of	O
the	O
easily	O
oxidisable	O
polyphenol	B
fraction	O
as	O
well	O
as	O
the	O
total	O
polyphenol	B
content	O
just	O
by	O
tuning	O
the	O
detection	O
potential	O
at	O
+	O
0.30	O
or	O
0.70	O
V	O
,	O
respectively	O
.	O

The	O
significance	O
of	O
the	O
electrochemical	O
results	O
was	O
demonstrated	O
through	O
correlation	O
studies	O
with	O
the	O
results	O
obtained	O
with	O
conventional	O
spectrophotometric	O
assays	O
for	O
polyphenols	B
(	O
Folin	O
-	O
Ciocalteu	O
,	O
absorbance	O
at	O
280	O
nm	O
index	O
and	O
colour	O
intensity	O
index	O
)	O
.	O

Use	O
of	O
an	O
electrodialytic	O
reactor	O
for	O
the	O
simultaneous	O
	O
-	O
lactoglobulin	O
enzymatic	O
hydrolysis	O
and	O
fractionation	O
of	O
generated	O
bioactive	O
peptides	O
.	O

The	O
enzymatic	O
hydrolysis	O
of	O
	O
-	O
lactoglobulin	O
and	O
the	O
fractionation	O
of	O
peptides	O
were	O
performed	O
in	O
one	O
step	O
in	O
an	O
electrodialysis	O
cell	O
with	O
ultrafiltration	O
membranes	O
stacked	O
.	O

After	O
240	O
min	O
of	O
treatment	O
,	O
15	O
anionic	O
and	O
4	O
cationic	O
peptides	O
were	O
detected	O
in	O
the	O
anionic	O
and	O
cationic	O
peptide	O
recovery	O
compartments	O
.	O

Amongst	O
these	O
15	O
anionic	O
peptides	O
,	O
2	O
hypocholesterolemic	O
,	O
3	O
antihypertensive	O
and	O
1	O
antibacterial	O
peptides	O
were	O
recovered	O
and	O
concentrated	O
with	O
migration	O
rates	O
ranging	O
from	O
5.5	O
%	O
and	O
81.7	O
%	O
.	O

Amongst	O
the	O
4	O
cationic	O
peptides	O
,	O
the	O
peptide	O
sequence	O
ALPMHIR	O
,	O
identified	O
as	O
lactokinin	B
and	O
known	O
to	O
exert	O
an	O
important	O
antihypertensive	O
effect	O
,	O
was	O
recovered	O
with	O
an	O
estimated	O
66	O
%	O
migration	O
rate	O
.	O

To	O
our	O
knowledge	O
,	O
it	O
was	O
the	O
first	O
attempt	O
to	O
perform	O
hydrolysis	O
under	O
an	O
electric	O
field	O
and	O
to	O
simultaneously	O
separate	O
anionic	O
and	O
cationic	O
peptides	O
produced	O
.	O

The	O
heat	O
treatment	O
and	O
the	O
gelation	O
are	O
strong	O
determinants	O
of	O
the	O
kinetics	O
of	O
milk	O
proteins	O
digestion	O
and	O
of	O
the	O
peripheral	O
availability	O
of	O
amino	B
acids	I
.	O

This	O
study	O
aimed	O
to	O
determine	O
the	O
kinetics	O
of	O
milk	O
protein	O
digestion	O
and	O
amino	B
acid	I
absorption	O
after	O
ingestion	O
of	O
four	O
dairy	O
matrices	O
by	O
six	O
minipigs	O
:	O
unheated	O
or	O
heated	O
skim	O
milk	O
and	O
corresponding	O
rennet	O
gels	O
.	O

Digestive	O
contents	O
and	O
plasma	O
samples	O
were	O
collected	O
over	O
a	O
7	O
h	O
-	O
period	O
after	O
meal	O
ingestion	O
.	O

Gelation	O
of	O
milk	O
slowed	O
down	O
the	O
outflow	O
of	O
the	O
meal	O
from	O
the	O
stomach	O
and	O
the	O
subsequent	O
absorption	O
of	O
amino	B
acids	I
,	O
and	O
decreased	O
their	O
bioavailability	O
in	O
peripheral	O
blood	O
.	O

The	O
gelled	O
rennet	O
matrices	O
also	O
led	O
to	O
low	O
levels	O
of	O
milk	O
proteins	O
at	O
the	O
duodenum	O
.	O

Caseins	O
and	O
	O
-	O
lactoglobulin	O
,	O
respectively	O
,	O
were	O
sensitive	O
and	O
resistant	O
to	O
hydrolysis	O
in	O
the	O
stomach	O
with	O
the	O
unheated	O
matrices	O
,	O
but	O
showed	O
similar	O
digestion	O
with	O
the	O
heated	O
matrices	O
,	O
with	O
a	O
heat	O
-	O
induced	O
susceptibility	O
to	O
hydrolysis	O
for	O
	O
-	O
lactoglobulin	O
.	O

These	O
results	O
suggest	O
a	O
significant	O
influence	O
of	O
the	O
meal	O
microstructure	O
(	O
resulting	O
from	O
heat	O
treatment	O
)	O
and	O
macrostructure	O
(	O
resulting	O
from	O
gelation	O
process	O
)	O
on	O
the	O
different	O
steps	O
of	O
milk	O
proteins	O
digestion	O
.	O

The	O
presence	O
of	O
D	B
-	I
fagomine	I
in	O
the	O
human	O
diet	O
from	O
buckwheat	O
-	O
based	O
foodstuffs	O
.	O

Buckwheat	O
(	O
Fagopyrum	O
esculentum	O
Moench	O
)	O
groats	O
contain	O
the	O
iminosugar	O
D	B
-	I
fagomine	I
as	O
a	O
minor	O
component	O
that	O
might	O
contribute	O
to	O
the	O
alleged	O
health	O
benefits	O
of	O
this	O
pseudo	O
-	O
cereal	O
.	O

This	O
study	O
presents	O
analysis	O
of	O
D	B
-	I
fagomine	I
in	O
buckwheat	O
-	O
based	O
foodstuffs	O
by	O
liquid	O
chromatography	O
coupled	O
to	O
mass	O
spectrometry	O
and	O
an	O
estimation	O
of	O
its	O
presence	O
in	O
the	O
human	O
diet	O
based	O
on	O
a	O
published	O
population	O
-	O
based	O
cross	O
-	O
sectional	O
nutrition	O
survey	O
.	O

D	B
-	I
fagomine	I
is	O
present	O
in	O
common	O
buckwheat	O
-	O
based	O
foodstuffs	O
in	O
amounts	O
ranging	O
from	O
1	O
to	O
25	O
mg	O
/	O
kg	O
or	O
mg	O
/	O
L	O
,	O
it	O
is	O
stable	O
during	O
boiling	O
,	O
baking	O
,	O
frying	O
and	O
fermentation	O
,	O
and	O
it	O
is	O
biosynthesised	O
upon	O
sprouting	O
.	O

The	O
estimated	O
total	O
intake	O
of	O
D	B
-	I
fagomine	I
resulting	O
from	O
a	O
diet	O
that	O
includes	O
such	O
foodstuffs	O
would	O
be	O
between	O
3	O
and	O
17	O
mg	O
per	O
day	O
(	O
mean	O
for	O
both	O
genders	O
;	O
range	O
from	O
P5	O
to	O
P95	O
)	O
.	O

A	O
diet	O
rich	O
in	O
buckwheat	O
products	O
would	O
provide	O
a	O
daily	O
amount	O
of	O
D	B
-	I
fagomine	I
that	O
may	O
in	O
part	O
explain	O
the	O
beneficial	O
properties	O
traditionally	O
attributed	O
to	O
buckwheat	O
consumption	O
.	O

The	O
in	O
vivo	O
antioxidant	O
and	O
antifibrotic	O
properties	O
of	O
green	O
tea	O
(	O
Camellia	O
sinensis	O
,	O
Theaceae	O
)	O
.	O

The	O
in	O
vivo	O
antioxidant	O
and	O
antifibrotic	O
properties	O
of	O
green	O
tea	O
(	O
Camellia	O
sinensis	O
,	O
Theaceae	O
)	O
were	O
investigated	O
with	O
a	O
study	O
of	O
carbon	B
tetrachloride	I
(	O
CCl	B
(	I
4	I
)	I
)	O
-induced	O
oxidative	O
stress	O
and	O
hepatic	O
fibrosis	O
in	O
male	O
ICR	O
mice	O
.	O

Oral	O
administration	O
of	O
green	O
tea	O
extract	O
at	O
doses	O
of	O
125	O
,	O
625	O
and	O
1250	O
mg	O
/	O
kg	O
for	O
8	O
weeks	O
significantly	O
reduced	O
(	O
p<0.05	O
)	O
the	O
levels	O
of	O
thiobarbituric	B
acid	I
-	O
reactive	O
substances	O
(	O
TBARS	O
)	O
and	O
protein	O
carbonyls	B
in	O
the	O
liver	O
by	O
at	O
least	O
28	O
%	O
compared	O
with	O
that	O
was	O
induced	O
by	O
CCl	B
(	I
4	I
)	I
(	O
1	O
mL	O
/	O
kg	O
)	O
in	O
mice	O
.	O

Moreover	O
,	O
green	O
tea	O
extract	O
administration	O
significantly	O
increased	O
(	O
p<0.05	O
)	O
the	O
activities	O
of	O
catalase	O
,	O
glutathione	B
peroxidase	O
(	O
GSH	B
-	O
Px	O
)	O
and	O
glutathione	B
reductase	O
(	O
GSH	B
-	O
Rd	O
)	O
in	O
the	O
liver	O
.	O

Our	O
study	O
found	O
that	O
oral	O
administration	O
of	O
green	O
tea	O
extract	O
prevented	O
CCl	B
(	I
4	I
)	I
-induced	O
hepatic	O
fibrosis	O
,	O
as	O
evidenced	O
by	O
a	O
decreased	O
hydroxyproline	B
level	O
in	O
the	O
liver	O
and	O
a	O
reduced	O
incidence	O
of	O
hepatic	O
fibrosis	O
by	O
histological	O
observations	O
.	O

These	O
results	O
indicate	O
that	O
green	O
tea	O
exhibits	O
potent	O
protective	O
effects	O
against	O
CCl	B
(	I
4	I
)	I
-induced	O
oxidative	O
stress	O
and	O
hepatic	O
fibrosis	O
in	O
mice	O
by	O
inhibiting	O
oxidative	O
damage	O
and	O
increasing	O
antioxidant	O
enzyme	O
activities	O
.	O

Whey	O
protein	O
hydrolysate	O
enhances	O
the	O
exercise	O
-	O
induced	O
heat	O
shock	O
protein	O
(	O
HSP70	O
)	O
response	O
in	O
rats	O
.	O

Whey	O
protein	O
has	O
been	O
suggested	O
to	O
be	O
potential	O
protective	O
agent	O
against	O
various	O
forms	O
of	O
stress	O
.	O

The	O
heat	O
shock	O
protein	O
HSP70	O
confers	O
greater	O
cellular	O
tolerance	O
against	O
stressors	O
.	O

The	O
present	O
study	O
evaluated	O
the	O
effects	O
of	O
whey	O
protein	O
intake	O
on	O
HSP70	O
expression	O
.	O

Forty	O
-	O
eight	O
male	O
Wistar	O
rats	O
were	O
divided	O
into	O
sedentary	O
and	O
exercised	O
groups	O
,	O
and	O
each	O
group	O
was	O
fed	O
as	O
a	O
protein	O
source	O
casein	O
(	O
CAS	O
)	O
,	O
whey	O
protein	O
(	O
WP	O
)	O
or	O
whey	O
protein	O
hydrolysate	O
(	O
WPH	O
)	O
for	O
3weeks	O
.	O

Exercise	O
on	O
a	O
treadmill	O
was	O
used	O
as	O
the	O
source	O
of	O
stress	O
in	O
the	O
animals	O
from	O
the	O
exercised	O
group	O
.	O

The	O
results	O
showed	O
a	O
larger	O
increase	O
in	O
HSP70	O
expression	O
in	O
the	O
soleus	O
,	O
gastrocnemius	O
and	O
lung	O
of	O
the	O
WPH	O
-	O
fed	O
rats	O
than	O
WP	O
or	O
casein	O
-	O
fed	O
rats	O
.	O

HSP70	O
expression	O
in	O
the	O
sedentary	O
rats	O
was	O
very	O
low	O
,	O
independent	O
of	O
the	O
diet	O
or	O
tissue	O
.	O

Protein	O
carbonyls	B
were	O
lower	O
in	O
the	O
group	O
that	O
consumed	O
WPH	O
.	O

These	O
data	O
suggest	O
that	O
the	O
consumption	O
of	O
WPH	O
enhances	O
HSP70	O
expression	O
.	O

A	O
new	O
QSAR	O
model	O
,	O
for	O
angiotensin	B
I	I
-	O
converting	O
enzyme	O
inhibitory	O
oligopeptides	O
.	O

A	O
new	O
quantitative	O
structure	O
activity	O
relationship	O
(	O
QSAR	O
)	O
model	O
is	O
established	O
for	O
oligopeptides	O
that	O
inhibit	O
angiotensin	B
I	I
-	O
converting	O
enzyme	O
(	O
ACE	O
)	O
.	O

Information	O
concerning	O
the	O
C	O
-	O
terminal	O
pentapeptide	O
is	O
considered	O
to	O
describe	O
the	O
peptide	O
structure	O
in	O
the	O
model	O
.	O

A	O
database	O
is	O
constructed	O
,	O
with	O
263	O
ACE	O
inhibitory	O
peptides	O
and	O
38	O
physicochemical	O
descriptors	O
,	O
abstracted	O
from	O
the	O
published	O
literature	O
.	O

The	O
model	O
is	O
generated	O
through	O
a	O
generalised	O
linear	O
model	O
,	O
with	O
a	O
gamma	O
distribution	O
that	O
yields	O
a	O
coefficient	O
of	O
determination	O
of	O
94.4	O
%	O
.	O

The	O
whole	O
C	O
-	O
terminal	O
pentapeptide	O
information	O
is	O
a	O
determinant	O
for	O
modelling	O
the	O
ACE	O
inhibition	O
activity	O
of	O
oligopeptides	O
.	O

Starting	O
from	O
the	O
C	O
-	O
terminus	O
,	O
the	O
C-1	O
position	O
is	O
the	O
most	O
relevant	O
position	O
in	O
the	O
model	O
;	O
this	O
is	O
followed	O
by	O
position	O
C-4	O
.	O

In	O
C-1	O
,	O
there	O
is	O
a	O
preference	O
for	O
aliphatic	O
and	O
tiny	O
residues	O
.	O

However	O
,	O
in	O
the	O
C-4	O
position	O
,	O
the	O
model	O
indicates	O
a	O
clear	O
preference	O
for	O
bulky	O
hydrophobic	O
amino	B
acids	I
and	O
for	O
sulphur	B
-	O
containing	O
amino	B
acids	I
.	O

Due	O
to	O
its	O
good	O
predictive	O
capability	O
,	O
this	O
model	O
could	O
be	O
used	O
as	O
a	O
tool	O
for	O
identifying	O
and	O
prioritizing	O
the	O
potential	O
ACE	O
inhibitory	O
peptides	O
present	O
in	O
a	O
complex	O
matrix	O
.	O

Total	O
polyphenols	B
,	O
catechin	B
profiles	O
and	O
antioxidant	O
activity	O
of	O
tea	O
products	O
from	O
purple	O
leaf	O
coloured	O
tea	O
cultivars	O
.	O

Black	O
(	O
aerated	O
)	O
and	O
green	O
(	O
unaerated	O
)	O
tea	O
products	O
,	O
processed	O
from	O
10	O
green	O
and	O
18	O
purple	O
leaf	O
coloured	O
cultivars	O
of	O
Kenyan	O
origin	O
,	O
and	O
two	O
tea	O
products	O
,	O
from	O
the	O
Japanese	O
cultivars	O
,	O
Yabukita	O
and	O
Yutakamidori	O
,	O
were	O
assayed	O
for	O
total	O
polyphenols	B
(	O
TP	O
)	O
content	O
,	O
individual	O
catechin	B
profiles	O
and	O
in	O
vitro	O
antioxidant	O
capacity	O
(	O
AA	O
)	O
.	O

In	O
addition	O
,	O
the	O
phenolic	B
content	O
of	O
the	O
tea	O
products	O
was	O
determined	O
using	O
the	O
Folin	B
-	I
Ciocalteu	I
phenol	I
reagent	O
.	O

Catechin	B
fractions	O
were	O
identified	O
using	O
reverse	O
phase	O
high	O
performance	O
liquid	O
chromatography	O
(	O
HPLC	O
)	O
with	O
a	O
binary	O
gradient	O
elution	O
system	O
.	O

The	O
AA%	O
of	O
the	O
tea	O
products	O
was	O
determined	O
using	O
a	O
2,2'-diphenyl	B
picrylhydrazyl	I
(	O
DPPH	B
)	O
radical	O
assay	O
method	O
.	O

The	O
results	O
showed	O
that	O
TPs	O
,	O
catechin	B
profiles	O
and	O
antioxidant	O
activities	O
were	O
significantly	O
(	O
p0.05	O
)	O
higher	O
in	O
unaerated	O
than	O
in	O
aerated	O
teas	O
.	O

Tea	O
products	O
from	O
the	O
purple	O
leaf	O
coloured	O
tea	O
cultivars	O
had	O
levels	O
of	O
TPs	O
,	O
total	O
catechin	B
(	O
TC	O
)	O
and	O
antioxidant	O
activities	O
similar	O
to	O
those	O
from	O
the	O
green	O
leaf	O
coloured	O
cultivars	O
,	O
except	O
for	O
teas	O
from	O
the	O
Japanese	O
cultivars	O
that	O
were	O
very	O
low	O
in	O
the	O
assayed	O
parameters	O
.	O

Caffeine	B
content	O
was	O
significantly	O
(	O
p0.05	O
)	O
lower	O
in	O
products	O
from	O
the	O
purple	O
leaf	O
coloured	O
cultivars	O
than	O
in	O
those	O
from	O
the	O
green	O
leaf	O
coloured	O
tea	O
cultivars	O
.	O

Antioxidant	O
activity	O
(	O
%	O
)	O
was	O
higher	O
in	O
tea	O
products	O
from	O
the	O
Kenyan	O
germplasm	O
than	O
in	O
those	O
from	O
the	O
Japanese	O
cultivars	O
.	O

Antioxidant	O
potency	O
of	O
tea	O
products	O
was	O
significantly	O
(	O
r=0.789	O
(	O
	O
)	O
,	O
p0.01	O
)	O
influenced	O
by	O
the	O
total	O
anthocyanin	B
content	O
of	O
the	O
purple	O
leaf	O
coloured	O
cultivars	O
.	O

Cyanidin-3-O	B
-	I
glucoside	I
was	O
the	O
anthocyanin	B
most	O
highly	O
correlated	O
with	O
AA%	O
(	O
r=0.843	O
(	O
	O
)	O
,	O
p0.01	O
in	O
unaerated	O
tea	O
)	O
.	O

Total	O
catechins	B
in	O
the	O
unaerated	O
products	O
from	O
the	O
green	O
leaf	O
coloured	O
tea	O
cultivars	O
were	O
also	O
significantly	O
correlated	O
with	O
antioxidant	O
capacity	O
(	O
r=0.818	O
(	O
	O
)	O
,	O
p0.01	O
)	O
.	O

Results	O
from	O
this	O
study	O
suggest	O
that	O
the	O
antioxidant	O
potency	O
of	O
teas	O
is	O
dependent	O
on	O
the	O
predominant	O
flavonoid	B
compound	O
,	O
the	O
type	O
of	O
tea	O
cultivar	O
and	O
the	O
processing	O
method	O
.	O

Simple	O
multiresidue	O
extraction	O
method	O
for	O
the	O
determination	O
of	O
fungicides	O
and	O
plant	O
growth	O
regulator	O
in	O
bean	O
sprouts	O
using	O
low	O
temperature	O
partitioning	O
and	O
tandem	O
mass	O
spectrometry	O
.	O

A	O
simple	O
multiresidue	O
analytical	O
method	O
is	O
developed	O
for	O
the	O
simultaneous	O
determination	O
of	O
carbendazim	B
(	O
CB	O
)	O
,	O
thiabendazole	B
(	O
TB	O
)	O
,	O
and	O
6-benzyl	B
aminopurine	I
(	O
6-BA	B
)	O
in	O
bean	O
sprouts	O
.	O

The	O
samples	O
were	O
extracted	O
with	O
acetonitrile	B
followed	O
by	O
partitioning	O
at	O
-80	O
	O
C	O
for	O
5	O
-	O
10	O
min	O
.	O

A	O
YMC	O
C	O
(	O
8	O
)	O
column	O
was	O
used	O
to	O
separate	O
the	O
analytes	O
before	O
being	O
qualitatively	O
and	O
quantitatively	O
determined	O
by	O
liquid	O
chromatography	O
-	O
electrospray	O
ionization	O
tandem	O
mass	O
spectrometry	O
(	O
LC	O
-	O
ESI	O
-	O
MS	O
/	O
MS	O
)	O
in	O
positive	O
ion	O
mode	O
using	O
multiple	O
reaction	O
monitoring	O
(	O
MRM	O
)	O
.	O

The	O
matrix	O
-	O
matched	O
calibration	O
curves	O
showed	O
good	O
linearity	O
in	O
the	O
range	O
0.01	O
-	O
1.0	O
mg	O
/	O
kg	O
with	O
correlation	O
coefficients	O
in	O
excess	O
of	O
0.998	O
.	O

The	O
mean	O
recoveries	O
were	O
in	O
the	O
range	O
of	O
80.4	O
-	O
96.3	O
%	O
at	O
0.1	O
and	O
0.5	O
spiked	O
levels	O
,	O
and	O
the	O
relative	O
standard	O
deviations	O
(	O
RSDs	O
)	O
were	O
in	O
the	O
range	O
of	O
0.5	O
-	O
7.6	O
%	O
.	O

The	O
limits	O
of	O
quantifications	O
(	O
LOQ	O
)	O
were	O
in	O
the	O
range	O
of	O
0.005	O
-	O
0.01	O
mg	O
/	O
kg	O
.	O

The	O
method	O
was	O
successfully	O
applied	O
to	O
90	O
samples	O
(	O
among	O
which	O
45	O
were	O
organic	O
)	O
collected	O
from	O
a	O
commercial	O
bean	O
sprout	O
production	O
house	O
throughout	O
the	O
city	O
.	O

Except	O
for	O
6-BA	B
,	O
the	O
rest	O
of	O
the	O
analytes	O
had	O
values	O
lower	O
than	O
their	O
LOQs	O
.	O

In	O
sum	O
,	O
carbendazim	B
,	O
thiabendazole	B
,	O
and	O
6-BA	B
were	O
extracted	O
in	O
a	O
single	O
step	O
,	O
and	O
no	O
steps	O
for	O
clean	O
-	O
up	O
or	O
concentration	O
of	O
the	O
extracts	O
were	O
needed	O
.	O

The	O
current	O
method	O
can	O
be	O
used	O
for	O
sensitive	O
and	O
accurate	O
determination	O
and	O
confirmation	O
of	O
residues	O
in	O
bean	O
sprout	O
samples	O
.	O

Screening	O
of	O
whey	O
protein	O
isolate	O
hydrolysates	O
for	O
their	O
dual	O
functionality	O
:	O
influence	O
of	O
heat	O
pre	O
-	O
treatment	O
and	O
enzyme	O
specificity	O
.	O

Heat	O
pre	O
-	O
treated	O
and	O
non	O
heat	O
pre	O
-	O
treated	O
whey	O
protein	O
isolate	O
(	O
WPI	O
)	O
were	O
hydrolysed	O
using	O
	O
-	O
chymotrypsin	O
(	O
chymotrypsin	O
)	O
,	O
pepsin	O
and	O
trypsin	O
.	O

The	O
in	O
vitro	O
antioxidant	O
activity	O
,	O
ACE	O
-	O
inhibition	O
activity	O
and	O
surface	O
hydrophobicities	O
of	O
the	O
hydrolysates	O
were	O
measured	O
in	O
order	O
to	O
determine	O
if	O
peptides	O
with	O
dual	O
functionalities	O
were	O
present	O
.	O

Dual	O
functional	O
peptides	O
have	O
both	O
biological	O
(	O
e.g.	O
antioxidant	O
,	O
ACE	O
-	O
inhibition	O
,	O
opioid	O
activities	O
)	O
and	O
technological	O
(	O
e.g.	O
nanoemulsification	O
abilities	O
)	O
functions	O
in	O
food	O
systems	O
.	O

Heat	O
pre	O
-	O
treatment	O
marginally	O
enhanced	O
the	O
hydrolysis	O
of	O
WPI	O
by	O
pepsin	O
and	O
trypsin	O
but	O
had	O
no	O
effect	O
on	O
WPI	O
hydrolysis	O
with	O
chymotrypsin	O
.	O

With	O
the	O
exception	O
of	O
the	O
hydrolysis	O
by	O
trypsin	O
,	O
heat	O
pre	O
-	O
treatment	O
did	O
not	O
affect	O
the	O
peptide	O
profile	O
of	O
the	O
hydrolysates	O
as	O
analysed	O
using	O
size	O
exclusion	O
chromatography	O
,	O
or	O
the	O
antioxidant	O
activity	O
(	O
P>0.05	O
)	O
.	O

Heat	O
pre	O
-	O
treatment	O
significantly	O
affected	O
the	O
ACE	O
-	O
inhibition	O
activities	O
and	O
the	O
surface	O
hydrophobicities	O
of	O
the	O
hydrolysates	O
(	O
P<0.05	O
)	O
,	O
which	O
was	O
a	O
function	O
of	O
the	O
specificity	O
of	O
the	O
hydrolysing	O
enzyme	O
.	O

Extended	O
hydrolysis	O
(	O
up	O
to	O
24	O
h	O
)	O
had	O
no	O
significant	O
effect	O
on	O
the	O
DH	O
and	O
the	O
molecular	O
weight	O
profiles	O
(	O
P>0.05	O
)	O
but	O
in	O
some	O
instances	O
caused	O
a	O
reduction	O
in	O
the	O
antioxidant	O
activity	O
of	O
WPI	O
hydrolysates	O
.	O

The	O
chymotrypsin	O
hydrolysate	O
showed	O
a	O
broad	O
MW	O
size	O
range	O
,	O
and	O
was	O
followed	O
by	O
pepsin	O
and	O
then	O
trypsin	O
.	O

The	O
bioactivities	O
of	O
the	O
hydrolysates	O
generally	O
decreased	O
in	O
the	O
order	O
;	O
chymotrypsin	O
>	O
trypsin	O
>	O
pepsin	O
.	O

This	O
study	O
showed	O
that	O
by	O
manipulating	O
protein	O
conformation	O
with	O
pre	O
-	O
hydrolysis	O
heat	O
treatment	O
,	O
combined	O
with	O
careful	O
enzyme	O
selection	O
,	O
peptides	O
with	O
dual	O
functionalities	O
can	O
be	O
produced	O
from	O
WPI	O
for	O
use	O
as	O
functional	O
ingredients	O
in	O
the	O
manufacture	O
of	O
functional	O
foods	O
.	O

Purification	O
,	O
physicochemical	O
characterisation	O
and	O
anticancer	O
activity	O
of	O
a	O
polysaccharide	O
from	O
Cyclocarya	O
paliurus	O
leaves	O
.	O

A	O
Cyclocarya	O
paliurus	O
(	O
Batal	O
.	O
)	O

Iljinskaja	O
polysaccharide	O
(	O
CPP	O
)	O
was	O
isolated	O
and	O
purified	O
by	O
hot	O
water	O
extraction	O
,	O
ethanol	B
precipitation	O
,	O
deproteinisation	O
and	O
anion	O
-	O
exchange	O
chromatography	O
.	O

Its	O
physicochemical	O
properties	O
were	O
characterised	O
by	O
gel	O
permeation	O
chromatography	O
(	O
GPC	O
)	O
,	O
gas	O
chromatography	O
-	O
mass	O
spectrometry	O
(	O
GC	O
-	O
MS	O
)	O
,	O
thermal	O
gravimetric	O
analysis	O
(	O
TGA	O
)	O
,	O
Fourier	O
transform	O
infrared	O
spectrometry	O
(	O
FTIR	O
)	O
,	O
UV	O
-	O
visible	O
spectrophotometry	O
,	O
dynamic	O
light	O
scattering	O
(	O
DLS	O
)	O
and	O
viscometry	O
analysis	O
.	O

The	O
anticancer	O
effect	O
of	O
CPP	O
in	O
human	O
gastric	O
cancer	O
HeLa	O
cells	O
was	O
also	O
evaluated	O
by	O
3-	B
(	I
4,5-dimethylthiazol-2-yl	I
)	I
-2,5-diphenyltetrazolium	I
bromide	I
(	O
MTT	B
)	O
assay	O
.	O

The	O
results	O
showed	O
that	O
the	O
molecular	O
weight	O
of	O
CPP	O
was	O
900	O
kDa	O
,	O
and	O
it	O
contained	O
64.8	O
%	O
total	O
sugar	O
,	O
23.5	O
%	O
uronic	B
acid	I
,	O
9.26	O
%	O
protein	O
,	O
and	O
six	O
kinds	O
of	O
monosaccharides	B
,	O
including	O
glucose	B
,	O
rhamnose	B
,	O
arabinose	B
,	O
xylose	B
,	O
mannose	B
and	O
galactose	B
,	O
with	O
molar	O
percentages	O
of	O
32.7	O
%	O
,	O
9.33	O
%	O
,	O
30.6	O
%	O
,	O
3.48	O
%	O
,	O
10.4	O
%	O
,	O
and	O
13.5	O
%	O
,	O
respectively	O
.	O

Furthermore	O
,	O
the	O
results	O
showed	O
that	O
CPP	O
exhibited	O
a	O
strong	O
inhibition	O
effect	O
on	O
the	O
growth	O
of	O
human	O
gastric	O
cancer	O
HeLa	O
cells	O
.	O

Field	O
application	O
of	O
farm	O
-	O
food	O
safety	O
risk	O
assessment	O
(	O
FRAMp	O
)	O
tool	O
for	O
small	O
and	O
medium	O
fresh	O
produce	O
farms	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
develop	O
a	O
farm	O
food	O
safety	O
-	O
risk	O
assessment	O
tool	O
(	O
FRAMp	O
)	O
which	O
serves	O
as	O
a	O
self	O
-	O
assessment	O
and	O
educational	O
tool	O
for	O
fresh	O
produce	O
farms	O
.	O

FRAMp	O
was	O
developed	O
in	O
Microsoft	O
	O
Excel	O
spreadsheet	O
software	O
using	O
standard	O
mathematical	O
and	O
logical	O
functions	O
and	O
utilised	O
a	O
qualitative	O
risk	O
assessment	O
approach	O
for	O
farmers	O
to	O
evaluate	O
their	O
food	O
safety	O
practices	O
.	O

The	O
FRAMp	O
tool	O
has	O
since	O
been	O
tested	O
on	O
12	O
fresh	O
produce	O
farms	O
throughout	O
UK	O
.	O

All	O
the	O
farms	O
determined	O
that	O
FRAMp	O
was	O
interesting	O
but	O
17	O
%	O
found	O
it	O
too	O
long	O
while	O
25	O
%	O
of	O
the	O
farms	O
felt	O
the	O
tool	O
was	O
too	O
complicated	O
.	O

The	O
instructions	O
on	O
FRAMp	O
usage	O
were	O
revised	O
and	O
farmers	O
were	O
given	O
the	O
options	O
to	O
skip	O
and	O
select	O
specific	O
steps	O
in	O
the	O
farm	O
risk	O
assessment	O
.	O

The	O
end	O
users	O
(	O
farmers	O
/	O
farm	O
managers	O
)	O
determined	O
that	O
developing	O
their	O
own	O
action	O
plans	O
and	O
using	O
it	O
as	O
proof	O
of	O
assessment	O
for	O
future	O
third	O
-	O
party	O
audits	O
were	O
most	O
useful	O
to	O
them	O
.	O

FRAMp	O
tool	O
can	O
be	O
described	O
as	O
an	O
illustrative	O
risk	O
ranking	O
tool	O
to	O
facilitate	O
farms	O
to	O
identify	O
potential	O
risk	O
factors	O
during	O
their	O
crop	O
production	O
.	O

Synthesis	O
and	O
antiplasmodial	O
evaluation	O
of	O
novel	O
(	B
4-aminobutyloxy	I
)	I
quinolines	I
.	O

A	O
variety	O
of	O
5-	B
,	I
6-	I
and	I
8-	I
(	I
4-aminobutyloxy	I
)	I
quinolines	I
as	O
novel	O
oxygen	B
analogues	O
of	O
known	O
4-	B
and	I
8-	I
(	I
4-aminobutylamino	I
)	I
quinoline	I
antimalarial	O
drugs	O
was	O
generated	O
from	O
hydroxyquinolines	B
through	O
a	O
three	O
-	O
step	O
approach	O
with	O
a	O
rhodium	B
-	O
catalyzed	O
hydroformylation	O
as	O
the	O
key	O
step	O
.	O

Antiplasmodial	O
assays	O
of	O
these	O
new	O
quinolines	B
revealed	O
micromolar	O
potency	O
for	O
all	O
representatives	O
against	O
a	O
chloroquine	B
-	O
sensitive	O
strain	O
of	O
Plasmodium	O
falciparum	O
,	O
and	O
three	O
compounds	O
showed	O
submicromolar	O
activity	O
against	O
a	O
chloroquine	B
-	O
resistant	O
strain	O
of	O
P.	O
falciparum	O
with	O
IC	O
(	O
50	O
)	O
-values	O
ranging	O
between	O
150	O
and	O
680	O
nM.	O

Reproductive	O
experience	O
modifies	O
the	O
effects	O
of	O
estradiol	B
on	O
learning	O
and	O
memory	O
bias	O
in	O
female	O
rats	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
estrogen	B
affects	O
whether	O
a	O
hippocampus	O
-	O
mediated	O
place	O
(	O
allocentric	O
)	O
or	O
a	O
striatum	O
-	O
mediated	O
response	O
(	O
egocentric	O
)	O
memory	O
system	O
is	O
employed	O
by	O
female	O
rats	O
when	O
searching	O
for	O
a	O
food	O
reward	O
in	O
a	O
maze	O
.	O

Because	O
it	O
has	O
been	O
suggested	O
that	O
reproductive	O
experience	O
alters	O
some	O
of	O
the	O
responses	O
to	O
E	O
in	O
the	O
brain	O
,	O
two	O
experiments	O
were	O
carried	O
out	O
to	O
investigate	O
whether	O
reproductive	O
experience	O
would	O
also	O
alter	O
the	O
effect	O
of	O
E	O
on	O
place	O
and	O
response	O
learning	O
.	O

In	O
experiment	O
1	O
,	O
152	O
ovariectomized	O
nulliparous	O
(	O
n=77	O
;	O
no	O
reproductive	O
experience	O
)	O
and	O
primiparous	O
(	O
n=74	O
;	O
having	O
had	O
and	O
raised	O
one	O
litter	O
of	O
pups	O
)	O

Wistar	O
rats	O
were	O
trained	O
on	O
an	O
ambiguous	O
t	O
-	O
maze	O
task	O
and	O
tested	O
for	O
memory	O
system	O
bias	O
.	O

In	O
experiment	O
2	O
,	O
35	O
ovariectomized	O
nulliparous	O
(	O
n=16	O
)	O
and	O
primiparous	O
(	O
n=19	O
)	O
Wistar	O
rats	O
were	O
trained	O
on	O
place	O
and	O
response	O
plus	O
-	O
maze	O
tasks	O
.	O

All	O
rats	O
were	O
exposed	O
to	O
no	O
,	O
chronic	O
low	O
or	O
chronic	O
low	O
with	O
pulsatile	O
high	O
17	B
-	I
estradiol	I
(	O
E2	O
)	O
replacement	O
.	O

Congruent	O
with	O
previous	O
findings	O
,	O
low	O
E2	O
nulliparous	O
rats	O
showed	O
predominant	O
use	O
of	O
response	O
memory	O
and	O
faster	O
response	O
learning	O
,	O
whereas	O
high	O
E2	O
nulliparous	O
rats	O
showed	O
a	O
trend	O
towards	O
predominant	O
place	O
memory	O
use	O
.	O

Interestingly	O
,	O
the	O
facilitatory	O
effect	O
of	O
low	O
E2	O
on	O
response	O
task	O
learning	O
and	O
memory	O
seen	O
in	O
nulliparous	O
rats	O
was	O
not	O
observed	O
in	O
low	O
E2	O
primiparous	O
rats	O
in	O
either	O
experiment	O
.	O

In	O
conclusion	O
,	O
E2	O
levels	O
do	O
dictate	O
the	O
rate	O
at	O
which	O
female	O
rats	O
learn	O
a	O
response	O
task	O
and	O
utilize	O
response	O
memory	O
,	O
but	O
only	O
in	O
those	O
with	O
no	O
reproductive	O
experience	O
.	O

Ubiquitin	O
-	O
dependent	O
regulation	O
of	O
phospho	B
-	O
AKT	O
dynamics	O
by	O
the	O
ubiquitin	O
E3	O
ligase	O
,	O
NEDD4	O
-	O
1	O
,	O
in	O
the	O
insulin	O
-	O
like	O
growth	O
factor-1	O
response	O
.	O

AKT	O
is	O
a	O
critical	O
effector	O
kinase	O
downstream	O
of	O
the	O
PI3	O
K	O
pathway	O
that	O
regulates	O
a	O
plethora	O
of	O
cellular	O
processes	O
including	O
cell	O
growth	O
,	O
death	O
,	O
differentiation	O
,	O
and	O
migration	O
.	O

Mechanisms	O
underlying	O
activated	O
phospho	B
-	O
AKT	O
(	O
pAKT	O
)	O
translocation	O
to	O
its	O
action	O
sites	O
remain	O
unclear	O
.	O

Here	O
we	O
show	O
that	O
NEDD4	O
-	O
1	O
is	O
a	O
novel	O
E3	O
ligase	O
that	O
specifically	O
regulates	O
ubiquitin	O
-	O
dependent	O
trafficking	O
of	O
pAKT	O
in	O
insulin	O
-	O
like	O
growth	O
factor	O
(	O
IGF	O
)	O
-1	O
signaling	O
.	O

NEDD4	O
-	O
1	O
physically	O
interacts	O
with	O
AKT	O
and	O
promotes	O
HECT	O
domain	O
-	O
dependent	O
ubiquitination	O
of	O
exogenous	O
and	O
endogenous	O
AKT	O
.	O

NEDD4	O
-	O
1	O
catalyzes	O
K63-type	O
polyubiquitin	O
chain	O
formation	O
on	O
AKT	O
in	O
vitro	O
.	O

Plasma	O
membrane	O
binding	O
is	O
the	O
key	O
step	O
for	O
AKT	O
ubiquitination	O
by	O
NEDD4	O
-	O
1	O
in	O
vivo	O
.	O

Ubiquitinated	O
pAKT	O
translocates	O
to	O
perinuclear	O
regions	O
,	O
where	O
it	O
is	O
released	O
into	O
the	O
cytoplasm	O
,	O
imported	O
into	O
the	O
nucleus	O
,	O
or	O
coupled	O
with	O
proteasomal	O
degradation	O
.	O

IGF-1	O
signaling	O
specifically	O
stimulates	O
NEDD4	O
-	O
1-mediated	O
ubiquitination	O
of	O
pAKT	O
,	O
without	O
altering	O
total	O
AKT	O
ubiquitination	O
.	O

A	O
cancer	O
-	O
derived	O
plasma	O
membrane	O
-	O
philic	O
mutant	O
AKT	O
(	O
E17	O
K	O
)	O
is	O
more	O
effectively	O
ubiquitinated	O
by	O
NEDD4	O
-	O
1	O
and	O
more	O
efficiently	O
trafficked	O
into	O
the	O
nucleus	O
compared	O
with	O
wild	O
type	O
AKT	O
.	O

This	O
study	O
reveals	O
a	O
novel	O
mechanism	O
by	O
which	O
a	O
specific	O
E3	O
ligase	O
is	O
required	O
for	O
ubiquitin	O
-	O
dependent	O
control	O
of	O
pAKT	O
dynamics	O
in	O
a	O
ligand	O
-	O
specific	O
manner	O
.	O

Identification	O
of	O
transporters	O
associated	O
with	O
Etoposide	B
sensitivity	O
of	O
stomach	O
cancer	O
cell	O
lines	O
and	O
methotrexate	B
sensitivity	O
of	O
breast	O
cancer	O
cell	O
lines	O
by	O
quantitative	O
targeted	O
absolute	O
proteomics	O
.	O

Membrane	O
transporter	O
proteins	O
may	O
influence	O
the	O
sensitivity	O
of	O
cancer	O
cells	O
to	O
anticancer	O
drugs	O
that	O
can	O
be	O
recognized	O
as	O
substrates	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
identify	O
proteins	O
that	O
play	O
a	O
key	O
role	O
in	O
the	O
drug	O
sensitivity	O
of	O
stomach	O
and	O
breast	O
cancer	O
cell	O
lines	O
by	O
measuring	O
the	O
absolute	O
protein	O
expression	O
levels	O
of	O
multiple	O
transporters	O
and	O
other	O
membrane	O
proteins	O
and	O
examining	O
their	O
correlation	O
to	O
drug	O
sensitivity	O
.	O

Absolute	O
protein	O
expression	O
levels	O
of	O
90	O
membrane	O
proteins	O
were	O
examined	O
by	O
quantitative	O
targeted	O
absolute	O
proteomics	O
using	O
liquid	O
chromatography	O
-	O
linked	O
tandem	O
mass	O
spectrometry	O
.	O

Among	O
them	O
,	O
11	O
and	O
14	O
membrane	O
proteins	O
,	O
including	O
transporters	O
,	O
were	O
present	O
in	O
quantifiable	O
amounts	O
in	O
membrane	O
fraction	O
of	O
stomach	O
cancer	O
and	O
breast	O
cancer	O
cell	O
lines	O
,	O
respectively	O
.	O

In	O
stomach	O
cancer	O
cell	O
lines	O
,	O
the	O
protein	O
expression	O
level	O
of	O
multidrug	O
resistance	O
-	O
associated	O
protein	O
1	O
(	O
MRP1	O
)	O
was	O
inversely	O
correlated	O
with	O
etoposide	B
sensitivity	O
.	O

MK571	B
,	O
an	O
MRP	O
inhibitor	O
,	O
increased	O
both	O
the	O
cell	O
-	O
to	O
-	O
medium	O
ratio	O
of	O
etoposide	O
and	O
the	O
etoposide	O
sensitivity	O
of	O
MRP1-expressing	O
stomach	O
cancer	O
cell	O
lines	O
.	O

In	O
breast	O
cancer	O
cell	O
lines	O
,	O
the	O
protein	O
expression	O
level	O
of	O
reduced	O
folate	O
carrier	O
1	O
(	O
RFC1	O
)	O
was	O
directly	O
correlated	O
with	O
methotrexate	B
(	O
MTX	B
)	O
sensitivity	O
.	O

Initial	O
uptake	O
rate	O
and	O
steady	O
-	O
state	O
cell	O
-	O
to	O
-	O
medium	O
ratio	O
of	O
[	B
(	I
3	I
)	I
H	I
]	I
MTX	I
were	O
correlated	O
with	O
both	O
RFC1	O
expression	O
level	O
and	O
MTX	B
sensitivity	O
.	O

These	O
results	O
suggest	O
that	O
MRP1	O
modulates	O
the	O
etoposide	B
sensitivity	O
of	O
stomach	O
cancer	O
cell	O
lines	O
and	O
RFC1	O
modulates	O
the	O
MTX	B
sensitivity	O
of	O
breast	O
cancer	O
cell	O
lines	O
.	O

Our	O
results	O
indicate	O
that	O
absolute	O
quantification	O
of	O
multiple	O
membrane	O
proteins	O
could	O
be	O
a	O
useful	O
strategy	O
for	O
identification	O
of	O
candidate	O
proteins	O
involved	O
in	O
drug	O
sensitivity	O
.	O

Assessment	O
of	O
immunotoxicity	O
using	O
precision	O
-	O
cut	O
tissue	O
slices	O
.	O

1.When	O
the	O
immune	O
system	O
encounters	O
incoming	O
infectious	O
agents	O
,	O
this	O
generally	O
leads	O
to	O
immunity	O
.	O

The	O
evoked	O
immune	O
response	O
is	O
usually	O
robust	O
,	O
but	O
can	O
be	O
severely	O
perturbed	O
by	O
potentially	O
harmful	O
environmental	O
agents	O
such	O
as	O
chemicals	O
,	O
pharmaceuticals	O
and	O
allergens	O
.	O

2.Immunosuppression	O
,	O
hypersensitivity	O
and	O
autoimmunity	O
may	O
occur	O
due	O
to	O
changed	O
immune	O
activity	O
.	O

Evaluation	O
of	O
the	O
immunotoxic	O
potency	O
of	O
agents	O
as	O
part	O
of	O
risk	O
assessment	O
is	O
currently	O
established	O
in	O
vivo	O
with	O
animal	O
models	O
and	O
in	O
vitro	O
with	O
cell	O
lines	O
or	O
primary	O
cells	O
.	O

3.Although	O
in	O
vivo	O
testing	O
is	O
usually	O
the	O
most	O
relevant	O
situation	O
for	O
many	O
agents	O
,	O
more	O
and	O
more	O
in	O
vitro	O
models	O
are	O
being	O
developed	O
for	O
assessment	O
of	O
immunotoxicity	O
.	O

In	O
this	O
context	O
,	O
hypersensitivity	O
and	O
immunosuppression	O
are	O
considered	O
to	O
be	O
a	O
primary	O
focus	O
for	O
developing	O
in	O
vitro	O
methods	O
.	O

Three	O
-	O
dimensional	O
organotypic	O
tissue	O
models	O
are	O
also	O
part	O
of	O
current	O
research	O
in	O
immunotoxicology	O
.	O

4.In	O
recent	O
years	O
,	O
there	O
has	O
been	O
a	O
revival	O
of	O
interest	O
in	O
organotypic	O
tissue	O
models	O
.	O

In	O
the	O
context	O
of	O
immunotoxicity	O
testing	O
,	O
precision	O
-	O
cut	O
lung	O
slices	O
in	O
particular	O
have	O
been	O
intensively	O
studied	O
.	O

Therefore	O
,	O
this	O
review	O
is	O
very	O
much	O
focused	O
on	O
pulmonary	O
immunotoxicology	O
.	O

Respiratory	O
hypersensitivity	O
and	O
inflammation	O
are	O
further	O
highlighted	O
aspects	O
of	O
this	O
review	O
.	O

Immunotoxicity	O
assessment	O
currently	O
is	O
of	O
limited	O
use	O
in	O
other	O
tissue	O
models	O
,	O
which	O
are	O
therefore	O
described	O
only	O
briefly	O
within	O
this	O
review	O
.	O

Recently	O
introduced	O
foods	O
as	O
new	O
allergenic	O
sources	O
:	O
sensitisation	O
to	O
Goji	O
berries	O
(	O
Lycium	O
barbarum	O
)	O
.	O

Goji	O
berries	O
(	O
GB	O
)	O
have	O
been	O
introduced	O
in	O
Western	O
diet	O
.	O

Preliminary	O
reports	O
have	O
demonstrated	O
its	O
allergenic	O
capacity	O
.	O

The	O
objectives	O
of	O
the	O
study	O
were	O
to	O
investigate	O
the	O
frequency	O
of	O
sensitisation	O
and	O
the	O
allergens	O
involved	O
.	O

566	O
individuals	O
,	O
with	O
respiratory	O
or	O
cutaneous	O
symptoms	O
were	O
skin	O
-	O
prick	O
tested	O
with	O
GB	O
extract	O
.	O

Thirty	O
three	O
were	O
positive	O
(	O
5.8	O
%	O
)	O
.	O

94	O
%	O
were	O
sensitised	O
to	O
other	O
allergens	O
.	O

Specific	O
IgE	O
to	O
GB	O
,	O
peach	O
,	O
tomato	O
and	O
nut	O
-	O
mix	O
was	O
measured	O
.	O

Thirteen	O
individuals	O
from	O
24	O
available	O
sera	O
(	O
54.2	O
%	O
)	O
had	O
positive	O
specific	O
IgE.	O
92.3	O
%	O
of	O
GB	O
positive	O
patients	O
were	O
positive	O
to	O
peach	O
.	O

Seven	O
individuals	O
recognised	O
8	O
bands	O
and	O
six	O
recognised	O
a	O
7kDa	O
band	O
.	O

This	O
band	O
was	O
identified	O
as	O
a	O
LTP	O
by	O
MS	O
/	O
MS	O
.	O

Cross	O
-	O
reactivity	O
was	O
demonstrated	O
with	O
tomato	O
,	O
tobacco	O
,	O
nutmix	O
,	O
Artemisia	O
pollen	O
and	O
purified	O
Lyc	O
e	O
3	O
and	O
Pru	O
p	O
3	O
.	O

GB	O
are	O
a	O
new	O
allergenic	O
source	O
with	O
high	O
prevalence	O
of	O
sensitisation	O
.	O

LTP	O
seems	O
to	O
be	O
the	O
major	O
allergen	O
involved	O
in	O
sensitisation	O
and	O
cross	O
-	O
reactivity	O
.	O

Inhibitors	O
of	O
HIV-1	O
attachment	O
.	O

Part	O
10	O
.	O

The	O
discovery	O
and	O
structure	O
-	O
activity	O
relationships	O
of	O
4-azaindole	B
cores	O
.	O

A	O
series	O
of	O
4-azaindole	B
oxoacetic	I
acid	I
piperazine	I
benzamides	I
was	O
synthesized	O
and	O
evaluated	O
in	O
an	O
effort	O
to	O
identify	O
an	O
oral	O
HIV-1	O
attachment	O
inhibitor	O
with	O
the	O
potential	O
to	O
improve	O
upon	O
the	O
pre	O
-	O
clinical	O
profile	O
of	O
BMS-378806	B
(	O
7	O
)	O
,	O
an	O
initial	O
clinical	O
compound	O
.	O

Modifications	O
at	O
the	O
7-position	O
of	O
the	O
4-azaindole	B
core	O
modulated	O
potency	O
significantly	O
and	O
SAR	O
showed	O
that	O
certain	O
compounds	O
with	O
a	O
5-membered	O
ring	O
heteroaryl	O
group	O
at	O
that	O
position	O
were	O
the	O
most	O
potent	O
.	O

Four	O
of	O
the	O
compounds	O
with	O
the	O
best	O
profiles	O
were	O
evaluated	O
in	O
a	O
rat	O
pharmacokinetic	O
model	O
and	O
all	O
had	O
superior	O
oral	O
bioavailability	O
and	O
lower	O
clearance	O
when	O
compared	O
with	O
7	O
.	O

Phosphodiesterase	O
inhibitors	O
.	O

Part	O
5	O
:	O
hybrid	O
PDE3	O
/	O
4	O
inhibitors	O
as	O
dual	O
bronchorelaxant	O
/	O
anti	O
-	O
inflammatory	O
agents	O
for	O
inhaled	O
administration	O
.	O

(	B
-	I
)	I
-6-	I
(	I
7-Methoxy-2-	I
(	I
trifluoromethyl	I
)	I
pyrazolo	I
[	I
1,5-a	I
]	I
pyridin-4-yl	I
)	I
-5-methyl-4,5-dihydropyridazin-3	I
(	I
2H	I
)	I
-one	I
(	O
KCA-1490	B
)	O
exhibits	O
moderate	O
dual	O
PDE3	O
/	O
4-inhibitory	O
activity	O
and	O
promises	O
as	O
a	O
combined	O
bronchodilatory	O
/	O
anti	O
-	O
inflammatory	O
agent	O
.	O

N	O
-	O
alkylation	O
of	O
the	O
pyridazinone	B
ring	O
markedly	O
enhances	O
potency	O
against	O
PDE4	O
but	O
suppresses	O
PDE3	O
inhibition	O
.	O

Addition	O
of	O
a	O
6-aryl-4,5-dihydropyridazin-3	B
(	I
2H	I
)	I
-one	I
extension	O
to	O
the	O
N	O
-	O
alkyl	O
group	O
facilitates	O
both	O
enhancement	O
of	O
PDE4-inhibitory	O
activity	O
and	O
restoration	O
of	O
potent	O
PDE3	O
inhibition	O
.	O

Both	O
dihydropyridazinone	B
rings	O
,	O
in	O
the	O
core	O
and	O
extension	O
,	O
can	O
be	O
replaced	O
by	O
achiral	O
4,4-dimethylpyrazolone	B
subunits	O
and	O
the	O
core	O
pyrazolopyridine	B
by	O
isosteric	O
bicyclic	O
heteroaromatics	O
.	O

In	O
combination	O
,	O
these	O
modifications	O
afford	O
potent	O
dual	O
PDE3	O
/	O
4	O
inhibitors	O
that	O
suppress	O
histamine	B
-	O
induced	O
bronchoconstriction	O
in	O
vivo	O
and	O
exhibit	O
promising	O
anti	O
-	O
inflammatory	O
activity	O
via	O
intratracheal	O
administration	O
.	O

Effects	O
of	O
pubertal	O
exposure	O
to	O
thiazole	B
-	O
Zn	B
on	O
thyroid	O
function	O
and	O
development	O
in	O
female	O
rats	O
.	O

Thiazole	B
-	O
Zn	B
is	O
a	O
newly	O
Chinese	O
-	O
created	O
systemic	O
fungicide	O
,	O
and	O
belongs	O
to	O
the	O
sort	O
of	O
thiadiazole	B
compounds	O
,	O
some	O
of	O
which	O
have	O
been	O
found	O
to	O
be	O
thyroid	O
disrupters	O
.	O

To	O
determine	O
the	O
probable	O
adverse	O
effects	O
of	O
thiazole	B
-	O
Zn	B
on	O
thyroid	O
gland	O
and	O
development	O
function	O
,	O
the	O
rodent	O
20-day	O
Pubertal	O
Female	O
Assay	O
in	O
this	O
study	O
was	O
used	O
.	O

Postnatal	O
days	O
(	O
PND	O
)	O
22-old	O
Sprague	O
-	O
Dawley	O
rats	O
were	O
administered	O
with	O
thiazole	B
-	O
Zn	B
daily	O
by	O
oral	O
gavage	O
at	O
doses	O
0	O
,	O
40	O
,	O
100	O
,	O
200	O
mg	O
/	O
kg	O
/	O
day	O
for	O
20	O
days	O
.	O

The	O
thyroid	O
endpoints	O
and	O
development	O
endpoints	O
were	O
assessed	O
.	O

The	O
results	O
indicated	O
that	O
serum	O
TT4	O
and	O
TSH	O
levels	O
were	O
significantly	O
increased	O
at	O
all	O
concentrations	O
,	O
serum	O
TT3	O
levels	O
were	O
significantly	O
reduced	O
only	O
at	O
40	O
mg	O
/	O
kg	O
thiazole	B
-	O
Zn	B
,	O
but	O
had	O
no	O
difference	O
from	O
controls	O
at	O
the	O
other	O
doses	O
.	O

Thyroid	O
histology	O
was	O
significantly	O
altered	O
at	O
all	O
doses	O
with	O
a	O
clear	O
dose	O
-	O
dependent	O
hypertrophy	O
and	O
hyperplasia	O
of	O
thyroid	O
cell	O
.	O

No	O
histological	O
changes	O
were	O
observed	O
in	O
any	O
of	O
the	O
other	O
observed	O
organs	O
.	O

In	O
addition	O
,	O
this	O
study	O
also	O
found	O
that	O
ovarian	O
weights	O
were	O
significantly	O
decreased	O
,	O
but	O
age	O
and	O
weight	O
at	O
vaginal	O
opening	O
(	O
VO	O
)	O
,	O
serum	O
E2	O
levels	O
were	O
unaffected	O
in	O
all	O
treatment	O
groups	O
.	O

These	O
results	O
demonstrate	O
that	O
thiazole	B
-	O
Zn	B
is	O
likely	O
a	O
thyroid	O
disrupter	O
,	O
but	O
did	O
not	O
demonstrate	O
that	O
it	O
has	O
estrogenic	O
/	O
anti	O
-	O
estrogenic	O
activity	O
.	O

A	O
10-minute	O
point	O
-	O
of	O
-	O
care	O
assay	O
for	O
detection	O
of	O
blood	O
protein	O
adducts	O
resulting	O
from	O
low	O
level	O
exposure	O
to	O
organophosphate	B
nerve	O
agents	O
.	O

The	O
OrganoTox	O
test	O
is	O
a	O
rapid	O
,	O
point	O
-	O
of	O
-	O
care	O
assay	O
capable	O
of	O
detecting	O
clinically	O
relevant	O
organophosphate	B
(	O
OP	O
)	O
poisoning	O
after	O
low	O
-	O
level	O
exposure	O
to	O
sarin	B
,	O
soman	B
,	O
tabun	B
,	O
or	O
VX	O
chemical	O
nerve	O
agents	O
.	O

The	O
test	O
utilizes	O
either	O
a	O
finger	O
stick	O
peripheral	O
blood	O
sample	O
or	O
plasma	O
specimen	O
.	O

While	O
high	O
-	O
level	O
nerve	O
agent	O
exposure	O
can	O
quickly	O
lead	O
to	O
death	O
,	O
low	O
-	O
level	O
exposure	O
produces	O
vague	O
,	O
nondescript	O
signs	O
and	O
symptoms	O
that	O
are	O
not	O
easily	O
clinically	O
differentiated	O
from	O
other	O
conditions	O
.	O

In	O
initial	O
testing	O
,	O
the	O
OrganoTox	O
test	O
was	O
used	O
to	O
detect	O
the	O
presence	O
of	O
blood	O
protein	O
-	O
nerve	O
agent	O
adducts	O
in	O
exposed	O
blood	O
samples	O
.	O

In	O
order	O
to	O
mimic	O
the	O
in	O
vivo	O
exposure	O
as	O
closely	O
as	O
possible	O
,	O
nerve	O
agents	O
stored	O
in	O
organic	O
solvents	O
were	O
spiked	O
in	O
minute	O
quantities	O
into	O
whole	O
blood	O
samples	O
.	O

For	O
performance	O
testing	O
,	O
40	O
plasma	O
samples	O
were	O
spiked	O
with	O
sarin	B
,	O
soman	B
,	O
tabun	B
,	O
or	O
VX	O
and	O
10	O
normal	O
plasma	O
samples	O
were	O
used	O
as	O
the	O
negative	O
control	O
.	O

The	O
40	O
nerve	O
agent	O
-	O
spiked	O
plasma	O
samples	O
included	O
10	O
replicates	O
of	O
each	O
agent	O
.	O

At	O
the	O
clinically	O
relevant	O
low	O
-	O
level	O
exposure	O
of	O
10ng	O
/	O
ml	O
,	O
the	O
OrganoTox	O
test	O
demonstrated	O
100	O
%	O
sensitivity	O
for	O
soman	B
,	O
tabun	B
,	O
and	O
VX	O
and	O
80	O
%	O
sensitivity	O
for	O
sarin	B
.	O

The	O
OrganoTox	O
test	O
demonstrated	O
greater	O
than	O
97	O
%	O
specificity	O
with	O
150	O
blood	O
samples	O
obtained	O
from	O
healthy	O
adults	O
.	O

No	O
cross	O
-	O
reactivity	O
or	O
interference	O
from	O
pesticide	O
precursor	O
compounds	O
was	O
found	O
.	O

A	O
rapid	O
test	O
for	O
nerve	O
agent	O
exposure	O
will	O
help	O
identify	O
affected	O
patients	O
earlier	O
in	O
the	O
clinical	O
course	O
and	O
trigger	O
more	O
appropriate	O
medical	O
management	O
in	O
a	O
more	O
timely	O
manner	O
.	O

Altered	O
expression	O
of	O
genes	O
involved	O
in	O
progesterone	B
biosynthesis	O
,	O
metabolism	O
and	O
action	O
in	O
endometrial	O
cancer	O
.	O

Endometrial	O
cancer	O
(	O
EC	O
)	O
is	O
one	O
of	O
the	O
most	O
common	O
gynecological	O
malignancies	O
worldwide	O
.	O

It	O
is	O
associated	O
with	O
prolonged	O
exposure	O
to	O
estrogens	O
that	O
is	O
unopposed	O
by	O
the	O
protective	O
effects	O
of	O
progesterone	B
,	O
which	O
suggests	O
that	O
altered	O
progesterone	B
biosynthesis	O
,	O
metabolism	O
and	O
actions	O
might	O
be	O
implicated	O
in	O
the	O
development	O
of	O
EC	O
.	O

Our	O
aim	O
was	O
to	O
evaluate	O
these	O
processes	O
through	O
quantitative	O
real	O
-	O
time	O
PCR	O
expression	O
analysis	O
in	O
up	O
to	O
47	O
pairs	O
of	O
EC	O
tissue	O
and	O
adjacent	O
control	O
endometrium	O
.	O

First	O
,	O
we	O
examined	O
the	O
expression	O
of	O
genes	O
encoding	O
proteins	O
associated	O
with	O
progesterone	B
biosynthesis	O
:	O
steroidogenic	O
acute	O
regulatory	O
protein	O
(	O
STAR	O
)	O
;	O
a	O
side	O
chain	O
cleavage	O
enzyme	O
(	O
CYP11A1	O
)	O
;	O
and	O
3	B
-	I
hydroxysteroid	I
dehydrogenase	O
/	O
ketosteroid	B
isomerase	O
(	O
HSD3B	O
)	O
.	O

There	O
were	O
1.9-	O
and	O
10.0-fold	O
decreased	O
expression	O
of	O
STAR	O
and	O
CYP11A1	O
,	O
respectively	O
,	O
in	O
EC	O
versus	O
adjacent	O
control	O
endometrium	O
,	O
with	O
no	O
significant	O
differences	O
in	O
the	O
expression	O
of	O
HSD3B1	O
and	O
HSD3B2	O
.	O

Next	O
,	O
we	O
examined	O
expression	O
of	O
genes	O
encoding	O
five	O
progesterone	B
metabolizing	O
enzymes	O
:	O
the	O
3-keto	B
and	I
20-ketosteroid	I
reductases	O
(	O
AKR1C1-AKR1C3	O
)	O
and	O
5	O
-	O
reductases	O
(	O
SRD5A1	O
and	O
SRD5A2	O
)	O
;	O
and	O
the	O
opposing	O
20	B
-	I
hydroxysteroid	I
dehydrogenase	O
(	O
HSD17B2	O
)	O
.	O

These	O
genes	O
are	O
expressed	O
in	O
EC	O
and	O
adjacent	O
control	O
endometrium	O
.	O

No	O
statistically	O
significant	O
differences	O
were	O
seen	O
in	O
mRNA	O
levels	O
of	O
AKR1C1	O
,	O
AKR1C2	O
,	O
AKR1C3	O
and	O
SRD5A1	O
.	O

Expression	O
of	O
HSD17B2	O
was	O
3.0-fold	O
increased	O
,	O
and	O
expression	O
of	O
SRD5A2	O
was	O
3.7-fold	O
decreased	O
,	O
in	O
EC	O
versus	O
adjacent	O
control	O
endometrium	O
.	O

We	O
also	O
examined	O
mRNA	O
levels	O
of	O
progesterone	B
receptors	O
A	O
and	O
B	O
(	O
PGR	O
)	O
,	O
and	O
separately	O
the	O
expression	O
of	O
progesterone	B
receptor	O
B	O
(	O
PR	O
-	O
B	O
)	O
.	O

Here	O
we	O
saw	O
1.8-	O
and	O
2.0-fold	O
lower	O
mRNA	O
levels	O
of	O
PGR	O
and	O
PR	O
-	O
B	O
,	O
respectively	O
,	O
in	O
EC	O
versus	O
adjacent	O
control	O
endometrium	O
.	O

This	O
down	O
-	O
regulation	O
of	O
STAR	O
,	O
CYP11A1	O
and	O
PGR	O
in	O
endometrial	O
cancer	O
may	O
lead	O
to	O
decreased	O
progesterone	B
biosynthesis	O
and	O
actions	O
although	O
the	O
effects	O
on	O
progesterone	B
levels	O
should	O
be	O
further	O
studied	O
.	O

Origin	O
and	O
evolution	O
of	O
medium	O
chain	O
alcohol	B
dehydrogenases	O
.	O

Different	O
lines	O
of	O
alcohol	B
dehydrogenases	O
(	O
ADHs	O
)	O
have	O
separate	O
superfamily	O
origins	O
,	O
already	O
recognized	O
but	O
now	O
extended	O
and	O
re	O
-	O
evaluated	O
by	O
re	O
-	O
screening	O
of	O
the	O
latest	O
databank	O
update	O
.	O

The	O
short	O
-	O
chain	O
form	O
(	O
SDR	O
)	O
is	O
still	O
the	O
superfamily	O
with	O
most	O
abundant	O
occurrence	O
,	O
most	O
multiple	O
divergence	O
,	O
most	O
prokaryotic	O
emphasis	O
,	O
and	O
most	O
non	O
-	O
complicated	O
architecture	O
.	O

This	O
pattern	O
is	O
compatible	O
with	O
an	O
early	O
appearance	O
at	O
the	O
time	O
of	O
the	O
emergence	O
of	O
prokaryotic	O
cellular	O
life	O
.	O

The	O
medium	O
-	O
chain	O
form	O
(	O
MDR	O
)	O
is	O
also	O
old	O
but	O
second	O
in	O
terms	O
of	O
all	O
the	O
parameters	O
above	O
,	O
and	O
therefore	O
compatible	O
with	O
a	O
second	O
emergence	O
.	O

However	O
,	O
this	O
step	O
appears	O
seemingly	O
earlier	O
than	O
previously	O
considered	O
,	O
and	O
may	O
indicate	O
sub	O
-	O
stages	O
of	O
early	O
emergences	O
at	O
the	O
increased	O
resolution	O
available	O
from	O
the	O
now	O
greater	O
number	O
of	O
data	O
entries	O
.	O

The	O
Zn	B
-	O
MDR	O
origin	O
constitutes	O
a	O
third	O
stage	O
,	O
possibly	O
compatible	O
with	O
the	O
transition	O
to	O
oxidative	O
conditions	O
on	O
earth	O
.	O

Within	O
all	O
these	O
three	O
lines	O
,	O
repeated	O
enzymogeneses	O
gave	O
the	O
present	O
divergence	O
.	O

MDR	O
-	O
ADH	O
origin	O
(	O
s	O
)	O
,	O
at	O
a	O
fourth	O
stage	O
,	O
may	O
also	O
be	O
further	O
resolved	O
in	O
multiple	O
or	O
extended	O
modes	O
,	O
but	O
the	O
classical	O
liver	O
MDR	O
-	O
ADH	O
of	O
the	O
liver	O
type	O
can	O
still	O
be	O
traced	O
to	O
a	O
gene	O
duplication	O
~550	O
MYA	O
(	O
million	O
years	O
ago	O
)	O
,	O
at	O
the	O
early	O
vertebrate	O
radiation	O
,	O
compatible	O
with	O
the	O
post	O
-	O
eon	O
-	O
shift	O
,	O
"	O
Cambrian	O
explosion	O
"	O
.	O

Classes	O
and	O
isozymes	O
correspond	O
to	O
subsequent	O
and	O
recent	O
duplicatory	O
events	O
,	O
respectively	O
.	O

They	O
illustrate	O
a	O
peculiar	O
pattern	O
with	O
functional	O
and	O
emerging	O
evolutionary	O
distinctions	O
between	O
parent	O
and	O
emerging	O
lines	O
,	O
suggesting	O
a	O
parallelism	O
between	O
duplicatory	O
and	O
mutational	O
events	O
,	O
now	O
also	O
visible	O
at	O
separate	O
sub	O
-	O
stages	O
.	O

Combined	O
,	O
all	O
forms	O
show	O
distinctive	O
patterns	O
at	O
different	O
levels	O
and	O
illustrate	O
correlations	O
with	O
global	O
events	O
.	O

They	O
further	O
show	O
that	O
simple	O
molecular	O
observations	O
on	O
patterns	O
,	O
multiplicities	O
and	O
occurrence	O
give	O
much	O
information	O
,	O
suggesting	O
common	O
divergence	O
rules	O
not	O
much	O
disturbed	O
by	O
horizontal	O
gene	O
transfers	O
after	O
the	O
initial	O
origins	O
.	O

Reduced	O
plasma	O
oxytocin	B
levels	O
in	O
female	O
patients	O
with	O
borderline	O
personality	O
disorder	O
.	O

The	O
neuropeptide	O
oxytocin	B
is	O
involved	O
in	O
social	O
cognition	O
and	O
interaction	O
across	O
species	O
and	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
regulation	O
of	O
affiliative	O
behaviors	O
.	O

Oxytocin	B
levels	O
in	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
,	O
but	O
also	O
in	O
plasma	O
or	O
urine	O
,	O
have	O
been	O
shown	O
to	O
be	O
negatively	O
associated	O
with	O
childhood	O
traumata	O
,	O
aggressive	O
behavior	O
,	O
and	O
suicide	O
attempts	O
.	O

Recently	O
,	O
an	O
altered	O
activity	O
of	O
the	O
oxytocin	B
system	O
has	O
been	O
discussed	O
to	O
play	O
a	O
prominent	O
role	O
in	O
borderline	O
personality	O
disorder	O
(	O
BPD	O
)	O
,	O
which	O
is	O
thought	O
to	O
be	O
closely	O
related	O
to	O
traumatic	O
experiences	O
in	O
childhood	O
and	O
is	O
characterized	O
by	O
(	O
para	O
)	O
suicidal	O
behaviors	O
as	O
well	O
as	O
aggressive	O
outbursts	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
compared	O
plasma	O
oxytocin	B
levels	O
of	O
women	O
with	O
and	O
without	O
BPD	O
in	O
the	O
follicular	O
phase	O
and	O
assessed	O
the	O
relationship	O
between	O
oxytocin	B
concentrations	O
and	O
childhood	O
traumata	O
.	O

Women	O
diagnosed	O
with	O
BPD	O
had	O
significantly	O
reduced	O
oxytocin	B
concentrations	O
,	O
even	O
after	O
controlling	O
for	O
estrogen	B
,	O
progesterone	B
,	O
and	O
contraceptive	O
intake	O
.	O

In	O
addition	O
,	O
plasma	O
oxytocin	B
correlated	O
negatively	O
with	O
experiences	O
of	O
childhood	O
traumata	O
,	O
in	O
particular	O
with	O
emotional	O
neglect	O
and	O
abuse	O
.	O

The	O
results	O
of	O
mediation	O
analyses	O
do	O
not	O
support	O
a	O
model	O
of	O
oxytocin	B
being	O
a	O
prominent	O
mediator	O
in	O
the	O
link	O
between	O
childhood	O
trauma	O
and	O
BPD	O
.	O

Thus	O
,	O
the	O
findings	O
indicate	O
dysregulations	O
in	O
the	O
oxytocin	B
system	O
of	O
patients	O
diagnosed	O
with	O
BPD	O
with	O
more	O
longitudinal	O
research	O
being	O
necessary	O
to	O
disentangle	O
the	O
relationship	O
between	O
childhood	O
adversities	O
,	O
oxytocin	B
system	O
,	O
and	O
psychopathology	O
.	O

Antimutagenic	O
evaluation	O
of	O
vitamins	B
B1	I
,	I
B6	I
and	I
B12	I
in	O
vitro	O
and	O
in	O
vivo	O
,	O
with	O
the	O
Ames	O
test	O
.	O

The	O
aim	O
of	O
this	O
work	O
is	O
to	O
evaluate	O
vitamins	B
B	I
antimutagenic	O
effect	O
against	O
alkylatings	O
methyl	B
-	I
N	I
-	I
nitro	I
-	I
N	I
-	I
nitrosoguanidine	I
(	O
MNNG	B
)	O
,	O
ethyl	B
-	I
N	I
-	I
nitro	I
-	I
N'-	I
nitrosoguanidine	I
(	O
ENNG	B
)	O
,	O
frameshift	O
mutagens	O
2-aminoanthracene	B
(	O
2AA	B
)	O
and	O
2-acetyl	B
-	I
amino	I
-	I
fluorene	I
(	O
2AF	B
)	O
and	O
ROS	O
-	O
generating	O
antibiotics	O
norfloxacin	B
(	O
NOR	B
)	O
and	O
nalidixic	B
acid	I
(	O
NLX	B
)	O
,	O
using	O
the	O
in	O
vitro	O
Ames	O
test	O
.	O

In	O
vivo	O
antimutagenesis	O
studies	O
were	O
performed	O
against	O
urinary	O
mutagens	O
induced	O
by	O
NOR	B
(	O
70	O
mg	O
/	O
kg	O
)	O
or	O
NLX	B
(	O
100	O
mg	O
/	O
kg	O
)	O
in	O
CD1	O
mice	O
.	O

Vitamin	B
B1	I
was	O
antimutagenic	O
against	O
alkylatings	O
MNNG	B
(	O
P<0.05	O
)	O
or	O
ENNG	B
(	O
P<0.001	O
)	O
.	O

In	O
fact	O
as	O
per	O
the	O
results	O
observed	O
during	O
the	O
current	O
study	O
,	O
none	O
of	O
the	O
vitamins	O
reduced	O
mutagenesis	O
caused	O
by	O
frameshift	O
mutagens	O
.	O

All	O
of	O
them	O
reduced	O
mutagenesis	O
of	O
NOR	B
or	O
NLX	B
(	O
P<0.001	O
)	O
.	O

In	O
vivo	O
studies	O
showed	O
that	O
vitamins	B
B1	I
and	I
B6	I
(	O
10	O
or	O
100	O
mg	O
/	O
kg	O
)	O
reduced	O
urinary	O
mutagens	O
from	O
NOR	B
(	O
P<0.001	O
)	O
or	O
NLX	B
(	O
P<0.02	O
)	O
either	O
free	O
or	O
	O
-	O
glucoronidase	O
-	O
conjugates	O
.	O

None	O
of	O
the	O
studied	O
samples	O
were	O
toxic	O
for	O
the	O
employed	O
antimutagenic	O
system	O
.	O

Vitamin	B
B12	I
(	O
4	O
mg	O
/	O
kg	O
)	O
reduced	O
urinary	O
mutagens	O
of	O
NOR	B
or	O
NLX	B
(	O
P<0.02	O
)	O
.	O

Vitamins	B
B	I
inhibited	O
DNA	O
mutations	O
induced	O
by	O
ROS	O
generated	O
by	O
NLX	B
or	O
NOR	B
,	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Vitamin	B
B1is	I
antimutagenic	O
against	O
mutations	O
induced	O
by	O
the	O
alkylating	O
MNNG	B
or	O
ENNG	B
.	O

Based	O
on	O
the	O
observations	O
,	O
employment	O
of	O
vitamins	B
B	I
in	O
vivo	O
can	O
be	O
a	O
promising	O
alternative	O
to	O
reduce	O
genotoxic	O
risk	O
exposure	O
to	O
ROS	O
.	O

Design	O
,	O
synthesis	O
and	O
crystallographic	O
analysis	O
of	O
nitrile	B
-	O
based	O
broad	O
-	O
spectrum	O
peptidomimetic	O
inhibitors	O
for	O
coronavirus	O
3C	O
-	O
like	O
proteases	O
.	O

Coronaviral	O
infection	O
is	O
associated	O
with	O
up	O
to	O
5	O
%	O
of	O
respiratory	O
tract	O
diseases	O
.	O

The	O
3C	O
-	O
like	O
protease	O
(	O
3CL	O
(	O
pro	O
)	O
)	O
of	O
coronaviruses	O
is	O
required	O
for	O
proteolytic	O
processing	O
of	O
polyproteins	O
and	O
viral	O
replication	O
,	O
and	O
is	O
a	O
promising	O
target	O
for	O
the	O
development	O
of	O
drugs	O
against	O
coronaviral	O
infection	O
.	O

We	O
designed	O
and	O
synthesized	O
four	O
nitrile	B
-	O
based	O
peptidomimetic	O
inhibitors	O
with	O
different	O
N	O
-	O
terminal	O
protective	O
groups	O
and	O
different	O
peptide	O
length	O
,	O
and	O
examined	O
their	O
inhibitory	O
effect	O
on	O
the	O
in	O
-	O
vitro	O
enzymatic	O
activity	O
of	O
3CL	O
(	O
pro	O
)	O
of	O
severe	O
-	O
acute	O
-	O
respiratory	O
-	O
syndrome	O
-	O
coronavirus	O
.	O

The	O
IC	O
(	O
50	O
)	O
values	O
of	O
the	O
inhibitors	O
were	O
in	O
the	O
range	O
of	O
4.6	O
-	O
49	O
M	O
,	O
demonstrating	O
that	O
the	O
nitrile	B
warhead	O
can	O
effectively	O
inactivate	O
the	O
3CL	O
(	O
pro	O
)	O
autocleavage	O
process	O
.	O

The	O
best	O
inhibitor	O
,	O
Cbz	B
-	O
AVLQ	O
-	O
CN	B
with	O
an	O
N	O
-	O
terminal	O
carbobenzyloxy	B
group	O
,	O
was	O
~10x	O
more	O
potent	O
than	O
the	O
other	O
inhibitors	O
tested	O
.	O

Crystal	O
structures	O
of	O
the	O
enzyme	O
-	O
inhibitor	O
complexes	O
showed	O
that	O
the	O
nitrile	B
warhead	O
inhibits	O
3CL	O
(	O
pro	O
)	O
by	O
forming	O
a	O
covalent	O
bond	O
with	O
the	O
catalytic	O
Cys145	B
residue	O
,	O
while	O
the	O
AVLQ	O
peptide	O
forms	O
a	O
number	O
of	O
favourable	O
interactions	O
with	O
the	O
S1-S4	O
substrate	O
-	O
binding	O
pockets	O
.	O

We	O
have	O
further	O
showed	O
that	O
the	O
peptidomimetic	O
inhibitor	O
,	O
Cbz	B
-	O
AVLQ	O
-	O
CN	B
,	O
has	O
broad	O
-	O
spectrum	O
inhibition	O
against	O
3CL	O
(	O
pro	O
)	O
from	O
human	O
coronavirus	O
strains	O
229E	O
,	O
NL63	O
,	O
OC43	O
,	O
HKU1	O
,	O
and	O
infectious	O
bronchitis	O
virus	O
,	O
with	O
IC	O
(	O
50	O
)	O
values	O
ranging	O
from	O
1.3	O
to	O
3.7	O
M	O
,	O
but	O
no	O
detectable	O
inhibition	O
against	O
caspase-3	O
.	O

In	O
summary	O
,	O
we	O
have	O
shown	O
that	O
the	O
nitrile	B
-	O
based	O
peptidomimetic	O
inhibitors	O
are	O
effective	O
against	O
3CL	O
(	O
pro	O
)	O
,	O
and	O
they	O
inhibit	O
3CL	O
(	O
pro	O
)	O
from	O
a	O
broad	O
range	O
of	O
coronaviruses	O
.	O

Our	O
results	O
provide	O
further	O
insights	O
into	O
the	O
future	O
design	O
of	O
drugs	O
that	O
could	O
serve	O
as	O
a	O
first	O
line	O
defence	O
against	O
coronaviral	O
infection	O
.	O

Synthesis	O
and	O
antibacterial	O
and	O
antifungal	O
evaluation	O
of	O
some	O
chalcone	B
based	O
sulfones	B
and	O
bisulfones	B
.	O

Two	O
series	O
of	O
chalcone	B
based	O
sulfone	B
and	O
bisulfone	B
derivatives	O
were	O
synthesized	O
using	O
chalcone	B
,	O
thiophenol	B
and	O
sodium	B
metal	O
at	O
room	O
temperature	O
,	O
followed	O
by	O
oxidation	O
of	O
chalcone	B
sulfides	I
with	O
m	B
-	I
CPBA	I
at	O
0	O
	O
C	O
in	O
a	O
novel	O
method	O
.	O

Both	O
sulfones	B
and	O
bisulfones	B
were	O
evaluated	O
for	O
their	O
antimicrobial	O
activities	O
against	O
Aspergillus	O
niger	O
and	O
Candida	O
albicans	O
(	O
yeast	O
)	O
,	O
Bacillus	O
subtilis	O
and	O
Staphylococcus	O
aureus	O
(	O
Gram	O
(	O
+	O
)	O
bacteria	O
)	O
and	O
Pseudomonas	O
aeruginosa	O
and	O
Salmonella	O
typhimurium	O
(	O
Gram	O
(	O
-	O
)	O
bacteria	O
)	O
strains	O
.	O

Among	O
them	O
,	O
compounds	O
2c	O
,	O
3c	O
,	O
6c	O
,	O
7c	O
,	O
8c	O
and	O
9c	O
have	O
shown	O
high	O
antifungal	O
activity	O
against	O
C.	O
albicans	O
compare	O
to	O
reference	O
drugs	O
viz	O
.	O

Amphotericin	B
-	I
B	I
and	O
Nystatin	B
.	O

Compound	O
1c	O
has	O
shown	O
slightly	O
better	O
antibacterial	O
activity	O
against	O
B.	O
subtilis	O
and	O
compounds	O
5c	O
,	O
6c	O
and	O
7c	O
have	O
shown	O
excellent	O
antibacterial	O
activity	O
against	O
S.	O
typhimurium	O
in	O
compare	O
to	O
reference	O
drugs	O
Ampicillin	B
and	O
Kanamycin	B
.	O

Identification	O
of	O
novel	O
chromenone	B
derivatives	O
as	O
interleukin-5	O
inhibitors	O
.	O

A	O
series	O
of	O
(	B
E	I
)	I
-5-alkoxy-3-	I
(	I
3-phenyl-3-oxoprop-1-enyl	I
)	I
-4H	I
-	I
chromen-4-ones	I
(	O
4	O
)	O
and	O
(	B
E	I
)	I
-5-alkoxy-3-	I
(	I
3-hydroxy-3-phenylprop-1-enyl	I
)	I
-4H	I
-	I
chromen-4-ones	I
(	O
5	O
)	O
were	O
synthesized	O
and	O
evaluated	O
for	O
their	O
IL-5	O
inhibitory	O
activity	O
.	O

Propenone	B
analogs	O
4	O
possess	O
some	O
of	O
the	O
structurally	O
important	O
characteristics	O
of	O
isoflavone	B
2	O
and	O
chalcone	B
3	O
previously	O
known	O
as	O
potent	O
IL-5	O
inhibitor	O
.	O

However	O
,	O
the	O
inhibitory	O
activity	O
of	O
4	O
was	O
weak	O
and	O
therefore	O
this	O
structural	O
hybridization	O
appears	O
to	O
be	O
ineffective	O
for	O
the	O
design	O
of	O
IL-5	O
inhibitor	O
.	O

Meanwhile	O
the	O
potent	O
activity	O
profile	O
of	O
compounds	O
5	O
was	O
discovered	O
.	O

This	O
enhanced	O
activity	O
of	O
5	O
compared	O
to	O
4	O
could	O
be	O
due	O
to	O
the	O
effective	O
location	O
of	O
hydroxyl	B
group	O
of	O
allylic	B
alcohol	I
moiety	O
of	O
5	O
in	O
the	O
3D	O
structure	O
.	O

The	O
electron	O
withdrawing	O
substituents	O
at	O
position	O
4	O
of	O
phenyl	B
ring	O
of	O
5	O
enhances	O
the	O
activity	O
possibly	O
due	O
to	O
an	O
increase	O
in	O
the	O
strength	O
of	O
hydrogen	B
bonding	O
property	O
of	O
hydroxyl	B
group	O
of	O
allylic	B
alcohol	I
moiety	O
.	O

Synthesis	O
,	O
antibacterial	O
activity	O
and	O
docking	O
of	O
14-membered	B
9-O-	I
(	I
3-arylalkyl	I
)	I
oxime	I
11,12-cyclic	I
carbonate	I
ketolides	I
.	O

A	O
series	O
of	O
9-O-	B
(	I
3-aryl-2-propargyl	I
)	I
oxime	I
ketolides	I
8	O
was	O
synthesized	O
and	O
evaluated	O
for	O
in	O
vitro	O
antibacterial	O
activity	O
.	O

Among	O
8	O
,	O
8b-8d	O
,	O
and	O
8h-8l	O
displayed	O
dramatically	O
improved	O
potency	O
against	O
inducibly	O
MLS	O
(	O
B	O
)	O
-resistant	O
and	O
efflux	O
-	O
resistant	O
pathogens	O
as	O
compared	O
to	O
clarithromycin	B
and	O
azithromycin	B
.	O

Especially	O
,	O
8i	O
(	O
Ar=4-isoquinolyl	O
)	O
possessed	O
an	O
MIC	O
of	O
0.064	O
g	O
/	O
mL	O
against	O
constitutively	O
MLS	O
(	O
B	O
)	O
-resistant	O
Streptococcus	O
pneumoniae	O
,	O
and	O
MICs	O
of	O
0.032	O
-	O
0.064	O
g	O
/	O
mL	O
against	O
methicillin	B
-	O
resistant	O
Staphylococcus	O
aureus	O
and	O
methicillin	B
-	O
resistant	O
Staphylococcus	O
hominis	O
.	O

The	O
analog	O
10	O
with	O
a	O
propyl	B
linker	O
was	O
less	O
effective	O
than	O
both	O
the	O
corresponding	O
8	O
and	O
9	O
containing	O
propynyl	B
and	O
propenyl	B
linkers	O
.	O

A	O
docking	O
study	O
was	O
performed	O
to	O
gain	O
insight	O
into	O
the	O
binding	O
mode	O
of	O
series	O
8	O
and	O
9	O
and	O
to	O
rationalize	O
the	O
disparity	O
found	O
in	O
the	O
SAR	O
of	O
8	O
and	O
9	O
.	O

Hybrid	O
furoxanyl	B
N	I
-	I
acylhydrazone	I
derivatives	O
as	O
hits	O
for	O
the	O
development	O
of	O
neglected	O
diseases	O
drug	O
candidates	O
.	O

Neglected	O
diseases	O
represent	O
a	O
major	O
health	O
problem	O
.	O

It	O
is	O
estimated	O
that	O
one	O
third	O
of	O
the	O
world	O
population	O
is	O
infected	O
with	O
tuberculosis	O
and	O
additionally	O
Leishmaniosis	O
and	O
Chagas	O
disease	O
affect	O
approximately	O
30	O
million	O
people	O
.	O

N	B
-	I
Acylhydrazone	I
moiety	O
is	O
a	O
repeated	O
functional	O
group	O
present	O
in	O
several	O
prototypes	O
and	O
drug	O
candidates	O
for	O
these	O
neglected	O
diseases	O
.	O

On	O
the	O
other	O
hand	O
,	O
furoxan	B
system	O
has	O
been	O
studied	O
as	O
pharmacophore	O
for	O
Leishmaniosis	O
and	O
Chagas	O
diseases	O
.	O

Here	O
we	O
report	O
on	O
the	O
design	O
and	O
preparation	O
of	O
forty	O
hybrid	O
furoxanyl	B
N	I
-	I
acylhydrazones	I
and	O
on	O
their	O
activity	O
on	O
Mycobacterium	O
tuberculosis	O
,	O
H37Rv	O
and	O
MDR	O
strains	O
,	O
Trypanosoma	O
cruzi	O
,	O
and	O
Leishmania	O
amazonensis	O
.	O

Among	O
them	O
,	O
four	O
derivatives	O
displayed	O
excellent	O
to	O
good	O
selectivity	O
indexes	O
against	O
the	O
three	O
different	O
microorganisms	O
.	O

Hybrid	O
compound	O
N'-	B
(	I
4-phenyl-3-furoxanylmethylidene	I
)	I
isoniazide	I
9	O
showed	O
the	O
best	O
antibacterial	O
profile	O
with	O
MIC	O
value	O
4.5	O
lesser	O
than	O
the	O
value	O
for	O
the	O
reference	O
isoniazid	B
against	O
MDR	O
strain	O
.	O

Furoxanyl	B
N	I
-	I
acylhydrazone	I
(	B
E	I
)	I
-2-methyl	I
-	I
N'-	I
(	I
4-phenyl-3-furoxanylmethylidene	I
)	I
-4H	I
-	I
imidazo	I
[	I
1,2-a	I
]	I
pyridine-3-carbohydrazide	I
15	O
was	O
ten	O
-	O
fold	O
more	O
potent	O
against	O
T.	O
cruzi	O
Amastigotes	O
than	O
the	O
standard	O
drug	O
nifurtimox	O
.	O

On	O
the	O
other	O
hand	O
,	O
derivatives	O
(	B
E	I
)	I
-N'-	I
(	I
5-benzofuroxanylmethylidene	I
)	I
benzo	I
[	I
d	I
]	I
[	I
1,3	I
]	I
dioxole-5-carbohydrazide	I
25	O
and	O
(	B
E	I
)	I
-N'-	I
(	I
4-hydroxy-3-methoxyphenylmethylidene	I
)	I
-3-methylfuroxan-4-carbohydrazide	I
37	O
emerged	O
as	O
leads	O
for	O
the	O
development	O
of	O
new	O
leishmanicidal	O
agents	O
.	O

The	O
adequate	O
stability	O
,	O
in	O
simulated	O
biological	O
system	O
and	O
plasma	O
,	O
and	O
the	O
lack	O
of	O
mutagenicity	O
of	O
these	O
derivatives	O
allow	O
us	O
to	O
propose	O
them	O
as	O
candidates	O
for	O
further	O
pre	O
-	O
clinical	O
studies	O
.	O

Synthesis	O
,	O
characterization	O
and	O
pharmacodynamics	O
of	O
vitamin	B
-	I
B	I
(	I
12	I
)	I
-conjugated	O
glucagon	O
-	O
like	O
peptide-1	O
.	O

Clearing	O
the	O
way	O
:	O
Glucagon	O
-	O
like	O
peptide-1	O
(	O
GLP-1	O
)	O
receptor	O
agonists	O
are	O
proving	O
a	O
potent	O
weapon	O
in	O
the	O
treatment	O
of	O
type	O
II	O
diabetes	O
.	O

A	O
new	O
vitamin	B
B	I
(	I
12	I
)	I
-GLP-1	O
conjugate	O
is	O
investigated	O
and	O
shown	O
to	O
have	O
insulinotropic	O
properties	O
similar	O
to	O
the	O
unmodified	O
peptide	O
.	O

These	O
results	O
are	O
critical	O
to	O
the	O
exploitation	O
of	O
the	O
vitamin	B
B	I
(	I
12	I
)	I
oral	O
uptake	O
pathway	O
for	O
peptide	O
delivery	O
.	O

iReckon	O
:	O
simultaneous	O
isoform	O
discovery	O
and	O
abundance	O
estimation	O
from	O
RNA	O
-	O
seq	O
data	O
.	O

High	O
-	O
throughput	O
RNA	O
sequencing	O
(	O
RNA	O
-	O
seq	O
)	O
promises	O
to	O
revolutionize	O
our	O
understanding	O
of	O
genes	O
and	O
their	O
role	O
in	O
human	O
disease	O
by	O
characterizing	O
the	O
RNA	O
content	O
of	O
tissues	O
and	O
cells	O
.	O

The	O
realization	O
of	O
this	O
promise	O
,	O
however	O
,	O
is	O
conditional	O
on	O
the	O
development	O
of	O
effective	O
computational	O
methods	O
for	O
the	O
identification	O
and	O
quantification	O
of	O
transcripts	O
from	O
incomplete	O
and	O
noisy	O
data	O
.	O

In	O
this	O
article	O
,	O
we	O
introduce	O
iReckon	O
,	O
a	O
method	O
for	O
simultaneous	O
determination	O
of	O
the	O
isoforms	O
and	O
estimation	O
of	O
their	O
abundances	O
.	O

Our	O
probabilistic	O
approach	O
incorporates	O
multiple	O
biological	O
and	O
technical	O
phenomena	O
,	O
including	O
novel	O
isoforms	O
,	O
intron	O
retention	O
,	O
unspliced	O
pre	O
-	O
mRNA	O
,	O
PCR	O
amplification	O
biases	O
,	O
and	O
multimapped	O
reads	O
.	O

iReckon	O
utilizes	O
regularized	O
expectation	O
-	O
maximization	O
to	O
accurately	O
estimate	O
the	O
abundances	O
of	O
known	O
and	O
novel	O
isoforms	O
.	O

Our	O
results	O
on	O
simulated	O
and	O
real	O
data	O
demonstrate	O
a	O
superior	O
ability	O
to	O
discover	O
novel	O
isoforms	O
with	O
a	O
significantly	O
reduced	O
number	O
of	O
false	O
-	O
positive	O
predictions	O
,	O
and	O
our	O
abundance	O
accuracy	O
prediction	O
outmatches	O
that	O
of	O
other	O
state	O
-	O
of	O
-	O
the	O
-	O
art	O
tools	O
.	O

Furthermore	O
,	O
we	O
have	O
applied	O
iReckon	O
to	O
two	O
cancer	O
transcriptome	O
data	O
sets	O
,	O
a	O
triple	O
-	O
negative	O
breast	O
cancer	O
patient	O
sample	O
and	O
the	O
MCF7	O
breast	O
cancer	O
cell	O
line	O
,	O
and	O
show	O
that	O
iReckon	O
is	O
able	O
to	O
reconstruct	O
the	O
complex	O
splicing	O
changes	O
that	O
were	O
not	O
previously	O
identified	O
.	O

QT	O
-	O
PCR	O
validations	O
of	O
the	O
isoforms	O
detected	O
in	O
the	O
MCF7	O
cell	O
line	O
confirmed	O
all	O
of	O
iReckon	O
's	O
predictions	O
and	O
also	O
showed	O
strong	O
agreement	O
(	O
r	O
(	O
2	O
)	O
=	O
0.94	O
)	O
with	O
the	O
predicted	O
abundances	O
.	O

Effects	O
of	O
the	O
lipid	O
environment	O
,	O
cholesterol	B
and	O
bile	B
acids	I
on	O
the	O
function	O
of	O
the	O
purified	O
and	O
reconstituted	O
human	O
ABCG2	O
protein	O
.	O

The	O
human	O
ABCG2	O
multidrug	O
transporter	O
actively	O
extrudes	O
a	O
wide	O
range	O
of	O
hydrophobic	O
drugs	O
and	O
xenobiotics	O
recognized	O
by	O
the	O
transporter	O
in	O
the	O
membrane	O
phase	O
.	O

In	O
order	O
to	O
examine	O
the	O
molecular	O
nature	O
of	O
the	O
transporter	O
and	O
its	O
effects	O
on	O
the	O
lipid	O
environment	O
,	O
we	O
have	O
established	O
an	O
efficient	O
protocol	O
for	O
the	O
purification	O
and	O
reconstitution	O
of	O
the	O
functional	O
protein	O
.	O

We	O
found	O
that	O
the	O
drug	O
-	O
stimulated	O
ATPase	O
and	O
the	O
transport	O
activity	O
of	O
ABCG2	O
are	O
fully	O
preserved	O
by	O
applying	O
excess	O
lipids	O
and	O
mild	O
detergents	O
during	O
solubilization	O
,	O
whereas	O
a	O
detergent	O
-	O
induced	O
dissociation	O
of	O
the	O
ABCG2	O
dimer	O
causes	O
an	O
irreversible	O
inactivation	O
.	O

By	O
using	O
the	O
purified	O
and	O
reconstituted	O
protein	O
we	O
demonstrate	O
that	O
cholesterol	B
is	O
an	O
essential	O
activator	O
,	O
whereas	O
bile	B
acids	I
are	O
important	O
modulators	O
of	O
ABCG2	O
activity	O
.	O

Both	O
wild	O
-	O
type	O
ABCG2	O
and	O
its	O
R482	O
G	O
mutant	O
variant	O
require	O
cholesterol	B
for	O
full	O
activity	O
,	O
although	O
they	O
exhibit	O
different	O
cholesterol	B
sensitivities	O
.	O

Bile	B
acids	I
strongly	O
decrease	O
the	O
basal	O
ABCG2-ATPase	O
activity	O
both	O
in	O
the	O
wild	O
-	O
type	O
ABCG2	O
and	O
in	O
the	O
mutant	O
variant	O
.	O

These	O
data	O
reinforce	O
the	O
results	O
for	O
the	O
modulatory	O
effects	O
of	O
cholesterol	B
and	O
bile	B
acids	I
of	O
ABCG2	O
investigated	O
in	O
a	O
complex	O
cell	O
membrane	O
environment	O
.	O

Moreover	O
,	O
these	O
experiments	O
open	O
the	O
possibility	O
to	O
perform	O
functional	O
and	O
structural	O
studies	O
with	O
a	O
purified	O
,	O
reconstituted	O
and	O
highly	O
active	O
ABCG2	O
multidrug	O
transporter	O
.	O

Spontaneous	O
periodic	O
diameter	O
oscillations	O
in	O
InP	B
nanowires	O
:	O
the	O
role	O
of	O
interface	O
instabilities	O
.	O

We	O
have	O
observed	O
that	O
thin	O
InP	B
nanowires	O
generated	O
by	O
vapor	O
-	O
liquid	O
-	O
solid	O
growth	O
display	O
spontaneous	O
periodic	O
diameter	O
oscillations	O
when	O
large	O
group	O
III	O
supersaturations	O
are	O
used	O
.	O

Diameter	O
variations	O
are	O
associated	O
with	O
a	O
large	O
number	O
of	O
stacking	O
faults	O
and	O
crystallographic	O
phase	O
changes	O
(	O
wurtzite	B
/	O
zinc	B
-	I
blende	I
)	O
;	O
also	O
the	O
axial	O
distance	O
between	O
oscillations	O
depends	O
on	O
the	O
indium	B
precursor	O
flow	O
used	O
during	O
the	O
run	O
.	O

We	O
attribute	O
the	O
morphology	O
changes	O
to	O
a	O
substantial	O
deformation	O
of	O
the	O
triple	O
phase	O
line	O
(	O
vapor	O
-	O
liquid	O
-	O
solid	O
)	O
at	O
the	O
catalyst	O
nanoparticle	O
edge	O
originated	O
from	O
multistep	O
nucleation	O
during	O
growth	O
.	O

The	O
deformation	O
alters	O
the	O
mechanical	O
force	O
balance	O
acting	O
on	O
the	O
nanoparticle	O
during	O
growth	O
in	O
such	O
a	O
way	O
that	O
the	O
particle	O
displaces	O
from	O
the	O
nanowire	O
top	O
and	O
wets	O
the	O
nanowire	O
sidewall	O
.	O

Subsequently	O
,	O
as	O
catalytic	O
growth	O
occurs	O
at	O
the	O
sidewall	O
,	O
the	O
associated	O
increase	O
in	O
diameter	O
will	O
eventually	O
push	O
the	O
NP	O
back	O
to	O
its	O
original	O
wire	O
-	O
top	O
position	O
until	O
the	O
onset	O
of	O
a	O
new	O
instability	O
at	O
the	O
triple	O
phase	O
line	O
.	O

Flexible	O
fiber	O
nanogenerator	O
with	O
209	O
V	O
output	O
voltage	O
directly	O
powers	O
a	O
light	O
-	O
emitting	O
diode	O
.	O

On	O
the	O
basis	O
of	O
a	O
vertically	O
aligned	O
ultralong	O
Pb	B
(	I
Zr	I
(	I
0.52	I
)	I
Ti	I
(	I
0.48	I
)	I
)	I
O	I
(	I
3	I
)	I
(	O
PZT	B
)	O
nanowire	O
array	O
fabricated	O
using	O
electrospinning	O
nanofibers	O
,	O
we	O
developed	O
a	O
new	O
type	O
of	O
integrated	O
nanogenerator	O
(	O
NG	O
)	O
with	O
ultrahigh	O
output	O
voltage	O
of	O
209	O
V	O
and	O
current	O
density	O
of	O
23.5	O
A	O
/	O
cm	O
(	O
2	O
)	O
,	O
which	O
are	O
3.6	O
times	O
and	O
2.9	O
times	O
of	O
the	O
previous	O
record	O
values	O
,	O
respectively	O
.	O

The	O
output	O
electricity	O
can	O
be	O
directly	O
used	O
to	O
stimulate	O
the	O
frog	O
's	O
sciatic	O
nerve	O
and	O
to	O
induce	O
a	O
contraction	O
of	O
a	O
frog	O
's	O
gastrocnemius	O
.	O

The	O
NG	O
can	O
instantaneously	O
power	O
a	O
commercial	O
light	O
-	O
emitting	O
diode	O
(	O
LED	O
)	O
without	O
the	O
energy	O
storage	O
process	O
.	O

Interactions	O
of	O
sarin	B
with	O
polyelectrolyte	O
membranes	O
:	O
a	O
molecular	O
dynamics	O
simulation	O
study	O
.	O

Nanostructured	O
polyelectrolyte	O
membranes	O
(	O
PEMs	O
)	O
,	O
which	O
are	O
widely	O
used	O
as	O
permselective	O
diffusion	O
barriers	O
in	O
fuel	O
cell	O
technologies	O
and	O
electrochemical	O
processing	O
,	O
are	O
considered	O
as	O
protective	O
membranes	O
suitable	O
for	O
blocking	O
warfare	O
toxins	O
,	O
including	O
water	O
-	O
soluble	O
nerve	O
agents	O
such	O
as	O
sarin	B
.	O

In	O
this	O
article	O
,	O
we	O
examine	O
the	O
mechanisms	O
of	O
sorption	O
and	O
diffusion	O
of	O
sarin	B
in	O
hydrated	O
PEMs	O
by	O
means	O
of	O
atomistic	O
molecular	O
dynamics	O
simulations	O
.	O

Three	O
PEMs	O
are	O
considered	O
:	O
Nafion	B
,	O
sulfonated	B
polystyrene	I
(	O
sPS	B
)	O
that	O
forms	O
the	O
hydrophilic	O
subphase	O
of	O
segregated	O
sPS	B
-	O
polyolefin	B
block	O
copolymers	O
,	O
and	O
random	O
sPS	B
-	O
polyethylene	B
copolymer	O
.	O

We	O
found	O
that	O
sarin	B
concentrates	O
at	O
the	O
interface	O
between	O
the	O
hydrophilic	O
and	O
hydrophobic	O
subphases	O
of	O
hydrated	B
Nafion	I
acting	O
as	O
a	O
surfactant	O
.	O

In	O
hydrated	B
sPS	I
,	O
where	O
the	O
scale	O
of	O
water	O
-	O
polymer	O
segregation	O
is	O
much	O
smaller	O
(	O
1	O
-	O
2	O
nm	O
)	O
,	O
sarin	B
also	O
interacts	O
favorably	O
with	O
hydrophobic	O
and	O
hydrophilic	O
components	O
.	O

Water	O
diffusion	O
slows	O
as	O
the	O
sarin	B
content	O
increases	O
despite	O
the	O
overall	O
increase	O
in	O
solvent	O
content	O
,	O
which	O
suggests	O
that	O
sarin	B
and	O
water	O
have	O
somewhat	O
different	O
pathways	O
through	O
the	O
segregated	O
membrane	O
.	O

Upon	O
replacement	O
of	O
counterions	O
of	O
monovalent	O
potassium	B
with	O
those	O
of	O
divalent	O
calcium	B
,	O
sarin	B
diffusion	O
slows	O
but	O
remains	O
substantial	O
in	O
all	O
ionomers	O
considered	O
,	O
especially	O
at	O
high	O
sarin	B
concentrations	O
.	O

The	O
behavior	O
of	O
sarin	B
is	O
similar	O
to	O
that	O
of	O
its	O
common	O
simulant	O
,	O
dimethyl	B
methylphosphonate	I
.	O

Invasion	O
genetics	O
of	O
the	O
introduced	O
black	O
rat	O
(	O
Rattus	O
rattus	O
)	O
in	O
Senegal	O
,	O
West	O
Africa	O
.	O

An	O
understanding	O
of	O
the	O
evolutionary	O
history	O
and	O
dynamics	O
of	O
invasive	O
species	O
is	O
required	O
for	O
the	O
construction	O
of	O
predictive	O
models	O
of	O
future	O
spread	O
and	O
the	O
design	O
of	O
biological	O
management	O
measures	O
.	O

The	O
black	O
rat	O
(	O
Rattus	O
rattus	O
)	O
is	O
a	O
major	O
vertebrate	O
invader	O
with	O
a	O
worldwide	O
distribution	O
.	O

Despite	O
the	O
severe	O
ecological	O
,	O
economic	O
and	O
health	O
impacts	O
of	O
this	O
species	O
,	O
its	O
evolutionary	O
history	O
has	O
been	O
little	O
studied	O
.	O

We	O
carried	O
out	O
extensive	O
specimen	O
sampling	O
in	O
Senegal	O
,	O
West	O
Africa	O
,	O
and	O
used	O
microsatellite	O
markers	O
to	O
describe	O
the	O
pattern	O
and	O
processes	O
of	O
invasion	O
in	O
this	O
large	O
continental	O
area	O
.	O

The	O
genetic	O
data	O
obtained	O
were	O
combined	O
with	O
historical	O
knowledge	O
concerning	O
the	O
presence	O
of	O
this	O
species	O
in	O
Senegal	O
.	O

Data	O
were	O
analysed	O
by	O
a	O
combination	O
of	O
Bayesian	O
clustering	O
and	O
approximate	O
Bayesian	O
computation	O
methods	O
.	O

The	O
invasion	O
pathways	O
closely	O
paralleled	O
the	O
history	O
of	O
human	O
trade	O
routes	O
in	O
Senegal	O
.	O

In	O
several	O
places	O
,	O
we	O
detected	O
the	O
occurrence	O
of	O
multiple	O
introductions	O
from	O
genetically	O
different	O
sources	O
.	O

Long	O
-	O
distance	O
migration	O
between	O
towns	O
and	O
villages	O
was	O
also	O
observed	O
.	O

Our	O
findings	O
suggest	O
that	O
genetic	O
bottlenecks	O
and	O
admixture	O
have	O
played	O
a	O
major	O
role	O
in	O
shaping	O
the	O
genetics	O
of	O
invasive	O
black	O
rats	O
.	O

These	O
two	O
processes	O
may	O
generate	O
genetic	O
novelty	O
and	O
favour	O
rapid	O
evolution	O
along	O
the	O
invasion	O
pathways	O
.	O

Multifunctional	O
Fe3O4@Ag	B
/	O
SiO2	B
/	O
Au	B
core	O
-	O
shell	O
microspheres	O
as	O
a	O
novel	O
SERS	O
-	O
activity	O
label	O
via	O
long	O
-	O
range	O
plasmon	O
coupling	O
.	O

Noble	O
metallic	O
nanostructures	O
exhibit	O
a	O
phenomenon	O
known	O
as	O
surface	O
-	O
enhanced	O
Raman	O
scattering	O
(	O
SERS	O
)	O
in	O
which	O
the	O
Raman	O
scattering	O
cross	O
sections	O
are	O
dramatically	O
enhanced	O
for	O
the	O
molecules	O
adsorbed	O
thereon	O
.	O

Due	O
to	O
their	O
wide	O
accessible	O
potential	O
range	O
in	O
aqueous	O
solutions	O
and	O
the	O
high	O
biocompatibility	O
,	O
Au	B
supports	O
are	O
preferred	O
for	O
spectro	O
-	O
electrochemical	O
investigations	O
.	O

However	O
,	O
the	O
optical	O
range	O
in	O
SERS	O
spectroscopy	O
is	O
restricted	O
to	O
excitation	O
lines	O
above	O
600	O
nm	O
,	O
which	O
is	O
shorter	O
than	O
the	O
Ag	B
supports	O
.	O

In	O
addition	O
,	O
these	O
SERS	O
-	O
activity	O
materials	O
are	O
not	O
easy	O
to	O
separate	O
and	O
reused	O
.	O

Herein	O
,	O
the	O
present	O
article	O
reports	O
the	O
novel	O
multifunctional	O
Fe	B
(	I
3	I
)	I
O	I
(	I
4	I
)	I
@Ag	O
/	O
SiO	B
(	I
2	I
)	I
/	O
Au	B
core	O
-	O
shell	O
microspheres	O
that	O
display	O
long	O
-	O
range	O
plasmon	O
transfer	O
of	O
Ag	B
to	O
Au	B
leading	O
to	O
enhanced	O
Raman	O
scattering	O
.	O

The	O
well	O
-	O
designed	O
microspheres	O
have	O
high	O
magnetization	O
and	O
uniform	O
sphere	O
size	O
.	O

As	O
a	O
result	O
,	O
Fe	B
(	I
3	I
)	I
O	I
(	I
4	I
)	I
@Ag	O
/	O
SiO	B
(	I
2	I
)	I
/	O
Au	B
microspheres	O
have	O
the	O
best	O
enhancement	O
effect	O
in	O
the	O
Raman	O
active	O
research	O
by	O
using	O
Rhodamine	B
-	I
b	I
(	O
RdB	B
)	O
as	O
a	O
probe	O
molecule	O
.	O

The	O
enhancement	O
factor	O
is	O
estimated	O
to	O
be	O
2.2	O
	O
10	O
(	O
4	O
)	O
for	O
RdB	B
from	O
the	O
long	O
-	O
range	O
plasmon	O
transfer	O
of	O
Ag	B
to	O
Au	B
,	O
corresponding	O
to	O
an	O
attenuation	O
of	O
the	O
enhancement	O
by	O
a	O
factor	O
of	O
only	O
0.672	O
	O
10	O
(	O
4	O
)	O
compared	O
to	O
RdB	B
adsorbed	O
directly	O
on	O
the	O
Fe	B
(	I
3	I
)	I
O	I
(	I
4	I
)	I
@Ag	O
microspheres	O
.	O

RdB	B
can	O
be	O
detected	O
down	O
to	O
10	O
(	O
-9	O
)	O
M	O
even	O
without	O
the	O
resonance	O
SERS	O
effect	O
.	O

The	O
unique	O
nanostructure	O
makes	O
the	O
microspheres	O
novel	O
stable	O
and	O
a	O
high	O
-	O
enhancement	O
effect	O
for	O
Raman	O
detection	O
.	O

Combining	O
QSAR	O
classification	O
models	O
for	O
predictive	O
modeling	O
of	O
human	O
monoamine	O
oxidase	O
inhibitors	O
.	O

Due	O
to	O
their	O
role	O
in	O
the	O
metabolism	O
of	O
monoamine	O
neurotransmitters	O
,	O
MAO	O
-	O
A	O
and	O
MAO	O
-	O
B	O
present	O
a	O
significant	O
pharmacological	O
interest	O
.	O

For	O
instance	O
the	O
inhibitors	O
of	O
human	O
MAO	O
-	O
B	O
are	O
considered	O
useful	O
tools	O
for	O
the	O
treatment	O
of	O
Parkinson	O
Disease	O
.	O

Therefore	O
,	O
the	O
rational	O
design	O
and	O
synthesis	O
of	O
new	O
MAOs	O
inhibitors	O
is	O
considered	O
of	O
great	O
importance	O
for	O
the	O
development	O
of	O
new	O
and	O
more	O
effective	O
treatments	O
of	O
Parkinson	O
Disease	O
.	O

In	O
this	O
work	O
,	O
Quantitative	O
Structure	O
Activity	O
Relationships	O
(	O
QSAR	O
)	O
has	O
been	O
developed	O
to	O
predict	O
the	O
human	O
MAO	O
inhibitory	O
activity	O
and	O
selectivity	O
.	O

The	O
first	O
step	O
was	O
the	O
selection	O
of	O
a	O
suitable	O
dataset	O
of	O
heterocyclic	O
compounds	O
that	O
include	O
chromones	B
,	O
coumarins	B
,	O
chalcones	B
,	O
thiazolylhydrazones	B
,	O
etc	O
.	O

These	O
compounds	O
were	O
previously	O
synthesized	O
in	O
one	O
of	O
our	O
laboratories	O
,	O
or	O
elsewhere	O
,	O
and	O
their	O
activities	O
measured	O
by	O
the	O
same	O
assays	O
and	O
for	O
the	O
same	O
laboratory	O
staff	O
.	O

Applying	O
linear	O
discriminant	O
analysis	O
to	O
data	O
derived	O
from	O
a	O
variety	O
of	O
molecular	O
representations	O
and	O
feature	O
selection	O
algorithms	O
,	O
reliable	O
QSAR	O
models	O
were	O
built	O
which	O
could	O
be	O
used	O
to	O
predict	O
for	O
test	O
compounds	O
the	O
inhibitory	O
activity	O
and	O
selectivity	O
toward	O
human	O
MAO	O
.	O

This	O
work	O
also	O
showed	O
how	O
several	O
QSAR	O
models	O
can	O
be	O
combined	O
to	O
make	O
better	O
predictions	O
.	O

The	O
final	O
models	O
exhibit	O
significant	O
statistics	O
,	O
interpretability	O
,	O
as	O
well	O
as	O
displaying	O
predictive	O
power	O
on	O
an	O
external	O
validation	O
set	O
made	O
up	O
of	O
chromone	O
derivatives	O
with	O
unknown	O
activity	O
(	O
that	O
are	O
being	O
reported	O
here	O
for	O
first	O
time	O
)	O
synthesized	O
by	O
our	O
group	O
,	O
and	O
coumarins	B
recently	O
reported	O
in	O
the	O
literature	O
.	O

From	O
in	O
situ	O
to	O
in	O
vivo	O
:	O
an	O
in	O
situ	O
click	O
-	O
chemistry	O
-	O
derived	O
carbonic	O
anhydrase	O
II	O
imaging	O
agent	O
for	O
positron	O
emission	O
tomography	O
.	O

CA	O
II	O
makes	O
a	O
good	O
PET	O
:	O
Discovering	O
positron	O
emission	O
tomography	O
(	O
PET	O
)	O
probes	O
with	O
high	O
target	O
affinities	O
is	O
challenging	O
.	O

PET	O
probe	O
discovery	O
using	O
in	O
situ	O
click	O
chemistry	O
uses	O
(	B
19	I
)	I
F	I
-	O
bearing	O
fragments	O
as	O
(	B
18	I
)	I
F	I
surrogates	O
.	O

This	O
ensures	O
that	O
the	O
lead	O
hits	O
and	O
PET	O
probes	O
have	O
equivalent	O
chemical	O
or	O
biological	O
characteristics	O
,	O
making	O
PET	O
probe	O
discovery	O
predictable	O
and	O
reliable	O
.	O

Enantiospecific	O
total	O
synthesis	O
of	O
(	B
-	I
)	I
-bengamide	I
E.	I
Total	O
synthesis	O
of	O
the	O
polyhydroxy	B
caprolactam	I
amide	I
natural	O
product	O
,	O
bengamide	B
E	I
,	O
is	O
accomplished	O
starting	O
from	O
tartaric	B
acid	I
.	O

Key	O
reactions	O
in	O
the	O
synthesis	O
include	O
desymmetrization	O
of	O
the	O
bis	B
(	I
dimethylamide	I
)	I
unit	O
of	O
tartaric	B
acid	I
,	O
Zn	B
(	I
BH	I
(	I
4	I
)	I
)	I
(	I
2	I
)	I
-mediated	O
anti	O
-	O
selective	O
reduction	O
,	O
and	O
a	O
Horner	O
-	O
Wadsworth	O
-	O
Emmons	O
olefination	O
.	O

Functional	O
requirement	O
for	O
a	O
highly	O
conserved	O
charged	O
residue	O
at	O
position	O
75	O
in	O
the	O
gap	O
junction	O
protein	O
connexin	O
32	O
.	O

Charcot	O
Marie	O
Tooth	O
disease	O
(	O
CMT	O
)	O
is	O
a	O
group	O
of	O
inherited	O
disorders	O
characterized	O
clinically	O
by	O
exclusively	O
or	O
predominantly	O
peripheral	O
nerve	O
dysfunction	O
.	O

CMT1X	O
,	O
the	O
most	O
common	O
form	O
of	O
X	O
-	O
linked	O
CMT	O
is	O
caused	O
by	O
mutations	O
in	O
connexin	O
32	O
(	O
Cx32	O
)	O
.	O

In	O
this	O
work	O
,	O
we	O
used	O
dual	O
whole	O
cell	O
patch	O
clamp	O
recording	O
to	O
examine	O
the	O
functional	O
effects	O
of	O
mutations	O
at	O
the	O
Arg	B
(	O
75	O
)	O
position	O
.	O

This	O
residue	O
is	O
highly	O
conserved	O
among	O
members	O
of	O
the	O
connexin	O
family	O
,	O
and	O
disease	O
-	O
causing	O
mutations	O
have	O
been	O
identified	O
at	O
this	O
(	O
or	O
the	O
corresponding	O
)	O
position	O
in	O
Cx26	O
,	O
Cx43	O
,	O
and	O
Cx46	O
.	O

Thus	O
,	O
a	O
better	O
understanding	O
of	O
the	O
effects	O
of	O
mutations	O
of	O
this	O
position	O
in	O
Cx32	O
may	O
have	O
relevance	O
to	O
pathogenesis	O
of	O
a	O
number	O
of	O
different	O
human	O
diseases	O
.	O

All	O
three	O
mutants	O
associated	O
with	O
CMT1X	O
(	O
R75P	O
,	O
R75Q	O
,	O
and	O
R75W	O
)	O
showed	O
very	O
low	O
levels	O
of	O
coupling	O
similar	O
to	O
those	O
of	O
the	O
cells	O
transfected	O
with	O
vector	O
alone	O
.	O

Heterotypic	O
pairing	O
with	O
Cx32	O
WT	O
showed	O
that	O
the	O
absence	O
of	O
coupling	O
for	O
these	O
mutants	O
in	O
the	O
homotypic	O
configuration	O
could	O
be	O
explained	O
by	O
shifts	O
in	O
their	O
hemichannel	O
G	O
(	O
j	O
)	O
-V	O
(	O
j	O
)	O
relations	O
.	O

Examination	O
of	O
the	O
expression	O
levels	O
and	O
gating	O
characteristics	O
of	O
seven	O
additional	O
mutants	O
(	O
R75A	O
,	O
R75D	O
,	O
R75E	O
,	O
R75H	O
,	O
R75	O
K	O
,	O
R75L	O
,	O
and	O
R75V	O
)	O
at	O
this	O
position	O
suggest	O
that	O
the	O
positive	O
charge	O
at	O
position	O
75	O
in	O
Cx32	O
is	O
required	O
for	O
normal	O
channel	O
function	O
but	O
not	O
for	O
gap	O
junction	O
assembly	O
.	O

Our	O
studies	O
also	O
suggest	O
that	O
disease	O
treatment	O
strategies	O
for	O
CMT1X	O
,	O
which	O
correct	O
trafficking	O
abnormalities	O
in	O
Cx32	O
,	O
may	O
be	O
ineffective	O
for	O
the	O
group	O
of	O
mutations	O
also	O
conferring	O
changes	O
in	O
gating	O
properties	O
of	O
Cx32	O
channels	O
.	O

Simulations	O
of	O
the	O
two	O
-	O
dimensional	O
electronic	O
spectroscopy	O
of	O
the	O
photosystem	O
II	O
reaction	O
center	O
.	O

We	O
report	O
simulations	O
of	O
the	O
two	O
-	O
dimensional	O
electronic	O
spectroscopy	O
of	O
the	O
Q	O
(	O
y	O
)	O
band	O
of	O
the	O
D1-D2-Cyt	O
b559	O
photosystem	O
II	O
reaction	O
center	O
at	O
77	O
K.	O
We	O
base	O
the	O
simulations	O
on	O
an	O
existing	O
Hamiltonian	O
that	O
was	O
derived	O
by	O
simultaneous	O
fitting	O
to	O
a	O
wide	O
range	O
of	O
linear	O
spectroscopic	O
measurements	O
and	O
described	O
within	O
modified	O
Redfield	O
theory	O
.	O

The	O
model	O
obtains	O
reasonable	O
agreement	O
with	O
most	O
aspects	O
of	O
the	O
two	O
-	O
dimensional	O
spectra	O
,	O
including	O
the	O
overall	O
peak	O
shapes	O
and	O
excited	O
state	O
absorption	O
features	O
.	O

It	O
does	O
not	O
reproduce	O
the	O
rapid	O
equilibration	O
from	O
high	O
energy	O
to	O
low	O
energy	O
excitonic	O
states	O
evident	O
by	O
a	O
strong	O
cross	O
-	O
peak	O
below	O
the	O
diagonal	O
.	O

We	O
explore	O
modifications	O
to	O
the	O
model	O
to	O
incorporate	O
new	O
structural	O
data	O
and	O
improve	O
agreement	O
with	O
the	O
two	O
-	O
dimensional	O
spectra	O
.	O

We	O
find	O
that	O
strengthening	O
the	O
system	O
-	O
bath	O
coupling	O
and	O
lowering	O
the	O
degree	O
of	O
disorder	O
significantly	O
improves	O
agreement	O
with	O
the	O
cross	O
-	O
peak	O
feature	O
,	O
while	O
lessening	O
agreement	O
with	O
the	O
relative	O
diagonal	O
/	O
antidiagonal	O
width	O
of	O
the	O
2D	O
spectra	O
.	O

We	O
conclude	O
that	O
two	O
-	O
dimensional	O
electronic	O
spectroscopy	O
provides	O
a	O
sensitive	O
test	O
of	O
excitonic	O
models	O
of	O
the	O
photosystem	O
II	O
reaction	O
center	O
and	O
discuss	O
avenues	O
for	O
further	O
refinement	O
of	O
such	O
models	O
.	O

Stabilization	O
and	O
inhibition	O
of	O
protein	O
-	O
protein	O
interactions	O
:	O
the	O
14	O
-	O
3	O
-	O
3	O
case	O
study	O
.	O

Small	O
-	O
molecule	O
modulation	O
of	O
protein	O
-	O
protein	O
interactions	O
(	O
PPIs	O
)	O
is	O
one	O
of	O
the	O
most	O
exciting	O
but	O
also	O
difficult	O
fields	O
in	O
chemical	O
biology	O
and	O
drug	O
development	O
.	O

As	O
one	O
of	O
the	O
most	O
important	O
"	O
hub	O
"	O
proteins	O
with	O
at	O
least	O
200	O
-	O
300	O
interaction	O
partners	O
,	O
the	O
14	O
-	O
3	O
-	O
3	O
proteins	O
are	O
an	O
especially	O
fruitful	O
case	O
for	O
PPI	O
intervention	O
.	O

Here	O
,	O
we	O
summarize	O
recent	O
success	O
stories	O
in	O
small	O
-	O
molecule	O
modulation	O
,	O
both	O
inhibition	O
and	O
stabilization	O
,	O
of	O
14	O
-	O
3	O
-	O
3	O
PPIs	O
.	O

The	O
chemical	O
breath	O
of	O
modulators	O
includes	O
natural	O
products	O
such	O
as	O
fusicoccin	B
A	I
and	O
derivatives	O
but	O
also	O
compounds	O
identified	O
via	O
high	O
-	O
throughput	O
and	O
in	O
silico	O
screening	O
,	O
which	O
has	O
yielded	O
a	O
toolbox	O
of	O
useful	O
inhibitors	O
and	O
stabilizers	O
for	O
this	O
interesting	O
class	O
of	O
adapter	O
proteins	O
.	O

Protein	O
-	O
protein	O
interactions	O
(	O
PPIs	O
)	O
are	O
involved	O
in	O
almost	O
all	O
biological	O
processes	O
,	O
with	O
any	O
given	O
protein	O
typically	O
engaged	O
in	O
complexes	O
with	O
other	O
proteins	O
for	O
the	O
majority	O
of	O
its	O
lifetime	O
.	O

Hence	O
,	O
proteins	O
function	O
not	O
simply	O
as	O
single	O
,	O
isolated	O
entities	O
but	O
display	O
their	O
roles	O
by	O
interacting	O
with	O
other	O
cellular	O
components	O
.	O

These	O
different	O
interaction	O
patterns	O
are	O
presumably	O
as	O
important	O
as	O
the	O
intrinsic	O
biochemical	O
activity	O
status	O
of	O
the	O
protein	O
itself	O
.	O

The	O
biological	O
role	O
of	O
a	O
protein	O
is	O
therefore	O
decisively	O
dependent	O
on	O
the	O
underlying	O
PPI	O
network	O
that	O
furthermore	O
can	O
show	O
great	O
spatial	O
and	O
temporal	O
variations	O
.	O

A	O
thorough	O
appreciation	O
and	O
understanding	O
of	O
this	O
concept	O
and	O
its	O
regulation	O
mechanisms	O
could	O
help	O
to	O
develop	O
new	O
therapeutic	O
agents	O
and	O
concepts	O
.	O

Protective	O
effect	O
of	O
70	O
%	O
ethanolic	O
extract	O
of	O
Lindera	O
obtusiloba	O
Blume	O
on	O
tert	B
-	I
butyl	I
hydroperoxide	I
-	O
induced	O
oxidative	O
hepatotoxicity	O
in	O
rats	O
.	O

Lindera	O
obtusiloba	O
Blume	O
,	O
a	O
native	O
plant	O
of	O
East	O
Asia	O
,	O
has	O
traditionally	O
been	O
used	O
as	O
a	O
folk	O
medicine	O
for	O
liver	O
disease	O
.	O

We	O
studied	O
the	O
in	O
vitro	O
antioxidant	O
and	O
in	O
vivo	O
hepatoprotective	O
activities	O
of	O
a	O
70	O
%	O
ethanolic	O
extract	O
of	O
L.	O
obtusiloba	O
(	O
LOE	O
)	O
containing	O
62.9	O
%	O
quercitrin	B
and	O
22.0	O
%	O
afzelin	B
.	O

LOE	O
prevented	O
tert	B
-	I
butyl	I
hydroperoxide	I
(	O
t	B
-	I
BHP	I
)	O
-induced	O
oxidative	O
damage	O
in	O
HepG2	O
cells	O
.	O

Along	O
with	O
its	O
high	O
antioxidant	O
potency	O
in	O
vitro	O
,	O
our	O
animal	O
study	O
confirmed	O
that	O
pretreatment	O
with	O
LOE	O
(	O
500	O
or	O
2000	O
mg	O
/	O
kg	O
)	O
for	O
7	O
days	O
prior	O
to	O
a	O
single	O
dose	O
of	O
t	B
-	I
BHP	I
(	O
i.p	O
.	O
:	O
0.5	O
mmol	O
/	O
kg	O
)	O
significantly	O
lowered	O
the	O
serum	O
levels	O
of	O
alanine	B
and	O
aspartate	B
aminotransferases	O
.	O

In	O
addition	O
,	O
glutathione	B
levels	O
were	O
increased	O
in	O
the	O
liver	O
,	O
and	O
lipid	O
peroxidation	O
levels	O
were	O
decreased	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

The	O
histopathological	O
examinations	O
of	O
rat	O
livers	O
showed	O
that	O
LOE	O
significantly	O
reduced	O
the	O
incidence	O
of	O
liver	O
lesions	O
induced	O
by	O
t	B
-	I
BHP	I
.	O

Therefore	O
,	O
we	O
concluded	O
that	O
LOE	O
has	O
merit	O
as	O
a	O
potent	O
candidate	O
to	O
protect	O
the	O
liver	O
against	O
oxidative	O
damage	O
.	O

ADP	B
-	O
ribosylation	O
of	O
guanosine	B
by	O
SCO5461	O
protein	O
secreted	O
from	O
Streptomyces	O
coelicolor	O
.	O

The	O
Streptomyces	O
coelicolor	O
A3	O
(	O
2	O
)	O
genome	O
encodes	O
a	O
possible	O
secretion	O
protein	O
,	O
SCO5461	O
,	O
that	O
shares	O
a	O
30	O
%	O
homology	O
with	O
the	O
activity	O
domains	O
of	O
two	O
toxic	O
ADP	B
-	O
ribosyltransferases	O
,	O
pierisins	O
and	O
mosquitocidal	O
toxin	O
.	O

We	O
found	O
ADP	B
-	O
ribosylating	O
activity	O
for	O
the	O
SCO5461	O
protein	O
product	O
through	O
its	O
co	O
-	O
incubation	O
with	O
guanosine	B
and	O
NAD	B
(	I
+	I
)	I
,	O
which	O
resulted	O
in	O
the	O
formation	O
of	O
N	B
(	I
2	I
)	I
-	I
(	I
ADP	I
-	I
ribos-1-yl	I
)	I
-guanosine	I
(	O
(	B
ar2	I
)	I
Guo	I
)	O
,	O
with	O
a	O
K	O
(	O
m	O
)	O
value	O
of	O
110	O
M.	O
SCO5461	O
was	O
further	O
found	O
to	O
ADP	B
-	O
ribosylate	O
deoxyguanosine	B
,	O
GMP	B
,	O
dGMP	B
,	O
GTP	B
,	O
dGTP	B
,	O
and	O
cyclic	B
GMP	I
with	O
k	O
(	O
cat	O
)	O
values	O
of	O
150	O
-	O
370	O
s	O
(	O
-1	O
)	O
.	O

Oligo	O
(	O
dG	O
)	O
,	O
oligo	O
(	O
G	O
)	O
,	O
and	O
yeast	O
tRNA	O
were	O
also	O
ADP	B
-	O
ribosylated	O
by	O
this	O
protein	O
,	O
although	O
with	O
much	O
lower	O
k	O
(	O
cat	O
)	O
values	O
of	O
0.2	O
s	O
(	O
-1	O
)	O
or	O
less	O
.	O

SCO5461	O
showed	O
maximum	O
ADP	B
-	O
ribosylation	O
activity	O
towards	O
guanosine	O
at	O
30	O
	O
C	O
,	O
and	O
maintained	O
20	O
%	O
of	O
these	O
maximum	O
activity	O
levels	O
even	O
at	O
0	O
	O
C	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
the	O
ADP	B
-	O
ribosylation	O
of	O
guanosine	B
and	O
guanine	B
mononucleotides	I
among	O
the	O
family	O
members	O
of	O
various	O
ADP	B
-	O
ribosylating	O
enzymes	O
.	O

We	O
additionally	O
observed	O
secretion	O
of	O
the	O
putative	O
gene	O
product	O
,	O
SCO5461	O
,	O
in	O
liquid	O
cultures	O
of	O
S.	O
coelicolor	O
.	O

We	O
thus	O
designated	O
the	O
SCO5461	O
protein	O
product	O
as	O
S.	O
coelicolor	O
ADP	B
-	O
ribosylating	O
protein	O
,	O
ScARP	O
.	O

Our	O
current	O
results	O
could	O
offer	O
new	O
insights	O
into	O
not	O
only	O
the	O
ADP	B
-	O
ribosylation	O
of	O
small	O
molecules	O
but	O
also	O
signal	O
transduction	O
events	O
via	O
enzymatic	O
nucleoside	B
modification	O
by	O
toxin	O
-	O
related	O
enzymes	O
.	O

Theoretical	O
study	O
of	O
the	O
reaction	O
of	O
CH2XO	B
(	O
X	O
=	O
F	B
,	O
Cl	B
,	O
Br	B
)	O
radicals	O
with	O
the	O
NO	B
radical	O
.	O

In	O
this	O
paper	O
,	O
we	O
focus	O
on	O
the	O
multiple	O
-	O
channel	O
reactions	O
of	O
CH	B
(	I
2	I
)	I
XO	I
(	O
X	O
=	O
F	O
,	O
Cl	B
,	O
Br	B
)	O
radicals	O
with	O
the	O
NO	B
radical	O
by	O
means	O
of	O
direct	O
dynamic	O
methods	O
.	O

All	O
structures	O
of	O
the	O
stationary	O
points	O
were	O
obtained	O
at	O
the	O
MP2	O
/	O
6	O
-	O
311+G	O
(	O
d	O
,	O
p	O
)	O
level	O
and	O
vibrational	O
frequency	O
analysis	O
was	O
also	O
performed	O
at	O
this	O
level	O
of	O
theory	O
.	O

The	O
minimum	O
energy	O
path	O
(	O
MEP	O
)	O
was	O
obtained	O
via	O
the	O
intrinsic	O
reaction	O
coordinate	O
(	O
IRC	O
)	O
theory	O
at	O
the	O
MP2	O
/	O
6	O
-	O
311+G	O
(	O
d	O
,	O
p	O
)	O
level	O
,	O
and	O
higher	O
-	O
level	O
energetic	O
information	O
was	O
refined	O
by	O
the	O
MC	O
-	O
QCISD	O
method	O
.	O

The	O
rate	O
constants	O
for	O
the	O
three	O
hydrogen	B
abstraction	O
reaction	O
channels	O
over	O
the	O
temperature	O
range	O
200	O
-	O
1,500	O
K	O
were	O
calculated	O
by	O
the	O
improved	O
canonical	O
variational	O
transition	O
state	O
theory	O
(	O
ICVT	O
)	O
with	O
a	O
correction	O
for	O
small	O
-	O
curvature	O
tunneling	O
(	O
SCT	O
)	O
.	O

The	O
rate	O
constants	O
calculated	O
in	O
this	O
manner	O
were	O
in	O
good	O
agreement	O
with	O
the	O
available	O
experimental	O
data	O
,	O
and	O
the	O
three	O
-	O
parameter	O
rate	O
-	O
temperature	O
formulae	O
for	O
the	O
temperature	O
range	O
200	O
-	O
1,500	O
K	O
were	O
k	O
(	O
1a	O
)	O
(	O
T	O
)	O
=	O
0.32	O
	O
10	O
(	O
-18	O
)	O
T	O
(	O
1.83	O
)	O
exp	O
(	O
1748.54	O
/	O
T	O
)	O
,	O
k	O
(	O
2a	O
)	O
(	O
T	O
)	O
=	O
0.22	O
	O
10	O
(	O
-19	O
)	O
T	O
(	O
2.19	O
)	O
exp	O
(	O
1770.19	O
/	O
T	O
)	O
,	O
k	O
(	O
3a	O
)	O
(	O
T	O
)	O
=	O
0.88	O
	O
10	O
(	O
-20	O
)	O
T	O
(	O
2.20	O
)	O
exp	O
(	O
1513.82	O
/	O
T	O
)	O
(	O
in	O
units	O
of	O
cm	O
(	O
3	O
)	O
molecule	O
(	O
-1	O
)	O
s	O
(	O
-1	O
)	O
)	O
.	O

The	O
V499G	O
/	O
Y501H	O
mutation	O
impairs	O
fast	O
motor	O
kinetics	O
of	O
prestin	O
and	O
has	O
significance	O
for	O
defining	O
functional	O
independence	O
of	O
individual	O
prestin	O
subunits	O
.	O

Outer	O
hair	O
cells	O
(	O
OHCs	O
)	O
are	O
a	O
mammalian	O
innovation	O
for	O
mechanically	O
amplifying	O
sound	O
energy	O
to	O
overcome	O
the	O
viscous	O
damping	O
of	O
the	O
cochlear	O
partition	O
.	O

Although	O
the	O
voltage	O
-	O
dependent	O
OHC	O
membrane	O
motor	O
,	O
prestin	O
,	O
has	O
been	O
demonstrated	O
to	O
be	O
essential	O
for	O
mammalian	O
cochlear	O
amplification	O
,	O
the	O
molecular	O
mechanism	O
by	O
which	O
prestin	O
converts	O
electrical	O
energy	O
into	O
mechanical	O
displacement	O
/	O
force	O
remains	O
elusive	O
.	O

Identifying	O
mutations	O
that	O
alter	O
the	O
motor	O
function	O
of	O
prestin	O
provides	O
vital	O
information	O
for	O
unraveling	O
the	O
energy	O
transduction	O
mechanism	O
of	O
prestin	O
.	O

We	O
show	O
that	O
the	O
V499G	O
/	O
Y501H	O
mutation	O
does	O
not	O
deprive	O
prestin	O
of	O
its	O
voltage	O
-	O
induced	O
motor	O
activity	O
,	O
but	O
it	O
does	O
significantly	O
impair	O
the	O
fast	O
motor	O
kinetics	O
and	O
voltage	O
operating	O
range	O
.	O

Furthermore	O
,	O
mutagenesis	O
studies	O
suggest	O
that	O
Val-499	B
is	O
the	O
primary	O
site	O
responsible	O
for	O
these	O
changes	O
.	O

We	O
also	O
show	O
that	O
V499G	O
/	O
Y501H	O
prestin	O
forms	O
heteromers	O
with	O
wild	O
-	O
type	O
prestin	O
and	O
that	O
the	O
fast	O
motor	O
kinetics	O
of	O
wild	O
-	O
type	O
prestin	O
is	O
not	O
affected	O
by	O
heteromer	O
formation	O
with	O
V499G	O
/	O
Y501H	O
prestin	O
.	O

These	O
results	O
suggest	O
that	O
prestin	O
subunits	O
are	O
individually	O
functional	O
within	O
a	O
given	O
multimer	O
.	O

Adsorption	O
of	O
phenanthrene	B
,	O
2-naphthol	B
,	O
and	O
1-naphthylamine	B
to	O
colloidal	O
oxidized	O
multiwalled	O
carbon	B
nanotubes	O
:	O
effects	O
of	O
humic	O
acid	O
and	O
surfactant	O
modification	O
.	O

Carbon	B
nanotubes	O
(	O
CNTs	O
)	O
can	O
exist	O
in	O
the	O
form	O
of	O
colloidal	O
suspension	O
in	O
aquatic	O
environments	O
,	O
particularly	O
in	O
the	O
presence	O
of	O
natural	O
organic	O
matter	O
or	O
surfactants	O
,	O
and	O
may	O
significantly	O
affect	O
the	O
fate	O
and	O
transport	O
of	O
organic	O
contaminants	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
authors	O
examined	O
the	O
adsorption	O
of	O
phenanthrene	B
,	O
2-naphthol	B
,	O
and	O
1-naphthylamine	B
to	O
three	O
colloidal	O
CNTs	O
,	O
including	O
a	O
stable	O
suspension	O
of	O
oxidized	O
multiwalled	O
carbon	B
nanotubes	O
(	O
O	O
-	O
MWNT	O
)	O
,	O
a	O
humic	O
acid	O
(	O
HA	O
)	O
-modified	O
colloidal	O
O	O
-	O
MWNT	O
,	O
and	O
a	O
sodium	B
dodecyl	I
sulfate	I
(	O
SDS	B
)	O
-modified	O
colloidal	O
O	O
-	O
MWNT	O
.	O

All	O
three	O
colloidal	O
O	O
-	O
MWNTs	O
exhibit	O
strong	O
adsorption	O
affinities	O
to	O
the	O
three	O
test	O
compounds	O
(	O
with	O
K	O
(	O
OC	O
)	O
values	O
orders	O
of	O
magnitude	O
greater	O
than	O
those	O
of	O
natural	O
organic	O
matter	O
)	O
,	O
likely	O
resulting	O
from	O
strong	O
nonhydrophobic	O
interactions	O
such	O
as	O
	O
-	O
	O
electron	O
donor	O
-	O
acceptor	O
interactions	O
and	O
Lewis	B
acid	I
-	O
base	O
interactions	O
.	O

When	O
thoroughly	O
mixed	O
,	O
HA	O
(	O
at	O
310	O
mg	O
HA	O
/	O
g	O
CNT	O
)	O
and	O
SDS	B
(	O
at	O
750	O
mg	O
SDS	B
/	O
g	O
CNT	O
)	O
significantly	O
affected	O
the	O
aggregation	O
properties	O
of	O
O	O
-	O
MWNT	O
,	O
causing	O
individually	O
dispersed	O
tubes	O
to	O
form	O
a	O
loosely	O
entangled	O
network	O
.	O

The	O
effects	O
of	O
HA	O
or	O
SDS	B
modification	O
on	O
adsorption	O
are	O
twofold	O
.	O

Adsorption	O
of	O
HA	O
/	O
SDS	B
significantly	O
reduces	O
surface	O
areas	O
of	O
O	O
-	O
MWNT	O
;	O
however	O
,	O
the	O
entangled	O
network	O
allows	O
adsorbate	O
molecules	O
to	O
interact	O
simultaneously	O
with	O
multiple	O
tubes	O
.	O

An	O
important	O
implication	O
is	O
that	O
humic	O
substances	O
and	O
surfactant	O
-	O
like	O
materials	O
not	O
only	O
facilitate	O
the	O
formation	O
of	O
colloidal	O
carbon	B
nanoparticles	O
but	O
also	O
affect	O
how	O
these	O
colloidal	O
carbon	B
nanoparticles	O
adsorb	O
organic	O
contaminants	O
.	O

Immunological	O
and	O
reproductive	O
health	O
assessment	O
in	O
herring	O
gulls	O
and	O
black	O
-	O
crowned	O
night	O
herons	O
in	O
the	O
Hudson	O
-	O
Raritan	O
Estuary	O
.	O

Previous	O
studies	O
have	O
shown	O
inexplicable	O
declines	O
in	O
breeding	O
waterbirds	O
within	O
western	O
New	O
York	O
/	O
New	O
Jersey	O
Harbor	O
between	O
1996	O
and	O
2002	O
and	O
elevated	O
polychlorinated	B
dibenzo	I
-	I
p	I
-	I
dioxins	I
and	O
polychlorinated	B
biphenyls	I
(	O
PCBs	B
)	O
in	O
double	O
-	O
crested	O
cormorant	O
(	O
Phalacrocorax	O
auritus	O
)	O
eggs	O
.	O

The	O
present	O
study	O
assessed	O
associations	O
between	O
immune	O
function	O
,	O
prefledgling	O
survival	O
,	O
and	O
selected	O
organochlorine	B
compounds	O
and	O
metals	O
in	O
herring	O
gulls	O
(	O
Larus	O
argentatus	O
)	O
and	O
black	O
-	O
crowned	O
night	O
herons	O
(	O
Nycticorax	O
nycticorax	O
)	O
in	O
lower	O
New	O
York	O
Harbor	O
during	O
2003	O
.	O

In	O
pipping	O
gull	O
embryos	O
,	O
lymphoid	O
cells	O
were	O
counted	O
in	O
the	O
thymus	O
and	O
bursa	O
of	O
Fabricius	O
(	O
sites	O
of	O
T	O
and	O
B	O
lymphocyte	O
maturation	O
,	O
respectively	O
)	O
.	O

The	O
phytohemagglutinin	O
(	O
PHA	O
)	O
skin	O
response	O
assessed	O
T	O
cell	O
function	O
in	O
gull	O
and	O
heron	O
chicks	O
.	O

Lymphocyte	O
proliferation	O
was	O
measured	O
in	O
vitro	O
in	O
adult	O
and	O
prefledgling	O
gulls	O
.	O

Reference	O
data	O
came	O
from	O
the	O
Great	O
Lakes	O
and	O
Bay	O
of	O
Fundy	O
.	O

Survival	O
of	O
prefledgling	O
gulls	O
was	O
poor	O
,	O
with	O
only	O
0.68	O
and	O
0.5	O
chicks	O
per	O
nest	O
surviving	O
to	O
three	O
and	O
four	O
weeks	O
after	O
hatch	O
,	O
respectively	O
.	O

Developing	O
lymphoid	O
cells	O
were	O
reduced	O
51	O
%	O
in	O
the	O
thymus	O
and	O
42	O
%	O
in	O
the	O
bursa	O
of	O
gull	O
embryos	O
from	O
New	O
York	O
Harbor	O
.	O

In	O
vitro	O
lymphocyte	O
assays	O
demonstrated	O
reduced	O
spontaneous	O
proliferation	O
,	O
reduced	O
T	O
cell	O
mitogen	O
-	O
induced	O
proliferation	O
,	O
and	O
increased	O
B	O
cell	O
mitogen	O
-	O
induced	O
proliferation	O
in	O
gull	O
chicks	O
from	O
New	O
York	O
Harbor	O
.	O

The	O
PHA	O
skin	O
response	O
was	O
suppressed	O
70	O
to	O
80	O
%	O
in	O
gull	O
and	O
heron	O
chicks	O
.	O

Strong	O
negative	O
correlations	O
(	O
r	O
=	O
-0.95	O
to	O
-0.98	O
)	O
between	O
the	O
PHA	O
response	O
and	O
dioxins	B
and	O
PCBs	B
in	O
gull	O
livers	O
was	O
strong	O
evidence	O
suggesting	O
that	O
these	O
chemicals	O
contribute	O
significantly	O
to	O
immunosuppression	O
in	O
New	O
York	O
Harbor	O
waterbirds	O
.	O

Functional	O
imaging	O
of	O
legumain	O
in	O
cancer	O
using	O
a	O
new	O
quenched	O
activity	O
-	O
based	O
probe	O
.	O

Legumain	O
is	O
a	O
lysosomal	O
cysteine	B
protease	O
whose	O
biological	O
function	O
remains	O
poorly	O
defined	O
.	O

Legumain	O
activity	O
is	O
up	O
-	O
regulated	O
in	O
most	O
human	O
cancers	O
and	O
inflammatory	O
diseases	O
most	O
likely	O
as	O
the	O
result	O
of	O
high	O
expression	O
in	O
populations	O
of	O
activated	O
macrophages	O
.	O

Within	O
the	O
tumor	O
microenvironment	O
,	O
legumain	O
activity	O
is	O
thought	O
to	O
promote	O
tumorigenesis	O
.	O

To	O
obtain	O
a	O
greater	O
understanding	O
of	O
the	O
role	O
of	O
legumain	O
activity	O
during	O
cancer	O
progression	O
and	O
inflammation	O
,	O
we	O
developed	O
an	O
activity	O
-	O
based	O
probe	O
that	O
becomes	O
fluorescent	O
only	O
upon	O
binding	O
active	O
legumain	O
.	O

This	O
probe	O
is	O
highly	O
selective	O
for	O
legumain	O
,	O
even	O
in	O
the	O
context	O
of	O
whole	O
cells	O
and	O
tissues	O
,	O
and	O
is	O
also	O
a	O
more	O
effective	O
label	O
of	O
legumain	O
than	O
previously	O
reported	O
probes	O
.	O

Here	O
we	O
present	O
the	O
synthesis	O
and	O
application	O
of	O
our	O
probe	O
to	O
the	O
analysis	O
of	O
legumain	O
activity	O
in	O
primary	O
macrophages	O
and	O
in	O
two	O
mouse	O
models	O
of	O
cancer	O
.	O

We	O
find	O
that	O
legumain	O
activity	O
is	O
highly	O
correlated	O
with	O
macrophage	O
activation	O
and	O
furthermore	O
that	O
it	O
is	O
an	O
ideal	O
marker	O
for	O
primary	O
tumor	O
inflammation	O
and	O
early	O
stage	O
metastatic	O
lesions	O
.	O

Optical	O
pumping	O
of	O
a	O
single	O
electron	O
spin	O
bound	O
to	O
a	O
fluorine	B
donor	O
in	O
a	O
ZnSe	B
nanostructure	O
.	O

Here	O
we	O
demonstrate	O
optical	O
pumping	O
of	O
a	O
single	O
electron	O
within	O
a	O
semiconductor	O
nanostructure	O
comprised	O
of	O
a	O
single	O
fluorine	B
donor	O
located	O
within	O
a	O
ZnSe	B
/	O
ZnMgSe	B
quantum	O
well	O
.	O

Experiments	O
were	O
performed	O
to	O
detect	O
optical	O
pumping	O
behavior	O
by	O
observing	O
single	O
photons	O
emitted	O
from	O
the	O
nanostructure	O
when	O
the	O
electron	O
changes	O
spin	O
state	O
.	O

These	O
results	O
demonstrate	O
initialization	O
and	O
read	O
-	O
out	O
of	O
the	O
electron	O
spin	O
qubit	O
and	O
open	O
the	O
door	O
for	O
coherent	O
optical	O
manipulation	O
of	O
a	O
spin	O
by	O
taking	O
advantage	O
of	O
an	O
unconventional	O
nanostructure	O
.	O

Interleukin-6	O
induces	O
vascular	O
endothelial	O
growth	O
factor	O
expression	O
and	O
promotes	O
angiogenesis	O
through	O
apoptosis	O
signal	O
-	O
regulating	O
kinase	O
1	O
in	O
human	O
osteosarcoma	O
.	O

Osteosarcoma	O
is	O
characterized	O
by	O
a	O
high	O
malignant	O
and	O
metastatic	O
potential	O
.	O

Angiogenesis	O
is	O
essential	O
for	O
the	O
caner	O
metastasis	O
.	O

Interleukin-6	O
(	O
IL-6	O
)	O
is	O
a	O
multifunctional	O
cytokine	O
that	O
is	O
associated	O
with	O
the	O
disease	O
status	O
and	O
outcomes	O
of	O
cancers	O
.	O

However	O
,	O
the	O
relationship	O
between	O
IL-6	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
expression	O
in	O
human	O
osteosarcoma	O
is	O
mostly	O
unknown	O
.	O

Here	O
we	O
found	O
that	O
the	O
IL-6	O
and	O
VEGF	O
expression	O
was	O
correlated	O
with	O
tumor	O
stage	O
and	O
significantly	O
higher	O
than	O
that	O
in	O
normal	O
bone	O
.	O

Incubation	O
of	O
osteosarcoma	O
cells	O
with	O
IL-6	O
increased	O
VEGF	O
mRNA	O
and	O
protein	O
expression	O
.	O

Pretreatment	O
of	O
cells	O
with	O
IL-6R	O
antibody	O
reduced	O
IL-6-mediated	O
VEGF	O
production	O
.	O

The	O
apoptosis	O
signal	O
-	O
regulating	O
kinase	O
1	O
(	O
ASK1	O
)	O
/	O
p38	O
/	O
AP-1	O
pathway	O
was	O
activated	O
after	O
IL-6	O
treatment	O
,	O
and	O
IL-6-induced	O
VEGF	O
expression	O
was	O
abolished	O
by	O
the	O
specific	O
inhibitor	O
and	O
siRNA	O
of	O
ASK1	O
,	O
p38	O
,	O
and	O
AP-1	O
cascades	O
.	O

Importantly	O
,	O
knockdown	O
IL-6	O
reduced	O
VEGF	O
expression	O
and	O
abolished	O
osteosarcoma	O
conditional	O
medium	O
-	O
mediated	O
angiogenesis	O
.	O

Taken	O
together	O
,	O
these	O
results	O
indicate	O
that	O
IL-6	O
occurs	O
through	O
ASK1	O
and	O
p38	O
,	O
which	O
in	O
turn	O
activates	O
AP-1	O
,	O
resulting	O
in	O
the	O
activations	O
of	O
VEGF	O
expression	O
and	O
contributing	O
the	O
angiogenesis	O
of	O
human	O
osteosarcoma	O
cells	O
.	O

4-tert	B
-	I
Octylphenol	I
stimulates	O
the	O
expression	O
of	O
cathepsins	O
in	O
human	O
breast	O
cancer	O
cells	O
and	O
xenografted	O
breast	O
tumors	O
of	O
a	O
mouse	O
model	O
via	O
an	O
estrogen	B
receptor	O
-	O
mediated	O
signaling	O
pathway	O
.	O

Endocrine	O
disrupting	O
chemicals	O
(	O
EDCs	O
)	O
are	O
defined	O
as	O
environmental	O
compounds	O
that	O
modulate	O
steroid	B
hormone	O
receptor	O
-	O
dependent	O
responses	O
an	O
abnormal	O
manner	O
,	O
resulting	O
in	O
adverse	O
health	O
problems	O
for	O
humans	O
such	O
as	O
cancer	O
growth	O
and	O
metastasis	O
.	O

Cathepsins	O
are	O
proteases	O
that	O
have	O
been	O
implicated	O
in	O
cancer	O
progression	O
.	O

However	O
,	O
there	O
have	O
been	O
few	O
studies	O
about	O
the	O
association	O
between	O
cathepsins	O
and	O
estrogenic	O
chemicals	O
during	O
the	O
cancer	O
progression	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
effect	O
(	O
s	O
)	O
of	O
4-tert	B
-	I
octylphenol	I
(	O
OP	O
)	O
,	O
a	O
potent	O
EDC	O
,	O
on	O
the	O
expression	O
of	O
cathepsins	O
B	O
and	O
D	O
in	O
human	O
MCF-7	O
breast	O
cancer	O
cells	O
and	O
a	O
xenograft	O
mouse	O
model	O
.	O

Treatment	O
with	O
OP	O
significantly	O
induced	O
the	O
proliferation	O
MCF-7	O
cells	O
in	O
an	O
MTT	B
assay	O
.	O

In	O
addition	O
,	O
the	O
expression	O
of	O
cathepsins	O
B	O
and	O
D	O
was	O
markedly	O
enhanced	O
in	O
MCF-7	O
cells	O
at	O
both	O
the	O
transcriptional	O
and	O
the	O
translational	O
levels	O
following	O
treatment	O
with	O
E2	O
or	O
OP	O
up	O
to	O
48h	O
.	O

These	O
results	O
demonstrated	O
the	O
ability	O
of	O
OP	O
to	O
disrupt	O
normal	O
transcriptional	O
regulation	O
of	O
cathepsins	O
B	O
and	O
D	O
in	O
human	O
breast	O
cancer	O
cells	O
.	O

However	O
,	O
the	O
effects	O
of	O
OP	O
on	O
cell	O
growth	O
or	O
overexpression	O
of	O
cathepsins	O
by	O
inhibiting	O
ER	O
-	O
mediated	O
signaling	O
were	O
abolished	O
by	O
an	O
ER	O
antagonist	O
and	O
siRNA	O
specific	O
for	O
ER	O
.	O

In	O
conclusion	O
,	O
our	O
findings	O
suggest	O
that	O
OP	O
at	O
10	O
(	O
-6	O
)	O
M	O
,	O
like	O
E2	O
,	O
may	O
accelerate	O
breast	O
cancer	O
cell	O
proliferation	O
and	O
the	O
expression	O
of	O
cathepsins	O
through	O
an	O
ER	O
-	O
mediated	O
signaling	O
pathway	O
.	O

In	O
addition	O
,	O
the	O
breast	O
cancer	O
cells	O
exposed	O
with	O
OP	O
to	O
a	O
xenograft	O
mouse	O
model	O
were	O
more	O
aggressive	O
according	O
to	O
our	O
histological	O
analysis	O
and	O
showed	O
markedly	O
increased	O
expression	O
of	O
cathepsin	O
B.	O
These	O
effects	O
of	O
mouse	O
model	O
resulted	O
in	O
an	O
increased	O
potential	O
for	O
metastasis	O
in	O
breast	O
cancer	O
.	O

Taken	O
together	O
,	O
we	O
determined	O
that	O
OP	O
can	O
adversely	O
affect	O
human	O
health	O
by	O
promoting	O
cancer	O
proliferation	O
and	O
metastasis	O
through	O
the	O
amplification	O
of	O
cathepsins	O
B	O
and	O
D	O
via	O
the	O
ER	O
-	O
mediated	O
signaling	O
pathway	O
.	O

Improvement	O
in	O
pelvic	O
pain	O
with	O
botulinum	O
toxin	O
type	O
A	O
-	O
Single	O
vs.	O
repeat	O
injections	O
.	O

The	O
aim	O
of	O
this	O
prospective	O
study	O
was	O
to	O
report	O
the	O
outcomes	O
of	O
pain	O
and	O
vaginal	O
pressures	O
of	O
successive	O
botulinum	O
toxin	O
type	O
A	O
injections	O
for	O
women	O
with	O
objective	O
pelvic	O
floor	O
muscle	O
overactivity	O
and	O
a	O
two	O
-	O
year	O
history	O
of	O
pelvic	O
pain	O
.	O

Between	O
2005	O
and	O
2008	O
,	O
37	O
women	O
underwent	O
injection	O
of	O
100	O
IU	O
of	O
botulinum	O
toxin	O
type	O
A	O
into	O
the	O
puborectalis	O
and	O
pubococcygeous	O
muscles	O
with	O
dysmenorrhoea	O
,	O
dyspareunia	O
,	O
dyschesia	O
,	O
and	O
non	O
-	O
menstrual	O
pelvic	O
pain	O
assessed	O
using	O
a	O
visual	O
analogue	O
scale	O
(	O
VAS	O
)	O
,	O
and	O
vaginal	O
pressure	O
measured	O
by	O
vaginal	O
manometry	O
,	O
at	O
0	O
,	O
4	O
,	O
12	O
and	O
26	O
weeks	O
from	O
each	O
injection	O
.	O

26	O
women	O
(	O
70	O
%	O
)	O
had	O
one	O
injection	O
of	O
botulinum	O
toxin	O
type	O
A	O
and	O
11	O
(	O
30	O
%	O
)	O
had	O
2	O
or	O
more	O
injections	O
.	O

The	O
second	O
injection	O
was	O
performed	O
at	O
the	O
earliest	O
at	O
26	O
weeks	O
after	O
the	O
first	O
,	O
with	O
subsequent	O
injections	O
having	O
a	O
median	O
time	O
to	O
re	O
-	O
injection	O
of	O
33.4	O
weeks	O
(	O
range	O
9.4	O
-	O
122.7	O
weeks	O
)	O
.	O

Single	O
and	O
repeated	O
injections	O
both	O
demonstrated	O
a	O
statistically	O
significant	O
reduction	O
in	O
dyspareunia	O
by	O
VAS	O
scores	O
from	O
54	O
to	O
30	O
in	O
the	O
single	O
injection	O
group	O
and	O
from	O
51	O
to	O
23	O
in	O
the	O
multiple	O
injection	O
group	O
(	O
p	O
=	O
.001	O
)	O
,	O
non	O
-	O
menstrual	O
pelvic	O
pain	O
VAS	O
from	O
37	O
to	O
25	O
(	O
p	O
=	O
.04	O
)	O
,	O
as	O
well	O
as	O
vaginal	O
pressures	O
;	O
40	O
versus	O
34	O
cm	O
H	B
(	I
2	I
)	I
O	I
(	O
p	O
=	O
.02	O
)	O
.	O

No	O
statistically	O
significant	O
difference	O
in	O
dysmenorrhoea	O
or	O
dyschesia	O
was	O
observed	O
for	O
either	O
group	O
from	O
their	O
baseline	O
scores	O
.	O

Multiple	O
injections	O
of	O
botulinum	O
toxin	O
type	O
A	O
in	O
women	O
with	O
pelvic	O
floor	O
muscle	O
overactivity	O
provide	O
significant	O
relief	O
from	O
dyspareunia	O
and	O
non	O
-	O
menstrual	O
pelvic	O
pain	O
.	O

The	O
upper	O
limit	O
between	O
re	O
-	O
injection	O
is	O
not	O
yet	O
determined	O
,	O
nor	O
is	O
the	O
maximum	O
number	O
of	O
treatments	O
.	O

Clinical	O
outcomes	O
for	O
single	O
and	O
subsequent	O
injection	O
of	O
botulinum	O
toxin	O
type	O
A	O
for	O
recurrent	O
pelvic	O
pain	O
are	O
equivalent	O
.	O

Women	O
who	O
have	O
had	O
benefit	O
from	O
a	O
single	O
injection	O
of	O
botulinum	O
toxin	O
type	O
A	O
can	O
be	O
reassured	O
that	O
if	O
symptoms	O
reoccur	O
,	O
repeated	O
injections	O
can	O
be	O
expected	O
to	O
be	O
equally	O
efficacious	O
.	O

A	O
polyacetylene	B
-	O
rich	O
extract	O
from	O
Gymnaster	O
koraiensis	O
strongly	O
inhibits	O
colitis	O
-	O
associated	O
colon	O
cancer	O
in	O
mice	O
.	O

Gymnaster	O
koraiensis	O
(	O
GK	O
)	O
is	O
a	O
Korean	O
herb	O
used	O
in	O
folk	O
medicine	O
and	O
recently	O
found	O
to	O
positively	O
impact	O
liver	O
health	O
.	O

Because	O
GK	O
contains	O
polyacetylenes	B
and	O
because	O
other	O
polyacetylenes	B
have	O
been	O
found	O
to	O
exhibit	O
anti	O
-	O
inflammatory	O
and	O
anti	O
-	O
cancer	O
activities	O
,	O
we	O
hypothesized	O
that	O
the	O
polyacetylene	B
gymnasterkoreayne	B
B	I
(	O
GKB	B
)	O
,	O
known	O
to	O
increase	O
hepatic	O
detoxification	O
enzymes	O
,	O
may	O
also	O
exert	O
anti	O
-	O
inflammatory	O
and	O
anti	O
-	O
cancer	O
activities	O
.	O

We	O
fed	O
male	O
C57BL	O
/	O
6	O
mice	O
purified	O
AIN93	O
G	O
diets	O
containing	O
no	O
additions	O
,	O
GKB	B
or	O
the	O
GKB	B
-	O
rich	O
fraction	O
of	O
an	O
ethanol	B
extract	O
(	O
GE	O
)	O
from	O
GK	O
to	O
determine	O
if	O
these	O
diets	O
would	O
slow	O
or	O
prevent	O
either	O
inflammation	O
or	O
inflammation	O
-	O
enhanced	O
colon	O
cancer	O
,	O
using	O
the	O
dextran	O
sulfate	O
sodium	B
/	O
azoxymethane	B
mouse	O
model	O
.	O

The	O
GKB	B
(	O
500	O
mol	O
/	O
kg	O
diet	O
daily	O
)	O
showed	O
some	O
anti	O
-	O
inflammatory	O
activity	O
,	O
but	O
GE	O
,	O
containing	O
an	O
equal	O
dose	O
of	O
GKB	B
,	O
protected	O
strongly	O
against	O
both	O
inflammation	O
and	O
colon	O
cancer	O
,	O
decreasing	O
adenocarcinomas	O
by	O
90	O
%	O
.	O

These	O
data	O
support	O
further	O
research	O
into	O
GK	O
as	O
a	O
promising	O
potential	O
anti	O
-	O
cancer	O
agent	O
.	O

The	O
diverse	O
roles	O
of	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drug	O
activated	O
gene	O
(	O
NAG-1	O
/	O
GDF15	O
)	O
in	O
cancer	O
.	O

Nonsteroidal	O
anti	O
-	O
inflammatory	O
drug	O
(	O
NSAID	O
)	O
activated	O
gene-1	O
,	O
NAG-1	O
,	O
is	O
a	O
divergent	O
member	O
of	O
the	O
transforming	O
growth	O
factor	O
-	O
beta	O
(	O
TGF	O
-	O
	O
)	O
superfamily	O
that	O
plays	O
a	O
complex	O
but	O
poorly	O
understood	O
role	O
in	O
several	O
human	O
diseases	O
including	O
cancer	O
.	O

NAG-1	O
expression	O
is	O
substantially	O
increased	O
during	O
cancer	O
development	O
and	O
progression	O
especially	O
in	O
gastrointestinal	O
,	O
prostate	O
,	O
pancreatic	O
,	O
colorectal	O
,	O
breast	O
,	O
melanoma	O
,	O
and	O
glioblastoma	O
brain	O
tumors	O
.	O

Aberrant	O
increases	O
in	O
the	O
serum	O
levels	O
of	O
secreted	O
NAG-1	O
correlate	O
with	O
poor	O
prognosis	O
and	O
patient	O
survival	O
rates	O
in	O
some	O
cancers	O
.	O

In	O
contrast	O
,	O
the	O
expression	O
of	O
NAG-1	O
is	O
up	O
-	O
regulated	O
by	O
several	O
tumor	O
suppressor	O
pathways	O
including	O
p53	O
,	O
GSK-3	O
,	O
and	O
EGR-1	O
.	O

NAG-1	O
expression	O
is	O
also	O
induced	O
by	O
many	O
drugs	O
and	O
dietary	O
compounds	O
which	O
are	O
documented	O
to	O
prevent	O
the	O
development	O
and	O
progression	O
of	O
cancer	O
in	O
mouse	O
models	O
.	O

Studies	O
with	O
transgenic	O
mice	O
expressing	O
human	O
NAG-1	O
demonstrated	O
that	O
the	O
expression	O
of	O
NAG-1	O
inhibits	O
the	O
development	O
of	O
intestinal	O
tumors	O
and	O
prostate	O
tumors	O
in	O
animal	O
models	O
.	O

Laboratory	O
and	O
clinical	O
evidence	O
suggest	O
that	O
NAG-1	O
,	O
like	O
other	O
TGF	O
-	O
	O
family	O
members	O
,	O
may	O
have	O
different	O
or	O
pleiotropic	O
functions	O
in	O
the	O
early	O
and	O
late	O
stages	O
of	O
carcinogenesis	O
.	O

Upon	O
understanding	O
the	O
molecular	O
mechanism	O
and	O
function	O
of	O
NAG-1	O
during	O
carcinogenesis	O
,	O
NAG-1	O
may	O
serve	O
as	O
a	O
potential	O
biomarker	O
for	O
the	O
diagnosis	O
and	O
prognosis	O
of	O
cancer	O
and	O
a	O
therapeutic	O
target	O
for	O
the	O
inhibition	O
and	O
treatment	O
of	O
cancer	O
development	O
and	O
progression	O
.	O

Induction	O
of	O
hepatic	O
CYP3A	O
enzymes	O
by	O
pregnancy	O
-	O
related	O
hormones	O
:	O
studies	O
in	O
human	O
hepatocytes	O
and	O
hepatic	O
cell	O
lines	O
.	O

CYP3A	O
activity	O
is	O
induced	O
by	O
approximately	O
2-fold	O
during	O
the	O
third	O
trimester	O
of	O
human	O
pregnancy	O
.	O

Placental	O
growth	O
hormone	O
(	O
PGH	O
)	O
,	O
estrogens	B
(	O
primarily	O
17	B
-	I
estradiol	I
)	O
,	O
cortisol	B
,	O
and	O
progesterone	B
have	O
the	O
potential	O
to	O
modulate	O
CYP3A	O
activity	O
.	O

Therefore	O
,	O
we	O
determined	O
whether	O
the	O
elevated	O
plasma	O
concentrations	O
of	O
these	O
hormones	O
during	O
pregnancy	O
induce	O
hepatic	O
CYP3A	O
expression	O
.	O

We	O
incubated	O
sandwich	O
-	O
cultured	O
human	O
hepatocytes	O
(	O
SCHH	O
)	O
from	O
premenopausal	O
female	O
donors	O
(	O
n	O
=	O
2	O
)	O
with	O
the	O
physiologic	O
(	O
unbound	O
,	O
1	O
	O
total	O
)	O
and	O
the	O
10	O
	O
total	O
third	O
trimester	O
hormone	O
plasma	O
concentrations	O
(	O
individually	O
and	O
in	O
combination	O
)	O
and	O
determined	O
their	O
effect	O
on	O
CYP3A	O
activity	O
and	O
the	O
transcripts	O
of	O
CYP3A4	O
,	O
CYP3A5	O
,	O
and	O
the	O
respective	O
hormone	O
receptors	O
(	O
growth	O
hormone	O
receptor	O
,	O
glucocorticoid	O
receptor	O
,	O
and	O
estrogen	B
receptor	O
alpha	O
)	O
.	O

Of	O
all	O
the	O
hormones	O
,	O
cortisol	B
was	O
the	O
most	O
potent	O
inducer	O
of	O
CYP3A	O
activity	O
and	O
CYP3A4	O
,	O
CYP3A5	O
mRNA	O
expression	O
.	O

The	O
combination	O
of	O
PGH	O
/	O
growth	O
hormone	O
and	O
cortisol	B
induced	O
CYP3A	O
activity	O
and	O
expression	O
significantly	O
more	O
than	O
did	O
cortisol	B
alone	O
.	O

When	O
incubated	O
with	O
the	O
unbound	O
or	O
total	O
plasma	O
concentration	O
of	O
all	O
the	O
hormones	O
,	O
CYP3A	O
activity	O
in	O
SCHH	O
was	O
induced	O
to	O
an	O
extent	O
comparable	O
to	O
that	O
observed	O
in	O
vivo	O
during	O
the	O
third	O
trimester	O
.	O

These	O
hormones	O
had	O
only	O
a	O
modest	O
effect	O
on	O
the	O
mRNA	O
expression	O
of	O
the	O
hormone	O
receptors	O
.	O

The	O
pattern	O
of	O
induction	O
observed	O
in	O
SCHH	O
was	O
reproduced	O
in	O
HepaRG	O
cells	O
but	O
not	O
in	O
HuH7	O
/	O
HepG2	O
cells	O
.	O

SCHH	O
or	O
HepaRG	O
cells	O
could	O
be	O
used	O
to	O
determine	O
the	O
mechanistic	O
basis	O
of	O
CYP3A	O
induction	O
during	O
pregnancy	O
and	O
to	O
predict	O
the	O
magnitude	O
of	O
induction	O
likely	O
to	O
be	O
observed	O
during	O
the	O
first	O
and	O
second	O
trimesters	O
,	O
when	O
phenotyping	O
studies	O
to	O
measure	O
in	O
vivo	O
CYP3A	O
activity	O
are	O
logistically	O
difficult	O
to	O
perform	O
.	O

Membrane	O
protein	O
native	O
state	O
discrimination	O
by	O
implicit	O
membrane	O
models	O
.	O

Four	O
implicit	O
membrane	O
models	O
[	O
IMM1	O
,	O
generalized	O
Born	O
(	O
GB	O
)	O
-surface	O
area	O
-	O
implicit	O
membrane	O
(	O
GBSAIM	O
)	O
,	O
GB	O
with	O
a	O
simple	O
switching	O
(	O
GBSW	O
)	O
,	O
and	O
heterogeneous	O
dielectric	O
GB	O
(	O
HDGB	O
)	O
]	O
were	O
tested	O
for	O
their	O
ability	O
to	O
discriminate	O
the	O
native	O
conformation	O
of	O
five	O
membrane	O
proteins	O
from	O
450	O
decoys	O
generated	O
by	O
the	O
Rosetta	O
-	O
Membrane	O
program	O
.	O

The	O
energy	O
ranking	O
of	O
the	O
native	O
state	O
and	O
Z	O
-	O
scores	O
were	O
used	O
to	O
assess	O
the	O
performance	O
of	O
the	O
models	O
.	O

The	O
effect	O
of	O
membrane	O
thickness	O
was	O
examined	O
and	O
was	O
found	O
to	O
be	O
substantial	O
.	O

Quite	O
satisfactory	O
discrimination	O
was	O
achieved	O
with	O
the	O
all	O
-	O
atom	O
IMM1	O
and	O
GBSW	O
models	O
at	O
25.4	O
	O
thickness	O
and	O
with	O
the	O
HDGB	O
model	O
at	O
28.5	O
	O
thickness	O
.	O

The	O
energy	O
components	O
by	O
themselves	O
were	O
not	O
discriminative	O
.	O

Both	O
van	O
der	O
Waals	O
and	O
electrostatic	O
interactions	O
contributed	O
to	O
native	O
state	O
discrimination	O
,	O
to	O
a	O
different	O
extent	O
in	O
each	O
model	O
.	O

Computational	O
efficiency	O
of	O
the	O
models	O
decreased	O
in	O
the	O
order	O
:	O
extended	O
-	O
atom	O
IMM1	O
>	O
all	O
-	O
atom	O
IMM1	O
>	O
GBSAIM	O
>	O
GBSW	O
>	O
HDGB	O
.	O

These	O
results	O
encourage	O
the	O
further	O
development	O
and	O
use	O
of	O
implicit	O
membrane	O
models	O
for	O
membrane	O
protein	O
structure	O
prediction	O
.	O

2-Phenoxy	B
-	I
nicotinamides	I
are	O
potent	O
agonists	O
at	O
the	O
bile	B
acid	I
receptor	O
GPBAR1	O
(	O
TGR5	O
)	O
.	O

Potency	O
with	O
potential	O
:	O
2-Phenoxy	B
-	I
nicotinamides	I
were	O
identified	O
as	O
potent	O
agonists	O
at	O
the	O
GPBAR1	O
receptor	O
,	O
a	O
target	O
in	O
the	O
treatment	O
of	O
obesity	O
,	O
type	O
2	O
diabetes	O
and	O
metabolic	O
syndrome	O
.	O

Extensive	O
structure	O
-	O
activity	O
relationship	O
studies	O
supported	O
by	O
homology	O
modeling	O
and	O
docking	O
resulted	O
in	O
the	O
identification	O
of	O
optimized	O
GPBAR1	O
agonists	O
,	O
potent	O
against	O
both	O
human	O
and	O
mouse	O
receptors	O
,	O
endowed	O
with	O
favorable	O
physicochemical	O
properties	O
and	O
good	O
metabolic	O
stability	O
.	O

Organotins	B
:	O
A	O
review	O
of	O
their	O
reproductive	O
toxicity	O
,	O
biochemistry	O
,	O
and	O
environmental	O
fate	O
.	O

The	O
review	O
purposes	O
are	O
to	O
(	O
1	O
)	O
evaluate	O
the	O
experimental	O
evidence	O
for	O
adverse	O
effects	O
on	O
reproduction	O
and	O
metabolism	O
and	O
(	O
2	O
)	O
identify	O
the	O
current	O
knowledge	O
of	O
analytical	O
procedures	O
,	O
biochemistry	O
and	O
environmental	O
aspects	O
relating	O
to	O
organotins	B
.	O

Organotins	B
are	O
pollutants	O
that	O
are	O
used	O
as	O
biocides	O
in	O
antifouling	O
paints	O
.	O

They	O
produce	O
endocrine	O
-	O
disrupting	O
effects	O
in	O
mollusks	O
,	O
such	O
as	O
imposex	O
.	O

In	O
rodents	O
,	O
organotin	B
exposure	O
induces	O
developmental	O
and	O
reproductive	O
toxicity	O
as	O
well	O
as	O
alteration	O
of	O
metabolic	O
homeostasis	O
through	O
its	O
action	O
as	O
an	O
obesogen	O
.	O

The	O
adverse	O
effects	O
that	O
appear	O
in	O
rodents	O
have	O
raised	O
concerns	O
about	O
organotins	B
'	O
potential	O
health	O
risk	O
to	O
humans	O
in	O
relation	O
to	O
organotin	B
exposure	O
.	O

At	O
present	O
,	O
triorganotin	B
,	O
such	O
as	O
tributyltin	B
,	O
have	O
been	O
demonstrated	O
to	O
produce	O
imposex	O
,	O
and	O
mammalian	O
reproductive	O
and	O
metabolic	O
toxicity	O
.	O

For	O
most	O
mammals	O
,	O
triorganotin	B
exposure	O
predominantly	O
occurs	O
through	O
the	O
ingestion	O
,	O
and	O
this	O
compound	O
can	O
cross	O
the	O
placenta	O
.	O

With	O
these	O
risks	O
in	O
mind	O
,	O
it	O
is	O
important	O
to	O
improve	O
our	O
knowledge	O
of	O
organotins	B
'	O
effects	O
on	O
environmental	O
health	O
.	O

Multiple	O
microRNAs	O
may	O
regulate	O
the	O
DNA	O
repair	O
enzyme	O
uracil	B
-	O
DNA	O
glycosylase	O
.	O

Human	O
nuclear	O
uracil	B
-	O
DNA	O
glycosylase	O
UNG2	O
is	O
essential	O
for	O
post	O
-	O
replicative	O
repair	O
of	O
uracil	B
in	O
DNA	O
,	O
and	O
UNG2	O
protein	O
and	O
mRNA	O
levels	O
rapidly	O
decline	O
in	O
G2	O
/	O
M	O
phase	O
.	O

Previous	O
work	O
has	O
demonstrated	O
regulation	O
of	O
UNG2	O
at	O
the	O
transcriptional	O
level	O
,	O
as	O
well	O
as	O
by	O
protein	O
phosphorylation	O
and	O
ubiquitylation	O
.	O

UNG2	O
mRNA	O
,	O
encoded	O
by	O
the	O
UNG	O
gene	O
,	O
contains	O
a	O
long	O
3'untranslated	O
region	O
(	O
3'UTR	O
)	O
of	O
previously	O
unknown	O
function	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
several	O
conserved	O
regions	O
in	O
the	O
3'UTR	O
are	O
potential	O
seed	O
sites	O
for	O
microRNAs	O
(	O
miRNAs	O
)	O
,	O
such	O
as	O
miR-16	O
,	O
miR-34c	O
,	O
and	O
miR-199a	O
.	O

Our	O
results	O
show	O
that	O
these	O
miRNAs	O
down	O
-	O
regulate	O
UNG	O
activity	O
,	O
UNG	O
mRNA	O
,	O
and	O
UNG	O
protein	O
levels	O
.	O

Down	O
-	O
regulation	O
was	O
dependent	O
on	O
the	O
3'UTR	O
,	O
indicating	O
that	O
the	O
miRNAs	O
directly	O
target	O
the	O
conserved	O
seed	O
sites	O
in	O
the	O
3'UTR	O
.	O

These	O
results	O
add	O
miRNAs	O
as	O
a	O
new	O
modality	O
to	O
UNG	O
's	O
increasing	O
list	O
of	O
complex	O
regulatory	O
mechanisms	O
.	O

Synthesis	O
and	O
antibacterial	O
evaluation	O
of	O
novel	O
11,4-disubstituted	B
azithromycin	I
analogs	O
with	O
greatly	O
improved	O
activity	O
against	O
erythromycin	B
-	O
resistant	O
bacteria	O
.	O

A	O
series	O
of	O
novel	O
11,4-disubstituted	B
azithromycin	I
analogs	O
were	O
synthesized	O
and	O
evaluated	O
for	O
their	O
antibacterial	O
activity	O
.	O

All	O
the	O
11,4-disubstituted	O
analogs	O
exhibited	O
excellent	O
activity	O
(	O
0.03	O
-	O
0.12	O
g	O
/	O
ml	O
)	O
against	O
erythromycin	B
-	O
susceptible	O
Streptococcus	O
pneumoniae	O
,	O
and	O
significantly	O
improved	O
activity	O
against	O
three	O
phenotypes	O
of	O
erythromycin	B
-	O
resistant	O
S.	O
pneumoniae	O
compared	O
with	O
erythromycin	B
A	I
,	O
clarithromycin	B
or	O
azithromycin	B
.	O

Among	O
them	O
,	O
compounds	O
26	O
-	O
28	O
showed	O
the	O
most	O
potent	O
activity	O
(	O
0.25	O
,	O
0.03	O
and	O
2	O
g	O
/	O
ml	O
)	O
against	O
S.	O
pneumoniae	O
expressing	O
the	O
erm	O
gene	O
,	O
the	O
mef	O
gene	O
and	O
the	O
erm	O
and	O
mef	O
genes	O
,	O
respectively	O
.	O

In	O
addition	O
,	O
compound	O
28	O
was	O
the	O
most	O
effective	O
(	O
0.03	O
and	O
0.12	O
g	O
/	O
ml	O
)	O
against	O
erythromycin	B
-	O
susceptible	O
S.	O
pneumoniae	O
and	O
Staphylococcus	O
aureus	O
as	O
well	O
.	O

It	O
is	O
noteworthy	O
that	O
the	O
most	O
active	O
compounds	O
described	O
above	O
possess	O
the	O
same	O
terminal	O
3,5-dinitrophenyl	B
groups	O
on	O
their	O
C-4	O
bisamide	B
side	O
chains	O
.	O

Neutral	O
and	O
charged	O
phosphine	B
/	I
scorpionate	I
copper	I
(	I
I	I
)	I
complexes	I
:	O
effects	O
of	O
ligand	O
assembly	O
on	O
their	O
antiproliferative	O
activity	O
.	O

Ligand	O
-	O
exchange	O
reactions	O
of	O
copper	B
(	I
I	I
)	I
precursors	O
(	O
[	B
Cu	I
(	I
CH	I
(	I
3	I
)	I
CN	I
)	I
(	I
4	I
)	I
]	I
BF	I
(	I
4	I
)	I
,	O
CuCl	B
)	O
with	O
a	O
panel	O
of	O
bis	B
(	I
azolyl	I
)	I
borates	I
or	O
poly	B
(	I
pyrazolyl	I
)	I
methanes	I
and	O
a	O
tertiary	B
monodentate	I
phosphine	I
(	O
PTA	B
=	O
1,3,5-triaza-7-phosphaadamantane	B
,	O
PCN	B
=	O
tris	B
(	I
cyanoethyl	I
)	I
phosphine	I
)	O
produced	O
two	O
series	O
of	O
heteroleptic	O
,	O
either	O
'	O
2	O
+	O
1	O
+	O
1'-	O
or	O
'	O
3	O
+	O
1'-type	O
complexes	O
,	O
which	O
have	O
been	O
characterized	O
by	O
elemental	O
analysis	O
,	O
FT	O
-	O
IR	O
,	O
ESI	O
-	O
MS	O
and	O
multinuclear	O
(	B
31	I
)	I
P	I
and	O
(	B
1	I
)	I
H	I
NMR	O
.	O
'	O
2	O
+	O
1	O
+	O
1'-type	O
complexes	O
include	O
a	O
N	O
,	B
N	O
-	O
bidentate	O
chelate	O
and	O
two	O
monodentate	O
phosphines	B
(	O
1	O
-	O
8	O
)	O
and	O
'	O
3	O
+	O
1'-type	O
complexes	O
comprise	O
a	O
N	O
,	B
N	O
,	B
O-	O
or	O
N	O
,	B
N	O
,	B
N	O
-	O
tridentate	O
chelate	O
and	O
one	O
monodentate	O
phosphine	B
(	O
9	O
-	O
12	O
)	O
.	O

All	O
these	O
complexes	O
adopt	O
a	O
four	O
-	O
coordinate	O
,	O
tetrahedral	O
geometry	O
.	O
'	O
3	O
+	O
1	O
'	O
complexes	O
show	O
better	O
red	O
-	O
ox	O
stability	O
and	O
a	O
greater	O
tendency	O
to	O
retain	O
the	O
native	O
'	O
3	O
+	O
1	O
'	O
mixed	O
-	O
ligand	O
structure	O
.	O

Conversely	O
,	O
'	O
2	O
+	O
1	O
+	O
1	O
'	O
complexes	O
exhibit	O
increased	O
propensity	O
to	O
dissociation	O
as	O
shown	O
by	O
ESI	O
-	O
MS	O
measurements	O
and	O
X	O
-	O
ray	O
structure	O
determination	O
at	O
low	O
temperature	O
(	O
150	O
K	O
)	O
of	O
the	O
polymeric	O
complex	O
{	B
[	I
H	I
(	I
2	I
)	I
B	I
(	I
tz	I
(	I
NO2	I
)	I
)	I
(	I
2	I
)	I
]	I
Cu	I
[	I
PCN	I
]	I
}	I
(	I
n	I
)	I
6b	O
.	O

In	O
this	O
complex	O
,	O
either	O
the	O
bis	B
(	I
triazolyl	I
)	I
borate	I
and	O
the	O
PCN	B
ligands	O
act	O
as	O
bidentate	O
,	O
with	O
PCN	B
being	O
also	O
the	O
	O
(	O
2	O
)	O
-bridiging	O
linker	O
between	O
adjacent	O
monomers	O
.	O

Compound	O
6b	O
is	O
the	O
first	O
reported	O
example	O
of	O
a	O
polymeric	O
PCN	B
compound	O
with	O
a	O
tetra	O
-	O
coordinate	O
metal	O
centre	O
.	O

Cytotoxic	O
activity	O
of	O
all	O
compounds	O
has	O
been	O
evaluated	O
by	O
MTT	B
test	O
against	O
a	O
panel	O
of	O
several	O
human	O
tumor	O
cell	O
lines	O
including	O
examples	O
of	O
breast	O
(	O
MCF-7	O
)	O
,	O
colon	O
(	O
HCT-15	O
and	O
LoVo	O
)	O
,	O
lung	O
(	O
A549	O
)	O
,	O
cervix	O
(	O
A431	O
)	O
and	O
ovarian	O
(	O
2008	O
and	O
its	O
cisplatin	B
resistant	O
variant	O
,	O
C13	O
*	O
)	O
carcinoma	O
,	O
melanoma	O
(	O
A375	O
)	O
and	O
promyelocytic	O
leukemia	O
(	O
HL60	O
)	O
.	O

Copper	B
complexes	O
generally	O
show	O
in	O
vitro	O
antitumour	O
activity	O
comparable	O
to	O
that	O
of	O
cisplatin	B
.	O

In	O
particular	O
,	O
neutral	O
'	O
3	O
+	O
1'-type	O
complexes	O
9	O
and	O
10	O
,	O
show	O
IC	O
(	O
50	O
)	O
values	O
appreciably	O
lower	O
than	O
those	O
exhibited	O
by	O
the	O
reference	O
metallodrug	O
.	O

Porphyrin	B
metabolisms	O
in	O
human	O
skin	O
commensal	O
Propionibacterium	O
acnes	O
bacteria	O
:	O
potential	O
application	O
to	O
monitor	O
human	O
radiation	O
risk	O
.	O

Propionibacterium	O
acnes	O
(	O
P.	O
acnes	O
)	O
,	O
a	O
Gram	O
-	O
positive	O
anaerobic	O
bacterium	O
,	O
is	O
a	O
commensal	O
organism	O
in	O
human	O
skin	O
.	O

Like	O
human	O
cells	O
,	O
the	O
bacteria	O
produce	O
porphyrins	B
,	O
which	O
exhibit	O
fluorescence	O
properties	O
and	O
make	O
bacteria	O
visible	O
with	O
a	O
Wood	O
's	O
lamp	O
.	O

In	O
this	O
review	O
,	O
we	O
compare	O
the	O
porphyrin	B
biosynthesis	O
in	O
humans	O
and	O
P.	O
acnes	O
.	O

Also	O
,	O
since	O
P.	O
acnes	O
living	O
on	O
the	O
surface	O
of	O
skin	O
receive	O
the	O
same	O
radiation	O
exposure	O
as	O
humans	O
,	O
we	O
envision	O
that	O
the	O
changes	O
in	O
porphyrin	B
profiles	O
(	O
the	O
absorption	O
spectra	O
and/or	O
metabolism	O
)	O
of	O
P.	O
acnes	O
by	O
radiation	O
may	O
mirror	O
the	O
response	O
of	O
human	O
cells	O
to	O
radiation	O
.	O

The	O
porphyrin	B
profiles	O
of	O
P.	O
acnes	O
may	O
be	O
a	O
more	O
accurate	O
reflection	O
of	O
radiation	O
risk	O
to	O
the	O
patient	O
than	O
other	O
biodosimeters	O
/	O
biomarkers	O
such	O
as	O
gene	O
up-	O
/	O
down	O
-	O
regulation	O
,	O
which	O
may	O
be	O
non	O
-	O
specific	O
due	O
to	O
patient	O
related	O
factors	O
such	O
as	O
autoimmune	O
diseases	O
.	O

Lastly	O
,	O
we	O
discuss	O
the	O
challenges	O
and	O
possible	O
solutions	O
for	O
using	O
the	O
P.	O
acnes	O
response	O
to	O
predict	O
the	O
radiation	O
risk	O
.	O

Design	O
and	O
synthesis	O
of	O
diazatricyclodecane	B
agonists	O
of	O
the	O
G	O
-	O
protein	O
-	O
coupled	O
receptor	O
119	O
.	O

A	O
series	O
of	O
GPR119	O
agonists	O
based	O
on	O
a	O
2,6-diazatricyclo	B
[	I
3.3.1.13,7	I
]	I
decane	I
ring	O
system	O
is	O
described	O
.	O

Also	O
provided	O
is	O
a	O
detailed	O
account	O
of	O
the	O
development	O
of	O
a	O
multigram	O
scale	O
synthesis	O
of	O
the	O
diazatricyclic	B
ring	O
system	O
,	O
which	O
was	O
achieved	O
using	O
a	O
Hofmann	O
-	O
Lffler	O
-	O
Freytag	O
reaction	O
as	O
the	O
key	O
step	O
.	O

The	O
basis	O
for	O
the	O
use	O
of	O
this	O
complex	O
framework	O
lies	O
in	O
an	O
attempt	O
to	O
constrain	O
one	O
end	O
of	O
the	O
molecule	O
in	O
the	O
"	O
agonist	O
conformation	O
"	O
as	O
was	O
previously	O
described	O
for	O
3-oxa-7-aza	B
-	I
bicyclo	I
[	I
3.3.1	I
]	I
nonanes	I
.	O

Optimization	O
of	O
carbamate	B
analogues	O
of	O
the	O
diazatricylic	B
compounds	O
led	O
to	O
the	O
identification	O
of	O
32i	O
as	O
a	O
potent	O
agonist	O
of	O
the	O
GPR119	O
receptor	O
with	O
low	O
unbound	O
human	O
liver	O
microsomal	O
clearance	O
.	O

The	O
use	O
of	O
an	O
agonist	O
response	O
weighted	O
ligand	O
lipophilic	O
efficiency	O
(	O
LLE	O
)	O
termed	O
AgLLE	O
is	O
discussed	O
along	O
with	O
the	O
issues	O
of	O
applying	O
efficiency	O
measures	O
to	O
agonist	O
programs	O
.	O

Ultimately	O
,	O
solubility	O
limited	O
absorption	O
and	O
poor	O
exposure	O
reduced	O
further	O
interest	O
in	O
these	O
molecules	O
.	O

Sulfonylureas	B
have	O
antifungal	O
activity	O
and	O
are	O
potent	O
inhibitors	O
of	O
Candida	O
albicans	O
acetohydroxyacid	O
synthase	O
.	O

The	O
sulfonylurea	B
herbicides	O
exert	O
their	O
activity	O
by	O
inhibiting	O
plant	O
acetohydroxyacid	O
synthase	O
(	O
AHAS	O
)	O
,	O
the	O
first	O
enzyme	O
in	O
the	O
branched	O
-	O
chain	O
amino	B
acid	I
biosynthesis	O
pathway	O
.	O

It	O
has	O
previously	O
been	O
shown	O
that	O
if	O
the	O
gene	O
for	O
AHAS	O
is	O
deleted	O
in	O
Candida	O
albicans	O
,	O
attenuation	O
of	O
virulence	O
is	O
achieved	O
,	O
suggesting	O
AHAS	O
as	O
an	O
antifungal	O
drug	O
target	O
.	O

Herein	O
,	O
we	O
have	O
cloned	O
,	O
expressed	O
,	O
and	O
purified	O
C.	O
albicans	O
AHAS	O
and	O
shown	O
that	O
several	O
sulfonylureas	B
are	O
inhibitors	O
of	O
this	O
enzyme	O
and	O
possess	O
antifungal	O
activity	O
.	O

The	O
most	O
potent	O
of	O
these	O
compounds	O
is	O
ethyl	B
2-	I
(	I
N-	I
(	I
(	I
4-iodo-6-methoxypyrimidin-2-yl	I
)	I
carbamoyl	I
)	I
sulfamoyl	I
)	I
benzoate	I
(	O
10c	O
)	O
,	O
which	O
has	O
a	O
K	O
(	O
i	O
)	O
value	O
of	O
3.8	O
nM	O
for	O
C.	O
albicans	O
AHAS	O
and	O
an	O
MIC	O
of	O
0.7	O
g	O
/	O
mL	O
for	O
this	O
fungus	O
in	O
cell	O
-	O
based	O
assays	O
.	O

For	O
the	O
sulfonylureas	B
tested	O
there	O
was	O
a	O
strong	O
correlation	O
between	O
inhibitory	O
activity	O
toward	O
C.	O
albicans	O
AHAS	O
and	O
fungicidal	O
activity	O
,	O
supporting	O
the	O
hypothesis	O
that	O
AHAS	O
is	O
the	O
target	O
for	O
their	O
inhibitory	O
activity	O
within	O
the	O
cell	O
.	O

Design	O
,	O
functionalization	O
strategies	O
and	O
biomedical	O
applications	O
of	O
targeted	O
biodegradable	O
/	O
biocompatible	O
polymer	O
-	O
based	O
nanocarriers	O
for	O
drug	O
delivery	O
.	O

Design	O
and	O
functionalization	O
strategies	O
for	O
multifunctional	O
nanocarriers	O
(	O
e.g.	O
,	O
nanoparticles	O
,	O
micelles	O
,	O
polymersomes	O
)	O
based	O
on	O
biodegradable	O
/	O
biocompatible	O
polymers	O
intended	O
to	O
be	O
employed	O
for	O
active	O
targeting	O
and	O
drug	O
delivery	O
are	O
reviewed	O
.	O

This	O
review	O
will	O
focus	O
on	O
the	O
nature	O
of	O
the	O
polymers	O
involved	O
in	O
the	O
preparation	O
of	O
targeted	O
nanocarriers	O
,	O
the	O
synthesis	O
methods	O
to	O
achieve	O
the	O
desired	O
macromolecular	O
architecture	O
,	O
the	O
selected	O
coupling	O
strategy	O
,	O
the	O
choice	O
of	O
the	O
homing	O
molecules	O
(	O
vitamins	O
,	O
hormones	O
,	O
peptides	O
,	O
proteins	O
,	O
etc	O
.	O
)	O
,	O
as	O
well	O
as	O
the	O
various	O
strategies	O
to	O
display	O
them	O
at	O
the	O
surface	O
of	O
nanocarriers	O
.	O

The	O
resulting	O
morphologies	O
and	O
the	O
main	O
colloidal	O
features	O
will	O
be	O
given	O
as	O
well	O
as	O
an	O
overview	O
of	O
the	O
biological	O
activities	O
,	O
with	O
a	O
special	O
focus	O
on	O
the	O
main	O
in	O
vivo	O
achievements	O
.	O

Characterization	O
of	O
arsenic	B
resistant	O
bacteria	O
from	O
arsenic	B
rich	O
groundwater	O
of	O
West	O
Bengal	O
,	O
India	O
.	O

Sixty	O
-	O
four	O
arsenic	B
(	O
As	B
)	O
resistant	O
bacteria	O
isolated	O
from	O
an	O
arsenic	B
rich	O
groundwater	O
sample	O
of	O
West	O
Bengal	O
were	O
characterized	O
to	O
investigate	O
their	O
potential	O
role	O
in	O
subsurface	O
arsenic	B
mobilization	O
.	O

Among	O
the	O
isolated	O
strains	O
predominance	O
of	O
genera	O
Agrobacterium	O
/	O
Rhizobium	O
,	O
Ochrobactrum	O
and	O
Achromobacter	O
which	O
could	O
grow	O
chemolitrophically	O
and	O
utilize	O
arsenic	B
as	O
electron	O
donor	O
were	O
detected	O
.	O

Higher	O
tolerance	O
to	O
As	B
(	I
3	I
+	I
)	I
[	O
maximum	O
tolerable	O
concentration	O
(	O
MTC	O
)	O
:	O
10	O
mM	O
]	O
,	O
As	B
(	O
5	O
+	O
)	O
(	O
MTC	O
:	O
100	O
mM	O
)	O
and	O
other	O
heavy	O
metals	O
like	O
Cu	B
(	I
2	I
+	I
)	I
,	O
Cr	B
(	I
2	I
+	I
)	I
,	O
Ni	B
(	I
2	I
+	I
)	I
etc	O
.	O

(	O
MTC	O
:	O
10	O
mM	O
)	O
,	O
presence	O
of	O
arsenate	B
reductase	O
and	O
siderophore	O
was	O
frequently	O
observed	O
among	O
the	O
isolates	O
.	O

Ability	O
to	O
produce	O
arsenite	B
oxidase	O
and	O
phosphatase	O
enzyme	O
was	O
detected	O
in	O
50	O
and	O
34	O
%	O
of	O
the	O
isolates	O
,	O
respectively	O
.	O

Although	O
no	O
direct	O
correlation	O
among	O
taxonomic	O
identity	O
of	O
bacterial	O
strains	O
and	O
their	O
metabolic	O
abilities	O
as	O
mentioned	O
above	O
was	O
apparent	O
,	O
several	O
isolates	O
affiliated	O
to	O
genera	O
Ochrobactrum	O
,	O
Achromobacter	O
and	O
unclassified	O
Rhizobiaceae	O
members	O
were	O
found	O
to	O
be	O
highly	O
resistant	O
to	O
As	B
(	I
3	I
+	I
)	I
and	O
As	B
(	I
5	I
+	I
)	I
and	O
positive	O
for	O
all	O
the	O
test	O
properties	O
.	O

Arsenate	B
reductase	O
activity	O
was	O
found	O
to	O
be	O
conferred	O
by	O
arsC	O
gene	O
,	O
which	O
in	O
many	O
strains	O
was	O
coupled	O
with	O
arsenite	B
efflux	O
gene	O
arsB	O
as	O
well	O
.	O

Phylogenetic	O
incongruence	O
between	O
the	O
16S	O
rRNA	O
and	O
ars	O
genes	O
lineages	O
indicated	O
possible	O
incidence	O
of	O
horizontal	O
gene	O
transfer	O
for	O
ars	O
genes	O
.	O

Based	O
on	O
the	O
results	O
we	O
propose	O
that	O
under	O
the	O
prevailing	O
low	O
nutrient	O
condition	O
inhabitant	O
bacteria	O
capable	O
of	O
using	O
inorganic	O
electron	O
donors	O
play	O
a	O
synergistic	O
role	O
wherein	O
siderophores	O
and	O
phosphatase	O
activities	O
facilitate	O
the	O
release	O
of	O
sediment	O
bound	O
As	B
(	I
5	I
+	I
)	I
,	O
which	O
is	O
subsequently	O
reduced	O
by	O
arsenate	B
reductase	O
resulting	O
into	O
the	O
mobilization	O
of	O
As	B
(	I
3	I
+	I
)	I
in	O
groundwater	O
.	O

Understanding	O
the	O
dark	O
and	O
light	O
-	O
enhanced	O
bactericidal	O
action	O
of	O
cationic	O
conjugated	O
polyelectrolytes	O
and	O
oligomers	O
.	O

A	O
multiscale	O
investigation	O
was	O
carried	O
out	O
to	O
study	O
the	O
dark	O
and	O
light	O
-	O
enhanced	O
bactericidal	O
mechanisms	O
of	O
poly	B
(	I
phenylene	I
ethynylene	I
)	I

(	O
PPE	B
)	O
-based	O
cationic	O
conjugated	O
polyelectrolytes	O
(	O
CPEs	O
)	O
and	O
oligo	B
-	I
phenylene	I
ethynylenes	I
(	O
OPEs	B
)	O
.	O

On	O
the	O
morphological	O
scale	O
,	O
Gram	O
-	O
negative	O
E.	O
coli	O
cells	O
exposed	O
to	O
CPE	O
and	O
OPE	B
compounds	O
in	O
the	O
dark	O
show	O
damage	O
to	O
the	O
cell	O
envelope	O
,	O
plasma	O
membrane	O
,	O
and	O
in	O
some	O
cases	O
the	O
cytoplasm	O
,	O
while	O
with	O
UV	O
-	O
irradiation	O
,	O
E.	O
coli	O
sustained	O
catastrophic	O
damages	O
to	O
both	O
the	O
cell	O
envelope	O
and	O
cytoplasm	O
.	O

In	O
contrast	O
,	O
the	O
Gram	O
-	O
positive	O
S.	O
epi	O
bacteria	O
appeared	O
intact	O
when	O
exposed	O
to	O
CPE	O
and	O
OPE	B
compounds	O
in	O
the	O
dark	O
but	O
showed	O
damages	O
to	O
the	O
cell	O
envelope	O
with	O
UV	O
-	O
irradiation	O
.	O

To	O
better	O
understand	O
the	O
molecular	O
basis	O
of	O
CPE-	O
and	O
OPE	B
-	O
induced	O
morphological	O
changes	O
and	O
damages	O
to	O
bacteria	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
these	O
compounds	O
on	O
model	O
bacterial	O
plasma	O
membrane	O
and	O
bacterial	O
proteins	O
and	O
plasmid	O
DNA	O
.	O

Measurements	O
of	O
dark	O
membrane	O
perturbation	O
activity	O
of	O
the	O
CPEs	O
and	O
OPEs	B
using	O
model	O
lipid	O
membranes	O
support	O
a	O
carpet	O
or	O
detergent	O
-	O
like	O
mechanism	O
by	O
which	O
the	O
antimicrobial	O
compounds	O
induce	O
membrane	O
collapse	O
and	O
phase	O
transitions	O
.	O

Under	O
UV	O
-	O
irradiation	O
,	O
E.	O
coli	O
bacteria	O
exposed	O
to	O
CPEs	O
and	O
OPEs	B
showed	O
covalent	O
modifications	O
and	O
damages	O
to	O
both	O
cellular	O
protein	O
and	O
plasmid	O
DNA	O
,	O
likely	O
through	O
oxidative	O
pathways	O
mediated	O
by	O
singlet	O
oxygen	B
and	O
subsequent	O
reactive	O
oxygen	B
species	O
sensitized	O
by	O
the	O
CPE	O
and	O
OPE	B
compounds	O
.	O

Our	O
finding	O
thus	O
show	O
that	O
the	O
antimicrobial	O
polymers	O
and	O
oligomers	O
exert	O
toxicity	O
toward	O
Gram	O
-	O
negative	O
bacteria	O
by	O
disrupting	O
the	O
morphology	O
and	O
structures	O
of	O
cell	O
envelope	O
and	O
cytoplasm	O
,	O
including	O
cellular	O
components	O
such	O
as	O
proteins	O
and	O
DNA	O
,	O
while	O
exert	O
toxicity	O
toward	O
Gram	O
-	O
positive	O
bacteria	O
by	O
binding	O
to	O
and	O
disrupting	O
just	O
the	O
cell	O
wall	O
.	O

Unconventional	O
growth	O
mechanism	O
for	O
monolithic	O
integration	O
of	O
III	O
-	O
V	O
on	O
silicon	B
.	O

The	O
heterogeneous	O
integration	O
of	O
III	O
-	O
V	O
optoelectronic	O
devices	O
with	O
Si	B
electronic	O
circuits	O
is	O
highly	O
desirable	O
because	O
it	O
will	O
enable	O
many	O
otherwise	O
unattainable	O
capabilities	O
.	O

However	O
,	O
direct	O
growth	O
of	O
III	O
-	O
V	O
thin	O
film	O
on	O
silicon	B
substrates	O
has	O
been	O
very	O
challenging	O
because	O
of	O
large	O
mismatches	O
in	O
lattice	O
constants	O
and	O
thermal	O
coefficients	O
.	O

Furthermore	O
,	O
the	O
high	O
epitaxial	O
growth	O
temperature	O
is	O
detrimental	O
to	O
transistor	O
performance	O
.	O

Here	O
,	O
we	O
present	O
a	O
detailed	O
studies	O
on	O
a	O
novel	O
growth	O
mode	O
which	O
yields	O
a	O
catalyst	O
-	O
free	O
(	O
Al	B
,	O
In	B
)	O
GaAs	B
nanopillar	O
laser	O
on	O
a	O
silicon	B
substrate	O
by	O
metal	O
-	O
organic	O
chemical	O
vapor	O
deposition	O
at	O
the	O
low	O
temperature	O
of	O
400	O
	O
C	O
.	O

We	O
study	O
the	O
growth	O
and	O
misfit	O
stress	O
relaxation	O
mechanism	O
by	O
cutting	O
through	O
the	O
center	O
of	O
the	O
InGaAs	B
/	O
GaAs	B
nanopillars	O
using	O
focused	O
ion	O
beam	O
and	O
inspecting	O
with	O
high	O
-	O
resolution	O
transmission	O
electron	O
microscopy	O
.	O

The	O
bulk	O
material	O
of	O
the	O
nanopillar	O
is	O
in	O
pure	O
wurtzite	B
crystal	O
phase	O
,	O
despite	O
the	O
6	O
%	O
lattice	O
mismatch	O
with	O
the	O
substrate	O
,	O
with	O
all	O
stacking	O
disorders	O
well	O
confined	O
in	O
the	O
bottom	O
-	O
most	O
transition	O
region	O
and	O
terminated	O
horizontally	O
.	O

Furthermore	O
,	O
InGaAs	B
was	O
found	O
to	O
be	O
in	O
direct	O
contact	O
with	O
silicon	B
,	O
in	O
agreement	O
with	O
the	O
observed	O
crystal	O
orientation	O
alignment	O
and	O
good	O
electrical	O
conduction	O
across	O
the	O
interface	O
.	O

This	O
is	O
in	O
sharp	O
contrast	O
to	O
many	O
III	O
-	O
V	O
nanowires	O
on	O
silicon	B
which	O
are	O
observed	O
to	O
stem	O
from	O
thin	O
SiN	B
(	I
x	I
)	I
,	O
SiO	B
(	I
2	I
)	I
,	O
or	O
SiO	B
(	I
2	I
)	I
/	O
Si	B
openings	O
.	O

In	O
addition	O
,	O
GaAs	B
was	O
found	O
to	O
grow	O
perfectly	O
as	O
a	O
shell	O
layer	O
on	O
In	B
(	I
0.2	I
)	I
Ga	I
(	I
0.8	I
)	I
As	I
with	O
an	O
extraordinary	O
thickness	O
,	O
which	O
is	O
15	O
times	O
greater	O
than	O
the	O
theoretical	O
thin	O
-	O
film	O
critical	O
thickness	O
for	O
a	O
1.5	O
%	O
lattice	O
mismatch	O
.	O

This	O
is	O
attributed	O
to	O
the	O
core	O
-	O
shell	O
radial	O
geometry	O
allowing	O
the	O
outer	O
layers	O
to	O
expand	O
and	O
release	O
the	O
strain	O
due	O
to	O
lattice	O
mismatch	O
.	O

The	O
findings	O
in	O
this	O
study	O
redefine	O
the	O
rules	O
for	O
lattice	O
-	O
mismatched	O
growth	O
on	O
heterogeneous	O
substrates	O
and	O
device	O
structure	O
design	O
.	O

Contrasting	O
toxicokinetic	O
evaluations	O
and	O
interspecies	O
pharmacokinetic	O
scaling	O
approaches	O
for	O
small	O
molecules	O
and	O
biologics	O
:	O
applicability	O
to	O
biosimilar	O
development	O
.	O

1	O
.	O

A	O
2-fold	O
threshold	O
typically	O
used	O
for	O
prediction	O
accuracy	O
of	O
interspecies	O
scaling	O
of	O
clearance	O
(	O
CL	O
)	O
may	O
be	O
too	O
liberal	O
when	O
using	O
pharmacokinetic	O
similarity	O
in	O
animals	O
to	O
advance	O
biosimilar	O
candidate	O
selection	O
for	O
clinical	O
testing	O
.	O

The	O
purpose	O
of	O
this	O
review	O
is	O
to	O
identify	O
interspecies	O
scaling	O
methods	O
for	O
use	O
in	O
de	O
-	O
risking	O
biosimilar	O
development	O
prior	O
to	O
clinical	O
testing	O
.	O

2	O
.	O

Scaling	O
approaches	O
for	O
predicting	O
macromolecule	O
CL	O
were	O
identified	O
through	O
literature	O
review	O
.	O

Reports	O
that	O
evaluated	O
predicted	O
and	O
observed	O
human	O
CLs	O
for	O
5	O
individual	O
compounds	O
were	O
considered	O
.	O

Absolute	O
average	O
fold	O
-	O
error	O
(	O
AAFE	O
)	O
was	O
calculated	O
for	O
each	O
method	O
along	O
with	O
the	O
proportion	O
of	O
compounds	O
with	O
individual	O
fold	O
-	O
error	O
values	O
within	O
a	O
tighter	O
threshold	O
of	O
0.7	O
-	O
1.3	O
.	O

3	O
.	O

Traditional	O
simple	O
allometry	O
with	O
a	O
minimum	O
of	O
three	O
species	O
and	O
the	O
rule	O
of	O
exponents	O
performed	O
inconsistently	O
with	O
some	O
groups	O
of	O
compounds	O
resulting	O
in	O
a	O
greater	O
than	O
2-fold	O
error	O
(	O
i.e.	O
AAFE	O
>	O
2	O
)	O
.	O

For	O
monoclonal	O
antibodies	O
(	O
mAbs	O
)	O
,	O
simplified	O
allometric	O
approaches	O
employing	O
a	O
single	O
species	O
(	O
monkey	O
)	O
with	O
a	O
fixed	O
exponent	O
of	O
0.85	O
consistently	O
resulted	O
in	O
lower	O
AAFEs	O
and	O
a	O
higher	O
proportion	O
of	O
compounds	O
within	O
the	O
tighter	O
range	O
of	O
0.7	O
-	O
1.3	O
.	O

4	O
.	O

For	O
macromolecules	O
,	O
and	O
particularly	O
mAbs	O
,	O
employing	O
single	O
-	O
species	O
monkey	O
"	O
simplified	O
"	O
allometric	O
approaches	O
with	O
a	O
fixed	O
exponent	O
of	O
0.85	O
may	O
be	O
more	O
appropriate	O
than	O
traditional	O
allometric	O
approaches	O
.	O

Peptide	O
/	O
protein	O
separation	O
with	O
cationic	O
polymer	O
brush	O
nanosponges	O
for	O
MALDI	O
-	O
MS	O
analysis	O
.	O

A	O
cationic	O
polymer	O
nanobrush	O
was	O
synthesized	O
,	O
attached	O
to	O
a	O
MALDI	O
target	O
,	O
and	O
used	O
for	O
the	O
fractionation	O
of	O
peptides	O
and	O
proteins	O
based	O
on	O
their	O
pI	O
,	O
prior	O
to	O
analysis	O
by	O
MALDI	O
-	O
MS	O
.	O

The	O
cationic	O
polymer	O
nanobrush	O
was	O
synthesized	O
on	O
a	O
gold	O
substrate	O
by	O
AIBN	B
photoinitiated	O
polymerization	O
,	O
using	O
a	O
70:30	O
ratio	O
of	O
2-aminoethyl	B
methacrylate	I
hydrochloride	I
(	O
AEMA	B
)	O
:N	O
-	B
isopropylacrylamide	I
(	O
NIPAAM	B
)	O
.	O

This	O
brush	O
showed	O
selectivity	O
for	O
adsorption	O
of	O
acidic	O
peptides	O
and	O
proteins	O
and	O
allowed	O
fractionation	O
of	O
simple	O
two	O
-	O
component	O
mixtures	O
to	O
be	O
completed	O
in	O
less	O
than	O
10	O
min	O
.	O

The	O
brush	O
-	O
adsorbed	O
biomolecules	O
were	O
recovered	O
by	O
treating	O
the	O
nanobrush	O
with	O
ammonium	B
hydroxide	I
,	O
which	O
effectively	O
collapsed	O
the	O
brush	O
,	O
thereby	O
releasing	O
the	O
trapped	O
compounds	O
for	O
MALDI	O
MS	O
analysis	O
.	O

These	O
results	O
demonstrate	O
that	O
nanobrush	O
can	O
serve	O
as	O
a	O
convenient	O
platform	O
for	O
rapid	O
fractionation	O
of	O
biomolecules	O
prior	O
to	O
analysis	O
by	O
MALDI	O
-	O
MS	O
.	O

Direct	O
measurement	O
of	O
Dirac	O
point	O
energy	O
at	O
the	O
graphene	B
/	O
oxide	B
interface	O
.	O

We	O
report	O
the	O
direct	O
measurement	O
of	O
the	O
Dirac	O
point	O
,	O
the	O
Fermi	O
level	O
,	O
and	O
the	O
work	O
function	O
of	O
graphene	B
by	O
performing	O
internal	O
photoemission	O
measurements	O
on	O
a	O
graphene	B
/	O
SiO	B
(	I
2	I
)	I
/	O
Si	B
structure	O
with	O
a	O
unique	O
optical	O
-	O
cavity	O
enhanced	O
test	O
structure	O
.	O

A	O
complete	O
electronic	O
band	O
alignment	O
at	O
the	O
graphene	B
/	O
SiO	B
(	I
2	I
)	I
/	O
Si	B
interfaces	O
is	O
accurately	O
established	O
.	O

The	O
observation	O
of	O
enhanced	O
photoemission	O
from	O
a	O
one	O
-	O
atom	O
thick	O
graphene	B
layer	O
was	O
possible	O
by	O
taking	O
advantage	O
of	O
the	O
constructive	O
optical	O
interference	O
in	O
the	O
SiO	B
(	I
2	I
)	I
cavity	O
.	O

The	O
photoemission	O
yield	O
was	O
found	O
to	O
follow	O
the	O
well	O
-	O
known	O
linear	O
density	O
-	O
of	O
-	O
states	O
dispersion	O
in	O
the	O
vicinity	O
of	O
the	O
Dirac	O
point	O
.	O

At	O
the	O
flat	O
band	O
condition	O
,	O
the	O
Fermi	O
level	O
was	O
extracted	O
and	O
found	O
to	O
reside	O
3.3	O
eV	O
	O
0.05	O
eV	O
below	O
the	O
bottom	O
of	O
the	O
SiO	B
(	I
2	I
)	I
conduction	O
band	O
.	O

When	O
combined	O
with	O
the	O
shift	O
of	O
the	O
Fermi	O
level	O
from	O
the	O
Dirac	O
point	O
,	O
we	O
are	O
able	O
to	O
ascertain	O
the	O
position	O
of	O
the	O
Dirac	O
point	O
at	O
3.6	O
eV	O
	O
0.05	O
eV	O
with	O
respect	O
to	O
the	O
bottom	O
of	O
the	O
SiO	B
(	I
2	I
)	I
conduction	O
band	O
edge	O
,	O
yielding	O
a	O
work	O
function	O
of	O
4.5	O
eV	O
	O
0.05	O
eV	O
which	O
is	O
in	O
an	O
excellent	O
agreement	O
with	O
theory	O
.	O

The	O
accurate	O
determination	O
of	O
the	O
work	O
function	O
of	O
graphene	B
is	O
of	O
significant	O
importance	O
to	O
the	O
engineering	O
of	O
graphene	B
-	O
based	O
devices	O
,	O
and	O
the	O
measurement	O
technique	O
we	O
have	O
advanced	O
in	O
this	O
Letter	O
will	O
have	O
significant	O
impact	O
on	O
numerous	O
applications	O
for	O
emerging	O
graphene	B
-	O
like	O
2-dimensional	O
material	O
systems	O
.	O

Overexpression	O
of	O
Escherichia	O
coli	O
nucleotide	B
excision	O
repair	O
genes	O
after	O
cisplatin	B
-	O
induced	O
damage	O
.	O

Cisplatin	B
is	O
currently	O
used	O
in	O
tumor	O
chemotherapy	O
to	O
induce	O
the	O
death	O
of	O
malignant	O
cells	O
through	O
blockage	O
of	O
DNA	O
replication	O
.	O

It	O
is	O
a	O
commonly	O
used	O
chemotherapeutic	O
agent	O
binding	O
mono-	O
or	O
bifunctionally	O
to	O
guanines	B
in	O
DNA	O
.	O

Escherichia	O
coli	O
K12	O
mutant	O
strains	O
deficient	O
in	O
nucleotide	B
excision	O
repair	O
(	O
NER	O
)	O
were	O
submitted	O
to	O
increasing	O
concentrations	O
of	O
cisplatin	B
,	O
and	O
the	O
results	O
revealed	O
that	O
uvrA	O
and	O
uvrB	O
mutants	O
are	O
sensitive	O
to	O
this	O
agent	O
,	O
while	O
uvrC	O
and	O
cho	O
mutants	O
remain	O
as	O
the	O
wild	O
type	O
strain	O
.	O

The	O
time	O
required	O
for	O
both	O
gene	O
expression	O
turn	O
-	O
off	O
and	O
return	O
to	O
normal	O
weight	O
DNA	O
in	O
wild	O
-	O
type	O
E.	O
coli	O
was	O
not	O
accomplished	O
even	O
after	O
4	O
h	O
post	O
-	O
treatment	O
with	O
cisplatin	B
,	O
while	O
the	O
same	O
process	O
takes	O
place	O
within	O
1.5	O
h	O
after	O
ultraviolet	O
radiation	O
(	O
UV	O
)	O
.	O

Besides	O
,	O
a	O
heavily	O
damaging	O
action	O
of	O
cisplatin	B
can	O
be	O
seen	O
not	O
only	O
by	O
persistent	O
nicks	O
on	O
genomic	O
DNA	O
,	O
but	O
also	O
by	O
NER	O
gene	O
expression	O
exceeding	O
manifold	O
that	O
seen	O
after	O
equivalent	O
lethal	O
doses	O
of	O
UV	O
.	O

Moreover	O
,	O
cisplatin	B
caused	O
an	O
increase	O
in	O
uvrB	O
gene	O
expression	O
from	O
its	O
putative	O
upstream	O
promoter	O
P3	O
in	O
an	O
SOS	O
-	O
independent	O
manner	O
.	O

Cockayne	O
syndrome	O
b	O
maintains	O
neural	O
precursor	O
function	O
.	O

Neurodevelopmental	O
defects	O
are	O
observed	O
in	O
the	O
hereditary	O
disorder	O
Cockayne	O
syndrome	O
(	O
CS	O
)	O
.	O

The	O
gene	O
most	O
frequently	O
mutated	O
in	O
CS	O
,	O
Cockayne	O
Syndrome	O
B	O
(	O
CSB	O
)	O
,	O
is	O
required	O
for	O
the	O
repair	O
of	O
bulky	O
DNA	O
adducts	O
in	O
transcribed	O
genes	O
during	O
transcription	O
-	O
coupled	O
nucleotide	O
excision	O
repair	O
.	O

CSB	O
also	O
plays	O
a	O
role	O
in	O
chromatin	O
remodeling	O
and	O
mitochondrial	O
function	O
.	O

The	O
role	O
of	O
CSB	O
in	O
neural	O
development	O
is	O
poorly	O
understood	O
.	O

Here	O
we	O
report	O
that	O
the	O
abundance	O
of	O
neural	O
progenitors	O
is	O
normal	O
in	O
Csb	O
(	O
-	O
/	O
-	O
)	O
mice	O
and	O
the	O
frequency	O
of	O
apoptotic	O
cells	O
in	O
the	O
neurogenic	O
niche	O
of	O
the	O
adult	O
subependymal	O
zone	O
is	O
similar	O
in	O
Csb	O
(	O
-	O
/	O
-	O
)	O
and	O
wild	O
type	O
mice	O
.	O

Both	O
embryonic	O
and	O
adult	O
Csb	O
(	O
-	O
/	O
-	O
)	O
neural	O
precursors	O
exhibited	O
defective	O
self	O
-	O
renewal	O
in	O
the	O
neurosphere	O
assay	O
.	O

In	O
Csb	O
(	O
-	O
/	O
-	O
)	O
neural	O
precursors	O
,	O
self	O
-	O
renewal	O
progressively	O
decreased	O
in	O
serially	O
passaged	O
neurospheres	O
.	O

The	O
data	O
also	O
indicate	O
that	O
Csb	O
and	O
the	O
nucleotide	O
excision	O
repair	O
protein	O
Xpa	O
preserve	O
embryonic	O
neural	O
stem	O
cell	O
self	O
-	O
renewal	O
after	O
UV	O
DNA	O
damage	O
.	O

Although	O
Csb	O
(	O
-	O
/	O
-	O
)	O
neural	O
precursors	O
do	O
not	O
exhibit	O
altered	O
neuronal	O
lineage	O
commitment	O
after	O
low	O
-	O
dose	O
UV	O
(	O
1J	O
/	O
m	O
(	O
2	O
)	O
)	O
in	O
vitro	O
,	O
neurons	O
differentiated	O
in	O
vitro	O
from	O
Csb	O
(	O
-	O
/	O
-	O
)	O
neural	O
precursors	O
that	O
had	O
been	O
irradiated	O
with	O
1J	O
/	O
m	O
(	O
2	O
)	O
UV	O
exhibited	O
defective	O
neurite	O
outgrowth	O
.	O

These	O
findings	O
identify	O
a	O
function	O
for	O
Csb	O
in	O
neural	O
precursors	O
.	O

Observation	O
of	O
direct	O
vibrational	O
excitation	O
in	O
gas	O
-	O
surface	O
collisions	O
of	O
CO	B
with	O
Au	B
(	O
111	O
)	O
:	O
a	O
new	O
model	O
system	O
for	O
surface	O
dynamics	O
.	O

We	O
report	O
vibrational	O
excitation	O
of	O
CO	B
from	O
its	O
ground	O
(	O
v	O
=	O
0	O
)	O
to	O
first	O
excited	O
(	O
v	O
=	O
1	O
)	O
vibrational	O
state	O
in	O
collision	O
with	O
Au	B
(	O
111	O
)	O
at	O
an	O
incidence	O
energy	O
of	O
translation	O
of	O
E	O
(	O
I	O
)	O
=	O
0.45	O
eV.	O
Unlike	O
past	O
work	O
,	O
we	O
can	O
exclude	O
an	O
excitation	O
mechanism	O
involving	O
temporary	O
adsorption	O
on	O
the	O
surface	O
followed	O
by	O
thermalization	O
and	O
desorption	O
.	O

The	O
angular	O
distributions	O
of	O
the	O
scattered	O
CO	B
molecules	O
are	O
narrow	O
,	O
consistent	O
with	O
direct	O
scattering	O
occurring	O
on	O
a	O
sub	O
-	O
ps	O
time	O
scale	O
.	O

The	O
absolute	O
excitation	O
probabilities	O
are	O
about	O
3	O
%	O
of	O
those	O
expected	O
from	O
thermal	O
accommodation	O
.	O

The	O
surface	O
temperature	O
dependence	O
of	O
excitation	O
,	O
which	O
was	O
measured	O
between	O
373	O
and	O
973	O
K	O
,	O
is	O
Arrhenius	O
-	O
like	O
with	O
an	O
activation	O
energy	O
equal	O
to	O
the	O
energy	O
required	O
for	O
vibrational	O
excitation	O
.	O

Our	O
measurements	O
are	O
consistent	O
with	O
a	O
vibrational	O
excitation	O
mechanism	O
involving	O
coupling	O
of	O
thermally	O
excited	O
electron	O
-	O
hole	O
pairs	O
of	O
the	O
solid	O
to	O
CO	B
vibration	O
.	O

Selective	O
focused	O
-	O
ion	O
-	O
beam	O
sculpting	O
of	O
TiO2	B
nanotubes	O
and	O
mechanism	O
understanding	O
.	O

Anodic	O
TiO	B
(	I
2	I
)	I
nanotubes	O
with	O
different	O
structures	O
,	O
doping	O
agents	O
,	O
and	O
decorations	O
have	O
been	O
studied	O
in	O
order	O
to	O
improve	O
energy	O
conversion	O
and	O
storage	O
efficiencies	O
such	O
as	O
in	O
dye	O
sensitized	O
solar	O
cells	O
,	O
solar	O
fuels	O
,	O
and	O
electrochemical	O
supercapacitors	O
.	O

However	O
,	O
the	O
top	O
surface	O
modification	O
of	O
TiO	B
(	I
2	I
)	I
nanotubes	O
has	O
never	O
been	O
addressed	O
.	O

In	O
this	O
study	O
,	O
anodic	O
TiO	B
(	I
2	I
)	I
nanotubes	O
have	O
been	O
selectively	O
closed	O
by	O
high	O
energy	O
focused	O
ion	O
beams	O
and	O
re	O
-	O
opened	O
by	O
low	O
energy	O
focused	O
ion	O
beams	O
.	O

Under	O
a	O
30	O
kV	O
Ga	B
(	I
+	I
)	I
beam	O
,	O
TiO	B
(	I
2	I
)	I
nanotubes	O
are	O
closed	O
with	O
a	O
65	O
nm	O
shield	O
layer	O
covering	O
the	O
top	O
entrance	O
when	O
the	O
ion	O
dose	O
is	O
larger	O
than	O
1.2	O
	O
10	O
(	O
17	O
)	O
ions	O
per	O
cm	O
(	O
2	O
)	O
;	O
under	O
a	O
5	O
kV	O
Ga	B
(	I
+	I
)	I
beam	O
,	O
the	O
shield	O
layer	O
is	O
removed	O
and	O
the	O
closed	O
tubes	O
are	O
re	O
-	O
opened	O
.	O

An	O
ion	O
-	O
induced	O
viscous	O
flow	O
model	O
has	O
been	O
proposed	O
to	O
explain	O
the	O
influence	O
of	O
Ga	B
(	I
+	I
)	I
ion	O
beam	O
flux	O
,	O
substrate	O
temperature	O
,	O
initial	O
tube	O
diameter	O
,	O
ion	O
beam	O
dwell	O
time	O
,	O
and	O
the	O
incidence	O
angle	O
of	O
the	O
ion	O
beam	O
.	O

Gene	O
transcription	O
reflects	O
poor	O
health	O
status	O
of	O
resident	O
European	O
eel	O
chronically	O
exposed	O
to	O
environmental	O
pollutants	O
.	O

Understanding	O
the	O
effects	O
of	O
chronic	O
exposure	O
to	O
pollutants	O
on	O
the	O
genome	O
and	O
transcriptome	O
of	O
diadromous	O
fish	O
populations	O
is	O
crucial	O
for	O
their	O
resilience	O
under	O
combined	O
anthropogenic	O
and	O
environmental	O
selective	O
pressures	O
.	O

The	O
catadromous	O
European	O
eel	O
(	O
Anguilla	O
anguilla	O
L.	O
)	O
has	O
suffered	O
a	O
dramatic	O
decline	O
in	O
recruitment	O
for	O
three	O
decades	O
,	O
necessitating	O
a	O
thorough	O
assessment	O
of	O
the	O
transcriptional	O
effects	O
of	O
environmental	O
pollutants	O
on	O
resident	O
and	O
migrating	O
eels	O
in	O
natural	O
systems	O
.	O

We	O
investigated	O
the	O
relationship	O
between	O
muscular	O
bioaccumulation	O
levels	O
of	O
metals	O
(	O
Hg	B
,	O
Cd	B
,	O
Pb	B
,	O
Cu	B
,	O
Zn	B
,	O
Ni	B
,	O
Cr	B
,	O
As	B
and	O
Se	B
)	O
,	O
PCBs	B
and	O
organochlorine	O
pesticides	O
(	O
DDTs	B
)	O
,	O
the	O
health	O
status	O
(	O
condition	O
factor	O
and	O
lipid	O
reserves	O
)	O
and	O
the	O
associated	O
transcriptional	O
response	O
in	O
liver	O
and	O
gill	O
tissues	O
for	O
genes	O
involved	O
in	O
metal	O
detoxification	O
(	O
metallothionein	O
,	O
MT	O
)	O
and	O
oxidative	O
metabolism	O
(	O
cytochrome	O
P4501A	O
,	O
CYP1A	O
)	O
of	O
xenobiotic	O
compounds	O
.	O

In	O
total	O
84	O
resident	O
eels	O
originating	O
from	O
three	O
Belgian	O
river	O
basins	O
(	O
Scheldt	O
,	O
Meuse	O
and	O
Yzer	O
)	O
were	O
analyzed	O
along	O
with	O
five	O
unpolluted	O
aquaculture	O
samples	O
as	O
control	O
group	O
.	O

There	O
was	O
a	O
large	O
spatial	O
variation	O
in	O
individual	O
contaminant	O
intensity	O
and	O
profile	O
,	O
while	O
tissue	O
pollution	O
levels	O
were	O
strongly	O
and	O
negatively	O
associated	O
with	O
condition	O
indices	O
,	O
suggesting	O
an	O
important	O
impact	O
of	O
pollution	O
on	O
the	O
health	O
of	O
sub	O
-	O
adult	O
resident	O
eels	O
.	O

Gene	O
transcription	O
patterns	O
revealed	O
a	O
complex	O
response	O
mechanism	O
to	O
a	O
cocktail	O
of	O
pollutants	O
,	O
with	O
a	O
high	O
variation	O
at	O
low	O
pollution	O
levels	O
,	O
but	O
strongly	O
down	O
-	O
regulated	O
hepatic	O
and	O
gill	O
gene	O
transcription	O
in	O
highly	O
polluted	O
eels	O
.	O

Resident	O
eels	O
clearly	O
experience	O
a	O
high	O
pollution	O
burden	O
and	O
seem	O
to	O
show	O
a	O
dysfunctional	O
gene	O
transcription	O
regulation	O
of	O
detoxification	O
genes	O
at	O
higher	O
pollutant	O
levels	O
,	O
correlated	O
with	O
low	O
energy	O
reserves	O
and	O
condition	O
.	O

To	O
fully	O
understand	O
the	O
evolutionary	O
implications	O
of	O
pollutants	O
on	O
eel	O
reproductive	O
fitness	O
,	O
analyses	O
of	O
mature	O
migrating	O
eels	O
and	O
the	O
characterization	O
of	O
their	O
transcriptome	O
-	O
wide	O
gene	O
transcription	O
response	O
would	O
be	O
appropriate	O
to	O
unveil	O
the	O
complex	O
responses	O
associated	O
with	O
multiple	O
interacting	O
stressors	O
and	O
the	O
long	O
-	O
term	O
consequences	O
at	O
the	O
entire	O
species	O
level	O
.	O

In	O
the	O
meanwhile	O
,	O
jointly	O
monitoring	O
environmental	O
and	O
tissue	O
pollution	O
levels	O
at	O
a	O
European	O
scale	O
should	O
be	O
initiated	O
,	O
while	O
preserving	O
high	O
quality	O
habitats	O
to	O
increase	O
the	O
recovery	O
chance	O
of	O
European	O
eel	O
in	O
the	O
future	O
.	O

A	O
comparative	O
VCD	O
study	O
of	O
methyl	B
mandelate	I
in	O
methanol	B
,	O
dimethyl	B
sulfoxide	I
,	O
and	O
chloroform	B
:	O
explicit	O
and	O
implicit	O
solvation	O
models	O
.	O

Vibrational	O
absorption	O
(	O
VA	O
)	O
and	O
vibrational	O
circular	O
dichroism	O
(	O
VCD	O
)	O
spectra	O
of	O
methyl	B
mandelate	I
,	O
a	O
prototype	O
chiral	O
molecule	O
,	O
in	O
a	O
series	O
of	O
organic	O
solvents	O
,	O
namely	O
methanol	B
(	O
MeOH	B
-	I
d	I
(	I
4	I
)	I
)	O
,	O
dimethyl	B
sulfoxide	I
(	O
DMSO	B
-	I
d	I
(	I
6	I
)	I
)	O
,	O
and	O
chloroform	B
(	O
CDCl	B
(	I
3	I
)	I
)	O
,	O
have	O
been	O
measured	O
in	O
the	O
finger	O
print	O
region	O
from	O
1800	O
to	O
1150	O
cm	O
(	O
-1	O
)	O
.	O

Implicit	O
solvation	O
models	O
in	O
the	O
form	O
of	O
polarizable	O
continuum	O
model	O
and	O
explicit	O
solvation	O
models	O
have	O
been	O
employed	O
independently	O
and	O
simultaneously	O
.	O

The	O
goal	O
is	O
to	O
evaluate	O
their	O
efficiencies	O
in	O
dealing	O
with	O
solvent	O
effects	O
in	O
each	O
solution	O
and	O
to	O
establish	O
a	O
general	O
strategy	O
to	O
adequately	O
account	O
for	O
effects	O
of	O
solvents	O
.	O

Molecular	O
dynamics	O
(	O
MD	O
)	O
simulation	O
and	O
radial	O
distribution	O
function	O
analysis	O
have	O
been	O
performed	O
to	O
aid	O
the	O
construction	O
of	O
the	O
explicit	O
solvation	O
models	O
.	O

Initial	O
geometry	O
searches	O
have	O
been	O
carried	O
out	O
at	O
the	O
B3LYP	O
/	O
6	O
-	O
31G	O
(	O
d	O
)	O
level	O
for	O
the	O
methyl	B
mandelate	I
monomer	O
and	O
its	O
explicit	O
1	O
:	O
1	O
and	O
1	O
:	O
2	O
solute	O
-	O
solvent	O
hydrogen	B
-	O
bonded	O
complexes	O
.	O

B3LYP	O
/	O
cc	O
-	O
pVTZ	O
has	O
been	O
used	O
for	O
all	O
the	O
final	O
geometry	O
optimizations	O
,	O
the	O
vibrational	O
frequency	O
,	O
VA	O
and	O
VCD	O
intensity	O
,	O
and	O
optical	O
rotation	O
dispersion	O
(	O
ORD	O
)	O
calculations	O
.	O

The	O
results	O
show	O
that	O
inclusion	O
of	O
solvent	O
explicitly	O
and	O
implicitly	O
at	O
the	O
same	O
time	O
has	O
significant	O
impacts	O
on	O
the	O
appearance	O
of	O
the	O
VA	O
and	O
VCD	O
spectra	O
,	O
and	O
is	O
crucial	O
for	O
reliable	O
spectral	O
assignments	O
when	O
solvents	O
are	O
capable	O
of	O
hydrogen	B
-	O
bonding	O
interactions	O
with	O
solutes	O
.	O

When	O
no	O
strong	O
solvent	O
-	O
solute	O
hydrogen	B
-	O
bonding	O
interactions	O
in	O
the	O
case	O
of	O
chloroform	B
are	O
expected	O
,	O
the	O
gas	O
phase	O
monomer	O
model	O
is	O
adequate	O
for	O
spectral	O
interpretation	O
,	O
while	O
inclusion	O
of	O
implicit	O
solvation	O
improves	O
the	O
frequency	O
agreement	O
with	O
experiment	O
.	O

ORD	O
spectra	O
of	O
methyl	B
mandelate	I
in	O
the	O
aforementioned	O
solvents	O
at	O
different	O
concentrations	O
under	O
5	O
excitation	O
wavelengths	O
have	O
also	O
been	O
measured	O
.	O

The	O
comparison	O
between	O
the	O
calculated	O
and	O
the	O
experimental	O
ORD	O
spectra	O
supports	O
the	O
conclusions	O
drawn	O
from	O
the	O
VA	O
and	O
VCD	O
investigations	O
.	O

Extremely	O
flexible	O
nanoscale	O
ultrathin	O
body	O
silicon	B
integrated	O
circuits	O
on	O
plastic	O
.	O

In	O
recent	O
years	O
,	O
flexible	O
devices	O
based	O
on	O
nanoscale	O
materials	O
and	O
structures	O
have	O
begun	O
to	O
emerge	O
,	O
exploiting	O
semiconductor	O
nanowires	O
,	O
graphene	B
,	O
and	O
carbon	B
nanotubes	O
.	O

This	O
is	O
primarily	O
to	O
circumvent	O
the	O
existing	O
shortcomings	O
of	O
the	O
conventional	O
flexible	O
electronics	O
based	O
on	O
organic	O
and	O
amorphous	O
semiconductors	O
.	O

The	O
aim	O
of	O
this	O
new	O
class	O
of	O
flexible	O
nanoelectronics	O
is	O
to	O
attain	O
high	O
-	O
performance	O
devices	O
with	O
increased	O
packing	O
density	O
.	O

However	O
,	O
highly	O
integrated	O
flexible	O
circuits	O
with	O
nanoscale	O
transistors	O
have	O
not	O
yet	O
been	O
demonstrated	O
.	O

Here	O
,	O
we	O
show	O
nanoscale	O
flexible	O
circuits	O
on	O
60	O
	O
thick	O
silicon	B
,	O
including	O
functional	O
ring	O
oscillators	O
and	O
memory	O
cells	O
.	O

The	O
100-stage	O
ring	O
oscillators	O
exhibit	O
the	O
stage	O
delay	O
of	O
~16	O
ps	O
at	O
a	O
power	O
supply	O
voltage	O
of	O
0.9	O
V	O
,	O
the	O
best	O
reported	O
for	O
any	O
flexible	O
circuits	O
to	O
date	O
.	O

The	O
mechanical	O
flexibility	O
is	O
achieved	O
by	O
employing	O
the	O
controlled	O
spalling	O
technology	O
,	O
enabling	O
the	O
large	O
-	O
area	O
transfer	O
of	O
the	O
ultrathin	O
body	O
silicon	B
devices	O
to	O
a	O
plastic	O
substrate	O
at	O
room	O
temperature	O
.	O

These	O
results	O
provide	O
a	O
simple	O
and	O
cost	O
-	O
effective	O
pathway	O
to	O
enable	O
ultralight	O
flexible	O
nanoelectronics	O
with	O
unprecedented	O
level	O
of	O
system	O
complexity	O
based	O
on	O
mainstream	O
silicon	B
technology	O
.	O

Enhancement	O
of	O
the	O
water	O
solubility	O
of	O
flavone	B
glycosides	I
by	O
disruption	O
of	O
molecular	O
planarity	O
of	O
the	O
aglycone	O
moiety	O
.	O

Enhancement	O
of	O
the	O
water	O
solubility	O
by	O
disruption	O
of	O
molecular	O
planarity	O
has	O
recently	O
been	O
reviewed	O
as	O
a	O
feasible	O
approach	O
in	O
small	O
-	O
molecule	O
drug	O
discovery	O
programs	O
.	O

We	O
applied	O
this	O
strategy	O
to	O
some	O
natural	O
flavone	B
glycosides	I
,	O
especially	O
diosmin	B
,	O
a	O
highly	O
insoluble	O
citroflavonoid	B
prescribed	O
as	O
an	O
oral	O
phlebotropic	O
drug	O
.	O

Disruption	O
of	O
planarity	O
at	O
the	O
aglycone	O
moiety	O
by	O
3-bromination	O
or	O
chlorination	O
afforded	O
3-bromo-	B
and	I
3-chlorodiosmin	I
,	O
displaying	O
a	O
dramatic	O
solubility	O
increase	O
compared	O
with	O
the	O
parent	O
compound	O
.	O

Interplay	O
between	O
structure	O
and	O
relaxations	O
in	O
perfluorosulfonic	B
acid	I
proton	O
conducting	O
membranes	O
.	O

This	O
study	O
focuses	O
on	O
changes	O
in	O
the	O
structure	O
of	O
ionomer	O
membranes	O
,	O
provided	O
by	O
the	O
3	O
M	O
Fuel	O
Cells	O
Component	O
Group	O
,	O
as	O
a	O
function	O
of	O
the	O
equivalent	O
weight	O
(	O
EW	O
)	O
and	O
the	O
relationship	O
between	O
the	O
structure	O
and	O
the	O
properties	O
of	O
the	O
membrane	O
.	O

Wide	O
-	O
angle	O
X	O
-	O
ray	O
diffraction	O
results	O
showed	O
evidence	O
of	O
both	O
non	O
-	O
crystalline	O
and	O
crystalline	O
ordered	O
hydrophobic	O
regions	O
in	O
all	O
the	O
EW	O
membranes	O
except	O
the	O
700	O
EW	O
membrane	O
.	O

The	O
spectral	O
changes	O
evident	O
in	O
the	O
vibrational	O
spectra	O
of	O
the	O
3	O
M	O
membranes	O
can	O
be	O
associated	O
with	O
two	O
major	O
phenomena	O
:	O
(	O
1	O
)	O
dissociation	O
of	O
the	O
proton	O
from	O
the	O
sulfonic	B
acid	I
groups	O
even	O
in	O
the	O
presence	O
of	O
small	O
amounts	O
of	O
water	O
;	O
and	O
(	O
2	O
)	O
changes	O
in	O
the	O
conformation	O
or	O
the	O
degree	O
of	O
crystallinity	O
of	O
the	O
poly	B
(	I
tetrafluoroethylene	I
)	I
hydrophobic	O
domains	O
both	O
as	O
a	O
function	O
of	O
EW	O
and	O
membrane	O
water	O
content	O
.	O

All	O
the	O
membranes	O
,	O
regardless	O
of	O
EW	O
,	O
are	O
thermally	O
stable	O
up	O
to	O
360	O
	O
C	O
.	O

The	O
wet	O
membranes	O
have	O
conductivities	O
between	O
7	O
and	O
20	O
mS	O
/	O
cm	O
at	O
125	O
	O
C	O
.	O

In	O
this	O
condition	O
,	O
the	O
conductivity	O
values	O
follow	O
VTF	O
behavior	O
,	O
which	O
suggests	O
that	O
the	O
proton	O
migration	O
occurs	O
via	O
proton	O
exchange	O
processes	O
between	O
delocalization	O
bodies	O
(	O
DBs	O
)	O
that	O
are	O
facilitated	O
by	O
the	O
dynamics	O
of	O
the	O
host	O
polymer	O
.	O

The	O
conductivity	O
along	O
the	O
interface	O
between	O
the	O
hydrophobic	O
and	O
hydrophilic	O
domains	O
makes	O
a	O
larger	O
contribution	O
in	O
the	O
smaller	O
EW	O
membranes	O
likely	O
due	O
to	O
the	O
existence	O
of	O
a	O
greater	O
number	O
of	O
interfaces	O
in	O
the	O
membrane	O
.	O

The	O
larger	O
crystalline	O
domains	O
present	O
in	O
the	O
higher	O
EW	O
membranes	O
provide	O
percolation	O
pathways	O
for	O
charge	O
migration	O
between	O
DBs	O
,	O
which	O
reduces	O
the	O
probability	O
of	O
charge	O
transfer	O
along	O
the	O
interface	O
.	O

Therefore	O
,	O
at	O
higher	O
EWs	O
although	O
there	O
is	O
charge	O
migration	O
along	O
the	O
interface	O
within	O
the	O
hydrophobic	O
-	O
hydrophilic	O
domains	O
,	O
the	O
exchange	O
of	O
protons	O
between	O
different	O
DBs	O
is	O
likely	O
the	O
rate	O
-	O
limiting	O
step	O
of	O
the	O
overall	O
conduction	O
process	O
.	O

Phase	O
behavior	O
and	O
molecular	O
dynamics	O
simulation	O
studies	O
of	O
new	O
aqueous	O
two	O
-	O
phase	O
separation	O
systems	O
induced	O
by	O
HEPES	O
buffer	O
.	O

Here	O
,	O
for	O
the	O
first	O
time	O
,	O
we	O
show	O
that	O
with	O
addition	O
of	O
a	O
biological	O
buffer	O
,	O
4-	B
(	I
2-hydroxyethyl	I
)	I
piperazine-1-ethanesulfonic	I
acid	I
(	O
HEPES	B
)	O
,	O
into	O
aqueous	O
solutions	O
of	O
tetrahydrofuran	B
(	O
THF	B
)	O
,	O
1,3-dioxolane	B
,	I
1,4-dioxane	I
,	I
1-propanol	I
,	O
2-propanol	B
,	O
tert	B
-	I
butanol	I
,	O
acetonitrile	B
,	O
or	O
acetone	B
,	O
the	O
organic	O
solvent	O
can	O
be	O
excluded	O
from	O
water	O
to	O
form	O
a	O
new	O
liquid	O
phase	O
.	O

The	O
phase	O
diagrams	O
have	O
been	O
determined	O
at	O
ambient	O
temperature	O
.	O

In	O
order	O
to	O
understand	O
why	O
and	O
how	O
a	O
zwitterion	O
solute	O
(	O
HEPES	B
)	O
induced	O
phase	O
separation	O
of	O
the	O
investigated	O
systems	O
,	O
molecular	O
dynamics	O
(	O
MD	O
)	O
simulation	O
studies	O
are	O
performed	O
for	O
HEPES	B
+	O
water	O
+	O
THF	B
system	O
.	O

The	O
MD	O
simulations	O
were	O
conducted	O
for	O
the	O
aqueous	O
mixtures	O
with	O
12	O
different	O
compositions	O
.	O

The	O
reliability	O
of	O
the	O
simulation	O
results	O
of	O
HEPES	B
in	O
pure	O
water	O
and	O
beyond	O
the	O
phase	O
separation	O
mixtures	O
was	O
justified	O
by	O
comparing	O
the	O
densities	O
obtained	O
from	O
MD	O
with	O
the	O
experimental	O
values	O
.	O

The	O
simulation	O
results	O
of	O
HEPES	B
in	O
pure	O
THF	B
and	O
in	O
a	O
composition	O
inside	O
the	O
phase	O
separation	O
region	O
were	O
justified	O
qualitatively	O
.	O

Interestingly	O
,	O
all	O
HEPES	B
molecules	O
entirely	O
aggregated	O
in	O
pure	O
THF	B
.	O

This	O
reveals	O
that	O
HEPES	B
is	O
insoluble	O
in	O
pure	O
THF	B
,	O
which	O
is	O
consistent	O
with	O
the	O
experimental	O
results	O
.	O

Even	O
more	O
interestingly	O
,	O
the	O
MD	O
simulation	O
for	O
the	O
mixture	O
with	O
composition	O
inside	O
the	O
phase	O
separation	O
region	O
showed	O
the	O
formation	O
of	O
two	O
phases	O
.	O

The	O
THF	B
molecules	O
are	O
squeezed	O
out	O
from	O
the	O
water	O
network	O
into	O
a	O
new	O
liquid	O
phase	O
.	O

The	O
hydrogen	O
bonds	O
(	O
HBs	O
)	O
,	O
HB	O
lifetime	O
,	O
HB	O
Gibbs	O
energy	O
(	O
G	O
)	O
,	O
radial	O
distribution	O
functions	O
(	O
RDFs	O
)	O
,	O
coordination	O
numbers	O
(	O
CNs	O
)	O
,	O
electrostatic	O
interactions	O
,	O
and	O
the	O
van	O
der	O
Waals	O
interactions	O
between	O
the	O
different	O
species	O
have	O
been	O
analyzed	O
.	O

Further	O
,	O
MD	O
simulations	O
for	O
the	O
other	O
phase	O
separation	O
systems	O
by	O
choosing	O
a	O
composition	O
inside	O
the	O
two	O
liquids	O
region	O
for	O
each	O
system	O
were	O
also	O
simulated	O
.	O

Our	O
findings	O
will	O
therefore	O
pave	O
the	O
way	O
for	O
designing	O
new	O
benign	O
separation	O
auxiliary	O
agents	O
.	O

Low	O
-	O
noise	O
nano	O
superconducting	O
quantum	O
interference	O
device	O
operating	O
in	O
Tesla	O
magnetic	O
fields	O
.	O

Superconductivity	O
in	O
the	O
cuprate	O
YBa	B
(	I
2	I
)	I
Cu	I
(	I
3	I
)	I
O	I
(	I
7	I
)	I
(	O
YBCO	B
)	O
persists	O
up	O
to	O
huge	O
magnetic	O
fields	O
(	O
B	O
)	O
up	O
to	O
several	O
tens	O
of	O
Teslas	O
,	O
and	O
sensitive	O
direct	O
current	O
(	O
dc	O
)	O
superconducting	O
quantum	O
interference	O
devices	O
(	O
SQUIDs	O
)	O
can	O
be	O
realized	O
in	O
epitaxially	O
grown	O
YBCO	B
films	O
by	O
using	O
grain	O
boundary	O
Josephson	O
junctions	O
(	O
GBJs	O
)	O
.	O

Here	O
we	O
present	O
the	O
realization	O
of	O
high	O
-	O
quality	O
YBCO	B
nanoSQUIDs	O
,	O
patterned	O
by	O
focused	O
ion	O
beam	O
milling	O
.	O

We	O
demonstrate	O
low	O
-	O
noise	O
performance	O
of	O
such	O
a	O
SQUID	O
up	O
to	O
B	O
=	O
1	O
T	O
applied	O
parallel	O
to	O
the	O
plane	O
of	O
the	O
SQUID	O
loop	O
at	O
the	O
temperature	O
T	O
=	O
4.2	O
K.	O
The	O
GBJs	O
are	O
shunted	O
by	O
a	O
thin	O
Au	B
layer	O
to	O
provide	O
nonhysteretic	O
current	O
voltage	O
characteristics	O
,	O
and	O
the	O
SQUID	O
incorporates	O
a	O
90	O
nm	O
wide	O
constriction	O
which	O
is	O
used	O
for	O
on	O
-	O
chip	O
modulation	O
of	O
the	O
magnetic	O
flux	O
through	O
the	O
SQUID	O
loop	O
.	O

The	O
white	O
flux	O
noise	O
of	O
the	O
device	O
increases	O
only	O
slightly	O
from	O
1.3	O
	O
(	O
0	O
)	O
/	O
(	O
Hz	O
)	O
(	O
1	O
/	O
2	O
)	O
at	O
B	O
=	O
0	O
to	O
2.3	O
	O
(	O
0	O
)	O
/	O
(	O
Hz	O
)	O
)	O
(	O
1	O
/	O
2	O
)	O
at	O
1	O
T.	O
Assuming	O
that	O
a	O
point	O
-	O
like	O
magnetic	O
particle	O
with	O
magnetization	O
in	O
the	O
plane	O
of	O
the	O
SQUID	O
loop	O
is	O
placed	O
directly	O
on	O
top	O
of	O
the	O
constriction	O
and	O
taking	O
into	O
account	O
the	O
geometry	O
of	O
the	O
SQUID	O
,	O
we	O
calculate	O
a	O
spin	O
sensitivity	O
S	O
(	O
	O
)	O
(	O
1	O
/	O
2	O
)	O
=	O
62	O
	O
(	O
B	O
)	O
/	O
(	O
Hz	O
)	O
)	O
(	O
1	O
/	O
2	O
)	O
at	O
B	O
=	O
0	O
and	O
110	O
	O
(	O
B	O
)	O
/	O
(	O
Hz	O
)	O
)	O
(	O
1	O
/	O
2	O
)	O
at	O
1	O
T.	O
The	O
demonstration	O
of	O
low	O
noise	O
of	O
such	O
a	O
SQUID	O
in	O
Tesla	O
fields	O
is	O
a	O
decisive	O
step	O
toward	O
utilizing	O
the	O
full	O
potential	O
of	O
ultrasensitive	O
nanoSQUIDs	O
for	O
direct	O
measurements	O
of	O
magnetic	O
hysteresis	O
curves	O
of	O
magnetic	O
nanoparticles	O
and	O
molecular	O
magnets	O
.	O

Role	O
of	O
pharmacogenetics	O
in	O
busulfan	B
/	O
cyclophosphamide	B
conditioning	O
therapy	O
prior	O
to	O
hematopoietic	O
stem	O
cell	O
transplantation	O
.	O

Hematopoietic	O
stem	O
cell	O
transplantation	O
(	O
HSCT	O
)	O
is	O
a	O
curative	O
treatment	O
for	O
several	O
malignant	O
and	O
nonmalignant	O
disorders	O
.	O

Busulfan	B
(	O
Bu	O
)	O
and	O
cyclophosphamide	B
(	O
Cy	O
)	O
are	O
the	O
most	O
commonly	O
used	O
alkylators	O
in	O
high	O
-	O
dose	O
pretransplant	O
conditioning	O
for	O
HSCT	O
;	O
a	O
treatment	O
that	O
is	O
correlated	O
with	O
drug	O
-	O
related	O
toxicity	O
and	O
relapse	O
.	O

Pharmacogenetic	O
investigations	O
have	O
shown	O
that	O
CYP450	O
,	O
as	O
well	O
as	O
aldehyde	B
dehydrogenase	O
,	O
are	O
clearly	O
involved	O
with	O
Cy	O
metabolism	O
and	O
are	O
associated	O
with	O
altered	O
treatment	O
response	O
,	O
Cy	O
metabolism	O
and	O
the	O
unique	O
stem	O
-	O
cell	O
sparing	O
capacity	O
.	O

Moreover	O
,	O
glutathione	B
-	B
S	O
-	O
transferase	O
isoenzymes	O
have	O
been	O
associated	O
with	O
cellular	O
outward	O
transport	O
of	O
various	O
alkylating	O
agents	O
,	O
including	O
Cy	O
metabolites	O
,	O
melphalan	B
,	O
Bu	O
and	O
chlorambucil	B
.	O

A	O
shift	O
from	O
genetic	O
-	O
based	O
studies	O
to	O
whole	O
-	O
genome	O
-	O
based	O
investigations	O
of	O
Cy-	O
and	O
Bu	O
-	O
associated	O
markers	O
may	O
contribute	O
to	O
personalizing	O
the	O
conditioning	O
therapy	O
and	O
enhancing	O
the	O
clinical	O
outcome	O
of	O
HSCT	O
.	O

Vasorelaxing	O
effects	O
and	O
inhibition	O
of	O
nitric	B
oxide	I
in	O
macrophages	O
by	O
new	O
iron	B
-	O
containing	O
carbon	B
monoxide	I
-	O
releasing	O
molecules	O
(	O
CO	O
-	O
RMs	O
)	O
.	O

Carbon	B
monoxide	I
-	O
releasing	O
molecules	O
(	O
CO	B
-	O
RMs	O
)	O
are	O
a	O
class	O
of	O
organometallo	B
carbonyl	I
complexes	O
capable	O
of	O
delivering	O
controlled	O
quantities	O
of	O
CO	B
gas	O
to	O
cells	O
and	O
tissues	O
thus	O
exerting	O
a	O
broad	O
spectrum	O
of	O
pharmacological	O
effects	O
.	O

Here	O
we	O
report	O
on	O
the	O
chemical	O
synthesis	O
,	O
CO	B
releasing	O
properties	O
,	O
cytotoxicity	O
profile	O
and	O
pharmacological	O
activities	O
of	O
four	O
novel	O
structurally	O
related	O
iron	B
-	I
allyl	I
carbonyls	I
.	O

The	O
major	O
difference	O
among	O
the	O
new	O
CO	B
-	O
RMs	O
tested	O
was	O
that	O
three	O
compounds	O
(	O
CORM-307	B
,	O
CORM-308	B
and	O
CORM-314	B
)	O
were	O
soluble	O
in	O
dimethylsulfoxide	B
(	O
DMSO	B
)	O
,	O
whereas	O
a	O
fourth	O
one	O
(	O
CORM-319	B
)	O
was	O
rendered	O
water	O
-	O
soluble	O
by	O
reacting	O
the	O
iron	B
-	I
carbonyl	I
with	O
hydrogen	B
tetrafluoroborate	I
.	O

We	O
found	O
that	O
despite	O
the	O
fact	O
all	O
compounds	O
liberated	O
CO	B
,	O
CO	B
-	O
RMs	O
soluble	O
in	O
DMSO	B
caused	O
a	O
more	O
pronounced	O
toxic	O
effect	O
both	O
in	O
vascular	O
and	O
inflammatory	O
cells	O
as	O
well	O
as	O
in	O
isolated	O
vessels	O
.	O

More	O
specifically	O
,	O
iron	B
carbonyls	I
soluble	O
in	O
DMSO	B
released	O
CO	B
with	O
a	O
fast	O
kinetic	O
and	O
displayed	O
a	O
marked	O
cytotoxic	O
effect	O
in	O
smooth	O
muscle	O
cells	O
and	O
RAW	O
247.6	O
macrophages	O
despite	O
exerting	O
a	O
rapid	O
and	O
pronounced	O
vasorelaxation	O
ex	O
vivo	O
.	O

In	O
contrast	O
,	O
CORM-319	B
that	O
is	O
soluble	O
in	O
water	O
and	O
liberated	O
CO	B
with	O
a	O
slower	O
rate	O
,	O
preserved	O
smooth	O
muscle	O
cell	O
viability	O
,	O
relaxed	O
aortic	O
tissue	O
and	O
exerted	O
a	O
significant	O
anti	O
-	O
inflammatory	O
effect	O
in	O
macrophages	O
challenged	O
with	O
endotoxin	O
.	O

These	O
data	O
suggest	O
that	O
iron	B
carbonyls	I
can	O
be	O
used	O
as	O
scaffolds	O
for	O
the	O
design	O
and	O
synthesis	O
of	O
pharmacologically	O
active	O
CO	B
-	O
RMs	O
and	O
indicate	O
that	O
increasing	O
water	O
solubility	O
and	O
controlling	O
the	O
rate	O
of	O
CO	B
release	O
are	O
important	O
parameters	O
for	O
limiting	O
their	O
potential	O
toxic	O
effects	O
.	O

Capture	O
and	O
stimulated	O
release	O
of	O
circulating	O
tumor	O
cells	O
on	O
polymer	O
-	O
grafted	O
silicon	B
nanostructures	O
.	O

A	O
platform	O
for	O
capture	O
and	O
release	O
of	O
circulating	O
tumor	O
cells	O
is	O
demonstrated	O
by	O
utilizing	O
polymer	O
grafted	O
silicon	B
nanowires	O
.	O

In	O
this	O
platform	O
,	O
integration	O
of	O
ligand	O
-	O
receptor	O
recognition	O
,	O
nanostructure	O
amplification	O
,	O
and	O
thermal	O
responsive	O
polymers	O
enables	O
a	O
highly	O
efficient	O
and	O
selective	O
capture	O
of	O
cancer	O
cells	O
.	O

Subsequently	O
,	O
these	O
captured	O
cells	O
are	O
released	O
upon	O
a	O
physical	O
stimulation	O
with	O
outstanding	O
cell	O
viability	O
.	O

Nanoscale	O
thermomechanics	O
of	O
wear	O
-	O
resilient	O
polymeric	O
bilayer	O
systems	O
.	O

We	O
explore	O
the	O
effect	O
of	O
an	O
ultrathin	O
elastic	O
coating	O
to	O
optimize	O
the	O
mechanical	O
stability	O
of	O
an	O
underlying	O
polymer	O
film	O
for	O
nanoscale	O
applications	O
.	O

The	O
coating	O
consists	O
of	O
a	O
several	O
nanometer	O
thin	O
plasma	O
-	O
polymerized	O
norbornene	B
layer	O
.	O

Scanning	O
probes	O
are	O
used	O
to	O
characterize	O
the	O
system	O
in	O
terms	O
of	O
shear	O
-	O
force	O
-	O
induced	O
wear	O
and	O
thermally	O
assisted	O
indentation	O
.	O

The	O
layer	O
transforms	O
a	O
weakly	O
performing	O
polystyrene	B
film	O
into	O
a	O
highly	O
wear	O
-	O
resistive	O
system	O
,	O
ideal	O
for	O
high	O
-	O
density	O
and	O
low	O
-	O
power	O
data	O
storage	O
applications	O
.	O

The	O
result	O
can	O
be	O
understood	O
from	O
the	O
indentation	O
characteristics	O
with	O
a	O
hot	O
and	O
sharp	O
indenter	O
tip	O
.	O

The	O
latter	O
gives	O
rise	O
to	O
a	O
deformation	O
mode	O
in	O
the	O
fully	O
plastic	O
regime	O
,	O
enabling	O
a	O
simple	O
interpretation	O
of	O
the	O
results	O
.	O

The	O
softening	O
transition	O
and	O
the	O
yield	O
stress	O
of	O
the	O
system	O
on	O
a	O
microsecond	O
time	O
scale	O
and	O
a	O
nanometer	O
size	O
scale	O
were	O
obtained	O
.	O

We	O
show	O
that	O
the	O
plastic	O
deformation	O
is	O
governed	O
by	O
yielding	O
in	O
the	O
polystyrene	B
sublayer	O
,	O
which	O
renders	O
the	O
overall	O
system	O
soft	O
for	O
plastic	O
deformation	O
.	O

The	O
ultrathin	O
protection	O
layer	O
contributes	O
as	O
an	O
elastic	O
skin	O
,	O
which	O
shields	O
part	O
of	O
the	O
temperature	O
and	O
pressure	O
and	O
enables	O
the	O
high	O
wear	O
resistance	O
against	O
lateral	O
forces	O
.	O

Moreover	O
,	O
the	O
method	O
of	O
probing	O
polymers	O
at	O
microsecond	O
and	O
nanometer	O
size	O
scales	O
opens	O
up	O
new	O
opportunities	O
for	O
studying	O
polymer	O
physics	O
in	O
a	O
largely	O
unexplored	O
regime	O
.	O

Thus	O
,	O
we	O
find	O
softening	O
temperatures	O
of	O
more	O
than	O
100	O
	O
C	O
above	O
the	O
polystyrene	B
glass	O
transition	O
,	O
which	O
implies	O
that	O
for	O
the	O
short	O
interaction	O
time	O
scales	O
the	O
glassy	O
state	O
of	O
the	O
polymer	O
is	O
preserved	O
up	O
to	O
this	O
temperature	O
.	O

Aspartic	O
protease	O
inhibitors	O
:	O
effective	O
drugs	O
against	O
the	O
human	O
fungal	O
pathogen	O
Candida	O
albicans	O
.	O

Candida	O
albicans	O
can	O
invade	O
humans	O
and	O
may	O
lead	O
to	O
mucosal	O
and	O
skin	O
infections	O
or	O
to	O
deep	O
-	O
seated	O
mycoses	O
of	O
almost	O
all	O
inner	O
organs	O
,	O
especially	O
in	O
immunocompromised	O
patients	O
.	O

In	O
this	O
context	O
,	O
both	O
the	O
host	O
immune	O
status	O
and	O
the	O
ability	O
of	O
C.	O
albicans	O
to	O
modulate	O
the	O
expression	O
of	O
its	O
virulence	O
factors	O
are	O
relevant	O
aspects	O
that	O
drive	O
the	O
candidal	O
susceptibility	O
or	O
resistance	O
;	O
in	O
this	O
last	O
case	O
,	O
culminating	O
in	O
the	O
establishment	O
of	O
successful	O
infection	O
known	O
as	O
candidiasis	O
.	O

C.	O
albicans	O
possesses	O
a	O
potent	O
armamentarium	O
consisting	O
of	O
several	O
virulence	O
molecules	O
that	O
help	O
the	O
fungal	O
cells	O
to	O
escape	O
from	O
the	O
host	O
immune	O
responses	O
.	O

There	O
is	O
no	O
doubt	O
that	O
the	O
secretion	O
of	O
aspartic	O
proteases	O
,	O
designated	O
as	O
Saps	O
,	O
is	O
one	O
of	O
the	O
major	O
virulence	O
attributes	O
produced	O
by	O
C.	O
albicans	O
cells	O
,	O
since	O
these	O
hydrolytic	O
enzymes	O
participate	O
in	O
a	O
wide	O
range	O
of	O
fungal	O
physiological	O
processes	O
as	O
well	O
as	O
in	O
different	O
facets	O
of	O
the	O
fungal	O
-	O
host	O
interactions	O
.	O

For	O
these	O
reasons	O
,	O
Saps	O
clearly	O
hold	O
promise	O
as	O
new	O
potential	O
drug	O
targets	O
.	O

Corroborating	O
this	O
hypothesis	O
,	O
the	O
introduction	O
of	O
anti	O
-	O
human	O
immunodeficiency	O
virus	O
drugs	O
of	O
the	O
aspartic	O
protease	O
inhibitor	O
-	O
type	O
(	O
HIV	O
PIs	O
)	O
have	O
emerged	O
as	O
new	O
agents	O
for	O
the	O
inhibition	O
of	O
Saps	O
.	O

The	O
introduction	O
of	O
HIV	O
PIs	O
has	O
revolutionized	O
the	O
treatment	O
of	O
HIV	O
disease	O
,	O
reducing	O
the	O
opportunistic	O
infections	O
,	O
especially	O
candidiasis	O
.	O

The	O
attenuation	O
of	O
candidal	O
infections	O
in	O
HIV	O
-	O
infected	O
individuals	O
might	O
not	O
solely	O
has	O
not	O
only	O
resulted	O
from	O
improved	O
immunological	O
status	O
,	O
but	O
also	O
as	O
a	O
result	O
of	O
direct	O
inhibition	O
of	O
C.	O
albicans	O
Saps	O
as	O
well	O
as	O
the	O
blockage	O
of	O
several	O
biological	O
processes	O
controlled	O
by	O
these	O
proteolytic	O
enzymes	O
.	O

The	O
present	O
article	O
will	O
discuss	O
the	O
updates	O
on	O
the	O
functional	O
implications	O
of	O
HIV	O
PIs	O
on	O
the	O
development	O
of	O
candidiasis	O
.	O

Optical	O
activity	O
of	O
achiral	O
ligand	O
SCH3	B
adsorbed	O
on	O
achiral	O
Ag55	B
clusters	O
:	O
relationship	O
between	O
adsorption	O
site	O
and	O
circular	O
dichroism	O
.	O

The	O
electronic	O
circular	O
dichroism	O
(	O
CD	O
)	O
spectra	O
of	O
a	O
methyl	B
-	I
thiol	I
adsorbed	O
at	O
different	O
sites	O
on	O
an	O
icosahedral	O
silver	B
nanoparticle	O
is	O
studied	O
by	O
using	O
time	O
-	O
perturbed	O
density	O
functional	O
theory	O
.	O

Despite	O
that	O
separately	O
molecule	O
and	O
nanoparticle	O
are	O
achiral	O
and	O
consequently	O
optically	O
inactive	O
,	O
the	O
Ag	B
(	I
55	I
)	I
-SCH	I
(	I
3	I
)	I
compound	O
emerges	O
with	O
a	O
new	O
symmetry	O
,	O
which	O
may	O
be	O
chiral	O
or	O
not	O
depending	O
on	O
the	O
adsorption	O
site	O
and	O
orientation	O
of	O
the	O
molecule	O
.	O

It	O
is	O
found	O
that	O
chirality	O
is	O
favored	O
when	O
the	O
thiol	B
is	O
adsorbed	O
between	O
two	O
atoms	O
of	O
different	O
coordination	O
number	O
.	O

Chiral	O
compounds	O
have	O
characteristic	O
CD	O
spectra	O
in	O
the	O
UV	O
-	O
visible	O
region	O
,	O
where	O
Ag	B
(	I
55	I
)	I
shows	O
optical	O
absorption	O
but	O
SCH	B
(	I
3	I
)	I
does	O
not	O
;	O
revealing	O
that	O
highly	O
degenerated	O
molecular	O
-	O
like	O
electronic	O
states	O
of	O
Ag	B
(	I
55	I
)	I
are	O
modified	O
by	O
the	O
presence	O
of	O
the	O
molecule	O
inducing	O
optical	O
activity	O
.	O

It	O
is	O
concluded	O
that	O
CD	O
line	O
-	O
shapes	O
and	O
magnitude	O
strongly	O
depend	O
on	O
the	O
site	O
where	O
the	O
adsorption	O
takes	O
place	O
,	O
while	O
its	O
intensity	O
is	O
modulated	O
by	O
the	O
molecule	O
orientation	O
.	O

Surfactant	O
-	O
Assisted	O
Assembly	O
of	O
Fullerene	B
(	O
C	B
(	I
60	I
)	I
)	O
Nanorods	O
and	O
Nanotubes	O
Formed	O
at	O
a	O
Liquid	O
-	O
Liquid	O
Interface	O
.	O

Herein	O
we	O
report	O
the	O
surfactant	O
-	O
triggered	O
assembly	O
of	O
fullerene	B
(	O
C	B
(	I
60	I
)	I
)	O
into	O
3D	O
flowerlike	O
microcrystals	O
at	O
the	O
liquid	O
-	O
liquid	O
interface	O
.	O

C	B
(	I
60	I
)	I
crystals	O
were	O
grown	O
using	O
a	O
liquid	O
-	O
liquid	O
interfacial	O
precipitation	O
(	O
LLIP	O
)	O
method	O
by	O
layering	O
surfactant	O
solution	O
in	O
butanol	B
with	O
a	O
saturated	O
solution	O
of	O
C	B
(	I
60	I
)	I
in	O
benzene	B
.	O

In	O
the	O
LLIP	O
method	O
,	O
it	O
is	O
suggested	O
that	O
the	O
crystal	O
formation	O
mechanism	O
is	O
driven	O
by	O
supersaturation	O
related	O
to	O
the	O
low	O
C	B
(	I
60	I
)	I
solubility	O
in	O
alcohol	O
.	O

We	O
found	O
that	O
the	O
dimensions	O
of	O
the	O
synthesized	O
C	B
(	I
60	I
)	I
flowers	O
depend	O
on	O
the	O
concentration	O
and	O
surfactant	O
type	O
.	O

In	O
the	O
absence	O
of	O
surfactant	O
(	O
i.e.	O
,	O
in	O
the	O
butanol	B
/	O
benzene	B
system	O
)	O
,	O
1D	O
C	B
(	I
60	I
)	I
nanowhiskers	O
(	O
nanorods	O
)	O
and	O
C	B
(	I
60	I
)	I
nanotubes	O
(	O
diameter	O
400	O
nm-2	O
m	O
and	O
length	O
5	O
-	O
20	O
m	O
)	O
are	O
obtained	O
.	O

However	O
,	O
when	O
surfactants	O
are	O
incorporated	O
into	O
the	O
system	O
flowerlike	O
microcrystals	O
consisting	O
of	O
C	B
(	I
60	I
)	I
nanotubes	O
are	O
observed	O
.	O

For	O
instance	O
,	O
crystals	O
grown	O
at	O
the	O
interface	O
of	O
a	O
0.01	O
%	O
diglycerol	B
monolaurate	I
(	O
C	B
(	I
12	I
)	I
G	I
(	I
2	I
)	I
)	O
nonionic	O
surfactant	O
in	O
butanol	B
with	O
benzene	B
lead	O
to	O
the	O
formation	O
of	O
flower	O
-	O
shaped	O
microcrystals	O
of	O
average	O
sizes	O
in	O
the	O
range	O
of	O
10	O
-	O
35	O
m	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
example	O
of	O
the	O
surfactant	O
-	O
assisted	O
assembly	O
of	O
C	B
(	I
60	I
)	I
crystals	O
.	O

X	O
-	O
ray	O
diffraction	O
(	O
XRD	O
)	O
and	O
transmission	O
electron	O
microscopy	O
(	O
TEM	O
)	O
measurements	O
have	O
shown	O
that	O
fullerene	B
flowers	O
have	O
a	O
hexagonal	O
structure	O
with	O
cell	O
dimensions	O
of	O
a	O
=	O
2.539	O
nm	O
and	O
c	O
=	O
1.021	O
nm	O
,	O
which	O
differ	O
from	O
that	O
of	O
pristine	O
C	B
(	I
60	I
)	I
.	O

Mixtures	O
of	O
flower	O
-	O
shaped	O
C	B
(	I
60	I
)	I
crystals	O
and	O
free	O
-	O
standing	O
C	B
(	I
60	I
)	I
nanotubes	O
are	O
found	O
in	O
the	O
0.1	O
%	O
C	B
(	I
12	I
)	I
G	I
(	I
2	I
)	I
/	O
butanol	B
system	O
.	O

However	O
,	O
clusters	O
or	O
giant	O
aggregates	O
of	O
nanowhiskers	O
lacking	O
any	O
specific	O
shape	O
are	O
observed	O
in	O
the	O
1	O
%	O
C	B
(	I
12	I
)	I
G	I
(	I
2	I
)	I
/	O
butanol	O
system	O
although	O
these	O
crystals	O
exhibit	O
hexagonal	O
close	O
-	O
packed	O
structures	O
.	O

Flower	O
-	O
shaped	O
C	B
(	I
60	I
)	I
microcrystals	O
are	O
also	O
observed	O
with	O
anionic	O
surfactants	O
cetyltrimethylammonium	B
bromide	I
(	O
CTAB	B
)	O
and	O
cetyltrimethylammonium	B
chloride	I
(	O
CTAC	B
)	O
.	O

C	B
(	I
60	I
)	I
flowers	O
obtained	O
from	O
0.01	O
%	O
CTAB	B
and	O
0.01	O
%	O
CTAC	B
also	O
exhibit	O
hexagonal	O
structures	O
with	O
cell	O
dimensions	O
of	O
a	O
=	O
2.329	O
nm	O
and	O
c	O
=	O
1.273	O
nm	O
,	O
a	O
=	O
2.459	O
nm	O
and	O
c	O
=	O
0.938	O
nm	O
,	O
respectively	O
.	O

Our	O
C	B
(	I
60	I
)	I
flowers	O
exhibit	O
intense	O
photoluminescence	O
(	O
PL	O
)	O
and	O
a	O
blue	O
-	O
shifted	O
PL	O
intensity	O
maximum	O
compared	O
to	O
the	O
same	O
parameters	O
for	O
pristine	O
C	B
(	I
60	I
)	I
,	O
demonstrating	O
the	O
potential	O
to	O
control	O
the	O
optoelectronic	O
properties	O
of	O
fullerene	B
-	O
based	O
nanostructures	O
.	O

Evaluation	O
of	O
drug	O
interactions	O
of	O
GSK1292263	B
(	O
a	O
GPR119	O
agonist	O
)	O
with	O
statins	O
:	O
from	O
in	O
vitro	O
data	O
to	O
clinical	O
study	O
design	O
.	O

1	O
.	O

This	O
work	O
investigated	O
the	O
drug	O
interaction	O
potential	O
of	O
GSK1292263	B
,	O
a	O
novel	O
GPR119	O
agonist	O
,	O
with	O
the	O
HMG	O
-	O
coA	O
reductase	O
inhibitors	O
simvastatin	B
and	O
rosuvastatin	B
.	O

2	O
.	O

In	O
vitro	O
experiments	O
assessed	O
the	O
inhibition	O
of	O
transporters	O
and	O
CYP	O
enzymes	O
by	O
GSK1292263	B
,	O
and	O
a	O
clinical	O
drug	O
interaction	O
study	O
investigated	O
the	O
effect	O
of	O
GSK1292263	B
(	O
300	O
mg	O
BID	O
)	O
on	O
the	O
pharmacokinetic	O
profile	O
of	O
simvastatin	B
(	O
40	O
mg	O
single	O
dose	O
)	O
and	O
rosuvastatin	B
(	O
10	O
mg	O
single	O
dose	O
)	O
.	O

3	O
.	O

In	O
vitro	O
,	O
GSK1292263	B
demonstrated	O
little	O
/	O
weak	O
inhibition	O
(	O
IC50	O
values	O
>	O
30	O
M	O
)	O
towards	O
CYPs	O
(	O
CYP1A2	O
,	O
2C9	O
,	O
2C19	O
,	O
2D6	O
,	O
3A4	O
)	O
,	O
Pgp	O
,	O
OATP1B3	O
,	O
or	O
OCT2	O
.	O

However	O
,	O
GSK1292263	B
inhibited	O
BCRP	O
and	O
OATP1B1	O
,	O
which	O
are	O
transporters	O
involved	O
in	O
statin	O
disposition	O
.	O

4	O
.	O

In	O
the	O
clinical	O
study	O
,	O
small	O
increases	O
in	O
the	O
AUC	O
(	O
0-inf	O
)	O
of	O
simvastatin	B
[	O
mean	O
ratio	O
(	O
90	O
%	O
CI	O
)	O
of	O
1.34	O
(	O
1.22	O
,	O
1.48	O
)	O
]	O
and	O
rosuvastatin	B
[	O
mean	O
ratio	O
(	O
90	O
%	O
CI	O
)	O
of	O
1.39	O
(	O
1.30	O
,	O
1.49	O
)	O
]	O
were	O
observed	O
when	O
co	O
-	O
administered	O
with	O
GSK1292263	B
,	O
which	O
is	O
consistent	O
with	O
an	O
inhibitory	O
effect	O
on	O
intestinal	O
BCRP	O
and	O
CYP3A4	O
.	O

In	O
contrast	O
,	O
GSK1292263	B
did	O
not	O
inhibit	O
OATP1B1	O
based	O
on	O
the	O
lack	O
of	O
changes	O
in	O
simvastatin	B
acid	O
exposure	O
[	O
mean	O
AUC	O
(	O
0-inf	O
)	O
ratio	O
(	O
90	O
%	O
CI	O
)	O
of	O
1.05	O
(	O
0.91	O
,	O
1.21	O
)	O
]	O
.	O

5	O
.	O
GSK1292263	B
has	O
a	O
weak	O
drug	O
interaction	O
with	O
simvastatin	B
and	O
rosuvastain	B
.	O

This	O
study	O
provides	O
a	O
mechanistic	O
understanding	O
of	O
the	O
in	O
vivo	O
inhibition	O
of	O
transporters	O
and	O
enzymes	O
by	O
GSK1292263	B
.	O

Characterization	O
of	O
steroidogenic	O
enzyme	O
expression	O
in	O
aldosterone	B
-	O
producing	O
adenoma	O
:	O
a	O
comparison	O
with	O
various	O
human	O
adrenal	O
tumors	O
.	O

We	O
analyzed	O
the	O
expression	O
profiles	O
of	O
several	O
steroidogenic	O
enzymes	O
in	O
normal	O
adrenals	O
,	O
aldosterone	B
-	O
producing	O
adenomas	O
(	O
APA	O
)	O
,	O
cortisol	B
-	O
producing	O
adenomas	O
combined	O
with	O
Cushing	O
's	O
syndrome	O
(	O
CPA	O
)	O
or	O
with	O
subclinical	O
Cushing	O
's	O
syndrome	O
(	O
SCPA	O
)	O
,	O
and	O
nonfunctioning	O
adrenal	O
adenomas	O
(	O
NFA	O
)	O
to	O
clarify	O
the	O
nature	O
and	O
characteristics	O
of	O
steroidogenesis	O
in	O
APA	O
.	O

Clinical	O
data	O
were	O
collected	O
for	O
all	O
subjects	O
.	O

In	O
resected	O
adrenal	O
glands	O
(	O
normal	O
adrenals	O
,	O
APA	O
,	O
CPA	O
,	O
SCPA	O
,	O
and	O
NFA	O
)	O
,	O
the	O
mRNA	O
expression	O
levels	O
of	O
the	O
CYP17	O
,	O
HSD3B2	O
,	O
CYP11B1	O
,	O
and	O
CYP11B2	O
genes	O
were	O
studied	O
using	O
real	O
-	O
time	O
quantitative	O
PCR	O
and	O
immunohistochemistry	O
.	O

The	O
CYP11B2	O
mRNA	O
level	O
in	O
APA	O
was	O
significantly	O
higher	O
than	O
that	O
in	O
other	O
groups	O
.	O

The	O
CYP17	O
/	O
HSD3B2	O
ratio	O
for	O
mRNA	O
in	O
APA	O
was	O
significantly	O
lower	O
than	O
those	O
in	O
the	O
other	O
groups	O
.	O

Low	O
ratio	O
of	O
CYP17	O
/	O
HSD3B2	O
with	O
high	O
expression	O
of	O
CYP11B2	O
seems	O
to	O
explain	O
steroidogenic	O
characteristics	O
of	O
APA	O
.	O

A	O
theoretical	O
analysis	O
of	O
the	O
effect	O
of	O
the	O
hydrogenation	O
of	O
graphene	B
to	O
graphane	B
on	O
its	O
mechanical	O
properties	O
.	O

We	O
investigated	O
the	O
effect	O
of	O
the	O
hydrogenation	O
of	O
graphene	B
to	O
graphane	B
on	O
its	O
mechanical	O
properties	O
using	O
first	O
-	O
principles	O
calculations	O
based	O
on	O
density	O
-	O
functional	O
theory	O
.	O

The	O
hydrogenation	O
reduces	O
the	O
ultimate	O
strengths	O
in	O
all	O
three	O
tested	O
deformation	O
modes	O
--	O
armchair	O
,	O
zigzag	O
,	O
and	O
biaxial	O
--	O
and	O
the	O
in	O
-	O
plane	O
stiffness	O
by	O
1	O
/	O
3	O
.	O

The	O
Poisson	O
ratio	O
was	O
reduced	O
from	O
0.178	O
to	O
0.078	O
,	O
a	O
56	O
%	O
decrease	O
.	O

However	O
,	O
the	O
ultimate	O
strain	O
in	O
zigzag	O
deformation	O
was	O
increased	O
by	O
8.7	O
%	O
.	O

The	O
shear	O
mode	O
elastic	O
constants	O
are	O
more	O
sensitive	O
than	O
longitudinal	O
ones	O
to	O
hydrogenation	O
.	O

The	O
fourth	O
and	O
fifth	O
order	O
longitudinal	O
mode	O
elastic	O
constants	O
are	O
inert	O
to	O
the	O
hydrogenation	O
,	O
in	O
contrast	O
to	O
a	O
large	O
decrease	O
of	O
those	O
in	O
second	O
and	O
third	O
order	O
.	O

The	O
hydrogenation	O
does	O
not	O
change	O
the	O
monotonic	O
decrement	O
of	O
the	O
Poisson	O
ratio	O
with	O
increasing	O
pressure	O
,	O
but	O
the	O
rate	O
is	O
tripled	O
.	O

Our	O
results	O
indicate	O
that	O
graphene	B
-	O
graphane	B
systems	O
could	O
be	O
used	O
for	O
hydrogen	B
storage	O
with	O
high	O
speed	O
of	O
charge	O
-	O
discharge	O
of	O
hydrogen	B
.	O

(	B
4,4'	I
)	I
-Bipyridine	I
in	O
vacuo	O
and	O
in	O
solvents	O
:	O
a	O
quantum	O
chemical	O
study	O
of	O
a	O
prototypical	O
floppy	O
molecule	O
from	O
a	O
molecular	O
transport	O
perspective	O
.	O

We	O
report	O
results	O
of	O
quantum	O
chemical	O
calculations	O
for	O
the	O
neutral	O
and	O
anionic	O
species	O
of	O
(	B
4,4'	I
)	I
-bipyridine	I
(	O
44BPY	B
)	O
,	O
a	O
prototypical	O
molecule	O
with	O
a	O
floppy	O
degree	O
of	O
freedom	O
,	O
placed	O
in	O
vacuo	O
and	O
in	O
solvents	O
.	O

In	O
addition	O
to	O
equilibrium	O
geometries	O
and	O
vibrational	O
frequencies	O
and	O
spectra	O
,	O
we	O
present	O
adiabatic	O
energy	O
curves	O
for	O
the	O
vibrational	O
modes	O
with	O
significant	O
intramolecular	O
reorganization	O
upon	O
charge	O
transfer	O
.	O

Special	O
attention	O
is	O
paid	O
to	O
the	O
floppy	O
strongly	O
anharmonic	O
degree	O
of	O
freedom	O
of	O
44BPY	B
,	O
which	O
is	O
related	O
to	O
the	O
most	O
salient	O
structural	O
feature	O
,	O
namely	O
the	O
twist	O
angle	O
	O
between	O
the	O
two	O
pyridine	B
rings	O
.	O

The	O
relevance	O
of	O
the	O
present	O
results	O
for	O
molecular	O
transport	O
will	O
be	O
emphasized	O
.	O

We	O
show	O
that	O
the	O
solvent	O
acts	O
as	O
a	O
selective	O
gate	O
electrode	O
and	O
propose	O
a	O
scissor	O
operator	O
to	O
account	O
for	O
solvent	O
effects	O
on	O
molecular	O
transport	O
.	O

Our	O
result	O
on	O
the	O
conductance	O
G	O
vs.	O
cos	O
(	O
2	O
)	O
	O
is	O
consistent	O
with	O
a	O
significant	O
transmission	O
in	O
perpendicular	O
conformation	O
indicated	O
by	O
previous	O
microscopic	O
analysis	O
.	O

Iron	B
L	O
-	O
edge	O
X	O
-	O
ray	O
absorption	O
spectroscopy	O
of	O
oxy	O
-	O
picket	O
fence	O
porphyrin	B
:	O
experimental	O
insight	O
into	O
Fe	B
-	O
O2	B
bonding	O
.	O

The	O
electronic	O
structure	O
of	O
the	O
Fe	B
-	O
O	B
(	I
2	I
)	I
center	O
in	O
oxy	O
-	O
hemoglobin	O
and	O
oxy	O
-	O
myoglobin	O
is	O
a	O
long	O
-	O
standing	O
issue	O
in	O
the	O
field	O
of	O
bioinorganic	O
chemistry	O
.	O

Spectroscopic	O
studies	O
have	O
been	O
complicated	O
by	O
the	O
highly	O
delocalized	O
nature	O
of	O
the	O
porphyrin	B
,	O
and	O
calculations	O
require	O
interpretation	O
of	O
multideterminant	O
wave	O
functions	O
for	O
a	O
highly	O
covalent	O
metal	O
site	O
.	O

Here	O
,	O
iron	B
L	O
-	O
edge	O
X	O
-	O
ray	O
absorption	O
spectroscopy	O
,	O
interpreted	O
using	O
a	O
valence	O
bond	O
configuration	O
interaction	O
multiplet	O
model	O
,	O
is	O
applied	O
to	O
directly	O
probe	O
the	O
electronic	O
structure	O
of	O
the	O
iron	B
in	O
the	O
biomimetic	O
Fe	B
-	O
O	B
(	I
2	I
)	I
heme	B
complex	O
[	B
Fe	I
(	I
pfp	I
)	I
(	I
1-MeIm	I
)	I
O	I
(	I
2	I
)	I
]	I
(	O
pfp	B
(	O
"	O
picket	B
fence	I
porphyrin	I
"	O
)	O
=	O
meso	B
-	I
tetra	I
(	I
	I
,	I
	I
,	I
	I
,	I
	I
-	I
o	I
-	I
pivalamidophenyl	I
)	I
porphyrin	I
or	O
TpivPP	B
)	O
.	O

This	O
method	O
allows	O
separate	O
estimates	O
of	O
	O
-	O
donor	O
,	O
	O
-	O
donor	O
,	O
and	O
	O
-	O
acceptor	O
interactions	O
through	O
ligand	O
-	O
to	O
-	O
metal	O
charge	O
transfer	O
and	O
metal	O
-	O
to	O
-	O
ligand	O
charge	O
transfer	O
mixing	O
pathways	O
.	O

The	O
L	O
-	O
edge	O
spectrum	O
of	O
[	B
Fe	I
(	I
pfp	I
)	I
(	I
1-MeIm	I
)	I
O	I
(	I
2	I
)	I
]	I
is	O
further	O
compared	O
to	O
those	O
of	O
[	B
Fe	I
(	I
II	I
)	I
(	I
pfp	I
)	I
(	I
1-MeIm	I
)	I
(	I
2	I
)	I
]	I
,	O
[	B
Fe	I
(	I
II	I
)	I
(	I
pfp	I
)	I
]	I
,	O
and	O
[	B
Fe	I
(	I
III	I
)	I
(	I
tpp	I
)	I
(	I
ImH	I
)	I
(	I
2	I
)	I
]	I
Cl	I
(	O
tpp	B
=	O
meso	B
-	I
tetraphenylporphyrin	I
)	O
which	O
have	O
Fe	B
(	I
II	I
)	I
S	O
=	O
0	O
,	O
Fe	B
(	I
II	I
)	I
S	O
=	O
1	O
,	O
and	O
Fe	B
(	I
III	I
)	I
S	O
=	O
1	O
/	O
2	O
ground	O
states	O
,	O
respectively	O
.	O

These	O
serve	O
as	O
references	O
for	O
the	O
three	O
possible	O
contributions	O
to	O
the	O
ground	O
state	O
of	O
oxy	B
-	I
pfp	I
.	O

The	O
Fe	B
-	O
O	B
(	I
2	I
)	I
pfp	B
site	O
is	O
experimentally	O
determined	O
to	O
have	O
both	O
significant	O
	O
-	O
donation	O
and	O
a	O
strong	O
	O
-	O
interaction	O
of	O
the	O
O	B
(	I
2	I
)	I
with	O
the	O
iron	B
,	O
with	O
the	O
latter	O
having	O
implications	O
with	O
respect	O
to	O
the	O
spin	O
polarization	O
of	O
the	O
ground	O
state	O
.	O

Probing	O
the	O
Bonding	O
and	O
Electronic	O
Structure	O
of	O
Single	O
Atom	O
Dopants	O
in	O
Graphene	B
with	O
Electron	O
Energy	O
Loss	O
Spectroscopy	O
.	O

A	O
combination	O
of	O
scanning	O
transmission	O
electron	O
microscopy	O
,	O
electron	O
energy	O
loss	O
spectroscopy	O
,	O
and	O
ab	O
initio	O
calculations	O
reveal	O
striking	O
electronic	O
structure	O
differences	O
between	O
two	O
distinct	O
single	O
substitutional	O
Si	B
defect	O
geometries	O
in	O
graphene	B
.	O

Optimised	O
acquisition	O
conditions	O
allow	O
for	O
exceptional	O
signal	O
-	O
to	O
-	O
noise	O
levels	O
in	O
the	O
spectroscopic	O
data	O
.	O

The	O
near	O
-	O
edge	O
fine	O
structure	O
can	O
be	O
compared	O
with	O
great	O
accuracy	O
to	O
simulations	O
and	O
reveal	O
either	O
an	O
sp	O
(	O
3	O
)	O
-like	O
configuration	O
for	O
a	O
trivalent	O
Si	B
or	O
a	O
more	O
complicated	O
hybridized	O
structure	O
for	O
a	O
tetravalent	O
Si	B
impurity	O
.	O

Controlling	O
the	O
pulsed	O
-	O
laser	O
-	O
induced	O
size	O
reduction	O
of	O
Au	B
and	O
Ag	B
nanoparticles	O
via	O
changes	O
in	O
the	O
external	O
pressure	O
,	O
laser	O
intensity	O
,	O
and	O
excitation	O
wavelength	O
.	O

The	O
laser	O
-	O
induced	O
size	O
reduction	O
of	O
aqueous	O
noble	O
metal	O
nanoparticles	O
has	O
been	O
the	O
subject	O
of	O
intensive	O
research	O
,	O
because	O
of	O
the	O
mechanistic	O
interest	O
in	O
the	O
light	O
-	O
nanoparticle	O
interactions	O
and	O
its	O
potential	O
application	O
to	O
size	O
control	O
.	O

The	O
photothermal	O
evaporation	O
hypothesis	O
has	O
gained	O
solid	O
support	O
.	O

However	O
,	O
the	O
polydispersity	O
of	O
the	O
final	O
products	O
is	O
considered	O
as	O
an	O
inherent	O
drawback	O
of	O
the	O
method	O
.	O

It	O
is	O
likely	O
that	O
the	O
polydispersity	O
arises	O
from	O
the	O
uncontrolled	O
heat	O
dissipation	O
caused	O
by	O
vapor	O
bubble	O
formation	O
in	O
the	O
ambient	O
atmosphere	O
.	O

To	O
overcome	O
this	O
problem	O
,	O
we	O
applied	O
high	O
pressures	O
of	O
30	O
-	O
100	O
MPa	O
.	O

The	O
particle	O
size	O
was	O
regulated	O
by	O
adjusting	O
three	O
parameters	O
:	O
the	O
pressure	O
,	O
laser	O
intensity	O
,	O
and	O
excitation	O
wavelength	O
.	O

For	O
example	O
,	O
starting	O
from	O
a	O
colloidal	O
solution	O
of	O
100	O
nm	O
diameter	O
gold	O
nanoparticles	O
,	O
highly	O
monodisperse	O
(	O
3	O
-	O
5	O
%	O
)	O
spheres	O
with	O
various	O
diameters	O
ranging	O
from	O
90	O
to	O
30	O
nm	O
were	O
fabricated	O
by	O
tuning	O
the	O
laser	O
intensity	O
at	O
100	O
MPa	O
,	O
using	O
an	O
excitation	O
wavelength	O
of	O
532	O
nm	O
.	O

Further	O
size	O
reduction	O
of	O
the	O
diameter	O
to	O
20	O
nm	O
was	O
achieved	O
by	O
reducing	O
the	O
pressure	O
and	O
switching	O
the	O
excitation	O
wavelength	O
to	O
355	O
nm	O
.	O

It	O
was	O
found	O
that	O
the	O
application	O
of	O
high	O
pressures	O
led	O
to	O
the	O
heat	O
loss	O
-	O
controlled	O
size	O
-	O
reduction	O
of	O
the	O
gold	O
nanoparticles	O
.	O

More	O
complicated	O
results	O
were	O
obtained	O
for	O
100	O
nm	O
silver	B
nanoparticles	O
,	O
possibly	O
because	O
of	O
the	O
different	O
size	O
-	O
dependent	O
light	O
-	O
absorbing	O
nature	O
of	O
these	O
particles	O
.	O

Based	O
on	O
our	O
extensive	O
experimental	O
studies	O
,	O
a	O
detailed	O
picture	O
was	O
developed	O
for	O
the	O
nanosecond	O
laser	O
-	O
induced	O
fabrication	O
of	O
gold	O
and	O
silver	B
nanoparticles	O
,	O
leading	O
to	O
unprecedented	O
size	O
control	O
.	O

Cell	O
-	O
cycle	O
and	O
DNA	O
damage	O
regulation	O
of	O
the	O
DNA	O
mismatch	O
repair	O
protein	O
Msh2	O
occurs	O
at	O
the	O
transcriptional	O
and	O
post	O
-	O
transcriptional	O
level	O
.	O

DNA	O
mismatch	O
repair	O
during	O
replication	O
is	O
a	O
conserved	O
process	O
essential	O
for	O
maintaining	O
genomic	O
stability	O
.	O

Mismatch	O
repair	O
is	O
also	O
implicated	O
in	O
cell	O
-	O
cycle	O
arrest	O
and	O
apoptosis	O
after	O
DNA	O
damage	O
.	O

Because	O
yeast	O
and	O
human	O
mismatch	O
repair	O
systems	O
are	O
well	O
conserved	O
,	O
we	O
have	O
employed	O
the	O
budding	O
yeast	O
Saccharomyces	O
cerevisiae	O
to	O
understand	O
the	O
regulation	O
and	O
function	O
of	O
the	O
mismatch	O
repair	O
gene	O
MSH2	O
.	O

Using	O
a	O
luciferase	O
-	O
based	O
transcriptional	O
reporter	O
,	O
we	O
defined	O
a	O
218-bp	O
region	O
upstream	O
of	O
MSH2	O
that	O
contains	O
cell	O
-	O
cycle	O
and	O
DNA	O
damage	O
responsive	O
elements	O
.	O

The	O
5	O
'	O
end	O
of	O
the	O
MSH2	O
transcript	O
was	O
mapped	O
by	O
primer	O
extension	O
and	O
was	O
found	O
to	O
encode	O
a	O
small	O
upstream	O
open	O
reading	O
frame	O
(	O
uORF	O
)	O
.	O

Mutagenesis	O
of	O
the	O
uORF	O
start	O
codon	O
or	O
of	O
the	O
uORF	O
stop	O
codon	O
,	O
which	O
creates	O
a	O
continuous	O
reading	O
frame	O
with	O
MSH2	O
,	O
increased	O
Msh2	O
steady	O
-	O
state	O
protein	O
levels	O
2-fold	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
the	O
cell	O
-	O
cycle	O
transcription	O
factors	O
Swi6	O
,	O
Swi4	O
,	O
and	O
Mbp1-along	O
with	O
SCB	O
/	O
MCB	O
cell	O
-	O
cycle	O
binding	O
sites	O
upstream	O
of	O
MSH2-are	O
all	O
required	O
for	O
full	O
basal	O
expression	O
of	O
MSH2	O
.	O

Mutagenesis	O
of	O
the	O
cell	O
-	O
cycle	O
boxes	O
resulted	O
in	O
a	O
minor	O
reduction	O
in	O
basal	O
Msh2	O
levels	O
and	O
a	O
3-fold	O
defect	O
in	O
mismatch	O
repair	O
.	O

Disruption	O
of	O
the	O
cell	O
-	O
cycle	O
boxes	O
also	O
affected	O
growth	O
in	O
a	O
DNA	O
polymerase	O
-	O
defective	O
strain	O
background	O
where	O
mismatch	O
repair	O
is	O
essential	O
,	O
particularly	O
in	O
the	O
presence	O
of	O
the	O
DNA	O
damaging	O
agent	O
methyl	B
methane	I
sulfonate	I
(	O
MMS	B
)	O
.	O

Promoter	O
replacements	O
conferring	O
constitutive	O
expression	O
of	O
MSH2	O
revealed	O
that	O
the	O
transcriptional	O
induction	O
in	O
response	O
to	O
MMS	B
is	O
required	O
to	O
maintain	O
induced	O
levels	O
of	O
Msh2	O
.	O

Turnover	O
experiments	O
confirmed	O
an	O
elevated	O
rate	O
of	O
degradation	O
in	O
the	O
presence	O
of	O
MMS	B
.	O

Taken	O
together	O
,	O
the	O
data	O
show	O
that	O
the	O
DNA	O
damage	O
regulation	O
of	O
Msh2	O
occurs	O
at	O
the	O
transcriptional	O
and	O
post	O
-	O
transcriptional	O
levels	O
.	O

The	O
transcriptional	O
and	O
translational	O
control	O
elements	O
identified	O
are	O
conserved	O
in	O
mammalian	O
cells	O
,	O
underscoring	O
the	O
use	O
of	O
yeast	O
as	O
a	O
model	O
system	O
to	O
examine	O
the	O
regulation	O
of	O
MSH2	O
.	O

Increased	O
urinary	O
excretion	O
of	O
albumin	O
,	O
hemopexin	O
,	O
transferrin	O
and	O
VDBP	O
correlates	O
with	O
chronic	O
sensitization	O
to	O
gentamicin	B
nephrotoxicity	O
in	O
rats	O
.	O

Drug	O
nephrotoxicity	O
is	O
a	O
serious	O
health	O
and	O
economic	O
problem	O
worldwide	O
.	O

Rats	O
can	O
be	O
acutely	O
sensitized	O
to	O
acute	O
kidney	O
injury	O
(	O
AKI	O
)	O
by	O
subnephrotoxic	O
treatments	O
with	O
potentially	O
nephrotoxic	O
drugs	O
.	O

Acquired	O
sensitization	O
to	O
AKI	O
poses	O
a	O
silent	O
risk	O
impossible	O
to	O
diagnose	O
pre	O
-	O
emptively	O
with	O
the	O
technology	O
available	O
at	O
the	O
clinical	O
level	O
.	O

Herein	O
,	O
we	O
hypothesized	O
whether	O
a	O
chronic	O
,	O
subnephrotoxic	O
insult	O
to	O
the	O
kidneys	O
might	O
result	O
in	O
chronically	O
acquired	O
sensitization	O
to	O
AKI	O
,	O
and	O
whether	O
chronic	O
sensitization	O
might	O
be	O
detected	O
through	O
specific	O
urinary	O
markers	O
.	O

To	O
this	O
end	O
,	O
rats	O
were	O
treated	O
with	O
a	O
subtoxic	O
dosage	O
of	O
the	O
experimental	O
nephrotoxin	O
uranyl	O
nitrate	B
(	O
UN	O
)	O
in	O
the	O
drinking	O
water	O
for	O
21	O
weeks	O
,	O
or	O
plain	O
water	O
(	O
as	O
control	O
)	O
,	O
and	O
then	O
with	O
low	O
-	O
dose	O
gentamicin	B
for	O
7	O
days	O
.	O

Renal	O
function	O
and	O
renal	O
tissue	O
damage	O
were	O
evaluated	O
through	O
the	O
experiment	O
.	O

The	O
mild	O
renal	O
damage	O
caused	O
by	O
gentamicin	B
was	O
markedly	O
magnified	O
in	O
rats	O
having	O
received	O
UN	O
chronically	O
,	O
which	O
was	O
evident	O
both	O
at	O
the	O
functional	O
and	O
histological	O
level	O
.	O

Four	O
proteins	O
,	O
namely	O
albumin	O
,	O
hemopexin	O
,	O
transferrin	O
and	O
vitamin	B
D	I
binding	O
protein	O
were	O
increased	O
in	O
the	O
urine	O
in	O
temporal	O
association	O
with	O
the	O
appearance	O
of	O
chronic	O
predisposition	O
.	O

Although	O
further	O
studies	O
are	O
necessary	O
,	O
our	O
results	O
suggest	O
that	O
these	O
proteins	O
might	O
be	O
potentially	O
used	O
as	O
markers	O
of	O
hidden	O
,	O
chronic	O
predisposition	O
to	O
gentamicin	B
nephrotoxicity	O
,	O
in	O
order	O
to	O
appropriately	O
and	O
pre	O
-	O
emptively	O
stratify	O
and	O
handle	O
individuals	O
according	O
to	O
their	O
specific	O
risk	O
in	O
the	O
long	O
term	O
,	O
and	O
to	O
conveniently	O
optimize	O
their	O
life	O
conditions	O
or	O
additional	O
clinical	O
procedures	O
or	O
treatments	O
that	O
might	O
trigger	O
the	O
disease	O
.	O

This	O
might	O
reduce	O
AKI	O
incidence	O
and	O
severity	O
and	O
the	O
associated	O
costs	O
.	O

Sequential	O
delivery	O
of	O
TAT	O
-	O
HSP27	O
and	O
VEGF	O
using	O
microsphere	O
/	O
hydrogel	O
hybrid	O
systems	O
for	O
therapeutic	O
angiogenesis	O
.	O

Ischemic	O
disease	O
is	O
associated	O
with	O
high	O
mortality	O
and	O
morbidity	O
rates	O
,	O
and	O
therapeutic	O
angiogenesis	O
via	O
systemic	O
or	O
local	O
delivery	O
of	O
protein	O
drugs	O
is	O
one	O
potential	O
approach	O
to	O
treat	O
the	O
disease	O
.	O

In	O
this	O
study	O
,	O
we	O
hypothesized	O
that	O
combined	O
delivery	O
of	O
TAT	O
-	O
HSP27	O
(	O
HSP27	O
fused	O
with	O
transcriptional	O
activator	O
)	O
and	O
VEGF	O
could	O
enhance	O
the	O
therapeutic	O
efficacy	O
in	O
an	O
ischemic	O
mouse	O
model	O
,	O
and	O
that	O
sequential	O
release	O
could	O
be	O
critical	O
in	O
therapeutic	O
angiogenesis	O
.	O

Alginate	O
hydrogels	O
containing	O
TAT	O
-	O
HSP27	O
as	O
an	O
anti	O
-	O
apoptotic	O
agent	O
were	O
prepared	O
,	O
and	O
porous	O
PLGA	O
microspheres	O
loaded	O
with	O
VEGF	O
as	O
an	O
angiogenic	O
agent	O
were	O
incorporated	O
into	O
the	O
hydrogels	O
to	O
prepare	O
microsphere	O
/	O
hydrogel	O
hybrid	O
delivery	O
systems	O
.	O

Sequential	O
in	O
vitro	O
release	O
of	O
TAT	O
-	O
HSP27	O
and	O
VEGF	O
was	O
achieved	O
by	O
the	O
hybrid	O
systems	O
.	O

TAT	O
-	O
HSP27	O
was	O
depleted	O
from	O
alginate	O
gels	O
in	O
7	O
days	O
,	O
while	O
VEGF	O
was	O
continually	O
released	O
for	O
28	O
days	O
.	O

The	O
release	O
rate	O
of	O
VEGF	O
was	O
attenuated	O
by	O
varying	O
the	O
porous	O
structures	O
of	O
PLGA	O
microspheres	O
.	O

Sequential	O
delivery	O
of	O
TAT	O
-	O
HSP27	O
and	O
VEGF	O
was	O
critical	O
to	O
protect	O
against	O
muscle	O
degeneration	O
and	O
fibrosis	O
,	O
as	O
well	O
as	O
to	O
promote	O
new	O
blood	O
vessel	O
formation	O
in	O
the	O
ischemic	O
site	O
of	O
a	O
mouse	O
model	O
.	O

This	O
approach	O
to	O
controlling	O
the	O
sequential	O
release	O
behaviors	O
of	O
multiple	O
drugs	O
could	O
be	O
useful	O
in	O
the	O
design	O
of	O
novel	O
drug	O
delivery	O
systems	O
for	O
therapeutic	O
angiogenesis	O
.	O

Synthesis	O
and	O
evaluation	O
of	O
a	O
backbone	O
biodegradable	O
multiblock	O
HPMA	B
copolymer	O
nanocarrier	O
for	O
the	O
systemic	O
delivery	O
of	O
paclitaxel	B
.	O

The	O
performance	O
and	O
safety	O
of	O
current	O
antineoplastic	O
agents	O
,	O
particularly	O
water	O
-	O
insoluble	O
drugs	O
,	O
are	O
still	O
far	O
from	O
satisfactory	O
.	O

For	O
example	O
,	O
the	O
currently	O
widely	O
used	O
Cremophor	O
EL	O
	O
-based	O
paclitaxel	B
(	O
PTX	B
)	O
formulation	O
exhibits	O
pharmacokinetic	O
concerns	O
and	O
severe	O
side	O
effects	O
.	O

Thus	O
,	O
the	O
concept	O
of	O
a	O
biodegradable	O
polymeric	O
drug	O
-	O
delivery	O
system	O
,	O
which	O
can	O
significantly	O
improve	O
therapeutic	O
efficacy	O
and	O
reduce	O
side	O
effects	O
is	O
advocated	O
.	O

The	O
present	O
work	O
aims	O
to	O
develop	O
a	O
new	O
-	O
generation	O
of	O
long	O
-	O
circulating	O
,	O
biodegradable	O
carriers	O
for	O
effective	O
delivery	O
of	O
PTX	B
.	O

First	O
,	O
a	O
multiblock	O
backbone	O
biodegradable	O
N-	B
(	I
2-hydroxypropyl	I
)	I
methacrylamide	I
(	O
HPMA	B
)	O
copolymer	O
-	O
PTX	B
conjugate	O
(	O
mP	O
-	O
PTX	B
)	O
with	O
molecular	O
weight	O
(	O
Mw	O
)	O
of	O
335	O
kDa	O
was	O
synthesized	O
by	O
RAFT	O
(	O
reversible	O
addition	O
-	O
fragmentation	O
chain	O
transfer	O
)	O
copolymerization	O
,	O
followed	O
by	O
chain	O
extension	O
.	O

In	O
vitro	O
studies	O
on	O
human	O
ovarian	O
carcinoma	O
A2780	O
cells	O
were	O
carried	O
out	O
to	O
investigate	O
the	O
cytotoxicity	O
of	O
free	O
PTX	B
,	O
HPMA	B
copolymer	O
-	O
PTX	B
conjugate	O
with	O
Mw	O
of	O
48	O
kDa	O
(	O
P	O
-	O
PTX	B
)	O
,	O
and	O
mP	O
-	O
PTX	B
.	O

The	O
experiments	O
demonstrated	O
that	O
mP	O
-	O
PTX	B
has	O
a	O
similar	O
cytotoxic	O
effect	O
against	O
A2780	O
cells	O
as	O
free	O
PTX	B
and	O
P	O
-	O
PTX	B
.	O

To	O
further	O
compare	O
the	O
behavior	O
of	O
this	O
new	O
biodegradable	O
conjugate	O
(	O
mP	O
-	O
PTX	B
)	O
with	O
free	O
PTX	B
and	O
P	O
-	O
PTX	B
in	O
vivo	O
evaluation	O
was	O
performed	O
using	O
female	O
nu	O
/	O
nu	O
mice	O
bearing	O
orthotopic	O
A2780	O
ovarian	O
tumors	O
.	O

Pharmacokinetics	O
study	O
showed	O
that	O
high	O
Mw	O
mP	O
-	O
PTX	B
was	O
cleared	O
more	O
slowly	O
from	O
the	O
blood	O
than	O
commercial	O
PTX	B
formulation	O
and	O
low	O
Mw	O
P	O
-	O
PTX	B
.	O

SPECT	O
/	O
CT	O
imaging	O
and	O
biodistribution	O
studies	O
demonstrated	O
biodegradability	O
as	O
well	O
as	O
elimination	O
of	O
mP	O
-	O
PTX	B
from	O
the	O
body	O
.	O

The	O
tumors	O
in	O
the	O
mP	O
-	O
PTX	B
treated	O
group	O
grew	O
more	O
slowly	O
than	O
those	O
treated	O
with	O
saline	O
,	O
free	O
PTX	B
,	O
and	O
P	O
-	O
PTX	B
(	O
single	O
dose	O
at	O
20	O
mg	O
PTX	B
/	O
kg	O
equivalent	O
)	O
.	O

Moreover	O
,	O
mice	O
treated	O
with	O
mP	O
-	O
PTX	B
had	O
no	O
obvious	O
ascites	O
and	O
body	O
-	O
weight	O
loss	O
.	O

Histological	O
analysis	O
indicated	O
that	O
mP	O
-	O
PTX	B
had	O
no	O
toxicity	O
in	O
liver	O
and	O
spleen	O
,	O
but	O
induced	O
massive	O
cell	O
death	O
in	O
the	O
tumor	O
.	O

In	O
summary	O
,	O
this	O
biodegradable	O
drug	O
delivery	O
system	O
has	O
a	O
great	O
potential	O
to	O
improve	O
performance	O
and	O
safety	O
of	O
current	O
antineoplastic	O
agents	O
.	O

C	B
(	I
22	I
)	I
-steroidal	I
lactone	I
glycosides	I
from	O
stems	O
and	O
leaves	O
of	O
Paris	O
polyphylla	O
var	O
.	O

yunnanensis	O
.	O

Further	O
phytochemical	O
investigation	O
on	O
the	O
stems	O
and	O
leaves	O
of	O
Paris	O
polyphylla	O
var	O
.	O

yunnanensis	O
has	O
led	O
to	O
the	O
isolation	O
of	O
three	O
C	B
(	I
22	I
)	I
-steroidal	I
lactone	I
glycosides	I
.	O

Two	O
of	O
these	O
are	O
new	O
compounds	O
,	O
designated	O
as	O
chonglouoside	B
SL-7	I
(	O
1	O
)	O
and	O
chonglouoside	B
SL-8	I
(	O
2	O
)	O
.	O

Their	O
structures	O
were	O
elucidated	O
on	O
the	O
basis	O
of	O
extensive	O
spectroscopic	O
analysis	O
,	O
as	O
well	O
as	O
comparison	O
with	O
the	O
reported	O
spectroscopic	O
data	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
C	B
(	I
22	I
)	I
-steroidal	I
lactone	I
glycosides	I
isolated	O
from	O
the	O
Paris	O
genus	O
.	O

Compounds	O
1	O
and	O
3	O
showed	O
moderate	O
antimicrobic	O
activity	O
against	O
Propionibacterium	O
acnes	O
with	O
MIC	O
values	O
of	O
31.3	O
and	O
3.9g	O
/	O
mL	O
,	O
respectively	O
.	O

Caffeine	B
-	O
induced	O
inhibition	O
of	O
the	O
activity	O
of	O
glutamate	B
transporter	O
type	O
3	O
expressed	O
in	O
Xenopus	O
oocytes	O
.	O

Caffeine	B
has	O
been	O
known	O
to	O
trigger	O
seizures	O
,	O
however	O
,	O
the	O
precise	O
mechanism	O
about	O
the	O
proconvulsive	O
effect	O
of	O
caffeine	B
remains	O
unclear	O
.	O

Glutamate	B
transporters	O
play	O
an	O
important	O
role	O
to	O
maintain	O
the	O
homeostasis	O
of	O
glutamate	B
concentration	O
in	O
the	O
brain	O
tissue	O
.	O

Especially	O
,	O
dysfunction	O
of	O
excitatory	O
amino	B
acid	I
transporter	O
type	O
3	O
(	O
EAAT3	O
)	O
can	O
lead	O
to	O
seizures	O
.	O

We	O
investigated	O
the	O
effects	O
of	O
caffeine	B
on	O
the	O
activity	O
of	O
EAAT3	O
and	O
the	O
involvement	O
of	O
protein	O
kinase	O
C	O
(	O
PKC	O
)	O
and	O
phosphatidylinositol	O
3-kinase	O
(	O
PI3	O
K	O
)	O
.	O

Rat	O
EAAT3	O
was	O
expressed	O
in	O
Xenopus	O
oocytes	O
by	O
injecting	O
EAAT3	O
mRNA	O
.	O

l	B
-	I
Glutamate	I
(	O
30M	O
)	O
-induced	O
inward	O
currents	O
were	O
recorded	O
via	O
the	O
two	O
-	O
electrode	O
voltage	O
clamp	O
method	O
.	O

Caffeine	B
decreased	O
EAAT3	O
activity	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Caffeine	B
(	O
30M	O
for	O
3min	O
)	O
significantly	O
reduced	O
V	O
(	O
max	O
)	O
,	O
but	O
did	O
not	O
alter	O
K	O
(	O
m	O
)	O
value	O
of	O
EAAT3	O
for	O
glutamate	B
.	O

When	O
preincubated	O
oocytes	O
with	O
phorbol-12-myristate-13-acetate	B
(	O
PMA	B
,	O
a	O
PKC	O
activator	O
)	O
were	O
exposed	O
to	O
caffeine	B
,	O
PMA	B
-	O
induced	O
increase	O
in	O
EAAT3	O
activity	O
was	O
abolished	O
.	O

Two	O
PKC	O
inhibitors	O
(	O
chelerythrine	B
and	O
staurosporine	B
)	O
significantly	O
reduced	O
basal	O
EAAT3	O
activity	O
.	O

Whereas	O
,	O
there	O
were	O
no	O
significant	O
differences	O
among	O
the	O
PKC	O
inhibitors	O
,	O
caffeine	B
,	O
and	O
PKC	O
inhibitors+caffeine	O
groups	O
.	O

In	O
similarly	O
fashion	O
,	O
wortmannin	B
(	O
a	O
PI3	O
K	O
inhibitor	O
)	O
significantly	O
decreased	O
EAAT3	O
activity	O
,	O
however	O
no	O
statistical	O
differences	O
were	O
observed	O
among	O
the	O
wortmannin	B
,	O
caffeine	B
,	O
and	O
wortmannin+caffeine	B
groups	O
.	O

Our	O
results	O
demonstrate	O
that	O
caffeine	B
attenuates	O
EAAT3	O
activity	O
and	O
this	O
reducing	O
effect	O
of	O
caffeine	B
seems	O
to	O
be	O
mediated	O
by	O
PKC	O
and	O
PI3	O
K	O
.	O

The	O
response	O
of	O
soil	O
organism	O
communities	O
to	O
the	O
application	O
of	O
the	O
insecticide	O
lindane	B
in	O
terrestrial	O
model	O
ecosystems	O
.	O

The	O
EU	O
plant	O
protection	O
regulation	O
1107	O
/	O
2009	O
/	O
EC	O
defines	O
the	O
requirements	O
for	O
active	O
ingredients	O
to	O
be	O
approved	O
,	O
specifically	O
including	O
the	O
assessment	O
of	O
effects	O
on	O
biodiversity	O
and	O
ecosystems	O
.	O

According	O
to	O
that	O
,	O
semi	O
-	O
field	O
methods	O
are	O
expected	O
to	O
be	O
more	O
important	O
in	O
the	O
near	O
future	O
.	O

Therefore	O
,	O
a	O
higher	O
-	O
tier	O
experiment	O
suitable	O
to	O
assess	O
the	O
risk	O
for	O
soil	O
organisms	O
was	O
conducted	O
to	O
further	O
develop	O
the	O
TME	O
(	O
terrestrial	O
model	O
ecosystems	O
)	O
methodology	O
in	O
a	O
dose	O
-	O
response	O
design	O
with	O
the	O
persistent	O
insecticidal	O
model	O
compound	O
lindane	B
(	O
gamma	B
-	I
HCH	I
)	O
.	O

The	O
effects	O
of	O
lindane	B
on	O
soil	O
communities	O
such	O
as	O
collembolans	O
,	O
oribatid	O
mites	O
,	O
nematodes	O
,	O
soil	O
fungi	O
and	O
plant	O
biomass	O
were	O
determined	O
in	O
42	O
TME	O
.	O

Intact	O
TME	O
-	O
soil	O
cores	O
(	O
diameter	O
300	O
mm	O
,	O
height	O
400	O
mm	O
)	O
from	O
undisturbed	O
grassland	O
were	O
stored	O
outdoor	O
under	O
natural	O
climatic	O
conditions	O
.	O

Lindane	B
was	O
applied	O
in	O
five	O
concentrations	O
between	O
0.032	O
mg	O
active	O
ingredients	O
(	O
ai	O
)	O
/	O
kg	O
dry	O
soil	O
and	O
3.2	O
mg	O
ai	O
/	O
kg	O
dry	O
weight	O
soil	O
,	O
six	O
-	O
fold	O
replicated	O
each	O
.	O

Twelve	O
TME	O
served	O
as	O
untreated	O
controls	O
.	O

Abundance	O
and	O
community	O
structures	O
of	O
oribatids	O
,	O
collembolans	O
,	O
enchytraeids	O
,	O
nematodes	O
and	O
fungi	O
were	O
recorded	O
.	O

Oribatid	O
mites	O
'	O
community	O
responded	O
3	O
months	O
after	O
treatment	O
,	O
although	O
they	O
were	O
not	O
significantly	O
affected	O
by	O
the	O
overall	O
treatment	O
regimen	O
.	O

Collembolans	O
in	O
total	O
and	O
species	O
-	O
specific	O
abundance	O
as	O
well	O
as	O
the	O
community	O
endpoints	O
(	O
principal	O
response	O
curves	O
,	O
diversity	O
measures	O
)	O
were	O
adversely	O
affected	O
by	O
moderate	O
dosages	O
of	O
lindane	O
.	O

Effects	O
were	O
transient	O
between	O
3	O
and	O
5	O
months	O
after	O
treatment	O
with	O
a	O
recovery	O
within	O
1	O
year	O
.	O

No	O
significant	O
effects	O
could	O
be	O
detected	O
for	O
enchytraeids	O
,	O
nematodes	O
and	O
fungi	O
.	O

The	O
study	O
design	O
and	O
the	O
obtained	O
results	O
allow	O
for	O
calculations	O
of	O
no	O
observed	O
effect	O
concentrations	O
below	O
the	O
highest	O
treatment	O
level	O
for	O
populations	O
and	O
for	O
soil	O
communities	O
as	O
defined	O
entities	O
,	O
as	O
well	O
as	O
effective	O
concentrations	O
.	O

The	O
paper	O
discusses	O
the	O
limits	O
of	O
effect	O
detection	O
in	O
the	O
light	O
of	O
achievable	O
coefficients	O
of	O
variation	O
and	O
by	O
means	O
of	O
minimum	O
detectable	O
differences	O
.	O

Outdoor	O
TME	O
are	O
useful	O
to	O
analyze	O
and	O
assess	O
functional	O
and	O
structural	O
endpoints	O
in	O
soil	O
organisms	O
'	O
communities	O
and	O
their	O
possible	O
recovery	O
after	O
pesticide	O
treatment	O
within	O
1	O
year	O
.	O

Dynamic	O
behavior	O
of	O
water	O
droplet	O
impact	O
on	O
microtextured	O
surfaces	O
:	O
the	O
effect	O
of	O
geometrical	O
parameters	O
on	O
anisotropic	O
wetting	O
and	O
the	O
maximum	O
spreading	O
diameter	O
.	O

Textured	O
silicon	B
surfaces	O
decorated	O
by	O
square	O
arrays	O
of	O
pillars	O
with	O
adjustable	O
pitch	O
were	O
fabricated	O
.	O

The	O
wetting	O
behavior	O
,	O
especially	O
for	O
direction	O
-	O
dependent	O
water	O
contact	O
angles	O
on	O
textured	O
silicon	B
surfaces	O
after	O
silanization	O
,	O
was	O
investigated	O
by	O
incorporating	O
the	O
contact	O
line	O
fraction	O
into	O
a	O
modified	O
Wenzel	O
model	O
.	O

Also	O
,	O
the	O
effect	O
of	O
geometrical	O
parameters	O
on	O
the	O
anisotropic	O
wetting	O
behavior	O
of	O
water	O
was	O
examined	O
with	O
respect	O
to	O
water	O
droplet	O
impact	O
on	O
the	O
textured	O
surface	O
.	O

Moreover	O
,	O
the	O
maximum	O
spreading	O
factor	O
was	O
studied	O
theoretically	O
in	O
terms	O
of	O
energy	O
conservation	O
,	O
allowing	O
for	O
surface	O
topography	O
and	O
viscous	O
friction	O
of	O
the	O
liquid	O
flowing	O
among	O
the	O
arrays	O
of	O
the	O
posts	O
.	O

Theoretical	O
models	O
were	O
found	O
to	O
be	O
in	O
good	O
agreement	O
with	O
experimental	O
data	O
.	O

Mineral	O
and	O
sensory	O
profile	O
of	O
seasoned	O
cracked	O
olives	O
packed	O
in	O
diverse	O
salt	O
mixtures	O
.	O

This	O
work	O
studies	O
the	O
effect	O
of	O
packing	O
cracked	O
seasoned	O
olives	O
with	O
NaCl	B
,	O
KCl	B
,	O
and	O
CaCl	B
(	I
2	I
)	I
mixture	O
brines	O
on	O
their	O
mineral	O
nutrients	O
and	O
sensory	O
attributes	O
,	O
using	O
RSM	O
methodology	O
.	O

The	O
Na	B
,	O
K	O
,	O
Ca	B
,	O
and	O
residual	O
natural	O
Mn	B
contents	O
in	O
flesh	O
as	O
well	O
as	O
saltiness	O
,	O
bitterness	O
and	O
fibrousness	O
were	O
significantly	O
related	O
to	O
the	O
initial	O
concentrations	O
of	O
salts	O
in	O
the	O
packing	O
solution	O
.	O

This	O
new	O
process	O
led	O
to	O
table	O
olives	O
with	O
a	O
significantly	O
lower	O
sodium	B
content	O
(	O
about	O
31	O
%	O
)	O
than	O
the	O
traditional	O
product	O
but	O
fortified	O
in	O
K	O
and	O
Ca	B
.	O

High	O
levels	O
of	O
Na	B
and	O
Ca	B
in	O
the	O
flesh	O
led	O
to	O
high	O
scores	O
of	O
acidity	O
and	O
saltiness	O
(	O
the	O
first	O
descriptor	O
)	O
and	O
bitterness	O
(	O
the	O
second	O
)	O
while	O
the	O
K	O
content	O
was	O
unrelated	O
to	O
any	O
sensory	O
descriptor	O
.	O

The	O
new	O
presentations	O
using	O
moderate	O
proportions	O
of	O
alternative	O
salts	O
will	O
therefore	O
have	O
improved	O
nutritional	O
value	O
and	O
healthier	O
characteristics	O
but	O
only	O
a	O
slightly	O
modified	O
sensory	O
profile	O
.	O

Direct	O
potentiometric	O
determination	O
of	O
starch	O
using	O
a	O
platinum	B
redox	O
sensor	O
.	O

Here	O
,	O
we	O
describe	O
the	O
development	O
of	O
a	O
platinum	B
redox	O
sensor	O
for	O
the	O
direct	O
potentiometric	O
quantification	O
of	O
starch	O
in	O
solution	O
.	O

The	O
sensor	O
measures	O
the	O
decrease	O
in	O
free	O
triiodide	B
ion	O
after	O
it	O
complexes	O
with	O
starch	O
to	O
form	O
a	O
starch	O
-	O
triiodide	B
complex	O
.	O

This	O
decrease	O
was	O
,	O
therefore	O
,	O
correlated	O
with	O
starch	O
concentration	O
,	O
and	O
the	O
composition	O
and	O
stability	O
of	O
the	O
potassium	B
triiodide	I
solution	O
were	O
optimised	O
.	O

The	O
starch	O
-	O
triiodide	B
complex	O
was	O
characterized	O
potentiometrically	O
at	O
variable	O
starch	O
and	O
triiodide	B
concentrations	O
.	O

We	O
also	O
propose	O
a	O
response	O
mechanism	O
for	O
the	O
platinum	B
redox	O
sensor	O
towards	O
starch	O
and	O
an	O
appropriate	O
theoretical	O
model	O
.	O

The	O
optimised	O
method	O
exhibited	O
satisfactory	O
accuracy	O
and	O
precision	O
and	O
was	O
in	O
good	O
agreement	O
with	O
a	O
standard	O
spectrophotometric	O
method	O
.	O

The	O
sensor	O
was	O
tested	O
over	O
a	O
range	O
of	O
0.4	O
-	O
9	O
mg	O
starch	O
,	O
with	O
recoveries	O
ranging	O
from	O
97.8	O
%	O
to	O
103.4	O
%	O
and	O
a	O
detection	O
limit	O
of	O
0.01	O
mg	O
starch	O
.	O

Rapid	O
detection	O
and	O
quantification	O
of	O
milk	O
adulteration	O
using	O
infrared	O
microspectroscopy	O
and	O
chemometrics	O
analysis	O
.	O

The	O
application	O
of	O
attenuated	O
total	O
reflectance	O
mid	O
-	O
infrared	O
microspectroscopy	O
(	O
MIR	O
-	O
microspectroscopy	O
)	O
was	O
evaluated	O
as	O
a	O
rapid	O
method	O
for	O
detection	O
and	O
quantification	O
of	O
milk	O
adulteration	O
.	O

Milk	O
samples	O
were	O
purchased	O
from	O
local	O
grocery	O
stores	O
(	O
Columbus	O
,	O
OH	O
,	O
USA	O
)	O
and	O
spiked	O
at	O
different	O
concentrations	O
of	O
whey	O
,	O
hydrogen	B
peroxide	I
,	O
synthetic	O
urine	O
,	O
urea	B
and	O
synthetic	O
milk	O
.	O

Samples	O
were	O
place	O
on	O
a	O
192-well	O
microarray	O
slide	O
,	O
air	O
-	O
dried	O
and	O
spectra	O
were	O
collected	O
by	O
using	O
MIR	O
-	O
microspectroscopy	O
.	O

Pattern	O
recognition	O
analysis	O
by	O
Soft	O
Independent	O
Modeling	O
of	O
Class	O
Analogy	O
(	O
SIMCA	O
)	O
showed	O
tight	O
and	O
well	O
-	O
separated	O
clusters	O
allowing	O
discrimination	O
of	O
control	O
samples	O
from	O
adulterated	O
milk	O
.	O

Partial	O
Least	O
Squares	O
Regression	O
(	O
PLSR	O
)	O
showed	O
standard	O
error	O
of	O
prediction	O
(	O
SEP	O
)	O
~2.33	O
,	O
0.06	O
,	O
0.41	O
,	O
0.30	O
and	O
0.014	O
g	O
/	O
L	O
for	O
estimation	O
of	O
levels	O
of	O
adulteration	O
with	O
whey	O
,	O
synthetic	O
milk	O
,	O
synthetic	O
urine	O
,	O
urea	B
and	O
hydrogen	B
peroxide	I
,	O
respectively	O
.	O

Results	O
showed	O
that	O
MIR	O
-	O
microspectroscopy	O
can	O
provide	O
an	O
alternative	O
methodology	O
to	O
the	O
dairy	O
industry	O
for	O
screening	O
potential	O
fraudulent	O
practice	O
for	O
economic	O
adulteration	O
of	O
cow	O
's	O
milk	O
.	O

Cashew	O
apple	O
(	O
Anacardium	O
occidentale	O
L.	O
)	O
extract	O
from	O
by	O
-	O
product	O
of	O
juice	O
processing	O
:	O
a	O
focus	O
on	O
carotenoids	O
.	O

Cashew	O
apple	O
fibrous	O
residue	O
is	O
a	O
by	O
-	O
product	O
of	O
the	O
cashew	O
juice	O
industry	O
.	O

After	O
pressing	O
using	O
a	O
helical	O
type	O
continuous	O
press	O
followed	O
by	O
crossflow	O
microfiltration	O
,	O
an	O
aqueous	O
extract	O
was	O
obtained	O
from	O
these	O
cashew	O
apple	O
fibres	O
.	O

It	O
was	O
characterised	O
by	O
an	O
intense	O
yellow	O
colour	O
due	O
to	O
carotenoid	O
pigments	O
.	O

Carotenoids	O
were	O
identified	O
and	O
quantified	O
in	O
the	O
cashew	O
apple	O
before	O
extraction	O
,	O
in	O
its	O
aqueous	O
extract	O
and	O
in	O
the	O
concentrate	O
obtained	O
by	O
microfiltration	O
.	O

Cashew	O
apple	O
aqueous	O
extract	O
and	O
its	O
concentrate	O
presented	O
a	O
carotenoid	O
profile	O
with	O
11	O
carotenoids	O
,	O
most	O
of	O
them	O
were	O
tentatively	O
identified	O
by	O
HPLC	O
-	O
DAD	O
-	O
MS	O
and	O
are	O
xanthophylls	O
present	O
under	O
an	O
esterified	O
form	O
.	O

Auroxanthin	O
and	O
	B
-	I
cryptoxanthin	I
represented	O
around	O
50	O
%	O
of	O
total	O
carotenoids	O
.	O

Concentration	O
of	O
the	O
extract	O
by	O
microfiltration	O
led	O
to	O
epoxy	B
-	O
furanoxy	B
rearrangement	O
of	O
violaxanthin	B
and	O
antheraxanthin	B
.	O

The	O
process	O
allowed	O
an	O
increase	O
of	O
10	O
times	O
total	O
carotenoid	O
content	O
compared	O
with	O
initial	O
cashew	O
apple	O
.	O

Total	O
carotenoid	O
content	O
of	O
the	O
final	O
concentrated	O
extract	O
reached	O
54	O
mg	O
/	O
kg	O
.	O

Inhibition	O
effects	O
and	O
induction	O
of	O
apoptosis	O
of	O
flavonoids	B
on	O
the	O
prostate	O
cancer	O
cell	O
line	O
PC-3	O
in	O
vitro	O
.	O

Myricetin	B
and	O
myricitrin	B
are	O
naturally	O
occurring	O
flavonoids	B
have	O
been	O
suggested	O
to	O
play	O
a	O
role	O
in	O
inhibition	O
of	O
proliferation	O
and	O
transformation	O
of	O
carcinogenic	O
cell	O
.	O

However	O
,	O
the	O
underlying	O
molecular	O
mechanisms	O
of	O
their	O
activity	O
have	O
not	O
yet	O
to	O
be	O
revealed	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
clarify	O
the	O
molecular	O
mechanisms	O
of	O
apoptosis	O
cell	O
on	O
the	O
prostate	O
cancer	O
induced	O
by	O
myricetin	B
,	O
myricitrin	B
,	O
quercetin	B
and	O
quercitrin	B
.	O

The	O
MTT	B
assay	O
confirmed	O
that	O
myricetin	B
had	O
the	O
strongest	O
inhibitory	O
effect	O
on	O
human	O
prostate	O
cancer	O
cell	O
line	O
PC-3	O
,	O
myricitrin	B
was	O
second	O
,	O
and	O
quercitrin	B
was	O
the	O
weakest	O
.	O

A	O
noticeable	O
synergistic	O
effect	O
was	O
observed	O
with	O
the	O
inhibition	O
of	O
cell	O
proliferation	O
when	O
myricetin	B
was	O
used	O
in	O
combination	O
with	O
myricitrin	B
.	O

In	O
the	O
concentration	O
range	O
of	O
37.5	O
-	O
300	O
mol	O
/	O
L	O
,	O
the	O
inhibitory	O
effects	O
of	O
these	O
flavonoids	B
were	O
enhanced	O
with	O
increasing	O
dose	O
and	O
treatment	O
time	O
.	O

The	O
acridine	B
orange	I
analysis	O
and	O
annexin	O
V	O
-	O
FITC	B
/	O
PI	O
double	O
-	O
staining	O
results	O
confirmed	O
that	O
myricetin	B
and	O
myricitrin	B
were	O
effective	O
in	O
inducing	O
PC-3	O
cell	O
apoptosis	O
.	O

The	O
results	O
showed	O
that	O
myricetin	B
was	O
more	O
effective	O
than	O
myricitrin	B
in	O
inducing	O
cell	O
apoptosis	O
.	O

The	O
apoptosis	O
rate	O
increased	O
with	O
increasing	O
flavonoid	B
concentration	O
in	O
a	O
dose	O
dependent	O
manner	O
.	O

A	O
synergistic	O
effect	O
was	O
observed	O
on	O
the	O
apoptosis	O
rate	O
when	O
myricetin	B
was	O
used	O
in	O
combination	O
with	O
myricitrin	B
.	O

Assessment	O
of	O
DFG	O
-	O
S19	O
method	O
for	O
the	O
determination	O
of	O
common	O
endocrine	O
disruptor	O
pesticides	O
in	O
wine	O
samples	O
with	O
an	O
estimation	O
of	O
the	O
uncertainty	O
of	O
the	O
analytical	O
results	O
.	O

A	O
gas	O
chromatographic	O
method	O
for	O
the	O
determination	O
of	O
endocrine	O
disruptor	O
pesticides	O
(	O
Chlorpyrifos	B
,	O
Penconazole	B
,	O
Procymidone	B
,	O
Iprodione	B
,	O
Bromopropylate	B
and	O
Lambda	B
-	I
Cyhalothrin	I
)	O
in	O
wine	O
samples	O
is	O
described	O
.	O

A	O
general	O
DFG	O
-	O
S19	O
method	O
for	O
residual	O
pesticide	O
determination	O
in	O
all	O
kind	O
of	O
food	O
stuff	O
was	O
investigated	O
to	O
simplify	O
and	O
adopt	O
for	O
wine	O
samples	O
in	O
this	O
work	O
.	O

Alternative	O
sample	O
preparation	O
routes	O
were	O
elucidated	O
and	O
compared	O
according	O
to	O
their	O
recovery	O
values	O
.	O

Four	O
different	O
separation	O
techniques	O
were	O
tested	O
and	O
the	O
method	O
employing	O
florosil	B
column	O
after	O
a	O
LLE	O
procedure	O
was	O
applied	O
for	O
wine	O
samples	O
with	O
satisfactory	O
recovery	O
ratios	O
(	O
72	O
-	O
97	O
%	O
)	O
.	O

The	O
pesticides	O
were	O
extracted	O
from	O
the	O
sample	O
by	O
cyclohexane	B
-	O
ethyl	B
acetate	I
mixture	O
(	O
1:1	O
v	O
/	O
v	O
)	O
and	O
cleaned	O
up	O
by	O
florosil	B
column	O
.	O

The	O
regression	O
coefficients	O
were	O
at	O
least	O
0.99	O
and	O
relative	O
standard	O
deviations	O
were	O
no	O
higher	O
than	O
16	O
%	O
.	O

Detection	O
limits	O
were	O
in	O
the	O
range	O
of	O
0.6	O
-	O
2.9	O
ng	O
/	O
mL	O
and	O
the	O
relative	O
expanded	O
measurement	O
uncertainties	O
were	O
calculated	O
in	O
the	O
7	O
-	O
22	O
%	O
range	O
.	O

Quality	O
of	O
bread	O
supplemented	O
with	O
mushroom	O
mycelia	O
.	O

Mushroom	O
mycelia	O
of	O
Antrodia	O
camphorata	O
,	O
Agaricus	O
blazei	O
,	O
Hericium	O
erinaceus	O
and	O
Phellinus	O
linteus	O
were	O
used	O
to	O
substitute	O
5	O
%	O
of	O
wheat	O
flour	O
to	O
make	O
bread	O
.	O

Bread	O
quality	O
,	O
including	O
specific	O
volume	O
,	O
colour	O
property	O
,	O
equivalent	O
umami	O
concentration	O
(	O
EUC	O
)	O
,	O
texture	O
profile	O
analysis	O
,	O
sensory	O
evaluation	O
and	O
functional	O
components	O
,	O
was	O
analysed	O
.	O

Mycelium	O
-	O
supplemented	O
bread	O
was	O
smaller	O
in	O
loaf	O
volume	O
and	O
coloured	O
,	O
and	O
had	O
lower	O
lightness	O
and	O
white	O
index	O
values	O
.	O

White	O
bread	O
contained	O
the	O
lowest	O
amounts	O
of	O
free	O
umami	O
amino	B
acids	I
and	O
umami	O
5'-nucleotides	O
and	O
showed	O
the	O
lowest	O
EUC	O
value	O
.	O

Incorporating	O
5	O
%	O
mushroom	O
mycelia	O
into	O
the	O
bread	O
formula	O
did	O
not	O
adversely	O
affect	O
the	O
texture	O
profile	O
of	O
the	O
bread	O
.	O

However	O
,	O
incorporating	O
5	O
%	O
mushroom	O
mycelia	O
into	O
the	O
bread	O
formula	O
did	O
lower	O
bread	O
's	O
acceptability	O
.	O

After	O
baking	O
,	O
mycelium	O
-	O
supplemented	O
bread	O
still	O
contained	O
substantial	O
amounts	O
of	O
	B
-	I
aminobutyric	I
acid	I
and	O
ergothioneine	B
(	O
0.23	O
-	O
0.86	O
and	O
0.79	O
-	O
2.10	O
mg	O
/	O
g	O
dry	O
matter	O
,	O
respectively	O
)	O
.	O

Overall	O
,	O
mushroom	O
mycelium	O
could	O
be	O
incorporated	O
into	O
bread	O
to	O
provide	O
its	O
beneficial	O
health	O
effects	O
.	O

Natural	O
occurrence	O
of	O
deoxynivalenol	B
in	O
wheat	O
from	O
Paran	O
State	O
,	O
Brazil	O
and	O
estimated	O
daily	O
intake	O
by	O
wheat	O
products	O
.	O

The	O
occurrence	O
of	O
deoxynivalenol	B
(	O
DON	B
)	O
was	O
evaluated	O
in	O
113	O
wheat	O
samples	O
from	O
the	O
northern	O
and	O
central	O
/	O
southwestern	O
regions	O
of	O
Paran	O
State	O
,	O
Brazil	O
during	O
the	O
2008	O
and	O
2009	O
growing	O
seasons	O
,	O
and	O
this	O
rate	O
of	O
occurrence	O
was	O
used	O
to	O
estimate	O
the	O
DON	B
dietary	O
exposure	O
.	O

The	O
DON	B
determination	O
was	O
carried	O
out	O
by	O
an	O
indirect	O
competitive	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

DON	B
was	O
detected	O
in	O
66.4	O
%	O
samples	O
at	O
levels	O
ranging	O
from	O
206.3	O
to	O
4732.3	O
g	O
/	O
kg	O
(	O
mean	O
1894.9	O
g	O
/	O
kg	O
)	O
.	O

The	O
estimated	O
daily	O
intake	O
(	O
EDI	O
)	O
of	O
DON	B
through	O
bread	O
and	O
pasta	O
was	O
evaluated	O
in	O
the	O
inhabitants	O
of	O
Londrina	O
City	O
in	O
northern	O
Paran	O
State	O
,	O
Brazil	O
.	O

The	O
average	O
intake	O
of	O
these	O
inhabitants	O
was	O
0.79	O
g	O
/	O
kg	O
body	O
weight	O
(	O
b.w	O
.	O
)	O
for	O
bread	O
and	O
0.35	O
g	O
/	O
kg	O
b.w	O
.	O

for	O
pasta	O
.	O

The	O
total	O
EDI	O
was	O
1.13	O
g	O
/	O
kg	O
,	O
which	O
is	O
above	O
the	O
Provisional	O
Tolerable	O
Daily	O
Maximum	O
Intake	O
(	O
PTDMI	O
)	O
of	O
1	O
g	O
/	O
kg	O
b.w	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
on	O
natural	O
DON	B
occurrence	O
in	O
wheat	O
and	O
DON	B
dietary	O
exposure	O
estimation	O
from	O
Paran	O
,	O
Brazil	O
.	O

Hepatoprotective	O
effect	O
of	O
2,3-dehydrosilybin	B
on	O
carbon	B
tetrachloride	I
-	O
induced	O
liver	O
injury	O
in	O
rats	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
protective	O
effect	O
of	O
2,3-dehydrosilybin	B
(	O
DHS	B
)	O
against	O
carbon	B
tetrachloride	I
(	O
CCl	B
(	I
4	I
)	I
)	O
-induced	O
liver	O
injury	O
in	O
rats	O
.	O

Administration	O
of	O
DHS	B
significantly	O
attenuated	O
the	O
levels	O
of	O
serum	O
aspartate	B
aminotransferase	O
,	O
alanine	B
aminotransferase	O
,	O
and	O
liver	O
lipid	O
peroxidation	O
in	O
CCl	B
(	I
4	I
)	I
-treated	O
rats	O
.	O

Moreover	O
,	O
we	O
showed	O
that	O
DHS	B
prevented	O
DNA	O
damage	O
and	O
decreased	O
the	O
protein	O
levels	O
of	O
	O
-	O
H2AX	O
,	O
which	O
is	O
a	O
specific	O
DNA	O
damage	O
marker	O
,	O
in	O
CCl	B
(	I
4	I
)	I
-treated	O
rat	O
livers	O
.	O

DHS	O
also	O
markedly	O
increased	O
the	O
activity	O
of	O
antioxidant	O
enzymes	O
,	O
such	O
as	O
superoxide	B
dismutase	O
,	O
catalase	O
,	O
glutathione	B
peroxidase	O
,	O
and	O
glutathione	O
reductase	O
in	O
CCl	B
(	I
4	I
)	I
-treated	O
rat	O
livers	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
DHS	B
significantly	O
inhibited	O
the	O
production	O
of	O
serum	O
nitric	B
oxide	I
as	O
well	O
as	O
the	O
levels	O
of	O
serum	O
IL-6	O
,	O
IFN	O
-	O
	O
,	O
and	O
TNF	O
-	O
	O
in	O
CCl	B
(	I
4	I
)	I
-treated	O
rats	O
.	O

Additionally	O
,	O
DHS	B
significantly	O
suppressed	O
iNOS	O
expression	O
on	O
the	O
protein	O
levels	O
in	O
CCl	B
(	I
4	I
)	I
-treated	O
rat	O
livers	O
.	O

Collectively	O
,	O
the	O
present	O
study	O
suggests	O
that	O
DHS	B
protects	O
the	O
liver	O
from	O
CCl	B
(	I
4	I
)	I
-induced	O
hepatic	O
damage	O
via	O
antioxidant	O
and	O
anti	O
-	O
inflammatory	O
mechanisms	O
.	O

Development	O
of	O
a	O
rapid	O
and	O
simple	O
voltammetric	O
method	O
to	O
determine	O
total	O
antioxidative	O
capacity	O
of	O
edible	O
oils	O
.	O

In	O
this	O
work	O
we	O
report	O
on	O
a	O
new	O
,	O
rapid	O
and	O
simple	O
voltammetric	O
method	O
to	O
determine	O
the	O
total	O
antioxidant	O
capacity	O
(	O
TAC	O
)	O
of	O
the	O
edible	O
oils	O
.	O

The	O
method	O
explores	O
the	O
ABTS	B
radical	O
(	O
2,2'-azinobis	B
(	I
3-ethylbenzothiazoline-6-sulphonic	I
acid	I
)	I
)	O
assay	O
as	O
a	O
redox	O
probe	O
and	O
it	O
relays	O
on	O
measuring	O
catalytic	O
voltammetric	O
currents	O
.	O

The	O
electrocatalysis	O
comprises	O
redox	O
regeneration	O
of	O
the	O
electrochemically	O
created	O
ABTS	B
(	I
+	I
)	I
radical	O
either	O
by	O
Trolox	B
(	O
6-hydroxy-2,5,7,8-tetramethychroman-2-carboxylic	B
acid	I
)	O
or	O
by	O
antioxidants	O
present	O
in	O
studied	O
oils	O
.	O

The	O
detection	O
limit	O
of	O
the	O
method	O
is	O
determined	O
to	O
be	O
0.5	O
mg	O
/	O
L	O
of	O
Trolox	B
equivalent	O
,	O
being	O
a	O
slightly	O
lower	O
than	O
the	O
corresponding	O
UV	O
-	O
VIS	O
spectrophotometric	O
method	O
.	O

Applying	O
the	O
proposed	O
voltammetric	O
method	O
the	O
total	O
antioxidant	O
capacity	O
of	O
three	O
types	O
of	O
commercially	O
available	O
cold	O
-	O
pressed	O
edible	O
oils	O
are	O
determined	O
,	O
and	O
the	O
results	O
are	O
found	O
to	O
be	O
in	O
a	O
very	O
good	O
agreement	O
with	O
those	O
obtained	O
by	O
UV	O
-	O
VIS	O
spectrophotometry	O
.	O

The	O
reported	O
voltammetric	O
method	O
is	O
cheap	O
,	O
rapid	O
and	O
simple	O
,	O
and	O
it	O
can	O
be	O
used	O
as	O
a	O
sustainable	O
alternative	O
to	O
the	O
UV	O
-	O
VIS	O
methods	O
for	O
the	O
determination	O
of	O
total	O
antioxidant	O
capacitance	O
of	O
oils	O
and	O
other	O
liquid	O
lipophilic	O
nutrients	O
.	O

Potent	O
antioxidant	O
capacity	O
of	O
studied	O
oils	O
was	O
also	O
confirmed	O
by	O
electron	O
paramagnetic	O
resonance	O
spectroscopy	O
of	O
superoxide	B
anion	O
produced	O
by	O
macrophages	O
.	O

Effect	O
of	O
the	O
genistein	B
metabolite	O
on	O
leptin	O
secretion	O
in	O
murine	O
adipocytes	O
in	O
vitro	O
.	O

Soy	O
isoflavonoids	B
have	O
many	O
useful	O
properties	O
.	O

However	O
,	O
they	O
are	O
metabolized	O
in	O
vivo	O
,	O
including	O
in	O
humans	O
.	O

The	O
effect	O
of	O
the	O
metabolism	O
of	O
soy	O
isoflavonoids	B
on	O
their	O
properties	O
is	O
not	O
fully	O
understood	O
.	O

We	O
have	O
isolated	O
the	O
bacterial	O
strain	O
SY8519	O
,	O
which	O
has	O
been	O
shown	O
to	O
metabolize	O
daidzein	B
to	O
O	B
-	I
desmethylangolensin	I
and	O
to	O
produce	O
2-	B
(	I
4-hydroxyphenyl	I
)	I
propionic	I
acid	I
from	O
genistein	B
.	O

According	O
to	O
chiral	O
HPLC	O
analysis	O
,	O
the	O
2-	B
(	I
4-hydroxyphenyl	I
)	I
propionic	I
acid	I
obtained	O
from	O
the	O
bacterium	O
was	O
optically	O
active	O
.	O

To	O
determine	O
the	O
absolute	O
stereochemistry	O
of	O
the	O
microbial	O
product	O
,	O
we	O
prepared	O
(	B
S	I
)	I
-2-	I
(	I
4-hydroxyphenyl	I
)	I
propionic	I
acid	I
from	O
(	B
S	I
)	I
-2-phenylpropionic	I
and	O
concluded	O
that	O
the	O
microbial	O
product	O
had	O
an	O
R	O
-	O
configuration	O
by	O
chiral	O
HPLC	O
analysis	O
.	O

We	O
also	O
applied	O
the	O
metabolite	O
to	O
mouse	O
adipocytes	O
and	O
found	O
that	O
2-HPPA	B
was	O
less	O
effective	O
at	O
reducing	O
leptin	O
secretion	O
than	O
the	O
parent	O
compound	O
genistein	B
.	O

Our	O
results	O
suggested	O
that	O
'	O
O	B
-	I
desmethylangolensin	I
-	O
production	O
'	O
attenuates	O
the	O
effect	O
of	O
soy	O
isoflavonoids	B
by	O
reducing	O
not	O
only	O
the	O
activity	O
of	O
daidzein	B
but	O
also	O
that	O
of	O
genistein	B
.	O

Simultaneous	O
detection	O
of	O
flavonoids	B
and	O
phenolic	B
acids	I
in	O
Herba	O
Lysimachiae	O
and	O
Herba	O
Desmodii	O
Styracifolii	O
using	O
liquid	O
chromatography	O
tandem	O
mass	O
spectrometry	O
.	O

A	O
sensitive	O
liquid	O
chromatography	O
and	O
tandem	O
mass	O
spectrometry	O
(	O
LC	O
-	O
MS	O
/	O
MS	O
)	O
method	O
was	O
developed	O
and	O
validated	O
for	O
the	O
simultaneous	O
analysis	O
of	O
15	O
flavonoids	B
and	O
3	O
phenolic	B
acids	I
in	O
Herba	O
Lysimachiae	O
and	O
Herba	O
Desmodii	O
Styracifolii	O
.	O

Separation	O
was	O
performed	O
using	O
a	O
Diamonsil	O
C	O
(	O
18	O
)	O
column	O
,	O
which	O
was	O
eluted	O
with	O
methanol	B
(	O
A	O
)	O
and	O
0.1	O
acetic	B
acid	I
(	O
B	O
)	O
.	O

The	O
gradient	O
condition	O
was	O
as	O
follows	O
:	O
0	O
-	O
34	O
min	O
,	O
20	O
-	O
34	O
%	O
A	O
;	O
34	O
-	O
38	O
min	O
,	O
34	O
-	O
95	O
%	O
A	O
;	O
maintained	O
95	O
%	O
A	O
for	O
the	O
next	O
4	O
min	O
.	O

Analytes	O
were	O
detected	O
using	O
a	O
hybrid	O
quadrupole	O
linear	O
ion	O
trap	O
mass	O
spectrometer	O
that	O
was	O
equipped	O
with	O
an	O
electrospray	O
ionisation	O
source	O
in	O
the	O
negative	O
ion	O
and	O
multiple	O
-	O
reaction	O
monitoring	O
modes	O
.	O

A	O
full	O
validation	O
of	O
the	O
method	O
was	O
performed	O
,	O
including	O
the	O
linearity	O
,	O
precision	O
,	O
and	O
accuracy	O
,	O
as	O
well	O
as	O
limits	O
of	O
detection	O
and	O
quantification	O
.	O

The	O
results	O
indicated	O
that	O
the	O
developed	O
method	O
was	O
simple	O
,	O
sensitive	O
and	O
reliable	O
.	O

Furthermore	O
,	O
the	O
method	O
was	O
successfully	O
applied	O
to	O
differentiate	O
16	O
batches	O
of	O
Herba	O
Lysimachiae	O
and	O
21	O
batches	O
of	O
Herba	O
Desmodii	O
Styracifolii	O
.	O

Differentiation	O
of	O
Sparidae	O
species	O
by	O
DNA	O
sequence	O
analysis	O
,	O
PCR	O
-	O
SSCP	O
and	O
IEF	O
of	O
sarcoplasmic	O
proteins	O
.	O

The	O
increasing	O
global	O
trade	O
of	O
fishery	O
and	O
aquaculture	O
products	O
makes	O
it	O
necessary	O
to	O
develop	O
methods	O
for	O
species	O
identification	O
in	O
case	O
of	O
fish	O
fillets	O
or	O
other	O
highly	O
processed	O
seafood	O
with	O
external	O
morphological	O
characteristics	O
(	O
e.g.	O
gills	O
,	O
fins	O
)	O
of	O
the	O
original	O
fish	O
being	O
removed	O
.	O

Species	O
identification	O
methods	O
based	O
on	O
DNA-	O
or	O
protein	O
-	O
analysis	O
,	O
like	O
DNA	O
sequencing	O
of	O
PCR	O
products	O
,	O
PCR	O
-	O
SSCP	O
(	O
polymerase	O
chain	O
reaction	O
-	O
single	O
strand	O
conformation	O
polymorphism	O
)	O
,	O
and	O
isoelectric	O
focusing	O
(	O
IEF	O
)	O
of	O
water	O
-	O
soluble	O
proteins	O
of	O
fish	O
fillet	O
were	O
applied	O
successfully	O
to	O
distinguish	O
between	O
various	O
sparid	O
species	O
including	O
Sparus	O
aurata	O
,	O
Spondyliosoma	O
cantharus	O
,	O
Boops	O
boops	O
,	O
Acanthopagrus	O
bifasciatus	O
,	O
Argyrops	O
spinifer	O
,	O
Pagellus	O
bogaraveo	O
and	O
Lithognathus	O
mormyrus	O
of	O
the	O
family	O
Sparidae	O
available	O
on	O
European	O
markets	O
.	O

Indication	O
of	O
the	O
presence	O
of	O
parvalbumins	O
in	O
light	O
muscle	O
of	O
all	O
of	O
the	O
studied	O
species	O
is	O
presented	O
by	O
the	O
location	O
of	O
heat	O
-	O
stable	O
proteins	O
in	O
the	O
anodic	O
range	O
of	O
the	O
IEF	O
gels	O
.	O

Exploration	O
of	O
Vanilla	O
pompona	O
from	O
the	O
Peruvian	O
Amazon	O
as	O
a	O
potential	O
source	O
of	O
vanilla	O
essence	O
:	O
quantification	O
of	O
phenolics	B
by	O
HPLC	O
-	O
DAD	O
.	O

This	O
study	O
provides	O
the	O
first	O
chemical	O
investigation	O
of	O
wild	O
-	O
harvested	O
fruits	O
of	O
Vanilla	O
pompona	O
ssp	O
.	O

grandiflora	O
(	O
Lindl	O
.	O
)	O

Soto	O
-	O
Arenas	O
developed	O
in	O
their	O
natural	O
habitat	O
in	O
the	O
Peruvian	O
Amazon	O
.	O

Flowers	O
were	O
hand	O
-	O
pollinated	O
and	O
the	O
resulting	O
fruits	O
were	O
analysed	O
at	O
different	O
developmental	O
stages	O
using	O
an	O
HPLC	O
-	O
DAD	O
method	O
validated	O
for	O
the	O
quantification	O
of	O
glucovanillin	B
and	O
seven	O
other	O
compounds	O
.	O

The	O
method	O
showed	O
satisfactory	O
linearity	O
(	O
r	O
(	O
2	O
)	O
>0.9969	O
)	O
,	O
precision	O
(	O
coefficient	O
of	O
variation	O
<	O
2	O
%	O
)	O
,	O
recoveries	O
(	O
70	O
-	O
100	O
%	O
)	O
,	O
limit	O
of	O
detection	O
(	O
0.008	O
-	O
0.212	O
g	O
/	O
ml	O
)	O
,	O
and	O
limit	O
of	O
quantification	O
(	O
0.027	O
-	O
0.707	O
g	O
/	O
ml	O
)	O
.	O

The	O
evaluation	O
of	O
crude	O
and	O
enzyme	O
-	O
hydrolyzed	O
Soxhlet	O
-	O
extracted	O
samples	O
confirmed	O
the	O
leading	O
role	O
of	O
glucosides	O
in	O
fruit	O
development	O
.	O

LC	O
-	O
ESI	O
-	O
MS	O
studies	O
corroborated	O
the	O
identities	O
of	O
four	O
glucosides	O
and	O
seven	O
aglycones	O
,	O
among	O
them	O
vanillin	B
(	O
5.7	O
/	O
100	O
g	O
)	O
,	O
4-hydroxybenzyl	B
alcohol	I
(	O
3.6	O
/	O
100	O
g	O
)	O
,	O
and	O
anisyl	B
alcohol	I
(	O
7.1	O
/	O
100	O
g	O
)	O
were	O
found	O
in	O
high	O
concentrations	O
.	O

The	O
attractive	O
flavor	O
/	O
aroma	O
profile	O
exhibited	O
by	O
wild	O
V.	O
pompona	O
fruits	O
supports	O
studies	O
focused	O
on	O
the	O
development	O
of	O
this	O
species	O
as	O
a	O
specialty	O
crop	O
.	O

Nutritive	O
value	O
of	O
masau	O
(	O
Ziziphus	O
mauritiana	O
)	O
fruits	O
from	O
Zambezi	O
Valley	O
in	O
Zimbabwe	O
.	O

Ziziphus	O
mauritiana	O
(	O
masau	O
)	O
fruits	O
are	O
consumed	O
by	O
many	O
people	O
in	O
Zimbabwe	O
.	O

The	O
fruits	O
contribute	O
significantly	O
to	O
people	O
's	O
diet	O
when	O
they	O
are	O
in	O
season	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
nutritional	O
content	O
of	O
the	O
fruits	O
and	O
,	O
hence	O
,	O
quantify	O
their	O
contribution	O
to	O
the	O
diet	O
.	O

Samples	O
of	O
masau	O
were	O
collected	O
in	O
two	O
seasons	O
(	O
August	O
2006	O
and	O
August	O
2007	O
)	O
.	O

Both	O
macronutrients	O
and	O
micronutrients	O
were	O
determined	O
using	O
standard	O
AOAC	O
methods	O
of	O
analysis	O
.	O

Dry	O
matter	O
content	O
ranged	O
from	O
21.10.2	O
to	O
24.10.3	O
g	O
100	O
g	O
(	O
-1	O
)	O
of	O
edible	O
portion	O
of	O
the	O
sweet	O
and	O
sour	O
fruits	O
,	O
and	O
84.80.2	O
to	O
87.20.2	O
g	O
100	O
g	O
(	O
-1	O
)	O
for	O
the	O
dried	O
fruit	O
.	O

Crude	O
protein	O
per	O
100	O
g	O
edible	O
portion	O
of	O
dry	O
weight	O
ranged	O
between	O
7.90.0	O
and	O
8.70.0	O
g	O
,	O
crude	O
fat	O
from	O
0.80.0	O
to	O
1.50.0	O
g	O
,	O
crude	O
fibre	O
from	O
4.90.0	O
to	O
7.30.0	O
g	O
,	O
ash	O
between	O
3.00.0	O
and	O
4.30.0	O
g	O
and	O
carbohydrate	B
between	O
79.50.0	O
and	O
83.20.0	O
g.	O

The	O
fruits	O
were	O
rich	O
in	O
vitamin	B
C	I
(	O
15.00.0	O
-	O
43.80.02	O
mg	O
100	O
g	O
(	O
-1	O
)	O
)	O
and	O
the	O
energy	O
values	O
ranged	O
between	O
1516.01.73	O
and	O
1575.02.3	O
kJ	O
100	O
g	O
(	O
-1	O
)	O
.	O

Furthermore	O
,	O
the	O
fruits	O
contained	O
(	O
mg	O
100	O
g	O
(	O
-1	O
)	O
of	O
dry	O
weight	O
)	O
potassium	B
from	O
1865.01.3	O
to	O
2441.01.1	O
,	O
calcium	B
from	O
160.00.3	O
to	O
254.00.1	O
,	O
sodium	B
between	O
185.00.1	O
and	O
223.00.2	O
,	O
magnesium	B
between	O
83.00.0	O
and	O
150.00.13	O
and	O
phosphorous	B
from	O
87.00.1	O
to	O
148.00.5	O
.	O

Manganese	B
and	O
copper	B
contents	O
ranged	O
between	O
0.70.03	O
and	O
1.60.03	O
,	O
while	O
iron	B
and	O
zinc	B
ranged	O
between	O
2.10.43	O
and	O
4.30.1	O
,	O
and	O
0.60.0	O
-	O
0.90.0	O
mg	O
100	O
g	O
(	O
-1	O
)	O
of	O
dry	O
weight	O
,	O
respectively	O
.	O

The	O
masau	O
fruit	O
is	O
therefore	O
a	O
good	O
potential	O
source	O
of	O
carbohydrates	B
,	O
proteins	O
and	O
micronutrients	O
,	O
such	O
as	O
calcium	B
,	O
potassium	B
,	O
sodium	B
,	O
phosphorous	B
,	O
copper	B
,	O
iron	B
,	O
Vitamin	B
C	I
and	O
zinc	B
.	O

Development	O
of	O
sample	O
preparation	O
method	O
for	O
isoliquiritigenin	B
,	O
liquiritin	B
,	O
and	O
glycyrrhizic	B
acid	I
analysis	O
in	O
licorice	O
by	O
ionic	O
liquids	O
-	O
ultrasound	O
based	O
extraction	O
and	O
high	O
-	O
performance	O
liquid	O
chromatography	O
detection	O
.	O

An	O
ionic	O
liquid	O
-	O
based	O
ultrasonic	O
-	O
assisted	O
extraction	O
(	O
ILUAE	O
)	O
method	O
had	O
been	O
used	O
for	O
the	O
effective	O
extraction	O
of	O
isoliquiritigenin	B
(	O
IQ	O
)	O
,	O
liquiritin	B
(	O
LQ	O
)	O
and	O
glycyrrhizic	B
acid	I
(	O
GA	O
)	O
from	O
licorice	O
.	O

The	O
ionic	O
liquids	O
with	O
different	O
cations	O
and	O
anions	O
were	O
investigated	O
in	O
this	O
work	O
and	O
0.5	O
M	O
1-butyl-3-methylimidazolium	B
bromide	I
solution	O
was	O
selected	O
as	O
solvent	O
.	O

In	O
addition	O
,	O
the	O
technical	O
parameters	O
including	O
soaking	O
time	O
,	O
solid	O
-	O
liquid	O
ratio	O
,	O
ultrasonic	O
power	O
and	O
time	O
were	O
optimized	O
.	O

Compared	O
with	O
the	O
conventional	O
solvent	O
extraction	O
,	O
the	O
proposed	O
approach	O
exhibited	O
higher	O
efficiency	O
,	O
which	O
indicated	O
the	O
ILUAE	O
was	O
an	O
efficient	O
,	O
rapid	O
and	O
simple	O
sample	O
preparation	O
technique	O
.	O

There	O
was	O
no	O
degradation	O
of	O
the	O
target	O
analytes	O
had	O
been	O
observed	O
at	O
the	O
optimum	O
conditions	O
which	O
was	O
evidenced	O
by	O
the	O
stability	O
studies	O
performed	O
with	O
standard	O
of	O
IQ	O
,	O
LQ	O
and	O
GA	O
.	O

The	O
proposed	O
method	O
also	O
showed	O
high	O
reproducibility	O
and	O
was	O
environmental	O
friendly	O
.	O

Comparative	O
formation	O
of	O
2-amino-1-methyl-6-phenylimidazo	B
[	I
4,5-b	I
]	I
pyridine	I
(	O
PhIP	B
)	O
in	O
creatinine	B
/	O
phenylalanine	B
and	O
creatinine	B
/	O
phenylalanine	B
/	O
4-oxo-2-nonenal	B
reaction	O
mixtures	O
.	O

The	O
comparative	O
formation	O
of	O
the	O
heterocyclic	O
aromatic	O
amine	O
2-amino-1-methyl-6-phenylimidazo	B
[	I
4,5-b	I
]	I
pyridine	I
(	O
PhIP	B
)	O
in	O
both	O
creatinine	B
/	O
phenylalanine	B
(	O
CRN	B
/	O
Phe	B
)	O
and	O
creatinine	B
/	O
phenylalanine	B
/	O
4-oxo-2-nonenal	B
(	O
CRN	B
/	O
Phe	B
/	O
ON	O
)	O
systems	O
was	O
studied	O
to	O
analyse	O
the	O
ability	O
of	O
lipid	O
-	O
derived	O
reactive	O
carbonyls	B
to	O
promote	O
PhIP	B
formation	O
.	O

Although	O
PhIP	B
was	O
produced	O
to	O
some	O
extent	O
in	O
the	O
CRN	B
/	O
Phe	B
system	O
,	O
the	O
presence	O
of	O
the	O
oxidized	O
lipid	O
increased	O
considerably	O
the	O
amount	O
of	O
PhIP	B
produced	O
.	O

This	O
increase	O
seemed	O
to	O
be	O
a	O
consequence	O
of	O
the	O
decrease	O
in	O
the	O
E	O
(	O
a	O
)	O
of	O
the	O
reaction	O
when	O
the	O
lipid	O
was	O
present	O
,	O
which	O
diminished	O
from	O
112.9	O
to	O
80.9	O
kJ	O
/	O
mol	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
addition	O
of	O
the	O
lipid	O
did	O
not	O
seem	O
to	O
produce	O
PhIP	B
by	O
an	O
alternative	O
mechanism	O
because	O
PhIP	B
was	O
formed	O
analogously	O
in	O
both	O
CRN	B
/	O
Phe	B
and	O
CRN	B
/	O
Phe	B
/	O
ON	O
systems	O
as	O
a	O
function	O
of	O
pH	O
,	O
creatinine	B
concentration	O
,	O
phenylalanine	B
concentration	O
,	O
time	O
,	O
temperature	O
,	O
oxygen	B
concentration	O
in	O
the	O
reaction	O
atmosphere	O
,	O
and	O
the	O
addition	O
of	O
different	O
amounts	O
of	O
ammonia	B
.	O

All	O
these	O
results	O
suggest	O
that	O
the	O
ability	O
of	O
lipid	O
oxidation	O
products	O
to	O
produce	O
PhIP	B
is	O
related	O
to	O
their	O
capacity	O
to	O
induce	O
the	O
Strecker	O
degradation	O
of	O
phenylalanine	B
to	O
phenylacetaldehyde	B
.	O

Therefore	O
,	O
any	O
other	O
reactive	O
carbonyl	B
compound	O
that	O
can	O
produce	O
the	O
Strecker	O
degradation	O
of	O
phenylalanine	B
should	O
also	O
be	O
considered	O
as	O
a	O
potential	O
inducer	O
of	O
PhIP	B
formation	O
under	O
appropriate	O
conditions	O
.	O

Rapid	O
detecting	O
total	O
acid	O
content	O
and	O
classifying	O
different	O
types	O
of	O
vinegar	O
based	O
on	O
near	O
infrared	O
spectroscopy	O
and	O
least	O
-	O
squares	O
support	O
vector	O
machine	O
.	O

More	O
than	O
3.2	O
million	O
litres	O
of	O
vinegar	O
is	O
consumed	O
every	O
day	O
in	O
China	O
.	O

There	O
are	O
many	O
types	O
of	O
vinegar	O
in	O
China	O
.	O

How	O
to	O
control	O
the	O
quality	O
of	O
vinegar	O
is	O
problem	O
.	O

Near	O
infrared	O
spectroscopy	O
(	O
NIR	O
)	O
transmission	O
technique	O
was	O
applied	O
to	O
achieve	O
this	O
purpose	O
.	O

Ninety	O
-	O
five	O
vinegar	O
samples	O
from	O
14	O
origins	O
covering	O
11	O
provinces	O
in	O
China	O
were	O
collected	O
.	O

They	O
were	O
classified	O
into	O
mature	O
vinegar	O
,	O
aromatic	O
vinegar	O
,	O
rice	O
vinegar	O
,	O
fruit	O
vinegar	O
,	O
and	O
white	O
vinegar	O
.	O

Fruit	O
vinegar	O
and	O
white	O
vinegar	O
were	O
separated	O
from	O
the	O
other	O
traditional	O
categories	O
in	O
the	O
two	O
-	O
dimension	O
principal	O
component	O
space	O
of	O
NIR	O
after	O
principle	O
component	O
analysis	O
(	O
PCA	O
)	O
.	O

Least	O
-	O
squares	O
support	O
vector	O
machine	O
(	O
LS	O
-	O
SVM	O
)	O
as	O
the	O
pattern	O
recognition	O
was	O
firstly	O
applied	O
to	O
identify	O
mature	O
vinegar	O
,	O
aromatic	O
vinegar	O
,	O
rice	O
vinegar	O
in	O
this	O
study	O
.	O

The	O
top	O
two	O
principal	O
components	O
(	O
PCs	O
)	O
were	O
extracted	O
as	O
the	O
input	O
of	O
LS	O
-	O
SVM	O
classifiers	O
by	O
principal	O
component	O
analysis	O
(	O
PCA	O
)	O
.	O

The	O
best	O
experimental	O
results	O
were	O
obtained	O
using	O
the	O
radial	O
basis	O
function	O
(	O
RBF	O
)	O
LS	O
-	O
SVM	O
classifier	O
with	O
=0.8	O
.	O

The	O
accuracies	O
of	O
identification	O
were	O
more	O
than	O
85	O
%	O
for	O
three	O
traditional	O
vinegar	O
categories	O
.	O

Compared	O
with	O
the	O
back	O
propagation	O
artificial	O
neural	O
network	O
(	O
BP	O
-	O
ANN	O
)	O
approach	O
,	O
LS	O
-	O
SVM	O
algorithm	O
showed	O
its	O
excellent	O
generalisation	O
for	O
identification	O
results	O
.	O

As	O
total	O
acid	O
content	O
(	O
TAC	O
)	O
is	O
highly	O
connecting	O
with	O
the	O
quality	O
of	O
vinegar	O
,	O
NIR	O
was	O
used	O
to	O
prediction	O
the	O
TAC	O
of	O
samples	O
.	O

LS	O
-	O
SVM	O
was	O
applied	O
to	O
building	O
the	O
TAC	O
prediction	O
model	O
based	O
on	O
spectral	O
transmission	O
rate	O
.	O

Compared	O
with	O
partial	O
least	O
-	O
square	O
(	O
PLS	O
)	O
model	O
,	O
LS	O
-	O
SVM	O
model	O
gave	O
better	O
precision	O
and	O
accuracy	O
in	O
predicting	O
TAC	O
.	O

The	O
determination	O
coefficient	O
for	O
prediction	O
(	O
R	O
(	O
p	O
)	O
)	O
of	O
the	O
LS	O
-	O
SVM	O
model	O
was	O
0.919	O
and	O
root	O
mean	O
square	O
error	O
for	O
prediction	O
(	O
RMSEP	O
)	O
was	O
0.3226	O
.	O

This	O
work	O
demonstrated	O
that	O
near	O
infrared	O
spectroscopy	O
technique	O
coupled	O
with	O
LS	O
-	O
SVM	O
could	O
be	O
used	O
as	O
a	O
quality	O
control	O
method	O
for	O
vinegar	O
.	O

Microwave	O
distillation	O
followed	O
by	O
headspace	O
single	O
drop	O
microextraction	O
coupled	O
to	O
gas	O
chromatography	O
-	O
mass	O
spectrometry	O
(	O
GC	O
-	O
MS	O
)	O
for	O
fast	O
analysis	O
of	O
volatile	O
components	O
of	O
Echinophora	O
platyloba	O
DC	O
.	O

To	O
avoid	O
the	O
traditional	O
and	O
time	O
consuming	O
hydrodistillation	O
,	O
the	O
analyses	O
of	O
volatile	O
components	O
in	O
aerial	O
parts	O
of	O
Echinophora	O
platyloba	O
DC	O
was	O
carried	O
out	O
by	O
a	O
simple	O
microwave	O
distillation	O
followed	O
by	O
headspace	O
single	O
drop	O
microextraction	O
(	O
MD	O
-	O
HS	O
-	O
SDME	O
)	O
coupled	O
to	O
gas	O
chromatography	O
-	O
mass	O
spectrometry	O
(	O
GC	O
-	O
MS	O
)	O
.	O

The	O
headspace	O
volatile	O
compounds	O
were	O
collected	O
after	O
irradiation	O
using	O
a	O
single	O
drop	O
of	O
n	B
-	I
heptadecan	I
.	O

The	O
extraction	O
conditions	O
were	O
optimised	O
using	O
the	O
relative	O
peak	O
areas	O
as	O
index	O
.	O

The	O
chemical	O
composition	O
of	O
the	O
MD	O
-	O
HS	O
-	O
SDME	O
extracts	O
was	O
confirmed	O
according	O
to	O
their	O
retention	O
indexes	O
and	O
mass	O
spectra	O
.	O

Fifty	O
-	O
three	O
components	O
were	O
extracted	O
and	O
identified	O
by	O
using	O
the	O
MD	O
-	O
HS	O
-	O
SDME	O
method	O
.	O

E	B
-	I
	I
-	I
ocimene	I
(	O
53.81	O
%	O
)	O
,	O
R	O
-	O
D	O
-	O
decalactone	O
(	O
12.75	O
%	O
)	O
,	O
	B
-	I
pinene	I
(	O
6.43	O
%	O
)	O
,	O
n	B
-	I
heptanol	I
(	O
6.27	O
%	O
)	O
,	O
	B
-	I
phellanderne	I
(	O
2.70	O
%	O
)	O
and	O
linalool	B
(	O
1.89	O
%	O
)	O
were	O
the	O
major	O
constituents	O
.	O

Compositional	O
analysis	O
of	O
leaf	O
cuticular	O
membranes	O
isolated	O
from	O
tea	O
plants	O
(	O
Camellia	O
sinensis	O
L.	O
)	O
.	O

Chemical	O
constituents	O
of	O
cuticular	O
membranes	O
(	O
CMs	O
)	O
isolated	O
from	O
three	O
tea	O
cultivars	O
(	O
Camellia	O
sinensis	O
(	O
L.	O
)	O
O.	O
Kuntze	O
cvs	O
.	O

Yabukita	O
,	O
Samidori	O
and	O
Gokou	O
)	O
were	O
compared	O
.	O

All	O
CMs	O
from	O
the	O
adaxial	O
side	O
of	O
the	O
leaves	O
showed	O
higher	O
accumulation	O
of	O
wax	O
,	O
cutin	O
and	O
polysaccharide	O
,	O
while	O
those	O
from	O
the	O
abaxial	O
side	O
were	O
abundant	O
in	O
cutan	O
,	O
showing	O
the	O
adaptation	O
of	O
the	O
adaxial	O
side	O
to	O
abiotic	O
stresses	O
,	O
such	O
as	O
wind	O
and	O
rain	O
,	O
in	O
contrast	O
to	O
the	O
abaxial	O
side	O
,	O
which	O
provides	O
defence	O
against	O
pathogens	O
.	O

Yabukita	O
,	O
a	O
major	O
tea	O
cultivar	O
in	O
Japan	O
,	O
developed	O
thick	O
CMs	O
while	O
Samidori	O
and	O
Gokou	O
,	O
shade	O
-	O
cultivated	O
tea	O
cultivars	O
,	O
had	O
lighter	O
CMs	O
,	O
reflecting	O
their	O
thin	O
and	O
soft	O
leaves	O
.	O

CMs	O
rapidly	O
accumulated	O
9,10-epoxy-18-hydroxyoctadecanoic	B
acid	I
at	O
a	O
very	O
early	O
stage	O
of	O
leaf	O
development	O
.	O

Additionally	O
,	O
shade	O
treatment	O
did	O
not	O
influence	O
cutin	O
biosynthesis	O
in	O
CMs	O
,	O
reflecting	O
high	O
adaptation	O
of	O
tea	O
leaves	O
under	O
low	O
light	O
levels	O
.	O

UPLC	O
and	O
HPLC	O
of	O
caffeoyl	B
esters	I
in	O
wild	O
and	O
cultivated	O
Arctium	O
lappa	O
L.	O
Analytical	O
methods	O
including	O
ultra	O
-	O
performance	O
liquid	O
chromatography	O
(	O
UPLC	O
)	O
and	O
high	O
-	O
performance	O
liquid	O
chromatography	O
(	O
HPLC	O
)	O
with	O
photodiode	O
array	O
(	O
PDA	O
)	O
detector	O
were	O
developed	O
for	O
the	O
analysis	O
of	O
caffeoylquinic	B
acid	I
derivatives	O
in	O
seeds	O
,	O
leaves	O
and	O
roots	O
of	O
Arctium	O
lappa	O
L.	O
Separation	O
was	O
performed	O
on	O
C	O
(	O
18	O
)	O
column	O
utilising	O
5	O
%	O
(	O
v	O
/	O
v	O
)	O
acetic	B
acid	I
in	O
water	O
and	O
acetonitrile	B
at	O
330	O
nm	O
.	O

Both	O
methodologies	O
were	O
validated	O
in	O
terms	O
of	O
linearity	O
,	O
precision	O
,	O
and	O
recovery	O
.	O

The	O
results	O
showed	O
that	O
the	O
major	O
advantages	O
of	O
UPLC	O
,	O
over	O
HPLC	O
were	O
the	O
fast	O
analysis	O
,	O
narrow	O
peaks	O
,	O
high	O
sensitivity	O
,	O
and	O
reduction	O
of	O
solvent	O
consumption	O
.	O

Subsequently	O
the	O
methods	O
were	O
applied	O
for	O
the	O
identification	O
and	O
quantification	O
of	O
chlorogenic	B
acid	I
(	O
5-CQA	B
)	O
and	O
1,5-dicaffeoylquinic	B
acid	I
(	O
1,5-DCQA	B
)	O
as	O
main	O
compounds	O
in	O
samples	O
.	O

The	O
total	O
phenolic	O
content	O
of	O
samples	O
ranged	O
from	O
3.93	O
to	O
14.13	O
g	O
of	O
5-CQA	B
equivalent	O
/	O
100	O
g	O
dry	O
weight	O
(	O
DW	O
)	O
.	O

There	O
was	O
a	O
significant	O
variability	O
from	O
89	O
to	O
571	O
mg	O
/	O
100	O
g	O
for	O
5-CQA	B
and	O
48	O
to	O
486	O
mg	O
/	O
100	O
g	O
for	O
1,5-DCQA	B
in	O
dry	O
material	O
.	O

Structural	O
property	O
of	O
soybean	O
lunasin	O
and	O
development	O
of	O
a	O
method	O
to	O
quantify	O
lunasin	O
in	O
plasma	O
using	O
an	O
optimized	O
immunoassay	O
protocol	O
.	O

Lunasin	O
is	O
a	O
43-amino	O
acid	O
naturally	O
occurring	O
chemopreventive	O
peptide	O
with	O
demonstrated	O
anti	O
-	O
cancer	O
and	O
anti	O
-	O
inflammatory	O
properties	O
.	O

The	O
objectives	O
of	O
this	O
study	O
were	O
to	O
determine	O
the	O
effect	O
of	O
temperature	O
on	O
the	O
secondary	O
structure	O
of	O
lunasin	O
,	O
to	O
develop	O
a	O
method	O
of	O
isolating	O
lunasin	O
from	O
human	O
plasma	O
using	O
an	O
ion	O
-	O
exchange	O
microspin	O
column	O
and	O
to	O
quantify	O
the	O
amount	O
of	O
lunasin	O
using	O
an	O
optimized	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
.	O

Lunasin	O
was	O
purified	O
using	O
a	O
combination	O
of	O
ion	O
-	O
exchange	O
chromatography	O
,	O
ultrafiltration	O
and	O
gel	O
filtration	O
chromatography	O
.	O

Circular	O
dichroism	O
showed	O
that	O
increased	O
in	O
temperature	O
from	O
25	O
to	O
100	O
	O
C	O
resulted	O
in	O
changes	O
on	O
the	O
secondary	O
structure	O
of	O
lunasin	O
and	O
its	O
capability	O
to	O
interact	O
with	O
rabbit	O
polyclonal	O
antibody	O
.	O

Enzyme	O
linked	O
immunosorbent	O
assay	O
showed	O
that	O
lunasin	O
rabbit	O
polyclonal	O
antibody	O
has	O
a	O
titer	O
of	O
250	O
and	O
a	O
specific	O
activity	O
of	O
0.05	O
mL	O
/	O
g	O
.	O

A	O
linear	O
response	O
was	O
detected	O
between	O
16	O
to	O
48	O
ng	O
lunasin	O
per	O
mL	O
(	O
y=0.03x-0.38	O
,	O
R	O
(	O
2	O
)	O
=0.96	O
)	O
.	O

The	O
use	O
of	O
diethylaminoethyl	B
microspin	O
column	O
to	O
isolate	O
spiked	O
lunasin	O
in	O
human	O
plasma	O
showed	O
that	O
most	O
lunasin	O
(	O
37.8	O
-	O
46.5	O
%	O
)	O
bound	O
to	O
the	O
column	O
eluted	O
with	O
Tris	B
-	I
HCl	I
buffer	O
,	O
pH	O
7.5	O
with	O
a	O
yield	O
up	O
to	O
76.6	O
%	O
.	O

In	O
conclusion	O
,	O
lunasin	O
can	O
be	O
isolated	O
from	O
human	O
plasma	O
by	O
a	O
simple	O
DEAE	O
microspin	O
column	O
technique	O
and	O
can	O
be	O
quantified	O
using	O
a	O
validated	O
and	O
optimized	O
immunoassay	O
procedure	O
.	O

This	O
method	O
can	O
be	O
used	O
directly	O
to	O
quantify	O
lunasin	O
from	O
plasma	O
in	O
different	O
human	O
and	O
animal	O
studies	O
aiming	O
to	O
determine	O
its	O
bioavailability	O
.	O

Influence	O
of	O
processing	O
on	O
the	O
volatile	O
profile	O
of	O
strawberry	O
spreads	O
made	O
with	O
isomaltulose	B
.	O

A	O
new	O
strawberry	O
spread	O
formulated	O
with	O
fructose	B
and	O
isomaltulose	B
(	O
replacing	O
sucrose	B
partially	O
or	O
totally	O
)	O
and	O
a	O
high	O
percentage	O
of	O
fruit	O
was	O
developed	O
in	O
line	O
with	O
the	O
new	O
trend	O
of	O
healthier	O
products	O
.	O

This	O
work	O
studies	O
the	O
influence	O
of	O
some	O
process	O
variables	O
(	O
percentage	O
of	O
sugar	B
,	O
pectin	O
and	O
citric	B
acid	I
,	O
and	O
time	O
of	O
thermal	O
treatment	O
)	O
on	O
the	O
volatile	O
profile	O
of	O
these	O
spreads	O
with	O
different	O
formulations	O
.	O

The	O
ripeness	O
of	O
the	O
raw	O
strawberries	O
influences	O
the	O
concentrations	O
of	O
some	O
of	O
the	O
compounds	O
in	O
the	O
spreads	O
,	O
such	O
as	O
isobutyl	B
acetate	I
,	O
butyl	B
butyrate	I
,	O
3-hexen-1-yl	B
acetate	I
or	O
propan-2-ol	B
.	O

The	O
process	O
conditions	O
have	O
an	O
important	O
effect	O
on	O
the	O
volatile	O
profiles	O
.	O

Most	O
of	O
the	O
esters	B
and	O
alcohols	B
decreased	O
whereas	O
13	O
new	O
compounds	O
appear	O
,	O
mostly	O
furans	B
(	O
furfural	B
,	O
2-acetylfurane	B
,	O
5-methyl	B
furfural	I
,	O
mesifurane	B
)	O
and	O
aldehydes	B
(	O
octanal	B
,	O
nonanal	B
,	O
decanal	B
and	O
benzaldeyhde	B
)	O
.	O

In	O
general	O
,	O
the	O
spreads	O
formulated	O
with	O
sucrose	B
-	O
isomaltulose	B
that	O
contained	O
higher	O
levels	O
of	O
pectin	O
and	O
citric	B
acid	I
gave	O
better	O
results	O
in	O
the	O
preservation	O
of	O
the	O
original	O
aromatic	O
compounds	O
in	O
raw	O
strawberries	O
.	O

Optimization	O
of	O
ABTS	B
radical	I
cation	I
assay	O
specifically	O
for	O
determination	O
of	O
antioxidant	O
capacity	O
of	O
intracellular	O
extracts	O
of	O
microalgae	O
and	O
cyanobacteria	O
.	O

A	O
renewed	O
interest	O
in	O
antioxidants	O
has	O
arisen	O
in	O
recent	O
years	O
;	O
microalgae	O
and	O
cyanobacteria	O
are	O
potential	O
sources	O
thereof	O
for	O
use	O
as	O
food	O
/	O
feed	O
ingredients	O
.	O

However	O
,	O
improved	O
methods	O
for	O
comprehensive	O
screening	O
of	O
antioxidant	O
capacity	O
specifically	O
in	O
intracellular	O
extracts	O
of	O
marine	O
microorganisms	O
are	O
required	O
-	O
encompassing	O
lipophilic	O
and	O
hydrophilic	O
compounds	O
simultaneously	O
.	O

The	O
original	O
ABTS	B
method	O
was	O
thus	O
improved	O
,	O
and	O
in	O
particular	O
the	O
procedures	O
of	O
cell	O
disruption	O
and	O
storage	O
were	O
optimized	O
.	O

The	O
best	O
solvent	O
found	O
was	O
ethanol	B
/	O
water	O
(	O
1:1	O
,	O
v	O
/	O
v	O
)	O
.	O

The	O
reaction	O
to	O
form	O
ABTS	B
(	I
+	I
)	I
in	O
said	O
solvent	O
was	O
essentially	O
complete	O
by	O
eight	O
hours	O
,	O
and	O
this	O
radical	O
cation	O
was	O
stable	O
for	O
at	O
least	O
6	O
days	O
;	O
at	O
room	O
temperature	O
,	O
the	O
ABTS	B
(	I
+	I
)	I
solution	O
remained	O
within	O
an	O
allowable	O
analytical	O
range	O
for	O
up	O
to	O
13	O
h.	O
Ultra	O
Turrax	O
was	O
the	O
best	O
cell	O
disruption	O
method	O
,	O
and	O
refrigeration	O
was	O
the	O
best	O
preservation	O
method	O
.	O

This	O
improved	O
methodology	O
was	O
validated	O
with	O
four	O
representative	O
strains	O
that	O
respond	O
poorly	O
to	O
cell	O
disruption	O
.	O

Biogenic	O
amines	B
formation	O
in	O
Streptococcus	O
thermophilus	O
isolated	O
from	O
home	O
-	O
made	O
natural	O
yogurt	O
.	O

Twelve	O
different	O
biogenic	O
amines	B
formation	O
in	O
58	O
isolates	O
of	O
Streptococcus	O
thermophilus	O
from	O
home	O
-	O
made	O
natural	O
yogurt	O
were	O
investigated	O
in	O
histidine	B
(	O
HDB	O
)	O
and	O
lysine	B
decarboxylase	O
broth	O
(	O
LDB	O
)	O
.	O

All	O
S.	O
thermophilus	O
isolates	O
had	O
an	O
ability	O
to	O
produce	O
twelve	O
different	O
biogenic	O
amines	B
in	O
HDB	O
and	O
LDB	O
.	O

Most	O
of	O
the	O
S.	O
thermophilus	O
isolates	O
formed	O
low	O
amounts	O
of	O
histamine	B
(	O
1	O
-	O
50	O
mg	O
/	O
L	O
)	O
from	O
histidine	B
.	O

Apart	O
from	O
one	O
isolate	O
,	O
S.	O
thermophilus	O
produced	O
tyramine	B
at	O
low	O
(	O
47	O
isolates	O
)	O
and	O
medium	O
(	O
10	O
isolates	O
)	O
levels	O
.	O

The	O
amount	O
of	O
each	O
specific	O
biogenic	O
amine	B
produced	O
by	O
S.	O
thermophilus	O
was	O
generally	O
lower	O
than	O
100	O
mg	O
L	O
(	O
-1	O
)	O
.	O

Also	O
,	O
the	O
presence	O
of	O
hdcA	O
gene	O
was	O
investigated	O
using	O
PCR	O
technique	O
and	O
relation	O
between	O
gene	O
and	O
histamine	B
production	O
was	O
conducted	O
in	O
S.	O
thermophilus	O
isolates	O
.	O

This	O
study	O
showed	O
that	O
most	O
of	O
the	O
S.	O
thermophilus	O
isolates	O
have	O
the	O
ability	O
to	O
form	O
biogenic	O
amines	B
,	O
especially	O
histamine	B
,	O
and	O
tyramine	B
,	O
which	O
is	O
an	O
important	O
consideration	O
when	O
selecting	O
strains	O
as	O
starter	O
cultures	O
.	O

Shelf	O
-	O
life	O
of	O
infrared	O
dry	O
-	O
roasted	O
almonds	O
.	O

Infrared	O
heating	O
was	O
recently	O
used	O
to	O
develop	O
a	O
more	O
efficient	O
roasting	O
technology	O
than	O
traditional	O
hot	O
air	O
roasting	O
.	O

Therefore	O
,	O
in	O
this	O
study	O
,	O
we	O
evaluated	O
the	O
shelf	O
-	O
life	O
of	O
almonds	O
roasted	O
with	O
three	O
different	O
approaches	O
,	O
namely	O
infrared	O
(	O
IR	O
)	O
,	O
sequential	O
infrared	O
and	O
hot	O
air	O
(	O
SIRHA	O
)	O
and	O
regular	O
hot	O
air	O
(	O
HA	O
)	O
.	O

Nine	O
medium	O
roasted	O
almond	O
samples	O
produced	O
by	O
the	O
aforementioned	O
heating	O
methods	O
were	O
processed	O
at	O
three	O
different	O
temperatures	O
(	O
130	O
,	O
140	O
and	O
150	O
	O
C	O
)	O
,	O
packed	O
in	O
paper	O
bags	O
and	O
then	O
stored	O
at	O
37	O
	O
C	O
for	O
three	O
,	O
six	O
or	O
eight	O
months	O
.	O

Shelf	O
-	O
life	O
of	O
the	O
roasted	O
almonds	O
was	O
determined	O
by	O
measuring	O
the	O
changes	O
in	O
colour	O
,	O
peroxide	B
value	O
,	O
moisture	O
content	O
,	O
water	O
activity	O
,	O
volatile	O
components	O
and	O
sensory	O
quality	O
.	O

No	O
significant	O
difference	O
was	O
observed	O
in	O
moisture	O
content	O
and	O
water	O
activity	O
among	O
the	O
almond	O
samples	O
processed	O
with	O
different	O
roasting	O
methods	O
and	O
stored	O
under	O
the	O
same	O
conditions	O
.	O

GC	O
/	O
MS	O
analysis	O
showed	O
that	O
aldehydes	B
,	O
alcohols	B
,	O
and	O
pyrazines	B
were	O
the	O
main	O
volatile	O
components	O
of	O
almonds	O
.	O

Aliphatic	B
aldehydes	I
such	O
as	O
hexanal	B
,	O
(	B
E	I
)	I
-2-octenal	I
,	O
and	O
nonanal	B
were	O
produced	O
as	O
off	O
-	O
odours	O
during	O
storage	O
.	O

Although	O
the	O
overall	O
quality	O
of	O
roasted	O
almonds	O
produced	O
with	O
SIRHA	O
and	O
HA	O
heating	O
was	O
similar	O
during	O
the	O
first	O
three	O
months	O
of	O
storage	O
,	O
their	O
peroxide	B
value	O
and	O
concentration	O
of	O
aliphatic	B
aldehydes	I
differed	O
significantly	O
for	O
different	O
roasting	O
methods	O
and	O
increased	O
significantly	O
in	O
all	O
roasted	O
samples	O
during	O
storage	O
.	O

We	O
postulate	O
that	O
hexanal	B
and	O
nonanal	B
might	O
be	O
better	O
indicators	O
of	O
the	O
shelf	O
life	O
of	O
roasted	O
almonds	O
than	O
the	O
current	O
standard	O
,	O
peroxide	B
value	O
.	O

Tri-	B
and	I
diorganotin	I
(	I
IV	I
)	I
complexes	O
of	O
biologically	O
important	O
orotic	B
acid	I
:	O
synthesis	O
,	O
spectroscopic	O
studies	O
,	O
in	O
vitro	O
anti	O
-	O
cancer	O
,	O
DNA	O
fragmentation	O
,	O
enzyme	O
assays	O
and	O
in	O
vivo	O
anti	O
-	O
inflammatory	O
activities	O
.	O

Tri	B
-	I
and	I
diorganotin	I
(	I
IV	I
)	I
orotates	I
of	O
general	O
formula	O
,	O
R	B
(	I
n	I
)	I
Sn	I
(	I
H	I
(	I
2	I
)	I
Or	I
)	I
(	I
m	I
)	I
[	O
n	O
=	O
3	O
/	O
2	O
,	O
m	O
=	O
1	O
/	O
2	O
,	O
R	O
=	O
Me	B
,	O
n	B
-	I
Bu	I
,	O
n	B
-	I
Oct	I
and	O
Ph	B
;	O
H	B
(	I
2	I
)	I
Or	I
(	I
-	I
)	I
=	O
monoanion	O
of	O
orotic	B
acid	I
(	O
H	B
(	I
3	I
)	I
Or	I
)	O
]	O
(	O
n	B
-	I
Bu	I
(	I
2	I
)	I
Sn	I
(	I
HOr	I
)	I
as	O
an	O
exception	O
)	O
have	O
been	O
synthesized	O
.	O

On	O
the	O
basis	O
of	O
various	O
spectroscopic	O
studies	O
it	O
is	O
revealed	O
that	O
R	B
(	I
3	I
)	I
Sn	I
(	I
H	I
(	I
2	I
)	I
Or	I
)	I
and	O
R	B
(	I
2	I
)	I
Sn	I
(	I
H	I
(	I
2	I
)	I
Or	I
)	I
(	I
2	I
)	I
exhibit	O
distorted	O
trigonal	O
-	O
bipyramidal	O
and	O
distorted	O
octahedral	O
geometry	O
,	O
respectively	O
,	O
and	O
n	B
-	I
Bu	I
(	I
2	I
)	I
Sn	I
(	I
HOr	I
)	I
shows	O
both	O
five	O
and	O
six	O
coordination	O
geometry	O
around	O
tin	O
.	O

In	O
vitro	O
anti	O
-	O
cancer	O
screening	O
against	O
MCF-7	O
(	O
mammary	O
)	O
,	O
HEK-293	O
(	O
kidney	O
)	O
,	O
PC-3	O
(	O
prostate	O
)	O
,	O
HCT-15	O
(	O
colon	O
)	O
and	O
HepG-2	O
(	O
liver	O
)	O
cancer	O
cell	O
lines	O
suggest	O
that	O
the	O
n	B
-	I
Oct	I
(	I
2	I
)	I
Sn	I
(	I
H	I
(	I
2	I
)	I
Or	I
)	I
(	I
2	I
)	I
is	O
the	O
most	O
active	O
complex	O
among	O
all	O
of	O
the	O
studied	O
complexes	O
.	O

DNA	O
fragmentation	O
and	O
antioxidant	O
enzyme	O
assays	O
suggest	O
that	O
cytotoxic	O
effect	O
of	O
the	O
complexes	O
is	O
selectively	O
mediated	O
through	O
the	O
induction	O
of	O
apoptosis	O
.	O

They	O
also	O
exhibit	O
low	O
toxicity	O
and	O
good	O
anti	O
-	O
inflammatory	O
activity	O
(	O
in	O
vivo	O
)	O
.	O

Determination	O
of	O
bioactive	O
,	O
free	O
isothiocyanates	B
from	O
a	O
glucosinolate	B
-	O
containing	O
phytotherapeutic	O
agent	O
:	O
a	O
pilot	O
study	O
with	O
in	O
vitro	O
models	O
and	O
human	O
intervention	O
.	O

Isothiocyanates	B
(	O
ITCs	B
)	O
derived	O
from	O
plants	O
of	O
the	O
order	O
Brassicales	O
are	O
known	O
for	O
their	O
antibacterial	O
,	O
anti	O
-	O
inflammatory	O
or	O
anticarcinogenic	O
potential	O
.	O

Although	O
only	O
the	O
free	O
ITCs	B
exert	O
bioactivity	O
,	O
quantification	O
in	O
vivo	O
is	O
almost	O
exclusively	O
performed	O
on	O
total	O
ITC	B
/	O
metabolite	O
content	O
.	O

We	O
therefore	O
investigated	O
in	O
a	O
pilot	O
study	O
the	O
amount	O
of	O
free	O
ITC	B
at	O
different	O
steps	O
critical	O
for	O
therapeutic	O
efficacy	O
.	O

A	O
sensitive	O
and	O
specific	O
GC	O
-	O
MS	O
/	O
MS	O
method	O
for	O
the	O
simultaneous	O
quantification	O
of	O
individual	O
free	O
ITC	B
after	O
solid	O
-	O
phase	O
extraction	O
(	O
SPE	O
)	O
was	O
developed	O
.	O

We	O
show	O
here	O
that	O
release	O
of	O
biologically	O
active	O
ITC	B
from	O
plants	O
occurs	O
at	O
not	O
only	O
alkaline	O
but	O
also	O
acidic	O
pH.	O
Furthermore	O
,	O
in	O
human	O
urine	O
conversion	O
of	O
the	O
ultimate	O
,	O
inactive	O
mercapturic	B
acid	I
conjugate	O
back	O
into	O
its	O
corresponding	O
bioactive	O
form	O
is	O
increased	O
at	O
alkaline	O
as	O
compared	O
to	O
neutral	O
pH.	O
This	O
was	O
also	O
observed	O
in	O
the	O
urine	O
of	O
human	O
volunteers	O
,	O
where	O
-	O
in	O
correlation	O
with	O
the	O
pH	O
value	O
-	O
a	O
mean	O
of	O
0.16	O
to	O
1.03	O
mol	O
ITC	B
was	O
detected	O
after	O
oral	O
application	O
of	O
a	O
phytotherapeutic	O
agent	O
containing	O
30.4	O
mol	O
of	O
the	O
initial	O
pro	O
-	O
drugs	O
.	O

The	O
amounts	O
of	O
free	O
ITC	B
being	O
necessary	O
for	O
bioactivity	O
in	O
vitro	O
were	O
found	O
to	O
be	O
indeed	O
achieved	O
in	O
vivo	O
.	O

These	O
data	O
might	O
be	O
helpful	O
to	O
better	O
understand	O
the	O
beneficial	O
effects	O
of	O
ITC	B
observed	O
in	O
vivo	O
.	O

Fucoidan	O
prevents	O
multiple	O
myeloma	O
cell	O
escape	O
from	O
chemotherapy	O
-	O
induced	O
drug	O
cytotoxicity	O
.	O

Minimal	O
residual	O
disease	O
(	O
MRD	O
)	O
occurrence	O
with	O
some	O
chemotherapy	O
drugs	O
that	O
promote	O
tumor	O
cell	O
escape	O
is	O
also	O
a	O
key	O
factor	O
in	O
blood	O
malignancy	O
relapse	O
.	O

We	O
observed	O
that	O
cytarabine	B
promotes	O
multiple	O
myeloma	O
(	O
MM	O
)	O
cell	O
escape	O
and	O
that	O
the	O
number	O
of	O
cells	O
in	O
the	O
lower	O
chamber	O
increased	O
with	O
increasing	O
clinical	O
disease	O
stage	O
in	O
in	O
vitro	O
model	O
which	O
was	O
constructed	O
by	O
a	O
Boyden	O
chamber	O
,	O
matrigel	O
glue	O
and	O
serum	O
from	O
MM	O
patients	O
in	O
different	O
disease	O
stages	O
.	O

The	O
mechanism	O
of	O
cytarabine	B
that	O
promotes	O
MM	O
cell	O
escape	O
is	O
closely	O
associated	O
with	O
the	O
up	O
-	O
regulation	O
of	O
CXCR4	O
.	O

SDF-1	O
can	O
up	O
-	O
regulate	O
the	O
expression	O
of	O
MMP9	O
and	O
RHoC	O
proteins	O
in	O
MM	O
cells	O
with	O
up	O
-	O
regulated	O
CXCR4	O
,	O
and	O
further	O
promote	O
the	O
cell	O
escape	O
.	O

Fucoidan	O
,	O
a	O
sulfated	O
polysaccharide	O
in	O
the	O
cell	O
wall	O
matrix	O
of	O
brown	O
algae	O
,	O
has	O
attracted	O
much	O
attention	O
for	O
its	O
multiple	O
biological	O
activities	O
,	O
and	O
we	O
further	O
explored	O
the	O
effects	O
and	O
possible	O
underlying	O
mechanisms	O
of	O
fucoidan	O
on	O
MM	O
cell	O
escape	O
from	O
cytarabine	B
cytotoxicity	O
.	O

The	O
results	O
show	O
that	O
fucoidan	O
may	O
decrease	O
MM	O
cell	O
escape	O
from	O
cytarabine	B
cytotoxicity	O
,	O
and	O
that	O
fucoidan	O
can	O
down	O
-	O
regulate	O
CXCR4	O
,	O
MMP9	O
and	O
RHoC	O
expression	O
.	O

This	O
research	O
provides	O
new	O
direction	O
for	O
investigating	O
MRD	O
occurrence	O
and	O
prevention	O
.	O

Cytotoxicity	O
and	O
structure	O
activity	O
relationships	O
of	O
phytosterol	B
from	O
Phyllanthus	O
emblica	O
.	O

Fourteen	O
sterols	B
(	O
1	O
-	O
14	O
)	O
,	O
including	O
two	O
new	O
sterols	B
,	O
trihydroxysitosterol	B
(	O
2	O
)	O
and	O
5,6,7-7	B
-	I
acetoxysitosterol	I
(	O
3	O
)	O
,	O
were	O
isolated	O
from	O
the	O
branches	O
and	O
leaves	O
of	O
Phyllanthus	O
emblica	O
L.	O

The	O
isolated	O
compounds	O
and	O
a	O
structurally	O
related	O
sterol	B
15	O
from	O
Aphanamixis	O
grandifolia	O
were	O
screened	O
for	O
cytotoxicity	O
in	O
two	O
tumor	O
cell	O
lines	O
(	O
HL-60	O
and	O
SMMC-7721	O
)	O
and	O
a	O
non	O
-	O
tumor	O
cell	O
line	O
(	O
HL-7702	O
)	O
using	O
RSB	O
assay	O
.	O

Within	O
the	O
series	O
of	O
phytosterol	B
derivatives	O
tested	O
,	O
compound	O
15	O
was	O
the	O
most	O
active	O
,	O
displaying	O
potent	O
cytotoxicity	O
against	O
HL-60	O
with	O
IC	O
(	O
50	O
)	O
of	O
5.10mol	O
/	O
L	O
,	O
and	O
most	O
of	O
the	O
active	O
compounds	O
showed	O
selective	O
cytotoxicity	O
against	O
tumor	O
and	O
non	O
-	O
tumor	O
cell	O
lines	O
,	O
especially	O
compound	O
10	O
with	O
a	O
safety	O
index	O
of	O
4.42	O
.	O

A	O
novel	O
non	O
-	O
radioactive	O
primase	O
-	O
pyrophosphatase	O
activity	O
assay	O
and	O
its	O
application	O
to	O
the	O
discovery	O
of	O
inhibitors	O
of	O
Mycobacterium	O
tuberculosis	O
primase	O
DnaG.	O
Bacterial	O
DNA	O
primase	O
DnaG	O
synthesizes	O
RNA	O
primers	O
required	O
for	O
chromosomal	O
DNA	O
replication	O
.	O

Biochemical	O
assays	O
measuring	O
primase	O
activity	O
have	O
been	O
limited	O
to	O
monitoring	O
formation	O
of	O
radioactively	O
labelled	O
primers	O
because	O
of	O
the	O
intrinsically	O
low	O
catalytic	O
efficiency	O
of	O
DnaG.	O
Furthermore	O
,	O
DnaG	O
is	O
prone	O
to	O
aggregation	O
and	O
proteolytic	O
degradation	O
.	O

These	O
factors	O
have	O
impeded	O
discovery	O
of	O
DnaG	O
inhibitors	O
by	O
high	O
-	O
throughput	O
screening	O
(	O
HTS	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
expressed	O
and	O
purified	O
the	O
previously	O
uncharacterized	O
primase	O
DnaG	O
from	O
Mycobacterium	O
tuberculosis	O
(	O
Mtb	O
DnaG	O
)	O
.	O

By	O
coupling	O
the	O
activity	O
of	O
Mtb	O
DnaG	O
to	O
that	O
of	O
another	O
essential	O
enzyme	O
,	O
inorganic	O
pyrophosphatase	O
from	O
M.	O
tuberculosis	O
(	O
Mtb	O
PPiase	O
)	O
,	O
we	O
developed	O
the	O
first	O
non	O
-	O
radioactive	O
primase	O
-	O
pyrophosphatase	O
assay	O
.	O

An	O
extensive	O
optimization	O
of	O
the	O
assay	O
enabled	O
its	O
efficient	O
use	O
in	O
HTS	O
(	O
Z	O
'	O
=	O
0.7	O
in	O
the	O
384-well	O
format	O
)	O
.	O

HTS	O
of	O
2560	O
small	O
molecules	O
to	O
search	O
for	O
inhibitory	O
compounds	O
yielded	O
several	O
hits	O
,	O
including	O
suramin	B
,	O
doxorubicin	B
and	O
ellagic	B
acid	I
.	O

We	O
demonstrate	O
that	O
these	O
three	O
compounds	O
inhibit	O
Mtb	O
DnaG.	O
Both	O
suramin	B
and	O
doxorubicin	B
are	O
potent	O
(	O
low-M	O
)	O
DNA-	O
and	O
nucleotide	B
triphosphate	I
-	O
competitive	O
priming	O
inhibitors	O
that	O
interact	O
with	O
more	O
than	O
one	O
site	O
on	O
Mtb	O
DnaG.	O
This	O
novel	O
assay	O
should	O
be	O
applicable	O
to	O
other	O
primases	O
and	O
inefficient	O
DNA	O
/	O
RNA	O
polymerases	O
,	O
facilitating	O
their	O
characterization	O
and	O
inhibitor	O
discovery	O
.	O

GBSA	O
:	O
a	O
comprehensive	O
software	O
for	O
analysing	O
whole	O
genome	O
bisulfite	B
sequencing	O
data	O
.	O

High	O
-	O
throughput	O
sequencing	O
is	O
increasingly	O
being	O
used	O
in	O
combination	O
with	O
bisulfite	B
(	O
BS	O
)	O
assays	O
to	O
study	O
DNA	O
methylation	O
at	O
nucleotide	B
resolution	O
.	O

Although	O
several	O
programmes	O
provide	O
genome	O
-	O
wide	O
alignment	O
of	O
BS	O
-	O
treated	O
reads	O
,	O
the	O
resulting	O
information	O
is	O
not	O
readily	O
interpretable	O
and	O
often	O
requires	O
further	O
bioinformatic	O
steps	O
for	O
meaningful	O
analysis	O
.	O

Current	O
post	O
-	O
alignment	O
BS	O
-	O
sequencing	O
programmes	O
are	O
generally	O
focused	O
on	O
the	O
gene	O
-	O
specific	O
level	O
,	O
a	O
restrictive	O
feature	O
when	O
analysis	O
in	O
the	O
non	O
-	O
coding	O
regions	O
,	O
such	O
as	O
enhancers	O
and	O
intergenic	O
microRNAs	O
,	O
is	O
required	O
.	O

Here	O
,	O
we	O
present	O
Genome	O
Bisulfite	B
Sequencing	O
Analyser	O
(	O
GBSA-http://ctrad-csi.nus.edu.sg/gbsa	O
)	O
,	O
a	O
free	O
open	O
-	O
source	O
software	O
capable	O
of	O
analysing	O
whole	O
-	O
genome	O
bisulfite	B
sequencing	O
data	O
with	O
either	O
a	O
gene	O
-	O
centric	O
or	O
gene	O
-	O
independent	O
focus	O
.	O

Through	O
analysis	O
of	O
the	O
largest	O
published	O
data	O
sets	O
to	O
date	O
,	O
we	O
demonstrate	O
GBSA	O
's	O
features	O
in	O
providing	O
sequencing	O
quality	O
assessment	O
,	O
methylation	O
scoring	O
,	O
functional	O
data	O
management	O
and	O
visualization	O
of	O
genomic	O
methylation	O
at	O
nucleotide	O
resolution	O
.	O

Additionally	O
,	O
we	O
show	O
that	O
GBSA	O
's	O
output	O
can	O
be	O
easily	O
integrated	O
with	O
other	O
high	O
-	O
throughput	O
sequencing	O
data	O
,	O
such	O
as	O
RNA	O
-	O
Seq	O
or	O
ChIP	O
-	O
seq	O
,	O
to	O
elucidate	O
the	O
role	O
of	O
methylated	O
intergenic	O
regions	O
in	O
gene	O
regulation	O
.	O

In	O
essence	O
,	O
GBSA	O
allows	O
an	O
investigator	O
to	O
explore	O
not	O
only	O
known	O
loci	O
but	O
also	O
all	O
the	O
genomic	O
regions	O
,	O
for	O
which	O
methylation	O
studies	O
could	O
lead	O
to	O
the	O
discovery	O
of	O
new	O
regulatory	O
mechanisms	O
.	O

Coming	O
full	O
circle	O
:	O
contributions	O
of	O
central	O
and	O
peripheral	O
oxytocin	B
actions	O
to	O
energy	O
balance	O
.	O

The	O
neuropeptide	O
oxytocin	B
has	O
emerged	O
as	O
an	O
important	O
anorexigen	B
in	O
the	O
regulation	O
of	O
energy	O
balance	O
.	O

Its	O
effects	O
on	O
food	O
intake	O
have	O
largely	O
been	O
attributed	O
to	O
limiting	O
meal	O
size	O
through	O
interactions	O
in	O
key	O
regulatory	O
brain	O
regions	O
such	O
as	O
the	O
hypothalamus	O
and	O
hindbrain	O
.	O

Pharmacologic	O
and	O
pair	O
-	O
feeding	O
studies	O
indicate	O
that	O
its	O
ability	O
to	O
reduce	O
body	O
mass	O
extends	O
beyond	O
that	O
of	O
food	O
intake	O
,	O
affecting	O
multiple	O
factors	O
that	O
determine	O
energy	O
balance	O
such	O
as	O
energy	O
expenditure	O
,	O
lipolysis	O
,	O
and	O
glucose	B
regulation	O
.	O

Systemic	O
administration	O
of	O
oxytocin	B
recapitulates	O
many	O
of	O
its	O
effects	O
when	O
administered	O
centrally	O
,	O
raising	O
the	O
questions	O
of	O
whether	O
and	O
to	O
what	O
extent	O
circulating	O
oxytocin	B
contributes	O
to	O
energy	O
regulation	O
.	O

Its	O
therapeutic	O
potential	O
to	O
treat	O
metabolic	O
conditions	O
remains	O
to	O
be	O
determined	O
,	O
but	O
data	O
from	O
diet	O
-	O
induced	O
and	O
genetically	O
obese	O
rodent	O
models	O
as	O
well	O
as	O
application	O
of	O
oxytocin	B
in	O
humans	O
in	O
other	O
areas	O
of	O
research	O
have	O
revealed	O
promising	O
results	O
thus	O
far	O
.	O

Safrole-2',3'-oxide	B
induces	O
atherosclerotic	O
plaque	O
vulnerability	O
in	O
apolipoprotein	O
E	O
-	O
knockout	O
mice	O
.	O

Safrole-2',3'-oxide	B
(	O
SFO	B
)	O
is	O
the	O
major	O
electrophilic	O
metabolite	O
of	O
safrole	B
(	O
4-allyl-1	B
,	I
2-methylenedioxybenzene	I
)	O
,	O
a	O
natural	O
plant	O
constituent	O
found	O
in	O
essential	O
oils	O
of	O
numerous	O
edible	O
herbs	O
and	O
spices	O
and	O
in	O
food	O
containing	O
these	O
herbs	O
,	O
such	O
as	O
pesto	O
sauce	O
,	O
cola	O
beverages	O
and	O
bologna	O
sausages	O
.	O

The	O
effects	O
of	O
SFO	B
in	O
mammalian	O
systems	O
,	O
especially	O
the	O
cardiovascular	O
system	O
,	O
are	O
little	O
known	O
.	O

Disruption	O
of	O
vulnerable	O
atherosclerotic	O
plaques	O
in	O
atherosclerosis	O
,	O
a	O
chronic	O
inflammatory	O
disease	O
,	O
is	O
the	O
main	O
cause	O
of	O
cardiovascular	O
events	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
SFO	B
-	O
induced	O
atherosclerotic	O
plaque	O
vulnerability	O
(	O
possibility	O
of	O
rupture	O
)	O
in	O
apolipoprotein	O
E	O
-	O
knockout	O
(	O
apoE	O
(	O
-	O
/	O
-	O
)	O
)	O
mice	O
.	O

Lipid	O
area	O
in	O
vessel	O
wall	O
reached	O
59.8	O
%	O
in	O
high	O
dose	O
SFO	B
(	O
SFO	B
-	O
HD	O
)	O
treated	O
group	O
,	O
which	O
is	O
only	O
31.2	O
%	O
in	O
control	O
group	O
.	O

SFO	B
treatment	O
changed	O
the	O
lesion	O
composition	O
to	O
an	O
unstable	O
phenotype	O
,	O
increased	O
the	O
number	O
of	O
apoptotic	O
cells	O
in	O
plaque	O
and	O
the	O
endothelium	O
in	O
plaques	O
was	O
damaged	O
after	O
SFO	B
treatment	O
.	O

Furthermore	O
,	O
compared	O
with	O
control	O
groups	O
,	O
the	O
plaque	O
endothelium	O
level	O
of	O
p75	O
(	O
NTR	O
)	O
was	O
3-fold	O
increased	O
and	O
the	O
liver	O
level	O
of	O
p75	O
(	O
NTR	O
)	O
was	O
17.4-fold	O
increased	O
by	O
SFO	B
-	O
HD	O
.	O

Meanwhile	O
,	O
the	O
serum	O
level	O
of	O
KC	O
(	O
a	O
functional	O
homolog	O
of	O
IL-8	O
and	O
the	O
main	O
proinflammatory	O
alpha	O
chemokine	O
in	O
mice	O
)	O
in	O
apoE	O
(	O
-	O
/	O
-	O
)	O
mice	O
was	O
up	O
to	O
357pg	O
/	O
ml	O
in	O
SFO	B
-	O
HD	O
treated	O
group	O
.	O

Thus	O
,	O
SFO	B
contributes	O
to	O
the	O
instability	O
of	O
atherosclerotic	O
plaque	O
in	O
apoE	O
(	O
-	O
/	O
-	O
)	O
mice	O
through	O
activating	O
p75	O
(	O
NTR	O
)	O
and	O
IL-8	O
and	O
cell	O
apoptosis	O
in	O
plaque	O
.	O

Nanodomain	O
coupling	O
at	O
an	O
excitatory	O
cortical	O
synapse	O
.	O

The	O
coupling	O
distance	O
between	O
presynaptic	O
Ca	B
(	I
2	I
+	I
)	I
influx	O
and	O
the	O
sensor	O
for	O
vesicular	O
transmitter	O
release	O
determines	O
speed	O
and	O
reliability	O
of	O
synaptic	O
transmission	O
.	O

Nanodomain	O
coupling	O
(	O
<	O
100	O
nm	O
)	O
favors	O
fidelity	O
and	O
is	O
employed	O
by	O
synapses	O
specialized	O
for	O
escape	O
reflexes	O
and	O
by	O
inhibitory	O
synapses	O
involved	O
in	O
synchronizing	O
fast	O
network	O
oscillations	O
.	O

Cortical	O
glutamatergic	O
synapses	O
seem	O
to	O
forgo	O
the	O
benefits	O
of	O
tight	O
coupling	O
,	O
yet	O
quantitative	O
detail	O
is	O
lacking	O
.	O

The	O
reduced	O
transmission	O
fidelity	O
of	O
loose	O
coupling	O
,	O
however	O
,	O
raises	O
the	O
question	O
whether	O
it	O
is	O
indeed	O
a	O
general	O
characteristic	O
of	O
cortical	O
synapses	O
.	O

Here	O
we	O
analyzed	O
excitatory	O
parallel	O
fiber	O
to	O
Purkinje	O
cell	O
synapses	O
,	O
major	O
processing	O
sites	O
for	O
sensory	O
information	O
and	O
well	O
suited	O
for	O
analysis	O
because	O
they	O
typically	O
harbor	O
only	O
a	O
single	O
active	O
zone	O
.	O

We	O
quantified	O
the	O
coupling	O
distance	O
by	O
combining	O
multiprobability	O
fluctuation	O
analyses	O
,	O
presynaptic	O
Ca	B
(	I
2	I
+	I
)	I
imaging	O
,	O
and	O
reaction	O
-	O
diffusion	O
simulations	O
in	O
wild	O
-	O
type	O
and	O
calretinin	O
-	O
deficient	O
mice	O
.	O

We	O
found	O
a	O
coupling	O
distance	O
of	O
<	O
30	O
nm	O
at	O
these	O
synapses	O
,	O
much	O
shorter	O
than	O
at	O
any	O
other	O
glutamatergic	O
cortical	O
synapse	O
investigated	O
to	O
date	O
.	O

Our	O
results	O
suggest	O
that	O
nanodomain	O
coupling	O
is	O
a	O
general	O
characteristic	O
of	O
conventional	O
cortical	O
synapses	O
involved	O
in	O
high	O
-	O
frequency	O
transmission	O
,	O
allowing	O
for	O
dense	O
gray	O
matter	O
packing	O
and	O
cost	O
-	O
effective	O
neurotransmission	O
.	O

The	O
use	O
of	O
Reamer	O
Irrigator	O
Aspirator	O
(	O
RIA	O
)	O
autograft	O
harvest	O
in	O
the	O
treatment	O
of	O
critical	O
-	O
sized	O
iliac	O
wing	O
defects	O
in	O
sheep	O
:	O
investigation	O
of	O
dexamethasone	B
and	O
beta	B
-	I
tricalcium	I
phosphate	I
augmentation	O
.	O

Bone	O
grafts	O
are	O
commonly	O
used	O
for	O
the	O
treatment	O
of	O
segmental	O
bone	O
defects	O
and	O
fracture	O
non	O
-	O
unions	O
.	O

Recently	O
,	O
osseous	O
particles	O
obtained	O
during	O
intermedullary	O
canal	O
reaming	O
(	O
using	O
a	O
Reamer	O
-	O
Irrigator	O
-	O
Aspirator	O
(	O
RIA	O
)	O
device	O
)	O
have	O
been	O
evaluated	O
as	O
graft	O
material	O
during	O
in	O
vitro	O
and	O
clinical	O
studies	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
and	O
quantify	O
new	O
bone	O
formation	O
after	O
implantation	O
of	O
bone	O
graft	O
material	O
obtained	O
after	O
reaming	O
of	O
the	O
tibia	O
in	O
a	O
bilateral	O
critical	O
-	O
sized	O
iliac	O
wing	O
defect	O
in	O
sheep	O
and	O
to	O
investigate	O
the	O
effect	O
of	O
the	O
augmentation	O
of	O
this	O
graft	O
.	O

A	O
reamer	O
bone	O
graft	O
alone	O
,	O
or	O
after	O
short	O
term	O
incubation	O
in	O
a	O
dexamethasone	B
enriched	O
solution	O
,	O
and	O
a	O
reamer	O
graft	O
collected	O
using	O
beta	B
-	I
tricalcium	I
phosphate	I
(	O
	B
-	I
TCP	I
)	O
granules	O
in	O
the	O
filter	O
of	O
the	O
RIA	O
collection	O
device	O
were	O
compared	O
to	O
autologous	O
iliac	O
wing	O
graft	O
.	O

In	O
addition	O
,	O
reamer	O
graft	O
was	O
combined	O
with	O
the	O
cellular	O
fraction	O
collected	O
from	O
the	O
irrigation	O
fluid	O
with	O
and	O
without	O
short	O
-	O
term	O
incubation	O
in	O
a	O
dexamethasone	B
enriched	O
solution	O
.	O

It	O
was	O
hypothesized	O
that	O
the	O
amount	O
of	O
physical	O
bone	O
in	O
the	O
reamer	O
bone	O
graft	O
groups	O
would	O
be	O
higher	O
than	O
the	O
amount	O
in	O
the	O
autologous	O
iliac	O
wing	O
graft	O
group	O
and	O
that	O
augmentation	O
of	O
a	O
reamer	O
bone	O
graft	O
would	O
increase	O
bone	O
formation	O
.	O

Three	O
months	O
after	O
implantation	O
,	O
the	O
amount	O
of	O
new	O
bone	O
formation	O
(	O
as	O
percentage	O
of	O
the	O
total	O
defect	O
volume	O
)	O
in	O
the	O
defects	O
was	O
evaluated	O
ex	O
-	O
vivo	O
by	O
means	O
of	O
micro	O
-	O
CT	O
and	O
histomorphometry	O
.	O

The	O
mean	O
amount	O
of	O
bone	O
in	O
the	O
autologous	O
iliac	O
wing	O
graft	O
group	O
was	O
17.7	O
%	O
and	O
16.8	O
%	O
for	O
micro	O
-	O
CT	O
and	O
histomorphometry	O
,	O
respectively	O
.	O

The	O
mean	O
amount	O
of	O
bone	O
in	O
all	O
reamer	O
graft	O
groups	O
ranged	O
between	O
20.4	O
-	O
29.2	O
%	O
(	O
micro	O
-	O
CT	O
)	O
and	O
17.0	O
-	O
25.4	O
%	O
(	O
histomorphometry	O
)	O
.	O

Reamer	O
graft	O
collected	O
using	O
	B
-	I
TCP	I
granules	O
(	O
29.21.7	O
%	O
)	O
in	O
the	O
filter	O
produced	O
a	O
significantly	O
higher	O
amount	O
of	O
bone	O
in	O
comparison	O
to	O
an	O
autologous	O
iliac	O
wing	O
graft	O
evaluated	O
by	O
micro	O
-	O
CT	O
.	O

RIA	O
bone	O
grafts	O
added	O
a	O
small	O
increase	O
in	O
bone	O
volume	O
to	O
the	O
3month	O
graft	O
volume	O
in	O
this	O
preclinical	O
sheep	O
model	O
.	O

The	O
current	O
model	O
does	O
not	O
support	O
the	O
use	O
of	O
short	O
-	O
term	O
high	O
concentration	O
dexamethasone	B
for	O
augmentation	O
of	O
a	O
graft	O
volume	O
.	O

If	O
avoidance	O
of	O
an	O
iliac	O
wing	O
graft	O
is	O
desirable	O
,	O
or	O
a	O
reaming	O
procedure	O
is	O
required	O
,	O
then	O
a	O
RIA	O
graft	O
or	O
RIA	O
graft	O
plus	O
	B
-	I
TCP	I
granules	O
are	O
as	O
good	O
as	O
the	O
current	O
gold	O
standard	O
for	O
this	O
model	O
.	O

Pharmacokinetics	O
explain	O
in	O
vivo	O
/	O
in	O
vitro	O
discrepancies	O
of	O
carcinogen	O
-	O
induced	O
gene	O
expression	O
alterations	O
in	O
rat	O
liver	O
and	O
cultivated	O
hepatocytes	O
.	O

Cultivated	O
hepatocytes	O
represent	O
a	O
well	O
-	O
established	O
in	O
vitro	O
system	O
.	O

However	O
,	O
the	O
applicability	O
of	O
hepatocytes	O
in	O
toxicogenomics	O
is	O
still	O
controversially	O
discussed	O
.	O

Recently	O
,	O
an	O
in	O
vivo	O
/	O
in	O
vitro	O
discrepancy	O
has	O
been	O
described	O
,	O
whereby	O
the	O
non	O
-	O
genotoxic	O
rat	O
liver	O
carcinogen	O
methapyrilene	B
alters	O
the	O
expression	O
of	O
the	O
metabolizing	O
genes	O
SULT1A1	O
and	O
ABAT	O
,	O
as	O
well	O
as	O
the	O
DNA	O
damage	O
response	O
gene	O
GADD34	O
in	O
vitro	O
,	O
but	O
not	O
in	O
vivo	O
.	O

If	O
the	O
collagen	O
sandwich	O
cultures	O
of	O
hepatocytes	O
really	O
produce	O
false	O
-	O
positive	O
data	O
,	O
this	O
would	O
compromise	O
its	O
application	O
in	O
toxicogenomics	O
.	O

To	O
revisit	O
the	O
putative	O
in	O
vivo	O
/	O
in	O
vitro	O
discrepancy	O
,	O
we	O
first	O
analyzed	O
and	O
modeled	O
methapyrilene	B
concentrations	O
in	O
the	O
portal	O
vein	O
of	O
rats	O
.	O

The	O
relatively	O
short	O
half	O
-	O
life	O
of	O
2.8	O
h	O
implies	O
a	O
rapid	O
decrease	O
in	O
orally	O
administered	O
methapyrilene	B
in	O
vivo	O
below	O
concentrations	O
that	O
can	O
cause	O
gene	O
expression	O
alterations	O
.	O

This	O
corresponded	O
to	O
the	O
time	O
-	O
dependent	O
alteration	O
levels	O
of	O
GADD34	O
,	O
ABAT	O
and	O
SULT1A1	O
RNA	O
in	O
the	O
liver	O
:	O
RNA	O
levels	O
are	O
altered	O
1	O
,	O
6	O
and	O
12	O
h	O
after	O
methapyrilene	B
administration	O
,	O
but	O
return	O
to	O
control	O
levels	O
after	O
24	O
and	O
72	O
h.	O
In	O
contrast	O
,	O
methapyrilene	B
concentrations	O
in	O
the	O
culture	O
medium	O
supernatant	O
of	O
primary	O
rat	O
hepatocyte	O
cultures	O
decreased	O
slowly	O
.	O

This	O
explains	O
why	O
GADD34	O
,	O
ABAT	O
and	O
SULT1A1	O
were	O
still	O
deregulated	O
after	O
24	O
h	O
exposure	O
in	O
vitro	O
,	O
but	O
not	O
in	O
vivo	O
.	O

It	O
should	O
also	O
be	O
considered	O
that	O
the	O
earliest	O
analyzed	O
time	O
point	O
in	O
the	O
previous	O
in	O
vivo	O
studies	O
was	O
24	O
h	O
after	O
methapyrilene	B
administration	O
.	O

In	O
conclusion	O
,	O
previously	O
observed	O
in	O
vitro	O
/	O
in	O
vivo	O
discrepancy	O
can	O
be	O
explained	O
by	O
different	O
pharmacokinetics	O
present	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

When	O
the	O
in	O
vivo	O
half	O
-	O
life	O
is	O
short	O
,	O
levels	O
of	O
some	O
initially	O
altered	O
genes	O
may	O
have	O
returned	O
to	O
control	O
levels	O
already	O
24	O
h	O
after	O
administration	O
.	O

RNA	O
dimerization	O
plays	O
a	O
role	O
in	O
ribosomal	O
frameshifting	O
of	O
the	O
SARS	O
coronavirus	O
.	O

Messenger	O
RNA	O
encoded	O
signals	O
that	O
are	O
involved	O
in	O
programmed	O
-1	O
ribosomal	O
frameshifting	O
(	O
-1	O
PRF	O
)	O
are	O
typically	O
two	O
-	O
stemmed	O
hairpin	O
(	O
H	O
)	O
-type	O
pseudoknots	O
(	O
pks	O
)	O
.	O

We	O
previously	O
described	O
an	O
unusual	O
three	O
-	O
stemmed	O
pseudoknot	O
from	O
the	O
severe	O
acute	O
respiratory	O
syndrome	O
(	O
SARS	O
)	O
coronavirus	O
(	O
CoV	O
)	O
that	O
stimulated	O
-1	O
PRF	O
.	O

The	O
conserved	O
existence	O
of	O
a	O
third	O
stem	O
-	O
loop	O
suggested	O
an	O
important	O
hitherto	O
unknown	O
function	O
.	O

Here	O
we	O
present	O
new	O
information	O
describing	O
structure	O
and	O
function	O
of	O
the	O
third	O
stem	O
of	O
the	O
SARS	O
pseudoknot	O
.	O

We	O
uncovered	O
RNA	O
dimerization	O
through	O
a	O
palindromic	O
sequence	O
embedded	O
in	O
the	O
SARS	O
-	O
CoV	O
Stem	O
3	O
.	O

Further	O
in	O
vitro	O
analysis	O
revealed	O
that	O
SARS	O
-	O
CoV	O
RNA	O
dimers	O
assemble	O
through	O
'	O
kissing	O
'	O
loop	O
-	O
loop	O
interactions	O
.	O

We	O
also	O
show	O
that	O
loop	O
-	O
loop	O
kissing	O
complex	O
formation	O
becomes	O
more	O
efficient	O
at	O
physiological	O
temperature	O
and	O
in	O
the	O
presence	O
of	O
magnesium	B
.	O

When	O
the	O
palindromic	O
sequence	O
was	O
mutated	O
,	O
in	O
vitro	O
RNA	O
dimerization	O
was	O
abolished	O
,	O
and	O
frameshifting	O
was	O
reduced	O
from	O
15	O
to	O
5.7	O
%	O
.	O

Furthermore	O
,	O
the	O
inability	O
to	O
dimerize	O
caused	O
by	O
the	O
silent	O
codon	O
change	O
in	O
Stem	O
3	O
of	O
SARS	O
-	O
CoV	O
changed	O
the	O
viral	O
growth	O
kinetics	O
and	O
affected	O
the	O
levels	O
of	O
genomic	O
and	O
subgenomic	O
RNA	O
in	O
infected	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
the	O
homodimeric	O
RNA	O
complex	O
formed	O
by	O
the	O
SARS	O
pseudoknot	O
occurs	O
in	O
the	O
cellular	O
environment	O
and	O
that	O
loop	O
-	O
loop	O
kissing	O
interactions	O
involving	O
Stem	O
3	O
modulate	O
-1	O
PRF	O
and	O
play	O
a	O
role	O
in	O
subgenomic	O
and	O
full	O
-	O
length	O
RNA	O
synthesis	O
.	O

Survey	O
of	O
recent	O
literature	O
related	O
to	O
the	O
biologically	O
active	O
4	B
(	I
3H	I
)	I
-quinazolinones	I
containing	O
fused	O
heterocycles	O
.	O

The	O
present	O
review	O
focuses	O
on	O
the	O
synthesis	O
and	O
biological	O
evaluation	O
of	O
polycyclic	B
4	I
(	I
3H	I
)	I
-quinazolinones	I
containing	O
fused	O
aromatic	O
or	O
heteroaromatic	O
rings	O
.	O

The	O
first	O
part	O
of	O
the	O
review	O
is	O
related	O
to	O
compounds	O
with	O
ring	O
fused	O
to	O
the	O
pyrimidine	B
part	O
of	O
the	O
quinazoline	B
core	O
.	O

Most	O
of	O
the	O
quinazolinone	B
alkaloids	I
belong	O
to	O
this	O
class	O
of	O
molecules	O
.	O

The	O
second	O
part	O
presents	O
molecules	O
bearing	O
extra	O
ring	O
(	O
s	O
)	O
fused	O
to	O
the	O
benzo	B
moiety	O
of	O
the	O
quinazolinone	B
skeleton	O
.	O

Their	O
structural	O
diversity	O
opens	O
new	O
fields	O
in	O
the	O
search	O
of	O
active	O
molecules	O
.	O

Deregulation	O
of	O
HOX	O
B13	O
expression	O
in	O
urinary	O
bladder	O
cancer	O
progression	O
.	O

Urinary	O
bladder	O
cancer	O
is	O
a	O
common	O
malignancy	O
in	O
industrialized	O
countries	O
.	O

More	O
than	O
90	O
%	O
of	O
bladder	O
cancer	O
originates	O
in	O
the	O
transitional	O
cells	O
.	O

Bladder	O
transitional	O
cancer	O
prognosis	O
is	O
,	O
according	O
to	O
the	O
most	O
recent	O
definition	O
related	O
to	O
the	O
level	O
of	O
tumor	O
infiltration	O
,	O
characterized	O
by	O
two	O
main	O
phenotypes	O
,	O
Non	O
Muscle	O
Invasive	O
Bladder	O
Transitional	O
Cancer	O
(	O
NMIBC	O
)	O
and	O
Muscle	O
Invasive	O
Bladder	O
Transitional	O
Cancer	O
(	O
MIBC	O
)	O
.	O

The	O
genetic	O
profile	O
and	O
the	O
clinical	O
course	O
of	O
the	O
two	O
subtypes	O
are	O
completely	O
different	O
,	O
however	O
among	O
NMIBC	O
the	O
prognosis	O
is	O
not	O
completely	O
predictable	O
,	O
since	O
20	O
%	O
of	O
the	O
cases	O
experience	O
a	O
relapse	O
,	O
even	O
in	O
the	O
form	O
of	O
MIBC	O
.	O

It	O
has	O
recently	O
been	O
reported	O
that	O
the	O
chromosomal	O
region	O
12q13	O
-	O
15	O
,	O
containing	O
crucial	O
cancer	O
genes	O
such	O
as	O
MDM2	O
,	O
CDK4	O
,	O
GLI	O
and	O
an	O
entire	O
cluster	O
of	O
HOX	O
genes	O
,	O
is	O
amplified	O
in	O
bladder	O
cancer	O
.	O

HOX	O
genes	O
codify	O
for	O
transcriptionl	O
factor	O
,	O
involved	O
in	O
embryonal	O
development	O
and	O
cancer	O
progression	O
,	O
with	O
main	O
nuclear	O
expression	O
.	O

Particularly	O
it	O
was	O
also	O
described	O
the	O
strong	O
involvement	O
of	O
HOX	O
B13	O
in	O
several	O
tumors	O
of	O
urogenital	O
system	O
.	O

In	O
this	O
study	O
we	O
have	O
been	O
investigated	O
,	O
by	O
immunohistochemisty	O
and	O
quantitative	O
Real	O
Time	O
PCR	O
,	O
the	O
HOX	O
B13	O
expression	O
in	O
bladder	O
cancer	O
evolution	O
and	O
progression	O
,	O
evaluating	O
its	O
ability	O
to	O
discriminate	O
between	O
NMIBC	O
and	O
MBCI	O
phenotypes	O
.	O

Cytoplasmic	O
HOX	O
B13	O
delocalization	O
significantly	O
relates	O
with	O
muscle	O
invasion	O
(	O
p	O
0.004	O
)	O
.	O

In	O
addition	O
in	O
the	O
series	O
of	O
NMIBC	O
nuclear	O
HOX	O
B13	O
expression	O
loss	O
is	O
significantly	O
associated	O
to	O
shorter	O
disease	O
free	O
survival	O
(	O
p	O
-	O
value=0.038	O
)	O
defining	O
a	O
potential	O
prognostic	O
role	O
.	O

Overexpression	O
of	O
HOX	O
B13	O
in	O
more	O
aggressive	O
phenotype	O
is	O
also	O
demonstrate	O
at	O
gene	O
level	O
by	O
quantitative	O
RT	O
-	O
PCR	O
.	O

The	O
de	O
-	O
regulation	O
and	O
delocalization	O
of	O
HOX	O
B13	O
in	O
urinary	O
bladder	O
cancer	O
supports	O
again	O
the	O
important	O
role	O
of	O
HOX	O
genes	O
in	O
tumor	O
evolution	O
and	O
represents	O
a	O
starting	O
point	O
to	O
establish	O
an	O
integrated	O
analysis	O
,	O
in	O
which	O
HOX	O
genes	O
represent	O
important	O
prognostic	O
and	O
predictive	O
markers	O
for	O
bladder	O
cancer	O
.	O

Display	O
of	O
amino	B
groups	O
on	O
substrate	O
surfaces	O
by	O
simple	O
dip	O
-	O
coating	O
of	O
methacrylate	B
-	O
based	O
polymers	O
and	O
its	O
application	O
to	O
DNA	O
immobilization	O
.	O

The	O
implementation	O
of	O
a	O
reactive	O
functional	O
group	O
onto	O
a	O
material	O
surface	O
is	O
of	O
great	O
importance	O
.	O

Reactive	O
functional	O
groups	O
(	O
e.g.	O
,	O
an	O
amino	B
group	O
and	O
a	O
hydroxyl	B
group	O
)	O
are	O
usually	O
hydrophilic	O
,	O
which	O
makes	O
it	O
difficult	O
to	O
display	O
them	O
on	O
a	O
dry	O
polymer	O
surface	O
.	O

We	O
here	O
propose	O
a	O
novel	O
method	O
for	O
displaying	O
amino	B
groups	O
on	O
the	O
surfaces	O
of	O
polymeric	O
substrates	O
through	O
dip	O
-	O
coating	O
of	O
a	O
methacrylate	B
-	O
based	O
copolymer	O
.	O

We	O
synthesized	O
copolymers	O
composed	O
of	O
methyl	B
methacrylate	I
and	O
2-aminoethyl	B
methacrylate	I
with	O
different	O
protecting	O
groups	O
or	O
ion	O
-	O
complexes	O
on	O
their	O
amino	B
groups	O
,	O
then	O
dip	O
-	O
coated	O
the	O
copolymers	O
onto	O
a	O
poly	B
(	I
methyl	I
methacrylate	I
)	I
(	O
PMMA	B
)	O
substrate	O
.	O

Evaluation	O
using	O
a	O
cleavable	O
fluorescent	O
compound	O
,	O
which	O
was	O
synthesized	O
in	O
the	O
present	O
study	O
to	O
quantify	O
a	O
small	O
amount	O
(	O
pmol	O
/	O
cm	O
(	O
2	O
)	O
)	O
of	O
amino	B
groups	O
on	O
a	O
solid	O
surface	O
,	O
revealed	O
that	O
the	O
protection	O
of	O
amino	B
groups	O
affected	O
their	O
surface	O
segregation	O
in	O
the	O
copolymer	O
coating	O
.	O

p	B
-	I
Toluenesulfonate	I
ion	O
-	O
complex	O
and	O
tert	B
-	I
butoxycarbonyl	I
(	O
Boc	B
)	O
protection	O
of	O
amino	B
groups	O
were	O
found	O
to	O
effectively	O
display	O
amino	B
groups	O
on	O
the	O
surface	O
(	O
more	O
than	O
70	O
pmol	O
/	O
cm	O
(	O
2	O
)	O
)	O
.	O

The	O
density	O
of	O
amino	B
groups	O
displayed	O
on	O
a	O
surface	O
can	O
be	O
easily	O
controlled	O
by	O
mixing	O
the	O
copolymer	O
and	O
PMMA	B
before	O
dip	O
-	O
coating	O
.	O

Dip	O
-	O
coating	O
of	O
the	O
copolymer	O
with	O
Boc	B
protection	O
on	O
various	O
polymeric	O
substrates	O
also	O
successfully	O
displayed	O
amino	B
groups	O
on	O
their	O
surfaces	O
.	O

Finally	O
,	O
we	O
demonstrated	O
that	O
the	O
amino	B
groups	O
displayed	O
can	O
be	O
utilized	O
for	O
the	O
immobilization	O
of	O
a	O
DNA	O
oligonucleotide	O
on	O
a	O
substrate	O
surface	O
.	O

Kinetics	O
of	O
the	O
reaction	O
of	O
crystal	B
violet	I
with	O
hydroxide	B
ion	O
in	O
the	O
critical	O
solution	O
of	O
2-butoxyethanol	B
+	O
water	O
.	O

The	O
kinetics	O
of	O
alkaline	O
fading	O
of	O
crystal	B
violet	I
(	O
CV	O
)	O
has	O
been	O
studied	O
by	O
UV	O
spectrophotometry	O
and	O
microcalorimetry	O
in	O
the	O
critical	O
binary	O
solution	O
of	O
2-butoxyethanol	B
+	O
water	O
at	O
the	O
initial	O
reaction	O
stage	O
and	O
various	O
temperatures	O
.	O

It	O
was	O
found	O
that	O
the	O
first	O
-	O
order	O
rate	O
constants	O
obtained	O
from	O
these	O
two	O
methods	O
are	O
well	O
accorded	O
with	O
each	O
other	O
,	O
and	O
the	O
temperature	O
dependence	O
of	O
the	O
rate	O
constant	O
obeyed	O
the	O
Arrhenius	O
equation	O
in	O
a	O
temperature	O
region	O
far	O
from	O
the	O
critical	O
point	O
.	O

The	O
critical	O
slowing	O
down	O
was	O
detected	O
by	O
both	O
methods	O
near	O
the	O
critical	O
point	O
.	O

A	O
simple	O
empirical	O
crossover	O
model	O
was	O
proposed	O
and	O
used	O
to	O
analyze	O
the	O
experimental	O
data	O
to	O
obtain	O
the	O
critical	O
exponents	O
,	O
which	O
were	O
0.158	O
	O
0.013	O
and	O
0.133	O
	O
0.012	O
from	O
UV	O
spectrophotometry	O
and	O
microcalorimetry	O
,	O
respectively	O
,	O
and	O
the	O
former	O
was	O
in	O
good	O
agreement	O
with	O
the	O
theoretical	O
prediction	O
of	O
0.151	O
.	O

The	O
slight	O
lower	O
value	O
derived	O
from	O
microcalorimetry	O
was	O
attributed	O
to	O
the	O
stirring	O
in	O
the	O
microcalorimeter	O
,	O
which	O
weakened	O
the	O
critical	O
reduction	O
of	O
the	O
diffusion	O
coefficient	O
.	O

Spatial	O
variation	O
of	O
available	O
electronic	O
excitations	O
within	O
individual	O
quantum	O
dots	O
.	O

Quantum	O
dots	O
(	O
QDs	O
)	O
allow	O
for	O
manipulation	O
of	O
the	O
position	O
and	O
energy	O
levels	O
of	O
electrons	O
at	O
sub-10	O
nm	O
length	O
scales	O
through	O
control	O
of	O
material	O
chemistry	O
,	O
size	O
,	O
and	O
shape	O
.	O

It	O
is	O
known	O
from	O
optical	O
studies	O
that	O
the	O
bandgap	O
of	O
semiconductor	O
QDs	O
increases	O
as	O
their	O
size	O
decreases	O
due	O
to	O
the	O
narrowing	O
of	O
the	O
quantum	O
confinement	O
potential	O
.	O

The	O
mechanism	O
of	O
quantum	O
confinement	O
also	O
indicates	O
that	O
the	O
localized	O
properties	O
within	O
individual	O
QDs	O
should	O
depend	O
on	O
their	O
shape	O
in	O
addition	O
to	O
their	O
size	O
,	O
but	O
direct	O
observations	O
of	O
this	O
effect	O
have	O
proven	O
challenging	O
due	O
to	O
the	O
limited	O
spatial	O
resolution	O
of	O
measurement	O
techniques	O
at	O
this	O
scale	O
and	O
the	O
ability	O
to	O
remove	O
contributions	O
from	O
the	O
surroundings	O
.	O

Here	O
we	O
present	O
experimental	O
evidence	O
of	O
spatial	O
variations	O
in	O
the	O
lowest	O
available	O
electron	O
transition	O
energy	O
within	O
a	O
series	O
of	O
single	O
electrically	O
isolated	O
QDs	O
due	O
to	O
a	O
dome	O
-	O
shaped	O
geometry	O
,	O
measured	O
using	O
electron	O
energy	O
-	O
loss	O
spectroscopy	O
in	O
a	O
(	O
scanning	O
)	O
transmission	O
electron	O
microscope	O
[	O
(	O
S	O
)	O
TEM	O
-	O
EELS	O
]	O
.	O

We	O
observe	O
a	O
consistent	O
increase	O
in	O
the	O
energy	O
onset	O
of	O
electronic	O
excitations	O
from	O
the	O
lateral	O
center	O
of	O
the	O
dot	O
toward	O
the	O
edges	O
,	O
which	O
we	O
attribute	O
purely	O
to	O
shape	O
.	O

This	O
trend	O
is	O
in	O
qualitative	O
agreement	O
with	O
a	O
simple	O
quantum	O
simulation	O
of	O
the	O
local	O
density	O
of	O
states	O
in	O
a	O
dome	O
-	O
shaped	O
QD	O
.	O

PXR	O
-	O
mediated	O
P	O
-	O
glycoprotein	O
induction	O
by	O
small	O
molecule	O
tyrosine	B
kinase	O
inhibitors	O
.	O

The	O
rapid	O
development	O
of	O
drug	O
resistance	O
as	O
a	O
result	O
of	O
exposure	O
to	O
small	O
molecule	O
tyrosine	B
kinase	O
inhibitors	O
(	O
TKIs	O
)	O
is	O
an	O
important	O
drawback	O
to	O
the	O
successful	O
use	O
of	O
these	O
agents	O
in	O
the	O
clinic	O
.	O

Although	O
one	O
of	O
the	O
most	O
established	O
mechanisms	O
by	O
which	O
cells	O
acquire	O
drug	O
resistance	O
to	O
anticancer	O
drugs	O
is	O
the	O
up	O
regulation	O
of	O
drug	O
efflux	O
transporters	O
such	O
as	O
P	O
-	O
glycoprotein	O
(	O
PGP	O
)	O
,	O
it	O
is	O
currently	O
still	O
unknown	O
whether	O
TKIs	O
have	O
the	O
propensity	O
to	O
induce	O
PGP	O
.	O

The	O
effect	O
of	O
TKIs	O
on	O
the	O
protein	O
expression	O
and	O
activity	O
of	O
PGP	O
was	O
assessed	O
after	O
treatment	O
of	O
LS180	O
cells	O
with	O
clinically	O
relevant	O
concentrations	O
of	O
the	O
TKIs	O
.	O

In	O
addition	O
,	O
the	O
involvement	O
of	O
the	O
nuclear	O
pregnane	B
X	O
receptor	O
(	O
PXR	O
)	O
,	O
a	O
known	O
regulator	O
of	O
PGP	O
expression	O
,	O
was	O
determined	O
.	O

At	O
least	O
five	O
out	O
of	O
the	O
nine	O
tested	O
TKIs	O
(	O
erlotinib	B
,	O
gefitinib	B
,	O
nilotinib	B
,	O
sorafenib	B
,	O
vandetanib	B
)	O
were	O
able	O
to	O
induce	O
the	O
expression	O
of	O
PGP	O
within	O
48	O
h	O
in	O
LS180	O
cells	O
.	O

Accordingly	O
,	O
these	O
TKIs	O
were	O
also	O
shown	O
to	O
affect	O
the	O
accumulation	O
of	O
a	O
P	O
-	O
glycoprotein	O
specific	O
probe	O
substrate	O
.	O

Furthermore	O
,	O
we	O
showed	O
that	O
the	O
pregnane	B
X	O
receptor	O
(	O
PXR	O
)	O
,	O
which	O
is	O
an	O
important	O
regulator	O
of	O
PGP	O
induction	O
,	O
is	O
involved	O
in	O
the	O
upregulation	O
of	O
PGP	O
protein	O
expression	O
following	O
exposure	O
to	O
these	O
TKIs	O
.	O

Our	O
data	O
show	O
that	O
PXR	O
-	O
mediated	O
upregulation	O
of	O
PGP	O
expression	O
by	O
TKIs	O
might	O
be	O
a	O
possible	O
mechanism	O
underlying	O
acquired	O
drug	O
resistance	O
in	O
cancer	O
cells	O
.	O

Development	O
of	O
a	O
dry	O
,	O
stable	O
and	O
inhalable	O
acyl	B
-	I
homoserine	I
-	I
lactone	I
-	O
acylase	O
powder	O
formulation	O
for	O
the	O
treatment	O
of	O
pulmonary	O
Pseudomonas	O
aeruginosa	O
infections	O
.	O

In	O
the	O
lungs	O
of	O
cystic	O
fibrosis	O
(	O
CF	O
)	O
patients	O
,	O
Pseudomonas	O
aeruginosa	O
commonly	O
causes	O
chronic	O
infections	O
.	O

It	O
has	O
been	O
shown	O
that	O
the	O
P.	O
aeruginosa	O
quorum	O
sensing	O
(	O
QS	O
)	O
system	O
controls	O
the	O
expression	O
of	O
virulence	O
factors	O
during	O
invasion	O
and	O
infection	O
to	O
host	O
cells	O
.	O

PvdQ	O
is	O
an	O
acyl	B
-	I
homoserine	I
lactone	I
(	O
AHL	B
)	O
acylase	O
able	O
to	O
degrade	O
the	O
signal	O
molecule	O
of	O
P.	O
aeruginosa	O
QS	O
.	O

The	O
role	O
of	O
PvdQ	O
in	O
inhibiting	O
the	O
QS	O
and	O
its	O
successive	O
virulence	O
determinants	O
has	O
been	O
established	O
in	O
in	O
vitro	O
as	O
well	O
as	O
in	O
in	O
vivo	O
,	O
the	O
latter	O
in	O
a	O
Caenorabdhitis	O
elegans	O
model	O
.	O

For	O
the	O
treatment	O
of	O
pulmonary	O
P.	O
aeruginosa	O
infections	O
,	O
we	O
propose	O
that	O
PvdQ	O
can	O
be	O
best	O
administered	O
directly	O
to	O
the	O
lungs	O
of	O
the	O
patients	O
as	O
a	O
dry	O
powder	O
because	O
this	O
is	O
expected	O
to	O
give	O
specific	O
advantages	O
in	O
delivery	O
as	O
compared	O
to	O
nebulizing	O
.	O

Therefore	O
in	O
this	O
study	O
we	O
investigated	O
the	O
production	O
of	O
a	O
PvdQ	O
powder	O
by	O
spray	O
-	O
freeze	O
drying	O
using	O
mannitol	B
,	O
trehalose	B
and	O
inulin	O
as	O
excipient	O
.	O

The	O
activity	O
of	O
PvdQ	O
in	O
the	O
powder	O
was	O
determined	O
immediately	O
after	O
production	O
and	O
after	O
subsequent	O
storage	O
during	O
4	O
weeks	O
at	O
20	O
	O
C	O
and	O
55	O
	O
C	O
.	O

We	O
found	O
that	O
the	O
enzymatic	O
activity	O
of	O
PvdQ	O
is	O
fully	O
maintained	O
during	O
spray	O
-	O
freeze	O
drying	O
using	O
mannitol	B
,	O
trehalose	B
or	O
inulin	O
as	O
excipient	O
.	O

However	O
,	O
mannitol	B
was	O
not	O
able	O
to	O
stabilize	O
the	O
protein	O
during	O
storage	O
,	O
while	O
PvdQ	O
incorporated	O
in	O
trehalose	B
or	O
inulin	O
was	O
fully	O
stabilized	O
even	O
during	O
storage	O
at	O
55	O
	O
C	O
for	O
at	O
least	O
4	O
weeks	O
.	O

The	O
poor	O
stabilizing	O
capacities	O
of	O
mannitol	B
during	O
storage	O
could	O
be	O
related	O
to	O
its	O
crystalline	O
nature	O
while	O
the	O
excellent	O
stabilizing	O
capacities	O
of	O
trehalose	B
and	O
inulin	O
during	O
storage	O
could	O
be	O
related	O
to	O
their	O
amorphous	O
nature	O
.	O

The	O
trehalose	B
and	O
inulin	O
-	O
based	O
particles	O
consisted	O
of	O
porous	O
spheres	O
with	O
a	O
volume	O
average	O
aerodynamical	O
diameter	O
of	O
1.8	O
m	O
implying	O
that	O
they	O
are	O
suitable	O
for	O
pulmonary	O
delivery	O
.	O

This	O
is	O
the	O
first	O
study	O
in	O
which	O
an	O
AHL	B
-	O
degrading	O
enzyme	O
is	O
processed	O
into	O
spray	O
-	O
freeze	O
-	O
dried	O
powder	O
suitable	O
for	O
inhalation	O
.	O

(	B
R	I
)	I
-	I
-	I
lysine	I
-	O
modified	O
elongation	O
factor	O
P	O
functions	O
in	O
translation	O
elongation	O
.	O

Post	O
-	O
translational	O
modification	O
of	O
bacterial	O
elongation	O
factor	O
P	O
(	O
EF	O
-	O
P	O
)	O
with	O
(	B
R	I
)	I
-	I
-	I
lysine	I
at	O
a	O
conserved	O
lysine	O
residue	O
activates	O
the	O
protein	O
in	O
vivo	O
and	O
increases	O
puromycin	O
reactivity	O
of	O
the	O
ribosome	O
in	O
vitro	O
.	O

The	O
additional	O
hydroxylation	O
of	O
EF	O
-	O
P	O
at	O
the	O
same	O
lysine	B
residue	O
by	O
the	O
YfcM	O
protein	O
has	O
also	O
recently	O
been	O
described	O
.	O

The	O
roles	O
of	O
modified	O
and	O
unmodified	O
EF	O
-	O
P	O
during	O
different	O
steps	O
in	O
translation	O
,	O
and	O
how	O
this	O
correlates	O
to	O
its	O
physiological	O
role	O
in	O
the	O
cell	O
,	O
have	O
recently	O
been	O
linked	O
to	O
the	O
synthesis	O
of	O
polyproline	B
stretches	O
in	O
proteins	O
.	O

Polysome	O
analysis	O
indicated	O
that	O
EF	O
-	O
P	O
functions	O
in	O
translation	O
elongation	O
,	O
rather	O
than	O
initiation	O
as	O
proposed	O
previously	O
.	O

This	O
was	O
further	O
supported	O
by	O
the	O
inability	O
of	O
EF	O
-	O
P	O
to	O
enhance	O
the	O
rate	O
of	O
formation	O
of	O
fMet	B
-	I
Lys	I
or	O
fMet	B
-	I
Phe	I
,	O
indicating	O
that	O
the	O
role	O
of	O
EF	O
-	O
P	O
is	O
not	O
to	O
specifically	O
stimulate	O
formation	O
of	O
the	O
first	O
peptide	O
bond	O
.	O

Investigation	O
of	O
hydroxyl-	B
(	I
	I
)	I
-lysyl	I
-	O
EF	O
-	O
P	O
showed	O
30	O
%	O
increased	O
puromycin	B
reactivity	O
but	O
no	O
differences	O
in	O
dipeptide	O
synthesis	O
rates	O
when	O
compared	O
with	O
the	O
	O
-	O
lysylated	O
form	O
.	O

Unlike	O
disruption	O
of	O
the	O
other	O
genes	O
required	O
for	O
EF	O
-	O
P	O
modification	O
,	O
deletion	O
of	O
yfcM	O
had	O
no	O
phenotypic	O
consequences	O
in	O
Salmonella	O
.	O

Taken	O
together	O
,	O
our	O
findings	O
indicate	O
that	O
EF	O
-	O
P	O
functions	O
in	O
translation	O
elongation	O
,	O
a	O
role	O
critically	O
dependent	O
on	O
post	O
-	O
translational	O
	O
-	O
lysylation	O
but	O
not	O
hydroxylation	O
.	O

Synthesis	O
and	O
Biological	O
Evaluation	O
of	O
[	B
1,2,4	I
]	I
Triazolo	I
[	I
3,4-a	I
]	I
phthalazine	I
and	O
Tetrazolo	B
[	I
5,1-a	I
]	I
phthalazine	I
Derivatives	O
Bearing	O
Substituted	O
Benzylpiperazine	B
Moieties	O
as	O
Positive	O
Inotropic	O
Agents	O
.	O

Two	O
series	O
of	O
[	B
1,2,4	I
]	I
triazolo	I
[	I
3,4-a	I
]	I
phthalazine	I
and	O
tetrazolo	B
[	I
5,1-a	I
]	I
phthalazine	I
derivatives	O
bearing	O
substituted	O
benzylpiperazine	B
moieties	O
have	O
been	O
synthesized	O
and	O
evaluated	O
for	O
their	O
positive	O
inotropic	O
activity	O
by	O
measuring	O
left	O
atrium	O
stroke	O
volume	O
on	O
isolated	O
rabbit	O
heart	O
preparations	O
.	O

The	O
majority	O
of	O
the	O
derivatives	O
exhibited	O
better	O
in	O
vitro	O
activity	O
than	O
the	O
existing	O
drug	O
,	O
milrinone	B
,	O
and	O
6-	B
(	I
(	I
4-	I
(	I
4-methoxyphenyl	I
)	I
piperazin-1-yl	I
)	I
methyl	I
)	I
tetrazolo	I
[	I
5,1-a	I
]	I
phthalazine	I
.	O

8	O
m	O
in	O
particular	O
was	O
identified	O
as	O
the	O
most	O
potent	O
with	O
an	O
increased	O
stroke	O
volume	O
of	O
12.02	O
	O
0.20	O
%	O
(	O
milrinone	B
:	O
2.46	O
	O
0.07	O
%	O
)	O
at	O
a	O
concentration	O
of	O
3	O
	O
10	O
(	O
-5	O
)	O
m.	O
The	O
chronotropic	O
effects	O
of	O
the	O
compounds	O
that	O
exhibited	O
good	O
potency	O
were	O
also	O
evaluated	O
.	O

Modulation	O
of	O
esterified	O
drug	O
metabolism	O
by	O
tanshinones	O
from	O
Salvia	O
miltiorrhiza	O
(	O
"	O
Danshen	O
"	O
)	O
.	O

The	O
roots	O
of	O
Salvia	O
miltiorrhiza	O
(	O
"	O
Danshen	O
"	O
)	O
are	O
used	O
in	O
traditional	O
Chinese	O
medicine	O
for	O
the	O
treatment	O
of	O
numerous	O
ailments	O
including	O
cardiovascular	O
disease	O
,	O
hypertension	O
,	O
and	O
ischemic	O
stroke	O
.	O

Extracts	O
of	O
S.	O
miltiorrhiza	O
roots	O
in	O
the	O
formulation	O
"	O
Compound	O
Danshen	O
Dripping	O
Pill	O
"	O
are	O
undergoing	O
clinical	O
trials	O
in	O
the	O
United	O
States	O
.	O

To	O
date	O
,	O
the	O
active	O
components	O
of	O
this	O
material	O
have	O
not	O
been	O
conclusively	O
identified	O
.	O

We	O
have	O
determined	O
that	O
S.	O
miltiorrhiza	O
roots	O
contain	O
potent	O
human	O
carboxylesterase	O
(	O
CE	O
)	O
inhibitors	O
,	O
due	O
to	O
the	O
presence	O
of	O
tanshinones	O
.	O

K	O
(	O
i	O
)	O
values	O
in	O
the	O
nM	O
range	O
were	O
determined	O
for	O
inhibition	O
of	O
both	O
the	O
liver	O
and	O
intestinal	O
CEs	O
.	O

As	O
CEs	O
hydrolyze	O
clinically	O
used	O
drugs	O
,	O
the	O
ability	O
of	O
tanshinones	O
and	O
S.	O
miltiorrhiza	O
root	O
extracts	O
to	O
modulate	O
the	O
metabolism	O
of	O
the	O
anticancer	O
prodrug	O
irinotecan	B
(	O
CPT-11	B
)	O
was	O
assessed	O
.	O

Our	O
results	O
indicate	O
that	O
marked	O
inhibition	O
of	O
human	O
CEs	O
occurs	O
following	O
incubation	O
with	O
both	O
pure	O
compounds	O
and	O
crude	O
material	O
and	O
that	O
drug	O
hydrolysis	O
is	O
significantly	O
reduced	O
.	O

Consequently	O
,	O
a	O
reduction	O
in	O
the	O
cytotoxicity	O
of	O
irinotecan	O
is	O
observed	O
following	O
dosing	O
with	O
either	O
purified	O
tanshinones	O
or	O
S.	O
miltiorrhiza	O
root	O
extracts	O
.	O

It	O
is	O
concluded	O
that	O
remedies	O
containing	O
tanshinones	O
should	O
be	O
avoided	O
when	O
individuals	O
are	O
taking	O
esterified	O
agents	O
and	O
that	O
patients	O
should	O
be	O
warned	O
of	O
the	O
potential	O
drug	O
-	O
drug	O
interaction	O
that	O
may	O
occur	O
with	O
this	O
material	O
.	O

Differential	O
anti	O
-	O
ischemic	O
efficacy	O
and	O
therapeutic	O
time	O
window	O
of	O
trans-	B
and	I
cis	I
-	I
hinokiresinols	I
:	O
Stereo	O
-	O
specific	O
antioxidant	O
and	O
anti	O
-	O
inflammatory	O
activities	O
.	O

During	O
cerebral	O
ischemia	O
,	O
neurons	O
are	O
injured	O
by	O
various	O
mechanisms	O
including	O
excitotoxicity	O
,	O
oxidative	O
stress	O
,	O
and	O
inflammatory	O
responses	O
.	O

Thus	O
,	O
pharmacological	O
manipulation	O
of	O
multiple	O
cytotoxic	O
pathways	O
has	O
been	O
pursued	O
for	O
the	O
treatment	O
of	O
ischemic	O
injury	O
.	O

Cis	B
-	I
hinokiresinol	I
,	O
a	O
naturally	O
occurring	O
phenylpropanoid	B
,	O
was	O
previously	O
reported	O
to	O
possess	O
anti	O
-	O
oxidant	O
,	O
anti	O
-	O
inflammatory	O
and	O
estrogen	B
-	O
like	O
activities	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
anti	O
-	O
ischemic	O
effects	O
of	O
trans-	B
and	I
cis	I
-	I
hinokiresinols	I
using	O
in	O
vitro	O
as	O
well	O
as	O
in	O
vivo	O
experimental	O
models	O
.	O

The	O
ORAC	O
and	O
DPPH	B
assays	O
showed	O
that	O
two	O
isomers	O
had	O
similar	O
free	O
radical	O
scavenging	O
activities	O
.	O

However	O
,	O
only	O
trans	B
-	I
hinokiresinol	I
significantly	O
decreased	O
neuronal	O
injury	O
in	O
cultured	O
cortical	O
neurons	O
exposed	O
to	O
oxygen	B
-	O
glucose	B
deprivation	O
(	O
75	O
min	O
)	O
followed	O
by	O
re	O
-	O
oxygenation	O
(	O
9	O
h	O
)	O
.	O

The	O
differential	O
neuroprotective	O
effect	O
could	O
be	O
due	O
to	O
the	O
stereo	O
-	O
specific	O
augmentation	O
of	O
Cu	B
/	O
Zn	B
-	O
SOD	O
activity	O
by	O
trans	B
-	I
hinokiresinol	I
,	O
when	O
compared	O
with	O
cis	B
-	I
hinokiresinol	I
.	O

Similarly	O
,	O
in	O
rats	O
subjected	O
to	O
transient	O
middle	O
cerebral	O
artery	O
occlusion	O
(	O
1.5	O
h	O
)	O
followed	O
by	O
24-h	O
reperfusion	O
,	O
pre	O
-	O
ischemic	O
treatment	O
with	O
trans	B
-	I
hinokiresinol	I
,	O
but	O
not	O
with	O
cis	O
-	O
isomer	O
,	O
reduced	O
cerebral	O
infarct	O
volume	O
.	O

Interestingly	O
,	O
however	O
,	O
post	O
-	O
ischemic	O
treatment	O
with	O
both	O
hinokiresinols	B
(	O
2	O
and	O
7	O
h	O
after	O
onset	O
of	O
ischemia	O
)	O
significantly	O
reduced	O
cerebral	O
infarct	O
.	O

When	O
administered	O
after	O
onset	O
of	O
ischemia	O
,	O
trans	B
-	I
hinokiresinol	I
,	O
but	O
not	O
its	O
cis	O
-	O
isomer	O
reduced	O
nitrotyrosine	B
immunoreactivity	O
in	O
ischemic	O
regions	O
.	O

In	O
contrast	O
,	O
both	O
hinokiresinols	B
suppressed	O
neutrophil	O
infiltration	O
and	O
IL-1	O
release	O
to	O
a	O
similar	O
extent	O
.	O

The	O
observed	O
differential	O
anti	O
-	O
oxidant	O
,	O
but	O
comparable	O
anti	O
-	O
inflammatory	O
,	O
activities	O
may	O
explain	O
the	O
stereo	O
-	O
specific	O
anti	O
-	O
ischemic	O
activities	O
and	O
different	O
therapeutic	O
time	O
windows	O
of	O
the	O
hinokiresinols	B
examined	O
.	O

More	O
detailed	O
delineation	O
of	O
the	O
anti	O
-	O
ischemic	O
mechanism	O
(	O
s	O
)	O
of	O
hinokiresinols	B
may	O
provide	O
a	O
better	O
strategy	O
for	O
development	O
of	O
efficacious	O
regimens	O
for	O
cerebral	O
ischemic	O
stroke	O
.	O

Influence	O
of	O
DNA	O
repair	O
on	O
nonlinear	O
dose	O
-	O
responses	O
for	O
mutation	O
.	O

Recent	O
evidence	O
has	O
challenged	O
the	O
default	O
assumption	O
that	O
all	O
DNA	O
-	O
reactive	O
alkylating	O
agents	O
exhibit	O
a	O
linear	O
dose	O
-	O
response	O
.	O

Emerging	O
evidence	O
suggests	O
that	O
the	O
model	O
alkylating	O
agents	O
methyl-	B
and	O
ethylmethanesulfonate	B
and	O
methylnitrosourea	B
(	O
MNU	B
)	O
and	O
ethylnitrosourea	B
observe	O
a	O
nonlinear	O
dose	O
-	O
response	O
with	O
a	O
no	O
observed	O
genotoxic	O
effect	O
level	O
(	O
NOGEL	O
)	O
.	O

Follow	O
-	O
up	O
mechanistic	O
studies	O
are	O
essential	O
to	O
understand	O
the	O
mechanism	O
of	O
cellular	O
tolerance	O
and	O
biological	O
relevance	O
of	O
such	O
NOGELs	O
.	O

MNU	B
is	O
one	O
of	O
the	O
most	O
mutagenic	O
simple	O
alkylators	O
.	O

Therefore	O
,	O
understanding	O
the	O
mechanism	O
of	O
mutation	O
induction	O
,	O
following	O
low	O
-	O
dose	O
MNU	B
treatment	O
,	O
sets	O
precedence	O
for	O
weaker	O
mutagenic	O
alkylating	O
agents	O
.	O

Here	O
,	O
we	O
tested	O
MNU	B
at	O
10-fold	O
lower	O
concentrations	O
than	O
a	O
previous	O
study	O
and	O
report	O
a	O
NOGEL	O
of	O
0.0075	O
g	O
/	O
ml	O
(	O
72.8nM	O
)	O
in	O
human	O
lymphoblastoid	O
cells	O
,	O
quantified	O
through	O
the	O
hypoxanthine	B
(	O
guanine	B
)	O
phosphoribosyltransferase	O
assay	O
(	O
OECD	O
476	O
)	O
.	O

Mechanistic	O
studies	O
reveal	O
that	O
the	O
NOGEL	O
is	O
dependent	O
upon	O
repair	O
of	O
O	B
(	I
6	I
)	I
-methylguanine	I
(	O
O	B
(	I
6	I
)	I
MeG	I
)	O
by	O
the	O
suicide	O
enzyme	O
O	B
(	I
6	I
)	I
MeG	I
-	O
DNA	O
methyltransferase	O
(	O
MGMT	O
)	O
.	O

Inactivation	O
of	O
MGMT	O
sensitizes	O
cells	O
to	O
MNU	B
-	O
induced	O
mutagenesis	O
and	O
shifts	O
the	O
NOGEL	O
to	O
the	O
left	O
on	O
the	O
dose	O
axis	O
.	O

An	O
animal	O
model	O
of	O
marginal	O
iodine	B
deficiency	O
during	O
development	O
:	O
the	O
thyroid	O
axis	O
and	O
neurodevelopmental	O
outcome	O
.	O

Thyroid	O
hormones	O
(	O
THs	O
)	O
are	O
essential	O
for	O
brain	O
development	O
,	O
and	O
iodine	B
is	O
required	O
for	O
TH	O
synthesis	O
.	O

Environmental	O
chemicals	O
that	O
perturb	O
the	O
thyroid	O
axis	O
result	O
in	O
modest	O
reductions	O
in	O
TH	O
,	O
yet	O
there	O
is	O
a	O
paucity	O
of	O
data	O
on	O
the	O
extent	O
of	O
neurological	O
impairments	O
associated	O
with	O
low	O
-	O
level	O
TH	O
disruption	O
.	O

This	O
study	O
examined	O
the	O
dose	O
-	O
response	O
characteristics	O
of	O
marginal	O
iodine	B
deficiency	O
(	O
ID	O
)	O
on	O
parameters	O
of	O
thyroid	O
function	O
and	O
neurodevelopment	O
.	O

Diets	O
deficient	O
in	O
iodine	B
were	O
prepared	O
by	O
adding	O
975	O
,	O
200	O
,	O
125	O
,	O
25	O
,	O
or	O
0	O
g	O
/	O
kg	O
potassium	B
iodate	I
to	O
the	O
base	O
casein	O
diet	O
to	O
produce	O
five	O
nominal	O
iodine	B
levels	O
ranging	O
from	O
ample	O
(	O
Diet	O
1	O
:	O
1000	O
g	O
iodine	B
/	O
kg	O
chow	O
,	O
D1	O
)	O
to	O
deficient	O
(	O
Diet	O
5	O
:	O
25	O
g	O
iodine	B
/	O
kg	O
chow	O
,	O
D5	O
)	O
.	O

Female	O
Long	O
Evans	O
rats	O
were	O
maintained	O
on	O
these	O
diets	O
beginning	O
7	O
weeks	O
prior	O
to	O
breeding	O
until	O
the	O
end	O
of	O
lactation	O
.	O

Dams	O
were	O
sacrificed	O
on	O
gestational	O
days	O
16	O
and	O
20	O
,	O
or	O
when	O
pups	O
were	O
weaned	O
on	O
postnatal	O
day	O
(	O
PN	O
)	O
21	O
.	O

Fetal	O
tissue	O
was	O
harvested	O
from	O
the	O
dams	O
,	O
and	O
pups	O
were	O
sacrificed	O
on	O
PN14	O
and	O
PN21	O
.	O

Blood	O
,	O
thyroid	O
gland	O
,	O
and	O
brain	O
were	O
collected	O
for	O
analysis	O
of	O
iodine	B
,	O
TH	O
,	O
and	O
TH	O
precursors	O
and	O
metabolites	O
.	O

Serum	O
and	O
thyroid	O
gland	O
iodine	B
and	O
TH	O
were	O
reduced	O
in	O
animals	O
receiving	O
two	O
diets	O
that	O
were	O
most	O
deficient	O
in	O
iodine	B
.	O

T4	O
was	O
reduced	O
in	O
the	O
fetal	O
brain	O
but	O
was	O
not	O
altered	O
in	O
the	O
neonatal	O
brain	O
.	O

Neurobehavior	O
,	O
assessed	O
by	O
acoustic	O
startle	O
,	O
water	O
maze	O
learning	O
,	O
and	O
fear	O
conditioning	O
,	O
was	O
unchanged	O
in	O
adult	O
offspring	O
,	O
but	O
excitatory	O
synaptic	O
transmission	O
was	O
impaired	O
in	O
the	O
dentate	O
gyrus	O
in	O
animals	O
receiving	O
two	O
diets	O
that	O
were	O
most	O
deficient	O
in	O
iodine	B
.	O

A	O
15	O
%	O
reduction	O
in	O
cortical	O
T4	O
in	O
the	O
fetal	O
brain	O
was	O
sufficient	O
to	O
induce	O
permanent	O
reductions	O
in	O
synaptic	O
function	O
in	O
adults	O
.	O

These	O
findings	O
have	O
implications	O
for	O
regulation	O
of	O
TH	O
-	O
disrupting	O
chemicals	O
and	O
suggest	O
that	O
standard	O
behavioral	O
assays	O
do	O
not	O
readily	O
detect	O
neurotoxicity	O
induced	O
by	O
modest	O
developmental	O
TH	O
disruption	O
.	O

Regiospecificity	O
and	O
stereospecificity	O
of	O
human	O
UDP	B
-	O
glucuronosyltransferases	O
in	O
the	O
glucuronidation	O
of	O
estriol	B
,	O
16-epiestriol	B
,	O
17-epiestriol	B
,	O
and	O
13-epiestradiol	B
.	O

The	O
glucuronidation	O
of	O
estriol	B
,	O
16-epiestriol	B
,	O
and	O
17-epiestriol	B
by	O
the	O
human	O
UDP	B
-	O
glucuronosyltransferases	O
(	O
UGTs	O
)	O
of	O
subfamilies	O
1A	O
,	O
2A	O
,	O
and	O
2B	O
was	O
examined	O
.	O

UGT1A10	O
is	O
highly	O
active	O
in	O
the	O
conjugation	O
of	O
the	O
3-OH	B
in	O
all	O
these	O
estriols	B
,	O
whereas	O
UGT2B7	O
is	O
the	O
most	O
active	O
UGT	O
toward	O
one	O
of	O
the	O
ring	O
D	O
hydroxyls	O
,	O
the	O
16-OH	B
in	O
estriol	B
and	O
16-epiestriol	B
,	O
but	O
the	O
17-OH	B
in	O
17-epiestriol	B
.	O

Kinetic	O
analyses	O
indicated	O
that	O
the	O
17-OH	B
configuration	O
plays	O
a	O
major	O
role	O
in	O
the	O
affinity	O
of	O
UGT2B7	O
for	O
estrogens	B
.	O

The	O
glucuronidation	O
of	O
the	O
different	O
estriols	B
by	O
the	O
human	O
liver	O
and	O
intestine	O
microsomes	O
reflects	O
the	O
activity	O
of	O
UGT1A10	O
and	O
UGT2B7	O
in	O
combination	O
with	O
the	O
tissues	O
'	O
difference	O
in	O
UGT1A10	O
expression	O
.	O

The	O
UGT1A10	O
mutant	O
1A10-F93	O
G	O
exhibited	O
much	O
higher	O
V	O
(	O
max	O
)	O
values	O
than	O
UGT1A10	O
in	O
estriol	B
and	O
17-epiestriol	B
glucuronidation	O
,	O
but	O
a	O
significantly	O
lower	O
value	O
in	O
16-epiestriol	B
glucuronidation	O
.	O

To	O
this	O
study	O
on	O
estriol	B
glucuronidation	O
we	O
have	O
added	O
experiments	O
with	O
13-epiestradiol	B
,	O
a	O
synthetic	O
estradiol	B
in	O
which	O
the	O
spatial	O
arrangement	O
of	O
the	O
methyl	B
on	O
C18	O
and	O
the	O
hydroxyl	B
on	O
C17	O
is	O
significantly	O
different	O
than	O
in	O
other	O
estrogens	B
.	O

In	O
comparison	O
with	O
estradiol	B
glucuronidation	O
,	O
the	O
C13	O
configuration	O
change	O
decreases	O
the	O
turnover	O
of	O
UGTs	O
that	O
conjugate	O
the	O
3-OH	B
,	O
but	O
increases	O
it	O
in	O
UGTs	O
that	O
primarily	O
conjugate	O
the	O
17-OH	B
.	O

Unexpectedly	O
,	O
UGT2B17	O
exhibited	O
similar	O
conjugation	O
rates	O
of	O
both	O
the	O
17-OH	B
and	O
3-OH	B
of	O
13-espiestradiol	B
.	O

The	O
combined	O
results	O
reveal	O
the	O
strong	O
preference	O
of	O
UGT1A10	O
for	O
the	O
3-OH	B
of	O
physiologic	O
estrogens	B
and	O
the	O
equivalently	O
strong	O
preference	O
of	O
UGT2B7	O
and	O
UGT2B17	O
for	O
the	O
hydroxyls	B
on	O
ring	O
D	O
of	O
such	O
steroid	B
hormones	I
.	O

A	O
interacts	O
with	O
both	O
the	O
iron	B
center	O
and	O
the	O
porphyrin	B
ring	O
of	O
heme	B
:	O
mechanism	O
of	O
heme	B
's	O
action	O
on	O
A	O
aggregation	O
and	O
disaggregation	O
.	O

Amyloid	O
	O
peptide	O
(	O
A	O
)	O
aggregation	O
is	O
a	O
pathological	O
hallmark	O
of	O
Alzheimer	O
's	O
disease	O
(	O
AD	O
)	O
.	O

Modulation	O
of	O
the	O
self	O
-	O
assembly	O
processes	O
,	O
therefore	O
,	O
is	O
thought	O
to	O
be	O
an	O
attractive	O
strategy	O
for	O
the	O
prevention	O
and	O
treatment	O
of	O
AD	O
.	O

Interestingly	O
,	O
heme	B
has	O
been	O
found	O
to	O
inhibit	O
A	O
aggregation	O
and	O
even	O
dismantle	O
A	O
aggregates	O
.	O

However	O
,	O
the	O
mechanism	O
remains	O
unresolved	O
.	O

Recent	O
research	O
has	O
shown	O
that	O
heme	B
binds	O
preferentially	O
to	O
the	O
His	B
(	O
13	O
)	O
residue	O
of	O
A	O
with	O
the	O
iron	B
center	O
,	O
while	O
the	O
hydrophobic	O
domain	O
of	O
A	O
is	O
also	O
able	O
to	O
bind	O
to	O
heme	B
.	O

Herein	O
,	O
absorption	O
spectrometric	O
,	O
Thioflavin	B
T	I
fluorescence	O
,	O
and	O
circular	O
dichroism	O
spectroscopic	O
and	O
transmission	O
electron	O
microscopic	O
measurements	O
revealed	O
that	O
the	O
iron	B
center	O
is	O
not	O
required	O
for	O
the	O
inhibition	O
of	O
A	O
aggregation	O
but	O
do	O
influence	O
the	O
binding	O
affinity	O
of	O
heme	B
toward	O
A	O
and	O
the	O
dismantlement	O
rate	O
and	O
degree	O
of	O
the	O
A	O
aggregates	O
.	O

By	O
studying	O
the	O
interaction	O
of	O
different	O
truncated	O
or	O
mutated	O
A	O
peptides	O
with	O
heme	B
or	O
protoporphyrin	B
,	O
we	O
further	O
found	O
that	O
the	O
porphyrin	B
ring	O
of	O
heme	B
is	O
implicated	O
to	O
interact	O
preferentially	O
with	O
the	O
Phe	B
(	O
19	O
)	O
residue	O
,	O
facilitating	O
the	O
binding	O
of	O
heme	B
to	O
A	O
and	O
disturbing	O
the	O
interstrand	O
aromatic	O
interaction	O
between	O
the	O
Phe	B
residues	O
,	O
which	O
is	O
crucial	O
for	O
A	O
fibrillation	O
.	O

These	O
findings	O
open	O
new	O
avenues	O
in	O
the	O
understanding	O
of	O
the	O
interaction	O
between	O
the	O
heme	B
and	O
A	O
and	O
the	O
pathways	O
for	O
modulation	O
of	O
A	O
aggregation	O
and	O
disaggregation	O
,	O
which	O
would	O
be	O
helpful	O
in	O
designing	O
therapeutic	O
strategies	O
against	O
AD	O
.	O

Aryl	B
hydrocarbon	I
receptor	O
activation	O
attenuates	O
Per1	O
gene	O
induction	O
and	O
influences	O
circadian	O
clock	O
resetting	O
.	O

Light	O
-	O
stimulated	O
adjustment	O
of	O
the	O
circadian	O
clock	O
is	O
an	O
important	O
adaptive	O
physiological	O
response	O
that	O
allows	O
maintenance	O
of	O
behavioral	O
synchrony	O
with	O
solar	O
time	O
.	O

Our	O
previous	O
studies	O
indicate	O
that	O
the	O
aryl	B
hydrocarbon	I
receptor	O
(	O
AhR	O
)	O
agonist	O
2,3,7,8-	B
tetrachlorodibenzo	I
-	I
p	I
-	I
dioxin	I
attenuates	O
light	O
-	O
induced	O
phase	O
resetting	O
in	O
early	O
night	O
.	O

However	O
,	O
the	O
mechanism	O
of	O
inhibition	O
remains	O
unclear	O
.	O

In	O
this	O
study	O
,	O
we	O
showed	O
that	O
another	O
potent	O
AhR	O
agonist	O
-	O
	B
-	I
naphthoflavone	I
(	O
BNF	B
)	O
-significantly	O
decreased	O
light	O
-	O
induced	O
phase	O
shifts	O
in	O
wild	O
-	O
type	O
(	O
WT	O
)	O
mice	O
,	O
whereas	O
AhR	O
knockout	O
mice	O
had	O
an	O
enhanced	O
response	O
to	O
light	O
that	O
was	O
unaffected	O
by	O
BNF	B
.	O

Mechanistically	O
,	O
BNF	B
blocked	O
light	O
induction	O
of	O
the	O
Per1	O
transcript	O
in	O
suprachiasmatic	O
nucleus	O
and	O
liver	O
in	O
WT	O
mice	O
,	O
and	O
BNF	B
blocked	O
forskolin	B
(	O
FSK	B
)	O
-induced	O
Per1	O
transcripts	O
in	O
Hepa-1c1c7	O
(	O
c7	O
)	O
cells	O
.	O

An	O
E	O
-	O
box	O
decoy	O
did	O
not	O
affect	O
BNF	B
inhibition	O
of	O
FSK	B
-	O
induced	O
Per1	O
transcripts	O
in	O
c7	O
cells	O
.	O

cAMP	B
-	O
response	O
element	O
(	O
CRE	O
)	O
-dependent	O
induction	O
of	O
Per1	O
promoter	O
activity	O
in	O
response	O
to	O
FSK	B
in	O
combination	O
with	O
phorbol	B
12-tetradecanoate	I
13-acetate	I
was	O
suppressed	O
in	O
cells	O
that	O
expressed	O
high	O
levels	O
of	O
AhR	O
(	O
c7	O
)	O
compared	O
with	O
cells	O
lacking	O
functional	O
AhR	O
activity	O
(	O
c12	O
)	O
.	O

In	O
addition	O
,	O
the	O
inhibitory	O
effect	O
of	O
BNF	B
on	O
FSK	B
-	O
induced	O
Per1	O
was	O
dependent	O
on	O
phosphorylation	O
of	O
JNK	O
.	O

Together	O
,	O
these	O
results	O
suggest	O
that	O
AhR	O
activation	O
inhibits	O
light	O
-	O
induced	O
phase	O
resetting	O
through	O
the	O
activation	O
of	O
JNK	O
,	O
negative	O
regulation	O
of	O
CREs	O
in	O
the	O
Per1	O
promoter	O
,	O
and	O
suppression	O
of	O
Per1	O
.	O

Preparation	O
,	O
preliminary	O
screening	O
of	O
new	O
types	O
of	O
steroid	B
conjugates	O
and	O
their	O
activities	O
on	O
steroid	B
receptors	O
.	O

There	O
were	O
synthesized	O
new	O
types	O
of	O
ribbon	O
type	O
steroidal	O
dimers	O
derived	O
from	O
three	O
types	O
of	O
steroidal	O
skeletons	O
(	O
cholic	B
acid	I
,	O
etienic	B
acid	I
,	O
estrone	B
)	O
using	O
Cu	B
(	I
I	I
)	I
catalyzed	O
1	O
,	O
3-dipolar	O
cycloaddition	O
reaction	O
.	O

Steroid	B
parts	O
of	O
the	O
molecular	O
"	O
ribbons	O
"	O
are	O
linked	O
by	O
heterocyclic	O
moiety	O
,	O
namely	O
by	O
2,6-bis	B
(	I
(	I
1H-1,2,3-triazol-1-yl	I
)	I
-methyl	I
)	I
pyridine	I
.	O

Compounds	O
synthesized	O
possess	O
different	O
cytotoxic	O
and	O
hormone	O
receptor	O
modulating	O
activities	O
.	O

Altered	O
matrix	O
mineralization	O
in	O
a	O
case	O
of	O
a	O
sclerosing	O
osteosarcoma	O
.	O

Little	O
is	O
known	O
about	O
the	O
tumor	O
matrix	O
mineralization	O
of	O
highly	O
sclerotic	O
osteosarcoma	O
.	O

We	O
used	O
quantitative	O
backscattered	O
electron	O
imaging	O
(	O
qBEI	O
)	O
to	O
determine	O
the	O
Bone	O
mineralization	O
density	O
distribution	O
(	O
BMDD	O
)	O
of	O
a	O
highly	O
sclerosing	O
osteosarcoma	O
of	O
the	O
proximal	O
tibia	O
as	O
well	O
as	O
adjacent	O
normal	O
bone	O
of	O
a	O
10-year	O
-	O
old	O
girl	O
following	O
chemotherapy	O
according	O
to	O
the	O
EURAMOS-1	O
protocol	O
.	O

Data	O
were	O
compared	O
to	O
recently	O
published	O
normative	O
reference	O
data	O
for	O
young	O
individuals	O
.	O

Backscattered	O
electron	O
imaging	O
of	O
the	O
tumor	O
region	O
revealed	O
a	O
dense	O
accumulation	O
of	O
mineralized	O
tumor	O
bone	O
matrix	O
(	O
up	O
to	O
90	O
%	O
of	O
the	O
medullar	O
space	O
)	O
.	O

The	O
BMDD	O
was	O
shifted	O
tremendously	O
towards	O
higher	O
matrix	O
mineralization	O
(	O
CaMean	O
+	O
18.5	O
%	O
,	O
CaPeak	O
+	O
22.5	O
%	O
,	O
CaHigh	O
+	O
100	O
fold	O
)	O
compared	O
to	O
normal	O
bone	O
.	O

Additionally	O
the	O
BMDD	O
became	O
much	O
wider	O
,	O
indicating	O
a	O
higher	O
heterogeneity	O
in	O
mineralization	O
(	O
CaWidth	O
+	O
40	O
%	O
)	O
.	O

In	O
contrast	O
to	O
lamellar	O
bone	O
,	O
which	O
mineralizes	O
via	O
a	O
mineralization	O
front	O
,	O
the	O
mineralization	O
of	O
the	O
tumor	O
matrix	O
starts	O
by	O
randomly	O
distributed	O
spots	O
of	O
mineral	O
clusters	O
fusing	O
together	O
to	O
a	O
highly	O
mineralized	O
non	O
-	O
lamellar	O
bone	O
matrix	O
.	O

We	O
also	O
found	O
an	O
altered	O
BMDD	O
of	O
the	O
patient	O
's	O
normal	O
bone	O
when	O
compared	O
with	O
the	O
reference	O
BMDD	O
of	O
young	O
individuals	O
.	O

In	O
conclusion	O
this	O
high	O
radiodensity	O
region	O
of	O
the	O
sclerosing	O
sarcoma	O
is	O
not	O
only	O
due	O
to	O
the	O
high	O
amount	O
of	O
tumor	O
matrix	O
but	O
also	O
to	O
its	O
high	O
mineralization	O
density	O
.	O

Chemotherapy	O
may	O
lead	O
to	O
altered	O
matrix	O
mineralization	O
of	O
normal	O
bone	O
due	O
to	O
suppression	O
of	O
bone	O
turnover	O
.	O

The	O
mechanism	O
of	O
matrix	O
mineralization	O
in	O
a	O
sclerosing	O
osteosarcoma	O
warrants	O
further	O
studies	O
.	O

Pregabalin	B
abuse	O
and	O
dependence	O
in	O
Germany	O
:	O
results	O
from	O
a	O
database	O
query	O
.	O

PURPOSE	O
:	O
Pregabalin	B
(	O
PRG	B
)	O
is	O
approved	O
for	O
the	O
treatment	O
of	O
neuropathic	O
pain	O
,	O
partial	O
seizures	O
and	O
generalised	O
anxiety	O
disorder	O
in	O
many	O
countries	O
and	O
currently	O
under	O
study	O
for	O
other	O
indications	O
.	O

Supported	O
by	O
case	O
reports	O
and	O
the	O
results	O
of	O
a	O
limited	O
number	O
of	O
studies	O
there	O
is	O
an	O
ongoing	O
debate	O
on	O
the	O
potential	O
of	O
PRG	B
to	O
cause	O
addictive	O
behaviours	O
.	O

However	O
,	O
currently	O
available	O
evidence	O
on	O
this	O
issue	O
is	O
sparse	O
,	O
and	O
any	O
definitive	O
assessment	O
of	O
PRG	B
's	O
potential	O
for	O
abuse	O
and	O
dependence	O
is	O
not	O
yet	O
in	O
sight	O
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
identify	O
the	O
number	O
of	O
cases	O
of	O
PRG	B
abuse	O
or	O
dependence	O
reported	O
to	O
the	O
database	O
of	O
a	O
German	O
medical	O
regulatory	O
body	O
and	O
to	O
obtain	O
insights	O
into	O
further	O
usage	O
-	O
specific	O
parameters	O
.	O

METHODS	O
:	O
We	O
conducted	O
a	O
query	O
of	O
the	O
entire	O
database	O
of	O
the	O
German	O
Federal	O
Institute	O
for	O
Drugs	O
and	O
Medical	O
Devices	O
(	O
BfArM	O
)	O
regarding	O
reports	O
of	O
PRG	B
abuse	O
or	O
dependence	O
and	O
analysed	O
these	O
cases	O
on	O
the	O
basis	O
of	O
several	O
parameters	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
55	O
reports	O
of	O
PRG	B
abuse	O
or	O
dependence	O
were	O
identified	O
(	O
mean	O
age	O
36	O
years	O
,	O
64	O
%	O
of	O
reports	O
involved	O
males	O
)	O
.	O

The	O
first	O
reports	O
were	O
submitted	O
to	O
BfArM	O
in	O
2008	O
,	O
and	O
the	O
reporting	O
frequency	O
has	O
increased	O
up	O
to	O
the	O
present	O
.	O

Mean	O
daily	O
PRG	B
dosage	O
was	O
1424	O
mg	O
.	O

Current	O
or	O
previous	O
polytoxicomania	O
was	O
present	O
in	O
40	O
and	O
42	O
%	O
of	O
cases	O
,	O
respectively	O
.	O

Psychiatric	O
diagnoses	O
other	O
than	O
substance	O
-	O
related	O
disorders	O
were	O
reported	O
in	O
13	O
(	O
24	O
%	O
)	O
cases	O
.	O

In	O
about	O
one	O
-	O
third	O
of	O
the	O
patients	O
withdrawal	O
syndromes	O
subsequent	O
to	O
discontinuation	O
of	O
PRG	B
were	O
reported	O
.	O

CONCLUSIONS	O
:	O
Cases	O
of	O
PRG	B
abuse	O
or	O
dependence	O
have	O
been	O
reported	O
to	O
the	O
BfArM	O
since	O
2008	O
,	O
with	O
a	O
marked	O
increase	O
of	O
such	O
reports	O
in	O
subsequent	O
years	O
.	O

Male	O
sex	O
and	O
a	O
history	O
of	O
polytoxicomania	O
may	O
be	O
possible	O
risk	O
factors	O
for	O
the	O
development	O
of	O
addictive	O
behaviours	O
related	O
to	O
PRG	B
.	O

Marked	O
decline	O
in	O
beta	O
cell	O
function	O
during	O
pregnancy	O
leads	O
to	O
the	O
development	O
of	O
glucose	B
intolerance	O
in	O
Japanese	O
women	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
investigate	O
glucose	B
metabolism	O
longitudinally	O
during	O
pregnancy	O
to	O
explore	O
mechanisms	O
underlying	O
gestational	O
diabetes	O
mellitus	O
(	O
GDM	O
)	O
.	O

We	O
reviewed	O
a	O
total	O
of	O
62	O
pregnant	O
Japanese	O
women	O
who	O
underwent	O
a	O
75	O
g	O
oral	O
glucose	B
tolerance	O
test	O
(	O
OGTT	O
)	O
twice	O
during	O
pregnancy	O
(	O
median	O
:	O
early	O
,	O
13	O
;	O
late	O
,	O
28	O
weeks	O
'	O
gestation	O
)	O
because	O
of	O
positive	O
GDM	O
screening	O
.	O

All	O
showed	O
normal	O
OGTT	O
results	O
in	O
early	O
pregnancy	O
.	O

Based	O
on	O
late	O
OGTT	O
,	O
15	O
had	O
GDM	O
(	O
late	O
-	O
onset	O
GDM	O
)	O
and	O
47	O
normal	O
glucose	B
tolerance	O
(	O
NGT	O
)	O
.	O

In	O
early	O
pregnancy	O
,	O
there	O
were	O
no	O
significant	O
differences	O
in	O
insulin	O
sensitivity	O
(	O
insulin	O
sensitivity	O
index	O
derived	O
from	O
OGTT	O
[	O
ISOGTT	O
]	O
and	O
homeostasis	O
model	O
assessment	O
for	O
insulin	O
resistance	O
[	O
HOMA	O
-	O
IR	O
]	O
)	O
and	O
insulin	O
secretion	O
(	O
a	O
ratio	O
of	O
the	O
total	O
area	O
-	O
under	O
-	O
the	O
-	O
insulin	O
-	O
curve	O
to	O
the	O
total	O
area	O
-	O
under	O
-	O
the	O
-	O
glucose	B
-	O
curve	O
[	O
AUCins	O
/	O
glu	O
]	O
and	O
insulinogenic	O
index	O
[	O
IGI	O
]	O
)	O
between	O
the	O
NGT	O
and	O
late	O
-	O
onset	O
GDM	O
groups	O
.	O

In	O
each	O
group	O
,	O
insulin	O
sensitivity	O
significantly	O
decreased	O
from	O
early	O
to	O
late	O
pregnancy	O
,	O
most	O
in	O
the	O
late	O
-	O
onset	O
GDM	O
group	O
(	O
each	O
p	O
<	O
0.05	O
)	O
.	O

The	O
insulin	O
secretion	O
showed	O
no	O
significant	O
changes	O
with	O
advancing	O
pregnancy	O
in	O
both	O
of	O
the	O
groups	O
,	O
although	O
late	O
-	O
onset	O
GDM	O
showed	O
significantly	O
lower	O
IGI	O
compared	O
with	O
NGT	O
in	O
late	O
OGTT	O
(	O
p	O
<	O
0.05	O
)	O
.	O

When	O
assessed	O
beta	O
cell	O
function	O
by	O
OGTT	O
-	O
derived	O
disposition	O
index	O
(	O
i.e.	O
Insulin	O
Secretion	O
-	O
Sensitivity	O
Index-2	O
and	O
IGI	O
/	O
fasting	O
insulin	O
)	O
,	O
the	O
indices	O
significantly	O
decreased	O
from	O
early	O
to	O
late	O
pregnancy	O
in	O
the	O
both	O
groups	O
(	O
each	O
p	O
<	O
0.05	O
)	O
.	O

Women	O
with	O
late	O
-	O
onset	O
GDM	O
showed	O
significantly	O
lower	O
indices	O
compared	O
with	O
NGT	O
(	O
each	O
p	O
<	O
0.05	O
)	O
.	O

The	O
failure	O
of	O
beta	O
cell	O
to	O
compensate	O
for	O
decreased	O
insulin	O
sensitivity	O
could	O
contribute	O
to	O
the	O
development	O
of	O
the	O
late	O
-	O
onset	O
GDM	O
.	O

In	O
vitro	O
assessment	O
of	O
drug	O
-	O
drug	O
interaction	O
potential	O
of	O
boceprevir	B
associated	O
with	O
drug	O
metabolizing	O
enzymes	O
and	O
transporters	O
.	O

The	O
inhibitory	O
effect	O
of	O
boceprevir	B
(	O
BOC	B
)	O
,	O
an	O
inhibitor	O
of	O
hepatitis	O
C	O
virus	O
nonstructural	O
protein	O
3	O
protease	O
was	O
evaluated	O
in	O
vitro	O
against	O
a	O
panel	O
of	O
drug	O
-	O
metabolizing	O
enzymes	O
and	O
transporters	O
.	O

BOC	B
,	O
a	O
known	O
substrate	O
for	O
cytochrome	O
P450	O
(	O
P450	O
)	O
CYP3A	O
and	O
aldo	O
-	O
ketoreductases	O
,	O
was	O
a	O
reversible	O
time	O
-	O
dependent	O
inhibitor	O
(	O
k	O
(	O
inact	O
)	O
=	O
0.12	O
minute	O
(	O
-1	O
)	O
,	O
K	O
(	O
I	O
)	O
=	O
6.1	O
M	O
)	O
of	O
CYP3A4	O
/	O
5	O
but	O
not	O
an	O
inhibitor	O
of	O
other	O
major	O
P450s	O
,	O
nor	O
of	O
UDP	B
-	O
glucuronosyltransferases	O
1A1	O
and	O
2B7	O
.	O

BOC	B
showed	O
weak	O
to	O
no	O
inhibition	O
of	O
breast	O
cancer	O
resistance	O
protein	O
(	O
BCRP	O
)	O
,	O
P	O
-	O
glycoprotein	O
(	O
Pgp	O
)	O
,	O
or	O
multidrug	O
resistance	O
protein	O
2	O
.	O

It	O
was	O
a	O
moderate	O
inhibitor	O
of	O
organic	O
anion	O
transporting	O
polypeptide	O
(	O
OATP	O
)	O
1B1	O
and	O
1B3	O
,	O
with	O
an	O
IC	O
(	O
50	O
)	O
of	O
18	O
and	O
4.9	O
M	O
,	O
respectively	O
.	O

In	O
human	O
hepatocytes	O
,	O
BOC	B
inhibited	O
CYP3A	O
-	O
mediated	O
metabolism	O
of	O
midazolam	O
,	O
OATP1B	O
-	O
mediated	O
hepatic	O
uptake	O
of	O
pitavastatin	B
,	O
and	O
both	O
the	O
uptake	O
and	O
metabolism	O
of	O
atorvastatin	B
.	O

The	O
inhibitory	O
potency	O
of	O
BOC	B
was	O
lower	O
than	O
known	O
inhibitors	O
of	O
CYP3A	O
(	O
ketoconazole	B
)	O
,	O
OATP1B	O
(	O
rifampin	B
)	O
,	O
or	O
both	O
(	O
telaprevir	B
)	O
.	O

BOC	B
was	O
a	O
substrate	O
for	O
Pgp	O
and	O
BCRP	O
but	O
not	O
for	O
OATP1B1	O
,	O
OATP1B3	O
,	O
OATP2B1	O
,	O
organic	O
cation	O
transporter	O
,	O
or	O
sodium	B
/	O
taurocholate	B
cotransporting	O
peptide	O
.	O

Overall	O
,	O
our	O
data	O
suggest	O
that	O
BOC	B
has	O
the	O
potential	O
to	O
cause	O
pharmacokinetic	O
interactions	O
via	O
inhibition	O
of	O
CYP3A	O
and	O
CYP3A	O
/	O
OATP1B	O
interplay	O
,	O
with	O
the	O
interaction	O
magnitude	O
lower	O
than	O
those	O
observed	O
with	O
known	O
potent	O
inhibitors	O
.	O

Conversely	O
,	O
pharmacokinetic	O
interactions	O
of	O
BOC	B
,	O
either	O
as	O
a	O
perpetrator	O
or	O
victim	O
,	O
via	O
other	O
major	O
P450s	O
and	O
transporters	O
tested	O
are	O
less	O
likely	O
to	O
be	O
of	O
clinical	O
significance	O
.	O

The	O
results	O
from	O
clinical	O
drug	O
-	O
drug	O
interaction	O
studies	O
conducted	O
thus	O
far	O
are	O
generally	O
supportive	O
of	O
these	O
conclusions	O
.	O

Inhibitors	O
of	O
the	O
Yersinia	O
protein	O
tyrosine	B
phosphatase	O
through	O
high	O
throughput	O
and	O
virtual	O
screening	O
approaches	O
.	O

The	O
bacterial	O
protein	O
tyrosine	B
phosphatase	O
YopH	O
is	O
an	O
essential	O
virulence	O
determinant	O
in	O
Yersinia	O
pestis	O
and	O
a	O
potential	O
antibacterial	O
drug	O
target	O
.	O

Here	O
we	O
report	O
our	O
studies	O
of	O
screening	O
for	O
small	O
molecule	O
inhibitors	O
of	O
YopH	O
using	O
both	O
high	O
throughput	O
and	O
in	O
silico	O
approaches	O
.	O

The	O
identified	O
inhibitors	O
represent	O
a	O
diversity	O
of	O
chemotypes	O
and	O
novel	O
pTyr	O
mimetics	O
,	O
providing	O
a	O
starting	O
point	O
for	O
further	O
development	O
and	O
fragment	O
-	O
based	O
design	O
of	O
multi	O
-	O
site	O
binding	O
inhibitors	O
.	O

We	O
demonstrate	O
that	O
the	O
applications	O
of	O
high	O
throughput	O
and	O
virtual	O
screening	O
,	O
when	O
guided	O
by	O
structural	O
binding	O
mode	O
analysis	O
,	O
is	O
an	O
effective	O
approach	O
for	O
identifying	O
potent	O
and	O
selective	O
inhibitors	O
of	O
YopH	O
and	O
other	O
protein	O
phosphatases	O
for	O
rational	O
drug	O
design	O
.	O

S	B
-	I
nitrosoglutathione	I
covalently	O
modifies	O
cysteine	B
residues	O
of	O
human	O
carbonyl	B
reductase	O
1	O
and	O
affects	O
its	O
activity	O
.	O

Carbonyl	B
reductase	O
1	O
(	O
CBR1	O
or	O
SDR21C1	O
)	O
is	O
a	O
ubiquitously	O
-	O
expressed	O
,	O
cytosolic	O
,	O
monomeric	O
,	O
and	O
NADPH	B
-	O
dependent	O
enzyme	O
.	O

CBR1	O
participates	O
in	O
apoptosis	O
,	O
carcinogenesis	O
and	O
drug	O
resistance	O
,	O
and	O
has	O
a	O
protective	O
role	O
in	O
oxidative	O
stress	O
,	O
cancer	O
and	O
neurodegeneration	O
.	O

S	B
-	I
Nitrosoglutathione	I
(	O
GSNO	B
)	O
represents	O
the	O
newest	O
addition	O
to	O
its	O
diverse	O
substrate	O
spectrum	O
,	O
which	O
includes	O
a	O
wide	O
range	O
of	O
xenobiotics	O
and	O
endogenous	O
substances	O
.	O

GSNO	B
has	O
also	O
been	O
shown	O
to	O
covalently	O
modify	O
and	O
inhibit	O
CBR1	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
quantify	O
and	O
characterize	O
the	O
resulting	O
modifications	O
.	O

Of	O
five	O
candidate	O
cysteines	O
for	O
modification	O
by	O
2	O
mM	O
GSNO	B
(	O
positions	O
26	O
,	O
122	O
,	O
150	O
,	O
226	O
,	O
227	O
)	O
,	O
the	O
last	O
four	O
were	O
analyzed	O
using	O
MALDI	O
-	O
TOF	O
/	O
TOF	O
mass	O
spectrometry	O
and	O
then	O
quantified	O
using	O
the	O
Selected	O
Reaction	O
Monitoring	O
Approach	O
on	O
hyphenated	O
HPLC	O
with	O
a	O
triple	O
quadrupole	O
mass	O
spectrometer	O
.	O

The	O
analysis	O
confirmed	O
GSNO	B
concentration	O
-	O
dependent	O
S	B
-	I
glutathionylation	I
of	O
cysteines	B
at	O
positions	O
122	O
,	O
150	O
,	O
226	O
,	O
227	O
which	O
was	O
2	O
-	O
700	O
times	O
higher	O
compared	O
to	O
wild	O
-	O
type	O
CBR1	O
(	O
WT	O
-	O
CBR1	O
)	O
.	O

Moreover	O
,	O
a	O
disulfide	B
bond	O
between	O
neighboring	O
Cys-226	B
and	O
Cys-227	B
was	O
detected	O
.	O

We	O
suggest	O
a	O
role	O
of	O
these	O
two	O
cysteines	B
as	O
a	O
redox	O
-	O
sensitive	O
cysteine	O
pair	O
.	O

The	O
catalytic	O
properties	O
of	O
wild	O
-	O
type	O
and	O
enzyme	O
modified	O
with	O
2	O
mM	O
GSNO	B
were	O
also	O
investigated	O
by	O
steady	O
state	O
kinetic	O
experiments	O
with	O
various	O
substrates	O
.	O

GSNO	B
treatment	O
of	O
CBR1	O
resulted	O
in	O
a	O
2	O
-	O
5-fold	O
decrease	O
in	O
kcat	O
with	O
menadione	B
,	O
4-benzoylpyridine	B
,	O
2,3-hexanedione	B
,	O
daunorubicin	B
and	O
1,4-naphthoquinone	B
.	O

In	O
contrast	O
,	O
the	O
same	O
treatment	O
increased	O
kcat	O
for	O
substrates	O
containing	O
a	O
1,2-diketo	B
group	O
in	O
a	O
ring	O
structure	O
(	O
1,2-naphthoquinone	B
,	O
9,10-phenanthrenequinone	B
,	O
isatin	B
)	O
.	O

Except	O
for	O
9,10-phenanthrenequinone	B
,	O
all	O
changes	O
in	O
kcat	O
were	O
at	O
least	O
in	O
part	O
compensated	O
for	O
by	O
a	O
similar	O
change	O
in	O
Km	O
,	O
overall	O
yielding	O
no	O
drastic	O
changes	O
in	O
catalytic	O
efficiency	O
.	O

The	O
findings	O
indicate	O
that	O
GSNO	B
-	O
induced	O
covalent	O
modification	O
of	O
cysteine	B
residues	O
affects	O
the	O
kinetic	O
mechanism	O
of	O
CBR1	O
both	O
in	O
terms	O
of	O
substrate	O
binding	O
and	O
turnover	O
rate	O
,	O
probably	O
by	O
covalent	O
modification	O
of	O
Cys-226	B
and/or	O
Cys-227	B
.	O

The	O
antinociceptive	O
effect	O
of	O
milnacipran	B
in	O
the	O
monosodium	B
iodoacetate	I
model	O
of	O
osteoarthritis	O
pain	O
and	O
its	O
relation	O
to	O
changes	O
in	O
descending	O
inhibition	O
.	O

Osteoarthritis	O
(	O
OA	O
)	O
is	O
a	O
chronic	O
joint	O
disorder	O
whose	O
principal	O
symptom	O
is	O
chronic	O
pain	O
.	O

Current	O
analgesics	O
are	O
inadequate	O
and	O
the	O
mechanisms	O
contributing	O
to	O
this	O
pain	O
are	O
poorly	O
understood	O
but	O
likely	O
to	O
include	O
both	O
local	O
joint	O
changes	O
and	O
central	O
consequences	O
.	O

These	O
studies	O
used	O
monoamine	B
receptor	O
agents	O
combined	O
with	O
behavioral	O
studies	O
and	O
single	O
-	O
unit	O
dorsal	O
horn	O
recordings	O
to	O
examine	O
whether	O
descending	O
noradrenergic	O
and	O
serotonergic	O
inhibitions	O
are	O
altered	O
in	O
the	O
monosodium	B
iodoacetate	I
model	O
of	O
OA	O
pain	O
,	O
and	O
whether	O
increasing	O
these	O
inhibitions	O
with	O
the	O
serotonin	B
/	O
noradrenaline	B
reuptake	O
inhibitor	O
milnacipran	B
can	O
attenuate	O
the	O
attendant	O
hypersensitivity	O
.	O

Early	O
and	O
late	O
in	O
the	O
course	O
of	O
this	O
model	O
,	O
milnacipran	B
(	O
s.c	O
.	O
)	O
reduced	O
behavioral	O
hypersensitivity	O
,	O
and	O
inhibited	O
evoked	O
responses	O
from	O
sensitized	O
dorsal	O
horn	O
neurons	O
.	O

In	O
nave	O
animals	O
and	O
the	O
early	O
,	O
but	O
not	O
late	O
,	O
phase	O
of	O
the	O
model	O
,	O
spinal	O
administration	O
of	O
the	O
	O
(	O
2	O
)	O
-adrenoceptor	O
antagonist	O
atipamezole	B
fully	O
reversed	O
this	O
neuronal	O
inhibition	O
,	O
whereas	O
atipamezole	B
administered	O
alone	O
revealed	O
that	O
endogenous	O
noradrenergic	O
inhibition	O
was	O
reduced	O
in	O
the	O
late	O
phase	O
.	O

Blocking	O
spinal	O
5-hydroxytryptamine-7	B
receptors	O
with	O
(	B
2R	I
)	I
-1-	I
[	I
(	I
3-hydroxyphenyl	I
)	I
sulfonyl	I
]	I
-2-	I
[	I
2-	I
(	I
4-methyl-1-piperidinyl	I
)	I
ethyl	I
]	I
pyrrolidine	I
hydrochloride	I
suggested	O
that	O
the	O
effects	O
of	O
milnacipran	B
in	O
the	O
late	O
phase	O
were	O
partly	O
mediated	O
by	O
these	O
receptors	O
,	O
and	O
that	O
descending	O
serotonergic	O
inhibition	O
was	O
increased	O
in	O
this	O
phase	O
.	O

An	O
opioidergic	O
mechanism	O
behind	O
the	O
effects	O
of	O
milnacipran	B
was	O
indicated	O
by	O
a	O
partial	O
reversal	O
of	O
these	O
effects	O
with	O
naloxone	B
.	O

These	O
studies	O
demonstrate	O
antinociceptive	O
effects	O
for	O
milnacipran	B
in	O
a	O
model	O
of	O
OA	O
pain	O
,	O
whose	O
effects	O
come	O
via	O
descending	O
serotonergic	O
and	O
noradrenergic	O
,	O
as	O
well	O
as	O
opioidergic	O
,	O
pathways	O
.	O

Variations	O
in	O
the	O
activity	O
of	O
these	O
pathways	O
over	O
the	O
course	O
of	O
this	O
model	O
may	O
contribute	O
to	O
the	O
presence	O
of	O
behavioral	O
hypersensitivity	O
and	O
determine	O
through	O
which	O
endogenous	O
systems	O
milnacipran	B
exerts	O
its	O
effects	O
.	O

Effects	O
of	O
garlic	O
fractions	O
consumption	O
on	O
male	O
reproductive	O
functions	O
.	O

Many	O
researchers	O
have	O
focused	O
on	O
the	O
preventive	O
and	O
curative	O
effects	O
of	O
garlic	O
(	O
Allium	O
sativum	O
)	O
,	O
particularly	O
on	O
cardiovascular	O
diseases	O
and	O
cancer	O
.	O

However	O
,	O
its	O
impacts	O
on	O
the	O
male	O
reproductive	O
system	O
have	O
not	O
been	O
clearly	O
defined	O
.	O

In	O
this	O
study	O
,	O
the	O
effect	O
of	O
chronic	O
consumption	O
of	O
two	O
garlic	O
fractions	O
was	O
tested	O
:	O
one	O
soluble	O
in	O
water	O
(	O
aqueous	O
solution	O
obtained	O
by	O
grinding	O
and	O
centrifugation	O
)	O
and	O
the	O
other	O
one	O
precipitated	O
by	O
ethanol	B
(	O
alcoholic	O
precipitate	O
obtained	O
by	O
precipitation	O
of	O
the	O
aqueous	O
solution	O
)	O
,	O
on	O
different	O
variables	O
of	O
male	O
rats	O
'	O
reproductive	O
functions	O
.	O

These	O
two	O
fractions	O
were	O
targeted	O
to	O
try	O
to	O
identify	O
the	O
nature	O
of	O
the	O
active	O
garlic	O
compounds	O
responsible	O
for	O
the	O
different	O
modifications	O
observed	O
on	O
testicular	O
parameters	O
.	O

The	O
observation	O
of	O
seminiferous	O
tubules	O
of	O
rats	O
treated	O
with	O
garlic	O
fractions	O
showed	O
an	O
increased	O
number	O
of	O
tubules	O
deprived	O
of	O
spermatozoa	O
.	O

In	O
addition	O
,	O
garlic	O
fractions	O
induced	O
apoptosis	O
of	O
testicular	O
germ	O
cells	O
(	O
TdT	O
-	O
mediated	O
dUTP	B
-	O
X	O
nick	O
-	O
end	O
labeling	O
[	O
TUNEL	O
]	O
approach	O
)	O
and	O
a	O
decrease	O
of	O
serum	O
testosterone	B
levels	O
and	O
seminiferous	O
tubule	O
DNA	O
concentrations	O
.	O

In	O
summary	O
,	O
our	O
histological	O
and	O
molecular	O
results	O
suggest	O
that	O
one	O
or	O
several	O
substances	O
,	O
soluble	O
in	O
water	O
and	O
precipitated	O
by	O
alcohol	B
,	O
impaired	O
spermatogenesis	O
.	O

Essential	O
oils	O
of	O
Thymus	O
leucospermus	O
Hartvig	O
,	O
a	O
Greek	O
endemic	O
rich	O
in	O
phenolic	B
monoterpenes	I
.	O

Thymus	O
leucospermus	O
Hartvig	O
is	O
a	O
Greek	O
endemic	O
species	O
of	O
Section	O
Teucrioides	O
Jalas	O
.	O

The	O
essential	O
oils	O
obtained	O
from	O
five	O
populations	O
growing	O
wild	O
in	O
the	O
National	O
Park	O
of	O
Northern	O
Pindhos	O
(	O
NW	O
Greece	O
)	O
were	O
studied	O
.	O

The	O
oil	O
content	O
ranged	O
between	O
1.1	O
and	O
2.0	O
mL	O
per	O
100	O
g	O
of	O
dry	O
plant	O
weight	O
.	O

The	O
oils	O
were	O
particularly	O
rich	O
in	O
phenolic	B
monoterpenes	I
:	O
they	O
had	O
a	O
high	O
thymol	B
(	O
64.7	O
-	O
92.0	O
%	O
)	O
or	O
carvacrol	B
(	O
93.4	O
%	O
)	O
content	O
,	O
whereas	O
in	O
one	O
of	O
the	O
oils	O
considerable	O
amount	O
of	O
both	O
compounds	O
was	O
found	O
(	O
thymol	B
61.6	O
%	O
and	O
carvacrol	B
26.4	O
%	O
)	O
.	O

Our	O
results	O
show	O
that	O
T.	O
leucospermus	O
is	O
a	O
high	O
-	O
quality	O
thyme	O
species	O
,	O
with	O
respect	O
to	O
both	O
oil	O
content	O
and	O
composition	O
.	O

Systematic	O
literature	O
review	O
of	O
the	O
effects	O
of	O
food	O
and	O
drink	O
advertising	O
on	O
food	O
and	O
drink	O
-	O
related	O
behaviour	O
,	O
attitudes	O
and	O
beliefs	O
in	O
adult	O
populations	O
.	O

A	O
large	O
body	O
of	O
research	O
confirms	O
that	O
food	O
advertising	O
affects	O
the	O
food	O
preferences	O
and	O
behaviour	O
of	O
children	O
.	O

The	O
impact	O
of	O
food	O
advertising	O
on	O
adults	O
is	O
less	O
clear	O
.	O

We	O
conducted	O
a	O
systematic	O
review	O
exploring	O
the	O
effects	O
of	O
advertising	O
of	O
food	O
and	O
non	O
-	O
alcoholic	O
drinks	O
(	O
referred	O
to	O
as	O
'	O
food	O
'	O
throughout	O
)	O
on	O
food	O
-	O
related	O
behaviour	O
,	O
attitudes	O
and	O
beliefs	O
in	O
adult	O
populations	O
.	O

We	O
searched	O
seven	O
electronic	O
databases	O
,	O
grey	O
literature	O
sources	O
,	O
and	O
references	O
and	O
citations	O
of	O
included	O
material	O
for	O
experimental	O
studies	O
written	O
in	O
English	O
investigating	O
the	O
effects	O
of	O
commercial	O
food	O
advertising	O
on	O
the	O
food	O
-	O
related	O
behaviours	O
,	O
attitudes	O
and	O
beliefs	O
of	O
adults	O
aged	O
16	O
years	O
and	O
over	O
.	O

Nine	O
studies	O
,	O
rated	O
moderate	O
to	O
poor	O
quality	O
,	O
were	O
included	O
in	O
the	O
review	O
;	O
all	O
were	O
from	O
developed	O
countries	O
and	O
explored	O
the	O
impact	O
of	O
televised	O
food	O
advertising	O
.	O

Overall	O
,	O
the	O
results	O
did	O
not	O
show	O
conclusively	O
whether	O
or	O
not	O
food	O
advertising	O
affects	O
food	O
-	O
related	O
behaviour	O
,	O
attitudes	O
or	O
beliefs	O
in	O
adults	O
,	O
but	O
suggest	O
that	O
the	O
impact	O
varies	O
inconsistently	O
within	O
subgroups	O
,	O
including	O
gender	O
,	O
weight	O
and	O
existing	O
food	O
psychology	O
.	O

The	O
identification	O
of	O
a	O
small	O
number	O
of	O
relevant	O
studies	O
,	O
none	O
of	O
which	O
were	O
high	O
quality	O
,	O
and	O
with	O
substantial	O
heterogeneity	O
,	O
highlights	O
the	O
need	O
for	O
further	O
research	O
.	O

Future	O
studies	O
investigating	O
longer	O
term	O
outcomes	O
,	O
diverse	O
advertising	O
formats	O
,	O
and	O
in	O
countries	O
with	O
different	O
levels	O
of	O
economic	O
development	O
will	O
be	O
of	O
particular	O
value	O
.	O

Tunable	O
morphology	O
and	O
mesophase	O
formation	O
by	O
naphthalene	B
-	O
containing	O
poly	B
(	I
aryl	I
ether	I
)	I
dendron	O
-	O
based	O
low	O
-	O
molecular	O
-	O
weight	O
fluorescent	O
gels	O
.	O

Novel	O
poly	B
(	I
aryl	I
ether	I
)	I
dendron	O
-	O
based	O
low	O
-	O
molecular	O
-	O
weight	O
organogelaters	O
(	O
LMWG	O
)	O
containing	O
naphthalene	B
units	O
at	O
the	O
core	O
have	O
been	O
synthesized	O
,	O
and	O
the	O
self	O
-	O
assembly	O
of	O
the	O
system	O
has	O
been	O
examined	O
in	O
a	O
variety	O
of	O
solvents	O
and	O
solvent	O
mixtures	O
.	O

The	O
compounds	O
readily	O
form	O
gels	O
with	O
attractive	O
critical	O
gel	O
concentration	O
values	O
associated	O
with	O
gelation	O
-	O
induced	O
enhanced	O
emission	O
(	O
GIEE	O
)	O
.	O

In	O
addition	O
to	O
the	O
remarkable	O
properties	O
of	O
the	O
previously	O
reported	O
anthracene	B
and	O
pyrene	B
analogues	O
(	O
Rajamalli	O
,	O
P.	O
;	O
Prasad	O
,	O
E.	O
Org	O
.	O

Lett.2011	O
,	O
13	O
,	O
3714	O
and	O
Rajamalli	O
,	O
P.	O
;	O
Prasad	O
,	O
E.	O
Soft	O
Matter2012	O
,	O
8	O
,	O
8896	O
)	O
,	O
the	O
self	O
-	O
assembled	O
systems	O
exhibit	O
distinctly	O
different	O
structure	O
-	O
property	O
relationships	O
.	O

Unlike	O
the	O
reported	O
ones	O
,	O
the	O
present	O
system	O
forms	O
sheetlike	O
morphology	O
in	O
nonpolar	O
solvent	O
mixtures	O
,	O
giant	O
vesicles	O
in	O
polar	O
solvent	O
mixtures	O
,	O
and	O
lamellar	O
or	O
hexagonal	O
columnar	O
phases	O
in	O
single	O
solvents	O
.	O

The	O
unique	O
properties	O
of	O
the	O
self	O
-	O
assembled	O
systems	O
,	O
which	O
were	O
analyzed	O
through	O
electron	O
microscopic	O
(	O
SEM	O
,	O
TEM	O
,	O
AFM	O
)	O
and	O
spectroscopic	O
techniques	O
(	O
POM	O
,	O
fluorescence	O
)	O
,	O
are	O
attributed	O
to	O
the	O
replacement	O
of	O
anthracene	B
/	O
pyrene	B
units	O
by	O
naphthalene	B
units	O
.	O

The	O
present	O
work	O
unravels	O
the	O
subtle	O
role	O
of	O
minute	O
structural	O
change	O
in	O
altering	O
the	O
properties	O
of	O
LMWGs	O
based	O
on	O
poly	B
(	I
aryl	I
ether	I
)	I
dendrons	O
.	O

Mechanism	O
of	O
solid	O
state	O
amorphization	O
of	O
glucose	B
upon	O
milling	O
.	O

Crystalline	O
	B
-	I
glucose	I
is	O
known	O
to	O
amorphize	O
upon	O
milling	O
at	O
-15	O
	O
C	O
while	O
it	O
remains	O
structurally	O
invariant	O
upon	O
milling	O
at	O
room	O
temperature	O
.	O

We	O
have	O
taken	O
advantage	O
of	O
this	O
behavior	O
to	O
compare	O
the	O
microstructural	O
evolutions	O
of	O
the	O
material	O
in	O
both	O
conditions	O
in	O
order	O
to	O
identify	O
the	O
essential	O
microstructural	O
features	O
which	O
drive	O
the	O
amorphization	O
process	O
upon	O
milling	O
.	O

The	O
investigations	O
have	O
been	O
performed	O
by	O
differential	O
scanning	O
calorimetry	O
and	O
by	O
powder	O
X	O
-	O
ray	O
diffraction	O
.	O

The	O
results	O
indicate	O
that	O
two	O
different	O
amorphization	O
mechanisms	O
occur	O
upon	O
milling	O
:	O
an	O
amorphization	O
at	O
the	O
surface	O
of	O
crystallites	O
due	O
to	O
the	O
mechanical	O
shocks	O
and	O
a	O
spontaneous	O
amorphization	O
of	O
the	O
crystallites	O
as	O
they	O
reach	O
a	O
critical	O
size	O
,	O
which	O
is	O
close	O
to	O
200	O
	O
in	O
the	O
particular	O
case	O
of	O
	B
-	I
glucose	I
.	O

Novel	O
P2	O
tris	B
-	I
tetrahydrofuran	I
group	O
in	O
antiviral	O
compound	O
1	O
(	O
GRL-0519	B
)	O
fills	O
the	O
S2	O
binding	O
pocket	O
of	O
selected	O
mutants	O
of	O
HIV-1	O
protease	O
.	O

GRL-0519	B
(	O
1	O
)	O
is	O
a	O
potent	O
antiviral	O
inhibitor	O
of	O
HIV-1	O
protease	O
(	O
PR	O
)	O
possessing	O
tris	B
-	I
tetrahydrofuran	I
(	O
tris	B
-	I
THF	I
)	O
at	O
P2	O
.	O

The	O
high	O
resolution	O
X	O
-	O
ray	O
crystal	O
structures	O
of	O
inhibitor	O
1	O
in	O
complexes	O
with	O
single	O
substitution	O
mutants	O
PR	O
(	O
R8Q	O
)	O
,	O
PR	O
(	O
D30N	O
)	O
,	O
PR	O
(	O
I50V	O
)	O
,	O
PR	O
(	O
I54	O
M	O
)	O
,	O
and	O
PR	O
(	O
V82A	O
)	O
were	O
analyzed	O
in	O
relation	O
to	O
kinetic	O
data	O
.	O

The	O
smaller	O
valine	O
side	O
chain	O
in	O
PR	O
(	O
I50V	O
)	O
eliminated	O
hydrophobic	O
interactions	O
with	O
inhibitor	O
and	O
the	O
other	O
subunit	O
consistent	O
with	O
60-fold	O
worse	O
inhibition	O
.	O

Asn30	O
in	O
PR	O
(	O
D30N	O
)	O
showed	O
altered	O
interactions	O
with	O
neighboring	O
residues	O
and	O
18-fold	O
worse	O
inhibition	O
.	O

Mutations	O
V82A	O
and	O
I54	O
M	O
showed	O
compensating	O
structural	O
changes	O
consistent	O
with	O
6	O
-	O
7-fold	O
lower	O
inhibition	O
.	O

Gln8	O
in	O
PR	O
(	O
R8Q	O
)	O
replaced	O
the	O
ionic	O
interactions	O
of	O
wild	O
type	O
Arg8	O
with	O
hydrogen	B
bond	O
interactions	O
without	O
changing	O
the	O
inhibition	O
significantly	O
.	O

The	O
carbonyl	B
oxygen	B
of	O
Gly48	O
showed	O
two	O
alternative	O
conformations	O
in	O
all	O
structures	O
likely	O
due	O
to	O
the	O
snug	O
fit	O
of	O
the	O
large	O
tris	B
-	I
THF	I
group	O
in	O
the	O
S2	O
subsite	O
in	O
agreement	O
with	O
high	O
antiviral	O
efficacy	O
of	O
1	O
on	O
resistant	O
virus	O
.	O

A	O
design	O
of	O
experiments	O
to	O
optimize	O
a	O
new	O
manufacturing	O
process	O
for	O
high	O
activity	O
protein	O
-	O
containing	O
submicron	O
particles	O
.	O

A	O
novel	O
method	O
for	O
the	O
manufacture	O
of	O
protein	O
/	O
peptide	O
-	O
containing	O
submicron	O
particles	O
was	O
developed	O
in	O
an	O
attempt	O
to	O
provide	O
particles	O
with	O
increased	O
activity	O
while	O
using	O
high	O
energy	O
input	O
technologies	O
.	O

The	O
method	O
consists	O
of	O
antisolvent	O
co	O
-	O
precipitation	O
from	O
an	O
aqueous	O
solution	O
containing	O
both	O
an	O
amino	B
acid	I
core	O
material	O
(	O
e.g.	O
D	B
,	I
L	I
-	I
valine	I
)	O
,	O
and	O
either	O
bovine	O
serum	O
albumin	O
(	O
BSA	O
)	O
or	O
lysozyme	O
(	O
Lys	O
)	O
as	O
model	O
proteins	O
.	O

The	O
aqueous	O
solution	O
was	O
added	O
to	O
the	O
organic	O
phase	O
by	O
means	O
of	O
a	O
nebulizer	O
to	O
increase	O
the	O
total	O
surface	O
area	O
of	O
interaction	O
for	O
the	O
precipitation	O
process	O
.	O

Sonication	O
proved	O
to	O
be	O
an	O
effective	O
method	O
to	O
produce	O
small	O
particle	O
sizes	O
while	O
maintaining	O
high	O
activity	O
of	O
Lys	O
.	O

The	O
use	O
of	O
a	O
polysorbate	B
or	O
sorbitan	B
ester	I
derivatives	O
as	O
stabilizers	O
proved	O
to	O
be	O
necessary	O
to	O
yield	O
submicron	O
particles	O
.	O

Particles	O
with	O
very	O
high	O
yields	O
(	O
approximately	O
100	O
%	O
)	O
and	O
very	O
high	O
activity	O
after	O
manufacture	O
(	O
approximately	O
100	O
%	O
)	O
could	O
be	O
obtained	O
.	O

A	O
particle	O
size	O
of	O
439.0	O
nm	O
,	O
with	O
a	O
yield	O
of	O
48.8	O
%	O
and	O
with	O
final	O
remaining	O
activity	O
of98.7	O
%	O
was	O
obtained	O
.	O

By	O
studying	O
various	O
factors	O
using	O
a	O
design	O
of	O
experiments	O
strategy	O
(	O
DoE	O
)	O
we	O
were	O
able	O
to	O
establish	O
the	O
critical	O
controlling	O
factors	O
for	O
this	O
new	O
method	O
of	O
manufacture	O
.	O

A	O
Serum	O
-	O
Tolerant	O
Hydroxyl	B
-	O
Modified	O
Polyethylenimine	B
as	O
Versatile	O
Carriers	O
of	O
pDNA	O
/	O
siRNA	O
.	O

The	O
polyethylenimine	B
(	O
PEI	B
)	O
derivatives	O
(	O
PTn	O
)	O
are	O
prepared	O
by	O
treating	O
PEI25k	O
with	O
Tris	B
(	I
hydroxymethyl	I
)	I
acrylamidomethane	I
via	O
the	O
Michael	O
addition	O
.	O

These	O
PTns	O
can	O
effectively	O
condense	O
nucleic	O
acids	O
into	O
nanosized	O
particles	O
with	O
positive	O
surface	O
charges	O
.	O

The	O
PTns	O
show	O
lower	O
cytotoxicity	O
and	O
better	O
serum	O
-	O
resistant	O
capacity	O
than	O
PEI25k	O
.	O

Specially	O
,	O
the	O
transfection	O
efficiency	O
of	O
PT26	O
/	O
DNA	O
is	O
29-fold	O
higher	O
than	O
that	O
of	O
PEI25k	O
in	O
HeLa	O
cells	O
in	O
serum	O
-	O
containing	O
medium	O
.	O

The	O
PTn	O
/	O
siRNA	O
complexes	O
show	O
superior	O
knockdown	O
effect	O
in	O
CT26	O
cells	O
in	O
serum	O
-	O
containing	O
medium	O
.	O

In	O
addition	O
,	O
flow	O
cytometry	O
analysis	O
shows	O
that	O
the	O
PTns	O
can	O
efficiently	O
mediate	O
the	O
entry	O
of	O
nucleic	O
acids	O
into	O
the	O
cell	O
.	O

Thus	O
,	O
PTns	O
are	O
potentially	O
applicable	O
as	O
non	O
-	O
viral	O
carriers	O
of	O
nucleic	O
acids	O
and	O
warrant	O
further	O
development	O
for	O
use	O
in	O
gene	O
therapy	O
.	O

Sociocultural	O
behavior	O
,	O
sex	O
-	O
biased	O
admixture	O
,	O
and	O
effective	O
population	O
sizes	O
in	O
Central	O
African	O
Pygmies	O
and	O
non	O
-	O
Pygmies	O
.	O

Sociocultural	O
phenomena	O
,	O
such	O
as	O
exogamy	O
or	O
phylopatry	O
,	O
can	O
largely	O
determine	O
human	O
sex	O
-	O
specific	O
demography	O
.	O

In	O
Central	O
Africa	O
,	O
diverging	O
patterns	O
of	O
sex	O
-	O
specific	O
genetic	O
variation	O
have	O
been	O
observed	O
between	O
mobile	O
hunter	O
-	O
gatherer	O
Pygmies	O
and	O
sedentary	O
agricultural	O
non	O
-	O
Pygmies	O
.	O

However	O
,	O
their	O
sex	O
-	O
specific	O
demography	O
remains	O
largely	O
unknown	O
.	O

Using	O
population	O
genetics	O
and	O
approximate	O
Bayesian	O
computation	O
approaches	O
,	O
we	O
inferred	O
male	O
and	O
female	O
effective	O
population	O
sizes	O
,	O
sex	O
-	O
specific	O
migration	O
,	O
and	O
admixture	O
rates	O
in	O
23	O
Central	O
African	O
Pygmy	O
and	O
non	O
-	O
Pygmy	O
populations	O
,	O
genotyped	O
for	O
autosomal	O
,	O
X	O
-	O
linked	O
,	O
Y	O
-	O
linked	O
,	O
and	O
mitochondrial	O
markers	O
.	O

We	O
found	O
much	O
larger	O
effective	O
population	O
sizes	O
and	O
migration	O
rates	O
among	O
non	O
-	O
Pygmy	O
populations	O
than	O
among	O
Pygmies	O
,	O
in	O
agreement	O
with	O
the	O
recent	O
expansions	O
and	O
migrations	O
of	O
non	O
-	O
Pygmies	O
and	O
,	O
conversely	O
,	O
the	O
isolation	O
and	O
stationary	O
demography	O
of	O
Pygmy	O
groups	O
.	O

We	O
found	O
larger	O
effective	O
sizes	O
and	O
migration	O
rates	O
for	O
males	O
than	O
for	O
females	O
for	O
Pygmies	O
,	O
and	O
vice	O
versa	O
for	O
non	O
-	O
Pygmies	O
.	O

Thus	O
,	O
although	O
most	O
Pygmy	O
populations	O
have	O
patrilocal	O
customs	O
,	O
their	O
sex	O
-	O
specific	O
genetic	O
patterns	O
resemble	O
those	O
of	O
matrilocal	O
populations	O
.	O

In	O
fact	O
,	O
our	O
results	O
are	O
consistent	O
with	O
a	O
lower	O
prevalence	O
of	O
polygyny	O
and	O
patrilocality	O
in	O
Pygmies	O
compared	O
with	O
non	O
-	O
Pygmies	O
and	O
a	O
potential	O
female	O
transmission	O
of	O
reproductive	O
success	O
in	O
Pygmies	O
.	O

Finally	O
,	O
Pygmy	O
populations	O
showed	O
variable	O
admixture	O
levels	O
with	O
the	O
non	O
-	O
Pygmies	O
,	O
with	O
often	O
much	O
larger	O
introgression	O
from	O
male	O
than	O
from	O
female	O
lineages	O
.	O

Social	O
discrimination	O
against	O
Pygmies	O
triggering	O
complex	O
movements	O
of	O
spouses	O
in	O
intermarriages	O
can	O
explain	O
these	O
male	O
-	O
biased	O
admixture	O
patterns	O
in	O
a	O
patrilocal	O
context	O
.	O

We	O
show	O
how	O
gender	O
-	O
related	O
sociocultural	O
phenomena	O
can	O
determine	O
highly	O
variable	O
sex	O
-	O
specific	O
demography	O
among	O
populations	O
,	O
and	O
how	O
population	O
genetic	O
approaches	O
contrasting	O
chromosomal	O
types	O
allow	O
inferring	O
detailed	O
human	O
sex	O
-	O
specific	O
demographic	O
history	O
.	O

Lower	O
Adiponectin	O
Levels	O
at	O
First	O
Trimester	O
of	O
Pregnancy	O
Are	O
Associated	O
With	O
Increased	O
Insulin	O
Resistance	O
and	O
Higher	O
Risk	O
of	O
Developing	O
Gestational	O
Diabetes	O
Mellitus	O
.	O

OBJECTIVETo	O
evaluate	O
the	O
associations	O
between	O
adiponectin	O
levels	O
and	O
1	O
)	O
the	O
risk	O
of	O
developing	O
gestational	O
diabetes	O
mellitus	O
(	O
GDM	O
)	O
,	O
and	O
2	O
)	O
insulin	O
resistance	O
/	O
sensitivity	O
,	O
	O
-	O
cell	O
function	O
,	O
and	O
compensation	O
indices	O
in	O
a	O
prospective	O
cohort	O
representative	O
of	O
the	O
general	O
population	O
of	O
pregnant	O
women	O
.	O

RESEARCH	O
DESIGN	O
AND	O
METHODSWe	O
performed	O
anthropometric	O
measurements	O
and	O
collected	O
blood	O
samples	O
at	O
1st	O
(	O
6	O
-	O
13	O
weeks	O
)	O
and	O
2nd	O
(	O
24	O
-	O
28	O
weeks	O
)	O
trimesters	O
.	O

Diagnosis	O
of	O
GDM	O
was	O
made	O
at	O
2nd	O
trimester	O
,	O
based	O
on	O
a	O
75-g	O
oral	O
glucose	B
tolerance	O
test	O
(	O
International	O
Association	O
of	O
Diabetes	O
and	O
Pregnancy	O
Study	O
Group	O
criteria	O
)	O
.	O

Insulin	O
was	O
measured	O
(	O
ELISA	O
;	O
Luminex	O
)	O
to	O
estimate	O
homeostasis	O
model	O
assessment	O
of	O
insulin	O
resistance	O
(	O
HOMA	O
-	O
IR	O
)	O
,	O
	O
-	O
cell	O
function	O
(	O
HOMA	O
-	O
B	O
)	O
,	O
insulin	O
sensitivity	O
(	O
Matsuda	O
index	O
)	O
,	O
insulin	O
secretion	O
(	O
AUC	O
(	O
insulin	O
/	O
glucose	B
)	O
)	O
,	O
and	O
	O
-	O
cell	O
compensation	O
(	O
insulin	O
secretion	O
sensitivity	O
index-2	O
)	O
.	O

Adiponectin	O
was	O
measured	O
by	O
radioimmunoassay	O
.	O

RESULTSAmong	O
the	O
445	O
participants	O
included	O
in	O
this	O
study	O
,	O
38	O
women	O
developed	O
GDM	O
.	O

Women	O
who	O
developed	O
GDM	O
had	O
lower	O
1st	O
-	O
trimester	O
adiponectin	O
levels	O
(	O
9.67	O
	O
3.84	O
vs.	O
11.92	O
	O
4.59	O
g	O
/	O
mL	O
in	O
women	O
with	O
normal	O
glucose	B
tolerance	O
)	O
.	O

Lower	O
adiponectin	O
levels	O
were	O
associated	O
with	O
higher	O
risk	O
of	O
developing	O
GDM	O
(	O
OR	O
,	O
1.12	O
per	O
1	O
g	O
/	O
mL	O
decrease	O
of	O
adiponectin	O
levels	O
;	O
P	O
=	O
0.02	O
,	O
adjusted	O
for	O
BMI	O
and	O
HbA	O
(	O
1c	O
)	O
at	O
1st	O
trimester	O
)	O
.	O

Adiponectin	O
levels	O
at	O
1st	O
and	O
2nd	O
trimesters	O
were	O
associated	O
with	O
HOMA	O
-	O
IR	O
(	O
both	O
:	O
r	O
=	O
-0.22	O
,	O
P	O
<	O
0.0001	O
)	O
and	O
Matsuda	O
index	O
(	O
r	O
=	O
0.28	O
,	O
P	O
<	O
0.0001	O
,	O
and	O
r	O
=	O
0.29	O
,	O
P	O
<	O
0.0001	O
)	O
.	O

After	O
adjustment	O
for	O
confounding	O
factors	O
,	O
we	O
found	O
no	O
significant	O
association	O
with	O
HOMA	O
-	O
B	O
and	O
AUC	O
(	O
insulin	O
/	O
glucose	B
)	O
.CONCLUSIONSPregnant	O
women	O
with	O
lower	O
adiponectin	O
levels	O
at	O
1st	O
trimester	O
have	O
higher	O
levels	O
of	O
insulin	O
resistance	O
and	O
are	O
more	O
likely	O
to	O
develop	O
GDM	O
independently	O
of	O
adiposity	O
or	O
glycemic	O
measurements	O
.	O

Nanoparticle	O
adhesion	O
to	O
the	O
cell	O
membrane	O
and	O
its	O
effect	O
on	O
nanoparticle	O
uptake	O
efficiency	O
.	O

The	O
interactions	O
between	O
nanosized	O
particles	O
and	O
living	O
systems	O
are	O
commonly	O
mediated	O
by	O
what	O
adsorbs	O
to	O
the	O
nanoparticle	O
in	O
the	O
biological	O
environment	O
,	O
its	O
biomolecular	O
corona	O
,	O
rather	O
than	O
the	O
pristine	O
surface	O
.	O

Here	O
,	O
we	O
characterize	O
the	O
adhesion	O
toward	O
the	O
cell	O
membrane	O
of	O
nanoparticles	O
of	O
different	O
material	O
and	O
size	O
and	O
study	O
how	O
this	O
is	O
modulated	O
by	O
the	O
presence	O
or	O
absence	O
of	O
a	O
corona	O
on	O
the	O
nanoparticle	O
surface	O
.	O

The	O
results	O
are	O
corroborated	O
with	O
adsorption	O
to	O
simple	O
model	O
supported	O
lipid	O
bilayers	O
using	O
a	O
quartz	B
crystal	O
microbalance	O
.	O

We	O
conclude	O
that	O
the	O
adsorption	O
of	O
proteins	O
on	O
the	O
nanoparticle	O
surface	O
strongly	O
reduces	O
nanoparticle	O
adhesion	O
in	O
comparison	O
to	O
what	O
is	O
observed	O
for	O
the	O
bare	O
material	O
.	O

Nanoparticle	O
uptake	O
is	O
described	O
as	O
a	O
two	O
-	O
step	O
process	O
,	O
where	O
the	O
nanoparticles	O
initially	O
adhere	O
to	O
the	O
cell	O
membrane	O
and	O
subsequently	O
are	O
internalized	O
by	O
the	O
cells	O
via	O
energy	O
-	O
dependent	O
pathways	O
.	O

The	O
lowered	O
adhesion	O
in	O
the	O
presence	O
of	O
proteins	O
thereby	O
causes	O
a	O
concomitant	O
decrease	O
in	O
nanoparticle	O
uptake	O
efficiency	O
.	O

The	O
presence	O
of	O
a	O
biomolecular	O
corona	O
may	O
confer	O
specific	O
interactions	O
between	O
the	O
nanoparticle	O
-	O
corona	O
complex	O
and	O
the	O
cell	O
surface	O
including	O
triggering	O
of	O
regulated	O
cell	O
uptake	O
.	O

An	O
important	O
effect	O
of	O
the	O
corona	O
is	O
,	O
however	O
,	O
a	O
reduction	O
in	O
the	O
purely	O
unspecific	O
interactions	O
between	O
the	O
bare	O
material	O
and	O
the	O
cell	O
membrane	O
,	O
which	O
in	O
itself	O
disregarding	O
specific	O
interactions	O
,	O
causes	O
a	O
decrease	O
in	O
cellular	O
uptake	O
.	O

We	O
suggest	O
that	O
future	O
nanoparticle	O
-	O
cell	O
studies	O
include	O
,	O
together	O
with	O
characterization	O
of	O
size	O
,	O
charge	O
,	O
and	O
dispersion	O
stability	O
,	O
an	O
evaluation	O
of	O
the	O
adhesion	O
properties	O
of	O
the	O
material	O
to	O
relevant	O
membranes	O
.	O

Aminoalkyl	B
derivatives	O
of	O
guanidine	B
diaromatic	O
minor	O
groove	O
binders	O
with	O
antiprotozoal	O
activity	O
.	O

Considering	O
the	O
strong	O
DNA	O
minor	O
groove	O
binding	O
observed	O
for	O
our	O
previous	O
series	O
of	O
diaromatic	O
symmetric	O
and	O
asymmetric	O
guanidinium	B
and	O
2-aminoimidazolinium	B
derivatives	O
,	O
we	O
report	O
now	O
the	O
synthesis	O
of	O
new	O
aminoalkyl	B
derivatives	O
of	O
diaromatic	O
guanidines	O
with	O
potential	O
as	O
DNA	O
minor	O
groove	O
binders	O
and	O
antiprotozoal	O
activity	O
.	O

The	O
preparation	O
of	O
these	O
aminoalkyl	B
derivatives	O
(	O
12a	O
-	O
e	O
,	O
13a	O
-	O
e	O
,	O
14a	O
-	O
c	O
,	O
e	O
,	O
15a	O
-	O
e	O
,	O
16a	O
-	O
e	O
)	O
is	O
presented	O
as	O
well	O
as	O
their	O
affinity	O
for	O
DNA	O
which	O
was	O
evaluated	O
by	O
means	O
of	O
DNA	O
thermal	O
denaturation	O
experiments	O
.	O

Finally	O
,	O
the	O
antiprotozoal	O
activity	O
of	O
most	O
of	O
these	O
aminoalkyl	B
minor	O
groove	O
binders	O
was	O
evaluated	O
in	O
vitro	O
against	O
Trypanosoma	O
brucei	O
rhodesiense	O
(	O
8	O
compounds	O
)	O
and	O
Plasmodium	O
falciparum	O
(	O
18	O
compounds	O
)	O
.	O

The	O
O	O
-	O
linked	O
derivatives	O
13c	O
and	O
14c	O
showed	O
100	O
nM	O
activities	O
against	O
P.	O
falciparum	O
,	O
whereas	O
for	O
T.	O
b.	O
rhodesiense	O
all	O
compounds	O
tested	O
showed	O
micromolar	O
activity	O
.	O

Some	O
of	O
the	O
derivatives	O
prepared	O
seem	O
to	O
exert	O
the	O
antimalarial	O
activity	O
by	O
binding	O
to	O
the	O
DNA	O
minor	O
groove	O
whereas	O
other	O
sets	O
of	O
compounds	O
could	O
exert	O
this	O
antimalarial	O
activity	O
by	O
inhibiting	O
the	O
parasite	O
dihydrofolate	B
reductase	O
,	O
for	O
example	O
.	O

A	O
powerful	O
aluminum	B
catalyst	O
for	O
the	O
synthesis	O
of	O
highly	O
functional	O
organic	B
carbonates	I
.	O

An	O
aluminum	B
complex	O
based	O
on	O
an	O
amino	B
triphenolate	I
ligand	O
scaffold	O
shows	O
unprecedented	O
high	O
activity	O
(	O
initial	O
TOFs	O
up	O
to	O
36,000	O
h	O
(	O
-1	O
)	O
)	O
,	O
broad	O
substrate	O
scope	O
,	O
and	O
functional	O
group	O
tolerance	O
in	O
the	O
formation	O
of	O
highly	O
functional	O
organic	B
carbonates	I
prepared	O
from	O
epoxides	B
and	O
CO	B
(	I
2	I
)	I
.	O

The	O
developed	O
catalytic	O
protocol	O
is	O
further	O
characterized	O
by	O
low	O
catalyst	O
loadings	O
and	O
relative	O
mild	O
reaction	O
conditions	O
using	O
a	O
cheap	O
,	O
abundant	O
,	O
and	O
nontoxic	O
metal	O
.	O

Lactobacillus	O
johnsonii	O
inhibits	O
indoleamine	B
2,3-dioxygenase	O
and	O
alters	O
tryptophan	B
metabolite	O
levels	O
in	O
BioBreeding	O
rats	O
.	O

In	O
our	O
previous	O
work	O
,	O
we	O
found	O
that	O
feeding	O
Lactobacillus	O
johnsonii	O
to	O
BioBreeding	O
diabetes	O
-	O
prone	O
(	O
BBDP	O
)	O
rats	O
decreased	O
the	O
incidence	O
of	O
diabetes	O
development	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
host	O
pathways	O
affected	O
by	O
L.	O
johnsonii	O
,	O
with	O
specific	O
focus	O
on	O
the	O
rate	O
-	O
limiting	O
enzyme	O
of	O
tryptophan	B
catabolism	O
,	O
indoleamine	B
2,3-dioxygenase	O
(	O
IDO	O
)	O
.	O

Suspensions	O
of	O
L.	O
johnsonii	O
or	O
an	O
equal	O
volume	O
of	O
vehicle	O
were	O
orally	O
administered	O
to	O
BBDP	O
rats	O
.	O

Tissue	O
IDO	O
was	O
investigated	O
using	O
quantitative	O
RT	O
-	O
PCR	O
and	O
Western	O
blot	O
,	O
whereas	O
tryptophan	B
,	O
kynurenine	B
,	O
and	O
5-hydroxytryptamine	B
(	O
5-HT	B
)	O
concentrations	O
were	O
quantified	O
by	O
HPLC	O
and	O
ELISA	O
.	O

IDO	O
activity	O
was	O
also	O
investigated	O
using	O
L.	O
johnsonii	O
culture	O
cell	O
-	O
free	O
supernatant	O
(	O
CFS	O
)	O
with	O
affinity	O
-	O
purified	O
IDO	O
and	O
HT-29	O
intestinal	O
epithelial	O
cells	O
.	O

L.	O
johnsonii	O
feeding	O
resulted	O
in	O
a	O
17	O
%	O
reduction	O
in	O
serum	O
kynurenine	B
compared	O
with	O
that	O
in	O
vehicle	O
-	O
fed	O
controls	O
,	O
correlating	O
with	O
a	O
1.4-fold	O
elevation	O
in	O
5-HT	B
levels	O
.	O

H2O2	B
produced	O
by	O
L.	O
johnsonii	O
abolished	O
IDO	O
activity	O
in	O
vitro	O
,	O
and	O
L.	O
johnsonii	O
feeding	O
resulted	O
in	O
a	O
3.9-fold	O
increase	O
in	O
ileum	O
lumen	O
H2O2	B
.	O

L.	O
johnsonii	O
CFS	O
significantly	O
reduced	O
IDO	O
activity	O
in	O
HT-29	O
intestinal	O
epithelial	O
cells	O
(	O
47	O
%	O
reduction	O
)	O
compared	O
with	O
that	O
in	O
vehicle	O
-	O
treated	O
controls	O
,	O
an	O
effect	O
abolished	O
by	O
catalase	O
treatment	O
.	O

These	O
data	O
support	O
the	O
role	O
of	O
H2O2	B
in	O
commensal	O
bacteria	O
-	O
host	O
interactions	O
and	O
highlight	O
the	O
influence	O
of	O
commensal	O
bacteria	O
-	O
derived	O
H2O2	B
on	O
host	O
physiology	O
.-	O
Valladares	O
,	O
R.	O
,	O
Bojilova	O
,	O
L.	O
,	O
Potts	O
,	O
A.	O
H.	O
,	O
Cameron	O
,	O
E.	O
,	O
Gardner	O
,	O
C.	O
,	O
Lorca	O
,	O
G.	O
,	O
Gonzalez	O
,	O
C.	O
F.	O
Lactobacillus	O
johnsonii	O
inhibits	O
indoleamine	B
2,3-dioxygenase	O
and	O
alters	O
tryptophan	B
metabolite	O
levels	O
in	O
BioBreeding	O
rats	O
.	O

Roughening	O
of	O
Pt	B
nanoparticles	O
induced	O
by	O
surface	O
-	O
oxide	B
formation	O
.	O

Using	O
density	O
functional	O
theory	O
(	O
DFT	O
)	O
and	O
thermodynamic	O
considerations	O
we	O
studied	O
the	O
equilibrium	O
shape	O
of	O
Pt	B
nanoparticles	O
(	O
NPs	O
)	O
under	O
electrochemical	O
conditions	O
.	O

We	O
found	O
that	O
at	O
very	O
high	O
oxygen	B
coverage	O
,	O
obtained	O
at	O
high	O
electrode	O
potentials	O
,	O
the	O
experimentally	O
-	O
observed	O
tetrahexahedral	O
(	O
THH	O
)	O
NPs	O
consist	O
of	O
high	O
-	O
index	O
(	O
520	O
)	O
faces	O
.	O

Since	O
high	O
-	O
index	O
surfaces	O
often	O
show	O
higher	O
(	O
electro-	O
)	O
chemical	O
activity	O
in	O
comparison	O
to	O
their	O
close	O
-	O
packed	O
counterparts	O
,	O
the	O
THH	O
NPs	O
can	O
be	O
promising	O
candidates	O
for	O
various	O
(	O
electro-	O
)	O
catalytic	O
applications	O
.	O

Sample	O
solution	O
constraints	O
on	O
motor	O
-	O
driven	O
diagnostic	O
nanodevices	O
.	O

The	O
last	O
decade	O
has	O
seen	O
appreciable	O
advancements	O
in	O
efforts	O
towards	O
increased	O
portability	O
of	O
lab	O
-	O
on	O
-	O
a	O
-	O
chip	O
devices	O
by	O
substituting	O
microfluidics	O
with	O
molecular	O
motor	O
-	O
based	O
transportation	O
.	O

As	O
of	O
now	O
,	O
first	O
proof	O
-	O
of	O
-	O
principle	O
devices	O
have	O
analyzed	O
protein	O
mixtures	O
of	O
low	O
complexity	O
,	O
such	O
as	O
target	O
protein	O
molecules	O
in	O
buffer	O
solutions	O
optimized	O
for	O
molecular	O
motor	O
performance	O
.	O

However	O
,	O
in	O
a	O
diagnostic	O
work	O
-	O
up	O
,	O
lab	O
-	O
on	O
-	O
a	O
-	O
chip	O
devices	O
need	O
to	O
be	O
compatible	O
with	O
complex	O
biological	O
samples	O
.	O

While	O
it	O
has	O
been	O
shown	O
that	O
such	O
samples	O
do	O
not	O
interfere	O
with	O
crucial	O
steps	O
in	O
molecular	O
diagnostics	O
(	O
for	O
example	O
antibody	O
-	O
antigen	O
recognition	O
)	O
,	O
their	O
effect	O
on	O
molecular	O
motors	O
is	O
unknown	O
.	O

This	O
critical	O
and	O
long	O
overlooked	O
issue	O
is	O
addressed	O
here	O
.	O

In	O
particular	O
,	O
we	O
studied	O
the	O
effects	O
of	O
blood	O
,	O
cell	O
lysates	O
and	O
solutions	O
containing	O
genomic	O
DNA	O
extracts	O
on	O
actomyosin	O
and	O
kinesin	O
-	O
microtubule	O
-	O
based	O
transport	O
,	O
the	O
two	O
biomolecular	O
motor	O
systems	O
that	O
are	O
most	O
promising	O
for	O
lab	O
-	O
on	O
-	O
a	O
-	O
chip	O
applications	O
.	O

We	O
found	O
that	O
motor	O
function	O
is	O
well	O
preserved	O
at	O
defined	O
dilutions	O
of	O
most	O
of	O
the	O
investigated	O
biological	O
samples	O
and	O
demonstrated	O
a	O
molecular	O
motor	O
-	O
driven	O
label	O
-	O
free	O
blood	O
type	O
test	O
.	O

Our	O
results	O
support	O
the	O
feasibility	O
of	O
molecular	O
-	O
motor	O
driven	O
nanodevices	O
for	O
diagnostic	O
point	O
-	O
of	O
-	O
care	O
applications	O
and	O
also	O
demonstrate	O
important	O
constraints	O
imposed	O
by	O
sample	O
composition	O
and	O
device	O
design	O
that	O
apply	O
both	O
to	O
kinesin	O
-	O
microtubule	O
and	O
actomyosin	O
driven	O
applications	O
.	O

Enhancing	O
catalytic	O
selectivity	O
of	O
supported	O
metal	O
nanoparticles	O
with	O
capping	O
ligands	O
.	O

Enhancing	O
catalytic	O
selectivity	O
of	O
supported	O
metal	O
nanoparticles	O
with	O
capping	O
ligands	O
is	O
demonstrated	O
using	O
an	O
Au	B
/	O
SiO	B
(	I
2	I
)	I
catalyst	O
in	O
liquid	O
phase	O
aerobic	O
oxidation	O
of	O
benzyl	B
alcohol	I
.	O

Chemisorption	O
of	O
an	O
appropriate	O
amount	O
of	O
polyvinylpyrrolidone	B
on	O
the	O
Au	B
/	O
SiO	B
(	I
2	I
)	I
catalyst	O
greatly	O
enhances	O
the	O
benzaldehyde	B
selectivity	O
from	O
43	O
%	O
to	O
~100	O
%	O
and	O
its	O
yield	O
from	O
4.9	O
%	O
to	O
7.2	O
%	O
.	O

Voltage	O
tuning	O
of	O
ferromagnetic	O
resonance	O
with	O
bistable	O
magnetization	O
switching	O
in	O
energy	O
-	O
efficient	O
magnetoelectric	O
composites	O
.	O

Dual	O
E-	O
and	O
H	O
-	O
field	O
control	O
of	O
microwave	O
performance	O
with	O
enhanced	O
ferromagnetic	O
resonance	O
(	O
FMR	O
)	O
tunability	O
has	O
been	O
demonstrated	O
in	O
microwave	O
composites	O
FeGaB	B
/	O
PZN	B
-	I
PT	I
(	O
011	O
)	O
.	O

A	O
voltage	O
-	O
impulse	O
-	O
induced	O
non	O
-	O
volatile	O
magnetization	O
switching	O
was	O
also	O
realized	O
in	O
this	O
work	O
,	O
resulting	O
from	O
the	O
hysteretic	O
type	O
of	O
phase	O
transition	O
in	O
PZN	B
-	I
PT	I
(	O
011	O
)	O
at	O
high	O
electric	O
fields	O
.	O

The	O
results	O
provide	O
a	O
framework	O
for	O
developing	O
lightweight	O
,	O
energy	O
efficient	O
,	O
voltage	O
-	O
tunable	O
RF	O
/	O
microwave	O
devices	O
.	O

Identification	O
of	O
aldo	O
-	O
keto	O
reductases	O
as	O
NRF2-target	O
marker	O
genes	O
in	O
human	O
cells	O
.	O

Transcription	O
factor	O
NF	O
-	O
E2-related	O
factor	O
2	O
(	O
NRF2	O
)	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
cellular	O
defense	O
against	O
oxidative	O
/	O
electrophilic	O
stress	O
by	O
up	O
-	O
regulating	O
multiple	O
antioxidant	O
genes	O
.	O

Numerous	O
studies	O
with	O
genetically	O
modified	O
animals	O
have	O
demonstrated	O
that	O
Nrf2	O
is	O
a	O
sensitivity	O
determining	O
factor	O
upon	O
the	O
exposure	O
to	O
environmental	O
chemicals	O
including	O
carcinogens	O
.	O

Moreover	O
,	O
recent	O
studies	O
have	O
demonstrated	O
that	O
polymorphism	O
in	O
the	O
human	O
NRF2	O
promoter	O
is	O
associated	O
with	O
higher	O
risks	O
for	O
developing	O
acute	O
lung	O
injury	O
,	O
gastric	O
mucosal	O
inflammation	O
,	O
and	O
nephritis	O
.	O

Therefore	O
,	O
the	O
identification	O
of	O
reliable	O
and	O
effective	O
human	O
target	O
genes	O
of	O
NRF2	O
may	O
allow	O
the	O
monitoring	O
of	O
NRF2	O
activity	O
and	O
to	O
predict	O
individual	O
sensitivity	O
to	O
environmental	O
stress	O
-	O
induced	O
damage	O
.	O

For	O
this	O
purpose	O
,	O
we	O
investigated	O
genes	O
that	O
are	O
tightly	O
controlled	O
by	O
NRF2	O
to	O
establish	O
markers	O
for	O
NRF2	O
activity	O
in	O
human	O
cells	O
.	O

Firstly	O
,	O
in	O
the	O
normal	O
human	O
renal	O
epithelial	O
HK-2	O
cells	O
,	O
the	O
measurement	O
of	O
the	O
expression	O
of	O
30	O
previously	O
reported	O
NRF2	O
target	O
genes	O
in	O
response	O
to	O
NRF2	O
inducers	O
(	O
sulforaphane	B
,	O
tert	B
-	I
butylhydroquinone	I
,	O
cinnamic	B
aldehyde	I
,	O
and	O
hydrogen	B
peroxide	I
)	O
showed	O
that	O
the	O
aldo	O
-	O
keto	O
reductase	O
(	O
AKR	O
)	O
1C1	O
is	O
highly	O
inducible	O
by	O
all	O
treatments	O
.	O

Accordantly	O
,	O
the	O
basal	O
and	O
inducible	O
expressions	O
of	O
AKRs	O
were	O
significantly	O
attenuated	O
in	O
NRF2-silenced	O
HK-2	O
cells	O
.	O

Whereas	O
,	O
cells	O
with	O
stable	O
KEAP1	O
knockdown	O
,	O
which	O
causes	O
a	O
modest	O
NRF2	O
activation	O
,	O
demonstrated	O
substantially	O
increased	O
levels	O
of	O
AKR1A1	O
,	O
1B1	O
,	O
1B10	O
,	O
1C1	O
,	O
1C2	O
,	O
and	O
1C3	O
.	O

Secondly	O
,	O
the	O
linkage	O
between	O
NRF2	O
and	O
the	O
AKRs	O
was	O
confirmed	O
in	O
human	O
monocytic	O
leukemia	O
cell	O
line	O
U937	O
,	O
which	O
can	O
be	O
a	O
model	O
of	O
peripherally	O
available	O
blood	O
cells	O
.	O

The	O
treatment	O
of	O
U937	O
cells	O
with	O
NRF2	O
inducers	O
including	O
sulforaphane	B
effectively	O
elevated	O
the	O
expression	O
of	O
AKR1B1	O
,	O
1B10	O
,	O
1C1	O
,	O
1C2	O
,	O
and	O
1C3	O
.	O

Whereas	O
,	O
the	O
levels	O
of	O
both	O
the	O
basal	O
and	O
sulforaphane	B
-	O
inducible	O
expression	O
of	O
AKR1C1	O
were	O
significantly	O
reduced	O
in	O
NRF2-silenced	O
stable	O
U937	O
cells	O
compared	O
to	O
the	O
control	O
cells	O
.	O

Similarly	O
,	O
the	O
inducible	O
expression	O
of	O
AKR1C1	O
was	O
observed	O
in	O
another	O
human	O
monocytic	O
leukemia	O
cell	O
line	O
THP-1	O
as	O
well	O
as	O
in	O
human	O
primary	O
blood	O
CD14	O
(	O
+	O
)	O
monocytes	O
.	O

In	O
conclusion	O
,	O
together	O
with	O
the	O
high	O
inducibility	O
and	O
NRF2	O
dependency	O
shown	O
in	O
renal	O
epithelial	O
cells	O
as	O
well	O
as	O
in	O
peripherally	O
available	O
blood	O
cells	O
,	O
current	O
findings	O
suggest	O
that	O
AKRs	O
can	O
be	O
utilized	O
as	O
a	O
marker	O
of	O
NRF2	O
activity	O
in	O
human	O
cells	O
.	O

Mitochondrial	O
dysfunction	O
contributes	O
to	O
the	O
cytotoxicity	O
of	O
some	O
3,5-bis	B
(	I
benzylidene	I
)	I
-4-piperidone	I
derivatives	O
in	O
colon	O
HCT-116	O
cells	O
.	O

The	O
objectives	O
of	O
this	O
study	O
are	O
to	O
investigate	O
the	O
possible	O
ways	O
by	O
which	O
the	O
curcumin	O
analogs	O
2a	O
and	O
2b	O
exert	O
their	O
antiproliferative	O
properties	O
.	O

The	O
analogs	O
2a	O
and	O
2b	O
have	O
submicromolar	O
IC	O
(	O
50	O
)	O
values	O
towards	O
human	O
HCT-116	O
colon	O
cancer	O
cells	O
but	O
are	O
far	O
less	O
toxic	O
to	O
human	O
non	O
-	O
malignant	O
CRL-1790	O
colon	O
cells	O
.	O

Both	O
compounds	O
affected	O
a	O
number	O
of	O
mitochondrial	O
functions	O
in	O
HCT-116	O
cells	O
namely	O
increasing	O
the	O
intracellular	O
concentrations	O
of	O
reactive	O
oxygen	B
species	O
,	O
inhibiting	O
oxygen	B
consumption	O
and	O
decreasing	O
the	O
mitochondrial	O
membrane	O
potential	O
.	O

These	O
molecules	O
also	O
produced	O
swelling	O
of	O
isolated	O
rat	O
liver	O
mitochondria	O
,	O
supporting	O
a	O
mitochondrial	O
mechanism	O
of	O
cytotoxicity	O
.	O

Both	O
compounds	O
reacted	O
with	O
glutathione	B
in	O
the	O
presence	O
of	O
glutathione	B
S	O
-	O
transferase	O
	O
and	O
hence	O
they	O
may	O
be	O
classified	O
as	O
thiol	B
alkylators	O
.	O

Preparation	O
of	O
apigenin	B
nanocrystals	O
using	O
supercritical	O
antisolvent	O
process	O
for	O
dissolution	O
and	O
bioavailability	O
enhancement	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
investigate	O
the	O
potential	O
of	O
nanocrystals	O
to	O
enhance	O
the	O
oral	O
bioavailability	O
of	O
apigenin	B
(	O
AP	O
)	O
,	O
a	O
bioactive	O
flavonoid	B
with	O
various	O
pharmacological	O
activities	O
but	O
poor	O
aqueous	O
solubility	O
.	O

In	O
the	O
present	O
investigation	O
,	O
the	O
AP	O
nanocrystals	O
were	O
prepared	O
by	O
the	O
supercritical	O
antisolvent	O
process	O
.	O

In	O
vitro	O
characterization	O
was	O
performed	O
by	O
scanning	O
electron	O
microscopy	O
,	O
FT	O
-	O
IR	O
,	O
differential	O
scanning	O
calorimetry	O
,	O
X	O
-	O
ray	O
powder	O
diffractometry	O
.	O

In	O
vitro	O
dissolution	O
of	O
prepared	O
nanocrystals	O
was	O
studied	O
and	O
compared	O
with	O
untreated	O
coarse	O
powder	O
.	O

In	O
addition	O
,	O
the	O
pharmacokinetic	O
study	O
of	O
AP	O
nanocrystals	O
,	O
in	O
comparison	O
to	O
coarse	O
powder	O
,	O
was	O
also	O
performed	O
in	O
rats	O
after	O
a	O
single	O
oral	O
dose	O
.	O

The	O
prepared	O
AP	O
nanocrystals	O
,	O
without	O
change	O
in	O
crystalline	O
structure	O
,	O
appeared	O
in	O
spherical	O
shape	O
with	O
particle	O
size	O
of	O
about	O
400	O
-	O
800	O
nm	O
.	O

The	O
reduction	O
of	O
particle	O
size	O
resulted	O
in	O
a	O
more	O
rapid	O
dissolution	O
of	O
AP	O
from	O
nanocrystals	O
than	O
from	O
coarse	O
powder	O
.	O

In	O
comparison	O
to	O
coarse	O
powder	O
,	O
AP	O
nanocrystals	O
exhibited	O
a	O
significantly	O
decreased	O
t	O
(	O
max	O
)	O
,	O
a	O
3.6-fold	O
higher	O
peak	O
plasma	O
concentration	O
(	O
C	O
(	O
max	O
)	O
)	O
and	O
3.4-fold	O
higher	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
.	O

Probing	O
circulating	O
tumor	O
cells	O
in	O
microfluidics	O
.	O

Circulating	O
tumor	O
cells	O
(	O
CTCs	O
)	O
are	O
important	O
targets	O
for	O
study	O
as	O
we	O
strive	O
to	O
better	O
understand	O
,	O
diagnose	O
,	O
and	O
treat	O
cancers	O
.	O

However	O
,	O
CTCs	O
are	O
found	O
in	O
blood	O
at	O
extremely	O
low	O
concentrations	O
;	O
this	O
makes	O
isolation	O
,	O
enrichment	O
,	O
and	O
characterization	O
of	O
CTCs	O
technically	O
challenging	O
.	O

Recently	O
,	O
the	O
development	O
of	O
CTC	O
separation	O
devices	O
has	O
grown	O
rapidly	O
in	O
both	O
academia	O
and	O
industry	O
.	O

Part	O
of	O
this	O
development	O
effort	O
centered	O
on	O
microfluidic	O
platforms	O
,	O
exploiting	O
the	O
advantages	O
of	O
microfluidics	O
to	O
improve	O
CTC	O
separation	O
performance	O
and	O
device	O
integration	O
.	O

In	O
this	O
Focus	O
article	O
,	O
we	O
highlight	O
some	O
of	O
the	O
recent	O
work	O
in	O
microfluidic	O
CTC	O
separation	O
and	O
detection	O
systems	O
and	O
discuss	O
our	O
appraisal	O
of	O
what	O
the	O
field	O
should	O
do	O
next	O
.	O

Tuning	O
optical	O
properties	O
of	O
Si	B
quantum	O
dots	O
by	O
	O
-	O
conjugated	O
capping	O
molecules	O
.	O

The	O
absorption	O
and	O
photoluminescence	O
(	O
PL	O
)	O
properties	O
of	O
silicon	B
quantum	O
dots	O
(	O
QDs	O
)	O
are	O
greatly	O
influenced	O
by	O
their	O
size	O
and	O
surface	O
chemistry	O
.	O

Herein	O
,	O
we	O
examined	O
the	O
optical	O
properties	O
of	O
three	O
Si	B
QDs	O
with	O
increasing	O
	O
-	O
	O
conjugation	O
length	O
:	O
octyl-	B
,	O
(	B
trimethylsilyl	I
)	I
vinyl-	I
,	O
and	O
2-phenylvinyl	B
-	O
capped	O
Si	B
QDs	O
.	O

The	O
PL	O
photon	O
energy	O
obtained	O
from	O
as	O
-	O
prepared	O
samples	O
decreased	O
by	O
0.1	O
-	O
0.3	O
eV	O
,	O
while	O
the	O
PL	O
excitation	O
(	O
PLE	O
)	O
extended	O
from	O
360	O
nm	O
(	O
octyl	B
-	O
capped	O
Si	B
QDs	O
)	O
to	O
400	O
nm	O
(	O
2-phenylvinyl	B
-	O
capped	O
Si	B
QDs	O
)	O
.	O

A	O
vibrational	O
PL	O
feature	O
was	O
observed	O
in	O
all	O
samples	O
with	O
an	O
energy	O
separation	O
of	O
about	O
0.1920.013	O
eV	O
,	O
which	O
was	O
explained	O
based	O
on	O
electron	O
-	O
phonon	O
coupling	O
.	O

After	O
soft	O
oxidization	O
through	O
drying	O
,	O
all	O
samples	O
showed	O
blue	O
PL	O
with	O
maxima	O
at	O
approximately	O
410	O
nm	O
.	O

A	O
similar	O
high	O
-	O
energy	O
peak	O
was	O
observed	O
with	O
the	O
bare	O
Si	B
QD	O
sample	O
.	O

The	O
changes	O
in	O
the	O
optical	O
properties	O
of	O
Si	B
QDs	O
were	O
mainly	O
explained	O
by	O
the	O
formation	O
of	O
additional	O
states	O
arising	O
from	O
the	O
strong	O
	O
-	O
	O
conjugation	O
and	O
QD	O
oxidation	O
.	O

Fine	O
Needle	O
Aspiration	O
of	O
Thyroid	O
Nodules	O
with	O
Macrocalcification	O
.	O

Background	O
:	O
The	O
presence	O
of	O
microcalcification	O
is	O
highly	O
suggestive	O
of	O
malignancy	O
;	O
however	O
,	O
the	O
association	O
of	O
macrocalcification	O
with	O
cancer	O
remains	O
unclear	O
and	O
controversial	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
diagnostic	O
yield	O
and	O
accuracy	O
of	O
ultrasound	O
(	O
US	O
)	O
-guided	O
fine	O
needle	O
aspiration	O
(	O
FNA	O
)	O
of	O
thyroid	O
nodules	O
with	O
macrocalcification	O
and	O
to	O
investigate	O
the	O
association	O
between	O
macrocalcification	O
subtype	O
and	O
malignancy	O
risk	O
.	O

Methods	O
:	O
We	O
retrospectively	O
reviewed	O
sonographic	O
findings	O
and	O
pathologic	O
results	O
of	O
thyroid	O
nodules	O
with	O
macrocalcification	O
in	O
patients	O
who	O
underwent	O
US	O
-	O
guided	O
FNA	O
in	O
our	O
hospital	O
from	O
January	O
2009	O
through	O
December	O
2010	O
.	O

Inclusion	O
criteria	O
were	O
as	O
follows	O
:	O
(	O
a	O
)	O
malignant	O
or	O
benign	O
nodules	O
confirmed	O
on	O
histologic	O
examination	O
of	O
surgical	O
specimens	O
after	O
US	O
-	O
guided	O
FNA	O
and	O
(	O
b	O
)	O
nodules	O
not	O
histologically	O
confirmed	O
that	O
were	O
subjected	O
to	O
FNA	O
at	O
least	O
twice	O
and	O
follow	O
-	O
up	O
US	O
examinations	O
for	O
2	O
years	O
.	O

Thyroid	O
nodules	O
with	O
macrocalcification	O
were	O
classified	O
into	O
4	O
groups	O
:	O
smooth	O
total	O
(	O
eggshell	O
)	O
calcification	O
,	O
smooth	O
partial	O
calcification	O
,	O
irregular	O
calcification	O
,	O
and	O
nodular	O
calcification	O
.	O

Diagnostic	O
yield	O
of	O
FNA	O
for	O
thyroid	O
nodules	O
with	O
macrocalcification	O
was	O
determined	O
by	O
cytology	O
.	O

Sensitivity	O
,	O
specificity	O
,	O
and	O
diagnostic	O
accuracy	O
of	O
preoperative	O
FNA	O
cytology	O
were	O
calculated	O
and	O
compared	O
with	O
those	O
of	O
histologic	O
examination	O
of	O
surgical	O
specimens	O
.	O

Results	O
:	O
There	O
were	O
188	O
nodules	O
with	O
macrocalcification	O
in	O
167	O
patients	O
;	O
of	O
these	O
,	O
95	O
were	O
benign	O
,	O
80	O
were	O
malignant	O
,	O
and	O
13	O
were	O
nondiagnostic	O
.	O

Diagnostic	O
yield	O
of	O
FNA	O
for	O
thyroid	O
nodules	O
with	O
macrocalcification	O
was	O
93.08	O
%	O
.	O

Sensitivity	O
,	O
specificity	O
,	O
positive	O
predictive	O
value	O
,	O
and	O
negative	O
predictive	O
value	O
were	O
98.51	O
%	O
,	O
90.91	O
%	O
,	O
95.65	O
%	O
,	O
and	O
96.77	O
%	O
,	O
respectively	O
.	O

The	O
false	O
-	O
positive	O
value	O
and	O
false	O
-	O
negative	O
value	O
were	O
9.09	O
%	O
and	O
1.49	O
%	O
,	O
respectively	O
.	O

The	O
diagnostic	O
accuracy	O
was	O
96	O
%	O
.	O

There	O
was	O
no	O
statistically	O
significant	O
difference	O
in	O
the	O
association	O
between	O
macrocalcification	O
subtype	O
and	O
malignancy	O
risk	O
(	O
P	O
>	O
0.05	O
)	O
.	O

Conclusions	O
:	O
Macrocalcification	O
associated	O
with	O
thyroid	O
nodules	O
is	O
not	O
a	O
reliable	O
criterion	O
for	O
malignancy	O
.	O

FNA	O
of	O
thyroid	O
nodules	O
with	O
macrocalcification	O
had	O
significantly	O
high	O
diagnostic	O
yield	O
and	O
reliable	O
accuracy	O
.	O

Consistency	O
between	O
FNA	O
and	O
histology	O
was	O
almost	O
perfect	O
.	O

Therefore	O
,	O
FNA	O
is	O
a	O
good	O
screening	O
method	O
for	O
malignancy	O
of	O
thyroid	O
nodules	O
with	O
macrocalcification	O
.	O

Trimethylamine	B
-	I
N	I
-	I
oxide	I
,	O
a	O
metabolite	O
associated	O
with	O
atherosclerosis	O
,	O
exhibits	O
complex	O
genetic	O
and	O
dietary	O
regulation	O
.	O

Circulating	O
trimethylamine	B
-	I
N	I
-	I
oxide	I
(	O
TMAO	B
)	O
levels	O
are	O
strongly	O
associated	O
with	O
atherosclerosis	O
.	O

We	O
now	O
examine	O
genetic	O
,	O
dietary	O
,	O
and	O
hormonal	O
factors	O
regulating	O
TMAO	B
levels	O
.	O

We	O
demonstrate	O
that	O
two	O
flavin	B
mono	O
-	O
oxygenase	O
family	O
members	O
,	O
FMO1	O
and	O
FMO3	O
,	O
oxidize	O
trimethylamine	B
(	O
TMA	B
)	O
,	O
derived	O
from	O
gut	O
flora	O
metabolism	O
of	O
choline	B
,	O
to	O
TMAO	B
.	O

Further	O
,	O
we	O
show	O
that	O
FMO3	O
exhibits	O
10-fold	O
higher	O
specific	O
activity	O
than	O
FMO1	O
.	O

FMO3	O
overexpression	O
in	O
mice	O
significantly	O
increases	O
plasma	O
TMAO	B
levels	O
while	O
silencing	O
FMO3	O
decreases	O
TMAO	B
levels	O
.	O

In	O
both	O
humans	O
and	O
mice	O
,	O
hepatic	O
FMO3	O
expression	O
is	O
reduced	O
in	O
males	O
compared	O
to	O
females	O
.	O

In	O
mice	O
,	O
this	O
reduction	O
in	O
FMO3	O
expression	O
is	O
due	O
primarily	O
to	O
downregulation	O
by	O
androgens	B
.	O

FMO3	O
expression	O
is	O
induced	O
by	O
dietary	O
bile	B
acids	I
by	O
a	O
mechanism	O
that	O
involves	O
the	O
farnesoid	O
X	O
receptor	O
(	O
FXR	O
)	O
,	O
a	O
bile	B
acid	I
-	O
activated	O
nuclear	O
receptor	O
.	O

Analysis	O
of	O
natural	O
genetic	O
variation	O
among	O
inbred	O
strains	O
of	O
mice	O
indicates	O
that	O
FMO3	O
and	O
TMAO	B
are	O
significantly	O
correlated	O
,	O
and	O
TMAO	B
levels	O
explain	O
11	O
%	O
of	O
the	O
variation	O
in	O
atherosclerosis	O
.	O

Diminutive	O
effect	O
on	O
T	O
and	O
B	O
-	O
cell	O
proliferation	O
of	O
non	O
-	O
cytotoxic	O
	B
-	I
santonin	I
derived	O
1,2,3-triazoles	B
:	O
a	O
report	O
.	O

	B
-	I
Santonin	I
derived	O
new	O
series	O
of	O
1,2,3-triazoles	B
synthesized	O
through	O
Azide	B
-	I
Alkyne	I
Huisgen	O
1,3-dipolar	O
cycloaddition	O
reaction	O
between	O
substituted	O
aryl	B
azide	I
and	O
a	O
propargylated	B
	I
-	I
desmotrosantonin	I
were	O
bio	O
-	O
evaluated	O
for	O
their	O
diminutive	O
effect	O
on	O
ConA	O
induced	O
T	O
-	O
cell	O
and	O
LPS	O
induced	O
B	O
-	O
cell	O
proliferation	O
.	O

Interestingly	O
,	O
most	O
of	O
the	O
synthesized	O
compounds	O
showed	O
better	O
immunosuppressant	O
activity	O
than	O
	B
-	I
santonin	I
.	O

Triazole	B
derivatives	O
9	O
,	O
10	O
,	O
17	O
,	O
18	O
,	O
29	O
,	O
and	O
30	O
displayed	O
significant	O
diminutive	O
effect	O
on	O
cell	O
proliferation	O
.	O

Compounds	O
12	O
and	O
13	O
were	O
found	O
selective	O
against	O
ConA	O
T	O
-	O
cell	O
proliferation	O
exhibiting	O
>	O
90	O
%	O
inhibition	O
at	O
1	O
	O
10	O
(	O
-6	O
)	O
M	O
concentration	O
.	O

The	O
present	O
study	O
resulted	O
in	O
identification	O
of	O
several	O
triazole	B
derivatives	O
as	O
effective	O
immunosuppressive	O
agents	O
.	O

Silica	B
nanoparticles	O
-	O
induced	O
cytotoxicity	O
,	O
oxidative	O
stress	O
and	O
apoptosis	O
in	O
cultured	O
A431	O
and	O
A549	O
cells	O
.	O

In	O
medicine	O
,	O
the	O
use	O
of	O
silica	B
nanoparticles	O
(	O
SiO	B
(	I
2	I
)	I
NPs	O
)	O
offers	O
new	O
perspectives	O
in	O
biosensor	O
,	O
drug	O
delivery	O
and	O
cancer	O
therapy	O
.	O

However	O
,	O
questions	O
about	O
potential	O
toxic	O
and	O
deleterious	O
effects	O
of	O
SiO	B
(	I
2	I
)	I
NPs	O
have	O
also	O
been	O
raised	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
induction	O
of	O
cytotoxicity	O
,	O
oxidative	O
stress	O
and	O
apoptosis	O
by	O
SiO	B
(	I
2	I
)	I
NPs	O
(	O
size	O
15	O
nm	O
)	O
in	O
human	O
skin	O
epithelial	O
(	O
A431	O
)	O
and	O
human	O
lung	O
epithelial	O
(	O
A549	O
)	O
cells	O
.	O

SiO	B
(	I
2	I
)	I
NPs	O
(	O
concentration	O
range	O
25	O
-	O
200	O
g	O
/	O
ml	O
)	O
induced	O
dose	O
-	O
dependent	O
cytotoxicity	O
in	O
both	O
types	O
of	O
cells	O
,	O
which	O
was	O
demonstrated	O
by	O
cell	O
viability	O
(	O
3-	B
(	I
4,5-dimethylthiazol-2-yl	I
)	I
-2,5-diphenyltetrazoliumbromide	I
)	O
and	O
lactate	B
dehydrogenase	O
leakage	O
assays	O
.	O

SiO	B
(	I
2	I
)	I
NPs	O
were	O
also	O
found	O
to	O
induce	O
oxidative	O
stress	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
indicated	O
by	O
depletion	O
of	O
glutathione	B
and	O
induction	O
of	O
reactive	O
oxygen	B
species	O
(	O
ROS	O
)	O
generation	O
and	O
lipid	O
peroxidation	O
.	O

Quantitative	O
real	O
-	O
time	O
polymerase	O
chain	O
reaction	O
analysis	O
showed	O
that	O
following	O
the	O
exposure	O
of	O
cells	O
to	O
SiO	B
(	I
2	I
)	I
NPs	O
,	O
the	O
messenger	O
RNA	O
level	O
of	O
apoptotic	O
genes	O
(	O
caspase-3	O
and	O
caspase-9	O
)	O
were	O
upregulated	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Moreover	O
,	O
activities	O
of	O
caspase-3	O
and	O
caspase-9	O
enzymes	O
were	O
also	O
significantly	O
higher	O
in	O
both	O
kinds	O
of	O
cells	O
exposed	O
to	O
SiO	B
(	I
2	I
)	I
NPs	O
.	O

This	O
study	O
suggested	O
that	O
SiO	B
(	I
2	I
)	I
NPs	O
induce	O
cytotoxicity	O
and	O
apoptosis	O
in	O
A431	O
and	O
A549	O
cells	O
,	O
which	O
is	O
likely	O
to	O
be	O
mediated	O
through	O
ROS	O
generation	O
and	O
oxidative	O
stress	O
.	O

Decreased	O
RB1	O
mRNA	O
,	O
Protein	O
,	O
and	O
Activity	O
Reflect	O
Obesity	O
-	O
Induced	O
Altered	O
Adipogenic	O
Capacity	O
in	O
Human	O
Adipose	O
Tissue	O
.	O

Retinoblastoma	O
(	O
Rb1	O
)	O
has	O
been	O
described	O
as	O
an	O
essential	O
player	O
in	O
white	O
adipocyte	O
differentiation	O
in	O
mice	O
.	O

No	O
studies	O
have	O
been	O
reported	O
thus	O
far	O
in	O
human	O
adipose	O
tissue	O
or	O
human	O
adipocytes	O
.	O

We	O
aimed	O
to	O
investigate	O
the	O
possible	O
role	O
and	O
regulation	O
of	O
RB1	O
in	O
adipose	O
tissue	O
in	O
obesity	O
using	O
human	O
samples	O
and	O
animal	O
and	O
cell	O
models	O
.	O

Adipose	O
RB1	O
(	O
mRNA	O
,	O
protein	O
,	O
and	O
activity	O
)	O
was	O
negatively	O
associated	O
with	O
BMI	O
and	O
insulin	O
resistance	O
(	O
HOMA	O
-	O
IR	O
)	O
while	O
positively	O
associated	O
with	O
the	O
expression	O
of	O
adipogenic	O
genes	O
(	O
PPAR	O
and	O
IRS1	O
)	O
in	O
both	O
visceral	O
and	O
subcutaneous	O
human	O
adipose	O
tissue	O
.	O

BMI	O
increase	O
was	O
the	O
main	O
contributor	O
to	O
adipose	O
RB1	O
downregulation	O
.	O

In	O
rats	O
,	O
adipose	O
Rb1	O
gene	O
expression	O
and	O
activity	O
decreased	O
in	O
parallel	O
to	O
dietary	O
-	O
induced	O
weight	O
gain	O
and	O
returned	O
to	O
baseline	O
with	O
weight	O
loss	O
.	O

RB1	O
gene	O
and	O
protein	O
expression	O
and	O
activity	O
increased	O
significantly	O
during	O
human	O
adipocyte	O
differentiation	O
.	O

In	O
fully	O
differentiated	O
adipocytes	O
,	O
transient	O
knockdown	O
of	O
Rb1	O
led	O
to	O
loss	O
of	O
the	O
adipogenic	O
phenotype	O
.	O

In	O
conclusion	O
,	O
Rb1	O
seems	O
to	O
play	O
a	O
permissive	O
role	O
for	O
human	O
adipose	O
tissue	O
function	O
,	O
being	O
downregulated	O
in	O
obesity	O
and	O
increased	O
during	O
differentiation	O
of	O
human	O
adipocytes	O
.	O

Rb1	O
knockdown	O
findings	O
further	O
implicate	O
Rb1	O
as	O
necessary	O
for	O
maintenance	O
of	O
adipogenic	O
characteristics	O
in	O
fully	O
differentiated	O
adipocytes	O
.	O

Solphenazines	B
A	I
-	I
F	I
,	O
glycosylated	B
phenazines	I
from	O
Streptomyces	O
sp.	O
strain	O
DL-93	O
.	O

During	O
a	O
survey	O
of	O
actinobacteria	O
known	O
to	O
suppress	O
the	O
growth	O
of	O
Streptomyces	O
scabies	O
(	O
the	O
causative	O
agent	O
of	O
potato	O
scab	O
disease	O
)	O
in	O
vivo	O
,	O
six	O
new	O
rhamnosylated	O
alkaloids	O
,	O
the	O
solphenazines	B
A	I
-	I
F	I
(	O
1	O
-	O
6	O
)	O
,	O
were	O
isolated	O
from	O
a	O
biological	O
control	O
strain	O
of	O
Streptomyces	O
(	O
DL-93	O
)	O
.	O

The	O
known	O
rhamnosyl	B
analogue	O
of	O
paraben	B
(	O
9	O
)	O
was	O
also	O
isolated	O
along	O
with	O
a	O
new	O
rhamnosylated	O
derivative	O
of	O
N	B
-	I
methyl	I
-	I
p	I
-	I
aminobenzoic	I
acid	I
(	O
10	O
)	O
.	O

None	O
of	O
the	O
compounds	O
exhibited	O
any	O
antibacterial	O
or	O
antifungal	O
activity	O
against	O
a	O
standard	O
panel	O
of	O
microorganisms	O
,	O
but	O
compounds	O
1	O
,	O
2	O
,	O
and	O
6	O
displayed	O
some	O
cytotoxicity	O
against	O
HCT-116	O
cancer	O
cells	O
.	O

Additional	O
in	O
vitro	O
testing	O
provided	O
data	O
suggesting	O
that	O
the	O
cytotoxic	O
activity	O
is	O
not	O
due	O
to	O
DNA	O
intercalation	O
or	O
topoisomerase	O
inhibition	O
.	O

Synthesis	O
and	O
biological	O
evaluation	O
as	O
microtubule	O
-	O
active	O
agents	O
of	O
several	O
tetrahydrofuran	B
and	O
spiroacetal	B
derivatives	O
.	O

The	O
stereoselective	O
preparation	O
of	O
several	O
molecules	O
containing	O
structural	O
fragments	O
of	O
the	O
tetrahydrofuran	B
and	O
spiroacetal	B
type	O
is	O
described	O
.	O

Their	O
degree	O
of	O
cytotoxicity	O
and	O
their	O
interactions	O
with	O
tubulin	O
have	O
been	O
investigated	O
.	O

It	O
has	O
been	O
confirmed	O
that	O
the	O
tetrahydrofuran	B
derivatives	O
are	O
cytotoxic	O
but	O
,	O
in	O
contrast	O
to	O
previous	O
reports	O
,	O
it	O
has	O
been	O
found	O
that	O
the	O
cytoxicity	O
is	O
not	O
due	O
to	O
interactions	O
with	O
the	O
microtubule	O
network	O
.	O

Furthermore	O
,	O
and	O
also	O
in	O
contrast	O
to	O
a	O
previous	O
report	O
on	O
closely	O
related	O
compounds	O
,	O
the	O
spiroacetal	B
derivatives	O
do	O
show	O
interactions	O
with	O
tubulin	O
,	O
even	O
though	O
the	O
precise	O
mechanism	O
and	O
the	O
binding	O
site	O
still	O
remain	O
to	O
be	O
established	O
.	O

The	O
oxygen	B
therapy	O
.	O

Oxygen	B
(	O
O	B
(	I
2	I
)	I
)	O
is	O
a	O
vital	O
element	O
.	O

Shortage	O
of	O
O	B
(	I
2	I
)	I
results	O
in	O
deranged	O
metabolism	O
and	O
important	O
changes	O
in	O
vascular	O
tone	O
with	O
opposite	O
effects	O
on	O
the	O
systemic	O
and	O
pulmonary	O
circulation	O
.	O

During	O
hypoxemia	O
,	O
oxidative	O
stress	O
exposes	O
the	O
organism	O
to	O
a	O
sort	O
of	O
accelerated	O
senescence	O
as	O
well	O
as	O
to	O
several	O
acute	O
untoward	O
effects	O
.	O

Thus	O
,	O
hypoxemia	O
should	O
be	O
promptly	O
recognized	O
and	O
treated	O
,	O
hopefully	O
by	O
measures	O
tailored	O
to	O
the	O
pathophysiological	O
mechanisms	O
underlying	O
hypoxemia	O
.	O

However	O
,	O
O	B
(	I
2	I
)	I
therapy	O
remains	O
the	O
most	O
common	O
therapy	O
of	O
hypoxemia	O
,	O
but	O
it	O
must	O
be	O
carefully	O
tailored	O
to	O
relieve	O
hypoxemia	O
without	O
provoking	O
hyperoxia	O
or	O
hypercarbia	O
.	O

Then	O
,	O
the	O
individual	O
response	O
to	O
O	B
(	I
2	I
)	I
as	O
well	O
as	O
changing	O
needs	O
of	O
O	B
(	I
2	I
)	I
during	O
sleep	O
or	O
exercise	O
must	O
be	O
evaluated	O
to	O
provide	O
the	O
best	O
O	B
(	I
2	I
)	I
therapy	O
.	O

Hyperoxia	O
,	O
the	O
effect	O
of	O
overcorrection	O
of	O
hypoxia	O
,	O
can	O
dramatically	O
impact	O
the	O
health	O
status	O
and	O
threaten	O
the	O
survival	O
of	O
the	O
newborn	O
and	O
,	O
through	O
different	O
mechanisms	O
and	O
effects	O
,	O
the	O
adult	O
.	O

A	O
thorough	O
knowledge	O
of	O
the	O
pathophysiological	O
bases	O
of	O
hypoxemia	O
and	O
O	B
(	I
2	I
)	I
storage	O
and	O
delivery	O
devices	O
is	O
then	O
mandatory	O
to	O
administer	O
O	B
(	I
2	I
)	I
therapy	O
guaranteeing	O
for	O
optimal	O
correction	O
of	O
hypoxemia	O
and	O
minimizing	O
the	O
risk	O
of	O
hyperoxia	O
.	O

Consistent	O
with	O
this	O
aim	O
also	O
is	O
a	O
careful	O
scrutiny	O
of	O
instruments	O
and	O
procedures	O
for	O
monitoring	O
the	O
individual	O
response	O
to	O
O	B
(	I
2	I
)	I
over	O
time	O
.	O

Thus	O
,	O
at	O
variance	O
from	O
classical	O
pharmacological	O
therapy	O
,	O
performing	O
O	B
(	I
2	I
)	I
therapy	O
requires	O
a	O
vast	O
array	O
of	O
clinical	O
and	O
technical	O
competences	O
.	O

The	O
optimal	O
integration	O
of	O
these	O
competences	O
is	O
needed	O
to	O
optimize	O
O	B
(	I
2	I
)	I
therapy	O
on	O
individual	O
bases	O
.	O

Recent	O
Developments	O
of	O
p38	O
MAP	O
Kinase	O
Inhibitors	O
as	O
Antiinflammatory	O
Agents	O
Based	O
on	O
the	O
Imidazole	B
Scaffolds	O
.	O

Rheumatoid	O
arthritis	O
(	O
RA	O
)	O
and	O
other	O
chronic	O
inflammatory	O
diseases	O
are	O
always	O
the	O
major	O
therapeutic	O
challenges	O
.	O

Recent	O
research	O
efforts	O
provided	O
new	O
insights	O
into	O
the	O
molecular	O
basis	O
of	O
these	O
diseases	O
and	O
new	O
opportunities	O
for	O
developing	O
improved	O
anti	O
-	O
inflammatory	O
drugs	O
.	O

The	O
p38	O
mitogen	O
-	O
activated	O
protein	O
(	O
MAP	O
)	O
kinase	O
plays	O
a	O
central	O
role	O
in	O
the	O
regulation	O
of	O
the	O
biosynthesis	O
and	O
release	O
of	O
several	O
proinflammatory	O
cytokines	O
including	O
tumor	O
necrosis	O
factor	O
alpha	O
(	O
TNF	O
-	O
	O
)	O
and	O
interleukin-1	O
beta	O
(	O
IL-1	O
)	O
.	O

Hence	O
,	O
inhibition	O
of	O
the	O
p38	O
MAP	O
kinase	O
is	O
regarded	O
as	O
a	O
promising	O
therapeutic	O
strategy	O
for	O
controlling	O
inflammatory	O
diseases	O
.	O

A	O
diverse	O
range	O
of	O
p38	O
MAP	O
kinase	O
inhibitors	O
have	O
been	O
developed	O
as	O
potential	O
anti	O
-	O
inflammatory	O
agents	O
,	O
and	O
some	O
of	O
them	O
have	O
entered	O
the	O
phase	O
II	O
clinical	O
trials	O
.	O

The	O
imidazole	B
derivatives	O
are	O
known	O
as	O
competitive	O
inhibitors	O
at	O
the	O
ATP	B
binding	O
site	O
of	O
the	O
p38	O
MAP	O
kinase	O
.	O

Modifications	O
on	O
the	O
imidazole	B
scaffold	O
have	O
led	O
to	O
a	O
large	O
amount	O
of	O
potent	O
p38	O
MAP	O
kinase	O
inhibitors	O
.	O

This	O
review	O
will	O
summarize	O
the	O
developments	O
of	O
small	O
molecule	O
p38	O
MAP	O
kinase	O
inhibitors	O
based	O
on	O
the	O
imidazole	B
core	O
scaffolds	O
in	O
recent	O
10	O
years	O
.	O

Variations	O
at	O
the	O
N1	O
,	O
C2	O
,	O
C4	O
and	O
C5	O
positions	O
of	O
imidazole	B
were	O
introduced	O
,	O
and	O
the	O
structure	O
-	O
activity	O
relationships	O
of	O
these	O
imidazole	B
inhibitors	O
were	O
also	O
discussed	O
.	O

Atomic	O
pair	O
distribution	O
functions	O
analysis	O
of	O
disordered	O
low	O
-	O
Z	O
materials	O
.	O

Results	O
of	O
high	O
-	O
energy	O
X	O
-	O
ray	O
diffraction	O
experiments	O
coupled	O
to	O
atomic	O
pair	O
distribution	O
function	O
analysis	O
of	O
disordered	O
low	O
-	O
Z	O
materials	O
are	O
presented	O
.	O

Several	O
scientifically	O
and	O
technologically	O
important	O
classes	O
of	O
disordered	O
low	O
-	O
Z	O
materials	O
such	O
as	O
small	O
and	O
large	O
organic	O
molecules	O
,	O
graphitic	B
powders	O
,	O
polymers	O
and	O
liquids	O
are	O
intentionally	O
explored	O
to	O
certify	O
the	O
technique	O
's	O
performance	O
.	O

Results	O
clearly	O
show	O
that	O
disordered	O
low	O
-	O
Z	O
materials	O
can	O
be	O
well	O
characterized	O
in	O
terms	O
of	O
material	O
's	O
phase	O
identity	O
,	O
relative	O
abundance	O
in	O
mixtures	O
and	O
atomic	O
-	O
scale	O
structure	O
.	O

The	O
demonstrated	O
efficiency	O
of	O
the	O
technique	O
provides	O
the	O
scientific	O
community	O
with	O
much	O
needed	O
confidence	O
to	O
apply	O
it	O
more	O
often	O
than	O
now	O
.	O

ErbB2	O
,	O
FoxM1	O
and	O
14	O
-	O
3	O
-	O
3	O
prime	O
breast	O
cancer	O
cells	O
for	O
invasion	O
in	O
response	O
to	O
ionizing	O
radiation	O
.	O

ErbB2	O
is	O
frequently	O
highly	O
expressed	O
in	O
premalignant	O
breast	O
cancers	O
,	O
including	O
ductal	O
carcinoma	O
in	O
situ	O
(	O
DCIS	O
)	O
;	O
however	O
,	O
little	O
is	O
known	O
about	O
the	O
signals	O
or	O
pathways	O
it	O
contributes	O
to	O
progression	O
into	O
the	O
invasive	O
/	O
malignant	O
state	O
.	O

Radiotherapy	O
is	O
often	O
used	O
to	O
treat	O
early	O
premalignant	O
lesions	O
regardless	O
of	O
ErbB2	O
status	O
.	O

Here	O
,	O
we	O
show	O
that	O
clinically	O
relevant	O
doses	O
of	O
ionizing	O
radiation	O
(	O
IR	O
)	O
-induce	O
cellular	O
invasion	O
of	O
ErbB2-expressing	O
breast	O
cancer	O
cells	O
,	O
as	O
well	O
as	O
MCF10A	O
cells	O
overexpressing	O
ErbB2	O
.	O

ErbB2-negative	O
breast	O
cancer	O
cells	O
,	O
such	O
as	O
MCF7	O
and	O
T47D	O
,	O
do	O
not	O
invade	O
following	O
treatment	O
with	O
IR	O
nor	O
do	O
MCF10A	O
cells	O
overexpressing	O
epidermal	O
growth	O
factor	O
receptor	O
.	O

ErbB2	O
becomes	O
phosphorylated	O
at	O
tyrosine	B
877	O
in	O
a	O
dose-	O
and	O
time-	O
dependent	O
manner	O
following	O
exposure	O
to	O
X	O
-	O
rays	O
,	O
and	O
activates	O
downstream	O
signaling	O
cascades	O
including	O
PI3K	O
/	O
Akt	O
.	O

Inhibition	O
of	O
these	O
pathways	O
,	O
as	O
well	O
as	O
inhibition	O
of	O
reactive	O
oxygen	B
species	O
(	O
ROS	O
)	O
with	O
antioxidants	O
,	O
prevents	O
IR	O
-	O
induced	O
invasion	O
.	O

Activation	O
of	O
ErbB2-dependent	O
signaling	O
results	O
in	O
upregulation	O
of	O
the	O
forkhead	O
family	O
transcription	O
factor	O
,	O
FoxM1	O
,	O
and	O
its	O
transcriptional	O
targets	O
,	O
including	O
matrix	O
metalloproteinase	O
2	O
(	O
MMP2	O
)	O
.	O

Inhibition	O
of	O
FoxM1	O
by	O
RNA	O
interference	O
prevented	O
induction	O
of	O
invasion	O
by	O
IR	O
,	O
and	O
overexpression	O
of	O
FoxM1	O
in	O
MCF10A	O
cells	O
was	O
sufficient	O
to	O
promote	O
IR	O
-	O
induced	O
invasion	O
.	O

Moreover	O
,	O
we	O
found	O
that	O
14	O
-	O
3	O
-	O
3	O
is	O
also	O
upregulated	O
by	O
IR	O
in	O
cancer	O
cells	O
in	O
a	O
ROS	O
-	O
dependent	O
manner	O
,	O
is	O
required	O
for	O
IR	O
-	O
induced	O
invasion	O
in	O
ErbB2-positive	O
breast	O
cancer	O
cells	O
and	O
together	O
with	O
FoxM1	O
is	O
sufficient	O
for	O
invasion	O
in	O
ErbB2-negative	O
breast	O
cancer	O
cells	O
.	O

Thus	O
,	O
our	O
data	O
show	O
that	O
IR	O
-	O
mediated	O
activation	O
of	O
ErbB2	O
and	O
induction	O
of	O
14	O
-	O
3	O
-	O
3	O
collaborate	O
to	O
regulate	O
FoxM1	O
and	O
promote	O
invasion	O
of	O
breast	O
cancer	O
cells	O
and	O
furthermore	O
,	O
may	O
serve	O
as	O
therapeutic	O
targets	O
to	O
enhance	O
radiosensitivity	O
of	O
breast	O
cancers	O
.	O

Oncogene	O
advance	O
online	O
publication	O
,	O
14	O
January	O
2013	O
;	O
doi:10.1038	O
/	O
onc.2012.629	O
.	O

TRIM3	O
,	O
a	O
tumor	O
suppressor	O
linked	O
to	O
regulation	O
of	O
p21	O
(	O
Waf1	O
/	O
Cip1	O
)	O
.	O

The	O
TRIM	O
family	O
of	O
genes	O
is	O
largely	O
studied	O
because	O
of	O
their	O
roles	O
in	O
development	O
,	O
differentiation	O
and	O
host	O
cell	O
antiviral	O
defenses	O
;	O
however	O
,	O
roles	O
in	O
cancer	O
biology	O
are	O
emerging	O
.	O

Loss	O
of	O
heterozygosity	O
of	O
the	O
TRIM3	O
locus	O
in	O
20	O
%	O
of	O
human	O
glioblastomas	O
raised	O
the	O
possibility	O
that	O
this	O
NHL	O
-	O
domain	O
containing	O
member	O
of	O
the	O
TRIM	O
gene	O
family	O
might	O
be	O
a	O
mammalian	O
tumor	O
suppressor	O
.	O

Consistent	O
with	O
this	O
,	O
reducing	O
TRIM3	O
expression	O
increased	O
the	O
incidence	O
of	O
and	O
accelerated	O
the	O
development	O
of	O
platelet	O
-	O
derived	O
growth	O
factor	O
-induced	O
glioma	O
in	O
mice	O
.	O

Furthermore	O
,	O
TRIM3	O
can	O
bind	O
to	O
the	O
cdk	O
inhibitor	O
p21	O
(	O
WAF1	O
/	O
CIP1	O
)	O
.	O

Thus	O
,	O
we	O
conclude	O
that	O
TRIM3	O
is	O
a	O
tumor	O
suppressor	O
mapping	O
to	O
chromosome	O
11p15.5	O
and	O
that	O
it	O
might	O
block	O
tumor	O
growth	O
by	O
sequestering	O
p21	O
and	O
preventing	O
it	O
from	O
facilitating	O
the	O
accumulation	O
of	O
cyclin	O
D1-cdk4.Oncogene	O
advance	O
online	O
publication	O
,	O
14	O
January	O
2013	O
;	O
doi:10.1038	O
/	O
onc.2012.596	O
.	O

Determinants	O
of	O
regioselectivity	O
and	O
chemoselectivity	O
in	O
fosfomycin	B
resistance	O
protein	O
FosA	O
from	O
QM	O
/	O
MM	O
calculations	O
.	O

FosA	O
is	O
a	O
manganese	B
-	O
dependent	O
enzyme	O
that	O
utilizes	O
a	O
Mn	B
(	I
2	I
+	I
)	I
ion	O
to	O
catalyze	O
the	O
inactivation	O
of	O
the	O
fosfomycin	B
antibiotic	O
by	O
glutathione	B
(	O
GSH	B
)	O
addition	O
.	O

We	O
report	O
a	O
theoretical	O
study	O
on	O
the	O
catalytic	O
mechanism	O
and	O
the	O
factors	O
governing	O
the	O
regioselectivity	O
and	O
chemoselectivity	O
of	O
FosA.	O
Density	O
functional	O
theory	O
(	O
DFT	O
)	O
calculations	O
on	O
the	O
uncatalyzed	O
reaction	O
give	O
high	O
barriers	O
and	O
almost	O
no	O
regioselectivity	O
even	O
when	O
adding	O
two	O
water	O
molecules	O
to	O
assist	O
the	O
proton	O
transfer	O
.	O

According	O
to	O
quantum	O
mechanics	O
/	O
molecular	O
mechanics	O
(	O
QM	O
/	O
MM	O
)	O
calculations	O
on	O
the	O
full	O
solvated	O
protein	O
,	O
the	O
enzyme	O
-	O
catalyzed	O
glutathione	B
addition	O
reaction	O
involves	O
two	O
major	O
chemical	O
steps	O
that	O
both	O
proceed	O
in	O
the	O
sextet	O
state	O
:	O
proton	O
transfer	O
from	O
the	O
GSH	B
thiol	I
group	O
to	O
the	O
Tyr39	B
anion	O
and	O
nucleophilic	O
attack	O
by	O
the	O
GSH	B
thiolate	I
leading	O
to	O
epoxide	B
ring	O
-	O
opening	O
.	O

The	O
second	O
step	O
is	O
rate	O
-	O
limiting	O
and	O
is	O
facilitated	O
by	O
the	O
presence	O
of	O
the	O
high	O
-	O
spin	O
Mn	B
(	I
2	I
+	I
)	I
ion	O
that	O
functions	O
as	O
a	O
Lewis	B
acid	I
and	O
stabilizes	O
the	O
leaving	O
oxyanion	O
through	O
direct	O
coordination	O
.	O

The	O
barrier	O
for	O
C1	O
attack	O
is	O
computed	O
to	O
be	O
8.9	O
kcal	O
/	O
mol	O
lower	O
than	O
that	O
for	O
C2	O
attack	O
,	O
in	O
agreement	O
with	O
the	O
experimentally	O
observed	O
regioselectivity	O
of	O
the	O
enzyme	O
.	O

Further	O
QM	O
/	O
MM	O
calculations	O
on	O
the	O
alternative	O
water	O
attack	O
predict	O
a	O
concerted	O
mechanism	O
for	O
this	O
reaction	O
,	O
where	O
the	O
deprotonation	O
of	O
water	O
,	O
nucleophilic	O
attack	O
,	O
and	O
epoxide	B
ring	O
-	O
opening	O
take	O
place	O
via	O
the	O
same	O
transition	O
state	O
.	O

The	O
calculated	O
barrier	O
is	O
8.3	O
kcal	O
/	O
mol	O
higher	O
than	O
that	O
for	O
GSH	B
attack	O
,	O
in	O
line	O
with	O
the	O
observed	O
chemoselectivity	O
of	O
the	O
enzyme	O
,	O
which	O
manages	O
to	O
catalyze	O
the	O
addition	O
of	O
GSH	B
in	O
the	O
presence	O
of	O
water	O
molecules	O
around	O
its	O
active	O
site	O
.	O

The	O
catalytic	O
efficiency	O
,	O
regioselectivity	O
,	O
and	O
chemoselectivity	O
of	O
FosA	O
are	O
rationalized	O
in	O
terms	O
of	O
the	O
influence	O
of	O
the	O
active	O
-	O
site	O
protein	O
environment	O
and	O
the	O
different	O
stabilization	O
of	O
the	O
distorted	O
substrates	O
in	O
the	O
relevant	O
transition	O
states	O
.	O

Lessons	O
on	O
conditional	O
gene	O
targeting	O
in	O
mouse	O
adipose	O
tissue	O
.	O

Conditional	O
gene	O
targeting	O
has	O
been	O
extensively	O
used	O
for	O
in	O
vivo	O
analysis	O
of	O
gene	O
function	O
in	O
adipocyte	O
cell	O
biology	O
but	O
often	O
with	O
debate	O
over	O
the	O
tissue	O
specificity	O
and	O
the	O
efficacy	O
of	O
inactivation	O
.	O

To	O
directly	O
compare	O
the	O
specificity	O
and	O
efficacy	O
of	O
different	O
Cre	O
lines	O
in	O
mediating	O
adipocyte	O
specific	O
recombination	O
,	O
transgenic	O
Cre	O
lines	O
driven	O
by	O
the	O
adipocyte	O
protein	O
2	O
(	O
aP2	O
)	O
and	O
adiponectin	O
(	O
Adipoq	O
)	O
gene	O
promoters	O
,	O
as	O
well	O
as	O
a	O
tamoxifen	B
-	O
inducible	O
Cre	O
driven	O
by	O
the	O
aP2	O
gene	O
promoter	O
(	O
iaP2	O
)	O
,	O
were	O
bred	O
to	O
the	O
Rosa26R	O
(	O
R26R	O
)	O
reporter	O
.	O

All	O
three	O
Cre	O
lines	O
demonstrated	O
recombination	O
in	O
the	O
brown	O
and	O
white	O
fat	O
pads	O
.	O

Using	O
different	O
floxed	O
loci	O
,	O
the	O
individual	O
Cre	O
lines	O
displayed	O
a	O
range	O
of	O
efficacy	O
to	O
Cre	O
-	O
mediated	O
recombination	O
that	O
ranged	O
from	O
no	O
observable	O
recombination	O
to	O
complete	O
recombination	O
within	O
the	O
fat	O
.	O

The	O
Adipoq	O
-	O
Cre	O
exhibited	O
no	O
observable	O
recombination	O
in	O
any	O
other	O
tissues	O
examined	O
,	O
whereas	O
both	O
aP2-Cre	O
lines	O
resulted	O
in	O
recombination	O
in	O
endothelial	O
cells	O
of	O
the	O
heart	O
and	O
nonendothelial	O
,	O
nonmyocyte	O
cells	O
in	O
the	O
skeletal	O
muscle	O
.	O

In	O
addition	O
,	O
the	O
aP2-Cre	O
line	O
can	O
lead	O
to	O
germline	O
recombination	O
of	O
floxed	O
alleles	O
in	O
~2	O
%	O
of	O
spermatozoa	O
.	O

Thus	O
,	O
different	O
"	O
adipocyte	O
-	O
specific	O
"	O
Cre	O
lines	O
display	O
different	O
degrees	O
of	O
efficiency	O
and	O
specificity	O
,	O
illustrating	O
important	O
differences	O
that	O
must	O
be	O
taken	O
into	O
account	O
in	O
their	O
use	O
for	O
studying	O
adipose	O
biology	O
.	O

Regulation	O
of	O
	O
-	O
opioid	O
receptors	O
:	O
desensitization	O
,	O
phosphorylation	O
,	O
internalization	O
,	O
and	O
tolerance	O
.	O

Morphine	B
and	O
related	O
-opioid	O
receptor	O
(	O
MOR	O
)	O
agonists	O
remain	O
among	O
the	O
most	O
effective	O
drugs	O
known	O
for	O
acute	O
relief	O
of	O
severe	O
pain	O
.	O

A	O
major	O
problem	O
in	O
treating	O
painful	O
conditions	O
is	O
that	O
tolerance	O
limits	O
the	O
long	O
-	O
term	O
utility	O
of	O
opioid	O
agonists	O
.	O

Considerable	O
effort	O
has	O
been	O
expended	O
on	O
developing	O
an	O
understanding	O
of	O
the	O
molecular	O
and	O
cellular	O
processes	O
that	O
underlie	O
acute	O
MOR	O
signaling	O
,	O
short	O
-	O
term	O
receptor	O
regulation	O
,	O
and	O
the	O
progression	O
of	O
events	O
that	O
lead	O
to	O
tolerance	O
for	O
different	O
MOR	O
agonists	O
.	O

Although	O
great	O
progress	O
has	O
been	O
made	O
in	O
the	O
past	O
decade	O
,	O
many	O
points	O
of	O
contention	O
and	O
controversy	O
cloud	O
the	O
realization	O
of	O
this	O
progress	O
.	O

This	O
review	O
attempts	O
to	O
clarify	O
some	O
confusion	O
by	O
clearly	O
defining	O
terms	O
,	O
such	O
as	O
desensitization	O
and	O
tolerance	O
,	O
and	O
addressing	O
optimal	O
pharmacological	O
analyses	O
for	O
discerning	O
relative	O
importance	O
of	O
these	O
cellular	O
mechanisms	O
.	O

Cellular	O
and	O
molecular	O
mechanisms	O
regulating	O
MOR	O
function	O
by	O
phosphorylation	O
relative	O
to	O
receptor	O
desensitization	O
and	O
endocytosis	O
are	O
comprehensively	O
reviewed	O
,	O
with	O
an	O
emphasis	O
on	O
agonist	O
-	O
biased	O
regulation	O
and	O
areas	O
where	O
knowledge	O
is	O
lacking	O
or	O
controversial	O
.	O

The	O
implications	O
of	O
these	O
mechanisms	O
for	O
understanding	O
the	O
substantial	O
contribution	O
of	O
MOR	O
signaling	O
to	O
opioid	O
tolerance	O
are	O
then	O
considered	O
in	O
detail	O
.	O

While	O
some	O
functional	O
MOR	O
regulatory	O
mechanisms	O
contributing	O
to	O
tolerance	O
are	O
clearly	O
understood	O
,	O
there	O
are	O
large	O
gaps	O
in	O
understanding	O
the	O
molecular	O
processes	O
responsible	O
for	O
loss	O
of	O
MOR	O
function	O
after	O
chronic	O
exposure	O
to	O
opioids	O
.	O

Further	O
elucidation	O
of	O
the	O
cellular	O
mechanisms	O
that	O
are	O
regulated	O
by	O
opioids	O
will	O
be	O
necessary	O
for	O
the	O
successful	O
development	O
of	O
MOR	O
-	O
based	O
approaches	O
to	O
new	O
pain	O
therapeutics	O
that	O
limit	O
the	O
development	O
of	O
tolerance	O
.	O

Microwave	O
absorption	O
in	O
powders	O
of	O
small	O
conducting	O
particles	O
for	O
heating	O
applications	O
.	O

In	O
microwave	O
chemistry	O
there	O
is	O
a	O
common	O
misconception	O
that	O
small	O
,	O
highly	O
conducting	O
particles	O
heat	O
profusely	O
when	O
placed	O
in	O
a	O
large	O
microwave	O
electric	O
field	O
.	O

However	O
,	O
this	O
is	O
not	O
the	O
case	O
;	O
with	O
the	O
simple	O
physical	O
explanation	O
that	O
the	O
electric	O
field	O
(	O
which	O
drives	O
the	O
heating	O
)	O
within	O
a	O
highly	O
conducting	O
particle	O
is	O
highly	O
screened	O
.	O

Instead	O
,	O
it	O
is	O
the	O
magnetic	O
absorption	O
associated	O
with	O
induction	O
that	O
accounts	O
for	O
the	O
large	O
experimental	O
heating	O
rates	O
observed	O
for	O
small	O
metal	O
particles	O
.	O

We	O
present	O
simple	O
principles	O
for	O
the	O
effective	O
heating	O
of	O
particles	O
in	O
microwave	O
fields	O
from	O
calculations	O
of	O
electric	O
and	O
magnetic	O
dipole	O
absorptions	O
for	O
a	O
range	O
of	O
practical	O
values	O
of	O
particle	O
size	O
and	O
conductivity	O
.	O

For	O
highly	O
conducting	O
particles	O
,	O
magnetic	O
absorption	O
dominates	O
electric	O
absorption	O
over	O
a	O
wide	O
range	O
of	O
particle	O
radii	O
,	O
with	O
an	O
optimum	O
absorption	O
set	O
by	O
the	O
ratio	O
of	O
mean	O
particle	O
radius	O
a	O
to	O
the	O
skin	O
depth	O
	O
(	O
specifically	O
,	O
by	O
the	O
condition	O
a	O
=	O
2.41	O
)	O
.	O

This	O
means	O
that	O
for	O
particles	O
of	O
any	O
conductivity	O
,	O
optimized	O
magnetic	O
absorption	O
(	O
and	O
hence	O
microwave	O
heating	O
by	O
magnetic	O
induction	O
)	O
can	O
be	O
achieved	O
by	O
simple	O
selection	O
of	O
the	O
mean	O
particle	O
size	O
.	O

For	O
weakly	O
conducting	O
samples	O
,	O
electric	O
dipole	O
absorption	O
dominates	O
,	O
and	O
is	O
maximized	O
when	O
the	O
conductivity	O
is	O
approximately	O
	O
	O
3	O
(	O
0	O
)	O
	O
0.4	O
S	O
m	O
(	O
-1	O
)	O
,	O
independent	O
of	O
particle	O
radius	O
.	O

Therefore	O
,	O
although	O
electric	O
dipole	O
heating	O
can	O
be	O
as	O
effective	O
as	O
magnetic	O
dipole	O
heating	O
for	O
a	O
powder	O
sample	O
of	O
the	O
same	O
volume	O
,	O
it	O
is	O
harder	O
to	O
obtain	O
optimized	O
conditions	O
at	O
a	O
fixed	O
frequency	O
of	O
microwave	O
field	O
.	O

The	O
absorption	O
of	O
sub	O
-	O
micron	O
particles	O
is	O
ineffective	O
in	O
both	O
magnetic	O
and	O
electric	O
fields	O
.	O

However	O
,	O
if	O
the	O
particles	O
are	O
magnetic	O
,	O
with	O
a	O
lossy	O
part	O
to	O
their	O
complex	O
permeability	O
,	O
then	O
magnetic	O
dipole	O
losses	O
are	O
dramatically	O
enhanced	O
compared	O
to	O
their	O
values	O
for	O
non	O
-	O
magnetic	O
particles	O
.	O

An	O
interesting	O
application	O
of	O
this	O
is	O
the	O
use	O
of	O
very	O
small	O
magnetic	O
particles	O
for	O
the	O
selective	O
microwave	O
heating	O
of	O
biological	O
samples	O
.	O

Insights	O
into	O
TIM	O
-	O
barrel	O
prenyl	O
transferase	O
mechanisms	O
:	O
crystal	O
structures	O
of	O
PcrB	O
from	O
Bacillus	O
subtilis	O
and	O
Staphylococcus	O
aureus	O
.	O

Well	O
structured	O
:	O
As	O
a	O
new	O
triose	B
phosphate	I
isomerase	O
(	O
TIM	O
)	O
barrel	O
-	O
fold	O
prenyl	O
transferase	O
,	O
PcrB	O
catalyzes	O
the	O
production	O
of	O
heptaprenylglyceryl	B
phosphate	I
from	O
heptaprenyl	B
diphosphate	I
and	O
glycerol-1-phosphate	B
.	O

Crystal	O
structures	O
of	O
PcrB	O
from	O
Bacillus	O
subtilis	O
and	O
Staphylococcus	O
aureus	O
in	O
complex	O
with	O
ligands	O
were	O
solved	O
,	O
and	O
together	O
with	O
site	O
-	O
directed	O
mutagenesis	O
and	O
bioinformatics	O
analyses	O
,	O
clearly	O
reveal	O
the	O
catalytic	O
mechanism	O
of	O
the	O
enzyme	O
.	O

Four	O
new	O
koumine	B
metabolites	O
in	O
rat	O
liver	O
microsomes	O
.	O

Four	O
new	O
metabolites	O
M-1	O
[	O
1,2,18,19-tetradehydro-4-demethyl-3,17-epoxy-7,20	B
(	I
2H,19H	I
)	I
-cyclovobasan	I
]	O
,	O
M-2	O
[	O
1,2,4,21,18,19-hexadehydro-4-demethyl-3,17-epoxy-7,20	B
(	I
2H,19H	I
)	I
-cyclovobasan	I
]	O
,	O
M-3	O
[	O
1,2,18,19-tetradehydro-4-demethyl-4-formaldehyde-3,17-epoxy-7,20	B
(	I
2H,19H	I
)	I
-cyclovobasan	I
]	O
,	O
and	O
M-4	O
[	O
1,2,4,21,18,19-hexadehydro-4-demethyl-4-oxy-3,17-epoxy-7,20	B
(	I
2H,19H	I
)	I
-cyclovobasan	I
]	O
were	O
isolated	O
from	O
the	O
chloroform	B
extract	O
of	O
koumine	B
incubated	O
with	O
phenobarbital	B
-	O
treated	O
rat	O
liver	O
microsomes	O
.	O

The	O
structures	O
of	O
M-1	O
,	O
M-2	O
,	O
M-3	O
,	O
and	O
M-4	O
were	O
elucidated	O
by	O
spectroscopic	O
methods	O
including	O
ESI	O
-	O
TOF	O
-	O
MS	O
,	O
1D	O
,	O
and	O
2D	O
NMR	O
experiments	O
.	O

The	O
metabolic	O
pathway	O
of	O
koumine	B
was	O
proposed	O
.	O

The	O
cytotoxic	O
activities	O
between	O
koumine	B
and	O
its	O
metabolites	O
were	O
also	O
compared	O
in	O
the	O
A549	O
cell	O
line	O
.	O

Polymorphism	O
of	O
GeSbTe	B
superlattice	O
nanowires	O
.	O

Scaling	O
-	O
down	O
of	O
phase	O
change	O
materials	O
to	O
a	O
nanowire	O
(	O
NW	O
)	O
geometry	O
is	O
critical	O
to	O
a	O
fast	O
switching	O
speed	O
of	O
nonvolatile	O
memory	O
devices	O
.	O

Herein	O
,	O
we	O
report	O
novel	O
composition	O
-	O
phase	O
-	O
tuned	O
GeSbTe	B
NWs	O
,	O
synthesized	O
by	O
a	O
chemical	O
vapor	O
transport	O
method	O
,	O
which	O
guarantees	O
promising	O
applications	O
in	O
the	O
field	O
of	O
nanoscale	O
electric	O
devices	O
.	O

As	O
the	O
Sb	B
content	O
increased	O
,	O
they	O
showed	O
a	O
distinctive	O
rhombohedral	O
-	O
cubic	O
-	O
rhombohedral	O
phase	O
evolution	O
.	O

Remarkable	O
superlattice	O
structures	O
were	O
identified	O
for	O
the	O
Ge	B
(	I
8	I
)	I
Sb	I
(	I
2	I
)	I
Te	I
(	I
11	I
)	I
,	O
Ge	B
(	I
3	I
)	I
Sb	I
(	I
2	I
)	I
Te	I
(	I
6	I
)	I
,	O
Ge	B
(	I
3	I
)	I
Sb	I
(	I
8	I
)	I
Te	I
(	I
6	I
)	I
,	O
and	O
Ge	B
(	I
2	I
)	I
Sb	I
(	I
7	I
)	I
Te	I
(	I
4	I
)	I
NWs	O
.	O

The	O
coexisting	O
cubic	O
-	O
rhombohedral	O
phase	O
Ge	B
(	I
3	I
)	I
Sb	I
(	I
2	I
)	I
Te	I
(	I
6	I
)	I
NWs	O
exhibited	O
an	O
exclusively	O
uniform	O
superlattice	O
structure	O
consisting	O
of	O
2.2	O
nm	O
period	O
slabs	O
.	O

The	O
rhombohedral	O
phase	O
Ge	B
(	I
3	I
)	I
Sb	I
(	I
8	I
)	I
Te	I
(	I
6	I
)	I
and	O
Ge	B
(	I
2	I
)	I
Sb	I
(	I
7	I
)	I
Te	I
(	I
4	I
)	I
NWs	O
adopted	O
an	O
innovative	O
structure	O
;	O
3Sb	B
(	I
2	I
)	I
layers	O
intercalated	O
the	O
Ge	B
(	I
3	I
)	I
Sb	I
(	I
2	I
)	I
Te	I
(	I
6	I
)	I
and	O
Ge	B
(	I
2	I
)	I
Sb	I
(	I
1	I
)	I
Te	I
(	I
4	I
)	I
domains	O
,	O
respectively	O
,	O
producing	O
3.4	O
and	O
2.7	O
nm	O
period	O
slabs	O
.	O

The	O
current	O
-	O
voltage	O
measurement	O
of	O
the	O
individual	O
NW	O
revealed	O
that	O
the	O
vacancy	O
layers	O
of	O
Ge	B
(	I
8	I
)	I
Sb	I
(	I
2	I
)	I
Te	I
(	I
11	I
)	I
and	O
Ge	B
(	I
3	I
)	I
Sb	I
(	I
2	I
)	I
Te	I
(	I
6	I
)	I
decreased	O
the	O
electrical	O
conductivity	O
.	O

A	O
new	O
flavonoid	B
with	O
6-phenyl	B
substituent	O
from	O
Selaginella	O
uncinata	O
.	O

A	O
new	O
flavonoid	B
,	O
6-	B
(	I
5-acetyl-2-methoxyphenyl	I
)	I
-apigenin	I
(	O
1	O
)	O
,	O
together	O
with	O
nine	O
known	O
compounds	O
(	O
2	O
-	O
10	O
)	O
,	O
was	O
isolated	O
from	O
Selaginella	O
uncinata	O
(	O
Desv	O
.	O
)	O

Spring	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
the	O
spectroscopic	O
data	O
of	O
compound	O
3	O
.	O

Compound	O
2	O
was	O
first	O
reported	O
from	O
this	O
species	O
.	O

The	O
structure	O
of	O
the	O
new	O
compound	O
was	O
elucidated	O
on	O
the	O
basis	O
of	O
spectroscopic	O
evidence	O
,	O
including	O
1D	O
and	O
2D	O
NMR	O
as	O
well	O
as	O
HR	O
-	O
EI	O
-	O
MS	O
analysis	O
.	O

Controlled	O
assembly	O
and	O
release	O
of	O
retinoic	B
acid	I
based	O
on	O
the	O
layer	O
-	O
by	O
-	O
layer	O
method	O
.	O

All	B
-	I
trans	I
retinoic	I
acid	I
(	O
RA	O
)	O
has	O
been	O
proved	O
to	O
play	O
important	O
roles	O
in	O
regulating	O
cell	O
growth	O
in	O
various	O
types	O
of	O
cells	O
.	O

Yet	O
most	O
experiments	O
were	O
performed	O
by	O
adding	O
RA	O
in	O
solution	O
previously	O
.	O

In	O
this	O
Article	O
,	O
we	O
focus	O
on	O
the	O
incorporation	O
of	O
RA	O
,	O
as	O
a	O
negatively	O
charged	O
moiety	O
,	O
into	O
layered	O
polyelectrolyte	O
films	O
on	O
surfaces	O
by	O
means	O
of	O
layer	O
-	O
by	O
-	O
layer	O
(	O
LbL	O
)	O
deposition	O
,	O
followed	O
by	O
adding	O
of	O
capping	O
layers	O
to	O
regulate	O
the	O
release	O
of	O
RA	O
from	O
the	O
films	O
.	O

The	O
incorporated	O
RA	O
was	O
designed	O
to	O
release	O
over	O
5	O
days	O
in	O
buffer	O
solution	O
.	O

The	O
assembly	O
and	O
release	O
of	O
RA	O
were	O
verified	O
by	O
UV	O
and	O
QCM	O
results	O
.	O

The	O
controlled	O
release	O
of	O
RA	O
from	O
multilayer	O
films	O
can	O
serve	O
as	O
a	O
model	O
system	O
to	O
study	O
the	O
influence	O
of	O
small	O
molecules	O
on	O
cell	O
growth	O
.	O

Phase	O
separation	O
induced	O
by	O
Au	B
catalysts	O
in	O
ternary	O
InGaAs	B
nanowires	O
.	O

We	O
report	O
a	O
novel	O
phase	O
separation	O
phenomenon	O
observed	O
in	O
the	O
growth	O
of	O
ternary	O
In	B
(	I
x	I
)	I
Ga	I
(	I
1-x	I
)	I
As	I
nanowires	O
by	O
metalorganic	O
chemical	O
vapor	O
deposition	O
.	O

A	O
spontaneous	O
formation	O
of	O
core	O
-	O
shell	O
nanowires	O
is	O
investigated	O
by	O
cross	O
-	O
sectional	O
transmission	O
electron	O
microscopy	O
,	O
revealing	O
the	O
compositional	O
complexity	O
within	O
the	O
ternary	O
nanowires	O
.	O

It	O
has	O
been	O
found	O
that	O
for	O
In	B
(	I
x	I
)	I
Ga	I
(	I
1-x	I
)	I
As	I
nanowires	O
high	O
precursor	O
flow	O
rates	O
generate	O
ternary	O
In	B
(	I
x	I
)	I
Ga	I
(	I
1-x	I
)	I
As	I
cores	O
with	O
In	O
-	O
rich	O
shells	O
,	O
while	O
low	O
precursor	O
flow	O
rates	O
produce	O
binary	O
GaAs	B
cores	O
with	O
ternary	O
In	B
(	I
x	I
)	I
Ga	I
(	I
1-x	I
)	I
As	I
shells	O
.	O

First	O
-	O
principle	O
calculations	O
combined	O
with	O
thermodynamic	O
considerations	O
suggest	O
that	O
this	O
phenomenon	O
is	O
due	O
to	O
competitive	O
alloying	O
of	O
different	O
group	O
-	O
III	O
elements	O
with	O
Au	B
catalysts	O
,	O
and	O
variations	O
in	O
elemental	O
concentrations	O
of	O
group	O
-	O
III	O
materials	O
in	O
the	O
catalyst	O
under	O
different	O
precursor	O
flow	O
rates	O
.	O

This	O
study	O
shows	O
that	O
precursor	O
flow	O
rates	O
are	O
critical	O
factors	O
for	O
manipulating	O
Au	B
catalysts	O
to	O
produce	O
nanowires	O
of	O
desired	O
composition	O
.	O

Synthesis	O
and	O
antibacterial	O
evaluation	O
of	O
typharin	B
analog	O
:	O
6,8-dihydroxy-7-methyl-3-styryl-3,4-dihydroisocoumarin	B
.	O

Synthesis	O
of	O
the	O
6-hydroxy-7-methyl	B
analog	O
of	O
typharin	B
(	O
8-dihydroxy-3-styryl-3,4-dihydroisocoumarin	B
)	O
isolated	O
from	O
the	O
rhizomes	O
of	O
Typha	O
capensis	O
has	O
been	O
described	O
.	O

Direct	O
condensation	O
of	O
3,5-dimethoxy-4-methylhomophthalic	B
acid	I
(	O
1	O
)	O
with	O
cinnamoyl	B
chloride	I
at	O
elevated	O
temperature	O
under	O
inert	O
conditions	O
afforded	O
6,8-dihydroxy-7-methyl-3-styrylisocoumarin	B
(	O
2	O
)	O
.	O

Hydrolysis	O
of	O
isocoumarin	B
to	O
keto	B
acid	I
(	O
3	O
)	O
followed	O
by	O
reduction	O
and	O
cyclodehydration	O
of	O
hydroxy	B
acid	I
analog	O
(	O
4	O
)	O
afforded	O
(	B
	I
)	I
-6,8-dimethoxy-3-	I
(	I
4-methoxyphenyl	I
)	I
-3,4-dihydroisocoumarin	I
(	O
5	O
)	O
.	O

Demethylation	O
of	O
the	O
latter	O
using	O
anhydrous	O
aluminum	B
chloride	I
/	O
ethane	B
thiol	I
furnished	O
the	O
title	O
isocoumarin	B
(	O
6	O
)	O
.	O

Compounds	O
(	O
1	O
-	O
6	O
)	O
were	O
screened	O
for	O
in	O
vitro	O
antibacterial	O
activity	O
against	O
a	O
representative	O
panel	O
of	O
Gram	O
-	O
positive	O
and	O
Gram	O
-	O
negative	O
bacteria	O
using	O
levofloxacin	B
as	O
the	O
reference	O
drug	O
.	O

Losmapimod	B
concentration	O
-	O
QT	O
relationship	O
in	O
healthy	O
volunteers	O
:	O
meta	O
-	O
analysis	O
of	O
data	O
from	O
six	O
clinical	O
trials	O
.	O

PURPOSE	O
:	O
The	O
objective	O
of	O
this	O
work	O
was	O
to	O
describe	O
the	O
losmapimod	B
concentration	O
-	O
QT	O
relationship	O
using	O
meta	O
-	O
analysis	O
of	O
data	O
from	O
clinical	O
trials	O
with	O
healthy	O
volunteers	O
and	O
to	O
evaluate	O
the	O
covariates	O
that	O
have	O
significant	O
impact	O
on	O
the	O
QT	O
prolongation	O
.	O

METHODS	O
:	O
Losmapimod	B
plasma	O
concentration	O
and	O
QT	O
interval	O
data	O
were	O
collected	O
from	O
six	O
early	O
clinical	O
studies	O
with	O
healthy	O
volunteers	O
.	O

The	O
electrocardiograms	O
(	O
ECGs	O
)	O
were	O
collected	O
at	O
baseline	O
and	O
at	O
a	O
number	O
of	O
post	O
-	O
dose	O
time	O
points	O
(	O
losmapimod	B
or	O
placebo	O
)	O
.	O

The	O
population	O
pharmacokinetic	O
/	O
pharmacodynamic	O
(	O
PK	O
/	O
PD	O
)	O
modelling	O
approach	O
was	O
applied	O
to	O
investigate	O
the	O
relationship	O
between	O
losmapimod	B
concentration	O
and	O
QT	O
prolongation	O
.	O

RESULTS	O
:	O
The	O
dataset	O
for	O
analysis	O
comprised	O
190	O
healthy	O
adults	O
who	O
took	O
at	O
least	O
one	O
dose	O
of	O
losmapimod	B
or	O
placebo	O
.	O

Of	O
the	O
2,494	O
QT	O
observations	O
collected	O
,	O
1,532	O
observations	O
had	O
matched	O
QT	O
and	O
losmapimod	B
plasma	O
concentration	O
data	O
.	O

Population	O
PK	O
/	O
PD	O
analyses	O
indicated	O
that	O
the	O
model	O
with	O
the	O
individual	O
heart	O
rate	O
correction	O
factor	O
(	O
	O
)	O
fitted	O
the	O
data	O
better	O
than	O
those	O
using	O
fixed	O
	O
(	O
0.33	O
for	O
Fridericia	O
's	O
correction	O
or	O
0.5	O
for	O
Bazett	O
's	O
correction	O
)	O
and	O
that	O
there	O
was	O
no	O
relationship	O
between	O
losmapimod	B
concentration	O
and	O
QT	O
interval	O
.	O

Female	O
volunteers	O
had	O
about	O
a	O
3	O
%	O
higher	O
QT	O
interval	O
at	O
baseline	O
than	O
the	O
male	O
volunteers	O
.	O

No	O
other	O
covariates	O
had	O
a	O
significant	O
effect	O
on	O
the	O
QT	O
interval	O
.	O

CONCLUSIONS	O
:	O
It	O
is	O
appropriate	O
to	O
apply	O
population	O
PK	O
/	O
PD	O
analysis	O
to	O
investigate	O
the	O
effect	O
of	O
drug	O
concentration	O
on	O
QT	O
prolongation	O
.	O

Our	O
meta	O
-	O
analysis	O
of	O
healthy	O
volunteer	O
data	O
indicated	O
no	O
relationship	O
between	O
systemic	O
losmapimod	B
concentration	O
and	O
QT	O
interval	O
in	O
healthy	O
volunteers	O
.	O

Activation	O
of	O
AMP	B
-	O
activated	O
Protein	O
Kinase	O
and	O
Phosphorylation	O
of	O
Glycogen	O
Synthase	O
Kinase3	O
	O
Mediate	O
Ursolic	B
Acid	I
Induced	O
Apoptosis	O
in	O
HepG2	O
Liver	O
Cancer	O
Cells	O
.	O

Despite	O
the	O
antitumour	O
effect	O
of	O
ursolic	B
acid	I
observed	O
in	O
several	O
cancers	O
,	O
the	O
underlying	O
mechanism	O
remains	O
unclear	O
.	O

Thus	O
,	O
in	O
the	O
present	O
study	O
,	O
the	O
roles	O
of	O
AMP	B
-	O
activated	O
protein	O
kinase	O
(	O
AMPK	O
)	O
and	O
glycogen	O
synthase	O
kinase	O
3	O
beta	O
(	O
GSK3	O
)	O
were	O
examined	O
in	O
ursolic	O
acid	O
induced	O
apoptosis	O
in	O
HepG2	O
hepatocellular	O
carcinoma	O
cells	O
.	O

Ursolic	B
acid	I
significantly	O
exerted	O
cytotoxicity	O
,	O
increased	O
the	O
sub	O
-	O
G1	O
population	O
and	O
the	O
number	O
of	O
ethidium	B
homodimer	O
and	O
terminal	O
deoxynucleotidyl	O
transferase	O
(	O
TdT	O
)	O
mediated	O
dUTP	B
nick	O
end	O
labeling	O
positive	O
cells	O
in	O
HepG2	O
cells	O
.	O

Also	O
,	O
ursolic	O
acid	O
enhanced	O
the	O
cleavages	O
of	O
poly	B
-	I
ADP	I
-	I
ribose	I
polymerase	O
(	O
PARP	O
)	O
and	O
caspase3	O
,	O
attenuated	O
the	O
expression	O
of	O
astrocyte	O
elevated	O
gene	O
(	O
AEG1	O
)	O
and	O
survivin	O
in	O
HepG2	O
cells	O
.	O

Interestingly	O
,	O
ursolic	B
acid	I
increased	O
the	O
phosphorylation	O
of	O
AMPK	O
and	O
coenzyme	O
A	O
carboxylase	O
and	O
also	O
enhanced	O
phosphorylation	O
of	O
GSK3	O
at	O
inactive	O
form	O
serine	B
9	O
,	O
whereas	O
ursolic	B
acid	I
attenuated	O
the	O
phosphorylation	O
of	O
AKT	O
and	O
mTOR	O
in	O
HepG2	O
cells	O
.	O

Conversely	O
,	O
AMPK	O
inhibitor	O
compound	B
C	I
or	O
GSK3	O
inhibitor	O
SB216763	B
blocked	O
the	O
cleavages	O
of	O
PARP	O
and	O
caspase	O
3	O
induced	O
by	O
ursolic	B
acid	I
in	O
HepG2	O
cells	O
.	O

Furthermore	O
,	O
proteosomal	O
inhibitor	O
MG132	B
suppressed	O
AMPK	O
activation	O
,	O
GSK3	O
phosphorylation	O
,	O
cleaved	O
PARP	O
and	O
deceased	O
AEG-1	O
induced	O
by	O
ursolic	B
acid	I
in	O
HepG2	O
cells	O
.	O

Overall	O
,	O
our	O
findings	O
suggest	O
that	O
ursolic	B
acid	I
induced	O
apoptosis	O
in	O
HepG2	O
cells	O
via	O
AMPK	O
activation	O
and	O
GSK3	O
phosphorylation	O
as	O
a	O
potent	O
chemopreventive	O
agent	O
.	O

Copyright	O
	O
2013	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd.	O

A	O
thermoplastic	O
elastomer	O
patch	O
matrix	O
for	O
traditional	O
Chinese	O
medicine	O
:	O
design	O
and	O
evaluation	O
.	O

Abstract	O
Objective	O
:	O
To	O
design	O
and	O
evaluate	O
a	O
novel	O
pressure	O
sensitive	O
adhesive	O
(	O
PSA	O
)	O
patch	O
containing	O
traditional	O
Chinese	O
medicine	O
(	O
TCM	O
)	O
using	O
styrene	B
-	I
isoprene	I
-	I
styrene	I
(	O
SIS	B
)	O
copolymer	O
.	O

Method	O
:	O
A	O
mixture	O
D	O
-	O
optimal	O
design	O
with	O
ternary	O
response	O
surface	O
diagram	O
was	O
employed	O
in	O
the	O
optimization	O
process	O
.	O

The	O
proportions	O
of	O
SIS	B
copolymer	O
,	O
tackifying	O
resin	O
and	O
plasticizer	O
were	O
selected	O
as	O
the	O
independent	O
variables	O
while	O
tack	O
force	O
,	O
peel	O
strength	O
of	O
the	O
patch	O
and	O
skin	O
penetrability	O
of	O
methyl	B
salicylate	I
were	O
selected	O
as	O
the	O
dependent	O
variables	O
.	O

The	O
optimized	O
patch	O
was	O
then	O
evaluated	O
including	O
in	O
vivo	O
absorption	O
,	O
pharmacological	O
activities	O
and	O
skin	O
irritation	O
,	O
by	O
comparing	O
with	O
a	O
commercial	O
patch	O
based	O
on	O
natural	O
rubber	O
.	O

Results	O
:	O
The	O
optimized	O
patch	O
,	O
which	O
comprised	O
30.0	O
%	O
SIS	B
copolymer	O
,	O
26.6	O
%	O
tackifying	O
resin	O
and	O
43.4	O
%	O
plasticizer	O
,	O
was	O
superior	O
to	O
commercial	O
patch	O
in	O
skin	O
permeation	O
,	O
pharmacological	O
activities	O
and	O
skin	O
biocompatibility	O
.	O

Conclusion	O
:	O
SIS	B
copolymer	O
was	O
a	O
suitable	O
substitute	O
to	O
natural	O
rubber	O
in	O
producing	O
patches	O
containing	O
TCM	O
formula	O
.	O

High	O
-	O
contrast	O
electrooptic	O
modulation	O
of	O
a	O
photonic	O
crystal	O
nanocavity	O
by	O
electrical	O
gating	O
of	O
graphene	B
.	O

We	O
demonstrate	O
high	O
-	O
contrast	O
electro	O
-	O
optic	O
modulation	O
of	O
a	O
photonic	O
crystal	O
nanocavity	O
integrated	O
with	O
an	O
electrically	O
gated	O
monolayer	O
graphene	B
.	O

A	O
silicon	O
air	O
-	O
slot	O
nanocavity	O
provides	O
strong	O
overlap	O
between	O
the	O
resonant	O
optical	O
field	O
and	O
graphene	B
.	O

Tuning	O
the	O
Fermi	O
energy	O
of	O
the	O
graphene	B
layer	O
to	O
0.85	O
eV	O
enables	O
strong	O
control	O
of	O
its	O
optical	O
conductivity	O
at	O
telecom	O
wavelengths	O
,	O
which	O
allows	O
modulation	O
of	O
cavity	O
reflection	O
in	O
excess	O
of	O
10	O
dB	O
for	O
a	O
swing	O
voltage	O
of	O
only	O
1.5	O
V.	O
The	O
cavity	O
resonance	O
at	O
1570	O
nm	O
is	O
found	O
to	O
undergo	O
a	O
shift	O
in	O
wavelength	O
of	O
nearly	O
2	O
nm	O
,	O
together	O
with	O
a	O
3-fold	O
increase	O
in	O
quality	O
factor	O
.	O

These	O
observations	O
enable	O
a	O
cavity	O
-	O
enhanced	O
determination	O
of	O
graphene	B
's	O
complex	O
optical	O
sheet	O
conductivity	O
at	O
different	O
doping	O
levels	O
.	O

Our	O
simple	O
device	O
demonstrates	O
the	O
feasibility	O
of	O
high	O
-	O
contrast	O
,	O
low	O
-	O
power	O
,	O
and	O
frequency	O
-	O
selective	O
electro	O
-	O
optic	O
modulators	O
in	O
graphene	B
-	O
integrated	O
silicon	B
photonic	O
integrated	O
circuits	O
.	O

Nucleophosmin	O
mutations	O
alter	O
its	O
nucleolar	O
localization	O
by	O
impairing	O
G	O
-	O
quadruplex	O
binding	O
at	O
ribosomal	O
DNA	O
.	O

Nucleophosmin	O
(	O
NPM1	O
)	O
is	O
an	O
abundant	O
nucleolar	O
protein	O
implicated	O
in	O
ribosome	O
maturation	O
and	O
export	O
,	O
centrosome	O
duplication	O
and	O
response	O
to	O
stress	O
stimuli	O
.	O

NPM1	O
is	O
the	O
most	O
frequently	O
mutated	O
gene	O
in	O
acute	O
myeloid	O
leukemia	O
.	O

Mutations	O
at	O
the	O
C	O
-	O
terminal	O
domain	O
led	O
to	O
variant	O
proteins	O
that	O
aberrantly	O
and	O
stably	O
translocate	O
to	O
the	O
cytoplasm	O
.	O

We	O
have	O
previously	O
shown	O
that	O
NPM1	O
C	O
-	O
terminal	O
domain	O
binds	O
with	O
high	O
affinity	O
G	O
-	O
quadruplex	O
DNA	O
.	O

Here	O
,	O
we	O
investigate	O
the	O
structural	O
determinants	O
of	O
NPM1	O
nucleolar	O
localization	O
.	O

We	O
show	O
that	O
NPM1	O
interacts	O
with	O
several	O
G	O
-	O
quadruplex	O
regions	O
found	O
in	O
ribosomal	O
DNA	O
,	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Furthermore	O
,	O
the	O
most	O
common	O
leukemic	O
NPM1	O
variant	O
completely	O
loses	O
this	O
activity	O
.	O

This	O
is	O
the	O
consequence	O
of	O
G	O
-	O
quadruplex	O
-	O
binding	O
domain	O
destabilization	O
,	O
as	O
mutations	O
aimed	O
at	O
refolding	O
the	O
leukemic	O
variant	O
also	O
result	O
in	O
rescuing	O
the	O
G	O
-	O
quadruplex	O
-	O
binding	O
activity	O
and	O
nucleolar	O
localization	O
.	O

Finally	O
,	O
we	O
show	O
that	O
treatment	O
of	O
cells	O
with	O
a	O
G	O
-	O
quadruplex	O
selective	O
ligand	O
results	O
in	O
wild	O
-	O
type	O
NPM1	O
dislocation	O
from	O
nucleoli	O
into	O
nucleoplasm	O
.	O

In	O
conclusion	O
,	O
this	O
work	O
establishes	O
a	O
direct	O
correlation	O
between	O
NPM1	O
G	O
-	O
quadruplex	O
binding	O
at	O
rDNA	O
and	O
its	O
nucleolar	O
localization	O
,	O
which	O
is	O
impaired	O
in	O
the	O
acute	O
myeloid	O
leukemia	O
-	O
associated	O
protein	O
variants	O
.	O

Novel	O
anticoagulants	O
in	O
the	O
therapy	O
of	O
peripheral	O
arterial	O
and	O
coronary	O
artery	O
disease	O
.	O

Anticoagulant	O
and	O
antiplatelet	O
drugs	O
are	O
used	O
and	O
studied	O
in	O
numerous	O
trials	O
for	O
primary	O
and	O
secondary	O
prevention	O
of	O
atherothrombosis	O
since	O
decades	O
.	O

The	O
annual	O
rate	O
for	O
cardiovascular	O
morbidity	O
and	O
mortality	O
is	O
high	O
in	O
patients	O
following	O
an	O
acute	O
coronary	O
syndrome	O
and	O
in	O
patients	O
with	O
peripheral	O
arterial	O
disease	O
(	O
PAD	O
)	O
due	O
to	O
concomitant	O
cardiac	O
and	O
cerebrovascular	O
diseases	O
.	O

Plaque	O
rupture	O
and	O
subsequent	O
thrombosis	O
involves	O
activation	O
of	O
both	O
platelets	O
and	O
coagulation	O
factors	O
.	O

Therefore	O
the	O
combination	O
of	O
aspirin	B
and	O
warfarin	B
to	O
improve	O
prevention	O
of	O
atherothrombosis	O
compared	O
to	O
antiplatelet	O
therapy	O
alone	O
was	O
studied	O
but	O
could	O
not	O
be	O
established	O
due	O
to	O
significantly	O
increased	O
risk	O
of	O
major	O
bleeding	O
compared	O
to	O
a	O
nonsignificant	O
reduction	O
in	O
ischemic	O
events	O
.	O

During	O
the	O
past	O
two	O
decades	O
,	O
clinical	O
trials	O
focused	O
on	O
combined	O
antiplatelet	O
therapies	O
for	O
the	O
prevention	O
of	O
secondary	O
events	O
following	O
acute	O
coronary	O
syndromes	O
and	O
very	O
recently	O
on	O
the	O
new	O
oral	O
anticoagulants	O
in	O
combination	O
with	O
antiplatelet	O
therapy	O
.	O

This	O
review	O
discusses	O
the	O
role	O
of	O
the	O
new	O
oral	O
anticoagulants	O
such	O
as	O
Factor	O
IIa	O
(	O
thrombin	O
)	O
and	O
Factor	O
Xa	O
inhibitors	O
in	O
atherothrombosis	O
,	O
their	O
pharmacological	O
properties	O
and	O
recently	O
published	O
clinical	O
data	O
in	O
secondary	O
prevention	O
of	O
atherothrombotic	O
events	O
and	O
potential	O
implications	O
for	O
patients	O
with	O
PAD	O
.	O

Mineralocorticoid	O
receptor	O
antagonists	O
for	O
therapy	O
of	O
coronary	O
artery	O
disease	O
and	O
related	O
complications	O
.	O

The	O
perception	O
of	O
aldosterone	B
action	O
to	O
be	O
restricted	O
to	O
regulation	O
of	O
fluid	O
balance	O
via	O
sodium	B
reabsorption	O
and	O
potassium	B
excretion	O
is	O
incomplete	O
;	O
plenty	O
of	O
experimental	O
and	O
clinical	O
studies	O
have	O
shown	O
that	O
aldosterone	B
plays	O
a	O
pivotal	O
role	O
in	O
a	O
variety	O
of	O
(	O
patho-	O
)	O
physiologic	O
conditions	O
within	O
the	O
cardiovascular	O
continuum	O
.	O

Deleterious	O
effects	O
include	O
cardiovascular	O
inflammation	O
,	O
endothelial	O
dysfunction	O
,	O
structural	O
and	O
electrical	O
remodelling	O
.	O

Mineralocorticoid	O
receptor	O
antagonists	O
(	O
MRAs	O
)	O
,	O
such	O
as	O
spironolactone	B
and	O
eplerenone	B
,	O
prevent	O
some	O
of	O
these	O
maladaptive	O
effects	O
on	O
the	O
cardiovascular	O
system	O
and	O
have	O
proven	O
to	O
be	O
a	O
highly	O
efficacious	O
pharmacological	O
therapy	O
.	O

In	O
this	O
article	O
we	O
review	O
the	O
current	O
clinical	O
impact	O
of	O
MRAs	O
in	O
the	O
treatment	O
of	O
coronary	O
artery	O
disease	O
(	O
CAD	O
)	O
and	O
its	O
related	O
complications	O
,	O
for	O
example	O
,	O
acute	O
myocardial	O
infarction	O
(	O
MI	O
)	O
and	O
chronic	O
heart	O
failure	O
.	O

Cryptotanshinone	B
and	O
dihydrotanshinone	B
I	I
exhibit	O
strong	O
inhibition	O
towards	O
human	O
liver	O
microsome	O
(	O
HLM	O
)	O
-catalyzed	O
propofol	B
glucuronidation	O
.	O

Danshen	O
is	O
one	O
of	O
the	O
most	O
famous	O
herbs	O
in	O
the	O
world	O
,	O
and	O
more	O
and	O
more	O
danshen	O
-	O
prescribed	O
drugs	O
interactions	O
have	O
been	O
reported	O
in	O
recent	O
years	O
.	O

Evaluation	O
of	O
inhibition	O
potential	O
of	O
danshen	O
's	O
major	O
ingredients	O
towards	O
UDP	B
-	O
glucuronosyltransferases	O
(	O
UGTs	O
)	O
will	O
be	O
helpful	O
for	O
understanding	O
detailed	O
mechanisms	O
for	O
danshen	O
-	O
drugs	O
interaction	O
.	O

Therefore	O
,	O
the	O
aim	O
of	O
the	O
present	O
study	O
is	O
to	O
investigate	O
the	O
inhibitory	O
situation	O
of	O
cryptotanshinone	B
and	O
dihydrotanshinone	B
I	I
towards	O
UGT	O
enzyme	O
-	O
catalyzed	O
propofol	B
glucuronidation	O
.	O

In	O
vitro	O
the	O
human	O
liver	O
microsome	O
(	O
HLM	O
)	O
incubation	O
system	O
was	O
used	O
,	O
and	O
the	O
results	O
showed	O
that	O
cryptotanshinone	B
and	O
dihydrotanshinone	B
I	I
exhibited	O
dose	O
-	O
dependent	O
inhibition	O
towards	O
HLM	O
-	O
catalyzed	O
propofol	B
glucuronidation	O
.	O

Dixon	O
plot	O
and	O
Lineweaver	O
-	O
Burk	O
plot	O
showed	O
that	O
the	O
inhibition	O
type	O
was	O
best	O
fit	O
to	O
competitive	O
inhibition	O
type	O
for	O
both	O
cryptotanshinone	B
and	O
dihydrotanshinone	B
I.	I
The	O
second	O
plot	O
using	O
the	O
slopes	O
from	O
the	O
Lineweaver	O
-	O
Burk	O
plot	O
versus	O
the	O
concentrations	O
of	O
cryptotanshinone	B
or	O
dihydrotanshinone	B
I	I
was	O
employed	O
to	O
calculate	O
the	O
inhibition	O
parameters	O
(	O
Ki	O
)	O
to	O
be	O
0.4	O
and	O
1.7M	O
,	O
respectively	O
.	O

Using	O
the	O
reported	O
maximum	O
plasma	O
concentration	O
(	O
Cmax	O
)	O
,	O
the	O
altered	O
in	O
vivo	O
exposure	O
of	O
propofol	B
increased	O
by	O
10	O
%	O
and	O
8.2	O
%	O
for	O
the	O
co	O
-	O
administration	O
of	O
dihydrotanshinone	B
I	I
and	O
cryptotanshinone	B
,	O
respectively	O
.	O

All	O
these	O
results	O
indicated	O
the	O
possible	O
danshen	O
-	O
propofol	B
interaction	O
due	O
to	O
the	O
inhibition	O
of	O
dihydrotanshinone	B
I	I
and	O
cryptotanshinone	B
towards	O
the	O
glucuronidation	O
reaction	O
of	O
propofol	B
.	O

Investigations	O
of	O
dipeptide	B
structures	O
containing	O
pyrrolysine	B
as	O
N	B
-	O
terminal	O
residues	O
:	O
a	O
DFT	O
study	O
in	O
gas	O
and	O
aqueous	O
phase	O
.	O

A	O
set	O
of	O
six	O
dipeptides	B
containing	O
pyrrolysine	B
invariably	O
at	O
their	O
N	O
-	O
terminal	O
positions	O
is	O
studied	O
in	O
gas	O
and	O
aqueous	O
phase	O
using	O
a	O
polarizable	O
continuum	O
model	O
(	O
PCM	O
)	O
.	O

The	O
molecular	O
geometries	O
of	O
the	O
dipeptides	B
are	O
fully	O
optimized	O
at	O
B3LYP	O
/	O
6	O
-	O
31++G	O
(	O
d	O
,	O
p	O
)	O
level	O
of	O
theory	O
and	O
a	O
second	O
derivative	O
(	O
frequency	O
)	O
analysis	O
confirms	O
that	O
all	O
the	O
optimized	O
geometries	O
are	O
true	O
minima	O
.	O

The	O
effects	O
of	O
solvation	O
and	O
identity	O
of	O
the	O
varying	O
C	O
-	O
terminal	O
residue	O
on	O
the	O
energetics	O
,	O
structural	O
features	O
of	O
the	O
peptide	O
planes	O
,	O
values	O
of	O
the	O
	O
and	O
	O
dihedrals	O
,	O
geometry	O
around	O
the	O
	B
-	I
carbon	I
atoms	O
and	O
theoretically	O
predicted	O
vibrational	O
spectra	O
of	O
the	O
dipeptides	B
are	O
thoroughly	O
analyzed	O
.	O

Solvation	O
effects	O
are	O
found	O
to	O
modify	O
the	O
gas	O
phase	O
conformation	O
of	O
the	O
dipeptides	B
around	O
	O
dihedrals	O
while	O
the	O
identity	O
of	O
the	O
varying	O
C	O
-	O
terminal	O
residue	O
affect	O
the	O
values	O
of	O
	O
,	O
planarity	O
of	O
the	O
peptide	O
planes	O
and	O
geometry	O
around	O
the	O
	B
-	I
carbon	I
atoms	O
.	O

The	O
presence	O
or	O
absence	O
of	O
three	O
types	O
of	O
intramolecular	O
H	O
-	O
bonds	O
,	O
namely	O
O	O
...	O
H	B
-	I
N	I
,	O
N	O
...	O
H	B
-	I
N	I
and	O
O	O
...	O
H	B
-	I
C	I
that	O
leave	O
noticeable	O
signatures	O
in	O
the	O
IR	O
spectra	O
,	O
play	O
crucial	O
roles	O
in	O
influencing	O
the	O
geometry	O
of	O
the	O
peptide	O
planes	O
and	O
in	O
determining	O
the	O
energetics	O
of	O
the	O
dipeptides	B
.	O

NMR	O
investigation	O
on	O
the	O
DNA	O
binding	O
and	O
B	O
-	O
Z	O
transition	O
pathway	O
of	O
the	O
Z	O
domain	O
of	O
human	O
ADAR1	O
.	O

Human	O
ADAR1	O
,	O
which	O
has	O
two	O
left	O
-	O
handed	O
Z	O
-	O
DNA	O
binding	O
domains	O
,	O
preferentially	O
binds	O
Z	O
-	O
DNA	O
rather	O
than	O
B	O
-	O
DNA	O
with	O
a	O
high	O
binding	O
affinity	O
.	O

Z	O
-	O
DNA	O
can	O
be	O
induced	O
in	O
long	O
genomic	O
DNA	O
by	O
Z	O
-	O
DNA	O
binding	O
proteins	O
through	O
the	O
formation	O
of	O
two	O
B	O
-	O
Z	O
junctions	O
with	O
the	O
extrusion	O
of	O
one	O
base	O
pair	O
from	O
each	O
junction	O
.	O

We	O
performed	O
NMR	O
experiments	O
on	O
complexes	O
of	O
Z	O
(	O
ADAR1	O
)	O
with	O
three	O
DNA	O
duplexes	O
at	O
a	O
variety	O
of	O
protein	O
-	O
to	O
-	O
DNA	O
molar	O
ratios	O
.	O

This	O
study	O
confirmed	O
that	O
the	O
Z	O
(	O
ADAR1	O
)	O
first	O
binds	O
to	O
an	O
8-bp	O
CG	O
-	O
rich	O
DNA	O
segment	O
via	O
a	O
unique	O
conformation	O
during	O
B	O
-	O
Z	O
transition	O
and	O
the	O
neighboring	O
AT	O
-	O
rich	O
region	O
becomes	O
destabilized	O
.	O

We	O
also	O
found	O
that	O
,	O
when	O
DNA	O
duplexes	O
have	O
only	O
6-bp	O
CG	O
-	O
rich	O
segment	O
,	O
the	O
interaction	O
with	O
Z	O
(	O
ADAR1	O
)	O
did	O
not	O
affect	O
the	O
thermal	O
stabilities	O
of	O
the	O
6-bp	O
CG	O
-	O
rich	O
segment	O
as	O
well	O
as	O
the	O
neighboring	O
two	O
AT	O
base	O
pairs	O
.	O

These	O
results	O
indicate	O
that	O
four	O
Z	O
(	O
ADAR1	O
)	O
proteins	O
interact	O
with	O
the	O
8-bp	O
DNA	O
sequence	O
containing	O
a	O
6-bp	O
CG	O
-	O
repeat	O
segment	O
as	O
well	O
as	O
a	O
dinucleotide	O
step	O
,	O
even	O
though	O
the	O
dinucleotid	O
step	O
contains	O
AT	O
base	O
pairs	O
.	O

Thus	O
this	O
study	O
suggests	O
that	O
the	O
length	O
of	O
the	O
CG	O
-	O
rich	O
region	O
is	O
more	O
important	O
than	O
the	O
specific	O
DNA	O
sequence	O
for	O
determining	O
which	O
base	O
-	O
pair	O
is	O
extruded	O
from	O
the	O
B	O
-	O
Z	O
junction	O
structure	O
.	O

This	O
study	O
also	O
found	O
that	O
the	O
Z	O
(	O
ADAR1	O
)	O
in	O
complex	O
with	O
a	O
11-bp	O
DNA	O
duplex	O
exhibits	O
a	O
Z	O
-	O
DNA	O
-	O
bound	O
conformation	O
distinct	O
from	O
that	O
of	O
free	O
Z	O
(	O
ADAR1	O
)	O
and	O
the	O
initial	O
contact	O
conformations	O
of	O
Z	O
(	O
ADAR1	O
)	O
complexed	O
with	O
13-bp	O
DNA	O
duplexes	O
.	O

Room	O
-	O
temperature	O
ferromagnetism	O
in	O
ZnO	B
-	O
encapsulated	O
1.9	O
nm	O
FePt3	B
nanoparticle	O
-	O
composite	O
thin	O
films	O
with	O
giant	O
interfacial	O
anisotropy	O
.	O

As	O
synthesized	O
1.9-nm	O
FePt3	B
nanoparticles	O
are	O
superparamagnetic	O
at	O
room	O
temperature	O
.	O

Coating	O
those	O
nanoparticles	O
with	O
ZnO	B
renders	O
them	O
permanently	O
ferromagnetic	O
with	O
coercivity	O
field	O
of	O
650	O
Oe	O
at	O
room	O
temperature	O
.	O

First	O
-	O
principles	O
calculations	O
indicate	O
that	O
giant	O
interfacial	O
anisotropy	O
,	O
induced	O
by	O
the	O
strong	O
spin	O
-	O
orbit	O
interaction	O
of	O
enhanced	O
orbit	O
momentum	O
of	O
Fe	B
,	O
overcomes	O
the	O
superparamagnetic	O
limit	O
,	O
leading	O
to	O
exceptional	O
room	O
-	O
temperature	O
permanent	O
ferromagnetism	O
.	O

The	O
findings	O
are	O
important	O
for	O
the	O
understanding	O
of	O
the	O
origin	O
of	O
permanent	O
ferromagnetism	O
at	O
ultrasmall	O
size	O
and	O
critical	O
for	O
ultrahigh	O
density	O
recording	O
and	O
information	O
processing	O
.	O

ZnO	B
is	O
a	O
CO	B
(	I
2	I
)	I
-selective	O
steam	O
reforming	O
catalyst	O
.	O

ZnO	B
was	O
tested	O
as	O
possible	O
methanol	B
and	O
-	O
since	O
formaldehyde	B
is	O
one	O
of	O
the	O
key	O
intermediates	O
in	O
methanol	B
conversion	O
reactions	O
-	O
also	O
as	O
formaldehyde	B
steam	O
reforming	O
catalyst	O
.	O

Catalytic	O
experiments	O
in	O
a	O
batch	O
as	O
well	O
as	O
a	O
flow	O
reactor	O
resulted	O
in	O
highly	O
selective	O
steam	O
reforming	O
,	O
though	O
at	O
low	O
specific	O
activities	O
,	O
of	O
formaldehyde	B
and	O
methanol	B
over	O
ZnO	B
toward	O
CO	B
(	I
2	I
)	I
(	O
selectivity	O
of	O
95	O
-	O
99.6	O
%	O
)	O
.	O

Comparison	O
of	O
the	O
behavior	O
of	O
ZnPd	B
near	O
-	O
surface	O
intermetallic	O
phases	O
,	O
unsupported	O
intermetallic	O
ZnPd	B
and	O
supported	O
ZnPd	B
/	O
ZnO	B
catalysts	O
reveals	O
that	O
formaldehyde	B
is	O
formed	O
from	O
methanol	B
in	O
parallel	O
with	O
CO	B
(	I
2	I
)	I
on	O
the	O
former	O
,	O
while	O
on	O
unsupported	O
intermetallic	O
ZnPd	B
and	O
ZnO	B
-	O
supported	O
ZnPd	B
,	O
it	O
is	O
efficiently	O
reacted	O
toward	O
CO	B
(	I
2	I
)	I
,	O
thus	O
,	O
a	O
beneficial	O
role	O
of	O
ZnO	B
in	O
oxidizing	O
formaldehyde	B
-	O
derived	O
intermediates	O
toward	O
CO	B
(	I
2	I
)	I
is	O
evident	O
.	O

Economic	O
and	O
technological	O
drivers	O
of	O
generic	O
sterile	O
injectable	O
drug	O
shortages	O
.	O

Over	O
the	O
past	O
few	O
years	O
,	O
an	O
increasing	O
number	O
of	O
critically	O
needed	O
medicines	O
have	O
been	O
in	O
short	O
supply	O
.	O

Using	O
economic	O
theory	O
to	O
frame	O
the	O
drug	O
-	O
shortage	O
problem	O
,	O
this	O
paper	O
explores	O
why	O
and	O
how	O
manufacturing	O
-	O
quality	O
problems	O
could	O
combine	O
with	O
other	O
economic	O
and	O
technological	O
factors	O
to	O
result	O
in	O
shortages	O
of	O
generic	O
sterile	O
injectable	O
drugs	O
.	O

The	O
fundamental	O
problem	O
we	O
identify	O
is	O
the	O
inability	O
of	O
the	O
market	O
to	O
observe	O
and	O
reward	O
quality	O
.	O

This	O
lack	O
of	O
reward	O
for	O
quality	O
can	O
reinforce	O
price	O
competition	O
and	O
encourage	O
manufacturers	O
to	O
keep	O
costs	O
down	O
by	O
minimizing	O
quality	O
investments	O
.	O

The	O
US	O
Food	O
and	O
Drug	O
Administration	O
's	O
(	O
FDA	O
's	O
)	O
need	O
to	O
use	O
its	O
regulatory	O
flexibility	O
,	O
on	O
behalf	O
of	O
patients	O
,	O
to	O
avoid	O
shortages	O
of	O
medically	O
necessary	O
drugs	O
may	O
further	O
strengthen	O
the	O
incentive	O
to	O
"	O
push	O
the	O
envelope	O
"	O
on	O
quality	O
.	O

These	O
dynamics	O
may	O
have	O
produced	O
a	O
market	O
situation	O
in	O
which	O
quality	O
problems	O
have	O
become	O
sufficiently	O
common	O
and	O
severe	O
to	O
result	O
in	O
drug	O
shortages	O
.	O

Reversal	O
of	O
diet	O
-	O
induced	O
obesity	O
increases	O
insulin	O
transport	O
into	O
cerebrospinal	O
fluid	O
and	O
restores	O
sensitivity	O
to	O
the	O
anorexic	O
action	O
of	O
central	O
insulin	O
in	O
male	O
rats	O
.	O

Diet	O
-	O
induced	O
obesity	O
(	O
DIO	O
)	O
reduces	O
the	O
ability	O
of	O
centrally	O
administered	O
insulin	O
to	O
reduce	O
feeding	O
behavior	O
and	O
also	O
reduces	O
the	O
transport	O
of	O
insulin	O
from	O
the	O
periphery	O
to	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
.	O

The	O
current	O
study	O
was	O
designed	O
to	O
determine	O
whether	O
reversal	O
of	O
high	O
-	O
fat	O
DIO	O
restores	O
the	O
anorexic	O
efficacy	O
of	O
central	O
insulin	O
and	O
whether	O
this	O
is	O
accompanied	O
by	O
restoration	O
of	O
the	O
compromised	O
insulin	O
transport	O
.	O

Adult	O
male	O
Long	O
-	O
Evans	O
rats	O
were	O
initially	O
maintained	O
on	O
either	O
a	O
low	O
-	O
fat	O
chow	O
diet	O
(	O
LFD	O
)	O
or	O
a	O
high	O
-	O
fat	O
diet	O
(	O
HFD	O
)	O
.	O

After	O
22	O
weeks	O
,	O
half	O
of	O
the	O
animals	O
on	O
the	O
HFD	O
were	O
changed	O
to	O
the	O
LFD	O
,	O
whereas	O
the	O
other	O
half	O
continued	O
on	O
the	O
HFD	O
for	O
an	O
additional	O
8	O
weeks	O
,	O
such	O
that	O
there	O
were	O
3	O
groups	O
:	O
1	O
)	O
a	O
LFD	O
control	O
group	O
(	O
Con	O
;	O
n	O
=	O
18	O
)	O
,	O
2	O
)	O
a	O
HFD	O
-	O
fed	O
,	O
DIO	O
group	O
(	O
n	O
=	O
17	O
)	O
,	O
and	O
3	O
)	O
a	O
HFD	O
to	O
LFD	O
,	O
DIO	O
-	O
reversal	O
group	O
(	O
DIO	O
-	O
rev	O
;	O
n	O
=	O
18	O
)	O
.	O

The	O
DIO	O
reversal	O
resulted	O
in	O
a	O
significant	O
reduction	O
of	O
body	O
weight	O
and	O
epididymal	O
fat	O
weight	O
relative	O
to	O
the	O
DIO	O
group	O
.	O

Acute	O
central	O
insulin	O
administration	O
(	O
8	O
mU	O
)	O
reduced	O
food	O
intake	O
and	O
caused	O
weight	O
loss	O
in	O
Con	O
and	O
DIO	O
-	O
rev	O
but	O
not	O
DIO	O
rats	O
.	O

Fasting	O
cerebrospinal	O
fluid	O
insulin	O
was	O
higher	O
in	O
DIO	O
than	O
Con	O
animals	O
.	O

However	O
,	O
after	O
a	O
peripheral	O
bolus	O
injection	O
of	O
insulin	O
,	O
cerebrospinal	O
fluid	O
insulin	O
increased	O
in	O
Con	O
and	O
DIO	O
-	O
rev	O
rats	O
but	O
not	O
in	O
the	O
DIO	O
group	O
.	O

These	O
data	O
provide	O
support	O
for	O
previous	O
reports	O
that	O
DIO	O
inhibits	O
both	O
the	O
central	O
effects	O
of	O
insulin	O
and	O
insulin	O
's	O
transport	O
to	O
the	O
CNS	O
.	O

Importantly	O
,	O
DIO	O
-	O
rev	O
restored	O
sensitivity	O
to	O
the	O
effects	O
of	O
central	O
insulin	O
on	O
food	O
intake	O
and	O
insulin	O
transport	O
into	O
the	O
CNS	O
.	O

Osteoblasts	O
survive	O
the	O
arsenic	B
trioxide	I
treatment	O
by	O
activation	O
of	O
ATM	O
-	O
mediated	O
pathway	O
.	O

Arsenic	B
trioxide	I
(	O
ATO	B
)	O
is	O
widely	O
used	O
in	O
tumor	O
treatment	O
,	O
but	O
excessive	O
arsenic	B
exposure	O
can	O
have	O
adverse	O
effects	O
.	O

We	O
recently	O
found	O
that	O
,	O
in	O
primary	O
osteoblasts	O
,	O
ATO	B
produces	O
oxidative	O
stress	O
and	O
causes	O
DNA	O
tailing	O
,	O
but	O
does	O
not	O
induce	O
apoptosis	O
.	O

We	O
further	O
examined	O
the	O
signaling	O
pathway	O
by	O
which	O
osteoblasts	O
survive	O
ATO	B
treatment	O
,	O
and	O
found	O
that	O
they	O
were	O
arrested	O
at	O
G2	O
/	O
M	O
phase	O
of	O
the	O
cell	O
cycle	O
at	O
30h	O
and	O
overrode	O
the	O
G2	O
/	O
M	O
boundary	O
at	O
48h	O
.	O

After	O
treatment	O
for	O
30h	O
,	O
there	O
was	O
increased	O
Cdc2	O
phosphorylation	O
and	O
expression	O
of	O
Wee1	O
,	O
a	O
Cdc2	O
kinase	O
,	O
and	O
expression	O
of	O
the	O
cell	O
cycle	O
inhibitor	O
,	O
p21	O
(	O
waf1	O
/	O
cip1	O
)	O
,	O
which	O
interacts	O
with	O
Cdc2	O
.	O

Furthermore	O
,	O
levels	O
of	O
the	O
phosphatase	O
Cdc25C	O
,	O
which	O
activates	O
Cdc2	O
,	O
were	O
decreased	O
,	O
while	O
the	O
ratio	O
of	O
its	O
phosphorylated	O
/	O
inactivated	O
form	O
to	O
the	O
total	O
amount	O
was	O
increased	O
.	O

Moreover	O
,	O
phosphorylation	O
/	O
activation	O
of	O
the	O
checkpoint	O
kinases	O
Chk1	O
,	O
Chk2	O
and	O
p53	O
levels	O
were	O
increased	O
,	O
as	O
were	O
levels	O
of	O
activated	O
ATM	O
and	O
	O
-	O
H2AX	O
.	O

The	O
cell	O
viability	O
was	O
decreased	O
as	O
an	O
ATM	O
inhibitor	O
was	O
added	O
.	O

Additionally	O
,	O
these	O
effects	O
of	O
ATO	B
on	O
	O
-	O
H2AX	O
,	O
Chk1	O
,	O
Chk2	O
,	O
p53	O
,	O
and	O
p21	O
(	O
waf1	O
/	O
cip1	O
)	O
were	O
reduced	O
by	O
an	O
ATM	O
inhibitor	O
.	O

These	O
findings	O
suggest	O
that	O
G2	O
/	O
M	O
phase	O
arrest	O
of	O
osteoblasts	O
is	O
mediated	O
by	O
Chk1	O
/	O
Chk2	O
activation	O
via	O
an	O
ATM	O
-	O
dependent	O
pathway	O
by	O
which	O
osteoblasts	O
survive	O
.	O

Anti	O
-	O
obesity	O
effects	O
of	O
3-hydroxychromone	B
derivative	O
,	O
a	O
novel	O
small	O
-	O
molecule	O
inhibitor	O
of	O
glycogen	O
synthase	O
kinase-3	O
.	O

Glycogen	O
synthase	O
kinase	O
3	O
(	O
GSK-3	O
)	O
plays	O
a	O
central	O
role	O
in	O
cellular	O
energy	O
metabolism	O
,	O
and	O
dysregulation	O
of	O
GSK-3	O
activity	O
is	O
implicated	O
in	O
a	O
variety	O
of	O
metabolic	O
disorders	O
,	O
including	O
obesity	O
,	O
type	O
2	O
diabetes	O
,	O
and	O
cancer	O
.	O

Hence	O
,	O
GSK-3	O
has	O
emerged	O
as	O
an	O
attractive	O
target	O
molecule	O
for	O
the	O
treatment	O
of	O
metabolic	O
disorders	O
.	O

Therefore	O
,	O
this	O
research	O
focused	O
on	O
identification	O
and	O
characterization	O
of	O
a	O
novel	O
small	O
-	O
molecule	O
GSK-3	O
inhibitor	O
.	O

Compound	O
1a	O
,	O
a	O
structure	O
based	O
on	O
3-hydroxychromone	B
bearing	O
isothiazolidine-1,1-dione	B
,	O
was	O
identified	O
from	O
chemical	O
library	O
as	O
a	O
highly	O
potent	O
GSK-3	O
inhibitor	O
.	O

An	O
in	O
vitro	O
kinase	O
assay	O
utilizing	O
a	O
panel	O
of	O
kinases	O
demonstrated	O
that	O
compound	O
1a	O
strongly	O
inhibits	O
GSK-3	O
.	O

The	O
potential	O
effects	O
of	O
compound	O
1a	O
on	O
the	O
inactivation	O
of	O
GSK-3	O
were	O
confirmed	O
in	O
human	O
liver	O
HepG2	O
and	O
human	O
embryonic	O
kidney	O
HEK293	O
cells	O
.	O

Stabilization	O
of	O
glycogen	O
synthase	O
and	O
	O
-	O
catenin	O
,	O
which	O
are	O
direct	O
targets	O
of	O
GSK-3	O
,	O
by	O
compound	O
1a	O
was	O
assessed	O
in	O
comparison	O
with	O
two	O
other	O
GSK-3	O
inhibitors	O
:	O
LiCl	B
and	O
SB-415286	B
.	O

In	O
mouse	O
3T3-L1	O
preadipocytes	O
,	O
compound	O
1a	O
markedly	O
blocked	O
adipocyte	O
differentiation	O
.	O

Consistently	O
,	O
intraperitoneal	O
administration	O
of	O
compound	O
1a	O
to	O
diet	O
-	O
induced	O
obese	O
mice	O
significantly	O
ameliorated	O
their	O
key	O
symptoms	O
such	O
as	O
body	O
weight	O
gain	O
,	O
increased	O
adiposity	O
,	O
dyslipidemia	O
,	O
and	O
hepatic	O
steatosis	O
due	O
to	O
the	O
marked	O
reduction	O
of	O
whole	O
-	O
body	O
lipid	O
level	O
.	O

In	O
vitro	O
and	O
in	O
vivo	O
effects	O
were	O
accompanied	O
by	O
upregulation	O
of	O
	O
-	O
catenin	O
stability	O
and	O
downregulation	O
of	O
the	O
expression	O
of	O
several	O
critical	O
genes	O
related	O
to	O
lipid	O
metabolism	O
.	O

From	O
these	O
results	O
,	O
it	O
can	O
be	O
concluded	O
that	O
compound	O
1a	O
,	O
a	O
novel	O
small	O
-	O
molecule	O
inhibitor	O
of	O
GSK-3	O
,	O
has	O
potential	O
as	O
a	O
new	O
class	O
of	O
therapeutic	O
agent	O
for	O
obesity	O
treatment	O
.	O

Understanding	O
drugs	O
and	O
diseases	O
by	O
systems	O
biology	O
?	O

Systems	O
biology	O
aims	O
to	O
provide	O
a	O
holistic	O
and	O
in	O
many	O
cases	O
dynamic	O
picture	O
of	O
biological	O
function	O
and	O
malfunction	O
,	O
in	O
case	O
of	O
disease	O
.	O

Technology	O
developments	O
in	O
the	O
generation	O
of	O
genome	O
-	O
wide	O
datasets	O
and	O
massive	O
improvements	O
in	O
computer	O
power	O
now	O
allow	O
to	O
obtain	O
new	O
insights	O
into	O
complex	O
biological	O
networks	O
and	O
to	O
copy	O
nature	O
by	O
computing	O
these	O
interactions	O
and	O
their	O
kinetics	O
and	O
by	O
generating	O
in	O
silico	O
models	O
of	O
cells	O
,	O
tissues	O
and	O
organs	O
.	O

The	O
expectations	O
are	O
high	O
that	O
systems	O
biology	O
will	O
pave	O
the	O
way	O
to	O
the	O
identification	O
of	O
novel	O
disease	O
genes	O
,	O
to	O
the	O
selection	O
of	O
successful	O
drug	O
candidates	O
--	O
that	O
do	O
not	O
fail	O
in	O
clinical	O
studies	O
due	O
to	O
toxicity	O
or	O
lack	O
of	O
human	O
efficacy	O
--	O
and	O
finally	O
to	O
a	O
more	O
successful	O
discovery	O
of	O
novel	O
therapeutics	O
.	O

However	O
,	O
further	O
research	O
is	O
necessary	O
to	O
fully	O
unleash	O
the	O
potential	O
of	O
systems	O
biology	O
.	O

Within	O
this	O
review	O
we	O
aim	O
to	O
highlight	O
the	O
most	O
important	O
and	O
promising	O
top	O
-	O
down	O
and	O
bottom	O
-	O
up	O
systems	O
biology	O
applications	O
in	O
drug	O
discovery	O
.	O

Polyoxometalate	B
-	O
biomolecule	O
conjugates	O
:	O
a	O
new	O
approach	O
to	O
create	O
hybrid	O
drugs	O
for	O
cancer	O
therapeutics	O
.	O

Some	O
polyoxometalate	B
(	O
POM	B
)	O
clusters	O
have	O
demonstrated	O
attractive	O
anticancer	O
properties	O
.	O

Unfortunately	O
,	O
their	O
cytotoxicity	O
upon	O
normal	O
cell	O
is	O
one	O
of	O
fateful	O
side	O
effects	O
obstructing	O
their	O
further	O
clinic	O
application	O
as	O
inorganic	O
drugs	O
.	O

In	O
this	O
communication	O
,	O
we	O
report	O
a	O
new	O
approach	O
to	O
create	O
hybrid	O
drugs	O
potentially	O
for	O
cancer	O
therapeutics	O
.	O

At	O
first	O
,	O
the	O
POM	B
cluster	O
bioconjugates	O
were	O
created	O
by	O
attaching	O
the	O
bioactive	O
ligands	O
on	O
an	O
amine	B
grafted	O
POM	O
via	O
simple	O
amidation	O
reaction	O
.	O

The	O
cytotoxicity	O
study	O
with	O
breast	O
cancer	O
cells	O
(	O
MCF-7	O
and	O
MDA	O
-	O
MB-231	O
)	O
and	O
non	O
-	O
cancerous	O
breast	O
epithelial	O
cell	O
(	O
MCF-10A	O
)	O
showed	O
that	O
rationally	O
selected	O
ligands	O
with	O
cancer	O
-	O
cell	O
targeting	O
ability	O
on	O
POM	B
-	O
biomolecule	O
conjugates	O
can	O
impart	O
enhanced	O
anti	O
-	O
tumor	O
activity	O
and	O
selectivity	O
,	O
thus	O
representing	O
a	O
new	O
concept	O
to	O
develop	O
novel	O
POM	B
-	O
biomolecule	O
hybrid	O
drugs	O
with	O
the	O
potential	O
synergistic	O
effect	O
:	O
increased	O
bioactivity	O
and	O
lower	O
side	O
effect	O
.	O

Novel	O
naphthoquinone	B
derivatives	O
:	O
synthesis	O
and	O
activity	O
against	O
human	O
African	O
trypanosomiasis	O
.	O

A	O
series	O
of	O
naphthoquinone	B
derivatives	O
has	O
been	O
synthesized	O
and	O
tested	O
for	O
its	O
biological	O
activity	O
against	O
human	O
African	O
trypanosomiasis	O
.	O

The	O
use	O
of	O
reverse	O
micellar	O
medium	O
not	O
only	O
enhanced	O
the	O
conversion	O
rate	O
,	O
but	O
also	O
showed	O
selectivity	O
towards	O
mono	O
-	O
coupled	O
product	O
in	O
aryl	B
chloride	I
-	O
aniline	B
coupling	O
reactions	O
.	O

Two	O
derivatives	O
of	O
naphthoquinone	B
(	O
9b	O
and	O
9c	O
)	O
exhibited	O
potent	O
activity	O
against	O
Trypanosoma	O
brucei	O
in	O
vitro	O
with	O
low	O
cytotoxicity	O
.	O

Electronic	O
and	O
EPR	O
spectra	O
of	O
the	O
species	O
involved	O
in	O
[	B
W10O32	I
]	I
4-	I
photocatalysis	O
.	O

A	O
relativistic	O
DFT	O
investigation	O
.	O

The	O
decatungstate	O
anion	O
[	B
W	I
(	I
10	I
)	I
O	I
(	I
32	I
)	I
]	I
(	I
4-	I
)	I
is	O
widely	O
used	O
as	O
a	O
photocatalyst	O
in	O
different	O
transformations	O
,	O
during	O
which	O
it	O
undergoes	O
one	O
-	O
electron	O
reduction	O
to	O
[	B
W	I
(	I
10	I
)	I
O	I
(	I
32	I
)	I
]	I
(	I
5-	I
)	I
,	O
possibly	O
protonated	O
;	O
the	O
bi	O
-	O
reduced	O
species	O
[	B
W	I
(	I
10	I
)	I
O	I
(	I
32	I
)	I
]	I
(	I
6-	I
)	I
is	O
obtained	O
by	O
ensuing	O
disproportionation	O
.	O

Relativistic	O
DFT	O
calculations	O
were	O
used	O
to	O
predict	O
the	O
UV	O
-	O
VIS	O
spectra	O
and	O
EPR	O
parameters	O
of	O
all	O
such	O
species	O
.	O

Local	O
deposition	O
of	O
anisotropic	O
nanoparticles	O
using	O
scanning	O
electrochemical	O
microscopy	O
(	O
SECM	O
)	O
.	O

We	O
demonstrate	O
localized	O
electrodeposition	O
of	O
anisotropic	O
metal	O
nanoobjects	O
,	O
namely	O
Au	B
nanorods	O
(	O
GNR	O
)	O
,	O
on	O
indium	B
tin	I
oxide	I
(	O
ITO	B
)	O
using	O
scanning	O
electrochemical	O
microscopy	O
(	O
SECM	O
)	O
.	O

A	O
gold	O
microelectrode	O
was	O
the	O
source	O
of	O
the	O
gold	O
ions	O
whereby	O
double	O
pulse	O
chronoamperometry	O
was	O
employed	O
to	O
generate	O
initially	O
Au	B
seeds	O
which	O
were	O
further	O
grown	O
under	O
controlled	O
conditions	O
.	O

The	O
distance	O
between	O
the	O
microelectrode	O
and	O
the	O
ITO	B
surface	O
as	O
well	O
as	O
the	O
different	O
experimental	O
parameters	O
(	O
electrodeposition	O
regime	O
,	O
solution	O
composition	O
and	O
temperature	O
)	O
were	O
optimized	O
to	O
produce	O
faceted	O
gold	O
seeds	O
with	O
the	O
required	O
characteristics	O
(	O
size	O
and	O
distribution	O
)	O
.	O

Colloidal	O
chemical	O
synthesis	O
was	O
successfully	O
exploited	O
for	O
better	O
understanding	O
the	O
role	O
of	O
the	O
surfactant	O
and	O
different	O
additives	O
in	O
breaking	O
the	O
crystallographic	O
symmetry	O
and	O
anisotropic	O
growth	O
of	O
GNR	O
.	O

Experiments	O
performed	O
in	O
a	O
conventional	O
three	O
-	O
electrode	O
cell	O
revealed	O
the	O
most	O
appropriate	O
electrochemical	O
conditions	O
allowing	O
high	O
yield	O
synthesis	O
of	O
nanorods	O
with	O
well	O
-	O
defined	O
shape	O
as	O
well	O
as	O
nanocubes	O
and	O
bipyramids	O
.	O

Impaired	O
fertility	O
and	O
FSH	O
synthesis	O
in	O
gonadotrope	O
-	O
specific	O
Foxl2	O
knockout	O
mice	O
.	O

Impairments	O
in	O
pituitary	O
FSH	O
synthesis	O
or	O
action	O
cause	O
infertility	O
.	O

However	O
,	O
causes	O
of	O
FSH	O
dysregulation	O
are	O
poorly	O
described	O
,	O
in	O
part	O
because	O
of	O
our	O
incomplete	O
understanding	O
of	O
mechanisms	O
controlling	O
FSH	O
synthesis	O
.	O

Previously	O
,	O
we	O
discovered	O
a	O
critical	O
role	O
for	O
forkhead	O
protein	O
L2	O
(	O
FOXL2	O
)	O
in	O
activin	O
-	O
stimulated	O
FSH	O
	O
-	O
subunit	O
(	O
Fshb	O
)	O
transcription	O
in	O
immortalized	O
cells	O
in	O
vitro	O
.	O

Here	O
,	O
we	O
tested	O
the	O
hypothesis	O
that	O
FOXL2	O
is	O
required	O
for	O
FSH	O
synthesis	O
in	O
vivo	O
.	O

Using	O
a	O
Cre	O
/	O
lox	O
approach	O
,	O
we	O
selectively	O
ablated	O
Foxl2	O
in	O
murine	O
anterior	O
pituitary	O
gonadotrope	O
cells	O
.	O

Conditional	O
knockout	O
(	O
cKO	O
)	O
mice	O
developed	O
overtly	O
normally	O
but	O
were	O
subfertile	O
in	O
adulthood	O
.	O

Testis	O
size	O
and	O
spermatogenesis	O
were	O
significantly	O
impaired	O
in	O
cKO	O
males	O
.	O

cKO	O
females	O
exhibited	O
reduced	O
ovarian	O
weight	O
and	O
ovulated	O
fewer	O
oocytes	O
in	O
natural	O
estrous	O
cycles	O
compared	O
with	O
controls	O
.	O

In	O
contrast	O
,	O
ovaries	O
of	O
juvenile	O
cKO	O
females	O
showed	O
normal	O
responses	O
to	O
exogenous	O
gonadotropin	O
stimulation	O
.	O

Both	O
male	O
and	O
female	O
cKO	O
mice	O
were	O
FSH	O
deficient	O
,	O
secondary	O
to	O
diminished	O
pituitary	O
Fshb	O
mRNA	O
production	O
.	O

Basal	O
and	O
activin	O
-	O
stimulated	O
Fshb	O
expression	O
was	O
similarly	O
impaired	O
in	O
Foxl2	O
depleted	O
primary	O
pituitary	O
cultures	O
.	O

Collectively	O
,	O
these	O
data	O
definitively	O
establish	O
FOXL2	O
as	O
the	O
first	O
identified	O
gonadotrope	O
-	O
restricted	O
transcription	O
factor	O
required	O
for	O
selective	O
FSH	O
synthesis	O
in	O
vivo	O
.	O

The	O
endocrine	O
disrupting	O
chemical	O
tolylfluanid	B
alters	O
adipocyte	O
metabolism	O
via	O
glucocorticoid	O
receptor	O
activation	O
.	O

Glucocorticoid	O
signaling	O
plays	O
a	O
critical	O
role	O
in	O
regulating	O
energy	O
metabolism	O
.	O

Emerging	O
data	O
implicate	O
environmental	O
endocrine	O
-	O
disrupting	O
chemicals	O
as	O
contributors	O
to	O
the	O
obesity	O
and	O
diabetes	O
epidemics	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
the	O
phenylsulfamide	B
fungicide	O
tolylfluanid	B
(	O
TF	O
)	O
augments	O
glucocorticoid	O
receptor	O
(	O
GR	O
)	O
-dependent	O
luciferase	O
expression	O
in	O
3T3-L1	O
preadipocytes	O
while	O
modulating	O
insulin	O
action	O
in	O
primary	O
murine	O
and	O
human	O
adipocytes	O
.	O

Studies	O
were	O
performed	O
to	O
interrogate	O
glucocorticoid	O
signaling	O
in	O
primary	O
adipocytes	O
exposed	O
to	O
TF	O
.	O

TF	O
mimicked	O
the	O
gene	O
transcription	O
profile	O
of	O
the	O
murine	O
glucocorticoid	O
corticosterone	B
(	O
Cort	B
)	O
.	O

Cellular	O
fractionation	O
assays	O
demonstrated	O
that	O
TF	O
treatment	O
promoted	O
the	O
activating	O
serine	B
phosphorylation	O
of	O
GR	O
,	O
augmenting	O
its	O
cytoplasmic	O
-	O
to	O
-	O
nuclear	O
translocation	O
as	O
well	O
as	O
its	O
enrichment	O
at	O
glucocorticoid	O
response	O
elements	O
on	O
the	O
glucocorticoid	O
-	O
induced	O
leucine	B
zipper	O
gene	O
promoter	O
.	O

After	O
acute	O
treatment	O
,	O
Cort	B
or	O
TF	O
promoted	O
insulin	O
receptor	O
substrate-1	O
(	O
IRS-1	O
)	O
gene	O
and	O
protein	O
expression	O
.	O

Either	O
treatment	O
also	O
enriched	O
GR	O
binding	O
at	O
an	O
identified	O
glucocorticoid	O
response	O
element	O
in	O
the	O
IRS-1	O
gene	O
.	O

TF	O
or	O
Cort	B
each	O
increased	O
insulin	O
-	O
stimulated	O
lipogenesis	O
,	O
an	O
effect	O
resulting	O
from	O
increased	O
lipogenic	O
gene	O
expression	O
and	O
enhanced	O
insulin	O
-	O
stimulated	O
dephosphorylation	O
of	O
acetyl	B
-	I
coenzyme	I
A	I
carboxylase	O
.	O

The	O
augmentation	O
of	O
insulin	O
-	O
stimulated	O
lipogenesis	O
was	O
mediated	O
through	O
a	O
specific	O
enhancement	O
of	O
Akt	O
phosphorylation	O
at	O
T308	O
.	O

These	O
findings	O
support	O
modulation	O
of	O
IRS-1	O
levels	O
as	O
a	O
mechanism	O
for	O
glucocorticoid	O
-	O
mediated	O
changes	O
in	O
insulin	O
action	O
in	O
primary	O
adipocytes	O
.	O

Albeit	O
with	O
less	O
affinity	O
than	O
Cort	B
,	O
in	O
silico	O
analysis	O
suggests	O
that	O
TF	O
can	O
interact	O
with	O
the	O
ligand	O
binding	O
pocket	O
of	O
GR	O
.	O

Collectively	O
,	O
these	O
studies	O
identify	O
TF	O
as	O
a	O
structurally	O
unique	O
environmental	O
glucocorticoid	O
.	O

Glucocorticoid	O
signaling	O
may	O
thus	O
represent	O
a	O
novel	O
pathway	O
by	O
which	O
environmental	O
toxicants	O
promote	O
the	O
development	O
of	O
metabolic	O
diseases	O
.	O

Perfluoroalkylated	O
compounds	O
induce	O
cell	O
death	O
and	O
formation	O
of	O
reactive	O
oxygen	B
species	O
in	O
cultured	O
cerebellar	O
granule	O
cells	O
.	O

The	O
present	O
communication	O
investigates	O
the	O
effects	O
of	O
different	O
perfluoroalkylated	O
compounds	O
(	O
PFCs	O
)	O
on	O
formation	O
of	O
reactive	O
oxygen	B
species	O
(	O
ROS	O
)	O
and	O
cell	O
death	O
in	O
cultured	O
cerebellar	O
granule	O
cells	O
.	O

This	O
allows	O
direct	O
comparison	O
with	O
similar	O
effects	O
found	O
for	O
other	O
environmental	O
contaminants	O
like	O
polychlorinated	B
biphenyls	I
and	O
brominated	O
flame	O
-	O
retardants	O
.	O

The	O
increase	O
in	O
ROS	O
formation	O
and	O
cell	O
death	O
was	O
assayed	O
using	O
the	O
fluorescent	O
probe	O
2,7-dichlorofluorescin	B
diacetate	I
(	O
DCFH	B
-	I
DA	I
)	O
and	O
the	O
trypan	B
blue	I
exclusion	O
assay	O
.	O

The	O
effects	O
of	O
the	O
PFCs	O
were	O
structure	O
dependent	O
.	O

Cell	O
death	O
was	O
induced	O
at	O
relatively	O
low	O
concentrations	O
by	O
perfluorooctyl	B
sulfonate	I
(	O
PFOS	B
)	O
,	O
perfluorooctane	B
sulfonylamide	I
(	O
PFOSA	B
)	O
and	O
the	O
fluorotelomer	B
alcohol	I
1H	B
,	I
1H	I
,	I
2H	I
,	I
2H	I
-	I
perfluorodecanol	I
(	O
FTOH	B
8:2	I
)	O
with	O
EC	O
(	O
50	O
)	O
-values	O
of	O
62	O
	O
7.6	O
,	O
13	O
	O
1.8	O
and	O
15	O
	O
4.2	O
M	O
(	O
mean	O
	O
SD	O
)	O
respectively	O
.	O

PFOS	B
,	O
perfluorooctanoic	B
acid	I
(	O
PFOA	B
)	O
and	O
PFOSA	B
induced	O
a	O
concentration	O
dependent	O
increase	O
in	O
ROS	O
formation	O
with	O
EC	O
(	O
50	O
)	O
-values	O
of	O
27	O
	O
9.0	O
,	O
25	O
	O
11	O
and	O
57	O
	O
19M	O
respectively	O
.	O

Reduced	O
cell	O
viability	O
and	O
ROS	O
formation	O
were	O
observed	O
at	O
concentration	O
level	O
close	O
to	O
what	O
is	O
found	O
in	O
serum	O
of	O
occupationally	O
exposed	O
workers	O
.	O

The	O
effect	O
of	O
PFCs	O
on	O
ROS	O
formation	O
and	O
cell	O
viability	O
was	O
compared	O
with	O
other	O
halogenated	O
compounds	O
and	O
future	O
investigations	O
should	O
emphasize	O
effects	O
of	O
mixtures	O
and	O
how	O
physical	O
chemical	O
properties	O
of	O
the	O
compounds	O
influence	O
their	O
toxicity	O
.	O

SeDeM	O
expert	O
system	O
a	O
new	O
innovator	O
tool	O
to	O
develop	O
pharmaceutical	O
forms	O
.	O

Abstract	O
Context	O
:	O

The	O
SeDeM	O
expert	O
system	O
is	O
based	O
on	O
the	O
experimental	O
study	O
and	O
quantitative	O
determination	O
of	O
the	O
characterization	O
parameters	O
of	O
powdered	O
substances	O
,	O
the	O
aim	O
being	O
to	O
determine	O
whether	O
a	O
substance	O
is	O
suitable	O
for	O
producing	O
tablets	O
by	O
means	O
of	O
direct	O
compression	O
(	O
DC	O
)	O
technology	O
,	O
thereby	O
reducing	O
the	O
lead	O
time	O
for	O
pre	O
-	O
formulation	O
studies	O
.	O

Additionally	O
,	O
this	O
expert	O
system	O
also	O
provides	O
formulations	O
with	O
a	O
minimum	O
number	O
of	O
excipients	O
.	O

Objective	O
:	O
We	O
used	O
this	O
system	O
to	O
analyze	O
suitable	O
formulas	O
for	O
the	O
production	O
of	O
orodispersible	O
ibuprofen	B
tablets	O
.	O

Method	O
:	O
Twenty	O
-	O
one	O
disintegrants	O
and	O
ibuprophen	B
were	O
characterized	O
using	O
SeDeM	O
methodology	O
.	O

Results	O
:	O
The	O
results	O
indicated	O
that	O
production	O
of	O
ibuprofen	B
tablets	O
by	O
DC	O
would	O
require	O
improvements	O
in	O
the	O
dimension	O
and	O
compressibility	O
factors	O
of	O
the	O
active	O
pharmaceutical	O
ingredient	O
.	O

The	O
expert	O
system	O
analysis	O
provided	O
the	O
specific	O
percentage	O
of	O
disintegrant	O
needed	O
to	O
blend	O
with	O
ibuprofen	B
and	O
a	O
standardized	O
formula	O
of	O
lubricants	O
in	O
order	O
to	O
obtain	O
a	O
powder	O
mix	O
that	O
would	O
successfully	O
produce	O
tablets	O
by	O
DC	O
.	O

The	O
eight	O
formulas	O
proposed	O
by	O
SeDeM	O
were	O
produced	O
and	O
tested	O
in	O
the	O
laboratory	O
.	O

Conclusion	O
:	O
All	O
eight	O
formulas	O
successfully	O
produced	O
tablets	O
by	O
DC	O
,	O
but	O
only	O
four	O
of	O
them	O
could	O
be	O
considered	O
suitable	O
for	O
use	O
as	O
an	O
orodispersible	O
tablet	O
and	O
accomplishes	O
all	O
the	O
pharmaceutical	O
quality	O
parameters	O
.	O

So	O
,	O
in	O
fact	O
,	O
the	O
use	O
of	O
the	O
SeDeM	O
system	O
reduced	O
the	O
time	O
of	O
medicine	O
's	O
development	O
and	O
therefore	O
the	O
cost	O
of	O
the	O
activity	O
.	O

Efficient	O
two	O
-	O
electron	O
reduction	O
of	O
dioxygen	B
to	O
hydrogen	B
peroxide	I
with	O
one	O
-	O
electron	O
reductants	O
with	O
a	O
small	O
overpotential	O
catalyzed	O
by	O
a	O
cobalt	B
chlorin	I
complex	O
.	O

A	O
cobalt	B
chlorin	I
complex	O
(	O
Co	B
(	I
II	I
)	I
(	I
Ch	I
)	I
)	O
efficiently	O
and	O
selectively	O
catalyzed	O
two	O
-	O
electron	O
reduction	O
of	O
dioxygen	B
(	O
O	B
(	I
2	I
)	I
)	O
by	O
one	O
-	O
electron	O
reductants	O
(	O
ferrocene	B
derivatives	O
)	O
to	O
produce	O
hydrogen	B
peroxide	I
(	O
H	B
(	I
2	I
)	I
O	I
(	I
2	I
)	I
)	O
in	O
the	O
presence	O
of	O
perchloric	B
acid	I
(	O
HClO	B
(	I
4	I
)	I
)	O
in	O
benzonitrile	B
(	O
PhCN	B
)	O
at	O
298	O
K.	O
The	O
catalytic	O
reactivity	O
of	O
Co	B
(	I
II	I
)	I
(	I
Ch	I
)	I
was	O
much	O
higher	O
than	O
that	O
of	O
a	O
cobalt	B
porphyrin	I
complex	O
(	O
Co	B
(	I
II	I
)	I
(	I
OEP	I
)	I
,	O
OEP	B
(	I
2-	I
)	I
=	O
octaethylporphyrin	B
dianion	O
)	O
,	O
which	O
is	O
a	O
typical	O
porphyrinoid	O
complex	O
.	O

The	O
two	O
-	O
electron	O
reduction	O
of	O
O	B
(	I
2	I
)	I
by	O
1,1'-dibromoferrocene	B
(	O
Br	B
(	I
2	I
)	I
Fc	I
)	O
was	O
catalyzed	O
by	O
Co	B
(	I
II	I
)	I
(	I
Ch	I
)	I
,	O
whereas	O
virtually	O
no	O
reduction	O
of	O
O	B
(	I
2	I
)	I
occurred	O
with	O
Co	B
(	I
II	I
)	I
(	I
OEP	I
)	I
.	O

In	O
addition	O
,	O
Co	B
(	I
II	I
)	I
(	I
Ch	I
)	I
is	O
more	O
stable	O
than	O
Co	B
(	I
II	I
)	I
(	I
OEP	I
)	I
,	O
where	O
the	O
catalytic	O
turnover	O
number	O
(	O
TON	O
)	O
of	O
the	O
two	O
-	O
electron	O
reduction	O
of	O
O	B
(	I
2	I
)	I
catalyzed	O
by	O
Co	B
(	I
II	I
)	I
(	I
Ch	I
)	I
exceeded	O
30000	O
.	O

The	O
detailed	O
kinetic	O
studies	O
have	O
revealed	O
that	O
the	O
rate	O
-	O
determining	O
step	O
in	O
the	O
catalytic	O
cycle	O
is	O
the	O
proton	O
-	O
coupled	O
electron	O
transfer	O
reduction	O
of	O
O	B
(	I
2	I
)	I
with	O
the	O
protonated	O
Co	B
(	I
II	I
)	I
(	I
Ch	I
)	I
(	O
[	B
Co	I
(	I
II	I
)	I
(	I
ChH	I
)	I
]	I
(	I
+	I
)	I
)	O
that	O
is	O
produced	O
by	O
facile	O
electron	O
-	O
transfer	O
reduction	O
of	O
[	B
Co	I
(	I
III	I
)	I
(	I
ChH	I
)	I
]	I
(	I
2	I
+	I
)	I
by	O
ferrocene	B
derivative	O
in	O
the	O
presence	O
of	O
HClO	B
(	I
4	I
)	I
.	O

The	O
one	O
-	O
electron	O
-	O
reduction	O
potential	O
of	O
[	B
Co	I
(	I
III	I
)	I
(	I
Ch	I
)	I
]	I
(	I
+	I
)	I
was	O
positively	O
shifted	O
from	O
0.37	O
V	O
(	O
vs	O
SCE	O
)	O
to	O
0.48	O
V	O
by	O
the	O
addition	O
of	O
HClO	B
(	I
4	I
)	I
due	O
to	O
the	O
protonation	O
of	O
[	B
Co	I
(	I
III	I
)	I
(	I
Ch	I
)	I
]	I
(	I
+	I
)	I
.	O

Such	O
a	O
positive	O
shift	O
of	O
[	B
Co	I
(	I
III	I
)	I
(	I
Ch	I
)	I
]	I
(	I
+	I
)	I
by	O
protonation	O
resulted	O
in	O
enhancement	O
of	O
the	O
catalytic	O
reactivity	O
of	O
[	B
Co	I
(	I
III	I
)	I
(	I
ChH	I
)	I
]	I
(	I
2	I
+	I
)	I
for	O
the	O
two	O
-	O
electron	O
reduction	O
of	O
O	B
(	I
2	I
)	I
with	O
a	O
lower	O
overpotential	O
as	O
compared	O
with	O
that	O
of	O
[	B
Co	I
(	I
III	I
)	I
(	I
OEP	I
)	I
]	I
(	I
+	I
)	I
.	O

Electrocatalytic	O
hydrogenation	O
and	O
deoxygenation	O
of	O
glucose	B
on	O
solid	O
metal	O
electrodes	O
.	O

This	O
Full	O
Paper	O
addresses	O
the	O
electrocatalytic	O
hydrogenation	O
of	O
glucose	B
to	O
sorbitol	B
or	O
2-deoxysorbitol	B
on	O
solid	O
metal	O
electrodes	O
in	O
neutral	O
media	O
.	O

Combining	O
voltammetry	O
and	O
online	O
product	O
analysis	O
with	O
high	O
-	O
performance	O
liquid	O
chromatography	O
(	O
HPLC	O
)	O
,	O
provides	O
both	O
qualitative	O
and	O
quantitative	O
information	O
regarding	O
the	O
reaction	O
products	O
as	O
a	O
function	O
of	O
potential	O
.	O

Three	O
groups	O
of	O
catalysts	O
clearly	O
show	O
affinities	O
toward	O
:	O
(	O
1	O
)	O
hydrogen	B
formation	O
[	O
on	O
early	O
transition	B
metals	I
(	O
Ti	B
,	O
V	O
,	O
Cr	B
,	O
Mn	B
,	O
Zr	B
,	O
Nb	B
,	O
Mo	B
,	O
Hf	B
,	O
Ta	B
,	O
We	B
,	O
and	O
Re	B
)	O
and	O
platinum	B
group	O
metals	O
(	O
Ru	B
,	O
Rh	B
,	O
Ir	B
,	O
and	O
Pt	B
)	O
]	O
,	O
(	O
2	O
)	O
sorbitol	B
formation	O
[	O
on	O
late	O
transition	B
metals	I
(	O
Fe	B
,	O
Co	B
,	O
Ni	B
,	O
Cu	B
,	O
Pd	B
,	O
Au	B
,	O
and	O
Ag	B
)	O
and	O
Al	B
(	O
sp	O
metal	O
)	O
]	O
,	O
and	O
(	O
3	O
)	O
sorbitol	B
and	O
2-deoxysorbitol	B
formation	O
[	O
on	O
post	O
-	O
transition	B
metals	I
(	O
In	B
,	O
Sn	B
,	O
Sb	B
,	O
Pb	B
,	O
and	O
Bi	B
)	O
,	O
as	O
well	O
as	O
Zn	B
and	O
Cd	B
(	O
d	O
metals	O
)	O
]	O
.	O

Ni	B
shows	O
the	O
lowest	O
overpotential	O
for	O
the	O
onset	O
of	O
sorbitol	B
formation	O
(	O
-0.25	O
V	O
)	O
whereas	O
Pb	B
generates	O
sorbitol	B
with	O
the	O
highest	O
yield	O
(	O
<	O
0.7	O
mM	O
cm	O
(	O
-2	O
)	O
)	O
.	O

Different	O
from	O
a	O
smooth	O
Pt	B
electrode	O
,	O
a	O
large	O
-	O
surface	O
-	O
area	O
Pt	B
/	B
C	O
electrode	O
hydrogenates	O
glucose	B
to	O
sorbitol	B
from	O
-0.21	O
V	O
with	O
relatively	O
low	O
current	O
.	O

This	O
emphasizes	O
the	O
importance	O
of	O
the	O
active	O
sites	O
and	O
the	O
surface	O
area	O
of	O
the	O
catalyst	O
.	O

The	O
mechanism	O
to	O
form	O
2-deoxysorbitol	B
from	O
glucose	B
and/or	O
fructose	B
is	O
discussed	O
according	O
to	O
the	O
observed	O
reaction	O
products	O
.	O

The	O
yield	O
and	O
selectivity	O
of	O
hydrogenated	O
products	O
are	O
highly	O
sensitive	O
to	O
the	O
chemical	O
nature	O
and	O
state	O
of	O
the	O
catalyst	O
surface	O
.	O

Characterisation	O
of	O
Nox4	O
inhibitors	O
from	O
edible	O
plants	O
.	O

NADPH	B
oxidases	O
transport	O
electrons	O
from	O
cytosolic	O
NADPH	B
through	O
biological	O
membranes	O
to	O
generate	O
reactive	O
oxygen	B
species	O
.	O

NADPH	B
oxidase	O
4	O
,	O
broadly	O
expressed	O
in	O
humans	O
,	O
is	O
an	O
interesting	O
pharmacological	O
target	O
,	O
since	O
its	O
activity	O
is	O
deregulated	O
in	O
several	O
diseases	O
,	O
including	O
pulmonary	O
fibrosis	O
,	O
diabetic	O
nephropathy	O
,	O
and	O
cardiac	O
hypertrophy	O
.	O

Whereas	O
several	O
candidate	O
NADPH	B
oxidase	O
4	O
inhibitors	O
were	O
recently	O
described	O
,	O
most	O
of	O
these	O
compounds	O
are	O
either	O
unspecific	O
or	O
toxic	O
.	O

Here	O
we	O
set	O
out	O
to	O
identify	O
new	O
NADPH	B
oxidase	O
4	O
inhibitors	O
from	O
edible	O
plants	O
,	O
in	O
an	O
attempt	O
to	O
decrease	O
the	O
number	O
of	O
hits	O
with	O
toxic	O
side	O
effects	O
.	O

We	O
screened	O
a	O
compound	O
library	O
prepared	O
from	O
edible	O
plants	O
for	O
new	O
bioactives	O
with	O
the	O
ability	O
to	O
inhibit	O
the	O
activity	O
of	O
NADPH	B
oxidase	O
4	O
.	O

Using	O
both	O
cell	O
-	O
based	O
and	O
cell	O
-	O
free	O
assays	O
,	O
we	O
identified	O
several	O
compounds	O
with	O
significant	O
inhibitory	O
activity	O
towards	O
NADPH	B
oxidase	O
4	O
.	O

For	O
selected	O
compounds	O
,	O
the	O
activity	O
profile	O
towards	O
NADPH	B
oxidase	O
2	O
and	O
NADPH	B
oxidase	O
5	O
was	O
established	O
,	O
and	O
controls	O
were	O
carried	O
out	O
to	O
exclude	O
general	O
reactive	O
oxygen	B
species	O
scavengers	O
.	O

A	O
number	O
of	O
promising	O
NADPH	B
oxidase	O
4	O
inhibitors	O
from	O
edible	O
plants	O
was	O
identified	O
and	O
characterised	O
.	O

Several	O
new	O
chemical	O
entities	O
are	O
disclosed	O
which	O
act	O
as	O
NADPH	B
oxidase	O
4	O
inhibitors	O
,	O
and	O
the	O
efficacies	O
of	O
our	O
best	O
hits	O
,	O
in	O
particular	O
several	O
diarylheptanoids	B
and	O
lignans	B
,	O
are	O
comparable	O
to	O
the	O
best	O
available	O
pharmacological	O
NADPH	B
oxidase	O
4	O
inhibitors	O
.	O

These	O
findings	O
will	O
provide	O
valuable	O
tools	O
to	O
study	O
mechanisms	O
of	O
NADPH	B
oxidase	O
inhibition	O
.	O

Structural	O
and	O
mechanical	O
heterogeneity	O
of	O
the	O
erythrocyte	O
membrane	O
reveals	O
hallmarks	O
of	O
membrane	O
stability	O
.	O

The	O
erythrocyte	O
membrane	O
,	O
a	O
metabolically	O
regulated	O
active	O
structure	O
that	O
comprises	O
lipid	O
molecules	O
,	O
junctional	O
complexes	O
,	O
and	O
the	O
spectrin	O
network	O
,	O
enables	O
the	O
cell	O
to	O
undergo	O
large	O
passive	O
deformations	O
when	O
passing	O
through	O
the	O
microvascular	O
system	O
.	O

Here	O
we	O
use	O
atomic	O
force	O
microscopy	O
(	O
AFM	O
)	O
imaging	O
and	O
quantitative	O
mechanical	O
mapping	O
at	O
nanometer	O
resolution	O
to	O
correlate	O
structure	O
and	O
mechanics	O
of	O
key	O
components	O
of	O
the	O
erythrocyte	O
membrane	O
,	O
crucial	O
for	O
cell	O
integrity	O
and	O
function	O
.	O

Our	O
data	O
reveal	O
structural	O
and	O
mechanical	O
heterogeneity	O
modulated	O
by	O
the	O
metabolic	O
state	O
at	O
unprecedented	O
nanometer	O
resolution	O
.	O

ATP	B
-	O
depletion	O
,	O
reducing	O
skeletal	O
junction	O
phosphorylation	O
in	O
RBC	O
cells	O
,	O
leads	O
to	O
membrane	O
stiffening	O
.	O

Analysis	O
of	O
ghosts	O
and	O
shear	O
-	O
force	O
opened	O
erythrocytes	O
show	O
that	O
,	O
in	O
the	O
absence	O
of	O
cytosolic	O
kinases	O
,	O
spectrin	O
phosphorylation	O
results	O
in	O
membrane	O
stiffening	O
at	O
the	O
extracellular	O
face	O
and	O
a	O
reduced	O
junction	O
remodeling	O
in	O
response	O
to	O
loading	O
forces	O
.	O

Topography	O
and	O
mechanical	O
mapping	O
of	O
single	O
components	O
at	O
the	O
cytoplasmic	O
face	O
reveal	O
that	O
,	O
surprisingly	O
,	O
spectrin	O
phosphorylation	O
by	O
ATP	B
softens	O
individual	O
filaments	O
.	O

Our	O
findings	O
suggest	O
that	O
,	O
besides	O
the	O
mechanical	O
signature	O
of	O
each	O
component	O
,	O
the	O
RBC	O
membrane	O
mechanics	O
is	O
regulated	O
by	O
the	O
metabolic	O
state	O
and	O
the	O
assembly	O
of	O
its	O
structural	O
elements	O
.	O

The	O
influence	O
of	O
endocrine	O
disruptors	O
in	O
a	O
selected	O
population	O
of	O
infertile	O
women	O
.	O

Abstract	O
Several	O
studies	O
report	O
that	O
endocrine	O
disrupting	O
chemicals	O
(	O
EDC	O
)	O
able	O
to	O
interfere	O
with	O
endocrine	O
homeostasis	O
may	O
affect	O
women	O
's	O
reproductive	O
health	O
.	O

We	O
analyzed	O
EDC	O
serum	O
levels	O
and	O
nuclear	O
receptors	O
(	O
NRs	O
)	O
expression	O
in	O
order	O
to	O
have	O
an	O
indication	O
of	O
the	O
internal	O
dose	O
of	O
biologically	O
active	O
compounds	O
and	O
a	O
measurement	O
of	O
indicators	O
of	O
their	O
effects	O
,	O
as	O
a	O
result	O
of	O
the	O
repeated	O
uptake	O
from	O
environmental	O
source	O
.	O

The	O
percentage	O
of	O
patients	O
with	O
detectable	O
bisphenol	B
A	I
(	O
BPA	B
)	O
concentrations	O
was	O
significantly	O
higher	O
in	O
the	O
infertile	O
patients	O
compared	O
with	O
fertile	O
subjects	O
.	O

No	O
significant	O
difference	O
was	O
found	O
between	O
the	O
groups	O
with	O
regard	O
to	O
perfluorooctane	B
sulfonate	I
(	O
PFOS	B
)	O
,	O
perfluorooctanoic	B
acid	I
(	O
PFOA	B
)	O
,	O
mono	B
-	I
ethylhexyl	I
phthalate	I
(	O
MEHP	B
)	O
and	O
di-	B
(	I
2-ethylhexyl	I
)	I
phthalate	I
(	O
DEHP	B
)	O
concentrations	O
.	O

Among	O
infertile	O
women	O
,	O
the	O
mean	O
expression	O
of	O
estrogen	B
receptor	O
alpha	O
(	O
ER	O
)	O
and	O
beta	O
(	O
Er	O
)	O
,	O
androgen	B
receptor	O
(	O
AR	O
)	O
and	O
pregnane	B
X	O
receptor	O
(	O
PXR	O
)	O
was	O
significantly	O
higher	O
than	O
fertile	O
patients	O
.	O

The	O
mean	O
expression	O
of	O
aryl	B
hydrocarbon	I
receptor	O
(	O
AhR	O
)	O
and	O
peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
gamma	O
(	O
PPAR	O
)	O
did	O
not	O
show	O
significant	O
differences	O
between	O
two	O
groups	O
.	O

Patients	O
with	O
endometriosis	O
had	O
higher	O
levels	O
of	O
PPAR	O
than	O
all	O
women	O
with	O
other	O
causes	O
of	O
infertility	O
.	O

This	O
study	O
led	O
further	O
support	O
to	O
EDC	O
exposure	O
as	O
a	O
risk	O
factor	O
for	O
women	O
's	O
fertility	O
.	O

A	O
novel	O
coating	O
concept	O
for	O
ileo	O
-	O
colonic	O
drug	O
targeting	O
:	O
Proof	O
of	O
concept	O
in	O
humans	O
using	O
scintigraphy	O
.	O

The	O
in	O
vivo	O
proof	O
of	O
concept	O
of	O
a	O
novel	O
double	O
-	O
coating	O
system	O
,	O
based	O
on	O
enteric	O
polymers	O
,	O
which	O
accelerated	O
drug	O
release	O
in	O
the	O
ileo	O
-	O
colonic	O
region	O
,	O
was	O
investigated	O
in	O
humans	O
.	O

Prednisolone	B
tablets	O
were	O
coated	O
with	O
a	O
double	O
-	O
coating	O
formulation	O
by	O
applying	O
an	O
inner	O
layer	O
composed	O
of	O
EUDRAGIT	B
	O
S	O
neutralised	O
to	O
pH	O
8.0	O
and	O
a	O
buffer	O
salt	O
(	O
10	O
%	O
KH	B
(	I
2	I
)	I
PO	I
(	I
4	I
)	I
)	O
,	O
which	O
was	O
overcoated	O
with	O
layer	O
of	O
standard	O
EUDRAGIT	B
	O
S	O
organic	O
solution	O
.	O

For	O
comparison	O
,	O
a	O
single	O
coating	O
system	O
was	O
produced	O
by	O
applying	O
the	O
same	O
amount	O
of	O
EUDRAGIT	B
	O
S	O
organic	O
solution	O
on	O
the	O
tablet	O
cores	O
.	O

Dissolution	O
tests	O
on	O
the	O
tablets	O
were	O
carried	O
out	O
using	O
USP	O
II	O
apparatus	O
in	O
0.1N	O
HCl	B
for	O
2h	O
and	O
subsequently	O
in	O
pH	O
7.4	O
Krebs	O
bicarbonate	O
buffer	O
.	O

For	O
comparison	O
,	O
tablets	O
were	O
also	O
tested	O
under	O
the	O
USP	O
method	O
established	O
for	O
modified	O
release	O
mesalamine	B
formulations	O
.	O

Ten	O
fasted	O
volunteers	O
received	O
the	O
double	O
-	O
coated	O
and	O
single	O
-	O
coated	O
tablets	O
in	O
a	O
two	O
-	O
way	O
crossover	O
study	O
.	O

The	O
formulations	O
were	O
radiolabelled	O
and	O
followed	O
by	O
gamma	O
scintigraphy	O
;	O
the	O
disintegration	O
times	O
and	O
positions	O
were	O
recorded	O
.	O

There	O
was	O
no	O
drug	O
release	O
from	O
the	O
single	O
-	O
coated	O
or	O
double	O
-	O
coated	O
tablets	O
in	O
0.1N	O
HCl	B
for	O
2h	O
.	O

The	O
single	O
-	O
coated	O
tablets	O
showed	O
slow	O
release	O
in	O
subsequent	O
Krebs	O
bicarbonate	O
buffer	O
with	O
a	O
lag	O
time	O
of	O
120min	O
,	O
while	O
in	O
contrast	O
drug	O
release	O
from	O
the	O
double	O
-	O
coated	O
tablets	O
was	O
initiated	O
at	O
60min	O
.	O

In	O
contrast	O
,	O
using	O
the	O
USP	O
dissolution	O
method	O
,	O
normally	O
employed	O
for	O
modified	O
release	O
mesalamine	B
products	O
,	O
no	O
discrimination	O
was	O
attained	O
.	O

The	O
in	O
vivo	O
disintegration	O
of	O
the	O
single	O
-	O
coated	O
EUDRAGIT	B
	O
S	O
tablets	O
in	O
the	O
large	O
intestine	O
was	O
erratic	O
.	O

Furthermore	O
,	O
in	O
2	O
volunteers	O
,	O
the	O
single	O
-	O
coated	O
tablet	O
was	O
voided	O
intact	O
.	O

Double	O
-	O
coated	O
tablets	O
disintegrated	O
in	O
a	O
more	O
consistent	O
way	O
,	O
mainly	O
in	O
the	O
ileo	O
-	O
caecal	O
junction	O
or	O
terminal	O
ileum	O
.	O

The	O
accelerated	O
in	O
vivo	O
disintegration	O
of	O
the	O
double	O
-	O
coating	O
EUDRAGIT	B
	O
S	O
system	O
can	O
overcome	O
the	O
limitations	O
of	O
conventional	O
enteric	O
coatings	O
targeting	O
the	O
colon	O
and	O
avoid	O
the	O
pass	O
-	O
through	O
of	O
intact	O
tablets	O
.	O

Moreover	O
,	O
Krebs	O
bicarbonate	B
buffer	O
has	O
the	O
ability	O
to	O
discriminate	O
between	O
formulations	O
designed	O
to	O
target	O
the	O
ileo	O
-	O
colonic	O
region	O
.	O

Disruption	O
of	O
the	O
cereblon	O
gene	O
enhances	O
hepatic	O
AMPK	O
activity	O
and	O
prevents	O
high	O
fat	O
diet	O
-	O
induced	O
obesity	O
and	O
insulin	O
resistance	O
in	O
mice	O
.	O

A	O
nonsense	O
mutation	O
in	O
cereblon	O
(	O
CRBN	O
)	O
causes	O
a	O
mild	O
type	O
of	O
mental	O
retardation	O
in	O
humans	O
.	O

An	O
earlier	O
study	O
showed	O
that	O
CRBN	O
negatively	O
regulates	O
the	O
functional	O
activity	O
of	O
AMP	B
-	O
activated	O
protein	O
kinase	O
(	O
AMPK	O
)	O
in	O
vitro	O
by	O
binding	O
directly	O
to	O
the	O
1	O
subunit	O
of	O
the	O
AMPK	O
complex	O
.	O

However	O
,	O
the	O
in	O
vivo	O
role	O
of	O
CRBN	O
was	O
not	O
studied	O
.	O

To	O
elucidate	O
the	O
physiological	O
functions	O
of	O
Crbn	O
,	O
a	O
mouse	O
strain	O
was	O
generated	O
in	O
which	O
the	O
Crbn	O
gene	O
was	O
deleted	O
throughout	O
the	O
whole	O
body	O
.	O

In	O
Crbn	O
-	O
deficient	O
mice	O
fed	O
a	O
normal	O
diet	O
,	O
AMPK	O
in	O
the	O
liver	O
showed	O
hyper	O
-	O
phosphorylation	O
,	O
which	O
indicated	O
the	O
constitutive	O
activation	O
of	O
AMPK	O
.	O

Since	O
Crbn	O
-	O
deficient	O
mice	O
showed	O
significantly	O
less	O
weight	O
gain	O
when	O
fed	O
a	O
high	O
fat	O
diet	O
and	O
their	O
insulin	O
sensitivity	O
was	O
considerably	O
improved	O
,	O
the	O
functions	O
of	O
Crbn	O
in	O
the	O
liver	O
were	O
primarily	O
investigated	O
.	O

These	O
results	O
provide	O
the	O
first	O
in	O
vivo	O
evidence	O
that	O
Crbn	O
is	O
a	O
negative	O
modulator	O
of	O
AMPK	O
,	O
which	O
suggests	O
that	O
Crbn	O
may	O
be	O
a	O
potential	O
target	O
for	O
metabolic	O
disorders	O
of	O
the	O
liver	O
.	O

	O
-	O
Cells	O
Are	O
Not	O
Generated	O
in	O
Pancreatic	O
Duct	O
Ligation	O
-	O
Induced	O
Injury	O
in	O
Adult	O
Mice	O
.	O

The	O
existence	O
of	O
adult	O
	O
-	O
cell	O
progenitors	O
remains	O
the	O
most	O
controversial	O
developmental	O
biology	O
topic	O
in	O
diabetes	O
research	O
.	O

It	O
has	O
been	O
reported	O
that	O
	O
-	O
cell	O
progenitors	O
can	O
be	O
activated	O
by	O
ductal	O
ligation	O
-	O
induced	O
injury	O
of	O
adult	O
mouse	O
pancreas	O
and	O
apparently	O
act	O
in	O
a	O
cell	O
-	O
autonomous	O
manner	O
to	O
double	O
the	O
functional	O
	O
-	O
cell	O
mass	O
within	O
a	O
week	O
by	O
differentiation	O
and	O
proliferation	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	O
pancreatic	O
duct	O
ligation	O
(	O
PDL	O
)	O
does	O
not	O
activate	O
progenitors	O
to	O
contribute	O
to	O
	O
-	O
cell	O
mass	O
expansion	O
.	O

Rather	O
,	O
PDL	O
stimulates	O
massive	O
pancreatic	O
injury	O
,	O
which	O
alters	O
pancreatic	O
composition	O
and	O
thus	O
complicates	O
accurate	O
measurement	O
of	O
	O
-	O
cell	O
content	O
via	O
traditional	O
morphometry	O
methodologies	O
that	O
superficially	O
sample	O
the	O
pancreas	O
.	O

To	O
overcome	O
this	O
potential	O
bias	O
,	O
we	O
quantified	O
	O
-	O
cells	O
from	O
the	O
entire	O
pancreas	O
and	O
observed	O
that	O
	O
-	O
cell	O
mass	O
and	O
insulin	O
content	O
are	O
totally	O
unchanged	O
by	O
PDL	O
-	O
induced	O
injury	O
.	O

Lineage	O
-	O
tracing	O
studies	O
using	O
sequential	O
administration	O
of	O
thymidine	B
analogs	O
,	O
rat	O
insulin	O
2	O
promoter	O
-	O
driven	O
cre	O
-	O
lox	O
,	O
and	O
low	O
-	O
frequency	O
ubiquitous	O
cre	O
-	O
lox	O
reveal	O
that	O
PDL	O
does	O
not	O
convert	O
progenitors	O
to	O
the	O
	O
-	O
cell	O
lineage	O
.	O

Thus	O
,	O
we	O
conclude	O
that	O
	O
-	O
cells	O
are	O
not	O
generated	O
in	O
injured	O
adult	O
mouse	O
pancreas	O
.	O

Galectin-3	O
Deficiency	O
Accelerates	O

High	O
-	O
Fat	O
Diet	O
Induced	O
Obesity	O
and	O
Amplifies	O
Inflammation	O
in	O
Adipose	O
Tissue	O
and	O
Pancreatic	O
Islets	O
.	O

Obesity	O
-	O
induced	O
diabetes	O
is	O
associated	O
with	O
low	O
-	O
grade	O
inflammation	O
in	O
adipose	O
tissue	O
and	O
macrophage	O
infiltration	O
of	O
islets	O
.	O

We	O
show	O
that	O
ablation	O
of	O
Galectin-3	O
,	O
a	O
galactoside	O
-	O
binding	O
lectin	O
,	O
accelerates	O
high	O
-	O
fat	O
diet	O
-	O
induced	O
obesity	O
and	O
diabetes	O
.	O

Obese	O
LGALS3	O
(	O
-	O
/	O
-	O
)	O
mice	O
have	O
increased	O
body	O
weight	O
,	O
amount	O
of	O
total	O
visceral	O
adipose	O
tissue	O
,	O
fasting	O
blood	O
glucose	B
and	O
insulin	O
levels	O
,	O
HOMA	O
-	O
IR	O
and	O
markers	O
of	O
systemic	O
inflammation	O
compared	O
to	O
diet	O
-	O
matched	O
WT	O
animals	O
.	O

Obese	O
LGALS3	O
(	O
-	O
/	O
-	O
)	O
visceral	O
adipose	O
tissue	O
exhibited	O
increased	O
incidence	O
of	O
Type-1	O
T	O
and	O
NKT	O
lymphocytes	O
and	O
pro	O
-	O
inflammatory	O
CD11c+CD11b	O
macrophages	O
and	O
decreased	O
CD4+CD25+FoxP3	O
+	O
Tregs	O
and	O
M2	O
macrophages	O
.	O

Pronounced	O
mononuclear	O
cell	O
infiltrate	O
,	O
increased	O
expression	O
of	O
NLRP3	O
inflammasome	O
and	O
IL-1	O
in	O
macrophages	O
and	O
increased	O
accumulation	O
of	O
advanced	O
glycation	O
endproducts	O
(	O
AGE	O
)	O
and	O
receptor	O
for	O
AGE	O
(	O
RAGE	O
)	O
expression	O
were	O
present	O
in	O
pancreatic	O
islets	O
of	O
obese	O
LGALS3	O
(	O
-	O
/	O
-	O
)	O
animals	O
accompanied	O
with	O
elevated	O
phosphorilated	O
NFB	O
p65	O
and	O
mature	O
Caspase-1	O
protein	O
expression	O
in	O
pancreatic	O
and	O
visceral	O
adipose	O
tissue	O
.	O

In	O
vitro	O
stimulation	O
of	O
LGALS3	O
(	O
-	O
/	O
-	O
)	O
peritoneal	O
macrophages	O
with	O
lypopolysaccharide	O
(	O
LPS	O
)	O
and	O
saturated	O
fatty	O
acid	O
palmitate	B
caused	O
increased	O
Caspase-1	O
dependent	O
IL-1	O
production	O
and	O
increased	O
phosphorilation	O
of	O
NFB	O
p65	O
compared	O
to	O
WT	O
cells	O
.	O

Transfection	O
of	O
LGALS3	O
(	O
-	O
/	O
-	O
)	O
macrophages	O
with	O
NLRP3	O
siRNA	O
attenuated	O
IL-1	O
production	O
in	O
response	O
to	O
palmitate	B
and	O
LPS	O
plus	O
palmitate	B
.	O

Obtained	O
results	O
suggest	O
important	O
protective	O
roles	O
for	O
Gal-3	O
in	O
obesity	O
-	O
induced	O
inflammation	O
and	O
diabetes	O
.	O

TSG-6	O
produced	O
by	O
hMSCs	O
delays	O
the	O
onset	O
of	O
autoimmune	O
diabetes	O
by	O
suppressing	O
Th1	O
development	O
and	O
enhancing	O
tolerogenicity	O
.	O

Genetic	O
and	O
immunological	O
screening	O
for	O
type	O
1	O
diabetes	O
has	O
led	O
to	O
the	O
possibility	O
of	O
preventing	O
disease	O
in	O
susceptible	O
individuals	O
.	O

Here	O
,	O
we	O
show	O
that	O
human	O
Mesenchymal	O
Stem	O
/	O
Stromal	O
Cells	O
(	O
hMSCs	O
)	O
and	O
TNF	O
-	O
	O
-	O
stimulated	O
gene	O
6	O
(	O
TSG-6	O
)	O
,	O
a	O
protein	O
produced	O
by	O
hMSCs	O
in	O
response	O
to	O
signals	O
from	O
injured	O
tissues	O
,	O
delayed	O
the	O
onset	O
of	O
spontaneous	O
autoimmune	O
diabetes	O
in	O
NOD	O
mice	O
by	O
inhibiting	O
insulitis	O
and	O
augmenting	O
regulatory	O
T	O
cells	O
(	O
Tregs	O
)	O
within	O
the	O
pancreas	O
.	O

Importantly	O
,	O
hMSCs	O
with	O
a	O
knockdown	O
of	O
tsg-6	O
were	O
ineffective	O
at	O
delaying	O
insulitis	O
and	O
the	O
onset	O
of	O
diabetes	O
in	O
mice	O
.	O

TSG-6	O
inhibited	O
the	O
activation	O
of	O
both	O
T	O
cell	O
and	O
antigen	O
presenting	O
cells	O
(	O
APCs	O
)	O
in	O
a	O
CD44-dependent	O
manner	O
.	O

Moreover	O
,	O
multiple	O
treatments	O
of	O
TSG-6	O
rendered	O
APCs	O
more	O
tolerogenic	O
,	O
capable	O
of	O
enhancing	O
Treg	O
generation	O
and	O
delaying	O
diabetes	O
in	O
an	O
adoptive	O
transfer	O
model	O
.	O

Therefore	O
,	O
these	O
results	O
could	O
provide	O
the	O
basis	O
for	O
a	O
novel	O
therapy	O
for	O
the	O
prevention	O
of	O
type	O
1	O
diabetes	O
.	O

The	O
role	O
of	O
GH	O
in	O
adipose	O
tissue	O
:	O
lessons	O
from	O
adipose	O
-	O
specific	O
GH	O
receptor	O
gene	O
-	O
disrupted	O
mice	O
.	O

GH	O
receptor	O
(	O
GHR	O
)	O
gene	O
-	O
disrupted	O
mice	O
(	O
GHR-	O
/	O
-	O
)	O
have	O
provided	O
countless	O
discoveries	O
as	O
to	O
the	O
numerous	O
actions	O
of	O
GH	O
.	O

Many	O
of	O
these	O
discoveries	O
highlight	O
the	O
importance	O
of	O
GH	O
in	O
adipose	O
tissue	O
.	O

For	O
example	O
GHR-	O
/	O
-	O
mice	O
are	O
insulin	O
sensitive	O
yet	O
obese	O
with	O
preferential	O
enlargement	O
of	O
the	O
sc	O
adipose	O
depot	O
.	O

GHR-	O
/	O
-	O
mice	O
also	O
have	O
elevated	O
levels	O
of	O
leptin	O
,	O
resistin	O
,	O
and	O
adiponectin	O
,	O
compared	O
with	O
controls	O
leading	O
some	O
to	O
suggest	O
that	O
GH	O
may	O
negatively	O
regulate	O
certain	O
adipokines	O
.	O

To	O
help	O
clarify	O
the	O
role	O
that	O
GH	O
exerts	O
specifically	O
on	O
adipose	O
tissue	O
in	O
vivo	O
,	O
we	O
selectively	O
disrupted	O
GHR	O
in	O
adipose	O
tissue	O
to	O
produce	O
Fat	O
GHR	O
Knockout	O
(	O
FaGHRKO	O
)	O
mice	O
.	O

Surprisingly	O
,	O
FaGHRKOs	O
shared	O
only	O
a	O
few	O
characteristics	O
with	O
global	O
GHR-	O
/	O
-	O
mice	O
.	O

Like	O
the	O
GHR-	O
/	O
-	O
mice	O
,	O
FaGHRKO	O
mice	O
are	O
obese	O
with	O
increased	O
total	O
body	O
fat	O
and	O
increased	O
adipocyte	O
size	O
.	O

However	O
,	O
FaGHRKO	O
mice	O
have	O
increases	O
in	O
all	O
adipose	O
depots	O
with	O
no	O
improvements	O
in	O
measures	O
of	O
glucose	B
homeostasis	O
.	O

Furthermore	O
,	O
resistin	O
and	O
adiponectin	O
levels	O
in	O
FaGHRKO	O
mice	O
are	O
similar	O
to	O
controls	O
(	O
or	O
slightly	O
decreased	O
)	O
unlike	O
the	O
increased	O
levels	O
found	O
in	O
GHR-	O
/	O
-	O
mice	O
,	O
suggesting	O
that	O
GH	O
does	O
not	O
regulate	O
these	O
adipokines	O
directly	O
in	O
adipose	O
tissue	O
in	O
vivo	O
.	O

Other	O
features	O
of	O
FaGHRKO	O
mice	O
include	O
decreased	O
levels	O
of	O
adipsin	O
,	O
a	O
near	O
-	O
normal	O
GH	O
/	O
IGF-1	O
axis	O
,	O
and	O
minimal	O
changes	O
to	O
a	O
large	O
assortment	O
of	O
circulating	O
factors	O
that	O
were	O
measured	O
such	O
as	O
IGF	O
-	O
binding	O
proteins	O
.	O

In	O
conclusion	O
,	O
specific	O
removal	O
of	O
GHR	O
in	O
adipose	O
tissue	O
is	O
sufficient	O
to	O
increase	O
adipose	O
tissue	O
and	O
decrease	O
circulating	O
adipsin	O
.	O

However	O
,	O
removal	O
of	O
GHR	O
in	O
adipose	O
tissue	O
alone	O
is	O
not	O
sufficient	O
to	O
increase	O
levels	O
of	O
resistin	O
or	O
adiponectin	O
and	O
does	O
not	O
alter	O
glucose	B
metabolism	O
.	O

Mineralocorticoid	O
receptor	O
-	O
mediated	O
vascular	O
insulin	O
resistance	O
:	O
an	O
early	O
contributor	O
to	O
diabetes	O
-	O
related	O
vascular	O
disease	O
?	O

Two	O
-	O
thirds	O
of	O
adults	O
in	O
the	O
U.S.	O
are	O
overweight	O
or	O
obese	O
,	O
and	O
another	O
26	O
million	O
have	O
type	O
2	O
diabetes	O
(	O
T2D	O
)	O
.	O

Patients	O
with	O
diabetes	O
and/or	O
the	O
metabolic	O
syndrome	O
have	O
a	O
significantly	O
increased	O
risk	O
of	O
heart	O
attack	O
and	O
stroke	O
compared	O
with	O
people	O
with	O
normal	O
insulin	O
sensitivity	O
.	O

Decreased	O
insulin	O
sensitivity	O
in	O
cardiovascular	O
tissues	O
as	O
well	O
as	O
in	O
traditional	O
targets	O
of	O
insulin	O
metabolic	O
signaling	O
,	O
such	O
as	O
skeletal	O
muscle	O
,	O
is	O
an	O
underlying	O
abnormality	O
in	O
obesity	O
,	O
hypertension	O
,	O
and	O
T2D	O
.	O

In	O
the	O
vasculature	O
,	O
insulin	O
signaling	O
plays	O
a	O
critical	O
role	O
in	O
normal	O
vascular	O
function	O
via	O
endothelial	O
cell	O
nitric	B
oxide	I
production	O
and	O
modulation	O
of	O
Ca	B
(	I
2	I
+	I
)	I
handling	O
and	O
sensitivity	O
in	O
vascular	O
smooth	O
muscle	O
cells	O
.	O

Available	O
evidence	O
suggests	O
that	O
impaired	O
vascular	O
insulin	O
sensitivity	O
may	O
be	O
an	O
early	O
,	O
perhaps	O
principal	O
,	O
defect	O
of	O
vascular	O
function	O
and	O
contributor	O
to	O
the	O
pathogenesis	O
of	O
vascular	O
disease	O
in	O
persons	O
with	O
obesity	O
,	O
hypertension	O
,	O
and	O
T2D	O
.	O

In	O
the	O
overweight	O
and	O
obese	O
individual	O
,	O
as	O
well	O
as	O
in	O
persons	O
with	O
hypertension	O
,	O
systemic	O
and	O
vascular	O
insulin	O
resistance	O
often	O
occur	O
in	O
concert	O
with	O
elevations	O
in	O
plasma	O
aldosterone	B
.	O

Indeed	O
,	O
basic	O
and	O
clinical	O
studies	O
have	O
demonstrated	O
that	O
elevated	O
plasma	O
aldosterone	B
levels	O
predict	O
the	O
development	O
of	O
insulin	O
resistance	O
and	O
that	O
aldosterone	B
directly	O
interferes	O
with	O
insulin	O
signaling	O
in	O
vascular	O
tissues	O
.	O

Furthermore	O
,	O
elevated	O
plasma	O
aldosterone	B
levels	O
are	O
associated	O
with	O
increased	O
heart	O
attack	O
and	O
stroke	O
risk	O
.	O

Conversely	O
,	O
renin	O
-	O
angiotensin	O
-	O
aldosterone	B
system	O
and	O
mineralocorticoid	O
receptor	O
(	O
MR	O
)	O
antagonism	O
reduces	O
cardiovascular	O
risk	O
in	O
these	O
patient	O
populations	O
.	O

Recent	O
and	O
accumulating	O
evidence	O
in	O
this	O
area	O
has	O
implicated	O
excessive	O
Ser	B
phosphorylation	O
and	O
proteosomal	O
degradation	O
of	O
the	O
docking	O
protein	O
,	O
insulin	O
receptor	O
substrate	O
,	O
and	O
enhanced	O
signaling	O
through	O
hybrid	O
insulin	O
/	O
IGF-1	O
receptor	O
as	O
important	O
mechanisms	O
underlying	O
aldosterone	B
-	O
mediated	O
interruption	O
of	O
downstream	O
vascular	O
insulin	O
signaling	O
.	O

Prevention	O
or	O
restoration	O
of	O
these	O
changes	O
via	O
blockade	O
of	O
aldosterone	B
action	O
in	O
the	O
vascular	O
wall	O
with	O
MR	O
antagonists	O
(	O
i.e.	O
,	O
spironolactone	B
,	O
eplerenone	B
)	O
may	O
therefore	O
account	O
for	O
the	O
clinical	O
benefit	O
of	O
these	O
compounds	O
in	O
obese	O
and	O
diabetic	O
patients	O
with	O
cardiovascular	O
disease	O
.	O

This	O
review	O
will	O
highlight	O
recent	O
evidence	O
supporting	O
the	O
hypothesis	O
that	O
aldosterone	B
and	O
MR	O
signaling	O
represent	O
an	O
ideal	O
candidate	O
pathway	O
linking	O
early	O
promoters	O
of	O
diabetes	O
,	O
especially	O
overnutrition	O
and	O
obesity	O
,	O
to	O
vascular	O
insulin	O
resistance	O
,	O
dysfunction	O
,	O
and	O
disease	O
.	O

In	O
vivo	O
microdialysis	O
for	O
the	O
evaluation	O
of	O
transfersomes	O
as	O
a	O
novel	O
transdermal	O
delivery	O
vehicle	O
for	O
cinnamic	B
acid	I
.	O

Abstract	O
In	O
this	O
study	O
,	O
cinnamic	B
acid	I
-	O
loaded	O
transfersomes	O
were	O
prepared	O
and	O
dermal	O
microdialysis	O
sampling	O
was	O
used	O
in	O
Sprague	O
-	O
Dawley	O
rats	O
to	O
compare	O
the	O
amount	O
of	O
drug	O
released	O
into	O
the	O
skin	O
using	O
transfersomes	O
as	O
transdermal	O
carriers	O
with	O
that	O
released	O
on	O
using	O
conventional	O
liposomes	O
.	O

The	O
formulation	O
of	O
cinnamic	B
acid	I
-	O
loaded	O
transfersomes	O
was	O
optimized	O
by	O
a	O
uniform	O
design	O
through	O
in	O
vitro	O
transdermal	O
permeation	O
studies	O
.	O

Hydration	O
time	O
was	O
confirmed	O
as	O
a	O
significant	O
factor	O
influencing	O
the	O
entrapment	O
efficiency	O
of	O
transfersomes	O
,	O
further	O
affecting	O
their	O
transdermal	O
flux	O
in	O
vitro	O
.	O

The	O
fluxes	O
of	O
cinnamic	B
acid	I
from	O
transfersomes	O
were	O
all	O
higher	O
than	O
those	O
from	O
conventional	O
liposomes	O
,	O
and	O
the	O
flux	O
from	O
the	O
optimal	O
transfersome	O
formulation	O
was	O
3.01-fold	O
higher	O
than	O
that	O
from	O
the	O
conventional	O
liposomes	O
(	O
p	O
<	O
0.05	O
)	O
.	O

An	O
in	O
vivo	O
microdialysis	O
sampling	O
method	O
revealed	O
that	O
the	O
dermal	O
drug	O
concentrations	O
from	O
transfersomes	O
applied	O
on	O
various	O
skin	O
regions	O
were	O
much	O
lower	O
than	O
those	O
required	O
with	O
conventional	O
liposomes	O
.	O

After	O
the	O
administration	O
of	O
drug	O
-	O
containing	O
transfersomes	O
and	O
liposomes	O
on	O
abdominal	O
skin	O
regions	O
of	O
rats	O
for	O
a	O
period	O
of	O
10	O
h	O
,	O
the	O
C	O
(	O
max	O
)	O
of	O
cinnamic	B
acid	I
from	O
the	O
compared	O
liposomes	O
was	O
3.21	O
	O
0.25	O
g	O
/	O
mL	O
and	O
that	O
from	O
the	O
transfersomes	O
was	O
merely	O
0.59	O
	O
0.02	O
g	O
/	O
mL.	O
The	O
results	O
suggest	O
that	O
transfersomes	O
can	O
be	O
used	O
as	O
carriers	O
to	O
enhance	O
the	O
transdermal	O
delivery	O
of	O
cinnamic	B
acid	I
,	O
and	O
that	O
these	O
vehicles	O
may	O
penetrate	O
the	O
skin	O
in	O
the	O
complete	O
form	O
,	O
given	O
their	O
significant	O
deformability	O
.	O

Iontophoresis	O
of	O
amoxicillin	B
and	O
cefuroxime	B
:	O
rapid	O
therapeutic	O
concentrations	O
in	O
skin	O
.	O

Abstract	O
Context	O
:	O
Amoxicillin	B
(	O
AMX	B
)	O
and	O
cefuroxime	B
(	O
CFX	B
)	O
are	O
antibiotics	O
used	O
often	O
to	O
treat	O
skin	O
bacterial	O
infections	O
.	O

Typically	O
,	O
high	O
oral	O
doses	O
are	O
required	O
to	O
achieve	O
minimum	O
inhibitory	O
concentration	O
(	O
MIC	O
)	O
at	O
the	O
site	O
of	O
infection	O
that	O
may	O
affect	O
only	O
a	O
very	O
small	O
area	O
of	O
skin	O
.	O

Objectives	O
:	O
To	O
lower	O
side	O
effects	O
and	O
increase	O
therapeutic	O
effectiveness	O
,	O
the	O
percutaneous	O
absorption	O
and	O
retention	O
of	O
AMX	B
and	O
CFX	B
administered	O
by	O
iontophoresis	O
was	O
investigated	O
in	O
a	O
rabbit	O
model	O
by	O
measuring	O
dermis	O
concentrations	O
via	O
microdialysis	O
.	O

Methods	O
:	O
Iontophoresis	O
was	O
performed	O
using	O
a	O
stainless	O
steel	O
electrode	O
and	O
a	O
non	O
-	O
woven	O
polypropylene	B
pad	O
.	O

The	O
cartridge	O
pad	O
was	O
soaked	O
with	O
a	O
solution	O
of	O
AMX	B
in	O
glycerin	O
or	O
of	O
CFX	B
in	O
glycerin	O
/	O
water	O
(	O
60:40	O
)	O
.	O

Constant	O
current	O
density	O
of	O
0	O
,	O
100	O
,	O
200	O
or	O
300	O
A	O
/	O
cm	O
(	O
2	O
)	O
was	O
applied	O
for	O
60	O
min	O
.	O

Results	O
:	O
For	O
AMX	B
,	O
therapeutically	O
effective	O
skin	O
concentrations	O
were	O
detected	O
immediately	O
after	O
the	O
application	O
of	O
electrical	O
current	O
for	O
any	O
of	O
the	O
current	O
density	O
tested	O
and	O
remained	O
above	O
it	O
for	O
at	O
least	O
2	O
h	O
from	O
the	O
end	O
of	O
iontophoresis	O
.	O

For	O
CFX	B
,	O
skin	O
concentrations	O
rose	O
above	O
MIC	O
only	O
at	O
the	O
higher	O
current	O
densities	O
and	O
fell	O
below	O
the	O
MIC	O
by	O
the	O
end	O
of	O
the	O
experiment	O
.	O

Conclusion	O
:	O

Iontophoresis	O
is	O
a	O
promising	O
method	O
to	O
obtain	O
a	O
fast	O
and	O
sustained	O
concentration	O
of	O
AMX	B
and	O
CFX	B
in	O
skin	O
.	O

Nano	O
-	O
optomechanical	O
actuator	O
and	O
pull	O
-	O
back	O
instability	O
.	O

This	O
paper	O
studies	O
the	O
nonlinear	O
behavior	O
of	O
a	O
nano	O
-	O
optomechanical	O
actuator	O
,	O
consisting	O
of	O
a	O
free	O
-	O
standing	O
arc	O
in	O
a	O
ring	O
resonator	O
that	O
is	O
coupled	O
to	O
a	O
bus	O
waveguide	O
through	O
evanescent	O
waves	O
.	O

The	O
arc	O
deflects	O
when	O
a	O
control	O
light	O
of	O
a	O
fixed	O
wavelength	O
and	O
optical	O
power	O
is	O
pumped	O
into	O
the	O
bus	O
waveguide	O
,	O
while	O
the	O
amount	O
of	O
deflection	O
is	O
monitored	O
by	O
measuring	O
the	O
transmission	O
spectrum	O
of	O
a	O
broadband	O
probe	O
light	O
.	O

This	O
nanoactuator	O
achieves	O
a	O
maximal	O
deflection	O
of	O
43.1	O
nm	O
,	O
with	O
a	O
resolution	O
of	O
0.28	O
nm	O
.	O

The	O
optical	O
force	O
is	O
a	O
nonlinear	O
function	O
of	O
the	O
deflection	O
of	O
the	O
arc	O
,	O
leading	O
to	O
pull	O
-	O
back	O
instability	O
when	O
the	O
control	O
light	O
is	O
red	O
-	O
tuned	O
.	O

This	O
instability	O
is	O
studied	O
by	O
a	O
combination	O
of	O
experiment	O
and	O
modeling	O
.	O

Potential	O
applications	O
of	O
the	O
nanoactuator	O
include	O
bio	O
-	O
nanomotor	O
,	O
optical	O
switches	O
,	O
and	O
optomechanical	O
memories	O
.	O

Increased	O
protein	O
sorption	O
in	O
poly	B
(	I
acrylic	I
acid	I
)	I
-containing	O
films	O
through	O
incorporation	O
of	O
comb	O
-	O
like	O
polymers	O
and	O
film	O
adsorption	O
at	O
low	O
pH	O
and	O
high	O
ionic	O
strength	O
.	O

In	O
principle	O
,	O
incorporation	O
of	O
comb	O
-	O
like	O
block	O
copolymers	O
in	O
multilayer	O
polyelectrolyte	O
films	O
can	O
both	O
increase	O
film	O
thickness	O
relative	O
to	O
coatings	O
containing	O
linear	O
polymers	O
and	O
provide	O
more	O
swollen	O
films	O
for	O
increased	O
sorption	O
of	O
proteins	O
.	O

In	O
the	O
absence	O
of	O
added	O
salt	O
,	O
alternating	O
adsorption	O
of	O
5	O
bilayers	O
of	O
protonated	O
poly	B
(	I
allylamine	I
)	I
(	O
PAH	B
)	O
and	O
comb	O
-	O
like	O
poly	B
(	I
2-hydroxyethyl	I
methacrylate	I
)	I
-graft	I
-	I
poly	I
(	I
acrylic	I
acid	I
)	I
(	O
PHEMA	B
-	I
g	I
-	I
PAA	I
)	O
leads	O
to	O
2-fold	O
thicker	O
coatings	O
than	O
adsorption	O
of	O
PAH	B
and	O
linear	O
PAA	B
,	O
and	O
the	O
difference	O
in	O
the	O
thicknesses	O
of	O
the	O
two	O
coatings	O
increases	O
with	O
the	O
number	O
of	O
bilayers	O
.	O

Moreover	O
,	O
the	O
(	O
PAH	B
/	O
PHEMA	B
-	I
g	I
-	I
PAA	I
)	O
n	O
films	O
sorb	O
2-	O
to	O
4-fold	O
more	O
protein	O
than	O
corresponding	O
films	O
prepared	O
with	O
linear	O
PAA	B
,	O
and	O
coatings	O
deposited	O
at	O
pH	O
3.0	O
sorb	O
more	O
protein	O
than	O
coatings	O
adsorbed	O
at	O
pH	O
5.0	O
,	O
7.0	O
,	O
or	O
9.0	O
.	O

In	O
fact	O
changes	O
in	O
deposition	O
pH	O
and	O
addition	O
of	O
0.5	O
M	O
NaCl	B
to	O
polyelectrolyte	O
adsorption	O
solutions	O
alter	O
protein	O
sorption	O
more	O
dramatically	O
than	O
variations	O
in	O
the	O
constituent	O
polymer	O
architecture	O
.	O

When	O
deposited	O
from	O
0.5	O
M	O
NaCl	B
at	O
pH	O
3.0	O
,	O
both	O
(	O
PAH	B
/	O
PHEMA	B
-	I
g	I
-	I
PAA	I
)	O
5	O
and	O
(	O
PAH	B
/	O
PAA	B
)	O
5	O
films	O
increase	O
in	O
thickness	O
more	O
than	O
400	O
%	O
upon	O
adsorption	O
of	O
lysozyme	O
.	O

These	O
films	O
contain	O
a	O
high	O
concentration	O
of	O
free	O
-COOH	O
groups	O
,	O
and	O
subsequent	O
deprotonation	O
of	O
these	O
groups	O
at	O
neutral	O
pH	O
likely	O
contributes	O
to	O
increased	O
protein	O
binding	O
.	O

Lysozyme	O
sorption	O
stabilizes	O
these	O
films	O
,	O
as	O
without	O
lysozyme	O
films	O
deposited	O
at	O
pH	O
3.0	O
from	O
0.5	O
M	O
NaCl	B
desorb	O
at	O
neutral	O
pH.	O
Films	O
deposited	O
at	O
pH	O
9.0	O
from	O
0.5	O
M	O
NaCl	B
are	O
more	O
stable	O
and	O
also	O
bind	O
large	O
amounts	O
of	O
lysozyme	O
.	O

The	O
high	O
binding	O
capacities	O
of	O
these	O
films	O
make	O
them	O
attractive	O
for	O
potential	O
applications	O
in	O
protein	O
isolation	O
or	O
immobilization	O
of	O
enzymes	O
.	O

Labdane	B
diterpenoids	I
and	O
lignans	B
from	O
Calocedrus	O
macrolepis	O
.	O

Three	O
new	O
labdane	B
diterpenoids	I
,	O
calomacrins	B
A	I
-	I
C	I
(	O
1	O
-	O
3	O
)	O
,	O
and	O
a	O
new	O
diaryl	B
butyrolactone	I
-	O
type	O
lignan	B
,	O
calomacrol	B
A	I
(	O
8)	O
,	O
as	O
well	O
as	O
four	O
known	O
labdane	B
diterpenoids	I
and	O
six	O
known	O
lignans	B
,	O
were	O
isolated	O
from	O
the	O
twigs	O
and	O
leaves	O
of	O
Calocedrus	O
macrolepis	O
.	O

Structures	O
of	O
the	O
new	O
compounds	O
were	O
elucidated	O
on	O
the	O
basis	O
of	O
their	O
spectroscopic	O
methods	O
,	O
including	O
1D	O
and	O
2D	O
NMR	O
techniques	O
.	O

Compounds	O
3	O
-	O
14	O
were	O
evaluated	O
for	O
cytotoxicity	O
against	O
HL-60	O
,	O
SMMC-7721	O
,	O
A-549	O
,	O
MCF-7	O
,	O
and	O
SW480	O
cell	O
lines	O
.	O

Tamoxifen	B
magnifies	O
therapeutic	O
impact	O
of	O
ceramide	B
in	O
human	O
colorectal	O
cancer	O
cells	O
independent	O
of	O
p53	O
.	O

Poor	O
prognosis	O
in	O
patients	O
with	O
later	O
stage	O
colorectal	O
cancer	O
(	O
CRC	O
)	O
necessitates	O
the	O
search	O
for	O
new	O
treatment	O
strategies	O
.	O

Ceramide	B
,	O
because	O
of	O
its	O
role	O
in	O
orchestrating	O
death	O
cascades	O
in	O
cancer	O
cells	O
,	O
is	O
a	O
versatile	O
alternative	O
.	O

Ceramide	B
can	O
be	O
generated	O
by	O
exposure	O
to	O
chemotherapy	O
or	O
ionizing	O
radiation	O
,	O
or	O
it	O
can	O
be	O
administered	O
in	O
the	O
form	O
of	O
short	O
-	O
chain	O
analogs	O
(	O
C6-ceramide	B
)	O
.	O

Because	O
intracellular	O
P	O
-	O
glycoprotein	O
(	O
P	O
-	O
gp	O
)	O
plays	O
a	O
role	O
in	O
catalyzing	O
the	O
conversion	O
of	O
ceramide	B
to	O
higher	O
sphingolipids	B
,	O
we	O
hypothesized	O
that	O
administration	O
of	O
P	O
-	O
gp	O
antagonists	O
with	O
C6-ceramide	B
would	O
magnify	O
cell	O
death	O
cascades	O
.	O

Human	O
CRC	O
cell	O
lines	O
were	O
employed	O
,	O
HCT-15	O
,	O
HT-29	O
,	O
and	O
LoVo	O
.	O

The	O
addition	O
of	O
either	O
tamoxifen	B
,	O
VX-710	B
,	O
verapamil	B
,	O
or	O
cyclosporin	B
A	I
,	O
antagonists	O
of	O
P	O
-	O
gp	O
,	O
enhanced	O
C6-ceramide	B
cytotoxicity	O
in	O
all	O
cell	O
lines	O
.	O

In	O
depth	O
studies	O
with	O
C6-ceramide	B
and	O
tamoxifen	B
in	O
LoVo	O
cells	O
showed	O
the	O
regimen	O
induced	O
PARP	O
cleavage	O
,	O
caspase	O
-	O
dependent	O
apoptosis	O
,	O
mitochondrial	O
membrane	O
permeabilization	O
(	O
MMP	O
)	O
,	O
and	O
cell	O
cycle	O
arrest	O
at	O
G1	O
and	O
G2	O
.	O

At	O
the	O
molecular	O
level	O
,	O
the	O
regimen	O
,	O
but	O
not	O
single	O
agents	O
,	O
induced	O
time	O
-	O
dependent	O
upregulation	O
of	O
tumor	O
suppressor	O
protein	O
p53	O
;	O
however	O
,	O
introduction	O
of	O
a	O
p53	O
inhibitor	O
staved	O
neither	O
MMP	O
nor	O
apoptosis	O
.	O

Nanoliposomal	O
formulations	O
of	O
C6-ceramide	B
and	O
tamoxifen	B
were	O
also	O
effective	O
,	O
yielding	O
synergistic	O
cell	O
kill	O
.	O

We	O
conclude	O
that	O
tamoxifen	B
is	O
a	O
favorable	O
adjuvant	O
for	O
enhancing	O
C6-ceramide	B
cytotoxicity	O
in	O
CRC	O
,	O
and	O
demonstrates	O
uniquely	O
integrated	O
effects	O
.	O

The	O
high	O
frequency	O
of	O
expression	O
of	O
P	O
-	O
gp	O
in	O
CRC	O
presents	O
an	O
adventitious	O
target	O
for	O
complementing	O
ceramide	B
-	O
based	O
therapies	O
,	O
a	O
strategy	O
that	O
could	O
hold	O
promise	O
for	O
treatment	O
of	O
resistant	O
disease	O
.	O

Involvement	O
of	O
Src	O
and	O
the	O
actin	O
cytoskeleton	O
in	O
the	O
antitumorigenic	O
action	O
of	O
adenosine	B
dialdehyde	I
.	O

Transmethylation	O
is	O
an	O
important	O
reaction	O
that	O
transfers	O
a	O
methyl	B
group	O
in	O
S	B
-	I
adenosylmethionine	I
(	O
SAM	B
)	O
to	O
substrates	O
such	O
as	O
DNA	O
,	O
RNA	O
,	O
and	O
proteins	O
.	O

It	O
is	O
known	O
that	O
transmethylation	O
plays	O
critical	O
roles	O
in	O
various	O
cellular	O
responses	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
effects	O
of	O
transmethylation	O
on	O
tumorigenic	O
responses	O
and	O
its	O
regulatory	O
mechanism	O
using	O
an	O
upregulation	O
strategy	O
of	O
adenosylhomocysteine	B
(	O
SAH	B
)	O
acting	O
as	O
a	O
negative	O
feedback	O
inhibitor	O
.	O

Treatment	O
with	O
adenosine	B
dialdehyde	I
(	O
AdOx	B
)	O
,	O
an	O
inhibitor	O
of	O
transmethylation	O
-	O
suppressive	O
adenosylhomocysteine	B
(	O
SAH	B
)	O
hydrolase	O
(	O
SAHH	O
)	O
,	O
enhanced	O
the	O
level	O
of	O
SAH	B
and	O
effectively	O
blocked	O
the	O
proliferation	O
,	O
migration	O
,	O
and	O
invasion	O
of	O
cancer	O
cells	O
;	O
the	O
treatment	O
also	O
induced	O
the	O
differentiation	O
of	O
C6	O
glioma	O
cells	O
and	O
suppressed	O
the	O
neovascular	O
genesis	O
of	O
eggs	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

Through	O
immunoblotting	O
analysis	O
,	O
it	O
was	O
found	O
that	O
AdOx	B
was	O
capable	O
of	O
indirectly	O
diminishing	O
the	O
phosphorylation	O
of	O
oncogenic	O
Src	O
and	O
its	O
kinase	O
activity	O
.	O

Interestingly	O
,	O
AdOx	B
disrupted	O
actin	O
cytoskeleton	O
structures	O
,	O
leading	O
to	O
morphological	O
changes	O
,	O
and	O
suppressed	O
the	O
formation	O
of	O
a	O
signaling	O
complex	O
composed	O
of	O
Src	O
and	O
p85	O
/	O
PI3	O
K	O
,	O
which	O
is	O
linked	O
to	O
various	O
tumorigenic	O
responses	O
.	O

In	O
agreement	O
with	O
these	O
data	O
,	O
the	O
exogenous	O
treatment	O
of	O
SAH	B
or	O
inhibition	O
of	O
SAHH	O
by	O
specific	O
siRNA	O
or	O
another	O
type	O
of	O
inhibitor	O
,	O
3-deazaadenosine	B
(	O
DAZA	B
)	O
,	O
similarly	O
resulted	O
in	O
antitumorigenic	O
responses	O
,	O
suppressive	O
activity	O
on	O
Src	O
,	O
the	O
alteration	O
of	O
actin	O
cytoskeleton	O
,	O
and	O
a	O
change	O
of	O
the	O
colocalization	O
pattern	O
between	O
actin	O
and	O
Src	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
SAH	B
/	O
SAHH	O
-	O
mediated	O
transmethylation	O
could	O
be	O
linked	O
to	O
the	O
tumorigenic	O
processes	O
through	O
cross	O
-	O
regulation	O
between	O
the	O
actin	O
cytoskeleton	O
and	O
Src	O
kinase	O
activity	O
.	O

Synthesis	O
of	O
derivatives	O
of	O
methyl	B
rosmarinate	I
and	O
their	O
inhibitory	O
activities	O
against	O
matrix	O
metalloproteinase-1	O
(	O
MMP-1	O
)	O
.	O

A	O
series	O
of	O
MMP-1	O
inhibitors	O
have	O
been	O
identified	O
based	O
upon	O
a	O
methyl	B
rosmarinate	I
scaffold	O
using	O
structure	O
-	O
based	O
drug	O
design	O
methods	O
.	O

The	O
best	O
compound	O
in	O
the	O
series	O
showed	O
an	O
IC50	O
value	O
of	O
0.4	O
M.	O
A	O
docking	O
study	O
was	O
conducted	O
for	O
compound	O
(	O
S	O
)	O
-10n	O
in	O
order	O
to	O
investigate	O
its	O
binding	O
interactions	O
with	O
MMP-1	O
.	O

The	O
structure	O
-	O
activity	O
relationships	O
(	O
SAR	O
)	O
were	O
also	O
briefly	O
discussed	O
.	O

Useful	O
SAR	O
was	O
established	O
which	O
provides	O
important	O
guidelines	O
for	O
the	O
design	O
of	O
future	O
generations	O
of	O
potent	O
inhibitors	O
against	O
MMP-1	O
.	O

Design	O
,	O
synthesis	O
and	O
anticancer	O
properties	O
of	O
5-arylbenzoxepins	B
as	O
conformationally	O
restricted	O
isocombretastatin	B
A-4	I
analogs	O
.	O

A	O
series	O
of	O
novel	O
benzoxepins	B
6	O
was	O
designed	O
and	O
prepared	O
as	O
rigid	O
-	O
isoCA-4	B
analogs	O
according	O
to	O
a	O
convergent	O
strategy	O
using	O
the	O
coupling	O
of	O
N	B
-	I
tosylhydrazones	I
with	O
aryl	B
iodides	I
under	O
palladium	B
catalysis	O
.	O

The	O
most	O
potent	O
compound	O
6b	O
,	O
having	O
the	O
greatest	O
resemblance	O
to	O
CA-4	B
and	O
isoCA-4	B
displayed	O
antiproliferative	O
activity	O
at	O
nanomolar	O
concentrations	O
against	O
various	O
cancer	O
cell	O
lines	O
and	O
inhibited	O
tubulin	O
assembly	O
at	O
a	O
micromolar	O
range	O
.	O

In	O
addition	O
,	O
benzoxepin	B
6b	O
led	O
to	O
the	O
arrest	O
of	O
HCT116	O
,	O
K562	O
,	O
H1299	O
and	O
MDA	O
-	O
MB231	O
cancer	O
cell	O
lines	O
in	O
the	O
G2	O
/	O
M	O
phase	O
of	O
the	O
cell	O
cycle	O
,	O
and	O
strongly	O
induced	O
apoptosis	O
at	O
low	O
concentrations	O
.	O

Docking	O
studies	O
demonstrated	O
that	O
benzoxepin	B
6b	O
adopt	O
an	O
orientation	O
similar	O
to	O
that	O
of	O
isoCA-4	B
at	O
the	O
colchicine	O
binding	O
site	O
on	O
	O
-	O
tubulin	O
.	O

Cytotoxicity	O
of	O
lapachol	B
,	O
	B
-	I
lapachone	I
and	O
related	O
synthetic	O
1,4-naphthoquinones	B
against	O
oesophageal	O
cancer	O
cells	O
.	O

Naphthoquinones	B
have	O
been	O
found	O
to	O
have	O
a	O
wide	O
range	O
of	O
biological	O
activities	O
,	O
including	O
cytotoxicity	O
to	O
cancer	O
cells	O
.	O

The	O
secondary	O
metabolites	O
lapachol	O
,	O
-	B
and	I
	I
-	I
lapachone	I
and	O
a	O
series	O
of	O
25	O
related	O
synthetic	O
1,4-naphthoquinones	B
were	O
screened	O
against	O
the	O
oesophageal	O
cancer	O
cell	O
line	O
(	O
WHCO1	O
)	O
.	O

Most	O
of	O
the	O
compounds	O
exhibited	O
enhanced	O
cytotoxicity	O
(	O
IC50	O
1.6	O
-	O
11.7	O
M	O
)	O
compared	O
to	O
the	O
current	O
drug	O
of	O
choice	O
cisplatin	B
(	O
IC50	O
=	O
16.5	O
M	O
)	O
.	O

This	O
study	O
also	O
established	O
that	O
the	O
two	O
new	O
synthetic	O
halogenated	O
compounds	O
12a	O
and	O
16a	O
(	O
IC50	O
=	O
3.0	O
and	O
7.3	O
M	O
)	O
and	O
the	O
previously	O
reported	O
compound	O
11a	O
(	O
IC50	O
=	O
3.9	O
M	O
)	O
,	O
were	O
non	O
-	O
toxic	O
to	O
NIH3T3	O
normal	O
fibroblast	O
cells	O
.	O

Cell	O
death	O
of	O
oesophageal	O
cancer	O
cells	O
by	O
processes	O
involving	O
PARP	O
cleavage	O
caused	O
by	O
11a	O
was	O
shown	O
to	O
be	O
associated	O
with	O
elevated	O
c	O
-	O
Jun	O
levels	O
,	O
suggesting	O
a	O
role	O
for	O
this	O
pathway	O
in	O
the	O
mechanism	O
of	O
action	O
of	O
this	O
cohort	O
of	O
naphthoquinone	B
compounds	O
.	O

Synthesis	O
of	O
an	O
MIF-1	B
analogue	O
containing	O
enantiopure	O
(	B
S	I
)	I
-	I
-	I
trifluoromethyl	I
-	I
proline	I
and	O
biological	O
evaluation	O
on	O
nociception	O
.	O

The	O
synthesis	O
and	O
the	O
effect	O
of	O
a	O
novel	O
MIF-1	B
analogue	O
on	O
nociception	O
during	O
acute	O
pain	O
in	O
rat	O
model	O
are	O
reported	O
.	O

The	O
synthesis	O
of	O
this	O
enantiopure	O
trifluoromethyl	B
group	O
containing	O
tripeptide	B
was	O
performed	O
through	O
a	O
peptide	O
coupling	O
reaction	O
between	O
the	O
HCl	B
.	I

Leu	B
-	I
Gly	I
-	I
NH2	I
and	O
the	O
(	B
S	I
)	I
-	I
-	I
Tfm	I
-	I
proline	I
.	O

The	O
analgesic	O
effect	O
of	O
the	O
CF3-	B
(	I
MIF-1	I
)	I
2	O
has	O
been	O
evaluated	O
in	O
vivo	O
on	O
rat	O
model	O
by	O
paw	O
pressure	O
(	O
PP	O
)	O
and	O
hot	O
plate	O
(	O
HP	O
)	O
tests	O
and	O
compared	O
to	O
the	O
native	O
peptide	O
MIF-1	B
.	O

Highest	O
analgesic	O
effect	O
was	O
observed	O
with	O
CF3-	B
(	I
MIF-1	I
)	I
2	O
only	O
in	O
PP	O
test	O
.	O

In	O
order	O
to	O
study	O
the	O
mechanisms	O
of	O
nociception	O
induced	O
by	O
the	O
studied	O
peptides	O
,	O
the	O
involvement	O
of	O
the	O
opioid	O
and	O
the	O
nitric	B
oxideergic	O
systems	O
was	O
investigated	O
.	O

The	O
results	O
are	O
in	O
favor	O
of	O
a	O
participation	O
of	O
both	O
system	O
since	O
pretreatment	O
,	O
20	O
min	O
before	O
injection	O
of	O
the	O
CF3-	B
(	I
MIF-1	I
)	I
2	O
,	O
with	O
the	O
non	O
-	O
competitive	O
antagonist	O
of	O
opiate	O
receptors	O
naloxone	B
,	O
the	O
nitric	B
oxide	I
synthase	O
(	O
NOS	O
)	O
inhibitor	O
l	B
-	I
N	I
(	I
G	I
)	I
-nitroarginine	I
ester	I
(	O
l	B
-	I
NAME	I
)	O
or	O
the	O
nitric	B
oxide	I
(	O
NO	B
)	O
donor	O
l	B
-	I
arginine	I
(	O
l	B
-	I
Arg	I
)	O
significantly	O
decreased	O
the	O
pain	O
perception	O
in	O
PP	O
and	O
HP	O
tests	O
.	O

Synthesis	O
,	O
characterization	O
,	O
cytotoxicity	O
and	O
antimicrobial	O
studies	O
on	O
bis	B
(	I
N	I
-	I
furfuryl	I
-	I
N-	I
(	I
2-phenylethyl	I
)	I
dithiocarbamato	I
-	I
S	I
,	I
S'	I
)	I
zinc	I
(	I
II	I
)	I
and	O
its	O
nitrogen	B
donor	O
adducts	O
.	O

[	O
Zn	B
(	I
fpedtc	I
)	I
2	I
]	O
(	O
1	O
)	O
,	O
[	O
Zn	B
(	I
fpedtc	I
)	I
2	I
(	I
py	I
)	I
]	O
(	O
2	O
)	O
,	O
[	O
Zn	B
(	I
fpedtc	I
)	I
2	I
(	I
1,10-phen	I
)	I
]	O
(	O
3	O
)	O
and	O
[	O
Zn	B
(	I
fpedtc	I
)	I
2	I
(	I
2,2'-bipy	I
)	I
]	O
(	O
4	O
)	O
(	O
where	O
fpedtc	B
=	O
N	B
-	I
furfuryl	I
-	I
N-	I
(	I
2-phenylethyl	I
)	I
dithiocarbamate	I
,	O
py	O
=	O
pyridine	B
,	O
1,10-phen	B
=	O
1,10-phenanthroline	B
and	O
2,2'-bipy	B
=	O
2,2'-bipyridine	B
)	O
were	O
synthesized	O
.	O

Characterization	O
of	O
the	O
complexes	O
were	O
achieved	O
by	O
IR	O
and	O
NMR	O
(	O
(	B
1	I
)	I
H	I
and	O
(	B
13	I
)	I
C	I
)	O
spectra	O
and	O
in	O
addition	O
,	O
for	O
2	O
and	O
3	O
,	O
by	O
X	O
-	O
ray	O
crystallography	O
.	O

Single	O
crystal	O
X	O
-	O
ray	O
structural	O
analysis	O
of	O
2	O
and	O
3	O
showed	O
that	O
complex	O
2	O
is	O
almost	O
half	O
way	O
between	O
trigonal	O
bipyramidal	O
and	O
square	O
pyramidal	O
and	O
complex	O
3	O
has	O
a	O
distorted	O
octahedral	O
geometry	O
.	O

Zn	B
-	B
N	O
distances	O
in	O
2	O
is	O
shorter	O
than	O
that	O
found	O
in	O
a	O
six	O
coordinate	O
complex	O
3	O
due	O
to	O
the	O
change	O
in	O
coordination	O
number	O
.	O

These	O
complexes	O
were	O
also	O
screened	O
for	O
in	O
vitro	O
antibacterial	O
and	O
antifungal	O
activities	O
and	O
significant	O
activities	O
have	O
been	O
found	O
.	O

In	O
vitro	O
cytotoxic	O
activity	O
of	O
all	O
the	O
synthesized	O
complexes	O
was	O
evaluated	O
on	O
HeLa	O
cell	O
line	O
.	O

Complex	O
1	O
exhibits	O
maximum	O
inhibitory	O
effect	O
at	O
a	O
concentration	O
of	O
40	O
g	O
mL	O
(	O
-1	O
)	O
on	O
HeLa	O
cell	O
line	O
.	O

Novel	O
agmatine	B
dipeptide	I
inhibitors	O
against	O
the	O
West	O
Nile	O
virus	O
NS2B	O
/	O
NS3	O
protease	O
:	O
A	O
P3	O
and	O
N	O
-	O
cap	O
optimization	O
study	O
.	O

This	O
communication	O
describes	O
the	O
synthesis	O
and	O
inhibitory	O
activities	O
of	O
thirty	O
-	O
seven	O
novel	O
C	O
-	O
terminal	O
agmatine	B
dipeptides	I
used	O
as	O
screening	O
compounds	O
to	O
study	O
the	O
structure	O
-	O
activity	O
relationship	O
between	O
active	O
-	O
site	O
peptidomimetics	O
and	O
the	O
West	O
Nile	O
virus	O
(	O
WNV	O
)	O
NS2B	O
/	O
NS3	O
serine	B
protease	O
.	O

Our	O
efforts	O
lead	O
to	O
the	O
discovery	O
of	O
a	O
novel	O
agmatine	B
dipeptide	I
inhibitor	O
(	O
compound	O
33	O
,	O
IC50	O
2.6	O
	O
0.3	O
M	O
)	O
with	O
improved	O
inhibitory	O
activity	O
in	O
comparison	O
to	O
the	O
most	O
potent	O
inhibitor	O
described	O
in	O
our	O
recent	O
report	O
[	O
IC50	O
4.7	O
	O
1.2	O
M	O
;	O
Lim	O
et	O
al.	O
,	O
Eur	O
.	O

J.	O
Med	O
.	O

Chem	O
.	O

46	O
(	O
2011	O
)	O
3130	O
-	O
3134	O
]	O
.	O

In	O
addition	O
,	O
our	O
study	O
cleared	O
the	O
contention	O
surrounding	O
the	O
previous	O
X	O
-	O
ray	O
co	O
-	O
crystallization	O
study	O
and	O
an	O
enzyme	O
inhibition	O
report	O
on	O
the	O
binding	O
conformation	O
adopted	O
by	O
active	O
-	O
site	O
peptide	O
aldehydes	B
.	O

Our	O
data	O
should	O
provide	O
valuable	O
insights	O
into	O
the	O
design	O
of	O
future	O
peptidomimetic	O
antivirals	O
against	O
WNV	O
infections	O
.	O

Synthesis	O
,	O
pharmacological	O
evaluation	O
and	O
QSAR	O
modeling	O
of	O
mono	O
-	O
substituted	O
4-phenylpiperidines	B
and	O
4-phenylpiperazines	B
.	O

A	O
series	O
of	O
mono	B
-	I
substituted	I
4-phenylpiperidines	I
and	I
-piperazines	I
have	O
been	O
synthesized	O
and	O
their	O
effects	O
on	O
the	O
dopaminergic	O
system	O
tested	O
in	O
vivo	O
.	O

The	O
structure	O
activity	O
relationship	O
(	O
SAR	O
)	O
revealed	O
that	O
the	O
position	O
and	O
physicochemical	O
character	O
of	O
the	O
aromatic	O
substituent	O
proved	O
to	O
be	O
critical	O
for	O
the	O
levels	O
of	O
3,4-dihydroxyphenylacetic	B
acid	I
(	O
DOPAC	B
)	O
in	O
the	O
brain	O
of	O
freely	O
moving	O
rats	O
.	O

In	O
order	O
to	O
investigate	O
how	O
the	O
structural	O
properties	O
of	O
these	O
compounds	O
affect	O
the	O
response	O
,	O
a	O
set	O
of	O
tabulated	O
and	O
calculated	O
physicochemical	O
descriptors	O
were	O
modeled	O
against	O
the	O
in	O
vivo	O
effects	O
using	O
partial	O
least	O
square	O
(	O
PLS	O
)	O
regression	O
.	O

Furthermore	O
,	O
the	O
binding	O
affinities	O
to	O
the	O
dopamine	B
D2	O
(	O
DA	O
D2	O
)	O
receptor	O
and	O
monoamine	B
oxidase	O
A	O
(	O
MAO	O
A	O
)	O
enzyme	O
were	O
determined	O
for	O
a	O
chosen	O
subset	O
and	O
QSAR	O
models	O
using	O
the	O
same	O
descriptors	O
as	O
in	O
the	O
in	O
vivo	O
model	O
were	O
produced	O
to	O
investigate	O
the	O
mechanisms	O
leading	O
to	O
the	O
observed	O
DOPAC	B
response	O
.	O

These	O
models	O
,	O
in	O
combination	O
with	O
a	O
strong	O
correlation	O
between	O
the	O
levels	O
of	O
striatal	O
DOPAC	B
and	O
the	O
affinities	O
to	O
DA	O
D2	O
and	O
MAO	O
A	O
,	O
provides	O
a	O
comprehensive	O
understanding	O
of	O
the	O
biological	O
response	O
for	O
compounds	O
in	O
this	O
class	O
.	O

Population	O
pharmacokinetics	O
of	O
piperacillin	B
/	O
tazobactam	B
in	O
neonates	O
and	O
young	O
infants	O
.	O

OBJECTIVES	O
:	O
To	O
develop	O
population	O
pharmacokinetic	O
(	O
PK	O
)	O
models	O
for	O
piperacillin	B
/	O
tazobactam	B
in	O
neonates	O
and	O
infants	O
of	O
less	O
than	O
2	O
months	O
of	O
age	O
in	O
order	O
to	O
determine	O
the	O
appropriate	O
dosing	O
regimen	O
and	O
provide	O
a	O
rational	O
basis	O
for	O
the	O
development	O
of	O
preliminary	O
dosing	O
guidelines	O
suitable	O
for	O
this	O
population	O
.	O

METHODS	O
:	O
A	O
two	O
-	O
stage	O
,	O
open	O
-	O
label	O
study	O
was	O
conducted	O
in	O
neonates	O
and	O
infants	O
less	O
than	O
2	O
months	O
of	O
age	O
in	O
the	O
neonatal	O
intensive	O
care	O
unit	O
(	O
NICU	O
)	O
.	O

A	O
total	O
of	O
207	O
piperacillin	B
and	O
204	O
tazobactam	B
concentration	O
-	O
time	O
data	O
sets	O
from	O
71	O
patients	O
were	O
analyzed	O
using	O
a	O
nonlinear	O
mixed	O
-	O
effect	O
modeling	O
approach	O
(	O
NONMEM	O
VII	O
)	O
.	O

PK	O
models	O
were	O
developed	O
for	O
piperacillin	B
and	O
tazobactam	B
.	O

The	O
final	O
models	O
were	O
evaluated	O
using	O
both	O
bootstrap	O
and	O
visual	O
predictive	O
checks	O
.	O

External	O
model	O
evaluations	O
were	O
made	O
in	O
20	O
additional	O
patients	O
.	O

RESULTS	O
:	O
For	O
neonates	O
and	O
young	O
infants	O
less	O
than	O
2	O
months	O
of	O
age	O
,	O
the	O
median	O
central	O
clearance	O
was	O
0.133	O
and	O
0.149	O
L	O
/	O
h	O
/	O
kg	O
for	O
piperacillin	B
and	O
tazobactam	B
,	O
respectively	O
.	O

Postmenstrual	O
age	O
(	O
PMA	O
)	O
was	O
identified	O
as	O
the	O
most	O
significant	O
covariate	O
on	O
central	O
clearance	O
of	O
piperacillin	B
and	O
tazobactam	B
.	O

However	O
,	O
the	O
combination	O
of	O
current	O
bodyweight	O
(	O
BW	O
)	O
and	O
postnatal	O
age	O
proved	O
to	O
be	O
superior	O
to	O
PMA	O
alone	O
.	O

BW	O
was	O
the	O
most	O
important	O
covariate	O
for	O
apparent	O
central	O
volume	O
of	O
distribution	O
.	O

Both	O
internal	O
and	O
external	O
evaluations	O
supported	O
the	O
prediction	O
of	O
the	O
final	O
piperacillin	B
and	O
tazobactam	B
PK	O
models	O
.	O

The	O
dosing	O
strategy	O
44.44	O
/	O
5.56	O
mg	O
/	O
kg	O
/	O
dose	O
piperacillin	B
/	O
tazobactam	B
every	O
8	O
or	O
12	O
h	O
evaluated	O
in	O
this	O
study	O
achieved	O
the	O
pharmacodynamic	O
target	O
(	O
free	O
piperacillin	B
concentrations	O
>	O
4	O
mg	O
/	O
L	O
for	O
more	O
than	O
50	O
%	O
of	O
the	O
dosing	O
interval	O
)	O
in	O
about	O
67	O
%	O
of	O
infants	O
.	O

CONCLUSIONS	O
:	O
Population	O
PK	O
models	O
accurately	O
described	O
the	O
PK	O
profiles	O
of	O
piperacillin	B
/	O
tazobactam	B
in	O
infants	O
less	O
than	O
2	O
months	O
of	O
age	O
.	O

The	O
results	O
indicated	O
that	O
higher	O
doses	O
or	O
more	O
frequent	O
dosing	O
regimens	O
may	O
be	O
required	O
for	O
controlling	O
infection	O
in	O
this	O
population	O
in	O
NICU	O
.	O

Structural	O
Basis	O
of	O
Signaling	O
Blockade	O
by	O
Anti	O
-	O
IL-13	O
Antibody	O
Lebrikizumab	O
.	O

The	O
cytokine	O
interleukin	O
13	O
(	O
IL-13	O
)	O
is	O
a	O
major	O
effector	O
molecule	O
for	O
T	O
-	O
helper	O
type	O
2	O
inflammation	O
and	O
is	O
pathogenic	O
in	O
allergic	O
diseases	O
such	O
as	O
asthma	O
.	O

The	O
effects	O
of	O
IL-13	O
are	O
mediated	O
via	O
a	O
pathway	O
that	O
is	O
initiated	O
by	O
binding	O
to	O
a	O
heterodimeric	O
receptor	O
consisting	O
of	O
IL-13R1	O
and	O
IL-4R	O
.	O

Antibodies	O
raised	O
against	O
IL-13	O
can	O
block	O
its	O
inflammatory	O
effects	O
by	O
interfering	O
with	O
binding	O
to	O
either	O
of	O
the	O
two	O
receptor	O
polypeptides	O
.	O

Lebrikizumab	O
is	O
a	O
monoclonal	O
anti	O
-	O
IL-13	O
antibody	O
that	O
has	O
shown	O
clinical	O
benefit	O
in	O
a	O
phase	O
II	O
study	O
for	O
the	O
treatment	O
of	O
moderate	O
-	O
to	O
-	O
severe	O
uncontrolled	O
asthma	O
.	O

Here	O
we	O
report	O
the	O
molecular	O
structure	O
of	O
IL-13	O
in	O
complex	O
with	O
the	O
Fab	O
from	O
lebrikizumab	O
by	O
X	O
-	O
ray	O
crystallography	O
at	O
1.9	O
resolution	O
.	O

We	O
show	O
that	O
lebrikizumab	O
inhibits	O
IL-13	O
signaling	O
by	O
binding	O
to	O
IL-13	O
with	O
very	O
high	O
affinity	O
and	O
blocking	O
IL-13	O
binding	O
to	O
IL-4R	O
.	O

In	O
addition	O
,	O
we	O
use	O
site	O
-	O
directed	O
mutations	O
to	O
identify	O
the	O
most	O
important	O
antibody	O
contributors	O
to	O
binding	O
.	O

Our	O
studies	O
define	O
key	O
features	O
of	O
lebrikizumab	O
binding	O
and	O
its	O
mechanism	O
of	O
action	O
that	O
may	O
contribute	O
to	O
its	O
clinical	O
effects	O
.	O

Constitutively	O
active	O
group	O
I	O
mGlu	O
receptors	O
and	O
PKMzeta	O
regulate	O
synaptic	O
transmission	O
in	O
developing	O
perirhinal	O
cortex	O
.	O

Synaptic	O
transmission	O
is	O
essential	O
for	O
early	O
development	O
of	O
the	O
central	O
nervous	O
system	O
.	O

However	O
,	O
the	O
mechanisms	O
that	O
regulate	O
early	O
synaptic	O
transmission	O
in	O
the	O
cerebral	O
cortex	O
are	O
unclear	O
.	O

PKM	O
is	O
a	O
kinase	O
essential	O
for	O
the	O
maintenance	O
of	O
LTP	O
.	O

We	O
show	O
for	O
the	O
first	O
time	O
that	O
inhibition	O
of	O
PKM	O
produces	O
a	O
profound	O
depression	O
of	O
basal	O
synaptic	O
transmission	O
in	O
neonatal	O
,	O
but	O
not	O
adult	O
,	O
rat	O
perirhinal	O
cortex	O
.	O

This	O
suggests	O
that	O
synapses	O
in	O
early	O
development	O
are	O
in	O
a	O
constitutive	O
LTP	O
-	O
like	O
state	O
.	O

Furthermore	O
,	O
basal	O
synaptic	O
transmission	O
in	O
immature	O
,	O
but	O
not	O
mature	O
,	O
perirhinal	O
cortex	O
relies	O
on	O
persistent	O
activity	O
of	O
metabotropic	O
glutamate	B
(	O
mGlu	O
)	O
receptor	O
,	O
PI3Kinase	O
and	O
mammalian	O
target	O
of	O
rapamycin	B
(	O
mTOR	O
)	O
.	O

Thus	O
early	O
in	O
development	O
,	O
cortical	O
synapses	O
exist	O
in	O
an	O
LTP	O
-	O
like	O
state	O
maintained	O
by	O
tonically	O
active	O
mGlu	O
receptor-	O
,	O
mTOR-	O
and	O
PKM-	O
dependent	O
cascades	O
.	O

These	O
results	O
provide	O
new	O
understanding	O
of	O
the	O
molecular	O
mechanisms	O
that	O
control	O
synapses	O
during	O
development	O
and	O
may	O
aid	O
our	O
understanding	O
of	O
developmental	O
disorders	O
such	O
as	O
autism	O
and	O
schizophrenia	O
.	O

This	O
article	O
is	O
part	O
of	O
a	O
Special	O
Issue	O
entitled	O
'	O
Metabotropic	O
Glutamate	B
Receptors	O
'	O
.	O

Synthesis	O
,	O
DNA	O
binding	O
and	O
antitumor	O
evaluation	O
of	O
styelsamine	B
and	O
cystodytin	B
analogues	O
.	O

A	O
series	O
of	O
N-14	O
sidechain	O
substituted	O
analogues	O
of	O
styelsamine	B
(	O
pyrido	B
[	I
4,3,2-mn	I
]	I
acridine	I
)	O
and	O
cystodytin	B
(	O
pyrido	B
[	I
4,3,2-mn	I
]	I
acridin-4-one	I
)	O
alkaloids	O
have	O
been	O
prepared	O
and	O
evaluated	O
for	O
their	O
DNA	O
binding	O
affinity	O
and	O
antiproliferative	O
activity	O
towards	O
a	O
panel	O
of	O
human	O
tumor	O
cell	O
lines	O
.	O

Overall	O
it	O
was	O
found	O
that	O
styelsamine	B
analogues	O
were	O
stronger	O
DNA	O
binders	O
,	O
with	O
the	O
natural	O
products	O
styelsamines	B
B	I
and	I
D	I
having	O
particularly	O
high	O
affinity	O
(	O
K	O
(	O
app	O
)	O
5.33	O
	O
10	O
(	O
6	O
)	O
and	O
3.64	O
	O
10	O
(	O
6	O
)	O
M	O
(	O
-1	O
)	O
,	O
respectively	O
)	O
.	O

In	O
comparison	O
,	O
the	O
cystodytin	B
iminoquinone	I
alkaloids	I
showed	O
lower	O
affinity	O
for	O
DNA	O
,	O
but	O
were	O
typically	O
just	O
as	O
active	O
as	O
styelsamine	B
analogues	O
at	O
inhibiting	O
proliferation	O
of	O
tumor	O
cells	O
in	O
vitro	O
.	O

Sub	O
-	O
panel	O
selectivity	O
towards	O
non	O
-	O
small	O
cell	O
lung	O
,	O
melanoma	O
and	O
renal	O
cancer	O
cell	O
lines	O
were	O
observed	O
for	O
a	O
number	O
of	O
the	O
analogues	O
.	O

Correlation	O
was	O
observed	O
between	O
whole	O
cell	O
activity	O
and	O
clogP	O
,	O
with	O
the	O
most	O
potent	O
antiproliferative	O
activity	O
being	O
observed	O
for	O
3-phenylpropanamide	B
analogues	O
37	O
and	O
41	O
(	O
NCI	O
panel	O
average	O
GI	O
(	O
50	O
)	O
0.4	O
M	O
and	O
0.32	O
M	O
,	O
respectively	O
)	O
with	O
clogP	O
~4.0	O
-	O
4.5	O
.	O

Anti	O
-	O
inflammatory	O
effects	O
of	O
a	O
special	O
carbohydrate	B
-	O
whey	O
protein	O
cake	O
after	O
exhaustive	O
cycling	O
in	O
humans	O
.	O

Intense	O
exercise	O
induces	O
increased	O
levels	O
of	O
pro	O
-	O
inflammatory	O
and	O
anti	O
-	O
inflammatory	O
cytokines	O
.	O

Thus	O
,	O
the	O
purpose	O
of	O
this	O
study	O
was	O
to	O
examine	O
the	O
effects	O
of	O
a	O
special	O
cake	O
(	O
consisting	O
of	O
carbohydrate	B
to	O
whey	O
protein	O
3.5:1	O
)	O
vs.	O
an	O
isocaloric	O
carbohydrate	B
cake	O
on	O
inflammatory	O
markers	O
after	O
exhaustive	O
cycling	O
in	O
humans	O
.	O

Nine	O
subjects	O
received	O
either	O
the	O
experimental	O
or	O
placebo	O
cake	O
in	O
a	O
counterbalanced	O
fashion	O
using	O
a	O
crossover	O
,	O
double	O
-	O
blind	O
,	O
repeated	O
-	O
measures	O
design	O
.	O

They	O
performed	O
one	O
trial	O
involving	O
a	O
2h	O
exercise	O
on	O
a	O
cycle	O
ergometer	O
at	O
60	O
-	O
65	O
%	O
VO2max	O
followed	O
by	O
a	O
4h	O
recovery	O
and	O
then	O
a	O
second	O
trial	O
involving	O
an	O
1h	O
exercise	O
at	O
60	O
-	O
65	O
%	O
VO2max	O
which	O
was	O
increased	O
at	O
95	O
%	O
VO2max	O
.	O

Blood	O
samples	O
were	O
collected	O
pre	O
-	O
exercise	O
,	O
30min	O
and	O
4h	O
post	O
-	O
exercise	O
,	O
post	O
-	O
time	O
Trial	O
and	O
48h	O
post	O
-	O
time	O
Trial	O
.	O

Cakes	O
were	O
consumed	O
immediately	O
post	O
-	O
exercise	O
and	O
every	O
1h	O
for	O
the	O
next	O
3h	O
.	O

The	O
results	O
showed	O
that	O
consumption	O
of	O
the	O
experimental	O
cake	O
reduced	O
significantly	O
(	O
p<0.05	O
)	O
,	O
4h	O
post	O
-	O
exercise	O
,	O
the	O
pro	O
-	O
inflammatory	O
protein	O
levels	O
IL-6	O
and	O
CRP	O
compared	O
to	O
the	O
control	O
group	O
by	O
50	O
%	O
and	O
46	O
%	O
respectively	O
.	O

Moreover	O
,	O
in	O
the	O
experimental	O
cake	O
group	O
,	O
the	O
level	O
of	O
the	O
anti	O
-	O
inflammatory	O
cytokine	O
IL-10	O
was	O
higher	O
by	O
118	O
%	O
,	O
4h	O
post	O
-	O
exercise	O
,	O
compared	O
to	O
the	O
control	O
group	O
but	O
not	O
statistically	O
significant	O
.	O

Self	O
-	O
assembly	O
of	O
mesoporous	O
CuO	B
nanosheets	O
-	O
CNT	O
3D	O
-	O
network	O
composites	O
for	O
lithium	B
-	O
ion	O
batteries	O
.	O

A	O
facile	O
,	O
flexible	O
and	O
large	O
-	O
scale	O
technique	O
was	O
proposed	O
to	O
prepare	O
a	O
CuO	B
-	O
CNT	O
3D	O
-	O
network	O
composite	O
with	O
the	O
aid	O
of	O
electrostatic	O
interactions	O
in	O
aqueous	O
solution	O
.	O

The	O
composite	O
greatly	O
improves	O
the	O
electrochemical	O
performance	O
.	O

At	O
a	O
rate	O
of	O
0.1	O
C	O
,	O
the	O
cycling	O
discharge	O
capacity	O
of	O
the	O
optimal	O
composite	O
is	O
more	O
than	O
2.3	O
times	O
of	O
that	O
of	O
unmodified	O
mesoporous	O
CuO	B
nanosheets	O
as	O
the	O
active	O
material	O
in	O
an	O
anode	O
after	O
40	O
cycles	O
.	O

Adsorbed	O
and	O
near	O
surface	O
structure	O
of	O
ionic	O
liquids	O
at	O
a	O
solid	O
interface	O
.	O

The	O
structure	O
of	O
solid	O
-	O
ionic	O
liquid	O
(	O
IL	O
)	O
interfaces	O
has	O
been	O
characterised	O
with	O
unprecedented	O
clarity	O
by	O
employing	O
a	O
range	O
of	O
atomic	O
force	O
microscopy	O
(	O
AFM	O
)	O
imaging	O
techniques	O
and	O
tip	O
pressures	O
appropriate	O
for	O
the	O
system	O
under	O
study	O
.	O

Soft	O
contact	O
and	O
amplitude	O
-	O
modulation	O
(	O
AM	O
)	O
AFM	O
imaging	O
have	O
been	O
used	O
to	O
elucidate	O
the	O
lateral	O
structure	O
of	O
ILs	O
adsorbed	O
onto	O
mica	O
,	O
and	O
in	O
the	O
near	O
surface	O
ion	O
layers	O
.	O

Data	O
is	O
presented	O
for	O
ethylammonium	B
nitrate	I
(	O
EAN	B
)	O
and	O
1-ethyl-3-methylimidazolium	B
bis	I
(	I
trifluoro	I
-	I
methylsulfonyl	I
)	I
imide	I
(	O
EMIm	B
TFSI	I
)	O
.	O

Whereas	O
EAN	B
is	O
a	O
protic	O
IL	O
that	O
forms	O
a	O
nanostructured	O
sponge	O
phase	O
in	O
the	O
bulk	O
,	O
EMIm	B
TFSI	I
is	O
aprotic	O
and	O
has	O
weak	O
(	O
or	O
absent	O
)	O
bulk	O
association	O
structure	O
.	O

Comparison	O
of	O
results	O
obtained	O
for	O
the	O
two	O
liquids	O
elucidates	O
how	O
the	O
strength	O
of	O
bulk	O
liquid	O
morphology	O
effects	O
lateral	O
organisation	O
at	O
the	O
surface	O
,	O
and	O
any	O
effect	O
of	O
IL	O
class	O
,	O
i.e.	O
protic	O
versus	O
aprotic	O
.	O

Imaging	O
reveals	O
EAN	B
self	O
assembles	O
at	O
the	O
solid	O
surface	O
in	O
a	O
worm	O
-	O
like	O
morphology	O
,	O
whereas	O
EMIm	B
cations	O
adsorb	O
in	O
a	O
more	O
isolated	O
fashion	O
,	O
but	O
still	O
in	O
rows	O
templated	O
by	O
the	O
mica	O
surface	O
.	O

To	O
the	O
authors	O
'	O
knowledge	O
,	O
the	O
wormlike	O
structures	O
present	O
at	O
the	O
EAN	B
-	O
mica	O
interface	O
are	O
the	O
smallest	O
self	O
-	O
assembled	O
aggregates	O
ever	O
imaged	O
on	O
a	O
solid	O
surface	O
.	O

Review	O
of	O
clinical	O
trials	O
for	O
mitochondrial	O
disorders	O
:	O
1997	O
-	O
2012	O
.	O

Over	O
the	O
last	O
15	O
years	O
,	O
some	O
16	O
open	O
and	O
controlled	O
clinical	O
trials	O
for	O
potential	O
treatments	O
of	O
mitochondrial	O
diseases	O
have	O
been	O
reported	O
or	O
are	O
in	O
progress	O
,	O
and	O
are	O
summarized	O
and	O
reviewed	O
herein	O
.	O

These	O
include	O
trials	O
of	O
administering	O
dichloroacetate	B
(	O
an	O
activator	O
of	O
pyruvate	B
dehydrogenase	O
complex	O
)	O
,	O
arginine	B
or	O
citrulline	B
(	O
precursors	O
of	O
nitric	B
oxide	I
)	O
,	O
coenzyme	B
Q10	I
(	O
CoQ10	B
;	O
part	O
of	O
the	O
electron	O
transport	O
chain	O
and	O
an	O
antioxidant	O
)	O
,	O
idebenone	B
(	O
a	O
synthetic	O
analogue	O
of	O
CoQ10	B
)	O
,	O
EPI-743	B
(	O
a	O
novel	O
oral	O
potent	O
2-electron	O
redox	O
cycling	O
agent	O
)	O
,	O
creatine	B
(	O
a	O
precursor	O
of	O
phosphocreatine	B
)	O
,	O
combined	O
administration	O
(	O
of	O
creatine	B
,	O
	B
-	I
lipoate	I
,	O
and	O
CoQ10	B
)	O
,	O
and	O
exercise	O
training	O
(	O
to	O
increase	O
muscle	O
mitochondria	O
)	O
.	O

These	O
trials	O
have	O
included	O
patients	O
with	O
various	O
mitochondrial	O
disorders	O
,	O
a	O
selected	O
subcategory	O
of	O
mitochondrial	O
disorders	O
,	O
or	O
specific	O
mitochondrial	O
disorders	O
(	O
Leber	O
hereditary	O
optic	O
neuropathy	O
or	O
mitochondrial	O
encephalopathy	O
,	O
lactic	O
acidosis	O
,	O
and	O
stroke	O
-	O
like	O
episodes	O
)	O
.	O

The	O
trial	O
designs	O
have	O
varied	O
from	O
open	O
-	O
label	O
/	O
uncontrolled	O
,	O
open	O
-	O
label	O
/	O
controlled	O
,	O
or	O
double	O
-	O
blind	O
/	O
placebo	O
-	O
controlled	O
/	O
crossover	O
.	O

Primary	O
outcomes	O
have	O
ranged	O
from	O
single	O
,	O
clinically	O
-	O
relevant	O
scores	O
to	O
multiple	O
measures	O
.	O

Eight	O
of	O
these	O
trials	O
have	O
been	O
well	O
-	O
controlled	O
,	O
completed	O
trials	O
.	O

Of	O
these	O
only	O
1	O
(	O
treatment	O
with	O
creatine	O
)	O
showed	O
a	O
significant	O
change	O
in	O
primary	O
outcomes	O
,	O
but	O
this	O
was	O
not	O
reproduced	O
in	O
2	O
subsequent	O
trials	O
with	O
creatine	B
with	O
different	O
patients	O
.	O

One	O
trial	O
(	O
idebenone	B
treatment	O
of	O
Leber	O
hereditary	O
optic	O
neuropathy	O
)	O
did	O
not	O
show	O
significant	O
improvement	O
in	O
the	O
primary	O
outcome	O
,	O
but	O
there	O
was	O
significant	O
improvement	O
in	O
a	O
subgroup	O
of	O
patients	O
.	O

Despite	O
the	O
paucity	O
of	O
benefits	O
found	O
so	O
far	O
,	O
well	O
-	O
controlled	O
clinical	O
trials	O
are	O
essential	O
building	O
blocks	O
in	O
the	O
continuing	O
search	O
for	O
more	O
effective	O
treatment	O
of	O
mitochondrial	O
disease	O
,	O
and	O
current	O
trials	O
based	O
on	O
information	O
gained	O
from	O
these	O
prior	O
experiences	O
are	O
in	O
progress	O
.	O

Because	O
of	O
difficulties	O
in	O
recruiting	O
sufficient	O
mitochondrial	O
disease	O
patients	O
and	O
the	O
relatively	O
large	O
expense	O
of	O
conducting	O
such	O
trials	O
,	O
advantageous	O
strategies	O
include	O
crossover	O
designs	O
(	O
where	O
possible	O
)	O
,	O
multicenter	O
collaboration	O
,	O
and	O
the	O
selection	O
of	O
very	O
few	O
,	O
clinically	O
relevant	O
,	O
primary	O
outcomes	O
.	O

Antenatal	O
manifestations	O
of	O
mitochondrial	O
disorders	O
.	O

Mitochondrial	O
respiratory	O
chain	O
diseases	O
are	O
a	O
heterogeneous	O
group	O
of	O
pathologies	O
caused	O
by	O
genetic	O
alterations	O
affecting	O
mitochondrial	O
energy	O
production	O
.	O

Theoretically	O
,	O
this	O
deficiency	O
may	O
lead	O
to	O
any	O
symptoms	O
,	O
in	O
any	O
organ	O
or	O
tissue	O
,	O
at	O
any	O
age	O
even	O
before	O
birth	O
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
identify	O
the	O
frequency	O
and	O
characterize	O
antenatal	O
manifestations	O
identifying	O
possible	O
associations	O
between	O
mitochondrial	O
disease	O
and	O
more	O
specific	O
and	O
earlier	O
manifestation	O
.	O

We	O
retrospectively	O
review	O
the	O
files	O
of	O
44	O
paediatric	O
subjects	O
with	O
genetic	O
and	O
biochemical	O
alterations	O
of	O
respiratory	O
chain	O
identified	O
in	O
the	O
first	O
decade	O
of	O
life	O
and	O
compare	O
data	O
with	O
a	O
control	O
group	O
(	O
n	O
=	O
88	O
)	O
.	O

Our	O
results	O
show	O
that	O
maternal	O
age	O
was	O
similar	O
in	O
both	O
groups	O
.	O

The	O
female	O
gender	O
was	O
predominant	O
in	O
patients	O
group	O
.	O

Gestational	O
age	O
at	O
delivery	O
was	O
similar	O
in	O
both	O
groups	O
.	O

Concerning	O
birth	O
weight	O
,	O
it	O
was	O
significantly	O
lower	O
(	O
p	O
=	O
0.001	O
)	O
in	O
patients	O
(	O
2899.9	O
	O
538.3	O
vs.	O
3246.6	O
	O
460.2	O
g	O
)	O
.	O

Fifteen	O
pregnancies	O
of	O
the	O
patients	O
group	O
were	O
considered	O
abnormal	O
.	O

Our	O
findings	O
show	O
that	O
intrauterine	O
growth	O
restriction	O
was	O
the	O
most	O
frequent	O
antenatal	O
feature	O
observed	O
.	O

Neonatal	O
morbidity	O
was	O
significantly	O
higher	O
(	O
fivefold	O
)	O
in	O
patients	O
(	O
p	O
<	O
0.001	O
)	O
.	O

The	O
clinical	O
findings	O
are	O
independent	O
of	O
the	O
molecular	O
defect	O
type	O
.	O

Our	O
results	O
are	O
preliminary	O
and	O
more	O
studies	O
are	O
needed	O
,	O
in	O
order	O
to	O
learn	O
more	O
about	O
mitochondrial	O
physiology	O
and	O
activity	O
in	O
embryological	O
development	O
for	O
the	O
assessment	O
of	O
mitochondrial	O
disease	O
progress	O
in	O
fetal	O
life	O
.	O

However	O
,	O
the	O
present	O
work	O
is	O
a	O
significant	O
contribution	O
,	O
given	O
the	O
scarcity	O
of	O
information	O
in	O
this	O
field	O
.	O

Left	O
ventricular	O
noncompaction	O
(	O
LVNC	O
)	O
and	O
low	O
mitochondrial	O
membrane	O
potential	O
are	O
specific	O
for	O
Barth	O
syndrome	O
.	O

Barth	O
syndrome	O
(	O
BTHS	O
)	O
is	O
an	O
X	O
-	O
linked	O
mitochondrial	O
defect	O
characterised	O
by	O
dilated	O
cardiomyopathy	O
,	O
neutropaenia	O
and	O
3-methylglutaconic	O
aciduria	O
(	O
3-MGCA	O
)	O
.	O

We	O
report	O
on	O
two	O
affected	O
brothers	O
with	O
c.646	O
G	O
>	O
A	O
(	O
p.	O

G216R	O
)	O
TAZ	O
gene	O
mutations	O
.	O

The	O
pathogenicity	O
of	O
the	O
mutation	O
,	O
as	O
indicated	O
by	O
the	O
structure	O
-	O
based	O
functional	O
analyses	O
,	O
was	O
further	O
confirmed	O
by	O
abnormal	O
monolysocardiolipin	B
/	O
cardiolipin	B
ratio	O
in	O
dry	O
blood	O
spots	O
of	O
the	O
patients	O
as	O
well	O
as	O
the	O
occurrence	O
of	O
this	O
mutation	O
in	O
another	O
reported	O
BTHS	O
proband	O
.	O

In	O
both	O
brothers	O
,	O
2D	O
-	O
echocardiography	O
revealed	O
some	O
features	O
of	O
left	O
ventricular	O
noncompaction	O
(	O
LVNC	O
)	O
despite	O
marked	O
differences	O
in	O
the	O
course	O
of	O
the	O
disease	O
;	O
the	O
eldest	O
child	O
presented	O
with	O
isolated	O
cardiomyopathy	O
from	O
late	O
infancy	O
,	O
whereas	O
the	O
youngest	O
showed	O
severe	O
lactic	O
acidosis	O
without	O
3-MGCA	O
during	O
the	O
neonatal	O
period	O
.	O

An	O
examination	O
of	O
the	O
patients	O
'	O
fibroblast	O
cultures	O
revealed	O
that	O
extremely	O
low	O
mitochondrial	O
membrane	O
potentials	O
(	O
mt	O
about	O
50	O
%	O
of	O
the	O
control	O
value	O
)	O
dominated	O
other	O
unspecific	O
mitochondrial	O
changes	O
detected	O
(	O
respiratory	O
chain	O
dysfunction	O
,	O
abnormal	O
ROS	O
production	O
and	O
depressed	O
antioxidant	O
defense	O
)	O
.	O

1	O
)	O
Our	O
studies	O
confirm	O
generalised	O
mitochondrial	O
dysfunction	O
in	O
the	O
skeletal	O
muscle	O
and	O
the	O
fibroblasts	O
of	O
BTHS	O
patients	O
,	O
especially	O
a	O
severe	O
impairment	O
in	O
the	O
mt	O
and	O
the	O
inhibition	O
of	O
complex	O
V	O
activity	O
.	O

It	O
can	O
be	O
hypothesised	O
that	O
impaired	O
mt	O
and	O
mitochondrial	O
ATP	B
synthase	O
activity	O
may	O
contribute	O
to	O
episodes	O
of	O
cardiac	O
arrhythmia	O
that	O
occurred	O
unexpectedly	O
in	O
BTHS	O
patients	O
.	O

2	O
)	O
Severe	O
lactic	O
acidosis	O
without	O
3-methylglutaconic	O
aciduria	O
in	O
male	O
neonates	O
as	O
well	O
as	O
an	O
asymptomatic	O
mild	O
left	O
ventricular	O
noncompaction	O
may	O
characterise	O
the	O
ranges	O
of	O
natural	O
history	O
of	O
Barth	O
syndrome	O
.	O

Facile	O
solution	O
synthesis	O
of	O
Ag@Pt	B
core	O
-	O
shell	O
nanoparticles	O
with	O
dendritic	O
Pt	B
shells	O
.	O

Ag@Pt	B
nanoparticles	O
with	O
various	O
dendritic	O
Pt	B
shells	O
were	O
successfully	O
synthesized	O
by	O
using	O
nonionic	O
surfactants	O
at	O
room	O
temperature	O
.	O

Our	O
recent	O
study	O
demonstrated	O
that	O
the	O
addition	O
of	O
nonionic	O
surfactant	O
plays	O
an	O
important	O
key	O
role	O
in	O
the	O
synthesis	O
of	O
dendritic	O
Pt	B
nanostructures	O
(	O
J.	O
Am	O
.	O

Chem	O
.	O

Soc	O
.	O
,	O
2010	O
,	O
132	O
,	O
13636	O
)	O
.	O

Here	O
we	O
extend	O
this	O
synthetic	O
concept	O
to	O
prepare	O
various	O
Ag@Pt	B
nanoarchitectures	O
.	O

The	O
different	O
nanostructured	O
Pt	B
shells	O
on	O
the	O
Ag	B
core	O
were	O
confirmed	O
by	O
ultraviolet	O
-	O
visible	O
absorption	O
spectroscopy	O
and	O
transmission	O
electron	O
microscopy	O
.	O

As	O
a	O
preliminary	O
electrochemical	O
application	O
,	O
the	O
obtained	O
Ag@Pt	B
nanostructures	O
were	O
applied	O
in	O
the	O
methanol	B
oxidation	O
reaction	O
(	O
MOR	O
)	O
in	O
0.5	O
M	O
H	B
(	I
2	I
)	I
SO	I
(	I
4	I
)	I
solution	O
containing	O
0.5	O
M	O
methanol	B
.	O

The	O
Ag@Pt	B
nanoparticles	O
with	O
thin	O
dendritic	O
Pt	B
shells	O
show	O
superior	O
CO	B
-	O
tolerance	O
performance	O
with	O
a	O
I	O
(	O
f	O
)	O
/	O
I	O
(	O
b	O
)	O
value	O
reaching	O
3.71	O
.	O

Our	O
Ag@Pt	B
nanostructures	O
with	O
good	O
CO	B
tolerant	O
activity	O
will	O
be	O
prominent	O
catalysts	O
for	O
MOR	O
.	O

Carboxylic	B
acid	I
(	O
bio	O
)	O
isosteres	O
in	O
drug	O
design	O
.	O

The	O
carboxylic	B
acid	I
functional	O
group	O
can	O
be	O
an	O
important	O
constituent	O
of	O
a	O
pharmacophore	O
,	O
however	O
,	O
the	O
presence	O
of	O
this	O
moiety	O
can	O
also	O
be	O
responsible	O
for	O
significant	O
drawbacks	O
,	O
including	O
metabolic	O
instability	O
,	O
toxicity	O
,	O
as	O
well	O
as	O
limited	O
passive	O
diffusion	O
across	O
biological	O
membranes	O
.	O

To	O
avoid	O
some	O
of	O
these	O
shortcomings	O
while	O
retaining	O
the	O
desired	O
attributes	O
of	O
the	O
carboxylic	B
acid	I
moiety	O
,	O
medicinal	O
chemists	O
often	O
investigate	O
the	O
use	O
of	O
carboxylic	B
acid	I
(	O
bio	O
)	O
isosteres	O
.	O

The	O
same	O
type	O
of	O
strategy	O
can	O
also	O
be	O
effective	O
for	O
a	O
variety	O
other	O
purposes	O
,	O
for	O
example	O
,	O
to	O
increase	O
the	O
selectivity	O
of	O
a	O
biologically	O
active	O
compound	O
or	O
to	O
create	O
new	O
intellectual	O
property	O
.	O

Several	O
carboxylic	B
acid	I
isosteres	O
have	O
been	O
reported	O
,	O
however	O
,	O
the	O
outcome	O
of	O
any	O
isosteric	O
replacement	O
can	O
not	O
be	O
readily	O
predicted	O
as	O
this	O
strategy	O
is	O
generally	O
found	O
to	O
be	O
dependent	O
upon	O
the	O
particular	O
context	O
(	O
i.e.	O
,	O
the	O
characteristic	O
properties	O
of	O
the	O
drug	O
and	O
the	O
drug	O
-	O
target	O
)	O
.	O

As	O
a	O
result	O
,	O
screening	O
of	O
a	O
panel	O
of	O
isosteres	O
is	O
typically	O
required	O
.	O

In	O
this	O
context	O
,	O
the	O
discovery	O
and	O
development	O
of	O
novel	O
carboxylic	B
acid	I
surrogates	O
that	O
could	O
complement	O
the	O
existing	O
palette	O
of	O
isosteres	O
remains	O
an	O
important	O
area	O
of	O
research	O
.	O

The	O
goal	O
of	O
this	O
Minireview	O
is	O
to	O
provide	O
an	O
overview	O
of	O
the	O
most	O
commonly	O
employed	O
carboxylic	B
acid	I
(	O
bio	O
)	O
isosteres	O
and	O
to	O
present	O
representative	O
examples	O
demonstrating	O
the	O
use	O
and	O
utility	O
of	O
each	O
isostere	O
in	O
drug	O
design	O
.	O

Development	O
of	O
Inhibitors	O
of	O
the	O
PAS	O
-	O
B	O
Domain	O
of	O
the	O
HIF-2	O
Transcription	O
Factor	O
.	O

Hypoxia	O
inducible	O
factors	O
(	O
HIFs	O
)	O
are	O
heterodimeric	O
transcription	O
factors	O
induced	O
in	O
a	O
variety	O
of	O
pathophysiological	O
settings	O
,	O
including	O
cancer	O
.	O

We	O
describe	O
the	O
first	O
detailed	O
structure	O
-	O
activity	O
relationship	O
study	O
of	O
small	O
molecules	O
designed	O
to	O
inhibit	O
HIF-2	O
-	O
ARNT	O
heterodimerization	O
by	O
binding	O
an	O
internal	O
cavity	O
of	O
the	O
HIF-2	O
PAS	O
-	O
B	O
domain	O
.	O

Through	O
a	O
series	O
of	O
biophysical	O
characterizations	O
of	O
inhibitor	O
-	O
protein	O
interactions	O
(	O
NMR	O
and	O
X	O
-	O
ray	O
crystallography	O
)	O
,	O
we	O
have	O
established	O
the	O
structural	O
requirements	O
for	O
artificial	O
inhibitors	O
of	O
the	O
HIF-2	O
-	O
ARNT	O
PAS	O
-	O
B	O
interaction	O
.	O

These	O
results	O
may	O
serve	O
as	O
a	O
foundation	O
for	O
discovering	O
therapeutic	O
agents	O
that	O
function	O
by	O
a	O
novel	O
mode	O
of	O
action	O
.	O

Adverse	O
effects	O
of	O
wood	O
smoke	O
PM	O
(	O
2.5	O
)	O
exposure	O
on	O
macrophage	O
functions	O
.	O

Epidemiological	O
studies	O
have	O
shown	O
a	O
correlation	O
between	O
chronic	O
biomass	O
smoke	O
exposure	O
and	O
increased	O
respiratory	O
infection	O
.	O

Pulmonary	O
macrophages	O
are	O
instrumental	O
in	O
both	O
the	O
innate	O
and	O
the	O
adaptive	O
immune	O
responses	O
to	O
respiratory	O
infection	O
.	O

In	O
the	O
present	O
study	O
,	O
in	O
vitro	O
systems	O
were	O
utilized	O
where	O
alveolar	O
macrophages	O
(	O
AM	O
)	O
and	O
bone	O
marrow	O
-	O
derived	O
macrophages	O
(	O
BMdM	O
)	O
were	O
exposed	O
to	O
concentrated	O
wood	O
smoke	O
-	O
derived	O
particulate	O
matter	O
(	O
WS	O
-	O
PM	O
)	O
and	O
mice	O
were	O
exposed	O
in	O
vivo	O
to	O
either	O
concentrated	O
WS	O
-	O
PM	O
or	O
inhaled	O
WS	O
.	O

In	O
vivo	O
studies	O
demonstrated	O
that	O
WS	O
-	O
exposed	O
mice	O
inoculated	O
with	O
Streptococcus	O
pneumoniae	O
had	O
a	O
higher	O
bacterial	O
load	O
24	O
h	O
post	O
-	O
exposure	O
,	O
and	O
corresponding	O
AM	O
were	O
found	O
to	O
have	O
decreased	O
lymphocyte	O
activation	O
activity	O
.	O

Additionally	O
,	O
while	O
classic	O
markers	O
of	O
inflammation	O
(	O
cellular	O
infiltration	O
,	O
total	O
protein	O
,	O
neutrophils	O
)	O
were	O
not	O
affected	O
,	O
there	O
were	O
changes	O
in	O
pulmonary	O
macrophages	O
populations	O
,	O
including	O
significant	O
decreases	O
in	O
macrophages	O
expressing	O
markers	O
of	O
activation	O
in	O
WS	O
-	O
exposed	O
mice	O
.	O

The	O
lymphocyte	O
activation	O
activity	O
of	O
WS	O
-	O
PM	O
-	O
exposed	O
AM	O
was	O
significantly	O
suppressed	O
,	O
but	O
the	O
phagocytic	O
activity	O
appeared	O
unchanged	O
.	O

In	O
an	O
effort	O
to	O
determine	O
a	O
pathway	O
for	O
WS	O
-	O
induced	O
suppression	O
,	O
RelB	O
activation	O
,	O
assessed	O
by	O
nuclear	O
translocation	O
,	O
was	O
observed	O
in	O
AM	O
exposed	O
to	O
either	O
inhaled	O
WS	O
or	O
instilled	O
WS	O
-	O
PM	O
.	O

Finally	O
,	O
an	O
analysis	O
of	O
WS	O
-	O
PM	O
fractions	O
determined	O
the	O
presence	O
of	O
4	O
-	O
5	O
polycyclic	B
aromatic	I
hydrocarbons	I
(	O
PAHs	B
)	O
,	O
and	O
preliminary	O
work	O
suggests	O
a	O
potential	O
role	O
for	O
these	O
PAHs	B
to	O
alter	O
macrophage	O
functions	O
.	O

These	O
studies	O
show	O
a	O
decreased	O
ability	O
of	O
WS	O
-	O
exposed	O
pulmonary	O
macrophages	O
to	O
effectively	O
mount	O
a	O
defense	O
against	O
infection	O
,	O
the	O
effect	O
lasts	O
at	O
least	O
a	O
week	O
post	O
-	O
exposure	O
,	O
and	O
appears	O
to	O
be	O
mediated	O
via	O
RelB	O
activation	O
.	O

Association	O
of	O
Inhalation	O
Toxicologists	O
'	O
(	O
AIT	O
)	O
review	O
of	O
regulatory	O
aspects	O
for	O
inhalation	O
toxicology	O
studies	O
.	O

Regulatory	O
guidelines	O
are	O
intended	O
to	O
provide	O
recommendations	O
on	O
ways	O
to	O
achieve	O
greater	O
harmonization	O
in	O
the	O
interpretation	O
and	O
application	O
of	O
technical	O
procedures	O
and	O
requirements	O
for	O
product	O
registration	O
in	O
order	O
to	O
reduce	O
or	O
obviate	O
replication	O
of	O
the	O
testing	O
carried	O
out	O
during	O
the	O
research	O
and	O
development	O
of	O
new	O
products	O
.	O

The	O
objectives	O
of	O
such	O
harmonization	O
are	O
more	O
economical	O
use	O
of	O
human	O
,	O
animal	O
and	O
material	O
resources	O
;	O
the	O
elimination	O
of	O
unnecessary	O
delay	O
in	O
the	O
global	O
development	O
and	O
availability	O
of	O
new	O
products	O
while	O
maintaining	O
safeguards	O
on	O
quality	O
,	O
safety	O
and	O
efficacy	O
;	O
and	O
the	O
fulfillment	O
of	O
regulatory	O
obligations	O
to	O
protect	O
public	O
health	O
.	O

Tetrabenzoporphyrins	B
:	O
synthetic	O
developments	O
and	O
applications	O
.	O

Tetrabenzoporphyrins	B
have	O
attracted	O
considerable	O
worldwide	O
attention	O
over	O
the	O
last	O
few	O
decades	O
.	O

Since	O
the	O
discovery	O
of	O
these	O
pigments	O
,	O
chemists	O
,	O
biologists	O
,	O
medical	O
professionals	O
and	O
material	O
scientists	O
have	O
devoted	O
pronounced	O
efforts	O
in	O
order	O
to	O
develop	O
synthetic	O
methods	O
and	O
discover	O
useful	O
applications	O
for	O
these	O
compounds	O
.	O

Nowadays	O
,	O
tetrabenzoporphyrins	B
occupy	O
a	O
prominent	O
position	O
in	O
porphyrin	B
chemistry	O
,	O
and	O
this	O
review	O
is	O
intended	O
to	O
cover	O
the	O
main	O
synthetic	O
methods	O
and	O
applications	O
of	O
these	O
compounds	O
.	O

Engineering	O
a	O
serum	O
-	O
resistant	O
and	O
thermostable	O
vesicular	O
stomatitis	O
virus	O
G	O
glycoprotein	O
for	O
pseudotyping	O
retroviral	O
and	O
lentiviral	O
vectors	O
.	O

Vesicular	O
stomatitis	O
virus	O
G	O
glycoprotein	O
(	O
VSV	O
-	O
G	O
)	O
is	O
the	O
most	O
widely	O
used	O
envelope	O
protein	O
for	O
retroviral	O
and	O
lentiviral	O
vector	O
pseudotyping	O
;	O
however	O
,	O
serum	O
inactivation	O
of	O
VSV	O
-	O
G	O
pseudotyped	O
vectors	O
is	O
a	O
significant	O
challenge	O
for	O
in	O
vivo	O
gene	O
delivery	O
.	O

To	O
address	O
this	O
problem	O
,	O
we	O
conducted	O
directed	O
evolution	O
of	O
VSV	O
-	O
G	O
to	O
increase	O
its	O
resistance	O
to	O
human	O
serum	O
neutralization	O
.	O

After	O
six	O
selection	O
cycles	O
,	O
numerous	O
common	O
mutations	O
were	O
present	O
.	O

On	O
the	O
basis	O
of	O
their	O
location	O
within	O
VSV	O
-	O
G	O
,	O
we	O
analyzed	O
whether	O
substitutions	O
in	O
several	O
surface	O
exposed	O
residues	O
could	O
endow	O
viral	O
vectors	O
with	O
higher	O
resistance	O
to	O
serum	O
.	O

S162	O
T	O
,	O
T230N	O
and	O
T368A	O
mutations	O
enhanced	O
serum	O
resistance	O
,	O
and	O
additionally	O
K66	O
T	O
,	O
T368A	O
and	O
E380	O
K	O
substitutions	O
increased	O
the	O
thermostability	O
of	O
VSV	O
-	O
G	O
pseudotyped	O
retroviral	O
vectors	O
,	O
an	O
advantageous	O
byproduct	O
of	O
the	O
selection	O
strategy	O
.	O

Analysis	O
of	O
a	O
number	O
of	O
combined	O
mutants	O
revealed	O
that	O
VSV	O
-	O
G	O
harboring	O
T230N+T368A	O
or	O
K66T+S162T+T230N+T368A	O
mutations	O
exhibited	O
both	O
higher	O
in	O
vitro	O
resistance	O
to	O
human	O
serum	O
and	O
higher	O
thermostability	O
,	O
as	O
well	O
as	O
enhanced	O
resistance	O
to	O
rabbit	O
and	O
mouse	O
serum	O
.	O

Finally	O
,	O
lentiviral	O
vectors	O
pseudotyped	O
with	O
these	O
variants	O
were	O
more	O
resistant	O
to	O
human	O
serum	O
in	O
a	O
murine	O
model	O
.	O

These	O
serum	O
-	O
resistant	O
and	O
thermostable	O
VSV	O
-	O
G	O
variants	O
may	O
aid	O
the	O
application	O
of	O
retroviral	O
and	O
lentiviral	O
vectors	O
to	O
gene	O
therapy	O
.	O

Gene	O
Therapy	O
advance	O
online	O
publication	O
,	O
31	O
January	O
2013	O
;	O
doi:10.1038	O
/	O
gt.2013.1	O
.	O

The	O
impact	O
of	O
functionalization	O
on	O
the	O
stability	O
,	O
work	O
function	O
,	O
and	O
photoluminescence	O
of	O
reduced	B
graphene	I
oxide	I
.	O

Reduced	B
graphene	I
oxide	I
(	O
rGO	B
)	O
is	O
a	O
promising	O
material	O
for	O
a	O
variety	O
of	O
thin	O
-	O
film	O
optoelectronic	O
applications	O
.	O

Two	O
main	O
barriers	O
to	O
its	O
widespread	O
use	O
are	O
the	O
lack	O
of	O
(	O
1	O
)	O
fabrication	O
protocols	O
leading	O
to	O
tailored	O
functionalization	O
of	O
the	O
graphene	B
sheet	O
with	O
oxygen	B
-	O
containing	O
chemical	O
groups	O
,	O
and	O
(	O
2	O
)	O
understanding	O
of	O
the	O
impact	O
of	O
such	O
functional	O
groups	O
on	O
the	O
stability	O
and	O
on	O
the	O
optical	O
and	O
electronic	O
properties	O
of	O
rGO	B
.	O

We	O
carry	O
out	O
classical	O
molecular	O
dynamics	O
and	O
density	O
functional	O
theory	O
calculations	O
on	O
a	O
large	O
set	O
of	O
realistic	O
rGO	B
structures	O
to	O
decompose	O
the	O
effects	O
of	O
different	O
functional	O
groups	O
on	O
the	O
stability	O
,	O
work	O
function	O
,	O
and	O
photoluminescence	O
.	O

Our	O
calculations	O
indicate	O
the	O
metastable	O
nature	O
of	O
carbonyl	B
-	O
rich	O
rGO	B
and	O
its	O
favorable	O
transformation	O
to	O
hydroxyl	B
-	O
rich	O
rGO	B
at	O
room	O
temperature	O
via	O
carbonyl	B
-	O
to	O
-	O
hydroxyl	B
conversion	O
reactions	O
near	O
carbon	B
vacancies	O
and	O
holes	O
.	O

We	O
demonstrate	O
a	O
significant	O
tunability	O
in	O
the	O
work	O
function	O
of	O
rGO	B
up	O
to	O
2.5	O
eV	O
by	O
altering	O
the	O
composition	O
of	O
oxygen	B
-	O
containing	O
functional	O
groups	O
for	O
a	O
fixed	O
oxygen	B
concentration	O
,	O
and	O
of	O
the	O
photoluminescence	O
emission	O
by	O
modulating	O
the	O
fraction	O
of	O
epoxy	B
and	O
carbonyl	B
groups	O
.	O

Taken	O
together	O
,	O
our	O
results	O
guide	O
the	O
application	O
of	O
tailored	O
rGO	B
structures	O
in	O
devices	O
for	O
optoelectronics	O
and	O
renewable	O
energy	O
.	O

pH	O
-	O
dependent	O
motion	O
of	O
self	O
-	O
propelled	O
droplets	O
due	O
to	O
Marangoni	O
effect	O
at	O
neutral	O
pH.	O
Oil	O
droplets	O
loaded	O
with	O
surfactant	O
propel	O
themselves	O
with	O
a	O
velocity	O
up	O
to	O
6	O
mm	O
s	O
(	O
-1	O
)	O
when	O
they	O
are	O
placed	O
in	O
an	O
aqueous	O
phase	O
of	O
NaOH	B
solution	O
or	O
buffer	O
solution	O
.	O

The	O
required	O
driving	O
force	O
for	O
such	O
motion	O
is	O
generated	O
on	O
the	O
interface	O
of	O
the	O
droplets	O
by	O
the	O
change	O
in	O
interfacial	O
tension	O
,	O
due	O
to	O
deprotonation	O
of	O
the	O
surfactant	O
.	O

This	O
force	O
induces	O
Marangoni	O
convection	O
,	O
which	O
gives	O
rise	O
to	O
a	O
circulating	O
flow	O
inside	O
the	O
droplets	O
.	O

The	O
droplets	O
begin	O
to	O
move	O
when	O
the	O
axis	O
of	O
this	O
circulation	O
deviates	O
from	O
the	O
vertical	O
line	O
.	O

This	O
motion	O
depends	O
on	O
the	O
pH	O
condition	O
of	O
the	O
aqueous	O
phase	O
.	O

When	O
the	O
initial	O
value	O
of	O
pH	O
is	O
adjusted	O
such	O
that	O
the	O
pH	O
exceeds	O
the	O
threshold	O
at	O
the	O
equilibrium	O
state	O
,	O
the	O
droplets	O
move	O
spontaneously	O
.	O

It	O
was	O
seen	O
that	O
the	O
droplets	O
were	O
independent	O
of	O
the	O
material	O
of	O
the	O
solid	O
substrates	O
because	O
the	O
droplets	O
were	O
not	O
directly	O
in	O
contact	O
with	O
the	O
surface	O
of	O
the	O
substrate	O
.	O

The	O
condition	O
for	O
the	O
onset	O
of	O
this	O
spontaneous	O
motion	O
was	O
verified	O
by	O
comparing	O
the	O
prediction	O
from	O
the	O
linear	O
stability	O
analysis	O
with	O
experiments	O
.	O

The	O
stability	O
analysis	O
overestimates	O
the	O
value	O
of	O
the	O
driving	O
force	O
,	O
causing	O
instability	O
.	O

Synthesis	O
and	O
characterization	O
of	O
a	O
matrix	O
-	O
metalloproteinase	O
responsive	O
silk	O
-	O
elastinlike	O
protein	O
polymer	O
.	O

Silk	O
-	O
elastinlike	O
protein	O
polymers	O
(	O
SELPs	O
)	O
are	O
recombinant	O
polymers	O
consisting	O
of	O
tandem	O
repeats	O
of	O
silk	O
(	O
GAGAGS	O
)	O
and	O
elastin	O
(	O
GVGVP	O
)	O
units	O
.	O

By	O
modification	O
of	O
the	O
length	O
and	O
composition	O
of	O
these	O
repeats	O
,	O
the	O
properties	O
of	O
SELP	O
hydrogels	O
can	O
be	O
controlled	O
for	O
specific	O
applications	O
including	O
nucleic	O
acid	O
and	O
virus	O
delivery	O
and	O
tissue	O
engineering	O
.	O

Here	O
,	O
the	O
structure	O
of	O
SELPs	O
is	O
further	O
modified	O
to	O
include	O
a	O
sequence	O
that	O
is	O
sensitive	O
to	O
matrix	O
-	O
metalloproteinases	O
(	O
MMPs	O
)	O
.	O

MMPs	O
are	O
a	O
ubiquitous	O
family	O
of	O
extracellular	O
matrix	O
-	O
modifying	O
enzymes	O
that	O
are	O
commonly	O
associated	O
with	O
numerous	O
vital	O
processes	O
.	O

Increased	O
levels	O
of	O
MMPs	O
are	O
found	O
at	O
high	O
levels	O
locally	O
in	O
many	O
types	O
of	O
solid	O
tumors	O
.	O

By	O
modifying	O
the	O
SELP	O
backbone	O
with	O
MMP	O
-	O
sensitive	O
peptide	O
sequences	O
,	O
a	O
hydrogel	O
that	O
is	O
degradable	O
by	O
MMPs	O
was	O
produced	O
.	O

The	O
MMP	O
-	O
sensitivity	O
of	O
the	O
polymer	O
was	O
examined	O
by	O
incubation	O
with	O
MMP-2	O
and	O
MMP-9	O
,	O
which	O
yielded	O
complete	O
cleavage	O
of	O
all	O
full	O
-	O
length	O
polymers	O
by	O
36	O
hours	O
and	O
48	O
hours	O
,	O
respectively	O
,	O
with	O
no	O
observable	O
effect	O
on	O
unmodified	O
SELP	O
.	O

Hydrogel	O
sensitivity	O
was	O
tested	O
by	O
exposure	O
to	O
MMP-2	O
or	O
MMP-9	O
for	O
2	O
weeks	O
,	O
during	O
which	O
samples	O
were	O
taken	O
to	O
analyze	O
protein	O
loss	O
from	O
the	O
hydrogel	O
and	O
release	O
of	O
100	O
nm	O
fluorescent	O
beads	O
.	O

Following	O
the	O
incubation	O
period	O
,	O
hydrogels	O
were	O
tested	O
in	O
mechanical	O
compression	O
to	O
examine	O
the	O
loss	O
of	O
hydrogel	O
stiffness	O
due	O
to	O
degradation	O
.	O

It	O
was	O
found	O
that	O
MMP-2	O
and	O
MMP-9	O
caused	O
63	O
%	O
and	O
44	O
%	O
increased	O
protein	O
loss	O
and	O
65	O
%	O
and	O
95	O
%	O
increased	O
release	O
from	O
MMP	O
-	O
sensitive	O
hydrogels	O
,	O
while	O
the	O
compressive	O
modulus	O
decreased	O
by	O
41	O
%	O
and	O
29	O
%	O
.	O

These	O
results	O
suggest	O
the	O
potential	O
of	O
MMP	O
-	O
responsive	O
SELPs	O
for	O
localized	O
delivery	O
of	O
bioactive	O
agents	O
where	O
MMPs	O
are	O
overexpressed	O
.	O

Biobased	O
polyesters	B
with	O
composition	O
-	O
dependent	O
thermomechanical	O
properties	O
:	O
synthesis	O
and	O
characterization	O
of	O
poly	B
(	I
butylene	I
succinate	I
-	I
co	I
-	I
butylene	I
azelate	I
)	I
.	O

Environmentally	O
friendly	O
poly	B
(	I
butylenesuccinate	I
-	I
co	I
-	I
butyleneazelate	I
)	I
(	O
P	B
(	I
BS	I
-	I
co	I
-	I
BAz	I
)	I
s	I
)	O
aliphatic	B
copolyesters	I
with	O
composition	O
-	O
dependent	O
thermomechanical	O
properties	O
were	O
synthesized	O
from	O
succinic	B
acid	I
(	O
SuA	B
)	O
,	O
1,4-butanediol	B
(	O
BDO	B
)	O
,	O
and	O
dimethylazelate	B
(	O
DMAz	B
)	O
through	O
a	O
two	O
-	O
step	O
polycondensation	O
reaction	O
.	O

The	O
molar	O
SuA	B
/	O
AzA	B
ratio	O
was	O
varied	O
from	O
4:1	O
to	O
1:4	O
,	O
and	O
the	O
chemical	O
structure	O
and	O
molecular	O
characteristics	O
of	O
resulting	O
(	B
co	I
)	I
polyesters	I
were	O
characterized	O
by	O
NMR	O
and	O
SEC	O
,	O
whereas	O
thermal	O
properties	O
and	O
crystallinity	O
were	O
studied	O
by	O
differential	O
scanning	O
calorimetry	O
(	O
DSC	O
)	O
,	O
dynamic	O
mechanical	O
thermal	O
analyses	O
(	O
DMTA	O
)	O
,	O
and	O
X	O
-	O
ray	O
diffraction	O
(	O
XRD	O
)	O
.	O

A	O
good	O
agreement	O
between	O
theoretical	O
and	O
experimental	O
SuA	B
/	O
AzA	B
molar	O
ratios	O
in	O
the	O
copolyesters	B
was	O
achieved	O
,	O
together	O
with	O
the	O
recovery	O
of	O
semicrystalline	O
random	O
copolymers	O
of	O
uniform	O
composition	O
along	O
the	O
chains	O
.	O

NMR	O
,	O
DSC	O
,	O
DMTA	O
,	O
and	O
XRD	O
results	O
show	O
that	O
depending	O
on	O
their	O
composition	O
the	O
P	B
(	I
BS	I
-	I
co	I
-	I
BAz	I
)	I
copolyesters	I
might	O
find	O
applications	O
from	O
elastomers	O
to	O
high	O
-	O
impact	O
thermoplastics	O
.	O

Formulation	O
,	O
in	O
vitro	O
evaluation	O
and	O
study	O
of	O
variables	O
on	O
tri	O
-	O
layered	O
gastro	O
-	O
retentive	O
delivery	O
system	O
of	O
diltiazem	B
HCl	I
.	O

Abstract	O
Context	O
:	O
Tri	O
-	O
layered	O
floating	O
tablets	O
using	O
only	O
one	O
grade	O
of	O
polyethylene	B
oxide	I
(	O
PEO	B
)	O
would	O
enable	O
easy	O
manufacturing	O
,	O
reproducibility	O
and	O
controlled	O
release	O
for	O
highly	O
soluble	O
drugs	O
.	O

Objective	O
:	O
To	O
evaluate	O
the	O
potential	O
of	O
PEO	B
as	O
a	O
sole	O
polymer	O
for	O
the	O
controlled	O
release	O
and	O
to	O
study	O
the	O
effect	O
of	O
formulation	O
variables	O
on	O
release	O
and	O
gastric	O
retention	O
of	O
highly	O
soluble	O
Diltiazem	B
hydrochloride	I
(	O
DTZ	B
)	O
.	O

Methods	O
:	O
Tablets	O
were	O
compressed	O
with	O
middle	O
layer	O
consisting	O
of	O
drug	O
and	O
polymer	O
while	O
outer	O
layers	O
consisted	O
of	O
polymer	O
with	O
sodium	B
bicarbonate	I
.	O

Design	O
of	O
formulation	O
to	O
obtain	O
12	O
h	O
,	O
zero	O
-	O
order	O
release	O
and	O
rapid	O
floatation	O
was	O
done	O
by	O
varying	O
the	O
grades	O
,	O
quantity	O
of	O
PEO	B
and	O
sodium	B
bicarbonate	I
.	O

Dissolution	O
data	O
were	O
fitted	O
in	O
drug	O
release	O
models	O
and	O
swelling	O
/	O
erosion	O
studies	O
were	O
undertaken	O
to	O
verify	O
the	O
drug	O
release	O
mechanism	O
.	O

Effect	O
of	O
formulation	O
variables	O
and	O
tablet	O
surface	O
morphology	O
using	O
scanning	O
electron	O
microscopy	O
were	O
studied	O
.	O

Results	O
and	O
discussion	O
:	O
The	O
optimized	O
formula	O
passed	O
the	O
criteria	O
of	O
USP	O
dissolution	O
test	O
I	O
and	O
exhibited	O
floating	O
lag	O
-	O
time	O
of	O
3	O
-	O
4	O
min	O
.	O

Drug	O
release	O
was	O
faster	O
from	O
low	O
molecular	O
weight	O
(	O
MW	O
)	O
PEO	B
as	O
compared	O
to	O
high	O
MW	O
.	O

With	O
an	O
increase	O
in	O
the	O
amount	O
of	O
sodium	B
bicarbonate	I
,	O
faster	O
buoyancy	O
was	O
achieved	O
due	O
to	O
the	O
increased	O
CO	B
(	I
2	I
)	I
gas	O
formation	O
.	O

Drug	O
release	O
followed	O
zero	O
-	O
order	O
and	O
gave	O
a	O
good	O
fit	O
to	O
the	O
Korsmeyer	O
-	O
Peppas	O
model	O
,	O
which	O
suggested	O
that	O
drug	O
release	O
was	O
due	O
to	O
diffusion	O
through	O
polymer	O
swelling	O
.	O

Conclusion	O
:	O
Zero	O
-	O
order	O
,	O
controlled	O
release	O
profile	O
with	O
the	O
desired	O
buoyancy	O
can	O
be	O
achieved	O
by	O
using	O
optimum	O
formula	O
quantities	O
of	O
sodium	B
bicarbonate	I
and	O
polymer	O
.	O

The	O
tri	O
-	O
layered	O
system	O
shows	O
promising	O
delivery	O
of	O
DTZ	B
,	O
and	O
possibly	O
other	O
water	O
-	O
soluble	O
drugs	O
.	O

Short	O
-	O
term	O
assessment	O
of	O
toxicological	O
aspects	O
,	O
oxidative	O
and	O
inflammatory	O
response	O
to	O
dietary	O
melon	O
superoxide	B
dismutase	O
in	O
rats	O
.	O

The	O
protective	O
effects	O
of	O
SODB	O
,	O
a	O
gastro	O
-	O
resistant	O
encapsulated	O
melon	O
superoxide	B
dismutase	O
,	O
on	O
haematological	O
and	O
biochemical	O
parameters	O
and	O
inflammatory	O
and	O
oxidative	O
status	O
,	O
were	O
evaluated	O
in	O
the	O
blood	O
and	O
liver	O
tissue	O
.	O

The	O
study	O
consisted	O
in	O
a	O
28-day	O
experiment	O
on	O
rats	O
supplemented	O
with	O
three	O
doses	O
(	O
10	O
,	O
40	O
and	O
160USOD	O
/	O
day	O
)	O
of	O
SODB	O
-	O
M	O
,	O
SODB	O
-	O
D	O
or	O
SODB	O
-	O
S	O
,	O
different	O
depending	O
on	O
the	O
nature	O
of	O
the	O
coating	O
(	O
palm	O
oil	O
,	O
shellac	O
or	O
gum	O
Arabic	O
respectively	O
)	O
.	O

No	O
mortality	O
,	O
abnormal	O
clinical	O
signs	O
,	O
behavioural	O
changes	O
or	O
macroscopic	O
findings	O
were	O
observed	O
whatever	O
the	O
groups	O
.	O

Haematological	O
parameters	O
(	O
total	O
red	O
blood	O
cell	O
count	O
,	O
haemoglobin	O
content	O
,	O
haematocrit	O
,	O
red	O
cell	O
indices	O
,	O
white	O
blood	O
cell	O
count	O
and	O
platelets	O
count	O
)	O
were	O
not	O
modified	O
in	O
SODB	O
treated	O
-	O
groups	O
.	O

No	O
marked	O
change	O
was	O
recorded	O
in	O
biochemical	O
parameters	O
(	O
plasma	O
urea	B
,	O
creatinine	B
,	O
lipids	O
,	O
electrolytes	O
,	O
bilirubin	B
,	O
transaminases	O
and	O
gamma	B
-	I
glutamyl	I
transferase	O
)	O
.	O

The	O
liver	O
endogenous	O
antioxidant	O
enzymes	O
(	O
copper	B
/	O
zinc	B
and	O
manganese	B
superoxide	I
dismutase	O
)	O
expressions	O
were	O
significantly	O
increased	O
in	O
the	O
rats	O
receiving	O
the	O
highest	O
dose	O
of	O
SODB	O
(	O
160USOD	O
/	O
day	O
)	O
whatever	O
the	O
coating	O
.	O

Moreover	O
,	O
interleukin-6	O
,	O
a	O
marker	O
of	O
inflammation	O
,	O
was	O
significantly	O
decreased	O
in	O
these	O
high	O
dose	O
-	O
treated	O
-	O
groups	O
.	O

The	O
present	O
study	O
indicates	O
that	O
dietary	O
supplementation	O
of	O
SODB	O
on	O
rats	O
has	O
no	O
harmful	O
side	O
effects	O
and	O
could	O
be	O
beneficial	O
especially	O
at	O
high	O
doses	O
.	O

Anti	O
-	O
oxidant	O
and	O
natural	O
killer	O
cell	O
activity	O
of	O
Korean	O
red	O
ginseng	O
(	O
Panax	O
ginseng	O
)	O
and	O
urushiol	B
(	O
Rhus	O
vernicifera	O
Stokes	O
)	O
on	O
non	O
-	O
alcoholic	O
fatty	O
liver	O
disease	O
of	O
rat	O
.	O

Anti	O
-	O
oxidative	O
and	O
immunologic	O
effects	O
of	O
the	O
Korea	O
red	O
ginseng	O
(	O
KRG	O
;	O
Panax	O
ginseng	O
)	O
and	O
urushiol	B
(	O
Rhus	O
vernicifera	O
Stokes	O
)	O
on	O
non	O
-	O
alcoholic	O
fatty	O
liver	O
disease	O
(	O
NAFLD	O
)	O
were	O
evaluated	O
.	O

Forty	O
-	O
five	O
rats	O
(	O
five	O
Long	O
-	O
Evans	O
Tokushima	O
Otsuka	O
and	O
40	O
Otsuka	O
Long	O
-	O
Evans	O
Tokushima	O
Fatty	O
[	O
OLETF	O
]	O
rats	O
)	O
received	O
chew	O
diets	O
for	O
10months	O
;	O
after	O
this	O
period	O
.	O

The	O
OLETF	O
rats	O
were	O
divided	O
into	O
the	O
following	O
four	O
groups	O
according	O
to	O
diet	O
for	O
2months	O
:	O
NAFLD	O
(	O
chew	O
)	O
,	O
KRG	O
(	O
chew+KRG	O
[	O
200mg	O
/	O
kg	O
/	O
day	O
]	O
)	O
,	O
urushiol	B
(	O
chew+urushiol	O
[	O
0.5mg	O
/	O
kg	O
/	O
day	O
]	O
)	O
,	O
and	O
ursodeoxycholic	B
acid	I
(	O
UDCA	B
)	O
(	O
chew+UDCA	O
[	O
15mg	O
/	O
kg	O
/	O
day	O
]	O
)	O
groups	O
.	O

Liver	O
function	O
,	O
lipid	O
profiles	O
and	O
anti	O
-	O
oxidant	O
activity	O
of	O
liver	O
and	O
serum	O
,	O
natural	O
killer	O
(	O
NK	O
)	O
cell	O
activity	O
,	O
and	O
pathology	O
were	O
compared	O
.	O

In	O
KRG	O
and	O
urushiol	B
groups	O
,	O
the	O
level	O
of	O
serum	O
triglyceride	B
(	O
[	O
302.070.4	O
and	O
275.263.8	O
]	O
vs.	O
527.7153.3mg	O
/	O
dL	O
)	O
were	O
lower	O
compared	O
with	O
that	O
of	O
NAFLD	O
group	O
(	O
p<0.05	O
)	O
.	O

The	O
levels	O
of	O
HDL	O
-	O
cholesterol	B
(	O
liver	O
tissue	O
:	O
[	O
4.80.2	O
and	O
4.80.5	O
]	O
vs.	O
4.20.2mg	O
/	O
g	O
)	O
and	O
NK	O
cell	O
activity	O
(	O
[	O
3485910	O
and	O
3559910	O
]	O
vs.	O
2486619	O
counts	O
)	O
were	O
significantly	O
higher	O
than	O
those	O
of	O
the	O
NAFLD	O
group	O
(	O
p<0.001	O
)	O
.	O

Inflammation	O
with	O
neutrophil	O
infiltration	O
was	O
observed	O
in	O
only	O
two	O
rats	O
in	O
the	O
NAFLD	O
group	O
.	O

These	O
results	O
suggest	O
that	O
2months	O
of	O
oral	O
KRG	O
or	O
urushiol	B
administration	O
improves	O
lipid	O
profiles	O
and	O
stimulates	O
NK	O
cell	O
activity	O
,	O
while	O
inhibiting	O
steatohepatitis	O
in	O
OLEFT	O
rats	O
.	O

TNF	O
and	O
Fas	O
/	O
FasL	O
pathways	O
are	O
involved	O
in	O
9-Methoxycamptothecin	B
-	O
induced	O
apoptosis	O
in	O
cancer	O
cells	O
with	O
oxidative	O
stress	O
and	O
G2	O
/	O
M	O
cell	O
cycle	O
arrest	O
.	O

9-Methoxycamptothecin	B
(	O
MCPT	B
)	O
has	O
been	O
recently	O
reported	O
to	O
have	O
a	O
strong	O
anticancer	O
activity	O
.	O

However	O
,	O
its	O
detailed	O
mechanism	O
of	O
action	O
in	O
human	O
cancer	O
cells	O
has	O
not	O
been	O
well	O
clarified	O
.	O

The	O
results	O
showed	O
that	O
MCPT	B
induced	O
cytotoxicity	O
in	O
seven	O
human	O
cancer	O
cell	O
lines	O
in	O
a	O
dose	O
dependent	O
manner	O
after	O
72h	O
,	O
with	O
A2780	O
and	O
Hela	O
cell	O
lines	O
more	O
sensitive	O
,	O
so	O
the	O
two	O
cell	O
lines	O
were	O
chosen	O
to	O
do	O
further	O
studies	O
.	O

MCPT	B
induced	O
strong	O
G2	O
/	O
M	O
arrest	O
in	O
both	O
A2780	O
cells	O
and	O
Hela	O
cells	O
after	O
24h	O
,	O
following	O
by	O
substantial	O
sub	O
-	O
G1	O
arrest	O
(	O
indicating	O
apoptosis	O
)	O
.	O

The	O
apoptosis	O
was	O
verified	O
by	O
staining	O
with	O
Annexin	O
V	O
-	O
FITC	B
and	O
propidium	B
iodide	I
.	O

ROS	O
generation	O
increased	O
significantly	O
in	O
MCPT	B
-	O
induced	O
apoptosis	O
.	O

Meanwhile	O
,	O
the	O
apoptosis	O
appeared	O
to	O
be	O
dependent	O
on	O
caspase-3	O
,	O
-8	O
and	O
-9	O
in	O
A2780	O
cells	O
,	O
and	O
caspase-3	O
in	O
Hela	O
cells	O
.	O

In	O
addition	O
,	O
MCPT	B
induced	O
up	O
-	O
regulation	O
expression	O
of	O
most	O
of	O
seventeen	O
genes	O
in	O
both	O
cell	O
lines	O
.	O

Western	O
blot	O
verified	O
that	O
changes	O
of	O
TNF	O
,	O
Fas	O
,	O
P53	O
and	O
P27	O
protein	O
level	O
were	O
consistent	O
with	O
their	O
gene	O
expression	O
changes	O
.	O

Taken	O
together	O
,	O
MCPT	B
plays	O
an	O
important	O
role	O
in	O
tumor	O
growth	O
suppression	O
by	O
inducing	O
apoptosis	O
in	O
both	O
cell	O
lines	O
via	O
extrinsic	O
and	O
intrinsic	O
apoptotic	O
pathways	O
,	O
and	O
has	O
the	O
potential	O
to	O
be	O
developed	O
into	O
an	O
antitumor	O
agent	O
.	O

Hierarchical	O
organization	O
of	O
osteoblasts	O
reveals	O
the	O
significant	O
role	O
of	O
CD166	O
in	O
hematopoietic	O
stem	O
cell	O
maintenance	O
and	O
function	O
.	O

The	O
role	O
of	O
osteoblasts	O
(	O
OB	O
)	O
in	O
maintaining	O
hematopoietic	O
stem	O
cells	O
(	O
HSC	O
)	O
in	O
their	O
niche	O
is	O
well	O
elucidated	O
,	O
but	O
the	O
exact	O
definition	O
,	O
both	O
phenotypically	O
and	O
hierarchically	O
of	O
OB	O
responsible	O
for	O
these	O
functions	O
is	O
not	O
clearly	O
known	O
.	O

We	O
previously	O
demonstrated	O
that	O
OB	O
maturational	O
status	O
influences	O
HSC	O
function	O
whereby	O
immature	O
OB	O
with	O
high	O
Runx2	O
expression	O
promote	O
hematopoietic	O
expansion	O
.	O

Here	O
,	O
we	O
show	O
that	O
Activated	O
Leukocyte	O
Cell	O
Adhesion	O
Molecule	O
(	O
ALCAM	O
)	O
or	O
CD166	O
expression	O
on	O
OB	O
is	O
directly	O
correlated	O
with	O
Runx2	O
expression	O
and	O
high	O
hematopoiesis	O
enhancing	O
activity	O
(	O
HEA	O
)	O
.	O

Fractionation	O
of	O
OB	O
with	O
lineage	O
markers	O
:	O
Sca1	O
,	O
osteopontin	O
(	O
OPN	O
)	O
,	O
CD166	O
,	O
CD44	O
,	O
and	O
CD90	O
revealed	O
that	O
Lin	O
-	O
Sca1-OPN+CD166	O
+	O
cells	O
(	O
CD166	O
+	O
)	O
and	O
their	O
subpopulations	O
fractionated	O
with	O
CD44	O
and	O
CD90	O
expressed	O
high	O
levels	O
of	O
Runx2	O
and	O
low	O
levels	O
of	O
osteocalcin	O
(	O
OC	O
)	O
demonstrating	O
the	O
relatively	O
immature	O
status	O
of	O
these	O
cells	O
.	O

Conversely	O
,	O
the	O
majority	O
of	O
the	O
Lin	O
-	O
Sca1-OPN+CD166-	O
cells	O
(	O
CD166-	O
)	O
expressed	O
high	O
OC	O
levels	O
suggesting	O
that	O
CD166-	O
OB	O
are	O
more	O
mature	O
.	O

In	O
vitro	O
hematopoietic	O
potential	O
of	O
LSK	O
cells	O
co	O
-	O
cultured	O
for	O
7days	O
with	O
fresh	O
OB	O
or	O
OB	O
pre	O
-	O
cultured	O
for	O
1	O
,	O
2	O
,	O
or	O
3	O
weeks	O
declined	O
precipitously	O
with	O
increasing	O
culture	O
duration	O
concomitant	O
with	O
loss	O
of	O
CD166	O
expression	O
.	O

Importantly	O
,	O
LSK	O
cells	O
co	O
-	O
cultured	O
with	O
CD166+CD44+CD90	O
+	O
OB	O
maintained	O
their	O
in	O
vivo	O
repopulating	O
potential	O
through	O
primary	O
and	O
secondary	O
transplantation	O
,	O
suggesting	O
that	O
robust	O
HEA	O
activity	O
is	O
best	O
mediated	O
by	O
immature	O
CD166	O
+	O
OB	O
with	O
high	O
Runx2	O
and	O
low	O
OC	O
expression	O
.	O

These	O
studies	O
begin	O
to	O
define	O
the	O
hierarchical	O
organization	O
of	O
osteoblastic	O
cells	O
and	O
provide	O
a	O
more	O
refined	O
definition	O
of	O
OB	O
that	O
can	O
mediate	O
HEA	O
.	O

Alteration	O
of	O
proteoglycan	O
sulfation	O
affects	O
bone	O
growth	O
and	O
remodeling	O
.	O

Diastrophic	O
dysplasia	O
(	O
DTD	O
)	O
is	O
a	O
chondrodysplasia	O
caused	O
by	O
mutations	O
in	O
the	O
SLC26A2	O
gene	O
,	O
leading	O
to	O
reduced	O
intracellular	O
sulfate	B
pool	O
in	O
chondrocytes	O
,	O
osteoblasts	O
and	O
fibroblasts	O
.	O

Hence	O
,	O
proteoglycans	O
are	O
undersulfated	O
in	O
the	O
cartilage	O
and	O
bone	O
of	O
DTD	O
patients	O
.	O

To	O
characterize	O
the	O
bone	O
phenotype	O
of	O
this	O
skeletal	O
dysplasia	O
we	O
used	O
the	O
Slc26a2	O
knock	O
-	O
in	O
mouse	O
(	O
dtd	O
mouse	O
)	O
,	O
that	O
was	O
previously	O
validated	O
as	O
an	O
animal	O
model	O
of	O
DTD	O
in	O
humans	O
.	O

X	O
-	O
rays	O
,	O
bone	O
densitometry	O
,	O
static	O
and	O
dynamic	O
histomorphometry	O
,	O
and	O
in	O
vitro	O
studies	O
revealed	O
a	O
primary	O
bone	O
defect	O
in	O
the	O
dtd	O
mouse	O
model	O
.	O

We	O
showed	O
in	O
vivo	O
that	O
this	O
primary	O
bone	O
defect	O
in	O
dtd	O
mice	O
is	O
due	O
to	O
decreased	O
bone	O
accrual	O
associated	O
with	O
a	O
decreased	O
trabecular	O
and	O
periosteal	O
appositional	O
rate	O
at	O
the	O
cell	O
level	O
in	O
one	O
month	O
-	O
old	O
mice	O
.	O

Although	O
the	O
osteoclast	O
number	O
evaluated	O
by	O
histomorphometry	O
was	O
not	O
different	O
in	O
dtd	O
compared	O
to	O
wild	O
-	O
type	O
mice	O
,	O
urine	O
analysis	O
of	O
deoxypyridinoline	B
cross	O
-	O
links	O
and	O
serum	O
levels	O
of	O
type	O
I	O
collagen	O
C	O
-	O
terminal	O
telopeptides	O
showed	O
a	O
higher	O
resorption	O
rate	O
in	O
dtd	O
mice	O
compared	O
to	O
wild	O
-	O
type	O
littermates	O
.	O

Electron	O
microscopy	O
studies	O
showed	O
that	O
collagen	O
fibrils	O
in	O
bone	O
were	O
thinner	O
and	O
less	O
organized	O
in	O
dtd	O
compared	O
to	O
wild	O
-	O
type	O
mice	O
.	O

These	O
data	O
suggest	O
that	O
the	O
low	O
bone	O
mass	O
observed	O
in	O
mutant	O
mice	O
could	O
possibly	O
be	O
linked	O
to	O
the	O
different	O
bone	O
matrix	O
compositions	O
/	O
organizations	O
in	O
dtd	O
mice	O
triggering	O
changes	O
in	O
osteoblast	O
and	O
osteoclast	O
activities	O
.	O

Overall	O
,	O
these	O
results	O
suggest	O
that	O
proteoglycan	O
undersulfation	O
not	O
only	O
affects	O
the	O
properties	O
of	O
hyaline	O
cartilage	O
,	O
but	O
can	O
also	O
lead	O
to	O
unbalanced	O
bone	O
modeling	O
and	O
remodeling	O
activities	O
,	O
demonstrating	O
the	O
importance	O
of	O
proteoglycan	O
sulfation	O
in	O
bone	O
homeostasis	O
.	O

APE1	O
/	O
Ref-1	O
prevents	O
oxidative	O
inactivation	O
of	O
ERK	O
for	O
G1-to	O
-	O
S	O
progression	O
following	O
lead	B
acetate	I
exposure	O
.	O

Apurinic	O
/	O
apyrimidinic	O
endonuclease	O
1	O
(	O
APE1	O
)	O
/	O
redox	O
effector	O
factor-1	O
is	O
a	O
multifunctional	O
enzyme	O
involved	O
in	O
DNA	O
base	O
excision	O
repair	O
and	O
protein	O
redox	O
regulation	O
.	O

Previously	O
,	O
we	O
have	O
showed	O
that	O
lead	B
acetate	I
(	O
Pb	B
)	O
elicits	O
EGFR	O
activation	O
to	O
initiate	O
the	O
SFK	O
/	O
PKC	O
/	O
Ras	O
/	O
Raf-1	O
/	O
MKK1	O
/	O
2	O
/	O
ERK	O
signaling	O
cascade	O
functioning	O
against	O
genotoxicity	O
.	O

Here	O
,	O
we	O
explore	O
whether	O
APE1	O
and	O
reactive	O
oxygen	B
species	O
(	O
ROS	O
)	O
affect	O
ERK	O
signaling	O
and	O
cell	O
cycle	O
progression	O
following	O
Pb	B
exposure	O
.	O

We	O
found	O
that	O
Pb	B
induced	O
APE1	O
expression	O
and	O
ROS	O
generation	O
in	O
CL3	O
human	O
lung	O
cancer	O
cells	O
.	O

The	O
Pb	B
-	O
elicited	O
ROS	O
levels	O
and	O
cytotoxicity	O
were	O
further	O
enhanced	O
by	O
introducing	O
small	O
interfering	O
RNA	O
specific	O
for	O
APE1	O
(	O
siAPE1	O
)	O
.	O

E3330	O
,	O
an	O
inhibitor	O
of	O
APE1	O
redox	O
activity	O
,	O
also	O
augmented	O
the	O
ROS	O
levels	O
and	O
cytotoxicity	O
in	O
Pb	B
-	O
treated	O
cells	O
.	O

Intriguingly	O
,	O
the	O
capability	O
of	O
Pb	B
to	O
activate	O
ERK	O
was	O
abolished	O
under	O
siAPE1	O
or	O
E3330	O
co	O
-	O
treatments	O
;	O
conversely	O
,	O
forced	O
expression	O
of	O
APE1	O
up	O
-	O
regulated	O
the	O
ERK	O
activation	O
by	O
Pb	B
or	O
serum	O
in	O
both	O
Cys65-redox	B
activity	O
dependent	O
and	O
independent	O
manners	O
.	O

Moreover	O
,	O
APE1	O
formed	O
complex	O
with	O
ERK2	O
,	O
and	O
its	O
redox	O
activity	O
could	O
rescue	O
ERK	O
oxidative	O
inactivation	O
.	O

APE1	O
redox	O
activity	O
also	O
facilitated	O
the	O
Cyclin	O
D1	O
expression	O
and	O
G1-to	O
-	O
S	O
progression	O
following	O
Pb	B
exposure	O
.	O

In	O
summary	O
,	O
the	O
results	O
indicate	O
that	O
APE1	O
is	O
a	O
direct	O
redox	O
regulator	O
of	O
ERK	O
for	O
maintaining	O
the	O
kinase	O
activity	O
to	O
promote	O
cell	O
proliferation	O
.	O

Synthesis	O
,	O
quantitative	O
structure	O
-	O
activity	O
relationship	O
and	O
biological	O
evaluation	O
of	O
1,3,4-oxadiazole	B
derivatives	O
possessing	O
diphenylamine	B
moiety	O
as	O
potential	O
anticancer	O
agents	O
.	O

Synthesis	O
of	O
2,5-disubstituted-1,3,4-oxadiazole	B
(	O
2a	O
-	O
c	O
)	O
,	O
3-substituted	B
aminomethyl-5-substituted-1,3,4-oxadiazole-2	I
(	I
3H	I
)	I
-thione	I
(	O
4a	O
-	O
m	O
)	O
and	O
2-substituted	B
thio-5-substituted-1,3,4-oxadiazole	I
(	O
5a	O
,	O
b	O
)	O
had	O
been	O
described	O
.	O

All	O
the	O
synthesized	O
derivatives	O
were	O
screened	O
for	O
anticancer	O
activity	O
against	O
HT29	O
and	O
MCF7	O
cancer	O
cell	O
lines	O
using	O
Sulfo	B
-	I
Rodamine	I
B	I
(	O
SRB	B
)	O
standard	O
method	O
.	O

Most	O
of	O
the	O
tested	O
compounds	O
exploited	O
potent	O
antiproliferative	O
activity	O
against	O
HT29	O
cancer	O
cell	O
line	O
rather	O
than	O
MCF7	O
cancer	O
cell	O
line	O
.	O

Compounds	O
2a	O
-	O
c	O
,	O
4f	O
and	O
5a	O
exhibited	O
potent	O
cytotoxicity	O
(	O
IC	O
(	O
50	O
)	O
1.3	O
-	O
2.0	O
M	O
)	O
and	O
selectivity	O
against	O
HT29	O
cancer	O
cell	O
line	O
.	O

Quantitative	O
structure	O
-	O
activity	O
relationship	O
(	O
QSAR	O
)	O
study	O
was	O
applied	O
to	O
find	O
a	O
correlation	O
between	O
the	O
experimental	O
antiproliferative	O
activities	O
of	O
the	O
newly	O
synthesized	O
oxadiazole	B
derivatives	O
with	O
their	O
physicochemical	O
parameter	O
and	O
topological	O
index	O
.	O

Statistical	O
modeling	O
,	O
optimization	O
and	O
characterization	O
of	O
spray	O
-	O
dried	O
solid	O
self	O
-	O
microemulsifying	O
drug	O
delivery	O
system	O
using	O
design	O
of	O
experiments	O
.	O

The	O
present	O
study	O
systematically	O
and	O
simultaneously	O
investigates	O
the	O
influence	O
of	O
process	O
variables	O
of	O
spray	O
-	O
drying	O
on	O
the	O
properties	O
of	O
solid	O
self	O
-	O
microemulsifying	O
drug	O
delivery	O
system	O
(	O
SMEDDS	O
)	O
using	O
design	O
of	O
experiment	O
(	O
DOE	O
)	O
and	O
optimizes	O
them	O
in	O
order	O
to	O
produce	O
solid	O
-	O
SMEDDS	O
satisfying	O
pre	O
-	O
defined	O
powder	O
quality	O
attributes	O
.	O

Flurbiprofen	B
-	O
loaded	O
liquid	O
-	O
SMEDDS	O
was	O
dispersed	O
in	O
dextran	O
and	O
spray	O
-	O
dried	O
.	O

After	O
preliminary	O
screening	O
,	O
the	O
independent	O
factors	O
selected	O
according	O
to	O
three	O
-	O
factor	O
,	O
three	O
-	O
level	O
Box	O
-	O
Behnken	O
design	O
were	O
inlet	O
temperature	O
(	O
X	O
(	O
1	O
)	O
)	O
,	O
feed	O
rate	O
(	O
X	O
(	O
2	O
)	O
)	O
and	O
carrier	O
concentration	O
(	O
X	O
(	O
3	O
)	O
)	O
.	O

The	O
responses	O
used	O
to	O
compute	O
the	O
effects	O
of	O
independent	O
factors	O
were	O
moisture	O
content	O
(	O
Y	O
(	O
1	O
)	O
)	O
,	O
yield	O
(	O
Y	O
(	O
2	O
)	O
)	O
,	O
drug	O
content	O
(	O
Y	O
(	O
3	O
)	O
)	O
and	O
droplet	O
size	O
(	O
Y	O
(	O
4	O
)	O
)	O
of	O
the	O
micro	O
-	O
emulsion	O
.	O

SMEDDS	O
powder	O
characteristics	O
such	O
as	O
morphology	O
,	O
thermal	O
behavior	O
,	O
crystallinity	O
and	O
flowability	O
were	O
also	O
considered	O
.	O

Models	O
were	O
developed	O
and	O
model	O
fitting	O
analysis	O
showed	O
an	O
adequate	O
fit	O
for	O
all	O
responses	O
,	O
indicating	O
good	O
predictability	O
.	O

Significant	O
effects	O
of	O
processing	O
parameters	O
on	O
powder	O
characteristics	O
were	O
observed	O
.	O

The	O
spray	O
-	O
drying	O
process	O
parameters	O
were	O
optimized	O
as	O
inlet	O
temperature	O
(	O
134	O
	O
C	O
)	O
,	O
feed	O
rate	O
(	O
5	O
%	O
)	O
and	O
carrier	O
concentration	O
(	O
0.6	O
%	O
)	O
to	O
produce	O
solid	O
-	O
SMEDDS	O
with	O
acceptable	O
moisture	O
content	O
(	O
0.720.02	O
%	O
)	O
,	O
yield	O
(	O
58.52.9	O
%	O
)	O
,	O
drug	O
content	O
(	O
70.12.7	O
mg	O
/	O
g	O
)	O
and	O
droplet	O
size	O
(	O
166.813.8	O
nm	O
)	O
.	O

Validation	O
of	O
the	O
optimization	O
process	O
in	O
five	O
batches	O
showed	O
experimental	O
value	O
very	O
close	O
to	O
the	O
predicted	O
one	O
,	O
ensuring	O
the	O
reproducibility	O
of	O
the	O
developed	O
models	O
.	O

Furthermore	O
,	O
optimized	O
parameters	O
resulted	O
a	O
highly	O
crystalline	O
flurbiprofen	B
changed	O
to	O
an	O
amorphous	O
form	O
.	O

In	O
conclusion	O
,	O
this	O
study	O
demonstrated	O
the	O
applicability	O
of	O
the	O
DOE	O
approach	O
for	O
optimizing	O
the	O
process	O
parameters	O
to	O
manufacture	O
solid	O
-	O
SMEDDS	O
with	O
desired	O
quality	O
attributes	O
.	O

Organosilicon	B
compounds	O
as	O
adult	O
T	O
-	O
cell	O
leukemia	O
cell	O
proliferation	O
inhibitors	O
.	O

Aggressive	O
forms	O
of	O
adult	O
T	O
-	O
cell	O
leukemia	O
(	O
ATL	O
)	O
respond	O
poorly	O
to	O
conventional	O
anticancer	O
chemotherapy	O
,	O
and	O
new	O
lead	O
compounds	O
are	O
required	O
for	O
the	O
development	O
of	O
drugs	O
to	O
treat	O
this	O
fatal	O
disease	O
.	O

Recently	O
,	O
we	O
developed	O
ATL	O
cell	O
-	O
selective	O
proliferation	O
inhibitors	O
based	O
on	O
a	O
tetrahydrotetramethylnaphthalene	B
(	O
TMN	B
)	O
skeleton	O
1	O
,	O
and	O
here	O
we	O
report	O
the	O
design	O
and	O
synthesis	O
of	O
silicon	B
analogs	O
of	O
TMN	B
derivatives	O
.	O

Among	O
them	O
,	O
compound	O
13	O
showed	O
the	O
most	O
potent	O
growth	O
-	O
inhibitory	O
activity	O
towards	O
the	O
ATL	O
cell	O
line	O
S1	O
T	O
,	O
though	O
its	O
selectivity	O
for	O
S1	O
T	O
over	O
the	O
non	O
-	O
ATL	O
cell	O
line	O
MOLT-4	O
was	O
only	O
moderate	O
.	O

This	O
result	O
,	O
as	O
well	O
as	O
computational	O
studies	O
,	O
suggests	O
that	O
sila	O
-	O
substitution	O
(	B
C	O
/	O
Si	B
exchange	O
)	O
is	O
useful	O
for	O
structure	O
optimization	O
of	O
these	O
inhibitors	O
.	O

Temporal	O
stability	O
of	O
magic	O
-	O
number	O
metal	O
clusters	O
:	O
beyond	O
the	O
shell	O
closing	O
model	O
.	O

The	O
anomalous	O
stability	O
of	O
magic	O
-	O
number	O
metal	O
clusters	O
has	O
been	O
associated	O
with	O
closed	O
geometric	O
and	O
electronic	O
shells	O
and	O
the	O
opening	O
of	O
HOMO	O
-	O
LUMO	O
gaps	O
.	O

Despite	O
this	O
enhanced	O
stability	O
,	O
magic	O
-	O
number	O
clusters	O
are	O
known	O
to	O
decay	O
and	O
react	O
in	O
the	O
condensed	O
phase	O
to	O
form	O
other	O
products	O
.	O

Improving	O
our	O
understanding	O
of	O
their	O
decay	O
mechanisms	O
and	O
developing	O
strategies	O
to	O
control	O
or	O
eliminate	O
cluster	O
instability	O
is	O
a	O
priority	O
,	O
to	O
develop	O
a	O
more	O
complete	O
theory	O
of	O
their	O
stability	O
,	O
to	O
avoid	O
studying	O
mixtures	O
of	O
clusters	O
produced	O
by	O
the	O
decay	O
of	O
purified	O
materials	O
,	O
and	O
to	O
enable	O
technology	O
development	O
.	O

Silver	B
clusters	O
are	O
sufficiently	O
reactive	O
to	O
facilitate	O
the	O
study	O
of	O
the	O
ambient	O
temporal	O
stability	O
of	O
magic	O
-	O
number	O
metal	O
clusters	O
and	O
to	O
begin	O
to	O
understand	O
their	O
decay	O
mechanisms	O
.	O

Here	O
,	O
the	O
solution	O
phase	O
stability	O
of	O
a	O
series	O
of	O
silver	B
:	O
glutathione	B
(	O
Ag	B
:	O
SG	O
)	O
clusters	O
was	O
studied	O
as	O
a	O
function	O
of	O
size	O
,	O
pH	O
and	O
chemical	O
environment	O
.	O

Cluster	O
stability	O
was	O
found	O
to	O
be	O
a	O
non	O
-	O
monotonic	O
function	O
of	O
size	O
.	O

Electrophoretic	O
separations	O
showed	O
that	O
the	O
dominant	O
mechanism	O
involved	O
the	O
redistribution	O
of	O
mass	O
toward	O
smaller	O
sizes	O
,	O
where	O
the	O
products	O
were	O
almost	O
exclusively	O
previously	O
known	O
cluster	O
sizes	O
.	O

Optical	O
absorption	O
spectra	O
showed	O
that	O
the	O
smaller	O
clusters	O
evolved	O
toward	O
the	O
two	O
most	O
stable	O
cluster	O
sizes	O
.	O

The	O
net	O
surface	O
charge	O
was	O
found	O
to	O
play	O
an	O
important	O
role	O
in	O
cluster	O
stabilization	O
although	O
charge	O
screening	O
had	O
no	O
effect	O
on	O
stability	O
,	O
contrary	O
to	O
DLVO	O
theory	O
.	O

The	O
decay	O
mechanism	O
was	O
found	O
to	O
involve	O
the	O
loss	O
of	O
Ag	B
(	I
+	I
)	I
ions	O
and	O
silver	B
glutathionates	I
.	O

Clusters	O
could	O
be	O
stabilized	O
by	O
the	O
addition	O
of	O
Ag	B
(	I
+	I
)	I
ions	O
and	O
destabilized	O
by	O
either	O
the	O
addition	O
of	O
glutathione	B
or	O
the	O
removal	O
of	O
Ag	B
(	I
+	I
)	I
ions	O
.	O

Clusters	O
were	O
also	O
found	O
to	O
be	O
most	O
stable	O
in	O
near	O
neutral	O
pH	O
,	O
where	O
they	O
had	O
a	O
net	O
negative	O
surface	O
charge	O
.	O

These	O
results	O
provide	O
new	O
mechanistic	O
insights	O
into	O
the	O
control	O
of	O
post	O
-	O
synthesis	O
stability	O
and	O
chemical	O
decay	O
of	O
magic	O
-	O
number	O
metal	O
clusters	O
,	O
which	O
could	O
be	O
used	O
to	O
develop	O
design	O
principles	O
for	O
synthesizing	O
specific	O
cluster	O
species	O
.	O

The	O
role	O
of	O
cortisol	B
and	O
psychopathy	O
in	O
the	O
cycle	O
of	O
violence	O
.	O

RATIONALE	O
:	O
Child	O
abuse	O
and	O
neglect	O
are	O
universal	O
risk	O
factors	O
for	O
delinquency	O
,	O
violence	O
,	O
and	O
aggression	O
;	O
this	O
phenomenon	O
is	O
known	O
as	O
the	O
cycle	O
of	O
violence	O
.	O

Additional	O
factors	O
-	O
psychopathy	O
,	O
impulsiveness	O
,	O
and	O
disruptions	O
in	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
(	O
HPA	O
)	O
axis	O
-	O
play	O
a	O
role	O
in	O
aggressive	O
behavior	O
but	O
have	O
rarely	O
been	O
examined	O
in	O
the	O
same	O
conceptual	O
and	O
experimental	O
framework	O
.	O

OBJECTIVES	O
:	O
We	O
sought	O
to	O
examine	O
the	O
above	O
-	O
mentioned	O
risk	O
factors	O
for	O
aggression	O
in	O
a	O
prospective	O
study	O
employing	O
psychopharmacologic	O
and	O
psychometric	O
techniques	O
.	O

METHODS	O
:	O
Sixty	O
-	O
seven	O
adult	O
participants	O
were	O
given	O
an	O
acute	O
dose	O
of	O
20	O
mg	O
cortisol	B
in	O
a	O
placebo	O
-	O
controlled	O
,	O
within	O
-	O
subject	O
,	O
counter	O
-	O
balanced	O
dosing	O
design	O
.	O

Salivary	O
cortisol	B
was	O
measured	O
at	O
baseline	O
and	O
at	O
regular	O
intervals	O
across	O
a	O
5	O
h	O
testing	O
period	O
.	O

Following	O
dosing	O
,	O
state	O
-	O
aggressive	O
behavior	O
was	O
measured	O
by	O
a	O
laboratory	O
task	O
,	O
the	O
Point	O
-	O
Subtraction	O
Aggression	O
Paradigm	O
.	O

History	O
of	O
child	O
abuse	O
/	O
neglect	O
,	O
psychopathy	O
,	O
impulsivity	O
,	O
and	O
a	O
trait	O
measure	O
of	O
aggression	O
were	O
assessed	O
through	O
self	O
-	O
report	O
questionnaires	O
.	O

RESULTS	O
:	O
Using	O
multiple	O
regression	O
,	O
a	O
model	O
including	O
abuse	O
/	O
neglect	O
,	O
psychopathy	O
,	O
impulsivity	O
,	O
and	O
baseline	O
cortisol	B
explained	O
58	O
%	O
of	O
the	O
variance	O
in	O
trait	O
aggression	O
and	O
26	O
%	O
of	O
the	O
variance	O
in	O
state	O
aggression	O
.	O

Abuse	O
/	O
neglect	O
predicted	O
diminished	O
HPA	O
-	O
axis	O
reactivity	O
and	O
HPA	O
-	O
axis	O
reactivity	O
showed	O
a	O
trend	O
toward	O
predicting	O
state	O
and	O
trait	O
aggression	O
,	O
although	O
it	O
was	O
not	O
a	O
significant	O
mediating	O
variable	O
between	O
abuse	O
/	O
neglect	O
and	O
aggression	O
.	O

CONCLUSIONS	O
:	O
The	O
results	O
indicate	O
that	O
child	O
maltreatment	O
,	O
psychopathy	O
and	O
HPA	O
-	O
axis	O
reactivity	O
interact	O
to	O
provide	O
a	O
confluence	O
over	O
aggressive	O
behavior	O
,	O
and	O
intervention	O
efforts	O
need	O
to	O
consider	O
all	O
these	O
factors	O
.	O

Manganese	B
supplementation	O
protects	O
against	O
diet	O
-	O
induced	O
diabetes	O
in	O
wild	O
type	O
mice	O
by	O
enhancing	O
insulin	O
secretion	O
.	O

Mitochondrial	O
dysfunction	O
is	O
both	O
a	O
contributing	O
mechanism	O
and	O
complication	O
of	O
diabetes	O
,	O
and	O
oxidative	O
stress	O
contributes	O
to	O
that	O
dysfunction	O
.	O

Mitochondrial	O
manganese	B
-	O
superoxide	B
dismutase	O
(	O
MnSOD	O
)	O
is	O
a	O
metalloenzyme	O
that	O
provides	O
antioxidant	O
protection	O
.	O

We	O
have	O
previously	O
shown	O
in	O
a	O
mouse	O
model	O
of	O
hereditary	O
iron	O
overload	O
that	O
cytosolic	O
iron	B
levels	O
affected	O
mitochondrial	O
manganese	B
availability	O
,	O
MnSOD	B
activity	O
,	O
and	O
insulin	O
secretion	O
.	O

We	O
therefore	O
sought	O
to	O
determine	O
the	O
metallation	O
status	O
of	O
MnSOD	B
in	O
wild	O
-	O
type	O
mice	O
and	O
whether	O
altering	O
that	O
status	O
affected	O
	O
-	O
cell	O
function	O
.	O

129	O
/	O
SvEVTac	O
mice	O
given	O
supplemental	O
manganese	O
exhibited	O
a	O
73	O
%	O
increase	O
in	O
hepatic	O
MnSOD	B
activity	O
and	O
increased	O
metallation	O
of	O
MnSOD	B
.	O

To	O
determine	O
whether	O
manganese	O
supplementation	O
offered	O
glucose	B
homeostasis	O
under	O
a	O
situation	O
of	O
	O
-	O
cell	O
stress	O
,	O
we	O
challenged	O
C57BL	O
/	O
6J	O
mice	O
,	O
which	O
are	O
more	O
susceptible	O
to	O
diet	O
-	O
induced	O
diabetes	O
,	O
with	O
a	O
high	O
-	O
fat	O
diet	O
for	O
12	O
weeks	O
.	O

Manganese	B
was	O
supplemented	O
or	O
not	O
for	O
the	O
final	O
8	O
weeks	O
on	O
that	O
diet	O
,	O
after	O
which	O
we	O
examined	O
glucose	B
tolerance	O
and	O
the	O
function	O
of	O
isolated	O
islets	O
.	O

Liver	O
mitochondria	O
from	O
manganese	B
-	O
injected	O
C57BL	O
/	O
6J	O
mice	O
had	O
similar	O
increases	O
in	O
MnSOD	B
activity	O
(	O
81	O
%	O
)	O
and	O
metallation	O
as	O
were	O
seen	O
in	O
129	O
/	O
SvEVTac	O
mice	O
.	O

The	O
manganese	B
-	O
treated	O
group	O
fed	O
high	O
fat	O
had	O
improved	O
glucose	B
tolerance	O
(	O
24	O
%	O
decrease	O
in	O
fasting	O
glucose	B
and	O
41	O
%	O
decrease	O
in	O
area	O
under	O
the	O
glucose	B
curve	O
)	O
,	O
comparable	O
with	O
mice	O
on	O
normal	O
chow	O
and	O
increased	O
serum	O
insulin	O
levels	O
.	O

Isolated	O
islets	O
from	O
the	O
manganese	B
-	O
treated	O
group	O
exhibited	O
improved	O
insulin	O
secretion	O
,	O
decreased	O
lipid	O
peroxidation	O
,	O
and	O
improved	O
mitochondrial	O
function	O
.	O

In	O
conclusion	O
,	O
MnSOD	B
metallation	O
and	O
activity	O
can	O
be	O
augmented	O
with	O
manganese	B
supplementation	O
in	O
normal	O
mice	O
on	O
normal	O
chow	O
,	O
and	O
manganese	B
treatment	O
can	O
increase	O
insulin	O
secretion	O
to	O
improve	O
glucose	B
tolerance	O
under	O
conditions	O
of	O
dietary	O
stress	O
.	O

Enter	O
the	O
matrix	O
:	O
shape	O
,	O
signal	O
and	O
superhighway	O
.	O

Mammalian	O
skeletal	O
muscle	O
is	O
notable	O
for	O
both	O
its	O
highly	O
ordered	O
biophysical	O
structure	O
and	O
its	O
regenerative	O
capacity	O
following	O
trauma	O
.	O

Critical	O
to	O
both	O
of	O
these	O
features	O
is	O
the	O
specialized	O
muscle	O
extracellular	O
matrix	O
,	O
comprising	O
both	O
the	O
multiple	O
concentric	O
sheaths	O
of	O
connective	O
tissue	O
surrounding	O
structural	O
units	O
from	O
single	O
myofibers	O
to	O
whole	O
muscles	O
and	O
the	O
dense	O
interstitial	O
matrix	O
that	O
occupies	O
the	O
space	O
between	O
them	O
.	O

Extracellular	O
matrix	O
-	O
dependent	O
interactions	O
affect	O
all	O
activities	O
of	O
the	O
resident	O
muscle	O
stem	O
cell	O
population	O
(	O
the	O
satellite	O
cells	O
)	O
,	O
from	O
maintenance	O
of	O
quiescence	O
and	O
stem	O
cell	O
potential	O
to	O
the	O
regulation	O
of	O
proliferation	O
and	O
differentiation	O
.	O

This	O
review	O
focuses	O
on	O
the	O
role	O
of	O
the	O
extracellular	O
matrix	O
in	O
muscle	O
regeneration	O
,	O
with	O
a	O
particular	O
emphasis	O
on	O
regulation	O
of	O
satellite	O
-	O
cell	O
activity	O
.	O

3'-R	B
/	I
S	I
-	I
Hydroxyvoacamine	I
,	O
a	O
potent	O
acetylcholinesterase	O
inhibitor	O
from	O
Tabernaemontana	O
divaricata	O
.	O

Guided	O
by	O
the	O
acetylcholinesterase	O
inhibiting	O
activity	O
,	O
the	O
bisindole	B
alkaloid	I
3'-R	B
/	I
S	I
-	I
hydroxyvoacamine	I
was	O
isolated	O
from	O
a	O
stem	O
extract	O
of	O
Tabernaemontana	O
divaricata	O
,	O
a	O
plant	O
used	O
in	O
Thailand	O
in	O
traditional	O
rejuvenation	O
remedies	O
for	O
improving	O
the	O
memory	O
.	O

The	O
structure	O
of	O
the	O
alkaloid	O
was	O
elucidated	O
by	O
extensive	O
use	O
of	O
NMR	O
spectroscopy	O
and	O
the	O
complete	O
assignment	O
of	O
the	O
(	B
1	I
)	I
H	I
and	O
(	B
13	I
)	I
C	I
NMR	O
spectra	O
is	O
reported	O
.	O

The	O
alkaloid	O
acted	O
as	O
a	O
non	O
-	O
competitive	O
inhibitor	O
against	O
AChE	O
with	O
an	O
IC50	O
value	O
of	O
7.001.99M.	O
An	O
HPLC	O
method	O
was	O
developed	O
for	O
the	O
quantitative	O
analysis	O
of	O
the	O
AChE	O
inhibitor	O
.	O

It	O
suggested	O
that	O
there	O
was	O
12.4	O
%	O
(	O
w	O
/	O
w	O
)	O
of	O
3'-R	B
/	I
S	I
-	I
hydroxyvoacamine	I
in	O
the	O
alkaloid	O
enriched	O
fraction	O
of	O
T.	O
divaricata	O
stem	O
.	O

Fibroblast	O
-	O
mediated	O
drug	O
resistance	O
in	O
cancer	O
.	O

Tumor	O
progression	O
relies	O
upon	O
the	O
dynamic	O
interaction	O
of	O
cancer	O
cells	O
with	O
host	O
fibroblasts	O
,	O
endothelial	O
cells	O
,	O
immune	O
cells	O
and	O
components	O
of	O
the	O
extracellular	O
matrix	O
,	O
collectively	O
known	O
as	O
the	O
tumor	O
microenvironment	O
.	O

Despite	O
this	O
,	O
relatively	O
little	O
is	O
known	O
about	O
how	O
normal	O
host	O
cells	O
dictate	O
the	O
response	O
of	O
tumors	O
to	O
anti	O
-	O
cancer	O
therapies	O
.	O

Emerging	O
data	O
suggests	O
that	O
host	O
factors	O
play	O
a	O
critical	O
role	O
in	O
determining	O
risks	O
for	O
tumor	O
progression	O
and	O
decreased	O
therapeutic	O
responses	O
.	O

In	O
particular	O
,	O
recent	O
findings	O
have	O
provided	O
evidence	O
that	O
the	O
tumor	O
microenvironment	O
provides	O
a	O
protective	O
niche	O
that	O
allows	O
minor	O
populations	O
of	O
cancer	O
cells	O
to	O
escape	O
from	O
the	O
cytotoxic	O
effects	O
of	O
radiation	O
,	O
chemotherapy	O
and	O
targeted	O
therapies	O
.	O

In	O
this	O
review	O
we	O
will	O
outline	O
the	O
mechanisms	O
by	O
which	O
tumor	O
cells	O
and	O
host	O
fibroblasts	O
co	O
-	O
operate	O
to	O
drive	O
tumor	O
initiation	O
and	O
progression	O
.	O

In	O
particular	O
,	O
we	O
will	O
focus	O
upon	O
the	O
mechanisms	O
by	O
which	O
tumor	O
cells	O
exposed	O
to	O
targeted	O
therapies	O
co	O
-	O
opt	O
the	O
host	O
leading	O
to	O
therapeutic	O
escape	O
and	O
resistance	O
.	O

We	O
will	O
end	O
by	O
discussing	O
the	O
idea	O
that	O
long	O
-	O
term	O
responses	O
to	O
targeted	O
anticancer	O
therapies	O
will	O
only	O
be	O
achieved	O
through	O
strategies	O
that	O
target	O
both	O
the	O
tumor	O
and	O
host	O
.	O

Characterization	O
of	O
the	O
mouse	O
promoter	O
region	O
of	O
the	O
acyl	B
-	I
CoA	I
synthetase	O
4	O
gene	O
:	O
role	O
of	O
Sp1	O
and	O
CREB	O
.	O

Acyl	B
-	I
CoA	I
synthetase	O
4	O
(	O
Acsl4	O
)	O
is	O
involved	O
in	O
several	O
cellular	O
functions	O
including	O
steroidogenesis	O
,	O
synaptic	O
development	O
and	O
cancer	O
metastasis	O
.	O

Although	O
the	O
expression	O
of	O
Acsl4	O
seems	O
to	O
be	O
regulated	O
by	O
tissue-	O
and	O
cell	O
-	O
specific	O
factors	O
as	O
well	O
as	O
pituitary	O
hormones	O
and	O
growth	O
factors	O
,	O
the	O
transcriptional	O
mechanisms	O
involved	O
remain	O
unknown	O
.	O

We	O
demonstrated	O
hCG	O
and	O
cAMP	B
regulation	O
of	O
Acsl4	O
mRNA	O
in	O
mouse	O
steroidogenic	O
MA-10	O
Leydig	O
cells	O
.	O

We	O
characterized	O
the	O
transcription	O
initiation	O
site	O
and	O
promoter	O
of	O
the	O
Acsl4	O
mouse	O
gene	O
and	O
identified	O
three	O
alternative	O
splice	O
variants	O
present	O
in	O
MA-10	O
cells	O
.	O

Sequence	O
analysis	O
of	O
a	O
1.5-kb	O
fragment	O
of	O
the	O
Acsl4	O
promoter	O
revealed	O
the	O
absence	O
of	O
a	O
TATA	O
box	O
and	O
the	O
presence	O
of	O
many	O
putative	O
binding	O
sites	O
for	O
transcription	O
factors	O
including	O
Sp1	O
and	O
CREB	O
.	O

Functional	O
characterization	O
revealed	O
that	O
the	O
specificity	O
protein	O
/	O
Krppel	O
-	O
like	O
factor	O
Sp1	O
binding	O
site	O
in	O
the	O
proximal	O
promoter	O
is	O
involved	O
in	O
basal	O
activity	O
and	O
that	O
the	O
cAMP	B
response	O
element	O
-	O
binding	O
site	O
is	O
involved	O
in	O
cAMP	B
stimulation	O
of	O
Acsl4	O
transcription	O
.	O

Synthesis	O
and	O
biological	O
evaluation	O
of	O
thieno	B
[	I
2',3':4,5	I
]	I
pyrimido	I
[	I
1,2-b	I
]	I
[	I
1,2,4	I
]	I
triazines	I
and	O
thieno	B
[	I
2,3-d	I
]	I
[	I
1,2,4	I
]	I
triazolo	I
[	I
1,5-a	I
]	I
pyrimidines	I
as	O
anti	O
-	O
inflammatory	O
and	O
analgesic	O
agents	O
.	O

A	O
new	O
series	O
of	O
thieno	B
[	I
2',3':4,5	I
]	I
pyrimido	I
[	I
1,2-b	I
]	I
[	I
1,2,4	I
]	I
triazines	I
and	O
thieno	B
[	I
2,3-d	I
]	I
[	I
1,2,4	I
]	I
triazolo	I
[	I
1,5-a	I
]	I
pyrimidines	I
was	O
synthesized	O
.	O

The	O
newly	O
synthesized	O
compounds	O
were	O
evaluated	O
for	O
their	O
anti	O
-	O
inflammatory	O
and	O
analgesic	O
activity	O
using	O
diclofenac	B
Na	I
as	O
a	O
reference	O
standard	O
.	O

Additionally	O
,	O
the	O
ulcerogenic	O
effects	O
and	O
acute	O
toxicity	O
(	O
ALD50	O
)	O
values	O
of	O
the	O
active	O
compounds	O
were	O
also	O
determined	O
.	O

In	O
general	O
,	O
the	O
thieno	B
[	I
2,3-d	I
]	I
[	I
1,2,4	I
]	I
triazolo	I
[	I
1,5-a	I
]	I
pyrimidine	I
derivatives	O
exhibited	O
better	O
biological	O
activities	O
than	O
the	O
thieno	B
[	I
2',3':4,5	I
]	I
pyrimido	I
[	I
1,2-b	I
]	I
[	I
1,2,4	I
]	I
triazines	I
.	O

Collectively	O
,	O
the	O
thienotriazolopyrimidine	B
derivatives	O
9	O
,	O
13	O
and	O
14a	O
were	O
proved	O
to	O
display	O
distinctive	O
anti	O
-	O
inflammatory	O
activity	O
at	O
the	O
acute	O
and	O
subacute	O
models	O
as	O
well	O
as	O
good	O
analgesic	O
profile	O
with	O
a	O
delayed	O
onset	O
of	O
action	O
.	O

Moreover	O
,	O
they	O
revealed	O
good	O
gastrointestinal	O
safety	O
profile	O
and	O
are	O
well	O
tolerated	O
by	O
experimental	O
animals	O
with	O
high	O
safety	O
margin	O
(	O
ALD50	O
>	O
0.3	O
g	O
/	O
kg	O
)	O
.	O

Molecular	O
insight	O
into	O
the	O
inhibition	O
mechanism	O
of	O
cyrtominetin	B
to	O
	O
-	O
hemolysin	O
by	O
molecular	O
dynamics	O
simulation	O
.	O

The	O
protein	O
	O
-	O
hemolysin	O
(	O
	O
-	O
HL	O
)	O
is	O
a	O
self	O
-	O
assembling	O
exotoxin	O
that	O
binds	O
to	O
the	O
membrane	O
of	O
a	O
susceptible	O
host	O
cell	O
.	O

In	O
this	O
paper	O
,	O
experimental	O
studies	O
show	O
that	O
cyrtominetin	B
(	O
CTM	B
)	O
can	O
inhibit	O
the	O
hemolytic	O
activity	O
of	O
	O
-	O
HL	O
.	O

To	O
understand	O
how	O
CTM	B
can	O
affect	O
hemolytic	O
activity	O
,	O
molecular	O
dynamics	O
simulations	O
were	O
carried	O
out	O
for	O
	O
-	O
HL	O
-	O
CTM	B
complex	O
and	O
these	O
results	O
were	O
compared	O
with	O
the	O
crystal	O
structure	O
of	O
monomeric	O
	O
-	O
HL	O
.	O

With	O
this	O
approach	O
,	O
the	O
analysis	O
revealed	O
that	O
the	O
inhibition	O
of	O
CTM	B
involves	O
CTM	B
directly	O
binding	O
to	O
	O
-	O
HL	O
.	O

Due	O
to	O
the	O
binding	O
of	O
CTM	B
,	O
the	O
conformation	O
of	O
the	O
critical	O
"	O
Loop	O
"	O
region	O
was	O
restrained	O
.	O

This	O
mechanism	O
was	O
confirmed	O
by	O
the	O
experimental	O
data	O
.	O

These	O
findings	O
indicate	O
that	O
CTM	B
hinders	O
the	O
lysis	O
activity	O
of	O
	O
-	O
HL	O
through	O
a	O
novel	O
mechanism	O
.	O

Influence	O
of	O
environmentally	O
relevant	O
concentrations	O
of	O
vinclozolin	B
on	O
quality	O
,	O
DNA	O
integrity	O
,	O
and	O
antioxidant	O
responses	O
of	O
sterlet	O
Acipenser	O
ruthenus	O
spermatozoa	O
.	O

The	O
effects	O
of	O
vinclozolin	B
(	O
VIN	B
)	O
,	O
an	O
anti	O
-	O
androgenic	O
fungicide	O
,	O
on	O
quality	O
,	O
oxidative	O
stress	O
,	O
DNA	O
integrity	O
,	O
and	O
ATP	B
level	O
of	O
sterlet	O
(	O
Acipenser	O
ruthenus	O
)	O
spermatozoa	O
were	O
investigated	O
in	O
vitro	O
.	O

Fish	O
spermatozoa	O
were	O
incubated	O
with	O
different	O
concentrations	O
of	O
vinclozolin	B
(	O
0.5	O
,	O
2	O
,	O
10	O
,	O
15	O
,	O
20	O
and	O
50g	O
/	O
l	O
)	O
for	O
2h	O
.	O

A	O
dose	O
-	O
dependent	O
reduction	O
in	O
spermatozoa	O
motility	O
and	O
velocity	O
was	O
observed	O
at	O
concentrations	O
of	O
2	O
-	O
50g	O
/	O
l	O
.	O

A	O
dramatic	O
increase	O
in	O
DNA	O
fragmentation	O
was	O
recorded	O
at	O
concentrations	O
10g	O
/	O
l	O
and	O
above	O
.	O

After	O
2h	O
exposure	O
at	O
higher	O
test	O
concentrations	O
(	O
10	O
-	O
50g	O
/	O
l	O
)	O
,	O
oxidative	O
stress	O
was	O
apparent	O
,	O
as	O
reflected	O
by	O
significantly	O
higher	O
levels	O
of	O
protein	O
and	O
lipid	O
oxidation	O
and	O
significantly	O
greater	O
superoxide	B
dismutase	O
activity	O
.	O

Intracellular	O
ATP	B
content	O
of	O
spermatozoa	O
decreased	O
with	O
increasing	O
concentrations	O
of	O
VIN	B
.	O

The	O
results	O
demonstrated	O
that	O
VIN	B
can	O
induce	O
reactive	O
oxygen	B
species	O
stress	O
in	O
fish	O
spermatozoa	O
,	O
which	O
could	O
impair	O
the	O
sperm	O
quality	O
,	O
DNA	O
integrity	O
,	O
ATP	B
content	O
,	O
and	O
the	O
antioxidant	O
defense	O
system	O
.	O

Elimination	O
and	O
utilization	O
of	O
oxidized	O
guanine	B
nucleotides	I
in	O
the	O
synthesis	O
of	O
RNA	O
and	O
its	O
precursors	O
.	O

Reactive	O
oxygen	B
species	O
are	O
produced	O
as	O
side	O
products	O
of	O
oxygen	B
utilization	O
and	O
can	O
lead	O
to	O
the	O
oxidation	O
of	O
nucleic	O
acids	O
and	O
their	O
precursor	O
nucleotides	B
.	O

Among	O
the	O
various	O
oxidized	O
bases	O
,	O
8-oxo-7,8-dihydroguanine	B
seems	O
to	O
be	O
the	O
most	O
critical	O
during	O
the	O
transfer	O
of	O
genetic	O
information	O
because	O
it	O
can	O
pair	O
with	O
both	O
cytosine	B
and	O
adenine	B
.	O

During	O
the	O
de	O
novo	O
synthesis	O
of	O
guanine	B
nucleotides	I
,	O
GMP	B
is	O
formed	O
first	O
,	O
and	O
it	O
is	O
converted	O
to	O
GDP	B
by	O
guanylate	B
kinase	O
.	O

This	O
enzyme	O
hardly	O
acts	O
on	O
an	O
oxidized	O
form	O
of	O
GMP	B
(	O
8-oxo	B
-	I
GMP	I
)	O
formed	O
by	O
the	O
oxidation	O
of	O
GMP	B
or	O
by	O
the	O
cleavage	O
of	O
8-oxo	B
-	I
GDP	I
and	O
8-oxo	B
-	I
GTP	I
by	O
MutT	O
protein	O
.	O

Although	O
the	O
formation	O
of	O
8-oxo	B
-	I
GDP	I
from	O
8-oxo	B
-	I
GMP	I
is	O
thus	O
prevented	O
,	O
8-oxo	B
-	I
GDP	I
itself	O
may	O
be	O
produced	O
by	O
the	O
oxidation	O
of	O
GDP	B
by	O
reactive	O
oxygen	B
species	O
.	O

The	O
8-oxo	B
-	I
GDP	I
thus	O
formed	O
can	O
be	O
converted	O
to	O
8-oxo	B
-	I
GTP	I
because	O
nucleoside	B
-	I
diphosphate	I
kinase	O
and	O
adenylate	B
kinase	O
,	O
both	O
of	O
which	O
catalyze	O
the	O
conversion	O
of	O
GDP	B
to	O
GTP	B
,	O
do	O
not	O
discriminate	O
8-oxo	B
-	I
GDP	I
from	O
normal	O
GDP	B
.	O

The	O
8-oxo	B
-	I
GTP	I
produced	O
in	O
this	O
way	O
and	O
by	O
the	O
oxidation	O
of	O
GTP	B
can	O
be	O
used	O
for	O
RNA	O
synthesis	O
.	O

This	O
misincorporation	O
is	O
prevented	O
by	O
MutT	O
protein	O
,	O
which	O
has	O
the	O
potential	O
to	O
cleave	O
8-oxo	B
-	I
GTP	I
as	O
well	O
as	O
8-oxo	B
-	I
GDP	I
to	O
8-oxo	B
-	I
GMP	I
.	O

When	O
(	B
14	I
)	I
C	I
-	I
labeled	I
8-oxo	I
-	I
GTP	I
was	O
applied	O
to	O
CaCl2-permeabilized	B
cells	O
of	O
a	O
mutT	O
(	O
-	O
)	O
mutant	O
strain	O
,	O
it	O
could	O
be	O
incorporated	O
into	O
RNA	O
at	O
4	O
%	O
of	O
the	O
rate	O
for	O
GTP	B
.	O

Escherichia	O
coli	O
cells	O
appear	O
to	O
possess	O
mechanisms	O
to	O
prevent	O
misincorporation	O
of	O
8-oxo-7,8-dihydroguanine	B
into	O
RNA	O
.	O

Bradykinin	B
modulates	O
spontaneous	O
nerve	O
growth	O
factor	O
production	O
and	O
stretch	O
-	O
induced	O
ATP	B
release	O
in	O
human	O
urothelium	O
.	O

The	O
urothelium	O
plays	O
a	O
crucial	O
role	O
in	O
integrating	O
urinary	O
bladder	O
sensory	O
outputs	O
,	O
responding	O
to	O
mechanical	O
stress	O
and	O
chemical	O
stimulation	O
by	O
producing	O
several	O
diffusible	O
mediators	O
,	O
including	O
ATP	B
and	O
,	O
possibly	O
,	O
neurotrophin	O
nerve	O
growth	O
factor	O
(	O
NGF	O
)	O
.	O

Such	O
urothelial	O
mediators	O
activate	O
underlying	O
afferents	O
and	O
thus	O
may	O
contribute	O
to	O
normal	O
bladder	O
sensation	O
and	O
possibly	O
to	O
the	O
development	O
of	O
bladder	O
overactivity	O
.	O

The	O
muscle	O
-	O
contracting	O
and	O
pain	O
-	O
inducing	O
peptide	O
bradykinin	B
is	O
produced	O
in	O
various	O
inflammatory	O
and	O
non	O
-	O
inflammatory	O
pathologies	O
associated	O
with	O
bladder	O
overactivity	O
,	O
but	O
the	O
effect	O
of	O
bradykinin	B
on	O
human	O
urothelial	O
function	O
has	O
not	O
yet	O
been	O
characterized	O
.	O

The	O
human	O
urothelial	O
cell	O
line	O
UROtsa	O
expresses	O
mRNA	O
for	O
both	O
B1	O
and	O
B2	O
subtypes	O
of	O
bradykinin	B
receptors	O
,	O
as	O
determined	O
by	O
real	O
-	O
time	O
PCR	O
.	O

Bradykinin	B
concentration	O
-	O
dependently	O
(	O
pEC50=8.3	O
,	O
Emax	O
4434277nM	O
)	O
increased	O
urothelial	O
intracellular	O
calcium	O
levels	O
and	O
induced	O
phosphorylation	O
of	O
the	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
ERK1	O
/	O
2	O
.	O

Activation	O
of	O
both	O
bradykinin	B
-	O
induced	O
signaling	O
pathways	O
was	O
completely	O
abolished	O
by	O
the	O
B2	O
antagonist	O
icatibant	O
(	O
1M	O
)	O
,	O
but	O
not	O
the	O
B1	O
antagonist	O
R715	O
(	O
1M	O
)	O
.	O

Bradykinin	B
-	O
induced	O
(	O
100nM	O
)	O
B2	O
receptor	O
activation	O
markedly	O
increased	O
(	O
19213	O
%	O
of	O
control	O
levels	O
)	O
stretch	O
-	O
induced	O
ATP	B
release	O
from	O
UROtsa	O
in	O
hypotonic	O
medium	O
,	O
the	O
effect	O
being	O
dependent	O
on	O
intracellular	O
calcium	O
elevations	O
.	O

UROtsa	O
cells	O
also	O
expressed	O
mRNA	O
and	O
protein	O
for	O
NGF	O
and	O
spontaneously	O
released	O
NGF	O
to	O
the	O
medium	O
in	O
the	O
course	O
of	O
hours	O
(	O
11.51.4pgNGF	O
/	O
mgprotein	O
/	O
h	O
)	O
.	O

Bradykinin	B
increased	O
NGF	O
mRNA	O
expression	O
and	O
accelerated	O
urothelial	O
NGF	O
release	O
to	O
1275	O
%	O
in	O
a	O
protein	O
kinase	O
C-	O
and	O
ERK1	O
/	O
2-dependent	O
manner	O
.	O

Finally	O
,	O
bradykinin	B
up	O
-	O
regulated	O
mRNA	O
for	O
transient	O
-	O
receptor	O
potential	O
vanilloid	O
(	O
TRPV1	O
)	O
sensory	O
ion	O
channel	O
in	O
UROtsa	O
.	O

In	O
conclusion	O
,	O
we	O
show	O
that	O
bradykinin	B
represents	O
a	O
versatile	O
modulator	O
of	O
human	O
urothelial	O
phenotype	O
,	O
accelerating	O
stretch	O
-	O
induced	O
ATP	B
release	O
,	O
spontaneous	O
release	O
of	O
NGF	O
,	O
as	O
well	O
as	O
expression	O
of	O
sensory	O
ion	O
channel	O
TRPV1	O
.	O

Bradykinin	B
-	O
induced	O
changes	O
in	O
urothelial	O
sensory	O
function	O
might	O
contribute	O
to	O
the	O
development	O
of	O
bladder	O
dysfunction	O
.	O

3D	O
Organotypic	O
Cultures	O
of	O
Human	O
HepaRG	O
Cells	O
:	O

A	O
Tool	O
for	O
In	O
Vitro	O
Toxicity	O
Studies	O
.	O

Drug	O
-	O
induced	O
human	O
hepatotoxicity	O
is	O
difficult	O
to	O
predict	O
using	O
the	O
current	O
in	O
vitro	O
systems	O
.	O

In	O
this	O
study	O
,	O
long	O
-	O
term	O
3D	O
organotypic	O
cultures	O
of	O
the	O
human	O
hepatoma	O
HepaRG	O
cell	O
line	O
were	O
prepared	O
using	O
a	O
high	O
-	O
throughput	O
hanging	O
drop	O
method	O
.	O

The	O
organotypic	O
cultures	O
were	O
maintained	O
for	O
3	O
weeks	O
and	O
assessed	O
for	O
(	O
1	O
)	O
liver	O
specific	O
functions	O
,	O
including	O
phase	O
I	O
enzyme	O
and	O
transporter	O
activities	O
,	O
(	O
2	O
)	O
expression	O
of	O
liver	O
-	O
specific	O
proteins	O
,	O
and	O
(	O
3	O
)	O
responses	O
to	O
three	O
drugs	O
(	O
acetaminophen	B
,	O
troglitazone	B
,	O
and	O
rosiglitazone	B
)	O
.	O

Our	O
results	O
show	O
that	O
the	O
organotypic	O
cultures	O
maintain	O
high	O
liver	O
-	O
specific	O
functionality	O
during	O
3	O
weeks	O
of	O
culture	O
.	O

The	O
immunohistochemistry	O
analyses	O
illustrate	O
that	O
the	O
organotypic	O
cultures	O
express	O
liver	O
-	O
specific	O
markers	O
such	O
as	O
albumin	O
,	O
CYP3A4	O
,	O
CYP2E1	O
,	O
and	O
MRP-2	O
throughout	O
the	O
cultivation	O
period	O
.	O

Accordingly	O
,	O
the	O
production	O
rates	O
of	O
albumin	O
and	O
glucose	B
,	O
as	O
well	O
as	O
CYP2E1	O
activity	O
,	O
were	O
significantly	O
higher	O
in	O
the	O
3D	O
versus	O
the	O
2D	O
cultures	O
.	O

Toxicity	O
studies	O
show	O
that	O
the	O
organotypic	O
cultures	O
are	O
more	O
sensitive	O
to	O
acetaminophen-	B
and	O
rosiglitazone	B
-	O
induced	O
toxicity	O
but	O
less	O
sensitive	O
to	O
troglitazone	B
-	O
induced	O
toxicity	O
than	O
the	O
2D	O
cultures	O
.	O

Furthermore	O
,	O
the	O
EC50	O
value	O
(	O
2.7mM	O
)	O
for	O
acetaminophen	B
on	O
the	O
3D	O
cultures	O
was	O
similar	O
to	O
in	O
vivo	O
toxicity	O
.	O

In	O
summary	O
,	O
the	O
results	O
from	O
our	O
study	O
suggest	O
that	O
the	O
3D	O
organotypic	O
HepaRG	O
culture	O
is	O
a	O
promising	O
in	O
vitro	O
tool	O
for	O
more	O
accurate	O
assessment	O
of	O
acute	O
and	O
also	O
possibly	O
for	O
chronic	O
drug	O
-	O
induced	O
hepatotoxicity	O
.	O

Mending	O
leaky	O
blood	O
vessels	O
:	O
the	O
angiopoietin	O
-	O
Tie2	O
pathway	O
in	O
sepsis	O
.	O

Sepsis	O
is	O
a	O
systemic	O
inflammatory	O
response	O
to	O
infection	O
.	O

A	O
common	O
end	O
-	O
feature	O
,	O
these	O
patients	O
regularly	O
suffer	O
from	O
is	O
the	O
so	O
-	O
called	O
multiple	O
organ	O
dysfunction	O
syndrome	O
,	O
an	O
often	O
fatal	O
consequence	O
of	O
organ	O
hypoperfusion	O
,	O
coagulopathy	O
,	O
immune	O
dysregulation	O
,	O
and	O
mitochondrial	O
dysfunction	O
.	O

Microvascular	O
dysfunction	O
critically	O
contributes	O
to	O
the	O
morbidity	O
and	O
mortality	O
of	O
this	O
disease	O
.	O

The	O
angiopoietin	O
(	O
Angpt	O
)	O
/	O
Tie2	O
system	O
consists	O
of	O
the	O
transmembrane	O
endothelial	O
tyrosine	B
kinase	O
Tie2	O
and	O
its	O
circulating	O
ligands	O
(	O
Angpt-1	O
,	O
-2	O
,	O
and	O
-3	O
/	O
4	O
)	O
.	O

The	O
balance	O
between	O
the	O
canonical	O
agonist	O
Angpt-1	O
and	O
its	O
competitive	O
inhibitor	O
,	O
Angpt-2	O
,	O
regulates	O
basal	O
endothelial	O
barrier	O
function	O
and	O
the	O
leakage	O
and	O
vascular	O
inflammation	O
that	O
develop	O
in	O
response	O
to	O
pathogens	O
and	O
cytokines	O
.	O

Here	O
we	O
summarize	O
recent	O
work	O
in	O
mice	O
and	O
men	O
to	O
highlight	O
the	O
therapeutic	O
potential	O
in	O
this	O
pathway	O
to	O
prevent	O
or	O
even	O
reverse	O
microvascular	O
dysfunction	O
in	O
this	O
deadly	O
disease	O
.	O

Structural	O
Modifications	O
to	O
Tetrahydropyridine-3-carboxylate	B
Esters	I
en	O
Route	O
to	O
the	O
Discovery	O
of	O
M	O
(	O
5	O
)	O
-Preferring	O
Muscarinic	O
Receptor	O
Orthosteric	O
Antagonists	O
.	O

The	O
M	O
(	O
5	O
)	O
muscarinic	O
acetylcholine	B
receptor	O
is	O
suggested	O
to	O
be	O
a	O
potential	O
pharmacotherapeutic	O
target	O
for	O
the	O
treatment	O
of	O
drug	O
abuse	O
.	O

We	O
describe	O
herein	O
the	O
discovery	O
of	O
a	O
series	O
of	O
M	O
(	O
5	O
)	O
-preferring	O
orthosteric	O
antagonists	O
based	O
on	O
the	O
scaffold	O
of	O
1,2,5,6-tetrahydropyridine-3-carboxylic	B
acid	I
.	O

Compound	O
56	O
,	O
the	O
most	O
selective	O
compound	O
in	O
this	O
series	O
,	O
possesses	O
an	O
11-fold	O
selectivity	O
for	O
the	O
M	O
(	O
5	O
)	O
over	O
M	O
(	O
1	O
)	O
receptor	O
and	O
shows	O
little	O
activity	O
at	O
M	O
(	O
2	O
)	O
-M	O
(	O
4	O
)	O
.	O

This	O
compound	O
,	O
although	O
exhibiting	O
modest	O
affinity	O
(	O
K	O
(	O
i	O
)	O
=	O
2.24	O
M	O
)	O
for	O
the	O
[	B
(	I
3	I
)	I
H	I
]	I
N	I
-	I
methylscopolamine	I
binding	O
site	O
on	O
the	O
M	O
(	O
5	O
)	O
receptor	O
,	O
is	O
potent	O
(	O
IC	O
(	O
50	O
)	O
=	O
0.45	O
nM	O
)	O
in	O
inhibiting	O
oxotremorine	B
-	O
evoked	O
[	B
(	I
3	I
)	I
H	I
]	I
DA	I
release	O
from	O
rat	O
striatal	O
slices	O
.	O

Further	O
,	O
a	O
homology	O
model	O
of	O
human	O
M	O
(	O
5	O
)	O
receptor	O
based	O
on	O
the	O
crystal	O
structure	O
of	O
the	O
rat	O
M	O
(	O
3	O
)	O
receptor	O
was	O
constructed	O
,	O
and	O
docking	O
studies	O
of	O
compounds	O
28	O
and	O
56	O
were	O
performed	O
in	O
an	O
attempt	O
to	O
understand	O
the	O
possible	O
binding	O
mode	O
of	O
these	O
novel	O
analogues	O
to	O
the	O
receptor	O
.	O

Bifunctional	O
inhibition	O
of	O
HIV-1	O
reverse	O
transcriptase	O
:	O
a	O
first	O
step	O
in	O
designing	O
a	O
bifunctional	O
triphosphate	B
.	O

The	O
onset	O
of	O
resistance	O
to	O
approved	O
anti	O
-	O
AIDS	O
drugs	O
by	O
HIV	O
necessitates	O
the	O
search	O
for	O
novel	O
inhibitors	O
of	O
HIV-1	O
reverse	O
transcriptase	O
(	O
RT	O
)	O
.	O

Developing	O
single	O
molecular	O
agents	O
concurrently	O
occupying	O
the	O
nucleoside	B
and	O
nonnucleoside	O
binding	O
sites	O
in	O
RT	O
is	O
an	O
intriguing	O
idea	O
but	O
the	O
proof	O
of	O
concept	O
has	O
so	O
far	O
been	O
elusive	O
.	O

As	O
a	O
first	O
step	O
,	O
we	O
describe	O
molecular	O
modeling	O
to	O
guide	O
focused	O
chemical	O
syntheses	O
of	O
conjugates	O
having	O
nucleoside	B
(	O
d4	B
T	I
)	O
and	O
nonnucleoside	O
(	O
TIBO	B
)	O
moieties	O
tethered	O
by	O
a	O
flexible	O
polyethylene	B
glycol	I
(	O
PEG	B
)	O
linker	O
.	O

A	O
triphosphate	B
of	O
d4T-6PEG	B
-	I
TIBO	I
conjugate	O
was	O
successfully	O
synthesized	O
that	O
is	O
recognized	O
as	O
a	O
substrate	O
by	O
HIV-1	O
RT	O
and	O
incorporated	O
into	O
a	O
double	O
-	O
stranded	O
DNA	O
.	O

Differential	O
autophagic	O
cell	O
death	O
under	O
stress	O
with	O
ectopic	O
cytoplasmic	O
and	O
mitochondrial	O
-	O
specific	O
PPP2R2B	O
in	O
human	O
neuroblastoma	O
cells	O
.	O

Protein	O
phosphatase	O
2A	O
is	O
one	O
of	O
four	O
major	O
classes	O
of	O
serine	B
/	O
threonine	B
phosphatases	O
.	O

Overexpression	O
of	O
brain	O
-	O
specific	O
regulatory	O
subunit	O
PPP2R2	O
in	O
neuron	O
cells	O
is	O
implicated	O
in	O
pathogenesis	O
.	O

The	O
alternative	O
splicing	O
of	O
PPP2R2B	O
encodes	O
two	O
isoforms	O
.	O

They	O
are	O
subunit	O
of	O
cytoplasmic	O
specific	O
B1	O
and	O
mitochondria	O
-	O
targeted	O
B2	O
.	O

The	O
two	O
constructs	O
were	O
transfected	O
into	O
human	O
neuroblastoma	O
cells	O
,	O
SK	O
-	O
N	O
-	O
SH	O
,	O
respectively	O
,	O
and	O
the	O
stable	O
clones	O
overexpressing	O
either	O
B1	O
or	O
B2	O
established	O
.	O

We	O
have	O
reported	O
that	O
B2	O
clones	O
are	O
sensitive	O
to	O
reactive	O
oxygen	B
species	O
(	O
ROS	O
)	O
treatment	O
by	O
inducing	O
autophagic	O
cell	O
death	O
.	O

To	O
study	O
more	O
on	O
the	O
onset	O
of	O
neuropathogenesis	O
under	O
strain	O
,	O
both	O
clones	O
were	O
exposed	O
to	O
different	O
environmental	O
stress	O
,	O
e.g.	O
starvation	O
and	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
stress	O
.	O

To	O
learn	O
how	O
PPP2R2B	O
overexpression	O
responds	O
to	O
starvation	O
,	O
cells	O
were	O
incubated	O
in	O
Hank	O
's	O
buffered	O
salt	O
solution	O
of	O
deprived	O
nutrient	O
.	O

Cell	O
death	O
was	O
induced	O
in	O
B1	O
clones	O
after	O
6	O
h	O
starvation	O
,	O
but	O
not	O
in	O
B2	O
clones	O
.	O

The	O
pharmacological	O
inhibitor	O
,	O
Bafilomycin	B
A1	I
,	O
rescued	O
the	O
cell	O
death	O
while	O
suppressing	O
autophagy	O
.	O

On	O
the	O
other	O
hand	O
,	O
to	O
assess	O
how	O
cells	O
respond	O
to	O
ER	O
stress	O
,	O
the	O
cells	O
were	O
treated	O
with	O
0.1	O
M	O
of	O
N	O
-	O
glycosylation	O
inhibitor	O
,	O
tunicamycin	B
(	O
TM	O
)	O
.	O

In	O
contrast	O
with	O
B1	O
,	O
the	O
apoptotic	O
cell	O
death	O
appeared	O
in	O
B2	O
after	O
48	O
h	O
treatment	O
.	O

The	O
formation	O
of	O
autophagolysosome	O
was	O
detected	O
in	O
B2	O
following	O
12	O
h	O
treatment	O
with	O
TM	O
as	O
evidenced	O
by	O
lysotracker	O
and	O
GFP	O
-	O
LC3	O
staining	O
for	O
fluorescence	O
microscopy	O
analysis	O
.	O

The	O
autophagy	O
inhibitor	O
,	O
3-methyladenine	B
,	O
salvaged	O
the	O
final	O
apoptosis	O
.	O

The	O
stable	O
cell	O
lines	O
with	O
ectopically	O
transfected	O
PPP2R2B	O
genes	O
encoding	O
isoforms	O
of	O
brain	O
-	O
specific	O
regulatory	O
subunit	O
exhibit	O
distinct	O
apoptosis	O
under	O
different	O
stressors	O
.	O

The	O
induced	O
autophagic	O
apoptotic	O
cell	O
death	O
is	O
related	O
to	O
mitochondrial	O
membrane	O
potential	O
drop	O
and	O
ROS	O
generation	O
.	O

Disturbance	O
of	O
autophagy	O
alleviates	O
the	O
induced	O
cell	O
death	O
.	O

The	O
results	O
promised	O
a	O
good	O
model	O
for	O
understanding	O
the	O
onset	O
in	O
pathogenesis	O
under	O
stress	O
in	O
neuron	O
cells	O
with	O
aberrant	O
PPP2R2B	O
expression	O
.	O

Absence	O
of	O
edge	O
States	O
in	O
covalently	O
bonded	O
zigzag	O
edges	O
of	O
graphene	B
on	O
ir	B
(	I
111	I
)	I
.	O

The	O
zigzag	O
edges	O
of	O
graphene	B
on	O
Ir	B
(	I
111	I
)	I
are	O
studied	O
by	O
ab	O
initio	O
simulations	O
and	O
low	O
-	O
temperature	O
scanning	O
tunneling	O
spectroscopy	O
,	O
providing	O
information	O
about	O
their	O
structural	O
,	O
electronic	O
,	O
and	O
magnetic	O
properties	O
.	O

No	O
edge	O
state	O
is	O
found	O
to	O
exist	O
,	O
which	O
is	O
explained	O
in	O
terms	O
of	O
the	O
interplay	O
between	O
a	O
strong	O
geometrical	O
relaxation	O
at	O
the	O
edge	O
and	O
a	O
hybridization	O
of	O
the	O
d	O
orbitals	O
of	O
Ir	O
atoms	O
with	O
the	O
graphene	B
orbitals	O
at	O
the	O
edge	O
.	O

Therapeutic	O
potential	O
of	O
neuregulin-1	O
in	O
cardiovascular	O
disease	O
.	O

Neuregulin-1	O
(	O
NRG-1	O
)	O
/	O
ErbB	O
signaling	O
has	O
an	O
indispensable	O
role	O
in	O
cardiac	O
development	O
and	O
in	O
the	O
maintenance	O
of	O
the	O
structural	O
and	O
functional	O
integrity	O
of	O
the	O
human	O
adult	O
heart	O
in	O
health	O
and	O
disease	O
.	O

Several	O
animal	O
studies	O
have	O
now	O
demonstrated	O
the	O
therapeutic	O
effects	O
of	O
NRG-1	O
during	O
acute	O
cardiac	O
injury	O
and	O
during	O
chronic	O
heart	O
failure	O
,	O
with	O
improvements	O
in	O
cardiac	O
performance	O
and	O
animal	O
survival	O
.	O

Phase	O
I	O
and	O
II	O
clinical	O
trials	O
for	O
chronic	O
heart	O
failure	O
in	O
humans	O
are	O
now	O
in	O
progress	O
.	O

Glucocorticoid	O
-	O
induced	O
suppression	O
of	O
	O
-	O
cell	O
proliferation	O
is	O
mediated	O
by	O
Mig6	O
.	O

Glucocorticoids	O
can	O
cause	O
steroid	B
-	O
induced	O
diabetes	O
or	O
accelerate	O
the	O
progression	O
to	O
diabetes	O
by	O
creating	O
systemic	O
insulin	O
resistance	O
and	O
decreasing	O
functional	O
	O
-	O
cell	O
mass	O
,	O
which	O
is	O
influenced	O
by	O
changes	O
in	O
	O
-	O
cell	O
function	O
,	O
growth	O
,	O
and	O
death	O
.	O

The	O
synthetic	O
glucocorticoid	O
agonist	O
dexamethasone	B
(	O
Dex	B
)	O
is	O
deleterious	O
to	O
functional	O
	O
-	O
cell	O
mass	O
by	O
decreasing	O
	O
-	O
cell	O
function	O
,	O
survival	O
,	O
and	O
proliferation	O
.	O

However	O
,	O
the	O
mechanism	O
by	O
which	O
Dex	B
decreases	O
	O
-	O
cell	O
proliferation	O
is	O
unknown	O
.	O

Interestingly	O
,	O
Dex	B
induces	O
the	O
transcription	O
of	O
an	O
antiproliferative	O
factor	O
and	O
negative	O
regulator	O
of	O
epidermal	O
growth	O
factor	O
receptor	O
signaling	O
,	O
Mig6	O
(	O
also	O
known	O
as	O
gene	O
33	O
,	O
RALT	O
,	O
and	O
Errfi1	O
)	O
.	O

We	O
,	O
therefore	O
,	O
hypothesized	O
that	O
Dex	B
impairs	O
	O
-	O
cell	O
proliferation	O
by	O
increasing	O
the	O
expression	O
of	O
Mig6	O
and	O
thereby	O
decreasing	O
downstream	O
signaling	O
of	O
epidermal	O
growth	O
factor	O
receptor	O
.	O

We	O
found	O
that	O
Dex	B
induced	O
Mig6	O
and	O
decreased	O
[	B
(	I
3	I
)	I
H	I
]	I
thymidine	I
incorporation	O
,	O
an	O
index	O
of	O
cellular	O
replication	O
,	O
in	O
mouse	O
,	O
rat	O
,	O
and	O
human	O
islets	O
.	O

Using	O
adenovirally	O
delivered	O
small	O
interfering	O
RNA	O
targeted	O
to	O
Mig6	O
in	O
rat	O
islets	O
,	O
we	O
were	O
able	O
to	O
limit	O
the	O
induction	O
of	O
Mig6	O
upon	O
exposure	O
to	O
Dex	B
,	O
compared	O
with	O
islets	O
treated	O
with	O
a	O
control	O
virus	O
,	O
and	O
completely	O
rescued	O
the	O
Dex	B
-	O
mediated	O
impairment	O
in	O
replication	O
.	O

We	O
demonstrated	O
that	O
both	O
Dex	B
and	O
overexpression	O
of	O
Mig6	O
attenuated	O
the	O
phosphorylation	O
of	O
ERK1	O
/	O
2	O
and	O
blocked	O
the	O
G	O
(	O
1	O
)	O
/	O
S	O
transition	O
of	O
the	O
cell	O
cycle	O
.	O

In	O
conclusion	O
,	O
Mig6	O
functions	O
as	O
a	O
molecular	O
brake	O
for	O
	O
-	O
cell	O
proliferation	O
during	O
glucocorticoid	O
treatment	O
in	O
	O
-	O
cells	O
,	O
and	O
thus	O
,	O
Mig6	O
may	O
be	O
a	O
novel	O
target	O
for	O
preventing	O
glucocorticoid	O
-	O
induced	O
impairments	O
in	O
functional	O
	O
-	O
cell	O
mass	O
.	O

Design	O
and	O
synthesis	O
of	O
imidazole	B
and	O
triazole	B
derivatives	O
as	O
Lp	O
-	O
PLA	O
inhibitors	O
and	O
the	O
unexpected	O
discovery	O
of	O
highly	O
potent	O
quaternary	B
ammonium	I
salts	I
.	O

New	O
Lp	O
-	O
PLA	O
(	O
2	O
)	O
inhibitors	O
were	O
synthesized	O
by	O
the	O
bioisosteric	O
replacement	O
of	O
the	O
amide	B
group	O
of	O
Darapladib	B
with	O
an	O
imidazole	B
or	O
a	O
triazole	B
.	O

Unfortunately	O
,	O
the	O
inhibitory	O
activities	O
of	O
these	O
derivatives	O
were	O
lower	O
than	O
that	O
of	O
Darapladib	B
.	O

But	O
interestingly	O
,	O
a	O
series	O
of	O
quaternary	B
ammonium	I
salts	I
that	O
were	O
isolated	O
as	O
by	O
-	O
products	O
during	O
this	O
synthetic	O
work	O
were	O
found	O
with	O
high	O
potency	O
.	O

Of	O
these	O
by	O
-	O
products	O
,	O
compound	O
22c	O
showed	O
a	O
similar	O
profile	O
to	O
Darapladib	B
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Synthesis	O
and	O
antibacterial	O
activities	O
of	O
new	O
piperidine	B
substituted	O
(	B
5R	I
)	I
-	I
[	I
1,2,3	I
]	I
triazolylmethyl	I
and	I
(	I
5R	I
)	I
-	I
[	I
(	I
4-F-	I
[	I
1,2,3	I
]	I
triazolyl	I
)	I
methyl	I
]	I
oxazolidinones	I
.	O

A	O
novel	O
series	O
of	O
5	B
(	I
R	I
)	I
-	I
[	I
1,2,3	I
]	I
triazolylmethyl	I
and	I
(	I
5R	I
)	I
-	I
[	I
(	I
4-F-	I
[	I
1,2,3	I
]	I
triazolyl	I
)	I
methyl	I
]	I
oxazolidinones	I
having	O
various	O
piperidine	B
group	O
were	O
synthesized	O
and	O
evaluated	O
antibacterial	O
activity	O
against	O
clinically	O
isolated	O
resistant	O
strains	O
of	O
Gram	O
-	O
positive	O
and	O
Gram	O
-	O
negative	O
bacteria	O
.	O

The	O
compound	O
12a	O
having	O
exo	B
-	I
cyanoethylidene	I
group	O
in	O
the	O
4-position	O
of	O
piperidine	B
ring	O
was	O
found	O
to	O
be	O
two	O
to	O
threefold	O
more	O
potent	O
than	O
the	O
linezolid	B
against	O
penicillin	B
-	O
resistant	O
Staphylococcus	O
pneumonia	O
and	O
Staphylococcus	O
agalactiae	O
,	O
and	O
also	O
exhibited	O
reduced	O
MAO	O
-	O
B	O
inhibitory	O
activity	O
.	O

Integrated	O
analysis	O
of	O
transcriptomics	O
and	O
metabonomics	O
profiles	O
in	O
aflatoxin	B
B1-induced	I
hepatotoxicity	O
in	O
rat	O
.	O

The	O
aim	O
of	O
this	O
work	O
was	O
to	O
identify	O
mechanisms	O
and	O
potential	O
biomarkers	O
for	O
predicting	O
the	O
development	O
and	O
progression	O
of	O
aflatoxin	B
B1	I
(	O
AFB1	B
)	O
-induced	O
acute	O
hepatotoxicity	O
.	O

In	O
this	O
study	O
,	O
microarray	O
analysis	O
and	O
metabolites	O
profiles	O
were	O
used	O
to	O
identify	O
shifts	O
in	O
gene	O
expression	O
and	O
metabolite	O
levels	O
associated	O
with	O
the	O
affected	O
physiological	O
processes	O
of	O
rats	O
treated	O
with	O
AFB1	B
.	O

Histopathological	O
examinations	O
and	O
serum	O
biochemical	O
analysis	O
were	O
simultaneously	O
performed	O
;	O
the	O
results	O
indicated	O
that	O
hepatotoxicity	O
occurred	O
in	O
higher	O
dosage	O
groups	O
.	O

However	O
,	O
gene	O
expression	O
analysis	O
and	O
metabolite	O
profiles	O
are	O
more	O
sensitive	O
than	O
general	O
toxicity	O
studies	O
for	O
detecting	O
AFB1-induced	B
acute	O
hepatotoxicity	O
as	O
the	O
patterns	O
of	O
low	O
-	O
dose	O
AFB1-treated	B
rats	O
in	O
these	O
two	O
technique	O
platforms	O
were	O
more	O
similar	O
to	O
the	O
rats	O
in	O
higher	O
dosage	O
groups	O
than	O
to	O
the	O
control	O
rats	O
.	O

Integrated	O
analysis	O
of	O
the	O
results	O
from	O
general	O
toxicity	O
studies	O
,	O
transcriptomics	O
and	O
metabonomics	O
profiles	O
suggested	O
that	O
p53	O
signaling	O
pathway	O
induced	O
by	O
oxidative	O
damage	O
was	O
the	O
crucial	O
step	O
in	O
AFB1-induced	B
acute	O
hepatotoxicity	O
,	O
whereas	O
gluconeogenesis	O
and	O
lipid	O
metabolism	O
disorder	O
were	O
found	O
to	O
be	O
the	O
major	O
metabolic	O
effects	O
after	O
acute	O
AFB1	B
exposure	O
.	O

The	O
genes	O
and	O
metabolites	O
significantly	O
affected	O
in	O
common	O
in	O
rat	O
liver	O
or	O
serum	O
of	O
three	O
doses	O
AFB1	B
treatments	O
served	O
as	O
potential	O
biomarkers	O
for	O
detecting	O
AFB1-induced	B
acute	O
hepatotoxicity	O
.	O

Preparation	O
and	O
evaluation	O
of	O
sustained	O
-	O
release	O
doxazosin	B
mesylate	I
pellets	O
.	O

Doxazosin	B
mesylate	I
(	O
DXM	B
)	O
sustained	O
release	O
pellets	O
were	O
prepared	O
by	O
an	O
extrusion	O
-	O
spheronization	O
and	O
fluid	O
-	O
bed	O
coating	O
technique	O
.	O

The	O
core	O
pellets	O
containing	O
DXM	B
were	O
prepared	O
by	O
extrusion	O
-	O
spheronization	O
technique	O
,	O
and	O
coated	O
by	O
a	O
fluid	O
-	O
bed	O
coater	O
to	O
control	O
the	O
release	O
of	O
DXM	B
.	O

The	O
factors	O
affecting	O
to	O
properties	O
of	O
pellets	O
,	O
such	O
as	O
diluent	O
content	O
,	O
type	O
and	O
coating	O
level	O
of	O
coating	O
agents	O
and	O
plasticizers	O
were	O
studied	O
in	O
the	O
present	O
study	O
.	O

Polymethacrylate	B
derivatives	O
(	O
Eudragit	B
	O
RS	O
PO	O
and	O
RL	O
PO	O
)	O
were	O
used	O
for	O
coating	O
agents	O
,	O
and	O
polyethylene	B
glycol	I
6000	I
(	O
PEG	B
6000	I
)	O
,	O
triethyl	B
citrate	I
(	O
TEC	B
)	O
and	O
castor	O
oil	O
were	O
as	O
plasticizers	O
.	O

To	O
evaluate	O
the	O
properties	O
of	O
prepared	O
pellets	O
,	O
the	O
size	O
of	O
prepared	O
pellets	O
was	O
investigated	O
by	O
sieve	O
analysis	O
technique	O
and	O
the	O
morphology	O
of	O
pellets	O
was	O
evaluated	O
by	O
scanning	O
electron	O
microscopy	O
.	O

Through	O
the	O
dissolution	O
test	O
,	O
factors	O
that	O
have	O
an	O
effect	O
on	O
the	O
dissolution	O
of	O
the	O
drug	O
were	O
evaluated	O
.	O

As	O
the	O
content	O
ratio	O
of	O
microcrystalline	O
cellulose	O
(	O
MCC	O
)	O
had	O
increased	O
,	O
the	O
dissolution	O
was	O
proportionally	O
sustained	O
.	O

Eudragit	B
	O
RS	O
PO	O
had	O
more	O
marked	O
sustaining	O
effect	O
on	O
the	O
dissolution	O
rate	O
than	O
Eudragit	B
	O
RL	O
PO	O
,	O
and	O
the	O
effect	O
was	O
more	O
pronounced	O
with	O
the	O
increased	O
coating	O
level	O
.	O

PEG	B
6000	I
was	O
an	O
appropriate	O
plasticizer	O
for	O
DXM	B
pellets	O
,	O
and	O
increasing	O
the	O
content	O
of	O
PEG	B
6000	I
,	O
was	O
also	O
slightly	O
decreasing	O
the	O
dissolution	O
rate	O
.	O

CYP21A2	O
Mutations	O
in	O
Women	O
with	O
Polycystic	O
Ovary	O
Syndrome	O
(	O
PCOS	O
)	O
.	O

The	O
question	O
of	O
the	O
contribution	O
of	O
CYP21A2	O
heterozygosity	O
to	O
the	O
development	O
of	O
polycystic	O
ovary	O
syndrome	O
(	O
PCOS	O
)	O
has	O
repeatedly	O
been	O
raised	O
in	O
the	O
literature	O
.	O

The	O
available	O
data	O
,	O
however	O
,	O
do	O
not	O
offer	O
a	O
satisfactory	O
answer	O
.	O

The	O
discrepancy	O
must	O
be	O
attributed	O
,	O
primarily	O
,	O
to	O
the	O
small	O
number	O
of	O
subjects	O
in	O
the	O
various	O
studies	O
,	O
the	O
type	O
of	O
selected	O
phenotype	O
,	O
and	O
the	O
number	O
of	O
searched	O
mutations	O
.	O

The	O
aim	O
of	O
the	O
study	O
was	O
to	O
define	O
the	O
contribution	O
of	O
CYP21A2	O
heterozygous	O
mutations	O
to	O
the	O
pathogenesis	O
of	O
PCOS	O
.	O

We	O
searched	O
for	O
14	O
molecular	O
defects	O
of	O
the	O
CYP21A2	O
gene	O
in	O
197	O
PCOS	O
women	O
,	O
employing	O
allele	O
specific	O
PCR	O
.	O

Androgen	B
levels	O
were	O
determined	O
at	O
baseline	O
by	O
appropriate	O
methodology	O
in	O
the	O
follicular	O
phase	O
.	O

PCOS	O
women	O
with	O
17-hydroxyprogesterone	B
(	O
17OHP	B
)	O
basal	O
values	O
>	O
2	O
ng	O
/	O
ml	O
and/or	O
post	O
-	O
ACTH	O
>	O
10	O
ng	O
/	O
ml	O
were	O
excluded	O
.	O

Appropriate	O
controls	O
were	O
included	O
.	O

The	O
frequency	O
of	O
the	O
CYP21A2	O
heterozygous	O
mutations	O
in	O
PCOS	O
women	O
and	O
in	O
controls	O
was	O
7.6	O
%	O
and	O
5.9	O
%	O
,	O
respectively	O
[	O
p	O
-	O
value	O
(	O
PCOS	O
vs.	O
controls	O
)	O
:	O
0.663	O
]	O
.	O

Homozygosity	O
for	O
CYP21A2	O
gene	O
defects	O
was	O
not	O
detected	O
.	O

In	O
conclusion	O
,	O
the	O
contribution	O
of	O
CYP21A2	O
heterozygous	O
mutations	O
to	O
the	O
pathogenesis	O
of	O
PCOS	O
is	O
not	O
substantiated	O
by	O
our	O
data	O
.	O

Moreover	O
,	O
17-hydroxyprogesterone	B
values	O
of	O
<	O
10	O
ng	O
/	O
ml	O
post	O
-	O
ACTH	O
exclude	O
homozygosity	O
of	O
CYP21A2	O
mutations	O
.	O

Effectiveness	O
of	O
an	O
educational	O
intervention	O
on	O
prescription	O
writing	O
skill	O
of	O
preclerkship	O
medical	O
students	O
in	O
a	O
problem	O
-	O
based	O
learning	O
curriculum	O
.	O

Medical	O
school	O
training	O
for	O
students	O
in	O
pharmacotherapy	O
is	O
suboptimal	O
and	O
junior	O
doctors	O
are	O
not	O
confident	O
to	O
prescribe	O
drugs	O
.	O

This	O
study	O
evaluated	O
the	O
effectiveness	O
of	O
an	O
optional	O
educational	O
intervention	O
on	O
prescribing	O
skill	O
of	O
pre	O
-	O
clerkship	O
medical	O
students	O
in	O
a	O
problem	O
-	O
based	O
learning	O
(	O
PBL	O
)	O
program	O
.	O

Performance	O
was	O
assessed	O
in	O
seven	O
end	O
-	O
unit	O
objective	O
structured	O
practical	O
examinations	O
(	O
OSPE	O
)	O
.	O

Physician	O
-	O
related	O
prescription	O
components	O
(	O
PRCs	O
)	O
and	O
drug	O
-	O
related	O
prescription	O
components	O
(	O
DRCs	O
)	O
were	O
assessed	O
.	O

The	O
performance	O
of	O
students	O
who	O
attended	O
the	O
intervention	O
sessions	O
(	O
attendees	O
)	O
and	O
non	O
-	O
attendees	O
was	O
compared	O
.	O

Approximately	O
half	O
of	O
the	O
students	O
attended	O
the	O
sessions	O
.	O

PRCs	O
were	O
written	O
appropriately	O
by	O
most	O
of	O
the	O
students	O
.	O

DRCs	O
were	O
written	O
less	O
competently	O
by	O
both	O
attendees	O
and	O
non	O
-	O
attendees	O
,	O
specifically	O
the	O
dosage	O
form	O
,	O
quantity	O
to	O
be	O
dispensed	O
and	O
directions	O
.	O

Performance	O
on	O
individual	O
DRCs	O
was	O
significantly	O
better	O
for	O
attendees	O
compared	O
to	O
non	O
-	O
attendees	O
.	O

The	O
mean	O
total	O
score	O
for	O
all	O
prescription	O
components	O
of	O
attendees	O
was	O
significantly	O
greater	O
than	O
that	O
of	O
non	O
-	O
attendees	O
.	O

The	O
percentage	O
of	O
high	O
achievers	O
was	O
significantly	O
greater	O
for	O
attendees	O
.	O

A	O
positive	O
correlation	O
was	O
found	O
between	O
student	O
attendance	O
and	O
the	O
total	O
score	O
.	O

An	O
optional	O
educational	O
intervention	O
during	O
the	O
preclerkship	O
phase	O
is	O
an	O
important	O
determinant	O
of	O
prescribing	O
performance	O
of	O
medical	O
students	O
.	O

Sesquiterpenes	B
from	O
the	O
rhizomes	O
of	O
Curcuma	O
heyneana	O
.	O

Four	O
new	O
germacranes	B
[	O
heyneanones	B
A	I
-	I
D	I
(	O
1	O
-	O
4	O
)	O
]	O
,	O
three	O
new	O
guaianes	B
[	O
4,10-epizedoarondiol	B
(	O
5	O
)	O
,	O
15-hydroxyprocurcumenol	B
(	O
6	O
)	O
,	O
12-hydroxycurcumenol	B
(	O
7	O
)	O
]	O
,	O
and	O
two	O
new	O
spirolactones	B
[	O
curcumanolides	B
C	O
(	O
8)	O
and	O
D	O
(	O
9	O
)	O
]	O
were	O
isolated	O
from	O
the	O
rhizomes	O
of	O
Curcuma	O
heyneana	O
together	O
with	O
13	O
known	O
sesquiterpenes	B
and	O
two	O
known	O
labdane	B
-	O
type	O
diterpenes	B
.	O

Among	O
the	O
isolated	O
compounds	O
,	O
heyneanone	B
A	I
(	O
1	O
)	O
,	O
heyneanone	B
C	I
(	O
3	O
)	O
,	O
4,10-epizedoarondiol	B
(	O
5	O
)	O
,	O
procurcumenol	B
(	O
16	O
)	O
,	O
aerugidiol	B
(	O
17	O
)	O
,	O
zerumin	B
A	I
(	O
23	O
)	O
,	O
and	O
(	B
E	I
)	I
-15,16-bisnorlabda-8	I
(	I
17	I
)	I
,11-dien-13-one	I
(	O
24	O
)	O
inhibited	O
protein	O
tyrosine	B
phosphatase	O
1B	O
(	O
PTP1B	O
)	O
with	O
IC	O
(	O
50	O
)	O
values	O
of	O
42.5	O
,	O
35.2	O
,	O
35.1	O
,	O
45.6	O
,	O
35.7	O
,	O
10.4	O
,	O
and	O
14.7	O
M	O
,	O
respectively	O
.	O

Public	O
health	O
challenges	O
and	O
prospects	O
for	O
malaria	O
control	O
and	O
elimination	O
.	O

The	O
past	O
decade	O
witnessed	O
unprecedented	O
efforts	O
to	O
control	O
malaria	O
,	O
including	O
renewed	O
political	O
and	O
financial	O
commitment	O
and	O
increased	O
availability	O
of	O
both	O
old	O
and	O
new	O
strategies	O
and	O
tools	O
.	O

However	O
,	O
malaria	O
still	O
represents	O
a	O
major	O
health	O
burden	O
,	O
particularly	O
in	O
Africa	O
.	O

Important	O
challenges	O
such	O
as	O
the	O
fragility	O
of	O
many	O
health	O
systems	O
,	O
the	O
rise	O
of	O
insecticide	O
and	O
drug	O
resistance	O
,	O
and	O
particularly	O
the	O
expected	O
decline	O
both	O
in	O
funding	O
and	O
in	O
the	O
coverage	O
of	O
key	O
interventions	O
if	O
they	O
are	O
not	O
replaced	O
as	O
needed	O
,	O
urgently	O
need	O
to	O
be	O
addressed	O
.	O

Further	O
research	O
and	O
development	O
is	O
also	O
becoming	O
increasingly	O
crucial	O
.	O

Among	O
other	O
needs	O
,	O
common	O
methodologies	O
for	O
estimating	O
and	O
tracking	O
the	O
malaria	O
burden	O
,	O
new	O
strategies	O
to	O
measure	O
transmission	O
,	O
better	O
understanding	O
of	O
immunity	O
,	O
and	O
increased	O
knowledge	O
of	O
the	O
mechanisms	O
and	O
effects	O
of	O
resistance	O
to	O
drugs	O
and	O
insecticides	O
stand	O
out	O
.	O

The	O
ongoing	O
efforts	O
in	O
research	O
and	O
development	O
for	O
new	O
antimalarial	O
drugs	O
,	O
more	O
sensitive	O
point	O
-	O
of	O
-	O
care	O
rapid	O
diagnostic	O
tests	O
and	O
new	O
insecticides	O
need	O
further	O
innovation	O
and	O
substantial	O
strengthening	O
.	O

Clearly	O
,	O
efforts	O
should	O
focus	O
not	O
only	O
on	O
Plasmodium	O
falciparum	O
but	O
also	O
and	O
increasingly	O
on	O
Plasmodium	O
vivax	O
,	O
the	O
neglected	O
human	O
malaria	O
parasite	O
.	O

Addressing	O
these	O
challenges	O
in	O
a	O
comprehensive	O
and	O
timely	O
way	O
will	O
allow	O
us	O
to	O
sustain	O
the	O
gains	O
made	O
so	O
far	O
and	O
make	O
further	O
progress	O
in	O
control	O
and	O
progressive	O
elimination	O
.	O

Signature	O
of	O
singlet	O
open	O
-	O
shell	O
character	O
on	O
the	O
optically	O
allowed	O
singlet	O
excitation	O
energy	O
and	O
singlet	O
-	O
triplet	O
energy	O
gap	O
.	O

A	O
signature	O
of	O
singlet	O
open	O
-	O
shell	O
character	O
on	O
the	O
optically	O
allowed	O
singlet	O
excitation	O
energy	O
and	O
singlet	O
-	O
triplet	O
energy	O
gap	O
is	O
theoretically	O
illuminated	O
for	O
open	O
-	O
shell	O
singlet	O
molecules	O
.	O

On	O
the	O
basis	O
of	O
a	O
two	O
-	O
site	O
diradical	O
model	O
with	O
two	O
electrons	O
in	O
two	O
orbitals	O
,	O
the	O
linear	O
dependence	O
of	O
these	O
excitation	O
energies	O
on	O
the	O
transfer	O
integral	O
,	O
which	O
is	O
equivalent	O
to	O
the	O
energy	O
gap	O
between	O
the	O
highest	O
occupied	O
(	O
HOMO	O
)	O
and	O
the	O
lowest	O
unoccupied	O
(	O
LUMO	O
)	O
molecular	O
orbitals	O
in	O
the	O
Hckel	O
theory	O
,	O
is	O
found	O
to	O
be	O
broken	O
down	O
in	O
the	O
high	O
diradical	O
character	O
region	O
due	O
to	O
an	O
increase	O
in	O
electron	O
correlation	O
in	O
the	O
open	O
-	O
shell	O
singlet	O
ground	O
state	O
.	O

A	O
series	O
of	O
polyacenes	B
shows	O
the	O
similar	O
behavior	O
of	O
the	O
optically	O
allowed	O
singlet	O
excitation	O
energies	O
obtained	O
by	O
time	O
-	O
dependent	O
spin	O
-	O
flip	O
density	O
functional	O
theory	O
calculations	O
and	O
experiments	O
,	O
which	O
bears	O
testimony	O
to	O
the	O
singlet	O
open	O
-	O
shell	O
character	O
in	O
long	O
polyacenes	O
.	O

High	O
-	O
resolution	O
zero	O
-	O
field	O
NMR	O
J	O
-	O
spectroscopy	O
of	O
aromatic	O
compounds	O
.	O

We	O
report	O
the	O
acquisition	O
and	O
interpretation	O
of	O
nuclear	O
magnetic	O
resonance	O
(	O
NMR	O
)	O
J	O
-	O
spectra	O
at	O
zero	O
magnetic	O
field	O
for	O
a	O
series	O
of	O
benzene	B
derivatives	O
,	O
demonstrating	O
the	O
analytical	O
capabilities	O
of	O
zero	O
-	O
field	O
NMR	O
.	O

The	O
zeroth	O
-	O
order	O
spectral	O
patterns	O
do	O
not	O
overlap	O
,	O
which	O
allows	O
for	O
straightforward	O
determination	O
of	O
the	O
spin	O
interactions	O
of	O
substituent	O
functional	O
groups	O
.	O

Higher	O
-	O
order	O
effects	O
cause	O
additional	O
line	O
splittings	O
,	O
revealing	O
additional	O
molecular	O
information	O
.	O

We	O
demonstrate	O
resonance	O
linewidths	O
as	O
narrow	O
as	O
11	O
mHz	O
,	O
permitting	O
resolution	O
of	O
minute	O
frequency	O
differences	O
and	O
precise	O
determination	O
of	O
long	O
-	O
range	O
J	O
-	O
couplings	O
.	O

The	O
measurement	O
of	O
J	O
-	O
couplings	O
with	O
the	O
high	O
precision	O
offered	O
by	O
zero	O
-	O
field	O
NMR	O
may	O
allow	O
further	O
refinements	O
in	O
the	O
determination	O
of	O
molecular	O
structure	O
and	O
conformation	O
.	O

Solvent	O
and	O
pressure	O
effects	O
on	O
the	O
motions	O
of	O
encapsulated	O
guests	O
:	O
tuning	O
the	O
flexibility	O
of	O
a	O
supramolecular	O
host	O
.	O

The	O
supramolecular	O
host	O
assembly	O
[	B
Ga4L6	I
]	I
(	I
12-	I
)	I
[	O
1	O
;	O
L	O
=	O
1,5-bis	B
(	I
2,3-dihydroxybenzamido	I
)	I
naphthalene	I
]	O
contains	O
a	O
flexible	O
,	O
hydrophobic	O
interior	O
cavity	O
that	O
can	O
encapsulate	O
cationic	O
guest	O
molecules	O
and	O
catalyze	O
a	O
variety	O
of	O
chemical	O
transformations	O
.	O

The	O
Ar	B
-	I
CH2	I
bond	O
rotational	O
barrier	O
for	O
encapsulated	O
ortho	B
-	I
substituted	I
benzyl	I
phosphonium	I
guest	O
molecules	O
is	O
sensitive	O
to	O
the	O
size	O
and	O
shape	O
of	O
the	O
host	O
interior	O
space	O
.	O

Here	O
we	O
examine	O
how	O
changes	O
in	O
bulk	O
solvent	O
(	O
water	O
,	O
methanol	B
,	O
or	O
DMF	B
)	O
or	O
applied	O
pressure	O
(	O
up	O
to	O
150	O
MPa	O
)	O
affect	O
the	O
rotational	O
dynamics	O
of	O
encapsulated	O
benzyl	B
phosphonium	I
guests	O
,	O
as	O
a	O
way	O
to	O
probe	O
changes	O
in	O
host	O
cavity	O
size	O
or	O
flexibility	O
.	O

When	O
host	O
1	O
is	O
dissolved	O
in	O
organic	O
solvents	O
with	O
large	O
solvent	O
internal	O
pressures	O
(	O
U	O
/	O
V	O
)	O
T	O
,	O
we	O
find	O
that	O
the	O
free	O
energy	O
barrier	O
to	O
Ar	B
-	I
CH2	I
bond	O
rotation	O
increases	O
by	O
1	O
-	O
2	O
kcal	O
/	O
mol	O
,	O
compared	O
with	O
that	O
in	O
aqueous	O
solution	O
.	O

Likewise	O
,	O
when	O
external	O
pressure	O
is	O
applied	O
to	O
the	O
host	O
-	O
guest	O
complex	O
in	O
solution	O
,	O
the	O
bond	O
rotational	O
rates	O
for	O
the	O
encapsulated	O
guests	O
decrease	O
.	O

The	O
magnitude	O
of	O
these	O
rate	O
changes	O
and	O
the	O
volumes	O
of	O
activation	O
obtained	O
using	O
either	O
solvent	O
internal	O
pressure	O
or	O
applied	O
external	O
pressure	O
are	O
very	O
similar	O
.	O

NOE	O
distance	O
measurements	O
reveal	O
shorter	O
average	O
host	O
-	O
guest	O
distances	O
(	O
~0.3	O
	O
)	O
in	O
organic	O
versus	O
aqueous	O
solution	O
.	O

These	O
experiments	O
demonstrate	O
that	O
increasing	O
solvent	O
internal	O
pressure	O
or	O
applied	O
external	O
pressure	O
reduces	O
the	O
host	O
cavity	O
size	O
or	O
flexibility	O
,	O
resulting	O
in	O
more	O
restricted	O
motions	O
for	O
encapsulated	O
guest	O
molecules	O
.	O

Changing	O
bulk	O
solvent	O
or	O
external	O
pressure	O
might	O
therefore	O
be	O
used	O
to	O
tune	O
the	O
physical	O
properties	O
or	O
reactivity	O
of	O
guest	O
molecules	O
encapsulated	O
in	O
a	O
flexible	O
supramolecular	O
host	O
.	O

Time	O
-	O
of	O
-	O
flight	O
magnetic	O
flow	O
cytometry	O
in	O
whole	O
blood	O
with	O
integrated	O
sample	O
preparation	O
.	O

Rapid	O
and	O
specific	O
rare	O
cell	O
detection	O
for	O
point	O
-	O
of	O
-	O
care	O
testing	O
requires	O
an	O
integration	O
of	O
the	O
sample	O
preparation	O
for	O
flow	O
cytometry	O
.	O

To	O
achieve	O
such	O
a	O
challenging	O
goal	O
we	O
have	O
developed	O
a	O
magnetic	O
flow	O
cytometry	O
technique	O
which	O
applies	O
magnetophoresis	O
to	O
perform	O
cell	O
enrichment	O
,	O
focusing	O
,	O
and	O
background	O
elimination	O
in	O
a	O
single	O
step	O
.	O

Time	O
-	O
of	O
-	O
flight	O
measurements	O
are	O
performed	O
with	O
integrated	O
magnetic	O
sensors	O
to	O
detect	O
specifically	O
cancer	O
cells	O
and	O
cell	O
diameters	O
in	O
whole	O
blood	O
.	O

Ventral	O
tegmental	O
area	O
GABA	B
neurons	O
and	O
opiate	O
motivation	O
.	O

RATIONALE	O
:	O
Past	O
research	O
has	O
demonstrated	O
that	O
when	O
an	O
animal	O
changes	O
from	O
a	O
previously	O
drug	O
-	O
naive	O
to	O
an	O
opiate	O
-	O
dependent	O
and	O
withdrawn	O
state	O
,	O
morphine	B
's	O
motivational	O
effects	O
are	O
switched	O
from	O
a	O
tegmental	O
pedunculopontine	O
nucleus	O
(	O
TPP	O
)	O
-dependent	O
to	O
a	O
dopamine	B
-	O
dependent	O
pathway	O
.	O

Interestingly	O
,	O
a	O
corresponding	O
change	O
is	O
observed	O
in	O
ventral	O
tegmental	O
area	O
(	O
VTA	O
)	O
GABA	B
(	O
A	O
)	O
receptors	O
,	O
which	O
change	O
from	O
mediating	O
hyperpolarization	O
of	O
VTA	O
GABA	B
neurons	O
to	O
mediating	O
depolarization	O
.	O

OBJECTIVES	O
:	O
The	O
present	O
study	O
investigated	O
whether	O
pharmacological	O
manipulation	O
of	O
VTA	O
GABA	B
(	O
A	O
)	O
receptor	O
activity	O
could	O
directly	O
influence	O
the	O
mechanisms	O
underlying	O
opiate	O
motivation	O
.	O

RESULTS	O
:	O
Using	O
an	O
unbiased	O
place	O
conditioning	O
procedure	O
,	O
we	O
demonstrated	O
that	O
in	O
Wistar	O
rats	O
,	O
intra	O
-	O
VTA	O
administration	O
of	O
furosemide	B
,	O
a	O
Cl	B
(	I
-	I
)	I
cotransporter	O
inhibitor	O
,	O
was	O
able	O
to	O
promote	O
a	O
switch	O
in	O
the	O
mechanisms	O
underlying	O
morphine	B
's	O
motivational	O
properties	O
,	O
one	O
which	O
is	O
normally	O
observed	O
only	O
after	O
chronic	O
opiate	O
exposure	O
.	O

This	O
behavioral	O
switch	O
was	O
prevented	O
by	O
intra	O
-	O
VTA	O
administration	O
of	O
acetazolamide	B
,	O
an	O
inhibitor	O
of	O
the	O
bicarbonate	B
ion	O
-	O
producing	O
carbonic	O
anhydrase	O
enzyme	O
.	O

Electrophysiological	O
recordings	O
of	O
mouse	O
VTA	O
showed	O
that	O
furosemide	B
reduced	O
the	O
sensitivity	O
of	O
VTA	O
GABA	B
neurons	O
to	O
inhibition	O
by	O
the	O
GABA	B
(	O
A	O
)	O
receptor	O
agonist	O
muscimol	B
,	O
instead	O
increasing	O
the	O
firing	O
rate	O
of	O
a	O
significant	O
subset	O
of	O
these	O
GABA	B
neurons	O
.	O

CONCLUSIONS	O
:	O
Our	O
results	O
suggest	O
that	O
the	O
carbonic	O
anhydrase	O
enzyme	O
may	O
constitute	O
part	O
of	O
a	O
common	O
VTA	O
GABA	B
neuron	O
-	O
based	O
biological	O
pathway	O
responsible	O
for	O
controlling	O
the	O
mechanisms	O
underlying	O
opiate	O
motivation	O
,	O
supporting	O
the	O
hypothesis	O
that	O
VTA	O
GABA	B
(	O
A	O
)	O
receptor	O
hyperpolarization	O
or	O
depolarization	O
is	O
responsible	O
for	O
selecting	O
TPP-	O
or	O
dopamine	B
-	O
dependent	O
motivational	O
outputs	O
,	O
respectively	O
.	O

Hyperbranched	O
Polyester	B
Hydrogels	O
with	O
Controlled	O
Drug	O
Release	O
and	O
Cell	O
Adhesion	O
Properties	O
.	O

Hyperbranched	O
polyesters	B
(	O
HPE	O
)	O
have	O
a	O
high	O
efficiency	O
to	O
encapsulate	O
bioactive	O
agents	O
,	O
including	O
drugs	O
,	O
genes	O
,	O
and	O
proteins	O
,	O
due	O
to	O
their	O
globe	O
-	O
like	O
nanostructure	O
.	O

However	O
,	O
the	O
use	O
of	O
these	O
highly	O
branched	O
polymeric	O
systems	O
for	O
tissue	O
engineering	O
applications	O
has	O
not	O
been	O
broadly	O
investigated	O
.	O

Here	O
,	O
we	O
report	O
synthesis	O
and	O
characterization	O
of	O
photocrosslinkable	O
HPE	O
hydrogels	O
with	O
sustained	O
drug	O
release	O
characteristics	O
for	O
cellular	O
therapies	O
.	O

These	O
HPE	O
can	O
encapsulate	O
hydrophobic	O
drug	O
molecules	O
within	O
the	O
HPE	O
cavities	O
due	O
to	O
the	O
presence	O
of	O
a	O
hydrophobic	O
inner	O
structure	O
that	O
is	O
otherwise	O
difficult	O
to	O
achieve	O
in	O
conventional	O
hydrogels	O
.	O

The	O
functionalization	O
of	O
HPE	O
with	O
photocrosslinkable	O
acrylate	B
moieties	O
renders	O
the	O
formation	O
of	O
hydrogels	O
with	O
a	O
highly	O
porous	O
interconnected	O
structure	O
and	O
mechanically	O
tough	O
network	O
.	O

The	O
compressive	O
modulus	O
of	O
HPE	O
hydrogels	O
was	O
tunable	O
by	O
changing	O
the	O
crosslinking	O
density	O
.	O

The	O
feasibility	O
of	O
using	O
these	O
HPE	O
networks	O
for	O
cellular	O
therapies	O
was	O
investigated	O
by	O
evaluating	O
cell	O
adhesion	O
,	O
spreading	O
,	O
and	O
proliferation	O
on	O
hydrogel	O
surface	O
.	O

Highly	O
crosslinked	O
and	O
mechanically	O
stiff	O
HPE	O
hydrogels	O
have	O
higher	O
cell	O
adhesion	O
,	O
spreading	O
,	O
and	O
proliferation	O
compared	O
to	O
soft	O
and	O
complaint	O
HPE	O
hydrogels	O
.	O

Overall	O
,	O
we	O
showed	O
that	O
hydrogels	O
made	O
from	O
HPE	O
could	O
be	O
used	O
for	O
biomedical	O
applications	O
that	O
require	O
spatial	O
control	O
of	O
cell	O
adhesion	O
and	O
controlled	O
release	O
of	O
hydrophobic	O
clues	O
.	O

One	O
-	O
pot	O
,	O
exchange	O
-	O
free	O
,	O
room	O
-	O
temperature	O
synthesis	O
of	O
sub-10	O
nm	O
aqueous	O
,	O
noninteracting	O
,	O
and	O
stable	O
zwitterated	B
iron	I
oxide	I
nanoparticles	O
.	O

Stable	O
aqueous	O
dispersions	O
of	O
superparamagnetic	O
iron	B
oxide	I
nanoparticles	O
were	O
synthesized	O
in	O
one	O
step	O
in	O
the	O
presence	O
of	O
a	O
zwitterionic	B
siloxane	I
as	O
the	O
stabilizing	O
/	O
capping	O
/	O
solubilizing	O
ligand	O
.	O

The	O
hydrodynamic	O
diameter	O
of	O
the	O
particles	O
was	O
tuned	O
by	O
controlling	O
the	O
concentration	O
of	O
zwitterion	B
siloxane	I
,	O
which	O
ultimately	O
yielded	O
monodisperse	O
nanoparticles	O
small	O
enough	O
for	O
renal	O
filtration	O
(	O
<	O
6	O
nm	O
diameter	O
)	O
.	O

The	O
zwitterated	O
nanoparticles	O
were	O
readily	O
dispersed	O
and	O
stable	O
in	O
aqueous	O
media	O
in	O
the	O
pH	O
range	O
6	O
-	O
9	O
but	O
exhibited	O
lower	O
magnetization	O
values	O
than	O
nonzwitterated	O
materials	O
due	O
to	O
amorphous	O
content	O
and	O
spin	O
canting	O
,	O
typical	O
for	O
particles	O
of	O
such	O
size	O
.	O

Turbidimetry	O
and	O
light	O
scattering	O
studies	O
revealed	O
no	O
interaction	O
between	O
the	O
particles	O
and	O
proteins	O
,	O
suggesting	O
the	O
materials	O
will	O
circulate	O
well	O
in	O
vivo	O
.	O

Saturable	O
active	O
efflux	O
by	O
p	O
-	O
glycoprotein	O
and	O
breast	O
cancer	O
resistance	O
protein	O
at	O
the	O
blood	O
-	O
brain	O
barrier	O
leads	O
to	O
nonlinear	O
distribution	O
of	O
elacridar	B
to	O
the	O
central	O
nervous	O
system	O
.	O

The	O
study	O
objective	O
was	O
to	O
investigate	O
factors	O
that	O
affect	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
distribution	O
of	O
elacridar	B
.	O

Elacridar	B
inhibits	O
transport	O
mediated	O
by	O
P	O
-	O
glycoprotein	O
(	O
P	O
-	O
gp	O
)	O
and	O
breast	O
cancer	O
resistance	O
protein	O
(	O
Bcrp	O
)	O
and	O
has	O
been	O
used	O
to	O
study	O
the	O
influence	O
of	O
transporters	O
on	O
brain	O
distribution	O
of	O
chemotherapeutics	O
.	O

Adequate	O
distribution	O
of	O
elacridar	B
across	O
the	O
blood	O
-	O
brain	O
barrier	O
(	O
BBB	O
)	O
and	O
into	O
the	O
brain	O
parenchyma	O
is	O
necessary	O
to	O
target	O
tumor	O
cells	O
in	O
the	O
brain	O
that	O
overexpress	O
transporters	O
and	O
reside	O
behind	O
an	O
intact	O
BBB	O
.	O

We	O
examined	O
the	O
role	O
of	O
P	O
-	O
gp	O
and	O
Bcrp	O
on	O
brain	O
penetration	O
of	O
elacridar	B
using	O
Friend	O
leukemia	O
virus	O
strain	O
B	O
wild	O
-	O
type	O
,	O
Mdr1a	O
/	O
b	O
(	O
-	O
/	O
-	O
)	O
,	O
Bcrp1	O
(	O
-	O
/	O
-	O
)	O
,	O
and	O
Mdr1a	O
/	O
b	O
(	O
-	O
/	O
-	O
)	O
Bcrp1	O
(	O
-	O
/	O
-	O
)	O
mice	O
.	O

Initially	O
,	O
the	O
mice	O
were	O
administered	O
2.5	O
mg	O
/	O
kg	O
of	O
elacridar	B
intravenously	O
,	O
and	O
the	O
plasma	O
and	O
brain	O
concentrations	O
were	O
determined	O
.	O

The	O
brain	O
-	O
to	O
-	O
plasma	O
partition	O
coefficient	O
of	O
elacridar	B
in	O
the	O
wild	O
-	O
type	O
mice	O
was	O
0.82	O
,	O
as	O
compared	O
with	O
3.5	O
in	O
Mdr1a	O
/	O
b	O
(	O
-	O
/	O
-	O
)	O
mice	O
,	O
6.6	O
in	O
Bcrp1	O
(	O
-	O
/	O
-	O
)	O
mice	O
,	O
and	O
15	O
in	O
Mdr1a	O
/	O
b	O
(	O
-	O
/	O
-	O
)	O
Bcrp1	O
(	O
-	O
/	O
-	O
)	O
mice	O
,	O
indicating	O
that	O
both	O
P	O
-	O
gp	O
and	O
Bcrp	O
limit	O
the	O
brain	O
distribution	O
of	O
elacridar	B
.	O

The	O
four	O
genotypes	O
were	O
then	O
administered	O
increasing	O
doses	O
of	O
elacridar	B
,	O
and	O
the	O
CNS	O
distribution	O
of	O
elacridar	B
was	O
determined	O
.	O

The	O
observed	O
and	O
model	O
predicted	O
maximum	O
brain	O
-	O
to	O
-	O
plasma	O
ratios	O
(	O
Emax	O
)	O
at	O
the	O
highest	O
dose	O
were	O
not	O
significantly	O
different	O
in	O
all	O
genotypes	O
.	O

However	O
,	O
the	O
ED50	O
was	O
lower	O
for	O
Mdr1a	O
/	O
b	O
(	O
-	O
/	O
-	O
)	O
mice	O
compared	O
with	O
Bcrp1	O
(	O
-	O
/	O
-	O
)	O
mice	O
.	O

These	O
findings	O
correlate	O
with	O
the	O
relative	O
expression	O
of	O
P	O
-	O
gp	O
and	O
Bcrp	O
at	O
the	O
BBB	O
in	O
these	O
mice	O
and	O
demonstrate	O
the	O
quantitative	O
enhancement	O
in	O
elacridar	O
CNS	O
distribution	O
as	O
a	O
function	O
of	O
its	O
dose	O
.	O

Overall	O
,	O
this	O
study	O
provides	O
useful	O
concepts	O
for	O
future	O
applications	O
of	O
elacridar	B
as	O
an	O
adjuvant	O
therapy	O
to	O
improve	O
targeting	O
of	O
chemotherapeutic	O
agents	O
to	O
tumor	O
cells	O
in	O
the	O
brain	O
parenchyma	O
.	O

Strong	O
effects	O
of	O
cluster	O
size	O
and	O
air	O
exposure	O
on	O
oxygen	B
reduction	O
and	O
carbon	B
oxidation	O
electrocatalysis	O
by	O
size	O
-	O
selected	O
Pt	B
(	I
n	I
)	I
(	O
n	O
	O
11	O
)	O
on	O
glassy	B
carbon	I
electrodes	O
.	O

Model	O
Pt	B
(	I
n	I
)	I
/	O
glassy	B
carbon	I
electrodes	O
(	O
Pt	B
(	I
n	I
)	I
/	O
GCE	O
)	O
were	O
prepared	O
by	O
deposition	O
of	O
mass	O
-	O
selected	O
Pt	B
(	I
n	I
)	I
(	I
+	I
)	I
(	O
n	O
	O
11	O
)	O
on	O
GCE	O
substrates	O
in	O
ultrahigh	O
vacuum	O
.	O

Electrocatalysis	O
under	O
conditions	O
appropriate	O
for	O
the	O
oxygen	B
reduction	O
reaction	O
(	O
ORR	O
)	O
was	O
studied	O
,	O
for	O
samples	O
both	O
in	O
situ	O
with	O
no	O
exposure	O
to	O
laboratory	O
air	O
and	O
with	O
air	O
exposure	O
prior	O
to	O
electrochemical	O
measurements	O
.	O

Of	O
the	O
small	O
clusters	O
,	O
only	O
a	O
few	O
cluster	O
sizes	O
show	O
the	O
expected	O
ORR	O
activity	O
,	O
and	O
in	O
those	O
cases	O
,	O
the	O
activity	O
per	O
Pt	B
atom	O
is	O
similar	O
to	O
that	O
seen	O
under	O
identical	O
conditions	O
with	O
a	O
conventionally	O
prepared	O
electrode	O
with	O
Pt	B
nanoparticles	O
grown	O
on	O
a	O
GCE	O
.	O

For	O
other	O
small	O
Pt	B
(	I
n	I
)	I
on	O
GCE	O
,	O
any	O
ORR	O
signal	O
is	O
overwhelmed	O
by	O
large	O
oxidative	O
currents	O
attributed	O
to	O
catalysis	O
of	O
carbon	B
oxidation	O
by	O
water	O
.	O

If	O
the	O
samples	O
are	O
exposed	O
to	O
air	O
prior	O
to	O
electrochemistry	O
,	O
both	O
ORR	O
and	O
carbon	B
oxidation	O
signals	O
are	O
absent	O
,	O
and	O
instead	O
only	O
small	O
capacitive	O
currents	O
or	O
currents	O
attributed	O
to	O
redox	O
chemistry	O
of	O
adventitious	O
organic	O
adsorbates	O
are	O
observed	O
,	O
indicating	O
that	O
air	O
exposure	O
results	O
in	O
passivation	O
of	O
the	O
small	O
Pt	B
clusters	O
.	O

Chromogenic	O
and	O
fluorogenic	O
chemosensors	O
and	O
reagents	O
for	O
anions	O
.	O

A	O
comprehensive	O
review	O
of	O
the	O
years	O
2010	O
-	O
2011	O
.	O

This	O
review	O
focuses	O
on	O
examples	O
reported	O
in	O
the	O
years	O
2010	O
-	O
2011	O
dealing	O
with	O
the	O
design	O
of	O
chromogenic	O
and	O
fluorogenic	O
chemosensors	O
or	O
reagents	O
for	O
anions	O
.	O

Tacticity	O
-	O
induced	O
changes	O
in	O
the	O
micellization	O
and	O
degradation	O
properties	O
of	O
poly	B
(	I
lactic	I
acid	I
)	I
-block	I
-	I
poly	I
(	I
ethylene	I
glycol	I
)	I
copolymers	O
.	O

Poly	B
(	I
lactic	I
acid	I
)	I
-block	I
-	I
poly	I
(	I
ethylene	I
glycol	I
)	I
copolymers	O
(	O
PLA	B
-	I
b	I
-	I
PEG	I
)	O
featuring	O
varying	O
tacticities	O
(	O
atactic	O
,	O
heterotactic	O
,	O
isotactic	O
)	O
in	O
the	O
PLA	B
block	O
were	O
synthesized	O
and	O
investigated	O
for	O
their	O
micellar	O
stability	O
,	O
degradation	O
,	O
and	O
thermal	O
properties	O
.	O

Utilizing	O
tin	B
(	I
II	I
)	I
bis	I
(	I
2-ethylhexanoate	I
)	I
,	O
aluminum	B
salan	I
,	O
and	O
aluminum	B
salen	I
catalysts	O
,	O
the	O
copolymers	O
were	O
synthesized	O
through	O
the	O
ring	O
-	O
opening	O
polymerization	O
of	O
d-	O
,	O
l-	O
,	O
rac-	O
,	O
or	O
a	O
blend	O
of	O
l-	B
and	I
rac	I
-	I
lactide	I
using	O
monomethoxy	B
-	I
poly	I
(	I
ethylene	I
glycol	I
)	I
as	O
a	O
macroinitiator	O
.	O

The	O
critical	O
micelle	O
concentration	O
,	O
which	O
reflects	O
the	O
micellar	O
stability	O
,	O
was	O
probed	O
using	O
a	O
fluorescence	O
spectroscopic	O
method	O
with	O
pyrene	B
as	O
the	O
probe	O
.	O

The	O
copolymers	O
were	O
degraded	O
in	O
a	O
methanolic	O
solution	O
of	O
1,5,7-triaza	B
-	I
bicyclo	I
[	I
4.4.0	I
]	I
dec-5-ene	I
and	O
the	O
degradation	O
was	O
measured	O
by	O
(	B
1	I
)	I
H	I
NMR	O
spectroscopic	O
and	O
gel	O
permeation	O
chromatographic	O
analyses	O
.	O

Differential	O
scanning	O
calorimetry	O
and	O
thermogravimetric	O
analysis	O
provided	O
information	O
on	O
the	O
thermal	O
properties	O
of	O
the	O
copolymers	O
.	O

Atactic	O
and	O
heterotactic	O
microstructures	O
in	O
the	O
PLA	B
block	O
resulted	O
in	O
lower	O
micellar	O
stability	O
,	O
as	O
well	O
as	O
faster	O
degradation	O
and	O
shorter	O
erosion	O
time	O
compared	O
to	O
polymers	O
with	O
high	O
isotactic	O
enchainment	O
(	O
Pm	O
)	O
.	O

By	O
modification	O
of	O
the	O
Pm	O
,	O
micellar	O
stability	O
,	O
degradation	O
,	O
and	O
erosion	O
rates	O
of	O
the	O
copolymers	O
can	O
be	O
tuned	O
to	O
specific	O
biomedical	O
applications	O
.	O

Interestingly	O
,	O
while	O
tin	B
(	I
II	I
)	I
bis	I
(	I
2-ethylhexanoate	I
)	I
and	O
aluminum	B
salan	I
-	O
catalyzed	O
PLA	B
-	I
b	I
-	I
PEG	I
copolymers	O
exhibited	O
similar	O
micellization	O
behavior	O
,	O
the	O
aluminum	B
salen	I
-	O
catalyzed	O
PLA	B
-	I
b	I
-	I
PEG	I
exhibited	O
unique	O
behavior	O
at	O
high	O
micelle	O
concentration	O
in	O
the	O
presence	O
of	O
the	O
pyrene	B
probe	O
.	O

This	O
unique	O
behavior	O
can	O
be	O
attributed	O
to	O
the	O
disintegration	O
of	O
the	O
micelles	O
through	O
the	O
interactions	O
of	O
long	O
isotactic	O
stereoblock	O
segments	O
.	O

HIV	O
protease	O
inhibitors	O
in	O
pregnancy	O
:	O
pharmacology	O
and	O
clinical	O
use	O
.	O

The	O
impact	O
of	O
antiretroviral	O
therapy	O
(	O
ART	O
)	O
on	O
the	O
natural	O
history	O
of	O
HIV-1	O
infection	O
has	O
resulted	O
in	O
dramatic	O
reductions	O
in	O
disease	O
-	O
associated	O
morbidity	O
and	O
mortality	O
.	O

Additionally	O
,	O
the	O
epidemiology	O
of	O
HIV-1	O
infection	O
worldwide	O
is	O
changing	O
,	O
as	O
women	O
now	O
represent	O
a	O
substantial	O
proportion	O
of	O
infected	O
adults	O
.	O

As	O
more	O
highly	O
effective	O
and	O
tolerable	O
antiretroviral	O
regimens	O
become	O
available	O
,	O
and	O
as	O
the	O
prevention	O
of	O
mother	O
-	O
to	O
-	O
child	O
transmission	O
becomes	O
an	O
attainable	O
goal	O
in	O
the	O
management	O
of	O
HIV	O
-	O
infected	O
individuals	O
,	O
more	O
and	O
more	O
HIV	O
-	O
positive	O
women	O
are	O
choosing	O
to	O
become	O
pregnant	O
and	O
have	O
children	O
.	O

Consequently	O
,	O
it	O
is	O
important	O
to	O
consider	O
the	O
efficacy	O
and	O
safety	O
of	O
antiretroviral	O
agents	O
in	O
pregnancy	O
.	O

Protease	O
inhibitors	O
are	O
a	O
common	O
class	O
of	O
medication	O
used	O
in	O
the	O
treatment	O
of	O
HIV-1	O
infection	O
and	O
are	O
increasingly	O
being	O
used	O
in	O
pregnancy	O
.	O

However	O
,	O
several	O
studies	O
have	O
raised	O
concerns	O
regarding	O
pharmacokinetic	O
alterations	O
in	O
pregnancy	O
,	O
particularly	O
in	O
the	O
third	O
trimester	O
,	O
which	O
results	O
in	O
suboptimal	O
drug	O
concentrations	O
and	O
a	O
theoretically	O
higher	O
risk	O
of	O
virologic	O
failure	O
and	O
perinatal	O
transmission	O
.	O

Drug	O
level	O
reductions	O
have	O
been	O
observed	O
with	O
each	O
individual	O
protease	O
inhibitor	O
and	O
dose	O
adjustments	O
in	O
pregnancy	O
are	O
suggested	O
for	O
certain	O
agents	O
.	O

Furthermore	O
,	O
studies	O
have	O
also	O
raised	O
concerns	O
regarding	O
the	O
safety	O
of	O
protease	O
inhibitors	O
in	O
pregnancy	O
,	O
particularly	O
as	O
they	O
may	O
increase	O
the	O
risk	O
of	O
pre	O
-	O
term	O
birth	O
and	O
metabolic	O
disturbances	O
.	O

Overall	O
,	O
protease	O
inhibitors	O
are	O
safe	O
and	O
effective	O
for	O
the	O
treatment	O
of	O
HIV	O
-	O
infected	O
pregnant	O
women	O
.	O

Specifically	O
,	O
ritonavir	B
-	O
boosted	O
lopinavir-	B
and	O
atazanavir	B
-	O
based	O
regimens	O
are	O
preferred	O
in	O
pregnancy	O
,	O
while	O
ritonavir	B
-	O
boosted	O
darunavir-	B
and	O
saquinavir	B
-	O
based	O
therapies	O
are	O
reasonable	O
alternatives	O
.	O

This	O
paper	O
reviews	O
the	O
use	O
of	O
protease	O
inhibitors	O
in	O
pregnancy	O
,	O
focusing	O
on	O
pharmacokinetic	O
and	O
safety	O
considerations	O
,	O
and	O
outlines	O
the	O
recommendations	O
for	O
use	O
of	O
this	O
class	O
of	O
medication	O
in	O
the	O
HIV-1-infected	O
pregnant	O
woman	O
.	O

Increased	O
immunoreactive	O
11-ketotestosterone	B
concentrations	O
in	O
sheep	O
feces	O
after	O
acth	O
challenge	O
.	O

11-Oxoetiocholanolone	B
and	O
related	O
substances	O
are	O
important	O
metabolites	O
of	O
cortisol	B
and	O
are	O
excreted	O
via	O
feces	O
in	O
ruminants	O
.	O

To	O
investigate	O
whether	O
11-ketotestosterone	B
(	O
11-KT	B
)	O
or	O
its	O
immunoreactive	O
metabolites	O
are	O
formed	O
and	O
excreted	O
in	O
ruminant	O
feces	O
,	O
an	O
enzyme	O
immunoassay	O
(	O
EIA	O
)	O
was	O
developed	O
and	O
validated	O
.	O

The	O
antibody	O
was	O
raised	O
in	O
rabbits	O
against	O
11-KT-3-CMO	B
:	O
bovine	O
serum	O
albumin	O
with	O
biotinylated	B
11-KT	I
as	O
a	O
label	O
.	O

The	O
assay	O
showed	O
a	O
sensitivity	O
of	O
0.3	O
pg	O
/	O
well	O
.	O

To	O
validate	O
the	O
assay	O
biologically	O
,	O
6	O
rams	O
were	O
injected	O
with	O
a	O
synthetic	O
analogue	O
of	O
the	O
adrenocorticotropic	O
hormone	O
(	O
Synacthen	O
,	O
2	O
g	O
/	O
kg	O
body	O
wt	O
)	O
.	O

An	O
aliquot	O
was	O
collected	O
of	O
each	O
fecal	O
portion	O
spontaneously	O
defecated	O
8	O
h	O
before	O
Synacthen	O
injection	O
to	O
24	O
h	O
after	O
injection	O
and	O
stored	O
at	O
-20	O
	O
C	O
until	O
analysis	O
.	O

Samples	O
(	O
0.5	O
g	O
)	O
were	O
extracted	O
using	O
80	O
%	O
methanol	B
and	O
immunoreactive	O
metabolites	O
measured	O
using	O
the	O
11-KT	B
EIA	O
and	O
an	O
already	O
established	O
11,17-dioxoandrostane	B
(	O
11,17-DOA	B
)	O
EIA	O
.	O

High	O
-	O
performance	O
liquid	O
chromatography	O
separation	O
revealed	O
no	O
peak	O
in	O
the	O
same	O
elution	O
position	O
as	O
authentic	O
11-KT	B
;	O
therefore	O
,	O
reacting	O
substances	O
were	O
referred	O
to	O
as	O
11-KT	B
equivalents	O
.	O

In	O
the	O
case	O
of	O
11-KT	B
immunoreactive	O
substances	O
,	O
the	O
values	O
increased	O
from	O
baseline	O
(	O
median	O
,	O
136	O
ng	O
/	O
g	O
feces	O
)	O
to	O
a	O
peak	O
concentration	O
(	O
median	O
,	O
424	O
ng	O
/	O
g	O
)	O
10	O
to	O
14	O
h	O
after	O
Synacthen	O
injection	O
and	O
declined	O
afterwards	O
.	O

Concentrations	O
of	O
11,17-DOA	B
showed	O
the	O
same	O
pattern	O
,	O
but	O
the	O
values	O
were	O
2	O
to	O
4	O
times	O
higher	O
.	O

From	O
this	O
data	O
,	O
the	O
authors	O
conclude	O
that	O
11-KT	B
-	O
like	O
substances	O
,	O
specifically	O
C19	B
O3	I
-androgens	I
with	O
a	O
17	B
-	I
hydroxy	I
group	O
,	O
were	O
present	O
in	O
the	O
feces	O
.	O

These	O
substances	O
originate	O
from	O
the	O
adrenals	O
and	O
are	O
most	O
likely	O
cortisol	B
metabolites	O
.	O

Environ	O
Toxicol	O
Chem	O
2013;32:1332	O
-	O
1336	O
.	O

	O
2013	O
SETAC	O
.	O

Fractionation	O
of	O
organosolv	O
lignin	O
from	O
olive	O
tree	O
clippings	O
and	O
its	O
valorization	O
to	O
simple	O
phenolic	B
compounds	O
.	O

Lignin	O
valorization	O
practices	O
have	O
attracted	O
a	O
great	O
deal	O
of	O
interest	O
in	O
recent	O
years	O
due	O
to	O
the	O
large	O
excess	O
of	O
lignin	O
produced	O
by	O
the	O
pulp	O
and	O
paper	O
industry	O
,	O
together	O
with	O
second	O
-	O
generation	O
bioethanol	O
plants	O
.	O

In	O
this	O
work	O
,	O
a	O
new	O
lignin	O
valorization	O
approach	O
is	O
proposed	O
.	O

It	O
involves	O
ultrafiltration	O
as	O
a	O
fractionation	O
process	O
to	O
separate	O
different	O
molecular	O
weight	O
lignin	O
fractions	O
followed	O
by	O
a	O
hydrogen	B
-	O
free	O
,	O
mild	O
,	O
hydrogenolytic	O
,	O
heterogeneously	O
catalyzed	O
methodology	O
assisted	O
by	O
microwave	O
irradiation	O
to	O
obtain	O
simple	O
phenolic	B
,	O
monomeric	O
products	O
by	O
depolymerization	O
using	O
a	O
nickel	O
-	O
based	O
catalyst	O
.	O

The	O
main	O
products	O
obtained	O
were	O
desaspidinol	B
,	O
syringaldehyde	B
,	O
and	O
syringol	B
;	O
this	O
proves	O
the	O
efficiency	O
of	O
the	O
depolymerization	O
conditions	O
applied	O
.	O

The	O
concentration	O
of	O
these	O
observed	O
compounds	O
increased	O
when	O
the	O
molecular	O
weights	O
of	O
the	O
lignin	O
fractions	O
increased	O
.	O

The	O
applied	O
depolymerization	O
conditions	O
,	O
which	O
take	O
advantage	O
of	O
the	O
use	O
of	O
formic	B
acid	I
as	O
a	O
hydrogen	B
-	O
donating	O
solvent	O
,	O
did	O
not	O
generate	O
any	O
biochar	O
in	O
the	O
systems	O
.	O

Searching	O
the	O
coding	O
region	O
for	O
microRNA	O
targets	O
.	O

Finding	O
microRNA	O
targets	O
in	O
the	O
coding	O
region	O
is	O
difficult	O
due	O
to	O
the	O
overwhelming	O
signal	O
encoding	O
the	O
amino	B
acid	I
sequence	O
.	O

Here	O
,	O
we	O
introduce	O
an	O
algorithm	O
(	O
called	O
PACCMIT	O
-	O
CDS	O
)	O
that	O
finds	O
potential	O
microRNA	O
targets	O
within	O
coding	O
sequences	O
by	O
searching	O
for	O
conserved	O
motifs	O
that	O
are	O
complementary	O
to	O
the	O
microRNA	O
seed	O
region	O
and	O
also	O
overrepresented	O
in	O
comparison	O
with	O
a	O
background	O
model	O
preserving	O
both	O
codon	O
usage	O
and	O
amino	B
acid	I
sequence	O
.	O

Precision	O
and	O
sensitivity	O
of	O
PACCMIT	O
-	O
CDS	O
are	O
evaluated	O
using	O
PAR	O
-	O
CLIP	O
and	O
proteomics	O
data	O
sets	O
.	O

Thanks	O
to	O
the	O
properly	O
constructed	O
background	O
,	O
the	O
new	O
algorithm	O
achieves	O
a	O
lower	O
rate	O
of	O
false	O
positives	O
and	O
better	O
ranking	O
of	O
predictions	O
than	O
do	O
currently	O
available	O
algorithms	O
,	O
which	O
were	O
designed	O
to	O
find	O
microRNA	O
targets	O
within	O
3	O
'	O
UTRs	O
.	O

Switchable	O
Elastin	O
-	O
Like	O
Polypeptides	O
that	O
Respond	O
to	O
Chemical	O
Inducers	O
of	O
Dimerization	O
.	O

Elastin	O
-	O
like	O
polypeptides	O
(	O
ELPs	O
)	O
are	O
protein	O
polymers	O
that	O
reversibly	O
phase	O
separate	O
in	O
response	O
to	O
increased	O
temperature	O
,	O
pressure	O
,	O
concentration	O
,	O
ionic	O
strength	O
,	O
and	O
molecular	O
weight	O
.	O

If	O
it	O
were	O
possible	O
to	O
engineer	O
their	O
phase	O
separation	O
to	O
respond	O
to	O
specific	O
molecular	O
substrates	O
,	O
ELP	O
fusion	O
proteins	O
might	O
be	O
engineered	O
as	O
biosensors	O
,	O
smart	O
biomaterials	O
,	O
diagnostic	O
imaging	O
agents	O
,	O
and	O
targeted	O
therapies	O
.	O

What	O
has	O
been	O
lacking	O
is	O
a	O
strategy	O
to	O
design	O
ELPs	O
to	O
respond	O
to	O
specific	O
substrates	O
.	O

To	O
address	O
this	O
deficiency	O
,	O
we	O
report	O
that	O
ELP	O
fusion	O
proteins	O
phase	O
separate	O
in	O
response	O
to	O
chemical	O
inducers	O
of	O
dimerization	O
(	O
CID	O
)	O
.	O

The	O
rationale	O
is	O
that	O
ELP	O
phase	O
separation	O
depends	O
on	O
molecular	O
weight	O
,	O
concentration	O
,	O
and	O
local	O
hydrophobicity	O
;	O
therefore	O
,	O
processes	O
that	O
affect	O
these	O
properties	O
,	O
including	O
noncovalent	O
dimerization	O
,	O
can	O
be	O
tuned	O
to	O
produce	O
isothermal	O
phase	O
separation	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
constructs	O
were	O
evaluated	O
consisting	O
of	O
an	O
immunophilin	O
:	O
human	O
FK-506	B
binding	O
protein	O
12	O
(	O
FKBP	O
)	O
attached	O
to	O
an	O
ELP	O
.	O

Under	O
stoichiometric	O
binding	O
of	O
a	O
CID	O
,	O
the	O
fusion	O
protein	O
homodimerizes	O
and	O
triggers	O
phase	O
separation	O
.	O

This	O
dimerization	O
is	O
reversible	O
upon	O
saturation	O
with	O
excess	O
CID	O
or	O
competitive	O
binding	O
of	O
a	O
small	O
lipophilic	O
macrolide	O
to	O
FKBP	O
.	O

By	O
modulating	O
the	O
ELP	O
molecular	O
weight	O
,	O
phase	O
separation	O
was	O
tuned	O
for	O
isothermal	O
response	O
to	O
CID	O
at	O
physiological	O
ionic	O
strength	O
and	O
temperature	O
(	O
37	O
	O
C	O
)	O
.	O

To	O
interpret	O
the	O
relationship	O
between	O
transition	O
temperature	O
and	O
equilibrium	O
binding	O
constants	O
,	O
an	O
empirical	O
mathematical	O
model	O
was	O
employed	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
report	O
is	O
the	O
first	O
demonstration	O
of	O
reversible	O
ELP	O
switching	O
in	O
response	O
to	O
controlled	O
dimerization	O
.	O

Due	O
to	O
its	O
simplicity	O
,	O
this	O
strategy	O
may	O
be	O
useful	O
to	O
design	O
ELP	O
fusion	O
proteins	O
that	O
respond	O
to	O
specific	O
dimeric	O
biological	O
entities	O
.	O

Cause	O
and	O
prevention	O
of	O
moisture	O
-	O
induced	O
degradation	O
of	O
resistance	O
random	O
access	O
memory	O
nanodevices	O
.	O

Dielectric	O
thin	O
films	O
in	O
nanodevices	O
may	O
absorb	O
moisture	O
,	O
leading	O
to	O
physical	O
changes	O
and	O
property	O
/	O
performance	O
degradation	O
,	O
such	O
as	O
altered	O
data	O
storage	O
and	O
readout	O
in	O
resistance	O
random	O
access	O
memory	O
.	O

Here	O
we	O
demonstrate	O
using	O
a	O
nanometallic	O
memory	O
that	O
such	O
degradation	O
proceeds	O
via	O
nanoporosity	O
,	O
which	O
facilitates	O
water	O
wetting	O
in	O
otherwise	O
nonwetting	O
dielectrics	O
.	O

Electric	O
degradation	O
only	O
occurs	O
when	O
the	O
device	O
is	O
in	O
the	O
charge	O
-	O
storage	O
state	O
,	O
which	O
provides	O
a	O
nanoscale	O
dielectrophoretic	O
force	O
directing	O
H2O	B
to	O
internal	O
field	O
centers	O
(	O
sites	O
of	O
trapped	O
charge	O
)	O
to	O
enable	O
bond	O
rupture	O
and	O
charged	O
hydroxyl	B
formation	O
.	O

While	O
these	O
processes	O
are	O
dramatically	O
enhanced	O
by	O
an	O
external	O
DC	O
or	O
AC	O
field	O
and	O
electron	O
-	O
donating	O
electrodes	O
,	O
they	O
can	O
be	O
completely	O
prevented	O
by	O
eliminating	O
nanoporosity	O
,	O
depositing	O
a	O
barrier	O
layer	O
,	O
or	O
using	O
an	O
oxidation	O
-	O
resistant	O
electrode	O
.	O

These	O
findings	O
provide	O
insight	O
for	O
understanding	O
high	O
-	O
performance	O
memory	O
and	O
field	O
-	O
assisted	O
degradation	O
of	O
nanodevices	O
.	O

Faecal	O
Excretion	O
Dynamic	O
during	O
Subacute	O
Oral	O
Exposure	O
to	O
Different	O
Pb	B
Species	O
in	O
Rattus	O
norvegicus	O
.	O

Faecal	O
excretion	O
is	O
a	O
basic	O
means	O
of	O
detoxification	O
upon	O
ingestion	O
of	O
Pb	B
-	O
contaminated	O
feed	O
.	O

In	O
order	O
to	O
determine	O
a	O
time	O
course	O
of	O
Pb	B
elimination	O
after	O
oral	O
exposure	O
to	O
two	O
different	O
forms	O
of	O
this	O
heavy	O
metal	O
(	O
lead	B
acetate	I
vs.	O
phyto	O
-	O
bound	O
Pb	B
)	O
,	O
a	O
feeding	O
study	O
was	O
carried	O
out	O
in	O
experimental	O
rats	O
using	O
the	O
Pb	B
phyto	O
-	O
hyperaccumulator	O
Pistia	O
stratiotes	O
as	O
a	O
model	O
diet	O
.	O

The	O
effect	O
of	O
starvation	O
on	O
Pb	B
excretion	O
was	O
further	O
studied	O
in	O
rats	O
that	O
were	O
fed	O
plant	O
material	O
.	O

Twelve	O
Pb	B
doses	O
(	O
7	O
g	O
Pb	B
/	O
1	O
g	O
BW	O
)	O
were	O
administered	O
orally	O
over	O
a	O
5-week	O
period	O
.	O

Faeces	O
samples	O
were	O
collected	O
24	O
and	O
72	O
h	O
post	O
-	O
exposure	O
.	O

Inductively	O
coupled	O
plasma	O
optical	O
emission	O
spectrometry	O
and	O
electrothermal	O
absorption	O
spectrometry	O
methods	O
were	O
used	O
for	O
determination	O
of	O
heavy	O
metal	O
concentrations	O
.	O

Up	O
to	O
53	O
%	O
of	O
ingested	O
Pb	B
was	O
rapidly	O
eliminated	O
from	O
the	O
exposed	O
rats	O
via	O
faeces	O
within	O
24	O
h	O
after	O
exposure	O
.	O

Faecal	O
excretion	O
in	O
exposed	O
rats	O
differed	O
significantly	O
when	O
compared	O
to	O
that	O
of	O
the	O
control	O
group	O
.	O

Fasting	O
before	O
exposure	O
reduced	O
Pb	B
excretion	O
by	O
up	O
to	O
50	O
%	O
.	O

Faecal	O
excretions	O
of	O
both	O
examined	O
Pb	B
forms	O
exhibited	O
almost	O
identical	O
patterns	O
.	O

Considerable	O
differences	O
were	O
revealed	O
concerning	O
total	O
excretion	O
levels	O
;	O
lead	B
acetate	I
was	O
excreted	O
in	O
amount	O
greater	O
extent	O
than	O
those	O
of	O
phytobound	O
Pb	B
.	O

Results	O
of	O
our	O
study	O
suggest	O
that	O
Pb	B
forms	O
occurring	O
in	O
the	O
P.	O
stratiotes	O
tissues	O
are	O
absorbed	O
through	O
the	O
gastrointestinal	O
tract	O
to	O
a	O
greater	O
extent	O
than	O
Pb	B
from	O
lead	B
acetate	I
.	O

Therefore	O
,	O
higher	O
portions	O
of	O
ingested	O
Pb	B
can	O
be	O
available	O
for	O
potential	O
accumulation	O
in	O
tissues	O
of	O
exposed	O
subjects	O
.	O

Echinacea	O
sanguinea	O
and	O
Echinacea	O
pallida	O
extracts	O
stimulate	O
glucuronidation	O
and	O
basolateral	O
transfer	O
of	O
Bauer	O
alkamides	B
8	O
and	O
10	O
and	O
ketone	B
24	O
and	O
inhibit	O
P	O
-	O
glycoprotein	O
transporter	O
in	O
Caco-2	O
cells	O
.	O

The	O
use	O
of	O
Echinacea	O
as	O
a	O
medicinal	O
herb	O
is	O
prominent	O
in	O
the	O
United	O
States	O
,	O
and	O
many	O
studies	O
have	O
assessed	O
the	O
effectiveness	O
of	O
Echinacea	O
as	O
an	O
immunomodulator	O
.	O

We	O
hypothesized	O
that	O
Bauer	O
alkamides	B
8	O
,	O
10	O
,	O
and	O
11	O
and	O
ketone	B
24	O
were	O
absorbed	O
similarly	O
either	O
as	O
pure	O
compounds	O
or	O
from	O
Echinacea	O
sanguinea	O
and	O
Echinacea	O
pallida	O
ethanol	B
extracts	O
,	O
and	O
that	O
these	O
Echinacea	O
extracts	O
could	O
inhibit	O
the	O
P	O
-	O
glycoprotein	O
transporter	O
in	O
Caco-2	O
human	O
intestinal	O
epithelial	O
cells	O
.	O

Using	O
HPLC	O
analysis	O
,	O
the	O
permeation	O
rate	O
of	O
Bauer	O
alkamides	B
by	O
passive	O
diffusion	O
across	O
Caco-2	O
cells	O
corresponded	O
with	O
compound	O
hydrophilicity	O
(	O
alkamide	B
8	O
>	O
10	O
>	O
11	O
)	O
,	O
independent	O
of	O
the	O
plant	O
extract	O
matrix	O
.	O

Both	O
Echinacea	O
ethanol	B
extracts	O
stimulated	O
apparent	O
glucuronidation	O
and	O
basolateral	O
efflux	O
of	O
glucuronides	O
of	O
alkamides	B
8	O
and	O
10	O
but	O
not	O
alkamide	B
11	O
.	O

Bauer	O
ketone	B
24	O
was	O
totally	O
metabolized	O
to	O
more	O
hydrophilic	O
metabolites	O
when	O
administered	O
as	O
a	O
single	O
compound	O
,	O
but	O
was	O
also	O
glucuronidated	O
when	O
present	O
in	O
Echinacea	O
extracts	O
.	O

Bauer	O
alkamides	B
8	O
,	O
10	O
,	O
and	O
11	O
(	O
175	O
-	O
230	O
M	O
)	O
and	O
ethanol	B
extracts	O
of	O
E.	O
sanguinea	O
(	O
1	O
mg	O
/	O
mL	O
,	O
containing	O
~	O
90	O
M	O
total	O
alkamides	B
)	O
and	O
E.	O
pallida	O
(	O
5	O
mg	O
/	O
mL	O
,	O
containing	O
285	O
M	O
total	O
alkamides	O
)	O
decreased	O
the	O
efflux	O
of	O
the	O
P	O
-	O
glycoprotein	O
transporter	O
probe	O
calcein	O
-	O
AM	O
from	O
Caco-2	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
other	O
constituents	O
in	O
these	O
Echinacea	O
extracts	O
facilitated	O
the	O
metabolism	O
and	O
efflux	O
of	O
alkamides	B
and	O
ketones	B
,	O
which	O
might	O
improve	O
therapeutic	O
benefits	O
.	O

Alkamides	B
and	O
Echinacea	O
extracts	O
might	O
be	O
useful	O
in	O
potentiating	O
some	O
chemotherapeutics	O
,	O
which	O
are	O
substrates	O
for	O
the	O
P	O
-	O
glycoprotein	O
transporter	O
.	O

Concentrations	O
and	O
trends	O
of	O
halogenated	O
flame	O
retardants	O
in	O
the	O
pooled	O
serum	O
of	O
residents	O
of	O
Laizhou	O
Bay	O
,	O
China	O
.	O

The	O
south	O
coast	O
of	O
Laizhou	O
Bay	O
,	O
in	O
northeastern	O
China	O
,	O
is	O
a	O
production	O
area	O
for	O
halogenated	O
flame	O
retardants	O
(	O
HFR	O
)	O
.	O

In	O
2007	O
,	O
the	O
authors	O
measured	O
serum	O
concentrations	O
of	O
polybrominated	B
diphenyl	I
ethers	I
(	O
PBDEs	B
)	O
in	O
Laizhou	O
Bay	O
residents	O
.	O

To	O
assess	O
the	O
PBDE	B
concentration	O
trend	O
,	O
and	O
determine	O
the	O
concentrations	O
of	O
the	O
emerging	O
flame	O
retardants	O
Dechlorane	B
Plus	I
(	O
DP	O
)	O
and	O
bis	B
(	I
2-ethylhexyl	I
)	I
-3,4,5,6-tetrabromophthalate	I
(	O
TBPH	B
)	O
,	O
the	O
authors	O
measured	O
the	O
concentrations	O
of	O
8	O
PBDE	B
congeners	O
,	O
2	O
DP	O
isomers	O
,	O
and	O
TBPH	B
in	O
10	O
composite	O
samples	O
,	O
which	O
were	O
pooled	O
from	O
the	O
serum	O
collected	O
from	O
305	O
Laizhou	O
Bay	O
residents	O
in	O
October	O
2011	O
.	O

The	O
average	O
concentration	O
of	O
the	O
total	O
PBDE	B
(	O
8	O
PBDE	B
)	O
concentration	O
in	O
all	O
serum	O
pools	O
was	O
240	O
ng	O
/	O
g	O
lipid	O
weight	O
,	O
and	O
the	O
highest	O
serum	O
pool	O
concentration	O
(	O
in	O
the	O
30-	O
to	O
39-yr	O
-	O
old	O
male	O
group	O
)	O
was	O
780	O
ng	O
/	O
g	O
lipid	O
weight	O
.	O

Brominated	B
diphenyl	I
ether-209	I
was	O
the	O
dominant	O
congener	O
,	O
accounting	O
for	O
87	O
%	O
of	O
8	O
PBDE	B
.	O

Compared	O
with	O
a	O
previous	O
study	O
,	O
8	O
PBDE	B
serum	O
concentrations	O
in	O
the	O
present	O
study	O
showed	O
no	O
change	O
in	O
order	O
of	O
magnitude	O
,	O
but	O
the	O
relative	O
contribution	O
of	O
BDE-209	B
to	O
8	O
PBDE	B
was	O
higher	O
.	O

The	O
average	O
concentration	O
of	O
DP	O
in	O
all	O
serum	O
pools	O
was	O
3.6	O
ng	O
/	O
g	O
lipid	O
weight	O
,	O
ranging	O
from	O
1.4	O
ng	O
/	O
g	O
lipid	O
weight	O
(	O
in	O
the	O
50-	O
to	O
59-yr	O
-	O
old	O
male	O
group	O
)	O
to	O
11	O
ng	O
/	O
g	O
lipid	O
weight	O
(	O
in	O
the	O
20-	O
to	O
29-yr	O
-	O
old	O
male	O
group	O
)	O
.	O

The	O
concentration	O
of	O
DP	O
was	O
lower	O
than	O
in	O
other	O
reported	O
studies	O
.	O

The	O
study	O
also	O
detected	O
TBPH	B
in	O
the	O
30-	O
to	O
39-yr	O
-	O
old	O
female	O
group	O
,	O
suggesting	O
that	O
TBPH	B
,	O
as	O
an	O
emerging	O
HFR	O
,	O
requires	O
further	O
monitoring	O
.	O

Environ	O
Toxicol	O
Chem	O
2013;32:1242	O
-	O
1247	O
.	O

	O
2013	O
SETAC	O
.	O

The	O
renin	O
-	O
angiotensin	O
system	O
:	O
new	O
insight	O
into	O
old	O
therapies	O
.	O

Although	O
the	O
renin	O
-	O
angiotensin	O
system	O
(	O
RAS	O
)	O
is	O
already	O
an	O
old	O
acquaintance	O
,	O
there	O
are	O
often	O
exciting	O
discoveries	O
that	O
improve	O
our	O
knowledge	O
of	O
it	O
and	O
open	O
new	O
therapeutic	O
possibilities	O
.	O

Moreover	O
,	O
well	O
-	O
established	O
drugs	O
,	O
such	O
as	O
angiotensin	O
-	O
converting	O
enzyme	O
inhibitors	O
(	O
ACEI	O
)	O
,	O
angiotensin	O
receptor	O
blockers	O
(	O
ARB	O
)	O
,	O
or	O
beta	O
-	O
blockers	O
,	O
show	O
that	O
their	O
mechanism	O
of	O
action	O
may	O
be	O
the	O
result	O
of	O
parallel	O
pathways	O
other	O
than	O
the	O
ones	O
initially	O
established	O
.	O

A	O
detailed	O
analysis	O
of	O
the	O
RAS	O
can	O
be	O
carried	O
out	O
in	O
part	O
through	O
the	O
study	O
of	O
the	O
enzymes	O
,	O
named	O
angiotensinases	O
,	O
involved	O
in	O
its	O
cascade	O
,	O
whose	O
activity	O
is	O
a	O
reflection	O
of	O
the	O
functionality	O
of	O
their	O
peptide	O
substrates	O
.	O

The	O
study	O
of	O
these	O
enzymes	O
offers	O
the	O
possibility	O
of	O
controlling	O
the	O
effects	O
of	O
angiotensins	O
through	O
various	O
pharmacological	O
manipulations	O
.	O

For	O
example	O
,	O
angiotensinase	O
inhibitors	O
or	O
activators	O
are	O
being	O
used	O
or	O
have	O
been	O
proposed	O
as	O
antihypertensive	O
agents	O
.	O

They	O
have	O
also	O
been	O
suggested	O
as	O
analgesic	O
and	O
antidepressant	O
drugs	O
or	O
targets	O
for	O
drug	O
development	O
against	O
different	O
pathologies	O
such	O
as	O
Alzheimer	O
's	O
disease	O
,	O
epilepsy	O
or	O
ischemia	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
analysis	O
of	O
brain	O
asymmetry	O
has	O
revealed	O
surprising	O
results	O
about	O
the	O
laterality	O
of	O
central	O
and	O
peripheral	O
components	O
of	O
the	O
RAS	O
.	O

Such	O
studies	O
indicate	O
that	O
the	O
neurovisceral	O
integration	O
,	O
already	O
proposed	O
by	O
Claude	O
Bernard	O
(	O
1867	O
)	O
should	O
also	O
be	O
analyzed	O
from	O
a	O
bilateral	O
perspective	O
.	O

In	O
this	O
review	O
,	O
the	O
RAS	O
and	O
the	O
role	O
of	O
various	O
angiotensinases	O
implicated	O
in	O
the	O
cascade	O
are	O
revisited	O
.	O

Therapeutic	O
strategies	O
involving	O
some	O
components	O
of	O
the	O
RAS	O
with	O
an	O
unusual	O
vision	O
resulting	O
from	O
a	O
bilateral	O
perspective	O
added	O
to	O
their	O
study	O
are	O
discussed	O
.	O

Myeloid	O
derived	O
suppressor	O
cells	O
and	O
their	O
role	O
in	O
diseases	O
.	O

Myeloid	O
derived	O
suppressor	O
cells	O
(	O
MDSCs	O
)	O
are	O
a	O
heterogeneous	O
population	O
of	O
myeloid	O
progenitors	O
that	O
can	O
play	O
a	O
major	O
role	O
in	O
tumour	O
development	O
and	O
chronic	O
inflammation	O
.	O

The	O
importance	O
of	O
the	O
suppressive	O
function	O
ofMDSCs	O
was	O
first	O
suggested	O
by	O
studies	O
involving	O
cancer	O
patients	O
and	O
cancer	O
-	O
bearing	O
mice	O
.	O

In	O
addition	O
,	O
recent	O
studies	O
have	O
demonstrated	O
that	O
MDSCs	O
can	O
also	O
be	O
involved	O
in	O
many	O
other	O
pathological	O
conditions	O
.	O

MDSCs	O
have	O
unique	O
ways	O
of	O
abrogatingan	O
immune	O
response	O
in	O
addition	O
to	O
those	O
utilised	O
by	O
other	O
immune	O
-	O
suppressive	O
cell	O
types	O
,	O
for	O
example	O
via	O
the	O
induction	O
of	O
arginase-1	O
and	O
consequent	O
upregulation	O
in	O
reactive	O
oxygen	B
species	O
(	O
ROS	O
)	O
production	O
.	O

Due	O
to	O
their	O
heterogeneity	O
,	O
they	O
further	O
can	O
express	O
a	O
variety	O
of	O
lineage	O
markers	O
,	O
which	O
overlap	O
with	O
other	O
myeloid	O
cell	O
types	O
such	O
as	O
Gr1,CD11b	O
,	O
MHCIIlo	O
,	O
Ly6C	O
and	O
Ly6	O
G	O
,	O
making	O
it	O
difficult	O
to	O
identify	O
them	O
by	O
surface	O
phenotype	O
alone	O
.	O

The	O
disparity	O
between	O
mouse	O
and	O
human	O
MDSCs	O
further	O
complicates	O
the	O
identification	O
of	O
these	O
elusive	O
cell	O
populations	O
.	O

In	O
this	O
review	O
,	O
we	O
will	O
summarise	O
the	O
recent	O
updates	O
on	O
the	O
methods	O
for	O
eliciting	O
and	O
studying	O
different	O
MDSC	O
subsets	O
,	O
including	O
newly	O
proposed	O
surface	O
phenotypes	O
,	O
as	O
well	O
as	O
insights	O
into	O
how	O
their	O
function	O
is	O
being	O
characterised	O
in	O
both	O
mice	O
and	O
humans	O
.	O

In	O
addition	O
,	O
exciting	O
new	O
discoveries	O
suggesting	O
their	O
involvement	O
across	O
a	O
number	O
of	O
different	O
pathological	O
settings	O
,	O
such	O
as	O
sepsis	O
,	O
autoimmunity	O
and	O
Leishmaniasis	O
,	O
will	O
be	O
discussed	O
.	O

Developing	O
FGFR4	O
inhibitors	O
as	O
potential	O
anti	O
-	O
cancer	O
agents	O
via	O
in	O
silico	O
design	O
,	O
supported	O
by	O
in	O
vitro	O
and	O
cell	O
-	O
based	O
testing	O
.	O

Fibroblast	O
growth	O
factor	O
receptor-4	O
(	O
FGFR4	O
)	O
is	O
a	O
tyrosine	B
kinase	O
with	O
a	O
range	O
of	O
important	O
physiological	O
functions	O
.	O

However	O
,	O
it	O
is	O
also	O
frequently	O
mutated	O
in	O
various	O
cancers	O
and	O
is	O
now	O
generating	O
significant	O
interest	O
as	O
a	O
potential	O
therapeutic	O
target	O
.	O

Unfortunately	O
,	O
biochemical	O
characterization	O
of	O
its	O
role	O
in	O
disease	O
,	O
and	O
further	O
evaluation	O
as	O
a	O
drug	O
target	O
is	O
hampered	O
by	O
lack	O
of	O
a	O
specific	O
inhibitor	O
.	O

We	O
aimed	O
to	O
discover	O
new	O
inhibitors	O
for	O
FGFR4	O
ab	O
initio	O
using	O
a	O
strategy	O
combining	O
in	O
silico	O
,	O
in	O
vitro	O
and	O
cell	O
-	O
based	O
assays	O
.	O

We	O
used	O
the	O
homologous	O
FGFR1	O
to	O
calculate	O
docking	O
scores	O
of	O
a	O
chemically	O
-	O
diverse	O
library	O
of	O
approximately	O
2000	O
potential	O
kinase	O
inhibitors	O
.	O

Nineteen	O
potential	O
inhibitors	O
and	O
ten	O
randomly-	O
selected	O
negative	O
controls	O
were	O
taken	O
forward	O
for	O
in	O
vitro	O
FGFR4	O
kinase	O
assays	O
.	O

All	O
compounds	O
with	O
good	O
docking	O
scores	O
significantly	O
inhibited	O
FGFR4	O
kinase	O
activity	O
,	O
some	O
with	O
sub	O
-	O
micromolar	O
(	O
most	O
potent	O
being	O
V4	B
-	I
015	I
with	O
an	O
IC	O
(	O
50	O
)	O
of	O
0.04	O
M	O
)	O
.	O

Four	O
of	O
these	O
compounds	O
also	O
demonstrated	O
substantial	O
activity	O
in	O
cellular	O
assays	O
using	O
the	O
FGFR4-	O
overexpressing	O
breast	O
carcinoma	O
cell	O
line	O
,	O
MDA	O
-	O
MB453	O
.	O

Through	O
immunoblot	O
assays	O
,	O
these	O
compounds	O
were	O
shown	O
to	O
block	O
the	O
phosphorylation	O
of	O
the	O
FGFR4	O
adaptor	O
protein	O
,	O
FGFR	O
substrate	O
protein-2	O
(	O
FRS2	O
)	O
.	O

The	O
most	O
potent	O
compound	O
to	O
date	O
,	O
V4	B
-	I
015	I
,	O
suppressed	O
proliferation	O
of	O
MDA	O
-	O
MB453	O
cells	O
at	O
sub	O
-	O
micromolar	O
concentrations	O
,	O
activated	O
the	O
pro	O
-	O
apoptotic	O
caspases	O
3	O
/	O
7	O
and	O
inhibited	O
cellular	O
migration	O
.	O

While	O
achieving	O
complete	O
selectivity	O
of	O
this	O
compound	O
for	O
FGFR4	O
will	O
require	O
further	O
lead	O
optimization	O
,	O
this	O
study	O
has	O
successfully	O
identified	O
new	O
chemical	O
scaffolds	O
with	O
unprecedented	O
FGFR4	O
inhibition	O
capacities	O
that	O
will	O
support	O
mechanism	O
of	O
action	O
studies	O
and	O
future	O
anti	O
-	O
cancer	O
drug	O
design	O
.	O

Long	O
-	O
Acting	O
Beta	O
-	O
Agonists	O
and	O
their	O
Association	O
with	O
Inhaled	O
Corticosteroids	O
in	O
COPD	O
.	O

Inhaled	O
bronchodilators	O
,	O
including	O
beta2-agonists	O
and	O
antimuscaric	O
receptor	O
antagonists	O
,	O
are	O
the	O
mainstay	O
of	O
pharmacotherapy	O
in	O
chronic	O
obstructive	O
pulmonary	O
disease	O
(	O
COPD	O
)	O
.	O

The	O
short	O
-	O
acting	O
beta2-agonists	O
,	O
including	O
salbutamol	B
,	O
and	O
fenoterol	B
,	O
have	O
a	O
rapid	O
onset	O
of	O
action	O
,	O
a	O
bronchodilating	O
effect	O
for	O
3	O
-	O
6	O
h	O
and	O
are	O
used	O
on	O
demand	O
.	O

The	O
longacting	O
beta2-agonists	O
(	O
LABAs	O
)	O
,	O
including	O
salmeterol	B
and	O
formoterol	B
,	O
have	O
12-hour	O
duration	O
of	O
action	O
and	O
are	O
used	O
with	O
a	O
twice	O
-	O
daily	O
dosing	O
regimen	O
for	O
long	O
-	O
term	O
COPD	O
treatment	O
.	O

Unlike	O
salmeterol	B
,	O
formoterol	B
has	O
a	O
rapid	O
onset	O
of	O
action	O
.	O

Pharmacological	O
characteristics	O
required	O
by	O
novel	O
inhaled	O
LABAs	O
include	O
24	O
h	O
bronchodilator	O
effect	O
in	O
vivo	O
which	O
would	O
make	O
them	O
suitable	O
for	O
once	O
daily	O
administration	O
(	O
ultra	O
-	O
LABA	O
)	O
,	O
high	O
potency	O
and	O
selectivity	O
for	O
beta2-adrenoceptors	O
,	O
rapid	O
onset	O
of	O
action	O
,	O
low	O
oral	O
bioavailability	O
(	O
<	O
5	O
%	O
)	O
after	O
inhalation	O
,	O
and	O
high	O
systemic	O
clearance	O
.	O

Indacaterol	B
,	O
which	O
has	O
been	O
approved	O
for	O
long	O
-	O
term	O
treatment	O
of	O
COPD	O
in	O
Europe	O
and	O
in	O
the	O
USA	O
,	O
has	O
a	O
24-h	O
duration	O
of	O
action	O
and	O
a	O
once	O
-	O
daily	O
dosing	O
regimen	O
.	O

Newer	O
ultra	O
-	O
LABAs	O
,	O
including	O
olodaterol	B
,	O
vilanterol	B
,	O
milveterol	B
,	O
carmoterol	B
,	O
and	O
abediterol	B
,	O
are	O
in	O
development	O
.	O

Combination	O
with	O
ICS	O
(	O
fluticasone	B
/	O
salmeterol	B
,	O
budesonide	B
/	O
formoterol	B
,	O
beclomethasone	B
/	O
formoterol	B
)	O
appears	O
to	O
provide	O
an	O
additional	O
benefit	O
over	O
the	O
monocomponent	O
therapy	O
,	O
although	O
the	O
extent	O
of	O
this	O
benefit	O
is	O
variable	O
and	O
often	O
not	O
clinically	O
significant	O
in	O
all	O
the	O
endpoints	O
assessed	O
.	O

In	O
patients	O
with	O
COPD	O
,	O
treatment	O
with	O
ICS	O
is	O
associated	O
with	O
increased	O
risk	O
of	O
pneumonia	O
which	O
should	O
be	O
carefully	O
considered	O
when	O
assessing	O
the	O
risk	O
/	O
benefit	O
ratio	O
of	O
ICS	O
/	O
LABA	O
combinations	O
.	O

Subphenotyping	O
of	O
patients	O
with	O
COPD	O
(	O
e.g.	O
,	O
frequent	O
exacerbations	O
,	O
sputum	O
eosinophilia	O
,	O
mixed	O
asthma	O
/	O
COPD	O
phenotype	O
)	O
might	O
help	O
identify	O
those	O
patients	O
who	O
are	O
most	O
likely	O
to	O
benefit	O
from	O
addition	O
of	O
ICS	O
to	O
bronchodilating	O
treatment	O
.	O

Ultra	O
-	O
LABA	O
/	O
long	O
-	O
acting	O
muscarinic	O
receptor	O
antagonist	O
(	O
LAMA	O
)	O
combination	O
treatment	O
is	O
under	O
development	O
and	O
is	O
likely	O
to	O
become	O
a	O
standard	O
pharmacological	O
strategy	O
for	O
COPD	O
.	O

Dual	O
-	O
pharmacology	O
inhaled	O
muscarinic	O
antagonist	O
-	O
beta2	O
agonist	O
(	O
MABA	O
)	O
molecules	O
provide	O
a	O
new	O
approach	O
to	O
the	O
treatment	O
of	O
COPD	O
.	O

The	O
therapeutic	O
potential	O
of	O
allosteric	O
ligands	O
for	O
free	O
fatty	B
acid	I
sensitive	O
GPCRs	O
.	O

G	O
protein	O
coupled	O
receptors	O
(	O
GPCRs	O
)	O
are	O
the	O
most	O
historically	O
successful	O
therapeutic	O
targets	O
.	O

Despite	O
this	O
success	O
there	O
are	O
many	O
important	O
aspects	O
of	O
GPCR	O
pharmacology	O
and	O
function	O
that	O
have	O
yet	O
to	O
be	O
exploited	O
to	O
their	O
full	O
therapeutic	O
potential	O
.	O

One	O
in	O
particular	O
that	O
has	O
been	O
gaining	O
attention	O
in	O
recent	O
times	O
is	O
that	O
of	O
GPCR	O
ligands	O
that	O
bind	O
to	O
allosteric	O
sites	O
on	O
the	O
receptor	O
distinct	O
from	O
the	O
orthosteric	O
site	O
of	O
the	O
endogenous	O
ligand	O
.	O

As	O
therapeutics	O
,	O
allosteric	O
ligands	O
possess	O
many	O
theoretical	O
advantages	O
over	O
their	O
orthosteric	O
counterparts	O
,	O
including	O
more	O
complex	O
modes	O
of	O
action	O
,	O
improved	O
safety	O
,	O
more	O
physiologically	O
appropriate	O
responses	O
,	O
better	O
target	O
selectivity	O
,	O
and	O
reduced	O
likelihood	O
of	O
desensitisation	O
and	O
tachyphylaxis	O
.	O

Despite	O
these	O
advantages	O
,	O
the	O
development	O
of	O
allosteric	O
ligands	O
is	O
often	O
difficult	O
from	O
a	O
medicinal	O
chemistry	O
standpoint	O
due	O
to	O
the	O
more	O
complex	O
challenge	O
of	O
identifying	O
allosteric	O
leads	O
and	O
their	O
often	O
flat	O
or	O
confusing	O
SAR	O
.	O

The	O
present	O
review	O
will	O
consider	O
the	O
advantages	O
and	O
challenges	O
associated	O
with	O
allosteric	O
GPCR	O
ligands	O
,	O
and	O
examine	O
how	O
the	O
particular	O
properties	O
of	O
these	O
ligands	O
may	O
be	O
exploited	O
to	O
uncover	O
the	O
therapeutic	O
potential	O
for	O
free	O
fatty	B
acid	I
sensitive	O
GPCRs	O
.	O

Aspulvinones	B
from	O
a	O
mangrove	O
rhizosphere	O
soil	O
-	O
derived	O
fungus	O
Aspergillus	O
terreus	O
Gwq-48	O
with	O
anti	O
-	O
influenza	O
A	O
viral	O
(	O
H1N1	O
)	O
activity	O
.	O

A	O
new	O
butenolide	B
isoaspulvinone	B
E	I
(	O
1	O
)	O
,	O
together	O
with	O
two	O
known	O
butenolides	B
aspulvinone	B
E	I
(	O
2	O
)	O
and	O
pulvic	B
acid	I
(	O
3	O
)	O
were	O
isolated	O
from	O
the	O
marine	O
-	O
derived	O
fungus	O
,	O
Aspergillus	O
terreus	O
Gwq-48	O
.	O

They	O
showed	O
significant	O
anti	O
-	O
influenza	O
A	O
H1N1	O
virus	O
activities	O
,	O
with	O
IC50	O
values	O
of	O
32.3	O
,	O
56.9	O
,	O
and	O
29.1g	O
/	O
mL	O
,	O
respectively	O
.	O

Moreover	O
,	O
only	O
compound	O
1	O
exhibited	O
effective	O
inhibitory	O
activity	O
against	O
H1N1	O
viral	O
neuraminidase	O
(	O
NA	O
)	O
,	O
and	O
docking	O
of	O
two	O
isomers	O
(	O
1	O
-	O
2	O
)	O
into	O
the	O
active	O
sites	O
of	O
NA	O
showed	O
that	O
the	O
E	O
double	O
bond	O
	O
(	O
5	O
(	O
10	O
)	O
)	O
was	O
essential	O
to	O
achieve	O
activity	O
.	O

A	O
novel	O
fluorogenic	O
substrate	O
for	O
dinuclear	O
Zn	B
(	I
II	I
)	I
-containing	O
metallo	O
-	O
	O
-	O
lactamases	O
.	O

In	O
an	O
effort	O
to	O
prepare	O
a	O
fluorogenic	O
substrate	O
to	O
be	O
used	O
in	O
activity	O
assays	O
with	O
metallo	O
-	O
	O
-	O
lactamases	O
,	O
(	B
6R,7R	I
)	I
-8-oxo-7-	I
(	I
2-oxo-2H	I
-	I
chromene-3-carboxamido	I
)	I
-3-	I
(	I
(	I
4-	I
(	I
2-oxo-2H	I
-	I
chromene-3-carboxamido	I
)	I
-phenylthio	I
)	I
methyl	I
)	I
-5-thia-1-azabicyclo	I
[	I
4.2.0	I
]	I
oct-2-ene-2-carboxylic	I
acid	I
(	O
CA	O
)	O
was	O
synthesized	O
and	O
characterized	O
.	O

CA	O
exhibited	O
a	O
fluorescence	O
quantum	O
yield	O
(	O
	O
)	O
of	O
0.0059	O
,	O
two	O
fluorescence	O
lifetimes	O
of	O
3.63	O
	O
10	O
(	O
-10	O
)	O
and	O
5.38	O
	O
10	O
(	O
-9	O
)	O
s	O
,	O
and	O
fluorescence	O
intensity	O
that	O
is	O
concentration	O
-	O
dependent	O
.	O

Steady	O
-	O
state	O
kinetic	O
assays	O
revealed	O
that	O
CA	O
is	O
a	O
substrate	O
for	O
metallo	O
-	O
	O
-	O
lactamases	O
(	O
MLs	O
)	O
L1	O
and	O
CcrA	O
,	O
exhibiting	O
Km	O
and	O
kcat	O
values	O
of	O
18M	O
and	O
5s	O
(	O
-1	O
)	O
and	O
11M	O
and	O
17s	O
(	O
-1	O
)	O
,	O
respectively	O
.	O

Synthesis	O
and	O
physicochemical	O
properties	O
of	O
new	O
tripodal	O
amphiphiles	O
bearing	O
fatty	B
acids	I
as	O
a	O
hydrophobic	O
group	O
.	O

Saturated	B
fatty	I
acids	I
(	O
FA	O
)	O
were	O
grafted	O
using	O
tyrosine	B
as	O
a	O
spacer	O
group	O
to	O
the	O
cyclotriphosphazene	B
ring	O
along	O
with	O
equimolar	O
hydrophilic	O
methoxy	B
poly	I
(	I
ethylene	I
glycol	I
)	I
(	O
MPEG	B
)	O
in	O
cis	O
-	O
nongeminal	O
way	O
.	O

Seven	O
new	O
cyclotriphosphazene	B
amphiphiles	O
were	O
prepared	O
from	O
combinations	O
of	O
hydrophilic	O
MPEGs	B
with	O
different	O
molecular	O
weights	O
of	O
350	O
,	O
550	O
,	O
750	O
and	O
1000	O
and	O
four	O
different	O
fatty	B
acids	I
of	O
different	O
hydrophobicity	O
including	O
lauric	B
,	I
myristic	I
,	I
palmitic	I
and	I
stearic	I
acids	I
.	O

These	O
steric	O
amphiphiles	O
bearing	O
fatty	B
acids	I
as	O
a	O
hydrophobic	O
group	O
were	O
found	O
to	O
form	O
more	O
stable	O
micelles	O
with	O
very	O
low	O
critical	O
micelle	O
concentrations	O
(	O
CMC	O
)	O
(	O
2.95	O
-	O
7.80mg	O
/	O
L	O
)	O
compared	O
with	O
oligopeptide	O
analogues	O
,	O
and	O
their	O
highly	O
hydrophobic	O
core	O
environment	O
is	O
unique	O
and	O
potentially	O
useful	O
for	O
various	O
biomedical	O
applications	O
.	O

Electrochemical	O
determination	O
of	O
Sudan	B
I	I
in	O
food	O
samples	O
at	O
graphene	B
modified	O
glassy	O
carbon	B
electrode	O
based	O
on	O
the	O
enhancement	O
effect	O
of	O
sodium	B
dodecyl	I
sulphonate	I
.	O

This	O
paper	O
describes	O
a	O
novel	O
electrochemical	O
method	O
for	O
the	O
determination	O
of	O
Sudan	B
I	I
in	O
food	O
samples	O
based	O
on	O
the	O
electrochemical	O
catalytic	O
activity	O
of	O
graphene	B
modified	O
glassy	O
carbon	B
electrode	O
(	O
GMGCE	O
)	O
and	O
the	O
enhancement	O
effect	O
of	O
an	O
anionic	O
surfactant	O
:	O
sodium	B
dodecyl	I
sulphonate	I
(	O
SDS	B
)	O
.	O

Using	O
pH	O
6.0	O
phosphate	B
buffer	O
solution	O
(	O
PBS	O
)	O
as	O
supporting	O
electrolyte	O
and	O
in	O
the	O
presence	O
of	O
1.5	O
	O
10	O
(	O
-4	O
)	O
mol	O
L	O
(	O
-1	O
)	O
SDS	B
,	O
Sudan	B
I	I
yielded	O
a	O
well	O
-	O
defined	O
and	O
sensitive	O
oxidation	O
peak	O
at	O
a	O
GMGCE	O
.	O

The	O
oxidation	O
peak	O
current	O
of	O
Sudan	B
I	I
remarkably	O
increased	O
in	O
the	O
presence	O
of	O
SDS	B
.	O

The	O
experimental	O
parameters	O
,	O
such	O
as	O
supporting	O
electrolyte	O
,	O
concentration	O
of	O
SDS	B
,	O
and	O
accumulation	O
time	O
,	O
were	O
optimised	O
for	O
Sudan	B
I	I
determination	O
.	O

The	O
oxidation	O
peak	O
current	O
showed	O
a	O
linear	O
relationship	O
with	O
the	O
concentrations	O
of	O
Sudan	B
I	I
in	O
the	O
range	O
of	O
7.50	O
	O
10	O
(	O
-8	O
)	O
-7.50	O
	O
10	O
(	O
-6	O
)	O
mol	O
L	O
(	O
-1	O
)	O
,	O
with	O
the	O
detection	O
limit	O
of	O
4.0	O
	O
10	O
(	O
-8	O
)	O
mol	O
L	O
(	O
-1	O
)	O
.	O

This	O
new	O
voltammetric	O
method	O
was	O
successfully	O
used	O
to	O
determine	O
Sudan	B
I	I
in	O
food	O
products	O
such	O
as	O
ketchup	O
and	O
chili	O
sauce	O
with	O
satisfactory	O
results	O
.	O

Pterostilbene	B
inhibits	O
dimethylnitrosamine	B
-	O
induced	O
liver	O
fibrosis	O
in	O
rats	O
.	O

Pterostilbene	B
,	O
found	O
in	O
grapes	O
and	O
berries	O
,	O
exhibits	O
pleiotropic	O
effects	O
,	O
including	O
anti	O
-	O
inflammatory	O
,	O
antioxidant	O
,	O
and	O
anti	O
-	O
proliferative	O
activities	O
.	O

This	O
study	O
was	O
conducted	O
to	O
investigate	O
the	O
effect	O
of	O
pterostilbene	B
on	O
liver	O
fibrosis	O
and	O
the	O
potential	O
underlying	O
mechanism	O
for	O
such	O
effect	O
.	O

Sprague	O
-	O
Dawley	O
rats	O
were	O
intraperitoneally	O
given	O
dimethyl	B
n	I
-	I
nitrosamine	I
(	O
DMN	B
)	O
(	O
10mg	O
/	O
kg	O
)	O
3	O
days	O
per	O
week	O
for	O
4	O
weeks	O
.	O

Pterostilbene	B
(	O
10	O
or	O
20mg	O
/	O
kg	O
)	O
was	O
administered	O
by	O
oral	O
gavage	O
daily	O
.	O

Liver	O
function	O
,	O
morphology	O
,	O
histochemistry	O
,	O
and	O
fibrotic	O
parameters	O
were	O
examined	O
.	O

Pterostilbene	B
supplementation	O
alleviated	O
the	O
DMN	B
-	O
induced	O
changes	O
in	O
the	O
serum	O
levels	O
of	O
alanine	O
transaminase	O
and	O
aspartate	O
transaminase	O
(	O
p<0.05	O
)	O
.	O

Fibrotic	O
status	O
and	O
the	O
activation	O
of	O
hepatic	O
stellate	O
cells	O
were	O
improved	O
upon	O
pterostilbene	B
supplementation	O
as	O
evidenced	O
by	O
histopathological	O
examination	O
as	O
well	O
as	O
the	O
expression	O
of	O
	O
-	O
smooth	O
muscle	O
actin	O
(	O
	O
-	O
SMA	O
)	O
,	O
transforming	O
growth	O
factor	O
-	O
1	O
(	O
TGF	O
-	O
1	O
)	O
,	O
and	O
matrix	O
metalloproteinase	O
2	O
(	O
MMP2	O
)	O
.	O

These	O
data	O
demonstrated	O
that	O
pterostilbene	B
exhibited	O
hepatoprotective	O
effects	O
on	O
experimental	O
fibrosis	O
,	O
potentially	O
by	O
inhibiting	O
the	O
TGF	O
-	O
1	O
/	O
Smad	O
signaling	O
.	O

Thermal	O
-	O
induced	O
changes	O
of	O
kale	O
's	O
antioxidant	O
activity	O
analyzed	O
by	O
HPLC	O
-	O
UV	O
/	O
Vis	O
-	O
online	O
-	O
TEAC	O
detection	O
.	O

Generally	O
,	O
boiling	O
of	O
vegetables	O
is	O
assumed	O
leading	O
to	O
lower	O
nutritional	O
values	O
because	O
of	O
leaching	O
effects	O
and	O
activity	O
loss	O
of	O
bioactive	O
compounds	O
.	O

Kale	O
(	O
Brassica	O
oleracea	O
var	O
.	O

sabellica	O
)	O
reveals	O
a	O
great	O
diversity	O
of	O
flavonoids	B
,	O
which	O
have	O
been	O
shown	O
to	O
be	O
good	O
antioxidants	O
.	O

As	O
Brassica	O
vegetables	O
are	O
mainly	O
consumed	O
cooked	O
,	O
the	O
influence	O
of	O
boiling	O
on	O
kale	O
's	O
flavonoids	B
and	O
their	O
antioxidant	O
activity	O
was	O
investigated	O
.	O

Therefore	O
,	O
three	O
kale	O
cultivars	O
were	O
cooked	O
at	O
100	O
	O
C	O
for	O
2	O
and	O
4h	O
prior	O
to	O
analysis	O
.	O

The	O
total	O
phenolic	O
content	O
(	O
TPC	O
)	O
and	O
the	O
total	O
antioxidant	O
activity	O
(	O
TEAC	O
assay	O
and	O
EPR	O
spectrometry	O
)	O
of	O
each	O
cultivar	O
were	O
determined	O
and	O
revealed	O
no	O
change	O
,	O
independent	O
of	O
cooking	O
time	O
,	O
although	O
kale	O
samples	O
visually	O
altered	O
.	O

Using	O
the	O
HPLC	O
-	O
UV	O
/	O
Vis	O
-	O
online	O
-	O
TEAC	O
approach	O
,	O
distinct	O
changes	O
in	O
composition	O
and	O
antioxidant	O
activity	O
of	O
the	O
flavonoids	B
were	O
detectable	O
.	O

Thus	O
,	O
it	O
was	O
observable	O
,	O
that	O
the	O
antioxidant	O
activities	O
of	O
the	O
reaction	O
products	O
compensated	O
the	O
"	O
loss	O
"	O
of	O
the	O
antioxidant	O
activity	O
of	O
the	O
original	O
compounds	O
of	O
the	O
uncooked	O
material	O
.	O

Dispersive	O
liquid	O
-	O
liquid	O
microextraction	O
combined	O
with	O
field	O
-	O
amplified	O
sample	O
stacking	O
in	O
capillary	O
electrophoresis	O
for	O
the	O
determination	O
of	O
non	O
-	O
steroidal	B
anti	O
-	O
inflammatory	O
drugs	O
in	O
milk	O
and	O
dairy	O
products	O
.	O

Dispersive	O
liquid	O
-	O
liquid	O
microextraction	O
(	O
DLLME	O
)	O
was	O
coupled	O
with	O
field	O
-	O
amplified	O
sample	O
stacking	O
in	O
capillary	O
electrophoresis	O
(	O
FASS	O
)	O
for	O
the	O
determination	O
of	O
five	O
non	O
-	O
steroidal	B
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
in	O
bovine	O
milk	O
and	O
dairy	O
products	O
.	O

After	O
extraction	O
,	O
the	O
enriched	O
analytes	O
were	O
back	O
-	O
extracted	O
into	O
a	O
basic	O
aqueous	O
solution	O
for	O
injection	O
into	O
CE	O
.	O

Under	O
optimum	O
conditions	O
,	O
enrichment	O
factors	O
were	O
in	O
the	O
range	O
46	O
-	O
229	O
.	O

Limits	O
of	O
detection	O
of	O
the	O
analytes	O
ranged	O
from	O
3.0	O
to	O
13.1	O
g	O
kg	O
(	O
-1	O
)	O
for	O
all	O
matrices	O
analysed	O
.	O

Calibration	O
graphs	O
showed	O
good	O
linearity	O
with	O
coefficients	O
of	O
determination	O
(	O
R	O
(	O
2	O
)	O
)	O
	O
0.9915	O
and	O
relative	O
standard	O
deviations	O
(	O
RSD%	O
)	O
of	O
the	O
analyses	O
in	O
the	O
range	O
of	O
0.6	O
-	O
6.2	O
%	O
(	O
n=5	O
)	O
.	O

Recoveries	O
of	O
all	O
NSAIDs	O
from	O
bottled	O
milk	O
,	O
raw	O
milk	O
,	O
yogurt	O
and	O
white	O
cheese	O
samples	O
were	O
in	O
the	O
ranges	O
of	O
86.6	O
-	O
109.3	O
%	O
,	O
84.3	O
-	O
100.5	O
%	O
,	O
77.4	O
-	O
107.3	O
%	O
,	O
and	O
90.9	O
-	O
101.6	O
%	O
,	O
respectively	O
.	O

DLLME	O
-	O
FASS	O
-	O
CE	O
was	O
demonstrated	O
to	O
be	O
a	O
rapid	O
and	O
convenient	O
method	O
for	O
the	O
determination	O
of	O
NSAIDs	O
in	O
milk	O
and	O
dairy	O
products	O
.	O

Antioxidant	O
activities	O
of	O
the	O
synthesized	O
thiol	B
-	O
contained	O
peptides	O
derived	O
from	O
computer	O
-	O
aided	O
pepsin	O
hydrolysis	O
of	O
yam	O
tuber	O
storage	O
protein	O
,	O
dioscorin	B
.	O

Our	O
previous	O
report	O
showed	O
that	O
yam	O
dioscorin	B
and	O
its	O
peptic	O
hydrolysates	O
exhibit	O
radical	O
scavenging	O
activities	O
;	O
however	O
,	O
the	O
functions	O
of	O
these	O
peptic	O
hydrolases	O
are	O
still	O
under	O
investigation	O
.	O

In	O
this	O
study	O
,	O
the	O
thiol	B
-	O
containing	O
peptides	O
derived	O
from	O
computer	O
-	O
aided	O
simulation	O
of	O
pepsin	O
hydrolysis	O
of	O
dioscorin	B
,	O
namely	O
,	O
KTCGNGME	O
(	O
diotide1	O
)	O
,	O
PPCSE	O
(	O
diotide2	O
)	O
,	O
CDDRVIRTPLT	O
(	O
diotide3	O
)	O
,	O
KTCGY	O
(	O
diotide4	O
)	O
,	O
and	O
PPCTE	O
(	O
diotide5	O
)	O
were	O
synthesized	O
to	O
compare	O
their	O
antioxidant	O
activities	O
with	O
GSH	B
and/or	O
carnosine	B
by	O
examining	O
hydroxyl	B
radical	O
scavenging	O
activity	O
by	O
electron	O
spin	O
resonance	O
spectrometry	O
,	O
anti	O
-	O
low	O
-	O
density	O
lipoprotein	O
peroxidation	O
,	O
anti	O
-	O
AAPH	B
-	O
induced	O
hemolysis	O
,	O
and	O
oxygen	B
radical	O
absorbance	O
capacity	O
activity	O
.	O

We	O
found	O
that	O
while	O
all	O
the	O
synthesized	O
diotides	O
showed	O
antioxidant	O
activity	O
,	O
diotide4	O
exhibited	O
the	O
highest	O
levels	O
.	O

Moreover	O
,	O
all	O
diotides	O
(	O
100	O
M	O
)	O
showed	O
protective	O
effects	O
against	O
methylglyoxal	B
-	O
induced	O
human	O
umbilical	O
vein	O
endothelial	O
cell	O
death	O
.	O

These	O
results	O
suggest	O
that	O
thiol	B
-	O
containing	O
diotides	O
derived	O
from	O
dioscorin	B
hydrolysis	O
exhibit	O
antioxidant	O
activities	O
and	O
reveal	O
the	O
benefits	O
of	O
yam	O
tuber	O
as	O
an	O
antioxidant	O
-	O
rich	O
food	O
.	O

Winter	O
wheat	O
hull	O
(	O
husk	O
)	O
is	O
a	O
valuable	O
source	O
for	O
tricin	B
,	O
a	O
potential	O
selective	O
cytotoxic	O
agent	O
.	O

The	O
flavone	B
,	O
tricin	B
(	O
5,7,4'-trihydroxy-3',5'-dimethoxyflavone	B
)	O
has	O
great	O
potential	O
as	O
an	O
anticancer	O
agent	O
,	O
due	O
to	O
its	O
specific	O
chemopreventive	O
activity	O
.	O

In	O
spite	O
of	O
these	O
characteristics	O
,	O
its	O
use	O
in	O
preclinical	O
studies	O
is	O
still	O
limited	O
,	O
mainly	O
because	O
of	O
its	O
limited	O
availability	O
and	O
high	O
production	O
cost	O
.	O

Tricin	B
is	O
found	O
mainly	O
in	O
cereal	O
grains	O
,	O
such	O
as	O
wheat	O
,	O
rice	O
,	O
barley	O
,	O
oat	O
and	O
maize	O
.	O

However	O
,	O
its	O
concentration	O
in	O
these	O
plants	O
is	O
not	O
sufficient	O
for	O
commercial	O
use	O
.	O

To	O
find	O
a	O
reliable	O
,	O
rich	O
source	O
of	O
tricin	B
,	O
we	O
investigated	O
its	O
distribution	O
in	O
different	O
parts	O
of	O
wheat	O
(	O
Triticum	O
aestivum	O
)	O
and	O
designed	O
an	O
efficient	O
method	O
for	O
its	O
isolation	O
and	O
purification	O
.	O

The	O
highest	O
amount	O
(	O
770	O
	O
157	O
mg	O
/	O
kg	O
dry	O
weight	O
)	O
was	O
found	O
in	O
the	O
husks	O
of	O
winter	O
wheat	O
.	O

This	O
concentration	O
is	O
one	O
of	O
the	O
highest	O
in	O
any	O
plant	O
species	O
and	O
is	O
considered	O
as	O
a	O
cheap	O
source	O
of	O
natural	O
tricin	B
.	O

The	O
purified	O
wheat	O
husks	O
tricin	B
was	O
found	O
to	O
be	O
a	O
selective	O
potent	O
inhibitor	O
of	O
two	O
cancer	O
cell	O
lines	O
of	O
liver	O
and	O
pancreas	O
,	O
while	O
having	O
no	O
side	O
effects	O
on	O
normal	O
cells	O
.	O

This	O
selective	O
action	O
suggests	O
that	O
tricin	B
could	O
be	O
considered	O
as	O
a	O
potential	O
candidate	O
for	O
pre	O
-	O
clinical	O
trials	O
as	O
a	O
chemopreventive	O
agent	O
.	O

In	O
addition	O
,	O
fibre	O
-	O
rich	O
crude	O
wheat	O
husk	O
could	O
be	O
used	O
as	O
a	O
natural	O
chemopreventive	O
agent	O
in	O
food	O
supplement	O
.	O

Multidisciplinary	O
analytical	O
investigation	O
of	O
phospholipids	O
and	O
triglycerides	B
in	O
offshore	O
farmed	O
gilthead	O
sea	O
bream	O
(	O
Sparus	O
aurata	O
)	O
fed	O
commercial	O
diets	O
.	O

In	O
this	O
work	O
,	O
a	O
quantitative	O
characterisation	O
of	O
lipid	O
(	O
both	O
triglycerides	B
and	O
phospholipids	O
)	O
rearrangements	O
in	O
the	O
muscle	O
of	O
offshore	O
-	O
raised	O
gilthead	O
sea	O
bream	O
was	O
carried	O
out	O
as	O
a	O
function	O
of	O
fish	O
growth	O
between	O
April	O
and	O
September	O
.	O

Relative	O
percentages	O
of	O
lipid	O
classes	O
and	O
fatty	O
acids	B
/	O
acyls	B
composition	O
of	O
the	O
commercial	O
feeds	O
and	O
fish	O
dorsal	O
muscles	O
were	O
assessed	O
by	O
means	O
of	O
an	O
interdisciplinary	O
analytical	O
approach	O
.	O

A	O
combination	O
of	O
preparative	O
chemistry	O
and	O
experimental	O
results	O
from	O
NMR	O
spectroscopy	O
,	O
GC	O
,	O
3D	O
-	O
TLC	O
as	O
well	O
as	O
proximate	O
analysis	O
permitted	O
the	O
observed	O
growth	O
parameters	O
in	O
key	O
metabolic	O
events	O
to	O
be	O
linked	O
with	O
fish	O
fattening	O
and	O
lipid	O
turnover	O
.	O

While	O
defined	O
effects	O
of	O
feed	O
composition	O
on	O
fatty	B
acid	I
profiles	O
of	O
fillets	O
were	O
ascertained	O
,	O
the	O
relative	O
increase	O
of	O
fatty	B
acyls	I
in	O
triglycerides	B
and	O
phospholipids	O
were	O
also	O
estimated	O
enabling	O
detailed	O
evaluation	O
of	O
TAG	O
:	O
PL	O
ratio	O
in	O
adult	O
offshore	O
-	O
farmed	O
gilthead	O
sea	O
bream	O
.	O

NMR	O
was	O
also	O
used	O
to	O
quantify	O
PUFA	B
regiospecific	O
distribution	O
in	O
TAG	B
and	O
PL	O
.	O

Non	O
-	O
destructive	O
determination	O
of	O
chemical	O
composition	O
in	O
intact	O
and	O
minced	O
pork	O
using	O
near	O
-	O
infrared	O
hyperspectral	O
imaging	O
.	O

In	O
this	O
study	O
a	O
near	O
-	O
infrared	O
(	O
NIR	O
)	O
hyperspectral	O
imaging	O
technique	O
was	O
investigated	O
for	O
non	O
-	O
destructive	O
determination	O
of	O
chemical	O
composition	O
of	O
intact	O
and	O
minced	O
pork	O
.	O

Hyperspectral	O
images	O
(	O
900	O
-	O
1700	O
nm	O
)	O
were	O
acquired	O
for	O
both	O
intact	O
and	O
minced	O
pork	O
samples	O
and	O
the	O
mean	O
spectra	O
were	O
extracted	O
by	O
automatic	O
segmentation	O
.	O

Protein	O
,	O
moisture	O
and	O
fat	O
contents	O
were	O
determined	O
by	O
traditional	O
methods	O
and	O
then	O
related	O
with	O
the	O
spectral	O
information	O
by	O
partial	O
least	O
-	O
squares	O
(	O
PLS	O
)	O
regression	O
models	O
.	O

The	O
coefficient	O
of	O
determination	O
obtained	O
by	O
cross	O
-	O
validated	O
PLS	O
models	O
indicated	O
that	O
the	O
NIR	O
spectral	O
range	O
had	O
an	O
excellent	O
ability	O
to	O
predict	O
the	O
content	O
of	O
protein	O
(	O
R	O
(	O
2	O
)	O
(	O
cv	O
)	O
=0.88	O
)	O
,	O
moisture	O
(	O
R	O
(	O
2	O
)	O
(	O
cv	O
)	O
=0.87	O
)	O
and	O
fat	O
(	O
R	O
(	O
2	O
)	O
(	O
cv	O
)	O
=0.95	O
)	O
in	O
pork	O
.	O

Regression	O
models	O
using	O
a	O
few	O
selected	O
feature	O
-	O
related	O
wavelengths	O
showed	O
that	O
chemical	O
composition	O
could	O
be	O
predicted	O
with	O
coefficients	O
of	O
determination	O
of	O
0.92	O
,	O
0.87	O
and	O
0.95	O
for	O
protein	O
,	O
moisture	O
and	O
fat	O
,	O
respectively	O
.	O

Prediction	O
of	O
chemical	O
contents	O
in	O
each	O
pixel	O
of	O
the	O
hyperspectral	O
image	O
using	O
these	O
prediction	O
models	O
yielded	O
spatially	O
distributed	O
visualisations	O
of	O
the	O
sample	O
composition	O
.	O

Simple	O
,	O
fast	O
,	O
and	O
efficient	O
process	O
for	O
producing	O
and	O
purifying	O
trehalulose	B
.	O

A	O
new	O
property	O
of	O
recombinant	O
trehalose	B
synthase	O
(	O
GTase	O
)	O
from	O
Thermus	O
thermophilus	O
HB-8	O
(	O
ATCC	O
27634	O
)	O
was	O
found	O
and	O
described	O
in	O
this	O
study	O
.	O

GTase	O
can	O
act	O
on	O
sucrose	B
and	O
catalyze	O
trehalulose	B
formation	O
without	O
isomaltose	B
,	O
isomaltulose	B
,	O
or	O
isomelezitose	B
,	O
releasing	O
small	O
amounts	O
of	O
glucose	B
and	O
fructose	B
as	O
byproducts	O
.	O

Maximum	O
trehalulose	B
yield	O
(	O
approximately	O
81	O
%	O
)	O
was	O
obtained	O
at	O
an	O
optimum	O
temperature	O
of	O
65	O
	O
C	O
and	O
was	O
independent	O
of	O
substrate	O
concentration	O
.	O

A	O
simple	O
,	O
fast	O
,	O
and	O
efficient	O
method	O
of	O
producing	O
and	O
purifying	O
trehalulose	B
is	O
then	O
described	O
.	O

In	O
the	O
first	O
step	O
,	O
GTase	O
catalyzed	O
trehalulose	B
formation	O
using	O
a	O
20	O
%	O
sucrose	B
substrate	O
.	O

Miscellaneous	O
sugars	B
were	O
then	O
rapidly	O
removed	O
,	O
while	O
trehalulose	B
was	O
completely	O
preserved	O
by	O
Saccharomyces	O
cerevisiae	O
cells	O
.	O

Finally	O
,	O
the	O
cells	O
were	O
separated	O
by	O
centrifugation	O
,	O
and	O
salt	O
ions	O
were	O
removed	O
by	O
an	O
ion	O
-	O
exchange	O
resin	O
,	O
subsequently	O
obtaining	O
a	O
high	O
-	O
purity	O
trehalulose	B
solution	O
.	O

A	O
trehalulose	B
recovery	O
rate	O
of	O
over	O
95	O
%	O
was	O
achieved	O
using	O
this	O
process	O
.	O

This	O
method	O
has	O
a	O
simple	O
process	O
,	O
fast	O
separation	O
efficiency	O
,	O
and	O
low	O
investment	O
in	O
production	O
equipment	O
,	O
so	O
greatly	O
to	O
improve	O
production	O
efficiency	O
and	O
reduce	O
production	O
costs	O
.	O

Immunosensor	O
based	O
on	O
immobilization	O
of	O
antigenic	O
peptide	O
NS5A-1	O
from	O
HCV	O
and	O
silk	O
fibroin	O
in	O
nanostructured	O
films	O
.	O

The	O
peptide	O
NS5A-1	O
(	O
PPLLESWKDPDYVPPWHG	O
)	O
,	O
derived	O
from	O
hepatitis	O
C	O
virus	O
(	O
HCV	O
)	O
NS5A	O
protein	O
,	O
was	O
immobilized	O
into	O
layer	O
-	O
by	O
-	O
layer	O
(	O
LbL	O
)	O
silk	O
fibroin	O
(	O
SF	O
)	O
films	O
.	O

Deposition	O
was	O
monitored	O
by	O
UV	O
-	O
vis	O
absorption	O
measurements	O
at	O
each	O
bilayer	O
deposited	O
.	O

The	O
interaction	O
SF	O
/	O
peptide	O
film	O
induced	O
secondary	O
structure	O
in	O
NS5A-1	O
as	O
indicated	O
by	O
fluorescence	O
and	O
circular	O
dichroism	O
(	O
CD	O
)	O
measurements	O
.	O

Voltammetric	O
sensor	O
(	O
SF	O
/	O
NS5A-1	O
)	O
properties	O
were	O
observed	O
when	O
the	O
composite	O
film	O
was	O
tested	O
in	O
the	O
presence	O
of	O
anti	O
-	O
HCV	O
.	O

The	O
peptide	O
-	O
silk	O
fibroin	O
interaction	O
studied	O
here	O
showed	O
new	O
architectures	O
for	O
immunosensors	O
based	O
on	O
antigenic	O
peptides	O
and	O
SF	O
as	O
a	O
suitable	O
immobilization	O
matrix	O
.	O

Developing	O
the	O
potential	O
ophthalmic	O
applications	O
of	O
pilocarpine	B
entrapped	O
into	O
polyvinylpyrrolidone	B
-	O
poly	B
(	I
acrylic	I
acid	I
)	I
nanogel	O
dispersions	O
prepared	O
by	O
	O
radiation	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
improve	O
the	O
stability	O
and	O
bioavailability	O
of	O
pilocarpine	B
in	O
order	O
to	O
maintain	O
an	O
adequate	O
concentration	O
of	O
the	O
pilocarpine	B
at	O
the	O
site	O
of	O
action	O
for	O
prolonged	O
period	O
of	O
time	O
.	O

Thus	O
,	O
pH	O
-	O
sensitive	O
polyvinylpyrrolidone	B
-	O
poly	B
(	I
acrylic	I
acid	I
)	I
(	O
PVP	B
/	O
PAAc	B
)	O
nanogels	O
prepared	O
by	O
	O
radiation	O
-	O
induced	O
polymerization	O
of	O
acrylic	B
acid	I
(	O
AAc	B
)	O
in	O
an	O
aqueous	O
solution	O
of	O
polyvinylpyrrolidone	B
(	O
PVP	B
)	O
as	O
a	O
template	O
polymer	O
were	O
used	O
to	O
encapsulate	O
pilocarpine	B
.	O

Factors	O
affecting	O
size	O
and	O
encapsulation	O
efficiency	O
were	O
optimized	O
to	O
obtain	O
nanogel	O
suitable	O
for	O
entrapping	O
drug	O
efficiently	O
.	O

The	O
PVP	B
/	O
PAAc	B
nanogel	O
particles	O
were	O
characterized	O
by	O
dynamic	O
light	O
scattering	O
(	O
DLS	O
)	O
,	O
zeta	O
potential	O
,	O
Fourier	O
transform	O
infrared	O
spectroscopy	O
(	O
FTIR	O
)	O
,	O
and	O
transmission	O
electron	O
microscopy	O
(	O
TEM	O
)	O
,	O
and	O
their	O
size	O
can	O
be	O
controlled	O
by	O
the	O
feed	O
composition	O
and	O
concentration	O
as	O
well	O
as	O
the	O
irradiation	O
dose	O
.	O

Pilocarpine	B
was	O
loaded	O
into	O
the	O
nanogel	O
particles	O
through	O
electrostatic	O
interactions	O
where	O
the	O
AAc	B
-	O
rich	O
nanogels	O
exhibited	O
the	O
highest	O
loading	O
efficiency	O
.	O

The	O
transmittance	O
,	O
mucoadhesion	O
,	O
and	O
rheological	O
characteristics	O
of	O
the	O
nanogel	O
particles	O
were	O
studied	O
to	O
evaluate	O
their	O
ocular	O
applicability	O
.	O

The	O
in	O
vitro	O
release	O
study	O
conducted	O
in	O
simulated	O
tear	O
fluid	O
showed	O
a	O
relatively	O
long	O
sustained	O
release	O
of	O
pilocarpine	B
from	O
the	O
prepared	O
PVP	B
/	O
PAAc	B
nanogel	O
particles	O
if	O
compared	O
with	O
pilocarpine	B
in	O
solution	O
.	O

High	O
-	O
Performance	O
Surface	O
Acoustic	O
Wave	O
Immunosensing	O
System	O
on	O
a	O
PEG	B
/	O
Aptamer	O
Hybridized	O
Surface	O
.	O

Label	O
-	O
free	O
immunoassay	O
systems	O
have	O
the	O
advantages	O
of	O
procedural	O
simplicity	O
and	O
a	O
low	O
construction	O
cost	O
of	O
surfaces	O
for	O
immunosensing	O
.	O

When	O
label	O
-	O
free	O
immunoassay	O
systems	O
are	O
considered	O
,	O
the	O
nonspecific	O
adsorption	O
of	O
unwanted	O
materials	O
should	O
be	O
eliminated	O
unless	O
it	O
aids	O
in	O
the	O
detection	O
of	O
error	O
.	O

PEG	B
is	O
well	O
-	O
known	O
as	O
a	O
blocking	O
agent	O
for	O
the	O
prevention	O
of	O
the	O
adsorption	O
of	O
nonspecific	O
binding	O
materials	O
when	O
coimmobilized	O
with	O
ligands	O
for	O
targets	O
such	O
as	O
antibodies	O
and	O
oligonucleotides	O
.	O

The	O
construction	O
strategy	O
for	O
PEG	B
/	O
ligand	O
coimmobilized	O
surfaces	O
is	O
an	O
important	O
point	O
in	O
the	O
preparation	O
of	O
a	O
high	O
-	O
performance	O
assays	O
because	O
the	O
physiological	O
condition	O
of	O
the	O
ligand	O
depends	O
strongly	O
on	O
its	O
interaction	O
with	O
the	O
PEG	B
chain	O
.	O

In	O
this	O
report	O
,	O
we	O
investigate	O
the	O
interaction	O
between	O
thrombin	O
and	O
a	O
thrombin	O
-	O
binding	O
aptamer	O
(	O
TBA	O
)	O
on	O
a	O
PEG	B
/	O
TBA	O
coimmobilized	O
surface	O
by	O
using	O
a	O
shear	O
horizontal	O
surface	O
acoustic	O
wave	O
(	O
SAW	O
)	O
sensor	O
.	O

The	O
thrombin	O
-	O
TBA	O
binding	O
property	O
shows	O
remarkable	O
differences	O
with	O
changes	O
in	O
the	O
PEG	B
density	O
and	O
the	O
distance	O
from	O
the	O
gold	O
surface	O
to	O
the	O
aptamer	O
.	O

Influence	O
of	O
the	O
bifunctional	O
chelator	O
on	O
the	O
pharmacokinetic	O
properties	O
of	O
99mTc	B
(	I
CO	I
)	I
3-labeled	I
cyclic	B
	I
-	I
melanocyte	I
stimulating	I
hormone	I
analog	O
.	O

Aiming	O
at	O
the	O
design	O
of	O
specific	O
melanocortin-1	O
receptor	O
(	O
MC1R	O
)	O
targeted	O
imaging	O
probes	O
,	O
we	O
report	O
on	O
the	O
effect	O
of	O
different	O
azolyl	B
-	O
ring	O
substitution	O
patterns	O
(	O
carboxylate	B
at	O
the	O
4-position	O
and/or	O
methyl	B
groups	O
at	O
the	O
3,5	O
positions	O
)	O
of	O
pyrazolyl	B
-	I
diamine	I
bifunctional	O
chelators	O
(	O
Pz	O
(	O
2	O
)	O
-Pz	O
(	O
4	O
)	O
)	O
on	O
the	O
pharmacokinetic	O
profile	O
of	O
the	O
(	B
99m	I
)	I
Tc	I
(	I
CO	I
)	I
3-labeled	I
lactam	B
bridge	O
-	O
cyclized	B
	I
-	I
melanocyte	I
stimulating	I
hormone	I
derivative	O
,	O
AlaNleCycMSH	B
(	I
hex	I
)	I
.	O

Three	O
pyrazolyl	B
-	I
diamine	I
-	O
containing	O
chelators	O
were	O
conjugated	O
to	O
AlaNleCycMSHhex	B
,	O
with	O
the	O
resulting	O
peptide	O
conjugates	O
displaying	O
subnanomolar	O
MC1R	O
binding	O
affinity	O
.	O

Biodistribution	O
studies	O
in	O
B16F1	O
melanoma	O
-	O
bearing	O
mice	O
show	O
that	O
all	O
radiopeptides	O
present	O
a	O
good	O
melanoma	O
uptake	O
.	O

The	O
introduction	O
of	O
a	O
carboxylate	B
group	O
in	O
the	O
azolyl	B
-	O
ring	O
leads	O
to	O
a	O
remarkable	O
reduction	O
of	O
the	O
kidney	O
(	O
>	O
89	O
%	O
)	O
and	O
liver	O
(	O
>	O
91	O
%	O
)	O
accumulation	O
for	O
(	B
99m	I
)	I
Tc	I
(	I
CO	I
)	I
3-Pz	I
(	I
3	I
)	I
-AlaNleCycMSH	I
(	I
hex	I
)	I
and	O
(	B
99m	I
)	I
Tc	I
(	I
CO	I
)	I
3-Pz	I
(	I
4	I
)	I
-AlaNleCycMSH	I
(	I
hex	I
)	I
when	O
compared	O
to	O
the	O
radiopeptide	O
(	B
99m	I
)	I
Tc	I
(	I
CO	I
)	I
3-Pz	I
(	I
1	I
)	I
-AlaNleCycMSH	I
(	I
hex	I
)	I
,	O
where	O
that	O
group	O
is	O
absent	O
.	O

The	O
good	O
tumor	O
uptake	O
and	O
favorable	O
tumor	O
-	O
to	O
-	O
nontarget	O
-	O
organs	O
ratios	O
of	O
(	B
99m	I
)	I
Tc	I
(	I
CO	I
)	I
3-Pz	I
(	I
3	I
)	I
-AlaNleCycMSH	I
(	I
hex	I
)	I
and	O
(	B
99m	I
)	I
Tc	I
(	I
CO	I
)	I
3-Pz	I
(	I
4	I
)	I
-AlaNleCycMSH	I
(	I
hex	I
)	I
highlights	O
the	O
potential	O
of	O
both	O
compounds	O
as	O
melanoma	O
imaging	O
agents	O
.	O

Vegfrecine	B
,	O
an	O
Inhibitor	O
of	O
VEGF	O
Receptor	O
Tyrosine	B
Kinases	O
Isolated	O
from	O
the	O
Culture	O
Broth	O
of	O
Streptomyces	O
sp.	O
A	O
new	O
inhibitor	O
of	O
VEGF	O
receptor	O
tyrosine	B
kinases	O
,	O
vegfrecine	B
(	O
1	O
)	O
,	O
was	O
isolated	O
from	O
the	O
culture	O
broth	O
of	O
Streptomyces	O
sp.	O
MK931-CF8	O
.	O

The	O
molecular	O
structure	O
of	O
1	O
was	O
determined	O
by	O
NMR	O
and	O
MS	O
analysis	O
combined	O
with	O
synthesis	O
.	O

Compound	O
1	O
showed	O
potent	O
inhibitory	O
activity	O
against	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
(	O
VEGFR	O
)	O
tyrosine	O
kinases	O
in	O
in	O
vitro	O
enzyme	O
assays	O
,	O
but	O
platelet	O
-	O
derived	O
growth	O
factor	O
receptors	O
(	O
PDGFRs	O
)	O
,	O
fibroblast	O
growth	O
factor	O
receptor	O
(	O
FGFR	O
)	O
,	O
and	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
responded	O
only	O
weakly	O
.	O

Compound	O
1	O
is	O
a	O
promising	O
new	O
selective	O
VEGFR	O
inhibitor	O
for	O
investigating	O
new	O
treatments	O
of	O
cancer	O
and	O
inflammatory	O
diseases	O
.	O

Stability	O
of	O
black	O
cohosh	O
triterpene	B
glycosides	I
and	O
polyphenols	B
:	O
Potential	O
clinical	O
relevance	O
.	O

Concurrent	O
to	O
a	O
clinical	O
trial	O
of	O
black	O
cohosh	O
for	O
menopausal	O
hot	O
flashes	O
,	O
the	O
long	O
-	O
term	O
stability	O
of	O
the	O
black	O
cohosh	O
,	O
over	O
the	O
duration	O
of	O
the	O
clinical	O
trial	O
,	O
was	O
examined	O
.	O

Analytical	O
results	O
showed	O
that	O
the	O
major	O
constituents	O
,	O
both	O
triterpene	B
glycosides	I
and	O
polyphenols	B
,	O
were	O
stable	O
over	O
the	O
3-year	O
period	O
of	O
testing	O
.	O

These	O
results	O
indicate	O
that	O
a	O
black	O
cohosh	O
product	O
stored	O
for	O
several	O
years	O
in	O
a	O
controlled	O
environment	O
does	O
not	O
undergo	O
significant	O
changes	O
in	O
its	O
major	O
constituents	O
.	O

These	O
results	O
have	O
implications	O
not	O
only	O
for	O
clinical	O
research	O
in	O
natural	O
products	O
,	O
but	O
for	O
basic	O
science	O
,	O
as	O
well	O
as	O
the	O
dietary	O
supplements	O
industry	O
.	O

Design	O
and	O
synthesis	O
of	O
bicyclic	B
pyrazinone	I
and	I
pyrimidinone	I
amides	I
as	O
potent	O
TF	O
-	O
FVIIa	O
inhibitors	O
.	O

Bicyclic	B
pyrazinone	I
and	I
pyrimidinone	I
amides	I
were	O
designed	O
and	O
synthesized	O
as	O
potent	O
TF	O
-	O
FVIIa	O
inhibitors	O
.	O

SAR	O
demonstrated	O
that	O
the	O
S2	O
and	O
S3	O
pockets	O
of	O
FVIIa	O
prefer	O
to	O
bind	O
small	O
,	O
lipophilic	O
groups	O
.	O

An	O
X	O
-	O
ray	O
crystal	O
structure	O
of	O
optimized	O
compound	O
9b	O
bound	O
in	O
the	O
active	O
site	O
of	O
FVIIa	O
showed	O
that	O
the	O
bicyclic	O
scaffold	O
provides	O
5	O
hydrogen	B
bonding	O
interactions	O
in	O
addition	O
to	O
projecting	O
groups	O
for	O
interactions	O
within	O
the	O
S1	O
,	O
S2	O
and	O
S3	O
pockets	O
.	O

Compound	O
9b	O
showed	O
excellent	O
FVIIa	O
potency	O
,	O
good	O
selectivity	O
against	O
FIXa	O
,	O
Xa	O
,	O
XIa	O
and	O
chymotrypsin	O
,	O
and	O
good	O
clotting	O
activity	O
.	O

Efficient	O
synthesis	O
of	O
anacardic	B
acid	I
analogues	O
and	O
their	O
antibacterial	O
activities	O
.	O

Anacardic	B
acid	I
derivatives	O
exhibit	O
a	O
broad	O
range	O
of	O
biological	O
activities	O
.	O

In	O
this	O
report	O
,	O
an	O
efficient	O
method	O
for	O
the	O
synthesis	O
of	O
anacardic	B
acid	I
derivatives	O
was	O
explored	O
,	O
and	O
a	O
small	O
set	O
of	O
salicylic	B
acid	I
variants	O
synthesised	O
retaining	O
a	O
constant	O
hydrophobic	O
element	O
(	O
a	O
naphthyl	B
tail	O
)	O
.	O

The	O
naphthyl	B
side	O
chain	O
was	O
introduced	O
via	O
Wittig	O
reaction	O
and	O
the	O
aldehyde	B
installed	O
using	O
directed	O
ortho	O
-	O
metalation	O
reaction	O
of	O
the	O
substituted	O
o	B
-	I
anisic	I
acids	I
.	O

The	O
failure	O
of	O
ortho	O
-	O
metalation	O
using	O
unprotected	O
carboxylic	B
acid	I
group	O
compelled	O
us	O
to	O
use	O
directed	O
ortho	O
-	O
metalation	O
in	O
which	O
a	O
tertiary	B
amide	I
was	O
used	O
as	O
a	O
strong	O
ortho	O
-	O
directing	O
group	O
.	O

In	O
the	O
initial	O
route	O
,	O
tertiary	B
amide	I
cleavage	O
during	O
final	O
step	O
was	O
challenging	O
,	O
but	O
cleaving	O
the	O
tertiary	B
amide	I
before	O
Wittig	O
reaction	O
was	O
beneficial	O
.	O

The	O
Wittig	O
reaction	O
with	O
protected	O
carboxylic	B
group	O
(	O
methyl	B
ester	I
)	O
resulted	O
in	O
side	O
-	O
products	O
whereas	O
using	O
sodium	B
salt	O
resulted	O
in	O
higher	O
yields	O
.	O

The	O
novel	O
compounds	O
were	O
screened	O
for	O
antibacterial	O
activity	O
and	O
cytotoxicity	O
.	O

Although	O
substitution	O
on	O
the	O
salicylic	B
head	O
group	O
enhanced	O
antibacterial	O
activities	O
they	O
also	O
enhanced	O
cytotoxicity	O
.	O

Substituted	O
piperidinyl	B
glycinyl	I
2-cyano-4,5-methano	I
pyrrolidines	I
as	O
potent	O
and	O
stable	O
dipeptidyl	O
peptidase	O
IV	O
inhibitors	O
.	O

Synthesis	O
and	O
structure	O
-	O
activity	O
relationship	O
of	O
a	O
series	O
of	O
substituted	O
piperidinyl	B
glycine	I
2-cyano-4,5-methano	I
pyrroline	I
DPP	O
-	O
IV	O
inhibitors	O
are	O
described	O
.	O

Improvement	O
of	O
the	O
inhibitory	O
activity	O
and	O
chemical	O
stability	O
of	O
this	O
series	O
of	O
compounds	O
was	O
respectively	O
achieved	O
by	O
the	O
introduction	O
of	O
bulky	O
groups	O
at	O
the	O
4-position	O
and	O
1-position	O
of	O
the	O
piperidinyl	B
glycine	I
,	O
leading	O
to	O
a	O
series	O
of	O
potent	O
and	O
stable	O
DPP	O
-	O
IV	O
inhibitors	O
.	O

A	O
multivalent	O
peptide	O
as	O
an	O
activator	O
of	O
hypoxia	O
inducible	O
factor-1	O
.	O

Hypoxia	O
inducible	O
factor-1	O
(	O
HIF-1	O
)	O
is	O
a	O
transcription	O
factor	O
found	O
in	O
mammalian	O
cells	O
under	O
hypoxia	O
.	O

While	O
HIF-1	O
in	O
hypoxia	O
translocates	O
to	O
the	O
nucleus	O
where	O
it	O
transcribes	O
the	O
target	O
genes	O
including	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
mRNA	O
,	O
HIF-1	O
is	O
degraded	O
under	O
normoxia	O
,	O
which	O
involves	O
its	O
proline	B
hydroxylation	O
and	O
subsequent	O
binding	O
to	O
the	O
von	O
Hippel	O
-	O
Lindau	O
protein	O
-	O
Elongin	O
B	O
-	O
Elogin	O
C	O
(	O
VBC	O
)	O
complex	O
.	O

Previously	O
,	O
peptide	O
inhibitors	O
against	O
this	O
interaction	O
between	O
hydroxylated	O
HIF-1	O
and	O
VBC	O
have	O
been	O
developed	O
to	O
stabilize	O
the	O
transcriptional	O
activity	O
of	O
HIF-1	O
by	O
preventing	O
the	O
degradation	O
of	O
the	O
protein	O
even	O
under	O
normoxia	O
.	O

Despite	O
the	O
specific	O
inhibition	O
by	O
these	O
peptides	O
,	O
their	O
poor	O
inhibition	O
potency	O
needs	O
to	O
be	O
improved	O
for	O
further	O
clinical	O
application	O
.	O

In	O
this	O
work	O
,	O
we	O
have	O
designed	O
and	O
prepared	O
a	O
streptavidin	O
-	O
based	O
multivalent	O
peptide	O
inhibitor	O
against	O
the	O
HIF-1	O
-	O
VBC	O
complexation	O
.	O

We	O
have	O
evaluated	O
the	O
potency	O
of	O
the	O
multivalent	O
peptide	O
in	O
terms	O
of	O
stabilization	O
of	O
HIF-1	O
and	O
the	O
downstream	O
effect	O
.	O

As	O
the	O
result	O
,	O
we	O
have	O
found	O
that	O
the	O
inhibitor	O
showed	O
about	O
13-fold	O
lowered	O
IC50	O
value	O
compared	O
with	O
that	O
of	O
the	O
corresponding	O
monovalent	O
peptide	O
,	O
thereby	O
activating	O
HIF-1	O
and	O
leading	O
to	O
up	O
-	O
regulation	O
of	O
VEGF	O
protein	O
at	O
the	O
cellular	O
level	O
.	O

The	O
34	O
*	O
nicotinic	O
acetylcholine	B
receptor	O
subtype	O
mediates	O
nicotine	B
reward	O
and	O
physical	O
nicotine	B
withdrawal	O
signs	O
independently	O
of	O
the	O
5	O
subunit	O
in	O
the	O
mouse	O
.	O

The	O
15q25	O
gene	O
cluster	O
contains	O
genes	O
that	O
code	O
for	O
the	O
5	O
,	O
3	O
,	O
and	O
4	O
nicotinic	O
acetylcholine	B
receptor	O
(	O
nAChRs	O
)	O
subunits	O
,	O
and	O
in	O
human	O
genetic	O
studies	O
,	O
has	O
shown	O
the	O
most	O
robust	O
association	O
with	O
smoking	O
behavior	O
and	O
nicotine	B
dependence	O
to	O
date	O
.	O

The	O
limited	O
available	O
animal	O
studies	O
implicate	O
a	O
role	O
for	O
the	O
5	O
and	O
4	O
nAChR	O
subunits	O
in	O
nicotine	B
dependence	O
and	O
withdrawal	O
;	O
however	O
studies	O
focusing	O
on	O
the	O
behavioral	O
role	O
of	O
the	O
34	O
*	O
nAChR	O
receptor	O
subtype	O
in	O
nicotine	B
dependence	O
are	O
lacking	O
.	O

Because	O
of	O
the	O
apparent	O
role	O
of	O
the	O
34	O
*	O
nAChR	O
subtype	O
in	O
nicotine	B
dependence	O
,	O
the	O
goal	O
of	O
the	O
current	O
study	O
was	O
to	O
better	O
evaluate	O
the	O
involvement	O
of	O
this	O
subtype	O
in	O
nicotine	B
mediated	O
behavioral	O
responses	O
.	O

Using	O
the	O
selective	O
34	O
*	O
nAChR	O
antagonist	O
,	O
	O
-	O
conotoxin	O
AuIB	O
,	O
we	O
assessed	O
the	O
role	O
of	O
34	O
*	O
nAChRs	O
in	O
acute	O
nicotine	B
,	O
nicotine	B
reward	O
,	O
and	O
physical	O
and	O
affective	O
nicotine	B
withdrawal	O
.	O

Because	O
5	O
has	O
also	O
been	O
implicated	O
in	O
nicotine	B
dependence	O
behaviors	O
in	O
mice	O
and	O
can	O
form	O
functional	O
receptors	O
with	O
34	O
*	O
,	O
we	O
also	O
evaluated	O
the	O
role	O
of	O
the	O
345	O
*	O
nAChR	O
subtype	O
in	O
nicotine	B
reward	O
and	O
somatic	O
nicotine	B
withdrawal	O
signs	O
by	O
blocking	O
the	O
34	O
*	O
nAChR	O
subtype	O
in	O
5	O
nAChR	O
knockout	O
mice	O
with	O
AuIB	O
.	O

AuIB	O
had	O
no	O
significant	O
effect	O
on	O
acute	O
nicotine	B
behaviors	O
,	O
but	O
dose	O
-	O
dependently	O
attenuated	O
nicotine	B
reward	O
and	O
physical	O
withdrawal	O
signs	O
,	O
with	O
no	O
significant	O
effect	O
in	O
affective	O
withdrawal	O
measures	O
.	O

Interestingly	O
,	O
AuIB	O
also	O
attenuated	O
nicotine	B
reward	O
and	O
somatic	O
signs	O
in	O
5	O
nAChR	O
knockout	O
mice	O
.	O

This	O
study	O
shows	O
that	O
34	O
*	O
nAChRs	O
mediate	O
nicotine	B
reward	O
and	O
physical	O
nicotine	B
withdrawal	O
,	O
but	O
not	O
acute	O
nicotine	B
behaviors	O
or	O
affective	O
nicotine	B
withdrawal	O
signs	O
in	O
mice	O
.	O

The	O
5	O
subunit	O
is	O
not	O
required	O
in	O
the	O
receptor	O
assembly	O
to	O
mediate	O
these	O
effects	O
.	O

Our	O
findings	O
suggest	O
an	O
important	O
role	O
for	O
the	O
34	O
*	O
nAChR	O
subtype	O
in	O
nicotine	B
reward	O
and	O
physical	O
aspects	O
of	O
the	O
nicotine	B
withdrawal	O
syndrome	O
.	O

Human	O
serum	O
albumin	O
-	O
based	O
design	O
of	O
a	O
diflunisal	B
prodrug	O
.	O

The	O
cyclooxygenase-2	O
inhibitor	O
,	O
diflunisal	B
,	O
is	O
used	O
in	O
the	O
clinic	O
for	O
its	O
anti	O
-	O
inflammatory	O
activity	O
.	O

About	O
99	O
%	O
of	O
a	O
dose	O
of	O
diflunisal	B
is	O
unavailable	O
for	O
reaction	O
with	O
the	O
target	O
enzyme	O
,	O
because	O
diflunisal	B
strongly	O
binds	O
to	O
human	O
serum	O
albumin	O
(	O
HSA	O
)	O
.	O

To	O
reduce	O
the	O
binding	O
affinity	O
of	O
diflunisal	B
to	O
albumin	O
,	O
we	O
designed	O
and	O
synthesized	O
the	O
prodrug	O
acetyldiflunisal	B
.	O

The	O
crystal	O
structure	O
of	O
HSA	O
complexed	O
with	O
fatty	B
acid	I
and	O
acetyldiflunisal	B
revealed	O
that	O
acetyldiflunisal	B
binds	O
to	O
the	O
IIA	O
subdomain	O
and	O
that	O
upon	O
binding	O
,	O
it	O
acetylates	O
lysine	B
199	O
.	O

Mass	O
spectrometry	O
confirmed	O
that	O
acetyldiflunisal	B
acetylates	O
Lys199	B
.	O

The	O
acetylated	O
albumin	O
had	O
twofold	O
weaker	O
binding	O
affinity	O
for	O
diflunisal	B
as	O
demonstrated	O
by	O
fluorescence	O
quenching	O
.	O

Reduced	O
binding	O
affinity	O
means	O
that	O
diflunisal	B
is	O
more	O
easily	O
released	O
from	O
acetylated	O
albumin	O
into	O
the	O
circulation	O
.	O

Therefore	O
,	O
lower	O
doses	O
of	O
acetyldiflunisal	B
compared	O
to	O
diflunisal	B
will	O
be	O
required	O
.	O

Taken	O
together	O
,	O
our	O
results	O
not	O
only	O
provide	O
a	O
template	O
for	O
design	O
of	O
HSA	O
-	O
based	O
prodrugs	O
,	O
but	O
also	O
pave	O
the	O
way	O
toward	O
more	O
effective	O
use	O
of	O
diflunisal	B
in	O
the	O
clinic	O
.	O

Molecular	O
phylogeny	O
of	O
the	O
Indian	O
Ocean	O
Terpsiphone	O
paradise	O
flycatchers	O
:	O
Undetected	O
evolutionary	O
diversity	O
revealed	O
amongst	O
island	O
populations	O
.	O

We	O
construct	O
a	O
molecular	O
phylogeny	O
of	O
Terpsiphone	O
flycatchers	O
of	O
the	O
Indian	O
Ocean	O
and	O
use	O
this	O
to	O
investigate	O
their	O
evolutionary	O
relationships	O
.	O

A	O
total	O
of	O
4.4	O
kb	O
of	O
mitochondrial	O
(	O
cyt	O
-	O
b	O
,	O
ND3	O
,	O
ND2	O
,	O
control	O
region	O
)	O
and	O
nuclear	O
(	O
G3PDH	O
,	O
MC1R	O
)	O
sequence	O
data	O
were	O
obtained	O
from	O
all	O
species	O
,	O
sub	O
-	O
species	O
and	O
island	O
populations	O
of	O
the	O
region	O
.	O

Colonisation	O
of	O
the	O
western	O
Indian	O
Ocean	O
has	O
been	O
within	O
the	O
last	O
two	O
million	O
years	O
and	O
greatly	O
postdates	O
the	O
formation	O
of	O
the	O
older	O
islands	O
of	O
the	O
region	O
.	O

A	O
minimum	O
of	O
two	O
independent	O
continent	O
-	O
island	O
colonisation	O
events	O
must	O
have	O
taken	O
place	O
in	O
order	O
to	O
explain	O
the	O
current	O
distribution	O
and	O
phylogenetic	O
placement	O
of	O
Terpsiphone	O
in	O
this	O
region	O
.	O

While	O
five	O
well	O
-	O
diverged	O
Indian	O
Ocean	O
clades	O
are	O
detected	O
,	O
the	O
relationship	O
between	O
them	O
is	O
unclear	O
.	O

Short	O
intermodal	O
branches	O
are	O
indicative	O
of	O
rapid	O
range	O
expansion	O
across	O
the	O
region	O
,	O
masking	O
exact	O
routes	O
and	O
chronology	O
of	O
colonisation	O
.	O

The	O
Indian	O
Ocean	O
Terpsiphone	O
taxa	O
fall	O
into	O
five	O
well	O
supported	O
clades	O
,	O
two	O
of	O
which	O
(	O
the	O
Seychelles	O
paradise	O
flycatcher	O
and	O
the	O
Mascarene	O
paradise	O
flycatcher	O
)	O
correspond	O
with	O
currently	O
recognised	O
species	O
,	O
whilst	O
a	O
further	O
three	O
(	O
within	O
the	O
Madagascar	O
paradise	O
flycatcher	O
)	O
are	O
not	O
entirely	O
predicted	O
by	O
taxonomy	O
,	O
and	O
are	O
neither	O
consistent	O
with	O
distance	O
-	O
based	O
nor	O
island	O
age	O
-	O
based	O
models	O
of	O
colonisation	O
.	O

We	O
identify	O
the	O
four	O
non	O
-	O
Mascarene	O
clades	O
as	O
Evolutionarily	O
Significant	O
Units	O
(	O
ESUs	O
)	O
,	O
while	O
the	O
Mascarene	O
paradise	O
flycatcher	O
contains	O
two	O
ESUs	O
corresponding	O
to	O
the	O
Mauritius	O
and	O
Runion	O
subspecies	O
.	O

All	O
six	O
ESUs	O
are	O
sufficiently	O
diverged	O
to	O
be	O
worthy	O
of	O
management	O
as	O
if	O
they	O
were	O
separate	O
species	O
.	O

This	O
phylogenetic	O
reconstruction	O
highlights	O
the	O
importance	O
of	O
sub	O
-	O
specific	O
molecular	O
phylogenetic	O
reconstructions	O
in	O
complex	O
island	O
archipelago	O
settings	O
in	O
clarifying	O
phylogenetic	O
history	O
and	O
ESUs	O
that	O
may	O
otherwise	O
be	O
overlooked	O
and	O
inadvertently	O
lost	O
.	O

Our	O
phylogenetic	O
reconstruction	O
has	O
identified	O
hidden	O
pockets	O
of	O
evolutionary	O
distinctiveness	O
,	O
which	O
provide	O
a	O
valuable	O
platform	O
upon	O
which	O
to	O
re	O
-	O
evaluate	O
investment	O
of	O
conservation	O
resources	O
within	O
the	O
Terpsiphone	O
flycatchers	O
of	O
the	O
Indian	O
Ocean	O
.	O

Improving	O
correlated	O
SERS	O
measurements	O
with	O
scanning	O
electron	O
microscopy	O
:	O
an	O
assessment	O
of	O
the	O
problem	O
arising	O
from	O
the	O
deposition	O
of	O
amorphous	O
carbon	B
.	O

For	O
surface	O
-	O
enhanced	O
Raman	O
scattering	O
(	O
SERS	O
)	O
substrates	O
with	O
nonspherical	O
symmetry	O
,	O
it	O
is	O
critical	O
to	O
correlate	O
spectroscopy	O
measurements	O
with	O
imaging	O
by	O
scanning	O
electron	O
microscopy	O
(	O
SEM	O
)	O
.	O

However	O
,	O
the	O
deposition	O
of	O
carbon	B
resulting	O
from	O
e	O
-	O
beam	O
exposure	O
during	O
SEM	O
imaging	O
contaminates	O
the	O
surface	O
of	O
nanoparticles	O
,	O
potentially	O
preventing	O
their	O
further	O
functionalization	O
with	O
Raman	O
probe	O
molecules	O
.	O

In	O
addition	O
,	O
the	O
deposited	O
carbon	B
leads	O
to	O
unwanted	O
background	O
SERS	O
signals	O
.	O

In	O
this	O
study	O
,	O
we	O
systematically	O
investigated	O
the	O
deposition	O
of	O
carbon	B
during	O
SEM	O
imaging	O
and	O
examined	O
how	O
it	O
affects	O
the	O
functionalization	O
of	O
nanoparticles	O
with	O
probe	O
molecules	O
and	O
impacts	O
the	O
detection	O
of	O
SERS	O
signals	O
.	O

Significantly	O
,	O
we	O
found	O
that	O
the	O
carbon	B
could	O
be	O
removed	O
or	O
replaced	O
from	O
the	O
surface	O
of	O
Ag	B
nanoparticles	O
through	O
chemical	O
or	O
physical	O
means	O
,	O
rendering	O
the	O
nanoparticles	O
the	O
capability	O
for	O
correlated	O
SEM	O
/	O
SERS	O
studies	O
.	O

The	O
first	O
report	O
on	O
some	O
toxic	O
effects	O
of	O
green	O
scat	O
,	O
Scatophagus	O
argus	O
an	O
Iranian	O
Persian	O
Gulf	O
venomous	O
fish	O
.	O

Green	O
scat	O
namely	O
as	O
Scatophagus	O
argus	O
is	O
a	O
venomous	O
aquarium	O
fish	O
belonging	O
to	O
Scatophagidae	O
family	O
.	O

It	O
can	O
induce	O
painful	O
wounds	O
in	O
injured	O
hand	O
with	O
partial	O
paralysis	O
to	O
whom	O
that	O
touch	O
the	O
spines	O
.	O

Dorsal	O
and	O
ventral	O
rough	O
spines	O
contain	O
cells	O
that	O
produce	O
venom	O
with	O
toxic	O
activities	O
.	O

According	O
to	O
unpublished	O
data	O
collected	O
from	O
local	O
hospitals	O
in	O
southern	O
coastal	O
region	O
of	O
Iran	O
,	O
S.	O
argus	O
is	O
reported	O
as	O
a	O
venomous	O
fish	O
.	O

Envenomation	O
induces	O
clinical	O
symptoms	O
such	O
as	O
local	O
pain	O
,	O
partial	O
paralysis	O
,	O
erythema	O
and	O
itching	O
.	O

In	O
the	O
present	O
study	O
green	O
scat	O
(	O
spotted	O
scat	O
)	O
was	O
collected	O
from	O
Persian	O
Gulf	O
coastal	O
waters	O
.	O

SDS	B
-	O
PAGE	O
indicated	O
12	O
distinct	O
bands	O
in	O
the	O
venom	O
ranged	O
between	O
7	O
and	O
250	O
kDa	O
.	O

The	O
crude	O
venom	O
had	O
hemolytic	O
activity	O
on	O
human	O
erythrocytes	O
(	O
1	O
%	O
)	O
with	O
an	O
LC100	O
(	O
Lytic	O
Concentration	O
)	O
of	O
about	O
1.7	O
g	O
.	O

The	O
crude	O
venom	O
can	O
release	O
813	O
g	O
protein	O
from	O
0.5	O
%	O
casein	O
.	O

Phospholipase	O
C	O
activity	O
was	O
recorded	O
at	O
3.125	O
g	O
of	O
total	O
venom	O
.	O

Our	O
findings	O
showed	O
that	O
the	O
edematic	O
activity	O
remained	O
over	O
24	O
h	O
after	O
injection	O
.	O

The	O
results	O
demonstrated	O
that	O
crude	O
venom	O
extracted	O
from	O
Iranian	O
coastal	O
border	O
has	O
different	O
toxic	O
and	O
enzymatic	O
activities	O
.	O

This	O
study	O
is	O
pending	O
to	O
further	O
investigation	O
on	O
animal	O
model	O
regarding	O
protein	O
purification	O
and	O
in	O
vivo	O
studies	O
.	O

Chimera	O
of	O
IL-2	O
Linked	O
to	O
Light	O
Chain	O
of	O
anti	O
-	O
IL-2	O
mAb	O
Mimics	O
IL-2	O
/	O
anti	O
-	O
IL-2	O
mAb	O
Complexes	O
Both	O
Structurally	O
and	O
Functionally	O
.	O

IL-2	O
/	O
anti	O
-	O
IL-2	O
mAb	O
immunocomplexes	O
were	O
described	O
to	O
have	O
dramatically	O
higher	O
activity	O
than	O
free	O
IL-2	O
in	O
vivo	O
.	O

We	O
designed	O
protein	O
chimera	O
consisting	O
of	O
IL-2	O
linked	O
to	O
light	O
chain	O
of	O
anti	O
-	O
IL-2	O
mAb	O
S4B6	O
through	O
flexible	O
oligopeptide	O
spacer	O
(	O
Gly4Ser	O
)	O
3	O
.	O

This	O
protein	O
chimera	O
mimics	O
the	O
structure	O
of	O
IL-2	O
/	O
S4B6	O
mAb	O
immunocomplexes	O
but	O
eliminates	O
general	O
disadvantages	O
of	O
immunocomplexes	O
like	O
possible	O
excess	O
of	O
either	O
IL-2	O
or	O
anti	O
-	O
IL-2	O
mAb	O
and	O
their	O
dissociation	O
to	O
antibody	O
and	O
IL-2	O
at	O
low	O
concentrations	O
.	O

This	O
novel	O
kind	O
of	O
protein	O
chimera	O
is	O
characterized	O
by	O
an	O
intramolecular	O
interaction	O
between	O
IL-2	O
and	O
binding	O
site	O
of	O
S4B6	O
mAb	O
similarly	O
as	O
in	O
IL-2	O
/	O
S4B6	O
mAb	O
immunocomplexes	O
.	O

Our	O
protein	O
chimera	O
has	O
biological	O
activity	O
comparable	O
to	O
IL-2	O
/	O
S4B6	O
mAb	O
immunocomplexes	O
in	O
vitro	O
,	O
as	O
shown	O
by	O
stimulation	O
of	O
proliferation	O
of	O
purified	O
and	O
activated	O
OT	O
-	O
I	O
CD8	O
(	O
+	O
)	O
T	O
cells	O
.	O

The	O
protein	O
chimera	O
exerts	O
higher	O
stimulatory	O
activity	O
to	O
drive	O
expansion	O
of	O
purified	O
CFSE	B
-	O
labeled	O
OT	O
-	O
I	O
CD8	O
(	O
+	O
)	O
T	O
cells	O
activated	O
by	O
an	O
injection	O
of	O
a	O
low	O
dose	O
of	O
SIINFEKL	O
peptide	O
than	O
IL-2	O
/	O
S4B6	O
mAb	O
immunocomplexes	O
in	O
vivo	O
.	O

Infected	O
nail	O
plate	O
model	O
made	O
of	O
human	O
hair	O
keratin	O
for	O
evaluating	O
the	O
efficacy	O
of	O
different	O
topical	O
antifungal	O
formulations	O
against	O
Trichophyton	O
rubrum	O
in	O
vitro	O
.	O

A	O
novel	O
model	O
of	O
infected	O
nail	O
plate	O
for	O
testing	O
the	O
efficacy	O
of	O
topical	O
antifungal	O
formulations	O
has	O
been	O
developed	O
.	O

This	O
model	O
utilized	O
keratin	O
film	O
made	O
of	O
human	O
hair	O
keratin	O
as	O
a	O
nail	O
plate	O
model	O
.	O

Subsequent	O
to	O
infection	O
by	O
Trichophyton	O
rubrum	O
,	O
the	O
common	O
causative	O
agent	O
of	O
onychomycosis	O
,	O
keratin	O
films	O
as	O
infected	O
nail	O
plate	O
models	O
were	O
treated	O
with	O
selected	O
topical	O
formulations	O
,	O
that	O
is	O
cream	O
,	O
gel	O
,	O
and	O
nail	O
lacquer	O
.	O

Bovine	O
hoof	O
was	O
compared	O
to	O
keratin	O
film	O
.	O

In	O
contrast	O
to	O
the	O
common	O
antifungal	O
susceptibility	O
test	O
,	O
the	O
antifungal	O
drugs	O
tested	O
were	O
applied	O
as	O
ready	O
-	O
to	O
-	O
use	O
formulations	O
because	O
the	O
vehicle	O
may	O
modify	O
and	O
control	O
the	O
drug	O
action	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Extrapolating	O
the	O
potency	O
of	O
an	O
antifungal	O
drug	O
from	O
an	O
in	O
vitro	O
susceptibility	O
test	O
only	O
would	O
not	O
be	O
representative	O
of	O
the	O
in	O
vivo	O
situation	O
since	O
these	O
drugs	O
are	O
applied	O
as	O
ready	O
-	O
to	O
-	O
use	O
formulations	O
,	O
for	O
example	O
as	O
a	O
nail	O
lacquer	O
.	O

Although	O
terbinafine	B
has	O
been	O
acknowledged	O
to	O
be	O
the	O
most	O
effective	O
antifungal	O
agent	O
against	O
T.	O
rubrum	O
,	O
its	O
antifungal	O
efficacy	O
was	O
improved	O
by	O
its	O
incorporation	O
into	O
an	O
optimal	O
formulation	O
.	O

Different	O
gels	O
proved	O
superior	O
to	O
cream	O
.	O

Therefore	O
,	O
this	O
study	O
is	O
able	O
to	O
discriminate	O
between	O
efficacies	O
of	O
different	O
topical	O
antifungal	O
formulations	O
based	O
on	O
their	O
activities	O
against	O
T.	O
rubrum	O
.	O

Use	O
of	O
near	O
-	O
infrared	O
spectroscopy	O
to	O
quantify	O
drug	O
content	O
on	O
a	O
continuous	O
blending	O
process	O
:	O
Influence	O
of	O
mass	O
flow	O
and	O
rotation	O
speed	O
variations	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
develop	O
a	O
quantitative	O
Near	O
-	O
Infrared	O
(	O
NIR	O
)	O
method	O
which	O
monitors	O
the	O
homogeneity	O
of	O
a	O
pharmaceutical	O
formulation	O
coming	O
out	O
of	O
a	O
continuous	O
blender	O
.	O

For	O
this	O
purpose	O
,	O
a	O
NIR	O
diode	O
array	O
spectrometer	O
with	O
fast	O
data	O
acquisition	O
was	O
selected	O
.	O

Additionally	O
,	O
the	O
dynamic	O
aspects	O
of	O
a	O
continuous	O
blending	O
process	O
were	O
studied	O
;	O
the	O
results	O
showed	O
a	O
well	O
-	O
defined	O
cluster	O
for	O
the	O
steady	O
state	O
,	O
and	O
the	O
paths	O
for	O
the	O
start	O
-	O
up	O
and	O
emptying	O
stages	O
were	O
clearly	O
identified	O
.	O

The	O
end	O
point	O
of	O
the	O
start	O
-	O
up	O
phase	O
was	O
detected	O
by	O
moving	O
block	O
of	O
standard	O
deviation	O
,	O
relative	O
standard	O
deviation	O
,	O
and	O
principal	O
component	O
analysis	O
.	O

A	O
partial	O
least	O
square	O
(	O
PLS	O
)	O
model	O
was	O
generated	O
for	O
the	O
quantification	O
of	O
the	O
drug	O
,	O
with	O
a	O
standard	O
error	O
of	O
prediction	O
of	O
0.2	O
%	O
m	O
/	O
m	O
.	O

The	O
PLS	O
model	O
was	O
successfully	O
applied	O
for	O
monitoring	O
the	O
drug	O
level	O
at	O
the	O
outlet	O
of	O
the	O
continuous	O
blender	O
.	O

Furthermore	O
,	O
the	O
PLS	O
model	O
was	O
tested	O
under	O
different	O
flow	O
and	O
stirring	O
rates	O
.	O

Flow	O
and	O
stirring	O
rate	O
variations	O
caused	O
different	O
powder	O
flow	O
dynamics	O
,	O
which	O
were	O
reflected	O
on	O
the	O
NIR	O
measurements	O
.	O

Therefore	O
,	O
the	O
PLS	O
model	O
was	O
sensitive	O
to	O
changes	O
in	O
mass	O
flow	O
and	O
rotation	O
speeds	O
.	O

Charge	O
affects	O
the	O
oral	O
toxicity	O
of	O
poly	B
(	I
amidoamine	I
)	I
dendrimers	O
.	O

Poly	B
(	I
amidoamine	I
)	I
(	O
PAMAM	B
)	O
dendrimers	O
have	O
been	O
evaluated	O
for	O
the	O
influence	O
of	O
surface	O
functionality	O
and	O
size	O
on	O
the	O
epithelial	O
barrier	O
of	O
the	O
gut	O
with	O
the	O
goal	O
of	O
identifying	O
safe	O
carriers	O
that	O
can	O
be	O
used	O
for	O
oral	O
drug	O
delivery	O
.	O

Limited	O
studies	O
are	O
conducted	O
to	O
date	O
,	O
however	O
,	O
to	O
assess	O
the	O
toxicity	O
of	O
PAMAM	B
dendrimers	O
in	O
vivo	O
when	O
administered	O
by	O
the	O
oral	O
route	O
.	O

The	O
goal	O
of	O
this	O
research	O
was	O
to	O
conduct	O
an	O
oral	O
acute	O
toxicity	O
study	O
of	O
PAMAM	B
dendrimers	O
as	O
a	O
function	O
of	O
size	O
and	O
charge	O
in	O
immune	O
competent	O
CD-1	O
mice	O
.	O

Maximum	O
tolerated	O
doses	O
(	O
MTD	O
)	O
of	O
PAMAM	B
dendrimers	O
as	O
a	O
function	O
of	O
size	O
and	O
surface	O
functionality	O
were	O
established	O
and	O
clinical	O
signs	O
of	O
toxicity	O
monitored	O
.	O

Results	O
demonstrate	O
that	O
positively	O
charged	O
dendrimers	O
caused	O
more	O
toxicity	O
,	O
whereas	O
their	O
anionic	O
counterparts	O
were	O
tolerated	O
at	O
ten	O
times	O
higher	O
doses	O
.	O

Severe	O
signs	O
of	O
toxicity	O
observed	O
for	O
large	O
(	O
G7	O
)	O
cationic	O
amine-	B
or	O
hydroxyl	B
-	O
terminated	O
dendrimers	O
include	O
hemobilia	O
and	O
spleenomegaly	O
.	O

The	O
MTD	O
for	O
these	O
dendrimers	O
ranged	O
from	O
30mg	O
/	O
kg	O
to	O
200mg	O
/	O
kg	O
.	O

Anionic	O
G6.5	O
or	O
smaller	O
molecular	O
weight	O
carboxyl-	B
,	O
amine-	B
,	O
or	O
hydroxyl	B
-	O
terminated	O
dendrimers	O
(	O
G3.5-COOH	O
,	O
G4-NH2	O
,	O
G4-OH	O
)	O
on	O
the	O
other	O
hand	O
were	O
tolerated	O
at	O
doses	O
of	O
up	O
to	O
500mg	O
/	O
kg	O
(	O
300mg	O
/	O
kg	O
in	O
some	O
cases	O
)	O
with	O
minimal	O
or	O
no	O
signs	O
of	O
toxicity	O
.	O

Establishing	O
the	O
MTD	O
of	O
orally	O
delivered	O
PAMAM	B
dendrimers	O
and	O
the	O
influence	O
of	O
surface	O
functionality	O
and	O
size	O
on	O
toxicity	O
aids	O
in	O
the	O
rational	O
design	O
of	O
PAMAM	B
-	O
drug	O
conjugates	O
for	O
oral	O
drug	O
delivery	O
applications	O
.	O

Modulation	O
of	O
mitochondrial	O
glutathione	B
status	O
and	O
cellular	O
energetics	O
in	O
primary	O
cultures	O
of	O
proximal	O
tubular	O
cells	O
from	O
remnant	O
kidney	O
of	O
uninephrectomized	O
rats	O
.	O

Compensatory	O
renal	O
hypertrophy	O
following	O
reduction	O
in	O
renal	O
mass	O
leads	O
to	O
a	O
hypermetabolic	O
state	O
and	O
increases	O
in	O
basal	O
mitochondrial	O
oxidative	O
stress	O
and	O
susceptibility	O
to	O
several	O
nephrotoxicants	O
.	O

Previous	O
studies	O
provide	O
conflicting	O
data	O
on	O
whether	O
renal	O
mitochondria	O
after	O
reduction	O
in	O
renal	O
mass	O
undergo	O
proliferation	O
or	O
hypertrophy	O
or	O
both	O
.	O

In	O
the	O
present	O
study	O
,	O
our	O
goal	O
was	O
to	O
determine	O
whether	O
mitochondria	O
of	O
hypertrophied	O
kidney	O
undergo	O
hypertrophy	O
or	O
proliferation	O
after	O
uninephrectomy	O
using	O
the	O
uninephrectomized	O
(	O
NPX	O
)	O
rat	O
model	O
.	O

Renal	O
proximal	O
tubular	O
(	O
PT	O
)	O
cells	O
from	O
NPX	O
rats	O
exhibited	O
increased	O
mitochondrial	O
density	O
,	O
membrane	O
potential	O
and	O
protein	O
but	O
no	O
significant	O
difference	O
in	O
mitochondrial	O
DNA	O
,	O
as	O
compared	O
to	O
PT	O
cells	O
from	O
control	O
rats	O
.	O

Our	O
previous	O
studies	O
showed	O
that	O
overexpression	O
of	O
two	O
mitochondrial	O
anion	O
transporters	O
,	O
the	O
dicarboxylate	B
(	O
DIC	B
,	O
Slc25a10	O
)	O
and	O
oxoglutarate	B
(	O
OGC	B
,	O
Slc25a11	O
)	O
carriers	O
,	O
in	O
NRK-52E	O
cells	O
resulted	O
in	O
increased	O
mitochondrial	O
uptake	O
of	O
glutathione	B
(	O
GSH	B
)	O
and	O
protection	O
from	O
chemically	O
induced	O
apoptosis	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
overexpressed	O
DIC-	B
and	O
OGC	B
-	O
cDNA	O
plasmids	O
to	O
assess	O
their	O
function	O
in	O
renal	O
PT	O
cells	O
after	O
compensatory	O
renal	O
hypertrophy	O
.	O

PT	O
cells	O
from	O
NPX	O
rats	O
that	O
were	O
first	O
preincubated	O
with	O
GSH	B
were	O
protected	O
from	O
cytotoxicity	O
due	O
to	O
the	O
mitochondrial	O
inhibitor	O
antimycin	B
A	I
by	O
overexpression	O
of	O
either	O
of	O
the	O
two	O
mitochondrial	O
GSH	B
transporters	O
.	O

Our	O
present	O
results	O
provide	O
further	O
evidence	O
that	O
compensatory	O
renal	O
hypertrophy	O
is	O
associated	O
primarily	O
with	O
mitochondrial	O
hypertrophy	O
and	O
hyperpolarization	O
and	O
that	O
manipulation	O
of	O
mitochondrial	O
GSH	B
transporters	O
in	O
PT	O
cells	O
of	O
hypertrophied	O
kidney	O
can	O
alter	O
susceptibility	O
to	O
chemically	O
induced	O
injury	O
under	O
appropriate	O
conditions	O
and	O
may	O
be	O
a	O
suitable	O
therapeutic	O
approach	O
.	O

Screening	O
of	O
transition	O
and	O
post	O
-	O
transition	O
metals	O
to	O
incorporate	O
into	O
copper	B
oxide	I
and	O
copper	B
bismuth	I
oxide	I
for	O
photoelectrochemical	O
hydrogen	B
evolution	O
.	O

A	O
new	O
dispenser	O
and	O
scanner	O
system	O
is	O
used	O
to	O
create	O
and	O
screen	O
Bi	B
-	O
M	O
-	O
Cu	B
oxide	B
arrays	O
for	O
cathodic	O
photoactivity	O
,	O
where	O
M	O
represents	O
1	O
of	O
22	O
different	O
transition	O
and	O
post	O
-	O
transition	O
metals	O
.	O

Over	O
3000	O
unique	O
Bi	B
:	O
M	O
:	O
Cu	B
atomic	O
ratios	O
are	O
screened	O
.	O

Of	O
the	O
22	O
metals	O
tested	O
,	O
10	O
show	O
a	O
M	O
-	O
Cu	B
oxide	I
with	O
higher	O
photoactivity	O
than	O
CuO	B
and	O
10	O
show	O
a	O
Bi	B
-	O
M	O
-	O
Cu	B
oxide	B
with	O
higher	O
photoactivity	O
than	O
CuBi2O4	B
.	O

Cd	B
,	O
Zn	B
,	O
Sn	B
,	O
and	O
Co	B
produce	O
the	O
most	O
photoactive	O
M	O
-	O
Cu	B
oxides	B
,	O
all	O
showing	O
a	O
200	O
-	O
300	O
%	O
improvement	O
in	O
photocurrent	O
over	O
CuO.	B
Ag	B
,	O
Cd	B
,	O
and	O
Zn	B
produce	O
the	O
highest	O
photoactivity	O
Bi	B
-	O
M	O
-	O
Cu	B
oxides	B
with	O
a	O
200	O
-	O
400	O
%	O
improvement	O
over	O
CuBi2O4	B
.	O

Most	O
notable	O
is	O
a	O
Bi	B
-	I
Ag	I
-	I
Cu	I
oxide	I
(	O
Bi	B
:	O
Ag	B
:	O
Cu	B
atomic	O
ratio	O
of	O
22	O
:	O
3	O
:	O
11	O
)	O
which	O
shows	O
4	O
times	O
higher	O
photocurrent	O
than	O
CuBi2O4	B
.	O

This	O
material	O
is	O
capable	O
of	O
evolving	O
hydrogen	B
under	O
illumination	O
in	O
neutral	O
electrolyte	O
solutions	O
at	O
0.6	O
V	O
vs.	O
RHE	O
when	O
Pt	B
is	O
added	O
to	O
the	O
surface	O
as	O
an	O
electrocatalyst	O
.	O

Glyconanosomes	O
:	O
disk	O
-	O
shaped	O
nanomaterials	O
for	O
the	O
water	O
solubilization	O
and	O
delivery	O
of	O
hydrophobic	O
molecules	O
.	O

Herein	O
,	O
we	O
describe	O
the	O
first	O
report	O
on	O
a	O
new	O
class	O
of	O
disk	O
-	O
shaped	O
and	O
quite	O
monodisperse	O
water	O
-	O
soluble	O
nanomaterials	O
that	O
we	O
named	O
glyconanosomes	O
(	O
GNS	O
)	O
.	O

GNSs	O
were	O
obtained	O
by	O
sliding	O
out	O
the	O
cylindrical	O
structures	O
formed	O
upon	O
self	O
-	O
organization	O
and	O
photopolymerization	O
of	O
glycolipid	O
1	O
on	O
single	O
-	O
walled	O
carbon	O
nanotube	O
(	O
SWCNT	O
)	O
sidewalls	O
.	O

GNSs	O
present	O
a	O
sheltered	O
hydrophobic	O
inner	O
cavity	O
formed	O
by	O
the	O
carbonated	O
tails	O
,	O
surrounded	O
by	O
PEG	B
and	O
lactose	O
moieties	O
.	O

The	O
amphiphilic	O
character	O
of	O
GNSs	O
allows	O
the	O
water	O
solubility	O
of	O
insoluble	O
hydrophobic	O
cargos	O
such	O
as	O
a	O
perylene	B
-	I
bisimide	I
derivative	O
,	O
[	B
60	I
]	I
fullerene	I
,	O
or	O
the	O
anti	O
-	O
carcinogenic	O
drug	O
camptothecin	B
(	O
CPT	B
)	O
.	O

GNS	O
/	O
C60	B
inclusion	O
complexes	O
are	O
able	O
to	O
establish	O
specific	O
interactions	O
between	O
peanut	O
agglutinin	O
(	O
PNA	O
)	O
lectin	O
and	O
the	O
lactose	O
moiety	O
surrounding	O
the	O
complexes	O
,	O
while	O
CPT	B
solubilized	O
by	O
GNS	O
shows	O
higher	O
cytotoxicity	O
toward	O
MCF7-type	O
breast	O
cancer	O
cells	O
than	O
CPT	B
alone	O
.	O

Thus	O
,	O
GNS	O
represents	O
an	O
attractive	O
extension	O
of	O
nanoparticle	O
-	O
based	O
drug	O
delivery	O
systems	O
.	O

Three	O
new	O
lanostanoid	B
triterpenes	I
from	O
the	O
fruiting	O
bodies	O
of	O
Ganoderma	O
tropicum	O
.	O

Three	O
new	O
lanostanoid	B
triterpenes	I
,	O
3,7,15	B
-	I
trihydroxy-11,23-dioxo	I
-	I
lanost-8,16-dien-26-oic	I
acid	I
(	O
1	O
)	O
,	O
3,7,15	B
-	I
trihydroxy-11,23-dioxo	I
-	I
lanost-8,16-dien-26-oic	I
acid	I
methyl	I
ester	I
(	O
2	O
)	O
,	O
and	O
3,15	B
-	I
dihydroxy-7,11,23-trioxo	I
-	I
lanost-8,16-dien-26-oic	I
acid	I
methyl	I
ester	I
(	O
3	O
)	O
were	O
isolated	O
from	O
the	O
EtOAc	B
extract	O
of	O
the	O
fruiting	O
bodies	O
of	O
Ganoderma	O
tropicum	O
.	O

Their	O
structures	O
were	O
elucidated	O
on	O
the	O
basis	O
of	O
1D	O
and	O
2D	O
NMR	O
spectroscopy	O
as	O
well	O
as	O
MS	O
.	O

The	O
bioassay	O
of	O
inhibitory	O
activity	O
against	O
acetylcholinesterase	O
(	O
AChE	O
)	O
of	O
these	O
isolates	O
was	O
evaluated	O
and	O
compound	O
2	O
exhibited	O
definite	O
inhibitory	O
activity	O
against	O
AChE.	O

Strategies	O
to	O
control	O
morphology	O
in	O
hybrid	O
group	O
III	O
-	O
V	O
/	O
group	O
IV	O
heterostructure	O
nanowires	O
.	O

By	O
combining	O
in	O
situ	O
and	O
ex	O
situ	O
transmission	O
electron	O
microscopy	O
measurements	O
,	O
we	O
examine	O
the	O
factors	O
that	O
control	O
the	O
morphology	O
of	O
"	O
hybrid	O
"	O
nanowires	O
that	O
include	O
group	O
III	O
-	O
V	O
and	O
group	O
IV	O
materials	O
.	O

We	O
focus	O
on	O
one	O
materials	O
pair	O
,	O
GaP	B
/	O
Si	B
,	O
for	O
which	O
we	O
use	O
a	O
wide	O
range	O
of	O
growth	O
parameters	O
.	O

We	O
show	O
through	O
video	O
imaging	O
that	O
nanowire	O
morphology	O
depends	O
on	O
growth	O
conditions	O
,	O
but	O
that	O
a	O
general	O
pattern	O
emerges	O
where	O
either	O
single	O
kinks	O
or	O
inclined	O
defects	O
form	O
some	O
distance	O
after	O
the	O
heterointerface	O
.	O

We	O
show	O
that	O
pure	O
Si	B
nanowires	O
can	O
be	O
made	O
to	O
exhibit	O
the	O
same	O
kinks	O
and	O
defects	O
by	O
changing	O
their	O
droplet	O
volume	O
.	O

From	O
this	O
we	O
derive	O
a	O
model	O
where	O
droplet	O
geometry	O
drives	O
growth	O
morphology	O
and	O
discuss	O
optimization	O
strategies	O
.	O

We	O
finally	O
discuss	O
morphology	O
control	O
for	O
material	O
pairs	O
where	O
the	O
second	O
material	O
kinks	O
immediately	O
at	O
the	O
heterointerface	O
and	O
show	O
that	O
an	O
interlayer	O
between	O
segments	O
can	O
enable	O
the	O
growth	O
of	O
unkinked	O
hybrid	O
nanowires	O
.	O

Molecular	O
tweezers	O
modulate	O
14	O
-	O
3	O
-	O
3	O
protein	O
-	O
protein	O
interactions	O
.	O

Supramolecular	O
chemistry	O
has	O
recently	O
emerged	O
as	O
a	O
promising	O
way	O
to	O
modulate	O
protein	O
functions	O
,	O
but	O
devising	O
molecules	O
that	O
will	O
interact	O
with	O
a	O
protein	O
in	O
the	O
desired	O
manner	O
is	O
difficult	O
as	O
many	O
competing	O
interactions	O
exist	O
in	O
a	O
biological	O
environment	O
(	O
with	O
solvents	O
,	O
salts	O
or	O
different	O
sites	O
for	O
the	O
target	O
biomolecule	O
)	O
.	O

We	O
now	O
show	O
that	O
lysine	B
-	O
specific	O
molecular	O
tweezers	O
bind	O
to	O
a	O
14	O
-	O
3	O
-	O
3	O
adapter	O
protein	O
and	O
modulate	O
its	O
interaction	O
with	O
partner	O
proteins	O
.	O

The	O
tweezers	O
inhibit	O
binding	O
between	O
the	O
14	O
-	O
3	O
-	O
3	O
protein	O
and	O
two	O
partner	O
proteins	O
--	O
a	O
phosphorylated	O
(	O
C	O
-	O
Raf	O
)	O
protein	O
and	O
an	O
unphosphorylated	O
one	O
(	O
ExoS	O
)	O
--in	O
a	O
concentration	O
-	O
dependent	O
manner	O
.	O

Protein	O
crystallography	O
shows	O
that	O
this	O
effect	O
arises	O
from	O
the	O
binding	O
of	O
the	O
tweezers	O
to	O
a	O
single	O
surface	O
-	O
exposed	O
lysine	B
(	O
Lys214	B
)	O
of	O
the	O
14	O
-	O
3	O
-	O
3	O
protein	O
in	O
the	O
proximity	O
of	O
its	O
central	O
channel	O
,	O
which	O
normally	O
binds	O
the	O
partner	O
proteins	O
.	O

A	O
combination	O
of	O
structural	O
analysis	O
and	O
computer	O
simulations	O
provides	O
rules	O
for	O
the	O
tweezers	O
'	O
binding	O
preferences	O
,	O
thus	O
allowing	O
us	O
to	O
predict	O
their	O
influence	O
on	O
this	O
type	O
of	O
protein	O
-	O
protein	O
interactions	O
.	O

SIRT1	O
inhibits	O
NADPH	B
oxidase	O
activation	O
and	O
protects	O
endothelial	O
function	O
in	O
the	O
rat	O
aorta	O
:	O
Implications	O
for	O
vascular	O
aging	O
.	O

Vascular	O
aging	O
is	O
characterized	O
by	O
up	O
-	O
regulation	O
of	O
NADPH	B
oxidase	O
,	O
oxidative	O
stress	O
and	O
endothelial	O
dysfunction	O
.	O

Previous	O
studies	O
demonstrate	O
that	O
the	O
activity	O
of	O
the	O
evolutionarily	O
conserved	O
NAD	B
(	I
+	I
)	I
-dependent	O
deacetylase	O
SIRT1	O
declines	O
with	O
age	O
and	O
that	O
pharmacological	O
activators	O
of	O
SIRT1	O
confer	O
significant	O
anti	O
-	O
aging	O
cardiovascular	O
effects	O
.	O

To	O
determine	O
whether	O
dysregulation	O
of	O
SIRT1	O
promotes	O
NADPH	B
oxidase	O
-	O
dependent	O
production	O
of	O
reactive	O
oxygen	B
species	O
(	O
ROS	O
)	O
and	O
impairs	O
endothelial	O
function	O
we	O
assessed	O
the	O
effects	O
of	O
three	O
structurally	O
different	O
inhibitors	O
of	O
SIRT1	O
(	O
nicotinamide	B
,	O
sirtinol	B
,	O
EX527	B
)	O
in	O
aorta	O
segments	O
isolated	O
from	O
young	O
Wistar	O
rats	O
.	O

Inhibition	O
of	O
SIRT1	O
induced	O
endothelial	O
dysfunction	O
,	O
as	O
shown	O
by	O
the	O
significantly	O
reduced	O
relaxation	O
to	O
the	O
endothelium	O
-	O
dependent	O
vasodilators	O
acetylcholine	B
and	O
the	O
calcium	B
ionophore	O
A23187	B
.	O

Endothelial	O
dysfunction	O
induced	O
by	O
SIRT1	O
inhibition	O
was	O
prevented	O
by	O
treatment	O
of	O
the	O
vessels	O
with	O
the	O
NADPH	B
oxidase	O
inhibitor	O
apocynin	B
or	O
superoxide	B
dismutase	O
.	O

Inhibition	O
of	O
SIRT1	O
significantly	O
increased	O
vascular	O
superoxide	B
production	O
,	O
enhanced	O
NADPH	B
oxidase	O
activity	O
,	O
and	O
mRNA	O
expression	O
of	O
its	O
subunits	O
p22	O
(	O
phox	O
)	O
and	O
NOX4	O
,	O
which	O
were	O
prevented	O
by	O
resveratrol	B
.	O

Peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
-	O
	O
(	O
PPAR	O
)	O
activation	O
mimicked	O
the	O
effects	O
of	O
resveratrol	B
while	O
PPAR	O
inhibition	O
prevented	O
the	O
effects	O
of	O
this	O
SIRT1	O
activator	O
.	O

SIRT1	O
co	O
-	O
precipitated	O
with	O
PPAR	O
and	O
nicotinamide	B
increased	O
the	O
acetylation	O
of	O
the	O
PPAR	O
coactivator	O
PGC-1	O
,	O
which	O
was	O
suppressed	O
by	O
resveratrol	B
.	O

In	O
conclusion	O
,	O
impaired	O
activity	O
of	O
SIRT1	O
induces	O
endothelial	O
dysfunction	O
and	O
up	O
-	O
regulates	O
NADPH	B
oxidase	O
-	O
derived	O
ROS	O
production	O
in	O
the	O
vascular	O
wall	O
,	O
mimicking	O
the	O
vascular	O
aging	O
phenotype	O
.	O

Moreover	O
,	O
a	O
new	O
mechanism	O
for	O
controlling	O
endothelial	O
function	O
after	O
SIRT1	O
activation	O
involves	O
a	O
decreased	O
PGC-1	O
acetylation	O
and	O
the	O
subsequent	O
PPAR	O
activation	O
,	O
resulting	O
in	O
both	O
decreased	O
NADPH	B
oxidase	O
-	O
driven	O
ROS	O
production	O
and	O
NO	B
inactivation	O
.	O

Block	O
/	O
homo	O
polyplex	O
micelle	O
-	O
based	O
GM	O
-	O
CSF	O
gene	O
therapy	O
via	O
intraperitoneal	O
administration	O
elicits	O
antitumor	O
immunity	O
against	O
peritoneal	O
dissemination	O
and	O
exhibits	O
safety	O
potentials	O
in	O
mice	O
and	O
cynomolgus	O
monkeys	O
.	O

A	O
block	O
/	O
homo	O
-	O
mixed	O
polyplex	O
micelle	O
,	O
comprising	O
of	O
cationic	O
homo	O
polymer	O
:	O
poly	B
{	I
N'-	I
[	I
N-	I
(	I
2-aminoethyl	I
)	I
-2-aminoethyl	I
]	I
aspartamide	I
}	I
P	B
[	I
Asp	I
(	I
DET	I
)	I
]	I
and	O
block	O
copolymer	O
:	O
polyethylene	B
glycol	I
(	B
PEG	I
)	I
-b	I
-	I
P	I
[	I
Asp	I
(	I
DET	I
)	I
]	I
,	O
has	O
been	O
reported	O
to	O
exhibit	O
the	O
efficient	O
transgene	O
expression	O
in	O
vivo	O
by	O
intratracheal	O
and	O
systemic	O
administration	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
potential	O
of	O
immunogene	O
therapy	O
by	O
intraperitoneal	O
(	O
i.p	O
.	O
)	O
administration	O
of	O
block	O
/	O
homo	O
polyplex	O
micelles	O
for	O
peritoneal	O
dissemination	O
.	O

For	O
evaluation	O
of	O
transgene	O
expression	O
in	O
vivo	O
,	O
block	O
/	O
homo	O
polyplex	O
micelles	O
showed	O
12-fold	O
higher	O
level	O
in	O
luciferase	O
expression	O
evaluated	O
by	O
bioluminescence	O
imaging	O
system	O
at	O
24h	O
after	O
the	O
i.p	O
.	O

administration	O
compared	O
with	O
block	O
polyplex	O
micelles	O
composed	O
with	O
only	O
PEG	B
-	I
b	I
-	I
P	I
[	I
Asp	I
(	I
DET	I
)	I
]	I
in	O
nude	O
mice	O
bearing	O
peritoneal	O
dissemination	O
.	O

The	O
distribution	O
of	O
block	O
/	O
homo	O
polyplex	O
micelles	O
and	O
intracellular	O
uptake	O
of	O
pDNA	O
was	O
observed	O
in	O
tumor	O
nodules	O
.	O

The	O
tumor	O
growth	O
and	O
the	O
prolonged	O
survival	O
rate	O
for	O
the	O
mice	O
harboring	O
disseminated	O
pancreatic	O
cancer	O
more	O
significantly	O
compared	O
with	O
the	O
mock	O
.	O

The	O
antitumor	O
effect	O
of	O
GM	O
-	O
CSF	O
gene	O
therapy	O
was	O
mediated	O
via	O
the	O
activation	O
of	O
natural	O
killer	O
cells	O
.	O

For	O
safety	O
evaluation	O
,	O
block	O
/	O
homo	O
polyplex	O
micelles	O
indicated	O
almost	O
no	O
adverse	O
events	O
for	O
patho	O
-	O
physical	O
findings	O
and	O
blood	O
examinations	O
in	O
mice	O
and	O
cynomolgus	O
monkeys	O
,	O
although	O
slight	O
increases	O
in	O
serum	O
fibrinogen	O
were	O
observed	O
in	O
the	O
monkey	O
model	O
.	O

In	O
conclusion	O
,	O
block	O
/	O
homo	O
polyplex	O
micelle	O
-	O
based	O
immunogene	O
therapy	O
via	O
i.p	O
.	O

administration	O
may	O
be	O
a	O
safe	O
and	O
effective	O
approach	O
for	O
suppressing	O
intractable	O
peritoneal	O
dissemination	O
.	O

Nuclear	O
Flux	O
Densities	O
during	O
a	O
Model	O
Pericyclic	O
Reaction	O
with	O
Energies	O
Well	O
Above	O
and	O
Below	O
the	O
Potential	O
Barrier	O
.	O

Pericyclic	O
reactions	O
with	O
energies	O
E	O
well	O
above	O
the	O
potential	O
energy	O
barrier	O
B	O
(	O
case	O
E	O
>	O
B	O
)	O
proceed	O
with	O
quantum	O
nuclear	O
flux	O
densities	O
	O
j	O
	O
which	O
are	O
essentially	O
proportional	O
to	O
the	O
nuclear	O
densities	O
	O
in	O
the	O
femtosecond	O
time	O
domain	O
.	O

This	O
corresponds	O
to	O
the	O
definition	O
of	O
classical	O
(	O
cl	O
)	O
mechanics	O
,	O
jcl	O
=	O
cl	O
cl	O
,	O
with	O
almost	O
constant	O
velocity	O
vcl	O
.	O

For	O
the	O
other	O
case	O
E	O
<	O
B	O
,	O
however	O
,	O
that	O
is	O
,	O
in	O
the	O
domain	O
of	O
coherent	O
tunneling	O
,	O
we	O
discover	O
the	O
opposite	O
trend	O
,	O
that	O
is	O
,	O
	O
j	O
	O
has	O
maximum	O
value	O
close	O
to	O
the	O
barrier	O
where	O
	O
is	O
a	O
minimum	O
(	O
in	O
fact	O
where	O
	O
is	O
close	O
to	O
zero	O
)	O
.	O

The	O
general	O
conclusion	O
is	O
that	O
quantum	O
mechanical	O
nuclear	O
flux	O
densities	O
may	O
be	O
at	O
variance	O
from	O
traditional	O
expectations	O
based	O
on	O
classical	O
trajectories	O
.	O

This	O
prediction	O
calls	O
for	O
experimental	O
demonstration	O
.	O

The	O
counter	O
-	O
intuitive	O
proof	O
-	O
of	O
-	O
principle	O
is	O
demonstrated	O
for	O
a	O
simple	O
,	O
one	O
-	O
dimensional	O
model	O
of	O
the	O
Cope	O
rearrangement	O
of	O
semibullvalene	O
.	O

The	O
influence	O
of	O
salinity	O
on	O
acute	O
nickel	B
toxicity	O
to	O
the	O
two	O
euryhaline	O
fish	O
species	O
,	O
Fundulus	O
heteroclitus	O
and	O
Kryptolebias	O
marmoratus	O
.	O

Nickel	B
(	O
Ni	B
)	O
is	O
a	O
common	O
pollutant	O
found	O
in	O
aquatic	O
environments	O
and	O
may	O
be	O
harmful	O
at	O
elevated	O
concentrations	O
.	O

Increasing	O
salinity	O
has	O
been	O
shown	O
to	O
decrease	O
the	O
bioavailability	O
and	O
toxicity	O
of	O
other	O
metals	O
to	O
aquatic	O
organisms	O
.	O

In	O
the	O
present	O
study	O
,	O
acute	O
Ni	B
toxicity	O
experiments	O
(	O
96-h	O
)	O
were	O
conducted	O
at	O
various	O
salinities	O
(	O
0	O
-	O
36	O
ppt	O
)	O
to	O
determine	O
the	O
effects	O
of	O
salinity	O
on	O
Ni	B
toxicity	O
to	O
2	O
euryhaline	O
fish	O
species	O
,	O
Kryptolebias	O
marmoratus	O
and	O
Fundulus	O
heteroclitus	O
.	O

Nickel	B
concentrations	O
causing	O
lethality	O
to	O
50	O
%	O
of	O
the	O
fish	O
ranged	O
from	O
2	O
mg	O
/	O
L	O
in	O
moderately	O
hard	O
freshwater	O
to	O
66.6	O
mg	O
/	O
L	O
in	O
36	O
ppt	O
saltwater	O
.	O

Nickel	B
toxicity	O
to	O
F.	O
heteroclitus	O
decreased	O
linearly	O
with	O
increasing	O
salinity	O
;	O
however	O
,	O
Ni	B
toxicity	O
to	O
K.	O
marmoratus	O
was	O
only	O
lowered	O
by	O
salinities	O
above	O
6	O
ppt	O
,	O
demonstrating	O
potential	O
physiological	O
differences	O
between	O
the	O
2	O
species	O
when	O
they	O
are	O
functioning	O
as	O
freshwater	O
fish	O
.	O

Furthermore	O
,	O
the	O
authors	O
investigated	O
the	O
influence	O
of	O
Mg	B
(	I
2	I
+	I
)	I
,	O
Ca	B
(	I
2	I
+	I
)	I
,	O
Na	B
(	I
+	I
)	I
,	O
and	O
Cl	B
(	I
-	I
)	I
on	O
Ni	B
toxicity	O
to	O
F.	O
heteroclitus	O
.	O

Freshwater	O
with	O
up	O
to	O
120	O
mg	O
/	O
L	O
Ca	B
(	I
2	I
+	I
)	I
as	O
CaSO4	B
,	O
250	O
mg	O
/	O
L	O
Mg	B
(	I
2	I
+	I
)	I
as	O
MgSO4	B
,	O
or	O
250	O
mg	O
/	O
L	O
Na	B
(	I
+	I
)	I
as	O
NaHCO3	B
did	O
not	O
provide	O
protection	O
against	O
Ni	B
toxicity	O
.	O

Alternatively	O
,	O
250	O
mg	O
/	O
L	O
Na	B
(	I
+	I
)	I
,	O
as	O
NaCl	B
,	O
was	O
protective	O
against	O
Ni	B
toxicity	O
;	O
and	O
the	O
extent	O
of	O
protection	O
was	O
similar	O
to	O
that	O
demonstrated	O
from	O
salt	O
water	O
with	O
the	O
same	O
Cl	B
(	I
-	I
)	I
concentration	O
.	O

These	O
results	O
suggest	O
that	O
Cl	B
(	I
-	I
)	I
is	O
the	O
predominant	O
ion	O
responsible	O
for	O
reducing	O
Ni	B
toxicity	O
to	O
K.	O
marmoratus	O
and	O
F.	O
heteroclitus	O
in	O
higher	O
salinity	O
waters	O
.	O

Environ	O
Toxicol	O
Chem	O
2013;32:1354	O
-	O
1359	O
.	O

	O
2013	O
SETAC	O
.	O

Evaluation	O
of	O
phytotoxicity	O
and	O
genotoxicity	O
of	O
nitrobenzene	B
with	O
A	O
battery	O
of	O
Vicia	O
Faba	O
assay	O
system	O
.	O

Nitrobenzene	B
(	O
NB	O
)	O
is	O
an	O
important	O
organic	O
compound	O
intermediate	O
that	O
is	O
used	O
widely	O
in	O
industry	O
.	O

In	O
the	O
present	O
study	O
,	O
to	O
evaluate	O
the	O
phytotoxicity	O
and	O
genotoxicity	O
of	O
NB	O
on	O
plants	O
,	O
Vicia	O
faba	O
was	O
exposed	O
to	O
increasing	O
concentrations	O
of	O
NB	O
(	O
5	O
mg	O
L	O
(	O
-1	O
)	O
,	O
10	O
mg	O
L	O
(	O
-1	O
)	O
,	O
25	O
mg	O
L	O
(	O
-1	O
)	O
,	O
50	O
mg	O
L	O
(	O
-1	O
)	O
,	O
and	O
100	O
mg	O
L	O
(	O
-1	O
)	O
)	O
.	O

The	O
data	O
revealed	O
that	O
germination	O
rate	O
and	O
radicle	O
length	O
of	O
V.	O
faba	O
seedlings	O
were	O
promoted	O
by	O
low	O
NB	O
concentrations	O
and	O
short	O
exposure	O
periods	O
,	O
whereas	O
these	O
parameters	O
were	O
inhibited	O
at	O
greater	O
NB	O
concentrations	O
and	O
longer	O
exposures	O
.	O

When	O
assessed	O
by	O
mitotic	O
index	O
,	O
micronucleus	O
,	O
and	O
chromosomal	O
aberration	O
assays	O
,	O
NB	O
showed	O
dose	O
-	O
dependent	O
genotoxicity	O
at	O
0	O
mg	O
L	O
(	O
-1	O
)	O
to	O
50	O
mg	O
L	O
(	O
-1	O
)	O
.	O

Environ	O
Toxicol	O
Chem	O
2013;32:1426	O
-	O
1432	O
.	O

	O
2013	O
SETAC	O
.	O

Experimental	O
models	O
of	O
disseminated	O
scedosporiosis	O
with	O
cerebral	O
involvement	O
.	O

Scedosporium	O
apiospermum	O
is	O
a	O
soil	O
fungus	O
which	O
can	O
cause	O
severe	O
and	O
often	O
fatal	O
cerebral	O
infections	O
in	O
both	O
immunocompetent	O
patients	O
in	O
the	O
event	O
of	O
near	O
drowning	O
and	O
immunosuppressed	O
patients	O
such	O
as	O
lung	O
transplant	O
recipients	O
.	O

Because	O
of	O
the	O
low	O
susceptibility	O
of	O
this	O
fungus	O
to	O
antifungal	O
drugs	O
,	O
and	O
the	O
low	O
permeability	O
of	O
the	O
blood	O
-	O
brain	O
barrier	O
(	O
BBB	O
)	O
,	O
therapeutic	O
drug	O
monitoring	O
is	O
necessary	O
to	O
reach	O
an	O
effective	O
tissue	O
concentration	O
with	O
limited	O
side	O
effects	O
.	O

Indeed	O
,	O
diffusion	O
of	O
the	O
drug	O
in	O
the	O
brain	O
is	O
dependent	O
on	O
several	O
parameters	O
,	O
such	O
as	O
the	O
integrity	O
of	O
the	O
BBB	O
and	O
the	O
activity	O
of	O
efflux	O
pumps	O
.	O

To	O
evaluate	O
drug	O
diffusion	O
,	O
two	O
experimental	O
models	O
were	O
developed	O
in	O
immunocompetent	O
and	O
immunosuppressed	O
rats	O
.	O

Inocula	O
were	O
administered	O
via	O
the	O
penile	O
vein	O
and	O
a	O
clinical	O
scale	O
(	O
0	O
-	O
9	O
)	O
was	O
established	O
,	O
based	O
on	O
weight	O
and	O
clinical	O
and	O
neurologic	O
signs	O
evaluated	O
by	O
the	O
tail	O
suspension	O
test	O
.	O

Cerebral	O
involvement	O
was	O
confirmed	O
by	O
magnetic	O
resonance	O
imaging	O
and	O
histologic	O
examination	O
of	O
brain	O
sections	O
after	O
hematoxylin	B
-	O
eosin	B
-	O
safran	O
or	O
silver	B
staining	O
.	O

Voriconazole	B
or	O
posaconazole	B
was	O
given	O
to	O
the	O
rats	O
at	O
doses	O
ranging	O
from	O
10	O
to	O
75	O
mg	O
/	O
kg	O
/	O
day	O
via	O
i.v	O
.	O
or	O
oral	O
routes	O
,	O
respectively	O
.	O

Whatever	O
the	O
immune	O
status	O
,	O
the	O
effective	O
doses	O
(	O
defined	O
by	O
a	O
doubling	O
of	O
the	O
survival	O
time	O
and	O
the	O
absence	O
of	O
neurologic	O
sequelae	O
)	O
were	O
30	O
mg	O
/	O
kg	O
/	O
day	O
for	O
voriconazole	B
and	O
50	O
mg	O
/	O
kg	O
/	O
day	O
for	O
posaconazole	B
.	O

Overall	O
,	O
the	O
results	O
demonstrated	O
that	O
these	O
models	O
may	O
constitute	O
valuable	O
tools	O
for	O
the	O
performance	O
of	O
pharmacokinetic	O
and	O
pharmacodynamic	O
studies	O
for	O
pharmacokinetic	O
-	O
pharmacodynamic	O
modeling	O
.	O

Serial	O
infusions	O
of	O
low	O
-	O
dose	O
ketamine	B
for	O
major	O
depression	O
.	O

Background	O
:	O
Single	O
infusions	O
of	O
ketamine	B
have	O
been	O
used	O
successfully	O
to	O
achieve	O
improvement	O
in	O
depressed	O
patients	O
.	O

Side	O
effects	O
during	O
the	O
infusions	O
have	O
been	O
common	O
.	O

It	O
is	O
not	O
known	O
whether	O
serial	O
infusions	O
or	O
lower	O
infusion	O
rates	O
result	O
in	O
greater	O
efficacy	O
.	O

Methods	O
:	O
Ten	O
depressed	O
patients	O
were	O
treated	O
with	O
twice	O
weekly	O
ketamine	B
infusions	O
of	O
ketamine	B
0.5	O
mg	O
/	O
kg	O
administered	O
over	O
100	O
min	O
until	O
either	O
remission	O
was	O
achieved	O
or	O
four	O
infusions	O
were	O
given	O
.	O

Side	O
effects	O
were	O
assessed	O
with	O
the	O
Young	O
Mania	O
Rating	O
Scale	O
(	O
YMRS	O
)	O
and	O
the	O
Brief	O
Psychiatric	O
Rating	O
Scale	O
(	O
BPRS	O
)	O
.	O

Patients	O
were	O
followed	O
naturalistically	O
at	O
weekly	O
intervals	O
for	O
four	O
weeks	O
after	O
completion	O
of	O
the	O
infusions	O
.	O

Results	O
:	O
Five	O
of	O
10	O
patients	O
achieved	O
remission	O
status	O
.	O

There	O
were	O
no	O
significant	O
increases	O
on	O
the	O
BPRS	O
or	O
YMRS	O
.	O

Two	O
of	O
the	O
remitting	O
patients	O
sustained	O
their	O
improvement	O
throughout	O
the	O
four	O
week	O
follow	O
-	O
up	O
period	O
.	O

Conclusions	O
:	O
Ketamine	B
infusions	O
at	O
a	O
lower	O
rate	O
than	O
previously	O
reported	O
have	O
demonstrated	O
similar	O
efficacy	O
and	O
excellent	O
tolerability	O
and	O
may	O
be	O
more	O
practically	O
available	O
for	O
routine	O
clinical	O
care	O
.	O

Serial	O
ketamine	B
infusions	O
appear	O
to	O
be	O
more	O
effective	O
than	O
a	O
single	O
infusion	O
.	O

Further	O
research	O
to	O
test	O
relapse	O
prevention	O
strategies	O
with	O
continuation	O
ketamine	B
infusions	O
is	O
indicated	O
.	O

Nephroprotective	O
effect	O
of	O
calcium	B
channel	O
blockers	O
against	O
toxicity	O
of	O
lead	O
exposure	O
in	O
mice	O
.	O

Exposure	O
to	O
lead	O
(	O
Pb	B
)	O
can	O
induce	O
kidney	O
damage	O
,	O
which	O
is	O
related	O
to	O
induction	O
of	O
oxidative	O
damage	O
and	O
disturbance	O
of	O
intracellular	O
calcium	B
homeostasis	O
.	O

Pb	B
can	O
readily	O
permeate	O
through	O
dihydropyridine	O
-	O
sensitive	O
L	O
-	O
type	O
calcium	B
channels	O
and	O
accumulate	O
within	O
cells	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
investigate	O
protective	O
effects	O
of	O
calcium	B
channel	O
blockers	O
(	O
CCBs	O
)	O
verapamil	B
and	O
nimodipine	B
on	O
nephrotoxicity	O
induced	O
by	O
Pb	B
acetate	I
in	O
mice	O
.	O

One	O
hundred	O
and	O
twenty	O
male	O
mice	O
were	O
randomly	O
divided	O
into	O
6	O
groups	O
:	O
control	O
,	O
Pb	B
,	O
low	O
-	O
dose	O
verapamil	B
,	O
high	O
-	O
dose	O
verapamil	B
,	O
low	O
-	O
dose	O
nimodipine	B
and	O
high	O
-	O
dose	O
nimodipine	B
(	O
n=20	O
per	O
group	O
)	O
.	O

Pb	B
acetate	I
was	O
injected	O
intraperitoneally	O
(	O
i.p	O
.	O
)	O
at	O
40	O
mg	O
/	O
kg	O
body	O
weight	O
/	O
day	O
for	O
10	O
days	O
to	O
establish	O
the	O
Pb	B
toxicity	O
model	O
.	O

While	O
control	O
mice	O
received	O
saline	O
,	O
mice	O
of	O
the	O
treated	O
groups	O
simultaneously	O
received	O
i.p	O
.	O

injections	O
of	O
verapamil	B
or	O
nimodipine	B
daily	O
for	O
10	O
days	O
.	O

Both	O
verapamil	B
and	O
nimodipine	B
showed	O
protection	O
against	O
Pb	B
-	O
induced	O
kidney	O
injury	O
,	O
including	O
alleviation	O
of	O
renal	O
pathological	O
damage	O
and	O
decreasing	O
the	O
level	O
of	O
Pb	B
in	O
kidney	O
homogenate	O
and	O
extent	O
of	O
apoptosis	O
in	O
nephrocytes	O
.	O

Moreover	O
,	O
verapamil	B
and	O
nimodipine	B
significantly	O
down	O
-	O
regulated	O
levels	O
of	O
blood	O
urea	B
nitrogen	B
and	O
creatinine	B
in	O
the	O
serum	O
.	O

In	O
addition	O
,	O
verapamil	B
and	O
nimodipine	B
administration	O
decreased	O
malondialdehyde	B
content	O
and	O
increased	O
activities	O
of	O
super	B
oxide	I
dismutase	O
activity	O
and	O
glutathione	B
peroxidase	O
in	O
the	O
kidney	O
homogenate	O
.	O

The	O
findings	O
in	O
the	O
present	O
study	O
implicate	O
the	O
therapeutic	O
potential	O
of	O
CCBs	O
for	O
Pb	B
-	O
induced	O
nephrotoxicity	O
,	O
which	O
were	O
at	O
least	O
partly	O
due	O
to	O
the	O
decrease	O
of	O
Pb	B
uptake	O
and	O
inhibition	O
of	O
lipid	O
peroxidation	O
.	O

The	O
role	O
of	O
lipid	O
domains	O
in	O
bacterial	O
cell	O
processes	O
.	O

Membranes	O
are	O
vital	O
structures	O
for	O
cellular	O
life	O
forms	O
.	O

As	O
thin	O
,	O
hydrophobic	O
films	O
,	O
they	O
provide	O
a	O
physical	O
barrier	O
separating	O
the	O
aqueous	O
cytoplasm	O
from	O
the	O
outside	O
world	O
or	O
from	O
the	O
interiors	O
of	O
other	O
cellular	O
compartments	O
.	O

They	O
maintain	O
a	O
selective	O
permeability	O
for	O
the	O
import	O
and	O
export	O
of	O
water	O
-	O
soluble	O
compounds	O
,	O
enabling	O
the	O
living	O
cell	O
to	O
maintain	O
a	O
stable	O
chemical	O
environment	O
for	O
biological	O
processes	O
.	O

Cell	O
membranes	O
are	O
primarily	O
composed	O
of	O
two	O
crucial	O
substances	O
,	O
lipids	O
and	O
proteins	O
.	O

Bacterial	O
membranes	O
can	O
sense	O
environmental	O
changes	O
or	O
communication	O
signals	O
from	O
other	O
cells	O
and	O
they	O
support	O
different	O
cell	O
processes	O
,	O
including	O
cell	O
division	O
,	O
differentiation	O
,	O
protein	O
secretion	O
and	O
supplementary	O
protein	O
functions	O
.	O

The	O
original	O
fluid	O
mosaic	O
model	O
of	O
membrane	O
structure	O
has	O
been	O
recently	O
revised	O
because	O
it	O
has	O
become	O
apparent	O
that	O
domains	O
of	O
different	O
lipid	O
composition	O
are	O
present	O
in	O
both	O
eukaryotic	O
and	O
prokaryotic	O
cell	O
membranes	O
.	O

In	O
this	O
review	O
,	O
we	O
summarize	O
different	O
aspects	O
of	O
phospholipid	O
domain	O
formation	O
in	O
bacterial	O
membranes	O
,	O
mainly	O
in	O
Gram	O
-	O
negative	O
Escherichia	O
coli	O
and	O
Gram	O
-	O
positive	O
Bacillus	O
subtilis	O
.	O

We	O
describe	O
the	O
role	O
of	O
these	O
lipid	O
domains	O
in	O
membrane	O
dynamics	O
and	O
the	O
localization	O
of	O
specific	O
proteins	O
and	O
protein	O
complexes	O
in	O
relation	O
to	O
the	O
regulation	O
of	O
cellular	O
function	O
.	O

Intracellular	O
localization	O
of	O
the	O
BCL-2	O
family	O
member	O
BOK	O
and	O
functional	O
implications	O
.	O

The	O
pro	O
-	O
apoptotic	O
BCL-2	O
family	O
member	O
BOK	O
is	O
widely	O
expressed	O
and	O
resembles	O
the	O
multi	O
-	O
BH	O
domain	O
proteins	O
BAX	O
and	O
BAK	O
based	O
on	O
its	O
amino	B
acid	I
sequence	O
.	O

The	O
genomic	O
region	O
encoding	O
BOK	O
was	O
reported	O
to	O
be	O
frequently	O
deleted	O
in	O
human	O
cancer	O
and	O
it	O
has	O
therefore	O
been	O
hypothesized	O
that	O
BOK	O
functions	O
as	O
a	O
tumor	O
suppressor	O
.	O

However	O
,	O
little	O
is	O
known	O
about	O
the	O
molecular	O
functions	O
of	O
BOK	O
.	O

We	O
show	O
that	O
enforced	O
expression	O
of	O
BOK	O
activates	O
the	O
intrinsic	O
(	O
mitochondrial	O
)	O
apoptotic	O
pathway	O
in	O
BAX	O
/	O
BAK	O
-	O
proficient	O
cells	O
but	O
fails	O
to	O
kill	O
cells	O
lacking	O
both	O
BAX	O
and	O
BAK	O
or	O
sensitize	O
them	O
to	O
cytotoxic	O
insults	O
.	O

Interestingly	O
,	O
major	O
portions	O
of	O
endogenous	O
BOK	O
are	O
localized	O
to	O
and	O
partially	O
inserted	O
into	O
the	O
membranes	O
of	O
the	O
Golgi	O
apparatus	O
as	O
well	O
as	O
the	O
endoplasmic	O
reticulum	O
(	O
ER	O
)	O
and	O
associated	O
membranes	O
.	O

The	O
C	O
-	O
terminal	O
transmembrane	O
domain	O
of	O
BOK	O
thereby	O
constitutes	O
a	O
'	O
tail	O
-	O
anchor	O
'	O
specific	O
for	O
targeting	O
to	O
the	O
Golgi	O
and	O
ER	O
.	O

Overexpression	O
of	O
full	O
-	O
length	O
BOK	O
causes	O
early	O
fragmentation	O
of	O
ER	O
and	O
Golgi	O
compartments	O
.	O

A	O
role	O
for	O
BOK	O
on	O
the	O
Golgi	O
apparatus	O
and	O
the	O
ER	O
is	O
supported	O
by	O
an	O
abnormal	O
response	O
of	O
Bok	O
-	O
deficient	O
cells	O
to	O
the	O
Golgi	O
/	O
ER	O
stressor	O
brefeldin	B
A.	I
Based	O
on	O
these	O
results	O
,	O
we	O
propose	O
that	O
major	O
functions	O
of	O
BOK	O
are	O
exerted	O
at	O
the	O
Golgi	O
and	O
ER	O
membranes	O
and	O
that	O
BOK	O
induces	O
apoptosis	O
in	O
a	O
manner	O
dependent	O
on	O
BAX	O
and	O
BAK	O
.	O

Cyclic	O
stretch	O
induces	O
inducible	O
nitric	B
oxide	I
synthase	O
and	O
soluble	O
guanylate	B
cyclase	O
in	O
pulmonary	O
artery	O
smooth	O
muscle	O
cells	O
.	O

In	O
the	O
pulmonary	O
vasculature	O
,	O
mechanical	O
forces	O
such	O
as	O
cyclic	O
stretch	O
induce	O
changes	O
in	O
vascular	O
signaling	O
,	O
tone	O
and	O
remodeling	O
.	O

Nitric	B
oxide	I
is	O
a	O
potent	O
regulator	O
of	O
soluble	O
guanylate	B
cyclase	O
(	O
sGC	O
)	O
,	O
which	O
drives	O
cGMP	B
production	O
,	O
causing	O
vasorelaxation	O
.	O

Pulmonary	O
artery	O
smooth	O
muscle	O
cells	O
(	O
PASMCs	O
)	O
express	O
inducible	O
nitric	B
oxide	I
synthase	O
(	O
iNOS	O
)	O
,	O
and	O
while	O
iNOS	O
expression	O
increases	O
during	O
late	O
gestation	O
,	O
little	O
is	O
known	O
about	O
how	O
cyclic	O
stretch	O
impacts	O
this	O
pathway	O
.	O

In	O
this	O
study	O
,	O
PASMC	O
were	O
subjected	O
to	O
cyclic	O
stretch	O
of	O
20	O
%	O
amplitude	O
and	O
frequency	O
of	O
1	O
Hz	O
for	O
24	O
h	O
and	O
compared	O
to	O
control	O
cells	O
maintained	O
under	O
static	O
conditions	O
.	O

Cyclic	O
stretch	O
significantly	O
increased	O
cytosolic	O
oxidative	O
stress	O
as	O
compared	O
to	O
static	O
cells	O
(	O
62.9	O
	O
5.9	O
%	O
vs.	O
33.3	O
	O
5.7	O
%	O
maximal	O
oxidation	O
)	O
,	O
as	O
measured	O
by	O
the	O
intracellular	O
redox	O
sensor	O
roGFP	O
.	O

Cyclic	O
stretch	O
also	O
increased	O
sGC	O
protein	O
expression	O
(	O
2.5	O
	O
0.9-fold	O
)	O
,	O
sGC	O
activity	O
(	O
1.5	O
	O
0.2-fold	O
)	O
and	O
cGMP	B
levels	O
(	O
1.8	O
	O
0.2-fold	O
)	O
,	O
as	O
well	O
as	O
iNOS	O
mRNA	O
and	O
protein	O
expression	O
(	O
3.0	O
	O
0.9	O
and	O
2.6	O
	O
0.7-fold	O
,	O
respectively	O
)	O
relative	O
to	O
control	O
cells	O
.	O

An	O
antioxidant	O
,	O
recombinant	O
human	O
superoxide	B
dismutase	O
(	O
rhSOD	O
)	O
,	O
significantly	O
decreased	O
stretch	O
-	O
induced	O
cytosolic	O
oxidative	O
stress	O
,	O
but	O
did	O
not	O
block	O
stretch	O
-	O
induced	O
sGC	O
activity	O
.	O

Inhibition	O
of	O
iNOS	O
with	O
1400	O
W	O
or	O
an	O
iNOS	O
-	O
specific	O
siRNA	O
inhibited	O
stretch	O
-	O
induced	O
sGC	O
activity	O
by	O
30	O
%	O
and	O
68	O
%	O
respectively	O
vs.	O
static	O
controls	O
.	O

In	O
conclusion	O
,	O
cyclic	O
stretch	O
increases	O
sGC	O
expression	O
and	O
activity	O
in	O
an	O
iNOS	O
-	O
dependent	O
manner	O
in	O
PASMC	O
from	O
fetal	O
lambs	O
.	O

The	O
mechanism	O
that	O
produces	O
iNOS	O
and	O
sGC	O
upregulation	O
is	O
not	O
yet	O
known	O
,	O
but	O
we	O
speculate	O
these	O
effects	O
represent	O
an	O
early	O
compensatory	O
mechanism	O
to	O
counteract	O
the	O
effects	O
of	O
stretch	O
-	O
induced	O
oxidative	O
stress	O
.	O

A	O
better	O
understanding	O
of	O
the	O
interplay	O
between	O
these	O
two	O
distinct	O
pathways	O
could	O
provide	O
key	O
insights	O
into	O
future	O
avenues	O
to	O
treat	O
infants	O
with	O
pulmonary	O
hypertension	O
.	O

Hypoxaemia	O
affects	O
male	O
reproduction	O
:	O
a	O
case	O
study	O
of	O
how	O
to	O
differentiate	O
between	O
primary	O
and	O
secondary	O
hypoxic	O
testicular	O
toxicity	O
due	O
to	O
chemical	O
exposure	O
.	O

Classification	O
for	O
fertility	O
is	O
based	O
on	O
two	O
conditions	O
,	O
namely	O
on	O
evidence	O
of	O
an	O
adverse	O
effect	O
on	O
sexual	O
function	O
and	O
fertility	O
and	O
that	O
the	O
effect	O
is	O
not	O
secondary	O
to	O
other	O
toxic	O
effects	O
.	O

To	O
decide	O
on	O
an	O
adverse	O
effect	O
is	O
a	O
relatively	O
simple	O
day	O
-	O
to	O
-	O
day	O
decision	O
in	O
toxicology	O
but	O
whether	O
this	O
effect	O
is	O
secondary	O
often	O
leads	O
to	O
serious	O
controversy	O
.	O

As	O
the	O
seminiferous	O
epithelium	O
operates	O
on	O
the	O
verge	O
of	O
hypoxia	O
,	O
oxygen	B
deficit	O
can	O
lead	O
to	O
secondary	O
impairment	O
of	O
testicular	O
function	O
.	O

This	O
is	O
well	O
known	O
from	O
healthy	O
mountaineers	O
exposing	O
themselves	O
to	O
high	O
altitude	O
.	O

They	O
have	O
reduced	O
blood	O
oxygen	B
content	O
that	O
goes	O
in	O
parallel	O
with	O
impairment	O
of	O
testicular	O
function	O
and	O
this	O
effect	O
remains	O
for	O
some	O
time	O
in	O
spite	O
of	O
a	O
compensatory	O
polycythaemia	O
.	O

Similar	O
findings	O
are	O
described	O
for	O
experimental	O
animals	O
exposed	O
to	O
hypobaric	O
oxygen	B
/	O
high	O
altitude	O
.	O

In	O
addition	O
,	O
testicular	O
function	O
is	O
affected	O
in	O
severe	O
diseases	O
in	O
humans	O
associated	O
with	O
systemic	O
oxygen	B
deficit	O
like	O
chronic	O
obstructive	O
pulmonary	O
disease	O
,	O
sickle	O
cell	O
disease	O
or	O
beta	O
-	O
thalassaemia	O
as	O
well	O
as	O
in	O
transgenic	O
animals	O
simulating	O
haemolytic	O
anaemia	O
or	O
sickle	O
cell	O
disease	O
.	O

The	O
problem	O
of	O
insufficient	O
oxygen	B
supply	O
as	O
the	O
underlying	O
cause	O
for	O
testicular	O
impairment	O
has	O
received	O
relatively	O
little	O
attention	O
in	O
toxicology	O
,	O
mainly	O
because	O
blood	O
oxygen	B
content	O
is	O
generally	O
not	O
measured	O
in	O
these	O
animal	O
experiments	O
.	O

The	O
difficulties	O
associated	O
with	O
the	O
decision	O
whether	O
testicular	O
toxicity	O
is	O
primary	O
or	O
secondary	O
to	O
hypoxia	O
are	O
exemplified	O
by	O
the	O
results	O
of	O
inhalation	O
studies	O
with	O
nickel	B
subsulphide	I
and	O
gallium	B
arsenide	I
(	O
GaAs	B
)	O
.	O

Both	O
of	O
these	O
particulate	O
substances	O
lead	O
to	O
severe	O
lung	O
toxicity	O
that	O
might	O
impair	O
oxygen	B
uptake	O
,	O
but	O
testicular	O
toxicity	O
is	O
only	O
observed	O
with	O
GaAs	B
.	O

This	O
may	O
first	O
be	O
explained	O
by	O
different	O
effects	O
on	O
the	O
blood	O
:	O
nickel	B
subsulphide	I
inhalation	O
leads	O
to	O
a	O
compensatory	O
erythropoiesis	O
that	O
may	O
mitigate	O
pulmonary	O
lack	O
of	O
oxygen	B
uptake	O
.	O

In	O
contrast	O
,	O
GaAs	B
exposure	O
is	O
associated	O
with	O
microcytic	O
haemolytic	O
anaemia	O
thereby	O
aggravating	O
any	O
possible	O
oxygen	B
undersupply	O
.	O

Furthermore	O
,	O
the	O
predominant	O
pulmonary	O
effect	O
caused	O
by	O
GaAs	B
(	O
but	O
not	O
by	O
nickel	B
subsulphide	I
)	O
is	O
alveolar	O
proteinosis	O
.	O

Pulmonary	O
alveolar	O
proteinosis	O
is	O
also	O
known	O
as	O
a	O
severe	O
disease	O
in	O
humans	O
associated	O
with	O
hypoxaemia	O
.	O

Therefore	O
,	O
we	O
conclude	O
that	O
the	O
testicular	O
effects	O
observed	O
after	O
GaAs	B
are	O
secondary	O
to	O
hypoxaemia	O
caused	O
by	O
the	O
combination	O
of	O
pulmonary	O
proteinosis	O
and	O
haemolytic	O
anaemia	O
.	O

This	O
publication	O
tries	O
to	O
raise	O
awareness	O
to	O
the	O
severe	O
consequences	O
of	O
hypoxaemia	O
on	O
testicular	O
function	O
that	O
may	O
already	O
be	O
caused	O
by	O
reduced	O
oxygen	B
pressure	O
at	O
high	O
altitude	O
without	O
any	O
chemical	O
exposure	O
.	O

Bacterial	O
infection	O
probes	O
and	O
imaging	O
strategies	O
in	O
clinical	O
nuclear	O
medicine	O
and	O
preclinical	O
molecular	O
imaging	O
.	O

At	O
present	O
,	O
a	O
limited	O
number	O
of	O
strategies	O
exist	O
for	O
diagnostic	O
imaging	O
of	O
patients	O
with	O
bacterial	O
infection	O
.	O

While	O
radiolabeled	O
probes	O
and	O
white	O
blood	O
cells	O
provide	O
robust	O
solutions	O
to	O
detect	O
bacteria	O
in	O
humans	O
,	O
they	O
also	O
give	O
false	O
positives	O
in	O
cases	O
of	O
sterile	O
inflammation	O
.	O

With	O
the	O
onset	O
of	O
bacterial	O
drug	O
resistance	O
,	O
and	O
a	O
clinical	O
trend	O
toward	O
reducing	O
the	O
prescription	O
of	O
antibiotics	O
,	O
the	O
need	O
for	O
highly	O
specific	O
infection	O
detection	O
protocols	O
has	O
been	O
renewed	O
.	O

The	O
preclinical	O
research	O
community	O
has	O
recently	O
utilized	O
new	O
optical	O
imaging	O
strategies	O
,	O
alongside	O
traditional	O
radioimaging	O
research	O
,	O
to	O
develop	O
novel	O
infection	O
probes	O
with	O
translational	O
potential	O
.	O

Here	O
we	O
review	O
the	O
current	O
clinical	O
methods	O
for	O
imaging	O
bacteria	O
in	O
humans	O
,	O
and	O
discuss	O
the	O
efforts	O
within	O
the	O
preclinical	O
community	O
to	O
validate	O
new	O
strategies	O
.	O

The	O
review	O
of	O
preclinical	O
infection	O
imaging	O
probes	O
is	O
limited	O
to	O
those	O
probes	O
that	O
could	O
be	O
feasibly	O
adapted	O
for	O
use	O
in	O
humans	O
with	O
currently	O
available	O
clinical	O
modalities	O
.	O

Transient	O
Receptor	O
Potential	O
(	O
TRP	O
)	O
Channels	O
and	O
Cardiac	O
Fibrosis	O
.	O

Cardiac	O
fibrosis	O
is	O
associated	O
with	O
most	O
cardiac	O
diseases	O
.	O

Fibrosis	O
is	O
an	O
accumulation	O
of	O
excessive	O
extracellular	O
matrix	O
proteins	O
(	O
ECM	O
)	O
synthesized	O
by	O
cardiac	O
fibroblasts	O
and	O
myofibroblasts	O
.	O

Fibroblasts	O
are	O
the	O
most	O
prevalent	O
cell	O
type	O
in	O
the	O
heart	O
,	O
comprising	O
75	O
%	O
of	O
cardiac	O
cells	O
.	O

Myofibroblasts	O
are	O
hardly	O
present	O
in	O
healthy	O
normal	O
heart	O
tissue	O
,	O
but	O
appear	O
abundantly	O
in	O
diseased	O
hearts	O
.	O

Cardiac	O
fibroblasts	O
are	O
activated	O
by	O
a	O
variety	O
of	O
pathological	O
stimuli	O
,	O
such	O
as	O
myocardial	O
injury	O
,	O
oxidative	O
stress	O
,	O
mechanical	O
stretch	O
,	O
and	O
elevated	O
autocrine	O
-	O
paracrine	O
mediators	O
,	O
thereby	O
undergoing	O
proliferation	O
,	O
differentiation	O
to	O
myofibroblasts	O
,	O
and	O
production	O
of	O
various	O
cytokines	O
and	O
ECM	O
proteins	O
.	O

A	O
number	O
of	O
signaling	O
pathways	O
and	O
bioactive	O
molecules	O
are	O
involved	O
and	O
work	O
in	O
concert	O
to	O
activate	O
fibroblasts	O
and	O
myofibroblasts	O
in	O
the	O
fibrogenesis	O
cascade	O
.	O

Fibroblasts	O
and	O
myofibroblasts	O
are	O
not	O
only	O
principal	O
ECM	O
producers	O
,	O
but	O
also	O
play	O
a	O
central	O
role	O
in	O
fibrogenesis	O
and	O
myocardial	O
remodeling	O
in	O
fibrotic	O
heart	O
disease	O
.	O

Thus	O
,	O
understanding	O
the	O
biological	O
processes	O
of	O
cardiac	O
fibroblasts	O
will	O
provide	O
novel	O
insights	O
into	O
the	O
underlying	O
mechanisms	O
of	O
fibrosis	O
and	O
provide	O
potential	O
targets	O
for	O
developing	O
antifibrotic	O
drugs	O
.	O

Recent	O
studies	O
demonstrate	O
that	O
Ca2	B
+	I
signal	O
is	O
essential	O
for	O
fibroblast	O
proliferation	O
,	O
differentiation	O
,	O
and	O
ECM	O
-	O
protein	O
production	O
.	O

This	O
review	O
focuses	O
on	O
the	O
recent	O
advances	O
in	O
understanding	O
molecular	O
mechanisms	O
of	O
Ca2	B
+	I
signaling	O
in	O
cardiac	O
fibrogenesis	O
,	O
and	O
potential	O
role	O
of	O
Ca2	B
+	I
-permeable	O
channels	O
,	O
in	O
particular	O
,	O
the	O
transient	O
potential	O
(	O
TRP	O
)	O
channels	O
in	O
fibrotic	O
heart	O
disease	O
.	O

TRP	O
channels	O
are	O
highly	O
expressed	O
in	O
cardiac	O
fibroblasts	O
.	O

TRPM7	O
has	O
been	O
shown	O
to	O
be	O
essential	O
in	O
TGF1	O
mediated	O
fibrogenesis	O
,	O
and	O
TRPC3	O
has	O
been	O
demonstrated	O
to	O
play	O
an	O
essential	O
role	O
in	O
regulating	O
fibroblast	O
function	O
.	O

Thus	O
,	O
the	O
Ca2	B
+	I
-permeable	O
TRP	O
channels	O
may	O
serve	O
as	O
potential	O
novel	O
targets	O
for	O
developing	O
anti	O
-	O
fibrotic	O
drugs	O
.	O

TRP	O
Channels	O
in	O
Vascular	O
Disorders	O
.	O

In	O
recent	O
years	O
,	O
research	O
on	O
the	O
roles	O
of	O
TRP	O
channels	O
in	O
vascular	O
function	O
and	O
disease	O
has	O
undergone	O
a	O
rapid	O
expansion	O
from	O
tens	O
of	O
reports	O
published	O
in	O
the	O
early	O
2000s	O
to	O
several	O
hundreds	O
of	O
papers	O
published	O
to	O
date	O
.	O

Multiple	O
TRP	O
subtypes	O
are	O
expressed	O
in	O
vascular	O
smooth	O
muscle	O
cells	O
and	O
endothelial	O
cells	O
,	O
where	O
they	O
form	O
diverse	O
non	O
-	O
selective	O
cation	O
channels	O
permeable	O
to	O
Ca2	B
+	I
.	O

These	O
channels	O
mediate	O
Ca2	B
+	I
entry	O
following	O
receptor	O
stimulation	O
,	O
Ca2	B
+	I
store	O
depletion	O
and	O
mechanical	O
stimulation	O
of	O
vascular	O
myocytes	O
and	O
endothelial	O
cells	O
.	O

The	O
complex	O
molecular	O
composition	O
and	O
signalling	O
pathways	O
leading	O
to	O
the	O
activation	O
of	O
various	O
vascular	O
TRP	O
channels	O
and	O
the	O
growing	O
evidence	O
for	O
their	O
involvement	O
in	O
various	O
vascular	O
disorders	O
,	O
including	O
dysregulation	O
of	O
vascular	O
tone	O
and	O
hypertension	O
,	O
impaired	O
endothelium	O
-	O
dependent	O
vasodilatation	O
,	O
increased	O
endothelial	O
permeability	O
,	O
occlusive	O
vascular	O
disease	O
,	O
vascular	O
injury	O
and	O
oxidative	O
stress	O
,	O
are	O
summarised	O
and	O
discussed	O
in	O
this	O
review	O
.	O

Oncogenic	O
and	O
anti	O
-	O
oncogenic	O
effects	O
of	O
transient	O
receptor	O
potential	O
channels	O
.	O

Transient	O
Receptor	O
Potential	O
(	O
TRP	O
)	O
channels	O
affect	O
several	O
inflammatory	O
and	O
neoplastic	O
conditions	O
.	O

About	O
thirty	O
TRPs	O
have	O
been	O
identified	O
to	O
date	O
and	O
divided	O
into	O
seven	O
families	O
:	O
TRPC	O
(	O
Canonical	O
)	O
,	O
TRPV	O
(	O
Vanilloid	B
)	O
,	O
TRPM	O
(	O
Melastatin	O
)	O
,	O
TRPML	O
(	O
Mucolipin	O
)	O
,	O
TRPP	O
(	O
Polycystin	O
)	O
,	O
and	O
TRPA	O
(	O
Ankyrin	O
transmembrane	O
protein	O
)	O
and	O
TRPN	O
(	O
NomPClike	O
)	O
.	O

Among	O
these	O
,	O
the	O
TRPC	O
,	O
TRPM	O
,	O
and	O
TRPV	O
families	O
have	O
been	O
mainly	O
correlated	O
with	O
malignant	O
growth	O
and	O
progression	O
.	O

The	O
aim	O
of	O
this	O
review	O
is	O
to	O
summarize	O
data	O
reported	O
so	O
far	O
on	O
the	O
expression	O
and	O
functional	O
role	O
of	O
TRP	O
channels	O
in	O
different	O
types	O
of	O
cancers	O
.	O

TRP	O
channels	O
have	O
been	O
recently	O
implicated	O
in	O
the	O
triggering	O
of	O
enhanced	O
proliferation	O
,	O
aberrant	O
differentiation	O
,	O
and	O
resistance	O
to	O
apoptotic	O
cell	O
death	O
,	O
leading	O
to	O
uncontrolled	O
tumor	O
growth	O
and	O
progression	O
.	O

Depending	O
on	O
cancer	O
stage	O
,	O
up	O
and	O
down	O
-	O
regulation	O
of	O
TRP	O
mRNAs	O
and	O
protein	O
expression	O
have	O
been	O
reported	O
.	O

These	O
changes	O
have	O
been	O
shown	O
to	O
exhibit	O
cancer	O
promoting	O
(	O
oncogenic	O
)	O
or	O
inhibiting	O
/	O
delaying	O
(	O
tumor	O
suppressor	O
)	O
effects	O
.	O

We	O
are	O
only	O
at	O
the	O
beginning	O
,	O
and	O
more	O
detailed	O
study	O
on	O
the	O
physiopathologic	O
role	O
of	O
TRP	O
channels	O
is	O
required	O
to	O
understand	O
how	O
the	O
deregulation	O
of	O
TRP	O
channel	O
expression	O
and	O
function	O
contributes	O
to	O
tumor	O
development	O
and	O
progression	O
.	O

It	O
is	O
hoped	O
that	O
greater	O
knowledge	O
about	O
TRP	O
biology	O
will	O
enable	O
future	O
development	O
of	O
new	O
chemotherapeutic	O
agents	O
for	O
specific	O
TRP	O
targets	O
,	O
and	O
the	O
use	O
of	O
TRP	O
channels	O
as	O
evaluable	O
markers	O
in	O
diagnostic	O
and/or	O
prognostic	O
analysis	O
.	O

Multiple	O
Roles	O
of	O
Transient	O
Receptor	O
Potential	O
(	O
TRP	O
)	O
Channels	O
in	O
Inflammatory	O
Conditions	O
and	O
Current	O
Status	O
of	O
Drug	O
Development	O
.	O

During	O
inflammation	O
,	O
several	O
Transient	O
Receptor	O
Potential	O
(	O
TRP	O
)	O
channels	O
are	O
directly	O
or	O
indirectly	O
activated	O
by	O
inflammatory	O
signaling	O
molecules	O
and	O
microenvironmental	O
changes	O
including	O
heat	O
,	O
oxidative	O
conditions	O
or	O
low	O
pH.	O
In	O
either	O
case	O
,	O
specific	O
TRP	O
isoforms	O
participate	O
in	O
chains	O
of	O
pro-	O
or	O
anti	O
-	O
inflammatory	O
signaling	O
cascades	O
often	O
including	O
activation	O
of	O
transcription	O
factors	O
,	O
protein	O
kinases	O
and	O
phospholipases	O
,	O
which	O
result	O
in	O
signal	O
integration	O
or	O
amplification	O
.	O

In	O
a	O
few	O
cases	O
,	O
their	O
potentials	O
as	O
therapeutic	O
targets	O
for	O
inflammatory	O
conditions	O
like	O
pruritis	O
,	O
cystitis	O
,	O
dermatitis	O
,	O
asthma	O
among	O
other	O
conditions	O
are	O
investigated	O
pre	O
-	O
clinically	O
or	O
clinically	O
by	O
pioneering	O
academic	O
groups	O
and	O
industries	O
.	O

Significant	O
efforts	O
are	O
still	O
devoted	O
to	O
the	O
understanding	O
of	O
the	O
detailed	O
physiological	O
roles	O
played	O
by	O
TRP	O
channels	O
during	O
inflammation	O
.	O

This	O
review	O
intends	O
to	O
summarize	O
key	O
biological	O
findings	O
and	O
reports	O
of	O
drug	O
discovery	O
activities	O
when	O
available	O
,	O
in	O
an	O
overview	O
of	O
the	O
current	O
status	O
and	O
recent	O
developments	O
in	O
the	O
field	O
.	O

Correlation	O
between	O
structural	O
,	O
spectroscopic	O
,	O
and	O
reactivity	O
properties	O
within	O
a	O
series	O
of	O
structurally	O
analogous	O
metastable	O
manganese	B
(	I
III	I
)	I
-alkylperoxo	I
complexes	I
.	O

Manganese	B
-	I
peroxos	I
are	O
proposed	O
as	O
key	O
intermediates	O
in	O
a	O
number	O
of	O
important	O
biochemical	O
and	O
synthetic	O
transformations	O
.	O

Our	O
understanding	O
of	O
the	O
structural	O
,	O
spectroscopic	O
,	O
and	O
reactivity	O
properties	O
of	O
these	O
metastable	O
species	O
is	O
limited	O
,	O
however	O
,	O
and	O
correlations	O
between	O
these	O
properties	O
have	O
yet	O
to	O
be	O
established	O
experimentally	O
.	O

Herein	O
we	O
report	O
the	O
crystallographic	O
structures	O
of	O
a	O
series	O
of	O
structurally	O
related	O
metastable	O
Mn	B
(	I
III	I
)	I
-OOR	I
compounds	O
,	O
and	O
examine	O
their	O
spectroscopic	O
and	O
reactivity	O
properties	O
.	O

The	O
four	O
reported	O
Mn	B
(	I
III	I
)	I
-OOR	I
compounds	O
extend	O
the	O
number	O
of	O
known	O
end	O
-	O
on	O
Mn	B
(	I
III	I
)	I
-	I
(	I
	I
(	I
1	I
)	I
-peroxos	I
)	I
to	O
six	O
.	O

The	O
ligand	O
backbone	O
is	O
shown	O
to	O
alter	O
the	O
metal	O
-	O
ligand	O
distances	O
and	O
modulate	O
the	O
electronic	O
properties	O
key	O
to	O
bonding	O
and	O
activation	O
of	O
the	O
peroxo	O
.	O

The	O
mechanism	O
of	O
thermal	O
decay	O
of	O
these	O
metastable	O
species	O
is	O
examined	O
via	O
variable	O
-	O
temperature	O
kinetics	O
.	O

Strong	O
correlations	O
between	O
structural	O
(	O
O	B
-	I
O	I
and	O
MnN	B
(	B
py	I
,	I
quin	I
)	I
distances	O
)	O
,	O
spectroscopic	O
(	O
E	O
(	O
v*	O
(	O
O	B
-	I
O	I
)	O
	O
Mn	B
CT	O
band	O
)	O
,	O
	O
(	O
O	B
-	I
O	I
)	O
)	O
,	O
and	O
kinetic	O
(	O
H	O
(	O
	O
)	O
and	O
S	O
(	O
	O
)	O
)	O
parameters	O
for	O
these	O
complexes	O
provide	O
compelling	O
evidence	O
for	O
rate	O
-	O
limiting	O
O	B
-	I
O	I
bond	O
cleavage	O
.	O

Products	O
identified	O
in	O
the	O
final	O
reaction	O
mixtures	O
of	O
Mn	B
(	I
III	I
)	I
-OOR	I
decay	O
are	O
consistent	O
with	O
homolytic	O
O	B
-	I
O	I
bond	O
scission	O
.	O

The	O
N	B
-	I
heterocyclic	I
amines	I
and	O
ligand	O
backbone	O
(	O
Et	O
vs	O
Pr	O
)	O
are	O
found	O
to	O
modulate	O
structural	O
and	O
reactivity	O
properties	O
,	O
and	O
O	B
-	I
O	I
bond	O
activation	O
is	O
shown	O
,	O
both	O
experimentally	O
and	O
theoretically	O
,	O
to	O
track	O
with	O
metal	O
ion	O
Lewis	O
acidity	O
.	O

The	O
peroxo	B
O	I
-	I
O	I
bond	O
is	O
shown	O
to	O
gradually	O
become	O
more	O
activated	O
as	O
the	O
N	B
-	I
heterocyclic	I
amines	I
move	O
closer	O
to	O
the	O
metal	O
ion	O
causing	O
a	O
decrease	O
in	O
	O
-	O
donation	O
from	O
the	O
peroxo	O
v*	O
(	O
O	B
-	I
O	I
)	O
orbital	O
.	O

The	O
reported	O
work	O
represents	O
one	O
of	O
very	O
few	O
examples	O
of	O
experimentally	O
verified	O
relationships	O
between	O
structure	O
and	O
function	O
.	O

Phase	O
discrimination	O
through	O
oxidant	O
selection	O
in	O
low	O
-	O
temperature	O
atomic	O
layer	O
deposition	O
of	O
crystalline	O
iron	B
oxides	I
.	O

Control	O
over	O
the	O
oxidation	O
state	O
and	O
crystalline	O
phase	O
of	O
thin	O
-	O
film	O
iron	B
oxides	I
was	O
achieved	O
by	O
low	O
-	O
temperature	O
atomic	O
layer	O
deposition	O
(	O
ALD	O
)	O
,	O
utilizing	O
a	O
novel	O
iron	B
precursor	O
,	O
bis	B
(	I
2,4-methylpentadienyl	I
)	I
iron	I
.	O

This	O
low	O
-	O
temperature	O
(	O
T	O
=	O
120	O
	O
C	O
)	O
route	O
to	O
conformal	O
deposition	O
of	O
crystalline	O
Fe3O4	B
or	O
	B
-	I
Fe2O3	I
thin	O
films	O
is	O
determined	O
by	O
the	O
choice	O
of	O
oxygen	B
source	O
selected	O
for	O
the	O
second	O
surface	O
half	O
-	O
reaction	O
.	O

The	O
approach	O
employs	O
ozone	O
to	O
produce	O
fully	O
oxidized	O
	B
-	I
Fe2O3	I
or	O
a	O
milder	O
oxidant	O
,	O
H2O2	B
,	O
to	O
generate	O
the	O
Fe	B
(	I
2+	I
)	I
/	O
Fe	B
(	I
3	I
+	I
)	I
spinel	O
,	O
Fe3O4	B
.	O

Both	O
processes	O
show	O
self	O
-	O
limiting	O
surface	O
reactions	O
and	O
deposition	O
rates	O
of	O
at	O
least	O
0.6	O
	O
/	O
cycle	O
,	O
a	O
significantly	O
high	O
growth	O
rate	O
at	O
such	O
mild	O
conditions	O
.	O

We	O
utilized	O
this	O
process	O
to	O
prepare	O
conformal	O
iron	B
oxide	I
thin	O
films	O
on	O
a	O
porous	O
framework	O
,	O
for	O
which	O
	B
-	I
Fe2O3	I
is	O
active	O
for	O
photocatalytic	O
water	O
splitting	O
.	O

Comprehensive	O
insights	O
into	O
the	O
structural	O
and	O
chemical	O
changes	O
in	O
mixed	O
-	O
anion	O
FeOF	B
electrodes	O
by	O
using	O
operando	O
PDF	O
and	O
NMR	O
spectroscopy	O
.	O

In	O
-	O
depth	O
analysis	O
of	O
operando	O
X	O
-	O
ray	O
pair	O
distribution	O
function	O
(	O
PDF	O
)	O
data	O
is	O
combined	O
with	O
Li	B
NMR	O
spectroscopy	O
to	O
gain	O
comprehensive	O
insights	O
into	O
the	O
electrochemical	O
reaction	O
mechanism	O
of	O
high	O
-	O
performance	O
iron	B
oxyfluoride	I
electrodes	O
.	O

While	O
the	O
full	O
discharge	O
capacity	O
could	O
be	O
recovered	O
upon	O
charge	O
,	O
implying	O
reversibility	O
of	O
the	O
electrochemical	O
reaction	O
,	O
the	O
atomic	O
structure	O
of	O
the	O
electrode	O
formed	O
after	O
cycling	O
(	O
discharge	O
-	O
charge	O
)	O
differs	O
from	O
the	O
pristine	O
uncycled	O
electrode	O
material	O
.	O

Instead	O
,	O
the	O
"	O
active	O
"	O
electrode	O
that	O
forms	O
upon	O
cycling	O
is	O
a	O
nanocomposite	O
of	O
an	O
amorphous	O
rutile	O
phase	O
and	O
a	O
nanoscale	O
rock	O
salt	O
phase	O
.	O

Bond	O
valence	O
sum	O
analysis	O
,	O
based	O
on	O
the	O
precise	O
structural	O
parameters	O
(	O
bond	O
lengths	O
and	O
coordination	O
number	O
)	O
extracted	O
from	O
the	O
in	O
situ	O
PDF	O
data	O
,	O
suggests	O
that	O
anion	O
partitioning	O
occurs	O
during	O
the	O
electrochemical	O
reaction	O
,	O
with	O
the	O
rutile	O
phase	O
being	O
F	O
-	O
rich	O
and	O
the	O
rock	O
salt	O
phase	O
being	O
O	O
-	O
rich	O
.	O

The	O
F-	O
and	O
O	O
-	O
rich	O
phases	O
react	O
sequentially	O
;	O
Fe	B
in	O
a	O
F	O
-	O
rich	O
environment	O
reacts	O
preferentially	O
during	O
both	O
discharge	O
and	O
charge	O
.	O

Coenzyme	B
Q10	I
protects	O
Pc12	O
cells	O
from	O
cisplatin	B
-	O
induced	O
DNA	O
damage	O
and	O
neurotoxicity	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
neuroprotective	O
effect	O
of	O
a	O
water	O
-	O
soluble	O
formulation	O
of	O
coenzyme	B
Q10	I
(	O
WS	O
-	O
CoQ10	B
)	O
in	O
PC12	O
cells	O
exposed	O
to	O
cisplatin	B
,	O
a	O
chemotherapeutic	O
agent	O
with	O
a	O
dose	O
-	O
limiting	O
factor	O
due	O
to	O
neurotoxicity	O
.	O

In	O
the	O
cytokinesis	O
-	O
block	O
micronucleus	O
cytome	O
assay	O
(	O
CBMN	O
Cyt	O
)	O
,	O
WS	O
-	O
CoQ10	B
(	O
at	O
concentrations	O
of	O
0.1	O
,	O
0.5	O
and	O
1.0gmL	O
(	O
-1	O
)	O
)	O
protected	O
PC12	O
cells	O
from	O
cisplatin	B
-	O
induced	O
DNA	O
damage	O
(	O
0.1gmL	O
(	O
-1	O
)	O
)	O
,	O
reducing	O
the	O
frequency	O
of	O
micronuclei	O
(	O
MNi	O
)	O
and	O
nuclear	O
buds	O
(	O
NBUDs	O
)	O
.	O

WS	O
-	O
CoQ10	B
did	O
not	O
alter	O
the	O
mRNA	O
expression	O
levels	O
of	O
Tp53	O
(	O
at	O
a	O
concentration	O
of	O
1.0gmL	O
(	O
-1	O
)	O
)	O
and	O
exhibited	O
neuroprotective	O
activity	O
by	O
stimulating	O
cisplatin	B
-	O
inhibited	O
neurite	O
outgrowth	O
in	O
nerve	O
growth	O
factor	O
(	O
NGF	O
)	O
-differentiated	O
PC12	O
cells	O
(	O
at	O
a	O
concentration	O
of	O
0.1gmL	O
(	O
-1	O
)	O
)	O
.	O

In	O
conclusion	O
,	O
WS	O
-	O
CoQ10	B
protected	O
the	O
PC12	O
cells	O
from	O
cisplatin	B
-	O
induced	O
DNA	O
damage	O
and	O
neurotoxicity	O
.	O

Moreover	O
,	O
the	O
neuroprotective	O
effects	O
of	O
WS	O
-	O
CoQ10	B
suggest	O
a	O
possible	O
application	O
in	O
chemotherapeutic	O
protocols	O
.	O

Rapid	O
and	O
Sensitive	O
Determination	O
of	O
Timosaponin	B
AIII	I
in	O
Rat	O
Plasma	O
by	O
LC	O
-	O
MS	O
/	O
MS	O
and	O
Its	O
Pharmacokinetic	O
Application	O
.	O

A	O
rapid	O
sensitive	O
and	O
selective	O
liquid	O
chromatography	O
-	O
tandem	O
mass	O
spectrometry	O
(	O
LC	O
-	O
MS	O
/	O
MS	O
)	O
method	O
was	O
developed	O
for	O
determination	O
of	O
timosaponin	B
AIII	I
(	O
TA	B
-	I
III	I
)	O
in	O
rat	O
plasma	O
,	O
using	O
ginsenoside	B
Re	I
as	O
an	O
internal	O
standard	O
(	O
IS	O
)	O
.	O

TA	B
-	I
III	I
and	O
the	O
IS	O
were	O
detected	O
in	O
MRM	O
mode	O
with	O
a	O
negative	O
ionization	O
electrospray	O
mass	O
spectrometer	O
.	O

The	O
calibration	O
curves	O
were	O
linear	O
over	O
the	O
concentration	O
ranges	O
from	O
11.14	O
to	O
1114	O
ng	O
/	O
mL	O
and	O
the	O
lower	O
limit	O
of	O
quantification	O
(	O
LLOQ	O
)	O
was	O
11.14	O
ng	O
/	O
mL.	O
Intra	O
-	O
day	O
and	O
inter	O
-	O
day	O
precisions	O
(	O
RSD	O
)	O
were	O
within	O
10	O
%	O
,	O
and	O
accuracy	O
ranged	O
from	O
6.4	O
%	O
to	O
9.1	O
%	O
.	O

The	O
extraction	O
recovery	O
at	O
three	O
concentrations	O
ranged	O
from	O
92.3	O
%	O
to	O
95.5	O
%	O
.	O

The	O
validated	O
method	O
was	O
successfully	O
applied	O
to	O
monitor	O
the	O
concentrations	O
of	O
TA	B
-	I
III	I
in	O
rat	O
plasma	O
after	O
intragastric	O
administration	O
.	O

The	O
best	O
fit	O
pharmacokinetic	O
model	O
to	O
estimate	O
the	O
pharmacokinetic	O
parameters	O
was	O
a	O
single	O
compartment	O
model	O
with	O
weight	O
of	O
1	O
/	O
x2	O
for	O
oral	O
administration	O
groups	O
of	O
rats	O
for	O
TA	B
-	I
III	I
.	O

International	O
journal	O
of	O
molecular	O
science	O
best	O
paper	O
award	O
2013	O
.	O

Since	O
2012	O
,	O
International	O
Journal	O
of	O
Molecular	O
Science	O
has	O
instituted	O
an	O
annual	O
award	O
to	O
recognize	O
outstanding	O
papers	O
in	O
the	O
area	O
of	O
chemistry	O
,	O
molecular	O
physics	O
and	O
molecular	O
biology	O
that	O
meet	O
the	O
aims	O
,	O
scope	O
and	O
high	O
standards	O
of	O
this	O
journal	O
[	O
1	O
]	O
.	O

We	O
are	O
pleased	O
to	O
announce	O
the	O
second	O
"	O
International	O
Journal	O
of	O
Molecular	O
Science	O
Best	O
Paper	O
Award	O
"	O
for	O
2013	O
.	O

Nominations	O
were	O
made	O
by	O
the	O
Section	O
Editor	O
-	O
in	O
-	O
Chiefs	O
of	O
International	O
Journal	O
of	O
Molecular	O
Science	O
,	O
with	O
all	O
papers	O
published	O
in	O
2009	O
eligible	O
for	O
consideration	O
.	O

The	O
awards	O
are	O
issued	O
for	O
reviews	O
and	O
articles	O
separately	O
.	O

All	O
-	O
Cause	O
and	O
Cardiovascular	O
Mortality	O
in	O
Middle	O
-	O
Aged	O
People	O
With	O
Type	O
2	O
Diabetes	O
Compared	O
With	O
People	O
Without	O
Diabetes	O
in	O
a	O
Large	O
U.K.	O
Primary	O
Care	O
Database	O
.	O

OBJECTIVEMiddle	O
-	O
aged	O
people	O
with	O
diabetes	O
have	O
been	O
reported	O
to	O
have	O
significantly	O
higher	O
risks	O
of	O
cardiovascular	O
events	O
than	O
people	O
without	O
diabetes	O
.	O

However	O
,	O
recent	O
falls	O
in	O
cardiovascular	O
disease	O
rates	O
and	O
more	O
active	O
management	O
of	O
risk	O
factors	O
may	O
have	O
abolished	O
the	O
increased	O
risk	O
.	O

We	O
aimed	O
to	O
provide	O
an	O
up	O
-	O
to	O
-	O
date	O
assessment	O
of	O
the	O
relative	O
risks	O
associated	O
with	O
type	O
2	O
diabetes	O
of	O
all	O
-	O
cause	O
and	O
cardiovascular	O
mortality	O
in	O
middle	O
-	O
aged	O
people	O
in	O
the	O
U.K.RESEARCH	O
DESIGN	O
AND	O
METHODSUsing	O
data	O
from	O
the	O
General	O
Practice	O
Research	O
Database	O
,	O
from	O
2004	O
to	O
2010	O
,	O
we	O
conducted	O
a	O
cohort	O
study	O
of	O
87,098	O
people	O
,	O
40	O
-	O
65	O
years	O
of	O
age	O
at	O
baseline	O
,	O
comparing	O
21,798	O
with	O
type	O
2	O
diabetes	O
and	O
65,300	O
without	O
diabetes	O
,	O
matched	O
on	O
age	O
,	O
sex	O
,	O
and	O
general	O
practice	O
.	O

We	O
produced	O
hazard	O
ratios	O
(	O
HRs	O
)	O
for	O
mortality	O
and	O
compared	O
rates	O
of	O
blood	O
pressure	O
testing	O
,	O
cholesterol	B
monitoring	O
,	O
and	O
use	O
of	O
aspirin	B
,	O
statins	O
,	O
and	O
antihypertensive	O
drugs	O
.	O

RESULTSPeople	O
with	O
type	O
2	O
diabetes	O
,	O
compared	O
with	O
people	O
without	O
diabetes	O
,	O
had	O
a	O
twofold	O
increased	O
risk	O
of	O
all	O
-	O
cause	O
mortality	O
(	O
HR	O
2.07	O
[	O
95	O
%	O
CI	O
1.95	O
-	O
2.20	O
]	O
,	O
adjusted	O
for	O
smoking	O
)	O
and	O
a	O
threefold	O
increased	O
risk	O
of	O
cardiovascular	O
mortality	O
(	O
3.25	O
[	O
2.87	O
-	O
3.68	O
]	O
,	O
adjusted	O
for	O
smoking	O
)	O
.	O

Women	O
had	O
a	O
higher	O
relative	O
risk	O
than	O
men	O
,	O
and	O
people	O
<	O
55	O
years	O
of	O
age	O
had	O
a	O
higher	O
relative	O
risk	O
than	O
those	O
>	O
55	O
years	O
of	O
age	O
.	O

Monitoring	O
and	O
medication	O
rates	O
were	O
higher	O
in	O
those	O
with	O
diabetes	O
(	O
all	O
P	O
<	O
0.001	O
)	O
.CONCLUSIONSDespite	O
efforts	O
to	O
manage	O
risk	O
factors	O
,	O
administer	O
effective	O
treatments	O
,	O
and	O
develop	O
new	O
therapies	O
,	O
middle	O
-	O
aged	O
people	O
with	O
type	O
2	O
diabetes	O
remain	O
at	O
significantly	O
increased	O
risk	O
of	O
death	O
.	O

Reduced	O
Heart	O
Rate	O
Variability	O
Is	O
Associated	O
With	O
Increased	O
Arterial	O
Stiffness	O
in	O
Youth	O
With	O
Type	O
1	O
Diabetes	O
:	O

The	O
SEARCH	O
Cardiovascular	O
Disease	O
Study	O
.	O

OBJECTIVEReduced	O
heart	O
rate	O
variability	O
(	O
HRV	O
)	O
and	O
increased	O
arterial	O
stiffness	O
(	O
AS	O
)	O
are	O
both	O
present	O
in	O
youth	O
with	O
type	O
1	O
diabetes	O
.	O

However	O
,	O
it	O
is	O
unclear	O
whether	O
they	O
are	O
associated	O
and	O
whether	O
their	O
association	O
is	O
independent	O
of	O
cardiovascular	O
disease	O
(	O
CVD	O
)	O
risk	O
factors	O
.	O

RESEARCH	O
DESIGN	O
AND	O
METHODSThe	O
SEARCH	O
Cardiovascular	O
Disease	O
Study	O
explored	O
the	O
cross	O
-	O
sectional	O
relationships	O
between	O
HRV	O
and	O
several	O
measures	O
of	O
AS	O
in	O
youth	O
with	O
(	O
n	O
=	O
344	O
)	O
and	O
without	O
(	O
n	O
=	O
171	O
)	O
type	O
1	O
diabetes	O
.	O

The	O
SphygmoCor	O
device	O
(	O
AtCor	O
Medical	O
,	O
Sydney	O
,	O
Australia	O
)	O
was	O
used	O
to	O
measure	O
HRV	O
using	O
SD	O
of	O
normal	O
R	O
-	O
R	O
interval	O
(	O
SDNN	O
)	O
,	O
as	O
well	O
as	O
AS	O
,	O
using	O
pulse	O
wave	O
velocity	O
in	O
the	O
carotid	O
to	O
femoral	O
segment	O
(	O
PWV	O
-	O
trunk	O
)	O
and	O
augmentation	O
index	O
adjusted	O
to	O
a	O
heart	O
rate	O
of	O
75	O
bpm	O
(	O
AIx75	O
)	O
.	O

Brachial	O
distensibility	O
(	O
BrachD	O
)	O
,	O
another	O
index	O
of	O
AS	O
,	O
was	O
measured	O
with	O
a	O
DynaPulse	O
instrument	O
(	O
Pulse	O
Metric	O
,	O
San	O
Diego	O
,	O
CA	O
)	O
.	O

Multiple	O
linear	O
regression	O
analyses	O
explored	O
the	O
associations	O
between	O
HRV	O
and	O
each	O
of	O
the	O
three	O
AS	O
measures	O
,	O
after	O
adjusting	O
for	O
demographic	O
characteristics	O
and	O
traditional	O
CVD	O
risk	O
factors	O
(	O
blood	O
pressure	O
,	O
lipids	O
,	O
obesity	O
,	O
microalbuminuria	O
,	O
and	O
smoking	O
)	O
separately	O
,	O
for	O
youth	O
with	O
and	O
without	O
type	O
1	O
diabetes	O
.	O

RESULTSAmong	O
youth	O
with	O
type	O
1	O
diabetes	O
,	O
lower	O
SDNN	O
was	O
associated	O
with	O
peripheral	O
AS	O
(	O
lower	O
BrachD	O
,	O
P	O
=	O
0.01	O
;	O
r	O
(	O
2	O
)	O
=	O
0.30	O
)	O
and	O
central	O
AS	O
(	O
higher	O
PVW	O
-	O
trunk	O
,	O
P	O
<	O
0.0001	O
;	O
r	O
(	O
2	O
)	O
=	O
0.37	O
;	O
and	O
higher	O
AIx75	O
,	O
P	O
=	O
0.007	O
;	O
r	O
(	O
2	O
)	O
=	O
0.08	O
)	O
.	O

These	O
associations	O
were	O
attenuated	O
with	O
adjustment	O
for	O
CVD	O
risk	O
factors	O
,	O
but	O
remained	O
statistically	O
significant	O
for	O
BrachD	O
and	O
PWV	O
-	O
trunk	O
.	O

While	O
a	O
similar	O
association	O
between	O
HRV	O
and	O
BrachD	O
was	O
present	O
in	O
control	O
youth	O
,	O
lower	O
HRV	O
was	O
not	O
associated	O
with	O
increased	O
central	O
AS	O
or	O
with	O
AIx75.CONCLUSIONSLongitudinal	O
studies	O
are	O
needed	O
to	O
understand	O
the	O
pathways	O
responsible	O
for	O
these	O
associations	O
.	O

Changes	O
in	O
A1C	O
Levels	O
Are	O
Significantly	O
Associated	O
With	O
Changes	O
in	O
Levels	O
of	O
the	O
Cardiovascular	O
Risk	O
Biomarker	O
hs	O
-	O
CRP	O
:	O
Results	O
from	O
SteP	O
Study	O
.	O

OBJECTIVEThe	O
effect	O
of	O
therapeutic	O
strategies	O
on	O
cardiovascular	O
(	O
CV	O
)	O
disease	O
can	O
be	O
evaluated	O
by	O
monitoring	O
changes	O
in	O
CV	O
risk	O
biomarkers	O
.	O

This	O
study	O
investigated	O
the	O
effect	O
of	O
a	O
structured	O
self	O
-	O
monitoring	O
of	O
blood	O
glucose	B
(	O
SMBG	O
)	O
protocol	O
and	O
the	O
resulting	O
improvements	O
in	O
glycemic	O
control	O
on	O
changes	O
in	O
high	O
-	O
sensitivity	O
C	O
-	O
reactive	O
protein	O
(	O
hs	O
-	O
CRP	O
)	O
in	O
insulin	O
-	O
nave	O
patients	O
with	O
type	O
2	O
diabetes	O
.	O

RESEARCH	O
DESIGN	O
AND	O
METHODSThe	O
Structured	O
Testing	O
Program	O
(	O
STeP	O
)	O
study	O
was	O
a	O
prospective	O
,	O
cluster	O
-	O
randomized	O
,	O
multicenter	O
trial	O
in	O
which	O
483	O
poorly	O
controlled	O
,	O
insulin	O
-	O
nave	O
patients	O
with	O
type	O
2	O
diabetes	O
were	O
randomized	O
to	O
active	O
control	O
(	O
ACG	O
)	O
or	O
structured	O
testing	O
(	O
STG	O
)	O
that	O
included	O
quarterly	O
structured	O
SMBG	O
.	O

Changes	O
in	O
A1C	O
,	O
hs	O
-	O
CRP	O
,	O
and	O
glycemic	O
variability	O
(	O
STG	O
subjects	O
only	O
)	O
were	O
measured	O
at	O
baseline	O
and	O
quarterly	O
.	O

RESULTSReductions	O
in	O
geometric	O
mean	O
hs	O
-	O
CRP	O
values	O
were	O
significantly	O
greater	O
in	O
the	O
STG	O
group	O
at	O
months	O
3	O
(	O
P	O
=	O
0.005	O
)	O
,	O
6	O
(	O
P	O
=	O
0.0003	O
)	O
,	O
and	O
12	O
(	O
P	O
=	O
0.04	O
)	O
than	O
in	O
the	O
ACG	O
group	O
.	O

STG	O
patients	O
at	O
high	O
CV	O
risk	O
(	O
>	O
3	O
mg	O
/	O
L	O
)	O
showed	O
significantly	O
greater	O
reductions	O
in	O
hs	O
-	O
CRP	O
levels	O
than	O
ACG	O
patients	O
at	O
high	O
CV	O
risk	O
:	O
-3.64	O
mg	O
/	O
dL	O
(	O
95	O
%	O
CI	O
-4.21	O
to	O
-3.06	O
)	O
versus	O
-2.18	O
mg	O
/	O
dL	O
(	O
-2.93	O
to	O
-1.43	O
)	O
,	O
respectively	O
(	O
P	O
=	O
0.002	O
)	O
.	O

There	O
was	O
a	O
strong	O
correlation	O
between	O
reductions	O
in	O
hs	O
-	O
CRP	O
and	O
A1C	O
in	O
both	O
groups	O
:	O
standardized	O
coefficient	O
(	O
	O
)	O
was	O
0.25	O
for	O
the	O
entire	O
cohort	O
(	O
P	O
<	O
0.0001	O
)	O
,	O
0.31	O
for	O
STG	O
(	O
P	O
<	O
0.0001	O
)	O
,	O
and	O
0.16	O
for	O
ACG	O
(	O
P	O
=	O
0.02	O
)	O
.CONCLUSIONSReductions	O
in	O
hs	O
-	O
CRP	O
level	O
are	O
associated	O
with	O
reductions	O
in	O
A1C	O
but	O
not	O
reductions	O
in	O
lipids	O
or	O
glycemic	O
variability	O
.	O

Comprehensive	O
structured	O
SMBG	O
-	O
based	O
interventions	O
that	O
lower	O
A1C	O
may	O
translate	O
into	O
improvements	O
in	O
CV	O
risk	O
,	O
as	O
evidenced	O
by	O
levels	O
of	O
the	O
biomarker	O
hs	O
-	O
CRP	O
.	O

The	O
characteristics	O
of	O
genistin	B
-	O
induced	O
inhibitory	O
effects	O
on	O
intestinal	O
motility	O
.	O

Genistin	B
belongs	O
to	O
isoflavones	B
.	O

Based	O
on	O
the	O
facts	O
that	O
genistin	B
exerts	O
inhibitory	O
effects	O
on	O
the	O
contractility	O
of	O
vascular	O
smooth	O
muscle	O
,	O
the	O
present	O
study	O
was	O
designed	O
to	O
characterize	O
the	O
effects	O
of	O
genistin	B
on	O
intestinal	O
contractility	O
and	O
evaluate	O
its	O
potential	O
clinical	O
implication	O
.	O

Ex	O
vivo	O
[	O
isolated	O
jejunal	O
segment	O
(	O
IJS	O
)	O
of	O
rat	O
]	O
,	O
in	O
vitro	O
,	O
and	O
in	O
vivo	O
assays	O
were	O
used	O
in	O
the	O
study	O
.	O

The	O
results	O
indicated	O
that	O
genistin	B
(	O
5	O
-	O
80	O
mol	O
/	O
L	O
)	O
inhibited	O
the	O
contraction	O
of	O
IJS	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
and	O
inhibited	O
the	O
increased	O
-	O
contractility	O
of	O
IJS	O
induced	O
by	O
acetylcholine	B
(	O
ACh	B
)	O
,	O
histamine	B
,	O
high	O
Ca	B
(	I
2	I
+	I
)	I
,	O
and	O
erythromycin	B
,	O
respectively	O
.	O

The	O
inhibitory	O
effects	O
of	O
genistin	B
were	O
correlated	O
with	O
the	O
stimulation	O
of	O
alpha	O
adrenergic	O
and	O
beta	O
adrenergic	O
receptors	O
since	O
these	O
inhibitory	O
effects	O
were	O
significantly	O
blocked	O
in	O
the	O
presence	O
of	O
phentolamine	B
and	O
propranolol	B
respectively	O
.	O

No	O
further	O
inhibitory	O
effects	O
of	O
genistin	B
were	O
observed	O
in	O
the	O
presence	O
of	O
verapamil	B
or	O
in	O
Ca	B
(	I
2+	I
)	I
-free	O
condition	O
,	O
indicating	O
genistin	B
-	O
induced	O
inhibitory	O
effects	O
are	O
Ca	B
(	I
2+	I
)	I
-dependent	O
.	O

Genistin	B
decreased	O
myosin	O
light	O
chain	O
kinase	O
(	O
MLCK	O
)	O
protein	O
contents	O
and	O
MLCK	O
mRNA	O
expression	O
in	O
IJS	O
,	O
and	O
inhibited	O
both	O
phosphorylation	O
and	O
Mg	B
(	I
2+	I
)	I
-ATPase	O
activity	O
of	O
purified	O
myosin	O
,	O
implicating	O
that	O
the	O
decrease	O
of	O
MLCK	O
contents	O
and	O
inhibition	O
of	O
MLCK	O
activity	O
are	O
involved	O
in	O
the	O
genistin	B
-	O
induced	O
inhibitory	O
effects	O
.	O

The	O
study	O
suggests	O
the	O
potential	O
clinical	O
implications	O
of	O
genistin	B
in	O
relieving	O
intestinal	O
hypercontractility	O
.	O

Effect	O
of	O
excipients	O
on	O
acetaminophen	B
metabolism	O
and	O
its	O
implications	O
for	O
prevention	O
of	O
liver	O
injury	O
.	O

Acetaminophen	B
poisoning	O
is	O
the	O
most	O
frequent	O
cause	O
of	O
acute	O
hepatic	O
failure	O
in	O
the	O
US	O
.	O

Toxicity	O
requires	O
reductive	O
metabolism	O
of	O
acetaminophen	B
,	O
primarily	O
via	O
CYP2E1	O
.	O

Liquid	O
acetaminophen	B
preparations	O
contain	O
propylene	B
glycol	I
,	O
a	O
common	O
excipient	O
that	O
has	O
been	O
shown	O
to	O
reduce	O
hepatocellular	O
injury	O
in	O
vitro	O
and	O
in	O
rodents	O
.	O

Children	O
are	O
less	O
susceptible	O
to	O
acetaminophen	B
toxicity	O
for	O
unclear	O
reasons	O
.	O

We	O
conducted	O
a	O
pharmacokinetic	O
single	O
-	O
blinded	O
crossover	O
study	O
of	O
15	O
healthy	O
adult	O
volunteers	O
comparing	O
the	O
CYP2E1	O
and	O
conjugative	O
metabolism	O
of	O
a	O
15	O
mg	O
/	O
kg	O
dose	O
of	O
liquid	O
versus	O
solid	O
preparations	O
of	O
acetaminophen	B
.	O

Measured	O
AUC	O
's	O
for	O
the	O
CYP2E1	O
metabolites	O
were	O
16	O
-	O
17	O
%	O
lower	O
and	O
extrapolated	O
AUC	O
's	O
were	O
25	O
-	O
28	O
%	O
lower	O
in	O
the	O
liquid	O
formulation	O
arm	O
while	O
there	O
was	O
no	O
difference	O
in	O
conjugative	O
metabolite	O
production	O
.	O

The	O
formation	O
rate	O
constants	O
for	O
reductive	O
metabolites	O
were	O
equivalent	O
between	O
solid	O
and	O
liquid	O
formulations	O
indicating	O
that	O
enzyme	O
inhibition	O
was	O
competitive	O
.	O

Propylene	B
glycol	I
,	O
an	O
established	O
CYP2E1	O
competitive	O
antagonist	O
,	O
was	O
detected	O
in	O
the	O
liquid	O
formulation	O
but	O
not	O
solid	O
formulation	O
arm	O
.	O

Since	O
children	O
tend	O
to	O
ingest	O
liquid	O
preparations	O
,	O
the	O
protective	O
effect	O
of	O
this	O
excipient	O
could	O
explain	O
their	O
decreased	O
susceptibility	O
to	O
acetaminophen	B
toxicity	O
.	O

A	O
less	O
hepatotoxic	O
formulation	O
of	O
acetaminophen	B
could	O
potentially	O
be	O
developed	O
if	O
co	O
-	O
formulated	O
with	O
a	O
CYP2E1	O
inhibitor	O
.	O

Addition	O
of	O
cilostazol	B
to	O
conventional	O
dual	O
antiplatelet	O
therapy	O
reduces	O
the	O
risk	O
of	O
cardiac	O
events	O
and	O
restenosis	O
after	O
drug	O
-	O
eluting	O
stent	O
implantation	O
:	O
a	O
meta	O
-	O
analysis	O
.	O

This	O
meta	O
-	O
analysis	O
was	O
performed	O
to	O
compare	O
the	O
risk	O
of	O
cardiac	O
events	O
and	O
restenosis	O
between	O
triple	O
antiplatelet	O
therapy	O
(	O
TAT	O
,	O
addition	O
of	O
cilostazol	B
to	O
aspirin	B
and	O
clopidogrel	B
)	O
and	O
conventional	O
dual	O
antiplatelet	O
therapy	O
(	O
DAT	O
,	O
aspirin	B
and	O
clopidogrel	B
)	O
in	O
drug	O
-	O
eluting	O
stents	O
(	O
DES	O
)	O
implantation	O
patients	O
.	O

We	O
performed	O
PUBMED	O
,	O
MEDLINE	O
,	O
EMBASE	O
,	O
and	O
Cochrane	O
CENTRAL	O
searches	O
for	O
randomized	O
clinical	O
trials	O
of	O
TAT	O
versus	O
DAT	O
in	O
patients	O
after	O
DES	O
implantation	O
.	O

Five	O
clinical	O
trials	O
were	O
involved	O
in	O
the	O
study	O
.	O

TAT	O
was	O
associated	O
with	O
a	O
36	O
%	O
reduction	O
in	O
major	O
adverse	O
cardiac	O
events	O
(	O
MACE	O
;	O
odds	O
ratio	O
(	O
OR	O
)	O
=	O
0.64	O
;	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
=	O
0.51	O
-	O
0.81	O
,	O
P	O
<	O
.01	O
)	O
,	O
a	O
40	O
%	O
reduction	O
(	O
OR	O
=	O
0.60	O
,	O
95	O
%	O
CI	O
=	O
0.44	O
-	O
0.80	O
;	O
P	O
<	O
.01	O
)	O
in	O
target	O
vessel	O
revascularization	O
(	O
TVR	O
)	O
,	O
a	O
44	O
%	O
reduction	O
(	O
OR	O
=	O
0.56	O
,	O
95	O
%	O
CI	O
=	O
0.34	O
-	O
0.91	O
;	O
P	O
=	O
.02	O
)	O
in	O
target	O
lesion	O
revascularization	O
(	O
TLR	O
)	O
and	O
a	O
47%	O
/	O
44	O
%	O
reduction	O
in	O
in	O
-	O
segment	O
/	O
in	O
-	O
stent	O
restenosis	O
(	O
P	O
<	O
.01	O
)	O
and	O
lower	O
in	O
-	O
segment	O
/	O
in	O
-	O
stent	O
late	O
loss	O
(	O
P	O
<	O
.01	O
)	O
.	O

As	O
regards	O
to	O
the	O
safety	O
assessment	O
,	O
there	O
was	O
no	O
significant	O
difference	O
about	O
the	O
risk	O
of	O
stent	O
thrombosis	O
and	O
bleeding	O
between	O
TAT	O
and	O
DAT	O
group	O
,	O
while	O
the	O
risk	O
of	O
gastrointestinal	O
trouble	O
was	O
significantly	O
higher	O
in	O
TAT	O
group	O
(	O
OR	O
=	O
2.46	O
,	O
95	O
%	O
CI	O
=	O
1.25	O
-	O
4.86	O
;	O
P	O
<	O
.01	O
)	O
.	O

Addition	O
of	O
cilostazol	B
to	O
DAT	O
reduced	O
the	O
incidence	O
of	O
MACE	O
,	O
TVR	O
,	O
and	O
TLR	O
after	O
DES	O
implantation	O
.	O

TAT	O
also	O
reduced	O
the	O
risk	O
of	O
restenosis	O
and	O
late	O
loss	O
in	O
patients	O
after	O
DES	O
implantation	O
.	O

Blood	O
Pressure	O
Lowering	O
Effect	O
of	O
Nigella	O
sativa	O
L.	O
Seed	O
Oil	O
in	O
Healthy	O
Volunteers	O
:	O

A	O
Randomized	O
,	O
Double	O
-	O
Blind	O
,	O
Placebo	O
-	O
controlled	O
Clinical	O
Trial	O
.	O

Nigella	O
sativa	O
L.	O
seeds	O
(	O
N.	O
sativa	O
)	O
have	O
been	O
used	O
as	O
a	O
traditional	O
remedy	O
for	O
a	O
wide	O
range	O
of	O
diseases	O
including	O
hypertension	O
.	O

The	O
present	O
study	O
was	O
performed	O
to	O
explore	O
the	O
effects	O
of	O
N.	O
sativa	O
oil	O
on	O
blood	O
pressure	O
(	O
BP	O
)	O
in	O
healthy	O
volunteers	O
.	O

In	O
a	O
double	O
-	O
blind	O
,	O
randomized	O
study	O
,	O
70	O
healthy	O
volunteers	O
aged	O
34	O
to	O
63	O
years	O
with	O
systolic	O
BP	O
from	O
110	O
to	O
140	O
mmHg	O
and	O
diastolic	O
BP	O
from	O
60	O
to	O
90	O
mmHg	O
were	O
randomly	O
allocated	O
to	O
receive	O
2.5	O
mL	O
N.	O
sativa	O
oil	O
or	O
placebo	O
two	O
times	O
a	O
day	O
for	O
8	O
weeks	O
.	O

The	O
systolic	O
and	O
diastolic	O
BPs	O
,	O
body	O
mass	O
index	O
and	O
blood	O
levels	O
of	O
aspartate	B
transaminase	O
,	O
alanine	B
transaminase	O
,	O
alkaline	O
phosphatase	O
,	O
creatinine	B
and	O
blood	O
urea	B
nitrogen	B
were	O
determined	O
at	O
baseline	O
and	O
endpoint	O
.	O

Results	O
showed	O
that	O
in	O
N.	O
sativa	O
oil	O
treated	O
group	O
the	O
systolic	O
and	O
diastolic	O
BPs	O
decreased	O
significantly	O
compared	O
with	O
baseline	O
and	O
placebo	O
group	O
at	O
the	O
endpoint	O
.	O

Other	O
parameters	O
did	O
not	O
significantly	O
change	O
in	O
both	O
groups	O
at	O
the	O
endpoint	O
.	O

No	O
adverse	O
effects	O
were	O
reported	O
.	O

In	O
conclusion	O
,	O
oral	O
daily	O
administration	O
of	O
5	O
mL	O
N.	O
sativa	O
oil	O
to	O
healthy	O
volunteers	O
for	O
8	O
weeks	O
lowers	O
systolic	O
and	O
diastolic	O
BPs	O
without	O
any	O
adverse	O
effects	O
.	O

Copyright	O
	O
2013	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd.	O

Readily	O
accessible	O
fluorescent	O
probes	O
for	O
sensitive	O
biological	O
imaging	O
of	O
hydrogen	B
peroxide	I
.	O

Hydrogen	B
peroxide	I
is	O
a	O
major	O
component	O
of	O
oxygen	B
metabolism	O
in	O
biological	O
systems	O
that	O
,	O
when	O
present	O
in	O
high	O
concentrations	O
,	O
can	O
lead	O
to	O
oxidative	O
stress	O
in	O
cells	O
.	O

Noninvasive	O
molecular	O
imaging	O
of	O
H	B
(	I
2	I
)	I
O	I
(	I
2	I
)	I
using	O
fluorogenic	O
systems	O
represents	O
an	O
effective	O
way	O
to	O
detect	O
and	O
measure	O
the	O
accumulation	O
of	O
this	O
metabolite	O
.	O

Herein	O
,	O
we	O
detail	O
the	O
development	O
of	O
robust	O
H	B
(	I
2	I
)	I
O	I
(	I
2	I
)	I
-sensitive	O
fluorescent	O
probes	O
using	O
a	O
boronic	B
ester	I
trigger	O
appended	O
to	O
the	O
fluorophore	O
through	O
a	O
benzyl	B
ether	I
linkage	O
.	O

A	O
major	O
advantage	O
of	O
the	O
probes	O
presented	O
here	O
is	O
their	O
synthetic	O
accessibility	O
,	O
with	O
only	O
one	O
step	O
needed	O
to	O
generate	O
the	O
probes	O
on	O
the	O
gram	O
scale	O
.	O

The	O
sensitivity	O
of	O
the	O
probes	O
was	O
evaluated	O
in	O
simulated	O
physiological	O
conditions	O
,	O
showing	O
micromolar	O
sensitivity	O
to	O
H	B
(	I
2	I
)	I
O	I
(	I
2	I
)	I
.	O

The	O
probes	O
were	O
tested	O
in	O
biological	O
model	O
systems	O
,	O
demonstrating	O
effective	O
imaging	O
of	O
unstimulated	O
,	O
endogenous	O
H	B
(	I
2	I
)	I
O	I
(	I
2	I
)	I
levels	O
in	O
RAW	O
264.7	O
cells	O
and	O
murine	O
brain	O
tissue	O
.	O

Mifepristone	B
for	O
management	O
of	O
Cushing	O
's	O
syndrome	O
.	O

Cushing	O
's	O
syndrome	O
is	O
a	O
debilitating	O
endocrine	O
disorder	O
caused	O
by	O
elevated	O
circulating	O
glucocorticoid	O
levels	O
.	O

Although	O
uncommon	O
,	O
Cushing	O
's	O
syndrome	O
is	O
associated	O
with	O
significant	O
morbidity	O
necessitating	O
rapid	O
reversal	O
of	O
hypercortisolemia	O
.	O

Primary	O
therapy	O
for	O
most	O
patients	O
with	O
Cushing	O
's	O
syndrome	O
is	O
surgical	O
,	O
but	O
many	O
patients	O
will	O
require	O
additional	O
treatments	O
with	O
radiation	O
or	O
drugs	O
.	O

Although	O
several	O
options	O
for	O
drug	O
therapy	O
exist	O
,	O
few	O
are	O
readily	O
available	O
and	O
all	O
have	O
dose	O
-	O
limiting	O
adverse	O
effects	O
.	O

Mifepristone	B
(	O
RU	B
486	I
)	O
,	O
a	O
first	O
-	O
in	O
-	O
class	O
glucocorticoid	O
receptor	O
antagonist	O
,	O
was	O
approved	O
by	O
the	O
United	O
States	O
Food	O
and	O
Drug	O
Administration	O
in	O
2012	O
for	O
use	O
in	O
Cushing	O
's	O
syndrome	O
to	O
control	O
hyperglycemia	O
in	O
patients	O
who	O
are	O
not	O
surgical	O
candidates	O
or	O
have	O
not	O
achieved	O
remission	O
from	O
surgery	O
.	O

The	O
drug	O
is	O
approved	O
for	O
oral	O
once	O
-	O
daily	O
administration	O
.	O

In	O
its	O
pivotal	O
trial	O
,	O
60	O
%	O
of	O
patients	O
responded	O
to	O
mifepristone	B
with	O
significant	O
improvements	O
in	O
glycemic	O
control	O
and	O
38	O
%	O
had	O
a	O
reduction	O
in	O
diastolic	O
blood	O
pressure	O
.	O

The	O
most	O
common	O
adverse	O
events	O
were	O
nausea	O
,	O
fatigue	O
,	O
headache	O
,	O
endometrial	O
hyperplasia	O
,	O
and	O
hypokalemia	O
.	O

Adrenal	O
insufficiency	O
occurred	O
in	O
fewer	O
than	O
5	O
%	O
of	O
patients	O
.	O

The	O
recommended	O
starting	O
dosage	O
of	O
mifepristone	B
is	O
300	O
mg	O
/	O
day	O
.	O

The	O
dosage	O
may	O
be	O
increased	O
every	O
2	O
-	O
4	O
weeks	O
up	O
to	O
a	O
maximum	O
of	O
1200	O
mg	O
/	O
day	O
,	O
although	O
it	O
should	O
not	O
exceed	O
20	O
mg	O
/	O
kg	O
/	O
day	O
.	O

Significant	O
drug	O
-	O
drug	O
interactions	O
exist	O
due	O
to	O
mifepristone	B
's	O
effects	O
on	O
a	O
number	O
of	O
cytochrome	O
P450	O
enzymes	O
.	O

Despite	O
its	O
limitations	O
,	O
mifepristone	B
is	O
a	O
welcome	O
addition	O
and	O
an	O
appropriate	O
alternative	O
to	O
the	O
available	O
drug	O
therapy	O
for	O
Cushing	O
's	O
syndrome	O
.	O

Pu	O
-	O
erh	O
tea	O
hot	O
-	O
water	O
extract	O
activates	O
Akt	O
and	O
induces	O
insulin	O
-	O
independent	O
glucose	B
transport	O
in	O
rat	O
skeletal	O
muscle	O
.	O

Skeletal	O
muscle	O
is	O
a	O
major	O
organ	O
that	O
is	O
important	O
for	O
whole	O
-	O
body	O
glucose	B
metabolism	O
.	O

We	O
found	O
that	O
when	O
isolated	O
rat	O
epitrochlearis	O
muscle	O
was	O
incubated	O
with	O
a	O
Pu	O
-	O
erh	O
tea	O
hot	O
-	O
water	O
extract	O
(	O
PTE	O
)	O
for	O
30	O
min	O
,	O
the	O
rate	O
of	O
3-O	B
-	I
methyl	I
-	I
D	I
-	I
glucose	I
(	O
3MG	B
)	O
transport	O
increased	O
in	O
the	O
absence	O
of	O
insulin	O
.	O

This	O
activation	O
was	O
associated	O
with	O
an	O
increase	O
in	O
Ser	B
(	O
473	O
)	O
phosphorylation	O
of	O
Akt	O
,	O
a	O
signaling	O
intermediary	O
leading	O
to	O
insulin	O
-	O
dependent	O
glucose	B
transport	O
,	O
but	O
not	O
Tyr	B
(	O
458	O
)	O
phosphorylation	O
of	O
phosphoinositide	O
3-kinase	O
p85	O
,	O
an	O
upstream	O
molecule	O
of	O
Akt	O
.	O

PTE	O
-	O
stimulated	O
3MG	O
transport	O
was	O
also	O
not	O
accompanied	O
by	O
Thr	B
(	O
172	O
)	O
phosphorylation	O
of	O
the	O
catalytic	O
	O
-	O
subunit	O
of	O
5'-AMP	O
-	O
activated	O
protein	O
kinase	O
(	O
AMPK	O
)	O
.	O

Gallic	B
acid	I
,	O
a	O
water	O
-	O
soluble	O
ingredient	O
in	O
Pu	O
-	O
erh	O
tea	O
,	O
stimulated	O
Akt	O
phosphorylation	O
,	O
but	O
not	O
AMPK	O
phosphorylation	O
.	O

These	O
results	O
suggest	O
that	O
Pu	O
-	O
erh	O
tea	O
potentially	O
promotes	O
skeletal	O
muscle	O
glucose	B
transport	O
at	O
least	O
in	O
part	O
by	O
activating	O
Akt	O
.	O

Potential	O
for	O
preventive	O
effects	O
of	O
cocoa	O
and	O
cocoa	O
polyphenols	B
in	O
cancer	O
.	O

Prevention	O
of	O
cancer	O
through	O
the	O
diet	O
is	O
receiving	O
increasing	O
interest	O
,	O
and	O
cocoa	O
because	O
of	O
its	O
polyphenolic	B
compounds	O
has	O
become	O
an	O
important	O
potential	O
chemopreventive	O
and	O
therapeutic	O
natural	O
agent	O
.	O

Cocoa	O
and	O
its	O
main	O
polyphenols	B
have	O
been	O
reported	O
to	O
interfere	O
at	O
the	O
initiation	O
,	O
promotion	O
and	O
progression	O
of	O
cancer	O
.	O

Cocoa	O
flavonoids	B
have	O
been	O
demonstrated	O
to	O
influence	O
several	O
important	O
biological	O
functions	O
in	O
vitro	O
and	O
in	O
vivo	O
by	O
their	O
free	O
radical	O
scavenging	O
ability	O
or	O
through	O
the	O
regulation	O
of	O
signal	O
transduction	O
pathways	O
to	O
stimulate	O
apoptosis	O
and	O
to	O
inhibit	O
inflammation	O
,	O
cellular	O
proliferation	O
,	O
apoptosis	O
,	O
angiogenesis	O
and	O
metastasis	O
.	O

Nevertheless	O
,	O
these	O
molecular	O
mechanisms	O
of	O
action	O
are	O
not	O
completely	O
characterized	O
and	O
many	O
features	O
remain	O
to	O
be	O
elucidated	O
.	O

The	O
aim	O
of	O
this	O
review	O
is	O
to	O
provide	O
insights	O
into	O
the	O
molecular	O
basis	O
of	O
the	O
potential	O
chemopreventive	O
activity	O
of	O
cocoa	O
and	O
its	O
polyphenolic	B
components	O
by	O
summarizing	O
cell	O
culture	O
and	O
animal	O
models	O
studies	O
,	O
as	O
well	O
as	O
interventional	O
and	O
epidemiological	O
studies	O
on	O
humans	O
.	O

Biosafety	O
and	O
antioxidant	O
effects	O
of	O
a	O
beverage	O
containing	O
silymarin	O
and	O
arginine	B
.	O

A	O
pilot	O
,	O
human	O
intervention	O
cross	O
-	O
over	O
trial	O
.	O

The	O
study	O
objective	O
was	O
to	O
investigate	O
the	O
potential	O
of	O
a	O
beverage	O
containing	O
silymarin	O
and	O
l	B
-	I
arginine	I
to	O
alter	O
basic	O
physiological	O
and	O
urodynamic	O
parameters	O
in	O
22	O
normal	O
healthy	O
men	O
aged	O
38	O
-	O
59years	O
.	O

The	O
volunteers	O
drank	O
500ml	O
/	O
day	O
beverage	O
without	O
silymarin	O
and	O
l	B
-	I
arginine	I
for	O
10days	O
followed	O
,	O
after	O
a	O
7-day	O
washout	O
period	O
,	O
by	O
the	O
beverage	O
with	O
400	O
mg	O
silymarin	O
and	O
295	O
mg	O
l	B
-	I
arginine	I
for	O
10days	O
.	O

Blood	O
and	O
urine	O
samples	O
were	O
collected	O
on	O
days	O
0	O
,	O
10	O
and	O
27	O
.	O

The	O
beverages	O
were	O
well	O
-	O
tolerated	O
with	O
no	O
adverse	O
effects	O
.	O

Most	O
of	O
the	O
biochemical	O
,	O
hematological	O
and	O
urodynamic	O
parameters	O
remained	O
unchanged	O
.	O

Total	O
antioxidant	O
capacity	O
,	O
total	O
level	O
of	O
antioxidants	O
,	O
lipoperoxidation	O
products	O
(	O
malondialdehyde	B
)	O
,	O
advanced	O
oxidation	O
products	O
of	O
proteins	O
in	O
plasma	O
and	O
glutathione	B
,	O
glutathione	B
peroxidase	O
,	O
glutathione	B
reductase	O
,	O
superoxide	B
dismutase	O
and	O
catalase	O
levels	O
in	O
erythrocytes	O
were	O
not	O
influenced	O
.	O

Serum	O
	O
-	O
glutamyl	O
transferase	O
,	O
malondialdehyde	B
level	O
and	O
activity	O
of	O
glutathione	B
S	O
-	O
transferase	O
in	O
erythrocytes	O
were	O
lowered	O
at	O
day	O
27	O
and	O
the	O
concentration	O
of	O
total	O
plasma	O
SH	B
-	O
groups	O
was	O
higher	O
on	O
day	O
10	O
.	O

Using	O
an	O
ex	O
vivo	O
system	O
,	O
we	O
found	O
that	O
silymarin	O
/	O
silybin	B
at	O
10	O
-	O
100M	O
is	O
able	O
to	O
adsorb	O
onto	O
human	O
erythrocytes	O
and	O
the	O
complexes	O
displayed	O
antioxidant	O
properties	O
as	O
studied	O
using	O
ex	O
situ	O
square	O
-	O
wave	O
voltammetry	O
.	O

The	O
trial	O
showed	O
that	O
silymarin	O
in	O
vivo	O
may	O
protect	O
erythrocytes	O
against	O
oxidative	O
damage	O
.	O

Ghrelin	O
inhibits	O
sodium	B
metabisulfite	I
induced	O
oxidative	O
stress	O
and	O
apoptosis	O
in	O
rat	O
gastric	O
mucosa	O
.	O

This	O
study	O
aimed	O
to	O
investigate	O
the	O
effect	O
of	O
ghrelin	O
administration	O
on	O
sulfite	B
induced	O
oxidative	O
and	O
apoptotic	O
changes	O
in	O
rat	O
gastric	O
mucosa	O
.	O

Forty	O
male	O
albino	O
Wistar	O
rats	O
were	O
randomized	O
into	O
control	O
(	O
C	O
)	O
,	O
sodium	B
metabisulfite	I
(	O
Na2S2O5	B
)	O
treated	O
(	O
S	O
)	O
,	O
ghrelin	O
treated	O
(	O
G	O
)	O
and	O
,	O
Na2S2O5+ghrelin	B
treated	O
(	O
SG	O
)	O
groups	O
.	O

Sodium	B
metabisulfite	I
(	O
100mg	O
/	O
kg	O
/	O
day	O
)	O
was	O
given	O
by	O
gastric	O
gavage	O
and	O
,	O
ghrelin	O
(	O
20g	O
/	O
kg	O
/	O
day	O
)	O
was	O
given	O
intraperitoneally	O
for	O
5weeks	O
.	O

Plasma	O
-	B
S	O
-	O
sulfonate	B
level	O
was	O
increased	O
in	O
S	O
and	O
SG	O
groups	O
.	O

Na2S2O5	B
administration	O
significantly	O
elevated	O
total	O
oxidant	O
status	O
(	O
TOS	O
)	O
levels	O
while	O
depleting	O
total	O
antioxidant	O
status	O
(	O
TAS	O
)	O
levels	O
in	O
gastric	O
mucosa	O
.	O

Ghrelin	O
significantly	O
decreased	O
gastric	O
TOS	O
levels	O
in	O
the	O
SG	O
group	O
compared	O
with	O
the	O
S	O
group	O
.	O

Additionally	O
,	O
TAS	O
levels	O
were	O
found	O
to	O
be	O
higher	O
in	O
SG	O
group	O
in	O
reference	O
to	O
S	O
group	O
.	O

Na2S2O5	B
administration	O
also	O
markedly	O
increased	O
the	O
number	O
of	O
apoptotic	O
cells	O
,	O
cleaved	O
caspase-3	O
and	O
PAR	O
expression	O
(	O
PARP	O
activity	O
indicator	O
)	O
and	O
,	O
decreased	O
Ki67	O
expression	O
(	O
cell	O
proliferation	O
index	O
)	O
in	O
gastric	O
mucosal	O
cells	O
.	O

Ghrelin	O
treatment	O
decreased	O
the	O
number	O
apoptotic	O
cells	O
,	O
cytochrome	O
C	O
release	O
,	O
PAR	O
and	O
,	O
caspase-3	O
expressions	O
while	O
increasing	O
Ki67	O
expression	O
in	O
gastric	O
mucosa	O
exposed	O
to	O
Na2S2O5	B
.	O

In	O
conclusion	O
,	O
we	O
suggest	O
that	O
ghrelin	O
treatment	O
might	O
ameliorate	O
ingested	O
-	O
Na2S2O5	B
induced	O
gastric	O
mucosal	O
injury	O
stemming	O
from	O
apoptosis	O
and	O
oxidative	O
stress	O
in	O
rats	O
.	O

Vitamin	B
A	I
and	O
retinoid	B
signaling	O
:	O
genomic	O
and	O
non	O
-	O
genomic	O
effects	O
.	O

Vitamin	B
A	I
or	O
retinol	B
is	O
arguably	O
the	O
most	O
multifunctional	O
vitamin	B
in	O
the	O
human	O
body	O
as	O
it	O
is	O
essential	O
from	O
embryogenesis	O
to	O
adulthood	O
.	O

The	O
pleiotropic	O
effects	O
of	O
vitamin	B
A	I
are	O
exerted	O
mainly	O
by	O
one	O
active	O
metabolite	O
,	O
all	B
-	I
trans	I
retinoic	I
acid	I
(	O
atRA	B
)	O
,	O
which	O
regulates	O
the	O
expression	O
of	O
a	O
battery	O
of	O
target	O
genes	O
through	O
several	O
families	O
of	O
nuclear	O
receptors	O
(	O
RARs	O
,	O
RXRs	O
and	O
PPAR	O
/	O
	O
)	O
,	O
polymorphic	O
retinoic	B
acid	I
(	O
RA	O
)	O
response	O
elements	O
and	O
multiple	O
coregulators	O
.	O

It	O
also	O
involves	O
extra	O
nuclear	O
and	O
non	O
-	O
transcriptional	O
effects	O
such	O
as	O
the	O
activation	O
of	O
kinase	O
cascades	O
,	O
which	O
are	O
integrated	O
in	O
the	O
nucleus	O
via	O
the	O
phosphorylation	O
of	O
several	O
actors	O
of	O
RA	O
signaling	O
.	O

However	O
,	O
vitamin	B
A	I
itself	O
proved	O
recently	O
to	O
be	O
active	O
and	O
RARs	O
to	O
be	O
present	O
in	O
the	O
cytosol	O
to	O
regulate	O
translation	O
and	O
cell	O
plasticity	O
.	O

All	O
these	O
new	O
concepts	O
expand	O
the	O
scope	O
of	O
the	O
biologic	O
functions	O
of	O
vitamin	B
A	I
and	O
RA	O
.	O

Synthesis	O
and	O
antiproliferative	O
activity	O
evaluation	O
of	O
imidazole	B
-	O
based	O
indeno	B
[	I
1,2-b	I
]	I
quinoline-9,11-dione	I
derivatives	O
.	O

A	O
series	O
of	O
new	O
imidazole	B
substituted	O
indeno	B
[	I
1,2-b	I
]	I
quinoline-9,11-dione	I
derivatives	O
were	O
synthesized	O
and	O
evaluated	O
for	O
their	O
antiproliferative	O
effects	O
on	O
HeLa	O
,	O
LS180	O
,	O
MCF-7	O
and	O
Jurkat	O
human	O
cancer	O
cell	O
lines	O
.	O

Antiproliferative	O
effects	O
were	O
evaluated	O
using	O
MTT	B
assay	O
.	O

Prepared	O
compounds	O
exhibited	O
weak	O
to	O
good	O
antiproliferative	O
activity	O
in	O
evaluated	O
cell	O
lines	O
.	O

Prepared	O
compounds	O
were	O
more	O
potent	O
in	O
Jurkat	O
cell	O
line	O
when	O
compared	O
to	O
LS180	O
,	O
HeLa	O
and	O
MCF-7	O
cell	O
lines	O
.	O

Compounds	O
29	O
(	O
IC16	O
=	O
0.7	O
M	O
)	O
and	O
31	O
(	O
IC16	O
=	O
1.7	O
M	O
)	O
and	O
33	O
(	O
IC16	O
=	O
1.7	O
M	O
)	O
were	O
found	O
to	O
be	O
the	O
most	O
potent	O
molecules	O
on	O
Jurkat	O
cell	O
lines	O
.	O

Moreover	O
;	O
it	O
was	O
found	O
that	O
some	O
of	O
the	O
tested	O
compounds	O
bearing	O
imidazole-2-yl	B
moiety	O
on	O
the	O
C11-position	O
of	O
dihydropyridine	B
ring	O
exhibited	O
superior	O
antiproliferative	O
activity	O
in	O
comparison	O
to	O
cis	B
-	I
platin	I
especially	O
in	O
Jurkat	O
cell	O
line	O
(	O
compounds	O
29	O
,	O
31	O
,	O
and	O
33	O
)	O
.	O

It	O
seemed	O
that	O
the	O
introduction	O
of	O
electron	O
-	O
withdrawing	O
groups	O
on	O
the	O
imidazole	B
ring	O
enhanced	O
the	O
antiproliferative	O
potential	O
of	O
these	O
compounds	O
(	O
compounds	O
27	O
,	O
29	O
and	O
31	O
)	O
.	O

The	O
results	O
of	O
this	O
study	O
proposed	O
that	O
some	O
of	O
the	O
imidazole	B
substituted	O
indeno	B
[	I
1,2-b	I
]	I
quinoline-9,11-dione	I
compounds	O
may	O
act	O
as	O
efficient	O
anticancer	O
agents	O
in	O
vitro	O
,	O
emphasizing	O
their	O
potential	O
role	O
as	O
a	O
source	O
for	O
rational	O
design	O
of	O
potent	O
antiproliferative	O
agents	O
.	O

Epigenetic	O
regulation	O
of	O
hypoxia	O
inducible	O
factor	O
in	O
diseases	O
and	O
therapeutics	O
.	O

Hypoxia	O
-	O
inducible	O
factors	O
(	O
HIFs	O
)	O
are	O
master	O
regulators	O
of	O
angiogenesis	O
and	O
cellular	O
adaptation	O
in	O
hypoxic	O
microenvironments	O
.	O

Accumulating	O
evidence	O
indicates	O
that	O
HIFs	O
also	O
regulate	O
cell	O
survival	O
,	O
glucose	B
metabolism	O
,	O
microenvironmental	O
remodeling	O
,	O
cancer	O
metastasis	O
,	O
and	O
tumor	O
progression	O
,	O
and	O
thus	O
,	O
HIFs	O
are	O
viewed	O
as	O
therapeutic	O
targets	O
in	O
many	O
diseases	O
.	O

Epigenetic	O
changes	O
are	O
involved	O
in	O
the	O
switching	O
'	O
on	O
'	O
and	O
'	O
off	O
'	O
of	O
many	O
genes	O
,	O
and	O
it	O
has	O
been	O
suggested	O
that	O
the	O
DNA	O
hypermethylation	O
of	O
specific	O
gene	O
promoters	O
,	O
histone	O
modifications	O
(	O
acetylation	O
,	O
phosphorylation	O
,	O
and	O
methylation	O
)	O
and	O
small	O
interfering	O
or	O
micro	O
RNAs	O
be	O
regarded	O
epigenetic	O
gene	O
targets	O
for	O
the	O
regulation	O
of	O
disease	O
-	O
associated	O
cellular	O
changes	O
.	O

Furthermore	O
,	O
the	O
hypoxic	O
microenvironment	O
is	O
one	O
of	O
the	O
most	O
important	O
cellular	O
stress	O
stimuli	O
in	O
terms	O
of	O
the	O
regulation	O
of	O
cellular	O
epigenetic	O
status	O
via	O
histone	O
modification	O
.	O

Therefore	O
,	O
drug	O
development	O
and	O
therapeutic	O
approaches	O
to	O
ischemic	O
diseases	O
or	O
cancer	O
for	O
targeting	O
HIFs	O
by	O
modulation	O
of	O
epigenetic	O
status	O
become	O
an	O
attractive	O
area	O
.	O

Here	O
,	O
the	O
authors	O
provide	O
a	O
review	O
of	O
the	O
literature	O
regarding	O
the	O
targeting	O
of	O
HIF	O
,	O
a	O
key	O
modulator	O
of	O
hypoxic	O
-	O
cell	O
response	O
under	O
various	O
disease	O
conditions	O
,	O
by	O
modulating	O
histone	O
or	O
DNA	O
using	O
endogenous	O
small	O
RNAs	O
or	O
exogenous	O
chemicals	O
.	O

Phase	O
stability	O
and	O
elastic	O
properties	O
of	O
chromium	B
borides	I
with	O
various	O
stoichiometries	O
.	O

Phase	O
stability	O
is	O
important	O
to	O
the	O
application	O
of	O
materials	O
.	O

By	O
first	O
-	O
principles	O
calculations	O
,	O
we	O
establish	O
the	O
phase	O
stability	O
of	O
chromium	B
borides	I
with	O
various	O
stoichiometries	O
.	O

Moreover	O
,	O
the	O
phases	O
of	O
CrB3	B
and	O
CrB4	B
have	O
been	O
predicted	O
by	O
using	O
a	O
newly	O
developed	O
particle	O
swarm	O
optimization	O
(	O
PSO	O
)	O
algorithm	O
.	O

Formation	O
enthalpy	O
-	O
pressure	O
diagrams	O
reveal	O
that	O
the	O
MoB	B
-	O
type	O
structure	O
is	O
more	O
energetically	O
favorable	O
than	O
the	O
TiI	B
-	O
type	O
structure	O
for	O
CrB.	B
For	O
CrB2	B
,	O
the	O
WB2	B
-type	O
structure	O
is	O
preferred	O
at	O
zero	O
pressure	O
.	O

The	O
predicted	O
new	O
phase	O
of	O
CrB3	B
belongs	O
to	O
the	O
hexagonal	O
P-6m2	O
space	O
group	O
and	O
it	O
transforms	O
into	O
an	O
orthorhombic	O
phase	O
as	O
the	O
pressure	O
exceeds	O
93	O
GPa	O
.	O

The	O
predicted	O
CrB4	B
(	O
space	O
group	O
:	O
Pnnm	O
)	O
phase	O
is	O
more	O
energetically	O
favorable	O
than	O
the	O
previously	O
proposed	O
Immm	O
structure	O
.	O

The	O
mechanical	O
and	O
thermodynamic	O
stabilities	O
of	O
predicted	O
CrB3	B
and	O
CrB4	B
are	O
verified	O
by	O
the	O
calculated	O
elastic	O
constants	O
and	O
formation	O
enthalpies	O
.	O

The	O
full	O
phonon	O
dispersion	O
calculations	O
confirm	O
the	O
dynamic	O
stability	O
of	O
WB2	B
-type	O
CrB2	B
and	O
predicted	O
CrB3	B
.	O

The	O
large	O
shear	O
moduli	O
,	O
large	O
Young	O
's	O
moduli	O
,	O
low	O
Poisson	O
ratios	O
,	O
and	O
low	O
bulk	O
and	O
shear	O
modulus	O
ratios	O
of	O
CrB4	B
PSC	O
and	O
CrB4	B
PSD	O
indicate	O
that	O
they	O
are	O
potential	O
hard	O
materials	O
.	O

Analyses	O
of	O
Debye	O
temperature	O
,	O
electronic	O
localization	O
function	O
,	O
and	O
electronic	O
structure	O
provide	O
further	O
understanding	O
of	O
the	O
chemical	O
and	O
physical	O
properties	O
of	O
these	O
borides	O
.	O

Nanomechanical	O
properties	O
of	O
proteins	O
and	O
membranes	O
depend	O
on	O
loading	O
rate	O
and	O
electrostatic	O
interactions	O
.	O

Knowing	O
the	O
dynamic	O
mechanical	O
response	O
of	O
tissue	O
,	O
cells	O
,	O
membranes	O
,	O
proteins	O
,	O
nucleic	O
acids	O
,	O
and	O
carbohydrates	B
to	O
external	O
perturbations	O
is	O
important	O
to	O
understand	O
various	O
biological	O
and	O
biotechnological	O
problems	O
.	O

Atomic	O
force	O
microscopy	O
(	O
AFM	O
)	O
-based	O
approaches	O
are	O
the	O
most	O
frequently	O
used	O
nanotechnologies	O
to	O
determine	O
the	O
mechanical	O
properties	O
of	O
biological	O
samples	O
that	O
range	O
in	O
size	O
from	O
microscopic	O
to	O
(	O
sub	O
)	O
nanoscopic	O
.	O

However	O
,	O
the	O
dynamic	O
nature	O
of	O
biomechanical	O
properties	O
has	O
barely	O
been	O
addressed	O
by	O
AFM	O
imaging	O
.	O

In	O
this	O
work	O
,	O
we	O
characterizethe	O
viscoelastic	O
properties	O
of	O
the	O
native	O
light	O
-	O
driven	O
proton	O
pump	O
bacteriorhodopsin	O
of	O
the	O
purple	O
membrane	O
of	O
Halobacterium	O
salinarum	O
.	O

Using	O
force	O
-	O
distance	O
curve	O
(	O
F	O
-	O
D	O
)	O
-based	O
AFM	O
we	O
imaged	O
purple	O
membranes	O
while	O
force	O
probing	O
their	O
mechanical	O
response	O
over	O
a	O
wide	O
range	O
of	O
loading	O
rates	O
(	O
from	O
0.5	O
to	O
100	O
N	O
/	O
s	O
)	O
.	O

Our	O
results	O
show	O
that	O
the	O
mechanical	O
stiffness	O
of	O
protein	O
and	O
membrane	O
increases	O
with	O
the	O
loading	O
rate	O
up	O
to	O
a	O
factor	O
of	O
10	O
(	O
from	O
0.3	O
to	O
3.2	O
N	O
/	O
m	O
)	O
.	O

In	O
addition	O
,	O
the	O
electrostatic	O
repulsion	O
between	O
AFM	O
tip	O
and	O
sample	O
can	O
alter	O
the	O
mechanical	O
stiffness	O
measured	O
by	O
AFM	O
up	O
to	O
60	O
%	O
(	O
from	O
0.8	O
to	O
1.3	O
N	O
/	O
m	O
)	O
.These	O
findings	O
indicate	O
that	O
the	O
mechanical	O
response	O
of	O
membranes	O
and	O
proteins	O
and	O
probably	O
of	O
other	O
biomolecular	O
systems	O
should	O
be	O
determined	O
at	O
different	O
loading	O
rates	O
to	O
fully	O
understand	O
their	O
properties	O
.	O

Through	O
the	O
looking	O
glass	O
:	O
adventures	O
in	O
kinase	O
inhibitor	O
design	O
and	O
optimization	O
.	O

Developing	O
a	O
viable	O
new	O
drug	O
candidate	O
is	O
difficult	O
.	O

Developing	O
one	O
that	O
is	O
a	O
small	O
molecule	O
kinase	O
inhibitor	O
that	O
binds	O
competitively	O
with	O
respect	O
to	O
ATP	B
with	O
superb	O
selectivity	O
is	O
even	O
more	O
difficult	O
,	O
which	O
makes	O
the	O
design	O
and	O
optimization	O
work	O
described	O
by	O
Jimenez	O
et	O
al.	O
(	O
J.	O
Med	O
.	O

Chem	O
.	O
,	O
DOI	O
:	O
10.1021	O
/	O
jm301465a	O
)	O
particularly	O
remarkable	O
.	O

They	O
took	O
a	O
lead	O
from	O
a	O
high	O
-	O
throughput	O
screen	O
against	O
protein	O
kinase	O
C	O
	O
(	O
PKC	O
)	O
through	O
a	O
series	O
of	O
optimization	O
steps	O
,	O
culminating	O
in	O
the	O
demonstration	O
of	O
in	O
vivo	O
activity	O
in	O
mice	O
.	O

Having	O
identified	O
and	O
improved	O
the	O
hinge	O
-	O
binding	O
"	O
warhead	O
"	O
at	O
one	O
end	O
of	O
their	O
lead	O
molecule	O
,	O
they	O
proceeded	O
to	O
use	O
structure	O
-	O
based	O
design	O
tools	O
to	O
guide	O
modification	O
of	O
the	O
other	O
end	O
to	O
enhance	O
selectivity	O
over	O
a	O
closely	O
related	O
isoform	O
of	O
the	O
kinase	O
.	O

With	O
that	O
accomplished	O
,	O
they	O
used	O
a	O
series	O
of	O
protection	O
and	O
deprotection	O
maneuvers	O
to	O
modify	O
the	O
central	O
portion	O
of	O
the	O
series	O
scaffold	O
to	O
further	O
enhance	O
potency	O
against	O
the	O
target	O
while	O
also	O
improving	O
pharmacokinetic	O
properties	O
.	O

The	O
project	O
was	O
a	O
success	O
at	O
the	O
preclinical	O
level	O
:	O
oral	O
administration	O
of	O
the	O
ultimate	O
analogue	O
obtained	O
was	O
effective	O
at	O
suppressing	O
interleukin-2	O
induction	O
in	O
mice	O
.	O

Correlation	O
of	O
photobleaching	O
,	O
oxidation	O
and	O
metal	O
induced	O
fluorescence	O
quenching	O
of	O
DNA	O
-	O
templated	O
silver	B
nanoclusters	O
.	O

Few	O
-	O
atom	O
noble	O
metal	O
nanoclusters	O
have	O
attracted	O
a	O
lot	O
of	O
interest	O
due	O
to	O
their	O
potential	O
applications	O
in	O
biosensor	O
development	O
,	O
imaging	O
and	O
catalysis	O
.	O

DNA	O
-	O
templated	O
silver	B
nanoclusters	O
(	O
AgNCs	O
)	O
are	O
of	O
particular	O
interest	O
as	O
different	O
emission	O
colors	O
can	O
be	O
obtained	O
by	O
changing	O
the	O
DNA	O
sequence	O
.	O

A	O
popular	O
analytical	O
application	O
is	O
fluorescence	O
quenching	O
by	O
Hg	B
(	I
2	I
+	I
)	I
,	O
where	O
d	O
(	O
10	O
)	O
-d	O
(	O
10	O
)	O
metallophilic	O
interaction	O
has	O
often	O
been	O
proposed	O
for	O
associating	O
Hg	B
(	I
2	I
+	I
)	I
with	O
nanoclusters	O
.	O

However	O
,	O
it	O
can	O
not	O
explain	O
the	O
lack	O
of	O
response	O
to	O
other	O
d	O
(	O
10	O
)	O
ions	O
such	O
as	O
Zn	B
(	I
2	I
+	I
)	I
and	O
Cd	B
(	I
2	I
+	I
)	I
.	O

In	O
our	O
effort	O
to	O
elucidate	O
the	O
quenching	O
mechanism	O
,	O
we	O
studied	O
a	O
total	O
of	O
eight	O
AgNCs	O
prepared	O
by	O
different	O
hairpin	O
DNA	O
sequences	O
;	O
they	O
showed	O
different	O
sensitivity	O
to	O
Hg	B
(	I
2	I
+	I
)	I
,	O
and	O
DNA	O
with	O
a	O
larger	O
cytosine	B
loop	O
size	O
produced	O
more	O
sensitive	O
AgNCs	O
.	O

In	O
all	O
the	O
cases	O
,	O
samples	O
strongly	O
quenched	O
by	O
Hg	B
(	I
2	I
+	I
)	I
were	O
also	O
more	O
easily	O
photobleached	O
.	O

Light	O
of	O
shorter	O
wavelengths	O
bleached	O
AgNCs	O
more	O
potently	O
,	O
and	O
photobleached	O
samples	O
can	O
be	O
recovered	O
by	O
NaBH4	B
.	O

Strong	O
fluorescence	O
quenching	O
was	O
also	O
observed	O
with	O
high	O
redox	O
potential	O
metal	O
ions	O
such	O
as	O
Ag	B
(	I
+	I
)	I
,	O
Au	B
(	I
3	I
+	I
)	I
,	O
Cu	B
(	I
2	I
+	I
)	I
and	O
Hg	B
(	I
2	I
+	I
)	I
,	O
but	O
not	O
with	O
low	O
redox	O
potential	O
ions	O
.	O

Such	O
metal	O
induced	O
quenching	O
can	O
not	O
be	O
recovered	O
by	O
NaBH4	B
.	O

Electronic	O
absorption	O
and	O
mass	O
spectrometry	O
studies	O
offered	O
further	O
insights	O
into	O
the	O
oxidation	O
reaction	O
.	O

Our	O
results	O
correlate	O
many	O
important	O
experimental	O
observations	O
and	O
will	O
fuel	O
the	O
further	O
growth	O
of	O
this	O
field	O
.	O

Eugenol	B
alters	O
the	O
integrity	O
of	O
cell	O
membrane	O
and	O
acts	O
against	O
the	O
nosocomial	O
pathogen	O
Proteus	O
mirabilis	O
.	O

Eugenol	B
,	O
a	O
member	O
of	O
the	O
phenylpropanoids	O
class	O
of	O
chemical	O
compounds	O
,	O
is	O
a	O
clear	O
to	O
pale	O
yellow	O
oily	O
liquid	O
extracted	O
from	O
certain	O
essential	O
oils	O
especially	O
from	O
clove	O
oil	O
,	O
nutmeg	O
,	O
cinnamon	O
,	O
and	O
bay	O
leaf	O
.	O

The	O
antibacterial	O
activity	O
of	O
eugenol	B
and	O
its	O
mechanism	O
of	O
bactericidal	O
action	O
against	O
Proteus	O
mirabilis	O
were	O
evaluated	O
.	O

Treatment	O
with	O
eugenol	B
at	O
their	O
minimum	O
inhibitory	O
concentration	O
[	O
0.125	O
%	O
(	O
v	O
/	O
v	O
)	O
]	O
and	O
minimum	O
bactericidal	O
concentration	O
[	O
0.25	O
%	O
(	O
v	O
/	O
v	O
)	O
]	O
reduced	O
the	O
viability	O
and	O
resulted	O
in	O
complete	O
inhibition	O
of	O
P.	O
mirabilis	O
.	O

A	O
strong	O
bactericidal	O
effect	O
on	O
P.	O
mirabilis	O
was	O
also	O
evident	O
,	O
as	O
eugenol	B
inactivated	O
the	O
bacterial	O
population	O
within	O
30	O
min	O
exposure	O
.	O

Chemo	O
-	O
attractant	O
property	O
and	O
the	O
observance	O
of	O
highest	O
antibacterial	O
activity	O
at	O
alkaline	O
pH	O
suggest	O
that	O
eugenol	B
can	O
work	O
more	O
effectively	O
when	O
given	O
in	O
vivo	O
.	O

Eugenol	B
inhibits	O
the	O
virulence	O
factors	O
produced	O
by	O
P.	O
mirabilis	O
as	O
observed	O
by	O
swimming	O
motility	O
,	O
swarming	O
behavior	O
and	O
urease	O
activity	O
.	O

It	O
interacts	O
with	O
cellular	O
membrane	O
of	O
P.	O
mirabilis	O
and	O
makes	O
it	O
highly	O
permeable	O
,	O
forming	O
nonspecific	O
pores	O
on	O
plasma	O
membrane	O
,	O
which	O
in	O
turn	O
directs	O
the	O
release	O
of	O
260	O
nm	O
absorbing	O
materials	O
and	O
uptake	O
of	O
more	O
crystal	B
violet	I
from	O
the	O
medium	O
into	O
the	O
cells	O
.	O

SDS	B
-	O
polyacrylamide	B
gel	O
,	O
scanning	O
electron	O
microscopy	O
and	O
Fourier	O
transform	O
infrared	O
analysis	O
further	O
proves	O
the	O
disruptive	O
action	O
of	O
eugenol	B
on	O
the	O
plasma	O
membrane	O
of	O
P.	O
mirabilis	O
.	O

The	O
findings	O
reveal	O
that	O
eugenol	B
shows	O
an	O
excellent	O
bactericidal	O
activity	O
against	O
P.	O
mirabilis	O
by	O
altering	O
the	O
integrity	O
of	O
cell	O
membrane	O
.	O

miR-7641	O
modulates	O
the	O
expression	O
of	O
CXCL1	O
during	O
endothelial	O
differentiation	O
derived	O
from	O
human	O
embryonic	O
stem	O
cells	O
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
a	O
class	O
of	O
small	O
noncoding	O
RNAs	O
that	O
negatively	O
regulate	O
gene	O
expression	O
through	O
binding	O
to	O
3	O
'	O
untranslated	O
region	O
.	O

We	O
identified	O
and	O
characterized	O
the	O
novel	O
miRNA	O
,	O
miR-7641	O
,	O
in	O
human	O
mesenchymal	O
stem	O
cells	O
.	O

The	O
expression	O
of	O
miR-7641	O
was	O
downregulated	O
during	O
differentiation	O
from	O
human	O
embryonic	O
stem	O
cells	O
to	O
endothelial	O
cells	O
.	O

The	O
CXCL1	O
,	O
a	O
member	O
of	O
the	O
CXC	O
chemokine	O
family	O
,	O
is	O
known	O
as	O
promoting	O
neovascularization	O
by	O
binding	O
G	O
-	O
protein	O
coupled	O
receptors	O
and	O
is	O
related	O
to	O
endothelial	O
cells	O
biogenesis	O
such	O
as	O
angiogenesis	O
,	O
and	O
it	O
was	O
predicted	O
as	O
target	O
gene	O
of	O
miR-7641	O
by	O
computerized	O
analysis	O
and	O
the	O
luciferase	O
reporter	O
assay	O
.	O

The	O
miR-7641	O
significantly	O
suppressed	O
CXCL1	O
of	O
transcriptional	O
and	O
post	O
-	O
translational	O
levels	O
.	O

These	O
data	O
suggest	O
that	O
miR-7641	O
might	O
be	O
related	O
with	O
differentiation	O
of	O
human	O
endothelial	O
cells	O
.	O

Phenolic	B
constituents	O
from	O
Parakmeria	O
yunnanensis	O
and	O
their	O
anti	O
-	O
HIV-1	O
activity	O
.	O

Three	O
new	O
phenolic	B
compounds	O
,	O
yunnanensins	B
A	I
-	I
C	I
(	O
1	O
-	O
3	O
)	O
,	O
together	O
with	O
fourteen	O
known	O
ones	O
(	O
4	O
-	O
17	O
)	O
,	O
were	O
isolated	O
from	O
the	O
leaves	O
and	O
stems	O
of	O
Parakmeria	O
yunnanensis	O
.	O

The	O
structures	O
of	O
new	O
compounds	O
were	O
established	O
on	O
the	O
basis	O
of	O
extensive	O
spectroscopic	O
analyses	O
.	O

Several	O
compounds	O
showed	O
weak	O
anti	O
-	O
HIV-1	O
activity	O
.	O

Selective	O
inhibition	O
of	O
an	O
apicoplastic	O
aminoacyl	B
-	O
tRNA	O
synthetase	O
from	O
Plasmodium	O
falciparum	O
.	O

The	O
resistance	O
of	O
malaria	O
parasites	O
to	O
available	O
drugs	O
continues	O
to	O
grow	O
,	O
and	O
this	O
makes	O
the	O
need	O
for	O
new	O
antimalarial	O
therapies	O
pressing	O
.	O

Aminoacyl	B
-	O
tRNA	O
synthetases	O
(	O
ARSs	O
)	O
are	O
essential	O
enzymes	O
and	O
well	O
-	O
established	O
antibacterial	O
targets	O
and	O
so	O
constitute	O
a	O
promising	O
set	O
of	O
targets	O
for	O
the	O
development	O
of	O
new	O
antimalarials	O
.	O

Despite	O
their	O
potential	O
as	O
drug	O
targets	O
,	O
apicoplastic	O
ARSs	O
remain	O
unexplored	O
.	O

We	O
have	O
characterized	O
the	O
lysylation	O
system	O
of	O
Plasmodium	O
falciparum	O
,	O
and	O
designed	O
,	O
synthesized	O
,	O
and	O
tested	O
a	O
set	O
of	O
inhibitors	O
based	O
on	O
the	O
structure	O
of	O
the	O
natural	O
substrate	O
intermediate	O
:	O
lysyl	B
-	I
adenylate	I
.	O

Here	O
we	O
demonstrate	O
that	O
selective	O
inhibition	O
of	O
apicoplastic	O
ARSs	O
is	O
feasible	O
and	O
describe	O
new	O
compounds	O
that	O
that	O
specifically	O
inhibit	O
Plasmodium	O
apicoplastic	O
lysyl	B
-	O
tRNA	O
synthetase	O
and	O
show	O
antimalarial	O
activities	O
in	O
the	O
micromolar	O
range	O
.	O

Characterization	O
,	O
pharmacokinetics	O
,	O
tissue	O
distribution	O
and	O
antitumor	O
activity	O
of	O
honokiol	B
submicron	O
lipid	O
emulsions	O
in	O
tumor	O
-	O
burdened	O
mice	O
.	O

Honokiol	B
,	O
isolated	O
from	O
the	O
Chinese	O
traditional	O
herb	O
magnolia	O
,	O
is	O
a	O
poorly	O
water	O
-	O
soluble	O
component	O
and	O
has	O
been	O
found	O
to	O
have	O
anti	O
-	O
tumor	O
properties	O
.	O

In	O
the	O
current	O
study	O
,	O
honokiol	B
submicron	O
lipid	O
emulsions	O
(	O
HK	O
-	O
SLEs	O
)	O
were	O
prepared	O
by	O
high	O
pressure	O
homogenization	O
technology	O
.	O

After	O
HK	O
-	O
SLEs	O
were	O
physically	O
characterized	O
,	O
their	O
pharmacokinetics	O
,	O
tissue	O
distribution	O
and	O
antitumor	O
activity	O
after	O
intravenous	O
(	O
i.v	O
.	O
)	O
administration	O
to	O
tumor	O
-	O
burdened	O
mice	O
were	O
examined	O
,	O
using	O
honokiol	B
solution	O
(	O
HK	O
-	O
SOL	O
)	O
as	O
the	O
control	O
.	O

The	O
results	O
showed	O
that	O
the	O
mean	O
particle	O
size	O
,	O
zeta	O
potential	O
,	O
pH	O
value	O
,	O
osmolality	O
,	O
drug	O
loading	O
(	O
DL	O
)	O
%	O
and	O
entrapment	O
efficiency	O
(	O
EE	O
)	O
%	O
of	O
HK	O
-	O
SLEs	O
were	O
186.6	O
+	O
/-	O

1.7	O
nm	O
,	O
-35.65	O
+	O
/-	O

0.67	O
mV	O
,	O
7.22	O
+	O
/-	O

0.26	O
,	O
298	O
+	O
/-	O

2.3	O
mOsm	O
/	O
L	O
,	O
7.1	O
+	O
/-	O

0.2	O
%	O
and	O
95.5	O
+	O
/-	O

0.2	O
%	O
,	O
respectively	O
.	O

HK	O
-	O
SLEs	O
were	O
stable	O
for	O
at	O
least	O
12	O
months	O
when	O
stored	O
at	O
4	O
+	O
/-	O

2	O
degrees	O
C.	O
The	O
pharmacokinetic	O
results	O
showed	O
that	O
the	O
drug	O
concentration	O
-	O
time	O
curves	O
of	O
HK	O
-	O
SLEs	O
and	O
HK	O
-	O
SOL	O
could	O
both	O
be	O
described	O
by	O
an	O
open	O
two	O
-	O
compartment	O
model	O
.	O

The	O
half	O
-	O
life	O
of	O
HK	O
-	O
SLEs	O
(	O
t1	O
/	O
2	O
(	O
alpha	O
)	O
=	O
8.014	O
min	O
,	O
t1	O
/	O
2	O
(	O
beta	O
)	O
=	O
35.784	O
min	O
)	O
was	O
remarkably	O
prolonged	O
compared	O
to	O
that	O
of	O
HK	O
-	O
SOL	O
(	O
t1	O
/	O
2	O
(	O
alpha	O
)	O
=	O
4.318	O
min	O
,	O
t1	O
/	O
2	O
(	O
beta	O
)	O
=	O
15.522	O
min	O
)	O
.	O

HK	O
-	O
SLEs	O
exhibited	O
a	O
greater	O
AUC	O
and	O
reduced	O
plasma	O
clearance	O
.	O

The	O
tissue	O
distribution	O
results	O
indicated	O
that	O
HK	O
-	O
SLEs	O
have	O
better	O
targeting	O
properties	O
to	O
lung	O
and	O
tumor	O
tissues	O
compared	O
with	O
those	O
of	O
HK	O
-	O
SOL	O
.	O

Both	O
HK	O
-	O
SLEs	O
and	O
HK	O
-	O
SOL	O
tended	O
to	O
accumulate	O
in	O
brain	O
tissue	O
.	O

In	O
vivo	O
study	O
showed	O
that	O
HK	O
-	O
SLEs	O
treatment	O
caused	O
significant	O
inhibition	O
of	O
mouse	O
sarcoma	O
S180	O
tumor	O
growth	O
compared	O
to	O
HK	O
-	O
SOL	O
.	O

These	O
results	O
suggest	O
that	O
HK	O
-	O
SLEs	O
might	O
be	O
an	O
effective	O
parenteral	O
carrier	O
for	O
honokiol	B
delivery	O
in	O
cancer	O
treatment	O
.	O

Rapid	O
method	O
for	O
the	O
separation	O
and	O
recovery	O
of	O
endocrine	O
-	O
disrupting	O
compound	O
bisphenol	B
AP	I
from	O
wastewater	O
.	O

The	O
removal	O
of	O
bisphenol	B
AP	I
(	O
BPAP	B
)	O
by	O
a	O
multiwalled	O
carbon	B
nanotube	O
(	O
MWCNT	O
)	O
was	O
investigated	O
.	O

BPAP	B
,	O
representing	O
typical	O
scenarios	O
for	O
the	O
BPAP	B
-	O
MWCNT	O
interactions	O
,	O
was	O
employed	O
as	O
a	O
probe	O
molecule	O
.	O

It	O
was	O
found	O
that	O
BPAP	B
exhibited	O
great	O
adsorptive	O
affinity	O
to	O
MWCNT	O
,	O
and	O
the	O
adsorption	O
kinetics	O
equilibrium	O
was	O
arrived	O
within	O
4.0	O
min	O
following	O
the	O
pseudo	O
-	O
second	O
-	O
order	O
model	O
.	O

The	O
overall	O
rate	O
process	O
was	O
mainly	O
controlled	O
by	O
the	O
external	O
mass	O
transfer	O
.	O

The	O
hydrogen	B
bond	O
,	O
hydrophobic	O
,	O
and	O
	O
-	O
	O
stacking	O
interactions	O
were	O
dominant	O
factors	O
for	O
the	O
strong	O
adsorption	O
of	O
BPAP	B
,	O
instead	O
of	O
the	O
pH	O
ionic	O
strength	O
and	O
other	O
ionic	O
species	O
in	O
contaminated	O
water	O
.	O

The	O
MWCNT	O
has	O
higher	O
stability	O
within	O
8	O
removal	O
-	O
regeneration	O
recycles	O
,	O
and	O
up	O
to	O
95	O
%	O
of	O
recovery	O
could	O
be	O
obtained	O
by	O
eluting	O
the	O
adsorbed	O
BPAP	B
on	O
MWCNT	O
adsorbent	O
using	O
ethanol	B
/	O
sodium	B
hydrate	I
solution	O
.	O

The	O
results	O
of	O
the	O
experiment	O
on	O
real	O
samples	O
verified	O
the	O
effectiveness	O
for	O
the	O
recovery	O
and	O
removal	O
of	O
BPAP	B
from	O
wastewater	O
samples	O
.	O

Hydrocarbons	B
(	O
jet	O
fuel	O
JP-8	O
)	O
induce	O
epigenetic	O
transgenerational	O
inheritance	O
of	O
obesity	O
,	O
reproductive	O
disease	O
and	O
sperm	O
epimutations	O
.	O

Environmental	O
compounds	O
have	O
been	O
shown	O
to	O
promote	O
epigenetic	O
transgenerational	O
inheritance	O
of	O
disease	O
.	O

The	O
current	O
study	O
was	O
designed	O
to	O
determine	O
if	O
a	O
hydrocarbon	B
mixture	O
involving	O
jet	O
fuel	O
(	O
JP-8	O
)	O
promotes	O
epigenetic	O
transgenerational	O
inheritance	O
of	O
disease	O
.	O

Gestating	O
F0	O
generation	O
female	O
rats	O
were	O
transiently	O
exposed	O
during	O
the	O
fetal	O
gonadal	O
development	O
period	O
.	O

The	O
direct	O
exposure	O
F1	O
generation	O
had	O
an	O
increased	O
incidence	O
of	O
kidney	O
abnormalities	O
in	O
both	O
females	O
and	O
males	O
,	O
prostate	O
and	O
pubertal	O
abnormalities	O
in	O
males	O
,	O
and	O
primordial	O
follicle	O
loss	O
and	O
polycystic	O
ovarian	O
disease	O
in	O
females	O
.	O

The	O
first	O
transgenerational	O
generation	O
is	O
the	O
F3	O
generation	O
,	O
and	O
the	O
jet	O
fuel	O
lineage	O
had	O
an	O
increased	O
incidence	O
of	O
primordial	O
follicle	O
loss	O
and	O
polycystic	O
ovarian	O
disease	O
in	O
females	O
,	O
and	O
obesity	O
in	O
both	O
females	O
and	O
males	O
.	O

Analysis	O
of	O
the	O
jet	O
fuel	O
lineage	O
F3	O
generation	O
sperm	O
epigenome	O
identified	O
33	O
differential	O
DNA	O
methylation	O
regions	O
,	O
termed	O
epimutations	O
.	O

Observations	O
demonstrate	O
hydrocarbons	B
can	O
promote	O
epigenetic	O
transgenerational	O
inheritance	O
of	O
disease	O
and	O
sperm	O
epimutations	O
,	O
potential	O
biomarkers	O
for	O
ancestral	O
exposures	O
.	O

The	O
n	O
-	O
SET	O
domain	O
of	O
Set1	O
regulates	O
H2B	O
ubiquitylation	O
-	O
dependent	O
H3K4	O
methylation	O
.	O

Past	O
studies	O
have	O
documented	O
a	O
crosstalk	O
between	O
H2B	O
ubiquitylation	O
(	O
H2Bub	O
)	O
and	O
H3K4	O
methylation	O
,	O
but	O
little	O
(	O
if	O
any	O
)	O
direct	O
evidence	O
exists	O
explaining	O
the	O
mechanism	O
underlying	O
H2Bub	O
-	O
dependent	O
H3K4	O
methylation	O
on	O
chromatin	O
templates	O
.	O

Here	O
,	O
we	O
took	O
advantage	O
of	O
an	O
in	O
vitro	O
histone	O
methyltransferase	O
assay	O
employing	O
a	O
reconstituted	O
yeast	O
Set1	O
complex	O
(	O
ySet1C	O
)	O
and	O
a	O
recombinant	O
chromatin	O
template	O
containing	O
fully	O
ubiquitylated	O
H2B	O
to	O
gain	O
valuable	O
insights	O
.	O

Combined	O
with	O
genetic	O
analyses	O
,	O
we	O
demonstrate	O
that	O
the	O
n	O
-	O
SET	O
domain	O
within	O
Set1	O
,	O
but	O
not	O
Swd2	O
,	O
is	O
essential	O
for	O
H2Bub	O
-	O
dependent	O
H3K4	O
methylation	O
.	O

Spp1	O
,	O
a	O
homolog	O
of	O
human	O
CFP1	O
,	O
is	O
conditionally	O
involved	O
in	O
this	O
crosstalk	O
.	O

Our	O
findings	O
extend	O
to	O
the	O
human	O
Set1	O
complex	O
,	O
underscoring	O
the	O
conserved	O
nature	O
of	O
this	O
disease	O
-	O
relevant	O
crosstalk	O
pathway	O
.	O

As	O
not	O
all	O
members	O
of	O
the	O
H3K4	O
methyltransferase	O
family	O
contain	O
n	O
-	O
SET	O
domains	O
,	O
our	O
studies	O
draw	O
attention	O
to	O
the	O
n	O
-	O
SET	O
domain	O
as	O
a	O
predictor	O
of	O
an	O
H2B	O
ubiquitylation	O
-	O
sensing	O
mechanism	O
that	O
leads	O
to	O
downstream	O
H3K4	O
methylation	O
.	O

Synthesis	O
and	O
anti	O
-	O
acetylcholinesterase	O
properties	O
of	O
novel	O
-	B
and	I
	I
-	I
substituted	I
alkoxy	I
organophosphonates	I
.	O

Activated	O
organophosphate	B
(	O
OP	O
)	O
insecticides	O
and	O
chemical	O
agents	O
inhibit	O
acetylcholinesterase	O
(	O
AChE	O
)	O
to	O
form	O
OP	O
-	O
AChE	O
adducts	O
.	O

Whereas	O
the	O
structure	O
of	O
the	O
OP	O
correlates	O
with	O
the	O
rate	O
of	O
inhibition	O
,	O
the	O
structure	O
of	O
the	O
OP	O
-	O
AChE	O
adduct	O
influences	O
the	O
rate	O
at	O
which	O
post	O
-	O
inhibitory	O
reactivation	O
or	O
aging	O
phenomena	O
occurs	O
.	O

In	O
this	O
report	O
,	O
we	O
prepared	O
a	O
panel	O
of	O
	B
-	I
substituted	I
ethoxy	I
and	I
	I
-	I
substituted	I
propoxy	I
phosphonoesters	I
of	O
the	O
type	O
p	B
-	I
NO	I
(	I
2	I
)	I
PhO	I
-	I
P	I
(	I
X	I
)	I
(	I
R	I
)	I
[	I
(	I
O	I
(	I
CH	I
(	I
2	I
)	I
)	I
(	I
n	I
)	I
Z	I
]	I
(	O
R	O
=	O
Me	B
,	O
Et	B
;	O
X	O
=	B
O	O
,	O
S	O
;	O
n=2	O
,	O
3	O
;	O
Z	O
=	O
halogen	B
,	O
OTs	B
)	O
and	O
examined	O
the	O
inhibition	O
of	O
three	O
AChEs	O
by	O
select	O
structures	O
in	O
the	O
panel	O
.	O

The	O
	B
-	I
fluoroethoxy	I
methylphosphonate	I
analog	O
(	O
R	O
=	O
Me	B
,	O
Z	O
=	B
F	O
,	O
n=2	O
)	O
was	O
the	O
most	O
potent	O
anti	O
-	O
AChE	O
compound	O
comparable	O
(	O
ki	O
6	O
	O
10	O
(	O
6	O
)	O
M	O
(	O
-1	O
)	O
min	O
(	O
-1	O
)	O
)	O
to	O
paraoxon	B
against	O
EEAChE.	O
Analogs	O
with	O
Z	O
=	O
Br	B
,	O
I	O
,	O
or	O
OTs	B
were	O
weak	O
inhibitors	O
of	O
the	O
AChEs	O
,	O
and	O
methyl	B
phosphonates	I
(	O
R	B
=	I
Me	I
)	O
were	O
more	O
potent	O
than	O
the	O
corresponding	O
ethyl	B
phosphonates	I
(	O
R	B
=	I
Et	I
)	O
.	O

As	O
expected	O
,	O
analogs	O
with	O
a	O
thionate	B
linkage	O
(	O
PS	O
)	O
were	O
poor	O
inhibitors	O
of	O
the	O
AChEs	O
.	O

N	B
-	I
Alkyldeoxynojirimycin	I
derivatives	O
with	O
novel	O
terminal	O
tertiary	B
amide	I
substitution	O
for	O
treatment	O
of	O
bovine	O
viral	O
diarrhea	O
virus	O
(	O
BVDV	O
)	O
,	O
Dengue	O
,	O
and	O
Tacaribe	O
virus	O
infections	O
.	O

Novel	O
N	B
-	I
alkyldeoxynojirimycins	I
(	O
NADNJs	B
)	O
with	O
two	O
hydrophobic	O
groups	O
attached	O
to	O
a	O
nitrogen	O
linker	O
on	O
the	O
alkyl	B
chain	O
were	O
designed	O
.	O

A	O
novel	O
NADNJ	B
containing	O
a	O
terminal	O
tertiary	B
carboxamide	I
moiety	O
was	O
discovered	O
that	O
was	O
a	O
potent	O
inhibitor	O
against	O
BVDV	O
.	O

Further	O
optimization	O
resulted	O
in	O
a	O
structurally	O
more	O
stable	O
lead	O
compound	O
24	O
with	O
a	O
submicromolar	O
EC50	O
against	O
BVDV	O
,	O
Dengue	O
,	O
and	O
Tacaribe	O
;	O
and	O
low	O
cytotoxicity	O
.	O

2-Substituted-2-amino-6-boronohexanoic	B
acids	I
as	O
arginase	O
inhibitors	O
.	O

Substitution	O
at	O
the	O
alpha	O
center	O
of	O
the	O
known	O
human	O
arginase	O
inhibitor	O
2-amino-6-boronohexanoic	B
acid	I
(	O
ABH	B
)	O
is	O
acceptable	O
in	O
the	O
active	O
site	O
pockets	O
of	O
both	O
human	O
arginase	O
I	O
and	O
arginase	O
II	O
.	O

In	O
particular	O
,	O
substituents	O
with	O
a	O
tertiary	B
amine	I
linked	O
via	O
a	O
two	O
carbon	B
chain	O
show	O
improved	O
inhibitory	O
potency	O
for	O
both	O
enzyme	O
isoforms	O
.	O

This	O
potency	O
improvement	O
can	O
be	O
rationalized	O
by	O
X	O
-	O
ray	O
crystallography	O
,	O
which	O
shows	O
a	O
water	O
-	O
mediated	O
contact	O
between	O
the	O
basic	O
nitrogen	B
and	O
the	O
carboxylic	B
acid	I
side	O
chain	O
of	O
Asp200	B
,	O
which	O
is	O
situated	O
at	O
the	O
mouth	O
of	O
the	O
active	O
site	O
pocket	O
of	O
arginase	O
II	O
(	O
Asp181	B
in	O
arginase	O
I	O
)	O
.	O

We	O
believe	O
that	O
this	O
is	O
the	O
first	O
literature	O
report	O
of	O
compounds	O
with	O
improved	O
arginase	O
inhibitory	O
activity	O
,	O
relative	O
to	O
ABH	B
,	O
and	O
represents	O
a	O
promising	O
starting	O
point	O
for	O
further	O
optimization	O
of	O
in	O
vitro	O
potency	O
and	O
the	O
identification	O
of	O
better	O
tool	O
molecules	O
for	O
in	O
vivo	O
investigations	O
of	O
the	O
potential	O
pathophysiological	O
roles	O
of	O
arginases	O
.	O

Tumor	O
delivery	O
of	O
Photofrin	B
	O
by	O
PLL	B
-	I
g	I
-	I
PEG	I
for	O
photodynamic	O
therapy	O
.	O

Photofrin	B
	O
(	O
porfimer	B
sodium	I
)	O
is	O
a	O
photosensitive	O
reagent	O
used	O
for	O
photodynamic	O
therapy	O
(	O
PDT	O
)	O
of	O
tumors	O
and	O
dysplasias	O
.	O

Because	O
only	O
photo	O
-	O
irradiated	O
sites	O
are	O
damaged	O
,	O
PDT	O
is	O
less	O
invasive	O
than	O
systemic	O
treatments	O
.	O

However	O
,	O
a	O
photosensitive	O
reaction	O
is	O
a	O
major	O
side	O
effect	O
of	O
systemically	O
delivered	O
Photofrin	B
.	O

To	O
enhance	O
localization	O
of	O
Photofrin	B
to	O
tumors	O
,	O
we	O
have	O
formulated	O
Photofrin	B
with	O
the	O
tumor	O
-	O
localizing	O
graft	O
copolymer	O
poly	B
(	I
ethylene	I
glycol	I
)	I
-grafted	I
poly	I
(	I
l	I
-	I
lysine	I
)	I
,	O
PLL	B
-	I
g	I
-	I
PEG	I
.	O

We	O
demonstrate	O
that	O
Photofrin	B
preferentially	O
interacts	O
with	O
PLL	B
-	I
g	I
-	I
PEG	I
through	O
both	O
ionic	O
and	O
hydrophobic	O
interactions	O
.	O

The	O
serum	O
competitive	O
study	O
showed	O
that	O
the	O
highly	O
PEG	B
-	I
grafted	I
PLL	I
is	O
better	O
for	O
preventing	O
serum	O
binding	O
to	O
the	O
Photofrin	B
/	O
PLL	B
-	I
g	I
-	I
PEG	I
complex	O
.	O

In	O
tumor	O
-	O
bearing	O
mice	O
,	O
formulation	O
of	O
Photofrin	B
with	O
PLL	B
-	I
g	I
-	I
PEG	I
enhanced	O
tumor	O
localization	O
of	O
Photofrin	B
as	O
twice	O
as	O
Photofrin	B
alone	O
and	O
concomitantly	O
suppressed	O
the	O
photosensitivity	O
reaction	O
drastically	O
.	O

Examination	O
of	O
the	O
effect	O
of	O
increasing	O
the	O
number	O
of	O
intra	O
-	O
disulfide	B
amino	I
functional	O
groups	O
on	O
the	O
performance	O
of	O
small	O
molecule	O
cyclic	O
polyamine	B
disulfide	I
vectors	O
.	O

Establishing	O
structure	O
-	O
activity	O
relationships	O
is	O
vital	O
if	O
the	O
efficacy	O
of	O
non	O
-	O
viral	O
vectors	O
is	O
to	O
match	O
that	O
of	O
their	O
viral	O
counter	O
-	O
parts	O
.	O

Recently	O
,	O
we	O
reported	O
on	O
the	O
ability	O
of	O
a	O
series	O
of	O
small	O
molecule	O
,	O
cyclic	B
polyamine	I
disulfides	I
to	O
condense	O
and	O
cage	O
plasmid	O
DNA	O
(	O
pDNA	O
)	O
by	O
a	O
process	O
of	O
thermodynamically	O
controlled	O
template	O
polymerization	O
,	O
leading	O
to	O
a	O
series	O
of	O
corresponding	O
pDNA	O
-	O
polyplex	O
nanoparticles	O
able	O
to	O
mediate	O
high	O
levels	O
of	O
transfection	O
with	O
no	O
associated	O
cytotoxicities	O
.	O

The	O
leading	O
cyclic	B
polyamine	I
disulfide	I
was	O
shown	O
to	O
be	O
the	O
spermine	B
tetra	I
-	I
amine	I
disulfide	I
(	O
TetraN-3,4,3	B
)	O
.	O

Herein	O
we	O
report	O
on	O
the	O
significantly	O
more	O
challenging	O
syntheses	O
of	O
cyclic	B
disulfides	I
with	O
longer	O
polyamine	O
motifs	O
.	O

Two	O
new	O
cyclic	B
polyamine	I
disulfides	I
,	O
based	O
on	O
hexa-	B
and	I
octa	I
-	I
amine	I
inserts	O
,	O
were	O
prepared	O
and	O
their	O
transfection	O
efficacies	O
and	O
cytotoxicities	O
compared	O
with	O
our	O
previously	O
reported	O
cyclic	B
tri-	I
and	I
tetra	I
-	I
amine	I
disulfides	I
.	O

The	O
new	O
cyclic	B
hexa-	I
and	I
octa	I
-	I
amine	I
disulfides	I
prove	O
more	O
effective	O
at	O
transfection	O
in	O
vitro	O
,	O
especially	O
of	O
lung	O
epithelial	O
A549	O
cell	O
line	O
.	O

By	O
contrast	O
,	O
our	O
original	O
cyclic	B
tetra	I
-	I
amine	I
disulfide	I
remains	O
the	O
most	O
efficient	O
agent	O
for	O
the	O
transfection	O
of	O
lung	O
epithelial	O
cells	O
in	O
vivo	O
following	O
intra	O
-	O
nasal	O
administration	O
.	O

Hypothetical	O
mechanistic	O
reasons	O
are	O
presented	O
to	O
explain	O
this	O
outcome	O
.	O

Our	O
data	O
in	O
toto	O
support	O
the	O
concept	O
of	O
shorter	O
cyclic	B
polyamine	I
disulfides	I
as	O
preferred	O
agents	O
for	O
polycation	O
-	O
mediated	O
controlled	O
condensation	O
and	O
functional	O
delivery	O
of	O
pDNA	O
to	O
lung	O
epithelial	O
cells	O
in	O
vivo	O
.	O

DNA	O
delivery	O
via	O
cationic	O
solid	O
lipid	O
nanoparticles	O
(	O
SLNs	O
)	O
.	O

In	O
recent	O
years	O
the	O
use	O
of	O
solid	O
lipid	O
nanoparticles	O
(	O
SLNs	O
)	O
as	O
transport	O
systems	O
for	O
the	O
delivery	O
of	O
drugs	O
and	O
biomolecules	O
has	O
become	O
particularly	O
important	O
.	O

The	O
use	O
of	O
cationic	O
SLNs	O
developed	O
by	O
the	O
technique	O
of	O
microemulsion	O
,	O
which	O
are	O
complexed	O
with	O
DNA	O
in	O
order	O
to	O
study	O
their	O
application	O
as	O
non	O
-	O
viral	O
vectors	O
in	O
gene	O
therapy	O
,	O
is	O
reported	O
.	O

The	O
nanoparticles	O
are	O
characterized	O
by	O
scanning	O
electron	O
microscopy	O
and	O
transmission	O
electron	O
microscopy	O
(	O
SEM	O
and	O
TEM	O
)	O
,	O
atomic	O
force	O
microscopy	O
(	O
AFM	O
)	O
and	O
differential	O
scanning	O
calorimetry	O
(	O
DSC	O
)	O
.	O

Furthermore	O
,	O
the	O
process	O
of	O
lyophilization	O
of	O
the	O
samples	O
and	O
their	O
stability	O
was	O
studied	O
.	O

The	O
nanoparticles	O
obtained	O
presented	O
a	O
particle	O
size	O
of	O
340	O
nm	O
with	O
a	O
positive	O
surface	O
charge	O
of	O
44mV	O
and	O
the	O
capability	O
of	O
forming	O
lipoplexes	O
with	O
DNA	O
plasmids	O
was	O
stated	O
.	O

Nitrosylation	O
:	O
An	O
adverse	O
factor	O
in	O
Uremic	O
Hemolytic	O
Syndrome	O
.	O

Antitoxin	O
effect	O
of	O
Ziziphus	O
mistol	O
Griseb	O
.	O

Toxins	O
of	O
Escherichia	O
coli	O
(	O
STEC	O
)	O
causing	O
Uremic	O
Hemolytic	O
Syndrome	O
(	O
UHS	O
)	O
generate	O
oxidative	O
stress	O
in	O
human	O
blood	O
with	O
more	O
production	O
of	O
nitric	B
oxide	I
(	O
NO	B
)	O
than	O
reactive	O
oxygen	B
species	O
(	O
ROS	O
)	O
.	O

Shiga	O
toxin	O
(	O
Stx	O
)	O
together	O
with	O
the	O
hemolysin	O
(	O
Hly	O
)	O
increased	O
lipid	O
oxidation	O
,	O
as	O
evaluated	O
by	O
malondialdehyde	B
MDA	B
and	O
oxidation	O
of	O
proteins	O
.	O

The	O
addition	O
of	O
Ziziphus	O
mistol	O
Griseb	O
extracts	O
decreased	O
NO	B
,	O
ROS	O
,	O
MDA	B
and	O
simultaneously	O
caused	O
an	O
increase	O
in	O
the	O
degradation	O
of	O
oxidized	O
proteins	O
to	O
advanced	O
oxidation	O
protein	O
products	O
(	O
AOPPs	O
)	O
in	O
controls	O
and	O
samples	O
with	O
toxins	O
.	O

Furthermore	O
,	O
the	O
nitrosylated	O
proteins	O
/	O
AOPP	O
ratio	O
was	O
reduced	O
,	O
due	O
to	O
the	O
increase	O
of	O
AOPP	O
.	O

Z.	O
mistol	O
Griseb	O
extracts	O
exhibited	O
a	O
high	O
proportion	O
of	O
polyphenols	B
and	O
flavonoids	B
,	O
with	O
evident	O
correlation	O
with	O
ferrous	B
reduction	O
antioxidant	O
potential	O
(	O
FRAP	O
)	O
.	O

The	O
plasma	O
of	O
eight	O
children	O
with	O
UHS	O
showed	O
oxidative	O
stress	O
and	O
NO	B
stimulus	O
,	O
comparable	O
to	O
the	O
effect	O
of	O
toxins	O
during	O
the	O
assays	O
in	O
vitro	O
.	O

UHS	O
children	O
presented	O
high	O
levels	O
of	O
nitrosylated	O
proteins	O
respect	O
to	O
control	O
children	O
of	O
similar	O
age	O
.	O

Although	O
the	O
degradation	O
of	O
oxidized	O
proteins	O
to	O
AOPP	O
rose	O
in	O
UHS	O
children	O
,	O
the	O
nitrosylated	O
proteins	O
/	O
AOPP	O
rate	O
increased	O
as	O
a	O
consequence	O
of	O
the	O
elevated	O
nitrosative	O
stress	O
observed	O
in	O
these	O
patients	O
.	O

PK	O
/	O
PD	O
assessment	O
in	O
CNS	O
drug	O
discovery	O
:	O
Prediction	O
of	O
CSF	O
concentration	O
in	O
rodents	O
for	O
P	O
-	O
glycoprotein	O
substrates	O
and	O
application	O
to	O
in	O
vivo	O
potency	O
estimation	O
.	O

The	O
unbound	O
drug	O
concentration	O
in	O
brain	O
parenchyma	O
is	O
considered	O
to	O
be	O
the	O
relevant	O
driver	O
for	O
interaction	O
with	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
biological	O
targets	O
.	O

Drug	O
levels	O
in	O
cerebrospinal	O
fluid	O
(	O
C_CSF	O
)	O
are	O
frequently	O
used	O
surrogates	O
for	O
the	O
unbound	O
concentrations	O
in	O
brain	O
.	O

For	O
drugs	O
actively	O
transported	O
across	O
the	O
blood	O
-	O
brain	O
barrier	O
(	O
BBB	O
)	O
,	O
C_CSF	O
differs	O
from	O
unbound	O
plasma	O
concentration	O
(	O
Cu_p	O
)	O
to	O
an	O
extent	O
that	O
is	O
commonly	O
unknown	O
.	O

In	O
this	O
study	O
,	O
the	O
relationship	O
between	O
CSF	O
-	O
to	O
-	O
unbound	O
plasma	O
drug	O
partitioning	O
in	O
rats	O
and	O
the	O
mouse	O
Pgp	O
(	O
Mdr1a	O
)	O
efflux	O
ratio	O
(	O
ER	O
)	O
obtained	O
from	O
in	O
vitro	O
transcellular	O
studies	O
has	O
been	O
investigated	O
for	O
a	O
set	O
of	O
61	O
CNS	O
compounds	O
exhibiting	O
substantial	O
diversity	O
in	O
chemical	O
structure	O
and	O
physico	O
-	O
chemical	O
properties	O
.	O

In	O
order	O
to	O
understand	O
the	O
in	O
vitro	O
-	O
in	O
vivo	O
extrapolation	O
of	O
Pgp	O
efflux	O
,	O
a	O
mechanistic	O
model	O
was	O
derived	O
relating	O
in	O
vivo	O
CNS	O
distribution	O
kinetics	O
to	O
in	O
vitro	O
active	O
transport	O
.	O

The	O
model	O
was	O
applied	O
to	O
predict	O
C_CSF	O
from	O
Cu_p	O
and	O
ER	O
data	O
for	O
19	O
proprietary	O
Roche	O
CNS	O
drug	O
candidates	O
.	O

The	O
calculated	O
CSF	O
concentrations	O
were	O
correlated	O
with	O
CNS	O
pharmacodynamic	O
responses	O
observed	O
in	O
rodent	O
models	O
.	O

The	O
correlation	O
between	O
in	O
vitro	O
and	O
in	O
vivo	O
potency	O
for	O
different	O
pharmacological	O
endpoints	O
indicated	O
that	O
the	O
predicted	O
C_CSF	O
is	O
a	O
valuable	O
surrogate	O
of	O
the	O
concentration	O
at	O
the	O
target	O
site	O
.	O

Overall	O
,	O
C_CSF	O
proved	O
superior	O
description	O
of	O
PK	O
/	O
PD	O
data	O
than	O
unbound	O
plasma	O
or	O
total	O
brain	O
concentration	O
for	O
Mdr1a	O
substrates	O
.	O

Predicted	O
C_CSF	O
can	O
be	O
used	O
as	O
a	O
default	O
approach	O
to	O
understand	O
the	O
PK	O
/	O
PD	O
relationships	O
in	O
CNS	O
efficacy	O
models	O
and	O
can	O
support	O
the	O
extrapolation	O
of	O
efficacious	O
brain	O
exposure	O
for	O
new	O
drug	O
candidates	O
from	O
rodent	O
to	O
man	O
.	O

Three	O
-	O
month	O
subchronic	O
intramuscular	O
toxicity	O
study	O
of	O
rotigotine	B
-	O
loaded	O
microspheres	O
in	O
SD	O
rats	O
.	O

Continuous	O
dopaminergic	O
stimulation	O
(	O
CDS	O
)	O
has	O
been	O
an	O
important	O
strategy	O
of	O
drug	O
development	O
for	O
the	O
treatment	O
of	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
.	O

Rotigotine	B
is	O
a	O
non	O
-	O
ergoline	B
D3	O
/	O
D2	O
/	O
D1	O
dopamine	B
agonist	O
for	O
treating	O
PD	O
.	O

As	O
a	O
new	O
treatment	O
option	O
for	O
CDS	O
,	O
rotigotine	B
-	O
loaded	O
microspheres	O
(	O
RoMS	O
)	O
,	O
a	O
long	O
-	O
acting	O
sustained	O
-	O
release	O
microspheres	O
for	O
injection	O
with	O
poly	B
(	I
lactide	I
-	I
co	I
-	I
glycolide	I
)	I
as	O
drug	O
carrier	O
,	O
are	O
now	O
being	O
evaluated	O
in	O
clinical	O
trial	O
.	O

In	O
this	O
study	O
,	O
subchronic	O
toxicity	O
of	O
RoMS	O
in	O
SD	O
rats	O
has	O
been	O
characterized	O
via	O
intramuscular	O
administration	O
with	O
RoMS	O
(	O
0	O
-	O
240mg	O
/	O
kg	O
/	O
week	O
)	O
on	O
a	O
consecutive	O
weekly	O
dosing	O
schedule	O
for	O
3months	O
followed	O
by	O
1-month	O
recovery	O
period	O
.	O

The	O
No	O
Observed	O
Adverse	O
Effect	O
Level	O
(	O
NOAEL	O
)	O
was	O
45mg	O
/	O
kg	O
/	O
week	O
.	O

One	O
male	O
at	O
240mg	O
/	O
kg	O
died	O
from	O
an	O
extensive	O
pulmonary	O
embolism	O
.	O

The	O
major	O
toxicological	O
effects	O
were	O
associated	O
with	O
the	O
dopamine	B
agonist	O
-	O
related	O
pharmacodynamic	O
properties	O
of	O
rotigotine	B
(	O
e.g.	O
hyperactivity	O
and	O
stereotype	O
,	O
enlarged	O
ovary	O
,	O
sporadic	O
gastric	O
mucous	O
membrane	O
lesions	O
,	O
decreased	O
body	O
weight	O
,	O
food	O
consumption	O
and	O
prolactin	O
,	O
and	O
increased	O
mononuclear	O
cell	O
,	O
neutrophil	O
granulocyte	O
,	O
aspartate	B
aminotransferase	O
and	O
alanine	B
aminotransferase	O
)	O
and	O
foreign	O
body	O
removal	O
reaction	O
induced	O
by	O
poly	B
(	I
lactide	I
-	I
co	I
-	I
glycolide	I
)	I
and	O
carboxymethycellulose	O
sodium	B
.	O

At	O
the	O
end	O
of	O
recovery	O
period	O
,	O
all	O
findings	O
had	O
recovered	O
to	O
a	O
normal	O
level	O
or	O
to	O
a	O
certain	O
degree	O
except	O
foreign	O
body	O
reaction	O
at	O
injection	O
sites	O
.	O

RoMS	O
has	O
exhibited	O
high	O
safety	O
on	O
SD	O
rats	O
.	O

A	O
cell	O
-	O
penetrating	O
peptide	O
suppresses	O
the	O
hypoxia	O
inducible	O
factor-1	O
function	O
by	O
binding	O
to	O
the	O
helix	O
-	O
loop	O
-	O
helix	O
domain	O
of	O
the	O
aryl	B
hydrocarbon	I
receptor	O
nuclear	O
translocator	O
.	O

The	O
heterodimeric	O
hypoxia	O
inducible	O
factor-1	O
(	O
HIF-1	O
)	O
complex	O
is	O
composed	O
of	O
the	O
hypoxia	O
inducible	O
factor-1	O
alpha	O
(	O
HIF-1	O
)	O
and	O
the	O
aryl	B
hydrocarbon	I
receptor	O
nuclear	O
translocator	O
(	O
ARNT	O
)	O
.	O

Activation	O
of	O
the	O
HIF-1	O
function	O
is	O
essential	O
for	O
tumor	O
growth	O
and	O
metastasis	O
.	O

We	O
previously	O
showed	O
that	O
transfection	O
of	O
a	O
plasmid	O
containing	O
an	O
ARNT	O
-	O
interacting	O
peptide	O
(	O
Ainp1	O
)	O
cDNA	O
suppresses	O
the	O
HIF-1	O
signaling	O
in	O
Hep3B	O
cells	O
.	O

Here	O
we	O
generated	O
TAT	O
fusion	O
of	O
the	O
Ainp1	O
peptide	O
(	O
6His	B
-	O
TAT	O
-	O
Ainp1	O
)	O
to	O
determine	O
whether	O
and	O
how	O
the	O
Ainp1	O
peptide	O
suppresses	O
the	O
HIF-1	O
function	O
.	O

The	O
bacterially	O
expressed	O
6His	B
-	O
TAT	O
-	O
Ainp1	O
was	O
purified	O
under	O
denatured	O
condition	O
and	O
then	O
refolded	O
by	O
limited	O
dialysis	O
.	O

The	O
refolded	O
6His	B
-	O
TAT	O
-	O
Ainp1	O
interacts	O
with	O
the	O
helix	O
-	O
loop	O
-	O
helix	O
(	O
HLH	O
)	O
domain	O
of	O
ARNT	O
in	O
a	O
similar	O
fashion	O
as	O
the	O
native	O
6His	B
-	O
Ainp1	O
.	O

6His	B
-	O
TAT	O
-	O
Ainp1	O
colocalizes	O
with	O
ARNT	O
in	O
the	O
nucleus	O
of	O
HeLa	O
and	O
Hep3B	O
cells	O
after	O
protein	O
transduction	O
.	O

The	O
transduced	O
protein	O
reaches	O
the	O
maximum	O
intracellular	O
levels	O
within	O
2h	O
while	O
remains	O
detectable	O
up	O
to	O
96h	O
in	O
HeLa	O
cells	O
.	O

At	O
2M	O
concentration	O
,	O
6His	B
-	O
TAT	O
-	O
Ainp1	O
is	O
not	O
cytotoxic	O
in	O
HeLa	O
cells	O
but	O
suppresses	O
the	O
cobalt	B
chloride	I
-	O
activated	O
,	O
hypoxia	O
responsive	O
enhancer	O
-	O
driven	O
luciferase	O
expression	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

In	O
addition	O
,	O
it	O
decreases	O
the	O
cobalt	B
chloride	I
-	O
dependent	O
induction	O
of	O
the	O
HIF-1	O
target	O
genes	O
at	O
both	O
the	O
message	O
(	O
vascular	O
endothelial	O
growth	O
factor	O
and	O
aldolase	O
C	O
)	O
and	O
protein	O
(	O
carbonic	O
anhydrase	O
IX	O
and	O
glucose	B
transporter	O
1	O
)	O
levels	O
.	O

The	O
protein	O
levels	O
of	O
HIF-1	O
and	O
ARNT	O
are	O
not	O
altered	O
in	O
the	O
presence	O
of	O
6His	B
-	O
TAT	O
-	O
Ainp1	O
.	O

In	O
summary	O
,	O
we	O
provided	O
evidence	O
to	O
support	O
that	O
the	O
Ainp1	O
peptide	O
directly	O
suppresses	O
the	O
HIF-1	O
function	O
by	O
interacting	O
with	O
the	O
ARNT	O
HLH	O
domain	O
,	O
and	O
in	O
turn	O
interfering	O
with	O
the	O
heterodimerization	O
of	O
HIF-1	O
and	O
ARNT	O
.	O

Genotoxicity	O
assessment	O
of	O
vaccine	O
adjuvant	O
squalene	B
.	O

The	O
genotoxic	O
potential	O
of	O
the	O
vaccine	O
adjuvant	O
Squalene	B
was	O
assessed	O
by	O
the	O
chromosomal	O
aberrations	O
(	O
CAs	O
)	O
,	O
sister	O
chromatid	O
exchanges	O
(	O
SCEs	O
)	O
and	O
micronucleus	O
(	O
MNs	O
)	O
tests	O
in	O
human	O
lymphocytes	O
and	O
comet	O
assay	O
in	O
both	O
human	O
and	O
rat	O
lymphocytes	O
.	O

Five	O
different	O
concentrations	O
of	O
squalene	B
(	O
1250	O
-	O
20,000g	O
/	O
ml	O
for	O
human	O
lymphocytes	O
and	O
0.07	O
-	O
1.12mg	O
/	O
kg	O
for	O
rat	O
lymphocytes	O
)	O
were	O
studied	O
.	O

Squalene	B
did	O
not	O
affect	O
the	O
CAs	O
and	O
MN	O
frequency	O
,	O
in	O
all	O
treatments	O
in	O
vitro	O
.	O

A	O
significant	O
increase	O
in	O
SCEs	O
was	O
observed	O
in	O
almost	O
all	O
concentrations	O
at	O
24h	O
treatment	O
.	O

Squalene	B
did	O
not	O
affect	O
significantly	O
the	O
comet	O
tail	O
length	O
(	O
CTL	O
)	O
(	O
except	O
2500g	O
/	O
ml	O
)	O
and	O
comet	O
tail	O
intensity	O
(	O
CTI	O
)	O
at	O
all	O
treatments	O
in	O
vitro	O
.	O

In	O
rats	O
,	O
squalene	B
significantly	O
increased	O
and	O
decreased	O
CTL	O
and	O
CTI	O
in	O
some	O
doses	O
.	O

Although	O
there	O
are	O
increasing	O
and	O
reduction	O
in	O
the	O
effect	O
,	O
squalene	B
can	O
not	O
be	O
regarded	O
as	O
genotoxic	O
in	O
human	O
lymphocytes	O
.	O

However	O
,	O
further	O
in	O
vivo	O
studies	O
are	O
required	O
to	O
be	O
sure	O
on	O
the	O
effect	O
.	O

Phenotypic	O
analysis	O
of	O
ovine	O
antigen	O
presenting	O
cells	O
loaded	O
with	O
nanoparticles	O
migrating	O
from	O
the	O
site	O
of	O
vaccination	O
.	O

Virus	O
-	O
sized	O
particulate	O
adjuvants	O
such	O
as	O
ISCOMs	O
,	O
polystyrene	B
nanoparticles	O
and	O
virus	O
-	O
like	O
particles	O
have	O
been	O
shown	O
to	O
target	O
dendritic	O
cells	O
,	O
resulting	O
in	O
the	O
activation	O
of	O
T	O
and	O
B	O
cells	O
in	O
vivo	O
.	O

Using	O
an	O
ovine	O
pseudo	O
-	O
afferent	O
lymph	O
cannulation	O
model	O
to	O
capture	O
APC	O
that	O
traffic	O
from	O
the	O
site	O
of	O
injection	O
to	O
the	O
local	O
lymph	O
node	O
,	O
we	O
show	O
that	O
40	O
-	O
50	O
nm	O
nanoparticles	O
are	O
taken	O
up	O
at	O
the	O
site	O
of	O
injection	O
by	O
dendritic	O
cells	O
(	O
DCs	O
)	O
migrating	O
to	O
the	O
draining	O
lymph	O
node	O
.	O

These	O
DCs	O
can	O
express	O
CD11c	O
,	O
CD1b	O
,	O
CD5	O
,	O
MHC	O
class	O
II	O
and	O
CD8	O
.	O

Nanoparticles	O
transported	O
by	O
DCs	O
migrating	O
from	O
the	O
site	O
of	O
injection	O
to	O
the	O
local	O
lymph	O
node	O
therefore	O
needs	O
to	O
be	O
considered	O
as	O
a	O
new	O
mechanism	O
underlying	O
the	O
immunogenicity	O
of	O
virus	O
-	O
sized	O
vaccine	O
delivery	O
systems	O
.	O

Toxic	O
and	O
genotoxic	O
effects	O
of	O
Roundup	B
on	O
tadpoles	O
of	O
the	O
Indian	O
skittering	O
frog	O
(	O
Euflictis	O
cyanophlyctis	O
)	O
in	O
the	O
presence	O
and	O
absence	O
of	O
predator	O
stress	O
.	O

Glyphosate	B
,	O
a	O
post	O
emergent	O
herbicide	O
,	O
has	O
become	O
the	O
backbone	O
of	O
no	O
-	O
till	O
agriculture	O
and	O
is	O
considered	O
safe	O
for	O
animals	O
.	O

However	O
,	O
the	O
impact	O
of	O
glyphosate	B
on	O
non	O
-	O
target	O
organisms	O
,	O
especially	O
on	O
amphibians	O
,	O
is	O
the	O
subject	O
of	O
major	O
concern	O
and	O
debate	O
in	O
recent	O
times	O
.	O

We	O
examined	O
the	O
toxic	O
and	O
genotoxic	O
effects	O
of	O
Roundup	B
,	O
a	O
commercial	O
formulation	O
of	O
glyphosate	B
,	O
in	O
the	O
tadpoles	O
of	O
the	O
Indian	O
skittering	O
frog	O
(	O
Euflictis	O
cyanophlyctis	O
)	O
.	O

Roundup	B
at	O
different	O
concentrations	O
(	O
0	O
,	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
and	O
8	O
mg	O
acid	O
equivalent	O
(	O
ae	O
)	O
/	O
L	O
)	O
,	O
tested	O
in	O
a	O
2	O
	O
6	O
factorial	O
design	O
in	O
the	O
presence	O
and	O
absence	O
of	O
predator	O
stress	O
,	O
induced	O
concentration	O
-	O
dependent	O
lethality	O
in	O
tadpoles	O
.	O

The	O
96-h	O
LC50	O
for	O
Roundup	B
in	O
the	O
absence	O
and	O
presence	O
of	O
predator	O
stress	O
were	O
3.76mgae	O
/	O
L	O
and	O
3.39mgae	O
/	O
L	O
,	O
respectively	O
.	O

The	O
10-day	O
LC50	O
value	O
for	O
Roundup	B
was	O
significantly	O
lower	O
,	O
2.12mgae	O
/	O
L	O
and	O
1.91mgae	O
/	O
L	O
in	O
the	O
absence	O
and	O
presence	O
of	O
predator	O
stress	O
,	O
respectively	O
.	O

Lower	O
concentrations	O
of	O
Roundup	B
(	O
1	O
,	O
2	O
and	O
3mgae	O
/	O
L	O
)	O
induced	O
the	O
formation	O
of	O
micronuclei	O
(	O
MN	O
)	O
in	O
the	O
erythrocytes	O
of	O
tadpoles	O
at	O
24-h	O
(	O
F3,56=10.286	O
,	O
p<0.001	O
)	O
,	O
48-h	O
(	O
F3,56=48.255	O
,	O
p<0.001	O
)	O
,	O
72-h	O
(	O
F3,56=118.933	O
,	O
p<0.001	O
)	O
and	O
96-h	O
(	O
F3,56=85.414	O
,	O
p<0.001	O
)	O
in	O
a	O
concentration	O
-	O
dependent	O
manner	O
.	O

Presence	O
of	O
predator	O
stress	O
apparently	O
increased	O
the	O
toxicity	O
and	O
genotoxicity	O
of	O
Roundup	B
;	O
but	O
these	O
effects	O
were	O
not	O
statistically	O
significant	O
.	O

These	O
findings	O
suggest	O
that	O
Roundup	B
at	O
environmentally	O
relevant	O
concentrations	O
has	O
lethal	O
and	O
genotoxic	O
impact	O
on	O
E.	O
cyanophlyctis	O
;	O
which	O
may	O
have	O
long	O
-	O
term	O
fitness	O
consequence	O
to	O
the	O
species	O
.	O

Insula	O
's	O
functional	O
connectivity	O
with	O
ventromedial	O
prefrontal	O
cortex	O
mediates	O
the	O
impact	O
of	O
trait	O
alexithymia	O
on	O
state	O
tobacco	O
craving	O
.	O

RATIONALE	O
:	O
Alexithymia	O
is	O
a	O
personality	O
trait	O
characterized	O
by	O
difficulty	O
indentifying	O
and	O
describing	O
subjective	O
emotional	O
experiences	O
.	O

Decreased	O
aptitude	O
in	O
the	O
perception	O
,	O
evaluation	O
,	O
and	O
communication	O
of	O
affectively	O
laden	O
mental	O
states	O
has	O
been	O
associated	O
with	O
reduced	O
emotion	O
regulation	O
,	O
more	O
severe	O
drug	O
craving	O
in	O
addicts	O
,	O
and	O
structural	O
/	O
functional	O
alterations	O
in	O
insula	O
and	O
anterior	O
cingulate	O
cortex	O
(	O
ACC	O
)	O
.	O

The	O
insula	O
and	O
ACC	O
represent	O
sites	O
of	O
convergence	O
between	O
the	O
putative	O
neural	O
substrates	O
of	O
alexithymia	O
and	O
those	O
perpetuating	O
cigarette	O
smoking	O
.	O

OBJECTIVES	O
:	O
We	O
examined	O
the	O
interrelations	O
between	O
alexithymia	O
,	O
tobacco	O
craving	O
,	O
and	O
insula	O
/	O
ACC	O
neurocircuitry	O
using	O
resting	O
-	O
state	O
functional	O
connectivity	O
(	O
rsFC	O
)	O
.	O

METHODS	O
:	O
Overnight	O
-	O
deprived	O
smokers	O
(	O
n	O
=	O
24	O
)	O
and	O
nonsmokers	O
(	O
n	O
=	O
20	O
)	O
completed	O
six	O
neuroimaging	O
assessments	O
on	O
different	O
days	O
both	O
in	O
the	O
absence	O
of	O
,	O
and	O
following	O
,	O
varenicline	B
and/or	O
nicotine	B
administration	O
.	O

In	O
this	O
secondary	O
analysis	O
of	O
data	O
from	O
a	O
larger	O
study	O
,	O
we	O
assessed	O
trait	O
alexithymia	O
and	O
state	O
tobacco	O
craving	O
using	O
self	O
-	O
reports	O
and	O
examined	O
the	O
rsFC	O
of	O
bilateral	O
insular	O
subregions	O
(	O
anterior	O
,	O
middle	O
,	O
posterior	O
)	O
and	O
dorsal	O
ACC	O
.	O

RESULTS	O
:	O
Higher	O
alexithymia	O
in	O
smokers	O
predicted	O
reduced	O
rsFC	O
strength	O
between	O
the	O
right	O
anterior	O
insula	O
(	O
aI	O
)	O
and	O
ventromedial	O
prefrontal	O
cortex	O
(	O
vmPFC	O
)	O
.	O

Higher	O
alexithymia	O
also	O
predicted	O
more	O
severe	O
tobacco	O
craving	O
during	O
nicotine	B
withdrawal	O
.	O

Critically	O
,	O
the	O
identified	O
aI	O
-	O
vmPFC	O
circuit	O
fully	O
mediated	O
this	O
alexithymia	O
-	O
craving	O
relation	O
.	O

That	O
is	O
,	O
elevated	O
alexithymia	O
predicted	O
decreased	O
aI	O
-	O
vmPFC	O
rsFC	O
and	O
,	O
in	O
turn	O
,	O
decreased	O
aI	O
-	O
vmPFC	O
rsFC	O
predicted	O
increased	O
craving	O
during	O
withdrawal	O
.	O

A	O
moderated	O
mediation	O
analysis	O
indicated	O
that	O
this	O
aI	O
-	O
vmPFC	O
mediational	O
effect	O
was	O
not	O
observed	O
following	O
drug	O
administration	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
suggest	O
that	O
a	O
weakened	O
right	O
aI	O
-	O
vmPFC	O
functional	O
circuit	O
confers	O
increased	O
liability	O
for	O
tobacco	O
craving	O
during	O
smoking	O
abstinence	O
.	O

Individual	O
differences	O
in	O
alexithymia	O
and/or	O
aI	O
-	O
vmPFC	O
functional	O
coupling	O
may	O
be	O
relevant	O
factors	O
for	O
smoking	O
cessation	O
success	O
.	O

Acute	O
behavioural	O
effects	O
of	O
bupropion	B
and	O
naltrexone	B
,	O
alone	O
and	O
in	O
combination	O
,	O
in	O
non	O
-	O
deprived	O
male	O
rats	O
presented	O
with	O
palatable	O
mash	O
.	O

RATIONALE	O
:	O
In	O
appetite	O
research	O
,	O
drugs	O
frequently	O
progress	O
to	O
clinical	O
trials	O
on	O
the	O
basis	O
of	O
outcome	O
(	O
reduced	O
food	O
intake	O
/	O
body	O
weight	O
gain	O
)	O
with	O
insufficient	O
attention	O
to	O
process	O
(	O
behavioural	O
analysis	O
)	O
.	O

Although	O
bupropion	B
and	O
naltrexone	B
(	O
alone	O
and	O
in	O
combination	O
)	O
reduce	O
food	O
consumption	O
in	O
rodents	O
and	O
humans	O
,	O
their	O
effects	O
on	O
behaviour	O
during	O
feeding	O
tests	O
have	O
not	O
been	O
thoroughly	O
investigated	O
.	O

OBJECTIVES	O
:	O
This	O
study	O
aimed	O
to	O
assess	O
the	O
behavioural	O
specificity	O
of	O
anorectic	O
responses	O
to	O
bupropion	B
,	O
naltrexone	B
and	O
their	O
combination	O
.	O

METHODS	O
:	O
Video	O
analysis	O
was	O
employed	O
to	O
characterise	O
the	O
behavioural	O
effects	O
of	O
acute	O
systemic	O
treatment	O
with	O
bupropion	B
(	O
10.0	O
-	O
40.0	O
mg	O
/	O
kg	O
)	O
,	O
naltrexone	B
(	O
0.1	O
-	O
3.0	O
mg	O
/	O
kg	O
)	O
and	O
combined	O
bupropion	B
(	O
20	O
mg	O
/	O
kg	O
)	O
plus	O
naltrexone	B
(	O
0.1	O
-	O
1.0	O
mg	O
/	O
kg	O
)	O
in	O
non	O
-	O
deprived	O
male	O
rats	O
exposed	O
for	O
1	O
h	O
to	O
palatable	O
mash	O
.	O

Particular	O
attention	O
was	O
paid	O
to	O
the	O
behavioural	O
satiety	O
sequence	O
(	O
BSS	O
)	O
.	O

RESULTS	O
:	O
In	O
experiment	O
1	O
,	O
the	O
anorectic	O
response	O
to	O
40	O
mg	O
/	O
kg	O
bupropion	B
was	O
associated	O
with	O
significant	O
psychomotor	O
stimulation	O
and	O
a	O
complete	O
disruption	O
of	O
the	O
BSS	O
.	O

In	O
experiment	O
2	O
,	O
the	O
anorectic	O
response	O
to	O
3	O
mg	O
/	O
kg	O
naltrexone	B
was	O
associated	O
with	O
an	O
accelerated	O
but	O
otherwise	O
normal	O
BSS	O
.	O

In	O
experiment	O
3	O
,	O
the	O
co	O
-	O
administration	O
of	O
20	O
mg	O
/	O
kg	O
bupropion	B
and	O
naltrexone	B
(	O
0.1	O
and	O
1.0	O
mg	O
/	O
kg	O
)	O
not	O
only	O
produced	O
an	O
additive	O
anorectic	O
profile	O
(	O
including	O
a	O
reduced	O
rate	O
of	O
eating	O
)	O
,	O
but	O
the	O
addition	O
of	O
the	O
opioid	O
receptor	O
antagonist	O
also	O
concurrently	O
attenuated	O
the	O
psychomotor	O
stimulant	O
response	O
to	O
the	O
atypical	O
antidepressant	O
.	O

CONCLUSIONS	O
:	O
Low	O
-	O
dose	O
co	O
-	O
treatment	O
with	O
naltrexone	B
and	O
bupropion	B
produces	O
a	O
stronger	O
suppression	O
of	O
appetite	O
than	O
that	O
seen	O
with	O
either	O
agent	O
alone	O
and	O
has	O
the	O
additional	O
advantage	O
of	O
reducing	O
some	O
of	O
the	O
unwanted	O
effects	O
of	O
bupropion	B
.	O

Genotoxic	O
,	O
antigenotoxic	O
and	O
antioxidant	O
properties	O
of	O
methanol	B
extracts	O
obtained	O
from	O
Peltigera	O
horizontalis	O
and	O
Peltigera	O
praetextata	O
.	O

Now	O
-	O
a	O
-	O
days	O
,	O
there	O
is	O
a	O
big	O
need	O
to	O
reduce	O
genotoxic	O
effects	O
of	O
mutagenic	O
and	O
carcinogenic	O
agents	O
in	O
environment	O
,	O
which	O
are	O
increased	O
by	O
the	O
technological	O
development	O
.	O

Lichens	O
produce	O
a	O
wide	O
variety	O
of	O
unique	O
metabolites	O
due	O
to	O
being	O
in	O
various	O
extreme	O
areas	O
and	O
being	O
symbiotic	O
organisms	O
of	O
fungi	O
and	O
algae	O
.	O

Therefore	O
,	O
this	O
study	O
was	O
planned	O
to	O
search	O
new	O
sources	O
having	O
antimutagenic	O
activity	O
by	O
researching	O
two	O
different	O
lichen	O
species	O
and	O
to	O
determine	O
whether	O
their	O
usage	O
is	O
safe	O
.	O

With	O
this	O
respect	O
,	O
the	O
mutagenic	O
and	O
antimutagenic	O
properties	O
of	O
methanol	B
extracts	O
of	O
the	O
lichens	O
were	O
determined	O
by	O
the	O
bacterial	O
reverse	O
mutation	O
and	O
sister	O
chromatid	O
exchange	O
assays	O
.	O

Furthermore	O
,	O
the	O
malondialdehyde	B
level	O
,	O
superoxide	B
dismutase	O
,	O
glutathione	B
and	O
glutathione	B
peroxidase	O
activities	O
against	O
aflatoxin	B
B1	I
were	O
determined	O
for	O
understanding	O
the	O
ways	O
in	O
which	O
the	O
lichens	O
showed	O
their	O
genotoxic	O
properties	O
.	O

Rapid	O
cortical	O
bone	O
loss	O
in	O
patients	O
with	O
chronic	O
kidney	O
disease	O
.	O

Chronic	O
kidney	O
disease	O
(	O
CKD	O
)	O
patients	O
may	O
have	O
high	O
rates	O
of	O
bone	O
loss	O
and	O
fractures	O
,	O
but	O
microarchitectural	O
and	O
biochemical	O
mechanisms	O
of	O
bone	O
loss	O
in	O
CKD	O
patients	O
have	O
not	O
been	O
fully	O
described	O
.	O

In	O
this	O
longitudinal	O
study	O
of	O
53	O
patients	O
with	O
CKD	O
Stages	O
2	O
-	O
5D	O
,	O
we	O
used	O
dual	O
energy	O
X	O
-	O
ray	O
absorptiometry	O
(	O
DXA	O
)	O
,	O
high	O
resolution	O
peripheral	O
quantitative	O
computed	O
tomography	O
(	O
HRpQCT	O
)	O
and	O
biochemical	O
markers	O
of	O
bone	O
metabolism	O
to	O
elucidate	O
effects	O
of	O
CKD	O
on	O
the	O
skeleton	O
.	O

Median	O
follow	O
-	O
up	O
was	O
1.5	O
years	O
(	O
Range	O
0.9	O
to	O
4.3	O
years	O
)	O
;	O
bone	O
changes	O
were	O
annualized	O
and	O
compared	O
to	O
baseline	O
.	O

By	O
DXA	O
,	O
there	O
were	O
significant	O
declines	O
in	O
areal	O
bone	O
mineral	O
density	O
(	O
BMD	O
)	O
of	O
the	O
total	O
hip	O
and	O
ultradistal	O
radius	O
:	O
-1.3	O
%	O
(	O
95	O
%	O
CI	O
:	O
-2.1	O
to	O
-0.6	O
)	O
and	O
-2.4	O
%	O
(	O
95	O
%	O
CI	O
:	O
-4.0	O
to	O
-0.9	O
)	O
,	O
respectively	O
.	O

By	O
HRpQCT	O
at	O
the	O
distal	O
radius	O
,	O
there	O
were	O
significant	O
declines	O
in	O
cortical	O
area	O
,	O
density	O
and	O
thickness	O
,	O
and	O
increases	O
in	O
porosity	O
:	O
-2.9	O
%	O
(	O
95	O
%	O
CI	O
-3.7	O
to	O
-2.2	O
)	O
,	O
-1.3	O
%	O
(	O
95	O
%	O
CI	O
-1.6	O
to	O
-0.6	O
)	O
,	O
-2.8	O
%	O
(	O
95	O
%	O
CI	O
-3.6	O
to	O
-1.9	O
)	O
,	O
and	O
+	O
4.2	O
%	O
(	O
95	O
%	O
CI	O
2.0	O
to	O
6.4	O
)	O
respectively	O
.	O

Radius	O
trabecular	O
area	O
increased	O
significantly	O
:	O
+	O
0.4	O
%	O
(	O
95	O
%	O
CI	O
0.2	O
to	O
0.6	O
)	O
,	O
without	O
significant	O
changes	O
in	O
trabecular	O
density	O
or	O
microarchitecture	O
.	O

Elevated	O
time	O
-	O
averaged	O
levels	O
of	O
parathyroid	O
hormone	O
(	O
PTH	O
)	O
and	O
bone	O
turnover	O
markers	O
predicted	O
cortical	O
deterioration	O
.	O

Higher	O
levels	O
of	O
serum	O
25-hydroxyvitamin	B
D	I
predicted	O
decreases	O
in	O
trabecular	O
network	O
heterogeneity	O
.	O

These	O
data	O
suggest	O
that	O
significant	O
cortical	O
loss	O
occurs	O
with	O
CKD	O
,	O
which	O
is	O
mediated	O
by	O
hyperparathyroidism	O
and	O
elevated	O
turnover	O
.	O

Future	O
investigations	O
are	O
required	O
to	O
determine	O
whether	O
these	O
cortical	O
losses	O
can	O
be	O
attenuated	O
by	O
treatments	O
that	O
reduce	O
PTH	O
levels	O
and	O
remodeling	O
rates	O
.	O

	O
2013	O
American	O
Society	O
for	O
Bone	O
and	O
Mineral	O
Research	O
.	O

TRAIL	O
-	O
Based	O
Therapeutic	O
Approaches	O
for	O
the	O
Treatment	O
of	O
Pediatric	O
Malignancies	O
.	O

Tumor	O
necrosis	O
factor	O
-	O
related	O
apoptosis	O
inducing	O
ligand	O
(	O
TRAIL	O
)	O
is	O
a	O
pro	O
-	O
apoptotic	O
ligand	O
that	O
has	O
shown	O
the	O
exquisite	O
ability	O
to	O
trigger	O
extrinsic	O
apoptosis	O
in	O
various	O
types	O
of	O
cancer	O
cells	O
without	O
significant	O
toxicity	O
toward	O
normal	O
cells	O
,	O
when	O
compared	O
to	O
other	O
pro	O
-	O
apoptotic	O
ligands	O
such	O
as	O
tumor	O
necrosis	O
factor	O
(	O
TNF	O
)	O
	O
or	O
Fas	O
ligand	O
.	O

Consequently	O
,	O
TRAIL	O
-	O
based	O
therapies	O
aim	O
to	O
trigger	O
apoptosis	O
in	O
cancer	O
cells	O
by	O
providing	O
the	O
soluble	O
TRAIL	O
or	O
monoclonal	O
antibodies	O
targeting	O
the	O
death	O
receptors	O
TRAIL	O
-	O
R1	O
or	O
TRAIL	O
-	O
R2	O
.	O

In	O
this	O
review	O
,	O
we	O
start	O
by	O
highlighting	O
the	O
relevance	O
of	O
the	O
tumor	O
microenvironment	O
in	O
tumor	O
development	O
and	O
elimination	O
.	O

We	O
then	O
address	O
conventional	O
and	O
targeted	O
therapeutic	O
approaches	O
for	O
cancer	O
treatment	O
,	O
highlighting	O
the	O
mechanisms	O
involved	O
or	O
targeted	O
.	O

We	O
describe	O
the	O
extrinsic	O
and	O
intrinsic	O
pro	O
-	O
apoptotic	O
pathways	O
of	O
TRAIL	O
,	O
together	O
with	O
the	O
evidences	O
for	O
its	O
pro	O
-	O
survival	O
signaling	O
,	O
and	O
with	O
the	O
relevance	O
of	O
these	O
pathways	O
in	O
therapy	O
.	O

Possible	O
mechanisms	O
of	O
resistance	O
to	O
TRAIL	O
-	O
induced	O
apoptosis	O
are	O
highlighted	O
(	O
i.e.	O
c	O
-	O
FLIP	O
,	O
Bcl-2	O
,	O
IAPs	O
,	O
p53	O
,	O
NF	O
-	O
	O
B	O
)	O
and	O
the	O
rationale	O
for	O
the	O
combined	O
administration	O
of	O
TRAIL	O
with	O
drugs	O
targeting	O
these	O
mechanisms	O
is	O
provided	O
.	O

Preclinical	O
data	O
are	O
reported	O
and	O
show	O
encouraging	O
evidences	O
for	O
TRAIL	O
consideration	O
in	O
pediatric	O
malignancies	O
(	O
i.e.	O
,	O
leukemia	O
,	O
lymphomas	O
,	O
neuroblastoma	O
,	O
osteosarcoma	O
,	O
medulloblastoma	O
)	O
.	O

Clinical	O
trials	O
of	O
TRAIL	O
-	O
based	O
therapies	O
on	O
the	O
overall	O
population	O
are	O
in	O
phase	O
I	O
or	O
II	O
,	O
and	O
we	O
put	O
particular	O
focus	O
on	O
the	O
pediatric	O
population	O
,	O
on	O
which	O
only	O
few	O
trials	O
have	O
been	O
conducted	O
or	O
are	O
ongoing	O
.	O

Finally	O
,	O
we	O
consider	O
emerging	O
cellular	O
therapies	O
based	O
on	O
TRAIL	O
,	O
such	O
as	O
TRAIL	O
-	O
engineered	O
mesenchymal	O
stem	O
cells	O
or	O
'	O
inflammatory	O
'	O
dendritic	O
cells	O
.	O

Potential	O
Advantages	O
of	O
Using	O
Synchrotron	O
X	O
-	O
ray	O
Based	O
Techniques	O
in	O
Pediatric	O
Research	O
.	O

Synchrotron	O
radiation	O
(	O
SR	O
)	O
,	O
which	O
combines	O
extremely	O
high	O
intensity	O
,	O
high	O
collimation	O
,	O
tunability	O
,	O
and	O
continuous	O
energy	O
spectrum	O
,	O
allows	O
the	O
development	O
of	O
advanced	O
X	O
-	O
ray	O
based	O
techniques	O
that	O
are	O
becoming	O
a	O
uniquely	O
useful	O
tool	O
in	O
life	O
science	O
research	O
,	O
along	O
providing	O
exciting	O
opportunities	O
in	O
biomedical	O
imaging	O
and	O
radiotherapy	O
.	O

This	O
review	O
summarize	O
emerging	O
techniques	O
and	O
their	O
potential	O
to	O
greatly	O
enhance	O
the	O
exploration	O
of	O
dynamical	O
biological	O
process	O
occurring	O
across	O
various	O
spatial	O
and	O
temporal	O
regimes	O
,	O
from	O
whole	O
body	O
physiology	O
,	O
down	O
to	O
the	O
location	O
of	O
individual	O
chemical	O
species	O
within	O
single	O
cells	O
.	O

In	O
recent	O
years	O
pediatric	O
research	O
and	O
clinic	O
practice	O
have	O
started	O
to	O
profit	O
from	O
these	O
new	O
opportunities	O
,	O
particularly	O
by	O
extending	O
the	O
diagnostic	O
and	O
therapeutic	O
capabilities	O
of	O
these	O
X	O
-	O
ray	O
based	O
techniques	O
.	O

In	O
diagnosis	O
,	O
technical	O
advances	O
in	O
DEI	O
and	O
KES	O
imaging	O
modalities	O
have	O
been	O
demonstrated	O
as	O
particularly	O
valuable	O
for	O
children	O
and	O
women	O
since	O
SR	O
allows	O
dose	O
minimization	O
,	O
with	O
significant	O
reductions	O
compared	O
to	O
conventional	O
approaches	O
.	O

However	O
,	O
the	O
greatest	O
expectations	O
are	O
in	O
the	O
field	O
of	O
SR	O
based	O
radiotherapy	O
,	O
increasingly	O
studies	O
are	O
demonstrating	O
SR	O
radiotherapy	O
provides	O
improved	O
chances	O
of	O
recovery	O
;	O
this	O
is	O
especially	O
the	O
case	O
for	O
pediatric	O
patients	O
.	O

In	O
addition	O
,	O
we	O
report	O
on	O
the	O
applicability	O
of	O
advanced	O
X	O
-	O
ray	O
microscopy	O
techniques	O
that	O
offer	O
exceptional	O
spatial	O
and	O
quantitative	O
resolution	O
in	O
elemental	O
detection	O
.	O

These	O
techniques	O
,	O
which	O
are	O
useful	O
for	O
in	O
vitro	O
studies	O
,	O
will	O
be	O
particularly	O
advantageous	O
where	O
investigators	O
seek	O
deeper	O
understanding	O
of	O
diseases	O
where	O
mismetabolism	O
of	O
metals	O
,	O
either	O
physiological	O
important	O
(	O
i.e.	O
Cu	B
,	O
Zn	B
)	O
or	O
outright	O
toxic	O
(	O
i.e.	O
Pb	B
)	O
,	O
underlies	O
pathogenesis	O
.	O

Pharmacogenomic	O
approaches	O
for	O
tailored	O
anti	O
-	O
leukemic	O
therapy	O
in	O
children	O
.	O

Several	O
lympholytic	O
and	O
cytotoxic	O
agents	O
are	O
used	O
in	O
acute	O
lymphoblastic	O
leukemia	O
(	O
ALL	O
)	O
polychemotherapy	O
.	O

Genetic	O
variants	O
for	O
cellular	O
components	O
involved	O
in	O
the	O
pharmacokinetics	O
and	O
pharmacodynamics	O
of	O
these	O
drugs	O
can	O
influence	O
the	O
pharmacological	O
response	O
,	O
and	O
molecular	O
characterization	O
of	O
these	O
genetic	O
variants	O
could	O
be	O
helpful	O
for	O
the	O
comprehension	O
of	O
the	O
mechanisms	O
of	O
resistance	O
or	O
increased	O
sensitivity	O
.	O

The	O
purpose	O
of	O
this	O
review	O
is	O
to	O
carry	O
out	O
an	O
update	O
of	O
recent	O
publications	O
on	O
genes	O
that	O
might	O
influence	O
ALL	O
treatment	O
in	O
terms	O
of	O
outcome	O
and/or	O
toxicity	O
and	O
to	O
underlie	O
the	O
role	O
of	O
genetic	O
variants	O
,	O
particularly	O
single	O
nucleotide	O
polymorphisms	O
(	O
SNP	O
)	O
,	O
in	O
predicting	O
clinical	O
response	O
,	O
with	O
particular	O
reference	O
to	O
the	O
current	O
protocol	O
for	O
ALL	O
therapy	O
used	O
in	O
Italy	O
,	O
AIEOP	O
-	O
BFM	O
ALL	O
2009	O
.	O

Potential	O
use	O
of	O
polymeric	O
nanoparticles	O
for	O
drug	O
delivery	O
across	O
the	O
blood	O
-	O
brain	O
barrier	O
.	O

Nanomedicine	O
is	O
certainly	O
one	O
of	O
the	O
scientific	O
and	O
technological	O
challenges	O
of	O
the	O
coming	O
years	O
.	O

In	O
particular	O
,	O
biodegradable	O
nanoparticles	O
formulated	O
from	O
poly	B
(	I
D	I
,	I
L	I
-	I
lactide	I
-	I
co	I
-	I
glycolide	I
)	I
(	O
PLGA	B
)	O
have	O
been	O
extensively	O
investigated	O
for	O
sustained	O
and	O
targeted	O
delivery	O
of	O
different	O
agents	O
,	O
including	O
recombinant	O
proteins	O
,	O
plasmid	O
DNA	O
,	O
and	O
low	O
molecular	O
weight	O
compounds	O
.	O

PLGA	B
NPs	O
present	O
some	O
very	O
attractive	O
properties	O
such	O
as	O
biodegradability	O
and	O
biocompatibility	O
,	O
protection	O
of	O
drug	O
from	O
degradation	O
,	O
possibility	O
of	O
sustained	O
release	O
,	O
and	O
the	O
possibility	O
to	O
modify	O
surface	O
properties	O
to	O
target	O
nanoparticles	O
to	O
specific	O
organs	O
or	O
cells	O
.	O

Moreover	O
,	O
PLGA	B
NPs	O
have	O
received	O
the	O
FDA	O
and	O
European	O
Medicine	O
Agency	O
approval	O
in	O
drug	O
delivery	O
systems	O
for	O
parenteral	O
administration	O
,	O
thus	O
reducing	O
the	O
time	O
for	O
human	O
clinical	O
applications	O
.	O

This	O
review	O
in	O
particular	O
deals	O
on	O
surface	O
modification	O
of	O
PLGA	B
NPs	O
and	O
their	O
possibility	O
of	O
clinical	O
applications	O
,	O
including	O
treatment	O
for	O
brain	O
pathologies	O
such	O
as	O
brain	O
tumors	O
and	O
Lysosomal	O
Storage	O
Disorders	O
with	O
neurological	O
involvement	O
.	O

Since	O
a	O
great	O
number	O
of	O
pharmacologically	O
active	O
molecules	O
are	O
not	O
able	O
to	O
cross	O
the	O
Blood	O
-	O
Brain	O
Barrier	O
(	O
BBB	O
)	O
and	O
reach	O
the	O
Central	O
Nervous	O
System	O
(	O
CNS	O
)	O
,	O
new	O
brain	O
targeted	O
polymeric	O
PLGA	B
NPs	O
modified	O
with	O
glycopeptides	O
(	O
g7-	O
NPs	O
)	O
have	O
been	O
recently	O
produced	O
.	O

In	O
this	O
review	O
several	O
in	O
vivo	O
biodistribution	O
studies	O
and	O
pharmacological	O
proof	O
-	O
of	O
evidence	O
of	O
brain	O
delivery	O
of	O
model	O
drugs	O
are	O
reported	O
,	O
demonstrating	O
the	O
ability	O
of	O
g7-NPs	O
to	O
create	O
BBB	O
interaction	O
and	O
trigger	O
an	O
efficacious	O
BBB	O
crossing	O
.	O

Moreover	O
,	O
another	O
relevant	O
development	O
of	O
NPs	O
surface	O
engineering	O
was	O
achieved	O
by	O
conjugating	O
to	O
the	O
surface	O
of	O
g7-NPs	O
,	O
some	O
specific	O
and	O
selective	O
antibodies	O
to	O
drive	O
NPs	O
directly	O
to	O
a	O
specific	O
cell	O
type	O
once	O
inside	O
the	O
CNS	O
parenchyma	O
.	O

In	O
vitro	O
and	O
in	O
vivo	O
evaluation	O
of	O
superparamagnetic	O
iron	B
oxide	I
nanoparticles	O
coated	O
by	O
bisphosphonates	B
:	O
The	O
effects	O
of	O
electrical	O
charge	O
and	O
molecule	O
length	O
.	O

Physicochemical	O
coating	O
properties	O
are	O
often	O
considered	O
to	O
be	O
determining	O
factors	O
for	O
in	O
vivo	O
characteristics	O
of	O
superparamagnetic	O
iron	B
oxide	I
nanoparticles	O
,	O
used	O
as	O
contrast	O
agent	O
in	O
Magnetic	O
Resonance	O
Imaging	O
(	O
MRI	O
)	O
.	O

To	O
investigate	O
the	O
electrical	O
charge	O
(	O
modified	O
by	O
zero	O
,	O
one	O
or	O
two	O
ammonium	B
groups	O
)	O
and	O
the	O
molecule	O
length	O
(	O
3	O
,	O
5	O
or	O
7	O
methylene	B
chains	O
)	O
effects	O
of	O
bisphosphonate	B
-	O
type	O
coatings	O
,	O
we	O
assessed	O
the	O
complement	O
activation	O
,	O
in	O
vivo	O
plasma	O
and	O
tissue	O
relaxation	O
time	O
alterations	O
of	O
intravenously	O
injected	O
small	O
iron	B
oxide	I
nanoparticles	O
(	O
<	O
25	O
nm	O
)	O
on	O
male	O
healthy	O
Wistar	O
rats	O
.	O

The	O
presence	O
of	O
ammonium	B
groups	O
induces	O
a	O
weak	O
activation	O
of	O
the	O
complement	O
whatever	O
the	O
size	O
and	O
the	O
concentration	O
of	O
particles	O
,	O
whereas	O
hydroxyethylenebisphosphonate	B
(	O
HEBP	B
)	O
-coated	O
particles	O
are	O
poor	O
complement	O
activators	O
only	O
at	O
the	O
lowest	O
concentration	O
.	O

In	O
vivo	O
,	O
HEBP	B
-	O
coated	O
nanoparticles	O
have	O
the	O
greatest	O
prolonged	O
relaxation	O
time	O
effects	O
,	O
despite	O
their	O
higher	O
negative	O
electrical	O
charge	O
,	O
contrary	O
to	O
two	O
ammonium	B
bearing	O
coatings	O
.	O

No	O
significant	O
differences	O
were	O
observed	O
between	O
mono	B
-	I
ammonium	I
molecular	O
coatings	O
.	O

Exploring	O
the	O
genetic	O
basis	O
of	O
chronic	O
periodontitis	O
:	O
a	O
genome	O
-	O
wide	O
association	O
study	O
.	O

Chronic	O
periodontitis	O
(	O
CP	O
)	O
is	O
a	O
common	O
oral	O
disease	O
that	O
confers	O
substantial	O
systemic	O
inflammatory	O
and	O
microbial	O
burden	O
and	O
is	O
a	O
major	O
cause	O
of	O
tooth	O
loss	O
.	O

Here	O
,	O
we	O
present	O
the	O
results	O
of	O
a	O
genome	O
-	O
wide	O
association	O
study	O
of	O
CP	O
that	O
was	O
carried	O
out	O
in	O
a	O
cohort	O
of	O
4504	O
European	O
Americans	O
(	O
EA	O
)	O
participating	O
in	O
the	O
Atherosclerosis	O
Risk	O
in	O
Communities	O
(	O
ARIC	O
)	O
Study	O
(	O
mean	O
age-62	O
years	O
,	O
moderate	O
CP-43	O
%	O
and	O
severe	O
CP-17	O
%	O
)	O
.	O

We	O
detected	O
no	O
genome	O
-	O
wide	O
significant	O
association	O
signals	O
for	O
CP	O
;	O
however	O
,	O
we	O
found	O
suggestive	O
evidence	O
of	O
association	O
(	O
P	O
<	O
5	O
	O
10	O
(	O
-6	O
)	O
)	O
for	O
six	O
loci	O
,	O
including	O
NIN	O
,	O
NPY	O
,	O
WNT5A	O
for	O
severe	O
CP	O
and	O
NCR2	O
,	O
EMR1	O
,	O
10p15	O
for	O
moderate	O
CP	O
.	O

Three	O
of	O
these	O
loci	O
had	O
concordant	O
effect	O
size	O
and	O
direction	O
in	O
an	O
independent	O
sample	O
of	O
656	O
adult	O
EA	O
participants	O
of	O
the	O
Health	O
,	O
Aging	O
,	O
and	O
Body	O
Composition	O
(	O
Health	O
ABC	O
)	O
Study	O
.	O

Meta	O
-	O
analysis	O
pooled	O
estimates	O
were	O
severe	O
CP	O
(	O
n	O
=	O
958	O
versus	O
health	O
:	O
n	O
=	O
1909	O
)	O
-NPY	O
,	O
rs2521634	O
[	O
G	O
]	O
:	O
odds	O
ratio	O
[	O
OR	O
=	O
1.49	O
(	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
=	O
1.28	O
-	O
1.73	O
,	O
P	O
=	O
3.5	O
	O
10	O
(	O
-7	O
)	O
)	O
)	O
]	O
;	O
moderate	O
CP	O
(	O
n	O
=	O
2293	O
)	O
-NCR2	O
,	O
rs7762544	O
[	O
G	O
]	O
:	O
OR	O
=	O
1.40	O
(	O
95	O
%	O
CI	O
=	O
1.24	O
-	O
1.59	O
,	O
P	O
=	O
7.5	O
	O
10	O
(	O
-8	O
)	O
)	O
,	O
EMR1	O
,	O
rs3826782	O
[	O
A	O
]	O
:	O
OR	O
=	O
2.01	O
(	O
95	O
%	O
CI	O
=	O
1.52	O
-	O
2.65	O
,	O
P	O
=	O
8.2	O
	O
10	O
(	O
-7	O
)	O
)	O
.	O

Canonical	O
pathway	O
analysis	O
indicated	O
significant	O
enrichment	O
of	O
nervous	O
system	O
signaling	O
,	O
cellular	O
immune	O
response	O
and	O
cytokine	O
signaling	O
pathways	O
.	O

A	O
significant	O
interaction	O
of	O
NUAK1	O
(	O
rs11112872	O
,	O
interaction	O
P	O
=	O
2.9	O
	O
10	O
(	O
-9	O
)	O
)	O
with	O
smoking	O
in	O
ARIC	O
was	O
not	O
replicated	O
in	O
Health	O
ABC	O
,	O
although	O
estimates	O
of	O
heritable	O
variance	O
in	O
severe	O
CP	O
explained	O
by	O
all	O
single	O
nucleotide	O
polymorphisms	O
increased	O
from	O
18	O
to	O
52	O
%	O
with	O
the	O
inclusion	O
of	O
a	O
genome	O
-	O
wide	O
interaction	O
term	O
with	O
smoking	O
.	O

These	O
genome	O
-	O
wide	O
association	O
results	O
provide	O
information	O
on	O
multiple	O
candidate	O
regions	O
and	O
pathways	O
for	O
interrogation	O
in	O
future	O
genetic	O
studies	O
of	O
CP	O
.	O

Carrier	O
free	O
rapamycin	B
loaded	O
drug	O
eluting	O
stent	O
:	O
In	O
vitro	O
and	O
in	O
vivo	O
evaluation	O
.	O

In	O
the	O
search	O
for	O
improving	O
the	O
performance	O
of	O
drug	O
eluting	O
stent	O
(	O
DES	O
)	O
various	O
developments	O
are	O
in	O
progress	O
worldwide	O
including	O
use	O
of	O
carrier	O
free	O
DES	O
,	O
use	O
of	O
biodegradable	O
polymers	O
,	O
biodegradable	O
stents	O
etc	O
.	O

In	O
this	O
work	O
,	O
carrier	O
free	O
-	O
rapamycin	B
(	O
RM	O
)	O
coated	O
DES	O
has	O
been	O
prepared	O
,	O
and	O
evaluated	O
by	O
in	O
vitro	O
and	O
in	O
vivo	O
procedures	O
necessary	O
for	O
clinical	O
development	O
.	O

In	O
vitro	O
drug	O
release	O
from	O
the	O
developed	O
stents	O
was	O
carried	O
in	O
different	O
release	O
media	O
,	O
normal	O
saline	O
-	O
isopropanol	B
(	O
NS	O
-	O
IP	O
)	O
,	O
phosphate	B
buffer	O
(	O
PB	O
)	O
,	O
phosphate	B
buffer	O
saline	O
(	O
PBS	O
)	O
and	O
in	O
human	O
plasma	O
.	O

Simultaneously	O
,	O
drug	O
released	O
at	O
site	O
of	O
implantation	O
and	O
biocompatibility	O
of	O
developed	O
stents	O
was	O
determined	O
after	O
subcutaneous	O
implantation	O
in	O
the	O
SD	O
rats	O
.	O

Developed	O
stent	O
coating	O
method	O
enables	O
fabrication	O
of	O
controllable	O
and	O
homogeneous	O
crystalline	O
RM	O
coatings	O
on	O
stent	O
scaffolds	O
.	O

Continuous	O
release	O
of	O
RM	O
was	O
observed	O
in	O
different	O
release	O
conditions	O
with	O
different	O
release	O
rate	O
,	O
maximum	O
in	O
NS	O
-	O
IP	O
and	O
least	O
in	O
PB	O
.	O

Similarly	O
,	O
after	O
subcutaneous	O
implantation	O
of	O
these	O
stents	O
,	O
RM	O
was	O
found	O
in	O
surrounding	O
tissues	O
and	O
in	O
implanted	O
stent	O
up	O
to	O
28days	O
.	O

Biocompatibility	O
studies	O
showed	O
no	O
evidence	O
for	O
presence	O
of	O
necrosis	O
,	O
foreign	O
body	O
giant	O
cell	O
reaction	O
or	O
any	O
type	O
of	O
increased	O
severity	O
of	O
inflammatory	O
reaction	O
,	O
proving	O
potential	O
of	O
developed	O
stents	O
for	O
further	O
clinical	O
development	O
.	O

Polyalkylcyanoacrylates	B
as	O
in	O
situ	O
formed	O
diffusion	O
barriers	O
in	O
multimaterial	O
drug	O
carriers	O
.	O

Polymeric	O
hydrogels	O
typically	O
release	O
their	O
drug	O
payload	O
rapidly	O
due	O
to	O
their	O
high	O
water	O
content	O
and	O
the	O
diffusivity	O
for	O
drug	O
molecules	O
.	O

This	O
study	O
proposes	O
a	O
multimaterial	O
system	O
to	O
sustain	O
the	O
release	O
by	O
covering	O
the	O
hydrogel	O
with	O
a	O
poly	B
(	I
alkyl-2-cyanoacrylate	I
)	I
[	O
PACA	B
]	O
-based	O
film	O
,	O
which	O
should	O
be	O
formed	O
by	O
an	O
in	O
situ	O
polymerization	O
on	O
the	O
hydrogel	O
surface	O
initiated	O
upon	O
contact	O
with	O
water	O
.	O

A	O
series	O
of	O
PACA	B
-	O
hydrogel	O
hybrid	O
systems	O
with	O
increasing	O
PACA	B
side	O
chain	O
hydrophobicity	O
was	O
prepared	O
using	O
physically	O
crosslinked	O
alginate	O
films	O
and	O
hydrophilic	O
diclofenac	B
sodium	I
as	O
model	O
hydrogel	O
/	O
drug	O
system	O
.	O

Successful	O
synthesis	O
of	O
PACA	B
at	O
the	O
hydrogel	O
surface	O
was	O
confirmed	O
and	O
the	O
PACA	B
layer	O
was	O
identified	O
to	O
be	O
most	O
homogeneous	O
for	O
poly	B
(	I
n	I
-	I
butyl-2-cyanoacrylate	I
)	I
on	O
both	O
the	O
micro-	O
and	O
nanolevel	O
.	O

At	O
the	O
same	O
time	O
,	O
the	O
diclofenac	B
release	O
from	O
the	O
hybrid	O
systems	O
was	O
substantially	O
sustained	O
from	O
~1day	O
for	O
unmodified	O
hydrogels	O
up	O
to	O
>	O
14days	O
depending	O
on	O
the	O
type	O
of	O
PACA	B
employed	O
as	O
diffusion	O
barrier	O
.	O

Overall	O
,	O
in	O
situ	O
polymerized	O
PACA	B
films	O
on	O
hydrogels	O
may	O
be	O
widely	O
applicable	O
to	O
various	O
hydrogel	O
matrices	O
,	O
different	O
matrix	O
sizes	O
as	O
well	O
as	O
more	O
complex	O
shaped	O
hydrogel	O
carriers	O
.	O

Comparison	O
of	O
the	O
metabolic	O
effects	O
of	O
sustained	O
CCK1	O
receptor	O
activation	O
alone	O
and	O
in	O
combination	O
with	O
upregulated	O
leptin	O
signalling	O
in	O
high	O
-	O
fat	O
-	O
fed	O
mice	O
.	O

AIMS	O
/	O
HYPOTHESIS	O
:	O
Cholecystokinin	O
(	O
CCK	O
)	O
and	O
leptin	O
are	O
important	O
hormones	O
with	O
effects	O
on	O
energy	O
balance	O
.	O

The	O
present	O
study	O
assessed	O
the	O
biological	O
effects	O
of	O
(	O
pGlu	O
-	O
Gln	O
)	O
-CCK-8	O
and	O
[	O
D	O
-	O
Leu-4	O
]	O
-OB3	O
,	O
smaller	O
isoforms	O
of	O
CCK	O
and	O
leptin	O
,	O
respectively	O
.	O

METHODS	O
:	O
The	O
actions	O
and	O
overall	O
therapeutic	O
use	O
of	O
(	O
pGlu	O
-	O
Gln	O
)	O
-CCK-8	O
and	O
[	O
D	O
-	O
Leu-4	O
]	O
-OB3	O
,	O
alone	O
and	O
in	O
combination	O
,	O
were	O
evaluated	O
in	O
normal	O
and	O
high	O
-	O
fat	O
-	O
fed	O
mice	O
.	O

RESULTS	O
:	O
(	O
pGlu	O
-	O
Gln	O
)	O
-CCK-8	O
had	O
prominent	O
(	O
p	O
<	O
0.01	O
to	O
p	O
<	O
0.001	O
)	O
,	O
acute	O
feeding	O
-	O
suppressive	O
effects	O
,	O
which	O
were	O
significantly	O
augmented	O
(	O
p	O
<	O
0.05	O
to	O
p	O
<	O
0.01	O
)	O
by	O
[	O
D	O
-	O
Leu-4	O
]	O
-OB3	O
.	O

In	O
agreement	O
,	O
the	O
acute	O
dose	O
-	O
dependent	O
glucose	B
-	O
lowering	O
and	O
insulinotropic	O
actions	O
of	O
(	O
pGlu	O
-	O
Gln	O
)	O
-CCK-8	O
were	O
significantly	O
enhanced	O
by	O
concurrent	O
administration	O
of	O
[	O
D	O
-	O
Leu-4	O
]	O
-OB3	O
.	O

Twice	O
daily	O
injection	O
of	O
(	O
pGlu	O
-	O
Gln	O
)	O
-CCK-8	O
alone	O
and	O
in	O
combination	O
with	O
[	O
D	O
-	O
Leu-4	O
]	O
-OB3	O
in	O
high	O
-	O
fat	O
-	O
fed	O
mice	O
for	O
18	O
days	O
decreased	O
body	O
weight	O
(	O
p	O
<	O
0.05	O
to	O
p	O
<	O
0.001	O
)	O
,	O
energy	O
intake	O
(	O
p	O
<	O
0.01	O
)	O
,	O
circulating	O
triacylglycerol	B
(	O
p	O
<	O
0.01	O
)	O
,	O
non	O
-	O
fasting	O
glucose	O
(	O
p	O
<	O
0.05	O
to	O
p	O
<	O
0.001	O
)	O
and	O
triacylglycerol	B
deposition	O
in	O
liver	O
and	O
adipose	O
tissue	O
(	O
p	O
<	O
0.001	O
)	O
.	O

All	O
treatment	O
regimens	O
improved	O
glucose	B
tolerance	O
(	O
p	O
<	O
0.05	O
to	O
p	O
<	O
0.001	O
)	O
and	O
insulin	O
sensitivity	O
(	O
p	O
<	O
0.001	O
)	O
.	O

Combined	O
treatment	O
with	O
(	O
pGlu	O
-	O
Gln	O
)	O
-CCK-8	O
and	O
[	O
D	O
-	O
Leu-4	O
]	O
-OB3	O
resulted	O
in	O
significantly	O
lowered	O
plasma	O
insulin	O
levels	O
,	O
normalisation	O
of	O
circulating	O
LDL	O
-	O
cholesterol	B
and	O
decreased	O
triacylglycerol	B
deposition	O
in	O
muscle	O
.	O

These	O
effects	O
were	O
superior	O
to	O
either	O
treatment	O
regimen	O
alone	O
.	O

There	O
were	O
no	O
changes	O
in	O
overall	O
locomotor	O
activity	O
or	O
respiratory	O
exchange	O
ratio	O
,	O
but	O
treatment	O
with	O
(	O
pGlu	O
-	O
Gln	O
)	O
-CCK-8	O
significantly	O
reduced	O
(	O
p	O
<	O
0.001	O
)	O
energy	O
expenditure	O
.	O

CONCLUSIONS	O
/	O
INTERPRETATION	O
:	O
These	O
studies	O
highlight	O
the	O
potential	O
of	O
(	O
pGlu	O
-	O
Gln	O
)	O
-CCK-8	O
alone	O
and	O
in	O
combination	O
with	O
[	O
D	O
-	O
Leu-4	O
]	O
-OB3	O
in	O
the	O
treatment	O
of	O
obesity	O
and	O
diabetes	O
.	O

Protein	O
fibrillation	O
and	O
nanoparticle	O
interactions	O
:	O
opportunities	O
and	O
challenges	O
.	O

Due	O
to	O
their	O
ultra	O
-	O
small	O
size	O
,	O
nanoparticles	O
(	O
NPs	O
)	O
have	O
distinct	O
properties	O
compared	O
with	O
the	O
bulk	O
form	O
of	O
the	O
same	O
materials	O
.	O

These	O
properties	O
are	O
rapidly	O
revolutionizing	O
many	O
areas	O
of	O
medicine	O
and	O
technology	O
.	O

NPs	O
are	O
recognized	O
as	O
promising	O
and	O
powerful	O
tools	O
to	O
fight	O
against	O
the	O
human	O
brain	O
diseases	O
such	O
as	O
multiple	O
sclerosis	O
or	O
Alzheimer	O
's	O
disease	O
.	O

In	O
this	O
review	O
,	O
after	O
an	O
introductory	O
part	O
on	O
the	O
nature	O
of	O
protein	O
fibrillation	O
and	O
the	O
existing	O
approaches	O
for	O
its	O
investigations	O
,	O
the	O
effects	O
of	O
NPs	O
on	O
the	O
fibrillation	O
process	O
have	O
been	O
considered	O
.	O

More	O
specifically	O
,	O
the	O
role	O
of	O
biophysicochemical	O
properties	O
of	O
NPs	O
,	O
which	O
define	O
their	O
affinity	O
for	O
protein	O
monomers	O
,	O
unfolded	O
monomers	O
,	O
oligomers	O
,	O
critical	O
nuclei	O
,	O
and	O
other	O
prefibrillar	O
states	O
,	O
together	O
with	O
their	O
influence	O
on	O
protein	O
fibrillation	O
kinetics	O
has	O
been	O
described	O
in	O
detail	O
.	O

In	O
addition	O
,	O
current	O
and	O
possible	O
-	O
future	O
strategies	O
for	O
controlling	O
the	O
desired	O
effect	O
of	O
NPs	O
and	O
their	O
corresponding	O
effects	O
on	O
the	O
conformational	O
changes	O
of	O
the	O
proteins	O
,	O
which	O
have	O
significant	O
roles	O
in	O
the	O
fibrillation	O
process	O
,	O
have	O
been	O
presented	O
.	O

Tubulin	O
:	O
an	O
example	O
of	O
targeted	O
chemotherapy	O
.	O

Anticancer	O
drugs	O
directed	O
against	O
the	O
microtubule	O
,	O
including	O
taxanes	B
and	O
vinca	B
alkaloids	I
,	O
have	O
been	O
the	O
backbone	O
of	O
many	O
chemotherapy	O
regimes	O
for	O
decades	O
.	O

These	O
drugs	O
have	O
,	O
however	O
,	O
significant	O
limitations	O
,	O
which	O
have	O
prompted	O
the	O
development	O
of	O
novel	O
microtubule	O
targeting	O
agents	O
(	O
MTAs	O
)	O
.	O

This	O
article	O
will	O
discuss	O
MTAs	O
for	O
anticancer	O
therapies	O
and	O
recent	O
debates	O
regarding	O
their	O
mechanisms	O
of	O
action	O
.	O

Furthermore	O
,	O
the	O
limitations	O
of	O
taxanes	B
,	O
including	O
hypersensitivity	O
reactions	O
,	O
neurotoxicity	O
,	O
drug	O
resistance	O
and	O
lack	O
of	O
validated	O
biomarkers	O
to	O
guide	O
therapy	O
will	O
be	O
discussed	O
,	O
all	O
of	O
which	O
have	O
driven	O
the	O
development	O
of	O
novel	O
agents	O
.	O

The	O
mechanisms	O
of	O
action	O
and	O
drug	O
development	O
of	O
new	O
generations	O
of	O
MTAs	O
will	O
also	O
be	O
outlined	O
.	O

Agents	O
demonstrating	O
utility	O
in	O
Phase	O
III	O
clinical	O
trials	O
,	O
including	O
eribulin	B
,	O
ixabepilone	B
,	O
cabazitaxel	B
and	O
trastuzumab	O
-	O
DM1	B
will	O
be	O
highlighted	O
,	O
as	O
well	O
as	O
novel	O
agents	O
currently	O
in	O
development	O
and	O
future	O
directions	O
for	O
MTAs	O
.	O

Hierarchical	O
or	O
not	O
?	O

Effect	O
of	O
the	O
length	O
scale	O
and	O
hierarchy	O
of	O
the	O
surface	O
roughness	O
on	O
omniphobicity	O
of	O
lubricant	O
-	O
infused	O
substrates	O
.	O

Lubricant	O
-	O
infused	O
textured	O
solid	O
substrates	O
are	O
gaining	O
remarkable	O
interest	O
as	O
a	O
new	O
class	O
of	O
omni	O
-	O
repellent	O
nonfouling	O
materials	O
and	O
surface	O
coatings	O
.	O

We	O
investigated	O
the	O
effect	O
of	O
the	O
length	O
scale	O
and	O
hierarchy	O
of	O
the	O
surface	O
topography	O
of	O
the	O
underlying	O
substrates	O
on	O
their	O
ability	O
to	O
retain	O
the	O
lubricant	O
under	O
high	O
shear	O
conditions	O
,	O
which	O
is	O
important	O
for	O
maintaining	O
nonwetting	O
properties	O
under	O
application	O
-	O
relevant	O
conditions	O
.	O

By	O
comparing	O
the	O
lubricant	O
loss	O
,	O
contact	O
angle	O
hysteresis	O
,	O
and	O
sliding	O
angles	O
for	O
water	O
and	O
ethanol	B
droplets	O
on	O
flat	O
,	O
microscale	O
,	O
nanoscale	O
,	O
and	O
hierarchically	O
textured	O
surfaces	O
subjected	O
to	O
various	O
spinning	O
rates	O
(	O
from	O
100	O
to	O
10	O
000	O
rpm	O
)	O
,	O
we	O
show	O
that	O
lubricant	O
-	O
infused	O
textured	O
surfaces	O
with	O
uniform	O
nanofeatures	O
provide	O
the	O
most	O
shear	O
-	O
tolerant	O
liquid	O
-	O
repellent	O
behavior	O
,	O
unlike	O
lotus	O
leaf	O
-	O
inspired	O
superhydrophobic	O
surfaces	O
,	O
which	O
generally	O
favor	O
hierarchical	O
structures	O
for	O
improved	O
pressure	O
stability	O
and	O
low	O
contact	O
angle	O
hysteresis	O
.	O

On	O
the	O
basis	O
of	O
these	O
findings	O
,	O
we	O
present	O
generalized	O
,	O
low	O
-	O
cost	O
,	O
and	O
scalable	O
methods	O
to	O
manufacture	O
uniform	O
or	O
regionally	O
patterned	O
nanotextured	O
coatings	O
on	O
arbitrary	O
materials	O
and	O
complex	O
shapes	O
.	O

After	O
functionalization	O
and	O
lubrication	O
,	O
these	O
coatings	O
show	O
robust	O
,	O
shear	O
-	O
tolerant	O
omniphobic	O
behavior	O
,	O
transparency	O
,	O
and	O
nonfouling	O
properties	O
against	O
highly	O
contaminating	O
media	O
.	O

PF-04859989	B
as	O
a	O
template	O
for	O
structure	O
-	O
based	O
drug	O
design	O
:	O
identification	O
of	O
new	O
pyrazole	B
series	O
of	O
irreversible	O
KAT	O
II	O
inhibitors	O
with	O
improved	O
lipophilic	O
efficiency	O
.	O

The	O
structure	O
-	O
based	O
design	O
,	O
synthesis	O
,	O
and	O
biological	O
evaluation	O
of	O
a	O
new	O
pyrazole	B
series	O
of	O
irreversible	O
KAT	O
II	O
inhibitors	O
are	O
described	O
herein	O
.	O

The	O
modification	O
of	O
the	O
inhibitor	O
scaffold	O
of	O
1	O
and	O
2	O
from	O
a	O
dihydroquinolinone	B
core	O
to	O
a	O
tetrahydropyrazolopyridinone	B
core	O
led	O
to	O
discovery	O
of	O
a	O
new	O
series	O
of	O
potent	O
KAT	O
II	O
inhibitors	O
with	O
excellent	O
physicochemical	O
properties	O
.	O

Compound	O
20	O
is	O
the	O
most	O
potent	O
and	O
lipophilically	O
efficient	O
of	O
these	O
new	O
pyrazole	B
analogs	O
,	O
with	O
a	O
k	O
(	O
inact	O
)	O
/	O
K	O
(	O
i	O
)	O
value	O
of	O
112,000	O
M	O
(	O
-1	O
)	O
s	O
(	O
-1	O
)	O
and	O
lipophilic	O
efficiency	O
(	O
LipE	O
)	O
of	O
8.53	O
.	O

The	O
X	O
-	O
ray	O
crystal	O
structure	O
of	O
20	O
with	O
KAT	O
II	O
demonstrates	O
key	O
features	O
that	O
contribute	O
to	O
this	O
remarkable	O
potency	O
and	O
binding	O
efficiency	O
.	O

Design	O
,	O
synthesis	O
and	O
antithrombotic	O
evaluation	O
of	O
novel	O
dabigatran	B
prodrugs	O
containing	O
methyl	B
ferulate	I
.	O

A	O
novel	O
series	O
of	O
prodrugs	O
containing	O
dabigatran	B
and	O
methyl	B
(	I
E	I
)	I
-3-	I
(	I
4-hydroxy-2-methoxyphenyl	I
)	I
propenoate	I
(	O
methyl	B
ferulate	I
)	O
were	O
synthesized	O
.	O

All	O
of	O
them	O
reveal	O
the	O
effect	O
of	O
thrombin	O
-	O
induced	O
anti	O
-	O
platelet	O
aggregation	O
in	O
vitro	O
.	O

In	O
addition	O
,	O
in	O
vivo	O
experiment	O
shows	O
that	O
one	O
of	O
the	O
target	O
compounds	O
,	O
X-2	O
(	O
ED50=3.7	O
	O
1.0	O
mol	O
/	O
kg	O
)	O
possesses	O
a	O
more	O
potent	O
activity	O
for	O
inhibiting	O
venous	O
thrombosis	O
than	O
that	O
of	O
dabigatran	B
etexilate	I
(	O
ED50=7.8	O
	O
1.5	O
mol	O
/	O
kg	O
)	O
.	O

A	O
new	O
series	O
of	O
N2-substituted-5-	B
(	I
p	I
-	I
toluenesulfonylamino	I
)	I
phthalimide	I
analogues	O
as	O
	O
-	O
glucosidase	O
inhibitors	O
.	O

Several	O
members	O
of	O
a	O
new	O
family	O
of	O
non	O
-	O
sugar	B
-	O
type	O
	O
-	O
glycosidase	O
inhibitors	O
,	O
bearing	O
a	O
5-	B
(	I
p	I
-	I
toluenesulfonylamino	I
)	I
phthalimide	I
moiety	O
and	O
various	O
substituent	O
at	O
the	O
N2	O
position	O
,	O
were	O
synthesized	O
and	O
their	O
activities	O
were	O
investigated	O
.	O

The	O
newly	O
synthesized	O
compounds	O
displayed	O
different	O
inhibition	O
profile	O
towards	O
yeast	O
	O
-	O
glycosidase	O
and	O
rat	O
intestinal	O
	O
-	O
glycosidase	O
.	O

Almost	O
all	O
the	O
compounds	O
had	O
strong	O
inhibitory	O
activities	O
against	O
yeast	O
	O
-	O
glycosidase	O
.	O

Regarding	O
rat	O
intestinal	O
	O
-	O
glycosidase	O
,	O
only	O
analogs	O
with	O
N2-aromatic	O
substituents	O
displayed	O
varying	O
degrees	O
of	O
inhibitory	O
activities	O
on	O
rat	O
intestinal	O
maltase	O
and	O
lactase	O
and	O
nearly	O
all	O
compounds	O
showed	O
no	O
inhibition	O
against	O
rat	O
intestinal	O
	O
-	O
amylase	O
.	O

Structure	O
-	O
activity	O
relationship	O
studies	O
indicated	O
that	O
5-	B
(	I
p	I
-	I
toluenesulfonylamino	I
)	I
phthalimide	I
moiety	O
is	O
a	O
favorable	O
scaffold	O
to	O
exert	O
the	O
	O
-	O
glucosidase	O
inhibitory	O
activity	O
and	O
substituents	O
at	O
the	O
N2	O
position	O
have	O
considerable	O
influence	O
on	O
the	O
efficacy	O
of	O
the	O
inhibition	O
activities	O
.	O

Efficient	O
synthesis	O
and	O
antimicrobial	O
activity	O
of	O
some	O
novel	O
S	B
-	I
	I
-	I
d	I
-	I
glucosides	I
of	O
5-aryl-1,2,4-triazole-3-thiones	B
derivatives	O
.	O

A	O
series	O
of	O
3-S	B
-	I
	I
-	I
d	I
-	I
glucosides-4-arylideneamino-5-aryl-1,2,4-triazoles	I
were	O
rationally	O
designed	O
and	O
synthesized	O
according	O
to	O
the	O
principle	O
of	O
superposition	O
of	O
bioactive	O
substructures	O
by	O
the	O
combination	O
of	O
1,2,4-triazole	B
,	O
Schiff	B
base	I
and	O
glucosides	B
.	O

The	O
structures	O
of	O
the	O
target	O
compounds	O
have	O
been	O
characterized	O
by	O
(	B
1	I
)	I
H	I
NMR	O
,	O
(	B
13	I
)	I
C	I
NMR	O
,	O
IR	O
,	O
MS	O
and	O
HRMS	O
.	O

All	O
the	O
newly	O
synthesized	O
compounds	O
have	O
been	O
evaluated	O
for	O
their	O
antimicrobial	O
activities	O
in	O
vitro	O
against	O
Staphylococcus	O
aureus	O
(	O
ATCC	O
6538	O
)	O
,	O
Escherichia	O
coli	O
(	O
ATCC	O
8099	O
)	O
as	O
well	O
as	O
Monilia	O
albican	O
(	O
ATCC	O
10231	O
)	O
.	O

The	O
bioactive	O
assay	O
showed	O
that	O
most	O
of	O
the	O
tested	O
compounds	O
displayed	O
variable	O
inhibitory	O
effects	O
on	O
the	O
growth	O
of	O
the	O
Gram	O
-	O
positive	O
bacterial	O
strain	O
(	O
Staphylococcus	O
aureus	O
)	O
,	O
Gram	O
-	O
negative	O
bacterial	O
strains	O
(	O
Escherichia	O
coli	O
)	O
and	O
fungal	O
strains	O
(	O
Monilia	O
albican	O
)	O
.	O

All	O
the	O
target	O
compounds	O
exhibited	O
better	O
antifungal	O
activity	O
than	O
antibacterial	O
activity	O
.	O

Especially	O
,	O
compounds	O
6b	O
,	O
6c	O
,	O
6f	O
,	O
6j	O
,	O
6k	O
and	O
6l	O
showed	O
excellent	O
activity	O
against	O
fungus	O
Monilia	O
albican	O
with	O
MIC	O
values	O
of	O
16	O
g	O
/	O
mL.	O

Noradrenergic	O
control	O
of	O
the	O
bed	O
nucleus	O
of	O
the	O
stria	O
terminalis	O
in	O
stress	O
and	O
reward	O
.	O

The	O
bed	O
nucleus	O
of	O
the	O
stria	O
terminalis	O
(	O
BNST	O
)	O
is	O
a	O
group	O
of	O
inter	O
-	O
connected	O
subnuclei	O
that	O
play	O
critical	O
roles	O
in	O
stress	O
-	O
reward	O
interactions	O
.	O

An	O
interesting	O
feature	O
of	O
this	O
brain	O
region	O
is	O
the	O
massive	O
noradrenergic	O
input	O
that	O
it	O
receives	O
.	O

Important	O
roles	O
for	O
norepinephrine	B
in	O
this	O
region	O
have	O
been	O
documented	O
in	O
a	O
number	O
of	O
stress	O
and	O
reward	O
related	O
behaviors	O
.	O

This	O
work	O
has	O
been	O
paralleled	O
over	O
the	O
last	O
several	O
years	O
by	O
efforts	O
to	O
understand	O
the	O
actions	O
of	O
norepinephrine	B
on	O
neuronal	O
function	O
in	O
the	O
region	O
.	O

In	O
this	O
review	O
,	O
we	O
will	O
summarize	O
the	O
current	O
state	O
of	O
these	O
research	O
areas	O
.	O

The	O
two	O
faces	O
of	O
the	O
pharmacological	O
interaction	O
of	O
mGlu2	O
and	O
5-HT2A	O
-	O
Relevance	O
of	O
receptor	O
heterocomplexes	O
and	O
interaction	O
through	O
functional	O
brain	O
pathways	O
.	O

Important	O
functional	O
interactions	O
between	O
the	O
metabotropic	O
glutamate	B
2	O
(	O
mGlu2	O
)	O
and	O
5-hydroxytryptamine2A	O
(	O
5-HT2A	O
)	O
neurotransmitter	O
receptors	O
have	O
been	O
established	O
based	O
on	O
electrophysiological	O
,	O
biochemical	O
and	O
behavioral	O
evidence	O
.	O

Over	O
the	O
last	O
several	O
years	O
,	O
dimerization	O
between	O
5-HT2A	O
and	O
mGlu2	O
receptors	O
has	O
been	O
proposed	O
to	O
account	O
for	O
the	O
functional	O
cross	O
-	O
talk	O
between	O
these	O
two	O
receptors	O
in	O
the	O
prefrontal	O
cortex	O
.	O

The	O
pros	O
and	O
cons	O
for	O
the	O
existence	O
of	O
a	O
heteromeric	O
complex	O
between	O
5-HT2A	O
and	O
mGlu2	O
receptors	O
will	O
be	O
reviewed	O
here	O
.	O

First	O
,	O
the	O
fundamental	O
criteria	O
needing	O
to	O
establish	O
evidence	O
for	O
heteromeric	O
complexes	O
will	O
be	O
reviewed	O
.	O

Then	O
,	O
the	O
in	O
vitro	O
evidence	O
for	O
and	O
against	O
heteromeric	O
complexes	O
between	O
5-HT2A	O
and	O
mGlu2	O
receptors	O
will	O
be	O
discussed	O
in	O
regard	O
to	O
physical	O
and	O
functional	O
interactions	O
.	O

Finally	O
,	O
the	O
data	O
with	O
native	O
in	O
situ	O
mGlu2	O
and	O
5-HT2A	O
receptors	O
will	O
be	O
discussed	O
with	O
respect	O
to	O
whether	O
heteromeric	O
complexes	O
or	O
a	O
simple	O
functional	O
interaction	O
between	O
two	O
distinct	O
GPCRs	O
based	O
on	O
brain	O
network	O
activity	O
is	O
the	O
more	O
simple	O
explanation	O
for	O
a	O
range	O
of	O
in	O
vivo	O
data	O
.	O

Reversal	O
of	O
P	O
-	O
glycoprotein	O
-	O
mediated	O
multidrug	O
resistance	O
is	O
induced	O
by	O
mollugin	B
in	O
MCF-7	O
/	O
adriamycin	O
cells	O
.	O

P	O
-	O
glycoprotein	O
(	O
P	O
-	O
gp	O
)	O
,	O
an	O
important	O
efflux	O
transporter	O
,	O
is	O
encoded	O
by	O
the	O
MDR1	O
class	O
of	O
genes	O
and	O
is	O
a	O
central	O
element	O
of	O
the	O
multidrug	O
resistance	O
(	O
MDR	O
)	O
phenomenon	O
in	O
cancer	O
cells	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
whether	O
mollugin	B
,	O
purified	O
from	O
roots	O
of	O
Rubica	O
cordifolia	O
L.	O
,	O
down	O
-	O
regulated	O
MDR1	O
expression	O
in	O
MCF-7	O
/	O
adriamycin	B
(	O
MCF-7	O
/	O
adr	O
)	O
cells	O
,	O
a	O
human	O
breast	O
multidrug	O
-	O
resistant	O
cancer	O
cell	O
line	O
.	O

Mollugin	B
treatment	O
significantly	O
inhibited	O
MDR1	O
expression	O
by	O
blocking	O
MDR1	O
transcription	O
.	O

Mollugin	B
treatment	O
also	O
significantly	O
increased	O
intracellular	O
accumulation	O
of	O
the	O
fluorescently	O
-	O
tagged	O
P	O
-	O
gp	O
substrate	O
,	O
rhodamine-123	B
.	O

The	O
suppression	O
of	O
MDR1	O
promoter	O
activity	O
and	O
protein	O
expression	O
was	O
mediated	O
through	O
mollugin	B
-	O
induced	O
activation	O
of	O
AMP	B
-	O
activated	O
protein	O
kinase	O
(	O
AMPK	O
)	O
.	O

Furthermore	O
,	O
mollugin	B
inhibited	O
MDR1	O
expression	O
through	O
the	O
suppression	O
of	O
NF	O
-	O
B	O
and	O
CREB	O
activation	O
.	O

Interestingly	O
,	O
mollugin	B
also	O
inhibited	O
COX-2	O
expression	O
.	O

These	O
results	O
suggest	O
that	O
mollugin	B
treatment	O
enhanced	O
suppression	O
of	O
P	O
-	O
gp	O
expression	O
by	O
inhibiting	O
the	O
NF	O
-	O
B	O
signaling	O
pathway	O
and	O
COX-2	O
expression	O
,	O
as	O
well	O
as	O
attenuating	O
CRE	O
transcriptional	O
activity	O
through	O
AMPK	O
activation	O
.	O

Optimizing	O
Small	O
Molecule	O
Inhibitors	O
of	O
Calcium	B
-	O
Dependent	O
Protein	O
Kinase	O
1	O
to	O
Prevent	O
Infection	O
by	O
Toxoplasma	O
gondii	O
.	O

Toxoplasma	O
gondii	O
is	O
sensitive	O
to	O
bulky	O
pyrazolo	B
[	I
3,4-d	I
]	I
pyrimidine	I
(	O
PP	O
)	O
inhibitors	O
due	O
to	O
the	O
presence	O
of	O
a	O
Gly	B
gatekeeper	O
in	O
the	O
essential	O
calcium	B
dependent	O
protein	O
kinase	O
1	O
(	O
CDPK1	O
)	O
.	O

Here	O
we	O
synthesized	O
a	O
number	O
of	O
new	O
derivatives	O
of	O
3-methyl	B
-	I
benzyl	I
-	I
PP	I
(	O
3-MB	B
-	I
PP	I
,	O
or	O
1	O
)	O
.	O

The	O
potency	O
of	O
PP	O
analogues	O
in	O
inhibiting	O
CDPK1	O
enzyme	O
activity	O
in	O
vitro	O
(	O
low	O
nM	O
IC50	O
values	O
)	O
and	O
blocking	O
parasite	O
growth	O
in	O
host	O
cell	O
monolayers	O
in	O
vivo	O
(	O
low	O
M	O
EC50	O
values	O
)	O
were	O
highly	O
correlated	O
and	O
occurred	O
in	O
a	O
CDPK1-specific	O
manner	O
.	O

Chemical	O
modification	O
of	O
the	O
PP	O
scaffold	O
to	O
increase	O
half	O
-	O
life	O
in	O
the	O
presence	O
of	O
microsomes	O
in	O
vitro	O
led	O
to	O
identification	O
of	O
compounds	O
with	O
enhanced	O
stability	O
while	O
retaining	O
activity	O
.	O

Several	O
of	O
these	O
more	O
potent	O
compounds	O
were	O
able	O
to	O
prevent	O
lethal	O
infection	O
with	O
T.	O
gondii	O
in	O
the	O
mouse	O
model	O
.	O

Collectively	O
,	O
the	O
strategies	O
outlined	O
here	O
provide	O
a	O
route	O
for	O
development	O
of	O
more	O
effective	O
compounds	O
for	O
treatment	O
of	O
toxoplasmosis	O
and	O
perhaps	O
related	O
parasitic	O
diseases	O
.	O

A	O
newly	O
synthesized	O
sinapic	B
Acid	I
derivative	O
inhibits	O
endothelial	O
activation	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Inhibition	O
of	O
oxidative	O
stress	O
and	O
inflammation	O
in	O
vascular	O
endothelial	O
cells	O
(	O
ECs	O
)	O
may	O
represent	O
a	O
new	O
therapeutic	O
strategy	O
against	O
endothelial	O
activation	O
.	O

Sinapic	B
acid	I
(	O
SA	O
)	O
,	O
a	O
phenylpropanoid	B
compound	O
,	O
is	O
found	O
in	O
natural	O
herbs	O
and	O
high	O
-	O
bran	O
cereals	O
and	O
has	O
moderate	O
antioxidant	O
activity	O
.	O

We	O
aimed	O
to	O
develop	O
new	O
SA	O
agents	O
with	O
the	O
properties	O
of	O
antioxidation	O
and	O
blocking	O
EC	O
activation	O
for	O
possible	O
therapy	O
of	O
cardiovascular	O
disease	O
.	O

We	O
designed	O
and	O
synthesized	O
10	O
SA	O
derivatives	O
according	O
to	O
their	O
chemical	O
structures	O
.	O

Preliminary	O
screening	O
of	O
the	O
compounds	O
involved	O
scavenging	O
hydroxyl	B
radicals	O
and	O
2,2-diphenyl-1-picrylhydrazyl	B
(	O
DPPH	B
(	I
	I
)	I
)	O
,	O
croton	O
oil	O
-	O
induced	O
ear	O
edema	O
in	O
mice	O
,	O
and	O
analysis	O
of	O
the	O
mRNA	O
expression	O
of	O
adhesion	O
molecules	O
in	O
ECs	O
.	O

1-Acetyl	B
-	I
sinapic	I
acyl-4-	I
(	I
3'-chlorine-	I
)	I
benzylpiperazine	I
(	O
SA9	B
)	O
had	O
the	O
strongest	O
antioxidant	O
and	O
anti	O
-	O
inflammatory	O
activities	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Thus	O
,	O
the	O
effect	O
of	O
SA9	B
was	O
further	O
studied	O
.	O

SA9	B
inhibited	O
tumor	O
necrosis	O
factor	O
	O
-	O
induced	O
upregulation	O
of	O
adhesion	O
molecules	O
in	O
ECs	O
at	O
both	O
mRNA	O
and	O
protein	O
levels	O
,	O
as	O
well	O
as	O
the	O
consequent	O
monocyte	O
adhesion	O
to	O
ECs	O
.	O

In	O
vivo	O
,	O
result	O
of	O
face	O
-	O
to	O
-	O
face	O
immunostaining	O
showed	O
that	O
SA9	O
reduced	O
lipopolysaccharide	O
-	O
induced	O
expression	O
of	O
intercellular	O
adhesion	O
molecule-1	O
in	O
mouse	O
aortic	O
intima	O
.	O

To	O
study	O
the	O
molecular	O
mechanism	O
,	O
results	O
from	O
luciferase	O
assay	O
,	O
nuclear	O
translocation	O
of	O
NF	O
-	O
B	O
,	O
and	O
Western	O
blot	O
indicated	O
that	O
the	O
mechanism	O
of	O
the	O
anti	O
-	O
inflammatory	O
effects	O
of	O
SA9	B
might	O
be	O
suppression	O
of	O
intracellular	O
generation	O
of	O
ROS	O
and	O
inhibition	O
of	O
NF	O
-	O
B	O
activation	O
in	O
ECs	O
.	O

SA9	B
is	O
a	O
prototype	O
of	O
a	O
novel	O
class	O
of	O
antioxidant	O
with	O
anti	O
-	O
inflammatory	O
effects	O
in	O
ECs	O
.	O

It	O
may	O
represent	O
a	O
new	O
therapeutic	O
approach	O
for	O
preventing	O
endothelial	O
activation	O
in	O
cardiovascular	O
disorders	O
.	O

A	O
new	O
anti	O
-	O
inflammatory	O
triterpene	B
saponin	I
isolated	O
from	O
Anabasis	O
setifera	O
.	O

A	O
bio	O
-	O
guided	O
fractionation	O
of	O
Anabasis	O
setifera	O
Moq	O
.	O

(	O
Chenopodiaceae	O
)	O
for	O
anti	O
-	O
inflammatory	O
activity	O
was	O
carried	O
out	O
using	O
carrageenin	O
rat	O
paw	O
edema	O
model	O
in	O
rats	O
.	O

On	O
the	O
basis	O
of	O
percent	O
edema	O
inhibition	O
after	O
3	O
h	O
of	O
carrageenin	O
injection	O
,	O
n	B
-	I
butanol	I
fraction	O
showed	O
promising	O
activity	O
through	O
a	O
significant	O
(	O
p	O
<	O
0.05	O
)	O
decrease	O
in	O
paw	O
volume	O
by	O
85.6	O
%	O
from	O
control	O
using	O
indomethacin	B
as	O
reference	O
standard	O
.	O

Moreover	O
,	O
the	O
n	B
-	I
butanol	I
fraction	O
significantly	O
(	O
p	O
<	O
0.05	O
)	O
decreased	O
PGE2	B
and	O
TNF	O
-	O
	O
in	O
the	O
exudates	O
of	O
rat	O
paw	O
edema	O
.	O

Chemical	O
investigation	O
of	O
n	B
-	I
butanol	I
fraction	O
afforded	O
	B
-	I
amyrin	I
3-O	I
-	I
glucopyranoside	I
(	O
1	O
)	O
,	O
patuletin	B
7-O	I
-	I
glucopyranoside	I
(	O
2	O
)	O
,	O
myricitrin	B
(	O
3	O
)	O
and	O
a	O
new	O
oleanane	B
triterpene	I
saponin	I
derivative	O
(	O
4	O
)	O
,	O
sophradiol	B
3-O	I
-	I
	I
-	I
L-	I
(	I
1	I
)	I
C4-rhamnopyranosyl-	I
(	I
1'''4''	I
)	I
-O	I
-	I
	I
-	I
D-	I
(	I
4	I
)	I
C1-galactopyranosyl	I
(	I
1''6'	I
)	I
-O	I
-	I
	I
-	I
D-	I
(	I
4	I
)	I
C1-glucopyranoside	I
.	O

The	O
structure	O
of	O
the	O
new	O
compound	O
was	O
determined	O
by	O
comprehensive	O
analyses	O
of	O
their	O
1D	O
and	O
2D	O
NMR	O
,	O
mass	O
spectral	O
data	O
and	O
comparison	O
with	O
previously	O
known	O
analogs	O
.	O

Only	O
compound	O
4	O
revealed	O
a	O
significant	O
(	O
p	O
<	O
0.05	O
)	O
inhibition	O
of	O
cyclooxygenase	O
1	O
and	O
2	O
(	O
COX	O
)	O
activities	O
.	O

Bladder	O
Polypoid	O
Cystitis	O
-	O
Derived	O
A20	O
Associates	O
with	O
Tumorigenesis	O
.	O

Bladder	O
chronic	O
inflammation	O
is	O
associated	O
with	O
the	O
pathogenesis	O
of	O
bladder	O
cancer	O
;	O
the	O
underlying	O
mechanism	O
is	O
unclear	O
.	O

The	O
PT53	O
gene	O
is	O
an	O
important	O
anticancer	O
gene	O
in	O
the	O
body	O
,	O
which	O
is	O
suppressed	O
in	O
cancer	O
.	O

The	O
ubiquitin	O
E3	O
ligase	O
A20	O
(	O
A20	O
)	O
plays	O
a	O
role	O
in	O
regulating	O
the	O
activities	O
of	O
epithelial	O
cells	O
.	O

This	O
study	O
was	O
designed	O
to	O
investigate	O
the	O
correlation	O
between	O
A20	O
and	O
the	O
pathogenesis	O
of	O
bladder	O
cancer	O
.	O

The	O
biopsy	O
tissues	O
of	O
human	O
bladder	O
cancer	O
,	O
bladder	O
polypoid	O
cystitis	O
,	O
and	O
chronic	O
inflammation	O
were	O
collected	O
;	O
the	O
levels	O
of	O
A20	O
and	O
p53	O
were	O
analyzed	O
by	O
quantitative	O
real	O
-	O
time	O
RT	O
-	O
PCR	O
,	O
Western	O
blotting	O
,	O
and	O
immune	O
precipitation	O
.	O

HEK293	O
cells	O
were	O
employed	O
to	O
test	O
the	O
role	O
of	O
overexpression	O
of	O
A20	O
in	O
the	O
suppression	O
of	O
the	O
p53	O
gene	O
in	O
the	O
cells	O
.	O

Fifty	O
-	O
six	O
patients	O
with	O
bladder	O
cancer	O
,	O
48	O
patients	O
with	O
bladder	O
polypoid	O
cystitis	O
,	O
and	O
16	O
patients	O
with	O
bladder	O
chronic	O
inflammation	O
were	O
recruited	O
into	O
this	O
study	O
.	O

Human	O
bladder	O
cancer	O
tissue	O
and	O
the	O
polypoid	O
tissue	O
showed	O
high	O
levels	O
of	O
A20	O
,	O
which	O
had	O
a	O
positive	O
correlation	O
with	O
the	O
tumorigenesis	O
in	O
the	O
bladder	O
;	O
12	O
out	O
of	O
46	O
(	O
26.1	O
%	O
)	O
patients	O
with	O
bladder	O
polypoid	O
cystitis	O
were	O
diagnosed	O
as	O
bladder	O
cancer	O
.	O

A20	O
bound	O
to	O
p53	O
to	O
form	O
complexes	O
in	O
bladder	O
cancer	O
tissue	O
and	O
bladder	O
polypoid	O
tissue	O
.	O

The	O
overexpression	O
of	O
A20	O
suppresses	O
p53	O
protein	O
levels	O
in	O
HEK293	O
cells	O
.	O

A20	O
has	O
a	O
positive	O
correlation	O
in	O
the	O
tumorigenesis	O
of	O
bladder	O
polypoid	O
disorders	O
.	O

Presence	O
of	O
hydrophobic	O
groups	O
may	O
modify	O
the	O
specific	O
ion	O
effect	O
in	O
aqueous	O
polyelectrolyte	O
solutions	O
.	O

Enthalpies	O
of	O
dilution	O
of	O
aqueous	O
solutions	O
of	O
aliphatic	B
6,12-	I
and	I
12,12-ionene	I
bromides	I
and	I
fluorides	I
and	O
enthalpies	O
of	O
mixing	O
with	O
low	O
molecular	O
-	O
weight	O
salts	O
,	O
such	O
as	O
sodium	B
fluoride	I
and	I
bromide	I
,	O
are	O
determined	O
.	O

In	O
the	O
second	O
part	O
of	O
the	O
study	O
,	O
the	O
various	O
x	O
,	O
y	O
-	O
ionenes	O
(	O
x	O
,	O
y	O
are	O
numbers	O
of	O
methylene	B
groups	O
between	O
the	O
adjacent	O
charges	O
)	O
with	O
fluoride	B
,	O
bromide	B
,	O
and	O
iodide	B
counterions	O
are	O
mixed	O
with	O
aqueous	O
sodium	B
sulfate	I
solution	O
.	O

The	O
polyelectrolytes	O
examined	O
in	O
this	O
part	O
of	O
the	O
work	O
are	O
3,3-	B
,	I
6,9-	I
,	I
6,12-	I
,	I
and	I
12,12-ionenes	I
.	O

A	O
comparison	O
with	O
theoretical	O
results	O
,	O
based	O
on	O
the	O
Poisson	O
-	O
Boltzmann	O
cell	O
model	O
,	O
is	O
presented	O
.	O

The	O
theory	O
predicts	O
for	O
the	O
enthalpy	O
of	O
dilution	O
to	O
be	O
exothermic	O
and	O
the	O
enthalpy	O
of	O
mixing	O
endothermic	O
,	O
while	O
experiments	O
show	O
that	O
signs	O
of	O
the	O
heat	O
effects	O
depend	O
on	O
the	O
nature	O
of	O
the	O
counterion	O
of	O
the	O
added	O
salt	O
,	O
as	O
also	O
on	O
the	O
hydrophobicity	O
(	O
numbers	O
x	O
,	O
y	O
of	O
methylene	B
groups	O
)	O
of	O
the	O
ionene	O
.	O

We	O
show	O
that	O
the	O
salts	O
when	O
ordered	O
by	O
heat	O
effects	O
produced	O
by	O
mixing	O
of	O
NaF	B
and	O
NaBr	B
with	O
3,3-	B
,	I
6,9-	I
,	I
or	I
6,12-ionene	I
fluorides	I
and	I
bromides	I
follow	O
the	O
opposite	O
ordering	O
than	O
in	O
the	O
case	O
when	O
the	O
same	O
alkali	B
halide	I
salts	O
are	O
mixed	O
with	O
more	O
hydrophobic	O
12,12-ionene	B
salts	O
.	O

The	O
results	O
for	O
the	O
enthalpy	O
of	O
mixing	O
of	O
ionenes	O
under	O
study	O
with	O
Na2SO4	B
follow	O
the	O
same	O
order	O
as	O
obtained	O
for	O
monovalent	O
salts	O
.	O

Do	O
the	O
physical	O
properties	O
of	O
water	O
in	O
mixed	O
reverse	O
micelles	O
follow	O
a	O
synergistic	O
effect	O
:	O
a	O
spectroscopic	O
investigation	O
.	O

In	O
this	O
contribution	O
we	O
have	O
tried	O
to	O
investigate	O
whether	O
the	O
mechanical	O
properties	O
of	O
the	O
reverse	O
micellar	O
(	O
RM	O
)	O
interface	O
dictate	O
the	O
physical	O
properties	O
of	O
entrapped	O
water	O
molecules	O
in	O
the	O
RM	O
waterpool	O
.	O

We	O
choose	O
AOT	B
/	O
Igepal-520	B
/	O
cyclohexane	B
(	O
Cy	O
)	O
mixed	O
RM	O
as	O
a	O
model	O
system	O
which	O
exhibits	O
synergistic	O
water	O
solubilization	O
behavior	O
as	O
a	O
function	O
of	O
interfacial	O
stoichiometry	O
.	O

Such	O
a	O
phenomenon	O
associates	O
systematic	O
modification	O
of	O
the	O
interface	O
curvature	O
.	O

Dynamic	O
light	O
scattering	O
(	O
DLS	O
)	O
studies	O
reveal	O
linear	O
increase	O
in	O
the	O
droplet	O
size	O
and	O
aggregation	O
number	O
of	O
the	O
RMs	O
with	O
increasing	O
XIgepal	O
(	O
mole	O
fraction	O
of	O
Igepal	B
in	O
the	O
surfactant	O
mixture	O
)	O
.	O

FTIR	O
study	O
in	O
the	O
3000	O
-	O
3800	O
cm	O
(	O
-1	O
)	O
region	O
identifies	O
that	O
the	O
relative	O
population	O
of	O
the	O
surface	O
-	O
bound	O
water	O
molecules	O
is	O
higher	O
in	O
AOT	B
RM	O
compared	O
to	O
that	O
in	O
Igepal	B
RM	O
,	O
and	O
in	O
mixed	O
systems	O
it	O
also	O
follows	O
a	O
linear	O
trend	O
with	O
XIgepal	O
.	O

Water	O
relaxation	O
dynamics	O
as	O
probed	O
by	O
time	O
-	O
resolved	O
fluorescence	O
spectroscopy	O
using	O
Coumarin-500	B
also	O
reveals	O
an	O
overall	O
linear	O
trend	O
with	O
no	O
characteristic	O
feature	O
around	O
the	O
solubilization	O
inflation	O
point	O
.	O

Our	O
study	O
clearly	O
identifies	O
that	O
the	O
physical	O
properties	O
of	O
water	O
in	O
RM	O
are	O
mostly	O
governed	O
by	O
the	O
interfacial	O
stoichiometry	O
and	O
water	O
content	O
,	O
and	O
merely	O
bares	O
any	O
dependence	O
on	O
the	O
mechanical	O
properties	O
of	O
the	O
interface	O
.	O

Discovery	O
of	O
(	B
R	I
)	I
-2-amino-6-borono-2-	I
(	I
2-	I
(	I
piperidin-1-yl	I
)	I
ethyl	I
)	I
hexanoic	I
acid	I
and	O
congeners	O
as	O
highly	O
potent	O
inhibitors	O
of	O
human	O
arginases	O
I	O
and	O
II	O
for	O
treatment	O
of	O
myocardial	O
reperfusion	O
injury	O
.	O

Recent	O
efforts	O
to	O
identify	O
treatments	O
for	O
myocardial	O
ischemia	O
reperfusion	O
injury	O
have	O
resulted	O
in	O
the	O
discovery	O
of	O
a	O
novel	O
series	O
of	O
highly	O
potent	O
	B
,	I
	I
-	I
disubstituted	I
amino	I
acid	I
-	O
based	O
arginase	O
inhibitors	O
.	O

The	O
lead	O
candidate	O
,	O
(	B
R	I
)	I
-2-amino-6-borono-2-	I
(	I
2-	I
(	I
piperidin-1-yl	I
)	I
ethyl	I
)	I
hexanoic	I
acid	I
,	O
compound	O
9	O
,	O
inhibits	O
human	O
arginases	O
I	O
and	O
II	O
with	O
IC50s	O
of	O
223	O
and	O
509	O
nM	O
,	O
respectively	O
,	O
and	O
is	O
active	O
in	O
a	O
recombinant	O
cellular	O
assay	O
overexpressing	O
human	O
arginase	O
I	O
(	O
CHO	O
cells	O
)	O
.	O

It	O
is	O
28	O
%	O
orally	O
bioavailable	O
and	O
significantly	O
reduces	O
the	O
infarct	O
size	O
in	O
a	O
rat	O
model	O
of	O
myocardial	O
ischemia	O
/	O
reperfusion	O
injury	O
.	O

Herein	O
,	O
we	O
report	O
the	O
design	O
,	O
synthesis	O
,	O
and	O
structure	O
-	O
activity	O
relationships	O
(	O
SAR	O
)	O
for	O
this	O
novel	O
series	O
of	O
inhibitors	O
along	O
with	O
pharmacokinetic	O
and	O
in	O
vivo	O
efficacy	O
data	O
for	O
compound	O
9	O
and	O
X	O
-	O
ray	O
crystallography	O
data	O
for	O
selected	O
lead	O
compounds	O
cocrystallized	O
with	O
arginases	O
I	O
and	O
II	O
.	O

Engineered	O
Magnetic	O
Shape	O
Anisotropy	O
in	O
BiFeO3-CoFe2O4	B
Self	O
-	O
Assembled	O
Thin	O
Films	O
.	O

We	O
report	O
growth	O
of	O
various	O
phase	O
architectures	O
of	O
self	O
-	O
assembled	O
BiFeO3-CoFe2O4	B
(	O
BFO	B
-	O
CFO	B
)	O
thin	O
films	O
on	O
differently	O
oriented	O
SrTiO3	B
(	O
STO	B
)	O
substrates	O
.	O

CFO	B
forms	O
segregated	O
square	O
,	O
stripe	O
,	O
and	O
triangular	O
nanopillars	O
embedded	O
in	O
a	O
coherent	O
BFO	B
matrix	O
on	O
(	O
001	O
)	O
-	O
,	O
(	O
110	O
)	O
-	O
,	O
and	O
(	O
111	O
)	O
-oriented	O
STO	B
substrates	O
,	O
respectively	O
.	O

Nanostructures	O
with	O
an	O
aspect	O
ratio	O
of	O
up	O
to	O
5:1	O
with	O
a	O
prominent	O
magnetic	O
anisotropy	O
were	O
obtained	O
on	O
both	O
(	O
001	O
)	O
and	O
(	O
110	O
)	O
STO	B
along	O
out	O
-	O
of	O
-	O
plane	O
and	O
in	O
-	O
plane	O
directions	O
.	O

Magnetic	O
easy	O
axis	O
rotation	O
from	O
in	O
-	O
plane	O
to	O
out	O
-	O
of	O
-	O
plane	O
directions	O
was	O
realized	O
through	O
aspect	O
ratio	O
control	O
.	O

An	O
intractable	O
in	O
-	O
plane	O
anisotropy	O
was	O
fixed	O
in	O
CFO	B
on	O
(	O
111	O
)	O
STO	B
due	O
to	O
the	O
triangular	O
shape	O
of	O
the	O
ferromagnetic	O
phase	O
nanopillars	O
.	O

These	O
studies	O
established	O
a	O
detailed	O
relationship	O
of	O
magnetic	O
anisotropy	O
with	O
specific	O
shape	O
and	O
dimensions	O
of	O
ordered	O
magnetic	O
arrays	O
.	O

The	O
results	O
suggest	O
a	O
way	O
to	O
effectively	O
control	O
the	O
magnetic	O
anisotropy	O
in	O
patterned	O
ferromagnetic	O
oxide	B
arrays	O
with	O
tunable	O
shape	O
,	O
aspect	O
ratio	O
,	O
and	O
elastic	O
strain	O
conditions	O
of	O
the	O
nanostructures	O
.	O

Biotransformation	O
of	O
Two	O
	O
-	O
Secretase	O
Inhibitors	O
Including	O
Ring	O
Opening	O
and	O
Contraction	O
of	O
a	O
Pyrimidine	B
Ring	O
.	O

Recently	O
,	O
the	O
discovery	O
of	O
the	O
aminoisoindoles	B
as	O
potent	O
and	O
selective	O
inhibitors	O
of	O
	O
-	O
secretase	O
was	O
reported	O
,	O
including	O
the	O
close	O
structural	O
analogs	O
compound	O
(	B
S	I
)	I
-1-pyridin-4-yl-4-fluoro-1-	I
(	I
3-	I
(	I
pyrimidin-5-yl	I
)	I
phenyl	I
)	I
-1H	I
-	I
isoindol-3-amine	I
[	O
(	O
S	O
)	O
-25	O
]	O
and	O
(	B
S	I
)	I
-1-	I
(	I
2-	I
(	I
difluoromethyl	I
)	I
pyridin-4-yl	I
)	I
-4-fluoro-1-	I
(	I
3-	I
(	I
pyrimidin-5-yl	I
)	I
phenyl	I
)	I
-1H	I
-	I
isoindol-3-amine	I
hemifumarate	I
(	O
AZD3839	B
)	O
,	O
the	O
latter	O
being	O
recently	O
progressed	O
to	O
the	O
clinic	O
.	O

The	O
biotransformation	O
of	O
(	O
S	O
)	O
-25	O
was	O
investigated	O
in	O
vitro	O
and	O
in	O
vivo	O
in	O
rat	O
,	O
rabbit	O
,	O
and	O
human	O
and	O
compared	O
with	O
AZD3839	B
to	O
further	O
understand	O
the	O
metabolic	O
fate	O
of	O
these	O
compounds	O
.	O

In	O
vitro	O
,	O
CYP3A4	O
was	O
the	O
major	O
responsible	O
enzyme	O
and	O
metabolized	O
both	O
compounds	O
to	O
a	O
large	O
extent	O
in	O
the	O
commonly	O
shared	O
pyridine	B
and	O
pyrimidine	B
rings	O
.	O

The	O
main	O
proposed	O
metabolic	O
pathways	O
in	O
various	O
in	O
vitro	O
systems	O
were	O
N	O
-	O
oxidation	O
of	O
the	O
pyridine	B
and/or	O
pyrimidine	B
ring	O
and	O
conversion	O
to	O
4-pyrimidone	B
and	O
pyrimidine-2,4-dione	B
.	O

Both	O
compounds	O
were	O
extensively	O
metabolized	O
,	O
and	O
more	O
than	O
90	O
%	O
was	O
excreted	O
in	O
feces	O
after	O
intravenous	O
administration	O
of	O
radiolabeled	O
compound	O
to	O
the	O
rat	O
.	O

Here	O
,	O
the	O
main	O
pathways	O
were	O
N	O
-	O
oxidation	O
of	O
the	O
pyridine	B
and/or	O
pyrimidine	B
ring	O
and	O
a	O
ring	O
contraction	O
of	O
the	O
pyrimidine	B
ring	O
into	O
an	O
imidazole	B
ring	O
.	O

Ring	O
-	O
contracted	O
metabolites	O
accounted	O
for	O
25	O
%	O
of	O
the	O
total	O
metabolism	O
in	O
the	O
rat	O
for	O
(	O
S	O
)	O
-25	O
,	O
whereas	O
the	O
contribution	O
was	O
much	O
smaller	O
for	O
AZD3839	B
.	O

This	O
metabolic	O
pathway	O
was	O
not	O
foreseen	O
on	O
the	O
basis	O
of	O
the	O
obtained	O
in	O
vitro	O
data	O
.	O

In	O
conclusion	O
,	O
we	O
discovered	O
an	O
unusual	O
metabolic	O
pathway	O
of	O
aryl	B
-	I
pyrimidine	I
-	O
containing	O
compounds	O
by	O
a	O
ring	O
-	O
opening	O
reaction	O
followed	O
by	O
elimination	O
of	O
a	O
carbon	B
atom	O
and	O
a	O
ring	O
closure	O
to	O
form	O
an	O
imidazole	B
ring	O
.	O

Mapping	O
genetic	O
alterations	O
causing	O
chemoresistance	O
in	O
cancer	O
:	O
identifying	O
the	O
roads	O
by	O
tracking	O
the	O
drivers	O
.	O

Although	O
new	O
agents	O
are	O
implemented	O
to	O
cancer	O
therapy	O
,	O
we	O
lack	O
fundamental	O
understandings	O
of	O
the	O
mechanisms	O
of	O
chemoresistance	O
,	O
the	O
main	O
obstacle	O
to	O
cure	O
in	O
cancer	O
.	O

Here	O
we	O
review	O
clinical	O
evidence	O
linking	O
molecular	O
defects	O
to	O
drug	O
resistance	O
across	O
different	O
tumour	O
forms	O
and	O
discuss	O
contemporary	O
experimental	O
evidence	O
exploring	O
these	O
mechanisms	O
.	O

Although	O
evidence	O
,	O
in	O
general	O
,	O
is	O
sparse	O
and	O
fragmentary	O
,	O
merging	O
knowledge	O
links	O
drug	O
resistance	O
,	O
and	O
also	O
sensitivity	O
,	O
to	O
defects	O
in	O
functional	O
pathways	O
having	O
a	O
key	O
role	O
in	O
cell	O
growth	O
arrest	O
or	O
death	O
and	O
DNA	O
repair	O
.	O

As	O
these	O
pathways	O
may	O
act	O
in	O
concert	O
,	O
there	O
is	O
a	O
need	O
to	O
explore	O
multiple	O
mechanisms	O
in	O
parallel	O
.	O

Taking	O
advantage	O
of	O
massive	O
parallel	O
sequencing	O
and	O
other	O
novel	O
high	O
-	O
throughput	O
technologies	O
and	O
base	O
research	O
on	O
biological	O
hypotheses	O
,	O
we	O
now	O
have	O
the	O
possibility	O
to	O
characterize	O
functional	O
defects	O
related	O
to	O
these	O
key	O
pathways	O
and	O
to	O
design	O
a	O
new	O
generation	O
of	O
studies	O
identifying	O
the	O
mechanisms	O
controlling	O
resistance	O
to	O
different	O
treatment	O
regimens	O
in	O
different	O
tumour	O
forms	O
.	O

Oncogene	O
advance	O
online	O
publication	O
,	O
11	O
March	O
2013	O
;	O
doi:10.1038	O
/	O
onc.2013.48	O
.	O

Isoflavone	B
supplementation	O
influenced	O
levels	O
of	O
triglyceride	B
and	O
luteunizing	O
hormone	O
in	O
Korean	O
postmenopausal	O
women	O
.	O

We	O
conducted	O
a	O
double	O
-	O
blind	O
,	O
randomized	O
,	O
placebo	O
-	O
controlled	O
trial	O
to	O
evaluate	O
the	O
effects	O
of	O
soy	O
-	O
derived	O
isoflavone	B
on	O
blood	O
glucose	B
,	O
lipid	O
profiles	O
,	O
and	O
sex	O
hormones	O
related	O
to	O
cardiovascular	O
disease	O
in	O
Korean	O
postmenopausal	O
women	O
.	O

One	O
hundred	O
thirteen	O
postmenopausal	O
women	O
were	O
recruited	O
from	O
the	O
Seoul	O
metropolitan	O
area	O
.	O

To	O
confirm	O
postmenopausal	O
and	O
gynecologic	O
status	O
,	O
the	O
subjects	O
were	O
clinically	O
examined	O
by	O
a	O
gynecologist	O
using	O
ultra	O
sound	O
and	O
X	O
-	O
ray	O
.	O

Finally	O
,	O
85	O
postmenopausal	O
women	O
whose	O
follicle	O
-	O
stimulating	O
hormone	O
(	O
FSH	O
)	O
levels	O
were	O
higher	O
than	O
40	O
IU	O
/	O
ml	O
were	O
enrolled	O
.	O

Subjects	O
received	O
either	O
70	O
mg	O
isoflavone	B
or	O
placebo	O
capsules	O
daily	O
for	O
12	O
weeks	O
.	O

As	O
a	O
result	O
,	O
the	O
values	O
of	O
fasting	O
glucose	B
,	O
insulin	O
and	O
HOMA	O
-	O
IR	O
,	O
as	O
well	O
as	O
those	O
of	O
TC	O
,	O
LDL	O
-	O
C	O
,	O
HDL	O
-	O
C	O
and	O
FFA	O
,	O
were	O
not	O
different	O
between	O
the	O
groups	O
after	O
supplementation	O
.	O

However	O
,	O
triglyceride	B
(	O
TG	O
)	O
levels	O
in	O
the	O
treatment	O
group	O
decreased	O
significantly	O
compared	O
with	O
those	O
of	O
the	O
placebo	O
group	O
(	O
p	O
=	O
0.0215	O
)	O
.	O

The	O
levels	O
of	O
luteinizing	O
hormone	O
(	O
LH	O
)	O
significantly	O
decreased	O
in	O
the	O
treatment	O
group	O
(	O
p	O
=	O
0.027	O
)	O
;	O
however	O
,	O
the	O
levels	O
of	O
FSH	O
,	O
estrone	B
and	O
estradiol	B
were	O
not	O
changed	O
after	O
intervention	O
.	O

In	O
conclusion	O
,	O
isoflavone	B
supplement	O
of	O
70	O
mg	O
/	O
day	O
for	O
12	O
weeks	O
decreased	O
blood	O
levels	O
of	O
TG	O
and	O
LH	O
in	O
Korean	O
postmenopausal	O
women	O
.	O

A	O
novel	O
nontoxic	O
inhibitor	O
of	O
the	O
activation	O
of	O
NADPH	B
oxidase	O
reduces	O
reactive	O
oxygen	B
species	O
production	O
in	O
mouse	O
lung	O
.	O

1-Hexadecyl-3-trifluoroethylglycero	B
-	I
sn-2-phosphomethanol	I
(	O
MJ33	B
)	O
is	O
a	O
fluorinated	O
phospholipid	O
analog	O
that	O
inhibits	O
the	O
phospholipase	O
A2	O
(	O
PLA2	O
)	O
activity	O
of	O
peroxiredoxin	O
6	O
(	O
Prdx6	O
)	O
.	O

Prdx6	O
PLA2	O
activity	O
is	O
required	O
for	O
activation	O
of	O
NADPH	B
oxidase	O
2	O
and	O
subsequent	O
generation	O
of	O
reactive	O
oxygen	B
species	O
(	O
ROS	O
)	O
.	O

In	O
vitro	O
,	O
MJ33	B
inhibited	O
agonist	O
-	O
stimulated	O
production	O
of	O
ROS	O
by	O
the	O
isolated	O
perfused	O
mouse	O
lung	O
,	O
lung	O
microvascular	O
endothelial	O
cells	O
,	O
and	O
polymorphonuclear	O
leukocytes	O
.	O

MJ33	B
(	O
0.02	O
-	O
0.5	O
mol	O
MJ33	B
/	O
kg	O
body	O
weight	O
)	O
in	O
mixed	O
unilamellar	O
liposomes	O
was	O
administered	O
to	O
C57BL	O
/	O
6	O
mice	O
by	O
either	O
intratracheal	O
(	O
i.t	O
.	O
)	O
or	O
i.v	O
.	O

routes	O
.	O

Lung	O
MJ33	B
content	O
,	O
measured	O
by	O
liquid	O
chromatography	O
/	O
mass	O
spectroscopy	O
,	O
showed	O
uptake	O
of	O
67	O
-	O
87	O
%	O
of	O
the	O
injected	O
dose	O
for	O
i.t	O
.	O

and	O
23	O
-	O
42	O
%	O
for	O
i.v	O
.	O

administration	O
at	O
4	O
hours	O
postinjection	O
.	O

PLA2	O
activity	O
of	O
lung	O
homogenates	O
was	O
markedly	O
inhibited	O
(	O
>	O
85	O
%	O
)	O
at	O
4	O
hours	O
postadministration	O
.	O

Both	O
MJ33	B
content	O
and	O
PLA2	O
activity	O
gradually	O
returned	O
to	O
near	O
control	O
levels	O
over	O
the	O
subsequent	O
24	O
-	O
72	O
hours	O
.	O

Mice	O
treated	O
with	O
MJ33	B
at	O
12.5	O
-	O
25	O
mol	O
/	O
kg	O
did	O
not	O
show	O
changes	O
(	O
compared	O
with	O
control	O
)	O
in	O
clinical	O
symptomatology	O
,	O
body	O
weight	O
,	O
hematocrit	O
,	O
and	O
histology	O
of	O
lung	O
,	O
liver	O
,	O
and	O
kidney	O
during	O
a	O
30-	O
to	O
50-day	O
observation	O
period	O
.	O

Thus	O
,	O
the	O
toxic	O
dose	O
of	O
MJ33	B
was	O
>	O
25	O
mol	O
/	O
kg	O
,	O
whereas	O
the	O
PLA2	O
inhibitory	O
dose	O
was	O
approximately	O
0.02	O
mol	O
/	O
kg	O
,	O
indicating	O
a	O
high	O
margin	O
of	O
safety	O
.	O

MJ33	B
administered	O
to	O
mice	O
prior	O
to	O
lung	O
isolation	O
markedly	O
reduced	O
ROS	O
production	O
and	O
tissue	O
lipid	O
and	O
protein	O
oxidation	O
during	O
ischemia	O
followed	O
by	O
reperfusion	O
.	O

Thus	O
,	O
MJ33	B
could	O
be	O
useful	O
as	O
a	O
therapeutic	O
agent	O
to	O
prevent	O
ROS	O
-	O
mediated	O
tissue	O
injury	O
associated	O
with	O
lung	O
inflammation	O
or	O
in	O
harvested	O
lungs	O
prior	O
to	O
transplantation	O
.	O

Discovery	O
and	O
gram	O
-	O
scale	O
synthesis	O
of	O
BMS-593214	B
,	O
a	O
potent	O
,	O
selective	O
FVIIa	O
inhibitor	O
.	O

A	O
6-amidinotetrahydroquinoline	B
screening	O
hit	O
was	O
driven	O
to	O
a	O
structurally	O
novel	O
,	O
potent	O
,	O
and	O
selective	O
FVIIa	O
inhibitor	O
through	O
a	O
combination	O
of	O
library	O
synthesis	O
and	O
rational	O
design	O
.	O

An	O
efficient	O
gram	O
-	O
scale	O
synthesis	O
of	O
the	O
active	O
enantiomer	O
BMS-593214	B
was	O
developed	O
,	O
which	O
required	O
significant	O
optimization	O
of	O
the	O
key	O
Povarov	O
annulation	O
.	O

Importantly	O
,	O
BMS-593214	B
showed	O
antithrombotic	O
efficacy	O
in	O
a	O
rabbit	O
arterial	O
thrombosis	O
model	O
.	O

A	O
crystal	O
structure	O
of	O
BMS-593214	B
bound	O
to	O
FVIIa	O
highlights	O
key	O
contacts	O
with	O
Asp	B
189	O
,	O
Lys	B
192	O
,	O
and	O
the	O
S2	O
pocket	O
.	O

Physicochemical	O
Properties	O
and	O
Supernucleophilicity	O
of	O
Oxime	B
-	O
Functionalized	O
Surfactants	O
:	O
Hydrolytic	O
Catalysts	O
toward	O
Dephosphorylation	O
of	O
Di-	B
and	I
Triphosphate	I
Esters	I
.	O

Aggregation	O
and	O
kinetic	O
studies	O
have	O
been	O
performed	O
to	O
understand	O
the	O
hydrolytic	O
potencies	O
of	O
the	O
series	O
of	O
oxime	B
-	O
functionalized	O
surfactants	O
,	O
viz	O
.	O
,	O
3-	B
hydroxyiminomethyl-1-alkylpyridinium	I
bromide	I
(	O
alkyl	B
=	O
CnH2n+1	B
,	O
n	O
=	O
10	O
,	O
12	O
,	O
14	O
,	O
16	O
,	O
18	O
)	O
in	O
the	O
cleavage	O
of	O
phosphate	B
esters	I
,	O
p	B
-	I
nitrophenyl	I
diphenyl	I
phosphate	I
(	O
PNPDPP	B
)	O
and	O
bis	B
(	I
2,4-dinitrophenyl	I
)	I
phosphate	I
(	O
BNDPP	B
)	O
,	O
in	O
mixed	O
micelles	O
with	O
cetylpyridinium	B
bromide	I
(	O
CPB	B
)	O
.	O

Micellization	O
and	O
surface	O
properties	O
of	O
mixed	O
micelles	O
functional	O
surfactants	O
with	O
CPB	B
were	O
studied	O
by	O
conductivity	O
and	O
surface	O
tension	O
measurements	O
.	O

Acid	O
dissociation	O
constants	O
(	O
pKa	O
)	O
were	O
determined	O
,	O
the	O
effect	O
of	O
functional	O
surfactant	O
alkyl	B
chain	O
length	O
and	O
pH	O
on	O
the	O
observed	O
rate	O
constant	O
(	O
kobs	O
)	O
for	O
phosphate	B
ester	I
cleavage	O
has	O
been	O
discussed	O
,	O
and	O
the	O
effect	O
of	O
substrate	O
on	O
the	O
supernucleophilicities	O
of	O
the	O
studied	O
oximes	B
was	O
monitored	O
.	O

Functionalized	O
oxime	B
-	O
based	O
surfactants	O
were	O
proved	O
to	O
be	O
supernucleophiles	O
to	O
attack	O
on	O
the	O
P	B
	I
O	I
center	O
of	O
tri-	B
and	I
diphosphate	I
esters	I
.	O

Oximes	B
with	O
hexadecyl	B
alkyl	B
chain	O
length	O
(	O
3-C16	B
)	O
showed	O
maximum	O
micellar	O
effect	O
on	O
the	O
rate	O
constants	O
toward	O
PNPDPP	B
.	O

Micellar	O
effects	O
were	O
analyzed	O
in	O
terms	O
of	O
the	O
pseudophase	O
model	O
.	O

Comparative	O
annotation	O
of	O
functional	O
regions	O
in	O
the	O
human	O
genome	O
using	O
epigenomic	O
data	O
.	O

Epigenetic	O
regulation	O
is	O
dynamic	O
and	O
cell	O
-	O
type	O
dependent	O
.	O

The	O
recently	O
available	O
epigenomic	O
data	O
in	O
multiple	O
cell	O
types	O
provide	O
an	O
unprecedented	O
opportunity	O
for	O
a	O
comparative	O
study	O
of	O
epigenetic	O
landscape	O
.	O

We	O
developed	O
a	O
machine	O
-	O
learning	O
method	O
called	O
ChroModule	O
to	O
annotate	O
the	O
epigenetic	O
states	O
in	O
eight	O
ENCyclopedia	O
Of	O
DNA	O
Elements	O
cell	O
types	O
.	O

The	O
trained	O
model	O
successfully	O
captured	O
the	O
characteristic	O
histone	O
-	O
modification	O
patterns	O
associated	O
with	O
regulatory	O
elements	O
,	O
such	O
as	O
promoters	O
and	O
enhancers	O
,	O
and	O
showed	O
superior	O
performance	O
on	O
identifying	O
enhancers	O
compared	O
with	O
the	O
state	O
-	O
of	O
-	O
art	O
methods	O
.	O

In	O
addition	O
,	O
given	O
the	O
fixed	O
number	O
of	O
epigenetic	O
states	O
in	O
the	O
model	O
,	O
ChroModule	O
allows	O
straightforward	O
illustration	O
of	O
epigenetic	O
variability	O
in	O
multiple	O
cell	O
types	O
.	O

Using	O
this	O
feature	O
,	O
we	O
found	O
that	O
invariable	O
and	O
variable	O
epigenetic	O
states	O
across	O
cell	O
types	O
correspond	O
to	O
housekeeping	O
functions	O
and	O
stimulus	O
response	O
,	O
respectively	O
.	O

Especially	O
,	O
we	O
observed	O
that	O
enhancers	O
,	O
but	O
not	O
the	O
other	O
regulatory	O
elements	O
,	O
dictate	O
cell	O
specificity	O
,	O
as	O
similar	O
cell	O
types	O
share	O
common	O
enhancers	O
,	O
and	O
cell	O
-	O
type	O
-	O
specific	O
enhancers	O
are	O
often	O
bound	O
by	O
transcription	O
factors	O
playing	O
critical	O
roles	O
in	O
that	O
cell	O
type	O
.	O

More	O
interestingly	O
,	O
we	O
found	O
some	O
genomic	O
regions	O
are	O
dormant	O
in	O
cell	O
type	O
but	O
primed	O
to	O
become	O
active	O
in	O
other	O
cell	O
types	O
.	O

These	O
observations	O
highlight	O
the	O
usefulness	O
of	O
ChroModule	O
in	O
comparative	O
analysis	O
and	O
interpretation	O
of	O
multiple	O
epigenomes	O
.	O

Direct	O
modulation	O
of	O
microtubule	O
stability	O
contributes	O
to	O
anthracene	B
general	O
anesthesia	O
.	O

Recently	O
,	O
we	O
identified	O
1-aminoanthracene	B
as	O
a	O
fluorescent	O
general	O
anesthetic	O
.	O

To	O
investigate	O
the	O
mechanism	O
of	O
action	O
,	O
a	O
photoactive	O
analogue	O
,	O
1-azidoanthracene	B
,	O
was	O
synthesized	O
.	O

Administration	O
of	O
1-azidoanthracene	B
to	O
albino	O
stage	O
40	O
-	O
47	O
tadpoles	O
was	O
found	O
to	O
immobilize	O
animals	O
upon	O
near	O
-	O
UV	O
irradiation	O
of	O
the	O
forebrain	O
region	O
.	O

The	O
immobilization	O
was	O
often	O
reversible	O
,	O
but	O
it	O
was	O
characterized	O
by	O
a	O
longer	O
duration	O
consistent	O
with	O
covalent	O
attachment	O
of	O
the	O
ligand	O
to	O
functionally	O
important	O
targets	O
.	O

IEF	O
/	O
SDS	O
-	O
PAGE	O
examination	O
of	O
irradiated	O
tadpole	O
brain	O
homogenate	O
revealed	O
labeled	O
protein	O
,	O
identified	O
by	O
mass	O
spectrometry	O
as	O
	O
-	O
tubulin	O
.	O

In	O
vitro	O
assays	O
with	O
aminoanthracene	B
-	O
cross	O
-	O
linked	O
tubulin	O
indicated	O
inhibition	O
of	O
microtubule	O
polymerization	O
,	O
similar	O
to	O
colchicine	B
.	O

Tandem	O
mass	O
spectrometry	O
confirmed	O
anthracene	B
binding	O
near	O
the	O
colchicine	B
site	O
.	O

Stage	O
40	O
-	O
47	O
tadpoles	O
were	O
also	O
incubated	O
1	O
h	O
with	O
microtubule	O
stabilizing	O
agents	O
,	O
epothilone	B
D	I
or	O
discodermolide	B
,	O
followed	O
by	O
dosing	O
with	O
1-aminoanthracene	B
.	O

The	O
effective	O
concentration	O
of	O
1-aminoanthracene	B
required	O
to	O
immobilize	O
the	O
tadpoles	O
was	O
significantly	O
increased	O
in	O
the	O
presence	O
of	O
either	O
microtubule	O
stabilizing	O
agent	O
.	O

Epothilone	B
D	I
similarly	O
mitigated	O
the	O
effects	O
of	O
a	O
clinical	O
neurosteroid	O
general	O
anesthetic	O
,	O
allopregnanolone	B
,	O
believed	O
to	O
occupy	O
the	O
colchicine	B
site	O
in	O
tubulin	O
.	O

We	O
conclude	O
that	O
neuronal	O
microtubules	O
are	O
"	O
on	O
-	O
pathway	O
"	O
targets	O
for	O
anthracene	B
general	O
anesthetics	O
and	O
may	O
also	O
represent	O
functional	O
targets	O
for	O
some	O
neurosteroid	O
general	O
anesthetics	O
.	O

Unraveling	O
the	O
Role	O
of	O
the	O
Protein	O
Environment	O
for	O
[	B
FeFe	I
]	I
-Hydrogenase	O
:	O
A	O
New	O
Application	O
of	O
Coarse	O
-	O
Graining	O
.	O

Hydrogenase	O
enzymes	O
are	O
natural	O
biocatalysts	O
that	O
might	O
be	O
harnessed	O
to	O
reduce	O
the	O
cost	O
of	O
hydrogen	B
gas	O
production	O
.	O

[	B
FeFe	I
]	I
-hydrogenases	O
are	O
the	O
most	O
effective	O
of	O
three	O
such	O
enzymes	O
at	O
catalyzing	O
H	B
(	I
+	I
)	I
reduction	O
.	O

In	O
this	O
study	O
,	O
we	O
develop	O
and	O
apply	O
a	O
novel	O
combination	O
of	O
all	O
-	O
atom	O
molecular	O
dynamics	O
and	O
coarse	O
-	O
grained	O
(	O
CG	O
)	O
analysis	O
to	O
characterize	O
two	O
important	O
steps	O
of	O
the	O
catalytic	O
cycle	O
of	O
[	B
FeFe	I
]	I
-hydrogenase	O
.	O

The	O
first	O
is	O
the	O
electron	O
transport	O
through	O
FeS	B
clusters	O
to	O
the	O
active	O
site	O
.	O

We	O
use	O
a	O
Marcus	O
formulation	O
to	O
compute	O
the	O
free	O
energy	O
and	O
the	O
reorganization	O
energy	O
of	O
three	O
electron	O
transport	O
steps	O
and	O
decompose	O
these	O
values	O
into	O
contributions	O
from	O
the	O
CG	O
protein	O
sites	O
and	O
the	O
solvent	O
.	O

The	O
three	O
-	O
step	O
transport	O
process	O
is	O
found	O
to	O
be	O
downhill	O
with	O
relative	O
free	O
energies	O
of	O
-11.7	O
for	O
the	O
first	O
step	O
,	O
-14.8	O
for	O
the	O
second	O
step	O
,	O
and	O
-17.1	O
kcal	O
/	O
mol	O
for	O
the	O
third	O
step	O
.	O

The	O
electron	O
-	O
transport	O
process	O
is	O
also	O
found	O
to	O
activate	O
a	O
water	O
channel	O
suggesting	O
a	O
coupled	O
mechanism	O
for	O
proton	O
and	O
electron	O
transport	O
to	O
the	O
active	O
site	O
.	O

The	O
channel	O
opening	O
is	O
orchestrated	O
by	O
three	O
CG	O
sites	O
located	O
in	O
the	O
active	O
-	O
site	O
domain	O
of	O
the	O
protein	O
with	O
one	O
of	O
the	O
sites	O
also	O
contributing	O
a	O
strong	O
attractive	O
electrostatic	O
potential	O
(	O
ESP	O
)	O
to	O
help	O
shuttle	O
protons	O
to	O
the	O
active	O
site	O
.	O

Overall	O
,	O
our	O
CG	O
analysis	O
points	O
to	O
a	O
concerted	O
mechanism	O
of	O
electron	O
and	O
proton	O
delivery	O
to	O
the	O
active	O
site	O
in	O
these	O
proteins	O
thus	O
providing	O
important	O
insight	O
for	O
the	O
development	O
of	O
biomimetic	O
devices	O
.	O

Therapeutic	O
effectiveness	O
of	O
botulinum	O
neurotoxin	O
A	O
:	O
Potent	O
blockade	O
of	O
autonomic	O
transmission	O
by	O
targeted	O
cleavage	O
of	O
only	O
the	O
pertinent	O
SNAP-25	O
.	O

In	O
search	O
of	O
a	O
basis	O
for	O
the	O
impressive	O
potency	O
of	O
an	O
endoprotease	O
that	O
cleaves	O
SNAP-25	O
,	O
botulinum	O
neurotoxin	O
type	O
A	O
(	O
BoNT	O
/	O
A	O
)	O
,	O
in	O
treating	O
numerous	O
diseases	O
due	O
to	O
hyper	O
-	O
active	O
autonomic	O
nerves	O
,	O
truncation	O
of	O
its	O
target	O
and	O
inhibition	O
of	O
neurotransmission	O
were	O
studied	O
in	O
rat	O
sympathetic	O
neurons	O
.	O

Tetrodotoxin	B
-	O
sensitive	O
spontaneous	O
cholinergic	O
neurotransmission	O
was	O
blocked	O
>	O
80	O
%	O
by	O
1	O
pM	O
BoNT	O
/	O
A	O
despite	O
cleaving	O
<	O
20	O
%	O
of	O
the	O
SNAP-25	O
.	O

A	O
maximum	O
cleavage	O
of	O
60	O
%	O
SNAP-25	O
could	O
be	O
achieved	O
with	O
>	O
1	O
nM	O
BoNT	O
/	O
A	O
,	O
despite	O
an	O
absence	O
of	O
non	O
-	O
cleavable	O
SNAP-25	O
in	O
the	O
detergent	O
-	O
solubilised	O
neurons	O
.	O

In	O
contrast	O
,	O
BoNT	O
/	O
E	O
(	O
100	O
nM	O
)	O
truncated	O
nearly	O
all	O
the	O
SNAP-25	O
in	O
the	O
intact	O
cells	O
,	O
but	O
was	O
unable	O
to	O
block	O
neurotransmission	O
at	O
low	O
concentrations	O
like	O
BoNT	O
/	O
A.	O
Chimeras	O
created	O
by	O
inserting	O
the	O
acceptor	O
-	O
binding	O
HC	O
domain	O
of	O
BoNT	O
/	O
A	O
into	O
BoNT	O
/	O
E	O
still	O
cleaved	O
all	O
the	O
SNAP-25	O
,	O
indicating	O
ubiquitous	O
expression	O
of	O
BoNT	O
/	O
A	O
acceptors	O
.	O

Accordingly	O
,	O
SV2	O
and	O
SNAP-25	O
were	O
found	O
to	O
be	O
co	O
-	O
expressed	O
and	O
broadly	O
co	O
-	O
localised	O
in	O
neurons	O
,	O
but	O
absent	O
from	O
non	O
-	O
neuronal	O
cells	O
.	O

On	O
the	O
other	O
hand	O
,	O
partial	O
cleavage	O
by	O
the	O
BoNT	O
/	O
A	O
protease	O
persisted	O
upon	O
replacing	O
its	O
HC	O
with	O
counterparts	O
from	O
BoNT	O
/	O
E	O
or	O
BoNT	O
/	O
B.	O
Moreover	O
,	O
limited	O
cleavage	O
of	O
SNAP-25	O
was	O
conferred	O
onto	O
the	O
protease	O
from	O
BoNT	O
/	O
E	O
when	O
fused	O
to	O
the	O
N	O
-	O
terminus	O
of	O
BoNT	O
/	O
A.	O
Thus	O
,	O
the	O
BoNT	O
/	O
A	O
protease	O
is	O
uniquely	O
well	O
-	O
adapted	O
for	O
selectively	O
inactivating	O
the	O
SNAP-25	O
directly	O
involved	O
in	O
neurotransmission	O
;	O
this	O
together	O
with	O
the	O
toxin	O
's	O
acceptor	O
and	O
its	O
target	O
being	O
localised	O
on	O
the	O
peri	O
-	O
somatic	O
boutons	O
likely	O
contribute	O
to	O
its	O
exceptional	O
therapeutic	O
utility	O
in	O
the	O
clinic	O
.	O

Structural	O
modifications	O
of	O
polymethacrylates	B
:	O
Impact	O
on	O
thermal	O
behavior	O
and	O
release	O
characteristics	O
of	O
glassy	O
solid	O
solutions	O
.	O

Polymethacrylates	B
such	O
as	O
Eudragit	B
	O
polymers	O
are	O
well	O
established	O
as	O
drug	O
delivery	O
matrix	O
.	O

Here	O
,	O
we	O
synthesize	O
several	O
Eudragit	B
E	I
PO	I
(	O
n	B
-	I
butyl-	I
,	O
dimethylaminoethyl-	B
,	O
methyl	B
-	I
methacrylate	I
-	O
terpolymer	B
)	O
analogues	O
via	O
free	O
radical	O
polymerization	O
.	O

These	O
polymers	O
are	O
processed	O
via	O
hot	O
melt	O
extrusion	O
,	O
followed	O
by	O
injection	O
molding	O
and	O
evaluated	O
as	O
carriers	O
to	O
produce	O
immediate	O
release	O
solid	O
solution	O
tablets	O
.	O

Three	O
chemical	O
modifications	O
increased	O
the	O
glass	O
transition	O
temperature	O
of	O
the	O
polymer	O
:	O
(	O
a	O
)	O
substitution	O
of	O
n	B
-	I
butyl	I
by	O
t	B
-	I
butyl	I
groups	O
,	O
(	O
b	O
)	O
reduction	O
of	O
the	O
dimethylaminoethyl	B
methacrylate	I
(	O
DMAEMA	B
)	O
content	O
,	O
and	O
(	O
c	O
)	O
incorporation	O
of	O
a	O
bulky	O
isobornyl	B
repeating	O
unit	O
.	O

These	O
structural	O
modifications	O
revealed	O
the	O
possibility	O
to	O
increase	O
the	O
mechanical	O
stability	O
of	O
the	O
tablets	O
via	O
altering	O
the	O
polymer	O
Tg	O
without	O
influencing	O
the	O
drug	O
release	O
characteristics	O
and	O
glassy	O
solid	O
solution	O
forming	O
properties	O
.	O

The	O
presence	O
of	O
DMAEMA	B
units	O
proved	O
to	O
be	O
crucial	O
with	O
respect	O
to	O
API	O
/	O
polymer	O
interaction	O
(	O
essential	O
in	O
creating	O
glassy	O
solid	O
solutions	O
)	O
and	O
drug	O
release	O
characteristics	O
.	O

Moreover	O
,	O
these	O
chemical	O
modifications	O
accentuate	O
the	O
need	O
for	O
a	O
more	O
rational	O
design	O
of	O
(	O
methacrylate	B
)	O
polymer	O
matrix	O
excipients	O
for	O
drug	O
formulation	O
via	O
hot	O
melt	O
extrusion	O
and	O
injection	O
molding	O
.	O

Mercury	B
in	O
fishes	O
from	O
Augusta	O
Bay	O
(	O
southern	O
Italy	O
)	O
:	O
Risk	O
assessment	O
and	O
health	O
implication	O
.	O

Our	O
study	O
reports	O
on	O
the	O
total	O
mercury	B
(	O
HgT	O
)	O
concentrations	O
measured	O
in	O
the	O
muscles	O
and	O
livers	O
of	O
several	O
benthic	O
,	O
demersal	O
and	O
pelagic	O
fish	O
species	O
caught	O
inside	O
and	O
outside	O
of	O
Augusta	O
Bay	O
(	O
southern	O
Italy	O
)	O
,	O
a	O
semi	O
-	O
enclosed	O
marine	O
area	O
,	O
highly	O
contaminated	O
by	O
the	O
uncontrolled	O
(	O
since	O
the	O
1950s	O
to	O
1978s	O
)	O
discharge	O
of	O
the	O
largest	O
European	O
petrochemical	O
plant	O
.	O

Mercury	B
levels	O
in	O
fish	O
tissues	O
are	O
discussed	O
with	O
regard	O
to	O
specific	O
habitat	O
,	O
size	O
and/or	O
age	O
of	O
the	O
specimens	O
and	O
HgT	O
distribution	O
in	O
the	O
bottom	O
sediments	O
.	O

Results	O
suggest	O
a	O
still	O
active	O
Hg	B
release	O
mechanism	O
from	O
the	O
polluted	O
sediments	O
to	O
the	O
marine	O
environment	O
.	O

Also	O
,	O
the	O
high	O
HgT	O
concentrations	O
measured	O
in	O
fishes	O
caught	O
in	O
the	O
external	O
area	O
of	O
the	O
bay	O
imply	O
a	O
potential	O
role	O
of	O
Augusta	O
Bay	O
as	O
a	O
pollutant	O
source	O
for	O
the	O
Mediterranean	O
ecosystem	O
.	O

Finally	O
,	O
values	O
of	O
hazard	O
target	O
quotient	O
(	O
THQ	O
)	O
and	O
estimated	O
weekly	O
intake	O
(	O
EWI	O
)	O
demonstrate	O
that	O
consumption	O
of	O
fishes	O
caught	O
inside	O
the	O
bay	O
represents	O
a	O
serious	O
risk	O
for	O
human	O
health	O
.	O

Also	O
,	O
data	O
indicate	O
that	O
intake	O
of	O
fishes	O
caught	O
from	O
the	O
external	O
area	O
of	O
the	O
bay	O
,	O
especially	O
for	O
that	O
concern	O
demersal	O
and	O
benthic	O
species	O
,	O
could	O
be	O
represent	O
a	O
significant	O
component	O
of	O
risk	O
for	O
the	O
local	O
population	O
.	O

A	O
systematic	O
comparison	O
of	O
the	O
properties	O
of	O
clinically	O
used	O
angiotensin	O
II	O
type	O
1	O
receptor	O
antagonists	O
.	O

Angiotensin	O
II	O
type	O
1	O
receptor	O
antagonists	O
(	O
ARBs	O
)	O
have	O
become	O
an	O
important	O
drug	O
class	O
in	O
the	O
treatment	O
of	O
hypertension	O
and	O
heart	O
failure	O
and	O
the	O
protection	O
from	O
diabetic	O
nephropathy	O
.	O

Eight	O
ARBs	O
are	O
clinically	O
available	O
[	O
azilsartan	B
,	O
candesartan	B
,	O
eprosartan	B
,	O
irbesartan	B
,	O
losartan	B
,	O
olmesartan	B
,	O
telmisartan	B
,	O
valsartan	B
]	O
.	O

Azilsartan	B
(	O
in	O
some	O
countries	O
)	O
,	O
candesartan	B
,	O
and	O
olmesartan	B
are	O
orally	O
administered	O
as	O
prodrugs	O
,	O
whereas	O
the	O
blocking	O
action	O
of	O
some	O
is	O
mediated	O
through	O
active	O
metabolites	O
.	O

On	O
the	O
basis	O
of	O
their	O
chemical	O
structures	O
,	O
ARBs	O
use	O
different	O
binding	O
pockets	O
in	O
the	O
receptor	O
,	O
which	O
are	O
associated	O
with	O
differences	O
in	O
dissociation	O
times	O
and	O
,	O
in	O
most	O
cases	O
,	O
apparently	O
insurmountable	O
antagonism	O
.	O

The	O
physicochemical	O
differences	O
between	O
ARBs	O
also	O
manifest	O
in	O
different	O
tissue	O
penetration	O
,	O
including	O
passage	O
through	O
the	O
blood	O
-	O
brain	O
barrier	O
.	O

Differences	O
in	O
binding	O
mode	O
and	O
tissue	O
penetration	O
are	O
also	O
associated	O
with	O
differences	O
in	O
pharmacokinetic	O
profile	O
,	O
particularly	O
duration	O
of	O
action	O
.	O

Although	O
generally	O
highly	O
specific	O
for	O
angiotensin	O
II	O
type	O
1	O
receptors	O
,	O
some	O
ARBs	O
,	O
particularly	O
telmisartan	B
,	O
are	O
partial	O
agonists	O
at	O
peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
-	O
	O
.	O

All	O
of	O
these	O
properties	O
are	O
comprehensively	O
reviewed	O
in	O
this	O
article	O
.	O

Although	O
there	O
is	O
general	O
consensus	O
that	O
a	O
continuous	O
receptor	O
blockade	O
over	O
a	O
24-hour	O
period	O
is	O
desirable	O
,	O
the	O
clinical	O
relevance	O
of	O
other	O
pharmacological	O
differences	O
between	O
individual	O
ARBs	O
remains	O
to	O
be	O
assessed	O
.	O

Understanding	O
multi	O
-	O
quantum	O
NMR	O
through	O
secular	O
approximation	O
.	O

With	O
the	O
development	O
of	O
technology	O
and	O
improved	O
understanding	O
of	O
nuclear	O
spin	O
-	O
spin	O
interactions	O
and	O
their	O
behavior	O
in	O
static	O
/	O
oscillating	O
magnetic	O
fields	O
,	O
NMR	O
spectroscopy	O
has	O
emerged	O
as	O
a	O
powerful	O
tool	O
for	O
characterizing	O
molecular	O
structure	O
in	O
a	O
wide	O
range	O
of	O
systems	O
of	O
chemical	O
,	O
physical	O
and	O
biological	O
relevance	O
.	O

Here	O
in	O
this	O
article	O
,	O
we	O
revisit	O
the	O
important	O
connection	O
between	O
"	O
Secular	O
-	O
Approximation	O
"	O
(	O
a	O
well	O
-	O
known	O
fundamental	O
concept	O
)	O
and	O
NMR	O
spectroscopy	O
.	O

Employing	O
recent	O
experimental	O
results	O
as	O
the	O
background	O
,	O
an	O
alternate	O
interpretation	O
of	O
the	O
secular	O
approximation	O
is	O
presented	O
for	O
describing	O
and	O
understanding	O
the	O
nuances	O
of	O
Multi	O
-	O
Quantum	O
(	O
MQ	O
)	O
NMR	O
spectroscopy	O
of	O
quadrupolar	O
nuclei	O
.	O

Since	O
MQ	O
NMR	O
spectroscopy	O
of	O
quadrupolar	O
nuclei	O
forms	O
the	O
basis	O
of	O
the	O
structural	O
characterization	O
of	O
inorganic	O
solids	O
and	O
clusters	O
,	O
we	O
believe	O
that	O
the	O
analytic	O
theory	O
presented	O
herein	O
would	O
be	O
beneficial	O
both	O
in	O
the	O
understanding	O
and	O
design	O
of	O
MQ	O
NMR	O
experiments	O
.	O

Additionally	O
,	O
the	O
analytic	O
results	O
are	O
corroborated	O
with	O
rigorous	O
numerical	O
simulations	O
and	O
could	O
be	O
employed	O
in	O
the	O
quantitative	O
interpretation	O
of	O
experimental	O
results	O
.	O

Heterogeneous	O
OH	B
oxidation	O
of	O
biomass	O
burning	O
organic	O
aerosol	O
surrogate	O
compounds	O
:	O
assessment	O
of	O
volatilisation	O
products	O
and	O
the	O
role	O
of	O
OH	B
concentration	O
on	O
the	O
reactive	O
uptake	O
kinetics	O
.	O

The	O
reactive	O
uptake	O
coefficients	O
(	O
	O
)	O
of	O
OH	B
by	O
levoglucosan	B
,	O
abietic	B
acid	I
,	O
and	O
nitroguaiacol	B
serving	O
as	O
surrogate	O
compounds	O
for	O
biomass	O
burning	O
aerosol	O
have	O
been	O
determined	O
employing	O
a	O
chemical	O
ionisation	O
mass	O
spectrometer	O
coupled	O
to	O
a	O
rotating	O
-	O
wall	O
flow	O
-	O
tube	O
reactor	O
over	O
a	O
wide	O
range	O
of	O
[	O
OH	B
]	O
10	O
(	O
7	O
)	O
-10	O
(	O
11	O
)	O
molecule	O
cm	O
(	O
-3	O
)	O
.	O

Volatilisation	O
products	O
of	O
these	O
organic	O
substrates	O
due	O
to	O
heterogeneous	O
oxidation	O
by	O
OH	B
have	O
been	O
determined	O
at	O
1	O
atm	O
using	O
a	O
high	O
resolution	O
proton	O
transfer	O
reaction	O
time	O
-	O
of	O
-	O
flight	O
mass	O
spectrometer	O
(	O
HR	O
-	O
PTR	O
-	O
ToF	O
-	O
MS	O
)	O
.	O

	O
range	O
within	O
0.05	O
-	O
1	O
for	O
[	O
OH	B
]	O
=	O
2.6	O
	O
10	O
(	O
7	O
)	O
-3	O
	O
10	O
(	O
9	O
)	O
molecule	O
cm	O
(	O
-3	O
)	O
for	O
all	O
investigated	O
organic	O
compounds	O
,	O
but	O
decrease	O
to	O
0.008	O
-	O
0.034	O
for	O
[	O
OH	B
]	O
=	O
4.1	O
	O
10	O
(	O
10	O
)	O
-6.7	O
	O
10	O
(	O
10	O
)	O
molecule	O
cm	O
(	O
-3	O
)	O
.	O

	O
as	O
a	O
function	O
of	O
[	O
OH	B
]	O
can	O
be	O
described	O
by	O
a	O
Langmuir	O
-	O
Hinshelwood	O
model	O
,	O
neglecting	O
bulk	O
processes	O
,	O
suggesting	O
that	O
despite	O
its	O
strong	O
reactivity	O
,	O
OH	B
is	O
mobile	O
on	O
surfaces	O
prior	O
to	O
reaction	O
.	O

The	O
best	O
fit	O
Langmuir	O
-	O
Hinshelwood	O
parameters	O
on	O
average	O
are	O
K	O
(	O
OH	B
)	O
=	O
3.81	O
	O
10	O
(	O
-10	O
)	O
cm	O
(	O
3	O
)	O
molecule	O
(	O
-1	O
)	O
and	O
k	O
(	O
s	O
)	O
=	O
9.71	O
	O
10	O
(	O
-17	O
)	O
cm	O
(	O
2	O
)	O
molecule	O
(	O
-1	O
)	O
s	O
(	O
-1	O
)	O
for	O
all	O
of	O
the	O
investigated	O
organic	O
compounds	O
.	O

Volatilised	O
products	O
have	O
been	O
identified	O
indicating	O
enhancements	O
over	O
background	O
of	O
50	O
%	O
up	O
to	O
a	O
factor	O
of	O
15	O
.	O

Amongst	O
the	O
common	O
volatile	O
organic	O
compounds	O
(	O
VOCs	O
)	O
identified	O
between	O
levoglucosan	B
,	O
abietic	B
acid	I
,	O
and	O
nitroguaiacol	B
were	O
methanol	B
,	O
acetaldehyde	B
,	O
formic	B
acid	I
,	O
and	O
acetic	B
acid	I
.	O

VOCs	O
having	O
the	O
greatest	O
enhancement	O
over	O
background	O
were	O
glucic	B
acid	I
from	O
levoglucosan	B
,	O
glycolic	B
acid	I
from	O
abietic	B
acid	I
,	O
and	O
methanol	B
and	O
nitric	B
acid	I
from	O
nitroguaiacol	B
.	O

Reaction	O
mechanisms	O
leading	O
to	O
the	O
formation	O
of	O
glucic	B
acid	I
,	O
glycolic	B
acid	I
,	O
methanol	B
,	O
and	O
nitric	B
acid	I
are	O
proposed	O
.	O

Estimated	O
lower	O
limits	O
of	O
atmospheric	O
lifetimes	O
of	O
biomass	O
burning	O
aerosol	O
particles	O
,	O
200	O
nm	O
in	O
diameter	O
,	O
by	O
heterogeneous	O
OH	B
oxidation	O
under	O
fresh	O
biomass	O
burning	O
plume	O
conditions	O
are	O
2	O
days	O
and	O
up	O
to	O
2	O
weeks	O
for	O
atmospheric	O
background	O
conditions	O
.	O

However	O
,	O
estimated	O
lifetimes	O
depend	O
crucially	O
on	O
[	O
OH	B
]	O
and	O
corresponding	O
	O
,	O
emphasising	O
the	O
need	O
to	O
determine	O
	O
under	O
relevant	O
conditions	O
.	O

Synthesis	O
,	O
crystal	O
structure	O
and	O
biological	O
evaluation	O
of	O
a	O
main	O
group	O
seven	O
-	O
coordinated	O
bismuth	B
(	I
III	I
)	I
complex	O
with	O
2-acetylpyridine	B
N4-phenylthiosemicarbazone	I
.	O

Up	O
to	O
now	O
,	O
bismuth	B
(	I
III	I
)	I
complexes	O
with	O
thiosemicarbazones	B
have	O
been	O
comparatively	O
rare	O
.	O

Here	O
,	O
a	O
main	O
group	O
seven	O
-	O
coordinated	O
bismuth	B
(	I
III	I
)	I
complex	O
[	O
Bi	B
(	I
L	I
)	I
(	I
NO3	I
)	I
2	I
(	I
CH3CH2OH	I
)	I
]	O
(	O
1	O
)	O
(	O
HL	O
=	O
2-acetylpyridine	B
N	I
(	I
4	I
)	I
-phenylthiosemicarbazone	I
)	O
has	O
been	O
synthesized	O
and	O
characterized	O
by	O
elemental	O
analysis	O
,	O
IR	O
,	O
(	B
1	I
)	I
H	I
NMR	O
and	O
single	O
-	O
crystal	O
X	O
-	O
ray	O
diffraction	O
studies	O
.	O

The	O
cytotoxicity	O
data	O
suggest	O
that	O
1	O
exhibits	O
higher	O
in	O
vitro	O
antiproliferative	O
activity	O
in	O
four	O
human	O
cancer	O
cells	O
tested	O
.	O

Its	O
possible	O
apoptotic	O
mechanism	O
has	O
been	O
evaluated	O
in	O
HepG2	O
cells	O
.	O

Compound	O
1	O
promotes	O
a	O
dose	O
-	O
dependent	O
apoptosis	O
in	O
HepG2	O
cells	O
and	O
the	O
apoptosis	O
is	O
associated	O
with	O
an	O
increase	O
in	O
intracellular	O
reactive	O
oxygen	B
species	O
(	O
ROS	O
)	O
production	O
and	O
reduction	O
of	O
mitochondrial	O
membrane	O
potential	O
(	O
MMP	O
)	O
.	O

Identification	O
and	O
synthesis	O
of	O
N-	B
(	I
thiophen-2-yl	I
)	I
benzamide	I
derivatives	O
as	O
BRAF	O
(	O
V600E	O
)	O
inhibitors	O
.	O

The	O
V600E	O
BRAF	O
kinase	O
mutation	O
,	O
which	O
activates	O
the	O
downstream	O
MAPK	O
signaling	O
pathway	O
,	O
commonly	O
occurs	O
in	O
about	O
8	O
%	O
of	O
all	O
human	O
malignancies	O
and	O
about	O
50	O
%	O
of	O
all	O
melanomas	O
.	O

In	O
this	O
study	O
,	O
we	O
employed	O
virtual	O
screening	O
and	O
chemical	O
synthesis	O
to	O
identify	O
a	O
series	O
of	O
N-	B
(	I
thiophen-2-yl	I
)	I
benzamide	I
derivatives	O
as	O
potent	O
BRAF	O
(	O
V600E	O
)	O
inhibitors	O
.	O

Structure	O
-	O
activity	O
relationship	O
studies	O
of	O
these	O
derivatives	O
revealed	O
that	O
compounds	O
b40	O
and	O
b47	O
are	O
the	O
two	O
most	O
potent	O
BRAF	O
(	O
V600E	O
)	O
inhibitors	O
in	O
this	O
series	O
.	O

Atmospheric	O
chemistry	O
of	O
CF3O2	B
:	O
a	O
theoretical	O
study	O
on	O
mechanisms	O
and	O
pathways	O
of	O
the	O
CF3O2	B
+	O
IO	B
reaction	O
.	O

The	O
mechanisms	O
and	O
reaction	O
pathways	O
for	O
the	O
CF3O2	B
+	O
IO	B
reaction	O
have	O
been	O
investigated	O
by	O
quantum	O
chemistry	O
methods	O
.	O

It	O
has	O
been	O
found	O
that	O
the	O
title	O
reaction	O
takes	O
place	O
on	O
both	O
the	O
singlet	O
and	O
triplet	O
potential	O
energy	O
surfaces	O
(	O
PES	O
)	O
.	O

On	O
the	O
singlet	O
PES	O
,	O
the	O
most	O
important	O
products	O
include	O
CF3OOOI	B
,	O
CF3OOIO	B
,	O
CF3OIO2	B
,	O
and	O
CF2O	B
+	O
FIO2	B
,	O
while	O
other	O
products	O
such	O
as	O
CF2O	B
+	O
FOIO	B
,	O
CF2O	B
+	O
FOOI	B
,	O
CF3OOI	B
+	O
O	O
(	O
(	O
3	O
)	O
P	O
)	O
,	O
CF3OI	B
+	O
O2	B
(	O
(	O
1	O
)	O
	O
and	O
(	O
3	O
)	O
	O
)	O
,	O
and	O
CF3O	B
+	O
OIO	B
are	O
negligible	O
due	O
to	O
high	O
barriers	O
or	O
unstable	O
formations	O
.	O

On	O
the	O
triplet	O
PES	O
,	O
CF3O	B
+	O
OIO	B
is	O
the	O
dominant	O
product	O
with	O
a	O
lower	O
barrier	O
.	O

As	O
for	O
FIO2	B
and	O
it	O
isomers	O
,	O
the	O
most	O
stable	O
one	O
is	O
FIO2	B
.	O

TDDFT	O
(	O
Time	O
Dependent	O
Density	O
Functional	O
Theory	O
)	O
calculation	O
indicates	O
that	O
CF3OOOI	B
,	O
CF3OOIO	B
and	O
CF3OIO2	B
undergo	O
photolysis	O
easily	O
under	O
sunlight	O
.	O

Moreover	O
,	O
a	O
minor	O
contribution	O
relative	O
to	O
hydrogen	B
is	O
found	O
in	O
the	O
CX3O2	B
+	O
IO	B
(	O
X	O
=	O
H	O
and	O
F	O
)	O
reactions	O
.	O

Optically	O
healable	O
polymers	O
.	O

Polymers	O
that	O
can	O
easily	O
be	O
repaired	O
after	O
being	O
damaged	O
are	O
attractive	O
as	O
this	O
characteristic	O
can	O
improve	O
the	O
reliability	O
,	O
functionality	O
,	O
and	O
lifetime	O
of	O
many	O
products	O
.	O

In	O
the	O
last	O
decade	O
,	O
researchers	O
have	O
thus	O
developed	O
new	O
approaches	O
to	O
create	O
stimuli	O
-	O
responsive	O
polymer	O
systems	O
,	O
which	O
have	O
the	O
ability	O
to	O
autonomously	O
heal	O
or	O
can	O
be	O
repaired	O
upon	O
exposure	O
to	O
an	O
external	O
stimulus	O
.	O

This	O
review	O
summarizes	O
the	O
current	O
knowledge	O
of	O
optically	O
healable	O
or	O
photo	O
-	O
healable	O
polymers	O
.	O

The	O
use	O
of	O
light	O
as	O
a	O
stimulus	O
for	O
healing	O
offers	O
several	O
attractive	O
features	O
,	O
including	O
the	O
ability	O
to	O
deliver	O
the	O
stimulus	O
locally	O
,	O
which	O
opens	O
up	O
the	O
possibility	O
of	O
healing	O
the	O
material	O
under	O
load	O
,	O
as	O
well	O
as	O
the	O
ability	O
to	O
tailor	O
the	O
wavelength	O
of	O
light	O
to	O
selectively	O
address	O
a	O
specific	O
component	O
of	O
the	O
material	O
,	O
e.g.	O
only	O
the	O
damaged	O
parts	O
.	O

So	O
far	O
,	O
two	O
main	O
classes	O
of	O
optically	O
healable	O
polymers	O
have	O
been	O
explored	O
,	O
which	O
are	O
structurally	O
dynamic	O
polymers	O
and	O
mechanically	O
activated	O
reactive	O
systems	O
.	O

Multiple	O
nicotine	B
training	O
doses	O
in	O
mice	O
as	O
a	O
basis	O
for	O
differentiating	O
the	O
effects	O
of	O
smoking	O
cessation	O
aids	O
.	O

RATIONALE	O
:	O
Receptor	O
mechanisms	O
underlying	O
the	O
behavioral	O
effects	O
of	O
clinically	O
used	O
nicotinic	O
acetylcholine	B
receptor	O
agonists	O
have	O
not	O
been	O
fully	O
established	O
.	O

OBJECTIVE	O
:	O
Drug	O
discrimination	O
was	O
used	O
to	O
compare	O
receptor	O
mechanisms	O
underlying	O
the	O
effects	O
of	O
smoking	O
cessation	O
aids	O
.	O

METHODS	O
:	O
Separate	O
groups	O
of	O
male	O
C57BL	O
/	O
6J	O
mice	O
discriminated	O
0.56	O
,	O
1	O
,	O
or	O
1.78	O
mg	O
/	O
kg	O
of	O
nicotine	B
base	O
.	O

Nicotine	B
,	O
varenicline	B
,	O
and	O
cytisine	B
were	O
administered	O
alone	O
,	O
in	O
combination	O
with	O
each	O
other	O
,	O
and	O
in	O
combination	O
with	O
mecamylamine	B
and	O
dihydro	B
-	I
	I
-	I
erythroidine	I
(	O
DHE	B
)	O
.	O

Midazolam	B
and	O
morphine	B
were	O
tested	O
to	O
examine	O
sensitivity	O
to	O
non	O
-	O
nicotinics	O
.	O

RESULTS	O
:	O
The	O
ED50	O
value	O
of	O
nicotine	B
to	O
produce	O
discriminative	O
stimulus	O
effects	O
systematically	O
increased	O
as	O
training	O
dose	O
increased	O
.	O

Varenicline	B
and	O
cytisine	B
did	O
not	O
fully	O
substitute	O
for	O
nicotine	B
and	O
,	O
as	O
compared	O
with	O
nicotine	B
,	O
their	O
ED50	O
values	O
varied	O
less	O
systematically	O
as	O
a	O
function	O
of	O
nicotine	B
training	O
dose	O
.	O

Morphine	B
did	O
not	O
substitute	O
for	O
nicotine	B
,	O
whereas	O
midazolam	B
substituted	O
for	O
the	O
low	O
and	O
not	O
the	O
higher	O
training	O
doses	O
of	O
nicotine	B
.	O

As	O
training	O
dose	O
increased	O
,	O
the	O
dose	O
of	O
mecamylamine	B
needed	O
to	O
produce	O
a	O
significant	O
rightward	O
shift	O
in	O
the	O
nicotine	O
dose	O
-	O
effect	O
function	O
also	O
increased	O
.	O

DHE	B
antagonized	O
nicotine	B
in	O
animals	O
discriminating	O
the	O
smallest	O
dose	O
of	O
nicotine	B
.	O

Varenicline	B
did	O
not	O
antagonize	O
the	O
effects	O
of	O
nicotine	B
,	O
whereas	O
cytisine	B
produced	O
a	O
modest	O
though	O
significant	O
antagonism	O
of	O
nicotine	B
.	O

CONCLUSIONS	O
:	O
These	O
results	O
suggest	O
that	O
differences	O
in	O
pharmacologic	O
mechanism	O
between	O
nicotine	B
,	O
varenicline	B
,	O
and	O
cytisine	B
include	O
not	O
only	O
differences	O
in	O
efficacy	O
at	O
a	O
common	O
subtype	O
of	O
nicotinic	O
acetylcholine	B
receptor	O
,	O
but	O
also	O
differential	O
affinity	O
and/or	O
efficacy	O
at	O
multiple	O
receptor	O
subtypes	O
.	O

Reinforcement	O
enhancing	O
effects	O
of	O
nicotine	B
via	O
smoking	O
.	O

RATIONALE	O
:	O
In	O
animals	O
,	O
nicotine	B
enhances	O
reinforcement	O
from	O
stimuli	O
unrelated	O
to	O
nicotine	B
intake	O
.	O

Human	O
research	O
is	O
suggestive	O
but	O
has	O
not	O
clearly	O
shown	O
a	O
similar	O
influence	O
of	O
nicotine	B
.	O

OBJECTIVES	O
:	O
We	O
assessed	O
acute	O
effects	O
of	O
nicotine	B
via	O
smoking	O
on	O
enhancement	O
of	O
positive	O
(	O
money	O
,	O
music	O
)	O
or	O
negative	O
(	O
termination	O
of	O
noise	O
)	O
reinforcers	O
,	O
or	O
no	O
"	O
reward	O
"	O
(	O
control	O
)	O
.	O

These	O
different	O
rewards	O
determined	O
the	O
generalizability	O
of	O
nicotine	B
effects	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Dependent	O
(	O
n	O
=	O
25	O
)	O
and	O
nondependent	O
(	O
n	O
=	O
27	O
)	O
smokers	O
participated	O
in	O
three	O
sessions	O
,	O
each	O
after	O
overnight	O
abstinence	O
.	O

Using	O
a	O
within	O
-	O
subjects	O
design	O
,	O
sessions	O
involved	O
no	O
smoking	O
or	O
smoking	O
denicotinized	O
(	O
0.05	O
mg	O
)	O
or	O
nicotine	B
(	O
0.6	O
mg	O
)	O
Quest	O
(	O
R	O
)	O
brand	O
cigarettes	O
.	O

For	O
comparison	O
,	O
a	O
fourth	O
session	O
involved	O
no	O
abstinence	O
prior	O
to	O
smoking	O
one	O
's	O
own	O
brand	O
to	O
gauge	O
responses	O
under	O
typical	O
nicotine	B
satiation	O
.	O

Reinforcement	O
was	O
assessed	O
by	O
responses	O
on	O
a	O
simple	O
operant	O
computer	O
task	O
for	O
the	O
rewards	O
,	O
each	O
available	O
singly	O
on	O
a	O
progressive	O
ratio	O
schedule	O
during	O
separate	O
trials	O
.	O

RESULTS	O
:	O
The	O
reinforcing	O
effect	O
of	O
music	O
,	O
but	O
not	O
other	O
rewards	O
,	O
was	O
greater	O
due	O
to	O
the	O
nicotine	B
cigarette	O
,	O
compared	O
to	O
the	O
denicotinized	O
cigarette	O
or	O
no	O
smoking	O
.	O

Reinforcement	O
enhancing	O
effects	O
of	O
nicotine	B
did	O
not	O
differ	O
between	O
dependent	O
and	O
nondependent	O
groups	O
,	O
indicating	O
no	O
influence	O
of	O
withdrawal	O
relief	O
.	O

Responding	O
due	O
to	O
acute	O
nicotine	B
after	O
abstinence	O
was	O
very	O
similar	O
to	O
responding	O
to	O
one	O
's	O
own	O
brand	O
after	O
no	O
abstinence	O
.	O

CONCLUSIONS	O
:	O
Acute	O
nicotine	B
intake	O
per	O
se	O
from	O
smoking	O
after	O
abstinence	O
enhances	O
the	O
reinforcing	O
value	O
of	O
rewards	O
unassociated	O
with	O
smoking	O
,	O
perhaps	O
in	O
a	O
manner	O
comparable	O
to	O
ad	O
lib	O
smoking	O
after	O
no	O
abstinence	O
.	O

Nicotine	B
's	O
reinforcement	O
enhancing	O
effects	O
may	O
be	O
specific	O
to	O
certain	O
rewards	O
,	O
perhaps	O
those	O
sensory	O
in	O
nature	O
.	O

P2X	O
and	O
P2Y	O
nucleotide	B
receptors	O
as	O
targets	O
in	O
cardiovascular	O
disease	O
.	O

Endogenous	O
nucleotides	B
have	O
widespread	O
actions	O
in	O
the	O
cardiovascular	O
system	O
,	O
but	O
it	O
is	O
only	O
recently	O
that	O
the	O
P2X	O
and	O
P2Y	O
receptor	O
subtypes	O
,	O
at	O
which	O
they	O
act	O
,	O
have	O
been	O
identified	O
and	O
subtype	O
-	O
selective	O
agonists	O
and	O
antagonists	O
developed	O
.	O

These	O
advances	O
have	O
greatly	O
increased	O
our	O
understanding	O
of	O
the	O
physiological	O
and	O
pathophysiological	O
functions	O
of	O
P2X	O
and	O
P2Y	O
receptors	O
,	O
but	O
investigation	O
of	O
the	O
clinical	O
usefulness	O
of	O
selective	O
ligands	O
is	O
at	O
an	O
early	O
stage	O
.	O

Nonetheless	O
,	O
the	O
evidence	O
considered	O
in	O
this	O
review	O
demonstrates	O
clearly	O
that	O
various	O
cardiovascular	O
disorders	O
,	O
including	O
vasospasm	O
,	O
hypertension	O
,	O
congestive	O
heart	O
failure	O
and	O
cardiac	O
damage	O
during	O
ischemic	O
episodes	O
,	O
may	O
be	O
viable	O
targets	O
.	O

With	O
further	O
development	O
of	O
novel	O
,	O
selective	O
agonists	O
and	O
antagonists	O
,	O
our	O
understanding	O
will	O
continue	O
to	O
improve	O
and	O
further	O
therapeutic	O
applications	O
are	O
likely	O
to	O
be	O
discovered	O
.	O

Therapeutic	O
applications	O
of	O
PI3	O
K	O
inhibitors	O
in	O
cardiovascular	O
diseases	O
.	O

PI3Ks	O
are	O
signaling	O
enzymes	O
engaged	O
by	O
different	O
types	O
of	O
membrane	O
receptors	O
and	O
activated	O
in	O
cardiovascular	O
diseases	O
such	O
as	O
hypertension	O
,	O
atherosclerosis	O
,	O
thrombosis	O
and	O
heart	O
failure	O
.	O

Studies	O
performed	O
on	O
genetically	O
modified	O
animals	O
have	O
provided	O
proof	O
-	O
of	O
-	O
concept	O
that	O
general	O
or	O
isoform	O
-	O
specific	O
blockade	O
of	O
these	O
enzymes	O
can	O
modify	O
disease	O
development	O
and	O
progression	O
.	O

Hence	O
,	O
therapeutic	O
inhibition	O
of	O
PI3Ks	O
with	O
novel	O
pharmacological	O
compounds	O
constitutes	O
a	O
promising	O
area	O
of	O
drug	O
development	O
.	O

In	O
particular	O
,	O
inhibitors	O
of	O
PI3Ks	O
have	O
the	O
potential	O
to	O
reduce	O
blood	O
pressure	O
,	O
restrain	O
the	O
development	O
of	O
atherosclerosis	O
and/or	O
stabilize	O
atherosclerotic	O
plaques	O
,	O
blunt	O
platelet	O
aggregation	O
,	O
prevent	O
left	O
ventricular	O
remodeling	O
and	O
preserve	O
myocardial	O
contractility	O
in	O
heart	O
failure	O
.	O

This	O
review	O
summarizes	O
the	O
rationale	O
of	O
PI3	O
K	O
inhibition	O
in	O
the	O
most	O
prevalent	O
cardiovascular	O
diseases	O
,	O
and	O
the	O
available	O
data	O
on	O
the	O
therapeutic	O
effects	O
of	O
PI3	O
K	O
inhibitors	O
in	O
their	O
preclinical	O
models	O
.	O

Implications	O
for	O
future	O
drug	O
development	O
and	O
human	O
therapy	O
are	O
also	O
discussed	O
.	O

Structural	O
Rearrangement	O
in	O
the	O
Formation	O
of	O
Jet	O
-	O
Cooled	O
Complexes	O
of	O
Chiral	O
(	B
S	I
)	I
-1,2,3,4-Tetrahydro-3-isoquinolinemethanol	I
with	O
Methyl	B
Lactate	I
:	O
Chirality	O
Effect	O
in	O
Conformer	O
Selection	O
.	O

The	O
jet	O
-	O
cooled	O
complexes	O
between	O
the	O
two	O
enantiomers	O
of	O
methyl	B
lactate	I
(	O
ML	O
)	O
and	O
(	B
S	I
)	I
-1,2,3,4-tetrahydro-3-isoquinolinemethanol	I
(	O
THIQM	B
)	O
are	O
studied	O
by	O
double	O
resonance	O
spectroscopy	O
combined	O
with	O
ab	O
initio	O
calculations	O
.	O

Both	O
diastereomer	O
complexes	O
exist	O
in	O
different	O
isomers	O
,	O
involving	O
either	O
direct	O
addition	O
of	O
THIQM	B
on	O
ML	O
with	O
no	O
structural	O
rearrangement	O
of	O
the	O
subunits	O
or	O
formation	O
of	O
very	O
stable	O
structures	O
involving	O
multiple	O
intermolecular	O
hydrogen	B
bonds	O
and	O
extensive	O
deformation	O
of	O
the	O
subunits	O
.	O

Competition	O
between	O
these	O
two	O
processes	O
and	O
its	O
dependence	O
upon	O
chirality	O
are	O
discussed	O
.	O

It	O
is	O
shown	O
that	O
the	O
most	O
stable	O
form	O
of	O
the	O
chromophore	O
(	O
THIQMI	B
with	O
an	O
OHN	B
hydrogen	B
bond	O
)	O
prefers	O
to	O
directly	O
stick	O
to	O
ML	O
to	O
form	O
the	O
addition	O
complex	O
whereas	O
the	O
second	O
conformer	O
(	O
THIQMII	B
with	O
NHO	B
hydrogen	B
bond	O
)	O
rearranges	O
to	O
form	O
a	O
strongly	O
bound	O
structure	O
.	O

The	O
two	O
structures	O
are	O
formed	O
for	O
the	O
homochiral	O
as	O
well	O
the	O
heterochiral	O
complex	O
,	O
however	O
with	O
different	O
relative	O
abundance	O
.	O

This	O
shows	O
an	O
enantioselective	O
binding	O
preference	O
of	O
ML	O
for	O
one	O
of	O
the	O
conformers	O
of	O
the	O
chromophore	O
.	O

Synthesis	O
,	O
preliminary	O
structure	O
-	O
activity	O
relationships	O
,	O
and	O
in	O
vitro	O
biological	O
evaluation	O
of	O
6-aryl-3-amino	B
-	I
thieno	I
[	I
2,3-b	I
]	I
pyridine	I
derivatives	O
as	O
potential	O
anti	O
-	O
inflammatory	O
agents	O
.	O

In	O
our	O
previous	O
study	O
,	O
a	O
series	O
of	O
6-aryl-3-amino	B
-	I
thieno	I
[	I
2,3-b	I
]	I
pyridine	I
derivatives	O
exhibited	O
potent	O
antiproliferative	O
activities	O
and	O
an	O
unique	O
hepatocellular	O
carcinoma	O
(	O
HCC	O
)	O
-specific	O
anticancer	O
activity	O
was	O
also	O
observed	O
.	O

In	O
further	O
anti	O
-	O
inflammatory	O
research	O
,	O
thienopyridine	B
derivative	O
1a	O
showed	O
potent	O
inhibition	O
of	O
nitric	B
oxide	I
(	O
NO	B
)	O
production	O
.	O

So	O
a	O
series	O
of	O
thienopyridine	B
analogues	O
of	O
1a	O
were	O
synthesized	O
and	O
evaluated	O
for	O
anti	O
-	O
inflammatory	O
activities	O
.	O

The	O
structure	O
-	O
activity	O
relationships	O
(	O
SARs	O
)	O
revealed	O
that	O
the	O
most	O
potent	O
analogues	O
1f	O
and	O
1o	O
were	O
identified	O
as	O
potent	O
inhibitors	O
of	O
NO	B
production	O
with	O
IC50	O
values	O
of	O
3.30	O
and	O
3.24	O
M	O
,	O
respectively	O
.	O

These	O
results	O
suggest	O
that	O
these	O
6-aryl-3-amino	B
-	I
thieno	I
[	I
2,3-b	I
]	I
pyridine	I
derivatives	O
might	O
potentially	O
constitute	O
a	O
novel	O
class	O
of	O
anti	O
-	O
inflammatory	O
agents	O
,	O
which	O
require	O
further	O
studies	O
.	O

Recombinant	O
proteins	O
that	O
trigger	O
production	O
of	O
antibodies	O
recognizing	O
botulinum	O
neurotoxin	O
while	O
not	O
possessing	O
sequences	O
of	O
this	O
toxin	O
.	O

Sequences	O
mimicking	O
epitopes	O
of	O
pathogens	O
can	O
be	O
used	O
as	O
effective	O
tools	O
for	O
fast	O
development	O
and	O
characterization	O
of	O
pathogen	O
-	O
specific	O
antibodies	O
.	O

To	O
demonstrate	O
this	O
,	O
we	O
used	O
phage	O
displays	O
and	O
isolated	O
a	O
number	O
of	O
short	O
peptides	O
mimicking	O
epitopes	O
of	O
botulinum	O
neurotoxin	O
serotype	O
A	O
(	O
BoNT	O
/	O
A	O
)	O
.	O

Presented	O
data	O
suggest	O
that	O
some	O
of	O
these	O
peptides	O
mimic	O
linear	O
epitopes	O
while	O
others	O
mimic	O
structural	O
epitopes	O
of	O
BoNT	O
/	O
A.	O
All	O
tested	O
peptides	O
retained	O
their	O
ability	O
to	O
be	O
recognized	O
by	O
BoNT	O
/	O
A	O
-	O
specific	O
antibodies	O
even	O
when	O
transferred	O
into	O
new	O
carrier	O
proteins	O
.	O

We	O
demonstrated	O
how	O
such	O
new	O
hybrids	O
can	O
be	O
used	O
for	O
fast	O
conversion	O
of	O
pathogen	O
-	O
specific	O
serums	O
into	O
panels	O
of	O
mono	O
-	O
epitope	O
specific	O
antibodies	O
.	O

We	O
also	O
demonstrated	O
that	O
hybrid	O
proteins	O
carrying	O
multiple	O
isolated	O
peptides	O
can	O
be	O
used	O
as	O
a	O
substitute	O
for	O
BoNT	O
/	O
A	O
in	O
immunization	O
studies	O
and	O
triggers	O
production	O
of	O
BoNT	O
/	O
A	O
-	O
specific	O
antibodies	O
.	O

Synthesis	O
and	O
antifungal	O
activity	O
of	O
C-21	O
steroids	B
with	O
an	O
aromatic	O
D	O
ring	O
.	O

Six	O
analogues	O
of	O
salpichrolides	B
with	O
a	O
simplified	O
side	O
chain	O
(	O
6	O
-	O
11	O
)	O
were	O
synthesized	O
using	O
a	O
new	O
methodology	O
to	O
obtain	O
steroids	B
with	O
an	O
aromatic	O
D	O
-	O
ring	O
.	O

The	O
key	O
step	O
was	O
the	O
elimination	O
of	O
HBr	B
in	O
a	O
vicinal	B
dibromo	I
D	I
-	I
homosteroid	I
by	O
treatment	O
with	O
1,4-diazabicyclo	B
[	I
2.2.2	I
]	I
octane	I
(	O
DABCO	B
)	O
.	O

All	O
new	O
compounds	O
were	O
completely	O
characterized	O
by	O
2D	O
NMR	O
techniques	O
and	O
tested	O
on	O
two	O
fungal	O
pathogenic	O
species	O
,	O
Fusarium	O
virguliforme	O
and	O
Fusarium	O
solani	O
.	O

DNA	O
barcoding	O
in	O
plants	O
:	O
Evolution	O
and	O
applications	O
of	O
in	O
silico	O
approaches	O
and	O
resources	O
.	O

Bioinformatics	O
has	O
played	O
an	O
important	O
role	O
in	O
the	O
analysis	O
of	O
DNA	O
barcoding	O
data	O
.	O

The	O
process	O
of	O
DNA	O
barcoding	O
initially	O
involves	O
the	O
available	O
data	O
collection	O
from	O
the	O
existing	O
databases	O
.	O

Many	O
databases	O
have	O
been	O
developed	O
in	O
recent	O
years	O
,	O
e.g.	O
MMDBD	O
[	O
Medicinal	O
Materials	O
DNA	O
Barcode	O
Database	O
]	O
,	O
BioBarcode	O
,	O
etc	O
.	O

In	O
case	O
of	O
non	O
-	O
availability	O
of	O
sequences	O
,	O
sequencing	O
has	O
to	O
be	O
done	O
in	O
vitro	O
for	O
which	O
a	O
recently	O
developed	O
software	O
ecoPrimers	O
can	O
be	O
helpful	O
.	O

This	O
is	O
followed	O
by	O
multiple	O
sequence	O
alignment	O
.	O

Further	O
,	O
basic	O
sequence	O
statistics	O
computation	O
and	O
phylogenetic	O
analysis	O
can	O
be	O
performed	O
by	O
MEGA	O
and	O
PHYLIP	O
/	O
PAUP	O
tools	O
respectively	O
.	O

Some	O
of	O
the	O
recent	O
tools	O
for	O
in	O
silico	O
and	O
statistical	O
analysis	O
specifically	O
designed	O
for	O
barcoding	O
viz	O
.	O

CAOS	O
(	O
Character	O
Based	O
DNA	O
Barcoding	O
)	O
,	O
BRONX	O
(	O
DNA	O
Barcode	O
Sequence	O
Identification	O
Incorporating	O
Taxonomic	O
Hierarchy	O
and	O
within	O
Taxon	O
Variability	O
)	O
,	O
Spider	O
(	O
Analysis	O
of	O
species	O
identity	O
and	O
evolution	O
,	O
particularly	O
DNA	O
barcoding	O
)	O
,	O
jMOTU	O
and	O
Taxonerator	O
(	O
Turning	O
DNA	O
Barcode	O
Sequences	O
into	O
Annotated	O
OTUs	O
)	O
,	O
OTUbase	O
(	O
Analysis	O
of	O
OTU	O
data	O
and	O
taxonomic	O
data	O
)	O
,	O
SAP	O
(	O
Statistical	O
Assignment	O
Package	O
)	O
,	O
etc	O
.	O
have	O
been	O
discussed	O
and	O
analysed	O
in	O
this	O
review	O
.	O

The	O
paper	O
presents	O
a	O
comprehensive	O
overview	O
of	O
the	O
various	O
in	O
silico	O
methods	O
,	O
tools	O
,	O
softwares	O
and	O
databases	O
used	O
for	O
DNA	O
barcoding	O
of	O
plants	O
.	O

Structural	O
Basis	O
for	O
the	O
ATP	B
-	O
Induced	O
Isomerization	O
of	O
Kinesin	O
.	O

Kinesin	O
superfamily	O
proteins	O
(	O
KIFs	O
)	O
are	O
microtubule	O
-	O
based	O
molecular	O
motors	O
driven	O
by	O
the	O
energy	O
derived	O
from	O
the	O
hydrolysis	O
of	O
ATP	B
.	O

Previous	O
studies	O
have	O
revealed	O
that	O
the	O
ATP	B
binding	O
step	O
is	O
crucial	O
both	O
for	O
the	O
power	O
stroke	O
to	O
produce	O
motility	O
and	O
for	O
the	O
inter	O
-	O
domain	O
regulation	O
of	O
ATPase	O
activity	O
to	O
guarantee	O
the	O
processive	O
movement	O
of	O
dimeric	O
KIFs	O
.	O

Here	O
,	O
we	O
report	O
the	O
first	O
crystal	O
structure	O
of	O
KIF4	O
complexed	O
with	O
the	O
non	O
-	O
hydrolyzable	O
ATP	B
analog	O
,	O
AMPPNP	B
(	O
adenylyl	B
imidodiphosphate	I
)	O
,	O
at	O
1.7	O
resolution	O
.	O

By	O
combining	O
our	O
structure	O
with	O
previously	O
solved	O
KIF1A	O
structures	O
complexed	O
with	O
two	O
ATP	B
analogs	O
,	O
molecular	O
snapshots	O
during	O
ATP	B
binding	O
reveal	O
that	O
the	O
closure	O
of	O
the	O
nucleotide	B
-	O
binding	O
pocket	O
during	O
ATP	B
binding	O
is	O
achieved	O
by	O
closure	O
of	O
the	O
backdoor	O
.	O

Closure	O
of	O
the	O
backdoor	O
stabilizes	O
two	O
mobile	O
regions	O
,	O
switch	O
I	O
and	O
switch	O
II	O
,	O
to	O
generate	O
the	O
phosphate	B
tube	O
from	O
which	O
hydrolyzed	O
phosphate	B
is	O
released	O
.	O

Through	O
the	O
stabilization	O
of	O
switch	O
II	O
,	O
the	O
local	O
conformational	O
change	O
at	O
the	O
catalytic	O
center	O
is	O
further	O
relayed	O
to	O
the	O
neck	O
-	O
linker	O
element	O
that	O
fully	O
docks	O
to	O
the	O
catalytic	O
core	O
to	O
produce	O
the	O
power	O
stroke	O
.	O

Because	O
the	O
neck	O
linker	O
is	O
a	O
sole	O
element	O
that	O
connects	O
the	O
partner	O
heads	O
in	O
dimeric	O
KIFs	O
,	O
this	O
tight	O
structural	O
coordination	O
between	O
the	O
catalytic	O
center	O
and	O
neck	O
linker	O
enables	O
inter	O
-	O
domain	O
communication	O
between	O
the	O
partner	O
heads	O
.	O

This	O
study	O
also	O
revealed	O
the	O
putative	O
microtubule	O
-	O
binding	O
site	O
of	O
KIF4	O
,	O
thus	O
providing	O
structural	O
insights	O
that	O
describe	O
the	O
specific	O
binding	O
of	O
KIF4	O
to	O
the	O
microtubule	O
.	O

A	O
Two	O
-	O
State	O
Cooperative	O
Expansion	O
Converts	O
the	O
Procapsid	O
Shell	O
of	O
Bacteriophage	O
T5	O
into	O
a	O
Highly	O
Stable	O
Capsid	O
Isomorphous	O
to	O
the	O
Final	O
Virion	O
Head	O
.	O

Capsids	O
of	O
double	O
-	O
stranded	O
DNA	O
(	O
dsDNA	O
)	O
bacteriophages	O
initially	O
assemble	O
into	O
compact	O
procapsids	O
,	O
which	O
undergo	O
expansion	O
upon	O
the	O
genome	O
packaging	O
.	O

This	O
shell	O
remodeling	O
results	O
from	O
a	O
structural	O
rearrangement	O
of	O
head	O
protein	O
subunits	O
.	O

It	O
is	O
a	O
critical	O
step	O
in	O
the	O
capsid	O
maturation	O
pathway	O
that	O
yields	O
final	O
particles	O
capable	O
to	O
withstand	O
the	O
huge	O
internal	O
pressure	O
generated	O
by	O
the	O
packed	O
DNA	O
.	O

Here	O
,	O
we	O
report	O
on	O
the	O
expansion	O
process	O
of	O
the	O
large	O
capsid	O
(	O
T=13	O
)	O
of	O
bacteriophage	O
T5	O
.	O

We	O
purified	O
the	O
intermediate	O
prohead	O
II	O
form	O
,	O
which	O
is	O
competent	O
for	O
packaging	O
the	O
121-kbp	O
dsDNA	O
genome	O
,	O
and	O
we	O
investigated	O
its	O
morphology	O
and	O
dimensions	O
using	O
cryo	O
-	O
electron	O
microscopy	O
and	O
small	O
-	O
angle	O
X	O
-	O
ray	O
scattering	O
.	O

Decreasing	O
the	O
pH	O
or	O
the	O
ionic	O
strength	O
triggers	O
expansion	O
of	O
prohead	O
II	O
,	O
converting	O
them	O
into	O
thinner	O
and	O
more	O
faceted	O
capsids	O
isomorphous	O
to	O
the	O
mature	O
virion	O
particles	O
.	O

At	O
low	O
pH	O
,	O
prohead	O
II	O
expansion	O
is	O
a	O
highly	O
cooperative	O
process	O
lacking	O
any	O
detectable	O
intermediate	O
.	O

This	O
two	O
-	O
state	O
reorganization	O
of	O
the	O
capsid	O
lattice	O
per	O
se	O
leads	O
to	O
a	O
remarkable	O
stabilization	O
of	O
the	O
particle	O
.	O

The	O
melting	O
temperature	O
of	O
expanded	O
T5	O
capsid	O
is	O
virtually	O
identical	O
with	O
that	O
of	O
more	O
complex	O
shells	O
that	O
are	O
reinforced	O
by	O
inter	O
-	O
subunit	O
cross	O
-	O
linking	O
(	O
HK97	O
)	O
or	O
by	O
additional	O
cementing	O
proteins	O
(	O
T4	O
)	O
.	O

The	O
T5	O
capsid	O
with	O
its	O
"	O
simple	O
"	O
two	O
-	O
state	O
conversion	O
thus	O
appears	O
to	O
be	O
a	O
very	O
attractive	O
model	O
for	O
investigating	O
the	O
mechanism	O
of	O
the	O
large	O
-	O
scale	O
allosteric	O
transition	O
that	O
takes	O
place	O
upon	O
the	O
genome	O
packaging	O
of	O
dsDNA	O
bacteriophages	O
.	O

Sorting	O
out	O
Semiconducting	O
Single	O
-	O
Walled	O
Carbon	B
Nanotube	O
Arrays	O
by	O
Washing	O
off	O
Metallic	O
Tubes	O
Using	O
SDS	B
Aqueous	O
Solution	O
.	O

Semiconducting	O
single	O
-	O
walled	O
carbon	B
nanotube	O
(	O
s	O
-	O
SWNT	O
)	O
arrays	O
are	O
produced	O
via	O
a	O
procedure	O
analogous	O
to	O
a	O
surfactant	O
-	O
assisted	O
decontamination	O
process	O
.	O

Aligned	O
individual	O
SWNT	O
arrays	O
grow	O
on	O
a	O
quartz	B
surface	O
as	O
a	O
mixture	O
of	O
metallic	O
SWNTs	O
(	O
m	O
-	O
SWNTs	O
)	O
and	O
s	O
-	O
SWNTs	O
.	O

They	O
are	O
immersed	O
in	O
a	O
sodium	B
dodecyl	I
sulfate	I
(	O
SDS	B
)	O
solution	O
,	O
and	O
the	O
SDS	B
molecules	O
selectively	O
adsorb	O
onto	O
m	O
-	O
SWNTs	O
.	O

This	O
SDS	B
coating	O
minimizes	O
the	O
interaction	O
between	O
m	O
-	O
SWNTs	O
and	O
the	O
substrate	O
,	O
thus	O
the	O
m	O
-	O
SWNTs	O
are	O
easily	O
washed	O
off	O
during	O
ultrasonication	O
while	O
the	O
s	O
-	O
SWNT	O
arrays	O
remain	O
on	O
the	O
substrate	O
.	O

The	O
percentage	O
of	O
s	O
-	O
SWNTs	O
in	O
the	O
arrays	O
can	O
be	O
higher	O
than	O
90	O
%	O
.	O

Electrochemical	O
Oxygen	B
Reduction	O
Behavior	O
of	O
Selectively	O
Deposited	O
Platinum	B
Atoms	O
on	O
Gold	O
Nanoparticles	O
.	O

Carbon	B
-	O
supported	O
Pt@Au	B
"	O
core	O
-	O
shell	O
"	O
nanoparticles	O
with	O
varying	O
surface	O
concentration	O
of	O
platinum	B
atoms	O
have	O
been	O
synthesized	O
using	O
a	O
novel	O
redox	O
-	O
mediated	O
synthesis	O
approach	O
.	O

The	O
synthesis	O
technique	O
allows	O
for	O
a	O
selective	O
deposition	O
of	O
platinum	B
atoms	O
on	O
the	O
surface	O
of	O
prefabricated	O
gold	O
nanoparticles	O
.	O

Energy	O
dispersive	O
spectroscopic	O
analyses	O
in	O
a	O
scanning	O
electron	O
microscope	O
reveal	O
that	O
the	O
platinum	B
to	O
gold	O
atomic	O
ratios	O
are	O
close	O
to	O
the	O
nominal	O
values	O
,	O
validating	O
the	O
synthesis	O
scheme	O
.	O

X	O
-	O
ray	O
diffraction	O
data	O
indicate	O
an	O
un	O
-	O
alloyed	O
structure	O
.	O

The	O
platinum	B
to	O
gold	O
surface	O
atomic	O
ratio	O
determined	O
from	O
cyclic	O
voltammetry	O
and	O
copper	B
under	O
-	O
potential	O
deposition	O
experiments	O
reveal	O
good	O
agreement	O
with	O
the	O
calculated	O
values	O
at	O
low	O
platinum	B
concentration	O
.	O

However	O
,	O
there	O
is	O
an	O
increase	O
in	O
non	O
-	O
uniformity	O
in	O
the	O
deposition	O
process	O
upon	O
increasing	O
the	O
platinum	B
concentration	O
.	O

Koutecky	O
-	O
Levich	O
analysis	O
of	O
the	O
samples	O
indicates	O
a	O
transition	O
of	O
the	O
total	O
number	O
of	O
electrons	O
transferred	O
(	O
n	O
)	O
in	O
the	O
electrochemical	O
oxygen	B
reduction	O
reaction	O
from	O
two	O
to	O
four	O
electrons	O
upon	O
increasing	O
the	O
surface	O
concentration	O
of	O
platinum	B
atoms	O
.	O

Furthermore	O
,	O
the	O
data	O
indicate	O
that	O
isolated	O
platinum	B
atoms	O
can	O
reduce	O
molecular	O
oxygen	B
but	O
via	O
a	O
two	O
-	O
electron	O
route	O
.	O

Moreover	O
,	O
successful	O
four	O
-	O
electron	O
reduction	O
of	O
molecular	O
oxygen	B
requires	O
clusters	O
of	O
platinum	B
atoms	O
.	O

Synthesis	O
of	O
phenyleneethynylene	B
-	O
doped	O
poly	B
(	I
pphenylenebutadiynylene	I
)	I
s	I
for	O
live	O
cell	O
imaging	O
.	O

We	O
developed	O
a	O
new	O
synthetic	O
approach	O
to	O
high	O
molecular	O
weight	O
poly	B
(	I
p	I
-	I
phenylenebutadiynylene	I
)	I
s	I
(	O
PPBs	B
)	O
by	O
increasing	O
backbone	O
flexibility	O
.	O

The	O
introduction	O
of	O
a	O
small	O
amount	O
of	O
flexible	O
units	O
along	O
the	O
backbone	O
improved	O
both	O
the	O
physical	O
and	O
photophysical	O
properties	O
of	O
the	O
polymers	O
.	O

These	O
materials	O
were	O
successfully	O
fabricated	O
into	O
conjugated	O
polymer	O
nanoparticles	O
(	O
CPNs	O
)	O
and	O
used	O
for	O
fluorescent	O
live	O
cell	O
imaging	O
for	O
the	O
first	O
time	O
.	O

Transition	O
to	O
Reinforced	O
State	O
by	O
Percolating	O
Domains	O
of	O
Intercalated	O
Brush	O
-	O
Modified	O
Cellulose	O
Nanocrystals	O
and	O
Poly	B
(	I
butadiene	I
)	I
in	O
Cross	O
-	O
Linked	O
Composites	O
Based	O
on	O
Thiol	B
-	I
ene	I
Click	O
Chemistry	O
.	O

The	O
classic	O
nanocomposite	O
approach	O
aims	O
at	O
percolation	O
of	O
low	O
fraction	O
of	O
exfoliated	O
individual	O
reinforcing	O
nanoscale	O
elements	O
within	O
a	O
polymeric	O
matrix	O
.	O

By	O
contrast	O
,	O
many	O
of	O
the	O
mechanically	O
excellent	O
biological	O
nanocomposites	O
involve	O
self	O
-	O
assembled	O
and	O
space	O
-	O
filled	O
structures	O
of	O
hard	O
reinforcing	O
and	O
soft	O
toughening	O
domains	O
,	O
with	O
high	O
weight	O
fraction	O
of	O
reinforcements	O
.	O

Here	O
we	O
inspect	O
a	O
new	O
concept	O
toward	O
mimicking	O
such	O
structures	O
by	O
studying	O
whether	O
percolation	O
of	O
intercalated	O
domains	O
consisting	O
of	O
alternating	O
rigid	O
and	O
reinforcing	O
,	O
and	O
soft	O
rubbery	O
domains	O
could	O
allow	O
a	O
transition	O
to	O
a	O
reinforced	O
state	O
.	O

Toward	O
that	O
,	O
we	O
present	O
the	O
functionalization	O
of	O
rigid	O
native	O
cellulose	O
nanocrystals	O
(	O
CNCs	O
)	O
by	O
esterification	O
with	O
a	O
dense	O
hydrocarbon	B
chain	O
brush	O
containing	O
cross	O
-	O
linkable	O
double	O
bonds	O
.	O

Composite	O
films	O
with	O
0	O
-	O
80	O
wt	O
%	O
of	O
such	O
modified	O
CNCs	O
(	O
mCNCs	O
)	O
within	O
a	O
poly	B
(	I
butadiene	I
)	I
(	O
PBD	B
)	O
rubber	O
matrix	O
were	O
prepared	O
via	O
cross	O
-	O
linking	O
by	O
UV	O
-	O
light	O
initiated	O
thiol	B
-	I
ene	I
click	O
reaction	O
.	O

Transmission	O
electron	O
microscopy	O
showed	O
structures	O
at	O
two	O
length	O
scales	O
,	O
where	O
the	O
mCNCs	O
and	O
PBD	B
form	O
domains	O
having	O
internal	O
aligned	O
self	O
-	O
assemblies	O
of	O
alternating	O
hard	O
mCNCs	O
and	O
soft	O
PBD	B
with	O
periodicity	O
of	O
ca	O
.	O

40	O
nm	O
,	O
and	O
where	O
additional	O
PBD	B
connects	O
such	O
domains	O
.	O

Increasing	O
the	O
weight	O
fraction	O
of	O
mCNCs	O
causes	O
an	O
uncommon	O
abrupt	O
transition	O
from	O
PBD	B
-	O
dominated	O
soft	O
materials	O
to	O
significantly	O
reinforced	O
mCNC	O
-	O
dominated	O
mechanical	O
properties	O
,	O
suggesting	O
that	O
the	O
intercalated	O
self	O
-	O
assembled	O
mCNC	O
/	O
PBD	B
domains	O
percolate	O
in	O
PBD	B
upon	O
passing	O
30	O
-	O
35	O
wt	O
%	O
of	O
mCNCs	O
.	O

Maximum	O
stress	O
of	O
16	O
MPa	O
at	O
mCNC	O
fraction	O
of	O
80	O
wt	O
%	O
was	O
obtained	O
.	O

The	O
mechanical	O
properties	O
of	O
the	O
composites	O
show	O
exceptional	O
insensitivity	O
to	O
air	O
humidity	O
.	O

The	O
shown	O
simple	O
concept	O
of	O
percolative	O
intercalated	O
nanocomposites	O
suggests	O
searching	O
for	O
more	O
general	O
biomimetic	O
compositions	O
involving	O
several	O
deformation	O
mechanisms	O
for	O
improved	O
mechanical	O
properties	O
.	O

Paths	O
to	O
selection	O
on	O
life	O
history	O
loci	O
in	O
different	O
natural	O
environments	O
across	O
the	O
native	O
range	O
of	O
Arabidopsis	O
thaliana	O
.	O

Selection	O
on	O
quantitative	O
trait	O
loci	O
(	O
QTL	O
)	O
may	O
vary	O
among	O
natural	O
environments	O
due	O
to	O
differences	O
in	O
the	O
genetic	O
architecture	O
of	O
traits	O
,	O
environment	O
-	O
specific	O
allelic	O
effects	O
or	O
changes	O
in	O
the	O
direction	O
and	O
magnitude	O
of	O
selection	O
on	O
specific	O
traits	O
.	O

To	O
dissect	O
the	O
environmental	O
differences	O
in	O
selection	O
on	O
life	O
history	O
QTL	O
across	O
climatic	O
regions	O
,	O
we	O
grew	O
a	O
panel	O
of	O
interconnected	O
recombinant	O
inbred	O
lines	O
(	O
RILs	O
)	O
of	O
Arabidopsis	O
thaliana	O
in	O
four	O
field	O
sites	O
across	O
its	O
native	O
European	O
range	O
.	O

For	O
each	O
environment	O
,	O
we	O
mapped	O
QTL	O
for	O
growth	O
,	O
reproductive	O
timing	O
and	O
development	O
.	O

Several	O
QTL	O
were	O
pleiotropic	O
across	O
environments	O
,	O
three	O
colocalizing	O
with	O
known	O
functional	O
polymorphisms	O
in	O
flowering	O
time	O
genes	O
(	O
CRY2	O
,	O
FRI	O
and	O
MAF2	O
-	O
5	O
)	O
,	O
but	O
major	O
QTL	O
differed	O
across	O
field	O
sites	O
,	O
showing	O
conditional	O
neutrality	O
.	O

We	O
used	O
structural	O
equation	O
models	O
to	O
trace	O
selection	O
paths	O
from	O
QTL	O
to	O
lifetime	O
fitness	O
in	O
each	O
environment	O
.	O

Only	O
three	O
QTL	O
directly	O
affected	O
fruit	O
number	O
,	O
measuring	O
fitness	O
.	O

Most	O
QTL	O
had	O
an	O
indirect	O
effect	O
on	O
fitness	O
through	O
their	O
effect	O
on	O
bolting	O
time	O
or	O
leaf	O
length	O
.	O

Influence	O
of	O
life	O
history	O
traits	O
on	O
fitness	O
differed	O
dramatically	O
across	O
sites	O
,	O
resulting	O
in	O
different	O
patterns	O
of	O
selection	O
on	O
reproductive	O
timing	O
and	O
underlying	O
QTL	O
.	O

In	O
two	O
oceanic	O
field	O
sites	O
with	O
high	O
prereproductive	O
mortality	O
,	O
QTL	O
alleles	O
contributing	O
to	O
early	O
reproduction	O
resulted	O
in	O
greater	O
fruit	O
production	O
,	O
conferring	O
selective	O
advantage	O
,	O
whereas	O
alleles	O
contributing	O
to	O
later	O
reproduction	O
resulted	O
in	O
larger	O
size	O
and	O
higher	O
fitness	O
in	O
a	O
continental	O
site	O
.	O

This	O
demonstrates	O
how	O
environmental	O
variation	O
leads	O
to	O
change	O
in	O
both	O
QTL	O
effect	O
sizes	O
and	O
direction	O
of	O
selection	O
on	O
traits	O
,	O
justifying	O
the	O
persistence	O
of	O
allelic	O
polymorphism	O
at	O
life	O
history	O
QTL	O
across	O
the	O
species	O
range	O
.	O

Binding	O
Specificity	O
and	O
Thermodynamics	O
of	O
Cellulose	O
-	O
Binding	O
Modules	O
from	O
Trichoderma	O
reesei	O
Cel7A	O
and	O
Cel6A	O
.	O

In	O
this	O
work	O
,	O
Family	O
1	O
cellulose	O
binding	O
modules	O
CBMCel7A	O
and	O
CBMCel6A	O
were	O
heterologously	O
expressed	O
and	O
purified	O
from	O
Escherichia	O
coli	O
,	O
and	O
the	O
binding	O
properties	O
between	O
these	O
CBMs	O
and	O
cellulose	O
substrates	O
were	O
studied	O
.	O

Cellulose	O
nanowhiskers	O
(	O
CNWs	O
,	O
the	O
crystalline	O
portion	O
of	O
cellulose	O
)	O
,	O
microcrystalline	O
cellulose	O
Avicel	O
PH101	O
(	O
partially	O
crystalline	O
cellulose	O
)	O
,	O
and	O
phosphoric	B
acid	I
swollen	O
cellulose	O
(	O
PASC	O
,	O
amorphous	O
cellulose	O
)	O
were	O
used	O
as	O
representative	O
models	O
for	O
cellulose	O
to	O
better	O
understand	O
the	O
binding	O
interactions	O
between	O
the	O
CBMs	O
and	O
different	O
regions	O
of	O
native	O
cellulose	O
.	O

Isothermal	O
titration	O
calorimetry	O
(	O
ITC	O
)	O
was	O
combined	O
with	O
adsorption	O
-	O
isotherm	O
experiment	O
to	O
analyze	O
the	O
thermodynamics	O
of	O
CBM	O
binding	O
to	O
various	O
cellulose	O
substrates	O
.	O

N2	B
adsorption	O
and	O
static	O
light	O
scattering	O
(	O
SLS	O
)	O
data	O
were	O
used	O
to	O
estimate	O
the	O
accessible	O
surface	O
area	O
of	O
cellulose	O
which	O
was	O
then	O
used	O
for	O
ITC	O
data	O
analysis	O
.	O

A	O
new	O
method	O
of	O
determining	O
the	O
cellulose	O
molarity	O
based	O
on	O
the	O
available	O
surface	O
area	O
for	O
CBM	O
binding	O
was	O
developed	O
,	O
which	O
allows	O
different	O
cellulose	O
substrates	O
to	O
be	O
compared	O
for	O
binding	O
experiments	O
.	O

The	O
ITC	O
results	O
showed	O
that	O
the	O
binding	O
constant	O
(	O
Ka	O
)	O
to	O
crystalline	O
CNWs	O
was	O
10	O
(	O
5	O
)	O
M	O
(	O
-1	O
)	O
for	O
CBMCel7A	O
,	O
while	O
10	O
(	O
6	O
)	O
M	O
(	O
-1	O
)	O
for	O
CBMCel6A	O
,	O
suggesting	O
a	O
higher	O
binding	O
affinity	O
of	O
CBMCel6A	O
to	O
CNWs	O
.	O

For	O
Avicel	O
,	O
lower	O
binding	O
constants	O
for	O
both	O
CBMs	O
were	O
observed	O
,	O
and	O
weak	O
bindings	O
to	O
PASC	O
were	O
characterized	O
,	O
suggesting	O
that	O
the	O
binding	O
between	O
CBMCel7A	O
,	O
Cel6A	O
and	O
cellulose	O
to	O
some	O
extent	O
relates	O
to	O
the	O
crystallinity	O
of	O
cellulose	O
.	O

Additionally	O
,	O
the	O
binding	O
reactions	O
were	O
driven	O
by	O
a	O
favorable	O
enthalpy	O
change	O
,	O
offset	O
partially	O
by	O
an	O
unfavorable	O
entropy	O
change	O
.	O

It	O
is	O
suggested	O
that	O
CBMCel6A	O
preferentially	O
binds	O
to	O
the	O
reducing	O
end	O
of	O
cellulose	O
chain	O
,	O
while	O
CBMCel7A	O
does	O
not	O
show	O
such	O
end	O
binding	O
specificities	O
.	O

Cello	O
-	O
oligosaccharides	O
less	O
than	O
two	O
glucose	B
units	O
did	O
not	O
bind	O
with	O
CBMs	O
,	O
and	O
improved	O
binding	O
affinities	O
were	O
observed	O
for	O
cello	O
-	O
oligosaccharides	O
with	O
longer	O
glucose	B
units	O
.	O

LC	O
-	O
MS	O
/	O
MS	O
Determination	O
of	O
Isoprostanes	B
in	O
Plasma	O
Samples	O
Collected	O
from	O
Mice	O
Exposed	O
to	O
Doxorubicin	B
or	O
Tert	B
-	I
Butyl	I
Hydroperoxide	I
.	O

Isoprostanes	B
are	O
stable	O
products	O
of	O
arachidonic	B
acid	I
peroxidation	O
and	O
are	O
regarded	O
as	O
the	O
most	O
reliable	O
markers	O
of	O
oxidative	O
stress	O
in	O
vivo	O
.	O

Here	O
we	O
describe	O
the	O
LC	O
-	O
MS	O
/	O
MS	O
procedure	O
enabling	O
simultaneous	O
determination	O
of	O
four	O
regioisomers	O
(	O
8-iso	B
prostaglandin	I
F2	I
,	O
8-iso-15	B
(	I
R	I
)	I
-prostaglandin	I
F2	I
,	O
11	B
-	I
prostaglandin	I
F2	I
,	O
15	B
(	I
R	I
)	I
-prostaglandin	I
F2	I
)	O
in	O
plasma	O
samples	O
collected	O
from	O
mice	O
.	O

The	O
four	O
plasma	O
isoprostanes	B
are	O
determined	O
by	O
LC	O
-	O
ESI	O
-	O
MS	O
/	O
MS	O
with	O
deuterated	O
8-iso	B
-	I
PGF2	I
-	I
d4	I
as	O
an	O
internal	O
standard	O
(	O
I.S.	O
)	O
.	O

For	O
plasma	O
samples	O
spiked	O
with	O
the	O
isoprostanes	B
at	O
a	O
level	O
of	O
200	O
pg	O
/	O
mL	O
each	O
,	O
the	O
method	O
imprecision	O
has	O
been	O
below	O
7.1	O
%	O
and	O
mean	O
inaccuracy	O
equaled	O
8.7	O
%	O
.	O

The	O
applicability	O
of	O
the	O
proposed	O
approach	O
has	O
been	O
verified	O
by	O
the	O
assessment	O
of	O
changes	O
in	O
isoprostane	B
levels	O
in	O
plasma	O
samples	O
derived	O
from	O
mice	O
exposed	O
to	O
tert	B
-	I
butyl	I
hydroperoxide	I
(	O
TBHP	B
)	O
,	O
a	O
model	O
inducer	O
of	O
oxidative	O
stress	O
,	O
or	O
to	O
antitumor	O
drug	O
doxorubicin	B
(	O
DOX	B
)	O
known	O
for	O
potent	O
stimulation	O
of	O
redox	O
cycling	O
.	O

Compared	O
to	O
the	O
control	O
group	O
of	O
mice	O
,	O
both	O
oxidative	O
stress	O
inducers	O
tested	O
increased	O
the	O
levels	O
of	O
three	O
out	O
of	O
four	O
isoprostanes	O
in	O
exposed	O
animals	O
;	O
11	B
-	I
prostaglandin	I
F2	I
being	O
the	O
exception	O
.	O

The	O
greatest	O
rise	O
was	O
observed	O
in	O
the	O
case	O
of	O
15	B
(	I
R	I
)	I
-prostaglandin	I
F2	I
,	O
by	O
about	O
50	O
%	O
and	O
70	O
%	O
in	O
plasma	O
samples	O
derived	O
from	O
mice	O
exposed	O
to	O
DOX	B
and	O
TBHP	B
,	O
respectively	O
.	O

Droplet	O
-	O
based	O
microfluidic	O
platform	O
for	O
heterogeneous	O
enzymatic	O
assays	O
.	O

Heterogeneous	O
enzymatic	O
reactions	O
are	O
used	O
in	O
many	O
industrial	O
processes	O
including	O
pulp	O
and	O
paper	O
,	O
food	O
,	O
and	O
biofuel	O
production	O
.	O

Industrially	O
-	O
relevant	O
optimization	O
of	O
the	O
enzymes	O
used	O
in	O
these	O
processes	O
requires	O
assaying	O
them	O
with	O
insoluble	O
substrates	O
.	O

However	O
,	O
platforms	O
for	O
high	O
throughput	O
heterogeneous	O
assays	O
do	O
not	O
exist	O
thereby	O
severely	O
increasing	O
the	O
cost	O
and	O
time	O
of	O
enzyme	O
optimization	O
,	O
or	O
leading	O
to	O
the	O
use	O
of	O
assays	O
with	O
soluble	O
substrates	O
for	O
convenient	O
,	O
but	O
non	O
-	O
ideal	O
,	O
optimization	O
.	O

We	O
present	O
an	O
innovative	O
approach	O
to	O
perform	O
heterogeneous	O
reactions	O
in	O
a	O
high	O
throughput	O
fashion	O
using	O
droplet	O
microfluidics	O
.	O

Droplets	O
provide	O
a	O
facile	O
platform	O
for	O
heterogeneous	O
reactions	O
as	O
internal	O
recirculation	O
allows	O
rapid	O
mixing	O
of	O
insoluble	O
substrates	O
with	O
soluble	O
enzymes	O
.	O

Moreover	O
,	O
it	O
is	O
easy	O
to	O
generate	O
hundreds	O
or	O
thousands	O
of	O
picoliter	O
droplets	O
in	O
a	O
small	O
footprint	O
chip	O
allowing	O
many	O
parallel	O
reactions	O
.	O

We	O
validate	O
our	O
approach	O
by	O
screening	O
combinations	O
of	O
cellulases	O
with	O
real	O
-	O
world	O
insoluble	O
substrates	O
,	O
and	O
demonstrate	O
that	O
the	O
chip	O
-	O
based	O
screening	O
is	O
in	O
excellent	O
agreement	O
with	O
the	O
conventional	O
screening	O
methods	O
,	O
while	O
offering	O
advantages	O
of	O
throughput	O
,	O
speed	O
and	O
lower	O
reagent	O
consumption	O
.	O

We	O
believe	O
that	O
our	O
approach	O
,	O
while	O
demonstrated	O
for	O
a	O
biofuel	O
application	O
,	O
provides	O
a	O
generic	O
platform	O
for	O
high	O
throughput	O
monitoring	O
of	O
heterogeneous	O
reactions	O
.	O

Lysophosphatidic	B
acid	I
impairs	O
glucose	B
homeostasis	O
and	O
inhibits	O
insulin	O
secretion	O
in	O
high	O
-	O
fat	O
diet	O
obese	O
mice	O
.	O

AIMS	O
/	O
HYPOTHESIS	O
:	O
Lysophosphatidic	B
acid	I
(	O
LPA	B
)	O
is	O
a	O
lipid	O
mediator	O
produced	O
by	O
adipocytes	O
that	O
acts	O
via	O
specific	O
G	O
-	O
protein	O
-	O
coupled	O
receptors	O
;	O
its	O
synthesis	O
is	O
modulated	O
in	O
obesity	O
.	O

We	O
previously	O
reported	O
that	O
reducing	O
adipocyte	O
LPA	B
production	O
in	O
high	O
-	O
fat	O
diet	O
(	O
HFD	O
)	O
-fed	O
obese	O
mice	O
is	O
associated	O
with	O
improved	O
glucose	B
tolerance	O
,	O
suggesting	O
a	O
negative	O
impact	O
of	O
LPA	B
on	O
glucose	B
homeostasis	O
.	O

Here	O
,	O
our	O
aim	O
was	O
to	O
test	O
this	O
hypothesis	O
.	O

METHODS	O
:	O
First	O
,	O
glucose	B
tolerance	O
and	O
plasma	O
insulin	O
were	O
assessed	O
after	O
acute	O
(	O
30	O
min	O
)	O
injection	O
of	O
LPA	B
(	O
50	O
mg	O
/	O
kg	O
)	O
or	O
of	O
the	O
LPA1	O
/	O
LPA3	O
receptor	O
antagonist	O
Ki16425	O
(	O
5	O
mg	O
kg	O
(	O
-1	O
)	O
day	O
(	O
-1	O
)	O
,	O
i.p	O
.	O
)	O
in	O
non	O
-	O
obese	O
mice	O
fed	O
a	O
normal	O
diet	O
(	O
ND	O
)	O
and	O
in	O
obese	O
/	O
prediabetic	O
(	O
defined	O
as	O
glucose	B
-	O
intolerant	O
)	O
HFD	O
mice	O
.	O

Glucose	B
and	O
insulin	O
tolerance	O
,	O
pancreas	O
morphology	O
,	O
glycogen	O
storage	O
,	O
glucose	B
oxidation	O
and	O
glucose	B
transport	O
were	O
then	O
studied	O
after	O
chronic	O
treatment	O
(	O
3	O
weeks	O
)	O
of	O
HFD	O
mice	O
with	O
Ki16425	O
.	O

RESULTS	O
:	O
In	O
ND	O
and	O
HFD	O
mice	O
,	O
LPA	B
acutely	O
impaired	O
glucose	B
tolerance	O
by	O
inhibiting	O
glucose	B
-	O
induced	O
insulin	O
secretion	O
.	O

These	O
effects	O
were	O
blocked	O
by	O
pre	O
-	O
injection	O
of	O
Ki16425	O
(	O
5	O
mg	O
/	O
kg	O
,	O
i.p	O
.	O
)	O
.	O

Inhibition	O
of	O
glucose	B
-	O
induced	O
insulin	O
secretion	O
by	O
LPA	B
also	O
occurred	O
in	O
isolated	O
mouse	O
islets	O
.	O

Plasma	O
LPA	B
was	O
higher	O
in	O
HFD	O
mice	O
than	O
in	O
ND	O
mice	O
and	O
Ki16425	O
transiently	O
improved	O
glucose	B
tolerance	O
.	O

The	O
beneficial	O
effect	O
of	O
Ki16425	O
became	O
permanent	O
after	O
chronic	O
treatment	O
and	O
was	O
associated	O
with	O
increased	O
pancreatic	O
islet	O
mass	O
and	O
higher	O
fasting	O
insulinaemia	O
.	O

Chronic	O
treatment	O
with	O
Ki16425	O
also	O
improved	O
insulin	O
tolerance	O
and	O
increased	O
liver	O
glycogen	O
storage	O
and	O
basal	O
glucose	B
use	O
in	O
skeletal	O
muscle	O
.	O

CONCLUSIONS	O
/	O
INTERPRETATION	O
:	O
Exogenous	O
and	O
endogenous	O
LPA	B
exerts	O
a	O
deleterious	O
effect	O
on	O
glucose	B
disposal	O
through	O
a	O
reduction	O
of	O
plasma	O
insulin	O
;	O
pharmacological	O
blockade	O
of	O
LPA	B
receptors	O
improves	O
glucose	B
homeostasis	O
in	O
obese	O
/	O
prediabetic	O
mice	O
.	O

Carbonic	O
anhydrase	O
inhibitors	O
:	O
Inhibition	O
of	O
the	O
	O
-	O
class	O
enzyme	O
from	O
the	O
pathogenic	O
yeast	O
Candida	O
glabrata	O
with	O
sulfonamides	B
,	O
sulfamates	B
and	O
sulfamides	B
.	O

The	O
fungal	O
pathogen	O
Candida	O
glabrata	O
encodes	O
for	O
a	O
	O
-	O
carbonic	O
anhydrase	O
(	O
CA	O
,	O
EC	O
4.2.1.1	O
)	O
,	O
CgNce103	O
,	O
recently	O
discovered	O
.	O

Only	O
anions	O
have	O
been	O
investigated	O
as	O
CgNce103	O
inhibitors	O
up	O
until	O
now	O
.	O

Here	O
we	O
report	O
the	O
first	O
sulfonamides	B
inhibition	O
study	O
of	O
this	O
enzyme	O
.	O

Simple	O
sulfonamides	B
showed	O
weak	O
or	O
moderate	O
CgNce103	O
inhibitory	O
properties	O
,	O
whereas	O
acetazolamide	B
,	O
and	O
a	O
series	O
of	O
4-substituted	B
ureido	I
-	I
benzene	I
-	I
sulfonamides	I
,	O
sulfamates	B
and	O
sulfamides	B
showed	O
effective	O
CgNce103	O
inhibitory	O
properties	O
,	O
with	O
KIs	O
in	O
the	O
range	O
of	O
4.1	O
-	O
115nM	O
,	O
being	O
also	O
ineffective	O
as	O
human	O
CA	O
II	O
inhibitors	O
.	O

As	O
there	O
is	O
significant	O
resistance	O
of	O
C.	O
glabrata	O
clinical	O
isolates	O
to	O
many	O
classical	O
antifungal	O
agents	O
,	O
inhibition	O
of	O
the	O
	O
-	O
CA	O
from	O
this	O
organism	O
may	O
allow	O
an	O
interesting	O
means	O
of	O
controlling	O
the	O
pathogen	O
growth	O
,	O
eventually	O
leading	O
to	O
antifungals	O
with	O
a	O
novel	O
mechanism	O
of	O
action	O
.	O

A	O
copper	B
hyperaccumulation	O
phenotype	O
correlates	O
with	O
pathogenesis	O
in	O
Cryptococcus	O
neoformans	O
.	O

Cryptococcus	O
neoformans	O
is	O
a	O
major	O
human	O
pathogen	O
and	O
a	O
cause	O
of	O
meningoencephalitis	O
in	O
immunocompromised	O
patients	O
.	O

Many	O
factors	O
contribute	O
to	O
the	O
extraordinary	O
survivability	O
and	O
pathogenicity	O
of	O
this	O
fungus	O
in	O
humans	O
,	O
including	O
copper	B
homeostasis	O
pathways	O
.	O

Previous	O
work	O
has	O
shown	O
that	O
deletion	O
of	O
the	O
copper	B
-	O
dependent	O
regulator	O
Cuf1	O
results	O
in	O
decreased	O
virulence	O
and	O
dissemination	O
in	O
brain	O
infection	O
,	O
suggesting	O
that	O
copper	B
acquisition	O
is	O
important	O
to	O
the	O
persistence	O
of	O
this	O
pathogen	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
minimal	O
copper	B
quota	O
of	O
C.	O
neoformans	O
is	O
maintained	O
at	O
a	O
high	O
level	O
even	O
when	O
grown	O
under	O
conditions	O
of	O
stringent	O
copper	B
limitation	O
.	O

Intriguingly	O
,	O
when	O
this	O
fungal	O
pathogen	O
is	O
grown	O
in	O
standard	O
and	O
copper	B
-	O
enriched	O
media	O
,	O
it	O
sequesters	O
even	O
higher	O
levels	O
of	O
this	O
essential	O
metal	O
,	O
achieving	O
levels	O
that	O
are	O
far	O
higher	O
than	O
non	O
-	O
pathogenic	O
S.	O
cerevisiae	O
.	O

The	O
hypothesis	O
that	O
copper	B
acquisition	O
plays	O
an	O
essential	O
role	O
in	O
virulence	O
is	O
further	O
corroborated	O
by	O
the	O
findings	O
that	O
a	O
hypovirulent	O
CUF1-deletant	O
strain	O
of	O
C.	O
neoformans	O
retrieved	O
from	O
infected	O
mice	O
contains	O
almost	O
a	O
6-fold	O
lower	O
concentration	O
of	O
intracellular	O
copper	B
than	O
the	O
pathogenic	O
wild	O
-	O
type	O
strain	O
.	O

The	O
concentration	O
difference	O
arises	O
in	O
part	O
from	O
larger	O
-	O
sized	O
cuf1	O
cell	O
.	O

Under	O
in	O
vitro	O
growth	O
conditions	O
,	O
the	O
size	O
of	O
the	O
cuf1	O
cells	O
is	O
normal	O
and	O
the	O
hypertrophy	O
phenotype	O
is	O
readily	O
induced	O
in	O
vitro	O
under	O
conditions	O
of	O
copper	B
starvation	O
.	O

Taken	O
together	O
,	O
these	O
data	O
suggest	O
that	O
acquisition	O
of	O
extraordinary	O
levels	O
of	O
copper	B
is	O
an	O
important	O
factor	O
in	O
the	O
survivability	O
of	O
the	O
pathogen	O
in	O
the	O
copper	B
-	O
deplete	O
environment	O
of	O
infection	O
,	O
and	O
effective	O
copper	B
concentration	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
C.	O
neoformans	O
.	O

Is	O
Artemisinin	B
the	O
Only	O
Antiplasmodial	O
Compound	O
in	O
the	O
Artemisia	O
annua	O
Tea	O
Infusion	O
?	O

An	O
in	O
Vitro	O
Study	O
.	O

In	O
our	O
ongoing	O
investigation	O
into	O
Artemisia	O
annua	O
for	O
the	O
treatment	O
of	O
malaria	O
,	O
we	O
decided	O
to	O
study	O
the	O
possibility	O
that	O
synergism	O
might	O
enhance	O
the	O
efficacy	O
of	O
artemisinin	B
.	O

Our	O
main	O
objective	O
was	O
to	O
test	O
tea	O
infusions	O
and	O
nonpolar	O
extracts	O
prepared	O
from	O
different	O
A.	O
annua	O
varieties	O
against	O
Plasmodium	O
falciparum	O
in	O
vitro	O
in	O
order	O
to	O
determine	O
if	O
synergism	O
will	O
increase	O
the	O
effectiveness	O
of	O
artemisinin	B
in	O
the	O
samples	O
as	O
compared	O
to	O
pure	O
artemisinin	B
.	O

We	O
found	O
that	O
the	O
IC50	O
of	O
artemisinin	B
in	O
the	O
tea	O
and	O
nonpolar	O
extracts	O
was	O
not	O
significantly	O
different	O
to	O
the	O
IC50	O
of	O
pure	O
artemisinin	B
.	O

We	O
could	O
show	O
that	O
the	O
year	O
and	O
country	O
of	O
harvest	O
or	O
storage	O
conditions	O
did	O
not	O
have	O
any	O
influence	O
on	O
the	O
activity	O
and	O
that	O
it	O
narrowly	O
followed	O
the	O
concentration	O
of	O
artemisinin	B
in	O
all	O
the	O
extracts	O
.	O

In	O
conclusion	O
,	O
based	O
on	O
these	O
in	O
vitro	O
results	O
,	O
artemisinin	B
seems	O
to	O
be	O
the	O
only	O
active	O
antiplasmodial	O
compound	O
in	O
A.	O
annua	O
.	O

Hop	O
Extracts	O
and	O
Hop	O
Substances	O
in	O
Treatment	O
of	O
Menopausal	O
Complaints	O
.	O

Hop	O
extract	O
is	O
a	O
long	O
used	O
medicinal	O
product	O
and	O
,	O
regarding	O
hormonal	O
activities	O
,	O
in	O
1999	O
a	O
number	O
of	O
prenylflavanones	B
have	O
been	O
identified	O
as	O
its	O
major	O
constituents	O
with	O
8-prenylnaringenin	B
(	O
8-PN	B
)	O
being	O
the	O
main	O
active	O
estrogenic	O
compound	O
.	O

There	O
have	O
been	O
several	O
in	O
vivo	O
studies	O
performed	O
that	O
demonstrate	O
the	O
potential	O
of	O
hop	O
extract	O
and	O
the	O
single	O
compound	O
8-PN	B
to	O
alleviate	O
climacteric	O
symptoms	O
like	O
osteoporosis	O
,	O
vasomotoric	O
complaints	O
,	O
and	O
sexual	O
motivation	O
.	O

On	O
the	O
other	O
hand	O
,	O
only	O
a	O
few	O
clinical	O
studies	O
have	O
been	O
performed	O
so	O
far	O
,	O
and	O
these	O
mainly	O
focused	O
on	O
menopausal	O
discomforts	O
,	O
especially	O
hot	O
flushes	O
,	O
yielding	O
rather	O
inconclusive	O
results	O
.	O

Despite	O
preferentially	O
activating	O
estrogen	B
receptor	O
	O
,	O
8-PN	B
is	O
only	O
slightly	O
uterotrophic	O
,	O
but	O
it	O
also	O
elucidates	O
estrogenic	O
effects	O
on	O
the	O
mammary	O
gland	O
.	O

In	O
conclusion	O
,	O
although	O
hop	O
extract	O
and	O
especially	O
8-PN	B
are	O
promising	O
candidates	O
as	O
a	O
relief	O
for	O
climacteric	O
symptoms	O
,	O
data	O
on	O
the	O
safety	O
and	O
efficacy	O
is	O
still	O
scarce	O
.	O

Cardamonin	B
Ameliorates	O
Insulin	O
Resistance	O
Induced	O
by	O
High	O
Insulin	O
and	O
High	O
Glucose	B
through	O
the	O
mTOR	O
and	O
Signal	O
Pathway	O
.	O

The	O
mammalian	O
target	O
of	O
rapamycin	B
is	O
crucial	O
in	O
the	O
regulation	O
of	O
cell	O
growth	O
and	O
metabolism	O
.	O

Recent	O
studies	O
suggest	O
that	O
the	O
mammalian	O
target	O
of	O
rapamycin	B
and	O
its	O
downstream	O
70-kDa	O
ribosomal	O
S6	O
kinase	O
1	O
negatively	O
modulate	O
the	O
insulin	O
-	O
signaling	O
pathway	O
,	O
which	O
is	O
considered	O
the	O
main	O
cause	O
of	O
insulin	O
resistance	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
investigate	O
the	O
effects	O
of	O
cardamonin	B
,	O
a	O
potential	O
inhibitor	O
of	O
the	O
mammalian	O
target	O
of	O
the	O
rapamycin	B
,	O
on	O
insulin	O
-	O
resistant	O
vascular	O
smooth	O
muscle	O
cells	O
and	O
the	O
molecular	O
mechanisms	O
involved	O
.	O

Vascular	O
smooth	O
muscle	O
cells	O
were	O
cultured	O
with	O
high	O
glucose	B
and	O
high	O
insulin	O
to	O
induce	O
insulin	O
resistance	O
.	O

The	O
mammalian	O
target	O
of	O
rapamycin	B
was	O
overstimulated	O
in	O
cells	O
that	O
were	O
incubated	O
with	O
high	O
glucose	B
and	O
high	O
insulin	O
,	O
as	O
reflected	O
by	O
the	O
excessive	O
activation	O
of	O
S6	O
kinase	O
1	O
.	O

Insulin	O
-	O
resistant	O
vascular	O
smooth	O
muscle	O
cells	O
displayed	O
hyperphosphorylation	O
of	O
insulin	O
receptor	O
substrate-1	O
at	O
Ser	B
residues	O
636	O
/	O
639	O
,	O
which	O
decreased	O
the	O
activity	O
of	O
insulin	O
receptor	O
substrate-1	O
.	O

Also	O
,	O
the	O
activation	O
of	O
protein	O
kinase	O
B	O
and	O
phosphorylation	O
of	O
glycogen	O
synthesis	O
kinase-3	O
were	O
inhibited	O
.	O

Cardamonin	B
increased	O
the	O
2-deoxyglucose	B
uptake	O
and	O
glycogen	O
concentration	O
,	O
which	O
was	O
reduced	O
by	O
insulin	O
resistance	O
.	O

As	O
with	O
rapamycin	B
,	O
cardamonin	B
inhibited	O
the	O
activity	O
of	O
the	O
mammalian	O
target	O
of	O
rapamycin	B
and	O
S6	O
kinase	O
1	O
,	O
decreased	O
the	O
Ser	B
636	O
/	O
639	O
phosphorylation	O
of	O
insulin	O
receptor	O
substrate-1	O
and	O
increased	O
the	O
activation	O
of	O
protein	O
kinase	O
B.	O
Both	O
of	O
them	O
increased	O
the	O
Ser9	B
phosphorylation	O
of	O
glycogen	O
synthesis	O
kinase-3	O
and	O
decreased	O
the	O
expression	O
of	O
glycogen	O
synthesis	O
kinase-3	O
.	O

However	O
,	O
neither	O
cardamonin	B
nor	O
rapamycin	B
increased	O
the	O
expression	O
of	O
glucose	B
transport	O
4	O
which	O
decreased	O
in	O
insulin	O
-	O
resistant	O
vascular	O
smooth	O
muscle	O
cells	O
.	O

This	O
study	O
suggests	O
that	O
cardamonin	B
inhibited	O
the	O
activity	O
of	O
the	O
mammalian	O
target	O
of	O
rapamycin	B
and	O
eliminated	O
the	O
negative	O
feedback	O
of	O
the	O
mammalian	O
target	O
of	O
rapamycin	B
and	O
S6	O
kinase	O
1	O
on	O
the	O
insulin	O
-	O
signaling	O
pathway	O
.	O

Cognitive	O
impairment	O
and	O
dietary	O
habits	O
among	O
elders	O
:	O
the	O
velestino	O
study	O
.	O

Abstract	O
To	O
investigate	O
the	O
association	O
of	O
dietary	O
habits	O
with	O
cognitive	O
function	O
among	O
elders	O
(	O
>	O
65	O
years	O
)	O
.	O

Complete	O
sociodemographic	O
,	O
dietary	O
information	O
,	O
serum	O
measurements	O
,	O
and	O
Mini	O
-	O
Mental	O
State	O
Examination	O
(	O
MMSE	O
)	O
assessments	O
were	O
available	O
for	O
237	O
elderly	O
men	O
and	O
320	O
women	O
residing	O
in	O
Velestino	O
,	O
Greece	O
(	O
a	O
rural	O
Greek	O
town	O
)	O
.	O

All	O
models	O
were	O
adjusted	O
for	O
age	O
,	O
education	O
,	O
social	O
activity	O
,	O
smoking	O
,	O
depression	O
symptomatology	O
(	O
using	O
the	O
Geriatric	O
Depression	O
Scale	O
)	O
,	O
MedDietScore	O
(	O
range	O
0	O
-	O
55	O
)	O
,	O
and	O
metabolic	O
syndrome	O
.	O

About	O
49.8	O
%	O
men	O
and	O
66.6	O
%	O
women	O
had	O
MMSE	O
scores	O
<	O
24	O
,	O
with	O
a	O
mean	O
MMSE	O
score	O
of	O
22.74.43	O
and	O
21.14.73	O
,	O
respectively	O
.	O

Adherence	O
to	O
the	O
Mediterranean	O
diet	O
was	O
moderate	O
(	O
mean	O
MedDietScore	O
of	O
34.13.25	O
in	O
men	O
and	O
35.12.48	O
in	O
women	O
)	O
.	O

Indicative	O
cognitive	O
impairment	O
(	O
MMSE	O
score	O
<	O
24	O
)	O
was	O
positively	O
associated	O
with	O
age	O
and	O
low	O
education	O
in	O
women	O
and	O
with	O
depressive	O
symptoms	O
,	O
low	O
education	O
status	O
,	O
and	O
low	O
social	O
activity	O
in	O
men	O
.	O

Adherence	O
to	O
the	O
Mediterranean	O
diet	O
was	O
positively	O
associated	O
with	O
MMSE	O
score	O
in	O
men	O
(	O
P=.02	O
)	O
,	O
but	O
inversely	O
associated	O
in	O
women	O
(	O
P=.04	O
)	O
.	O

Concerning	O
the	O
food	O
groups	O
studied	O
,	O
intake	O
of	O
pulses	O
,	O
nuts	O
,	O
and	O
seeds	O
was	O
associated	O
with	O
lower	O
likelihood	O
of	O
having	O
MMSE	O
score<24	O
in	O
men	O
(	O
P=.04	O
)	O
.	O

Only	O
the	O
Mediterranean	O
dietary	O
pattern	O
showed	O
a	O
significant	O
association	O
with	O
MMSE	O
score	O
positive	O
for	O
cognitive	O
impairment	O
(	O
i.e.	O
,	O
protective	O
in	O
men	O
,	O
but	O
not	O
in	O
women	O
)	O
,	O
while	O
individual	O
food	O
groups	O
or	O
nutrients	O
did	O
not	O
achieve	O
significance	O
.	O

The	O
latter	O
findings	O
support	O
the	O
role	O
of	O
whole	O
diet	O
in	O
the	O
prevention	O
of	O
mental	O
disorders	O
,	O
and	O
state	O
a	O
research	O
hypothesis	O
for	O
a	O
sex	O
-	O
diet	O
interaction	O
on	O
cognitive	O
function	O
among	O
elders	O
.	O

Oxidative	O
and	O
Photoxidative	O
Polymerization	O
of	O
Humic	O
Suprastructures	O
by	O
Heterogeneous	O
Biomimetic	O
Catalysis	O
.	O

The	O
meso	B
-	I
tetra	I
(	I
2,6-dichloro-3-sulfonatophenyl	I
)	I
porphyrinate	I
of	O
manganese	B
(	I
III	I
)	I
chloride	I
[	B
Mn-	I
(	I
TDCPPS	I
)	I
Cl	I
]	I
biomimetic	O
catalyst	O
immobilized	O
on	O
spacer	O
-	O
functionalized	O
kaolinite	B
clay	O
mineral	O
was	O
employed	O
in	O
the	O
oxidative	O
coupling	O
reaction	O
of	O
a	O
dissolved	O
humic	O
acid	O
(	O
HA	O
)	O
suprastructure	O
with	O
either	O
chemical	O
(	O
H2O2	B
)	O
or	O
UV	O
-	O
light	O
oxidation	O
.	O

The	O
changes	O
in	O
molecular	O
size	O
of	O
humic	O
matter	O
subjected	O
to	O
catalyzed	O
oxidative	O
reaction	O
were	O
followed	O
by	O
high	O
-	O
performance	O
size	O
exclusion	O
chromatography	O
(	O
HPSEC	O
)	O
with	O
UV	O
-	O
vis	O
and	O
refractive	O
index	O
(	O
RI	O
)	O
detectors	O
in	O
series	O
,	O
and	O
by	O
thermogravimetric	O
(	O
TGA	O
)	O
analysis	O
.	O

Both	O
the	O
enhanced	O
molecular	O
size	O
shown	O
by	O
differences	O
between	O
HPSEC	O
chromatograms	O
of	O
humic	O
reaction	O
mixtures	O
at	O
either	O
pH	O
6	O
or	O
3.5	O
and	O
the	O
increase	O
of	O
thermogravimetric	O
stability	O
suggest	O
that	O
the	O
heterogeneous	O
biomimetic	O
catalysis	O
promoted	O
the	O
stabilization	O
of	O
humic	O
conformations	O
by	O
new	O
intermolecular	O
covalent	O
bonds	O
during	O
oxidative	O
coupling	O
.	O

The	O
similarity	O
between	O
chemical	O
and	O
light	O
-	O
induced	O
oxidation	O
results	O
suggests	O
potential	O
multiple	O
applications	O
of	O
the	O
kaolinite	B
-	O
supported	O
heterogeneous	O
catalyst	O
in	O
controlling	O
the	O
reactivity	O
of	O
natural	O
organic	O
matter	O
within	O
biogeochemical	O
cycles	O
and	O
environmental	O
reactions	O
.	O

Biological	O
activity	O
of	O
Pd	B
(	I
II	I
)	I
complexes	O
with	O
mono-	B
and	I
disubstituted	I
pyridines	I
-	O
Experimental	O
and	O
theoretical	O
studies	O
.	O

Due	O
to	O
the	O
similarity	O
between	O
Pd	B
and	O
Pt	B
,	O
the	O
complexes	O
of	O
palladium	B
(	I
II	I
)	I
can	O
be	O
considered	O
as	O
potential	O
anticancer	O
agents	O
.	O

Activity	O
of	O
six	O
PdCl2	B
(	I
X2Py	I
)	I
2	I
complexes	O
(	O
Py	B
=	O
pyridine	B
,	O
and	O
X	O
=	O
CH3	B
or	O
Cl	B
)	O
was	O
measured	O
by	O
MTT	B
test	O
using	O
MCF7	O
,	O
CCRF	O
-	O
SB	O
,	O
PC3	O
and	O
human	O
B	O
-	O
lymphoblastoid	O
cell	O
lines	O
.	O

We	O
found	O
that	O
the	O
effect	O
of	O
PdCl2	B
(	I
XnPy	I
)	I
2	I
was	O
cell	O
-	O
specific	O
and	O
time	O
-	O
dependent	O
.	O

Obtained	O
results	O
were	O
discussed	O
and	O
compared	O
with	O
the	O
activation	O
parameters	O
calculated	O
for	O
the	O
hydrolysis	O
of	O
PdCl2	B
(	I
XnPy	I
)	I
2	I
,	O
indicating	O
a	O
correlation	O
between	O
viability	O
of	O
MCF7	O
and	O
CCRF	O
-	O
SB	O
cells	O
and	O
rates	O
of	O
hydrolysis	O
of	O
the	O
Pd	B
(	I
II	I
)	I
complexes	O
.	O

Pathogenesis	O
of	O
preeclampsia	O
:	O
Implications	O
of	O
apoptotic	O
markers	O
and	O
oxidative	O
stress	O
.	O

This	O
study	O
aimed	O
to	O
investigate	O
the	O
implication	O
of	O
some	O
apoptotic	O
and	O
lipid	O
peroxidation	O
markers	O
in	O
preeclampsia	O
(	O
PE	O
)	O
.	O

A	O
total	O
of	O
25	O
women	O
with	O
PE	O
and	O
25	O
age-	O
and	O
parity	O
-	O
matched	O
normal	O
pregnant	O
women	O
were	O
enrolled	O
in	O
this	O
study	O
.	O

The	O
malondialdehyde	B
(	O
MDA	B
)	O
level	O
,	O
caspase-9	O
activity	O
and	O
the	O
percentage	O
of	O
DNA	O
fragmentation	O
were	O
significantly	O
higher	O
in	O
placental	O
tissue	O
of	O
PE	O
than	O
in	O
control	O
women	O
.	O

The	O
serum	O
level	O
of	O
MDA	B
was	O
significantly	O
elevated	O
in	O
women	O
with	O
PE	O
having	O
delivery	O
by	O
cesarean	O
section	O
(	O
CS	O
)	O
than	O
in	O
women	O
with	O
PE	O
having	O
vaginal	O
delivery	O
.	O

In	O
vitro	O
study	O
demonstrated	O
that	O
the	O
addition	O
of	O
0.5	O
mM	O
Fe	B
(	I
2	I
+	I
)	I
and	O
0.1	O
mM	O
ascorbate	B
caused	O
increase	O
in	O
the	O
production	O
of	O
MDA	B
level	O
in	O
placental	O
tissue	O
with	O
PE	O
than	O
normal	O
placentas	O
,	O
and	O
vitamin	B
E	I
(	O
100	O
M	O
)	O
caused	O
lower	O
inhibition	O
of	O
in	O
vitro	O
lipid	O
peroxidation	O
in	O
placental	O
tissue	O
with	O
PE	O
when	O
compared	O
with	O
normal	O
tissue	O
.	O

The	O
activity	O
of	O
caspase-9	O
and	O
percentage	O
of	O
DNA	O
fragmentation	O
were	O
associated	O
with	O
the	O
severity	O
of	O
the	O
PE	O
and	O
both	O
could	O
differentiate	O
between	O
PE	O
and	O
control	O
women	O
with	O
88	O
%	O
and	O
100	O
%	O
sensitivity	O
and	O
96	O
%	O
and	O
100	O
%	O
specificity	O
,	O
respectively	O
.	O

The	O
activities	O
of	O
caspase-8	O
and/or	O
-9	O
were	O
positively	O
correlated	O
with	O
the	O
maternal	O
age	O
but	O
only	O
caspase-8	O
was	O
negatively	O
correlated	O
with	O
neonatal	O
birth	O
weight	O
and	O
placental	O
weight	O
.	O

In	O
conclusion	O
,	O
the	O
elevations	O
of	O
MDA	B
,	O
caspase-9	O
activity	O
and	O
the	O
percentage	O
of	O
DNA	O
fragmentation	O
in	O
the	O
placentas	O
of	O
women	O
with	O
PE	O
implicate	O
the	O
involvement	O
of	O
lipid	O
peroxidation	O
and	O
apoptosis	O
in	O
PE	O
.	O

The	O
placenta	O
represents	O
a	O
considerable	O
source	O
of	O
the	O
elevated	O
circulating	O
MDA	B
in	O
PE	O
.	O

Decreased	O
expression	O
of	O
hepatic	O
low	O
-	O
density	O
lipoprotein	O
related	O
protein	O
1	O
in	O
hypothyroidism	O
:	O
a	O
novel	O
mechanism	O
of	O
atherogenic	O
dyslipidemia	O
in	O
hypothyroidism	O
.	O

Background	O
:	O
The	O
atherogenic	O
effects	O
of	O
hypothyroidism	O
on	O
lipid	O
metabolism	O
could	O
result	O
,	O
in	O
part	O
,	O
from	O
the	O
reduced	O
clearance	O
of	O
remnant	O
lipoproteins	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
expression	O
of	O
hepatic	O
low	O
-	O
density	O
lipoprotein	O
receptor	O
-	O
related	O
protein	O
1	O
(	O
LRP1	O
)	O
,	O
a	O
receptor	O
for	O
remnant	O
lipoproteins	O
,	O
in	O
hypothyroidism	O
and	O
the	O
effect	O
of	O
triiodothyronine	B
(	O
T3	O
)	O
treatment	O
on	O
hepatic	O
LRP1	O
expression	O
.	O

Methods	O
:	O
C57BL	O
/	O
6	O
mice	O
were	O
fed	O
a	O
normal	O
diet	O
(	O
control	O
group	O
)	O
or	O
a	O
low	O
iodine	B
diet	O
supplemented	O
with	O
0.15	O
%	O
propylthiouracil	B
(	O
PTU	B
/	O
LI	O
group	O
)	O
for	O
4	O
weeks	O
.	O

Mice	O
in	O
PTU	B
/	O
LI	O
group	O
were	O
injected	O
intraperitoneally	O
with	O
T3	O
(	O
0	O
,	O
30	O
,	O
and	O
150	O
g	O
/	O
kg	O
of	O
body	O
weight	O
)	O
for	O
7	O
days	O
.	O

HepG2	O
cells	O
were	O
incubated	O
in	O
fetal	O
bovine	O
serum	O
(	O
FBS	O
)	O
or	O
charcoal	O
-	O
stripped	O
FBS	O
(	O
CSS	O
)	O
with	O
various	O
concentrations	O
of	O
T3	O
.	O

The	O
expression	O
and	O
function	O
of	O
LRP1	O
in	O
liver	O
samples	O
and	O
cells	O
were	O
analyzed	O
.	O

Results	O
:	O
Hypothyroidism	O
was	O
successfully	O
induced	O
in	O
PTU	B
/	O
LI	O
group	O
mice	O
.	O

Hepatic	O
LRP1	O
protein	O
expression	O
was	O
lower	O
in	O
the	O
PTU	B
/	O
LI	O
group	O
than	O
the	O
control	O
group	O
.	O

T3	O
treatment	O
up	O
-	O
regulated	O
hepatic	O
LRP1	O
protein	O
expression	O
in	O
PTU	B
/	O
LI	O
group	O
mice	O
.	O

LRP1	O
expression	O
in	O
HepG2	O
cells	O
was	O
reduced	O
after	O
incubation	O
in	O
media	O
containing	O
CSS	O
,	O
which	O
mimics	O
hypothyroidism	O
in	O
vitro	O
,	O
and	O
was	O
recovered	O
by	O
T3	O
treatment	O
.	O

The	O
protein	O
expression	O
of	O
LRP1	O
in	O
HepG2	O
cells	O
was	O
increased	O
by	O
T3	O
treatment	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
up	O
to	O
2.0	O
nM	O
T3	O
.	O

However	O
,	O
LRP1	O
mRNA	O
transcription	O
was	O
not	O
affected	O
by	O
hypothyroidism	O
conditions	O
or	O
T3	O
treatment	O
,	O
either	O
in	O
liver	O
samples	O
or	O
HepG2	O
cells	O
.	O

T3	O
treatment	O
on	O
HepG2	O
cells	O
increased	O
cellular	O
uptake	O
of	O
lipid	O
-	O
conjugated	O
apolipoprotein	O
E	O
through	O
LRP1	O
.	O

Conclusions	O
:	O
Our	O
data	O
demonstrate	O
that	O
hepatic	O
LRP1	O
expression	O
and	O
function	O
decrease	O
in	O
hypothyroidism	O
and	O
are	O
regulated	O
by	O
thyroid	B
hormone	I
.	O

These	O
results	O
suggest	O
that	O
in	O
hypothyroidism	O
,	O
decreased	O
expression	O
of	O
hepatic	O
LRP1	O
may	O
be	O
associated	O
with	O
reduced	O
clearance	O
of	O
circulating	O
remnant	O
lipoproteins	O
.	O

Chemical	O
characterization	O
of	O
domestic	O
oral	O
tobacco	O
products	O
:	O
Total	O
nicotine	B
,	O
pH	O
,	O
unprotonated	O
nicotine	B
and	O
tobacco	O
-	O
specific	O
N	B
-	I
nitrosamines	I
.	O

In	O
the	O
United	O
States	O
,	O
moist	O
snuff	O
has	O
been	O
studied	O
more	O
widely	O
than	O
other	O
distinct	O
categories	O
of	O
oral	O
tobacco	O
.	O

In	O
this	O
study	O
,	O
we	O
measured	O
pH	O
,	O
moisture	O
,	O
nicotine	B
(	O
total	O
and	O
unprotonated	O
)	O
,	O
and	O
tobacco	O
-	O
specific	O
N	B
-	I
nitrosamines	I
(	O
TSNAs	O
)	O
for	O
other	O
established	O
(	O
twist	O
,	O
loose	O
leaf	O
,	O
plug	O
,	O
and	O
dry	O
snuff	O
without	O
pouch	O
)	O
and	O
emerging	O
oral	O
tobacco	O
products	O
(	O
dry	O
snuff	O
pouch	O
,	O
US	O
-	O
made	O
snus	O
,	O
and	O
dissolvable	O
tobacco	O
)	O
.	O

Among	O
the	O
seven	O
product	O
categories	O
,	O
product	O
pH	O
ranged	O
from	O
4.7	O
to	O
7.9	O
,	O
and	O
total	O
nicotine	B
concentration	O
spanned	O
from	O
3.9	O
to	O
40.1mg	O
/	O
g	O
.	O

The	O
most	O
readily	O
absorbable	O
form	O
of	O
nicotine	B
(	O
unprotonated	O
nicotine	B
)	O
varied	O
more	O
than	O
350-fold	O
,	O
ranging	O
from	O
0.01	O
to	O
3.7mg	O
/	O
g	O
.	O

While	O
the	O
highest	O
total	O
nicotine	B
concentrations	O
were	O
observed	O
in	O
twist	O
products	O
,	O
snus	O
and	O
dissolvable	O
tobacco	O
had	O
the	O
highest	O
unprotonated	O
nicotine	B
levels	O
.	O

Among	O
all	O
products	O
,	O
total	O
TSNA	O
concentrations	O
ranged	O
from	O
313	O
to	O
76,500ng	O
/	O
g	O
with	O
dry	O
snuff	O
having	O
the	O
highest	O
total	O
TSNA	O
concentrations	O
.	O

This	O
study	O
demonstrates	O
the	O
diversity	O
among	O
oral	O
tobacco	O
products	O
and	O
highlights	O
the	O
potential	O
of	O
these	O
products	O
to	O
deliver	O
a	O
wide	O
range	O
of	O
nicotine	B
and	O
carcinogenic	O
TSNAs	O
.	O

Characterizing	O
the	O
chemical	O
content	O
of	O
these	O
products	O
may	O
be	O
helpful	O
in	O
further	O
understanding	O
the	O
risk	O
of	O
marketing	O
these	O
products	O
to	O
oral	O
tobacco	O
users	O
and	O
smokers	O
as	O
an	O
alternative	O
and	O
discrete	O
form	O
of	O
tobacco	O
.	O

SMC6	O
is	O
an	O
essential	O
gene	O
in	O
mice	O
,	O
but	O
a	O
hypomorphic	O
mutant	O
in	O
the	O
ATPase	O
domain	O
has	O
a	O
mild	O
phenotype	O
with	O
a	O
range	O
of	O
subtle	O
abnormalities	O
.	O

Smc5	O
-	O
6	O
is	O
a	O
highly	O
conserved	O
protein	O
complex	O
related	O
to	O
cohesin	O
and	O
condensin	O
involved	O
in	O
the	O
structural	O
maintenance	O
of	O
chromosomes	O
.	O

In	O
yeasts	O
the	O
Smc5	O
-	O
6	O
complex	O
is	O
essential	O
for	O
proliferation	O
and	O
is	O
involved	O
in	O
DNA	O
repair	O
and	O
homologous	O
recombination	O
.	O

siRNA	O
depletion	O
of	O
genes	O
involved	O
in	O
the	O
Smc5	O
-	O
6	O
complex	O
in	O
cultured	O
mammalian	O
cells	O
results	O
in	O
sensitivity	O
to	O
some	O
DNA	O
damaging	O
agents	O
.	O

In	O
order	O
to	O
gain	O
further	O
insight	O
into	O
its	O
role	O
in	O
mammals	O
we	O
have	O
generated	O
mice	O
mutated	O
in	O
the	O
Smc6	O
gene	O
.	O

A	O
complete	O
knockout	O
resulted	O
in	O
early	O
embryonic	O
lethality	O
,	O
demonstrating	O
that	O
this	O
gene	O
is	O
essential	O
in	O
mammals	O
.	O

However	O
,	O
mutation	O
of	O
the	O
highly	O
conserved	O
serine-994	B
to	O
alanine	B
in	O
the	O
ATP	B
hydrolysis	O
motif	O
in	O
the	O
SMC6	O
C	O
-	O
terminal	O
domain	O
,	O
resulted	O
in	O
mice	O
with	O
a	O
surprisingly	O
mild	O
phenotype	O
.	O

With	O
the	O
neo	O
gene	O
selection	O
marker	O
in	O
the	O
intron	O
following	O
the	O
mutation	O
,	O
resulting	O
in	O
reduced	O
expression	O
of	O
the	O
SMC6	O
gene	O
,	O
the	O
mice	O
were	O
reduced	O
in	O
size	O
,	O
but	O
fertile	O
and	O
had	O
normal	O
lifespans	O
.	O

When	O
the	O
neo	O
gene	O
was	O
removed	O
,	O
the	O
mice	O
had	O
normal	O
size	O
,	O
but	O
detailed	O
phenotypic	O
analysis	O
revealed	O
minor	O
abnormalities	O
in	O
glucose	B
tolerance	O
,	O
haematopoiesis	O
,	O
nociception	O
and	O
global	O
gene	O
expression	O
patterns	O
.	O

Embryonic	O
fibroblasts	O
derived	O
from	O
the	O
ser994	B
mutant	O
mice	O
were	O
not	O
sensitive	O
to	O
killing	O
by	O
a	O
range	O
of	O
DNA	O
damaging	O
agents	O
,	O
but	O
they	O
were	O
sensitive	O
to	O
the	O
induction	O
of	O
sister	O
chromatid	O
exchanges	O
induced	O
by	O
ultraviolet	O
light	O
or	O
mitomycin	B
C.	I
They	O
also	O
accumulated	O
more	O
oxidative	O
damage	O
than	O
wild	O
-	O
type	O
cells	O
.	O

A	O
Redox	O
Responsive	O
,	O
Fluorescent	O
Supramolecular	O
Metallohydrogel	O
Consists	O
of	O
Nanofibers	O
with	O
Single	O
-	O
Molecule	O
Width	O
.	O

The	O
integration	O
of	O
a	O
tripeptide	B
derivative	O
,	O
which	O
is	O
a	O
versatile	O
self	O
-	O
assembly	O
motif	O
,	O
with	O
a	O
ruthenium	B
(	I
II	I
)	I
tris	I
(	I
bipyridine	I
)	I
complex	O
affords	O
the	O
first	O
supramolecular	O
metallo	O
-	O
hydrogelator	O
that	O
not	O
only	O
self	O
assembles	O
in	O
water	O
to	O
form	O
a	O
hydrogel	O
but	O
also	O
exhibits	O
gel	O
-	O
sol	O
transition	O
upon	O
oxidation	O
of	O
the	O
metal	O
center	O
.	O

Surprisingly	O
,	O
the	O
incorporation	O
of	O
the	O
metal	O
complex	O
in	O
the	O
hydrogelator	O
results	O
in	O
the	O
nanofibers	O
,	O
formed	O
by	O
the	O
self	O
-	O
assembly	O
of	O
the	O
hydrogelator	O
in	O
water	O
,	O
to	O
have	O
the	O
width	O
of	O
a	O
single	O
molecule	O
of	O
the	O
hydrogelator	O
.	O

These	O
results	O
illustrate	O
that	O
metal	O
complexes	O
,	O
besides	O
being	O
able	O
to	O
impart	O
rich	O
optical	O
,	O
electronic	O
,	O
redox	O
,	O
or	O
magnetic	O
properties	O
to	O
supramolecular	O
hydrogels	O
,	O
also	O
offer	O
a	O
unique	O
geometrical	O
control	O
to	O
prearrange	O
the	O
self	O
-	O
assembly	O
motif	O
prior	O
to	O
self	O
-	O
assembling	O
.	O

The	O
use	O
of	O
metal	O
complexes	O
to	O
modulate	O
the	O
dimensionality	O
of	O
intermolecular	O
interactions	O
may	O
also	O
help	O
elucidate	O
the	O
interactions	O
of	O
the	O
molecular	O
nanofibers	O
with	O
other	O
molecules	O
,	O
thus	O
facilitating	O
the	O
development	O
of	O
supramolecular	O
hydrogel	O
materials	O
for	O
a	O
wide	O
range	O
of	O
applications	O
.	O

Avermectin	B
induces	O
P	O
-	O
glycoprotein	O
expression	O
in	O
S2	O
cells	O
via	O
the	O
calcium	B
/	O
calmodulin	O
/	O
NF	O
-	O
B	O
pathway	O
.	O

Avermectin	B
(	O
AVM	B
)	O
is	O
a	O
macrocyclic	O
lactone	B
agent	O
widely	O
used	O
as	O
a	O
nematicide	O
,	O
acaricide	O
and	O
insecticide	O
in	O
veterinary	O
medicine	O
and	O
plant	O
protection	O
.	O

P	O
-	O
glycoprotein	O
(	O
P	O
-	O
gp	O
)	O
is	O
an	O
ATP	B
-	O
dependent	O
drug	O
efflux	O
pump	O
for	O
xenobiotic	O
compounds	O
,	O
and	O
is	O
involved	O
in	O
multidrug	O
resistance	O
.	O

To	O
understand	O
the	O
development	O
of	O
AVM	B
resistance	O
in	O
invertebrates	O
,	O
we	O
investigated	O
the	O
mechanisms	O
by	O
which	O
AVM	B
affected	O
P	O
-	O
gp	O
expression	O
in	O
Drosophila	O
S2	O
cells	O
.	O

We	O
found	O
that	O
AVM	B
induced	O
upregulation	O
of	O
P	O
-	O
gp	O
protein	O
expression	O
,	O
increased	O
P	O
-	O
gp	O
ATPase	O
activity	O
and	O
enhanced	O
cellular	O
efflux	O
of	O
the	O
P	O
-	O
gp	O
substrate	O
rhodamine	B
123	I
from	O
cells	O
.	O

Furthermore	O
,	O
we	O
observed	O
that	O
AVM	B
-	O
induced	O
expression	O
of	O
P	O
-	O
gp	O
was	O
due	O
to	O
elevation	O
of	O
intracellular	O
calcium	B
concentration	O
(	O
[	O
Ca	B
(	I
2+	I
)	I
]	O
i	O
)	O
.	O

This	O
occurred	O
both	O
directly	O
,	O
by	O
activating	O
calcium	B
ion	O
channels	O
,	O
and	O
indirectly	O
,	O
by	O
activating	O
chloride	B
ion	O
channels	O
.	O

These	O
results	O
are	O
supported	O
by	O
our	O
observations	O
that	O
verapamil	B
,	O
a	O
Ca	B
(	I
2	I
+	I
)	I
channel	O
blocker	O
,	O
and	O
niflumic	B
acid	I
,	O
a	O
chloride	B
channel	O
antagonist	O
,	O
significantly	O
attenuated	O
AVM	B
-	O
induced	O
[	O
Ca	B
(	I
2+	I
)	I
]	O
i	O
elevation	O
,	O
thereby	O
reducing	O
P	O
-	O
gp	O
expression	O
.	O

Inhibition	O
of	O
P	O
-	O
gp	O
with	O
anti	O
-	O
P	O
-	O
gp	O
antibody	O
or	O
cyclosporine	B
A	I
(	O
a	O
P	O
-	O
gp	O
inhibitor	O
)	O
reduced	O
the	O
AVM	B
-	O
induced	O
elevation	O
of	O
[	O
Ca	B
(	I
2+	I
)	I
]	O
i	O
,	O
implying	O
that	O
P	O
-	O
gp	O
and	O
[	O
Ca	B
(	I
2+	I
)	I
]	O
i	O
regulate	O
each	O
other	O
.	O

Finally	O
,	O
we	O
found	O
that	O
trifluoperazine	B
,	O
a	O
calmodulin	O
inhibitor	O
,	O
and	O
pyrrolidine	B
dithiocarbamic	I
acid	I
,	O
an	O
NF	O
-	O
B	O
inhibitor	O
,	O
attenuated	O
the	O
AVM	B
-	O
induced	O
expression	O
of	O
P	O
-	O
gp	O
,	O
suggesting	O
that	O
AVM	B
induces	O
P	O
-	O
gp	O
protein	O
expression	O
via	O
the	O
calmodulin	O
/	O
Relish	O
(	O
NF	O
-	O
B	O
)	O
signaling	O
pathway	O
.	O

Evidence	O
of	O
securin	O
-	O
mediated	O
resistance	O
to	O
gefitinib	B
-	O
induced	O
apoptosis	O
in	O
human	O
cancer	O
cells	O
.	O

Gefitinib	B
,	O
a	O
tyrosine	B
kinase	O
inhibitor	O
of	O
the	O
epidermal	O
growth	O
factor	O
receptor	O
(	O
EGFR	O
)	O
,	O
has	O
been	O
used	O
to	O
treat	O
numerous	O
cancers	O
;	O
however	O
,	O
evidence	O
has	O
shown	O
that	O
cancer	O
cells	O
can	O
become	O
resistant	O
to	O
gefitinib	B
during	O
therapy	O
.	O

Here	O
,	O
we	O
report	O
a	O
human	O
proto	O
-	O
oncogene	O
,	O
securin	O
,	O
which	O
displays	O
resistance	O
to	O
death	O
in	O
cancer	O
cells	O
.	O

Gefitinib	B
treatment	O
decreases	O
securin	O
levels	O
at	O
the	O
protein	O
level	O
by	O
inducing	O
protein	O
instability	O
but	O
did	O
not	O
affect	O
on	O
the	O
securin	O
gene	O
expression	O
.	O

Treatment	O
with	O
gefitinib	B
induced	O
cytotoxicity	O
in	O
various	O
human	O
cancer	O
cell	O
types	O
,	O
including	O
RKO	O
(	O
colon	O
cancer	O
)	O
,	O
A549	O
(	O
lung	O
cancer	O
)	O
,	O
BFTC905	O
(	O
bladder	O
cancer	O
)	O
,	O
MCF7	O
(	O
breast	O
cancer	O
)	O
and	O
A375	O
(	O
skin	O
cancer	O
)	O
.	O

BFTC905	O
and	O
A549	O
cells	O
expressed	O
relatively	O
high	O
levels	O
of	O
the	O
phosphorylated	O
and	O
total	O
EGFR	O
proteins	O
;	O
however	O
,	O
A375	O
,	O
MCF7	O
and	O
RKO	O
cells	O
did	O
not	O
markedly	O
express	O
these	O
proteins	O
.	O

Moreover	O
,	O
following	O
treatment	O
with	O
gefitinib	B
,	O
the	O
securin	O
-	O
wild	O
type	O
cancer	O
cells	O
were	O
more	O
resistant	O
to	O
apoptotic	O
induction	O
than	O
the	O
securin	O
-	O
null	O
cancer	O
cells	O
.	O

Surprisingly	O
,	O
both	O
the	O
securin	O
-	O
wild	O
type	O
and	O
securin	O
-	O
null	O
cancer	O
cells	O
expressed	O
the	O
EGFR	O
protein	O
at	O
similar	O
levels	O
.	O

Treatment	O
with	O
gefitinib	B
induced	O
mitochondrial	O
dysfunction	O
,	O
cytochrome	O
c	O
release	O
,	O
caspase-3	O
activation	O
and	O
poly	B
(	I
ADP	I
-	I
ribose	I
)	I
polymerase	O
protein	O
cleavage	O
,	O
indicating	O
that	O
apoptosis	O
occurred	O
in	O
these	O
cancer	O
cells	O
.	O

The	O
transfection	O
of	O
a	O
GPF	O
-	O
securin	O
expression	O
vector	O
increased	O
both	O
the	O
proliferation	O
rates	O
and	O
resistance	O
to	O
gefitinib	B
-	O
induced	O
death	O
in	O
these	O
cancer	O
cells	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
demonstrate	O
that	O
the	O
presence	O
of	O
securin	O
promotes	O
resistance	O
to	O
gefitinib	B
-	O
induced	O
apoptosis	O
via	O
an	O
EGFR	O
-	O
independent	O
pathway	O
in	O
human	O
cancer	O
cells	O
.	O

Copper	B
induces	O
apoptotic	O
cell	O
death	O
through	O
reactive	O
oxygen	B
species	O
-	O
triggered	O
oxidative	O
stress	O
in	O
the	O
intertidal	O
copepod	O
Tigriopus	O
japonicus	O
.	O

The	O
copepod	O
,	O
Tigriopus	O
japonicus	O
is	O
an	O
important	O
model	O
for	O
toxicity	O
testing	O
.	O

However	O
,	O
no	O
attempt	O
has	O
been	O
made	O
in	O
analyzing	O
the	O
effect	O
of	O
toxicants	O
at	O
the	O
level	O
of	O
the	O
ROS	O
-	O
mediated	O
signal	O
transduction	O
pathway	O
.	O

To	O
understand	O
copper	B
-	O
induced	O
cytotoxicity	O
at	O
the	O
molecular	O
level	O
,	O
we	O
employed	O
several	O
cellular	O
and	O
biochemical	O
assays	O
after	O
exposure	O
to	O
copper	B
,	O
and	O
found	O
a	O
significant	O
induction	O
of	O
enzyme	O
activities	O
of	O
antioxidant	O
proteins	O
with	O
increased	O
intracellular	O
reactive	O
oxygen	B
species	O
(	O
ROS	O
)	O
as	O
well	O
as	O
an	O
increase	O
of	O
TUNEL	O
-	O
positive	O
cells	O
,	O
but	O
a	O
decrease	O
of	O
BrdU	B
-	O
positive	O
cells	O
.	O

In	O
addition	O
,	O
several	O
important	O
genes	O
such	O
as	O
p38	O
MAPK	O
,	O
antioxidant	O
-	O
related	O
genes	O
,	O
Hsps	O
,	O
and	O
apoptosis	O
-	O
related	O
genes	O
were	O
significantly	O
modulated	O
by	O
copper	B
exposure	O
.	O

Taken	O
together	O
,	O
we	O
suggest	O
that	O
copper	B
-	O
induced	O
cytotoxicity	O
is	O
mediated	O
by	O
the	O
formation	O
of	O
intracellular	O
ROS	O
and	O
oxidative	O
stress	O
in	O
T.	O
japonicus	O
.	O

Whole	O
body	O
biochemical	O
assays	O
such	O
as	O
TUNEL-	O
and	O
BrdU	B
-	O
assay	O
will	O
provide	O
a	O
better	O
understanding	O
of	O
cellular	O
responses	O
such	O
as	O
apoptosis	O
and	O
cell	O
death	O
upon	O
cytotoxic	O
exposure	O
of	O
copper	B
in	O
T.	O
japonicus	O
.	O

Effect	O
of	O
quercetin	B
-	O
rich	O
onion	O
peel	O
extracts	O
on	O
arterial	O
thrombosis	O
in	O
rats	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
examine	O
whether	O
oral	O
supplementation	O
of	O
quercetin	B
-	O
rich	O
onion	O
peel	O
extract	O
(	O
OPE	O
)	O
influences	O
blood	O
coagulation	O
and	O
arterial	O
thrombosis	O
in	O
Sprague	O
-	O
Dawley	O
(	O
SD	O
)	O
rats	O
.	O

24	O
male	O
rats	O
,	O
5weeks	O
old	O
,	O
were	O
divided	O
into	O
three	O
groups	O
with	O
different	O
diets	O
(	O
C	O
:	O
control	O
,	O
2	O
mg	O
OPE	O
:	O
chow	O
diet	O
with	O
2	O
mg	O
OPE	O
supplementation	O
,	O
10	O
mg	O
OPE	O
:	O
chow	O
diet	O
with	O
10	O
mg	O
OPE	O
supplementation	O
)	O
for	O
6weeks	O
.	O

Blood	O
coagulation	O
parameters	O
including	O
prothrombin	O
time	O
(	O
PT	O
)	O
,	O
activated	O
partial	O
thromboplastin	O
time	O
(	O
aPTT	O
)	O
and	O
platelet	O
aggregation	O
were	O
examined	O
.	O

The	O
OPE	O
did	O
not	O
affect	O
blood	O
cholesterol	B
levels	O
but	O
significantly	O
decreased	O
blood	O
triglyceride	B
and	O
glucose	B
levels	O
.	O

PT	O
,	O
aPTT	O
and	O
platelet	O
aggregation	O
were	O
not	O
significantly	O
different	O
among	O
all	O
tested	O
groups	O
.	O

However	O
,	O
in	O
vivo	O
arterial	O
thrombosis	O
was	O
significantly	O
delayed	O
in	O
groups	O
that	O
were	O
fed	O
2	O
mg	O
and	O
10	O
mg	O
OPE	O
diets	O
compared	O
to	O
the	O
control	O
group	O
.	O

In	O
addition	O
,	O
the	O
OPE	O
greatly	O
diminished	O
thrombin	O
-	O
induced	O
expression	O
of	O
tissue	O
factor	O
in	O
human	O
umbilical	O
vein	O
endothelial	O
cells	O
(	O
HUVECs	O
)	O
,	O
a	O
coagulation	O
initiator	O
.	O

In	O
addition	O
,	O
extracellular	O
signal	O
-	O
regulated	O
kinase	O
(	O
ERK	O
)	O
and	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
(	O
JNK	O
)	O
signaling	O
pathways	O
activated	O
by	O
thrombin	O
treatment	O
were	O
prevented	O
by	O
the	O
OPE	O
pre	O
-	O
treatment	O
.	O

These	O
results	O
indicate	O
that	O
OPE	O
may	O
have	O
anti	O
-	O
thrombotic	O
effects	O
through	O
restricting	O
the	O
induced	O
expression	O
of	O
tissue	O
factor	O
via	O
down	O
-	O
regulating	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
activation	O
upon	O
coagulation	O
stimulus	O
,	O
leading	O
to	O
the	O
prolongation	O
of	O
time	O
for	O
arterial	O
thrombosis	O
.	O

Modelling	O
the	O
surface	O
free	O
energy	O
parameters	O
of	O
polyurethane	B
coats	O
-	O
part	O
1	O
.	O

Solvent	O
-	O
based	O
coats	O
obtained	O
from	O
linear	O
polyurethane	B
elastomers	O
.	O

Polyurethane	B
elastomers	O
coating	O
were	O
synthesised	O
by	O
using	O
typical	O
diisocyanates	B
,	O
polyether	B
and	O
polyester	B
polyols	I
and	O
HO	B
-	O
tertiary	B
amines	I
or	O
diols	B
as	O
a	O
chain	O
extenders	O
.	O

Mole	O
fractions	O
of	O
structural	O
fragments	O
(	O
	O
exp	O
)	O
responsible	O
for	O
the	O
polar	O
interactions	O
within	O
polyurethane	B
chains	O
were	O
calculated	O
by	O
(	B
1	I
)	I
H	I
NMR	O
method	O
.	O

Obtained	O
results	O
were	O
confronted	O
with	O
the	O
analogous	O
parameter	O
values	O
(	O
	O
theor	O
)	O
calculated	O
on	O
the	O
basis	O
of	O
process	O
stoichiometry	O
,	O
considering	O
the	O
stage	O
of	O
the	O
production	O
of	O
isocyanate	B
prepolymers	O
and	O
reaction	O
of	O
their	O
extension	O
for	O
polyurethanes	B
.	O

Trials	O
of	O
linear	O
correlation	O
between	O
the	O
	O
exp	O
parameters	O
and	O
surface	O
free	O
energy	O
(	O
SFE	O
)	O
values	O
of	O
investigated	O
coatings	O
were	O
presented	O
.	O

SFE	O
values	O
were	O
determined	O
by	O
Owens	O
-	O
Wendt	O
method	O
,	O
using	O
contact	O
angles	O
measured	O
with	O
the	O
goniometric	O
method	O
.	O

Based	O
on	O
achieved	O
results	O
,	O
another	O
empirical	O
models	O
,	O
allowing	O
for	O
prediction	O
the	O
influence	O
of	O
the	O
kind	O
of	O
polyurethane	B
raw	O
materials	O
on	O
SFE	O
values	O
of	O
received	O
coatings	O
were	O
determined	O
.	O

It	O
was	O
found	O
that	O
it	O
is	O
possible	O
to	O
regulate	O
the	O
SFE	O
in	O
the	O
range	O
millijoules	O
per	O
cubic	O
metre	O
by	O
the	O
selection	O
of	O
appropriate	O
substrates	O
.	O

It	O
has	O
been	O
found	O
that	O
use	O
of	O
2,2,3,3-tetrafluoro-1,4-butanediol	B
as	O
a	O
fluorinated	O
extender	O
of	O
prepolymer	O
chains	O
is	O
essential	O
to	O
obtain	O
coatings	O
with	O
increased	O
hydrophobicity	O
,	O
applied	O
among	O
others	O
as	O
biomaterials	O
-	O
next	O
to	O
diphenylmethane	B
diisocyanate	I
and	O
polyoxyethylene	B
glycol	I
.	O

Biocomposites	O
of	O
pHEMA	B
with	O
HA	O
/	O
	B
-TCP	I
(	O
60	O
/	O
40	O
)	O
for	O
bone	O
tissue	O
engineering	O
:	O
Swelling	O
,	O
hydrolytic	O
degradation	O
,	O
and	O
in	O
vitro	O
behavior	O
.	O

The	O
field	O
of	O
bone	O
and	O
cartilage	O
tissue	O
engineering	O
has	O
a	O
pressing	O
need	O
for	O
novel	O
,	O
biocompatible	O
,	O
biodegradable	O
biocomposites	O
comprising	O
polymers	O
with	O
bioceramics	O
or	O
bioglasses	O
to	O
meet	O
numerous	O
requirements	O
for	O
these	O
applications	O
.	O

We	O
created	O
hydrolytically	O
degradable	O
hydrogel	O
/	O
bioceramic	O
biocomposites	O
,	O
comprising	O
poly	B
(	I
2-hydroxyethyl	I
methacrylate	I
)	I
(	O
pHEMA	B
)	O
hydrogels	O
and	O
50	O
wt%	O
biphasic	O
hydroxyapatite	B
/	O
	B
-	I
tricalcium	I
phosphate	I
(	O
60	O
/	O
40	O
)	O
through	O
in	O
situ	O
polymerization	O
.	O

The	O
hydrolytic	O
degradation	O
starts	O
with	O
hydrolysis	O
of	O
the	O
cross	O
-	O
linker	O
,	O
N	B
,	I
O	I
-	I
dimethacryloyl	I
hydroxylamine	I
,	O
which	O
was	O
synthesized	O
in	O
house	O
.	O

Swelling	O
and	O
degradation	O
were	O
examined	O
in	O
details	O
at	O
a	O
phosphate	B
buffered	O
saline	O
solution	O
at	O
37	O
	O
C	O
over	O
a	O
12-week	O
period	O
of	O
time	O
.	O

To	O
vary	O
degradability	O
,	O
a	O
co	O
-	O
monomer	O
,	O
acrylic	B
acid	I
(	O
AA	O
)	O
or	O
2-hydroxypropyl	B
methacrylamide	I
(	O
HPMA	B
)	O
,	O
was	O
introduced	O
,	O
coupled	O
with	O
altering	O
the	O
concentration	O
of	O
the	O
cross	O
-	O
linker	O
and	O
of	O
the	O
bioceramic	O
.	O

The	O
co	O
-	O
monomer	O
HPMA	B
was	O
found	O
to	O
be	O
more	O
effective	O
than	O
AA	O
in	O
enhancing	O
degradation	O
,	O
though	O
AA	O
led	O
to	O
greater	O
swelling	O
ratios	O
.	O

33	O
%	O
of	O
weight	O
loss	O
was	O
achieved	O
in	O
some	O
of	O
the	O
biocomposites	O
containing	O
HPMA	B
.	O

Porous	O
structures	O
were	O
developed	O
during	O
swelling	O
and	O
degradation	O
in	O
biocomposites	O
with	O
AA	O
but	O
not	O
in	O
those	O
containing	O
HPMA	B
,	O
suggesting	O
different	O
degradation	O
mechanisms	O
:	O
bulk	O
erosion	O
vs.	O
bulk	O
degradation	O
.	O

Good	O
biocompatibility	O
,	O
as	O
evidenced	O
by	O
attachment	O
and	O
proliferation	O
of	O
mouse	O
-	O
derived	O
osteoblast	O
precursor	O
cells	O
from	O
the	O
MC3T3-E1	O
lineage	O
,	O
was	O
observed	O
on	O
these	O
biomaterials	O
,	O
regardless	O
of	O
the	O
type	O
of	O
the	O
co	O
-	O
monomer	O
.	O

The	O
rationale	O
and	O
approaches	O
employed	O
here	O
open	O
up	O
new	O
opportunities	O
for	O
creating	O
novel	O
,	O
complex	O
organic	O
-	O
inorganic	O
biomaterials	O
in	O
orthopedic	O
tissue	O
engineering	O
.	O

The	O
pre	O
-	O
clinical	O
absorption	O
,	O
distribution	O
,	O
metabolism	O
and	O
excretion	O
properties	O
of	O
IPI-926	B
,	O
an	O
orally	O
bioavailable	O
antagonist	O
of	O
the	O
hedgehog	O
signal	O
transduction	O
pathway	O
.	O

Abstract	O
1	O
.	O

IPI-926	B
is	O
a	O
novel	O
semisynthetic	O
cyclopamine	B
derivative	O
that	O
is	O
a	O
potent	O
and	O
selective	O
Smoothened	O
inhibitor	O
that	O
blocks	O
the	O
hedgehog	O
signal	O
transduction	O
pathway	O
.	O

2	O
.	O

The	O
in	O
vivo	O
clearance	O
of	O
IPI-926	B
is	O
low	O
in	O
mouse	O
and	O
dog	O
and	O
moderate	O
in	O
monkey	O
.	O

The	O
volume	O
of	O
distribution	O
is	O
high	O
across	O
species	O
.	O

Oral	O
bioavailability	O
ranges	O
from	O
moderate	O
in	O
monkey	O
to	O
high	O
in	O
mouse	O
and	O
dog	O
.	O

Predicted	O
human	O
clearance	O
using	O
simple	O
allometry	O
is	O
low	O
(	O
24	O
L	O
h	O
(	O
-1	O
)	O
)	O
,	O
predicted	O
volume	O
of	O
distribution	O
is	O
high	O
(	O
469	O
L	O
)	O
and	O
predicted	O
half	O
-	O
life	O
is	O
long	O
(	O
20	O
h	O
)	O
.	O

3	O
.	O
IPI-926	B
is	O
highly	O
bound	O
to	O
plasma	O
proteins	O
and	O
has	O
minimal	O
interaction	O
with	O
human	O
-1-acid	O
glycoprotein	O
.	O

4	O
.	O

In	O
vitro	O
metabolic	O
stability	O
ranges	O
from	O
stable	O
to	O
moderately	O
stable	O
.	O

Twelve	O
oxidative	O
metabolites	O
were	O
detected	O
in	O
mouse	O
,	O
rat	O
,	O
dog	O
,	O
monkey	O
and	O
human	O
liver	O
microsome	O
incubations	O
and	O
none	O
were	O
unique	O
to	O
human	O
.	O

5	O
.	O

IPI-926	B
is	O
not	O
a	O
potent	O
reversible	O
inhibitor	O
of	O
CYP1A2	O
,	O
2C8	O
,	O
2C9	O
or	O
3A4	O
(	O
testosterone	B
)	O
.	O

IPI-926	B
is	O
a	O
moderate	O
inhibitor	O
of	O
CYP2C19	O
,	O
2D6	O
and	O
3A4	O
(	O
midazolam	B
)	O
with	O
KI	O
values	O
of	O
19	O
,	O
16	O
and	O
4.5	O
M	O
,	O
respectively	O
.	O

IPI-926	B
is	O
both	O
a	O
substrate	O
and	O
inhibitor	O
(	O
IC50	O
=	O
1.9	O
M	O
)	O
of	O
P	O
-	O
glycoprotein	O
.	O

6	O
.	O

In	O
summary	O
,	O
IPI-926	B
has	O
desirable	O
pre	O
-	O
clinical	O
absorption	O
,	O
distribution	O
,	O
metabolism	O
and	O
excretion	O
properties	O
.	O

A	O
multiple	O
perspectives	O
on	O
atypical	O
polypoid	O
adenomyoma	O
of	O
uterus	O
.	O

Abstract	O
Atypical	O
polypoid	O
adenomyoma	O
(	O
APA	O
)	O
is	O
a	O
rare	O
benign	O
uterine	O
tumor	O
,	O
with	O
less	O
than	O
200	O
cases	O
have	O
been	O
reported	O
in	O
English	O
literature	O
.	O

Although	O
,	O
it	O
is	O
considered	O
as	O
a	O
benign	O
lesion	O
and	O
treated	O
conservatively	O
previously	O
,	O
more	O
and	O
more	O
cases	O
show	O
that	O
APA	O
has	O
a	O
high	O
rate	O
of	O
recurrence	O
or	O
residual	O
,	O
and	O
is	O
found	O
to	O
precede	O
the	O
development	O
of	O
carcinoma	O
.	O

Given	O
the	O
data	O
from	O
present	O
research	O
on	O
APA	O
,	O
the	O
therapy	O
of	O
APA	O
becomes	O
more	O
complex	O
and	O
must	O
be	O
cautious	O
,	O
especially	O
for	O
the	O
nulliparous	O
and	O
premenopausal	O
patients	O
.	O

In	O
addition	O
,	O
because	O
of	O
the	O
low	O
incidence	O
,	O
studies	O
on	O
this	O
disease	O
are	O
less	O
,	O
and	O
the	O
etiology	O
and	O
pathogenesis	O
of	O
APA	O
is	O
still	O
unclear	O
.	O

In	O
this	O
review	O
,	O
we	O
aim	O
to	O
summarize	O
recent	O
researches	O
concerning	O
APA	O
from	O
multiple	O
perspectives	O
,	O
including	O
clinical	O
presentation	O
,	O
histogenesis	O
,	O
immunohistochemistry	O
and	O
molecular	O
features	O
,	O
diagnosis	O
and	O
differential	O
diagnosis	O
,	O
treatment	O
opinion	O
and	O
prognosis	O
,	O
which	O
may	O
provide	O
theory	O
and	O
clinical	O
basis	O
for	O
the	O
future	O
clinical	O
treatment	O
and	O
research	O
of	O
this	O
rare	O
disease	O
.	O

Path	O
-	O
Branching	O
Representation	O
for	O
Nonadiabatic	O
Electron	O
Dynamics	O
in	O
Conical	O
Intersection	O
.	O

Path	O
-	O
branching	O
representation	O
(	O
or	O
phase	O
-	O
space	O
averaging	O
and	O
natural	O
branching	O
method	O
(	O
PSANB	O
)	O
as	O
its	O
approximation	O
)	O
of	O
nonadiabatic	O
electron	O
wavepacket	O
dynamics	O
is	O
now	O
known	O
to	O
work	O
well	O
for	O
avoided	O
crossings	O
in	O
many	O
dimensional	O
nonadiabatic	O
transitions	O
[	O
Yonehara	O
,	O
T.	O
;	O
Hanasaki	O
,	O
K.	O
;	O
Takatsuka	O
,	O
K.	O
Chem	O
.	O

Rev.	O
2012	O
,	O
112	O
,	O
499	O
]	O
.	O

In	O
this	O
paper	O
we	O
examine	O
feasibility	O
of	O
the	O
path	O
-	O
branching	O
representation	O
in	O
the	O
theoretical	O
studies	O
of	O
conical	O
intersection	O
(	O
CI	O
)	O
.	O

The	O
most	O
characteristic	O
feature	O
of	O
CI	O
is	O
the	O
Herzberg	O
-	O
Longuet	O
-	O
Higgins	O
phase	O
(	O
or	O
the	O
Berry	O
phase	O
)	O
arising	O
from	O
the	O
electronic	O
part	O
of	O
the	O
total	O
wave	O
function	O
,	O
and	O
accordingly	O
quantum	O
phases	O
of	O
both	O
electronic	O
and	O
nuclear	O
dynamics	O
should	O
be	O
taken	O
into	O
account	O
in	O
a	O
balanced	O
manner	O
.	O

We	O
first	O
show	O
the	O
PSANB	O
can	O
well	O
capture	O
the	O
essential	O
feature	O
of	O
the	O
phase	O
dynamics	O
of	O
CI	O
.	O

However	O
,	O
the	O
nuclear	O
phases	O
,	O
the	O
wavelength	O
of	O
which	O
is	O
far	O
shorter	O
than	O
that	O
of	O
the	O
electronic	O
phases	O
,	O
make	O
the	O
computation	O
of	O
nonadiabatic	O
transition	O
extremely	O
oscillatory	O
,	O
resulting	O
in	O
very	O
slow	O
convergence	O
with	O
respect	O
to	O
the	O
number	O
of	O
sampling	O
paths	O
.	O

A	O
similar	O
difficulty	O
quite	O
often	O
takes	O
place	O
in	O
theoretical	O
chemical	O
dynamics	O
.	O

To	O
cope	O
with	O
this	O
situation	O
,	O
we	O
devise	O
a	O
simple	O
and	O
tractable	O
approximation	O
in	O
the	O
application	O
of	O
PSANB	O
resting	O
on	O
the	O
fact	O
that	O
a	O
small	O
number	O
of	O
PSANB	O
paths	O
already	O
reproduce	O
accurate	O
nonadiabatic	O
transition	O
probability	O
.	O

Complement	O
activation	O
by	O
PEGylated	O
liposomes	O
containing	O
prednisolone	B
.	O

Infusion	O
of	O
PEGylated	O
liposomes	O
can	O
give	O
rise	O
to	O
hypersensitivity	O
reactions	O
(	O
HSRs	O
)	O
in	O
a	O
relatively	O
large	O
number	O
of	O
patients	O
.	O

Previously	O
it	O
has	O
been	O
shown	O
that	O
these	O
reactions	O
can	O
be	O
caused	O
by	O
activation	O
of	O
the	O
complement	O
(	O
C	O
)	O
system	O
by	O
a	O
negative	O
charge	O
on	O
the	O
anchor	O
molecule	O
of	O
PEG	B
at	O
the	O
liposomal	O
surface	O
.	O

In	O
this	O
study	O
it	O
is	O
tested	O
whether	O
the	O
activation	O
of	O
the	O
C	O
system	O
by	O
PEG	B
-	O
liposomes	O
could	O
be	O
significantly	O
reduced	O
to	O
values	O
comparable	O
to	O
nonreactive	O
liposomal	O
formulations	O
,	O
by	O
changing	O
the	O
PEGylation	O
-	O
profile	O
on	O
the	O
liposomal	O
surface	O
.	O

Therefore	O
,	O
the	O
formation	O
of	O
C	O
activation	O
markers	O
SC5b-9	O
,	O
C3a	O
,	O
C4d	O
and	O
Bb	O
in	O
normal	O
human	O
serum	O
by	O
both	O
prednisolone	B
loaded	O
and	O
empty	O
liposomes	O
with	O
a	O
variation	O
of	O
PEG	B
chain	O
length	O
,	O
PEG	B
surface	O
concentration	O
,	O
PEG	B
anchor	O
molecule	O
and	O
liposomal	O
size	O
was	O
determined	O
using	O
in	O
vitro	O
assays	O
.	O

The	O
tested	O
liposomes	O
caused	O
no	O
or	O
only	O
mild	O
(	O
30	O
%	O
)	O
activation	O
of	O
C	O
except	O
for	O
one	O
formulation	O
wherein	O
the	O
PEG2000	B
was	O
anchored	O
to	O
cholesterol	B
(	O
CHOL	B
-	I
PEG2000	I
)	O
.	O

The	O
latter	O
liposomes	O
caused	O
paralleling	O
rises	O
in	O
SC5b-9	O
and	O
Bb	O
levels	O
,	O
suggesting	O
excess	O
activation	O
of	O
the	O
alternative	O
pathway	O
.	O

While	O
the	O
relative	O
safety	O
of	O
weak	O
C	O
activator	O
liposomes	O
remains	O
to	O
be	O
confirmed	O
in	O
vivo	O
,	O
the	O
unique	O
,	O
non	O
-	O
charge	O
and	O
non	O
-	O
antibody	O
-	O
mediated	O
direct	O
conversion	O
of	O
C3	O
by	O
CHOL	B
-	I
PEG2000	I
liposomes	O
(	O
although	O
argues	O
against	O
the	O
clinical	O
development	O
of	O
these	O
vesicles	O
)	O
opens	O
new	O
opportunities	O
to	O
understand	O
liposomal	O
C	O
activation	O
at	O
the	O
molecular	O
level	O
.	O

Technological	O
and	O
biopharmaceutical	O
optimization	O
of	O
nystatin	B
release	O
from	O
a	O
multiparticulate	O
based	O
bioadhesive	O
drug	O
delivery	O
system	O
.	O

Formulation	O
considerations	O
of	O
a	O
new	O
drug	O
delivery	O
system	O
include	O
controlling	O
the	O
site	O
of	O
release	O
of	O
the	O
active	O
ingredient	O
,	O
maintaining	O
drug	O
level	O
for	O
a	O
suitable	O
time	O
and	O
decreasing	O
dosage	O
frequency	O
.	O

In	O
research	O
and	O
development	O
practice	O
,	O
these	O
therapeutic	O
benefits	O
can	O
be	O
attained	O
by	O
selecting	O
suitable	O
active	O
ingredients	O
and	O
optimizing	O
procedure	O
parameters	O
,	O
determining	O
the	O
composition	O
of	O
the	O
medicine	O
,	O
and	O
dissolution	O
properties	O
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
design	O
a	O
pharmaceutical	O
preparation	O
with	O
increased	O
local	O
therapeutic	O
effect	O
in	O
the	O
therapy	O
of	O
gastrointestinal	O
candidiasis	O
.	O

The	O
polyene	B
antibiotic	O
nystatin	B
may	O
be	O
an	O
optimal	O
choice	O
for	O
active	O
agent	O
,	O
incorporated	O
in	O
a	O
bioadhesive	O
multiparticulate	O
system	O
.	O

Choosing	O
the	O
proper	O
excipients	O
in	O
the	O
proper	O
dosage	O
form	O
and	O
ensuring	O
prolonged	O
residence	O
time	O
may	O
further	O
improve	O
the	O
optimal	O
treatment	O
.	O

Using	O
an	O
experimental	O
design	O
,	O
the	O
micropellets	O
were	O
prepared	O
with	O
5	O
%	O
nystatin	B
content	O
,	O
taking	O
the	O
factors	O
average	O
pellet	O
size	O
(	O
200	O
to	O
800m	O
)	O
and	O
the	O
amount	O
of	O
applied	O
carbomer	O
and	O
hydroxyethylcellulose	O
(	O
0	O
-	O
5	O
%	O
)	O
into	O
consideration	O
.	O

Dissolution	O
of	O
the	O
active	O
ingredient	O
was	O
detected	O
by	O
UV	O
spectrophotometric	O
and	O
microbiological	O
assay	O
.	O

The	O
bioadhesive	O
character	O
of	O
the	O
multiparticulate	O
dosage	O
form	O
was	O
examined	O
by	O
ex	O
vivo	O
wash	O
-	O
off	O
test	O
.	O

The	O
only	O
factor	O
which	O
significantly	O
influenced	O
the	O
examined	O
parameters	O
was	O
average	O
pellet	O
size	O
.	O

The	O
proportion	O
of	O
applied	O
bioadhesive	O
excipients	O
had	O
significance	O
mostly	O
in	O
interactions	O
with	O
average	O
pellet	O
size	O
.	O

Eventually	O
,	O
optimized	O
drug	O
release	O
(	O
5	O
-	O
10min	O
mean	O
dissolution	O
time	O
,	O
50	O
-	O
55	O
%	O
bioadhesion	O
retention	O
)	O
could	O
be	O
achieved	O
with	O
550m	O
pellet	O
size	O
,	O
containing	O
carbomer	O
and	O
hydroxyethylcellulose	O
in	O
85:15	O
ratio	O
.	O

The	O
molecular	O
fingerprint	O
of	O
high	O
grade	O
serous	O
ovarian	O
cancer	O
reflects	O
its	O
fallopian	O
tube	O
origin	O
.	O

High	O
grade	O
serous	O
ovarian	O
cancer	O
(	O
HGSC	O
)	O
,	O
the	O
most	O
lethal	O
and	O
frequent	O
type	O
of	O
epithelial	O
ovarian	O
cancer	O
(	O
EOC	O
)	O
,	O
has	O
poor	O
long	O
term	O
prognosis	O
due	O
to	O
a	O
combination	O
of	O
factors	O
:	O
late	O
detection	O
,	O
great	O
metastatic	O
potential	O
and	O
the	O
capacity	O
to	O
develop	O
resistance	O
to	O
available	O
therapeutic	O
drugs	O
.	O

Furthermore	O
,	O
there	O
has	O
been	O
considerable	O
controversy	O
concerning	O
the	O
etiology	O
of	O
this	O
malignancy	O
.	O

New	O
studies	O
,	O
both	O
clinical	O
and	O
molecular	O
,	O
strongly	O
suggest	O
that	O
HGSC	O
originates	O
not	O
from	O
the	O
surface	O
of	O
the	O
ovary	O
,	O
but	O
from	O
the	O
epithelial	O
layer	O
of	O
the	O
neighboring	O
fallopian	O
tube	O
fimbriae	O
.	O

In	O
this	O
paper	O
we	O
summarize	O
data	O
supporting	O
the	O
central	O
role	O
of	O
fallopian	O
tube	O
epithelium	O
in	O
the	O
development	O
of	O
HGSC	O
.	O

Specifically	O
,	O
we	O
address	O
cellular	O
pathways	O
and	O
regulatory	O
mechanisms	O
which	O
are	O
modulated	O
in	O
the	O
process	O
of	O
transformation	O
,	O
but	O
also	O
genetic	O
changes	O
which	O
accumulate	O
during	O
disease	O
progression	O
.	O

Similarities	O
between	O
fallopian	O
tube	O
mucosa	O
and	O
the	O
malignant	O
tissue	O
of	O
HGSC	O
warrant	O
a	O
closer	O
analysis	O
of	O
homeostatic	O
mechanisms	O
in	O
healthy	O
epithelium	O
in	O
order	O
to	O
elucidate	O
key	O
steps	O
in	O
disease	O
development	O
.	O

Finally	O
,	O
we	O
highlight	O
the	O
importance	O
of	O
the	O
cancer	O
stem	O
cell	O
(	O
CSC	O
)	O
identification	O
and	O
understanding	O
of	O
its	O
niche	O
regulation	O
for	O
improvement	O
of	O
therapeutic	O
strategies	O
.	O

Broadband	O
Light	O
-	O
Trapping	O
Enhancement	O
in	O
an	O
Ultrathin	O
Film	O
a	O
-	O
Si	B
Absorber	O
Using	O
Whispering	O
Gallery	O
Modes	O
and	O
Guided	O
Wave	O
Modes	O
with	O
Dielectric	O
Surface	O
-	O
Textured	O
Structures	O
.	O

An	O
embedded	O
nanosphere	O
dielectric	O
structure	O
on	O
an	O
a	O
-	O
Si	B
ultrathin	O
film	O
improves	O
weighted	O
absorption	O
from	O
23.8	O
%	O
to	O
39.9	O
%	O
.	O

The	O
PMMA	B
embedding	O
layer	O
offers	O
a	O
guided	O
wave	O
mode	O
as	O
well	O
as	O
mechanical	O
robustness	O
,	O
in	O
addition	O
to	O
the	O
resonant	O
whispering	O
gallery	O
modes	O
coupling	O
.	O

Broadband	O
light	O
-	O
trapping	O
enhancements	O
are	O
observed	O
by	O
dielectric	O
surface	O
textured	O
structures	O
of	O
hemispheres	O
,	O
nanocones	O
,	O
nanospheres	O
,	O
or	O
embedded	O
nanospheres	O
.	O

The	O
Protective	O
Effects	O
of	O
	B
-	I
Lipoic	I
Acid	I
on	O
Kidneys	O
in	O
Type	O
2	O
Diabetic	O
Goto	O
-	O
Kakisaki	O
Rats	O
via	O
Reducing	O
Oxidative	O
Stress	O
.	O

To	O
evaluate	O
the	O
protective	O
effects	O
of	O
	B
-	I
lipoic	I
acid	I
on	O
the	O
kidneys	O
of	O
Goto	O
-	O
Kakisaki	O
(	O
GK	O
)	O
diabetic	O
rats	O
,	O
ten	O
GK	O
diabetic	O
rats	O
were	O
randomly	O
divided	O
into	O
a	O
diabetic	O
control	O
group	O
and	O
a	O
lipoic	B
acid	I
-	O
treated	O
diabetic	O
group	O
with	O
	B
-	I
lipoic	I
acid	I
35	O
mgKg-1	O
intraperitoneal	O
injections	O
.	O

Four	O
healthy	O
Wistar	O
rats	O
served	O
as	O
normal	O
controls	O
.	O

Malonaldehyde	B
(	O
MDA	B
)	O
,	O
ascorbic	B
acid	I
(	O
vitamin	B
C	I
)	O
,	O
vitamin	B
E	I
,	O
glutathione	B
(	O
GSH	B
)	O
and	O
superoxide	B
dismutase	O
(	O
SOD	O
)	O
levels	O
in	O
renal	O
homogenate	O
,	O
and	O
urine	O
protein	O
excretion	O
were	O
measured	O
.	O

The	O
expression	O
of	O
mRNA	O
for	O
NF	O
-	O
B	O
,	O
NADPH	B
oxidase	O
subunits	O
p22phox	O
and	O
p47phox	O
in	O
renal	O
tissue	O
was	O
examined	O
by	O
realtime	O
PCR	O
.	O

Pathological	O
changes	O
in	O
renal	O
tissue	O
were	O
evaluated	O
by	O
light	O
and	O
electron	O
microscopy	O
.	O

There	O
were	O
significant	O
increases	O
in	O
urine	O
protein	O
excretion	O
,	O
MDA	B
levels	O
and	O
the	O
expression	O
of	O
mRNA	O
of	O
NF	O
-	O
B	O
,	O
p22phox	O
and	O
p47phox	O
,	O
and	O
significant	O
decreases	O
in	O
GSH	B
,	O
SOD	O
,	O
vitamin	B
C	I
and	O
vitamin	B
E	I
levels	O
in	O
the	O
diabetic	O
control	O
group	O
compared	O
with	O
the	O
normal	O
control	O
group	O
.	O

Pathological	O
changes	O
of	O
renal	O
tissue	O
were	O
more	O
progressive	O
in	O
the	O
diabetic	O
control	O
group	O
than	O
in	O
the	O
normal	O
control	O
group	O
.	O

All	O
the	O
parameters	O
above	O
were	O
improved	O
in	O
the	O
	B
-	I
lipoic	I
acid	I
-	O
treated	O
diabetic	O
group	O
.	O

Oxidative	O
stress	O
is	O
increased	O
in	O
the	O
kidney	O
of	O
type	O
2	O
diabetic	O
GK	O
rats	O
.	O

It	O
is	O
associated	O
with	O
the	O
progression	O
of	O
diabetic	O
nephropathy	O
.	O

	B
-	I
lipoic	I
acid	I
can	O
protect	O
renal	O
function	O
in	O
diabetic	O
rats	O
via	O
its	O
antioxidant	O
activity	O
.	O

Effect	O
of	O
oxygen	B
concentration	O
and	O
selected	O
protocol	O
factors	O
on	O
viability	O
and	O
gene	O
expression	O
of	O
mouse	O
liver	O
slices	O
.	O

Precision	O
cut	O
liver	O
slices	O
(	O
PCLSs	O
)	O
are	O
widely	O
used	O
as	O
a	O
model	O
to	O
study	O
hepatotoxicity	O
.	O

For	O
culturing	O
of	O
PCLS	O
diverse	O
protocols	O
are	O
used	O
which	O
could	O
affect	O
slices	O
viability	O
and	O
results	O
.	O

We	O
aimed	O
to	O
identify	O
the	O
most	O
optimal	O
culture	O
protocol	O
for	O
mouse	O
PCLS	O
.	O

Slices	O
were	O
cultured	O
for	O
24h	O
under	O
different	O
concentrations	O
of	O
serum	O
,	O
glucose	B
,	O
insulin	O
,	O
and	O
oxygen	B
.	O

Thereafter	O
,	O
slices	O
viability	O
was	O
assessed	O
by	O
biochemical	O
methods	O
.	O

Transcriptome	O
analysis	O
was	O
performed	O
to	O
identify	O
changes	O
introduced	O
by	O
culture	O
at	O
different	O
oxygen	B
concentrations	O
(	O
20	O
%	O
,	O
40	O
%	O
,	O
60	O
%	O
,	O
and	O
80	O
%	O
of	O
oxygen	B
)	O
.	O

Medium	O
composition	O
did	O
not	O
affect	O
the	O
slices	O
viability	O
.	O

Although	O
metabolic	O
competence	O
was	O
unaffected	O
by	O
oxygen	B
concentrations	O
,	O
culturing	O
at	O
80	O
%	O
of	O
oxygen	B
yielded	O
slices	O
with	O
the	O
best	O
biochemical	O
characteristics	O
.	O

The	O
comparison	O
of	O
uncultured	O
vs.	O
cultured	O
slices	O
revealed	O
2524	O
genes	O
to	O
be	O
differentially	O
expressed	O
.	O

Genes	O
involved	O
in	O
drug	O
metabolism	O
,	O
peroxisomal	O
and	O
mitochondrial	O
functions	O
were	O
down	O
-	O
regulated	O
while	O
several	O
adaptive	O
/	O
stress	O
response	O
processes	O
were	O
up	O
-	O
regulated	O
.	O

Moreover	O
,	O
80	O
%	O
of	O
oxygen	B
was	O
the	O
most	O
favorable	O
condition	O
with	O
respect	O
to	O
maintenance	O
of	O
expression	O
of	O
genes	O
involved	O
in	O
drug	O
and	O
energy	O
metabolism	O
.	O

The	O
outcome	O
of	O
this	O
study	O
indicates	O
that	O
mouse	O
PCLS	O
are	O
a	O
valuable	O
tool	O
in	O
research	O
on	O
hepatic	O
functions	O
and	O
toxicity	O
,	O
particularly	O
if	O
they	O
are	O
cultured	O
under	O
a	O
controlled	O
oxygen	B
concentration	O
of	O
80	O
%	O
.	O

The	O
noncellular	O
reduction	O
of	O
MTT	B
tetrazolium	I
salt	I
by	O
TiO2	B
nanoparticles	O
and	O
its	O
implications	O
for	O
cytotoxicity	O
assays	O
.	O

We	O
report	O
results	O
of	O
noncellular	O
tests	O
,	O
revealing	O
the	O
occurrence	O
of	O
photocatalytic	O
interactions	O
between	O
titanium	B
dioxide	I
(	O
TiO2	B
,	O
titania	B
)	O
nanoparticles	O
and	O
the	O
MTT	B
[	O
3-	B
(	I
4,5-Dimethylthiazol-2-yl	I
)	I
-2,5-diphenyltetrazolium	I
-	I
bromide	I
]	O
cytotoxicity	O
indicator	O
.	O

These	O
interactions	O
induce	O
the	O
reduction	O
of	O
MTT	B
and	O
formation	O
of	O
purple	O
formazan	O
under	O
biologically	O
relevant	O
conditions	O
.	O

Classical	O
MTT	B
assays	O
have	O
been	O
performed	O
to	O
evaluate	O
the	O
production	O
of	O
formazan	B
in	O
DMEM	O
-	O
F12	O
and	O
RPMI-1640	O
cell	O
culture	O
media	O
(	O
containing	O
10	O
%	O
fetal	O
bovine	O
serum	O
-	O
FBS	O
)	O
treated	O
with	O
Degussa	O
-	O
P25	B
TiO2	I
nanoparticles	O
,	O
in	O
the	O
absence	O
of	O
cells	O
.	O

The	O
colorimetric	O
determinations	O
revealed	O
the	O
noncellular	O
MTT	B
to	O
formazan	B
transformation	O
induced	O
by	O
TiO2	B
nanoparticles	O
,	O
under	O
conditions	O
commonly	O
used	O
for	O
in	O
vitro	O
cytotoxicity	O
testing	O
of	O
nanomaterials	O
.	O

The	O
formazan	B
precipitation	O
was	O
found	O
to	O
be	O
proportional	O
to	O
the	O
TiO2	B
concentration	O
,	O
being	O
enhanced	O
under	O
laboratory	O
daylight	O
exposure	O
.	O

The	O
photocatalytic	O
nature	O
of	O
the	O
studied	O
effect	O
was	O
assessed	O
under	O
UV	O
irradiation	O
at	O
365	O
nm	O
.	O

The	O
biological	O
significance	O
of	O
the	O
reported	O
reaction	O
was	O
established	O
with	O
respect	O
to	O
cellular	O
reference	O
experiments	O
performed	O
on	O
V79	O
-	O
4	O
,	O
HeLa	O
and	O
B16	O
cell	O
lines	O
.	O

The	O
results	O
show	O
false	O
viability	O
increases	O
with	O
up	O
to	O
14	O
%	O
(	O
for	O
TiO2	B
concentrations	O
generally	O
higher	O
than	O
50g	O
/	O
ml	O
)	O
,	O
induced	O
by	O
the	O
TiO2-MTT	B
reaction	O
.	O

This	O
type	O
of	O
artifacts	O
may	O
lead	O
to	O
underestimated	O
toxicity	O
or	O
false	O
proliferation	O
results	O
.	O

Streptococcal	O
collagen	O
-	O
like	O
protein	O
A	O
and	O
general	O
stress	O
protein	O
24	O
are	O
immunomodulating	O
virulence	O
factors	O
of	O
group	O
A	O
Streptococcus	O
.	O

In	O
Western	O
countries	O
,	O
invasive	O
infections	O
caused	O
by	O
M1T1	O
serotype	O
group	O
A	O
Streptococcus	O
(	O
GAS	O
)	O
are	O
epidemiologically	O
linked	O
to	O
mutations	O
in	O
the	O
control	O
of	O
virulence	O
regulatory	O
2-component	O
operon	O
(	O
covRS	O
)	O
.	O

In	O
indigenous	O
communities	O
and	O
developing	O
countries	O
,	O
severe	O
GAS	O
disease	O
is	O
associated	O
with	O
genetically	O
diverse	O
non	O
-	O
M1T1	O
GAS	O
serotypes	O
.	O

Hypervirulent	O
M1T1	O
covRS	O
mutant	O
strains	O
arise	O
through	O
selection	O
by	O
human	O
polymorphonuclear	O
cells	O
for	O
increased	O
expression	O
of	O
GAS	O
virulence	O
factors	O
such	O
as	O
the	O
DNase	O
Sda1	O
,	O
which	O
promotes	O
neutrophil	O
resistance	O
.	O

The	O
GAS	O
bacteremia	O
isolate	O
NS88.2	O
(	O
emm	O
98.1	O
)	O
is	O
a	O
covS	O
mutant	O
that	O
exhibits	O
a	O
hypervirulent	O
phenotype	O
and	O
neutrophil	O
resistance	O
yet	O
lacks	O
the	O
phage	O
-	O
encoded	O
Sda1	O
.	O

Here	O
,	O
we	O
have	O
employed	O
a	O
comprehensive	O
systems	O
biology	O
(	O
genomic	O
,	O
transcriptomic	O
,	O
and	O
proteomic	O
)	O
approach	O
to	O
identify	O
NS88.2	O
virulence	O
determinants	O
that	O
enhance	O
neutrophil	O
resistance	O
in	O
the	O
non	O
-	O
M1T1	O
GAS	O
genetic	O
background	O
.	O

Using	O
this	O
approach	O
,	O
we	O
have	O
identified	O
streptococcal	O
collagen	O
-	O
like	O
protein	O
A	O
and	O
general	O
stress	O
protein	O
24	O
proteins	O
as	O
NS88.2	O
determinants	O
that	O
contribute	O
to	O
survival	O
in	O
whole	O
blood	O
and	O
neutrophil	O
resistance	O
in	O
non	O
-	O
M1T1	O
GAS	O
.	O

This	O
study	O
has	O
revealed	O
new	O
factors	O
that	O
contribute	O
to	O
GAS	O
pathogenicity	O
that	O
may	O
play	O
important	O
roles	O
in	O
resisting	O
innate	O
immune	O
defenses	O
and	O
the	O
development	O
of	O
human	O
invasive	O
infections	O
-	O
Tsatsaronis	O
,	O
J.	O
A.	O
,	O
Hollands	O
,	O
A.	O
,	O
Cole	O
,	O
J.	O
N.	O
,	O
Maamary	O
,	O
P.	O
G.	O
,	O
Gillen	O
,	O
C.	O
M.	O
,	O
Ben	O
Zakour	O
,	O
N.	O
L.	O
,	O
Kotb	O
,	O
M.	O
,	O
Nizet	O
,	O
V.	O
,	O
Beatson	O
,	O
S.	O
A.	O
Walker	O
,	O
M.	O
J.	O
,	O
Sanderson	O
-	O
Smith	O
,	O
M.	O
L.	O
Streptococcal	O
collagen	O
-	O
like	O
protein	O
A	O
and	O
general	O
stress	O
protein	O
24	O
are	O
immunomodulating	O
virulence	O
factors	O
of	O
group	O
A	O
Streptococcus	O
.	O

Analysis	O
of	O
visible	O
-	O
light	O
-	O
active	O
Sn	B
(	I
ii	I
)	I
-TiO2	O
photocatalysts	O
.	O

The	O
influence	O
of	O
Sn	B
(	I
ii	I
)	I
species	O
on	O
TiO2	B
is	O
investigated	O
.	O

The	O
absorption	O
spectra	O
of	O
these	O
materials	O
are	O
red	O
-	O
shifted	O
by	O
115	O
nm	O
to	O
the	O
visible	O
region	O
of	O
the	O
solar	O
spectrum	O
compared	O
with	O
P25	B
TiO2	I
.	O

This	O
prominent	O
red	O
-	O
shift	O
is	O
attributed	O
to	O
the	O
interaction	O
of	O
Sn	B
(	I
ii	I
)	I
5s	O
orbitals	O
with	O
the	O
TiO2	B
decreasing	O
the	O
band	O
gap	O
of	O
TiO2	B
by	O
raising	O
its	O
valence	O
band	O
.	O

The	O
tin	B
oxidation	O
state	O
and	O
the	O
materials	O
electronic	O
structure	O
are	O
evaluated	O
using	O
Mssbauer	O
spectroscopy	O
and	O
valence	O
band	O
X	O
-	O
ray	O
photoelectron	O
spectroscopy	O
respectively	O
.	O

These	O
materials	O
are	O
active	O
for	O
sacrificial	O
photo	O
-	O
generation	O
of	O
hydrogen	B
in	O
visible	O
light	O
.	O

A	O
pyrrolidinium	B
nitrate	I
protic	O
ionic	O
liquid	O
-	O
based	O
electrolyte	O
for	O
very	O
low	O
-	O
temperature	O
electrical	O
double	O
-	O
layer	O
capacitors	O
.	O

This	O
study	O
describes	O
the	O
use	O
of	O
the	O
pyrrolidinium	B
nitrate	I
(	O
[	B
Pyrr	I
]	I
[	I
NO3	I
]	I
)	O
protic	O
ionic	O
liquid	O
(	O
PIL	O
)	O
in	O
a	O
mixture	O
with	O
gamma	B
butyrolactone	I
(	O
	B
-	I
BL	I
)	O
as	O
an	O
electrolyte	O
for	O
carbon	B
-	O
based	O
supercapacitors	O
with	O
an	O
operating	O
voltage	O
of	O
2.0	O
V	O
and	O
at	O
very	O
low	O
temperature	O
.	O

Thermal	O
and	O
transport	O
properties	O
of	O
this	O
electrolyte	O
were	O
firstly	O
evaluated	O
from	O
-40	O
	O
C	O
to	O
80	O
	O
C	O
.	O

The	O
evolution	O
of	O
conductivity	O
with	O
the	O
addition	O
of	O
	B
-	I
BL	I
rendered	O
it	O
possible	O
to	O
determine	O
the	O
optimal	O
composition	O
for	O
electrochemical	O
application	O
,	O
with	O
a	O
molar	O
fraction	O
of	O
	B
-	I
BL	I
of	O
0.6	O
.	O

This	O
mixture	O
shows	O
a	O
Newtonian	O
behavior	O
with	O
a	O
low	O
viscosity	O
value	O
of	O
5	O
mPa	O
s	O
at	O
25	O
	O
C	O
,	O
and	O
exhibits	O
high	O
conductivity	O
values	O
of	O
up	O
to	O
65	O
mS	O
cm	O
(	O
-1	O
)	O
at	O
80	O
	O
C	O
.	O

At	O
the	O
same	O
time	O
,	O
exceptional	O
residual	O
conductivity	O
was	O
measured	O
for	O
this	O
composition	O
at	O
-40	O
	O
C	O
(	O
9	O
mS	O
cm	O
(	O
-1	O
)	O
)	O
,	O
thanks	O
to	O
the	O
superionic	O
character	O
of	O
pyrrolidinium	B
nitrate	I
PIL	O
.	O

Electrochemical	O
characterization	O
of	O
this	O
electrolyte	O
demonstrated	O
,	O
at	O
first	O
,	O
a	O
passivation	O
on	O
the	O
aluminum	B
collector	O
,	O
secondly	O
good	O
cycling	O
performances	O
with	O
an	O
activated	O
carbon	B
electrode	O
from	O
50	O
	O
C	O
to	O
-40	O
	O
C	O
with	O
capacitance	O
up	O
to	O
132	O
F	O
g	O
(	O
-1	O
)	O
at	O
room	O
temperature	O
and	O
a	O
wide	O
voltage	O
window	O
(	O
2.0	O
V	O
)	O
.	O

Finally	O
at	O
very	O
low	O
temperature	O
(	O
-40	O
	O
C	O
)	O
,	O
this	O
system	O
demonstrates	O
an	O
unprecedented	O
combination	O
of	O
high	O
specific	O
capacitance	O
(	O
up	O
to	O
117	O
F	O
g	O
(	O
-1	O
)	O
)	O
,	O
and	O
rapid	O
charging	O
-	O
discharging	O
even	O
at	O
high	O
current	O
density	O
,	O
which	O
is	O
very	O
promising	O
for	O
the	O
progress	O
of	O
energy	O
storage	O
systems	O
with	O
environmentally	O
friendly	O
electrolytes	O
at	O
such	O
very	O
low	O
temperatures	O
.	O

Tryptophan	B
residue	O
at	O
active	O
-	O
site	O
tunnel	O
entrance	O
of	O
Trichoderma	O
reesei	O
cellobiohydrolase	O
Cel7A	O
is	O
important	O
to	O
initiate	O
degradation	O
of	O
crystalline	O
cellulose	O
.	O

Glycoside	O
hydrolase	O
family-7	O
cellobiohydrolase	O
from	O
Trichoderma	O
reesei	O
(	O
TrCel7A	O
)	O
is	O
one	O
of	O
the	O
best	O
-	O
studied	O
cellulases	O
with	O
the	O
ability	O
to	O
degrade	O
highly	O
crystalline	O
cellulose	O
(	O
HCC	O
)	O
.	O

The	O
catalytic	O
domain	O
(	O
cat	O
)	O
and	O
cellulose	O
-	O
binding	O
domain	O
(	O
CBD	O
)	O
are	O
both	O
necessary	O
for	O
full	O
activity	O
on	O
crystalline	O
substrates	O
.	O

Our	O
previous	O
high	O
-	O
speed	O
AFM	O
studies	O
showed	O
that	O
mutation	O
of	O
tryptophan	B
residue	O
(	O
Trp40	B
;	O
W40	O
)	O
at	O
the	O
entrance	O
of	O
the	O
catalytic	O
tunnel	O
drastically	O
decreases	O
the	O
ability	O
to	O
degrade	O
crystalline	O
cellulose	O
.	O

Here	O
,	O
we	O
examined	O
the	O
activities	O
of	O
the	O
wild	O
-	O
type	O
(	O
WT	O
)	O
enzyme	O
and	O
tryptophan	B
to	O
alanine	B
mutant	O
(	O
W40A	O
)	O
enzyme	O
,	O
with	O
and	O
without	O
the	O
CBD	O
,	O
towards	O
various	O
substrates	O
.	O

Evaluation	O
and	O
comparison	O
of	O
the	O
specific	O
activities	O
of	O
the	O
enzymes	O
(	O
WT	O
,	O
WTcat	O
,	O
W40A	O
,	O
and	O
W40Acat	O
)	O
adsorbed	O
on	O
crystalline	O
cellulose	O
indicated	O
that	O
Trp40	B
is	O
involved	O
in	O
recruiting	O
individual	O
substrate	O
chains	O
into	O
the	O
active	O
site	O
tunnel	O
to	O
initiate	O
processive	O
hydrolysis	O
.	O

This	O
idea	O
was	O
supported	O
by	O
molecular	O
dynamics	O
simulation	O
study	O
,	O
i.e.	O
,	O
the	O
reducing	O
-	O
end	O
glucose	B
unit	O
was	O
effectively	O
loaded	O
into	O
the	O
active	O
site	O
of	O
WTcat	O
,	O
but	O
not	O
into	O
that	O
of	O
W40Acat	O
.	O

when	O
the	O
simulation	O
was	O
started	O
from	O
subsite	O
-7	O
.	O

However	O
,	O
when	O
the	O
similar	O
simulations	O
were	O
carried	O
out	O
starting	O
from	O
subsite	O
-5	O
,	O
both	O
enzymes	O
hold	O
the	O
substrate	O
in	O
50	O
ns	O
,	O
indicating	O
that	O
the	O
major	O
difference	O
between	O
WTcat	O
and	O
W40Acat	O
is	O
the	O
length	O
of	O
free	O
chain	O
-	O
end	O
of	O
the	O
substrate	O
required	O
to	O
allow	O
initiation	O
of	O
processive	O
movements	O
;	O
this	O
also	O
reflects	O
the	O
difference	O
between	O
crystalline	O
and	O
amorphous	O
celluloses	O
.	O

The	O
CBD	O
is	O
important	O
for	O
enhancing	O
the	O
enzyme	O
population	O
on	O
crystalline	O
substrate	O
,	O
but	O
it	O
also	O
decreases	O
the	O
specific	O
activity	O
of	O
the	O
adsorbed	O
enzyme	O
,	O
possibly	O
by	O
attaching	O
the	O
enzyme	O
to	O
non	O
-	O
optimal	O
places	O
on	O
cellulose	O
surface	O
and/or	O
hindering	O
processive	O
hydrolysis	O
.	O

A	O
Novel	O
Automethylation	O
Reaction	O
in	O
the	O
Aspergillus	O
nidulans	O
LaeA	O
Protein	O
Generates	O
S	B
-	I
Methylmethionine	I
.	O

The	O
filamentous	O
fungi	O
in	O
the	O
genus	O
Aspergillus	O
are	O
opportunistic	O
plant	O
and	O
animal	O
pathogens	O
that	O
can	O
adapt	O
to	O
their	O
environment	O
by	O
producing	O
various	O
secondary	O
metabolites	O
including	O
lovastatin	B
,	O
penicillin	B
,	O
and	O
aflatoxin	B
.	O

The	O
synthesis	O
of	O
these	O
small	O
molecules	O
is	O
dependent	O
on	O
gene	O
clusters	O
that	O
are	O
globally	O
regulated	O
by	O
the	O
LaeA	O
protein	O
.	O

Null	O
mutants	O
of	O
LaeA	O
in	O
all	O
pathogenic	O
fungi	O
examined	O
to	O
date	O
show	O
decreased	O
virulence	O
coupled	O
with	O
reduced	O
secondary	O
metabolism	O
.	O

Although	O
the	O
amino	B
acid	I
sequence	O
of	O
LaeA	O
contains	O
the	O
motifs	O
characteristic	O
of	O
seven	O
-	O
beta	O
-	O
strand	O
methyltransferases	O
,	O
a	O
methyl	B
-	O
accepting	O
substrate	O
of	O
LaeA	O
has	O
not	O
been	O
identified	O
.	O

In	O
this	O
work	O
,	O
we	O
did	O
not	O
find	O
a	O
methyl	B
-	O
accepting	O
substrate	O
in	O
A.	O
nidulans	O
with	O
various	O
assays	O
including	O
in	O
vivo	O
S	B
-	I
adenosyl-	I
[	I
methyl-	I
(	I
3	I
)	I
H	I
]	I
methionine	I
labeling	O
,	O
targeted	O
in	O
vitro	O
methylation	O
experiments	O
using	O
putative	O
protein	O
substrates	O
,	O
or	O
in	O
vitro	O
methylation	O
assays	O
using	O
whole	O
cell	O
extracts	O
grown	O
under	O
different	O
conditions	O
.	O

However	O
,	O
in	O
each	O
experiment	O
LaeA	O
was	O
shown	O
to	O
self	O
-	O
methylate	O
.	O

Amino	B
acid	I
hydrolysis	O
of	O
radioactively	O
-	O
labeled	O
LaeA	O
followed	O
by	O
cation	O
exchange	O
and	O
reverse	O
phase	O
chromatography	O
identified	O
methionine	B
as	O
the	O
modified	O
residue	O
.	O

Point	O
mutations	O
show	O
that	O
the	O
major	O
site	O
of	O
modification	O
of	O
LaeA	O
is	O
on	O
methionine-207	B
.	O

However	O
,	O
in	O
vivo	O
complementation	O
showed	O
that	O
methionine-207	B
is	O
not	O
required	O
for	O
the	O
biological	O
function	O
of	O
LaeA.	O
LaeA	O
is	O
the	O
first	O
protein	O
to	O
exhibit	O
automethylation	O
at	O
a	O
methionine	B
residue	O
.	O

These	O
findings	O
not	O
only	O
indicate	O
LaeA	O
may	O
perform	O
novel	O
chemistry	O
with	O
S	B
-	I
adenosylmethionine	I
,	O
but	O
also	O
provide	O
new	O
insights	O
into	O
the	O
physiological	O
function	O
of	O
LaeA.	O

Synthesis	O
and	O
in	O
Vitro	O
Characterisation	O
of	O
Ifenprodil	B
-	O
Based	O
Fluorescein	B
Conjugates	O
as	O
GluN1	O
/	O
GluN2B	O
N	B
-	I
Methyl	I
-	I
D	I
-	I
aspartate	I
Receptor	O
Antagonists	O
.	O

GluN2B	O
-	O
containing	O
NMDA	B
receptors	O
are	O
involved	O
in	O
many	O
important	O
physiological	O
functions	O
and	O
play	O
a	O
pivotal	O
role	O
in	O
mediating	O
pain	O
as	O
well	O
as	O
in	O
several	O
neurodegenerative	O
disorders	O
.	O

We	O
aimed	O
to	O
develop	O
fluorescent	O
probes	O
to	O
target	O
the	O
GluN2B	O
subunit	O
selectively	O
in	O
order	O
to	O
allow	O
better	O
understanding	O
of	O
the	O
relationships	O
between	O
receptor	O
localisation	O
and	O
physiological	O
importance	O
.	O

Ifenprodil	B
,	O
known	O
as	O
the	O
GluNR2B	O
antagonist	O
of	O
reference	O
,	O
was	O
chosen	O
as	O
the	O
template	O
for	O
the	O
elaboration	O
of	O
probes	O
.	O

We	O
had	O
previously	O
reported	O
a	O
fluorescein	B
conjugate	O
that	O
was	O
shown	O
(	O
by	O
confocal	O
microscopy	O
imaging	O
of	O
DS	O
-	O
red	O
-	O
labelled	O
cortical	O
neurons	O
)	O
to	O
bind	O
specifically	O
to	O
GluN2B	O
.	O

To	O
elaborate	O
this	O
probe	O
,	O
we	O
explored	O
the	O
influence	O
of	O
both	O
the	O
nature	O
and	O
the	O
attachment	O
point	O
of	O
the	O
spacer	O
between	O
the	O
fluorophore	O
and	O
the	O
parent	O
compound	O
,	O
ifenprodil	B
.	O

We	O
performed	O
chemical	O
modifications	O
of	O
ifenprodil	B
at	O
the	O
benzylic	B
position	O
and	O
on	O
the	O
phenol	B
ring	O
by	O
introducing	O
secondary	B
amine	I
or	I
amide	I
functions	O
and	O
evaluated	O
alkyl	O
chains	O
from	O
two	O
to	O
20	O
bonds	O
either	O
including	O
or	O
not	O
including	O
secondary	B
amide	I
functions	O
as	O
spacers	O
.	O

The	O
previously	O
developed	O
probe	O
was	O
found	O
to	O
display	O
the	O
greatest	O
activity	O
in	O
the	O
inhibition	O
of	O
NMDA	B
-	O
induced	O
Ca	B
(	I
2	I
+	I
)	I
influx	O
by	O
calcium	B
imaging	O
experiments	O
on	O
HEK293	O
cells	O
transfected	O
with	O
the	O
cDNA	O
encoding	O
for	O
GluN1	O
-	O
1A	O
and	O
GluN2B	O
.	O

Further	O
investigations	O
revealed	O
that	O
this	O
probe	O
had	O
a	O
neuroprotective	O
effect	O
equivalent	O
to	O
that	O
of	O
ifenprodil	B
in	O
a	O
standard	O
test	O
for	O
neurotoxicity	O
.	O

Despite	O
effects	O
of	O
lesser	O
amplitude	O
with	O
these	O
probes	O
relative	O
to	O
ifenprodil	B
,	O
we	O
demonstrated	O
that	O
they	O
displaced	O
[	B
(	I
3	I
)	I
H	I
]	I
ifenprodil	I
in	O
mouse	O
brain	O
slices	O
in	O
a	O
similar	O
manner	O
.	O

Pickering	O
-	O
Emulsion	O
-	O
Polymerized	O
Polystyrene	B
/	O
Fe2O3	B
Composite	O
Particles	O
and	O
Their	O
Magnetoresponsive	O
Characteristics	O
.	O

Core	O
-	O
shell	O
-	O
structured	O
magnetic	O
polystyrene	B
(	O
PS	O
)	O
/	O
inorganic	O
particles	O
were	O
fabricated	O
by	O
Pickering	O
emulsion	O
polymerization	O
using	O
nanosized	O
Fe2O3	B
particles	O
as	O
a	O
solid	O
stabilizer	O
.	O

Scanning	O
electron	O
microscopy	O
and	O
transmission	O
electron	O
microscopy	O
confirmed	O
the	O
synthesized	O
PS	O
/	O
Fe2O3	B
particles	O
to	O
be	O
comprised	O
of	O
a	O
PS	O
surface	O
coated	O
with	O
Fe2O3	B
nanoparticles	O
.	O

The	O
chemical	O
structure	O
of	O
the	O
composite	O
nanospheres	O
was	O
characterized	O
by	O
Fourier	O
transform	O
infrared	O
spectroscopy	O
and	O
X	O
-	O
ray	O
diffraction	O
.	O

The	O
thermal	O
properties	O
of	O
composite	O
nanospheres	O
and	O
corresponding	O
pure	O
polymer	O
were	O
examined	O
by	O
thermogravimetric	O
analysis	O
.	O

The	O
rheological	O
properties	O
of	O
the	O
core	O
-	O
shell	O
-	O
structured	O
magnetic	O
PS	O
/	O
inorganic	O
particles	O
dispersed	O
in	O
silicone	O
oil	O
were	O
investigated	O
under	O
an	O
external	O
magnetic	O
field	O
strength	O
using	O
a	O
rotational	O
rheometer	O
.	O

The	O
particles	O
with	O
extremely	O
lower	O
density	O
than	O
common	O
magnetic	O
particles	O
exhibited	O
solid	O
-	O
like	O
magnetorheological	O
phase	O
characteristics	O
,	O
and	O
the	O
flow	O
curves	O
were	O
fitted	O
to	O
the	O
Cho	O
-	O
Choi	O
-	O
Jhon	O
model	O
of	O
the	O
rheological	O
equation	O
of	O
state	O
.	O

Engineering	O
the	O
Microstructure	O
of	O
Electrospun	O
Fibrous	O
Scaffolds	O
by	O
Microtopography	O
.	O

Controlling	O
the	O
structure	O
and	O
organization	O
of	O
electrospun	O
fibers	O
is	O
desirable	O
for	O
fabricating	O
scaffolds	O
and	O
materials	O
with	O
defined	O
microstructures	O
.	O

However	O
,	O
the	O
effects	O
of	O
microtopography	O
on	O
the	O
deposition	O
and	O
,	O
in	O
turn	O
,	O
the	O
organization	O
of	O
the	O
electrospun	O
fibers	O
are	O
not	O
well	O
understood	O
.	O

In	O
this	O
study	O
,	O
conductive	O
polydimethylsiloxane	B
(	O
PDMS	B
)	O
templates	O
with	O
different	O
micropatterns	O
were	O
fabricated	O
by	O
combining	O
photolithography	O
,	O
silicon	B
wet	O
etching	O
,	O
and	O
PDMS	B
molding	O
techniques	O
.	O

The	O
fiber	O
organization	O
was	O
varied	O
by	O
fine	O
-	O
tuning	O
the	O
microtopography	O
of	O
the	O
electrospinning	O
collector	O
.	O

Fiber	O
conformity	O
and	O
alignment	O
were	O
influenced	O
by	O
the	O
depth	O
and	O
the	O
slope	O
of	O
microtopography	O
features	O
,	O
resulting	O
in	O
scaffolds	O
comprising	O
either	O
an	O
array	O
of	O
microdomains	O
with	O
different	O
porosity	O
and	O
fiber	O
alignment	O
or	O
an	O
array	O
of	O
microwells	O
.	O

Microtopography	O
affected	O
the	O
fiber	O
organization	O
for	O
hundreds	O
of	O
micrometers	O
below	O
the	O
scaffold	O
surface	O
,	O
resulting	O
in	O
scaffolds	O
with	O
distinct	O
surface	O
properties	O
on	O
each	O
side	O
.	O

In	O
addition	O
,	O
the	O
fiber	O
diameter	O
was	O
also	O
affected	O
by	O
the	O
fiber	O
conformity	O
.	O

The	O
effects	O
of	O
the	O
fiber	O
arrangement	O
in	O
the	O
scaffolds	O
on	O
the	O
morphology	O
,	O
migration	O
,	O
and	O
infiltration	O
of	O
cells	O
were	O
examined	O
by	O
in	O
vitro	O
and	O
in	O
vivo	O
experiments	O
.	O

Cell	O
morphology	O
and	O
organization	O
were	O
guided	O
by	O
the	O
fibers	O
in	O
the	O
microdomains	O
,	O
and	O
cell	O
migration	O
was	O
enhanced	O
by	O
the	O
aligned	O
fibers	O
and	O
the	O
three	O
-	O
dimensional	O
scaffold	O
structure	O
.	O

Cell	O
infiltration	O
was	O
correlated	O
with	O
the	O
microdomain	O
porosity	O
.	O

Microscale	O
control	O
of	O
the	O
fiber	O
organization	O
and	O
the	O
porosity	O
at	O
the	O
surface	O
and	O
through	O
the	O
thickness	O
of	O
the	O
fibrous	O
scaffolds	O
,	O
as	O
demonstrated	O
by	O
the	O
results	O
of	O
this	O
study	O
,	O
provides	O
a	O
powerful	O
means	O
of	O
engineering	O
the	O
three	O
-	O
dimensional	O
structure	O
of	O
electrospun	O
fibrous	O
scaffolds	O
for	O
cell	O
and	O
tissue	O
engineering	O
.	O

Directing	O
Chondrogenesis	O
of	O
Stem	O
Cells	O
with	O
Specific	O
Blends	O
of	O
Cellulose	O
and	O
Silk	O
.	O

Biomaterials	O
that	O
can	O
stimulate	O
stem	O
cell	O
differentiation	O
without	O
growth	O
factor	O
supplementation	O
provide	O
potent	O
and	O
cost	O
-	O
effective	O
scaffolds	O
for	O
regenerative	O
medicine	O
.	O

We	O
hypothesize	O
that	O
a	O
scaffold	O
prepared	O
from	O
cellulose	O
and	O
silk	O
blends	O
can	O
direct	O
stem	O
cell	O
chondrogenic	O
fate	O
.	O

We	O
systematically	O
prepared	O
cellulose	O
blends	O
with	O
silk	O
at	O
different	O
compositions	O
using	O
an	O
environmentally	O
benign	O
processing	O
method	O
based	O
on	O
ionic	O
liquids	O
as	O
a	O
common	O
solvent	O
.	O

We	O
tested	O
the	O
effect	O
of	O
blend	O
compositions	O
on	O
the	O
physical	O
properties	O
of	O
the	O
materials	O
as	O
well	O
as	O
on	O
their	O
ability	O
to	O
support	O
mesenchymal	O
stem	O
cell	O
(	O
MSC	O
)	O
growth	O
and	O
chondrogenic	O
differentiation	O
.	O

The	O
stiffness	O
and	O
tensile	O
strength	O
of	O
cellulose	O
was	O
significantly	O
reduced	O
by	O
blending	O
with	O
silk	O
.	O

The	O
characterized	O
materials	O
were	O
tested	O
using	O
MSCs	O
derived	O
from	O
four	O
different	O
patients	O
.	O

Growing	O
MSCs	O
on	O
a	O
specific	O
blend	O
combination	O
of	O
cellulose	O
and	O
silk	O
in	O
a	O
75:25	O
ratio	O
significantly	O
upregulated	O
the	O
chondrogenic	O
marker	O
genes	O
SOX9	O
,	O
aggrecan	O
,	O
and	O
type	O
II	O
collagen	O
in	O
the	O
absence	O
of	O
specific	O
growth	O
factors	O
.	O

This	O
chondrogenic	O
effect	O
was	O
neither	O
found	O
with	O
neat	O
cellulose	O
nor	O
the	O
cellulose	O
/	O
silk	O
50:50	O
blend	O
composition	O
.	O

No	O
adipogenic	O
or	O
osteogenic	O
differentiation	O
was	O
detected	O
on	O
the	O
blends	O
,	O
suggesting	O
that	O
the	O
cellulose	O
/	O
silk	O
75:25	O
blend	O
induced	O
specific	O
stem	O
cell	O
differentiation	O
into	O
the	O
chondrogenic	O
lineage	O
without	O
addition	O
of	O
the	O
soluble	O
growth	O
factor	O
TGF	O
-	O
	O
.	O

The	O
cellulose	O
/	O
silk	O
blend	O
we	O
identified	O
can	O
be	O
used	O
both	O
for	O
in	O
vitro	O
tissue	O
engineering	O
and	O
as	O
an	O
implantable	O
device	O
for	O
stimulating	O
endogenous	O
stem	O
cells	O
to	O
initiate	O
cartilage	O
repair	O
.	O

Recent	O
developments	O
in	O
design	O
and	O
synthesis	O
of	O
bicyclic	B
azasugars	I
,	O
carbasugars	B
and	O
related	O
molecules	O
as	O
glycosidase	O
inhibitors	O
.	O

The	O
importance	O
of	O
glycosidase	O
inhibitors	O
and	O
especially	O
the	O
bicyclic	O
molecules	O
has	O
led	O
to	O
design	O
and	O
assessment	O
of	O
many	O
analogs	O
of	O
naturally	O
occurring	O
molecules	O
.	O

This	O
review	O
focuses	O
on	O
the	O
synthesis	O
and	O
enzyme	O
inhibitions	O
of	O
a	O
few	O
selected	O
(	O
synthetic	O
or	O
non	O
-	O
naturally	O
occurring	O
)	O
molecules	O
that	O
have	O
been	O
reported	O
in	O
the	O
last	O
decade	O
,	O
which	O
allow	O
one	O
to	O
draw	O
some	O
connection	O
between	O
varying	O
the	O
structural	O
features	O
and	O
their	O
effect	O
on	O
glycosidase	O
inhibitions	O
.	O

It	O
is	O
expected	O
that	O
further	O
improvements	O
based	O
on	O
these	O
features	O
could	O
lead	O
to	O
improved	O
inhibitors	O
.	O

Neuroprotective	O
Effects	O
of	O
Cilostazol	B
on	O
Retinal	O
Ganglion	O
Cell	O
damage	O
in	O
Diabetic	O
Rats	O
.	O

Neurodegeneration	O
is	O
an	O
important	O
component	O
of	O
diabetic	O
retinopathy	O
with	O
increasing	O
evidence	O
that	O
retinal	O
ganglion	O
cell	O
(	O
RGC	O
)	O
death	O
occurs	O
early	O
in	O
diabetes	O
.	O

We	O
investigated	O
the	O
effects	O
of	O
cilostazol	B
,	O
which	O
has	O
been	O
widely	O
used	O
to	O
manage	O
diabetic	O
complications	O
,	O
on	O
retinal	O
ganglion	O
cell	O
death	O
in	O
diabetic	O
retina	O
.	O

Four	O
-	O
week	O
-	O
old	O
Otsuka	O
Long	O
-	O
Evans	O
Tokushima	O
Fatty	O
(	O
OLETF	O
)	O
rats	O
and	O
Long	O
-	O
Evans	O
Tokushima	O
Otsuka	O
(	O
LETO	O
)	O
rats	O
as	O
matched	O
nondiabetic	O
controls	O
were	O
treated	O
with	O
daily	O
oral	O
cilostazol	B
at	O
30mg	O
/	O
kg	O
or	O
0.9	O
%	O
saline	O
solution	O
.	O

In	O
OLETF	O
rats	O
at	O
the	O
age	O
of	O
40	O
weeks	O
,	O
glial	O
fibrillary	O
acidic	O
protein	O
(	O
GFAP	O
)	O
immunofluorescence	O
staining	O
was	O
upregulated	O
in	O
vertical	O
sections	O
and	O
showed	O
a	O
more	O
ramified	O
pattern	O
in	O
whole	O
-	O
mount	O
retinas	O
compared	O
with	O
that	O
in	O
LETO	O
rats	O
.	O

Vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
expression	O
was	O
limited	O
to	O
the	O
ganglion	O
cell	O
layer	O
in	O
LETO	O
rats	O
,	O
but	O
extended	O
into	O
the	O
outer	O
plexiform	O
layer	O
in	O
OLETF	O
rats	O
.	O

Immunofluorescence	O
staining	O
and	O
western	O
blotting	O
demonstrated	O
that	O
cilostazol	B
treatment	O
reduced	O
GFAP	O
and	O
VEGF	O
expression	O
in	O
the	O
retinas	O
of	O
OLETF	O
rats	O
.	O

Terminal	O
deoxynucleotidyl	O
transferase	O
-	O
mediated	O
dUTP	B
nick	O
-	O
end	O
labeling	O
(	O
TUNLEL	O
)	O
staining	O
revealed	O
an	O
increase	O
in	O
the	O
RGC	O
layer	O
in	O
OLETF	O
compared	O
with	O
LETO	O
rats	O
(	O
P<0.05	O
)	O
,	O
and	O
cilostazol	B
treatment	O
reduced	O
the	O
number	O
of	O
TUNEL	O
-	O
positive	O
cells	O
in	O
OLETF	O
rats	O
(	O
P<0.05	O
)	O
.	O

Relieving	O
retinal	O
ischemia	O
by	O
systemic	O
cilostazol	B
treatment	O
had	O
a	O
noticeable	O
protective	O
effect	O
on	O
RGCs	O
in	O
diabetic	O
rats	O
.	O

Cilostazol	B
treatment	O
may	O
be	O
useful	O
for	O
the	O
management	O
of	O
diabetic	O
retinal	O
vascular	O
dysfunction	O
and	O
neuronal	O
degeneration	O
.	O

Chrysin	B
Ameliorates	O
Chemically	O
Induced	O
Colitis	O
in	O
the	O
Mouse	O
Through	O
Modulation	O
of	O
a	O
PXR	O
/	O
NF	O
-	O
B	O
Signaling	O
Pathway	O
.	O

Targeted	O
activation	O
of	O
pregnane	O
X	O
receptor	O
(	O
PXR	O
)	O
in	O
recent	O
years	O
has	O
become	O
a	O
therapeutic	O
strategy	O
for	O
inflammatory	O
bowel	O
disease	O
(	O
IBD	O
)	O
.	O

Chrysin	B
is	O
a	O
naturally	O
occurring	O
flavonoid	B
with	O
anti	O
-	O
inflammation	O
activity	O
.	O

The	O
current	O
study	O
investigated	O
the	O
role	O
of	O
chrysin	B
as	O
a	O
putative	O
mouse	O
PXR	O
agonist	O
in	O
preventing	O
experimental	O
colitis	O
.	O

Pre	O
-	O
administration	O
of	O
chrysin	B
ameliorated	O
inflammatory	O
symptoms	O
in	O
mouse	O
models	O
of	O
colitis	O
(	O
DSS-	O
and	O
TNBS	O
-	O
induced	O
)	O
and	O
resulted	O
in	O
down	O
-	O
regulation	O
of	O
NF	O
-	O
B	O
target	O
genes	O
(	O
iNOS	O
,	O
ICAM-1	O
,	O
MCP-1	O
,	O
Cox2	O
,	O
TNF	O
-	O
	O
and	O
IL-6	O
)	O
in	O
the	O
colon	O
mucosa	O
.	O

Chrysin	B
inhibited	O
the	O
phosphorylation	O
/	O
degradation	O
of	O
IB	O
,	O
which	O
correlated	O
with	O
the	O
decline	O
in	O
the	O
activity	O
of	O
myeloperoxidase	O
(	O
MPO	O
)	O
and	O
the	O
levels	O
of	O
TNF	O
-	O
	O
and	O
IL-6	O
in	O
the	O
colon	O
.	O

Consistent	O
with	O
the	O
in	O
vivo	O
results	O
,	O
chrysin	B
blocked	O
LPS	O
-	O
stimulated	O
nuclear	O
translocation	O
of	O
NF	O
-	O
B	O
p65	O
in	O
mouse	O
macrophage	O
RAW264.7	O
.	O

Furthermore	O
,	O
chrysin	B
dose	O
-	O
dependently	O
activated	O
human	O
/	O
mouse	O
PXR	O
in	O
reporter	O
gene	O
assays	O
and	O
up	O
-	O
regulated	O
xenobiotic	O
detoxification	O
genes	O
in	O
the	O
colon	O
mucosa	O
,	O
but	O
not	O
in	O
the	O
liver	O
.	O

Silencing	O
of	O
PXR	O
by	O
RNAi	O
demonstrated	O
necessity	O
of	O
PXR	O
in	O
mediating	O
chrysin	B
's	O
ability	O
to	O
induce	O
xenobiotic	O
detoxification	O
genes	O
and	O
NF	O
-	O
B	O
inactivation	O
.	O

The	O
repression	O
of	O
NF	O
-	O
B	O
transcription	O
activity	O
by	O
chrysin	B
was	O
confirmed	O
by	O
in	O
vitro	O
PXR	O
transduction	O
.	O

These	O
findings	O
suggest	O
the	O
effect	O
of	O
chrysin	B
in	O
preventing	O
chemically	O
induced	O
colitis	O
is	O
mediated	O
in	O
large	O
part	O
by	O
a	O
PXR	O
/	O
NF	O
-	O
B	O
pathway	O
.	O

The	O
data	O
also	O
suggest	O
that	O
chrysin	B
or	O
chrysin	B
-	O
like	O
flavonoids	B
could	O
be	O
further	O
developed	O
as	O
intestine	O
-	O
specific	O
PXR	O
activators	O
.	O

An	O
ultra	O
-	O
low	O
dose	O
of	O
tetrahydrocannabinol	B
provides	O
cardioprotection	O
.	O

Tetrahydrocannabinol	B
(	O
THC	B
)	O
,	O
the	O
major	O
psychoactive	O
component	O
of	O
marijuana	O
,	O
is	O
a	O
cannabinoid	O
agonist	O
that	O
exerts	O
its	O
effects	O
by	O
activating	O
at	O
least	O
two	O
specific	O
receptors	O
(	O
CB1	O
and	O
CB2	O
)	O
that	O
belong	O
to	O
the	O
seven	O
transmembrane	O
G	O
-	O
protein	O
coupled	O
receptor	O
(	O
GPCR	O
)	O
family	O
.	O

Both	O
CB1	O
and	O
CB2	O
mRNA	O
and	O
proteins	O
are	O
present	O
in	O
the	O
heart	O
.	O

THC	B
treatment	O
was	O
beneficial	O
against	O
hypoxia	O
in	O
neonatal	O
cardiomyocytes	O
in	O
vitro	O
.	O

We	O
also	O
observed	O
a	O
neuroprotective	O
effect	O
of	O
an	O
ultra	O
low	O
dose	O
of	O
THC	B
when	O
applied	O
to	O
mice	O
before	O
brain	O
insults	O
.	O

The	O
present	O
study	O
was	O
aimed	O
to	O
test	O
and	O
characterize	O
the	O
cardioprotective	O
effects	O
of	O
a	O
very	O
low	O
dose	O
(	O
0.002mg	O
/	O
kg	O
)	O
of	O
THC	B
which	O
is	O
3	O
-	O
4	O
orders	O
of	O
magnitude	O
lower	O
than	O
the	O
conventional	O
doses	O
,	O
administered	O
before	O
myocardial	O
infarction	O
in	O
mice	O
in	O
vivo	O
.	O

Three	O
regimens	O
of	O
THC	B
administration	O
were	O
tested	O
:	O
single	O
THC	B
application	O
2h	O
or	O
48h	O
before	O
the	O
induction	O
of	O
infarct	O
,	O
or	O
3	O
weeks	O
continuous	O
treatment	O
before	O
MI	O
.	O

All	O
protocols	O
of	O
THC	B
administration	O
were	O
found	O
to	O
be	O
beneficial	O
.	O

In	O
the	O
case	O
of	O
THC	B
treatment	O
2h	O
before	O
MI	O
,	O
fractional	O
shortening	O
was	O
elevated	O
(	O
374	O
%	O
vs.	O
421	O
%	O
,	O
p<0.04	O
)	O
,	O
troponin	O
T	O
leakage	O
to	O
the	O
blood	O
was	O
reduced	O
(	O
143ng	O
/	O
ml	O
vs.	O
104ng	O
/	O
ml	O
,	O
p<0.008	O
)	O
,	O
infarct	O
size	O
decreased	O
(	O
294	O
%	O
vs.	O
234	O
%	O
,	O
p<0.02	O
)	O
,	O
and	O
the	O
accumulation	O
of	O
neutrophils	O
to	O
the	O
infarct	O
area	O
declined	O
(	O
3610cells	O
/	O
field	O
vs.	O
194cells	O
/	O
field	O
,	O
p<0.007	O
)	O
in	O
THC-	B
compared	O
to	O
vehicle	O
-	O
pretreated	O
mice	O
,	O
24h	O
after	O
MI	O
.	O

ERK1	O
/	O
2	O
phosphorylation	O
following	O
infarct	O
was	O
also	O
inhibited	O
by	O
pre	O
-	O
treatment	O
with	O
THC	B
(	O
p<0.01	O
)	O
.	O

CONCLUSION	O
:	O
A	O
single	O
ultra	O
low	O
dose	O
of	O
THC	B
before	O
ischemia	O
is	O
a	O
safe	O
and	O
effective	O
treatment	O
that	O
reduces	O
myocardial	O
ischemic	O
damage	O
.	O

Systematic	O
evaluation	O
of	O
640	O
FDA	O
drugs	O
for	O
their	O
effect	O
on	O
CD4	O
(	O
+	O
)	O
Foxp3	O
(	O
+	O
)	O
regulatory	O
T	O
cells	O
using	O
a	O
novel	O
cell	O
-	O
based	O
high	O
throughput	O
screening	O
assay	O
.	O

Regulatory	O
T	O
cells	O
(	O
Treg	O
)	O
,	O
which	O
play	O
a	O
pivotal	O
role	O
in	O
maintaining	O
immune	O
homeostasis	O
by	O
suppressing	O
the	O
proliferation	O
of	O
effector	O
T	O
cells	O
,	O
have	O
great	O
therapeutic	O
potential	O
for	O
autoimmune	O
diseases	O
and	O
transplantation	O
.	O

However	O
,	O
progress	O
on	O
their	O
clinical	O
application	O
has	O
been	O
hampered	O
by	O
the	O
lack	O
of	O
high	O
throughput	O
screening	O
(	O
HTS	O
)	O
strategies	O
for	O
the	O
systematic	O
and	O
rapid	O
evaluation	O
of	O
existing	O
drugs	O
and	O
the	O
identification	O
of	O
novel	O
drug	O
candidates	O
.	O

In	O
this	O
report	O
,	O
we	O
present	O
an	O
innovative	O
in	O
vitro	O
HTS	O
assay	O
using	O
CD4	O
(	O
+	O
)	O
T	O
cells	O
from	O
Foxp3-GFP	O
transgenic	O
mice	O
that	O
specifically	O
express	O
the	O
GFP	O
signal	O
in	O
Foxp3	O
(	O
+	O
)	O

Treg	O
cells	O
detectable	O
by	O
FACS	O
analysis	O
in	O
a	O
high	O
throughput	O
manner	O
.	O

Systematic	O
evaluation	O
of	O
640	O
FDA	O
-	O
approved	O
drugs	O
revealed	O
that	O
70	O
drugs	O
increased	O
the	O
number	O
of	O
Treg	O
cells	O
with	O
suppression	O
function	O
only	O
in	O
the	O
presence	O
of	O
TGF	O
,	O
75	O
drugs	O
increased	O
Treg	O
numbers	O
even	O
in	O
the	O
absence	O
of	O
TGF	O
,	O
and	O
32	O
drugs	O
increased	O
Treg	O
numbers	O
synergistically	O
with	O
TGF	O
.	O

The	O
identified	O
Treg	O
-	O
promoting	O
drugs	O
include	O
those	O
previously	O
known	O
to	O
induce	O
Treg	O
(	O
rapamycin	B
and	O
retinoic	B
acid	I
)	I
,	O
statins	O
,	O
glucocorticoids	O
and	O
drugs	O
in	O
many	O
other	O
categories	O
.	O

Furthermore	O
,	O
Treg	O
cells	O
cultured	O
with	O
the	O
identified	O
drugs	O
possess	O
surface	O
and	O
intracellular	O
markers	O
characteristic	O
of	O
natural	O
Treg	O
cells	O
and	O
possess	O
suppressive	O
function	O
.	O

These	O
results	O
suggest	O
that	O
this	O
Treg	O
HTS	O
assay	O
can	O
be	O
used	O
to	O
screen	O
compound	O
libraries	O
to	O
identify	O
novel	O
chemical	O
entities	O
for	O
Treg	O
-	O
based	O
immune	O
therapies	O
.	O

The	O
effect	O
of	O
a	O
Cimicifuga	O
racemosa	O
extracts	O
Ze	B
450	I
in	O
the	O
treatment	O
of	O
climacteric	O
complaints	O
-	O
an	O
observational	O
study	O
.	O

BACKGROUND	O
:	O
Root	O
extracts	O
of	O
Cimicifuga	O
racemosa	O
(	O
L.	O
)	O
Nutt	O
.	O
have	O
been	O
successfully	O
used	O
in	O
the	O
treatment	O
of	O
climacteric	O
complaints	O
.	O

METHOD	O
:	O
In	O
this	O
observational	O
study	O
,	O
Cimicifuga	O
racemosa	O
(	O
CR	O
)	O
extract	O
Ze	B
450	I
was	O
studied	O
in	O
442	O
unselected	O
ambulatory	O
female	O
outpatients	O
with	O
menopausal	O
complaints	O
under	O
daily	O
practice	O
conditions	O
.	O

Physicians	O
were	O
suggested	O
to	O
treat	O
patients	O
for	O
the	O
first	O
3	O
months	O
with	O
13mg	O
/	O
d	O
CR	O
(	O
high	O
dose	O
,	O
HD	O
)	O
and	O
to	O
continue	O
over	O
additional	O
6	O
months	O
either	O
with	O
this	O
treatment	O
or	O
to	O
switch	O
to	O
6.5mg	O
/	O
d	O
CR	O
(	O
low	O
dose	O
,	O
LD	O
)	O
.	O

The	O
choice	O
of	O
treatment	O
and	O
its	O
dose	O
,	O
however	O
,	O
was	O
fully	O
at	O
the	O
discretion	O
of	O
the	O
physician	O
.	O

RESULTS	O
:	O
After	O
3-months	O
treatment	O
with	O
HD	O
,	O
symptom	O
severity	O
(	O
Kupperman	O
Menopause	O
Index	O
,	O
KMI	O
)	O
decreased	O
significantly	O
(	O
p<0.001	O
)	O
from	O
baseline	O
values	O
.	O

Continuation	O
of	O
treatment	O
with	O
HD	O
or	O
LD	O
decreased	O
total	O
KMI	O
and	O
its	O
sub	O
-	O
item	O
scores	O
further	O
(	O
HD	O
,	O
LD	O
:	O
p<0.001	O
)	O
.	O

However	O
,	O
more	O
patients	O
(	O
84.9	O
%	O
)	O
responded	O
to	O
HD	O
than	O
to	O
LD	O
(	O
78.4	O
%	O
)	O
and	O
showed	O
an	O
improvement	O
of	O
symptoms	O
(	O
p=0.011	O
)	O
.	O

CONCLUSION	O
:	O
This	O
observational	O
study	O
demonstrated	O
that	O
treatment	O
with	O
CR	O
in	O
unselected	O
patients	O
with	O
climacteric	O
complaints	O
under	O
the	O
conditions	O
of	O
daily	O
practice	O
resulted	O
in	O
a	O
significant	O
improvement	O
of	O
menopausal	O
symptoms	O
assessed	O
by	O
the	O
total	O
KMI	O
score	O
and	O
its	O
sub	O
-	O
item	O
scores	O
with	O
an	O
effect	O
size	O
similar	O
to	O
that	O
in	O
a	O
previous	O
randomized	O
,	O
controlled	O
clinical	O
trial	O
.	O

Combination	O
of	O
essential	O
oils	O
and	O
antibiotics	O
reduce	O
antibiotic	O
resistance	O
in	O
plasmid	O
-	O
conferred	O
multidrug	O
resistant	O
bacteria	O
.	O

In	O
this	O
study	O
we	O
investigated	O
the	O
relationship	O
between	O
several	O
selected	O
commercially	O
available	O
essential	O
oils	O
and	O
beta	B
-	I
lactam	I
antibiotics	O
on	O
their	O
antibacterial	O
effect	O
against	O
multidrug	O
resistant	O
bacteria	O
.	O

The	O
antibacterial	O
activity	O
of	O
essential	O
oils	O
and	O
antibiotics	O
was	O
assessed	O
using	O
broth	O
microdilution	O
.	O

The	O
combined	O
effects	O
between	O
essential	O
oils	O
of	O
cinnamon	O
bark	O
,	O
lavender	O
,	O
marjoram	O
,	O
tea	O
tree	O
,	O
peppermint	O
and	O
ampicillin	B
,	O
piperacillin	B
,	O
cefazolin	B
,	O
cefuroxime	B
,	O
carbenicillin	B
,	O
ceftazidime	B
,	O
meropenem	B
,	O
were	O
evaluated	O
by	O
means	O
of	O
the	O
checkerboard	O
method	O
against	O
beta	O
-	O
lactamase	O
-	O
producing	O
Escherichia	O
coli	O
.	O

In	O
the	O
latter	O
assays	O
,	O
fractional	O
inhibitory	O
concentration	O
(	O
FIC	O
)	O
values	O
were	O
calculated	O
to	O
characterize	O
interaction	O
between	O
the	O
combinations	O
.	O

Substantial	O
susceptibility	O
of	O
the	O
bacteria	O
toward	O
natural	O
antibiotics	O
and	O
a	O
considerable	O
reduction	O
in	O
the	O
minimum	O
inhibitory	O
concentrations	O
(	O
MIC	O
)	O
of	O
the	O
antibiotics	O
were	O
noted	O
in	O
some	O
paired	O
combinations	O
of	O
antibiotics	O
and	O
essential	O
oils	O
.	O

Out	O
of	O
35	O
antibiotic	O
-	O
essential	O
oil	O
pairs	O
tested	O
,	O
four	O
of	O
them	O
showed	O
synergistic	O
effect	O
(	O
FIC0.5	O
)	O
and	O
31	O
pairs	O
showed	O
no	O
interaction	O
(	O
FIC>0.5	O
-	O
4.0	O
)	O
.	O

The	O
preliminary	O
results	O
obtained	O
highlighted	O
the	O
occurrence	O
of	O
a	O
pronounced	O
synergistic	O
relationship	O
between	O
piperacillin	B
/	O
cinnamon	O
bark	O
oil	O
,	O
piperacillin	B
/	O
lavender	O
oil	O
,	O
piperacillin	B
/	O
peppermint	O
oil	O
as	O
well	O
as	O
meropenem	B
/	O
peppermint	O
oil	O
against	O
two	O
of	O
the	O
three	O
bacteria	O
under	O
study	O
with	O
a	O
FIC	O
index	O
in	O
the	O
range	O
0.26	O
-	O
0.5	O
.	O

The	O
finding	O
highlighted	O
the	O
potential	O
of	O
peppermint	O
,	O
cinnamon	O
bark	O
and	O
lavender	O
essential	O
oils	O
being	O
as	O
antibiotic	O
resistance	O
modifying	O
agent	O
.	O

Reduced	O
usage	O
of	O
antibiotics	O
could	O
be	O
employed	O
as	O
a	O
treatment	O
strategy	O
to	O
decrease	O
the	O
adverse	O
effects	O
and	O
possibly	O
to	O
reverse	O
the	O
beta	B
-	I
lactam	I
antibiotic	O
resistance	O
.	O

The	O
conjugation	O
of	O
microcystin	B
-	I
RR	I
by	O
human	O
recombinant	O
GSTs	O
and	O
hepatic	O
cytosol	O
.	O

Many	O
cyanobacterial	O
species	O
can	O
produce	O
cyanotoxins	O
,	O
among	O
which	O
mycrocistins	B
(	O
MC	O
)	O
are	O
a	O
group	O
of	O
100	O
congeners	O
of	O
hepatotoxic	O
cyclic	B
heptapeptides	I
.	O

MC	B
-	I
RR	I
differs	O
from	O
MC	B
-	I
LR	I
,	O
the	O
most	O
studied	O
congener	O
only	O
for	O
one	O
residue	O
(	O
arginine	B
vs	O
leucine	B
)	O
,	O
resulting	O
in	O
a	O
ten	O
-	O
fold	O
difference	O
in	O
the	O
acute	O
toxicity	O
in	O
mice	O
.	O

Although	O
humans	O
may	O
be	O
exposed	O
to	O
MC	O
through	O
several	O
routes	O
and	O
kinetics	O
appeared	O
to	O
be	O
the	O
major	O
factor	O
affecting	O
congener	O
-	O
specific	O
toxicity	O
,	O
little	O
is	O
known	O
on	O
MC	O
metabolism	O
.	O

The	O
accepted	O
pathway	O
for	O
MC	O
detoxication	O
is	O
GSH	B
conjugation	O
:	O
here	O
the	O
MC	B
-	I
RR	I
conjugation	O
with	O
GSH	B
catalyzed	O
by	O
5	O
recombinant	O
human	O
GSTs	O
and	O
human	O
liver	O
cytosol	O
(	O
HLC	O
)	O
has	O
been	O
characterized	O
and	O
appeared	O
to	O
be	O
more	O
efficient	O
than	O
MC	B
-	I
LR	I
conjugation	O
.	O

The	O
catalytic	O
efficiency	O
score	O
is	O
T1	O
-	O
1	O
>	O
A1	O
-	O
1P1	O
-	O
1	O
>	O
M1	O
-	O
1	O
>	O
A3	O
-	O
3	O
(	O
0.161	O
-	O
0.056pmol	O
GSMC	O
-	O
RR	O
(	O
gproteinminM	O
)	O
(	O
-1	O
)	O
)	O
.	O

In	O
HLC	O
the	O
spontaneous	O
reaction	O
is	O
favored	O
vs	O
the	O
enzymatic	O
one	O
(	O
ratio	O
3:1	O
)	O
at	O
physiological	O
GSH	B
content	O
.	O

However	O
,	O
at	O
low	O
MC	B
-	I
RR	I
concentrations	O
,	O
representative	O
of	O
repeated	O
oral	O
exposure	O
,	O
and	O
low	O
GSH	B
content	O
(	O
down	O
to	O
0.05mM	O
)	O
,	O
possibly	O
associated	O
to	O
exposure	O
to	O
drugs	O
or	O
in	O
patients	O
affected	O
by	O
several	O
pathologies	O
,	O
the	O
relevance	O
of	O
the	O
enzymatic	O
reaction	O
progressively	O
increases	O
,	O
providing	O
the	O
predominant	O
contribution	O
to	O
MC	B
-	I
RR	I
detoxication	O
.	O

Activating	O
glucocorticoid	O
receptor	O
-	O
ERK	O
signaling	O
pathway	O
contributes	O
to	O
ginsenoside	B
Rg1	I
protection	O
against	O
	O
-	O
amyloid	O
peptide	O
-	O
induced	O
human	O
endothelial	O
cells	O
apoptosis	O
.	O

The	O
deposition	O
of	O
	O
-	O
amyloid	O
(	O
A	O
)	O
in	O
neurons	O
and	O
vascular	O
cells	O
of	O
the	O
brain	O
has	O
been	O
characterized	O
in	O
Alzheimer	O
's	O
disease	O
.	O

Ginsenoside	B
Rg1	I
(	O
Rg1	B
)	O
is	O
an	O
active	O
components	O
in	O
Panax	O
ginseng	O
,	O
a	O
famous	O
traditional	O
Chinese	O
medicines	O
recorded	O
in	O
Compendium	O
of	O
Materia	O
Medica	O
.	O

Present	O
study	O
attempted	O
to	O
evaluate	O
the	O
potential	O
mechanisms	O
of	O
A	O
-	O
mediated	O
insult	O
and	O
the	O
protective	O
effects	O
of	O
Rg1	B
on	O
human	O
endothelial	O
cells	O
.	O

Rg1	B
attenuated	O
the	O
A25	O
-	O
35-associated	O
mitochondrial	O
apoptotic	O
events	O
,	O
accompanied	O
by	O
inhibiting	O
HIF-1	O
expression	O
followed	O
by	O
intracellular	O
reactive	O
nitrogen	B
species	O
generation	O
,	O
and	O
protein	O
nitrotyrosination	O
.	O

These	O
protective	O
effects	O
were	O
abolished	O
by	O
glucocorticoid	O
receptor	O
(	O
GR	O
)	O
antagonist	O
RU486	B
or	O
p	O
-	O
ERK	O
inhibitor	O
U0126	B
rather	O
than	O
estrogen	B
receptor	O
	O
antagonist	O
ICI	B
82,780	I
.	O

Taken	O
together	O
,	O
our	O
results	O
suggested	O
that	O
Rg1	B
protected	O
against	O
A25	O
-	O
35-induced	O
apoptosis	O
at	O
least	O
in	O
part	O
by	O
two	O
complementary	O
GR	O
-	O
dependent	O
ERK	O
phosphorylation	O
pathways	O
:	O
(	O
1	O
)	O
down	O
-	O
regulating	O
HIF-1	O
initiated	O
protein	O
nitrotyrosination	O
,	O
and	O
(	O
2	O
)	O
inhibiting	O
mitochondrial	O
apoptotic	O
cascades	O
.	O

These	O
data	O
provided	O
a	O
novel	O
insight	O
to	O
the	O
mechanisms	O
of	O
Rg1protective	B
effects	O
on	O
A25	O
-	O
35-induced	O
endothelial	O
cells	O
apoptosis	O
,	O
suggesting	O
that	O
GR	O
-	O
ERK	O
signaling	O
pathway	O
might	O
play	O
an	O
important	O
role	O
in	O
it	O
.	O

Cadmium	B
Tolerance	O
and	O
Removal	O
from	O
Cunninghamella	O
elegans	O
Related	O
to	O
the	O
Polyphosphate	O
Metabolism	O
.	O

The	O
aim	O
of	O
the	O
present	O
work	O
was	O
to	O
study	O
the	O
cadmium	B
effects	O
on	O
growth	O
,	O
ultrastructure	O
and	O
polyphosphate	O
metabolism	O
,	O
as	O
well	O
as	O
to	O
evaluate	O
the	O
metal	O
removal	O
and	O
accumulation	O
by	O
Cunninghamella	O
elegans	O
(	O
IFM	O
46109	O
)	O
growing	O
in	O
culture	O
medium	O
.	O

The	O
presence	O
of	O
cadmium	B
reduced	O
growth	O
,	O
and	O
a	O
longer	O
lag	O
phase	O
was	O
observed	O
.	O

However	O
,	O
the	O
phosphate	B
uptake	O
from	O
the	O
culture	O
medium	O
increased	O
15	O
%	O
when	O
compared	O
to	O
the	O
control	O
.	O

Moreover	O
,	O
C.	O
elegans	O
removed	O
70%-81	O
%	O
of	O
the	O
cadmium	B
added	O
to	O
the	O
culture	O
medium	O
during	O
its	O
growth	O
.	O

The	O
C.	O
elegans	O
mycelia	O
showed	O
a	O
removal	O
efficiency	O
of	O
280	O
mg	O
/	O
g	O
at	O
a	O
cadmium	B
concentration	O
of	O
22.10	O
mg	O
/	O
L	O
,	O
and	O
the	O
removal	O
velocity	O
of	O
cadmium	B
was	O
0.107	O
mg	O
/	O
h	O
.	O

Additionally	O
,	O
it	O
was	O
observed	O
that	O
cadmium	B
induced	O
vacuolization	O
,	O
the	O
presence	O
of	O
electron	O
dense	O
deposits	O
in	O
vacuoles	O
,	O
cytoplasm	O
and	O
cell	O
membranes	O
,	O
as	O
well	O
as	O
the	O
distinct	O
behavior	O
of	O
polyphosphate	O
fractions	O
.	O

The	O
results	O
obtained	O
with	O
C.	O
elegans	O
suggest	O
that	O
precipitation	O
,	O
vacuolization	O
and	O
polyphosphate	O
fractions	O
were	O
associated	O
to	O
cadmium	B
tolerance	O
,	O
and	O
this	O
species	O
demonstrated	O
a	O
higher	O
potential	O
for	O
bioremediation	O
of	O
heavy	O
metals	O
.	O

Inhibitors	O
of	O
bacterial	O
tubulin	O
target	O
bacterial	O
membranes	O
in	O
vivo	O
.	O

FtsZ	O
is	O
a	O
homolog	O
of	O
eukaryotic	O
tubulin	O
that	O
is	O
widely	O
conserved	O
among	O
bacteria	O
and	O
coordinates	O
the	O
assembly	O
of	O
the	O
cell	O
division	O
machinery	O
.	O

FtsZ	O
plays	O
a	O
central	O
role	O
in	O
cell	O
replication	O
and	O
is	O
a	O
target	O
of	O
interest	O
for	O
antibiotic	O
development	O
.	O

Several	O
FtsZ	O
inhibitors	O
have	O
been	O
reported	O
.	O

We	O
characterized	O
the	O
mechanism	O
of	O
these	O
compounds	O
in	O
bacteria	O
and	O
found	O
that	O
many	O
of	O
them	O
disrupt	O
the	O
localization	O
of	O
membrane	O
-	O
associated	O
proteins	O
,	O
including	O
FtsZ	O
,	O
by	O
reducing	O
the	O
transmembrane	O
potential	O
or	O
perturbing	O
membrane	O
permeability	O
.	O

We	O
tested	O
whether	O
the	O
reported	O
phenotypes	O
of	O
a	O
broad	O
collection	O
of	O
FtsZ	O
inhibitors	O
disrupt	O
the	O
transmembrane	O
potential	O
in	O
Bacillus	O
subtilis	O
strain	O
168	O
.	O

Using	O
a	O
combination	O
of	O
flow	O
cytometry	O
and	O
microscopy	O
,	O
we	O
found	O
that	O
zantrin	B
Z1	I
,	O
cinnamaldehyde	B
,	O
totarol	B
,	O
sanguinarine	B
,	O
and	O
viriditoxin	B
decreased	O
the	O
B.	O
subtilis	O
transmembrane	O
potential	O
or	O
perturbed	O
membrane	O
permeability	O
,	O
and	O
influenced	O
the	O
localization	O
of	O
the	O
membrane	O
-	O
associated	O
,	O
division	O
protein	O
MinD.	O
These	O
studies	O
demonstrate	O
that	O
small	O
molecules	O
that	O
disrupt	O
membrane	O
function	O
in	O
bacterial	O
cells	O
produce	O
phenotypes	O
that	O
are	O
similar	O
to	O
the	O
inhibition	O
of	O
proteins	O
associated	O
with	O
membranes	O
in	O
vivo	O
,	O
including	O
bacterial	O
cytoskeleton	O
homologs	O
,	O
such	O
as	O
FtsZ.	O
The	O
results	O
provide	O
a	O
new	O
dimension	O
for	O
consideration	O
in	O
the	O
design	O
and	O
testing	O
of	O
inhibitors	O
of	O
bacterial	O
targets	O
that	O
are	O
membrane	O
-	O
associated	O
and	O
provide	O
additional	O
insight	O
into	O
the	O
structural	O
characteristics	O
of	O
antibiotics	O
that	O
disrupt	O
the	O
membrane	O
.	O

Transfer	O
of	O
lipids	O
to	O
high	O
-	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
is	O
altered	O
in	O
patients	O
with	O
familial	O
hypercholesterolemia	O
.	O

OBJECTIVE	O
:	O
In	O
familial	O
hypercholesterolemia	O
(	O
FH	O
)	O
,	O
the	O
metabolism	O
and	O
anti	O
-	O
atherogenic	O
functions	O
of	O
HDL	O
can	O
be	O
affected	O
by	O
the	O
continuous	O
interactions	O
with	O
excess	O
LDL	O
amounts	O
.	O

Here	O
,	O
lipid	O
transfers	O
to	O
HDL	O
,	O
an	O
important	O
step	O
for	O
HDL	O
intravascular	O
metabolism	O
and	O
for	O
HDL	O
role	O
in	O
reverse	O
cholesterol	B
transport	O
(	O
RCT	O
)	O
were	O
investigated	O
in	O
FH	O
patients	O
.	O

METHODS	O
:	O
Seventy	O
-	O
one	O
FH	O
patients	O
(	O
3915years	O
,	O
LDL	O
-	O
cholesterol=274101	B
;	O
HDL	O
-	O
cholesterol=5014mg	B
/	O
dl	O
)	O
and	O
66	O
normolipidemic	O
subjects	O
(	O
NL	O
)	O
(	O
3811years	O
,	O
LDL	O
-	O
cholesterol=10527	B
;	O
HDL	O
-	O
cholesterol=5212mg	B
/	O
dl	O
)	O
were	O
studied	O
.	O

In	O
vitro	O
,	O
lipid	O
transfers	O
were	O
evaluated	O
by	O
incubation	O
of	O
plasma	O
samples	O
(	O
37	O
	O
C	O
,	O
1h	O
)	O
with	O
a	O
donor	O
lipid	O
nanoemulsion	O
labeled	O
with	O
3H	B
-	I
triglycerides	I
(	O
TG	O
)	O
and	O
14C	B
-	O
unesterified	O
cholesterol	B
(	O
UC	O
)	O
or	O
with	O
3H	B
-	I
cholesteryl	I
ester	I
(	O
EC	O
)	O
and	O
14C	B
-	O
phospholipids	O
(	O
PL	O
)	O
.	O

Radioactivity	O
was	O
counted	O
at	O
the	O
HDL	O
fraction	O
after	O
chemical	O
precipitation	O
of	O
apolipoprotein	O
(	O
apo	O
)	O
B	O
-	O
containing	O
lipoproteins	O
and	O
the	O
nanoemulsion	O
.	O

Data	O
are	O
%	O
of	O
total	O
radioactivity	O
measured	O
in	O
the	O
HDL	O
fraction	O
.	O

RESULTS	O
:	O
Transfer	O
of	O
UC	O
to	O
HDL	O
was	O
lower	O
in	O
FH	O
than	O
in	O
NL	O
(	O
5.62.1	O
vs	O
6.72.0	O
%	O
,	O
p=0.0005	O
)	O
whereas	O
TG	O
(	O
5.53.1	O
vs	O
3.70.9	O
%	O
,	O
p=0.018	O
)	O
and	O
PL	O
(	O
20.94.6	O
vs	O
18.23.7	O
%	O
,	O
p=0.023	O
)	O
transfers	O
were	O
higher	O
in	O
FH	O
.	O

EC	O
transfer	O
was	O
equal	O
.	O

By	O
multivariate	O
analysis	O
,	O
transfers	O
of	O
all	O
four	O
lipids	O
correlated	O
with	O
HDL	O
-	O
cholesterol	B
and	O
with	O
apo	O
A	O
-	O
I.	O
CONCLUSION	O
:	O
FH	O
elicited	O
marked	O
changes	O
in	O
three	O
of	O
the	O
four	O
tested	O
lipid	O
transfers	O
to	O
HDL	O
.	O

The	O
entry	O
of	O
UC	O
into	O
HDL	O
for	O
subsequent	O
esterification	O
is	O
an	O
important	O
driving	O
force	O
for	O
RCT	O
and	O
reduction	O
of	O
UC	O
transfer	O
to	O
HDL	O
was	O
previously	O
associated	O
to	O
precocious	O
coronary	O
heart	O
disease	O
.	O

Therefore	O
,	O
in	O
FH	O
,	O
HDL	O
functions	O
can	O
be	O
lessened	O
,	O
which	O
can	O
also	O
contribute	O
to	O
atherogenesis	O
.	O

Synthesis	O
and	O
biological	O
evaluation	O
of	O
Foscan	B
(	O
	O
)	O
bile	B
acid	I
conjugates	O
to	O
target	O
esophageal	O
cancer	O
cells	O
.	O

Porphyrins	B
and	O
chlorins	B
such	O
as	O
Foscan	B
	O
have	O
a	O
natural	O
proclivity	O
to	O
accumulate	O
in	O
cancer	O
cells	O
.	O

This	O
trait	O
has	O
made	O
them	O
good	O
candidates	O
for	O
photosensitizers	O
and	O
as	O
imaging	O
agents	O
in	O
phototherapy	O
.	O

In	O
order	O
to	O
improve	O
on	O
cellular	O
selectivity	O
to	O
lower	O
post	O
-	O
treatment	O
photosensitivity	O
bile	B
acid	I
porphyrin	I
bioconjugates	O
have	O
been	O
prepared	O
and	O
investigated	O
in	O
esophageal	O
cancer	O
cells	O
.	O

Bile	B
acids	I
which	O
are	O
known	O
to	O
selectively	O
bind	O
to	O
,	O
or	O
be	O
readily	O
taken	O
up	O
by	O
cancer	O
cells	O
were	O
chosen	O
as	O
targeting	O
moieties	O
.	O

Synthesis	O
of	O
the	O
conjugates	O
was	O
achieved	O
via	O
selective	O
nucleophilic	O
monofunctionalization	O
of	O
5,10,15,20-tetrahydroxyphenylporphyrins	B
with	O
propargyl	B
bromide	I
followed	O
by	O
Cu	B
(	I
I	I
)	I
mediated	O
cycloaddition	O
with	O
bile	B
acid	I
azides	I
in	O
good	O
yields	O
.	O

The	O
compounds	O
were	O
readily	O
taken	O
up	O
by	O
esophageal	O
cancer	O
cells	O
but	O
showed	O
no	O
PDT	O
activity	O
.	O

A	O
diazen-1-ium-1,2-diolate	B
analog	O
of	O
7-azabenzobicyclo	B
[	I
2.2.1	I
]	I
heptane	I
:	O
Synthesis	O
,	O
nitric	B
oxide	I
and	O
nitroxyl	B
release	O
,	O
in	O
vitro	O
hemodynamic	O
,	O
and	O
anti	O
-	O
hypertensive	O
studies	O
.	O

1-	B
(	I
7-Azabenzobicyclo	I
[	I
2.2.1	I
]	I
heptane	I
)	I
diazen-1-ium-1,2-diolate	I
(	O
16	O
)	O
was	O
designed	O
with	O
the	O
expectation	O
that	O
it	O
would	O
act	O
as	O
a	O
dual	O
nitric	B
oxide	I
(	O
NO	B
)	O
and	O
nitroxyl	B
(	O
HNO	B
)	O
donor	O
that	O
is	O
not	O
carcinogenic	O
or	O
genotoxic	O
.	O

Compound	O
16	O
,	O
with	O
a	O
suitable	O
half	O
-	O
life	O
(	O
17.8min	O
)	O
in	O
PBS	O
at	O
pH	O
7	O
,	O
released	O
NO	B
(	O
19	O
%	O
)	O
and	O
HNO	B
(	O
22	O
%	O
)	O
during	O
a	O
2h	O
incubation	O
in	O
PBS	O
at	O
pH	O
7	O
.	O

In	O
addition	O
,	O
compound	O
16	O
exhibited	O
a	O
significant	O
in	O
vitro	O
positive	O
inotropic	O
effect	O
,	O
increased	O
the	O
rates	O
of	O
contraction	O
and	O
relaxation	O
,	O
and	O
increased	O
coronary	O
flow	O
rate	O
,	O
but	O
did	O
not	O
induce	O
a	O
chronotropic	O
effect	O
.	O

Furthermore	O
,	O
compound	O
16	O
(	O
13.7mgkg	O
(	O
-1	O
)	O
,	O
po	O
dose	O
)	O
provided	O
a	O
significant	O
reduction	O
in	O
the	O
blood	O
pressure	O
of	O
mice	O
up	O
to	O
3h	O
post	O
-	O
drug	O
administration	O
.	O

All	O
these	O
data	O
suggest	O
that	O
compound	O
16	O
constitutes	O
an	O
attractive	O
'	O
lead	O
-	O
compound	O
'	O
that	O
could	O
have	O
potential	O
applications	O
to	O
treat	O
cardiovascular	O
disease	O
(	O
s	O
)	O
such	O
as	O
congestive	O
heart	O
failure	O
.	O

Synthetic	O
oligoureas	O
of	O
metaphenylenediamine	B
mimic	O
host	O
defence	O
peptides	O
in	O
their	O
antimicrobial	O
behaviour	O
.	O

Oligomeric	O
ureas	B
of	O
m	B
-	I
phenylenediamine	I
target	O
anionic	O
DMPG	B
(	O
dimyristoylphosphatidylglycerol	B
)	O
and	O
possess	O
promise	O
as	O
antimicrobial	O
agents	O
.	O

Their	O
similar	O
size	O
,	O
shape	O
and	O
hydrophobicity	O
to	O
helical	O
antimicrobial	O
peptides	O
(	O
AMPs	O
)	O
may	O
be	O
important	O
for	O
activity	O
to	O
exist	O
and	O
the	O
ability	O
of	O
these	O
compounds	O
to	O
insert	O
into	O
a	O
well	O
ordered	O
lipid	O
environment	O
.	O

PEG	B
mediated	O
synthesis	O
and	O
pharmacological	O
evaluation	O
of	O
some	O
fluoro	B
substituted	I
pyrazoline	I
derivatives	O
as	O
antiinflammatory	O
and	O
analgesic	O
agents	O
.	O

A	O
new	O
series	O
of	O
fluoro	B
substituted	I
pyrazoline	I
derivatives	O
5a	O
-	O
g	O
and	O
6a	O
-	O
g	O
were	O
synthesized	O
in	O
good	O
to	O
excellent	O
yield	O
from	O
the	O
corresponding	O
pyrazole	B
chalcones	I
,	O
4a	O
-	O
g	O
,	O
by	O
using	O
polyethylene	B
glycol-400	I
(	O
PEG-400	B
)	O
as	O
an	O
alternative	O
reaction	O
medium	O
.	O

The	O
newly	O
synthesized	O
compounds	O
were	O
characterized	O
and	O
screened	O
for	O
their	O
in	O
vivo	O
antiinflammatory	O
and	O
analgesic	O
activity	O
.	O

Compounds	O
5	O
g	O
and	O
6	O
g	O
were	O
found	O
to	O
be	O
more	O
potent	O
than	O
standard	O
drug	O
Diclofenac	B
and	O
six	O
other	O
compounds	O
5b	O
,	O
5c	O
,	O
5f	O
,	O
6b	O
,	O
6c	O
and	O
6f	O
showed	O
significant	O
antiinflammatory	O
activity	O
as	O
compared	O
to	O
standard	O
drug	O
.	O

Compounds	O
5c	O
,	O
5d	O
,	O
5e	O
,	O
5f	O
,	O
6c	O
,	O
6d	O
,	O
6e	O
and	O
6f	O
showed	O
significant	O
analgesic	O
activity	O
as	O
compared	O
to	O
standard	O
drug	O
Aspirin	O
.	O

Identification	O
of	O
metal	O
ion	O
binding	O
peptides	O
containing	O
unnatural	O
amino	B
acids	I
by	O
phage	O
display	O
.	O

The	O
bidentate	O
metal	O
binding	O
amino	B
acid	I
bipyridylalanine	B
(	O
BpyAla	B
)	O
was	O
incorporated	O
into	O
a	O
disulfide	B
linked	O
cyclic	O
peptide	O
phage	O
displayed	O
library	O
to	O
identify	O
metal	O
ion	O
binding	O
peptides	O
.	O

Selection	O
against	O
Ni	B
(	I
2+	I
)	I
-nitrilotriacetic	O
acid	B
(	O
NTA	B
)	O
enriched	O
for	O
sequences	O
containing	O
histidine	B
and	O
BpyAla	B
.	O

BpyAla	B
predominated	O
when	O
selections	O
were	O
carried	O
out	O
at	O
lower	O
pH	O
,	O
consistent	O
with	O
the	O
differential	O
pKa	O
's	O
of	O
histidine	B
and	O
BpyAla	B
.	O

Two	O
peptides	O
containing	O
BpyAla	B
were	O
synthesized	O
and	O
found	O
to	O
bind	O
Ni	B
(	I
2	I
+	I
)	I
with	O
low	O
micromolar	O
dissociation	O
constants	O
.	O

Incorporation	O
of	O
BpyAla	B
and	O
other	O
metal	O
binding	O
amino	B
acids	I
into	O
peptide	O
and	O
protein	O
libraries	O
should	O
enable	O
the	O
evolution	O
of	O
novel	O
binding	O
and	O
catalytic	O
activities	O
.	O

Tuning	O
into	O
diversity	O
of	O
homeostatic	O
synaptic	O
plasticity	O
.	O

Neurons	O
are	O
endowed	O
with	O
the	O
remarkable	O
ability	O
to	O
integrate	O
activity	O
levels	O
over	O
time	O
and	O
tune	O
their	O
excitability	O
such	O
that	O
action	O
potential	O
firing	O
is	O
maintained	O
within	O
a	O
computationally	O
optimal	O
range	O
.	O

These	O
feedback	O
mechanisms	O
,	O
collectively	O
referred	O
to	O
as	O
"	O
homeostatic	O
plasticity	O
"	O
,	O
enable	O
neurons	O
to	O
respond	O
and	O
adapt	O
to	O
prolonged	O
alterations	O
in	O
neuronal	O
activity	O
by	O
regulating	O
several	O
determinants	O
of	O
cellular	O
excitability	O
.	O

Perhaps	O
the	O
best	O
-	O
characterized	O
of	O
these	O
homeostatic	O
responses	O
involves	O
the	O
regulation	O
of	O
excitatory	O
glutamatergic	O
transmission	O
.	O

This	O
homeostatic	O
synaptic	O
plasticity	O
(	O
HSP	O
)	O
operates	O
bidirectionally	O
,	O
thus	O
providing	O
a	O
means	O
for	O
neurons	O
to	O
tune	O
cellular	O
excitability	O
in	O
response	O
to	O
either	O
elevations	O
or	O
reductions	O
in	O
net	O
activity	O
.	O

The	O
last	O
decade	O
has	O
seen	O
rapid	O
growth	O
in	O
interest	O
and	O
efforts	O
to	O
understand	O
the	O
mechanistic	O
underpinnings	O
of	O
HSP	O
in	O
part	O
because	O
of	O
the	O
theoretical	O
stabilization	O
that	O
HSP	O
confers	O
to	O
neural	O
network	O
function	O
.	O

Since	O
the	O
initial	O
reports	O
describing	O
HSP	O
in	O
central	O
neurons	O
,	O
innovations	O
in	O
experimental	O
approaches	O
have	O
permitted	O
the	O
mechanistic	O
dissection	O
of	O
this	O
cellular	O
adaptive	O
response	O
and	O
,	O
as	O
a	O
result	O
,	O
key	O
advances	O
have	O
been	O
made	O
in	O
our	O
understanding	O
of	O
the	O
cellular	O
and	O
molecular	O
basis	O
of	O
HSP	O
.	O

Here	O
,	O
we	O
review	O
recent	O
evidence	O
that	O
outline	O
the	O
presence	O
of	O
distinct	O
forms	O
of	O
HSP	O
at	O
excitatory	O
glutamatergic	O
synapses	O
which	O
operate	O
at	O
different	O
sub	O
-	O
cellular	O
levels	O
.	O

We	O
further	O
present	O
theoretical	O
considerations	O
on	O
the	O
potential	O
computational	O
roles	O
afforded	O
by	O
local	O
,	O
synapse	O
-	O
specific	O
homeostatic	O
regulation	O
.	O

This	O
article	O
is	O
part	O
of	O
a	O
Special	O
Issue	O
entitled	O
'	O
Homeostatic	O
Plasticity	O
'	O
.	O

Antagonists	O
reversibly	O
reverse	O
chemical	O
LTD	O
induced	O
by	O
group	O
I	O
,	O
group	O
II	O
and	O
group	O
III	O
metabotropic	O
glutamate	B
receptors	O
.	O

Metabotropic	O
glutamate	B
(	O
mGlu	O
)	O
receptors	O
are	O
implicated	O
in	O
many	O
neurological	O
and	O
psychiatric	O
diseases	O
and	O
are	O
the	O
targets	O
of	O
therapeutic	O
agents	O
currently	O
in	O
clinical	O
development	O
.	O

Their	O
activation	O
has	O
diverse	O
effects	O
in	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
that	O
includes	O
an	O
involvement	O
in	O
synaptic	O
plasticity	O
.	O

We	O
previously	O
reported	O
that	O
the	O
brief	O
exposure	O
of	O
hippocampal	O
slices	O
to	O
dihydroxyphenylglycine	B
(	O
DHPG	B
)	O
can	O
result	O
in	O
a	O
long	O
-	O
term	O
depression	O
(	O
LTD	O
)	O
of	O
excitatory	O
synaptic	O
transmission	O
.	O

Surprisingly	O
,	O
this	O
LTD	O
could	O
be	O
fully	O
reversed	O
by	O
mGlu	O
receptor	O
antagonists	O
in	O
a	O
manner	O
that	O
was	O
itself	O
fully	O
reversible	O
upon	O
washout	O
of	O
the	O
antagonist	O
.	O

Here	O
,	O
15	O
years	O
after	O
the	O
discovery	O
of	O
DHPG	B
-	O
LTD	O
and	O
its	O
reversible	O
reversibility	O
,	O
we	O
summarise	O
these	O
initial	O
findings	O
.	O

We	O
then	O
present	O
new	O
data	O
on	O
DHPG	B
-	O
LTD	O
,	O
which	O
demonstrates	O
that	O
evoked	O
epileptiform	O
activity	O
triggered	O
by	O
activation	O
of	O
group	O
I	O
mGlu	O
receptors	O
can	O
also	O
be	O
reversibly	O
reversed	O
by	O
mGlu	O
receptor	O
antagonists	O
.	O

Furthermore	O
,	O
we	O
show	O
that	O
the	O
phenomenon	O
of	O
reversible	O
reversibility	O
is	O
not	O
specific	O
to	O
group	O
I	O
mGlu	O
receptors	O
.	O

We	O
report	O
that	O
activation	O
of	O
group	O
II	O
mGlu	O
receptors	O
in	O
the	O
temporo	O
-	O
ammonic	O
pathway	O
(	O
TAP	O
)	O
and	O
mossy	O
fibre	O
pathway	O
within	O
the	O
hippocampus	O
and	O
in	O
the	O
cortical	O
input	O
to	O
neurons	O
of	O
the	O
lateral	O
amygdala	O
induces	O
an	O
LTD	O
that	O
is	O
reversed	O
by	O
LY341495	B
,	O
a	O
group	O
II	O
mGlu	O
receptor	O
antagonist	O
.	O

We	O
also	O
show	O
that	O
activation	O
of	O
group	O
III	O
mGlu8	O
receptors	O
induces	O
an	O
LTD	O
at	O
lateral	O
perforant	O
path	O
inputs	O
to	O
the	O
dentate	O
gyrus	O
and	O
that	O
this	O
LTD	O
is	O
reversed	O
by	O
MDCPG	O
,	O
an	O
mGlu8	O
receptor	O
antagonist	O
.	O

In	O
conclusion	O
,	O
we	O
have	O
shown	O
that	O
activation	O
of	O
representative	O
members	O
of	O
each	O
of	O
the	O
three	O
groups	O
of	O
mGlu	O
receptors	O
can	O
induce	O
forms	O
of	O
LTD	O
than	O
can	O
be	O
reversed	O
by	O
antagonists	O
,	O
and	O
that	O
in	O
each	O
case	O
washout	O
of	O
the	O
antagonist	O
is	O
associated	O
with	O
the	O
re	O
-	O
establishment	O
of	O
the	O
LTD	O
.	O

This	O
article	O
is	O
part	O
of	O
a	O
Special	O
Issue	O
entitled	O
'	O
GluR	O
-	O
dep	O
synaptic	O
plasticity	O
'	O
.	O

Arsenic	B
trioxide	I
depletes	O
cancer	O
stem	O
-	O
like	O
cells	O
and	O
inhibits	O
repopulation	O
of	O
neurosphere	O
derived	O
from	O
glioblastoma	O
by	O
downregulation	O
of	O
Notch	O
pathway	O
.	O

Notch	O
signaling	O
has	O
been	O
demonstrated	O
to	O
have	O
a	O
central	O
role	O
in	O
cancer	O
stem	O
-	O
like	O
cells	O
(	O
CSLCs	O
)	O
in	O
glioblastoma	O
multiforme	O
(	O
GBM	O
)	O
.	O

We	O
have	O
recently	O
demonstrated	O
the	O
inhibitory	O
effect	O
of	O
arsenic	B
trioxide	I
(	O
ATO	B
)	O
on	O
CSLCs	O
in	O
glioblastoma	O
cell	O
lines	O
.	O

In	O
this	O
study	O
we	O
used	O
neurosphere	O
recovery	O
assay	O
that	O
measured	O
neurosphere	O
formation	O
at	O
three	O
time	O
points	O
to	O
assess	O
the	O
capacity	O
of	O
the	O
culture	O
to	O
repopulate	O
after	O
ATO	B
treatment	O
.	O

Our	O
results	O
provided	O
strong	O
evidence	O
that	O
ATO	B
depleted	O
CSLCs	O
in	O
GBM	O
,	O
and	O
inhibited	O
neurosphere	O
recovery	O
and	O
secondary	O
neurosphere	O
formation	O
.	O

ATO	B
inhibited	O
the	O
phosphorylation	O
and	O
activation	O
of	O
AKT	O
and	O
STAT3	O
through	O
Notch	O
signaling	O
blockade	O
.	O

These	O
data	O
show	O
that	O
the	O
ATO	B
is	O
a	O
promising	O
new	O
approach	O
to	O
decrease	O
glioblastoma	O
proliferation	O
and	O
recurrence	O
by	O
downregulation	O
of	O
Notch	O
pathway	O
.	O

Structure	O
-	O
activity	O
relationship	O
of	O
5-chloro-2-methyl-3-	B
(	I
1,2,3,6-tetrahydropyridin-4-yl	I
)	I
-1H	I
-	I
indole	I
analogues	O
as	O
5-HT6	O
receptor	O
agonists	O
.	O

To	O
further	O
investigate	O
the	O
structure	O
-	O
activity	O
relationship	O
(	O
SAR	O
)	O
of	O
the	O
5-hydroxytryptamine	B
type	O
6	O
(	O
5-HT6	O
)	O
receptor	O
agonist	O
5-chloro-2-methyl-3-	B
(	I
1,2,3,6-tetrahydropyridin-4-yl	I
)	I
-1H	I
-	I
indole	I
(	O
EMD386088	B
,	O
6	O
)	O
,	O
a	O
series	O
of	O
2-methyl-3-	B
(	I
1,2,3,6-tetrahydropyridin-4-yl	I
)	I
-1H	I
-	I
indoles	I
were	O
synthesized	O
,	O
and	O
in	O
vitro	O
affinity	O
to	O
,	O
and	O
functional	O
activity	O
at	O
5-HT6	O
receptors	O
was	O
tested	O
.	O

We	O
focused	O
on	O
substituents	O
made	O
at	O
the	O
indole	B
N	O
(	O
1	O
)	O
-	O
,	O
2-	O
and	O
5-positions	O
and	O
these	O
were	O
found	O
to	O
not	O
only	O
influence	O
the	O
affinity	O
at	O
5-HT6	O
receptors	O
but	O
also	O
the	O
intrinsic	O
activity	O
leading	O
to	O
antagonists	O
,	O
partial	O
agonists	O
and	O
full	O
agonists	O
.	O

In	O
order	O
for	O
a	O
compound	O
to	O
demonstrate	O
potent	O
5-HT6	O
receptor	O
agonist	O
properties	O
,	O
the	O
indole	B
N	O
(	O
1	O
)	O
should	O
be	O
unsubstituted	O
,	O
an	O
alkyl	B
group	O
such	O
as	O
2-methyl	B
is	O
needed	O
and	O
finally	O
halogen	B
substituents	O
in	O
the	O
indole	B
5-position	O
(	O
fluoro	B
,	O
chloro	B
or	O
,	O
bromo	B
)	O
were	O
essential	O
requirements	O
.	O

However	O
,	O
the	O
introduction	O
of	O
a	O
benzenesulfonyl	B
group	O
at	O
N	O
(	O
1	O
)	O
-position	O
switched	O
the	O
full	O
agonist	O
6	O
to	O
be	O
a	O
5-HT6	O
receptor	O
antagonist	O
(	O
30	O
)	O
.	O

A	O
few	O
compounds	O
within	O
the	O
2-methyl-3-	B
(	I
1,2,3,6-tetrahydropyridin-4-yl	I
)	I
-1H	I
-	I
indoles	I
were	O
also	O
screened	O
for	O
off	O
-	O
targets	O
and	O
generally	O
they	O
displayed	O
low	O
affinity	O
for	O
other	O
5-HT	B
subtypes	O
and	O
serotonin	B
transporter	O
protein	O
(	O
SERT	O
)	O
.	O

Induction	O
of	O
G2	O
/	O
M	O
arrest	O
,	O
caspase	O
activation	O
and	O
apoptosis	O
by	O
	B
-	I
santonin	I
derivatives	O
in	O
HL-60	O
cells	O
.	O

Sesquiterpene	B
lactones	I
(	O
SLs	B
)	O
are	O
natural	O
products	O
with	O
a	O
variety	O
of	O
biological	O
activities	O
.	O

Previously	O
,	O
we	O
demonstrated	O
the	O
cytotoxic	O
effects	O
of	O
three	O
new	O
	B
-	I
santonin	I
derivatives	O
on	O
different	O
tumor	O
cell	O
lines	O
with	O
low	O
toxic	O
effects	O
upon	O
peripheral	O
human	O
leukocytes	O
.	O

Here	O
,	O
we	O
evaluated	O
the	O
mechanism	O
of	O
action	O
triggered	O
by	O
these	O
derivatives	O
.	O

HL-60	O
cell	O
cycle	O
determined	O
after	O
24h	O
treatment	O
revealed	O
a	O
significant	O
inhibition	O
on	O
cell	O
-	O
cycle	O
progression	O
and	O
leading	O
to	O
an	O
increasing	O
of	O
cells	O
in	O
G2	O
/	O
M	O
[	O
7.6	O
%	O
and	O
9.0	O
%	O
for	O
compound	O
3	O
%	O
and	O
9.0	O
%	O
and	O
8.6	O
%	O
for	O
compound	O
4	O
(	O
1	O
and	O
2M	O
,	O
respectively	O
)	O
]	O
.	O

However	O
,	O
after	O
48h	O
exposure	O
,	O
all	O
compounds	O
caused	O
G2	O
/	O
M	O
reduction	O
and	O
a	O
significant	O
DNA	O
fragmentation	O
.	O

Compounds	O
2	O
,	O
3	O
and	O
4	O
were	O
able	O
to	O
induce	O
apoptosis	O
on	O
leukemia	O
cells	O
,	O
which	O
was	O
corroborated	O
by	O
phosphatidyserine	O
externalization	O
and	O
activation	O
of	O
caspases-3	O
and	O
-7	O
after	O
24h	O
exposure	O
.	O

None	O
of	O
the	O
derivatives	O
analyzed	O
caused	O
depolarization	O
of	O
mitochondrial	O
membrane	O
within	O
24h	O
of	O
incubation	O
,	O
suggesting	O
the	O
involvement	O
of	O
the	O
extrinsic	O
apoptotic	O
pathway	O
in	O
the	O
death	O
process	O
.	O

The	O
antiproliferative	O
action	O
of	O
these	O
compounds	O
is	O
related	O
to	O
the	O
DNA	O
synthesis	O
inhibition	O
and	O
cell	O
cycle	O
arrest	O
,	O
which	O
probably	O
lead	O
to	O
apoptosis	O
activation	O
.	O

Therefore	O
,	O
these	O
santonin	B
derivatives	O
are	O
promising	O
lead	O
candidates	O
for	O
development	O
of	O
new	O
cytotoxic	O
agents	O
.	O

Systematic	O
review	O
of	O
the	O
effects	O
of	O
maternal	O
hypertension	O
in	O
pregnancy	O
and	O
antihypertensive	O
therapies	O
on	O
child	O
neurocognitive	O
development	O
.	O

As	O
many	O
as	O
15	O
%	O
of	O
women	O
experience	O
hypertension	O
during	O
pregnancy	O
.	O

Large	O
proportions	O
of	O
them	O
are	O
receiving	O
antihypertensive	O
medications	O
.	O

This	O
review	O
investigated	O
whether	O
hypertension	O
itself	O
,	O
or	O
the	O
antihypertensive	O
medications	O
,	O
adversely	O
affect	O
long	O
term	O
child	O
neurocognitive	O
development	O
.	O

The	O
existing	O
evidence	O
suggests	O
that	O
methyldopa	B
and	O
labetalol	B
probably	O
do	O
not	O
adversely	O
affect	O
neurobehavioral	O
development	O
.	O

Although	O
an	O
increasing	O
body	O
of	O
evidence	O
suggests	O
adverse	O
neurocognitive	O
effects	O
of	O
the	O
hypertension	O
itself	O
,	O
none	O
of	O
the	O
existing	O
studies	O
examined	O
simultaneously	O
the	O
effects	O
of	O
both	O
hypertension	O
and	O
the	O
drugs	O
used	O
therapeutically	O
.	O

The	O
confounding	O
effects	O
by	O
indication	O
must	O
be	O
addressed	O
in	O
future	O
studies	O
.	O

Comparison	O
of	O
the	O
Therapeutic	O
Effectiveness	O
of	O
Sustained	O
Low	O
-	O
Efficiency	O
Dialysis	O
(	O
SLED	O
)	O
with	O
Continuous	O
Blood	O
Purification	O
(	O
CBP	O
)	O
in	O
Critically	O
Ill	O
Patients	O
.	O

The	O
differences	O
in	O
therapeutic	O
effectiveness	O
between	O
sustained	O
low	O
-	O
efficiency	O
dialysis	O
(	O
SLED	O
)	O
and	O
continuous	O
blood	O
purification	O
(	O
CBP	O
)	O
were	O
investigated	O
.	O

In	O
order	O
to	O
assess	O
the	O
different	O
treatment	O
methods	O
,	O
56	O
critically	O
ill	O
patients	O
were	O
divided	O
into	O
two	O
groups	O
,	O
the	O
CBP	O
group	O
and	O
the	O
SLED	O
group	O
.	O

A	O
comparison	O
was	O
made	O
between	O
all	O
the	O
biochemical	O
indicators	O
,	O
in	O
-	O
hospital	O
duration	O
,	O
hemodynamic	O
parameters	O
,	O
acute	O
physiology	O
and	O
chronic	O
health	O
evaluation	O
(	O
APACHE	O
-	O
II	O
)	O
,	O
the	O
survival	O
,	O
and	O
the	O
mortality	O
rates	O
.	O

After	O
treatment	O
,	O
the	O
levels	O
of	O
serum	O
creatine	B
kinase	O
isozyme	O
MB	O
(	O
CK	O
-	O
MB	O
)	O
,	O
creatine	B
kinase	O
,	O
creatinine	B
,	O
glutamate	B
-	O
oxalacetate	B
transaminase	O
(	O
AST	O
)	O
,	O
glutamate	B
-	O
pyruvate	B
transaminase	O
(	O
ALT	O
)	O
,	O
APACHE	O
II	O
score	O
on	O
the	O
1st	O
,	O
2nd	O
,	O
and	O
7th	O
day	O
in	O
both	O
the	O
treatment	O
groups	O
were	O
lower	O
than	O
that	O
before	O
the	O
treatment	O
(	O
P	O
<	O
0.05	O
)	O
.	O

There	O
are	O
no	O
statistical	O
differences	O
in	O
in	O
-	O
hospital	O
duration	O
,	O
biochemical	O
indicators	O
,	O
APACHE	O
II	O
score	O
,	O
hemodynamic	O
parameters	O
,	O
the	O
survival	O
rate	O
and	O
the	O
mortality	O
rate	O
between	O
the	O
two	O
groups	O
(	O
P	O
>	O
0.05	O
)	O
.	O

It	O
was	O
concluded	O
that	O
SLED	O
has	O
similar	O
hemodynamic	O
stability	O
with	O
CBP	O
and	O
the	O
two	O
methods	O
have	O
similar	O
treatment	O
effects	O
in	O
critically	O
ill	O
patients	O
.	O

However	O
,	O
we	O
noticed	O
that	O
SLED	O
can	O
be	O
relatively	O
economical	O
and	O
convenient	O
for	O
critically	O
ill	O
patients	O
in	O
clinical	O
practice	O
.	O

Virtual	O
medicinal	O
chemistry	O
:	O
In	O
silico	O
pre	O
-	O
docking	O
functional	O
group	O
transformation	O
for	O
discovery	O
of	O
novel	O
inhibitors	O
of	O
botulinum	O
toxin	O
serotype	O
A	O
light	O
chain	O
.	O

A	O
novel	O
method	O
for	O
applying	O
high	O
-	O
throughput	O
docking	O
to	O
challenging	O
metalloenzyme	O
targets	O
is	O
described	O
.	O

The	O
method	O
utilizes	O
information	O
-	O
based	O
virtual	O
transformation	O
of	O
library	O
carboxylates	B
to	O
hydroxamic	B
acids	I
prior	O
to	O
docking	O
,	O
followed	O
by	O
compound	O
acquisition	O
,	O
one	O
-	O
pot	O
(	O
two	O
steps	O
)	O
chemical	O
synthesis	O
and	O
in	O
vitro	O
screening	O
.	O

In	O
two	O
experiments	O
targeting	O
the	O
botulinum	O
neurotoxin	O
serotype	O
A	O
metalloprotease	O
light	O
chain	O
,	O
hit	O
rates	O
of	O
32	O
%	O
and	O
18	O
%	O
were	O
observed	O
.	O

Excess	O
androgens	B
in	O
utero	O
alters	O
fetal	O
testis	O
development	O
.	O

Prenatal	O
androgenization	O
induces	O
a	O
polycystic	O
ovary	O
syndrome	O
-	O
like	O
phenotype	O
in	O
adult	O
female	O
offspring	O
,	O
which	O
is	O
associated	O
with	O
alterations	O
that	O
can	O
be	O
detected	O
in	O
the	O
fetal	O
ovary	O
,	O
suggesting	O
gestational	O
origins	O
of	O
this	O
condition	O
.	O

We	O
therefore	O
investigated	O
whether	O
increased	O
prenatal	O
androgen	B
exposure	O
also	O
altered	O
testicular	O
development	O
using	O
ovine	O
animal	O
models	O
.	O

Biweekly	O
maternal	O
testosterone	B
propionate	I
(	O
TP	O
;	O
100	O
mg	O
)	O
from	O
day	O
62	O
to	O
day	O
70	O
/	O
day	O
90	O
of	O
gestation	O
altered	O
male	O
developmental	O
trajectory	O
.	O

In	O
male	O
fetuses	O
serum	O
LH	O
was	O
decreased	O
(	O
P	O
<	O
.01	O
)	O
,	O
and	O
testicular	O
STAR	O
,	O
CYP11	O
,	O
and	O
CYP17	O
abundance	O
were	O
reduced	O
.	O

Coincident	O
with	O
this	O
,	O
basal	O
testicular	O
T	O
synthesis	O
was	O
decreased	O
in	O
vitro	O
(	O
P	O
<	O
.001	O
)	O
.	O

Leydig	O
cell	O
distribution	O
was	O
severely	O
perturbed	O
in	O
all	O
testes	O
prenatally	O
exposed	O
to	O
TP	O
(	O
P	O
<	O
.001	O
)	O
.	O

To	O
examine	O
the	O
contribution	O
of	O
estrogens	B
,	O
fetuses	O
were	O
injected	O
with	O
TP	O
(	O
20	O
mg	O
)	O
,	O
the	O
potent	O
estrogen	B
agonist	O
,	O
diethylstilbestrol	B
(	O
DES	B
;	O
20	O
mg	O
)	O
,	O
or	O
vehicle	O
control	O
at	O
day	O
62	O
and	O
day	O
82	O
and	O
assessed	O
at	O
day	O
90	O
.	O

The	O
effects	O
of	O
fetal	O
(	O
direct	O
)	O
TP	O
treatment	O
,	O
but	O
not	O
DES	B
,	O
paralleled	O
maternal	O
(	O
indirect	O
)	O
TP	O
exposure	O
,	O
supporting	O
a	O
direct	O
androgen	B
effect	O
.	O

Cessation	O
of	O
maternal	O
androgenization	O
at	O
day	O
102	O
returned	O
Leydig	O
cell	O
distribution	O
to	O
normal	O
but	O
increased	O
basal	O
T	O
output	O
,	O
at	O
day	O
112	O
,	O
demonstrating	O
Leydig	O
cell	O
developmental	O
plasticity	O
.	O

Earlier	O
maternal	O
androgen	B
exposure	O
from	O
day	O
30	O
similarly	O
influenced	O
Leydig	O
cell	O
development	O
at	O
day	O
90	O
but	O
additionally	O
affected	O
the	O
expression	O
of	O
Sertoli	O
and	O
germ	O
cell	O
markers	O
.	O

We	O
show	O
in	O
this	O
study	O
that	O
increased	O
prenatal	O
androgen	O
exposure	O
alters	O
development	O
and	O
function	O
of	O
Leydig	O
cells	O
at	O
a	O
time	O
when	O
androgen	B
production	O
is	O
paramount	O
for	O
male	O
development	O
.	O

This	O
supports	O
the	O
concept	O
that	O
gestational	O
antecedents	O
associated	O
with	O
polycystic	O
ovary	O
syndrome	O
may	O
have	O
effects	O
on	O
the	O
male	O
fetus	O
.	O

Budesonide	B
/	O
cyclodextrin	O
complex	O
-	O
loaded	O
lyophilized	O
microparticles	O
for	O
intranasal	O
application	O
.	O

Abstract	O
Objective	O
:	O
Lyophilized	O
microparticles	O
composed	O
of	O
budesonide	B
(	O
BDS	B
)	O
,	O
hydroxypropyl	B
-	I
	I
-	I
cyclodextrin	I
(	O
HP	B
-	I
	I
-	I
CD	I
)	O
,	O
and	O
hydroxypropylmethylcellulose	O
(	O
HPMC	O
)	O
or	O
sodium	B
carboxymethylcellulose	O
(	O
CMC	O
-	O
Na	B
)	O
were	O
developed	O
for	O
intranasal	O
delivery	O
and	O
their	O
characteristics	O
were	O
evaluated	O
.	O

Materials	O
and	O
methods	O
:	O
The	O
particle	O
size	O
and	O
morphology	O
were	O
assessed	O
by	O
mean	O
diameter	O
measurement	O
and	O
scanning	O
electron	O
microscopy	O
(	O
SEM	O
)	O
image	O
,	O
respectively	O
.	O

The	O
solid	O
-	O
state	O
of	O
products	O
was	O
tested	O
by	O
X	O
-	O
ray	O
powder	O
diffraction	O
(	O
XRPD	O
)	O
,	O
Fourier	O
transform	O
infrared	O
spectroscopy	O
(	O
FT	O
-	O
IR	O
)	O
and	O
differential	O
scanning	O
calorimetry	O
(	O
DSC	O
)	O
.	O

In	O
vitro	O
drug	O
release	O
and	O
cytotoxicity	O
to	O
the	O
primary	O
human	O
nasal	O
epithelial	O
(	O
HNE	O
)	O
cells	O
were	O
also	O
evaluated	O
.	O

Results	O
and	O
discussion	O
:	O
Lyophilized	O
microparticles	O
exhibited	O
vanishment	O
of	O
crystallinity	O
of	O
drug	O
in	O
XRPD	O
analysis	O
,	O
the	O
enfeeblement	O
of	O
carbonyl	B
(	O
C	B
=	I
O	I
)	O
stretching	O
bands	O
of	O
carboxyl	B
group	O
in	O
BDS	B
in	O
FT	O
-	O
IR	O
spectra	O
and	O
the	O
disappearance	O
of	O
endothermic	O
peak	O
of	O
drug	O
in	O
the	O
results	O
of	O
DSC	O
study	O
.	O

Based	O
on	O
the	O
results	O
of	O
solid	O
-	O
state	O
studies	O
,	O
BDS	B
was	O
existed	O
as	O
an	O
amorphous	O
form	O
in	O
the	O
lyophilized	O
microparticles	O
.	O

CD	O
complexation	O
enhanced	O
drug	O
solubility	O
and	O
release	O
rate	O
,	O
and	O
HPMC	O
or	O
CMC	O
-	O
Na	B
also	O
improved	O
drug	O
dissolution	O
rates	O
.	O

Cytotoxicity	O
of	O
developed	O
microparticles	O
to	O
the	O
HNE	O
cells	O
was	O
measured	O
and	O
their	O
safety	O
to	O
HNE	O
cell	O
was	O
identified	O
.	O

Conclusion	O
:	O
Developed	O
microparticles	O
can	O
efficiently	O
deliver	O
insoluble	O
drug	O
,	O
such	O
as	O
BDS	B
,	O
to	O
the	O
nasal	O
epithelium	O
and	O
thus	O
it	O
may	O
improve	O
therapeutic	O
efficacy	O
in	O
the	O
respiratory	O
tract	O
.	O

Serotonin	B
(	O
5-HT	B
)	O
in	O
the	O
Regulation	O
of	O
Depression	O
-	O
Related	O
Emotionality	O
:	O
Insight	O
from	O
5-HT	B
Transporter	O
and	O
Tryptophan	B
Hydroxylase-2	O
Knockout	O
Mouse	O
Models	O
.	O

Disorders	O
of	O
emotion	O
regulation	O
such	O
as	O
anxiety	O
disorders	O
and	O
depression	O
are	O
common	O
and	O
yet	O
debilitating	O
.	O

Accumulating	O
evidence	O
suggests	O
involvement	O
of	O
serotonin	B
(	O
5-HT	B
)	O
in	O
the	O
regulation	O
of	O
emotion	O
.	O

Mice	O
with	O
targeted	O
deletion	O
of	O
genes	O
encoding	O
mediators	O
of	O
the	O
serotonergic	O
transmission	O
have	O
proven	O
to	O
be	O
a	O
powerful	O
tool	O
for	O
understanding	O
contributions	O
of	O
such	O
mediators	O
of	O
emotion	O
regulation	O
.	O

Over	O
the	O
last	O
decade	O
,	O
research	O
on	O
mice	O
with	O
a	O
targeted	O
inactivation	O
of	O
the	O
5-HT	B
transporter	O
(	O
5-Htt	O
,	O
Sert	O
,	O
Slc6a4	O
)	O
has	O
considerably	O
advanced	O
our	O
knowledge	O
about	O
functions	O
that	O
the	O
5-HTT	O
plays	O
in	O
the	O
context	O
of	O
emotion	O
related	O
to	O
depression	O
.	O

Moreover	O
,	O
the	O
recent	O
advent	O
of	O
knockout	O
(	O
KO	O
)	O
mice	O
for	O
tryptophan	B
hydroxylase	O
2	O
(	O
Tph2	O
KO	O
)	O
,	O
which	O
lacks	O
the	O
rate	O
-	O
limiting	O
enzyme	O
for	O
5-HT	B
synthesis	O
in	O
the	O
brain	O
,	O
has	O
further	O
provided	O
insight	O
to	O
the	O
brain	O
serotonergic	O
system	O
and	O
its	O
role	O
in	O
emotion	O
dysregulation	O
.	O

Here	O
,	O
we	O
first	O
highlight	O
basic	O
characteristics	O
of	O
the	O
serotonergic	O
system	O
including	O
the	O
biosynthesis	O
of	O
5-HT	B
as	O
well	O
as	O
the	O
anatomy	O
and	O
firing	O
activity	O
of	O
serotonergic	O
neurons	O
.	O

Furthermore	O
,	O
characteristics	O
of	O
5-Htt	O
and	O
Tph2	O
KO	O
mice	O
are	O
covered	O
together	O
with	O
association	O
studies	O
on	O
human	O
variants	O
of	O
5-HTT	O
and	O
TPH2	O
in	O
emotional	O
regulation	O
.	O

Among	O
various	O
targets	O
of	O
serotonergic	O
projections	O
,	O
which	O
originate	O
from	O
the	O
raphe	O
nuclei	O
in	O
the	O
brain	O
stem	O
,	O
particular	O
focus	O
is	O
placed	O
on	O
the	O
hippocampus	O
due	O
to	O
its	O
unique	O
dual	O
role	O
in	O
memory	O
and	O
emotion	O
.	O

Finally	O
,	O
effects	O
of	O
therapeutic	O
drugs	O
and	O
psychoactive	O
drugs	O
on	O
KO	O
mouse	O
models	O
as	O
well	O
as	O
on	O
synaptic	O
plasticity	O
will	O
be	O
discussed	O
.	O

Controllable	O
Hydrogen	B
Sulfide	I
Donors	O
and	O
Their	O
Activity	O
against	O
Myocardial	O
Ischemia	O
-	O
Reperfusion	O
Injury	O
.	O

Hydrogen	B
sulfide	I
(	O
H2S	B
)	O
,	O
known	O
as	O
an	O
important	O
cellular	O
signaling	O
molecule	O
,	O
plays	O
critical	O
roles	O
in	O
many	O
physiological	O
and/or	O
pathological	O
processes	O
.	O

Modulation	O
of	O
H2S	B
levels	O
could	O
have	O
tremendous	O
therapeutic	O
value	O
.	O

However	O
,	O
the	O
study	O
on	O
H2S	B
has	O
been	O
hindered	O
due	O
to	O
the	O
lack	O
of	O
controllable	O
H2S	B
releasing	O
agents	O
that	O
could	O
mimic	O
the	O
slow	O
and	O
moderate	O
H2S	B
release	O
in	O
vivo	O
.	O

In	O
this	O
work	O
we	O
report	O
the	O
design	O
,	O
synthesis	O
,	O
and	O
biological	O
evaluation	O
of	O
a	O
new	O
class	O
of	O
controllable	O
H2S	B
donors	O
.	O

Twenty	O
-	O
five	O
donors	O
were	O
prepared	O
and	O
tested	O
.	O

Their	O
structures	O
were	O
based	O
on	O
a	O
perthiol	B
template	O
,	O
which	O
was	O
suggested	O
to	O
be	O
involved	O
in	O
H2S	B
biosynthesis	O
.	O

H2S	B
release	O
mechanism	O
from	O
these	O
donors	O
was	O
studied	O
and	O
proved	O
to	O
be	O
thiol	B
-	O
dependent	O
.	O

We	O
also	O
developed	O
a	O
series	O
of	O
cell	O
-	O
based	O
assays	O
to	O
access	O
their	O
H2S	B
-	O
related	O
activities	O
.	O

H9c2	O
cardiac	O
myocytes	O
were	O
used	O
in	O
these	O
experiments	O
.	O

We	O
tested	O
lead	O
donors	O
'	O
cytotoxicity	O
and	O
confirmed	O
their	O
H2S	B
production	O
in	O
cells	O
.	O

Finally	O
we	O
demonstrated	O
that	O
selected	O
donors	O
showed	O
potent	O
protective	O
effects	O
in	O
an	O
in	O
vivo	O
murine	O
model	O
of	O
myocardial	O
ischemia	O
-	O
reperfusion	O
injury	O
,	O
through	O
a	O
H2S	B
-	O
related	O
mechanism	O
.	O

Interfacial	O
Nanoarchitectonics	O
:	O
Lateral	O
and	O
Vertical	O
,	O
Static	O
and	O
Dynamic	O
.	O

The	O
exploration	O
of	O
nanostructures	O
and	O
nanomaterials	O
is	O
essential	O
to	O
the	O
development	O
of	O
advanced	O
functions	O
.	O

For	O
such	O
innovations	O
,	O
nanoarchitectonics	O
has	O
been	O
proposed	O
as	O
a	O
novel	O
paradigm	O
of	O
nanotechnology	O
aimed	O
at	O
assembling	O
nanoscale	O
structural	O
units	O
into	O
predesigned	O
configurations	O
or	O
arrangements	O
.	O

In	O
this	O
Feature	O
Article	O
,	O
we	O
provide	O
an	O
overview	O
of	O
several	O
recent	O
research	O
works	O
from	O
the	O
viewpoint	O
of	O
interfacial	O
nanoarchitectonics	O
with	O
features	O
developed	O
in	O
lateral	O
directions	O
or	O
grown	O
in	O
vertical	O
directions	O
with	O
construction	O
on	O
solid	O
,	O
static	O
,	O
or	O
flexible	O
dynamic	O
surfaces	O
.	O

Lateral	O
nanoarchitectonics	O
at	O
a	O
static	O
interface	O
provides	O
molecular	O
organization	O
by	O
bottom	O
-	O
up	O
nanoarchitectonics	O
and	O
can	O
also	O
be	O
used	O
to	O
realize	O
device	O
integration	O
by	O
top	O
-	O
down	O
nanoarchitectonics	O
.	O

In	O
particular	O
,	O
in	O
the	O
latter	O
case	O
,	O
the	O
fabrication	O
of	O
novel	O
devices	O
,	O
so	O
-	O
called	O
atomic	O
switches	O
,	O
are	O
introduced	O
as	O
a	O
demonstration	O
of	O
atomic	O
-	O
level	O
electronics	O
.	O

Lateral	O
nanoarchitectonics	O
at	O
dynamic	O
interfaces	O
is	O
exemplified	O
by	O
2D	O
molecular	O
patterning	O
and	O
molecular	O
machine	O
operation	O
induced	O
by	O
macroscopic	O
motion	O
.	O

The	O
dynamic	O
nature	O
of	O
interfaces	O
enables	O
us	O
to	O
operate	O
molecular	O
-	O
sized	O
machines	O
by	O
macroscopic	O
mechanical	O
stimuli	O
such	O
as	O
our	O
hand	O
motion	O
,	O
which	O
we	O
refer	O
to	O
as	O
hand	O
-	O
operated	O
nanotechnology	O
.	O

Vertical	O
nanoarchitectonics	O
is	O
mainly	O
discussed	O
in	O
relation	O
to	O
layer	O
-	O
by	O
-	O
layer	O
(	O
LbL	O
)	O
assembly	O
.	O

By	O
using	O
this	O
technique	O
,	O
we	O
can	O
assemble	O
a	O
variety	O
of	O
functional	O
materials	O
in	O
ultrathin	O
film	O
structures	O
of	O
defined	O
thickness	O
and	O
layer	O
sequence	O
.	O

The	O
organization	O
of	O
biomolecules	O
(	O
or	O
even	O
living	O
cells	O
)	O
within	O
thin	O
films	O
and	O
their	O
integration	O
with	O
device	O
structures	O
is	O
exemplified	O
.	O

Finally	O
,	O
the	O
anticipated	O
research	O
directions	O
of	O
interfacial	O
nanoarchitectonics	O
are	O
described	O
.	O

Polycyclic	O
Hybrid	O
Isoprenoids	B
from	O
a	O
Reed	O
Rhizosphere	O
Soil	O
Derived	O
Streptomyces	O
sp.	O
CHQ-64	O
.	O

Two	O
new	O
hybrid	O
isoprenoids	B
,	O
named	O
indotertine	B
B	I
(	O
2	O
)	O
and	O
drimentine	B
H	I
(	O
3	O
)	O
,	O
along	O
with	O
the	O
known	O
analogue	O
drimentine	B
C	I
(	O
4	O
)	O
,	O
were	O
isolated	O
from	O
the	O
reed	O
rhizosphere	O
soil	O
derived	O
actinomycete	O
Streptomyces	O
sp.	O
CHQ-64	O
.	O

The	O
structures	O
of	O
these	O
compounds	O
,	O
including	O
absolute	O
configurations	O
,	O
were	O
elucidated	O
by	O
extensive	O
NMR	O
,	O
MS	O
,	O
and	O
CD	O
analyses	O
.	O

Indotertine	B
B	I
(	O
2	O
)	O
exists	O
as	O
a	O
pair	O
of	O
rotamers	O
about	O
the	O
N	B
-	I
C	I
(	I
O	I
)	I
bond	O
with	O
a	O
2:1	O
ratio	O
and	O
displays	O
activities	O
against	O
HCT-8	O
and	O
A549	O
tumor	O
cell	O
lines	O
with	O
IC50	O
values	O
of	O
6.96	O
and	O
4.88	O
M	O
,	O
respectively	O
.	O

A	O
mass	O
-	O
tagging	O
approach	O
for	O
enhanced	O
sensitivity	O
of	O
dynamic	O
cytokine	O
detection	O
using	O
a	O
label	O
-	O
free	O
biosensor	O
.	O

Monitoring	O
cytokine	O
release	O
by	O
cells	O
allows	O
the	O
investigation	O
of	O
cellular	O
response	O
to	O
specific	O
external	O
stimuli	O
,	O
such	O
as	O
pathogens	O
or	O
candidate	O
drugs	O
.	O

Unlike	O
conventional	O
colorimetric	O
techniques	O
,	O
label	O
-	O
free	O
detection	O
of	O
cytokines	O
enables	O
studying	O
cellular	O
secretions	O
in	O
real	O
time	O
by	O
eliminating	O
additional	O
wash	O
and	O
labeling	O
steps	O
after	O
the	O
binding	O
step	O
.	O

However	O
,	O
label	O
-	O
free	O
techniques	O
that	O
are	O
based	O
on	O
measuring	O
mass	O
accumulation	O
on	O
a	O
sensor	O
surface	O
are	O
challenging	O
for	O
measuring	O
small	O
cytokines	O
binding	O
to	O
much	O
larger	O
capture	O
agents	O
(	O
usually	O
antibodies	O
)	O
because	O
the	O
relative	O
signal	O
change	O
is	O
small	O
.	O

This	O
problem	O
is	O
exacerbated	O
when	O
the	O
capturing	O
antibodies	O
desorb	O
from	O
the	O
surface	O
,	O
a	O
phenomenon	O
that	O
almost	O
inevitably	O
occurs	O
in	O
immunoassays	O
but	O
is	O
rarely	O
accounted	O
for	O
.	O

Here	O
,	O
we	O
demonstrate	O
a	O
quantitative	O
dynamic	O
detection	O
of	O
interleukine-6	O
(	O
IL-6	O
)	O
,	O
a	O
pro	O
-	O
inflammatory	O
cytokine	O
,	O
using	O
an	O
interferometric	O
reflectance	O
imaging	O
sensor	O
(	O
IRIS	O
)	O
.	O

We	O
improved	O
the	O
accuracy	O
of	O
the	O
quantitative	O
analysis	O
of	O
this	O
relatively	O
small	O
protein	O
(	O
21	O
kDa	O
)	O
by	O
characterizing	O
the	O
antibody	O
desorption	O
rate	O
and	O
compensating	O
for	O
the	O
antibody	O
loss	O
during	O
the	O
binding	O
experiment	O
.	O

By	O
correcting	O
for	O
protein	O
desorption	O
,	O
we	O
achieved	O
an	O
analytical	O
limit	O
of	O
detection	O
at	O
19	O
ng	O
/	O
mL	O
IL-6	O
concentration	O
.	O

We	O
enhanced	O
the	O
sensitivity	O
by	O
7-fold	O
by	O
using	O
detection	O
antibodies	O
that	O
recognize	O
a	O
different	O
epitope	O
of	O
the	O
cytokine	O
.	O

We	O
demonstrate	O
that	O
these	O
detection	O
antibodies	O
,	O
which	O
we	O
call	O
"	O
mass	O
tags	O
"	O
,	O
can	O
be	O
used	O
concurrently	O
with	O
the	O
target	O
analyte	O
to	O
eliminate	O
an	O
additional	O
wash	O
and	O
binding	O
step	O
.	O

Finally	O
,	O
we	O
report	O
successful	O
label	O
-	O
free	O
detection	O
of	O
IL-6	O
in	O
cell	O
culture	O
medium	O
(	O
with	O
10	O
%	O
serum	O
)	O
with	O
comparable	O
signal	O
to	O
that	O
obtained	O
in	O
PBS	O
.	O

This	O
work	O
is	O
the	O
first	O
to	O
report	O
quantitative	O
dynamic	O
label	O
-	O
free	O
detection	O
of	O
small	O
protein	O
in	O
a	O
complex	O
biological	O
fluid	O
using	O
IRIS	O
.	O

Cytokines	O
as	O
biomarkers	O
of	O
nanoparticle	O
immunotoxicity	O
.	O

Nanoscale	O
objects	O
,	O
whether	O
of	O
biologic	O
origin	O
or	O
synthetically	O
created	O
,	O
are	O
being	O
developed	O
into	O
devices	O
for	O
a	O
variety	O
of	O
bionanotechnology	O
diagnostic	O
and	O
pharmaceutical	O
applications	O
.	O

However	O
,	O
the	O
potential	O
immunotoxicity	O
of	O
these	O
nanomaterials	O
and	O
mechanisms	O
by	O
which	O
they	O
may	O
induce	O
adverse	O
reactions	O
have	O
not	O
received	O
sufficient	O
attention	O
.	O

Nanomaterials	O
,	O
depending	O
on	O
their	O
characteristics	O
and	O
compositions	O
,	O
can	O
interact	O
with	O
the	O
immune	O
system	O
in	O
several	O
ways	O
and	O
either	O
enhance	O
or	O
suppress	O
immune	O
system	O
function	O
.	O

Cytokines	O
perform	O
pleiotropic	O
functions	O
to	O
mediate	O
and	O
regulate	O
the	O
immune	O
response	O
and	O
are	O
generally	O
recognized	O
as	O
biomarkers	O
of	O
immunotoxicity	O
.	O

While	O
the	O
specificity	O
and	O
validity	O
of	O
certain	O
cytokines	O
as	O
markers	O
of	O
adverse	O
immune	O
response	O
has	O
been	O
established	O
for	O
chemicals	O
,	O
small	O
and	O
macromolecular	O
drugs	O
,	O
research	O
on	O
their	O
applicability	O
for	O
predicting	O
and	O
monitoring	O
the	O
immunotoxicity	O
of	O
engineered	O
nanomaterials	O
is	O
still	O
ongoing	O
.	O

The	O
goal	O
of	O
this	O
review	O
is	O
to	O
provide	O
guidelines	O
as	O
to	O
important	O
cytokines	O
that	O
can	O
be	O
utilized	O
for	O
evaluating	O
the	O
immunotoxicity	O
of	O
nanomaterials	O
and	O
to	O
highlight	O
the	O
role	O
of	O
those	O
cytokines	O
in	O
mediating	O
adverse	O
reactions	O
,	O
which	O
is	O
of	O
particular	O
importance	O
for	O
the	O
clinical	O
development	O
of	O
nanopharmaceuticals	O
and	O
other	O
nanotechnology	O
-	O
based	O
products	O
.	O

Importantly	O
,	O
the	O
rational	O
design	O
of	O
nanomaterials	O
of	O
low	O
immunotoxicity	O
will	O
be	O
discussed	O
,	O
focusing	O
on	O
synthetic	O
nanodevices	O
,	O
with	O
emphasis	O
on	O
both	O
the	O
nanoparticle	O
-	O
forming	O
materials	O
and	O
the	O
embedded	O
cargoes	O
.	O

A	O
high	O
throughput	O
assay	O
for	O
the	O
glucuronidation	O
of	O
7-hydroxy-4-trifluoromethylcoumarin	B
by	O
recombinant	O
human	O
UDP	B
-	O
glucuronosyltransferases	O
and	O
liver	O
microsomes	O
.	O

Abstract	O
1	O
.	O

UDP	B
-	O
glucuronosyltransferases	O
(	O
UGTs	O
)	O
are	O
versatile	O
and	O
important	O
conjugation	O
enzymes	O
in	O
the	O
metabolism	O
of	O
drugs	O
and	O
other	O
xenobiotics	O
.	O

2	O
.	O

We	O
have	O
developed	O
a	O
convenient	O
quantitative	O
multi	O
-	O
well	O
plate	O
assay	O
to	O
measure	O
the	O
glucuronidation	O
rate	O
of	O
7-hydroxy-4-trifluoromethylcoumarin	B
(	O
HFC	B
)	O
for	O
several	O
UGTs	O
.	O

3	O
.	O
We	O
have	O
used	O
this	O
method	O
to	O
screen	O
11	O
recombinant	O
human	O
UGTs	O
for	O
HFC	B
glucuronidation	O
activity	O
and	O
studied	O
the	O
reaction	O
kinetics	O
with	O
the	O
most	O
active	O
enzymes	O
.	O

We	O
have	O
also	O
examined	O
the	O
HFC	B
glucuronidation	O
activity	O
of	O
liver	O
microsomes	O
from	O
human	O
,	O
pig	O
,	O
rabbit	O
and	O
rat	O
.	O

4	O
.	O

At	O
a	O
substrate	O
concentration	O
of	O
20	O
M	O
,	O
the	O
most	O
active	O
HFC	B
glucuronidation	O
catalysts	O
were	O
UGT1A10	O
followed	O
by	O
UGT1A6	O
>	O
UGT1A7	O
>	O
UGT2A1	O
,	O
whereas	O
at	O
300	O
M	O
UGT1A6	O
was	O
about	O
10	O
times	O
better	O
catalyst	O
than	O
the	O
other	O
recombinant	O
UGTs	O
.	O

The	O
activities	O
of	O
UGTs	O
1A3	O
,	O
1A8	O
,	O
1A9	O
,	O
2B4	O
and	O
2B7	O
were	O
low	O
,	O
whereas	O
UGT1A1	O
and	O
UGT2B17	O
exhibited	O
no	O
HFC	B
glucuronidation	O
activity	O
.	O

UGT1A6	O
exhibited	O
a	O
significantly	O
higher	O
Vmax	O
and	O
Km	O
values	O
toward	O
both	O
HFC	B
and	O
UDP	B
-	O
glucuronic	B
acid	I
than	O
the	O
other	O
UGTs	O
.	O

5	O
.	O
Human	O
,	O
pig	O
and	O
rabbit	O
,	O
but	O
not	O
rat	O
liver	O
microsomes	O
,	O
catalyzed	O
HFC	B
glucuronidation	O
at	O
high	O
rates	O
.	O

6	O
.	O

This	O
new	O
method	O
is	O
particularly	O
suitable	O
for	O
fast	O
activity	O
screenings	O
of	O
UGTs	O
1A6	O
,	O
1A7	O
,	O
1A10	O
and	O
2A1	O
and	O
HFC	B
glucuronidation	O
activity	O
determination	O
from	O
various	O
samples	O
.	O

Package	O
-	O
Free	O
Flexible	O
Organic	O
Solar	O
Cells	O
with	O
Graphene	B
top	O
Electrodes	O
.	O

Package	O
-	O
free	O
flexible	O
organic	O
solar	O
cells	O
were	O
fabricated	O
with	O
multilayer	O
graphene	B
as	O
top	O
transparent	O
electrodes	O
,	O
which	O
show	O
the	O
highest	O
power	O
conversion	O
efficiency	O
of	O
about	O
3.2	O
%	O
and	O
excellent	O
flexibility	O
and	O
bending	O
stability	O
.	O

The	O
devices	O
also	O
show	O
good	O
air	O
stability	O
,	O
indicating	O
that	O
multilayer	O
graphene	B
is	O
a	O
promising	O
environmental	O
barrier	O
that	O
can	O
protect	O
the	O
organic	O
solar	O
cells	O
from	O
air	O
contamination	O
.	O

High	O
Mobility	O
Field	O
-	O
Effect	O
Transistors	O
with	O
Versatile	O
Processing	O
from	O
a	O
Small	O
-	O
Molecule	O
Organic	O
Semiconductor	O
.	O

Trialkylgermyl	B
functionalization	O
allows	O
development	O
of	O
high	O
-	O
performance	O
soluble	O
small	O
-	O
molecule	O
organic	O
semiconductors	O
with	O
mobilities	O
greater	O
than	O
5	O
cm	O
(	O
2	O
)	O
V	O
(	O
-1	O
)	O
s	O
(	O
-1	O
)	O
.	O

Spray	O
-	O
deposited	O
organic	O
thin	O
-	O
film	O
transistors	O
show	O
a	O
record	O
mobility	O
of	O
2.2	O
cm	O
(	O
2	O
)	O
V	O
(	O
-1	O
)	O
s	O
(	O
-1	O
)	O
and	O
demonstrate	O
the	O
potential	O
for	O
incorporation	O
in	O
large	O
-	O
area	O
,	O
low	O
-	O
cost	O
electronic	O
applications	O
.	O

Bone	O
remodeling	O
is	O
regulated	O
by	O
inner	O
ear	O
vestibular	O
signals	O
.	O

Bone	O
remodeling	O
allows	O
the	O
conservation	O
of	O
normal	O
bone	O
mass	O
despite	O
constant	O
changes	O
in	O
internal	O
and	O
external	O
environments	O
.	O

The	O
adaptation	O
of	O
the	O
skeleton	O
to	O
these	O
various	O
stimuli	O
led	O
credence	O
to	O
the	O
notion	O
that	O
bone	O
remodeling	O
is	O
a	O
true	O
homeostatic	O
function	O
,	O
and	O
as	O
such	O
is	O
under	O
the	O
control	O
of	O
specific	O
centers	O
in	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
.	O

Hypothalamic	O
and	O
brainstem	O
centers	O
,	O
as	O
well	O
as	O
the	O
sympathetic	O
nervous	O
system	O
(	O
SNS	O
)	O
,	O
have	O
been	O
identified	O
as	O
regulators	O
of	O
bone	O
remodeling	O
.	O

However	O
,	O
the	O
nature	O
of	O
the	O
afferent	O
CNS	O
stimuli	O
that	O
may	O
modulate	O
CNS	O
centers	O
involved	O
in	O
the	O
control	O
of	O
bone	O
remodeling	O
,	O
with	O
the	O
exception	O
of	O
leptin	O
,	O
remains	O
unclear	O
.	O

Based	O
on	O
the	O
partial	O
efficacy	O
of	O
exercise	O
and	O
mechanical	O
stimulation	O
regimens	O
to	O
prevent	O
microgravity	O
-	O
induced	O
bone	O
loss	O
and	O
the	O
known	O
alterations	O
in	O
vestibular	O
functions	O
associated	O
with	O
space	O
flights	O
,	O
we	O
hypothesized	O
that	O
inner	O
ear	O
vestibular	O
signals	O
may	O
contribute	O
to	O
the	O
regulation	O
of	O
bone	O
remodeling	O
.	O

Using	O
an	O
established	O
model	O
of	O
bilateral	O
vestibular	O
lesions	O
and	O
microtomographic	O
and	O
histomorphometric	O
bone	O
analyses	O
,	O
we	O
show	O
here	O
that	O
induction	O
of	O
bilateral	O
vestibular	O
lesion	O
in	O
rats	O
generates	O
significant	O
bone	O
loss	O
,	O
which	O
is	O
restricted	O
to	O
weight	O
-	O
bearing	O
bones	O
and	O
associated	O
with	O
a	O
significant	O
reduction	O
in	O
bone	O
formation	O
,	O
as	O
observed	O
in	O
rats	O
under	O
microgravity	O
conditions	O
.	O

Importantly	O
,	O
this	O
bone	O
loss	O
was	O
not	O
associated	O
with	O
reduced	O
locomotor	O
activity	O
or	O
metabolic	O
abnormalities	O
,	O
was	O
accompanied	O
with	O
molecular	O
signs	O
of	O
increased	O
sympathetic	O
outflow	O
,	O
and	O
could	O
be	O
prevented	O
by	O
the	O
	O
-	O
blocker	O
propranolol	B
.	O

Collectively	O
,	O
these	O
data	O
suggest	O
that	O
the	O
homeostatic	O
process	O
of	O
bone	O
remodeling	O
has	O
a	O
vestibulo	O
-	O
sympathetic	O
regulatory	O
component	O
and	O
that	O
vestibular	O
system	O
pathologies	O
might	O
be	O
accompanied	O
by	O
bone	O
fragility	O
.	O

	O
2013	O
American	O
Society	O
for	O
Bone	O
and	O
Mineral	O
Research	O
.	O

Determination	O
of	O
Specific	O
Binding	O
Interactions	O
at	O
l	B
-	I
Cystine	I
Crystal	O
Surfaces	O
with	O
Chemical	O
Force	O
Microscopy	O
.	O

The	O
pathogenesis	O
of	O
l	B
-	I
cystine	I
kidney	O
stones	O
involves	O
four	O
critical	O
steps	O
:	O
nucleation	O
,	O
crystal	O
growth	O
,	O
crystal	O
aggregation	O
,	O
and	O
crystal	O
adhesion	O
to	O
cells	O
.	O

Although	O
inhibition	O
of	O
crystal	O
growth	O
by	O
l	B
-	I
cystine	I
"	O
imposters	O
"	O
at	O
l	B
-	I
cystine	I
crystal	O
surfaces	O
has	O
been	O
suggested	O
as	O
a	O
plausible	O
route	O
for	O
the	O
suppression	O
of	O
stones	O
,	O
understanding	O
the	O
factors	O
that	O
govern	O
crystal	O
-	O
crystal	O
aggregation	O
and	O
adhesion	O
of	O
crystals	O
to	O
epithelial	O
cells	O
also	O
is	O
essential	O
for	O
devising	O
strategies	O
to	O
mitigate	O
l	B
-	I
cystine	I
stone	O
formation	O
.	O

Chemical	O
force	O
microscopy	O
performed	O
with	O
atomic	O
force	O
microscope	O
tips	O
decorated	O
with	O
functional	O
groups	O
commonly	O
found	O
in	O
urinary	O
constituents	O
that	O
likely	O
mediate	O
aggregation	O
and	O
attachment	O
(	O
e.g.	O
,	O
COOH	B
,	O
NH2	B
,	O
SH	B
,	O
CH3	B
,	O
OH	B
)	O
revealed	O
signatures	O
that	O
reflect	O
differences	O
in	O
the	O
chemical	O
affinity	O
of	O
these	O
groups	O
for	O
the	O
(	O
001	O
)	O
and	O
{	O
100	O
}	O
faces	O
of	O
the	O
naturally	O
occurring	O
hexagonal	O
form	O
of	O
l	B
-	I
cystine	I
single	O
crystals	O
and	O
the	O
{	O
110	O
}	O
faces	O
of	O
the	O
non	O
-	O
native	O
tetragonal	O
form	O
.	O

These	O
signatures	O
can	O
be	O
explained	O
by	O
the	O
different	O
chemical	O
compositions	O
of	O
the	O
crystal	O
faces	O
,	O
and	O
they	O
reveal	O
a	O
remarkable	O
binding	O
specificity	O
of	O
the	O
thiol	O
group	O
for	O
the	O
sulfur	B
-	O
rich	O
{	O
100	O
}	O
and	O
{	O
110	O
}	O
faces	O
of	O
the	O
hexagonal	O
and	O
tetragonal	O
forms	O
,	O
respectively	O
.	O

Collectively	O
,	O
these	O
observations	O
suggest	O
that	O
alterations	O
of	O
the	O
crystal	O
habit	O
and	O
polymorph	O
by	O
crystal	O
growth	O
inhibitors	O
may	O
not	O
affect	O
crystal	O
aggregation	O
or	O
adhesion	O
to	O
cells	O
significantly	O
.	O

Association	O
of	O
serum	O
adiponectin	O
and	O
IGF	O
-	O
I	O
levels	O
with	O
parameters	O
of	O
cardiac	O
remodeling	O
in	O
severely	O
obese	O
patients	O
.	O

Background	O
.	O

Obesity	O
is	O
associated	O
with	O
various	O
changes	O
in	O
cardiac	O
geometry	O
and	O
this	O
process	O
involves	O
both	O
hemodynamic	O
and	O
non	O
-	O
hemodynamic	O
factors	O
,	O
among	O
which	O
adipocitokines	O
and	O
growth	O
factors	O
may	O
play	O
an	O
important	O
role	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
identify	O
the	O
extent	O
and	O
pattern	O
of	O
cardiac	O
remodeling	O
in	O
a	O
group	O
of	O
severely	O
obese	O
patients	O
and	O
analyze	O
the	O
relationship	O
between	O
adiponectin	O
,	O
IGF	O
-	O
I	O
and	O
cardiac	O
parameters	O
reflecting	O
obesity	O
associated	O
structural	O
changes	O
.	O

Subjects	O
and	O
methods	O
.	O

Our	O
study	O
included	O
344	O
patients	O
(	O
104	O
men	O
)	O
with	O
severe	O
obesity	O
(	O
mean	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
=	O
45.78.5	O
kg	O
/	O
m2	O
)	O
,	O
extensively	O
evaluated	O
clinically	O
and	O
biologically	O
(	O
complete	O
metabolic	O
tests	O
,	O
serum	O
adiponectin	O
and	O
IGF	O
-	O
I	O
measurements	O
)	O
.	O

Left	O
ventricular	O
mass	O
index	O
(	O
LVMI	O
)	O
,	O
left	O
atrium	O
(	O
LA	O
)	O
size	O
and	O
LV	O
geometry	O
were	O
determined	O
by	O
means	O
of	O
cardiac	O
ultrasound	O
.	O

Results	O
.	O

The	O
most	O
prevalent	O
pattern	O
of	O
LV	O
geometry	O
was	O
eccentric	O
hypertrophy	O
(	O
28.7	O
%	O
of	O
patients	O
)	O
.	O

In	O
a	O
gender	O
,	O
age	O
,	O
BMI	O
,	O
diabetes	O
and	O
hypertension	O
adjusted	O
general	O
linear	O
model	O
,	O
patients	O
with	O
concentric	O
or	O
eccentric	O
hypertrophy	O
had	O
significantly	O
lower	O
values	O
of	O
adiponectin	O
than	O
those	O
with	O
normal	O
geometry	O
(	O
6.750.41	O
,	O
6.960.53	O
,	O
versus	O
9.040.42	O
mg	O
/	O
l	O
,	O
p<0.05	O
)	O
.	O

In	O
multivariate	O
analysis	O
,	O
independent	O
determinants	O
for	O
LVMI	O
were	O
BMI	O
(	O
B=0.364	O
,	O
p<0.001	O
)	O
,	O
systolic	O
blood	O
pressure	O
(	O
BP	O
)	O
(	O
=0.187	O
,	O
p=0.004	O
)	O
,	O
age	O
(	O
=0.246	O
,	O
p<0.001	O
)	O
,	O
adiponectin	O
(	O
=-0.151	O
,	O
p=0.012	O
)	O
and	O
IGF	O
-	O
I	O
z	O
-	O
score	O
(	O
=0.134	O
,	O
p=0.025	O
)	O
while	O
factors	O
independently	O
related	O
to	O
LA	O
size	O
were	O
systolic	O
BP	O
(	O
=0.218	O
,	O
p<0.001	O
)	O
,	O
BMI	O
(	O
=0.194	O
,	O
p<0.001	O
)	O
,	O
age	O
(	O
=0.273	O
,	O
p<0.001	O
)	O
,	O
gender	O
(	O
=-0.195	O
,	O
p<0.001	O
)	O
and	O
adiponectin	O
(	O
=-0.180	O
,	O
p=0.005	O
)	O
.	O

Conclusions	O
:	O
In	O
patients	O
with	O
severe	O
obesity	O
,	O
IGF	O
-	O
I	O
z	O
score	O
and	O
adiponectin	O
correlate	O
with	O
parameters	O
of	O
cardiac	O
remodeling	O
independently	O
of	O
anthropometric	O
,	O
hemodynamic	O
or	O
metabolic	O
factors	O
.	O

Straight	O
talk	O
with	O
...	O

Miyoung	O
Chun	O
.	O

It	O
was	O
a	O
single	O
tweet	O
.	O

In	O
February	O
,	O
after	O
US	O
President	O
Barack	O
Obama	O
made	O
a	O
subtle	O
nod	O
to	O
a	O
new	O
neuroscience	O
project	O
in	O
his	O
annual	O
State	O
of	O
the	O
Union	O
address	O
,	O
Francis	O
Collins	O
,	O
director	O
of	O
the	O
country	O
's	O
National	O
Institutes	O
of	O
Health	O
(	O
NIH	O
)	O
,	O
posted	O
on	O
the	O
@NIHDirector	O
Twitter	O
feed	O
:	O
"	O
Obama	O
mentions	O
the	O
#	O
NIH	O
Brain	O
Activity	O
Map	O
in	O
#	O
SOTU	O
.	O
"	O

Instantly	O
,	O
scientists	O
were	O
buzzing	O
with	O
rumors	O
that	O
the	O
Brain	O
Activity	O
Map	O
could	O
be	O
the	O
next	O
moon	O
shot	O
,	O
with	O
a	O
budget	O
and	O
timeline	O
similar	O
to	O
the	O
Human	O
Genome	O
Project	O
.	O

The	O
brain	O
map	O
began	O
as	O
a	O
brief	O
white	O
paper	O
and	O
has	O
grown	O
into	O
a	O
large	O
-	O
and	O
still	O
largely	O
undefined	O
-	O
collaboration	O
of	O
several	O
government	O
agencies	O
,	O
nonprofit	O
foundations	O
and	O
private	O
companies	O
.	O

As	O
the	O
stakeholders	O
describe	O
in	O
a	O
commentary	O
published	O
last	O
month	O
(	O
339	O
,	O
1284	O
-	O
1285	O
,	O
2013	O
10.1126	O
/	O
science.1236939	O
)	O
,	O
the	O
goal	O
of	O
the	O
initiative	O
is	O
to	O
understand	O
how	O
thousands	O
of	O
neurons	O
work	O
in	O
concert	O
to	O
control	O
behavior	O
and	O
trigger	O
disease	O
.	O

Miyoung	O
Chun	O
,	O
vice	O
president	O
for	O
science	O
programs	O
at	O
The	O
Kavli	O
Foundation	O
in	O
Oxnard	O
,	O
California	O
,	O
has	O
been	O
developing	O
the	O
project	O
since	O
the	O
beginning	O
and	O
is	O
the	O
self	O
-	O
described	O
"	O
glue	O
"	O
between	O
its	O
many	O
diverse	O
stakeholders	O
.	O

Chun	O
spoke	O
with	O
Virginia	O
Hughes	O
about	O
the	O
evolution	O
of	O
the	O
project	O
and	O
what	O
it	O
might	O
mean	O
for	O
biomedicine	O
.	O

Drosophila	O
homologues	O
of	O
Adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
and	O
the	O
formin	O
Diaphanous	O
collaborate	O
by	O
a	O
conserved	O
mechanism	O
to	O
stimulate	O
actin	O
filament	O
assembly	O
.	O

Adenomatous	O
polyposis	O
coli	O
(	O
APC	O
)	O
is	O
a	O
large	O
multi	O
-	O
domain	O
protein	O
that	O
regulates	O
the	O
cytoskeleton	O
.	O

Recently	O
,	O
it	O
was	O
shown	O
that	O
vertebrate	O
APC	O
through	O
its	O
Basic	O
domain	O
directly	O
collaborates	O
with	O
the	O
formin	O
mDia1	O
to	O
stimulate	O
actin	O
filament	O
assembly	O
in	O
the	O
presence	O
of	O
nucleation	O
barriers	O
.	O

However	O
,	O
it	O
has	O
been	O
unclear	O
whether	O
these	O
activities	O
extend	O
to	O
homologues	O
of	O
APC	O
and	O
Dia	O
in	O
other	O
organisms	O
.	O

Drosophila	O
APC	O
and	O
Dia	O
are	O
each	O
required	O
to	O
promote	O
actin	O
furrow	O
formation	O
in	O
the	O
syncytial	O
embryo	O
,	O
suggesting	O
a	O
potential	O
collaboration	O
in	O
actin	O
assembly	O
,	O
but	O
low	O
sequence	O
homology	O
between	O
the	O
Basic	O
domains	O
of	O
Drosophila	O
and	O
vertebrate	O
APC	O
has	O
left	O
their	O
functional	O
and	O
mechanistic	O
parallels	O
uncertain	O
.	O

To	O
address	O
this	O
question	O
,	O
we	O
purified	O
Drosophila	O
APC1	O
and	O
Dia	O
and	O
determined	O
their	O
individual	O
and	O
combined	O
effects	O
on	O
actin	O
assembly	O
using	O
both	O
bulk	O
fluorescence	O
assays	O
and	O
total	O
internal	O
reflection	O
fluorescence	O
(	O
TIRF	O
)	O
microscopy	O
.	O

Our	O
data	O
show	O
that	O
APC1	O
,	O
similar	O
to	O
its	O
vertebrate	O
homologue	O
,	O
bound	O
to	O
actin	O
monomers	O
and	O
nucleated	O
and	O
bundled	O
filaments	O
.	O

Further	O
,	O
Drosophila	O
Dia	O
nucleated	O
actin	O
assembly	O
,	O
and	O
protected	O
growing	O
filament	O
barbed	O
ends	O
from	O
capping	O
protein	O
.	O

Drosophila	O
APC1	O
and	O
Dia	O
directly	O
interacted	O
and	O
collaborated	O
to	O
promote	O
actin	O
assembly	O
in	O
the	O
combined	O
presence	O
of	O
profilin	O
and	O
capping	O
protein	O
.	O

Thus	O
,	O
despite	O
limited	O
sequence	O
homology	O
,	O
Drosophila	O
and	O
vertebrate	O
APCs	O
exhibit	O
highly	O
related	O
activities	O
and	O
mechanisms	O
,	O
and	O
directly	O
collaborate	O
with	O
formins	O
.	O

These	O
results	O
suggest	O
that	O
APC	O
-	O
Dia	O
interactions	O
in	O
actin	O
assembly	O
are	O
conserved	O
and	O
may	O
underlie	O
important	O
in	O
vivo	O
functions	O
in	O
a	O
broad	O
range	O
of	O
animal	O
phyla	O
.	O

Synergistic	O
Interactions	O
between	O
Grafted	O
Hyaluronic	O
Acid	O
and	O
Lubricin	O
Provide	O

Enhanced	O
Wear	O
Protection	O
and	O
Lubrication	O
.	O

Normal	O
(	O
e.g.	O
,	O
adhesion	O
)	O
and	O
lateral	O
(	O
friction	O
)	O
forces	O
were	O
measured	O
between	O
physisorbed	O
and	O
chemically	O
grafted	O
layers	O
of	O
hyaluronic	O
acid	O
(	O
HA	O
)	O
,	O
an	O
anionic	O
polyelectrolyte	O
in	O
the	O
presence	O
of	O
lubricin	O
(	O
Lub	O
)	O
,	O
a	O
mucinous	O
glycoprotein	O
,	O
on	O
mica	O
surfaces	O
using	O
a	O
surface	O
forces	O
apparatus	O
(	O
SFA	O
)	O
.	O

This	O
work	O
demonstrates	O
that	O
high	O
friction	O
coefficients	O
between	O
the	O
surfaces	O
do	O
not	O
necessarily	O
correlate	O
with	O
surface	O
damage	O
and	O
that	O
chemically	O
grafted	O
HA	O
acts	O
synergistically	O
with	O
Lub	O
to	O
provide	O
friction	O
reduction	O
and	O
enhanced	O
wear	O
protection	O
to	O
the	O
surfaces	O
.	O

Surface	O
immobilization	O
of	O
HA	O
by	O
grafting	O
is	O
necessary	O
for	O
such	O
wear	O
protection	O
.	O

Increasing	O
the	O
concentration	O
of	O
Lub	O
enhances	O
the	O
threshold	O
load	O
that	O
a	O
chemically	O
grafted	O
HA	O
surface	O
can	O
be	O
subjected	O
to	O
before	O
the	O
onset	O
of	O
wear	O
.	O

Addition	O
of	O
Lub	O
does	O
not	O
have	O
any	O
beneficial	O
effect	O
if	O
HA	O
is	O
physisorbed	O
to	O
the	O
mica	O
surfaces	O
.	O

Damage	O
occurs	O
at	O
loads	O
less	O
than	O
1	O
mN	O
regardless	O
of	O
the	O
amount	O
of	O
Lub	O
,	O
indicating	O
that	O
the	O
molecules	O
in	O
the	O
bulk	O
play	O
little	O
or	O
no	O
role	O
in	O
protecting	O
the	O
surfaces	O
from	O
damage	O
.	O

Lub	O
penetrates	O
into	O
the	O
chemically	O
bound	O
HA	O
to	O
form	O
a	O
visco	O
-	O
elastic	O
gel	O
that	O
reduces	O
the	O
coefficient	O
of	O
friction	O
as	O
well	O
as	O
boosts	O
the	O
strength	O
of	O
the	O
surface	O
against	O
abrasive	O
wear	O
(	O
damage	O
)	O
.	O

LC	O
-	O
ESI	O
-	O
TOF	O
-	O
MS	O
identification	O
of	O
bioactive	O
secondary	O
metabolites	O
involved	O
in	O
the	O
antioxidant	O
,	O
anti	O
-	O
inflammatory	O
and	O
anticancer	O
activities	O
of	O
the	O
edible	O
halophyte	O
Zygophyllum	O
album	O
Desf	O
.	O

In	O
this	O
work	O
,	O
liquid	O
chromatography	O
coupled	O
to	O
electrospray	O
time	O
-	O
of	O
-	O
flight	O
mass	O
spectrometry	O
(	O
LC	O
-	O
ESI	O
-	O
TOF	O
-	O
MS	O
)	O
has	O
been	O
applied	O
to	O
screen	O
bioactive	O
metabolites	O
in	O
shoot	O
extract	O
of	O
the	O
medicinal	O
halophyte	O
Zygophyllum	O
album	O
.	O

Among	O
10	O
compounds	O
identified	O
(	O
saponins	B
,	O
flavonoids	B
and	O
sterols	B
)	O
five	O
were	O
reported	O
for	O
the	O
first	O
time	O
in	O
Z.	O
album	O
.	O

Furthermore	O
,	O
novel	O
biological	O
activities	O
of	O
hexane	B
,	O
dichloromethane	B
and	O
methanolic	O
extracts	O
were	O
assessed	O
.	O

Results	O
showed	O
that	O
methanolic	O
extract	O
exhibit	O
the	O
highest	O
antioxidant	O
activity	O
using	O
in	O
vitro	O
ORAC	O
test	O
and	O
anti	O
-	O
inflammatory	O
activity	O
,	O
inhibiting	O
by	O
84.8	O
%	O
NO	B
release	O
in	O
RAW264.7	O
macrophages	O
.	O

However	O
,	O
dichloromethane	B
extract	O
proved	O
the	O
utmost	O
antioxidant	O
activity	O
in	O
cell	O
(	O
WS1	O
)	O
based	O
-	O
assay	O
(	O
IC50=57g	O
/	O
ml	O
)	O
and	O
interesting	O
anticancer	O
capacity	O
against	O
human	O
lung	O
carcinoma	O
(	O
A-549	O
)	O
and	O
colon	O
adenocarcinoma	O
(	O
DLD-1	O
)	O
cells	O
(	O
IC50=37	O
and	O
48g	O
/	O
ml	O
,	O
respectively	O
)	O
.	O

These	O
findings	O
can	O
be	O
attributed	O
to	O
the	O
presence	O
of	O
triterpenes	B
,	O
flavonoids	B
and	O
sterols	B
in	O
Z.	O
album	O
,	O
which	O
are	O
widely	O
known	O
as	O
powerful	O
antioxidants	O
and	O
used	O
in	O
various	O
industrial	O
fields	O
.	O

Degradation	O
of	O
complex	O
carbohydrate	B
:	O
Immobilization	O
of	O
pectinase	O
from	O
Bacillus	O
licheniformis	O
KIBGE	O
-	O
IB21	O
using	O
calcium	B
alginate	O
as	O
a	O
support	O
.	O

Pectinases	O
are	O
heterogeneous	O
group	O
of	O
enzymes	O
that	O
catalyse	O
the	O
hydrolysis	O
of	O
pectin	O
substances	O
which	O
is	O
responsible	O
for	O
the	O
turbidity	O
and	O
undesirable	O
cloudiness	O
in	O
fruits	O
juices	O
.	O

In	O
current	O
study	O
,	O
partially	O
purified	O
pectinase	O
from	O
Bacillus	O
licheniformis	O
KIBGE	O
-	O
IB21	O
was	O
immobilized	O
in	O
calcium	B
alginate	O
beads	O
.	O

The	O
effect	O
of	O
sodium	B
alginate	O
and	O
calcium	B
chloride	I
concentration	O
on	O
immobilization	O
was	O
studied	O
and	O
it	O
was	O
found	O
that	O
the	O
optimal	O
sodium	B
alginate	O
and	O
calcium	B
chloride	I
concentration	O
was	O
3.0	O
%	O
and	O
0.2	O
M	O
,	O
respectively	O
.	O

It	O
was	O
found	O
that	O
immobilization	O
increases	O
the	O
optimal	O
reaction	O
time	O
for	O
pectin	O
degradation	O
from	O
5	O
to	O
10min	O
and	O
temperature	O
from	O
45	O
to	O
55	O
	O
C	O
,	O
whereas	O
,	O
the	O
optimal	O
pH	O
remained	O
same	O
with	O
reference	O
to	O
free	O
enzyme	O
.	O

Thermal	O
stability	O
of	O
enzyme	O
increased	O
after	O
immobilization	O
and	O
immobilized	O
pectinase	O
retained	O
more	O
than	O
80	O
%	O
of	O
its	O
initial	O
activity	O
after	O
5days	O
at	O
30	O
	O
C	O
as	O
compared	O
with	O
free	O
enzyme	O
which	O
showed	O
only	O
30	O
%	O
of	O
residual	O
activity	O
.	O

The	O
immobilized	O
enzyme	O
also	O
exhibited	O
good	O
operational	O
stability	O
and	O
65	O
%	O
of	O
its	O
initial	O
activity	O
was	O
observed	O
during	O
third	O
cycle	O
.	O

In	O
term	O
of	O
pectinase	O
immobilization	O
efficiency	O
and	O
stability	O
,	O
this	O
calcium	B
alginate	O
beads	O
approach	O
seemed	O
to	O
permit	O
good	O
results	O
and	O
can	O
be	O
used	O
to	O
make	O
a	O
bioreactor	O
for	O
various	O
applications	O
in	O
food	O
industries	O
.	O

Influence	O
of	O
pH	O
,	O
metal	O
chelator	O
,	O
free	O
radical	O
scavenger	O
and	O
interfacial	O
characteristics	O
on	O
the	O
oxidative	O
stability	O
of	O
	B
-	I
carotene	I
in	O
conjugated	O
whey	O
protein	O
-	O
pectin	O
stabilised	O
emulsion	O
.	O

The	O
influence	O
of	O
whey	O
protein	O
isolate	O
(	O
WPI	O
)	O
-beet	O
pectin	O
conjugates	O
formed	O
by	O
dry	O
-	O
heating	O
on	O
the	O
oxidative	O
stability	O
of	O
	B
-	I
carotene	I
in	O
O	O
/	O
W	O
emulsions	O
was	O
studied	O
.	O

It	O
was	O
mainly	O
focused	O
on	O
the	O
influence	O
of	O
pH	O
,	O
metal	O
chelator	O
,	O
free	O
radical	O
scavenger	O
and	O
interfacial	O
characteristics	O
on	O
the	O
degradation	O
of	O
	B
-	I
carotene	I
in	O
the	O
emulsion	O
stabilised	O
by	O
conjugate	O
.	O

The	O
conjugate	O
increased	O
the	O
oxidative	O
stability	O
of	O
	B
-	I
carotene	I
in	O
the	O
emulsion	O
as	O
compared	O
to	O
their	O
unconjugated	O
mixture	O
at	O
pH	O
7.0	O
.	O

The	O
desferoxamine	B
retarded	O
	B
-	I
carotene	I
degradation	O
at	O
pH	O
4.0	O
more	O
effectively	O
than	O
pH	O
7.0	O
and	O
more	O
effectively	O
in	O
the	O
emulsion	O
with	O
the	O
conjugate	O
than	O
the	O
unconjugated	O
mixture	O
(	O
p<0.05	O
)	O
.	O

The	O
addition	O
of	O
200mg	O
/	O
kg	O
	B
-	I
tocopherol	I
significantly	O
improved	O
the	O
stability	O
of	O
	B
-	I
carotene	I
in	O
the	O
conjugate	O
stabilised	O
emulsion	O
.	O

The	O
emulsions	O
were	O
washed	O
to	O
remove	O
conjugate	O
not	O
absorbed	O
to	O
the	O
emulsion	O
droplet	O
interface	O
,	O
indicating	O
that	O
unabsorbed	O
emulsifiers	O
could	O
protect	O
	B
-	I
carotene	I
.	O

It	O
suggested	O
that	O
WPI	O
-	O
pectin	O
conjugate	O
could	O
be	O
used	O
to	O
protect	O
bioactive	O
lipids	O
in	O
emulsions	O
.	O

Beneficial	O
effects	O
of	O
asiaticoside	B
on	O
cognitive	O
deficits	O
in	O
senescence	O
-	O
accelerated	O
mice	O
.	O

The	O
effect	O
of	O
asiaticoside	B
isolated	O
from	O
Hydrocotyle	O
sibthorpioides	O
(	O
AHS	O
)	O
on	O
the	O
promotion	O
of	O
cognition	O
in	O
senescence	O
-	O
accelerated	O
mice	O
(	O
SAMP	O
)	O
was	O
evaluated	O
.	O

Six	O
-	O
month	O
old	O
male	O
SAMP8	O
mice	O
were	O
orally	O
administered	O
20	O
,	O
40	O
or	O
80mg	O
/	O
kg	O
AHS	O
daily	O
for	O
three	O
months	O
.	O

SAMR1	O
mice	O
were	O
used	O
as	O
a	O
"	O
normal	O
aging	O
"	O
control	O
.	O

The	O
results	O
showed	O
that	O
treatment	O
with	O
AHS	O
significantly	O
improved	O
learning	O
and	O
memory	O
abilities	O
in	O
behavioral	O
tests	O
.	O

AHS	O
-	O
treated	O
mice	O
showed	O
higher	O
antioxidant	O
enzyme	O
activity	O
and	O
lower	O
lipid	O
oxidation	O
in	O
serum	O
compared	O
with	O
untreated	O
SAMP8	O
mice	O
.	O

Mechanistically	O
,	O
studies	O
showed	O
that	O
AHS	O
markedly	O
reduced	O
the	O
content	O
and	O
deposition	O
of	O
	O
-	O
amyloid	O
peptide	O
(	O
A	O
)	O
by	O
inhibiting	O
the	O
expression	O
of	O
mRNA	O
for	O
amyloid	O
protein	O
precursor	O
,	O
	O
-	O
site	O
amyloid	O
cleaving	O
enzyme-1	O
and	O
cathepsin	O
B	O
and	O
promoting	O
the	O
expression	O
of	O
mRNA	O
for	O
neprilysin	O
and	O
insulin	O
degrading	O
enzyme	O
.	O

In	O
addition	O
,	O
AHS	O
significantly	O
increased	O
the	O
expression	O
of	O
plasticity	O
-	O
related	O
proteins	O
including	O
postsynaptic	O
density-95	O
,	O
phosphor	O
-	O
N	B
-	I
methyl	I
-	I
d	I
-	I
aspartate	I
receptor	O
1	O
,	O
phospho	B
-	O
calcium	B
-	O
calmodulin	O
dependent	O
kinase	O
II	O
,	O
phospho	B
-	O
protein	O
kinase	O
A	O
Catalytic	O
subunit	O
,	O
protein	O
kinase	O
C	O
subunit	O
,	O
phospho	B
-	O
CREB	O
and	O
brain	O
derived	O
neurotrophic	O
factor	O
.	O

Furthermore	O
,	O
AHS	O
increased	O
the	O
levels	O
of	O
acetylcholine	B
(	O
Ach	B
)	O
,	O
but	O
decreased	O
cholinesterase	O
(	O
AchE	O
)	O
activity	O
.	O

These	O
results	O
demonstrated	O
that	O
AHS	O
administration	O
may	O
prevent	O
spatial	O
learning	O
and	O
memory	O
decline	O
by	O
scavenging	O
free	O
radicals	O
,	O
up	O
-	O
regulating	O
the	O
activity	O
of	O
antioxidant	O
enzymes	O
,	O
decreasing	O
the	O
level	O
of	O
A	O
,	O
ameliorating	O
dysfunction	O
in	O
synaptic	O
plasticity	O
,	O
and	O
reversing	O
abnormal	O
changes	O
in	O
Ach	B
level	O
and	O
AchE	O
activity	O
.	O

Thus	O
,	O
AHS	O
should	O
be	O
developed	O
as	O
a	O
new	O
drug	O
to	O
prevent	O
age	O
-	O
related	O
cognitive	O
deficits	O
.	O

Bioreducible	O
alginate	O
-	O
poly	B
(	I
ethylenimine	I
)	I
nanogels	O
as	O
an	O
antigen	O
-	O
delivery	O
system	O
robustly	O
enhance	O
vaccine	O
-	O
elicited	O
humoral	O
and	O
cellular	O
immune	O
responses	O
.	O

Although	O
polysaccharide	O
nanogels	O
have	O
emerged	O
as	O
a	O
novel	O
antigen	O
delivery	O
system	O
for	O
vaccine	O
development	O
,	O
whether	O
modulating	O
the	O
redox	O
sensitivity	O
of	O
nanogels	O
could	O
improve	O
vaccine	O
efficacy	O
remains	O
unclear	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
generated	O
bioreducible	O
cationic	O
alginate	O
-	O
polyethylenimine	B
(	O
PEI	B
)	O
nanogels	O
as	O
a	O
novel	O
vaccine	O
delivery	O
system	O
.	O

Briefly	O
,	O
nanogels	O
were	O
prepared	O
by	O
the	O
electrostatic	O
interaction	O
of	O
negatively	O
charged	O
alginate	O
sodium	B
with	O
branched	O
PEI2k	O
,	O
followed	O
by	O
disulfide	B
cross	O
-	O
linking	O
to	O
generate	O
bioreducible	O
nanogels	O
(	O
AP	O
-	O
SS	O
)	O
.	O

The	O
AP	O
-	O
SS	O
nanogels	O
demonstrated	O
great	O
antigen	O
-	O
loading	O
capacity	O
and	O
minimal	O
cytotoxicity	O
.	O

The	O
in	O
vitro	O
study	O
showed	O
that	O
reducible	O
AP	O
-	O
SS	O
nanogels	O
not	O
only	O
facilitated	O
antigen	O
uptake	O
by	O
mouse	O
bone	O
marrow	O
dendritic	O
cells	O
(	O
BMDCs	O
)	O
,	O
but	O
also	O
promoted	O
intracellular	O
antigen	O
degradation	O
and	O
cytosolic	O
release	O
.	O

Moreover	O
,	O
AP	O
-	O
SS	O
nanogels	O
significantly	O
enhanced	O
both	O
MHC	O
class	O
I	O
and	O
II	O
antigen	O
presentation	O
by	O
BMDCs	O
.	O

Compared	O
with	O
the	O
non	O
-	O
reducible	O
nanogels	O
,	O
AP	O
-	O
SS	O
nanogels	O
more	O
potently	O
enhanced	O
vaccine	O
-	O
induced	O
antibody	O
production	O
and	O
CD8	O
(	O
+	O
)	O
T	O
cell	O
-	O
mediated	O
tumor	O
cell	O
lysis	O
.	O

Hence	O
,	O
the	O
bioreducible	O
alginate	O
-	O
PEI	O
nanogels	O
could	O
serve	O
as	O
a	O
potent	O
adjuvant	O
to	O
improve	O
vaccine	O
-	O
elicited	O
humoral	O
and	O
cellular	O
immune	O
responses	O
.	O

A	O
protocol	O
for	O
the	O
classification	O
of	O
wet	O
mass	O
in	O
extrusion	O
-	O
spheronization	O
.	O

In	O
this	O
study	O
,	O
a	O
structured	O
protocol	O
for	O
the	O
classification	O
of	O
wet	O
mass	O
in	O
extrusion	O
-	O
spheronization	O
was	O
developed	O
to	O
predict	O
formation	O
and	O
pellet	O
quality	O
.	O

The	O
wet	O
masses	O
of	O
120	O
formulae	O
were	O
prepared	O
taking	O
microcrystalline	O
celluloses	O
as	O
pelletization	O
aid	O
and	O
lactose	B
,	O
hydroxypropyl	B
methylcellulose	O
grades	O
,	O
herbal	O
medicines	O
as	O
model	O
drugs	O
.	O

Physical	O
properties	O
of	O
the	O
wet	O
masses	O
such	O
as	O
hardness	O
,	O
adhesiveness	O
,	O
springiness	O
,	O
cohesiveness	O
,	O
chewiness	O
,	O
and	O
resilience	O
were	O
tested	O
,	O
respectively	O
,	O
using	O
a	O
texture	O
analyzer	O
.	O

Particles	O
were	O
produced	O
by	O
spheronization	O
process	O
,	O
and	O
the	O
quality	O
of	O
spherical	O
pellets	O
was	O
also	O
evaluated	O
.	O

Data	O
were	O
analyzed	O
by	O
principal	O
component	O
analysis	O
,	O
factor	O
analysis	O
,	O
and	O
classification	O
analysis	O
.	O

The	O
wet	O
masses	O
could	O
be	O
classified	O
into	O
five	O
groups	O
taking	O
the	O
ratio	O
of	O
hardness	O
to	O
springiness	O
(	O
Ha	O
/	O
Sp	O
)	O
as	O
the	O
first	O
classification	O
index	O
and	O
chewiness	O
,	O
resilience	O
as	O
the	O
second	O
and	O
the	O
third	O
classification	O
index	O
.	O

The	O
wet	O
masses	O
of	O
different	O
classification	O
could	O
correspondingly	O
form	O
the	O
different	O
shapes	O
.	O

So	O
,	O
a	O
new	O
protocol	O
could	O
be	O
devised	O
,	O
for	O
example	O
,	O
if	O
the	O
range	O
of	O
Ha	O
/	O
Sp	O
of	O
the	O
wet	O
masses	O
was	O
30,992	O
-	O
47,689	O
g	O
,	O
at	O
the	O
same	O
time	O
,	O
the	O
value	O
of	O
chewiness	O
was	O
less	O
than	O
4842	O
,	O
and	O
the	O
value	O
of	O
resilience	O
was	O
no	O
more	O
than	O
0.139	O
;	O
it	O
would	O
form	O
spherical	O
pellets	O
under	O
the	O
experimental	O
condition	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
proposed	O
protocol	O
could	O
be	O
a	O
valuable	O
asset	O
in	O
a	O
formulation	O
development	O
project	O
to	O
assess	O
the	O
physical	O
properties	O
of	O
wet	O
masses	O
and	O
to	O
predict	O
formation	O
and	O
pellet	O
quality	O
.	O

So	O
,	O
the	O
tedious	O
and	O
expensive	O
pre	O
-	O
production	O
(	O
pre	O
-	O
formulation	O
and	O
optimization	O
)	O
work	O
could	O
be	O
considerably	O
reduced	O
.	O

Assessing	O
triclosan	B
-	O
induced	O
ecological	O
and	O
trans	O
-	O
generational	O
effects	O
in	O
natural	O
phytoplankton	O
communities	O
:	O
a	O
trait	O
-	O
based	O
field	O
method	O
.	O

We	O
exposed	O
replicated	O
phytoplankton	O
communities	O
confined	O
in	O
semi	O
-	O
permeable	O
membrane	O
-	O
based	O
mesocosms	O
to	O
0	O
,	O
0.1	O
,	O
1	O
and	O
10	O
g	O
L	O
(	O
-1	O
)	O
triclosan	B
(	O
TCS	B
)	O
and	O
placed	O
them	O
back	O
in	O
their	O
original	O
environment	O
to	O
investigate	O
the	O
occurrence	O
of	O
trans	O
-	O
generational	O
responses	O
at	O
individual	O
,	O
population	O
and	O
community	O
levels	O
.	O

TCS	B
diffused	O
out	O
of	O
mesocosms	O
with	O
a	O
half	O
-	O
life	O
of	O
less	O
than	O
8	O
h	O
,	O
so	O
that	O
only	O
the	O
parental	O
generation	O
was	O
directly	O
stressed	O
.	O

At	O
the	O
beginning	O
of	O
the	O
experiment	O
and	O
after	O
7	O
days	O
(	O
approximately	O
2	O
generations	O
)	O
we	O
analysed	O
responses	O
in	O
the	O
phytoplankton	O
using	O
scanning	O
flow	O
-	O
cytometry	O
.	O

We	O
acquired	O
information	O
on	O
several	O
individually	O
expressed	O
phenotypic	O
traits	O
,	O
such	O
as	O
size	O
,	O
biovolume	O
,	O
pigment	O
fluorescence	O
and	O
packaging	O
,	O
for	O
thousands	O
of	O
individuals	O
per	O
replicated	O
population	O
and	O
derived	O
population	O
and	O
community	O
aggregated	O
traits	O
.	O

We	O
found	O
significant	O
changes	O
in	O
community	O
functioning	O
(	O
increased	O
productivity	O
in	O
terms	O
of	O
biovolume	O
and	O
total	O
fluorescence	O
)	O
,	O
with	O
maximal	O
effects	O
at	O
1	O
g	O
L	O
(	O
-1	O
)	O
TCS	B
.	O

We	O
detected	O
significant	O
and	O
dose	O
-	O
dependent	O
responses	O
on	O
population	O
traits	O
,	O
such	O
as	O
changes	O
in	O
abundance	O
for	O
several	O
populations	O
,	O
increased	O
average	O
size	O
and	O
fluorescence	O
of	O
cells	O
,	O
and	O
strong	O
changes	O
in	O
within	O
-	O
population	O
trait	O
mean	O
and	O
variance	O
(	O
suggesting	O
micro	O
-	O
evolutionary	O
effects	O
)	O
.	O

We	O
applied	O
the	O
Price	O
equation	O
approach	O
to	O
partition	O
community	O
effects	O
(	O
changes	O
in	O
biovolume	O
or	O
fluorescence	O
)	O
in	O
their	O
physiological	O
and	O
ecological	O
components	O
,	O
and	O
quantified	O
the	O
residual	O
component	O
(	O
including	O
also	O
evolutionary	O
responses	O
)	O
.	O

Our	O
results	O
suggested	O
that	O
evolutionary	O
or	O
inheritable	O
phenotypic	O
plasticity	O
responses	O
may	O
represent	O
a	O
significant	O
component	O
of	O
the	O
total	O
observed	O
change	O
following	O
exposure	O
and	O
over	O
relatively	O
small	O
temporal	O
scales	O
.	O

Human	O
Precision	O
-	O
Cut	O
Liver	O
Slices	O
as	O
an	O
ex	O
Vivo	O
Model	O
to	O
Study	O
Idiosyncratic	O
Drug	O
-	O
Induced	O
Liver	O
Injury	O
.	O

Idiosyncratic	O
drug	O
-	O
induced	O
liver	O
injury	O
(	O
IDILI	O
)	O
is	O
a	O
major	O
problem	O
during	O
drug	O
development	O
and	O
has	O
caused	O
drug	O
withdrawal	O
and	O
black	O
-	O
box	O
warnings	O
.	O

Because	O
of	O
the	O
low	O
concordance	O
of	O
the	O
hepatotoxicity	O
of	O
drugs	O
in	O
animals	O
and	O
humans	O
,	O
robust	O
screening	O
methods	O
using	O
human	O
tissue	O
are	O
needed	O
to	O
predict	O
IDILI	O
in	O
humans	O
.	O

According	O
to	O
the	O
inflammatory	O
stress	O
hypothesis	O
,	O
the	O
effects	O
of	O
inflammation	O
interact	O
with	O
the	O
effects	O
of	O
a	O
drug	O
or	O
its	O
reactive	O
metabolite	O
,	O
precipitating	O
toxic	O
reactions	O
in	O
the	O
liver	O
.	O

As	O
a	O
follow	O
-	O
up	O
to	O
our	O
recently	O
published	O
mouse	O
precision	O
-	O
cut	O
liver	O
slices	O
model	O
,	O
an	O
ex	O
vivo	O
model	O
involving	O
human	O
precision	O
-	O
cut	O
liver	O
slices	O
(	O
hPCLS	O
)	O
,	O
co	O
-	O
incubated	O
for	O
24	O
h	O
with	O
IDILI	O
-	O
related	O
drugs	O
and	O
lipopolysaccharide	O
(	O
LPS	O
)	O
,	O
was	O
developed	O
to	O
study	O
IDILI	O
mechanisms	O
related	O
to	O
inflammatory	O
stress	O
in	O
humans	O
and	O
to	O
detect	O
potential	O
biomarkers	O
.	O

LPS	O
exacerbated	O
the	O
effects	O
of	O
ketoconazole	B
and	O
clozapine	B
toxicity	O
but	O
not	O
those	O
of	O
their	O
non	O
-	O
IDILI	O
-	O
related	O
comparators	O
,	O
voriconazole	B
and	O
olanzapine	B
.	O

However	O
,	O
the	O
IDILI	O
-	O
related	O
drugs	O
diclofenac	B
,	O
carbamazepine	B
,	O
and	O
troglitazone	B
did	O
not	O
show	O
synergistic	O
toxicity	O
with	O
LPS	O
after	O
incubation	O
for	O
24	O
h.	O
Co	O
-	O
incubation	O
of	O
ketoconazole	B
and	O
clozapine	B
with	O
LPS	O
decreased	O
the	O
levels	O
of	O
glutathione	B
in	O
hPCLS	O
,	O
but	O
this	O
was	O
not	O
seen	O
for	O
the	O
other	O
drugs	O
.	O

All	O
drugs	O
affected	O
LPS	O
-	O
induced	O
cytokine	O
release	O
,	O
but	O
interestingly	O
,	O
only	O
ketoconazole	B
and	O
clozapine	B
increased	O
the	O
level	O
of	O
LPS	O
-	O
induced	O
TNF	O
release	O
.	O

Decreased	O
levels	O
of	O
glutathione	B
and	O
cysteine	B
conjugates	O
of	O
clozapine	B
were	O
detected	O
in	O
IDILI	O
-	O
responding	O
livers	O
following	O
cotreatment	O
with	O
LPS	O
.	O

In	O
conclusion	O
,	O
we	O
identified	O
ketoconazole	B
and	O
clozapine	B
as	O
drugs	O
that	O
exhibited	O
synergistic	O
toxicity	O
with	O
LPS	O
,	O
while	O
glutathione	B
and	O
TNF	O
were	O
found	O
to	O
be	O
potential	O
biomarkers	O
for	O
IDILI	O
-	O
inducing	O
drugs	O
mediated	O
by	O
inflammatory	O
stress	O
.	O

hPCLS	O
appear	O
to	O
be	O
suitable	O
for	O
further	O
unraveling	O
the	O
mechanisms	O
of	O
inflammatory	O
stress	O
-	O
associated	O
IDILI	O
.	O

Controlling	O
the	O
Effective	O
Surface	O
Area	O
and	O
Pore	O
Size	O
Distribution	O
of	O
sp	O
(	O
2	O
)	O
Carbon	B
Materials	O
and	O
Their	O
Impact	O
on	O
the	O
Capacitance	O
Performance	O
of	O
These	O
Materials	O
.	O

A	O
series	O
of	O
sp	O
(	O
2	O
)	O
carbon	B
materials	O
with	O
different	O
specific	O
surface	O
area	O
(	O
SSA	O
)	O
and	O
controlled	O
pore	O
size	O
distribution	O
(	O
PSD	O
)	O
were	O
synthesized	O
at	O
large	O
scale	O
through	O
a	O
facile	O
and	O
low	O
-	O
cost	O
method	O
.	O

The	O
SSA	O
and	O
PSD	O
of	O
these	O
carbon	B
materials	O
were	O
controlled	O
by	O
using	O
different	O
carbon	B
sources	O
and	O
preparation	O
methods	O
.	O

With	O
different	O
total	O
and	O
effective	O
SSA	O
(	O
E	O
-	O
SSA	O
)	O
and	O
PSD	O
,	O
the	O
impacts	O
on	O
their	O
capacitance	O
performance	O
were	O
investigated	O
thoroughly	O
,	O
which	O
demonstrated	O
that	O
both	O
E	O
-	O
SSA	O
and	O
PSD	O
played	O
the	O
most	O
important	O
roles	O
in	O
their	O
capacitance	O
performance	O
.	O

Furthermore	O
,	O
theoretical	O
modeling	O
was	O
performed	O
,	O
and	O
the	O
results	O
are	O
in	O
agreement	O
with	O
the	O
experimental	O
results	O
for	O
the	O
influence	O
of	O
E	O
-	O
SSA	O
and	O
PSD	O
on	O
their	O
capacitance	O
performance	O
.	O

Based	O
on	O
these	O
,	O
a	O
general	O
model	O
using	O
the	O
slit	O
/	O
cylindrical	O
NL	O
-	O
DFT	O
approach	O
is	O
proposed	O
for	O
the	O
estimation	O
of	O
the	O
specific	O
capacitance	O
of	O
sp	O
(	O
2	O
)	O
carbon	B
materials	O
,	O
which	O
offers	O
a	O
simple	O
but	O
reliable	O
method	O
to	O
predict	O
the	O
capacitance	O
performance	O
of	O
these	O
materials	O
,	O
thus	O
speeding	O
up	O
the	O
design	O
and	O
screening	O
of	O
the	O
materials	O
for	O
high	O
-	O
performance	O
supercapacitor	O
and	O
other	O
surface	O
area	O
related	O
devices	O
.	O

Approach	O
to	O
dark	O
spin	O
cooling	O
in	O
a	O
diamond	B
nanocrystal	O
.	O

Using	O
a	O
Hartman	O
-	O
Hahn	O
protocol	O
,	O
we	O
demonstrate	O
spin	O
polarization	O
transfer	O
from	O
a	O
single	O
,	O
optically	O
polarized	O
nitrogen	B
-	O
vacancy	O
(	O
NV	O
)	O
center	O
to	O
the	O
ensemble	O
of	O
paramagnetic	O
defects	O
hosted	O
by	O
an	O
individual	O
diamond	B
nanocrystal	O
.	O

Owing	O
to	O
the	O
strong	O
NV	O
-	O
bath	O
coupling	O
,	O
the	O
transfer	O
takes	O
place	O
on	O
a	O
short	O
,	O
microsecond	O
time	O
scale	O
.	O

Upon	O
fast	O
repetition	O
of	O
the	O
pulse	O
sequence	O
,	O
we	O
observe	O
strong	O
polarization	O
transfer	O
blockade	O
,	O
which	O
we	O
interpret	O
as	O
an	O
indication	O
of	O
spin	O
bath	O
cooling	O
.	O

Numerical	O
simulations	O
indicate	O
that	O
the	O
spin	O
bath	O
polarization	O
is	O
nonuniform	O
throughout	O
the	O
nanoparticle	O
,	O
averaging	O
approximately	O
5	O
%	O
over	O
the	O
crystal	O
volume	O
,	O
but	O
reaching	O
up	O
to	O
25	O
%	O
in	O
the	O
immediate	O
vicinity	O
of	O
the	O
NV	O
.	O

These	O
observations	O
may	O
prove	O
relevant	O
to	O
the	O
planning	O
of	O
future	O
bath	O
-	O
assisted	O
magnetometry	O
tests	O
.	O

The	O
role	O
of	O
intracrine	O
androgen	B
metabolism	O
,	O
androgen	B
receptor	O
and	O
apoptosis	O
in	O
the	O
survival	O
and	O
recurrence	O
of	O
prostate	O
cancer	O
during	O
androgen	B
deprivation	O
therapy	O
.	O

Prostate	O
cancer	O
(	O
CaP	O
)	O
is	O
the	O
most	O
frequently	O
diagnosed	O
cancer	O
and	O
leading	O
cause	O
of	O
cancer	O
death	O
in	O
American	O
men	O
.	O

Almost	O
all	O
men	O
present	O
with	O
advanced	O
CaP	O
and	O
some	O
men	O
who	O
fail	O
potentially	O
curative	O
therapy	O
are	O
treated	O
with	O
androgen	B
deprivation	O
therapy	O
(	O
ADT	O
)	O
.	O

ADT	O
is	O
not	O
curative	O
and	O
CaP	O
recurs	O
as	O
the	O
lethal	O
phenotype	O
.	O

The	O
goal	O
of	O
this	O
review	O
is	O
to	O
apply	O
our	O
current	O
understanding	O
of	O
CaP	O
and	O
castration	O
-	O
recurrent	O
CaP	O
(	O
CR	O
-	O
CaP	O
)	O
to	O
earlier	O
studies	O
that	O
characterized	O
ADT	O
and	O
the	O
molecular	O
mechanisms	O
that	O
facilitate	O
the	O
transition	O
from	O
androgen	B
-	O
stimulated	O
CaP	O
to	O
CR	O
-	O
CaP.	O
Reexamination	O
of	O
earlier	O
studies	O
also	O
may	O
provide	O
a	O
better	O
understanding	O
of	O
how	O
more	O
newly	O
recognized	O
mechanisms	O
,	O
such	O
as	O
intracrine	O
metabolism	O
,	O
may	O
be	O
involved	O
with	O
the	O
early	O
events	O
that	O
allow	O
CaP	O
survival	O
after	O
initiation	O
of	O
ADT	O
and	O
subsequent	O
development	O
of	O
CR	O
-	O
CaP.	O

Real	O
-	O
time	O
evaluation	O
of	O
binding	O
mechanisms	O
in	O
multivalent	O
interactions	O
:	O
a	O
surface	O
plasmon	O
resonance	O
kinetic	O
approach	O
.	O

Multivalency	O
is	O
a	O
key	O
,	O
ubiquitous	O
phenomenon	O
in	O
nature	O
characterized	O
by	O
a	O
complex	O
combination	O
of	O
binding	O
mechanisms	O
,	O
with	O
special	O
relevance	O
in	O
carbohydrate	B
-	O
lectin	O
recognition	O
.	O

Herein	O
we	O
introduce	O
an	O
original	O
surface	O
plasmon	O
resonance	O
kinetic	O
approach	O
to	O
analyze	O
multivalent	O
interactions	O
that	O
has	O
been	O
validated	O
with	O
dendrimers	O
as	O
monodisperse	O
multivalent	O
analytes	O
binding	O
to	O
lectin	O
clusters	O
.	O

The	O
method	O
,	O
based	O
on	O
the	O
analysis	O
of	O
early	O
association	O
and	O
late	O
dissociation	O
phases	O
of	O
the	O
sensorgrams	O
provides	O
robust	O
information	O
of	O
the	O
glycoconjugate	O
binding	O
efficiency	O
and	O
real	O
-	O
time	O
structural	O
data	O
of	O
the	O
binding	O
events	O
under	O
the	O
complex	O
scenario	O
of	O
the	O
glyco	O
-	O
cluster	O
effect	O
.	O

Notably	O
,	O
it	O
reveals	O
the	O
dynamic	O
nature	O
of	O
the	O
interaction	O
and	O
offers	O
experimental	O
evidence	O
on	O
the	O
contribution	O
of	O
binding	O
mechanisms	O
.	O

Enhancing	O
Catalytic	O
Performance	O
of	O
Palladium	B
in	O
Gold	O
and	O
Palladium	B
Alloy	O
Nanoparticles	O
for	O
Organic	O
Synthesis	O
Reactions	O
through	O
Visible	O
Light	O
Irradiation	O
at	O
Ambient	O
Temperatures	O
.	O

The	O
intrinsic	O
catalytic	O
activity	O
of	O
palladium	B
(	O
Pd	B
)	O
is	O
significantly	O
enhanced	O
in	O
gold	O
(	O
Au	B
)	O
-Pd	O
alloy	O
nanoparticles	O
(	O
NPs	O
)	O
under	O
visible	O
light	O
irradiation	O
at	O
ambient	O
temperatures	O
.	O

The	O
alloy	O
NPs	O
strongly	O
absorb	O
light	O
and	O
efficiently	O
enhance	O
the	O
conversion	O
of	O
several	O
reactions	O
,	O
including	O
Suzuki	O
-	O
Miyaura	O
cross	O
coupling	O
,	O
oxidative	O
addition	O
of	O
benzylamine	B
,	O
selective	O
oxidation	O
of	O
aromatic	B
alcohols	I
to	O
corresponding	O
aldehydes	B
and	O
ketones	B
,	O
and	O
phenol	B
oxidation	O
.	O

The	O
Au	B
/	O
Pd	B
molar	O
ratio	O
of	O
the	O
alloy	O
NPs	O
has	O
an	O
important	O
impact	O
on	O
performance	O
of	O
the	O
catalysts	O
since	O
it	O
determines	O
both	O
the	O
electronic	O
heterogeneity	O
and	O
the	O
distribution	O
of	O
Pd	B
sites	O
at	O
the	O
NP	O
surface	O
,	O
with	O
these	O
two	O
factors	O
playing	O
key	O
roles	O
in	O
the	O
catalytic	O
activity	O
.	O

Irradiating	O
with	O
light	O
produces	O
an	O
even	O
more	O
profound	O
enhancement	O
in	O
the	O
catalytic	O
performance	O
of	O
the	O
NPs	O
.	O

For	O
example	O
,	O
the	O
best	O
conversion	O
rate	O
achieved	O
thermally	O
at	O
30	O
	O
C	O
for	O
Suzuki	O
-	O
Miyaura	O
cross	O
coupling	O
was	O
37	O
%	O
at	O
a	O
Au	B
/	O
Pd	B
ratio	O
of	O
1:1.86	O
,	O
while	O
under	O
light	O
illumination	O
the	O
yield	O
increased	O
to	O
96	O
%	O
under	O
the	O
same	O
conditions	O
.	O

The	O
catalytic	O
activity	O
of	O
the	O
alloy	O
NPs	O
depends	O
on	O
the	O
intensity	O
and	O
wavelength	O
of	O
incident	O
light	O
.	O

Light	O
absorption	O
due	O
to	O
the	O
Localized	O
Surface	O
Plasmon	O
Resonance	O
of	O
gold	O
nanocrystals	O
plays	O
an	O
important	O
role	O
in	O
enhancing	O
catalyst	O
performance	O
.	O

We	O
believe	O
that	O
the	O
conduction	O
electrons	O
of	O
the	O
NPs	O
gain	O
the	O
light	O
absorbed	O
energy	O
producing	O
energetic	O
electrons	O
at	O
the	O
surface	O
Pd	B
sites	O
,	O
which	O
enhances	O
the	O
sites	O
'	O
intrinsic	O
catalytic	O
ability	O
.	O

These	O
findings	O
provide	O
useful	O
guidelines	O
for	O
designing	O
efficient	O
catalysts	O
composed	O
of	O
alloys	O
of	O
a	O
plasmonic	O
metal	O
and	O
a	O
catalytically	O
active	O
transition	B
metal	I
for	O
various	O
organic	O
syntheses	O
driven	O
by	O
sunlight	O
.	O

Effects	O
of	O
Curcumin	B
on	O
Apoptosis	O
and	O
Oxidoinflammatory	O
Regulation	O
in	O
a	O
Rat	O
Model	O
of	O
Acetic	B
Acid	I
-	O
Induced	O
Colitis	O
:	O
The	O
Roles	O
of	O
c	O
-	O
Jun	O
N	B
-	O
Terminal	O
Kinase	O
and	O
p38	O
Mitogen	O
-	O
Activated	O
Protein	O
Kinase	O
.	O

Abstract	O
The	O
present	O
study	O
evaluated	O
the	O
effects	O
of	O
curcumin	B
on	O
epithelial	O
cell	O
apoptosis	O
,	O
the	O
immunoreactivity	O
of	O
the	O
phospho	O
-	O
c	O
-	O
Jun	O
N	O
-	O
terminal	O
kinase	O
(	O
JNK	O
)	O
and	O
phospho	O
-	O
p38	O
mitogen	O
-	O
activated	O
protein	O
kinases	O
(	O
MAPKs	O
)	O
in	O
inflamed	O
colon	O
mucosa	O
,	O
and	O
oxidative	O
stress	O
in	O
a	O
rat	O
model	O
of	O
ulcerative	O
colitis	O
induced	O
by	O
acetic	B
acid	I
.	O

Rats	O
were	O
randomly	O
divided	O
into	O
three	O
groups	O
:	O
control	O
,	O
acetic	B
acid	I
,	O
and	O
acetic	B
acid+curcumin	I
.	O

Curcumin	B
(	O
100	O
mg	O
/	O
kg	O
per	O
day	O
,	O
intragastrically	O
)	O
was	O
administered	O
10	O
days	O
before	O
the	O
induction	O
of	O
colitis	O
and	O
was	O
continued	O
for	O
two	O
additional	O
days	O
.	O

Acetic	B
acid	I
-	O
induced	O
colitis	O
caused	O
a	O
significant	O
increase	O
in	O
the	O
macroscopic	O
and	O
microscopic	O
tissue	O
ranking	O
scores	O
as	O
well	O
as	O
an	O
elevation	O
in	O
colonic	O
myeloperoxidase	O
(	O
MPO	O
)	O
activity	O
,	O
malondialdehyde	B
(	O
MDA	B
)	O
levels	O
,	O
and	O
the	O
number	O
of	O
apoptotic	O
epithelial	O
cells	O
in	O
colon	O
tissue	O
compared	O
to	O
controls	O
.	O

In	O
the	O
rat	O
colon	O
,	O
immunoreactivity	O
of	O
phospho	O
-	O
p38	O
MAPK	O
was	O
increased	O
,	O
whereas	O
the	O
phospho	O
-	O
JNK	O
activity	O
was	O
decreased	O
following	O
the	O
induction	O
of	O
colitis	O
.	O

Curcumin	B
treatment	O
was	O
associated	O
with	O
amelioration	O
of	O
macroscopic	O
and	O
microscopic	O
colitis	O
sores	O
,	O
decreased	O
MPO	O
activity	O
,	O
and	O
decreased	O
MDA	B
levels	O
in	O
acetic	B
acid	I
-	O
induced	O
colitis	O
.	O

Furthermore	O
,	O
oral	O
curcumin	B
supplementation	O
clearly	O
prevented	O
programmed	O
cell	O
death	O
and	O
restored	O
immunreactivity	O
of	O
MAPKs	O
in	O
the	O
colons	O
of	O
colitic	O
rats	O
.	O

The	O
results	O
of	O
this	O
study	O
suggest	O
that	O
oral	O
curcumin	B
treatment	O
decreases	O
colon	O
injury	O
and	O
is	O
associated	O
with	O
decreased	O
inflammatory	O
reactions	O
,	O
lipid	O
peroxidation	O
,	O
apoptotic	O
cell	O
death	O
,	O
and	O
modulating	O
p38-	O
and	O
JNK	O
-	O
MAPK	O
pathways	O
.	O

Oligonol	O
supplementation	O
attenuates	O
body	O
temperature	O
and	O
the	O
circulating	O
levels	O
of	O
prostaglandin	B
e2	I
and	O
cyclooxygenase-2	O
after	O
heat	O
stress	O
in	O
humans	O
.	O

Abstract	O
Oligonol	O
,	O
a	O
phenolic	B
production	O
from	O
lychee	O
,	O
has	O
been	O
reported	O
to	O
exhibit	O
anti	O
-	O
oxidative	O
and	O
anti	O
-	O
inflammatory	O
effects	O
.	O

This	O
study	O
investigated	O
the	O
effect	O
of	O
Oligonol	O
supplementation	O
on	O
circulating	O
levels	O
of	O
prostaglandin	B
E2	I
(	O
PGE2	B
)	O
and	O
cyclooxygenase	O
(	O
COX	O
)	O
-2	O
,	O
as	O
well	O
as	O
body	O
temperature	O
,	O
after	O
heat	O
stress	O
in	O
17	O
healthy	O
human	O
male	O
volunteers	O
(	O
age	O
,	O
21.62.1	O
years	O
)	O
.	O

All	O
experiments	O
were	O
performed	O
in	O
an	O
automated	O
climate	O
chamber	O
(	O
26.0	O
	O
C0.5	O
	O
C	O
,	O
relative	O
humidity	O
60%3.0	O
%	O
,	O
air	O
velocity	O
less	O
than	O
1	O
m	O
/	O
sec	O
)	O
between	O
2	O
and	O
5	O
p.m.	O
Subjects	O
ingested	O
an	O
Oligonol	O
(	O
100	O
mg	O
)	O
-containing	O
beverage	O
or	O
placebo	O
beverage	O
before	O
half	O
-	O
body	O
immersion	O
into	O
hot	O
water	O
(	O
42	O
	O
C0.5	O
	O
C	O
for	O
30	O
min	O
)	O
.	O

Tympanic	O
and	O
skin	O
temperatures	O
were	O
measured	O
and	O
mean	O
body	O
temperatures	O
were	O
calculated	O
.	O

Serum	O
concentrations	O
of	O
PGE2	B
and	O
COX-2	O
were	O
analyzed	O
before	O
,	O
immediately	O
after	O
,	O
and	O
60	O
min	O
after	O
immersion	O
.	O

Oligonol	O
intake	O
significantly	O
prevented	O
elevation	O
of	O
tympanic	O
(	O
temperature	O
difference	O
:	O
0.17	O
	O
C	O
at	O
Post	O
,	O
P<.05	O
;	O
0.17	O
	O
C	O
at	O
Re-60	O
,	O
P<.05	O
)	O
and	O
mean	O
body	O
temperatures	O
(	O
temperature	O
difference	O
:	O
0.18	O
	O
C	O
at	O
Post	O
,	O
P<.05	O
;	O
0.15	O
	O
C	O
at	O
Re-60	O
,	O
P<.05	O
)	O
,	O
and	O
lowered	O
concentrations	O
of	O
serum	O
PGE2	B
(	O
increased	O
by	O
13.3	O
%	O
vs.	O
29.6	O
%	O
at	O
Post	O
,	O
P<.05	O
)	O
and	O
COX-2	O
(	O
increased	O
by	O
15.6	O
%	O
vs.	O
21.8	O
%	O
at	O
Post	O
,	O
P<.05	O
)	O
,	O
compared	O
to	O
placebo	O
beverage	O
.	O

Our	O
result	O
suggests	O
that	O
Oligonol	O
has	O
the	O
potential	O
to	O
suppress	O
increases	O
in	O
body	O
temperature	O
under	O
heat	O
stress	O
,	O
and	O
this	O
is	O
associated	O
with	O
decreases	O
in	O
serum	O
levels	O
of	O
PGE2	B
and	O
COX-2	O
.	O

Flaxseed	O
-	O
derived	O
enterolactone	B
is	O
inversely	O
associated	O
with	O
tumor	O
cell	O
proliferation	O
in	O
men	O
with	O
localized	O
prostate	O
cancer	O
.	O

Abstract	O
Enterolactone	B
and	O
enterodiol	B
,	O
mammalian	O
lignans	B
derived	O
from	O
dietary	O
sources	O
such	O
as	O
flaxseed	O
,	O
sesame	O
seeds	O
,	O
kale	O
,	O
broccoli	O
,	O
and	O
apricots	O
,	O
may	O
impede	O
tumor	O
proliferation	O
by	O
inhibiting	O
activation	O
of	O
nuclear	O
factor	O
kappa	O
B	O
(	O
NFB	O
)	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
.	O

We	O
examined	O
the	O
associations	O
between	O
urinary	O
enterolactone	B
and	O
enterodiol	B
with	O
prostatic	O
tumor	O
expression	O
of	O
NFB	O
,	O
VEGF	O
,	O
and	O
Ki67	O
among	O
147	O
patients	O
with	O
prostate	O
cancer	O
who	O
participated	O
in	O
a	O
presurgical	O
trial	O
of	O
flaxseed	O
supplementation	O
(	O
30	O
g	O
/	O
day	O
)	O
for	O
30	O
days	O
.	O

Urinary	O
enterolignans	B
and	O
tissue	O
biomarkers	O
were	O
determined	O
by	O
high	O
-	O
performance	O
liquid	O
chromatography	O
and	O
immunohistochemistry	O
,	O
respectively	O
.	O

After	O
supplementation	O
,	O
we	O
observed	O
significant	O
correlations	O
between	O
intakes	O
of	O
plant	O
lignan	B
and	O
urinary	O
concentrations	O
of	O
total	O
enterolignans	B
(	O
=0.677	O
,	O
P<.0001	O
)	O
,	O
enterolactone	B
(	O
=0.676	O
,	O
P<.0001	O
)	O
,	O
and	O
enterodiol	B
(	O
=0.628	O
,	O
P<.0001	O
)	O
.	O

Importantly	O
,	O
we	O
observed	O
that	O
total	O
urinary	O
enterolignans	B
and	O
enterolactone	B
were	O
significantly	O
and	O
inversely	O
correlated	O
with	O
Ki67	O
in	O
the	O
tumor	O
tissue	O
(	O
=-0.217	O
,	O
P=.011	O
,	O
and	O
=-0.230	O
,	O
P=.007	O
,	O
respectively	O
)	O
,	O
and	O
a	O
near	O
-	O
significant	O
inverse	O
association	O
was	O
observed	O
for	O
enterodiol	B
(	O
=-0.159	O
,	O
P=.064	O
)	O
.	O

An	O
inverse	O
association	O
was	O
observed	O
between	O
enterolactone	B
and	O
VEGF	O
(	O
=-0.143	O
,	O
P=.141	O
)	O
,	O
although	O
this	O
did	O
not	O
reach	O
statistical	O
significance	O
.	O

We	O
did	O
not	O
observe	O
an	O
association	O
between	O
enterolignans	B
and	O
NFB.	O
In	O
conclusion	O
,	O
flaxseed	O
-	O
derived	O
enterolignans	B
may	O
hinder	O
cancer	O
cell	O
proliferation	O
via	O
VEGF	O
-	O
associated	O
pathways	O
.	O

Lyophilization	O
of	O
a	O
triply	O
unsaturated	O
phospholipid	O
:	O
Effects	O
of	O
trace	O
metal	O
contaminants	O
.	O

As	O
liquid	O
liposomal	O
formulations	O
are	O
prone	O
to	O
chemical	O
degradation	O
and	O
aggregation	O
,	O
these	O
formulations	O
often	O
require	O
freeze	O
drying	O
(	O
e.g.	O
,	O
lyophilization	O
)	O
to	O
achieve	O
sufficient	O
shelf	O
-	O
life	O
.	O

However	O
,	O
liposomal	O
formulations	O
may	O
undergo	O
oxidation	O
during	O
lyophilization	O
and/or	O
during	O
prolonged	O
storage	O
.	O

The	O
goal	O
of	O
the	O
current	O
study	O
was	O
to	O
characterize	O
the	O
degradation	O
of	O
1,2-dilinolenoyl	B
-	I
sn	I
-	I
glycero-3-phosphocholine	I
(	O
DLPC	B
)	O
during	O
lyophilization	O
and	O
to	O
also	O
probe	O
the	O
influence	O
of	O
metal	O
contaminants	O
in	O
promoting	O
the	O
observed	O
degradation	O
.	O

Aqueous	O
sugar	B
formulations	O
containing	O
DLPC	B
(	O
0.01mg	O
/	O
ml	O
)	O
were	O
lyophilized	O
,	O
and	O
DLPC	B
degradation	O
was	O
monitored	O
using	O
HPLC	O
/	O
UV	O
and	O
GC	O
/	O
MS	O
methods	O
.	O

The	O
effect	O
of	O
ferrous	B
ion	O
and	O
sucrose	B
concentration	O
,	O
as	O
well	O
as	O
lyophilization	O
stage	O
promoting	O
lipid	O
degradation	O
,	O
was	O
investigated	O
.	O

DLPC	B
degradation	O
increased	O
with	O
higher	O
levels	O
of	O
ferrous	B
ion	O
.	O

After	O
lyophilization	O
,	O
103.11.1	O
%	O
,	O
66.90.8	O
%	O
,	O
and	O
28.70.7	O
%	O
DLPC	B
remained	O
in	O
the	O
sucrose	B
samples	O
spiked	O
with	O
0.0ppm	O
,	O
0.2ppm	O
,	O
and	O
1.0ppm	O
ferrous	B
ion	O
,	O
respectively	O
.	O

Lipid	O
degradation	O
predominantly	O
occurs	O
during	O
the	O
freezing	O
stage	O
of	O
lyophilization	O
.	O

Sugar	B
concentration	O
and	O
buffer	O
ionic	O
strength	O
also	O
influence	O
the	O
extent	O
of	O
lipid	O
degradation	O
,	O
and	O
DLPC	B
loss	O
correlated	O
with	O
degradation	O
product	O
formation	O
.	O

We	O
conclude	O
that	O
DLPC	B
oxidation	O
during	O
the	O
freezing	O
stage	O
of	O
lyophilization	O
dramatically	O
compromises	O
the	O
stability	O
of	O
lipid	O
-	O
based	O
formulations	O
.	O

In	O
addition	O
,	O
we	O
demonstrate	O
that	O
metal	O
contaminants	O
in	O
sugars	B
can	O
become	O
highly	O
active	O
when	O
lyophilized	O
in	O
the	O
presence	O
of	O
a	O
reducing	O
agent	O
.	O

The	O
cyclin	O
D1	O
(	O
CCND1	O
)	O
rs9344	O
G	O
>	O
A	O
polymorphism	O
predicts	O
clinical	O
outcome	O
in	O
colon	O
cancer	O
patients	O
treated	O
with	O
adjuvant	O
5-FU	B
-	O
based	O
chemotherapy	O
.	O

Recent	O
evidence	O
indicates	O
a	O
potential	O
prognostic	O
and	O
predictive	O
value	O
for	O
germline	O
polymorphisms	O
in	O
genes	O
involved	O
in	O
cell	O
cycle	O
control	O
.	O

We	O
investigated	O
the	O
effect	O
of	O
cyclin	O
D1	O
(	O
CCND1	O
)	O
rs9344	O
G	O
>	O
A	O
in	O
stage	O
II	O
/	O
III	O
colon	O
cancer	O
patients	O
and	O
validated	O
the	O
findings	O
in	O
an	O
independent	O
study	O
cohort	O
.	O

For	O
evaluation	O
and	O
validation	O
set	O
,	O
a	O
total	O
of	O
264	O
and	O
234	O
patients	O
were	O
included	O
.	O

Patients	O
treated	O
with	O
5-fluorouracil	B
-	O
based	O
chemotherapy	O
,	O
carrying	O
the	O
CCND1	O
rs9344	O
A	O
/	O
A	O
genotype	O
had	O
significantly	O
decreased	O
time	O
-	O
to	O
-	O
tumor	O
recurrence	O
(	O
TTR	O
)	O
in	O
univariate	O
analysis	O
and	O
multivariate	O
analysis	O
(	O
hazard	O
ratio	O
(	O
HR	O
)	O
2.47	O
;	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
1.16	O
-	O
5.29	O
;	O
P=0.019	O
)	O
.	O

There	O
was	O
no	O
significant	O
association	O
between	O
CCND1	O
rs9344	O
G	O
>	O
A	O
and	O
TTR	O
in	O
patients	O
with	O
curative	O
surgery	O
alone	O
.	O

In	O
the	O
validation	O
set	O
,	O
the	O
A	O
allele	O
of	O
CCND1	O
rs9344	O
G	O
>	O
A	O
remained	O
significantly	O
associated	O
with	O
decreased	O
TTR	O
in	O
univariate	O
and	O
multivariate	O
analyses	O
(	O
HR	O
1.94	O
;	O
95	O
%	O
CI	O
1.05	O
-	O
3.58	O
;	O
P=0.035	O
)	O
.	O

CCND1	O
rs9344	O
G	O
>	O
A	O
may	O
be	O
a	O
predictive	O
and/or	O
prognostic	O
biomarker	O
in	O
stage	O
II	O
/	O
III	O
colon	O
cancer	O
patients	O
,	O
however	O
,	O
prospective	O
trials	O
are	O
warranted	O
to	O
confirm	O
our	O
findings	O
.	O

The	O
Pharmacogenomics	O
Journal	O
advance	O
online	O
publication	O
,	O
9	O
April	O
2013	O
;	O
doi:10.1038	O
/	O
tpj.2013.15	O
.	O

Signaling	O
mechanism	O
of	O
tumor	O
cell	O
-	O
induced	O
up	O
-	O
regulation	O
of	O
E3	O
ubiquitin	O
ligase	O
UBR2	O
.	O

The	O
N	O
-	O
end	O
rule	O
pathway	O
contributes	O
significantly	O
to	O
accelerated	O
muscle	O
proteolysis	O
mediated	O
by	O
the	O
ubiquitin	O
-	O
proteasome	O
pathway	O
in	O
various	O
catabolic	O
conditions	O
.	O

UBR2	O
(	O
aka	O
E3	O
-	O
II	O
)	O
is	O
the	O
only	O
known	O
E3	O
ubiquitin	O
ligase	O
of	O
the	O
N	O
-	O
end	O
rule	O
pathway	O
that	O
is	O
up	O
-	O
regulated	O
by	O
cachectic	O
stimuli	O
including	O
proinflammatory	O
cytokines	O
and	O
tumors	O
.	O

However	O
,	O
the	O
signaling	O
mechanism	O
through	O
which	O
UBR2	O
is	O
up	O
-	O
regulated	O
remains	O
undetermined	O
.	O

Here	O
we	O
identify	O
a	O
signaling	O
pathway	O
that	O
mediates	O
tumor	O
cell	O
-	O
induced	O
up	O
-	O
regulation	O
of	O
UBR2	O
.	O

UBR2	O
expression	O
in	O
C2C12	O
myotubes	O
was	O
up	O
-	O
regulated	O
by	O
conditioned	O
medium	O
from	O
Lewis	O
lung	O
carcinoma	O
cells	O
or	O
C26	O
colon	O
adenocarcinoma	O
cells	O
,	O
which	O
was	O
blocked	O
by	O
a	O
pharmacological	O
inhibitor	O
of	O
p38	O
/	O
	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
MAPK	O
)	O
,	O
SB202190	B
.	O

Similarly	O
,	O
SB202190	B
administration	O
(	O
i.p	O
.	O
)	O
abolished	O
UBR2	O
up	O
-	O
regulation	O
in	O
the	O
tibialis	O
anterior	O
of	O
LLC	O
tumor	O
-	O
bearing	O
mice	O
.	O

Genetic	O
gain	O
and	O
loss	O
of	O
function	O
assays	O
in	O
C2C12	O
myotubes	O
indicated	O
that	O
tumor	O
-	O
induced	O
activation	O
of	O
the	O
p38	O
isoform	O
is	O
sufficient	O
and	O
necessary	O
for	O
UBR2	O
up	O
-	O
regulation	O
.	O

In	O
addition	O
,	O
UBR2	O
up	O
-	O
regulation	O
required	O
p38	O
-	O
mediated	O
phosphorylation	O
of	O
CCAAT	O
/	O
enhancer	O
binding	O
protein	O
(	O
C	O
/	O
EBP	O
)	O
-	O
Thr-188	B
,	O
which	O
was	O
critical	O
to	O
C	O
/	O
EBP	O
binding	O
to	O
the	O
UBR2	O
promoter	O
.	O

Furthermore	O
,	O
luciferase	O
reporter	O
assay	O
revealed	O
that	O
the	O
C	O
/	O
EBP	O
binding	O
motif	O
in	O
the	O
UBR2	O
promoter	O
is	O
a	O
functional	O
C	O
/	O
EBP	O
-	O
responsive	O
cis	O
-	O
element	O
that	O
enhances	O
the	O
promoter	O
activity	O
on	O
activation	O
by	O
p38	O
.	O

Finally	O
,	O
genetic	O
ablation	O
of	O
C	O
/	O
EBP	O
blocked	O
UBR2	O
up	O
-	O
regulation	O
in	O
LLC	O
tumor	O
-	O
bearing	O
mice	O
.	O

These	O
results	O
suggest	O
that	O
UBR2	O
up	O
-	O
regulation	O
in	O
cachectic	O
muscle	O
is	O
mediated	O
by	O
the	O
p38	O
-	O
C	O
/	O
EBP	O
signaling	O
pathway	O
responsible	O
for	O
the	O
bulk	O
of	O
tumor	O
-	O
induced	O
muscle	O
proteolysis	O
.-	O
Zhang	O
,	O
G.	O
,	O
Lin	O
,	O
R	O
.-	O
K.	O
,	O
Kwon	O
,	O
Y.	O
T.	O
,	O
Li	O
,	O
Y	O
.-	O
P.	O
Signaling	O
mechanism	O
of	O
tumor	O
cell	O
-	O
induced	O
up	O
-	O
regulation	O
of	O
E3	O
ubiquitin	O
ligase	O
UBR2	O
.	O

Structural	O
and	O
functional	O
characterization	O
of	O
a	O
phosphatase	O
domain	O
within	O
yeast	O
general	O
transcription	O
factor	O
TFIIIC	O
.	O

Saccharomyces	O
cerevisiae	O
55	O
,	O
a	O
subunit	O
of	O
the	O
RNA	O
polymerase	O
III	O
-	O
specific	O
general	O
transcription	O
factor	O
TFIIIC	O
,	O
comprises	O
an	O
N	O
-	O
terminal	O
histidine	B
phosphatase	O
domain	O
(	O
55-HPD	O
)	O
whose	O
catalytic	O
activity	O
and	O
cellular	O
function	O
is	O
poorly	O
understood	O
.	O

We	O
solved	O
the	O
crystal	O
structures	O
of	O
55-HPD	O
and	O
its	O
closely	O
related	O
paralogue	O
Huf	O
and	O
used	O
in	O
silico	O
docking	O
methods	O
to	O
identify	O
phospho	B
-	I
serine	I
and	O
phospho	B
-	I
tyrosine	I
containing	O
peptides	O
as	O
possible	O
substrates	O
that	O
were	O
subsequently	O
validated	O
using	O
in	O
vitro	O
phosphatase	O
assays	O
.	O

A	O
comparative	O
phospho	B
-	O
proteomic	O
study	O
identified	O
additional	O
phosphopeptides	O
as	O
possible	O
targets	O
,	O
which	O
show	O
the	O
involvement	O
of	O
these	O
two	O
phosphatases	O
in	O
the	O
regulation	O
of	O
a	O
variety	O
of	O
cellular	O
functions	O
.	O

Our	O
results	O
identify	O
55-HPD	O
and	O
Huf	O
as	O
bona	O
fide	O
protein	O
phosphatases	O
,	O
characterize	O
their	O
substrate	O
specificities	O
and	O
provide	O
a	O
small	O
set	O
of	O
regulated	O
phosphosite	O
targets	O
in	O
vivo	O
.	O

Adenine	B
-	O
DNA	O
Adducts	O
Derived	O
from	O
the	O
Highly	O
Tumorigenic	O
Dibenzo	B
[	I
a	I
,	I
l	I
]	I
pyrene	I
Are	O
Resistant	O
to	O
Nucleotide	B
Excision	O
Repair	O
while	O
Guanine	B
Adducts	O
Are	O
Not	O
.	O

The	O
structural	O
origins	O
of	O
differences	O
in	O
susceptibilities	O
of	O
various	O
DNA	O
lesions	O
to	O
nucleotide	B
excision	O
repair	O
(	O
NER	O
)	O
are	O
poorly	O
understood	O
.	O

Here	O
we	O
compared	O
,	O
in	O
the	O
same	O
sequence	O
context	O
,	O
the	O
relative	O
NER	O
dual	O
incision	O
efficiencies	O
elicited	O
by	O
two	O
stereochemically	O
distinct	O
pairs	O
of	O
guanine	B
(	O
N	O
(	O
2	O
)	O
-dG	O
)	O
and	O
adenine	B
(	O
N	O
(	O
6	O
)	O
-dA	O
)	O
DNA	O
lesions	O
,	O
derived	O
from	O
enantiomeric	O
genotoxic	O
diol	B
epoxides	I
of	O
the	O
highly	O
tumorigenic	O
fjord	O
region	O
polycyclic	O
aromatic	O
hydrocarbon	O
dibenzo	B
[	I
a	I
,	I
l	I
]	I
pyrene	I
(	O
DB	B
[	I
a	I
,	I
l	I
]	I
P	I
)	O
.	O

Remarkably	O
,	O
in	O
cell	O
-	O
free	O
HeLa	O
cell	O
extracts	O
,	O
the	O
guanine	B
adduct	O
with	O
R	O
absolute	O
chemistry	O
at	O
the	O
N	O
(	O
2	O
)	O
-dG	O
linkage	O
site	O
is	O
35	O
times	O
more	O
susceptible	O
to	O
NER	O
dual	O
incisions	O
than	O
the	O
stereochemically	O
identical	O
N	O
(	O
6	O
)	O
-dA	O
adduct	O
.	O

For	O
the	O
guanine	B
and	O
adenine	B
adducts	O
with	O
S	O
stereochemistry	O
,	O
a	O
similar	O
but	O
somewhat	O
smaller	O
effect	O
(	O
factor	O
of	O
15	O
)	O
is	O
observed	O
.	O

The	O
striking	O
resistance	O
of	O
the	O
bulky	O
N	O
(	O
6	O
)	O
-dA	O
in	O
contrast	O
to	O
the	O
modest	O
to	O
good	O
susceptibilities	O
of	O
the	O
N	O
(	O
2	O
)	O
-dG	O
adducts	O
to	O
NER	O
is	O
interpreted	O
in	O
terms	O
of	O
the	O
balance	O
between	O
lesion	O
-	O
induced	O
DNA	O
distorting	O
and	O
DNA	O
stabilizing	O
van	O
der	O
Waals	O
interactions	O
in	O
their	O
structures	O
,	O
that	O
are	O
partly	O
reflected	O
in	O
the	O
overall	O
thermal	O
stabilities	O
of	O
the	O
modified	O
duplexes	O
.	O

Our	O
results	O
are	O
consistent	O
with	O
the	O
hypothesis	O
that	O
the	O
high	O
genotoxic	O
activity	O
of	O
DB	B
[	I
a	I
,	I
l	I
]	I
P	I
is	O
related	O
to	O
the	O
formation	O
of	O
NER	O
-	O
resistant	O
and	O
persistent	O
DB	B
[	I
a	I
,	I
l	I
]	I
P	I
-	O
derived	O
adenine	B
adducts	O
in	O
cellular	O
DNA	O
.	O

Reactions	O
of	O
Hydrocarbon	B
Radicals	I
and	I
Biradicals	I
.	O

Experimental	O
measurements	O
of	O
the	O
rate	O
coefficients	O
for	O
several	O
types	O
of	O
gas	O
phase	O
radical	O
reactions	O
are	O
reviewed	O
.	O

They	O
include	O
radical	O
isomerization	O
and	O
dissociation	O
,	O
radical	O
+	O
radical	O
association	O
,	O
and	O
unimolecular	O
reactions	O
of	O
peroxy	B
radicals	O
.	O

Some	O
reactions	O
of	O
methylene	B
in	O
its	O
lowest	O
singlet	O
state	O
are	O
also	O
considered	O
.	O

The	O
links	O
to	O
theories	O
of	O
chemical	O
reaction	O
rates	O
and	O
especially	O
of	O
capture	O
rates	O
for	O
radical	O
+	O
radical	O
reactions	O
are	O
examined	O
.	O

Many	O
of	O
the	O
reactions	O
involve	O
formation	O
of	O
adducts	O
,	O
which	O
can	O
isomerize	O
and	O
dissociate	O
.	O

Such	O
reactions	O
frequently	O
involve	O
energy	O
distributions	O
of	O
the	O
adducts	O
that	O
are	O
far	O
from	O
Boltzmann	O
,	O
and	O
the	O
interpretation	O
of	O
measurements	O
requires	O
the	O
use	O
of	O
master	O
equation	O
techniques	O
.	O

The	O
basis	O
of	O
these	O
methods	O
and	O
the	O
use	O
of	O
matrix	O
diagonalization	O
and	O
eigenvector	O
/	O
eigenvalue	O
analysis	O
to	O
extract	O
phenomenological	O
rate	O
coefficients	O
are	O
discussed	O
.	O

The	O
relevance	O
of	O
the	O
measurements	O
to	O
applications	O
in	O
atmospheric	O
chemistry	O
and	O
,	O
especially	O
,	O
in	O
combustion	O
is	O
briefly	O
considered	O
.	O

Ion	O
impacts	O
on	O
graphene	B
/	O
ir	B
(	I
111	I
)	I
:	O
interface	O
channeling	O
,	O
vacancy	O
funnels	O
,	O
and	O
a	O
nanomesh	O
.	O

By	O
combining	O
ion	O
beam	O
experiments	O
and	O
atomistic	O
simulations	O
we	O
study	O
the	O
production	O
of	O
defects	O
in	O
graphene	B
on	O
Ir	B
(	I
111	I
)	I
under	O
grazing	O
incidence	O
of	O
low	O
energy	O
Xe	B
ions	O
.	O

We	O
demonstrate	O
that	O
the	O
ions	O
are	O
channeled	O
in	O
between	O
graphene	B
and	O
the	O
substrate	O
,	O
giving	O
rise	O
to	O
chains	O
of	O
vacancy	O
clusters	O
with	O
their	O
edges	O
bending	O
down	O
toward	O
the	O
substrate	O
.	O

These	O
clusters	O
self	O
-	O
organize	O
to	O
a	O
graphene	B
nanomesh	O
via	O
thermally	O
activated	O
diffusion	O
as	O
their	O
formation	O
energy	O
varies	O
within	O
the	O
graphene	B
moir	O
supercell	O
.	O

A	O
facile	O
strategy	O
to	O
design	O
zeolite	B
L	I
crystals	O
with	O
tunable	O
morphology	O
and	O
surface	O
architecture	O
.	O

Tailoring	O
the	O
anisotropic	O
growth	O
rates	O
of	O
materials	O
to	O
achieve	O
desired	O
structural	O
outcomes	O
is	O
a	O
pervasive	O
challenge	O
in	O
synthetic	O
crystallization	O
.	O

Here	O
we	O
discuss	O
a	O
method	O
to	O
selectively	O
control	O
the	O
growth	O
of	O
zeolite	B
crystals	O
,	O
which	O
are	O
used	O
extensively	O
in	O
a	O
wide	O
range	O
of	O
industrial	O
applications	O
.	O

This	O
facile	O
method	O
cooperatively	O
tunes	O
crystal	O
properties	O
,	O
such	O
as	O
morphology	O
and	O
surface	O
architecture	O
,	O
through	O
the	O
use	O
of	O
inexpensive	O
,	O
commercially	O
available	O
chemicals	O
with	O
specificity	O
for	O
binding	O
to	O
crystallographic	O
surfaces	O
and	O
mediating	O
anisotropic	O
growth	O
.	O

We	O
examined	O
over	O
30	O
molecules	O
as	O
potential	O
zeolite	B
growth	O
modifiers	O
(	O
ZGMs	O
)	O
of	O
zeolite	B
L	I
(	O
LTL	O
type	O
)	O
crystallization	O
.	O

ZGM	O
efficacy	O
was	O
quantified	O
through	O
a	O
combination	O
of	O
macroscopic	O
(	O
bulk	O
)	O
and	O
microscopic	O
(	O
surface	O
)	O
investigations	O
that	O
identified	O
modifiers	O
capable	O
of	O
dramatically	O
altering	O
the	O
cylindrical	O
morphology	O
of	O
LTL	O
crystals	O
.	O

We	O
demonstrate	O
an	O
ability	O
to	O
tailor	O
properties	O
critical	O
to	O
zeolite	B
performance	O
,	O
such	O
as	O
external	O
porous	O
surface	O
area	O
,	O
crystal	O
shape	O
,	O
and	O
pore	O
length	O
,	O
which	O
can	O
enhance	O
sorbate	B
accessibility	O
to	O
LTL	O
pores	O
,	O
tune	O
the	O
supramolecular	O
organization	O
of	O
guest	O
-	O
host	O
composites	O
,	O
and	O
minimize	O
the	O
diffusion	O
path	O
length	O
,	O
respectively	O
.	O

We	O
report	O
that	O
a	O
synergistic	O
combination	O
of	O
ZGMs	O
and	O
the	O
judicious	O
adjustment	O
of	O
synthesis	O
parameters	O
produce	O
LTL	O
crystals	O
with	O
unique	O
surface	O
features	O
,	O
and	O
a	O
range	O
of	O
length	O
-	O
to	O
-	O
diameter	O
aspect	O
ratios	O
spanning	O
3	O
orders	O
of	O
magnitude	O
.	O

A	O
systematic	O
examination	O
of	O
different	O
ZGM	O
structures	O
and	O
molecular	O
compositions	O
(	O
i.e.	O
,	O
hydrophobicity	O
and	O
binding	O
moieties	O
)	O
reveal	O
interesting	O
physicochemical	O
properties	O
governing	O
their	O
efficacy	O
and	O
specificity	O
.	O

Results	O
of	O
this	O
study	O
suggest	O
this	O
versatile	O
strategy	O
may	O
prove	O
applicable	O
for	O
a	O
host	O
of	O
framework	O
types	O
to	O
produce	O
unrivaled	O
materials	O
that	O
have	O
eluded	O
more	O
conventional	O
techniques	O
.	O

Silver	B
Nanoparticles	O
Induced	O
RNA	O
Polymerase	O
-	O
Silver	B
Binding	O
and	O
RNA	O
Transcription	O
Inhibition	O
in	O
Erythroid	O
Progenitor	O
Cells	O
.	O

Due	O
to	O
its	O
antimicrobial	O
activity	O
,	O
nanosilver	O
(	O
nAg	O
)	O
has	O
become	O
the	O
most	O
widely	O
used	O
nanomaterial	O
.	O

Thus	O
far	O
,	O
the	O
mechanisms	O
responsible	O
for	O
nAg	O
-	O
induced	O
antimicrobial	O
properties	O
and	O
nAg	O
-	O
mediated	O
toxicity	O
to	O
organisms	O
have	O
not	O
been	O
clearly	O
recognized	O
.	O

Silver	B
(	O
Ag	B
)	O
ions	O
certainly	O
play	O
a	O
crucial	O
role	O
,	O
and	O
the	O
form	O
of	O
nanoparticles	O
can	O
change	O
the	O
dissolution	O
rate	O
,	O
bioavailability	O
,	O
biodistribution	O
,	O
and	O
cellular	O
uptake	O
of	O
Ag	B
.	O

However	O
,	O
whether	O
nAg	O
exerts	O
direct	O
"	O
particle	O
-	O
specific	O
"	O
effects	O
has	O
been	O
under	O
debate	O
.	O

Here	O
we	O
demonstrated	O
that	O
nAg	O
exhibited	O
a	O
robust	O
inhibition	O
on	O
RNA	O
polymerase	O
activity	O
and	O
overall	O
RNA	O
transcription	O
through	O
direct	O
Ag	B
binding	O
to	O
RNA	O
polymerase	O
,	O
which	O
is	O
separated	O
from	O
the	O
cytotoxicity	O
pathway	O
induced	O
by	O
Ag	B
ions	O
.	O

nAg	O
treatment	O
in	O
vitro	O
resulted	O
in	O
reduced	O
hemoglobin	O
concentration	O
in	O
erythroid	O
cells	O
;	O
in	O
vivo	O
administration	O
of	O
nAg	O
in	O
mice	O
caused	O
profound	O
reduction	O
of	O
hemoglobin	O
content	O
in	O
embryonic	O
erythrocytes	O
,	O
associated	O
with	O
anemia	O
in	O
the	O
embryos	O
.	O

Embryonic	O
anemia	O
and	O
general	O
proliferation	O
deficit	O
due	O
to	O
the	O
significant	O
inhibition	O
on	O
RNA	O
synthesis	O
,	O
at	O
least	O
partially	O
,	O
accounted	O
for	O
embryonic	O
developmental	O
retardation	O
upon	O
nAg	O
administration	O
.	O

To	O
date	O
,	O
there	O
is	O
no	O
conclusive	O
answer	O
to	O
the	O
sources	O
of	O
nAg	O
-	O
mediated	O
toxicity	O
:	O
Ag	B
ions	O
or	O
"	O
particle	O
-	O
specific	O
"	O
effects	O
,	O
or	O
both	O
.	O

We	O
here	O
demonstrated	O
that	O
both	O
Ag	B
ions	O
and	O
nAg	O
particles	O
simultaneously	O
existed	O
inside	O
cells	O
,	O
demonstrating	O
the	O
"	O
Trojan	O
horse	O
"	O
effects	O
of	O
nAg	O
particles	O
in	O
posing	O
biological	O
impacts	O
on	O
erythroid	O
cells	O
.	O

Moreover	O
,	O
our	O
results	O
suggested	O
that	O
"	O
particle	O
-	O
specific	O
"	O
effects	O
could	O
be	O
the	O
predominant	O
mediator	O
in	O
eliciting	O
biological	O
influences	O
on	O
erythroid	O
cells	O
under	O
relatively	O
low	O
concentrations	O
of	O
nAg	O
exposure	O
.	O

The	O
combined	O
data	O
highlighted	O
the	O
inhibitory	O
effect	O
of	O
nAg	O
on	O
RNA	O
polymerase	O
activity	O
through	O
a	O
direct	O
reciprocal	O
interaction	O
.	O

Pyranocycloartobiloxanthone	B
A	I
,	O
a	O
novel	O
gastroprotective	O
compound	O
from	O
Artocarpus	O
obtusus	O
Jarret	O
,	O
against	O
ethanol	B
-	O
induced	O
acute	O
gastric	O
ulcer	O
in	O
vivo	O
.	O

Pyranocycloartobiloxanthone	B
A	I
(	O
PA	O
)	O
,	O
a	O
xanthone	B
derived	O
from	O
the	O
Artocarpus	O
obtusus	O
Jarret	O
,	O
belongs	O
to	O
the	O
Moraceae	O
family	O
which	O
is	O
native	O
to	O
the	O
tropical	O
forest	O
of	O
Malaysia	O
.	O

In	O
this	O
study	O
,	O
the	O
efficacy	O
of	O
PA	O
as	O
a	O
gastroprotective	O
compound	O
was	O
examined	O
against	O
ethanol	B
-	O
induced	O
ulcer	O
model	O
in	O
rats	O
.	O

The	O
rats	O
were	O
pretreated	O
with	O
PA	O
and	O
subsequently	O
exposed	O
to	O
acute	O
gastric	O
lesions	O
induced	O
by	O
absolute	O
ethanol	B
.	O

The	O
ulcer	O
index	O
,	O
gastric	O
juice	O
acidity	O
,	O
mucus	O
content	O
,	O
histological	O
analysis	O
,	O
glutathione	B
(	O
GSH	B
)	O
levels	O
,	O
malondialdehyde	B
level	O
(	O
MDA	B
)	O
,	O
nitric	B
oxide	I
(	O
NO	B
)	O
and	O
non	O
-	O
protein	O
sulfhydryl	B
group	O
(	O
NP	O
-	O
SH	B
)	O
contents	O
were	O
evaluated	O
in	O
vivo	O
.	O

The	O
activities	O
of	O
PA	O
as	O
anti	O
-	O
Helicobacter	O
pylori	O
,	O
cyclooxygenase-2	O
(	O
COX-2	O
)	O
inhibitor	O
and	O
free	O
radical	O
scavenger	O
were	O
also	O
investigated	O
in	O
vitro	O
.	O

The	O
results	O
showed	O
that	O
the	O
oral	O
administration	O
of	O
PA	O
protects	O
gastric	O
mucosa	O
from	O
ethanol	B
-	O
induced	O
gastric	O
lesions	O
.	O

PA	O
pretreatment	O
significantly	O
(	O
p<0.05	O
)	O
restored	O
the	O
depleted	O
GSH	B
,	O
NP	O
-	O
SH	B
and	O
NO	B
levels	O
in	O
the	O
gastric	O
homogenate	O
.	O

Moreover	O
,	O
PA	O
significantly	O
(	O
p<0.05	O
)	O
reduced	O
the	O
elevated	O
MDA	B
level	O
due	O
to	O
ethanol	B
administration	O
.	O

The	O
gastroprotective	O
effect	O
of	O
PA	O
was	O
associated	O
with	O
an	O
over	O
expression	O
of	O
HSP70	O
and	O
suppression	O
of	O
Bax	O
proteins	O
in	O
the	O
ulcerated	O
tissue	O
.	O

In	O
addition	O
,	O
PA	O
exhibited	O
a	O
potent	O
FRAP	O
value	O
and	O
significant	O
COX-2	O
inhibition	O
.	O

It	O
also	O
showed	O
a	O
significant	O
minimum	O
inhibitory	O
concentration	O
(	O
MIC	O
)	O
against	O
H.	O
pylori	O
bacterium	O
.	O

The	O
efficacy	O
of	O
PA	O
was	O
accomplished	O
safely	O
without	O
the	O
presence	O
of	O
any	O
toxicological	O
parameters	O
.	O

The	O
results	O
of	O
the	O
present	O
study	O
indicate	O
that	O
the	O
gastroprotective	O
effect	O
of	O
PA	O
might	O
contribute	O
to	O
the	O
antioxidant	O
and	O
anti	O
-	O
inflammatory	O
properties	O
as	O
well	O
as	O
the	O
anti	O
-	O
apoptotic	O
mechanism	O
and	O
antibacterial	O
action	O
against	O
Helicobacter	O
pylori	O
.	O

Bioinspired	O
design	O
and	O
macroscopic	O
assembly	O
of	O
poly	B
(	I
vinyl	I
alcohol	I
)	I
-coated	O
graphene	B
into	O
kilometers	O
-	O
long	O
fibers	O
.	O

Nacre	O
is	O
characterized	O
by	O
its	O
excellent	O
mechanical	O
performance	O
due	O
to	O
the	O
well	O
-	O
recognized	O
"	O
brick	O
and	O
mortar	O
"	O
structure	O
.	O

Many	O
efforts	O
have	O
been	O
applied	O
to	O
make	O
nacre	O
-	O
mimicking	O
materials	O
,	O
but	O
it	O
is	O
still	O
a	O
big	O
challenge	O
to	O
realize	O
their	O
continuous	O
production	O
.	O

Here	O
,	O
we	O
prepared	O
sandwich	O
-	O
like	O
building	O
blocks	O
of	O
poly	B
(	I
vinyl	I
alcohol	I
)	I
(	O
PVA	B
)	O
-coated	O
graphene	B
,	O
and	O
achieved	O
high	O
-	O
nanofiller	O
-	O
content	O
kilometers	O
-	O
long	O
fibers	O
by	O
continuous	O
wet	O
-	O
spinning	O
assembly	O
technology	O
.	O

The	O
fibers	O
have	O
a	O
strict	O
"	O
brick	O
and	O
mortar	O
"	O
layered	O
structure	O
,	O
with	O
graphene	B
sheet	O
as	O
rigid	O
brick	O
and	O
PVA	B
as	O
soft	O
mortar	O
.	O

The	O
mortar	O
thickness	O
can	O
be	O
precisely	O
tuned	O
from	O
2.01	O
to	O
3.31	O
nm	O
by	O
the	O
weight	O
feed	O
ratio	O
of	O
PVA	O
to	O
graphene	B
,	O
as	O
demonstrated	O
by	O
both	O
atomic	O
force	O
microscopy	O
and	O
X	O
-	O
ray	O
diffraction	O
measurements	O
.	O

The	O
mechanical	O
strength	O
of	O
the	O
nacre	O
-	O
mimicking	O
fibers	O
increases	O
with	O
increasing	O
the	O
content	O
of	O
PVA	B
,	O
and	O
it	O
rises	O
gradually	O
from	O
81	O
MPa	O
for	O
the	O
fiber	O
with	O
53.1	O
wt%	O
PVA	B
to	O
161	O
MPa	O
for	O
the	O
fiber	O
with	O
65.8	O
wt%	O
PVA	B
.	O

The	O
mechanical	O
performance	O
of	O
our	O
fibers	O
was	O
independent	O
of	O
the	O
molecular	O
weight	O
(	O
MW	O
)	O
of	O
PVA	B
in	O
the	O
wide	O
range	O
of	O
2	O
-	O
100	O
kDa	O
,	O
indicating	O
that	O
low	O
MW	O
polymers	O
can	O
also	O
be	O
used	O
to	O
make	O
strong	O
nanocomposites	O
.	O

The	O
tensile	O
stress	O
of	O
fibers	O
immersed	O
in	O
PVA	B
5	O
wt%	O
solution	O
reached	O
ca	O
.	O

200	O
MPa	O
,	O
surpassing	O
the	O
values	O
of	O
nacre	O
and	O
most	O
of	O
other	O
nacre	O
-	O
mimicking	O
materials	O
.	O

The	O
nacre	O
-	O
mimicking	O
fibers	O
are	O
highly	O
electrically	O
conductive	O
(	O
350	O
S	O
m	O
(	O
-1	O
)	O
)	O
after	O
immersing	O
in	O
hydroiodic	B
acid	I
,	O
enabling	O
them	O
to	O
connect	O
a	O
circuit	O
to	O
illuminate	O
an	O
LED	O
lamp	O
.	O

Proposed	O
diagnostic	O
criteria	O
for	O
subclinical	O
Cushing	O
's	O
syndrome	O
associated	O
with	O
adrenal	O
incidentaloma	O
.	O

Subclinical	O
Cushing	O
's	O
syndrome	O
(	O
SCS	O
)	O
associated	O
with	O
adrenal	O
incidentaloma	O
is	O
usually	O
characterized	O
by	O
autonomous	O
cortisol	B
secretion	O
without	O
overt	O
symptoms	O
of	O
Cushing	O
's	O
syndrome	O
(	O
CS	O
)	O
.	O

Although	O
the	O
diagnostic	O
criteria	O
for	O
SCS	O
differ	O
among	O
countries	O
,	O
the	O
1	O
mg	O
dexamethasone	B
suppression	O
test	O
(	O
DST	O
)	O
is	O
essential	O
to	O
confirm	O
the	O
presence	O
and	O
the	O
extent	O
of	O
cortisol	B
overproduction	O
.	O

Since	O
1995	O
,	O
SCS	O
has	O
been	O
diagnosed	O
in	O
Japan	O
based	O
on	O
serum	O
cortisol	B
levels	O
3	O
g	O
/	O
dl	O
(	O
measured	O
by	O
radioimmunoassay	O
[	O
RIA	O
]	O
)	O
after	O
a	O
1	O
mg	O
DST	O
.	O

However	O
,	O
the	O
increasing	O
use	O
of	O
enzyme	O
immunoassays	O
(	O
EIA	O
)	O
instead	O
of	O
RIA	O
has	O
hindered	O
the	O
diagnosis	O
of	O
SCS	O
because	O
of	O
the	O
differing	O
sensitivities	O
of	O
commercially	O
available	O
assays	O
,	O
particularly	O
for	O
serum	O
cortisol	B
levels	O
of	O
around	O
3	O
g	O
/	O
dl	O
.	O

One	O
way	O
to	O
overcome	O
this	O
problem	O
is	O
to	O
lower	O
the	O
cortisol	B
threshold	O
level	O
after	O
a	O
1	O
mg	O
DST	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
examined	O
the	O
clinical	O
applicability	O
of	O
lowering	O
the	O
cortisol	B
threshold	O
to	O
1.8	O
g	O
/	O
dl	O
,	O
similar	O
to	O
the	O
American	O
Endocrine	O
Society	O
's	O
guidelines	O
for	O
CS	O
,	O
by	O
reanalyzing	O
119	O
patients	O
with	O
adrenal	O
incidentaloma	O
.	O

Our	O
findings	O
indicate	O
that	O
serum	O
cortisol	B
levels	O
1.8	O
g	O
/	O
dl	O
after	O
1	O
mg	O
DST	O
are	O
useful	O
to	O
confirm	O
the	O
diagnosis	O
of	O
SCS	O
if	O
both	O
of	O
the	O
following	O
criteria	O
are	O
met	O
:	O
(	O
1	O
)	O
basal	O
ACTH	O
level	O
<	O
10	O
pg	O
/	O
ml	O
(	O
or	O
poor	O
plasma	O
ACTH	O
response	O
to	O
corticotrophin	O
-	O
releasing	O
hormone	O
)	O
and	O
(	O
2	O
)	O
serum	O
cortisol	B
5	O
g	O
/	O
dl	O
at	O
21:00	O
to	O
23:00	O
h.	O
If	O
only	O
one	O
of	O
(	O
1	O
)	O
and	O
(	O
2	O
)	O
are	O
met	O
,	O
we	O
recommend	O
that	O
other	O
clinical	O
features	O
are	O
considered	O
in	O
the	O
diagnosis	O
of	O
SCS	O
,	O
including	O
serum	O
dehydroepiandrosterone	B
sulfate	I
levels	O
,	O
urine	O
free	O
cortisol	B
levels	O
,	O
adrenal	O
scintigraphy	O
,	O
and	O
clinical	O
manifestation	O
.	O

Boron	B
Enhances	O
Odontogenic	O
and	O
Osteogenic	O
Differentiation	O
of	O
Human	O
Tooth	O
Germ	O
Stem	O
Cells	O
(	O
hTGSCs	O
)	O
In	O
Vitro	O
.	O

Stem	O
cell	O
technology	O
has	O
been	O
a	O
great	O
hope	O
for	O
the	O
treatment	O
of	O
many	O
common	O
problems	O
such	O
as	O
Parkinson	O
's	O
disease	O
,	O
Alzheimer	O
's	O
disease	O
,	O
diabetes	O
,	O
cancer	O
,	O
and	O
tissue	O
regeneration	O
.	O

Therefore	O
,	O
the	O
main	O
challenge	O
in	O
hard	O
tissue	O
engineering	O
is	O
to	O
make	O
a	O
successful	O
combination	O
of	O
stem	O
cells	O
and	O
efficient	O
inductors	O
in	O
the	O
concept	O
of	O
stem	O
cell	O
differentiation	O
into	O
odontogenic	O
and	O
osteogenic	O
cell	O
types	O
.	O

Although	O
some	O
boron	B
derivatives	O
have	O
been	O
reported	O
to	O
promote	O
bone	O
and	O
teeth	O
growth	O
in	O
vivo	O
,	O
the	O
molecular	O
mechanism	O
of	O
bone	O
formation	O
has	O
not	O
been	O
elucidated	O
yet	O
.	O

Different	O
concentrations	O
of	O
sodium	B
pentaborate	I
pentahydrate	I
(	O
NaB	B
)	O
were	O
prepared	O
for	O
the	O
analysis	O
of	O
cell	O
toxicity	O
and	O
differentiation	O
evaluations	O
.	O

The	O
odontogenic	O
,	O
osteogenic	O
differentiation	O
and	O
biomineralization	O
of	O
human	O
tooth	O
germ	O
stem	O
cells	O
(	O
hTGSCs	O
)	O
were	O
evaluated	O
by	O
analyzing	O
the	O
mRNA	O
expression	O
levels	O
,	O
odontogenic	O
and	O
osteogenic	O
protein	O
expressions	O
,	O
alkaline	O
phosphatase	O
(	O
ALP	O
)	O
activity	O
,	O
mineralization	O
,	O
and	O
calcium	B
deposits	O
.	O

The	O
NaB	B
-	O
treated	O
group	O
displayed	O
the	O
highest	O
ALP	O
activity	O
and	O
expression	O
of	O
osteo-	O
and	O
odontogenic	O
-	O
related	O
genes	O
and	O
proteins	O
compared	O
to	O
the	O
other	O
groups	O
and	O
baseline	O
.	O

In	O
the	O
current	O
study	O
,	O
increased	O
in	O
vitro	O
odontogenic	O
and	O
osteogenic	O
differentiation	O
capacity	O
of	O
hTGSCs	O
by	O
NaB	B
application	O
has	O
been	O
shown	O
for	O
the	O
first	O
time	O
.	O

The	O
study	O
offers	O
considerable	O
promise	O
for	O
the	O
development	O
of	O
new	O
scaffold	O
systems	O
combined	O
with	O
NaB	B
in	O
both	O
functional	O
bone	O
and	O
tooth	O
tissue	O
engineering	O
.	O

Cryptococcal	O
infections	O
:	O
changing	O
epidemiology	O
and	O
implications	O
for	O
therapy	O
.	O

Although	O
the	O
incidence	O
of	O
HIV	O
-	O
associated	O
cryptococcosis	O
has	O
decreased	O
in	O
developed	O
countries	O
since	O
the	O
introduction	O
of	O
antiretroviral	O
therapy	O
,	O
this	O
disease	O
continues	O
to	O
cause	O
significant	O
morbidity	O
and	O
mortality	O
in	O
sub	O
-	O
Saharan	O
Africa	O
among	O
patients	O
with	O
AIDS	O
.	O

Important	O
strides	O
have	O
been	O
made	O
in	O
an	O
attempt	O
to	O
decrease	O
the	O
burden	O
of	O
disease	O
,	O
particularly	O
the	O
development	O
of	O
the	O
lateral	O
flow	O
assay	O
cryptococcal	O
antigen	O
(	O
LFA	O
CrAg	O
)	O
as	O
a	O
diagnostic	O
tool	O
in	O
resource	O
-	O
limited	O
settings	O
,	O
coupled	O
with	O
the	O
introduction	O
of	O
pre	O
-	O
emptive	O
treatment	O
with	O
fluconazole	B
for	O
HIV	O
-	O
positive	O
patients	O
at	O
risk	O
for	O
cryptococcosis	O
with	O
a	O
positive	O
LFA	O
CrAg	O
.	O

Among	O
solid	O
organ	O
transplant	O
recipients	O
,	O
recent	O
prospective	O
studies	O
have	O
identified	O
cryptococcosis	O
as	O
the	O
third	O
most	O
common	O
invasive	O
fungal	O
infection	O
,	O
and	O
progress	O
is	O
being	O
made	O
toward	O
earlier	O
diagnosis	O
and	O
more	O
effective	O
therapy	O
.	O

Finally	O
,	O
the	O
Cryptococcus	O
gattii	O
outbreak	O
in	O
British	O
Columbia	O
,	O
Canada	O
and	O
the	O
US	O
Pacific	O
Northwest	O
is	O
providing	O
important	O
new	O
insights	O
into	O
the	O
emergence	O
of	O
this	O
pathogen	O
in	O
geographic	O
areas	O
previously	O
considered	O
low	O
risk	O
for	O
acquisition	O
of	O
infection	O
.	O

Understanding	O
the	O
similarities	O
and	O
differences	O
among	O
C.	O
gattii	O
and	O
C.	O
neoformans	O
infections	O
will	O
provide	O
critical	O
insights	O
into	O
the	O
behavior	O
of	O
these	O
organisms	O
in	O
the	O
human	O
host	O
.	O

Both	O
pathogens	O
affect	O
immunocompetent	O
and	O
immunosuppressed	O
hosts	O
,	O
causing	O
pulmonary	O
,	O
central	O
nervous	O
system	O
and	O
widely	O
disseminated	O
infections	O
.	O

Treatment	O
recommendations	O
in	O
the	O
future	O
will	O
necessarily	O
take	O
into	O
account	O
the	O
site	O
of	O
infection	O
,	O
clinical	O
severity	O
of	O
the	O
infection	O
,	O
Cryptococcus	O
species	O
,	O
host	O
immune	O
status	O
and	O
economic	O
resources	O
.	O

Congruence	O
of	O
Phytochemical	O
and	O
Morphological	O
Profiles	O
along	O
an	O
Altitudinal	O
Gradient	O
in	O
Origanum	O
vulgare	O
ssp	O
.	O

vulgare	O
from	O
Venetian	O
Region	O
(	O
NE	O
Italy	O
)	O
.	O

Plants	O
of	O
Origanum	O
vulgare	O
L.	O
ssp	O
.	O

vulgare	O
from	O
the	O
Veneto	O
region	O
(	O
NE	O
Italy	O
)	O
were	O
selected	O
to	O
study	O
the	O
variability	O
of	O
the	O
essential	O
-	O
oil	O
composition	O
from	O
leaves	O
and	O
inflorescences	O
throughout	O
an	O
elevation	O
gradient	O
.	O

We	O
investigated	O
also	O
the	O
morphology	O
of	O
non	O
-	O
glandular	O
and	O
glandular	O
trichomes	O
,	O
their	O
distribution	O
on	O
the	O
vegetative	O
and	O
reproductive	O
organs	O
,	O
as	O
well	O
as	O
the	O
histochemistry	O
of	O
the	O
secreted	O
products	O
,	O
with	O
special	O
focus	O
on	O
the	O
terpenoidic	O
fraction	O
.	O

Since	O
glandular	O
trichomes	O
are	O
prerequisite	O
for	O
the	O
essential	O
-	O
oil	O
synthesis	O
,	O
the	O
second	O
objective	O
was	O
to	O
establish	O
whether	O
its	O
production	O
is	O
related	O
to	O
glandular	O
hair	O
number	O
,	O
and	O
density	O
.	O

Essential	O
-	O
oil	O
contents	O
decline	O
with	O
increasing	O
altitude	O
,	O
and	O
the	O
micromorphological	O
observations	O
revealed	O
a	O
decrease	O
in	O
trichome	O
density	O
along	O
the	O
same	O
direction	O
.	O

Moreover	O
,	O
GC	O
/	O
MS	O
analysis	O
together	O
with	O
principal	O
component	O
analysis	O
(	O
PCA	O
)	O
showed	O
that	O
the	O
three	O
investigated	O
populations	O
were	O
significantly	O
different	O
in	O
chemical	O
composition	O
.	O

Therefore	O
,	O
an	O
important	O
interpopulation	O
variability	O
for	O
low-	O
,	O
mid-	O
,	O
and	O
high	O
-	O
altitude	O
sites	O
was	O
established	O
,	O
suggesting	O
the	O
likely	O
occurrence	O
of	O
different	O
biotypes	O
associated	O
with	O
altitudinal	O
levels	O
.	O

Hence	O
,	O
the	O
involvement	O
of	O
abiotic	O
factors	O
such	O
as	O
temperature	O
and	O
drought	O
in	O
the	O
chemical	O
polymorphism	O
of	O
O.	O
vulgare	O
associated	O
with	O
elevation	O
is	O
briefly	O
discussed	O
.	O

Configurational	O
Assignment	O
of	O
Secondary	O
Hydroxyl	B
Groups	O
and	O
Methyl	B
Branches	O
in	O
Polyketide	O
Natural	O
Products	O
through	O
Bioinformatic	O
Analysis	O
of	O
the	O
Ketoreductase	O
Domain	O
.	O

Profile	O
hidden	O
Markov	O
models	O
(	O
HMMs	O
)	O
were	O
used	O
to	O
predict	O
the	O
configuration	O
of	O
secondary	B
alcohols	I
and	O
	B
-	I
methyl	I
branches	O
of	O
modular	O
polyketides	O
.	O

Based	O
on	O
the	O
configurations	O
of	O
two	O
chiral	O
centers	O
in	O
these	O
polyketides	O
,	O
78	O
ketoreductases	O
were	O
classified	O
into	O
four	O
different	O
types	O
of	O
polyketide	O
producers	O
.	O

The	O
identification	O
of	O
positions	O
that	O
discriminate	O
between	O
these	O
protein	O
families	O
was	O
followed	O
by	O
fitting	O
six	O
profile	O
HMMs	O
to	O
the	O
data	O
set	O
and	O
the	O
corresponding	O
subsets	O
,	O
to	O
model	O
the	O
conserved	O
regions	O
of	O
the	O
protein	O
types	O
.	O

Ultimately	O
,	O
the	O
profile	O
HMMs	O
described	O
herein	O
predict	O
protein	O
subtypes	O
based	O
on	O
the	O
complete	O
information	O
-	O
rich	O
region	O
;	O
consequently	O
,	O
slight	O
changes	O
in	O
a	O
multiple	O
sequence	O
alignment	O
do	O
not	O
significantly	O
alter	O
the	O
outcome	O
of	O
this	O
classification	O
method	O
.	O

Additionally	O
,	O
Viterbi	O
scores	O
can	O
be	O
used	O
to	O
assess	O
the	O
reliability	O
of	O
the	O
classification	O
.	O

Probing	O
the	O
Mechanism	O
of	O
TBAF	B
-	O
Catalyzed	O
Deacylation	O
of	O
Cellulose	O
Esters	B
.	O

The	O
mechanism	O
of	O
the	O
recently	O
discovered	O
,	O
unusual	O
tetrabutylammonium	B
fluoride	I
(	O
TBAF	B
)	O
deacylation	O
of	O
cellulose	O
esters	O
has	O
been	O
investigated	O
by	O
methods	O
including	O
kinetic	O
isotope	O
effect	O
(	O
KIE	O
)	O
studies	O
.	O

The	O
secondary	O
KIE	O
(	O
kH	O
/	O
kD	O
=	O
1.26	O
	O
0.04	O
)	O
measured	O
for	O
deacylation	O
at	O
C-2	O
/	O
3	O
suggests	O
a	O
mechanism	O
involving	O
a	O
ketene	O
intermediate	O
for	O
those	O
positions	O
.	O

An	O
inverse	O
KIE	O
(	O
kH	O
/	O
kD	O
=	O
0.87	O
	O
0.03	O
)	O
for	O
the	O
deacylation	O
at	O
C-6	O
indicates	O
the	O
involvement	O
of	O
a	O
tetrahedral	O
intermediate	O
in	O
the	O
mechanism	O
.	O

Additional	O
studies	O
suggest	O
the	O
possibility	O
that	O
TBAF	B
chelation	O
by	O
neighboring	O
acyl	B
groups	O
may	O
account	O
for	O
the	O
unexpected	O
regioselectivity	O
at	O
the	O
secondary	B
alcohol	I
esters	I
that	O
is	O
observed	O
in	O
the	O
TBAF	B
deacylation	O
of	O
cellulose	O
esters	B
.	O

Liquid	O
/	O
Gas	O
and	O
Liquid	O
/	O
Liquid	O
Phase	O
Equilibria	O
of	O
the	O
System	O
Water	O
/	O
Bovine	O
Serum	O
Albumin	O
.	O

The	O
thermodynamic	O
behavior	O
of	O
the	O
system	O
H2O	B
/	O
BSA	O
was	O
studied	O
at	O
25	O
	O
C	O
within	O
the	O
entire	O
composition	O
range	O
:	O
vapor	O
pressure	O
measurements	O
via	O
head	O
space	O
sampling	O
gas	O
chromatography	O
demonstrate	O
that	O
the	O
attainment	O
of	O
equilibria	O
takes	O
more	O
than	O
one	O
week	O
.	O

A	O
miscibility	O
gap	O
was	O
detected	O
via	O
turbidity	O
and	O
the	O
coexisting	O
phases	O
were	O
analyzed	O
.	O

At	O
6	O
	O
C	O
the	O
two	O
phase	O
region	O
extends	O
from	O
ca	O
.	O

34	O
to	O
40	O
wt	O
%	O
BSA	O

;	O
it	O
shrinks	O
upon	O
heating	O
.	O

The	O
polymer	O
rich	O
phase	O
is	O
locally	O
ordered	O
,	O
as	O
can	O
be	O
seen	O
under	O
the	O
optical	O
microscope	O
using	O
crossed	O
polarizers	O
.	O

The	O
Flory	O
-	O
Huggins	O
theory	O
turns	O
out	O
to	O
be	O
inappropriate	O
for	O
the	O
modeling	O
of	O
experimental	O
results	O
.	O

A	O
phenomenological	O
expression	O
is	O
employed	O
which	O
uses	O
three	O
adjustable	O
parameters	O
and	O
describes	O
the	O
vapor	O
pressures	O
quantitatively	O
;	O
it	O
also	O
forecasts	O
the	O
existence	O
of	O
a	O
miscibility	O
gap	O
.	O

Monitoring	O
Controlled	O
Release	O
of	O
Payload	O
from	O
Gold	O
Nanocages	O
Using	O
Surface	O
Enhanced	O
Raman	O
Scattering	O
.	O

Novel	O
organic	O
and	O
inorganic	O
nanostructures	O
for	O
localized	O
and	O
externally	O
triggered	O
delivery	O
of	O
therapeutic	O
agents	O
at	O
a	O
target	O
site	O
have	O
received	O
immense	O
attention	O
over	O
the	O
past	O
decade	O
owing	O
to	O
their	O
enormous	O
potential	O
in	O
treating	O
complex	O
diseases	O
such	O
as	O
cancer	O
.	O

Gold	O
nanocages	O
,	O
a	O
novel	O
class	O
of	O
hollow	O
plasmonic	O
nanostructures	O
,	O
have	O
been	O
recently	O
demonstrated	O
to	O
serve	O
as	O
carriers	O
for	O
the	O
delivery	O
of	O
payload	O
with	O
external	O
trigger	O
such	O
as	O
light	O
or	O
ultrasound	O
.	O

In	O
this	O
article	O
,	O
we	O
demonstrate	O
that	O
surface	O
enhanced	O
Raman	O
spectroscopy	O
(	O
SERS	O
)	O
can	O
be	O
employed	O
to	O
noninvasively	O
monitor	O
the	O
release	O
of	O
payload	O
from	O
these	O
hollow	O
plasmonic	O
nanostructures	O
.	O

The	O
large	O
enhancement	O
of	O
electromagnetic	O
(	O
EM	O
)	O
field	O
at	O
the	O
interior	O
surface	O
of	O
these	O
nanostructures	O
enables	O
us	O
to	O
monitor	O
the	O
controlled	O
release	O
of	O
Raman	O
-	O
active	O
cargo	O
from	O
nanocages	O
.	O

Considering	O
that	O
SERS	O
can	O
be	O
excited	O
and	O
collected	O
in	O
near	O
-	O
infrared	O
(	O
NIR	O
)	O
therapeutic	O
window	O
,	O
this	O
technique	O
can	O
serve	O
as	O
a	O
powerful	O
tool	O
to	O
monitor	O
the	O
drug	O
release	O
in	O
vivo	O
,	O
providing	O
additional	O
control	O
over	O
externally	O
triggered	O
drug	O
administration	O
.	O

Carcinogenicity	O
Prediction	O
of	O
Noncongeneric	O
Chemicals	O
by	O
a	O
Support	O
Vector	O
Machine	O
.	O

The	O
ability	O
to	O
identify	O
carcinogenic	O
compounds	O
is	O
of	O
fundamental	O
importance	O
to	O
the	O
safe	O
application	O
of	O
chemicals	O
.	O

In	O
this	O
study	O
,	O
we	O
generated	O
an	O
array	O
of	O
in	O
silico	O
models	O
allowing	O
the	O
classification	O
of	O
compounds	O
into	O
carcinogenic	O
and	O
noncarcinogenic	O
agents	O
based	O
on	O
a	O
data	O
set	O
of	O
852	O
noncongeneric	O
chemicals	O
collected	O
from	O
the	O
Carcinogenic	O
Potency	O
Database	O
(	O
CPDBAS	O
)	O
.	O

Twenty	O
-	O
four	O
molecular	O
descriptors	O
were	O
selected	O
by	O
Pearson	O
correlation	O
,	O
F	O
-	O
score	O
,	O
and	O
stepwise	O
regression	O
analysis	O
.	O

These	O
descriptors	O
cover	O
a	O
range	O
of	O
physicochemical	O
properties	O
,	O
including	O
electrophilicity	O
,	O
geometry	O
,	O
molecular	O
weight	O
,	O
size	O
,	O
and	O
solubility	O
.	O

The	O
descriptor	O
mutagenic	O
showed	O
the	O
highest	O
correlation	O
coefficient	O
with	O
carcinogenicity	O
.	O

On	O
the	O
basis	O
of	O
these	O
descriptors	O
,	O
a	O
support	O
vector	O
machine	O
-	O
based	O
(	O
SVM	O
)	O
classification	O
model	O
was	O
developed	O
and	O
fine	O
-	O
tuned	O
by	O
a	O
10-fold	O
cross	O
-	O
validation	O
approach	O
.	O

Both	O
the	O
SVM	O
model	O
(	O
Model	O
A1	O
)	O
and	O
the	O
best	O
model	O
from	O
the	O
10-fold	O
cross	O
-	O
validation	O
(	O
Model	O
B3	O
)	O
runs	O
gave	O
good	O
results	O
on	O
the	O
test	O
set	O
with	O
prediction	O
accuracy	O
over	O
80	O
%	O
,	O
sensitivity	O
over	O
76	O
%	O
,	O
and	O
specificity	O
over	O
82	O
%	O
.	O

In	O
addition	O
,	O
extended	O
connectivity	O
fingerprints	O
(	O
ECFPs	O
)	O
and	O
the	O
Toxtree	O
software	O
were	O
used	O
to	O
analyze	O
the	O
functional	O
groups	O
and	O
substructures	O
linked	O
to	O
carcinogenicity	O
.	O

It	O
was	O
found	O
that	O
the	O
results	O
of	O
both	O
methods	O
are	O
in	O
good	O
agreement	O
.	O

Monoacylglycerol	B
lipase	O
inhibition	O
-	O
induced	O
changes	O
in	O
plasma	O
corticosterone	B
levels	O
,	O
anxiety	O
and	O
locomotor	O
activity	O
in	O
male	O
CD1	O
mice	O
.	O

The	O
hypothalamus	O
-	O
pituitary	O
-	O
adrenal	O
-	O
axis	O
is	O
strongly	O
controlled	O
by	O
the	O
endocannabinoid	O
system	O
.	O

The	O
specific	O
impact	O
of	O
enhanced	O
2-arachidonoylglycerol	B
signaling	O
on	O
corticosterone	B
plasma	O
levels	O
,	O
however	O
,	O
was	O
not	O
investigated	O
so	O
far	O
.	O

Here	O
we	O
studied	O
the	O
effects	O
of	O
the	O
recently	O
developed	O
monoacylglycerol	B
lipase	O
inhibitor	O
JZL184	B
on	O
basal	O
and	O
stress	O
-	O
induced	O
corticosterone	B
levels	O
in	O
male	O
CD1	O
mice	O
,	O
and	O
found	O
that	O
this	O
compound	O
dramatically	O
increased	O
basal	O
levels	O
without	O
affecting	O
stress	O
responses	O
.	O

Since	O
acute	O
changes	O
in	O
corticosterone	B
levels	O
can	O
affect	O
behavior	O
,	O
JZL184	B
was	O
administered	O
concurrently	O
with	O
the	O
corticosterone	B
synthesis	O
inhibitor	O
metyrapone	B
,	O
to	O
investigate	O
whether	O
the	O
previously	O
shown	O
behavioral	O
effects	O
of	O
JZL184	B
are	O
dependent	O
on	O
corticosterone	B
.	O

We	O
found	O
that	O
in	O
the	O
elevated	O
plus	O
-	O
maze	O
,	O
the	O
effects	O
of	O
JZL184	B
on	O
"	O
classical	O
"	O
anxiety	O
-	O
related	O
measures	O
were	O
abolished	O
by	O
corticosterone	B
synthesis	O
blockade	O
.	O

By	O
contrast	O
,	O
effects	O
on	O
the	O
"	O
ethological	O
"	O
measures	O
of	O
anxiety	O
(	O
i.e.	O
risk	O
assessment	O
)	O
were	O
not	O
affected	O
by	O
metyrapone	B
.	O

In	O
the	O
open	O
-	O
field	O
,	O
the	O
locomotion	O
-	O
enhancing	O
effects	O
of	O
the	O
compound	O
were	O
not	O
changed	O
either	O
.	O

These	O
findings	O
show	O
that	O
monoacylglycerol	B
lipase	O
inhibition	O
dramatically	O
increases	O
basal	O
levels	O
of	O
corticosterone	B
.	O

This	O
endocrine	O
effect	O
partly	O
affects	O
the	O
anxiolytic	O
,	O
but	O
not	O
the	O
locomotion	O
-	O
enhancing	O
effects	O
of	O
monoacylglycerol	B
lipase	O
blockade	O
.	O

Effect	O
of	O
N	B
-	I
acetyl	I
cysteine	I
(	O
NAC	B
)	O
,	O
an	O
organosulfur	B
compound	O
from	O
Allium	O
plants	O
,	O
on	O
experimentally	O
induced	O
hepatic	O
prefibrogenic	O
events	O
in	O
wistar	O
rat	O
.	O

Aim	O
of	O
present	O
study	O
was	O
to	O
investigate	O
the	O
effect	O
of	O
NAC	B
on	O
experimental	O
chronic	O
hepatotoxicity	O
models	O
induced	O
by	O
carbon	B
tetrachloride	I
(	O
CCl4	B
)	O
and	O
thioacetamide	B
(	O
TAA	B
)	O
.	O

CCl4	O
toxicity	O
was	O
induced	O
by	O
administering	O
200l	O
CCl4	B
(	O
diluted	O
2:3	O
in	O
coconut	O
oil	O
)	O
/	O
100	O
g	O
body	O
weight	O
,	O
p.o	O
.	O
,	O
twice	O
weekly	O
for	O
8	O
weeks	O
.	O

TAA	B
toxicity	O
was	O
induced	O
by	O
administering	O
150mg	O
/	O
kg	O
b.	O
wt	O
.	O
of	O
TAA	B
i.p	O
.	O
,	O
twice	O
weekly	O
for	O
8	O
weeks	O
.	O

NAC	B
treatment	O
was	O
started	O
along	O
with	O
toxicants	O
(	O
CCl4	B
and	O
TAA	B
)	O
for	O
8	O
weeks	O
and	O
continued	O
for	O
further	O
4	O
weeks	O
.	O

Self	O
reversal	O
group	O
was	O
kept	O
without	O
any	O
treatment	O
for	O
4	O
weeks	O
after	O
completion	O
of	O
toxicant	O
treatments	O
.	O

Alanine	B
aminotransferase	O
(	O
ALT	O
)	O
,	O
Aspartate	B
aminotransferase	O
(	O
AST	O
)	O
,	O
Alkaline	O
phosphatase	O
(	O
ALP	O
)	O
,	O
Bilirubin	B
were	O
measured	O
in	O
serum	O
.	O

Hydroxyproline	B
(	O
HP	O
)	O
,	O
lipid	O
peroxidation	O
(	O
LPO	O
)	O
,	O
catalase	O
(	O
CAT	O
)	O
,	O
Glutathione	B
peroxidase	O
(	O
GPx	O
)	O
and	O
Glutathione	B
(	O
GSH	B
)	O
were	O
determined	O
in	O
liver	O
samples	O
by	O
colorimetric	O
methods	O
.	O

Cytochrome	O
P450	O
2E1	O
(	O
CYP	O
450	O
2E1	O
)	O
,	O
activity	O
was	O
determined	O
as	O
hydroxylation	O
of	O
aniline	B
in	O
liver	O
microsomes	O
.	O

General	O
examination	O
and	O
histological	O
analysis	O
were	O
also	O
performed	O
.	O

Serum	O
markers	O
of	O
liver	O
damage	O
(	O
AST	O
,	O
ALT	O
,	O
ALP	O
and	O
Bilirubin	B
)	O
were	O
increased	O
by	O
CCl4	B
and	O
TAA	B
intoxication	O
(	O
p<0.001	O
)	O
,	O
whereas	O
co	O
-	O
treatment	O
with	O
NAC	B
reversed	O
such	O
changes	O
(	O
p<0.001	O
)	O
.	O

HP	O
was	O
enhanced	O
in	O
toxicant	O
groups	O
(	O
p<0.001	O
in	O
CCl4	B
and	O
TAA	B
)	O
,	O
but	O
inhibited	O
by	O
NAC	B
(	O
p<0.001	O
)	O
.	O

LPO	O
was	O
increased	O
while	O
as	O
GSH	B
,	O
CAT	O
and	O
GPx	O
decreased	O
by	O
the	O
administration	O
of	O
CCl4	O
and	O
TAA	O
(	O
p<0.001	O
)	O
;	O
co	O
-	O
administration	O
of	O
NAC	B
restored	O
these	O
liver	O
markers	O
to	O
normal	O
levels	O
(	O
p<0.001	O
)	O
.	O

Biochemical	O
determinations	O
were	O
corroborated	O
by	O
general	O
and	O
histological	O
findings	O
.	O

Keeping	O
in	O
view	O
the	O
biochemical	O
and	O
histopathological	O
studies	O
,	O
it	O
was	O
concluded	O
that	O
CCl4	B
and	O
TAA	B
are	O
strong	O
hepatotoxic	O
agents	O
that	O
produce	O
liver	O
fibrosis	O
with	O
close	O
proximity	O
to	O
human	O
etiology	O
(	O
micronodular	O
cirrhosis	O
)	O
and	O
NAC	B
has	O
a	O
significant	O
protective	O
activity	O
against	O
CCl4	B
and	O
TAA	B
.	O

NAC	B
has	O
also	O
been	O
validated	O
as	O
a	O
model	O
against	O
oxidative	O
burden	O
in	O
chronic	O
liver	O
pathology	O
.	O

Pancreatic	O
beta	O
-	O
cell	O
response	O
to	O
increased	O
metabolic	O
demand	O
and	O
to	O
pharmacologic	O
secretagogues	O
requires	O
EPAC2A	O
.	O

Incretin	O
hormone	O
action	O
on	O
	O
-	O
cells	O
stimulates	O
in	O
parallel	O
two	O
different	O
intracellular	O
cyclic	B
AMP	I
-	O
dependent	O
signaling	O
branches	O
mediated	O
by	O
PKA	O
and	O
EPAC2A	O
.	O

Both	O
pathways	O
contribute	O
towards	O
potentiation	O
of	O
glucose	B
-	O
stimulated	O
insulin	O
secretion	O
(	O
GSIS	O
)	O
.	O

However	O
,	O
the	O
overall	O
functional	O
role	O
of	O
EPAC2A	O
in	O
	O
-	O
cells	O
as	O
it	O
relates	O
to	O
in	O
vivo	O
glucose	B
homeostasis	O
remains	O
incompletely	O
understood	O
.	O

Therefore	O
,	O
we	O
have	O
examined	O
in	O
vivo	O
GSIS	O
in	O
global	O
EPAC2A	O
knockout	O
mice	O
.	O

Additionally	O
,	O
we	O
have	O
conducted	O
in	O
vitro	O
studies	O
of	O
GSIS	O
and	O
calcium	B
dynamics	O
in	O
isolated	O
EPAC2A	O
-	O
deficient	O
islets	O
.	O

EPAC2A	O
deficiency	O
does	O
not	O
impact	O
glucose	B
-	O
stimulated	O
insulin	O
secretion	O
in	O
mice	O
under	O
basal	O
conditions	O
.	O

However	O
,	O
when	O
mice	O
are	O
exposed	O
to	O
diet	O
-	O
induced	O
insulin	O
resistance	O
,	O
pharmacologic	O
secretagogue	O
stimulation	O
of	O
	O
-	O
cells	O
with	O
an	O
incretin	O
hormone	O
glucagon	O
-	O
like	O
peptide-1	O
analogue	O
or	O
with	O
a	O
Fatty	B
Acid	I
Receptor	O
1	O
/	O
GPR40	O
selective	O
activator	O
,	O
EPAC2A	O
is	O
required	O
for	O
the	O
increased	O
	O
-	O
cell	O
response	O
to	O
secretory	O
demand	O
.	O

Under	O
these	O
circumstances	O
,	O
EPAC2A	O
is	O
required	O
for	O
potentiating	O
the	O
early	O
dynamic	O
increase	O
in	O
islet	O
calcium	B
levels	O
after	O
glucose	B
stimulation	O
,	O
which	O
is	O
reflected	O
in	O
potentiated	O
first	O
phase	O
insulin	O
secretion	O
.	O

These	O
studies	O
broaden	O
our	O
understanding	O
of	O
EPAC2A	O
function	O
and	O
highlight	O
its	O
significance	O
during	O
increased	O
secretory	O
demand	O
or	O
drive	O
on	O
	O
-	O
cells	O
.	O

Our	O
findings	O
advance	O
the	O
rationale	O
for	O
developing	O
EPAC2A	O
selective	O
pharmacologic	O
activators	O
for	O
	O
-	O
cell	O
targeted	O
pharmacotherapy	O
in	O
type	O
2	O
diabetes	O
mellitus	O
.	O

Salicylic	B
acid	I
alleviates	O
copper	B
toxicity	O
in	O
rice	O
(	O
Oryza	O
sativa	O
L.	O
)	O
seedlings	O
by	O
up	O
-	O
regulating	O
antioxidative	O
and	O
glyoxalase	O
systems	O
.	O

The	O
present	O
study	O
investigated	O
the	O
effect	O
of	O
salicylic	B
acid	I
(	O
SA	O
)	O
on	O
toxic	O
symptoms	O
,	O
lipid	O
peroxidation	O
,	O
reactive	O
oxygen	B
species	O
generation	O
and	O
responses	O
of	O
antioxidative	O
and	O
glyoxalase	O
systems	O
in	O
rice	O
seedlings	O
grown	O
hydroponically	O
under	O
copper	B
(	O
Cu	B
)	O
stress	O
for	O
48	O
h.	O
Exposures	O
of	O
75	O
and	O
150	O
M	O
Cu	B
(	I
2	I
+	I
)	I
caused	O
toxicity	O
symptoms	O
(	O
chlorosis	O
,	O
necrosis	O
and	O
rolling	O
in	O
leaves	O
)	O
,	O
sharp	O
increases	O
in	O
malondialdehyde	B
(	O
MDA	B
)	O
,	O
hydrogen	B
peroxide	I
(	O
H2O2	B
)	O
contents	O
and	O
lipoxygenase	O
(	O
LOX	O
)	O
activity	O
with	O
concomitant	O
reductions	O
of	O
chlorophyll	O
(	O
Chl	O
)	O
and	O
relative	O
water	O
content	O
(	O
RWC	O
)	O
.	O

Both	O
levels	O
of	O
Cu	B
decreased	O
ascorbic	B
acid	I
(	O
AsA	B
)	O
,	O
glutathione	B
(	O
GSH	B
)	O
,	O
non	O
-	O
protein	O
thiol	B
(	O
NPT	O
)	O
and	O
proline	B
contents	O
in	O
roots	O
but	O
rather	O
increased	O
in	O
leaves	O
except	O
that	O
AsA	B
decreased	O
in	O
leaves	O
too	O
.	O

These	O
results	O
together	O
with	O
overaccumulation	O
of	O
superoxide	B
(	O
O	B
2	I
(	I
-	I
)	I
)	O
and	O
H2O2	B
in	O
leaves	O
revealed	O
that	O
Cu	B
exposures	O
induced	O
oxidative	O
stress	O
.	O

Contrary	O
,	O
SA	O
-	O
pretreatment	O
(	O
100	O
M	O
for	O
24	O
h	O
)	O
reduced	O
toxicity	O
symptoms	O
and	O
diminished	O
Cu	B
-	O
induced	O
increases	O
in	O
LOX	O
activity	O
,	O
H2O2	B
,	O
MDA	B
and	O
proline	B
contents	O
while	O
the	O
levels	O
of	O
RWC	O
,	O
Chl	O
,	O
AsA	B
and	O
redox	O
ratios	O
were	O
elevated	O
.	O

Higher	O
levels	O
of	O
GSH	B
and	O
NPT	O
were	O
also	O
observed	O
in	O
roots	O
of	O
SA	O
-	O
pretreated	O
Cu	B
-	O
exposed	O
seedlings	O
.	O

SA	O
-	O
pretreatment	O
also	O
exerted	O
its	O
beneficial	O
role	O
by	O
inhibiting	O
the	O
Cu	B
upward	O
process	O
.	O

Studies	O
on	O
antioxidant	O
enzymes	O
showed	O
that	O
SA	O
further	O
enhanced	O
the	O
activities	O
of	O
superoxide	B
dismutase	O
,	O
ascorbate	B
peroxidase	O
,	O
glutathione	B
reductase	O
and	O
glutathione	B
peroxidase	O
,	O
and	O
also	O
elevated	O
the	O
depressed	O
activities	O
of	O
catalase	O
,	O
dehydroascorbate	B
reductase	O
and	O
glutathione	B
S	O
-	O
transferase	O
particularly	O
at	O
150	O
M	O
Cu	B
(	I
2	I
+	I
)	I
stress	O
.	O

In	O
addition	O
,	O
the	O
activity	O
of	O
glyoxalase	O
system	O
(	O
glyoxalase	O
I	O
and	O
II	O
)	O
was	O
further	O
elevated	O
by	O
SA	O
pretreatment	O
in	O
the	O
Cu	B
-	O
exposed	O
seedlings	O
.	O

These	O
results	O
concluded	O
that	O
SA	O
-	O
mediated	O
retention	O
of	O
Cu	B
in	O
roots	O
and	O
enhanced	O
capacity	O
of	O
both	O
antioxidative	O
and	O
glyoxalase	O
systems	O
might	O
be	O
associated	O
with	O
the	O
alleviation	O
of	O
Cu	B
-	O
toxicity	O
in	O
rice	O
seedlings	O
.	O

Endowing	O
carbon	B
nanotubes	O
with	O
superparamagnetic	O
properties	O
:	O
applications	O
for	O
cell	O
labeling	O
,	O
MRI	O
cell	O
tracking	O
and	O
magnetic	O
manipulations	O
.	O

Coating	O
of	O
carbon	B
nanotubes	O
(	O
CNTs	O
)	O
with	O
magnetic	O
nanoparticles	O
(	O
NPs	O
)	O
imparts	O
novel	O
magnetic	O
,	O
optical	O
,	O
and	O
thermal	O
properties	O
with	O
potential	O
applications	O
in	O
the	O
biomedical	O
domain	O
.	O

Multi	O
-	O
walled	O
CNTs	O
have	O
been	O
decorated	O
with	O
iron	B
oxide	I
superparamagnetic	O
NPs	O
.	O

Two	O
different	O
approaches	O
have	O
been	O
investigated	O
based	O
on	O
ligand	O
exchange	O
or	O
"	O
click	O
chemistry	O
"	O
.	O

The	O
presence	O
of	O
the	O
NPs	O
on	O
the	O
nanotube	O
surface	O
allows	O
conferring	O
magnetic	O
properties	O
to	O
CNTs	O
.	O

We	O
have	O
evaluated	O
the	O
potential	O
of	O
the	O
NP	O
/	O
CNT	O
hybrids	O
as	O
a	O
contrast	O
agent	O
for	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
and	O
their	O
interactions	O
with	O
cells	O
.	O

The	O
capacity	O
of	O
the	O
hybrids	O
to	O
magnetically	O
monitor	O
and	O
manipulate	O
cells	O
has	O
also	O
been	O
investigated	O
.	O

The	O
NP	O
/	O
CNTs	O
can	O
be	O
manipulated	O
by	O
a	O
remote	O
magnetic	O
field	O
with	O
enhanced	O
contrast	O
in	O
MRI	O
.	O

They	O
are	O
internalized	O
into	O
tumor	O
cells	O
without	O
showing	O
cytotoxicity	O
.	O

The	O
labeled	O
cells	O
can	O
be	O
magnetically	O
manipulated	O
as	O
they	O
display	O
magnetic	O
mobility	O
and	O
are	O
detected	O
at	O
a	O
single	O
cell	O
level	O
through	O
high	O
resolution	O
MRI	O
.	O

The	O
lack	O
of	O
association	O
between	O
components	O
of	O
metabolic	O
syndrome	O
and	O
treatment	O
resistance	O
in	O
depression	O
.	O

RATIONALE	O
:	O
Although	O
a	O
number	O
of	O
studies	O
investigated	O
the	O
link	O
between	O
major	O
depressive	O
disorder	O
(	O
MDD	O
)	O
and	O
metabolic	O
syndrome	O
(	O
MetS	O
)	O
,	O
the	O
association	O
between	O
MetS	O
and	O
treatment	O
-	O
resistant	O
depression	O
(	O
TRD	O
)	O
is	O
still	O
not	O
clear	O
.	O

OBJECTIVES	O
:	O
The	O
aim	O
of	O
the	O
study	O
was	O
to	O
investigate	O
the	O
relationship	O
between	O
TRD	O
and	O
MetS	O
and/or	O
components	O
of	O
MetS	O
and	O
cardiovascular	O
risk	O
factors	O
.	O

Given	O
the	O
high	O
prevalence	O
of	O
both	O
conditions	O
,	O
the	O
hypothesis	O
was	O
that	O
TRD	O
would	O
be	O
significantly	O
associated	O
with	O
MetS.	O
METHODS	O
:	O
This	O
cross	O
-	O
sectional	O
study	O
included	O
203	O
inpatients	O
with	O
MDD	O
,	O
assessed	O
for	O
the	O
treatment	O
resistance	O
,	O
MetS	O
and	O
its	O
components	O
,	O
and	O
severity	O
of	O
MDD	O
.	O

Diagnoses	O
and	O
evaluations	O
were	O
made	O
with	O
SCID	O
based	O
on	O
DSM	O
-	O
IV	O
,	O
National	O
Cholesterol	B
Education	O
Program	O
Adult	O
Treatment	O
Panel	O
III	O
criteria	O
,	O
and	O
the	O
Hamilton	O
Depression	O
Rating	O
Scale	O
.	O

RESULTS	O
:	O
TRD	O
prior	O
to	O
study	O
entry	O
was	O
found	O
in	O
26.1	O
%	O
of	O
patients	O
,	O
while	O
MetS	O
was	O
observed	O
in	O
33.5	O
%	O
of	O
patients	O
.	O

The	O
prevalence	O
of	O
MetS	O
did	O
not	O
differ	O
significantly	O
between	O
TRD	O
and	O
non	O
-	O
TRD	O
patients	O
.	O

In	O
addition	O
,	O
the	O
frequency	O
of	O
the	O
altered	O
values	O
of	O
particular	O
components	O
of	O
the	O
MetS	O
or	O
cardiovascular	O
risk	O
factors	O
was	O
not	O
associated	O
with	O
treatment	O
resistance	O
in	O
depressed	O
patients	O
.	O

Patients	O
with	O
TRD	O
were	O
older	O
,	O
had	O
a	O
higher	O
number	O
of	O
lifetime	O
episodes	O
of	O
depression	O
and	O
suicide	O
attempts	O
,	O
and	O
longer	O
duration	O
of	O
MDD	O
compared	O
to	O
non	O
-	O
TRD	O
patients	O
.	O

CONCLUSIONS	O
:	O
The	O
occurrence	O
of	O
either	O
MetS	O
or	O
the	O
particular	O
components	O
of	O
the	O
MetS	O
and	O
other	O
cardiovascular	O
risk	O
factors	O
was	O
similar	O
between	O
TRD	O
and	O
non	O
-	O
TRD	O
patients	O
.	O

Although	O
there	O
is	O
a	O
bidirectional	O
relationship	O
between	O
depression	O
and	O
MetS	O
,	O
neither	O
MetS	O
nor	O
its	O
components	O
appear	O
to	O
influence	O
treatment	O
resistance	O
to	O
antidepressants	O
.	O

Application	O
of	O
Ultra	O
-	O
Performance	O
Liquid	O
Chromatography	O
/	O
Mass	O
Spectrometry	O
-	O
Based	O
Metabonomic	O
Techniques	O
to	O
Analyze	O
the	O
Joint	O
Toxic	O
Action	O
of	O
Long	O
-	O
Term	O
Low	O
-	O
Level	O
Exposure	O
to	O
a	O
Mixture	O
of	O
Organophosphate	B
Pesticides	O
on	O
Rat	O
Urine	O
Profile	O
.	O

In	O
previously	O
published	O
articles	O
,	O
we	O
evaluated	O
the	O
toxicity	O
of	O
four	O
organophosphate	B
(	O
OP	O
)	O
pesticides	O
(	O
dichlorvos	B
,	O
dimethoate	B
,	O
acephate	B
and	O
phorate	B
)	O
to	O
rats	O
using	O
metabonomic	O
technology	O
at	O
their	O
corresponding	O
no	O
observed	O
adverse	O
effect	O
level	O
(	O
NOAEL	O
)	O
.	O

Results	O
show	O
that	O
a	O
single	O
pesticide	O
elicits	O
no	O
toxic	O
response	O
.	O

The	O
present	O
study	O
aimed	O
to	O
determine	O
whether	O
chronic	O
exposure	O
to	O
a	O
mixture	O
of	O
the	O
above	O
four	O
pesticides	O
(	O
at	O
their	O
corresponding	O
NOAEL	O
)	O
can	O
lead	O
to	O
joint	O
toxic	O
action	O
in	O
rats	O
using	O
the	O
same	O
technology	O
.	O

Pesticides	O
were	O
administered	O
daily	O
to	O
rats	O
through	O
drinking	O
water	O
for	O
24	O
weeks	O
.	O

The	O
above	O
mixture	O
of	O
the	O
four	O
pesticides	O
showed	O
joint	O
toxic	O
action	O
at	O
the	O
NOAEL	O
of	O
each	O
pesticide	O
.	O

The	O
metabonomic	O
profiles	O
of	O
rats	O
urine	O
were	O
analyzed	O
by	O
ultra	O
-	O
performance	O
liquid	O
chromatography	O
/	O
mass	O
spectrometry	O
.	O

The	O
16	O
metabolites	O
statistically	O
significantly	O
changed	O
in	O
all	O
treated	O
groups	O
compared	O
with	O
the	O
control	O
group	O
.	O

Dimethylphosphate	B
and	O
dimethyldithiophosphate	B
exclusively	O
detected	O
in	O
all	O
treated	O
groups	O
can	O
be	O
used	O
as	O
early	O
,	O
sensitive	O
biomarkers	O
for	O
exposure	O
to	O
a	O
mixture	O
of	O
the	O
OP	O
pesticides	O
.	O

Moreover	O
,	O
exposure	O
to	O
the	O
OP	O
pesticides	O
resulted	O
in	O
increased	O
7-methylguanine	B
,	O
ribothymidine	B
,	O
cholic	B
acid	I
,	O
4-pyridoxic	B
acid	I
,	O
kynurenine	B
and	O
indoxyl	B
sulfate	I
levels	O
,	O
as	O
well	O
as	O
decreased	O
hippuric	B
acid	I
,	O
creatinine	B
,	O
uric	B
acid	I
,	O
gentisic	B
acid	I
,	O
C18-dihydrosphingosine	B
,	O
phytosphingosine	B
,	O
suberic	B
acid	I
and	O
citric	B
acid	I
.	O

The	O
results	O
indicated	O
that	O
a	O
mixture	O
of	O
OP	O
pesticides	O
induced	O
DNA	O
damage	O
,	O
oxidative	O
stress	O
,	O
disturbed	O
the	O
metabolism	O
of	O
lipids	O
as	O
well	O
as	O
interfered	O
with	O
the	O
tricarboxylic	B
acid	I
cycle	O
.	O

Ensuring	O
food	O
safety	O
requires	O
not	O
only	O
the	O
toxicology	O
test	O
data	O
of	O
each	O
pesticide	O
for	O
the	O
calculation	O
of	O
the	O
acceptable	O
daily	O
intake	O
,	O
but	O
also	O
the	O
joint	O
toxic	O
action	O
.	O

Anti	O
-	O
Ulcerative	O
Colitis	O
Activity	O
of	O
Compounds	O
from	O
Euphorbia	O
granuleta	O
Forssk	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
the	O
anti	O
-	O
ulcerative	O
colitis	O
(	O
UC	O
)	O
activity	O
of	O
the	O
total	O
alcohol	B
extracts	O
of	O
Euphorbia	O
granuleta	O
Forssk	O
.	O

(	O
Euphorpiaceae	O
)	O
,	O
isolate	O
and	O
identify	O
the	O
active	O
compounds	O
that	O
could	O
be	O
responsible	O
for	O
the	O
activity	O
,	O
in	O
addition	O
to	O
determination	O
of	O
the	O
possible	O
mechanism	O
of	O
action	O
.	O

Six	O
compounds	O
were	O
isolated	O
and	O
identified	O
from	O
this	O
plant	O
:	O
three	O
phenolic	B
compounds	O
(	O
kampferol	B
,	O
kampferol-3-glucoside	B
and	O
kampferol-3-galactoside	B
)	O
in	O
addition	O
to	O
three	O
steroidal	O
compounds	O
(	O
1-ethoxypentacosane	B
,	O
heptacosan-1-ol	B
and	O
	B
-	I
sitosterol	I
)	O
.	O

Three	O
compounds	O
(	O
heptacosan-1-ol	B
,	O
	B
-	I
sitosterol	I
and	O
kampferol-3-galactoside	B
)	O
were	O
found	O
to	O
be	O
responsible	O
for	O
the	O
anti	O
-	O
UC	O
activity	O
of	O
E.	O
granuleta	O
extract	O
.	O

The	O
anti	O
-	O
UC	O
activity	O
of	O
these	O
compounds	O
may	O
be	O
explained	O
by	O
reducing	O
the	O
pro	O
-	O
inflammatory	O
cytokine	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
	O
)	O
,	O
in	O
addition	O
to	O
reduction	O
of	O
colonic	O
malondialdehyde	B
(	O
MDA	B
)	O
contents	O
.	O

No	O
side	O
effects	O
were	O
reported	O
on	O
liver	O
and	O
kidney	O
functions	O
.	O

The	O
active	O
compounds	O
reduced	O
both	O
serum	O
TNF	O
-	O
	O
and	O
mucosal	O
MDA	B
levels	O
.	O

Copyright	O
	O
2013	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd.	O

Decursin	B
Exerts	O
Anti	O
-	O
cancer	O
Activity	O
in	O
MDA	O
-	O
MB-231	O
Breast	O
Cancer	O
Cells	O
Via	O
Inhibition	O
of	O
the	O
Pin1	O
Activity	O
and	O
Enhancement	O
of	O
the	O
Pin1	O
/	O
p53	O
Association	O
.	O

The	O
peptidyl	O
-	O
prolyl	B
cis	O
/	O
trans	O
isomerase	O
Pin1	O
is	O
overexpressed	O
in	O
a	O
wide	O
variety	O
of	O
cancer	O
cells	O
and	O
thus	O
considered	O
as	O
an	O
important	O
target	O
molecule	O
for	O
cancer	O
therapy	O
.	O

This	O
study	O
demonstrates	O
that	O
decursin	B
,	O
a	O
bioactive	O
compound	O
from	O
Angelica	O
gigas	O
,	O
exert	O
the	O
anti	O
-	O
cancer	O
effect	O
against	O
breast	O
cancer	O
cells	O
via	O
regulation	O
of	O
Pin1	O
and	O
its	O
related	O
signaling	O
molecules	O
.	O

We	O
observed	O
that	O
decursin	B
induced	O
G1	O
arrest	O
with	O
decrease	O
in	O
cyclin	O
D1	O
level	O
in	O
Pin1-expressing	O
breast	O
cancer	O
cells	O
MDA	O
-	O
MB-231	O
,	O
but	O
not	O
Pin1-non	O
-	O
expressing	O
breast	O
cancer	O
cells	O
MDA	O
-	O
MB-157	O
.	O

In	O
addition	O
,	O
decursin	B
significantly	O
reduced	O
protein	O
expression	O
and	O
enzymatic	O
activity	O
of	O
Pin1	O
in	O
MDA	O
-	O
MB-231	O
cells	O
.	O

Further	O
,	O
we	O
found	O
that	O
decursin	B
treatment	O
enhanced	O
the	O
p53	O
expression	O
level	O
and	O
failed	O
to	O
down	O
-	O
regulate	O
Pin1	O
in	O
the	O
cells	O
transfected	O
with	O
p53	O
siRNA	O
,	O
indicating	O
the	O
importance	O
of	O
p53	O
in	O
the	O
decursin	B
-	O
mediated	O
Pin1	O
inhibition	O
in	O
MDA	O
-	O
MB-231	O
cells	O
.	O

Decursin	B
stimulated	O
association	O
between	O
Pin1	O
to	O
p53	O
.	O

Moreover	O
,	O
decursin	B
facilitated	O
p53	O
transcription	O
in	O
MDA	O
-	O
MB-231	O
cells	O
.	O

Overall	O
,	O
our	O
current	O
study	O
suggests	O
the	O
potential	O
of	O
decursin	B
as	O
an	O
attractive	O
cancer	O
therapeutic	O
agent	O
for	O
breast	O
cancer	O
by	O
targeting	O
Pin1	O
protein	O
.	O

Copyright	O
	O
2013	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd.	O

Pharmacological	O
Inhibition	O
of	O
Platelet	O
-	O
tumor	O
Cell	O
Cross	O
-	O
talk	O
Prevents	O
Platelet	O
-	O
induced	O
Overexpression	O
of	O
Cyclooxygenase-2	O
in	O
HT29	O
Human	O
Colon	O
Carcinoma	O
Cells	O
.	O

Cyclooxygenase	O
(	O
COX	O
)	O
-2-derived	O
prostanoids	B
can	O
influence	O
several	O
processes	O
that	O
are	O
linked	O
to	O
carcinogenesis	O
.	O

We	O
aimed	O
to	O
address	O
the	O
hypothesis	O
that	O
platelets	O
contribute	O
to	O
aberrant	O
COX-2	O
expression	O
in	O
HT29	O
colon	O
carcinoma	O
cells	O
and	O
to	O
reveal	O
the	O
role	O
of	O
platelet	O
-	O
induced	O
COX-2	O
on	O
the	O
expression	O
of	O
proteins	O
involved	O
in	O
malignancy	O
and	O
marker	O
genes	O
of	O
epithelial	O
-	O
mesenchymal	O
transition	O
(	O
EMT	O
)	O
.	O

Human	O
platelets	O
co	O
-	O
cultured	O
with	O
HT29	O
cells	O
rapidly	O
adhered	O
to	O
cancer	O
cells	O
and	O
induced	O
COX-2	O
mRNA	O
expression	O
,	O
but	O
not	O
protein	O
synthesis	O
which	O
required	O
the	O
late	O
release	O
of	O
platelet	O
PDGF	O
and	O
COX-2	O
mRNA	O
stabilization	O
.	O

Platelet	O
-	O
induced	O
COX-2-dependent	O
PGE2	B
synthesis	O
in	O
HT29	O
cells	O
was	O
involved	O
in	O
downregulation	O
of	O
p21	O
(	O
WAF1	O
/	O
CIP1	O
)	O
and	O
upregulation	O
of	O
cyclinB1	O
,	O
since	O
these	O
effects	O
were	O
prevented	O
by	O
rofecoxib	B
(	O
a	O
selective	O
COX-2	O
inhibitor	O
)	O
and	O
rescued	O
by	O
exogenous	O
PGE2	B
.	O

Galectin-3	O
,	O
highly	O
expressed	O
in	O
HT29	O
cells	O
,	O
is	O
unique	O
among	O
galectins	O
because	O
it	O
contains	O
a	O
collagen	O
-	O
like	O
domain	O
.	O

Thus	O
,	O
we	O
studied	O
the	O
role	O
of	O
galectin-3	O
and	O
platelet	O
collagen	O
receptors	O
in	O
platelet	O
-	O
induced	O
COX-2	O
overexpression	O
.	O

Inhibitors	O
of	O
galectin-3	O
function	O
(	O
	B
-	I
lactose	I
,	O
a	O
dominant	O
-	O
negative	O
form	O
of	O
galectin-3,Gal-3C	O
,	O
and	O
anti	O
-	O
galectin-3	O
antibody	O
M3	O
/	O
38	O
)	O
or	O
collagen	O
receptor	O
-	O
mediated	O
platelet	O
adhesion	O
(	O
revacept	O
,	O
a	O
dimeric	O
collagen	O
receptor	O
GPVI	O
-	O
Fc	O
)	O
prevented	O
aberrant	O
COX-2	O
expression	O
.	O

Inhibition	O
of	O
platelet	O
-	O
cancer	O
cell	O
interaction	O
by	O
revacept	O
was	O
more	O
effective	O
than	O
rofecoxib	B
in	O
preventing	O
platelet	O
-	O
induced	O
mRNA	O
changes	O
of	O
EMT	O
markers	O
suggesting	O
that	O
direct	O
cell	O
-	O
cell	O
contact	O
and	O
aberrant	O
COX-2	O
expression	O
synergistically	O
induced	O
gene	O
expression	O
modifications	O
associated	O
with	O
EMT	O
.	O

In	O
conclusion	O
,	O
our	O
findings	O
provide	O
the	O
rationale	O
for	O
testing	O
blockers	O
of	O
collagen	O
binding	O
sites	O
,	O
such	O
as	O
revacept	O
,	O
and	O
galectin-3	O
inhibitors	O
in	O
the	O
prevention	O
of	O
colon	O
cancer	O
metastasis	O
in	O
animal	O
models	O
followed	O
by	O
studies	O
in	O
patients	O
.	O

The	O
absence	O
of	O
ER	O
results	O
in	O
altered	O
gene	O
expression	O
in	O
ovarian	O
granulosa	O
cells	O
isolated	O
from	O
in	O
vivo	O
preovulatory	O
follicles	O
.	O

Determining	O
the	O
spatial	O
and	O
temporal	O
expression	O
of	O
genes	O
involved	O
in	O
the	O
ovulatory	O
pathway	O
is	O
critical	O
for	O
the	O
understanding	O
of	O
the	O
role	O
of	O
each	O
estrogen	B
receptor	O
in	O
the	O
modulation	O
of	O
folliculogenesis	O
and	O
ovulation	O
.	O

Estrogen	B
receptor	O
(	O
ER	O
)	O
	O
is	O
highly	O
expressed	O
in	O
ovarian	O
granulosa	O
cells	O
and	O
mice	O
lacking	O
ER	O
(	O
ERKO	O
)	O
are	O
subfertile	O
due	O
to	O
inefficient	O
ovulation	O
.	O

Previous	O
work	O
has	O
focused	O
on	O
isolated	O
granulosa	O
cells	O
or	O
cultured	O
follicles	O
and	O
while	O
informative	O
,	O
provides	O
confounding	O
results	O
due	O
to	O
the	O
heterogeneous	O
cell	O
types	O
present	O
including	O
granulosa	O
,	O
theca	O
and	O
oocytes	O
and	O
exposure	O
to	O
in	O
vitro	O
conditions	O
.	O

Herein	O
,	O
we	O
isolated	O
preovulatory	O
granulosa	O
cells	O
from	O
WT	O
and	O
ER	O
-	O
null	O
mice	O
using	O
laser	O
capture	O
microdissection	O
to	O
examine	O
the	O
genomic	O
transcriptional	O
response	O
downstream	O
of	O
PMSG	O
(	O
mimicking	O
FSH	O
)	O
and	O
PMSG	O
/	O
hCG	O
(	O
mimicking	O
LH	O
)	O
stimulation	O
.	O

This	O
allows	O
for	O
a	O
direct	O
comparison	O
of	O
in	O
vivo	O
granulosa	O
cells	O
at	O
the	O
same	O
stage	O
of	O
development	O
from	O
both	O
WT	O
and	O
ER	O
-	O
null	O
ovaries	O
.	O

ER	O
-	O
null	O
granulosa	O
cells	O
showed	O
altered	O
expression	O
of	O
genes	O
known	O
to	O
be	O
regulated	O
by	O
FSH	O
(	O
Akap12	O
and	O
Runx2	O
)	O
as	O
well	O
as	O
not	O
previously	O
reported	O
(	O
Arnt2	O
and	O
Pou5f1	O
)	O
in	O
WT	O
granulosa	O
cells	O
.	O

Our	O
analysis	O
also	O
identified	O
304	O
genes	O
not	O
previously	O
associated	O
with	O
ER	O
in	O
granulosa	O
cells	O
.	O

LH	O
responsive	O
genes	O
including	O
Abcb1b	O
and	O
Fam110c	O
show	O
reduced	O
expression	O
in	O
ER	O
-	O
null	O
granulosa	O
cells	O
;	O
however	O
novel	O
genes	O
including	O
Rassf2	O
and	O
Megf10	O
were	O
also	O
identified	O
as	O
being	O
downstream	O
of	O
LH	O
signaling	O
in	O
granulosa	O
cells	O
.	O

Collectively	O
,	O
our	O
data	O
suggests	O
that	O
granulosa	O
cells	O
from	O
ER	O
-	O
null	O
ovaries	O
may	O
not	O
be	O
appropriately	O
differentiated	O
and	O
are	O
unable	O
to	O
respond	O
properly	O
to	O
gonadotropin	O
stimulation	O
.	O

A	O
Butterfly	O
-	O
Shaped	O
Pyrene	B
Derivative	O
of	O
Cholesterol	B
and	O
Its	O
Uses	O
as	O
a	O
Fluorescent	O
Probe	O
.	O

A	O
butterfly	O
-	O
shaped	O
pyrene	O
derivative	O
of	O
cholesterol	B
,	O
namely	O
,	O
N	B
,	I
N'-	I
(	I
ethane-1,2-diyl	I
)	I
-bis	I
(	I
N-	I
(	I
2-	I
(	I
chol	I
-	I
amino	I
)	I
ethyl	I
)	I
pyrene-1-sulfonamide	I
)	I
(	O
ECPS	B
)	O
,	O
has	O
been	O
designed	O
and	O
synthesized	O
.	O

Solvent	O
effect	O
studies	O
revealed	O
that	O
in	O
good	O
solvents	O
such	O
as	O
n	B
-	I
hexane	I
,	O
benzene	B
,	O
and	O
1,4-dioxane	B
,	O
the	O
profile	O
of	O
the	O
fluorescence	O
emission	O
of	O
the	O
compound	O
is	O
characterized	O
by	O
pyrene	B
monomer	O
emission	O
,	O
but	O
in	O
poor	O
solvent	O
such	O
as	O
water	O
,	O
the	O
emission	O
is	O
dominated	O
by	O
pyrene	O
excimer	O
emission	O
.	O

Quantitatively	O
speaking	O
,	O
the	O
ratio	O
of	O
the	O
excimer	O
emission	O
to	O
monomer	O
emission	O
changes	O
from	O
50	O
to	O
0	O
when	O
ECPS	O
is	O
dissolved	O
in	O
water	O
and	O
n	B
-	I
hexane	I
,	O
respectively	O
.	O

In	O
contrast	O
,	O
for	O
a	O
commonly	O
used	O
polarity	O
probe	O
pyrene	B
,	O
the	O
ratio	O
of	O
I3	O
/	O
I1	O
varies	O
only	O
from	O
0.6	O
to	O
1.7	O
,	O
where	O
I3	O
and	O
I1	O
stand	O
for	O
the	O
intensities	O
of	O
the	O
fluorescence	O
emission	O
at	O
peak	O
3	O
and	O
peak	O
1	O
,	O
respectively	O
.	O

This	O
value	O
suggests	O
that	O
a	O
more	O
powerful	O
discriminating	O
ability	O
of	O
the	O
new	O
compound	O
in	O
polarity	O
sensing	O
.	O

Furthermore	O
,	O
unlike	O
the	O
main	O
components	O
of	O
the	O
compound	O
,	O
pyrene	B
and	O
cholesterol	B
,	O
its	O
main	O
chain	O
is	O
composed	O
of	O
multiple	O
hydrophilic	O
structures	O
,	O
and	O
it	O
is	O
this	O
structure	O
that	O
makes	O
the	O
emission	O
of	O
the	O
compound	O
in	O
organic	O
solvents	O
sensitive	O
to	O
the	O
presence	O
of	O
water	O
.	O

Accordingly	O
,	O
the	O
applicability	O
of	O
the	O
compound	O
in	O
determination	O
of	O
the	O
trace	O
amount	O
of	O
water	O
in	O
some	O
organic	O
solvents	O
was	O
evaluated	O
.	O

As	O
expected	O
,	O
the	O
detection	O
limit	O
of	O
the	O
compound	O
toward	O
water	O
in	O
acetonitrile	B
reaches	O
7	O
ppm	O
,	O
a	O
result	O
never	O
reached	O
before	O
.	O

Furthermore	O
,	O
the	O
fluorescence	O
emission	O
of	O
the	O
compound	O
is	O
also	O
sensitive	O
to	O
viscosity	O
variation	O
.	O

Therefore	O
,	O
it	O
is	O
assumed	O
that	O
ECPS	B
may	O
be	O
used	O
both	O
as	O
a	O
polarity	O
probe	O
and	O
a	O
viscosity	O
probe	O
.	O

On	O
the	O
bases	O
of	O
a	O
series	O
of	O
steady	O
-	O
state	O
and	O
time	O
-	O
resolved	O
fluorescence	O
,	O
as	O
well	O
as	O
dynamic	O
light	O
scattering	O
studies	O
,	O
a	O
structural	O
model	O
was	O
proposed	O
to	O
rationalize	O
the	O
fluorescence	O
behavior	O
of	O
the	O
compound	O
in	O
different	O
solvents	O
and	O
its	O
polarity	O
and	O
viscosity	O
probing	O
performances	O
.	O

Condensation	O
of	O
DNA	O
-	O
A	O
putative	O
obstruction	O
for	O
repair	O
process	O
in	O
abasic	O
clustered	O
DNA	O
damage	O
.	O

Clustered	O
DNA	O
damages	O
are	O
defined	O
as	O
two	O
or	O
more	O
closely	O
located	O
DNA	O
damage	O
lesions	O
that	O
may	O
be	O
present	O
within	O
a	O
few	O
helical	O
turns	O
of	O
the	O
DNA	O
double	O
strand	O
.	O

These	O
damages	O
are	O
potential	O
signatures	O
of	O
ionizing	O
radiation	O
and	O
are	O
often	O
found	O
to	O
be	O
repair	O
resistant	O
.	O

Types	O
of	O
damaged	O
lesions	O
frequently	O
found	O
inside	O
clustered	O
DNA	O
damage	O
sites	O
include	O
oxidized	O
bases	O
,	O
abasic	O
sites	O
,	O
nucleotide	B
dimers	I
,	O
strand	O
breaks	O
or	O
their	O
complex	O
combinations	O
.	O

In	O
this	O
study	O
,	O
we	O
used	O
a	O
bistranded	O
two	O
-	O
lesion	O
abasic	O
cluster	O
DNA	O
damage	O
model	O
to	O
access	O
the	O
repair	O
process	O
of	O
DNA	O
in	O
condensate	O
form	O
.	O

Oligomer	O
DNA	O
duplexes	O
(	O
47bp	O
)	O
were	O
designed	O
to	O
have	O
two	O
deoxyuridine	B
in	O
the	O
middle	O
of	O
the	O
sequences	O
,	O
three	O
bases	O
apart	O
in	O
opposite	O
strands	O
.	O

The	O
deoxyuridine	B
residues	O
were	O
converted	O
into	O
abasic	O
sites	O
by	O
treatment	O
with	O
UDG	O
enzyme	O
creating	O
an	O
abasic	O
clustered	O
damage	O
site	O
in	O
a	O
precise	O
position	O
in	O
each	O
of	O
the	O
single	O
strand	O
of	O
the	O
DNA	O
duplex	O
.	O

This	O
oligomer	O
duplex	O
having	O
compatible	O
cohesive	O
ends	O
was	O
ligated	O
to	O
pUC19	O
plasmid	O
,	O
linearized	O
with	O
HindIII	O
restriction	O
endonuclease	O
.	O

The	O
plasmid	O
-	O
oligomer	O
conjugate	O
was	O
transformed	O
into	O
condensates	O
by	O
treating	O
them	O
with	O
spermidine	B
.	O

The	O
efficiency	O
of	O
strand	O
cleavage	O
action	O
of	O
ApeI	O
enzyme	O
on	O
the	O
abasic	O
sites	O
was	O
determined	O
by	O
denaturing	O
PAGE	O
after	O
timed	O
incubation	O
of	O
the	O
oligomer	O
duplex	O
and	O
the	O
oligomer	O
-	O
plasmid	O
conjugate	O
in	O
presence	O
and	O
absence	O
of	O
spermidine	B
.	O

The	O
efficiency	O
of	O
double	O
strand	O
breaks	O
was	O
determined	O
similarly	O
by	O
native	O
PAGE	O
.	O

Quantitative	O
gel	O
analysis	O
revealed	O
that	O
rate	O
of	O
abasic	O
site	O
cleavage	O
is	O
reduced	O
in	O
the	O
DNA	O
condensates	O
as	O
compared	O
to	O
the	O
oligomer	O
DNA	O
duplex	O
or	O
the	O
linear	O
ligated	O
oligomer	O
-	O
plasmid	O
conjugates	O
.	O

Generation	O
of	O
double	O
strand	O
break	O
is	O
significantly	O
reduced	O
also	O
,	O
suggesting	O
that	O
their	O
creation	O
is	O
not	O
proportionate	O
to	O
the	O
number	O
of	O
abasic	O
sites	O
cleaved	O
in	O
the	O
condensate	O
model	O
.	O

All	O
these	O
suggest	O
that	O
the	O
ApeI	O
enzyme	O
have	O
difficulty	O
to	O
access	O
the	O
abasic	O
sites	O
located	O
deep	O
into	O
the	O
condensates	O
leading	O
to	O
repair	O
refractivity	O
of	O
the	O
damages	O
.	O

In	O
addition	O
,	O
we	O
found	O
that	O
presence	O
of	O
a	O
polyamine	B
such	O
as	O
spermidine	B
has	O
no	O
notable	O
effect	O
in	O
the	O
incision	O
activity	O
of	O
ApeI	O
enzyme	O
in	O
linear	O
oligomer	O
DNA	O
duplexes	O
in	O
our	O
experimental	O
concentration	O
.	O

Synthesis	O
and	O
antitumor	O
activity	O
of	O
1,3,4-oxadiazole	B
possessing	O
1,4-benzodioxan	B
moiety	O
as	O
a	O
novel	O
class	O
of	O
potent	O
methionine	B
aminopeptidase	O
type	O
II	O
inhibitors	O
.	O

A	O
series	O
of	O
1,3,4-oxadiazole	B
derivatives	O
containing	O
1,4-benzodioxan	B
moiety	O
(	O
7a-7q	O
)	O
have	O
been	O
designed	O
,	O
synthesized	O
and	O
evaluated	O
for	O
their	O
antitumor	O
activity	O
.	O

Most	O
of	O
the	O
synthesized	O
compounds	O
were	O
proved	O
to	O
have	O
potent	O
antitumor	O
activity	O
and	O
low	O
toxicity	O
.	O

Among	O
them	O
,	O
compound	O
7a	O
showed	O
the	O
most	O
potent	O
biological	O
activity	O
against	O
Human	O
Umbilical	O
Vein	O
Endothelial	O
cells	O
,	O
which	O
was	O
comparable	O
to	O
the	O
positive	O
control	O
.	O

The	O
results	O
of	O
apoptosis	O
and	O
flow	O
cytometry	O
(	O
FCM	O
)	O
demonstrated	O
that	O
compound	O
7a	O
induce	O
cell	O
apoptosis	O
by	O
the	O
inhibition	O
of	O
MetAP2	B
pathway	O
.	O

Molecular	O
docking	O
was	O
performed	O
to	O
position	O
compound	O
7a	O
into	O
MetAP2	B
binding	O
site	O
in	O
order	O
to	O
explore	O
the	O
potential	O
target	O
.	O

Nr4a1-Dependent	O
Ly6C	O
(	O
low	O
)	O

Monocytes	O
Monitor	O
Endothelial	O
Cells	O
and	O
Orchestrate	O
Their	O
Disposal	O
.	O

The	O
functions	O
of	O
Nr4a1-dependent	O
Ly6C	O
(	O
low	O
)	O
monocytes	O
remain	O
enigmatic	O
.	O

We	O
show	O
that	O
they	O
are	O
enriched	O
within	O
capillaries	O
and	O
scavenge	O
microparticles	O
from	O
their	O
lumenal	O
side	O
in	O
a	O
steady	O
state	O
.	O

In	O
the	O
kidney	O
cortex	O
,	O
perturbation	O
of	O
homeostasis	O
by	O
a	O
TLR7-dependent	O
nucleic	O
acid	O
"	O
danger	O
"	O
signal	O
,	O
which	O
may	O
signify	O
viral	O
infection	O
or	O
local	O
cell	O
death	O
,	O
triggers	O
Gi	O
-	O
dependent	O
intravascular	O
retention	O
of	O
Ly6C	O
(	O
low	O
)	O
monocytes	O
by	O
the	O
endothelium	O
.	O

Then	O
,	O
monocytes	O
recruit	O
neutrophils	O
in	O
a	O
TLR7-dependent	O
manner	O
to	O
mediate	O
focal	O
necrosis	O
of	O
endothelial	O
cells	O
,	O
whereas	O
the	O
monocytes	O
remove	O
cellular	O
debris	O
.	O

Prevention	O
of	O
Ly6C	O
(	O
low	O
)	O
monocyte	O
development	O
,	O
crawling	O
,	O
or	O
retention	O
in	O
Nr4a1	O
(	O
-	O
/	O
-	O
)	O
,	O
Itgal	O
(	O
-	O
/	O
-	O
)	O
,	O
and	O
Tlr7	O
(	O
host-	O
/	O
-BM+	O
/	O
+	O
)	O
and	O
Cx3cr1	O
(	O
-	O
/	O
-	O
)	O
mice	O
,	O
respectively	O
,	O
abolished	O
neutrophil	O
recruitment	O
and	O
endothelial	O
killing	O
.	O

Prevention	O
of	O
neutrophil	O
recruitment	O
in	O
Tlr7	O
(	O
host+	O
/	O
+BM-	O
/	O
-	O
)	O
mice	O
or	O
by	O
neutrophil	O
depletion	O
also	O
abolished	O
endothelial	O
cell	O
necrosis	O
.	O

Therefore	O
,	O
Ly6C	O
(	O
low	O
)	O
monocytes	O
are	O
intravascular	O
housekeepers	O
that	O
orchestrate	O
the	O
necrosis	O
by	O
neutrophils	O
of	O
endothelial	O
cells	O
that	O
signal	O
a	O
local	O
threat	O
sensed	O
via	O
TLR7	O
followed	O
by	O
the	O
in	O
situ	O
phagocytosis	O
of	O
cellular	O
debris	O
.	O

Thermal	O
stability	O
of	O
oligodeoxynucleotide	O
duplexes	O
containing	O
l	B
-	I
deoxynucleotide	I
at	O
termini	O
.	O

The	O
effects	O
of	O
substituting	O
l	B
-	I
deoxynucleotide	I
for	O
d	B
-	I
deoxynucleotide	I
at	O
duplex	O
termini	O
were	O
evaluated	O
and	O
the	O
terminal	O
substitutions	O
were	O
found	O
to	O
show	O
much	O
less	O
effects	O
on	O
duplex	O
destabilization	O
and	O
to	O
show	O
a	O
similar	O
tendency	O
in	O
base	O
pairing	O
selectivity	O
,	O
compared	O
with	O
internal	O
chiral	O
substitutions	O
.	O

Agonistic	O
activity	O
of	O
ICI	B
182	I
780	I
on	O
activation	O
of	O
GSK	O
3	O
/	O
AKT	O
pathway	O
in	O
the	O
rat	O
uterus	O
during	O
the	O
estrous	O
cycle	O
.	O

We	O
examined	O
the	O
ability	O
of	O
ICI	B
182,780	I
(	O
ICI	B
)	O
to	O
block	O
uterine	O
cell	O
proliferation	O
via	O
protein	O
kinase	O
b	O
/	O
AKT	O
pathway	O
in	O
the	O
uterus	O
of	O
the	O
rat	O
during	O
the	O
estrous	O
cycle	O
.	O

Intact	O
rats	O
,	O
with	O
regular	O
estrous	O
cycles	O
,	O
received	O
a	O
subcutaneous	O
(	O
s.c	O
.	O
)	O
injection	O
of	O
either	O
vehicle	O
or	O
ICI	B
at	O
08:00h	O
on	O
the	O
day	O
of	O
proestrus	O
or	O
at	O
00:00h	O
on	O
the	O
day	O
of	O
estrus	O
and	O
sacrificed	O
at	O
13:00h	O
of	O
metaestrus	O
.	O

Estradiol	B
(	O
E2	O
)	O
and	O
progesterone	B
(	O
P4	O
)	O
plasma	O
levels	O
were	O
measured	O
by	O
radioimmunoassay	O
.	O

Both	O
ICI	B
treatments	O
,	O
induced	O
a	O
significant	O
decrease	O
(	O
p<0.01	O
)	O
in	O
uterine	O
estrogen	B
receptor	O
alpha	O
(	O
ER	O
)	O
content	O
,	O
had	O
no	O
effect	O
on	O
uterine	O
progesterone	B
receptor	O
(	O
PR	O
)	O
protein	O
expression	O
and	O
caused	O
marked	O
nuclear	O
localization	O
of	O
cyclin	O
D1	O
,	O
in	O
both	O
luminal	O
and	O
glandular	O
uterine	O
epithelium	O
,	O
as	O
compared	O
to	O
vehicle	O
-	O
treated	O
animals	O
.	O

Furthermore	O
,	O
we	O
detected	O
that	O
ICI	B
treatment	O
induced	O
glycogen	O
synthase	O
kinase	O
(	O
Gsk3-	O
)	O
Ser	O
9	O
phosphorylation	O
,	O
which	O
correlates	O
with	O
cyclin	O
D1	O
nuclear	O
localization	O
.	O

However	O
,	O
some	O
differences	O
were	O
observed	O
between	O
the	O
two	O
different	O
time	O
schedules	O
of	O
administration	O
.	O

We	O
observed	O
that	O
the	O
administration	O
of	O
ICI	B
at	O
08:00h	O
on	O
proestrus	O
day	O
produced	O
a	O
15	O
%	O
inhibition	O
of	O
luminal	O
epithelial	O
cell	O
proliferation	O
,	O
reduced	O
uterine	O
wet	O
weight	O
by	O
21	O
%	O
and	O
caused	O
reduction	O
of	O
Akt	O
phosphorylation	O
at	O
Ser	B
473	O
as	O
compared	O
to	O
vehicle	O
-	O
treated	O
animals	O
,	O
whereas	O
ICI	B
treatment	O
at	O
00:00h	O
on	O
estrus	O
day	O
had	O
no	O
effect	O
on	O
these	O
parameters	O
.	O

The	O
overall	O
results	O
indicate	O
that	O
ICI	B
may	O
exert	O
agonistic	O
and	O
antagonistic	O
effects	O
on	O
uterine	O
cell	O
proliferation	O
through	O
differential	O
activation	O
of	O
the	O
Akt	O
pathway	O
depending	O
on	O
the	O
administration	O
period	O
during	O
the	O
estrous	O
cycle	O
,	O
and	O
indicates	O
that	O
the	O
mechanism	O
of	O
cell	O
proliferation	O
during	O
the	O
physiological	O
conditions	O
of	O
the	O
estrous	O
cycle	O
,	O
is	O
under	O
a	O
different	O
and	O
more	O
complex	O
regulation	O
than	O
in	O
the	O
ovariectomized	O
+	O
E2	O
animal	O
model	O
.	O

Chronic	O
Administration	O
of	O
Small	O
Non	O
-	O
Erythropoietic	O
Peptide	O
Sequence	O
of	O
Erythropoietin	O
Effectively	O
Ameliorates	O
the	O
Progression	O
of	O
Post	O
Myocardial	O
Infarction	O
Dilated	O
Cardiomyopathy	O
.	O

The	O
cardioprotective	O
properties	O
of	O
erythropoietin	O
(	O
EPO	O
)	O
in	O
pre	O
-	O
clinical	O
studies	O
are	O
well	O
documented	O
,	O
but	O
erythropoietic	O
and	O
prothrombotic	O
properties	O
of	O
EPO	O
preclude	O
its	O
use	O
in	O
chronic	O
heart	O
failure	O
(	O
CHF	O
)	O
.	O

We	O
tested	O
the	O
effect	O
of	O
long	O
-	O
term	O
treatment	O
with	O
a	O
small	O
peptide	O
sequence	O
within	O
the	O
EPO	O
molecule	O
,	O
Helix	O
B	O
surface	O
peptide	O
(	O
HBSP	O
)	O
,	O
that	O
possess	O
tissue	O
-	O
protective	O
,	O
but	O
not	O
erythropoietic	O
properties	O
of	O
EPO	O
,	O
on	O
mortality	O
and	O
cardiac	O
remodeling	O
in	O
post	O
-	O
myocardial	O
infarction	O
dilated	O
cardiomyopaty	O
in	O
rats	O
.	O

Starting	O
two	O
weeks	O
after	O
permanent	O
left	O
coronary	O
artery	O
ligation	O
,	O
rats	O
received	O
i.p	O
.	O

injections	O
of	O
HBSP	O
(	O
60g	O
/	O
kg	O
)	O
or	O
saline	O
2	O
times	O
/	O
week	O
for	O
10	O
months	O
.	O

Treatment	O
did	O
not	O
elicit	O
an	O
immune	O
response	O
,	O
and	O
did	O
not	O
affect	O
the	O
hematocrit	O
.	O

Compared	O
to	O
untreated	O
rats	O
,	O
HBSP	O
treatment	O
reduced	O
mortality	O
by	O
50	O
%	O
(	O
p<0.05	O
)	O
.	O

Repeated	O
echocardiography	O
demonstrated	O
remarkable	O
attenuation	O
of	O
left	O
ventricular	O
dilatation	O
(	O
EDV	O
:	O
41	O
%	O
vs.	O
86	O
%	O
;	O
ESV	O
:	O
44	O
%	O
vs.	O
135	O
%	O
;	O
p<0.05	O
)	O
,	O
LV	O
functional	O
deterioration	O
(	O
EF	O
:	O
-4	O
%	O
vs.	O
-63	O
%	O
;	O
p<0.05	O
)	O
and	O
MI	O
expansion	O
(	O
3	O
%	O
vs.	O
38	O
%	O
;	O
p<0.05	O
)	O
.	O

A	O
hemodynamic	O
assessment	O
at	O
study	O
termination	O
demonstrated	O
normal	O
preload	O
independent	O
stroke	O
work	O
(	O
635	O
vs.	O
404	O
;	O
p<0.05	O
)	O
and	O
arterio	O
-	O
ventricular	O
coupling	O
(	O
1.20.2	O
vs.	O
2.70.7	O
;	O
p<0.05	O
)	O
.	O

Histological	O
analysis	O
revealed	O
reduced	O
apoptosis	O
(	O
p<0.05	O
)	O
and	O
fibrosis	O
(	O
p<0.05	O
)	O
,	O
increased	O
cardiomyocyte	O
density	O
(	O
p<0.05	O
)	O
,	O
and	O
increased	O
number	O
of	O
cardiomyocytes	O
in	O
myocardium	O
among	O
HBSP	O
-	O
treated	O
rats	O
.	O

The	O
results	O
indicate	O
that	O
HBSP	O
effectively	O
reduces	O
mortality	O
,	O
ameliorates	O
the	O
MI	O
expansion	O
and	O
CHF	O
progression	O
,	O
and	O
preserves	O
systolic	O
reserve	O
in	O
the	O
rat	O
post	O
MI	O
model	O
.	O

There	O
is	O
also	O
a	O
suggestion	O
that	O
HBSP	O
promoted	O
the	O
increase	O
of	O
the	O
myocytes	O
number	O
in	O
the	O
myocardial	O
wall	O
remote	O
from	O
the	O
infarct	O
.	O

Thus	O
HBSP	O
peptide	O
merits	O
consideration	O
for	O
clinical	O
testing	O
.	O

Diamond	B
-	O
Lipid	O
Hybrids	O
Enhance	O
Chemotherapeutic	O
Tolerance	O
and	O
Mediate	O
Tumor	O
Regression	O
.	O

Self	O
-	O
assembled	O
nanodiamond	O
-	O
lipid	O
hybrid	O
particles	O
(	O
NDLPs	O
)	O
harness	O
the	O
potent	O
interaction	O
between	O
the	O
nanodiamond	O
(	O
ND	O
)	O
-surface	O
and	O
small	O
molecules	O
,	O
while	O
providing	O
a	O
mechanism	O
for	O
cell	O
-	O
targeted	O
imaging	O
and	O
therapy	O
of	O
triple	O
negative	O
breast	O
cancers	O
.	O

Epidermal	O
growth	O
factor	O
receptor	O
-	O
targeted	O
NDLPs	O
are	O
highly	O
biocompatible	O
particles	O
that	O
provide	O
cell	O
-	O
specific	O
imaging	O
,	O
promote	O
tumor	O
retention	O
of	O
ND	O
-	O
complexes	O
,	O
prevent	O
epirubicin	B
toxicities	O
and	O
mediate	O
regression	O
of	O
triple	O
negative	O
breast	O
cancers	O
.	O

Alkane	B
Oxidation	O
by	O
an	O
Immobilized	O
Nickel	B
Complex	O
Catalyst	O
:	O
Structural	O
and	O
Reactivity	O
Differences	O
Induced	O
by	O
Surface	O
-	O
Ligand	O
Density	O
on	O
Mesoporous	O
Silica	B
.	O

Immobilized	O
nickel	B
catalysts	O
SBA*-L	O
-	O
x	O
/	O
Ni	B
(	O
L	O
=	O
bis	B
(	I
2-pyridylmethyl	I
)	I
(	I
1H-1,2,3-triazol-4-ylmethyl	I
)	I
amine	I
)	O
with	O
various	O
ligand	O
densities	O
(	O
L	O
content	O
(	O
x	O
)	O
=0.5	O
,	O
1	O
,	O
2	O
,	O
4	O
mol	O
%	O
Si	B
)	O
have	O
been	O
prepared	O
from	O
azidopropyl	B
-	O
functionalized	O
mesoporous	O
silicas	B
SBA	O
-	O
N3	O
-x	O
.	O

Related	O
homogeneous	O
ligand	O
L	B
(	I
t	I
)	I
(	I
Bu	I
)	I
and	O
its	O
Ni	B
(	I
II	I
)	I
complexes	O
,	O
[	B
Ni	I
(	I
L	I
(	I
t	I
)	I
(	I
Bu	I
)	I
)	I
(	I
OAc	I
)	I
2	I
(	I
H2	I
O	I
)	I
]	I
(	I
L	I
(	I
t	I
)	I
(	I
Bu	I
)	I
/Ni	I
)	I
and	O
[	B
Ni	I
(	I
L	I
(	I
t	I
)	I
(	I
Bu	I
)	I
)	I
2	I
]	I
BF4	I
(	I
2	I
L	I
(	I
t	I
)	I
(	I
Bu	I
)	I
/Ni	I
)	I
,	O
have	O
been	O
synthesized	O
.	O

The	O
L	O
/	O
Ni	B
ratio	O
(	O
0.9	O
-	O
1.7:1	O
)	O
in	O
SBA*-L	O
-	O
x	O
/	O
Ni	B
suggests	O
the	O
formation	O
of	O
an	O
inert	O
[	O
NiL2	B
]	O
site	O
on	O
the	O
surface	O
at	O
higher	O
ligand	O
loadings	O
.	O

SBA*-L	O
-	O
x	O
/	O
Ni	B
has	O
been	O
applied	O
to	O
the	O
catalytic	O
oxidation	O
of	O
cyclohexane	B
with	O
m	B
-	I
chloroperbenzoic	I
acid	I
(	O
mCPBA	B
)	O
.	O

The	O
catalyst	O
with	O
the	O
lowest	O
loading	O
shows	O
high	O
activity	O
in	O
its	O
initial	O
use	O
as	O
the	O
homogeneous	O
L	B
(	I
t	I
)	I
(	I
Bu	I
)	I
/Ni	O
catalyst	O
,	O
with	O
some	O
metal	O
leaching	O
.	O

As	O
the	O
ligand	O
loading	O
increases	O
,	O
the	O
activity	O
and	O
Ni	B
leaching	O
are	O
suppressed	O
.	O

The	O
importance	O
of	O
site	O
-	O
density	O
control	O
for	O
the	O
development	O
of	O
immobilized	O
catalysts	O
has	O
been	O
demonstrated	O
.	O

Simulating	O
Lifetime	O
Outcomes	O
Associated	O
with	O
Complications	O
for	O
People	O
with	O
Type	O
1	O
Diabetes	O
.	O

OBJECTIVES	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
develop	O
a	O
discrete	O
-	O
time	O
simulation	O
model	O
for	O
people	O
with	O
type	O
1	O
diabetes	O
mellitus	O
,	O
to	O
estimate	O
and	O
compare	O
mean	O
life	O
expectancy	O
and	O
quality	O
-	O
adjusted	O
life	O
-	O
years	O
(	O
QALYs	O
)	O
over	O
a	O
lifetime	O
between	O
intensive	O
and	O
conventional	O
blood	O
glucose	B
treatment	O
groups	O
.	O

METHODS	O
:	O
We	O
synthesized	O
evidence	O
on	O
type	O
1	O
diabetes	O
patients	O
using	O
several	O
published	O
sources	O
.	O

The	O
simulation	O
model	O
was	O
based	O
on	O
13	O
equations	O
to	O
estimate	O
risks	O
of	O
events	O
and	O
mortality	O
.	O

Cardiovascular	O
disease	O
(	O
CVD	O
)	O
risk	O
was	O
obtained	O
from	O
results	O
of	O
the	O
DCCT	O
(	O
diabetes	O
control	O
and	O
complications	O
trial	O
)	O
.	O

Mortality	O
post	O
-	O
CVD	O
event	O
was	O
based	O
on	O
a	O
study	O
using	O
linked	O
administrative	O
data	O
on	O
people	O
with	O
diabetes	O
from	O
Western	O
Australia	O
.	O

Information	O
on	O
incidence	O
of	O
renal	O
disease	O
and	O
the	O
progression	O
to	O
CVD	O
was	O
obtained	O
from	O
studies	O
in	O
Finland	O
and	O
Italy	O
.	O

Lower	O
-	O
extremity	O
amputation	O
(	O
LEA	O
)	O
risk	O
was	O
based	O
on	O
the	O
type	O
1	O
diabetes	O
Swedish	O
inpatient	O
registry	O
,	O
and	O
the	O
risk	O
of	O
blindness	O
was	O
obtained	O
from	O
results	O
of	O
a	O
German	O
-	O
based	O
study	O
.	O

Where	O
diabetes	O
-	O
specific	O
data	O
were	O
unavailable	O
,	O
information	O
from	O
other	O
populations	O
was	O
used	O
.	O

We	O
examine	O
the	O
degree	O
and	O
source	O
of	O
parameter	O
uncertainty	O
and	O
illustrate	O
an	O
application	O
of	O
the	O
model	O
in	O
estimating	O
lifetime	O
outcomes	O
of	O
using	O
intensive	O
and	O
conventional	O
treatments	O
for	O
blood	O
glucose	B
control	O
.	O

RESULTS	O
:	O
From	O
15	O
years	O
of	O
age	O
,	O
male	O
and	O
female	O
patients	O
had	O
an	O
estimated	O
life	O
expectancy	O
of	O
47.2	O
(	O
95	O
%	O
CI	O
35.2	O
-	O
59.2	O
)	O
and	O
52.7	O
(	O
95	O
%	O
CI	O
41.7	O
-	O
63.6	O
)	O
years	O
in	O
the	O
intensive	O
treatment	O
group	O
.	O

The	O
model	O
produced	O
estimates	O
of	O
the	O
lifetime	O
benefits	O
of	O
intensive	O
treatment	O
for	O
blood	O
glucose	B
from	O
the	O
DCCT	O
of	O
4.0	O
(	O
95	O
%	O
CI	O
1.2	O
-	O
6.8	O
)	O
QALYs	O
for	O
women	O
and	O
4.6	O
(	O
95	O
%	O
CI	O
2.7	O
-	O
6.9	O
)	O
QALYs	O
for	O
men	O
.	O

Absolute	O
risk	O
per	O
1,000	O
person	O
-	O
years	O
for	O
fatal	O
CVD	O
events	O
was	O
simulated	O
to	O
be	O
1.37	O
and	O
2.51	O
in	O
intensive	O
and	O
conventional	O
treatment	O
groups	O
,	O
respectively	O
.	O

CONCLUSIONS	O
:	O
The	O
model	O
incorporates	O
diabetic	O
complications	O
risk	O
data	O
from	O
a	O
type	O
1	O
diabetes	O
population	O
and	O
synthesizes	O
other	O
type	O
1-specific	O
data	O
to	O
estimate	O
long	O
-	O
term	O
outcomes	O
of	O
CVD	O
,	O
end	O
-	O
stage	O
renal	O
disease	O
,	O
LEA	O
and	O
risk	O
of	O
blindness	O
,	O
along	O
with	O
life	O
expectancy	O
and	O
QALYs	O
.	O

External	O
validation	O
was	O
carried	O
out	O
using	O
life	O
expectancy	O
and	O
absolute	O
risk	O
for	O
fatal	O
CVD	O
events	O
.	O

Because	O
of	O
the	O
flexible	O
and	O
transparent	O
nature	O
of	O
the	O
model	O
,	O
it	O
has	O
many	O
potential	O
future	O
applications	O
.	O

tert	B
-	I
Butylhydroquinone	I
reduces	O
lipid	O
accumulation	O
in	O
C57BL	O
/	O
6	O
mice	O
with	O
lower	O
body	O
weight	O
gain	O
.	O

tert	B
-	I
Butylhydroquinone	I
(	O
tBHQ	B
)	O
is	O
a	O
commonly	O
used	O
antioxidant	O
additive	O
that	O
is	O
approved	O
for	O
human	O
use	O
by	O
both	O
the	O
Food	O
and	O
Agriculture	O
Organization	O
and	O
the	O
World	O
Health	O
Organization	O
(	O
FAO	O
/	O
WHO	O
)	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
effect	O
of	O
tBHQ	B
on	O
body	O
weight	O
gain	O
and	O
found	O
that	O
food	O
supplementation	O
with	O
0.001	O
%	O
(	O
w	O
/	O
w	O
)	O
tBHQ	B
inhibited	O
61.4	O
%	O
(	O
P	O
<	O
0.01	O
)	O
of	O
body	O
weight	O
gain	O
in	O
high	O
-	O
fat	O
diet	O
(	O
HFD	O
)	O
-induced	O
C57BL	O
/	O
6	O
mice	O
,	O
and	O
the	O
oral	O
administration	O
of	O
tBHQ	B
(	O
1.5	O
mg	O
/	O
kg	O
)	O
reduced	O
47.5	O
%	O
(	O
P	O
<	O
0.05	O
)	O
of	O
body	O
weight	O
gain	O
in	O
normal	O
diet	O
fed	O
db	O
/	O
db	O
mice	O
.	O

The	O
HFD	O
increased	O
lipid	O
deposit	O
in	O
adipocytes	O
,	O
but	O
these	O
were	O
reduced	O
significantly	O
by	O
tBHQ	B
treatment	O
in	O
C57BL	O
/	O
6	O
mice	O
.	O

tBHQ	B
supplementation	O
significantly	O
lowered	O
the	O
plasma	O
triglyceride	B
and	O
total	O
cholesterol	B
,	O
with	O
reduced	O
size	O
of	O
accumulated	O
fat	O
mass	O
.	O

The	O
rate	O
limiting	O
enzyme	O
of	O
beta	O
-	O
oxidation	O
(	O
ACOX1	O
)	O
was	O
significantly	O
over	O
-	O
expressed	O
in	O
the	O
liver	O
with	O
tBHQ	B
treatment	O
.	O

These	O
results	O
indicate	O
that	O
tBHQ	B
suppresses	O
body	O
weight	O
gain	O
in	O
mice	O
,	O
possibly	O
at	O
least	O
related	O
to	O
the	O
up	O
-	O
regulation	O
of	O
ACOX1	O
gene	O
expression	O
.	O

Tandem	O
Assays	O
of	O
Protein	O
and	O
Glucose	B
with	O
Functionalized	O
Core	O
/	O
Shell	O
Particles	O
Based	O
on	O
Magnetic	O
Separation	O
and	O
Surface	O
-	O
Enhanced	O
Raman	O
Scattering	O
.	O

Tandem	O
assays	O
of	O
protein	O
and	O
glucose	B
in	O
combination	O
with	O
mannose	B
-	O
functionalized	O
Fe3	B
O4	I
@SiO2	O
and	O
Ag@SiO2	B
tag	O
particles	O
have	O
promising	O
potential	O
in	O
effective	O
magnetic	O
separation	O
and	O
highly	O
sensitive	O
and	O
selective	O
SERS	O
assays	O
of	O
biomaterials	O
.	O

It	O
is	O
for	O
the	O
first	O
time	O
that	O
tandem	O
assay	O
of	O
glucose	B
is	O
developed	O
using	O
SERS	O
based	O
on	O
the	O
Con	O
A	O
-	O
sandwiched	O
microstructures	O
between	O
the	O
functionalized	O
magnetic	O
and	O
tag	O
particles	O
.	O

Ligand	O
Based	O
Approach	O
to	O
L	O
-	O
Type	O
Calcium	B
Channel	O
by	O
Imidazo	B
[	I
2,1-b	I
]	I
thiazole-1,4-Dihydropyridines	I
:	O
from	O
Heart	O
Activity	O
to	O
Brain	O
Affinity	O
.	O

The	O
synthesis	O
,	O
characterization	O
,	O
and	O
functional	O
in	O
vitro	O
assay	O
in	O
cardiac	O
and	O
smooth	O
muscle	O
(	O
vascular	O
and	O
nonvascular	O
)	O
of	O
a	O
series	O
of	O
4-imidazo	B
[	I
2,1-b	I
]	I
thiazole-1,4-dihydropyridines	I
are	O
reported	O
.	O

To	O
define	O
the	O
calcium	B
blocker	O
nature	O
of	O
the	O
imidazo	B
[	I
2,1-b	I
]	I
thiazole-1,4-DHPs	I
and	O
their	O
selectivity	O
on	O
Cav1.2	O
and	O
Cav1.3	O
isoforms	O
we	O
performed	O
binding	O
studies	O
on	O
guinea	O
pig	O
atrial	O
and	O
ventricular	O
membranes	O
,	O
on	O
intact	O
cells	O
expressing	O
the	O
cloned	O
Cav1.2a	O
subunit	O
and	O
on	O
rat	O
brain	O
cortex	O
.	O

To	O
get	O
major	O
insights	O
into	O
the	O
reasons	O
for	O
the	O
affinity	O
for	O
Cav1.2	O
and/or	O
Cav1.3	O
molecular	O
modelling	O
studies	O
were	O
also	O
undertaken	O
.	O

Some	O
physicochemical	O
and	O
pharmacokinetic	O
properties	O
of	O
selected	O
compounds	O
were	O
calculated	O
and	O
compared	O
.	O

All	O
the	O
biological	O
data	O
collected	O
and	O
reported	O
herein	O
allowed	O
us	O
to	O
rationalize	O
the	O
structure	O
-	O
activity	O
relationship	O
of	O
the	O
4-imidazo	B
[	I
2,1-b	I
]	I
thiazole-1,4-DHPs	I
and	O
to	O
identify	O
which	O
of	O
these	O
enhanced	O
the	O
activity	O
at	O
the	O
central	O
level	O
.	O

Synthesis	O
of	O
chemicals	O
using	O
solar	O
energy	O
with	O
stable	O
photoelectrochemically	O
active	O
heterostructures	O
.	O

Efficient	O
and	O
cost	O
-	O
effective	O
conversion	O
of	O
solar	O
energy	O
to	O
useful	O
chemicals	O
and	O
fuels	O
could	O
lead	O
to	O
a	O
significant	O
reduction	O
in	O
fossil	O
hydrocarbon	B
use	O
.	O

Artificial	O
systems	O
that	O
use	O
solar	O
energy	O
to	O
produce	O
chemicals	O
have	O
been	O
reported	O
for	O
more	O
than	O
a	O
century	O
.	O

However	O
the	O
most	O
efficient	O
devices	O
demonstrated	O
,	O
based	O
on	O
traditionally	O
fabricated	O
compound	O
semiconductors	O
,	O
have	O
extremely	O
short	O
working	O
lifetimes	O
due	O
to	O
photocorrosion	O
by	O
the	O
electrolyte	O
.	O

Here	O
we	O
report	O
a	O
stable	O
,	O
scalable	O
design	O
and	O
molecular	O
level	O
fabrication	O
strategy	O
to	O
create	O
photoelectrochemically	O
active	O
heterostructure	O
(	O
PAH	O
)	O
units	O
consisting	O
of	O
an	O
efficient	O
semiconductor	O
light	O
absorber	O
in	O
contact	O
with	O
oxidation	O
and	O
reduction	O
electrocatalysts	O
and	O
otherwise	O
protected	O
by	O
alumina	B
.	O

The	O
functional	O
heterostructures	O
are	O
fabricated	O
by	O
layer	O
-	O
by	O
-	O
layer	O
,	O
template	O
-	O
directed	O
,	O
electrochemical	O
synthesis	O
in	O
porous	O
anodic	O
aluminum	B
oxide	I
membranes	O
to	O
produce	O
high	O
density	O
arrays	O
of	O
electronically	O
autonomous	O
,	O
nanostructured	O
,	O
corrosion	O
resistant	O
,	O
photoactive	O
units	O
(	O
10	O
(	O
9	O
)	O
-10	O
(	O
10	O
)	O
PAHs	O
per	O
cm	O
(	O
2	O
)	O
)	O
.	O

Each	O
PAH	O
unit	O
is	O
isolated	O
from	O
its	O
neighbor	O
by	O
the	O
transparent	O
electrically	O
insulating	O
oxide	B
cellular	O
enclosure	O
that	O
makes	O
the	O
overall	O
assembly	O
fault	O
tolerant	O
.	O

When	O
illuminated	O
with	O
visible	O
light	O
,	O
the	O
free	O
floating	O
devices	O
have	O
been	O
demonstrated	O
to	O
produce	O
hydrogen	B
at	O
a	O
stable	O
rate	O
for	O
over	O
24	O
h	O
in	O
corrosive	O
hydroiodic	B
acid	I
electrolyte	O
with	O
light	O
as	O
the	O
only	O
input	O
.	O

The	O
quantum	O
efficiency	O
(	O
averaged	O
over	O
the	O
solar	O
spectrum	O
)	O
for	O
absorbed	O
photons	O
-	O
to	O
-	O
hydrogen	B
conversion	O
was	O
7.4	O
%	O
and	O
solar	O
-	O
to	O
-	O
hydrogen	B
energy	O
efficiency	O
of	O
incident	O
light	O
was	O
0.9	O
%	O
.	O

The	O
fabrication	O
approach	O
is	O
scalable	O
for	O
commercial	O
manufacturing	O
and	O
readily	O
adaptable	O
to	O
a	O
variety	O
of	O
earth	O
abundant	O
semiconductors	O
which	O
might	O
otherwise	O
be	O
unstable	O
as	O
photoelectrocatalysts	O
.	O

The	O
role	O
of	O
external	O
defects	O
in	O
chemical	O
sensing	O
of	O
graphene	B
field	O
-	O
effect	O
transistors	O
.	O

A	O
fundamental	O
understanding	O
of	O
chemical	O
sensing	O
mechanisms	O
in	O
graphene	B
-	O
based	O
chemical	O
field	O
-	O
effect	O
transistors	O
(	O
chemFETs	O
)	O
is	O
essential	O
for	O
the	O
development	O
of	O
next	O
generation	O
chemical	O
sensors	O
.	O

Here	O
we	O
explore	O
the	O
hidden	O
sensing	O
modalities	O
responsible	O
for	O
tailoring	O
the	O
gas	O
detection	O
ability	O
of	O
pristine	B
graphene	I
sensors	O
by	O
exposing	O
graphene	B
chemFETs	O
to	O
electron	O
donor	O
and	O
acceptor	O
trace	O
gas	O
vapors	O
.	O

We	O
uncover	O
that	O
the	O
sensitivity	O
(	O
in	O
terms	O
of	O
modulation	O
in	O
electrical	O
conductivity	O
)	O
of	O
pristine	B
graphene	I
chemFETs	O
is	O
not	O
necessarily	O
intrinsic	O
to	O
graphene	B
,	O
but	O
rather	O
it	O
is	O
facilitated	O
by	O
external	O
defects	O
in	O
the	O
insulating	O
substrate	O
,	O
which	O
can	O
modulate	O
the	O
electronic	O
properties	O
of	O
graphene	B
.	O

We	O
disclose	O
a	O
mixing	O
effect	O
caused	O
by	O
partial	O
overlap	O
of	O
the	O
highest	O
occupied	O
molecular	O
orbital	O
(	O
HOMO	O
)	O
and	O
lowest	O
unoccupied	O
molecular	O
orbital	O
(	O
LUMO	O
)	O
of	O
adsorbed	O
gas	O
molecules	O
to	O
explain	O
graphene	B
's	O
ability	O
to	O
detect	O
adsorbed	O
molecules	O
.	O

Our	O
results	O
open	O
a	O
new	O
design	O
space	O
,	O
suggesting	O
that	O
control	O
of	O
external	O
defects	O
in	O
supporting	O
substrates	O
can	O
lead	O
to	O
tunable	O
graphene	O
chemical	O
sensors	O
,	O
which	O
could	O
be	O
developed	O
without	O
compromising	O
the	O
intrinsic	O
electrical	O
and	O
structural	O
properties	O
of	O
graphene	B
.	O

Study	O
of	O
the	O
microcharacter	O
of	O
ultrastable	O
aqueous	O
foam	O
stabilized	O
by	O
a	O
kind	O
of	O
flexible	O
connecting	O
bipolar	O
-	O
headed	O
surfactant	O
with	O
existence	O
of	O
magnesium	B
ion	O
.	O

In	O
this	O
paper	O
,	O
ultrastable	O
aqueous	O
foam	O
stabilized	O
by	O
a	O
kind	O
of	O
flexible	O
connecting	O
bipolar	O
-	O
headed	O
surfactant	O
alkyl	B
polyoxyethylene	I
sulfate	I
(	O
AE3S	B
)	O
with	O
coexisting	O
Mg	B
(	I
2	I
+	I
)	I
was	O
reported	O
.	O

Detailed	O
molecular	O
behaviors	O
of	O
AE3S	B
in	O
foam	O
film	O
with	O
coexisting	O
divalent	O
cationic	O
Ca	B
(	I
2	I
+	I
)	I
or	O
Mg	B
(	I
2	I
+	I
)	I
were	O
investigated	O
by	O
molecular	O
dynamic	O
simulation	O
,	O
comparing	O
with	O
the	O
traditional	O
surfactant	O
sodium	B
dodecyl	I
sulfate	I
(	O
SDS	B
)	O
,	O
to	O
find	O
out	O
how	O
the	O
microcharacter	O
and	O
array	O
behavior	O
of	O
molecules	O
in	O
the	O
foam	O
film	O
determined	O
by	O
molecular	O
interaction	O
effect	O
the	O
foam	O
stability	O
.	O

It	O
was	O
found	O
that	O
the	O
ultrastable	O
foam	O
film	O
obtained	O
by	O
the	O
cooperation	O
of	O
magnesium	B
ions	O
and	O
AE3S	B
was	O
driven	O
from	O
two	O
aspects	O
:	O
one	O
is	O
the	O
favorable	O
arrangement	O
of	O
surfactant	O
molecules	O
,	O
and	O
the	O
other	O
is	O
the	O
increase	O
of	O
capacity	O
of	O
foam	O
films	O
for	O
resolutely	O
holding	O
water	O
molecules	O
deduced	O
by	O
a	O
dipolar	O
pair	O
formed	O
by	O
the	O
flexible	O
connecting	O
head	O
groups	O
of	O
AE3S	B
and	O
hydrated	B
Mg	I
(	I
2	I
+	I
)	I
via	O
intermolecular	O
coactions	O
,	O
both	O
related	O
to	O
the	O
presence	O
of	O
magnesium	B
ions	O
.	O

Foam	O
lamella	O
stability	O
measurement	O
and	O
foam	O
decay	O
method	O
were	O
both	O
used	O
to	O
evaluate	O
the	O
stability	O
of	O
foam	O
.	O

Fourier	O
transform	O
infrared	O
(	O
FT	O
-	O
IR	O
)	O
was	O
used	O
to	O
detect	O
the	O
composition	O
variation	O
of	O
foam	O
film	O
in	O
the	O
drainage	O
process	O
;	O
the	O
vibration	O
peak	O
of	O
OH	B
for	O
water	O
molecule	O
shifted	O
from	O
the	O
3390	O
cm	O
(	O
-1	O
)	O
(	O
being	O
assigned	O
to	O
the	O
bulk	O
water	O
integrated	O
by	O
hydrogen	B
bonds	O
)	O
to	O
3685	O
cm	O
(	O
-1	O
)	O
(	O
being	O
assigned	O
to	O
the	O
vibration	O
of	O
isolated	O
water	O
molecules	O
)	O
for	O
the	O
ultrastable	O
foam	O
film	O
after	O
complete	O
drainage	O
,	O
which	O
agreed	O
very	O
well	O
with	O
the	O
molecular	O
simulation	O
results	O
.	O

Quinoline	B
Drug	O
-	O
Heme	B
Interactions	O
and	O
Implications	O
for	O
Antimalarial	O
Cytostatic	O
versus	O
Cytocidal	O
Activities	O
.	O

Historically	O
,	O
the	O
most	O
successful	O
molecular	O
target	O
for	O
antimalarial	O
drugs	O
has	O
been	O
heme	O
biomineralization	O
within	O
the	O
malarial	O
parasite	O
digestive	O
vacuole	O
.	O

Heme	B
released	O
from	O
catabolized	O
host	O
red	O
blood	O
cell	O
hemoglobin	O
is	O
toxic	O
,	O
so	O
malarial	O
parasites	O
crystallize	O
heme	B
to	O
nontoxic	O
hemozoin	O
.	O

For	O
years	O
it	O
has	O
been	O
accepted	O
that	O
a	O
number	O
of	O
effective	O
quinoline	B
antimalarial	O
drugs	O
(	O
e.g.	O
,	O
chloroquine	B
,	O
quinine	B
,	O
amodiaquine	B
)	O
function	O
by	O
preventing	O
hemozoin	O
crystallization	O
.	O

However	O
,	O
recent	O
studies	O
over	O
the	O
past	O
decade	O
have	O
revealed	O
a	O
surprising	O
molecular	O
diversity	O
in	O
quinoline	B
-	O
heme	B
molecular	O
interactions	O
.	O

This	O
diversity	O
shows	O
that	O
even	O
closely	O
related	O
quinoline	B
drugs	O
may	O
have	O
quite	O
different	O
molecular	O
pharmacology	O
.	O

This	O
paper	O
reviews	O
the	O
molecular	O
diversity	O
and	O
highlights	O
important	O
implications	O
for	O
understanding	O
quinoline	B
antimalarial	O
drug	O
resistance	O
and	O
for	O
future	O
drug	O
design	O
.	O

Why	O
Clinical	O
Inhibition	O
of	O
Efflux	O
Transport	O
at	O
the	O
Blood	O
-	O
Brain	O
Barrier	O
is	O
Unlikely	O
:	O

The	O
ITC	O
Evidence	O
-	O
Based	O
Position	O
.	O

Drug	O
interactions	O
due	O
to	O
efflux	O
transporter	O
inhibition	O
at	O
the	O
blood	O
-	O
brain	O
barrier	O
have	O
been	O
receiving	O
increasing	O
scrutiny	O
due	O
to	O
the	O
theoretical	O
possibility	O
of	O
adverse	O
CNS	O
effects	O
based	O
on	O
findings	O
from	O
preclinical	O
studies	O
.	O

In	O
this	O
commentary	O
,	O
evidence	O
from	O
pharmacokinetic	O
,	O
pharmacodynamic	O
,	O
imaging	O
,	O
pharmacogenetic	O
,	O
and	O
pharmacovigilance	O
studies	O
,	O
along	O
with	O
drug	O
safety	O
reports	O
,	O
is	O
presented	O
supporting	O
a	O
low	O
probability	O
of	O
inhibiting	O
efflux	O
transporters	O
at	O
the	O
human	O
blood	O
-	O
brain	O
barrier	O
by	O
currently	O
marketed	O
drugs	O
.	O

Clinical	O
Pharmacology	O
&	O
Therapeutics	O
(	O
2013	O
)	O
;	O
accepted	O
article	O
preview	O
14	O
February	O
2013	O
doi:10.1038	O
/	O
clpt.2013.34	O
.	O

A	O
Physiologically	O
-	O
Based	O
Pharmacokinetic	O
Modelling	O
Approach	O
to	O
Predict	O
Disease	O
-	O
Drug	O
Interactions	O
:	O
Suppression	O
of	O
CYP3A	O
by	O
IL-6	O
.	O

Elevated	O
cytokine	O
levels	O
can	O
down	O
-	O
regulate	O
expression	O
of	O
cytochrome	O
P450	O
enzymes	O
(	O
CYPs	O
)	O
and	O
suppress	O
their	O
activity	O
.	O

Treatment	O
of	O
inflammation	O
or	O
infection	O
with	O
cytokine	O
-	O
modulating	O
therapeutic	O
proteins	O
(	O
TP	O
)	O
could	O
reverse	O
suppression	O
manifesting	O
as	O
therapeutic	O
protein	O
-	O
drug	O
drug	O
interactions	O
(	O
TP	O
-	O
DDI	O
)	O
.	O

A	O
physiologically	O
-	O
based	O
pharmacokinetic	O
model	O
was	O
used	O
to	O
quantitatively	O
predict	O
the	O
impact	O
of	O
IL-6	O
on	O
sensitive	O
CYP3A4	O
substrates	O
.	O

Elevated	O
simvastatin	B
AUC	O
in	O
virtual	O
rheumatoid	O
arthritis	O
patients	O
,	O
following	O
100	O
pg	O
/	O
mL	O
of	O
IL-6	O
was	O
comparable	O
to	O
observed	O
clinical	O
data	O
(	O
59	O
%	O
versus	O
58	O
%	O
)	O
.	O

In	O
virtual	O
bone	O
marrow	O
transplant	O
(	O
BMT	O
)	O
patients	O
,	O
500	O
pg	O
/	O
ml	O
of	O
IL-6	O
resulted	O
in	O
increase	O
in	O
cyclosporine	B
AUC	O
that	O
was	O
in	O
good	O
agreement	O
with	O
the	O
observed	O
data	O
(	O
45	O
%	O
versus	O
39	O
%	O
)	O
.	O

In	O
a	O
different	O
group	O
of	O
BMT	O
patients	O
treated	O
with	O
cyclosporine	B
,	O
the	O
magnitude	O
of	O
interaction	O
with	O
IL-6	O
was	O
under	O
predicted	O
~3-fold	O
.	O

The	O
complexity	O
of	O
TP	O
-	O
DDI	O
highlights	O
underlying	O
pathophysiological	O
factors	O
to	O
be	O
considered	O
but	O
these	O
simulations	O
provide	O
valuable	O
first	O
steps	O
towards	O
predictions	O
of	O
TP	O
-	O
DDI	O
risk	O
.	O

Clinical	O
Pharmacology	O
&	O
Therapeutics	O
(	O
2013	O
)	O
;	O
accepted	O
article	O
preview	O
online	O
10	O
April	O
2013	O
doi:10.1038	O
/	O
clpt.2013.79	O
.	O

Model	O
-	O
Based	O
Drug	O
Development	O
:	O

A	O
Rational	O
Approach	O
to	O
Efficiently	O
Accelerate	O
Drug	O
Development	O
.	O

The	O
pharmaceutical	O
industry	O
continues	O
to	O
face	O
significant	O
challenges	O
.	O

Very	O
few	O
compounds	O
that	O
enter	O
development	O
reach	O
the	O
marketplace	O
,	O
and	O
the	O
investment	O
required	O
for	O
each	O
success	O
can	O
surpass	O
$	O
1.8	O
billion	O
.	O

Despite	O
attempts	O
to	O
improve	O
efficiency	O
and	O
increase	O
productivity	O
,	O
total	O
investment	O
continues	O
to	O
rise	O
whereas	O
the	O
output	O
of	O
new	O
medicines	O
declines	O
.	O

With	O
costs	O
increasing	O
exponentially	O
through	O
each	O
development	O
phase	O
,	O
it	O
is	O
failure	O
in	O
phase	O
II	O
and	O
phase	O
III	O
that	O
is	O
most	O
wasteful	O
.	O

In	O
today	O
's	O
development	O
paradigm	O
,	O
late	O
-	O
stage	O
failure	O
is	O
principally	O
a	O
result	O
of	O
insufficient	O
efficacy	O
.	O

This	O
is	O
manifested	O
as	O
either	O
a	O
failure	O
to	O
differentiate	O
sufficiently	O
from	O
placebo	O
(	O
shown	O
for	O
both	O
novel	O
and	O
precedented	O
mechanisms	O
)	O
or	O
a	O
failure	O
to	O
demonstrate	O
sufficient	O
differentiation	O
from	O
existing	O
compounds	O
.	O

Set	O
in	O
this	O
context	O
,	O
this	O
article	O
will	O
discuss	O
the	O
role	O
model	O
-	O
based	O
drug	O
development	O
(	O
MBDD	O
)	O
approaches	O
can	O
and	O
do	O
play	O
in	O
accelerating	O
and	O
optimizing	O
compound	O
development	O
strategies	O
through	O
a	O
series	O
of	O
illustrative	O
examples	O
.	O

Clinical	O
Pharmacology	O
&	O
Therapeutics	O
(	O
2013	O
)	O
;	O
advance	O
online	O
publication	O
1	O
May	O
2013	O
.	O

doi:10.1038	O
/	O
clpt.2013.54	O
.	O

pH	O
-	O
Responsive	O
Nanoparticle	O
Vaccines	O
for	O
Dual	O
-	O
Delivery	O
of	O
Antigens	O
and	O
Immunostimulatory	O
Oligonucleotides	O
.	O

Protein	O
subunit	O
vaccines	O
offer	O
important	O
potential	O
advantages	O
over	O
live	O
vaccine	O
vectors	O
but	O
generally	O
elicit	O
weaker	O
and	O
shorter	O
-	O
lived	O
cellular	O
immune	O
responses	O
.	O

Here	O
we	O
investigate	O
the	O
use	O
of	O
pH	O
-	O
responsive	O
,	O
endosomolytic	O
polymer	O
nanoparticles	O
that	O
were	O
originally	O
developed	O
for	O
RNA	O
delivery	O
as	O
vaccine	O
delivery	O
vehicles	O
for	O
enhancing	O
cellular	O
and	O
humoral	O
immune	O
responses	O
.	O

Micellar	O
nanoparticles	O
were	O
assembled	O
from	O
amphiphilic	O
diblock	O
copolymers	O
composed	O
of	O
an	O
ampholytic	O
core	O
-	O
forming	O
block	O
and	O
a	O
redesigned	O
polycationic	O
corona	O
block	O
doped	O
with	O
thiol	B
-	O
reactive	O
pyridyl	B
disulfide	I
groups	O
to	O
enable	O
dual	O
-	O
delivery	O
of	O
antigens	O
and	O
immunostimulatory	O
CpG	B
oligodeoxynucleotide	O
(	O
CpG	B
ODN	O
)	O
adjuvants	O
.	O

Polymers	O
assembled	O
into	O
23	O
nm	O
particles	O
with	O
simultaneous	O
packaging	O
of	O
CpG	B
ODN	O
and	O
a	O
thiolated	O
protein	O
antigen	O
,	O
ovalbumin	O
(	O
ova	O
)	O
.	O

Conjugation	O
of	O
ova	O
to	O
nanoparticles	O
significantly	O
enhanced	O
antigen	O
cross	O
-	O
presentation	O
in	O
vitro	O
relative	O
to	O
free	O
ova	O
or	O
an	O
unconjugated	O
,	O
physical	O
mixture	O
of	O
the	O
parent	O
compounds	O
.	O

Subcutaneous	O
vaccination	O
of	O
mice	O
with	O
ova	O
-	O
nanoparticle	O
conjugates	O
elicited	O
a	O
significantly	O
higher	O
CD8	O
(	O
+	O
)	O
T	O
cell	O
response	O
(	O
0.5	O
%	O
IFN	O
-	O
	O
(	O
+	O
)	O
of	O
CD8	O
(	O
+	O
)	O
)	O
compared	O
to	O
mice	O
vaccinated	O
with	O
free	O
ova	O
or	O
a	O
physical	O
mixture	O
of	O
the	O
two	O
components	O
.	O

Significantly	O
,	O
immunization	O
with	O
ova	O
-	O
nanoparticle	O
conjugates	O
electrostatically	O
complexed	O
with	O
CpG	B
ODN	O
(	O
dual	O
-	O
delivery	O
)	O
enhanced	O
CD8	O
(	O
+	O
)	O
T	O
cell	O
responses	O
(	O
3.4	O
%	O
IFN	O
-	O
	O
(	O
+	O
)	O
of	O
CD8	O
(	O
+	O
)	O
)	O
7-	O
,	O
18-	O
,	O
and	O
8-fold	O
relative	O
to	O
immunization	O
with	O
conjugates	O
,	O
ova	O
administered	O
with	O
free	O
CpG	B
,	O
or	O
a	O
formulation	O
containing	O
free	O
ova	O
and	O
CpG	B
complexed	O
to	O
micelles	O
,	O
respectively	O
.	O

Similarly	O
,	O
dual	O
-	O
delivery	O
carriers	O
significantly	O
increased	O
CD4	O
(	O
+	O
)	O
IFN	O
-	O
	O
(	O
+	O
)	O
(	O
Th1	O
)	O
responses	O
and	O
elicited	O
a	O
balanced	O
IgG1	O
/	O
IgG2c	O
antibody	O
response	O
.	O

Intradermal	O
administration	O
further	O
augmented	O
cellular	O
immune	O
responses	O
,	O
with	O
dual	O
-	O
delivery	O
carriers	O
inducing	O
7	O
%	O
antigen	O
-	O
specific	O
CD8	O
(	O
+	O
)	O
T	O
cells	O
.	O

This	O
work	O
demonstrates	O
the	O
ability	O
of	O
pH	O
-	O
responsive	O
,	O
endosomolytic	O
nanoparticles	O
to	O
actively	O
promote	O
antigen	O
cross	O
-	O
presentation	O
and	O
augment	O
cellular	O
and	O
humoral	O
immune	O
responses	O
via	O
dual	O
-	O
delivery	O
of	O
protein	O
antigens	O
and	O
CpG	B
ODN	O
.	O

Hence	O
,	O
pH	O
-	O
responsive	O
polymeric	O
nanoparticles	O
offer	O
promise	O
as	O
a	O
delivery	O
platform	O
for	O
protein	O
subunit	O
vaccines	O
.	O

Improved	O
Carrier	O
Mobility	O
in	O
Few	O
-	O
Layer	O
MoS2	B
Field	O
-	O
Effect	O
Transistors	O
with	O
Ionic	O
-	O
Liquid	O
Gating	O
.	O

We	O
report	O
the	O
fabrication	O
of	O
ionic	O
liquid	O
(	O
IL	O
)	O
-gated	O
field	O
-	O
effect	O
transistors	O
(	O
FETs	O
)	O
consisting	O
of	O
bilayer	O
and	O
few	O
-	O
layer	O
MoS2	B
.	O

Our	O
transport	O
measurements	O
indicate	O
that	O
the	O
electron	O
mobility	O
	O
	O
60	O
cm	O
(	O
2	O
)	O
V	O
(	O
-1	O
)	O
s	O
(	O
-1	O
)	O
at	O
250	O
K	O
in	O
IL	O
-	O
gated	O
devices	O
exceeds	O
significantly	O
that	O
of	O
comparable	O
back	O
-	O
gated	O
devices	O
.	O

IL	O
-	O
FETs	O
display	O
a	O
mobility	O
increase	O
from	O
100	O
cm	O
(	O
2	O
)	O
V	O
(	O
-1	O
)	O
s	O
(	O
-1	O
)	O
at	O
180	O
K	O
to	O
220	O
cm	O
(	O
2	O
)	O
V	O
(	O
-1	O
)	O
s	O
(	O
-1	O
)	O
at	O
77	O
K	O
in	O
good	O
agreement	O
with	O
the	O
true	O
channel	O
mobility	O
determined	O
from	O
four	O
-	O
terminal	O
measurements	O
,	O
ambipolar	O
behavior	O
with	O
a	O
high	O
ON	O
/	O
OFF	O
ratio	O
>	O
10	O
(	O
7	O
)	O
(	O
10	O
(	O
4	O
)	O
)	O
for	O
electrons	O
(	O
holes	O
)	O
,	O
and	O
a	O
near	O
ideal	O
subthreshold	O
swing	O
of	O
50	O
mV	O
/	O
dec	O
at	O
250	O
K.	O
We	O
attribute	O
the	O
observed	O
performance	O
enhancement	O
,	O
specifically	O
the	O
increased	O
carrier	O
mobility	O
that	O
is	O
limited	O
by	O
phonons	O
,	O
to	O
the	O
reduction	O
of	O
the	O
Schottky	O
barrier	O
at	O
the	O
source	O
and	O
drain	O
electrode	O
by	O
band	O
bending	O
caused	O
by	O
the	O
ultrathin	O
IL	O
dielectric	O
layer	O
.	O

pH	O
-	O
Responsive	O
Aggregation	O
States	O
of	O
Chiral	O
Polymerizable	O
Amphiphiles	O
from	O
l	B
-	I
Tyrosine	I
and	O
l	B
-	I
Phenyl	I
Alanine	I
in	O
Water	O
.	O

Sodium	B
salts	O
of	O
maleamic	B
acid	I
derivatives	O
of	O
lauryl	B
ester	I
of	O
tyrosine	B
(	O
MTNa	O
)	O
and	O
phenyl	B
alanine	I
(	O
MPNa	O
)	O
in	O
water	O
exhibited	O
strong	O
pH	O
-	O
responsive	O
behaviors	O
of	O
viscosity	O
and	O
specific	O
conductivity	O
that	O
originate	O
from	O
the	O
concentration	O
and	O
pH	O
dependence	O
of	O
their	O
aggregation	O
states	O
.	O

The	O
aggregates	O
were	O
characterized	O
by	O
a	O
novel	O
spin	O
-	O
probe	O
-	O
partitioning	O
electron	O
paramagnetic	O
resonance	O
(	O
SPPEPR	O
)	O
method	O
and	O
dynamic	O
light	O
scattering	O
(	O
DLS	O
)	O
.	O

Results	O
of	O
high	O
-	O
precision	O
fitting	O
of	O
the	O
second	O
-	O
harmonic	O
EPR	O
spectra	O
of	O
the	O
small	O
spin	O
probe	O
di	B
-	I
tert	I
-	I
butyl	I
nitroxide	I
(	O
DTBN	B
)	O
in	O
these	O
aggregates	O
together	O
with	O
viscosity	O
,	O
conductivity	O
,	O
and	O
DLS	O
showed	O
that	O
,	O
at	O
pH	O
	O
7.54	O
,	O
MTNa	O
formed	O
micelles	O
and	O
MPNa	O
vesicles	O
and	O
MTNa	O
exhibited	O
a	O
pH	O
-	O
induced	O
micelle	O
to	O
vesicle	O
transition	O
as	O
pH	O
was	O
lowered	O
toward	O
6	O
.	O

MTNa	O
,	O
at	O
pH	O
	O
7.54	O
,	O
formed	O
small	O
micelles	O
at	O
low	O
concentrations	O
that	O
transformed	O
to	O
long	O
worm	O
-	O
like	O
micelles	O
for	O
concentrations	O
	O
0.05	O
M	O
,	O
accompanied	O
by	O
a	O
30-fold	O
increase	O
in	O
solution	O
viscosity	O
.	O

The	O
hydrodynamic	O
radii	O
from	O
DLS	O
confirmed	O
the	O
presence	O
of	O
small	O
micellar	O
aggregates	O
of	O
radius	O
	O
2	O
nm	O
in	O
MTNa	O
at	O
pH	O
	O
7.54	O
at	O
the	O
lower	O
concentrations	O
,	O
with	O
coexisting	O
micelles	O
(	O
2	O
nm	O
)	O
and	O
vesicles	O
(	O
50	O
nm	O
)	O
at	O
pH	O
near	O
6.5	O
,	O
vesicles	O
(	O
radii	O
	O
70	O
nm	O
)	O
at	O
pH	O
near	O
6	O
,	O
and	O
large	O
vesicles	O
(	O
85	O
nm	O
)	O
in	O
MPNa	O
at	O
pH	O
	O
7.60	O
.	O

Both	O
MTNa	O
and	O
MPNa	O
precipitated	O
upon	O
reduction	O
of	O
pH	O
below	O
6	O
and	O
below	O
7	O
,	O
respectively	O
.	O

The	O
rate	O
of	O
transfer	O
of	O
DTBN	B
between	O
the	O
aqueous	O
phase	O
and	O
the	O
aggregate	O
was	O
calculated	O
from	O
the	O
high	O
-	O
field	O
Lorentzian	O
linewidths	O
of	O
the	O
electron	O
paramagnetic	O
resonance	O
(	O
EPR	O
)	O
spectra	O
.	O

The	O
activation	O
energy	O
for	O
the	O
transfer	O
determined	O
from	O
the	O
temperature	O
dependence	O
of	O
the	O
rate	O
of	O
transfer	O
is	O
12.7	O
kJ	O
/	O
mol	O
for	O
MTNa	O
vesicles	O
(	O
pH	O
	O
6	O
)	O
and	O
20.6	O
	O
1.3	O
kJ	O
/	O
mol	O
for	O
MPNa	O
(	O
pH	O
	O
7.60	O
)	O
.	O

The	O
pH	O
-	O
induced	O
transformations	O
were	O
reversible	O
.	O

Discovery	O
of	O
aryl	B
ureas	I
and	O
aryl	B
amides	I
as	O
potent	O
and	O
selective	O
histamine	B
H3	O
receptor	O
antagonists	O
for	O
the	O
treatment	O
of	O
obesity	O
(	O
Part	O
I	O
)	O
.	O

A	O
series	O
of	O
structurally	O
novel	O
aryl	B
ureas	I
was	O
derived	O
from	O
optimization	O
of	O
the	O
HTS	O
lead	O
as	O
selective	O
histamine	B
H3	O
receptor	O
(	O
H3R	O
)	O
antagonists	O
.	O

The	O
SAR	O
was	O
explored	O
and	O
the	O
data	O
obtained	O
set	O
up	O
the	O
starting	O
point	O
and	O
foundation	O
for	O
further	O
optimization	O
.	O

The	O
most	O
potent	O
tool	O
compounds	O
,	O
as	O
exemplified	O
by	O
compounds	O
2l	O
,	O
5b	O
,	O
5d	O
,	O
and	O
5e	O
,	O
displayed	O
antagonism	O
potencies	O
in	O
the	O
subnanomolar	O
range	O
in	O
in	O
vitro	O
human	O
-	O
H3R	O
FLIPR	O
assays	O
and	O
rhesus	O
monkey	O
H3R	O
binding	O
assays	O
.	O

Phenanthroimidazole	B
-	O
based	O
thiobenzamide	B
as	O
an	O
effective	O
sensor	O
for	O
highly	O
selective	O
detection	O
of	O
mercury	B
(	I
II	I
)	I
.	O

Based	O
on	O
highly	O
selective	O
and	O
irreversible	O
Hg	B
(	I
2+	I
)	I
-promoted	O
desulfurization	O
reaction	O
,	O
a	O
new	O
and	O
simple	O
phenanthroimidazole	B
-	O
type	O
sensor	O
was	O
prepared	O
and	O
exhibited	O
high	O
selectivity	O
towards	O
Hg	B
(	I
2	I
+	I
)	I
ion	O
over	O
other	O
metal	O
ions	O
,	O
accompanied	O
by	O
transformation	O
of	O
a	O
weakly	O
fluorescent	O
thioamide	B
moiety	O
(	O
colorless	O
)	O
to	O
a	O
highly	O
fluorescent	O
amide	B
one	O
(	O
blue	O
)	O
,	O
with	O
a	O
136-fold	O
increase	O
in	O
fluorescent	O
intensity	O
in	O
aqueous	O
solution	O
with	O
a	O
pH	O
span	O
2.57	O
-	O
9.12	O
.	O

Cerebral	O
ischemia	O
-	O
induced	O
difference	O
in	O
sensitivity	O
to	O
depression	O
and	O
potential	O
therapeutics	O
in	O
rats	O
.	O

The	O
'	O
vascular	O
depression	O
'	O
hypothesis	O
has	O
recently	O
attracted	O
significant	O
research	O
attention	O
,	O
although	O
the	O
causal	O
relationship	O
between	O
vascular	O
-	O
related	O
injuries	O
and	O
depression	O
has	O
not	O
been	O
established	O
.	O

Here	O
,	O
we	O
show	O
that	O
one	O
episode	O
of	O
cerebral	O
ischemia	O
was	O
sufficient	O
to	O
greatly	O
increase	O
the	O
sensitivity	O
of	O
rats	O
to	O
potentially	O
depressogenic	O
events	O
,	O
evaluated	O
at	O
below	O
-	O
threshold	O
intensities	O
in	O
the	O
open	O
space	O
swim	O
test	O
.	O

The	O
induced	O
'	O
ischemic	O
depression	O
'	O
was	O
lasting	O
and	O
sensitive	O
to	O
an	O
acute	O
administration	O
of	O
brain	O
-	O
derived	O
neurotrophic	O
factor	O
or	O
bryostatin-1	B
,	O
a	O
relatively	O
selective	O
activator	O
of	O
protein	O
kinase	O
C	O
,	O
during	O
the	O
induction	O
phase	O
.	O

Chronic	O
treatment	O
with	O
bryostatin-1	B
(	O
5	O
weeks	O
)	O
after	O
the	O
induction	O
of	O
depressive	O
behavior	O
reversed	O
the	O
depressive	O
immobility	O
and	O
produced	O
a	O
lasting	O
therapeutic	O
effect	O
,	O
which	O
remained	O
effective	O
3	O
weeks	O
after	O
discontinuation	O
of	O
the	O
treatment	O
.	O

Similar	O
treatment	O
with	O
alaproclate	B
,	O
a	O
selective	O
serotonin	B
reuptake	O
inhibitor	O
,	O
in	O
contrast	O
,	O
produced	O
temporary	O
relief	O
from	O
the	O
depressive	O
symptoms	O
,	O
with	O
the	O
therapeutic	O
effect	O
disappearing	O
soon	O
after	O
the	O
end	O
of	O
the	O
treatment	O
.	O

The	O
results	O
strongly	O
suggest	O
that	O
cerebral	O
ischemia	O
has	O
a	O
direct	O
role	O
in	O
shaping	O
the	O
sensitivity	O
of	O
an	O
individual	O
to	O
depressogenic	O
events	O
and	O
that	O
bryostatin-1-like	B
agents	O
may	O
be	O
developed	O
as	O
therapeutics	O
for	O
treating	O
ischemic	O
depression	O
in	O
humans	O
.	O

Current	O
status	O
of	O
liposomal	O
porphyrinoid	B
photosensitizers	O
.	O

The	O
complete	O
eradication	O
of	O
various	O
targets	O
,	O
such	O
as	O
infectious	O
agents	O
or	O
cancer	O
cells	O
,	O
while	O
leaving	O
healthy	O
host	O
cells	O
untouched	O
,	O
is	O
still	O
a	O
great	O
challenge	O
faced	O
in	O
the	O
field	O
of	O
medicine	O
.	O

Photodynamic	O
therapy	O
(	O
PDT	O
)	O
seems	O
to	O
be	O
a	O
promising	O
approach	O
for	O
anticancer	O
treatment	O
,	O
as	O
well	O
as	O
to	O
combat	O
various	O
dermatologic	O
and	O
ophthalmic	O
diseases	O
and	O
microbial	O
infections	O
.	O

The	O
application	O
of	O
liposomes	O
as	O
delivery	O
systems	O
for	O
porphyrinoids	B
has	O
helped	O
overcome	O
many	O
drawbacks	O
of	O
conventional	O
photosensitizers	O
and	O
facilitated	O
the	O
development	O
of	O
novel	O
effective	O
photosensitizers	O
that	O
can	O
be	O
encapsulated	O
in	O
liposomes	O
.	O

The	O
development	O
,	O
preclinical	O
studies	O
and	O
future	O
directions	O
for	O
liposomal	O
delivery	O
of	O
conventional	O
and	O
novel	O
photosensitizers	O
are	O
reviewed	O
.	O

Effects	O
of	O
Selenium	B
Intervention	O
on	O
Chronic	O
Fluorosis	O
-	O
Induced	O
Renal	O
Cell	O
Apoptosis	O
in	O
Rats	O
.	O

This	O
study	O
aims	O
to	O
explore	O
the	O
effect	O
of	O
selenium	B
in	O
fluoride	B
-	O
induced	O
renal	O
cell	O
apoptosis	O
in	O
rats	O
and	O
determine	O
the	O
optimal	O
level	O
of	O
selenium	B
in	O
drinking	O
water	O
to	O
prevent	O
fluorosis	O
.	O

Experimental	O
animals	O
were	O
divided	O
into	O
a	O
control	O
group	O
,	O
a	O
sodium	B
fluoride	I
-	O
treated	O
group	O
(	O
NaF	B
,	O
50	O
mg	O
/	O
L	O
)	O
,	O
three	O
sodium	B
selenite	I
-	O
treated	O
groups	O
(	O
Na2SeO3	B
,	O
0.375	O
,	O
0.75	O
,	O
and	O
1.5	O
mg	O
/	O
L	O
)	O
,	O
and	O
three	O
selenium	B
+	O
NaF	B
-	O
treated	O
groups	O
(	O
Na2SeO3	B
,	O
0.375	O
,	O
0.75	O
,	O
and	O
1.5	O
mg	O
/	O
L	O
;	O
NaF	B
,	O
50	O
mg	O
/	O
L	O
)	O
.	O

Ultrastructural	O
changes	O
in	O
the	O
kidney	O
tissues	O
of	O
each	O
group	O
were	O
observed	O
by	O
transmission	O
electron	O
microscopy	O
.	O

Apoptosis	O
was	O
detected	O
by	O
terminal	O
deoxynucleotidyl	O
transferase	O
-	O
mediated	O
dUTP	B
nick	O
-	O
end	O
labeling	O
assay	O
and	O
the	O
expressions	O
of	O
Bcl-2	O
and	O
Bax	O
proteins	O
were	O
detected	O
by	O
immunohistochemical	O
methods	O
.	O

The	O
expressions	O
of	O
Bcl-2	O
and	O
Bax	O
mRNA	O
were	O
detected	O
by	O
reverse	O
transcription	O
-	O
polymerase	O
chain	O
reaction	O
.	O

The	O
results	O
showed	O
that	O
Bcl-2	O
,	O
Bax	O
,	O
and	O
Bax	O
/	O
Bcl-2	O
protein	O
expressions	O
in	O
the	O
fluoride	B
and	O
high	O
selenium	B
groups	O
were	O
highly	O
elevated	O
compared	O
with	O
the	O
control	O
group	O
(	O
P	O
<	O
0.01	O
)	O
.	O

Bax	O
expression	O
in	O
the	O
low	O
selenium	B
group	O
and	O
Bcl-2	O
,	O
Bax	O
,	O
and	O
Bax	O
/	O
Bcl-2	O
protein	O
expressions	O
in	O
the	O
moderate	O
selenium	B
groups	O
were	O
observably	O
elevated	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Bax	O
and	O
Bax	O
/	O
Bcl-2	O
expressions	O
in	O
the	O
fluoride	B
group	O
and	O
Bax	O
mRNA	O
expression	O
in	O
the	O
high	O
selenium	B
group	O
were	O
highly	O
elevated	O
(	O
P	O
<	O
0.01	O
)	O
.	O

Bax	O
/	O
Bcl-2	O
mRNA	O
expression	O
in	O
the	O
high	O
selenium	B
group	O
was	O
also	O
highly	O
elevated	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Compared	O
with	O
the	O
fluoride	B
group	O
,	O
the	O
group	O
treated	O
with	O
low	O
selenium	B
has	O
Bax	O
protein	O
expression	O
that	O
was	O
observably	O
reduced	O
(	O
P	O
<	O
0.05	O
)	O
;	O
the	O
group	O
treated	O
with	O
moderate	O
selenium	B
has	O
Bcl-2	O
protein	O
expression	O
that	O
was	O
observably	O
elevated	O
(	O
P	O
<	O
0.05	O
)	O
,	O
Bax	O
protein	O
expression	O
that	O
was	O
highly	O
reduced	O
(	O
P	O
<	O
0.01	O
)	O
,	O
and	O
Bax	O
/	O
Bcl-2	O
protein	O
expression	O
that	O
was	O
observably	O
reduced	O
(	O
P	O
<	O
0.05	O
)	O
;	O
the	O
group	O
treated	O
with	O
high	O
selenium	B
has	O
Bcl-2	O
protein	O
expression	O
that	O
was	O
highly	O
elevated	O
(	O
P	O
<	O
0.01	O
)	O
,	O
Bax	O
protein	O
expression	O
that	O
was	O
highly	O
elevated	O
(	O
P	O
<	O
0.01	O
)	O
,	O
and	O
Bax	O
/	O
Bcl-2	O
protein	O
expression	O
that	O
was	O
highly	O
reduced	O
(	O
P	O
<	O
0.01	O
)	O
;	O
the	O
groups	O
treated	O
with	O
moderate	O
selenium	B
and	O
high	O
selenium	B
have	O
Bax	O
mRNA	O
expression	O
that	O
was	O
highly	O
reduced	O
(	O
P	O
<	O
0.01	O
)	O
,	O
and	O
the	O
groups	O
treated	O
with	O
high	O
selenium	B
have	O
Bax	O
/	O
Bcl-2	O
mRNA	O
expression	O
that	O
was	O
observably	O
reduced	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Selenium	B
may	O
inhibit	O
the	O
apoptosis	O
of	O
renal	O
cells	O
in	O
fluorosis	O
rats	O
by	O
regulating	O
the	O
expressions	O
of	O
Bcl-2	O
and	O
Bax	O
.	O

The	O
optimal	O
dose	O
of	O
Na2SeO3	B
to	O
protect	O
against	O
fluoride	B
-	O
induced	O
renal	O
cell	O
apoptosis	O
was	O
determined	O
to	O
be	O
1.5	O
mg	O
/	O
L.	O

Melatonin	B
and	O
its	O
analogue	O
5-MCA	B
-	I
NAT	I
potentiate	O
adrenergic	O
receptor	O
-	O
mediated	O
ocular	O
hypotensive	O
effects	O
in	O
rabbits	O
:	O
Significance	O
for	O
combination	O
therapy	O
in	O
glaucoma	O
.	O

Melatonin	B
is	O
currently	O
considered	O
as	O
a	O
promising	O
drug	O
for	O
glaucoma	O
treatment	O
due	O
to	O
its	O
ocular	O
hypotensive	O
and	O
neuroprotective	O
effects	O
.	O

We	O
have	O
investigated	O
the	O
effect	O
of	O
melatonin	B
and	O
its	O
analogue	O
5-methoxycarbonylamino	B
-	I
N	I
-	I
acetyltryptamine	I
,	O
5-MCA	B
-	I
NAT	I
,	O
on	O
2	O
/	O
2A	O
-	O
adrenergic	O
receptor	O
mRNA	O
as	O
well	O
as	O
protein	O
expression	O
in	O
cultured	O
rabbit	O
non	O
-	O
pigmented	O
ciliary	O
epithelial	O
cells	O
.	O

Quantitative	O
PCR	O
and	O
immunocytochemical	O
assays	O
revealed	O
a	O
significant	O
2-adrenergic	O
receptor	O
down	O
-	O
regulation	O
as	O
well	O
as	O
2A	O
-	O
adrenergic	O
receptor	O
up	O
-	O
regulation	O
of	O
treated	O
cells	O
(	O
p<0.001	O
,	O
maximal	O
significant	O
effect	O
)	O
.	O

In	O
addition	O
,	O
we	O
have	O
studied	O
the	O
effect	O
of	O
these	O
drugs	O
upon	O
the	O
ocular	O
hypotensive	O
action	O
of	O
a	O
non	O
-	O
selective	O
	O
-	O
adrenergic	O
receptor	O
(	O
timolol	B
)	O
and	O
a	O
selective	O
2-adrenergic	O
receptor	O
agonist	O
(	O
brimonidine	B
)	O
in	O
normotensive	O
rabbits	O
.	O

IOP	O
experiments	O
showed	O
that	O
the	O
administration	O
of	O
timolol	B
in	O
rabbits	O
pre	O
-	O
treated	O
with	O
melatonin	B
or	O
5-MCA	B
-	I
NAT	I
evoked	O
an	O
additional	O
IOP	O
reduction	O
of	O
14.02	O
	O
5.8	O
%	O
or	O
16.75	O
	O
5.48	O
%	O
(	O
p<0.01	O
)	O
in	O
comparison	O
with	O
rabbits	O
treated	O
with	O
timolol	B
alone	O
for	O
24	O
hours	O
.	O

Concerning	O
brimonidine	B
hypotensive	O
action	O
,	O
an	O
additional	O
IOP	O
reduction	O
of	O
29.26	O
	O
5.21	O
%	O
or	O
39.07	O
	O
5.81	O
%	O
(	O
p<0.001	O
)	O
was	O
observed	O
in	O
rabbits	O
pretreated	O
with	O
melatonin	B
or	O
5-MCA	B
-	I
NAT	I
when	O
compared	O
with	O
animals	O
treated	O
with	O
brimonidine	B
alone	O
for	O
24	O
hours	O
.	O

Additionally	O
,	O
a	O
sustained	O
potentiating	O
effect	O
of	O
a	O
single	O
dose	O
of	O
5-MCA	B
-	I
NAT	I
was	O
seen	O
in	O
rabbits	O
treated	O
with	O
brimonidine	B
once	O
daily	O
for	O
up	O
four	O
days	O
(	O
extra	O
IOP	O
decrease	O
of	O
15.57	O
	O
5.15	O
%	O
,	O
p<0.05	O
,	O
compared	O
to	O
brimonidine	B
alone	O
)	O
.	O

These	O
data	O
confirm	O
the	O
indirect	O
action	O
of	O
melatoninergic	O
compounds	O
on	O
adrenergic	O
receptors	O
and	O
their	O
remarkable	O
effect	O
upon	O
the	O
ocular	O
hypotensive	O
action	O
mainly	O
of	O
2-adrenergic	O
receptor	O
agonists	O
but	O
also	O
of	O
	O
-	O
adrenergic	O
antagonists	O
.	O

Focal	O
adhesion	O
kinase	O
regulates	O
collagen	O
I	O
-	O
induced	O
airway	O
smooth	O
muscle	O
phenotype	O
switching	O
.	O

Increased	O
extracellular	O
matrix	O
(	O
ECM	O
)	O
deposition	O
and	O
airway	O
smooth	O
muscle	O
(	O
ASM	O
)	O
mass	O
are	O
major	O
contributors	O
to	O
airway	O
remodeling	O
in	O
asthma	O
.	O

Recently	O
,	O
we	O
have	O
demonstrated	O
that	O
the	O
ECM	O
protein	O
collagen	O
I	O
,	O
which	O
is	O
increased	O
surrounding	O
asthmatic	O
ASM	O
,	O
induces	O
a	O
proliferative	O
,	O
hypocontractile	O
ASM	O
phenotype	O
.	O

Little	O
is	O
known	O
,	O
however	O
,	O
on	O
the	O
signaling	O
pathways	O
involved	O
.	O

Using	O
bovine	O
tracheal	O
smooth	O
muscle	O
,	O
we	O
investigated	O
the	O
role	O
of	O
focal	O
adhesion	O
kinase	O
(	O
FAK	O
)	O
and	O
downstream	O
signaling	O
pathways	O
in	O
collagen	O
I	O
-	O
induced	O
ASM	O
phenotype	O
modulation	O
.	O

Phosphorylation	O
of	O
FAK	O
was	O
increased	O
during	O
adhesion	O
to	O
both	O
uncoated	O
and	O
collagen	O
I	O
-	O
coated	O
culture	O
dishes	O
,	O
without	O
differences	O
between	O
these	O
matrices	O
.	O

No	O
differences	O
in	O
cellular	O
adhesion	O
were	O
found	O
either	O
.	O

Inhibition	O
of	O
FAK	O
activity	O
by	O
overexpression	O
of	O
the	O
FAK	O
deletion	O
mutants	O
FAT	O
(	O
focal	O
adhesion	O
targeting	O
domain	O
)	O
and	O
FRNK	O
(	O
FAK	O
-	O
related	O
non	O
-	O
kinase	O
)	O
attenuated	O
adhesion	O
.	O

After	O
attachment	O
,	O
FAK	O
phosphorylation	O
was	O
time	O
-	O
dependently	O
increased	O
in	O
cells	O
cultured	O
on	O
collagen	O
I	O
,	O
whereas	O
no	O
activation	O
was	O
found	O
on	O
an	O
uncoated	O
plastic	O
matrix	O
.	O

In	O
addition	O
,	O
collagen	O
I	O
time-	O
and	O
concentration	O
-	O
dependently	O
increased	O
cell	O
proliferation	O
,	O
which	O
was	O
fully	O
inhibited	O
by	O
FAT	O
and	O
FRNK	O
.	O

Similarly	O
,	O
the	O
specific	O
pharmacological	O
FAK	O
inhibitor	O
PF-573,228	B
as	O
well	O
as	O
specific	O
inhibitors	O
of	O
p38	O
MAPK	O
and	O
Src	O
also	O
fully	O
inhibited	O
collagen	O
I	O
-	O
induced	O
proliferation	O
,	O
whereas	O
partial	O
inhibition	O
was	O
observed	O
by	O
inhibition	O
of	O
PI3-kinase	O
and	O
MEK	O
.	O

The	O
inhibition	O
of	O
cell	O
proliferation	O
by	O
these	O
inhibitors	O
was	O
associated	O
with	O
attenuation	O
of	O
the	O
collagen	O
I	O
-	O
induced	O
hypocontractility	O
.	O

Collectively	O
,	O
the	O
results	O
indicate	O
that	O
induction	O
of	O
a	O
proliferative	O
,	O
hypocontractile	O
ASM	O
phenotype	O
by	O
collagen	O
I	O
is	O
mediated	O
by	O
FAK	O
and	O
downstream	O
signaling	O
pathways	O
.	O

Selective	O
Smad4	O
Knockout	O
in	O
Ovarian	O
Preovulatory	O
Follicles	O
Results	O
in	O
Multiple	O
Defects	O
in	O
Ovulation	O
.	O

The	O
TGF	O
-	O
	O
signaling	O
pathway	O
is	O
involved	O
with	O
multiple	O
processes	O
in	O
the	O
mammalian	O
ovary	O
,	O
including	O
primordial	O
follicle	O
formation	O
,	O
granulosa	O
cell	O
(	O
GC	O
)	O
proliferation	O
,	O
follicle	O
atresia	O
,	O
ovulation	O
,	O
and	O
feedback	O
regulation	O
between	O
the	O
pituitary	O
and	O
ovary	O
.	O

The	O
transcriptional	O
factor	O
SMAD4	O
is	O
the	O
central	O
component	O
of	O
the	O
canonical	O
TGF	O
-	O
	O
signaling	O
pathway	O
.	O

Smad4	O
knockout	O
using	O
Amhr2-Cre	O
,	O
which	O
is	O
expressed	O
in	O
GCs	O
of	O
immature	O
developing	O
follicles	O
,	O
causes	O
premature	O
luteinization	O
.	O

In	O
this	O
study	O
,	O
we	O
specifically	O
depleted	O
Smad4	O
in	O
GCs	O
of	O
preovulatory	O
follicles	O
using	O
Cyp19-Cre	O
mice	O
.	O

As	O
different	O
from	O
results	O
with	O
Smad4	O
(	O
fl	O
/	O
fl	O
)	O
;Amhr2-Cre	O
mice	O
,	O
Smad4	O
depletion	O
in	O
preovulatory	O
follicles	O
did	O
not	O
cause	O
premature	O
luteinization	O
or	O
suppress	O
GC	O
proliferation	O
;	O
rather	O
,	O
it	O
increased	O
follicle	O
atresia	O
.	O

In	O
addition	O
,	O
Nppc	O
and	O
Npr2	O
expressions	O
were	O
reduced	O
by	O
Smad4	O
depletion	O
;	O
thus	O
,	O
their	O
effect	O
of	O
maintaining	O
oocyte	O
meiotic	O
arrest	O
was	O
weakened	O
in	O
Smad4	O
conditional	O
knockout	O
mice	O
.	O

Smad4	O
(	O
fl	O
/	O
fl	O
)	O
;Cyp19-Cre	O
female	O
mice	O
were	O
subfertile	O
and	O
had	O
irregular	O
estrous	O
cycles	O
and	O
ovulation	O
defects	O
.	O

Smad4	O
knockout	O
also	O
blocked	O
luteinizing	O
hormone	O
(	O
LH	O
)	O
-induced	O
cumulus	O
expansion	O
and	O
follicle	O
rupture	O
,	O
but	O
not	O
oocyte	O
meiotic	O
resumption	O
.	O

Our	O
results	O
also	O
indicated	O
that	O
SMAD4	O
was	O
required	O
for	O
LH	O
-	O
stimulated	O
activation	O
of	O
ERK1	O
/	O
2	O
and	O
the	O
expressions	O
of	O
ovulation	O
-	O
related	O
genes	O
.	O

The	O
defects	O
arising	O
from	O
SMAD4	O
depletion	O
could	O
not	O
be	O
rescued	O
by	O
intra	O
-	O
ovarian	O
mediators	O
of	O
LH	O
actions	O
,	O
such	O
as	O
EGF	O
-	O
like	O
factors	O
and	O
prostaglandin	B
E2	I
.	O

Furthermore	O
,	O
corpus	O
lutea	O
did	O
not	O
form	O
in	O
Smad4	O
(	O
fl	O
/	O
fl	O
)	O
;Cyp19-Cre	O
female	O
mice	O
,	O
indicating	O
that	O
SMAD4	O
was	O
crucial	O
for	O
GCs	O
terminal	O
differentiation	O
.	O

Thus	O
,	O
by	O
characterizing	O
the	O
ovarian	O
phenotypes	O
of	O
preovulatory	O
follicle	O
-	O
specific	O
Smad4	O
knockout	O
mice	O
,	O
we	O
identified	O
the	O
developmental	O
stage	O
-	O
specific	O
functions	O
of	O
the	O
canonical	O
TGF	O
-	O
	O
signaling	O
pathway	O
in	O
ovulation	O
and	O
luteinization	O
.	O

Charge	O
-	O
Transfer	O
Interaction	O
between	O
Few	O
-	O
Layer	O
MoS2	B
and	O
Tetrathiafulvalene	B
.	O

Graphene	B
look	O
-	O
alike	O
:	O
MoS2	B
has	O
a	O
layered	O
structure	O
similar	O
to	O
graphene	B
.	O

Tetrathiafulvalene	B
(	O
TTF	B
)	O
interacts	O
with	O
thin	O
,	O
few	O
-	O
layer	O
MoS2	B
material	O
by	O
donating	O
an	O
electron	O
,	O
resulting	O
in	O
the	O
formation	O
of	O
TTF	B
radical	O
cation	O
and	O
n	O
-	O
type	O
doping	O
of	O
MoS2	B
.	O

Electron	O
-	O
withdrawing	O
tetracyanoethylene	B
,	O
in	O
contrast	O
,	O
does	O
not	O
cause	O
p	O
-	O
type	O
doping	O
in	O
MoS2	B
.	O

Matrix	O
Isolation	O
Spectroscopy	O
and	O
Nuclear	O
Spin	O
Conversion	O
of	O
NH3	B
and	O
ND3	B
in	O
Solid	O
Parahydrogen	B
.	O

We	O
present	O
matrix	O
isolation	O
infrared	O
absorption	O
spectra	O
of	O
NH3	B
and	O
ND3	B
trapped	O
in	O
solid	O
parahydrogen	B
(	O
pH2	B
)	O
at	O
temperatures	O
around	O
1.8	O
K.	O
We	O
used	O
the	O
relatively	O
slow	O
nuclear	O
spin	O
conversion	O
(	O
NSC	O
)	O
of	O
NH3	B
and	O
ND3	B
in	O
freshly	O
deposited	O
pH2	B
samples	O
as	O
a	O
tool	O
to	O
assign	O
the	O
sparse	O
vibration	O
-	O
inversion	O
-	O
rotation	O
(	O
VIR	O
)	O
spectra	O
of	O
NH3	B
in	O
the	O
regions	O
of	O
the	O
2	O
,	O
4	O
,	O
24	O
,	O
1	O
,	O
and	O
3	O
bands	O
and	O
ND3	B
in	O
the	O
regions	O
of	O
the	O
2	O
,	O
4	O
,	O
1	O
,	O
and	O
3	O
fundamentals	O
.	O

Partial	O
assignments	O
are	O
also	O
presented	O
for	O
various	O
combination	O
bands	O
of	O
NH3	B
.	O

Detailed	O
analysis	O
of	O
the	O
2	O
bands	O
of	O
NH3	B
and	O
ND3	B
indicates	O
that	O
both	O
isotopomers	O
are	O
nearly	O
free	O
rotors	O
;	O
that	O
the	O
vibrational	O
energy	O
is	O
blue	O
-	O
shifted	O
by	O
1	O
-	O
2	O
%	O
;	O
and	O
that	O
the	O
rotational	O
constants	O
and	O
inversion	O
tunneling	O
splitting	O
are	O
91	O
-	O
94	O
%	O
and	O
67	O
-	O
75	O
%	O
,	O
respectively	O
,	O
of	O
the	O
gas	O
-	O
phase	O
values	O
.	O

The	O
line	O
shapes	O
of	O
the	O
VIR	O
absorptions	O
are	O
narrow	O
(	O
0.2	O
-	O
0.4	O
cm	O
(	O
-1	O
)	O
)	O
for	O
upper	O
states	O
that	O
can	O
not	O
rotationally	O
relax	O
and	O
broad	O
(	O
>	O
1	O
cm	O
(	O
-1	O
)	O
)	O
for	O
upper	O
states	O
that	O
can	O
rotationally	O
relax	O
.	O

We	O
report	O
and	O
assign	O
a	O
number	O
of	O
NH3-induced	B
infrared	O
absorption	O
features	O
of	O
the	O
pH2	B
host	O
near	O
4150	O
cm	O
(	O
-1	O
)	O
,	O
along	O
with	O
a	O
cooperative	O
transition	O
that	O
involves	O
simultaneous	O
vibrational	O
excitation	O
of	O
a	O
pH2	B
molecule	O
and	O
rotation	O
-	O
inversion	O
excitation	O
of	O
NH3	B
.	O

The	O
NSCs	O
of	O
NH3	B
and	O
ND3	B
were	O
found	O
to	O
follow	O
first	O
-	O
order	O
kinetics	O
with	O
rate	O
constants	O
at	O
1.8	O
K	O
of	O
k	O
=	O
1.88	O
(	O
16	O
)	O
	O
10	O
(	O
-3	O
)	O
s	O
(	O
-1	O
)	O
and	O
k	O
=	O
1.08	O
(	O
8	O
)	O
	O
10	O
(	O
-3	O
)	O
s	O
(	O
-1	O
)	O
,	O
respectively	O
.	O

These	O
measured	O
rate	O
constants	O
are	O
compared	O
to	O
previous	O
measurements	O
for	O
NH3	B
in	O
an	O
Ar	O
matrix	O
and	O
with	O
the	O
rate	O
constants	O
measured	O
for	O
other	O
dopant	O
molecules	O
isolated	O
in	O
solid	O
pH2	B
.	O

Development	O
and	O
validation	O
of	O
NIR	O
-	O
chemometric	O
methods	O
for	O
chemical	O
and	O
pharmaceutical	O
characterization	O
of	O
meloxicam	B
tablets	O
.	O

Abstract	O
Context	O
:	O
Near	O
-	O
Infrared	O
(	O
NIR	O
)	O
spectroscopy	O
is	O
an	O
important	O
component	O
of	O
a	O
Process	O
Analytical	O
Technology	O
(	O
PAT	O
)	O
toolbox	O
and	O
is	O
a	O
key	O
technology	O
for	O
enabling	O
the	O
rapid	O
analysis	O
of	O
pharmaceutical	O
tablets	O
.	O

Objective	O
:	O

The	O
aim	O
of	O
this	O
research	O
work	O
was	O
to	O
develop	O
and	O
validate	O
NIR	O
-	O
chemometric	O
methods	O
not	O
only	O
for	O
the	O
determination	O
of	O
active	O
pharmaceutical	O
ingredients	O
content	O
but	O
also	O
pharmaceutical	O
properties	O
(	O
crushing	O
strength	O
,	O
disintegration	O
time	O
)	O
of	O
meloxicam	B
tablets	O
.	O

Materials	O
and	O
methods	O
:	O
The	O
development	O
of	O
the	O
method	O
for	O
active	O
content	O
assay	O
was	O
performed	O
on	O
samples	O
corresponding	O
to	O
80	O
%	O
,	O
90	O
%	O
,	O
100	O
%	O
,	O
110	O
%	O
and	O
120	O
%	O
of	O
meloxicam	B
content	O
and	O
the	O
development	O
of	O
the	O
methods	O
for	O
pharmaceutical	O
characterization	O
was	O
performed	O
on	O
samples	O
prepared	O
at	O
seven	O
different	O
compression	O
forces	O
(	O
ranging	O
from	O
7	O
to	O
45	O
kN	O
)	O
using	O
NIR	O
transmission	O
spectra	O
of	O
intact	O
tablets	O
and	O
PLS	O
as	O
a	O
regression	O
method	O
.	O

Results	O
:	O
The	O
results	O
show	O
that	O
the	O
developed	O
methods	O
have	O
good	O
trueness	O
,	O
precision	O
and	O
accuracy	O
and	O
are	O
appropriate	O
for	O
direct	O
active	O
content	O
assay	O
in	O
tablets	O
(	O
ranging	O
from	O
12	O
to	O
18	O
mg	O
/	O
tablet	O
)	O
and	O
also	O
for	O
predicting	O
crushing	O
strength	O
and	O
disintegration	O
time	O
of	O
intact	O
meloxicam	B
tablets	O
.	O

Discussion	O
:	O
The	O
comparative	O
data	O
show	O
that	O
the	O
proposed	O
methods	O
are	O
in	O
good	O
agreement	O
with	O
the	O
reference	O
methods	O
currently	O
used	O
for	O
the	O
characterization	O
of	O
meloxicam	B
tablets	O
(	O
HPLC	O
-	O
UV	O
methods	O
for	O
the	O
assay	O
and	O
European	O
Pharmacopeia	O
methods	O
for	O
determining	O
the	O
crushing	O
strength	O
and	O
disintegration	O
time	O
)	O
.	O

Conclusion	O
:	O
The	O
results	O
show	O
the	O
possibility	O
to	O
predict	O
both	O
chemical	O
properties	O
(	O
active	O
content	O
)	O
and	O
physical	O
/	O
pharmaceutical	O
properties	O
(	O
crushing	O
strength	O
and	O
disintegration	O
time	O
)	O
directly	O
,	O
without	O
any	O
sample	O
preparation	O
,	O
from	O
the	O
same	O
NIR	O
transmission	O
spectrum	O
of	O
meloxicam	B
tablets	O
.	O

Physicochemical	O
characterization	O
of	O
phyllanthin	B
from	O
Phyllanthus	O
amarus	O
Schum	O
.	O

et	O
Thonn	O
.	O

Abstract	O
Phyllanthin	B
is	O
a	O
major	O
bioactive	O
lignan	B
component	O
of	O
Phyllanthus	O
amarus	O
,	O
with	O
several	O
known	O
biological	O
activities	O
.	O

This	O
study	O
dealt	O
with	O
the	O
isolation	O
and	O
physicochemical	O
characterization	O
of	O
phyllanthin	B
.	O

Phyllanthin	B
was	O
isolated	O
from	O
P.	O
amarus	O
leaves	O
by	O
column	O
chromatography	O
and	O
purified	O
by	O
recrystallization	O
to	O
obtain	O
phyllanthin	B
crystals	O
with	O
a	O
purity	O
of	O
more	O
than	O
98	O
%	O
.	O

UV	O
,	O
IR	O
,	O
MS	O
,	O
(	B
1	I
)	I
H	I
NMR	O
and	O
(	B
13	I
)	I
C	I
NMR	O
spectra	O
were	O
employed	O
to	O
identify	O
phyllanthin	B
.	O

The	O
physicochemical	O
properties	O
of	O
phyllanthin	B
were	O
characterized	O
using	O
differential	O
scanning	O
calorimetry	O
,	O
thermogravimetric	O
analysis	O
,	O
X	O
-	O
ray	O
diffraction	O
,	O
pH	O
-	O
solubility	O
,	O
ionization	O
property	O
and	O
lipophilicity	O
.	O

The	O
results	O
indicated	O
that	O
phyllanthin	B
crystals	O
had	O
the	O
melting	O
point	O
and	O
melting	O
enthalpy	O
range	O
of	O
96.67	O
-	O
97.03	O
	O
C	O
and	O
109.61	O
-	O
116.34	O
J	O
/	O
g	O
,	O
respectively	O
.	O

Three	O
kinds	O
of	O
phyllanthin	B
crystals	O
,	O
recrystallized	O
by	O
petroleum	B
ether	I
,	O
absolute	O
ethanol	B
and	O
25	O
%	O
ethanol	B
solution	O
,	O
showed	O
only	O
one	O
polymorph	O
and	O
no	O
polymorphic	O
impurity	O
.	O

Phyllanthin	B
in	O
a	O
solid	O
state	O
was	O
found	O
to	O
undergo	O
significant	O
thermal	O
decomposition	O
above	O
200	O
	O
C	O
.	O

The	O
compound	O
demonstrated	O
good	O
stability	O
in	O
aqueous	O
solution	O
over	O
a	O
pH	O
range	O
of	O
1.07	O
-	O
10.02	O
for	O
at	O
least	O
4	O
h.	O
The	O
solubility	O
of	O
phyllanthin	B
appeared	O
to	O
be	O
pH	O
-	O
independent	O
of	O
pH	O
range	O
from	O
1.07	O
to	O
10.26	O
.	O

Ionization	O
property	O
studied	O
by	O
absorbance	O
spectroscopy	O
method	O
was	O
in	O
agreement	O
with	O
the	O
result	O
of	O
pH	O
-	O
solubility	O
study	O
,	O
showing	O
that	O
phyllanthin	B
has	O
no	O
pKa	O
over	O
a	O
pH	O
range	O
of	O
1.12	O
-	O
10.02	O
.	O

The	O
log	O
Pow	O
value	O
of	O
phyllanthin	B
was	O
found	O
to	O
be	O
3.30	O
	O
0.05	O
at	O
pH	O
7.48	O
,	O
suggesting	O
that	O
phyllanthin	B
may	O
have	O
good	O
permeability	O
through	O
biological	O
membranes	O
.	O

The	O
findings	O
could	O
be	O
useful	O
tools	O
for	O
the	O
development	O
of	O
stable	O
and	O
bioavailable	O
oral	O
dosage	O
forms	O
of	O
phyllanthin	B
.	O

Genistein	O
-	O
Modified	O
Poly	B
(	I
ethylene	I
oxide	I
)	I
/	O
Poly	B
(	I
d	I
,	I
l	I
-	I
lactic	I
acid	I
)	I
Electrospun	O
Mats	O
with	O
Improved	O
Antioxidant	O
and	O
Anti	O
-	O
inflammatory	O
Properties	O
.	O

Genistein	B
is	O
a	O
phytochemical	O
with	O
a	O
broad	O
range	O
of	O
desirable	O
biological	O
activity	O
for	O
wound	O
healing	O
.	O

However	O
,	O
its	O
poor	O
bioavailability	O
requires	O
developing	O
a	O
new	O
method	O
for	O
fabricating	O
an	O
appropriate	O
carrier	O
vehicle	O
to	O
deliver	O
genistein	B
in	O
a	O
sustained	O
manner	O
.	O

Based	O
on	O
the	O
guidance	O
afforded	O
by	O
the	O
ternary	O
phase	O
diagram	O
of	O
poly	B
(	I
d	I
,	I
l	I
-	I
lactic	I
acid	I
)	I
(	O
PDLLA	B
)	O
,	O
poly	B
(	I
ethylene	I
oxide	I
)	I
(	O
PEO	B
)	O
,	O
and	O
genistein	B
blends	O
,	O
certain	O
selective	O
compositions	O
were	O
electrospun	O
.	O

We	O
obtained	O
a	O
uniformly	O
smooth	O
surface	O
morphology	O
in	O
unmodified	O
and	O
genistein	B
-	O
modified	O
PEO	B
/	O
PDLLA	B
fibers	O
,	O
documented	O
by	O
scanning	O
electron	O
microscopy	O
.	O

Moreover	O
,	O
wide	O
-	O
angle	O
X	O
-	O
ray	O
diffraction	O
and	O
(	B
1	I
)	I
H	I
NMR	O
studies	O
revealed	O
that	O
the	O
genistein	B
molecules	O
,	O
successfully	O
incorporated	O
in	O
the	O
blends	O
,	O
remained	O
chemically	O
stable	O
after	O
electrospinning	O
.	O

Besides	O
surface	O
wettability	O
and	O
dimensional	O
stability	O
of	O
the	O
electrospun	O
mats	O
,	O
the	O
released	O
genistein	B
amount	O
has	O
been	O
evaluated	O
as	O
a	O
function	O
of	O
PEO	B
concentration	O
.	O

Our	O
biocompatibility	O
investigations	O
suggest	O
that	O
genistein	B
-	O
modified	O
PEO	B
/	O
PDLLA	B
electrospun	O
mats	O
exhibit	O
strong	O
antioxidant	O
and	O
anti	O
-	O
inflammatory	O
activities	O
which	O
indicate	O
they	O
have	O
potential	O
applications	O
for	O
wound	O
dressings	O
.	O

Cannabis	O
intoxication	O
inhibits	O
avoidance	O
action	O
tendencies	O
:	O
a	O
field	O
study	O
in	O
the	O
Amsterdam	O
coffee	O
shops	O
.	O

RATIONALE	O
:	O
Experimental	O
laboratory	O
studies	O
suggest	O
that	O
the	O
approach	O
bias	O
(	O
relatively	O
fast	O
approach	O
responses	O
)	O
toward	O
substance	O
-	O
related	O
materials	O
plays	O
an	O
important	O
role	O
in	O
problematic	O
substance	O
use	O
.	O

How	O
this	O
bias	O
is	O
moderated	O
by	O
intention	O
to	O
use	O
versus	O
recent	O
use	O
remains	O
unknown	O
.	O

Moreover	O
,	O
the	O
relationship	O
between	O
approach	O
bias	O
and	O
other	O
motivational	O
processes	O
(	O
satiation	O
and	O
craving	O
)	O
and	O
executive	O
functioning	O
remains	O
unclear	O
.	O

OBJECTIVES	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
cannabis	O
approach	O
bias	O
before	O
and	O
after	O
cannabis	O
use	O
in	O
real	O
-	O
life	O
setting	O
(	O
Amsterdam	O
coffee	O
shops	O
)	O
and	O
to	O
assess	O
the	O
relationship	O
between	O
approach	O
bias	O
,	O
craving	O
,	O
satiation	O
,	O
cannabis	O
use	O
,	O
and	O
response	O
inhibition	O
.	O

METHODS	O
:	O
Cannabis	O
,	O
tobacco	O
,	O
and	O
neutral	O
approach	O
and	O
avoidance	O
action	O
tendencies	O
were	O
measured	O
with	O
the	O
Approach	O
Avoidance	O
Task	O
and	O
compared	O
between	O
42	O
heavy	O
cannabis	O
users	O
with	O
the	O
intention	O
to	O
use	O
and	O
45	O
heavy	O
cannabis	O
users	O
shortly	O
after	O
cannabis	O
use	O
.	O

The	O
classical	O
Stroop	O
was	O
used	O
to	O
measure	O
response	O
inhibition	O
.	O

Multiple	O
regression	O
analyses	O
were	O
conducted	O
to	O
investigate	O
relationships	O
between	O
approach	O
bias	O
,	O
satiation	O
,	O
craving	O
,	O
cannabis	O
use	O
,	O
and	O
response	O
inhibition	O
.	O

RESULTS	O
:	O
In	O
contrast	O
to	O
the	O
hypotheses	O
,	O
heavy	O
cannabis	O
users	O
with	O
the	O
intention	O
to	O
use	O
did	O
not	O
show	O
a	O
cannabis	O
approach	O
bias	O
,	O
whereas	O
intoxicated	O
cannabis	O
users	O
did	O
show	O
an	O
approach	O
bias	O
regardless	O
of	O
image	O
category	O
.	O

This	O
could	O
be	O
attributed	O
to	O
a	O
general	O
slowing	O
of	O
avoidance	O
action	O
tendencies	O
.	O

Moreover	O
,	O
craving	O
was	O
negatively	O
associated	O
with	O
the	O
approach	O
bias	O
,	O
and	O
no	O
relationships	O
were	O
observed	O
between	O
the	O
cannabis	O
approach	O
bias	O
,	O
satiation	O
,	O
prior	O
cannabis	O
use	O
,	O
and	O
response	O
inhibition	O
.	O

CONCLUSION	O
:	O
Cannabis	O
intoxication	O
in	O
a	O
real	O
-	O
life	O
setting	O
inhibited	O
general	O
avoidance	O
.	O

Expression	O
of	O
the	O
cannabis	O
approach	O
bias	O
appeared	O
not	O
to	O
be	O
modulated	O
by	O
satiation	O
or	O
response	O
inhibition	O
.	O

Metabolism	O
and	O
pathways	O
for	O
denitration	O
of	O
organic	O
nitrates	B
in	O
the	O
human	O
liver	O
.	O

Liver	O
first	O
-	O
pass	O
metabolism	O
differs	O
considerably	O
among	O
organic	O
nitrates	B
but	O
little	O
information	O
exists	O
on	O
the	O
mechanism	O
of	O
denitration	O
of	O
these	O
compounds	O
in	O
hepatic	O
tissue	O
.	O

The	O
metabolism	O
of	O
nitrooxybutyl	B
-	I
esters	I
of	O
flurbiprofen	B
and	O
ferulic	B
-	I
acid	I
,	O
a	O
class	O
of	O
organic	O
nitrates	B
with	O
potential	O
therapeutic	O
implication	O
in	O
variety	O
of	O
different	O
conditions	O
,	O
was	O
investigated	O
in	O
comparison	O
with	O
glyceryl	B
trinitrate	I
(	O
GTN	B
)	O
in	O
human	O
liver	O
by	O
a	O
multiple	O
approach	O
,	O
using	O
a	O
spontaneous	O
metabolism	O
-	O
independent	O
NO	B
donor	O
(	O
NOC-5	B
)	O
as	O
a	O
reference	O
tool	O
.	O

Nitrooxybutyl	B
-	I
esters	I
were	O
rapidly	O
and	O
quantitatively	O
metabolized	O
to	O
their	O
respective	O
parent	O
compounds	O
and	O
the	O
organic	O
nitrate	B
moiety	O
nitrooxybutyl	B
-	I
alcohol	I
(	O
NOBA	B
)	O
.	O

Differently	O
from	O
GTN	B
which	O
was	O
rapidly	O
and	O
completely	O
metabolized	O
to	O
nitrite	B
,	O
NOBA	B
was	O
slowly	O
metabolized	O
to	O
nitrate	B
.	O

In	O
contrast	O
to	O
the	O
spontaneous	O
NO	B
donor	O
NOC-5	B
,	O
NOBA	B
and	O
GTN	B
did	O
not	O
generate	O
detectable	O
NO	B
and	O
failed	O
to	O
suppress	O
the	O
activity	O
of	O
cytochromeP450	O
;	O
an	O
enzyme	O
known	O
to	O
be	O
inhibited	O
by	O
NO	B
.	O

The	O
direct	O
identification	O
of	O
NOBA	B
following	O
liver	O
metabolism	O
targets	O
this	O
compound	O
as	O
the	O
functional	O
organic	O
nitrate	B
metabolite	O
of	O
nitrooxybutyl	B
-	I
esters	I
.	O

Moreover	O
the	O
investigation	O
of	O
the	O
pathways	O
for	O
denitration	O
of	O
NOBA	B
and	O
GTN	B
suggests	O
that	O
organic	O
nitrates	B
are	O
not	O
primarily	O
metabolized	O
to	O
NO	B
in	O
the	O
liver	O
but	O
to	O
different	O
extents	O
of	O
nitrite	B
or	O
nitrate	B
depending	O
from	O
their	O
different	O
chemical	O
structure	O
.	O

It	O
follows	O
that	O
cytochromeP450-dependent	O
metabolism	O
of	O
concomitant	O
drugs	O
is	O
not	O
likely	O
to	O
be	O
affected	O
by	O
oral	O
co	O
-	O
administration	O
of	O
organic	O
nitrates	B
.	O

However	O
the	O
first	O
-	O
pass	O
may	O
differently	O
affect	O
the	O
pharmacological	O
profile	O
of	O
organic	O
nitrates	B
in	O
connection	O
with	O
the	O
different	O
extent	O
of	O
denitration	O
and	O
the	O
distinct	O
bioactive	O
species	O
generated	O
and	O
exported	O
from	O
the	O
liver	O
(	O
nitrate	B
or	O
nitrite	B
)	O
.	O

Determining	O
osmotic	O
pressure	O
of	O
drug	O
solutions	O
by	O
air	O
humidity	O
in	O
equilibrium	O
method	O
.	O

Abstract	O
Objective	O
:	O
To	O
establish	O
a	O
new	O
osmotic	O
pressure	O
measuring	O
method	O
with	O
a	O
wide	O
measuring	O
range	O
.	O

Method	O
:	O
The	O
osmotic	O
pressure	O
of	O
drug	O
solutions	O
is	O
determined	O
by	O
measuring	O
the	O
relative	O
air	O
humidity	O
in	O
equilibrium	O
with	O
the	O
solution	O
.	O

The	O
freezing	O
point	O
osmometry	O
is	O
used	O
as	O
a	O
control	O
.	O

Results	O
:	O
The	O
data	O
obtained	O
by	O
the	O
proposed	O
method	O
are	O
comparable	O
to	O
those	O
by	O
the	O
control	O
method	O
,	O
and	O
the	O
measuring	O
range	O
of	O
the	O
proposed	O
method	O
is	O
significantly	O
wider	O
than	O
that	O
of	O
the	O
control	O
method	O
.	O

Conclusion	O
:	O
The	O
proposed	O
method	O
is	O
performed	O
in	O
an	O
isothermal	O
and	O
equilibrium	O
state	O
,	O
so	O
it	O
overcomes	O
the	O
defects	O
of	O
the	O
freezing	O
point	O
and	O
dew	O
point	O
osmometries	O
which	O
result	O
from	O
the	O
heterothermal	O
process	O
in	O
the	O
measurement	O
,	O
and	O
therefore	O
is	O
not	O
limited	O
to	O
diluted	O
solutions	O
.	O

Enantioselective	O
thiourea	B
-	O
catalyzed	O
intramolecular	O
cope	O
-	O
type	O
hydroamination	O
.	O

Catalysis	O
of	O
Cope	O
-	O
type	O
rearrangements	O
of	O
bis	B
-	I
homoallylic	I
hydroxylamines	I
is	O
demonstrated	O
using	O
chiral	O
thiourea	O
derivatives	O
.	O

This	O
formal	O
intramolecular	O
hydroamination	O
reaction	O
provides	O
access	O
to	O
highly	O
enantioenriched	O
	O
-	O
substituted	O
pyrrolidine	B
products	O
and	O
represents	O
a	O
complementary	O
approach	O
to	O
metal	O
-	O
catalyzed	O
methods	O
.	O

Flavone	B
C	I
-	I
glycosides	I
from	O
the	O
flowers	O
of	O
Trollius	O
chinensis	O
and	O
their	O
anti	O
-	O
complementary	O
activity	O
.	O

Phytochemical	O
investigation	O
of	O
ethanol	B
extract	O
from	O
the	O
flowers	O
of	O
Trollius	O
chinensis	O
Bunge	O
resulted	O
in	O
the	O
isolation	O
of	O
two	O
new	O
flavone	B
C	I
-	I
glycosides	I
(	O
1	O
-	O
2	O
)	O
,	O
along	O
with	O
10	O
known	O
compounds	O
(	O
3	O
-	O
12	O
)	O
.	O

The	O
structures	O
of	O
the	O
new	O
compounds	O
were	O
established	O
as	O
6-	B
(	I
3-hydroxy-3-methylglutaroyl	I
)	I
-2-O	I
-	I
	I
-	I
d	I
-	I
galactopyranosyl	I
orientin	I
(	O
1	O
)	O
and	O
6-	B
(	I
3-hydroxy-3-methylglutaroyl	I
)	I
-2-O	I
-	I
	I
-	I
d	I
-	I
galactopyranosyl	I
vitexin	I
(	O
2	O
)	O
on	O
the	O
basis	O
of	O
various	O
spectroscopic	O
analysis	O
(	O
including	O
different	O
1D	O
and	O
2D	O
NMR	O
spectroscopies	O
,	O
high	O
-	O
resolution	O
electrospray	O
ionization	O
mass	O
spectrometry	O
)	O
and	O
chemical	O
evidences	O
.	O

Bioassay	O
showed	O
that	O
eight	O
flavonoids	B
inhibited	O
complement	O
activation	O
on	O
the	O
classic	O
pathway	O
in	O
vitro	O
,	O
with	O
their	O
IC50	O
values	O
ranging	O
from	O
0.88	O
to	O
4.02	O
mM	O
,	O
which	O
may	O
contribute	O
to	O
the	O
applications	O
of	O
the	O
herb	O
in	O
treatment	O
of	O
acute	O
respiratory	O
distress	O
syndrome	O
,	O
etc	O
.	O

In	O
Vitro	O
Reconstitution	O
of	O
Complexes	O
between	O
proMatrix	O
Metalloproteinase-9	O
and	O
the	O
Proteoglycans	O
Serglycin	O
and	O
Versican	O
.	O

Previously	O
we	O
have	O
shown	O
that	O
a	O
fraction	O
of	O
the	O
matrix	O
metalloproteinase-9	O
(	O
MMP-9	O
)	O
synthesized	O
by	O
the	O
macrophage	O
cell	O
line	O
THP-1	O
was	O
bound	O
to	O
a	O
chondroitin	O
sulphate	O
proteoglycan	O
(	O
CSPG	O
)	O
core	O
protein	O
as	O
a	O
reduction	O
sensitive	O
heteromer	O
.	O

It	O
was	O
also	O
shown	O
that	O
the	O
hemopexin	O
-	O
like	O
(	O
PEX	O
)	O
domain	O
and	O
the	O
fibronectin	O
-	O
like	O
(	O
FnII	O
)	O
module	O
in	O
the	O
enzyme	O
are	O
involved	O
in	O
the	O
heteromer	O
formation	O
.	O

In	O
the	O
present	O
work	O
we	O
show	O
that	O
reduction	O
sensitive	O
and	O
SDS	B
-	O
stable	O
heteromers	O
can	O
be	O
reconstituted	O
in	O
vitro	O
by	O
mixing	O
proMMP-9	O
with	O
either	O
serglycin	O
,	O
versican	O
or	O
CSPGs	O
isolated	O
from	O
various	O
monocytic	O
cell	O
lines	O
.	O

In	O
addition	O
,	O
a	O
strong	O
but	O
SDS	B
-	O
soluble	O
proMMP-9CSPG	O
heteromer	O
was	O
formed	O
.	O

The	O
two	O
macromolecules	O
in	O
the	O
SDS	B
-	O
stable	O
reduction	O
sensitive	O
heteromers	O
were	O
not	O
linked	O
together	O
by	O
disulphide	B
bonds	O
.	O

As	O
for	O
the	O
heteromer	O
isolated	O
from	O
THP-1	O
cells	O
,	O
the	O
in	O
vitro	O
reconstituted	O
SDS	B
-	O
stable	O
and	O
SDS	B
-	O
soluble	O
heteromers	O
had	O
a	O
weaker	O
binding	O
to	O
gelatin	O
than	O
the	O
proMMP-9	O
monomer	O
.	O

Furthermore	O
,	O
gelatin	O
inhibited	O
the	O
in	O
vitro	O
reconstitution	O
of	O
the	O
heteromers	O
,	O
showing	O
that	O
the	O
FnII	O
module	O
is	O
involved	O
in	O
the	O
complex	O
formation	O
.	O

TIMP-1	O
could	O
not	O
be	O
detected	O
in	O
the	O
formed	O
proMMP-9CSPG	O
complexes	O
.	O

However	O
,	O
the	O
presence	O
of	O
TIMP-1	O
inhibited	O
the	O
formation	O
of	O
the	O
SDS	B
-	O
soluble	O
heteromer	O
,	O
but	O
not	O
the	O
SDS	B
-	O
stable	O
reduction	O
sensitive	O
heteromer	O
.	O

This	O
indicates	O
that	O
different	O
regions	O
in	O
the	O
PEX	O
domain	O
are	O
involved	O
the	O
formation	O
of	O
these	O
heteromers	O
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O

Synthesis	O
and	O
biological	O
evaluation	O
of	O
phosphorylated	B
flavonoids	I
as	O
potent	O
and	O
selective	O
inhibitors	O
of	O
cholesterol	B
esterase	O
.	O

A	O
series	O
of	O
phosphorylated	B
flavonoids	I
were	O
synthesized	O
and	O
investigated	O
in	O
vitro	O
as	O
inhibitors	O
of	O
pancreatic	O
cholesterol	B
esterase	O
(	O
CEase	O
)	O
and	O
acetylcholinesterase	O
(	O
AChE	O
)	O
.	O

The	O
results	O
showed	O
that	O
most	O
of	O
the	O
synthesized	O
compounds	O
exhibited	O
nanomolar	O
potency	O
against	O
CEase	O
,	O
much	O
better	O
than	O
the	O
parent	O
flavonoids	B
.	O

Furthermore	O
,	O
these	O
phosphorylated	B
flavonoids	I
demonstrated	O
good	O
to	O
high	O
selectivity	O
for	O
CEase	O
over	O
AChE	O
,	O
which	O
only	O
showed	O
micromolar	O
potency	O
inhibition	O
of	O
AChE.	O
The	O
most	O
selective	O
and	O
potent	O
inhibitor	O
of	O
CEase	O
(	O
3e	O
)	O
had	O
IC50	O
value	O
of	O
0.72	O
nM	O
and	O
11800-fold	O
selectivity	O
for	O
CEase	O
over	O
AChE.	O
The	O
structure	O
-	O
activity	O
relationships	O
revealed	O
that	O
the	O
free	O
hydroxyl	B
group	O
at	O
position	O
5	O
and	O
phosphate	B
group	O
at	O
position	O
7	O
of	O
the	O
phosphorylated	B
flavonoids	I
are	O
favorable	O
to	O
the	O
inhibition	O
of	O
CEase	O
.	O

The	O
inhibition	O
mechanism	O
and	O
kinetic	O
characterization	O
studies	O
indicated	O
that	O
they	O
are	O
irreversible	O
competitive	O
inhibitors	O
of	O
CEase	O
.	O

Flies	O
Cope	O
with	O
Uncontrollable	O
Stress	O
by	O
Learned	O
Helplessness	O
.	O

In	O
a	O
wide	O
range	O
of	O
animals	O
,	O
uncontrollable	O
stressful	O
events	O
can	O
induce	O
a	O
condition	O
called	O
"	O
learned	O
helplessness	O
.	O
"	O

In	O
mammals	O
it	O
is	O
associated	O
with	O
low	O
general	O
activity	O
,	O
poor	O
learning	O
,	O
disorders	O
of	O
sleep	O
and	O
feeding	O
,	O
ulcers	O
,	O
and	O
reduced	O
immune	O
status	O
,	O
as	O
well	O
as	O
with	O
increased	O
serotonin	B
in	O
parts	O
of	O
the	O
brain	O
.	O

It	O
is	O
considered	O
an	O
animal	O
model	O
of	O
depression	O
in	O
humans	O
[	O
1	O
-	O
4	O
]	O
.	O

Here	O
we	O
investigate	O
learned	O
helplessness	O
in	O
Drosophila	O
,	O
showing	O
that	O
this	O
behavioral	O
state	O
consists	O
of	O
a	O
cognitive	O
and	O
a	O
modulatory	O
,	O
possibly	O
mood	O
-	O
like	O
,	O
component	O
.	O

A	O
fly	O
,	O
getting	O
heated	O
as	O
soon	O
as	O
it	O
stops	O
walking	O
,	O
reliably	O
resumes	O
walking	O
to	O
escape	O
the	O
heat	O
.	O

If	O
,	O
in	O
contrast	O
,	O
the	O
fly	O
is	O
not	O
in	O
control	O
of	O
the	O
heat	O
,	O
it	O
learns	O
that	O
its	O
behavior	O
has	O
no	O
effect	O
and	O
quits	O
responding	O
.	O

In	O
this	O
state	O
,	O
the	O
fly	O
walks	O
slowly	O
and	O
takes	O
longer	O
and	O
more	O
frequent	O
rests	O
,	O
as	O
if	O
it	O
were	O
"	O
depressed	O
.	O
"	O

This	O
downregulation	O
of	O
walking	O
behavior	O
is	O
more	O
pronounced	O
in	O
females	O
than	O
in	O
males	O
.	O

Learned	O
helplessness	O
in	O
Drosophila	O
is	O
an	O
example	O
of	O
how	O
,	O
in	O
a	O
certain	O
situation	O
,	O
behavior	O
is	O
organized	O
according	O
to	O
its	O
expected	O
consequences	O
.	O

Multiple	O
treatments	O
with	O
liposomal	O
doxorubicin	B
and	O
ultrasound	O
-	O
induced	O
disruption	O
of	O
blood	O
-	O
tumor	O
and	O
blood	O
-	O
brain	O
barriers	O
improve	O
outcomes	O
in	O
a	O
rat	O
glioma	O
model	O
.	O

The	O
blood	O
-	O
brain	O
-	O
barrier	O
(	O
BBB	O
)	O
prevents	O
the	O
transport	O
of	O
most	O
anticancer	O
agents	O
to	O
the	O
central	O
nervous	O
system	O
and	O
restricts	O
delivery	O
to	O
infiltrating	O
brain	O
tumors	O
.	O

The	O
heterogeneous	O
vascular	O
permeability	O
in	O
tumor	O
vessels	O
,	O
along	O
with	O
several	O
other	O
factors	O
,	O
creates	O
additional	O
barriers	O
for	O
drug	O
treatment	O
of	O
brain	O
tumors	O
.	O

Focused	O
ultrasound	O
(	O
FUS	O
)	O
,	O
when	O
combined	O
with	O
circulating	O
microbubbles	O
,	O
is	O
an	O
emerging	O
noninvasive	O
method	O
to	O
temporarily	O
permeabilize	O
the	O
BBB	O
and	O
the	O
"	O
blood	O
-	O
tumor	O
barrier	O
"	O
.	O

Here	O
,	O
we	O
tested	O
the	O
impact	O
of	O
three	O
weekly	O
sessions	O
of	O
FUS	O
and	O
liposomal	O
doxorubicin	B
(	O
DOX	B
)	O
in	O
9L	O
rat	O
glioma	O
tumors	O
.	O

Animals	O
that	O
received	O
FUS+DOX	O
(	O
N=8	O
)	O
had	O
a	O
median	O
survival	O
time	O
that	O
was	O
increased	O
significantly	O
(	O
P<0.001	O
)	O
compared	O
to	O
animals	O
who	O
received	O
DOX	B
only	O
(	O
N=6	O
)	O
,	O
FUS	O
only	O
(	O
N=8	O
)	O
,	O
or	O
no	O
treatment	O
(	O
N=7	O
)	O
.	O

Median	O
survival	O
for	O
animals	O
that	O
received	O
FUS+DOX	O
was	O
increased	O
by	O
100	O
%	O
relative	O
to	O
untreated	O
controls	O
,	O
whereas	O
animals	O
who	O
received	O
DOX	B
alone	O
had	O
only	O
a	O
16	O
%	O
improvement	O
.	O

Animals	O
who	O
received	O
only	O
FUS	O
showed	O
no	O
improvement	O
.	O

No	O
tumor	O
cells	O
were	O
found	O
in	O
histology	O
in	O
4	O
/	O
8	O
animals	O
in	O
the	O
FUS+DOX	O
group	O
,	O
and	O
in	O
two	O
animals	O
,	O
only	O
a	O
few	O
tumor	O
cells	O
were	O
detected	O
.	O

Adverse	O
events	O
in	O
the	O
treatment	O
group	O
included	O
skin	O
toxicity	O
,	O
impaired	O
activity	O
,	O
damage	O
to	O
surrounding	O
brain	O
tissue	O
,	O
and	O
tissue	O
loss	O
at	O
the	O
tumor	O
site	O
.	O

In	O
one	O
animal	O
,	O
intratumoral	O
hemorrhage	O
was	O
observed	O
.	O

These	O
events	O
are	O
largely	O
consistent	O
with	O
known	O
side	O
effects	O
of	O
doxorubicin	B
and	O
with	O
an	O
extensive	O
tumor	O
burden	O
.	O

Overall	O
this	O
work	O
demonstrates	O
that	O
multiple	O
sessions	O
using	O
this	O
FUS	O
technique	O
to	O
enhance	O
the	O
delivery	O
of	O
liposomal	O
doxorubicin	B
have	O
a	O
pronounced	O
therapeutic	O
effect	O
in	O
this	O
rat	O
glioma	O
model	O
.	O

Global	O
analytical	O
strategy	O
to	O
measure	O
drug	O
-	O
plasma	O
protein	O
interactions	O
:	O
from	O
high	O
-	O
throughput	O
to	O
in	O
-	O
depth	O
analysis	O
.	O

The	O
selection	O
of	O
drug	O
candidates	O
with	O
improved	O
pharmacokinetics	O
is	O
essential	O
to	O
reduce	O
the	O
attrition	O
rates	O
during	O
drug	O
development	O
and	O
represents	O
one	O
of	O
the	O
big	O
challenges	O
faced	O
by	O
the	O
pharmaceutical	O
industry	O
.	O

Plasma	O
protein	O
binding	O
(	O
PPB	O
)	O
is	O
an	O
important	O
parameter	O
with	O
significant	O
implications	O
for	O
in	O
vivo	O
drug	O
performance	O
.	O

Today	O
,	O
the	O
most	O
widely	O
used	O
techniques	O
for	O
PPB	O
measurement	O
in	O
the	O
pharmaceutical	O
community	O
are	O
equilibrium	O
dialysis	O
(	O
ED	O
)	O
and	O
ultrafiltration	O
(	O
UF	O
)	O
.	O

However	O
,	O
these	O
techniques	O
have	O
some	O
limitations	O
.	O

Thus	O
,	O
we	O
emphasize	O
an	O
alternative	O
strategy	O
,	O
based	O
on	O
a	O
global	O
,	O
new	O
and	O
easy	O
-	O
to	O
-	O
follow	O
methodology	O
,	O
to	O
screen	O
and	O
perform	O
determination	O
of	O
PPB	O
,	O
using	O
orthogonal	O
techniques	O
(	O
i.e.	O
liquid	O
chromatography	O
,	O
capillary	O
electrophoresis	O
(	O
CE	O
)	O
,	O
surface	O
plasmon	O
resonance	O
(	O
SPR	O
)	O
based	O
biosensor	O
)	O
.	O

We	O
anticipate	O
that	O
the	O
increased	O
knowledge	O
gained	O
through	O
this	O
strategy	O
will	O
lead	O
to	O
improved	O
drug	O
candidates	O
.	O

BID	O
-	O
induced	O
structural	O
changes	O
in	O
BAK	O
promote	O
apoptosis	O
.	O

The	O
BCL-2-family	O
protein	O
BAK	O
is	O
responsible	O
for	O
mitochondrial	O
outer	O
-	O
membrane	O
permeabilization	O
(	O
MOMP	O
)	O
,	O
which	O
leads	O
to	O
apoptosis	O
.	O

The	O
BCL-2	O
homology	O
3	O
(	O
BH3	O
)	O
-only	O
protein	O
BID	O
activates	O
BAK	O
to	O
perform	O
this	O
function	O
.	O

We	O
report	O
the	O
NMR	O
solution	O
structure	O
of	O
the	O
human	O
BID	O
BH3-BAK	O
complex	O
,	O
which	O
identified	O
the	O
activation	O
site	O
at	O
the	O
canonical	O
BH3-binding	O
groove	O
of	O
BAK	O
.	O

Mutating	O
the	O
BAK	O
BH1	O
in	O
the	O
groove	O
prevented	O
activation	O
and	O
MOMP	O
but	O
not	O
the	O
binding	O
of	O
BID	O
.	O

BAK	O
BH3	O
mutations	O
allowed	O
BID	O
binding	O
and	O
activation	O
but	O
blunted	O
function	O
by	O
blocking	O
BAK	O
oligomerization	O
.	O

BAK	O
activation	O
follows	O
a	O
'	O
hit	O
-	O
and	O
-	O
run	O
'	O
mechanism	O
whereby	O
BID	O
dissociates	O
from	O
the	O
trigger	O
site	O
,	O
which	O
allows	O
BAK	O
oligomerization	O
at	O
an	O
overlapping	O
interface	O
.	O

In	O
contrast	O
,	O
the	O
BH3-only	O
proteins	O
NOXA	O
and	O
BAD	O
are	O
predicted	O
to	O
clash	O
with	O
the	O
trigger	O
site	O
and	O
are	O
not	O
activators	O
of	O
BAK	O
.	O

These	O
findings	O
provide	O
insights	O
into	O
the	O
early	O
stages	O
of	O
BAK	O
activation	O
.	O

Facile	O
Preparation	O
of	O
Ordered	O
Porous	O
Graphene	B
-	O
Metal	B
Oxide@C	I
Binder	O
-	O
Free	O
Electrodes	O
with	O
High	O
Li	B
Storage	O
Performance	O
.	O

A	O
facile	O
and	O
general	O
method	O
is	O
reported	O
to	O
prepare	O
ordered	O
porous	O
graphene	B
-	O
based	O
binder	O
-	O
free	O
electrodes	O
on	O
a	O
large	O
scale	O
.	O

This	O
preparation	O
process	O
allows	O
the	O
easy	O
adjustment	O
of	O
the	O
selected	O
components	O
,	O
weight	O
ratio	O
of	O
componets	O
,	O
and	O
the	O
thickness	O
of	O
the	O
electrodes	O
.	O

Such	O
ordered	O
porous	O
electrodes	O
demonstrate	O
superior	O
Li	B
storage	O
properties	O
;	O
for	O
example	O
,	O
graphene	B
-	O
Fe3	B
O4	I
@C	O
depicts	O
high	O
capacities	O
of	O
1123.8	O
and	O
505	O
mAh	O
g	O
(	O
-1	O
)	O
at	O
current	O
densities	O
of	O
0.5	O
and	O
10	O
A	O
g	O
(	O
-1	O
)	O
,	O
respectively	O
.	O

On	O
the	O
association	O
between	O
Hashimoto	O
's	O
thyroiditis	O
and	O
papillary	O
thyroid	O
carcinoma	O
.	O

Looking	O
100	O
years	O
back	O
and	O
,	O
hopefully	O
,	O
fewer	O
years	O
ahead	O
to	O
sort	O
out	O
this	O
association	O
.	O

NOT	O
required	O
for	O
a	O
LETTER	O
TO	O
THE	O
EDITOR	O
.	O

Designing	O
degradable	O
hydrogels	O
for	O
orthogonal	O
control	O
of	O
cell	O
microenvironments	O
.	O

Degradable	O
and	O
cell	O
-	O
compatible	O
hydrogels	O
can	O
be	O
designed	O
to	O
mimic	O
the	O
physical	O
and	O
biochemical	O
characteristics	O
of	O
native	O
extracellular	O
matrices	O
and	O
provide	O
tunability	O
of	O
degradation	O
rates	O
and	O
related	O
properties	O
under	O
physiological	O
conditions	O
.	O

Hence	O
,	O
such	O
hydrogels	O
are	O
finding	O
widespread	O
application	O
in	O
many	O
bioengineering	O
fields	O
,	O
including	O
controlled	O
bioactive	O
molecule	O
delivery	O
,	O
cell	O
encapsulation	O
for	O
controlled	O
three	O
-	O
dimensional	O
culture	O
,	O
and	O
tissue	O
engineering	O
.	O

Cellular	O
processes	O
,	O
such	O
as	O
adhesion	O
,	O
proliferation	O
,	O
spreading	O
,	O
migration	O
,	O
and	O
differentiation	O
,	O
can	O
be	O
controlled	O
within	O
degradable	O
,	O
cell	O
-	O
compatible	O
hydrogels	O
with	O
temporal	O
tuning	O
of	O
biochemical	O
or	O
biophysical	O
cues	O
,	O
such	O
as	O
growth	O
factor	O
presentation	O
or	O
hydrogel	O
stiffness	O
.	O

However	O
,	O
thoughtful	O
selection	O
of	O
hydrogel	O
base	O
materials	O
,	O
formation	O
chemistries	O
,	O
and	O
degradable	O
moieties	O
is	O
necessary	O
to	O
achieve	O
the	O
appropriate	O
level	O
of	O
property	O
control	O
and	O
desired	O
cellular	O
response	O
.	O

In	O
this	O
review	O
,	O
hydrogel	O
design	O
considerations	O
and	O
materials	O
for	O
hydrogel	O
preparation	O
,	O
ranging	O
from	O
natural	O
polymers	O
to	O
synthetic	O
polymers	O
,	O
are	O
overviewed	O
.	O

Recent	O
advances	O
in	O
chemical	O
and	O
physical	O
methods	O
to	O
crosslink	O
hydrogels	O
are	O
highlighted	O
,	O
as	O
well	O
as	O
recent	O
developments	O
in	O
controlling	O
hydrogel	O
degradation	O
rates	O
and	O
modes	O
of	O
degradation	O
.	O

Special	O
attention	O
is	O
given	O
to	O
spatial	O
or	O
temporal	O
presentation	O
of	O
various	O
biochemical	O
and	O
biophysical	O
cues	O
to	O
modulate	O
cell	O
response	O
in	O
static	O
(	O
i.e.	O
,	O
non	O
-	O
degradable	O
)	O
or	O
dynamic	O
(	O
i.e.	O
,	O
degradable	O
)	O
microenvironments	O
.	O

This	O
review	O
provides	O
insight	O
into	O
the	O
design	O
of	O
new	O
cell	O
-	O
compatible	O
,	O
degradable	O
hydrogels	O
to	O
understand	O
and	O
modulate	O
cellular	O
processes	O
for	O
various	O
biomedical	O
applications	O
.	O

The	O
Beneficial	O
Effect	O
of	O
Total	O
Glucosides	O
of	O
Paeony	O
on	O
Psoriatic	O
Arthritis	O
Links	O
to	O
Circulating	O
Tregs	O
and	O
Th1	O
Cell	O
Function	O
.	O

Total	O
glycosides	O
of	O
peony	O
(	O
TGP	O
)	O
is	O
a	O
natural	O
immuno	O
-	O
modulatory	O
drug	O
extracted	O
from	O
traditional	O
Chinese	O
herb	O
peony	O
.	O

It	O
has	O
been	O
approved	O
by	O
State	O
Food	O
and	O
Drug	O
Administration	O
for	O
the	O
treatment	O
of	O
rheumatoid	O
arthritis	O
.	O

However	O
,	O
data	O
of	O
TGP	O
effect	O
on	O
psoriatic	O
arthritis	O
(	O
PsA	O
)	O
is	O
still	O
scarce	O
.	O

In	O
this	O
study	O
,	O
19	O
patients	O
with	O
PsA	O
received	O
12-week	O
treatment	O
of	O
TGP	O
,	O
and	O
clinical	O
efficacy	O
in	O
joint	O
manifestations	O
was	O
evaluated	O
by	O
DAS28	O
at	O
weeks	O
0	O
,	O
4	O
,	O
8	O
and	O
12	O
.	O

Peripheral	O
percentages	O
of	O
Tregs	O
,	O
Th1	O
,	O
Th2	O
and	O
NK	O
cells	O
were	O
analyzed	O
,	O
and	O
serum	O
Th1-type	O
cytokines	O
(	O
IL-12	O
,	O
IFN	O
-	O
	O
and	O
TNF	O
-	O
	O
)	O
,	O
Th2-type	O
cytokines	O
(	O
IL-4	O
,	O
IL-5	O
and	O
IL-10	O
)	O
as	O
well	O
as	O
pro	O
-	O
inflammatory	O
factors	O
(	O
IL-2	O
,	O
IL-6	O
and	O
IL-8	O
)	O
were	O
concomitantly	O
examined	O
.	O

Six	O
patients	O
(	O
32	O
%	O
)	O
exhibited	O
25	O
%	O
decrease	O
of	O
DAS28	O
(	O
responders	O
)	O
.	O

Interestingly	O
,	O
all	O
responders	O
displayed	O
a	O
continuous	O
decrease	O
in	O
Treg	O
and	O
Th1	O
numbers	O
during	O
TGP	O
treatment	O
,	O
concomitant	O
with	O
significant	O
decreases	O
in	O
Th1-type	O
cytokine	O
levels	O
.	O

Serum	O
IL-6	O
also	O
showed	O
a	O
significant	O
decline	O
in	O
responders	O
.	O

Non	O
-	O
responders	O
lacked	O
these	O
sequential	O
alterations	O
.	O

Thus	O
,	O
TGP	O
merits	O
further	O
consideration	O
as	O
a	O
promising	O
therapeutic	O
option	O
for	O
PsA.	O
The	O
result	O
indicated	O
that	O
recovery	O
of	O
Tregs	O
and	O
Th1	O
may	O
serve	O
as	O
prognostic	O
markers	O
to	O
assess	O
responsiveness	O
to	O
TGP	O
treatment	O
in	O
PsA.	O
Copyright	O
	O
2013	O
John	O
Wiley	O
&	O
Sons	O
,	O
Ltd.	O

Amphiphilic	O
Polypeptides	O
as	O
a	O
Bifunctional	O
Template	O
in	O
the	O
Mineralization	O
of	O
Calcium	B
Carbonate	I
at	O
the	O
Air	O
/	O
Water	O
Interface	O
.	O

A	O
well	O
-	O
defined	O
amphiphilic	O
polypeptide	O
,	O
poly	B
(	I
glutamic	I
acid	I
)	I
22	I
-block	I
-	I
poly	I
(	I
alanine	I
)	I
8	I
(	O
PGlu22	B
-b	I
-	I
PAla8	I
)	O
,	O
which	O
plays	O
the	O
roles	O
of	O
both	O
soluble	O
(	O
functional	O
)	O
additive	O
and	O
insoluble	O
(	O
structural	O
)	O
matrix	O
,	O
is	O
employed	O
to	O
mediate	O
the	O
mineralization	O
of	O
CaCO3	B
at	O
the	O
air	O
/	O
water	O
interface	O
.	O

X	O
-	O
ray	O
diffraction	O
(	O
XRD	O
)	O
and	O
Raman	O
spectroscopy	O
,	O
for	O
example	O
,	O
show	O
that	O
the	O
polymorph	O
of	O
CaCO3	B
particles	O
obtained	O
is	O
calcite	B
.	O

The	O
observations	O
from	O
SEM	O
and	O
TEM	O
suggest	O
that	O
PGlu22	B
-b	I
-	I
PAla8	I
initiates	O
the	O
amorphous	O
precursor	O
phase	O
and	O
heterogeneous	O
nucleation	O
of	O
CaCO3	B
at	O
the	O
air	O
/	O
water	O
interface	O
,	O
while	O
temporarily	O
stabilizes	O
the	O
gelatinous	O
precursors	O
as	O
a	O
process	O
-	O
directing	O
agent	O
;	O
nevertheless	O
,	O
the	O
initial	O
concentration	O
of	O
Ca	B
(	I
2	I
+	I
)	I
controls	O
the	O
procedure	O
of	O
crystallization	O
and	O
the	O
final	O
morphology	O
of	O
CaCO3	B
particles	O
.	O

Such	O
"	O
bifunctional	O
"	O
amphiphilic	O
-	O
polypeptide	O
-	O
regulated	O
mineralization	O
at	O
the	O
air	O
/	O
water	O
interface	O
may	O
be	O
applied	O
to	O
the	O
synthesis	O
of	O
many	O
kinds	O
of	O
symmetrical	O
inorganic	O
/	O
organic	O
hybrids	O
.	O

Very	O
Low	O
Calorie	O
Diet	O
Mimics	O
the	O
Early	O
Beneficial	O
Effect	O
of	O
Roux	O
-	O
en	O
-	O
Y	O
Gastric	O
Bypass	O
on	O
Insulin	O
Sensitivity	O
and	O
Beta	O
-	O
Cell	O
Function	O
in	O
Type	O
2	O
Diabetic	O
Patients	O
.	O

Marked	O
improvement	O
in	O
glycemic	O
control	O
occurs	O
in	O
patients	O
with	O
type	O
2	O
diabetes	O
(	O
T2DM	O
)	O
shortly	O
after	O
Roux	O
-	O
en	O
-	O
Y	O
gastric	O
bypass	O
surgery	O
(	O
RYGB	O
)	O
and	O
before	O
there	O
is	O
major	O
weight	O
loss	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
if	O
the	O
magnitude	O
of	O
this	O
change	O
is	O
primarily	O
due	O
to	O
caloric	O
restriction	O
or	O
is	O
unique	O
to	O
the	O
surgical	O
procedure	O
.	O

We	O
studied	O
eleven	O
subjects	O
who	O
underwent	O
RYGB	O
and	O
fourteen	O
subjects	O
mean	O
-	O
matched	O
for	O
BMI	O
,	O
HbA1c	O
and	O
diabetes	O
duration	O
who	O
were	O
admitted	O
to	O
our	O
inpatient	O
research	O
unit	O
and	O
given	O
a	O
very	O
low	O
calorie	O
diet	O
(	O
VLCD	O
)	O
of	O
500	O
kcal	O
/	O
day	O
with	O
a	O
macronutrient	O
content	O
similar	O
to	O
that	O
consumed	O
by	O
patients	O
after	O
RYGB	O
.	O

Frequently	O
sampled	O
intravenous	O
glucose	B
tolerance	O
tests	O
were	O
performed	O
before	O
and	O
after	O
interventions	O
.	O

Both	O
groups	O
lost	O
an	O
equivalent	O
amount	O
of	O
weight	O
over	O
a	O
mean	O
study	O
period	O
of	O
21	O
days	O
.	O

Insulin	O
sensitivity	O
,	O
acute	O
insulin	O
secretion	O
after	O
intravenous	O
glucose	B
administration	O
and	O
beta	O
-	O
cell	O
function	O
as	O
determined	O
by	O
disposition	O
index	O
improved	O
to	O
a	O
similar	O
extent	O
in	O
both	O
groups	O
.	O

Likewise	O
,	O
changes	O
in	O
fasting	O
glucose	B
and	O
fructosamine	B
levels	O
were	O
similar	O
.	O

Based	O
on	O
these	O
data	O
,	O
VLCD	O
improves	O
insulin	O
sensitivity	O
and	O
beta	O
-	O
cell	O
function	O
just	O
as	O
well	O
as	O
RYGB	O
in	O
the	O
short	O
term	O
.	O

This	O
study	O
was	O
registered	O
in	O
ClinicalTrials.gov	O
NCT00627484	O
.	O

Central	O
Pulse	O
Pressure	O
and	O
Its	O
Hemodynamic	O
Determinants	O
in	O
Middle	O
-	O
Aged	O
Adults	O
With	O
Impaired	O
Fasting	O
Glucose	B
and	O
Diabetes	O
:	O

The	O
Asklepios	O
study	O
.	O

OBJECTIVEPulse	O
pressure	O
(	O
PP	O
)	O
,	O
a	O
strong	O
predictor	O
of	O
cardiovascular	O
events	O
in	O
type	O
2	O
diabetes	O
,	O
is	O
a	O
composite	O
measure	O
affected	O
by	O
several	O
hemodynamic	O
factors	O
.	O

Little	O
is	O
known	O
about	O
the	O
hemodynamic	O
determinants	O
of	O
central	O
PP	O
in	O
type	O
2	O
diabetes	O
or	O
whether	O
abnormalities	O
in	O
central	O
pulsatile	O
hemodynamics	O
are	O
already	O
present	O
in	O
individuals	O
with	O
impaired	O
fasting	O
glucose	B
(	O
IFG	O
)	O
.	O

In	O
a	O
population	O
-	O
based	O
study	O
,	O
we	O
aimed	O
to	O
compare	O
central	O
PP	O
and	O
its	O
hemodynamic	O
determinants	O
among	O
adults	O
with	O
normal	O
fasting	O
glucose	B
(	O
n	O
=	O
1654	O
)	O
,	O
IFG	O
(	O
n	O
=	O
240	O
)	O
,	O
and	O
type	O
2	O
diabetes	O
(	O
n	O
=	O
33	O
)	O
.RESEARCH	O
DESIGN	O
AND	O
METHODSWe	O
measured	O
carotid	O
pressure	O
,	O
left	O
ventricular	O
outflow	O
,	O
aortic	O
root	O
diameter	O
,	O
carotid	O
artery	O
flow	O
,	O
and	O
distension	O
in	O
order	O
to	O
measure	O
various	O
structural	O
and	O
hemodynamic	O
arterial	O
parameters	O
.	O

RESULTSIFG	O
was	O
associated	O
with	O
a	O
greater	O
mean	O
arterial	O
pressure	O
(	O
MAP	O
)	O
but	O
was	O
not	O
associated	O
with	O
intrinsic	O
aortic	O
stiffening	O
or	O
abnormal	O
aortic	O
pulsatile	O
indices	O
after	O
adjustment	O
for	O
MAP	O
.	O

After	O
adjustment	O
for	O
age	O
,	O
sex	O
,	O
and	O
MAP	O
,	O
type	O
2	O
diabetes	O
was	O
associated	O
with	O
a	O
higher	O
aortic	O
root	O
characteristic	O
impedance	O
(	O
Zc	O
)	O
,	O
aortic	O
root	O
elastance	O
-	O
thickness	O
product	O
(	O
Eh	O
)	O
,	O
and	O
aortic	O
root	O
pulse	O
wave	O
velocity	O
(	O
but	O
not	O
aortic	O
root	O
diameter	O
)	O
,	O
a	O
greater	O
carotid	O
-	O
femoral	O
pulse	O
wave	O
velocity	O
,	O
and	O
lower	O
total	O
arterial	O
compliance	O
and	O
wave	O
reflection	O
magnitude	O
.	O

Carotid	O
size	O
,	O
Zc	O
,	O
distensibility	O
,	O
or	O
Eh	O
did	O
not	O
significantly	O
differ	O
between	O
the	O
groups	O
.	O

CONCLUSIONSType	O
2	O
diabetes	O
,	O
but	O
not	O
IFG	O
,	O
is	O
associated	O
with	O
greater	O
large	O
artery	O
stiffness	O
,	O
without	O
abnormalities	O
in	O
aortic	O
root	O
diameter	O
or	O
carotid	O
stiffness	O
.	O

Subjects	O
with	O
type	O
2	O
diabetes	O
demonstrate	O
a	O
decreased	O
reflection	O
magnitude	O
,	O
which	O
may	O
indicate	O
an	O
increased	O
penetration	O
of	O
pulsatile	O
energy	O
to	O
distal	O
vascular	O
beds	O
.	O

Structure	O
of	O
hydrated	O
cobalt	B
ions	O
confined	O
in	O
the	O
nanospace	O
of	O
single	O
-	O
walled	O
carbon	B
nanotubes	O
.	O

The	O
structure	O
of	O
hydrated	O
Co	B
ions	O
confined	O
in	O
the	O
nanospace	O
of	O
single	O
-	O
walled	O
carbon	B
nanotubes	O
(	O
SWNTs	O
)	O
has	O
been	O
studied	O
using	O
the	O
X	O
-	O
ray	O
absorption	O
fine	O
structure	O
(	O
XAFS	O
)	O
technique	O
.	O

Water	O
adsorption	O
isotherms	O
on	O
Co	B
-	O
impregnated	O
SWNTs	O
indicate	O
a	O
high	O
affinity	O
of	O
Co	B
ions	O
to	O
water	O
molecules	O
.	O

The	O
results	O
of	O
XAFS	O
analysis	O
provided	O
the	O
information	O
on	O
the	O
proportion	O
of	O
dissolved	O
species	O
in	O
nanospaces	O
against	O
the	O
total	O
amount	O
of	O
cobalt	B
ions	O
adsorbed	O
on	O
the	O
open	O
-	O
pored	O
SWNT	O
.	O

The	O
structural	O
information	O
of	O
the	O
first	O
shell	O
around	O
a	O
Co	B
ion	O
was	O
expressed	O
in	O
terms	O
of	O
the	O
hydration	O
number	O
,	O
Co	B
-	I
O	I
distance	O
and	O
Debye	O
-	O
Waller	O
factor	O
.	O

The	O
actual	O
coordination	O
number	O
and	O
the	O
interatomic	O
distance	O
of	O
Co	B
-	I
O	I
for	O
the	O
dissolved	O
species	O
were	O
remarkably	O
reduced	O
compared	O
to	O
the	O
bulk	O
aqueous	O
solution	O
indicating	O
the	O
dehydration	O
of	O
water	O
molecules	O
from	O
Co	B
ions	O
and	O
a	O
compact	O
hydrated	O
structure	O
in	O
the	O
micropore	O
of	O
SWNTs	O
.	O

One	O
-	O
Pot	O
in	O
Situ	O
Mixed	O
Film	O
Formation	O
by	O
Azo	B
Coupling	O
and	O
Diazonium	B
Salt	I
Electrografting	O
.	O

So	O
simple	O
:	O
The	O
in	O
situ	O
synthesis	O
of	O
an	O
aryldiazonium	B
salt	I
and	O
an	O
azo	B
-	I
aryldiazonium	I
salt	I
by	O
azo	B
coupling	O
from	O
sulfanilic	B
acid	I
and	O
aniline	B
is	O
reported	O
.	O

Formation	O
of	O
a	O
mixed	O
organic	O
layer	O
is	O
monitored	O
by	O
cyclic	O
voltammetry	O
and	O
atomic	O
force	O
microscopy	O
.	O

A	O
compact	O
mixed	O
layer	O
is	O
obtained	O
with	O
a	O
global	O
roughness	O
of	O
0.4	O
nm	O
and	O
10	O
-	O
15	O
%	O
vertical	O
extension	O
in	O
the	O
range	O
1.5	O
-	O
6	O
nm	O
.	O

Grb10-mediated	O
Negative	O
Regulation	O
of	O
IGF1R	O
-	O
Activated	O
Signalling	O
Pathway	O
Results	O
in	O
Cognitive	O
Disorder	O
in	O
Diabetic	O
Rats	O
.	O

Growth	O
factor	O
receptor	O
-	O
bound	O
protein	O
10	O
(	O
Grb10	O
)	O
is	O
a	O
Src	O
homology	O
2	O
(	O
SH2	O
)	O
domain	O
-	O
containing	O
protein	O
and	O
one	O
of	O
the	O
binding	O
partners	O
for	O
several	O
trans	O
-	O
membrane	O
tyrosine	B
-	O
kinase	O
receptors	O
,	O
including	O
insulin	O
receptor	O
(	O
IR	O
)	O
and	O
insulin	O
-	O
like	O
growth	O
factor-1	O
receptor	O
(	O
IGF1-R	O
)	O
.	O

The	O
hippocampus	O
,	O
which	O
is	O
critical	O
for	O
cognitive	O
functions	O
,	O
is	O
one	O
of	O
the	O
main	O
distribution	O
areas	O
of	O
Grb10	O
in	O
the	O
central	O
nervous	O
system	O
.	O

In	O
recent	O
years	O
,	O
diabetic	O
encephalopathy	O
has	O
been	O
defined	O
as	O
a	O
third	O
type	O
of	O
diabetes	O
and	O
the	O
IGF1-IR	O
pathway	O
has	O
been	O
shown	O
to	O
be	O
critical	O
for	O
the	O
neuropathogenic	O
process	O
of	O
cognitive	O
disorder	O
in	O
diabetes	O
.	O

However	O
,	O
the	O
role	O
of	O
endogenous	O
Grb10	O
in	O
regulating	O
the	O
IGF1-IR	O
pathway	O
and	O
neurobehavioral	O
changes	O
is	O
not	O
explicit	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
in	O
vivo	O
function	O
of	O
endogenous	O
Grb10	O
in	O
diabetic	O
encephalopathy	O
and	O
the	O
underlying	O
mechanisms	O
.	O

Using	O
stereotaxic	O
surgical	O
techniques	O
and	O
lentiviral	O
vectors	O
expressing	O
specific	O
short	O
hairpin	O
RNA	O
(	O
shRNA	O
)	O
,	O
we	O
could	O
steadily	O
knock	O
down	O
Grb10	O
expression	O
in	O
the	O
hippocampus	O
.	O

More	O
importantly	O
,	O
we	O
demonstrated	O
that	O
hippocampus	O
-	O
specific	O
modulation	O
of	O
Grb10	O
protein	O
levels	O
led	O
to	O
a	O
prominent	O
remission	O
of	O
cognitive	O
disorder	O
,	O
including	O
improvements	O
in	O
both	O
ultrastructural	O
pathology	O
and	O
abnormal	O
neurobehavioural	O
changes	O
.	O

Our	O
findings	O
indicate	O
that	O
endogenous	O
overexpression	O
of	O
Grb10	O
functions	O
as	O
a	O
suppressor	O
of	O
the	O
IGF1-IR	O
pathway	O
,	O
which	O
may	O
represent	O
an	O
important	O
mechanism	O
that	O
regulates	O
cognitive	O
disorder	O
in	O
diabetes	O
.	O

This	O
article	O
is	O
protected	O
by	O
copyright	O
.	O

All	O
rights	O
reserved	O
.	O

A	O
new	O
ent	B
-	I
kaurane	I
diterpenoid	B
glycoside	I
from	O
Isodon	O
japonica	O
var	O
.	O

glaucocalyx	O
.	O

A	O
new	O
ent	B
-	I
kaurane	I
diterpenoid	B
glycoside	I
(	O
1	O
)	O
,	O
named	O
glaucocalyxin	B
G	I
,	O
has	O
been	O
isolated	O
from	O
the	O
n	B
-	I
butanol	I
-	O
soluble	O
fraction	O
of	O
the	O
dried	O
whole	O
plants	O
of	O
Isodon	O
japonica	O
var	O
.	O

glaucocalyx	O
along	O
with	O
two	O
known	O
compounds	O
,	O
namely	O
arjunglucoside	B
(	O
2	O
)	O
and	O
kaempferol-3-O	B
-	I
rutinoside	I
(	O
3	O
)	O
.	O

The	O
structures	O
of	O
the	O
isolated	O
compounds	O
were	O
assigned	O
on	O
the	O
basis	O
of	O
their	O
(	B
1	I
)	I
H	I
and	O
(	B
13	I
)	I
C	I
NMR	O
spectra	O
including	O
two	O
-	O
dimensional	O
NMR	O
techniques	O
such	O
as	O
HMQC	O
,	O
HMBC	O
,	O
and	O
NOESY	O
experiments	O
and	O
comparison	O
with	O
the	O
literature	O
data	O
.	O

Assessment	O
of	O
genotoxic	O
effects	O
of	O
flumorph	B
by	O
the	O
comet	O
assay	O
in	O
mice	O
organs	O
.	O

The	O
present	O
study	O
investigated	O
the	O
genotoxic	O
effects	O
of	O
flumorph	B
in	O
various	O
organs	O
(	O
brain	O
,	O
liver	O
,	O
spleen	O
,	O
kidney	O
and	O
sperm	O
)	O
of	O
mice	O
.	O

The	O
DNA	O
damage	O
,	O
measured	O
as	O
comet	O
tail	O
length	O
(	O
m	O
)	O
,	O
was	O
determined	O
using	O
the	O
alkaline	O
comet	O
assay	O
.	O

The	O
comet	O
assay	O
is	O
a	O
sensitive	O
assay	O
for	O
the	O
detection	O
of	O
genotoxicity	O
caused	O
by	O
flumorph	B
using	O
mice	O
as	O
a	O
model	O
.	O

Statistically	O
significant	O
increases	O
in	O
comet	O
assay	O
for	O
both	O
dose	O
-	O
dependent	O
and	O
duration	O
-	O
dependent	O
DNA	O
damage	O
were	O
observed	O
in	O
all	O
the	O
organs	O
assessed	O
.	O

The	O
organs	O
exhibited	O
the	O
maximum	O
DNA	O
damage	O
in	O
96	O
h	O
at	O
54	O
mg	O
/	O
kg	O
body	O
weight	O
.	O

Brain	O
showed	O
maximum	O
DNA	O
damage	O
followed	O
by	O
spleen	O
>	O
kidney	O
>	O
liver	O
>	O
sperm	O
.	O

Our	O
data	O
demonstrated	O
that	O
flumorph	B
had	O
induced	O
systemic	O
genotoxicity	O
in	O
mammals	O
as	O
it	O
caused	O
DNA	O
damage	O
in	O
all	O
tested	O
vital	O
organs	O
,	O
especially	O
in	O
brain	O
and	O
spleen	O
.	O

In	O
Vitro	O
Activity	O
of	O
Paclitaxel	B
-	O
Loaded	O
Polymeric	O
Expansile	O
Nanoparticles	O
in	O
Breast	O
Cancer	O
Cells	O
.	O

Through	O
a	O
series	O
of	O
in	O
vitro	O
studies	O
,	O
the	O
essential	O
steps	O
for	O
intracellular	O
drug	O
delivery	O
of	O
paclitaxel	B
using	O
a	O
pH	O
-	O
responsive	O
nanoparticle	O
system	O
have	O
been	O
investigated	O
in	O
breast	O
cancer	O
cells	O
.	O

We	O
successfully	O
encapsulated	O
paclitaxel	B
within	O
polymeric	O
expansile	O
nanoparticles	O
(	O
Pax	B
-	O
eNPs	O
)	O
at	O
5	O
%	O
loading	O
via	O
a	O
miniemulsion	O
polymerization	O
procedure	O
.	O

Fluorescently	O
tagged	O
eNPs	O
were	O
readily	O
taken	O
up	O
by	O
MDA	O
-	O
MB-231	O
breast	O
cancer	O
cells	O
grown	O
in	O
culture	O
as	O
confirmed	O
by	O
confocal	O
microscopy	O
and	O
flow	O
cytometry	O
.	O

The	O
ability	O
of	O
the	O
encapsulated	O
paclitaxel	B
to	O
reach	O
the	O
cytoplasm	O
was	O
also	O
observed	O
using	O
confocal	O
microscopy	O
and	O
fluorescently	O
labeled	O
paclitaxel	B
.	O

Pax	B
-	O
eNPs	O
were	O
shown	O
to	O
be	O
efficacious	O
against	O
three	O
in	O
vitro	O
human	O
breast	O
adenocarcinoma	O
cell	O
lines	O
(	O
MDA	O
-	O
MB-231	O
,	O
MCF-7	O
and	O
SK	O
-	O
BR-3	O
)	O
as	O
well	O
as	O
cells	O
isolated	O
from	O
the	O
pleural	O
effusions	O
of	O
two	O
different	O
breast	O
cancer	O
patients	O
.	O

Lastly	O
,	O
macropinocytosis	O
was	O
identified	O
as	O
the	O
major	O
cellular	O
pathway	O
responsible	O
for	O
eNP	O
uptake	O
,	O
as	O
confirmed	O
using	O
temperature	O
-	O
sensitive	O
metabolic	O
reduction	O
,	O
pharmacologic	O
inhibitors	O
,	O
and	O
fluid	O
-	O
phase	O
marker	O
co	O
-	O
localization	O
.	O

LiGen	O
:	O
a	O
High	O
Performance	O
workflow	O
for	O
chemistry	O
driven	O
de	O
novo	O
design	O
.	O

Tools	O
for	O
molecular	O
de	O
novo	O
design	O
are	O
actively	O
sought	O
incorporating	O
sets	O
of	O
chemical	O
rules	O
for	O
fast	O
and	O
efficient	O
identification	O
of	O
structurally	O
new	O
chemotypes	O
endowed	O
with	O
a	O
desired	O
set	O
of	O
biological	O
properties	O
.	O

In	O
this	O
paper	O
,	O
we	O
present	O
LiGen	O
,	O
a	O
suite	O
of	O
programs	O
which	O
can	O
be	O
used	O
sequentially	O
or	O
as	O
stand	O
-	O
alone	O
tools	O
for	O
specific	O
purposes	O
.	O

In	O
its	O
standard	O
application	O
,	O
LiGen	O
modules	O
are	O
used	O
to	O
define	O
input	O
constraints	O
,	O
either	O
structure	O
-	O
based	O
,	O
through	O
active	O
site	O
identification	O
,	O
or	O
ligand	O
-	O
based	O
,	O
through	O
pharmacophore	O
definition	O
,	O
to	O
docking	O
and	O
to	O
de	O
novo	O
generation	O
.	O

Alternatively	O
,	O
individual	O
modules	O
can	O
be	O
combined	O
in	O
a	O
user	O
-	O
defined	O
manner	O
to	O
generate	O
project	O
-	O
centric	O
workflows	O
.	O

Specific	O
features	O
of	O
LiGen	O
are	O
the	O
use	O
of	O
a	O
pharmacophore	O
-	O
based	O
docking	O
procedure	O
which	O
allows	O
Flexible	O
docking	O
without	O
conformer	O
enumeration	O
and	O
accurate	O
and	O
flexible	O
reactant	O
mapping	O
coupled	O
with	O
reactant	O
tagging	O
through	O
substructure	O
searching	O
.	O

The	O
full	O
description	O
of	O
LiGen	O
functionalities	O
is	O
herein	O
presented	O
.	O

Structures	O
,	O
Dynamics	O
,	O
and	O
Stabilities	O
of	O
Fully	O
Modified	O
Locked	O
Nucleic	O
Acid	O
(	O
	O
-	O
d	O
-	O
LNA	O
and	O
	O
-	O
l	O
-	O
LNA	O
)	O
Duplexes	O
in	O
Comparison	O
to	O
Pure	O
DNA	O
and	O
RNA	O
Duplexes	O
.	O

Locked	O
nucleic	O
acid	O
(	O
LNA	O
)	O
is	O
a	O
chemical	O
modification	O
which	O
introduces	O
a	O
-O	O
-	B
CH2-	I
linkage	O
in	O
the	O
furanose	B
sugar	I
of	O
nucleic	O
acids	O
and	O
blocks	O
its	O
conformation	O
in	O
a	O
particular	O
state	O
.	O

Two	O
types	O
of	O
modifications	O
,	O
namely	O
,	O
2'-O,4'-C	B
-	I
methylene	I
-	I
	I
-	I
d	I
-	I
ribofuranose	I
(	O
	O
-	O
d	O
-	O
LNA	O
)	O
and	O
2'-O,4'-C	B
-	I
methylene	I
-	I
	I
-	I
l	I
-	I
ribofuranose	I
(	O
	O
-	O
l	O
-	O
LNA	O
)	O
,	O
have	O
been	O
shown	O
to	O
yield	O
RNA	O
and	O
DNA	O
duplex	O
-	O
like	O
structures	O
,	O
respectively	O
.	O

LNA	O
modifications	O
lead	O
to	O
increased	O
melting	O
temperatures	O
of	O
DNA	O
and	O
RNA	O
duplexes	O
,	O
and	O
have	O
been	O
suggested	O
as	O
potential	O
therapeutic	O
agents	O
in	O
antisense	O
therapy	O
.	O

In	O
this	O
study	O
,	O
molecular	O
dynamics	O
(	O
MD	O
)	O
simulations	O
were	O
performed	O
on	O
fully	O
modified	O
LNA	O
duplexes	O
and	O
pure	O
DNA	O
and	O
RNA	O
duplexes	O
sharing	O
a	O
similar	O
sequence	O
to	O
investigate	O
their	O
structure	O
,	O
stabilities	O
,	O
and	O
solvation	O
properties	O
.	O

Both	O
LNA	O
duplexes	O
undergo	O
unwinding	O
of	O
the	O
helical	O
structure	O
compared	O
to	O
the	O
pure	O
DNA	O
and	O
RNA	O
duplexes	O
.	O

Though	O
the	O
	O
-	O
LNA	O
substituent	O
has	O
been	O
proposed	O
to	O
mimic	O
deoxyribose	B
sugar	B
in	O
its	O
conformational	O
properties	O
,	O
the	O
fully	O
modified	O
duplex	O
was	O
found	O
to	O
exhibit	O
unique	O
structural	O
and	O
dynamic	O
properties	O
with	O
respect	O
to	O
the	O
other	O
three	O
nucleic	O
acid	O
structures	O
.	O

Free	O
energy	O
calculations	O
accurately	O
capture	O
the	O
enhanced	O
stabilization	O
of	O
the	O
LNA	O
duplex	O
structures	O
compared	O
to	O
DNA	O
and	O
RNA	O
molecules	O
as	O
observed	O
in	O
experiments	O
.	O

	O
-	O
stacking	O
interaction	O
between	O
bases	O
from	O
complementary	O
strands	O
is	O
shown	O
to	O
be	O
one	O
of	O
the	O
contributors	O
to	O
enhanced	O
stabilization	O
upon	O
LNA	O
substitution	O
.	O

A	O
combination	O
of	O
two	O
factors	O
,	O
namely	O
,	O
nature	O
of	O
the	O
-O	O
-	B
CH2-	I
linkage	O
in	O
the	O
LNAs	O
vs	O
their	O
absence	O
in	O
the	O
pure	O
duplexes	O
and	O
similar	O
conformations	O
of	O
the	O
sugar	O
rings	O
in	O
DNA	O
and	O
	O
-	O
LNA	O
vs	O
the	O
other	O
two	O
,	O
is	O
suggested	O
to	O
contribute	O
to	O
the	O
stark	O
differences	O
among	O
the	O
four	O
duplexes	O
studied	O
here	O
in	O
terms	O
of	O
their	O
structural	O
,	O
dynamic	O
,	O
and	O
energetic	O
properties	O
.	O

Interview	O
with	O
m	O
frederick	O
hawthorne	O
.	O

M	O
Frederick	O
Hawthorne	O
is	O
a	O
world	O
-	O
renowned	O
scientist	O
in	O
the	O
field	O
of	O
molecular	O
medicine	O
and	O
a	O
pioneer	O
in	O
boron	B
chemistry	O
.	O

He	O
currently	O
serves	O
as	O
the	O
founding	O
Director	O
of	O
the	O
University	O
of	O
Missouri	O
International	O
Institute	O
of	O
Nano	O
and	O
Molecular	O
Medicine	O
(	O
MO	O
,	O
USA	O
)	O
.	O

Prof.	O
Hawthorne	O
is	O
a	O
University	O
of	O
Missouri	O
Curators	O
'	O
Distinguished	O
Professor	O
and	O
University	O
Professor	O
of	O
Chemistry	O
Emeritus	O
of	O
the	O
University	O
of	O
California	O
,	O
Los	O
Angeles	O
(	O
CA	O
,	O
USA	O
)	O
.	O

He	O
is	O
a	O
member	O
of	O
the	O
US	O
National	O
Academy	O
of	O
Sciences	O
and	O
the	O
recipient	O
of	O
many	O
national	O
and	O
international	O
honors	O
,	O
including	O
the	O
2003	O
King	O
Faisal	O
Prize	O
in	O
Science	O
,	O
the	O
American	O
Chemical	O
Society	O
's	O
2009	O
Priestley	O
Medal	O
and	O
the	O
2011	O
National	O
Medal	O
of	O
Science	O
.	O

Prof.	O
Hawthorne	O
has	O
authored	O
or	O
co	O
-	O
authored	O
more	O
than	O
540	O
research	O
articles	O
,	O
30	O
patents	O
,	O
ten	O
book	O
chapters	O
and	O
two	O
books	O
.	O

Prof.	O
Hawthorne	O
spoke	O
to	O
Future	O
Medicinal	O
Chemistry	O
on	O
how	O
he	O
became	O
involved	O
in	O
the	O
field	O
,	O
the	O
future	O
of	O
boron	B
neutron	O
capture	O
therapy	O
,	O
and	O
provides	O
his	O
advice	O
for	O
the	O
next	O
generation	O
of	O
boron	B
scientists	O
.	O

Interview	O
conducted	O
by	O
Isaac	O
Bruce	O
,	O
Managing	O
Commissioning	O
Editor	O
.	O

Boron	B
chemicals	O
in	O
diagnosis	O
and	O
therapeutics	O
.	O

Advances	O
in	O
the	O
field	O
of	O
boron	B
chemistry	O
have	O
expanded	O
the	O
application	O
of	O
boron	B
from	O
material	O
use	O
to	O
medicine	O
.	O

Boron	B
-	O
based	O
drugs	O
represent	O
a	O
new	O
class	O
of	O
molecules	O
that	O
possess	O
several	O
biomedical	O
applications	O
including	O
use	O
as	O
imaging	O
agents	O
for	O
both	O
optical	O
and	O
nuclear	O
imaging	O
as	O
well	O
as	O
therapeutic	O
agents	O
with	O
anticancer	O
,	O
antiviral	O
,	O
antibacterial	O
,	O
antifungal	O
and	O
other	O
disease	O
-	O
specific	O
activities	O
.	O

For	O
example	O
,	O
bortezomib	B
(	O
Velcade	B
(	O
	O
)	O
)	O
,	O
the	O
only	O
drug	O
in	O
clinical	O
use	O
with	O
boron	B
as	O
an	O
active	O
element	O
,	O
was	O
approved	O
in	O
2003	O
as	O
a	O
proteasome	O
inhibitor	O
for	O
the	O
treatment	O
of	O
multiple	O
myeloma	O
and	O
non	O
-	O
Hodgkin	O
's	O
lymphoma	O
.	O

Several	O
other	O
boron	B
-	O
based	O
compounds	O
are	O
in	O
various	O
phases	O
of	O
clinical	O
trials	O
,	O
which	O
illustrates	O
the	O
promise	O
of	O
this	O
approach	O
for	O
medicinal	O
chemists	O
working	O
in	O
the	O
area	O
of	O
boron	B
chemistry	O
.	O

It	O
is	O
expected	O
that	O
in	O
the	O
near	O
future	O
,	O
several	O
boron	B
-	O
containing	O
drugs	O
should	O
become	O
available	O
in	O
the	O
market	O
with	O
better	O
efficacy	O
and	O
potency	O
than	O
existing	O
drugs	O
.	O

This	O
article	O
discusses	O
the	O
current	O
status	O
of	O
the	O
development	O
of	O
boron	B
-	O
based	O
compounds	O
as	O
diagnostic	O
and	O
therapeutic	O
agents	O
in	O
humans	O
.	O

Boronated	B
carbohydrate	I
derivatives	O
as	O
potential	O
boron	B
neutron	O
capture	O
therapy	O
reagents	O
.	O

The	O
treatment	O
of	O
cancer	O
remains	O
one	O
of	O
the	O
most	O
challenging	O
problems	O
for	O
humanity	O
.	O

Boron	B
neutron	O
capture	O
therapy	O
is	O
a	O
binary	O
approach	O
for	O
cancer	O
treatment	O
that	O
is	O
particularly	O
attractive	O
in	O
treating	O
high	O
-	O
grade	O
gliomas	O
and	O
metastatic	O
brain	O
tumors	O
.	O

Among	O
the	O
types	O
of	O
boron	B
-	O
containing	O
molecules	O
used	O
as	O
boron	B
neutron	O
capture	O
therapy	O
agents	O
,	O
boronated	B
carbohydrate	I
derivatives	O
have	O
received	O
significant	O
attention	O
because	O
of	O
their	O
preferential	O
uptake	O
by	O
growing	O
tumor	O
cells	O
.	O

This	O
review	O
provides	O
a	O
summary	O
of	O
the	O
recent	O
developments	O
in	O
the	O
chemistry	O
of	O
carborane	B
-	O
containing	O
carbohydrates	B
.	O

Characterization	O
of	O
the	O
nucleation	O
process	O
of	O
lysozyme	O
at	O
physiological	O
pH	O
:	O
Primary	O
but	O
not	O
sole	O
process	O
.	O

We	O
report	O
on	O
a	O
kinetic	O
study	O
of	O
the	O
heat	O
-	O
induced	O
aggregation	O
process	O
of	O
lysozyme	O
at	O
physiological	O
pH.	O
The	O
time	O
evolution	O
of	O
the	O
aggregation	O
extent	O
and	O
the	O
conformational	O
changes	O
of	O
the	O
protein	O
were	O
followed	O
by	O
dynamic	O
light	O
scattering	O
(	O
DLS	O
)	O
and	O
FTIR	O
spectroscopy	O
,	O
respectively	O
,	O
whereas	O
the	O
morphology	O
of	O
the	O
aggregates	O
was	O
observed	O
by	O
Atomic	O
Force	O
Microscopy	O
(	O
AFM	O
)	O
.	O

The	O
conformational	O
changes	O
of	O
the	O
secondary	O
and	O
tertiary	O
structures	O
were	O
simultaneous	O
and	O
distinct	O
in	O
time	O
with	O
respect	O
to	O
the	O
formation	O
of	O
aggregates	O
.	O

Oligomer	O
formation	O
occurred	O
through	O
at	O
least	O
two	O
different	O
aggregation	O
processes	O
:	O
a	O
nucleation	O
process	O
and	O
a	O
homogeneous	O
non	O
-	O
nucleative	O
diffusion	O
-	O
controlled	O
process	O
.	O

FTIR	O
measurements	O
showed	O
that	O
supramolecular	O
aggregation	O
proceeded	O
without	O
the	O
formation	O
of	O
	O
-	O
aggregated	O
structures	O
and	O
AFM	O
images	O
revealed	O
the	O
presence	O
of	O
oligomers	O
and	O
amorphous	O
aggregates	O
;	O
no	O
fibrillar	O
structures	O
were	O
observed	O
.	O

Tandutinib	B
(	O
MLN518	B
/	O
CT53518	B
)	O
targeted	O
to	O
stem	O
-	O
like	O
cells	O
by	O
inhibiting	O
the	O
function	O
of	O
ATP	B
-	O
binding	O
cassette	O
subfamily	O
G	O
member	O
2	O
.	O

Tandutinib	B
is	O
a	O
novel	O
inhibitor	O
of	O
tyrosine	B
kinases	O
FLT3	O
,	O
PDGFR	O
and	O
KIT	O
.	O

Our	O
study	O
was	O
to	O
explore	O
the	O
capability	O
of	O
tandutinib	B
to	O
reverse	O
ABC	O
transporter	O
-	O
mediated	O
multidrug	O
resistance	O
.	O

Tandutinib	B
reversed	O
ABCG2-mediated	O
drug	O
resistance	O
in	O
ABCG2	O
-	O
482-R2	O
,	O
ABCG2	O
-	O
482-G2	O
,	O
ABCG2	O
-	O
482-T7	O
and	O
S1-M1	O
-	O
80	O
cells	O
and	O
increased	O
the	O
accumulation	O
of	O
doxorubicin	B
,	O
rhodamine	B
123	I
and	O
[	B
H	I
(	I
3	I
)	I
]	I
mitoxantrone	I
in	O
ABCG2-overexpressing	O
cells	O
.	O

Importantly	O
,	O
tandutinib	B
selectively	O
sensitized	O
side	O
population	O
cells	O
to	O
mitoxantrone	B
.	O

Taken	O
together	O
,	O
our	O
results	O
advocate	O
the	O
potency	O
of	O
tandutinib	B
as	O
an	O
ABCG2	O
modulator	O
and	O
stem	O
-	O
like	O
cells	O
targeted	O
agent	O
to	O
increase	O
efficiency	O
of	O
anticancer	O
drugs	O
.	O

How	O
do	O
polymeric	O
micelles	O
cross	O
epithelial	O
barriers	O
?	O

Non	O
-	O
parenteral	O
delivery	O
of	O
drugs	O
using	O
nanotechnology	O
-	O
based	O
delivery	O
systems	O
is	O
a	O
promising	O
non	O
-	O
invasive	O
way	O
to	O
achieve	O
effective	O
local	O
or	O
systemic	O
drug	O
delivery	O
.	O

The	O
efficacy	O
of	O
drugs	O
administered	O
non	O
-	O
parenterally	O
is	O
limited	O
by	O
their	O
ability	O
to	O
cross	O
biological	O
barriers	O
,	O
and	O
epithelial	O
tissues	O
particularly	O
present	O
challenges	O
.	O

Polymeric	O
micelles	O
can	O
achieve	O
transepithelial	O
drug	O
delivery	O
because	O
of	O
their	O
ability	O
to	O
be	O
internalized	O
into	O
cells	O
and/or	O
cross	O
epithelial	O
barriers	O
,	O
thereby	O
delivering	O
drugs	O
either	O
locally	O
or	O
systematically	O
following	O
non	O
-	O
parenteral	O
administration	O
.	O

This	O
review	O
discusses	O
the	O
particular	O
characteristics	O
of	O
various	O
epithelial	O
barriers	O
and	O
assesses	O
their	O
potential	O
as	O
non	O
-	O
parenteral	O
routes	O
of	O
delivery	O
.	O

The	O
material	O
characteristics	O
of	O
polymeric	O
micelles	O
(	O
e.g.	O
,	O
size	O
,	O
surface	O
charge	O
,	O
and	O
surface	O
decoration	O
)	O
and	O
of	O
unimers	O
dissociated	O
from	O
polymeric	O
micelles	O
determine	O
their	O
interactions	O
(	O
non	O
-	O
specific	O
and/or	O
specific	O
)	O
with	O
mucus	O
and	O
epithelial	O
cells	O
as	O
well	O
as	O
their	O
intracellular	O
fate	O
.	O

This	O
paper	O
outlines	O
the	O
mechanisms	O
governing	O
the	O
major	O
modes	O
of	O
internalization	O
of	O
polymeric	O
micelles	O
into	O
epithelial	O
cells	O
,	O
with	O
an	O
emphasis	O
on	O
specific	O
recent	O
examples	O
of	O
the	O
transport	O
of	O
drug	O
-	O
loaded	O
polymeric	O
micelles	O
across	O
epithelial	O
barriers	O
.	O

Polymorphism	O
in	O
porphyrin	B
monolayers	O
:	O
the	O
relation	O
between	O
adsorption	O
configuration	O
and	O
molecular	O
conformation	O
.	O

Self	O
-	O
assembled	O
monolayers	O
of	O
meso-5,10,15,20-tetrakis	B
(	I
undecyl	I
)	I
porphyrin	I
copper	I
(	I
ii	I
)	I
on	O
a	O
graphite	B
/	O
1-octanoic	B
acid	I
interface	O
have	O
been	O
studied	O
by	O
Scanning	O
Tunnelling	O
Microscopy	O
.	O

Four	O
distinct	O
polymorphs	O
were	O
observed	O
,	O
varying	O
in	O
their	O
unit	O
cell	O
size	O
.	O

Arrays	O
of	O
unit	O
cells	O
of	O
the	O
various	O
polymorphs	O
seamlessly	O
connect	O
to	O
each	O
other	O
via	O
shared	O
unit	O
cell	O
vectors	O
.	O

The	O
monolayers	O
are	O
not	O
commensurate	O
,	O
but	O
coincident	O
with	O
the	O
underlying	O
graphite	B
substrate	O
.	O

The	O
seamless	O
transition	O
between	O
the	O
polymorphs	O
is	O
proposed	O
to	O
be	O
the	O
result	O
of	O
an	O
adaptation	O
of	O
the	O
molecular	O
conformations	O
in	O
the	O
polymorphs	O
and	O
at	O
the	O
boundaries	O
,	O
which	O
is	O
enabled	O
by	O
the	O
conformational	O
freedom	O
of	O
the	O
alkyl	B
tails	O
of	O
these	O
molecules	O
.	O

Random	O
Regret	O
-	O
Based	O
Discrete	O
-	O
Choice	O
Modelling	O
:	O

An	O
Application	O
to	O
Healthcare	O
.	O

BACKGROUND	O
:	O
A	O
new	O
modelling	O
approach	O
for	O
analysing	O
data	O
from	O
discrete	O
-	O
choice	O
experiments	O
(	O
DCEs	O
)	O
has	O
been	O
recently	O
developed	O
in	O
transport	O
economics	O
based	O
on	O
the	O
notion	O
of	O
regret	O
minimization	O
-	O
driven	O
choice	O
behaviour	O
.	O

This	O
so	O
-	O
called	O
Random	O
Regret	O
Minimization	O
(	O
RRM	O
)	O
approach	O
forms	O
an	O
alternative	O
to	O
the	O
dominant	O
Random	O
Utility	O
Maximization	O
(	O
RUM	O
)	O
approach	O
.	O

The	O
RRM	O
approach	O
is	O
able	O
to	O
model	O
semi	O
-	O
compensatory	O
choice	O
behaviour	O
and	O
compromise	O
effects	O
,	O
while	O
being	O
as	O
parsimonious	O
and	O
formally	O
tractable	O
as	O
the	O
RUM	O
approach	O
.	O

OBJECTIVES	O
:	O
Our	O
objectives	O
were	O
to	O
introduce	O
the	O
RRM	O
modelling	O
approach	O
to	O
healthcare	O
-	O
related	O
decisions	O
,	O
and	O
to	O
investigate	O
its	O
usefulness	O
in	O
this	O
domain	O
.	O

METHODS	O
:	O
Using	O
data	O
from	O
DCEs	O
aimed	O
at	O
determining	O
valuations	O
of	O
attributes	O
of	O
osteoporosis	O
drug	O
treatments	O
and	O
human	O
papillomavirus	O
(	O
HPV	O
)	O
vaccinations	O
,	O
we	O
empirically	O
compared	O
RRM	O
models	O
,	O
RUM	O
models	O
and	O
Hybrid	O
RUM	O
-	O
RRM	O
models	O
in	O
terms	O
of	O
goodness	O
of	O
fit	O
,	O
parameter	O
ratios	O
and	O
predicted	O
choice	O
probabilities	O
.	O

RESULTS	O
:	O
In	O
terms	O
of	O
model	O
fit	O
,	O
the	O
RRM	O
model	O
did	O
not	O
outperform	O
the	O
RUM	O
model	O
significantly	O
in	O
the	O
case	O
of	O
the	O
osteoporosis	O
DCE	O
data	O
(	O
p	O
=	O
0.21	O
)	O
,	O
whereas	O
in	O
the	O
case	O
of	O
the	O
HPV	O
DCE	O
data	O
,	O
the	O
Hybrid	O
RUM	O
-	O
RRM	O
model	O
outperformed	O
the	O
RUM	O
model	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Differences	O
in	O
predicted	O
choice	O
probabilities	O
between	O
RUM	O
models	O
and	O
(	O
Hybrid	O
RUM-	O
)	O
RRM	O
models	O
were	O
small	O
.	O

Derived	O
parameter	O
ratios	O
did	O
not	O
differ	O
significantly	O
between	O
model	O
types	O
,	O
but	O
trade	O
-	O
offs	O
between	O
attributes	O
implied	O
by	O
the	O
two	O
models	O
can	O
vary	O
substantially	O
.	O

CONCLUSION	O
:	O
Differences	O
in	O
model	O
fit	O
between	O
RUM	O
,	O
RRM	O
and	O
Hybrid	O
RUM	O
-	O
RRM	O
were	O
found	O
to	O
be	O
small	O
.	O

Although	O
our	O
study	O
did	O
not	O
show	O
significant	O
differences	O
in	O
parameter	O
ratios	O
,	O
the	O
RRM	O
and	O
Hybrid	O
RUM	O
-	O
RRM	O
models	O
did	O
feature	O
considerable	O
differences	O
in	O
terms	O
of	O
the	O
trade	O
-	O
offs	O
implied	O
by	O
these	O
ratios	O
.	O

In	O
combination	O
,	O
our	O
results	O
suggest	O
that	O
RRM	O
and	O
Hybrid	O
RUM	O
-	O
RRM	O
modelling	O
approach	O
hold	O
the	O
potential	O
of	O
offering	O
new	O
and	O
policy	O
-	O
relevant	O
insights	O
for	O
health	O
researchers	O
and	O
policy	O
makers	O
.	O

Genetic	O
Variants	O
in	O
2q31	O
and	O
5p15	O
Are	O
Associated	O
With	O
Aggressive	O
Benign	O
Prostatic	O
Hyperplasia	O
in	O
a	O
Chinese	O
Population	O
.	O

BACKGROUND	O
:	O
Benign	O
prostatic	O
hyperplasia	O
(	O
BPH	O
)	O
is	O
a	O
common	O
disease	O
prevalent	O
in	O
elderly	O
men	O
.	O

However	O
,	O
the	O
genetic	O
determinants	O
of	O
BPH	O
remain	O
unclear	O
.	O

Because	O
BPH	O
and	O
prostate	O
cancer	O
(	O
PCa	O
)	O
share	O
some	O
common	O
pathological	O
characteristics	O
,	O
we	O
investigated	O
whether	O
susceptibility	O
loci	O
for	O
PCa	O
contributed	O
to	O
BPH	O
risk	O
and	O
BPH	O
aggressiveness	O
in	O
Chinese	O
men	O
.	O

METHODS	O
:	O
Fourteen	O
SNPs	O
associated	O
with	O
PCa	O
risk	O
in	O
a	O
Chinese	O
population	O
were	O
genotyped	O
in	O
426	O
BPH	O
cases	O
(	O
184	O
aggressive	O
and	O
242	O
non	O
-	O
aggressive	O
BPH	O
cases	O
)	O
and	O
1,008	O
controls	O
.	O

The	O
association	O
between	O
the	O
SNPs	O
and	O
BPH	O
risk	O
/	O
aggressiveness	O
was	O
estimated	O
using	O
logistic	O
regression	O
analysis	O
.	O

In	O
addition	O
,	O
effects	O
of	O
the	O
14	O
SNPs	O
on	O
BPH	O
related	O
clinical	O
traits	O
,	O
including	O
International	O
Prostate	O
Symptom	O
Score	O
(	O
IPSS	O
)	O
,	O
prostate	O
volume	O
,	O
total	O
PSA	O
,	O
and	O
free	O
PSA	O
were	O
evaluated	O
using	O
linear	O
regression	O
analysis	O
.	O

RESULTS	O
:	O
Two	O
SNPs	O
,	O
rs12621278	O
in	O
ITGA6	O
at	O
2q31	O
(	O
OR	O
=	O
0.82	O
,	O
P	O
=	O
0.05	O
)	O
and	O
rs339331	O
in	O
RFX6	O
at	O
6q22	O
(	O
OR	O
=	O
1.22	O
,	O
P	O
=	O
0.04	O
)	O
were	O
significantly	O
associated	O
with	O
BPH	O
.	O

In	O
addition	O
,	O
rs12621278	O
(	O
OR	O
=	O
0.73	O
,	O
P	O
=	O
0.05	O
)	O
and	O
rs12653946	O
,	O
13	O
kb	O
upstream	O
of	O
IRX4	O
at	O
5p15	O
(	O
OR	O
=	O
1.40	O
,	O
0.03	O
)	O
,	O
were	O
significantly	O
associated	O
with	O
aggressive	O
BPH	O
.	O

Moreover	O
,	O
the	O
risk	O
allele	O
of	O
rs12621278	O
(	O
G	O
)	O
and	O
rs12653946	O
(	O
T	O
)	O
for	O
aggressive	O
BPH	O
were	O
significantly	O
associated	O
with	O
elevated	O
IPSS	O
after	O
treatment	O
(	O
P	O
=	O
0.01	O
)	O
.	O

CONCLUSIONS	O
:	O
This	O
is	O
the	O
first	O
systematic	O
investigation	O
on	O
the	O
contributions	O
of	O
PCa	O
susceptibility	O
loci	O
to	O
risk	O
and	O
aggressiveness	O
of	O
BPH	O
.	O

Our	O
findings	O
advance	O
our	O
understanding	O
of	O
the	O
genetic	O
basis	O
of	O
BPH	O
,	O
especially	O
aggressive	O
BPH	O
.	O

In	O
addition	O
,	O
our	O
results	O
provide	O
new	O
insights	O
into	O
the	O
genetic	O
determinants	O
shared	O
between	O
BPH	O
and	O
PCa	O
.	O

Prostate	O
9999	O
:	O
XX	O
-	O
XX	O
.	O

	O
2013	O

Wiley	O
Periodicals	O
,	O
Inc.	O

Microbial	O
degradation	O
of	O
microcystins	B
.	O

Hepatotoxic	O
microcystins	B
that	O
are	O
produced	O
by	O
freshwater	O
cyanobacteria	O
pose	O
a	O
risk	O
to	O
public	O
health	O
.	O

These	O
compounds	O
may	O
be	O
eliminated	O
by	O
enzymatic	O
degradation	O
.	O

Here	O
,	O
we	O
review	O
the	O
enzymatic	O
pathways	O
for	O
the	O
degradation	O
of	O
these	O
hepatotoxins	O
,	O
some	O
of	O
which	O
are	O
newly	O
discovered	O
processes	O
.	O

The	O
efficiencies	O
of	O
microcystin	B
biodegradation	O
pathways	O
are	O
documented	O
in	O
several	O
papers	O
and	O
are	O
compared	O
here	O
.	O

Additionally	O
,	O
a	O
comprehensive	O
description	O
of	O
the	O
microcystin	B
enzymatic	O
degradation	O
scheme	O
has	O
been	O
supplemented	O
with	O
a	O
proposal	O
for	O
a	O
new	O
biodegradation	O
pathway	O
.	O

Critical	O
comments	O
on	O
less	O
documented	O
hypotheses	O
are	O
also	O
included	O
in	O
this	O
review	O
.	O

The	O
genetic	O
aspects	O
of	O
biodegradation	O
activity	O
are	O
discussed	O
in	O
detail	O
.	O

We	O
also	O
describe	O
some	O
methods	O
that	O
are	O
useful	O
for	O
studying	O
the	O
biological	O
decomposition	O
of	O
microcystins	B
,	O
including	O
screening	O
for	O
microcystin	B
degraders	O
and	O
detecting	O
microcystin	B
degradation	O
products	O
,	O
with	O
an	O
emphasis	O
on	O
mass	O
spectrometric	O
methodology	O
.	O

Insertion	O
of	O
CO2	B
and	O
COS	B
into	O
Bi	B
-	I
C	I
Bonds	O
:	O
Reactivity	O
of	O
a	O
Bismuth	B
NCN	I
Pincer	O
Complex	O
of	O
an	O
Oxyaryl	B
Dianionic	O
Ligand	O
,	O
[	B
2,6-	I
(	I
Me2NCH2	I
)	I
2C6H3	I
]	I
Bi	I
(	I
C6H2tBu2O	I
)	I
.	O

The	O
reactivity	O
of	O
the	O
unusual	O
oxyaryl	B
dianionic	O
ligand	O
,	O
(	B
C6H2tBu2	I
-	I
3,5-O-4	I
)	I
2-	I
,	O
in	O
the	O
Bi3	B
+	I
NCN	I
pincer	O
complex	O
Ar'Bi	B
(	I
C6H2tBu2	I
-	I
3,5-O-4	I
)	I
,	O
1	O
,	O
[	O
Ar	O
'	O
=	O
2,6-	B
(	I
Me2NCH2	I
)	I
2C6H3	I
]	O
has	O
been	O
explored	O
with	O
small	O
molecule	O
substrates	O
and	O
electrophiles	O
.	O

The	O
first	O
insertion	O
reactions	O
of	O
CO2	B
and	O
COS	B
into	O
Bi	B
-	I
C	I
bonds	O
are	O
observed	O
with	O
this	O
oxyaryl	B
dianionic	O
ligand	O
complex	O
.	O

These	O
reactions	O
generate	O
new	O
dianions	O
that	O
have	O
quinoidal	O
character	O
similar	O
to	O
the	O
oxyaryl	B
dianionic	O
ligand	O
in	O
1	O
.	O

The	O
oxyarylcarboxy	B
and	O
oxyarylthiocarboxy	B
dianionic	O
ligands	O
were	O
identified	O
by	O
X	O
-	O
ray	O
crystallography	O
in	O
Ar'Bi	B
[	I
O2C	I
(	I
C6H2tBu2	I
-	I
3	I
-	I
5-O-4	I
)	I
-2O	I
,	I
O	I
'	I
]	I
,	O
2	O
and	O
Ar'Bi	B
[	I
OSC	I
(	I
C6H2tBu2	I
-	I
3	I
-	I
5-O-4	I
)	I
-2O	I
,	I
S	I
]	I
,	O
3	O
,	O
respectively	O
.	O

Silyl	B
halides	I
and	O
pseudohalides	B
,	O
R3SiX	B
(	O
X	O
=	O
Cl	B
,	O
CN	B
,	O
N3	B
;	O
R	O
=	O
Me	B
,	O
Ph	B
)	O
,	O
react	O
with	O
1	O
by	O
attaching	O
X	O
to	O
bismuth	B
and	O
R3Si	B
to	O
the	O
oxyaryl	B
oxygen	B
to	O
form	O
Ar'Bi	B
(	I
X	I
)	I
(	I
C6H2tBu2	I
-	I
3,5-OSiR3	I
-	I
4	I
)	I
complexes	O
,	O
a	O
formal	O
addition	O
across	O
five	O
bonds	O
.	O

These	O
react	O
with	O
additional	O
R3SiX	B
to	O
generate	O
Ar'BiX2	B
complexes	O
and	O
R3SiOC6H3tBu2	B
-	I
2,6	I
.	O

The	O
reaction	O
of	O
1	O
with	O
I2	B
forms	O
Ar'BiI2	B
and	O
the	O
coupled	O
quinone	B
,	O
3,3',5,5'-tetra	B
-	I
tert	I
-	I
butyl-4,4'-diphenoquinone	I
,	O
by	O
oxidative	O
coupling	O
.	O

High	O
-	O
Accuracy	O
Estimates	O
for	O
the	O
Vinylidene	B
-	O
Acetylene	B
Isomerization	O
Energy	O
and	O
the	O
Ground	O
State	O
Rotational	O
Constants	O
of	O
:	B
C	I
=	I
CH2	I
.	O

Highly	O
accurate	O
calculations	O
are	O
reported	O
for	O
properties	O
of	O
vinylidene	B
(	O
H2C	B
=	I
C	I
:	I
)	O
,	O
specically	O
the	O
position	O
of	O
its	O
zero	O
-	O
point	O
vibrational	O
level	O
relative	O
to	O
that	O
of	O
acetylene	B
and	O
its	O
equilibrium	O
structure	O
and	O
ground	O
state	O
rotational	O
constants	O
.	O

The	O
isomerization	O
energy	O
of	O
vinylidene	B
calculated	O
at	O
the	O
HEAT-456QP	O
level	O
of	O
theory	O
is	O
45.530.15	O
kcal	O
mol1	O
,	O
in	O
agreement	O
with	O
the	O
previous	O
best	O
estimate	O
,	O
but	O
associated	O
with	O
a	O
much	O
smaller	O
uncertainty	O
.	O

In	O
addition	O
,	O
the	O
thermochemical	O
calculations	O
presented	O
here	O
also	O
allow	O
a	O
determination	O
of	O
the	O
:	B
C	I
=	I
CH2	I
bond	O
energy	O
of	O
the	O
vinyl	B
radical	O
at	O
the	O
HEAT-345	O
(	O
Q	O
)	O
level	O
of	O
theory	O
,	O
which	O
is	O
77.70.3	O
kcal	O
mol1	O
.	O

The	O
equilibrium	O
structure	O
of	O
vinylidene	B
,	O
estimated	O
with	O
an	O
additivity	O
scheme	O
that	O
includes	O
treatment	O
of	O
correlation	O
eects	O
beyond	O
CCSD	O
(	O
T	O
)	O
as	O
well	O
as	O
relativistic	O
and	O
adiabatic	O
(	O
diagonal	O
Born	O
-	O
Oppenheimer	O
correction	O
)	O
contributions	O
is	O
rCC=1.29820.0003	O
A	O
;	O
rCH=1.08440.0003	O
A	O
;	O
and	O
CCH=120.050.05o	B
,	O
with	O
zero	O
-	O
point	O
rotational	O
constants	O
(	O
including	O
vibrational	O
contributions	O
and	O
electronic	O
contributions	O
to	O
the	O
moment	O
of	O
inertia	O
)	O
estimated	O
to	O
be	O
A0	O
=	O
9.49250.0150	O
cm1	O
;	O
B0	O
=	O
1.32170.0017	O
cm1	O
and	O
C0	O
=	O
1.16020.0016	O
cm1	O
.	O

INTRODUCTION	O
.	O

An	O
archaeal	O
RadA	O
paralog	O
influences	O
presynaptic	O
filament	O
formation	O
.	O

Recombinases	O
of	O
the	O
RecA	O
family	O
play	O
vital	O
roles	O
in	O
homologous	O
recombination	O
,	O
a	O
high	O
-	O
fidelity	O
mechanism	O
to	O
repair	O
DNA	O
double	O
-	O
stranded	O
breaks	O
.	O

These	O
proteins	O
catalyze	O
strand	O
invasion	O
and	O
exchange	O
after	O
forming	O
dynamic	O
nucleoprotein	O
filaments	O
on	O
ssDNA	O
.	O

Increasing	O
evidence	O
suggests	O
that	O
stabilization	O
of	O
these	O
dynamic	O
filaments	O
is	O
a	O
highly	O
conserved	O
function	O
across	O
diverse	O
species	O
.	O

Here	O
,	O
we	O
analyze	O
the	O
presynaptic	O
filament	O
formation	O
and	O
DNA	O
binding	O
characteristics	O
of	O
the	O
Sulfolobus	O
solfataricus	O
recombinase	O
SsoRadA	O
in	O
conjunction	O
with	O
the	O
SsoRadA	O
paralog	O
SsoRal1	O
.	O

In	O
addition	O
to	O
constraining	O
SsoRadA	O
ssDNA	O
-	O
dependent	O
ATPase	O
activity	O
,	O
the	O
paralog	O
also	O
enhances	O
SsoRadA	O
ssDNA	O
binding	O
,	O
effectively	O
influencing	O
activities	O
necessary	O
for	O
presynaptic	O
filament	O
formation	O
.	O

These	O
activities	O
result	O
in	O
enhanced	O
SsoRadA	O
-	O
mediated	O
strand	O
invasion	O
in	O
the	O
presence	O
of	O
SsoRal1	O
and	O
suggest	O
a	O
filament	O
stabilization	O
function	O
for	O
the	O
SsoRal1	O
protein	O
.	O

Developmental	O
immunotoxicity	O
in	O
male	O
rats	O
after	O
juvenile	O
exposure	O
to	O
ethanol	B
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
the	O
sensitivity	O
of	O
the	O
developing	O
immune	O
system	O
to	O
ethanol	B
(	O
EtOH	B
)	O
after	O
exposure	O
from	O
postnatal	O
day	O
(	O
PND	O
)	O
10	O
onward	O
.	O

Adult	O
Wistar	O
dams	O
and	O
litters	O
were	O
exposed	O
to	O
EtOH	B
via	O
drinking	O
water	O
(	O
0	O
,	O
0.25	O
,	O
1.5	O
,	O
2.75	O
,	O
4	O
,	O
5.25	O
,	O
or	O
6.5	O
%	O
(	O
w	O
/	O
v	O
)	O
EtOH	B
ad	O
libitum	O
)	O
and	O
drinking	O
water	O
exposure	O
of	O
the	O
F1	O
was	O
continued	O
from	O
weaning	O
until	O
sacrifice	O
.	O

Immune	O
assessments	O
were	O
performed	O
at	O
postnatal	O
days	O
(	O
PNDs	O
)	O
21	O
,	O
42	O
,	O
and	O
70	O
.	O

Furthermore	O
,	O
Keyhole	O
Limpet	O
Hemocyanin	O
(	O
KLH	O
)	O
specific	O
immune	O
responses	O
were	O
evaluated	O
following	O
subcutaneous	O
immunizations	O
on	O
PNDs	O
21	O
and	O
35	O
.	O

EtOH	B
exposure	O
affected	O
innate	O
immune	O
responses	O
,	O
such	O
as	O
LPS	O
-	O
induced	O
NO	B
-	O
production	O
by	O
adherent	O
splenocytes	O
,	O
as	O
well	O
as	O
adaptive	O
immune	O
responses	O
as	O
represented	O
by	O
KLH	O
-	O
specific	O
parameters	O
.	O

The	O
most	O
sensitive	O
developmental	O
parameters	O
included	O
effects	O
on	O
maternal	O
and	O
pup	O
bodyweight	O
with	O
calculated	O
BMDs	O
of	O
4.0	O
%	O
and	O
4.3	O
%	O
EtOH	B
,	O
respectively	O
.	O

The	O
most	O
sensitive	O
immune	O
parameters	O
were	O
affected	O
at	O
dose	O
levels	O
lower	O
than	O
those	O
affecting	O
developmental	O
parameters	O
and	O
included	O
KLH	O
-	O
specific	O
immune	O
responses	O
,	O
LPS	O
-	O
induced	O
NO	B
production	O
by	O
adherent	O
splenocytes	O
,	O
and	O
IL-10	O
production	O
by	O
ConA	O
stimulated	O
splenocytes	O
.	O

Calculated	O
BMDs	O
for	O
these	O
parameters	O
were	O
between	O
0.01	O
%	O
and	O
0.1	O
%	O
EtOH	B
.	O

A	O
comparison	O
of	O
the	O
results	O
of	O
this	O
juvenile	O
study	O
with	O
an	O
extended	O
one	O
-	O
generation	O
reproductive	O
toxicity	O
study	O
revealed	O
that	O
the	O
juvenile	O
study	O
design	O
may	O
result	O
in	O
a	O
higher	O
sensitivity	O
related	O
to	O
differences	O
in	O
the	O
exposure	O
design	O
.	O

These	O
findings	O
demonstrate	O
the	O
relative	O
sensitivity	O
of	O
the	O
developing	O
immune	O
system	O
for	O
EtOH	B
exposure	O
,	O
the	O
additional	O
value	O
of	O
assessing	O
functional	O
immune	O
parameters	O
,	O
and	O
the	O
importance	O
of	O
the	O
juvenile	O
window	O
in	O
developmental	O
immunotoxicity	O
testing	O
.	O

Growth	O
and	O
potential	O
damage	O
of	O
human	O
bone	O
-	O
derived	O
cells	O
on	O
fresh	O
and	O
aged	O
fullerene	B
c60	B
films	O
.	O

Fullerenes	B
are	O
nanoparticles	O
composed	O
of	O
carbon	B
atoms	O
arranged	O
in	O
a	O
spherical	O
hollow	O
cage	O
-	O
like	O
structure	O
.	O

Numerous	O
studies	O
have	O
evaluated	O
the	O
therapeutic	O
potential	O
of	O
fullerene	B
derivates	O
against	O
oxidative	O
stress	O
-	O
associated	O
conditions	O
,	O
including	O
the	O
prevention	O
or	O
treatment	O
of	O
arthritis	O
.	O

On	O
the	O
other	O
hand	O
,	O
fullerenes	B
are	O
not	O
only	O
able	O
to	O
quench	O
,	O
but	O
also	O
to	O
generate	O
harmful	O
reactive	O
oxygen	B
species	O
.	O

The	O
reactivity	O
of	O
fullerenes	B
may	O
change	O
in	O
time	O
due	O
to	O
the	O
oxidation	O
and	O
polymerization	O
of	O
fullerenes	B
in	O
an	O
air	O
atmosphere	O
.	O

In	O
this	O
study	O
,	O
we	O
therefore	O
tested	O
the	O
dependence	O
between	O
the	O
age	O
of	O
fullerene	B
films	O
(	O
from	O
one	O
week	O
to	O
one	O
year	O
)	O
and	O
the	O
proliferation	O
,	O
viability	O
and	O
metabolic	O
activity	O
of	O
human	O
osteosarcoma	O
cells	O
(	O
lines	O
MG-63	O
and	O
U-2	O
OS	O
)	O
.	O

We	O
also	O
monitored	O
potential	O
membrane	O
and	O
DNA	O
damage	O
and	O
morphological	O
changes	O
of	O
the	O
cells	O
.	O

After	O
seven	O
days	O
of	O
cultivation	O
,	O
we	O
did	O
not	O
observe	O
any	O
cytotoxic	O
morphological	O
changes	O
,	O
such	O
as	O
enlarged	O
cells	O
or	O
cytosolic	O
vacuole	O
formation	O
.	O

Furthermore	O
,	O
there	O
was	O
no	O
increased	O
level	O
of	O
DNA	O
damage	O
.	O

The	O
increasing	O
age	O
of	O
the	O
fullerene	B
films	O
did	O
not	O
cause	O
enhancement	O
of	O
cytotoxicity	O
.	O

On	O
the	O
contrary	O
,	O
it	O
resulted	O
in	O
an	O
improvement	O
in	O
the	O
properties	O
of	O
these	O
materials	O
,	O
which	O
are	O
more	O
suitable	O
for	O
cell	O
cultivation	O
.	O

Therefore	O
,	O
fullerene	B
films	O
could	O
be	O
considered	O
as	O
a	O
promising	O
material	O
with	O
potential	O
use	O
as	O
a	O
bioactive	O
coating	O
of	O
cell	O
carriers	O
for	O
bone	O
tissue	O
engineering	O
.	O

Excitation	O
and	O
Adaptation	O
in	O
Bacteria	O
-	O
a	O
Model	O
Signal	O
Transduction	O
System	O
that	O
Controls	O
Taxis	O
and	O
Spatial	O
Pattern	O
Formation	O
.	O

The	O
machinery	O
for	O
transduction	O
of	O
chemotactic	O
stimuli	O
in	O
the	O
bacterium	O
E.	O
coli	O
is	O
one	O
of	O
the	O
most	O
completely	O
characterized	O
signal	O
transduction	O
systems	O
,	O
and	O
because	O
of	O
its	O
relative	O
simplicity	O
,	O
quantitative	O
analysis	O
of	O
this	O
system	O
is	O
possible	O
.	O

Here	O
we	O
discuss	O
models	O
which	O
reproduce	O
many	O
of	O
the	O
important	O
behaviors	O
of	O
the	O
system	O
.	O

The	O
important	O
characteristics	O
of	O
the	O
signal	O
transduction	O
system	O
are	O
excitation	O
and	O
adaptation	O
,	O
and	O
the	O
latter	O
implies	O
that	O
the	O
transduction	O
system	O
can	O
function	O
as	O
a	O
"	O
derivative	O
sensor	O
"	O
with	O
respect	O
to	O
the	O
ligand	O
concentration	O
in	O
that	O
the	O
DC	O
component	O
of	O
a	O
signal	O
is	O
ultimately	O
ignored	O
if	O
it	O
is	O
not	O
too	O
large	O
.	O

This	O
temporal	O
sensing	O
mechanism	O
provides	O
the	O
bacterium	O
with	O
a	O
memory	O
of	O
its	O
passage	O
through	O
spatially-	O
or	O
temporally	O
-	O
varying	O
signal	O
fields	O
,	O
and	O
adaptation	O
is	O
essential	O
for	O
successful	O
chemotaxis	O
.	O

We	O
also	O
discuss	O
some	O
of	O
the	O
spatial	O
patterns	O
observed	O
in	O
populations	O
and	O
indicate	O
how	O
cell	O
-	O
level	O
behavior	O
can	O
be	O
embedded	O
in	O
population	O
-	O
level	O
descriptions	O
.	O

Mechanistic	O
Aspects	O
of	O
hSOD1	O
Maturation	O
from	O
the	O
Solution	O
Structure	O
of	O
Cu	B
(	I
I	I
)	I
-Loaded	O
hCCS	O
Domain	O
1	O
and	O
Analysis	O
of	O
Disulfide	B
-	O
Free	O
hSOD1	O
Mutants	O
.	O

Superoxide	B
dismutase	O
1	O
(	O
SOD1	O
)	O
maturation	O
within	O
the	O
cell	O
is	O
mainly	O
accomplished	O
with	O
the	O
SOD1-specific	O
chaperone	O
,	O
CCS	O
,	O
a	O
dimeric	O
protein	O
with	O
three	O
distinct	O
domains	O
in	O
each	O
monomer	O
.	O

We	O
recently	O
showed	O
that	O
the	O
first	O
domain	O
of	O
human	O
CCS	O
(	O
hCCSD1	O
)	O
is	O
responsible	O
for	O
copper	B
transfer	O
to	O
its	O
protein	O
partner	O
,	O
human	O
SOD1	O
(	O
hSOD1	O
)	O
.	O

The	O
NMR	O
solution	O
structure	O
of	O
the	O
copper	B
(	I
I	I
)	I
-loaded	O
form	O
of	O
hCCSD1	O
reported	O
here	O
contributes	O
further	O
to	O
characterization	O
of	O
the	O
copper	O
-	O
transfer	O
mechanism	O
to	O
hSOD1	O
.	O

NMR	O
spectroscopy	O
was	O
also	O
used	O
to	O
examine	O
the	O
hSOD1	O
mutants	O
C57A	O
,	O
C146A	O
,	O
and	O
C57A	O
/	O
C146A	O
,	O
which	O
are	O
unable	O
to	O
form	O
the	O
structurally	O
conserved	O
disulfide	B
bond	O
in	O
SOD1	O
,	O
in	O
order	O
to	O
investigate	O
the	O
role	O
of	O
these	O
cysteines	B
during	O
hSOD1	O
copper	O
acquisition	O
.	O

Together	O
,	O
the	O
information	O
on	O
both	O
hCCS	O
and	O
hSOD1	O
,	O
along	O
with	O
a	O
sequence	O
analysis	O
of	O
eukaryotic	O
CCSD1	O
,	O
allows	O
us	O
to	O
propose	O
important	O
mechanistic	O
aspects	O
regarding	O
the	O
copper	B
-	O
transfer	O
process	O
from	O
hCCS	O
to	O
hSOD1	O
.	O

Metoprolol	B
and	O
diltiazem	B
ameliorate	O
ziprasidone	B
-	O
induced	O
prolonged	O
corrected	O
QT	O
interval	O
in	O
rats	O
.	O

Ziprasidone	B
,	O
an	O
atypical	O
antipsychotic	O
agent	O
,	O
has	O
been	O
shown	O
to	O
increase	O
the	O
corrected	O
QT	O
(	O
QTc	O
)	O
interval	O
in	O
some	O
patients	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
reveal	O
the	O
effects	O
of	O
metoprolol	B
and	O
diltiazem	B
on	O
ziprasidone	B
drug	O
-	O
induced	O
prolonged	O
QTc	O
interval	O
.	O

A	O
total	O
of	O
24	O
rats	O
were	O
equally	O
divided	O
into	O
the	O
following	O
four	O
groups	O
:	O
the	O
first	O
group	O
was	O
used	O
as	O
the	O
control	O
and	O
received	O
1	O
mL	O
/	O
kg	O
saline	O
;	O
3	O
mg	O
/	O
kg	O
ziprasidone	B
and	O
saline	O
were	O
administered	O
to	O
the	O
second	O
group	O
;	O
3	O
mg	O
/	O
kg	O
ziprasidone	B
and	O
1	O
mg	O
/	O
kg	O
metoprolol	B
were	O
administered	O
to	O
the	O
third	O
group	O
and	O
3	O
mg	O
/	O
kg	O
ziprasidone	B
and	O
2	O
mg	O
/	O
kg	O
diltiazem	B
were	O
administered	O
to	O
the	O
fourth	O
group	O
.	O

Two	O
hours	O
following	O
application	O
of	O
the	O
drugs	O
,	O
the	O
QTc	O
was	O
calculated	O
by	O
performing	O
electrocardiography	O
in	O
derivation	O
(	O
D	O
)	O
I.	O
The	O
duration	O
of	O
QTc	O
interval	O
was	O
compared	O
among	O
the	O
four	O
groups	O
.	O

The	O
mean	O
QTc	O
intervals	O
were	O
significantly	O
increased	O
in	O
the	O
third	O
and	O
fourth	O
groups	O
compared	O
with	O
the	O
second	O
group	O
(	O
p	O
<	O
0.0005	O
and	O
p	O
<	O
0.0001	O
,	O
respectively	O
)	O
.	O

The	O
study	O
demonstrated	O
the	O
effectiveness	O
of	O
metoprolol	B
and	O
diltiazem	B
in	O
the	O
prevention	O
of	O
ziprasidone	B
-	O
induced	O
elongation	O
in	O
the	O
QTc	O
interval	O
.	O

Both	O
metoprolol	B
and	O
diltiazem	B
may	O
be	O
considered	O
in	O
the	O
prophylactic	O
therapy	O
of	O
high	O
-	O
risk	O
patients	O
who	O
are	O
using	O
ziprasidone	B
.	O

Store	O
-	O
operated	O
Ca2	B
+	I
Entry	O
(	O
SOCE	O
)	O
Induced	O
by	O
Protease	O
-	O
activated	O
Receptor-1	O
mediates	O
STIM1	O
Phosphorylation	O
to	O
inhibit	O
SOCE	O
in	O
Endothelial	O
Cells	O
through	O
AMP	B
-	O
activated	O
Protein	O
Kinase	O
and	O
p38beta	O
Mitogen	O
-	O
activated	O
Protein	O
Kinase	O
.	O

The	O
Ca2	B
+	I
sensor	O
STIM1	O
is	O
crucial	O
for	O
activation	O
of	O
store	O
-	O
operated	O
Ca2	B
+	I
entry	O
(	O
SOCE	O
)	O
through	O
TRPC	O
and	O
Orai	O
channels	O
.	O

STIM1	O
phosphorylation	O
serves	O
as	O
an	O
off	O
-	O
switch	O
for	O
SOCE	O
.	O

However	O
,	O
the	O
signaling	O
pathway	O
for	O
STIM1	O
phosphorylation	O
is	O
unknown	O
.	O

Here	O
we	O
show	O
that	O
SOCE	O
activates	O
AMP	B
-	O
activated	O
protein	O
kinase	O
(	O
AMPK	O
)	O
;	O
its	O
effector	O
p38	O
mitogen	O
-	O
activated	O
protein	O
kinase	O
(	O
p38	O
MAPK	O
)	O
phosphorylates	O
STIM1	O
,	O
thus	O
inhibiting	O
SOCE	O
in	O
human	O
lung	O
microvascular	O
endothelial	O
cells	O
(	O
ECs	O
)	O
.	O

Activation	O
of	O
AMPK	O
using	O
AICAR	B
resulted	O
in	O
STIM1	O
phosphorylation	O
on	O
serine	B
residues	O
and	O
prevented	O
PAR-1-induced	O
Ca2	B
+	I
entry	O
.	O

Further	O
,	O
AICAR	B
pretreatment	O
blocked	O
PAR-1-induced	O
increase	O
in	O
permeability	O
of	O
mouse	O
-	O
lung	O
microvessels	O
.	O

Activation	O
of	O
SOCE	O
with	O
thrombin	O
caused	O
phosphorylation	O
of	O
isoform	O
1	O
,	O
but	O
not	O
2	O
of	O
the	O
AMPK	O
catalytic	O
subunit	O
.	O

Moreover	O
,	O
knockdown	O
of	O
AMPK1	O
augmented	O
SOCE	O
induced	O
by	O
thrombin	O
.	O

Interestingly	O
,	O
SB203580	B
,	O
a	O
selective	O
inhibitor	O
of	O
p38	O
MAPK	O
,	O
blocked	O
STIM1	O
phosphorylation	O
and	O
led	O
to	O
sustained	O
STIM1-puncta	O
formation	O
and	O
Ca2	B
+	I
entry	O
.	O

Of	O
the	O
three	O
p38	O
MAPK	O
isoforms	O
expressed	O
in	O
ECs	O
,	O
p38	O
knockdown	O
prevented	O
PAR-1-mediated	O
STIM1	O
phosphorylation	O
and	O
potentiated	O
SOCE	O
.	O

In	O
addition	O
,	O
inhibition	O
of	O
the	O
SOCE	O
downstream	O
target	O
CaMKK	O
or	O
knockdown	O
of	O
AMPK1	O
suppressed	O
PAR-1-mediated	O
phosphorylation	O
of	O
p38	O
and	O
hence	O
STIM1	O
.	O

Thus	O
,	O
our	O
findings	O
demonstrate	O
that	O
SOCE	O
activates	O
CaMKK	O
-	O
AMPK1-p38	O
MAPK	O
signaling	O
to	O
phosphorylate	O
STIM1	O
,	O
thereby	O
suppressing	O
endothelial	O
SOCE	O
and	O
permeability	O
responses	O
.	O

Novel	O
pentablock	O
copolymer	O
(	O
PLA	B
-	O
PCL	B
-	O
PEG	B
-	O
PCL	B
-	O
PLA	B
)	O
based	O
nanoparticles	O
for	O
controlled	O
drug	O
delivery	O
:	O
Effect	O
of	O
copolymer	O
compositions	O
on	O
the	O
crystallinity	O
of	O
copolymers	O
and	O
in	O
vitro	O
drug	O
release	O
profile	O
from	O
nanoparticles	O
.	O

The	O
purpose	O
of	O
this	O
investigation	O
was	O
to	O
design	O
novel	O
pentablock	O
copolymers	O
(	O
polylatide	B
-	O
polycaprolactone	B
-	O
polyethylene	B
glycol-	I
polycaprolactone	B
-	O
polylatide	B
)	O
(	O
PLA	B
-	O
PCL	B
-	O
PEG	B
-	O
PCL	B
-	O
PLA	B
)	O
to	O
prepare	O
nanoparticle	O
formulations	O
which	O
provide	O
continuous	O
delivery	O
of	O
steroids	B
over	O
a	O
longer	O
duration	O
with	O
minimal	O
burst	O
effect	O
.	O

Another	O
purpose	O
was	O
to	O
evaluate	O
the	O
effect	O
of	O
poly	B
(	I
L	I
-	I
lactide	I
)	I
(	O
PLLA	B
)	O
or	O
poly	B
(	I
D	I
,	I
L	I
-	I
lactide	I
)	I
(	O
PDLLA	B
)	O
incorporation	O
on	O
crystallinity	O
of	O
pentablock	O
copolymers	O
and	O
in	O
vitro	O
release	O
profile	O
of	O
triamcinolone	B
acetonide	I
(	O
selected	O
as	O
model	O
drug	O
)	O
from	O
nanoparticles	O
.	O

PLA	B
-	O
PCL	B
-	O
PEG	B
-	O
PCL	B
-	O
PLA	B
copolymers	O
with	O
different	O
block	O
ratio	O
of	O
PCL	B
/	O
PLA	B
segment	O
were	O
synthesized	O
.	O

Release	O
of	O
triamcinolone	B
acetonide	I
from	O
nanoparticles	O
was	O
significantly	O
affected	O
by	O
crystallinity	O
of	O
the	O
copolymers	O
.	O

Burst	O
release	O
of	O
triamcinolone	B
acetonide	I
from	O
nanoparticles	O
was	O
significantly	O
minimized	O
with	O
incorporation	O
of	O
proper	O
ratio	O
of	O
PDLLA	B
in	O
the	O
existing	O
triblock	O
(	O
PCL	B
-	O
PEG	B
-	O
PCL	B
)	O
copolymer	O
.	O

Moreover	O
,	O
pentablock	O
copolymer	O
based	O
nanoparticles	O
exhibited	O
continuous	O
release	O
of	O
triamcinolone	B
acetonide	I
.	O

Pentablock	O
copolymer	O
based	O
nanoparticles	O
can	O
be	O
utilized	O
to	O
achieve	O
continuous	O
near	O
zero	O
-	O
order	O
delivery	O
of	O
corticosteroids	O
from	O
nanoparticles	O
without	O
any	O
burst	O
effect	O
.	O

Broad	O
-	O
Range	O
Modulation	O
of	O
Light	O
Emission	O
in	O
Two	O
-	O
Dimensional	O
Semiconductors	O
by	O
Molecular	O
Physisorption	O
Gating	O
.	O

In	O
the	O
monolayer	O
limit	O
,	O
transition	B
metal	I
dichalcogenides	I
become	O
direct	O
-	O
bandgap	O
,	O
light	O
-	O
emitting	O
semiconductors	O
.	O

The	O
quantum	O
yield	O
of	O
light	O
emission	O
is	O
low	O
and	O
extremely	O
sensitive	O
to	O
the	O
substrate	O
used	O
,	O
while	O
the	O
underlying	O
physics	O
remains	O
elusive	O
.	O

In	O
this	O
work	O
,	O
we	O
report	O
over	O
100	O
times	O
modulation	O
of	O
light	O
emission	O
efficiency	O
of	O
these	O
two	O
-	O
dimensional	O
semiconductors	O
by	O
physical	O
adsorption	O
of	O
O2	B
and/or	O
H2O	B
molecules	O
,	O
while	O
inert	O
gases	O
do	O
not	O
cause	O
such	O
effect	O
.	O

The	O
O2	B
and/or	O
H2O	B
pressure	O
acts	O
quantitatively	O
as	O
an	O
instantaneously	O
reversible	O
"	O
molecular	O
gating	O
"	O
force	O
,	O
providing	O
orders	O
of	O
magnitude	O
broader	O
control	O
of	O
carrier	O
density	O
and	O
light	O
emission	O
than	O
conventional	O
electric	O
field	O
gating	O
.	O

Physi	O
-	O
sorbed	O
O2	B
and/or	O
H2O	B
molecules	O
electronically	O
deplete	O
n	O
-	O
type	O
materials	O
such	O
as	O
MoS2	B
and	O
MoSe2	B
,	O
which	O
weakens	O
electrostatic	O
screening	O
that	O
would	O
otherwise	O
destabilize	O
excitons	O
,	O
leading	O
to	O
the	O
drastic	O
enhancement	O
in	O
photoluminescence	O
.	O

In	O
p	O
-	O
type	O
materials	O
such	O
as	O
WSe2	B
,	O
the	O
molecular	O
physisorption	O
results	O
in	O
the	O
opposite	O
effect	O
.	O

Unique	O
and	O
universal	O
in	O
two	O
-	O
dimensional	O
semiconductors	O
,	O
the	O
effect	O
offers	O
a	O
new	O
mechanism	O
for	O
modulating	O
electronic	O
interactions	O
and	O
implementing	O
optical	O
devices	O
.	O

Combinatorial	O
Growth	O
and	O
Anisotropy	O
Control	O
of	O
Self	O
-	O
Assembled	O
Epitaxial	O
Ultrathin	O
Alloy	O
Nanowires	O
.	O

Self	O
-	O
assembled	O
vertical	O
epitaxial	O
nanostructures	O
form	O
a	O
new	O
class	O
of	O
heterostructured	O
materials	O
that	O
has	O
emerged	O
in	O
recent	O
years	O
.	O

Interestingly	O
,	O
such	O
kind	O
of	O
architectures	O
can	O
be	O
grown	O
using	O
combinatorial	O
processes	O
,	O
implying	O
sequential	O
deposition	O
of	O
distinct	O
materials	O
.	O

Although	O
opening	O
many	O
perspectives	O
,	O
this	O
combinatorial	O
nature	O
has	O
not	O
been	O
fully	O
exploited	O
yet	O
.	O

This	O
work	O
demonstrates	O
that	O
the	O
combinatorial	O
character	O
of	O
the	O
growth	O
can	O
be	O
further	O
exploited	O
in	O
order	O
to	O
obtain	O
alloy	O
nanowires	O
coherently	O
embedded	O
in	O
a	O
matrix	O
.	O

This	O
issue	O
is	O
illustrated	O
in	O
the	O
case	O
of	O
a	O
fully	O
epitaxial	O
system	O
:	O
CoxNi1-x	B
nanowires	O
in	O
CeO2	B
/	O
SrTiO3	B
(	O
001	O
)	O
.	O

The	O
advantage	O
brought	O
by	O
the	O
ability	O
to	O
grow	O
alloys	O
is	O
illustrated	O
by	O
the	O
control	O
of	O
the	O
magnetic	O
anisotropy	O
of	O
the	O
nanowires	O
when	O
passing	O
from	O
pure	O
Ni	B
wires	O
to	O
CoxNi1-x	B
alloys	O
.	O

Further	O
exploitation	O
of	O
this	O
combinatorial	O
approach	O
may	O
pave	O
the	O
way	O
toward	O
full	O
three	O
-	O
dimensional	O
heteroepitaxial	O
architectures	O
through	O
axial	O
structuring	O
of	O
the	O
wires	O
.	O

Conformational	O
determinants	O
of	O
the	O
activity	O
of	O
Antiproliferative	O
factor	O
glycopeptide	O
.	O

The	O
antiproliferative	O
factor	O
(	O
APF	O
)	O
involved	O
in	O
interstitial	O
cystitis	O
is	O
a	O
glycosylated	O
nonapeptide	B
(	O
TVPAAVVVA	O
)	O
containing	O
a	O
sialylated	O
core	O
	B
-	I
O	I
-	I
disaccharide	I
linked	O
to	O
the	O
N	O
-	O
terminal	O
threonine	B
.	O

The	O
chemical	O
structure	O
of	O
APF	O
was	O
deduced	O
using	O
spectroscopic	O
techniques	O
and	O
confirmed	O
using	O
total	O
syn	O
-	O
thesis	O
.	O

The	O
synthetic	O
APF	O
provided	O
a	O
platform	O
to	O
study	O
amino	B
acid	I
modifications	O
and	O
their	O
effect	O
on	O
APF	O
activity	O
,	O
based	O
on	O
which	O
a	O
structure	O
-	O
activity	O
relationship	O
(	O
SAR	O
)	O
for	O
APF	O
activity	O
was	O
previously	O
proposed	O
.	O

However	O
,	O
this	O
SAR	O
model	O
could	O
not	O
explain	O
the	O
change	O
in	O
activity	O
associated	O
with	O
minor	O
al	O
-	O
terations	O
in	O
the	O
peptide	O
sequence	O
.	O

Presented	O
is	O
computational	O
analysis	O
of	O
14	O
APF	O
derivatives	O
to	O
identify	O
structural	O
trends	O
from	O
which	O
a	O
more	O
detailed	O
SAR	O
is	O
obtained	O
.	O

The	O
APF	O
activity	O
is	O
found	O
to	O
be	O
dictated	O
by	O
the	O
close	O
interplay	O
between	O
carbohydrate	B
-	O
peptide	O
and	O
peptide	O
-	O
peptide	O
interactions	O
.	O

The	O
former	O
in	O
-	O
volves	O
hydrogen	B
bond	O
and	O
hydrophobic	O
interactions	O
and	O
the	O
latter	O
is	O
dominated	O
by	O
hydrophobic	O
interac	O
-	O
tions	O
.	O

The	O
highly	O
flexible	O
hydrophobic	O
peptide	O
adopts	O
collapsed	O
conformations	O
separated	O
by	O
low	O
energy	O
barriers	O
.	O

APF	O
activity	O
correlates	O
with	O
hydrophobic	O
clustering	O
associated	O
with	O
amino	B
acids	I
4A	O
,	O
6V	O
and	O
8V	O
.	O

Peptide	O
conformations	O
are	O
highly	O
sensitive	O
to	O
single	O
point	O
mutations	O
,	O
which	O
explain	O
the	O
experi	O
-	O
mental	O
trends	O
.	O

The	O
presented	O
SAR	O
will	O
act	O
as	O
a	O
guide	O
for	O
lead	O
optimization	O
of	O
more	O
potent	O
APF	O
ana	O
-	O
logues	O
of	O
potential	O
therapeutic	O
utility	O
.	O

Active	O
Layer	O
-	O
Incorporated	O
,	O
Spectrally	O
-	O
Tuned	O
Au	B
/	O
SiO2	B
Core	O
/	O
Shell	O
Nanorod	O
-	O
Based	O
Light	O
Trapping	O
for	O
Organic	O
Photovoltaics	O
.	O

We	O
demonstrated	O
that	O
incorporation	O
of	O
octadecyltrimethoxysilane	B
(	O
OTMS	B
)	O
functionalized	O
,	O
spectrally	O
tuned	O
,	O
gold	O
/	O
silica	B
(	O
Au	B
/	O
SiO2	B
)	O
core	O
/	O
shell	O
nanospheres	O
and	O
nanorods	O
into	O
the	O
active	O
layer	O
of	O
an	O
organic	O
photovoltaic	O
(	O
OPV	O
)	O
device	O
led	O
to	O
an	O
in	O
increase	O
photo	O
conversion	O
efficiency	O
(	O
PCE	O
)	O
.	O

A	O
silica	B
shell	O
layer	O
was	O
added	O
onto	O
Au	B
core	O
nanospheres	O
and	O
nanorods	O
in	O
order	O
to	O
provide	O
an	O
electrically	O
insulating	O
surface	O
that	O
does	O
not	O
interfere	O
with	O
carrier	O
generation	O
and	O
transport	O
inside	O
the	O
active	O
layer	O
.	O

Functionalization	O
of	O
the	O
Au	B
/	O
SiO2	B
core	O
/	O
shell	O
nanoparticles	O
with	O
the	O
OTMS	B
organic	O
ligand	O
was	O
then	O
necessary	O
in	O
order	O
to	O
transfer	O
the	O
Au	B
/	O
SiO2	B
core	O
/	O
shell	O
nanoparticles	O
from	O
an	O
ethanol	B
solution	O
into	O
an	O
OPV	O
polymer	O
-	O
compatible	O
solvent	O
,	O
such	O
as	O
dichlorobenzene	B
(	O
DCB	B
)	O
.	O

The	O
OTMS	B
-	O
functionalized	O
Au	B
/	O
SiO2	B
core	O
/	O
shell	O
nanorods	O
and	O
nanospheres	O
were	O
then	O
incorporated	O
into	O
the	O
active	O
layers	O
of	O
two	O
OPV	O
polymer	O
systems	O
:	O
a	O
poly	B
(	I
3-hexylthiophene	I
)	I
:	O
[	B
6,6	I
]	I
-phenyl	I
-	I
C61-butyric	I
acid	I
methyl	I
ester	I
(	O
P3HT	B
:	O
PCB60	B
M	I
)	O
OPV	O
device	O
and	O
a	O
poly	B
[	I
2,6	I
-	I
4,8-di	I
(	I
5-ethylhexylthienyl	I
)	I
benzo	I
[	I
1,2-b;3,4-b	I
]	I
dithiophene	I
-	I
alt-5-dibutyloctyl-3,6-bis	I
(	I
5-bromothiophen-2-yl	I
)	I
pyrrolo	I
[	I
3,4-c	I
]	I
pyrrole-1,4-dione	I
]	I
(	O
PBDTT	B
-	I
DPP	I
:	O
PC60BM	B
)	O
OPV	O
device	O
.	O

For	O
the	O
P3HT	B
:	O
PC60BM	B
polymer	O
with	O
a	O
band	O
edge	O
of	O
~700	O
nm	O
,	O
the	O
addition	O
of	O
the	O
core	O
/	O
shell	O
nanorods	O
with	O
an	O
aspect	O
ratio	O
(	O
AR	O
)	O
of	O
~2.5	O
(	O
extinction	O
peak	O
~670	O
nm	O
)	O
resulted	O
in	O
a	O
7.1	O
%	O
improvement	O
in	O
PCE	O
,	O
while	O
for	O
the	O
PBDTT	B
-	I
DPP	I
:	O
PC60BM	B
polymer	O
with	O
a	O
band	O
edge	O
~860	O
nm	O
,	O
the	O
addition	O
of	O
core	O
/	O
shell	O
nanorods	O
with	O
an	O
AR	O
of	O
~4	O
(	O
extinction	O
peak	O
~830	O
nm	O
)	O
resulted	O
in	O
a	O
14.4	O
%	O
improvement	O
in	O
PCE	O
.	O

The	O
addition	O
of	O
Au	B
/	O
SiO2	B
core	O
/	O
shell	O
nanospheres	O
to	O
the	O
P3HT	B
:	O
PC60BM	B
-	O
polymer	O
resulted	O
in	O
a	O
2.7	O
%	O
improvement	O
in	O
PCE	O
,	O
while	O
their	O
addition	O
to	O
a	O
PBDTT	B
-	I
DPP	I
:	O
PC60BM	B
polymer	O
resulted	O
in	O
a	O
9.1	O
%	O
improvement	O
.	O

The	O
PCE	O
and	O
Jsc	O
enhancements	O
were	O
consistent	O
with	O
external	O
quantum	O
efficiency	O
(	O
EQE	O
)	O
measurements	O
and	O
the	O
EQE	O
enhancements	O
spectrally	O
matched	O
the	O
extinction	O
spectra	O
of	O
Au	B
/	O
SiO2	B
nanospheres	O
and	O
nanorods	O
in	O
both	O
OPV	O
polymer	O
systems	O
.	O

Interactions	O
between	O
solid	O
surfaces	O
with	O
pre	O
-	O
adsorbed	O
poly	B
(	I
ethylenimine	I
)	I
(	O
PEI	B
)	O
layers	O
:	O
effect	O
of	O
unadsorbed	O
free	O
PEI	B
chains	O
.	O

Poly	B
(	I
ethylenimine	I
)	I
(	O
PEI	B
)	O
polyelectrolytes	O
have	O
been	O
widely	O
used	O
to	O
tune	O
the	O
stability	O
,	O
rheology	O
,	O
or	O
adhesion	O
properties	O
of	O
colloidal	O
suspensions	O
due	O
to	O
their	O
strong	O
tendency	O
to	O
adsorb	O
to	O
solid	O
surfaces	O
.	O

They	O
have	O
also	O
gained	O
importance	O
as	O
gene	O
carriers	O
in	O
biomedical	O
applications	O
,	O
in	O
which	O
the	O
anionic	O
DNA	O
chains	O
are	O
complexed	O
and	O
condensed	O
to	O
form	O
PEI	B
/	O
DNA	O
polyplexes	O
.	O

Some	O
reported	O
literatures	O
have	O
recently	O
shown	O
that	O
the	O
overdosed	O
PEI	B
chains	O
,	O
which	O
are	O
free	O
in	O
the	O
solution	O
mixture	O
,	O
also	O
play	O
a	O
vital	O
role	O
in	O
promoting	O
the	O
gene	O
transfection	O
,	O
but	O
the	O
reason	O
is	O
unclear	O
.	O

In	O
this	O
work	O
,	O
we	O
present	O
the	O
results	O
of	O
using	O
total	O
internal	O
reflection	O
microscopy	O
(	O
TIRM	O
)	O
to	O
measure	O
the	O
interaction	O
forces	O
between	O
a	O
Brownian	O
colloidal	O
sphere	O
and	O
a	O
flat	O
glass	O
plate	O
in	O
the	O
presence	O
of	O
overdosed	O
free	O
PEI	B
cationic	O
chains	O
,	O
when	O
both	O
surfaces	O
were	O
saturated	O
adsorbed	O
with	O
the	O
PEI	B
chains	O
.	O

The	O
colloidal	O
sphere	O
pre	O
-	O
adsorbed	O
with	O
PEI	B
chains	O
was	O
chosen	O
to	O
mimic	O
the	O
PEI	B
/	O
DNA	O
polyplex	O
.	O

Results	O
for	O
the	O
potential	O
energy	O
of	O
interaction	O
measured	O
for	O
model	O
polyplex	O
(	O
e.g.	O
,	O
PEI	B
-	O
coated	O
sphere	O
)	O
interacting	O
with	O
a	O
PEI	B
-	O
coated	O
glass	O
surface	O
in	O
the	O
presence	O
of	O
overdosed	O
free	O
PEI	B
chains	O
at	O
various	O
pH	O
values	O
and	O
salt	O
concentrations	O
were	O
presented	O
.	O

As	O
can	O
be	O
shown	O
by	O
direct	O
force	O
measurements	O
,	O
the	O
interaction	O
potentials	O
in	O
NaCl	B
salt	O
solution	O
are	O
dominated	O
by	O
repulsive	O
forces	O
originating	O
from	O
diffuse	O
layer	O
overlap	O
and	O
gravitational	O
attraction	O
.	O

However	O
,	O
the	O
presence	O
of	O
free	O
PEI	B
chains	O
in	O
the	O
solution	O
mixture	O
produces	O
a	O
long	O
-	O
ranged	O
(	O
>	O
60	O
nm	O
)	O
attractive	O
force	O
between	O
two	O
PEI	B
-	O
coated	O
surfaces	O
with	O
the	O
range	O
and	O
magnitude	O
tunable	O
by	O
pH	O
value	O
,	O
PEI	B
and	O
salt	O
concentrations	O
.	O

The	O
possible	O
mechanisms	O
of	O
this	O
long	O
-	O
ranged	O
attractive	O
force	O
are	O
discussed	O
.	O

A	O
better	O
understanding	O
of	O
this	O
free	O
PEI	B
-	O
induced	O
attractive	O
force	O
will	O
be	O
useful	O
in	O
the	O
development	O
of	O
improved	O
PEI	B
/	O
DNA	O
polyplexes	O
systems	O
for	O
biomedical	O
applications	O
.	O

Strong	O
Parent	O
-	O
of	O
-	O
Origin	O
Effects	O
in	O
the	O
Association	O
of	O
KCNQ1	O
Variants	O
with	O
Type	O
2	O
Diabetes	O
Mellitus	O
in	O
American	O
Indians	O
.	O

Parent	O
-	O
of	O
-	O
origin	O
effects	O
were	O
observed	O
in	O
an	O
Icelandic	O
population	O
for	O
several	O
genetic	O
variants	O
associated	O
with	O
type	O
2	O
diabetes	O
,	O
including	O
those	O
in	O
KLF14	O
(	O
rs4731702	O
)	O
,	O
MOB2	O
(	O
rs2334499	O
)	O
and	O
KCNQ1	O
(	O
rs2237892	O
,	O
rs231362	O
)	O
.	O

We	O
analyzed	O
parent	O
-	O
of	O
-	O
origin	O
effects	O
for	O
these	O
variants	O
,	O
along	O
with	O
two	O
others	O
in	O
KCNQ1	O
identified	O
in	O
previous	O
genome	O
-	O
wide	O
association	O
studies	O
(	O
rs2237895	O
,	O
rs2299620	O
)	O
,	O
in	O
7351	O
Pima	O
Indians	O
from	O
4549	O
nuclear	O
families	O
;	O
34	O
%	O
of	O
participants	O
had	O
diabetes	O
.	O

In	O
a	O
subset	O
of	O
287	O
normoglycemic	O
individuals	O
,	O
acute	O
insulin	O
secretion	O
was	O
measured	O
by	O
an	O
intravenous	O
glucose	B
tolerance	O
test	O
.	O

Statistically	O
significant	O
(	O
P<0.05	O
)	O
parent	O
-	O
of	O
-	O
origin	O
effects	O
were	O
seen	O
for	O
association	O
with	O
type	O
2	O
diabetes	O
for	O
all	O
variants	O
.	O

The	O
strongest	O
effect	O
was	O
seen	O
at	O
rs2299620	O
in	O
KCNQ1	O
:	O
the	O
C	O
allele	O
was	O
associated	O
with	O
increased	O
diabetes	O
when	O
maternally	O
-	O
derived	O
(	O
odds	O
ratio=1.92	O
,	O
P=4.1x10	O
(	O
-12	O
)	O
)	O
,	O
but	O
not	O
when	O
paternally	O
-	O
derived	O
(	O
odds	O
ratio=0.93	O
,	O
P=0.47	O
;	O
P=9.9x10	O
(	O
-6	O
)	O
for	O
difference	O
in	O
maternal	O
and	O
paternal	O
effects	O
)	O
.	O

A	O
maternally	O
-	O
derived	O
C	O
allele	O
was	O
also	O
associated	O
with	O
a	O
28	O
%	O
decrease	O
in	O
insulin	O
secretion	O
(	O
P=0.002	O
)	O
.	O

This	O
study	O
confirms	O
parent	O
-	O
of	O
-	O
origin	O
effects	O
in	O
the	O
association	O
with	O
type	O
2	O
diabetes	O
for	O
variants	O
in	O
KLF14	O
,	O
MOB2	O
and	O
KCNQ1	O
.	O

In	O
Pima	O
Indians	O
the	O
effect	O
of	O
maternally	O
-	O
derived	O
KCNQ1	O
variants	O
appears	O
to	O
be	O
mediated	O
through	O
decreased	O
insulin	O
secretion	O
,	O
and	O
is	O
particularly	O
strong	O
,	O
accounting	O
for	O
4	O
%	O
of	O
the	O
variance	O
in	O
liability	O
to	O
diabetes	O
.	O

Designed	O
amphiphilic	O
	O
-	O
sheet	O
peptides	O
as	O
templates	O
for	O
paraoxon	B
adsorption	O
and	O
detection	O
.	O

Amphiphilic	O
peptides	O
were	O
designed	O
to	O
fold	O
into	O
a	O
	O
-	O
sheet	O
monolayer	O
structure	O
while	O
presenting	O
the	O
catalytic	O
triad	O
residues	O
of	O
the	O
enzyme	O
,	O
acetylcholinesterase	O
(	O
Glu	B
,	O
His	B
and	O
Ser	B
)	O
,	O
to	O
a	O
solution	O
containing	O
the	O
organophosphate	B
,	O
paraoxon	B
.	O

Three	O
peptides	O
,	O
in	O
which	O
the	O
catalytic	O
triad	O
residues	O
were	O
arranged	O
in	O
different	O
orders	O
along	O
the	O
strand	O
,	O
were	O
generated	O
to	O
reveal	O
potential	O
differences	O
in	O
interactions	O
with	O
paraoxon	B
as	O
a	O
function	O
of	O
the	O
order	O
of	O
these	O
amino	B
acids	I
.	O

One	O
additional	O
peptide	O
with	O
amino	B
acids	I
introduced	O
in	O
random	O
order	O
was	O
studied	O
to	O
highlight	O
the	O
contribution	O
of	O
the	O
	O
-	O
sheet	O
secondary	O
structure	O
to	O
any	O
interactions	O
with	O
paraoxon	B
.	O

Langmuir	O
isotherms	O
,	O
Brewster	O
angle	O
microscope	O
at	O
interfaces	O
and	O
circular	O
dichroism	O
measurements	O
in	O
bulk	O
showed	O
that	O
both	O
the	O
	O
-	O
sheet	O
conformation	O
and	O
the	O
order	O
of	O
the	O
amino	B
acids	I
along	O
the	O
strand	O
influenced	O
the	O
interactions	O
of	O
paraoxon	B
with	O
the	O
peptides	O
.	O

Compression	O
isotherm	O
curves	O
,	O
as	O
well	O
as	O
Brewster	O
-	O
angle	O
microscopy	O
images	O
,	O
provided	O
evidence	O
for	O
enhanced	O
adsorption	O
of	O
the	O
paraoxon	B
to	O
the	O
monolayers	O
of	O
peptides	O
which	O
present	O
neighboring	O
Glu	B
and	O
Ser	B
residues	O
along	O
the	O
hydrophilic	O
face	O
of	O
the	O
	O
-	O
strand	O
.	O

Circular	O
dichroism	O
revealed	O
that	O
the	O
peptide	O
most	O
sensitive	O
to	O
interactions	O
with	O
paraoxon	B
was	O
that	O
with	O
the	O
triad	O
residues	O
in	O
the	O
order	O
Glu	B
,	O
Ser	B
and	O
His	B
,	O
which	O
appears	O
to	O
be	O
appropriate	O
for	O
supporting	O
a	O
catalytic	O
mechanism	O
similar	O
to	O
that	O
in	O
acetylcholinesterase	O
enzyme	O
.	O

These	O
rationally	O
designed	O
peptides	O
may	O
be	O
further	O
utilized	O
for	O
the	O
development	O
of	O
technologies	O
for	O
organophosphate	B
adsorption	O
and	O
detection	O
.	O

Evaluation	O
of	O
intratympanic	O
formulations	O
for	O
inner	O
ear	O
delivery	O
:	O
methodology	O
and	O
sustained	O
release	O
formulation	O
testing	O
.	O

Abstract	O
A	O
convenient	O
and	O
efficient	O
in	O
vitro	O
diffusion	O
cell	O
method	O
to	O
evaluate	O
formulations	O
for	O
inner	O
ear	O
delivery	O
via	O
the	O
intratympanic	O
route	O
is	O
currently	O
not	O
available	O
.	O

The	O
existing	O
in	O
vitro	O
diffusion	O
cell	O
systems	O
commonly	O
used	O
to	O
evaluate	O
drug	O
formulations	O
do	O
not	O
resemble	O
the	O
physical	O
dimensions	O
of	O
the	O
middle	O
ear	O
and	O
round	O
window	O
membrane	O
.	O

The	O
objectives	O
of	O
this	O
study	O
were	O
to	O
examine	O
a	O
modified	O
in	O
vitro	O
diffusion	O
cell	O
system	O
of	O
a	O
small	O
diffusion	O
area	O
for	O
studying	O
sustained	O
release	O
formulations	O
in	O
inner	O
ear	O
drug	O
delivery	O
and	O
to	O
identify	O
a	O
formulation	O
for	O
sustained	O
drug	O
delivery	O
to	O
the	O
inner	O
ear	O
.	O

Four	O
formulations	O
and	O
a	O
control	O
were	O
examined	O
in	O
this	O
study	O
using	O
cidofovir	B
as	O
the	O
model	O
drug	O
.	O

Drug	O
release	O
from	O
the	O
formulations	O
in	O
the	O
modified	O
diffusion	O
cell	O
system	O
was	O
slower	O
than	O
that	O
in	O
the	O
conventional	O
diffusion	O
cell	O
system	O
due	O
to	O
the	O
decrease	O
in	O
the	O
diffusion	O
surface	O
area	O
of	O
the	O
modified	O
diffusion	O
cell	O
system	O
.	O

The	O
modified	O
diffusion	O
cell	O
system	O
was	O
able	O
to	O
show	O
different	O
drug	O
release	O
behaviors	O
among	O
the	O
formulations	O
and	O
allowed	O
formulation	O
evaluation	O
better	O
than	O
the	O
conventional	O
diffusion	O
cell	O
system	O
.	O

Among	O
the	O
formulations	O
investigated	O
,	O
poly	B
(	I
lactic	I
-	I
co	I
-	I
glycolic	I
acid	I
)	I
-poly	O
(	B
ethylene	I
glycol	I
)	I
-poly	O
(	B
lactic	I
-	I
co	I
-	I
glycolic	I
acid	I
)	I
triblock	O
copolymer	O
systems	O
provided	O
the	O
longest	O
sustained	O
drug	O
delivery	O
,	O
probably	O
due	O
to	O
their	O
rigid	O
gel	O
structures	O
and/or	O
polymer	O
-	O
to	O
-	O
cidofovir	B
interactions	O
.	O

Membrane	O
fusion	O
-	O
competent	O
virus	O
-	O
like	O
proteoliposomes	O
and	O
proteinaceous	O
supported	O
bilayers	O
made	O
directly	O
from	O
cell	O
plasma	O
membranes	O
.	O

Virus	O
-	O
like	O
particles	O
are	O
useful	O
materials	O
for	O
studying	O
virus	O
-	O
host	O
interactions	O
in	O
a	O
safe	O
manner	O
.	O

However	O
,	O
the	O
standard	O
production	O
of	O
pseudovirus	O
based	O
on	O
the	O
Vesicular	O
Stomatitis	O
Virus	O
(	O
VSV	O
)	O
backbone	O
is	O
an	O
intricate	O
procedure	O
that	O
requires	O
trained	O
laboratory	O
personnel	O
.	O

In	O
this	O
work	O
,	O
a	O
new	O
strategy	O
for	O
creating	O
virus	O
-	O
like	O
proteoliposomes	O
(	O
VLPLs	O
)	O
and	O
virus	O
-	O
like	O
supported	O
bilayers	O
(	O
VLSBs	O
)	O
is	O
presented	O
.	O

This	O
strategy	O
uses	O
a	O
cell	O
blebbing	O
technique	O
to	O
induce	O
the	O
formation	O
of	O
nanoscale	O
vesicles	O
from	O
the	O
plasma	O
membrane	O
of	O
BHK	O
cells	O
expressing	O
the	O
hemagglutinin	O
(	O
HA	O
)	O
fusion	O
protein	O
of	O
influenza	O
X-31	O
.	O

These	O
vesicles	O
and	O
supported	O
bilayers	O
contain	O
HA	O
and	O
are	O
used	O
to	O
carry	O
out	O
single	O
particle	O
membrane	O
fusion	O
events	O
,	O
monitored	O
using	O
total	O
internal	O
reflection	O
fluorescence	O
microscopy	O
.	O

The	O
results	O
of	O
these	O
studies	O
show	O
that	O
the	O
VLPLs	O
and	O
VLSBs	O
contain	O
HA	O
proteins	O
that	O
are	O
fully	O
competent	O
to	O
carry	O
out	O
membrane	O
fusion	O
,	O
including	O
the	O
formation	O
of	O
a	O
fusion	O
pore	O
and	O
the	O
release	O
of	O
fluorophores	O
loaded	O
into	O
vesicles	O
.	O

This	O
new	O
strategy	O
for	O
creating	O
spherical	O
and	O
planar	O
geometry	O
virus	O
-	O
like	O
membranes	O
has	O
many	O
potential	O
applications	O
.	O

VLPLs	O
could	O
be	O
used	O
to	O
study	O
fusion	O
proteins	O
of	O
virulent	O
viruses	O
in	O
a	O
safe	O
manner	O
,	O
or	O
they	O
could	O
be	O
used	O
as	O
therapeutic	O
delivery	O
particles	O
to	O
transport	O
beneficial	O
proteins	O
co	O
-	O
expressed	O
in	O
the	O
cells	O
to	O
a	O
target	O
cell	O
.	O

VLSBs	O
could	O
facilitate	O
high	O
throughput	O
screening	O
of	O
antiviral	O
drugs	O
or	O
pathogen	O
-	O
host	O
cell	O
interactions	O
.	O

Synthesis	O
of	O
Amylose	O
-	O
Polystyrene	B
Inclusion	O
Complexes	O
by	O
a	O
Facile	O
Preparation	O
Route	O
.	O

The	O
formation	O
of	O
amylose	O
-	O
polystyrene	B
inclusion	O
complexes	O
via	O
a	O
novel	O
two	O
-	O
step	O
approach	O
is	O
described	O
.	O

In	O
the	O
first	O
-	O
step	O
,	O
styrene	O
was	O
inserted	O
inside	O
the	O
amylose	O
helical	O
cavity	O
,	O
followed	O
by	O
free	O
radical	O
polymerization	O
in	O
the	O
second	O
step	O
.	O

The	O
inclusion	O
complexes	O
were	O
characterized	O
by	O
Attenuated	O
Total	O
Reflection	O
Fourier	O
Transform	O
Infrared	O
Spectroscopy	O
(	O
ATR	O
-	O
FTIR	O
)	O
,	O
Ultraviolet	O
Spectroscopy	O
(	O
UV	O
)	O
,	O
X	O
-	O
ray	O
Diffraction	O
(	O
XRD	O
)	O
,	O
Atomic	O
Force	O
Microscopy	O
(	O
AFM	O
)	O
,	O
and	O
Differential	O
Scanning	O
Calorimetry	O
(	O
DSC	O
)	O
.	O

The	O
formation	O
of	O
polystyrene	B
was	O
confirmed	O
by	O
gel	O
Permeation	O
Chromatography	O
(	O
GPC	O
)	O
.	O

The	O
molecular	O
weight	O
of	O
polystyrene	B
can	O
be	O
varied	O
by	O
using	O
amylose	O
bearing	O
different	O
molar	O
masses	O
.	O

The	O
approach	O
described	O
here	O
is	O
general	O
and	O
could	O
be	O
used	O
to	O
synthesis	O
other	O
host	O
-	O
polymer	O
inclusion	O
complexes	O
for	O
which	O
long	O
chains	O
of	O
polymeric	O
guests	O
are	O
difficult	O
to	O
insert	O
into	O
the	O
host	O
cavity	O
.	O

Synthesis	O
of	O
Silver	B
Octahedra	O
with	O
Controlled	O
Sizes	O
and	O
Optical	O
Properties	O
via	O
Seed	O
-	O
Mediated	O
Growth	O
.	O

Silver	B
octahedra	O
with	O
edge	O
lengths	O
controlled	O
in	O
the	O
range	O
of	O
20	O
-	O
72	O
nm	O
were	O
synthesized	O
via	O
seed	O
-	O
mediated	O
growth	O
.	O

The	O
key	O
to	O
the	O
success	O
of	O
this	O
synthesis	O
is	O
the	O
use	O
of	O
single	O
-	O
crystal	O
Ag	B
seeds	O
with	O
uniform	O
and	O
precisely	O
controlled	O
sizes	O
to	O
direct	O
the	O
growth	O
and	O
the	O
use	O
of	O
citrate	B
as	O
a	O
selective	O
capping	O
agent	O
for	O
the	O
{	O
111	O
}	O
facets	O
.	O

Our	O
mechanistic	O
studies	O
demonstrated	O
that	O
Ag	B
seeds	O
with	O
both	O
cubic	O
and	O
quasi	O
-	O
spherical	O
shapes	O
could	O
evolve	O
into	O
octahedra	O
.	O

For	O
the	O
first	O
time	O
,	O
we	O
were	O
able	O
to	O
precisely	O
control	O
the	O
edge	O
lengths	O
of	O
Ag	B
octahedra	O
below	O
100	O
nm	O
,	O
and	O
the	O
lower	O
limit	O
of	O
size	O
could	O
even	O
be	O
pushed	O
down	O
to	O
20	O
nm	O
.	O

Using	O
the	O
as	O
-	O
obtained	O
Ag	B
octahedra	O
as	O
sacrificial	O
templates	O
,	O
Au	B
nanocages	O
with	O
an	O
octahedral	O
shape	O
and	O
precisely	O
tunable	O
optical	O
properties	O
were	O
synthesized	O
through	O
a	O
galvanic	O
replacement	O
reaction	O
.	O

Such	O
hollow	O
nanostructures	O
are	O
promising	O
candidates	O
for	O
a	O
broad	O
range	O
of	O
applications	O
related	O
to	O
optics	O
,	O
catalysis	O
,	O
and	O
biomedicine	O
.	O

Highly	O
Enantioselective	O
Zirconium	B
-	O
Catalyzed	O
Cyclization	O
of	O
Aminoalkenes	B
.	O

Aminoalkenes	B
are	O
catalytically	O
cyclized	O
in	O
the	O
presence	O
of	O
cyclopentadienylbis	B
(	I
oxazolinyl	I
)	I
borato	I
group	O
4	O
complexes	O
{	B
PhB	I
(	I
C5H4	I
)	I
(	I
Ox	I
(	I
R	I
)	I
)	I
2	I
}	I
M	I
(	I
NMe2	I
)	I
2	I
(	O
M	O
=	O
Ti	B
,	O
Zr	B
,	O
Hf	B
;	O
Ox	B
(	I
R	I
)	I
=	O
4,4-dimethyl-2-oxazoline	B
,	O
4S	B
-	I
isopropyl-5,5-dimethyl-2-oxazoline	I
,	O
4S	B
-	I
tert	I
-	I
butyl-2-oxazoline	I
)	O
at	O
room	O
temperature	O
and	O
below	O
,	O
affording	O
five-	O
,	O
six-	O
,	O
and	O
seven	O
-	O
membered	O
N	B
-	I
heterocyclic	I
amines	I
with	O
enantiomeric	O
excesses	O
of	O
>	O
90	O
%	O
in	O
many	O
cases	O
and	O
up	O
to	O
99	O
%	O
.	O

Mechanistic	O
investigations	O
of	O
this	O
highly	O
selective	O
system	O
employed	O
synthetic	O
tests	O
,	O
kinetics	O
,	O
and	O
stereochemistry	O
.	O

Secondary	B
aminopentene	I
cyclizations	O
require	O
a	O
primary	B
amine	I
(	O
1	O
-	O
2	O
equiv	O
vs	O
catalyst	O
)	O
.	O

Aminoalkenes	B
are	O
unchanged	O
in	O
the	O
presence	O
of	O
a	O
zirconium	B
monoamido	I
complex	O
{	B
PhB	I
(	I
C5H4	I
)	I
(	I
Ox	I
(	I
4S	I
-	I
iPr	I
,	I
Me2	I
)	I
)	I
2	I
}	I
Zr	I
(	I
NMe2	I
)	I
Cl	I
or	O
a	O
cyclopentadienylmono	B
(	I
oxazolinyl	I
)	I
borato	I
zirconium	I
diamide	I
{	B
Ph2B	I
(	I
C5H4	I
)	I
(	I
Ox	I
(	I
4S	I
-	I
iPr	I
,	I
Me2	I
)	I
)	I
}	I
Zr	I
(	I
NMe2	I
)	I
2	I
.	O

Plots	O
of	O
initial	O
rate	O
versus	O
[	O
substrate	O
]	O
show	O
a	O
rate	O
dependence	O
that	O
evolves	O
from	O
first	O
-	O
order	O
at	O
low	O
concentration	O
to	O
zero	O
-	O
order	O
at	O
high	O
concentration	O
,	O
and	O
this	O
is	O
consistent	O
with	O
a	O
reversible	O
substrate	O
-	O
catalyst	O
interaction	O
preceding	O
an	O
irreversible	O
step	O
.	O

Primary	O
kinetic	O
isotope	O
effects	O
from	O
substrate	O
conversion	O
measurements	O
(	O
k'obs	O
(	O
(	O
H	O
)	O
)	O
/	O
k'obs	O
(	O
(	O
D	O
)	O
)	O
=	O
3.3	O
	O
0.3	O
)	O
and	O
from	O
initial	O
rate	O
analysis	O
(	O
k2	O
(	O
(	O
H	O
)	O
)	O
/	O
k2	O
(	O
(	O
D	O
)	O
)	O
=	O
2.3	O
	O
0.4	O
)	O
indicate	O
that	O
a	O
N	B
-	I
H	I
bond	O
is	O
broken	O
in	O
the	O
turnover	O
-	O
limiting	O
and	O
irreversible	O
step	O
of	O
the	O
catalytic	O
cycle	O
.	O

Asymmetric	O
hydroamination	O
/	O
cyclization	O
of	O
N	B
-	I
deutero	I
-	I
aminoalkenes	I
provides	O
products	O
with	O
higher	O
optical	O
purities	O
than	O
obtained	O
with	O
N	B
-	I
proteo	I
-	I
aminoalkenes	I
.	O

Transition	O
state	O
theory	O
,	O
applied	O
to	O
the	O
rate	O
constant	O
k2	O
that	O
characterizes	O
the	O
irreversible	O
step	O
,	O
provides	O
activation	O
parameters	O
consistent	O
with	O
a	O
highly	O
organized	O
transition	O
state	O
(	O
S	O
(	O
	O
)	O
=	O
-43	O
(	O
7	O
)	O
calmol	O
(	O
-1	O
)	O
K	O
(	O
-1	O
)	O
)	O
and	O
a	O
remarkably	O
low	O
enthalpic	O
barrier	O
(	O
H	O
(	O
	O
)	O
=	O
6.7	O
(	O
2	O
)	O
kcalmol	O
(	O
-1	O
)	O
)	O
.	O

A	O
six	O
-	O
centered	O
,	O
concerted	O
transition	O
state	O
for	O
C	B
-	I
N	I
and	O
C	B
-	I
H	I
bond	O
formation	O
and	O
N	B
-	I
H	I
bond	O
cleavage	O
involving	O
two	O
amidoalkene	B
ligands	O
is	O
proposed	O
as	O
most	O
consistent	O
with	O
the	O
current	O
data	O
.	O

Elucidation	O
of	O
the	O
biochemical	O
basis	O
for	O
a	O
clinical	O
drug	O
-	O
drug	O
interaction	O
between	O
atorvastatin	B
and	O
5-	B
(	I
N-	I
(	I
4-	I
(	I
(	I
4-ethylbenzyl	I
)	I
thio	I
)	I
phenyl	I
)	I
sulfamoyl	I
)	I
-2-methyl	I
benzoic	I
acid	I
(	O
CP-778	B
875	I
)	O
,	O
a	O
subtype	O
selective	O
agonist	O
of	O
the	O
peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
alpha	O
.	O

Abstract	O
1	O
.	O
5-	B
(	I
N-	I
(	I
4-	I
(	I
(	I
4-ethylbenzyl	I
)	I
thio	I
)	I
phenyl	I
)	I
sulfamoyl	I
)	I
-2-methyl	I
benzoic	I
acid	I
(	O
CP-778	B
875	I
)	O
,	O
an	O
agonist	O
of	O
the	O
peroxisome	O
proliferator	O
-	O
activated	O
receptor	O
alpha	O
,	O
has	O
been	O
evaluated	O
in	O
the	O
clinic	O
to	O
treat	O
dyslipidemia	O
and	O
type	O
2	O
diabetes	O
mellitus	O
.	O

Herein	O
,	O
we	O
investigate	O
the	O
effect	O
of	O
CP-778	B
875	I
on	O
the	O
pharmacokinetics	O
of	O
atorvastatin	B
acid	I
and	O
its	O
metabolites	O
in	O
humans	O
.	O

2	O
.	O

The	O
study	O
incorporated	O
a	O
fixed	O
-	O
sequence	O
design	O
conducted	O
in	O
two	O
groups	O
.	O

Group	O
A	O
was	O
designed	O
to	O
estimate	O
the	O
effects	O
of	O
multiple	O
doses	O
of	O
CP-778	B
875	I
on	O
the	O
single	O
dose	O
pharmacokinetics	O
of	O
atorvastatin	B
.	O

Subjects	O
in	O
group	O
A	O
(	O
n	O
=	O
26	O
)	O
received	O
atorvastatin	B
(	O
40	O
mg	O
)	O
on	O
days	O
1	O
and	O
9	O
and	O
CP-778	B
875	I
(	O
1.0	O
mg	O
QD	O
)	O
on	O
days	O
5	O
-	O
12	O
.	O

Group	O
B	O
was	O
designed	O
to	O
examine	O
the	O
effects	O
of	O
multiple	O
doses	O
of	O
atorvastatin	B
on	O
the	O
single	O
dose	O
pharmacokinetics	O
of	O
CP-778	B
875	I
.	O

Subjects	O
in	O
group	O
B	O
(	O
n	O
=	O
29	O
)	O
received	O
CP-778	B
875	I
(	O
0.3	O
mg	O
)	O
on	O
days	O
1	O
and	O
9	O
and	O
atorvastatin	B
(	O
40	O
mg	O
QD	O
)	O
on	O
days	O
5	O
-	O
12	O
.	O

3	O
.	O
Mean	O
maximum	O
serum	O
concentration	O
(	O
Cmax	O
)	O
and	O
area	O
under	O
the	O
curve	O
of	O
atorvastatin	B
were	O
increased	O
by	O
45	O
%	O
and	O
20	O
%	O
,	O
respectively	O
,	O
upon	O
co	O
-	O
administration	O
with	O
CP-778	B
875	I
.	O

Statistically	O
significant	O
increases	O
in	O
the	O
systemic	O
exposure	O
of	O
ortho-	B
and	I
para	I
-	I
hydroxyatorvastatin	I
were	O
also	O
observed	O
upon	O
concomitant	O
dosing	O
with	O
CP-778	B
875	I
.	O

CP-778	B
875	I
pharmacokinetics	O
,	O
however	O
,	O
were	O
not	O
impacted	O
upon	O
concomitant	O
dosing	O
with	O
atorvastatin	B
.	O

4	O
.	O
Inhibition	O
of	O
organic	O
anion	O
transporting	O
polypeptide	O
1B1	O
by	O
CP-778	B
875	I
(	O
IC50	O
=	O
2.14	O
0.40	O
M	O
)	O
could	O
be	O
the	O
dominant	O
cause	O
of	O
the	O
pharmacokinetic	O
interaction	O
as	O
CP-778	B
875	I
did	O
not	O
exhibit	O
significant	O
inhibition	O
of	O
cytochrome	O
P450	O
3A4	O
/	O
3A5	O
,	O
multidrug	O
resistant	O
protein	O
1	O
or	O
breast	O
cancer	O
resistant	O
protein	O
,	O
which	O
are	O
also	O
involved	O
in	O
the	O
hepatobiliary	O
disposition	O
of	O
atorvastatin	B
.	O

Simultaneous	O
determination	O
by	O
LC	O
-	O
MS	O
/	O
MS	O
of	O
25-methoxydammarane-3,12,20-triol	B
epimers	O
and	O
active	O
metabolites	O
in	O
rat	O
plasma	O
after	O
intravenous	O
administration	O
.	O

Abstract	O
1	O
.	O

The	O
pharmacokinetics	O
of	O
the	O
25-OCH3-PPD	B
epimers	O
and	O
active	O
metabolites	O
in	O
rat	O
plasma	O
after	O
a	O
single	O
intravenous	O
(	O
i.v	O
.	O
)	O
administration	O
were	O
studied	O
by	O
a	O
rapid	O
,	O
selective	O
and	O
sensitive	O
UPLC	O
-	O
MS	O
/	O
MS	O
method	O
.	O

2	O
.	O

Chromatographic	O
separation	O
was	O
performed	O
on	O
an	O
Acquity	O
UPLC	O
with	O
Agela	O
C18	O
column	O
,	O
and	O
the	O
solvents	O
of	O
5	O
mM	O
ammonium	B
acetate	I
(	O
pH	O
7.8	O
)	O
-	O
acetonitrile	B
(	O
65	O
:	O
35	O
,	O
v	O
/	O
v	O
)	O
were	O
used	O
as	O
mobile	O
phase	O
for	O
elution	O
.	O

The	O
quantification	O
was	O
performed	O
with	O
the	O
transitions	O
of	O
m	O
/	O
z	O
493.5	O
	O
475.5	O
for	O
20	B
(	I
R	I
,	I
S	I
)	I
-25-OCH3-PPD	I
,	O
m	O
/	O
z	O
479.5	O
	O
461.5	O
for	O
20	B
(	I
R	I
,	I
S	I
)	I
-25-OH	I
-	I
PPD	I
.	O

The	O
Lower	O
Limit	O
Of	O
Quantitation	O
(	O
LLOQ	O
)	O
was	O
20.0	O
ng	O
mL	O
(	O
-1	O
)	O
for	O
20	B
(	I
R	I
,	I
S	I
)	I
-25-OCH3-PPD	I
,	O
2.0	O
ng	O
mL	O
(	O
-1	O
)	O
for	O
20	B
(	I
R	I
,	I
S	I
)	I
-25-OH	I
-	I
PPD	I
in	O
the	O
plasma	O
samples	O
assay	O
.	O

3	O
.	O

The	O
pharmacokinetic	O
parameters	O
of	O
AUC	O
,	O
t1	O
/	O
2	O
and	O
MRT	O
had	O
no	O
difference	O
between	O
20	B
(	I
R	I
)	I
-	I
and	I
(	I
S	I
)	I
-25-OCH3-PPD	I
,	O
but	O
S	O
-	O
epimer	O
has	O
a	O
lower	O
plasma	O
clearance	O
compared	O
to	O
the	O
R	O
-	O
isomer	O
.	O

The	O
active	O
metabolite	O
20	B
(	I
S	I
)	I
-25-OH	I
-	I
PPD	I
showed	O
significantly	O
higher	O
AUC	O
,	O
MRT	O
and	O
a	O
longer	O
half	O
-	O
life	O
than	O
that	O
of	O
20	B
(	I
R	I
)	I
-25-OH	I
-	I
PPD	I
.	O

These	O
assay	O
results	O
are	O
necessary	O
for	O
the	O
evaluation	O
of	O
the	O
pharmacokinetic	O
behavior	O
of	O
25-methoxydammarane-3,12,20-triol	B
in	O
vivo	O
.	O

Single	O
Ion	O
Channel	O
Recordings	O
with	O
CMOS	O
-	O
Anchored	O
Lipid	O
Membranes	O
.	O

We	O
present	O
single	O
-	O
ion	O
-	O
channel	O
recordings	O
performed	O
with	O
biomimetic	O
lipid	O
membranes	O
which	O
are	O
directly	O
attached	O
to	O
the	O
surface	O
of	O
a	O
complementary	O
metal	B
-	I
oxide	I
-	O
semiconductor	O
(	O
CMOS	O
)	O
preamplifier	O
chip	O
.	O

With	O
this	O
system	O
we	O
resolve	O
single	O
-	O
channel	O
currents	O
from	O
several	O
types	O
of	O
bacterial	O
ion	O
channels	O
,	O
including	O
fluctuations	O
of	O
a	O
single	O
alamethicin	O
channel	O
at	O
a	O
bandwidth	O
of	O
1	O
MHz	O
which	O
represent	O
the	O
fastest	O
single	O
-	O
ion	O
-	O
channel	O
recordings	O
reported	O
to	O
date	O
.	O

The	O
platform	O
is	O
also	O
used	O
for	O
high	O
-	O
resolution	O
	O
-	O
hemolysin	O
nanopore	O
recordings	O
.	O

These	O
results	O
illustrate	O
the	O
high	O
signal	O
fidelity	O
,	O
fine	O
temporal	O
resolution	O
,	O
small	O
geometry	O
,	O
and	O
multiplexed	O
integration	O
which	O
can	O
be	O
achieved	O
by	O
leveraging	O
integrated	O
semiconductor	O
platforms	O
for	O
advanced	O
ion	O
channel	O
interfaces	O
.	O

Indazole	B
-	O
based	O
Potent	O
and	O
Cell	O
-	O
Active	O
Mps1	O
Kinase	O
Inhibitors	O
:	O
Rational	O
Design	O
from	O
Pan	O
-	O
Kinase	O
Inhibitor	O
Anthrapyrazolone	B
(	O
SP600125	B
)	O
.	O

Monopolar	O
spindle	O
1	O
(	O
Mps1	O
)	O
is	O
essential	O
for	O
centrosome	O
duplication	O
,	O
the	O
spindle	O
assembly	O
check	O
point	O
,	O
and	O
the	O
maintenance	O
of	O
chromosomal	O
instability	O
.	O

Mps1	O
is	O
highly	O
expressed	O
in	O
cancer	O
cells	O
,	O
and	O
its	O
expression	O
levels	O
correlate	O
with	O
the	O
histological	O
grades	O
of	O
cancers	O
.	O

Thus	O
,	O
selective	O
Mps1	O
inhibitors	O
offer	O
an	O
attractive	O
opportunity	O
for	O
the	O
development	O
of	O
novel	O
cancer	O
therapies	O
.	O

To	O
design	O
novel	O
Mps1	O
inhibitors	O
,	O
we	O
utilized	O
the	O
pan	O
-	O
kinase	O
inhibitor	O
anthrapyrazolone	B
(	O
4	O
,	O
SP600125	B
)	O
and	O
its	O
crystal	O
structure	O
bound	O
to	O
JNK1	O
.	O

Our	O
design	O
efforts	O
led	O
to	O
the	O
identification	O
of	O
indazole	B
-	O
based	O
lead	O
6	O
with	O
an	O
Mps1	O
IC50	O
value	O
of	O
498	O
nM.	O
Optimization	O
of	O
the	O
3-	O
and	O
6-positions	O
on	O
the	O
indazole	B
core	O
of	O
6	O
resulted	O
in	O
23c	O
with	O
improved	O
Mps1	O
activity	O
(	O
IC50	O
=	O
3.06	O
nM	O
)	O
.	O

Finally	O
,	O
application	O
of	O
structure	O
-	O
based	O
design	O
using	O
the	O
X	O
-	O
ray	O
structure	O
of	O
23d	O
bound	O
to	O
Mps1	O
culminated	O
in	O
the	O
discovery	O
of	O
32a	O
and	O
32b	O
with	O
improved	O
potency	O
for	O
cellular	O
Mps1	O
and	O
A549	O
lung	O
cancer	O
cells	O
.	O

Moreover	O
,	O
32a	O
and	O
32b	O
exhibited	O
reasonable	O
selectivities	O
over	O
120	O
and	O
166	O
kinases	O
,	O
respectively	O
.	O

Enhanced	O
beta	O
cell	O
function	O
and	O
anti	O
-	O
inflammatory	O
effect	O
after	O
chronic	O
treatment	O
with	O
the	O
dipeptidyl	O
peptidase-4	O
inhibitor	O
vildagliptin	B
in	O
an	O
advanced	O
-	O
aged	O
diet	O
-	O
induced	O
obesity	O
mouse	O
model	O
.	O

AIMS	O
/	O
HYPOTHESIS	O
:	O
Studies	O
have	O
shown	O
that	O
dipeptidyl	O
peptidase-4	O
(	O
DPP4	O
)	O
inhibitors	O
stimulate	O
insulin	O
secretion	O
and	O
increase	O
beta	O
cell	O
mass	O
in	O
rodents	O
.	O

However	O
,	O
in	O
these	O
models	O
hyperglycaemia	O
has	O
been	O
induced	O
early	O
on	O
in	O
life	O
and	O
the	O
treatment	O
periods	O
have	O
been	O
short	O
.	O

To	O
explore	O
the	O
long	O
-	O
term	O
effects	O
of	O
DPP4	O
inhibition	O
on	O
insulin	O
secretion	O
and	O
beta	O
cell	O
mass	O
,	O
we	O
have	O
generated	O
a	O
high	O
-	O
fat	O
diet	O
(	O
HFD	O
)	O
-induced	O
-	O
obesity	O
model	O
in	O
mice	O
of	O
advanced	O
age	O
(	O
10	O
months	O
old	O
)	O
.	O

METHODS	O
:	O
After	O
1	O
month	O
of	O
HFD	O
alone	O
,	O
the	O
mice	O
were	O
given	O
the	O
DPP4	O
inhibitor	O
vildagliptin	B
for	O
a	O
further	O
11	O
months	O
.	O

At	O
multiple	O
time	O
points	O
throughout	O
the	O
study	O
,	O
OGTTs	O
were	O
performed	O
and	O
beta	O
cell	O
area	O
and	O
long	O
-	O
term	O
survival	O
were	O
evaluated	O
.	O

RESULTS	O
:	O
Beta	O
cell	O
function	O
and	O
glucose	B
tolerance	O
were	O
significantly	O
improved	O
by	O
vildagliptin	B
with	O
both	O
diets	O
.	O

In	O
contrast	O
,	O
in	O
spite	O
of	O
the	O
long	O
treatment	O
period	O
,	O
beta	O
cell	O
area	O
was	O
not	O
significantly	O
different	O
between	O
vildagliptin	B
-	O
treated	O
mice	O
and	O
controls	O
.	O

Mice	O
of	O
advanced	O
age	O
chronically	O
fed	O
an	O
HFD	O
displayed	O
clear	O
and	O
extensive	O
pancreatic	O
inflammation	O
and	O
peri	O
-	O
insulitis	O
,	O
mainly	O
formed	O
by	O
CD3-positive	O
T	O
cells	O
,	O
which	O
were	O
completely	O
prevented	O
by	O
vildagliptin	B
treatment	O
.	O

Chronic	O
vildagliptin	B
treatment	O
also	O
improved	O
survival	O
rates	O
for	O
HFD	O
-	O
fed	O
mice	O
.	O

CONCLUSIONS	O
/	O
INTERPRETATION	O
:	O
In	O
a	O
unique	O
advanced	O
-	O
aged	O
HFD	O
-	O
induced	O
-	O
obesity	O
mouse	O
model	O
,	O
insulin	O
secretion	O
was	O
improved	O
and	O
the	O
extensive	O
peri	O
-	O
insulitis	O
prevented	O
by	O
chronic	O
DPP4	O
inhibition	O
.	O

The	O
improved	O
survival	O
rates	O
for	O
obese	O
mice	O
chronically	O
treated	O
with	O
vildagliptin	B
suggest	O
that	O
chronic	O
DPP4	O
inhibition	O
potentially	O
results	O
in	O
additional	O
quality	O
-	O
adjusted	O
life	O
-	O
years	O
for	O
individuals	O
with	O
type	O
2	O
diabetes	O
,	O
which	O
is	O
the	O
primary	O
goal	O
of	O
any	O
diabetes	O
therapy	O
.	O

PT	O
-	O
ACRAMTU	O
,	O
A	O
Platinum	B
-	O
Acridine	B
Anticancer	O
Agent	O
,	O
Lengthens	O
and	O
Aggregates	O
,	O
but	O
does	O
not	O
Stiffen	O
or	O
Soften	O
DNA	O
.	O

We	O
used	O
atomic	O
force	O
microscopy	O
(	O
AFM	O
)	O
to	O
study	O
the	O
dose	O
-	O
dependent	O
change	O
in	O
conformational	O
and	O
mechanical	O
properties	O
of	O
DNA	O
treated	O
with	O
PT	B
-	I
ACRAMTU	I
(	B
[	I
PtCl	I
(	I
en	I
)	I
(	I
ACRAMTU	I
-	I
S	I
)	I
]	I
(	I
NO3	I
)	I
2	I
,	O
(	O
en	O
=	O
ethane-1,2-diamine	B
,	O
ACRAMTU	B
=	O
1-	B
[	I
2-	I
(	I
acridin-9-ylamino	I
)	I
ethyl	I
]	I
-1,3-dimethylthiourea	I
.	O

PT	B
-	I
ACRAMTU	I
is	O
the	O
parent	O
drug	O
of	O
a	O
family	O
of	O
non	O
-	O
classical	O
platinum	B
-	O
based	O
agents	O
that	O
show	O
potent	O
activity	O
in	O
non	O
-	O
small	O
cell	O
lung	O
cancer	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Its	O
acridine	B
moiety	O
intercalates	O
between	O
DNA	O
bases	O
,	O
while	O
the	O
platinum	B
group	O
forms	O
mono	O
-	O
adducts	O
with	O
DNA	O
bases	O
.	O

AFM	O
images	O
show	O
that	O
PT	B
-	I
ACRAMTU	I
causes	O
some	O
DNA	O
looping	O
and	O
aggregation	O
at	O
drug	O
-	O
to	O
-	O
base	O
pair	O
ratio	O
(	O
r	O
b	O
)	O
of	O
0.1	O
and	O
higher	O
.	O

Very	O
significant	O
lengthening	O
of	O
the	O
DNA	O
was	O
observed	O
with	O
increasing	O
doses	O
of	O
PT	B
-	I
ACRAMTU	I
,	O
and	O
reached	O
saturation	O
at	O
an	O
r	O
b	O
of	O
0.15	O
.	O

At	O
r	O
b	O
of	O
0.1	O
,	O
lengthening	O
was	O
0.6	O
nm	O
per	O
drug	O
molecule	O
,	O
which	O
is	O
more	O
than	O
one	O
fully	O
stretched	O
base	O
pair	O
stack	O
can	O
accommodate	O
,	O
indicating	O
that	O
ACRAMTU	B
also	O
disturbs	O
the	O
stacking	O
of	O
neighboring	O
base	O
pair	O
stacks	O
.	O

Analysis	O
of	O
the	O
AFM	O
images	O
based	O
on	O
the	O
worm	O
-	O
like	O
chain	O
(	O
WLC	O
)	O
model	O
showed	O
that	O
PT	B
-	I
ACRAMTU	I
did	O
not	O
change	O
the	O
flexibility	O
of	O
(	O
non	O
-	O
aggregated	O
)	O
DNA	O
,	O
despite	O
the	O
extreme	O
lengthening	O
.	O

The	O
persistence	O
length	O
of	O
untreated	O
DNA	O
and	O
DNA	O
treated	O
with	O
PT	B
-	I
ACRAMTU	I
was	O
in	O
the	O
range	O
of	O
49	O
-	O
65	O
nm	O
.	O

Potential	O
consequences	O
of	O
the	O
perturbations	O
caused	O
by	O
this	O
agent	O
for	O
the	O
recognition	O
and	O
processing	O
of	O
the	O
DNA	O
adducts	O
it	O
forms	O
are	O
discussed	O
.	O

A	O
dihydrochalcone	B
and	O
several	O
homoisoflavonoids	B
from	O
Polygonatum	O
odoratum	O
are	O
activators	O
of	O
adenosine	B
monophosphate	I
-	O
activated	O
protein	O
kinase	O
.	O

Adenosine	B
monophosphate	I
(	O
AMP	B
)	O
-activated	O
protein	O
kinase	O
(	O
AMPK	O
)	O
is	O
a	O
major	O
cellular	O
energy	O
sensor	O
and	O
master	O
regulator	O
of	O
metabolic	O
homeostasis	O
;	O
thus	O
,	O
AMPK	O
plays	O
a	O
central	O
role	O
in	O
studies	O
on	O
diabetes	O
and	O
related	O
metabolic	O
diseases	O
.	O

From	O
the	O
rhizomes	O
of	O
Polygonatum	O
odoratum	O
(	O
Mill	O
.	O
)	O

Druce	O
,	O
six	O
homoisoflavonoids	B
(	O
1	O
-	O
6	O
)	O
and	O
one	O
dihydrochalcone	B
(	O
7	O
)	O
were	O
isolated	O
,	O
and	O
the	O
structures	O
of	O
polygonatones	B
A	I
-	I
D	I
(	O
4	O
-	O
7	O
)	O
were	O
elucidated	O
by	O
various	O
spectroscopic	O
analyses	O
.	O

Compounds	O
1	O
-	O
7	O
were	O
evaluated	O
for	O
their	O
effect	O
on	O
AMPK	O
activation	O
.	O

The	O
amount	O
of	O
active	O
phosphorylated	O
AMPK	O
and	O
acetyl	B
-	I
CoA	I
carboxylase	O
in	O
rat	O
liver	O
epithelial	O
IAR-20	O
cells	O
increased	O
when	O
the	O
cells	O
were	O
incubated	O
with	O
the	O
aforementioned	O
compounds	O
.	O

Specifically	O
,	O
(	B
3R	I
)	I
-5,7-dihydroxyl-6-methyl-8-methoxyl-3-	I
(	I
4'-hydroxylbenzyl	I
)	I
-chroman-4-one	I
(	O
1	O
)	O
,	O
(	B
3R	I
)	I
-5,7-dihydroxyl-6,8-dimethyl-3-	I
(	I
4'-hydroxylbenzyl	I
)	I
-chroman-4-one	I
(	O
2	O
)	O
,	O
(	B
3R	I
)	I
-5,7-dihydroxyl-6-methyl-3-	I
(	I
4'-hydroxylbenzyl	I
)	I
-chroman-4-one	I
(	O
3	O
)	O
,	O
and	O
polygonatone	B
D	I
(	O
7	O
)	O
exhibited	O
significant	O
activation	O
effects	O
.	O

Synthesis	O
and	O
structure	O
-	O
activity	O
relationships	O
of	O
a	O
novel	O
and	O
selective	O
bone	O
morphogenetic	O
protein	O
receptor	O
(	O
BMP	O
)	O
inhibitor	O
derived	O
from	O
the	O
pyrazolo	B
[	I
1.5-a	I
]	I
pyrimidine	I
scaffold	O
of	O
Dorsomorphin	O
:	O
The	O
discovery	O
of	O
ML347	B
as	O
an	O
ALK2	O
versus	O
ALK3	O
selective	O
MLPCN	O
probe	O
.	O

A	O
structure	O
-	O
activity	O
relationship	O
of	O
the	O
3-	O
and	O
6-positions	O
of	O
the	O
pyrazolo	B
[	I
1,5-a	I
]	I
pyrimidine	I
scaffold	O
of	O
the	O
known	O
BMP	O
inhibitors	O
dorsomorphin	B
,	O
1	O
,	O
LDN-193189	B
,	O
2	O
,	O
and	O
DMH1	B
,	O
3	O
,	O
led	O
to	O
the	O
identification	O
of	O
a	O
potent	O
and	O
selective	O
compound	O
for	O
ALK2	O
versus	O
ALK3	O
.	O

The	O
potency	O
contributions	O
of	O
several	O
3-position	O
substituents	O
were	O
evaluated	O
with	O
subtle	O
structural	O
changes	O
leading	O
to	O
significant	O
changes	O
in	O
potency	O
.	O

From	O
these	O
studies	O
,	O
a	O
novel	O
5-quinoline	B
molecule	O
was	O
identified	O
and	O
designated	O
an	O
MLPCN	O
probe	O
molecule	O
,	O
ML347	B
,	O
which	O
shows	O
>	O
300-fold	O
selectivity	O
for	O
ALK2	O
and	O
presents	O
the	O
community	O
with	O
a	O
selective	O
molecular	O
probe	O
for	O
further	O
biological	O
evaluation	O
.	O

Synthesis	O
and	O
in	O
vitro	O
evaluation	O
of	O
a	O
PDT	O
active	O
BODIPY	O
-	O
NLS	O
conjugate	O
.	O

Two	O
new	O
photosensitizers	O
based	O
on	O
the	O
BODIPY	B
scaffold	O
have	O
been	O
synthesized	O
,	O
of	O
which	O
one	O
bears	O
an	O
NLS	O
peptide	O
,	O
which	O
is	O
linked	O
to	O
the	O
BODIPY	O
's	O
core	O
using	O
the	O
copper	B
catalysed	O
azide	B
-	O
alkyne	B
click	O
reaction	O
.	O

The	O
phototoxicities	O
of	O
these	O
BODIPY	B
based	O
photosensitizers	O
have	O
been	O
determined	O
,	O
as	O
well	O
as	O
their	O
dark	O
toxicities	O
.	O

Although	O
the	O
conjugation	O
of	O
a	O
single	O
NLS	O
peptide	O
to	O
the	O
BODIPY	B
did	O
not	O
lead	O
to	O
any	O
observable	O
nuclear	O
localization	O
,	O
the	O
photosensitizer	O
did	O
exhibit	O
a	O
superior	O
photoxicity	O
.	O

Cellular	O
co	O
-	O
localization	O
experiments	O
revealed	O
a	O
localization	O
of	O
both	O
dyes	O
in	O
the	O
lysosomes	O
,	O
as	O
well	O
as	O
a	O
partial	O
localization	O
within	O
the	O
ER	O
(	O
for	O
the	O
peptide	O
-	O
bearing	O
BODIPY	B
)	O
.	O

Barnacle	O
Cement	O
as	O
Surface	O
Anchor	O
for	O
'	O
Clicking	O
'	O
of	O
Antifouling	O
and	O
Antimicrobial	O
Polymer	O
Brushes	O
on	O
Stainless	O
Steel	O
.	O

Barnacle	O
cement	O
(	O
BC	O
)	O
was	O
utilized	O
'	O
beneficially	O
'	O
as	O
a	O
surface	O
anchor	O
on	O
stainless	O
steel	O
(	O
SS	O
)	O
for	O
coupling	O
of	O
functional	O
polymer	O
brushes	O
via	O
'	O
click	O
'	O
reactions	O
in	O
both	O
"	O
grafting	O
-	O
to	O
"	O
and	O
"	O
grafting	O
-	O
from	O
"	O
processes	O
.	O

Ethylene	B
sulfide	I
(	O
ES	O
)	O
,	O
propargyl	B
carbonylimidazole	I
(	O
PPC	B
)	O
and	O
azidoethyl	B
carbonylimidazole	I
(	O
AEC	B
)	O
reacted	O
with	O
amine	B
and/or	O
hydroxyl	B
groups	O
in	O
BC	O
to	O
introduce	O
the	O
corresponding	O
thiol	B
,	O
alkyne	B
and	O
azide	B
groups	O
on	O
SS	O
surfaces	O
(	O
SS	O
-	O
thiol	B
,	O
SS	O
-	O
alkyne	B
and	O
SS	O
-	O
azide	B
,	O
respectively	O
)	O
.	O

Antifouling	O
zwitterionic	O
SS	O
-	O
PMPC	O
surface	O
was	O
prepared	O
by	O
thiol	B
-	O
ene	O
photopolymerization	O
of	O
2-methacryloyloxyethyl	B
phosphorylcholine	I
(	O
MPC	B
)	O
from	O
the	O
SS	O
-	O
thiol	B
surface	O
.	O

Protein	O
-	O
resistant	O
SS	O
-	O
PPEGMA	B
and	O
protein	O
-	O
adsorbing	O
SS	O
-	O
PPFS	B
surfaces	O
were	O
prepared	O
by	O
coupling	O
of	O
the	O
respective	O
azide	B
-	O
functionalized	O
poly	B
(	I
poly	I
(	I
ethylene	I
glycol	I
)	I
methyl	I
ether	I
methacrylate	I
)	I
(	O
azido	B
-	I
PPEGMA	I
)	O
and	O
poly	B
(	I
2,3,4,5,6-pentafluorostyrene	I
)	I
(	O
azido	B
-	I
PPFS	I
)	O
polymer	O
brushes	O
in	O
azide	B
-	O
alkyne	B
'	O
click	O
'	O
reaction	O
.	O

Antifouling	O
alkyne	B
-	O
functionalized	O
poly	B
(	I
N	I
-	I
hydroxyethyl	I
acrylamide	I
)	I
(	O
alkynyl	B
-	I
PHEAA	I
)	O
and	O
antibacterial	O
alkyne	B
-	O
functionalized	O
poly	B
(	I
2-	I
(	I
methacryloyloxy	I
)	I
ethyl	I
trimethylammonium	I
chloride	I
)	I
(	O
alkynyl	B
-	I
PMETA	I
)	O
polymer	O
brushes	O
were	O
clicked	O
on	O
the	O
SS	O
-	O
azide	B
surface	O
.	O

Adsorption	O
of	O
bovine	O
serum	O
albumin	O
and	O
bacteria	O
fouling	O
of	O
Gram	O
-	O
negative	O
Escherichia	O
coli	O
(	O
E.	O
coli	O
)	O
and	O
Gram	O
-	O
positive	O
Staphylococcus	O
epidermidis	O
(	O
S.	O
epidermidis	O
)	O
were	O
investigated	O
on	O
the	O
polymer	O
-	O
functionalized	O
SS	O
surfaces	O
.	O

The	O
versatile	O
bio	O
-	O
anchor	O
and	O
functional	O
polymer	O
brush	O
coatings	O
are	O
stable	O
in	O
abiotic	O
aqueous	O
environment	O
for	O
over	O
a	O
month	O
.	O

Vibrational	O
Perturbations	O
of	O
W	B
(	I
CO	I
)	I
6	I
Trapped	O
in	O
a	O
Molecular	O
Lattice	O
Probed	O
by	O
Linear	O
and	O
Non	O
Linear	O
Spectroscopy	O
.	O

Vibrational	O
dynamics	O
of	O
the	O
T1u	O
CO	B
stretching	O
mode	O
of	O
tungsten	B
hexacarbonyl	I
is	O
explored	O
when	O
the	O
molecule	O
is	O
embedded	O
in	O
a	O
nitrogen	B
matrix	O
at	O
low	O
temperature	O
.	O

Experiments	O
combined	O
IR	O
absorption	O
spectroscopy	O
and	O
IR	O
stimulated	O
photon	O
echoes	O
at	O
the	O
femtosecond	O
timescale	O
.	O

W	B
(	I
CO	I
)	I
6	I
is	O
found	O
to	O
be	O
trapped	O
in	O
two	O
main	O
families	O
of	O
sites	O
differing	O
by	O
their	O
symmetries	O
(	O
called	O
hereafter	O
Oh	O
and	O
D2h	O
)	O
.	O

In	O
Oh	O
sites	O
,	O
the	O
vibrational	O
coherence	O
is	O
strongly	O
temperature	O
dependent	O
,	O
exhibiting	O
a	O
coupling	O
with	O
librational	O
phonons	O
of	O
the	O
nitrogen	B
lattice	O
.	O

Perturbation	O
in	O
D2h	O
sites	O
results	O
in	O
the	O
splitting	O
of	O
the	O
T1u	O
band	O
in	O
three	O
components	O
.	O

Each	O
component	O
is	O
inhomogeneously	O
broadened	O
,	O
with	O
dephasing	O
times	O
in	O
the	O
tens	O
of	O
picoseconds	O
,	O
weakly	O
coupled	O
to	O
the	O
lattice	O
phonons	O
.	O

Experiments	O
in	O
solid	O
krypton	B
are	O
performed	O
to	O
compare	O
the	O
effect	O
of	O
atomic	O
and	O
diatomic	O
host	O
lattices	O
.	O

Dephasing	O
time	O
in	O
Kr	B
does	O
not	O
depend	O
on	O
temperature	O
and	O
remains	O
in	O
the	O
hundreds	O
of	O
picosecond	O
,	O
highlighting	O
the	O
molecular	O
origin	O
of	O
dephasing	O
process	O
in	O
N2	B
.	O

Additionally	O
,	O
non	O
linear	O
signals	O
show	O
oscillations	O
due	O
to	O
quantum	O
beats	O
and	O
polarization	O
interferences	O
between	O
different	O
frequency	O
components	O
of	O
the	O
induced	O
third	O
order	O
polarization	O
,	O
giving	O
information	O
,	O
in	O
particular	O
,	O
on	O
the	O
overtone	O
vibrational	O
transition	O
.	O

Melamine	B
activates	O
NFB	O
/	O
COX-2	O
/	O
PGE2	O
pathway	O
and	O
increases	O
NADPH	B
oxidase	O
-	O
dependent	O
ROS	O
production	O
in	O
macrophages	O
and	O
human	O
embryonic	O
kidney	O
cells	O
.	O

Melamine	B
is	O
a	O
wildly	O
used	O
compound	O
in	O
manufactures	O
of	O
plastics	O
and	O
resins	O
.	O

A	O
variety	O
of	O
toxic	O
effects	O
from	O
melamine	B
,	O
including	O
nephrolithiasis	O
,	O
chronic	O
kidney	O
inflammation	O
,	O
and	O
bladder	O
carcinoma	O
,	O
have	O
been	O
mentioned	O
.	O

Oxidative	O
stress	O
is	O
considered	O
to	O
be	O
an	O
important	O
pathogenic	O
mechanism	O
of	O
kidney	O
disease	O
which	O
may	O
develop	O
from	O
an	O
increasing	O
free	O
radical	O
production	O
through	O
inflammation	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
investigate	O
melamine	B
-	O
induced	O
oxidative	O
stress	O
and	O
inflammation	O
in	O
macrophage	O
-	O
like	O
cell	O
line	O
RAW	O
264.7	O
and	O
human	O
embryonic	O
kidney	O
cell	O
line	O
HEK293	O
.	O

Results	O
indicated	O
melamine	B
activated	O
nuclear	O
factor	O
(	O
NF	O
)	O
-B	O
through	O
increasing	O
IB	O
-	O
	O
degradation	O
and	O
NF	O
-	O
B	O
p65	O
/	O
p50	O
DNA	O
-	O
binding	O
activity	O
.	O

In	O
addition	O
,	O
melamine	B
significantly	O
increased	O
COX-2	O
expression	O
and	O
prostaglandin	B
E2	I
(	O
PGE2	B
)	O
production	O
.	O

Moreover	O
,	O
melamine	B
activated	O
NADPH	B
oxidase	O
(	O
NOX	O
)	O
,	O
including	O
NOX1	O
,	O
2	O
and	O
4	O
,	O
accompanied	O
with	O
an	O
increase	O
in	O
reactive	O
oxygen	B
species	O
(	O
ROS	O
)	O
production	O
.	O

Furthermore	O
,	O
melamine	B
-	O
induced	O
ROS	O
production	O
could	O
be	O
attenuated	O
by	O
apocynin	B
,	O
a	O
NOX	O
inhibitor	O
.	O

In	O
conclusion	O
,	O
our	O
findings	O
suggest	O
melamine	B
increased	O
inflammation	O
and	O
oxidative	O
stress	O
via	O
activation	O
of	O
NF	O
-	O
B	O
/	O
COX-2	O
and	O
NOX	O
/	O
ROS	O
pathway	O
,	O
and	O
first	O
revealed	O
the	O
critical	O
role	O
of	O
NOX	O
in	O
melamine	B
-	O
induced	O
ROS	O
production	O
,	O
suggesting	O
the	O
potential	O
of	O
NOX	O
inhibitor	O
against	O
melamine	B
toxicity	O
.	O

Genetic	O
Polymorphism	O
at	O
Val	B
(	O
80	O
)	O
(	O
rs700518	O
)	O
of	O
the	O
CYP19A1	O
Gene	O
is	O
Associated	O
with	O
Aromatase	O
Inhibitor	O
Associated	O
Bone	O
Loss	O
in	O
Women	O
with	O
ER	O
(	O
+	O
)	O
Breast	O
Cancer	O
.	O

PURPOSE	O
:	O
Polymorphisms	O
in	O
the	O
CYP19A1	O
(	O
aromatase	O
)	O
gene	O
have	O
been	O
reported	O
to	O
influence	O
disease	O
-	O
free	O
survival	O
and	O
the	O
incidence	O
of	O
musculoskeletal	O
complaints	O
in	O
patients	O
taking	O
aromatase	O
inhibitors	O
(	O
AIs	O
)	O
for	O
estrogen	B
receptor	O
positive	O
(	O
ER+	O
)	O
breast	O
cancer	O
.	O

Bone	O
loss	O
and	O
fractures	O
are	O
well	O
-	O
recognized	O
complications	O
from	O
AI	O
therapy	O
.	O

The	O
objective	O
of	O
this	O
study	O
is	O
to	O
determine	O
the	O
influence	O
of	O
polymorphisms	O
in	O
the	O
CYP19A1	O
gene	O
on	O
bone	O
loss	O
among	O
patients	O
taking	O
aromatase	O
inhibitors	O
for	O
ER+	O
breast	O
cancer	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
The	O
subjects	O
consisted	O
of	O
97	O
postmenopausal	O
women	O
with	O
ER+	O
breast	O
cancer	O
who	O
were	O
initiated	O
on	O
third	O
-	O
generation	O
AIs	O
.	O

Bone	O
mineral	O
density	O
(	O
BMD	O
)	O
was	O
measured	O
by	O
dual	O
energy	O
x	O
-	O
ray	O
absorptiometry	O
at	O
baseline	O
and	O
at	O
6	O
and	O
12	O
months	O
.	O

Twenty	O
-	O
four	O
hour	O
urine	O
N	O
-	O
telopeptide	O
(	O
NTX	O
)	O
was	O
measured	O
by	O
Elisa	O
and	O
serum	O
estradiol	B
was	O
measured	O
by	O
ultrasensitive	O
radioimmunoassay	O
at	O
baseline	O
,	O
and	O
at	O
6	O
months	O
.	O

Genotyping	O
was	O
done	O
by	O
Taqman	O
SNP	O
allelic	O
discrimination	O
assay	O
.	O

RESULTS	O
:	O
Women	O
with	O
the	O
AA	O
genotype	O
for	O
the	O
rs700518	O
(	O
G	O
/	O
A	O
at	O
Val	B
(	O
80	O
)	O
)	O
developed	O
significant	O
bone	O
loss	O
at	O
the	O
lumbar	O
spine	O
and	O
the	O
total	O
hip	O
at	O
12	O
months	O
relative	O
to	O
patients	O
carrying	O
the	O
G	O
allele	O
(	O
GA	O
/	O
GG	O
)	O
;	O
both	O
p=0.03	O
.	O

There	O
was	O
a	O
borderline	O
greater	O
increase	O
in	O
urinary	O
NTX	O
in	O
those	O
with	O
the	O
AA	O
genotype	O
compared	O
to	O
patients	O
with	O
the	O
G	O
allele	O
,	O
p=0.05	O
;	O
but	O
no	O
significant	O
difference	O
in	O
changes	O
in	O
estradiol	B
levels	O
among	O
the	O
genotypes	O
.	O

CONCLUSION	O
:	O
Patients	O
with	O
the	O
AA	O
genotype	O
for	O
the	O
rs700518	O
polymorphism	O
in	O
the	O
CYP19A1	O
gene	O
are	O
at	O
risk	O
for	O
AI	O
-	O
associated	O
bone	O
loss	O
and	O
deserve	O
close	O
follow	O
-	O
up	O
during	O
long	O
-	O
term	O
AI	O
therapy	O
.	O

Epigenetic	O
Mechanisms	O
of	O
Drug	O
Addiction	O
.	O

Drug	O
addiction	O
involves	O
potentially	O
life	O
-	O
long	O
behavioral	O
abnormalities	O
that	O
are	O
caused	O
in	O
vulnerable	O
individuals	O
by	O
repeated	O
exposure	O
to	O
a	O
drug	O
of	O
abuse	O
.	O

The	O
persistence	O
of	O
these	O
behavioral	O
changes	O
suggests	O
that	O
long	O
-	O
lasting	O
changes	O
in	O
gene	O
expression	O
,	O
within	O
particular	O
regions	O
of	O
the	O
brain	O
,	O
may	O
contribute	O
importantly	O
to	O
the	O
addiction	O
phenotype	O
.	O

Work	O
over	O
the	O
past	O
decade	O
has	O
demonstrated	O
a	O
crucial	O
role	O
for	O
epigenetic	O
mechanisms	O
in	O
driving	O
lasting	O
changes	O
in	O
gene	O
expression	O
in	O
diverse	O
tissues	O
,	O
including	O
brain	O
.	O

This	O
has	O
prompted	O
recent	O
research	O
aimed	O
at	O
characterizing	O
the	O
influence	O
of	O
epigenetic	O
regulatory	O
events	O
in	O
mediating	O
the	O
lasting	O
effects	O
of	O
drugs	O
of	O
abuse	O
on	O
the	O
brain	O
in	O
animal	O
models	O
of	O
drug	O
addiction	O
.	O

This	O
review	O
provides	O
a	O
progress	O
report	O
of	O
this	O
still	O
early	O
work	O
in	O
the	O
field	O
.	O

As	O
will	O
be	O
seen	O
,	O
there	O
is	O
robust	O
evidence	O
that	O
repeated	O
exposure	O
to	O
drugs	O
of	O
abuse	O
induces	O
changes	O
within	O
the	O
brain	O
's	O
reward	O
regions	O
in	O
three	O
major	O
modes	O
of	O
epigenetic	O
regulation	O
-	O
histone	O
modifications	O
such	O
as	O
acetylation	O
and	O
methylation	O
,	O
DNA	O
methylation	O
,	O
and	O
non	O
-	O
coding	O
RNAs	O
.	O

In	O
several	O
instances	O
,	O
it	O
has	O
been	O
possible	O
to	O
demonstrate	O
directly	O
the	O
contribution	O
of	O
such	O
epigenetic	O
changes	O
to	O
addiction	O
-	O
related	O
behavioral	O
abnormalities	O
.	O

Studies	O
of	O
epigenetic	O
mechanisms	O
of	O
addiction	O
are	O
also	O
providing	O
an	O
unprecedented	O
view	O
of	O
the	O
range	O
of	O
genes	O
and	O
non	O
-	O
genic	O
regions	O
that	O
are	O
affected	O
by	O
repeated	O
drug	O
exposure	O
and	O
the	O
precise	O
molecular	O
basis	O
of	O
that	O
regulation	O
.	O

Work	O
is	O
now	O
needed	O
to	O
validate	O
key	O
aspects	O
of	O
this	O
work	O
in	O
human	O
addiction	O
and	O
evaluate	O
the	O
possibility	O
of	O
mining	O
this	O
information	O
to	O
develop	O
new	O
diagnostic	O
tests	O
and	O
more	O
effective	O
treatments	O
for	O
addiction	O
syndromes	O
.	O

A	O
new	O
perspective	O
on	O
muscarinic	O
receptor	O
antagonism	O
in	O
obstructive	O
airways	O
diseases	O
.	O

Acetylcholine	B
has	O
traditionally	O
only	O
been	O
regarded	O
as	O
a	O
neurotransmitter	O
of	O
the	O
parasympathetic	O
nervous	O
system	O
,	O
causing	O
bronchoconstriction	O
and	O
mucus	O
secretion	O
in	O
asthma	O
and	O
COPD	O
by	O
muscarinic	O
receptor	O
activation	O
on	O
airway	O
smooth	O
muscle	O
and	O
mucus	O
-	O
producing	O
cells	O
.	O

Recent	O
studies	O
in	O
experimental	O
models	O
indicate	O
that	O
muscarinic	O
receptor	O
stimulation	O
in	O
the	O
airways	O
also	O
induces	O
pro	O
-	O
inflammatory	O
,	O
pro	O
-	O
proliferative	O
and	O
pro	O
-	O
fibrotic	O
effects	O
,	O
which	O
may	O
involve	O
activation	O
of	O
airway	O
structural	O
and	O
inflammatory	O
cells	O
by	O
neuronal	O
as	O
well	O
as	O
non	O
-	O
neuronal	O
acetylcholine	B
.	O

In	O
addition	O
,	O
mechanical	O
changes	O
caused	O
by	O
muscarinic	O
agonist	O
-	O
induced	O
bronchoconstriction	O
may	O
be	O
involved	O
in	O
airway	O
remodeling	O
.	O

Crosstalk	O
between	O
muscarinic	O
receptors	O
and	O
2-adrenoceptors	O
on	O
airway	O
smooth	O
muscle	O
causes	O
a	O
reduced	O
bronchodilator	O
response	O
to	O
2-agonists	O
,	O
and	O
a	O
similar	O
mechanism	O
could	O
possibly	O
apply	O
to	O
the	O
poor	O
inhibition	O
of	O
inflammatory	O
and	O
remodeling	O
processes	O
by	O
these	O
drugs	O
.	O

Collectively	O
,	O
these	O
findings	O
provide	O
novel	O
perspectives	O
for	O
muscarinic	O
receptor	O
antagonists	O
in	O
asthma	O
and	O
COPD	O
,	O
since	O
these	O
drugs	O
may	O
not	O
only	O
acutely	O
affect	O
cholinergic	O
airways	O
obstruction	O
,	O
but	O
also	O
have	O
important	O
beneficial	O
effects	O
on	O
2-agonist	O
responsiveness	O
,	O
airway	O
inflammation	O
and	O
remodeling	O
.	O

The	O
clinical	O
relevance	O
of	O
these	O
findings	O
is	O
presently	O
under	O
investigation	O
and	O
starting	O
to	O
emerge	O
.	O

Enhanced	O
excitability	O
in	O
the	O
infralimbic	O
cortex	O
produces	O
anxiety	O
-	O
like	O
behaviors	O
.	O

The	O
medial	O
prefrontal	O
cortex	O
(	O
mPFC	O
)	O
has	O
been	O
implicated	O
in	O
modulating	O
anxiety	O
.	O

However	O
,	O
it	O
is	O
unknown	O
whether	O
excitatory	O
or	O
inhibitory	O
neurotransmission	O
in	O
the	O
infralimbic	O
(	O
IL	O
)	O
subregion	O
of	O
the	O
mPFC	O
underlies	O
the	O
pathology	O
of	O
anxiety	O
-	O
related	O
behavior	O
.	O

To	O
address	O
this	O
issue	O
,	O
we	O
infused	O
the	O
GABAA	O
receptor	O
(	O
GABAAR	O
)	O
antagonist	O
bicuculline	B
to	O
temporarily	O
activate	O
the	O
IL	O
cortex	O
.	O

IL	O
cortex	O
activation	O
decreased	O
the	O
time	O
spent	O
in	O
the	O
center	O
area	O
in	O
the	O
open	O
field	O
test	O
,	O
decreased	O
exploration	O
of	O
the	O
open	O
-	O
arms	O
in	O
the	O
elevated	O
plus	O
maze	O
test	O
,	O
and	O
increased	O
the	O
latency	O
to	O
bite	O
food	O
in	O
the	O
novelty	O
-	O
suppressed	O
feeding	O
test	O
.	O

These	O
findings	O
substantiate	O
the	O
GABAergic	B
system	O
's	O
role	O
in	O
anxiety	O
-	O
related	O
behaviors	O
.	O

IL	O
cortex	O
inactivation	O
with	O
the	O
AMPA	B
receptor	O
(	O
AMPAR	O
)	O
antagonist	O
CNQX	O
produced	O
opposite	O
,	O
anxiolytic	O
effects	O
.	O

However	O
,	O
infusion	O
of	O
the	O
NMDA	B
receptor	O
(	O
NMDAR	O
)	O
antagonist	O
AP5	O
into	O
the	O
IL	O
cortex	O
had	O
no	O
significant	O
effect	O
.	O

Additionally	O
,	O
we	O
did	O
not	O
observe	O
motor	O
activity	O
deficits	O
or	O
appetite	O
deficits	O
following	O
inhibition	O
of	O
GABAergic	B
or	O
glutamatergic	O
neurotransmission	O
.	O

Interestingly	O
,	O
we	O
found	O
parallel	O
and	O
corresponding	O
electrophysiological	O
changes	O
in	O
anxious	O
mice	O
;	O
compared	O
to	O
mice	O
with	O
relatively	O
low	O
anxiety	O
,	O
the	O
relatively	O
high	O
anxiety	O
mice	O
exhibited	O
smaller	O
evoked	O
inhibitory	O
postsynaptic	O
currents	O
(	O
eIPSCs	O
)	O
and	O
larger	O
AMPA	B
-	O
mediated	O
evoked	O
excitatory	O
postsynaptic	O
currents	O
(	O
eEPSCs	O
)	O
in	O
pyramidal	O
neurons	O
in	O
the	O
IL	O
cortex	O
.	O

The	O
changes	O
of	O
eIPSCs	O
and	O
eEPSCs	O
were	O
due	O
to	O
presynaptic	O
mechanisms	O
.	O

Our	O
results	O
suggest	O
that	O
imbalances	O
of	O
neurotransmission	O
in	O
the	O
IL	O
cortex	O
may	O
cause	O
a	O
net	O
increase	O
in	O
excitatory	O
inputs	O
onto	O
pyramidal	O
neurons	O
,	O
which	O
may	O
underlie	O
the	O
pathogenic	O
mechanism	O
of	O
anxiety	O
disorders	O
.	O

Haloperidol	B
promotes	O
mTORC1-dependent	O
phosphorylation	O
of	O
ribosomal	O
protein	O
S6	O
via	O
dopamine-	B
and	O
cAMP	B
-	O
regulated	O
phosphoprotein	O
of	O
32	O
kDa	O
and	O
inhibition	O
of	O
protein	O
phosphatase-1	O
.	O

The	O
ribosomal	O
protein	O
S6	O
(	O
rpS6	O
)	O
is	O
a	O
component	O
of	O
the	O
small	O
40S	O
ribosomal	O
subunit	O
,	O
involved	O
in	O
multiple	O
physiological	O
functions	O
.	O

Here	O
,	O
we	O
examined	O
the	O
effects	O
produced	O
by	O
haloperidol	B
,	O
a	O
typical	O
antipsychotic	O
drug	O
,	O
on	O
the	O
phosphorylation	O
of	O
rpS6	O
at	O
Ser240	B
/	O
244	O
in	O
the	O
striatum	O
,	O
a	O
brain	O
region	O
involved	O
in	O
neurodegenerative	O
and	O
neuropsychiatric	O
disorders	O
.	O

Administration	O
of	O
haloperidol	B
increased	O
Ser240	B
/	O
244	O
phosphorylation	O
in	O
a	O
subpopulation	O
of	O
GABA	B
-	O
ergic	O
medium	O
spiny	O
neurons	O
(	O
MSNs	O
)	O
,	O
which	O
express	O
dopamine	B
D2	O
receptors	O
(	O
D2Rs	O
)	O
.	O

This	O
effect	O
was	O
prevented	O
by	O
rapamycin	B
,	O
an	O
inhibitor	O
of	O
the	O
mammalian	O
target	O
of	O
rapamycin	B
complex	O
1	O
(	O
mTORC1	O
)	O
,	O
or	O
by	O
PF470867	B
,	O
a	O
selective	O
inhibitor	O
of	O
the	O
p70	O
ribosomal	O
S6	O
kinase	O
1	O
(	O
S6K1	O
)	O
.	O

We	O
also	O
found	O
that	O
the	O
effect	O
of	O
haloperidol	B
on	O
Ser240	B
/	O
244	O
phosphorylation	O
was	O
prevented	O
by	O
functional	O
inactivation	O
of	O
dopamine-	B
and	O
cAMP	B
-	O
regulated	O
phosphoprotein	O
of	O
32	O
kDa	O
(	O
DARPP-32	O
)	O
,	O
an	O
endogenous	O
inhibitor	O
of	O
protein	O
phosphatase-1	O
(	O
PP-1	O
)	O
.	O

In	O
line	O
with	O
this	O
observation	O
,	O
incubation	O
of	O
striatal	O
slices	O
with	O
okadaic	B
acid	I
and	O
calyculin	B
A	I
,	O
two	O
inhibitors	O
of	O
PP-1	O
,	O
increased	O
Ser240	B
/	O
244	O
phosphorylation	O
.	O

These	O
results	O
show	O
that	O
haloperidol	B
promotes	O
mTORC1-	O
and	O
S6K1-dependent	O
phosphorylation	O
of	O
rpS6	O
at	O
Ser240	B
/	O
244	O
,	O
in	O
a	O
subpopulation	O
of	O
striatal	O
MSNs	O
expressing	O
D2Rs	O
.	O

They	O
also	O
indicate	O
that	O
this	O
effect	O
is	O
exerted	O
by	O
suppressing	O
dephosphorylation	O
at	O
Ser240	B
/	O
244	O
,	O
through	O
PKA	O
-	O
dependent	O
activation	O
of	O
DARPP-32	O
and	O
inhibition	O
of	O
PP-1	O
.	O

Arylpiperazine	B
-	O
mediated	O
activation	O
of	O
Akt	O
protects	O
SH	O
-	O
SY5Y	O
neuroblastoma	O
cells	O
from	O
6-hydroxydopamine	B
-	O
induced	O
apoptotic	O
and	O
autophagic	O
death	O
.	O

We	O
investigated	O
the	O
ability	O
of	O
19	O
recently	O
synthesized	O
arylpiperazine	B
compounds	O
to	O
protect	O
human	O
SH	O
-	O
SY5Y	O
neuroblastoma	O
cells	O
from	O
the	O
neurotoxin	O
6-hydroxydopamine	B
(	O
6-OHDA	B
)	O
.	O

The	O
compound	O
with	O
the	O
most	O
potent	O
neuroprotective	O
action	O
was	O
N-	B
{	I
3-	I
[	I
2-	I
(	I
4-phenyl	I
-	I
piperazin-1-yl	I
)	I
-ethyl	I
]	I
-phenyl	I
}	I
-picolinamide	I
(	O
6b	O
)	O
,	O
which	O
reduced	O
6-OHDA	B
-	O
induced	O
apoptotic	O
death	O
through	O
stabilization	O
of	O
mitochondrial	O
membrane	O
and	O
subsequent	O
prevention	O
of	O
superoxide	B
production	O
,	O
caspase	O
activation	O
and	O
DNA	O
fragmentation	O
.	O

6-OHDA	B
-	O
triggered	O
autophagic	O
response	O
was	O
also	O
reduced	O
by	O
6b	O
,	O
which	O
prevented	O
inactivation	O
of	O
the	O
main	O
autophagy	O
repressor	O
mTOR	O
,	O
upregulation	O
of	O
pro	O
-	O
autophagic	O
beclin-1	O
,	O
conversion	O
of	O
microtubule	O
-	O
associated	O
protein	O
1	O
light	O
chain	O
3	O
(	O
LC3	O
)	O
-I	O
to	O
autophagosome	O
-	O
associated	O
LC3-II	O
,	O
as	O
well	O
as	O
intracytoplasmic	O
acidification	O
induced	O
by	O
6-OHDA	B
.	O

The	O
inhibition	O
of	O
autophagy	O
using	O
LC3	O
gene	O
silencing	O
or	O
pharmacological	O
autophagy	O
blockers	O
3-methyladenine	B
or	O
bafilomycin	B
A1	I
,	O
mimicked	O
the	O
cytoprotective	O
effect	O
of	O
6b	O
.	O

While	O
the	O
treatment	O
with	O
6b	O
had	O
no	O
effect	O
on	O
the	O
phosphorylation	O
of	O
proapoptotic	O
MAP	O
kinases	O
ERK	O
and	O
JNK	O
,	O
it	O
markedly	O
increased	O
the	O
phosphorylation	O
of	O
the	O
prosurvival	O
kinase	O
Akt	O
in	O
6-OHDA	B
-	O
treated	O
cells	O
.	O

Akt	O
inhibitor	O
DEBC	O
or	O
RNA	O
interference	O
-	O
mediated	O
Akt	O
silencing	O
reduced	O
the	O
ability	O
of	O
6b	O
to	O
block	O
6-OHDA	B
-	O
triggered	O
apoptotic	O
and	O
autophagic	O
responses	O
,	O
thus	O
confirming	O
their	O
dependency	O
on	O
Akt	O
activation	O
.	O

The	O
cytoprotective	O
effect	O
of	O
6b	O
was	O
also	O
observed	O
in	O
6-OHDA	B
-	O
treated	O
neuronal	O
PC12	O
cells	O
,	O
but	O
not	O
in	O
SH	O
-	O
SY5Y	O
or	O
PC12	O
cells	O
exposed	O
to	O
1-methyl-4-phenylpyridinium	B
,	O
indicating	O
that	O
the	O
observed	O
neuroprotection	O
was	O
dependent	O
on	O
the	O
cytotoxic	O
stimulus	O
.	O

Because	O
of	O
the	O
ability	O
to	O
prevent	O
6-OHDA	B
induced	O
apoptotic	O
/	O
autophagic	O
cell	O
death	O
through	O
activation	O
of	O
Akt	O
,	O
the	O
investigated	O
arylpiperazines	B
could	O
be	O
potential	O
candidates	O
for	O
treatment	O
of	O
neurodegenerative	O
diseases	O
.	O

The	O
fatty	B
acid	I
amide	I
hydrolase	O
inhibitor	O
,	O
URB597	B
,	O
promotes	O
retinal	B
ganglion	O
cell	O
neuroprotection	O
in	O
a	O
rat	O
model	O
of	O
optic	O
nerve	O
axotomy	O
.	O

The	O
endocannabinoid	O
,	O
N	B
-	I
arachidonoylethanolamine	I
(	O
AEA	B
)	O
,	O
is	O
degraded	O
by	O
the	O
enzyme	O
fatty	B
acid	I
amide	I
hydrolase	O
(	O
FAAH	O
)	O
.	O

This	O
study	O
examined	O
whether	O
the	O
FAAH	O
inhibitor	O
,	O
URB597	O
,	O
increases	O
retinal	B
ganglion	O
cell	O
(	O
RGC	O
)	O
survival	O
following	O
optic	O
nerve	O
axotomy	O
in	O
young	O
and	O
aged	O
animals	O
.	O

URB597	B
alone	O
,	O
or	O
together	O
with	O
either	O
a	O
CB1	O
or	O
CB2	O
receptor	O
antagonist	O
,	O
was	O
administered	O
daily	O
for	O
1	O
or	O
2	O
weeks	O
post	O
-	O
axotomy	O
.	O

Histological	O
assessment	O
of	O
retinas	O
indicated	O
that	O
URB597	B
increased	O
RGC	O
survival	O
in	O
young	O
retina	O
at	O
1	O
and	O
2	O
weeks	O
post	O
-	O
axotomy	O
.	O

The	O
increase	O
in	O
RGC	O
survival	O
at	O
2	O
weeks	O
was	O
accompanied	O
by	O
a	O
reduction	O
in	O
phagocytic	O
microglia	O
.	O

The	O
CB1	O
antagonist	O
,	O
AM281	B
,	O
but	O
not	O
the	O
CB2	O
antagonist	O
,	O
AM630	B
,	O
ablated	O
URB597-mediated	B
RGC	O
neuroprotection	O
.	O

CB1	O
or	O
CB2	O
antagonism	O
increased	O
phagocytic	O
microglia	O
in	O
URB597	B
and	O
vehicle	O
-	O
treated	O
animals	O
.	O

In	O
aged	O
animals	O
,	O
URB597	B
increased	O
RGC	O
survival	O
at	O
1	O
week	O
,	O
but	O
not	O
at	O
2	O
weeks	O
post	O
-	O
axotomy	O
and	O
had	O
no	O
effect	O
on	O
microglia	O
.	O

Retinal	B
Iba-1	O
positive	O
microglia	O
were	O
also	O
decreased	O
in	O
URB597-treated	B
axotomized	O
young	O
animals	O
and	O
this	O
decrease	O
was	O
mitigated	O
by	O
CB1	O
but	O
not	O
CB2	O
antagonism	O
.	O

As	O
seen	O
with	O
phagocytotic	O
microglia	O
,	O
the	O
CB2	O
antagonist	O
,	O
AM630	B
,	O
increased	O
Iba-1	O
positive	O
microglia	O
in	O
the	O
absence	O
of	O
URB597	B
treatment	O
.	O

Measurement	O
of	O
retinal	B
endocannabinoid	O
levels	O
in	O
URB597-treated	B
animals	O
at	O
2	O
weeks	O
post	O
-	O
axotomy	O
revealed	O
a	O
significant	O
increase	O
in	O
AEA	B
levels	O
,	O
accompanied	O
by	O
a	O
decrease	O
by	O
a	O
decrease	O
in	O
the	O
AEA	B
metabolite	O
,	O
N	B
-	I
arachidonoylglycine	I
,	O
in	O
young	O
animals	O
but	O
not	O
aged	O
animals	O
.	O

2-arachidonoylglycerol	B
levels	O
were	O
similar	O
across	O
all	O
experimental	O
groups	O
.	O

These	O
data	O
demonstrate	O
that	O
URB597-mediated	B
retinal	B
neuroprotective	O
effects	O
are	O
mediated	O
primarily	O
through	O
CB1	O
receptors	O
and	O
that	O
URB597	B
neuroprotective	O
efficacy	O
declines	O
with	O
age	O
.	O

Differential	O
Effects	O
of	O
Cholinergic	O
and	O
Noradrenergic	O
Neuromodulation	O
on	O
Spontaneous	O
Cortical	O
Network	O
Dynamics	O
.	O

Cholinergic	O
and	O
noradrenergic	O
neuromodulation	O
play	O
a	O
key	O
role	O
in	O
determining	O
overall	O
behavioral	O
state	O
by	O
shaping	O
the	O
underlying	O
cortical	O
network	O
dynamics	O
.	O

The	O
effects	O
of	O
these	O
systems	O
on	O
synaptic	O
and	O
intrinsic	O
cellular	O
targets	O
are	O
quite	O
diverse	O
and	O
a	O
comprehensive	O
understanding	O
of	O
how	O
these	O
neuromodulators	O
regulate	O
(	O
spontaneous	O
)	O
cortical	O
network	O
activity	O
has	O
remained	O
elusive	O
.	O

Here	O
,	O
we	O
used	O
multielectrode	O
electrophysiology	O
in	O
vitro	O
to	O
investigate	O
the	O
effect	O
of	O
these	O
neuromodulators	O
on	O
spontaneous	O
network	O
dynamics	O
in	O
acute	O
slices	O
of	O
mouse	O
visual	O
cortex	O
.	O

We	O
found	O
that	O
application	O
of	O
Carbachol	B
(	O
CCh	B
)	O
and	O
Norepinephrine	B
(	O
NE	O
)	O
both	O
enhanced	O
the	O
spontaneous	O
network	O
dynamics	O
by	O
increasing	O
(	O
1	O
)	O
the	O
activity	O
levels	O
,	O
(	O
2	O
)	O
the	O
temporal	O
complexity	O
of	O
the	O
network	O
activity	O
,	O
and	O
(	O
3	O
)	O
the	O
spatial	O
complexity	O
by	O
decorrelating	O
the	O
network	O
activity	O
over	O
a	O
wide	O
range	O
of	O
neuromodulator	O
concentrations	O
(	O
1M	O
,	O
10M	O
,	O
50M	O
,	O
and	O
100M	O
)	O
.	O

Interestingly	O
,	O
we	O
found	O
that	O
cholinergic	O
neuromodulation	O
was	O
limited	O
to	O
the	O
presence	O
of	O
CCh	B
in	O
the	O
bath	O
whereas	O
the	O
effects	O
of	O
NE	O
,	O
in	O
particular	O
for	O
higher	O
concentrations	O
,	O
induced	O
plasticity	O
that	O
caused	O
outlasting	O
effects	O
most	O
prominently	O
in	O
the	O
deep	O
cortical	O
layers	O
.	O

Together	O
,	O
these	O
results	O
provide	O
a	O
comprehensive	O
network	O
-	O
level	O
understanding	O
of	O
the	O
similarities	O
and	O
differences	O
of	O
cholinergic	O
and	O
noradrenergic	O
modulation	O
of	O
spontaneous	O
network	O
dynamics	O
.	O

Assessment	O
of	O
subjective	O
cognitive	O
and	O
emotional	O
effects	O
of	O
antipsychotic	O
drugs	O
.	O

Effect	O
by	O
defect	O
?	O

Antipsychotic	O
medication	O
represents	O
the	O
first	O
-	O
line	O
treatment	O
of	O
schizophrenia	O
.	O

While	O
it	O
is	O
undisputed	O
that	O
antipsychotics	O
ameliorate	O
positive	O
symptoms	O
,	O
the	O
exact	O
cognitive	O
and	O
emotional	O
pathways	O
through	O
which	O
its	O
effect	O
is	O
exerted	O
has	O
remained	O
unclear	O
.	O

The	O
present	O
study	O
investigated	O
the	O
subjective	O
effects	O
of	O
antipsychotics	O
across	O
various	O
domains	O
of	O
cognition	O
and	O
emotion	O
in	O
both	O
patients	O
with	O
psychotic	O
symptoms	O
and	O
patients	O
with	O
other	O
psychiatric	O
diagnoses	O
.	O

A	O
total	O
of	O
69	O
patients	O
with	O
a	O
probable	O
history	O
of	O
psychosis	O
or	O
psychotic	O
symptoms	O
and	O
26	O
patients	O
with	O
psychiatric	O
diagnoses	O
other	O
than	O
psychosis	O
participated	O
in	O
a	O
survey	O
conducted	O
over	O
the	O
Internet	O
.	O

Multiple	O
control	O
measures	O
aimed	O
to	O
secure	O
response	O
validity	O
.	O

All	O
patients	O
were	O
currently	O
or	O
had	O
previously	O
been	O
treated	O
with	O
antipsychotic	O
agents	O
.	O

A	O
questionnaire	O
comprising	O
49	O
items	O
and	O
measuring	O
possible	O
effects	O
of	O
antipsychotics	O
on	O
cognition	O
and	O
emotion	O
was	O
administered	O
.	O

For	O
30	O
out	O
of	O
49	O
items	O
a	O
clear	O
response	O
pattern	O
emerged	O
,	O
which	O
was	O
similar	O
for	O
patients	O
with	O
psychotic	O
disorders	O
and	O
patients	O
with	O
other	O
diagnoses	O
.	O

Factor	O
analysis	O
of	O
these	O
items	O
revealed	O
three	O
main	O
effects	O
of	O
antipsychotic	O
medication	O
related	O
to	O
doubt	O
and	O
self	O
-	O
doubt	O
,	O
cognitive	O
and	O
emotional	O
numbing	O
,	O
and	O
social	O
withdrawal	O
.	O

Antipsychotic	O
treatment	O
appears	O
to	O
be	O
connected	O
to	O
a	O
number	O
of	O
negative	O
subjective	O
effects	O
on	O
cognition	O
and	O
emotion	O
.	O

Further	O
studies	O
are	O
warranted	O
to	O
assess	O
how	O
these	O
effects	O
impact	O
on	O
the	O
patients	O
'	O
subjective	O
well	O
-	O
being	O
and	O
quality	O
of	O
life	O
,	O
as	O
well	O
as	O
their	O
association	O
with	O
antipsychotic	O
efficacy	O
on	O
the	O
one	O
hand	O
,	O
and	O
adherence	O
rates	O
on	O
the	O
other	O
.	O

The	O
induction	O
of	O
doubt	O
and	O
the	O
dampening	O
of	O
emotion	O
may	O
be	O
one	O
reason	O
why	O
antipsychotics	O
work	O
and	O
at	O
the	O
same	O
time	O
offer	O
an	O
explanation	O
why	O
they	O
are	O
experienced	O
as	O
rather	O
unpleasant	O
and	O
are	O
eventually	O
discontinued	O
by	O
many	O
patients	O
.	O

Controlling	O
the	O
Physical	O
form	O
of	O
Mannitol	B
in	O
Freeze	O
-	O
Dried	O
Systems	O
.	O

A	O
potential	O
drawback	O
with	O
the	O
use	O
of	O
mannitol	B
as	O
a	O
bulking	O
agent	O
is	O
its	O
existence	O
as	O
mannitol	B
hemihydrate	I
(	O
MHH	B
;	O
C6H14O6	B
(	I
.	I
)	I
0.5H2O	I
)	O
in	O
the	O
lyophile	O
.	O

Once	O
formed	O
during	O
freeze	O
-	O
drying	O
,	O
MHH	B
dehydration	O
may	O
require	O
secondary	O
drying	O
under	O
aggressive	O
conditions	O
which	O
can	O
be	O
detrimental	O
to	O
the	O
stability	O
of	O
thermolabile	O
components	O
.	O

If	O
MHH	B
is	O
retained	O
in	O
the	O
lyophile	O
,	O
the	O
water	O
released	O
by	O
MHH	B
dehydration	O
during	O
storage	O
has	O
the	O
potential	O
to	O
cause	O
product	O
instability	O
.	O

We	O
systematically	O
identified	O
the	O
conditions	O
under	O
which	O
anhydrous	O
mannitol	B
and	O
MHH	B
crystallized	O
in	O
frozen	O
systems	O
with	O
the	O
goal	O
of	O
preventing	O
MHH	B
formation	O
during	O
freeze	O
-	O
drying	O
.	O

When	O
mannitol	B
solutions	O
were	O
cooled	O
,	O
the	O
temperature	O
of	O
solute	O
crystallization	O
was	O
the	O
determinant	O
of	O
the	O
physical	O
form	O
of	O
mannitol	B
.	O

Based	O
on	O
low	O
temperature	O
X	O
-	O
ray	O
diffractometry	O
(	O
using	O
both	O
laboratory	O
and	O
synchrotron	O
sources	O
)	O
,	O
MHH	B
formation	O
was	O
observed	O
when	O
solute	O
crystallization	O
occurred	O
at	O
temperatures	O
	O
-20	O
	O
C	O
while	O
anhydrous	O
mannitol	B
crystallized	O
at	O
temperatures	O
	O
-10	O
	O
C	O
.	O

The	O
transition	O
temperature	O
(	O
anhydrate	O
-	O
MHH	B
)	O
appears	O
to	O
be	O
	O
-15	O
	O
C	O
.	O

The	O
use	O
of	O
a	O
freeze	O
-	O
dryer	O
with	O
controlled	O
ice	O
nucleation	O
technology	O
enabled	O
anhydrous	O
mannitol	B
crystallization	O
at	O
	O
-5	O
	O
C	O
.	O

Thus	O
,	O
ice	O
crystallization	O
followed	O
by	O
annealing	O
at	O
temperatures	O
	O
-10	O
	O
C	O
can	O
be	O
an	O
effective	O
strategy	O
to	O
prevent	O
MHH	B
formation	O
.	O

Investigation	O
on	O
the	O
interaction	O
of	O
the	O
toxicant	O
,	O
gentian	B
violet	I
,	O
with	O
bovine	O
hemoglobin	O
.	O

Gentian	B
violet	I
(	O
GV	O
)	O
is	O
a	O
well	O
-	O
known	O
triarylmethane	B
dye	O
that	O
is	O
used	O
in	O
aquacultural	O
,	O
industrial	O
and	O
medicinal	O
fields	O
.	O

But	O
concerns	O
in	O
growing	O
number	O
have	O
been	O
paid	O
to	O
its	O
potential	O
health	O
problems	O
to	O
human	O
beings	O
and	O
its	O
hazardous	O
effects	O
to	O
environment	O
.	O

Herein	O
,	O
the	O
toxic	O
interaction	O
of	O
GV	O
with	O
bovine	O
hemoglobin	O
(	O
BHb	O
)	O
was	O
investigated	O
by	O
a	O
series	O
of	O
spectroscopic	O
methods	O
and	O
molecular	O
modeling	O
method	O
.	O

The	O
fluorescence	O
emission	O
profile	O
exhibited	O
a	O
remarkable	O
quenching	O
upon	O
addition	O
of	O
GV	O
to	O
the	O
buffered	O
aqueous	O
solution	O
of	O
BHb	O
and	O
the	O
analysis	O
of	O
results	O
revealed	O
the	O
dominant	O
role	O
of	O
static	O
quenching	O
mechanism	O
in	O
GV	O
-	O
BHb	O
interaction	O
.	O

The	O
negative	O
H	O
and	O
positive	O
S	O
values	O
demonstrated	O
that	O
the	O
electrostatic	O
interactions	O
mainly	O
stabilized	O
this	O
toxicant	O
-	O
protein	O
complex	O
.	O

Synchronous	O
fluorescence	O
,	O
UV	O
-	O
vis	O
absorption	O
and	O
CD	O
spectroscopic	O
studies	O
proved	O
that	O
the	O
conformational	O
change	O
of	O
BHb	O
was	O
induced	O
by	O
GV	O
's	O
combination	O
.	O

Molecular	O
modeling	O
studies	O
exhibited	O
the	O
binding	O
mode	O
of	O
GV	O
-	O
BHb	O
complex	O
and	O
the	O
detailed	O
information	O
of	O
related	O
driving	O
forces	O
.	O

During	O
the	O
1H	B
nuclear	O
magnetic	O
resonance	O
spectra	O
(	O
1H	B
NMR	O
)	O
study	O
,	O
the	O
chemical	O
shift	O
perturbation	O
and	O
spin	O
-	O
lattice	O
relaxation	O
times	O
of	O
different	O
protons	O
were	O
further	O
used	O
to	O
investigate	O
the	O
interaction	O
of	O
GV	O
with	O
BHb	O
and	O
the	O
results	O
indicated	O
that	O
GV	O
bound	O
orientationally	O
to	O
BHb	O
.	O

Design	O
,	O
synthesis	O
and	O
antiproliferative	O
activity	O
studies	O
of	O
novel	O
1,2,3-triazole	B
-	I
dithiocarbamate	I
-	I
urea	I
hybrids	O
.	O

A	O
series	O
of	O
novel	O
1,2,3-triazole	B
-	I
dithiocarbamate	I
-	I
urea	I
hybrids	O
were	O
designed	O
,	O
synthesized	O
and	O
their	O
antiproliferative	O
activities	O
against	O
four	O
selected	O
human	O
cancer	O
cell	O
lines	O
were	O
evaluated	O
.	O

The	O
results	O
showed	O
that	O
a	O
number	O
of	O
the	O
hybrids	O
exhibited	O
potent	O
activity	O
in	O
selected	O
human	O
cancer	O
cell	O
lines	O
.	O

Among	O
them	O
,	O
compounds	O
27	O
and	O
34	O
showed	O
broad	O
spectrum	O
anticancer	O
activity	O
with	O
IC50	O
values	O
ranging	O
from	O
1.62	O
to	O
20.84	O
M	O
and	O
0.76	O
to	O
13.55	O
M	O
,	O
respectively	O
.	O

Interestingly	O
,	O
compounds	O
27	O
and	O
34	O
,	O
being	O
very	O
potent	O
against	O
MGC-803	O
cells	O
,	O
exhibited	O
no	O
significant	O
cytotoxicity	O
against	O
normal	O
human	O
embryonic	O
kidney	O
cells	O
at	O
up	O
to	O
55	O
M	O
and	O
70	O
M	O
,	O
respectively	O
.	O

Evidences	O
of	O
cell	O
cycle	O
arrest	O
and	O
apoptosis	O
induction	O
were	O
obtained	O
for	O
the	O
most	O
effective	O
compounds	O
27	O
and	O
34	O
by	O
means	O
of	O
flow	O
cytometry	O
and	O
microscopic	O
techniques	O
.	O

Elucidation	O
of	O
the	O
pharmacophore	O
of	O
echinocystic	B
acid	I
,	O
a	O
new	O
lead	O
for	O
blocking	O
HCV	O
entry	O
.	O

To	O
elucidate	O
the	O
pharmacophore	O
of	O
echinocystic	B
acid	I
(	O
EA	O
)	O
,	O
an	O
oleanane	B
-	O
type	O
triterpene	B
displaying	O
substantial	O
inhibitory	O
activity	O
on	O
HCV	O
entry	O
,	O
two	O
microbial	O
strains	O
,	O
Rhizopus	O
chinensis	O
CICC	O
3043	O
and	O
Alternaria	O
alternata	O
AS	O
3.4578	O
,	O
were	O
utilized	O
to	O
modify	O
the	O
chemical	O
structure	O
of	O
EA	O
.	O

Eight	O
new	O
metabolites	O
with	O
regio-	O
and	O
stereo	O
-	O
selective	O
introduction	O
of	O
hydroxyl	B
and	O
lactone	B
groups	O
at	O
various	O
inert	O
carbon	B
positions	O
were	O
obtained	O
.	O

The	O
anti	O
-	O
HCV	O
entry	O
activity	O
of	O
the	O
metabolites	O
2	O
-	O
13	O
,	O
along	O
with	O
their	O
parental	O
compound	O
EA	O
and	O
other	O
analogs	O
14	O
-	O
15	O
,	O
were	O
evaluated	O
.	O

Most	O
of	O
the	O
metabolites	O
showed	O
no	O
improvement	O
but	O
detrimental	O
effect	O
on	O
potency	O
except	O
compound	O
5	O
and	O
6	O
,	O
which	O
showed	O
similar	O
and	O
even	O
a	O
litter	O
higher	O
anti	O
-	O
HCV	O
entry	O
activity	O
than	O
that	O
of	O
EA	O
.	O

The	O
results	O
demonstrated	O
that	O
ring	O
A	O
,	O
B	O
,	O
C	O
and	O
the	O
left	O
side	O
of	O
ring	O
E	O
of	O
EA	O
are	O
highly	O
conserved	O
,	O
while	O
ring	O
D	O
and	O
the	O
right	O
side	O
of	O
ring	O
E	O
of	O
EA	O
are	O
flexible	O
.	O

Introduction	O
of	O
a	O
hydroxyl	B
group	O
at	O
C-16	O
enhanced	O
the	O
triterpene	B
potency	O
.	O

Further	O
analysis	O
indicated	O
that	O
the	O
hemolytic	O
effect	O
of	O
EA	O
disappeared	O
upon	O
such	O
modifications	O
.	O

Ligand	O
-	O
based	O
design	O
,	O
synthesis	O
,	O
and	O
experimental	O
evaluation	O
of	O
novel	O
benzofuroxan	B
derivatives	O
as	O
anti	O
-	O
Trypanosoma	O
cruzi	O
agents	O
.	O

A	O
set	O
of	O
substituted-	O
[	O
N'-	B
(	I
benzofuroxan-5-yl	I
)	I
methylene	I
]	I
benzohydrazides	I
(	O
4a	O
-	O
t	O
)	O
,	O
previously	O
designed	O
and	O
synthesized	O
,	O
was	O
experimentally	O
assayed	O
against	O
Trypanosoma	O
cruzi	O
,	O
the	O
etiological	O
agent	O
of	O
Chagas	O
'	O
disease	O
,	O
one	O
of	O
the	O
most	O
neglected	O
tropical	O
diseases	O
.	O

Exploratory	O
data	O
analysis	O
,	O
Hansch	O
approach	O
and	O
VolSurf	O
formalism	O
were	O
applied	O
to	O
aid	O
the	O
ligand	O
-	O
based	O
design	O
of	O
novel	O
anti	O
-	O
T.	O
cruzi	O
agents	O
.	O

The	O
best	O
2D	O
-	O
QSAR	O
model	O
showed	O
suitable	O
statistical	O
measures	O
[	O
n	O
=	O
18	O
;	O
s	O
=	O
0.11	O
;	O
F	O
=	O
42.19	O
;	O
R	O
(	O
2	O
)	O
=	O
0.90	O
and	O
Q	O
(	O
2	O
)	O
=	O
0.77	O
(	O
SDEP	O
=	O
0.15	O
)	O
]	O
,	O
and	O
according	O
to	O
the	O
optimum	O
3D	O
-	O
QSAR	O
model	O
[	O
R	O
(	O
2	O
)	O
=	O
0.98	O
,	O
Q	O
(	O
2	O
)	O
=	O
0.93	O
(	O
SDEP	O
=	O
0.08	O
)	O
]	O
,	O
three	O
latent	O
variables	O
explained	O
62	O
%	O
of	O
the	O
total	O
variance	O
from	O
original	O
data	O
.	O

Steric	O
and	O
hydrophobic	O
properties	O
were	O
pointed	O
out	O
as	O
the	O
key	O
for	O
biological	O
activity	O
.	O

Based	O
upon	O
the	O
findings	O
,	O
six	O
novel	O
benzofuroxan	B
derivatives	O
(	O
4u	O
-	O
z	O
)	O
were	O
designed	O
,	O
synthesized	O
,	O
and	O
in	O
vitro	O
assayed	O
to	O
perform	O
the	O
QSAR	O
external	O
prediction	O
.	O

Then	O
,	O
the	O
predictability	O
for	O
the	O
both	O
models	O
,	O
2D	O
-	O
QSAR	O
(	O
Rpred	O
(	O
2	O
)	O
=	O
0.91	O
)	O
and	O
3D	O
-	O
QSAR	O
(	O
Rpred	O
(	O
2	O
)	O
=	O
0.77	O
)	O
,	O
was	O
experimentally	O
validated	O
,	O
and	O
compound	O
4u	O
was	O
identified	O
as	O
the	O
most	O
active	O
anti	O
-	O
T.	O
cruzi	O
hit	O
(	O
IC50	O
=	O
3.04	O
M	O
)	O
.	O

N	B
-	I
Alkylated	I
2,3,3-trimethylindolenines	I
and	O
2-methylbenzothiazoles	B
.	O

Potential	O
lead	O
compounds	O
in	O
the	O
fight	O
against	O
Saccharomyces	O
cerevisiae	O
infections	O
.	O

The	O
synthesis	O
of	O
a	O
variety	O
of	O
N	B
-	I
alkylated	I
2,3,3-trimethylindolenines	I
and	O
2-methylbenzothiazoles	B
is	O
reported	O
herein	O
.	O

Their	O
potential	O
as	O
antifungal	O
agents	O
is	O
evaluated	O
by	O
preliminary	O
screening	O
against	O
Saccharomyces	O
cerevisiae	O
(	O
S.	O
cerevisiae	O
)	O
,	O
Schizosaccharomyces	O
pombe	O
(	O
S.	O
pombe	O
)	O
,	O
and	O
Candida	O
albicans	O
(	O
C.	O
albicans	O
)	O
.	O

Statistical	O
analyses	O
illustrate	O
a	O
strong	O
relationship	O
between	O
chain	O
length	O
and	O
growth	O
inhibition	O
for	O
S.	O
cerevisiae	O
and	O
S.	O
pombe	O
(	O
p	O
<	O
0.0001	O
in	O
every	O
case	O
)	O
.	O

Of	O
particular	O
interest	O
is	O
the	O
activity	O
of	O
both	O
sets	O
of	O
compounds	O
against	O
S.	O
cerevisiae	O
,	O
as	O
this	O
is	O
emerging	O
as	O
an	O
opportunistic	O
pathogen	O
,	O
especially	O
in	O
immunosuppressed	O
and	O
immunocompromised	O
patients	O
.	O

Bioassays	O
were	O
set	O
up	O
to	O
compare	O
the	O
efficacy	O
of	O
our	O
range	O
of	O
N	O
-	O
alkylated	O
compounds	O
against	O
classic	O
antifungal	O
agents	O
;	O
Amphotericin	B
B	I
and	O
Thiabendazole	B
.	O

Synthesis	O
and	O
biological	O
characterization	O
of	O
spiro	B
[	I
2H-	I
(	I
1,3	I
)	I
-benzoxazine-2,4'-piperidine	I
]	I
based	O
histone	O
deacetylase	O
inhibitors	O
.	O

Histone	O
Deacetylases	O
(	O
HDACs	O
)	O
have	O
become	O
important	O
targets	O
for	O
the	O
treatment	O
of	O
cancer	O
and	O
other	O
diseases	O
.	O

In	O
previous	O
studies	O
we	O
described	O
the	O
development	O
of	O
novel	O
spirocyclic	O
HDAC	O
inhibitors	O
based	O
on	O
the	O
combination	O
of	O
privileged	O
structures	O
with	O
hydroxamic	B
acid	I
moieties	O
as	O
zinc	B
binding	O
group	O
.	O

Herein	O
,	O
we	O
report	O
further	O
explorations	O
,	O
which	O
resulted	O
in	O
the	O
discovery	O
of	O
a	O
new	O
class	O
of	O
spiro	B
[	I
2H-	I
(	I
1,3	I
)	I
-benzoxazine-2,4'-piperidine	I
]	I
derivatives	O
.	O

Several	O
compounds	O
showed	O
good	O
potency	O
of	O
around	O
100	O
nM	O
and	O
less	O
in	O
the	O
HDAC	O
inhibition	O
assays	O
,	O
submicromolar	O
IC50	O
values	O
when	O
tested	O
against	O
tumour	O
cell	O
lines	O
and	O
a	O
remarkable	O
stability	O
in	O
human	O
and	O
mouse	O
microsomes	O
.	O

Two	O
representative	O
examples	O
exhibited	O
a	O
good	O
pharmacokinetic	O
profile	O
with	O
an	O
oral	O
bioavailability	O
equal	O
or	O
higher	O
than	O
35	O
%	O
and	O
one	O
of	O
them	O
studied	O
in	O
an	O
HCT116	O
murine	O
xenograft	O
model	O
showing	O
a	O
robust	O
tumour	O
growth	O
inhibition	O
.	O

In	O
addition	O
,	O
the	O
two	O
benzoxazines	B
were	O
found	O
to	O
have	O
a	O
minor	O
affinity	O
for	O
the	O
hERG	O
potassium	B
channel	O
compared	O
to	O
their	O
corresponding	O
ketone	B
analogues	O
.	O

Synthesis	O
and	O
in	O
vitro	O
anticancer	O
studies	O
of	O
novel	O
C-2	O
arylidene	O
congeners	O
of	O
lantadenes	B
.	O

The	O
antitumor	O
pentacyclic	O
triterpenoids	O
,	O
Lantadene	B
A	I
(	I
1	I
)	I
and	I
B	I
(	O
2	O
)	O
were	O
isolated	O
from	O
the	O
leaves	O
of	O
weed	O
Lantana	O
camara	O
L.	O
(	O
Verbenaceae	O
)	O
and	O
were	O
structurally	O
transformed	O
to	O
bioactive	O
intermediates	O
3	O
-	O
6	O
.	O

The	O
Claisen	O
-	O
Schmidt	O
reaction	O
of	O
22	B
-	I
hydroxy-3-oxoolean-12-en-28-oic	I
acid	I
(	O
5	O
)	O
with	O
requisite	O
aldehydes	B
afforded	O
2-arylidene-22	B
-	I
hydroxy-3-oxoolean-12-en-28-oic	I
acids	I
(	O
7	O
-	O
16	O
)	O
.	O

The	O
compounds	O
were	O
evaluated	O
for	O
their	O
in	O
-	O
vitro	O
anticancer	O
activity	O
by	O
National	O
Cancer	O
Institute	O
(	O
NCI	O
)	O
,	O
USA	O
and	O
some	O
of	O
these	O
compounds	O
showed	O
marked	O
cytotoxicity	O
in	O
micromolar	O
range	O
.	O

The	O
mean	O
graph	O
midpoint	O
(	O
MG_MID	O
)	O
value	O
of	O
compound	O
3	O
(	O
MG_MID	O
-5.69	O
)	O
was	O
higher	O
than	O
standard	O
drug	O
cisplatin	B
(	O
MG_MID	O
-5.66	O
)	O
while	O
comparable	O
in	O
case	O
of	O
compound	O
12	O
(	O
MG_MID	O
-5.52	O
)	O
.	O

The	O
NCI	O
's	O
COMPARE	O
molecular	O
mechanistic	O
analysis	O
showed	O
that	O
these	O
compounds	O
were	O
in	O
significant	O
correlations	O
with	O
activity	O
patterns	O
of	O
mechanistic	O
set	O
of	O
compounds	O
(	O
PCC	O
	O
0.60	O
)	O
.	O

Low	O
molecular	O
weight	O
dual	O
inhibitors	O
of	O
factor	O
Xa	O
and	O
fibrinogen	O
binding	O
to	O
GPIIb	O
/	O
IIIa	O
with	O
highly	O
overlapped	O
pharmacophores	O
.	O

Dual	O
antithrombotic	O
agents	O
acting	O
as	O
anticoagulants	O
and	O
aggregation	O
inhibitors	O
could	O
have	O
substantial	O
advantages	O
over	O
currently	O
prescribed	O
combinations	O
of	O
antithrombotic	O
drugs	O
.	O

Herein	O
,	O
we	O
report	O
compounds	O
with	O
moderate	O
inhibitory	O
activity	O
for	O
factor	O
Xa	O
and	O
fibrinogen	O
GPIIb	O
/	O
IIIa	O
binding	O
(	O
both	O
in	O
the	O
micromolar	O
range	O
)	O
.	O

These	O
compounds	O
resulted	O
from	O
our	O
efforts	O
to	O
merge	O
the	O
pharmacophores	O
of	O
selective	O
factor	O
Xa	O
inhibitor	O
rivaroxaban	B
with	O
a	O
mimic	O
of	O
the	O
Arg	B
-	I
Gly	I
-	I
Asp	I
(	O
RGD	O
)	O
sequence	O
of	O
fibrinogen	O
to	O
obtain	O
designed	O
multiple	O
ligands	O
with	O
potential	O
antithrombotic	O
activity	O
.	O

Resulting	O
from	O
this	O
study	O
,	O
a	O
structurally	O
novel	O
class	O
of	O
submicromolar	O
fibrinogen	O
GPIIb	O
/	O
IIIa	O
binding	O
inhibitor	O
bearing	O
1,2,4-oxadiazol-5	B
(	I
4H	I
)	I
-one	I
moiety	O
is	O
also	O
described	O
.	O

Synthesis	O
and	O
biological	O
evaluation	O
of	O
N-	B
(	I
4-hydroxy-3-mercaptonaphthalen-1-yl	I
)	I
amides	I
as	O
inhibitors	O
of	O
angiogenesis	O
and	O
tumor	O
growth	O
.	O

A	O
series	O
of	O
N-	B
(	I
4-hydroxy-3-mercaptonaphthalen-1-yl	I
)	I
amides	I
were	O
synthesized	O
and	O
investigated	O
for	O
their	O
in	O
vitro	O
antiangiogenic	O
activity	O
.	O

Among	O
these	O
compounds	O
,	O
6d	O
,	O
which	O
possesses	O
an	O
ortho	B
-	I
nitro	I
group	O
at	O
the	O
benzene	B
ring	O
,	O
exhibited	O
potent	O
inhibitory	O
effect	O
on	O
the	O
proliferation	O
of	O
HUVECs	O
,	O
A549	O
,	O
K562	O
,	O
PC-3	O
,	O
HCT116	O
,	O
MDA	O
-	O
MB-231	O
and	O
MCF-7	O
cells	O
(	O
IC50	O
=	O
5.34	O
,	O
40.53	O
,	O
10.81	O
,	O
52.52	O
,	O
10.19	O
,	O
21.37	O
and	O
2.81	O
M	O
,	O
respectively	O
)	O
.	O

Meanwhile	O
,	O
compound	O
6d	O
inhibited	O
in	O
vitro	O
angiogenesis	O
markedly	O
in	O
both	O
HUVECs	O
tube	O
formation	O
assay	O
and	O
the	O
rat	O
thoracic	O
aorta	O
rings	O
test	O
.	O

Further	O
kinase	O
assay	O
study	O
showed	O
that	O
compound	O
6d	O
had	O
good	O
VEGFR2	O
,	O
ALK	O
,	O
AKT1	O
and	O
ABL	O
inhibitory	O
activities	O
and	O
moderate	O
EGFR	O
and	O
PDGFR	O
-	O
	O
inhibitory	O
activities	O
.	O

The	O
data	O
supports	O
the	O
further	O
investigation	O
of	O
this	O
class	O
of	O
compounds	O
as	O
potential	O
antiangiogenic	O
and	O
anticancer	O
agents	O
.	O

Correction	O
:	O
Wiedmann	O
,	O
M.	O
,	O
et	O
al.	O
Exploration	O
of	O
the	O
Role	O
of	O
the	O
Non	O
-	O
Coding	O
RNA	O
SbrE	O
in	O
L.	O
monocytogenes	O
Stress	O
Response	O
.	O

Int	O
.	O

J.	O
Mol	O
.	O

Sci	O
.	O
2013	O
,	O
14	O
,	O
378	O
-	O
393	O
.	O

The	O
original	O
version	O
of	O
the	O
paper	O
in	O
Section	O
3.8	O
reports	O
that	O
"	O
The	O
peptide	O
mass	O
tolerance	O
and	O
fragment	O
mass	O
tolerance	O
values	O
were	O
10	O
ppm	O
and	O
30	O
mDa	O
,	O
respectively	O
"	O
[	O
1	O
]	O
(	O
p.	O
387	O
)	O
.	O

To	O
help	O
others	O
who	O
may	O
want	O
to	O
use	O
the	O
same	O
methods	O
in	O
the	O
future	O
,	O
the	O
authors	O
would	O
like	O
to	O
correct	O
the	O
wording	O
to	O
:	O
"	O
The	O
peptide	O
mass	O
tolerance	O
and	O
fragment	O
mass	O
tolerance	O
values	O
were	O
30	O
ppm	O
and	O
0.15	O
Da	O
,	O
respectively	O
.	O

In	O
order	O
to	O
decrease	O
the	O
probability	O
of	O
false	O
peptide	O
identification	O
,	O
only	O
peptides	O
with	O
significance	O
scores	O
above	O
the	O
identity	O
threshold	O
(	O
at	O
the	O
95	O
%	O
confidence	O
interval	O
)	O
,	O
defined	O
by	O
Mascot	O
probability	O
analysis	O
(	O
www.matrixscience.com/help/scoring_help.html#PBM	O
)	O
,	O
were	O
considered	O
to	O
be	O
confidently	O
identified	O
and	O
used	O
for	O
protein	O
identification	O
.	O

Furthermore	O
,	O
only	O
proteins	O
identified	O
in	O
all	O
four	O
iTRAQ	O
samples	O
through	O
at	O
least	O
two	O
peptides	O
with	O
a	O
p	O
-	O
value	O
of	O
<	O
0.05	O
(	O
expectation	O
value	O
)	O
were	O
further	O
analyzed	O
"	O
.	O

The	O
authors	O
would	O
like	O
to	O
apologize	O
for	O
any	O
inconvenience	O
this	O
may	O
have	O
caused	O
to	O
the	O
readers	O
of	O
this	O
journal	O
.	O

Cortical	O
excitability	O
in	O
smoking	O
and	O
not	O
smoking	O
individuals	O
with	O
and	O
without	O
nicotine	B
.	O

RATIONAL	O
:	O
Activation	O
of	O
nicotinic	O
acetylcholine	B
receptors	O
has	O
a	O
major	O
neuromodulatory	O
impact	O
on	O
central	O
nervous	O
system	O
function	O
.	O

Beyond	O
acute	O
activation	O
,	O
chronic	O
nicotine	B
intake	O
has	O
long	O
-	O
lasting	O
effects	O
on	O
cortical	O
excitability	O
in	O
animal	O
experiments	O
,	O
caused	O
by	O
receptor	O
up-	O
or	O
down	O
-	O
regulation	O
.	O

Knowledge	O
about	O
the	O
impact	O
of	O
nicotine	B
on	O
cortical	O
excitability	O
in	O
humans	O
,	O
however	O
,	O
is	O
limited	O
.	O

OBJECTIVES	O
:	O
We	O
therefore	O
aimed	O
to	O
explore	O
the	O
effect	O
of	O
nicotine	B
intake	O
on	O
cortical	O
excitability	O
in	O
healthy	O
human	O
smokers	O
and	O
non	O
-	O
smokers	O
.	O

METHODS	O
:	O
The	O
primary	O
motor	O
cortex	O
served	O
as	O
model	O
,	O
and	O
cortical	O
excitability	O
was	O
monitored	O
via	O
transcranial	O
magnetic	O
stimulation	O
(	O
TMS	O
)	O
.	O

Corticospinal	O
excitability	O
and	O
intracortical	O
excitability	O
were	O
recorded	O
before	O
and	O
after	O
application	O
of	O
nicotine	B
patch	O
in	O
both	O
groups	O
.	O

Corticospinal	O
excitability	O
was	O
explored	O
by	O
motor	O
threshold	O
and	O
input	O
/	O
output	O
curve	O
(	O
I	O
/	O
O	O
curve	O
)	O
,	O
and	O
intracortical	O
excitability	O
was	O
explored	O
by	O
means	O
of	O
paired	O
-	O
pulse	O
TMS	O
techniques	O
(	O
intracortical	O
facilitation	O
(	O
ICF	O
)	O
,	O
short	O
-	O
latency	O
intracortical	O
inhibition	O
(	O
SICI	O
)	O
,	O
I	O
-	O
wave	O
facilitation	O
and	O
short	O
-	O
latency	O
afferent	O
inhibition	O
(	O
SAI	O
)	O
)	O
.	O

RESULTS	O
:	O
The	O
results	O
show	O
that	O
smokers	O
during	O
nicotine	B
withdrawal	O
display	O
increased	O
corticospinal	O
excitability	O
with	O
regard	O
to	O
the	O
I	O
/	O
O	O
curve	O
(	O
TMS	O
intensity	O
150	O
%	O
of	O
resting	O
motor	O
threshold	O
)	O
compared	O
to	O
non	O
-	O
smokers	O
and	O
furthermore	O
enhanced	O
SAI	O
and	O
diminished	O
ICF	O
at	O
the	O
intracortical	O
circuit	O
level	O
.	O

After	O
administration	O
of	O
nicotine	B
,	O
intracortical	O
facilitation	O
in	O
smokers	O
increased	O
,	O
while	O
in	O
non	O
-	O
smokers	O
,	O
inhibition	O
(	O
SICI	O
,	O
SAI	O
)	O
was	O
enhanced	O
.	O

CONCLUSION	O
:	O
Our	O
results	O
show	O
that	O
chronic	O
nicotine	B
consumption	O
in	O
smokers	O
alters	O
cortical	O
excitability	O
independent	O
from	O
acute	O
nicotine	B
consumption	O
and	O
that	O
acute	O
nicotine	B
has	O
different	O
effects	O
on	O
motor	O
cortical	O
excitability	O
in	O
both	O
groups	O
.	O

Neuritogenic	O
and	O
Neuroprotective	O
Effects	O
of	O
Polar	O
Steroids	B
from	O
the	O
Far	O
East	O
Starfishes	O
Patiria	O
pectinifera	O
and	O
Distolasterias	O
nipon	O
.	O

The	O
neuritogenic	O
and	O
neuroprotective	O
activities	O
of	O
six	O
starfish	O
polar	O
steroids	B
,	O
asterosaponin	B
1	I
,	O
(	B
25S	I
)	I
-5	I
-	I
cholestane-3,4,6,7,8,15,16,26-octaol	I
,	O
and	O
(	B
25S	I
)	I
-5	I
-	I
cholestane-3,6,7,8,15,16,26-heptaol	I
(	O
1	O
-	O
3	O
)	O
from	O
the	O
starfish	O
Patiria	O
pectinifera	O
and	O
distolasterosides	B
D1-D3	I
(	O
4	O
-	O
6	O
)	O
from	O
the	O
starfish	O
Distolasterias	O
nipon	O
were	O
analyzed	O
using	O
the	O
mouse	O
neuroblastoma	O
(	O
NB	O
)	O
C-1300	O
cell	O
line	O
and	O
an	O
organotypic	O
rat	O
hippocampal	O
slice	O
culture	O
(	O
OHSC	O
)	O
.	O

All	O
of	O
these	O
compounds	O
enhanced	O
neurite	O
outgrowth	O
in	O
NB	O
cells	O
.	O

Dose	O
-	O
dependent	O
responses	O
to	O
compounds	O
1	O
-	O
3	O
were	O
observed	O
within	O
the	O
concentration	O
range	O
of	O
10	O
-	O
100	O
nM	O
,	O
and	O
dose	O
-	O
dependent	O
responses	O
to	O
glycosides	O
4	O
-	O
6	O
were	O
observed	O
at	O
concentrations	O
of	O
1	O
-	O
50	O
nM.	O
All	O
the	O
tested	O
substances	O
exhibited	O
notable	O
synergistic	O
effects	O
with	O
trace	O
amounts	O
of	O
nerve	O
growth	O
factor	O
(	O
NGF	O
,	O
1	O
ng	O
/	O
mL	O
)	O
or	O
brain	O
-	O
derived	O
neurotrophic	O
factor	O
(	O
BDNF	O
,	O
0.1	O
ng	O
/	O
mL	O
)	O
.	O

Using	O
NB	O
cells	O
and	O
OHSCs	O
,	O
it	O
was	O
shown	O
for	O
the	O
first	O
time	O
that	O
starfish	O
steroids	B
1	O
-	O
6	O
act	O
as	O
neuroprotectors	O
against	O
oxygen	B
-	O
glucose	B
deprivation	O
(	O
OGD	O
)	O
by	O
increasing	O
the	O
number	O
of	O
surviving	O
cells	O
.	O

Altogether	O
,	O
these	O
results	O
suggest	O
that	O
neurotrophin	O
-	O
like	O
neuritogenic	O
and	O
neuroprotective	O
activities	O
are	O
most	O
likely	O
common	O
properties	O
of	O
starfish	O
polyhydroxysteroids	B
and	O
the	O
related	O
glycosides	O
,	O
although	O
the	O
magnitude	O
of	O
the	O
effect	O
depended	O
on	O
the	O
particular	O
compound	O
structure	O
.	O

Self	O
-	O
assembling	O
doxorubicin	B
silk	O
hydrogels	O
for	O
the	O
focal	O
treatment	O
of	O
primary	O
breast	O
cancer	O
.	O

Standard	O
care	O
for	O
early	O
stage	O
breast	O
cancer	O
includes	O
tumor	O
resection	O
and	O
local	O
radiotherapy	O
to	O
achieve	O
long	O
-	O
term	O
remission	O
.	O

Systemic	O
chemotherapy	O
provides	O
only	O
low	O
locoregional	O
control	O
of	O
the	O
disease	O
;	O
therefore	O
,	O
we	O
describe	O
self	O
-	O
assembling	O
silk	O
hydrogels	O
that	O
can	O
retain	O
and	O
then	O
deliver	O
doxorubicin	B
locally	O
.	O

Self	O
-	O
assembling	O
silk	O
hydrogels	O
show	O
no	O
swelling	O
,	O
are	O
readily	O
loaded	O
with	O
doxorubicin	B
under	O
aqueous	O
conditions	O
and	O
release	O
drug	O
over	O
4	O
weeks	O
in	O
amounts	O
that	O
can	O
be	O
fine	O
-	O
tuned	O
by	O
varying	O
the	O
silk	O
content	O
.	O

Following	O
successful	O
in	O
vitro	O
studies	O
,	O
locally	O
injected	O
silk	O
hydrogels	O
loaded	O
with	O
doxorubicin	B
show	O
excellent	O
antitumor	O
response	O
in	O
mice	O
,	O
outperforming	O
the	O
equivalent	O
amount	O
of	O
doxorubicin	B
delivered	O
intravenously	O
.	O

In	O
addition	O
to	O
reducing	O
primary	O
tumor	O
growth	O
,	O
doxorubicin	B
-	O
loaded	O
silk	O
hydrogels	O
reduce	O
metastatic	O
spread	O
and	O
are	O
well	O
tolerated	O
in	O
vivo	O
.	O

Thus	O
,	O
silk	O
hydrogels	O
are	O
well	O
suited	O
for	O
the	O
local	O
delivery	O
of	O
chemotherapy	O
and	O
provide	O
a	O
promising	O
approach	O
to	O
improve	O
locoregional	O
control	O
of	O
breast	O
cancer	O
.	O

Serial	O
measurements	O
of	O
antineutrophil	O
cytoplasmic	O
autoantibodies	O
in	O
patients	O
with	O
systemic	O
vasculitis	O
.	O

PURPOSE	O
:	O
To	O
assess	O
the	O
value	O
of	O
serial	O
determinations	O
of	O
antineutrophil	O
cytoplasmic	O
autoantibodies	O
(	O
ANCA	O
)	O
for	O
monitoring	O
disease	O
activity	O
in	O
patients	O
with	O
systemic	O
vasculitis	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Forty	O
-	O
three	O
patients	O
with	O
histologically	O
proven	O
vasculitis	O
(	O
21	O
with	O
Wegener	O
's	O
granulomatosis	O
,	O
17	O
with	O
microscopic	O
polyangiitis	O
,	O
and	O
5	O
with	O
renal	O
-	O
limited	O
vasculitis	O
)	O
were	O
studied	O
for	O
a	O
median	O
follow	O
-	O
up	O
of	O
22	O
months	O
.	O

Disease	O
activity	O
was	O
prospectively	O
assessed	O
and	O
quantified	O
by	O
the	O
Birmingham	O
Vasculitis	O
Activity	O
Score	O
.	O

A	O
total	O
of	O
347	O
sera	O
were	O
analyzed	O
for	O
ANCA	O
determination	O
.	O

RESULTS	O
:	O
Relapses	O
occurred	O
in	O
23	O
(	O
54	O
%	O
)	O
of	O
43	O
patients	O
.	O

Diagnostic	O
category	O
(	O
Wegener	O
's	O
granulomatosis	O
vs	O
micropolyangiitis	O
and	O
renal	O
-	O
limited	O
vasculitis	O
)	O
,	O
severity	O
of	O
initial	O
symptoms	O
(	O
mean	O
vasculitis	O
activity	O
score	O
,	O
mean	O
number	O
of	O
organs	O
involved	O
)	O
,	O
and	O
ANCA	O
pattern	O
[	O
cytoplasmic	O
-	O
ANCA	O
(	O
c	O
-	O
ANCA	O
)	O
vs	O
perinuclear	O
-	O
ANCA	O
(	O
p	O
-	O
ANCA	O
)	O
]	O
did	O
not	O
significantly	O
differ	O
between	O
relapsers	O
and	O
nonrelapsers	O
.	O

Lung	O
involvement	O
was	O
more	O
frequent	O
at	O
onset	O
among	O
relapsers	O
[	O
16	O
of	O
23	O
(	O
)	O
vs	O
6	O
of	O
(	O
)	O
;	O
P	O
=	O
0.02	O
]	O
.	O

Relapses	O
were	O
slightly	O
,	O
but	O
not	O
significantly	O
,	O
more	O
frequent	O
in	O
patients	O
with	O
Wegener	O
's	O
granulomatosis	O
or	O
a	O
c	O
-	O
ANCA	O
pattern	O
.	O

The	O
percentage	O
of	O
relapsers	O
was	O
greater	O
in	O
patients	O
with	O
persistently	O
positive	O
ANCA	O
than	O
in	O
patients	O
with	O
negative	O
or	O
decreasing	O
ANCA	O
titers	O
(	O
86	O
%	O
vs	O
,	O
P	O
=	O
0.0001	O
)	O
.	O

However	O
,	O
the	O
predictive	O
value	O
of	O
an	O
increase	O
in	O
ANCA	O
titers	O
for	O
the	O
occurrence	O
of	O
a	O
subsequent	O
relapse	O
was	O
only	O
28	O
%	O
(	O
4	O
of	O
14	O
)	O
for	O
c	O
-	O
ANCA	O
,	O
12	O
%	O
(	O
2	O
of	O
17	O
)	O
for	O
anti	O
-	O
proteinase	O
3	O
-	O
ANCA	O
,	O
and	O
43	O
%	O
(	O
6	O
of	O
14	O
)	O
for	O
anti	O
-	O
myeloperoxidase	O
-	O
ANCA	O
.	O

An	O
increase	O
in	O
ANCA	O
occurred	O
before	O
or	O
during	O
relapse	O
in	O
33	O
%	O
(	O
of	O
)	O
of	O
cases	O
for	O
c	O
-	O
ANCA	O
/	O
anti	O
-	O
proteinase	O
3	O
antibodies	O
,	O
and	O
73	O
%	O
(	O
11	O
of	O
15	O
)	O
of	O
cases	O
for	O
anti	O
-	O
myeloperoxidase	O
antibodies	O
.	O

CONCLUSION	O
:	O
The	O
persistence	O
of	O
ANCA	O
positivity	O
is	O
strongly	O
associated	O
with	O
relapses	O
.	O

However	O
,	O
an	O
increase	O
in	O
ANCA	O
titers	O
has	O
a	O
poor	O
value	O
for	O
the	O
early	O
prediction	O
of	O
a	O
subsequent	O
relapse	O
and	O
should	O
not	O
be	O
used	O
as	O
a	O
sole	O
parameter	O
for	O
therapeutic	O
intervention	O
.	O

In	O
addition	O
,	O
our	O
results	O
suggest	O
that	O
serial	O
anti	O
-	O
myeloperoxidase	O
determination	O
may	O
be	O
useful	O
as	O
a	O
prognostic	O
marker	O
in	O
patients	O
who	O
are	O
p	O
-	O
ANCA	O
positive	O
.	O

Serum	O
lipid	B
and	O
leptin	O
concentrations	O
in	O
hypopituitary	O
patients	O
with	O
growth	O
hormone	O
deficiency	O
.	O

OBJECTIVE	O
:	O
To	O
investigate	O
the	O
effects	O
of	O
growth	O
hormone	O
(	O
GH	O
)	O
deficiency	O
on	O
serum	O
lipid	B
and	O
leptin	O
concentrations	O
in	O
hypopituitary	O
patients	O
taking	O
conventional	O
replacement	O
therapy	O
and	O
to	O
determine	O
the	O
relations	O
between	O
leptin	O
and	O
gender	O
and	O
anthropometric	O
and	O
metabolic	O
variables	O
.	O

SUBJECTS	O
:	O
Twenty	O
-	O
one	O
GH	O
deficient	O
adult	O
hypopituitary	O
patients	O
(	O
15	O
women	O
,	O
six	O
men	O
)	O
and	O
21	O
(	O
14	O
women	O
,	O
seven	O
men	O
)	O
age	O
,	O
sex	O
and	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
matched	O
healthy	O
controls	O
.	O

MEASUREMENTS	O
:	O
After	O
an	O
overnight	O
fast	O
,	O
anthropometric	O
parameters	O
were	O
measured	O
and	O
body	O
composition	O
was	O
determined	O
by	O
a	O
bioelectrical	O
impedance	O
analyser	O
.	O

Venous	O
blood	O
samples	O
were	O
obtained	O
for	O
the	O
measurements	O
of	O
glucose	B
,	O
total	O
cholesterol	B
,	O
high	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
cholesterol	B
,	O
triglyceride	B
,	O
intact	O
insulin	O
,	O
insulin	O
-	O
like	O
growth	O
factor	O
1	O
(	O
IGF	O
-	O
1	O
)	O
and	O
leptin	O
concentrations	O
.	O

Serum	O
leptin	O
and	O
hormones	O
were	O
analysed	O
by	O
radioimmunoassay	O
.	O

RESULTS	O
:	O
Hypopituitary	O
patients	O
with	O
GH	O
deficiency	O
showed	O
significantly	O
higher	O
triglyceride	B
,	O
total	O
and	O
low	O
density	O
lipoprotein	O
(	O
LDL	O
)	O
cholesterol	B
and	O
lower	O
HDL	O
cholesterol	B
concentrations	O
on	O
conventional	O
replacement	O
therapy	O
.	O

The	O
unfavourable	O
lipid	B
profile	O
was	O
particularly	O
evident	O
in	O
women	O
.	O

Significantly	O
higher	O
leptin	O
concentrations	O
were	O
found	O
in	O
patients	O
compared	O
with	O
healthy	O
controls	O
with	O
similar	O
body	O
fat	O
content	O
(	O
23	O
.	O
5	O
+	O
/	O
-	O
11.8	O
ng	O
/	O
ml	O
vs	O
11.7	O
+	O
/	O
-	O
6.9	O
ng	O
/	O
ml	O
,	O
P	O
=	O
0.01	O
)	O
.	O

This	O
difference	O
remained	O
significant	O
even	O
when	O
leptin	O
values	O
were	O
expressed	O
in	O
relation	O
to	O
fat	O
mass	O
percentage	O
(	O
0.79	O
+	O
/	O
-	O
0.40	O
vs.	O
0.42	O
+	O
/	O
-	O
0.17	O
ng	O
/	O
ml	O
%	O
,	O
P	O
<	O
0.05	O
)	O
and	O
fat	O
mass	O
kg	O
(	O
1.32	O
+	O
/	O
-	O
0.81	O
vs	O
0.66	O
+	O
/	O
-	O
0.30	O
ng	O
/	O
ml	O
kg	O
,	O
P	O
<	O
0	O
.	O
05	O
)	O
.	O

Significant	O
positive	O
correlations	O
were	O
observed	O
between	O
leptin	O
concentrations	O
and	O
body	O
fat	O
percentage	O
and	O
age	O
in	O
the	O
control	O
group	O
.	O

In	O
patients	O
the	O
sole	O
significant	O
relation	O
between	O
leptin	O
and	O
study	O
parameters	O
was	O
the	O
positive	O
correlation	O
observed	O
between	O
leptin	O
and	O
total	O
cholesterol	B
concentrations	O
.	O

Serum	O
leptin	O
concentrations	O
were	O
significantly	O
higher	O
in	O
women	O
than	O
men	O
in	O
the	O
control	O
group	O
,	O
but	O
not	O
in	O
the	O
patients	O
.	O

No	O
significant	O
gender	O
difference	O
was	O
observed	O
when	O
leptin	O
concentrations	O
were	O
expressed	O
in	O
relation	O
to	O
fat	O
mass	O
(	O
percentage	O
and	O
kg	O
)	O
.	O

CONCLUSION	O
:	O
Growth	O
hormone	O
deficient	O
hypopituitary	O
patients	O
(	O
particularly	O
women	O
)	O
on	O
conventional	O
replacement	O
therapy	O
have	O
a	O
more	O
atherogenic	O
lipid	B
profile	O
.	O

Leptin	O
concentrations	O
are	O
increased	O
in	O
GH	O
deficient	O
adults	O
even	O
after	O
adjustment	O
for	O
percentage	O
body	O
fat	O
and	O
body	O
fat	O
mass	O
(	O
kg	O
)	O
.	O

Although	O
the	O
nature	O
of	O
our	O
data	O
does	O
not	O
allow	O
us	O
to	O
draw	O
any	O
conclusions	O
on	O
the	O
mechanism	O
(	O
s	O
)	O
of	O
increased	O
leptin	O
concentrations	O
in	O
GH	O
deficiency	O
,	O
decreased	O
central	O
sensitivity	O
to	O
leptin	O
and	O
increased	O
leptin	O
production	O
from	O
per	O
unit	O
fat	O
mass	O
,	O
or	O
alterations	O
in	O
leptin	O
clearance	O
,	O
might	O
be	O
operative	O
.	O

At	O
physiological	O
pH	O
,	O
the	O
spatial	O
arrangement	O
of	O
the	O
three	O
charges	O
of	O
DL	B
-	I
tetrazol	I
-	I
5	I
-	I
ylglycine	I
(	O
5	O
)	O
could	O
be	O
viewed	O
as	O
similar	O
to	O
those	O
found	O
in	O
certain	O
conformations	O
of	O
the	O
two	O
excitatory	O
amino	O
acids	O
(	O
EAAs	O
)	O
-	O
-	O
aspartic	B
and	O
glutamic	B
acids	I
.	O

Given	O
significant	O
binding	O
to	O
one	O
or	O
more	O
EAA	O
receptors	O
,	O
5	O
would	O
offer	O
unique	O
modeling	O
and	O
perhaps	O
biological	O
opportunities	O
.	O

We	O
have	O
previously	O
shown	O
it	O
to	O
be	O
the	O
most	O
potent	O
NMDA	B
agonist	O
known	O
,	O
with	O
a	O
unique	O
and	O
marked	O
in	O
vitro	O
neutrotoxicity	O
at	O
depolarizing	O
concentrations	O
.	O

Now	O
we	O
report	O
the	O
details	O
required	O
for	O
its	O
synthesis	O
,	O
together	O
with	O
its	O
potency	O
and	O
efficacy	O
in	O
two	O
assays	O
of	O
functional	O
activation	O
of	O
the	O
NMDA	O
receptor	O
,	O
namely	O
agonist	O
-	O
influenced	O
[	B
3H	I
]	I
MK801	I
binding	O
and	O
agonist	O
-	O
induced	O
release	O
of	O
the	O
neurotransmitter	O
[	B
3H	I
]	I
-	I
norepinephrine	I
from	O
brain	O
slices	O
.	O

In	O
both	O
these	O
assays	O
DL	B
-	I
tetrazol	I
-	I
5	I
-	I
ylglycine	I
proved	O
to	O
be	O
more	O
potent	O
and	O
efficacious	O
than	O
NMDA	B
and	O
cis	B
-	I
methanoglutamate	I
.	O

It	O
was	O
more	O
potent	O
than	O
,	O
and	O
equally	O
efficacious	O
to	O
,	O
L	B
-	I
glutamate	I
in	O
[	B
3H	I
]	I
MK801	I
binding	O
.	O

The	O
structural	O
features	O
of	O
5	O
may	O
well	O
reflect	O
optimal	O
agonist	O
interaction	O
at	O
the	O
NMDA	O
receptor	O
site	O
.	O

(	O
We	O
considered	O
the	O
possibility	O
that	O
some	O
decarboxylation	O
of	O
DL	B
-	I
tetrazol	I
-	I
5	I
-	I
ylglycine	I
may	O
have	O
occurred	O
during	O
testing	O
.	O

This	O
would	O
give	O
5	B
-	I
(	I
aminomethyl	I
)	I
tetrazole	I
(	O
13	O
)	O
,	O
the	O
tetrazole	B
acid	I
analog	B
of	O
glycine	B
;	O
and	O
glycine	B
is	O
involved	O
in	O
NMDA	O
receptor	O
activation	O
.	O

Compound	O
13	O
does	O
not	O
affect	O
[	B
3H	I
]	I
glycine	I
binding	O
at	O
the	O
strychnine	B
-	O
insensitive	O
glycine	B
binding	O
site	O
,	O
and	O
[	B
3H	I
]	I
MK801	I
binding	O
studies	O
showed	O
that	O
the	O
(	B
aminomethyl	I
)	I
-	I
tetrazole	I
,	O
even	O
if	O
is	O
formed	O
,	O
would	O
probably	O
have	O
no	O
effect	O
on	O
the	O
activity	O
of	O
tetrazol	B
-	I
5	I
-	I
ylglycine	I
at	O
the	O
NMDA	O
receptor	O
.	O

Implied	O
preference	O
for	O
seismic	O
design	O
level	O
and	O
earthquake	O
insurance	O
.	O

Seismic	O
risk	O
can	O
be	O
reduced	O
by	O
implementing	O
newly	O
developed	O
seismic	O
provisions	O
in	O
design	O
codes	O
.	O

Furthermore	O
,	O
financial	O
protection	O
or	O
enhanced	O
utility	O
and	O
happiness	O
for	O
stakeholders	O
could	O
be	O
gained	O
through	O
the	O
purchase	O
of	O
earthquake	O
insurance	O
.	O

If	O
this	O
is	O
not	O
so	O
,	O
there	O
would	O
be	O
no	O
market	O
for	O
such	O
insurance	O
.	O

However	O
,	O
perceived	O
benefit	O
associated	O
with	O
insurance	O
is	O
not	O
universally	O
shared	O
by	O
stakeholders	O
partly	O
due	O
to	O
their	O
diverse	O
risk	O
attitudes	O
.	O

This	O
study	O
investigates	O
the	O
implied	O
seismic	O
design	O
preference	O
with	O
insurance	O
options	O
for	O
decisionmakers	O
of	O
bounded	O
rationality	O
whose	O
preferences	O
could	O
be	O
adequately	O
represented	O
by	O
the	O
cumulative	O
prospect	O
theory	O
(	O
CPT	O
)	O
.	O

The	O
investigation	O
is	O
focused	O
on	O
assessing	O
the	O
sensitivity	O
of	O
the	O
implied	O
seismic	O
design	O
preference	O
with	O
insurance	O
options	O
to	O
model	O
parameters	O
of	O
the	O
CPT	O
and	O
to	O
fair	O
and	O
unfair	O
insurance	O
arrangements	O
.	O

Numerical	O
results	O
suggest	O
that	O
human	O
cognitive	O
limitation	O
and	O
risk	O
perception	O
can	O
affect	O
the	O
implied	O
seismic	O
design	O
preference	O
by	O
the	O
CPT	O
significantly	O
.	O

The	O
mandatory	O
purchase	O
of	O
fair	O
insurance	O
will	O
lead	O
the	O
implied	O
seismic	O
design	O
preference	O
to	O
the	O
optimum	O
design	O
level	O
that	O
is	O
dictated	O
by	O
the	O
minimum	O
expected	O
lifecycle	O
cost	O
rule	O
.	O

Unfair	O
insurance	O
decreases	O
the	O
expected	O
gain	O
as	O
well	O
as	O
its	O
associated	O
variability	O
,	O
which	O
is	O
preferred	O
by	O
risk	O
-	O
averse	O
decisionmakers	O
.	O

The	O
obtained	O
results	O
of	O
the	O
implied	O
preference	O
for	O
the	O
combination	O
of	O
the	O
seismic	O
design	O
level	O
and	O
insurance	O
option	O
suggest	O
that	O
property	O
owners	O
,	O
financial	O
institutions	O
,	O
and	O
municipalities	O
can	O
take	O
advantage	O
of	O
affordable	O
insurance	O
to	O
establish	O
successful	O
seismic	O
risk	O
management	O
strategies	O
.	O

Oribatid	O
Mite	O
Communities	O
in	O
the	O
Canopy	O
of	O
Montane	O
Abies	O
amabilis	O
and	O
Tsuga	O
heterophylla	O
Trees	O
on	O
Vancouver	O
Island	O
,	O
British	O
Columbia	O
.	O

To	O
study	O
the	O
oribatid	O
mite	O
community	O
inhabiting	O
microhabitats	O
in	O
the	O
canopy	O
of	O
montane	O
Abies	O
amabilis	O
[	O
(	O
Douglas	O
ex	O
D	O
.	O

Don	O
)	O
Lindl	O
.	O
]	O
and	O
Tsuga	O
heterophylla	O
[	O
(	O
Raf	O
.	O
)	O

Sarg	O
]	O
tree	O
species	O
across	O
five	O
elevational	O
sites	O
,	O
we	O
collected	O
branch	O
tips	O
and	O
foliose	O
/	O
crustose	O
lichen	O
samples	O
over	O
three	O
time	O
periods	O
.	O

Thirty	O
-	O
three	O
species	O
of	O
oribatid	O
mites	O
were	O
identified	O
from	O
the	O
study	O
area	O
.	O

Mite	O
species	O
richness	O
and	O
abundance	O
was	O
significantly	O
affected	O
by	O
microhabitat	O
,	O
and	O
this	O
association	O
was	O
independent	O
of	O
sampling	O
time	O
.	O

At	O
the	O
microhabitat	O
scale	O
,	O
distinct	O
species	O
assemblages	O
were	O
associated	O
with	O
lichen	O
and	O
branch	O
tip	O
habitats	O
,	O
and	O
to	O
a	O
lesser	O
degree	O
,	O
tree	O
species	O
.	O

Conifer	O
specificity	O
was	O
most	O
apparent	O
in	O
the	O
closely	O
related	O
species	O
of	O
Jugatala	O
,	O
where	O
Jugatala	O
tuberosa	O
Ewing	O
was	O
only	O
found	O
on	O
branch	O
tips	O
from	O
A	O
.	O

amabilis	O
and	O
Jugatala	O
sp	O
.	O
was	O
primarily	O
found	O
on	O
branch	O
tips	O
from	O
T	O
.	O

heterophylla	O
.	O

Microhabitat	O
specificity	O
was	O
most	O
pronounced	O
in	O
Dendrozetes	O
sp	O
.	O

where	O
most	O
individuals	O
were	O
found	O
on	O
branch	O
tips	O
and	O
Anachiperia	O
geminus	O
Lindo	O
et	O
al.	O
that	O
occurred	O
primarily	O
on	O
lichens	O
.	O

Principal	O
components	O
analysis	O
of	O
oribatid	O
mite	O
community	O
composition	O
further	O
showed	O
a	O
high	O
degree	O
of	O
association	O
with	O
microhabitat	O
and	O
tree	O
species	O
.	O

Habitat	O
profiles	O
are	O
difficult	O
to	O
discern	O
for	O
many	O
species	O
because	O
tree	O
,	O
microhabitat	O
,	O
and	O
elevation	O
preferences	O
confound	O
distribution	O
patterns	O
.	O

Given	O
the	O
significant	O
tree	O
-	O
microhabitat	O
associations	O
in	O
species	O
composition	O
in	O
this	O
montane	O
canopy	O
study	O
,	O
we	O
suggest	O
that	O
sampling	O
multiple	O
microhabitats	O
across	O
elevations	O
to	O
look	O
for	O
patterns	O
in	O
community	O
structure	O
offers	O
opportunities	O
to	O
explicitly	O
test	O
organizing	O
principles	O
in	O
community	O
ecology	O
.	O

Unilateral	O
hearing	O
disturbance	O
could	O
be	O
an	O
isolated	O
manifestation	O
prior	O
to	O
ipsilateral	O
anterior	O
inferior	O
cerebellar	O
artery	O
infarction	O
.	O

A	O
-	O
year	O
-	O
old	O
man	O
presented	O
with	O
a	O
sudden	O
onset	O
of	O
right	O
-	O
sided	O
hearing	O
disturbance	O
.	O

His	O
hearing	O
disturbance	O
improved	O
gradually	O
,	O
however	O
,	O
dysarthria	O
,	O
right	O
-	O
sided	O
facial	O
weakness	O
and	O
dysesthesia	O
,	O
and	O
gait	O
disturbance	O
was	O
developed	O
11	O
days	O
after	O
the	O
onset	O
of	O
hearing	O
disturbance	O
.	O

MR	O
imaging	O
revealed	O
fresh	O
infarctions	O
of	O
the	O
right	O
dorsolateral	O
pons	O
and	O
middle	O
cerebellar	O
peduncle	O
localized	O
in	O
the	O
territory	O
of	O
anterior	O
inferior	O
cerebellar	O
artery	O
.	O

Unilateral	O
hearing	O
disturbance	O
could	O
be	O
an	O
isolated	O
manifestation	O
prior	O
to	O
ipsilateral	O
anterior	O
inferior	O
cerebellar	O
artery	O
infarction	O
.	O

The	O
synthesis	O
of	O
2	B
'	I
-	I
fluoro	I
-	I
-	I
propargyl	I
-	I
5,8	I
-	I
dideazafolic	I
acid	I
and	O
its	O
2	B
-	I
desamino	I
,	O
2	B
-	I
desamino	I
-	I
2	I
-	I
hydroxymethyl	I
,	O
and	O
2	B
-	I
desamino	I
-	I
2	I
-	I
methoxy	I
analogues	B
is	O
described	O
.	O

In	O
general	O
the	O
synthetic	O
route	O
involved	O
the	O
coupling	O
of	O
diethyl	B
N	I
-	I
[	I
2	I
-	I
fluoro	I
-	I
4	I
-	I
(	I
prop	I
-	I
2	I
-	I
ynylamino	I
)	I
benzoyl	I
]	I
-	I
L	I
-	I
glutamate	I
with	O
the	O
appropriate	O
6	B
-	I
(	I
bromomethyl	I
)	I
quinazoline	I
followed	O
by	O
deprotection	O
with	O
mild	O
alkali	O
.	O

These	O
four	O
compounds	O
together	O
with	O
the	O
2	B
-	I
desamino	I
-	I
2	I
-	I
methyl	I
analogue	B
were	O
tested	O
for	O
their	O
activity	O
against	O
L1210	O
thymidylate	O
synthase	O
(	O
TS	O
)	O
.	O

They	O
were	O
also	O
examined	O
for	O
their	O
inhibition	O
of	O
the	O
growth	O
of	O
the	O
L1210	O
cell	O
line	O
and	O
of	O
two	O
mutant	O
L1210	O
cell	O
lines	O
,	O
the	O
L1210	O
:	O
R7A	O
that	O
overproduces	O
dihydrofolate	O
reductase	O
(	O
DHFR	O
)	O
and	O
the	O
L1210	O
:	O
1565	O
that	O
has	O
impaired	O
uptake	O
of	O
reduced	O
folates	O
.	O

Compared	O
with	O
their	O
non	O
-	O
fluorinated	O
parent	O
compounds	O
,	O
the	O
2	B
'	I
-	I
fluoro	I
analogues	B
were	O
all	O
approximately	O
2	O
-	O
fold	O
more	O
potent	O
as	O
TS	O
inhibitors	O
.	O

Similarly	O
,	O
they	O
also	O
showed	O
improved	O
inhibition	O
of	O
L1210	O
cell	O
growth	O
(	O
1.5	O
-	O
5	O
-	O
fold	O
)	O
,	O
and	O
this	O
activity	O
was	O
prevented	O
by	O
co	O
-	O
incubation	O
with	O
thymidine	O
.	O

All	O
had	O
retained	O
or	O
improved	O
activity	O
against	O
both	O
the	O
L1210	O
:	O
R7A	O
and	O
L1210	O
:	O
1565	O
cell	O
lines	O
.	O

N	O
-	O
Methylacetazolamide	O
was	O
shown	O
to	O
be	O
active	O
topically	O
in	O
reducing	O
intraocular	O
pressure	O
(	O
IOP	O
)	O
to	O
a	O
small	O
but	O
statistically	O
significant	O
level	O
in	O
the	O
normotensive	O
rabbit	O
eye	O
.	O

In	O
vivo	O
experiments	O
with	O
N	B
-	I
methylacetazolamide	I
suggest	O
that	O
ocular	O
metabolism	O
to	O
acetazolamide	B
was	O
responsible	O
for	O
the	O
observed	O
topical	O
activity	O
.	O

Examination	O
of	O
initial	O
rate	O
kinetics	O
of	O
carbonic	O
anhydrase	O
catalyzed	O
p	B
-	I
nitrophenyl	I
acetate	I
hydrolysis	O
showed	O
that	O
N	B
-	I
methylacetazolamide	I
was	O
a	O
competitive	O
inhibitor	O
,	O
in	O
contrast	O
to	O
noncompetitive	O
inhibition	O
seen	O
with	O
acetazolamide	B
and	O
other	O
primary	O
sulfonamide	B
inhibitors	O
.	O

N	B
-	I
Substituted	I
and	O
unsubstituted	B
4	I
-	I
chlorobenzene	I
-	I
and	O
4	B
-	I
nitrobenzenesulfonamides	I
were	O
also	O
synthesized	O
,	O
and	O
their	O
biochemical	O
characteristics	O
and	O
in	O
vivo	O
ability	O
to	O
lower	O
IOP	O
when	O
applied	O
topically	O
were	O
determined	O
.	O

The	O
primary	O
sulfonamides	B
were	O
reversible	O
noncompetitive	O
inhibitors	O
of	O
carbonic	O
anhydrase	O
,	O
with	O
no	O
effect	O
on	O
IOP	O
after	O
topical	O
administration	O
.	O

4	B
-	I
Nitrobenzene	I
-	I
and	O
4	B
-	I
chlorobenzenesulfonamides	I
containing	O
both	O
N	B
-	I
hydroxy	I
and	O
N	B
-	I
methyl	I
substituents	B
were	O
model	O
irreversible	O
inhibitors	O
of	O
carbonic	O
anhydrase	O
and	O
exhibited	O
a	O
trend	O
toward	O
topical	O
activity	O
in	O
reducing	O
IOP	O
in	O
normotensive	O
rabbit	O
eyes	O
.	O

Therefore	O
,	O
this	O
paper	O
describes	O
the	O
synthesis	O
and	O
characterization	O
of	O
two	O
types	O
of	O
carbonic	O
anhydrase	O
inhibitors	O
;	O
the	O
N	B
-	I
methyl	I
-	I
substituted	I
sulfonamides	I
are	O
reversible	O
competitive	O
inhibitors	O
of	O
carbonic	O
anhydrase	O
,	O
while	O
the	O
N	B
-	I
hydroxy	I
-	I
N	I
-	I
methyl	I
-	I
substituted	I
sulfonamides	I
are	O
irreversible	O
inhibitors	O
.	O

This	O
study	O
emphasizes	O
the	O
importance	O
of	O
the	O
metabolic	O
conversion	O
of	O
the	O
enantiomers	O
of	O
3	B
-	I
(	I
3	I
-	I
hydroxyphenyl	I
)	I
-	I
N	I
-	I
n	I
-	I
propylpiperidine	I
(	O
3	B
-	I
PPP	I
)	O
into	O
their	O
catechol	B
analogues	B
,	O
the	O
enantiomers	O
of	O
3	B
-	I
(	I
3,4	I
-	I
dihydroxyphenyl	I
)	I
-	I
N	I
-	I
n	I
-	I
propylpiperidine	I
.	O

These	O
isomers	O
are	O
both	O
shown	O
to	O
be	O
excellent	O
substrates	O
for	O
COMT	O
,	O
with	O
a	O
slight	O
preference	O
for	O
the	O
S	O
-	O
(	O
-	O
)	O
enantiomer	O
.	O

Assessment	O
of	O
the	O
dopaminergic	O
activity	O
of	O
these	O
catechols	O
and	O
the	O
results	O
from	O
the	O
determination	O
of	O
brain	O
levels	O
of	O
the	O
enantiomers	O
of	O
3	B
-	I
PPP	I
and	O
their	O
metabolites	O
indicate	O
that	O
the	O
metabolites	O
probably	O
do	O
not	O
alter	O
the	O
pharmacological	O
profiles	O
established	O
for	O
(	B
R	I
)	I
-	I
(	I
+	I
)	I
-	I
and	O
(	B
S	I
)	I
-	I
(	I
-	I
)	I
-	I
3	I
-	I
PPP	I
.	O

The	O
conversion	O
of	O
the	O
monophenols	B
into	O
catecholic	O
metabolites	O
is	O
only	O
1	O
-	O
5	O
%	O
,	O
and	O
the	O
further	O
conversion	O
of	O
these	O
catecholic	O
metabolites	O
into	O
methoxylated	O
analogues	O
is	O
very	O
rapid	O
.	O

However	O
,	O
the	O
very	O
interesting	O
observation	O
was	O
made	O
that	O
,	O
when	O
inhibiting	O
COMT	O
by	O
means	O
of	O
tropolone	B
and	O
subsequently	O
treating	O
the	O
rats	O
with	O
high	O
doses	O
of	O
(	B
S	I
)	I
-	I
(	I
-	I
)	I
-	I
3	I
-	I
PPP	I
(	O
ip	O
)	O
,	O
postsynaptic	O
dopaminergic	O
activity	O
was	O
elicited	O
.	O

This	O
has	O
never	O
been	O
seen	O
for	O
(	B
S	I
)	I
-	I
(	I
-	I
)	I
-	I
3	I
-	I
PPP	I
without	O
tropolone	B
pretreatment	O
and	O
might	O
indicate	O
that	O
,	O
in	O
this	O
special	O
case	O
,	O
the	O
catecholic	O
metabolite	O
affects	O
the	O
in	O
vivo	O
pharmacological	O
profile	O
of	O
(	B
S	I
)	I
-	I
(	I
-	I
)	I
-	I
3	I
-	I
PPP	I
.	O

The	O
syntheses	O
and	O
anthelmintic	O
activities	O
of	O
31	O
3	B
-	I
and	O
5	B
-	I
(	I
isothiocyanatophenyl	I
)	I
-	I
1,2,4	I
-	I
oxadiazoles	I
are	O
reported	O
.	O

In	O
the	O
primary	O
anthelmintic	O
screen	O
,	O
3	B
-	I
(	I
4	I
-	I
isothiocyanatophenyl	I
)	I
-	I
1,2,4	I
-	I
oxadiazole	I
(	O
39	O
)	O
showed	O
nematocidal	O
activity	O
and	O
3	B
-	I
(	I
2	I
-	I
furanyl	I
)	I
-	I
5	I
-	I
(	I
4	I
-	I
isothiocyanatophenyl	I
)	I
-	I
1,2,4	I
-	I
oxadiazole	I
(	O
63	O
)	O
,	O
3	B
-	I
(	I
2	I
-	I
furanyl	I
)	I
-	I
5	I
-	I
(	I
2	I
-	I
chloro	I
-	I
4	I
-	I
isothiocyanatophenyl	I
)	I
-	I
1,2,4	I
-	I
oxadiazole	I
(	O
64	O
)	O
,	O
and	O
3	B
-	I
(	I
2	I
-	I
furanyl	I
)	I
-	I
5	I
-	I
(	I
4	I
-	I
chloro	I
-	I
3	I
-	I
isothiocyanatophenyl	I
)	I
-	I
1,2,4	I
-	I
oxadiazole	I
(	O
66	O
)	O
showed	O
taeniacidal	O
activity	O
when	O
administered	O
orally	O
to	O
mice	O
.	O

The	O
two	O
most	O
active	O
members	O
of	O
this	O
series	O
,	O
39	O
and	O
63	O
,	O
were	O
active	O
against	O
the	O
gastrointestinal	O
nematodes	O
of	O
sheep	O
at	O
mg	O
/	O
kg	O
.	O

In	O
addition	O
,	O
39	O
was	O
also	O
found	O
to	O
be	O
active	O
against	O
hookworms	O
in	O
dogs	O
at	O
a	O
single	O
,	O
oral	O
dose	O
of	O
mg	O
/	O
kg	O
.	O

